PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Eckerdt, F; Yuan, JP; Strebhardt, K				Eckerdt, F; Yuan, JP; Strebhardt, K			Polo-like kinases and oncogenesis	ONCOGENE			English	Review						polo-like kinase; oncogenesis; tumor suppressor; checkpoint; cell cycle; mitosis	PROTEIN-SERINE/THREONINE KINASE; SACCHAROMYCES-CEREVISIAE CDC5; ATM-DEPENDENT PHOSPHORYLATION; INTEGRIN-BINDING PROTEIN; CELL-CYCLE PROGRESSION; DNA-DAMAGE CHECKPOINT; KINESIN-LIKE PROTEIN; DROSOPHILA-POLO; PROGNOSTIC-SIGNIFICANCE; DOWN-REGULATION	Polo-like kinases (Plks) play pivotal roles in the regulation of cell cycle progression. Plk1, the best characterized family member among mammalian Plks, strongly promotes the progression of cells through mitosis. Furthermore, Plk1 is found to be overexpressed in a variety of human tumors and its expression correlates with cellular proliferation and prognosis of tumor patients. Although all Plks share two conserved elements, the N-terminal Ser/Thr kinase domain and a highly homologues C-terminal region termed the polo-box motif, their functions diverge considerably. While Plk1 is inhibited by different checkpoint pathways, Plk2 and Plk3 are activated by the spindle checkpoint or the DNA damage checkpoint. Thus, Plk2 and Plk3 seem to inhibit oncogenic transformation. Deregulation of Plk1 activity contributes to genetic instability, which in turn leads to oncogenic transformation. In contrast, Plk2 and Plk3 are involved in checkpoint-mediated cell cycle arrest to ensure genetic stability, thereby inhibiting the accumulation of genetic defects. In this review, we shall discuss the roles of Plks in oncogenesis and Plk1 as a target for therapeutic intervention against cancer.	Goethe Univ Frankfurt, Sch Med, Dept Gynecol & Obstet, D-60590 Frankfurt, Germany	Goethe University Frankfurt	Strebhardt, K (corresponding author), Univ Colorado, Sch Med, Dept Pharmacol, Denver, CO 80262 USA.	frank.eckerdt@uchsc.edu; strebhardt@em.uni-frankfurt.de	Strebhardt, Klaus/E-8765-2011	Strebhardt, Klaus/0000-0003-2173-9763				Abrieu A, 1998, J CELL SCI, V111, P1751; Ahmad N, 2004, FASEB J, V18, P5, DOI 10.1096/fj.03-0848hyp; Ando K, 2004, J BIOL CHEM, V279, P25549, DOI 10.1074/jbc.M314182200; Avides MD, 2001, NAT CELL BIOL, V3, P421, DOI 10.1038/35070110; Bahassi ELM, 2004, ONCOGENE, V23, P2658, DOI 10.1038/sj.onc.1207425; Bahassi EM, 2002, ONCOGENE, V21, P6633, DOI 10.1038/sj.onc.1205850; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bin OY, 1999, ONCOGENE, V18, P6029, DOI 10.1038/sj.onc.1202983; Bin OY, 1997, J BIOL CHEM, V272, P28646, DOI 10.1074/jbc.272.45.28646; Boveri T., 1914, FRAGE ENTSTEHUNG MAL; Burns TF, 2003, MOL CELL BIOL, V23, P5556, DOI 10.1128/MCB.23.16.5556-5571.2003; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Carmena M, 1998, J CELL BIOL, V143, P659, DOI 10.1083/jcb.143.3.659; Cheng KY, 2003, EMBO J, V22, P5757, DOI 10.1093/emboj/cdg558; CLAY FJ, 1993, P NATL ACAD SCI USA, V90, P4882, DOI 10.1073/pnas.90.11.4882; Cogswell JP, 2000, CELL GROWTH DIFFER, V11, P615; Conn CW, 2000, CANCER RES, V60, P6826; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Dai W, 2002, ONCOGENE, V21, P6195, DOI 10.1038/sj.onc.1205710; Dai W, 2002, INT J ONCOL, V20, P121; Dai W, 2000, GENE CHROMOSOME CANC, V27, P332, DOI 10.1002/(SICI)1098-2264(200003)27:3<332::AID-GCC15>3.0.CO;2-K; Dai Wei, 2003, Prog Cell Cycle Res, V5, P327; de Carcer G, 2001, EMBO J, V20, P2878, DOI 10.1093/emboj/20.11.2878; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; Donaldson MM, 2001, J CELL BIOL, V153, P663, DOI 10.1083/jcb.153.4.663; Elez R, 2000, BIOCHEM BIOPH RES CO, V269, P352, DOI 10.1006/bbrc.2000.2291; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; FODE C, 1994, P NATL ACAD SCI USA, V91, P6388, DOI 10.1073/pnas.91.14.6388; Gatei M, 2003, J BIOL CHEM, V278, P14806, DOI 10.1074/jbc.M210862200; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; Gray PJ, 2004, MOL CANCER THER, V3, P641; Gunawardena RW, 2004, J BIOL CHEM, V279, P29278, DOI 10.1074/jbc.M400395200; HAMANAKA R, 1994, CELL GROWTH DIFFER, V5, P249; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Holtrich U, 2000, ONCOGENE, V19, P4832, DOI 10.1038/sj.onc.1203845; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; Hudson JW, 2001, CURR BIOL, V11, P441, DOI 10.1016/S0960-9822(01)00117-8; Ito Y, 2004, BRIT J CANCER, V90, P414, DOI 10.1038/sj.bjc.6601540; Jang YJ, 2002, J BIOL CHEM, V277, P44115, DOI 10.1074/jbc.M202172200; Karn T, 1997, ONCOL REP, V4, P505; Kauselmann G, 1999, EMBO J, V18, P5528, DOI 10.1093/emboj/18.20.5528; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Knecht R, 1999, CANCER RES, V59, P2794; Knecht R, 2000, INT J CANCER, V89, P535; Kneisel L, 2002, J CUTAN PATHOL, V29, P354, DOI 10.1034/j.1600-0560.2002.290605.x; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; LAKE RJ, 1993, MOL CELL BIOL, V13, P7793, DOI 10.1128/MCB.13.12.7793; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Larson JS, 1997, CANCER RES, V57, P3351; LEE KS, 1995, MOL CELL BIOL, V15, P7143; Lee KS, 1998, P NATL ACAD SCI USA, V95, P9301, DOI 10.1073/pnas.95.16.9301; Lee KS, 1997, MOL CELL BIOL, V17, P3408, DOI 10.1128/MCB.17.6.3408; Lee M, 2004, ONCOGENE, V23, P865, DOI 10.1038/sj.onc.1207223; Leung GC, 2002, NAT STRUCT BIOL, V9, P719, DOI 10.1038/nsb848; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li B, 1996, J BIOL CHEM, V271, P19402, DOI 10.1074/jbc.271.32.19402; Lin HR, 2003, J BIOL CHEM, V278, P35979, DOI 10.1074/jbc.M210659200; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; Liu XQ, 2004, J CELL SCI, V117, P3233, DOI 10.1242/jcs.01173; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; Ma S, 2003, MOL CELL BIOL, V23, P6936, DOI 10.1128/MCB.23.19.6936-6943.2003; Ma S, 2003, MOL CANCER RES, V1, P376; Macmillan JC, 2001, ANN SURG ONCOL, V8, P729, DOI 10.1245/aso.2001.8.9.729; Marmorstein LY, 2001, CELL, V104, P247, DOI 10.1016/S0092-8674(01)00209-4; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Mundt KE, 1997, BIOCHEM BIOPH RES CO, V239, P377, DOI 10.1006/bbrc.1997.7378; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Neef R, 2003, J CELL BIOL, V162, P863, DOI 10.1083/jcb.200306009; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Ree AH, 2003, ONCOGENE, V22, P8952, DOI 10.1038/sj.onc.1207000; Roshak AK, 2000, CELL SIGNAL, V12, P405, DOI 10.1016/S0898-6568(00)00080-2; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; SCHILD D, 1980, GENETICS, V96, P859; Seong YS, 2002, J BIOL CHEM, V277, P32282, DOI 10.1074/jbc.M202602200; Shimizu-Yoshida Y, 2001, BIOCHEM BIOPH RES CO, V289, P491, DOI 10.1006/bbrc.2001.5993; Simizu S, 2000, NAT CELL BIOL, V2, P852, DOI 10.1038/35041102; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Spankuch B, 2004, JNCI-J NATL CANCER I, V96, P862, DOI 10.1093/jnci/djh146; Spankuch-Schmitt B, 2002, JNCI-J NATL CANCER I, V94, P1863, DOI 10.1093/jnci/94.24.1863; Spankuch-Schmitt B, 2002, ONCOGENE, V21, P3162, DOI 10.1038/sj.onc.1205412; Strebhardt K, 2000, JAMA-J AM MED ASSOC, V283, P479, DOI 10.1001/jama.283.4.479; Sumara I, 2002, MOL CELL, V9, P515, DOI 10.1016/S1097-2765(02)00473-2; SUNKEL CE, 1988, J CELL SCI, V89, P25; Takahashi T, 2003, CANCER SCI, V94, P148, DOI 10.1111/j.1349-7006.2003.tb01411.x; Takai N, 2001, CANCER LETT, V169, P41, DOI 10.1016/S0304-3835(01)00522-5; Takai N, 2001, CANCER LETT, V164, P41, DOI 10.1016/S0304-3835(00)00703-5; Tokumitsu Y, 1999, INT J ONCOL, V15, P687; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; Tsvetkov L, 2003, J BIOL CHEM, V278, P8468, DOI 10.1074/jbc.M211202200; van Vugt MATM, 2001, J BIOL CHEM, V276, P41656, DOI 10.1074/jbc.M101831200; van Vugt MATM, 2004, J BIOL CHEM, V279, P36841, DOI 10.1074/jbc.M313681200; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Wang Q, 2002, MOL CELL BIOL, V22, P3450, DOI 10.1128/MCB.22.10.3450-3459.2002; Warnke S, 2004, CURR BIOL, V14, P1200, DOI 10.1016/j.cub.2004.06.059; Weichert W, 2004, BRIT J CANCER, V90, P815, DOI 10.1038/sj.bjc.6601610; Weichert W, 2004, PROSTATE, V60, P240, DOI 10.1002/pros.20050; Wiest J, 2001, GENE CHROMOSOME CANC, V32, P384, DOI 10.1002/gcc.1204; Wolf G, 2000, PATHOL RES PRACT, V196, P753, DOI 10.1016/S0344-0338(00)80107-7; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862; Xie SQ, 2001, J BIOL CHEM, V276, P43305, DOI 10.1074/jbc.M106050200; Xie SQ, 2002, CELL CYCLE, V1, P424, DOI 10.4161/cc.1.6.271; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Yuan JH, 2004, MOL CANCER RES, V2, P417; Yuan JP, 2002, CANCER RES, V62, P4186; Yuan JP, 2002, ONCOGENE, V21, P8282, DOI 10.1038/sj.onc.1206011; Yuan JP, 1997, AM J PATHOL, V150, P1165; Yuan JP, 2004, ONCOGENE, V23, P5843, DOI 10.1038/sj.onc.1207757; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou T, 2003, DEV CELL, V5, P127, DOI 10.1016/S1534-5807(03)00186-2	116	314	328	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2005	24	2					267	276		10.1038/sj.onc.1208273	http://dx.doi.org/10.1038/sj.onc.1208273			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	885UR	15640842				2022-12-17	WOS:000226183100007
J	Davidson, AJ; Zon, LI				Davidson, AJ; Zon, LI			The 'definitive' (and 'primitive') guide to zebrafish hematopoiesis	ONCOGENE			English	Review						zebrafish; blood; hematopoietic stem cell; embryo; leukemia; hematopoiesis	HOMEOBOX GENE CDX2; T-CELL LEUKEMIA; IN-VIVO; EXPRESSION PATTERN; POSITIONAL CLONING; EARLY MACROPHAGES; BINDING-PROTEIN; TAIL MESODERM; BLOOD; MODEL	Progressive advances using zebrafish as a model organism have provided hematologists with an additional genetic system to study blood cell formation and hematological malignancies. Despite extensive evolutionary divergence between bony fish (teleosts) and mammals, the molecular pathways governing hematopoiesis have been highly conserved. As a result, most (if not all) of the critical hematopoietic transcription factor genes identified in mammals have orthologues in zebrafish. As in other vertebrates, all of the teleost blood lineages are believed to originate from a pool of pluripotent, self-renewing hematopoietic stem cells. Here, we provide a detailed review of the timing, anatomical location, and transcriptional regulation of zebrafish 'primitive' and 'definitive' hematopoiesis as well as discuss a model of T-cell leukemia and recent advances in blood cell transplantation. Given that many of the regulatory genes that control embryonic hematopoiesis have been implicated in oncogenic pathways in adults, an understanding of blood cell ontogeny is likely to provide insights into the pathophysiology of human leukemias.	Childrens Hosp, Div Hematol Oncol, Dept Med, Boston, MA 02115 USA; Howard Hughes Med Inst, Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Howard Hughes Medical Institute	Zon, LI (corresponding author), Childrens Hosp, Div Hematol Oncol, Dept Med, KARP7,1 Blackfan Circle, Boston, MA 02115 USA.	zon@enders.tch.harvard.edu						ALADHAMI MA, 1976, ROUX ARCH DEV BIOL, V179, P393, DOI 10.1007/BF00848245; ALADHAMI MA, 1977, DEV GROWTH DIFFER, V19, P171; Amacher SL, 2002, DEVELOPMENT, V129, P3311; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; Bennett CM, 2001, BLOOD, V98, P643, DOI 10.1182/blood.V98.3.643; Bouchard M, 2002, GENE DEV, V16, P2958, DOI 10.1101/gad.240102; BRECHER G, 1993, P NATL ACAD SCI USA, V90, P6028, DOI 10.1073/pnas.90.13.6028; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; Brown LA, 2000, MECH DEVELOP, V90, P237, DOI 10.1016/S0925-4773(99)00256-7; Brownlie A, 2003, DEV BIOL, V255, P48, DOI 10.1016/S0012-1606(02)00041-6; Brownlie A, 1998, NAT GENET, V20, P244, DOI 10.1038/3049; Burns CE, 2002, EXP HEMATOL, V30, P1381, DOI 10.1016/S0301-472X(02)00955-4; CATTON WT, 1951, BLOOD, V6, P39, DOI 10.1182/blood.V6.1.39.39; Chase A, 1999, BLOOD, V93, P1025, DOI 10.1182/blood.V93.3.1025.403a20_1025_1031; CHEN XD, 1995, J IMMUNOL, V154, P2557; Childs S, 2000, CURR BIOL, V10, P1001, DOI 10.1016/S0960-9822(00)00653-9; Cumano A, 1996, CELL, V86, P907, DOI 10.1016/S0092-8674(00)80166-X; Danilova N, 2002, P NATL ACAD SCI USA, V99, P13711, DOI 10.1073/pnas.212515999; Davidson AJ, 2003, NATURE, V425, P300, DOI 10.1038/nature01973; DETRICH HW, 1995, P NATL ACAD SCI USA, V92, P10713, DOI 10.1073/pnas.92.23.10713; DIETERLENLIEVRE F, 2001, HEMATOPOIESIS DEV AP; Donovan A, 2000, NATURE, V403, P776, DOI 10.1038/35001596; DOOLEY KA, 2004, IN PRESS DEV BIOL; Favier B, 1997, MOL HUM REPROD, V3, P115, DOI 10.1093/molehr/3.2.115; Fisher RC, 2004, LEUKEMIA RES, V28, P83, DOI 10.1016/S0145-2126(03)00178-4; Galloway JL, 2003, CURR TOP DEV BIOL, V53, P139, DOI 10.1016/S0070-2153(03)53004-6; Gering M, 2003, DEVELOPMENT, V130, P6187, DOI 10.1242/dev.00875; Gering M, 1998, EMBO J, V17, P4029, DOI 10.1093/emboj/17.14.4029; Gregory M, 2002, BLOOD CELL MOL DIS, V28, P418, DOI 10.1006/bcmd.2002.0527; Griffin KJP, 1998, DEVELOPMENT, V125, P3379; Haffter P, 1996, DEVELOPMENT, V123, P1; Hammerschmidt M, 1996, DEVELOPMENT, V123, P143; Harshbarger JC, 2001, MAR BIOTECHNOL, V3, pS115; HAWKINS WE, 1985, J APPL TOXICOL, V5, P261, DOI 10.1002/jat.2550050408; Herbomel P, 1999, DEVELOPMENT, V126, P3735; Herbomel P, 2001, DEV BIOL, V238, P274, DOI 10.1006/dbio.2001.0393; Hill DJ, 1996, BRIT J HAEMATOL, V92, P200, DOI 10.1046/j.1365-2141.1996.280814.x; Jagadeeswaran P, 1999, BRIT J HAEMATOL, V107, P731, DOI 10.1046/j.1365-2141.1999.01763.x; Jessen JR, 1998, P NATL ACAD SCI USA, V95, P5121, DOI 10.1073/pnas.95.9.5121; Jessen JR, 2001, GENESIS, V29, P156, DOI 10.1002/gene.1019; Kalev-Zylinska ML, 2003, DEV DYNAM, V228, P323, DOI 10.1002/dvdy.10388; Kalev-Zylinska ML, 2002, DEVELOPMENT, V129, P2015; KIMMEL CB, 1990, DEVELOPMENT, V108, P581; KIMMEL CB, 1989, NATURE, V337, P358, DOI 10.1038/337358a0; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Lam SH, 2002, DEV DYNAM, V225, P87, DOI 10.1002/dvdy.10127; Lane MC, 2002, DEV DYNAM, V225, P434, DOI 10.1002/dvdy.10182; Lane MC, 2000, DEV BIOL, V225, P37, DOI 10.1006/dbio.2000.9803; Langenau DM, 2004, P NATL ACAD SCI USA, V101, P7369, DOI 10.1073/pnas.0402248101; Langenau DM, 2003, SCIENCE, V299, P887, DOI 10.1126/science.1080280; Liao EC, 1998, GENE DEV, V12, P621, DOI 10.1101/gad.12.5.621; Liao EC, 2002, DEVELOPMENT, V129, P649; Liao EC, 2000, DEVELOPMENT, V127, P5123; Liao W, 1997, DEVELOPMENT, V124, P381; Liao W, 2000, DEVELOPMENT, V127, P4303; Lieschke GJ, 2002, DEV BIOL, V246, P274, DOI 10.1006/dbio.2002.0657; Lieschke GJ, 2001, BLOOD, V98, P3087, DOI 10.1182/blood.V98.10.3087; Lin HF, 2001, BLOOD, V98, p514A; Lin HF, 2000, BLOOD, V96, p36A; Liu F, 2002, MECH DEVELOP, V113, P69, DOI 10.1016/S0925-4773(01)00658-X; LLOYDEVANS P, 1994, BBA-LIPID LIPID MET, V1215, P291, DOI 10.1016/0005-2760(94)90056-6; Lohnes D, 2003, BIOESSAYS, V25, P971, DOI 10.1002/bies.10340; Long QM, 1997, DEVELOPMENT, V124, P4105; Lyons SE, 2002, P NATL ACAD SCI USA, V99, P5454, DOI 10.1073/pnas.082695299; Lyons SE, 2001, BLOOD, V97, P2611, DOI 10.1182/blood.V97.9.2611; Majumdar A, 2000, DEVELOPMENT, V127, P2089; MESEGUER J, 1991, ARCH HISTOL CYTOL, V54, P299, DOI 10.1679/aohc.54.299; Munoz-Sanjuan I, 2001, DEV BIOL, V237, P1, DOI 10.1006/dbio.2001.0350; Nishikawa K, 2003, MOL CELL BIOL, V23, P8295, DOI 10.1128/MCB.23.22.8295-8305.2003; Oates AC, 1999, BLOOD, V94, P2622, DOI 10.1182/blood.V94.8.2622.420k39_2622_2636; Oates AC, 2001, BLOOD, V98, P1792, DOI 10.1182/blood.V98.6.1792; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Owens BM, 2002, STEM CELLS, V20, P364, DOI 10.1634/stemcells.20-5-364; Parker L, 1999, DEVELOPMENT, V126, P2643; Paw BH, 2003, NAT GENET, V34, P59, DOI 10.1038/ng1137; Pfeffer PL, 1998, DEVELOPMENT, V125, P3063; Pratt SJ, 2002, PHYSIOL GENOMICS, V11, P91, DOI 10.1152/physiolgenomics.00112.2001; Ransom DG, 1996, DEVELOPMENT, V123, P311; RANSOM DG, 2004, IN PRESS PLOS BIOL; Rawat VPS, 2004, P NATL ACAD SCI USA, V101, P817, DOI 10.1073/pnas.0305555101; RIEB J-P, 1973, Annales d'Embryologie et de Morphogenese, V6, P43; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; Ruvinsky I, 1998, DEV GENES EVOL, V208, P94, DOI 10.1007/s004270050158; Schorpp M, 2002, MECH DEVELOP, V118, P179, DOI 10.1016/S0925-4773(02)00241-1; Shafizadeh E, 2002, DEVELOPMENT, V129, P4359; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; STAINIER DYR, 1995, DEVELOPMENT, V121, P3141; STANTON MF, 1965, JNCI-J NATL CANCER I, V34, P117, DOI 10.1093/jnci/34.1.117; Stern HM, 2003, NAT REV CANCER, V3, P533, DOI 10.1038/nrc1126; Stockard CR, 1915, AM J ANAT, V18, P227, DOI 10.1002/aja.1000180205; Sumoy L, 1997, MECH DEVELOP, V63, P15, DOI 10.1016/S0925-4773(97)00671-0; Tavian M, 1996, BLOOD, V87, P67, DOI 10.1182/blood.V87.1.67.bloodjournal87167; Thompson MA, 1998, DEV BIOL, V197, P248, DOI 10.1006/dbio.1998.8887; Toyama R, 1998, MECH DEVELOP, V71, P197, DOI 10.1016/S0925-4773(97)00202-5; Traver D, 2003, NAT IMMUNOL, V4, P1238, DOI 10.1038/ni1007; TRAVER D, 2004, IN PRESS BLOOD; Traver D, 2003, ADV IMMUNOL, V81, P253; Trede NS, 2001, TRENDS IMMUNOL, V22, P302, DOI 10.1016/S1471-4906(01)01939-1; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Walmsley M, 2002, DEVELOPMENT, V129, P5683, DOI 10.1242/dev.00169; Wang H, 1998, NAT GENET, V20, P239, DOI 10.1038/3041; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Ward AC, 2003, BLOOD, V102, P3238, DOI 10.1182/blood-2003-03-0966; Warga RM, 1999, DEVELOPMENT, V126, P827; Weinstein BM, 1996, DEVELOPMENT, V123, P303; Wellbrock C, 2002, MICROSC RES TECHNIQ, V58, P456, DOI 10.1002/jemt.10163; Wienholds E, 2002, SCIENCE, V297, P99, DOI 10.1126/science.1071762; Willett CE, 1999, DEV DYNAM, V214, P323, DOI 10.1002/(SICI)1097-0177(199904)214:4<323::AID-AJA5>3.0.CO;2-3; Willett CE, 1997, IMMUNOGENETICS, V45, P394, DOI 10.1007/s002510050221; Willett CE, 2001, DEV DYNAM, V222, P694, DOI 10.1002/dvdy.1223; WINGERT RA, 2003, HEMATOPOIETIC STEM C; YODER MC, 2001, HEMATOPOIESIS DEV AP; ZAPATA A, 1979, DEV COMP IMMUNOL, V3, P55, DOI 10.1016/S0145-305X(79)80006-3	115	314	339	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2004	23	43					7233	7246		10.1038/sj.onc.1207943	http://dx.doi.org/10.1038/sj.onc.1207943			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	855TZ	15378083				2022-12-17	WOS:000223998800009
J	Wu, H; Goel, V; Haluska, FG				Wu, H; Goel, V; Haluska, FG			PTEN signaling pathways in melanoma	ONCOGENE			English	Article						PTEN; melanoma; signaling	CELL-CYCLE ARREST; TUMOR-SUPPRESSOR GENE; PRIMARY CUTANEOUS MELANOMA; ENDOMETRIAL CANCER-CELLS; MALIGNANT-MELANOMA; PTEN/MMAC1 GENE; PROSTATE-CANCER; PHOSPHATASE-ACTIVITY; COWDEN-DISEASE; ALLELIC LOSS	Phosphatase and tensin homolog deleted in from chromosome ten (PTEN), initially also known as mutated in multiple advanced cancers or TGF-beta-regulated and epithelia cell-enriched phosphatase, is a tumor suppressor gene that is mutated in a large fraction of human melanomas. A broad variety of human cancers carry PTEN alterations, including glioblastomas, endometrial, breast, thyroid and prostate cancers. The PTEN protein has at least two biochemical functions: it has both lipid phosphatase and protein phosphatase activity. The lipid phosphatase activity of PTEN decreases intracellutar PtdIns(3,4,5)P-3 level and downstream Akt activity. Cell-cycle progression is arrested at G1/S, mediated at least partially through the upregutation of the cyclin-dependent kinase inhibitor p27. In addition, agonist-induced apoptosis is mediated by PTEN, through the upregulation of proapoptotic machinery involving caspases and BID, and the downregulation of antiapoptotic proteins such as Bcl2. The protein phosphatase activity of PTEN is apparently less central to its involvement in tumorigenesis. It is involved in the inhibition of focal adhesion formation, cell spreading and migration, as well as the inhibition of growth factor-stimulated MAPK signaling. Therefore, the combined effects of the loss of PTEN lipid and protein phosphatase activity may result in aberrant cell growth and escape from apoptosis, as well as abnormal cell spreading and migration. In melanoma, PTEN loss has been mostly observed as a late event, although a dose-dependent loss of PTEN protein and function has been implicated in early stages of tumorigenesis as well. In addition, loss of PTEN and oncogenic activation of RAS seem to occur in a reciprocal fashion, both of which could cooperate with CDKN2A loss in contribution to melanoma tumorigenesis.	Massachusetts Gen Hosp, Dept Hematol Oncol, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Haluska, FG (corresponding author), Massachusetts Gen Hosp, Dept Hematol Oncol, GRJ1021,55 Fruit St, Boston, MA 02114 USA.	haluska.frank@mgh.harvard.edu						Adachi J, 1999, J NEUROSURG, V91, P822, DOI 10.3171/jns.1999.91.5.0822; Birck A, 2000, J INVEST DERMATOL, V114, P277, DOI 10.1046/j.1523-1747.2000.00877.x; Boni R, 1998, MELANOMA RES, V8, P300; Bonneau D, 2000, HUM MUTAT, V16, P109, DOI 10.1002/1098-1004(200008)16:2<109::AID-HUMU3>3.0.CO;2-0; Bruni P, 2000, ONCOGENE, V19, P3146, DOI 10.1038/sj.onc.1203633; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Celebi JT, 2000, J MED GENET, V37, P653, DOI 10.1136/jmg.37.9.653; Cheyney IW, 1999, CANCER RES, V59, P2318; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; Dahia PLM, 1997, CANCER RES, V57, P4710; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Flores JF, 1996, CANCER RES, V56, P5023; FOUNTAIN JW, 1990, CANCER SURV, V9, P645; FUJITA N, 2002, J BIOL CHEM, V31, P31; FULTS D, 1993, GENE CHROMOSOME CANC, V7, P173, DOI 10.1002/gcc.2870070311; Ghosh AK, 1999, GENE, V235, P85, DOI 10.1016/S0378-1119(99)00206-1; Gimm O, 2000, AM J PATHOL, V156, P1693, DOI 10.1016/S0002-9440(10)65040-7; Gottschalk AR, 2001, CANCER RES, V61, P2105; Gu JG, 1998, J CELL BIOL, V143, P1375, DOI 10.1083/jcb.143.5.1375; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Guldberg P, 1997, CANCER RES, V57, P3660; Haluska FG, 1998, J CLIN ONCOL, V16, P670, DOI 10.1200/JCO.1998.16.2.670; HEALY E, 1995, GENE CHROMOSOME CANC, V12, P152, DOI 10.1002/gcc.2870120211; Herbst RA, 1999, ARCH DERMATOL RES, V291, P567, DOI 10.1007/s004030050456; HERBST RA, 1994, CANCER RES, V54, P3111; Huang H, 2001, J BIOL CHEM, V276, P38830, DOI 10.1074/jbc.M103632200; Hwang PH, 2001, CANCER LETT, V172, P83, DOI 10.1016/S0304-3835(01)00632-2; Ikeda T, 2000, ONCOL REP, V7, P567; ISSHIKI K, 1993, CANCER GENET CYTOGEN, V69, P108; Ittmann M, 1996, CANCER RES, V56, P2143; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; Kurose K, 1998, JPN J CANCER RES, V89, P842, DOI 10.1111/j.1349-7006.1998.tb00638.x; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Lilja JF, 2001, ANTICANCER RES, V21, P1969; LIU L, 1995, ONCOGENE, V11, P405; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Mamillapalli R, 2001, CURR BIOL, V11, P263, DOI 10.1016/S0960-9822(01)00065-3; Matsushima-Nishiu M, 2001, CANCER RES, V61, P3741; MOELLING K, 2002, J BIOL CHEM, V4, P4; Mograbi B, 2001, J BIOL CHEM, V276, P45307, DOI 10.1074/jbc.M101220200; Mohiuddin I, 2002, ANN SURG ONCOL, V9, P310, DOI 10.1007/BF02573071; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Nelen MR, 1997, HUM MOL GENET, V6, P1383, DOI 10.1093/hmg/6.8.1383; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; PARMITER AH, 1988, CANCER GENET CYTOGEN, V30, P313, DOI 10.1016/0165-4608(88)90200-2; Penninger JM, 2001, SCIENCE, V294, P2116, DOI 10.1126/science.1067931; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Poetsch M, 2002, CANCER GENET CYTOGEN, V132, P20, DOI 10.1016/S0165-4608(01)00509-X; Poetsch M, 2001, CANCER GENET CYTOGEN, V125, P21, DOI 10.1016/S0165-4608(00)00353-8; Pollock PM, 2000, CLIN LAB MED, V20, P667; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Reifenberger J, 2000, VIRCHOWS ARCH, V436, P487, DOI 10.1007/s004280050477; Robertson GP, 1998, P NATL ACAD SCI USA, V95, P9418, DOI 10.1073/pnas.95.16.9418; Saida T, 2001, J DERMATOL SCI, V26, P1, DOI 10.1016/S0923-1811(01)00085-8; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Tashiro H, 1997, CANCER RES, V57, P3935; Teng DHF, 1997, CANCER RES, V57, P5221; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Tsao H, 2000, CANCER RES, V60, P1800; Tsao HS, 1998, ONCOGENE, V16, P3397, DOI 10.1038/sj.onc.1201881; Vazquez F, 2000, BBA-REV CANCER, V1470, pM21, DOI 10.1016/S0304-419X(99)00032-3; Weng LP, 1999, CANCER RES, V59, P5808; Weng LP, 2001, HUM MOL GENET, V10, P251, DOI 10.1093/hmg/10.3.251; Weng LP, 2001, HUM MOL GENET, V10, P237, DOI 10.1093/hmg/10.3.237; Weng LP, 2001, HUM MOL GENET, V10, P599, DOI 10.1093/hmg/10.6.599; Weng LP, 2001, HUM MOL GENET, V10, P605, DOI 10.1093/hmg/10.6.605; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Whiteman DC, 2002, INT J CANCER, V99, P63, DOI 10.1002/ijc.10294; Wu RC, 2000, MOL CELL BIOCHEM, V203, P59, DOI 10.1023/A:1007024624967; Yamada KM, 2001, J CELL SCI, V114, P2375; You MJ, 2002, P NATL ACAD SCI USA, V99, P1455, DOI 10.1073/pnas.022632099; Yuan XJ, 2002, ONCOGENE, V21, P319, DOI 10.1038/sj/onc/1205054; Yuvaniyama J, 1996, SCIENCE, V272, P1328, DOI 10.1126/science.272.5266.1328; Zhou XP, 2000, AM J PATHOL, V157, P1123, DOI 10.1016/S0002-9440(10)64627-5; Zhu XY, 2001, CANCER RES, V61, P4569	85	314	335	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2003	22	20					3113	3122		10.1038/sj.onc.1206451	http://dx.doi.org/10.1038/sj.onc.1206451			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	682MV	12789288				2022-12-17	WOS:000183096600013
J	Pietras, RJ; Pegram, MD; Finn, RS; Maneval, DA; Slamon, DJ				Pietras, RJ; Pegram, MD; Finn, RS; Maneval, DA; Slamon, DJ			Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs	ONCOGENE			English	Article						breast cancer; ovarian cancer; monoclonal antibody; HER-2/neu; cisplatin; doxorubicin	GROWTH-FACTOR RECEPTOR; NEU DIFFERENTIATION FACTOR; MAMMARY EPITHELIAL-CELLS; OVARIAN-CARCINOMA CELLS; INTERSTRAND CROSS-LINKS; PROTEIN-KINASE-C; TYROSINE KINASE; TUMOR-CELLS; C-ERBB-2 EXPRESSION; SIGNAL-TRANSDUCTION	HER-2 oncogene encodes a transmembrane growth factor receptor that is overexpressed in 25-30% of patients with primary breast and ovarian cancer, A murine monoclonal antibody, 4D5, to the extracellular domain of HER-2 receptor elicits cytostatic growth inhibition of tumor cells overexpressing HER-2 protein, but clinical use of this antibody is limited by genesis of human anti-mouse antibodies, To avoid this problem, a recombinant humanized 4D5 monoclonal antibody (rhuMAb HER-2) was developed and tested using a human tumor xenograft model, Human breast and ovarian cancer cells which overexpress HER-2 were inhibited in vivo by the rhuMAb HER-2 antibody, Tumor growth relative to control was reduced at all doses of antibody tested, and the magnitude of growth inhibition was directly related to dose of rhuMAb HER-2, Tumor growth resumed on termination of antibody therapy, indicating a cytostatic effect, To elicit a cytotoxic response, human breast tumor xenografts were treated with a combination of antibody and antitumor drugs, cisplatin or doxorubicin, The combination of antibody with either cisplatin or doxorubicin resulted in significantly greater growth inhibition, with the cisplatin combination demonstrating a greater response, In addition, therapy with cisplatin and antireceptor antibody elicited complete tumor remissions after 2-3 cycles of therapy, The schedule of administration of antireceptor antibody and cisplatin was critical for occurrence of antibody-induced potentiation in cisplatin cytotoxicity. Enhanced killing of tumor cells was found only if antibody and drug were given in close temporal proximity, Since interference with DNA repair pathways may contribute to this receptor-enhanced chemosensitivity, repair of cisplatin-damaged reporter DNA (pCMV-beta) was determined in human breast cells, As in studies of antibody-enhanced cisplatin cytotoxicity in vivo, treatment with rhuMAb HER-2 blocked the repair of cisplatin-damaged DNA. only if the antibody was administered in close temporal proximity to transfection of the drug-exposed reporter DNA, An alternative measure of DNA repair, unscheduled DNA synthesis, was also assessed, Treatment with either cisplatin or doxorubicin led to an increase in unscheduled DNA synthesis that was reduced by combined therapy with antireceptor antibody specific to HER-2-overexpressing breast cancer cells, Using a direct measure of DNA repair, therapy of HER-2-overexpressing cells with rhuMAb HER-2 also blocked the removal of cisplatin-induced DNA adducts. Expression of p21/WAF1, an important mediator of DNA repair, was disrupted in breast cancer cells with HER-2 overexpression, but not in control cells, after treatment with HER-2 antibody, thus suggesting cross-communication between the HER-2 signaling and DNA repair pathways, These data demonstrate an in vivo antiproliferative effect of rhuMAb HER-2 on tumors that overexpress HER-2 receptor and a therapeutic advantage in the administration of the antireceptor antibody in combination with chemotherapeutic agents.	Univ Calif Los Angeles, Sch Med, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA; Genentech Inc, San Francisco, CA 90078 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Roche Holding; Genentech	Slamon, DJ (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA.			Pietras, Richard/0000-0002-2846-3192	NCI NIH HHS [P01-CA32737, R01-CA60835, R01-CA36827] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA032737, R01CA036827] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ABOUDPIRAK E, 1989, P NATL ACAD SCI USA, V86, P3778, DOI 10.1073/pnas.86.10.3778; ABOUDPIRAK E, 1988, J NATL CANCER I, V80, P1605, DOI 10.1093/jnci/80.20.1605; ALLRED DC, 1992, J CLIN ONCOL, V10, P599, DOI 10.1200/JCO.1992.10.4.599; ANDREWS PA, 1988, CANCER RES, V48, P68; ARTEAGA CL, 1994, CANCER RES, V54, P3758; Bacus SS, 1996, ONCOGENE, V12, P2535; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BENZ CC, 1993, BREAST CANCER RES TR, V24, P85; BERENBAUM MC, 1989, PHARMACOL REV, V41, P93; Boven E, 1996, EUR J CANCER, V32A, P1382, DOI 10.1016/0959-8049(96)00110-4; CAMPBELL RC, 1976, STAT BIOL; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; CHAZIN VR, 1992, ONCOGENE, V7, P1859; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; CHRISTEN RD, 1990, J CLIN INVEST, V86, P1632, DOI 10.1172/JCI114885; CHU G, 1994, J BIOL CHEM, V269, P787; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; Cutts SM, 1996, J BIOL CHEM, V271, P5422, DOI 10.1074/jbc.271.10.5422; DESANTES K, 1992, CANCER RES, V52, P1916; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Dixit M, 1997, J NATL CANCER I, V89, P365, DOI 10.1093/jnci/89.5.365; DREBIN JA, 1988, ONCOGENE, V2, P387; ELDIERY WS, 1993, CELL, V75, P817; FENDLY BM, 1990, CANCER RES, V50, P1550; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; HANCOCK MC, 1991, CANCER RES, V51, P4575; HARRIS JR, 1992, NEW ENGL J MED, V327, P473, DOI 10.1056/NEJM199208133270706; HOFMANN J, 1988, INT J CANCER, V42, P382, DOI 10.1002/ijc.2910420313; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; ISONISHI S, 1991, CANCER RES, V51, P5903; ISONISHI S, 1990, J BIOL CHEM, V265, P3623; JENSEN L, 1988, MOL CELL BIOL, V8, P3964, DOI 10.1128/MCB.8.9.3964; JONES JC, 1991, J BIOL CHEM, V266, P7101; KASTAN MB, 1991, CANCER RES, V51, P6304; KINZEL V, 1990, CANCER RES, V50, P7932; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; Kurbacher CM, 1996, CANCER LETT, V103, P183, DOI 10.1016/0304-3835(96)04212-7; LEMOINE NR, 1990, ONCOGENE, V5, P237; Lewis GD, 1996, CANCER RES, V56, P1457; Liu Y, 1996, CANCER RES, V56, P31; Lofts F J, 1992, Cancer Treat Res, V61, P161; MANEVAL DC, 1991, J NUCL MED, V32, P1837; MARTE BM, 1995, ONCOGENE, V10, P167; McDonald E, 1996, CANCER RES, V56, P2250; Mendelsohn J, 1997, J NATL CANCER I, V89, P341, DOI 10.1093/jnci/89.5.341; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; Nielsen D, 1996, GEN PHARMACOL-VASC S, V27, P251, DOI 10.1016/0306-3623(95)02013-6; OLSON EN, 1993, CELL GROWTH DIFFER, V4, P699; Pauletti G, 1996, ONCOGENE, V13, P63; PEGRAM M, 1995, P AN M AM SOC CLIN, V14, P106; Pegram MD, 1997, ONCOGENE, V15, P537, DOI 10.1038/sj.onc.1201222; PIERCE JH, 1991, ONCOGENE, V6, P1189; PIETRAS RJ, 1994, ONCOGENE, V9, P1829; PRESS MF, 1993, CANCER RES, V53, P4960; PRESS MF, 1990, ONCOGENE, V5, P953; PUREWAL M, 1993, CANCER CHEMOTH PHARM, V33, P239, DOI 10.1007/BF00686222; Reese DM, 1997, STEM CELLS, V15, P1, DOI 10.1002/stem.150001; RO J, 1989, CANCER RES, V49, P6941; SARUP JC, 1991, GROWTH REGULAT, V1, P72; SAWYER TW, 1988, CARCINOGENESIS, V9, P1197, DOI 10.1093/carcin/9.7.1197; SCANLON KJ, 1989, ANTICANCER RES, V9, P1301; SCOTT GK, 1991, J BIOL CHEM, V266, P14300; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6479; SESHADRI R, 1993, J CLIN ONCOL, V11, P1936, DOI 10.1200/JCO.1993.11.10.1936; SHEPARD HM, 1991, J CLIN IMMUNOL, V11, P117, DOI 10.1007/BF00918679; SLAMON DJ, 1989, CANCER CEL, V7, P371; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SORENSON CM, 1990, JNCI-J NATL CANCER I, V82, P749, DOI 10.1093/jnci/82.9.749; SOULE HD, 1980, CANCER LETT, V10, P177, DOI 10.1016/0304-3835(80)90042-7; Tsai CM, 1996, CANCER RES, V56, P1068; TSAI CM, 1993, J NATL CANCER I, V85, P897, DOI 10.1093/jnci/85.11.897; VANDIEST PJ, 1992, PATHOL RES PRACT, V188, P344, DOI 10.1016/S0344-0338(11)81215-X; WAMPLER GL, 1992, CANCER CHEMOTH PHARM, V31, P111, DOI 10.1007/BF00685096; Wu GS, 1996, CLIN CANCER RES, V2, P623; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; Yen L, 1997, ONCOGENE, V14, P1827, DOI 10.1038/sj.onc.1201019; Zhang LS, 1996, ONCOGENE, V12, P571; ZHEN WP, 1992, MOL CELL BIOL, V12, P3689, DOI 10.1128/MCB.12.9.3689	85	314	349	1	20	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 29	1998	17	17					2235	2249		10.1038/sj.onc.1202132	http://dx.doi.org/10.1038/sj.onc.1202132			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	133QX	9811454				2022-12-17	WOS:000076698200009
J	TENDIJKE, P; ICHIJO, H; FRANZEN, P; SCHULZ, P; SARAS, J; TOYOSHIMA, H; HELDIN, CH; MIYAZONO, K				TENDIJKE, P; ICHIJO, H; FRANZEN, P; SCHULZ, P; SARAS, J; TOYOSHIMA, H; HELDIN, CH; MIYAZONO, K			ACTIVIN RECEPTOR-LIKE KINASES - A NOVEL SUBCLASS OF CELL-SURFACE RECEPTORS WITH PREDICTED SERINE THREONINE KINASE-ACTIVITY	ONCOGENE			English	Note								Human cDNA clones encoding four novel putative transmembrane protein serine/threonine kinases, denoted activin receptor-like kinase (ALK) -1, -2, -3 and -4, were obtained using a polymerase chain reaction (PCR)-based strategy. The PCR primers were designed based upon the sequence similarity between the activin receptor type II and Daf-1. The cDNA clones for ALK-1, -2 and -3 encode complete proteins of 503, 509 and 532 amino acids respectively. The ALK-4 cDNA is incomplete and the predicted protein of 383 amino acids has a truncated extracellular domain. The ALKs share similar domain structures, comprising predicted signal sequences at the N-terminals, followed by hydrophilic cysteine-rich ligand-binding domains, single hydrophobic transmembrane regions and C-terminal intracellular portions that consist almost entirety of putative serine/threonine kinase domains. The ALKs have approximately 40% sequence identity to activin receptors type II and IIB, transforming growth factor-beta (TGF-beta) type II receptor and Daf-1 in the kinase domains. However, the sequence identities are higher (60-79%) between ALK-1, -2, -3 and -4, suggesting that they form a subfamily among the putative receptor serine/threonine kinases. The extracellular domains of ALKs show only tittle sequence identity to other putative receptor serine/threonine kinases, but the cysteine residues are conserved. Their structural properties suggest that ALK-1 to -4 are receptors that may bind ligands that are members of the TGF-beta super-family. The expression of mRNA in human tissues varied for the different ALKs; ALK-2 and ALK-4 showed ubiquitous tissue expression patterns, whereas the distribution of ALK-1 and ALK-3 varied strongly between different tissues with more restricted expression patterns. These results suggest that each ALK may have different in vivo functions.	UNIV TOKYO, DEPT INTERNAL MED 3, TOKYO 113, JAPAN	University of Tokyo	TENDIJKE, P (corresponding author), BIOMED CTR, LUDWIG INST CANC RES, BOX 595, S-75124 UPPSALA, SWEDEN.		Dijke, Peter ten/AAG-4660-2021	Dijke, Peter ten/0000-0002-7234-342X; Ichijo, Hidenori/0000-0002-5005-6438				ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; BOYD FT, 1989, J BIOL CHEM, V264, P2272; CATE RL, 1986, CELL, V45, P685, DOI 10.1016/0092-8674(86)90783-X; CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843; CHEIFETZ S, 1986, J BIOL CHEM, V261, P9972; CHIEFETZ S, 1992, J BIOL CHEM, V267, P19027; CHIEFETZ S, 1988, J BIOL CHEM, V263, P17225; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; DONALDSON CJ, 1992, BIOCHEM BIOPH RES CO, V184, P310, DOI 10.1016/0006-291X(92)91194-U; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; FORAGE RG, 1986, P NATL ACAD SCI USA, V83, P3091, DOI 10.1073/pnas.83.10.3091; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEIN J, 1990, METHOD ENZYMOL, V183, P626; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HINO M, 1989, J BIOL CHEM, V264, P10309; KAMB A, 1989, P NATL ACAD SCI USA, V86, P4372, DOI 10.1073/pnas.86.12.4372; KONDO M, 1991, BIOCHEM BIOPH RES CO, V181, P684, DOI 10.1016/0006-291X(91)91245-8; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LEGERSKI R, 1992, BIOCHEM BIOPH RES CO, V183, P672, DOI 10.1016/0006-291X(92)90535-S; Lin Herbert Y., 1993, Trends in Cell Biology, V3, P14, DOI 10.1016/0962-8924(93)90195-7; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LING N, 1986, NATURE, V321, P779, DOI 10.1038/321779a0; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; MASIAKOWSKI P, 1992, J BIOL CHEM, V267, P26181; MASON AJ, 1985, NATURE, V318, P659, DOI 10.1038/318659a0; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MASSAGUE J, 1985, J BIOL CHEM, V260, P2636; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MATZUK MM, 1992, BIOCHIM BIOPHYS ACTA, V1130, P105, DOI 10.1016/0167-4781(92)90472-C; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; NAKAMURA T, 1992, J BIOL CHEM, V267, P18924; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; OZKAYNAK E, 1992, J BIOL CHEM, V267, P25220; OZKAYNAK E, 1990, EMBO J, V9, P2085, DOI 10.1002/j.1460-2075.1990.tb07376.x; PARALKAR VM, 1991, P NATL ACAD SCI USA, V88, P3397, DOI 10.1073/pnas.88.8.3397; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PONCZ M, 1987, BLOOD, V69, P219; RAZ V, 1991, ONCOGENE, V6, P753; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGARINI PR, 1989, MOL ENDOCRINOL, V3, P261, DOI 10.1210/mend-3-2-261; SING GK, 1988, BLOOD, V72, P1504; VALE W, 1986, NATURE, V321, P776, DOI 10.1038/321776a0; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4863; WANG EA, 1988, P NATL ACAD SCI USA, V85, P9484, DOI 10.1073/pnas.85.24.9484; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S	60	314	347	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1993	8	10					2879	2887						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8397373				2022-12-17	WOS:A1993LX34300034
J	CROOK, T; WREDE, D; VOUSDEN, KH				CROOK, T; WREDE, D; VOUSDEN, KH			P53 POINT MUTATION IN HPV NEGATIVE HUMAN CERVICAL-CARCINOMA CELL-LINES	ONCOGENE			English	Note							HUMAN FORESKIN KERATINOCYTES; HUMAN PAPILLOMAVIRUS TYPE-16; EARLY GENES; CANCER; IMMORTALIZATION; TRANSCRIPTION; ASSOCIATION; EXPRESSION; SEQUENCES; DNAS	Clinical and experimental evidence is consistent with a key role for transforming human papilloma viruses (HPVs) in the aetiology of anogenital carcinoma. Cervical carcinoma does, however, occasionally occur in the absence of HPV sequences (Riou et al., 1990). We have used a direct cDNA/PCR sequencing protocol to analyse the sequence of p53 mRNA expressed by HPV positive and negative cervical carcinoma cell lines. Six cell lines which contain HPV sequences express p53 mRNA which has wild-type sequence throughout conserved boxes 2, 3, 4 and 5. The two HPV negative cell lines (C33a and HT3) express mutant p53 mRNA. In each case the mutation. occurs in an evolutionarily conserved amino acid. Our data suggest that loss of wild-type p53 function is important in development of cervical carcinoma, and that this might be achieved either by mutation within the p53 gene or the presence of a virally encoded p53 binding protein.	SAMARITAN HOSP WOMEN,DEPT GYNAECOL ONCOL,LONDON NW1,ENGLAND		CROOK, T (corresponding author), ST MARYS HOSP,SCH MED,LUDWIG INST CANC RES,NORFOLK PL,LONDON W2 1PG,ENGLAND.							CROOK T, 1991, J VIROL, V65, P505, DOI 10.1128/JVI.65.1.505-510.1991; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PATER MM, 1985, VIROLOGY, V145, P313, DOI 10.1016/0042-6822(85)90164-3; PECORARO G, 1989, P NATL ACAD SCI USA, V86, P563, DOI 10.1073/pnas.86.2.563; RIOU G, 1990, LANCET, V335, P1171; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; SOUSSI T, 1987, ONCOGENE, V1, P71; VOUSDEN KH, 1989, CANCER CELL-MON REV, V1, P43; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WOODWORTH CD, 1989, J VIROL, V63, P159, DOI 10.1128/JVI.63.1.159-164.1989; YEE C, 1985, AM J PATHOL, V119, P361	17	314	317	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1991	6	5					873	875						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	1646990				2022-12-17	WOS:A1991GT82500026
J	Rizzo, P; Osipo, C; Foreman, K; Golde, T; Osborne, B; Miele, L				Rizzo, P.; Osipo, C.; Foreman, K.; Golde, T.; Osborne, B.; Miele, L.			Rational targeting of Notch signaling in cancer	ONCOGENE			English	Review						Notch; cancer; targeted therapy	T-CELL LEUKEMIA; NF-KAPPA-B; GAMMA-SECRETASE INHIBITORS; ENDOTHELIAL GROWTH-FACTOR; CARCINOMA-IN-SITU; BREAST-CANCER; TUMOR-SUPPRESSOR; STRUCTURAL BASIS; DOWN-REGULATION; SELF-RENEWAL	Accumulating preclinical and clinical evidence supports a pro-oncogenic function for Notch signaling in several solid tumors, particularly but not exclusively in breast cancer. Notch inhibitory agents, such as gamma-secretase inhibitors, are being investigated as candidate cancer therapeutic agents. Interest in therapeutic modulation of the Notch pathway has been increased by recent reports, indicating that its role is important in controlling the fate of putative 'breast cancer stem cells'. However, as is the case for most targeted therapies, successful targeting of Notch signaling in cancer will require a considerable refinement of our understanding of the regulation of this pathway and its effects in both normal and cancer cells. Notch signaling has bidirectional 'cross talk' interaction with multiple other pathways that include candidate therapeutic targets. Understanding these interactions will greatly increase our ability to design rational combination regimens. To determine which patients are most likely to benefit from treatment with Notch inhibitors, it will be necessary to develop molecular tests to accurately measure pathway activity in specific tumors. Finally, mechanism-based toxicities will have to be addressed by a careful choice of therapeutic agents, combinations and regimens. This article summarizes the current state of the field, and briefly describes opportunities and challenges for Notch-targeted therapies in oncology.	[Rizzo, P.; Osipo, C.; Foreman, K.; Miele, L.] Loyola Univ, Cardinal Bernardin Canc Ctr, Breast Canc Program, Chicago, IL 60163 USA; [Golde, T.] Mayo Clin, Dept Neurol, Jacksonville, FL USA; [Osborne, B.] Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA	Loyola University Chicago; Mayo Clinic; University of Massachusetts System; University of Massachusetts Amherst	Miele, L (corresponding author), Loyola Univ, Cardinal Bernardin Canc Ctr, Breast Canc Program, 2160 S 1st Ave,Room 236, Chicago, IL 60163 USA.	lmiele@lumc.edu		rizzo, paola/0000-0001-7174-9674; Miele, Lucio/0000-0002-5853-7287	NIH [P01 AG2553101]; DOD IDEA [W81XWH-04-1-0478]; NATIONAL INSTITUTE ON AGING [P01AG025531] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD IDEA; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by NIH grant P01 AG2553101 and DOD IDEA grant . We are grateful to Antonio Pannuti for helpful discussions.W81XWH-04-1-0478	Allenspach EJ, 2002, CANCER BIOL THER, V1, P466, DOI 10.4161/cbt.1.5.159; Bash J, 1999, EMBO J, V18, P2803, DOI 10.1093/emboj/18.10.2803; Bellavia D, 2007, CELL CYCLE, V6, P2730, DOI 10.4161/cc.6.22.4894; Berman JN, 2007, CURR DRUG TARGETS, V8, P727, DOI 10.2174/138945007780830818; Beverly LJ, 2003, CANCER CELL, V3, P551, DOI 10.1016/S1535-6108(03)00137-5; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Chen YB, 2007, CANCER RES, V67, P7954, DOI 10.1158/0008-5472.CAN-07-1229; Dallman MJ, 2005, CURR OPIN IMMUNOL, V17, P259, DOI 10.1016/j.coi.2005.04.002; Deftos ML, 1998, IMMUNITY, V9, P777, DOI 10.1016/S1074-7613(00)80643-3; Dickson BC, 2007, MODERN PATHOL, V20, P685, DOI 10.1038/modpathol.3800785; Fan X, 2004, CANCER RES, V64, P7787, DOI 10.1158/0008-5472.CAN-04-1446; Farnie G, 2005, BREAST CANCER RES TR, V94, pS14; Farnie G, 2007, STEM CELL REV, V3, P169, DOI 10.1007/s12015-007-0023-5; Farnie G, 2007, JNCI-J NATL CANCER I, V99, P616, DOI 10.1093/jnci/djk133; Gordon WR, 2007, NAT STRUCT MOL BIOL, V14, P295, DOI 10.1038/nsmb1227; Gupta-Rossi N, 2004, J CELL BIOL, V166, P73, DOI 10.1083/jcb.200310098; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Houde C, 2004, BLOOD, V104, P3697, DOI 10.1182/blood-2003-12-4114; Jundt F, 2004, BLOOD, V103, P3511, DOI 10.1182/blood-2003-07-2254; Jundt F, 2002, BLOOD, V99, P3398, DOI 10.1182/blood.V99.9.3398; Kathrein KL, 2008, J BIOL CHEM, V283, P10476, DOI 10.1074/jbc.M709643200; Koch U, 2007, CELL MOL LIFE SCI, V64, P2746, DOI 10.1007/s00018-007-7164-1; Kopan R, 2004, NAT REV MOL CELL BIO, V5, P499, DOI 10.1038/nrm1406; Kukar T, 2008, CURR TOP MED CHEM, V8, P47, DOI 10.2174/156802608783334042; Kwon C, 2005, P NATL ACAD SCI USA, V102, P18986, DOI 10.1073/pnas.0509535102; Lai EC, 2005, GENE DEV, V19, P1067, DOI 10.1101/gad.1291905; Li K, 2008, J BIOL CHEM, V283, P8046, DOI 10.1074/jbc.M800170200; Liu ZJ, 2003, MOL CELL BIOL, V23, P14, DOI 10.1128/MCB.23.1.14-25.2003; Malyukova A, 2007, CANCER RES, V67, P5611, DOI 10.1158/0008-5472.CAN-06-4381; McKenzie GJ, 2005, EXPERT OPIN THER TAR, V9, P395, DOI 10.1517/14728222.9.2.395; Miele L, 2006, CLIN CANCER RES, V12, P1074, DOI 10.1158/1078-0432.CCR-05-2570; Miele L, 2006, CURR MOL MED, V6, P905, DOI 10.2174/156652406779010830; Minato Y, 2005, INT J HEMATOL, V82, P302, DOI 10.1532/IJH97.05095; Minter LM, 2005, NAT IMMUNOL, V6, P680, DOI 10.1038/ni1209x; Mukherjee A, 2005, NAT CELL BIOL, V7, P1191, DOI 10.1038/ncb1327; Nam Y, 2006, CELL, V124, P973, DOI 10.1016/j.cell.2005.12.037; Nam YS, 2007, P NATL ACAD SCI USA, V104, P2103, DOI 10.1073/pnas.0611092104; Nickoloff BJ, 2005, J INVEST DERM SYMP P, V10, P95, DOI 10.1111/j.1087-0024.2005.200404.x; Nickoloff BJ, 2002, CELL DEATH DIFFER, V9, P842, DOI 10.1038/sj.cdd.4401036; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Noguera-Troise Irene, 2007, Novartis Found Symp, V283, P106; O'Neil J, 2007, J EXP MED, V204, P1813, DOI 10.1084/jem.20070876; O'Neill CF, 2007, AM J PATHOL, V171, P1023, DOI 10.2353/ajpath.2007.061029; Okajima T, 2002, CELL, V111, P893, DOI 10.1016/S0092-8674(02)01114-5; Osipo C, 2008, LAB INVEST, V88, P11, DOI 10.1038/labinvest.3700700; Oswald F, 2005, MOL CELL BIOL, V25, P10379, DOI 10.1128/MCB.25.23.10379-10390.2005; Oswald F, 2002, EMBO J, V21, P5417, DOI 10.1093/emboj/cdf549; Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636; Parry M, 2004, GLOBAL ENVIRON CHANG, V14, P1, DOI 10.1016/j.gloenvcha.2003.10.003; Pece S, 2004, J CELL BIOL, V167, P215, DOI 10.1083/jcb.200406140; Pinnix CC, 2007, PIGM CELL RES, V20, P458, DOI 10.1111/j.1600-0749.2007.00410.x; Pitsouli C, 2005, DEVELOPMENT, V132, P4041, DOI 10.1242/dev.01979; Reedijk M, 2005, CANCER RES, V65, P8530, DOI 10.1158/0008-5472.CAN-05-1069; Ridgway J, 2006, NATURE, V444, P1083, DOI 10.1038/nature05313; Roy M, 2007, CURR OPIN GENET DEV, V17, P52, DOI 10.1016/j.gde.2006.12.001; Sansone P, 2007, STEM CELLS, V25, P807, DOI 10.1634/stemcells.2006-0442; Santolini E, 2000, J CELL BIOL, V151, P1345, DOI 10.1083/jcb.151.6.1345; Shih IM, 2007, CANCER RES, V67, P1879, DOI 10.1158/0008-5472.CAN-06-3958; Song LL, 2007, EXPERT OPIN BIOL TH, V7, P431, DOI 10.1517/14712598.7.4.431; Thompson BJ, 2007, J EXP MED, V204, P1825, DOI 10.1084/jem.20070872; Thurston G, 2007, NAT REV CANCER, V7, P327, DOI 10.1038/nrc2130; Tu LL, 2005, J EXP MED, V202, P1037, DOI 10.1084/jem.20050923; Vilimas T, 2007, NAT MED, V13, P70, DOI 10.1038/nm1524; Wang Y, 2004, P NATL ACAD SCI USA, V101, P9458, DOI 10.1073/pnas.0308126101; Wang ZW, 2006, CANCER RES, V66, P2778, DOI 10.1158/0008-5472.CAN-05-4281; Wang ZW, 2006, INT J CANCER, V118, P1930, DOI 10.1002/ijc.21589; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754; Wong GT, 2004, J BIOL CHEM, V279, P12876, DOI 10.1074/jbc.M311652200; Wu J, 2005, MOL CELL BIOL, V25, P1458, DOI 10.1128/MCB.25.4.1458-1474.2005; Wu J, 2007, MOL CELL BIOL, V27, P2411, DOI 10.1128/MCB.02152-06; Yan MH, 2007, CLIN CANCER RES, V13, P7243, DOI 10.1158/1078-0432.CCR-07-1393; Yoo AS, 2005, SCIENCE, V310, P1330, DOI 10.1126/science.1119481; Zeng QH, 2005, CANCER CELL, V8, P13, DOI 10.1016/j.ccr.2005.06.004	73	313	324	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2008	27	38					5124	5131		10.1038/onc.2008.226	http://dx.doi.org/10.1038/onc.2008.226			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GM	18758481				2022-12-17	WOS:000258914900006
J	Dauer, DJ; Ferraro, B; Song, LX; Yu, B; Mora, L; Buettner, R; Enkemann, S; Jove, R; Haura, EB				Dauer, DJ; Ferraro, B; Song, LX; Yu, B; Mora, L; Buettner, R; Enkemann, S; Jove, R; Haura, EB			Stat3 regulates genes common to both wound healing and cancer	ONCOGENE			English	Article						STAT proteins; cancer; wound healing; Stat3; lung cancer	BUTYLATED HYDROXYTOLUENE BHT; CONSTITUTIVE ACTIVATION; PLASMINOGEN-ACTIVATOR; SIGNAL TRANSDUCER; EPITHELIAL-CELLS; BINDING PROTEIN; CARCINOMA-CELLS; LUNG-CARCINOMA; IL-6 RESPONSE; EXPRESSION	Wound healing and cancer are both characterized by cell proliferation, remodeling of extracellular matrix, cell invasion and migration, new blood vessel formation, and modulation of blood coagulation. The mechanisms that link wound healing and cancer are poorly understood. We report here that Stat3, a common signaling mechanism involved in oncogenesis and tissue injury, regulates a common set of genes involved in wound healing and cancer. Using oligonucleotide gene arrays and quantitative real-time PCR, we evaluated changes in global gene expression resulting from expression of Stat3 in lung epithelial cells. We report here previously uncharacterized genes induced by Stat3 implicated in signaling pathways common to both wound healing and cancer including cell invasion and migration, angiogenesis, modulation of coagulation, and repression of interferon-inducible genes. Consistent with these results, we found increased Stat3 activity associated with wound healing in chronically inflamed mouse lungs and increased Stat3 activity was identified at the leading edge of lung tumors invading adjacent nontumor stroma. These findings provide a molecular basis for understanding cancer as a deregulation of normal wound healing processes.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Thorac Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Expt Therapeut Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Haura, EB (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Thorac Oncol Program, MRC3 East,Room 3056,12902 Magnolia Dr, Tampa, FL 33612 USA.	hauraeb@mofitt.usf.edu						Bauer AK, 2001, EXP LUNG RES, V27, P197, DOI 10.1080/019021401300053948; Bauer AK, 2001, TOXICOLOGY, V169, P1, DOI 10.1016/S0300-483X(01)00475-9; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Chan KS, 2004, J CLIN INVEST, V114, P720, DOI 10.1172/JCI200421032; Chang HY, 2004, PLOS BIOL, V2, P206, DOI 10.1371/journal.pbio.0020007; Chawla-Sarkar M, 2003, APOPTOSIS, V8, P237, DOI 10.1023/A:1023668705040; Christensen PJ, 2004, AM J PHYSIOL-LUNG C, V286, pL68, DOI 10.1152/ajplung.00079.2003; Costa-Pereira AP, 2002, P NATL ACAD SCI USA, V99, P8043, DOI 10.1073/pnas.122236099; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Duan HO, 2003, J BIOL CHEM, V278, P41270, DOI 10.1074/jbc.M304210200; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Epperly MW, 2000, RADIAT RES, V154, P365, DOI 10.1667/0033-7587(2000)154[0365:DPRROM]2.0.CO;2; FUJITANI Y, 1994, BIOCHEM BIOPH RES CO, V202, P1181, DOI 10.1006/bbrc.1994.2053; Gao HW, 2004, J IMMUNOL, V172, P7703, DOI 10.4049/jimmunol.172.12.7703; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He B, 2003, BIOCHEM BIOPH RES CO, V301, P386, DOI 10.1016/S0006-291X(02)03071-1; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hokuto I, 2004, J CLIN INVEST, V113, P28, DOI 10.1172/JCI200419491; Hur GC, 2003, CLIN CANCER RES, V9, P5768; Hutt JA, 2000, J BIOL CHEM, V275, P29123, DOI 10.1074/jbc.M004476200; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Kano A, 2003, J EXP MED, V198, P1517, DOI 10.1084/jem.20030077; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Khatri P, 2002, GENOMICS, V79, P266, DOI 10.1006/geno.2002.6698; Khatri P, 2004, NUCLEIC ACIDS RES, V32, pW449, DOI 10.1093/nar/gkh409; Kulaeva OI, 2003, ONCOGENE, V22, P4118, DOI 10.1038/sj.onc.1206594; Lakka SS, 2001, CLIN CANCER RES, V7, P1087; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; LIEBER M, 1976, INT J CANCER, V17, P62, DOI 10.1002/ijc.2910170110; Mora LB, 2002, CANCER RES, V62, P6659; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Palumbo JS, 2000, BLOOD, V96, P3302, DOI 10.1182/blood.V96.10.3302; Palumbo JS, 2002, CANCER RES, V62, P6966; Rao JS, 2003, NAT REV CANCER, V3, P489, DOI 10.1038/nrc1121; Reiland J, 1999, PROSTATE, V41, P78; Reljic R, 2000, J EXP MED, V192, P1841, DOI 10.1084/jem.192.12.1841; ROMER J, 1994, J INVEST DERMATOL, V102, P519, DOI 10.1111/1523-1747.ep12373187; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; SAUNDERS NA, 1994, AM J RESP CELL MOL, V11, P147, DOI 10.1165/ajrcmb.11.2.8049075; Schumann RR, 1996, MOL CELL BIOL, V16, P3490; Severgnini M, 2004, AM J PHYSIOL-LUNG C, V286, pL1282, DOI 10.1152/ajplung.00349.2003; Shou JY, 2002, P NATL ACAD SCI USA, V99, P2830, DOI 10.1073/pnas.052705299; Song LX, 2003, ONCOGENE, V22, P4150, DOI 10.1038/sj.onc.1206479; Steinman RA, 2003, ONCOGENE, V22, P3608, DOI 10.1038/sj.onc.1206523; Sue RD, 2004, J IMMUNOL, V172, P3860, DOI 10.4049/jimmunol.172.6.3860; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; Vultur A, 2004, ONCOGENE, V23, P2600, DOI 10.1038/sj.onc.1207378; WAKABAYASHI H, 1995, CANCER RES, V55, P4458; Wang TH, 2004, NAT MED, V10, P48, DOI 10.1038/nm976; Warrington JA, 2000, PHYSIOL GENOMICS, V2, P143, DOI 10.1152/physiolgenomics.2000.2.3.143; Yan H, 2002, NAT GENET, V30, P25, DOI 10.1038/ng799; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275	59	313	323	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2005	24	21					3397	3408		10.1038/sj.onc.1208469	http://dx.doi.org/10.1038/sj.onc.1208469			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925FT	15735721				2022-12-17	WOS:000229038800002
J	Silva, CM				Silva, CM			Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis	ONCOGENE			English	Review						STAT5; STAT3; c-Src; breast cancer; tumorigenesis	GROWTH-FACTOR RECEPTOR; C-SRC; V-SRC; CONSTITUTIVE ACTIVATION; TRANSCRIPTIONAL CONTROL; TYROSINE KINASES; PATHWAYS; REQUIRES; PHOSPHORYLATION; TRANSFORMATION	The signal transducers and activators of transcription (STATs) were originally identified in the signaling pathway activated by the nontyrosine kinase containing cytokine receptors. The role of these STATs in hematopoietic cell signaling has been well described. In the case of cytokine receptors, activation of STAT tyrosine phosphorylation occurs through ligand-induced recruitment, and activation of the intracellular JAK kinases. However, STATs can also be activated by growth factor receptors, particularly the EGFR; as well as by members of the Src Family of Kinases (SFKs), particularly c-Src. In many cases, there is a differential activation of the STATs by these tyrosine kinases as compared to activation by the cytokine receptors. This difference provides for the potential of unique actions of STATs in response to growth factor receptor and SFK activation. Since there are many cancers in which SFKs and c-Src in particular, are co-overexpressed with growth factor receptors, it is not surprising that STATs play an important role in the tumorigenesis process induced by c-Src. The activation paradigm and role of STATs in these cancers, with particular emphasis on breast cancer models, is discussed.	Univ Virginia Hlth Syst, Ctr Canc, Dept Internal Med, Charlottesville, VA 22908 USA; Univ Virginia Hlth Syst, Ctr Canc, Dept Microbiol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Silva, CM (corresponding author), Univ Virginia Hlth Syst, Ctr Canc, Dept Internal Med, Box 800578, Charlottesville, VA 22908 USA.	cms3e@virginia.edu		Silva, Corinne/0000-0002-3707-2919	NATIONAL CANCER INSTITUTE [R01CA085462] Funding Source: NIH RePORTER; NCI NIH HHS [CA085462] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Biscardi JS, 1998, MOL CARCINOGEN, V21, P261, DOI 10.1002/(SICI)1098-2744(199804)21:4<261::AID-MC5>3.0.CO;2-N; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Calo V, 2003, J CELL PHYSIOL, V197, P157, DOI 10.1002/jcp.10364; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Chin H, 1998, BLOOD, V91, P3734; Darnell JE, 1998, J INTERF CYTOK RES, V18, P549, DOI 10.1089/jir.1998.18.549; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Guren TK, 2003, J CELL PHYSIOL, V196, P113, DOI 10.1002/jcp.10282; HARRIS JR, 1992, NEW ENGL J MED, V327, P473, DOI 10.1056/NEJM199208133270706; IHLE J, 2003, STATS ACTIVATION BIO, P559; Kabotyanski EB, 2003, J BIOL CHEM, V278, P17218, DOI 10.1074/jbc.M301578200; Kazansky AV, 1999, J BIOL CHEM, V274, P22484, DOI 10.1074/jbc.274.32.22484; Kazansky AV, 2001, CELL GROWTH DIFFER, V12, P1; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Kloth MT, 2003, J BIOL CHEM, V278, P1671, DOI 10.1074/jbc.M207289200; Kloth MT, 2002, J BIOL CHEM, V277, P8693, DOI 10.1074/jbc.M111884200; Laird AD, 2003, MOL CANCER THER, V2, P461; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Lin TS, 2000, ONCOGENE, V19, P2496, DOI 10.1038/sj.onc.1203486; Lund TC, 1999, J VIROL, V73, P1689, DOI 10.1128/JVI.73.2.1689-1694.1999; Lund TC, 1997, J VIROL, V71, P6677, DOI 10.1128/JVI.71.9.6677-6682.1997; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Odajima J, 2000, J BIOL CHEM, V275, P24096, DOI 10.1074/jbc.M001606200; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Ren ZY, 2002, J BIOL CHEM, V277, P38486, DOI 10.1074/jbc.M112438200; SAINSBURY J, 1987, J CLIN PATHOL, V38, P1225; SCHINDLER CW, 2003, STATS ACTIVATION BIO, P137; Schreiner SJ, 2002, J BIOL CHEM, V277, P45680, DOI 10.1074/jbc.M204255200; Seidel HM, 2000, ONCOGENE, V19, P2645, DOI 10.1038/sj.onc.1203550; SILVA CM, 2003, SIGNAL TRANSDUCERS A, P223; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; TOI M, 1991, EUR J CANCER, V27, P977, DOI 10.1016/0277-5379(91)90262-C; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Xi SC, 2003, CANCER RES, V63, P6763; Xi SC, 2003, J BIOL CHEM, V278, P31574, DOI 10.1074/jbc.M303499200; Yu CL, 1997, J IMMUNOL, V159, P5206; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Zhang Y, 2000, J BIOL CHEM, V275, P24935, DOI 10.1074/jbc.M002383200	45	313	331	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2004	23	48					8017	8023		10.1038/sj.onc.1208159	http://dx.doi.org/10.1038/sj.onc.1208159			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	863JR	15489919	Bronze			2022-12-17	WOS:000224558300012
J	Chang, BD; Xuan, YZ; Broude, EV; Zhu, HM; Schott, B; Fang, J; Roninson, IB				Chang, BD; Xuan, YZ; Broude, EV; Zhu, HM; Schott, B; Fang, J; Roninson, IB			Role of p53 and p21(waf1/cip1) in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs	ONCOGENE			English	Article						drug effects; p53; p21; senescence; cell death	RETROVIRAL VECTORS; HUMAN FIBROBLASTS; DNA-DAMAGE; ANTICANCER AGENTS; GROWTH ARREST; CYCLE ARREST; G(1) ARREST; P16(INK4A); DEATH; INDUCTION	Exposure of human tumor cell lines to moderate doses of anticancer agents induces terminal proliferation arrest accompanied by morphologic and enzymatic changes that resemble senescence of normal cells, We have investigated the role of p53 and p21(waf1/cip1) in the induction of this response in drug-treated tumor cells. Doxorubicin treatment induced the senescence-like phenotype (SLP) and its associated terminal growth arrest in wild-type HCT116 colon carcinoma cells; this response was strongly decreased but not abolished in HCT116 lines with homozygous knockout of p53 or p21, Transduction of HT1080 fibrosarcoma cells with a genetic inhibitor of p53 also decreased the induction of SLP and increased drug-induced mitotic cell death, To determine if drug-stimulated p21 expression was responsible for senescence-like growth arrest, we have expressed different levels of p21 from an inducible promoter, While high-level overexpression of p21 was sufficient to induce SLP in HT1080 cells, the levels of p21 expressed in doxorubicin-treated cells could account for only a fraction of doxorubicin-induced SLP, Our results indicate that p53 and p21 act as positive regulators of senescence-like terminal proliferation arrest, but their function is neither sufficient nor absolutely required for this treatment response in tumor cells.	Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Roninson, IB (corresponding author), Univ Illinois, Dept Mol Genet, M-C 669,900 S Ashland Ave, Chicago, IL 60607 USA.		Roninson, Igor/K-1310-2017	Roninson, Igor/0000-0002-9211-1327	NCI NIH HHS [R37CA40333, R01CA62099] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA040333, R01CA062099] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Campisi J, 1997, EUR J CANCER, V33, P703, DOI 10.1016/S0959-8049(96)00058-5; Chang BD, 1999, CANCER RES, V59, P3761; Chang BD, 1996, GENE, V183, P137, DOI 10.1016/S0378-1119(96)00532-X; CHEN Q, 1994, P NATL ACAD SCI USA, V91, P4130, DOI 10.1073/pnas.91.10.4130; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Duncan EL, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1263; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARPER JW, 1993, CELL, V75, P805; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Hendry JH, 1997, INT J RADIAT BIOL, V71, P709, DOI 10.1080/095530097143716; Holt SE, 1997, P NATL ACAD SCI USA, V94, P10687, DOI 10.1073/pnas.94.20.10687; HORAN PK, 1989, NATURE, V340, P167, DOI 10.1038/340167a0; Jordan MA, 1996, CANCER RES, V56, P816; Kandel ES, 1997, SOMAT CELL MOLEC GEN, V23, P325, DOI 10.1007/BF02674280; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; Lock RB, 1996, CANCER RES, V56, P4006; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Myohanen SK, 1998, CANCER RES, V58, P591; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pellegata NS, 1996, P NATL ACAD SCI USA, V93, P15209, DOI 10.1073/pnas.93.26.15209; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; PERRY ME, 1992, MUTAT RES, V276, P189, DOI 10.1016/0165-1110(92)90008-W; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; SCHOTT B, 1996, SOMAT CELL MOLEC GEN, V22, P292; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shay JW, 1997, J CELL PHYSIOL, V173, P266, DOI 10.1002/(SICI)1097-4652(199711)173:2<266::AID-JCP33>3.0.CO;2-B; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; Torres K, 1998, CANCER RES, V58, P3620; Uhrbom L, 1997, ONCOGENE, V15, P505, DOI 10.1038/sj.onc.1201227; Vogt M, 1998, CELL GROWTH DIFFER, V9, P139; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang XH, 1998, CANCER RES, V58, P5019; Wang YC, 1998, ONCOGENE, V17, P1923, DOI 10.1038/sj.onc.1202113; Weinberg RA, 1997, CELL, V88, P573, DOI 10.1016/S0092-8674(00)81897-8; WHITAKER NJ, 1995, ONCOGENE, V11, P971; Xu HJ, 1997, ONCOGENE, V15, P2589, DOI 10.1038/sj.onc.1201446; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	43	313	332	1	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 26	1999	18	34					4808	4818		10.1038/sj.onc.1203078	http://dx.doi.org/10.1038/sj.onc.1203078			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229GH	10490814				2022-12-17	WOS:000082184800005
J	Ljungman, M; Zhang, FF				Ljungman, M; Zhang, FF			Blockage of RNA polymerase as a possible trigger for uv light-induced apoptosis	ONCOGENE			English	Article						preferential repair; p53; xeroderma pigmentosum; Cockayne's syndrome; uv light; ionizing radiation	TRANSCRIPTION-COUPLED REPAIR; XERODERMA PIGMENTOSUM-CELLS; DNA-DAMAGE; COCKAYNES-SYNDROME; NUCLEAR ACCUMULATION; TORSIONAL TENSION; EXCISION-REPAIR; STRAND BREAKS; ACTIVE GENES; GROUP-C	To study the triggering mechanism(s) of the induction of apoptosis following exposure to u.v. light, we used a genetic approach involving cell strains derived from patients with inherited deficiencies in nucleotide excision repair, It was found that cells from patients with Cockayne's syndrome, which are deficient in the processing of u.v.-induced pyrimidine dimers from the transcribed DNA strand, are induced to undergo apoptosis at much lower doses of u.v. light than cells with proficient strand-specific repair, The induction of apoptosis correlated to the induction of p53 and to the inhibition of total RNA and poly(A) mRNA synthesis, We also show that active p53 proteins accumulate following u.v.-irradiation without any apparent requirement for DNA strand breaks or excision repair intermediates, We propose that the blockage of RNA polymerases at DNA lesions in the transcribed strand triggers the induction of a pathway leading to apoptosis, These findings may help explain a long standing enigma of why, despite the DNA repair deficiency, patients with Cockayne's syndrome do not experience an elevated risk for skin cancer since potentially pre-mutagenic cells are eliminated by an easily triggered apoptotic pathway.			Ljungman, M (corresponding author), UNIV MICHIGAN, MED CTR, DEPT RADIAT ONCOL, DIV CANC BIOL, ANN ARBOR, MI 48109 USA.				NCI NIH HHS [P30-CA46592] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA046592] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BOOTSMA D, 1995, PHILOS T ROY SOC B, V347, P75, DOI 10.1098/rstb.1995.0012; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHERNOVA OB, 1995, TRENDS BIOCHEM SCI, V20, P431, DOI 10.1016/S0968-0004(00)89094-5; CLEAVER JE, 1995, AM J HUM GENET, V56, P1257; CLEAVER JE, 1975, ANNU REV GENET, V9, P19, DOI 10.1146/annurev.ge.09.120175.000315; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; DUNN WC, 1979, MOL PHARMACOL, V15, P367; ERIXON K, 1979, MUTAT RES, V59, P257, DOI 10.1016/0027-5107(79)90164-7; EVANS MK, 1993, J BIOL CHEM, V268, P4839; FISCELLA M, 1993, ONCOGENE, V8, P1519; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; FORNACE AJ, 1983, RADIAT RES, V93, P107, DOI 10.2307/3575948; Friedberg E.C., 2016, DNA REPAIR MUTAGENES, V33, P35; FRITSCHE M, 1993, ONCOGENE, V8, P307; GOTTLIEB T, 1994, TIBS             NOV, P500; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; LEHMANN AR, 1979, CANCER RES, V39, P4237; Leonard C J, 1995, Important Adv Oncol, P33; LJUNGMAN M, 1992, P NATL ACAD SCI USA, V89, P6055, DOI 10.1073/pnas.89.13.6055; LJUNGMAN M, 1995, NUCLEIC ACIDS RES, V23, P1782, DOI 10.1093/nar/23.10.1782; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUCHNIK AN, 1988, NUCLEIC ACIDS RES, V16, P5175, DOI 10.1093/nar/16.11.5175; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MAYNE LV, 1982, CANCER RES, V42, P1473; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; RODI CP, 1989, J CELL PHYSIOL, V141, P346, DOI 10.1002/jcp.1041410216; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SQUIRES S, 1982, MUTAT RES, V95, P389, DOI 10.1016/0027-5107(82)90273-1; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; VITO P, 1996, NATURE, V271, P521; WALKER PR, 1993, BIOTECHNIQUES, V15, P1032; WHITACRE CM, 1995, CANCER RES, V55, P3697; WYLLIE AH, 1994, PHILOS T R SOC B, V345, P237, DOI 10.1098/rstb.1994.0099; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; ZEITLIN S, 1995, NAT GENET, V11, P155, DOI 10.1038/ng1095-155; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	48	313	314	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	1996	13	4					823	831						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761304				2022-12-17	WOS:A1996VD43300018
J	TAM, SW; THEODORAS, AM; SHAY, JW; DRAETTA, GF; PAGANO, M				TAM, SW; THEODORAS, AM; SHAY, JW; DRAETTA, GF; PAGANO, M			DIFFERENTIAL EXPRESSION AND REGULATION OF CYCLIN D1 PROTEIN IN NORMAL AND TUMOR HUMAN-CELLS - ASSOCIATION WITH CDK4 IS REQUIRED FOR CYCLIN D1 FUNCTION IN G1 PROGRESSION	ONCOGENE			English	Review							HUMAN-DIPLOID FIBROBLASTS; HUMAN BREAST-CANCER; DNA POLYMERASE-DELTA; RETINOBLASTOMA PROTEIN; NUCLEAR ANTIGEN; GENE-EXPRESSION; P53 GENE; SUBUNIT REARRANGEMENT; AUXILIARY PROTEIN; DEPENDENT KINASES	In this study we have surveyed by immunoblotting the protein levels of Cyclin D1, D2, D3 and their catalytic partners, Cdk4 and Cdk6 in normal and transformed human cells. We found that all these proteins were differentially expressed in diploid cells derived from different tissues, in contrast to Cyclin E, Cyclin A and Cdk2 which are ubiquitously expressed. D-type Cyclins were never dramatically overexpressed and often very poorly expressed in tumor cell lines when compared to the levels in their normal counterparts. In contrast, Cdk4 was expressed at high levels in several tumor cell lines and Cdk6 was ectopically expressed in two sarcoma lines, suggesting a possible involvement of these two Cdks in oncogenesis. Interestingly, low levels of Cyclin D1 and D3 proteins always correlated with functional inactivation of the retinoblastoma gene product (pRb). In cells displaying active pRb, Cyclin D1 was found associated with Cdk4 regardless of whether the p53 gene was wild-type or mutant. Microinjection during G1 of Cyclin D1 anti-sense cDNA or anti-Cyclin D1 antibody in these cells arrested the cell cycle in G1. In cells lacking pRb function, Cyclin D1 was dissociated from Cdk4. Microinjection during G1 of Cyclin D1 antisense cDNA or anti-Cyclin D1 antibody in these cells did not affect G1 progression. These results show that (i) in the absence of pRb, Cyclin D1 is expressed at low levels, is dissociated from Cdk4 and becomes dispensable in G1; (ii) Cyclin D1 needs to be associated with its catalytic subunit, Cdk4, to function as a positive regulator of G1 progression.	MITOTIX INC, CAMBRIDGE, MA 02139 USA; UNIV TEXAS, SW MED CTR, DEPT CELL BIOL & NEUROSCI, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Shay, Jerry W/F-7878-2011	pagano, michele/0000-0003-3210-2442	NCI NIH HHS [CA50195] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050195] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; ANSORGE W, 1988, J BIOCHEM BIOPH METH, V16, P283, DOI 10.1016/0165-022X(88)90062-0; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARTEK J, 1992, ONCOGENE, V7, P101; BARTEK J, 1990, ONCOGENE, V5, P893; BATES S, 1994, ONCOGENE, V9, P71; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BUCHOU T, 1993, ONCOGENE, V8, P1765; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CHANDAR N, 1992, BRIT J CANCER, V65, P208, DOI 10.1038/bjc.1992.43; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FAHA B, 1993, J VIROL, V67, P2456, DOI 10.1128/JVI.67.5.2456-2465.1993; GALLANT P, 1992, J CELL BIOL, V117, P213, DOI 10.1083/jcb.117.1.213; GLOTZE RM, 1990, NATURE, V349, P132; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HALL FL, 1993, ONCOGENE, V8, P1377; HANNA Z, 1993, ONCOGENE, V8, P1661; HARPER JW, 1993, CELL, V75, P805; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; JASKULSKI D, 1988, SCIENCE, V240, P1544, DOI 10.1126/science.2897717; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1993, ONCOGENE, V8, P3447; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KHATIB ZA, 1993, CANCER RES, V53, P5535; KIYOKAWA H, 1992, P NATL ACAD SCI USA, V89, P2444, DOI 10.1073/pnas.89.6.2444; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LEW J, 1992, J BIOL CHEM, V267, P25922; LOVEC H, 1994, ONCOGENE, V9, P323; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; LUKAS J, 1994, ONCOGENE, V9, P707; Maniatis T., 1982, MOL CLONING; MATSUOKA S, 1994, J BIOL CHEM, V269, P11030; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MATSUSHIME H, 1991, COLD SPRING HARBOR S, V56; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PAGANO M, 1994, IN PRESS GENES DEV; PALMERO I, 1993, ONCOGENE, V8, P1049; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SEWING A, 1993, J CELL SCI, V104, P545; SHAY JW, 1992, EXP GERONTOL, V27, P477, DOI 10.1016/0531-5565(92)90003-I; SHAY JW, 1993, ONCOGENE, V8, P1407; Sherr Charles J., 1994, Trends in Cell Biology, V4, P15, DOI 10.1016/0962-8924(94)90033-7; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SPITKOVSKY D, 1994, J VIROL, V68, P2206, DOI 10.1128/JVI.68.4.2206-2214.1994; STRATTON MR, 1990, ONCOGENE, V5, P1297; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TOMINAGA O, 1993, ONCOGENE, V8, P2653; TSAI LH, 1993, DEVELOPMENT, V119, P1029; WASEEM NH, 1990, J CELL SCI, V96, P121; WILLIAMS RT, 1993, J BIOL CHEM, V268, P8871; WINSTON JT, 1993, MOL BIOL CELL, V4, P1133, DOI 10.1091/mbc.4.11.1133; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	103	313	329	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1994	9	9					2663	2674						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058330				2022-12-17	WOS:A1994PC05400027
J	Friedman, AD				Friedman, A. D.			Transcriptional control of granulocyte and monocyte development	ONCOGENE			English	Review						granulocyte; monocyte; differentiation; C/EBP alpha; PU.1	NF-KAPPA-B; BINDING-PROTEIN-ALPHA; HEMATOPOIETIC PROGENITOR CELLS; CCAAT DISPLACEMENT PROTEIN; C-JUN EXPRESSION; STIMULATING FACTOR-RECEPTOR; C/EBP FAMILY-MEMBERS; MYELOID STEM-CELLS; RETINOIC ACID; DNA-BINDING	PU.1 directs the hematopoietic stem cell to the lymphoid-myeloid progenitor ( LMP) and interacts with GATA-binding protein 1 to inhibit commitment to the megakaryocyte-erythroid progenitor. The CCAAT/ enhancerbinding protein ( C/ EBP)alpha then directs the LMP to the granulocyte- monocyte progenitor ( GMP) stage, while inhibiting lymphoid development via cross- inhibition of Pax5 and potentially other regulators. Increased PU. 1 activity favors monocytic commitment of the GMP. Induction of PU.1 by C/EBP alpha and interaction of PU.1 with c-Jun elevates PU. 1 activity. Zippering of C/ EBP alpha with c- Jun or c- Fos also contributes to monocyte lineage specification. An additional factor, potentially an Id1-regulated basic helix - loop - helix protein, may be required for the GMP to commit to the granulocyte lineage. Egr- 1, Egr- 2, Vitamin D Receptor, MafB/ c: Fos and PU. 1: interferon regulatory factor 8 complexes direct further monocytic maturation, while retinoic acid receptor ( RAR) and C/ EBP epsilon direct granulopoiesis. Both C/ EBP alpha and RARs induce C/ EBP epsilon, and PU.1 is also required, albeit at lower levels, for granulocytic maturation. HoxA10 and CAAT displacement protein act as transcriptional repressors to delay expression of terminal differentiation. Gfi-1 and Egr- 1,2/ Nab2 complexes repress each other to maintain myeloid lineage fidelity. NF-kappa B directly binds and cooperates with C/ EBP beta to induce the inflammatory response in mature myeloid cells and potentially also cooperates with C/ EBP alpha to regulate early myelopoiesis.	Johns Hopkins Univ, Div Pediat Oncol, Baltimore, MD 21231 USA	Johns Hopkins University	Friedman, AD (corresponding author), Johns Hopkins Univ, Div Pediat Oncol, Canc Res Bldg 1,Room 253,1650 Orleans St, Baltimore, MD 21231 USA.	afriedm2@jhmi.edu						Adolfsson J, 2005, CELL, V121, P295, DOI 10.1016/j.cell.2005.02.013; Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Anderson K, 2007, BLOOD, V109, P3697, DOI 10.1182/blood-2006-05-026021; Antonson P, 1996, GENOMICS, V35, P30, DOI 10.1006/geno.1996.0319; Arinobu Y, 2006, BLOOD, V108, p472A, DOI 10.1182/blood.V108.11.1656.1656; Aziz A, 2006, MOL CELL BIOL, V26, P6808, DOI 10.1128/MCB.00245-06; Bakri Y, 2005, BLOOD, V105, P2707, DOI 10.1182/blood-2004-04-1448; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; Bastie JN, 2004, MOL ENDOCRINOL, V18, P2685, DOI 10.1210/me.2003-0412; Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; Bei L, 2005, J BIOL CHEM, V280, P12359, DOI 10.1074/jbc.M408138200; Bourette RP, 1997, EMBO J, V16, P5880, DOI 10.1093/emboj/16.19.5880; Bush TS, 2003, BLOOD, V101, P311, DOI 10.1182/blood.V101.1.311; Cadieux C, 2006, CANCER RES, V66, P9492, DOI 10.1158/0008-5472.CAN-05-4230; Cai DH, 2006, BLOOD, V108, p345A; Calkhoven CF, 2000, GENE DEV, V14, P1920; Cammenga J, 2003, BLOOD, V101, P2206, DOI 10.1182/blood-2002-05-1546; CHENG ADY, 1995, GRAVITATION COSMOLOG, V1, P1; Chih DY, 1997, BLOOD, V90, P2987, DOI 10.1182/blood.V90.8.2987; CHRISPEELS MJ, 1991, PLANT CELL, V3, P1, DOI 10.1105/tpc.3.1.1; Chumakov AM, 2007, BLOOD, V109, P4209, DOI 10.1182/blood-2005-09-031963; Chumakov AM, 1997, MOL CELL BIOL, V17, P1375, DOI 10.1128/MCB.17.3.1375; Cleaves R, 2004, ONCOGENE, V23, P716, DOI 10.1038/sj.onc.1207172; CROSBY SD, 1991, MOL CELL BIOL, V11, P3835, DOI 10.1128/MCB.11.8.3835; Dahl R, 2003, NAT IMMUNOL, V4, P1029, DOI 10.1038/ni973; Dahl R, 2007, J BIOL CHEM, V282, P6473, DOI 10.1074/jbc.M607613200; Dakic A, 2005, J EXP MED, V201, P1487, DOI 10.1084/jem.20050075; deKoning JP, 1996, BLOOD, V87, P1335, DOI 10.1182/blood.V87.4.1335.bloodjournal8741335; DeKoter RP, 1998, EMBO J, V17, P4456, DOI 10.1093/emboj/17.15.4456; DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; Dionne CJ, 2005, DEV BIOL, V280, P448, DOI 10.1016/j.ydbio.2005.01.027; DOUER D, 1982, J CLIN INVEST, V69, P1039, DOI 10.1172/JCI110507; Duan ZJ, 2003, P NATL ACAD SCI USA, V100, P5932, DOI 10.1073/pnas.1031694100; DUNN SM, 1994, BLOOD, V83, P2469, DOI 10.1182/blood.V83.9.2469.2469; Eferl R, 1999, J CELL BIOL, V145, P1049, DOI 10.1083/jcb.145.5.1049; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; Eklund EA, 2000, J BIOL CHEM, V275, P20117, DOI 10.1074/jbc.M907915199; Endo M, 2006, J IMMUNOL, V176, P6245, DOI 10.4049/jimmunol.176.10.6245; Fazi F, 2005, CELL, V123, P819, DOI 10.1016/j.cell.2005.09.023; Ford AM, 1996, P NATL ACAD SCI USA, V93, P10838, DOI 10.1073/pnas.93.20.10838; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; Friedman AD, 1996, CANCER RES, V56, P3250; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; Friedman AD, 2002, ONCOGENE, V21, P3377, DOI 10.1038/sj.onc.1205324; Fukuchi Y, 2006, EMBO J, V25, P3398, DOI 10.1038/sj.emboj.7601199; Ginhoux F, 2006, NAT IMMUNOL, V7, P265, DOI 10.1038/ni1307; Gombart AF, 2005, J LEUKOCYTE BIOL, V78, P1153, DOI 10.1189/jlb.0504286; Gombart AF, 2001, BLOOD, V97, P2561, DOI 10.1182/blood.V97.9.2561; Grimes HL, 1996, MOL CELL BIOL, V16, P6263; Grondin B, 2007, MOL CELL BIOL, V27, P2919, DOI 10.1128/MCB.00936-06; Guzman ML, 2001, BLOOD, V98, P2301, DOI 10.1182/blood.V98.8.2301; Heath V, 2004, BLOOD, V104, P1639, DOI 10.1182/blood-2003-11-3963; Heavey B, 2003, EMBO J, V22, P3887, DOI 10.1093/emboj/cdg380; Hegde SP, 1999, BLOOD, V94, P1578, DOI 10.1182/blood.V94.5.1578.417k18_1578_1589; Henkel GW, 1999, BLOOD, V93, P2849; Himes SR, 2006, J IMMUNOL, V176, P2219, DOI 10.4049/jimmunol.176.4.2219; Hirai H, 2006, NAT IMMUNOL, V7, P732, DOI 10.1038/ni1354; Hock H, 2003, IMMUNITY, V18, P109, DOI 10.1016/S1074-7613(02)00501-0; Hoffmann A, 2003, EMBO J, V22, P5530, DOI 10.1093/emboj/cdg534; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Hsu CL, 2006, P NATL ACAD SCI USA, V103, P672, DOI 10.1073/pnas.0510304103; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; HUANG G, 2007, IN PRESS NATURE GENE; Huang WQ, 2007, J BIOL CHEM, V282, P6629, DOI 10.1074/jbc.M607760200; Iwama A, 2002, J EXP MED, V195, P547, DOI 10.1084/jem.20011465; Iwasaki H, 2005, BLOOD, V106, P1590, DOI 10.1182/blood-2005-03-0860; Jankovic V, 2007, P NATL ACAD SCI USA, V104, P1260, DOI 10.1073/pnas.0607894104; Johansen LM, 2001, MOL CELL BIOL, V21, P3789, DOI 10.1128/MCB.21.11.3789-3806.2001; Johnson PF, 2005, J CELL SCI, V118, P2545, DOI 10.1242/jcs.02459; Jones LC, 2002, BLOOD, V99, P2032, DOI 10.1182/blood.V99.6.2032; Kakar R, 2005, J LEUKOCYTE BIOL, V77, P120, DOI 10.1189/jlb.0704429; Karsunky H, 2002, NAT GENET, V30, P295, DOI 10.1038/ng831; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; Kautz B, 2001, J BIOL CHEM, V276, P37868; Keeshan K, 2006, CANCER CELL, V10, P401, DOI 10.1016/j.ccr.2006.09.012; Kelly LM, 2000, EMBO J, V19, P1987, DOI 10.1093/emboj/19.9.1987; Khanna-Gupta A, 2001, P NATL ACAD SCI USA, V98, P8000, DOI 10.1073/pnas.141229598; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOEFFLER HP, 1984, CANCER RES, V44, P5624; Krishnaraju K, 1998, BLOOD, V92, P1957, DOI 10.1182/blood.V92.6.1957.418k24_1957_1966; KRISHNARAJU K, 1995, MOL CELL BIOL, V15, P5499; Krishnaraju K, 2001, BLOOD, V97, P1298, DOI 10.1182/blood.V97.5.1298; Krysinska H, 2007, MOL CELL BIOL, V27, P878, DOI 10.1128/MCB.01915-06; Kummalue T, 2003, J LEUKOCYTE BIOL, V74, P464, DOI 10.1189/jlb.1202622; KUNSCH C, 1994, J IMMUNOL, V153, P153; Labrecque J, 1998, BLOOD, V92, P607, DOI 10.1182/blood.V92.2.607.414k06_607_615; Lacaud G, 1998, IMMUNITY, V9, P827, DOI 10.1016/S1074-7613(00)80648-2; Laiosa CV, 2006, IMMUNITY, V25, P731, DOI 10.1016/j.immuni.2006.09.011; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; Laslo P, 2006, CELL, V126, P755, DOI 10.1016/j.cell.2006.06.052; LAWRENCE HJ, 1995, EXP HEMATOL, V23, P1160; Lawson ND, 1998, BLOOD, V91, P2517, DOI 10.1182/blood.V91.7.2517.2517_2517_2524; Lee SL, 1996, MOL CELL BIOL, V16, P4566; Leeanansaksiri W, 2005, J IMMUNOL, V174, P7014, DOI 10.4049/jimmunol.174.11.7014; Lekstrom-Himes JA, 2001, STEM CELLS, V19, P125, DOI 10.1634/stemcells.19-2-125; Lekstrom-Himes JA, 1999, J EXP MED, V189, P1847, DOI 10.1084/jem.189.11.1847; Li AC, 1998, J BIOL CHEM, V273, P5389, DOI 10.1074/jbc.273.9.5389; LI JM, 1994, CELL GROWTH DIFFER, V5, P743; Liew CW, 2006, J BIOL CHEM, V281, P28296, DOI 10.1074/jbc.M602830200; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; Lindsey S, 2007, J BIOL CHEM, V282, P2237, DOI 10.1074/jbc.M608642200; Liu HT, 2003, BLOOD, V101, P3885, DOI 10.1182/blood-2002-07-2212; Liu J, 2006, MOL CELL, V21, P467, DOI 10.1016/j.molcel.2005.12.020; Lopez-Bergami P, 2005, MOL CELL, V19, P309, DOI 10.1016/j.molcel.2005.06.025; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; Luo W, 1996, J BIOL CHEM, V271, P18203, DOI 10.1074/jbc.271.30.18203; Maehara K, 1999, FEBS LETT, V449, P115, DOI 10.1016/S0014-5793(99)00408-1; Manz MG, 2001, BLOOD, V97, P3333, DOI 10.1182/blood.V97.11.3333; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Meraro D, 2002, J IMMUNOL, V168, P6224, DOI 10.4049/jimmunol.168.12.6224; Meraro D, 1999, J IMMUNOL, V163, P6468; Miller M, 2003, J BIOL CHEM, V278, P15178, DOI 10.1074/jbc.M300417200; Montecino-Rodriguez E, 2001, NAT IMMUNOL, V2, P83, DOI 10.1038/83210; Moriguchi T, 2006, MOL CELL BIOL, V26, P5715, DOI 10.1128/MCB.00001-06; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; Muller C, 1995, EMBO J, V14, P6127, DOI 10.1002/j.1460-2075.1995.tb00303.x; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; Newman JRS, 2003, SCIENCE, V300, P2097, DOI 10.1126/science.1084648; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; Okuno Y, 2005, MOL CELL BIOL, V25, P2832, DOI 10.1128/MCB.25.7.2832-2845.2005; Ortiz MA, 1999, P NATL ACAD SCI USA, V96, P2740, DOI 10.1073/pnas.96.6.2740; OSHEA EK, 1993, CURR BIOL, V3, P658, DOI 10.1016/0960-9822(93)90063-T; Papin S, 2003, J BIOL CHEM, V278, P48839, DOI 10.1074/jbc.M305166200; Passegue E, 2001, CELL, V104, P21, DOI 10.1016/S0092-8674(01)00188-X; Paz-Priel I, 2005, MOL CANCER RES, V3, P585, DOI 10.1158/1541-7786.MCR-05-0111; Person RE, 2003, NAT GENET, V34, P308, DOI 10.1038/ng1170; Pierce A, 1998, J CELL BIOL, V140, P1511, DOI 10.1083/jcb.140.6.1511; Porse BT, 2005, J EXP MED, V202, P85, DOI 10.1084/jem.20050067; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; Rangatia J, 2003, ONCOGENE, V22, P4760, DOI 10.1038/sj.onc.1206664; Rangatia J, 2002, MOL CELL BIOL, V22, P8681, DOI 10.1128/MCB.22.24.8681-8694.2002; Reddy VA, 2002, BLOOD, V100, P483, DOI 10.1182/blood.V100.2.483; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; Rekhtman N, 2003, MOL CELL BIOL, V23, P7460, DOI 10.1128/MCB.23.21.7460-7474.2003; Roodman GD, 1996, ENDOCR REV, V17, P308, DOI 10.1210/er.17.4.308; Rosenbauer F, 2004, NAT GENET, V36, P624, DOI 10.1038/ng1361; Ross SE, 2004, MOL CELL BIOL, V24, P675, DOI 10.1128/MCB.24.2.675-686.2004; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SCOTT LM, 1992, BLOOD, V80, P1725; Sebastian T, 2006, CELL CYCLE, V5, P953, DOI 10.4161/cc.5.9.2733; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Sharf R, 1997, J BIOL CHEM, V272, P9785; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shimozaki K, 1997, J BIOL CHEM, V272, P25184, DOI 10.1074/jbc.272.40.25184; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; Smith LT, 1996, BLOOD, V88, P1234, DOI 10.1182/blood.V88.4.1234.bloodjournal8841234; Spain LM, 1999, J IMMUNOL, V163, P2681; Steidl U, 2006, NAT GENET, V38, P1269, DOI 10.1038/ng1898; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Stopka T, 2005, EMBO J, V24, P3712, DOI 10.1038/sj.emboj.7600834; Suh HC, 2006, BLOOD, V107, P4308, DOI 10.1182/blood-2005-06-2216; SZABO E, 1994, CELL GROWTH DIFFER, V5, P439; Taghon T, 2002, BLOOD, V99, P1197, DOI 10.1182/blood.V99.4.1197; Tagoh H, 2006, EMBO J, V25, P1070, DOI 10.1038/sj.emboj.7600997; Tamura T, 2005, BLOOD, V106, P1938, DOI 10.1182/blood-2005-01-0080; Taschner S, 2007, BLOOD, V109, P971, DOI 10.1182/blood-2006-04-020552.7; Traver D, 2001, BLOOD, V98, P627, DOI 10.1182/blood.V98.3.627; TSAI S, 1993, P NATL ACAD SCI USA, V90, P7153, DOI 10.1073/pnas.90.15.7153; Tsujimura H, 2002, J IMMUNOL, V169, P1261, DOI 10.4049/jimmunol.169.3.1261; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; Walkley CR, 2004, BLOOD, V103, P1286, DOI 10.1182/blood-2003-07-2391; Wang D, 2006, BLOOD, V108, P1223, DOI 10.1182/blood-2005-12-008763; Wang QF, 2003, ONCOGENE, V22, P2548, DOI 10.1038/sj.onc.1206360; Wang QF, 2002, BLOOD, V99, P2776, DOI 10.1182/blood.V99.8.2776; Wang W, 2001, LEUKEMIA, V15, P779, DOI 10.1038/sj.leu.2402094; Wang XP, 1999, BLOOD, V94, P560, DOI 10.1182/blood.V94.2.560.414k41_560_571; Weston CR, 2002, CURR OPIN GENET DEV, V12, P14, DOI 10.1016/S0959-437X(01)00258-1; Williamson EA, 1998, J BIOL CHEM, V273, P14796, DOI 10.1074/jbc.273.24.14796; Xia CL, 1997, INT J BIOCHEM CELL B, V29, P1525, DOI 10.1016/S1357-2725(97)00083-6; Xie HF, 2004, CELL, V117, P663, DOI 10.1016/S0092-8674(04)00419-2; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P13187, DOI 10.1073/pnas.94.24.13187; Yang ZY, 2000, J BIOL CHEM, V275, P21272, DOI 10.1074/jbc.M000145200; YEAMANS C, 2007, IN PRESS BLOOD; Yoshida K, 2002, J BIOL CHEM, V277, P48372, DOI 10.1074/jbc.M205485200; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; Zhang P, 2000, BLOOD, V96, P2641; Zhang P, 1998, J EXP MED, V188, P1173, DOI 10.1084/jem.188.6.1173; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705; Zhang P, 2004, IMMUNITY, V21, P853, DOI 10.1016/j.immuni.2004.11.006; Zhang P, 2002, BLOOD, V99, P4406, DOI 10.1182/blood.V99.12.4406; Zou GM, 2005, P NATL ACAD SCI USA, V102, P13236, DOI 10.1073/pnas.0506218102; ZweidlerMcKay PA, 1996, MOL CELL BIOL, V16, P4024	194	312	326	2	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	47					6816	6828		10.1038/sj.onc.1210764	http://dx.doi.org/10.1038/sj.onc.1210764			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220HE	17934488				2022-12-17	WOS:000250147000012
J	Gray, MJ; Zhang, J; Ellis, LM; Semenza, GL; Evans, DB; Watowich, SS; Gallick, GE				Gray, MJ; Zhang, J; Ellis, LM; Semenza, GL; Evans, DB; Watowich, SS; Gallick, GE			HIF-1 alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complexthat regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas	ONCOGENE			English	Article						HIF-1a; VEGF; STAT3; Src; hypoxia; angiogenesis	ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; INDUCIBLE FACTOR-I; HUMAN COLORECTAL-CANCER; DNA-BINDING ACTIVITY; C-SRC; SIGNAL-TRANSDUCTION; TUMOR-GROWTH; CELL-LINE; V-SRC	Hypoxia stimulates a number of pathways critical to cancer cell survival, including the activation of vascular endothelial growth factor ( VEGF) transcription. In normal fibroblasts, hypoxia-induced activation of the protein tyrosine kinase, Src, is required for VEGF expression. We show here in both pancreatic and prostate carcinoma cell lines cobalt chloride ( used to mimic hypoxia) - induced VEGF expression requires Src activation and leads to increased steady-state levels of HIF-1 alpha and increased phosphorylation of signal and transducer of transcription 3 (STAT3). STAT3 and hypoxia-inducible factor (HIF)-1 alpha bind simultaneously to the VEGF promoter, where they form a molecular complex with the transcription coactivators CBP/p300 and Ref-1/APE. Expression of activated Src from an inducible promoter is sufficient to increase VEGF expression and form these STAT3/HIF-1 alpha-containing promoter complexes. Inhibition of DNA binding by expression of either STAT3 or HIF-1 alpha dominant negative mutants significantly reduces VEGF expression. These data suggest that the binding of both STAT3 and HIF-1 alpha to the VEGF promoter is required for maximum transcription of VEGF mRNA following hypoxia.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Program Canc Biol, Houston, TX USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Johns Hopkins Univ, Sch Med, Inst Cell Engn, Vasc Program, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas System; UTMD Anderson Cancer Center; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University of Texas System; UTMD Anderson Cancer Center	Gallick, GE (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	ggallick@mdanderson.org		Watowich, Stephanie/0000-0003-1969-659X	NATIONAL CANCER INSTITUTE [U54CA090810, R01CA065527] Funding Source: NIH RePORTER; NCI NIH HHS [2RO-1 CA65527, U54 CA 090810-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM SE, 1993, ONCOGENE, V8, P1639; Alvarez-Tejado M, 2001, J BIOL CHEM, V276, P22368, DOI 10.1074/jbc.M011688200; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Bardos JI, 2004, BIOESSAYS, V26, P262, DOI 10.1002/bies.20002; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Buchler P, 2003, PANCREAS, V26, P56, DOI 10.1097/00006676-200301000-00010; Calo V, 2003, J CELL PHYSIOL, V197, P157, DOI 10.1002/jcp.10364; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Chan DA, 2002, J BIOL CHEM, V277, P40112, DOI 10.1074/jbc.M206922200; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Ellis LM, 1996, EUR J CANCER, V32A, P2451, DOI 10.1016/S0959-8049(96)00389-9; Ellis LM, 1998, J BIOL CHEM, V273, P1052, DOI 10.1074/jbc.273.2.1052; FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021; Fleming RYD, 1997, SURGERY, V122, P501, DOI 10.1016/S0039-6060(97)90044-1; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Folkman J, 1992, Semin Cancer Biol, V3, P65; Fontanini G, 2002, BRIT J CANCER, V86, P558, DOI 10.1038/sj.bjc.6600130; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gu J, 2001, J BIOL CHEM, V276, P3550, DOI 10.1074/jbc.M009522200; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hartenbach EM, 1997, CANCER LETT, V121, P169, DOI 10.1016/S0304-3835(97)00350-9; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Ishigami SI, 1998, BRIT J CANCER, V78, P1379, DOI 10.1038/bjc.1998.688; Itakura J, 1997, CLIN CANCER RES, V3, P1309; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jackson MW, 1997, J UROLOGY, V157, P2323, DOI 10.1016/S0022-5347(01)64774-8; Jiang BH, 1997, CANCER RES, V57, P5328; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Joung YH, 2003, EXP MOL MED, V35, P350, DOI 10.1038/emm.2003.46; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kaptein A, 1996, J BIOL CHEM, V271, P5961, DOI 10.1074/jbc.271.11.5961; Karni R, 2002, J BIOL CHEM, V277, P42919, DOI 10.1074/jbc.M206141200; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Liu XH, 2002, J BIOL CHEM, V277, P50081, DOI 10.1074/jbc.M201095200; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mayerhofer M, 2002, BLOOD, V100, P3767, DOI 10.1182/blood-2002-01-0109; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; MINCHENKO A, 1994, LAB INVEST, V71, P374; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Nam DH, 2004, ONCOL REP, V11, P863; Namiki A, 1995, J BIOL CHEM, V270, P31189, DOI 10.1074/jbc.270.52.31189; Niedergethmann M, 2002, PANCREAS, V25, P122, DOI 10.1097/00006676-200208000-00002; Niu G, 2002, ONCOGENE, V21, P7001, DOI 10.1038/sj.onc.1205859; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; PUGH CW, 1994, BBA-GENE STRUCT EXPR, V1217, P297, DOI 10.1016/0167-4781(94)90289-5; Ray S, 2002, MOL ENDOCRINOL, V16, P824, DOI 10.1210/me.16.4.824; Schaefer LK, 1999, BIOCHEM BIOPH RES CO, V266, P481, DOI 10.1006/bbrc.1999.1853; Schuringa JJ, 2001, FEBS LETT, V495, P71, DOI 10.1016/S0014-5793(01)02354-7; Semenza GL, 2002, INTERNAL MED, V41, P79, DOI 10.2169/internalmedicine.41.79; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Senger DR, 1996, AM J PATHOL, V149, P293; SHWEIKI D, 1992, NATURE, V359, P845; Staley CA, 1997, CELL GROWTH DIFFER, V8, P269; Stoeltzing O, 2003, AM J PATHOL, V163, P1001, DOI 10.1016/S0002-9440(10)63460-8; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; TAKAHASHI Y, 1995, CANCER RES, V55, P3964; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; Thornton RD, 2000, BIOCHEM J, V350, P307, DOI 10.1042/0264-6021:3500307; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Uehara M, 2004, ORAL ONCOL, V40, P321, DOI 10.1016/j.oraloncology.2003.08.020; Watanabe Y, 1997, ONCOGENE, V14, P2025, DOI 10.1038/sj.onc.1201033; Wei DY, 2003, ONCOGENE, V22, P319, DOI 10.1038/sj.onc.1206122; Wiener JR, 1999, CLIN CANCER RES, V5, P2164; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; Yahata Y, 2003, J BIOL CHEM, V278, P40026, DOI 10.1074/jbc.M301866200; Yamashita K, 2001, J BIOL CHEM, V276, P12645, DOI 10.1074/jbc.M011344200; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Ziel KA, 2004, FASEB J, V18, P986, DOI 10.1096/fj.03-1160fje	81	312	338	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2005	24	19					3110	3120		10.1038/sj.onc.1208513	http://dx.doi.org/10.1038/sj.onc.1208513			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735682				2022-12-17	WOS:000228728100005
J	Schnelzer, A; Prechtel, D; Knaus, U; Dehne, K; Gerhard, M; Graeff, H; Harbeck, N; Schmitt, M; Lengyel, E				Schnelzer, A; Prechtel, D; Knaus, U; Dehne, K; Gerhard, M; Graeff, H; Harbeck, N; Schmitt, M; Lengyel, E			Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b	ONCOGENE			English	Article						Rho GTPases; Rac1; isoform; breast cancer; ductal carcinoma-in-situ; metastasis	GTP-BINDING PROTEIN; RAS TRANSFORMATION; NADPH OXIDASE; GROWTH-FACTOR; CELL-LINES; EXPRESSION; RHO; GTPASES; FAMILY; CDC42	Rac1 is a member of the Ras superfamily of small guanosine triphosphatases (GTPases) that act as molecular switches to control cytoskeletal rearrangements and cell growth. Analogous to Ras, constitutively activating point mutations of Rad cause tumorigenic transformation of cell lines. However, there is no information about whether Rad is also mutated in vivo, After RT-PCR of Rad, several clones of seven benign and 10 malignant breast cancer tissues as well as eight breast cancer cell lines were sequenced. Only single-nucleotide polymorphisms of Rad could be detected, and none of these corresponded to constitutively activating point mutations that have been used in cell lines for transformation. While sequencing Rad in breast tissues, a new Rad isoform with an insertion of 19 codons within the reading frame of Rad close to switch region II was identified and named Rac1b, The Rac1b protein acts like a fast cycling GTPase in GTP binding and hydrolysis assays, In Northern and Western blot experiments both Rad RNA and Rad protein had a significantly higher expression in breast cancer tissues compared to normal breast tissue samples. Immunohistochemical staining of Rad showed weak Rad expression in benign breast disease but high expression level in ductal carcinoma-in-situ, primary breast cancer, and lymph node metastases. In addition, breast tumor cells from patients with recurrent disease had Rad expression at the plasma membrane, suggesting activation of Rad, in patients with aggressive breast cancer.	Tech Univ Munich, Klinikum Rechts Isar, Dept Obstet & Gynecol, D-81675 Munich, Germany; Tech Univ Munich, Klinikum Rechts Isar, Dept Pathol, D-81675 Munich, Germany; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Tech Univ Munich, Dept Internal Med 2, D-81675 Munich, Germany	Technical University of Munich; Technical University of Munich; Scripps Research Institute; Technical University of Munich	Lengyel, E (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Dept Obstet & Gynecol, Ismaninger Str 22, D-81675 Munich, Germany.		Gerhard, Markus/P-8996-2019; Lengyel, Ernst/D-9220-2014; Gerhard, Markus/N-3387-2014	Gerhard, Markus/0000-0001-9110-3950; Lengyel, Ernst/0000-0001-8624-1507; Gerhard, Markus/0000-0001-9110-3950; Schnelzer, Andreas/0000-0002-5410-3561				Anand-Apte B, 1997, J BIOL CHEM, V272, P30688, DOI 10.1074/jbc.272.49.30688; BACHER A, 1992, EXP CELL RES, V200, P97, DOI 10.1016/S0014-4827(05)80076-X; BEAUDET AL, 1993, HUM MUTAT, V2, P245, DOI 10.1002/humu.1380020402; BOS JL, 1989, CANCER RES, V49, P4682; Burstein ES, 1998, ONCOGENE, V17, P1617, DOI 10.1038/sj.onc.1202067; CHUANG TH, 1994, BIOCHEM J, V303, P761, DOI 10.1042/bj3030761; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Dickson R B, 1992, Cancer Treat Res, V61, P249; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; Fleming IN, 1996, J BIOL CHEM, V271, P33067, DOI 10.1074/jbc.271.51.33067; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Harbeck N, 1999, BREAST CANCER RES TR, V54, P147, DOI 10.1023/A:1006118828278; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Jordan P, 1999, ONCOGENE, V18, P6835, DOI 10.1038/sj.onc.1203233; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; Krizman DB, 1996, CANCER RES, V56, P5380; Lengyel E, 1996, J BIOL CHEM, V271, P23176, DOI 10.1074/jbc.271.38.23176; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PARADA LF, 1982, NATURE, V297, P474, DOI 10.1038/297474a0; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QUINN MT, 1993, J BIOL CHEM, V268, P20983; Schaller G, 1996, CLIN CANCER RES, V2, P1879; Schiedt K., 1995, CAROTENOIDS, V1A, P81; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; Xu XM, 1997, BIOCHEMISTRY-US, V36, P626, DOI 10.1021/bi962059h; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	31	312	322	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2000	19	26					3013	3020		10.1038/sj.onc.1203621	http://dx.doi.org/10.1038/sj.onc.1203621			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323TQ	10871853	Green Published			2022-12-17	WOS:000087581400008
J	Altucci, L; Addeo, R; Cicatiello, L; Dauvois, S; Parker, MG; Truss, M; Beato, M; Sica, V; Bresciani, F; Weisz, A				Altucci, L; Addeo, R; Cicatiello, L; Dauvois, S; Parker, MG; Truss, M; Beato, M; Sica, V; Bresciani, F; Weisz, A			17 beta-Estradiol induces cyclin D-1 gene transcription, p36(D1)-p34(cdk4) complex activation and p105(Rb) phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer	ONCOGENE			English	Article						estrogen; breast cancer; cell cycle; cyclins; HMG-CoA reductase; retinoblastoma protein	MYC ONCOGENE EXPRESSION; CELL-CYCLE; RETINOBLASTOMA PROTEIN; NUCLEAR-PROTEIN; GROWTH-FACTOR; OVEREXPRESSION; PROGRESSION; FIBROBLASTS; INHIBITION; LOVASTATIN	MCF-7 human breast cancer cells express functional estrogen receptor and grow in response to estrogen stimulation. G(1)-synchronized MCF-7 cells, made quiescent by exposure to the HMG-CoA reductase inhibitor Simvastatin in estrogen-free medium, readily resume cell cycle progression up-on stimulation with 17 beta-estradiol (E(2)), even under conditions where polypeptide growth factor-triggered signal transduction pathways are inhibited by the continuous presence of Simvastatin in the culture medium. Under these conditions, cyclin D-1 gene transcription is transiently induced within the first 1-9 h of stimulation, as shown by the accumulation of cyclin D-1 mRNA and protein (p36(D1)) in the cell and by enhanced expression of stably transfected D-1 promoter-luciferase hybrid genes. Estrogen-induced p36(D1) associates readily with p32(cdk2) and p34(cdk4), but not with p31(cdk5) which is however abundantly expressed in these cells. Only p36(D1)-p34(cdk4) complexes are activated by E(2), as detected in cell extracts by immunoprecipitation with anti-D-1 antibodies followed by assessment of phosphotransferase activity toward the retinoblastoma (Rb) gene product and by analysis of p105(Rb) phosphorylation in vivo, An estrogen-responsive regulatory region has been mapped within the first 944 bp upstream of the transcriptional startsite of the human D-1 gene. Sequence analysis of this DNA region reveals that the cis-acting elements responsive to estrogen are likely to be different in this case from the canonical EREs.	UNIV NAPLES 2, FAC MED & CHIRURG, IST PATOL GEN & ONCOL, I-80138 NAPLES, ITALY; IMPERIAL CANC RES FUND, MOLEC ENDOCRINOL LAB, LONDON WC2A 3PX, ENGLAND; UNIV MARBURG, INST MOLEK BIOL & TUMORFORSCH, D-35037 MARBURG, GERMANY	Universita della Campania Vanvitelli; Cancer Research UK; Philipps University Marburg			Altucci, Lucia/S-8031-2019; Weisz, Alessandro/A-1317-2014; Beato, Miguel/B-5564-2015	Weisz, Alessandro/0000-0003-0455-2083; Beato, Miguel/0000-0002-2878-2222; altucci, lucia/0000-0002-7312-5387				ADDEO R, 1996, IN PRESS BIOCH BIOPH; AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BATES S, 1994, ONCOGENE, V9, P71; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; Bonapace IM, 1996, ONCOGENE, V12, P753; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DOYLE A, 1994, CELL TISSUE CULTURE; DUBIK D, 1987, CANCER RES, V47, P6517; DUBIK D, 1992, ONCOGENE, V7, P1587; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FILMUS J, 1994, ONCOGENE, V9, P3627; GRANA X, 1995, ONCOGENE, V11, P211; HALL FL, 1993, ONCOGENE, V8, P1377; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harlow E LD, 1988, ANTIBODIES LAB MANUA; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HERBER B, 1994, ONCOGENE, V9, P1295; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JAKOBISIAK M, 1991, P NATL ACAD SCI USA, V88, P3628, DOI 10.1073/pnas.88.9.3628; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; JIANG W, 1993, ONCOGENE, V8, P3447; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KEYOMARSI K, 1991, CANCER RES, V51, P3602; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LANDERS J P, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P19; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; LUKAS J, 1995, ONCOGENE, V10, P2125; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESTNITZKY D, 1994, MOL CELL BIOL, V14, P1669; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SUKOVICH DA, 1994, MOL CELL BIOL, V14, P7134, DOI 10.1128/MCB.14.11.7134; TAM SW, 1994, ONCOGENE, V9, P2663; VEDECKIS WV, 1992, P SOC EXP BIOL MED, V199, P1; VINCENT TS, 1991, BIOCHEM BIOPH RES CO, V180, P1284, DOI 10.1016/S0006-291X(05)81334-8; WATTS CKW, 1994, BREAST CANCER RES TR, V31, P95, DOI 10.1007/BF00689680; WEISZ A, 1993, CRIT REV ONCOGENESIS, V4, P361; WEISZ A, 1990, MOL ENDOCRINOL, V4, P1041, DOI 10.1210/mend-4-7-1041; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	68	312	316	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	1996	12	11					2315	2324						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649771				2022-12-17	WOS:A1996UQ22000008
J	Chen, J; Xie, J; Jiang, Z; Wang, B; Wang, Y; Hu, X				Chen, J.; Xie, J.; Jiang, Z.; Wang, B.; Wang, Y.; Hu, X.			Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2	ONCOGENE			English	Article						shikonin; alkannin; pyruvate kinase-M2; glycolysis; inhibitor	ALLOSTERIC REGULATION; DRUG-RESISTANCE; DEATH; M2; IDENTIFICATION; INDUCTION; ISOZYMES; METABOLISM; APOPTOSIS; GROWTH	We recently reported that shikonin and its analogs were a class of necroptotic inducers that could bypass cancer drug resistance. However, the molecular targets of shikonin are not known. Here, we showed that shikonin and its analogs are inhibitors of tumor-specific pyruvate kinase-M2 (PKM2), among which shikonin and its enantiomeric isomer alkannin were the most potent and showed promising selectivity, that is, shikonin and alkannin at concentrations that resulted in over 50% inhibition of PKM2 activity did not inhibit PKM1 and pyruvate kinase-L (PKL). Shikonin and alkannin significantly inhibited the glycolytic rate, as manifested by cellular lactate production and glucose consumption in drug-sensitive and resistant cancer cell lines (MCF-7, MCF-7/Adr, MCF-7/Bcl-2, MCF-7/Bcl-x(L) and A549) that primarily express PKM2. HeLa cells transfected with PKM1 showed reduced sensitivity to shikonin-or alkannin-induced cell death. To the best of our knowledge, shikonin and alkannin are the most potent and specific inhibitors to PKM2 reported so far. As PKM2 universally expresses in cancer cells and dictates the last rate-limiting step of glycolysis vital for cancer cell proliferation and survival, enantiomeric shikonin and alkannin may have potential in future clinical application. Oncogene (2011) 30, 4297-4306; doi: 10.1038/onc.2011.137; published online 25 April 2011	[Chen, J.; Xie, J.; Wang, B.; Hu, X.] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Inst Canc, Hangzhou 310009, Zhejiang, Peoples R China; [Jiang, Z.; Wang, Y.] Zhejiang Univ, Dept Chem, Hangzhou 310009, Zhejiang, Peoples R China	Zhejiang University; Zhejiang University	Hu, X (corresponding author), Zhejiang Univ, Sch Med, Affiliated Hosp 2, Inst Canc, 88 Jiefang Rd, Hangzhou 310009, Zhejiang, Peoples R China.	huxun@zju.edu.cn			China National 863 project [2007AA02Z143]; China Natural Sciences Foundation [30772544, 81071802]; Fundamental Research Funds for the Central Universities, National Ministry of Education, China	China National 863 project(National High Technology Research and Development Program of China); China Natural Sciences Foundation(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities, National Ministry of Education, China	We thank BPS Bioscience Inc (San Diego, CA, USA) for technical support of their product-recombinant human PKM2. This work was supported in part by the China National 863 project (2007AA02Z143) to XH; China Natural Sciences Foundation projects (30772544, 81071802) to XH and the Fundamental Research Funds for the Central Universities, National Ministry of Education, China, to XH.	AHN BZ, 1995, J MED CHEM, V38, P1044, DOI 10.1021/jm00006a025; Altenberg B, 2004, GENOMICS, V84, P1014, DOI 10.1016/j.ygeno.2004.08.010; ANDERSON SR, 1964, J BIOL CHEM, V239, P2991; Bailly C, 2000, CURR MED CHEM, V7, P39, DOI 10.2174/0929867003375489; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83; Dombrauckas JD, 2005, BIOCHEMISTRY-US, V44, P9417, DOI 10.1021/bi0474923; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Guo X P, 1991, Zhong Xi Yi Jie He Za Zhi, V11, P598; Han WD, 2007, MOL CANCER THER, V6, P1641, DOI 10.1158/1535-7163.MCT-06-0511; Han WD, 2009, APOPTOSIS, V14, P674, DOI 10.1007/s10495-009-0334-x; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hirayama A, 2009, CANCER RES, V69, P4918, DOI 10.1158/0008-5472.CAN-08-4806; Hitomi JI, 2008, CELL, V135, P1311, DOI 10.1016/j.cell.2008.10.044; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Hu X, 2008, CANCER LETT, V259, P127, DOI 10.1016/j.canlet.2007.11.007; IBSEN KH, 1977, CANCER RES, V37, P341; Ikeda Y, 1998, J BIOL CHEM, V273, P12227, DOI 10.1074/jbc.273.20.12227; IMAMURA K, 1973, J BIOCHEM, V74, P1165, DOI 10.1093/oxfordjournals.jbchem.a130344; Jurica MS, 1998, STRUCTURE, V6, P195, DOI 10.1016/S0969-2126(98)00021-5; Kim SH, 2001, CANCER LETT, V172, P171, DOI 10.1016/S0304-3835(01)00665-6; Li L, 2007, CANCER RES, V67, P4894, DOI 10.1158/0008-5472.CAN-06-3818; Liu K, 2008, J MED CHEM, V51, P7843, DOI 10.1021/jm800869t; Masuda Y, 2004, J BIOL CHEM, V279, P42503, DOI 10.1074/jbc.M404256200; Masuda Y, 2003, ONCOGENE, V22, P1012, DOI 10.1038/sj.onc.1206200; Mazurek S, 2008, ERNST SCHERING FOUND, V4, P99, DOI 10.1007/2789_2008_091; Mazurek S, 2005, SEMIN CANCER BIOL, V15, P300, DOI 10.1016/j.semcancer.2005.04.009; Mazurek S, 2003, ANTICANCER RES, V23, P1149; Mazurek S, 2002, BRIT J NUTR, V87, pS23, DOI [10.1079/BJN2001454, 10.1079/BJN2001455]; Nakaya K, 2003, ANTI-CANCER DRUG, V14, P683, DOI 10.1097/01.cad.0000092781.37568.df; NOGUCHI T, 1987, J BIOL CHEM, V262, P14366; NOGUCHI T, 1986, J BIOL CHEM, V261, P3807; PAPAGEORGIOU VPA, 1999, ANGEW CHEM INT EDIT, V38, P32; PARKISON C, 1991, BIOCHEM BIOPH RES CO, V179, P668, DOI 10.1016/0006-291X(91)91424-B; Shimada N, 2008, GENES CELLS, V13, P245, DOI 10.1111/j.1365-2443.2008.01165.x; Spoden GA, 2008, INT J CANCER, V123, P312, DOI 10.1002/ijc.23512; Spoden GA, 2009, EXP CELL RES, V315, P2765, DOI 10.1016/j.yexcr.2009.06.024; Vander Heiden MG, 2010, BIOCHEM PHARMACOL, V79, P1118, DOI 10.1016/j.bcp.2009.12.003; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Xuan YY, 2009, CANCER LETT, V274, P233, DOI 10.1016/j.canlet.2008.09.029; Yang HJ, 2009, INT J CANCER, V124, P2450, DOI 10.1002/ijc.24195	43	311	324	14	99	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2011	30	42					4297	4306		10.1038/onc.2011.137	http://dx.doi.org/10.1038/onc.2011.137			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	839HP	21516121				2022-12-17	WOS:000296356400001
J	Belmokhtar, CA; Hillion, J; Segal-Bendirdjian, E				Belmokhtar, CA; Hillion, J; Segal-Bendirdjian, E			Staurosporine induces apoptosis through both caspase-dependent and caspase-independent mechanisms	ONCOGENE			English	Article						staurosporine; apoptosis; caspase; L1210	CELL-DEATH; CROSS-RESISTANCE; GRANZYME-B; PROTEASES; LEUKEMIA; ACTIVATION; CLEAVAGE; NECROSIS; PATHWAY; FAMILY	Sensitivity of tumor cells to anticancer therapy depends on the ability of the drug to induce apoptosis, However, multiple signaling pathways control this induction and thus determine this sensitivity. We report here that staurosporine, a well known inducer of apoptosis in a wide range of cell lines, displays distinct ability to trigger apoptosis in two different L1210 sublines (termed 1,1210/ S and L1210/0). Staurosporine treatment resulted in an early cell death (within 3 h) in L1210/S cells, while in L1210/0 cells, death occurred only after 12 h. In both instances, death occurred by apoptosis. A broad spectrum caspase inhibitor, z-VAD-fmk, blocked early apoptosis in L1210/S cells but did not confer any protection on late apoptosis in L1210/0 cells. Protection by z-VAD-fmk observed in L1210/S cells was not lasting and unmasked a secondary process of cell death that also exhibited characteristics of apoptosis. Thus, staurosporine induces apoptotic cell death through at least two redundant parallel pathways. These two pathways normally coexist in L1210/S cells. However, the early cell death mechanism depending on caspase activation disguises the late caspase-independent apoptotic process. Staurosporine-induced apoptosis in L1210/0 cells develops only by the caspase-independent mechanism due to a general defect in caspase activation.	Hop St Louis, INSERM, U496, Ctr G Hayem, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Segal-Bendirdjian, E (corresponding author), Hop St Louis, INSERM, U496, Ctr G Hayem, 1 Ave Claude Vellefaux, F-75010 Paris, France.			Segal-Bendirdjian, Evelyne/0000-0001-9813-4880				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; ALNEMRI ES, 1990, J BIOL CHEM, V265, P17323; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; Brunet CL, 1998, CELL DEATH DIFFER, V5, P107, DOI 10.1038/sj.cdd.4400334; BURCHENAL JH, 1977, CANCER RES, V37, P3455; Coelho D, 2000, BRIT J CANCER, V83, P642, DOI 10.1054/bjoc.2000.1322; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Deas O, 1998, J IMMUNOL, V161, P3375; DIVE C, 1991, BRIT J CANCER, V64, P192, DOI 10.1038/bjc.1991.269; EASTMAN A, 1981, BIOCHEM PHARMACOL, V30, P2721, DOI 10.1016/0006-2952(81)90546-3; FERNANDES RS, 1993, ANTICANCER RES, V13, P1253; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; Kim WJ, 2000, EXP EYE RES, V71, P225, DOI 10.1006/exer.2000.0872; Kumar S, 1996, CELL DEATH DIFFER, V3, P255; LANOTTE M, 1991, BLOOD, V77, P1080; Lavoie JN, 1998, J CELL BIOL, V140, P637, DOI 10.1083/jcb.140.3.637; LAW LW, 1949, J NATL CANCER I, V10, P179; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lemaire C, 1998, FEBS LETT, V425, P266, DOI 10.1016/S0014-5793(98)00252-X; Los M, 1997, BLOOD, V90, P3118, DOI 10.1182/blood.V90.8.3118; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; MCCONKEY DJ, 1989, J IMMUNOL, V143, P1801; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; MOORE GE, 1966, JNCI-J NATL CANCER I, V36, P405; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; SARRE AT, 1999, CANCER RES, V59, P3565; SEGALBENDIRDJIAN E, 1995, EXP CELL RES, V218, P201, DOI 10.1006/excr.1995.1148; SEN S, 1992, FEBS LETT, V307, P122, DOI 10.1016/0014-5793(92)80914-3; Tainton KM, 2000, BIOCHEM BIOPH RES CO, V276, P231, DOI 10.1006/bbrc.2000.3459; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Trapani JA, 1998, J BIOL CHEM, V273, P27934, DOI 10.1074/jbc.273.43.27934; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559	40	311	316	0	33	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2001	20	26					3354	3362		10.1038/sj.onc.1204436	http://dx.doi.org/10.1038/sj.onc.1204436			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	441UW	11423986				2022-12-17	WOS:000169248800006
J	YOKOTA, J; AKIYAMA, T; FUNG, YKT; BENEDICT, WF; NAMBA, Y; HANAOKA, M; WADA, M; TERASAKI, T; SHIMOSATO, Y; SUGIMURA, T; TERADA, M				YOKOTA, J; AKIYAMA, T; FUNG, YKT; BENEDICT, WF; NAMBA, Y; HANAOKA, M; WADA, M; TERASAKI, T; SHIMOSATO, Y; SUGIMURA, T; TERADA, M			ALTERED EXPRESSION OF THE RETINOBLASTOMA (RB) GENE IN SMALL-CELL CARCINOMA OF THE LUNG	ONCOGENE			English	Article									KYOTO UNIV,INST VIRUS RES,KYOTO 606,JAPAN; UNIV SO CALIF,SCH MED,DEPT PEDIAT & MICROBIOL,LOS ANGELES,CA 90033; CHILDRENS HOSP LOS ANGELES,DIV OPHTHALMOL,LOS ANGELES,CA 90027; UNIV SO CALIF,SCH MED,DEPT OPHTHALMOL & PEDIAT,LOS ANGELES,CA 90033; CHILDRENS HOSP LOS ANGELES,DIV HEMATOL ONCOL,LOS ANGELES,CA 90027	Kyoto University; University of Southern California; Children's Hospital Los Angeles; University of Southern California; Children's Hospital Los Angeles	YOKOTA, J (corresponding author), NATL CANC CTR,RES INST,STUDIES METASTASIS SECT,1-1 TSUKIJI 5 CHOME,CHUO KU,TOKYO 104,JAPAN.				NEI NIH HHS [EY-02715] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY002715] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AKIYAMA T, 1984, BIOCHEM BIOPH RES CO, V123, P797, DOI 10.1016/0006-291X(84)90300-0; AKIYAMA T, 1986, ARCH BIOCHEM BIOPHYS, V245, P531, DOI 10.1016/0003-9861(86)90246-8; CAVENEE W, 1984, AM J HUM GENET, V36, P10; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GAMOU S, 1987, CANCER RES, V47, P2668; GODDARD AD, 1988, MOL CELL BIOL, V8, P2082, DOI 10.1128/MCB.8.5.2082; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; TERASAKI T, 1986, JPN J CLIN ONCOL, V16, P203; WILLARD HF, 1985, CYTOGENET CELL GENET, V40, P360, DOI 10.1159/000132180; YAMADA T, 1985, JPN J CANCER RES, V76, P967; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252	20	311	347	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1988	3	4					471	475						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q7739	2856251				2022-12-17	WOS:A1988Q773900017
J	Corradetti, MN; Guan, KL				Corradetti, M. N.; Guan, K-L			Upstream of the mammalian target of rapamycin: do all roads pass through mTOR?	ONCOGENE			English	Review						mTOR; rapamycin; Akt; cellular stress; translation; mTORC1	ACTIVATED PROTEIN-KINASE; TUBEROUS SCLEROSIS COMPLEX; P70 S6 KINASE; GROWTH-FACTOR RECEPTOR; CELL-GROWTH; HYDROGEN-PEROXIDE; OSMOTIC-STRESS; PHOSPHATIDYLINOSITOL 3-KINASE; REPLICATING ADENOVIRUSES; ENHANCED SENSITIVITY	The mammalian target of rapamycin ( mTOR) is a serine/threonine kinase that controls many aspects of cellular physiology, including transcription, translation, cell size, cytoskeletal organization and autophagy. Recent advances in the mTOR signaling field have found that mTOR exists in two heteromeric complexes, mTORC1 and mTORC2. The activity of mTORC1 is regulated by the integration of many signals, including growth factors, insulin, nutrients, energy availability and cellular stressors such as hypoxia, osmotic stress, reactive oxygen species and viral infection. In this review we highlight recent advances in the mTOR signaling field that relate to how the two mTOR complexes are regulated, and we discuss stress conditions linked to the mTOR signaling network that have not been extensively covered in other reviews. Given the diversity of signals that have been shown to impinge on mTOR, we also speculate on other signal-transduction pathways that may be linked to mTOR in the future.	Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Inst Gerontol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Corradetti, MN (corresponding author), Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA.	mcorrade@umich.edu; kunliang@umich.edu			NICHD NIH HHS [5-T32-HD075005] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R21HD075005] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Andreoni KA, 2002, J MED VIROL, V67, P33, DOI 10.1002/jmv.2189; Arsham AM, 2003, J BIOL CHEM, V278, P29655, DOI 10.1074/jbc.M212770200; Astrinidis A, 2006, HUM MOL GENET, V15, P287, DOI 10.1093/hmg/ddi444; Avruch J, 2005, CURR OPIN CLIN NUTR, V8, P67, DOI 10.1097/00075197-200501000-00010; Baas AF, 2003, EMBO J, V22, P3062, DOI 10.1093/emboj/cdg292; Bader AG, 2004, ONCOGENE, V23, P3145, DOI 10.1038/sj.onc.1207550; Bae GU, 1999, J BIOL CHEM, V274, P32596, DOI 10.1074/jbc.274.46.32596; Beuvink I, 2005, CELL, V120, P747, DOI 10.1016/j.cell.2004.12.040; Birchenall-Roberts MC, 2004, J BIOL CHEM, V279, P25605, DOI 10.1074/jbc.M402790200; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Bolster DR, 2002, J BIOL CHEM, V277, P23977, DOI 10.1074/jbc.C200171200; Boonstra J, 2004, GENE, V337, P1, DOI 10.1016/j.gene.2004.04.032; Bosotti R, 2000, TRENDS BIOCHEM SCI, V25, P225, DOI 10.1016/S0968-0004(00)01563-2; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Brugarolas JB, 2003, CANCER CELL, V4, P147, DOI 10.1016/S1535-6108(03)00187-9; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Byfield MP, 2005, J BIOL CHEM, V280, P33076, DOI 10.1074/jbc.M507201200; Castedo M, 2002, EMBO J, V21, P4070, DOI 10.1093/emboj/cdf391; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; Constantinou C, 2005, ONCOGENE, V24, P4839, DOI 10.1038/sj.onc.1208648; Corradetti MN, 2004, GENE DEV, V18, P1533, DOI 10.1101/gad.1199104; Corradetti MN, 2005, J BIOL CHEM, V280, P9769, DOI 10.1074/jbc.C400557200; Dames SA, 2005, J BIOL CHEM, V280, P20558, DOI 10.1074/jbc.M501116200; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Desai BN, 2002, P NATL ACAD SCI USA, V99, P4319, DOI 10.1073/pnas.261702698; Dong LQ, 2005, AM J PHYSIOL-ENDOC M, V289, pE187, DOI 10.1152/ajpendo.00011.2005; Edinger AL, 2003, CANCER RES, V63, P8451; Eisen HJ, 2003, NEW ENGL J MED, V349, P847, DOI 10.1056/NEJMoa022171; Ellisen LW, 2002, MOL CELL, V10, P995, DOI 10.1016/S1097-2765(02)00706-2; Eng C, 2003, HUM MUTAT, V22, P183, DOI 10.1002/humu.10257; Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Finlay GA, 2005, CANCER RES, V65, P10881, DOI 10.1158/0008-5472.CAN-05-1394; Finlay GA, 2004, J BIOL CHEM, V279, P23114, DOI 10.1074/jbc.M401912200; Frese KK, 2003, ONCOGENE, V22, P710, DOI 10.1038/sj.onc.1206151; Gan BY, 2005, J CELL BIOL, V170, P379, DOI 10.1083/jcb.200411106; Gangloff YG, 2004, MOL CELL BIOL, V24, P9508, DOI 10.1128/MCB.24.21.9508-9516.2004; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; Hansen IA, 2004, P NATL ACAD SCI USA, V101, P10626, DOI 10.1073/pnas.0403460101; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Haruta T, 2000, MOL ENDOCRINOL, V14, P783, DOI 10.1210/me.14.6.783; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024; Homicsko K, 2005, CANCER RES, V65, P6882, DOI 10.1158/0008-5472.CAN-05-0309; Horton LE, 2002, ONCOGENE, V21, P5325, DOI 10.1038/sj.onc.1205662; Huang CS, 2002, CANCER RES, V62, P5689; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Iijima Y, 2002, J BIOL CHEM, V277, P23065, DOI 10.1074/jbc.M200328200; Inoki K, 2005, NAT GENET, V37, P19, DOI 10.1038/ng1494; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; Johannessen CM, 2005, P NATL ACAD SCI USA, V102, P8573, DOI 10.1073/pnas.0503224102; Johnson L, 2002, CANCER CELL, V1, P325, DOI 10.1016/S1535-6108(02)00060-0; Johnson RA, 2001, J VIROL, V75, P6022, DOI 10.1128/JVI.75.13.6022-6032.2001; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Jung DK, 2003, EXP CELL RES, V290, P144, DOI 10.1016/S0014-4827(03)00320-3; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kimura N, 2003, GENES CELLS, V8, P65, DOI 10.1046/j.1365-2443.2003.00615.x; Krause U, 2002, EUR J BIOCHEM, V269, P3751, DOI 10.1046/j.1432-1033.2002.03074.x; KRUPPA J, 1984, EMBO J, V3, P95, DOI 10.1002/j.1460-2075.1984.tb01767.x; Kudchodkar SB, 2004, J VIROL, V78, P11030, DOI 10.1128/JVI.78.20.11030-11039.2004; Li Y, 2004, MOL CELL BIOL, V24, P7965, DOI 10.1128/MCB.24.18.7965-7975.2004; LI Y, 2003, J BIOL CHEM, V11, P11; Lin L, 2005, BIOCHEM J, V392, P93, DOI 10.1042/BJ20050553; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Long X, 2005, CURR BIOL, V15, P702, DOI 10.1016/j.cub.2005.02.053; Long XM, 2005, J BIOL CHEM, V280, P23433, DOI 10.1074/jbc.C500169200; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Ma L, 2005, GENE DEV, V19, P1779, DOI 10.1101/gad.1314405; Mahfouz MM, 2006, PLANT CELL, V18, P477, DOI 10.1105/tpc.105.035931; Majumder PK, 2005, ONCOGENE, V24, P7465, DOI 10.1038/sj.onc.1209096; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549; Manning BD, 2005, GENE DEV, V19, P1773, DOI 10.1101/gad.1314605; Manning BD, 2004, J CELL BIOL, V167, P399, DOI 10.1083/jcb.200408161; Martin DE, 2005, CURR OPIN CELL BIOL, V17, P158, DOI 10.1016/j.ceb.2005.02.008; Mata J, 2005, TRENDS BIOCHEM SCI, V30, P506, DOI 10.1016/j.tibs.2005.07.005; Menand B, 2003, CURR TOP MICROBIOL, V279, P97; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Murakami M, 2004, MOL CELL BIOL, V24, P6710, DOI 10.1128/mcb.24.15.6710-6718.2004; Naegele S, 2004, J BIOL CHEM, V279, P46023, DOI 10.1074/jbc.M404945200; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Nobukuni T, 2005, P NATL ACAD SCI USA, V102, P14238, DOI 10.1073/pnas.0506925102; O'Shea C, 2005, EMBO J, V24, P1211, DOI 10.1038/sj.emboj.7600597; O'Shea CC, 2005, CELL CYCLE, V4, P883, DOI 10.4161/cc.4.7.1791; O'Shea CC, 2005, CURR OPIN GENET DEV, V15, P18, DOI 10.1016/j.gde.2004.12.010; Parrott LA, 1999, J BIOL CHEM, V274, P24731, DOI 10.1074/jbc.274.35.24731; Patel J, 2002, EUR J BIOCHEM, V269, P3076, DOI 10.1046/j.1432-1033.2002.02992.x; Perry J, 2003, CELL, V112, P151, DOI 10.1016/S0092-8674(03)00033-3; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Ponticelli C, 2004, J NEPHROL, V17, P762; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Prendergast GC, 2003, CANCER CELL, V4, P244, DOI 10.1016/S1535-6108(03)00247-2; Proud CG, 2003, CURR TOP MICROBIOL, V279, P215; Proud CG, 2004, DNA REPAIR, V3, P927, DOI 10.1016/j.dnarep.2004.03.012; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Rajasekhar VK, 2004, ONCOGENE, V23, P3248, DOI 10.1038/sj.onc.1207546; Reiling JH, 2004, GENE DEV, V18, P2879, DOI 10.1101/gad.322704; Rosner M, 2004, J BIOL CHEM, V279, P48707, DOI 10.1074/jbc.M405528200; Rosner M, 2004, AMINO ACIDS, V27, P119, DOI 10.1007/s00726-004-0119-z; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; SABORIO JL, 1974, J MOL BIOL, V85, P195, DOI 10.1016/0022-2836(74)90360-X; Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009; Sarbassov DD, 2005, J BIOL CHEM, V280, P39505, DOI 10.1074/jbc.M506096200; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; Shah OJ, 2004, CURR BIOL, V14, P1650, DOI 10.1016/j.cub.2004.08.026; Shamji AF, 2003, MOL CELL, V12, P271, DOI 10.1016/j.molcel.2003.08.016; Shaw RJ, 2005, SCIENCE, V310, P1642, DOI 10.1126/science.1120781; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Shi YJ, 2002, CANCER RES, V62, P5027; Shioi T, 2002, MOL CELL BIOL, V22, P2799, DOI 10.1128/MCB.22.8.2799-2809.2002; Shioi T, 2003, CIRCULATION, V107, P1664, DOI 10.1161/01.CIR.0000057979.36322.88; Shoshani T, 2002, MOL CELL BIOL, V22, P2283, DOI 10.1128/MCB.22.7.2283-2293.2002; Smith EM, 2005, J BIOL CHEM, V280, P18717, DOI 10.1074/jbc.M414499200; Sofer A, 2005, MOL CELL BIOL, V25, P5834, DOI 10.1128/MCB.25.14.5834-5845.2005; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Stolovich M, 2002, MOL CELL BIOL, V22, P8101, DOI 10.1128/MCB.22.23.8101-8113.2002; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Tee AR, 2003, J BIOL CHEM, V278, P37288, DOI 10.1074/jbc.M303257200; Tee AR, 2000, ONCOGENE, V19, P3021, DOI 10.1038/sj.onc.1203622; Temple MD, 2005, TRENDS CELL BIOL, V15, P319, DOI 10.1016/j.tcb.2005.04.003; Thomas GV, 2006, NAT MED, V12, P122, DOI 10.1038/nm1337; Tirado OM, 2003, CANCER RES, V63, P6290; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Urano J, 2005, MOL MICROBIOL, V58, P1074, DOI 10.1111/j.1365-2958.2005.04877.x; Wang X, 2003, NATURE, V424, P456, DOI 10.1038/nature01818; Wang ZQ, 2003, J BIOL CHEM, V278, P27053, DOI 10.1074/jbc.M303723200; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Zacharek SJ, 2005, CANCER RES, V65, P11354, DOI 10.1158/0008-5472.CAN-05-2236; Zhang HB, 2000, GENE DEV, V14, P2712, DOI 10.1101/gad.835000; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505	152	310	321	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2006	25	48					6347	6360		10.1038/sj.onc.1209885	http://dx.doi.org/10.1038/sj.onc.1209885			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	096MH	17041621				2022-12-17	WOS:000241380700002
J	Boya, P; Gonzalez-Polo, RA; Poncet, D; Andreau, K; Vieira, HLA; Roumier, T; Perfettini, JL; Kroemer, G				Boya, P; Gonzalez-Polo, RA; Poncet, D; Andreau, K; Vieira, HLA; Roumier, T; Perfettini, JL; Kroemer, G			Mitochondrial membrane permeabilization is a critical step of lysosome-initiated apoptosis induced by hydroxychloroquine	ONCOGENE			English	Article						Bax; Bcl-2; cell death; lysosomes; mitochondria	CELL-DEATH; GLYCOPROTEIN COMPLEX; CYTOCHROME-C; BCL-2; BAX; P53; TRANSLOCATION; CHLOROQUINE; DYSFUNCTION; ACTIVATION	Hydroxychloroquine (HCQ) is a lysosomotropic amine with cytotoxic properties. Here, we show that HCQ induces signs of lysosomal membrane permeabilization (LMP), such as the decrease in the lysosomal pH gradient and the release of cathepsin B from the lysosomal lumen, followed by signs of apoptosis including caspase activation, phosphatidylserine exposure, and chromatin condensation with DNA loss. HCQ also induces mitochondrial membrane permeabilization (MMP), as indicated by the insertion of Bax into mitochondrial membranes, the conformational activation of Bax within mitochondria, the release of cytochrome c from mitochondria, and the loss of the mitochondrial transmembrane potential. To determine the molecular order among these events, we introduced inhibitors of LMP (bafilomycin A(1)), MMP (Bcl-X-L, wild-type Bcl-2, mitochondrion-targeted Bcl-2, or viral mitochondrial inhibitor of apoptosis from cytomegalovirus), and caspases (Z-VAD.fmk) into the system. Our data indicate that caspase-independent MMP is rate-limiting for LMP-mediated caspase activation. Mouse embryonic fibroblasts lacking the expression of both Bax and Bak are resistant against hydroxychloroquine-induced apoptosis. Such Bax(-/-) Bak(-/-) cells manifest normal LMP, yet fail to undergo MMP and subsequent cell death. The data reported herein indicate that LMP does not suffice to trigger caspase activation and that Bax/Bak-dependent MMP is a critical step of LMP-induced cell death.	Inst Gustave Roussy, Ctr Natl Rech Sci, UMR 8125, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Kroemer, G (corresponding author), Inst Gustave Roussy, Ctr Natl Rech Sci, UMR 8125, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	González-Polo, Rosa A./I-6076-2016; Poncet, Delphine A/A-7190-2016; Boya, Patricia/K-2911-2014; Vieira, Helena/AAZ-9562-2021; Kroemer, Guido/AAY-9859-2020; Boya, Patricia/P-8345-2019; PERFETTINI, Jean-Luc/N-4699-2017; KROEMER, Guido/B-4263-2013	González-Polo, Rosa A./0000-0002-0163-2953; Poncet, Delphine A/0000-0003-0446-5262; Boya, Patricia/0000-0003-3045-951X; Boya, Patricia/0000-0003-3045-951X; PERFETTINI, Jean-Luc/0000-0002-2427-2604; KROEMER, Guido/0000-0002-9334-4405; Andreau, Karine/0000-0002-9773-0733; Vieira, Helena/0000-0001-9415-3742				Aillet F, 1998, J VIROL, V72, P9698, DOI 10.1128/JVI.72.12.9698-9705.1998; Annis MG, 2001, ONCOGENE, V20, P1939, DOI 10.1038/sj.onc.1204288; BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3; Boya P, 2002, CELL DEATH DIFFER, V9, P465, DOI 10.1038/sj.cdd.4401006; BOYA P, IN PRESS; Castedo M, 2002, J IMMUNOL METHODS, V265, P39, DOI 10.1016/S0022-1759(02)00069-8; Castedo M, 1996, J IMMUNOL, V157, P512; Castedo M, 2001, J EXP MED, V194, P1097, DOI 10.1084/jem.194.8.1097; Cohen I, 2002, TRENDS CELL BIOL, V12, P293, DOI 10.1016/S0962-8924(02)02299-7; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; DEDUVE C, 1966, ANNU REV PHYSIOL, V28, P435, DOI 10.1146/annurev.ph.28.030166.002251; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Ferri KF, 2000, J EXP MED, V192, P1081, DOI 10.1084/jem.192.8.1081; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; Goldmacher VS, 1999, P NATL ACAD SCI USA, V96, P12536, DOI 10.1073/pnas.96.22.12536; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Inbal B, 2002, J CELL BIOL, V157, P455, DOI 10.1083/jcb.200109094; Kitanaka C, 2002, J NATL CANCER I, V94, P358; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lai JH, 2001, J IMMUNOL, V166, P6914, DOI 10.4049/jimmunol.166.11.6914; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Levy-Strumpf N, 1998, ONCOGENE, V17, P3331, DOI 10.1038/sj.onc.1202588; Lockshin RA, 2001, NAT REV MOL CELL BIO, V2, P545, DOI 10.1038/35080097; Marmor MF, 2002, OPHTHALMOLOGY, V109, P1377, DOI 10.1016/S0161-6420(02)01168-5; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Mathiasen IS, 2002, TRENDS MOL MED, V8, P212, DOI 10.1016/S1471-4914(02)02328-6; MORIYAMA Y, 1989, J BIOL CHEM, V264, P18445; Munafo DB, 2001, J CELL SCI, V114, P3619; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Ravagnan L, 2002, J CELL PHYSIOL, V192, P131, DOI 10.1002/jcp.10111; Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726; Roberg K, 2001, LAB INVEST, V81, P149, DOI 10.1038/labinvest.3780222; Schotte P, 1998, BIOCHEM BIOPH RES CO, V251, P379, DOI 10.1006/bbrc.1998.9425; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Vancompernolle K, 1998, FEBS LETT, V438, P150, DOI 10.1016/S0014-5793(98)01275-7; Vieira HLA, 2001, ONCOGENE, V20, P4305, DOI 10.1038/sj.onc.1204575; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Xue L, 2001, CURR BIOL, V11, P361, DOI 10.1016/S0960-9822(01)00100-2; Yuan XM, 2002, P NATL ACAD SCI USA, V99, P6286, DOI 10.1073/pnas.092135599; Zaidi AU, 2001, J NEUROPATH EXP NEUR, V60, P937, DOI 10.1093/jnen/60.10.937; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zamzami N, 2003, CURR BIOL, V13, pR71, DOI 10.1016/S0960-9822(02)01433-1; Zamzami N, 2000, ONCOGENE, V19, P6342, DOI 10.1038/sj.onc.1204030; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; Zhao M, 2001, FEBS LETT, V509, P405, DOI 10.1016/S0014-5793(01)03185-4; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x	52	310	317	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2003	22	25					3927	3936		10.1038/sj.onc.1206622	http://dx.doi.org/10.1038/sj.onc.1206622			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	691NH	12813466				2022-12-17	WOS:000183612000012
J	Hideshima, T; Chauhan, D; Schlossman, R; Richardson, P; Anderson, KC				Hideshima, T; Chauhan, D; Schlossman, R; Richardson, P; Anderson, KC			The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications	ONCOGENE			English	Article						TNF alpha; multiple myeloma; adhesion molecule; IL-6; NF-kappa B	MARROW STROMAL CELLS; NF-KAPPA-B; ADHESION MOLECULES; INDUCED APOPTOSIS; DRUG-RESISTANCE; GROWTH-FACTOR; INTERLEUKIN-6; THALIDOMIDE; ACTIVATION; EXPRESSION	In this study we demonstrate that tumor necrosis factor alpha (TNF alpha) triggers only modest proliferation, as well as p44/p42 mitogen-activated protein kinase (MAPK) and NF-kappaB activation, in MM.1S multiple myeloma (MM) cells. TNF alpha also activates NF-kappaB and markedly upregulates (fivefold) secretion of interleukin-6 (IL-6), a myeloma growth and survival factor, in bone marrow stromal cells (BMSCs). TNF alpha in both a dose and time dependent fashion induced expression of CD11a (LFA-1), CD54 (intercellular adhesion molecule-1, ICAM-1), CD106 (vascular cell adhesion molecule-1, VCAM-1), CD49d (very late activating antigen-4, VLA-4), and/or MUC-1 on MM cell lines; as well as CD106 (VCAM-1) and CD54 (ICAM-1) expression on BMSCs. This resulted in increased (2-4-fold) per cent specific binding of MM cells to BMSCs, with related IL-6 secretion. Importantly, the proteasome inhibitor PS-341 abrogated TNF alpha -induced NF-kappaB activation, induction of ICAM-1 or VCAM-1, and increased adhesion of MM cells to BMSCs. Agents which act to inhibit TNF alpha may therefore abrogate the paracrine growth and survival advantage conferred by MM cell adhesion in the BM microenvironment.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Anderson, KC (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.	kenneth_anderson@dfci.harvard.edu			PHS HHS [P01 78378] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; BORSET M, 1994, EUR J HAEMATOL, V53, P31; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chauhan D, 1997, BLOOD, V89, P227, DOI 10.1182/blood.V89.1.227.227_227_234; Chauhan D, 1996, BLOOD, V87, P1104, DOI 10.1182/blood.V87.3.1104.bloodjournal8731104; Chauhan D, 2000, J BIOL CHEM, V275, P27845; Corral LG, 1999, J IMMUNOL, V163, P380; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Dankbar Berno, 2000, Blood, V95, P2630; Davies FE, 2000, J CLIN ONCOL, V18, P2843, DOI 10.1200/JCO.2000.18.15.2843; DAVIES FE, 2001, IN PRESS BLOOD; Filella X, 1996, CANCER DETECT PREV, V20, P52; GARRETT IR, 1987, NEW ENGL J MED, V317, P526, DOI 10.1056/NEJM198708273170902; GUPTA D, 2001, IN PRESS LEUKEMIA; Haslett PAJ, 1998, J EXP MED, V187, P1885, DOI 10.1084/jem.187.11.1885; Hideshima T, 2001, CANCER RES, V61, P3071; Hideshima T, 2000, BLOOD, V96, P2943, DOI 10.1182/blood.V96.9.2943; Jourdan M, 1999, EUR CYTOKINE NETW, V10, P65; Junn E, 2000, J IMMUNOL, V165, P2190, DOI 10.4049/jimmunol.165.4.2190; KIM I, 1994, BRIT J HAEMATOL, V87, P483, DOI 10.1111/j.1365-2141.1994.tb08302.x; Li P, 2000, J IMMUNOL, V164, P5990, DOI 10.4049/jimmunol.164.11.5990; LICHTENSTEIN A, 1989, BLOOD, V74, P1266; LICHTENSTEIN A, 1995, CELL IMMUNOL, V162, P248, DOI 10.1006/cimm.1995.1076; Marriott JB, 1998, J IMMUNOL, V161, P4236; Ogata A, 1997, J IMMUNOL, V159, P2212; Palombella VJ, 1998, P NATL ACAD SCI USA, V95, P15671, DOI 10.1073/pnas.95.26.15671; PODAR K, 2001, IN PRESS BLOOD; Raje N, 1999, NEW ENGL J MED, V341, P1606, DOI 10.1056/NEJM199911183412110; RAY A, 1989, MOL CELL BIOL, V9, P5537, DOI 10.1128/MCB.9.12.5537; Sati HIA, 1999, BRIT J HAEMATOL, V104, P350, DOI 10.1046/j.1365-2141.1999.01193.x; Singhal S, 1999, NEW ENGL J MED, V341, P1565, DOI 10.1056/NEJM199911183412102; Teoh G, 1997, HEMATOL ONCOL CLIN N, V11, P27, DOI 10.1016/S0889-8588(05)70413-5; TREON SP, 2001, IN PRESS J IMMUNOTHE; UCHIYAMA H, 1992, BLOOD, V80, P2306; UCHIYAMA H, 1993, BLOOD, V82, P3712; Urashima M, 1997, BLOOD, V90, P279; Urashima M, 1996, BLOOD, V87, P1928; Vacca A, 1999, BLOOD, V93, P3064	39	310	341	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2001	20	33					4519	4527		10.1038/sj.onc.1204623	http://dx.doi.org/10.1038/sj.onc.1204623			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494147				2022-12-17	WOS:000170074900009
J	Bullock, AN; Henckel, J; Fersht, AR				Bullock, AN; Henckel, J; Fersht, AR			Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy	ONCOGENE			English	Article						tumour suppressor; stability; denaturation; activity; protein	TUMOR-SUPPRESSOR P53; WILD-TYPE; PROTEIN STABILITY; TEMPERATURE SENSITIVITY; M-VALUES; IN-VIVO; APOPTOSIS; TRANSACTIVATION; BARNASE; CELLS	The tumour suppressor p53 is mutated in half of all human cancers, most frequently with missense substitutions in its core domain. We present a new assessment of the mutation database based on quantitative folding and DNA-binding studies of the isolated core domain. Our data identify five distinct mutant classes that correlate with four well-defined regions of the core domain structure. On extrapolation to 37 degrees C the wild-type protein has a stability of 3.0 kcal/mol, This also emerges as an oncogenic threshold: all beta-sandwich mutants destabilized by this amount (50% denatured) are expected to promote cancer. Other weakly destabilizing mutations are restricted to loop 3 in the DNA-binding region, Drugs that stabilize mutant p53 folding have the potential to reactivate apoptotic signalling pathways in tumour cells either by transactivation-dependent or independent pathways. Using an affinity ligand as a proof of principle we have recovered the thermodynamic stability of the hotspot G245S. With reference states for the five mutant classes as a guide, future therapeutic strategies may similarly stabilize partially structured or binding states of mutant p53 that restore limited p53 pathways to tumour suppression.	Univ Cambridge, Chem Lab, Cambridge CB2 2QH, England; MRC Ctr, Cambridge Ctr Prot Engn, Cambridge CB2 2QH, England	University of Cambridge; MRC Laboratory Molecular Biology; University of Cambridge	Fersht, AR (corresponding author), Univ Cambridge, Chem Lab, Hills Rd, Cambridge CB2 2QH, England.		Fersht, Alan R/B-2189-2008					BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; Bennett WP, 1999, J PATHOL, V187, P8, DOI 10.1002/(SICI)1096-9896(199901)187:1<8::AID-PATH232>3.0.CO;2-Y; Brown CR, 1997, J CLIN INVEST, V99, P1432, DOI 10.1172/JCI119302; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; Bycroft M, 1999, EMBO J, V18, P297, DOI 10.1093/emboj/18.2.297; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chene P, 1998, J MOL BIOL, V281, P205, DOI 10.1006/jmbi.1998.1897; Chene P, 1999, J MOL BIOL, V286, P1269, DOI 10.1006/jmbi.1999.2563; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLARKE J, 1993, BIOCHEMISTRY-US, V32, P4322, DOI 10.1021/bi00067a022; Dalby PA, 1998, J MOL BIOL, V276, P625, DOI 10.1006/jmbi.1997.1546; Di Como CJ, 1998, ONCOGENE, V16, P2527; Durocher D, 1999, MOL CELL, V4, P387, DOI 10.1016/S1097-2765(00)80340-8; Fahraeus R, 1999, J PATHOL, V187, P138; Fersht A., 1999, STRUCTURE MECH PROTE; FERSHT AR, 1993, CURR OPIN STRUC BIOL, V3, P75, DOI 10.1016/0959-440X(93)90205-Y; Fourie AM, 1997, J BIOL CHEM, V272, P19471, DOI 10.1074/jbc.272.31.19471; Friedlander P, 1996, J BIOL CHEM, V271, P25468, DOI 10.1074/jbc.271.41.25468; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Guillouf C, 1998, INT J ONCOL, V13, P107; Hansen S, 1996, J BIOL CHEM, V271, P3917; Harris CC, 1996, JNCI-J NATL CANCER I, V88, P1442, DOI 10.1093/jnci/88.20.1442; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Haupt Ygal, 1997, Leukemia (Basingstoke), V11, P337; Hernandez-Boussard T, 1999, HUM MUTAT, V14, P1; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUBBARD SJ, 1991, J MOL BIOL, V220, P507, DOI 10.1016/0022-2836(91)90027-4; Hubbard SJ, 1993, NACCESS COMPUTER PRO; Hupp TR, 1999, CELL MOL LIFE SCI, V55, P88, DOI 10.1007/s000180050272; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; KASTAN MB, 1991, CANCER RES, V51, P6304; Kirsch DG, 1998, J CLIN ONCOL, V16, P3158, DOI 10.1200/JCO.1998.16.9.3158; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; MILNER J, 1995, TRENDS BIOCHEM SCI, V20, P49, DOI 10.1016/S0968-0004(00)88954-9; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Munoz V, 1996, FOLD DES, V1, pR71, DOI 10.1016/S1359-0278(96)00036-3; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; Nikolova PV, 1998, P NATL ACAD SCI USA, V95, P14675, DOI 10.1073/pnas.95.25.14675; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; Pace C N, 1986, Methods Enzymol, V131, P266; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Ponchel F, 1998, BRIT J CANCER, V77, P1555, DOI 10.1038/bjc.1998.256; Radford SE, 1999, CELL, V97, P291, DOI 10.1016/S0092-8674(00)80739-4; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; ROLLEY N, 1995, ONCOGENE, V11, P763; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; SAUER RT, 1992, CURR OPIN STRUC BIOL, V2, P46; Selivanova G, 1999, MOL CELL BIOL, V19, P3395; SERRANO L, 1992, J MOL BIOL, V224, P783, DOI 10.1016/0022-2836(92)90562-X; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; THUKRAL SK, 1994, MOL CELL BIOL, V14, P8315, DOI 10.1128/MCB.14.12.8315; Wacey AI, 1999, HUM GENET, V104, P15, DOI 10.1007/s004390050904; Walker DR, 1999, ONCOGENE, V18, P211, DOI 10.1038/sj.onc.1202298; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; Wiman KG, 1998, MED ONCOL, V15, P222, DOI 10.1007/BF02787204; Wong KB, 1999, P NATL ACAD SCI USA, V96, P8438, DOI 10.1073/pnas.96.15.8438; Yaffe MB, 1999, NATURE, V402, P30; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x	70	310	319	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2000	19	10					1245	1256		10.1038/sj.onc.1203434	http://dx.doi.org/10.1038/sj.onc.1203434			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	291NW	10713666				2022-12-17	WOS:000085743800001
J	MITSUDOMI, T; VIALLET, J; MULSHINE, JL; LINNOILA, RI; MINNA, JD; GAZDAR, AF				MITSUDOMI, T; VIALLET, J; MULSHINE, JL; LINNOILA, RI; MINNA, JD; GAZDAR, AF			MUTATIONS OF RAS GENES DISTINGUISH A SUBSET OF NON-SMALL-CELL LUNG-CANCER CELL-LINES FROM SMALL-CELL LUNG-CANCER CELL-LINES	ONCOGENE			English	Article							BLADDER-CARCINOMA ONCOGENE; POINT MUTATION; TUMOR PROGRESSION; P53 GENE; ACTIVATION; ADENOCARCINOMA; CARCINOGENESIS; AMPLIFICATION; INITIATION; EXPRESSION	We screened a panel of 103 human lung cancer cell lines for the presence of point mutations at codons 12, 13 or 61 of the human K-, H- and N-ras genes, using restriction fragment length polymorphisms (RFLP), created through mismatched primers during polymerase chain reaction (PCR) of genomic DNA. We found ras mutations in 22/61 (36%) non-small-cell lung cancer (NSCLC) cell lines, predominantly in K-ras codon 12. Identical mutations were present in uncultured tumor materials corresponding to 11 cell lines containing mutated ras genes. ras mutations were found not only in adenocarcinoma cell lines (9/32, 28%), but also in cell lines derived from other types of NSCLC (13/29, 45%). In contrast, none of 37 small-cell lung cancer (SCLC) cell lines and five extrapulmonary small-cell cancer cell lines had ras mutations. ras mutations were not correlated with sex of the patients, tumor extent, prior therapy status or in vitro culture time. G to T or A to T transversions were the most common base substitutions, occurring in codons 12 and 61 respectively. We conclude that ras mutations play a role in the pathogenesis of a subset of NSCLC but are not involved in SCLC.	NATL NAVAL MED CTR, NCI NAVY MED ONCOL BRANCH, BDG 8, RM 5101, BETHESDA, MD 20889 USA; NCI, NAVY MED ONCOL BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Walter Reed National Military Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Mitsudomi, Tetsuya/0000-0001-9860-8505; Mulshine, James/0000-0002-4648-9177				BAKER SJ, 1990, CANCER RES, V50, P7717; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Battey, 1986, BASIC METHODS MOL BI; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BOS JL, 1984, NUCLEIC ACIDS RES, V12, P9155, DOI 10.1093/nar/12.23.9155; BOS JL, 1989, CANCER RES, V49, P4682; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CARNEY DN, 1985, CANCER RES, V45, P2913; CHIBA I, 1990, ONCOGENE, V5, P1603; COHEN JB, 1988, NATURE, V334, P119, DOI 10.1038/334119a0; FALCO JP, 1990, J CLIN INVEST, V85, P1740, DOI 10.1172/JCI114630; GAZDAR AF, 1986, CANCER GENET CYTOGEN, V19, P5, DOI 10.1016/0165-4608(86)90365-1; GAZDAR AF, 1990, JNCI-J NATL CANCER I, V82, P117, DOI 10.1093/jnci/82.2.117; GAZDAR AF, 1988, CANCER RES, V48, P4078; GUERRERO I, 1984, P NATL ACAD SCI USA, V79, P2845; JIANG W, 1989, ONCOGENE, V4, P923; JOHNSON BE, 1989, J NATL CANCER I, V81, P1223, DOI 10.1093/jnci/81.16.1223; KAGIMOTO M, 1985, INT J CANCER, V35, P809, DOI 10.1002/ijc.2910350618; KUMAR R, 1989, ONCOGENE RES, V1, P235; MABRY M, 1988, P NATL ACAD SCI USA, V85, P6523, DOI 10.1073/pnas.85.17.6523; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; MILLICI A, 1986, BIOCHEM BIOPH RES CO, V140, P699; MINNA JD, 1989, CC MOL BIOL, P57; Minna JD, 1989, CANCER PRINCIPLES PR, P591; MUSCHEL RJ, 1985, AM J PATHOL, V121, P1; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; PEDERSENBJERGAARD J, 1988, CANCER RES, V48, P1812; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; REMICK SC, 1987, MEDICINE, V66, P457, DOI 10.1097/00005792-198711000-00004; RODENHUIS S, 1987, NEW ENGL J MED, V317, P929, DOI 10.1056/NEJM198710083171504; RODENHUIS S, 1988, CANCER RES, V48, P5738; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTOS E, 1984, SCIENCE, V223, P661, DOI 10.1126/science.6695174; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SLEBOS RJC, 1990, NEW ENGL J MED, V323, P561, DOI 10.1056/NEJM199008303230902; STEVENSON H, 1990, ANN INTERN MED, V113, P764, DOI 10.7326/0003-4819-113-10-764; SUZUKI Y, 1990, ONCOGENE, V5, P1037; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; VALENZUELA DM, 1986, NUCLEIC ACIDS RES, V14, P843, DOI 10.1093/nar/14.2.843; VERLAANDEVRIES M, 1986, GENE, V50, P313, DOI 10.1016/0378-1119(86)90335-5; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WINTER E, 1985, P NATL ACAD SCI USA, V82, P7575, DOI 10.1073/pnas.82.22.7575; YOU M, 1989, P NATL ACAD SCI USA, V86, P3070, DOI 10.1073/pnas.86.9.3070; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	47	310	316	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1353	1362						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1679529				2022-12-17	WOS:A1991GX27200010
J	Romagosa, C; Simonetti, S; Lopez-Vicente, L; Mazo, A; Lleonart, ME; Castellvi, J; Cajal, SRY				Romagosa, C.; Simonetti, S.; Lopez-Vicente, L.; Mazo, A.; Lleonart, M. E.; Castellvi, J.; Ramon y Cajal, S.			p16(Ink4a) overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors	ONCOGENE			English	Review						p16(Ink4a); overexpression; cancer; senescence; high grade	GASTROINTESTINAL STROMAL TUMORS; CDKN2A GERMLINE MUTATIONS; SQUAMOUS-CELL CARCINOMA; ONCOGENE-INDUCED SENESCENCE; P16 EXPRESSION; BREAST-CANCER; DNA-DAMAGE; CYCLIN D1; IN-VIVO; SUBCELLULAR-LOCALIZATION	p16(Ink4a) is a protein involved in regulation of the cell cycle. Currently, p16(Ink4a) is considered a tumor suppressor protein because of its physiological role and downregulated expression in a large number of tumors. Intriguingly, overexpression of p16(Ink4a) has also been described in several tumors. This review attempts to elucidate when and why p16(Ink4a) overexpression occurs, and to suggest possible implications of p16(Ink4a) in the diagnosis, prognosis and treatment of cancer. Oncogene (2011) 30, 2087-2097; doi:10.1038/onc.2010.614; published online 7 February 2011	[Romagosa, C.; Lopez-Vicente, L.; Lleonart, M. E.; Castellvi, J.; Ramon y Cajal, S.] Univ Autonoma Barcelona, Dept Pathol, Fundacio Inst Recerca, Hosp Univ Vall Hebron, E-08193 Barcelona, Spain; [Simonetti, S.] USP Dexeus Univ Inst, Oncol Lab, Barcelona, Spain; [Mazo, A.] Univ Barcelona, Inst Biomed IBUB, Dept Biochem & Mol Biol, Barcelona, Spain	Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); University of Barcelona	Cajal, SRY (corresponding author), Hosp Univ Vall Hebron, Fundacio Inst Recerca, Dept Pathol, Passeig Vall Hebron 119-129, Barcelona 08035, Spain.	sramon@vhebron.net	Pérez-Portabell, Cleofé Romagosa/Q-3342-2016; LLeonart, Matilde E./Q-2662-2019; Simonetti, Sara/AAD-7963-2020; Ramon y Cajal, Santiago/H-4955-2016; Castellvi, Josep/C-5092-2014	LLeonart, Matilde E./0000-0002-6196-7405; Simonetti, Sara/0000-0003-2406-030X; Ramon y Cajal, Santiago/0000-0002-3867-1390; Castellvi, Josep/0000-0001-5745-9996	Fondo de Investigaciones Sanitarias [05/0818, 08/0143]; Fundacio Marato TV3 [052710]; Mutua Madrilena [FMMA/2009/02]; Redes tematicas de Investigacion Cooperativa en Salud [RD06/0020/0104, RD06/0020/1020]; Generalitat de Catalunya [2005SGR00144, 2009SGR624]; Ministerio de Ciencia y Tecnologia [BIO2008-04692-C03-03]; Grupo espanol de Investigacion en Sarcomas [GEIS/2008]	Fondo de Investigaciones Sanitarias(Instituto de Salud Carlos III); Fundacio Marato TV3; Mutua Madrilena; Redes tematicas de Investigacion Cooperativa en Salud; Generalitat de Catalunya(Generalitat de Catalunya); Ministerio de Ciencia y Tecnologia(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Grupo espanol de Investigacion en Sarcomas	We are grateful to M Serrano for his careful reading and suggestions, and C Cavallo and S Illing for English editing. SRC is supported by grants from the 'Fondo de Investigaciones Sanitarias' (Ref.05/0818 and 08/0143), 'Fundacio Marato TV3' (Ref.052710), 'Mutua Madrilena' (FMMA/2009/02), 'Redes tematicas de Investigacion Cooperativa en Salud' (Ref.RD06/0020/0104 and RD06/0020/1020) and 'Generalitat de Catalunya' (Ref.2005SGR00144), AM is supported by grants from the 'Ministerio de Ciencia y Tecnologia (Ref.BIO2008-04692-C03-03) and Generalitat de Catalunya (Ref 2009SGR624), and CR is supported by a grant from the 'Grupo espanol de Investigacion en Sarcomas' (Ref. GEIS/2008).	Adachi Y, 2001, J BIOL CHEM, V276, P47171, DOI 10.1074/jbc.M104334200; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Andujar P, 2010, LUNG CANCER, V67, P23, DOI 10.1016/j.lungcan.2009.03.018; Angiero F, 2008, ANTICANCER RES, V28, P2535; Arifin MT, 2006, J NEURO-ONCOL, V77, P273, DOI 10.1007/s11060-005-9037-5; Armes JE, 2005, INT J GYNECOL PATHOL, V24, P363, DOI 10.1097/01.pgp.0000172083.94934.1e; Atkins KA, 2008, AM J SURG PATHOL, V32, P98, DOI 10.1097/PAS.0b013e3181574d1e; Ayhan S, 2010, HEPATO-GASTROENTEROL, V57, P251; Bardeesy N, 2006, P NATL ACAD SCI USA, V103, P5947, DOI 10.1073/pnas.0601273103; Bartsch DK, 2002, ANN SURG, V236, P730, DOI 10.1097/00000658-200212000-00005; Bastide K, 2009, LUNG CANCER, V63, P348, DOI 10.1016/j.lungcan.2008.06.007; Beasley MB, 2003, HUM PATHOL, V34, P136, DOI 10.1053/hupa.2003.8; Bennecke M, 2010, CANCER CELL, V18, P135, DOI 10.1016/j.ccr.2010.06.013; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Brambilla E, 1999, J PATHOL, V188, P351, DOI 10.1002/(SICI)1096-9896(199908)188:4<351::AID-PATH385>3.0.CO;2-W; Brambilla E, 1999, CLIN CANCER RES, V5, P243; Bringold F, 2000, EXP GERONTOL, V35, P317, DOI 10.1016/S0531-5565(00)00083-8; Buajeeb W, 2009, J ORAL PATHOL MED, V38, P104, DOI 10.1111/j.1600-0714.2008.00710.x; Calbo J, 2004, CELL DEATH DIFFER, V11, P1055, DOI 10.1038/sj.cdd.4401481; Calbo J, 2001, CANCER GENE THER, V8, P740, DOI 10.1038/sj.cgt.7700374; Campo-Trapero J, 2008, ACTA ONCOL, V47, P1464, DOI 10.1080/02841860802183612; Canepa ET, 2007, IUBMB LIFE, V59, P419, DOI 10.1080/15216540701488358; Carnero A, 2011, BIOL REV, V86, P443, DOI 10.1111/j.1469-185X.2010.00154.x; Carragher LAS, 2010, EMBO MOL MED, V2, P458, DOI 10.1002/emmm.201000099; Chao DL, 2008, CLIN CANCER RES, V14, P6988, DOI 10.1158/1078-0432.CCR-07-5063; Chen JH, 2005, DNA REPAIR, V4, P1140, DOI 10.1016/j.dnarep.2005.06.003; Chien WW, 2010, CELL CYCLE, V9, P3286, DOI 10.4161/cc.9.16.12600; Chim CS, 2003, ANN HEMATOL, V82, P738, DOI 10.1007/s00277-003-0744-8; Chintala SK, 1997, ONCOGENE, V15, P2049, DOI 10.1038/sj.onc.1201382; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003; Courtois-Cox S, 2006, CANCER CELL, V10, P459, DOI 10.1016/j.ccr.2006.10.003; Crea F, 2009, MOL CANCER THER, V8, P1964, DOI 10.1158/1535-7163.MCT-09-0027; Dai CY, 2000, GASTROENTEROLOGY, V119, P929, DOI 10.1053/gast.2000.17952; Daniotti M, 2009, J INVEST DERMATOL, V129, P1759, DOI 10.1038/jid.2008.422; Di Vinci A, 2005, INT J CANCER, V114, P414, DOI 10.1002/ijc.20771; Dublin EA, 1998, INT J CANCER, V79, P71, DOI 10.1002/(SICI)1097-0215(19980220)79:1<71::AID-IJC14>3.0.CO;2-K; Emig R, 1998, BRIT J CANCER, V78, P1661, DOI 10.1038/bjc.1998.739; Evangelou K, 2004, BIOTECH HISTOCHEM, V79, P5, DOI 10.1080/10520290310001659466; Fahraeus R, 1999, EMBO J, V18, P2106, DOI 10.1093/emboj/18.8.2106; Fischer CA, 2010, INT J CANCER, V126, P1256, DOI 10.1002/ijc.24842; Fordyce C, 2010, CANCER PREV RES, V3, P190, DOI 10.1158/1940-6207.CAPR-09-0229; Fukushima N, 2002, AM J PATHOL, V160, P1573, DOI 10.1016/S0002-9440(10)61104-2; Garcia V, 2004, MUTAT RES-FUND MOL M, V554, P215, DOI 10.1016/j.mrfmmm.2004.04.008; Ghiorzo P, 2004, ANN ONCOL, V15, P70, DOI 10.1093/annonc/mdg498; Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987; Gonzalez S, 2006, CELL CYCLE, V5, P1382, DOI 10.4161/cc.5.13.2901; Gorgoulis VG, 1998, AM J PATHOL, V153, P1749, DOI 10.1016/S0002-9440(10)65690-8; Gray-Schopfer VC, 2006, BRIT J CANCER, V95, P496, DOI 10.1038/sj.bjc.6603283; Guenova M, 1999, MODERN PATHOL, V12, P1062; Guida M, 2009, EUR J GYNAECOL ONCOL, V30, P267; Gump J, 2003, J BIOL CHEM, V278, P6619, DOI 10.1074/jbc.C200622200; Gupta AK, 2009, INT J RADIAT ONCOL, V74, P928, DOI 10.1016/j.ijrobp.2009.03.004; Haller F, 2010, HISTOPATHOLOGY, V56, P305, DOI 10.1111/j.1365-2559.2010.03478.x; Hara E, 1996, MOL CELL BIOL, V16, P859; Harada H, 1999, CANCER RES, V59, P3783; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HERMAN JG, 1995, CANCER RES, V55, P4525; Herschkowitz JI, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2142; Hilliard NJ, 2009, J CUTAN PATHOL, V36, P753, DOI 10.1111/j.1600-0560.2008.01154.x; Hiroyasu M, 2002, AM J PATHOL, V160, P419, DOI 10.1016/S0002-9440(10)64860-2; Horree N, 2007, HUM PATHOL, V38, P1232, DOI 10.1016/j.humpath.2007.01.008; Hruban Ralph H, 2007, Expert Rev Gastroenterol Hepatol, V1, P81, DOI 10.1586/17474124.1.1.81; HUANG PS, 1993, MOL CELL BIOL, V13, P953, DOI 10.1128/MCB.13.2.953; Ivanova TA, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-47; Jung A, 2001, AM J PATHOL, V159, P1613, DOI 10.1016/S0002-9440(10)63007-6; Kannengiesser C, 2009, HUM MUTAT, V30, P564, DOI 10.1002/humu.20845; Kataoka M, 2000, ONCOGENE, V19, P1589, DOI 10.1038/sj.onc.1203466; Katsuda K, 2002, ONCOGENE, V21, P2108, DOI 10.1038/sj.onc.1205272; Kerlikowske K, 2010, JNCI-J NATL CANCER I, V102, P627, DOI 10.1093/jnci/djq101; Kim J, 2009, CLIN CANCER RES, V15, P81, DOI 10.1158/1078-0432.CCR-08-0170; Kourea HP, 1999, AM J PATHOL, V155, P1855, DOI 10.1016/S0002-9440(10)65504-6; Krishnamurthty J, 2004, J CLIN INVEST, V114, P1299, DOI 10.1172/JCI200422475; Ksiazek K, 2006, J APPL PHYSIOL, V100, P988, DOI 10.1152/japplphysiol.01086.2005; Lam AKY, 2008, PATHOLOGY, V40, P580, DOI 10.1080/00313020802320713; Lassen P, 2009, J CLIN ONCOL, V27, P1992, DOI 10.1200/JCO.2008.20.2853; Li LY, 2010, J CANCER, V1, P126; LLeonart ME, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-3; Lobo GP, 2008, HUM MOL GENET, V17, P2877, DOI 10.1093/hmg/ddn185; Lopez-Vicente L, 2009, CLIN CANCER RES, V15, P4546, DOI 10.1158/1078-0432.CCR-08-3159; Lynch BC, 2008, ANN DIAGN PATHOL, V12, P161, DOI 10.1016/j.anndiagpath.2007.06.003; Magnusson S, 2008, FAM CANCER, V7, P331, DOI 10.1007/s10689-008-9195-7; Marchan S, 2010, ANAL CELL PATHOL, V33, P191, DOI [10.1155/2010/917013, 10.3233/ACP-CLO-2010-0538]; Marsh KL, 1998, BRIT J CANCER, V77, P1460, DOI 10.1038/bjc.1998.240; Martin A, 2000, AM J PATHOL, V156, P1573, DOI 10.1016/S0002-9440(10)65029-8; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Milde-Langosch K, 2001, BREAST CANCER RES TR, V67, P61, DOI 10.1023/A:1010623308275; Minami R, 2003, EXP HEMATOL, V31, P355, DOI 10.1016/S0301-472X(03)00040-7; Modesitt SC, 2001, CLIN CANCER RES, V7, P1765; Monnerat C, 2007, FAM CANCER, V6, P453, DOI 10.1007/s10689-007-9143-y; Moore PS, 2001, BRIT J CANCER, V84, P253, DOI 10.1054/bjoc.2000.1567; Moore PS, 2001, VIRCHOWS ARCH, V439, P798, DOI 10.1007/s004280100474; Mulvany NJ, 2008, PATHOLOGY, V40, P335, DOI 10.1080/00313020802035907; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; Natarajan E, 2003, AM J PATHOL, V163, P477, DOI 10.1016/S0002-9440(10)63677-2; Nielsen GP, 1999, AM J PATHOL, V155, P1879, DOI 10.1016/S0002-9440(10)65507-1; Nilsson K, 2006, INT J CANCER, V118, P1120, DOI 10.1002/ijc.21466; Nilsson K, 2004, MODERN PATHOL, V17, P1464, DOI 10.1038/modpathol.3800220; O'Neill CJ, 2007, HISTOPATHOLOGY, V50, P851, DOI 10.1111/j.1365-2559.2007.02699.x; Ohtani N, 2003, J CELL BIOL, V162, P173, DOI 10.1083/jcb.200302085; Orlow I, 2007, J INVEST DERMATOL, V127, P1234, DOI 10.1038/sj.jid.5700689; Palmqvist R, 2000, AM J PATHOL, V157, P1947, DOI 10.1016/S0002-9440(10)64833-X; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Paulson TG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003809; Pei XH, 2005, ONCOGENE, V24, P2787, DOI 10.1038/sj.onc.1208611; Perrone F, 2003, CLIN CANCER RES, V9, P4132; Quereda V, 2007, ONCOGENE, V26, P7665, DOI 10.1038/sj.onc.1210578; Ressler S, 2006, AGING CELL, V5, P379, DOI 10.1111/j.1474-9726.2006.00231.x; Reuschenbach M, 2008, INT J CANCER, V123, P2626, DOI 10.1002/ijc.23837; ROMAGOSA C, 2009, VIRCHOWS ARCH, V455, P372; Ruas M, 2007, MOL CELL BIOL, V27, P4273, DOI 10.1128/MCB.02286-06; Rutter JL, 2003, ONCOGENE, V22, P4444, DOI 10.1038/sj.onc.1206564; Sabah M, 2006, APPL IMMUNOHISTO M M, V14, P97, DOI 10.1097/01.pai.0000143787.80564.f5; Sanchez-Beato M, 1999, BLOOD, V94, P765, DOI 10.1182/blood.V94.2.765.414a29_765_772; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Schmitt Estelle, 2007, Journal of Zhejiang University-Science B, V8, P377, DOI 10.1631/jzus.2007.B0377; Schneider-Stock R, 2005, CLIN CANCER RES, V11, P638; Schwabe M, 2007, CURR PHARM BIOTECHNO, V8, P382, DOI 10.2174/138920107783018372; Schwartz B, 1998, MOL CELL BIOCHEM, V188, P21, DOI 10.1023/A:1006831330340; Serrano C, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.10043; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; Serrano M, 2007, NEW ENGL J MED, V356, P1996, DOI 10.1056/NEJMcibr071461; Shen WW, 2007, NEOPLASIA, V9, P812, DOI 10.1593/neo.07403; Souza-Rodrigues E, 2007, PROTEOMICS, V7, P4102, DOI 10.1002/pmic.200700133; Steigen SE, 2008, MODERN PATHOL, V21, P46, DOI 10.1038/modpathol.3800976; Svensson S, 2003, CANCER RES, V63, P1737; Tanaka T, 1999, ONCOGENE, V18, P3793, DOI 10.1038/sj.onc.1202707; Ueki K, 1996, CANCER RES, V56, P150; Wang YA, 2005, ONCOGENE, V24, P3042, DOI 10.1038/sj.onc.1208390; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Wu JF, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000164; Yogev O, 2006, J BIOL CHEM, V281, P34475, DOI 10.1074/jbc.M602865200; Zhang ZH, 2006, MODERN PATHOL, V19, P1339, DOI 10.1038/modpathol.3800655; Zhao P, 2006, WORLD J GASTROENTERO, V12, P6391, DOI 10.3748/wjg.v12.i39.6391; Zhu DG, 2002, J CELL PHYSIOL, V193, P19, DOI 10.1002/jcp.10147; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	136	309	329	2	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2011	30	18					2087	2097		10.1038/onc.2010.614	http://dx.doi.org/10.1038/onc.2010.614			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	759ML	21297668				2022-12-17	WOS:000290249600001
J	Levrero, M				Levrero, M.			Viral hepatitis and liver cancer: the case of hepatitis C	ONCOGENE			English	Review						hepatocellular carcinoma; hepatitis C; HCV core; NS5A; Wnt/beta-catenin pathway; p53-family; p73	VIRUS CORE PROTEIN; NF-KAPPA-B; GENE-EXPRESSION PROFILES; ENDOTHELIAL GROWTH-FACTOR; NONSTRUCTURAL 5A PROTEIN; NECROSIS-FACTOR-ALPHA; P53 TUMOR-SUPPRESSOR; BETA-CATENIN GENE; HEPATOCELLULAR-CARCINOMA; ENDOPLASMIC-RETICULUM	Chronic infection with the hepatitis C virus (HCV) is a major risk factor for the development of hepatocellular carcinoma (HCC) worldwide. The pathogenesis of HCC in HCV infection has extensively been analysed. Hepatitis C virus-induced chronic inflammation and the effects of cytokines in the development of fibrosis and liver cell proliferation are considered as one of the major pathogenic mechanisms. Increasing experimental evidence suggests that HCV contributes to HCC by directly modulating pathways that promote the malignant transformation of hepatocytes. Hepatitis C virus is an RNA virus that does not integrate into the host genome but HCV proteins interact with many host-cell factors well beyond their roles in the viral life cycle and are involved in a wide range of activities, including cell signaling, transcription, cell proliferation, apoptosis, membrane rearrangements, vesicular trafficking and translational regulation. At least four of the HCV gene products, namely HCV core, NS3, NS4B and NS5A, have been shown to exhibit transformation potential in tissue culture and several potentially oncogenic pathways have been shown to be altered by the expression of HCV proteins. Both HCV core and NS5A induce the accumulation of wild-type beta-catenin and the Wnt-beta-catenin pathway emerges as a common target for HCV (and HBV) in human HCCs, also independently from axin/beta-catenin gene mutations. Induction of both endoplasmic reticulum stress and oxidative stress by HCV proteins might also contribute to HCV transformation. Most of the putative transforming functions of the HCV proteins have been defined in artificial cellular systems, which may not be applicable to HCV infection in vivo, and still need to be established in relevant infection and disease models.	Univ Roma La Sapienza, Dept Internal Med, I-00161 Rome, Italy; Fdn Andrea Cesalpino, Lab Gene Express, Rome, Italy; Regina Elena Canc Ctr, AIRC Ctr Mol Oncogenom, Rome, Italy; Regina Elena Canc Ctr, Dept Expt Oncol, Rome, Italy	Sapienza University Rome	Levrero, M (corresponding author), Univ Roma La Sapienza, Dept Internal Med, Viale Policlin 155, I-00161 Rome, Italy.	Massimo.levrero@uniroma1.it	Levrero, Massimo/G-5680-2016	Levrero, Massimo/0000-0002-4978-0875				AGUILAR F, 1993, P NATL ACAD SCI USA, V90, P8586, DOI 10.1073/pnas.90.18.8586; Alam SS, 2002, ACTA MED OKAYAMA, V56, P141; Alisi A, 2003, ONCOGENE, V22, P2573, DOI 10.1038/sj.onc.1206333; [Anonymous], 2002, NIH Consens State Sci Statements, V19, P1; Aoki H, 2000, J VIROL, V74, P1736, DOI 10.1128/JVI.74.4.1736-1741.2000; Arima N, 2001, J BIOL CHEM, V276, P12675, DOI 10.1074/jbc.M008329200; Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; Barba G, 1997, P NATL ACAD SCI USA, V94, P1200, DOI 10.1073/pnas.94.4.1200; Bataller R, 2004, GASTROENTEROLOGY, V126, P529, DOI 10.1053/j.gastro.2003.11.018; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Blindenbacher A, 2003, GASTROENTEROLOGY, V124, P1465, DOI 10.1016/S0016-5085(03)00290-7; Bluteau O, 2002, NAT GENET, V32, P312, DOI 10.1038/ng1001; Boige V, 1997, CANCER RES, V57, P1986; Borowski P, 1999, J CLIN VIROL, V13, P61, DOI 10.1016/S1386-6532(99)00007-4; Borowski P, 1999, ARCH VIROL, V144, P687, DOI 10.1007/s007050050536; Borowski P, 1999, J BIOL CHEM, V274, P30722, DOI 10.1074/jbc.274.43.30722; Bosch FX, 1999, SEMIN LIVER DIS, V19, P271, DOI 10.1055/s-2007-1007117; Brass V, 2002, J BIOL CHEM, V277, P8130, DOI 10.1074/jbc.M111289200; Brechot C, 1998, J HEPATOL, V29, P173, DOI 10.1016/S0168-8278(98)80001-9; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; Breuhahn K, 2004, CANCER RES, V64, P6058, DOI 10.1158/0008-5472.CAN-04-0292; Brunt EM, 2004, HUM PATHOL, V35, P1070, DOI 10.1016/j.humpath.2004.04.017; Cacciola I, 1999, NEW ENGL J MED, V341, P22, DOI 10.1056/NEJM199907013410104; CHANG SC, 1994, BIOCHEM BIOPH RES CO, V205, P1284, DOI 10.1006/bbrc.1994.2804; Chen CJ, 2002, HEPATOLOGY, V36, P1046, DOI 10.1053/jhep.2002.37084; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; Cho JW, 2001, BBA-MOL CELL RES, V1538, P59, DOI 10.1016/S0167-4889(00)00137-3; Chung KM, 2000, J VIROL, V74, P5233, DOI 10.1128/JVI.74.11.5233-5241.2000; Crotta S, 2002, J EXP MED, V195, P35, DOI 10.1084/jem.20011124; Davila JA, 2005, GUT, V54, P533, DOI 10.1136/gut.2004.052167; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Delpuech O, 2002, ONCOGENE, V21, P2926, DOI 10.1038/sj.onc.1205392; Deuffic S, 1998, LANCET, V351, P214, DOI 10.1016/S0140-6736(05)78179-4; Ding QQ, 2005, MOL CELL, V19, P159, DOI 10.1016/j.molcel.2005.06.009; Disson O, 2004, GASTROENTEROLOGY, V126, P859, DOI 10.1053/j.gastro.2003.12.005; El-Serag H, 2003, ANN INTERN MED, V139, P817, DOI 10.7326/0003-4819-139-10-200311180-00009; El-Serag HB, 1999, NEW ENGL J MED, V340, P745, DOI 10.1056/NEJM199903113401001; Erhardt A, 2002, VIROLOGY, V292, P272, DOI 10.1006/viro.2001.1227; Farazi PA, 2003, CANCER RES, V63, P5021; Foy E, 2003, SCIENCE, V300, P1145, DOI 10.1126/science.1082604; Fukuda K, 2001, HEPATOLOGY, V33, P159, DOI 10.1053/jhep.2001.20794; Fukutomi T, 2005, HEPATOLOGY, V41, P1096, DOI 10.1002/hep.20668; FURUYA K, 1988, CANCER, V61, P99, DOI 10.1002/1097-0142(19880101)61:1<99::AID-CNCR2820610117>3.0.CO;2-U; Gale M, 1999, J VIROL, V73, P6506, DOI 10.1128/JVI.73.8.6506-6516.1999; Gale MJ, 1997, VIROLOGY, V230, P217, DOI 10.1006/viro.1997.8493; Ghosh AK, 2000, J BIOL CHEM, V275, P7184, DOI 10.1074/jbc.275.10.7184; Giambartolomei S, 2001, ONCOGENE, V20, P2606, DOI 10.1038/sj.onc.1204372; Goh PY, 2001, VIROLOGY, V290, P224, DOI 10.1006/viro.2001.1195; Gong GZ, 2001, P NATL ACAD SCI USA, V98, P9599, DOI 10.1073/pnas.171311298; Guo JT, 2001, J VIROL, V75, P8516, DOI 10.1128/JVI.75.18.8516-8523.2001; Hayashi J, 2000, HEPATOLOGY, V32, P958, DOI 10.1053/jhep.2000.19343; Henry SH, 1999, SCIENCE, V286, P2453, DOI 10.1126/science.286.5449.2453; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; Honda A, 1999, J MED VIROL, V59, P281, DOI 10.1002/(SICI)1096-9071(199911)59:3<281::AID-JMV4>3.0.CO;2-S; Hope RG, 2002, J BIOL CHEM, V277, P4261, DOI 10.1074/jbc.M108798200; Hsieh TY, 1998, J BIOL CHEM, V273, P17651, DOI 10.1074/jbc.273.28.17651; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; Ide Y, 1996, GENE, V182, P203, DOI 10.1016/S0378-1119(96)00555-0; Iizuka N, 2002, CANCER RES, V62, P3939; Ikeda M, 2002, J VIROL, V76, P2997, DOI 10.1128/JVI.76.6.2997-3006.2002; Ishido S, 1998, FEBS LETT, V438, P258, DOI 10.1016/S0014-5793(98)01312-X; Ishido S, 1997, BIOCHEM BIOPH RES CO, V230, P431, DOI 10.1006/bbrc.1996.5980; Jin DY, 2000, EMBO J, V19, P729, DOI 10.1093/emboj/19.4.729; Joo MS, 2005, J VIROL, V79, P7648, DOI 10.1128/JVI.79.12.7648-7657.2005; Jordan R, 2002, J VIROL, V76, P9588, DOI 10.1128/JVI.76.19.9588-9599.2002; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kawamura T, 1997, HEPATOLOGY, V25, P1014, DOI 10.1002/hep.510250437; Kinoshita T, 2002, BBA-MOL CELL RES, V1592, P303, DOI 10.1016/S0167-4889(02)00323-3; Kittlesen DJ, 2000, J CLIN INVEST, V106, P1239, DOI 10.1172/JCI10323; Koike K, 1997, P NATL ACAD SCI USA, V94, P233, DOI 10.1073/pnas.94.1.233; Kojiro M, 2005, BEST PRACT RES CL GA, V19, P39, DOI 10.1016/j.bpg.2004.10.007; Lan KH, 2002, ONCOGENE, V21, P4801, DOI 10.1038/sj.onc.1205589; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Lee JS, 2004, HEPATOLOGY, V40, P667, DOI 10.1002/hep.20375; Lee JS, 2002, HEPATOLOGY, V35, P1134, DOI 10.1053/jhep.2002.33165; Legoix P, 1999, ONCOGENE, V18, P4044, DOI 10.1038/sj.onc.1202800; Lerat H, 2002, GASTROENTEROLOGY, V122, P352, DOI 10.1053/gast.2002.31001; Lerat H, 1998, BLOOD, V91, P3841, DOI 10.1182/blood.V91.10.3841.3841_3841_3849; Levrero M, 2000, J CELL SCI, V113, P1661; Liew CT, 1999, ONCOGENE, V18, P789, DOI 10.1038/sj.onc.1202359; Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1; Lohmann V, 2001, J VIROL, V75, P1437, DOI 10.1128/JVI.75.3.1437-1449.2001; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Lu W, 1999, VIROLOGY, V264, P134, DOI 10.1006/viro.1999.9979; Ma YJ, 2001, CELL, V107, P827, DOI 10.1016/S0092-8674(01)00623-7; Macdonald GA, 1998, HEPATOLOGY, V28, P90, DOI 10.1002/hep.510280114; Machida K, 2001, J BIOL CHEM, V276, P12140, DOI 10.1074/jbc.M010137200; Majumder M, 2003, FEBS LETT, V555, P528, DOI 10.1016/S0014-5793(03)01337-1; Majumder M, 2002, VIROLOGY, V294, P94, DOI 10.1006/viro.2001.1309; Majumder M, 2001, J VIROL, V75, P1401, DOI 10.1128/JVI.75.3.1401-1407.2001; Mamiya N, 1999, J BIOL CHEM, V274, P15751, DOI 10.1074/jbc.274.22.15751; Marcellin P, 2002, HEPATOLOGY, V36, pS47, DOI 10.1053/jhep.2002.36993; Marchio A, 1997, GENE CHROMOSOME CANC, V18, P59, DOI 10.1002/(SICI)1098-2264(199701)18:1<59::AID-GCC7>3.3.CO;2-N; Marusawa H, 1999, J VIROL, V73, P4713, DOI 10.1128/JVI.73.6.4713-4720.1999; Matsumoto M, 1997, J VIROL, V71, P1301, DOI 10.1128/JVI.71.2.1301-1309.1997; Merle P, 2004, GASTROENTEROLOGY, V127, P1110, DOI 10.1053/j.gastro.2004.07.009; Ming L, 2002, HEPATOLOGY, V36, P1214, DOI 10.1053/jhep.2002.36366; Mise M, 1996, HEPATOLOGY, V23, P455; Mitsuhashi N, 2003, HEPATOLOGY, V37, P1105, DOI 10.1053/jhep.2003.50204; Miyoshi Y, 1998, CANCER RES, V58, P2524; Moradpour D, 2005, EUR J GASTROEN HEPAT, V17, P477, DOI 10.1097/00042737-200505000-00002; MORADPOUR D, 2002, MOL PATHOGENESIS HEP; Moriya K, 1997, J GEN VIROL, V78, P1527, DOI 10.1099/0022-1317-78-7-1527; Moriya K, 2001, CANCER RES, V61, P4365; Moriya K, 1998, NAT MED, V4, P1065, DOI 10.1038/2053; Muller M, 2005, CELL DEATH DIFFER, V12, P1564, DOI 10.1038/sj.cdd.4401774; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; Nam SW, 2005, HEPATOLOGY, V42, P809, DOI 10.1002/hep.20878; Nelson DR, 1997, J VIRAL HEPATITIS, V4, P29, DOI 10.1046/j.1365-2893.1997.00124.x; Neo SY, 2004, HEPATOLOGY, V39, P944, DOI 10.1002/hep.20105; Neuman MG, 2002, CYTOKINE, V17, P108, DOI 10.1006/cyto.2001.0997; NISHIDA N, 1994, CANCER RES, V54, P3107; Ohata K, 2003, CANCER-AM CANCER SOC, V97, P3036, DOI 10.1002/cncr.11427; Okabe H, 2001, CANCER RES, V61, P2129; Okuda M, 2002, GASTROENTEROLOGY, V122, P366, DOI 10.1053/gast.2002.30983; Otsuka M, 2000, J BIOL CHEM, V275, P34122, DOI 10.1074/jbc.M000578200; Owsianka AM, 1999, VIROLOGY, V257, P330, DOI 10.1006/viro.1999.9659; Ozturk M, 1999, SEMIN LIVER DIS, V19, P235, DOI 10.1055/s-2007-1007113; PALESCANDOLO E, 2006, UNPUB; Park JS, 2000, BIOCHEM BIOPH RES CO, V267, P581, DOI 10.1006/bbrc.1999.1999; Pasquinelli C, 1997, HEPATOLOGY, V25, P719, DOI 10.1002/hep.510250338; Patil MA, 2005, ONCOGENE, V24, P3737, DOI 10.1038/sj.onc.1208479; Pavio N, 2005, ONCOGENE, V24, P6119, DOI 10.1038/sj.onc.1208749; Perlemuter G, 2002, FASEB J, V16, P185, DOI 10.1096/fj.01-0396com; Pflugheber J, 2002, P NATL ACAD SCI USA, V99, P4650, DOI 10.1073/pnas.062055699; Piao Z, 2000, INT J ONCOL, V17, P507; Pietschmann T, 2002, J VIROL, V76, P4008, DOI 10.1128/JVI.76.8.4008-4021.2002; Pollicino T, 2004, GASTROENTEROLOGY, V126, P102, DOI 10.1053/j.gastro.2003.10.048; Polyak SJ, 1998, J VIROL, V72, P4288, DOI 10.1128/JVI.72.5.4288-4296.1998; Polyak SJ, 2001, J VIROL, V75, P6095, DOI 10.1128/JVI.75.13.6095-6106.2001; Putzer B, 2003, CELL DEATH DIFFER, V10, P612, DOI 10.1038/sj.cdd.4401205; Qadri I, 2002, BBA-MOL CELL RES, V1592, P193, DOI 10.1016/S0167-4889(02)00315-4; RAVAGGI A, 1994, J HEPATOL, V20, P833, DOI 10.1016/S0168-8278(05)80157-6; Ray RB, 2002, VIRUS RES, V87, P21, DOI 10.1016/S0168-1702(02)00046-1; Ray RB, 1998, J BIOL CHEM, V273, P2256, DOI 10.1074/jbc.273.4.2256; Ray RB, 1996, J VIROL, V70, P4438, DOI 10.1128/JVI.70.7.4438-4443.1996; Ray RB, 1997, J BIOL CHEM, V272, P10983; Ruggieri A, 1997, VIROLOGY, V229, P68, DOI 10.1006/viro.1996.8420; Ruster B, 2001, J MED VIROL, V63, P128, DOI 10.1002/1096-9071(20000201)63:2&lt;128::AID-JMV1007&gt;3.0.CO;2-S; Sabile A, 1999, HEPATOLOGY, V30, P1064, DOI 10.1002/hep.510300429; SAKAMURO D, 1995, J VIROL, V69, P3893, DOI 10.1128/JVI.69.6.3893-3896.1995; SantoniRugiu E, 1996, P NATL ACAD SCI USA, V93, P9577, DOI 10.1073/pnas.93.18.9577; Satoh S, 2000, VIROLOGY, V270, P476, DOI 10.1006/viro.2000.0287; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Shi ST, 2002, VIROLOGY, V292, P198, DOI 10.1006/viro.2001.1225; SHIMODA R, 1994, CANCER RES, V54, P3171; Shintani Y, 2004, GASTROENTEROLOGY, V126, P840, DOI 10.1053/j.gastro.2003.11.056; Shirota Y, 2001, HEPATOLOGY, V33, P832, DOI 10.1053/jhep.2001.23003; Smith MW, 2003, CANCER RES, V63, P859; Soo HM, 2002, VIROLOGY, V303, P253, DOI 10.1006/viro.2002.1617; Squadrito G, 2006, CANCER-AM CANCER SOC, V106, P1326, DOI 10.1002/cncr.21702; Street A, 2005, J VIROL, V79, P5006, DOI 10.1128/JVI.79.8.5006-5016.2005; Street A, 2004, J BIOL CHEM, V279, P12232, DOI 10.1074/jbc.M312245200; Sumida Y, 2000, J HEPATOL, V33, P616, DOI 10.1034/j.1600-0641.2000.033004616.x; Sun ZT, 1999, HEPATOLOGY, V30, P379, DOI 10.1002/hep.510300204; SUZUKI R, 1995, J GEN VIROL, V76, P53, DOI 10.1099/0022-1317-76-1-53; Tai DI, 2000, HEPATOLOGY, V31, P656, DOI 10.1002/hep.510310316; Tai DI, 2000, CANCER, V89, P2274, DOI 10.1002/1097-0142(20001201)89:11<2274::AID-CNCR16>3.0.CO;2-2; Tan SL, 1999, P NATL ACAD SCI USA, V96, P5533, DOI 10.1073/pnas.96.10.5533; Tanaka S, 1999, J CLIN INVEST, V103, P341, DOI 10.1172/JCI4891; Taniguchi H, 2004, J MED VIROL, V72, P52, DOI 10.1002/jmv.10545; Tanimoto A, 1997, BIOCHEM BIOPH RES CO, V236, P360, DOI 10.1006/bbrc.1997.6967; Tardif KD, 2002, J VIROL, V76, P7453, DOI 10.1128/JVI.76.15.7453-7459.2002; Taylor DR, 1999, SCIENCE, V285, P107, DOI 10.1126/science.285.5424.107; TaylorRobinson SD, 1997, LANCET, V350, P1142, DOI 10.1016/S0140-6736(05)63789-0; Tellinghuisen TL, 2002, CURR OPIN MICROBIOL, V5, P419, DOI 10.1016/S1369-5274(02)00341-7; TERADA T, 1993, VIRCHOWS ARCH A, V422, P381, DOI 10.1007/BF01605457; Thimme R, 2002, P NATL ACAD SCI USA, V99, P15661, DOI 10.1073/pnas.202608299; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Thorgeirsson SS, 2006, HEPATOLOGY, V43, pS145, DOI 10.1002/hep.21063; Torbenson M, 2002, LANCET INFECT DIS, V2, P479, DOI 10.1016/S1473-3099(02)00345-6; Tseng CTK, 2002, J EXP MED, V195, P43, DOI 10.1084/jem.20011145; Tsuchihara K, 2000, FEBS LETT, V478, P299, DOI 10.1016/S0014-5793(00)01838-X; Tu H, 1999, VIROLOGY, V263, P30, DOI 10.1006/viro.1999.9893; Varaklioti A, 2002, J BIOL CHEM, V277, P17713, DOI 10.1074/jbc.M201722200; Vossio S, 2002, ONCOGENE, V21, P3796, DOI 10.1038/sj.onc.1205465; Wakita T, 1998, J BIOL CHEM, V273, P9001, DOI 10.1074/jbc.273.15.9001; Wakita T, 2000, J MED VIROL, V62, P308, DOI 10.1002/1096-9071(200011)62:3<308::AID-JMV2>3.0.CO;2-6; Walewski JL, 2001, RNA, V7, P710, DOI 10.1017/S1355838201010111; Wang F, 2000, BIOCHEM BIOPH RES CO, V273, P479, DOI 10.1006/bbrc.2000.2970; Waris G, 2002, BIOCHEM PHARMACOL, V64, P1425, DOI 10.1016/S0006-2952(02)01300-X; Xu ZM, 2001, EMBO J, V20, P3840, DOI 10.1093/emboj/20.14.3840; Yamaguchi R, 1998, HEPATOLOGY, V28, P68, DOI 10.1002/hep.510280111; Yamanaka T, 2002, BIOCHEM BIOPH RES CO, V294, P521, DOI 10.1016/S0006-291X(02)00507-7; Ye QH, 2003, NAT MED, V9, P416, DOI 10.1038/nm843; Yoshida T, 2002, J EXP MED, V196, P641, DOI 10.1084/jem.20012127; You LR, 1999, J VIROL, V73, P2841, DOI 10.1128/JVI.73.4.2841-2853.1999; Zhao LJ, 2005, EXP CELL RES, V305, P23, DOI 10.1016/j.yexcr.2004.12.024; Zhou TL, 1997, CANCER RES, V57, P2749; Zhu NL, 1998, J VIROL, V72, P3691, DOI 10.1128/JVI.72.5.3691-3697.1998; Zhu NL, 2001, VIROLOGY, V283, P178, DOI 10.1006/viro.2001.0896	191	309	327	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	27					3834	3847		10.1038/sj.onc.1209562	http://dx.doi.org/10.1038/sj.onc.1209562			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	056XY	16799625	Green Published			2022-12-17	WOS:000238559600011
J	Suliman, A; Lam, A; Datta, R; Srivastava, RK				Suliman, A; Lam, A; Datta, R; Srivastava, RK			Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways	ONCOGENE			English	Article						TRAIL; death receptor; FADD; caspase; mitochondria; Bcl-2; Bcl-X-L	CYTOCHROME-C RELEASE; CYTOTOXIC LIGAND TRAIL; PROGRAMMED CELL-DEATH; NF-KAPPA-B; MEDIATED APOPTOSIS; CANCER-CELLS; FAS LIGAND; IONIZING-RADIATION; BACULOVIRUS P35; CD95 APO-1/FAS	Tumor necrosis (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF family of cytokines that promotes apoptosis, TRAIL induces apoptosis via death receptors (DR4 and DR5) in a wide variety of tumor cells but not in normal cells. The objectives of this study are to investigate the intracellular mechanisms by which TRAIL induces apoptosis, The death receptor Fas, upon ligand binding, trimerizes and recruits the adaptor protein FADD through the cytoplasmic death domain of Fas, FADD then binds and activates procaspase-8. It is unclear whether FADD is required for TRAIL-induced apoptosis, Here we show that the signaling complex of DR4/DR5 is assembled in response to TRAIL binding. FADD and caspase-8, but not caspase-10, are recruited to the receptor, and cells deficient in either FADD or caspase-8 blocked TRAIL-induced apoptosis, In addition, TRAIL initiates the activation of caspases, the loss of mitochondrial transmembrane potential (Delta psi (m)), the cleavage of BID, and the redistribution of mitochondrial cytochrome c, Treatment of Jurkat cells with cyclosporin A delayed TRAIL-induced Delta psi (m), caspase-3 activation and apoptosis, Similarly, Overexpression of Bcl-2 or Bcl-X-L delayed, but did not inhibit, TRAIL-induced Delta psi (m) and apoptosis, In contrast, XIAP, cowpox virus CrmA and baculovirus p35 inhibited TRAIL-induced apoptosis, These data suggest that death receptors (DR4 and DR5) and Fas receptors induced apoptosis through identical signaling pathway, and TRAIL-induced apoptosis via both mitochondrial-dependent and -independent pathways.	Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	University System of Maryland; University of Maryland Baltimore; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Srivastava, RK (corresponding author), Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, 20 N Pine St, Baltimore, MD 21201 USA.							Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; Bertin J, 1996, J VIROL, V70, P6251, DOI 10.1128/JVI.70.9.6251-6259.1996; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; CLEN RJ, 1994, MOL CELL BIOL, V14, P5212; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; Decaudin D, 1997, CANCER RES, V57, P62; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; Enari M, 2000, SEIKAGAKU, V72, P6; French LE, 1999, NAT MED, V5, P146, DOI 10.1038/5505; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Golstein P, 1997, CURR BIOL, V7, pR750, DOI 10.1016/S0960-9822(06)90000-1; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Griffith TS, 1998, J IMMUNOL, V161, P2833; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Gura T, 1997, SCIENCE, V277, P768, DOI 10.1126/science.277.5327.768; Han ZY, 1999, MOL CELL BIOL, V19, P1381; HAY BA, 1994, DEVELOPMENT, V120, P2121; He LH, 2000, J BIOL CHEM, V275, P12175, DOI 10.1074/jbc.275.16.12175; Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Keogh SA, 2000, FEBS LETT, V471, P93, DOI 10.1016/S0014-5793(00)01375-2; Kim EJ, 2001, INT J ONCOL, V18, P187; Kim KH, 2000, CLIN CANCER RES, V6, P335; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KORSMEYER SJ, 1999, CANCER RES, V59, P1693; Krammer P H, 1999, Adv Immunol, V71, P163; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Miller LK, 1999, TRENDS CELL BIOL, V9, P323, DOI 10.1016/S0962-8924(99)01609-8; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Peter M E, 1999, Results Probl Cell Differ, V23, P25; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Salvesen GS, 1999, APMIS, V107, P73, DOI 10.1111/j.1699-0463.1999.tb01528.x; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Schneider P, 1997, FEBS LETT, V416, P329, DOI 10.1016/S0014-5793(97)01231-3; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Screaton GR, 1997, CURR BIOL, V7, P693, DOI 10.1016/S0960-9822(06)00297-1; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Simonian PL, 1997, BLOOD, V90, P1208, DOI 10.1182/blood.V90.3.1208.1208_1208_1216; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Srivastava RK, 1999, J EXP MED, V190, P253, DOI 10.1084/jem.190.2.253; Srivastava RK, 1999, MOL CELL BIOL, V19, P5659; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; Srivastava RK, 1999, ONCOGENE, V18, P1755, DOI 10.1038/sj.onc.1202464; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; Tanaka M, 1997, J IMMUNOL, V158, P2303; TEWARI M, 1995, J BIOL CHEM, V270, P18738, DOI 10.1074/jbc.270.32.18738; TEWARI M, 1995, J BIOL CHEM, V270, P22705, DOI 10.1074/jbc.270.39.22705; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wolf BB, 1999, BLOOD, V94, P1683, DOI 10.1182/blood.V94.5.1683.417k37_1683_1692; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954	87	309	323	0	20	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 19	2001	20	17					2122	2133		10.1038/sj.onc.1204282	http://dx.doi.org/10.1038/sj.onc.1204282			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	422KH	11360196				2022-12-17	WOS:000168116700007
J	Ogawa, K; Pasqualini, R; Lindberg, RA; Kain, R; Freeman, AL; Pasquale, EB				Ogawa, K; Pasqualini, R; Lindberg, RA; Kain, R; Freeman, AL; Pasquale, EB			The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization	ONCOGENE			English	Article						Eph receptor tyrosine kinases; angiogenesis; endothelial cells	PROTEIN-TYROSINE KINASE; BLOOD-VESSEL FORMATION; VASCULAR DEVELOPMENT; CARDIOVASCULAR DEVELOPMENT; MELANOMA PROGRESSION; RESPONSE GENE; CELL-LINES; ANGIOGENESIS; B61; ECK	Eph receptor tyrosine kinases and their ephrin ligands have been implicated in embryonic vascular development and in in vivo models of angiogenesis. Eph proteins may also regulate tumor neovascularization, but this role has not been previously investigated. To screen for Eph proteins expressed in tumor blood vessels, we used tumor xenografts grown in nude mice from MDA-MB-435 human breast cancer cells or KS1767 human Kaposi's sarcoma cells, By immunohistochemistry, the ephrin-A1 ligand and one of its receptors, EphA2, were detected throughout tumor vasculature. Double-labeling with anti-CD34 antibodies demonstrated that both ephrin-A1 and EphA2 were expressed in xenograft endothelial cells and also tumor cells. Furthermore, EphA2 was tyrosine-phosphorylated in the xenograft tumors, indicating that it was activated, presumably by interacting with ephrin-A1. Ephrin-A1 and EphA2 were also detected in both the vasculature and tumor cells of surgically removed human cancers. In an in vitro angiogenesis model, a dominant negative form of EphA2 inhibited capillary tube-like formation by human umbilical vein endothelial cells (HUVECs), demonstrating a requirement for EphA receptor signaling, These data suggest that ephrin-A1 and EphA2 play a role in human cancers, at least in part by influencing tumor neovascularization. Eph proteins may represent promising new targets for antiangiogenic cancer treatments.	Burnham Inst, La Jolla, CA 92037 USA; Iwate Univ, Fac Agr, Dept Vet Anat, Morioka, Iwate 2028550, Japan; Amgen Inc, Amgen Ctr, Thousand Oaks, CA 91320 USA; Univ Vienna, AK Hosp, Inst Clin Pathol, A-1090 Vienna, Austria	Sanford Burnham Prebys Medical Discovery Institute; Iwate University; Amgen; University of Vienna	Pasquale, EB (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Kain, Renate/ACR-4709-2022	Kain, Renate/0000-0002-2428-543X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD026351, R01HD026351] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA082713] Funding Source: NIH RePORTER; NCI NIH HHS [CA82713] Funding Source: Medline; NICHD NIH HHS [HD26351] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295; ANDRES AC, 1994, ONCOGENE, V9, P1461; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; Berclaz G, 1996, BIOCHEM BIOPH RES CO, V226, P869, DOI 10.1006/bbrc.1996.1442; Bobik A, 1997, TUMOUR ANGIOGENESIS, P169; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; DANIEL TO, 1996, KIDNEY INT S, V57, P73; Davy A, 1999, GENE DEV, V13, P3125, DOI 10.1101/gad.13.23.3125; DODELET VC, 2000, IN PRESS ONCOGENE; EASTY DJ, 1995, INT J CANCER, V60, P129, DOI 10.1002/ijc.2910600119; Easty DJ, 1999, INT J CANCER, V84, P494, DOI 10.1002/(SICI)1097-0215(19991022)84:5<494::AID-IJC8>3.3.CO;2-F; Eberhart J, 2000, DEV NEUROSCI-BASEL, V22, P237, DOI 10.1159/000017446; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Flanagan JG, 1997, CELL, V90, P403; Flenniken AM, 1996, DEV BIOL, V179, P382, DOI 10.1006/dbio.1996.0269; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; FOX SB, 1995, J PATHOL, V177, P369, DOI 10.1002/path.1711770407; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; Gasparini G, 1997, TUMOUR ANGIOGENESIS, P29; Gerety SS, 1999, MOL CELL, V4, P403, DOI 10.1016/S1097-2765(00)80342-1; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; HERNDIER BG, 1994, AIDS, V8, P575, DOI 10.1097/00002030-199405000-00002; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; Holash JA, 1995, DEV BIOL, V172, P683, DOI 10.1006/dbio.1995.8039; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; Huynh-Do U, 1999, EMBO J, V18, P2165, DOI 10.1093/emboj/18.8.2165; Kalo MS, 1999, CELL TISSUE RES, V298, P1, DOI 10.1007/PL00008807; KIYOKAWA E, 1994, CANCER RES, V54, P3645; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; Magal E, 1996, J NEUROSCI RES, V43, P735, DOI 10.1002/(SICI)1097-4547(19960315)43:6<735::AID-JNR10>3.0.CO;2-X; MARU Y, 1988, MOL CELL BIOL, V8, P3770, DOI 10.1128/MCB.8.9.3770; MARU Y, 1990, ONCOGENE, V5, P445; McBride JL, 1998, MECH DEVELOP, V77, P201, DOI 10.1016/S0925-4773(98)00142-7; Mellitzer G, 1999, NATURE, V400, P77, DOI 10.1038/21907; Merenmies J, 1997, CELL GROWTH DIFFER, V8, P3; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; Pasqualini R, 1997, NAT BIOTECHNOL, V15, P542, DOI 10.1038/nbt0697-542; PRICE JE, 1990, CANCER RES, V50, P717; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SARMA V, 1992, J IMMUNOL, V148, P3302; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SOANS C, 1994, ONCOGENE, V9, P3353; Soans C, 1996, J CELL BIOL, V135, P781, DOI 10.1083/jcb.135.3.781; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; TAKAHASHI H, 1995, ONCOGENE, V11, P879; UICC/AJCC, 1997, TNM CLASS MAL TUM; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Walker-Daniels J, 1999, PROSTATE, V41, P275, DOI 10.1002/(SICI)1097-0045(19991201)41:4<275::AID-PROS8>3.0.CO;2-T; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Xu QL, 1999, NATURE, V399, P267, DOI 10.1038/20452; Zisch AH, 2000, ONCOGENE, V19, P177, DOI 10.1038/sj.onc.1203304	59	309	344	0	15	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 7	2000	19	52					6043	6052		10.1038/sj.onc.1204004	http://dx.doi.org/10.1038/sj.onc.1204004			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146556				2022-12-17	WOS:000165827900011
J	Gu, Z; Thomas, G; Yamashiro, J; Shintaku, IP; Dorey, F; Raitano, A; Witte, ON; Said, JW; Loda, M; Reiter, RE				Gu, Z; Thomas, G; Yamashiro, J; Shintaku, IP; Dorey, F; Raitano, A; Witte, ON; Said, JW; Loda, M; Reiter, RE			Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer	ONCOGENE			English	Article						prostate; neoplasm; prostate stem cell antigen (PSCA); antibody	IN-SITU HYBRIDIZATION; GPI-ANCHORED PROTEINS; MEMBRANE ANTIGEN; INTRAEPITHELIAL NEOPLASIA; CHROMOSOMAL-ANOMALIES; MONOCLONAL-ANTIBODIES; EXTRACELLULAR DOMAIN; CARCINOMA; SURFACE; ADENOCARCINOMA	Prostate stem cell antigen (PSCA) is a recently defined homologue of the Thy-1/Ly-6 family of glycosylphosphatidylinositol (GPI)-anchored cell surface antigens, PSCA mRNA is expressed in the basal cells of normal prostate and in more than 80% of prostate cancers, The purpose of the present study was to examine PSCA protein expression in clinical specimens of human prostate cancer, Five monoclonal antibodies were raised against a PSCA-GST fusion protein and screened for their ability to recognize PSCA on the cell surface of human prostate cancer cells. Immunohistochemical analysis of PSCA expression was performed on paraffin-embedded sections from 25 normal tissues, 112 primary prostate cancers and nine prostate cancers metastatic to bone. The level of PSCA expression in prostate tumors was quantified and compared with expression in adjacent normal glands, The antibodies detect PSCA expression on the cell surface of normal and malignant prostate cells and distinguish three extracellular epitopes on PSCA, Prostate and transitional epithelium reacted strongly with PSCA, PSCA staining was also seen in placental trophoblasts, renal collecting duets and neuroendocrine cells in the stomach and colon, All other normal tissues tested were negative. PSCA protein expression was identified in 105/112 (94%) primary prostate tumors and 9/9 (100%) bone metastases, The level of PSCA expression increased with higher Gleason score (P = 0.016), higher tumor stage (P = 0.010) and progression to androgen-independence (P = 0.021). Intense, homogeneous staining was seen in all nine bone metastases. PSCA is a cell surface protein with limited expression in extraprostatic normal tissues, PSCA expression correlates with tumor stage, grade and androgen independence and may have prognostic utility. Because expression on the surface of prostate cancer cells increases with tumor progression, PSCA may be a useful molecular target in advanced prostate cancer.	Univ Calif Los Angeles, Dept Urol, Ctr Hlth Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Pathol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Orthoped, Los Angeles, CA 90095 USA; Urogenesys Inc, Santa Monica, CA 90404 USA; Univ Calif Los Angeles, Howard Hughes Med Inst, Inst Mol Biol, Dept Microbiol & Mol Genet, Los Angeles, CA 90095 USA; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; Harvard University; Dana-Farber Cancer Institute	Reiter, RE (corresponding author), Univ Calif Los Angeles, Dept Urol, Ctr Hlth Sci, 10833 Conte Ave, Los Angeles, CA 90095 USA.			Thomas, George V/0000-0001-7416-8840	NATIONAL CANCER INSTITUTE [K08CA074169] Funding Source: NIH RePORTER; NCI NIH HHS [K08 CA74169] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alers JC, 1997, LAB INVEST, V77, P437; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Antica M, 1997, IMMUNOL LETT, V55, P47, DOI 10.1016/S0165-2478(96)02682-X; Arienti G, 1997, BBA-GEN SUBJECTS, V1336, P533, DOI 10.1016/S0304-4165(97)00071-8; CHER ML, 1994, GENE CHROMOSOME CANC, V11, P153, DOI 10.1002/gcc.2870110304; CLASSON BJ, 1994, P NATL ACAD SCI USA, V91, P5296, DOI 10.1073/pnas.91.12.5296; Cordon-Cardo C, 1998, JNCI-J NATL CANCER I, V90, P1284, DOI 10.1093/jnci/90.17.1284; Disis ML, 1997, ADV CANCER RES, V71, P343, DOI 10.1016/S0065-230X(08)60103-7; EPSTEIN JI, 1995, UROLOGY, V45, P81, DOI 10.1016/S0090-4295(95)96904-7; Fair WR, 1997, PROSTATE, V32, P140; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Hanas JS, 1999, CANCER-AM CANCER SOC, V86, P756, DOI 10.1002/(SICI)1097-0142(19990901)86:5<756::AID-CNCR9>3.0.CO;2-X; Hoessli DC, 1998, TRENDS CELL BIOL, V8, P87, DOI 10.1016/S0962-8924(98)80018-4; Jenkins RB, 1997, CANCER RES, V57, P524; Kawakami M, 1997, CANCER RES, V57, P2321; KOKONTIS J, 1994, CANCER RES, V54, P1566; Lalani EN, 1997, CANCER METAST REV, V16, P29, DOI 10.1023/A:1005792206377; Liu H, 1997, CANCER RES, V57, P3629; MagiGalluzzi C, 1997, LAB INVEST, V76, P37; MagiGalluzzi C, 1997, MODERN PATHOL, V10, P839; MagiGalluzzi C, 1996, EUR UROL, V30, P167; MCNEAL JE, 1986, CANCER, V58, P1714, DOI 10.1002/1097-0142(19861015)58:8<1714::AID-CNCR2820580823>3.0.CO;2-M; Murphy GP, 1998, CANCER-AM CANCER SOC, V83, P2259, DOI 10.1002/(SICI)1097-0142(19981201)83:11<2259::AID-CNCR5>3.0.CO;2-T; Murphy GP, 1998, J UROLOGY, V160, P2396, DOI 10.1016/S0022-5347(01)62198-0; OMALLEY FP, 1990, VIRCHOWS ARCH A, V417, P191, DOI 10.1007/BF01600133; Qian JQ, 1997, MODERN PATHOL, V10, P1113; Reiter RE, 2000, GENE CHROMOSOME CANC, V27, P95, DOI 10.1002/(SICI)1098-2264(200001)27:1<95::AID-GCC12>3.0.CO;2-3; Reiter RE, 1998, P NATL ACAD SCI USA, V95, P1735, DOI 10.1073/pnas.95.4.1735; Rubin MA, 1998, AM J SURG PATHOL, V22, P840, DOI 10.1097/00000478-199807000-00006; Said JW, 1998, MODERN PATHOL, V11, P1; SATO K, 1999, J UROLOGY, V161, pA60; Sauvageot J, 1998, PROSTATE, V34, P29, DOI 10.1002/(SICI)1097-0045(19980101)34:1<29::AID-PROS4>3.0.CO;2-F; Silver DA, 1997, CLIN CANCER RES, V3, P81; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; THOMAS PM, 1992, J BIOL CHEM, V267, P12317; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4	38	309	388	0	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 2	2000	19	10					1288	1296		10.1038/sj.onc.1203426	http://dx.doi.org/10.1038/sj.onc.1203426			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	291NW	10713670				2022-12-17	WOS:000085743800005
J	Cayrol, C; Knibiehler, M; Ducommun, B				Cayrol, C; Knibiehler, M; Ducommun, B			p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells	ONCOGENE			English	Article						cell cycle; cyclin-dependent kinase; growth arrest; p21(CIP1/WAF1); PCNA	DEPENDENT-KINASE INHIBITOR; NUCLEOTIDE EXCISION-REPAIR; C-TERMINAL REGION; NUCLEAR ANTIGEN; DNA-REPLICATION; TUMOR SUPPRESSION; P21(WAF1/CIP1); PROTEIN; EXPRESSION; P21(CIP1)	A unique feature of p21 that distinguishes it from the other cyclin-dependent kinase (CDK) inhibitors is its ability to associate with the proliferating cell nuclear antigen (PCNA), an auxiliary factor for DNA polymerases delta and epsilon. While it is now well established that inhibition of cyclin/CDK complexes by p21 can result in G1 cell cycle arrest, the consequences of p21/PCNA interaction on cell cycle progression have not yet been determined. Here, we show, using a tetracycline-regulated system, that expression of wild-type p21 in p53-deficient DLD1 human colon cancer cells inhibits DNA synthesis and causes G1 and G2 cell cycle arrest. Similar effects are observed in cells expressing p21(CDK-) mutant impaired in the interaction with CDKs, but not in cells expressing p21(PCNA-), a mutant deficient for the interaction with PCNA. Analysis of cells treated with a p21-derived PCNA-binding peptide provides additional evidence that the growth inhibitory effects of p21 and p21(CDK-) result from their ability to bind to PCNA. Our results suggest that p21 might inhibit cell cycle progression by two independent mechanisms, inhibition of cyclin/CDK complexes, and inhibition of PCNA function resulting in both G1 and G2 arrest.	Univ Toulouse 3, CNRS, Inst Pharmacol & Biol Struct, F-31077 Toulouse, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Ducommun, B (corresponding author), Univ Toulouse 3, CNRS, Inst Pharmacol & Biol Struct, 205 Route Narbonne, F-31077 Toulouse, France.		CAYROL, Corinne/C-2106-2011; DUCOMMUN, Bernard/B-3208-2008	CAYROL, Corinne/0000-0002-7813-4397; DUCOMMUN, Bernard/0000-0002-7126-8368				BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARBOULE N, 1995, INT J CANCER, V63, P611, DOI 10.1002/ijc.2910630502; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Chen JJ, 1996, NUCLEIC ACIDS RES, V24, P1727, DOI 10.1093/nar/24.9.1727; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chen JJ, 1996, P NATL ACAD SCI USA, V93, P11597, DOI 10.1073/pnas.93.21.11597; CHEN YQ, 1995, CANCER RES, V55, P4536; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, TRENDS CELL BIOL, V6, P388, DOI 10.1016/0962-8924(96)10030-1; ENOCH T, 1995, TRENDS BIOCHEM SCI, V20, P426, DOI 10.1016/S0968-0004(00)89093-3; Fahraeus R, 1996, CURR BIOL, V6, P84, DOI 10.1016/S0960-9822(02)00425-6; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Fotedar R, 1996, ONCOGENE, V12, P2155; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOUBIN F, 1995, ONCOGENE, V10, P2281; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; JUNG JM, 1995, ONCOGENE, V11, P2021; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; Knibiehler M, 1996, FEBS LETT, V391, P66, DOI 10.1016/0014-5793(96)00702-8; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Li R, 1996, CURR BIOL, V6, P189, DOI 10.1016/S0960-9822(02)00452-9; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MORRIS GF, 1989, J BIOL CHEM, V264, P13856; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P8869, DOI 10.1021/bi00027a039; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Savio M, 1996, ONCOGENE, V13, P1591; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sheikh MS, 1997, ONCOGENE, V14, P1875, DOI 10.1038/sj.onc.1201004; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; TOSCHI L, 1988, J CELL BIOL, V107, P1623, DOI 10.1083/jcb.107.5.1623; Tournier S, 1996, MOL BIOL CELL, V7, P651, DOI 10.1091/mbc.7.4.651; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; ZAKUT R, 1995, ONCOGENE, V11, P393	49	309	316	3	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	1998	16	3					311	320		10.1038/sj.onc.1201543	http://dx.doi.org/10.1038/sj.onc.1201543			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT262	9467956	Bronze			2022-12-17	WOS:000071582100003
J	van Geldermalsen, M; Wang, Q; Nagarajah, R; Marshall, AD; Thoeng, A; Gao, D; Ritchie, W; Feng, Y; Bailey, CG; Deng, N; Harvey, K; Beith, JM; Selinger, CI; O'Toole, SA; Rasko, JEJ; Holst, J				van Geldermalsen, M.; Wang, Q.; Nagarajah, R.; Marshall, A. D.; Thoeng, A.; Gao, D.; Ritchie, W.; Feng, Y.; Bailey, C. G.; Deng, N.; Harvey, K.; Beith, J. M.; Selinger, C. I.; O'Toole, S. A.; Rasko, J. E. J.; Holst, J.			ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer	ONCOGENE			English	Article							ACUTE MYELOID-LEUKEMIA; AMINO-ACID-TRANSPORT; HUMAN HEPATOMA-CELLS; MOLECULAR SUBTYPE; LUNG-CANCER; METABOLISM; EXPRESSION; TARGET; PROGRESSION; SENSITIVITY	Alanine, serine, cysteine-preferring transporter 2 (ASCT2; SLC1A5) mediates uptake of glutamine, a conditionally essential amino acid in rapidly proliferating tumour cells. Uptake of glutamine and subsequent glutaminolysis is critical for activation of the mTORC1 nutrient-sensing pathway, which regulates cell growth and protein translation in cancer cells. This is of particular interest in breast cancer, as glutamine dependence is increased in high-risk breast cancer subtypes. Pharmacological inhibitors of ASCT2-mediated transport significantly reduced glutamine uptake in human breast cancer cell lines, leading to the suppression of mTORC1 signalling, cell growth and cell cycle progression. Notably, these effects were subtype-dependent, with ASCT2 transport critical only for triple-negative (TN) basal-like breast cancer cell growth compared with minimal effects in luminal breast cancer cells. Both stable and inducible shRNA-mediated ASCT2 knockdown confirmed that inhibiting ASCT2 function was sufficient to prevent cellular proliferation and induce rapid cell death in TN basal-like breast cancer cells, but not in luminal cells. Using a bioluminescent orthotopic xenograft mouse model, ASCT2 expression was then shown to be necessary for both successful engraftment and growth of HCC1806 TN breast cancer cells in vivo. Lower tumoral expression of ASCT2 conferred a significant survival advantage in xenografted mice. These responses remained intact in primary breast cancers, where gene expression analysis showed high expression of ASCT2 and glutamine metabolism-related genes, including GLUL and GLS, in a cohort of 90 TN breast cancer patients, as well as correlations with the transcriptional regulators, MYC and ATF4. This study provides preclinical evidence for the feasibility of novel therapies exploiting ASCT2 transporter activity in breast cancer, particularly in the high-risk basal-like subgroup of TN breast cancer where there is not only high expression of ASCT2, but also a marked reliance on its activity for sustained cellular proliferation.	[van Geldermalsen, M.; Wang, Q.; Nagarajah, R.; Holst, J.] Centenary Inst, Origins Canc Program, Camperdown, NSW, Australia; [van Geldermalsen, M.; Wang, Q.; Nagarajah, R.; Marshall, A. D.; Thoeng, A.; Gao, D.; Ritchie, W.; Feng, Y.; Bailey, C. G.; Rasko, J. E. J.; Holst, J.] Centenary Inst, Gene & Stem Cell Therapy Program, Camperdown, NSW, Australia; [van Geldermalsen, M.; Wang, Q.; Nagarajah, R.; Marshall, A. D.; Thoeng, A.; Gao, D.; Ritchie, W.; Feng, Y.; Bailey, C. G.; Beith, J. M.; O'Toole, S. A.; Rasko, J. E. J.; Holst, J.] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia; [Gao, D.; Ritchie, W.] Centenary Inst, Bioinformat Lab, Camperdown, NSW, Australia; [Deng, N.; Harvey, K.; O'Toole, S. A.] St Vincents Hosp, Garvan Inst Med Res, Kinghorn Canc Ctr, Darlinghurst, NSW 2010, Australia; [Deng, N.; Harvey, K.; O'Toole, S. A.] St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Darlinghurst, NSW 2010, Australia; [Deng, N.] Univ New S Wales, Fac Med, St Vincents Clin Sch, Sydney, NSW, Australia; [Harvey, K.; Selinger, C. I.; O'Toole, S. A.] Royal Prince Alfred Hosp, Dept Tissue Pathol & Diagnost Oncol, Camperdown, NSW 2050, Australia; [Beith, J. M.] Chris OBrien Lifehouse, Dept Med Oncol, Camperdown, NSW, Australia; [Rasko, J. E. J.] Royal Prince Alfred Hosp, Cell & Mol Therapies, Sydney, NSW, Australia	University of Sydney; Centenary Institute; University of Sydney; Centenary Institute; University of Sydney; University of Sydney; Centenary Institute; Garvan Institute of Medical Research; St Vincents Hospital Sydney; Garvan Institute of Medical Research; St Vincents Hospital Sydney; University of New South Wales Sydney; University of Sydney; University of Sydney; University of Sydney	Holst, J (corresponding author), Centenary Inst, Origins Canc Program, Locked Bag 6, Newtown, NSW 2042, Australia.	j.holst@centenary.org.au	Gao, Dadi/AAW-4359-2020; Holst, Jeff/H-7634-2012	Gao, Dadi/0000-0002-3638-8479; Holst, Jeff/0000-0002-0377-9318; Deng, Niantao/0000-0001-9717-2236; Wang, Qian (Kevin)/0000-0002-6514-3470; Bailey, Charles/0000-0002-4725-7829; Marshall, Amy/0000-0001-5803-3815; rasko, John/0000-0003-2975-807X	National Breast Cancer Foundation [ECF-12-05]; Movember through the Prostate Cancer Foundation of Australia [YI0813, YI0707]; Cancer Institute NSW; Cancer Council NSW [APP1080503]; University of Sydney; Tour de Cure Fellowship; Sydney Breast Cancer Foundation; RT Hall Foundation; Cure the Future and an anonymous foundation; National Breast Cancer Foundation [PRAC-16-006] Funding Source: researchfish	National Breast Cancer Foundation; Movember through the Prostate Cancer Foundation of Australia; Cancer Institute NSW; Cancer Council NSW(Cancer Council New South Wales); University of Sydney(University of Sydney); Tour de Cure Fellowship; Sydney Breast Cancer Foundation; RT Hall Foundation; Cure the Future and an anonymous foundation; National Breast Cancer Foundation	This work was supported by grants from the National Breast Cancer Foundation (ECF-12-05 to JH); Movember through the Prostate Cancer Foundation of Australia (YI0813 to QW; YI0707 to JH); Cancer Institute NSW (WR and MvG); Cancer Council NSW (APP1080503 to JH); University of Sydney (AM); Cure the Future and an anonymous foundation (JEJR); Tour de Cure Fellowship (CGB); Sydney Breast Cancer Foundation and the RT Hall Foundation (SO'T). We thank Michael P Kuligowski from Centenary Imaging Facility for assistance with Volocity image analysis and staff at the Advanced Cytometry Facility, Sydney for FACS assistance.	Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Chen XS, 2010, TUMORI J, V96, P103, DOI 10.1177/030089161009600117; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Duran RV, 2012, MOL CELL, V47, P349, DOI 10.1016/j.molcel.2012.05.043; Esslinger CS, 2005, BIOORGAN MED CHEM, V13, P1111, DOI 10.1016/j.bmc.2004.11.028; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Fuchs BC, 2004, AM J PHYSIOL-GASTR L, V286, pG467, DOI 10.1152/ajpgi.00344.2003; Fuchs BC, 2007, AM J PHYSIOL-CELL PH, V293, pC55, DOI 10.1152/ajpcell.00330.2006; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Gluz O, 2009, ANN ONCOL, V20, P1913, DOI 10.1093/annonc/mdp492; Green DR, 2014, SCIENCE, V345, P1466, DOI 10.1126/science.1250256; Gross MI, 2014, MOL CANCER THER, V13, P890, DOI 10.1158/1535-7163.MCT-13-0870; Haffty BG, 2006, J CLIN ONCOL, V24, P5652, DOI 10.1200/JCO.2006.06.5664; Hassanein M, 2015, INT J CANCER, V137, P1587, DOI 10.1002/ijc.29535; Hassanein M, 2013, CLIN CANCER RES, V19, P560, DOI 10.1158/1078-0432.CCR-12-2334; Herold MJ, 2008, P NATL ACAD SCI USA, V105, P18507, DOI 10.1073/pnas.0806213105; Jacque N, 2015, BLOOD, V126, P1346, DOI 10.1182/blood-2015-01-621870; Jeon YJ, 2015, CANCER CELL, V27, P354, DOI 10.1016/j.ccell.2015.02.006; Kanai Y, 2004, PFLUG ARCH EUR J PHY, V447, P469, DOI 10.1007/s00424-003-1146-4; Kekuda R, 1996, J BIOL CHEM, V271, P18657, DOI 10.1074/jbc.271.31.18657; Kim S, 2013, ENDOCR-RELAT CANCER, V20, P339, DOI 10.1530/ERC-12-0398; Kung HN, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002229; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Nicklin P, 2009, CELL, V136, P521, DOI 10.1016/j.cell.2008.11.044; Perou CM, 2010, ONCOLOGIST, V15, P39, DOI 10.1634/theoncologist.2010-S5-39; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Puca R, 2010, ONCOGENE, V29, P4378, DOI 10.1038/onc.2010.183; Qing GL, 2012, CANCER CELL, V22, P631, DOI 10.1016/j.ccr.2012.09.021; Rakha EA, 2007, CANCER-AM CANCER SOC, V109, P25, DOI 10.1002/cncr.22381; Ren P, 2015, J PATHOL, V235, P90, DOI 10.1002/path.4429; Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535; Sancak Y, 2010, CELL, V141, P290, DOI 10.1016/j.cell.2010.02.024; Saqcena M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074157; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Terunuma A, 2014, J CLIN INVEST, V124, P398, DOI 10.1172/JCI71180; Tiffen JC, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-299; Timmerman LA, 2013, CANCER CELL, V24, P450, DOI 10.1016/j.ccr.2013.08.020; Wang Q, 2015, J PATHOL, V236, P278, DOI 10.1002/path.4518; Wang Q, 2014, INT J CANCER, V135, P1060, DOI 10.1002/ijc.28749; Wang Q, 2013, JNCI-J NATL CANCER I, V105, P1463, DOI 10.1093/jnci/djt241; Wang Q, 2011, CANCER RES, V71, P7525, DOI 10.1158/0008-5472.CAN-11-1821; Willems L, 2013, BLOOD, V122, P3521, DOI 10.1182/blood-2013-03-493163; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Yee KS, 2009, CELL DEATH DIFFER, V16, P1135, DOI 10.1038/cdd.2009.28	47	308	317	9	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2016	35	24					3201	3208		10.1038/onc.2015.381	http://dx.doi.org/10.1038/onc.2015.381			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO9GI	26455325	hybrid, Green Published			2022-12-17	WOS:000378092700011
J	Wang, B; Hsu, SH; Majumder, S; Kutay, H; Huang, W; Jacob, ST; Ghoshal, K				Wang, B.; Hsu, S-H; Majumder, S.; Kutay, H.; Huang, W.; Jacob, S. T.; Ghoshal, K.			TGF beta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3	ONCOGENE			English	Article						miR-181b; TIMP3; hepatocarcinogenesis; CDAA diet; doxorubicin; hepatocullular carcinoma	CHOLINE-DEFICIENT; TISSUE INHIBITOR; BREAST-CANCER; IN-VIVO; MICRORNA; GENE; EXPRESSION; HSA-MIR-181B; INFLAMMATION; BIOGENESIS	To identify microRNAs (miRNAs) that may have a causal role in hepatocarcinogenesis, we used an animal model in which C57BL/6 mice fed choline-deficient and amino acid defined (CDAA) diet develop preneoplastic lesions at 65 weeks and hepatocellular carcinomas after 84 weeks. miRNA expression profiling showed significant upregulation of miR-181b and miR-181d in the livers of mice as early as 32 weeks that persisted at preneoplastic stage. The expression of tissue inhibitor of metalloprotease 3 (TIMP3), a tumor suppressor and a validated miR-181 target, was markedly suppressed in the livers of mice fed CDAA diet. Upregulation of hepatic transforming growth factor (TGF)beta and its downstream mediators Smad 2, 3 and 4 and increase in phospho-Smad2 in the liver nuclear extract correlated with elevated miR-181b/d in mice fed CDAA diet. The levels of the precursor and mature miR-181b were augmented on exposure of hepatic cells to TGF beta and were significantly reduced by small interference RNA-mediated depletion of Smad4, showing the involvement of TGFb signaling pathway in miR-181b expression. Ectopic expression and depletion of miR-181b showed that miR-181b enhanced matrix metallopeptidases (MMP)2 and MMP9 activity and promoted growth, clonogenic survival, migration and invasion of hepatocellular carcinoma (HCC) cells that could be reversed by modulating TIMP3 level. Further, depletion of miR-181b inhibited tumor growth of HCC cells in nude mice. miR-181b also enhanced resistance of HCC cells to the anticancer drug doxorubicin. On the basis of these results, we conclude that upregulation of miR-181b at early stages of feeding CDAA diet promotes hepatocarcinogenesis. Oncogene (2010) 29, 1787-1797; doi:10.1038/onc.2009.468; published online 21 December 2009	[Wang, B.; Hsu, S-H; Majumder, S.; Kutay, H.; Huang, W.; Jacob, S. T.; Ghoshal, K.] Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; [Jacob, S. T.; Ghoshal, K.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Jacob, ST (corresponding author), Ohio State Univ, Dept Mol & Cellular Biochem, 420 W 12th Ave,646 TMRF, Columbus, OH 43210 USA.	Samson.Jacob@osumc.edu; kalpana.ghoshal@osumc.edu	Jacob, Samson/H-3135-2011; Huang, Wei/E-3270-2011; Wang, Bo/F-6519-2011	Wang, Bo/0000-0001-9234-035X; HSU, SHU-HAO/0000-0002-9444-4192	National Institutes of Health [CA086978, CA101956]; NATIONAL CANCER INSTITUTE [P01CA101956, R01CA086978] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs David P Bartel and John Taylor for pIS0 vectors and Huh-7 cells, respectively. This work was supported by the grants CA086978 and CA101956 from National Institutes of Health. Grant support: CA086978 and CA101956 from National Institutes of Health.	Aravalli RN, 2008, HEPATOLOGY, V48, P2047, DOI 10.1002/hep.22580; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Calin GA, 2007, BEST PRACT RES CL HA, V20, P425, DOI 10.1016/j.beha.2007.02.003; Carthew RW, 2009, CELL, V136, P642, DOI 10.1016/j.cell.2009.01.035; Cheung O, 2008, HEPATOLOGY, V48, P1810, DOI 10.1002/hep.22569; Coulouarn C, 2008, HEPATOLOGY, V47, P2059, DOI 10.1002/hep.22283; Datta J, 2008, CANCER RES, V68, P5049, DOI 10.1158/0008-5472.CAN-07-6655; Davis BN, 2008, NATURE, V454, P56, DOI 10.1038/nature07086; Day CP, 2006, LIVER INT, V26, P1021, DOI 10.1111/j.1478-3231.2006.01323.x; Denda A, 2002, JPN J CANCER RES, V93, P125, DOI 10.1111/j.1349-7006.2002.tb01250.x; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Elmen J, 2008, NATURE, V452, P896, DOI 10.1038/nature06783; Esau C, 2006, CELL METAB, V3, P87, DOI 10.1016/j.cmet.2006.01.005; Eulalio A, 2008, CELL, V132, P9, DOI 10.1016/j.cell.2007.12.024; Gabriely G, 2008, MOL CELL BIOL, V28, P5369, DOI 10.1128/MCB.00479-08; Ghoshal K, 2006, J NUTR, V136, P1522, DOI 10.1093/jn/136.6.1522; Ji JF, 2009, HEPATOLOGY, V50, P472, DOI 10.1002/hep.22989; Kim VN, 2009, NAT REV MOL CELL BIO, V10, P126, DOI 10.1038/nrm2632; Kong W, 2008, MOL CELL BIOL, V28, P6773, DOI 10.1128/MCB.00941-08; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Lee EJ, 2007, INT J CANCER, V120, P1046, DOI 10.1002/ijc.22394; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Menghini R, 2009, GASTROENTEROLOGY, V136, P663, DOI 10.1053/j.gastro.2008.10.079; Miller TE, 2008, J BIOL CHEM, V283, P29897, DOI 10.1074/jbc.M804612200; Mohammed FF, 2004, NAT GENET, V36, P969, DOI 10.1038/ng1413; Nakajima Go, 2006, Cancer Genomics & Proteomics, V3, P317; Nasser MW, 2008, J BIOL CHEM, V283, P33394, DOI 10.1074/jbc.M804788200; Schickel R, 2008, ONCOGENE, V27, P5959, DOI 10.1038/onc.2008.274; Selaru FM, 2009, HEPATOLOGY, V49, P1595, DOI 10.1002/hep.22838; Shi L, 2008, BRAIN RES, V1236, P185, DOI 10.1016/j.brainres.2008.07.085; Soifer HS, 2007, MOL THER, V15, P2070, DOI 10.1038/sj.mt.6300311; Sun Q, 2008, NUCLEIC ACIDS RES, V36, P2690, DOI 10.1093/nar/gkn032; Thomas M, 2009, J GASTROENTEROL, V44, P136, DOI 10.1007/s00535-008-2252-z; Visone R, 2009, AM J PATHOL, V174, P1131, DOI 10.2353/ajpath.2009.080794; Wang B, 2009, HEPATOLOGY, V50, P1152, DOI 10.1002/hep.23100; Winter J, 2009, NAT CELL BIOL, V11, P228, DOI 10.1038/ncb0309-228; Yan LX, 2008, RNA, V14, P2348, DOI 10.1261/rna.1034808	38	308	333	2	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2010	29	12					1787	1797		10.1038/onc.2009.468	http://dx.doi.org/10.1038/onc.2009.468			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574VR	20023698	Green Accepted			2022-12-17	WOS:000276022800008
J	Sementchenko, VI; Watson, DK				Sementchenko, VI; Watson, DK			Ets target genes: past, present and future	ONCOGENE			English	Review						Ets; transcription; target genes; expression arrays	COLONY-STIMULATING FACTOR; GA-BINDING-PROTEIN; NF-KAPPA-B; HEAVY-CHAIN GENE; VIRUS TYPE-I; TRANSCRIPTION FACTOR-BINDING; LONG TERMINAL REPEAT; CELL ANTIGEN RECEPTOR; SERUM RESPONSE FACTOR; CIS-ACTING ELEMENTS	Ets is a family of transcription factors present in species ranging from sponges to human. All family members contain an approximately 85 amino acid DNA binding domain, designated the Ets domain. Ets proteins bind to specific purine-rich DNA sequences with a core motif of GGAA/T, and transcriptionally regulate a number of viral and cellular genes. Thus, Ets proteins are an important family of transcription factors that control the expression of genes that are critical for several biological processes, including cellular proliferation, differentiation, development, transformation, and apoptosis. Here, we tabulate genes that are regulated by Ets factors and describe past, present and future strategies for the identification and validation of Ets target genes. Through definition of authentic target genes, we will begin to understand the mechanisms by which Ets factors control normal and abnormal cellular processes.	Med Univ S Carolina, Hollings Canc Ctr, Ctr Mol & Struct Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29403 USA	Medical University of South Carolina; Medical University of South Carolina	Watson, DK (corresponding author), Med Univ S Carolina, Hollings Canc Ctr, Ctr Mol & Struct Biol, 86 Jonathan Lucas St, Charleston, SC 29425 USA.				NATIONAL CANCER INSTITUTE [P01CA078582] Funding Source: NIH RePORTER; NCI NIH HHS [CA78582] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHNE B, 1994, J BIOL CHEM, V269, P17794; Ainbinder E, 1997, EUR J BIOCHEM, V243, P49, DOI 10.1111/j.1432-1033.1997.0049a.x; Akbarali Y, 1996, J BIOL CHEM, V271, P26007, DOI 10.1074/jbc.271.42.26007; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ALEXANDER WS, 1995, ONCOGENE, V10, P795; Amato SF, 1996, J IMMUNOL, V157, P146; ANSIEAU S, 1993, GENOMICS, V18, P537, DOI 10.1016/S0888-7543(11)80010-8; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; AURIGEMMA RE, 1992, J VIROL, V66, P3056, DOI 10.1128/JVI.66.5.3056-3061.1992; Avots A, 1997, MOL CELL BIOL, V17, P4381, DOI 10.1128/MCB.17.8.4381; Bamberger AM, 1997, MOL CELL ENDOCRINOL, V127, P71, DOI 10.1016/S0303-7207(96)03991-3; Bastian LS, 1996, J BIOL CHEM, V271, P18554, DOI 10.1074/jbc.271.31.18554; Bastian LS, 1999, BLOOD, V93, P2637, DOI 10.1182/blood.V93.8.2637.408k20_2637_2644; Beier F, 1999, J BIOL CHEM, V274, P30273, DOI 10.1074/jbc.274.42.30273; Berland R, 1998, J IMMUNOL, V161, P277; BESSER D, 1995, CELL GROWTH DIFFER, V6, P1009; Block KL, 1996, BLOOD, V88, P2071, DOI 10.1182/blood.V88.6.2071.bloodjournal8862071; Blumenthal SG, 1999, J BIOL CHEM, V274, P12910, DOI 10.1074/jbc.274.18.12910; Boccia LM, 1996, MOL CELL BIOL, V16, P1929; BOCKAMP EO, 1995, BLOOD, V86, P1502, DOI 10.1182/blood.V86.4.1502.bloodjournal8641502; Bockamp EO, 1998, J BIOL CHEM, V273, P29032, DOI 10.1074/jbc.273.44.29032; Boehlk S, 2000, EUR J IMMUNOL, V30, P1102, DOI 10.1002/(SICI)1521-4141(200004)30:4<1102::AID-IMMU1102>3.0.CO;2-X; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; Botelho FM, 1998, J BIOL CHEM, V273, P5211, DOI 10.1074/jbc.273.9.5211; BOTTINGER EP, 1994, MOL CELL BIOL, V14, P2604; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; Bradford AP, 1997, MOL CELL BIOL, V17, P1065, DOI 10.1128/MCB.17.3.1065; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; BURAS JA, 1995, MOL IMMUNOL, V32, P541, DOI 10.1016/0161-5890(95)00018-A; Burk O, 1999, BBA-GENE STRUCT EXPR, V1446, P243, DOI 10.1016/S0167-4781(99)00097-4; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; Buttice G, 1996, ONCOGENE, V13, P2297; CARDOT P, 1994, BIOCHEMISTRY-US, V33, P12139, DOI 10.1021/bi00206a017; CARTER RS, 1992, J BIOL CHEM, V267, P23418; CARTER RS, 1994, J BIOL CHEM, V269, P4381; CARVALHO M, 1993, J VIROL, V67, P3885, DOI 10.1128/JVI.67.7.3885-3890.1993; Castillo AI, 1998, ONCOGENE, V16, P1981, DOI 10.1038/sj.onc.1200204; Cederberg A, 1999, J BIOL CHEM, V274, P165, DOI 10.1074/jbc.274.1.165; Chan YJ, 1996, J VIROL, V70, P8590, DOI 10.1128/JVI.70.12.8590-8605.1996; Chang LF, 1996, J BIOL CHEM, V271, P6467, DOI 10.1074/jbc.271.11.6467; Chapman SC, 1999, J BIOL CHEM, V274, P18625, DOI 10.1074/jbc.274.26.18625; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CHEN HM, 1995, ONCOGENE, V11, P1549; Chen JH, 1996, ONCOGENE, V13, P1667; Chiang SY, 2000, J BIOL CHEM, V275, P24246, DOI 10.1074/jbc.M000820200; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; Chotani MA, 2000, J BIOL CHEM, V275, P30432, DOI 10.1074/jbc.M003545200; CLARK NM, 1993, J VIROL, V67, P5522, DOI 10.1128/JVI.67.9.5522-5528.1993; COFFER P, 1994, ONCOGENE, V9, P911; Coles LS, 2000, J BIOL CHEM, V275, P14482, DOI 10.1074/jbc.275.19.14482; Darby TG, 1997, ONCOGENE, V15, P3067, DOI 10.1038/sj.onc.1201503; Day RN, 1998, J BIOL CHEM, V273, P31909, DOI 10.1074/jbc.273.48.31909; Deramaudt BMJM, 1999, J CELL BIOCHEM, V72, P311, DOI 10.1002/(SICI)1097-4644(19990301)72:3<311::AID-JCB1>3.3.CO;2-7; DESMET C, 1995, IMMUNOGENETICS, V42, P282, DOI 10.1007/BF00176446; DeSmet C, 1996, P NATL ACAD SCI USA, V93, P7149, DOI 10.1073/pnas.93.14.7149; Deveaux S, 1996, BLOOD, V87, P4678, DOI 10.1182/blood.V87.11.4678.bloodjournal87114678; DITTMER J, 1994, J BIOL CHEM, V269, P21428; DITTMER J, 1993, J VIROL, V67, P6087, DOI 10.1128/JVI.67.10.6087-6095.1993; Dittmer J, 1997, J BIOL CHEM, V272, P4953, DOI 10.1074/jbc.272.8.4953; DITTMER J, 1998, BIOCHIM BIOPHYS ACTA, V1377, pR1; DONAHUE JP, 1994, BBA-GENE STRUCT EXPR, V1219, P228, DOI 10.1016/0167-4781(94)90278-X; DONOVANPELUSO M, 1994, J BIOL CHEM, V269, P1361; Doubeikovski A, 1997, J BIOL CHEM, V272, P24300, DOI 10.1074/jbc.272.39.24300; Du KY, 1998, J BIOL CHEM, V273, P35208, DOI 10.1074/jbc.273.52.35208; Dube A, 1999, CIRC RES, V84, P1177, DOI 10.1161/01.RES.84.10.1177; DUPRIEZ VJ, 1993, P NATL ACAD SCI USA, V90, P8224, DOI 10.1073/pnas.90.17.8224; Edelman GM, 2000, P NATL ACAD SCI USA, V97, P3038, DOI 10.1073/pnas.040569897; Egan BS, 1999, J BIOL CHEM, V274, P9098, DOI 10.1074/jbc.274.13.9098; EICHBAUM QG, 1994, J EXP MED, V179, P1985, DOI 10.1084/jem.179.6.1985; EISENBEIS CF, 1993, MOL CELL BIOL, V13, P6452, DOI 10.1128/MCB.13.10.6452; Erman B, 1996, EMBO J, V15, P4665, DOI 10.1002/j.1460-2075.1996.tb00843.x; Ernst P, 1996, MOL CELL BIOL, V16, P6121; ERNST P, 1993, MOL CELL BIOL, V13, P2982, DOI 10.1128/MCB.13.5.2982; ESPINAS ML, 1994, MOL CELL BIOL, V14, P4116, DOI 10.1128/MCB.14.6.4116; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Ezashi T, 1998, P NATL ACAD SCI USA, V95, P7882, DOI 10.1073/pnas.95.14.7882; Fears S, 1997, P NATL ACAD SCI USA, V94, P1949, DOI 10.1073/pnas.94.5.1949; FEINMAN R, 1994, EMBO J, V13, P3852, DOI 10.1002/j.1460-2075.1994.tb06696.x; Fenrick R, 2000, MOL CELL BIOL, V20, P5828, DOI 10.1128/MCB.20.16.5828-5839.2000; Flajolet M, 1997, ONCOGENE, V15, P1103, DOI 10.1038/sj.onc.1201257; Foulds CE, 1997, NUCLEIC ACIDS RES, V25, P2485, DOI 10.1093/nar/25.12.2485; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; FUJIMURA Y, 1994, NUCLEIC ACIDS RES, V22, P613, DOI 10.1093/nar/22.4.613; FUJITANI Y, 1994, BIOCHEM BIOPH RES CO, V202, P1181, DOI 10.1006/bbrc.1994.2053; Funaoka K, 1997, BIOCHEM BIOPH RES CO, V236, P79, DOI 10.1006/bbrc.1997.6909; Gagnon ML, 1999, J CELL BIOCHEM, V72, P492, DOI 10.1002/(SICI)1097-4644(19990315)72:4<492::AID-JCB5>3.0.CO;2-H; Gambarotta G, 1996, ONCOGENE, V13, P1911; GASTON K, 1995, GENE, V157, P257, DOI 10.1016/0378-1119(95)00120-U; GASTON K, 1995, NUCLEIC ACIDS RES, V23, P901, DOI 10.1093/nar/23.6.901; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; Ghozi MC, 1996, P NATL ACAD SCI USA, V93, P1935, DOI 10.1073/pnas.93.5.1935; GHYSDAEL J, 1997, PROG GENE EXPRESS, P29; GITLIN SD, 1991, J VIROL, V65, P5513, DOI 10.1128/JVI.65.10.5513-5523.1991; GOMOLIN HI, 1993, BLOOD, V82, P1868; Gory S, 1998, J BIOL CHEM, V273, P6750, DOI 10.1074/jbc.273.12.6750; GOTO M, 1993, NUCLEIC ACIDS RES, V21, P209, DOI 10.1093/nar/21.2.209; Gramolini AO, 1999, P NATL ACAD SCI USA, V96, P3223, DOI 10.1073/pnas.96.6.3223; Granger SW, 1998, J VIROL, V72, P8961, DOI 10.1128/JVI.72.11.8961-8970.1998; GRANT PA, 1995, EMBO J, V14, P4501, DOI 10.1002/j.1460-2075.1995.tb00129.x; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Gri G, 1998, J BIOL CHEM, V273, P6431, DOI 10.1074/jbc.273.11.6431; Grombacher T, 1996, DNA CELL BIOL, V15, P581, DOI 10.1089/dna.1996.15.581; Groupp ER, 1996, J BIOL CHEM, V271, P12423, DOI 10.1074/jbc.271.21.12423; GROVE M, 1993, MOL CELL BIOL, V13, P5276, DOI 10.1128/MCB.13.9.5276; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; GUNTHER CV, 1994, MOL CELL BIOL, V14, P7569, DOI 10.1128/MCB.14.11.7569; Gupta M, 1998, MOL CELL BIOL, V18, P7243, DOI 10.1128/MCB.18.12.7243; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; Halle JP, 1997, MOL CELL BIOL, V17, P4220, DOI 10.1128/MCB.17.8.4220; HAMBOR JE, 1993, MOL CELL BIOL, V13, P7056, DOI 10.1128/MCB.13.11.7056; Harris VK, 1998, J BIOL CHEM, V273, P19130, DOI 10.1074/jbc.273.30.19130; Hart A, 2000, IMMUNITY, V13, P167, DOI 10.1016/S1074-7613(00)00017-0; HASHIMOTO Y, 1995, J BIOL CHEM, V270, P24532, DOI 10.1074/jbc.270.41.24532; HENKEL G, 1994, P NATL ACAD SCI USA, V91, P7737, DOI 10.1073/pnas.91.16.7737; Hermand P, 1996, BLOOD, V87, P2962, DOI 10.1182/blood.V87.7.2962.bloodjournal8772962; HEWETT PW, 1998, BIOCHEM BIOPH RES CO, V252, P456; Heydemann A, 1996, MOL CELL BIOL, V16, P1676; HICKEY MJ, 1993, J BIOL CHEM, V268, P3438; HICKSTEIN DD, 1992, P NATL ACAD SCI USA, V89, P2105, DOI 10.1073/pnas.89.6.2105; HIGASHINO F, 1995, ONCOGENE, V10, P1461; HILFINGER JM, 1993, J VIROL, V67, P4448, DOI 10.1128/JVI.67.7.4448-4453.1993; Himelstein BP, 1997, ONCOGENE, V14, P1995, DOI 10.1038/sj.onc.1201012; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; Hoffmeyer A, 1998, J BIOL CHEM, V273, P10112, DOI 10.1074/jbc.273.17.10112; HOHAUS S, 1995, MOL CELL BIOL, V15, P5830; HOLZMEISTER J, 1993, BIOCHEM BIOPH RES CO, V197, P1229, DOI 10.1006/bbrc.1993.2608; HOWARD PW, 1995, J BIOL CHEM, V270, P20930, DOI 10.1074/jbc.270.36.20930; Iljin K, 1999, FASEB J, V13, P377, DOI 10.1096/fasebj.13.2.377; Inaba T, 1996, MOL CELL BIOL, V16, P2264; Iwama A, 1998, NUCLEIC ACIDS RES, V26, P3034, DOI 10.1093/nar/26.12.3034; Iwamoto S, 2000, J BIOL CHEM, V275, P27324; JABRANEFERRAT N, 1994, MOL CELL BIOL, V14, P7314, DOI 10.1128/MCB.14.11.7314; JACOB KK, 1995, J BIOL CHEM, V270, P27773, DOI 10.1074/jbc.270.46.27773; Jang SI, 2000, J BIOL CHEM, V275, P15295, DOI 10.1074/jbc.275.20.15295; Jayaraman G, 1999, J BIOL CHEM, V274, P17342, DOI 10.1074/jbc.274.24.17342; JOHANNSEN E, 1995, J VIROL, V69, P253, DOI 10.1128/JVI.69.1.253-262.1995; JOHN S, 1995, MOL CELL BIOL, V15, P1786; JUDDE JG, 1992, MOL CELL BIOL, V12, P5206, DOI 10.1128/MCB.12.11.5206; Kai H, 1999, J BIOL CHEM, V274, P20098, DOI 10.1074/jbc.274.29.20098; Kambe M, 1998, BBA-GENE STRUCT EXPR, V1395, P209, DOI 10.1016/S0167-4781(97)00152-8; Kamura T, 1997, J BIOL CHEM, V272, P11361; Kang R, 1996, J BIOL CHEM, V271, P26706, DOI 10.1074/jbc.271.43.26706; Kappel A, 1999, BLOOD, V93, P4284, DOI 10.1182/blood.V93.12.4284.412k25_4284_4292; Karantzoulis-Fegaras F, 1999, J BIOL CHEM, V274, P3076, DOI 10.1074/jbc.274.5.3076; Kaya M, 1996, ONCOGENE, V12, P221; Khurana TS, 1999, MOL BIOL CELL, V10, P2075, DOI 10.1091/mbc.10.6.2075; Kienker LJ, 1998, J IMMUNOL, V161, P791; KISTLER B, 1995, ONCOGENE, V11, P1095; Ko JH, 1999, J BIOL CHEM, V274, P22941, DOI 10.1074/jbc.274.33.22941; KOIZUMI H, 1993, MOL CELL BIOL, V13, P6690, DOI 10.1128/MCB.13.11.6690; KOMINATO Y, 1995, MOL CELL BIOL, V15, P59; Kondoh N, 1998, BRIT J CANCER, V78, P718, DOI 10.1038/bjc.1998.567; KRAMER B, 1995, J BIOL CHEM, V270, P6577; Krehan A, 2000, J BIOL CHEM, V275, P18327, DOI 10.1074/jbc.M909736199; Kuprash DV, 1996, J IMMUNOL, V156, P2465; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; Lambert PF, 1997, MOL BIOL CELL, V8, P313, DOI 10.1091/mbc.8.2.313; LAUX G, 1994, EMBO J, V13, P5624, DOI 10.1002/j.1460-2075.1994.tb06900.x; Leduc I, 1996, MOL IMMUNOL, V33, P1277, DOI 10.1016/S0161-5890(96)00109-5; LEIDEN JM, 1992, J VIROL, V66, P5890, DOI 10.1128/JVI.66.10.5890-5897.1992; Lepage A, 1999, BLOOD, V94, P3366, DOI 10.1182/blood.V94.10.3366.422k35_3366_3380; LEUNG S, 1993, ONCOGENE, V8, P989; Li AC, 1998, J BIOL CHEM, V273, P5389, DOI 10.1074/jbc.273.9.5389; Li RH, 1999, P NATL ACAD SCI USA, V96, P3876, DOI 10.1073/pnas.96.7.3876; Li SL, 1999, J BIOL CHEM, V274, P32453, DOI 10.1074/jbc.274.45.32453; Li XR, 1999, J BIOL CHEM, V274, P35203, DOI 10.1074/jbc.274.49.35203; LIAO WC, 1994, NUCLEIC ACIDS RES, V22, P4044, DOI 10.1093/nar/22.20.4044; LIBERMANN TA, 1993, MOL CELL BIOL, V13, P5957, DOI 10.1128/MCB.13.10.5957; Lin CS, 1997, DNA CELL BIOL, V16, P9, DOI 10.1089/dna.1997.16.9; LIN CS, 1993, J BIOL CHEM, V268, P2793; LIN JX, 1993, MOL CELL BIOL, V13, P6201, DOI 10.1128/MCB.13.10.6201; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Liu DR, 1997, ONCOGENE, V14, P1445, DOI 10.1038/sj.onc.1200965; LIU SH, 1994, BIOCHEM BIOPH RES CO, V201, P1406, DOI 10.1006/bbrc.1994.1860; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; Lok CN, 2000, J BIOL CHEM, V275, P24185, DOI 10.1074/jbc.M000944200; Ma XJ, 1997, J BIOL CHEM, V272, P10389; Ma YS, 1998, J BIOL CHEM, V273, P8727, DOI 10.1074/jbc.273.15.8727; Mainguy G, 2000, NAT BIOTECHNOL, V18, P746, DOI 10.1038/77312; Manzanares M, 1997, NATURE, V387, P191, DOI 10.1038/387191a0; MARCHIONI M, 1993, MOL CELL BIOL, V13, P6479, DOI 10.1128/MCB.13.10.6479; Markiewicz S, 1996, J BIOL CHEM, V271, P14849, DOI 10.1074/jbc.271.25.14849; MARKOVITZ DM, 1992, J VIROL, V66, P5479, DOI 10.1128/JVI.66.9.5479-5484.1992; Maul RS, 1998, J BIOL CHEM, V273, P33239, DOI 10.1074/jbc.273.50.33239; MAURY W, 1994, J VIROL, V68, P6270, DOI 10.1128/JVI.68.10.6270-6279.1994; Mayall TP, 1997, GENE DEV, V11, P887, DOI 10.1101/gad.11.7.887; MCCRACKEN S, 1994, ONCOGENE, V9, P3609; McDonough J, 2000, J BIOL CHEM, V275, P28962, DOI 10.1074/jbc.M004181200; McKinlay LH, 1998, J IMMUNOL, V161, P4098; MCKNIGHT RA, 1995, MOL ENDOCRINOL, V9, P717, DOI 10.1210/me.9.6.717; McNagny KM, 1998, EMBO J, V17, P3669, DOI 10.1093/emboj/17.13.3669; MELOTTI P, 1994, J BIOL CHEM, V269, P25303; Minami T, 1998, EUR J BIOCHEM, V258, P879, DOI 10.1046/j.1432-1327.1998.2580879.x; MIYAJIMA I, 1995, BLOOD, V85, P1246, DOI 10.1182/blood.V85.5.1246.bloodjournal8551246; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; Muller S, 1996, ONCOGENE, V13, P1955; Munaut C, 1999, J BIOL CHEM, V274, P5588, DOI 10.1074/jbc.274.9.5588; Murakami K, 1997, DNA CELL BIOL, V16, P173, DOI 10.1089/dna.1997.16.173; Nakada M, 1999, J NEUROPATH EXP NEUR, V58, P329, DOI 10.1097/00005072-199904000-00003; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; NERLOV C, 1991, ONCOGENE, V6, P1583; Nguyen VT, 2000, J BIOL CHEM, V275, P23674, DOI 10.1074/jbc.M002482200; Nimer S, 1996, BLOOD, V88, P66, DOI 10.1182/blood.V88.1.66.bloodjournal88166; Nimer SD, 1996, BLOOD, V87, P3694, DOI 10.1182/blood.V87.9.3694.bloodjournal8793694; Nishiyama C, 1999, J IMMUNOL, V163, P623; NOTHIAS JY, 1993, J VIROL, V67, P3036, DOI 10.1128/JVI.67.6.3036-3047.1993; Noti JD, 1996, MOL IMMUNOL, V33, P115, DOI 10.1016/0161-5890(95)00140-9; Nozawa M, 2000, CANCER RES, V60, P1348; Nuchprayoon I, 1999, J BIOL CHEM, V274, P1085, DOI 10.1074/jbc.274.2.1085; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; Nuchprayoon I, 1997, BLOOD, V89, P4546, DOI 10.1182/blood.V89.12.4546; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; OHBO K, 1995, J BIOL CHEM, V270, P7479, DOI 10.1074/jbc.270.13.7479; Olsen J, 1997, BIOCHEM J, V322, P899, DOI 10.1042/bj3220899; OPREY J, 1993, MOL CELL BIOL, V13, P6290, DOI 10.1128/MCB.13.10.6290; Orlando V, 2000, TRENDS BIOCHEM SCI, V25, P99, DOI 10.1016/S0968-0004(99)01535-2; PAHL HL, 1993, J BIOL CHEM, V268, P5014; Panitz F, 1998, EMBO J, V17, P4414, DOI 10.1093/emboj/17.15.4414; PANKOV R, 1994, MOL CELL BIOL, V14, P7744, DOI 10.1128/MCB.14.12.7744; PANKOV R, 1994, P NATL ACAD SCI USA, V91, P873, DOI 10.1073/pnas.91.3.873; Park JS, 2000, MOL BIOL CELL, V11, P2915, DOI 10.1091/mbc.11.9.2915; Pastorcic M, 1999, J BIOL CHEM, V274, P24297, DOI 10.1074/jbc.274.34.24297; Pelczar H, 1997, BIOCHEM BIOPH RES CO, V239, P252, DOI 10.1006/bbrc.1997.7363; PEREZ C, 1994, MOL CELL BIOL, V14, P5023, DOI 10.1128/MCB.14.8.5023; POKHOLOK DK, 1995, P NATL ACAD SCI USA, V92, P674, DOI 10.1073/pnas.92.3.674; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; POSPELOV VA, 1994, CELL GROWTH DIFFER, V5, P187; Postigo AA, 1997, EMBO J, V16, P3924, DOI 10.1093/emboj/16.13.3924; Prandini MH, 1996, BLOOD, V88, P2062, DOI 10.1182/blood.V88.6.2062.bloodjournal8862062; PUNTURIERI A, 1993, J IMMUNOL, V150, P139; Quan TH, 1999, J BIOL CHEM, V274, P28566, DOI 10.1074/jbc.274.40.28566; Rao E, 1997, J BIOL CHEM, V272, P6722, DOI 10.1074/jbc.272.10.6722; Rao S, 1999, J BIOL CHEM, V274, P34245, DOI 10.1074/jbc.274.48.34245; Ratajczak MZ, 1998, BLOOD, V91, P1934, DOI 10.1182/blood.V91.6.1934.1934_1934_1946; RAYGALLET D, 1995, ONCOGENE, V11, P303; Rebay I, 2000, GENETICS, V154, P695; REDDY MA, 1994, J EXP MED, V180, P2309, DOI 10.1084/jem.180.6.2309; Rehli M, 1999, J IMMUNOL, V162, P1559; Rellahan BL, 1998, J IMMUNOL, V160, P2794; Rhodes K, 1998, J BIOL CHEM, V273, P26534, DOI 10.1074/jbc.273.41.26534; Ried S, 1999, J BIOL CHEM, V274, P16377, DOI 10.1074/jbc.274.23.16377; Ritchie KA, 1999, LEUKEMIA, V13, P1790, DOI 10.1038/sj.leu.2401494; Rius C, 1998, BLOOD, V92, P4677; RIVERA RR, 1993, MOL CELL BIOL, V13, P7163, DOI 10.1128/MCB.13.11.7163; Robinson L, 1997, P NATL ACAD SCI USA, V94, P7170, DOI 10.1073/pnas.94.14.7170; Rodrigo I, 1999, EXP CELL RES, V248, P358, DOI 10.1006/excr.1999.4438; ROEBUCK KA, 1995, J BIOL CHEM, V270, P18966, DOI 10.1074/jbc.270.32.18966; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; ROSEN GD, 1994, J BIOL CHEM, V269, P15652; ROSMARIN AG, 1995, P NATL ACAD SCI USA, V92, P801, DOI 10.1073/pnas.92.3.801; ROSMARIN AG, 1995, J BIOL CHEM, V270, P23627, DOI 10.1074/jbc.270.40.23627; Rosmarin AG, 1998, J BIOL CHEM, V273, P13097, DOI 10.1074/jbc.273.21.13097; Ross IL, 1998, J BIOL CHEM, V273, P6662, DOI 10.1074/jbc.273.12.6662; Rubin GM, 2000, SCIENCE, V287, P2216, DOI 10.1126/science.287.5461.2216; Rushton JJ, 1997, EUR J BIOCHEM, V245, P768, DOI 10.1111/j.1432-1033.1997.00768.x; SADASIVAN E, 1994, J BIOL CHEM, V269, P4725; SALMON P, 1993, P NATL ACAD SCI USA, V90, P7739, DOI 10.1073/pnas.90.16.7739; Sapi E, 1998, CANCER RES, V58, P1027; Sapru MK, 1998, P NATL ACAD SCI USA, V95, P1289, DOI 10.1073/pnas.95.3.1289; Sark MWJ, 1998, J BIOL CHEM, V273, P24683, DOI 10.1074/jbc.273.38.24683; Sato M, 1998, ONCOGENE, V17, P1517, DOI 10.1038/sj.onc.1202064; SAVOYSKY E, 1994, ONCOGENE, V9, P1839; Sawada J, 1999, J BIOL CHEM, V274, P35475, DOI 10.1074/jbc.274.50.35475; Schaeffer L, 1998, EMBO J, V17, P3078, DOI 10.1093/emboj/17.11.3078; Schlaeger TM, 1997, P NATL ACAD SCI USA, V94, P3058, DOI 10.1073/pnas.94.7.3058; Schwachtgen JL, 1997, ONCOGENE, V15, P3091, DOI 10.1038/sj.onc.1201502; SCHWARZENBACH H, 1995, J BIOL CHEM, V270, P898, DOI 10.1074/jbc.270.2.898; SCOTT GK, 1994, J BIOL CHEM, V269, P19848; Sementchenko VI, 1998, ONCOGENE, V17, P2883, DOI 10.1038/sj.onc.1202220; Serdobova I, 1997, J EXP MED, V185, P1211, DOI 10.1084/jem.185.7.1211; SETH A, 1993, ONCOGENE, V8, P1783; SETH A, 1994, ONCOGENE, V9, P469; Sevilla L, 1999, MOL CELL BIOL, V19, P2624; SHAPIRO LH, 1995, J BIOL CHEM, V270, P8763, DOI 10.1074/jbc.270.15.8763; SHELLEY CS, 1993, P NATL ACAD SCI USA, V90, P5364, DOI 10.1073/pnas.90.11.5364; SHIN MK, 1993, GENE DEV, V7, P2006, DOI 10.1101/gad.7.10.2006; Shirasaki F, 1999, ONCOGENE, V18, P7755, DOI 10.1038/sj.onc.1203360; SIDERAS P, 1994, J IMMUNOL, V153, P5607; Sieweke MH, 1998, EMBO J, V17, P1728, DOI 10.1093/emboj/17.6.1728; Smith MF, 1998, J BIOL CHEM, V273, P24272, DOI 10.1074/jbc.273.37.24272; Soldatenkov VA, 1999, ONCOGENE, V18, P3954, DOI 10.1038/sj.onc.1202778; Spyropoulos DD, 2000, MOL CELL BIOL, V20, P5643, DOI 10.1128/MCB.20.15.5643-5652.2000; STACEY KJ, 1995, MOL CELL BIOL, V15, P3430; Starck J, 1999, MOL CELL BIOL, V19, P121; Steer JH, 2000, J BIOL CHEM, V275, P18432, DOI 10.1074/jbc.M906304199; Stutz AM, 1999, J IMMUNOL, V163, P4383; Sullivan J, 1997, J BIOL CHEM, V272, P1943, DOI 10.1074/jbc.272.3.1943; Sumarsono SH, 1996, NATURE, V379, P534, DOI 10.1038/379534a0; Suzuki S, 1998, P NATL ACAD SCI USA, V95, P6085, DOI 10.1073/pnas.95.11.6085; Tajima A, 2000, BBA-GENE STRUCT EXPR, V1492, P377, DOI 10.1016/S0167-4781(00)00121-4; Takaoka AS, 1998, J BIOL CHEM, V273, P33848, DOI 10.1074/jbc.273.50.33848; Tamir A, 1999, MOL CELL BIOL, V19, P4452; TANIMURA A, 1993, J VIROL, V67, P5375, DOI 10.1128/JVI.67.9.5375-5382.1993; TAYLOR JM, 1995, J BIOL CHEM, V270, P2535, DOI 10.1074/jbc.270.6.2535; Thomas RS, 1997, ONCOGENE, V14, P2845, DOI 10.1038/sj.onc.1201125; THOMAS RS, 1995, ONCOGENE, V11, P2135; Thompson AA, 1996, BLOOD, V87, P666, DOI 10.1182/blood.V87.2.666.bloodjournal872666; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; Townsend KJ, 1999, J BIOL CHEM, V274, P1801, DOI 10.1074/jbc.274.3.1801; Tsai EY, 2000, MOL CELL BIOL, V20, P6084, DOI 10.1128/MCB.20.16.6084-6094.2000; Turque N, 1997, INT J DEV BIOL, V41, P103; Umezawa A, 1997, MOL CELL BIOL, V17, P4885, DOI 10.1128/MCB.17.9.4885; van Dijk TB, 1998, BLOOD, V92, P3636, DOI 10.1182/blood.V92.10.3636.422k45_3636_3646; VANLINT C, 1994, J VIROL, V68, P2632, DOI 10.1128/JVI.68.4.2632-2648.1994; Venanzoni MC, 1996, ONCOGENE, V12, P1199; VILLENA JA, 1994, J BIOL CHEM, V269, P32649; VIRBASIUS JV, 1991, MOL CELL BIOL, V11, P5631, DOI 10.1128/MCB.11.11.5631; VONDERAHE D, 1993, NUCLEIC ACIDS RES, V21, P5636, DOI 10.1093/nar/21.24.5636; Voo KS, 1999, BLOOD, V93, P3512, DOI 10.1182/blood.V93.10.3512.410k19_3512_3520; Wakiya K, 1996, J BIOL CHEM, V271, P30823, DOI 10.1074/jbc.271.48.30823; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; WANG LG, 1994, CELL GROWTH DIFFER, V5, P1243; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; Watabe T, 1998, INT J CANCER, V77, P128, DOI 10.1002/(SICI)1097-0215(19980703)77:1<128::AID-IJC20>3.0.CO;2-9; Watson D K, 2000, Methods Mol Biol, V130, P1; WATSON D K, 1990, Critical Reviews in Oncogenesis, V1, P409; WATSON DK, 2001, ENCY CANC; WELTE T, 1994, EUR J BIOCHEM, V223, P997, DOI 10.1111/j.1432-1033.1994.tb19078.x; WEN SC, 1995, EXP CELL RES, V217, P8, DOI 10.1006/excr.1995.1057; Wilkinson NC, 1999, J BIOL CHEM, V274, P438, DOI 10.1074/jbc.274.1.438; WOTTON D, 1993, LEUKEMIA, V7, pS55; Yamamoto H, 1998, GENE DEV, V12, P1315, DOI 10.1101/gad.12.9.1315; Yan SF, 1999, J BIOL CHEM, V274, P15030, DOI 10.1074/jbc.274.21.15030; Yan SQ, 2000, DNA CELL BIOL, V19, P79, DOI 10.1089/104454900314591; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218; Yang ZY, 2000, J BIOL CHEM, V275, P21272, DOI 10.1074/jbc.M000145200; Yang ZY, 1998, J BIOL CHEM, V273, P891, DOI 10.1074/jbc.273.2.891; Ying H, 1998, J IMMUNOL, V160, P2287; YOGANATHAN T, 1992, EUR J BIOCHEM, V207, P195, DOI 10.1111/j.1432-1033.1992.tb17037.x; YOKOMORI N, 1995, MOL CELL BIOL, V15, P5355; Youn BS, 1996, J IMMUNOL, V157, P3499; Zhang CY, 1997, J BIOL CHEM, V272, P26236, DOI 10.1074/jbc.272.42.26236; Zhang DE, 1996, CURR TOP MICROBIOL, V211, P137; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; ZHANG LQ, 1995, MOL CELL BIOL, V15, P6961; Zhang M, 1997, P NATL ACAD SCI USA, V94, P5673, DOI 10.1073/pnas.94.11.5673; Zhang M, 1997, CELL GROWTH DIFFER, V8, P179; Zhang YG, 1997, J IMMUNOL, V158, P1734	344	308	320	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	2000	19	55					6533	6548		10.1038/sj.onc.1204034	http://dx.doi.org/10.1038/sj.onc.1204034			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395RL	11175369				2022-12-17	WOS:000166595000015
J	Honda, R; Yasuda, H				Honda, R; Yasuda, H			Activity of MDM2, a ubiquitin Ligase, toward p53 or itself is dependent on the RING finger domain of the ligase	ONCOGENE			English	Article						MDM2; p53; ubiquitin ligase; E3; RING finger domain	DNA-DAMAGE; PHOSPHORYLATION; DEGRADATION	We previously showed that oncoprotein MDM2 has ubiquitin ligase activity toward tumor suppressor p53, In that paper, we showed very weak homology in the carboxyl terminal portion between MDM2 and E6AP (HECT domain). We mutated the cysteine residue (C464) corresponding to the residue essential for the ubiquitin ligase activity of E6AP and this mutation diminished the ligase activity of MDM2. The cysteine residue described above is also one of the cysteine residues that form the RING finger domain of MDM2. We tried to find out whether the diminishing of the activity by the mutation is attributable to the disruption of the RING finger domain or not. When the ring finger domain of MDM2 was deleted, the truncation mutant did not have the ubiquitin ligase activity. When we mutated the seven cysteine residues of RING finger domain of MDM2 in the carboxyl terminus, the disruption of each residue in the RING finger completely diminished the ubiquitin ligase activity of MDM2 toward MDM2 itself and toward tumor suppressor p53. These data indicate that the RING finger domain in MDM2 is essential for its ubiquitin ligase activity toward p53 and itself.	Tokyo Univ Pharm & Life Sci, Sch Life Sci, Hachioji, Tokyo 1920392, Japan	Tokyo University of Pharmacy & Life Sciences	Yasuda, H (corresponding author), Tokyo Univ Pharm & Life Sci, Sch Life Sci, 1432-1 Horinouchi, Hachioji, Tokyo 1920392, Japan.							Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BODDY MN, 1994, TRENDS BIOCHEM SCI, V19, P198, DOI 10.1016/0968-0004(94)90020-5; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Maki CG, 1996, CANCER RES, V56, P2649; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Xie YM, 1999, EMBO J, V18, P6832, DOI 10.1093/emboj/18.23.6832	19	308	323	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 9	2000	19	11					1473	1476		10.1038/sj.onc.1203464	http://dx.doi.org/10.1038/sj.onc.1203464			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295AD	10723139				2022-12-17	WOS:000085942700013
J	ROSNET, O; MARCHETTO, S; DELAPEYRIERE, O; BIRNBAUM, D				ROSNET, O; MARCHETTO, S; DELAPEYRIERE, O; BIRNBAUM, D			MURINE FLT3, A GENE ENCODING A NOVEL TYROSINE KINASE RECEPTOR OF THE PDGFR CSF1R FAMILY	ONCOGENE			English	Article							FMS PROTO-ONCOGENE; C-KIT RECEPTOR; GROWTH-FACTOR; CSF-1 RECEPTOR; CDNA CLONING; W-LOCUS; CELL DIFFERENTIATION; EXTRACELLULAR DOMAIN; MOUSE EMBRYOGENESIS; POINT MUTATIONS	Receptor-type tyrosine kinases presenting an extracellular region with five immunoglobulin-like domains, and strongly related by sequence similarities in the intracellular region, constitute a family of receptors involved in development and function of various cell lineages. We have isolated and characterized the mouse Flt3 gene, encoding the sixth member of this family. The Flt3 gene possesses an open reading frame of 3000 nucleotides, and therefore appears to code for a protein of 1000 amino acids. The deduced structure of the FLT3 protein presents all the characteristics of a receptor-type kinase of this family. The gene is expressed in placenta, in various adult tissues including gonads and brain, and in hematopoietic cells. The Flt3 transcript is 3.7 kb long, except in the testis, where two shorter post-meiotic transcripts are detected. These results suggest a role for this novel receptor and its yet unidentified ligand in placenta, gonads and hematopoietic and nervous systems.	INSERM, U119, 27 BLD LEI ROURE, F-13009 MARSEILLE, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)			Rosnet, Olivier/G-3536-2013	Birnbaum, Daniel/0000-0001-7920-9883; Rosnet, Olivier/0000-0002-3020-910X				BAGOT M, 1988, MED SCI, V5, P287; BAIROCH A, 1990, PROSITE DICT PROTEIN; BARKER W, 1978, ATLAS PROTEIN SEQUEN, V5; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BRUCE J, 1981, J IMMUNOL, V127, P2496; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DUBREUIL P, 1988, LYMPHOCYTE ACTIVATIO, P351; GALLAND F, 1990, BIOCHIMIE, V72, P759, DOI 10.1016/0300-9084(90)90161-9; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GISSELBRECHT S, 1987, NATURE, V329, P259, DOI 10.1038/329259a0; HALABAN R, 1991, IN PRESS CANCER META; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEARD JM, 1987, CELL, V51, P663, DOI 10.1016/0092-8674(87)90135-8; HEISTERKAMP N, 1983, VIROLOGY, V126, P248, DOI 10.1016/0042-6822(83)90476-2; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; KODAMA H, 1991, J EXP MED, V173, P269, DOI 10.1084/jem.173.1.269; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MERCOLA M, 1990, DEV BIOL, V138, P114, DOI 10.1016/0012-1606(90)90181-H; MULLER R, 1983, MOL CELL BIOL, V3, P1062; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; PANTAZIS P, 1990, EUR J HAEMATOL, V45, P127; POLLARD JW, 1987, NATURE, V330, P484, DOI 10.1038/330484a0; PROPST F, 1988, TRENDS GENET, V4, P183, DOI 10.1016/0168-9525(88)90073-X; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; RAPPOLEE DA, 1988, SCIENCE, V241, P1823, DOI 10.1126/science.3175624; REGENSTREIF LJ, 1989, DEV BIOL, V133, P284, DOI 10.1016/0012-1606(89)90319-9; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; RIDGE SA, 1990, P NATL ACAD SCI USA, V87, P1377, DOI 10.1073/pnas.87.4.1377; ROBERTS WM, 1988, CELL, V55, P655, DOI 10.1016/0092-8674(88)90224-3; ROSNET O, 1991, GENOMICS, V9, P380, DOI 10.1016/0888-7543(91)90270-O; ROTHWELL VM, 1987, ONCOGENE RES, V1, P311; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; ROUSSEL MF, 1990, ONCOGENE, V5, P25; RUGH R, 1990, MOUSE ITS REPRODUCTI; RUTA M, 1988, ONCOGENE, V3, P9; SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1; SHERR CJ, 1990, BLOOD, V75, P1; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHIBUYA M, 1990, ONCOGENE, V5, P519; SMART JE, 1981, P NATL ACAD SCI-BIOL, V78, P6013, DOI 10.1073/pnas.78.10.6013; SORRENTINO V, 1991, ONCOGENE, V6, P149; STENMAN G, 1989, GENE CHROMOSOME CANC, V1, P155, DOI 10.1002/gcc.2870010208; STEPHENSON DA, 1991, P NATL ACAD SCI USA, V88, P6, DOI 10.1073/pnas.88.1.6; STEWART W, 1989, Methods in Molecular and Cellular Biology, V1, P73; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VISVADER J, 1989, MOL CELL BIOL, V9, P1336, DOI 10.1128/MCB.9.3.1336; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VU TH, 1989, MOL CELL BIOL, V9, P4563, DOI 10.1128/MCB.9.10.4563; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	68	308	327	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1991	6	9					1641	1650						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1656368				2022-12-17	WOS:A1991GX27400020
J	PURDIE, CA; HARRISON, DJ; PETER, A; DOBBIE, L; WHITE, S; HOWIE, SEM; SALTER, DM; BIRD, CC; WYLLIE, AH; HOOPER, ML; CLARKE, AR				PURDIE, CA; HARRISON, DJ; PETER, A; DOBBIE, L; WHITE, S; HOWIE, SEM; SALTER, DM; BIRD, CC; WYLLIE, AH; HOOPER, ML; CLARKE, AR			TUMOR-INCIDENCE, SPECTRUM AND PLOIDY IN MICE WITH A LARGE DELETION IN THE P53 GENE	ONCOGENE			English	Article							WILD-TYPE P53; CELL-CYCLE CHECKPOINT; CANCER; EXPRESSION; MUTATIONS; ANTIGEN; AMPLIFICATION; PROTEIN; LINE; IRRADIATION	In human tumourigenesis the tumour suppressor gene most commonly affected by mutation, inactivation or allele loss is p53. Loss of p53 function is associated both with failure to maintain a normal diploid status and inability to delete cells by apoptosis following DNA damage. To investigate further the role of p53 we have generated mice carrying a large deletion within the gene. All animals homozygous for this deletion develop spontaneous tumours, predominantly lymphomas, by the age of 6 months. 10% of heterozygotes develop a range of neoplasms, with a lower predisposition towards lymphoma, by 9 months. Both tumour incidence and spectrum in heterozygotes differ from those previously reported in another p53 mutant stock, suggesting either difference in exposure to carcinogens between the two stocks, or a role for modulating genes within different genetic backgrounds. Tumours showed frequent loss of diploid status, and the majority of those arising in heterozygotes showed loss of the wild type allele. These findings are consistent with the concept that p53 acts as a tumour suppressor by preventing the propagation of DNA damage to daughter cells.	UNIV EDINBURGH,SCH MED,DEPT PATHOL,CRC LABS,EDINBURGH,MIDLOTHIAN,SCOTLAND	University of Edinburgh			clarke, alan r/P-2820-2014; Clarke, Alan R/A-6256-2008	Purdie, Colin/0000-0002-1258-4010; Clarke, Alan/0000-0002-4281-426X; rose, lorraine/0000-0001-5135-8262				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1990, CANCER RES, V50, P7717; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BODNER SM, 1992, ONCOGENE, V7, P743; CARDER P, 1993, ONCOGENE, V8, P1397; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FYFE L, 1993, IMMUNOL LETT, V35, P45, DOI 10.1016/0165-2478(93)90146-S; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HALL PA, 1993, ONCOGENE, V8, P203; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; KASTAN MB, 1991, CANCER RES, V51, P6304; Kerr J.F.R., 1987, P93; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MOSER AR, 1992, J CELL BIOL, V116, P1517, DOI 10.1083/jcb.116.6.1517; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PURDIE CA, 1991, AM J PATHOL, V138, P807; QUIRKE P, 1985, BRIT J CANCER, V51, P99, DOI 10.1038/bjc.1985.14; RAULET DH, 1985, NATURE, V314, P103, DOI 10.1038/314103a0; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; RUIZ JC, 1990, MOL CELL BIOL, V10, P3056, DOI 10.1128/MCB.10.6.3056; SAID JW, 1992, AM J PATHOL, V141, P1343; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHMID P, 1991, DEVELOPMENT, V113, P857; SMITH GS, 1973, J NATL CANCER I, V50, P1195, DOI 10.1093/jnci/50.5.1195; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STURZBECHER HW, 1990, ONCOGENE, V5, P795; SYMONDS H, 1991, J VIROL, V65, P5417, DOI 10.1128/JVI.65.10.5417-5424.1991; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	46	307	313	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					603	609						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290271				2022-12-17	WOS:A1994MW24800028
J	WENNSTROM, S; SIEGBAHN, A; YOKOTE, K; ARVIDSSON, AK; HELDIN, CH; MORI, S; CLAESSONWELSH, L				WENNSTROM, S; SIEGBAHN, A; YOKOTE, K; ARVIDSSON, AK; HELDIN, CH; MORI, S; CLAESSONWELSH, L			MEMBRANE RUFFLING AND CHEMOTAXIS TRANSDUCED BY THE PDGF BETA-RECEPTOR REQUIRE THE BINDING-SITE FOR PHOSPHATIDYLINOSITOL 3' KINASE	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; PROTEIN-TYROSINE KINASE; SMOOTH-MUSCLE CELLS; MIDDLE T-ANTIGEN; B-TYPE RECEPTOR; SIGNAL TRANSDUCTION; PHOSPHOLIPASE-C; SH3 DOMAINS; EXPRESSION CLONING; INDUCED ACTIVATION	Activation of the platelet-derived growth factor (PDGF) beta-receptor results in motility responses in the forms of membrane ruffling and chemotaxis. Porcine aortic endothelial cells expressing the PDGF beta-receptor or a chimeric fibroblast growth factor (FGF) receptor, in which the endogenous kinase insert was replaced with the corresponding region from the PDGF beta-receptor, migrated efficiently towards a concentration gradient of PDGF-BB and bFGF, respectively, and exhibited both pronounced edge ruffling and circular membrane ruffling in response to ligand-stimulation. The wildtype FGF receptor-1 showed weak or no response in these assays. Further analyses were conducted on mutant receptors, in which tyrosine residues that can serve as autophosphorylation sites and thereby mediate interactions with specific signal transduction molecules, were changed to phenylalanine residues. Each one of the analysed mutants were mitogenically active, however, a mutant in which Tyr740 and Tyr751 were replaced failed to mediate ruffling and chemotaxis. These two residues are implicated in the binding of phosphatidylinositol 3' kinase. The notion that this enzyme is involved in PDGF beta-receptor-induced cell motility is furthermore supported by the finding that another mutant, in which Met743 and Met754 were replaced, and which failed to interact with phosphatidylinositol 3' kinase, was also unable to mediate motility responses.	LUDWIG INST CANC RES,CTR BIOMED,S-75124 UPPSALA,SWEDEN; UNIV HOSP UPPSALA,DEPT CLIN CHEM,S-75185 UPPSALA,SWEDEN	Ludwig Institute for Cancer Research; Uppsala University; Uppsala University Hospital				Claesson-Welsh, Lena/0000-0003-4275-2000				ADAMS RJ, 1989, NATURE, V340, P565, DOI 10.1038/340565a0; ARVIDSSON AK, 1992, CELL GROWTH DIFFER, V3, P881; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; CLAESSONWELSH L, 1989, J BIOL CHEM, V264, P1742; CLAESSONWELSH L, 1993, BIOL PLATELET DERIVE, V5, P31; COOPER J, 1993, BIOL PLATELET DERIVE, V5, P44; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; ESCOBEDO JA, 1988, NATURE, V335, P85, DOI 10.1038/335085a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; Ferns GAA, 1990, GROWTH FACTORS, V3, P315, DOI 10.3109/08977199009003674; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GROTENDORST GR, 1981, P NATL ACAD SCI-BIOL, V78, P3669, DOI 10.1073/pnas.78.6.3669; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; Herman Paul K., 1992, Trends in Cell Biology, V2, P363, DOI 10.1016/0962-8924(92)90048-R; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; HOSANG M, 1989, J CELL PHYSIOL, V140, P558, DOI 10.1002/jcp.1041400322; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KASHISHIAN A, 1993, MOL BIOL CELL, V4, P49, DOI 10.1091/mbc.4.1.49; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOYAMA N, 1992, J BIOL CHEM, V267, P22806; LAROSE L, 1993, ONCOGENE, V8, P2493; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MCAVOY JW, 1989, DEVELOPMENT, V107, P221; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; MELLSTROM K, 1988, EXP CELL RES, V177, P347, DOI 10.1016/0014-4827(88)90468-5; MIYAZONO K, 1988, J BIOL CHEM, V263, P6407; MORI S, 1991, J BIOL CHEM, V266, P21158; MORI S, 1992, J BIOL CHEM, V267, P6429; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISTER M, 1988, CELL, V52, P791, DOI 10.1016/0092-8674(88)90421-7; Ostman A, 1989, GROWTH FACTORS, V1, P271, DOI 10.3109/08977198908998003; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; Panayotou George, 1992, Trends in Cell Biology, V2, P358, DOI 10.1016/0962-8924(92)90042-L; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAINES EW, 1990, HDB EXPT PHARM 1, V95, P173; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHOFIELD PN, 1992, FEBS LETT, V298, P154, DOI 10.1016/0014-5793(92)80044-H; SENIOR RM, 1983, J CELL BIOL, V96, P382, DOI 10.1083/jcb.96.2.382; SEPPA H, 1982, J CELL BIOL, V92, P584, DOI 10.1083/jcb.92.2.584; SIEGBAHN A, 1990, J CLIN INVEST, V85, P916, DOI 10.1172/JCI114519; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; STOKER M, 1991, BIOCHIM BIOPHYS ACTA, V1072, P81, DOI 10.1016/0304-419X(91)90008-9; TAYLOR GR, 1989, EMBO J, V8, P2029, DOI 10.1002/j.1460-2075.1989.tb03611.x; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULUG ET, 1990, J VIROL, V64, P3895, DOI 10.1128/JVI.64.8.3895-3904.1990; VALIUS B, 1993, CELL, V73, P321; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; WAHL M, 1991, BIOESSAYS, V13, P107, DOI 10.1002/bies.950130303; WENNSTROM S, 1992, J BIOL CHEM, V267, P13749; Wennstrom S, 1991, GROWTH FACTORS, V4, DOI 10.3109/08977199109104816; WESTERMARK B, 1985, J CELL PHYSIOL, V124, P43, DOI 10.1002/jcp.1041240108; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YU JC, 1991, MOL CELL BIOL, V11, P3780, DOI 10.1128/MCB.11.7.3780	81	307	307	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					651	660						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290276				2022-12-17	WOS:A1994MW24800034
J	CRAWFORD, D; ZBINDEN, I; AMSTAD, P; CERUTTI, P				CRAWFORD, D; ZBINDEN, I; AMSTAD, P; CERUTTI, P			OXIDANT STRESS INDUCES THE PROTO-ONCOGENES CIS-FOS AND CIS-MYC IN MOUSE EPIDERMAL-CELLS	ONCOGENE			English	Article									SWISS INST EXPTL CANC RES,DEPT CARCINOGENESIS,CH-1066 EPALINGES,SWITZERLAND	Swiss Institute Experimental Cancer Research								ANGEL P, 1985, CANCER CELL, V3, P315; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; Battey, 1986, BASIC METHODS MOL BI; BENTLEY D, 1986, NATURE, V321, P703; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CERUTTI PA, 1988, GROWTH FACTORS TUMOR, P239; CRAWFORD D, 1988, IN PRESS ANTICARCINO; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; CURRAN T, 1984, CELL, V36, P259; DOTTO GP, 1986, EMBO J, V5, P2853, DOI 10.1002/j.1460-2075.1986.tb04579.x; ELDER PK, 1984, P NATL ACAD SCI-BIOL, V81, P7476, DOI 10.1073/pnas.81.23.7476; FAVERA RD, 1982, P NATL ACAD SCI USA, V79, P7824; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; GERSTENFELD LC, 1984, MOL CELL BIOL, V4, P1483, DOI 10.1128/MCB.4.8.1483; Gindhart T D, 1985, Carcinog Compr Surv, V8, P341; GINDHART TD, 1985, CARCINOGENESIS, V6, P309, DOI 10.1093/carcin/6.2.309; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KANDJIAN EW, 1987, BIOTECHNOLOGY, V5, P165; KOZUMBO WJ, 1985, CHEM-BIOL INTERACT, V54, P199, DOI 10.1016/S0009-2797(85)80163-0; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LAN L, 1987, P NATL ACAD SCI USA, V84, P1182; MINTY AJ, 1983, J MOL BIOL, V167, P77, DOI 10.1016/S0022-2836(83)80035-7; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; MOUGNEAU E, 1987, C ONCOGENES GROWTH C, P127; MUEHLEMATTER D, 1988, CARCINOGENESIS, V9, P239, DOI 10.1093/carcin/9.2.239; Muller R, 1986, Biochim Biophys Acta, V823, P207, DOI 10.1016/0304-419X(86)90003-X; MULLER R, 1986, TIG              APR, P93; NAKAMURA Y, 1985, CARCINOGENESIS, V6, P229, DOI 10.1093/carcin/6.2.229; NAKAMURA Y, 1988, CARCINOGENESIS, V9, P203, DOI 10.1093/carcin/9.2.203; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; PRYWES R, 1986, CELL, V47, P778; RAU W, 1986, P NATL ACAD SCI US, V83, P8216; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; SHALL S, 1987, C ONCOGENES GROWTH C, P161; SHUIN T, 1986, CANCER RES, V46, P5302; STUDZINSKI GP, 1986, SCIENCE, V234, P467, DOI 10.1126/science.3532322; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; VERMA IC, 1986, TRENDS GENET     APR, P93	47	307	311	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1988	3	1					27	32						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	P0354					2022-12-17	WOS:A1988P035400005
J	Noonan, EJ; Place, RF; Pookot, D; Basak, S; Whitson, JM; Hirata, H; Giardina, C; Dahiya, R				Noonan, E. J.; Place, R. F.; Pookot, D.; Basak, S.; Whitson, J. M.; Hirata, H.; Giardina, C.; Dahiya, R.			miR-449a targets HDAC-1 and induces growth arrest in prostate cancer	ONCOGENE			English	Article						miRNA; miR-449a; miR-34; HDAC-1; HDAC inhibitors; prostate cancer; senescence	HISTONE DEACETYLASE INHIBITORS; MICRORNA EXPRESSION; CLASS-I; VALPROIC ACID; SOLID TUMORS; CELLS; APOPTOSIS; SENESCENCE; MIR-34A; GENE	Histone deacetylases (HDACs) are frequently over-expressed in broad range of cancer types, where they alter cellular epigenetic programming to promote cell proliferation and survival. However, the mechanism by which HDACs become overexpressed in human cancers remains somewhat of a mystery. In this study, we investigated the expression and functional significance of miR-449a in prostate cancer cells. Using real-time PCR, we found that miR-449a is downregulated in prostate cancer tissues relative to patient-matched control tissue. Introduction of miR-449a into PC-3 prostate cancer cells resulted in cell-cycle arrest, apoptosis and a senescent-like phenotype. In silico analysis of 3'-UTR regions identified a number of genes involved in cell-cycle regulation as putative targets of miR-449a. Using a luciferase 3'-UTR reporter system, we established that HDAC-1 (histone deacetylase 1), a gene that is frequently overexpressed in many types of cancer, is a direct target of miR-449a. Further, our data indicate that miR-449a regulates cell growth and viability in part by repressing the expression of HDAC-1 in prostate cancer cells. Our findings provide new insight into the function of miRNA in regulating HDAC expression in normal versus cancerous tissue.	[Noonan, E. J.; Place, R. F.; Pookot, D.; Basak, S.; Hirata, H.; Dahiya, R.] Vet Affairs Med Ctr, Dept Urol, San Francisco, CA 94121 USA; [Place, R. F.; Whitson, J. M.; Dahiya, R.] Univ Calif San Francisco, Sch Med, Dept Urol, San Francisco, CA 94143 USA; [Giardina, C.] Univ Connecticut, Dept Mol & Cell Biol, Storrs, CT 06269 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of Connecticut	Noonan, EJ (corresponding author), Vet Affairs Med Ctr, Dept Urol, 4150 Clement St, San Francisco, CA 94121 USA.	emily.noonan@gmail.com; Rdahiya@urology.ucsf.edu			Veterans Affairs Research Enhancement Award Program (REAP); National Institutes of Health [RO1CA101844, RO1CA111470s, T32DK007790]; NATIONAL CANCER INSTITUTE [R01CA101844] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007790] Funding Source: NIH RePORTER	Veterans Affairs Research Enhancement Award Program (REAP)(US Department of Veterans Affairs); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank R Erickson for his critical reading and discussion of the paper. This work was supported by the Veterans Affairs Research Enhancement Award Program (REAP), VA Merit Review grant and the National Institutes of Health grants RO1CA101844, RO1CA111470s and T32DK007790 (PI: Rajvir Dahiya).	Blenkiron C, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r214; Chen JS, 2005, J CELL PHYSIOL, V202, P87, DOI 10.1002/jcp.20094; Chen YX, 2007, CANCER RES, V67, P976, DOI 10.1158/0008-5472.CAN-06-3667; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Duan H, 2005, MOL CELL BIOL, V25, P1608, DOI 10.1128/MCB.25.5.1608-1619.2005; Fulci V, 2007, BLOOD, V109, P4944, DOI 10.1182/blood-2006-12-062398; Garcia-Manero G, 2008, BLOOD, V111, P1060, DOI 10.1182/blood-2007-06-098061; Gaur A, 2007, CANCER RES, V67, P2456, DOI 10.1158/0008-5472.CAN-06-2698; Glaser KB, 2003, BIOCHEM BIOPH RES CO, V310, P529, DOI 10.1016/j.bbrc.2003.09.043; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Halkidou K, 2004, PROSTATE, V59, P177, DOI 10.1002/pros.20022; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Hitomi T, 2003, FEBS LETT, V554, P347, DOI 10.1016/S0014-5793(03)01186-4; Iacomino G, 2008, ANTICANCER RES, V28, P855; Inoue S, 2006, CANCER RES, V66, P6785, DOI 10.1158/0008-5472.CAN-05-4563; Jiang JM, 2005, NUCLEIC ACIDS RES, V33, P5394, DOI 10.1093/nar/gki863; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Kim HR, 2006, EXP MOL MED, V38, P616, DOI 10.1038/emm.2006.73; Kim JH, 2004, J GASTROEN HEPATOL, V19, P218, DOI 10.1111/j.1440-1746.2004.03336.x; Kim JH, 2001, COMPOS INTERFACE, V7, P443, DOI 10.1163/156855400750262932; Kummar S, 2007, CLIN CANCER RES, V13, P5411, DOI 10.1158/1078-0432.CCR-07-0791; Kurz DJ, 2000, J CELL SCI, V113, P3613; Lagger G, 2002, EMBO J, V21, P2672, DOI 10.1093/emboj/21.11.2672; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Mann BS, 2007, ONCOLOGIST, V12, P1247, DOI 10.1634/theoncologist.12-10-1247; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Mattie MD, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-24; Mehnert JM, 2007, CANCER J, V13, P23, DOI 10.1097/PPO.0b013e31803c72ba; Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022; Ozen M, 2008, ONCOGENE, V27, P1788, DOI 10.1038/sj.onc.1210809; Pan Y, 2001, GENE CHROMOSOME CANC, V30, P187, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1075>3.3.CO;2-8; Patra SK, 2001, BIOCHEM BIOPH RES CO, V287, P705, DOI 10.1006/bbrc.2001.5639; Place RF, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-37; Place RF, 2008, P NATL ACAD SCI USA, V105, P1608, DOI 10.1073/pnas.0707594105; Porkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533; Pressman S, 2007, CELL, V130, DOI 10.1016/j.cell.2007.07.042; Qian DZ, 2007, PROSTATE, V67, P1182, DOI 10.1002/pros.20611; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; Senese S, 2007, MOL CELL BIOL, V27, P4784, DOI 10.1128/MCB.00494-07; Shabbeer S, 2007, PROSTATE, V67, P1099, DOI 10.1002/pros.20587; Shell S, 2007, P NATL ACAD SCI USA, V104, P11400, DOI 10.1073/pnas.0704372104; Spurling CC, 2008, MOL CARCINOGEN, V47, P137, DOI 10.1002/mc.20373; Tarasov V, 2007, CELL CYCLE, V6, P1586, DOI 10.4161/cc.6.13.4436; Tazawa H, 2007, P NATL ACAD SCI USA, V104, P15472, DOI 10.1073/pnas.0707351104; Tong AW, 2008, CANCER GENE THER, V15, P341, DOI 10.1038/cgt.2008.8; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wagner M, 2001, FEBS LETT, V499, P101, DOI 10.1016/S0014-5793(01)02524-8; Wedel SA, 2008, J CELL MOL MED, V12, P2457, DOI 10.1111/j.1582-4934.2008.00271.x; Weichert W, 2008, BRIT J CANCER, V98, P604, DOI 10.1038/sj.bjc.6604199; Weichert W, 2008, CLIN CANCER RES, V14, P1669, DOI 10.1158/1078-0432.CCR-07-0990; Wiklund F, 2003, PROSTATE, V57, P290, DOI 10.1002/pros.10303; Wilson AJ, 2006, J BIOL CHEM, V281, P13548, DOI 10.1074/jbc.M510023200; Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620; Yoshikawa M, 2007, J AM SOC NEPHROL, V18, P58, DOI 10.1681/ASN.2005111187; Zhang ZH, 2005, BREAST CANCER RES TR, V94, P11, DOI 10.1007/s10549-005-6001-1	57	306	326	0	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 9	2009	28	14					1714	1724		10.1038/onc.2009.19	http://dx.doi.org/10.1038/onc.2009.19			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	430WQ	19252524				2022-12-17	WOS:000265022000006
J	Menard, S; Pupa, SM; Campiglio, M; Tagliabue, E				Menard, S; Pupa, SM; Campiglio, M; Tagliabue, E			Biologic and therapeutic role of HER2 in cancer	ONCOGENE			English	Review						HER2; biological role; prognostic value; predictive value; therapy	EPIDERMAL-GROWTH-FACTOR; POSITIVE BREAST-CANCER; FACTOR RECEPTOR FAMILY; HER-2/NEU GENE AMPLIFICATION; MAMMARY-TUMOR DEVELOPMENT; T-CELL IMMUNITY; MONOCLONAL-ANTIBODY; SIGNAL-TRANSDUCTION; ESTROGEN-RECEPTOR; DNA VACCINATION	Overexpression of the human epidermal growth factor-2 (HER2) oncogene in human breast carcinomas has been associated with a more aggressive course of disease. The reason for this association is still unclear, although it has been suggested to rest in increased proliferation, vessel formation, and/or invasiveness. Alternatively, prognosis may not be directly related to the presence of the oncoprotein on the cell membrane, but instead to the breast carcinoma subset identified by HER2 overexpression and characterized by a peculiar gene expression profile. HER2 has also been associated with sensitivity to anthracyclins and resistance to endocrine therapy, suggesting that tyrosine kinase receptor and hormone receptor pathways represent two major proliferation pathways exclusively active in breast carcinomas, one sensitive to chemotherapeutic drugs and the other to antiestrogens. HER2 currently represents one of the most appropriate targets for specific therapy. Indeed, trastuzumab, a monoclonal antibody directed against the extracellular domain of HER2, is therapeutically active in HER2-positive breast carcinomas. However, a consistent number of HER2-positive tumors is not responsive to HER2-driven therapy, indicating the need for a better understanding of the mechanism of action of this new biological drug in vivo. While preclinical studies suggest antibody-dependent cell cytotoxicity as the major mechanism, determination of NK activity at the time of treatment remains mandatory, especially in patients treated with immunosuppressive drugs. The efficacy of prophylactic vaccination has been fully demonstrated in preclinical models, whereas ongoing studies of active immunotherapy using a variety of vaccination regimens against HER2 in tumor-bearing mice and patients have met with only moderate success.	Ist Nazl Tumori, Dept Expt Oncol, Mol Targeting Unit, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan	Menard, S (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Mol Targeting Unit, Via Venezian 1, I-20133 Milan, Italy.	sylvie.menard@istitutotumori.mi.it	menard, sylvie mm/C-7940-2011; Pupa, Serenella/K-6388-2016; Tagliabue, Elda/B-9377-2017	Pupa, Serenella/0000-0002-4592-6830; Tagliabue, Elda/0000-0001-9877-2903				Allgayer H, 2000, J CLIN ONCOL, V18, P2201, DOI 10.1200/JCO.2000.18.11.2201; Amici A, 2000, GENE THER, V7, P703, DOI 10.1038/sj.gt.3301151; Bocchia M, 2000, HAEMATOLOGICA, V85, P1172; Bocker W, 2002, LAB INVEST, V82, P737, DOI 10.1097/01.LAB.0000017371.72714.C5; Burstein HJ, 2003, J CLIN ONCOL, V21, P46, DOI 10.1200/JCO.2003.03.124; Campiglio M, 2003, INT J CANCER, V105, P568, DOI 10.1002/ijc.11113; CAMPIGLIO M, 1994, J CELL BIOCHEM, V55, P409, DOI 10.1002/jcb.240550402; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; Casalini P, 2001, J BIOL CHEM, V276, P12449, DOI 10.1074/jbc.M009732200; Cavallo F, 1997, J NATL CANCER I, V89, P1049, DOI 10.1093/jnci/89.14.1049; Cavallo F, 1999, CANCER RES, V59, P414; Cefai D, 1999, INT J CANCER, V83, P393, DOI 10.1002/(SICI)1097-0215(19991029)83:3<393::AID-IJC16>3.0.CO;2-M; Clarke M, 1998, LANCET, V351, P1451; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Colombo MP, 1996, CANCER METAST REV, V15, P317, DOI 10.1007/BF00046345; Cooke T, 2001, EUR J CANCER, V37, pS3, DOI 10.1016/S0959-8049(00)00402-0; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; Dakappagari NK, 2000, CANCER RES, V60, P3782; Daly JM, 1997, CANCER RES, V57, P3804; Daly JM, 1999, ONCOGENE, V18, P3440, DOI 10.1038/sj.onc.1202700; De Vecchi R, 1999, CANCER RES, V59, P4471; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; DESANTES K, 1992, CANCER RES, V52, P1916; Di Carlo E, 2001, CLIN CANCER RES, V7, p830S; Di Leo A, 2002, CLIN CANCER RES, V8, P1107; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Disis ML, 2002, J CLIN ONCOL, V20, P2624, DOI 10.1200/JCO.2002.06.171; Disis ML, 1997, J CLIN ONCOL, V15, P3363, DOI 10.1200/JCO.1997.15.11.3363; Disis ML, 1997, ADV CANCER RES, V71, P343, DOI 10.1016/S0065-230X(08)60103-7; DISIS ML, 1994, CANCER RES, V54, P16; Dittmar T, 2002, FASEB J, V16, P1823, DOI 10.1096/fj.02-0096fje; Elledge RM, 1998, CLIN CANCER RES, V4, P7; Esserman LJ, 1999, CANCER IMMUNOL IMMUN, V47, P337, DOI 10.1007/s002620050539; Feldner JC, 2002, EXP CELL RES, V272, P93, DOI 10.1006/excr.2001.5385; FENDLY BM, 1990, CANCER RES, V50, P1550; Finn OJ, 2002, CURR OPIN IMMUNOL, V14, P172, DOI 10.1016/S0952-7915(02)00317-5; Forni G, 2000, CANCER RES, V60, P2571; Foy TM, 2002, SEMIN ONCOL, V29, P53, DOI 10.1053/sonc.2002.34056; Franklin WA, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.31520; Gambaletta D, 2000, J BIOL CHEM, V275, P10604, DOI 10.1074/jbc.275.14.10604; Gancberg D, 2002, BREAST CANCER RES TR, V74, P113, DOI 10.1023/A:1016146130767; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Geddert H, 2002, AM J CLIN PATHOL, V118, P60; Giani C, 1998, ONCOGENE, V17, P425, DOI 10.1038/sj.onc.1201954; Goebel SU, 2002, CANCER RES, V62, P3702; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRUNT TW, 1995, INT J CANCER, V63, P560, DOI 10.1002/ijc.2910630417; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Haynes NM, 2002, BLOOD, V100, P3155, DOI 10.1182/blood-2002-04-1041; HIEKEN TJ, 1996, P AN M AM SOC CLIN, V15, P113; Hirsch FR, 2002, BRIT J CANCER, V86, P1449, DOI 10.1038/sj.bjc.6600286; Huang GC, 2002, BRIT J CANCER, V86, P1104, DOI 10.1038/sj/bjc/6600219; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; Izumi Y, 2002, NATURE, V416, P279, DOI 10.1038/416279b; Jager E, 2002, CURR OPIN IMMUNOL, V14, P178, DOI 10.1016/S0952-7915(02)00318-7; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Kerbel RS, 2000, EUR J CANCER, V36, P1248, DOI 10.1016/S0959-8049(00)00092-7; Khan AJ, 2002, CLIN CANCER RES, V8, P540; Kiessling R, 2002, ADV CANCER RES, V85, P101, DOI 10.1016/S0065-230X(02)85004-7; Kim S, 2000, P NATL ACAD SCI USA, V97, P2731, DOI 10.1073/pnas.050588297; Knutson KL, 2001, J CLIN INVEST, V107, P477, DOI 10.1172/JCI11752; Konecny G, 2003, J NATL CANCER I, V95, P142, DOI 10.1093/jnci/95.2.142; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; Latif Z, 2002, BJU INT, V89, P5, DOI 10.1046/j.1464-6.2001.01372.x; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; LIU YL, 1995, BREAST CANCER RES TR, V34, P97, DOI 10.1007/BF00665783; Lollini PL, 2002, CANCER IMMUNOL IMMUN, V51, P409, DOI 10.1007/s00262-002-0293-3; Ludewig B, 2000, J EXP MED, V191, P795, DOI 10.1084/jem.191.5.795; Masood S, 2002, MICROSC RES TECHNIQ, V59, P102, DOI 10.1002/jemt.10181; MAYORDOMO JI, 1995, NAT MED, V1, P1297, DOI 10.1038/nm1295-1297; Menard S, 2001, ONCOLOGY-BASEL, V61, P67, DOI 10.1159/000055404; Menard S, 2000, J CELL PHYSIOL, V182, P150, DOI 10.1002/(SICI)1097-4652(200002)182:2<150::AID-JCP3>3.0.CO;2-E; Menard S, 2002, CLIN CANCER RES, V8, P520; Menard S, 2001, ANN ONCOL, V12, P15, DOI 10.1023/A:1011151505425; Menard S, 1996, J CLIN ONCOL, V14, P2407; Menard S, 2001, J CLIN ONCOL, V19, P329, DOI 10.1200/JCO.2001.19.2.329; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; Miles DW, 1999, INT J CANCER, V84, P354, DOI 10.1002/(SICI)1097-0215(19990820)84:4<354::AID-IJC4>3.0.CO;2-6; Moliterni A, 2003, J CLIN ONCOL, V21, P458, DOI 10.1200/JCO.2003.04.021; MURTHY SM, 1989, CANCER, V64, P2035, DOI 10.1002/1097-0142(19891115)64:10<2035::AID-CNCR2820641012>3.0.CO;2-L; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Nagata Y, 1997, J IMMUNOL, V159, P1336; Nakamura H, 2003, INT J CANCER, V103, P61, DOI 10.1002/ijc.10795; Nanni P, 2001, J EXP MED, V194, P1195, DOI 10.1084/jem.194.9.1195; Nanni P, 1999, ANN ONCOL, V10, P261, DOI 10.1023/A:1008304721889; Nicolini G, 1996, J BIOL CHEM, V271, P30290, DOI 10.1074/jbc.271.47.30290; O-charoenrat P, 1999, CLIN EXP METASTAS, V17, P631, DOI 10.1023/A:1006751016860; Ohashi PS, 2002, CURR OPIN IMMUNOL, V14, P744, DOI 10.1016/S0952-7915(02)00406-5; Paik S, 2002, JNCI-J NATL CANCER I, V94, P852, DOI 10.1093/jnci/94.11.852; Paik SM, 1998, JNCI-J NATL CANCER I, V90, P1361, DOI 10.1093/jnci/90.18.1361; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; PIERCE JH, 1991, ONCOGENE, V6, P1189; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Press MF, 1997, J CLIN ONCOL, V15, P2894, DOI 10.1200/JCO.1997.15.8.2894; PRESS MF, 1990, ONCOGENE, V5, P953; Pupa SM, 1996, J CLIN ONCOL, V14, P85, DOI 10.1200/JCO.1996.14.1.85; PUPA SM, 1993, CANCER RES, V53, P5864; Pupa SM, 2001, GENE THER, V8, P75, DOI 10.1038/sj.gt.3301360; Rhodes A, 2002, AM J CLIN PATHOL, V118, P408; RILKE F, 1991, INT J CANCER, V49, P44, DOI 10.1002/ijc.2910490109; Roche PC, 2002, JNCI-J NATL CANCER I, V94, P855, DOI 10.1093/jnci/94.11.855; Ross JA, 1998, INT J CANCER, V78, P26; Rovero S, 2000, J IMMUNOL, V165, P5133, DOI 10.4049/jimmunol.165.9.5133; SARUP JC, 1991, GROWTH REGULAT, V1, P72; Sfondrini L, 2002, FASEB J, V16, P1749, DOI 10.1096/fj.02-0383com; SHEPARD HM, 1991, J CLIN IMMUNOL, V11, P117, DOI 10.1007/BF00918679; Sibilia M, 1998, EMBO J, V17, P719, DOI 10.1093/emboj/17.3.719; SIEWEKE MH, 1994, CRIT REV ONCOGENESIS, V5, P297, DOI 10.1615/CritRevOncog.v5.i2-3.90; Sirotnak FM, 2000, CLIN CANCER RES, V6, P4885; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Sliwkowski MX, 1999, SEMIN ONCOL, V26, P60; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Soule S, 2002, J CLIN PATHOL, V55, P656, DOI 10.1136/jcp.55.9.656; Tagliabue E, 1998, EUR J CANCER, V34, P1982; Tagliabue E, 1996, BRIT J CANCER, V74, P1427, DOI 10.1038/bjc.1996.560; Tagliabue E, 2001, BREAST CANCER RES TR, V70, P155, DOI 10.1023/A:1012955229031; Tan M, 1997, CANCER RES, V57, P1199; Thor AD, 1998, JNCI-J NATL CANCER I, V90, P1346, DOI 10.1093/jnci/90.18.1346; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Tsavaris N, 2002, BRIT J CANCER, V87, P21, DOI 10.1038/sj.bjc.6600347; Tubbs RR, 2002, ARCH PATHOL LAB MED, V126, P803; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; Volpi A, 2000, BREAST CANCER RES TR, V63, P181, DOI 10.1023/A:1006464426977; Waterman H, 1999, EMBO J, V18, P3348, DOI 10.1093/emboj/18.12.3348; Witters L, 2002, ONCOL REP, V9, P1163; Yan J, 2002, CANCER GENET CYTOGEN, V132, P116, DOI 10.1016/S0165-4608(01)00542-8; Yarden Y, 2001, EUR J CANCER, V37, pS3; Zhou BHP, 2002, SEMIN ONCOL, V29, P62, DOI 10.1053/sonc.2002.34057; Zitvogel L, 1996, J EXP MED, V183, P87, DOI 10.1084/jem.183.1.87	136	306	337	2	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2003	22	42					6570	6578		10.1038/sj.onc.1206779	http://dx.doi.org/10.1038/sj.onc.1206779			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	728DV	14528282				2022-12-17	WOS:000185700700014
J	Takimoto, R; El-Deiry, WS				Takimoto, R; El-Deiry, WS			Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site	ONCOGENE			English	Article						p53; KILLER/DR5; p53 DNA-binding site; apoptosis	TUMOR-SUPPRESSOR P53; DEATH RECEPTOR GENE; NF-KAPPA-B; P21(WAF1/CIP1) EXPRESSION; LIGAND TRAIL; MDM2 GENE; BAX GENE; CYCLIN-G; APOPTOSIS; IDENTIFICATION	KILLER/DR5, a tumor necrosis factor-related apoptosis-inducing Ligand (TRAIL) death receptor gene, has been shown to be induced by DNA damaging agents and radiation in a p53-dependent manner. Although TRAIL is a potential therapeutic agent for cancer, the induction mechanism of its receptors is poorly understood, Here we show the identification of three p53 DNA-binding sites in the KILLER/DR5 genomic locus located upstream (BS1; -0.82 Kb) of the ATG site, within Intron 1 (BS2; + 0.25 Kb downstream of the ATG) and within Intron 2 (BS3; + 1.25 Kb downstream of the ATG), A modified p53-binding and immunoselection protocol using a wildtype p53-expressing adenovirus vector (Ad-p53) was used to identify the binding sites and to show that each binding site can bind specifically to wild-type p53 protein (wt-p53), A reporter assay revealed that only BS2 could enhance luciferase expression driven by a basal promoter. We constructed a reporter plasmid carrying the genomic regulatory region of KILLER/DR5 including the three p53 DNA-binding sites but no additional basal promoter. The genomic fragment showed basal transcriptional activity which was induced by wt-p53 but not by mutant p53, and human papilloma virus E6 inhibited the p53-dependent activation. Mutation of BS2 abrogated not only the binding activity of wt-p53 but also the induction of the KILLER/DR5 genomic promoter-reporter gene, indicating that BS2 is responsible for the p53-dependent transactivation of KILLER/DR5, In p53-wild-type but not -mutant or -null cell lines, doxorubicin treatment stabilized p53 protein, and increased specific binding to BS2 as revealed by EMSA, and upregulated the KILLER/DR5 promoter-luciferase reporter gene. These results suggest that the transactivation of KILLER/DR5 is directly regulated by exogenous or endogenous wt-p53 and establishes KILLER/DR5 as a p53 target gene that can signal apoptotic death.	Univ Penn, Sch Med, Lab Mol Oncol & Cell Cycle Regulat, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med Pharmacol & Genet, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Canc, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Inst Human Gene Therapy, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	El-Deiry, WS (corresponding author), Univ Penn, Sch Med, Lab Mol Oncol & Cell Cycle Regulat, Howard Hughes Med Inst, 415 Curie Blvd,CRB 437A, Philadelphia, PA 19104 USA.		El-Deiry, Wafik/AAJ-6080-2020	El-Deiry, Wafik/0000-0002-9577-8266	NCI NIH HHS [P01 CA75138-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA075138] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kim KH, 2000, CLIN CANCER RES, V6, P335; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; Meng RD, 2000, MOL THER, V1, P130, DOI 10.1006/mthe.2000.0025; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Mongkolsapaya J, 1998, J IMMUNOL, V160, P3; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Pai SI, 1998, CANCER RES, V58, P3513; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Schneider P, 1997, FEBS LETT, V416, P329, DOI 10.1016/S0014-5793(97)01231-3; Screaton GR, 1997, CURR BIOL, V7, P693, DOI 10.1016/S0960-9822(06)00297-1; Sheikh MS, 1997, ONCOGENE, V15, P1095, DOI 10.1038/sj.onc.1201264; Sheikh MS, 1998, CANCER RES, V58, P1593; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; TSANG NM, 1995, ONCOGENE, V10, P2403; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu GS, 1999, ONCOGENE, V18, P6411, DOI 10.1038/sj.onc.1203025; Wu GS, 1999, CANCER RES, V59, P2770; Wu GS, 1998, ONCOGENE, V16, P2177, DOI 10.1038/sj.onc.1201755; Wu GS, 1996, CLIN CANCER RES, V2, P623; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; Zeng YX, 1997, BIOTECHNIQUES, V23, P88, DOI 10.2144/97231bm19; Zeng YX, 1996, ONCOGENE, V12, P1557	50	306	313	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 30	2000	19	14					1735	1743		10.1038/sj.onc.1203489	http://dx.doi.org/10.1038/sj.onc.1203489			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301DG	10777207				2022-12-17	WOS:000086292500001
J	Bowden, ET; Barth, M; Thomas, D; Glazer, RI; Mueller, SC				Bowden, ET; Barth, M; Thomas, D; Glazer, RI; Mueller, SC			An invasion-related complex of cortactin, paxillin and PKC mu associates with invadopodia at sites of extracellular matrix degradation	ONCOGENE			English	Article						invasion; cortactin; paxillin; PKC mu; breast cancer	FOCAL ADHESION KINASE; BREAST-CANCER CELLS; TYROSINE PHOSPHORYLATION; TRANSFORMED-CELLS; CARCINOMA-CELLS; CONTACT SITES; CELLULAR INVASION; V-SRC; EXPRESSION; INTEGRIN	Invasive breast cancer cells have the ability to extend membrane protrusions, invadopodia, into the extracellular matrix (EC). These structures are associated with sites of active matrix degradation. The amount of matrix degradation associated with the activity of these membrane protrusions has been shown to directly correlate with invasive potential. We demonstrate here that microinjection of polyclonal anti-cortactin antibodies blocks matrix degradation at invadopodia supporting the hypothesis that cortactin has a direct role in invasive behavior. MDA-MB-231, invasive breast cancer cells were sheared from the surface of a gelatin matrix to isolate invadopodia. Cortactin, paxillin and protein kinase C (PKC) mu, a serine kinase, were co-immunoprecipitated as a complex from invadopodia-enriched membranes. We confirmed the subcellular distribution of these proteins by immunolocalization and Western blotting. We also determined that, in contrast to its presence in invasive cells, this complex of proteins was not detected in lysates from non-invasive cells that do not form invadopodia. Taken together, these data suggest that the formation of this cortactin-containing complex correlates,vith cellular invasiveness. We hypothesize that this complex of molecules has a role in the formation and function of invadopodia during cellular invasion.	Georgetown Univ, Sch Med, Lombardi Canc Ctr, Dept Cell Biol, Washington, DC 20007 USA; Georgetown Univ, Sch Med, Lombardi Canc Ctr, Dept Pharmacol, Washington, DC 20007 USA	Georgetown University; Georgetown University	Mueller, SC (corresponding author), Georgetown Univ, Sch Med, Lombardi Canc Ctr, Dept Cell Biol, Washington, DC 20007 USA.				NCI NIH HHS [R21CA62232, R01CA61273] Funding Source: Medline; NIDDK NIH HHS [R01DK48910] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061273, R21CA062232] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048910] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABEDI H, 1995, J BIOL CHEM, V270, P11367, DOI 10.1074/jbc.270.19.11367; Bellis SL, 1997, BIOCHEM J, V325, P375, DOI 10.1042/bj3250375; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Campbell DH, 1996, INT J CANCER, V68, P485, DOI 10.1002/(SICI)1097-0215(19961115)68:4<485::AID-IJC14>3.0.CO;2-4; CHEN WT, 1989, J EXP ZOOL, V251, P167, DOI 10.1002/jez.1402510206; Coopman PJ, 1998, CLIN CANCER RES, V4, P507; Coopman PJ, 1996, MOL BIOL CELL, V7, P1789, DOI 10.1091/mbc.7.11.1789; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; KELLY T, 1994, J CELL PHYSIOL, V158, P299, DOI 10.1002/jcp.1041580212; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; Lewis JM, 1996, J CELL BIOL, V134, P1323, DOI 10.1083/jcb.134.5.1323; McCormack SJ, 1997, ONCOGENE, V15, P265, DOI 10.1038/sj.onc.1201186; MIYATA Y, 1989, J BIOL CHEM, V264, P15565; MONSKY WL, 1994, CANCER RES, V54, P5702; MONSKY WL, 1993, CANCER RES, V53, P3159; Moonga BS, 1996, CALCIFIED TISSUE INT, V59, P105, DOI 10.1007/s002239900095; MUELLER SC, 1991, J CELL SCI, V99, P213; MUELLER SC, 1992, J CELL BIOL, V119, P1309, DOI 10.1083/jcb.119.5.1309; Nakahara H, 1996, J BIOL CHEM, V271, P27221, DOI 10.1074/jbc.271.44.27221; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; OBRIAN CA, 1989, CANCER METAST REV, V8, P199, DOI 10.1007/BF00047337; OKAMURA H, 1995, J BIOL CHEM, V270, P26613, DOI 10.1074/jbc.270.44.26613; Patel AS, 1998, ONCOGENE, V16, P3227, DOI 10.1038/sj.onc.1201850; Prestle J, 1996, J CELL BIOL, V134, P1401, DOI 10.1083/jcb.134.6.1401; SCHUURING E, 1993, MOL CELL BIOL, V13, P2891, DOI 10.1128/MCB.13.5.2891; SCHUURING E, 1992, ONCOGENE, V7, P355; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Tamaki M, 1996, J NEUROSURG, V84, P1013, DOI 10.3171/jns.1996.84.6.1013; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; vanDamme H, 1997, J BIOL CHEM, V272, P7374, DOI 10.1074/jbc.272.11.7374; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; XIE B, 1994, AM J PATHOL, V144, P1058; Yazaki T, 1996, MOL PHARMACOL, V50, P236; YEBRA M, 1995, MOL BIOL CELL, V6, P841, DOI 10.1091/mbc.6.7.841	39	306	316	0	18	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 5	1999	18	31					4440	4449		10.1038/sj.onc.1202827	http://dx.doi.org/10.1038/sj.onc.1202827			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	222YT	10442635				2022-12-17	WOS:000081813500006
J	Scaltriti, M; Verma, C; Guzman, M; Jimenez, J; Parra, JL; Pedersen, K; Smith, DJ; Landolfi, S; Cajal, SRY; Arribas, J; Baselga, J				Scaltriti, M.; Verma, C.; Guzman, M.; Jimenez, J.; Parra, J. L.; Pedersen, K.; Smith, D. J.; Landolfi, S.; Ramon y Cajal, S.; Arribas, J.; Baselga, J.			Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity	ONCOGENE			English	Article						ErbB receptor; trastuzumab; tyrosine kinase inhibitor; antibody-dependent cell cytotoxicity (ADCC); breast cancer	FACTOR RECEPTOR EGFR; METASTATIC BREAST-CANCER; MONOCLONAL-ANTIBODY; ADJUVANT CHEMOTHERAPY; DOWN-REGULATION; PHASE-II; GROWTH; ERBB2; HERCEPTIN; EXPRESSION	Lapatinib is a human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitor (TKI) that has clinical activity in HER2-amplified breast cancer. In vitro studies have shown that lapatinib enhances the effects of the monoclonal antibody trastuzumab suggesting partially non-overlapping mechanisms of action. To dissect these mechanisms, we have studied the effects of lapatinib and trastuzumab on receptor expression and receptor signaling and have identified a new potential mechanism for the enhanced antitumor activity of the combination. Lapatinib, given alone or in combination with trastuzumab to HER2-overexpressing breast cancer cells SKBR3 and MCF7-HER2, inhibited HER2 phosphorylation, prevented receptor ubiquitination and resulted in a marked accumulation of inactive receptors at the cell surface. By contrast, trastuzumab alone caused enhanced HER2 phosphorylation, ubiquitination and degradation of the receptor. By immunoprecipitation and computational protein modeling techniques we have shown that the lapatinib-induced HER2 accumulation at the cell surface also results in the stabilization of inactive HER2 homo- (HER2/HER2) and hetero- (HER2/EGFR and HER2/HER3) dimers. Lapatinib-induced accumulation of HER2 and trastuzumab-mediated downregulation of HER2 was also observed in vivo, where the combination of the two agents triggered complete tumor remissions in all cases after 10 days of treatment. Accumulation of HER2 at the cell surface by lapatinib enhanced immune-mediated trastuzumab-dependent cytotoxicity. We propose that this is a novel mechanism of action of the combination that may be clinically relevant and exploitable in the therapy of patients with HER2-positive tumors.	[Scaltriti, M.; Guzman, M.; Parra, J. L.; Pedersen, K.; Arribas, J.; Baselga, J.] Vall Hebron Univ Hosp, Dept Med Oncol, Vall Hebron Res Inst, Barcelona 08035, Spain; [Verma, C.; Smith, D. J.] Bioinformat Inst, Biomol Modeling & Design Grp, Singapore, Singapore; [Jimenez, J.; Landolfi, S.; Ramon y Cajal, S.] Vall Hebron Univ Hosp, Dept Pathol, Barcelona 08035, Spain; [Baselga, J.] Univ Autonoma Barcelona, E-08193 Barcelona, Spain	Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Agency for Science Technology & Research (A*STAR); A*STAR - Bioinformatics Institute (BII); Hospital Universitari Vall d'Hebron; Autonomous University of Barcelona	Baselga, J (corresponding author), Vall Hebron Univ Hosp, Dept Med Oncol, Vall Hebron Res Inst, Paseo Vall Hebron 119-129, Barcelona 08035, Spain.	jbaselga@vhebron.net	Arribas, Joaquin/M-4482-2014; 高, 雨莉/HGU-8187-2022; Ramon y Cajal, Santiago/H-4955-2016	Arribas, Joaquin/0000-0002-0504-0664; Ramon y Cajal, Santiago/0000-0002-3867-1390; Landolfi, Stefania/0000-0002-1059-635X; Jimenez, Jose/0000-0002-2576-1776	Breast Cancer Research Foundation; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	Breast Cancer Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in full by a grant of the Breast Cancer Research Foundation.	Anido J, 2003, CLIN CANCER RES, V9, P1274; Arteaga CL, 1997, J BIOL CHEM, V272, P23247, DOI 10.1074/jbc.272.37.23247; Austin CD, 2004, MOL BIOL CELL, V15, P5268, DOI 10.1091/mbc.E04-07-0591; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Baselga J, 1998, CANCER RES, V58, P2825; Baselga J., 2006, J CLIN ONCOL, V24, P3006; Baselga J, 2006, SCIENCE, V312, P1175, DOI 10.1126/science.1125951; Bleeker WK, 2004, J IMMUNOL, V173, P4699, DOI 10.4049/jimmunol.173.7.4699; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Chu I, 2005, CANCER RES, V65, P18; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Cuello M, 2001, CANCER RES, V61, P4892; Diermeier S, 2005, EXP CELL RES, V304, P604, DOI 10.1016/j.yexcr.2004.12.008; Gan HK, 2007, J BIOL CHEM, V282, P2840, DOI 10.1074/jbc.M605136200; Gennari R, 2004, CLIN CANCER RES, V10, P5650, DOI 10.1158/1078-0432.CCR-04-0225; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; Henson ES, 2006, CLIN CANCER RES, V12, P845, DOI 10.1158/1078-0432.CCR-05-0754; Hommelgaard AM, 2004, MOL BIOL CELL, V15, P1557, DOI 10.1091/mbc.E03-08-0596; Huang SM, 2004, CANCER RES, V64, P5355, DOI 10.1158/0008-5472.CAN-04-0562; Izumi Y, 2002, NATURE, V416, P279, DOI 10.1038/416279b; Johns TG, 2003, P NATL ACAD SCI USA, V100, P15871, DOI 10.1073/pnas.2036503100; Kim JY, 2003, J NEUROSCI, V23, P5561; Klapper LN, 2000, CANCER RES, V60, P3384; Konecny GE, 2006, CANCER RES, V66, P1630, DOI 10.1158/0008-5472.CAN-05-1182; Li X, 2007, CANCER RES, V67, P8716, DOI 10.1158/0008-5472.CAN-06-3731; Lichtner RB, 2001, CANCER RES, V61, P5790; Longva KE, 2005, INT J CANCER, V116, P359, DOI 10.1002/ijc.21015; Lu Y, 2007, CANCER RES, V67, P8240, DOI 10.1158/0008-5472.CAN-07-0589; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; Marty M, 2005, J CLIN ONCOL, V23, P4265, DOI 10.1200/JCO.2005.04.173; Matar P, 2004, CLIN CANCER RES, V10, P6487, DOI 10.1158/1078-0432.CCR-04-0870; Milella M, 2004, CLIN CANCER RES, V10, P7747, DOI 10.1158/1078-0432.CCR-04-0908; Mimura K, 2005, CLIN CANCER RES, V11, P4898, DOI 10.1158/1078-0432.CCR-04-2476; Musolino A, 2008, J CLIN ONCOL, V26, P1789, DOI 10.1200/JCO.2007.14.8957; OSHAUGHNESSY J, 2008, J CLIN ONCOL S, V26; Ozcelik C, 2002, P NATL ACAD SCI USA, V99, P8880, DOI 10.1073/pnas.122249299; Perera RM, 2005, CLIN CANCER RES, V11, P6390, DOI 10.1158/1078-0432.CCR-04-2653; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Rusnak DW, 2001, MOL CANCER THER, V1, P85; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Scaltriti M, 2007, J NATL CANCER I, V99, P628, DOI 10.1093/jnci/djk134; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; Serra V, 2008, CANCER RES, V68, P8022, DOI 10.1158/0008-5472.CAN-08-1385; SLAMON D, 2005, 28 ANN SAN ANT BREAS; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sliwkowski MX, 1999, SEMIN ONCOL, V26, P60; Tang Y, 2007, J IMMUNOL, V179, P2815, DOI 10.4049/jimmunol.179.5.2815; Tseng PH, 2006, MOL PHARMACOL, V70, P1534, DOI 10.1124/mol.106.023911; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Valabrega G, 2005, ONCOGENE, V24, P3002, DOI 10.1038/sj.onc.1208478; Wang ZX, 1999, MOL BIOL CELL, V10, P1621, DOI 10.1091/mbc.10.5.1621; Wolpoe ME, 2003, J IMMUNOL, V171, P2161, DOI 10.4049/jimmunol.171.4.2161; Wood ER, 2004, CANCER RES, V64, P6652, DOI 10.1158/0008-5472.CAN-04-1168; Xia WL, 2005, ONCOGENE, V24, P6213, DOI 10.1038/sj.onc.1208774; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yuste L, 2005, CANCER RES, V65, P6801, DOI 10.1158/0008-5472.CAN-04-4023; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013; ZHENG JH, 1993, ACTA CRYSTALLOGR D, V49, P362, DOI 10.1107/S0907444993000423	62	305	314	2	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	6					803	814		10.1038/onc.2008.432	http://dx.doi.org/10.1038/onc.2008.432			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406UI	19060928				2022-12-17	WOS:000263320000003
J	Grassmann, R; Aboud, M; Jeang, KT				Grassmann, R; Aboud, M; Jeang, KT			Molecular mechanisms of cellular transformation by HTLV-1 Tax	ONCOGENE			English	Review						HTLV; leukemia; T-lymphocyte; cell cycle; transformation; immortalization; Tax; ATLL apoptosis	VIRUS TYPE-I; NF-KAPPA-B; HUMAN T-CELLS; INTERLEUKIN-2 GENE-EXPRESSION; PRIMARY HUMAN-LYMPHOCYTES; TUMOR-SUPPRESSOR GENES; ACUTE MYELOID-LEUKEMIA; CREB BINDING-PROTEIN; LONG TERMINAL REPEAT; ONCOGENE PRODUCT TAX	The HTLV Tax protein is crucial for viral replication and for initiating malignant transformation leading to the development of adult T-cell leukemia. Tax has been shown to be oncogenic, since it transforms and immortalizes rodent. broblasts and human T-lymphocytes. Through CREB, NF-kappa B and SRF pathways Tax transactivates cellular promoters including those of cytokines (IL-13, IL-15), cytokine receptors (IL- 2R alpha) and costimulatory surface receptors (OX40/OX40L) leading to upregulated protein expression and activated signaling cascades ( e. g. Jak/STAT, PI3Kinase, JNK). Tax also stimulates cell growth by direct binding to cyclin-dependent kinase holenzymes and/or inactivating tumor suppressors (e.g. p53, DLG). Moreover, Tax silences cellular checkpoints, which guard against DNA structural damage and chromosomal missegregation, thereby favoring the manifestation of a mutator phenotype in cells.	Univ Erlangen Nurnberg, Inst Klin & Mol Virol, Erlangen, Germany; Ben Gurion Univ Negev, Dept Microbiol, IL-84105 Beer Sheva, Israel; NIAID, Mol Microbiol Lab, Bethesda, MD 20892 USA	University of Erlangen Nuremberg; Ben Gurion University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Grassmann, R (corresponding author), Univ Erlangen Nurnberg, Inst Klin & Mol Virol, Schlossgarten 4, Erlangen, Germany.	Ralph.Grassmann@viro.med.uni-erlangen.de	Jeang, Kuan-Teh/A-2424-2008		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000547, ZIAAI000547] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADYA N, 1995, J VIROL, V69, P1834, DOI 10.1128/JVI.69.3.1834-1841.1995; Akagi T, 1997, FEBS LETT, V406, P263, DOI 10.1016/S0014-5793(97)00280-9; Akagi T, 1997, ONCOGENE, V14, P2071, DOI 10.1038/sj.onc.1201045; AKAGI T, 1993, J VIROL, V67, P1211, DOI 10.1128/JVI.67.3.1211-1217.1993; AKAGI T, 1995, BLOOD, V86, P4243, DOI 10.1182/blood.V86.11.4243.bloodjournal86114243; Akagi T, 1996, ONCOGENE, V12, P1645; Ariumi Y, 2000, ONCOGENE, V19, P1491, DOI 10.1038/sj.onc.1203450; Arnulf B, 2002, BLOOD, V100, P4129, DOI 10.1182/blood-2001-12-0372; Azimi N, 1999, J IMMUNOL, V163, P4064; Azimi N, 1998, P NATL ACAD SCI USA, V95, P2452, DOI 10.1073/pnas.95.5.2452; Azran I, 2005, ONCOGENE, V24, P4521, DOI 10.1038/sj.onc.1208645; Azran Inbal, 2004, Retrovirology, V1, P20; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; Bartoe JT, 2000, J VIROL, V74, P1094, DOI 10.1128/JVI.74.3.1094-1100.2000; BAUM PR, 1994, EMBO J, V13, P3992, DOI 10.1002/j.1460-2075.1994.tb06715.x; Bex F, 1997, J VIROL, V71, P3484, DOI 10.1128/JVI.71.5.3484-3497.1997; Bex F, 1998, MOL CELL BIOL, V18, P2392, DOI 10.1128/MCB.18.4.2392; Brauweiler A, 1997, VIROLOGY, V231, P135, DOI 10.1006/viro.1997.8509; Byrd JC, 2002, BLOOD, V100, P4325, DOI 10.1182/blood-2002-03-0772; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; CARON C, 1993, EMBO J, V12, P4269, DOI 10.1002/j.1460-2075.1993.tb06111.x; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; Chiari E, 2004, J VIROL, V78, P11823, DOI 10.1128/JVI.78.21.11823-11832.2004; Ching Yick-Pang, 2004, Retrovirology, V1, P18, DOI 10.1186/1742-4690-1-18; Chlichlia K, 1997, ONCOGENE, V14, P2265, DOI 10.1038/sj.onc.1201070; CHLICHLIA K, 1995, ONCOGENE, V10, P269; Chlichlia K, 2002, ANTIOXID REDOX SIGN, V4, P471, DOI 10.1089/15230860260196263; Chowdhury IH, 2003, INT J CANCER, V107, P603, DOI 10.1002/ijc.11316; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Chung HK, 2003, BLOOD, V102, P4130, DOI 10.1182/blood-2003-04-1043; COPELAND KFT, 1994, AIDS RES HUM RETROV, V10, P1259, DOI 10.1089/aid.1994.10.1259; D'Agostino DM, 2002, J BIOL CHEM, V277, P34424, DOI 10.1074/jbc.M203023200; de la Fuente C, 2003, MOL CELL BIOCHEM, V245, P99, DOI 10.1023/A:1022866027585; Derse D, 1997, VIROLOGY, V237, P123, DOI 10.1006/viro.1997.8781; Ding W, 2002, J VIROL, V76, P10374, DOI 10.1128/JVI.76.20.10374-10382.2002; Duensing Stefan, 2003, Prog Cell Cycle Res, V5, P383; Endo K, 2002, J VIROL, V76, P2648, DOI 10.1128/JVI.76.6.2648-2653.2002; Etoh K, 1997, CANCER RES, V57, P4862; FLINT J, 1994, AM J HUM GENET, V55, P505; FUJITA M, 1995, ONCOGENE, V11, P15; Fung MM, 2005, ONCOGENE, V24, P4624, DOI 10.1038/sj.onc.1208507; Gabet AS, 2000, ONCOGENE, V19, P4954, DOI 10.1038/sj.onc.1203870; Gabet AS, 2003, ONCOGENE, V22, P3734, DOI 10.1038/sj.onc.1206468; GESSAIN A, 1985, LANCET, V2, P407; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; Good LF, 1996, EMBO J, V15, P3744, DOI 10.1002/j.1460-2075.1996.tb00744.x; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Haller K, 2002, MOL CELL BIOL, V22, P3327, DOI 10.1128/MCB.22.10.3327-3338.2002; Haller K, 2000, AIDS RES HUM RETROV, V16, P1683, DOI 10.1089/08892220050193146; Hangaishi A, 1996, BLOOD, V87, P4949, DOI 10.1182/blood.V87.12.4949.bloodjournal87124949; Haoudi A, 2003, VIROLOGY, V305, P229, DOI 10.1006/viro.2002.1642; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Harrod R, 2000, J BIOL CHEM, V275, P11852, DOI 10.1074/jbc.275.16.11852; Hatta Y, 2002, LEUKEMIA, V16, P1069, DOI 10.1038/sj.leu.2402458; Hirata A, 2004, VIROLOGY, V318, P327, DOI 10.1016/j.virol.2003.10.006; HOYOS B, 1989, SCIENCE, V244, P457, DOI 10.1126/science.2497518; Huang H, 1997, J IMMUNOL, V159, P3731; Iha H, 2003, ONCOGENE, V22, P8912, DOI 10.1038/sj.onc.1207058; INOUE H, 1994, EXP CELL RES, V215, P68, DOI 10.1006/excr.1994.1316; Iwanaga R, 2001, ONCOGENE, V20, P2055, DOI 10.1038/sj.onc.1204304; Iwanaga Y, 2002, J BIOL CHEM, V277, P31005, DOI 10.1074/jbc.M110666200; JEANG KT, 1988, J VIROL, V62, P4499, DOI 10.1128/JVI.62.12.4499-4509.1988; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jeang KT, 2001, CYTOKINE GROWTH F R, V12, P207, DOI 10.1016/S1359-6101(00)00028-9; Jeong SJ, 2005, J BIOL CHEM, V280, P10326, DOI 10.1074/jbc.M412643200; Jin DY, 1997, J BIOL CHEM, V272, P25816, DOI 10.1074/jbc.272.41.25816; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Jin DY, 1999, GENOMICS, V55, P363, DOI 10.1006/geno.1998.5654; Johnson JM, 2001, J VIROL, V75, P6086, DOI 10.1128/JVI.75.13.6086-6094.2001; Kao SY, 2000, ONCOGENE, V19, P2240, DOI 10.1038/sj.onc.1203559; Kao SY, 2001, VIROLOGY, V291, P292, DOI 10.1006/viro.2001.1200; Kasai T, 2002, J BIOL CHEM, V277, P5187, DOI 10.1074/jbc.M110295200; Kawakami A, 1999, BLOOD, V94, P3847, DOI 10.1182/blood.V94.11.3847.423a24_3847_3854; Kawata S, 2003, J VIROL, V77, P7291, DOI 10.1128/JVI.77.13.7291-7299.2003; Kehn K, 2005, ONCOGENE, V24, P525, DOI 10.1038/sj.onc.1208105; Kehn Kylene, 2004, Retrovirology, V1, P6, DOI 10.1186/1742-4690-1-6; Kelly-Welch AE, 2003, SCIENCE, V300, P1527, DOI 10.1126/science.1085458; KIM SJ, 1990, J EXP MED, V172, P121, DOI 10.1084/jem.172.1.121; Kirken RA, 2000, J IMMUNOL, V165, P5097, DOI 10.4049/jimmunol.165.9.5097; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee DK, 2002, J BIOL CHEM, V277, P33766, DOI 10.1074/jbc.M200150200; Lefebvre L, 2002, J VIROL, V76, P1400, DOI 10.1128/JVI.76.3.1400-1414.2002; Lemasson I, 1998, J BIOL CHEM, V273, P23598, DOI 10.1074/jbc.273.36.23598; Li JN, 2003, BIOCHEMISTRY-US, V42, P6921, DOI 10.1021/bi034369n; Liang MH, 2002, J VIROL, V76, P4022, DOI 10.1128/JVI.76.8.4022-4033.2002; Liu BY, 2005, P NATL ACAD SCI USA, V102, P63, DOI 10.1073/pnas.0406424101; Liu Y, 2001, ONCOGENE, V20, P2514, DOI 10.1038/sj.onc.1204364; Loeb KR, 2000, CARCINOGENESIS, V21, P379, DOI 10.1093/carcin/21.3.379; Low KG, 1997, J VIROL, V71, P1956, DOI 10.1128/JVI.71.3.1956-1962.1997; Majone F, 2000, J BIOL CHEM, V275, P32906, DOI 10.1074/jbc.C000538200; Margolis RL, 2003, J CELL BIOCHEM, V88, P673, DOI 10.1002/jcb.10411; Mariner JM, 2001, J IMMUNOL, V166, P2602, DOI 10.4049/jimmunol.166.4.2602; Marriott SJ, 2002, J BIOMED SCI, V9, P292, DOI 10.1159/000064998; Martino A, 2001, J IMMUNOL, V166, P1723, DOI 10.4049/jimmunol.166.3.1723; Matsumoto K, 1997, J VIROL, V71, P4445, DOI 10.1128/JVI.71.6.4445-4451.1997; MCGUIRE KL, 1993, J VIROL, V67, P1590, DOI 10.1128/JVI.67.3.1590-1599.1993; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; Miyazato A, 2005, J VIROL, V79, P9346, DOI 10.1128/JVI.79.14.9346-9350.2005; Moon JJ, 2004, J BIOL CHEM, V279, P5520, DOI 10.1074/jbc.M308998200; Mori N, 2001, BLOOD, V97, P2137, DOI 10.1182/blood.V97.7.2137; MORIN GB, 1991, NATURE, V353, P454, DOI 10.1038/353454a0; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Neuveut C, 1998, MOL CELL BIOL, V18, P3620, DOI 10.1128/MCB.18.6.3620; Neuveut C, 2002, FRONT BIOSCI-LANDMRK, V7, pD157, DOI 10.2741/neuveut; Ng PWP, 2001, ONCOGENE, V20, P4484, DOI 10.1038/sj.onc.1204513; Nicot C, 2000, BLOOD, V96, P275, DOI 10.1182/blood.V96.1.275.013k43_275_281; Nicot C, 2001, BLOOD, V98, P823, DOI 10.1182/blood.V98.3.823; Ohtani K, 2000, J BIOL CHEM, V275, P11154, DOI 10.1074/jbc.275.15.11154; Okada M, 2002, J VIROL, V76, P12564, DOI 10.1128/JVI.76.24.12564-12573.2002; OSAME M, 1986, LANCET, V1, P1031; Pankow R, 2000, J IMMUNOL, V165, P263, DOI 10.4049/jimmunol.165.1.263; Peloponese JM, 2004, J VIROL, V78, P11686, DOI 10.1128/JVI.78.21.11686-11695.2004; Perucho M, 1996, NAT MED, V2, P630, DOI 10.1038/nm0696-630; Philpott SM, 1999, J NATL CANCER I, V91, P933, DOI 10.1093/jnci/91.11.933; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; Pise-Masison CA, 2002, CANCER RES, V62, P3562; Pise-Masison CA, 2000, AIDS RES HUM RETROV, V16, P1669, DOI 10.1089/08892220050193128; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; Rasnick D, 2002, CANCER GENET CYTOGEN, V136, P66, DOI 10.1016/S0165-4608(01)00665-3; REID RL, 1993, ONCOGENE, V8, P3029; Robek MD, 1998, J VIROL, V72, P4458, DOI 10.1128/JVI.72.5.4458-4462.1998; Robek MD, 2000, J VIROL, V74, P11988, DOI 10.1128/JVI.74.24.11988-11992.2000; Rosin O, 1998, J BIOL CHEM, V273, P6698, DOI 10.1074/jbc.273.12.6698; Rousset R, 1998, ONCOGENE, V16, P643, DOI 10.1038/sj.onc.1201567; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; Ruckes T, 2001, BLOOD, V98, P1150, DOI 10.1182/blood.V98.4.1150; Santiago F, 1999, J VIROL, V73, P9917, DOI 10.1128/JVI.73.12.9917-9927.1999; Schmitt I, 1998, J VIROL, V72, P633, DOI 10.1128/JVI.72.1.633-640.1998; Scrable H J, 1990, Adv Cancer Res, V54, P25, DOI 10.1016/S0065-230X(08)60807-6; SEMMES OJ, 1995, J VIROL, V69, P1827, DOI 10.1128/JVI.69.3.1827-1833.1995; Semmes OJ, 1996, VIROLOGY, V217, P373, DOI 10.1006/viro.1996.0126; Semmes OJ, 1996, J VIROL, V70, P6347, DOI 10.1128/JVI.70.9.6347-6357.1996; Shankar DB, 2005, CANCER CELL, V7, P351, DOI 10.1016/j.ccr.2005.02.018; SMITH MR, 1991, J CLIN INVEST, V88, P1038, DOI 10.1172/JCI115364; Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276; Suzuki T, 1999, ONCOGENE, V18, P5967, DOI 10.1038/sj.onc.1203008; Suzuki T, 1999, VIROLOGY, V259, P384, DOI 10.1006/viro.1999.9760; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; Takemoto S, 2000, BLOOD, V95, P3939; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Torgeman A, 2001, EXP CELL RES, V271, P169, DOI 10.1006/excr.2001.5363; Tsukahara T, 1999, J VIROL, V73, P7981, DOI 10.1128/JVI.73.10.7981-7987.1999; Van Orden K, 1999, ONCOGENE, V18, P3766, DOI 10.1038/sj.onc.1202703; Van PL, 2001, J VIROL, V75, P396, DOI 10.1128/JVI.75.1.396-407.2001; Waldele K, 2004, J VIROL, V78, P6081, DOI 10.1128/JVI.78.12.6081-6090.2004; WILKIE AOM, 1990, NATURE, V346, P868, DOI 10.1038/346868a0; Xu X, 1996, ONCOGENE, V13, P135; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534	157	305	319	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2005	24	39					5976	5985		10.1038/sj.onc.1208978	http://dx.doi.org/10.1038/sj.onc.1208978			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960WH	16155604				2022-12-17	WOS:000231623400007
J	Davis, RL; Turner, DL				Davis, RL; Turner, DL			Vertebrate hairy and Enhancer of split related proteins: transcriptional repressors regulating cellular differentiation and embryonic patterning	ONCOGENE			English	Review						basic-helix-loop-helix; transcription; Notch; corepressor; hairy	LOOP-HELIX REPRESSOR; PROMOTES NEURONAL DIFFERENTIATION; SOMITE BOUNDARY FORMATION; CENTRAL-NERVOUS-SYSTEM; PAN-NEURAL GENE; LUNATIC-FRINGE; XENOPUS-EMBRYOS; PRESOMITIC MESODERM; NOTCH PATHWAY; FATE SPECIFICATION	The basic-helix-loop-helix (bHLH) proteins are a superfamily of DNA-binding transcription factors that regulate numerous biological processes in both invertebrates and vertebrates. One family of bRLH transcriptional repressors is related to the Drosophila hairy and Enhancer-of-split proteins. These repressors contain a tandem arrangement of the bHLH domain and an adjacent sequence known as the Orange domain, so we refer to these proteins as bHLH-Orange or bHLH-O proteins. Phylogenetic analysis reveals the existence of four bHLH-O subfamilies, with distinct, evolutionarily conserved features. A principal function of bHLH-O proteins is to bind to specific DNA sequences and recruit transcriptional corepressors to inhibit target gene expression. However, it is likely that bHLH-O proteins repress transcription by additional mechanisms as well. Many vertebrate bHLH-O proteins are effectors of the Notch signaling pathway, and bHLH-O proteins are involved in regulating neurogenesis, vasculogenesis, mesoderm segmentation, myogenesis, and T lymphocyte development. In this review, we discuss mechanisms of action and biological roles for the vertebrate bHLH-O proteins, as well as some of the unresolved questions about the functions and regulation of these proteins during development and in human disease.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Univ Michigan, Mental Hlth Res Inst, Ann Arbor, MI 48104 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48104 USA	Harvard University; Harvard Medical School; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Turner, DL (corresponding author), Neurosci Lab Bldg,1103 E Huron, Ann Arbor, MI 48104 USA.	dlturner@umich.edu						AKAZAWA C, 1992, J BIOL CHEM, V267, P21879; Alifragis P, 1997, P NATL ACAD SCI USA, V94, P13099, DOI 10.1073/pnas.94.24.13099; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Aulehla A, 1999, DEV BIOL, V207, P49, DOI 10.1006/dbio.1998.9164; Bae SK, 2000, DEVELOPMENT, V127, P2933; BAILEY AM, 1995, GENE DEV, V9, P2609, DOI 10.1101/gad.9.21.2609; Bally-Cuif L, 2000, GENE DEV, V14, P1664; Barrantes ID, 1999, CURR BIOL, V9, P470, DOI 10.1016/S0960-9822(99)80212-7; BAXEVANIS AD, 1993, CURR OPIN GENET DEV, V3, P278, DOI 10.1016/0959-437X(93)90035-N; Bessho Y, 2001, GENES CELLS, V6, P175, DOI 10.1046/j.1365-2443.2001.00409.x; BIER E, 1992, GENE DEV, V6, P2137, DOI 10.1101/gad.6.11.2137; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; Boudjelal M, 1997, GENE DEV, V11, P2052, DOI 10.1101/gad.11.16.2052; Castella P, 2000, MOL CELL BIOL, V20, P6170, DOI 10.1128/MCB.20.16.6170-6183.2000; Castella P, 1999, J NEUROSCI RES, V56, P229, DOI 10.1002/(SICI)1097-4547(19990501)56:3<229::AID-JNR2>3.0.CO;2-Z; Cau E, 2000, DEVELOPMENT, V127, P2323; Cau E, 1997, DEVELOPMENT, V124, P1611; Chen GQ, 2000, GENE, V249, P1, DOI 10.1016/S0378-1119(00)00161-X; Chen H, 1997, P NATL ACAD SCI USA, V94, P5355, DOI 10.1073/pnas.94.10.5355; Chin MT, 2000, J BIOL CHEM, V275, P6381, DOI 10.1074/jbc.275.9.6381; CHITNIS A, 1995, NATURE, V375, P761, DOI 10.1038/375761a0; CONLON RA, 1995, DEVELOPMENT, V121, P1533; Cooke J, 1998, TRENDS GENET, V14, P85, DOI 10.1016/S0168-9525(98)01396-1; COOKE J, 1975, NATURE, V254, P196, DOI 10.1038/254196a0; Crews ST, 1999, CURR OPIN GENET DEV, V9, P580, DOI 10.1016/S0959-437X(99)00003-9; Damen WGM, 2000, P NATL ACAD SCI USA, V97, P4515, DOI 10.1073/pnas.97.9.4515; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; Davis RL, 2001, DEV CELL, V1, P553, DOI 10.1016/S1534-5807(01)00054-5; DAWSON SR, 1995, MOL CELL BIOL, V15, P6923; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; Deblandre GA, 1999, DEVELOPMENT, V126, P4715; delaPompa J, 1997, DEVELOPMENT, V124, P1139; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Evrard YA, 1998, NATURE, V394, P377, DOI 10.1038/28632; FEDER JN, 1993, MOL CELL BIOL, V13, P105, DOI 10.1128/MCB.13.1.105; Fisher A, 1998, BIOESSAYS, V20, P298, DOI 10.1002/(SICI)1521-1878(199804)20:4&lt;298::AID-BIES6&gt;3.0.CO;2-M; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; Fisher AL, 1996, MOL CELL BIOL, V16, P2670; Forsberg H, 1998, CURR BIOL, V8, P1027, DOI 10.1016/S0960-9822(07)00424-1; Furukawa T, 2000, NEURON, V26, P383, DOI 10.1016/S0896-6273(00)81171-X; Gao XM, 2001, J CELL BIOL, V154, P1161, DOI 10.1083/jcb.200104058; Garriga-Canut M, 2001, J BIOL CHEM, V276, P14821, DOI 10.1074/jbc.M011619200; Giebel B, 1997, P NATL ACAD SCI USA, V94, P6250, DOI 10.1073/pnas.94.12.6250; Grbavec D, 1998, EUR J BIOCHEM, V258, P339, DOI 10.1046/j.1432-1327.1998.2580339.x; Grbavec D, 1996, BIOCHEM BIOPH RES CO, V223, P701, DOI 10.1006/bbrc.1996.0959; Handler M, 2000, DEVELOPMENT, V127, P2593; Henderson AM, 2001, J BIOL CHEM, V276, P6169, DOI 10.1074/jbc.M008506200; Hirata H, 2000, J BIOL CHEM, V275, P19083, DOI 10.1074/jbc.M001075200; Hirsinger E, 2001, DEVELOPMENT, V128, P107; Hojo M, 2000, DEVELOPMENT, V127, P2515; Holley SA, 2000, GENE DEV, V14, P1678; ISHIBASHI M, 1993, EUR J BIOCHEM, V215, P645, DOI 10.1111/j.1432-1033.1993.tb18075.x; ISHIBASHI M, 1994, EMBO J, V13, P1799, DOI 10.1002/j.1460-2075.1994.tb06448.x; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; Ito T, 2000, DEVELOPMENT, V127, P3913; Ivanova AV, 2001, J BIOL CHEM, V276, P15306, DOI 10.1074/jbc.M010516200; Izon DJ, 2001, IMMUNITY, V14, P253, DOI 10.1016/S1074-7613(01)00107-8; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; Jen WC, 1999, GENE DEV, V13, P1486, DOI 10.1101/gad.13.11.1486; Jen WC, 1997, DEVELOPMENT, V124, P1169; JENNINGS B, 1994, DEVELOPMENT, V120, P3537; Jennings BH, 1999, MOL CELL BIOL, V19, P4600; Jiang YJ, 1998, CURR BIOL, V8, pR868, DOI 10.1016/S0960-9822(07)00547-7; Jiang YJ, 2000, NATURE, V408, P475, DOI 10.1038/35044091; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; Jouve C, 2000, DEVELOPMENT, V127, P1421; Kageyama R, 2000, MOL CELLS, V10, P1, DOI 10.1007/s10059-000-0001-0; Kim HK, 1998, MOL CELL BIOL, V18, P7166, DOI 10.1128/MCB.18.12.7166; Kokubo H, 1999, BIOCHEM BIOPH RES CO, V260, P459, DOI 10.1006/bbrc.1999.0880; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Koyano-Nakagawa N, 2000, DEVELOPMENT, V127, P4203; Kuroda K, 1999, J BIOL CHEM, V274, P7238, DOI 10.1074/jbc.274.11.7238; LANGELAND JA, 1993, DEVELOPMENT, V117, P585; Lawrence P., 1992, MAKING FLY GENETICS; Lee JS, 1999, FEBS LETT, V455, P276, DOI 10.1016/S0014-5793(99)00901-1; Leimeister C, 2000, DEV BIOL, V227, P91, DOI 10.1006/dbio.2000.9884; Leimeister C, 2000, MECH DEVELOP, V98, P175, DOI 10.1016/S0925-4773(00)00459-7; Leimeister C, 1999, MECH DEVELOP, V85, P173, DOI 10.1016/S0925-4773(99)00080-5; Lin MH, 2000, DEVELOPMENT, V127, P2421; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; Maier MM, 2000, BIOCHEM BIOPH RES CO, V275, P652, DOI 10.1006/bbrc.2000.3354; McGrew MJ, 1998, CURR BIOL, V8, P979, DOI 10.1016/S0960-9822(98)70401-4; MEINHARDT H, 1986, SOMITES DEV EMBRYOS, P179; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Moore AW, 2000, P NATL ACAD SCI USA, V97, P10436, DOI 10.1073/pnas.170301897; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Nakagawa O, 1999, DEV BIOL, V216, P72, DOI 10.1006/dbio.1999.9454; Nakagawa O, 2000, P NATL ACAD SCI USA, V97, P13655, DOI 10.1073/pnas.250485597; Nellesen DT, 1999, DEV BIOL, V213, P33, DOI 10.1006/dbio.1999.9324; Nibu Y, 1998, SCIENCE, V280, P101, DOI 10.1126/science.280.5360.101; Nieto M, 2001, NEURON, V29, P401, DOI 10.1016/S0896-6273(01)00214-8; NYE JS, 1994, DEVELOPMENT, V120, P2421; OHSAKO S, 1994, GENE DEV, V8, P2743, DOI 10.1101/gad.8.22.2743; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; OKA C, 1995, DEVELOPMENT, V121, P3291; Palmeirim I, 1997, CELL, V91, P639, DOI 10.1016/S0092-8674(00)80451-1; Palmeirim I, 1998, DEV GENET, V23, P77, DOI 10.1002/(SICI)1520-6408(1998)23:1<77::AID-DVG8>3.0.CO;2-3; PARKHURST SM, 1990, CELL, V63, P1179, DOI 10.1016/0092-8674(90)90414-A; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Phippen TM, 2000, J BIOL CHEM, V275, P37628, DOI 10.1074/jbc.M004234200; Pissarra L, 2000, MECH DEVELOP, V95, P275, DOI 10.1016/S0925-4773(00)00348-8; Poortinga G, 1998, EMBO J, V17, P2067, DOI 10.1093/emboj/17.7.2067; Pourquie O, 2000, CURR TOP DEV BIOL, V47, P81; Pourquie O, 1999, CURR OPIN GENET DEV, V9, P559, DOI 10.1016/S0959-437X(99)00011-8; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; Rossner MJ, 1997, MOL CELL NEUROSCI, V9, P460, DOI 10.1006/mcne.1997.0640; Rostomily RC, 1997, CANCER RES, V57, P3526; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; Satow T, 2001, J NEUROSCI, V21, P1265; SCHNEIDER ML, 2001, IN PRESS MOL CELL NE, V18; Shawber C, 1996, DEVELOPMENT, V122, P3765; SOMMER RJ, 1993, NATURE, V361, P448, DOI 10.1038/361448a0; Stern CD, 2000, CURR TOP DEV BIOL, V47, P107; Stern CD, 1998, BIOESSAYS, V20, P528, DOI 10.1002/(SICI)1521-1878(199807)20:7<528::AID-BIES2>3.0.CO;2-G; Strom A, 1997, GENE DEV, V11, P3168, DOI 10.1101/gad.11.23.3168; Sun H, 2000, P NATL ACAD SCI USA, V97, P4058, DOI 10.1073/pnas.070526297; Sun Y, 2001, CELL, V104, P365, DOI 10.1016/S0092-8674(01)00224-0; TAKEBAYASHI K, 1994, J BIOL CHEM, V269, P5150; Takke C, 1999, DEVELOPMENT, V126, P3005; Takke C, 1999, DEVELOPMENT, V126, P1811; TIETZE K, 1992, P NATL ACAD SCI USA, V89, P6152, DOI 10.1073/pnas.89.13.6152; Tomita K, 2000, EMBO J, V19, P5460, DOI 10.1093/emboj/19.20.5460; Tomita K, 1999, GENE DEV, V13, P1203, DOI 10.1101/gad.13.9.1203; Tomita K, 1996, NEURON, V16, P723, DOI 10.1016/S0896-6273(00)80093-8; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; VANDOREN M, 1994, GENE DEV, V8, P2729, DOI 10.1101/gad.8.22.2729; Vasiliauskas D, 2000, MECH DEVELOP, V98, P133, DOI 10.1016/S0925-4773(00)00443-3; Wettstein DA, 1997, DEVELOPMENT, V124, P693; Wolfer A, 2001, NAT IMMUNOL, V2, P235, DOI 10.1038/85294; Yao J, 2001, MOL CELL BIOL, V21, P1962, DOI 10.1128/MCB.21.6.1962-1972.2001; YOUNGERSHEPHERD S, 1992, CELL, V70, P911, DOI 10.1016/0092-8674(92)90242-5; Zhang HL, 1999, P NATL ACAD SCI USA, V96, P535, DOI 10.1073/pnas.96.2.535; Zhang NA, 1998, NATURE, V394, P374, DOI 10.1038/28625; Zheng JL, 2000, DEVELOPMENT, V127, P4551; Zhong TP, 2000, SCIENCE, V287, P1820, DOI 10.1126/science.287.5459.1820	139	305	312	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 20	2001	20	58					8342	8357		10.1038/sj.onc.1205094	http://dx.doi.org/10.1038/sj.onc.1205094			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512HT	11840327				2022-12-17	WOS:000173319500008
J	Pettersson, K; Delaunay, F; Gustafsson, JA				Pettersson, K; Delaunay, F; Gustafsson, JA			Estrogen receptor beta acts as a dominant regulator of estrogen signaling	ONCOGENE			English	Article						ER alpha; ER beta; heterodimerization; agonists; antagonists	NUCLEAR HORMONE RECEPTORS; MESSENGER-RNA EXPRESSION; BREAST-CANCER; PROMOTER-CONTEXT; ER-BETA; GLUCOCORTICOID RECEPTOR; CELL-TYPE; ALPHA; TRANSCRIPTION; HETERODIMERS	The physiological effects of estrogens are mediated by two intracellular transcription factors, the estrogen receptors (ERs), that regulate transcription of target genes through binding to specific DNA target sequences. Here we describe alterations in cellular responses to different ER agonists and to the anti-estrogenic compound tamoxifen resulting from co-expression of the two ERs in transient co-transfection experiments. Our results demonstrate that ER beta can act as a negative or positive dominant regulator of ER activity. This is manifested through reduced transcriptional activity at low concentrations of estradiol (E-2); increased antagonistic effects of tamoxifen on E-2 stimulated activity; and enhanced agonistic action of the phytoestrogenic compound genistein, Furthermore, using chimeric proteins lacking the N-terminal activation function 1 (AF-1), we show that the differential responses of ER alpha and ER beta to different agonists and antagonists are primarily dictated by inherent differences in the C-terminal ligand-binding domains of the receptors, whereas the magnitude of transcriptional activity is influenced by ER alpha AF-1, but not ER beta AF-1, The ER alpha AF-1 activity appears to be modulated upon co-expression of both ERs, The alterations in transcriptional activity resulting from co-expression of ER alpha and ER beta are probably due to the formation of alpha/beta heterodimeric complexes, This study demonstrates that co-localization and subsequent heterodimerization of ER alpha and ER beta may result in receptor activity distinct from that of ER homodimers.	Karolinska Inst, Novum, Dept Med Nutr, S-14186 Huddinge, Sweden	Karolinska Institutet	Pettersson, K (corresponding author), Karolinska Inst, Novum, Dept Med Nutr, S-14186 Huddinge, Sweden.			Delaunay, Franck/0000-0003-4927-1701				Barkhem T, 1998, MOL PHARMACOL, V54, P105, DOI 10.1124/mol.54.1.105; Beato M, 1996, ANN NY ACAD SCI, V784, P93, DOI 10.1111/j.1749-6632.1996.tb16231.x; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; Chen SY, 1997, J BIOL CHEM, V272, P14087, DOI 10.1074/jbc.272.22.14087; Ciocca DR, 1997, TRENDS ENDOCRIN MET, V8, P313, DOI 10.1016/S1043-2760(97)00122-7; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; Dotzlaw H, 1999, CANCER RES, V59, P529; Farhat MY, 1996, FASEB J, V10, P615, DOI 10.1096/fasebj.10.5.8621060; FORMAN BM, 1995, ANN NY ACAD SCI, V761, P29, DOI 10.1111/j.1749-6632.1995.tb31366.x; Grohe C, 1997, FEBS LETT, V416, P107, DOI 10.1016/S0014-5793(97)01179-4; Grohe C, 1998, J ENDOCRINOL, V156, pR1, DOI 10.1677/joe.0.156R001; Gronemeyer H, 1995, PROTEIN PROFILE, V2, P1173; Hess RA, 1997, NATURE, V390, P509, DOI 10.1038/37352; HILLIER SG, 1989, J MOL ENDOCRINOL, V2, P39, DOI 10.1677/jme.0.0020039; Ingram D, 1997, LANCET, V350, P990, DOI 10.1016/S0140-6736(97)01339-1; Jordan VC, 1999, ENDOCR REV, V20, P253, DOI 10.1210/edrv.20.3.0368; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Kurzer MS, 1997, ANNU REV NUTR, V17, P353, DOI 10.1146/annurev.nutr.17.1.353; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; Leygue E, 1998, CANCER RES, V58, P3197; Li X, 1997, NEUROENDOCRINOLOGY, V66, P63, DOI 10.1159/000127221; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; McInerney EM, 1998, ENDOCRINOLOGY, V139, P4513, DOI 10.1210/en.139.11.4513; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; Perlmann T, 1996, MOL ENDOCRINOL, V10, P958, DOI 10.1210/me.10.8.958; Pettersson K, 1997, MOL ENDOCRINOL, V11, P1486, DOI 10.1210/me.11.10.1486; Saji S, 2000, P NATL ACAD SCI USA, V97, P337, DOI 10.1073/pnas.97.1.337; Sasano H, 1999, J CLIN ENDOCR METAB, V84, P781, DOI 10.1210/jc.84.2.781; Speirs V, 1999, CANCER RES, V59, P525; TRAPP T, 1994, NEURON, V13, P1457, DOI 10.1016/0896-6273(94)90431-6; Tremblay GB, 1999, MOL CELL BIOL, V19, P1919; Tremblay GB, 1997, MOL ENDOCRINOL, V11, P353, DOI 10.1210/me.11.3.353; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; Vanacker JM, 1999, EMBO J, V18, P4270, DOI 10.1093/emboj/18.15.4270; Watanabe T, 1997, BIOCHEM BIOPH RES CO, V236, P140, DOI 10.1006/bbrc.1997.6915; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605	39	305	315	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 12	2000	19	43					4970	4978		10.1038/sj.onc.1203828	http://dx.doi.org/10.1038/sj.onc.1203828			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363KF	11042684				2022-12-17	WOS:000089834300004
J	MARICS, I; ADELAIDE, J; RAYBAUD, F; MATTEI, MG; COULIER, F; PLANCHE, J; DELAPEYRIERE, O; BIRNBAUM, D				MARICS, I; ADELAIDE, J; RAYBAUD, F; MATTEI, MG; COULIER, F; PLANCHE, J; DELAPEYRIERE, O; BIRNBAUM, D			CHARACTERIZATION OF THE HST-RELATED FGF-6 GENE, A NEW MEMBER OF THE FIBROBLAST GROWTH-FACTOR GENE FAMILY	ONCOGENE			English	Article									INSERM, U119, 27 BD LEI ROURE, F-13009 MARSEILLE, FRANCE; HOP ENFANTS TIMONE, INSERM, U242, F-13385 MARSEILLE 5, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille			ADELAIDE, José JA/O-4390-2017; Coulier, François/G-6098-2015	ADELAIDE, José JA/0000-0003-4364-9857; Coulier, François/0000-0002-6288-7773; Birnbaum, Daniel/0000-0001-7920-9883				ADELAIDE J, 1988, ONCOGENE, V2, P413; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOVI PD, 1987, P NATL ACAD SCI USA, V84, P5660, DOI 10.1073/pnas.84.16.5660; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GOSPODAROWICZ D, 1987, J CELL PHYSIOL, P15; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; KODA T, 1987, JPN J CANCER RES, V78, P325; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; Maniatis T., 1982, MOL CLONING; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; NGUYEN C, 1988, ONCOGENE, V3, P703; NOGUCHI T, 1988, CANCER DETECT PREV, V12, P383; NOGUCHI T, 1987, EMBO J, V6, P1301, DOI 10.1002/j.1460-2075.1987.tb02368.x; PERUCHO M, 1981, CELL, V27, P467, DOI 10.1016/0092-8674(81)90388-3; RAYBAUD F, 1988, CANCER RES, V48, P950; SAKAMOTO H, 1988, BIOCHEM BIOPH RES CO, V151, P965, DOI 10.1016/S0006-291X(88)80460-1; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; Schwartz RM, 1978, ATLAS PROTEIN SEQ S3, P353; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; THEILLET C, IN PRESS CANCER CELL; TSUDA T, 1988, JPN J CANCER RES, V79, P584, DOI 10.1111/j.1349-7006.1988.tb00026.x; VARLEY JM, 1988, ONCOGENE, V3, P87; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; YUASA Y, 1987, JPN J CANCER RES, V78, P1036; ZHAN X, 1987, ONCOGENE, V1, P369; ZHAN X, 1986, MOL CELL BIOL, V6, P3541, DOI 10.1128/MCB.6.10.3541; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487; ZHOU DJ, 1988, ONCOGENE, V2, P279	33	305	326	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1989	4	3					335	340						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5676	2649847				2022-12-17	WOS:A1989U567600009
J	Singh, SS; Vats, S; Chia, AYQ; Tan, TZ; Deng, S; Ong, MS; Arfuso, F; Yap, CT; Goh, BC; Sethi, G; Huang, RYJ; Shen, HM; Manjithaya, R; Kumar, AP				Singh, Shikha Satendra; Vats, Somya; Chia, Amelia Yi-Qian; Tan, Tuan Zea; Deng, Shuo; Ong, Mei Shan; Arfuso, Frank; Yap, Celestial T.; Goh, Boon Cher; Sethi, Gautam; Huang, Ruby Yun-Ju; Shen, Han Ming; Manjithaya, Ravi; Kumar, Alan Prem			Dual role of autophagy in hallmarks of cancer	ONCOGENE			English	Review							HYPOXIA-INDUCED AUTOPHAGY; CELL-DEATH; EPIGENETIC REGULATION; LC3 CONJUGATION; COMPLEX; INHIBITION; INDUCTION; BECLIN-1; STRESS; TUMORIGENESIS	Evolutionarily conserved across eukaryotic cells, macroautophagy (herein autophagy) is an intracellular catabolic degradative process targeting damaged and superfluous cellular proteins, organelles, and other cytoplasmic components. Mechanistically, it involves formation of double-membrane vesicles called autophagosomes that capture cytosolic cargo and deliver it to lysosomes, wherein the breakdown products are eventually recycled back to the cytoplasm. Dysregulation of autophagy often results in various disease manifestations, including neurodegeneration, microbial infections, and cancer. In the case of cancer, extensive attention has been devoted to understanding the paradoxical roles of autophagy in tumor suppression and tumor promotion. In this review, while we summarize how this self-eating process is implicated at various stages of tumorigenesis, most importantly, we address the link between autophagy and hallmarks of cancer. This would eventually provide a better understanding of tumor dependence on autophagy. We also discuss how therapeutics targeting autophagy can counter various transformations involved in tumorigenesis. Finally, this review will provide a novel insight into the mutational landscapes of autophagy-related genes in several human cancers, using genetic information collected from an array of cancers.	[Singh, Shikha Satendra; Tan, Tuan Zea; Goh, Boon Cher; Huang, Ruby Yun-Ju; Kumar, Alan Prem] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore; [Singh, Shikha Satendra; Chia, Amelia Yi-Qian; Goh, Boon Cher; Sethi, Gautam; Kumar, Alan Prem] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pharmacol, Singapore, Singapore; [Vats, Somya; Manjithaya, Ravi] Jawaharlal Nehru Ctr Adv Sci Res, Mol Biol & Genet Unit, Bengaluru, Karnataka, India; [Deng, Shuo; Ong, Mei Shan; Yap, Celestial T.; Shen, Han Ming] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore, Singapore; [Arfuso, Frank] Curtin Univ, Curtin Hlth Innovat Res Inst, Sch Biomed Sci, Stem Cell & Canc Biol Lab, Perth, WA, Australia; [Goh, Boon Cher] Natl Univ Hlth Syst, Natl Univ Hosp, Dept Haematol Oncol, Singapore, Singapore; [Goh, Boon Cher; Kumar, Alan Prem] Natl Univ Hlth Syst, Natl Univ Canc Inst, Singapore, Singapore; [Sethi, Gautam] Curtin Univ, Curtin Hlth Innovat Res Inst, Sch Biomed Sci, Perth, WA, Australia; [Huang, Ruby Yun-Ju] Natl Univ Hlth Syst, Dept Obstet & Gynaecol, Singapore, Singapore; [Huang, Ruby Yun-Ju] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, Singapore, Singapore; [Shen, Han Ming] Natl Univ Singapore, NUS Grad Sch Integrat Sci & Engn, Singapore, Singapore; [Kumar, Alan Prem] Curtin Univ, Curtin Med Sch, Fac Hlth Sci, Perth, WA, Australia; [Kumar, Alan Prem] Natl Univ Singapore, Yong Loo Lin Sch Med, Med Sci Cluster, Singapore, Singapore	National University of Singapore; National University of Singapore; Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR); National University of Singapore; Curtin University; National University of Singapore; National University of Singapore; Curtin University; National University of Singapore; National University of Singapore; National University of Singapore; Curtin University; National University of Singapore	Kumar, AP (corresponding author), Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore.; Kumar, AP (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pharmacol, Singapore, Singapore.; Manjithaya, R (corresponding author), Jawaharlal Nehru Ctr Adv Sci Res, Mol Biol & Genet Unit, Bengaluru, Karnataka, India.; Kumar, AP (corresponding author), Natl Univ Hlth Syst, Natl Univ Canc Inst, Singapore, Singapore.; Kumar, AP (corresponding author), Curtin Univ, Curtin Med Sch, Fac Hlth Sci, Perth, WA, Australia.; Kumar, AP (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Med Sci Cluster, Singapore, Singapore.	ravim@jncasr.ac.in; csiapk@nus.edu.sg	Sethi, Gautam/F-2372-2011; Kumar, Alan Prem/ABE-7492-2020; SHEN, Han-Ming/B-5942-2011; Huang, Ruby Yun-Ju/AAE-8854-2019; Manjithaya, Ravi/T-4248-2019; Tan, Tuan Zea/I-9227-2019; Arfuso, Frank/H-8761-2014	Sethi, Gautam/0000-0002-8677-8475; Kumar, Alan Prem/0000-0002-3754-5712; SHEN, Han-Ming/0000-0001-7369-5227; Huang, Ruby Yun-Ju/0000-0001-6376-3185; Manjithaya, Ravi/0000-0002-0923-5485; Tan, Tuan Zea/0000-0001-6624-1593; Yap, Celestial T/0000-0003-0323-135X; Arfuso, Frank/0000-0001-7678-9472	National Medical Research Council of Singapore; NCIS Yong Siew Yoon Research Grant; Singapore Ministry of Education under its Research Centers of Excellence initiative to Cancer Science Institute of Singapore, National University of Singapore; Wellcome Trust/DBT India Alliance Intermediate Fellowship [509159/Z/09/Z]; JNCASR intramural funds; NUHS Basic seed grant [T1-BSRG 2015-02]; Ministry of Education Tier 1 grant; Cancer Council, Western Australia; National Medical Research Council Singapore (NMRC) [NMRC-CIRG/1346/2012, NMRC/CIRG/1373/2013]	National Medical Research Council of Singapore(National Medical Research Council, Singapore); NCIS Yong Siew Yoon Research Grant; Singapore Ministry of Education under its Research Centers of Excellence initiative to Cancer Science Institute of Singapore, National University of Singapore(Ministry of Education, SingaporeNational University of Singapore); Wellcome Trust/DBT India Alliance Intermediate Fellowship(Wellcome Trust DBT India Alliance); JNCASR intramural funds; NUHS Basic seed grant; Ministry of Education Tier 1 grant; Cancer Council, Western Australia(Cancer Council Western Australia); National Medical Research Council Singapore (NMRC)(National Medical Research Council, Singapore)	APK was supported by grants from National Medical Research Council of Singapore, NCIS Yong Siew Yoon Research Grant through donations from the Yong Loo Lin Trust and by the National Research Foundation Singapore and the Singapore Ministry of Education under its Research Centers of Excellence initiative to Cancer Science Institute of Singapore, National University of Singapore. This work was also supported by Wellcome Trust/DBT India Alliance Intermediate Fellowship (509159/Z/09/Z) and JNCASR intramural funds to RM. The JNCASR doctoral fellowship to SV is also acknowledged. We also thank Dr. Prathibha Ranganathan (Centre for Human Genetics, Bengaluru), Aparna Hebbar and members of Autophagy lab (JNCASR) for critical reading of the manuscript. This work was supported by NUHS Basic seed grant [T1-BSRG 2015-02] and Ministry of Education Tier 1 grant to GS. The John Nott Cancer Fellowship from Cancer Council, Western Australia also supported GS. This work is supported in part by National Medical Research Council Singapore (NMRC) grants (NMRC-CIRG/1346/2012 and NMRC/CIRG/1373/2013) to HMS.	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851; Ameisen JC, 2002, CELL DEATH DIFFER, V9, P367, DOI 10.1038/sj.cdd.4400950; B'chir W, 2013, NUCLEIC ACIDS RES, V41, P7683, DOI 10.1093/nar/gkt563; Bauckman KA, 2015, METHODS, V75, P120, DOI 10.1016/j.ymeth.2014.12.005; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Cavallaro U, 2000, J NEURO-ONCOL, V50, P63, DOI 10.1023/A:1006414621286; Chandra P, 2016, AUTOPHAGY, V12, P608, DOI 10.1080/15548627.2016.1139263; Chatterjee A, 2015, CANCER LETT, V360, P134, DOI 10.1016/j.canlet.2015.01.043; Chauhan S, 2013, MOL CELL, V50, P16, DOI 10.1016/j.molcel.2013.01.024; Chung YC, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/306705; Cianfanelli Valentina, 2015, Nat Cell Biol, V17, P706, DOI 10.1038/ncb3171; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Cook KL, 2011, EXPERT REV ANTICANC, V11, P1283, DOI [10.1586/era.11.111, 10.1586/ERA.11.111]; Copeland RA, 2009, NAT REV DRUG DISCOV, V8, P724, DOI 10.1038/nrd2974; Crazzolara R, 2009, BLOOD, V113, P3297, DOI 10.1182/blood-2008-02-137752; de Narvajas AAM, 2013, MOL CELL BIOL, V33, P3983, DOI 10.1128/MCB.00813-13; Dibble CC, 2013, NAT CELL BIOL, V15, P555, DOI 10.1038/ncb2763; DOI S, 1989, ARCH MICROBIOL, V151, P20; Dooley HC, 2014, MOL CELL, V55, P238, DOI 10.1016/j.molcel.2014.05.021; Eisenberg-Lerner A, 2009, APOPTOSIS, V14, P376, DOI 10.1007/s10495-008-0307-5; Errafiy R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083318; Eskelinen EL, 2005, AUTOPHAGY, V1, P1, DOI 10.4161/auto.1.1.1270; Eskelinen EL, 2003, TRENDS CELL BIOL, V13, P137, DOI 10.1016/S0962-8924(03)00005-9; Fernald K, 2013, TRENDS CELL BIOL, V23, P620, DOI 10.1016/j.tcb.2013.07.006; Filomeni G, 2015, CELL DEATH DIFFER, V22, P377, DOI 10.1038/cdd.2014.150; Fujita N, 2008, MOL BIOL CELL, V19, P2092, DOI 10.1091/mbc.E07-12-1257; Fullgrabe J, 2014, NAT REV MOL CELL BIO, V15, P65, DOI 10.1038/nrm3716; Fullgrabe J, 2013, NATURE, V500, P468, DOI 10.1038/nature12313; Furuya N, 2005, AUTOPHAGY, V1, P46, DOI 10.4161/auto.1.1.1542; Gallagher LE, 2013, ESSAYS BIOCHEM, V55, P1, DOI [10.1042/bse0550001, 10.1042/BSE0550001]; Ganley IG, 2013, ESSAYS BIOCHEM, V55, P65, DOI [10.1042/bse0550065, 10.1042/BSE0550065]; Gilmore AP, 2005, CELL DEATH DIFFER, V12, P1473, DOI 10.1038/sj.cdd.4401723; Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697; Guadamillas MC, 2011, J CELL SCI, V124, P3189, DOI 10.1242/jcs.072165; Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128; Guo JY, 2013, GENE DEV, V27, P1447, DOI 10.1101/gad.219642.113; Gutierrez MG, 2004, J CELL SCI, V117, P2687, DOI 10.1242/jcs.01114; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He SS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8839; Hsieh YY, 2016, AM J CANCER RES, V6, P1661; Hu YL, 2012, CANCER RES, V72, P1773, DOI 10.1158/0008-5472.CAN-11-3831; Huang R, 2015, MOL CELL, V57, P456, DOI 10.1016/j.molcel.2014.12.013; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Itakura E, 2012, CELL, V151, P1256, DOI 10.1016/j.cell.2012.11.001; Jain K, 2013, AM J CANCER RES, V3, P251; Jiang P, 2014, MOL BIOL CELL, V25, P1327, DOI 10.1091/mbc.E13-08-0447; Josset E, 2013, ANTICANCER RES, V33, P1845; Kanzawa T, 2003, CANCER RES, V63, P2103; Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707; Kenific CM, 2015, TRENDS CELL BIOL, V25, P37, DOI 10.1016/j.tcb.2014.09.001; Kenific CM, 2010, CURR OPIN CELL BIOL, V22, P241, DOI 10.1016/j.ceb.2009.10.008; Khaminets A, 2016, TRENDS CELL BIOL, V26, P6, DOI 10.1016/j.tcb.2015.08.010; Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152; Kim KW, 2013, AUTOPHAGY, V9, P1579, DOI 10.4161/auto.25987; Kim MJ, 2011, J BIOL CHEM, V286, P12924, DOI 10.1074/jbc.M110.138958; Kimmelman AC, 2011, GENE DEV, V25, P1999, DOI 10.1101/gad.17558811; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kohli L, 2013, CANCER RES, V73, P4395, DOI 10.1158/0008-5472.CAN-12-3765; Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023; Kung CP, 2011, CRIT REV EUKAR GENE, V21, P71, DOI 10.1615/CritRevEukarGeneExpr.v21.i1.50; Lamb CA, 2013, NAT REV MOL CELL BIO, V14, P759, DOI 10.1038/nrm3696; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Levine B, 2005, CELL, V120, P159, DOI 10.1016/j.cell.2005.01.005; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Li J, 2013, CARCINOGENESIS, V34, P1343, DOI 10.1093/carcin/bgt063; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Liu EY, 2012, J CELL SCI, V125, P2349, DOI 10.1242/jcs.093708; Liu YL, 2010, AUTOPHAGY, V6, P1057, DOI 10.4161/auto.6.8.13365; Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048; Mauvezin C, 2015, AUTOPHAGY, V11, P1437, DOI 10.1080/15548627.2015.1066957; Meadows KL, 2012, COLD SPRING HARB PER, P2; Milano V, 2009, MOL CANCER THER, V8, P394, DOI 10.1158/1535-7163.MCT-08-0669; MITCHENER JS, 1976, AM J PATHOL, V83, P485; Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207; Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028; MORTIMORE GE, 1977, NATURE, V270, P174, DOI 10.1038/270174a0; Motzer RJ, 2008, LANCET, V372, P449, DOI 10.1016/S0140-6736(08)61039-9; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nakatogawa H, 2013, ESSAYS BIOCHEM, V55, P39, DOI [10.1042/BSE0550039, 10.1042/bse0550039]; Nishikawa T, 2010, ANGIOGENESIS, V13, P227, DOI 10.1007/s10456-010-9180-2; Nixon RA, 2013, NAT MED, V19, P983, DOI 10.1038/nm.3232; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; Noguchi M, 2014, BBA-REV CANCER, V1846, P342, DOI 10.1016/j.bbcan.2014.07.013; Oberstein A, 2007, J BIOL CHEM, V282, P13123, DOI 10.1074/jbc.M700492200; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Qiang L, 2014, P NATL ACAD SCI USA, V111, P9241, DOI 10.1073/pnas.1322913111; Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497; Ramakrishnan S, 2007, AUTOPHAGY, V3, P512; Rebecca VW, 2016, ONCOGENE, V35, P1, DOI 10.1038/onc.2015.99; Roy S, 2010, SEMIN IMMUNOPATHOL, V32, P383, DOI 10.1007/s00281-010-0213-0; Russell RC, 2014, CELL RES, V24, P42, DOI 10.1038/cr.2013.166; Salazar M, 2009, J CLIN INVEST, V119, P1359, DOI 10.1172/JCI37948; Sancak Y, 2010, CELL, V141, P290, DOI 10.1016/j.cell.2010.02.024; Satoo K, 2009, EMBO J, V28, P1341, DOI 10.1038/emboj.2009.80; Schaaf MBE, 2016, FASEB J, V30, P3961, DOI 10.1096/fj.201600698R; Scott RC, 2004, DEV CELL, V7, P167, DOI 10.1016/j.devcel.2004.07.009; Selvakumaran M, 2013, CLIN CANCER RES, V19, P2995, DOI 10.1158/1078-0432.CCR-12-1542; Selvi BR, 2010, J BIOL CHEM, V285, P7143, DOI 10.1074/jbc.M109.063933; Settembre C, 2011, SCIENCE, V332, P1429, DOI 10.1126/science.1204592; Shao YF, 2004, P NATL ACAD SCI USA, V101, P18030, DOI 10.1073/pnas.0408345102; Shen Y, 2008, AUTOPHAGY, V4, P1067, DOI 10.4161/auto.6827; Shin HJR, 2016, NATURE, V534, P553, DOI 10.1038/nature18014; Simonsen A, 2009, J CELL BIOL, V186, P773, DOI 10.1083/jcb.200907014; Son JH, 2012, EXP MOL MED, V44, P89, DOI 10.3858/emm.2012.44.2.031; Son Yong, 2011, J Signal Transduct, V2011, P792639, DOI 10.1155/2011/792639; Song JR, 2009, AUTOPHAGY, V5, P1131, DOI 10.4161/auto.5.8.9996; Stolz A, 2014, NAT CELL BIOL, V16, P495, DOI 10.1038/ncb2979; Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350; Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634; Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211; Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009; Tooze SA, 2010, NAT CELL BIOL, V12, P831, DOI 10.1038/ncb0910-831; Wang J, 2014, J BIOL CHEM, V289, P17163, DOI 10.1074/jbc.M114.558288; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Wei FZ, 2015, AUTOPHAGY, V11, P2309, DOI 10.1080/15548627.2015.1117734; Wei HJ, 2011, GENE DEV, V25, P1510, DOI 10.1101/gad.2051011; White E, 2013, GENE DEV, V27, P2065, DOI 10.1101/gad.228122.113; White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262; Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111; Yang YP, 2013, ACTA PHARMACOL SIN, V34, P625, DOI 10.1038/aps.2013.5; Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047; Yazbeck VY, 2008, EXP HEMATOL, V36, P443, DOI 10.1016/j.exphem.2007.12.008; Zhai HY, 2015, ONCOTARGET, V6, P19735, DOI 10.18632/oncotarget.3771	131	304	310	6	107	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	9					1142	1158		10.1038/s41388-017-0046-6	http://dx.doi.org/10.1038/s41388-017-0046-6			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FY0MK	29255248				2022-12-17	WOS:000426505400002
J	Marmor, MD; Yarden, Y				Marmor, MD; Yarden, Y			Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases	ONCOGENE			English	Review						E3 ligase; endocytosis; growth factor; oncogene; signal transduction; tyrosine kinase; ubiquitin	EPIDERMAL-GROWTH-FACTOR; UBIQUITIN-INTERACTING MOTIF; LIGAND-INDUCED UBIQUITINATION; ERBB SIGNALING NETWORK; HRS-BINDING-PROTEIN; C-CBL; DOWN-REGULATION; EGF-RECEPTOR; MULTIVESICULAR-BODY; ADAPTER PROTEIN	Growth factors and their transmembrane receptor tyrosine kinases play pivotal roles in morphogenesis, cell fate determination and pathogenesis, including multiple stages of cancer. The amplitude and kinetics of signaling by growth factor receptors are determined by an endocytic process, which sorts activated, autophosphorylated receptors to degradation in lysosomes. Recent studies uncovered the role of protein ubiquitylation in vesicular trafficking of growth factor receptors. Decoration of ligand-activated receptors by multiple monomeric ubiquitins distinguishes this degradative route from the proteasome-mediated pathway, which involves polymeric chains of ubiquitin. Although receptor ubiquitylation occurs at the cell surface, its major role is to sort internalized receptors to the lumen of the multivesicular body, en route to the lysosome. The ubiquitin ligases that control this late sorting event belong to the Cbl family of RING finger adaptors, which bind specific phosphotyrosine residues in the receptors upon activation by ligand. Another group of E3 ubiquitin ligases, the Nedd4 family, regulates the initial sorting event, which targets receptors to clathrin-coated regions of the plasma membrane. This step entails ubiquitin-dependent assembly of a clathrin-binding complex of adaptors such as epsins, which share ubiquitin-interacting motifs. The concerted action of both ubiquitin-binding adaptors of membrane coats and E3 ligases, as well as their regulation by protein phosphorylation and ubiquitylation, ensure robust endocytosis of growth factor receptors. Genetic defects and virus-mediated manipulations of the endocytic pathway divert receptors to a default recycling pathway, thereby enabling unrestrained signaling characteristic to transformed cells.	Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Yarden, Y (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.	yosef.yarden@weizmann.ac.il	高, 雨莉/HGU-8187-2022; YARDEN, YOSEF/K-1467-2012		NATIONAL CANCER INSTITUTE [R37CA072981, R01CA072981] Funding Source: NIH RePORTER; NCI NIH HHS [CA72981] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amerik AY, 2000, MOL BIOL CELL, V11, P3365, DOI 10.1091/mbc.11.10.3365; Asao H, 1997, J BIOL CHEM, V272, P32785, DOI 10.1074/jbc.272.52.32785; Babst M, 2002, DEV CELL, V3, P283, DOI 10.1016/S1534-5807(02)00219-8; Babst M, 2000, TRAFFIC, V1, P248, DOI 10.1034/j.1600-0854.2000.010307.x; Bache KG, 2003, J CELL BIOL, V162, P435, DOI 10.1083/jcb.200302131; Bache KG, 2003, J BIOL CHEM, V278, P12513, DOI 10.1074/jbc.M210843200; Bao J, 2000, J BIOL CHEM, V275, P26178, DOI 10.1074/jbc.M002367200; Bao J, 2003, P NATL ACAD SCI USA, V100, P2438, DOI 10.1073/pnas.0437945100; Bartkiewicz M, 1999, J BIOL CHEM, V274, P30887, DOI 10.1074/jbc.274.43.30887; Baulida J, 1996, J BIOL CHEM, V271, P5251; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; Bilodeau PS, 2002, NAT CELL BIOL, V4, P534, DOI 10.1038/ncb815; Bishop N, 2002, J CELL BIOL, V157, P91, DOI 10.1083/jcb.200112080; Bishop N, 2001, J BIOL CHEM, V276, P11735, DOI 10.1074/jbc.M009863200; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Cadavid ALM, 2000, DEVELOPMENT, V127, P1727; Carbone R, 1997, CANCER RES, V57, P5498; Chen LY, 2002, TRAFFIC, V3, P110, DOI 10.1034/j.1600-0854.2002.030204.x; Chin LS, 2001, J BIOL CHEM, V276, P7069, DOI 10.1074/jbc.M004129200; Citri A, 2002, EMBO J, V21, P2407, DOI 10.1093/emboj/21.10.2407; Confalonieri S, 2000, J CELL BIOL, V150, P905, DOI 10.1083/jcb.150.4.905; Conibear E, 1998, BBA-MOL CELL RES, V1404, P211, DOI 10.1016/S0167-4889(98)00058-5; Courbard JR, 2002, J BIOL CHEM, V277, P45267, DOI 10.1074/jbc.M206460200; de Melker AA, 2001, J CELL SCI, V114, P2167; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; De Sepulveda P, 1999, EMBO J, V18, P904; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Di Fiore PP, 1999, CURR OPIN CELL BIOL, V11, P483, DOI 10.1016/S0955-0674(99)80069-6; Di Fiore PP, 2003, NAT REV MOL CELL BIO, V4, P491, DOI 10.1038/nrm1124; Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955-0674(03)00004-8; Donaldson KM, 2003, CURR BIOL, V13, P258, DOI 10.1016/S0960-9822(03)00043-5; Duan L, 2003, J BIOL CHEM, V278, P28950, DOI 10.1074/jbc.M304474200; Dunn R, 2001, J BIOL CHEM, V276, P25974, DOI 10.1074/jbc.M104113200; EBNER R, 1991, CELL REGUL, V2, P599, DOI 10.1091/mbc.2.8.599; Esters H, 2001, J MOL BIOL, V310, P141, DOI 10.1006/jmbi.2001.4735; Ettenberg SA, 2001, J BIOL CHEM, V276, P27677, DOI 10.1074/jbc.M102641200; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; Fiorini M, 2001, FEBS LETT, V490, P132, DOI 10.1016/S0014-5793(01)02116-0; Frederick L, 2000, CANCER RES, V60, P1383; Freed EO, 2003, TRENDS MICROBIOL, V11, P56, DOI 10.1016/S0966-842X(02)00013-6; FRENCH AR, 1994, J BIOL CHEM, V269, P15749; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Gayther SA, 1997, ONCOGENE, V15, P2119, DOI 10.1038/sj.onc.1201591; Govers P, 1998, J BIOL CHEM, V273, P16426, DOI 10.1074/jbc.273.26.16426; Govers R, 1999, EMBO J, V18, P28, DOI 10.1093/emboj/18.1.28; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Haglund K, 2002, P NATL ACAD SCI USA, V99, P12191, DOI 10.1073/pnas.192462299; Hall AB, 2003, CURR BIOL, V13, P308, DOI 10.1016/S0960-9822(03)00086-1; Hayakawa A, 2000, J BIOL CHEM, V275, P29636, DOI 10.1074/jbc.M002696200; Heilker R, 1999, BIOESSAYS, V21, P558, DOI 10.1002/(SICI)1521-1878(199907)21:7<558::AID-BIES4>3.0.CO;2-R; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hofmann K, 2001, TRENDS BIOCHEM SCI, V26, P347, DOI 10.1016/S0968-0004(01)01835-7; Jiang XJ, 2003, MOL BIOL CELL, V14, P858, DOI 10.1091/mbc.E02-08-0532; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kang RS, 2003, CELL, V113, P621, DOI 10.1016/S0092-8674(03)00362-3; Kato M, 2000, J BIOL CHEM, V275, P37481, DOI 10.1074/jbc.M007251200; Katz M, 2002, TRAFFIC, V3, P740, DOI 10.1034/j.1600-0854.2002.31006.x; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Katzmann DJ, 2003, J CELL BIOL, V162, P413, DOI 10.1083/jcb.200302136; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Kikonyogo A, 2001, P NATL ACAD SCI USA, V98, P11199, DOI 10.1073/pnas.201268998; Klapisz E, 2002, J BIOL CHEM, V277, P30746, DOI 10.1074/jbc.M203004200; Klapper LN, 1999, P NATL ACAD SCI USA, V96, P4995, DOI 10.1073/pnas.96.9.4995; Klapper LN, 2000, CANCER RES, V60, P3384; Komada M, 2001, BIOCHEM BIOPH RES CO, V281, P1065, DOI 10.1006/bbrc.2001.4441; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Lee MP, 1997, CANCER RES, V57, P3131; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Levkowitz G, 1996, ONCOGENE, V12, P1117; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Lin SY, 1998, J GASTROEN HEPATOL, V13, P1111, DOI 10.1111/j.1440-1746.1998.tb00585.x; Liu RT, 2002, ONCOGENE, V21, P4830, DOI 10.1038/sj.onc.1205612; Lloyd TE, 2002, CELL, V108, P261, DOI 10.1016/S0092-8674(02)00611-6; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Lu Q, 2003, P NATL ACAD SCI USA, V100, P7626, DOI 10.1073/pnas.0932599100; Madura K, 2002, CELL CYCLE, V1, P233, DOI 10.4161/cc.1.4.130; Marchese A, 2001, J BIOL CHEM, V276, P45509, DOI 10.1074/jbc.C100527200; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Meyer HH, 2002, EMBO J, V21, P5645, DOI 10.1093/emboj/cdf579; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Morrione A, 1999, J BIOL CHEM, V274, P24094, DOI 10.1074/jbc.274.34.24094; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; NESTEROV A, 1995, P NATL ACAD SCI USA, V92, P8719, DOI 10.1073/pnas.92.19.8719; Nesterov A, 1999, EMBO J, V18, P2489, DOI 10.1093/emboj/18.9.2489; Oldham CE, 2002, CURR BIOL, V12, P1112, DOI 10.1016/S0960-9822(02)00900-4; Orsini MJ, 1999, J BIOL CHEM, V274, P31076, DOI 10.1074/jbc.274.43.31076; Penengo L, 2003, ONCOGENE, V22, P3669, DOI 10.1038/sj.onc.1206585; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Peschard P, 2003, CANCER CELL, V3, P519, DOI 10.1016/S1535-6108(03)00136-3; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Pornillos O, 2002, EMBO J, V21, P2397, DOI 10.1093/emboj/21.10.2397; Pornillos O, 2003, J CELL BIOL, V162, P425, DOI 10.1083/jcb.200302138; Pornillos O, 2002, TRENDS CELL BIOL, V12, P569, DOI 10.1016/S0962-8924(02)02402-9; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Raiborg C, 2001, EMBO J, V20, P5008, DOI 10.1093/emboj/20.17.5008; Rubin C, 2003, CURR BIOL, V13, P297, DOI 10.1016/S0960-9822(03)00053-8; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; Santolini E, 1999, EXP CELL RES, V253, P186, DOI 10.1006/excr.1999.4694; Schmidt MHH, 2003, P NATL ACAD SCI USA, V100, P6505, DOI 10.1073/pnas.1031790100; Shekhtman A, 2002, BIOCHEM BIOPH RES CO, V296, P1222, DOI 10.1016/S0006-291X(02)02006-5; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Shih SC, 2003, EMBO J, V22, P1273, DOI 10.1093/emboj/cdg140; Shtiegman K, 2003, SEMIN CANCER BIOL, V13, P29, DOI 10.1016/S1044-579X(02)00097-4; SHU HKG, 1991, J VIROL, V65, P6173, DOI 10.1128/JVI.65.11.6173-6180.1991; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Springael JY, 1999, BIOCHEM BIOPH RES CO, V257, P561, DOI 10.1006/bbrc.1999.0505; Stang E, 2000, J BIOL CHEM, V275, P13940, DOI 10.1074/jbc.275.18.13940; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; STRAIGHT SW, 1995, J VIROL, V69, P3185, DOI 10.1128/JVI.69.5.3185-3192.1995; Sun W, 2003, J CELL BIOL, V162, P125, DOI 10.1083/jcb.200302083; Takata H, 2000, GENES CELLS, V5, P57, DOI 10.1046/j.1365-2443.2000.00303.x; Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0; Thien CBF, 2001, MOL CELL, V7, P355, DOI 10.1016/S1097-2765(01)00183-6; Thien CBF, 1997, ONCOGENE, V15, P2909, DOI 10.1038/sj.onc.1201468; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Torrisi MR, 1999, MOL BIOL CELL, V10, P417, DOI 10.1091/mbc.10.2.417; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; Tsygankov AY, 2001, ONCOGENE, V20, P6382, DOI 10.1038/sj.onc.1204781; Tzahar E, 1998, EMBO J, V17, P5948, DOI 10.1093/emboj/17.20.5948; Urbe S, 2000, MOL CELL BIOL, V20, P7685, DOI 10.1128/MCB.20.20.7685-7692.2000; vanDelft S, 1997, J CELL BIOL, V136, P811, DOI 10.1083/jcb.136.4.811; Vecchione A, 2003, MOL CELL BIOL, V23, P3363, DOI 10.1128/MCB.23.9.3363-3372.2003; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; Wendland B, 1998, J CELL BIOL, V141, P71, DOI 10.1083/jcb.141.1.71; Wilde A, 1999, CELL, V96, P677, DOI 10.1016/S0092-8674(00)80578-4; Wiley HS, 2001, TRAFFIC, V2, P12, DOI 10.1034/j.1600-0854.2001.020103.x; WILEY HS, 1991, J BIOL CHEM, V266, P11083; Wilhelmsen K, 2002, ONCOGENE, V21, P1079, DOI 10.1038/sj.onc.1205166; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; Wong A, 2002, P NATL ACAD SCI USA, V99, P6684, DOI 10.1073/pnas.052138899; Wong ESM, 2002, EMBO J, V21, P4796, DOI 10.1093/emboj/cdf493; Worthylake R, 1999, J BIOL CHEM, V274, P8865, DOI 10.1074/jbc.274.13.8865; Xu WP, 2002, P NATL ACAD SCI USA, V99, P12847, DOI 10.1073/pnas.202365899; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yokouchi M, 1999, ONCOGENE, V18, P759, DOI 10.1038/sj.onc.1202326; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Yokouchi M, 2001, J BIOL CHEM, V276, P35185, DOI 10.1074/jbc.M102219200; Zheng FF, 2000, CANCER RES, V60, P2090	155	304	317	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2004	23	11					2057	2070		10.1038/sj.onc.1207390	http://dx.doi.org/10.1038/sj.onc.1207390			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	803EC	15021893				2022-12-17	WOS:000220213400010
J	Krieg, M; Haas, R; Brauch, H; Acker, T; Flamme, I; Plate, KH				Krieg, M; Haas, R; Brauch, H; Acker, T; Flamme, I; Plate, KH			Up-regulation of hypoxia-inducible factors HIF-1 alpha and HIF-2 alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function	ONCOGENE			English	Article						von Hippel-Lindau (VHL) tumor suppressor; gene; hypoxia-inducible factors HIF-1 alpha and HIF-2 alpha; protein stability; renal clear cell carcinoma cell lines	ENDOTHELIAL GROWTH-FACTOR; PAS DOMAIN PROTEIN-1; TRANSCRIPTION FACTOR; MESSENGER-RNA; FACTOR-I; FACTOR 1-ALPHA; ALPHA-SUBUNIT; FACTOR-1-ALPHA; ACTIVATION; EXPRESSION	Hypoxia induces transcription of a range of physiologically important genes including erythropoietin and vascular endothelial growth factor. The transcriptional activation is mediated by the hypoxia-inducible factor-1 (HIF-1), a heterodimeric member of the basic helix-loop-helix PAS family, composed of alpha and beta subunits, HLF-1 alpha shares 48 per cent identity with the recently identified HIF-2 alpha protein that is also stimulated by hypoxia, In a previous study of hemangioblastomas, the most frequent manifestation of hereditary von Hippel-Lindau disease (VHL), we found elevated levels of vascular endothelial growth factor and HIF-2 alpha. mRNA in stromal cells of the tumors. Mutations of the VHL tumor suppressor gene are associated with a variety of tumors such as renal clear cell carcinomas (RCC), In this study, we analysed the expression of the hypoxia-inducible factors HIF-1 alpha and HIF-2 alpha in a range of VHL wildtype and VHL deficient RCC cell lines. In the presence of functional VHL protein, HIF-1 alpha mRNA levels are elevated, whereas HIF-2 alpha mRNA expression is increased only in cells lacking a functional VHL gene product. On the protein levels, however, in VHL deficient cell lines, both HIF-alpha subunits are constitutively expressed, whereas re-introduction of a functional VHL gene restores the instability of HIF-1 alpha and HIF-2 alpha proteins under normoxic conditions. Moreover, immunohistochemical analyses of RCCs and hemangioblastomas demonstrate up-regulation of HIF-1 alpha and HIF-2 alpha in the tumor cells. The data presented here provide evidence for a role of the VHL protein in regulation of angiogenesis and erythropoiesis mediated by the HIF-1 alpha and HIF-2 alpha proteins.	Univ Erlangen Nurnberg, Dept Neuropathol, D-91054 Erlangen, Germany; Univ Freiburg, Sch Med, Neuroctr, D-79106 Freiburg, Germany; Dr Margarete Fischer Bosch Inst Clin Pharmacol, D-70376 Stuttgart, Germany; Univ Cologne, Ctr Mol Biol & Med, D-50931 Cologne, Germany	University of Erlangen Nuremberg; University of Freiburg; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Cologne	Plate, KH (corresponding author), Univ Erlangen Nurnberg, Dept Neuropathol, Krankenhausstr 8-10, D-91054 Erlangen, Germany.			Acker, Till/0000-0001-6357-7227; Brauch, Hiltrud/0000-0001-7531-2736				Aso T, 1996, EMBO J, V15, P5557, DOI 10.1002/j.1460-2075.1996.tb00940.x; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Flamme I, 1997, MECH DEVELOP, V63, P51, DOI 10.1016/S0925-4773(97)00674-6; Flamme I, 1998, AM J PATHOL, V153, P25, DOI 10.1016/S0002-9440(10)65541-1; Glavac D, 1996, HUM GENET, V98, P271, DOI 10.1007/s004390050206; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; Gorospe M, 1999, MOL CELL BIOL, V19, P1289; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; NEUMANN HPH, 1995, BRAIN PATHOL, V5, P181, DOI 10.1111/j.1750-3639.1995.tb00592.x; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; PLATE KH, 1993, CANCER RES, V53, P5822; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 1998, J LAB CLIN MED, V131, P207, DOI 10.1016/S0022-2143(98)90091-9; Siemeister G, 1996, CANCER RES, V56, P2299; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Thrash-Bingham CA, 1999, JNCI-J NATL CANCER I, V91, P143, DOI 10.1093/jnci/91.2.143; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wenger RH, 1998, BLOOD, V91, P3471, DOI 10.1182/blood.V91.9.3471.3471_3471_3480; Wenger RH, 1997, KIDNEY INT, V51, P560, DOI 10.1038/ki.1997.79; Wenger RH, 1997, BIOL CHEM, V378, P609; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268	38	304	319	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	2000	19	48					5435	5443		10.1038/sj.onc.1203938	http://dx.doi.org/10.1038/sj.onc.1203938			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375JQ	11114720				2022-12-17	WOS:000165396100003
J	SOZERI, O; VOLLMER, K; LIYANAGE, M; FRITH, D; KOUR, G; MARK, GE; STABEL, S				SOZERI, O; VOLLMER, K; LIYANAGE, M; FRITH, D; KOUR, G; MARK, GE; STABEL, S			ACTIVATION OF THE C-RAF PROTEIN-KINASE BY PROTEIN-KINASE-C PHOSPHORYLATION	ONCOGENE			English	Note							TYROSINE PHOSPHORYLATION; GROWTH; CELLS; EXPRESSION; INSULIN; C-RAF-1; SERINE; RECEPTOR; PROTOONCOGENE; DEFINITION	The product of the c-raf-1 proto-oncogene is a cytoplasmic serine/threonine protein kinase that appears to be activated in signal transduction from a variety of cell-surface receptors. The mechanism of c-Raf activation upon stimulation of cell-surface receptors is not clear, but there seem to exist multiple pathways of activation which involve tyrosine and/or serine phosphorylation of the c-Raf protein in vivo. The activated state of Raf is reflected in an increased apparent molecular weight of the Raf protein in sodium dodecyl sulfate-polyacrylamide gels owing to hyperphosphorylation. The tumor promoter 12-O-tetradecanoyl phorbol 13-acetate (TPA) is one of the agents able to induce this hyperphosphorylation of Raf in vivo, suggesting that protein kinase C (PKC) may be involved in the activation of c-Raf in particular situations. Using recombinant baculoviruses expressing PKC and Raf polypeptides, we show here that conventional PKC types (alpha, beta, gamma) but not novel types (delta, zeta, eta) or the unrelated Mos kinase are able to activate c-Raf in a TPA-dependent manner upon coexpression in insect cells. Direct phosphorylation of the Raf protein with PKC in vitro also enhanced the kinase activity of c-Raf, suggesting that c-Raf acts immediately down-stream of PKC in a protein kinase cascade which is triggered by TPA and may lead to transcriptional activation of TPA-inducible genes and tumor promotion.	MAX PLANCK GESELL, MAX DELBRUCK LAB, CARL VON LINNE WEG 10, W-5000 COLOGNE 30, GERMANY; MERCK SHARP & DOHME LTD, RAHWAY, NJ 07065 USA; IMPERIAL CANC RES FUND, LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND	Max Planck Society; Merck & Company; Cancer Research UK								ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; BACCARINI M, 1991, J BIOL CHEM, V266, P10941; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; FREISEWINKEL I, 1991, FEBS LETT, V280, P262, DOI 10.1016/0014-5793(91)80307-O; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; IZUMI T, 1991, J BIOL CHEM, V266, P7933; JAMAL S, 1990, ANTURE, V344, P43; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; LEE RM, 1991, J BIOL CHEM, V266, P10351; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; LIYANAGE M, 1992, BIOCHEM J, V283, P781, DOI 10.1042/bj2830781; MOLDERS H, 1985, EMBO J, V4, P693, DOI 10.1002/j.1460-2075.1985.tb03685.x; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; PATEL G, 1989, CELL SIGNAL, V1, P227, DOI 10.1016/0898-6568(89)90040-5; PFEIFER AMA, 1989, P NATL ACAD SCI USA, V86, P10075, DOI 10.1073/pnas.86.24.10075; RAPP UR, 1991, ONCOGENE, V6, P495; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; SIEGFRIED Z, 1990, MOL CELL BIOL, V10, P6073, DOI 10.1128/MCB.10.11.6073; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; STABEL S, 1991, METHOD ENZYMOL, V200, P670; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; WASYLYK C, 1989, MOL CELL BIOL, V9, P247; WAYS DK, 1992, J BIOL CHEM, V267, P4799; WSIEGEL JN, 1990, J BIOL CHEM, V265, P18472; ZMUIDZINAS A, 1991, MOL CELL BIOL, V11, P2794, DOI 10.1128/MCB.11.5.2794	36	304	305	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1992	7	11					2259	2262						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437148				2022-12-17	WOS:A1992JW66500018
J	Schmidt, EV				Schmidt, EV			The role of c-myc in cellular growth control	ONCOGENE			English	Review						translation initiation; rDNA transcription; eIF4E; translational control	RIBOSOMAL-RNA SYNTHESIS; INITIATION-FACTOR 4E; TARGETED HOMOLOGOUS RECOMBINATION; RETINOBLASTOMA GENE-PRODUCT; POLYMERASE-I TRANSCRIPTION; FACTOR TIF-IA; TRANSLATION INITIATION; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; PROTEIN-SYNTHESIS	Cell division is coupled to cell growth. Since some c-myc target genes are regulators of cell growth while others function in cell division pathways, c-myc is apparently poised at the interface of these processes. Cell culture systems have shown specific myc-associated growth phenotypes, Increased cell growth precedes DNA synthesis after myc activation in cells expressing myc-estrogen receptor fuson constructs and cells lacking c-myc exhibit a marked loss of protein synthesis. A number of candidate c-myc target genes regulate processes required for cell growth including rRNA transcription and processing, ribosomal protein transcription and translation, and translation initiation. These interactions all have the potential to account for the growth phenotypes in c-myc mutant cells. The ability of translation initiation factors, including eIF4E, to transform cells makes them particularly interesting targets of c-myc. Further evaluation of these target genes will provide important insights into growth control and c-myc's functions in cellular proliferation.	Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Serv Pediat, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Schmidt, EV (corresponding author), Massachusetts Gen Hosp, Ctr Canc, Bldg 149,13th St, Charlestown, MA 02129 USA.				NATIONAL CANCER INSTITUTE [R01CA063117, R01CA069069] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA63117, R01-CA69069] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amati Bruno, 1998, Frontiers in Bioscience, V3, pD250; Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; Austen M, 1997, CURR TOP MICROBIOL, V224, P123; Avni D, 1997, NUCLEIC ACIDS RES, V25, P995, DOI 10.1093/nar/25.5.995; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BRENNER C, 1988, MOL CELL BIOL, V8, P3556, DOI 10.1128/MCB.8.8.3556; BROOME JD, 1981, CANCER TREAT REP, V65, P111; BROOME JD, 1961, NATURE, V191, P1114, DOI 10.1038/1911114a0; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; BUSSOLATI O, 1995, EXP CELL RES, V220, P283, DOI 10.1006/excr.1995.1317; BUTTGEREIT D, 1985, NUCLEIC ACIDS RES, V13, P8165, DOI 10.1093/nar/13.22.8165; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; CHUNG S, 1993, NUCLEIC ACIDS RES, V21, P3301, DOI 10.1093/nar/21.14.3301; COOPER HL, 1971, J BIOL CHEM, V246, P5059; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; Dang CV, 1997, J BIOENERG BIOMEMBR, V29, P345, DOI 10.1023/A:1022446730452; Datta PK, 1997, EXP CELL RES, V231, P198, DOI 10.1006/excr.1996.3446; Daugeron MC, 1998, RNA, V4, P566, DOI 10.1017/S1355838298980190; de la Cruz J, 1998, EMBO J, V17, P1128, DOI 10.1093/emboj/17.4.1128; DUDOV KP, 1983, BIOCHEM J, V210, P183, DOI 10.1042/bj2100183; DUNCAN R, 1985, J BIOL CHEM, V260, P5486; DUNCAN R, 1983, J BIOL CHEM, V258, P7228; EFIOK BJS, 1994, J BIOL CHEM, V269, P18921; EICHLER DC, 1994, PROG NUCLEIC ACID RE, V49, P197; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; Gaal T, 1997, SCIENCE, V278, P2092, DOI 10.1126/science.278.5346.2092; Gallant P, 1996, SCIENCE, V274, P1523, DOI 10.1126/science.274.5292.1523; Gallego C, 1997, EMBO J, V16, P7196, DOI 10.1093/emboj/16.23.7196; GEBALLE AP, 1996, TRANSLATIONAL CONTRO, P173; Ghosh AK, 1997, ONCOGENE, V14, P589, DOI 10.1038/sj.onc.1200866; Gourse RL, 1996, ANNU REV MICROBIOL, V50, P645, DOI 10.1146/annurev.micro.50.1.645; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; GRUMMT I, 1976, CELL, V7, P439, DOI 10.1016/0092-8674(76)90174-4; GRUMMT I, 1976, CELL, V7, P447, DOI 10.1016/0092-8674(76)90175-6; Hall DD, 1998, EMBO J, V17, P4370, DOI 10.1093/emboj/17.15.4370; HANICJOYCE PJ, 1987, J BIOL CHEM, V262, P2845; HANICJOYCE PJ, 1985, GENETICS, V110, P591; HANSON KD, 1994, MOL CELL BIOL, V14, P5748, DOI 10.1128/MCB.14.9.5748; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; HARIHARAN N, 1989, NUCLEIC ACIDS RES, V17, P5323, DOI 10.1093/nar/17.13.5323; HARIHARAN N, 1990, P NATL ACAD SCI USA, V87, P1526, DOI 10.1073/pnas.87.4.1526; HATEBOER G, 1993, P NATL ACAD SCI USA, V90, P8489, DOI 10.1073/pnas.90.18.8489; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; HUMBELIN M, 1989, GENE, V81, P315, DOI 10.1016/0378-1119(89)90192-3; JACOB ST, 1995, BIOCHEM J, V306, P617, DOI 10.1042/bj3060617; Johnston KA, 1998, MOL CELL BIOL, V18, P5621, DOI 10.1128/MCB.18.10.5621; Jones RM, 1996, MOL CELL BIOL, V16, P4754; KEREKATTE V, 1995, INT J CANCER, V64, P27, DOI 10.1002/ijc.2910640107; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kressler D, 1998, MOL CELL BIOL, V18, P1855, DOI 10.1128/MCB.18.4.1855; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LODISH HF, 1974, NATURE, V251, P385, DOI 10.1038/251385a0; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; MAHESWARAN S, 1991, ONCOGENE, V6, P1965; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Meyuhas Oded, 1996, V30, P363; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARDEE AB, 1978, ANNU REV BIOCHEM, V47, P715, DOI 10.1146/annurev.bi.47.070178.003435; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; PAUSE A, 1994, EMBO J, V13, P1205, DOI 10.1002/j.1460-2075.1994.tb06370.x; PERRY RP, 1990, ENZYME, V44, P83, DOI 10.1159/000468749; Polymenis M, 1997, GENE DEV, V11, P2522, DOI 10.1101/gad.11.19.2522; POLYMENIS M, 1998, UNPUB; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PROUTY SM, 1993, ONCOGENE, V8, P899; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; Rosenwald IB, 1996, CANCER LETT, V102, P113, DOI 10.1016/0304-3835(96)04171-7; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SAFRANY G, 1993, P NATL ACAD SCI USA, V90, P5559, DOI 10.1073/pnas.90.12.5559; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SCHNAPP A, 1990, EMBO J, V9, P2857, DOI 10.1002/j.1460-2075.1990.tb07475.x; Shama Silvian, 1995, Gene Expression, V4, P241; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHICHIRI M, 1993, CELL GROWTH DIFFER, V4, P93; Shim H, 1998, P NATL ACAD SCI USA, V95, P1511, DOI 10.1073/pnas.95.4.1511; Shors ST, 1998, J BIOL CHEM, V273, P34703, DOI 10.1074/jbc.273.52.34703; Shrivastava A, 1996, P NATL ACAD SCI USA, V93, P10638, DOI 10.1073/pnas.93.20.10638; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SOLLNERWEBB B, 1986, ANNU REV BIOCHEM, V55, P801, DOI 10.1146/annurev.biochem.55.1.801; SONENBERG N, 1994, BIOCHIMIE, V76, P839, DOI 10.1016/0300-9084(94)90185-6; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; STORY MD, 1993, CANCER CHEMOTH PHARM, V32, P129, DOI 10.1007/BF00685615; TARNOWKA MA, 1979, J CELL PHYSIOL, V99, P359, DOI 10.1002/jcp.1040990311; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; Voit R, 1997, MOL CELL BIOL, V17, P4230, DOI 10.1128/MCB.17.8.4230; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; Zaffran S, 1998, DEVELOPMENT, V125, P3571	105	303	313	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	1999	18	19					2988	2996		10.1038/sj.onc.1202751	http://dx.doi.org/10.1038/sj.onc.1202751			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197VZ	10378694				2022-12-17	WOS:000080387800008
J	Fojo, T; Bates, S				Fojo, T; Bates, S			Strategies for reversing drug resistance	ONCOGENE			English	Review						ABC transporters; p53; apoptosis; methylation; glutathione	P53 GENE-TRANSFER; PHASE-I TRIAL; CELL LUNG-CANCER; MEDIATED MULTIDRUG-RESISTANCE; ACUTE MYELOGENOUS LEUKEMIA; ACUTE MYELOID-LEUKEMIA; HUMAN TUMOR-CELLS; P-GLYCOPROTEIN; ANTISENSE OLIGONUCLEOTIDES; BUTHIONINE SULFOXIMINE	Drug resistance, intrinsic or acquired, is a problem for all chemotherapeutic agents. In this review, we examine numerous strategies that have been tested or proposed to reverse drug resistance. Included among these strategies are approaches targeting the apoptosis pathway. Although the process of apoptosis is complex, it provides several potential sites for therapeutic intervention. A variety of targets and approaches are being pursued, including the suppression of proteins inhibiting apoptosis using antisense oligonucleotides (ASOs), and small molecules targeted at proteins that modulate apoptosis. An alternate strategy is based on numerous studies that have documented methylation of critical regions in the genome in human cancers. Consequently, efforts have been directed at re-expressing genes, including genes that affect drug sensitivity, using 5-azacytidine and 2'-deoxy-5-azacytidine (DAC, decitabine) as demethylating agents. While this strategy may be effective as a single modality, success will most likely be achieved if it is used to modulate gene expression in combination with other modalities such as chemotherapy. At a more basic level, attempts have been made to modulate glutathione (GSH) levels. Owing to its reactivity and high intracellular concentrations, GSH has been implicated in resistance to several chemotherapeutic agents. Several approaches designed to deplete intracellular GSH levels have been pursued including the use of buthionine-(S, R)-sulfoxime (BSO), a potent and specific inhibitor of gamma-glutamyl cysteine synthetase (gamma-GCS), the rate-limiting step in the synthesis of GSH, a hammerhead ribozyme against gamma-GCS mRNA to downregulate specifically its levels and targeting cJun expression to reduce GSH levels. Alternate strategies have targeted p53. The frequent occurrence of p53 mutations in human cancer has led to the development of numerous approaches to restore wild-type (wt) p53. The goals of these interventions are to either revert the malignant phenotype or enhance drug sensitivity. The approach most extensively investigated has utilized one of several viral vectors. An alternate approach, the use of small molecules to restore wt function to mutant p53, remains an option. Finally, the conceptually simplest mechanism of resistance is one that reduces intracellular drug accumulation. Such reduction can be effected by a variety of drug efflux pumps, of which the most widely studied is P-glycoprotein (Pgp). The first strategy utilized to inhibit Pgp function relied on the identication of nonchemotherapeutic agents as competitors. Other approaches have included the use of hammerhead ribozymes against the MDR-1 gene and MDR-1-targeted ASOs. Although modulation of drug resistance has not yet been proven to be an effective clinical tool, we have learned an enormous amount about drug resistance. Should we succeed, these pioneering basic and clinical studies will have paved the road for future developments.	NCI, Ctr Canc Res, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Fojo, T (corresponding author), NCI, Ctr Canc Res, Bldg 10,Room 12C103,9000 Rockville Pike, Bethesda, MD 20892 USA.	tfojo@helix.nih.gov	Bates, Susan/AFP-9514-2022		NATIONAL CANCER INSTITUTE [Z01BC010620, ZIABC010620, Z01SC006732, ZIASC006732] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Advani R, 1999, BLOOD, V93, P787, DOI 10.1182/blood.V93.3.787.403k30_787_795; Aebi S, 1997, CLIN CANCER RES, V3, P1763; Aina OH, 2002, BIOPOLYMERS, V66, P184, DOI 10.1002/bip.10257; Avendano C, 2002, CURR MED CHEM, V9, P159, DOI 10.2174/0929867023371175; BAILEY HH, 1994, J CLIN ONCOL, V12, P194, DOI 10.1200/JCO.1994.12.1.194; Bailey HH, 1998, CHEM-BIOL INTERACT, V112, P239, DOI 10.1016/S0009-2797(97)00164-6; BARTLETT NL, 1994, J CLIN ONCOL, V12, P835, DOI 10.1200/JCO.1994.12.4.835; BARTON CM, 1995, BRIT J CANCER, V71, P429, DOI 10.1038/bjc.1995.88; Bender CM, 1998, CANCER RES, V58, P95; Benderra Z, 2000, EUR J CANCER, V36, P428, DOI 10.1016/S0959-8049(99)00288-9; Bergelson JM, 1998, J VIROL, V72, P415, DOI 10.1128/JVI.72.1.415-419.1998; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Blagosklonny MV, 1998, INT J CANCER, V75, P933, DOI 10.1002/(SICI)1097-0215(19980316)75:6<933::AID-IJC17>3.0.CO;2-3; Borst P, 2000, JNCI-J NATL CANCER I, V92, P1295, DOI 10.1093/jnci/92.16.1295; Borst P, 2000, BBA-MOL CELL BIOL L, V1486, P128, DOI 10.1016/S1388-1981(00)00053-6; Boulay JL, 2000, CANCER GENE THER, V7, P1215, DOI 10.1038/sj.cgt.7700227; Bourdon JC, 2002, J CELL BIOL, V158, P235, DOI 10.1083/jcb.200203006; Bouvet M, 1998, CANCER RES, V58, P2288; Bradshaw DM, 1998, J CLIN ONCOL, V16, P3674, DOI 10.1200/JCO.1998.16.11.3674; Brown R, 1997, ONCOGENE, V15, P45, DOI 10.1038/sj.onc.1201167; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chan JYW, 1999, LIFE SCI, V65, P63, DOI 10.1016/S0024-3205(99)00219-2; Chan JYW, 2000, LIFE SCI, V67, P2117, DOI 10.1016/S0024-3205(00)00798-0; Childs S, 1998, CANCER RES, V58, P4160; Clayman GL, 1999, CLIN CANCER RES, V5, P1715; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Dai J, 1999, BLOOD, V93, P268, DOI 10.1182/blood.V93.1.268.401a21_268_277; DAMERON KM, 1994, COLD SPRING HARB SYM, V59, P483, DOI 10.1101/SQB.1994.059.01.053; DANO K, 1973, BIOCHIM BIOPHYS ACTA, V323, P466, DOI 10.1016/0005-2736(73)90191-0; Dantzig AH, 1999, J PHARMACOL EXP THER, V290, P854; Dassow H, 2000, INT J CLIN PHARM TH, V38, P209; de Bruin M, 1999, CANCER LETT, V146, P117, DOI 10.1016/S0304-3835(99)00182-2; Dedoussis GVZ, 2001, EUR J CELL BIOL, V80, P608, DOI 10.1078/0171-9335-00193; Degterev A, 2001, NAT CELL BIOL, V3, P173, DOI 10.1038/35055085; Dix BR, 2001, J VIROL, V75, P5443, DOI 10.1128/JVI.75.12.5443-5447.2001; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; Durant ST, 1999, CURR BIOL, V9, P51, DOI 10.1016/S0960-9822(99)80047-5; Fakhrai H, 1996, P NATL ACAD SCI USA, V93, P2909, DOI 10.1073/pnas.93.7.2909; Fechner H, 1999, GENE THER, V6, P1520, DOI 10.1038/sj.gt.3301030; FEDELI L, 1989, CANCER, V64, P1805, DOI 10.1002/1097-0142(19891101)64:9<1805::AID-CNCR2820640908>3.0.CO;2-D; Fernandez-Salas E, 2002, MOL CELL BIOL, V22, P3610, DOI 10.1128/MCB.22.11.3610-3620.2002; Ferry DR, 1996, EUR J CANCER, V32A, P1070, DOI 10.1016/0959-8049(96)00091-3; FISHER GA, 1995, HEMATOL ONCOL CLIN N, V9, P363, DOI 10.1016/S0889-8588(18)30099-6; Fisher GA, 1996, EUR J CANCER, V32A, P1082, DOI 10.1016/0959-8049(96)00111-6; FORD JM, 1990, PHARMACOL REV, V42, P155; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Gao ZQ, 1999, INT J CANCER, V82, P346, DOI 10.1002/(SICI)1097-0215(19990730)82:3<346::AID-IJC7>3.0.CO;2-#; Gartenhaus RB, 2002, CLIN CANCER RES, V8, P566; Germann UA, 1997, ANTI-CANCER DRUG, V8, P141, DOI 10.1097/00001813-199702000-00005; GLOVER AB, 1987, CANCER TREAT REP, V71, P737; GODWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070, DOI 10.1073/pnas.89.7.3070; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; Hamel E, 2002, BIOPOLYMERS, V66, P142, DOI 10.1002/bip.10255; Heere-Ress E, 2002, INT J CANCER, V99, P29, DOI 10.1002/ijc.10248; Hipfner DR, 1999, BBA-BIOMEMBRANES, V1461, P359, DOI 10.1016/S0005-2736(99)00168-6; HOLM PS, 1994, BRIT J CANCER, V70, P239, DOI 10.1038/bjc.1994.286; HSIEH CL, 1994, MOL CELL BIOL, V14, P5487, DOI 10.1128/MCB.14.8.5487; Huesker M, 2002, HEPATOLOGY, V36, P874, DOI 10.1053/jhep.2002.35619; Irie A, 1997, Adv Pharmacol, V40, P207, DOI 10.1016/S1054-3589(08)60141-6; Jedlitschky G, 1996, CANCER RES, V56, P988; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; KERR DJ, 1986, CANCER CHEMOTH PHARM, V18, P239; Khuri FR, 2000, NAT MED, V6, P879, DOI 10.1038/78638; KIMURA S, 1995, CANCER RES, V55, P1379; Klasa RJ, 2002, ANTISENSE NUCLEIC A, V12, P193, DOI 10.1089/108729002760220798; KOBAYASHI H, 1994, CANCER RES, V54, P1271; Kornblau SM, 1997, J CLIN ONCOL, V15, P1796, DOI 10.1200/JCO.1997.15.5.1796; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; Kowalski P, 2002, CANCER GENE THER, V9, P579, DOI 10.1038/sj.cgt.7700471; KRAMER RA, 1988, SCIENCE, V241, P694, DOI 10.1126/science.3399900; LAI GM, 1991, INT J CANCER, V49, P688, DOI 10.1002/ijc.2910490511; Laing NM, 1998, CANCER RES, V58, P1332; Lee EJ, 1999, J CLIN ONCOL, V17, P2831, DOI 10.1200/JCO.1999.17.9.2831; Lehnert M, 1996, EUR J CANCER, V32A, P862, DOI 10.1016/0959-8049(96)00004-4; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; LIST AF, 1993, J CLIN ONCOL, V11, P1652, DOI 10.1200/JCO.1993.11.9.1652; List AF, 2001, BLOOD, V98, P3212, DOI 10.1182/blood.V98.12.3212; Liu C, 1996, CLIN SCI, V91, P93, DOI 10.1042/cs0910093; Loe DW, 1998, CANCER RES, V58, P5130; Lorico A, 2002, BIOCHEM BIOPH RES CO, V291, P617, DOI 10.1006/bbrc.2002.6489; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LUM BL, 1992, J CLIN ONCOL, V10, P1635, DOI 10.1200/JCO.1992.10.10.1635; Mackay HJ, 2000, J CLIN ONCOL, V18, P87, DOI 10.1200/JCO.2000.18.1.87; Maliepaard M, 2001, CLIN CANCER RES, V7, P935; McCormick F, 2001, NAT REV CANCER, V1, P130, DOI 10.1038/35101008; MILLWARD MJ, 1993, BRIT J CANCER, V67, P1031, DOI 10.1038/bjc.1993.189; Mistry P, 2001, CANCER RES, V61, P749; Miyake H, 2000, INT J CANCER, V86, P855, DOI 10.1002/(SICI)1097-0215(20000615)86:6<855::AID-IJC15>3.3.CO;2-#; Miyake K, 1999, CANCER RES, V59, P8; MIYASHITA T, 1995, CELL, V80, P293; Moller MB, 1999, CLIN CANCER RES, V5, P1085; Momparler RL, 1997, LEUKEMIA, V11, P175, DOI 10.1038/sj.leu.2400550; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; Nagata J, 2002, INT J ONCOL, V21, P1021; Nagata J, 2001, BIOCHEM BIOPH RES CO, V286, P406, DOI 10.1006/bbrc.2001.5399; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nemunaitis J, 2001, J CLIN ONCOL, V19, P289, DOI 10.1200/JCO.2001.19.2.289; Newman MJ, 2000, CANCER RES, V60, P2964; O'Neal WK, 1998, HUM GENE THER, V9, P1587, DOI 10.1089/hum.1998.9.11-1587; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Olie RA, 2001, DRUG RESIST UPDATE, V4, P9, DOI 10.1054/drup.2001.0181; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Plumb JA, 2000, CANCER RES, V60, P6039; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rabindran SK, 2000, CANCER RES, V60, P47; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; Relling MV, 1996, THER DRUG MONIT, V18, P350, DOI 10.1097/00007691-199608000-00006; Rizk NP, 1999, CANCER GENE THER, V6, P291, DOI 10.1038/sj.cgt.7700059; Robey R, 1999, BLOOD, V93, P306, DOI 10.1182/blood.V93.1.306.401k42_306_314; Rochlitz CF, 2001, SWISS MED WKLY, V131, P4; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; Rowinsky EK, 1998, J CLIN ONCOL, V16, P2964, DOI 10.1200/JCO.1998.16.9.2964; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; Solary E, 1996, BLOOD, V88, P1198, DOI 10.1182/blood.V88.4.1198.bloodjournal8841198; Song S, 1998, DRUG METAB DISPOS, V26, P1128; Sorrentino BR, 2002, NAT REV CANCER, V2, P431, DOI 10.1038/nrc823; Sparreboom A, 1999, ANTI-CANCER DRUG, V10, P719, DOI 10.1097/00001813-199909000-00005; Stewart A, 2000, CLIN CANCER RES, V6, P4186; Stewart AJ, 1996, BIOCHEM PHARMACOL, V51, P461, DOI 10.1016/0006-2952(95)02220-1; Strathdee G, 1999, ONCOGENE, V18, P2335, DOI 10.1038/sj.onc.1202540; Swisher SG, 1999, J NATL CANCER I, V91, P763, DOI 10.1093/jnci/91.9.763; Tamm I, 2001, LANCET, V358, P489, DOI 10.1016/S0140-6736(01)05629-X; Tango Y, 2002, HUM GENE THER, V13, P1373, DOI 10.1089/104303402760128595; TRUMP DL, 1992, JNCI-J NATL CANCER I, V84, P1811, DOI 10.1093/jnci/84.23.1811; TSURUO T, 1983, CANCER RES, V43, P2267; Tzung SP, 2001, NAT CELL BIOL, V3, P183, DOI 10.1038/35055095; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; Vahrmeijer AL, 2000, BIOCHEM PHARMACOL, V59, P1557, DOI 10.1016/S0006-2952(00)00286-0; van Zuylen L, 2000, CLIN CANCER RES, V6, P1365; Vernhet L, 2000, TOXICOLOGY, V142, P127; Vulevic B, 2001, CANCER RES, V61, P3339; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; WILSON WH, 1995, J CLIN ONCOL, V13, P1985, DOI 10.1200/JCO.1995.13.8.1985; YAO KS, 1995, CANCER RES, V55, P4367; YAO KS, 1993, CANCER RES, V53, P3662; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zangemeister-Wittke U, 2000, CLIN CANCER RES, V6, P2547	141	302	331	3	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2003	22	47					7512	7523		10.1038/sj.onc.1206951	http://dx.doi.org/10.1038/sj.onc.1206951			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KL	14576855				2022-12-17	WOS:000186112500020
J	Jiang, M; Milner, J				Jiang, M; Milner, J			Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference	ONCOGENE			English	Article						RNA interference; HPV 16; human cervical cancer	HUMAN-PAPILLOMAVIRUS TYPE-16; DOUBLE-STRANDED-RNA; MESSENGER-RNA; P53; PROTEIN; E6; DEGRADATION; INHIBITION	Selective silencing of mammalian gene expression has recently been achieved using short interfering RNA (siRNA). Synthetic siRNA targets homologous mRNA for degradation and the process is highly efficient. Here we demonstrate siRNA silencing of pathogenic viral gene expression. As a well characterized model we chose cervical carcinoma cells positive for human papillomavirus type 16. Over 90% of human cervical cancers are positive for papillomavirus and abnormal cell proliferation is driven by co-operative effects of viral E6 and E7 genes. We sought to silence HPV E6 and E7 gene expression using siRNAs to target the respective viral mRNAs. Our results indicate selective degradation of E6 and E7 mRNAs. Silencing was sustained for at least 4 days following a single dose of siRNA. E6 silencing induced accumulation of cellular p53 protein, transactivation of the cell cycle control p21 gene and reduced cell growth. In contrast, E7 silencing induced apoptotic cell death. HPV-negative cells appeared unaffected by the anti-viral siRNAs. Thus we demonstrate for the first time (i) that siRNA can induce selective silencing of exogenous viral genes in mammalian cells, and (ii) that the process of siRNA interference does not interfere with the recovery of cellular regulatory systems previously inhibited by viral gene expression.	Univ York, Dept Biol, YCR P53 Res Grp, York YO10 5DD, N Yorkshire, England	University of York - UK	Milner, J (corresponding author), Univ York, Dept Biol, YCR P53 Res Grp, York YO10 5DD, N Yorkshire, England.	ajm24@york.ac.uk		Jiang, Ming/0000-0003-3361-9881				Aguilar-Lemarroy A, 2002, ONCOGENE, V21, P165, DOI 10.1038/sj.onc.1204979; BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; BUTZ K, 1995, ONCOGENE, V10, P927; Butz K, 1996, INT J CANCER, V68, P506, DOI 10.1002/(SICI)1097-0215(19961115)68:4<506::AID-IJC17>3.0.CO;2-2; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Carthew RW, 2001, CURR OPIN CELL BIOL, V13, P244, DOI 10.1016/S0955-0674(00)00204-0; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gu W, 2002, J CELL BIOL, V156, P41, DOI 10.1083/jcb.200105133; Hengstermann A, 2001, P NATL ACAD SCI USA, V98, P1218, DOI 10.1073/pnas.031470698; Hietanen S, 2000, P NATL ACAD SCI USA, V97, P8501, DOI 10.1073/pnas.97.15.8501; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Knight SW, 2001, SCIENCE, V293, P2269, DOI 10.1126/science.1062039; Koromilas AE, 2001, CYTOKINE GROWTH F R, V12, P157, DOI 10.1016/S1359-6101(00)00023-X; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lipardi C, 2001, CELL, V107, P297, DOI 10.1016/S0092-8674(01)00537-2; McMurray HR, 2001, INT J EXP PATHOL, V82, P15, DOI 10.1046/j.1365-2613.2001.00177.x; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Novina CD, 2002, NAT MED, V8, P681, DOI 10.1038/nm725; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; STEELE C, 1993, CANCER RES, V53, P2330; Thomas M, 1999, ONCOGENE, V18, P7690, DOI 10.1038/sj.onc.1202953; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0	26	302	386	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2002	21	39					6041	6048		10.1038/sj.onc.1205878	http://dx.doi.org/10.1038/sj.onc.1205878			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203116				2022-12-17	WOS:000177671300007
J	Shimizu, S; Eguchi, Y; Kamiike, W; Waguri, S; Uchiyama, Y; Matsuda, H; Tsujimoto, Y				Shimizu, S; Eguchi, Y; Kamiike, W; Waguri, S; Uchiyama, Y; Matsuda, H; Tsujimoto, Y			Bcl-2 blocks loss of mitochondrial membrane potential while ICE inhibitors act at a different step during inhibition of death induced by respiratory chain inhibitors	ONCOGENE			English	Article						apoptosis; bcl-2; bcl-x; ICE; mitochondrial membrane potential; necrosis	PROGRAMMED CELL-DEATH; HUMAN FOLLICULAR LYMPHOMA; CHROMOSOMAL BREAKPOINT; GROWTH-FACTOR; GENE CED-3; APOPTOSIS; PROTEIN; HEPATOCYTES; EXPRESSION; ENZYME	Bcl-2, Bcl-x(L), CrmA and tetrapeptide ICE inhibitor reduce the extent of necrotic cell death induced by cyanide, which primarily damages mitochondria, Although none of them affects the drastic decrease in ATP levels induced by cyanide, Bcl-2 and Bcl-x(L) but not CrmA or ICE inhibitor inhibit the cyanide-induced decrease in mitochondrial membrane potential, A similar blocking effect is observed on necrotic cell death induced by other respiration inhibitors, rotenone and antimycin A, and on apoptotic cell death induced by etoposide or calcium ionophore. These results indicate that Bcl-2 and Bcl-x(L) protect mitochondria against the loss of function during both apoptosis and at least some forms of necrotic cell death, The ICE family proteases act at a different step other than the loss of mitochondrial membrane potential.	OSAKA UNIV,SCH MED,DEPT MED GENET,CTR BIOMED RES,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT ANAT 1,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT PHYSIOL 1,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,SUITA,OSAKA 565,JAPAN	Osaka University; Osaka University; Osaka University; Osaka University								AKAO Y, 1994, CANCER RES, V54, P2468; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BERGER ML, 1989, HEPATOLOGY, V9, P219, DOI 10.1002/hep.1840090210; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; DAVIES KJA, 1986, J BIOL CHEM, V261, P3060; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; GORES GJ, 1990, HEPATOLOGY, V11, P690, DOI 10.1002/hep.1840110425; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOEK JB, 1980, J BIOL CHEM, V255, P1458; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; JOHNSON LV, 1981, J CELL BIOL, V88, P526, DOI 10.1083/jcb.88.3.526; KANE AB, 1985, AM J PHYSIOL, V249, pC256, DOI 10.1152/ajpcell.1985.249.3.C256; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KANE DJ, 1995, J NEUROSCI RES, V40, P269, DOI 10.1002/jnr.490400216; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; KRONER H, 1986, BIOL CHEM H-S, V367, P483, DOI 10.1515/bchm3.1986.367.1.483; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LEMASTERS JJ, 1987, NATURE, V325, P78, DOI 10.1038/325078a0; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MAH SP, 1993, J NEUROCHEM, V60, P1183, DOI 10.1111/j.1471-4159.1993.tb03275.x; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PASTORINO JG, 1993, J BIOL CHEM, V268, P13791; PASTORINO JG, 1995, AM J PHYSIOL-CELL PH, V268, pC676, DOI 10.1152/ajpcell.1995.268.3.C676; PEZZELLA F, 1990, AM J PATHOL, V137, P225; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SHIMIZU S, 1996, IN PRESS ONCOGENE; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; TAGAWA K, 1988, CALCIUM DEPENDENT PR, P221; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Tsujimoto Y, 1996, Prog Mol Subcell Biol, V16, P72; TSUJIMOTO Y, 1989, ONCOGENE, V4, P1331; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WALKER JE, 1994, CURR OPIN STRUC BIOL, V4, P912, DOI 10.1016/0959-440X(94)90274-7; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533	58	302	304	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 4	1996	13	1					21	29						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700549				2022-12-17	WOS:A1996UX31900003
J	Knudsen, KE; Diehl, JA; Haiman, CA; Knudsen, ES				Knudsen, KE; Diehl, JA; Haiman, CA; Knudsen, ES			Cyclin D1: polymorphism, aberrant splicing and cancer risk	ONCOGENE			English	Review						cell cycle; cyclin-dependent kinase; alternative splicing; nuclear localization; retinoblastoma tumor suppressor	SQUAMOUS-CELL CARCINOMA; AGE-OF-ONSET; DEPENDENT-KINASE; RETINOBLASTOMA-PROTEIN; G870A POLYMORPHISM; ANDROGEN RECEPTOR; GENE POLYMORPHISM; MESSENGER-RNA; ALTERNATIVE TRANSCRIPTS; CCND1 POLYMORPHISM	The cyclin D1 proto-oncogene exercises powerful control over the mechanisms that regulate the mitotic cell cycle, and excessive cyclin D1 expression and/or activity is common in human cancers. Although somatic mutations of the cyclin D1 locus are rarely observed, mounting evidence demonstrates that a specific polymorphism of cyclin D1 (G/A870) and a protein product of a potentially related alternate splicing event (cyclin D1b) may influence cancer risk and outcome. Herein, we review the epidemiological and functional literatures that link these alterations of cyclin D1 to human tumor development and progression.	Univ Cincinnati, Ctr Canc, Ctr Environm Genet, Dept Cell Biol, Cincinnati, OH 45267 USA; Univ Penn, Abramson Family Canc Res Inst, Ctr Canc, Philadelphia, PA 19104 USA; Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA USA	University System of Ohio; University of Cincinnati; University of Pennsylvania; Pennsylvania Medicine; University of Southern California	Knudsen, KE (corresponding author), Univ Cincinnati, Ctr Canc, Ctr Environm Genet, Dept Cell Biol, 3125 Eden Ave, Cincinnati, OH 45267 USA.	erik.knudsen@uc.edu		Knudsen, Karen/0000-0002-1301-890X	NATIONAL CANCER INSTITUTE [R01CA099996, R01CA111360] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U01ES011038] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA099996, 1R01CA111360] Funding Source: Medline; NIEHS NIH HHS [U01-ES011038] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Bala S, 2001, CANCER RES, V61, P6042; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; Bergsagel PL, 2005, J CLIN ONCOL, V23, P6333, DOI 10.1200/JCO.2005.05.021; BETTICHER DC, 1995, ONCOGENE, V11, P1005; Bienvenu F, 2001, J BIOL CHEM, V276, P16840, DOI 10.1074/jbc.M100795200; Bigoni R, 1996, ONCOGENE, V13, P797; BOSCH F, 1994, BLOOD, V84, P2726; Buch S, 2005, MOL CARCINOGEN, V42, P222, DOI 10.1002/mc.20086; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Burd CJ, 2005, MOL ENDOCRINOL, V19, P607, DOI 10.1210/me.2004-0266; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; Canhoto AJ, 2000, ONCOGENE, V19, P5116, DOI 10.1038/sj.onc.1203893; Casson AG, 2005, CANCER-AM CANCER SOC, V104, P730, DOI 10.1002/cncr.21229; Catarino R, 2005, CANCER GENET CYTOGEN, V160, P49, DOI 10.1016/j.cancergencyto.2004.11.017; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Coqueret O, 2002, GENE, V299, P35, DOI 10.1016/S0378-1119(02)01055-7; Cortessis VK, 2003, CARCINOGENESIS, V24, P1645, DOI 10.1093/carcin/bgg128; Costea I, 2003, PHARMACOGENETICS, V13, P577, DOI 10.1097/00008571-200309000-00006; Deng L, 2002, ACTA BIOCH BIOPH SIN, V34, P16; DEWOLFPEETERS C, 1994, ANN ONCOL, V5, pS35, DOI 10.1093/annonc/5.suppl_1.S35; Dhar KK, 1999, INT J GYNECOL CANCER, V9, P342, DOI 10.1046/j.1525-1438.1999.99048.x; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 2002, CANCER BIOL THER, V1, P226, DOI 10.4161/cbt.72; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Dragnev KH, 2001, ANN NY ACAD SCI, V952, P13, DOI 10.1111/j.1749-6632.2001.tb02724.x; Dufourny B, 2000, J ENDOCRINOL, V166, P329, DOI 10.1677/joe.0.1660329; Ewen ME, 2004, TRENDS MOL MED, V10, P158, DOI 10.1016/j.molmed.2004.02.005; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Fry DW, 2004, MOL CANCER THER, V3, P1427; GEDDERT H, 2005, J CANCER RES CLIN, V131, P1; Gijtenbeek JMM, 2005, J NEURO-ONCOL, V74, P261, DOI 10.1007/s11060-004-7326-z; GILLETT C, 1994, CANCER RES, V54, P1812; Gladden AB, 2005, J CELL BIOCHEM, V96, P906, DOI 10.1002/jcb.20613; Grieu F, 2003, ANTICANCER RES, V23, P4257; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HERBER B, 1994, ONCOGENE, V9, P1295; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Holley SL, 2005, INT J CANCER, V114, P364, DOI 10.1002/ijc.20750; Holley SL, 2005, ORAL ONCOL, V41, P156, DOI 10.1016/j.oraloncology.2004.08.005; Holley SL, 2001, AM J PATHOL, V159, P1917, DOI 10.1016/S0002-9440(10)63038-6; Hong Y, 2005, EUR J CANCER, V41, P1037, DOI 10.1016/j.ejca.2005.01.009; Hosokawa Y, 1997, CANCER LETT, V113, P123, DOI 10.1016/S0304-3835(97)04605-3; HOSOKAWA Y, 1995, CANCER LETT, V93, P165, DOI 10.1016/0304-3835(95)03805-7; Hosokawa Y, 1999, INT J CANCER, V81, P616, DOI 10.1002/(SICI)1097-0215(19990517)81:4<616::AID-IJC18>3.3.CO;2-J; Hou XW, 2005, INT J HEMATOL, V82, P206, DOI 10.1532/IJH97.A10418; Howe D, 2001, HAEMATOLOGICA, V86, P563; Inoue K, 1998, MOL CELL BIOL, V18, P1590, DOI 10.1128/MCB.18.3.1590; Ito M, 2004, UROLOGY, V64, P74, DOI 10.1016/j.urology.2004.03.001; Jeffrey PD, 2000, GENE DEV, V14, P3115, DOI 10.1101/gad.851100; Jeon YT, 2005, CANCER LETT, V223, P259, DOI 10.1016/j.canlet.2004.12.024; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1992, CANCER RES, V52, P2980; KATO J, 1993, GENE DEV, V7, P331; KELLEY MJ, 1995, JNCI-J NATL CANCER I, V87, P756, DOI 10.1093/jnci/87.10.756; Keyomarsi K, 2002, NEW ENGL J MED, V347, P1566, DOI 10.1056/NEJMoa021153; Knudsen KE, 1999, CANCER RES, V59, P2297; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Koike H, 2003, ANTICANCER RES, V23, P4947; Kong SM, 2001, JNCI-J NATL CANCER I, V93, P1106, DOI 10.1093/jnci/93.14.1106; Kong SM, 2000, CANCER RES, V60, P249; Krippl P, 2003, BREAST CANCER RES TR, V82, P165, DOI 10.1023/B:BREA.0000004372.20461.33; Ladha MH, 1998, MOL CELL BIOL, V18, P6605, DOI 10.1128/MCB.18.11.6605; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; Lamb J, 2000, MOL CELL BIOL, V20, P8667, DOI 10.1128/MCB.20.23.8667-8675.2000; Le Marchand L, 2003, JAMA-J AM MED ASSOC, V290, P2843, DOI 10.1001/jama.290.21.2843; Leng XH, 2002, MOL CELL BIOL, V22, P2242, DOI 10.1128/MCB.22.7.2242-2254.2002; Lewis RC, 2003, CANCER RES, V63, P8549; Lin SK, 2000, MOL CELL BIOL, V20, P7903, DOI 10.1128/MCB.20.21.7903-7913.2000; Liu EB, 2004, J BIOL CHEM, V279, P17283, DOI 10.1074/jbc.C300549200; Liu F, 2005, CELL CYCLE, V4, P63, DOI 10.4161/cc.4.1.1366; Lu FM, 2003, CANCER RES, V63, P7056; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Matthias C, 1998, CLIN CANCER RES, V4, P2411; McKay JA, 2000, INT J CANCER, V88, P77, DOI 10.1002/1097-0215(20001001)88:1<77::AID-IJC12>3.0.CO;2-O; McMahon C, 1999, P NATL ACAD SCI USA, V96, P5382, DOI 10.1073/pnas.96.10.5382; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; Mumberg D, 1997, NUCLEIC ACIDS RES, V25, P2098, DOI 10.1093/nar/25.11.2098; Nishimoto IN, 2004, ORAL ONCOL, V40, P604, DOI 10.1016/j.oraloncology.2003.12.009; OTTERSON GA, 1994, ONCOGENE, V9, P3375; Oyama T, 1998, CANCER RES, V58, P2876; Pakakasama S, 2004, ONCOGENE, V23, P4789, DOI 10.1038/sj.onc.1207499; Palmero I, 1996, CANCER SURV, V27, P351; Petre CE, 2002, J BIOL CHEM, V277, P2207, DOI 10.1074/jbc.M106399200; Petre-Draviam CE, 2005, ONCOGENE, V24, P431, DOI 10.1038/sj.onc.1208200; Pibiri M, 2001, FASEB J, V15, P1006, DOI 10.1096/fj.00-0416com; Porter DC, 2001, MOL CELL BIOL, V21, P6254, DOI 10.1128/MCB.21.18.6254-6269.2001; Porter DC, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.23.e101; Porter TR, 2002, ONCOGENE, V21, P1928, DOI 10.1038/sj.onc.1205245; Qin CH, 2003, CANCER RES, V63, P958; Ratineau C, 2002, J BIOL CHEM, V277, P8847, DOI 10.1074/jbc.M110747200; Reutens AT, 2001, MOL ENDOCRINOL, V15, P797, DOI 10.1210/me.15.5.797; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; RYDZANICZ M, 2005, EUR ARCH OTORHINOLAR; Sabbah M, 1999, P NATL ACAD SCI USA, V96, P11217, DOI 10.1073/pnas.96.20.11217; Sanyal S, 2004, CARCINOGENESIS, V25, P729, DOI 10.1093/carcin/bgh058; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SHERR CJ, 1992, CIBA F SYMP, V170, P209; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Shi QL, 2003, CARCINOGENESIS, V24, P1499, DOI 10.1093/carcin/bgg035; Shu XO, 2005, CANCER EPIDEM BIOMAR, V14, P91; Simpson DJ, 2001, CARCINOGENESIS, V22, P1801, DOI 10.1093/carcin/22.11.1801; Solomon DA, 2003, J BIOL CHEM, V278, P30339, DOI 10.1074/jbc.M303969200; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Toogood PL, 2005, J MED CHEM, V48, P2388, DOI 10.1021/jm049354h; Wang LZ, 2003, INT J CANCER, V103, P116, DOI 10.1002/ijc.10793; Wang LZ, 2002, CARCINOGENESIS, V23, P257, DOI 10.1093/carcin/23.2.257; Wang Rui, 2003, Zhonghua Yi Xue Za Zhi, V83, P1089; WIERINGA B, 1983, NATURE, V301, P38, DOI 10.1038/301038a0; WINSTON JT, 1993, MOL BIOL CELL, V4, P1133, DOI 10.1091/mbc.4.11.1133; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; Wong YK, 2003, J ORAL PATHOL MED, V32, P265, DOI 10.1034/j.1600-0714.2003.00131.x; Yu JG, 2004, J UROLOGY, V172, P2410, DOI 10.1097/01.ju.0000138156.24384.16; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; Zatyka M, 2002, CANCER RES, V62, P3803; Zhang JH, 2003, INT J CANCER, V105, P281, DOI 10.1002/ijc.11067; ZHANG YJ, 1993, BIOCHEM BIOPH RES CO, V196, P1010, DOI 10.1006/bbrc.1993.2350; Zhang YJ, 2002, MOL CARCINOGEN, V33, P125, DOI 10.1002/mc.10028; Zhang ZZ, 2004, CLIN CHIM ACTA, V342, P137, DOI 10.1016/j.cccn.2003.12.010; Zheng YX, 2001, CARCINOGENESIS, V22, P1195, DOI 10.1093/carcin/22.8.1195; Zukerberg LR, 1996, BLOOD, V88, P268, DOI 10.1182/blood.V88.1.268.bloodjournal881268; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488	136	301	315	2	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	11					1620	1628		10.1038/sj.onc.1209371	http://dx.doi.org/10.1038/sj.onc.1209371			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020JL	16550162				2022-12-17	WOS:000235904700004
J	LOBANENKOV, VV; NICOLAS, RH; ADLER, VV; PATERSON, H; KLENOVA, EM; POLOTSKAJA, AV; GOODWIN, GH				LOBANENKOV, VV; NICOLAS, RH; ADLER, VV; PATERSON, H; KLENOVA, EM; POLOTSKAJA, AV; GOODWIN, GH			A NOVEL SEQUENCE-SPECIFIC DNA-BINDING PROTEIN WHICH INTERACTS WITH 3 REGULARLY SPACED DIRECT REPEATS OF THE CCCTC-MOTIF IN THE 5'-FLANKING SEQUENCE OF THE CHICKEN C-MYC GENE	ONCOGENE			English	Article							TRANSCRIPTION FACTOR SP1; BETA-GLOBIN GENE; MODULATE EXPRESSION; PROMOTER ELEMENTS; BURKITT-LYMPHOMA; HL60 CELLS; KINASE-C; REGION; UPSTREAM; PURIFICATION	The chicken c-myc 5'-flanking sequence has previously been shown to bind multiple proteins present in undifferentiated and differentiated red blood cells. In this report the protein binding to one specific region within a hypersensitive site approximately 200 base pairs upstream of the start of transcription has been analysed in detail. Using a combination of a modified agarose gel retardation assay with O-phenanthroline-copper foot-printing in situ, missing contact point and methylation interference techniques, two proteins were found to bind to overlapping sequences within 180-230 bp upstream of the start of transcription. One protein resembles the transcription factor Sp1, the other is a protein which binds to three regularly spaced repeats of the core sequence CCCTC. This CCCTC-binding factor was termed CTCF. It requires additional sequences outside the three recognition motifs for tight binding. CTCF was purified to near homogeneity by sequence-specific DNA chromatography. The approximate molecular weight of the CTCF was estimated to be 130 000. Removal of 110 bp sequence binding both CTCF and Sp1-like proteins leads to a 4 to 8-fold increase in transcription of stably transfected c-myc fusion constructs in chicken embryonic fibroblasts, suggesting that the CTCF is likely to be one of multiple nuclear factors involved in the transcriptional regulation of the chicken c-myc gene.	INST CANC RES,CHESTER BEATTY LABS,FULHAM RD,LONDON SW3 6JB,ENGLAND; ALL UNION CANC RES CTR,INST CARCINOGENESIS,MOSCOW 115478,USSR	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK			Lobanenkov, Victor/ABD-5710-2021; Lobanenkov, Victor V./AGQ-8903-2022	Lobanenkov, Victor/0000-0001-6665-3635				ASSELIN C, 1989, ONCOGENE, V4, P549; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BRUNELLE A, 1987, P NATL ACAD SCI USA, V84, P6673, DOI 10.1073/pnas.84.19.6673; CHUNG J, 1986, P NATL ACAD SCI USA, V83, P7918, DOI 10.1073/pnas.83.20.7918; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; DAVIS TL, 1989, P NATL ACAD SCI USA, V86, P9682, DOI 10.1073/pnas.86.24.9682; DYNAN WS, 1986, NATURE, V319, P246, DOI 10.1038/319246a0; EMERSON BM, 1985, CELL, V41, P21, DOI 10.1016/0092-8674(85)90057-1; GOODWIN GH, 1988, J VIROL, V62, P2186, DOI 10.1128/JVI.62.6.2186-2190.1988; HALL DJ, 1987, J BIOL CHEM, V262, P15302; HALL DJ, 1990, ONCOGENE, V5, P47; HAY N, 1989, GENE DEV, V3, P293, DOI 10.1101/gad.3.3.293; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; IGUCHIARIGA SMM, 1988, EMBO J, V7, P3135, DOI 10.1002/j.1460-2075.1988.tb03180.x; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; KAKKIS E, 1987, P NATL ACAD SCI USA, V84, P7031, DOI 10.1073/pnas.84.20.7031; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; LETOVSKY J, 1989, NUCLEIC ACIDS RES, V17, P2639, DOI 10.1093/nar/17.7.2639; LEWIS CD, 1988, GENE DEV, V2, P863, DOI 10.1101/gad.2.7.863; LINIAL M, 1985, P NATL ACAD SCI USA, V82, P53, DOI 10.1073/pnas.82.1.53; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; LOBANENKOV VV, 1986, EUR J BIOCHEM, V159, P181, DOI 10.1111/j.1432-1033.1986.tb09850.x; LOBANENKOV VV, 1990, GENE REGULATION AIDS, P45; Maniatis T., 1982, MOL CLONING; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCCAFFREY P, 1987, J BIOL CHEM, V262, P1442; MILLER H, 1989, MOL CELL BIOL, V9, P5340, DOI 10.1128/MCB.9.12.5340; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; PERKINS ND, 1989, NUCLEIC ACIDS RES, V17, P1299, DOI 10.1093/nar/17.4.1299; PIECHACZYK M, 1985, CELL, V42, P589, DOI 10.1016/0092-8674(85)90116-3; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; Plumb M A, 1988, Methods Mol Biol, V4, P139, DOI 10.1385/0-89603-127-6:139; PLUMB MA, 1986, NUCLEIC ACIDS RES, V14, P7675, DOI 10.1093/nar/14.19.7675; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; REMMERS EF, 1986, EMBO J, V5, P899, DOI 10.1002/j.1460-2075.1986.tb04301.x; ROSENFELD PJ, 1986, J BIOL CHEM, V261, P1398; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SHIH CK, 1984, P NATL ACAD SCI-BIOL, V81, P4697, DOI 10.1073/pnas.81.15.4697; SIEBENLIST U, 1988, MOL CELL BIOL, V8, P867, DOI 10.1128/MCB.8.2.867; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; TAKIMOTO M, 1989, J BIOL CHEM, V264, P8992; WANG J, 1987, NUCLEIC ACIDS RES, V15, P10105, DOI 10.1093/nar/15.24.10105; WEISINGER G, 1988, ONCOGENE, V3, P635; YANG JQ, 1986, EMBO J, V5, P3553, DOI 10.1002/j.1460-2075.1986.tb04682.x	50	301	315	0	25	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1990	5	12					1743	1753						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET436	2284094				2022-12-17	WOS:A1990ET43600002
J	FIRMBACHKRAFT, I; BYERS, M; SHOWS, T; DALLAFAVERA, R; KROLEWSKI, JJ				FIRMBACHKRAFT, I; BYERS, M; SHOWS, T; DALLAFAVERA, R; KROLEWSKI, JJ			TYK2, PROTOTYPE OF A NOVEL CLASS OF NONRECEPTOR TYROSINE KINASE GENES	ONCOGENE			English	Article									COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,CTR CANC,NEW YORK,NY 10032; NEW YORK STATE DEPT HLTH,ROSWELL PK MEM INST,DEPT HUMAN GENET,BUFFALO,NY 14263	Columbia University; Columbia University; Roswell Park Cancer Institute					NCI NIH HHS [CA44029] Funding Source: Medline; NICHD NIH HHS [HD05196] Funding Source: Medline; NIGMS NIH HHS [GM20454] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD005196] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA044029] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020454] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F., 1992, MOL REPROD DEV, DOI DOI 10.1002/MRD.1080010210; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BEN-NERIAH Y, 1988, NATURE, V333, P672, DOI 10.1038/333672a0; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEARY ML, 1988, J EXP MED, V167, P682, DOI 10.1084/jem.167.2.682; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DECLUE JE, 1987, P NATL ACAD SCI USA, V84, P9064, DOI 10.1073/pnas.84.24.9064; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HALUSKA FG, 1987, ANNU REV GENET, V21, P321, DOI 10.1146/annurev.ge.21.120187.001541; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOFFMANN FM, 1983, CELL, V35, P393, DOI 10.1016/0092-8674(83)90172-1; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KROLEWSKI JJ, 1990, ONCOGENE, V5, P277; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Maniatis T., 1982, MOL CLONING; MARTH JD, 1988, NATURE, V332, P171, DOI 10.1038/332171a0; MARTH JD, 1987, EMBO J, V6, P2727, DOI 10.1002/j.1460-2075.1987.tb02566.x; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MELLENTIN JD, 1989, SCIENCE, V246, P379, DOI 10.1126/science.2799390; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; OPPERMANN H, 1981, VIROLOGY, V108, P47, DOI 10.1016/0042-6822(81)90526-2; PAWSON T, 1988, ONCOGENE, V3, P491; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; RUTA M, 1988, ONCOGENE, V3, P9; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WILLIAMS DL, 1984, CELL, V36, P101, DOI 10.1016/0092-8674(84)90078-3; WOOLFORD J, 1985, MOL CELL BIOL, V5, P3458, DOI 10.1128/MCB.5.12.3458; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZABEL BU, 1983, P NATL ACAD SCI-BIOL, V80, P6932, DOI 10.1073/pnas.80.22.6932	44	301	322	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1990	5	9					1329	1336						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EC241	2216457				2022-12-17	WOS:A1990EC24100008
J	FUKUMOTO, Y; KAIBUCHI, K; HORI, Y; FUJIOKA, H; ARAKI, S; UEDA, T; KIKUCHI, A; TAKAI, Y				FUKUMOTO, Y; KAIBUCHI, K; HORI, Y; FUJIOKA, H; ARAKI, S; UEDA, T; KIKUCHI, A; TAKAI, Y			MOLECULAR-CLONING AND CHARACTERIZATION OF A NOVEL TYPE OF REGULATORY PROTEIN (GDI) FOR THE RHO PROTEINS, RAS P21-LIKE SMALL GTP-BINDING PROTEINS	ONCOGENE			English	Article									KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN	Kobe University								ADAMVIZI V, 1988, FEBS LETT, V238, P277, DOI 10.1016/0014-5793(88)80496-4; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOURNE HR, 1986, NATURE, V321, P814, DOI 10.1038/321814a0; BRAUN U, 1989, FEBS LETT, V243, P70, DOI 10.1016/0014-5793(89)81220-7; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; CHARDIN P, 1988, NUCLEIC ACIDS RES, V16, P2717, DOI 10.1093/nar/16.6.2717; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; DAYHOFF MO, 1978, NATL BIOMED RES F, V3, P345; FUKUMOTO T, 1990, J BIOL CHEM, V265, P775; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HALL A, 1986, J BIOL CHEM, V261, P963; HANAHAN D, 1983, METHOD ENZYMOL, V100, P333; HENIKOFF S, 1984, GENE, V128, P315; HOSHIJIMA M, 1990, MOL BRAIN RES, V7, P9, DOI 10.1016/0169-328X(90)90067-N; HOSHINO M, 1987, J BIOCHEM-TOKYO, V102, P503, DOI 10.1093/oxfordjournals.jbchem.a122082; HOUSE C, 1987, J BIOL CHEM, V262, P772; ISOMURA M, 1990, IN PRESS BIOCH BIOPH; KAIBUCHI K, 1989, J BIOL CHEM, V264, P13489; KANEHISA M, 1982, NUCLEIC ACIDS RES, V10, P183, DOI 10.1093/nar/10.1.183; KAWATA M, 1988, J BIOL CHEM, V263, P18965; KAZIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P95, DOI 10.1016/0304-4173(78)90009-5; KIKUCHI A, 1989, J BIOL CHEM, V264, P9133; KIKUCHI A, 1988, J BIOL CHEM, V263, P16303; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; KURODA S, 1989, BIOCHEM BIOPH RES CO, V163, P674, DOI 10.1016/0006-291X(89)92276-6; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MATSUI Y, 1988, J BIOL CHEM, V263, P11071; MATSUI Y, 1990, BIOCHEM BIOPH RES CO, V166, P1010, DOI 10.1016/0006-291X(90)90911-6; MUNDER T, 1988, MOL GEN GENET, V214, P271, DOI 10.1007/BF00337721; NARUMIYA S, 1988, J BIOL CHEM, V263, P17255; OHGA N, 1989, BIOCHEM BIOPH RES CO, V163, P1523, DOI 10.1016/0006-291X(89)91153-4; PAIN VM, 1986, BIOCHEM J, V235, P625, DOI 10.1042/bj2350625; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; PIZON V, 1988, ONCOGENE, V3, P201; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANO K, 1989, BIOCHEM BIOPH RES CO, V158, P377, DOI 10.1016/S0006-291X(89)80058-0; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SHOJI I, 1989, BIOCHEM BIOPH RES CO, V162, P273, DOI 10.1016/0006-291X(89)91992-X; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; TAKAI Y, 1988, PROGR ENDOCRINOLOGY, V2, P995; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; UEDA T, 1989, BIOCHEM BIOPH RES CO, V159, P1411, DOI 10.1016/0006-291X(89)92267-5; UEDA T, 1990, J BIOL CHEM, V265, P9373; UI M, 1984, TRENDS PHARMACOL SCI, V5, P277, DOI 10.1016/0165-6147(84)90444-9; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WEST M, 1990, FEBS LETT, V259, P245, DOI 10.1016/0014-5793(90)80019-F; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; YAMAMOTO J, 1990, IN PRESS MOL BRAIN R; YAMAMOTO K, 1988, J BIOL CHEM, V263, P9926; YAMAMOTO T, 1990, IN PRESS J BIOL CHEM; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YERAMIAN P, 1987, NUCLEIC ACIDS RES, V15, P1869, DOI 10.1093/nar/15.4.1869	65	301	304	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1990	5	9					1321	1328						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EC241	2120668				2022-12-17	WOS:A1990EC24100007
J	Joerger, AC; Fersht, AR				Joerger, A. C.; Fersht, A. R.			Structure-function-rescue: the diverse nature of common p53 cancer mutants	ONCOGENE			English	Review						p53; cancer; mutation; structure; drug design	DNA-BINDING DOMAIN; TUMOR-SUPPRESSOR PROTEIN; FULL-LENGTH P53; CAVITY-CREATING MUTATIONS; C-TERMINAL DOMAIN; CORE DOMAIN; CRYSTAL-STRUCTURE; TETRAMERIZATION DOMAIN; TRANSCRIPTIONAL ACTIVATION; ONCOGENIC MUTATIONS	The tumor suppressor protein p53 is inactivated by mutation in about half of all human cancers. Most mutations are located in the DNA-binding domain of the protein. It is, therefore, important to understand the structure of p53 and how it responds to mutation, so as to predict the phenotypic response and cancer prognosis. In this review, we present recent structural and systematic functional data that elucidate the molecular basis of how p53 is inactivated by different types of cancer mutation. Intriguingly, common cancer mutants exhibit a variety of distinct local structural changes, while the overall structural scaffold is largely preserved. The diverse structural and energetic response to mutation determines: (i) the folding state of a particular mutant under physiological conditions; (ii) its affinity for the various p53 target DNA sequences; and (iii) its protein-protein interactions both within the p53 tetramer and with a multitude of regulatory proteins. Further, the structural details of individual mutants provide the basis for the design of specific and generic drugs for cancer therapy purposes. In combination with studies on second-site suppressor mutations, it appears that some mutants are ideal rescue candidates, whereas for others simple pharmacological rescue by small molecule drugs may not be successful.	MRC Ctr, Ctr Prot Engn, Cambridge CB2 0QH, England	MRC Laboratory Molecular Biology; University of Cambridge	Joerger, AC (corresponding author), MRC Ctr, Ctr Prot Engn, Hills rd, Cambridge CB2 0QH, England.	acj2@mrc-lmb.cam.ac.uk; arf25@cam.ac.uk	Fersht, Alan R/B-2189-2008	Joerger, Andreas/0000-0002-1232-0138	MRC [MC_U105474168] Funding Source: UKRI; Medical Research Council [MC_U105474168] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		AGUILAR F, 1993, P NATL ACAD SCI USA, V90, P8586, DOI 10.1073/pnas.90.18.8586; Ang HC, 2006, J BIOL CHEM, V281, P21934, DOI 10.1074/jbc.M604209200; BALAGURUMOORTHY P, 1995, P NATL ACAD SCI USA, V92, P8591, DOI 10.1073/pnas.92.19.8591; Baroni TE, 2004, P NATL ACAD SCI USA, V101, P4930, DOI 10.1073/pnas.0401162101; Bell S, 2002, J MOL BIOL, V322, P917, DOI 10.1016/S0022-2836(02)00848-3; Blagosklonny MV, 2000, FASEB J, V14, P1901, DOI 10.1096/fj.99-1078rev; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Brachmann RK, 1998, EMBO J, V17, P1847, DOI 10.1093/emboj/17.7.1847; Braithwaite AW, 2006, CELL DEATH DIFFER, V13, P984, DOI 10.1038/sj.cdd.4401924; BUCKLE AM, 1993, J MOL BIOL, V234, P847, DOI 10.1006/jmbi.1993.1630; Buckle AM, 1996, BIOCHEMISTRY-US, V35, P4298, DOI 10.1021/bi9524676; Bullock AN, 2000, ONCOGENE, V19, P1245, DOI 10.1038/sj.onc.1203434; Buschmann T, 2000, J MOL BIOL, V295, P1009, DOI 10.1006/jmbi.1999.3387; Butler JS, 2005, J MOL BIOL, V350, P906, DOI 10.1016/j.jmb.2005.05.060; Butler JS, 2003, BIOCHEMISTRY-US, V42, P2396, DOI 10.1021/bi026635n; Bykov VJN, 2003, EUR J CANCER, V39, P1828, DOI 10.1016/S0959-8049(03)00454-4; Canadillas JMP, 2006, P NATL ACAD SCI USA, V103, P2109, DOI 10.1073/pnas.0510941103; Chan WM, 2004, MOL CELL BIOL, V24, P3536, DOI 10.1128/MCB.24.8.3536-3551.2004; Chene P, 2001, ONCOGENE, V20, P2611, DOI 10.1038/sj.onc.1204373; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1995, NAT STRUCT BIOL, V2, P321, DOI 10.1038/nsb0495-321; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; Cuff AL, 2004, J MOL BIOL, V344, P1199, DOI 10.1016/j.jmb.2004.10.015; Cuff AL, 2006, BIOINFORMATICS, V22, P1464, DOI 10.1093/bioinformatics/btl120; Dawson R, 2003, J MOL BIOL, V332, P1131, DOI 10.1016/j.jmb.2003.08.008; Dearth LR, 2007, CARCINOGENESIS, V28, P289, DOI 10.1093/carcin/bgl132; Dehner A, 2005, ANGEW CHEM INT EDIT, V44, P5247, DOI 10.1002/anie.200501887; DeLano W. L, 2002, PYMOL MOL GENETICS G; Derbyshire DJ, 2002, EMBO J, V21, P3863, DOI 10.1093/emboj/cdf383; Di Como CJ, 1998, ONCOGENE, V16, P2527; DiGiammarino EL, 2002, NAT STRUCT BIOL, V9, P12, DOI 10.1038/nsb730; Duan JX, 2006, BIOCHEMISTRY-US, V45, P7483, DOI 10.1021/bi0603165; Dunker AK, 2005, FEBS J, V272, P5129, DOI 10.1111/j.1742-4658.2005.04948.x; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; Friedler A, 2005, J BIOL CHEM, V280, P8051, DOI 10.1074/jbc.M411176200; Friedler A, 2004, J MOL BIOL, V336, P187, DOI 10.1016/j.jmb.2003.12.005; Friedler A, 2003, J BIOL CHEM, V278, P24108, DOI 10.1074/jbc.M302458200; Friedler A, 2002, P NATL ACAD SCI USA, V99, P937, DOI 10.1073/pnas.241629998; Friedler A, 2005, STRUCTURE, V13, P629, DOI 10.1016/j.str.2005.01.020; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GHEBRANIOUS N, 1995, MOL CARCINOGEN, V13, P104, DOI 10.1002/mc.2940130207; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Grossman SR, 2001, EUR J BIOCHEM, V268, P2773, DOI 10.1046/j.1432-1327.2001.02226.x; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Hamroun D, 2006, HUM MUTAT, V27, P14, DOI 10.1002/humu.20269; HARTMAN PE, 1973, ADV GENET, V17, P1, DOI 10.1016/S0065-2660(08)60170-4; Higashimoto Y, 2006, BIOCHEMISTRY-US, V45, P1608, DOI 10.1021/bi051192j; Ho WC, 2006, J BIOL CHEM, V281, P20494, DOI 10.1074/jbc.M603634200; Huyen Y, 2004, STRUCTURE, V12, P1237, DOI 10.1016/j.str.2004.05.007; Inga A, 2001, ONCOGENE, V20, P501, DOI 10.1038/sj.onc.1204116; Ishioka C, 1997, BIOCHEM BIOPH RES CO, V232, P54, DOI 10.1006/bbrc.1997.6216; Issaeva N, 2003, P NATL ACAD SCI USA, V100, P13303, DOI 10.1073/pnas.1835733100; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; Joerger AC, 2005, J BIOL CHEM, V280, P16030, DOI 10.1074/jbc.M500179200; Joerger AC, 2004, J BIOL CHEM, V279, P1291, DOI 10.1074/jbc.M309732200; Joerger AC, 2006, P NATL ACAD SCI USA, V103, P15056, DOI 10.1073/pnas.0607286103; Joo WS, 2002, GENE DEV, V16, P583, DOI 10.1101/gad.959202; Kato S, 2003, P NATL ACAD SCI USA, V100, P8424, DOI 10.1073/pnas.1431692100; Kawaguchi T, 2005, ONCOGENE, V24, P6976, DOI 10.1038/sj.onc.1208839; Kitayner M, 2006, MOL CELL, V22, P741, DOI 10.1016/j.molcel.2006.05.015; Klein C, 2001, J BIOL CHEM, V276, P49020, DOI 10.1074/jbc.M107516200; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Laurent-Puig P, 2006, ONCOGENE, V25, P3778, DOI 10.1038/sj.onc.1209547; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Lee H, 2000, J BIOL CHEM, V275, P29426, DOI 10.1074/jbc.M003107200; LEGROS Y, 1994, ONCOGENE, V9, P3689; Lilyestrom W, 2006, GENE DEV, V20, P2373, DOI 10.1101/gad.1456306; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; Lunter G, 2004, BIOINFORMATICS, V20, P216, DOI 10.1093/bioinformatics/bth901; Marine JC, 2006, CELL DEATH DIFFER, V13, P927, DOI 10.1038/sj.cdd.4401912; Mateu MG, 1998, EMBO J, V17, P2748, DOI 10.1093/emboj/17.10.2748; Mateu MG, 1999, P NATL ACAD SCI USA, V96, P3595, DOI 10.1073/pnas.96.7.3595; Mathe E, 2006, NUCLEIC ACIDS RES, V34, P1317, DOI 10.1093/nar/gkj518; Mathe E, 2006, HUM MUTAT, V27, P163, DOI 10.1002/humu.20284; Matsumura I, 1999, PROTEIN SCI, V8, P731; Menendez D, 2006, MOL CELL BIOL, V26, P2297, DOI 10.1128/MCB.26.6.2297-2308.2006; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; Mittl PRE, 1998, ACTA CRYSTALLOGR D, V54, P86, DOI 10.1107/S0907444997006550; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Muller-Tiemann BF, 1998, P NATL ACAD SCI USA, V95, P6079, DOI 10.1073/pnas.95.11.6079; Nicholls CD, 2002, J BIOL CHEM, V277, P12937, DOI 10.1074/jbc.M108815200; Nikolova PV, 2000, EMBO J, V19, P370, DOI 10.1093/emboj/19.3.370; Nikolova PV, 1998, P NATL ACAD SCI USA, V95, P14675, DOI 10.1073/pnas.95.25.14675; OLIVEIRA LS, 1994, DRY TECHNOL, V12, P1167, DOI 10.1080/07373939408960994; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Olivier M, 2003, CANCER RES, V63, P6643; Pan YP, 2006, BIOCHEMISTRY-US, V45, P3925, DOI 10.1021/bi052242n; Pan YP, 2005, BIOCHEMISTRY-US, V44, P1423, DOI 10.1021/bi047845y; PETITJEAN A, 2007, IN PRESS ONCOGENE; Poon A, 2005, GENETICS, V170, P1323, DOI 10.1534/genetics.104.037259; POTEETE AR, 1991, BIOCHEMISTRY-US, V30, P1425, DOI 10.1021/bi00219a037; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; Qian H, 2002, ONCOGENE, V21, P7901, DOI 10.1038/sj.onc.1205974; Resnick MA, 2003, P NATL ACAD SCI USA, V100, P9934, DOI 10.1073/pnas.1633803100; Rippin TM, 2002, J MOL BIOL, V319, P351, DOI 10.1016/S0022-2836(02)00326-1; Rosal R, 2004, BIOCHEMISTRY-US, V43, P1854, DOI 10.1021/bi035718g; Rustandi RR, 2000, NAT STRUCT BIOL, V7, P570; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Sakaguchi K, 1997, J PROTEIN CHEM, V16, P553, DOI 10.1023/A:1026334116189; Saller E, 1999, EMBO J, V18, P4424, DOI 10.1093/emboj/18.16.4424; SERRANO L, 1992, J MOL BIOL, V224, P783, DOI 10.1016/0022-2836(92)90562-X; Shiraishi K, 2004, J BIOL CHEM, V279, P348, DOI 10.1074/jbc.M310815200; Sigal A, 2000, CANCER RES, V60, P6788; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; Sujatha S, 2001, MOL GEN GENET, V264, P531, DOI 10.1007/s004380000353; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Tidow H, 2006, J BIOL CHEM, V281, P32526, DOI 10.1074/jbc.M604725200; Trigiante G, 2006, NAT REV CANCER, V6, P217, DOI 10.1038/nrc1818; Veprintsev DB, 2006, P NATL ACAD SCI USA, V103, P2115, DOI 10.1073/pnas.0511130103; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wang PL, 2001, ONCOGENE, V20, P2318, DOI 10.1038/sj.onc.1204316; Weinberg RL, 2005, J MOL BIOL, V348, P589, DOI 10.1016/j.jmb.2005.03.014; Weinberg RL, 2004, J MOL BIOL, V341, P1145, DOI 10.1016/j.jmb.2004.06.071; Weinberg RL, 2004, J MOL BIOL, V342, P801, DOI 10.1016/j.jmb.2004.07.042; Wieczorek AM, 1996, NAT MED, V2, P1143, DOI 10.1038/nm1096-1143; Wiman KG, 2006, CELL DEATH DIFFER, V13, P921, DOI 10.1038/sj.cdd.4401921; Wong KB, 1999, P NATL ACAD SCI USA, V96, P8438, DOI 10.1073/pnas.96.15.8438; Wray JW, 1999, J MOL BIOL, V292, P1111, DOI 10.1006/jmbi.1999.3102; Xu JA, 1998, PROTEIN SCI, V7, P158, DOI 10.1002/pro.5560070117; Yip YL, 2006, HUM MUTAT, V27, P926, DOI 10.1002/humu.20379; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x; Zhao KH, 2001, J BIOL CHEM, V276, P12120, DOI 10.1074/jbc.M011644200; Zupnick A, 2006, J BIOL CHEM, V281, P20464, DOI 10.1074/jbc.M603387200	124	300	307	0	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 2	2007	26	15					2226	2242		10.1038/sj.onc.1210291	http://dx.doi.org/10.1038/sj.onc.1210291			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	152XE	17401432				2022-12-17	WOS:000245394800012
J	LUKAS, J; PAGANO, M; STASKOVA, Z; DRAETTA, G; BARTEK, J				LUKAS, J; PAGANO, M; STASKOVA, Z; DRAETTA, G; BARTEK, J			CYCLIN D1 PROTEIN OSCILLATES AND IS ESSENTIAL FOR CELL-CYCLE PROGRESSION IN HUMAN TUMOR-CELL LINES	ONCOGENE			English	Article							CHROMOSOME 11Q13; SQUAMOUS-CELL; MESSENGER-RNA; S-PHASE; EXPRESSION; CLONING; KINASE; GENES; AMPLIFICATION; MITOSIS	Among the key cell cycle regulators, cyclin D1 has been implicated most strongly in oncogenesis. This G1 cyclin is a putative proto-oncogene whose clonal rearrangement and/or amplification and mRNA overexpression occurs in several types of human neoplasias. We have now raised a series of monoclonal antibodies to human cyclin D1 and analysed its regulation at the protein level in 40 human tumour cell lines. We found that 12 cell lines displayed low or undetectable cyclin D1 protein level, while the remaining lines accumulated the protein to a level comparable to, or moderately higher than, that of four normal diploid non-immortalized cell types. The cell cycle-dependent oscillation and subcellular localization of cyclin D1 were similar in both tumour and normal cells. The protein localized to the nucleus of G1 cells, and it was reduced to immunocytochemically undetectable level in DNA-replicating cells. At the functional level, microinjection and electroporation of anti-D1 antibodies revealed that in most tumour cell lines studied, including those with amplification at the cyclin D1 locus, this cyclin is essential for cell cycle progression in G1. Some tumours, however, seem to have evolved mechanism(s) that enable them to bypass the requirement for functional cyclin D1.	DANISH CANC SOC, DIV CANC BIOL, DK-2100 COPENHAGEN 0, DENMARK; EUROPEAN MOLEC BIOL LAB, DIFFERENTIAT PROGRAMME, W-6900 HEIDELBERG, GERMANY; MITOTIX, CAMBRIDGE, MA 02139 USA	Danish Cancer Society; European Molecular Biology Laboratory (EMBL)			Bartek, Jiri/G-5870-2014	Lukas, Jiri/0000-0001-9087-506X; pagano, michele/0000-0003-3210-2442				AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; ANSORGE W, 1988, J BIOCHEM BIOPH METH, V16, P283, DOI 10.1016/0165-022X(88)90062-0; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARTEK J, 1993, STEM CELLS, V11, P51, DOI 10.1002/stem.5530110611; BERENSON JR, 1990, ONCOGENE, V5, P1343; BRECHOT C, 1993, CURR OPIN GENET DEV, V3, P11, DOI 10.1016/S0959-437X(05)80335-1; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; FAHA B, 1993, J VIROL, V67, P2456, DOI 10.1128/JVI.67.5.2456-2465.1993; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; HAMAGUCHI JR, 1992, J CELL BIOL, V117, P1041, DOI 10.1083/jcb.117.5.1041; HARLOW E, 1988, ANTIBODIES LABORATOR; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUMBERT C, 1992, J CELL SCI, V103, P97; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; JIANG W, 1992, CANCER RES, V52, P2980; KATO J, 1993, GENE DEV, V7, P331; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KIYOKAWA H, 1992, P NATL ACAD SCI USA, V89, P2444, DOI 10.1073/pnas.89.6.2444; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MATSUSHIME H, 1991, COLD SPRING HARB SYM, V56, P69; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PAGANO M, 1991, Progress in Growth Factor Research, V3, P267, DOI 10.1016/0955-2235(91)90004-N; PALMERO I, 1993, ONCOGENE, V8, P1049; PEPPERKOK R, 1988, P NATL ACAD SCI USA, V85, P6748, DOI 10.1073/pnas.85.18.6748; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PROCTOR AJ, 1991, ONCOGENE, V6, P789; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; ROSENBERG CL, 1993, ONCOGENE, V8, P519; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SCHUURING E, 1992, ONCOGENE, V7, P355; SETO M, 1992, ONCOGENE, V7, P1401; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; TOMMASINO M, 1993, ONCOGENE, V8, P195; TSAI LH, 1993, ONCOGENE, V8, P1593; WANG J, 1992, ONCOGENE, V7, P1653; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WILLIAMS RT, 1993, J BIOL CHEM, V268, P8871; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	63	300	306	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1994	9	3					707	718						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108113				2022-12-17	WOS:A1994MW55100005
J	JAATTELA, M; BENEDICT, M; TEWARI, M; SHAYMAN, JA; DIXIT, VM				JAATTELA, M; BENEDICT, M; TEWARI, M; SHAYMAN, JA; DIXIT, VM			BCL-X AND BCL-2 INHIBIT TNF AND FAS-INDUCED APOPTOSIS AND ACTIVATION OF PHOSPHOLIPASE A(2) IN BREAST-CARCINOMA CELLS	ONCOGENE			English	Article						CELL DEATH; CERAMIDE; FAS; TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION	TUMOR-NECROSIS-FACTOR; FACTOR-MEDIATED CYTOTOXICITY; MOLECULAR-CLONING; FACTOR-ALPHA; MONOCLONAL-ANTIBODY; CYTO-TOXICITY; EXPRESSION; RECEPTOR; PROTEIN; DEATH	Tumor necrosis factor (TNF) induces cell death in several tumor cell lines by undefined mechanisms. Using a cDNA expression cloning strategy we identified two cDNAs that completely inhibit the TNF-induced death pathway in MCF7 breast carcinoma cells. These cDNAs encoded for Bcl-2 and Bcl-x. To compare the cytotoxic signal transduction pathway induced by the TNF receptor versus that induced by Fas, we transfected MCF7 cells with a Fas expression construct. The resulting cell line, MCF-Fas, was highly sensitive to cytotoxicity induced by TNF or anti-Fas. Expression of either bcl-2 or bcl-x in these cells rendered them completely resistant to lysis induced by either TNF or Pas. Interestingly, exposure of MCF-Pas cells to anti-Fas or TNF induced activation of phospholipase A(2) (PLA(2)), while only TNF activated NF-kappa B. Activation of PLA(2) was completely blocked whereas activation of NF-kappa B was unaffected by overexpression of either bcl-x or bcl-2. Moreover, PLA(2)-inhibitors, quinacrine and dexamethasone, partially inhibited cytotoxicity induced by either TNF or anti-Pas. These data suggest an involvement of PLA(2) in both TNF- and Fas-mediated cytotoxicity and a novel mechanism of action for bcl-2 and bcl-x, i.e. inhibition of arachidonic acid metabolism, by which they may, in addition of apoptosis, modulate inflammation.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	JAATTELA, M (corresponding author), DANISH CANC SOC,RES CTR,DEPT TUMOR CELL BIOL,DK-2100 COPENHAGEN,DENMARK.		Jäättelä, Marja/AAT-7932-2021; dixit, vishva m/A-4496-2012	Jäättelä, Marja/0000-0001-5950-7111; dixit, vishva m/0000-0001-6983-0326				BETTS JC, 1994, J BIOL CHEM, V269, P8455; BOISE LH, 1993, CELL, V744, P597; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; CIFONE MG, 1993, J EXP MED, V177, P1547; EICHEN CM, 1994, J IMMUNOL, V153, P1947; HASHIZUME T, 1991, ARCH BIOCHEM BIOPHYS, V289, P47, DOI 10.1016/0003-9861(91)90440-T; HAYAKAWA M, 1993, J BIOL CHEM, V268, P11290; HENNET T, 1993, CANCER RES, V53, P1456; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; IRVINE RF, 1982, BIOCHEM J, V204, P3, DOI 10.1042/bj2040003; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1993, J IMMUNOL, V151, P621; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JAATTELA M, 1991, LAB INVEST, V64, P724; JAATTELA M, 1991, LYMPHOKINE CYTOK RES, V10, P119; JAATTELA M, 1989, EUR J IMMUNOL, V19, P1413, DOI 10.1002/eji.1830190810; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; JAATTELA M, 1993, J IMMUNOL, V151, P4286; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; KNAUER MF, 1990, J CELL PHYSIOL, V142, P469, DOI 10.1002/jcp.1041420305; KORSMEYER SJ, 1992, IMMUNOL TODAY, V13, P285, DOI 10.1016/0167-5699(92)90037-8; KRASNOW SW, 1991, CYTOKINE, V3, P372, DOI 10.1016/1043-4666(91)90040-K; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASTER SM, 1988, J IMMUNOL, V141, P2629; LEGERSKI R, 1992, NATURE, V359, P70, DOI 10.1038/359070a0; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NEALE ML, 1988, IMMUNOLOGY, V64, P81; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; OWENSCHAUB LB, 1994, CANCER RES, V54, P1580; PETERSON C, 1991, GENE, V107, P279, DOI 10.1016/0378-1119(91)90328-9; PREISS J, 1986, J BIOL CHEM, V261, P8597; SAKSELA K, 1993, MOL CELL BIOL, V13, P3698, DOI 10.1128/MCB.13.6.3698; SALGO MG, 1993, ARCH BIOCHEM BIOPHYS, V304, P123, DOI 10.1006/abbi.1993.1330; Sambrook J., 1989, MOL CLONING LAB MANU; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; THOMA B, 1990, J EXP MED, V172, P1019, DOI 10.1084/jem.172.4.1019; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VANHAESEBROECK B, 1993, ONCOGENE, V8, P1075; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	60	299	307	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 15	1995	10	12					2297	2305						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7540278				2022-12-17	WOS:A1995RE54300004
J	Sveen, A; Kilpinen, S; Ruusulehto, A; Lothe, RA; Skotheim, RI				Sveen, A.; Kilpinen, S.; Ruusulehto, A.; Lothe, R. A.; Skotheim, R. I.			Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes	ONCOGENE			English	Review							GROWTH-FACTOR RECEPTOR; EPITHELIAL-MESENCHYMAL TRANSITION; TYROSINE KINASE INHIBITORS; MESSENGER-RNA; SOMATIC MUTATIONS; RECURRENT MUTATIONS; HUMAN TRANSCRIPTOME; ANTITUMOR-ACTIVITY; TUMOR-SUPPRESSOR; HUMAN TISSUES	Alternative splicing is a widespread process contributing to structural transcript variation and proteome diversity. In cancer, the splicing process is commonly disrupted, resulting in both functional and non-functional end-products. Cancer-specific splicing events are known to contribute to disease progression; however, the dysregulated splicing patterns found on a genome-wide scale have until recently been less well-studied. In this review, we provide an overview of aberrant RNA splicing and its regulation in cancer. We then focus on the executors of the splicing process. Based on a comprehensive catalog of splicing factor encoding genes and analyses of available gene expression and somatic mutation data, we identify cancer-associated patterns of dysregulation. Splicing factor genes are shown to be significantly differentially expressed between cancer and corresponding normal samples, and to have reduced inter-individual expression variation in cancer. Furthermore, we identify enrichment of predicted cancer-critical genes among the splicing factors. In addition to previously described oncogenic splicing factor genes, we propose 24 novel cancer-critical splicing factors predicted from somatic mutations.	[Sveen, A.; Lothe, R. A.; Skotheim, R. I.] Oslo Univ Hosp, Norwegian Radium Hosp, Inst Canc Res, Dept Mol Oncol, POB 4953, NO-0424 Oslo, Norway; [Sveen, A.; Lothe, R. A.; Skotheim, R. I.] Oslo Univ Hosp, KG Jebsen Colorectal Canc Res Ctr, NO-0424 Oslo, Norway; [Sveen, A.; Lothe, R. A.; Skotheim, R. I.] Univ Oslo, Fac Med, Ctr Canc Biomed, Oslo, Norway; [Kilpinen, S.; Ruusulehto, A.] MediSapiens Ltd, Helsinki, Finland	University of Oslo; University of Oslo; University of Oslo	Skotheim, RI (corresponding author), Oslo Univ Hosp, Norwegian Radium Hosp, Inst Canc Res, Dept Mol Oncol, POB 4953, NO-0424 Oslo, Norway.	rolf.i.skotheim@rr-research.no	Skotheim, Rolf I./H-6192-2017	Skotheim, Rolf I./0000-0002-5609-4048; Lothe, Ragnhild A./0000-0002-1693-1032; Sveen, Anita/0000-0001-8219-6251	Southern and Eastern Norway Regional Health Authority (Research Grant 'Genome Medicine of Colorectal Cancer') [2011024]; Norwegian Cancer Society [PR-2007-0166, PR-2006-0442]; KG Jebsen foundation; Research Council of Norway [179571]	Southern and Eastern Norway Regional Health Authority (Research Grant 'Genome Medicine of Colorectal Cancer'); Norwegian Cancer Society(Norwegian Cancer Society); KG Jebsen foundation; Research Council of Norway(Research Council of Norway)	This study was supported by the Southern and Eastern Norway Regional Health Authority (Research Grant 'Genome Medicine of Colorectal Cancer', project number 2011024), the Norwegian Cancer Society (PR-2007-0166 and PR-2006-0442), the KG Jebsen foundation and the Research Council of Norway through its Centres of Excellence funding scheme (project number 179571).	Adesso L, 2013, ONCOGENE, V32, P2848, DOI 10.1038/onc.2012.306; Adler AS, 2014, GENE DEV, V28, P1068, DOI 10.1101/gad.237206.113; Agrawal S, 2006, HUM MOL GENET, V15, P777, DOI 10.1093/hmg/ddi492; Albert FW, 2015, NAT REV GENET, V16, P197, DOI 10.1038/nrg3891; Antonarakis ES, 2015, JAMA ONCOL, V1, P582, DOI 10.1001/jamaoncol.2015.1341; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Astrof S, 2009, ANGIOGENESIS, V12, P165, DOI 10.1007/s10456-009-9136-6; Babic I, 2013, CELL METAB, V17, P1000, DOI 10.1016/j.cmet.2013.04.013; Bai AL, 2010, CANCER RES, V70, P7630, DOI 10.1158/0008-5472.CAN-10-1489; Barash Y, 2010, NATURE, V465, P53, DOI 10.1038/nature09000; Bartel F, 2002, CANCER CELL, V2, P9, DOI 10.1016/S1535-6108(02)00091-0; Bates DO, 2012, CLIN CANCER RES, V18, P6384, DOI 10.1158/1078-0432.CCR-12-2223; Bauman J, 2009, OLIGONUCLEOTIDES, V19, P1, DOI 10.1089/oli.2008.0161; Bauman John A, 2011, Bioeng Bugs, V2, P125; Bauman JA, 2010, NUCLEIC ACIDS RES, V38, P8348, DOI 10.1093/nar/gkq731; Bemmo A, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-529; Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547; Birzele F, 2015, CLIN CANCER RES, V21, P2753, DOI 10.1158/1078-0432.CCR-14-2141; Bland CS, 2010, NUCLEIC ACIDS RES, V38, P7651, DOI 10.1093/nar/gkq614; Blencowe BJ, 2006, CELL, V126, P37, DOI 10.1016/j.cell.2006.06.023; Blencowe BJ, 2000, RNA, V6, P111, DOI 10.1017/S1355838200991982; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Boutz PL, 2007, GENE DEV, V21, P71, DOI 10.1101/gad.1500707; Braeutigam C, 2014, ONCOGENE, V33, P1082, DOI 10.1038/onc.2013.50; Bria E, 2014, ONCOTARGET, V5, P11054, DOI 10.18632/oncotarget.2609; Brinkman BMN, 2004, CLIN BIOCHEM, V37, P584, DOI 10.1016/j.clinbiochem.2004.05.015; Brock A, 2009, NAT REV GENET, V10, P336, DOI 10.1038/nrg2556; Brooks AN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087361; Carbon S, 2009, BIOINFORMATICS, V25, P288, DOI 10.1093/bioinformatics/btn615; Carstens RP, 1997, ONCOGENE, V15, P3059, DOI 10.1038/sj.onc.1201498; Carter H, 2009, CANCER RES, V69, P6660, DOI 10.1158/0008-5472.CAN-09-1133; Chen HH, 2006, MOL CELL BIOL, V26, P2736, DOI 10.1128/MCB.26.7.2736-2745.2006; Chen J, 2015, ONCOGENE, V34, P1, DOI 10.1038/onc.2013.570; Chen L, 2011, HUM MOL GENET, V20, P4422, DOI 10.1093/hmg/ddr370; Choi JW, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001351; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Clark J, 1997, ONCOGENE, V15, P2233, DOI 10.1038/sj.onc.1201394; Clark TA, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-4-r64; COHEN JB, 1989, CELL, V58, P461, DOI 10.1016/0092-8674(89)90427-3; Cohen-Eliav M, 2013, J PATHOL, V229, P630, DOI 10.1002/path.4129; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Dales JP, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-44; Dao T, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005661; Dardenne E, 2012, NAT STRUCT MOL BIOL, V19, P1139, DOI 10.1038/nsmb.2390; David CJ, 2010, GENE DEV, V24, P2343, DOI 10.1101/gad.1973010; Davies RC, 1998, GENE DEV, V12, P3217, DOI 10.1101/gad.12.20.3217; DeBoever C, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004105; Dees ND, 2012, GENOME RES, V22, P1589, DOI 10.1101/gr.134635.111; Dehm SM, 2013, CANCER RES, V73, P5309, DOI 10.1158/0008-5472.CAN-13-0444; Ding L, 2010, HUM MOL GENET, V19, pR188, DOI 10.1093/hmg/ddq391; Dixon RJ, 2007, BIOINFORMATICS, V23, P150, DOI 10.1093/bioinformatics/btl575; Djebali S, 2012, NATURE, V489, P101, DOI 10.1038/nature11233; Dorman SN, 2014, SCI REP-UK, V4, DOI 10.1038/srep07063; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Dvinge H, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0168-9; Ecker S, 2015, GENOME MED, V7, DOI 10.1186/s13073-014-0125-z; Elliott DJ, 2006, REPRODUCTION, V132, P811, DOI 10.1530/REP-06-0147; Engstrom PG, 2013, NAT METHODS, V10, P1185, DOI [10.1038/NMETH.2722, 10.1038/nmeth.2722]; Eswaran J, 2013, SCI REP-UK, V3, DOI 10.1038/srep01689; Fackenthal JD, 2008, DIS MODEL MECH, V1, P37, DOI 10.1242/dmm.000331; Faustino NA, 2003, GENE DEV, V17, P419, DOI 10.1101/gad.1048803; Feltes CM, 2002, CANCER RES, V62, P6688; Femel J, 2014, ONCOTARGET, V5, P12418, DOI 10.18632/oncotarget.2628; Feng SJ, 1997, CANCER RES, V57, P5369; Ferrarese R, 2014, J CLIN INVEST, V124, P2861, DOI 10.1172/JCI68836; Ferreira PG, 2014, GENOME RES, V24, P212, DOI 10.1101/gr.152132.112; Finta C, 2000, GENOMICS, V63, P433, DOI 10.1006/geno.1999.6063; Flouriot G, 2002, J BIOL CHEM, V277, P26244, DOI 10.1074/jbc.M203513200; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Frampton GM, 2015, CANCER DISCOV, V5, P850, DOI 10.1158/2159-8290.CD-15-0285; French PJ, 2007, CANCER RES, V67, P5635, DOI 10.1158/0008-5472.CAN-06-2869; Fu XD, 2014, NAT REV GENET, V15, P689, DOI 10.1038/nrg3778; Furney SJ, 2013, CANCER DISCOV, V3, P1122, DOI 10.1158/2159-8290.CD-13-0330; Fushimi K, 2008, P NATL ACAD SCI USA, V105, P15708, DOI 10.1073/pnas.0805569105; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Gaffney DJ, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003501; Garcia-Blanco MA, 2004, NAT BIOTECHNOL, V22, P535, DOI 10.1038/nbt964; Gardina PJ, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-325; Garraway LA, 2013, CELL, V153, P17, DOI 10.1016/j.cell.2013.03.002; Ge K, 1999, P NATL ACAD SCI USA, V96, P9689, DOI 10.1073/pnas.96.17.9689; Ghigna C, 2005, MOL CELL, V20, P881, DOI 10.1016/j.molcel.2005.10.026; Giannini G, 2002, EMBO REP, V3, P248, DOI 10.1093/embo-reports/kvf044; Gonsalvez GB, 2007, J CELL BIOL, V178, P733, DOI 10.1083/jcb.200702147; Gonzalez-Perez A, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks743; Gonzalez-Porta M, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-7-r70; Goransson M, 2009, ONCOGENE, V28, P270, DOI 10.1038/onc.2008.378; Goswami S, 2009, CLIN EXP METASTAS, V26, P153, DOI 10.1007/s10585-008-9225-8; Graubert TA, 2012, NAT GENET, V44, P53, DOI 10.1038/ng.1031; Gray-Owen SD, 2006, NAT REV IMMUNOL, V6, P433, DOI 10.1038/nri1864; Grosso AR, 2008, EMBO REP, V9, P1087, DOI 10.1038/embor.2008.189; Grosso AR, 2008, NUCLEIC ACIDS RES, V36, P4823, DOI 10.1093/nar/gkn463; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; Guo R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062729; Hahn CN, 2015, IMMUNOL REV, V263, P257, DOI 10.1111/imr.12241; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harbour JW, 2013, NAT GENET, V45, P133, DOI 10.1038/ng.2523; Harrow J, 2012, GENOME RES, V22, P1760, DOI 10.1101/gr.135350.111; Hartel M, 2008, EUR J CANCER, V44, P1895, DOI 10.1016/j.ejca.2008.06.030; Hatami R, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004688; He CJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004732; Himeji D, 2002, BLOOD, V99, P4070, DOI 10.1182/blood.V99.11.4070; Hirschi B, 2013, INT J CANCER, V133, P590, DOI 10.1002/ijc.28061; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Hong J, 2014, CANCER RES, V74, P1845, DOI 10.1158/0008-5472.CAN-13-2104; Hooper JE, 2014, HUM GENOMICS, V8, DOI 10.1186/1479-7364-8-3; Horowitz DS, 2002, EMBO J, V21, P470, DOI 10.1093/emboj/21.3.470; Hudson TJ, 2010, NATURE, V464, P993, DOI 10.1038/nature08987; Huelga SC, 2012, CELL REP, V1, P167, DOI 10.1016/j.celrep.2012.02.001; Iacobucci I, 2008, BLOOD, V112, P3847, DOI 10.1182/blood-2007-09-112631; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Ji HB, 2006, P NATL ACAD SCI USA, V103, P7817, DOI 10.1073/pnas.0510284103; Jia PL, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0489-9; Jiang SW, 2013, INT J MOL SCI, V14, P22655, DOI 10.3390/ijms141122655; Johnson JM, 2003, SCIENCE, V302, P2141, DOI 10.1126/science.1090100; Johnston JJ, 2010, AM J HUM GENET, V86, P743, DOI 10.1016/j.ajhg.2010.04.007; Kalyana-Sundaram S, 2012, NEOPLASIA, V14, P702, DOI 10.1593/neo.12914; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Karni R, 2007, NAT STRUCT MOL BIOL, V14, P185, DOI 10.1038/nsmb1209; Kato M, 2012, CANCER SCI, V103, P1363, DOI 10.1111/j.1349-7006.2012.02298.x; Kelemen O, 2013, GENE, V514, P1, DOI 10.1016/j.gene.2012.07.083; Kikuta K, 2012, J PROTEOMICS, V75, P1089, DOI 10.1016/j.jprot.2011.10.005; Kilpinen S, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r139; Kim Yun-Ji, 2012, Genomics & Informatics, V10, P74, DOI 10.5808/GI.2012.10.2.74; Knudsen KE, 2006, ONCOGENE, V25, P1620, DOI 10.1038/sj.onc.1209371; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Konno R, 2000, CLIN CANCER RES, V6, P3576; Koscielny G, 2009, GENOMICS, V93, P213, DOI 10.1016/j.ygeno.2008.11.003; Koslowski M, 2002, CANCER RES, V62, P6750; Krawczak M, 2007, HUM MUTAT, V28, P150, DOI 10.1002/humu.20400; Ladd AN, 2001, MOL CELL BIOL, V21, P1285, DOI 10.1128/MCB.21.4.1285-1296.2001; Ladomery Michael, 2013, Int J Cell Biol, V2013, P463786, DOI 10.1155/2013/463786; Ladomery MR, 2007, CANCER LETT, V249, P133, DOI 10.1016/j.canlet.2006.08.015; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lappalainen T, 2013, NATURE, V501, P506, DOI 10.1038/nature12531; Lapuk A, 2010, MOL CANCER RES, V8, P961, DOI 10.1158/1541-7786.MCR-09-0528; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Lee JH, 2003, CANCER RES, V63, P7247; Lee TK, 2011, J CLIN INVEST, V121, P880, DOI 10.1172/JCI40433; LeFave CV, 2011, EMBO J, V30, P4084, DOI 10.1038/emboj.2011.259; Lenos K, 2012, CANCER RES, V72, P4074, DOI 10.1158/0008-5472.CAN-12-0215; Lewis BP, 2003, P NATL ACAD SCI USA, V100, P189, DOI 10.1073/pnas.0136770100; Li H, 2008, SCIENCE, V321, P1357, DOI 10.1126/science.1156725; Li ZM, 2013, CANCER LETT, V328, P278, DOI 10.1016/j.canlet.2012.09.026; Lin KT, 2014, ONCOGENE, V33, P4786, DOI 10.1038/onc.2013.424; Listerman I, 2013, CANCER RES, V73, P2817, DOI 10.1158/0008-5472.CAN-12-3082; Liu JF, 2012, GENOME RES, V22, P2315, DOI 10.1101/gr.140988.112; Lokody I, 2014, NAT REV CANCER, V14, DOI 10.1038/nrc3753; Lovf M, 2014, INT J CANCER, V135, P2077, DOI 10.1002/ijc.28855; Lovf M, 2011, GENE CHROMOSOME CANC, V50, P348, DOI 10.1002/gcc.20860; Lu J, 2015, NAT REV UROL, V12, P137, DOI 10.1038/nrurol.2015.13; Lu XW, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3124; Lukas J, 2001, CANCER RES, V61, P3212; Ma YL, 2005, STRUCTURE, V13, P883, DOI 10.1016/j.str.2005.03.014; Marcel V, 2014, CELL DEATH DIFFER, V21, P1377, DOI 10.1038/cdd.2014.73; Matera AG, 2014, NAT REV MOL CELL BIO, V15, P108, DOI 10.1038/nrm3742; Matos P, 2008, MOL CANCER RES, V6, P1178, DOI 10.1158/1541-7786.MCR-08-0008; Matsuda Y, 2012, MOL CANCER THER, V11, P2010, DOI 10.1158/1535-7163.MCT-12-0243; Mazin P, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2012.67; McGlincy NJ, 2008, TRENDS BIOCHEM SCI, V33, P385, DOI 10.1016/j.tibs.2008.06.001; Melamud E, 2009, NUCLEIC ACIDS RES, V37, P4873, DOI 10.1093/nar/gkp471; Mele M, 2015, SCIENCE, V348, P660, DOI 10.1126/science.aaa0355; Miura K, 2012, CARCINOGENESIS, V33, P2311, DOI 10.1093/carcin/bgs347; Moscatello DK, 1996, ONCOGENE, V13, P85; Mukherjee B, 2009, CANCER RES, V69, P4252, DOI 10.1158/0008-5472.CAN-08-4853; Nacu S, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-11; Nagano O, 2013, ONCOGENE, V32, P5191, DOI 10.1038/onc.2012.638; Ng KP, 2012, NAT MED, V18, P521, DOI 10.1038/nm.2713; Nilsen TW, 2010, NATURE, V463, P457, DOI 10.1038/nature08909; Olsson M, 2011, CELL DEATH DIFFER, V18, P1441, DOI 10.1038/cdd.2011.30; Oltean S, 2014, ONCOGENE, V33, P5311, DOI 10.1038/onc.2013.533; Oscier DG, 2013, BLOOD, V121, P468, DOI 10.1182/blood-2012-05-429282; Pajares MJ, 2007, LANCET ONCOL, V8, P349, DOI 10.1016/S1470-2045(07)70104-3; Palve V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111927; Pan DS, 2012, BIOCHEM BIOPH RES CO, V422, P727, DOI 10.1016/j.bbrc.2012.05.070; Pan Q, 2004, MOL CELL, V16, P929, DOI 10.1016/j.molcel.2004.12.004; Pan Q, 2008, NAT GENET, V40, P1413, DOI 10.1038/ng.259; Parada GE, 2014, NUCLEIC ACIDS RES, V42, P10564, DOI 10.1093/nar/gku744; Park SJ, 2001, BIOCHEM BIOPH RES CO, V289, P1205, DOI 10.1006/bbrc.2001.6086; Pickrell JK, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001236; Pieter A, 2012, CANCER BIOL THER, V13, P1185, DOI 10.4161/cbt.21348; Planque C, 2010, CLIN CHEM, V56, P987, DOI 10.1373/clinchem.2009.138917; Plowman SJ, 2006, J EXP CLIN CANC RES, V25, P259; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Pruitt KD, 2009, GENOME RES, V19, P1316, DOI 10.1101/gr.080531.108; Przychodzen B, 2013, BLOOD, V122, P999, DOI 10.1182/blood-2013-01-480970; Qian J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045760; Quesada V, 2012, NAT GENET, V44, P47, DOI 10.1038/ng.1032; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Ramalingam Satish, 2012, Immunogastroenterology, V1, P27; Reimand J, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2012.68; Renkonen E, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.017269; Revenkova E, 2009, HUM MOL GENET, V18, P418, DOI 10.1093/hmg/ddn369; Rocak S, 2004, NAT REV MOL CELL BIO, V5, P232, DOI 10.1038/nrm1335; Rossi D, 2011, BLOOD, V118, P6904, DOI 10.1182/blood-2011-08-373159; Rouas-Freiss N, 2005, INT J CANCER, V117, P114, DOI 10.1002/ijc.21151; Rubio-Perez C, 2015, CANCER CELL, V27, P382, DOI 10.1016/j.ccell.2015.02.007; Ryan MC, 2012, BIOINFORMATICS, V28, P2385, DOI 10.1093/bioinformatics/bts452; Safa Ahmad R, 2011, Cancers (Basel), V3, P1639, DOI 10.3390/cancers3021639; Sahin U, 2008, CLIN CANCER RES, V14, P7624, DOI 10.1158/1078-0432.CCR-08-1547; Saltzman AL, 2011, GENE DEV, V25, P373, DOI 10.1101/gad.2004811; Salzman J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030733; Samatov TR, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-107; SAVAGNER P, 1994, MOL BIOL CELL, V5, P851, DOI 10.1091/mbc.5.8.851; Schubert EL, 1997, HUM GENET, V100, P557, DOI 10.1007/s004390050551; Schwerk C, 2005, MOL CELL, V19, P1, DOI 10.1016/j.molcel.2005.05.026; Scott LM, 2013, JNCI-J NATL CANCER I, V105, P1540, DOI 10.1093/jnci/djt257; Sebestyen E, 2015, NUCLEIC ACIDS RES, V43, P1345, DOI 10.1093/nar/gku1392; Shao CW, 2014, NAT STRUCT MOL BIOL, V21, P997, DOI 10.1038/nsmb.2906; Shapiro IM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002218; Shehadeh LA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009104; Shieh JJ, 2009, J INVEST DERMATOL, V129, P2497, DOI 10.1038/jid.2009.83; Shirai CL, 2015, CANCER CELL, V27, P631, DOI 10.1016/j.ccell.2015.04.008; Shitashige M, 2007, GASTROENTEROLOGY, V132, P1039, DOI 10.1053/j.gastro.2007.01.007; Silipo M, 2015, J MOL CELL BIOL; Singh R, 2005, NAT STRUCT MOL BIOL, V12, P645, DOI 10.1038/nsmb961; Singh RK, 2012, TRENDS MOL MED, V18, P472, DOI 10.1016/j.molmed.2012.06.006; Skotheim RI, 2007, INT J BIOCHEM CELL B, V39, P1432, DOI 10.1016/j.biocel.2007.02.016; Stark M, 2009, BLOOD, V113, P4362, DOI 10.1182/blood-2008-08-173799; Sterne-Weiler T, 2014, GENOME BIOL, V15, DOI 10.1186/gb4150; Sugiura T, 2007, CANCER BIOL THER, V6, P957, DOI 10.4161/cbt.6.6.4192; Sun SH, 2010, J CLIN INVEST, V120, P2715, DOI 10.1172/JCI41824; Surget S, 2014, ONCOTARGETS THER, V7, P57, DOI 10.2147/OTT.S53876; Sveen A, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-672; Sveen A, 2012, INT J CANCER, V131, P1479, DOI 10.1002/ijc.27399; Sveen A, 2011, GENOME MED, V3, DOI 10.1186/gm248; Talwar S, 2013, RNA BIOL, V10, P277, DOI 10.4161/rna.23315; Tamborero D, 2013, SCI REP-UK, V3, DOI 10.1038/srep02650; Tamborero D, 2013, BIOINFORMATICS, V29, P2238, DOI 10.1093/bioinformatics/btt395; Tanackovic G, 2005, MOL BIOL CELL, V16, P1366, DOI 10.1091/mbc.E04-11-1034; Thomas M, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1500-x; Thorsen K, 2008, MOL CELL PROTEOMICS, V7, P1214, DOI 10.1074/mcp.M700590-MCP200; Thorsen K, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.002998; Tilgner H, 2015, NAT BIOTECHNOL, V33, P736, DOI 10.1038/nbt.3242; Todaro M, 2014, CELL STEM CELL, V14, P342, DOI 10.1016/j.stem.2014.01.009; Tomsic J, 2015, SCI REP-UK, V5, DOI 10.1038/srep10566; Tsunoda T, 2003, AM J PATHOL, V162, P1857, DOI 10.1016/S0002-9440(10)64320-9; Uckun FM, 2015, INTEGR BIOL-UK, V7, P237, DOI 10.1039/c4ib00221k; Ullrich N, 2015, CANCER RES, V75, P1897, DOI 10.1158/0008-5472.CAN-14-1752; Valles I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042086; van Doorn R, 2002, CANCER RES, V62, P5389; Vauchy C, 2015, INT J CANCER, V137, P116, DOI 10.1002/ijc.29366; Venables JP, 2004, CANCER RES, V64, P7647, DOI 10.1158/0008-5472.CAN-04-1910; Venables JP, 2006, BIOESSAYS, V28, P378, DOI 10.1002/bies.20390; Venables JP, 2013, MOL CELL BIOL, V33, P396, DOI 10.1128/MCB.01174-12; Venables JP, 2009, NAT STRUCT MOL BIOL, V16, P670, DOI 10.1038/nsmb.1608; Vivas-Mejia PE, 2011, CLIN CANCER RES, V17, P3716, DOI 10.1158/1078-0432.CCR-11-0233; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Voice JK, 1999, J BIOL CHEM, V274, P17164, DOI 10.1074/jbc.274.24.17164; Vudattu NK, 2009, GENES IMMUN, V10, P132, DOI 10.1038/gene.2008.90; Wahl MC, 2009, CELL, V136, P701, DOI 10.1016/j.cell.2009.02.009; Waks Z, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.32; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Wang GS, 2007, NAT REV GENET, V8, P749, DOI 10.1038/nrg2164; Wang H, 2011, NEOPLASIA, V13, P461, DOI 10.1593/neo.101744; Wang LL, 2011, NEW ENGL J MED, V365, P2497, DOI 10.1056/NEJMoa1109016; Wang XQ, 2005, CLIN CANCER RES, V11, P483; Wang Y, 2014, CANCER CELL, V26, P374, DOI 10.1016/j.ccr.2014.07.010; Wang YB, 2013, EMBO MOL MED, V5, P1431, DOI 10.1002/emmm.201302663; Wang ZF, 2008, RNA, V14, P802, DOI 10.1261/rna.876308; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Watson IR, 2013, NAT REV GENET, V14, P703, DOI 10.1038/nrg3539; Wegran F, 2006, CLIN CANCER RES, V12, P5794, DOI 10.1158/1078-0432.CCR-06-0725; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; Weischenfeldt J, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-5-r35; Wheeler DA, 2013, GENOME RES, V23, P1054, DOI 10.1101/gr.157602.113; Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030; Will CL, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a003707; Wong MS, 2014, TRENDS GENET, V30, P430, DOI 10.1016/j.tig.2014.07.006; Wong MS, 2013, CELL REP, V3, P1028, DOI 10.1016/j.celrep.2013.03.011; Xi LQ, 2008, NUCLEIC ACIDS RES, V36, P6535, DOI 10.1093/nar/gkn697; Xu Q, 2002, NUCLEIC ACIDS RES, V30, P3754, DOI 10.1093/nar/gkf492; Xu WH, 2011, P NATL ACAD SCI USA, V108, P3707, DOI 10.1073/pnas.1019753108; Yadav SP, 2014, HUM MOL GENET, V23, P2132, DOI 10.1093/hmg/ddt609; Yan Y, 2015, STEM CELLS TRANSL ME; Yao RS, 2014, CANCER RES, V74, P5656, DOI 10.1158/0008-5472.CAN-14-0800; Yeo G, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r74; Yi YJ, 2009, MOL CYTOGENET, V2, DOI 10.1186/1755-8166-2-18; Yoshida K, 2011, NATURE, V478, P64, DOI 10.1038/nature10496; Zammarchi F, 2011, P NATL ACAD SCI USA, V108, P17779, DOI 10.1073/pnas.1108482108; Zhang J, 2013, CANCER DISCOV, V3, P1228, DOI 10.1158/2159-8290.CD-13-0253; Zhao Q, 2013, CLIN CANCER RES, V19, P2460, DOI 10.1158/1078-0432.CCR-12-3708; Zhao S, 2014, TRANSL ONCOL, V7, P429, DOI 10.1016/j.tranon.2014.04.001; Zhou C, 2013, ONCOGENE, V32, P903, DOI 10.1038/onc.2012.99	287	298	306	2	100	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2016	35	19					2413	2427		10.1038/onc.2015.318	http://dx.doi.org/10.1038/onc.2015.318			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GQ	26300000				2022-12-17	WOS:000376165500001
J	Rahaman, SO; Harbor, PC; Chernova, O; Barnett, GH; Vogelbaum, MA; Haque, SJ				Rahaman, SO; Harbor, PC; Chernova, O; Barnett, GH; Vogelbaum, MA; Haque, SJ			Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells	ONCOGENE			English	Article						glioblastoma; Jak-Stat signal transduction; apoptosis; IL-6; Stat3	HUMAN-BRAIN; CONFERS RESISTANCE; MALIGNANT GLIOMA; IL-6 FAMILY; JAK-STAT; ACTIVATION; RECEPTOR; GENE; PROTEIN; GROWTH	Glioblastoma multiforme (GBM), the most common and malignant central nervous system tumor in humans, is highly proliferative and resistant to apoptosis. Stat3, a latent transcription factor being activated by aberrant cytokine or growth factor signaling, acts as a suppressor of apoptosis in a number of cancer cells. Here we report that GBM tumors and cell lines contain high levels of constitutively activated Stat3 when compared with normal human astrocytes, white matter, and normal tissue adjacent to tumor. The persistent activation of Stat3 is in part, attributable to an autocrine action of interleukin-6 in the GBM cell tine U251. Janus kinase inhibitor AG490 inhibits Stat3 activation with a concomitant reduction in steady-state levels of Bcl-X-L, Bcl-2 and Mel-1 proteins and induces apoptosis in U251 cells as revealed by Poly (ADP-ribose) polymerase cleavage and Annexin-V staining. Expression of a dominant negative mutant Stat3 protein or treatment with AG490 markedly reduces the proliferation of U251 cells by inhibiting the constitutive activation of Stat3. These results provide evidence that constitutive activation of Stat3 contributes to the pathogenesis of glioblastoma by promoting both proliferation and survival of GBM cells. Therefore, targeting Stat3 signaling may provide a potential therapeutic intervention for GBM.	Cleveland Clin Fdn, Dept Canc Biol, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Neurosurg, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Pulm & Crit Care Med, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Haque, SJ (corresponding author), Cleveland Clin Fdn, Dept Canc Biol, Lerner Res Inst, NB-40,9500 Euclid Ave, Cleveland, OH 44195 USA.	haquej@ccf.org			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060533] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM60533] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Badache A, 2001, CANCER RES, V61, P383; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Goswami S, 1998, J NEUROCHEM, V71, P1837; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Halfter H, 2000, MOL BRAIN RES, V80, P198, DOI 10.1016/S0169-328X(00)00162-5; Haque SJ, 1997, P NATL ACAD SCI USA, V94, P8563, DOI 10.1073/pnas.94.16.8563; Haque SJ, 2000, J BIOL CHEM, V275, P26500, DOI 10.1074/jbc.275.34.26500; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HIRANO T, 1990, IMMUNOL TODAY, V11, P443, DOI 10.1016/0167-5699(90)90173-7; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Holland EC, 2000, P NATL ACAD SCI USA, V97, P6242, DOI 10.1073/pnas.97.12.6242; Ichimura K, 2000, CANCER RES, V60, P417; Ivanchuk SM, 2001, J NEURO-ONCOL, V51, P219, DOI 10.1023/A:1010632309113; Kaptein A, 1996, J BIOL CHEM, V271, P5961, DOI 10.1074/jbc.271.11.5961; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Levin Victor A., 1997, P2022; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; Lilja A, 2001, INT J ONCOL, V19, P495; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Paillaud E, 2002, J NEUROSCI RES, V67, P670, DOI 10.1002/jnr.10110; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; Prados Michael D., 2000, Seminars in Oncology, V27, P1; Rahaman SO, 2002, CANCER RES, V62, P1103; Rasheed B K, 1999, Curr Opin Oncol, V11, P162; REIFENBERGER G, 1993, CANCER RES, V53, P2736; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; Rolhion C, 2001, J NEUROSURG, V94, P97, DOI 10.3171/jns.2001.94.1.0097; Schaefer LK, 2002, ONCOGENE, V21, P2058, DOI 10.1038/sj.onc.1205263; SCHMIDT EE, 1994, CANCER RES, V54, P6321; Schuringa JJ, 2000, BLOOD, V95, P3765, DOI 10.1182/blood.V95.12.3765; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Sun S, 2002, J GEN VIROL, V83, P1651, DOI 10.1099/0022-1317-83-7-1651; Tchirkov A, 2001, BRIT J CANCER, V85, P518, DOI 10.1054/bjoc.2001.1942; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VAN MEIR E, 1990, CANCER RES, V50, P6683; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Wechsler-Reya R, 2001, ANNU REV NEUROSCI, V24, P385, DOI 10.1146/annurev.neuro.24.1.385; WELLER M, 1995, J CLIN INVEST, V95, P2633, DOI 10.1172/JCI117965; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	51	298	324	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	2002	21	55					8404	8413		10.1038/sj.onc.1206047	http://dx.doi.org/10.1038/sj.onc.1206047			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466961				2022-12-17	WOS:000179480100004
J	Wood, DE; Thomas, A; Devi, LA; Berman, Y; Beavis, RC; Reed, JC; Newcomb, EW				Wood, DE; Thomas, A; Devi, LA; Berman, Y; Beavis, RC; Reed, JC; Newcomb, EW			Bax cleavage is mediated by calpain during drug-induced apoptosis	ONCOGENE			English	Article						drug-induced apoptosis; calpain; Bax cleavage; HL-60 cells; mitochondrial membranes	PROGRAMMED CELL-DEATH; RAT-LIVER MITOCHONDRIA; CYTOCHROME-C; ENDOPLASMIC-RETICULUM; LIMITED PROTEOLYSIS; NEUTRAL PROTEASE; HL-60 CELLS; ION-CHANNEL; BCL-2; INHIBITION	The anti-apoptotic molecule Bcl-2 is located in the mitochondrial and endoplasmic reticulum membranes as well as the nuclear envelope. Although its location has not been as rigorously defined, the pro-apoptotic molecule Pax appears to be mainly a cytosolic protein which translocates to the mitochondria upon induction of apoptosis, Here me identify a protease activity in mitochondria-enriched membrane fractions from HL-60 cells capable of cleaving Pax which is absent from the cytosolic fraction, Pax protease activity is blocked in vitro by cysteine protease inhibitors including E-64 which distinguishes it from all known caspases and granzyme B, both of which are involved in apoptosis, Protease activity is also blocked by inhibitors against the calcium-activated neutral cysteine endopeptidase calpain, Partial purification of the Pax protease activity from HL-60 cell membrane fractions by column chromatography revealed that a calpain-like activity was the protease responsible for Pax cleavage, In addition, purified calpain enzymes cleaved Pax in a calcium-dependent manner. Pretreatment of HL-60 cells with the specific calpain inhibitor calpeptin effectively blocked both drug-induced Pax cleavage and calpain activation, but not PARP cleavage or cell death. These results suggest that calpains and caspases are activated during drug-induced apoptosis and that calpains, along with caspases, may be involved in modulating cell death by acting selectively on cellular substrates.	NYU, Med Ctr, Dept Pathol, New York, NY 10016 USA; NYU, Med Ctr, Dept Pharmacol, New York, NY 10016 USA; Kaplan Comprehens Canc Ctr, New York, NY 10016 USA; Burnham Inst, La Jolla, CA 92037 USA	New York University; New York University; Sanford Burnham Prebys Medical Discovery Institute	Newcomb, EW (corresponding author), NYU, Med Ctr, Dept Pathol, 550 1st Ave, New York, NY 10016 USA.		Devi P, Lakshmi/GXM-5982-2022	Devi P, Lakshmi/0000-0001-9274-4776	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026880, K04NS001788, R29NS026880] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 01788, NS 26880] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aguilar HI, 1996, GASTROENTEROLOGY, V110, P558, DOI 10.1053/gast.1996.v110.pm8566604; AKAO Y, 1994, CANCER RES, V54, P2468; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BEER DG, 1982, BIOCHEM BIOPH RES CO, V109, P1276, DOI 10.1016/0006-291X(82)91915-5; BLACK RA, 1989, FEBS LETT, V247, P386, DOI 10.1016/0014-5793(89)81376-6; BOYD JM, 1995, ONCOGENE, V11, P1921; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Choi YH, 1997, J BIOL CHEM, V272, P28479, DOI 10.1074/jbc.272.45.28479; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; CROALL DE, 1986, BIOCHIM BIOPHYS ACTA, V882, P287, DOI 10.1016/0304-4165(86)90250-3; Decaudin D, 1997, CANCER RES, V57, P62; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Friedlander RM, 1996, J EXP MED, V184, P717, DOI 10.1084/jem.184.2.717; GEERAERTS MD, 1991, AM J PHYSIOL, V261, pC889, DOI 10.1152/ajpcell.1991.261.5.C889; Gu Y, 1997, SCIENCE, V275, P206, DOI 10.1126/science.275.5297.206; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; JURGENSMEIER JM, 1998, IN PRESS P NATL ACAD; Kawasaki H, 1996, MOL MEMBR BIOL, V13, P217, DOI 10.3109/09687689609160599; KENNEY DM, 1994, BRIT J HAEMATOL, V87, P773, DOI 10.1111/j.1365-2141.1994.tb06737.x; Kim CN, 1997, CANCER RES, V57, P3115; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEE KS, 1991, P NATL ACAD SCI USA, V88, P7233, DOI 10.1073/pnas.88.16.7233; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LONDON E, 1992, BIOCHIM BIOPHYS ACTA, V1113, P25, DOI 10.1016/0304-4157(92)90033-7; Manon S, 1997, FEBS LETT, V415, P29, DOI 10.1016/S0014-5793(97)01087-9; Martins LM, 1997, J BIOL CHEM, V272, P7421, DOI 10.1074/jbc.272.11.7421; MEHDI S, 1991, TRENDS BIOCHEM SCI, V16, P150, DOI 10.1016/0968-0004(91)90058-4; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Molinari M, 1997, J MEMBRANE BIOL, V156, P1, DOI 10.1007/s002329900181; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; NICHOLS JC, 1994, GASTROENTEROLOGY, V106, P168, DOI 10.1016/S0016-5085(94)95147-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; PINTER M, 1992, BIOCHEMISTRY-US, V31, P8201, DOI 10.1021/bi00150a012; POE M, 1991, J BIOL CHEM, V266, P98; Polverino AJ, 1997, J BIOL CHEM, V272, P7013, DOI 10.1074/jbc.272.11.7013; Porter AG, 1997, BIOESSAYS, V19, P501, DOI 10.1002/bies.950190609; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SARIN A, 1993, J EXP MED, V178, P1693, DOI 10.1084/jem.178.5.1693; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Squier MKT, 1997, J IMMUNOL, V158, P3690; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Talanian RV, 1997, J BIOL CHEM, V272, P9677; TAVARES A, 1991, BIOMED BIOCHIM ACTA, V50, P523; Thomas A, 1996, ONCOGENE, V12, P1055; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Vanags DM, 1996, J BIOL CHEM, V271, P31075, DOI 10.1074/jbc.271.49.31075; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zamzami N, 1997, J BIOENERG BIOMEMBR, V29, P185, DOI 10.1023/A:1022694131572; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zha HB, 1996, MOL CELL BIOL, V16, P6494; Zhao H, 1997, J BIOL CHEM, V272, P21625, DOI 10.1074/jbc.272.34.21625	71	298	308	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	1998	17	9					1069	1078		10.1038/sj.onc.1202034	http://dx.doi.org/10.1038/sj.onc.1202034			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114FL	9764817	Green Published			2022-12-17	WOS:000075598400002
J	Gilmore, TD; Koedood, M; Piffat, KA; White, DW				Gilmore, TD; Koedood, M; Piffat, KA; White, DW			Rel/NF-kappa B/I kappa B proteins and cancer	ONCOGENE			English	Review							T-CELL LEUKEMIA; EPSTEIN-BARR-VIRUS; CHICKEN-EMBRYO FIBROBLASTS; LATENT MEMBRANE-PROTEIN; CHRONIC LYMPHOCYTIC-LEUKEMIA; POLYMERASE CHAIN-REACTION; RECEPTOR FUSION PROTEIN; I TAX-PROTEIN; V-REL; C-REL				Gilmore, TD (corresponding author), BOSTON UNIV,DEPT BIOL,5 CUMMINGTON ST,BOSTON,MA 02215, USA.				NCI NIH HHS [CA47763] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA047763, R01CA047763] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; Akagi T, 1996, ONCOGENE, V12, P1645; ARSURA M, 1996, IMMUNITY, V5, P1; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAICHWAL VR, 1988, ONCOGENE, V2, P461; Baker SJ, 1996, ONCOGENE, V12, P1; Baldassarre F, 1995, J BIOL CHEM, V270, P31244, DOI 10.1074/jbc.270.52.31244; Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BARTH CF, 1988, J EXP MED, V167, P89, DOI 10.1084/jem.167.1.89; BARTH CF, 1990, J VIROL, V64, P6054, DOI 10.1128/JVI.64.12.6054-6062.1990; BEAUPARLANT P, 1994, ONCOGENE, V9, P3189; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BHAT GV, 1990, ONCOGENE, V5, P625; BOEHMELT G, 1995, CELL, V80, P341, DOI 10.1016/0092-8674(95)90417-4; BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BRADY JN, 1992, AIDS RES HUM RETROV, V8, P724; BROWNELL E, 1988, ONCOGENE, V2, P527; Caamano JH, 1996, MOL CELL BIOL, V16, P1342; CAPOBIANCO AJ, 1992, J VIROL, V66, P3758, DOI 10.1128/JVI.66.6.3758-3767.1992; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CAPOBIANCO AJ, 1991, ONCOGENE, V6, P2203; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; CHANG CC, 1995, MOL CELL BIOL, V15, P5180; CHEN W, 1996, J VIROL, V70, P4843; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; Chirillo P, 1996, J VIROL, V70, P641, DOI 10.1128/JVI.70.1.641-646.1996; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DEJARDIN E, 1995, ONCOGENE, V11, P1835; DeLuca C, 1996, J VIROL, V70, P5183, DOI 10.1128/JVI.70.8.5183-5193.1996; DEPPER JM, 1984, J IMMUNOL, V133, P1691; DIEHL JA, 1994, MOL CELL BIOL, V14, P6635, DOI 10.1128/MCB.14.10.6635; DUYAO MP, 1992, J BIOL CHEM, V267, P16288; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; Fujii M, 1996, ONCOGENE, V12, P2193; GELINAS C, 1988, ONCOGENE, V3, P349; GILMAN M, 1993, NATURE, V361, P687, DOI 10.1038/361687a0; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90421-L; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; GILMORE TD, 1995, DNA PROVIRUS, P109; GILMORE TD, 1995, FRONTIERS MOL BIOL E, P102; Good LF, 1996, J VIROL, V70, P2730, DOI 10.1128/JVI.70.5.2730-2735.1996; GOOTENBERG JE, 1981, J EXP MED, V154, P1403, DOI 10.1084/jem.154.5.1403; GRASSMANN R, 1994, ADV CANCER RES, V63, P211, DOI 10.1016/S0065-230X(08)60401-7; GREEN JE, 1989, MOL CELL BIOL, V9, P4731, DOI 10.1128/MCB.9.11.4731; GRIMM S, 1994, ONCOGENE, V9, P2391; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HANNINK M, 1990, ONCOGENE, V5, P1843; HANNINK M, 1991, Critical Reviews in Oncogenesis, V2, P293; HERRERO JA, 1995, J VIROL, V69, P2168, DOI 10.1128/JVI.69.4.2168-2174.1995; HIMES SR, 1993, ONCOGENE, V8, P3189; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; HIRAI H, 1994, P NATL ACAD SCI USA, V91, P3584, DOI 10.1073/pnas.91.9.3584; HIRAI H, 1992, ONCOGENE, V7, P1737; HISCOTT J, 1995, VIROLOGY, V214, P3, DOI 10.1006/viro.1995.9960; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; Houldsworth J, 1996, BLOOD, V87, P25; HRDLICKOVA R, 1994, J VIROL, V68, P308; HRDLICKOVA R, 1994, J VIROL, V68, P2371; HU HM, 1994, J BIOL CHEM, V269, P30069; HUEN DS, 1995, ONCOGENE, V10, P549; HWANG S, 1995, CANCER BIOCHEM BIOPH, V14, P265; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; ISHIKAWA H, 1993, ONCOGENE, V8, P2889; JUNG M, 1995, SCIENCE, V268, P1619, DOI 10.1126/science.7777860; KABRUN N, 1991, P NATL ACAD SCI USA, V88, P1783, DOI 10.1073/pnas.88.5.1783; KABRUN N, 1990, MOL CELL BIOL, V10, P4788, DOI 10.1128/MCB.10.9.4788; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KANNO T, 1994, MOL CELL BIOL, V14, P6443, DOI 10.1128/MCB.14.10.6443; KANNO T, 1994, P NATL ACAD SCI USA, V91, P12634, DOI 10.1073/pnas.91.26.12634; KAYE KM, 1995, J VIROL, V69, P675, DOI 10.1128/JVI.69.2.675-683.1995; Khaled Z, 1996, NUCLEIC ACIDS RES, V24, P737, DOI 10.1093/nar/24.4.737; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KINOSHITA T, 1989, P NATL ACAD SCI USA, V86, P5620, DOI 10.1073/pnas.86.14.5620; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; KLAMAN LD, 1995, J VIROL, V69, P871, DOI 10.1128/JVI.69.2.871-881.1995; KLEIN G, 1994, CELL, V77, P791, DOI 10.1016/0092-8674(94)90125-2; Klement JF, 1996, MOL CELL BIOL, V16, P2341; KORBER B, 1991, J VIROL, V65, P5471, DOI 10.1128/JVI.65.10.5471-5476.1991; LACOSTE J, 1995, J VIROL, V69, P564, DOI 10.1128/JVI.69.1.564-569.1995; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LANOIX J, 1994, ONCOGENE, V9, P841; LEE HY, 1995, J EXP MED, V181, P1169, DOI 10.1084/jem.181.3.1169; LENARDO M, 1994, IMMUNOL TODAY, V15, P145, DOI 10.1016/0167-5699(94)90308-5; LI CCH, 1993, J VIROL, V67, P4205, DOI 10.1128/JVI.67.7.4205-4213.1993; LILIENBAUM A, 1993, J BIOL CHEM, V268, P2180; LIPTAY S, 1992, GENOMICS, V13, P287, DOI 10.1016/0888-7543(92)90244-M; LU D, 1991, ONCOGENE, V6, P1235; LUCITO R, 1992, J VIROL, V66, P983, DOI 10.1128/JVI.66.2.983-991.1992; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MATHEW S, 1993, ONCOGENE, V8, P191; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; MIGLIAZZA A, 1994, BLOOD, V84, P3850, DOI 10.1182/blood.V84.11.3850.bloodjournal84113850; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MIYATAKE S, 1988, NUCLEIC ACIDS RES, V16, P6547, DOI 10.1093/nar/16.14.6547; MOORE BE, 1988, VIROLOGY, V162, P377, DOI 10.1016/0042-6822(88)90478-3; MORIN PJ, 1995, CELL GROWTH DIFFER, V6, P789; MORRISON LE, 1992, ONCOGENE, V7, P1137; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; MOSIALOS G, 1993, ONCOGENE, V8, P721; MUKHOPADHYAY T, 1995, ONCOGENE, V11, P999; MULLER CW, 1995, FEBS LETT, V369, P113, DOI 10.1016/0014-5793(95)00541-G; MUNOZ E, 1994, J VIROL, V68, P8035; MURAKAMI T, 1995, VIROLOGY, V206, P1066, DOI 10.1006/viro.1995.1029; NARAYANAN R, 1992, SCIENCE, V256, P367, DOI 10.1126/science.256.5055.367; NARAYANAN R, 1994, IN VIVO, V8, P787; NEIMAN PE, 1991, P NATL ACAD SCI USA, V88, P5857, DOI 10.1073/pnas.88.13.5857; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; OHNO H, 1993, LEUKEMIA, V7, P2057; Pak J, 1996, J VIROL, V70, P4167, DOI 10.1128/JVI.70.6.4167-4172.1996; PEREZ P, 1995, MOL CELL BIOL, V15, P3523; PETRENKO O, 1995, GENE, V160, P305, DOI 10.1016/0378-1119(95)00210-W; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; Romero Paolo, 1994, Journal of Virology, V69, P301; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Rousset R, 1996, NATURE, V381, P328, DOI 10.1038/381328a0; SALAHUDDIN SZ, 1984, SCIENCE, V223, P703, DOI 10.1126/science.6320367; SARKAR S, 1993, ONCOGENE, V8, P2245; SCHATZLE JD, 1995, J VIROL, V69, P5383, DOI 10.1128/JVI.69.9.5383-5390.1995; SCHRECK R, 1992, J VIROL, V66, P6288, DOI 10.1128/JVI.66.11.6288-6293.1992; SCHWARTZ RC, 1988, VIROLOGY, V165, P182, DOI 10.1016/0042-6822(88)90671-X; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SIF S, 1994, J VIROL, V68, P7131, DOI 10.1128/JVI.68.11.7131-7138.1994; SIF S, 1993, J VIROL, V67, P7612, DOI 10.1128/JVI.67.12.7612-7617.1993; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; SMITH MR, 1991, J CLIN INVEST, V88, P1038, DOI 10.1172/JCI115364; SU F, 1986, J VIROL, V70, P4558; SUZUKI T, 1994, ONCOGENE, V9, P3099; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; THAKUR S, 1994, ONCOGENE, V9, P2335; THEILEN GH, 1966, J NATL CANCER I, V37, P731; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; WALKER AK, 1986, ONCOGENE, V12, P2515; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; WATANABE M, 1993, ONCOGENE, V8, P2949; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; WHITE DW, 1993, J VIROL, V67, P6876, DOI 10.1128/JVI.67.11.6876-6881.1993; White DW, 1996, MOL CELL BIOL, V16, P1169; WHITE DW, 1995, ONCOGENE, V10, P857; WHITE DW, 1996, IN PRESS ONCOGENE, V13; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wilson JB, 1996, EMBO J, V15, P3117, DOI 10.1002/j.1460-2075.1996.tb00674.x; WILSON JB, 1990, CELL, V61, P1315, DOI 10.1016/0092-8674(90)90695-B; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; YAMASHITA I, 1994, BLOOD, V84, P1573; Yoshida M, 1993, Trends Microbiol, V1, P131, DOI 10.1016/0966-842X(93)90127-D; ZAKNOEN SL, 1992, LEUKEMIA, V6, P675; Zhang GQ, 1996, ONCOGENE, V12, P1153; ZHANG GQ, 1995, MOL CELL BIOL, V15, P1806	171	298	308	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 3	1996	13	7					1367	1378						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875974				2022-12-17	WOS:A1996VL38400001
J	Bannister, AJ; Oehler, T; Wilhelm, D; Angel, P; Kouzarides, T				Bannister, AJ; Oehler, T; Wilhelm, D; Angel, P; Kouzarides, T			Stimulation of c-Jun activity by CBP: c-Jun residues Ser63/73 are required for CBP induced stimulation in vivo and CBP binding in vitro	ONCOGENE			English	Article						c-Jun; c-Fos; AP-1; CBP; transcription; activation	DNA-BINDING; ACTIVATION DOMAIN; TRANSCRIPTIONAL ACTIVATION; PROTO-ONCOGENE; LEUCINE ZIPPER; V-JUN; FOS; PHOSPHORYLATION; INVITRO; KINASE	The CBP protein mediates PKA induced transcription by binding to the PKA phosphorylated activation domain of CREB. Here we show that CBP also stimulates the activity of both c-Jun and v-Jun in vivo. The CREB binding domain of CBP is sufficient to contact to c-Jun in vitro. When this domain of CBP is linked to the activation domain of VP16 and expressed in vivo it stimulates c-Jun dependent transcription. Deletion analysis of c-Jun indicate that the CBP binding site is within the N-terminal activation domain. Loss of binding to CBP in vitro correlates with severely reduced transactivation capacity in vivo. Mutation of Ser63/73 in c-Jun, or the corresponding position in v-Jun (Ser36/46) leads to reduced binding to CBP in vitro and abolishes augmentation of transcription in vivo. These data are consistent with a mechanism by which CBP acts as a co-activator protein for Jun dependent transcription by interacting with the Jun IV-terminal activation domain.	UNIV CAMBRIDGE, WELLCOME CRC INST, CAMBRIDGE CB2 1QR, ENGLAND; UNIV CAMBRIDGE, DEPT PATHOL, CAMBRIDGE CB2 1QR, ENGLAND; FORSCHUNGSZENTRUM KARLSRUHE, INST GENET, D-76021 KARLSRUHE, GERMANY	University of Cambridge; University of Cambridge; Helmholtz Association; Karlsruhe Institute of Technology			Wilhelm, Dagmar/B-6915-2009; Piris, Miguel A/AAP-1445-2020	Wilhelm, Dagmar/0000-0002-7757-4075; Piris, Miguel A/0000-0001-5839-3634; Bannister, Andrew/0000-0002-6312-4436; Kouzarides, Tony/0000-0002-8918-4162	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANNWEILER A, 1991, NUCLEIC ACIDS RES, V19, P3750, DOI 10.1093/nar/19.13.3750; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BANNISTER AJ, 1994, NUCLEIC ACIDS RES, V22, P5173, DOI 10.1093/nar/22.24.5173; BANNISTER AJ, 1991, ONCOGENE, V6, P1243; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BLACK EJ, 1994, ONCOGENE, V9, P2363; BROWN HJ, 1995, EMBO J, V14, P124, DOI 10.1002/j.1460-2075.1995.tb06982.x; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DAI TN, 1995, ONCOGENE, V10, P849; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DIXIT VM, 1989, J BIOL CHEM, V264, P16905; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; KOUZARIDES T, 1989, CANCER CELL-MON REV, V1, P71; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; OEHLER T, 1993, ONCOGENE, V8, P1141; OEHLER T, 1992, MOL CELL BIOL, V12, P5508, DOI 10.1128/MCB.12.12.5508; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; PULVERER BJ, 1993, ONCOGENE, V8, P407; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1994, EMBO J, V13, P6006, DOI 10.1002/j.1460-2075.1994.tb06946.x; SUTHERLAND JA, 1992, GENE DEV, V6, P1810, DOI 10.1101/gad.6.9.1810	36	298	300	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 21	1995	11	12					2509	2514						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545107				2022-12-17	WOS:A1995TP18800006
J	JIANG, W; KAHN, SM; GUILLEM, JG; LU, SH; WEINSTEIN, IB				JIANG, W; KAHN, SM; GUILLEM, JG; LU, SH; WEINSTEIN, IB			RAPID DETECTION OF RAS ONCOGENES IN HUMAN-TUMORS - APPLICATIONS TO COLON, ESOPHAGEAL, AND GASTRIC-CANCER	ONCOGENE			English	Article									COLUMBIA UNIV COLL PHYS & SURG,CTR COMPREHENS CANC,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,INST CANC RES,NEW YORK,NY 10032; CHINESE ACAD MED SCI,INST CANC,BEIJING,PEOPLES R CHINA	Columbia University; Columbia University; Chinese Academy of Medical Sciences - Peking Union Medical College				Jiang, Wei/0000-0002-2309-9571				ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; ANDERSON MLM, 1988, ANTICANCER RES, V8, P873; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOS JL, 1986, NUCLEIC ACIDS RES, V14, P1209, DOI 10.1093/nar/14.3.1209; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BOS JL, 1984, NUCLEIC ACIDS RES, V12, P9155, DOI 10.1093/nar/12.23.9155; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; COHEN JB, 1988, NATURE, V334, P119, DOI 10.1038/334119a0; DENG G, 1988, NUCLEIC ACIDS RES, V16, P6231, DOI 10.1093/nar/16.13.6231; DENG G, 1987, CANCER RES, V47, P3195; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; FUJITA K, 1987, GASTROENTEROLOGY, V93, P1339, DOI 10.1016/0016-5085(87)90264-2; HIGUCHI R, 1988, NATURE, V332, P543, DOI 10.1038/332543a0; HOLLSTEIN MC, 1988, CANCER RES, V48, P5119; KNUDSON AG, 1985, CANCER RES, V45, P1437; KOZMA SC, 1987, NUCLEIC ACIDS RES, V15, P5963; KUMAR R, 1988, ONCOGENE, V3, P647; LU SH, 1988, INT J CANCER, V42, P502, DOI 10.1002/ijc.2910420406; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; NISHIDA J, 1987, BIOCHEM BIOPH RES CO, V146, P247, DOI 10.1016/0006-291X(87)90717-0; OHARA BM, 1986, CANCER RES, V46, P4695; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SMIT VTHBM, 1988, NUCLEIC ACIDS RES, V16, P7773, DOI 10.1093/nar/16.16.7773; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; VRIES V, 1986, GENE, V50, P313; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; WEINSTEIN IB, 1987, J CELL BIOCHEM, V33, P213, DOI 10.1002/jcb.240330308; WINTER E, 1985, P NATL ACAD SCI USA, V82, P7575, DOI 10.1073/pnas.82.22.7575	33	298	315	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1989	4	7					923	928						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE584	2666911				2022-12-17	WOS:A1989AE58400016
J	Xue, X; Yang, YA; Zhang, A; Fong, KW; Kim, J; Song, B; Li, S; Zhao, JC; Yu, J				Xue, X.; Yang, Y. A.; Zhang, A.; Fong, K-W; Kim, J.; Song, B.; Li, S.; Zhao, J. C.; Yu, J.			LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer	ONCOGENE			English	Article							LONG NONCODING RNAS; HUMAN PROSTATE-CANCER; ANDROGEN RECEPTOR; PROGNOSTIC MARKER; GENE-EXPRESSION; ESTROGEN; PROGRESSION; METASTASIS; BINDING; CELLS	Tamoxifen, an estrogen receptor (ER) antagonist, is the mainstay treatment of breast cancer and the development of resistance represents a major obstacle for a cure. Although long non-coding RNAs such as HOTAIR have been implicated in breast tumorigenesis, their roles in chemotherapy resistance remain largely unknown. In this study, we report that HOTAIR (HOX antisense intergenic RNA) is upregulated in tamoxifen-resistant breast cancer tissues compared to their primary counterparts. Mechanistically, HOTAIR is a direct target of ER-mediated transcriptional repression and is thus restored upon the blockade of ER signaling, either by hormone deprivation or by tamoxifen treatment. Interestingly, this elevated HOTAIR increases ER protein level and thus enhances ER occupancy on the chromatin and potentiates its downstream gene regulation. HOTAIR overexpression is sufficient to activate the ER transcriptional program even under hormone-deprived conditions. Functionally, we found that HOTAIR overexpression increases breast cancer cell proliferation, whereas its depletion significantly impairs cell survival and abolishes tamoxifen-resistant cell growth. In conclusion, the long non-coding RNA HOTAIR is directly repressed by ER and its upregulation promotes ligand-independent ER activities and contributes to tamoxifen resistance.	[Xue, X.] Guangzhou Med Univ, Ctr Canc, Div Thorac Surg, Guangzhou, Guangdong, Peoples R China; [Xue, X.; Yang, Y. A.; Zhang, A.; Fong, K-W; Kim, J.; Song, B.; Li, S.; Zhao, J. C.; Yu, J.] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Div Hematol Oncol,Dept Med, 303 E Super St Lurie 5-117, Chicago, IL 60611 USA; [Yu, J.] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA	Guangzhou Medical University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center	Yu, J (corresponding author), Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Div Hematol Oncol,Dept Med, 303 E Super St Lurie 5-117, Chicago, IL 60611 USA.	jindan-yu@northwestern.edu	li, shangze/AAW-6317-2021; Kim, Jung/Q-7801-2016	Fong, Ka-wing/0000-0001-6995-0264; Yang, Angela/0000-0002-9868-7431; Kim, Jung/0000-0001-6274-2841	Office of the Provost; Northwestern University Information Technology; US Department of Defense [W81XWH-13-1-0319]; Research Scholar Award from the American Cancer Society [RSG-12-085-01]; National Institutes of Health Training Program in Oncogenesis and Developmental Biology [T32 CA080621]; National Institutes of Health/National Cancer Institute training grant [T32 CA009560]; NATIONAL CANCER INSTITUTE [T32CA080621, T32CA009560] Funding Source: NIH RePORTER	Office of the Provost; Northwestern University Information Technology; US Department of Defense(United States Department of Defense); Research Scholar Award from the American Cancer Society(American Cancer Society); National Institutes of Health Training Program in Oncogenesis and Developmental Biology; National Institutes of Health/National Cancer Institute training grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Bioinformatic analysis was supported by the computational resources and staff contributions provided for the Quest high-performance computing facility at Northwestern University, which is jointly supported by the Office of the Provost, the Office for Research, and Northwestern University Information Technology. This work was supported by the the US Department of Defense W81XWH-13-1-0319 (to JY) and the Research Scholar Award RSG-12-085-01 (to JY) from the American Cancer Society. JK was supported in part by the National Institutes of Health Training Program in Oncogenesis and Developmental Biology (T32 CA080621), and YAY was supported in part by the National Institutes of Health/National Cancer Institute training grant T32 CA009560.	Bussemakers MJG, 1999, CANCER RES, V59, P5975; Chen DH, 2012, NAT MED, V18, P1511, DOI 10.1038/nm.2940; Chisholm KM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047998; Clarke R, 2001, PHARMACOL REV, V53, P25; Davis ME, 2010, NATURE, V464, P1067, DOI 10.1038/nature08956; Doisneau-Sixou SF, 2003, ENDOCR-RELAT CANCER, V10, P179, DOI 10.1677/erc.0.0100179; Fan MY, 2006, CANCER RES, V66, P11954, DOI 10.1158/0008-5472.CAN-06-1666; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Gupta S, 2010, CANCER RES, V70, P6735, DOI 10.1158/0008-5472.CAN-10-0244; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Iyer MK, 2015, NAT GENET, V47, P199, DOI 10.1038/ng.3192; Joseph R, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.109; Kaneko S, 2010, GENE DEV, V24, P2615, DOI 10.1101/gad.1983810; Lee GL, 2011, NAT REV UROL, V8, P123, DOI 10.1038/nrurol.2011.10; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521; Mourtada-Maarabouni M, 2009, ONCOGENE, V28, P195, DOI 10.1038/onc.2008.373; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006; Prensner JR, 2013, NAT GENET, V45, P1392, DOI 10.1038/ng.2771; Prensner JR, 2011, CANCER DISCOV, V1, P391, DOI 10.1158/2159-8290.CD-11-0209; Prensner JR, 2011, NAT BIOTECHNOL, V29, P742, DOI 10.1038/nbt.1914; Ring A, 2004, ENDOCR-RELAT CANCER, V11, P643, DOI 10.1677/erc.1.00776; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Ross-Innes CS, 2012, NATURE, V481, P389, DOI 10.1038/nature10730; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Sorensen KP, 2013, BREAST CANCER RES TR, V142, P529, DOI 10.1007/s10549-013-2776-7; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002; Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018; Wilusz JE, 2009, GENE DEV, V23, P1494, DOI 10.1101/gad.1800909; Wu L, 2014, ONCOGENE, V33, P504, DOI 10.1038/onc.2012.602; Yoon JH, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3939; Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018; Zhou Y, 2007, J BIOL CHEM, V282, P24731, DOI 10.1074/jbc.M702029200	36	297	318	2	96	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2016	35	21					2746	2755		10.1038/onc.2015.340	http://dx.doi.org/10.1038/onc.2015.340			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MJ	26364613	Green Accepted			2022-12-17	WOS:000377472700008
J	Guo, F; Wang, Y; Liu, J; Mok, SC; Xue, F; Zhang, W				Guo, F.; Wang, Y.; Liu, J.; Mok, S. C.; Xue, F.; Zhang, W.			CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks	ONCOGENE			English	Review							CHEMOKINE RECEPTOR CXCR4; EPITHELIAL-MESENCHYMAL TRANSITION; CHRONIC LYMPHOCYTIC-LEUKEMIA; LYMPH-NODE METASTASIS; OVARIAN-CANCER; COLORECTAL-CANCER; CXCR4/CXCL12 AXIS; TUMOR-SUPPRESSOR; PROSTATE-CANCER; CARCINOMA-CELLS	Increasing evidence indicates that the tumor microenvironment has critical roles in all aspects of cancer biology, including growth, angiogenesis, metastasis and progression. Although chemokines and their receptors were originally identified as mediators of inflammatory diseases, it is being increasingly recognized that they serve as critical communication bridges between tumor cells and stromal cells to create a permissive microenvironment for tumor growth and metastasis. Thus, an important therapeutic strategy for cancer is to break this communication channel and isolate tumor cells for long-term elimination. Cytokine CXCL12 (also known as stromal-derived factor 1a) and its receptor CXCR4 represent the most promising actionable targets for this strategy. Both are overexpressed in various cancer types, and this aberrant expression strongly promotes proliferation, migration and invasion through multiple signal pathways. Several molecules that target CXCL12 or CXCR4 have been developed to interfere with tumor growth and metastasis. In this article, we review our current understanding of the CXCL12/CXCR4 axis in cancer tumorigenesis and progression and discuss its therapeutic implications.	[Guo, F.; Wang, Y.; Xue, F.] Tianjin Med Univ, Dept Gynecol & Obstet, Gen Hosp, 154 Anshan Rd, Tianjin 300052, Peoples R China; [Guo, F.; Liu, J.; Zhang, W.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, 1515 Holcombe Blvd Unit 85, Houston, TX 77030 USA; [Mok, S. C.] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Houston, TX 77030 USA	Tianjin Medical University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Xue, F (corresponding author), Tianjin Med Univ, Dept Gynecol & Obstet, Gen Hosp, 154 Anshan Rd, Tianjin 300052, Peoples R China.; Zhang, W (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Pathol, 1515 Holcombe Blvd Unit 85, Houston, TX 77030 USA.	fengxiaxue1962@163.com; wzhang@mdanderson.org			Tianjin Municipal Science and Technology Commission International Cooperation Foundation [15RCGFSY00108]; Natural Science Fund of Tianjin Municipal Science and Technology Commission [12JCYBJC17900]; Tianjin Medical University Science Foundation [2014KYQ03]; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	Tianjin Municipal Science and Technology Commission International Cooperation Foundation; Natural Science Fund of Tianjin Municipal Science and Technology Commission; Tianjin Medical University Science Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Ann Sutton from the Department of Scientific Publications at The University of Texas MD Anderson Cancer Center for editing this manuscript. This work was partially supported by funds from the Tianjin Municipal Science and Technology Commission International Cooperation Foundation (No. 15RCGFSY00108), the Natural Science Fund of Tianjin Municipal Science and Technology Commission (No. 12JCYBJC17900), and the Tianjin Medical University Science Foundation (No. 2014KYQ03).	Agarwal A, 2014, LEUKEMIA RES, V38, P1097, DOI 10.1016/j.leukres.2014.05.017; Archibald KM, 2012, ONCOGENE, V31, P4987, DOI 10.1038/onc.2011.653; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Barbero S, 2003, CANCER RES, V63, P1969; Barbieri F, 2010, J ONCOL, V2010, DOI 10.1155/2010/426956; Barbolina MV, 2010, MOL CANCER RES, V8, P653, DOI 10.1158/1541-7786.MCR-09-0463; Bartolome RA, 2009, AM J PATHOL, V174, P602, DOI 10.2353/ajpath.2009.080636; Beider K, 2014, ONCOTARGET, V5, P11283, DOI 10.18632/oncotarget.2207; Bignotti E, 2007, AM J OBSTET GYNECOL, V196, P245, DOI 10.1016/j.ajog.2006.10.874; Boudot A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020898; Buechli ME, 2013, STEM CELLS DEV, V22, P1288, DOI 10.1089/scd.2012.0411; Byrne SN, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.27562; Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075; Chatterjee S, 2014, ADV CANCER RES, V124, P31, DOI 10.1016/B978-0-12-411638-2.00002-1; Chen L, 2010, ACTA BIOCH BIOPH SIN, V42, P1, DOI 10.1093/abbs/gmp108; Chu CY, 2009, CARCINOGENESIS, V30, P205, DOI 10.1093/carcin/bgn228; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; Conley-LaComb MK, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-85; Crowther-Swanepoel D, 2009, BLOOD, V114, P4843, DOI 10.1182/blood-2009-07-235184; Cui X. Y., 2014, CHINESE GEN PRACTICE, V21, P1929, DOI [10.3969/j.issn.1674-4748.2014.21.005, DOI 10.3969/J.ISSN.1674-4748.2014.21.005, DOI 10.1002/HEP.27665]; Darash-Yahana M, 2004, FASEB J, V18, P1240, DOI 10.1096/fj.03-0935fje; de Nigris F, 2012, RECENT PAT ANTI-CANC, V7, P251, DOI 10.2174/157489212801820039; Deutsch AJA, 2013, MODERN PATHOL, V26, P182, DOI 10.1038/modpathol.2012.134; Domanska UM, 2012, NEOPLASIA, V14, P709, DOI 10.1593/neo.12324; Douglass S, 2014, J PATHOL, V234, P74, DOI 10.1002/path.4381; Duan FT, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-164; Duda DG, 2011, CLIN CANCER RES, V17, P2074, DOI 10.1158/1078-0432.CCR-10-2636; Durr C, 2010, CANCER RES, V70, P10170, DOI 10.1158/0008-5472.CAN-10-1943; Feig C, 2013, P NATL ACAD SCI USA, V110, P20212, DOI 10.1073/pnas.1320318110; Forde S, 2007, BLOOD, V109, P1825, DOI 10.1182/blood-2006-05-023028; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Ganzfried BF, 2013, DATABASE-OXFORD, DOI 10.1093/database/bat013; Gelmini S, 2009, CLIN EXP METASTAS, V26, P261, DOI 10.1007/s10585-009-9240-4; Ghanem I, 2014, AM J TRANSL RES, V6, P340; Gil M, 2014, J IMMUNOL, V193, P5327, DOI 10.4049/jimmunol.1400201; Gil M, 2013, P NATL ACAD SCI USA, V110, pE1291, DOI 10.1073/pnas.1220580110; Grunewald M, 2006, CELL, V124, P175, DOI 10.1016/j.cell.2005.10.036; Guo Li, 2011, Chin J Cancer, V30, P336; Guo Qing, 2013, Zhonghua Yi Xue Za Zhi, V93, P1677; Guyon A, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00065; Hall JM, 2003, MOL ENDOCRINOL, V17, P792, DOI 10.1210/me.2002-0438; Heckmann D, 2014, CLIN CANCER RES, V20, P604, DOI 10.1158/1078-0432.CCR-13-0582; Heinrich EL, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-68; Hoellenriegel J, 2014, BLOOD, V123, P1032, DOI 10.1182/blood-2013-03-493924; Hsieh JY, 2013, NUCLEIC ACIDS RES, V41, P9753, DOI 10.1093/nar/gkt666; Hu TH, 2014, CANCER LETT, V354, P417, DOI 10.1016/j.canlet.2014.08.012; Huang AF, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-115; Huang Y, 2013, CHIN J CANCER, V32, P289, DOI 10.5732/cjc.012.10063; Huang Z, 2014, GUT, V63, P1247, DOI 10.1136/gutjnl-2012-304213; Ierano C, 2009, CELL CYCLE, V8, P1228, DOI 10.4161/cc.8.8.8250; Infantino S, 2006, J IMMUNOL, V176, P2197, DOI 10.4049/jimmunol.176.4.2197; Iwasa S, 2009, ANTICANCER RES, V29, P4751; Jaszczynska-Nowinka K, 2014, ONCOL LETT, V7, P1618, DOI 10.3892/ol.2014.1897; Jee SH, 2004, J INVEST DERMATOL, V123, P1169, DOI 10.1111/j.0022-202X.2004.23497.x; Jeon ES, 2008, STEM CELLS, V26, P789, DOI 10.1634/stemcells.2007-0742; Jiang YP, 2006, GYNECOL ONCOL, V103, P226, DOI 10.1016/j.ygyno.2006.02.036; Jiang Yu-Ping, 2007, Zhonghua Fu Chan Ke Za Zhi, V42, P403; Kajiyama H, 2008, INT J CANCER, V122, P91, DOI 10.1002/ijc.23083; Kajiyama H, 2007, CELL TISSUE RES, V330, P221, DOI 10.1007/s00441-007-0455-x; Kang KS, 2013, BIOCHEM BIOPH RES CO, V432, P333, DOI 10.1016/j.bbrc.2013.01.102; Karin N, 2010, J LEUKOCYTE BIOL, V88, P463, DOI 10.1189/jlb.0909602; Kawaguchi A, 2009, BLOOD, V114, P2961, DOI 10.1182/blood-2008-11-189308; Kim J, 2006, ANN SURG, V244, P113, DOI 10.1097/01.sla.0000217690.65909.9c; Ko SY, 2012, J CLIN INVEST, V122, P3603, DOI 10.1172/JCI62229; Kojima K, 2011, BLOOD, V118, P4431, DOI 10.1182/blood-2011-02-334136; Konopleva MY, 2011, J CLIN ONCOL, V29, P591, DOI 10.1200/JCO.2010.31.0904; Kryczek I, 2005, CANCER RES, V65, P465; Kryczek I, 2007, AM J PHYSIOL-CELL PH, V292, pC987, DOI 10.1152/ajpcell.00406.2006; Kulbe H, 2005, CANCER RES, V65, P10355, DOI 10.1158/0008-5472.CAN-05-0957; Kulbe H, 2007, CANCER RES, V67, P585, DOI 10.1158/0008-5472.CAN-06-2941; Kwong J, 2009, MOL CANCER THER, V8, P1893, DOI 10.1158/1535-7163.MCT-08-0966; Lee YH, 2010, CLIN ENDOCRINOL, V72, P209, DOI 10.1111/j.1365-2265.2009.03629.x; Leone V, 2011, J CLIN ENDOCR METAB, V96, pE1388, DOI 10.1210/jc.2011-0345; Li XQ, 2014, MOL CELL BIOCHEM, V392, P77, DOI 10.1007/s11010-014-2020-8; Li XQ, 2012, CANCER LETT, V322, P169, DOI 10.1016/j.canlet.2012.02.035; Liang JJ, 2010, CANCER EPIDEM BIOMAR, V19, P2598, DOI 10.1158/1055-9965.EPI-10-0405; Liang Z, 2007, BIOCHEM BIOPH RES CO, V359, P716, DOI 10.1016/j.bbrc.2007.05.182; Liao AY, 2016, MOL NEUROBIOL, V53, P210, DOI 10.1007/s12035-014-9006-0; Lim JB, 2015, CYTOKINE, V73, P16, DOI 10.1016/j.cyto.2015.01.010; Limon-Flores AY, 2009, TOXICOL SCI, V112, P144, DOI 10.1093/toxsci/kfp181; Lin L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.392; Lin SY, 2013, INT J ONCOL, V43, P1817, DOI 10.3892/ijo.2013.2109; Liu FF, 2009, HISTOPATHOLOGY, V54, P741, DOI 10.1111/j.1365-2559.2009.03289.x; Liu SC, 2014, NEURO-ONCOLOGY, V16, P21, DOI 10.1093/neuonc/not149; Liu YL, 2014, INT J ONCOL, V44, P203, DOI 10.3892/ijo.2013.2168; Liu Yu-Qiang, 2014, J Anal Methods Chem, V2014, P617367, DOI 10.1155/2014/617367; Liu Z, 2015, CIRC-CARDIOVASC GENE, V8, P11, DOI 10.1161/CIRCGENETICS.114.000598; Lu J, 2014, CARCINOGENESIS, V35, P554, DOI 10.1093/carcin/bgt354; Lu ML, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065719; Luo HN, 2014, MED ONCOL, V31, DOI 10.1007/s12032-013-0789-z; Machelon V, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-97; Madden SF, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-241; Martin SK, 2010, HAEMATOL-HEMATOL J, V95, P776, DOI 10.3324/haematol.2009.015628; Monteagudo C, 2012, CLIN EXP METASTAS, V29, P625, DOI 10.1007/s10585-012-9476-2; Monterrubio M, 2009, BIOCHEM BIOPH RES CO, V388, P199, DOI 10.1016/j.bbrc.2009.07.153; Moskovits N, 2006, CANCER RES, V66, P10671, DOI 10.1158/0008-5472.CAN-06-2323; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nervi B, 2009, BLOOD, V113, P6206, DOI 10.1182/blood-2008-06-162123; Niedermeier M, 2009, BLOOD, V113, P5549, DOI 10.1182/blood-2008-06-165068; Obermajer N, 2011, CANCER RES, V71, P7463, DOI 10.1158/0008-5472.CAN-11-2449; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Perim AD, 2013, MOL BIOL REP, V40, P4591, DOI 10.1007/s11033-013-2551-1; Pietkiewicz PP, 2010, BIOMED PHARMACOTHER, V64, P54, DOI 10.1016/j.biopha.2009.04.041; Pillai MM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014304; Ping YF, 2011, J PATHOL, V224, P344, DOI 10.1002/path.2908; Polyak K, 2009, TRENDS GENET, V25, P30, DOI 10.1016/j.tig.2008.10.012; Popple A, 2012, BRIT J CANCER, V106, P1306, DOI 10.1038/bjc.2012.49; Porcile C, 2004, ANN NY ACAD SCI, V1030, P162, DOI 10.1196/annals.1329.021; Porcile C, 2005, EXP CELL RES, V308, P241, DOI 10.1016/j.yexcr.2005.04.024; Qu QX, 2012, ONCOL RES, V20, P383, DOI 10.3727/096504013X13657689382653; Quattrocchi L, 2013, J OBSTET GYNAECOL RE, V39, P297, DOI 10.1111/j.1447-0756.2012.01949.x; Ramakrishnan M, 2013, CANCER RES, V73, P5360, DOI 10.1158/0008-5472.CAN-13-0896; Ramos EAS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029461; Ramos EAS, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-23; Ratajczak MZ, 2006, LEUKEMIA, V20, P1915, DOI 10.1038/sj.leu.2404357; Ratajczak MZ, 2013, J OVARIAN RES, V6, DOI 10.1186/1757-2215-6-95; Ray P, 2011, NEOPLASIA, V13, P1152, DOI 10.1593/neo.111076; Redjal N, 2006, CLIN CANCER RES, V12, P6765, DOI 10.1158/1078-0432.CCR-06-1372; Rehman AO, 2009, INT J ORAL SCI, V1, P105, DOI 10.4248/IJOS.09059; Righi E, 2011, CANCER RES, V71, P5522, DOI 10.1158/0008-5472.CAN-10-3143; Rigo A, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-273; Roccaro AM, 2014, CELL REP, V9, P118, DOI 10.1016/j.celrep.2014.08.042; Romain B, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-58; Salomonnson E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051500; Sanchez-Martin L, 2013, TRENDS MOL MED, V19, P12, DOI 10.1016/j.molmed.2012.10.004; Sanz-Pamplona R, 2012, MOL BIOSYST, V8, P2085, DOI 10.1039/c2mb25104c; Sarchio SNE, 2014, J INVEST DERMATOL, V134, P1091, DOI 10.1038/jid.2013.424; Scotton CJ, 2001, CANCER RES, V61, P4961; Scotton CJ, 2002, CANCER RES, V62, P5930; Shaked Y, 2008, CANCER CELL, V14, P263, DOI 10.1016/j.ccr.2008.08.001; Shen PF, 2014, PROSTATE, V74, P756, DOI 10.1002/pros.22795; Shen XY, 2009, J HUAZHONG U SCI-MED, V29, P363, DOI 10.1007/s11596-009-0320-0; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Smith MCP, 2004, CANCER RES, V64, P8604, DOI 10.1158/0008-5472.CAN-04-1844; Spinello I, 2011, BLOOD CANCER J, V1, DOI 10.1038/bcj.2011.24; Staton AA, 2011, NAT GENET, V43, P204, DOI 10.1038/ng.758; Su YC, 2006, BREAST, V15, P533, DOI 10.1016/j.breast.2005.08.034; Tang JQ, 2012, CANCER INVEST, V30, P380, DOI 10.3109/07357907.2012.666692; Taverna S, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-169; Thiele S, 2014, BRIT J PHARMACOL, V171, P5313, DOI 10.1111/bph.12842; Thomas RM, 2008, GUT, V57, P1555, DOI 10.1136/gut.2007.143941; Toritsuka M, 2013, P NATL ACAD SCI USA, V110, P17552, DOI 10.1073/pnas.1312661110; Tsukamoto H, 2007, CLIN EXP METASTAS, V24, P423, DOI 10.1007/s10585-007-9079-5; Uchida D, 2003, EXP CELL RES, V290, P289, DOI 10.1016/S0014-4827(03)00344-6; Uygur B, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-139; Vater A, 2013, CLIN PHARMACOL THER, V94, P150, DOI 10.1038/clpt.2013.58; Wagner PL, 2009, J THORAC CARDIOV SUR, V137, P615, DOI 10.1016/j.jtcvs.2008.07.039; Wang H, 2014, ONCOL LETT, V7, P1581, DOI 10.3892/ol.2014.1926; Wang JH, 2005, CELL SIGNAL, V17, P1578, DOI 10.1016/j.cellsig.2005.03.022; Wang JH, 2007, CANCER RES, V67, P149, DOI 10.1158/0008-5472.CAN-06-2971; Wang Z, 2008, BRIT J CANCER, V99, P1695, DOI 10.1038/sj.bjc.6604745; Wei S, 2007, CANCER RES, V67, P7487, DOI 10.1158/0008-5472.CAN-07-0565; Welschinger R, 2013, EXP HEMATOL, V41, P293, DOI 10.1016/j.exphem.2012.11.004; Wertel I, 2011, GINEKOL POL, V82, P414; Wu MH, 2008, J CELL BIOCHEM, V103, P245, DOI 10.1002/jcb.21400; Xu L, 2009, CANCER RES, V69, P7905, DOI 10.1158/0008-5472.CAN-09-2099; Xu M, 2010, J ORAL PATHOL MED, V39, P63, DOI 10.1111/j.1600-0714.2009.00801.x; Xue BY, 2013, MOL CELL BIOCHEM, V380, P177, DOI 10.1007/s11010-013-1671-1; Yang BG, 2007, J IMMUNOL, V179, P4376, DOI 10.4049/jimmunol.179.7.4376; Yang P, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0377-x; Yang-Hartwich Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep06116; Yoon Y, 2007, CANCER RES, V67, P7518, DOI 10.1158/0008-5472.CAN-06-2263; Yu T, 2014, ONCOGENE, V33, P5017, DOI 10.1038/onc.2013.448; Yu Y, 2014, BRIT J CANCER, V110, P724, DOI 10.1038/bjc.2013.768; Yu YC, 2007, EUR J CANCER PREV, V16, P430, DOI 10.1097/01.cej.0000236259.88146.a4; Yu YC, 2013, ONCOL RES, V21, P217, DOI 10.3727/096504014X13907540404879; Yu YC, 2014, DNA CELL BIOL, V33, P543, DOI 10.1089/dna.2013.2289; Zannettino ACW, 1998, BLOOD, V92, P2613, DOI 10.1182/blood.V92.8.2613.420k15_2613_2628; Zeng ZH, 2009, BLOOD, V113, P6215, DOI 10.1182/blood-2008-05-158311; Zhang Y, 2013, NAT CELL BIOL, V15, P284, DOI 10.1038/ncb2690; Zhao ED, 2012, ONCOIMMUNOLOGY, V1, P152, DOI 10.4161/onci.1.2.18480; Zhi Y, 2012, DIGEST DIS SCI, V57, P650, DOI 10.1007/s10620-011-1922-5; Zhou JD, 2014, INT J CLIN EXP PATHO, V7, P7182; Zhou W, 2009, J CANCER RES CLIN, V135, P91, DOI 10.1007/s00432-008-0435-x; Zhu S, 2010, ONCOGENE, V29, P1763, DOI 10.1038/onc.2009.459	176	297	311	6	98	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2016	35	7					816	826		10.1038/onc.2015.139	http://dx.doi.org/10.1038/onc.2015.139			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RO	25961926	Bronze			2022-12-17	WOS:000370332200002
J	LEONE, A; FLATOW, U; VANHOUTTE, K; STEEG, PS				LEONE, A; FLATOW, U; VANHOUTTE, K; STEEG, PS			TRANSFECTION OF HUMAN NM23-H1 INTO THE HUMAN MDA-MB-435 BREAST-CARCINOMA CELL-LINE - EFFECTS ON TUMOR METASTATIC POTENTIAL, COLONIZATION AND ENZYMATIC-ACTIVITY	ONCOGENE			English	Article							NUCLEOSIDE DIPHOSPHATE KINASE; YEAST SCHIZOSACCHAROMYCES-POMBE; GTP-BINDING PROTEINS; COLORECTAL-CARCINOMA; DISEASE PROGRESSION; GOOD PROGNOSIS; EXPRESSION; GENE; CANCER; DROSOPHILA	We report the phenotypic effects of transfection of human nm23-H1 cDNA into the human MDA-MB-435 breast carcinoma cell line. Upon mammary fat pad or subcutaneous injection into nude mice, both the nm23-H1 and control transfected lines produced primary tumors; however, the nm23-H1-transfected lines produced metastases in significantly fewer mice than did control transfected lines. Reductions in tumor metastatic potential in vivo were accompanied by decreased colonization in soft agar and an altered colonization response to transforming growth factor beta in vitro. Total nucleoside diphosphate kinase activity, an enzymatic activity possessed by the Nm23 family, was not directly correlated with Nm23-H1 expression levels or suppression of metastatic potential in all cases examined. The data establish that nm23-H1 has functional suppressive effects on the tumor metastatic potential of a human breast carcinoma cell line, and suggest that it may regulate signal responsiveness in the colonization response.	NIH,PATHOL LAB,BLDG 10,ROOM 2A33,BETHESDA,MD 20892; FREDERICK CANC RES & DEV FACIL,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA			leone, alvaro/AAQ-7051-2020; Leone, Alvaro/K-6410-2016	Leone, Alvaro/0000-0003-3815-9052				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARNES R, 1991, AM J PATHOL, V139, P245; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; COHN KH, 1991, LANCET, V338, P722, DOI 10.1016/0140-6736(91)91444-Y; CREANOR J, 1989, J CELL SCI, V93, P185; DEAROLF CR, 1988, DEV BIOL, V129, P169, DOI 10.1016/0012-1606(88)90171-6; DEAROLF CR, 1988, DEV BIOL, V129, P159, DOI 10.1016/0012-1606(88)90170-4; DICKINSON JR, 1983, J CELL SCI, V60, P355; FLORENES VA, 1992, CANCER RES, V52, P6088; GILLES AM, 1991, J BIOL CHEM, V266, P8784; GOLDEN A, 1993, ONCOGENES TUMOR SUPP, P345; GORSCH SM, 1992, CANCER RES, V52, P6949; HAILAT N, 1991, J CLIN INVEST, V88, P341, DOI 10.1172/JCI115299; Hart I R, 1991, Semin Cancer Biol, V2, P87; HAUT M, 1991, J NATL CANCER I, V83, P712, DOI 10.1093/jnci/83.10.712; HENNESSY C, 1991, J NATL CANCER I, V83, P281, DOI 10.1093/jnci/83.4.281; HIGASHIYAMA M, 1992, BRIT J CANCER, V66, P533, DOI 10.1038/bjc.1992.308; HIRAYAMA R, 1991, J NATL CANCER I, V83, P1249, DOI 10.1093/jnci/83.17.1249; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KANTOR JD, 1993, CANCER RES, V53, P1971; KEIM D, 1992, J CLIN INVEST, V89, P919, DOI 10.1172/JCI115672; KIKKAWA S, 1990, J BIOL CHEM, V265, P21536; KIKKAWA S, 1991, J BIOL CHEM, V266, P12795; KOBAYASHI S, 1992, JPN J CANCER RES, V83, P859, DOI 10.1111/j.1349-7006.1992.tb01991.x; LAKSO M, 1992, CELL GROWTH DIFFER, V3, P873; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LEONE A, 1993, ONCOGENE, V8, P855; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MELKI R, 1992, BIOCHEM BIOPH RES CO, V187, P65, DOI 10.1016/S0006-291X(05)81459-7; NAKAYAMA T, 1992, J NATL CANCER I, V84, P1349, DOI 10.1093/jnci/84.17.1349; NICKERSON JA, 1984, J BIOL CHEM, V259, P1297; NICOLSON GL, 1987, CANCER RES, V47, P1473; OKABEKADO J, 1992, BIOCHEM BIOPH RES CO, V182, P987, DOI 10.1016/0006-291X(92)91829-F; PRICE JE, 1990, CANCER RES, V50, P717; RANDAZZO PA, 1991, SCIENCE, V254, P850, DOI 10.1126/science.1658935; RANDAZZO PA, 1992, J BIOL CHEM, V267, P18182; RIES AB, 1990, CANCER STATISTICS RE; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; ROYDS JA, 1993, J NATL CANCER I, V85, P727, DOI 10.1093/jnci/85.9.727; SASTREGARAU X, 1992, INT J CANCER, V50, P533, DOI 10.1002/ijc.2910500406; SCHWARZ LC, 1988, CANCER RES, V48, P6999; SIMPSON JF, 1993, LAB INVEST, V68, pA20; STAHL JA, 1991, CANCER RES, V51, P445; STEEG PS, 1993, BREAST CANCER RES TR, V25, P175, DOI 10.1007/BF00662142; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; TENG DHF, 1991, NATURE, V353, P437, DOI 10.1038/353437a0; THEODORESCU D, 1991, J CELL PHYSIOL, V148, P380, DOI 10.1002/jcp.1041480308; THOMAS DG, 1975, COMPUT BIOMED RES, V8, P423, DOI 10.1016/0010-4809(75)90048-8; TUBIANA M, 1991, BREAST CANCER RES TR, V18, P125, DOI 10.1007/BF01990028; VANDEVIJVER MJ, 1991, BIOCHIM BIOPHYS ACTA, V1072, P33, DOI 10.1016/0304-419X(91)90005-6; WANG LM, 1993, CANCER RES, V53, P717	52	297	309	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2325	2333						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8395676				2022-12-17	WOS:A1993LT36800002
J	Sinha, S; Levine, B				Sinha, S.; Levine, B.			The autophagy effector Beclin 1: a novel BH3-only protein	ONCOGENE			English	Review						Beclin 1; autophagy; BH3-only; apoptosis; Bcl-2; tumor suppressor	PROGRAMMED CELL-DEATH; BCL-2 FAMILY PROTEINS; LIFE-SPAN EXTENSION; TUMOR-SUPPRESSOR; C-ELEGANS; 3-KINASE COMPLEX; PEPTIDE COMPLEX; JNK1-MEDIATED PHOSPHORYLATION; 1-DEPENDENT AUTOPHAGY; REGULATES AUTOPHAGY	BH3 domains were originally discovered in the context of apoptosis regulators and they mediate binding of proapoptotic Bcl-2 family members to antiapoptotic Bcl-2 family members. Yet, recent studies indicate that BH3 domains do not function uniquely in apoptosis regulation; they also function in the regulation of another critical pathway involved in cellular and tissue homeostasis called autophagy. Antiapoptotic Bcl-2 homologs downregulate autophagy through interactions with the essential autophagy effector and haploinsufficient tumor suppressor, Beclin 1. Beclin 1 contains a BH3 domain, similar to that of Bcl-2 proteins, which is necessary and sufficient for binding to antiapoptotic Bcl- 2 homologs and required for Bcl-2-mediated inhibition of autophagy. This review will summarize the evidence that the BH3 domain of Beclin 1 serves as a key structural motif that enables Bcl- 2 to function not only as an antiapoptotic protein, but also as an antiautophagy protein. Oncogene (2009) 27, S137-S148; doi: 10.1038/onc.2009.51	[Sinha, S.] N Dakota State Univ, Dept Chem Biochem & Mol Biol, Fargo, ND 58105 USA; [Levine, B.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA; [Levine, B.] Univ Texas SW Med Ctr Dallas, Dept Microbiol, Dallas, TX 75390 USA; [Levine, B.] Univ Texas SW Med Ctr Dallas, Howard Hughes Med Inst, Dallas, TX 75390 USA	North Dakota State University Fargo; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Southwestern Medical Center Dallas	Sinha, S (corresponding author), N Dakota State Univ, Dept Chem Biochem & Mol Biol, Fargo, ND 58105 USA.	Sangita.Sinha@ndsu.edu; beth.levine@utsouthwestern.edu			NIH [R21 AI78108-01, RO1 CA109618, R01 CA084254]; NATIONAL CANCER INSTITUTE [R01CA084254, R01CA109618] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI078108] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The work in the authors' laboratory was funded by NIH Grants R21 AI78108-01 to SS and RO1 CA109618 and R01 CA084254 to BL.	Abedin MJ, 2007, CELL DEATH DIFFER, V14, P500, DOI 10.1038/sj.cdd.4402039; Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851; Apel A, 2008, CANCER RES, V68, P1485, DOI 10.1158/0008-5472.CAN-07-0562; Bohensky J, 2007, AUTOPHAGY, V3, P207, DOI 10.4161/auto.3708; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Chang CP, 2007, HEPATOLOGY, V45, P286, DOI 10.1002/hep.21509; Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034; Daido S, 2004, CANCER RES, V64, P4286, DOI 10.1158/0008-5472.CAN-03-3084; Daniel F, 2006, WORLD J GASTROENTERO, V12, P2895, DOI 10.3748/wjg.v12.i18.2895; Edinger AL, 2003, CANCER CELL, V4, P422, DOI 10.1016/S1535-6108(03)00306-4; ESCALATINE A, 2009, AUTOPHAGY I IN PRESS; Feng W, 2007, J MOL BIOL, V372, P223, DOI 10.1016/j.jmb.2007.06.069; Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102; Fimia GM, 2007, NATURE, V447, P1121, DOI 10.1038/nature05925; Fujiki Y, 2007, PLANT PHYSIOL, V143, P1132, DOI 10.1104/pp.106.093864; Fujiwara K, 2008, J BIOL CHEM, V283, P388, DOI 10.1074/jbc.M611043200; FURUYA N, 2005, AUTOPHAGY, P242; Furuya N, 2005, AUTOPHAGY, V1, P46, DOI 10.4161/auto.1.1.1542; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Hamacher-Brady A, 2007, CELL DEATH DIFFER, V14, P146, DOI 10.1038/sj.cdd.4401936; Hansen M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0040024; Harada M, 2008, EXP CELL RES, V314, P1753, DOI 10.1016/j.yexcr.2008.01.035; Hars ES, 2007, AUTOPHAGY, V3, P93, DOI 10.4161/auto.3636; He CC, 2008, MOL BIOL CELL, V19, P5506, DOI 10.1091/mbc.E08-05-0544; Huang QL, 2003, J MOL BIOL, V332, P1123, DOI 10.1016/j.jmb.2003.08.007; Huang QL, 2002, P NATL ACAD SCI USA, V99, P3428, DOI 10.1073/pnas.062525799; Itakura E, 2008, MOL BIOL CELL, V19, P5360, DOI 10.1091/mbc.E08-01-0080; Jia KL, 2007, AUTOPHAGY, V3, P597, DOI 10.4161/auto.4989; Jin SK, 2006, AUTOPHAGY, V2, P80, DOI 10.4161/auto.2.2.2460; Kametaka S, 1998, J BIOL CHEM, V273, P22284, DOI 10.1074/jbc.273.35.22284; Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707; Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061; Kim HP, 2008, AUTOPHAGY, V4, P887, DOI 10.4161/auto.6767; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529; Ku B, 2008, AUTOPHAGY, V4, P519, DOI 10.4161/auto.5846; Ku B, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040025; Levine B, 2006, AUTOPHAGY, V2, P65, DOI 10.4161/auto.2.2.2457; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Levine B, 2008, NAT CELL BIOL, V10, P637, DOI 10.1038/ncb0608-637; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Levine B, 2007, NAT REV IMMUNOL, V7, P767, DOI 10.1038/nri2161; Liang CG, 2008, AUTOPHAGY, V4, P268, DOI 10.4161/auto.5210; Liang CY, 2007, AUTOPHAGY, V3, P69, DOI 10.4161/auto.3437; Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Liang XH, 2001, CANCER RES, V61, P3443; Liu XQ, 2003, IMMUNITY, V19, P341, DOI 10.1016/S1074-7613(03)00234-6; Liu Y, 2005, CELL, V121, P567, DOI 10.1016/j.cell.2005.03.007; Loh J, 2005, PLOS PATHOG, V1, P80, DOI 10.1371/journal.ppat.0010010; Maiuri MC, 2009, CELL DEATH DIFFER, V16, P87, DOI 10.1038/cdd.2008.131; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; Melendez A, 2003, SCIENCE, V301, P1387, DOI 10.1126/science.1087782; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Morselli E, 2008, CELL CYCLE, V7, P3056, DOI 10.4161/cc.7.19.6751; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nguyen TMB, 2007, BLOOD, V109, P4793, DOI 10.1182/blood-2006-11-059352; Obara K, 2008, AUTOPHAGY, V4, P952, DOI 10.4161/auto.6790; Oberstein A, 2007, J BIOL CHEM, V282, P13123, DOI 10.1074/jbc.M700492200; Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Orvedahl A, 2009, CELL DEATH DIFFER, V16, P57, DOI 10.1038/cdd.2008.130; Orvedahl A, 2007, CELL HOST MICROBE, V1, P23, DOI 10.1016/j.chom.2006.12.001; Panaretou C, 1997, J BIOL CHEM, V272, P2477; Patel S, 2008, AUTOPHAGY, V4, P20, DOI 10.4161/auto.5056; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Pattingre S, 2006, CANCER RES, V66, P2885, DOI 10.1158/0008-5472.CAN-05-4412; Petros AM, 2000, PROTEIN SCI, V9, P2528, DOI 10.1017/S096183680000331X; Pickford F, 2008, J CLIN INVEST, V118, P2190, DOI 10.1172/JCI33585; QU X, 2007, CELL, V128, P833; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Ramakrishnan S, 2007, AUTOPHAGY, V3, P512; Rashmi R, 2008, ONCOGENE, V27, P1366, DOI 10.1038/sj.onc.1210783; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Schmid D, 2006, J MOL MED-JMM, V84, P194, DOI 10.1007/s00109-005-0014-4; Schweers RL, 2007, P NATL ACAD SCI USA, V104, P19500, DOI 10.1073/pnas.0708818104; Seaman MNJ, 1997, J CELL BIOL, V137, P79, DOI 10.1083/jcb.137.1.79; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Sinha S, 2008, AUTOPHAGY, V4, P989, DOI 10.4161/auto.6803; Takacs-Vellai K, 2005, CURR BIOL, V15, P1513, DOI 10.1016/j.cub.2005.07.035; Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634; Tannous P, 2008, P NATL ACAD SCI USA, V105, P9745, DOI 10.1073/pnas.0706802105; Tasdemir E, 2008, CELL CYCLE, V7, P3006, DOI 10.4161/cc.7.19.6702; Tasdemir E, 2008, AUTOPHAGY, V4, P810, DOI 10.4161/auto.6486; Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730; Tavernarakis N, 2008, AUTOPHAGY, V4, P870, DOI 10.4161/auto.6730; Toth ML, 2008, AUTOPHAGY, V4, P330, DOI 10.4161/auto.5618; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wang JR, 2008, AUTOPHAGY, V4, P947, DOI 10.4161/auto.6787; Wei YJ, 2008, AUTOPHAGY, V4, P949, DOI 10.4161/auto.6788; Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001; Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007-1102; Yang C, 2008, AM J PHYSIOL-RENAL, V294, pF777, DOI 10.1152/ajprenal.00590.2007; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100; Zeng XH, 2006, J CELL SCI, V119, P259, DOI 10.1242/jcs.02735; Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200	99	296	315	1	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27			1			S137	S148		10.1038/onc.2009.51	http://dx.doi.org/10.1038/onc.2009.51			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	478DA	19641499	Green Accepted			2022-12-17	WOS:000268566800012
J	Lorimore, SA; Coates, PJ; Scobie, GE; Milne, G; Wright, EG				Lorimore, SA; Coates, PJ; Scobie, GE; Milne, G; Wright, EG			Inflammatory-type responses after exposure to ionizing radiation in vivo: a mechanism for radiation-induced bystander effects?	ONCOGENE			English	Article						ionizing radiation; macrophage; inflammation; genetics; bystander	INDUCED CHROMOSOMAL INSTABILITY; BONE-MARROW TRANSPLANTATION; NITRIC-OXIDE; ALPHA-PARTICLES; UNIRRADIATED CELLS; P53 ACCUMULATION; APOPTOTIC CELLS; MAMMALIAN-CELLS; STROMAL CELLS; WHOLE-BODY	Haemopoietic tissues exposed to ionizing radiation are shown to exhibit increased macrophage activation, defined by ultrastructural characteristics and increased lysosomal and nitric oxide synthase enzyme activities. Macrophage activation post-irradiation was also associated with enhanced respiratory burst activities and an unexpected neutrophil infiltration. Examination of p53-null mice demonstrated that macrophage activation and neutrophil infiltration were not direct effects of irradiation, but were a consequence of the recognition and clearance of radiation-induced apoptotic cells. Increased phagocytic cell activity was maintained after apoptotic bodies had been removed. These findings demonstrate that, contrary to expectation, recognition and clearance of apoptotic cells after exposure to radiation produces both a persistent macrophage activation and an inflammatory-type response. We also demonstrate a complexity of macrophage activation following radiation that is genotype dependent, indicating that the in vivo macrophage responses to radiation damage are genetically modified processes. These short-term responses of macrophages to radiation-induced apoptosis and their genetic modification are likely to be important determinants of the longer-term consequences of radiation exposure. Furthermore, in addition to any effects attributable to immediate radiation-induced damage, our findings provide a mechanism for the production of damage via a 'bystander' effect which may contribute to radiation-induced genomic instability and leukaemogenesis.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland	University of Dundee	Coates, PJ (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland.		Coates, Philip J/H-6854-2019	Coates, Philip J/0000-0003-1518-6306				ADAMS DO, 1992, MACROPHAGE, P75; Brockhaus F, 1999, ONCOGENE, V18, P6403, DOI 10.1038/sj.onc.1203058; Brune B, 1996, BIOCHEM BIOPH RES CO, V229, P396, DOI 10.1006/bbrc.1996.1816; DUHRSEN U, 1990, BLOOD, V75, P190; Giles KM, 2000, BRIT J HAEMATOL, V109, P1, DOI 10.1046/j.1365-2141.2000.01805.x; GIRALT SA, 1994, BLOOD, V84, P3603, DOI 10.1182/blood.V84.11.3603.bloodjournal84113603; Gorbunov NV, 2000, RADIAT RES, V154, P73, DOI 10.1667/0033-7587(2000)154[0073:AOTNOS]2.0.CO;2; Greenberger JS, 1996, ACTA HAEMATOL-BASEL, V96, P1; Gregory CD, 2000, CURR OPIN IMMUNOL, V12, P27, DOI 10.1016/S0952-7915(99)00047-3; Handel-Fernandez ME, 2000, MACROPHAGES PRACTICA, P1; Iyer R, 2000, ARCH BIOCHEM BIOPHYS, V376, P14, DOI 10.1006/abbi.1999.1684; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Komarova EA, 1998, ONCOGENE, V17, P1089, DOI 10.1038/sj.onc.1202303; Lehnert BE, 1997, CANCER RES, V57, P2164; Little JB, 2000, CARCINOGENESIS, V21, P397, DOI 10.1093/carcin/21.3.397; Lorimore SA, 1998, P NATL ACAD SCI USA, V95, P5730, DOI 10.1073/pnas.95.10.5730; Lyng FM, 2000, BRIT J CANCER, V83, P1223, DOI 10.1054/bjoc.2000.1433; MCCANN SR, 1993, LEUKEMIA LYMPHOMA, V10, P419, DOI 10.3109/10428199309148198; McKinney LC, 1998, J LEUKOCYTE BIOL, V64, P459, DOI 10.1002/jlb.64.4.459; MOLE RH, 1983, BRIT J CANCER, V47, P285, DOI 10.1038/bjc.1983.37; Mothersill C, 1997, INT J RADIAT BIOL, V71, P421, DOI 10.1080/095530097144030; Mothersill CE, 1999, CARCINOGENESIS, V20, P2273, DOI 10.1093/carcin/20.12.2273; Narayanan PK, 1997, CANCER RES, V57, P3963; Nathan C, 2000, P NATL ACAD SCI USA, V97, P8841, DOI 10.1073/pnas.97.16.8841; Necas E, 1998, STEM CELLS, V16, P107; NOMURA T, 1992, J RADIAT RES, V33, P109, DOI 10.1269/jrr.33.SUPPLEMENT_109; Ponnaiya B, 1997, RADIAT RES, V147, P121, DOI 10.2307/3579411; Prise KM, 1998, INT J RADIAT BIOL, V74, P793, DOI 10.1080/095530098141087; SILVER LM, 1995, MOUSE GENETICS CONCE, P195; Uchimura E, 2000, J LEUKOCYTE BIOL, V67, P780, DOI 10.1002/jlb.67.6.780; WALBURG HE, 1968, INT J CANCER, V3, P150, DOI 10.1002/ijc.2910030118; Watson GE, 1997, INT J RADIAT BIOL, V71, P497, DOI 10.1080/095530097143824; Watson GE, 2000, CANCER RES, V60, P5608; Wink DA, 1998, CARCINOGENESIS, V19, P711, DOI 10.1093/carcin/19.5.711; Wood W, 2000, DEVELOPMENT, V127, P5245; Wright EG, 1998, INT J RADIAT BIOL, V74, P681, DOI 10.1080/095530098140943; Wu LJ, 1999, P NATL ACAD SCI USA, V96, P4959, DOI 10.1073/pnas.96.9.4959; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Xu WM, 2000, NAT CELL BIOL, V2, P339, DOI 10.1038/35014028; YAMAMOTO K, 1984, J EXP MED, V159, P405, DOI 10.1084/jem.159.2.405; YOSHIDA K, 1993, LEUKEMIA RES, V17, P437, DOI 10.1016/0145-2126(93)90099-7; Zhou HN, 2000, P NATL ACAD SCI USA, V97, P2099, DOI 10.1073/pnas.030420797	42	296	312	0	10	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 25	2001	20	48					7085	7095		10.1038/sj.onc.1204903	http://dx.doi.org/10.1038/sj.onc.1204903			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485DY	11704832				2022-12-17	WOS:000171739300011
J	Yoshihara, K; Wang, Q; Torres-Garcia, W; Zheng, S; Vegesna, R; Kim, H; Verhaak, RGW				Yoshihara, K.; Wang, Q.; Torres-Garcia, W.; Zheng, S.; Vegesna, R.; Kim, H.; Verhaak, R. G. W.			The landscape and therapeutic relevance of cancer-associated transcript fusions	ONCOGENE			English	Article							GENE FUSIONS; TYROSINE KINASE; BREAST-CANCER; IDENTIFICATION; GENOME; REARRANGEMENTS; ABERRATIONS; INHIBITION; RESOURCE; PATTERNS	Transcript fusions as a result of chromosomal rearrangements have been a focus of attention in cancer as they provide attractive therapeutic targets. To identify novel fusion transcripts with the potential to be exploited therapeutically, we analyzed RNA sequencing, DNA copy number and gene mutation data from 4366 primary tumor samples. To avoid false positives, we implemented stringent quality criteria that included filtering of fusions detected in RNAseq data from 364 normal tissue samples. Our analysis identified 7887 high confidence fusion transcripts across 13 tumor types. Our fusion prediction was validated by evidence of a genomic rearrangement for 78 of 79 fusions in 48 glioma samples where whole-genome sequencing data were available. Cancers with higher levels of genomic instability showed a corresponding increase in fusion transcript frequency, whereas tumor samples harboring fusions contained statistically significantly fewer driver gene mutations, suggesting an important role for tumorigenesis. We identified at least one in-frame protein kinase fusion in 324 of 4366 samples (7.4%). Potentially druggable kinase fusions involving ALK, ROS, RET, NTRK and FGFR gene families were detected in bladder carcinoma (3.3%), glioblastoma (4.4%), head and neck cancer (1.0%), low-grade glioma (1.5%), lung adenocarcinoma (1.6%), lung squamous cell carcinoma (2.3%) and thyroid carcinoma (8.7%), suggesting a potential for application of kinase inhibitors across tumor types. Inframe fusion transcripts involving histone methyltransferase or histone demethylase genes were detected in 111 samples (2.5%) and may additionally be considered as therapeutic targets. In summary, we described the landscape of transcript fusions detected across a large number of tumor samples and revealed fusion events with clinical relevance that have not been previously recognized. Our results support the concept of basket clinical trials where patients are matched with experimental therapies based on their genomic profile rather than the tissue where the tumor originated.	[Yoshihara, K.; Wang, Q.; Torres-Garcia, W.; Zheng, S.; Vegesna, R.; Kim, H.; Verhaak, R. G. W.] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA; [Yoshihara, K.] Niigata Univ, Grad Sch Med & Dent Sci, Dept Obstet & Gynecol, Niigata, Japan; [Verhaak, R. G. W.] Univ Texas MD Anderson Canc Ctr, Dept Genome Med, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Niigata University; University of Texas System; UTMD Anderson Cancer Center	Verhaak, RGW (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Dept Bioinformat & Computat Biol, 1400 Pressler St,Unit 1410, Houston, TX 77030 USA.	rverhaak@mdanderson.org	Yoshihara, Kosuke/AAU-9874-2020; Kim, Hoon/AAL-9283-2020; Verhaak, Roel/ABE-7058-2020; Torres-Garcia, Wandaliz/L-6347-2017	Yoshihara, Kosuke/0000-0002-2254-3378; Kim, Hoon/0000-0003-4244-6126; 	Mary K Chapman Foundation; Michael & Susan Dell Foundation; US National Cancer Institute (MD Anderson TCGA Genome Data Analysis Center) [CA143883, CA083639]; MD Anderson Cancer Center [P30 CA016672]; NATIONAL CANCER INSTITUTE [P30CA016672, U24CA143883, P50CA083639] Funding Source: NIH RePORTER	Mary K Chapman Foundation; Michael & Susan Dell Foundation; US National Cancer Institute (MD Anderson TCGA Genome Data Analysis Center); MD Anderson Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The results published here are in whole or part based upon data generated by The Cancer Genome Atlas project established by the NCI and NHGRI. Information about TCGA and the investigators and institutions who constitute the TCGA research network can be found at 'http://cancergenome.nih.gov'. This work was supported in part by the Mary K Chapman Foundation, the Michael & Susan Dell Foundation (honoring Lorraine Dell), US National Cancer Institute (MD Anderson TCGA Genome Data Analysis Center) grant numbers CA143883 and CA083639, and MD Anderson Cancer Center Support Grant P30 CA016672 (the Bioinformatics Shared Resource).	Arrowsmith CH, 2012, NAT REV DRUG DISCOV, V11, P384, DOI 10.1038/nrd3674; Asmann YW, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr362; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Cadot B, 2009, CANCER RES, V69, P6074, DOI 10.1158/0008-5472.CAN-08-2796; Chen K, 2009, NAT METHODS, V6, P677, DOI [10.1038/nmeth.1363, 10.1038/NMETH.1363]; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Daigle SR, 2011, CANCER CELL, V20, P53, DOI 10.1016/j.ccr.2011.06.009; Edgren H, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-1-r6; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Gough SM, 2014, CANCER DISCOV, V4, P564, DOI 10.1158/2159-8290.CD-13-0419; Guo GW, 2013, NAT GENET, V45, P1459, DOI 10.1038/ng.2798; Hallberg B, 2013, NAT REV CANCER, V13, P685, DOI 10.1038/nrc3580; Hojfeldt JW, 2013, NAT REV DRUG DISCOV, V12, P917, DOI 10.1038/nrd4154; Honeyman JN, 2014, SCIENCE, V343, P1010, DOI 10.1126/science.1249484; Kalyana-Sundaram S, 2012, NEOPLASIA, V14, P702, DOI 10.1593/neo.12914; Kantarjian H, 2006, CANCER-AM CANCER SOC, V106, P1794, DOI 10.1002/cncr.21792; Kantarjian H, 2010, NEW ENGL J MED, V362, P2260, DOI 10.1056/NEJMoa1002315; Kim P, 2010, NUCLEIC ACIDS RES, V38, pD81, DOI 10.1093/nar/gkp982; Lam ET, 2010, J CLIN ONCOL, V28, P2323, DOI 10.1200/JCO.2009.25.0068; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689; Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Li J, 2013, NAT METHODS, V10, P1046, DOI [10.1038/nmeth.2650, 10.1038/NMETH.2650]; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Mermel CH, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-r41; Meyerson M, 2010, NAT REV GENET, V11, P685, DOI 10.1038/nrg2841; Mitelman F, 2004, NAT GENET, V36, P331, DOI 10.1038/ng1335; Mitelman F, 2007, NAT REV CANCER, V7, P233, DOI 10.1038/nrc2091; NOWELL PC, 1960, SCIENCE, V132, P1497; Olsen EA, 2007, J CLIN ONCOL, V25, P3109, DOI 10.1200/JCO.2006.10.2434; Parker M, 2014, NATURE, V506, P451, DOI 10.1038/nature13109; R Core Team, 2019, R LANG ENV STAT COMP; Seo JS, 2012, GENOME RES, V22, P2109, DOI 10.1101/gr.145144.112; Shah N, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-818; Shaw AT, 2013, NAT REV CANCER, V13, P772, DOI 10.1038/nrc3612; Shaw AT, 2013, NEW ENGL J MED, V368, P2385, DOI 10.1056/NEJMoa1214886; Shern JF, 2014, CANCER DISCOV, V4, P216, DOI 10.1158/2159-8290.CD-13-0639; Singh D, 2012, SCIENCE, V337, P1231, DOI 10.1126/science.1220834; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Teng YC, 2013, CANCER RES, V73, P4711, DOI 10.1158/0008-5472.CAN-12-3165; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Torres-Garcia W, 2014, BIOINFORMATICS, V30, P2224, DOI 10.1093/bioinformatics/btu169; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vaishnavi A, 2013, NAT MED, V19, P1469, DOI 10.1038/nm.3352; Watson IR, 2013, NAT REV GENET, V14, P703, DOI 10.1038/nrg3539; Wells SA, 2010, J CLIN ONCOL, V28, P767, DOI 10.1200/JCO.2009.23.6604; Wu CX, 2012, J PATHOL, V227, P53, DOI 10.1002/path.3987; Wu YM, 2013, CANCER DISCOV, V3, P636, DOI 10.1158/2159-8290.CD-13-0050; Zack TI, 2013, NAT GENET, V45, P1134, DOI 10.1038/ng.2760; Zhao M, 2013, NUCLEIC ACIDS RES, V41, pD970, DOI 10.1093/nar/gks937; Zheng SY, 2013, GENE DEV, V27, P1462, DOI 10.1101/gad.213686.113	53	295	299	0	38	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2015	34	37					4845	4854		10.1038/onc.2014.406	http://dx.doi.org/10.1038/onc.2014.406			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR0YP	25500544	Green Accepted			2022-12-17	WOS:000361050000005
J	Turner, N; Lambros, MB; Horlings, HM; Pearson, A; Sharpe, R; Natrajan, R; Geyer, FC; van Kouwenhove, M; Kreike, B; Mackay, A; Ashworth, A; de Vijver, MJV; Reis-Filho, JS				Turner, N.; Lambros, M. B.; Horlings, H. M.; Pearson, A.; Sharpe, R.; Natrajan, R.; Geyer, F. C.; van Kouwenhove, M.; Kreike, B.; Mackay, A.; Ashworth, A.; de Vijver, M. J. van; Reis-Filho, J. S.			Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets	ONCOGENE			English	Article						triple negative breast cancer; microarrays; gene expression; comparative genomic hybridization; FGFR2	COMPARATIVE GENOMIC HYBRIDIZATION; COPY-NUMBER ALTERATIONS; MICROARRAY PLATFORMS; IN-SITU; EXPRESSION; PATTERNS; GENES; CELLS; ARRAY; RESOLUTION	Triple negative breast cancers (TNBCs) have a relatively poor prognosis and cannot be effectively treated with current targeted therapies. We searched for genes that have the potential to be therapeutic targets by identifying genes consistently overexpressed when amplified. Fifty-six TNBCs were subjected to high-resolution microarray-based comparative genomic hybridization (aCGH), of which 24 were subjected to genome-wide gene expression analysis. TNBCs were genetically heterogeneous; no individual focal amplification was present at high frequency, although 78.6% of TNBCs harboured at least one focal amplification. Integration of aCGH and expression data revealed 40 genes significantly overexpressed when amplified, including the known oncogenes and potential therapeutic targets, FGFR2 (10q26.3), BUB3 (10q26.3), RAB20 (13q34), PKN1 (19p13.12) and NOTCH3 (19p13.12). We identified two TNBC cell lines with FGFR2 amplification, which both had constitutive activation of FGFR2. Amplified cell lines were highly sensitive to FGFR inhibitor PD173074, and to RNAi silencing of FGFR2. Treatment with PD173074 induced apoptosis resulting partly from inhibition of PI3K-AKT signalling. Independent validation using publicly available aCGH data sets revealed FGFR2 gene was amplified in 4% (6/165) of TNBC, but not in other subtypes (0/214, P = 0.0065). Our analysis demonstrates that TNBCs are heterogeneous tumours with amplifications of FGFR2 in a subgroup of tumours. Oncogene (2010) 29, 2013-2023; doi: 10.1038/onc.2009.489; published online 18 January 2010	[Turner, N.; Lambros, M. B.; Pearson, A.; Sharpe, R.; Natrajan, R.; Geyer, F. C.; Mackay, A.; Ashworth, A.; Reis-Filho, J. S.] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England; [Horlings, H. M.; van Kouwenhove, M.; de Vijver, M. J. van] Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands; [Horlings, H. M.; de Vijver, M. J. van] Netherlands Canc Inst, Div Expt Therapy, NL-1066 CX Amsterdam, Netherlands; [Kreike, B.] Netherlands Canc Inst, Div Radiat Oncol, NL-1066 CX Amsterdam, Netherlands	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Netherlands Cancer Institute; Netherlands Cancer Institute	Turner, N (corresponding author), Inst Canc Res, Breakthrough Breast Canc Res Ctr, 237 Fulham Rd, London SW3 6JB, England.	nicholas.turner@icr.ac.uk; jorge.reis-filho@icr.ac.uk		Kreike, Bas/0000-0003-0030-8200; Natrajan, Rachael/0000-0002-9987-2946; Turner, Nicholas/0000-0001-8937-0873; van de Vijver, Marc/0000-0002-0385-4787	Cancer Research UK and Breakthrough Breast Cancer; NHS	Cancer Research UK and Breakthrough Breast Cancer; NHS	This work was supported by grants from Cancer Research UK and Breakthrough Breast Cancer. Dr Nicholas Turner is a CRUK clinician scientist. We acknowledge NHS funding to the NIHR Biomedical Research Centre.	Adelaide J, 2007, CANCER RES, V67, P11565, DOI 10.1158/0008-5472.CAN-07-2536; Agrawal G, 2007, J CLIN ONCOL, V25, P2618, DOI 10.1200/JCO.2007.11.3084; Andre F, 2009, CLIN CANCER RES, V15, P441, DOI 10.1158/1078-0432.CCR-08-1791; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bernard-Pierrot I, 2008, CANCER RES, V68, P7165, DOI 10.1158/0008-5472.CAN-08-1360; Bertucci F, 2008, INT J CANCER, V123, P236, DOI 10.1002/ijc.23518; Byron SA, 2008, CANCER RES, V68, P6902, DOI 10.1158/0008-5472.CAN-08-0770; Carey LA, 2007, CLIN CANCER RES, V13, P2329, DOI 10.1158/1078-0432.CCR-06-1109; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Coe BP, 2007, GENOMICS, V89, P647, DOI 10.1016/j.ygeno.2006.12.012; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Dent R, 2009, BREAST CANCER RES TR, V115, P423, DOI 10.1007/s10549-008-0086-2; Easton DF, 2007, NATURE, V447, P1087, DOI 10.1038/nature05887; Garcia-Closas M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000054; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Gunnarsson R, 2008, GENE CHROMOSOME CANC, V47, P697, DOI 10.1002/gcc.20575; Han W, 2008, GENE CHROMOSOME CANC, V47, P490, DOI 10.1002/gcc.20550; Hannemann J, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1613; Harris LN, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1622; Hicks J, 2006, GENOME RES, V16, P1465, DOI 10.1101/gr.5460106; Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96; Hughes TR, 2000, NAT GENET, V25, P333, DOI 10.1038/77116; Jonsson G, 2005, CANCER RES, V65, P7612, DOI 10.1158/0008-5472.CAN-05-0570; Kreike B, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1771; Lambros MBK, 2006, LAB INVEST, V86, P398, DOI 10.1038/labinvest.3700390; Mackay A, 2009, BREAST CANCER RES TR, V118, P481, DOI 10.1007/s10549-008-0296-7; Maira SM, 2008, MOL CANCER THER, V7, P1851, DOI 10.1158/1535-7163.MCT-08-0017; Marchio C, 2008, J PATHOL, V216, P399, DOI 10.1002/path.2423; Mohammadi M, 1998, EMBO J, V17, P5896, DOI 10.1093/emboj/17.20.5896; NATRAJAN R, 2009, BREAST CANC RES TREA; Natrajan R, 2009, CLIN CANCER RES, V15, P2711, DOI 10.1158/1078-0432.CCR-08-1878; Ng G, 2006, J MOL DIAGN, V8, P449, DOI 10.2353/jmoldx.2006.060033; Orsetti B, 2004, CANCER RES, V64, P6453, DOI 10.1158/0008-5472.CAN-04-0756; Reis-Filho JS, 2008, HISTOPATHOLOGY, V52, P108, DOI 10.1111/j.1365-2559.2007.02889.x; Reis-Filho JS, 2008, NAT GENET, V40, P809, DOI 10.1038/ng0708-809b; Reis JS, 2006, CLIN CANCER RES, V12, P6652, DOI 10.1158/1078-0432.CCR-06-1164; Schneider BP, 2008, CLIN CANCER RES, V14, P8010, DOI 10.1158/1078-0432.CCR-08-1208; Tan DSP, 2007, LAB INVEST, V87, P737, DOI 10.1038/labinvest.3700593; Tannheimer SL, 2000, BREAST CANCER RES, V2, P311, DOI 10.1186/bcr73; Tischkowitz MD, 2006, CELL CYCLE, V5, P963, DOI 10.4161/cc.5.9.2713; Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457; Turner NC, 2008, EMBO J, V27, P1368, DOI 10.1038/emboj.2008.61; Weigelt B, 2008, J PATHOL, V216, P141, DOI 10.1002/path.2407; Yamaguchi N, 2008, CANCER RES, V68, P1881, DOI 10.1158/0008-5472.CAN-07-1597; Yuan BB, 2006, CLIN CANCER RES, V12, P405, DOI 10.1158/1078-0432.CCR-05-0903; Zhao JJ, 2005, P NATL ACAD SCI USA, V102, P18443, DOI 10.1073/pnas.0508988102	47	295	304	3	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 8	2010	29	14					2013	2023		10.1038/onc.2009.489	http://dx.doi.org/10.1038/onc.2009.489			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579UX	20101236	Green Accepted, Green Submitted			2022-12-17	WOS:000276402800001
J	Nausch, N; Cerwenka, A				Nausch, N.; Cerwenka, A.			NKG2D ligands in tumor immunity	ONCOGENE			English	Review						NKG2D; RAE-1; MIC-A; ULBP; NK cells; tumor immunology	NATURAL-KILLER-CELL; I-RELATED CHAIN; V-DELTA-1 T-LYMPHOCYTES; NK CELLS; CUTTING EDGE; DENDRITIC CELLS; DOWN-REGULATION; CYTOTOXIC RESPONSES; MEDIATED REJECTION; SURFACE EXPRESSION	The activating receptor NKG2D (natural-killer group 2, member D) and its ligands play an important role in the NK, gamma delta(+) and CD8(+) T-cell-mediated immune response to tumors. Ligands for NKG2D are rarely detectable on the surface of healthy cells and tissues, but are frequently expressed by tumor cell lines and in tumor tissues. It is evident that the expression levels of these ligands on target cells have to be tightly regulated to allow immune cell activation against tumors, but at the same time avoid destruction of healthy tissues. Importantly, it was recently discovered that another safeguard mechanism controlling activation via the receptor NKG2D exists. It was shown that NKG2D signaling is coupled to the IL-15 receptor pathway in a cell-specific manner suggesting that priming of NKG2D-mediated activation depends on the cellular microenvironment and the distinct cellular context. This review will provide a broad overview of our up-to-date knowledge of the NKG2D receptor and its ligands in the context of tumor immunology. Strategies to amplify NKG2D-mediated antitumor responses and counteract tumor immune escape mechanisms will be discussed.	[Nausch, N.; Cerwenka, A.] German Canc Res Ctr, Div Innate Immun, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Cerwenka, A (corresponding author), German Canc Res Ctr, Div Innate Immun, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	a.cerwenka@dkfz.de	Nausch, Norman/M-4526-2019; Nausch, Norman/L-9276-2013	Nausch, Norman/0000-0002-9704-2148; Nausch, Norman/0000-0002-9704-2148; Cerwenka, Adelheid/0000-0001-6977-3536	Marie Curie Excellent; Deutsche Jose Carreras Leukamie Stiftung; German-Israel DKFZ/MOST; Boehringer Ingelheim Fonds	Marie Curie Excellent(European Commission); Deutsche Jose Carreras Leukamie Stiftung; German-Israel DKFZ/MOST(German-Israeli Foundation for Scientific Research and Development); Boehringer Ingelheim Fonds(Boehringer Ingelheim)	We thank Professor Lewis Lanier and Ioanna Galani for critically reading the paper. The work is supported by a Marie Curie Excellent Grant, Deutsche Jose Carreras Leukamie Stiftung, German-Israel DKFZ/MOST cooperation and Boehringer Ingelheim Fonds. We want to apologize to all authors whose work could not be cited in this review because of space limitations.	Allez M, 2007, GASTROENTEROLOGY, V132, P2346, DOI 10.1053/j.gastro.2007.03.025; Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; Armeanu S, 2005, CANCER RES, V65, P6321, DOI 10.1158/0008-5472.CAN-04-4252; Bacon L, 2004, J IMMUNOL, V173, P1078, DOI 10.4049/jimmunol.173.2.1078; Bahram S, 2005, CURR OPIN IMMUNOL, V17, P505, DOI 10.1016/j.coi.2005.07.016; BAHRAM S, 1994, P NATL ACAD SCI USA, V91, P6259, DOI 10.1073/pnas.91.14.6259; Barnett B, 2005, AM J REPROD IMMUNOL, V54, P369, DOI 10.1111/j.1600-0897.2005.00330.x; Bauer S, 1999, SCIENCE, V285, P727, DOI 10.1126/science.285.5428.727; Boissel N, 2006, J IMMUNOL, V176, P5108, DOI 10.4049/jimmunol.176.8.5108; Borchers MT, 2006, INFECT IMMUN, V74, P2578, DOI 10.1128/IAI.74.5.2578-2586.2006; Bravo MJ, 2007, TISSUE ANTIGENS, V69, P358, DOI 10.1111/j.1399-0039.2007.00823.x; Bryceson YT, 2006, BLOOD, V107, P159, DOI 10.1182/blood-2005-04-1351; Bui JD, 2006, J IMMUNOL, V176, P905, DOI 10.4049/jimmunol.176.2.905; Burgess SJ, 2006, J IMMUNOL, V176, P1490, DOI 10.4049/jimmunol.176.3.1490; Cao W, 2007, J BIOL CHEM, V282, P18922, DOI 10.1074/jbc.M702504200; Carayannopoulos LN, 2002, J IMMUNOL, V169, P4079, DOI 10.4049/jimmunol.169.8.4079; Carbone E, 2005, BLOOD, V105, P251, DOI 10.1182/blood-2004-04-1422; Carlsten M, 2007, CANCER RES, V67, P1317, DOI 10.1158/0008-5472.CAN-06-2264; Castriconi R, 2003, P NATL ACAD SCI USA, V100, P4120, DOI 10.1073/pnas.0730640100; Castriconi R, 2007, EUR J IMMUNOL, V37, P3190, DOI 10.1002/eji.200737546; Catellani S, 2007, BLOOD, V109, P2078, DOI 10.1182/blood-2006-06-028985; Cerboni C, 2007, BLOOD, V110, P606, DOI 10.1182/blood-2006-10-052720; Cerwenka A, 2000, IMMUNITY, V12, P721, DOI 10.1016/S1074-7613(00)80222-8; Cerwenka A, 2001, P NATL ACAD SCI USA, V98, P11521, DOI 10.1073/pnas.201238598; Cerwenka A, 2001, IMMUNOL REV, V181, P158, DOI 10.1034/j.1600-065X.2001.1810113.x; Chalupny NJ, 2003, BIOCHEM BIOPH RES CO, V305, P129, DOI 10.1016/S0006-291X(03)00714-9; Chan CW, 2006, NAT MED, V12, P207, DOI 10.1038/nm1352; Chang CW, 1999, J IMMUNOL, V163, P4651; Choi BK, 2007, CANCER RES, V67, P8891, DOI 10.1158/0008-5472.CAN-07-1056; Cosman D, 2001, IMMUNITY, V14, P123, DOI 10.1016/S1074-7613(01)00095-4; Coudert JD, 2005, BLOOD, V106, P1711, DOI 10.1182/blood-2005-03-0918; Dasgupta S, 2005, J IMMUNOL, V175, P5541, DOI 10.4049/jimmunol.175.8.5541; Diefenbach A, 2000, NAT IMMUNOL, V1, P119, DOI 10.1038/77793; Diefenbach A, 2003, EUR J IMMUNOL, V33, P381, DOI 10.1002/immu.200310012; Diefenbach A, 2002, NAT IMMUNOL, V3, P1142, DOI 10.1038/ni858; Diefenbach A, 2001, NATURE, V413, P165, DOI 10.1038/35093109; Diermayr S, 2008, BLOOD, V111, P1428, DOI 10.1182/blood-2007-07-101311; Doubrovina ES, 2003, J IMMUNOL, V171, P6891, DOI 10.4049/jimmunol.171.12.6891; Eagle RA, 2007, NAT REV IMMUNOL, V7, P737, DOI 10.1038/nri2144; Ehrlich LIR, 2005, J IMMUNOL, V174, P1922, DOI 10.4049/jimmunol.174.4.1922; Eisele G, 2006, BRAIN, V129, P2416, DOI 10.1093/brain/awl205; El-Sherbiny YM, 2007, CANCER RES, V67, P8444, DOI 10.1158/0008-5472.CAN-06-4230; Friese MA, 2004, CANCER RES, V64, P7596, DOI 10.1158/0008-5472.CAN-04-1627; Friese MA, 2003, CANCER RES, V63, P8996; Garrity D, 2005, P NATL ACAD SCI USA, V102, P7641, DOI 10.1073/pnas.0502439102; Gasser S, 2005, NATURE, V436, P1186, DOI 10.1038/nature03884; Germain C, 2005, CLIN CANCER RES, V11, P7516, DOI 10.1158/1078-0432.CCR-05-0872; Ghiringhelli F, 2005, J EXP MED, V202, P1075, DOI 10.1084/jem.20051511; Gilfillan S, 2002, NAT IMMUNOL, V3, P1150, DOI 10.1038/ni857; Girardi M, 2001, SCIENCE, V294, P605, DOI 10.1126/science.1063916; Glienke J, 1998, IMMUNOGENETICS, V48, P163, DOI 10.1007/s002510050420; Groh V, 2003, P NATL ACAD SCI USA, V100, P9452, DOI 10.1073/pnas.1632807100; Groh V, 1999, P NATL ACAD SCI USA, V96, P6879, DOI 10.1073/pnas.96.12.6879; Groh V, 2002, NATURE, V419, P734, DOI 10.1038/nature01112; Groh V, 1996, P NATL ACAD SCI USA, V93, P12445, DOI 10.1073/pnas.93.22.12445; Groh V, 2006, NAT IMMUNOL, V7, P755, DOI 10.1038/ni1350; Guerra N, 2008, IMMUNITY, V28, P571, DOI 10.1016/j.immuni.2008.02.016; Guilloton F, 2005, LEUKEMIA, V19, P2206, DOI 10.1038/sj.leu.2403952; Gumireddy K, 2007, P NATL ACAD SCI USA, V104, P6696, DOI 10.1073/pnas.0701145104; Hamerman JA, 2005, CURR OPIN IMMUNOL, V17, P29, DOI 10.1016/j.coi.2004.11.001; Hamerman JA, 2004, J IMMUNOL, V172, P2001, DOI 10.4049/jimmunol.172.4.2001; Ho EL, 1998, P NATL ACAD SCI USA, V95, P6320, DOI 10.1073/pnas.95.11.6320; Holdenrieder S, 2006, INT J CANCER, V118, P684, DOI 10.1002/ijc.21382; Holdenrieder S, 2006, CANCER IMMUNOL IMMUN, V55, P1584, DOI 10.1007/s00262-006-0167-1; Horng T, 2007, NAT IMMUNOL, V8, P1345, DOI 10.1038/ni1524; HOUCHINS JP, 1991, J EXP MED, V173, P1017, DOI 10.1084/jem.173.4.1017; Hue S, 2004, IMMUNITY, V21, P367, DOI 10.1016/j.immuni.2004.06.018; Jack A, 2006, SURG ONCOL, V15, P13, DOI 10.1016/j.suronc.2006.05.003; Jamieson AM, 2002, IMMUNITY, V17, P19, DOI 10.1016/S1074-7613(02)00333-3; Jinushi M, 2005, J HEPATOL, V43, P1013, DOI 10.1016/j.jhep.2005.05.026; Jinushi M, 2003, INT J CANCER, V104, P354, DOI 10.1002/ijc.10966; Jinushi M, 2003, J IMMUNOL, V170, P1249, DOI 10.4049/jimmunol.170.3.1249; Jinushi M, 2008, P NATL ACAD SCI USA, V105, P1285, DOI 10.1073/pnas.0711293105; Kaiser BK, 2007, NATURE, V447, P482, DOI 10.1038/nature05768; Kriegeskorte AK, 2005, P NATL ACAD SCI USA, V102, P11805, DOI 10.1073/pnas.0502026102; Lee JC, 2004, J IMMUNOL, V172, P7335, DOI 10.4049/jimmunol.172.12.7335; Li J, 2005, EUR J IMMUNOL, V35, P439, DOI 10.1002/eji.200425621; Liu CR, 2007, BLOOD, V109, P4336, DOI 10.1182/blood-2006-09-046201; Lucas M, 2007, IMMUNITY, V26, P503, DOI 10.1016/j.immuni.2007.03.006; Maccalli C, 2003, EUR J IMMUNOL, V33, P2033, DOI 10.1002/eji.200323909; Marten A, 2006, INT J CANCER, V119, P2359, DOI 10.1002/ijc.22186; Malarkannan S, 1998, J IMMUNOL, V161, P3501; Meresse B, 2004, IMMUNITY, V21, P357, DOI 10.1016/j.immuni.2004.06.020; Mistry AR, 2007, IMMUNOLOGY, V121, P439, DOI 10.1111/j.1365-2567.2007.02652.x; Molinero LL, 2004, J IMMUNOL, V173, P5583, DOI 10.4049/jimmunol.173.9.5583; Molinero LL, 2002, J LEUKOCYTE BIOL, V71, P791; Morgan RA, 2006, SCIENCE, V314, P126, DOI 10.1126/science.1129003; Nausch N, 2006, J IMMUNOL, V176, P7, DOI 10.4049/jimmunol.176.1.7; Nedvetzki S, 2007, BLOOD, V109, P3776, DOI 10.1182/blood-2006-10-052977; Nomura M, 1996, J BIOCHEM-TOKYO, V120, P987; Nowbakht P, 2005, BLOOD, V105, P3615, DOI 10.1182/blood-2004-07-2585; O'Callaghan CA, 2001, IMMUNITY, V15, P201, DOI 10.1016/S1074-7613(01)00187-X; Ogasawara K, 2005, J CLIN IMMUNOL, V25, P534, DOI 10.1007/s10875-005-8786-4; Ogasawara K, 2005, NAT IMMUNOL, V6, P938, DOI 10.1038/ni1236; Oppenheim DE, 2005, NAT IMMUNOL, V6, P928, DOI 10.1038/ni1239; Paloneva J, 2000, NAT GENET, V25, P357, DOI 10.1038/77153; Pappworth IY, 2007, J VIROL, V81, P474, DOI 10.1128/JVI.01777-06; Pende D, 2002, CANCER RES, V62, P6178; Pillarisetty VG, 2004, J IMMUNOL, V172, P1009, DOI 10.4049/jimmunol.172.2.1009; Poggi A, 2004, CANCER RES, V64, P9172, DOI 10.1158/0008-5472.CAN-04-2417; Rabinovich B, 2006, IMMUNOGENETICS, V58, P81, DOI 10.1007/s00251-005-0078-x; Rabinovich BA, 2003, J IMMUNOL, V170, P3572, DOI 10.4049/jimmunol.170.7.3572; Radosavljevic M, 2002, GENOMICS, V79, P114, DOI 10.1006/geno.2001.6673; Raffaghello L, 2004, NEOPLASIA, V6, P558, DOI 10.1593/neo.04316; Rausch A, 2006, EUR J IMMUNOL, V36, P1156, DOI 10.1002/eji.200535290; Roberts AI, 2001, J IMMUNOL, V167, P5527, DOI 10.4049/jimmunol.167.10.5527; Roda-Navarro P, 2007, FASEB J, V21, P1636, DOI 10.1096/fj.06-7488rev; Roda-Navarro P, 2006, P NATL ACAD SCI USA, V103, P11258, DOI 10.1073/pnas.0600721103; Rohner A, 2007, LEUKEMIA RES, V31, P1393, DOI 10.1016/j.leukres.2007.02.020; Roos WP, 2006, TRENDS MOL MED, V12, P440, DOI 10.1016/j.molmed.2006.07.007; Rosen DB, 2004, J IMMUNOL, V173, P2470, DOI 10.4049/jimmunol.173.4.2470; Routes JM, 2005, J EXP MED, V202, P1477, DOI 10.1084/jem.20050240; Salih HR, 2006, HUM IMMUNOL, V67, P188, DOI 10.1016/j.humimm.2006.02.008; Salih HR, 2003, BLOOD, V102, P1389, DOI 10.1182/blood-2003-01-0019; Salih HR, 2002, J IMMUNOL, V169, P4098, DOI 10.4049/jimmunol.169.8.4098; Schrambach S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000518; Siren J, 2004, J GEN VIROL, V85, P2357, DOI 10.1099/vir.0.80105-0; Smyth MJ, 2004, J EXP MED, V200, P1325, DOI 10.1084/jem.20041522; Smyth MJ, 2006, J IMMUNOL, V176, P1582, DOI 10.4049/jimmunol.176.3.1582; Smyth MJ, 2005, J EXP MED, V202, P583, DOI 10.1084/jem.20050994; Song H, 2006, CELL IMMUNOL, V242, P39, DOI 10.1016/j.cellimm.2006.09.002; Song H, 2006, CELL IMMUNOL, V239, P22, DOI 10.1016/j.cellimm.2006.03.002; Steinle A, 2001, IMMUNOGENETICS, V53, P279, DOI 10.1007/s002510100325; Strong RK, 2002, MOL IMMUNOL, V38, P1029, DOI 10.1016/S0161-5890(02)00032-9; Taieb J, 2006, NAT MED, V12, P214, DOI 10.1038/nm1356; Takada A, 2008, J IMMUNOL, V180, P1678, DOI 10.4049/jimmunol.180.3.1678; Takaki R, 2005, J IMMUNOL, V175, P2167, DOI 10.4049/jimmunol.175.4.2167; Tallman MS, 2006, BEST PRACT RES CL HA, V19, P311, DOI 10.1016/j.beha.2005.11.006; Teng MWL, 2005, J BIOL CHEM, V280, P38235, DOI 10.1074/jbc.M505331200; Tieng V, 2002, P NATL ACAD SCI USA, V99, P2977, DOI 10.1073/pnas.032668099; Turkcapar N, 2007, RHEUMATOL INT, V27, P545, DOI 10.1007/s00296-006-0255-8; Venkataraman GM, 2007, J IMMUNOL, V178, P961, DOI 10.4049/jimmunol.178.2.961; Verneris MR, 2004, BLOOD, V103, P3065, DOI 10.1182/blood-2003-06-2125; Vetter CS, 2002, J INVEST DERMATOL, V118, P600, DOI 10.1046/j.1523-1747.2002.01700.x; Vilarinho S, 2007, P NATL ACAD SCI USA, V104, P18187, DOI 10.1073/pnas.0708968104; Vosshenrich CAJ, 2007, J EXP MED, V204, P2569, DOI 10.1084/jem.20071451; Waldhauer I, 2006, CANCER RES, V66, P2520, DOI 10.1158/0008-5472.CAN-05-2520; Ward J, 2007, BLOOD, V110, P1207, DOI 10.1182/blood-2006-06-028175; Watson NFS, 2006, INT J CANCER, V118, P1445, DOI 10.1002/ijc.21510; Weizman N, 2003, J BIOL CHEM, V278, P6741, DOI 10.1074/jbc.M211168200; Wiemann K, 2005, J IMMUNOL, V175, P720, DOI 10.4049/jimmunol.175.2.720; Wu J, 1999, SCIENCE, V285, P730, DOI 10.1126/science.285.5428.730; Yokoyama WM, 2002, NATURE, V419, P679, DOI 10.1038/419679a; Zhang C, 2005, INT IMMUNOPHARMACOL, V5, P1057, DOI 10.1016/j.intimp.2005.02.003; Zhang J, 2004, HAEMATOLOGICA, V89, P338; Zhang T, 2005, BLOOD, V106, P1544, DOI 10.1182/blood-2004-11-4365; Zhang T, 2007, CANCER RES, V67, P11029, DOI 10.1158/0008-5472.CAN-07-2251; Zhou H, 2006, BLOOD, V107, P3251, DOI 10.1182/blood-2005-10-4231; Zhou H, 2005, P NATL ACAD SCI USA, V102, P10846, DOI 10.1073/pnas.0502208102; Zou ZH, 1996, J BIOCHEM-TOKYO, V119, P319	150	295	314	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2008	27	45					5944	5958		10.1038/onc.2008.272	http://dx.doi.org/10.1038/onc.2008.272			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	355QE	18836475				2022-12-17	WOS:000259722600009
J	Iwamaru, A; Szymanski, S; Iwado, E; Aoki, H; Yokoyama, T; Fokt, I; Hess, K; Conrad, C; Madden, T; Sawaya, R; Kondo, S; Priebe, W; Kondo, Y				Iwamaru, A.; Szymanski, S.; Iwado, E.; Aoki, H.; Yokoyama, T.; Fokt, I.; Hess, K.; Conrad, C.; Madden, T.; Sawaya, R.; Kondo, S.; Priebe, W.; Kondo, Y.			A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo	ONCOGENE			English	Article						STAT3; apoptosis; malignant glioma	ACTIVATION; CANCER; GLIOBLASTOMA; KINASE; TUMORS; INTERLEUKIN-6; EXPRESSION; PROTEINS; MCL-1	Signal transducer and activator of transcription-3 (STAT3) is constitutively activated in a variety of cancer types, including malignant gliomas. STAT3 is activated by phosphorylation of a tyrosine residue, after which it dimerizes and translocates into the nucleus. There it regulates the expression of several genes responsible for proliferation and survival at the transcriptional level. A selective inhibitor of STAT3 phosphorylation, AG490, has been shown to inhibit growth and induce apoptosis in some cancer cell types. However, although AG490 routinely shows in vitro anticancer activity, it has not consistently demonstrated an in vivo anticancer effect in animal models. Here, we have tested WP1066, a novel inhibitor structurally related to AG490 but significantly more potent and active, against human malignant glioma U87MG and U373-MG cells in vitro and in vivo. IC50 values for WP1066 were 5.6 mu M in U87-MG cells and 3.7 mu M in U373-MG cells, which represents 18-fold and eightfold increases in potency, respectively, over that of AG490. WP1066 activated Bax, suppressed the expression of c-myc, Bcl-X-L and Mcl-1, and induced apoptosis. Systemic intraperitoneal administration of WP1066 in mice significantly (P < 0.001) inhibited the growth of subcutaneous malignant glioma xenografts during the 30-day follow-up period. Immunohistochemical analysis of the excised tumors revealed that phosphorylated STAT3 levels in the WP1066 treatment group remained inhibited at 3 weeks after the final WP1066 injection, whereas tumors from the control group expressed high levels of phosphorylated STAT3. We conclude that WP1066 holds promise as a therapeutic agent against malignant gliomas.	Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci Houston, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; University of Texas System	Kondo, Y (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Unit BSRB1004,1515 Holcombe Blvd, Houston, TX 77030 USA.	yaskondo@mdanderson.org	Hess, Kenneth/K-6546-2019	Hess, Kenneth/0000-0003-1377-6070	NCI NIH HHS [CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bhattacharya S, 2005, BIOCHEM J, V392, P335, DOI 10.1042/BJ20050465; Bogler O, 2002, FRONT BIOSCI, V7, pE339, DOI 10.2741/bogler; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 2001, BIOESSAYS, V23, P161, DOI 10.1002/1521-1878(200102)23:2<161::AID-BIES1023>3.0.CO;2-0; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; Fesik SW, 2005, NAT REV CANCER, V5, P876, DOI 10.1038/nrc1736; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; Ito H, 2005, HUM GENE THER, V16, P685, DOI 10.1089/hum.2005.16.685; Kanzawa T, 2006, ONCOGENE, V25, P3638, DOI 10.1038/sj.onc.1209414; Kanzawa T, 2005, ONCOGENE, V24, P980, DOI 10.1038/sj.onc.1208095; Kapoor GS, 2003, NEUROSURGERY, V52, P1425, DOI 10.1227/01.NEU.0000065135.28143.39; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215; Kondo Y, 2004, INT J ONCOL, V24, P1101; Konnikova L, 2005, CANCER RES, V65, P6516, DOI 10.1158/0008-5472.CAN-05-0924; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; LICHTOR T, 1994, NEUROSURGERY, V34, P669, DOI 10.1227/00006123-199404000-00015; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Ohgaki H, 2004, CANCER RES, V64, P6892, DOI 10.1158/0008-5472.CAN-04-1337; Rahaman SO, 2002, ONCOGENE, V21, P8404, DOI 10.1038/sj.onc.1206047; Reardon DA, 2006, J CLIN ONCOL, V24, P1253, DOI 10.1200/JCO.2005.04.5302; Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496; Schaefer LK, 2002, ONCOGENE, V21, P2058, DOI 10.1038/sj.onc.1205263; Song H, 2005, P NATL ACAD SCI USA, V102, P4700, DOI 10.1073/pnas.0409894102; Sonoda Y, 2001, CANCER RES, V61, P4956; Sun JZ, 2005, ONCOGENE, V24, P3236, DOI 10.1038/sj.onc.1208470; Turkson J, 2004, MOL CANCER THER, V3, P1533; VAN MEIR E, 1990, CANCER RES, V50, P6683; Wang PB, 2003, J BIOL CHEM, V278, P19917, DOI 10.1074/jbc.M210337200; Weissenberger J, 2004, ONCOGENE, V23, P3308, DOI 10.1038/sj.onc.1207455; Yau CYF, 2005, CANCER RES, V65, P1497, DOI 10.1158/0008-5472.CAN-04-2940	36	295	323	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2007	26	17					2435	2444		10.1038/sj.onc.1210031	http://dx.doi.org/10.1038/sj.onc.1210031			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YG	17043651				2022-12-17	WOS:000245831000004
J	Unruh, A; Ressel, A; Mohamed, HG; Johnson, RS; Nadrowitz, R; Richter, E; Katschinski, DM; Wenger, RH				Unruh, A; Ressel, A; Mohamed, HG; Johnson, RS; Nadrowitz, R; Richter, E; Katschinski, DM; Wenger, RH			The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy	ONCOGENE			English	Article						chemotherapy resistance; glycolysis; transcriptional gene regulation; tumor irradiation; tumor oxygenation	SOLID TUMORS; GENE-EXPRESSION; FACTOR 1-ALPHA; UP-REGULATION; HIF-ALPHA; FACTOR-I; CELL; GROWTH; HIF-1-ALPHA; P53	Tumor hypoxia negatively regulates cell growth and causes a more malignant phenotype by increasing the expression of genes encoding angiogenic, metabolic and metastatic factors. Of clinical importance, insufficient tumor oxygenation affects the efficiency of chemotherapy and radiotherapy by poorly understood mechanisms. The hypoxia-inducible factor (HIF)-1 is a master transcriptional activator of oxygen-regulated genes and HIF-1 is constitutively upregulated in several tumor types. HIF-1 might thus be implicated in tumor therapy resistance. We found that transformed mouse embryonic fibroblasts deficient for HIF-1alpha are more susceptible to the treatment with carboplatin, etoposide and ionizing radiation than wild-type cells. Increased cell death in HIF-1alpha-deficient cells was because of apoptosis and did not involve p53 induction. Tumor chemotherapy of experimental fibrosarcoma in immunocompromised mice with carboplatin and etoposide confirmed the enhanced susceptibility of HIF1alpha-deficient cells. Agents that did not cause DNA double-strand breaks, such as DNA-synthesis inhibitors or a DNA single-strand break-causing agent equally impaired cell growth, independent of the HIF-1alpha genotype. Functional repair of a fragmented reporter gene was decreased in HIF-la-deficient cells. Thus, hypoxia-independent basal HIF-1alpha expression in tumor cells, as known from untransformed embryonic stem cells, is sufficient to induce target gene expression, probably including DNA double strand break repair enzymes.	Univ Leipzig, Carl Ludwig Inst Physiol, D-04103 Leipzig, Germany; Med Univ Lubeck, Inst Physiol, D-23538 Lubeck, Germany; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Med Univ Lubeck, Clin Radiotherapy & Nucl Med, D-23538 Lubeck, Germany	Leipzig University; University of Lubeck; University of California System; University of California San Diego; University of Lubeck	Wenger, RH (corresponding author), Univ Leipzig, Carl Ludwig Inst Physiol, Liebigstr 27, D-04103 Leipzig, Germany.	wenr@medizin.uni-leipzig.de	Johnson, Randall/AAM-1189-2021; Wenger, Roland H./B-7953-2009	Johnson, Randall/0000-0002-4084-6639; Wenger, Roland H./0000-0001-7592-4839				Aebersold DM, 2001, CANCER RES, V61, P2911; Alarcon R, 1999, CANCER RES, V59, P6046; Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Birner P, 2000, CANCER RES, V60, P4693; Brown JM, 2000, MOL MED TODAY, V6, P157, DOI 10.1016/S1357-4310(00)01677-4; Brown JM, 1998, CANCER RES, V58, P1408; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Comerford KM, 2002, CANCER RES, V62, P3387; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Farinelli SE, 1996, J NEUROSCI, V16, P1150, DOI 10.1523/jneurosci.16-03-01150.1996; Gao J, 2001, BLOOD, V98, P842, DOI 10.1182/blood.V98.3.842; Gassmann M, 1997, KIDNEY INT, V51, P567, DOI 10.1038/ki.1997.81; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Griffiths JR, 2002, CANCER RES, V62, P688; Hammond EM, 2002, MOL CELL BIOL, V22, P1834, DOI 10.1128/MCB.22.6.1834-1843.2002; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hockel M, 1999, CANCER RES, V59, P4525; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; Hopfl G, 2002, CANCER RES, V62, P2962; Isaacs JS, 2002, J BIOL CHEM, V277, P29936, DOI 10.1074/jbc.M204733200; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jewell UR, 2001, FASEB J, V15, P1312, DOI 10.1096/fj.00-0732fje; Jiang BH, 1997, CANCER RES, V57, P5328; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Katschinski DM, 2002, J BIOL CHEM, V277, P9262, DOI 10.1074/jbc.M110377200; Katschinski DM, 1999, CANCER RES, V59, P3404; Koukourakis MI, 2002, INT J RADIAT ONCOL, V53, P1192, DOI 10.1016/S0360-3016(02)02848-1; Krieg M, 2000, ONCOGENE, V19, P5435, DOI 10.1038/sj.onc.1203938; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; LEDERMAN HM, 1984, BLOOD, V64, P748; Mabjeesh NJ, 2002, CANCER RES, V62, P2478; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; Minchenko A, 2002, J BIOL CHEM, V277, P6183, DOI 10.1074/jbc.M110978200; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Rapisarda A, 2002, CANCER RES, V62, P4316; Ravi R, 2000, GENE DEV, V14, P34; Ryan HE, 2000, CANCER RES, V60, P4010; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Seagroves TN, 2001, MOL CELL BIOL, V21, P3436, DOI 10.1128/MCB.21.10.3436-3444.2001; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; Semenza GL, 2000, CRIT REV BIOCHEM MOL, V35, P71, DOI 10.1080/10409230091169186; Vaupel P, 2001, MED ONCOL, V18, P243, DOI 10.1385/MO:18:4:243; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wanner RM, 2000, BLOOD, V96, P1558, DOI 10.1182/blood.V96.4.1558.h8001558_1558_1565; Wenger RH, 1998, CANCER RES, V58, P5678; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Williams KJ, 2002, ONCOGENE, V21, P282, DOI 10.1038/sj.onc.1205047; Zhong H, 1999, CANCER RES, V59, P5830; Zundel W, 2000, GENE DEV, V14, P391	54	295	324	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2003	22	21					3213	3220		10.1038/sj.onc.1206385	http://dx.doi.org/10.1038/sj.onc.1206385			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681MM	12761491				2022-12-17	WOS:000183040000003
J	Unoki, M; Nakamura, Y				Unoki, M; Nakamura, Y			Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway	ONCOGENE			English	Article						EGR2; BPOZ; PTEN; tumor suppressor gene; PINK1	HUMAN OVARIAN-CANCER; ZINC FINGER PROTEIN; MOLECULAR-CLONING; PROSTATE-CANCER; BTB/POZ DOMAIN; NERVOUS-SYSTEM; CELLS; TRANSCRIPTION; MUTATIONS; DIFFERENTIATION	Defects in PTEN a tumor suppressor, have been found in cancers arising in a variety of human tissues. To elucidate the tumor-suppressive function of this gene, we have been analysing expression profiles of cancer cells after introduction of exogenous PTEN Those experiments identified 99 candidate genes that were transcriptionally transactivated. Among them, we report here the further analyses of eight genes, EGR2/Krox-20, BPOZ, APS, HCLS1/HS1, DUSP1/MKP1, NDRG1/Drg1/ RTP, NFIL3/E4BP4, and a novel gene (PINK], PTEN-induced putative kinase). Expression of six of them (PINK], EGR2, HCLS1, DUSP1, BPOZ, and NFIL3) was decreased in ovarian tumors compared with corresponding normal tissues. Colony-formation assays using plasmid clones designed to express each gene indicated that EGR2 and BPOZ were able to suppress growth of cancer cells significantly; in particular, cancer-cell lines stably expressing BPOZ grew more slowly than control cells containing mock vector. Flow cytometry suggested that over-expression of BPOZ inhibited progression of the cell cycle at the G(1)/S transition. Anti-sense oligonucleotides for BPOZ or EGR2 effectively inhibited their expression, and cell growth was accelerated. Therefore both genes appear to be novel candidates as mediators of the PTEN growth-suppressive signaling pathway.	Univ Tokyo, Inst Med Sci, Mol Med Lab, Ctr Human Genome,Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Nakamura, Y (corresponding author), Univ Tokyo, Inst Med Sci, Mol Med Lab, Ctr Human Genome,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	yusuke@ims.u-tokyo.ac.jp	Unoki, Motoko/X-3285-2019	Unoki, Motoko/0000-0002-9629-3818				Abdulkadir SA, 2001, NAT MED, V7, P101, DOI 10.1038/83231; Arlt MF, 1996, HUM MOL GENET, V5, P1017, DOI 10.1093/hmg/5.7.1017; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Borg A, 1996, CANCER RES, V56, P2497; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; Dahia PLM, 2000, ENDOCR-RELAT CANCER, V7, P115, DOI 10.1677/erc.0.0070115; Dai KS, 2000, BIOCHEM BIOPH RES CO, V273, P991, DOI 10.1006/bbrc.2000.3053; de la Luna S, 1999, EMBO J, V18, P212, DOI 10.1093/emboj/18.1.212; Dzialo-Hatton R, 2001, J IMMUNOL, V166, P4534, DOI 10.4049/jimmunol.166.7.4534; Eid MA, 1998, CANCER RES, V58, P2461; Guang RJ, 2000, CANCER RES, V60, P749; Hoatlin ME, 1999, BLOOD, V94, P3737, DOI 10.1182/blood.V94.11.3737.423k39_3737_3747; Hong TM, 2000, AM J RESP CELL MOL, V23, P355, DOI 10.1165/ajrcmb.23.3.4002; Huang RP, 1997, INT J CANCER, V72, P102, DOI 10.1002/(SICI)1097-0215(19970703)72:1<102::AID-IJC15>3.0.CO;2-L; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liu CT, 1998, CANCER GENE THER, V5, P3; Matsushima-Nishiu M, 2001, CANCER RES, V61, P3741; Maxwell GL, 1998, GYNECOL ONCOL, V70, P13, DOI 10.1006/gyno.1998.5039; Minaguchi T, 1999, CANCER RES, V59, P6063; Mittelstadt PR, 1999, J BIOL CHEM, V274, P3222, DOI 10.1074/jbc.274.5.3222; Nakagawa H, 2000, ONCOGENE, V19, P210, DOI 10.1038/sj.onc.1203308; Obata K, 1998, CANCER RES, V58, P2095; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Ono K, 2000, CANCER RES, V60, P5007; RANGNEKAR VM, 1990, NUCLEIC ACIDS RES, V18, P2749, DOI 10.1093/nar/18.9.2749; Reuter S, 1998, EMBO J, V17, P215, DOI 10.1093/emboj/17.1.215; Risinger JI, 1997, CANCER RES, V57, P4736; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; TOPILKO P, 1994, NATURE, V371, P796, DOI 10.1038/371796a0; Warner LE, 1998, NAT GENET, V18, P382, DOI 10.1038/ng0498-382; Yokomizo A, 1998, INT J ONCOL, V13, P101; Yokouchi M, 1999, ONCOGENE, V18, P759, DOI 10.1038/sj.onc.1202326; Zorick TS, 1996, MOL CELL NEUROSCI, V8, P129, DOI 10.1006/mcne.1996.0052	35	295	312	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2001	20	33					4457	4465		10.1038/sj.onc.1204608	http://dx.doi.org/10.1038/sj.onc.1204608			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494141				2022-12-17	WOS:000170074900003
J	Lipsick, JS				Lipsick, JS			One billion years of Myb	ONCOGENE			English	Review						myb; DNA binding; evolution; gene duplication	DNA-BINDING DOMAIN; AVIAN-MYELOBLASTOSIS VIRUS; HUMAN C-MYB; TPA-INDUCED DIFFERENTIATION; NEGATIVE REGULATORY DOMAIN; HUMAN HEMATOPOIETIC-CELLS; AMINO-TERMINAL REGION; HUMAN LYMPHOCYTES-T; V-MYB; B-MYB	The v-myb oncogene of the avian myeloblastosis virus has led to the discovery of a large and growing family of myb-related genes in a wide variety of eukaryotes including animals, plants, fungi and slime molds. The Myb-related proteins contain a highly conserved sequence, often present in multiple tandem repeats which constitute a DNA-binding domain. These proteins generally function in the regulation of cell growth and differentiation, often by coregulating gene expression along with DNA-binding proteins of other classes. This review focuses on the evolution of the myb gene family and the role of these genes in development.	STANFORD UNIV, SCH MED, PROGRAM MOL & GENET MED, STANFORD, CA 94305 USA	Stanford University	Lipsick, JS (corresponding author), STANFORD UNIV, SCH MED, DEPT PATHOL, STANFORD, CA 94305 USA.							ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; AMARAVADI L, 1994, ONCOGENE, V9, P971; ARSURA M, 1992, BLOOD, V79, P2708; AZIZ N, 1995, P NATL ACAD SCI USA, V92, P6429, DOI 10.1073/pnas.92.14.6429; BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; BALUDA MA, 1994, ONCOGENE, V9, P2761; BARANOWSKIJ N, 1994, EMBO J, V13, P5383, DOI 10.1002/j.1460-2075.1994.tb06873.x; BAUMANN P, 1995, TRENDS GENET, V11, P279, DOI 10.1016/S0168-9525(00)89075-7; BERBEE ML, 1993, CAN J BOT, V71, P1114, DOI 10.1139/b93-131; BEUG H, 1987, GENE DEV, V1, P277, DOI 10.1101/gad.1.3.277; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BIN X, 1993, J VIROL, V67, P7332, DOI 10.1128/JVI.67.12.7332-7339.1993; BLACKWELL TK, 1994, SCIENCE, V266, P621, DOI 10.1126/science.7939715; BODEAU JP, 1992, MOL GEN GENET, V233, P379, DOI 10.1007/BF00265434; BORTNER DM, 1991, NUCLEIC ACIDS RES, V19, P1533, DOI 10.1093/nar/19.7.1533; BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BOYLE WJ, 1985, MOL CELL BIOL, V5, P3017, DOI 10.1128/MCB.5.11.3017; BOYLE WJ, 1986, P NATL ACAD SCI USA, V83, P4685, DOI 10.1073/pnas.83.13.4685; BRANDL CJ, 1990, MOL CELL BIOL, V10, P4256, DOI 10.1128/MCB.10.8.4256; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; CATRON KM, 1992, J IMMUNOL, V148, P934; CHASMAN DI, 1990, GENE DEV, V4, P503, DOI 10.1101/gad.4.4.503; CHEN RH, 1995, ONCOGENE, V11, P1771; CHEN RH, 1993, MOL CELL BIOL, V13, P4423, DOI 10.1128/MCB.13.7.4423; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COLL J, 1983, EXP CELL RES, V149, P151, DOI 10.1016/0014-4827(83)90388-9; CONE KC, 1993, PLANT CELL, V5, P1795, DOI 10.1105/tpc.5.12.1795; DAIGNANFORNIER B, 1992, P NATL ACAD SCI USA, V89, P6746, DOI 10.1073/pnas.89.15.6746; DASGUPTA P, 1989, ONCOGENE, V4, P1419; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DESBIENS X, 1991, DEVELOPMENT, V111, P699; DINI PW, 1995, J VIROL, V69, P2515, DOI 10.1128/JVI.69.4.2515-2524.1995; DINI PW, 1993, MOL CELL BIOL, V13, P7334, DOI 10.1128/MCB.13.12.7334; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; DUDEK H, 1989, ONCOGENE, V4, P1489; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; DURBAN EM, 1981, J VIROL, V37, P488, DOI 10.1128/JVI.37.1.488-492.1981; ENGELKE U, 1994, J VIROL, V68, P2752, DOI 10.1128/JVI.68.4.2752-2755.1994; ENGELKE U, 1995, ONCOGENE, V11, P735; ENGLAND BP, 1992, P NATL ACAD SCI USA, V89, P683, DOI 10.1073/pnas.89.2.683; ERWIN DH, 1991, TRENDS ECOL EVOL, V6, P131, DOI 10.1016/0169-5347(91)90092-C; ESS KC, 1995, MOL CELL BIOL, V15, P5707; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; FAVIER D, 1994, ONCOGENE, V9, P305; FENG DF, 1990, METHOD ENZYMOL, V183, P375; FIELD KG, 1988, SCIENCE, V239, P748, DOI 10.1126/science.3277277; FOOS G, 1994, ONCOGENE, V9, P2481; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; FRAMPTON J, 1993, EMBO J, V12, P1333, DOI 10.1002/j.1460-2075.1993.tb05778.x; FRAMPTON J, 1991, PROTEIN ENG, V4, P891, DOI 10.1093/protein/4.8.891; FRAMPTON J, 1989, NATURE, V342, P134, DOI 10.1038/342134a0; GABRIELSEN OS, 1991, SCIENCE, V253, P1140, DOI 10.1126/science.1887237; GARCIA A, 1991, ONCOGENE, V6, P265; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GOFF SA, 1992, GENE DEV, V6, P864, DOI 10.1101/gad.6.5.864; GOLAY J, 1991, BLOOD, V77, P149; GOLAY J, 1994, J IMMUNOL, V153, P543; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; GRASSER FA, 1992, ONCOGENE, V7, P1005; GROTEWOLD E, 1994, CELL, V76, P543, DOI 10.1016/0092-8674(94)90117-1; GUEHMANN S, 1992, NUCLEIC ACIDS RES, V20, P2279, DOI 10.1093/nar/20.9.2279; GUERIN M, 1990, ONCOGENE, V5, P131; GUERRA J, 1995, BLOOD, V86, P1873, DOI 10.1182/blood.V86.5.1873.bloodjournal8651873; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; HERR W, 1995, GENE DEV, V9, P1679, DOI 10.1101/gad.9.14.1679; HOLLAND PWH, 1994, DEVELOPMENT, P125; HOVRING PI, 1994, J BIOL CHEM, V269, P17663; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HSIANG YHH, 1995, J IMMUNOL, V154, P5195; HU YL, 1991, ONCOGENE, V6, P1549; HULSKAMP M, 1994, CELL, V76, P555, DOI 10.1016/0092-8674(94)90118-X; IBANEZ CE, 1988, J VIROL, V62, P1981, DOI 10.1128/JVI.62.6.1981-1988.1988; IBANEZ CE, 1988, J VIROL, V62, P4398, DOI 10.1128/JVI.62.11.4398-4402.1988; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; JACKSON D, 1991, PLANT CELL, V3, P115, DOI 10.1105/tpc.3.2.115; JU QD, 1990, MOL CELL BIOL, V10, P5226, DOI 10.1128/MCB.10.10.5226; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KANEIISHII C, 1990, J BIOL CHEM, V265, P19990; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KANTER MR, 1988, J VIROL, V62, P1423, DOI 10.1128/JVI.62.4.1423-1432.1988; KATZEN AL, 1985, CELL, V41, P449, DOI 10.1016/S0092-8674(85)80018-0; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KLEMPNAUER KH, 1986, MOL CELL BIOL, V6, P62, DOI 10.1128/MCB.6.1.62; KNOLL AH, 1992, SCIENCE, V256, P622, DOI 10.1126/science.1585174; KU DH, 1993, J BIOL CHEM, V268, P2255; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LANG WH, 1994, CELL, V79, P527, DOI 10.1016/0092-8674(94)90261-5; LEECH MJ, 1993, PLANT J, V3, P51, DOI 10.1111/j.1365-313X.1993.tb00010.x; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; LIPSICK JS, 1987, J VIROL, V61, P3284, DOI 10.1128/JVI.61.10.3284-3287.1987; LIPSICK JS, 1987, MOL CELL BIOL, V7, P3358, DOI 10.1128/MCB.7.9.3358; LLOYD AM, 1992, SCIENCE, V258, P1773, DOI 10.1126/science.1465611; LOOMIS WF, 1990, P NATL ACAD SCI USA, V87, P9093, DOI 10.1073/pnas.87.23.9093; LUDWIG SR, 1989, P NATL ACAD SCI USA, V86, P7092, DOI 10.1073/pnas.86.18.7092; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MANAK JR, 1994, DEVELOPMENT, P61; MARSHALL CR, 1994, P NATL ACAD SCI USA, V91, P12283, DOI 10.1073/pnas.91.25.12283; MCCLINTOCK B, 1949, YB 48; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; MELOTTI P, 1994, J EXP MED, V179, P1023, DOI 10.1084/jem.179.3.1023; MORROW BE, 1993, MOL CELL BIOL, V13, P1173, DOI 10.1128/MCB.13.2.1173; MOSCOVICI C, 1975, VIROLOGY, V68, P173, DOI 10.1016/0042-6822(75)90159-2; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; MOSSING MC, 1990, SCIENCE, V250, P1712, DOI 10.1126/science.2148648; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; MYRSET AH, 1993, EMBO J, V12, P4625, DOI 10.1002/j.1460-2075.1993.tb06151.x; NAZAROV V, 1995, J VIROL, V69, P3885, DOI 10.1128/JVI.69.6.3885-3888.1995; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NICOLAIDES NC, 1991, MOL CELL BIOL, V11, P6166, DOI 10.1128/MCB.11.12.6166; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; NODA K, 1994, NATURE, V369, P661, DOI 10.1038/369661a0; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; OEHLER T, 1993, ONCOGENE, V8, P1141; OEHLER T, 1990, NUCLEIC ACIDS RES, V18, P1703, DOI 10.1093/nar/18.7.1703; OGATA K, 1995, NAT STRUCT BIOL, V2, P309, DOI 10.1038/nsb0495-309; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; OHI R, 1994, EMBO J, V13, P471, DOI 10.1002/j.1460-2075.1994.tb06282.x; OPPENHEIMER DG, 1991, CELL, V67, P483, DOI 10.1016/0092-8674(91)90523-2; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PAZARES J, 1987, EMBO J, V6, P3553, DOI 10.1002/j.1460-2075.1987.tb02684.x; PETERS CWB, 1987, EMBO J, V6, P3085, DOI 10.1002/j.1460-2075.1987.tb02616.x; PIZER E, 1989, J VIROL, V63, P1630, DOI 10.1128/JVI.63.4.1630-1640.1989; PRESS RD, 1994, MOL CELL BIOL, V14, P2278, DOI 10.1128/MCB.14.4.2278; QUATTROCCHIO F, 1993, PLANT CELL, V5, P1497, DOI 10.1105/tpc.5.11.1497; RAMSAY RG, 1989, ONCOGENE RES, V4, P259; RAMSAY RG, 1992, CELL GROWTH DIFFER, V3, P723; RAMSAY RG, 1995, ONCOGENE, V11, P2113; RAMSAY RG, 1991, ONCOGENE, V6, P1875; RERIE WG, 1994, GENE DEV, V8, P1388, DOI 10.1101/gad.8.12.1388; RHOADES MM, 1984, ANNU REV GENET, V18, P1, DOI 10.1146/annurev.ge.18.120184.000245; ROTH BA, 1991, PLANT CELL, V3, P317, DOI 10.1105/tpc.3.3.317; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SCHUUR ER, 1993, ONCOGENE, V8, P1839; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SENECA S, 1993, ONCOGENE, V8, P2335; SHENONG GLC, 1987, EMBO J, V6, P4035, DOI 10.1002/j.1460-2075.1987.tb02748.x; SHENONG GLC, 1989, MOL CELL BIOL, V9, P5456, DOI 10.1128/MCB.9.12.5456; SHENONG GLC, 1984, SCIENCE, V226, P1077, DOI 10.1126/science.6093260; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; SMARDA J, 1994, ONCOGENE, V9, P237; STOBERGRASSER U, 1992, ONCOGENE, V7, P589; TANIKAWA J, 1993, P NATL ACAD SCI USA, V90, P9320, DOI 10.1073/pnas.90.20.9320; TASHIRO S, 1995, ONCOGENE, V10, P1699; TAUTH K, 1994, EMBO J, V13, P5994; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TICEBALDWIN K, 1989, SCIENCE, V246, P931, DOI 10.1126/science.2683089; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TORELLI G, 1985, MOL CELL BIOL, V5, P2874, DOI 10.1128/MCB.5.10.2874; TORELLI G, 1987, CANCER RES, V47, P5266; TRAVALI S, 1991, ONCOGENE, V6, P887; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594; URAO T, 1993, PLANT CELL, V5, P1529, DOI 10.1105/tpc.5.11.1529; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; WIESER J, 1995, GENE DEV, V9, P491, DOI 10.1101/gad.9.4.491	173	295	332	6	62	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	1996	13	2					223	235						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710361				2022-12-17	WOS:A1996VA25200001
J	Majumder, PK; Sellers, WR				Majumder, PK; Sellers, WR			Akt-regulated pathways in prostate cancer	ONCOGENE			English	Review						PTEN; AKT; prostate cancer; phosphoinostide; 3-kinase	GROWTH-FACTOR-I; TUMOR-SUPPRESSOR GENE; RECEPTOR KINASE INHIBITOR; HIGH GLEASON SCORE; STEM-CELL ANTIGEN; GERMLINE MUTATIONS; ANTITUMOR-ACTIVITY; COWDEN-DISEASE; PIK3CA GENE; INTRAEPITHELIAL NEOPLASIA	Prostate cancer remains a major cause of cancer-related mortality. Genetic clues to the molecular pathways driving the most aggressive forms of prostate cancer have been limited. Genetic inactivation of PTEN through either gene deletion or point mutation is reasonably common in metastatic prostate cancer and the resulting activation of phosphoinostide 3-kinase, AKT and mTOR provides a major therapeutic opportunity in this disease as mTOR inhibitors, HSP90 inhibitors and PI3K inhibitors begin to enter clinical development.	Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Internal Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Harvard Univ, Broad Inst, Cambridge, MA 02141 USA; MIT, Cambridge, MA 02141 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Massachusetts Institute of Technology (MIT)	Sellers, WR (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.	William_Sellers@dfci.harvard.edu						Abate-Shen C, 2003, CANCER RES, V63, P3886; Abraham RT, 2003, CURR TOP MICROBIOL, V279, P299; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Bachman KE, 2004, CANCER BIOL THER, V3, P772, DOI 10.4161/cbt.3.8.994; Backman SA, 2004, P NATL ACAD SCI USA, V101, P1725, DOI 10.1073/pnas.0308217100; Banerji U, 2005, J CLIN ONCOL, V23, P4152, DOI 10.1200/JCO.2005.00.612; Barnett SF, 2005, BIOCHEM J, V385, P399, DOI 10.1042/BJ20041140; Basso AD, 2002, ONCOGENE, V21, P1159, DOI 10.1038/sj.onc.1205184; Broderick DK, 2004, CANCER RES, V64, P5048, DOI 10.1158/0008-5472.CAN-04-1170; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Brugarolas JB, 2003, CANCER CELL, V4, P147, DOI 10.1016/S1535-6108(03)00187-9; Burtrum D, 2003, CANCER RES, V63, P8912; Campbell IG, 2004, CANCER RES, V64, P7678, DOI 10.1158/0008-5472.CAN-04-2933; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Casey G, 2002, NAT GENET, V32, P582, DOI 10.1038/ng1021; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Cheung KMJ, 2005, BIOORG MED CHEM LETT, V15, P3338, DOI 10.1016/j.bmcl.2005.05.046; Chiosis G, 2003, CURR CANCER DRUG TAR, V3, P371, DOI 10.2174/1568009033481778; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; Cohen BD, 2005, CLIN CANCER RES, V11, P2063, DOI 10.1158/1078-0432.CCR-04-1070; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; Dahia PLM, 1997, CANCER RES, V57, P4710; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; DiGiovanni J, 2000, P NATL ACAD SCI USA, V97, P3455, DOI 10.1073/pnas.97.7.3455; Dong JT, 1998, ONCOGENE, V17, P1979, DOI 10.1038/sj.onc.1202119; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Eaton SR, 1998, J MED CHEM, V41, P4329, DOI 10.1021/jm9802766; Gao H, 2004, P NATL ACAD SCI USA, V101, P17204, DOI 10.1073/pnas.0407693101; Garcia-Echeverria C, 2004, CANCER CELL, V5, P231, DOI 10.1016/S1535-6108(04)00051-0; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Gills JJ, 2004, EXPERT OPIN INV DRUG, V13, P787, DOI 10.1517/13543784.13.7.787; Gray IC, 1998, BRIT J CANCER, V78, P1296, DOI 10.1038/bjc.1998.674; GRAY IC, 1995, CANCER RES, V55, P4800; Gu Z, 2000, ONCOGENE, V19, P1288, DOI 10.1038/sj.onc.1203426; Guldberg P, 1997, CANCER RES, V57, P3660; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hostein I, 2001, CANCER RES, V61, P4003; Hsieh CL, 2001, AM J HUM GENET, V69, P148, DOI 10.1086/321281; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Kau TR, 2003, CANCER CELL, V4, P463, DOI 10.1016/S1535-6108(03)00303-9; Komiya A, 1996, GENE CHROMOSOME CANC, V17, P245; Kreisberg JI, 2004, CANCER RES, V64, P5232, DOI 10.1158/0008-5472.CAN-04-0272; Lesche R, 2002, GENESIS, V32, P148, DOI 10.1002/gene.10036; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liao YD, 2003, INT J CANCER, V107, P676, DOI 10.1002/ijc.11471; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Lindsley CW, 2005, BIOORG MED CHEM LETT, V15, P761, DOI 10.1016/j.bmcl.2004.11.011; Liu WG, 1997, CANCER RES, V57, P5254; Luo J, 2005, P NATL ACAD SCI USA, V102, P10238, DOI 10.1073/pnas.0504378102; Luo Y, 2005, MOL CANCER THER, V4, P977, DOI 10.1158/1535-7163.MCT-05-0005; Lynch ED, 1997, AM J HUM GENET, V61, P1254, DOI 10.1086/301639; Ma L, 2005, GENE DEV, V19, P1779, DOI 10.1101/gad.1314405; Ma XQ, 2005, CANCER RES, V65, P5730, DOI 10.1158/0008-5472.CAN-04-4519; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Majumder PK, 2003, P NATL ACAD SCI USA, V100, P7841, DOI 10.1073/pnas.1232229100; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Malik SN, 2002, CLIN CANCER RES, V8, P1168; Maloney EK, 2003, CANCER RES, V63, P5073; Marsh DJ, 1997, CANCER RES, V57, P500; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; McMenamin ME, 1999, CANCER RES, V59, P4291; MCSHEEHY PM, 2005, SOC NUC MED; Meuillet EJ, 2004, ONCOL RES, V14, P513, DOI 10.3727/0965040042380487; Mitsiades CS, 2004, CANCER CELL, V5, P221, DOI 10.1016/S1535-6108(04)00050-9; Miwa W, 1996, BIOCHEM BIOPH RES CO, V225, P968, DOI 10.1006/bbrc.1996.1280; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Nelen MR, 1997, HUM MOL GENET, V6, P1383, DOI 10.1093/hmg/6.8.1383; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Rasheed BKA, 1997, CANCER RES, V57, P4187; Reiter RE, 1998, P NATL ACAD SCI USA, V95, P1735, DOI 10.1073/pnas.95.4.1735; Rennert H, 2002, AM J HUM GENET, V71, P981, DOI 10.1086/342775; Risinger JI, 1997, CANCER RES, V57, P4736; Rokman A, 2002, AM J HUM GENET, V70, P1299, DOI 10.1086/340450; Ruan WF, 1999, ENDOCRINOLOGY, V140, P1984, DOI 10.1210/en.140.5.1984; Ruggeri BA, 1998, MOL CARCINOGEN, V21, P81, DOI 10.1002/(SICI)1098-2744(199802)21:2<81::AID-MC1>3.0.CO;2-R; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Scotlandi K, 2005, CANCER RES, V65, P3868, DOI 10.1158/0008-5472.CAN-04-3192; SELLERS WR, 2002, PROSTATE CANC PRINCI; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Solit DB, 2003, CANCER RES, V63, P2139; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stiles B, 2002, MOL CELL BIOL, V22, P3842, DOI 10.1128/MCB.22.11.3842-3851.2002; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; Suzuki H, 1998, CANCER RES, V58, P204; Tabellini G, 2004, BRIT J HAEMATOL, V126, P574, DOI 10.1111/j.1365-2141.2004.05073.x; Tashiro H, 1997, CANCER RES, V57, P3935; THIMMAIAH KN, 2005, J BIOL CHEM; Thompson FH, 1996, CANCER GENET CYTOGEN, V87, P55, DOI 10.1016/0165-4608(95)00248-0; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; Tsao HS, 1998, ONCOGENE, V16, P3397, DOI 10.1038/sj.onc.1201881; Van de Sande T, 2005, J PATHOL, V206, P214, DOI 10.1002/path.1760; Vlietstra RJ, 1998, CANCER RES, V58, P2720; Wang SI, 1998, CLIN CANCER RES, V4, P811; Wang SI, 1997, CANCER RES, V57, P4183; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Ward S, 2003, CHEM BIOL, V10, P207, DOI 10.1016/S1074-5521(03)00048-6; Warshamana-Greene GS, 2005, CLIN CANCER RES, V11, P1563, DOI 10.1158/1078-0432.CCR-04-1544; Wolk A, 1998, J NATL CANCER I, V90, P911, DOI 10.1093/jnci/90.12.911; Workman P, 2004, BIOCHEM SOC T, V32, P393, DOI 10.1042/BST0320393; Xu JF, 2002, NAT GENET, V32, P321, DOI 10.1038/ng994; Xu JF, 2001, AM J HUM GENET, V68, P901, DOI 10.1086/319513; You MJ, 2002, P NATL ACAD SCI USA, V99, P1455, DOI 10.1073/pnas.022632099; Zhong H, 2000, CANCER RES, V60, P1541	122	294	307	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2005	24	50					7465	7474		10.1038/sj.onc.1209096	http://dx.doi.org/10.1038/sj.onc.1209096			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982ZW	16288293				2022-12-17	WOS:000233201900009
J	LIEBERMANN, DA; HOFFMAN, B; STEINMAN, RA				LIEBERMANN, DA; HOFFMAN, B; STEINMAN, RA			MOLECULAR CONTROLS OF GROWTH ARREST AND APOPTOSIS - P53-DEPENDENT AND INDEPENDENT PATHWAYS	ONCOGENE			English	Review						APOPTOSIS; GROWTH ARREST; P53; DIFFERENTIATION; HEMATOPOIESIS	PROGRAMMED CELL-DEATH; MYELOID LEUKEMIC-CELLS; WILD-TYPE P53; CYCLIN-DEPENDENT KINASES; CONSTITUTIVE C-MYC; ATAXIA-TELANGIECTASIA; TERMINAL DIFFERENTIATION; NUCLEAR ANTIGEN; GENE-EXPRESSION; RESPONSE GENE	Cell homeostasis is regulated by a balance between proliferation, growth arrest and programmed cell death (apoptosis). Until recently, studies on oncogenesis have focused on the regulation of cell proliferation. The recognition that negative growth control, including growth arrest and programmed cell death, must be understood to comprehend how appropriate cell numbers are maintained and how alterations in any part of the equation can contribute to malignancy has led to a burst of work in this field. This review focuses on what has been learned about distinct settings of negative growth control, analyzing p53-dependent and independent pathways of growth arrest and apoptosis either coupled or uncoupled from differentiation, with an emphasis on the use of hematopoietic cells. The importance of understanding the molecular biology of apoptotic and growth arrest pathways in cancer therapy, and future directions to study negative growth control are addressed as well.	UNIV PITTSBURGH, SCH MED, PITTSBURGH CANC INST, PITTSBURGH, PA 15213 USA; UNIV PITTSBURGH, SCH MED, DEPT MED, PITTSBURGH, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	LIEBERMANN, DA (corresponding author), TEMPLE UNIV, SCH MED, FELS INST CANC RES & MOLEC BIOL, PHILADELPHIA, PA 19140 USA.							ABDOLLAHI A, 1991, ONCOGENE, V6, P165; ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; ALBERTS B, 1994, MOL BIOL CELL, pCH21; ANTOUN GR, 1991, LEUKEMIA RES, V15, P1029, DOI 10.1016/0145-2126(91)90108-6; ASKEW DS, 1991, ONCOGENE, V6, P1915; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BEADLING C, 1993, P NATL ACAD SCI USA, V90, P2719, DOI 10.1073/pnas.90.7.2719; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BUSSE PM, 1977, RADIAT RES, V71, P666, DOI 10.2307/3574634; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CHOU J, 1992, P NATL ACAD SCI USA, V89, P3266, DOI 10.1073/pnas.89.8.3266; CHOU J, 1994, P NATL ACAD SCI USA, V91, P5247, DOI 10.1073/pnas.91.12.5247; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COHEN JJ, 1991, ADV IMMUNOL, V50, P55; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DIETRICH DR, 1993, CRIT REV TOXICOL, V23, P77, DOI 10.3109/10408449309104075; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cellbio.7.1.663; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FORNACE AJ, 1992, ANN NY ACAD SCI, V663, P139, DOI 10.1111/j.1749-6632.1992.tb38657.x; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; FURUKAWA Y, 1994, CANCER RES, V54, P6533; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUILLOUF C, 1995, IN PRESS ONCOGEN JUN; GUILLOUF C, 1995, IN PRESS BLOOD   MAY; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HENDERSON DS, 1994, EMBO J, V13, P1450, DOI 10.1002/j.1460-2075.1994.tb06399.x; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HILTON DJ, 1992, TRENDS BIOCHEM SCI, V17, P72, DOI 10.1016/0968-0004(92)90505-4; HOFFMAN B, 1994, ONCOGENE, V9, P1807; HOFFMANLIEBERMANN B, 1981, INT J CANCER, V28, P615, DOI 10.1002/ijc.2910280514; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; IMRAY FP, 1983, MUTAT RES, V112, P369; JIANG HP, 1994, ONCOGENE, V9, P3397; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KIYOKAWA H, 1993, P NATL ACAD SCI USA, V90, P6746, DOI 10.1073/pnas.90.14.6746; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KORSMEYER SJ, 1992, BLOOD, V80, P879; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; KSHIMOTO T, 1992, SCIENCE, V258, P593; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LIEBERMANN D, 1981, INT J CANCER, V28, P285, DOI 10.1002/ijc.2910280306; Liebermann D A, 1994, Curr Opin Hematol, V1, P24; LIEBERMANN DA, 1994, STEM CELLS, V12, P352, DOI 10.1002/stem.5530120402; LIN EY, 1993, J IMMUNOL, V151, P1979; LORD KA, 1990, ONCOGENE, V5, P387; LORD KA, 1990, NUCLEIC ACIDS RES, V18, P2823, DOI 10.1093/nar/18.9.2823; LOTEM J, 1992, BLOOD, V80, P1750; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MARX J, 1993, SCIENCE, V259, P760, DOI 10.1126/science.8430327; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MCGEOCH DJ, 1991, NATURE, V353, P609, DOI 10.1038/353609b0; MCILWRATH AJ, 1994, CANCER RES, V54, P3718; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOBERG KH, 1992, J CELL BIOCHEM, V49, P208, DOI 10.1002/jcb.240490213; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; NAGASAWA H, 1983, MUTAT RES, V109, P297, DOI 10.1016/0027-5107(83)90054-4; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NATARAJAN AT, 1980, HUM GENET, V54, P183, DOI 10.1007/BF00278969; NEVINS JR, 1992, SCIENCE, V258, P424; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OBERG F, 1991, P NATL ACAD SCI USA, V88, P5567, DOI 10.1073/pnas.88.13.5567; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; OCONNOR PM, 1992, CELL GROWTH DIFFER, V3, P43; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PETERS G, 1994, NATURE, V371, P204, DOI 10.1038/371204a0; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; QUENSBERY PJ, 1994, WILLIAMS HEMATOLOGY, pCH22; REES JJ, 1994, CELL BIOIL, V124, P1; ROTELLO RJ, 1991, P NATL ACAD SCI USA, V88, P3412, DOI 10.1073/pnas.88.8.3412; RUSCETTI F, 1993, ANN NY ACAD SCI, V685, P488, DOI 10.1111/j.1749-6632.1993.tb35911.x; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SELVAKUMARAN M, 1993, BLOOD, V81, P2257; SELVAKUMARAN M, 1994, BLOOD, V84, P1036; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHIMIZU T, 1995, CANCER RES, V55, P228; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SOLARY E, 1994, LEUKEMIA LYMPHOMA, V15, P21, DOI 10.3109/10428199409051674; STANBRIDGE EJ, 1990, CELL, V63, P867, DOI 10.1016/0092-8674(90)90490-6; STEINMAN RA, 1994, ONCOGENE, V9, P3389; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; STEWART N, 1995, ONCOGENE, V10, P109; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; TARUNINA M, 1993, ONCOGENE, V8, P3165; THACKER J, 1990, MUTAT RES, V235, P49, DOI 10.1016/0921-8777(90)90057-C; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WALDREN CA, 1978, RADIAT RES, V73, P95, DOI 10.2307/3574576; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WANG YS, 1993, ONCOGENE, V8, P3427; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1985, ANTICANCER RES, V5, P131; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YEN A, 1993, CANCER RES, V53, P3085; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; ZHAN QM, 1994, ONCOGENE, V9, P3743	173	294	301	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	1995	11	1					199	210						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624128				2022-12-17	WOS:A1995RJ29500023
J	Di Virgilio, F; Adinolfi, E				Di Virgilio, F.; Adinolfi, E.			Extracellular purines, purinergic receptors and tumor growth	ONCOGENE			English	Review							A(3) ADENOSINE RECEPTORS; P2X7 RECEPTOR; P2X(7) RECEPTOR; CARCINOMA-CELLS; HEPATOCELLULAR-CARCINOMA; NEUROBLASTOMA-CELLS; P2Y2 RECEPTOR; P-2X RECEPTOR; PORE DILATION; ATP RELEASE	Virtually, all tumor cells as well as all immune cells express plasma membrane receptors for extracellular nucleosides (adenosine) and nucleotides (ATP, ADP, UTP, UDP and sugar UDP). The tumor microenvironment is characterized by an unusually high concentration of ATP and adenosine. Adenosine is a major determinant of the immunosuppressive tumor milieu. Sequential hydrolysis of extracellular ATP catalyzed by CD39 and CD73 is the main pathway for the generation of adenosine in the tumor interstitium. Extracellular ATP and adenosine mold both host and tumor responses. Depending on the specific receptor activated, extracellular purines mediate immunosuppression or immunostimulation on the host side, and growth stimulation or cytotoxicity on the tumor side. Recent progress in this field is providing the key to decode this complex scenario and to lay the basis to harness the potential benefits for therapy. Preclinical data show that targeting the adenosine-generating pathway (that is, CD73) or adenosinergic receptors (that is, A2A) relieves immunosuppresion and potently inhibits tumor growth. On the other hand, growth of experimental tumors is strongly inhibited by targeting the P2X7 ATP-selective receptor of cancer and immune cells. This review summarizes the recent data on the role played by extracellular purines (purinergic signaling) in host-tumor interaction and highlights novel therapeutic options stemming from recent advances in this field.	[Di Virgilio, F.; Adinolfi, E.] Univ Ferrara, Sect Pathol Oncol & Expt Biol, Dept Morphol Surg & Expt Med, Via Borsari 46, I-44121 Ferrara, Italy	University of Ferrara	Di Virgilio, F (corresponding author), Univ Ferrara, Sect Pathol Oncol & Expt Biol, Dept Morphol Surg & Expt Med, Via Borsari 46, I-44121 Ferrara, Italy.	fdv@unife.it	DI VIRGILIO, Francesco/O-4634-2019; Di Virgilio, Francesco/J-3754-2018; Adinolfi, Elena/F-9169-2010	DI VIRGILIO, Francesco/0000-0003-3566-1362; Di Virgilio, Francesco/0000-0003-3566-1362; Adinolfi, Elena/0000-0001-8129-9929	AIRC [IG 13025, IG16812]; Telethon [GGP 11014]; ERA-NET Neuron 'Nanostroke'; EU COST Program [BM1406]; Ministry of Health of Italy [RF-2011-02348435]; Italian Ministry of Education, University and Research [RBAP11FXBC_001]; University of Ferrara; 7th Framework Program [HEALTH-F2-2007-202231]; Region Emilia Romagna (Bando Alessandro Liberati)	AIRC(Fondazione AIRC per la ricerca sul cancro); Telethon(Fondazione Telethon); ERA-NET Neuron 'Nanostroke'; EU COST Program; Ministry of Health of Italy(Ministry of Health, Italy); Italian Ministry of Education, University and Research; University of Ferrara; 7th Framework Program(European Commission); Region Emilia Romagna (Bando Alessandro Liberati)	FDV is supported by grants from AIRC (no. IG 13025), Telethon (no. GGP 11014), ERA-NET Neuron 'Nanostroke', EU COST Program no. BM1406, the Ministry of Health of Italy (no. RF-2011-02348435), the Italian Ministry of Education, University and Research (no. RBAP11FXBC_001) and funds from the University of Ferrara. FDV was also supported by the 7th Framework Program HEALTH-F2-2007-202231 'ATPBone'. EA is supported by AIRC (IG16812), a Young investigator grant of the Region Emilia Romagna (Bando Alessandro Liberati) and Institutional funds from the University of Ferrara.	Abbracchio MP, 2006, PHARMACOL REV, V58, P281, DOI 10.1124/pr.58.3.3; Adinolfi E, 2005, MOL BIOL CELL, V16, P3260, DOI 10.1091/mbc.E04-11-1025; Adinolfi E, 2002, BLOOD, V99, P706, DOI 10.1182/blood.V99.2.706; Adinolfi E, 2015, CANCER RES, V75, P635, DOI 10.1158/0008-5472.CAN-14-1259; Adinolfi E, 2015, CURR MED CHEM, V22, P878, DOI 10.2174/0929867321666141012172913; Adinolfi E, 2012, CANCER RES, V72, P2957, DOI 10.1158/0008-5472.CAN-11-1947; Adinolfi E, 2010, FASEB J, V24, P3393, DOI 10.1096/fj.09-153601; Adinolfi E, 2009, J BIOL CHEM, V284, P10120, DOI 10.1074/jbc.M805805200; Aliagas E, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/509027; Allard B, 2013, CLIN CANCER RES, V19, P5626, DOI 10.1158/1078-0432.CCR-13-0545; Allsopp RC, 2015, J BIOL CHEM, V290, P14556, DOI 10.1074/jbc.M115.642033; Amoroso F, 2015, ONCOGENE, V34, P5240, DOI 10.1038/onc.2014.444; Amoroso F, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.105; Antonioli L, 2013, NAT REV CANCER, V13, P842, DOI 10.1038/nrc3613; Barbera-Cremades M, 2012, FASEB J, V26, P2951, DOI 10.1096/fj.12-205765; Baricordi OR, 1996, BLOOD, V87, P682, DOI 10.1182/blood.V87.2.682.bloodjournal872682; Bastid J, 2013, ONCOGENE, V32, P1743, DOI 10.1038/onc.2012.269; Beigi R., 1999, AM J PHYSIOL, V276, P267; Bergamin LS, 2015, J CELL BIOCHEM, V116, P721, DOI 10.1002/jcb.25018; Bianchi G, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.109; Bianco F, 2006, J NEUROCHEM, V99, P745, DOI 10.1111/j.1471-4159.2006.04101.x; Blay J, 1997, CANCER RES, V57, P2602; Borea PA, 2015, PHARMACOL REV, V67, P74, DOI 10.1124/pr.113.008540; Bours Martijn Jan Leo, 2011, Front Biosci (Schol Ed), V3, P1443; Bowser JL, 2016, J CLIN INVEST, V126, P220, DOI 10.1172/JCI79380; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; Burnstock G, 2006, PHARMACOL REV, V58, P58, DOI 10.1124/pr.58.1.5; Burnstock G, 2014, EXP PHYSIOL, V99, P16, DOI 10.1113/expphysiol.2013.071951; Burnstock G, 2013, PURINERG SIGNAL, V9, P541, DOI 10.1007/s11302-013-9381-4; Cappellari AR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047468; Casares N, 2005, J EXP MED, V202, P1691, DOI 10.1084/jem.20050915; Cekic C, 2014, CANCER RES, V74, P7250, DOI 10.1158/0008-5472.CAN-13-3583; Cekic C, 2012, J IMMUNOL, V188, P198, DOI 10.4049/jimmunol.1101845; Chadet S, 2014, CARCINOGENESIS, V35, P1238, DOI 10.1093/carcin/bgt493; Chong JH, 2010, BIOCHEM BIOPH RES CO, V391, P498, DOI 10.1016/j.bbrc.2009.11.087; COCKCROFT S, 1979, NATURE, V279, P541, DOI 10.1038/279541a0; Coddou C, 2011, PHARMACOL REV, V63, P641, DOI 10.1124/pr.110.003129; Compan V, 2012, J NEUROSCI, V32, P4284, DOI 10.1523/JNEUROSCI.6332-11.2012; Corriden R, 2007, AM J PHYSIOL-CELL PH, V293, pC1420, DOI 10.1152/ajpcell.00271.2007; Corriden R, 2014, FASEB J, V28, P4211, DOI 10.1096/fj.13-247270; Coutinho-Silva R, 2005, AM J PHYSIOL-GASTR L, V288, pG1024, DOI 10.1152/ajpgi.00211.2004; De Marchi E, 2016, ADV PROTEIN CHEM STR, V104, P39, DOI 10.1016/bs.apcsb.2015.11.004; Di Virgilio F, 1998, CELL DEATH DIFFER, V5, P191; Di Virgilio F., 1994, CELL TISSUE CULTURE; Di Virgilio F, 2015, CURR MED CHEM, V22, P866; Di Virgilio F, 2012, CANCER RES, V72, P5441, DOI 10.1158/0008-5472.CAN-12-1600; DIVIRGILIO F, 1989, J IMMUNOL, V143, P1955; Drury AN, 1929, J PHYSIOL-LONDON, V68, P213, DOI 10.1113/jphysiol.1929.sp002608; Eltzschig HK, 2009, BLOOD, V113, P224, DOI 10.1182/blood-2008-06-165746; Etique N, 2009, ONCOL REP, V21, P977, DOI 10.3892/or_00000311; Falzoni S, 2013, INTERFACE FOCUS, V3, DOI 10.1098/rsfs.2012.0101; Fang JQ, 2015, CANCER BIOL THER, V16, P498, DOI 10.1080/15384047.2015.1016663; Ferrari D, 2004, J IMMUNOL, V173, P4652, DOI 10.4049/jimmunol.173.7.4652; Fishman P, 2004, ONCOGENE, V23, P2465, DOI 10.1038/sj.onc.1207355; Galluzzi L, 2015, CANCER CELL, V28, P690, DOI 10.1016/j.ccell.2015.10.012; Gessi S, 2004, CLIN CANCER RES, V10, P5895, DOI 10.1158/1078-0432.CCR-1134-03; Gessi S, 2011, BBA-BIOMEMBRANES, V1808, P1400, DOI 10.1016/j.bbamem.2010.09.020; Gessi S, 2010, BIOCHEM PHARMACOL, V79, P1483, DOI 10.1016/j.bcp.2010.01.009; Ghalali A, 2014, CARCINOGENESIS, V35, P1547, DOI 10.1093/carcin/bgu019; Ghiringhelli F, 2009, NAT MED, V15, P1170, DOI 10.1038/nm.2028; Giannuzzo A, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0472-4; Gines S, 2000, P NATL ACAD SCI USA, V97, P8606, DOI 10.1073/pnas.150241097; Giuliani AL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107224; Gomez-Villafuertes R, 2015, SCI REP-UK, V5, DOI 10.1038/srep18417; Greig AVH, 2003, J INVEST DERMATOL, V121, P315, DOI 10.1046/j.1523-1747.2003.12379.x; Hasko G, 2008, NAT REV DRUG DISCOV, V7, P759, DOI 10.1038/nrd2638; Hatfield SM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa1260; Hayashi S, 2004, SCI STKE, V2004, pl14; Hill LM, 2010, J IMMUNOL, V185, P3028, DOI 10.4049/jimmunol.1001298; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hofman P, 2015, CANCER RES, V75, P835, DOI 10.1158/0008-5472.CAN-14-1778; Hoskin DW, 2002, INT J CANCER, V99, P386, DOI 10.1002/ijc.10325; Iannone R, 2013, NEOPLASIA, V15, P1400, DOI 10.1593/neo.131748; Idzko M, 2014, NATURE, V509, P310, DOI 10.1038/nature13085; Jackson SW, 2007, AM J PATHOL, V171, P1395, DOI 10.2353/ajpath.2007.070190; Jacobson KA, 2016, NEUROPHARMACOLOGY, V104, P31, DOI 10.1016/j.neuropharm.2015.12.001; Jacques-Silva MC, 2004, BRIT J PHARMACOL, V141, P1106, DOI 10.1038/sj.bjp.0705685; Jajoo S, 2009, NEOPLASIA, V11, P1132, DOI 10.1593/neo.09744; Jelassi B, 2011, ONCOGENE, V30, P2108, DOI 10.1038/onc.2010.593; Jiang LH, 2005, AM J PHYSIOL-CELL PH, V289, pC1295, DOI 10.1152/ajpcell.00253.2005; Jin XW, 1997, J CLIN INVEST, V100, P2849, DOI 10.1172/JCI119833; Joo YN, 2014, ONCOTARGET, V5, P9322; Kasama H, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1577-2; Khakh BS, 2006, NATURE, V442, P527, DOI 10.1038/nature04886; Khakh BS, 1999, NAT NEUROSCI, V2, P322, DOI 10.1038/7233; Koizumi S, 2007, NATURE, V446, P1091, DOI 10.1038/nature05704; Kotnis S, 2010, MOL PHARMACOL, V77, P953, DOI 10.1124/mol.110.063636; Kroemer G, 2013, ANNU REV IMMUNOL, V31, P51, DOI 10.1146/annurev-immunol-032712-100008; Kunzli BM, 2011, PURINERG SIGNAL, V7, P231, DOI 10.1007/s11302-011-9228-9; Kumar V, 2013, PURINERG SIGNAL, V9, P145, DOI 10.1007/s11302-012-9349-9; Kwon Ji Hyun, 2014, Korean J Pathol, V48, P30, DOI 10.4132/KoreanJPathol.2014.48.1.30; Lazarowski ER, 2015, MOL PHARMACOL, V88, P151, DOI 10.1124/mol.115.098756; Lazarowski ER, 2012, PURINERG SIGNAL, V8, P359, DOI 10.1007/s11302-012-9304-9; Le KT, 1997, FEBS LETT, V418, P195, DOI 10.1016/S0014-5793(97)01380-X; Leclerc BG, 2016, CLIN CANCER RES, V22, P158, DOI 10.1158/1078-0432.CCR-15-1181; Li MF, 2015, NAT NEUROSCI, V18, P1577, DOI 10.1038/nn.4120; Li W, 2015, INTERNATIONAL CONFERENCE ON COMPUTER SCIENCE AND ENVIRONMENTAL ENGINEERING (CSEE 2015), P1; Li WH, 2013, BRIT J CANCER, V109, P1666, DOI 10.1038/bjc.2013.484; Lin Z, 2010, ONCOGENE, V29, P1114, DOI 10.1038/onc.2009.409; Linden J, 2012, ARTERIOSCL THROM VAS, V32, P2097, DOI 10.1161/ATVBAHA.111.226837; Llaudet E, 2005, ANAL CHEM, V77, P3267, DOI 10.1021/ac048106q; Lohmann K, 1929, NATURWISSENSCHAFTEN, V17, P624; Loi S, 2013, P NATL ACAD SCI USA, V110, P11091, DOI 10.1073/pnas.1222251110; Longhi MS, 2013, J MOL MED, V91, P165, DOI 10.1007/s00109-012-0991-z; Loo JM, 2015, CELL, V160, P393, DOI 10.1016/j.cell.2014.12.018; MACKENZIE WM, 1994, CANCER RES, V54, P3521; Madi L, 2004, CLIN CANCER RES, V10, P4472, DOI 10.1158/1078-0432.CCR-03-0651; Mandapathil M, 2010, J BIOL CHEM, V285, P7176, DOI 10.1074/jbc.M109.047423; Martins I, 2009, CELL CYCLE, V8, P3723, DOI 10.4161/cc.8.22.10026; Maynard JP, 2015, ONCOTARGET, V6, P41162, DOI 10.18632/oncotarget.6240; Merighi S, 2002, J INVEST DERMATOL, V119, P923, DOI 10.1046/j.1523-1747.2002.00111.x; Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347; Mirza A, 2005, CANCER BIOL THER, V4, P1355, DOI 10.4161/cbt.4.12.2196; Mittal D, 2014, CANCER RES, V74, P3652, DOI 10.1158/0008-5472.CAN-14-0957; Monif M, 2009, J NEUROSCI, V29, P3781, DOI 10.1523/JNEUROSCI.5512-08.2009; Mousavi S, 2015, PROSTATE, V75, P735, DOI 10.1002/pros.22955; Munn DH, 2016, CURR OPIN IMMUNOL, V39, P1, DOI 10.1016/j.coi.2015.10.009; Norde WJ, 2009, BLOOD, V113, P2312, DOI 10.1182/blood-2008-04-153825; Ntantie E, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003374; Ohta A, 2001, NATURE, V414, P916, DOI 10.1038/414916a; Ohta A, 2006, P NATL ACAD SCI USA, V103, P13132, DOI 10.1073/pnas.0605251103; Overes IM, 2008, BRIT J HAEMATOL, V141, P799, DOI 10.1111/j.1365-2141.2008.07125.x; Pelegrin P, 2006, EMBO J, V25, P5071, DOI 10.1038/sj.emboj.7601378; Pellegatti P, 2005, MOL BIOL CELL, V16, P3659, DOI 10.1091/mbc.E05-03-0222; Pellegatti P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002599; Qiu Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114371; Raffaghello L, 2006, CANCER RES, V66, P907, DOI 10.1158/0008-5472.CAN-05-3185; Reymond N, 2013, NAT REV CANCER, V13, P858, DOI 10.1038/nrc3628; Rigato C, 2012, J NEUROSCI, V32, P11559, DOI 10.1523/JNEUROSCI.1042-12.2012; Rijke BC, 2005, J CLIN INVEST, V115, P3506, DOI 10.1172/JCI24832; Roger S, 2014, BIOCHIM BIOPHYS ACTA, V1848, P2584; Rossi L, 2007, BLOOD, V109, P533, DOI 10.1182/blood-2006-01-035634; Rossi L, 2012, BLOOD, V120, P2365, DOI 10.1182/blood-2012-04-422378; Ryzhov S, 2011, J IMMUNOL, V187, P6120, DOI 10.4049/jimmunol.1101225; Ryzhov SV, 2014, J IMMUNOL, V193, P3155, DOI 10.4049/jimmunol.1400578; Schneider SW, 1999, P NATL ACAD SCI USA, V96, P12180, DOI 10.1073/pnas.96.21.12180; Schumacher D, 2013, CANCER CELL, V24, P130, DOI 10.1016/j.ccr.2013.05.008; Shabbir M, 2008, BJU INT, V102, P108, DOI 10.1111/j.1464-410X.2008.07578.x; Sitkovsky MV, 2009, TRENDS IMMUNOL, V30, P102, DOI 10.1016/j.it.2008.12.002; Solini A, 2015, ONCOTARGET, V6, P28743, DOI 10.18632/oncotarget.4926; Stagg J, 2010, ONCOGENE, V29, P5346, DOI 10.1038/onc.2010.292; Stagg J, 2011, CANCER RES, V71, P2892, DOI 10.1158/0008-5472.CAN-10-4246; Stagg J, 2010, P NATL ACAD SCI USA, V107, P1547, DOI 10.1073/pnas.0908801107; Stegner D, 2014, THROMB RES, V133, pS149, DOI 10.1016/S0049-3848(14)50025-4; STEINBERG TH, 1987, J BIOL CHEM, V262, P3118; Stemmer SM, 2013, ONCOLOGIST, V18, P25, DOI 10.1634/theoncologist.2012-0211; Sun SH, 2010, MOL NEUROBIOL, V41, P351, DOI 10.1007/s12035-010-8120-x; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Surprenant A, 2009, ANNU REV PHYSIOL, V71, P333, DOI 10.1146/annurev.physiol.70.113006.100630; Synnestvedt K, 2002, J CLIN INVEST, V110, P993, DOI 10.1172/JCI200215337; Tafani M, 2011, CARCINOGENESIS, V32, P1167, DOI 10.1093/carcin/bgr101; Takai E, 2014, PURINERG SIGNAL, V10, P487, DOI 10.1007/s11302-014-9411-x; Thompson BAN, 2012, CELL SIGNAL, V24, P770, DOI 10.1016/j.cellsig.2011.11.012; Tung HC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124654; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; Vazquez-Cuevas FG, 2014, J CELL BIOCHEM, V115, P1955, DOI 10.1002/jcb.24867; Virginio C, 1999, NAT NEUROSCI, V2, P315, DOI 10.1038/7225; WEBB TE, 1993, FEBS LETT, V324, P219, DOI 10.1016/0014-5793(93)81397-I; Weber FC, 2010, J EXP MED, V207, P2609, DOI 10.1084/jem.20092489; WILEY JS, 1994, BRIT J PHARMACOL, V112, P946, DOI 10.1111/j.1476-5381.1994.tb13172.x; Wilhelm K, 2010, NAT MED, V16, P1434, DOI 10.1038/nm.2242; Wilson FH, 2015, CANCER CELL, V27, P397, DOI 10.1016/j.ccell.2015.02.005; Xia JY, 2015, ONCOL REP, V34, P103, DOI 10.3892/or.2015.3979; Xie R, 2014, J BIOL CHEM, V289, P19137, DOI 10.1074/jbc.M113.540047; Yang G, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/1756-9966-33-53; Yegutkin GG, 2014, CRIT REV BIOCHEM MOL, V49, P473, DOI 10.3109/10409238.2014.953627; Young A, 2014, CANCER DISCOV, V4, P879, DOI 10.1158/2159-8290.CD-14-0341; Young JD, 2013, MOL ASPECTS MED, V34, P529, DOI 10.1016/j.mam.2012.05.007; Zimmermann H, 2000, N-S ARCH PHARMACOL, V362, P299, DOI 10.1007/s002100000309	169	293	302	14	72	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 19	2017	36	3					293	303		10.1038/onc.2016.206	http://dx.doi.org/10.1038/onc.2016.206			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IB	27321181	hybrid, Green Published			2022-12-17	WOS:000394166000001
J	Djavaheri-Mergny, M; Maiuri, MC; Kroemer, G				Djavaheri-Mergny, M.; Maiuri, M. C.; Kroemer, G.			Cross talk between apoptosis and autophagy by caspase-mediated cleavage of Beclin 1	ONCOGENE			English	Review						Beclin 1; autophagy; apoptosis	BCL-2	Beclin 1 has a key role in the initiation of autophagy, a process of self-cannibalism in which cytoplasmic constituents are sequestered and targeted for lysosomal degradation. In a recent issue of Cell Death & Disease, Wirawan et al. report the significant finding that caspases can cleave Beclin 1, thereby destroying its pro-autophagic activity. Moreover, the C-terminal fragment of Beclin 1 that results from this cleavage acquires a new function and can amplify mitochondrion-mediated apoptosis. Of note, the BH3 domain of Beclin 1 remains within the N-terminal fragment, which has no detectable pro-apoptotic activity. These findings provide important insights into the molecular cross talk between autophagy and apoptosis. Oncogene (2010) 29, 1717-1719; doi:10.1038/onc.2009.519; published online 25 January 2010	[Djavaheri-Mergny, M.] INSERM, VINCO U916, Inst Bergonie, F-33076 Bordeaux, France; [Djavaheri-Mergny, M.] Univ Bordeaux, Bordeaux, France; [Maiuri, M. C.; Kroemer, G.] Inst Gustave Roussy, INSERM, U848, F-94805 Villejuif, France; [Maiuri, M. C.; Kroemer, G.] Univ Paris 11, Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; UNICANCER; Institut Bergonie; UDICE-French Research Universities; Universite de Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay	Djavaheri-Mergny, M (corresponding author), INSERM, VINCO U916, Inst Bergonie, 229 Cours Argonne, F-33076 Bordeaux, France.	mojgan.mergny@inserm.fr; kroemer@orange.fr	KROEMER, Guido/B-4263-2013; Djavaheri-Mergny, Mojgan/N-6315-2017; Djavaheri-Mergny, Mojgan/L-3890-2019; Kroemer, Guido/AAY-9859-2020	KROEMER, Guido/0000-0002-9334-4405; Djavaheri-Mergny, Mojgan/0000-0003-4893-6505; Djavaheri-Mergny, Mojgan/0000-0003-4893-6505; 	EU; Ligue contre le Cancer; Agence Nationale pour la Recherche; Institut National sur le Cancer; Canceropole Ile-de-France; Fondation pour la Recherche Medicale	EU(European Commission); Ligue contre le Cancer(Ligue nationale contre le cancer); Agence Nationale pour la Recherche(French National Research Agency (ANR)); Institut National sur le Cancer; Canceropole Ile-de-France(Region Ile-de-France); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale)	This work was supported by funds from the EU 6th and 7th Framework Programs, as well as by grants from Ligue contre le Cancer (equipe labelisee), Agence Nationale pour la Recherche, Institut National sur le Cancer, Canceropole Ile-de-France and Fondation pour la Recherche Medicale (to GK) and by grant from Ligue contre le Cancer (to MD-M).	Betin VMS, 2009, J CELL SCI, V122, P2554, DOI 10.1242/jcs.046250; Boya P, 2009, ONCOGENE, V28, P2125, DOI 10.1038/onc.2009.83; Cho DH, 2009, CANCER LETT, V274, P95, DOI 10.1016/j.canlet.2008.09.004; CHUA BT, 2003, NAT CELL BIOL, V11, P1241; Ciechomska IA, 2009, ONCOGENE, V28, P2128, DOI 10.1038/onc.2009.60; Lee JS, 2009, NAT CELL BIOL, V11, P1355, DOI 10.1038/ncb1980; Luo S, 2010, CELL DEATH DIFFER, V17, P268, DOI 10.1038/cdd.2009.121; Maiuri MC, 2009, CELL DEATH DIFFER, V16, P87, DOI 10.1038/cdd.2008.131; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Sinha S, 2008, ONCOGENE, V27, pS137, DOI 10.1038/onc.2009.51; Thompson J, 2008, J EXP MED, V205, P1029, DOI 10.1084/jem.20080101; WIRAWAN E, 2010, CELL DEATH IN PRESS; Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007-1102; Yi CH, 2009, DEV CELL, V16, P21, DOI 10.1016/j.devcel.2008.12.012; Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482	16	293	317	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2010	29	12					1717	1719		10.1038/onc.2009.519	http://dx.doi.org/10.1038/onc.2009.519			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574VR	20101204				2022-12-17	WOS:000276022800001
J	Jaiswal, AS; Marlow, BP; Gupta, N; Narayan, S				Jaiswal, AS; Marlow, BP; Gupta, N; Narayan, S			beta-Catenin-mediated transactivation and cell - cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells	ONCOGENE			English	Article						curcumin; caspase-3; beta-catenin; c-Myc; cell-cell adhesion; G(2)/M arrest; apoptosis	C-MYC; ADENOMATOUS POLYPOSIS; CARCINOMA-CELLS; IN-VITRO; P53-DEPENDENT APOPTOSIS; ADHERENS JUNCTIONS; DIETARY CURCUMIN; CYCLE ARREST; APC PROTEIN; E-CADHERIN	The development of nontoxic natural agents with chemopreventive activity against colon cancer is the focus of investigation in many laboratories. Curcumin (feruylmethane), a natural plant product, possesses such chemopreventive activity, but the mechanisms by which it prevents cancer growth are not well understood. In the present study, we examined the mechanisms by which curcumin treatment affects the growth of colon cancer cells in vitro. Results showed that curcumin treatment causes p53- and p21-independent G(2)/M phase arrest and apoptosis in HCT-116(p53(+/+)), HCT-116(p53(-/-)) and HCT-116(p21(-/-)) cell lines. We further investigated the association of the beta-catenin-mediated c-Myc expression and the cell-cell adhesion pathways in curcumin-induced G(2)/M arrest and apoptosis in HCT-116 cells. Results described a caspase-3-mediated cleavage of beta-catenin, decreased transactivation of beta-catenin/Tcf-Lef, decreased promoter DNA binding activity of the beta-catenin/Tcf-Lef complex, and decreased levels of c-Myc protein. These activities were linked with decreased Cdc2/cyclin B1 kinase activity, a function of the G2/M phase arrest. The decreased transactivation of beta-catenin in curcumin-treated HCT-116 cells was unpreventable by caspase-3 inhibitor Z-DEVD-fmk, even though the curcumin-induced cleavage of beta-catenin was blocked in Z-DEVD-fmk pretreated cells. The curcumin treatment also induced caspase-3-mediated degradation of cell-cell adhesion proteins beta-catenin, E-cadherin and APC, which were linked with apoptosis, and this degradation was prevented with the caspase-3 inhibitor. Our results suggest that curcumin treatment impairs both Wnt signaling and cell-cell adhesion pathways, resulting in G(2)/M phase arrest and apoptosis in HCT-116 cells.	Univ Florida, UF Shands Canc Ctr, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; Univ Florida, Coll Med, UF Shands Canc Ctr, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Narayan, S (corresponding author), Univ Florida, Coll Med, UF Shands Canc Ctr, Acad Res Bldg,Room R4-216,POB 100232, Gainesville, FL 32610 USA.	snarayan@ufscc.ufl.edu			NCI NIH HHS [CA77721] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077721] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad N, 1997, JNCI-J NATL CANCER I, V89, P1881, DOI 10.1093/jnci/89.24.1881; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Bordonaro M, 1999, CELL GROWTH DIFFER, V10, P713; Boxer LM, 2001, ONCOGENE, V20, P5595, DOI 10.1038/sj.onc.1204595; Brancolini C, 1998, CELL DEATH DIFFER, V5, P1042, DOI 10.1038/sj.cdd.4400443; Browne SJ, 1998, CELL DEATH DIFFER, V5, P206, DOI 10.1038/sj.cdd.4400331; BROWNE SJ, 1994, INT J CANCER, V59, P56, DOI 10.1002/ijc.2910590113; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; BUSH JA, 2001, ONCOGENE, V20, P7597; Chan TA, 2000, GENE DEV, V14, P1584; Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87; Citro G, 1998, CANCER RES, V58, P283; Clement MV, 1998, BLOOD, V92, P996; Daniels DL, 2001, TRENDS BIOCHEM SCI, V26, P672, DOI 10.1016/S0968-0004(01)01952-1; Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Goel A, 2001, CANCER LETT, V172, P111, DOI 10.1016/S0304-3835(01)00655-3; Goss KH, 2000, J CLIN ONCOL, V18, P1967, DOI 10.1200/JCO.2000.18.9.1967; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Heatwole V M, 1999, Methods Mol Biol, V115, P141; Huang MT, 1997, J CELL BIOCHEM, P26; Huelsken J, 2001, CURR OPIN GENET DEV, V11, P547, DOI 10.1016/S0959-437X(00)00231-8; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; INOUE M, 1994, BIOCHEM BIOPH RES CO, V204, P898, DOI 10.1006/bbrc.1994.2544; Jaiswal AS, 2001, J BIOL CHEM, V276, P18193, DOI 10.1074/jbc.M101298200; Jee SH, 1998, J INVEST DERMATOL, V111, P656, DOI 10.1046/j.1523-1747.1998.00352.x; Jiang MC, 1996, NUTR CANCER, V26, P111, DOI 10.1080/01635589609514468; Kawamori T, 1999, CANCER RES, V59, P597; KELLOFF GJ, 1994, CANCER RES, V54, pS2015; Kelloff GJ, 1996, J CELL BIOCHEM, P54, DOI 10.1002/jcb.240630705; Kim K, 2000, MOL BIOL CELL, V11, P3509, DOI 10.1091/mbc.11.10.3509; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; KUTTAN R, 1987, TUMORI, V73, P29, DOI 10.1177/030089168707300105; Law BK, 2000, J BIOL CHEM, V275, P38261, DOI 10.1074/jbc.M005545200; Ling YH, 2001, MOL PHARMACOL, V59, P593, DOI 10.1124/mol.59.3.593; Mahmoud NN, 2000, CARCINOGENESIS, V21, P921, DOI 10.1093/carcin/21.5.921; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Manson MM, 2000, TOXICOL LETT, V112, P499, DOI 10.1016/S0378-4274(99)00211-8; McCarty MF, 2001, MED HYPOTHESES, V56, P137, DOI 10.1054/mehy.2000.1126; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Moragoda L, 2001, ANTICANCER RES, V21, P873; Mukhopadhyay A, 2001, ONCOGENE, V20, P7597, DOI 10.1038/sj.onc.1204997; Narayan S, 1997, J BIOL CHEM, V272, P30619, DOI 10.1074/jbc.272.49.30619; Narayan S, 2001, BRIT J CANCER, V85, P898, DOI 10.1054/bjoc.2001.2002; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; Papkoff J, 1997, J BIOL CHEM, V272, P4536; Pawlak G, 2001, CURR OPIN GENET DEV, V11, P41, DOI 10.1016/S0959-437X(00)00154-4; Pereira MA, 1999, ADV EXP MED BIOL, V470, P55; Phan TT, 2001, J TRAUMA, V51, P927, DOI 10.1097/00005373-200111000-00017; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; Polakis P, 2000, GENE DEV, V14, P1837; RAO CV, 1995, CANCER RES, V55, P259; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; Schmeiser K, 1999, CELL DEATH DIFFER, V6, P377, DOI 10.1038/sj.cdd.4400504; Schuler M, 2001, BIOCHEM SOC T, V29, P684, DOI 10.1042/0300-5127:0290684; Sharma RA, 2001, CLIN CANCER RES, V7, P1894; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Soldani C, 2002, APOPTOSIS, V7, P321, DOI 10.1023/A:1016119328968; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; Steinhusen U, 2000, J BIOL CHEM, V275, P16345, DOI 10.1074/jbc.M001458200; Steinhusen U, 2001, J BIOL CHEM, V276, P4972, DOI 10.1074/jbc.M006102200; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VINDELOV LL, 1990, CYTOMETRY, V11, P753, DOI 10.1002/cyto.990110702; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; Wargovich MJ, 1997, CANCER LETT, V114, P11, DOI 10.1016/S0304-3835(97)04616-8; Williams C, 1999, ANN NY ACAD SCI, V889, P72, DOI 10.1111/j.1749-6632.1999.tb08725.x; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119	70	293	317	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	2002	21	55					8414	8427		10.1038/sj.onc.1205947	http://dx.doi.org/10.1038/sj.onc.1205947			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466962				2022-12-17	WOS:000179480100005
J	Zabarovsky, ER; Lerman, MI; Minna, JD				Zabarovsky, ER; Lerman, MI; Minna, JD			Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers	ONCOGENE			English	Review						lung cancer; tumor supressor gene; human chromosome 3; deletion mapping; preneoplasia; gene therapy	ABERRANT PROMOTER METHYLATION; HOMOZYGOUS DELETION REGION; RENAL-CELL CARCINOMA; ARGININE-RICH PROTEIN; JAAGSIEKTE SHEEP RETROVIRUS; ACID RECEPTOR BETA-2; FHIT GENE; SHORT ARM; EPIGENETIC INACTIVATION; MICROCELL HYBRIDS	Loss of heterozygosity (LOH) involving several chromosome 3p regions accompanied by chromosome 3p deletions are detected in almost 100% of small (SCLCs) and more than 90% of non-small (NSCLCs) cell lung cancers. In addition, these changes appear early in the pathogenesis of lung cancer and are found as clonal lesions in the smoking damaged respiratory epithelium including histologically normal epithelium as well as in epithelium showing histologic changes of preneoplasia. These 3p genetic alterations lead to the conclusion that the short arm of human chromosome 3 contains several tumor suppressor gene(s) (TSG(s)). Although the first data suggesting that 3p alterations were involved in lung carcinogenesis were published more than 10 years ago, only recently has significant progress been achieved in identifying the candidate TSGs and beginning to demonstrate their functional role in tumor pathogenesis. Some of the striking results of these findings has been the discovery of multiple 3p TSGs and the importance of tumor acquired promoter DNA methylation as an epigenetic mechanism for inactivating the expression of these genes in lung cancer. This progress, combined with the well known role of smoking as an environmental causative risk factor in lung cancer pathogenesis, is leading to the development of new diagnostic and therapeutic strategies which can be translated into the clinic to combat and prevent the lung cancer epidemic. It is clear now that genetic and epigenetic abnormalities of several genes residing in chromosome region 3p are important for the development of lung cancers but it is still obscure how many of them exist and which of the numerous candidate TSGs are the key players in lung cancer pathogenesis. We review herein our current knowledge and describe the most credible candidate genes.	Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden; Karolinska Inst, Ctr Genomics & Bioinformat, S-17177 Stockholm, Sweden; NCI, Immunobiol Lab, Ctr Canc Res, Frederick, MD 21702 USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA	Karolinska Institutet; Karolinska Institutet; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Zabarovsky, ER (corresponding author), Karolinska Inst, MTC, Box 280, S-17177 Stockholm, Sweden.	eugzab@ki.se; lerman@mail.ncifcrf.gov; John.Minna@UTSouthwestern.edu	Zabarovsky, Eugene R/A-6645-2010		NATIONAL CANCER INSTITUTE [P50CA070907, R01CA071618] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA70907, CA71618] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acevedo CM, 2002, CANCER-AM CANCER SOC, V94, P793, DOI 10.1002/cncr.10275; ADORJAN P, 2002, NUCLEIC ACIDS RES, V30, P1; Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; AGATHANGGELOU A, 2002, P AACR, V42, P614; Alimov A, 2000, ONCOGENE, V19, P1392, DOI 10.1038/sj.onc.1203449; ANGELBORG G, 2002, P AACR, V42; ANGELONI D, 2001, HUMAN LUNG CANC CANC, V23, P169; Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968; Banham AH, 2001, CANCER RES, V61, P8820; Bateman A, 1999, NUCLEIC ACIDS RES, V27, P260, DOI 10.1093/nar/27.1.260; Berard J, 1996, FASEB J, V10, P1091, DOI 10.1096/fasebj.10.9.8801172; Blaker H, 1999, GENE CHROMOSOME CANC, V25, P399; Boldog F, 1997, HUM MOL GENET, V6, P193, DOI 10.1093/hmg/6.2.193; Braga E, 2002, INT J CANCER, V100, P534, DOI 10.1002/ijc.10511; Braga E, 1999, FEBS LETT, V454, P215, DOI 10.1016/S0014-5793(99)00807-8; Brambilla E, 2000, AM J PATHOL, V156, P939, DOI 10.1016/S0002-9440(10)64962-0; BUCHHAGEN DL, 1994, INT J CANCER, V57, P473, DOI 10.1002/ijc.2910570406; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Caballero OL, 2001, GENE CHROMOSOME CANC, V32, P119, DOI 10.1002/gcc.1173; CHEN LC, 1994, CANCER RES, V54, P3021; Cheng Y, 1998, P NATL ACAD SCI USA, V95, P3042, DOI 10.1073/pnas.95.6.3042; Croce CM, 1999, J CLIN ONCOL, V17, P1618, DOI 10.1200/JCO.1999.17.5.1618; Csoka AB, 2001, MATRIX BIOL, V20, P499, DOI 10.1016/S0945-053X(01)00172-X; Dahiya R, 1997, INT J CANCER, V71, P20, DOI 10.1002/(SICI)1097-0215(19970328)71:1<20::AID-IJC5>3.3.CO;2-G; Daigo Y, 1999, CANCER RES, V59, P1966; Daigo Y, 1999, DNA Res, V6, P37, DOI 10.1093/dnares/6.1.37; Dallol A, 2002, ONCOGENE, V21, P3020, DOI 10.1038/sj.onc.1205421; DALMAU J, 1992, MEDICINE, V71, P59, DOI 10.1097/00005792-199203000-00001; DALY MC, 1991, GENOMICS, V9, P113, DOI 10.1016/0888-7543(91)90227-6; DALY MC, 1993, ONCOGENE, V8, P1721; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; De las Heras M, 2000, EUR RESPIR J, V16, P330, DOI 10.1034/j.1399-3003.2000.16b23.x; Drabkin HA, 1999, ONCOGENE, V18, P2589, DOI 10.1038/sj.onc.1202601; DRABKIN HA, 1992, GENE CHROMOSOME CANC, V5, P67, DOI 10.1002/gcc.2870050110; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Drumheller T, 1996, J MED GENET, V33, P842, DOI 10.1136/jmg.33.10.842; Dumon KR, 2001, P NATL ACAD SCI USA, V98, P3346, DOI 10.1073/pnas.061020098; Dumon KR, 2001, CANCER RES, V61, P4827; Edamatsu H, 2000, GENES CELLS, V5, P849, DOI 10.1046/j.1365-2443.2000.00370.x; Esteller M, 1999, CANCER RES, V59, P67; Esteller M, 2001, CANCER RES, V61, P3225; Fan X, 2001, CANCER GENET CYTOGEN, V128, P97, DOI 10.1016/S0165-4608(01)00398-3; Fong KM, 1997, CANCER RES, V57, P2256; Fong LYY, 2000, P NATL ACAD SCI USA, V97, P4742, DOI 10.1073/pnas.080063497; Frost GI, 2000, ONCOGENE, V19, P870, DOI 10.1038/sj.onc.1203317; Fujisawa H, 1998, CURR OPIN NEUROBIOL, V8, P587, DOI 10.1016/S0959-4388(98)80085-8; Fullwood P, 1999, CANCER RES, V59, P4662; GANLY PS, 1992, GENOMICS, V12, P221, DOI 10.1016/0888-7543(92)90369-4; Gao BN, 2000, J BIOL CHEM, V275, P12237, DOI 10.1074/jbc.275.16.12237; Garcia-Rostan G, 2001, AM J PATHOL, V158, P987, DOI 10.1016/S0002-9440(10)64045-X; Gemmill RM, 1998, P NATL ACAD SCI USA, V95, P9572, DOI 10.1073/pnas.95.16.9572; GERADTS J, 1993, CELL GROWTH DIFFER, V4, P799; Geradts J, 2000, BRIT J CANCER, V82, P1191, DOI 10.1054/bjoc.1999.1062; Geradts J, 1999, CLIN CANCER RES, V5, P791; Geurts JMW, 1997, CANCER RES, V57, P13; Girard L, 2000, CANCER RES, V60, P4894; Gnarra JR, 1997, P NATL ACAD SCI USA, V94, P9102, DOI 10.1073/pnas.94.17.9102; GRAHAM S, 1984, JNCI-J NATL CANCER I, V73, P1423; Greenspan DL, 1997, CANCER RES, V57, P4692; Guo ZM, 2000, INT J CANCER, V86, P518, DOI 10.1002/(SICI)1097-0215(20000515)86:4<518::AID-IJC12>3.0.CO;2-Y; Gure AO, 1998, CANCER RES, V58, P1034; Helland A, 2000, INT J CANCER, V88, P217; Heppell-Parton AC, 1999, CANCER GENET CYTOGEN, V111, P105, DOI 10.1016/S0165-4608(98)00208-8; Hirano A, 2001, CLIN CANCER RES, V7, P876; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; Hu LF, 1996, GENE CHROMOSOME CANC, V17, P118, DOI 10.1002/(SICI)1098-2264(199610)17:2<118::AID-GCC7>3.0.CO;2-8; Huebner K, 2001, NAT REV CANCER, V1, P214, DOI 10.1038/35106058; Ikeda T, 2000, ONCOL REP, V7, P323; IMREH S, 1994, GENE CHROMOSOME CANC, V11, P237, DOI 10.1002/gcc.2870110406; Ishii H, 2001, CANCER RES, V61, P1578; Ishikawa S, 1997, DNA Res, V4, P35, DOI 10.1093/dnares/4.1.35; Ivanov S, 2001, AM J PATHOL, V158, P905, DOI 10.1016/S0002-9440(10)64038-2; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Ji L, 2002, CANCER RES, V62, P2715; Ji L, 1999, CANCER RES, V59, P3333; Julicher K, 1999, J NATL CANCER I, V91, P1563, DOI 10.1093/jnci/91.18.1563; KASHUBA VI, 1995, CANCER GENET CYTOGEN, V81, P144, DOI 10.1016/0165-4608(94)00215-W; Keith RL, 2000, CLIN CANCER RES, V6, P1616; Kholodnyuk I, 1997, GENE CHROMOSOME CANC, V18, P200, DOI 10.1002/(SICI)1098-2264(199703)18:3<200::AID-GCC6>3.0.CO;2-5; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; KILLARY AM, 1992, P NATL ACAD SCI USA, V89, P10877, DOI 10.1073/pnas.89.22.10877; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kiss H, 2002, EUR J HUM GENET, V10, P52, DOI 10.1038/sj.ejhg.5200758; Knudson AG, 1995, ADV CANCER RES, V67, P1, DOI 10.1016/S0065-230X(08)60708-3; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Kondo M, 2001, ONCOGENE, V20, P6258, DOI 10.1038/sj.onc.1204832; Kosaki R, 1999, CANCER RES, V59, P1141; Kuzmin I, 2002, CANCER RES, V62, P3498; LATIF F, 1992, GENE CHROMOSOME CANC, V5, P119, DOI 10.1002/gcc.2870050205; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Le Beau MM, 1998, GENE CHROMOSOME CANC, V21, P281, DOI 10.1002/(SICI)1098-2264(199804)21:4<281::AID-GCC1>3.0.CO;2-V; Lee MG, 2001, CANCER RES, V61, P6688; Lepperdinger G, 1998, J BIOL CHEM, V273, P22466, DOI 10.1074/jbc.273.35.22466; Lerman MI, 2000, CANCER RES, V60, P6116; Li JF, 2002, P NATL ACAD SCI USA, V99, P10724, DOI 10.1073/pnas.132271699; Lindblad-Toh K, 2000, NAT BIOTECHNOL, V18, P1001, DOI 10.1038/79269; Liu J, 1999, FEBS LETT, V462, P121, DOI 10.1016/S0014-5793(99)01523-9; Liu NF, 2001, CANCER RES, V61, P5207; Lo KW, 2001, CANCER RES, V61, P3877; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; Lott ST, 1998, CANCER RES, V58, P3533; Lounis H, 1998, ONCOGENE, V17, P2359, DOI 10.1038/sj.onc.1202152; Lovell M, 1999, CANCER RES, V59, P2182; Maitra A, 2001, AM J PATHOL, V159, P119, DOI 10.1016/S0002-9440(10)61679-3; Manning AP, 1999, MOL CARCINOGEN, V24, P218, DOI 10.1002/(SICI)1098-2744(199903)24:3<218::AID-MC8>3.0.CO;2-A; Maruyama R, 2001, CANCER RES, V61, P8659; Maruyama R, 2002, CLIN CANCER RES, V8, P514; Matsumoto S, 1997, GENE CHROMOSOME CANC, V20, P268; Matsumoto S, 2000, CANCER LETT, V152, P63, DOI 10.1016/S0304-3835(99)00431-0; Mirabelli-Primdahl L, 1999, CANCER RES, V59, P3346; Morrissey C, 2001, CANCER RES, V61, P7277; Muller CY, 1998, J NATL CANCER I, V90, P433, DOI 10.1093/jnci/90.6.433; MURATA Y, 1994, HUM MOL GENET, V3, P1341, DOI 10.1093/hmg/3.8.1341; Nelson HH, 1998, CANCER RES, V58, P1804; Orikasa K, 1998, CANCER GENET CYTOGEN, V104, P104, DOI 10.1016/S0165-4608(97)00470-6; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Otterson GA, 1998, J NATL CANCER I, V90, P426, DOI 10.1093/jnci/90.6.426; Palmarini M, 1999, J VIROL, V73, P6964, DOI 10.1128/JVI.73.8.6964-6972.1999; Palmisano WA, 2000, CANCER RES, V60, P5954; PANDIS N, 1993, GENE CHROMOSOME CANC, V6, P151, DOI 10.1002/gcc.2870060304; Pifarre A, 1997, BRIT J CANCER, V75, P184, DOI 10.1038/bjc.1997.31; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Protopopov AI, 2002, J GENE MED, V4, P397, DOI 10.1002/jgm.283; RABBITTS P, 1990, GENE CHROMOSOME CANC, V2, P231, DOI 10.1002/gcc.2870020312; Rai SK, 2001, P NATL ACAD SCI USA, V98, P4443, DOI 10.1073/pnas.071572898; RIMESSI P, 1994, ONCOGENE, V9, P3467; Roche J, 1996, ONCOGENE, V12, P1289; ROCHE J, 2002, P AACR, V43; Roz L, 2002, P NATL ACAD SCI USA, V99, P3615, DOI 10.1073/pnas.062030799; SANCHEZ Y, 1994, P NATL ACAD SCI USA, V91, P3383, DOI 10.1073/pnas.91.8.3383; Sard L, 1999, P NATL ACAD SCI USA, V96, P8489, DOI 10.1073/pnas.96.15.8489; Sato M, 1998, GENE CHROMOSOME CANC, V23, P367; Schlosshauer PW, 2000, MODERN PATHOL, V13, P1066, DOI 10.1038/modpathol.3880196; SEKIDO Y, 1994, ONCOGENE, V9, P1599; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Sekido Y, 1996, P NATL ACAD SCI USA, V93, P4120, DOI 10.1073/pnas.93.9.4120; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; Shigemitsu K, 2001, ONCOGENE, V20, P4249, DOI 10.1038/sj.onc.1204557; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Shridhar R, 1996, CANCER RES, V56, P5576; Shridhar V, 1996, ONCOGENE, V12, P1931; Shridhar V, 1997, ONCOGENE, V14, P2213, DOI 10.1038/sj.onc.1201054; Siprashvili Z, 1997, P NATL ACAD SCI USA, V94, P13771, DOI 10.1073/pnas.94.25.13771; Sozzi G, 1998, CANCER RES, V58, P5032; Sozzi G, 1997, CANCER RES, V57, P5207; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Su TH, 2000, GYNECOL ONCOL, V76, P193, DOI 10.1006/gyno.1999.5659; SUNDARESAN V, 1995, ANN ONCOL, V6, P27, DOI 10.1093/annonc/6.suppl_1.S27; Sundaresan V, 1998, ONCOGENE, V17, P1723, DOI 10.1038/sj.onc.1202103; Sundaresan V, 1998, MOL CELL NEUROSCI, V11, P29, DOI 10.1006/mcne.1998.0672; Sutherland LC, 2000, ONCOGENE, V19, P3774, DOI 10.1038/sj.onc.1203720; Sutherland LC, 2001, ONCOGENE, V20, P2713, DOI 10.1038/sj.onc.1204371; Szeles A, 1997, GENE CHROMOSOME CANC, V20, P329; Tanaka H, 1998, CANCER RES, V58, P3429; Thiagalingam S, 1996, CANCER RES, V56, P2936; Timmer T, 1999, EUR J HUM GENET, V7, P478, DOI 10.1038/sj.ejhg.5200334; Todd MC, 1996, ONCOGENE, V13, P2387; Todd S, 1997, CANCER RES, V57, P1344; Tomizawa Y, 2001, P NATL ACAD SCI USA, V98, P13954, DOI 10.1073/pnas.231490898; Toulouse A, 2000, LUNG CANCER-J IASLC, V28, P127, DOI 10.1016/S0169-5002(99)00122-1; Toyooka KO, 2001, CANCER RES, V61, P4556; Toyooka S, 2000, BIOCHEM BIOPH RES CO, V278, P671, DOI 10.1006/bbrc.2000.3870; Triggs-Raine B, 1999, P NATL ACAD SCI USA, V96, P6296, DOI 10.1073/pnas.96.11.6296; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Tschentscher F, 2001, CANCER RES, V61, P3439; Tse C, 2002, CANCER RES, V62, P542; Tseng JE, 1999, CANCER RES, V59, P4798; Uzawa N, 1998, CANCER GENET CYTOGEN, V107, P125, DOI 10.1016/S0165-4608(98)00097-1; vandenBerg A, 1997, GENE CHROMOSOME CANC, V19, P220, DOI 10.1002/(SICI)1098-2264(199708)19:4<220::AID-GCC3>3.0.CO;2-Z; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Vieten L, 1998, GENE CHROMOSOME CANC, V21, P39, DOI 10.1002/(SICI)1098-2264(199801)21:1<39::AID-GCC6>3.0.CO;2-9; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; Virmani AK, 2002, CANCER EPIDEM BIOMAR, V11, P291; Virmani AK, 2001, CLIN CANCER RES, V7, P584; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Waber PG, 1996, ONCOGENE, V12, P365; Wang L, 1998, ONCOGENE, V16, P635, DOI 10.1038/sj.onc.1201576; Wang L, 2000, GENE CHROMOSOME CANC, V27, P1, DOI 10.1002/(SICI)1098-2264(200001)27:1<1::AID-GCC1>3.0.CO;2-6; Wei MH, 1996, CANCER RES, V56, P1487; Werner NS, 2000, CANCER RES, V60, P2780; Wistuba II, 2000, CANCER RES, V60, P1949; Wistuba II, 2001, SEMIN ONCOL, V28, P3, DOI 10.1053/sonc.2001.25738; Wistuba II, 1997, CANCER RES, V57, P3154; Wu R, 2000, J NATL CANCER I, V92, P338, DOI 10.1093/jnci/92.4.338; Wu XF, 1998, CANCER RES, V58, P1605; Xian J, 2001, P NATL ACAD SCI USA, V98, P15062, DOI 10.1073/pnas.251407098; Xiang RH, 1996, GENOMICS, V32, P39, DOI 10.1006/geno.1996.0074; Xiang RH, 2002, CANCER RES, V62, P2637; Yamato T, 1999, CYTOGENET CELL GENET, V87, P291, DOI 10.1159/000015452; Yang QF, 2001, ANTICANCER RES, V21, P1829; Yang QF, 2001, AM J PATHOL, V158, P299, DOI 10.1016/S0002-9440(10)63969-7; Yang Y, 2001, P NATL ACAD SCI USA, V98, P1136, DOI 10.1073/pnas.98.3.1136; Zanesi N, 2001, P NATL ACAD SCI USA, V98, P10250, DOI 10.1073/pnas.191345898; ZHANG LR, 1995, CANCER RES, V55, P428; Zochbauer-Muller S, 2001, CANCER RES, V61, P249; Zochbauer-Muller S, 2002, ANNU REV PHYSIOL, V64, P681, DOI 10.1146/annurev.physiol.64.081501.155828; Zochbauer-Muller S, 2001, CANCER RES, V61, P3581	198	293	323	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2002	21	45					6915	6935		10.1038/sj.onc.1205835	http://dx.doi.org/10.1038/sj.onc.1205835			21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604UV	12362274				2022-12-17	WOS:000178640200007
J	Hazlehurst, LA; Damiano, JS; Buyuksal, I; Pledger, WJ; Dalton, WS				Hazlehurst, LA; Damiano, JS; Buyuksal, I; Pledger, WJ; Dalton, WS			Adhesion to fibronectin via beta 1 integrins regulates p27(kip1) levels and contributes to cell adhesion mediated drug resistance (CAM-DR)	ONCOGENE			English	Article						beta 1 integrins; drug resistance; p27(kip1); cell adhesion; myeloma; CAM-DR	DEPENDENT KINASE INHIBITOR; HEMATOPOIETIC PROGENITOR PROLIFERATION; BALB/C 3T3 CELLS; CYCLE PROGRESSION; GROWTH-FACTOR; EXTRACELLULAR-MATRIX; CONTACT INHIBITION; HL-60 CELLS; IN-VIVO; APOPTOSIS	The tumor cell environment may influence drug response through interactions with the extracellular matrix (ECM). We recently reported that adhesion of myeloma cells to fibronectin (FN), via beta 1 integrins is associated with a cell adhesion mediated drug resistance (CAM-DR), Activation of beta 1 integrins is known to influence both apoptosis and cell growth. We hypothesized that the FN mediated cytoprotection mag be in part due to perturbations in cell cycle progression. In this report we demonstrate that adhesion of myeloma cells to FN results in a G(1) arrest associated,vith increased p27(kip1) protein levels and inhibition of cyclin A and E associated kinase activity. Disruption of cells from FN adhesion resulted in a rapid recruitment of cells into S phase, a decrease in p27(kip1) levels, and reversion to a drug sensitive phenotype. Treatment of cells with p27(Kip1) antisense oligonucleotides did not affect FN adhesion; however, p27(Kip1) protein levels were reduced and cells became sensitive to cytotoxic drugs. These studies demonstrate that beta 1 mediated adhesion of myeloma cells to FN regulates p27(Kip1) levels and that p27(kip1) levels are causally related to CAM-DR. Disruption of beta 1 integrin mediated FN adhesion may represent a potential target for the potentiation of drug induced apoptosis.	Univ S Florida, Dept Oncol, Tampa, FL 33612 USA; Univ S Florida, Clin Invest Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Dalton, WS (corresponding author), Univ S Florida, Dept Oncol, Tampa, FL 33612 USA.							Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Belkin AM, 1998, J BIOL CHEM, V273, P15234, DOI 10.1074/jbc.273.24.15234; BOHNSACK JF, 1994, BLOOD, V83, P543; Chiarle R, 2000, BLOOD, V95, P619, DOI 10.1182/blood.V95.2.619; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Cook G, 1997, ACTA HAEMATOL-BASEL, V97, P81; Damiano JS, 2000, LEUKEMIA LYMPHOMA, V38, P71, DOI 10.3109/10428190009060320; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Dong F, 1998, MOL BIOL CELL, V9, P2081, DOI 10.1091/mbc.9.8.2081; DURAND RE, 1972, EXP CELL RES, V71, P75, DOI 10.1016/0014-4827(72)90265-0; Erhardt JA, 1998, J BIOL CHEM, V273, P23517, DOI 10.1074/jbc.273.36.23517; Eymin B, 1999, ONCOGENE, V18, P1411, DOI 10.1038/sj.onc.1202437; Fornaro M, 1999, J CLIN INVEST, V103, P321, DOI 10.1172/JCI4585; FORNARO M, 1995, J BIOL CHEM, V270, P24666, DOI 10.1074/jbc.270.42.24666; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Hakem A, 1999, J EXP MED, V189, P957, DOI 10.1084/jem.189.6.957; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Hauser PJ, 1997, CELL GROWTH DIFFER, V8, P203; Hiromura K, 1999, J CLIN INVEST, V103, P597, DOI 10.1172/JCI5461; Hoyt DG, 1996, CANCER RES, V56, P4146; Hurley RW, 1997, EXP HEMATOL, V25, P321; HURLEY RW, 1995, J CLIN INVEST, V96, P511, DOI 10.1172/JCI118063; JENSEN GS, 1993, AM J HEMATOL, V43, P29, DOI 10.1002/ajh.2830430108; Jiang YH, 2000, BLOOD, V95, P846, DOI 10.1182/blood.V95.3.846.003k31_846_854; Katayose Y, 1997, CANCER RES, V57, P5441; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Kramer A, 1999, P NATL ACAD SCI USA, V96, P2087, DOI 10.1073/pnas.96.5.2087; Kudo Y, 2000, CANCER LETT, V151, P217, DOI 10.1016/S0304-3835(99)00419-X; Lee JW, 2000, MOL BIOL CELL, V11, P1973, DOI 10.1091/mbc.11.6.1973; Levenberg S, 1999, ONCOGENE, V18, P869, DOI 10.1038/sj.onc.1202396; LIN CQ, 1993, FASEB J, V7, P737, DOI 10.1096/fasebj.7.9.8330681; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Liu DF, 1999, J CLIN LAB ANAL, V13, P291, DOI 10.1002/(SICI)1098-2825(1999)13:6<291::AID-JCLA7>3.0.CO;2-K; Lundell BI, 1996, BLOOD, V87, P2450, DOI 10.1182/blood.V87.6.2450.bloodjournal8762450; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; MEREDITH J, 1995, SCIENCE, V269, P1570, DOI 10.1126/science.7545312; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Naumann U, 1999, BIOCHEM BIOPH RES CO, V261, P890, DOI 10.1006/bbrc.1999.1126; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Pozzi M, 1998, J CELL BIOL, V142, P587; Ruan S, 1998, CANCER RES, V58, P1538; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; SOLARY E, 1993, BLOOD, V81, P1359; St Croix B, 1998, J CELL BIOL, V142, P557, DOI 10.1083/jcb.142.2.557; StCroix B, 1996, NAT MED, V2, P1204; TEICHER BA, 1990, SCIENCE, V247, P1457, DOI 10.1126/science.2108497; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Wang MWJ, 1998, CELL GROWTH DIFFER, V9, P105; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	56	293	317	1	9	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 7	2000	19	38					4319	4327		10.1038/sj.onc.1203782	http://dx.doi.org/10.1038/sj.onc.1203782			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980607				2022-12-17	WOS:000089271900002
J	Pickl, M; Ries, CH				Pickl, M.; Ries, C. H.			Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab	ONCOGENE			English	Article						HER2 signaling; membrane raft; trastuzumab; 3D cell culture	HERCEPTIN-INDUCED INHIBITION; HUMAN-BREAST; LIPID RAFTS; IN-VIVO; CANCER; GROWTH; ERBB2; OVEREXPRESSION; KINASE; CELLS	Three-dimensional (3D) cell culture techniques are frequently used to model alterations in tissue architecture critically important for tumor development. Here, we report on a detailed comparison of a spheroid model of human epidermal growth factor receptor (HER2) over-expressing cancer cells with the traditional monolayer culture. In 2D culture, HER2 and HER3 form heterodimers, whereas in multicellular spheroids HER2 homodimers are formed. These homodimers localize in membrane rafts, resulting in enhanced inhibition of the proliferation of cancer cells with trastuzumab (Herceptin), a monoclonal antibody specifically targeting HER2. Within the tumor spheroids, HER2 homodimerization leads to enhanced activation of HER2 and results in a switch in signaling pathways from phosphoinositide 3-kinase (PI3K) to mitogen-activated protein kinase (MAPK). Diminished PI3K signaling is accompanied by the activation of the integrin beta 4/Rac1/PAK 2 signaling cascade. We propose that the described 3D culture system may better reflect some in vivo aspects of HER signaling and can be used to further improve the understanding of the molecular mechanisms of trastuzumab action. Furthermore, the described human multicellular tumor spheroids may allow identification of new targets for the treatment of HER2-positive breast cancer patients who currently benefit suboptimally from trastuzumab treatment.	[Pickl, M.; Ries, C. H.] Roche Diagnost GmbH, Pharmaceut Res Oncol, D-82377 Penzberg, Germany	Roche Holding	Ries, CH (corresponding author), Roche Diagnost GmbH, Pharmaceut Res Oncol, Nonnenwald 2, D-82377 Penzberg, Germany.	carola.ries@roche.com						Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448; Guo Hua, 2005, Zhonghua Bing Li Xue Za Zhi, V34, P140; Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; Jung JH, 2005, J BIOL CHEM, V280, P40025, DOI 10.1074/jbc.M509075200; Kwon T, 2000, J BIOL CHEM, V275, P423, DOI 10.1074/jbc.275.1.423; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Longva KE, 2005, INT J CANCER, V116, P359, DOI 10.1002/ijc.21015; MILJAN EA, 2002, SCI STKE, pRE15; Mocanu MM, 2005, CANCER LETT, V227, P201, DOI 10.1016/j.canlet.2005.01.028; Nagy P, 2002, J CELL SCI, V115, P4251, DOI 10.1242/jcs.00118; Nahta R, 2006, CANCER LETT, V232, P123, DOI 10.1016/j.canlet.2005.01.041; Owens Marilyn A, 2004, Clin Breast Cancer, V5, P63, DOI 10.3816/CBC.2004.n.011; PETERSEN OW, 1992, P NATL ACAD SCI USA, V89, P9064, DOI 10.1073/pnas.89.19.9064; Pike LJ, 2006, J LIPID RES, V47, P1597, DOI 10.1194/jlr.E600002-JLR200; Razani B, 2001, BIOCHEM SOC T, V29, P494, DOI 10.1042/BST0290494; Ritter CA, 2007, CLIN CANCER RES, V13, P4909, DOI 10.1158/1078-0432.CCR-07-0701; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Shaw KRM, 2004, J MAMMARY GLAND BIOL, V9, P297, DOI 10.1007/s10911-004-1402-z; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Sottocornola E, 2006, FEBS J, V273, P1821, DOI 10.1111/j.1742-4658.2006.05203.x; Sottocornola E, 2003, BBA-MOL CELL BIOL L, V1635, P55, DOI 10.1016/j.bbalip.2003.10.006; Timms JF, 2002, ONCOGENE, V21, P6573, DOI 10.1038/sj.onc.1205847; Wang SC, 2001, SEMIN ONCOL, V28, P115, DOI 10.1016/S0093-7754(01)90289-1; Weaver VM, 2002, CANCER CELL, V2, P205, DOI 10.1016/S1535-6108(02)00125-3; Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775; Yakes FM, 2002, CANCER RES, V62, P4132; Yamada KM, 2007, CELL, V130, P601, DOI 10.1016/j.cell.2007.08.006; Yarden Y, 2001, EUR J CANCER, V37, pS3; Yaziji H, 2004, JAMA-J AM MED ASSOC, V291, P1972, DOI 10.1001/jama.291.16.1972; Zhou XY, 2004, CLIN CANCER RES, V10, P6779, DOI 10.1158/1078-0432.CCR-04-0112	32	292	295	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2009	28	3					461	468		10.1038/onc.2008.394	http://dx.doi.org/10.1038/onc.2008.394			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395UZ	18978815	Bronze			2022-12-17	WOS:000262550300013
J	Mujtaba, S; Zeng, L; Zhou, MM				Mujtaba, S.; Zeng, L.; Zhou, M-M			Structure and acetyl-lysine recognition of the bromodomain	ONCOGENE			English	Review						bromodomain; chromatin remodeling; histone modification; lysine acetylation; transcriptional regulation	HISTONE H3; PROTEIN BRD4; P53 ACTIVITY; PHD FINGER; HIV-1 TAT; CHROMATIN; BINDING; RSC; METHYLATION; LIGAND	Histone lysine acetylation is central to epigenetic control of gene transcription. The bromodomain, found in chromatin-associated proteins and histone acetyltranferases, functions as the sole protein module known to bind acetyl-lysine motifs. Recent structural and functional analyses of bromodomains' recognition of lysine-acetylated peptides derived from major acetylation sites in histones and cellular proteins provide new insights into differences in ligand binding selectivity as well as unifying features of histone recognition by the bromodomains. These new findings highlight the functional importance of bromodomain/acetyl-lysine binding as a pivotal mechanism for regulating protein-protein interactions in histone-directed chromatin remodeling and gene transcription. These new studies also support the notion that functional diversity of a conserved bromodomain structural fold is achieved by evolutionary changes of structurally flexible amino-acid sequences in the ligand binding site such as the ZA and BC loops.	CUNY Mt Sinai Sch Med, Dept Struct & Chem Biol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Zhou, MM (corresponding author), CUNY Mt Sinai Sch Med, Dept Struct & Chem Biol, 1425 Madison Ave,Box 1677, New York, NY 10029 USA.	ming-ming.zhou@mssm.edu						ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Berger J, 2005, BIOCHEM SOC T, V33, P1537, DOI 10.1042/BST0331537; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Cairns BR, 1999, MOL CELL, V4, P715, DOI 10.1016/S1097-2765(00)80382-2; Carey M, 2006, MOL CELL, V24, P481, DOI 10.1016/j.molcel.2006.09.012; CHUA P, 1995, MOL CELL BIOL, V15, P3685; Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117; Dey A, 2000, MOL CELL BIOL, V20, P6537, DOI 10.1128/MCB.20.17.6537-6549.2000; Dey A, 2003, P NATL ACAD SCI USA, V100, P8758, DOI 10.1073/pnas.1433065100; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Dorr A, 2002, EMBO J, V21, P2715, DOI 10.1093/emboj/21.11.2715; Du J, 1998, GENETICS, V150, P987; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; Fujiki R, 2005, EMBO J, V24, P3881, DOI 10.1038/sj.emboj.7600853; GEORGAKOPOULOS T, 1995, MOL GEN GENET, V246, P723, DOI 10.1007/BF00290718; Greenwald RJ, 2004, BLOOD, V103, P1475, DOI 10.1182/blood-2003-06-2116; Hassan AH, 2001, CELL, V104, P817, DOI 10.1016/S0092-8674(01)00279-3; Hassan AH, 2002, CELL, V111, P369, DOI 10.1016/S0092-8674(02)01005-X; Hassan AH, 2006, J BIOL CHEM, V281, P18126, DOI 10.1074/jbc.M602851200; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Huang J, 2006, NATURE, V444, P629, DOI 10.1038/nature05287; Hudson BP, 2000, J MOL BIOL, V304, P355, DOI 10.1006/jmbi.2000.4207; Jacobs SA, 2002, SCIENCE, V295, P2080, DOI 10.1126/science.1069473; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Jang MK, 2005, MOL CELL, V19, P523, DOI 10.1016/j.molcel.2005.06.027; Jeanmougin F, 1997, TRENDS BIOCHEM SCI, V22, P151, DOI 10.1016/S0968-0004(97)01042-6; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kasten M, 2004, EMBO J, V23, P1348, DOI 10.1038/sj.emboj.7600143; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Ladurner AG, 2003, MOL CELL, V11, P365, DOI 10.1016/S1097-2765(03)00035-2; Lemon B, 2001, NATURE, V414, P924, DOI 10.1038/414924a; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Li HT, 2006, NATURE, V442, P91, DOI 10.1038/nature04802; Martinez-Campa C, 2004, MOL CELL, V15, P69, DOI 10.1016/j.molcel.2004.05.022; Muchardt C, 1999, SEMIN CELL DEV BIOL, V10, P189, DOI 10.1006/scdb.1999.0300; Muchardt C, 1998, EMBO J, V17, P223, DOI 10.1093/emboj/17.1.223; Mujtaba S, 2004, MOL CELL, V13, P251, DOI 10.1016/S1097-2765(03)00528-8; Mujtaba S, 2002, MOL CELL, V9, P575, DOI 10.1016/S1097-2765(02)00483-5; Nakamura Y, 2007, J BIOL CHEM, V282, P4193, DOI 10.1074/jbc.M605971200; Neely KE, 2002, MOL GENET METAB, V76, P1, DOI 10.1016/S1096-7192(02)00014-8; Nielsen PR, 2002, NATURE, V416, P103, DOI 10.1038/nature722; Owen DJ, 2000, EMBO J, V19, P6141, DOI 10.1093/emboj/19.22.6141; Pena PV, 2006, NATURE, V442, P100, DOI 10.1038/nature04814; Qiu J, 2006, NATURE, V441, P143, DOI 10.1038/441143a; Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014; Sachchidanand, 2006, CHEM BIOL, V13, P81, DOI 10.1016/j.chembiol.2005.10.014; Schweiger MR, 2006, J VIROL, V80, P4276, DOI 10.1128/JVI.80.9.4276-4285.2006; Shen WQ, 2007, BIOCHEMISTRY-US, V46, P2100, DOI 10.1021/bi0611208; Shi XB, 2006, NATURE, V442, P96, DOI 10.1038/nature04835; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Syntichaki P, 2000, NATURE, V404, P414, DOI 10.1038/35006136; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; Turner BM, 1998, CELL MOL LIFE SCI, V54, P21, DOI 10.1007/s000180050122; Workman JL, 2006, GENE DEV, V20, P2009, DOI 10.1101/gad.1435706; Wysocka J, 2006, NATURE, V442, P86, DOI 10.1038/nature04815; Zeng L, 2002, FEBS LETT, V513, P124, DOI 10.1016/S0014-5793(01)03309-9; Zeng L, 2005, J AM CHEM SOC, V127, P2376, DOI 10.1021/ja044885g; Zhou YG, 2005, CURR BIOL, V15, P1434, DOI 10.1016/j.cub.2005.06.057	62	292	299	2	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2007	26	37					5521	5527		10.1038/sj.onc.1210618	http://dx.doi.org/10.1038/sj.onc.1210618			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CR	17694091				2022-12-17	WOS:000248674300018
J	Zamo, A; Chiarle, R; Piva, R; Howes, J; Fan, Y; Chilosi, M; Levy, DE; Inghirami, G				Zamo, A; Chiarle, R; Piva, R; Howes, J; Fan, Y; Chilosi, M; Levy, DE; Inghirami, G			Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death	ONCOGENE			English	Article						ALCL; t(2;5); NPM-ALK signaling; Stat3; Bcl-x(L), apoptosis	NON-HODGKINS-LYMPHOMA; RECEPTOR TYROSINE KINASE; SIGNAL TRANSDUCER; GENE; TRANSCRIPTION; APOPTOSIS; INHIBITOR; FUSION; NPM; EXPRESSION	The anaplastic lymphoma kinase (ALK) gene is characteristically translocated in Anaplastic Large Cell Lymphomas (ALCL) and the juxtaposion of the ALK gene to multiple partners results in its constitutive protein tyrosine kinase activity. We show here that expression of activated ALK induces the constitutive phosphorylation of Stat3 in transfected cells as well as in primary human ALCLs. Furthermore, immunohistochemical studies demonstrate that among distinct human B and T cell lymphomas, activation of Stat3 nuclear translocation is uniquely associated with ALK expression. NPM-ALK also binds and activates Jak3; however, Jak3 is not required for Stat3 activation or for cell transformation in vitro. Moreover, src family kinases are not necessary for NPM-ALK-mediated Stat3 activation or transformation, suggesting that Stat3 may be phosphorylated directly by ALK. To evaluate relevant targets of ALK-activated Stat3, we investigated the regulation of the anti-apoptotic protein Bcl-x(L) and its role in cell survival in NPM-ALK positive cells. NPM-ALK expression caused enhanced Bcl-x(L) transcription, largely mediated by Stat3. Increased expression of Bcl-x(L) provided sufficient anti-apoptotic signals to protect cells from treatment with specific inhibitors of the Jaks/Stat pathway or the Brc-Abl kinase. These studies support a pathogenic mechanism whereby stimulation of anti-apoptotic signals through activation of Stat3 contributes to the successful outgrowth of ALK positive tumor cells.	NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; NYU, Sch Med, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA; Univ Verona, Dept Pathol, Rome, Italy; Univ Turin, Dept Pathol, Turin, Italy	New York University; New York University; University of Verona; University of Turin	Inghirami, G (corresponding author), NYU, Sch Med, Dept Pathol, 550 1st Ave, New York, NY 10016 USA.		Piva, Roberto/H-7315-2013; Levy, David/GPS-4945-2022; Levy, David/AAG-6202-2019; Zamò, Alberto/ABF-4436-2020; Piva, Roberto/B-9580-2018	Levy, David/0000-0002-7320-7788; Piva, Roberto/0000-0002-2273-3470; Zamo, Alberto/0000-0001-6203-7966; CHIARLE, Roberto/0000-0003-1564-8531	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028900] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 28900] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akira S, 1999, STEM CELLS, V17, P138, DOI 10.1002/stem.170138; Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chen RY, 2001, J BIOL CHEM, V276, P31858, DOI 10.1074/jbc.C100271200; Chiarle R, 2000, BLOOD, V95, P619, DOI 10.1182/blood.V95.2.619; Chiarle R, 1999, J IMMUNOL, V163, P194; Deininger MWN, 1997, BLOOD, V90, P3691, DOI 10.1182/blood.V90.9.3691; Donato NJ, 2001, BLOOD, V97, P2846, DOI 10.1182/blood.V97.9.2846; Drexler HG, 2000, LEUKEMIA, V14, P1533, DOI 10.1038/sj.leu.2401878; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; Gesbert F, 2000, BLOOD, V96, P2269, DOI 10.1182/blood.V96.6.2269.h8002269_2269_2276; Grignani F, 1998, CANCER RES, V58, P14; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HARRIS NL, 1994, BLOOD, V84, P1361; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Lamant L, 2000, AM J PATHOL, V156, P1711, DOI 10.1016/S0002-9440(10)65042-0; Lawrence B, 2000, AM J PATHOL, V157, P377, DOI 10.1016/S0002-9440(10)64550-6; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Nieborowska-Skorska M, 2001, CANCER RES, V61, P6517; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Shen YH, 2001, P NATL ACAD SCI USA, V98, P1543, DOI 10.1073/pnas.041588198; Slupianek A, 2001, CANCER RES, V61, P2194; Takeda K, 1998, J IMMUNOL, V161, P4652; Trinei M, 2000, CANCER RES, V60, P793; Vigneri P, 2001, NAT MED, V7, P228, DOI 10.1038/84683; Wang YZ, 2000, ONCOGENE, V19, P2075, DOI 10.1038/sj.onc.1203548	34	292	303	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2002	21	7					1038	1047		10.1038/sj.onc.1205152	http://dx.doi.org/10.1038/sj.onc.1205152			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850821	Bronze			2022-12-17	WOS:000173580100007
J	Amundson, SA; Bittner, M; Chen, YD; Trent, J; Meltzer, P; Fornace, AJ				Amundson, SA; Bittner, M; Chen, YD; Trent, J; Meltzer, P; Fornace, AJ			Fluorescent cDNA microarray hybridization reveals complexity and heterogeneity of cellular genotoxic stress responses	ONCOGENE			English	Article						cDNA microarray; ionizing radiation; leukemia; p53; genotoxic stress	GENE-EXPRESSION PATTERNS; GAMMA-RAY RESPONSE; TUMOR-SUPPRESSOR; DNA-DAMAGE; GROWTH ARREST; P53; INDUCTION; APOPTOSIS; ATF3; PROTEINS	The fate of cells exposed to ionizing radiation (IR) may depend greatly on changes in gene expression, so that an improved, view of gene induction profiles is important for understanding mechanisms of checkpoint control, repair and cell death following such exposures. We have used a quantitative fluorescent cDNA microarray hybridization approach to identify genes regulated in response gamma- irradiation in the p53 wild-type ML-1 human myeloid cell line. Hybridization of the array to fluorescently-labeled RNA from treated and untreated cells Has followed by computer analysis to derive relative changes in expression levels of the genes present in the array which agreed well with actual quantitative changes in expression. Forty-eight sequences, 30 not previously identified as IR-responsive, were significantly regulated by IR. Induction by IR and other stresses of a subset of these genes, including the previously characterized CIP1/WAF1, MDM and BAX genes, as well as nine genes not previously reported to be IR-responsive, was examined in a panel of 12 human cell lines. Responses varied widely in cell lines with different tissues of origin and different genetic backgrounds, highlighting the importance of cellular contest to genotoxic stress responses. Two of the newly identified IR-responsive genes, FRA-1 and ATF3, showed a p53-associated component to their IR-induction, and this was confirmed both in isogenic human cell lines and in mouse thymus. The majority of the IR-responsive genes, however, showed no indication of p53-dependent regulation, representing a potentially important class of stress-responsive genes in leukemic cells.	NCI, NIH, Bethesda, MD 20892 USA; Natl Human Genome Res Inst, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Amundson, SA (corresponding author), NCI, NIH, 37 Convent Dr,Bldg 37-Rm 5C09, Bethesda, MD 20892 USA.		Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X	DIVISION OF BASIC SCIENCES - NCI [Z01BC007184] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ariizumi K, 1996, J DERMATOL SCI, V12, P147, DOI 10.1016/0923-1811(95)00474-2; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; Chen BPC, 1996, MOL CELL BIOL, V16, P1157, DOI 10.1128/mcb.16.3.1157; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; Chen Y, 1997, J Biomed Opt, V2, P364, DOI 10.1117/12.281504; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CUOMO CA, 1994, P NATL ACAD SCI USA, V91, P6156, DOI 10.1073/pnas.91.13.6156; DeRisi J, 1996, NAT GENET, V14, P457; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAN CM, 1990, GENE DEV, V4, P29, DOI 10.1101/gad.4.1.29; FARGNOLI J, 1990, ANAL BIOCHEM, V187, P364, DOI 10.1016/0003-2697(90)90471-K; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; Gorospe M, 1996, MOL CELL DIFFER, V4, P47; Hagmeyer BM, 1996, ONCOGENE, V12, P1025; Heller RA, 1997, P NATL ACAD SCI USA, V94, P2150, DOI 10.1073/pnas.94.6.2150; HOLBROOK NJ, 1996, STRESS INDUCIBLE CEL, P273; HOLLANDER MC, 1990, BIOTECHNIQUES, V9, P174; HSU JC, 1992, MOL CELL BIOL, V12, P4654, DOI 10.1128/MCB.12.10.4654; IVANOV VN, 1995, INT IMMUNOL, V7, P1709, DOI 10.1093/intimm/7.11.1709; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Komarova EA, 1998, ONCOGENE, V17, P1089, DOI 10.1038/sj.onc.1202303; Lashkari DA, 1997, P NATL ACAD SCI USA, V94, P13057, DOI 10.1073/pnas.94.24.13057; Liang GS, 1996, J BIOL CHEM, V271, P1695, DOI 10.1074/jbc.271.3.1695; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; Madden SL, 1997, ONCOGENE, V15, P1079, DOI 10.1038/sj.onc.1201091; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; SEIDAH NG, 1991, GENOMICS, V11, P103, DOI 10.1016/0888-7543(91)90106-O; SMITH ML, 1995, ONCOGENE, V10, P1053; Smith ML, 1996, MUTAT RES-REV GENET, V340, P109, DOI 10.1016/S0165-1110(96)90043-3; Smith ML, 1996, AM J PATHOL, V148, P1019; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Zhan QM, 1997, ONCOGENE, V14, P1031, DOI 10.1038/sj.onc.1200927; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; Zhan QM, 1996, ONCOGENE, V13, P2287; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, ONCOGENE, V9, P3743; ZHAN QM, 1995, INT J ONCOL, V6, P937; ZHANG Q, 1994, MOL CELL BIOL, V14, P3915, DOI 10.1128/MCB.14.6.3915	45	292	315	1	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 17	1999	18	24					3666	3672		10.1038/sj.onc.1202676	http://dx.doi.org/10.1038/sj.onc.1202676			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	206QZ	10380890				2022-12-17	WOS:000080891700014
J	Duerr, EM; Rollbrocker, B; Hayashi, Y; Peters, N; Meyer-Puttlitz, B; Louis, DN; Schramm, J; Wiestler, OD; Parsons, R; Eng, C; von Deimling, A				Duerr, EM; Rollbrocker, B; Hayashi, Y; Peters, N; Meyer-Puttlitz, B; Louis, DN; Schramm, J; Wiestler, OD; Parsons, R; Eng, C; von Deimling, A			PTEN mutations in gliomas and glioneuronal tumors	ONCOGENE			English	Article						PTEN mutations; glioblastoma; oligodendroglioma; ganglioglioma	LHERMITTE-DUCLOS DISEASE; HUMAN GLIOBLASTOMA-MULTIFORME; MOLECULAR-GENETIC-ANALYSIS; COWDEN SYNDROME; P53 MUTATIONS; CHROMOSOME-10; HETEROZYGOSITY; AMPLIFICATION; ASTROCYTOMA; LOCI	Cytogenetic and loss of heterozygosity studies have suggested the presence of at least one tumor suppressor gene on chromosome 10 involved in the formation of high grade gliomas, Recently, the PTEN gene, also termed MMAC1 or TEP1, on chromosomal band 10q23 has been identified. Initial studies revealed mutations of PTEN in limited series of glioma cell lines and glioblastomas. In order to systematically evaluate the involvement of PTEN in gliomas, we have analysed the entire PTEN coding sequence by SSCP and direct sequencing in a series of 331 gliomas and glioneuronal tumors. PTEN mutations mere detected in 20/142 glioblastomas, 1/7 giant cell glioblastomas, 1/2 gliosarcomas, 1/30 pilocytic astrocytomas and 2/22 oligodendrogliomas, No PTEN mutations were detected in 52 astrocytomas, 37 oligoastrocytomas, three subependymal giant cell astrocytomas, four pleomorphic xanthoastrocytomas, 15 ependymomas, 16 gangliogliomas and one dysembryoplastic neuroepithelial tumor. In addition, all tumors were examined for the presence of homozygous deletions of the PTEN gene; these were detected in 7 glioblastomas that did not have PTEN mutations. Therefore, PTEN mutations occur in approximately 20% of glioblastomas but are rare in lower grade gliomas, These findings confirm that PTEN is one of the chromosome 10 tumor suppressor genes involved in the development of glioblastomas.	Univ Bonn, Ctr Med, Dept Neuropathol, D-53105 Bonn, Germany; Massachusetts Gen Hosp, CS Kubik Lab Neuropathol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Mol Neurooncol Lab, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Univ Bonn, Med Ctr, Dept Neurosurg, D-53105 Bonn, Germany; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	University of Bonn; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Bonn; Columbia University; Columbia University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	von Deimling, A (corresponding author), Univ Kliniken Bonn, Inst Neuropathol, Sigmund Freud Str 25, D-53105 Bonn, Germany.		von Deimling, Andreas/F-7774-2013	von Deimling, Andreas/0000-0002-5863-540X; Eng, Charis/0000-0002-3693-5145; Parsons, Ramon/0000-0002-6656-3514	NCI NIH HHS [CA57683] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057683] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albarosa R, 1996, AM J HUM GENET, V58, P1260; ALBRECHT S, 1992, CANCER-AM CANCER SOC, V70, P869, DOI 10.1002/1097-0142(19920815)70:4<869::AID-CNCR2820700424>3.0.CO;2-E; BENDER B, 1994, BIOTECHNIQUES, V16, P204; Eng C, 1997, J Genet Couns, V6, P181, DOI 10.1023/A:1025664119494; ENG C, 1994, J MED GENET, V31, P458, DOI 10.1136/jmg.31.6.458; FUJIMOTO M, 1989, GENOMICS, V4, P210, DOI 10.1016/0888-7543(89)90302-9; FULTS D, 1992, CANCER RES, V52, P674; FULTS D, 1990, CANCER RES, V50, P5784; Hayashi Y, 1997, BRAIN PATHOL, V7, P871, DOI 10.1111/j.1750-3639.1997.tb00890.x; Hsu SC, 1996, CANCER RES, V56, P5684; JAMES CD, 1988, CANCER RES, V48, P5546; Kleihues P, 1993, HISTOLOGICAL TYPING; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; LOUIS DN, 1993, J NEUROPATH EXP NEUR, V52, P507, DOI 10.1097/00005072-199309000-00009; Maintz D, 1997, J NEUROPATH EXP NEUR, V56, P1098, DOI 10.1097/00005072-199710000-00003; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; MeyerPuttlitz B, 1997, AM J PATHOL, V151, P853; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; OHGAKI H, 1991, CANCER RES, V51, P6202; PADBERG GW, 1991, ANN NEUROL, V29, P517, DOI 10.1002/ana.410290511; PERSHOUSE MA, 1993, CANCER RES, V53, P5043; RASHEED BKA, 1992, GENE CHROMOSOME CANC, V5, P75, DOI 10.1002/gcc.2870050111; REIFENBERGER G, 1994, CANCER RES, V54, P4299; REIFENBERGER J, 1994, AM J PATHOL, V145, P1175; Rollbrocker B, 1996, ACTA NEUROPATHOL, V92, P70, DOI 10.1007/s004010050491; SCHMIDT EE, 1994, CANCER RES, V54, P6321; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STECK PA, 1995, GENE CHROMOSOME CANC, V12, P255; VONDEIMLING A, 1992, J NEUROSURG, V77, P295, DOI 10.3171/jns.1992.77.2.0295; VONDEIMLING A, 1992, CANCER RES, V52, P4277; VONDEIMLING A, 1993, BRAIN PATHOL, V3, P19; VONDEIMLING A, 1993, NEUROPATH APPL NEURO, V19, P524; VONDEIMLING A, 1992, CANCER RES, V52, P2987; WELLENREUTHER R, 1995, AM J PATHOL, V146, P827	37	292	304	0	11	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 30	1998	16	17					2259	2264		10.1038/sj.onc.1201756	http://dx.doi.org/10.1038/sj.onc.1201756			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZK226	9619835				2022-12-17	WOS:000073298000011
J	Gorospe, M; Cirielli, C; Wang, XT; Seth, P; Capogrossi, MC; Holbrook, NJ				Gorospe, M; Cirielli, C; Wang, XT; Seth, P; Capogrossi, MC; Holbrook, NJ			p21(Waf1/Cip1) protects against p53-mediated apoptosis of human melanoma cells	ONCOGENE			English	Article						melanoma; p53; p21; apoptosis	CYCLE CONTROL; G(1) ARREST; P53; EXPRESSION; ADENOVIRUS; CANCER; P21	The tumor suppressive effect of p53 is believed to be rooted in its two primary functions: the implementation of cellular growth arrest and the execution of apoptotic cell death, While p53-regulated expression of the cyclin-dependent kinase inhibitor p21(Waf1/Cip1) appears to be central for the implementation of G(1) arrest, the participation of p21(Waf1/Cip1) in p53-triggered cell death remains controversial, In the present study, overexpression of p53 in human melanoma SK-MEL-110 cells through use of an adenoviral expression vector (AdCMV,p53) was found to result in apoptosis, while similar infection of primary vascular smooth muscle cells (VSMC) instead resulted in a moderate inhibition of growth, Expression of p21(Waf1/Cip1) was strongly elevated in VSMC, but showed little change in SK-MEL-110 cells, although expression of another p53-regulated gene (GADD45) was comparable in both AdCMV.p53-infected cell types, Evidence that p21(Waf1/Cip1) expression may be required for surviving p53-induced cell death was further supported by the finding that p53 overexpression was highly toxic for p21-deficient mouse embryonal fibroblasts (p21(-/-) MEFs), In both SK-MEL-110 and p21(-/-) MEFs, adenovirus-driven ectopic expression of p21(Waf1/Cip1) resulted in a substantial protection against p53-induced apoptosis, indicating that p21(Waf1/Cip1) rescued cells from a path of programmed cell death to one of enhanced survival.	NIA,NIH,CELLULAR & MOL BIOL LAB,BALTIMORE,MD 21224; NIA,NIH,CARDIOVASC SCI LAB,BALTIMORE,MD 21224; NCI,MED BRANCH,MED BREAST CANC SECT,NIH,BETHESDA,MD 20892; IST DERMOPAT IMMACOLATA,LAB PATOL VASCOLARE,I-00167 ROME,ITALY	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); IRCCS Istituto Dermopatico dell'Immacolata (IDI)				Cirielli, Corrado/0000-0003-2524-7889				Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CIRIELLI C, 1995, INT J CANCER, V63, P1; CLAYMAN GL, 1995, CANCER RES, V55, P1; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DRAZAN KE, 1994, SURGERY, V116, P197; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gorospe M, 1996, MOL CELL BIOL, V16, P762; Gorospe M, 1996, MOL CELL DIFFER, V4, P47; GOROSPE M, 1996, IN PRESS MOL CELL BI; GOROSPE M, 1996, CANCER RES, V56, P457; Hainaut Pierre, 1995, Current Opinion in Oncology, V7, P76; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; KATAYOSE D, 1995, BIOCHEM BIOPH RES CO, V215, P446, DOI 10.1006/bbrc.1995.2485; KATAYOSE D, 1995, CELL GROWTH DIFFER, V6, P1207; KIM YH, 1992, J IMMUNOL, V149, P17; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morris GF, 1996, P NATL ACAD SCI USA, V93, P895, DOI 10.1073/pnas.93.2.895; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Poluha W, 1996, MOL CELL BIOL, V16, P1335; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANG CL, 1995, CANCER RES, V55, P4210	35	292	298	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 27	1997	14	8					929	935		10.1038/sj.onc.1200897	http://dx.doi.org/10.1038/sj.onc.1200897			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK344	9050992				2022-12-17	WOS:A1997WK34400006
J	Krieg, AM				Krieg, A. M.			Toll-like receptor 9 (TLR9) agonists in the treatment of cancer	ONCOGENE			English	Review						PF-3512676; CpG ODN TLR9; toll-like receptor agonists; vaccine adjuvant	CPG-OLIGODEOXYNUCLEOTIDE; IMMUNOSTIMULATORY OLIGODEOXYNUCLEOTIDES; GENE-EXPRESSION; IFN-ALPHA; T-CELLS; VACCINATION; OLIGONUCLEOTIDE; MODULATION; GENERATION; INTERFERON	Although still early in clinical development, agonists of Toll-like receptor 9 (TLR9) have demonstrated potential for the treatment of cancer. TLR9 agonists directly induce activation and maturation of plasmacytoid dendritic cells and enhance differentiation of B cells into antibody-secreting plasma cells. Preclinical and early clinical data support the use of TLR9 agonists in patients with solid tumors and hematologic malignancies. In preclinical studies, TLR9 agonists have shown activity not only as monotherapy, but also in combination with multiple other therapies, including vaccines, antibodies, cellular therapies, other immunotherapies, antiangiogenic agents, radiotherapy, cryotherapy and some chemotherapies. Phase I and II clinical trials have indicated that these agents have antitumor activity as single agents and enhance the development of antitumor T-cell responses when used as therapeutic vaccine adjuvants. The activity and safety of these novel anticancer agents are being explored in a wide range of tumor types as part of a variety of therapeutic strategies with the goal of harnessing the immune response to fight cancer.	Coley Pharmaceut Grp Inc, Wellesley, MA 02481 USA	Coley Pharmaceutical Group	Krieg, AM (corresponding author), Coley Pharmaceut Grp Inc, Suite 101,93 Worcester St, Wellesley, MA 02481 USA.	akrieg@coleypharma.com	Krieg, Arthur M/K-8109-2019; Krieg, Art/R-6166-2019					Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Appay V, 2006, J IMMUNOL, V177, P1670, DOI 10.4049/jimmunol.177.3.1670; Baines J, 2003, CLIN CANCER RES, V9, P2693; Carpentier A, 2006, NEURO-ONCOLOGY, V8, P60, DOI 10.1215/S1522851705000475; Daftarian P, 2004, CANCER RES, V64, P5407, DOI 10.1158/0008-5472.CAN-04-0169; Damiano V, 2006, CLIN CANCER RES, V12, P577, DOI 10.1158/1078-0432.CCR-05-1943; Damiano V, 2007, P NATL ACAD SCI USA, V104, P12468, DOI 10.1073/pnas.0705226104; Davila E, 2003, CANCER RES, V63, P3281; Decker T, 2000, BLOOD, V95, P999, DOI 10.1182/blood.V95.3.999.003k10_999_1006; Droemann D, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-1; Friedberg JW, 2005, BLOOD, V105, P489, DOI 10.1182/blood-2004-06-2156; Gelman AE, 2006, IMMUNITY, V25, P783, DOI 10.1016/j.immuni.2006.08.023; Hayashi F, 2003, BLOOD, V102, P2660, DOI 10.1182/blood-2003-04-1078; HOFMANN MA, UNPUB SAFETY ACTIVIT; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Jahrsdorfer B, 2005, J LEUKOCYTE BIOL, V77, P378, DOI 10.1189/jlb.0604373; Jahrsdorfer B, 2001, J LEUKOCYTE BIOL, V69, P81; KIM Y, 2004, ASH ANN M ABSTR, V104; KRIEG AM, 2006, CURR ONCOL REP, V5, P471; Krieg AM, 2007, J CLIN INVEST, V117, P1184, DOI 10.1172/JCI31414; Krieg Arthur M, 2004, Curr Oncol Rep, V6, P88, DOI 10.1007/s11912-004-0019-0; Krieg AM, 2006, NAT REV DRUG DISCOV, V5, P471, DOI 10.1038/nrd2059; Latz E, 2007, NAT IMMUNOL, V8, P772, DOI 10.1038/ni1479; Lebre MC, 2007, J INVEST DERMATOL, V127, P331, DOI 10.1038/sj.jid.5700530; Lee J, 2006, NAT CELL BIOL, V8, P1327, DOI 10.1038/ncb1500; LEONARD JP, 2007, IN PRESS CLIN CANC R; Li J, 2004, AM J PHYSIOL-LUNG C, V287, pL552, DOI 10.1152/ajplung.00436.2003; Link BK, 2006, J IMMUNOTHER, V29, P558, DOI 10.1097/01.cji.0000211304.60126.8f; MANEGOLD C, 2007, IN PRESS J CLIN ONCO; Milas L, 2004, CANCER RES, V64, P5074, DOI 10.1158/0008-5472.CAN-04-0926; Molenkamp BG, 2007, CLIN CANCER RES, V13, P2961, DOI 10.1158/1078-0432.CCR-07-0050; Pashenkov M, 2006, J CLIN ONCOL, V24, P5716, DOI 10.1200/JCO.2006.07.9129; Pedersen G, 2005, CLIN EXP IMMUNOL, V141, P298, DOI 10.1111/j.1365-2249.2005.02848.x; Platz J, 2004, J IMMUNOL, V173, P1219, DOI 10.4049/jimmunol.173.2.1219; READETT DRJ, 2007, 12 WORLD C LUNG CANC; Sabel MS, 2003, ONCOLOGIST, V8, P451, DOI 10.1634/theoncologist.8-5-451; Saikh KU, 2004, J IMMUNOL, V173, P7426, DOI 10.4049/jimmunol.173.12.7426; Siren J, 2005, J IMMUNOL, V174, P1932, DOI 10.4049/jimmunol.174.4.1932; Speiser DE, 2005, J CLIN INVEST, V115, P739, DOI 10.1172/JCI200523373; Thompson JA, 2004, J CLIN ONCOL, V22, p417S; TREFZER U, 2002, P AM SOC CLIN ONNCOL, V21; Van den Eertwegh AJ, 2006, J CLIN ONCOL, V24, p107S; VANOJIK H, 2002, ANN ONCOL, V13, P157; WEERATNA RD, 2004, J CLIN ONCOL S, V22, P699; Weigel BJ, 2003, CLIN CANCER RES, V9, P3105; Wooldridge James E., 2003, Current Opinion in Oncology, V15, P440, DOI 10.1097/00001622-200311000-00006; Wooldridge JE, 1997, BLOOD, V89, P2994, DOI 10.1182/blood.V89.8.2994; Wysocka M, 2004, BLOOD, V104, P4142, DOI 10.1182/blood-2004-03-1190	48	291	321	3	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2008	27	2					161	167		10.1038/sj.onc.1210911	http://dx.doi.org/10.1038/sj.onc.1210911			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248OO	18176597				2022-12-17	WOS:000252163600002
J	Gao, SJ; Boshoff, C; Jayachandra, S; Weiss, RA; Chang, Y; Moore, PS				Gao, SJ; Boshoff, C; Jayachandra, S; Weiss, RA; Chang, Y; Moore, PS			KSHV ORF K9 (vIRF) is an oncogene which inhibits the interferon signaling pathway	ONCOGENE			English	Article						Kaposi's sarcoma-associated herpesvirus; interferon; oncogenesis; p21; lymphoma	KAPOSIS-SARCOMA; DNA-SEQUENCES; REGULATED EXPRESSION; CELL-GROWTH; BETA-GENE; HERPESVIRUS; TRANSCRIPTION; ALPHA; PROTEINS; IRF-1	Kaposi's sarcoma-associated herpesvirus (KSHV) is a gammaherpesvirus linked to the development of Kaposi's sarcoma and a rare B cell lymphoma, primary effusion lymphoma, The KSHV gene ORF K9 encodes vIRF which is a protein with low but significant homology to members of the interferon (IFN) regulatory factor (IRF) family responsible for regulating intracellular interferon signal transduction (Moore PS, Boshoff C, Weiss RA and Chang Y. (1996), Science, 274, 1739-1744), vIRF inhibits IPN-beta signal transduction as measured using an IFN-responsive ISG54 reporter construct co-transfected with ORI; K9 into HeLa and 293 cells, vIRF also suppresses genes under IFN regulatory control as shown by inhibition of the IFN-beta inducibility of p21(WAF1/CIP1), however, no direct DNA-binding or protein-protein interactions characteristic for IRF repressor proteins were identified, Stable transfectant NIH3T3 clones expressing vIRF grew in soft agar and at low serum concentrations, lost contact inhibition and formed tumors after injection into nude mice indicating that vIRF has the properties of a viral oncogene, Since vIRF is primarily expressed in KSHV-infected B cells, not KS spindle cells, this study suggests that vIRF is a transforming oncogene active in B cell neoplasias that may provide a unique immune escape mechanism for infected cells, This data is consistent with tumor suppressor pathways serving a dual function as host cell antiviral pathways.	COLUMBIA UNIV,SCH PUBL HLTH,DIV EPIDEMIOL,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND	Columbia University; Columbia University; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK			Gao, Shou-Jiang/B-8641-2012; Chang, Yuan/F-4146-2011; Moore, Patrick S./F-3960-2011; Moore, Patrick/GVR-8294-2022	Chang, Yuan/0000-0003-1125-4041; Moore, Patrick S./0000-0002-8132-858X; Gao, Shou-Jiang/0000-0001-6194-1742	NATIONAL CANCER INSTITUTE [R01CA067391] Funding Source: NIH RePORTER; NCI NIH HHS [CA67391] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; BLUYSSEN HAR, 1994, EUR J BIOCHEM, V220, P395, DOI 10.1111/j.1432-1033.1994.tb18636.x; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, INFECT AGENT DIS, V5, P215; Chang Y, 1996, NATURE, V382, P410, DOI 10.1038/382410a0; Cheng EHY, 1997, P NATL ACAD SCI USA, V94, P690, DOI 10.1073/pnas.94.2.690; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Foreman KE, 1997, NEW ENGL J MED, V336, P163, DOI 10.1056/NEJM199701163360302; FUJITA T, 1985, CELL, V41, P489, DOI 10.1016/S0092-8674(85)80022-2; Gao SJ, 1996, NEW ENGL J MED, V335, P233, DOI 10.1056/NEJM199607253350403; GoddenKent D, 1997, J VIROL, V71, P4193, DOI 10.1128/JVI.71.6.4193-4198.1997; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HASSANAIN HH, 1993, ANAL BIOCHEM, V213, P162, DOI 10.1006/abio.1993.1400; Hobeika AC, 1997, ONCOGENE, V14, P1165, DOI 10.1038/sj.onc.1200939; JansenDurr P, 1996, TRENDS GENET, V12, P270, DOI 10.1016/0168-9525(96)81455-7; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; Li MT, 1997, J VIROL, V71, P1984, DOI 10.1128/JVI.71.3.1984-1991.1997; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; Moore PS, 1996, SCIENCE, V274, P1739, DOI 10.1126/science.274.5293.1739; MOORE PS, 1997, IN PRESS J NCI; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; Neil JC, 1997, TRENDS MICROBIOL, V5, P115, DOI 10.1016/S0966-842X(96)10083-4; Nicholas J, 1997, NAT MED, V3, P287, DOI 10.1038/nm0397-287; Offermann MK, 1996, TRENDS MICROBIOL, V4, P383, DOI 10.1016/0966-842X(96)10060-3; OLSEN SJ, 1997, IN PRESS MOL IMMUNOL; RABKIN CS, 1995, CLIN CANCER RES, V1, P257; Rabkin CS, 1997, NEW ENGL J MED, V336, P988, DOI 10.1056/NEJM199704033361403; Rainbow L, 1997, J VIROL, V71, P5915, DOI 10.1128/JVI.71.8.5915-5921.1997; REICH N, 1988, J VIROL, V62, P114, DOI 10.1128/JVI.62.1.114-119.1988; RotemYehudar R, 1996, J EXP MED, V183, P499, DOI 10.1084/jem.183.2.499; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Sangfelt O, 1997, ONCOGENE, V14, P415, DOI 10.1038/sj.onc.1200832; Sarid R, 1997, NAT MED, V3, P293, DOI 10.1038/nm0397-293; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Staskus KA, 1997, J VIROL, V71, P715, DOI 10.1128/JVI.71.1.715-719.1997; Strathdee S A, 1996, AIDS, V10 Suppl A, pS51, DOI 10.1097/00002030-199601001-00008; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANIGUCHI T, 1995, J CANCER RES CLIN, V121, P516, DOI 10.1007/BF01197763; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Weinberg RA, 1997, CELL, V88, P573, DOI 10.1016/S0092-8674(00)81897-8; Wold William S. M., 1994, Trends in Microbiology, V2, P437, DOI 10.1016/0966-842X(94)90801-X; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	52	291	301	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 16	1997	15	16					1979	1985		10.1038/sj.onc.1201571	http://dx.doi.org/10.1038/sj.onc.1201571			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA872	9365244				2022-12-17	WOS:A1997YA87200012
J	Pantel, K; Speicher, MR				Pantel, K.; Speicher, M. R.			The biology of circulating tumor cells	ONCOGENE			English	Review							BREAST-CANCER PATIENTS; BONE-MARROW; PROGNOSTIC-SIGNIFICANCE; CLONAL EVOLUTION; LIQUID BIOPSY; ARRAY-CGH; METASTASIS; GENOME; DISSEMINATION; DNA	Metastasis is a biologically complex process consisting of numerous stochastic events which may tremendously differ across various cancer types. Circulating tumor cells (CTCs) are cells that are shed from primary tumors and metastatic deposits into the blood stream. CTCs bear a tremendous potential to improve our understanding of steps involved in the metastatic cascade, starting from intravasation of tumor cells into the circulation until the formation of clinically detectable metastasis. These efforts were propelled by novel high-resolution approaches to dissect the genomes and transcriptomes of CTCs. Furthermore, capturing of viable CTCs has paved the way for innovative culturing technologies to study fundamental characteristics of CTCs such as invasiveness, their kinetics and responses to selection barriers, such as given therapies. Hence the study of CTCs is not only instrumental as a basic research tool, but also allows the serial monitoring of tumor genotypes and may therefore provide predictive and prognostic biomarkers for clinicians. Here, we review how CTCs have contributed to significant insights into the metastatic process and how they may be utilized in clinical practice.	[Pantel, K.] Univ Med Ctr Hamburg Eppendorf, Inst Tumor Biol, Martinistr 52, D-20246 Hamburg, Germany; [Speicher, M. R.] Med Univ Graz, Inst Human Genet, Harrachgasse 21-8, A-8010 Graz, Austria	University of Hamburg; University Medical Center Hamburg-Eppendorf; Medical University of Graz	Pantel, K (corresponding author), Univ Med Ctr Hamburg Eppendorf, Inst Tumor Biol, Martinistr 52, D-20246 Hamburg, Germany.; Speicher, MR (corresponding author), Med Univ Graz, Inst Human Genet, Harrachgasse 21-8, A-8010 Graz, Austria.	pantel@uke.de; michael.speicher@medunigraz.at	Speicher, Michael R/B-5362-2013	Speicher, Michael R/0000-0003-0105-955X	Austrian Science Fund (FWF) [P20338, P23284]; Oesterreichische Nationalbank [15093]; ERC Advanced Investigator Grant DISSECT; Deutsche Forschungsgemeinschaft (DFG) [PA 341/19]; Cancer-ID - Innovative Medicines Joint Undertaking (IMI JU); TRANSCAN ERA-Network: Grant CTC-SCAN	Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Oesterreichische Nationalbank; ERC Advanced Investigator Grant DISSECT; Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Cancer-ID - Innovative Medicines Joint Undertaking (IMI JU); TRANSCAN ERA-Network: Grant CTC-SCAN	This work was supported in the laboratory of MRS by the Austrian Science Fund (FWF) (grant#: P20338 and P23284), the Oesterreichische Nationalbank (project#: 15093) and in the laboratory of KP by the ERC Advanced Investigator Grant DISSECT, TRANSCAN ERA-Network: Grant CTC-SCAN and Deutsche Forschungsgemeinschaft (DFG) grant PA 341/19. Both authors are supported by Cancer-ID, a project funded by the Innovative Medicines Joint Undertaking (IMI JU).	Aceto N, 2014, CELL, V158, P1110, DOI 10.1016/j.cell.2014.07.013; Alix-Panabieres C, 2007, CLIN CHEM, V53, P537, DOI 10.1373/clinchem.2006.079509; Alix-Panabieres C, 2014, NAT REV CANCER, V14, P623, DOI 10.1038/nrc3820; Alix-Panabieres C, 2013, CLIN CHEM, V59, P110, DOI 10.1373/clinchem.2012.194258; Alix-Panabieres Catherine, 2012, Recent Results Cancer Res, V195, P69, DOI 10.1007/978-3-642-28160-0_6; Allard WJ, 2004, CLIN CANCER RES, V10, P6897, DOI 10.1158/1078-0432.CCR-04-0378; Almendro V, 2014, CELL REP, V6, P514, DOI 10.1016/j.celrep.2013.12.041; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Attard G, 2009, CANCER RES, V69, P2912, DOI 10.1158/0008-5472.CAN-08-3667; Baccelli I, 2013, NAT BIOTECHNOL, V31, P539, DOI 10.1038/nbt.2576; Bailey CK, 2012, J BIOL CHEM, V287, P19472, DOI 10.1074/jbc.M112.345728; Bednarz-Knoll N, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2940; Bettegowda C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007094; Campbell PJ, 2010, NATURE, V467, P1109, DOI 10.1038/nature09460; Campos M, 2008, J HISTOCHEM CYTOCHEM, V56, P667, DOI 10.1369/jhc.2008.951111; Cayrefourcq L, 2015, CANCER RES, V75, P892, DOI 10.1158/0008-5472.CAN-14-2613; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chen HB, 2008, J CLIN ONCOL, V26, P3284, DOI 10.1200/JCO.2008.16.3543; Cho EH, 2012, PHYS BIOL, V9, DOI 10.1088/1478-3975/9/1/016001; Cohen SJ, 2009, ANN ONCOL, V20, P1223, DOI 10.1093/annonc/mdn786; Cristofanilli M, 2004, NEW ENGL J MED, V351, P781, DOI 10.1056/NEJMoa040766; Dawson SJ, 2013, NEW ENGL J MED, V368, P1199, DOI 10.1056/NEJMoa1213261; de Bono JS, 2008, CLIN CANCER RES, V14, P6302, DOI 10.1158/1078-0432.CCR-08-0872; Deneve E, 2013, CLIN CHEM, V59, P1384, DOI 10.1373/clinchem.2013.202846; Ding L, 2012, NATURE, V481, P506, DOI 10.1038/nature10738; Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989; FIDLER IJ, 1973, EUR J CANCER, V9, P223, DOI 10.1016/S0014-2964(73)80022-2; Fiegler H, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkl1030; Fischer JC, 2013, P NATL ACAD SCI USA, V110, P16580, DOI 10.1073/pnas.1313594110; Fonkem E, 2011, J CLIN ONCOL, V29, P4594, DOI 10.1200/JCO.2011.39.0187; Gao D, 2014, CELL, V159, P176, DOI 10.1016/j.cell.2014.08.016; Gao H, 2012, CELL, V150, P764, DOI 10.1016/j.cell.2012.06.035; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Ghajar CM, 2013, NAT CELL BIOL, V15, P807, DOI 10.1038/ncb2767; Goss PE, 2010, NAT REV CANCER, V10, P871, DOI 10.1038/nrc2933; Guzvic M, 2014, CANCER RES, V74, P7383, DOI 10.1158/0008-5472.CAN-14-0934; Haber DA, 2014, CANCER DISCOV, V4, P650, DOI 10.1158/2159-8290.CD-13-1014; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He W, 2007, P NATL ACAD SCI USA, V104, P11760, DOI 10.1073/pnas.0703875104; Heidary M, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0421-y; Heitzer E, 2013, GENOME MED, V5, DOI 10.1186/gm477; Heitzer E, 2013, INT J CANCER, V133, P346, DOI 10.1002/ijc.28030; Heitzer E, 2013, CANCER RES, V73, P2965, DOI 10.1158/0008-5472.CAN-12-4140; Hodgkinson CL, 2014, NAT MED, V20, P897, DOI 10.1038/nm.3600; Holen I, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3201; Hou JM, 2012, J CLIN ONCOL, V30, P525, DOI 10.1200/JCO.2010.33.3716; Hou Y, 2012, CELL, V148, P873, DOI 10.1016/j.cell.2012.02.028; Hudson TJ, 2010, NATURE, V464, P993, DOI 10.1038/nature08987; Husemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003; Janni W, 2011, CLIN CANCER RES, V17, P2967, DOI 10.1158/1078-0432.CCR-10-2515; Jones S, 2008, P NATL ACAD SCI USA, V105, P4283, DOI 10.1073/pnas.0712345105; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kang YB, 2013, CANCER CELL, V23, P573, DOI 10.1016/j.ccr.2013.04.017; Karthaus WR, 2014, CELL, V159, P163, DOI 10.1016/j.cell.2014.08.017; Kidess E, 2013, GENOME MED, V5, DOI 10.1186/gm474; Kienast Y, 2010, NAT MED, V16, P116, DOI 10.1038/nm.2072; Kim MY, 2009, CELL, V139, P1315, DOI 10.1016/j.cell.2009.11.025; Klein CA, 2009, NAT REV CANCER, V9, P302, DOI 10.1038/nrc2627; Krebs MG, 2014, NAT REV CLIN ONCOL, V11, P129, DOI 10.1038/nrclinonc.2013.253; Krebs MG, 2011, J CLIN ONCOL, V29, P1556, DOI 10.1200/JCO.2010.28.7045; Kreso A, 2013, SCIENCE, V339, P543, DOI 10.1126/science.1227670; Labelle M, 2012, CANCER DISCOV, V2, P1091, DOI 10.1158/2159-8290.CD-12-0329; Labelle M, 2011, CANCER CELL, V20, P576, DOI 10.1016/j.ccr.2011.09.009; Lancaster MA, 2014, SCIENCE, V345, DOI 10.1126/science.1247125; LeBleu VS, 2014, NAT CELL BIOL, V16, P992, DOI 10.1038/ncb3039; LIOTTA LA, 1976, CANCER RES, V36, P889; Lohr JG, 2014, NAT BIOTECHNOL, V32, P479, DOI 10.1038/nbt.2892; Lu X, 2011, CANCER CELL, V20, P701, DOI 10.1016/j.ccr.2011.11.002; Maheswaran S, 2008, NEW ENGL J MED, V359, P366, DOI 10.1056/NEJMoa0800668; MANDYBUR TI, 1984, ACTA NEUROPATHOL, V63, P203, DOI 10.1007/BF00685246; Mathiesen RR, 2012, INT J CANCER, V131, pE405, DOI 10.1002/ijc.26444; Meng SD, 2004, CLIN CANCER RES, V10, P8152, DOI 10.1158/1078-0432.CCR-04-1110; Metzker Michael L, 2010, Nat Rev Genet, V11, P31, DOI 10.1038/nrg2626; Muller C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009095; Nagrath S, 2007, NATURE, V450, P1235, DOI 10.1038/nature06385; Navin N, 2011, NATURE, V472, P90, DOI 10.1038/nature09807; Navin NE, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0452-9; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Ni XH, 2013, P NATL ACAD SCI USA, V110, P21083, DOI 10.1073/pnas.1320659110; Oskarsson T, 2014, CELL STEM CELL, V14, P306, DOI 10.1016/j.stem.2014.02.002; Ozkumur E, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005616; Pantel K, 1998, J CLIN ONCOL, V16, P1407, DOI 10.1200/JCO.1998.16.4.1407; Pantel K, 2004, NAT REV CANCER, V4, P448, DOI 10.1038/nrc1370; Pantel Klaus, 2014, Bonekey Rep, V3, P584, DOI 10.1038/bonekey.2014.79; Pantel K, 2013, CANCER RES, V73, P6384, DOI 10.1158/0008-5472.CAN-13-2030; Pantel K, 2012, CLIN CHEM, V58, P936, DOI 10.1373/clinchem.2011.175570; Podsypanina K, 2008, SCIENCE, V321, P1841, DOI 10.1126/science.1161621; Powell AA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033788; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Sanger N, 2011, INT J CANCER, V129, P2522, DOI 10.1002/ijc.25895; Sandberg R, 2014, NAT METHODS, V11, P22, DOI 10.1038/nmeth.2764; Schwarzenbach H, 2011, NAT REV CANCER, V11, P426, DOI 10.1038/nrc3066; SEIDEN MV, 1994, J CLIN ONCOL, V12, P2634, DOI 10.1200/JCO.1994.12.12.2634; Seoane J, 2014, CANCER DISCOV, V4, P1259, DOI 10.1158/2159-8290.CD-14-1178; Shiozawa Y, 2011, J CLIN INVEST, V121, P1298, DOI 10.1172/JCI43414; Sosa MS, 2014, NAT REV CANCER, V14, P611, DOI 10.1038/nrc3793; Speicher MR, 2014, NAT BIOTECHNOL, V32, P441, DOI 10.1038/nbt.2897; Stott SL, 2010, P NATL ACAD SCI USA, V107, P18392, DOI 10.1073/pnas.1012539107; Stott SL, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000403; Tarin D, 2005, CANCER RES, V65, P5996, DOI 10.1158/0008-5472.CAN-05-0699; Ting DT, 2014, CELL REP, V8, P1905, DOI 10.1016/j.celrep.2014.08.029; Uhra JW, 2011, P NATL ACAD SCI USA, V108, P12396, DOI 10.1073/pnas.1106613108; Valiente M, 2014, CELL, V156, P1002, DOI 10.1016/j.cell.2014.01.040; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Van Loo P, 2014, CURR OPIN GENET DEV, V24, P82, DOI 10.1016/j.gde.2013.12.004; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vanharanta S, 2013, CANCER CELL, V24, P410, DOI 10.1016/j.ccr.2013.09.007; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wan LL, 2013, NAT MED, V19, P1450, DOI 10.1038/nm.3391; Wang Y, 2014, NATURE, V512, P155, DOI 10.1038/nature13600; Xi L, 2007, CLIN CHEM, V53, P1206, DOI 10.1373/clinchem.2006.081828; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515; Yu M, 2014, SCIENCE, V345, P216, DOI 10.1126/science.1253533; Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522; Yu M, 2012, NATURE, V487, P510, DOI 10.1038/nature11217; Yu M, 2011, J CELL BIOL, V192, P373, DOI 10.1083/jcb.201010021; Zhang LX, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005109; Zong CH, 2012, SCIENCE, V338, P1622, DOI 10.1126/science.1229164	119	290	304	7	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2016	35	10					1216	1224		10.1038/onc.2015.192	http://dx.doi.org/10.1038/onc.2015.192			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG0NY	26050619				2022-12-17	WOS:000371763100002
J	Fisher, SG; Fisher, RI				Fisher, SG; Fisher, RI			The epidemiology of non-Hodgkin's lymphoma	ONCOGENE			English	Review						non-Hodgkin's lymphoma; epidemiology; etiology	CARDIAC-TRANSPLANT RECIPIENTS; EPSTEIN-BARR-VIRUS; UNITED-STATES; HELICOBACTER-PYLORI; LYMPHOPROLIFERATIVE DISORDERS; GASTRIC LYMPHOMA; TIME TRENDS; RHEUMATOID-ARTHRITIS; BLOOD-TRANSFUSION; CELL LYMPHOMAS	The incidence of non-Hodgkin's lymphoma (NHL) has doubled over the past two decades in the US and most other westernized countries. While improved cancer reporting, changes in lymphoma classification, and increases in AIDS-associated lymphomas have contributed to the startling escalation of disease incidence, these factors are estimated to account for only about 50% of the increase in observed incidence. The elucidation of etiologic factors and their mechanistic role in the pathogenesis of this malignancy are critical to advancements in disease prevention and treatment. Current evidence suggests that factors/conditions that precipitate either chronic antigenic stimulation or immunosuppression may provide a preferential milieu for development of NHL. High rates of lymphoma have been observed among individuals with autoimmune disease, organ transplants, and primary or acquired immunodeficiencies. Ultraviolet radiation, previously demonstrated to have an immunosuppressive effect, has also been suggested as a possible risk factor for NHL. Several pathogens have been linked to the risk of lymphoma, including Epstein-Barr virus, human immunodeficiency virus, human T-cell lymphotropic virus-1, Helicobacter pylori, hepatitis C, and simian virus 40. Whether these microbes are responsible for specific genetic mutations that initiate tumor growth, antigenic stimulation leading to B-cell proliferation, and increased potential of random cell replication errors, or immunosuppression, which thereby promotes tumor growth, has not been clearly delineated. Other exogenous factors which have been implicated in lymphomagenesis are chemicals and agricultural exposures, hair dyes, and blood transfusions. We must build on our current knowledge regarding the etiology of NHL in order that prevention, treatment, and ultimately, cure of this malignancy becomes a reality.	Univ Rochester, Sch Med & Dent, Dept Community & Prevent Med, Div Epidemiol, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, James P Wilmot Canc Ctr, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Fisher, SG (corresponding author), Univ Rochester, Sch Med & Dent, Dept Community & Prevent Med, Div Epidemiol, 601 Elmwood Ave,Box 644, Rochester, NY 14642 USA.	susan_fisher@urmc.rochester.edu						*AM CANC SOC, 2001, CANC FACTS FIG; Ambinder RF, 1999, CANC TREAT, V99, P27; American Cancer Society, 2004, CANC FACTS FIG; Baecklund E, 1998, BRIT MED J, V317, P180, DOI 10.1136/bmj.317.7152.180; BANKS PM, 1992, CANCER RES, V52, pS5453; Biggar RJ, 2001, J ACQ IMMUN DEF SYND, V26, P371, DOI 10.1097/00126334-200104010-00015; BLAIR A, 1991, OCCUP MED, V6, P335; BLOMBERG J, 1993, EUR J CANCER, V29A, P2101, DOI 10.1016/0959-8049(93)90042-E; BRESLIN P, 1988, J OCCUP ENVIRON MED, V30, P412, DOI 10.1097/00043764-198805000-00007; Cerhan JR, 2001, CANCER EPIDEM BIOMAR, V10, P361; CERHAN JR, 1993, ANN INTERN MED, V119, P8, DOI 10.7326/0003-4819-119-1-199307010-00002; Chiu BCH, 1999, BRIT J CANCER, V80, P1476, DOI 10.1038/sj.bjc.6690547; CINQUE P, 1993, LANCET, V342, P398, DOI 10.1016/0140-6736(93)92814-A; CLEARY ML, 1984, LANCET, V2, P489; CLEGHORN FR, 1995, JNCI-J NATL CANCER I, V87, P1009, DOI 10.1093/jnci/87.13.1009; Dal Maso L, 2003, LANCET ONCOL, V4, P110, DOI 10.1016/S1470-2045(03)00983-5; DAMORE F, 1992, HEMATOL REV, V6, P183; David H, 2001, CANCER LETT, V162, P57, DOI 10.1016/S0304-3835(00)00628-5; De Re V, 2000, BLOOD, V96, P3578; DEVESA SS, 1992, CANCER RES, V52, pS5432; DeVita S, 1997, BLOOD, V90, P776, DOI 10.1182/blood.V90.2.776; Eltom MA, 2002, J NATL CANCER I, V94, P1204, DOI 10.1093/jnci/94.16.1204; Ferreri AJM, 2004, J NATL CANCER I, V96, P586, DOI 10.1093/jnci/djh102; FILIPOVICH AH, 1992, CANCER RES, V52, pS5465; FISHER MS, 1982, SCIENCE, V216, P1133, DOI 10.1126/science.6210958; GAIDANO G, 1997, CANC PRINCIPLES PRA, V3, P2131; Garabrant DH, 2002, CRIT REV TOXICOL, V32, P233, DOI 10.1080/20024091064237; Gisbert JP, 2003, GASTROENTEROLOGY, V125, P1723, DOI 10.1053/j.gastro.2003.09.025; Goedert JJ, 2000, SEMIN ONCOL, V27, P390; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; GROGAN TM, 1995, CANC TREATMENT, P979; Groves FD, 2000, JNCI-J NATL CANCER I, V92, P1240, DOI 10.1093/jnci/92.15.1240; Harris NL, 1999, ANN ONCOL, V10, P1419, DOI 10.1023/A:1008375931236; HARRIS NL, 1994, BLOOD, V84, P1361; HARRIS OD, 1967, AM J MED, V42, P899, DOI 10.1016/0002-9343(67)90071-X; HARTGE P, 1992, CANCER RES, V52, pS5566; HAYES HM, 1991, J NATL CANCER I, V83, P1226, DOI 10.1093/jnci/83.17.1226; HOAR SK, 1986, JAMA-J AM MED ASSOC, V256, P1141, DOI 10.1001/jama.256.9.1141; HOLFORD TR, 1992, CANCER RES, V52, pS5443; Holly EA, 1999, AM J EPIDEMIOL, V150, P375, DOI 10.1093/oxfordjournals.aje.a010017; HOOVER RN, 1992, CANCER RES, V52, pS5477; Hussell T, 1996, J PATHOL, V178, P122, DOI 10.1002/(SICI)1096-9896(199602)178:2<122::AID-PATH486>3.0.CO;2-D; HUSSELL T, 1993, LANCET, V342, P571, DOI 10.1016/0140-6736(93)91408-E; *INT AG RES CANC M, 1978, MON INT AG RES CANC, V16; *INT AG RES CANC W, 1996, IARC MON EV CARC RIS, V67, P67; International Agency for Research on Cancer, 1997, MON EV CARC RISKS HU; Jacobson LP, 1999, J ACQ IMMUN DEF SYND, V21, pS34; JEEVAN A, 1990, CELL IMMUNOL, V130, P32, DOI 10.1016/0008-8749(90)90159-O; Jonsson V, 1999, J INTERN MED, V245, P277, DOI 10.1046/j.1365-2796.1999.0443f.x; KAMEL OW, 1995, LEUKEMIA LYMPHOMA, V16, P363, DOI 10.3109/10428199509054421; KAST WM, 1998, ENCY LIFE SCI; KINLEN L, 1992, CANCER RES, V52, pS5474; KIRKLEY SA, 1995, LANCET, V345, P527, DOI 10.1016/S0140-6736(95)90627-4; Klein HG, 1999, ANESTHESIOLOGY, V91, P861, DOI 10.1097/00000542-199909000-00040; KRIPKE ML, 1994, CANCER RES, V54, P6102; Landers DF, 1996, ANESTH ANALG, V82, P187, DOI 10.1097/00000539-199601000-00035; Lecuit M, 2004, NEW ENGL J MED, V350, P239, DOI 10.1056/NEJMoa031887; Levi F, 1996, BRIT J CANCER, V74, P1847, DOI 10.1038/bjc.1996.642; LEVINE AM, 1994, ANN ONCOL, V5, pS29, DOI 10.1093/annonc/5.suppl_2.S29; LINET MS, 1992, CANCER RES, V52, pS5468; Luppi M, 1996, BRIT J HAEMATOL, V94, P373, DOI 10.1046/j.1365-2141.1996.d01-1791.x; McMichael AJ, 1996, BRIT J CANCER, V73, P945, DOI 10.1038/bjc.1996.169; Melbye M, 1996, ACTA ONCOL, V35, P655, DOI 10.3109/02841869609083994; MELBYE M, 2002, TXB CANC EPIDEMIOLOG, V25, P535; MEMON A, 1994, INT J CANCER, V58, P366, DOI 10.1002/ijc.2910580310; Moore RD, 1999, AIDS, V13, P1933, DOI 10.1097/00002030-199910010-00017; MORROW RH, 1976, JNCI-J NATL CANCER I, V56, P479, DOI 10.1093/jnci/56.3.479; MORTON LM, 2004, P AACR, V45, P490; MUELLER NE, 1992, CANCER RES, V52, pS5479; MURPHY EL, 1991, AM J EPIDEMIOL, V133, P1114, DOI 10.1093/oxfordjournals.aje.a115824; Nakatsuka S, 2003, CANCER RES, V63, P7606; Nelson RA, 1997, BRIT J CANCER, V76, P1532, DOI 10.1038/bjc.1997.590; OFFIT K, 1991, BLOOD, V77, P1508; OPELZ G, 1993, LANCET, V342, P1514, DOI 10.1016/S0140-6736(05)80084-4; OPELZ G, 1973, TRANSPLANT P, V5, P253; Palackdharry C S, 1994, Oncology (Williston Park), V8, P67; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Paltiel O, 2000, CANCER, V88, P2357, DOI 10.1002/(SICI)1097-0142(20000515)88:10<2357::AID-CNCR21>3.3.CO;2-V; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; PEARCE N, 1989, BRIT J IND MED, V46, P143; PETTERSSON T, 1992, ANN RHEUM DIS, V51, P437, DOI 10.1136/ard.51.4.437; PIMENTAL D, 1993, HDB PEST MANAGEMENT, V1, P679; RABKIN CS, 1991, INT J CANCER, V47, P692, DOI 10.1002/ijc.2910470511; Reed D., 1902, JOHNS HOPKINS HOS RE, V10, P133; Ries L, 2001, SEER CANC STAT REV; RIVAS JM, 1992, J IMMUNOL, V149, P3865; Rizzo P, 1999, CHEST, V116, p470S, DOI 10.1378/chest.116.suppl_3.470S; *SEER, 2003, SURV EP END RES PROG; SELIK RM, 1987, AIDS, V1, P175; SHIPP MA, 1997, CANC PRINCIPLES PRAC, V3, P2165; Shivapurkar N, 2002, LANCET, V359, P851, DOI 10.1016/S0140-6736(02)07921-7; SWINNEN LJ, 1990, NEW ENGL J MED, V323, P1723, DOI 10.1056/NEJM199012203232502; TAKATSUKI K, 1976, TOPICS HEMATOLOGY, P73; Tavani A, 2000, EUR J CANCER PREV, V9, P59, DOI 10.1097/00008469-200002000-00008; TYCKO B, 1990, CANCER CELL-MON REV, V2, P1; VERMEER M, 1990, PHOTODERMATOL PHOTO, V7, P258; Vilchez RA, 2002, LANCET, V359, P817, DOI 10.1016/S0140-6736(02)07950-3; Vink AA, 1996, PHOTOCHEM PHOTOBIOL, V63, P383; WAHL SM, 1983, ARTHRITIS RHEUM-US, V26, P1076, DOI 10.1002/art.1780260904; Wiernik PH, 2000, BRIT J HAEMATOL, V108, P72, DOI 10.1046/j.1365-2141.2000.01815.x; WIGLE DT, 1990, J NATL CANCER I, V82, P575, DOI 10.1093/jnci/82.7.575; Willemze R, 1997, BLOOD, V90, P354; WOTHERSPOON AC, 1991, LANCET, V338, P1175, DOI 10.1016/0140-6736(91)92035-Z; YE BH, 2002, CANC INVESTIG, V18, P356; YOSIDA M, 1985, RETROVIRUSES HUMAN L, P39; Zahm S H, 1990, Epidemiology, V1, P349, DOI 10.1097/00001648-199009000-00004; Zahm SH, 1997, CANCER CAUSE CONTROL, V8, P159, DOI 10.1023/A:1018412027985; Zhang YW, 2004, AM J EPIDEMIOL, V159, P148, DOI 10.1093/aje/kwh033; ZHENG TZ, 1992, CANCER, V70, P840, DOI 10.1002/1097-0142(19920815)70:4&lt;840::AID-CNCR2820700420&gt;3.0.CO;2-I; Zhu KM, 1998, CANCER CAUSE CONTROL, V9, P77, DOI 10.1023/A:1008853421083	110	290	301	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2004	23	38					6524	6534		10.1038/sj.onc.1207843	http://dx.doi.org/10.1038/sj.onc.1207843			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	848LJ	15322522				2022-12-17	WOS:000223468800016
J	Strathdee, G; MacKean, MJ; Illand, M; Brown, R				Strathdee, G; MacKean, MJ; Illand, M; Brown, R			A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer	ONCOGENE			English	Article						mismatch repair; methylation; cisplatin; drug resistance; ovarian cancer	DNA MISMATCH REPAIR; NONPOLYPOSIS COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; TUMOR-CELLS; HMSH2 GENE; CISPLATIN; HYPERMETHYLATION; NEOPLASMS; MUTATION	Experimental evidence from several sources has identified a link between mismatch repair deficiency and cytotoxic drug resistance, Selection for cisplatin resistance in the human ovarian cancer cell line A2780, results in loss of expression of the mismatch repair protein hMLH1 in most (90%) of the resultant cisplatin-resistant cell lines, Here me demonstrate that the cisplatin sensitive parental cell line displays methylation of the promoter of only one hMLH1 allele, but that the resistant cell lines all exhibit hyper-methylation of the promoters of both hMLH1 alleles, Full methylation of all sites tested was found to be invariably associated with loss of hMLH1 expression, whereas a partial increase in methylation appears compatible with either loss or maintenance of expression, In addition treatment of two of the resistant cell lines with 5-azacytidine, a known inhibitor of methylation, results in re-expression of hMLH1, Clonogenic assays demonstrate that the 5-azacytidine treated cells show increased sensitivity to cisplatin, Furthermore, 12.5% (3/24) of ovarian tumours show hypermethylation of the hMLH1 promoter, Expression of hMLH1 is absent in the tumours that are hypermethylated, while all the unmethylated tumours still express the protein, This analysis suggests that methylation of the hMLH1 promoter may be a common mechanism for loss of hMLH1 expression, and possibly for cisplatin-resistance, in ovarian cancer.	Univ Glasgow, CRC, Dept Med Oncol, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute; University of Glasgow	Brown, R (corresponding author), Univ Glasgow, CRC, Dept Med Oncol, Beatson Labs, Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.			Strathdee, Gordon/0000-0001-9681-8429				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Aebi S, 1996, CANCER RES, V56, P3087; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Brown R, 1997, ONCOGENE, V15, P45, DOI 10.1038/sj.onc.1201167; Eshleman James R., 1995, Current Opinion in Oncology, V7, P83; Fink D, 1996, CANCER RES, V56, P4881; Fink D, 1998, CLIN CANCER RES, V4, P1; Fink D, 1997, INT J ONCOL, V11, P539; FROST P, 1990, CANCER RES, V50, P4572; Fujita M, 1995, INT J CANCER, V64, P361, DOI 10.1002/ijc.2910640602; Hatta Y, 1997, INT J ONCOL, V11, P465; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Kane MF, 1997, CANCER RES, V57, P808; Kaye SB, 1996, ANN ONCOL, V7, P9; KING BL, 1995, BRIT J CANCER, V72, P376, DOI 10.1038/bjc.1995.341; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; Modrich P, 1997, J BIOL CHEM, V272, P24727, DOI 10.1074/jbc.272.40.24727; NEIJT JP, 1997, TXB MED ONCOLOGY, P87; NYCE J, 1989, CANCER RES, V49, P5829; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Reitmair AH, 1996, CANCER RES, V56, P3842; Thibodeau SN, 1996, CANCER RES, V56, P4836; Zingg JM, 1997, CARCINOGENESIS, V18, P869, DOI 10.1093/carcin/18.5.869	25	290	312	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 8	1999	18	14					2335	2341		10.1038/sj.onc.1202540	http://dx.doi.org/10.1038/sj.onc.1202540			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184DT	10327053				2022-12-17	WOS:000079595500005
J	Peter, M; Couturier, J; Pacquement, H; Michon, J; Thomas, G; Magdelenat, H; Delattre, O				Peter, M; Couturier, J; Pacquement, H; Michon, J; Thomas, G; Magdelenat, H; Delattre, O			A new member of the ETS family fused to EWS in Ewing tumors	ONCOGENE			English	Article						ETS family; Ewing tumor; EWS; transcription; fusion	ACUTE LYMPHOBLASTIC-LEUKEMIA; DNA-BINDING; TRANSCRIPTIONAL ACTIVATOR; GENE FUSION; CHROMOSOMAL TRANSLOCATION; SARCOMA TRANSLOCATION; CHIMERIC TRANSCRIPTS; TRANSFORMING GENE; TEL GENE; PROTEIN	As a result of chromosome translocations, the EWS gene is fused to a variety of transcription factors in human solid neoplasia. In Ewing tumors EWS can be fused to four different members of the ETS family, namely FLI-1, ERG, ETV1 and E1AF We have identified a new member of the ETS family, called FEV, which is fused to EWS in a subset of Ewing tumors, FEV encodes a 238 amino acid protein which contains an ETS DNA binding domain closely related to that of FLI-1 and ERG, However, the N-terminal portion of FEV is only 42 amino acids long which suggests that FEV is lacking important transcription regulatory domains contained in FLI-1 and ERG N-terminal parts. The C-terminal end of FEV is rich in alanine residues which may indicate that FEV is a transcription repressor. The FEV gene is encoded by three exons and is located on chromosome 2. I;EV expression was only detected in adult prostate and small intestine but not in other adult nor in fetal tissues, thus indicating that FEV has a restricted expression pattern, Following a scheme similar to previously described translocations in Ewing tumors, a t(2;22) chromosome translocation fuses the N-terminal domain of EWS to the ETS DNA binding domain of FEV.	INST CURIE,LAB GENET TUMEURS,INSERM U434,F-75231 PARIS 05,FRANCE; INST CURIE,LAB TRANSFERT,F-75231 PARIS 05,FRANCE; INST CURIE,DEPT PATHOL,F-75231 PARIS 05,FRANCE; INST CURIE,DEPT PEDIAT ONCOL,F-75231 PARIS 05,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie				delattre, olivier/0000-0002-8730-2276				BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BUIJS A, 1995, ONCOGENE, V10, P1511; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Clark J, 1996, ONCOGENE, V12, P229; DELATTRE O, 1994, NEW ENGL J MED, V331, P294, DOI 10.1056/NEJM199408043310503; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; GIOVANNINI M, 1994, J CLIN INVEST, V94, P489, DOI 10.1172/JCI117360; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Horowitz ME, 1993, PRINCIPLES PRACTICE, P795; ICHIKAWA H, 1994, CANCER RES, V54, P2865; JEON IS, 1995, ONCOGENE, V10, P1229; Kaneko Y, 1996, GENE CHROMOSOME CANC, V15, P115, DOI 10.1002/(SICI)1098-2264(199602)15:2<115::AID-GCC6>3.0.CO;2-6; KLEMSZ MJ, 1993, J BIOL CHEM, V268, P5769; LABELLE Y, 1995, HUM MOL GENET, V4, P2219, DOI 10.1093/hmg/4.12.2219; LADANYI M, 1994, CANCER RES, V54, P2837; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; Maniatis T., 1989, MOL CLONING LAB MAN; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; OHNO T, 1993, CANCER RES, V53, P5859; Panagopoulos I, 1996, ONCOGENE, V12, P489; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; RAO VN, 1993, ONCOGENE, V8, P2167; REDDY ESP, 1991, ONCOGENE, V6, P2285; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; YEUNG KC, 1994, GENE DEV, V8, P2097, DOI 10.1101/gad.8.17.2097; ZHANG LQ, 1993, ONCOGENE, V8, P1621; ZOUBEK A, 1994, BRIT J CANCER, V70, P908, DOI 10.1038/bjc.1994.419; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	35	290	301	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 13	1997	14	10					1159	1164		10.1038/sj.onc.1200933	http://dx.doi.org/10.1038/sj.onc.1200933			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121764				2022-12-17	WOS:A1997WM78200004
J	Mowers, EE; Sharifi, MN; Macleod, KF				Mowers, E. E.; Sharifi, M. N.; Macleod, K. F.			Autophagy in cancer metastasis	ONCOGENE			English	Review							EPITHELIAL-MESENCHYMAL TRANSITION; FOCAL ADHESION KINASE; HYPOXIA-INDUCED AUTOPHAGY; SUPPRESSOR GENE ARHI; BREAST-CANCER; EXTRACELLULAR-MATRIX; STEM-CELLS; OVARIAN-CANCER; TUMOR-CELLS; BONE-MARROW	Autophagy is a highly conserved self-degradative process that has a key role in cellular stress responses and survival. Recent work has begun to explore the function of autophagy in cancer metastasis, which is of particular interest given the dearth of effective therapeutic options for metastatic disease. Autophagy is induced upon progression of various human cancers to metastasis and together with data from genetically engineered mice and experimental metastasis models, a role for autophagy at nearly every phase of the metastatic cascade has been identified. Specifically, autophagy has been shown to be involved in modulating tumor cell motility and invasion, cancer stem cell viability and differentiation, resistance to anoikis, epithelial-to-mesenchymal transition, tumor cell dormancy and escape from immune surveillance, with emerging functions in establishing the pre-metastatic niche and other aspects of metastasis. In this review, we provide a general overview of how autophagy modulates cancer metastasis and discuss the significance of new findings for disease management.	[Mowers, E. E.; Sharifi, M. N.; Macleod, K. F.] Univ Chicago, Ben May Dept Canc Res, 929 East 57th St GCIS W338, Chicago, IL 60422 USA; [Mowers, E. E.] Univ Chicago, Interdisciplinary Scientist Training Program, Chicago, IL 60637 USA; [Sharifi, M. N.] Univ Chicago, Med Scientist Training Program, Chicago, IL USA; [Sharifi, M. N.; Macleod, K. F.] Univ Chicago, Comm Canc Biol, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago; University of Chicago	Macleod, KF (corresponding author), Univ Chicago, Ben May Dept Canc Res, 929 East 57th St GCIS W338, Chicago, IL 60422 USA.	kmacleod@uchicago.edu		Sharifi, Marina/0000-0003-0128-3033	NIH [RO1 CA 162405, T32 GM007281, T32 CA009594]; NATIONAL CANCER INSTITUTE [R01CA162405, T32CA009594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007281] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Grant support for this work includes NIH RO1 CA 162405 to KFM, T32 GM007281 supported EEM and T32 CA009594 supported MNS.	Abbi S, 2002, MOL BIOL CELL, V13, P3178, DOI 10.1091/mbc.E02-05-0295; Akalay I, 2013, CANCER RES, V73, P2418, DOI 10.1158/0008-5472.CAN-12-2432; Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833; Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; Apel A, 2008, CANCER RES, V68, P1485, DOI 10.1158/0008-5472.CAN-07-0562; Avivar-Valderas A, 2013, ONCOGENE, V32, P4932, DOI 10.1038/onc.2012.512; Avivar-Valderas A, 2011, MOL CELL BIOL, V31, P3616, DOI 10.1128/MCB.05164-11; Baginska J, 2013, P NATL ACAD SCI USA, V110, P17450, DOI 10.1073/pnas.1304790110; Baixauli F, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00403; Balic M, 2006, CLIN CANCER RES, V12, P5615, DOI 10.1158/1078-0432.CCR-06-0169; Belaid A, 2013, CANCER RES, V73, P4311, DOI 10.1158/0008-5472.CAN-12-4142; Bertrand M, 2015, CELL CYCLE, V14, P364, DOI 10.4161/15384101.2014.987619; Brabletz T, 2012, NAT REV CANCER, V12, P425, DOI 10.1038/nrc3265; Caino MC, 2013, J CLIN INVEST, V123, P2907, DOI 10.1172/JCI67841; Capparelli C, 2012, CELL CYCLE, V11, P2285, DOI 10.4161/cc.20718; Caramel J, 2013, CANCER CELL, V24, P466, DOI 10.1016/j.ccr.2013.08.018; Carmeliet P, 2011, NAT REV DRUG DISCOV, V10, P417, DOI 10.1038/nrd3455; Carroll B, 2013, DEV CELL, V25, P15, DOI 10.1016/j.devcel.2013.03.005; Catalano M, 2015, MOL ONCOL, V9, P1612, DOI 10.1016/j.molonc.2015.04.016; Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chan EYW, 2007, J BIOL CHEM, V282, P25464, DOI 10.1074/jbc.M703663200; Charafe-Jauffret E, 2009, CANCER RES, V69, P1302, DOI 10.1158/0008-5472.CAN-08-2741; Chen CYC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015939; Chen GC, 2008, AUTOPHAGY, V4, P37, DOI 10.4161/auto.5141; Chen N, 2013, AUTOPHAGY, V9, P1214, DOI 10.4161/auto.24870; Chen S, 2016, GENE DEV, V30, P856, DOI 10.1101/gad.276428.115; Colombo M, 2014, ANNU REV CELL DEV BI, V30, P255, DOI 10.1146/annurev-cellbio-101512-122326; Comen E, 2011, NAT REV CLIN ONCOL, V8, P369, DOI 10.1038/nrclinonc.2011.64; Commisso C, 2013, NATURE, V497, P633, DOI 10.1038/nature12138; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Costa-Silva B, 2015, NAT CELL BIOL, V17, P816, DOI 10.1038/ncb3169; Criollo A, 2010, EMBO J, V29, P619, DOI 10.1038/emboj.2009.364; Cufi S, 2011, CELL CYCLE, V10, P3871, DOI 10.4161/cc.10.22.17976; Deakin NO, 2008, J CELL SCI, V121, P2435, DOI 10.1242/jcs.018044; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Deretic V, 2013, NAT REV IMMUNOL, V13, P722, DOI 10.1038/nri3532; Deretic V, 2012, TRENDS CELL BIOL, V22, P397, DOI 10.1016/j.tcb.2012.04.008; Di Vizio D, 2009, CELL CYCLE, V8, P2420, DOI 10.4161/cc.8.15.9116; Drake LE, 2014, J PATHOL, V232, P283, DOI 10.1002/path.4298; Dupont N, 2011, EMBO J, V30, P4701, DOI 10.1038/emboj.2011.398; Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371; Erler JT, 2009, CANCER CELL, V15, P35, DOI 10.1016/j.ccr.2008.11.012; Espina V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010240; Ewing J., 1928, NEOPLASTIC DIS TREAT; Ezratty EJ, 2005, NAT CELL BIOL, V7, P581, DOI 10.1038/ncb1262; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Frasa MAM, 2010, CURR BIOL, V20, P198, DOI 10.1016/j.cub.2009.12.053; Fung C, 2008, MOL BIOL CELL, V19, P797, DOI 10.1091/mbc.E07-10-1092; Galavotti S, 2013, ONCOGENE, V32, P699, DOI 10.1038/onc.2012.111; Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784; Galluzzi L, 2014, CELL, V159, P1263, DOI 10.1016/j.cell.2014.11.006; Gan BY, 2006, J BIOL CHEM, V281, P37321, DOI 10.1074/jbc.M605241200; Gan BY, 2006, J CELL BIOL, V175, P121, DOI 10.1083/jcb.200604129; Gan BY, 2005, J CELL BIOL, V170, P379, DOI 10.1083/jcb.200411106; Garcia-Prat L, 2016, NATURE, V529, P37, DOI 10.1038/nature16187; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Giancotti FG, 2013, CELL, V155, P750, DOI 10.1016/j.cell.2013.10.029; Grange C, 2011, CANCER RES, V71, P5346, DOI 10.1158/0008-5472.CAN-11-0241; Guadamillas MC, 2011, J CELL SCI, V124, P3189, DOI 10.1242/jcs.072165; Guo JY, 2013, GENE DEV, V27, P1447, DOI 10.1101/gad.219642.113; Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Gupta A, 2010, P NATL ACAD SCI USA, V107, P14333, DOI 10.1073/pnas.1000248107; Gupta PB, 2011, CELL, V146, P633, DOI 10.1016/j.cell.2011.07.026; Gurkar AU, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3189; Gutierrez MG, 2004, J CELL SCI, V117, P2687, DOI 10.1242/jcs.01114; Han CR, 2011, TOHOKU J EXP MED, V223, P243, DOI 10.1620/tjem.223.243; Hara T, 2008, J CELL BIOL, V181, P497, DOI 10.1083/jcb.200712064; Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756; Huotari J, 2011, EMBO J, V30, P3481, DOI 10.1038/emboj.2011.286; Jiang S, 2013, J INNATE IMMUN, V5, P471, DOI 10.1159/000346707; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kadandale P, 2010, P NATL ACAD SCI USA, V107, P10502, DOI 10.1073/pnas.0914168107; Kang C, 2015, SCIENCE, V349, DOI 10.1126/science.aaa5612; Karrison TG, 1999, JNCI-J NATL CANCER I, V91, P80, DOI 10.1093/jnci/91.1.80; Karsli-Uzunbas G, 2014, CANCER DISCOV, V4, P914, DOI 10.1158/2159-8290.CD-14-0363; Kenific CM, 2016, J CELL BIOL, V212, P577, DOI 10.1083/jcb.201503075; Kenific CM, 2010, CURR OPIN CELL BIOL, V22, P241, DOI 10.1016/j.ceb.2009.10.008; Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152; Kim SI, 2012, J BIOL CHEM, V287, P11677, DOI 10.1074/jbc.M111.308460; Kim YH, 2016, FEBS LETT, V590, P1365, DOI 10.1002/1873-3468.12172; Kiyono K, 2009, CANCER RES, V69, P8844, DOI 10.1158/0008-5472.CAN-08-4401; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Ladoire S, 2016, AUTOPHAGY, V12, P864, DOI 10.1080/15548627.2016.1154244; Langley RR, 2011, INT J CANCER, V128, P2527, DOI 10.1002/ijc.26031; Lazova R, 2012, CLIN CANCER RES, V18, P370, DOI 10.1158/1078-0432.CCR-11-1282; Lazova R, 2010, J CUTAN PATHOL, V37, P256, DOI 10.1111/j.1600-0560.2009.01359.x; Li J, 2013, CARCINOGENESIS, V34, P1343, DOI 10.1093/carcin/bgt063; Liang JY, 2007, NAT CELL BIOL, V9, P218, DOI 10.1038/ncb1537; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Lock R, 2008, CURR OPIN CELL BIOL, V20, P583, DOI 10.1016/j.ceb.2008.05.002; Lock R, 2014, CANCER DISCOV, V4, P466, DOI 10.1158/2159-8290.CD-13-0841; Loffler AS, 2011, AUTOPHAGY, V7, P696, DOI 10.4161/auto.7.7.15451; Lu Z, 2014, CELL DEATH DIFFER, V21, P1275, DOI 10.1038/cdd.2014.48; Lu Z, 2008, J CLIN INVEST, V118, P3917, DOI 10.1172/JCI35512; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Ma YT, 2013, IMMUNITY, V39, P211, DOI 10.1016/j.immuni.2013.07.017; Macintosh RL, 2012, CELL CYCLE, V11, P2022, DOI 10.4161/cc.20424; Mack NA, 2011, CELL CYCLE, V10, P1571, DOI 10.4161/cc.10.10.15612; Maes H, 2014, CANCER CELL, V26, P190, DOI 10.1016/j.ccr.2014.06.025; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Martinez-Outschoorn UE, 2010, CELL CYCLE, V9, P2423, DOI 10.4161/cc.9.12.12048; May CD, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2789; McAllister SS, 2014, NAT CELL BIOL, V16, P717, DOI 10.1038/ncb3015; McGowan PM, 2009, FUTURE ONCOL, V5, P1083, DOI [10.2217/fon.09.73, 10.2217/FON.09.73]; Meade J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019684; Melkoumian ZK, 2005, CANCER RES, V65, P6676, DOI 10.1158/0008-5472.CAN-04-4142; Messai Y, 2014, CANCER RES, V74, P6820, DOI 10.1158/0008-5472.CAN-14-0303; Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026; Mleczak A, 2013, CELL SIGNAL, V25, P1, DOI 10.1016/j.cellsig.2012.09.010; Morselli E, 2011, CELL CYCLE, V10, P2763, DOI 10.4161/cc.10.16.16868; Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980; Nakano A, 2010, NAT CELL BIOL, V12, P583, DOI 10.1038/ncb2060; Neill T, 2014, AM J PATHOL, V184, P2146, DOI 10.1016/j.ajpath.2014.05.010; Noman MZ, 2011, CANCER RES, V71, P5976, DOI 10.1158/0008-5472.CAN-11-1094; Oliver L, 2012, STEM CELLS DEV, V21, P2779, DOI 10.1089/scd.2012.0124; Olson MF, 2009, CLIN EXP METASTAS, V26, P273, DOI 10.1007/s10585-008-9174-2; Paget S., 1889, LANCET, V1, P571, DOI DOI 10.1016/S0140-6736(00)49915-0; Pang R, 2010, CELL STEM CELL, V6, P603, DOI 10.1016/j.stem.2010.04.001; Parsons JT, 2010, NAT REV MOL CELL BIO, V11, P633, DOI 10.1038/nrm2957; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Peng YF, 2013, AUTOPHAGY, V9, P2056, DOI 10.4161/auto.26398; Peng YF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074407; Perera R, 2015, NATURE, V524, P361, DOI 10.1038/nature14587; Pietrocola F, 2016, CANCER CELL, V30, P147, DOI 10.1016/j.ccell.2016.05.016; Ponpuak M, 2015, CURR OPIN CELL BIOL, V35, P106, DOI 10.1016/j.ceb.2015.04.016; Qiang L, 2014, P NATL ACAD SCI USA, V111, P9241, DOI 10.1073/pnas.1322913111; Ranganathan AC, 2006, CANCER RES, V66, P1702, DOI 10.1158/0008-5472.CAN-05-3092; Rao S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4056; Ratajczak J, 2006, LEUKEMIA, V20, P1487, DOI 10.1038/sj.leu.2404296; Ridley AJ, 2011, CELL, V145, P1012, DOI 10.1016/j.cell.2011.06.010; Rioux JD, 2007, NAT GENET, V39, P596, DOI 10.1038/ng2032; Robinson-Smith TM, 2007, CANCER RES, V67, P5708, DOI 10.1158/0008-5472.CAN-06-4375; Roh-Johnson M, 2014, ONCOGENE, V33, P4203, DOI 10.1038/onc.2013.377; Rosen DG, 2004, CLIN CANCER RES, V10, P6559, DOI 10.1158/1078-0432.CCR-04-0698; Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865; Rouschop KMA, 2010, J CLIN INVEST, V120, P127, DOI 10.1172/JCI40027; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Salah FS, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.93; Sandilands E, 2012, NAT CELL BIOL, V14, P51, DOI 10.1038/ncb2386; Santanam U, 2016, GENE DEV, V30, P399, DOI 10.1101/gad.274134.115; Sceneay J, 2013, CANCER METAST REV, V32, P449, DOI 10.1007/s10555-013-9420-1; Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Settembre C, 2012, EMBO J, V31, P1095, DOI 10.1038/emboj.2012.32; Sharifi MN, 2016, CELL REP, V15, P1660, DOI 10.1016/j.celrep.2016.04.065; Shi CS, 2012, NAT IMMUNOL, V13, P255, DOI 10.1038/ni.2215; Sosa MS, 2014, NAT REV CANCER, V14, P611, DOI 10.1038/nrc3793; Strohecker AM, 2013, CANCER DISCOV, V3, P1272, DOI 10.1158/2159-8290.CD-13-0397; Tra T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027485; Till A, 2015, AUTOPHAGY, V11, P1652, DOI 10.1080/15548627.2015.1059558; Tittarelli A, 2015, J BIOL CHEM, V290, P23670, DOI 10.1074/jbc.M115.651547; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Vazquez P, 2012, AUTOPHAGY, V8, P187, DOI 10.4161/auto.8.2.18535; Warr MR, 2013, NATURE, V494, P323, DOI 10.1038/nature11895; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Wei HJ, 2011, GENE DEV, V25, P1510, DOI 10.1101/gad.2051011; Wels J, 2008, GENE DEV, V22, P559, DOI 10.1101/gad.1636908; Witkiewicz AK, 2009, CANCER BIOL THER, V8, P1071, DOI 10.4161/cbt.8.11.8874; Wolf J, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3576; Wong PM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9048; Wyckoff JB, 2007, CANCER RES, V67, P2649, DOI 10.1158/0008-5472.CAN-06-1823; Xie XQ, 2015, CANCER DISCOV, V5, P410, DOI 10.1158/2159-8290.CD-14-1473; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111; Ye X, 2015, NATURE, V525, P256, DOI 10.1038/nature14897; Zhao H, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0475-1; Zhong ZY, 2016, CELL, V166, P288, DOI 10.1016/j.cell.2016.05.051; Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663	178	289	301	3	108	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	12					1619	1630		10.1038/onc.2016.333	http://dx.doi.org/10.1038/onc.2016.333			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP6AP	27593926	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000397460600002
J	Giordano, TJ; Kuick, R; Thomas, DG; Misek, DE; Vinco, M; Sanders, D; Zhu, ZW; Ciampi, R; Roh, M; Shedden, K; Gauger, P; Doherty, G; Thompson, NW; Hanash, S; Koenig, RJ; Nikiforov, YE				Giordano, TJ; Kuick, R; Thomas, DG; Misek, DE; Vinco, M; Sanders, D; Zhu, ZW; Ciampi, R; Roh, M; Shedden, K; Gauger, P; Doherty, G; Thompson, NW; Hanash, S; Koenig, RJ; Nikiforov, YE			Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis	ONCOGENE			English	Article						thyroid cancer; molecular profiling; DNA microarray; activating mutation; RET/RAS/RAF/MAPK signaling pathway	GROWTH-FACTOR-RECEPTOR; TALL-CELL VARIANT; FOLLICULAR VARIANT; HIGH PREVALENCE; CLINICAL-IMPLICATIONS; ONCOGENE ACTIVATION; ANTITUMOR-ACTIVITY; IMMUNE-RESPONSE; LUNG-CANCER; EARLY EVENT	Thyroid cancer poses a significant clinical challenge, and our understanding of its pathogenesis is incomplete. To gain insight into the pathogenesis of papillary thyroid carcinoma, transcriptional profiles of four normal thyroids and 51 papillary carcinomas (PCs) were generated using DNA microarrays. The tumors were genotyped for their common activating mutations: BRAF V600E point mutation, RET/PTC1 and 3 rearrangement and point mutations of KRAS, HRAS and NRAS. Principal component analysis based on the entire expression data set separated the PCs into three groups that were found to reflect tumor morphology and mutational status. By combining expression profiles with mutational status, we defined distinct expression profiles for the BRAF, RET/PTC1 and RAS mutation groups. Using small numbers of genes, a simple classifier was able to classify correctly the mutational status of all 40 tumors with known mutations. One tumor without a detectable mutation was predicted by the classifier to have a RET/PTC rearrangement and was shown to contain one by fluorescence in situ hybridization analysis. Among the mutation-specific expression signatures were genes whose differential expression was a direct consequence of the mutation, as well as genes involved in a variety of biological processes including immune response and signal transduction. Expression of one mutation-specific differentially expressed gene, TPO, was validated at the protein level using immunohistochemistry and tissue arrays containing an independent set of tumors. The results demonstrate that mutational status is the primary determinant of gene expression variation within these tumors, a finding that may have clinical and diagnostic significance and predicts success for therapies designed to prevent the consequences of these mutations.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pediat, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Cincinnati, Sch Med, Dept Pathol, Cincinnati, OH USA; Univ Michigan, Sch Med, Dept Stat, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Surg, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University System of Ohio; University of Cincinnati; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Giordano, TJ (corresponding author), Univ Michigan, Sch Med, Dept Pathol, UH 2G3320054, Ann Arbor, MI 48109 USA.	Giordano@umich.edu	Gauger, Paul/W-8176-2019; Ciampi, Raffaele/E-5350-2015	Giordano, Thomas/0000-0003-0641-8873; Ciampi, Raffaele/0000-0001-6345-9343; Doherty, Gerard/0000-0002-1685-9552	NCI NIH HHS [CA84952, 5 P30 CA46592] Funding Source: Medline; NIDDK NIH HHS [DK20572, DK58771] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA046592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020572, P60DK020572] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aldred MA, 2004, J CLIN ONCOL, V22, P3531, DOI 10.1200/JCO.2004.08.127; Allander SV, 2001, CANCER RES, V61, P8624; BAKER JR, 1995, J CLIN ENDOCR METAB, V80, P3419, DOI 10.1210/jc.80.12.3419; Balmain A, 2003, NAT GENET, V33, P238, DOI 10.1038/ng1107; Barden CB, 2003, CLIN CANCER RES, V9, P1792; Batistatou A, 2002, ENDOCR PATHOL, V13, P111, DOI 10.1385/EP:13:2:111; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Begum S, 2004, MODERN PATHOL, V17, P1359, DOI 10.1038/modpathol.3800198; Bertucci F, 2004, ONCOGENE, V23, P2564, DOI 10.1038/sj.onc.1207361; BONGARZONE I, 1989, ONCOGENE, V4, P1457; Bongarzone I, 2003, TUMORI, V89, P514, DOI 10.1177/030089160308900510; Bounacer A, 1997, ONCOGENE, V15, P1263, DOI 10.1038/sj.onc.1200206; Capella G, 1996, DIAGN MOL PATHOL, V5, P45, DOI 10.1097/00019606-199603000-00008; Carlomagno F, 2002, CANCER RES, V62, P7284; Carlomagno F, 2003, J CLIN ENDOCR METAB, V88, P1897, DOI 10.1210/jc.2002-021278; Chevillard S, 2004, CLIN CANCER RES, V10, P6586, DOI 10.1158/1078-0432.CCR-04-0053; Ciampi R, 2005, J CLIN INVEST, V115, P94, DOI 10.1172/JCI200523237; Ciro M, 2003, CURR OPIN CELL BIOL, V15, P213, DOI 10.1016/S0955-0674(03)00007-3; Cohen J, 2003, J NATL CANCER I, V95, P625, DOI 10.1093/jnci/95.8.625; Cuccuru G, 2004, JNCI-J NATL CANCER I, V96, P1006, DOI 10.1093/jnci/djh184; Dancey JE, 2004, CANCER CELL, V5, P411, DOI 10.1016/S1535-6108(04)00122-9; De Micco C, 2003, AM J CLIN PATHOL, V120, P803; DEGROOT LJ, 1990, J CLIN ENDOCR METAB, V71, P414, DOI 10.1210/jcem-71-2-414; DeLellis RA., 2004, TUMOURS ENDOCRINE OR; DOBASHI Y, 1994, DIAGN MOL PATHOL, V3, P9, DOI 10.1097/00019606-199403010-00003; DONGHI R, 1993, J CLIN INVEST, V91, P1753, DOI 10.1172/JCI116385; Ezzat S, 1996, THYROID, V6, P409, DOI 10.1089/thy.1996.6.409; Fagin JA, 2002, ENDOCRINOLOGY, V143, P2025, DOI 10.1210/en.143.6.2025; Finley DJ, 2004, J CLIN ENDOCR METAB, V89, P3214, DOI 10.1210/jc.2003-031811; Frattini M, 2004, ONCOGENE, V23, P7436, DOI 10.1038/sj.onc.1207980; Frisk T, 2002, GENE CHROMOSOME CANC, V35, P74, DOI 10.1002/gcc.10098; Giordano TJ, 2003, AM J PATHOL, V162, P521, DOI 10.1016/S0002-9440(10)63846-1; Giordano TJ, 2001, AM J PATHOL, V159, P1231, DOI 10.1016/S0002-9440(10)62509-6; Giuffrida D, 2000, ANN ONCOL, V11, P1083, DOI 10.1023/A:1008322002520; Hanash S, 2004, NAT REV CANCER, V4, P638, DOI 10.1038/nrc1414; Hawthorn L, 2004, HEAD NECK-J SCI SPEC, V26, P1069, DOI 10.1002/hed.20099; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; Ho CL, 2004, CANCER RES, V64, P6915, DOI 10.1158/0008-5472.CAN-04-2067; Huang Y, 2001, P NATL ACAD SCI USA, V98, P15044, DOI 10.1073/pnas.251547398; Hundahl SA, 1998, CANCER-AM CANCER SOC, V83, P2638, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1; Jazaeri AA, 2002, JNCI-J NATL CANCER I, V94, P990, DOI 10.1093/jnci/94.13.990; Juhasz F, 1996, J CLIN ENDOCR METAB, V81, P4175, DOI 10.1210/jcem.81.11.8923882; Karasarides M, 2004, ONCOGENE, V23, P6292, DOI 10.1038/sj.onc.1207785; KARGA H, 1991, J CLIN ENDOCR METAB, V73, P832, DOI 10.1210/jcem-73-4-832; Kimura ET, 2003, CANCER RES, V63, P1454; LiVolsi V A, 1996, Clin Oncol (R Coll Radiol), V8, P281, DOI 10.1016/S0936-6555(05)80712-5; Lloyd RV, 2004, AM J SURG PATHOL, V28, P1336, DOI 10.1097/01.pas.0000135519.34847.f6; Lowinger TB, 2002, CURR PHARM DESIGN, V8, P2269, DOI 10.2174/1381612023393125; Luo J, 2003, CANCER INVEST, V21, P937, DOI 10.1081/CNV-120025096; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Lyons JF, 2001, ENDOCR-RELAT CANCER, V8, P219, DOI 10.1677/erc.0.0080219; Machens A, 2004, LANGENBECK ARCH SURG, V389, P278, DOI 10.1007/s00423-004-0485-8; Mazzanti C, 2004, CANCER RES, V64, P2898, DOI 10.1158/0008-5472.CAN-03-3811; Miyagi E, 2004, MOL CARCINOGEN, V41, P98, DOI 10.1002/mc.20042; Moretti F, 2000, BEST PRACT RES CL EN, V14, P517, DOI 10.1053/beem.2000.0101; NAMBA H, 1990, MOL ENDOCRINOL, V4, P1474, DOI 10.1210/mend-4-10-1474; Nardone HC, 2003, CANCER, V98, P1386, DOI 10.1002/cncr.11638; Nikiforov YE, 2002, ENDOCR PATHOL, V13, P3, DOI 10.1385/EP:13:1:03; Nikiforova MN, 2002, INT J SURG PATHOL, V10, P15, DOI 10.1177/106689690201000104; Nikiforova MN, 2003, J CLIN ENDOCR METAB, V88, P5399, DOI 10.1210/jc.2003-030838; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pavey S, 2004, ONCOGENE, V23, P4060, DOI 10.1038/sj.onc.1207563; Prendiville S, 2000, OTOLARYNG HEAD NECK, V122, P352, DOI 10.1016/S0194-5998(00)70047-7; Rabes HM, 2000, CLIN CANCER RES, V6, P1093; Ruco LP, 2001, J PATHOL, V194, P4, DOI 10.1002/path.847; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; Sawyers CL, 2003, GENE DEV, V17, P2998, DOI 10.1101/gad.1152403; Schaefer KL, 2004, CANCER RES, V64, P3395, DOI 10.1158/0008-5472.CAN-03-0809; Schwartz DR, 2002, CANCER RES, V62, P4722; Segev DL, 2003, SURG ONCOL, V12, P69, DOI 10.1016/S0960-7404(03)00037-9; Singer G, 2003, J NATL CANCER I, V95, P484, DOI 10.1093/jnci/95.6.484; SMANIK PA, 1994, BIOCHEM BIOPH RES CO, V198, P948, DOI 10.1006/bbrc.1994.1135; Soares P, 2003, ONCOGENE, V22, P4578, DOI 10.1038/sj.onc.1206706; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; STONE M, 1977, BIOMETRIKA, V64, P29; SUAREZ HG, 1988, ONCOGENE, V2, P403; Sweet-Cordero A, 2005, NAT GENET, V37, P48, DOI 10.1038/ng1490; Tanaka T, 1996, J PATHOL, V179, P89; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; Wasenius VM, 2003, CLIN CANCER RES, V9, P68; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Wreesmann VB, 2004, CANCER RES, V64, P3780, DOI 10.1158/0008-5472.CAN-03-1460; Zhu ZW, 2003, AM J CLIN PATHOL, V120, P71, DOI 10.1309/ND8D9LAJTRCTG6QD	83	289	308	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2005	24	44					6646	6656		10.1038/sj.onc.1208822	http://dx.doi.org/10.1038/sj.onc.1208822			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	971FL	16007166				2022-12-17	WOS:000232367800006
J	Buzzai, M; Bauer, DE; Jones, RG; DeBerardinis, RJ; Hatzivassiliou, G; Elstrom, RL; Thompson, CB				Buzzai, M; Bauer, DE; Jones, RG; DeBerardinis, RJ; Hatzivassiliou, G; Elstrom, RL; Thompson, CB			The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation	ONCOGENE			English	Article						Akt; AMPK; fatty acid oxidation; metabolism; glucose	PROTEIN-KINASE; CANCER-CELLS; SKELETAL-MUSCLE; GLYCOLYSIS; METABOLISM; PHOSPHORYLATION; INHIBITION; DISORDERS; TOLERANCE; SURVIVAL	Activation of the oncogenic kinase Akt stimulates glucose uptake and metabolism in cancer cells and renders these cells susceptible to death in response to glucose withdrawal. Here we show that 5-aminoimidazole-4-carboxamide ribonucleoside ( AICAR) reverses the sensitivity of Akt-expressing glioblastoma cells to glucose deprivation. AICAR's protection depends on the activation of AMPK, as expression of a dominant-negative form of AMPK abolished this effect. AMPK is a cellular energy sensor whose activation can both block anabolic pathways such as protein synthesis and activate catabolic reactions such as fatty acid oxidation to maintain cellular bioenergetics. While rapamycin treatment mimicked the effect of AICAR on inhibiting markers of cap-dependent translation, it failed to protect Akt-expressing cells from death upon glucose withdrawal. Compared to control cells, Akt-expressing cells were impaired in the ability to induce fatty acid oxidation in response to glucose deprivation unless stimulated with AICAR. Stimulation of fatty acid oxidation was sufficient to maintain cell survival as activation of fatty acid oxidation with bezafibrate also protected Akt-expressing cells from glucose withdrawal-induced death. Conversely, treatment with a CPT-1 inhibitor to block fatty acid import into mitochondria prevented AICAR from stimulating fatty acid oxidation and promoting cell survival in the absence of glucose. Finally, cell survival did not require reversal of Akt's effects on either protein translation or lipid synthesis as the addition of the cell penetrant oxidizable substrate methyl-pyruvate was sufficient to maintain survival of Akt-expressing cells deprived of glucose. Together, these data suggest that activation of Akt blocks the ability of cancer cells to metabolize nonglycolytic bioenergetic substrates, leading to glucose addiction.	Univ Penn, Dept Canc Biol, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Human Genet & Mol Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Thompson, CB (corresponding author), Univ Penn, Dept Canc Biol, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.	craig@mail.med.upenn.edu	Jones, Russell Graham/ABD-5261-2021; Jones, Russell/AAC-2861-2022	Jones, Russell Graham/0000-0003-2250-4675; 	NIGMS NIH HHS [5T32-GM008638-08] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008638] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berwick DC, 2002, J BIOL CHEM, V277, P33895, DOI 10.1074/jbc.M204681200; Bolster DR, 2002, J BIOL CHEM, V277, P23977, DOI 10.1074/jbc.C200171200; BRIVET M, 1995, ANN CLIN BIOCHEM, V32, P154, DOI 10.1177/000456329503200204; Carlson M, 1999, CURR OPIN MICROBIOL, V2, P202, DOI 10.1016/S1369-5274(99)80035-6; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.tb20498.x; Culmsee C, 2001, J MOL NEUROSCI, V17, P45, DOI 10.1385/JMN:17:1:45; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; DAVIES SP, 1990, EUR J BIOCHEM, V187, P183, DOI 10.1111/j.1432-1033.1990.tb15293.x; DISERENS AC, 1981, ACTA NEUROPATHOL, V53, P21, DOI 10.1007/BF00697180; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Halford NG, 1998, PLANT MOL BIOL, V37, P735, DOI 10.1023/A:1006024231305; Hardie DG, 2003, ENDOCRINOLOGY, V144, P5179, DOI 10.1210/en.2003-0982; Hashimoto K, 2002, BIOCHEM BIOPH RES CO, V290, P263, DOI 10.1006/bbrc.2001.6193; Horman S, 2002, CURR BIOL, V12, P1419, DOI 10.1016/S0960-9822(02)01077-1; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Jijakli H, 1996, ARCH BIOCHEM BIOPHYS, V335, P245, DOI 10.1006/abbi.1996.0505; Kato K, 2002, ONCOGENE, V21, P6082, DOI 10.1038/sj.onc.1205737; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Kovacic S, 2003, J BIOL CHEM, V278, P39422, DOI 10.1074/jbc.M305371200; LILLY K, 1992, BIOCHEM PHARMACOL, V43, P353, DOI 10.1016/0006-2952(92)90298-W; Merrill GF, 1997, AM J PHYSIOL-ENDOC M, V273, pE1107, DOI 10.1152/ajpendo.1997.273.6.E1107; MOON A, 1987, J CLIN INVEST, V79, P59, DOI 10.1172/JCI112808; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; OMURA S, 1995, J ANTIBIOT, V48, P535, DOI 10.7164/antibiotics.48.535; Rolfe DFS, 1997, PHYSIOL REV, V77, P731, DOI 10.1152/physrev.1997.77.3.731; VAN MEIR EG, 1994, CANCER RES, V54, P649; WARBURG O, 1956, SCIENCE, V124, P269; Wolfrum C, 2004, NATURE, V432, P1027, DOI 10.1038/nature03047	30	289	297	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2005	24	26					4165	4173		10.1038/sj.onc.1208622	http://dx.doi.org/10.1038/sj.onc.1208622			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY	15806154				2022-12-17	WOS:000229815300001
J	SANTORO, M; DATHAN, NA; BERLINGIERI, MT; BONGARZONE, I; PAULIN, C; GRIECO, M; PIEROTTI, MA; VECCHIO, G; FUSCO, A				SANTORO, M; DATHAN, NA; BERLINGIERI, MT; BONGARZONE, I; PAULIN, C; GRIECO, M; PIEROTTI, MA; VECCHIO, G; FUSCO, A			MOLECULAR CHARACTERIZATION OF RET/PTC3 - A NOVEL REARRANGED VERSION OF THE RET PROTOONCOGENE IN A HUMAN THYROID PAPILLARY CARCINOMA	ONCOGENE			English	Article							RET PROTO-ONCOGENE; TRANSFORMING GENE; TYROSINE KINASE; MESSENGER-RNAS; II ONCOGENE; ACTIVATION; PROTOONCOGENE; PRODUCT; PTC; IDENTIFICATION	The RET proto-oncogene encodes a transmembrane receptor of the tyrosine kinase family and has frequently been found activated in human thyroid carcinomas of the papillary subtype. In most cases the activation consisted of the fusion of its tyrosine-kinase domain with the 5'-terminal region of a gene designated H4 or D10S170. We have named the resulting H4/RET chimeric oncogene RET/PTC. Another activated form of the RET oncogene has subsequently been found in a thyroid carcinoma and is now referred to as RET/PTC2. Here we report the identification and cloning of a novel rearranged version of the RET oncogene in a human thyroid papillary carcinoma. In this case the tyrosine-kinase domain of RET was fused to a sequence 790 bp long belonging to a new gene that we have named RFG (RET I;used Gene). This novel chimeric oncogene has been designated RET/PTC3. In order to have more insights into the function of RI;G we have completely cloned and sequenced its cDNA. RFG predicted amino-acid sequence does not have any significant homology to any already known genes and is ubiquitously expressed in human and mouse tissues. Finally we provide evidence indicating that the rearrangement leading to the generation of RET/PTC3 occurred in vivo in the original tumor DNA.	UNIV NAPOLI,FAC MED & CHIRURG,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC,I-80131 NAPLES,ITALY; IST NAZL TUMORI,DIV ONCOL SPERIMENTALE A,I-20133 MILAN,ITALY; CTR HOSP LYON SUD,HISTOL & CYTOL LAB,F-69310 PIERRE BENITE,FRANCE; FAC MED LYON SUD,CNRS,URA 1454,F-69600 OULLINS,FRANCE; UNIV REGGIO CALABRIA,FAC MED & CHIRURG CATANZARO,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CANTANZARO,ITALY	University of Naples Federico II; Fondazione IRCCS Istituto Nazionale Tumori Milan; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Universita Mediterranea di Reggio Calabria	SANTORO, M (corresponding author), CNR,CTR ENDOCRINOL & ONCOL SPERIMENTALE,VIA S PANSINI 5,I-80131 NAPLES,ITALY.		Bongarzone, Italia/B-9544-2017	Bongarzone, Italia/0000-0003-2530-9170; Grieco, Michele/0000-0002-4212-7814; Fusco, Alfredo/0000-0003-3332-5197; Pierotti, Marco Alessandro/0000-0002-7431-8332				ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; BONGARZONE I, 1989, ONCOGENE, V4, P1457; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; FABIEN N, 1992, BRIT J CANCER, V66, P1094, DOI 10.1038/bjc.1992.416; FUSCO A, 1987, NATURE, V328, P7072; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; IKEDA I, 1990, ONCOGENE, V5, P1291; ISHIZAKA Y, 1989, ONCOGENE, V4, P789; ISHIZAKA Y, 1992, ONCOGENE, V7, P1441; ISHIZAKA Y, 1990, BIOCHEM BIOPH RES CO, V168, P402, DOI 10.1016/0006-291X(90)92335-W; ISHIZAKA Y, 1988, ONCOGENE RES, V3, P193; JHIANG SM, 1992, ONCOGENE, V7, P1331; KODA T, 1988, Hokkaido Journal of Medical Science, V63, P913; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LANZI C, 1992, ONCOGENE, V7, P2189; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; OU JH, 1984, P NATL ACAD SCI USA, V82, P83; PIEROTTI MA, 1992, P NATL ACAD SCI USA, V89, P1616, DOI 10.1073/pnas.89.5.1616; Sambrook J., 1989, MOL CLONING LAB MANU; SANTORO M, 1990, ONCOGENE, V5, P1595; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SANTORO M, 1993, BRIT J CANCER, V68, pH60; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1988, ONCOGENE, V3, P571; WAJJWALKU W, 1992, JPN J CANCER RES, V83, P671, DOI 10.1111/j.1349-7006.1992.tb01963.x; [No title captured]	32	289	299	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					509	516						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290261				2022-12-17	WOS:A1994MW24800018
J	HARPUR, AG; ANDRES, AC; ZIEMIECKI, A; ASTON, RR; WILKS, AF				HARPUR, AG; ANDRES, AC; ZIEMIECKI, A; ASTON, RR; WILKS, AF			JAK2, A 3RD MEMBER OF THE JAK FAMILY OF PROTEIN TYROSINE KINASES	ONCOGENE			English	Article							MEMBRANE GUANYLATE-CYCLASE; POLYMERASE CHAIN-REACTION; CATALYTIC DOMAINS; RECEPTOR; GENE; SEQUENCE; PHOSPHATASES; EXPRESSION; DIVERSITY; CELLS	We have isolated cDNA clones encoding a third, widely expressed, member of the JAK family of protein tyrosine kinases (PTKs). The anticipated amino acid sequence of JAK2 predicts the presence of two kinase-related domains, a feature characteristic of this family of PTKs. The structural similarity of JAK2 to the other members of this family extends towards their N-termini, beyond the two kinase-related domains, and reveals five further domains of substantial amino acid similarity. The C-terminal portion of one of these domains, the JH4 domain, bears an intriguing, albeit tenuous, similarity to the core element of the SH2 domain, whereas the remaining JAK homology domains do not appear to be a feature of other known proteins.	LUDWIG INST CANC RES,MELBOURNE TUMOR BIOL BRANCH,MELBOURNE,VIC 3050,AUSTRALIA; UNIV BERN,INST CLIN & EXPTL CANC RES,CH-3004 BERN,SWITZERLAND	Ludwig Institute for Cancer Research; University of Bern			Wilks, Andrew F/R-5542-2019	Wilks, Andrew F/0000-0002-8554-2399				CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANSK SK, 1991, METHOD ENZYMOL, V200, P38; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOLTZMAN DA, 1987, P NATL ACAD SCI USA, V84, P8325, DOI 10.1073/pnas.84.23.8325; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; Maniatis T., 1982, MOL CLONING; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; NISHIZAWA M, 1986, MOL CELL BIOL, V6, P511, DOI 10.1128/MCB.6.2.511; PAWSON T, 1988, ONCOGENE, V3, P491; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SINGH S, 1988, NATURE, V334, P708, DOI 10.1038/334708a0; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; SUKEGAWA J, 1987, MOL CELL BIOL, V7, P41, DOI 10.1128/MCB.7.1.41; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; WILKS A F, 1990, Progress in Growth Factor Research, V2, P97, DOI 10.1016/0955-2235(90)90026-G; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237	35	289	298	0	12	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1347	1353						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1620548				2022-12-17	WOS:A1992HZ97100013
J	Kong, W; He, L; Richards, EJ; Challa, S; Xu, CX; Permuth-Wey, J; Lancaster, JM; Coppola, D; Sellers, TA; Djeu, JY; Cheng, JQ				Kong, W.; He, L.; Richards, E. J.; Challa, S.; Xu, C-X; Permuth-Wey, J.; Lancaster, J. M.; Coppola, D.; Sellers, T. A.; Djeu, J. Y.; Cheng, J. Q.			Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer	ONCOGENE			English	Article						miR-155; angiogenesis; VHL; breast cancer; inflammation	B-CELL LYMPHOMAS; TNF-ALPHA; MICRORNA-155; GROWTH; MIR-155; GENE; INFLAMMATION; EXPRESSION; TUMORIGENESIS; MACROPHAGES	MicroRNA-155 (miR-155) is frequently upregulated in various types of human cancer; however, its role in cancer angiogenesis remains unknown. Here, we demonstrate the role of miR-155 in angiogenesis through targeting von Hippel-Lindau (VHL) tumour suppressor in breast cancer. Ectopic expression of miR-155 induced whereas knockdown of miR-155 inhibited human umbilical vein endothelial cell network formation, proliferation, invasion and migration. Furthermore, mammary fat pad xenotransplantation of ectopically expressed miR-155 resulted in extensive angiogenesis, proliferation, tumour necrosis and recruitment of pro-inflammatory cells such as tumour-associated macrophages. Expression of VHL abrogated these miR-155 effects. Moreover, miR-155 expression inversely correlates with VHL expression level and is associated with late-stage, lymph node metastasis and poor prognosis, as well as triple-negative tumour in breast cancer. These findings indicate that miR-155 has a pivotal role in tumour angiogenesis by downregulation of VHL, and provide a basis for miR-155-expressing tumours to embody an aggressive malignant phenotype, and therefore miR-155 is an important therapeutic target in breast cancer.	[Kong, W.; He, L.; Richards, E. J.; Challa, S.; Xu, C-X; Cheng, J. Q.] H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, Tampa, FL 33612 USA; [Permuth-Wey, J.; Sellers, T. A.] H Lee Moffitt Canc Ctr & Res Inst, Dept Canc Epidemiol, Tampa, FL 33612 USA; [Lancaster, J. M.] H Lee Moffitt Canc Ctr & Res Inst, Dept Womens Oncol, Tampa, FL 33612 USA; [Coppola, D.] H Lee Moffitt Canc Ctr & Res Inst, Dept Pathol, Tampa, FL 33612 USA; [Djeu, J. Y.] H Lee Moffitt Canc Ctr & Res Inst, Dept Immunol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute	Cheng, JQ (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, 12909 Magnolia Dr,SRB3, Tampa, FL 33612 USA.	Jin.Cheng@moffitt.org	Xu, Cheng-Xiong/ACD-3271-2022; Xu, Cheng-Xiong/AAV-7733-2021	Xu, Cheng-Xiong/0000-0001-5714-8207; CHALLA, SRIDEVI/0000-0002-5308-9243	National Institute of Health [CA114343, CA115308, CA137041]; Florida Bankhead-Coley Cancer Research Program [2BB01]; NATIONAL CANCER INSTITUTE [R01CA137041, R01CA160455, P30CA076292, R01CA114343, T32CA115308] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Florida Bankhead-Coley Cancer Research Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the National Institute of Health (CA114343 to TAS, CA115308 to JYD, and CA137041 to JQC) and Florida Bankhead-Coley Cancer Research Program (2BB01 to JQC).	Albini A, 2005, CANCER RES, V65, P10637, DOI 10.1158/0008-5472.CAN-05-3473; Allavena P, 2008, CRIT REV ONCOL HEMAT, V66, P1, DOI 10.1016/j.critrevonc.2007.07.004; Andorfer CA, 2011, TRENDS MOL MED, V17, P313, DOI 10.1016/j.molmed.2011.01.006; Babar IA, 2011, CANCER BIOL THER, V12, P908, DOI 10.4161/cbt.12.10.17681; Baeriswyl V, 2009, SEMIN CANCER BIOL, V19, P329, DOI 10.1016/j.semcancer.2009.05.003; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Bergers G, 1998, INT J DEV BIOL, V42, P995; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; Cha ST, 2010, CANCER RES, V70, P2675, DOI 10.1158/0008-5472.CAN-09-2448; Chang SH, 2011, NAT MED, V17, P1275, DOI 10.1038/nm.2459; Coultas L, 2005, NATURE, V438, P937, DOI 10.1038/nature04479; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Eis PS, 2005, P NATL ACAD SCI USA, V102, P3627, DOI 10.1073/pnas.0500613102; Fang L, 2011, ONCOGENE, V30, P806, DOI 10.1038/onc.2010.465; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Foulkes WD, 2003, J NATL CANCER I, V95, P1482, DOI 10.1093/jnci/djg050; Greer SN, 2012, EMBO J, V31, P2448, DOI 10.1038/emboj.2012.125; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685; Jiang SA, 2010, CANCER RES, V70, P3119, DOI 10.1158/0008-5472.CAN-09-4250; Kaelin WG, 2008, NAT REV CANCER, V8, P865, DOI 10.1038/nrc2502; Karginov FV, 2007, P NATL ACAD SCI USA, V104, P19291, DOI 10.1073/pnas.0709971104; Keene JD, 2006, NAT PROTOC, V1, P302, DOI 10.1038/nprot.2006.47; Kim WY, 2004, J CLIN ONCOL, V22, P4991, DOI 10.1200/JCO.2004.05.061; Kluiver J, 2005, J PATHOL, V207, P243, DOI 10.1002/path.1825; Kong W, 2008, MOL CELL BIOL, V28, P6773, DOI 10.1128/MCB.00941-08; Kong W, 2010, J BIOL CHEM, V285, P17869, DOI 10.1074/jbc.M110.101055; Krishnamachary B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044078; Lakhani SR, 2005, CLIN CANCER RES, V11, P5175, DOI 10.1158/1078-0432.CCR-04-2424; Li MQ, 2011, J CELL MOL MED, V15, P187, DOI 10.1111/j.1582-4934.2010.01238.x; Luo JL, 2004, CANCER CELL, V6, P297, DOI 10.1016/j.ccr.2004.08.012; Montagner M, 2012, NATURE, V487, P380, DOI 10.1038/nature11207; O'Connell RM, 2007, P NATL ACAD SCI USA, V104, P1604, DOI 10.1073/pnas.0610731104; Ono M, 2008, CANCER SCI, V99, P1501, DOI 10.1111/j.1349-7006.2008.00853.x; Pedersen IM, 2009, EMBO MOL MED, V1, P288, DOI 10.1002/emmm.200900028; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Skobe M, 1997, NAT MED, V3, P1222, DOI 10.1038/nm1197-1222; Solinas G, 2009, J LEUKOCYTE BIOL, V86, P1065, DOI 10.1189/jlb.0609385; Suarez Y, 2008, P NATL ACAD SCI USA, V105, P14082, DOI 10.1073/pnas.0804597105; Suarez Y, 2009, CIRC RES, V104, P442, DOI 10.1161/CIRCRESAHA.108.191270; Thai TH, 2007, SCIENCE, V316, P604, DOI 10.1126/science.1141229; Tili E, 2007, J IMMUNOL, V179, P5082, DOI 10.4049/jimmunol.179.8.5082; Tili E, 2011, P NATL ACAD SCI USA, V108, P4908, DOI 10.1073/pnas.1101795108; Vigorito E, 2007, IMMUNITY, V27, P847, DOI 10.1016/j.immuni.2007.10.009; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Yamakuchi M, 2010, P NATL ACAD SCI USA, V107, P6334, DOI 10.1073/pnas.0911082107; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Zia MK, 2007, INT J MOL MED, V20, P605	53	288	300	6	86	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2014	33	6					679	689		10.1038/onc.2012.636	http://dx.doi.org/10.1038/onc.2012.636			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5IL	23353819	Green Accepted			2022-12-17	WOS:000331129200003
J	Wu, S; Huang, S; Ding, J; Zhao, Y; Liang, L; Liu, T; Zhan, R; He, X				Wu, S.; Huang, S.; Ding, J.; Zhao, Y.; Liang, L.; Liu, T.; Zhan, R.; He, X.			Multiple microRNAs modulate p21Cip1/Waf1 expression by directly targeting its 3 ' untranslated region	ONCOGENE			English	Article						miRNA; p21Cip1/Waf1; 3 ' untranslated region	P21; INHIBITOR; MECHANISM; KINASES; CANCER; GENES	Cyclin-dependent kinase inhibitor 1A ( CDKN1A), also known as p21Cip1/Waf1, is a master downstream effector of tumor suppressors.In this study, we experimentally demonstrate through a high-throughput luciferase reporter screen that p21Cip1/Waf1 can be directly targeted by nearly 28 microRNAs ( miRNAs). The results were further confirmed by a series of mutational analyses and luciferase reporter assays. These 28 miRNAs can substantially inhibit p21Cip1/Waf1 expression, predominantly at translational level. Many of these miRNAs were upregulated in cancers and might serve as modulators of oncogenesis. Furthermore, 8 of these 28 p21-regulating miRNAs are located in the chromosome 19 miRNA cluster, the largest miRNA gene cluster in humans, and they can clearly promote cell proliferation and cell-cycle progression in choriocarcinoma cells. In conclusion, our screening strategy provides an alternative approach to uncovering miRNA modulators of an individual mRNA, and it has identified multiple miRNAs that can suppress p21Cip1/Waf1 expression by directly targeting its 30 untranslated region. Oncogene (2010) 29, 2302-2308; doi: 10.1038/onc.2010.34; published online 1 March 2010	[Wu, S.; Huang, S.; Ding, J.; Zhao, Y.; Liang, L.; He, X.] Shanghai Jiao Tong Univ, Sch Med, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes, Shanghai 200032, Peoples R China; [Wu, S.; Zhan, R.] Fujian Med Univ, Union Hosp, Fujian Inst Hematol, Dept Hematol, Fuzhou 350001, Peoples R China; [Liu, T.] Shanghai Jiao Tong Univ, Sch Med, Int Peace Matern & Child Hlth Hosp, Shanghai 200032, Peoples R China	Shanghai Jiao Tong University; Fujian Medical University; Shanghai Jiao Tong University	He, X (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes, 25 Ln 2200,Xie Tu Rd, Shanghai 200032, Peoples R China.	deanzhanrong@yahoo.com.cn; xhhe@shsci.org	liang, linhui/AAW-4176-2021; He, Xianghuo/I-1497-2014; Huang, Shenglin/N-9472-2018	He, Xianghuo/0000-0001-8872-668X; Huang, Shenglin/0000-0003-1279-0794	Science & Technology Commission of Shanghai Municipality [07DJ14006]; Ministry of Health of China [2008ZX10002-017]; Ministry of Human Resources and Social Security of China [2007-170]; Doctoral Program of Higher Education of China [200802480076]	Science & Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); Ministry of Health of China; Ministry of Human Resources and Social Security of China; Doctoral Program of Higher Education of China(Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP))	We are most grateful for Dr T Didier's gifts of the pWPXL, psPAX2 and pMD2. G lentivirus plasmids. This work was supported by grants from the Science & Technology Commission of Shanghai Municipality (07DJ14006), the Ministry of Health of China (2008ZX10002-017), the Ministry of Human Resources and Social Security of China (2007-170) and the Doctoral Program of Higher Education of China (200802480076).	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bentwich I, 2005, NAT GENET, V37, P766, DOI 10.1038/ng1590; Bortolin-Cavaille ML, 2009, NUCLEIC ACIDS RES, V37, P3464, DOI 10.1093/nar/gkp205; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gottardo F, 2007, UROL ONCOL-SEMIN ORI, V25, P387, DOI 10.1016/j.urolonc.2007.01.019; Guled M, 2009, GENE CHROMOSOME CANC, V48, P615, DOI 10.1002/gcc.20669; HARPER JW, 1993, CELL, V75, P805; Hausser J, 2009, NUCLEIC ACIDS RES, V37, pW266, DOI 10.1093/nar/gkp412; Ivanovska I, 2008, MOL CELL BIOL, V28, P2167, DOI 10.1128/MCB.01977-07; Jongen-Lavrencic M, 2008, BLOOD, V111, P5078, DOI 10.1182/blood-2008-01-133355; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lionetti M, 2009, BLOOD, V114, pE20, DOI 10.1182/blood-2009-08-237495; Lv K, 2008, BIOCHEM BIOPH RES CO, V374, P101, DOI 10.1016/j.bbrc.2008.06.102; Martin-Caballero J, 2001, CANCER RES, V61, P6234; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; van Rooij E, 2007, SCIENCE, V316, P575, DOI 10.1126/science.1139089; Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037; Wong TS, 2008, CLIN CANCER RES, V14, P2588, DOI 10.1158/1078-0432.CCR-07-0666; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	23	288	303	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	15					2302	2308		10.1038/onc.2010.34	http://dx.doi.org/10.1038/onc.2010.34			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583NT	20190813				2022-12-17	WOS:000276685200015
J	Nagy, Z; Tora, L				Nagy, Z.; Tora, L.			Distinct GCN5/PCAF-containing complexes function as co-activators and are involved in transcription factor and global histone acetylation	ONCOGENE			English	Review						TFTC; STAGA; ATAC; SAGA complexes; global histone acetylation; cofactors	TATA-BINDING PROTEIN; DEPENDENT GENE ACTIVATION; DROSOPHILA ADA2 HOMOLOGS; HUMAN STAGA COMPLEX; ACETYLTRANSFERASE COMPLEX; C-MYC; CHROMATIN-STRUCTURE; LYSINE ACETYLATION; POSTTRANSLATIONAL MODIFICATIONS; TAF(II)-CONTAINING COMPLEX	Transcription in eukaryotes is a tightly regulated, multistep process. Gene-specific transcriptional activators, several different co-activators and general transcription factors are necessary to access specific loci to allow precise initiation of RNA polymerase II transcription. As the dense chromatin folding of the genome does not allow the access of these sites by the huge multiprotein transcription machinery, remodelling is required to loosen up the chromatin structure for successful transcription initiation. In the present review, we summarize the recent evolution of our under standing of the function of two histone acetyl transferases ( ATs) from metazoan organisms: GCN5 and PCAF. Their overall structure and the multiprotein complexes in which they are carrying out their activities are discussed. Metazoan GCN5 and PCAF are subunits of at least two types of multiprotein complexes, one having a molecular weight of 2MDa ( SPT3-TAF9-GCN5 acetyl transferase/ TATA binding protein ( TBP)-free-TAF complex/ PCAF complexes) and a second type with about a size of 700 kDa ( ATAC complex). These complexes possess global histone acetylation activity and locus-specific co-activatorfunctions together with AT activity on non-histone substrates. Thus, their biological functions cover a wide range of tasks and render them indispensable for the normal function of cells. That deregulation of the global and/or specific AT activities of these complexes leads to the cancerous transformation of the cells highlights their importance in cellular processes. The possible effects of GCN5 and PCAF in tumorigenesis are also discussed.	IGBMC, CNRS, UMR 7104, Transcript Dept, Illkirch Graffenstaden, France; Univ Strasbourg 1, INSERM, U596, Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Tora, L (corresponding author), IGBMC, CNRS, UMR 7104, Transcript Dept, BP 10142-67404, Illkirch Graffenstaden, France.	laszlo@igbmc.u-strasbg.fr	Tora, Laszlo/E-9999-2018	Tora, Laszlo/0000-0001-7398-2250				Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Akhtar A, 2000, MOL CELL, V5, P367, DOI 10.1016/S1097-2765(00)80431-1; Anafi M, 2000, MOL ENDOCRINOL, V14, P718, DOI 10.1210/me.14.5.718; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Avvakumov N, 2003, ONCOGENE, V22, P3833, DOI 10.1038/sj.onc.1206562; Baker SP, 2007, ONCOGENE, V26, P5329, DOI 10.1038/sj.onc.1210603; Bannister AJ, 2000, CELL MOL LIFE SCI, V57, P1184, DOI 10.1007/PL00000758; Barlev NA, 2003, MOL CELL BIOL, V23, P6944, DOI 10.1128/MCB.23.19.6944-6957.2003; Barrera LO, 2006, CURR OPIN CELL BIOL, V18, P291, DOI 10.1016/j.ceb.2006.04.002; Barsyte-Lovejoy D, 2006, CANCER RES, V66, P5330, DOI 10.1158/0008-5472.CAN-06-0037; Benkirane M, 1998, J BIOL CHEM, V273, P24898, DOI 10.1074/jbc.273.38.24898; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; BOOTSMA D, 1993, NATURE, V363, P114, DOI 10.1038/363114a0; Boulton SJ, 2006, BIOCHEM SOC T, V34, P633, DOI 10.1042/BST0340633; Boulton SJ, 2006, CELL CYCLE, V5, P1481, DOI 10.4161/cc.5.14.2930; Brand M, 1999, SCIENCE, V286, P2151, DOI 10.1126/science.286.5447.2151; Brand M, 2001, EMBO J, V20, P3187, DOI 10.1093/emboj/20.12.3187; Brand M, 1999, J BIOL CHEM, V274, P18285, DOI 10.1074/jbc.274.26.18285; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; Carey M, 2006, MOL CELL, V24, P481, DOI 10.1016/j.molcel.2006.09.012; Caron C, 2005, BIOESSAYS, V27, P408, DOI 10.1002/bies.20210; Carre C, 2005, MOL CELL BIOL, V25, P8228, DOI 10.1128/MCB.25.18.8228-8238.2005; Carrozza MJ, 2003, TRENDS GENET, V19, P321, DOI 10.1016/S0168-9525(03)00115-X; Carruthers LM, 2000, J BIOL CHEM, V275, P37285, DOI 10.1074/jbc.M006801200; Cavusoglu N, 2003, PROTEOMICS, V3, P217, DOI 10.1002/pmic.200390030; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Cheung WL, 2000, CURR OPIN CELL BIOL, V12, P326, DOI 10.1016/S0955-0674(00)00096-X; Ciurciu A, 2006, MOL CELL BIOL, V26, P9413, DOI 10.1128/MCB.01401-06; Clements A, 1999, EMBO J, V18, P3521, DOI 10.1093/emboj/18.13.3521; Das BK, 1999, MOL CELL BIOL, V19, P6796; de la Cruz X, 2005, BIOESSAYS, V27, P164, DOI 10.1002/bies.20176; Demeny MA, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000316; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Di Stefano V, 2005, ONCOGENE, V24, P5431, DOI 10.1038/sj.onc.1208717; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Eberharter A, 1999, MOL CELL BIOL, V19, P6621; Eberharter A, 2002, EMBO REP, V3, P224, DOI 10.1093/embo-reports/kvf053; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Feng LJ, 2005, MOL CELL BIOL, V25, P5389, DOI 10.1128/MCB.25.13.5389-5395.2005; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; Flinn EM, 2002, J BIOL CHEM, V277, P23399, DOI 10.1074/jbc.M201704200; Forsberg EC, 1997, BIOCHEMISTRY-US, V36, P15918, DOI 10.1021/bi971664x; Frank SR, 2003, EMBO REP, V4, P575, DOI 10.1038/sj.embor.embor861; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Fuks F, 1998, ONCOGENE, V17, P2531, DOI 10.1038/sj.onc.1202475; Georgieva S, 2000, MOL CELL BIOL, V20, P1639, DOI 10.1128/MCB.20.5.1639-1648.2000; Georgieva S, 2001, MOL CELL BIOL, V21, P5223, DOI 10.1128/MCB.21.15.5223-5231.2001; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; Govind CK, 2007, MOL CELL, V25, P31, DOI 10.1016/j.molcel.2006.11.020; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1999, J BIOL CHEM, V274, P5895, DOI 10.1074/jbc.274.9.5895; Grant PA, 1998, TRENDS CELL BIOL, V8, P193, DOI 10.1016/S0962-8924(98)01263-X; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Guelman S, 2006, MOL CELL BIOL, V26, P871, DOI 10.1128/MCB.26.3.871-882.2006; Guelman S, 2006, MOL CELL BIOL, V26, P7178, DOI 10.1128/MCB.00130-06; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Harrod R, 2000, J BIOL CHEM, V275, P11852, DOI 10.1074/jbc.275.16.11852; Harrod R, 2003, J BIOL CHEM, V278, P12310, DOI 10.1074/jbc.M211167200; Hassan AH, 2001, FRONT BIOSCI, V6, pD1054, DOI 10.2741/Hassan; Hassan AH, 2001, CELL, V104, P817, DOI 10.1016/S0092-8674(01)00279-3; Hassan AH, 2002, CELL, V111, P369, DOI 10.1016/S0092-8674(02)01005-X; Hassan AH, 2007, BIOCHEM J, V402, P125, DOI 10.1042/BJ20060907; Helmlinger D, 2006, PLOS BIOL, V4, P432, DOI 10.1371/journal.pbio.0040067; Helmlinger D, 2004, HUM MOL GENET, V13, P1257, DOI 10.1093/hmg/ddh139; Helmlinger D, 2006, TRENDS GENET, V22, P562, DOI 10.1016/j.tig.2006.07.010; Hudson BP, 2000, J MOL BIOL, V304, P355, DOI 10.1006/jmbi.2000.4207; Imoberdorf RM, 2006, MOL CELL BIOL, V26, P1610, DOI 10.1128/MCB.26.5.1610-1616.2006; Jia L, 2006, MOL CELL BIOL, V26, P7331, DOI 10.1128/MCB.00581-06; Jiang H, 1999, MOL CELL BIOL, V19, P8136; Johnson DG, 2006, CURR MOL MED, V6, P731; Kahata K, 2004, GENES CELLS, V9, P143, DOI 10.1111/j.1365-2443.2004.00706.x; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; Kikuchi H, 2005, GENE, V347, P83, DOI 10.1016/j.gene.2004.12.007; Kim SY, 2004, BIOGERONTOLOGY, V5, P305, DOI 10.1007/s10522-004-2568-x; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; Knoepfler PS, 2006, EMBO J, V25, P2723, DOI 10.1038/sj.emboj.7601152; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Krajewski WA, 1998, P NATL ACAD SCI USA, V95, P1540, DOI 10.1073/pnas.95.4.1540; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; KURABE N, 2007, ONCOGENE; Kurdistani SK, 2003, NAT REV MOL CELL BIO, V4, P276, DOI 10.1038/nrm1075; Kusch T, 2003, MOL CELL BIOL, V23, P3305, DOI 10.1128/MCB.23.9.3305-3319.2003; Lancaster JM, 1996, NAT GENET, V13, P238, DOI 10.1038/ng0696-238; Lang SE, 2001, J BIOL CHEM, V276, P32627, DOI 10.1074/jbc.M102067200; Lebedeva LA, 2005, P NATL ACAD SCI USA, V102, P18087, DOI 10.1073/pnas.0509063102; Leriche M., 1926, MEM SOC GEOL NORD, V32, P365; Lin HY, 2006, MED RES REV, V26, P397, DOI 10.1002/med.20056; Linares LK, 2007, NAT CELL BIOL, V9, P331, DOI 10.1038/ncb1545; Liu L, 1999, MOL CELL BIOL, V19, P1202; Liu XH, 2003, J BIOL CHEM, V278, P20405, DOI 10.1074/jbc.M211795200; Marmorstein R, 2001, CELL MOL LIFE SCI, V58, P693, DOI 10.1007/PL00000893; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; Martinez E, 1998, J BIOL CHEM, V273, P23781, DOI 10.1074/jbc.273.37.23781; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; Masumi A, 1999, MOL CELL BIOL, V19, P1810; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Morris SA, 2007, J BIOL CHEM, V282, P7632, DOI 10.1074/jbc.M607909200; Muratoglu S, 2003, MOL CELL BIOL, V23, P306, DOI 10.1128/MCB.23.1.306-321.2003; Mutskov V, 1998, MOL CELL BIOL, V18, P6293, DOI 10.1128/MCB.18.11.6293; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Oishi H, 2006, J BIOL CHEM, V281, P20, DOI 10.1074/jbc.M510157200; Owen DJ, 2000, EMBO J, V19, P6141, DOI 10.1093/emboj/19.22.6141; Palhan VB, 2005, P NATL ACAD SCI USA, V102, P8472, DOI 10.1073/pnas.0503505102; Pankotai T, 2005, MOL CELL BIOL, V25, P8215, DOI 10.1128/MCB.25.18.8215-8227.2005; Paulson M, 2002, NAT CELL BIOL, V4, P140, DOI 10.1038/ncb747; PINA B, 1993, MOL CELL BIOL, V13, P5981, DOI 10.1128/MCB.13.10.5981; Powell DW, 2004, MOL CELL BIOL, V24, P7249, DOI 10.1128/MCB.24.16.7249-7259.2004; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; Qi D, 2004, MOL CELL BIOL, V24, P8080, DOI 10.1128/MCB.24.18.8080-8089.2004; Roberts SM, 1996, MOL CELL BIOL, V16, P3206; Rockx DAP, 2000, P NATL ACAD SCI USA, V97, P10503, DOI 10.1073/pnas.180169797; Rodriguez-Navarro S, 2004, CELL, V116, P75, DOI 10.1016/S0092-8674(03)01025-0; Rojas JR, 1999, NATURE, V401, P93, DOI 10.1038/43487; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sanders SL, 2002, MOL CELL BIOL, V22, P4723, DOI 10.1128/MCB.22.13.4723-4738.2002; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672; Sermwittayawong D, 2006, EMBO J, V25, P3791, DOI 10.1038/sj.emboj.7601265; Shamoo Y, 2003, CURR OPIN STRUC BIOL, V13, P206, DOI 10.1016/S0959-440X(03)00033-2; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422; Shin S, 2003, P NATL ACAD SCI USA, V100, P7201, DOI 10.1073/pnas.1132020100; Shogren-Knaak M, 2006, SCIENCE, V311, P844, DOI 10.1126/science.1124000; Smith R, 1998, J MED SCREEN, V5, P5, DOI 10.1136/jms.5.1.5; Snijders PJF, 2006, J PATHOL, V208, P152, DOI 10.1002/path.1866; Soutoglou E, 2005, MOL CELL BIOL, V25, P4092, DOI 10.1128/MCB.25.10.4092-4104.2005; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Stockinger EJ, 2001, NUCLEIC ACIDS RES, V29, P1524, DOI 10.1093/nar/29.7.1524; Taubert S, 2004, MOL CELL BIOL, V24, P4546, DOI 10.1128/MCB.24.10.4546-4556.2004; Timmers HTM, 2005, TRENDS BIOCHEM SCI, V30, P7, DOI 10.1016/j.tibs.2004.11.007; Tora L, 2002, GENE DEV, V16, P673, DOI 10.1101/gad.976402; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; Turner N, 2005, CURR OPIN PHARMACOL, V5, P388, DOI 10.1016/j.coph.2005.03.006; Ura K, 2001, EMBO J, V20, P2004, DOI 10.1093/emboj/20.8.2004; Verdone L, 2005, BIOCHEM CELL BIOL, V83, P344, DOI 10.1139/o05-041; Vetting MW, 2005, ARCH BIOCHEM BIOPHYS, V433, P212, DOI 10.1016/j.abb.2004.09.003; Vlachonasios KE, 2003, PLANT CELL, V15, P626, DOI 10.1105/tpc.007922; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; Wang L, 2000, P NATL ACAD SCI USA, V97, P430, DOI 10.1073/pnas.97.1.430; Waterborg JH, 2000, J BIOL CHEM, V275, P13007, DOI 10.1074/jbc.275.17.13007; Wieczorek E, 1998, NATURE, V393, P187, DOI 10.1038/30283; Winston F, 1998, COLD SPRING HARB SYM, V63, P553, DOI 10.1101/sqb.1998.63.553; Wolffe AP, 2001, CELL, V104, P631, DOI 10.1016/S0092-8674(02)01453-8; Wu PYJ, 2004, MOL CELL, V15, P199, DOI 10.1016/j.molcel.2004.06.005; Xu WT, 1998, MOL CELL BIOL, V18, P5659, DOI 10.1128/MCB.18.10.5659; Xu WT, 2000, NAT GENET, V26, P229, DOI 10.1038/79973; Yamauchi T, 2000, P NATL ACAD SCI USA, V97, P11303, DOI 10.1073/pnas.97.21.11303; Yanagisawa J, 2002, MOL CELL, V9, P553, DOI 10.1016/S1097-2765(02)00478-1; Yang XJ, 2004, BIOESSAYS, V26, P1076, DOI 10.1002/bies.20104; Yang XJ, 2004, NUCLEIC ACIDS RES, V32, P959, DOI 10.1093/nar/gkh252; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Zeng L, 2002, FEBS LETT, V513, P124, DOI 10.1016/S0014-5793(01)03309-9; Zhu B, 2005, MOL CELL, V20, P601, DOI 10.1016/j.molcel.2005.09.025	166	288	294	2	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2007	26	37					5341	5357		10.1038/sj.onc.1210604	http://dx.doi.org/10.1038/sj.onc.1210604			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CR	17694077				2022-12-17	WOS:000248674300004
J	ELIOPOULOS, AG; KERR, DJ; HEROD, J; HODGKINS, L; KRAJEWSKI, S; REED, JC; YOUNG, LS				ELIOPOULOS, AG; KERR, DJ; HEROD, J; HODGKINS, L; KRAJEWSKI, S; REED, JC; YOUNG, LS			THE CONTROL OF APOPTOSIS AND DRUG-RESISTANCE IN OVARIAN-CANCER - INFLUENCE OF P53 AND BCL-2	ONCOGENE			English	Article						BCL-2; BAX; P53; OVARIAN; CISPLATIN; DRUG-RESISTANCE	PROGRAMMED CELL-DEATH; WILD-TYPE P53; B-CELLS; GENE AMPLIFICATION; ANTICANCER AGENTS; LEUKEMIC-CELLS; CYCLE CONTROL; C-MYC; PROTEIN; DNA	Modulation of apoptosis may influence resistance to chemotherapy and therefore affect the outcome of cancer treatment. Ovarian cancer, one of the most fatal malignancies in women, is often associated with drug resistance but the cellular pathways contributing to this effect remain obscure. We have found that Bcl-2 and p53, two proteins implicated in the control of apoptosis, are frequently expressed in fresh biopsies of primary ovarian carcinoma. Examination of Bcl-2 and p53 protein levels in pairs of cis-platin sensitive and resistant ovarian cell lines demonstrated that the resistant variants over-express Bcl-2 and/or p53, apparently due to progressive expansion of Bcl-2 and/or p53 positive subpopulations during the in vitro development of resistance. Exogenous expression of Bcl-2 or a temperature sensitive mutant p53 (ts p53) in the ovarian cell line A2780 resulted in protection from drug-induced apoptosis and a delay in drug-mediated S-phase arrest. Interestingly, p53 accumulation in response to DNA damage induced by different agents was significantly delayed and reduced in the Bcl-2 transfectants compared to the control A2780 line, suggesting that Bcl-2 may act upstream of the p53 pathway. Similarly, the induction of Bax mRNA and protein was also found to be delayed in the presence of Bcl-2. Overall, our data provide further evidence for cross-talk between Bcl-2, p53 and Bax and suggest that these genes are important determinants of drug-induced apoptosis thereby modulating resistance to chemotherapy.	UNIV BIRMINGHAM, SCH MED, CRC, INST CANC STUDIES, BIRMINGHAM B15 2TH, W MIDLANDS, ENGLAND; LA JOLLA CANC RES FDN, CANC RES CTR, LA JOLLA, CA 92037 USA	University of Birmingham; Sanford Burnham Prebys Medical Discovery Institute			Young, Lawrence S/B-7213-2009; ELIOPOULOS, ARISTIDES/R-9449-2018; ELIOPOULOS, ARISTIDES/ABI-6632-2020	Young, Lawrence S/0000-0003-3919-4298; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761	NCI NIH HHS [CA60138] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA060138] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEHRENS BC, 1987, CANCER RES, V47, P414; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BROWN R, 1993, INT J CANCER, V55, P678, DOI 10.1002/ijc.2910550428; CAMPOS L, 1993, BLOOD, V81, P3091; CANNISTRA SA, 1993, NEW ENGL J MED, V329, P1550, DOI 10.1056/NEJM199311183292108; CHANG EH, 1987, SCIENCE, V237, P1036, DOI 10.1126/science.3616624; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CLEARY ML, 1987, CELL, V47, P2537; COLOMBEL M, 1993, AM J PATHOL, V143, P390; DAWSON CW, 1995, ONCOGENE, V10, P69; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DIVE C, 1991, BRIT J CANCER, V64, P192, DOI 10.1038/bjc.1991.269; DIVE C, 1993, FRONTIERS PHARM CANC, P21; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; EASTMAN A, 1991, MOL CLIN ADV ANTICAN, P233; EASTMAN A, 1994, NEW MOL TARGETS CANC, P143; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FRITSCHE M, 1993, ONCOGENE, V8, P307; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAGUE A, 1994, ONCOGENE, V9, P3367; HALDAR S, 1994, CANCER RES, V54, P2095; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KASTAN MB, 1991, CANCER RES, V51, P6304; KELLAND LR, 1992, CANCER RES, V52, P3857; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KUPRYJANCZYK J, 1993, P NATL ACAD SCI USA, V90, P4961, DOI 10.1073/pnas.90.11.4961; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEEK RD, 1994, BRIT J CANCER, V69, P135, DOI 10.1038/bjc.1994.22; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARKS JR, 1991, CANCER RES, V51, P2979; MASUDA H, 1990, CANCER RES, V50, P1863; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1992, CANCER RES, V52, P5407; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MONTENARH M, 1992, INT J ONCOL, V1, P37; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PEZZELLA F, 1993, NEW ENGL J MED, V329, P690, DOI 10.1056/NEJM199309023291003; SACHS L, 1993, BLOOD, V82, P15, DOI 10.1182/blood.V82.1.15.bloodjournal82115; Sambrook J., 1989, MOL CLONING LAB MANU; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SILVESTRINI R, 1994, J NATL CANCER I, V86, P499, DOI 10.1093/jnci/86.7.499; SPANDIDOS DA, 1984, IN VITRO TRANSCRIPTI, P1; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; TEYSSIER JR, 1989, CANCER GENET CYTOGEN, V39, P35, DOI 10.1016/0165-4608(89)90227-6; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; TSUJIMOTO Y, 1989, ONCOGENE, V4, P1331; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YUNIS JJ, 1989, NEW ENGL J MED, V320, P1047, DOI 10.1056/NEJM198904203201605; ZHAN QM, 1994, ONCOGENE, V9, P3743	74	288	301	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	1995	11	7					1217	1228						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478541				2022-12-17	WOS:A1995RY96700001
J	OHTANIFUJITA, N; FUJITA, T; AOIKE, A; OSIFCHIN, NE; ROBBINS, PD; SAKAI, T				OHTANIFUJITA, N; FUJITA, T; AOIKE, A; OSIFCHIN, NE; ROBBINS, PD; SAKAI, T			CPG METHYLATION INACTIVATES THE PROMOTER ACTIVITY OF THE HUMAN RETINOBLASTOMA TUMOR-SUPPRESSOR GENE	ONCOGENE			English	Article							DNA METHYLATION; TRANSCRIPTIONAL ACTIVATION; TUMORIGENIC EXPRESSION; CYTOSINE METHYLATION; HUMAN CHROMOSOME-11; HUMAN NEOPLASIA; FACTOR BINDING; HUMAN CANCERS; SP1; HYPOMETHYLATION	Cytosine methylation of CpG sites in the promoter region of eucaryotic genes is involved in the inactivation of expression of certain genes. Given that methylation can lead to reduced transcription, it is possible that expression of tumor-suppressor genes is also inactivated by hypermethylation, thereby contributing to the etiology of cancer. Recently we found five sporadic retinoblastoma tumors (16% of all unilateral cases) with hypermethylation of the 5' end of the retinoblastoma gene without detecting any structural abnormalities. However, it is unclear whether the promoter of the retinoblastoma gene is actually inactivated by its hypermethylation. Here we show that specific hypermethylation in the promoter region of the retinoblastoma gene reduces its expression to only 8% of the unmethylated control. Furthermore, we have found that two transcription factors important for the promoter activity, an activating transcription factor (ATF)-like factor and the retinoblastoma binding factor 1, do not bind when their recognition sequences are CpG methylated. These results in vitro strongly support the hypothesis that CpG methylation of the human tumor-suppressor gene can result in the inactivation of the gene and thus lead to oncogenesis.	KYOTO PREFECTURAL UNIV MED,DEPT PREVENT MED,KAMIKYO KU,KYOTO 602,JAPAN; UNIV PITTSBURGH,SCH MED,DEPT MOLEC GENET & BIOCHEM,PITTSBURGH,PA 15261	Kyoto Prefectural University of Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								ADAMS RLP, 1990, BIOCHEM J, V265, P309, DOI 10.1042/bj2650309; BAYLIN SB, 1991, CANCER CELL-MON REV, V3, P383; BENHATTAR J, 1989, NUCLEIC ACIDS RES, V17, P10179, DOI 10.1093/nar/17.24.10179; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; CHEAH MSC, 1984, JNCI-J NATL CANCER I, V73, P1057; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; DEBUSTROS A, 1988, P NATL ACAD SCI USA, V85, P5693; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; FEINBERG AP, 1983, BIOCHEM BIOPH RES CO, V111, P47, DOI 10.1016/S0006-291X(83)80115-6; GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435; GREGER V, 1989, HUM GENET, V83, P155, DOI 10.1007/BF00286709; HARRINGTON MA, 1988, P NATL ACAD SCI USA, V85, P2066, DOI 10.1073/pnas.85.7.2066; HOLLER M, 1988, GENE DEV, V2, P1127, DOI 10.1101/gad.2.9.1127; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Jones P A, 1990, Adv Cancer Res, V54, P1, DOI 10.1016/S0065-230X(08)60806-4; JONES PA, 1986, CANCER RES, V46, P461; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; MAKOS M, 1992, P NATL ACAD SCI USA, V89, P1929, DOI 10.1073/pnas.89.5.1929; SAKAI T, 1991, AM J HUM GENET, V48, P880; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816	27	288	298	0	11	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					1063	1067						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455933				2022-12-17	WOS:A1993KT22000031
J	SUNDARESAN, V; GANLY, P; HASLETON, P; RUDD, R; SINHA, G; BLEEHEN, NM; RABBITTS, P				SUNDARESAN, V; GANLY, P; HASLETON, P; RUDD, R; SINHA, G; BLEEHEN, NM; RABBITTS, P			P53 AND CHROMOSOME-3 ABNORMALITIES, CHARACTERISTIC OF MALIGNANT LUNG-TUMORS, ARE DETECTABLE IN PREINVASIVE LESIONS OF THE BRONCHUS	ONCOGENE			English	Article							POLYMERASE CHAIN-REACTION; REACTION PCR; THRB GENE; BAMHI POLYMORPHISM; RSAI POLYMORPHISM; SUPPRESSOR GENE; D3S32 LOCUS; REGION 3P21; CELL-LINES; CANCER	Bronchial epithelial dysplasia is believed to precede invasive squamous cell carcinoma of the lung. Six paired dysplasia and tumour samples were distinguished histologically in sections of formalin-fixed paraffin-embedded lung tissue from patients with lung cancer. Additionally, samples of dysplastic bronchial epithelium were obtained from patients without lung tumours. Microdissection of the unstained sections provided dysplastic and tumour samples from which DNA was prepared for comparison with the patients' constitutional genotype, using polymerase chain reaction-based restriction fragment length polymorphism analysis. All six samples of tumour and the paired adjacent samples of bronchial dysplasia showed loss of heterozygosity (LOH) at loci on the short arm of chromosome 3. Five of the six cases showed involvement of the p53 gene as assessed by LOH at the AccII site within the gene, and by immunoreactivity to CM-1, an antibody which recognizes the mutated form of the p53 protein in paraffin-embedded material. Of the dysplastic samples, obtained from patients without invasive tumours, all three showed LOH at 3p; one sample showed LOH at the AccII polymorphic locus within the p53 gene, and another sample, uninformative at this locus, stained positively with this antibody. These results indicate that somatic genetic changes are present in preinvasive lesions in the bronchus.	MRC,CLIN ONCOL & RADIOTHERAPEUT UNIT,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND; ADDENBROOKES HOSP,DEPT HISTOPATHOL,CAMBRIDGE CB2 2QQ,ENGLAND; LONDON CHEST HOSP,DEPT RESP MED,LONDON E2 9JX,ENGLAND; WYTHENSHAWE HOSP,REG CARDIOTHORAC CTR,DEPT PATHOL,MANCHESTER M23 9LT,LANCS,ENGLAND; LONDON CHEST HOSP,DEPT PATHOL,LONDON E2 9JX,ENGLAND	University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of London; Queen Mary University London; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; University of London; Queen Mary University London				Ganly, Peter/0000-0003-0335-2063				AUERBACH O, 1962, NEW ENGL J MED, V267, P111, DOI 10.1056/NEJM196207192670301; AUERBACH O, 1957, NEW ENGL J MED, V256, P97, DOI 10.1056/NEJM195701172560301; AUERBACH O, 1979, NEW ENGL J MED, V300, P381, DOI 10.1056/NEJM197902223000801; BARTEK J, 1991, ONCOGENE, V6, P1699; BUYS C, 1991, EUR J CANCER S2, V27, P82; CHIBA I, 1990, ONCOGENE, V5, P1603; DELACALLEMARTIN O, 1990, NUCLEIC ACIDS RES, V18, P4963, DOI 10.1093/nar/18.16.4963; DONTI E, 1990, HUM GENET, V84, P391; ERLANDSSON R, 1990, ONCOGENE, V5, P1207; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GANLY PS, 1992, GENOMICS, V12, P221, DOI 10.1016/0888-7543(92)90369-4; GANLY PS, 1991, NUCLEIC ACIDS RES, V19, P3761, DOI 10.1093/nar/19.13.3761; GANLY PS, 1991, NUCLEIC ACIDS RES, V19, P3760; GANLY PS, 1991, NUCLEIC ACIDS RES, V19, P3757, DOI 10.1093/nar/19.13.3757-a; GANLY PS, 1991, NUCLEIC ACIDS RES, V19, P3758, DOI 10.1093/nar/19.13.3758; GEBERT JF, 1991, ONCOGENE, V6, P1859; GORADIA TM, 1991, GENOMICS, V10, P748, DOI 10.1016/0888-7543(91)90459-R; GREENWALD BD, 1992, CANCER RES, V52, P741; GUSTERSON BA, 1991, ONCOGENE, V6, P1785; HOULE B, 1991, GENE CHROMOSOME CANC, V3, P358, DOI 10.1002/gcc.2870030506; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; HUNG J, 1991, LASER SURG MED, V11, P99, DOI 10.1002/lsm.1900110203; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; KIM JH, 1991, J NATL CANCER I, V83, P938, DOI 10.1093/jnci/83.13.938; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MELTZER SJ, 1991, P NATL ACAD SCI USA, V88, P4976, DOI 10.1073/pnas.88.11.4976; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MITSUDOMI T, 1992, ONCOGENE, V7, P171; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; OKA K, 1991, MOL CARCINOGEN, V4, P10, DOI 10.1002/mc.2940040104; PAABO S, 1989, J BIOL CHEM, V264, P9709; PAL N, 1990, ONCOGENE, V5, P1665; PONDER B, 1988, NATURE, V335, P400, DOI 10.1038/335400a0; RABBITTS P, 1989, GENE CHROMOSOME CANC, V1, P95, DOI 10.1002/gcc.2870010115; RABBITTS PH, 1991, DIAGN ONCOL, V1, P298; SHIBATA D, 1988, CANCER RES, V48, P4564; SOZZI G, 1991, CANCER RES, V51, P400; STRETCH JR, 1991, CANCER RES, V51, P5976; TOKUDA Y, 1990, J CLIN PATHOL, V43, P748, DOI 10.1136/jcp.43.9.748; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; WILKINS RJ, 1988, LANCET, V1, P329; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153; YAMADA Y, 1991, CANCER RES, V51, P5800	47	288	291	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					1989	1997						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408139				2022-12-17	WOS:A1992JP42400012
J	Goldsmith, ZG; Dhanasekaran, DN				Goldsmith, Z. G.; Dhanasekaran, D. N.			G protein regulation of MAPK networks	ONCOGENE			English	Review						GPCR; signal transduction; G protein; MAPK; oncogene; cancer	N-TERMINAL KINASE; NUCLEOTIDE-EXCHANGE FACTOR; JUN NH2-TERMINAL KINASE; GROWTH-FACTOR RECEPTOR; G-BETA-GAMMA; HETEROTRIMERIC G-PROTEINS; RAS-DEPENDENT ACTIVATION; MUTANT ALPHA-SUBUNIT; MUSCARINIC ACETYLCHOLINE-RECEPTORS; EMBRYONAL CARCINOMA-CELLS	G proteins provide signal-coupling mechanisms to heptahelical cell surface receptors and are critically involved in the regulation of different mitogen-activated protein kinase (MAPK) networks. The four classes of G proteins, defined by the G(s), G(i), G(q) and G(12) families, regulate ERK1/2, JNK, p38MAPK, ERK5 and ERK6 modules by different mechanisms. The alpha- as well as beta gamma-subunits are involved in the regulation of these MAPK modules in a context-specific manner. While the alpha- and beta gamma-subunits primarily regulate the MAPK pathways via their respective effector-mediated signaling pathways, recent studies have unraveled several novel signaling intermediates including receptor tyrosine kinases and small GTPases through which these G-protein subunits positively as well as negatively regulate specific MAPK modules. Multiple mechanisms together with specific scaffold proteins that can link G-protein-coupled receptors or G proteins to distinct MAPK modules contribute to the context-specific and spatio-temporal regulation of mitogen-activated protein signaling networks by G proteins.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19104 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Dhanasekaran, DN (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19104 USA.	danny001@temple.edu			NIGMS NIH HHS [GM 49897] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn YH, 2005, CANCER RES, V65, P4896, DOI 10.1158/0008-5472.CAN-04-3122; Ahn YH, 2006, J CELL PHYSIOL, V209, P1039, DOI 10.1002/jcp.20821; Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; Ambrosini A, 2000, MOL BRAIN RES, V75, P54, DOI 10.1016/S0169-328X(99)00294-6; Amsen EM, 2006, J BIOL CHEM, V281, P121, DOI 10.1074/jbc.M507595200; ARAGAY AM, 1995, J BIOL CHEM, V270, P20073, DOI 10.1074/jbc.270.34.20073; Arai K, 2003, MOL PHARMACOL, V63, P478, DOI 10.1124/mol.63.3.478; Araki S, 1997, KIDNEY INT, V51, P631, DOI 10.1038/ki.1997.92; Berestetskaya YV, 1998, J BIOL CHEM, V273, P27816, DOI 10.1074/jbc.273.43.27816; Blaukat A, 1999, J BIOL CHEM, V274, P14893, DOI 10.1074/jbc.274.21.14893; Blaukat A, 2000, MOL CELL BIOL, V20, P6837, DOI 10.1128/MCB.20.18.6837-6848.2000; Boire A, 2005, CELL, V120, P303, DOI 10.1016/j.cell.2004.12.018; Booden MA, 2004, MOL CELL BIOL, V24, P1990, DOI 10.1128/MCB.24.5.1990-1999.2004; Booden MA, 2002, MOL CELL BIOL, V22, P4053, DOI 10.1128/MCB.22.12.4053-4061.2002; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Bos JL, 2006, TRENDS BIOCHEM SCI, V31, P680, DOI 10.1016/j.tibs.2006.10.002; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Buchsbaum RJ, 2002, MOL CELL BIOL, V22, P4073, DOI 10.1128/MCB.22.12.4073-4085.2002; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; Chadee DN, 2004, NAT CELL BIOL, V6, P770, DOI 10.1038/ncb1152; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chikumi H, 2002, J BIOL CHEM, V277, P12463, DOI 10.1074/jbc.M108504200; Coffield VM, 2004, J EXP MED, V200, P1315, DOI 10.1084/jem.20040944; Collins LR, 1997, ONCOGENE, V15, P595, DOI 10.1038/sj.onc.1201220; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; Conway AM, 1999, BIOCHEM J, V337, P171, DOI 10.1042/0264-6021:3370171; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; Coso OA, 1996, J BIOL CHEM, V271, P3963; Crespo P, 1996, ONCOGENE, V13, P455; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DAAKA Y, 2004, SCI STKE, V216, P2; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Deng JB, 1998, J BIOL CHEM, V273, P16787, DOI 10.1074/jbc.273.27.16787; Denis-Henriot D, 1998, ENDOCRINOLOGY, V139, P2892, DOI 10.1210/en.139.6.2892; Dermott JM, 2004, ONCOGENE, V23, P226, DOI 10.1038/sj.onc.1207009; DHANASEKARAN DN, 2006, SCI STKE, V347, pPE31; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; Dhanasekaran N, 1998, ONCOGENE, V17, P1447, DOI 10.1038/sj.onc.1202251; Dhanasekaran N, 1998, BIOL SIGNAL RECEPT, V7, P109; Dhillon AS, 2002, MOL CELL BIOL, V22, P3237, DOI 10.1128/MCB.22.10.3237-3246.2002; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; DOLKI F, 1998, P NATL ACAD SCI USA, V95, P15394; Dumaz N, 2005, FEBS J, V272, P3491, DOI 10.1111/j.1742-4658.2005.04763.x; Edamatsu H, 1998, FEBS LETT, V440, P231, DOI 10.1016/S0014-5793(98)01457-4; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Elion EA, 2001, J CELL SCI, V114, P3967; Elion EA, 2005, SCIENCE, V307, P687, DOI 10.1126/science.1109500; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; FAURE M, 1994, J BIOL CHEM, V269, P7851; Fleming Y, 2000, BIOCHEM J, V352, P145, DOI 10.1042/0264-6021:3520145; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Fukue M, 2000, DEV ARID REG RES SER, V1, P13; Fukuhara S, 2000, J BIOL CHEM, V275, P21730, DOI 10.1074/jbc.M002410200; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gerasimovskaya EV, 2002, J BIOL CHEM, V277, P44638, DOI 10.1074/jbc.M203012200; Ghosh SK, 2002, J BIOL CHEM, V277, P21325, DOI 10.1074/jbc.M201608200; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Girardin SE, 2001, EMBO J, V20, P3437, DOI 10.1093/emboj/20.13.3437; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; GOULD KL, 1985, CELL, V42, P849, DOI 10.1016/0092-8674(85)90281-8; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; Gros R, 2006, CIRC RES, V99, P845, DOI 10.1161/01.RES.0000245189.21703.c0; Gross EA, 2002, J BIOL CHEM, V277, P13873, DOI 10.1074/jbc.M111994200; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Guo FF, 2001, J BIOL CHEM, V276, P25568, DOI 10.1074/jbc.M101277200; GUPTA KC, 1992, INT J MICROWAVE MILL, V2, P1; GUPTA SK, 1992, MOL CELL BIOL, V12, P190, DOI 10.1128/MCB.12.1.190; Gutkind JS, 1998, CONT ENDOCRINOL, V6, P101; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; GUTKIND JS, 2000, SCI STKE, V40, P1; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; Higashiyama S, 2005, BBA-PROTEINS PROTEOM, V1751, P110, DOI 10.1016/j.bbapap.2004.11.009; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; HOUSLAY MD, 2006, SCI STKE, V349, pPE32; Huang CC, 2004, J BIOL CHEM, V279, P12286, DOI 10.1074/jbc.M312868200; Hubbard KB, 2006, CELL SIGNAL, V18, P135, DOI 10.1016/j.cellsig.2005.08.004; Ichiba T, 1999, J BIOL CHEM, V274, P14376, DOI 10.1074/jbc.274.20.14376; Iwasaki H, 1999, ENDOCRINOLOGY, V140, P4659, DOI 10.1210/en.140.10.4659; Jho EH, 1997, J BIOL CHEM, V272, P24468, DOI 10.1074/jbc.272.39.24468; Jho EH, 1997, J BIOL CHEM, V272, P24461, DOI 10.1074/jbc.272.39.24461; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454; JOHNSON GL, 1989, ENDOCR REV, V10, P317, DOI 10.1210/edrv-10-3-317; Kam AYF, 2004, J NEUROCHEM, V89, P391, DOI 10.1111/j.1471-4159.2004.02338.x; Kashef K, 2005, BIOCHEMISTRY-US, V44, P14090, DOI 10.1021/bi050604l; Kashef K, 2006, J CELL BIOCHEM, V98, P715, DOI 10.1002/jcb.20930; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Kim KY, 2004, J BIOL CHEM, V279, P29478, DOI 10.1074/jbc.M313947200; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Kodama H, 2003, HYPERTENSION, V41, P1372, DOI 10.1161/01.HYP.0000069698.11814.F4; Kohout TA, 2003, MOL PHARMACOL, V63, P9, DOI 10.1124/mol.63.1.9; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; Kranenburg O, 2001, ONCOGENE, V20, P1540, DOI 10.1038/sj.onc.1204187; Kranenburg O, 1999, BIOCHEM J, V339, P11, DOI 10.1042/0264-6021:3390011; Kranenburg O, 1997, EMBO J, V16, P3097, DOI 10.1093/emboj/16.11.3097; Kranenburg O, 1999, J BIOL CHEM, V274, P35301, DOI 10.1074/jbc.274.50.35301; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; Kumar RN, 2006, MOL CELL BIOL, V26, P50, DOI 10.1128/MCB.26.1.50-62.2006; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; Laroche-Joubert N, 2002, J BIOL CHEM, V277, P18598, DOI 10.1074/jbc.M201868200; Lawler S, 1998, CURR BIOL, V8, P1387, DOI 10.1016/S0960-9822(98)00019-0; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; Lee CM, 2002, P NATL ACAD SCI USA, V99, P14189, DOI 10.1073/pnas.232310199; Lee YN, 2004, J BIOL CHEM, V279, P54896, DOI 10.1074/jbc.M407581200; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Lisnock J, 2000, BIOCHEMISTRY-US, V39, P3141, DOI 10.1021/bi992410+; Liu JL, 1997, J BIOL CHEM, V272, P29438, DOI 10.1074/jbc.272.47.29438; LOWNDES JM, 1991, J BIOL CHEM, V266, P14193; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; Mao JH, 1998, EMBO J, V17, P5638, DOI 10.1093/emboj/17.19.5638; Marinissen MJ, 2003, J BIOL CHEM, V278, P46814, DOI 10.1074/jbc.M305709200; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; Marinissen MT, 2001, GENE DEV, V15, P535, DOI 10.1101/gad.855801; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Minamino T, 2002, P NATL ACAD SCI USA, V99, P3866, DOI 10.1073/pnas.062453699; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MITCHELL FM, 1995, BIOCHEM J, V309, P381, DOI 10.1042/bj3090381; Mitsui H, 1997, J BIOL CHEM, V272, P4904, DOI 10.1074/jbc.272.8.4904; Miyamoto Y, 2003, J BIOL CHEM, V278, P29890, DOI 10.1074/jbc.M301559200; Mochizuki N, 2000, J BIOL CHEM, V275, P12667, DOI 10.1074/jbc.275.17.12667; Mochizuki N, 1999, NATURE, V400, P891, DOI 10.1038/23738; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; MOYERS JS, 1993, MOL CELL BIOL, V13, P2391, DOI 10.1128/MCB.13.4.2391; Murasawa S, 1998, CIRC RES, V82, P1338, DOI 10.1161/01.RES.82.12.1338; Nagao M, 1999, ONCOGENE, V18, P4425, DOI 10.1038/sj.onc.1202832; Nagao M, 1998, J BIOL CHEM, V273, P22892, DOI 10.1074/jbc.273.36.22892; Needham LK, 1998, J BIOL CHEM, V273, P14626, DOI 10.1074/jbc.273.23.14626; Norum JH, 2007, FEBS LETT, V581, P15, DOI 10.1016/j.febslet.2006.11.069; Norum JH, 2005, FEBS J, V272, P2304, DOI 10.1111/j.1742-4658.2005.04658.x; Norum JH, 2003, J BIOL CHEM, V278, P3098, DOI 10.1074/jbc.M206237200; Obara Y, 2004, J CELL SCI, V117, P6085, DOI 10.1242/jcs.01527; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; Ohtsu H, 2006, AM J PHYSIOL-CELL PH, V291, pC1, DOI 10.1152/ajpcell.00620.2005; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; PACE AM, 1995, MOL BIOL CELL, V6, P1685, DOI 10.1091/mbc.6.12.1685; Pearson GW, 2006, MOL CELL BIOL, V26, P3039, DOI 10.1128/MCB.26.8.3039-3047.2006; PIZON V, 1988, ONCOGENE, V3, P201; POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211; Praefcke GJK, 2004, NAT REV MOL CELL BIO, V5, P133, DOI 10.1038/nrm1313; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Quilliam LA, 2002, PROG NUCLEIC ACID RE, V71, P391, DOI 10.1016/S0079-6603(02)71047-7; Radhika V, 2004, J BIOL CHEM, V279, P49406, DOI 10.1074/jbc.M408836200; Radhika V, 2001, ONCOGENE, V20, P1607, DOI 10.1038/sj.onc.1204274; Ramirez MT, 1997, J BIOL CHEM, V272, P14057, DOI 10.1074/jbc.272.22.14057; Roy S, 2002, MOL CELL BIOL, V22, P5128, DOI 10.1128/MCB.22.14.5128-5140.2002; Rozengurt E, 1998, J CELL PHYSIOL, V177, P507, DOI 10.1002/(SICI)1097-4652(199812)177:4<507::AID-JCP2>3.0.CO;2-K; Schafer B, 2004, ONCOGENE, V23, P991, DOI 10.1038/sj.onc.1207278; Schmitt JM, 2000, J BIOL CHEM, V275, P25342, DOI 10.1074/jbc.M003213200; Schmitt JM, 2002, J BIOL CHEM, V277, P43024, DOI 10.1074/jbc.M204006200; Schmitt JM, 2002, MOL CELL, V9, P85, DOI 10.1016/S1097-2765(01)00432-4; Schmitt JM, 2001, MOL CELL BIOL, V21, P3671, DOI 10.1128/MCB.21.11.3671-3683.2001; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Sellers LA, 1999, J BIOL CHEM, V274, P16423, DOI 10.1074/jbc.274.23.16423; Servitja JM, 2003, J BIOL CHEM, V278, P34339, DOI 10.1074/jbc.M302960200; SEUWEN K, 1992, ADV CANCER RES, V58, P75, DOI 10.1016/S0065-230X(08)60291-2; Shan DD, 2006, DEV CELL, V10, P707, DOI 10.1016/j.devcel.2006.03.014; Shapiro PS, 1996, J BIOL CHEM, V271, P5750, DOI 10.1074/jbc.271.10.5750; Shenoy SK, 2003, BIOCHEM J, V375, P503, DOI 10.1042/BJ20031076; SHOU CC, 1995, ONCOGENE, V10, P1887; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Sodhi A, 2000, CANCER RES, V60, P4873; Soltoff SP, 1998, J BIOL CHEM, V273, P23110, DOI 10.1074/jbc.273.36.23110; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Sun WY, 2001, J BIOL CHEM, V276, P5093, DOI 10.1074/jbc.M003719200; Suzuki N, 2003, P NATL ACAD SCI USA, V100, P733, DOI 10.1073/pnas.0234057100; Takahashi M, 2003, J BIOCHEM, V133, P181, DOI 10.1093/jb/mvg022; Takeuchi Y, 2003, J NEUROCHEM, V85, P729, DOI 10.1046/j.1471-4159.2003.01711.x; Tanaka S, 1998, J BIOL CHEM, V273, P1281, DOI 10.1074/jbc.273.3.1281; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; Todisco A, 1997, AM J PHYSIOL-GASTR L, V272, pG721, DOI 10.1152/ajpgi.1997.272.4.G721; Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Tsygankova OM, 2000, ONCOGENE, V19, P3609, DOI 10.1038/sj.onc.1203680; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; VAN BT, 1995, NATURE, V376, P781; Vomastek T, 2004, P NATL ACAD SCI USA, V101, P6981, DOI 10.1073/pnas.0305894101; von Kriegsheim A, 2006, NAT CELL BIOL, V8, P1011, DOI 10.1038/ncb1465; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Wan Y, 1998, J BIOL CHEM, V273, P14533, DOI 10.1074/jbc.273.23.14533; Wang HY, 2002, J BIOL CHEM, V277, P3530, DOI 10.1074/jbc.M107031200; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; Wang YP, 2006, J BIOL CHEM, V281, P35965, DOI 10.1074/jbc.M605503200; Wang ZP, 2006, MOL CELL BIOL, V26, P2130, DOI 10.1128/MCB.26.6.2130-2145.2006; Waters CM, 2005, CELL SIGNAL, V17, P263, DOI 10.1016/j.cellsig.2004.07.011; Weissman JT, 2004, ONCOGENE, V23, P241, DOI 10.1038/sj.onc.1207014; Werry TD, 2005, TRENDS ENDOCRIN MET, V16, P26, DOI 10.1016/j.tem.2004.11.008; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Wunderlich L, 1999, CELL SIGNAL, V11, P25, DOI 10.1016/S0898-6568(98)00027-8; Wylie PG, 1999, BIOCHEM J, V338, P619, DOI 10.1042/0264-6021:3380619; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; Yamaguchi Y, 2002, CURR BIOL, V12, P1353, DOI 10.1016/S0960-9822(02)01034-5; Yamauchi J, 2000, J BIOL CHEM, V275, P7633, DOI 10.1074/jbc.275.11.7633; Yamauchi J, 1999, J BIOL CHEM, V274, P1957, DOI 10.1074/jbc.274.4.1957; Yamauchi J, 2001, BIOCHEM BIOPH RES CO, V281, P1019, DOI 10.1006/bbrc.2001.4472; Yamauchi JJ, 1997, J BIOL CHEM, V272, P27771, DOI 10.1074/jbc.272.44.27771; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Zheng M, 2000, J BIOL CHEM, V275, P40635, DOI 10.1074/jbc.M006325200; Zhong M, 2003, ENDOCRINOLOGY, V144, P2947, DOI 10.1210/en.2002-221039; Zhu DG, 2004, J BIOL CHEM, V279, P54983, DOI 10.1074/jbc.C400508200; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160; Zwick E, 1997, J BIOL CHEM, V272, P24767, DOI 10.1074/jbc.272.40.24767	245	287	293	3	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2007	26	22					3122	3142		10.1038/sj.onc.1210407	http://dx.doi.org/10.1038/sj.onc.1210407			21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169PH	17496911				2022-12-17	WOS:000246603600004
J	Brenner, C; Cadiou, H; Vieira, HLA; Zamzami, N; Marzo, I; Xie, ZH; Leber, B; Andrews, D; Duclohier, H; Reed, JC; Kroemer, G				Brenner, C; Cadiou, H; Vieira, HLA; Zamzami, N; Marzo, I; Xie, ZH; Leber, B; Andrews, D; Duclohier, H; Reed, JC; Kroemer, G			Bcl-2 and Bax regulate the channel activity of the mitochondrial adenine nucleotide translocator	ONCOGENE			English	Article						anti-oncogene; mitochondrial transmembrane potential; oncogene; permeability transition; planar lipid bilayer	PERMEABILITY TRANSITION PORE; CYTOCHROME-C; ION-CHANNEL; IN-VIVO; APOPTOSIS; MEMBRANES; RELEASE; CYCLOPHILIN; PROTEINS; FORMS	Bcl-2 family protein including anti-apoptotic (Bcl-2) or pro-apoptotic (Bax) members can form ion channels when incorporated into synthetic lipid bilayers. This contrasts with the observation that Bcl-2 stabilizes the mitochondrial membrane barrier function and inhibits the permeability transition pore complex (PTPC). Here we provide experimental data which may explain this apparent paradox. Bax and adenine nucleotide translocator (ANT), the most abundant inner mitochondrial membrane protein, can interact in artificial lipid bilayers to yield an efficient composite channel whose electrophysiological properties differ quantitatively and qualitatively from the channels formed by Bax or ANT alone. The formation of this composite channel can be observed in conditions in which Bax protein alone has no detectable channel activity. Cooperative channel formation by Bax and ANT is stimulated by the ANT ligand atractyloside (Atr) but inhibited by ATP, indicating that it depends on the conformation of ANT. In contrast to the combination of Bax and ANT, ANT does not form active channels when incorporated into membranes with Bcl-2. Rather, ANT and Bcl-2 exhibit mutual inhibition of channel formation. Bcl-2 prevents channel formation by Atr-treated ANT and neutralizes the cooperation between Bax and ANT. Our data are compatible with a menage a trois model of mitochondrial apoptosis regulation in which ANT, the likely pore forming protein within the PTPC, interacts with Bax or Bcl-2 which influence its pore forming potential in opposing manners.	Ctr Natl Rech Sci, UPR420, F-94801 Villejuif, France; Univ Technol Compiegne, Ctr Natl Rech Sci, UPRESA6022, F-60205 Compiegne, France; Univ Rouen, Ctr Natl Rech Sci, UMR6522, IFRMP 23, F-76821 Mont St Aignan, France; Burnham Inst, La Jolla, CA 92037 USA; McMaster Univ, Med Ctr, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Picardie Universites; Universite de Technologie de Compiegne; Centre National de la Recherche Scientifique (CNRS); Universite de Rouen Normandie; Sanford Burnham Prebys Medical Discovery Institute; McMaster University; McMaster University	Kroemer, G (corresponding author), 19 Rue Guy Moquet,BP 8, F-94801 Villejuif, France.		Marzo, Isabel/E-6918-2016; KROEMER, Guido/B-4263-2013; Vieira, Helena/AAZ-9562-2021; brenner, catherine/AAE-8632-2020; Kroemer, Guido/AAY-9859-2020	Marzo, Isabel/0000-0002-2315-9079; KROEMER, Guido/0000-0002-9334-4405; Leber, Brian/0000-0001-5502-1480; Vieira, Helena/0000-0001-9415-3742	NIA NIH HHS [AG 15393] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG015393] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BRULLEMANS M, 1994, EUR BIOPHYS J BIOPHY, V23, P39, DOI 10.1007/BF00192204; Brustovetsky N, 1996, BIOCHEMISTRY-US, V35, P8483, DOI 10.1021/bi960833v; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; GironCalle J, 1996, BIOCHEMISTRY-US, V35, P15440, DOI 10.1021/bi960840j; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HANKE W, 1984, BIOELECTROCH BIOENER, V12, P329, DOI 10.1016/0302-4598(84)87013-0; HILLE B, 1984, IONIC CHANNELS EXCIT, P226; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mancini M, 1998, J CELL BIOL, V140, P1485, DOI 10.1083/jcb.140.6.1485; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Matsuyama S, 1998, J BIOL CHEM, V273, P30995, DOI 10.1074/jbc.273.47.30995; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; MONTAL M, 1972, P NATL ACAD SCI USA, V69, P3561, DOI 10.1073/pnas.69.12.3561; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Ruck A, 1998, FEBS LETT, V426, P97, DOI 10.1016/S0014-5793(98)00317-2; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schendel SL, 1998, CELL DEATH DIFFER, V5, P372, DOI 10.1038/sj.cdd.4400365; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; SUSIN SA, 1999, IN PRESS METH ENZYMO; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Woodfield K, 1998, BIOCHEM J, V336, P287, DOI 10.1042/bj3360287; Xie FK, 1998, J PERIPHER NERV SYST, V3, P37; YING XM, 1994, NATURE, V369, P321; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x	40	287	316	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2000	19	3					329	336		10.1038/sj.onc.1203298	http://dx.doi.org/10.1038/sj.onc.1203298			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656679				2022-12-17	WOS:000084873700002
J	Smith, JS; Alderete, B; Minn, Y; Borell, TJ; Perry, A; Mohapatra, G; Hosek, SM; Kimmel, D; O'Fallon, J; Yates, A; Feuerstein, BG; Burger, PC; Scheithauer, BW; Jenkins, RB				Smith, JS; Alderete, B; Minn, Y; Borell, TJ; Perry, A; Mohapatra, G; Hosek, SM; Kimmel, D; O'Fallon, J; Yates, A; Feuerstein, BG; Burger, PC; Scheithauer, BW; Jenkins, RB			Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype	ONCOGENE			English	Article						diffuse glioma; tumor suppressor gene; loss of heterozygosity; fluorescence in situ hybridization; comparative genomic hybridization; chromosome 1; chromosome 19	COMPARATIVE GENOMIC HYBRIDIZATION; IN-SITU HYBRIDIZATION; OLIGODENDROGLIAL TUMORS; CYTOGENETIC ANALYSIS; PCV CHEMOTHERAPY; GENETIC-ANALYSIS; CELL-LINES; HETEROZYGOSITY; OLIGOASTROCYTOMAS; ASTROCYTOMAS	Allelic alterations of chromosomes 1 and 19 are frequent events in human diffuse gliomas and have recently proven to be strong predictors of chemotherapeutic response and prolonged survival in oligodendrogliomas (Cairncross ct al., 1998; Smith et al,, submitted), Using 115 human diffuse gliomas, we localized regions of common allelic loss on chromosomes 1 and 19 and assessed the association of these deletion intervals with glioma histological subtypes. Further, we evaluated the capacity of multiple modalities to detect these alterations, including loss of heterozygosity (LOH), fluorescence in situ hybridization (FISH), and comparative genomic hybridization (CGH), The correlation coefficients for detection of 1p and 19q alterations, respectively, between modalities were: 0.98 and 0.87 for LOH and FISH, 0.79 and 0.60 for LOH and CGH, and 0.79 and 0.53 for FISH and CGH, Minimal deletion regions were defined on 19q13.3 (D19S412-D19S596) and 1p (D1S468-D1S1612), Loss of the 1p36 region was found in 18% of astrocytomas (10/55) and in 73% (24/33) of oligodendrogliomas (P < 0.0001), and loss of the 19q13.3 region was found in 38% (21/55) of astrocytomas and 73% (24/33) of oligodendrogliomas (P = 0.0017), Loss of both regions was found in 11% (6/55) of astrocytomas and in 63% (21/33) of oligodendrogliomas (P < 0.0001). All gliomas with LOH on either 1p or 19q demonstrated loss of the corresponding FISH probe, 1p36 or 19q13.3, suggesting not only locations of putative tumor suppressor genes, but also a simple assay for assessment of 1p and 19q alterations as diagnostic and prognostic markers.	Mayo Clin & Mayo Fdn, Div Lab Genet, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Anat Pathol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Neurol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biostat, Rochester, MN 55905 USA; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94115 USA; Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94115 USA; Univ Calif San Francisco, Brain Tumor Res Ctr, San Francisco, CA 94115 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21287 USA; Ohio State Univ, Div Neuropathol, Columbus, OH 43210 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Johns Hopkins University; University System of Ohio; Ohio State University	Jenkins, RB (corresponding author), Mayo Clin & Mayo Fdn, Div Lab Genet, 200 1st St SW, Rochester, MN 55905 USA.		Feuerstein, Burt G/A-5186-2015	Feuerstein, Burt G/0000-0001-7276-8842; Perry, Arie/0000-0002-8300-7261	NATIONAL CANCER INSTITUTE [U01CA064898, U01CA050910, U01CA050905] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASHWORTH LK, 1995, NAT GENET, V11, P422, DOI 10.1038/ng1295-422; BAER R, 1993, SEMIN CANCER BIOL, V4, P341; BELLO MJ, 1995, INT J CANCER, V64, P207; BELLO MJ, 1994, INT J CANCER, V57, P172, DOI 10.1002/ijc.2910570207; CAIRNCROSS G, 1994, J CLIN ONCOL, V12, P2013, DOI 10.1200/JCO.1994.12.10.2013; Cairncross JG, 1998, J NATL CANCER I, V90, P1473, DOI 10.1093/jnci/90.19.1473; CAIRNCROSS JG, 1988, ANN NEUROL, V23, P360, DOI 10.1002/ana.410230408; CHUNG R, 1991, GENE CHROMOSOME CANC, V3, P323, DOI 10.1002/gcc.2870030502; CLIBY W, 1993, CANCER RES, V53, P2393; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; COLLINS A, 1992, P NATL ACAD SCI USA, V89, P4598, DOI 10.1073/pnas.89.10.4598; FRANKEL RH, 1992, CANCER RES, V52, P1427; FULTS D, 1992, CANCER RES, V52, P674; *GDB TM, HUM GEN DAT; GLASS J, 1992, J NEUROSURG, V76, P741, DOI 10.3171/jns.1992.76.5.0741; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; KIM DH, 1995, INT J CANCER, V60, P812, DOI 10.1002/ijc.2910600615; Kim L, 1996, J NEUROSURG, V85, P602, DOI 10.3171/jns.1996.85.4.0602; KLEIHUES P, 1992, HISTOLOGICAL TYPING; KRAUS JA, 1995, J NEUROPATH EXP NEUR, V54, P91, DOI 10.1097/00005072-199501000-00011; LEVIN VA, 1993, CANC PRINCIPLES PRAC, P1679; LINDBLOM A, 1993, CANCER RES, V53, P4356; Louis DN, 1997, BRAIN PATHOL, V7, P755, DOI 10.1111/j.1750-3639.1997.tb01062.x; LOUIS DN, 1995, TRENDS GENET, V11, P412, DOI 10.1016/S0168-9525(00)89125-8; Maintz D, 1997, J NEUROPATH EXP NEUR, V56, P1098, DOI 10.1097/00005072-199710000-00003; Mason WP, 1996, NEUROLOGY, V46, P203, DOI 10.1212/WNL.46.1.203; Mohapatra G, 1998, GENE CHROMOSOME CANC, V21, P195, DOI 10.1002/(SICI)1098-2264(199803)21:3<195::AID-GCC3>3.3.CO;2-A; MOHAPATRA G, 1995, GENE CHROMOSOME CANC, V13, P86, DOI 10.1002/gcc.2870130203; Muliokandov MR, 1996, CANCER RES, V56, P197; MURRAY JC, 1994, SCIENCE, V265, P2049, DOI 10.1126/science.8091227; Nunnally JC., 1994, PSYCHOMETRIC THEORY, V3, DOI DOI 10.1037/018882; Perry A, 1997, J NEUROPATH EXP NEUR, V56, P999, DOI 10.1097/00005072-199709000-00005; PIPER J, 1995, CYTOMETRY, V19, P10, DOI 10.1002/cyto.990190104; QIAN JQ, 1995, CANCER RES, V55, P5408; RANSOM DT, 1992, GENE CHROMOSOME CANC, V5, P357, DOI 10.1002/gcc.2870050412; REIFENBERGER J, 1994, AM J PATHOL, V145, P1175; RITLAND SR, 1995, GENE CHROMOSOME CANC, V12, P277, DOI 10.1002/gcc.2870120407; Rosenberg JE, 1996, ONCOGENE, V13, P2483; SALTMAN DL, 1990, GENE CHROMOSOME CANC, V2, P259, DOI 10.1002/gcc.2870020402; Schwab M, 1996, GENE CHROMOSOME CANC, V16, P211, DOI 10.1002/(SICI)1098-2264(199608)16:4<211::AID-GCC1>3.0.CO;2-0; SEIZINGER BR, 1991, CYTOGENET CELL GENET, V58, P1080, DOI 10.1159/000133722; Smith J. C., UNPUB; Smith MAJ, 1997, PROBAB ENG INFORM SC, V11, P451, DOI 10.1017/S0269964800004976; TESTA JR, 1994, GENE CHROMOSOME CANC, V11, P178, DOI 10.1002/gcc.2870110307; Weber RG, 1996, ONCOGENE, V13, P983	45	287	299	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	1999	18	28					4144	4152		10.1038/sj.onc.1202759	http://dx.doi.org/10.1038/sj.onc.1202759			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	216FP	10435596				2022-12-17	WOS:000081431000012
J	Boyault, C; Sadoul, K; Pabion, M; Khochbin, S				Boyault, C.; Sadoul, K.; Pabion, M.; Khochbin, S.			HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination	ONCOGENE			English	Review						microtubule; actin; HSP90; virus; aggresome; transcription	HISTONE DEACETYLASE INHIBITORS; POSITIVE BREAST-CANCER; 2 CATALYTIC DOMAINS; LYSINE-ACETYLATION; GENE-EXPRESSION; DEUBIQUITINATING ENZYMES; MICROTUBULE ACETYLATION; GLUCOCORTICOID-RECEPTOR; TUBULIN DEACETYLASE; CHAPERONE FUNCTION	Histone deacetylase 6 ( HDAC6) is a unique enzyme with specific structural and functional features. It is actively or stably maintained in the cytoplasm and is the only member, within the histone deacetylase family, that harbors a full duplication of its deacetylase homology region followed by a specific ubiquitin-binding domain at the C-terminus end. Accordingly, this deacetylase functions at the heart of a cellular regulatory mechanism capable of coordinating various cellular functions largely relying on the microtubule network. Moreover, HDAC6 action as a regulator of the HSP90 chaperone activity adds to the multifunctionality of the protein, and allows us to propose a critical role for HDAC6 in mediating and coordinating various cellular events in response to different stressful stimuli.	Univ Grenoble 1, INSERM, U823, Inst Albert Bonniot, La Tronche, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Khochbin, S (corresponding author), Univ Grenoble 1, INSERM, U823, Inst Albert Bonniot, Domaine Merci, La Tronche, France.	khochbin@ujf-grenoble.fr	Sadoul, Karin/N-2649-2013; 高, 雨莉/HGU-8187-2022; Khochbin, Saadi/M-8090-2013; Boyault, Cyril/K-3593-2014	Sadoul, Karin/0000-0001-7174-5016; Khochbin, Saadi/0000-0002-0455-0857; Boyault, Cyril/0000-0001-9614-4292				Adachi N, 2002, J BIOL CHEM, V277, P35688, DOI 10.1074/jbc.M204640200; Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Amerik AY, 2000, BIOL CHEM, V381, P981, DOI 10.1515/BC.2000.121; Bali P, 2005, J BIOL CHEM, V280, P26729, DOI 10.1074/jbc.C500186200; Barlow AL, 2001, EXP CELL RES, V265, P90, DOI 10.1006/excr.2001.5162; Bershadsky AD, 2006, EUR J CELL BIOL, V85, P165, DOI 10.1016/j.ejcb.2005.11.001; Bertos NR, 2004, J BIOL CHEM, V279, P48246, DOI 10.1074/jbc.M408583200; Blagosklonny MV, 2002, LEUKEMIA, V16, P455, DOI 10.1038/sj.leu.2402415; Boyault C, 2006, EMBO J, V25, P3357, DOI 10.1038/sj.emboj.7601210; Bradbury C, 2005, LEUKEMIA, V19, P1751, DOI 10.1038/sj.leu.2403910; Brush MH, 2004, J BIOL CHEM, V279, P7685, DOI 10.1074/jbc.M310997200; Cabrero JR, 2006, MOL BIOL CELL, V17, P3435, DOI 10.1091/mbc.E06-01-0008; Caron C, 2003, BIOESSAYS, V25, P58, DOI 10.1002/bies.10202; Caron C, 2005, BIOESSAYS, V27, P408, DOI 10.1002/bies.20210; Carta S, 2006, BLOOD, V108, P1618, DOI 10.1182/blood-2006-03-014126; Cohen HY, 2004, MOL CELL, V13, P627, DOI 10.1016/S1097-2765(04)00094-2; Corcoran LJ, 2004, CURR BIOL, V14, P488, DOI 10.1016/j.cub.2004.03.003; Destaing O, 2005, J CELL SCI, V118, P2901, DOI 10.1242/jcs.02425; Dihazi H, 2005, BIOL CHEM, V386, P895, DOI 10.1515/BC.2005.104; Fernandes I, 2003, MOL CELL, V11, P139, DOI 10.1016/S1097-2765(03)00014-5; Fischer DD, 2002, J BIOL CHEM, V277, P6656, DOI 10.1074/jbc.M108055200; Furumai R, 2002, CANCER RES, V62, P4916; Gao L, 2002, J BIOL CHEM, V277, P25748, DOI 10.1074/jbc.M111871200; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; Goldberg AL, 2002, MOL IMMUNOL, V39, P147, DOI 10.1016/S0161-5890(02)00098-6; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Guardiola AR, 2002, J BIOL CHEM, V277, P3350, DOI 10.1074/jbc.M109861200; Gurvich N, 2004, CANCER RES, V64, P1079, DOI 10.1158/0008-5472.CAN-03-0799; Haggarty SJ, 2003, P NATL ACAD SCI USA, V100, P4389, DOI 10.1073/pnas.0430973100; Hallows WC, 2006, P NATL ACAD SCI USA, V103, P10230, DOI 10.1073/pnas.0604392103; Hayashi Shin-ichi, 2006, Breast Cancer, V13, P123, DOI 10.2325/jbcs.13.123; Hideshima T, 2005, P NATL ACAD SCI USA, V102, P8567, DOI 10.1073/pnas.0503221102; Hook SS, 2002, P NATL ACAD SCI USA, V99, P13425, DOI 10.1073/pnas.172511699; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Hurst DR, 2006, BIOCHEM BIOPH RES CO, V348, P1429, DOI 10.1016/j.bbrc.2006.08.005; Iwabata H, 2005, PROTEOMICS, V5, P4653, DOI 10.1002/pmic.200500042; Iwata A, 2005, J BIOL CHEM, V280, P40282, DOI 10.1074/jbc.M508786200; Kao HY, 2002, J BIOL CHEM, V277, P187, DOI 10.1074/jbc.M108931200; Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5; Kim SC, 2006, MOL CELL, V23, P607, DOI 10.1016/j.molcel.2006.06.026; Kong XG, 2006, MOL CELL BIOL, V26, P2019, DOI 10.1128/MCB.26.6.2019-2028.2006; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Kovacs JJ, 2005, MOL CELL, V18, P601, DOI 10.1016/j.molcel.2005.04.021; Ling L, 2004, J BIOL CHEM, V279, P32737, DOI 10.1074/jbc.M400601200; Ma H, 2005, ONCOGENE, V24, P3619, DOI 10.1038/sj.onc.1208433; Marcus AI, 2006, CANCER RES, V66, P8838, DOI 10.1158/0008-5472.CAN-06-0699; Marcus AI, 2005, CANCER RES, V65, P3883, DOI 10.1158/0008-5472.CAN-04-3757; Matsuyama A, 2002, EMBO J, V21, P6820, DOI 10.1093/emboj/cdf682; Mosley AJ, 2006, BLOOD, V108, P3801, DOI 10.1182/blood-2006-03-013235; Murphy PJM, 2005, J BIOL CHEM, V280, P33792, DOI 10.1074/jbc.M506997200; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; Nusinzon I, 2006, MOL CELL BIOL, V26, P3106, DOI 10.1128/MCB.26.8.3106-3113.2006; Osada H, 2004, INT J CANCER, V112, P26, DOI 10.1002/ijc.20395; Pantaloni D, 2001, SCIENCE, V292, P1502, DOI 10.1126/science.1059975; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Qian DZ, 2006, CANCER RES, V66, P8814, DOI 10.1158/0008-5472.CAN-05-4598; Reed NA, 2006, CURR BIOL, V16, P2166, DOI 10.1016/j.cub.2006.09.014; Romisch K, 2005, ANNU REV CELL DEV BI, V21, P435, DOI 10.1146/annurev.cellbio.21.012704.133250; Rumpf S, 2006, MOL CELL, V21, P261, DOI 10.1016/j.molcel.2005.12.014; Saji S, 2005, ONCOGENE, V24, P4531, DOI 10.1038/sj.onc.1208646; Sakuma T, 2006, INT J ONCOL, V29, P117; Schwer B, 2006, P NATL ACAD SCI USA, V103, P10224, DOI 10.1073/pnas.0603968103; Scroggins BT, 2007, MOL CELL, V25, P151, DOI 10.1016/j.molcel.2006.12.008; Seigneurin-Berny D, 2001, MOL CELL BIOL, V21, P8035, DOI 10.1128/MCB.21.23.8035-8044.2001; Serrador JM, 2004, IMMUNITY, V20, P417, DOI 10.1016/S1074-7613(04)00078-0; Shimazu T, 2007, J BIOL CHEM, V282, P4470, DOI 10.1074/jbc.M609745200; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Tong JJ, 2002, NUCLEIC ACIDS RES, V30, P1114, DOI 10.1093/nar/30.5.1114; Valenzuela-Fernandez A, 2005, MOL BIOL CELL, V16, P5445, DOI 10.1091/mbc.E05-04-0354; Verdel A, 2000, CURR BIOL, V10, P747, DOI 10.1016/S0960-9822(00)00542-X; Verdel A, 1999, J BIOL CHEM, V274, P2440, DOI 10.1074/jbc.274.4.2440; Wang Q, 2003, BIOCHEM BIOPH RES CO, V300, P253, DOI 10.1016/S0006-291X(02)02840-1; Watts GDJ, 2004, NAT GENET, V36, P377, DOI 10.1038/ng1332; Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982-7992.2002; Yang XJ, 2005, MOL CELL BIOL, V25, P2873, DOI 10.1128/MCB.25.8.2873-2884.2005; Yang XJ, 2004, BIOESSAYS, V26, P1076, DOI 10.1002/bies.20104; Yoshida N, 2004, CANCER SCI, V95, P496, DOI 10.1111/j.1349-7006.2004.tb03239.x; Zhang WZ, 2002, AM J PHYSIOL-RENAL, V283, pF904, DOI 10.1152/ajprenal.00156.2002; Zhang Y, 2003, EMBO J, V22, P1168, DOI 10.1093/emboj/cdg115; Zhang Y, 2006, J BIOL CHEM, V281, P2401, DOI 10.1074/jbc.C500241200; Zhang ZH, 2004, CLIN CANCER RES, V10, P6962, DOI 10.1158/1078-0432.CCR-04-0455; Zhao RM, 2005, CELL, V120, P715, DOI 10.1016/j.cell.2004.12.024; Zou H, 2006, BIOCHEM BIOPH RES CO, V341, P45, DOI 10.1016/j.bbrc.2005.12.144	85	286	299	4	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 13	2007	26	37					5468	5476		10.1038/sj.onc.1210614	http://dx.doi.org/10.1038/sj.onc.1210614			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CR	17694087				2022-12-17	WOS:000248674300014
J	Catteau, A; Harris, WH; Xu, CF; Solomon, E				Catteau, A; Harris, WH; Xu, CF; Solomon, E			Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics	ONCOGENE			English	Article						breast cancer; ovarian cancer; BRCA1 promoter; methylation	TUMOR-SUPPRESSOR GENE; ESTROGEN-RECEPTOR GENE; DNA METHYLATION; CPG ISLAND; HYPERMETHYLATION; EXPRESSION; CARCINOMAS; RETINOBLASTOMA; MUTATIONS; IDENTIFICATION	Reduced expression of BRCA1 has been reported in sporadic breast cancer, although the mechanisms underlying this phenomenon remain unclear. Abnormal methylation leading to silencing of tumour suppressor genes has been implicated in tumorigenesis in a wide range of sporadic cancers. Therefore, we sought to determine the frequency of methylation within the BRCA1 promoter region in a large group of sporadic invasive breast (n=96) and ovarian (n=43) carcinomas using Southern analyses. Overall, methylation was detected in 11% of breast cancer cases and in 5% of ovarian tumours, Methylation of the BRCA1 promoter region was strongly correlated with lack of estrogen and progesterone receptor expression. It is clear from the frequency of abnormal methylation of the BRCA1 promoter region, that this cannot be the sole mechanism mediating the reduced expression of BRCA1 that has previously been reported to occur in the majority of invasive sporadic breast tumours, Nevertheless this study suggests that abnormal methylation of the BRCA1 promoter may be important in tumorigenesis in a subset of sporadic breast and ovarian cancers.	UMDS, Div Med & Mol Genet, Guys Hosp, London SE1 9RT, England; Guys Hosp, Hedley Atkins ICRF Breast Pathol Lab, London SE1 9RT, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust	Catteau, A (corresponding author), UMDS, Div Med & Mol Genet, Guys Hosp, 8th Floor,Guys Tower, London SE1 9RT, England.			Xu, Chun-Fang/0000-0002-8747-0683	Medical Research Council [G9600577] Funding Source: Medline; MRC [G9600577] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Barker DF, 1996, GENOMICS, V38, P215, DOI 10.1006/geno.1996.0618; Barnes DM, 1996, BRIT J CANCER, V74, P1445, DOI 10.1038/bjc.1996.563; BARNES DM, 1995, PROG PATHOL, V2, P89; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Brown MA, 1996, ONCOGENE, V12, P2507; CATTEAU A, 1999, IN PRESS BR J CANC; CLIBY W, 1993, CANCER RES, V53, P2393; Couch FJ, 1996, HUM MUTAT, V8, P8, DOI 10.1002/humu.1380080102; CROPP CS, 1993, CANCER RES, V53, P5617; Dobrovic A, 1997, CANCER RES, V57, P3347; FERGUSON AT, 1995, CANCER RES, V55, P2279; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GRAFF JR, 1995, CANCER RES, V55, P5195; GREGER V, 1994, HUM GENET, V94, P491; Hakkarainen M, 1996, INT J CANCER, V69, P471, DOI 10.1002/(SICI)1097-0215(19961220)69:6<471::AID-IJC9>3.3.CO;2-A; Herman JG, 1996, CANCER RES, V56, P722; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; Hiltunen MO, 1997, INT J CANCER, V70, P644, DOI 10.1002/(SICI)1097-0215(19970317)70:6<644::AID-IJC3>3.3.CO;2-2; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; HOSKING L, 1995, NAT GENET, V9, P343, DOI 10.1038/ng0495-343; Huang THM, 1997, CANCER RES, V57, P1030; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; Lapidus RG, 1996, CLIN CANCER RES, V2, P805; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; OTTAVIANO YL, 1994, CANCER RES, V54, P2552; READ LD, 1988, MOL ENDOCRINOL, V2, P263, DOI 10.1210/mend-2-3-263; RUSSELL SEH, 1990, ONCOGENE, V5, P1581; SAITO H, 1993, CANCER RES, V53, P3382; SAKAI T, 1991, AM J HUM GENET, V48, P880; Smith TM, 1996, GENOME RES, V6, P1029, DOI 10.1101/gr.6.11.1029; Sourvinos G, 1998, BIOCHEM BIOPH RES CO, V245, P75, DOI 10.1006/bbrc.1998.8379; TAKAHASHI H, 1995, CANCER RES, V55, P2998; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; XU CF, 1995, HUM MOL GENET, V4, P2259, DOI 10.1093/hmg/4.12.2259; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994; YANGFENG TL, 1993, INT J CANCER, V54, P546, DOI 10.1002/ijc.2910540405	44	286	301	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	1999	18	11					1957	1965		10.1038/sj.onc.1202509	http://dx.doi.org/10.1038/sj.onc.1202509			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177DC	10208417				2022-12-17	WOS:000079191300005
J	Dumont, A; Hehner, SP; Hofmann, TG; Ueffing, M; Droge, W; Schmitz, ML				Dumont, A; Hehner, SP; Hofmann, TG; Ueffing, M; Droge, W; Schmitz, ML			Hydrogen peroxide-induced apoptosis is CD95-independent, requires the release of mitochondria-derived reactive oxygen species and the activation of NF-kappa B	ONCOGENE			English	Article						apoptosis; hydrogen peroxide; reactive oxygen species; mitochondria; NF-kappa B	TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; GLUTATHIONE DISULFIDE; THYMOCYTE APOPTOSIS; FOREBRAIN NEURONS; CELL-DEATH; E1B 19K; PROTEIN; BCL-2; EXPRESSION	Reactive oxygen species (ROS) play an important role in cell death induced by many different stimuli. This study shows that hydrogen peroxide-induced apoptosis in T-cells did not require tyrosine kinase p56(lck), phosphatase CD45, the CD95 receptor and its associated Caspase-8, H2O2-triggered cell death led to the induced cleavage and activation of Caspase-3, Hydrogen peroxide-treatment of T-cells resulted in the formation of mitochondrial permeability transition pores, a rapid decrease of the mitochondrial transmembrane potential Delta Psi(m) and the release of Cytochrome C, Inhibition of the mitochondrial permeability transition by bongkrekic acid (BA), or interference with the mitochondrial electron transport system by rotenone or menadione prevented the cytotoxic effect of H2O2, Antimycin A, a mitochondrial inhibitor that increases the release of mitochondrial ROS (MiROS), enhanced apoptosis. Overexpression of Bcl-2 and the viral anti-apoptotic proteins BHRF-1 and E1B 19K counteracted H2O2-induced apoptosis, Pharmacological and genetic inhibition of transcription factor NF-kappa B protected cells from hydrogen peroxide-elicited cell death. This detrimental effect of NF-kappa B mediating hydrogen peroxide-induced cell death presumably relies on the induced expression of death effector genes such as p53, which was NF-kappa B-dependently upregulated in the presence of H2O2.	German Canc Res Ctr, DKFZ, Dept Immunochem, D-69120 Heidelberg, Germany; Univ Munich, Mol Eye Genet Grp, Munich, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); University of Munich	Schmitz, ML (corresponding author), German Canc Res Ctr, DKFZ, Dept Immunochem, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Schmitz, M. Lienhard/D-9328-2017	Schmitz, M. Lienhard/0000-0002-6984-7192				ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; Baeuerle PA, 1996, PATHOL BIOL, V44, P29; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bauer MKA, 1998, J BIOL CHEM, V273, P8048, DOI 10.1074/jbc.273.14.8048; Clemens JA, 1997, STROKE, V28, P1073, DOI 10.1161/01.STR.28.5.1073; Clement MV, 1996, EMBO J, V15, P216, DOI 10.1002/j.1460-2075.1996.tb00352.x; DELCARMEN RRM, 1997, EUR J IMMUNOL, V27, P1442; Droge W, 1997, FASEB J, V11, P1077, DOI 10.1096/fasebj.11.13.9367343; DROGE W, 1994, FASEB J, V8, P1131; EISCHEN CM, 1994, J IMMUNOL, V153, P1947; Farrow SN, 1996, CURR OPIN GENET DEV, V6, P45, DOI 10.1016/S0959-437X(96)90009-X; Galter Dagmar, 1994, European Journal of Biochemistry, V221, P639; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; Han J, 1996, MOL CELL BIOL, V16, P5857; Hehner SP, 1998, J BIOL CHEM, V273, P1288, DOI 10.1074/jbc.273.3.1288; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hoyt KR, 1997, NEUROCHEM RES, V22, P333, DOI 10.1023/A:1022403224901; HUG H, 1994, FEBS LETT, V351, P311, DOI 10.1016/0014-5793(94)00852-3; Hug H, 1997, J BIOL CHEM, V272, P28191, DOI 10.1074/jbc.272.45.28191; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Khanim F, 1997, J GEN VIROL, V78, P2987, DOI 10.1099/0022-1317-78-11-2987; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Limbourg FP, 1996, J BIOL CHEM, V271, P20392, DOI 10.1074/jbc.271.34.20392; LIN KI, 1995, J CELL BIOL, V131, P1149, DOI 10.1083/jcb.131.5.1149; LOS M, 1995, EMBO J, V14, P3731, DOI 10.1002/j.1460-2075.1995.tb00043.x; Macho A, 1997, J IMMUNOL, V158, P4612; Mancini M, 1997, J CELL BIOL, V138, P449, DOI 10.1083/jcb.138.2.449; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Mollereau B, 1997, J IMMUNOL, V159, P2668; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Qin ZH, 1998, MOL PHARMACOL, V53, P33, DOI 10.1124/mol.53.1.33; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schmitz ML, 1996, MOL CELL BIOL, V16, P4052; SCHRAVEN B, 1995, FEBS LETT, V368, P491, DOI 10.1016/0014-5793(95)00720-T; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Sha WC, 1998, J EXP MED, V187, P143, DOI 10.1084/jem.187.2.143; SIES H, 1993, EUR J BIOCHEM, V215, P213, DOI 10.1111/j.1432-1033.1993.tb18025.x; Slater AFG, 1995, TOXICOL LETT, V82-3, P149, DOI 10.1016/0378-4274(95)03474-9; SUBRAMANIAN T, 1993, GENE, V124, P173, DOI 10.1016/0378-1119(93)90391-F; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; WAUTIER JL, 1994, P NATL ACAD SCI USA, V91, P7742, DOI 10.1073/pnas.91.16.7742; WHITE E, 1990, MOL CELL BIOL, V10, P120, DOI 10.1128/MCB.10.1.120; WU HY, 1994, J BIOL CHEM, V269, P20067; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YOUSEFI S, 1994, P NATL ACAD SCI USA, V91, P10868, DOI 10.1073/pnas.91.23.10868; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533	63	286	298	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	1999	18	3					747	757		10.1038/sj.onc.1202325	http://dx.doi.org/10.1038/sj.onc.1202325			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989825				2022-12-17	WOS:000078394400020
J	Wolf, G; Elez, R; Doermer, A; Holtrich, U; Ackermann, H; Stutte, HJ; Altmannsberger, HM; RubsamenWaigmann, H; Strebhardt, K				Wolf, G; Elez, R; Doermer, A; Holtrich, U; Ackermann, H; Stutte, HJ; Altmannsberger, HM; RubsamenWaigmann, H; Strebhardt, K			Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer	ONCOGENE			English	Article						serine/threonine kinase; mRNA expression; prognosis; non-small cell lung cancer; polo-like kinase	PROTEIN-TYROSINE KINASES; K-RAS ONCOGENE; NUCLEAR ANTIGEN; PARAFFIN SECTIONS; DROSOPHILA POLO; CYCLE ANALYSIS; ADENOCARCINOMA; TUMORS; INDEX; GENE	Our previous data indicate that the expression of the PLK gene which codes for a serine/threonine kinase is restricted to proliferating cells. In Northern blot experiments PLK mRNA expression was at the limit of detection in normal lung tissue but elevated in most samples of non-small cell lung cancer (NSCLC). A very low frequency of PLK transcripts was only found in bronchiolo-alveolar carcinomas. NSCLC patients whose tumors showed moderate PLK expression survived significantly longer (5 year survival rate=51.8%) than those with high levels of PLK transcripts (24.2%, P=0.001). No statistically significant correlation was found between PLK mRNA expression and age, sex, TNM status, histological type or degree of differentiation, Interestingly, the prognosis of patients in postsurgical stages I and II was correlated with PLK expression (5 year survival rates in stage I: 69.1% (moderate PLK) - 43.5% (high PLK), P=0.03 or in stage II: 51.9% (moderate PLK) - 9.9% (high PLK), P=0.006). These results suggest that PLK mRNA expression provides a new independent prognostic indicator for patients with NSCLC.	CHEMOTHERAPEUT FORSCHUNGSINST,D-60596 FRANKFURT,GERMANY; KRANKENHAUS NORDSTADT,DEPT THORAC & VASC SURG,FRANKFURT,GERMANY; KRANKENHAUS NW FRANKFURT,DEPT PATHOL,FRANKFURT,GERMANY; UNIV FRANKFURT,SCH MED,DEPT PATHOL,D-60596 FRANKFURT,GERMANY; UNIV FRANKFURT,SCH MED,DEPT BIOMATH,D-60596 FRANKFURT,GERMANY; BAYER AG,PHARMA RES CTR,INST VIROL,D-42096 WUPPERTAL,GERMANY	Krankenhaus Nordwest; Goethe University Frankfurt; Goethe University Frankfurt; Bayer AG			Strebhardt, Klaus/E-8765-2011	Strebhardt, Klaus/0000-0003-2173-9763				BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOHME B, 1993, ONCOGENE, V8, P2857; BONGIORNO PF, 1994, J THORAC CARDIOV SUR, V107, P590, DOI 10.1016/S0022-5223(94)70107-5; BRAUNINGER A, 1992, GENE, V110, P205, DOI 10.1016/0378-1119(92)90649-A; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLAYTON F, 1991, CANCER, V68, P1309, DOI 10.1002/1097-0142(19910915)68:6<1309::AID-CNCR2820680621>3.0.CO;2-I; DEAN PN, 1984, CELL TISSUE KINET, V17, P427, DOI 10.1111/j.1365-2184.1984.tb00601.x; FONTANINI G, 1992, CANCER-AM CANCER SOC, V70, P1520, DOI 10.1002/1097-0142(19920915)70:6<1520::AID-CNCR2820700613>3.0.CO;2-K; FUJII M, 1993, ACTA MED OKAYAMA, V47, P103; GERDES J, 1984, J IMMUNOL, V133, P1710; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; GOULD VE, 1989, THORACIC ONCOLOGY, P77; Haldane JBS, 1940, BIOMETRIKA, V31, P346, DOI 10.1093/biomet/31.3-4.346; HALL PA, 1990, J PATHOL, V162, P285, DOI 10.1002/path.1711620403; HAMANAKA R, 1994, CELL GROWTH DIFFER, V5, P249; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARRIS EK, 1991, SURVIVORSHIP ANAL CL; HENDERSON BE, 1991, SCIENCE, V254, P1131, DOI 10.1126/science.1957166; HOLTRICH U, 1991, P NATL ACAD SCI USA, V88, P10411, DOI 10.1073/pnas.88.23.10411; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; KARN T, 1993, ONCOGENE, V8, P3433; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; LAKE RJ, 1993, MOL CELL BIOL, V13, P7793, DOI 10.1128/MCB.13.12.7793; MALAISE EP, 1973, EUR J CANCER, V9, P305, DOI 10.1016/0014-2964(73)90099-6; MATHEWS MB, 1984, NATURE, V309, P374, DOI 10.1038/309374a0; Miller RG, 1981, COMPUTER VISION, DOI [DOI 10.1007/S11263, DOI 10.1007/s11263-015-0816-y]; MOORE DF, 1995, LUNG CANC STAGING PR, P481; PENCE JC, 1993, ARCH SURG-CHICAGO, V128, P1382; QUIRKE P, 1986, J PATHOL, V149, P79, DOI 10.1002/path.1711490202; RODENHUIS S, 1987, NEW ENGL J MED, V317, P929, DOI 10.1056/NEJM198710083171504; RODENHUIS S, 1988, CANCER RES, V48, P5737; Sambrook J, 1989, MOL CLONING LAB MANU; SLEBOS RJC, 1990, NEW ENGL J MED, V323, P561, DOI 10.1056/NEJM199008303230902; STREBHARDT K, 1994, ONCOL REP, V1, P195; SUNKEL CE, 1988, J CELL SCI, V89, P25; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; VOLM M, 1993, J CANCER RES CLIN, V119, P507, DOI 10.1007/BF01686458	39	286	305	1	13	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 6	1997	14	5					543	549		10.1038/sj.onc.1200862	http://dx.doi.org/10.1038/sj.onc.1200862			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WF524	9053852				2022-12-17	WOS:A1997WF52400005
J	BONGARZONE, I; PIEROTTI, MA; MONZINI, N; MONDELLINI, P; MANENTI, G; DONGHI, R; PILOTTI, S; GRIECO, M; SANTORO, M; FUSCO, A; VECCHIO, G; DELLAPORTA, G				BONGARZONE, I; PIEROTTI, MA; MONZINI, N; MONDELLINI, P; MANENTI, G; DONGHI, R; PILOTTI, S; GRIECO, M; SANTORO, M; FUSCO, A; VECCHIO, G; DELLAPORTA, G			HIGH-FREQUENCY OF ACTIVATION OF TYROSINE KINASE ONCOGENES IN HUMAN PAPILLARY THYROID-CARCINOMA	ONCOGENE			English	Article									IST NAZL TUMORI,DIV ONCOL SPERIMENTALE A,VIA G VENEZIAN 1,I-20133 MILAN,ITALY; IST NAZL TUMORI,FAC MED & CHIRURG 2,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC,CNR,I-20133 MILAN,ITALY; NAPLES UNIV,DIV ANAT PATOL,I-80131 NAPLES,ITALY	Fondazione IRCCS Istituto Nazionale Tumori Milan; Consiglio Nazionale delle Ricerche (CNR); Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Naples Federico II			Manenti, Giacomo/J-3339-2017; Bongarzone, Italia/B-9544-2017	Manenti, Giacomo/0000-0002-4887-4482; Bongarzone, Italia/0000-0003-2530-9170; Fusco, Alfredo/0000-0003-3332-5197; Pierotti, Marco Alessandro/0000-0002-7431-8332; Grieco, Michele/0000-0002-4212-7814				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BRENNAN MF, 1985, CANCER PRINCIPLES PR, P1179; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DONGHI R, 1989, ONCOGENE, V4, P521; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; HEMPELMANN LH, 1975, J NATL CANCER I, V55, P519, DOI 10.1093/jnci/55.3.519; KOZMA SC, 1988, EMBO J, V7, P147, DOI 10.1002/j.1460-2075.1988.tb02794.x; LEMOINE NR, 1989, ONCOGENE, V4, P159; LEMOINE NR, 1988, CANCER RES, V48, P4459; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MITRA G, 1987, P NATL ACAD SCI USA, V84, P6707, DOI 10.1073/pnas.84.19.6707; NERI A, 1988, P NATL ACAD SCI USA, V85, P9268, DOI 10.1073/pnas.85.23.9268; OSKAM R, 1988, P NATL ACAD SCI USA, V85, P2964, DOI 10.1073/pnas.85.9.2964; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SOUYRI M, 1983, P NATL ACAD SCI-BIOL, V80, P6676, DOI 10.1073/pnas.80.21.6676; SUAREZ HG, 1988, ONCOGENE, V2, P403; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; WILLIAMS ED, 1979, CLIN ENDOCRINOL META, V8, P193, DOI 10.1016/S0300-595X(79)80017-1	20	286	307	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1989	4	12					1457	1462						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB659	2594368				2022-12-17	WOS:A1989CB65900006
J	He, XX; Chang, Y; Meng, FY; Wang, MY; Xie, QH; Tang, F; Li, PY; Song, YH; Lin, JS				He, X-X; Chang, Y.; Meng, F-Y; Wang, M-Y; Xie, Q-H; Tang, F.; Li, P-Y; Song, Y-H; Lin, J-S			MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo	ONCOGENE			English	Article						microRNA-375; AEG-1; hepatocellular carcinoma	ASTROCYTE-ELEVATED GENE-1; NON-TUMOROUS TISSUES; HEPATOCYTE ISOLATION; PATIENT SURVIVAL; BREAST-CANCER; EXPRESSION; PROGRESSION; HEPATITIS; PATHOGENESIS; METASTASIS	MicroRNAs (miRNAs) are believed to have fundamental roles in tumorigenesis and have great potential for the diagnosis and treatment of cancer. However, the roles of miRNAs in hepatocellular carcinogenesis are still not fully elucidated. We investigated the aberrantly expressed miRNAs involved in hepatoma by comparison of miRNA expression profiles in cancerous hepatocytes with normal primary human hepatocytes, and 37 dysregulated miRNAs were screened out by twofold change with a significant difference (P<0.05). Clustering analysis based on 13 miRNAs with changes over 15-folds showed that the miRNA expression patterns between the cancerous and normal hepatocytes were clearly different. Among the 13 miRNAs, we found that miR-375 was significantly downregulated in hepatocellular carcinoma (HCC) tissues and cell lines. Overexpression of miR-375 in liver cancer cells decreased cell proliferation, clonogenicity, migration/ invasion and also induced G1 arrest and apoptosis. To unveil the molecular mechanism of miR-375-mediated phenotype in hepatoma cells described above, we examined the putative targets using bioinformatics tools and found that astrocyte elevated gene-1 (AEG-1) was a potential target of miR-375. Then we demonstrated that miR-375 bound directly to the 30-untranslated region of AEG-1 and inhibited the expression of AEG-1. TaqMan quantitative reverse transcriptase-PCR and western blot analysis showed that miR-375 expression was inversely correlated with AEG-1 expression in HCC tissues. Knockdown of AEG-1 by RNAi in HCC cells, similar to miR-375 overexpression, suppressed tumor properties. Ectopic expression of AEG-1, conversely, could partially reverse the antitumor effects of miR-375. In a mouse model, therapeutic administration of cholesterol-conjugated 20-O-methyl-modified miR-375 mimics (Chol-miR375) could significantly suppress the growth of hepatoma xenografts in nude mice. In conclusion, our findings indicate that miR-375 targets AEG-1 in HCC and suppresses liver cancer cell growth in vitro and in vivo, and highlight the therapeutic potential of miR-375 in HCC treatment. Oncogene (2012) 31, 3357-3369; doi: 10.1038/onc.2011.500; published online 7 November 2011	[He, X-X; Chang, Y.; Xie, Q-H; Tang, F.; Li, P-Y; Song, Y-H; Lin, J-S] Huazhong Univ Sci & Technol, Tongji Hosp, Inst Liver Dis, Tongji Med Coll, Wuhan 430030, Peoples R China; [Meng, F-Y] Huazhong Univ Sci & Technol, Tongji Hosp, Inst Organ Transplantat,Tongji Med Coll, Key Lab Organ Transplantat,Minist Educ,Minist Hlt, Wuhan 430030, Peoples R China; [Wang, M-Y] Huazhong Univ Sci & Technol, Dept Oncol, Tongji Hosp, Tongji Med Coll, Wuhan 430030, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology	Lin, JS (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Inst Liver Dis, Tongji Med Coll, 1095 Jie Fang Ave, Wuhan 430030, Peoples R China.	jslin@tjh.tjmu.edu.cn	He, Xing-Xing/G-9200-2014	He, Xing-Xing/0000-0003-0001-8473	National Basic Research Program of China [2007CB512903]; National Natural Science Foundation of China [81101824, 30872237]	National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank Dr Xin Chen of University of California, San Francisco for critical review of the manuscript. This work was financially supported by the National Basic Research Program of China (no. 2007CB512903) and the National Natural Science Foundation of China (no. 81101824 and 30872237).	Avissar M, 2009, CLIN CANCER RES, V15, P2850, DOI 10.1158/1078-0432.CCR-08-3131; Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Braconi C, 2008, HEPATOLOGY, V47, P1807, DOI 10.1002/hep.22326; Budhu A, 2008, HEPATOLOGY, V47, P897, DOI 10.1002/hep.22160; Emdad L, 2007, PHARMACOL THERAPEUT, V114, P155, DOI 10.1016/j.pharmthera.2007.01.010; Gramantieri L, 2007, CANCER RES, V67, P6092, DOI 10.1158/0008-5472.CAN-06-4607; Gramantieri L, 2008, J CELL MOL MED, V12, P2189, DOI 10.1111/j.1582-4934.2008.00533.x; Hu GH, 2009, CLIN CANCER RES, V15, P5615, DOI 10.1158/1078-0432.CCR-09-0049; Huang YS, 2008, J GASTROEN HEPATOL, V23, P87, DOI 10.1111/j.1440-1746.2007.05223.x; Jiang J, 2008, CLIN CANCER RES, V14, P419, DOI 10.1158/1078-0432.CCR-07-0523; Kang DC, 2005, GENE, V353, P8, DOI [10.1016/j.gene.2005.04.006, 10.1016/j.gene.2005.04.005]; Kikuno N, 2007, ONCOGENE, V26, P7647, DOI 10.1038/sj.onc.1210572; Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021; Ladeiro Y, 2008, HEPATOLOGY, V47, P1955, DOI 10.1002/hep.22256; Lee EJ, 2007, INT J CANCER, V120, P1046, DOI 10.1002/ijc.22394; Lee SG, 2008, ONCOGENE, V27, P1114, DOI 10.1038/sj.onc.1210713; Lee SG, 2009, ONCOGENE, V28, P2476, DOI 10.1038/onc.2009.93; Lee SG, 2006, P NATL ACAD SCI USA, V103, P17390, DOI 10.1073/pnas.0608386103; Li J, 2008, CLIN CANCER RES, V14, P3319, DOI 10.1158/1078-0432.CCR-07-4054; Li Y, 2004, J CANCER RES CLIN, V130, P460, DOI 10.1007/s00432-004-0564-9; Liu AM, 2010, BIOCHEM BIOPH RES CO, V394, P623, DOI 10.1016/j.bbrc.2010.03.036; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Malarkey DE, 2005, TOXICOL PATHOL, V33, P27, DOI 10.1080/01926230590881826; Maruyama M, 2003, CELL TRANSPLANT, V12, P593, DOI 10.3727/000000003108747190; Meng FY, 2010, WORLD J GASTROENTERO, V16, P1660, DOI 10.3748/wjg.v16.i13.1660; Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022; Murakami Y, 2006, ONCOGENE, V25, P2537, DOI 10.1038/sj.onc.1209283; Petri A, 2009, CANCER RES, V69, P393, DOI 10.1158/0008-5472.CAN-08-2749; Poy MN, 2004, NATURE, V432, P226, DOI 10.1038/nature03076; Santamaria E, 2007, LIVER INT, V27, P163, DOI 10.1111/j.1478-3231.2007.01447.x; Scherr M, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm971; Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121; Tili Esmerina, 2007, Future Oncol, V3, P521, DOI 10.2217/14796694.3.5.521; Tsukamoto Y, 2010, CANCER RES, V70, P2339, DOI 10.1158/0008-5472.CAN-09-2777; Varnholt H, 2008, HEPATOLOGY, V47, P1223, DOI 10.1002/hep.22158; Vester B, 2004, BIOCHEMISTRY-US, V43, P13233, DOI 10.1021/bi0485732; Xu JB, 2011, MED ONCOL, V28, P455, DOI 10.1007/s12032-010-9475-6; Yoo BK, 2009, J CLIN INVEST, V119, P465, DOI 10.1172/JCI36460; Yu CP, 2009, CARCINOGENESIS, V30, P894, DOI 10.1093/carcin/bgp064; Zhang B, 2011, CARCINOGENESIS, V32, P2, DOI 10.1093/carcin/bgq209	40	285	309	0	73	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2012	31	28					3357	3369		10.1038/onc.2011.500	http://dx.doi.org/10.1038/onc.2011.500			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973NT	22056881				2022-12-17	WOS:000306367600005
J	French, CA; Ramirez, CL; Kolmakova, J; Hickman, TT; Cameron, MJ; Thyne, ME; Kutok, JL; Toretsky, JA; Tadavarthy, AK; Kees, UR; Fletcher, JA; Aster, JC				French, C. A.; Ramirez, C. L.; Kolmakova, J.; Hickman, T. T.; Cameron, M. J.; Thyne, M. E.; Kutok, J. L.; Toretsky, J. A.; Tadavarthy, A. K.; Kees, U. R.; Fletcher, J. A.; Aster, J. C.			BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells	ONCOGENE			English	Article						BRD3-NUT; t(15;19); t(9;15); NUT midline carcinoma	BROMODOMAIN PROTEIN; AGGRESSIVE CARCINOMA; S-PHASE; P-TEFB; REARRANGEMENT; INTERACTS; EXPORT; BINDS; CRM1	An unusual group of carcinomas, here termed nuclear protein in testis (NUT) midline carcinomas (NMC), are characterized by translocations that involve NUT, a novel gene on chromosome 15. In about 2/3rds of cases, NUT is fused to BRD4 on chromosome 19. Using a candidate gene approach, we identified two NMCs harboring novel rearrangements that result in the fusion of NUT to BRD3 on chromosome 9. The BRD3-NUT fusion gene encodes a protein composed of two tandem chromatin-binding bromodomains, an extra-terminal domain, a bipartite nuclear localization sequence, and almost the entirety of NUT that is highly homologous to BRD4-NUT. The function of NUT is unknown, but here we show that NUT contains nuclear localization and export sequences that promote nuclear-cytoplasmic shuttling via a leptomycin-sensitive pathway. In contrast, BRD3-NUT and BRD4-NUT are strictly nuclear, implying that the BRD moiety retains NUT in the nucleus via interactions with chromatin. Consistent with this idea, FRAP studies show that BRD4, BRD4-NUT and BRD3-NUT have significantly slower rates of lateral nuclear diffusion than that of NUT. To investigate the functional role of BRD-NUT fusion proteins in NMCs, we investigated the effects of siRNA-induced BRD3-NUT and BRD4-NUT withdrawal. Silencing of these proteins in NMC cell lines resulted in squamous differentiation and cell cycle arrest. Together, these data suggest that BRD-NUT fusion proteins contribute to carcinogenesis by associating with chromatin and interfering with epithelial differentiation.	[French, C. A.; Hickman, T. T.; Cameron, M. J.; Thyne, M. E.; Kutok, J. L.; Fletcher, J. A.; Aster, J. C.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [French, C. A.; Hickman, T. T.; Cameron, M. J.; Thyne, M. E.; Kutok, J. L.; Fletcher, J. A.; Aster, J. C.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA; [Ramirez, C. L.] Harvard Univ, Sch Med, Dept Biol, Cambridge, MA 02138 USA; [Ramirez, C. L.] Harvard Univ, Sch Med, Dept Biomed Sci, Cambridge, MA 02138 USA; [Kolmakova, J.] Boston Univ, Sch Med, Boston, MA 02215 USA; [Toretsky, J. A.] Georgetown Univ, Lombardi Comprehens Canc Ctr & Pediat, Dept Oncol, Washington, DC 20057 USA; [Tadavarthy, A. K.] Allina Hosp & Clin, Minneapolis, MN USA; [Kees, U. R.] Univ Western Australia, Telethon Inst Child Hlth Res, Perth, WA 6009, Australia; [Kees, U. R.] Univ Western Australia, Ctr Child Hlth Res, Perth, WA 6009, Australia	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard University; Harvard University; Boston University; Georgetown University; Telethon Kids Institute; University of Western Australia; University of Western Australia	French, CA (corresponding author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.	Cfrench@partners.org		Ramirez, Cherie/0000-0002-0397-6872; Hickman, Tyler/0000-0003-2623-3251				Dey A, 2003, P NATL ACAD SCI USA, V100, P8758, DOI 10.1073/pnas.1433065100; Farina A, 2004, MOL CELL BIOL, V24, P9059, DOI 10.1128/MCB.24.20.9059-9069.2004; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; French CA, 2004, J CLIN ONCOL, V22, P4135, DOI 10.1200/JCO.2004.02.107; French CA, 2003, CANCER RES, V63, P304; French CA, 2001, AM J PATHOL, V159, P1987, DOI 10.1016/S0002-9440(10)63049-0; Haruki N, 2005, J MED GENET, V42, P558, DOI 10.1136/jmg.2004.029686; Jang MK, 2005, MOL CELL, V19, P523, DOI 10.1016/j.molcel.2005.06.027; KEES UR, 1991, AM J PEDIAT HEMATOL, V13, P459; Maruyama T, 2002, MOL CELL BIOL, V22, P6509, DOI 10.1128/MCB.22.18.6509-6520.2002; MERTENS F, 2006, PEDIAT BLOOD CA 0102; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Ottinger M, 2006, J VIROL, V80, P10772, DOI 10.1128/JVI.00804-06; Toretsky JA, 2003, AM J CLIN ONCOL-CANC, V26, P300, DOI 10.1097/00000421-200306000-00019; Yang ZY, 2005, MOL CELL, V19, P535, DOI 10.1016/j.molcel.2005.06.029	15	285	347	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 3	2008	27	15					2237	2242		10.1038/sj.onc.1210852	http://dx.doi.org/10.1038/sj.onc.1210852			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	283FE	17934517				2022-12-17	WOS:000254621300014
J	Widlund, HR; Fisher, DE				Widlund, HR; Fisher, DE			Microphthalamia-associated transcription factor: a critical regulator of pigment cell development and survival	ONCOGENE			English	Article						MITF; melanoma; development; melanocyte; survival	WAARDENBURG SYNDROME TYPE-2; CREST-DERIVED MELANOCYTES; WNT SIGNALING PATHWAY; NEURAL-CREST; TYROSINASE GENE; BETA-CATENIN; MITF GENE; HIRSCHSPRUNG-DISEASE; MALIGNANT-MELANOMA; POLYCYSTIC KIDNEY	The microphthalamia-associated transcription factor (MITF) is an integral transcriptional regulator in melanocyte, the lineage from which melanoma cells originate. This basic-helix-loop-helix-leucine-zipper (bHLHzip) protein is critical for melanocyte cell-fate choice during commitment from pluripotent precursor cells in the neural crest. Its role in differentiation pathways has been highlighted by its potent transcriptional and lineage-specific regulation of the three major pigment enzymes: tyrosinase, Tyrp1, and Dell as well as other pigmentation factors. However, the cellular functions of MITF seem to be wider than differentiation and celt-fate pathways alone, since melanocytes and melanoma cells appear to require an expression of this factor. Here, we discuss the transcriptional networks in which MITF is thought to reside and describe signaling pathways in the cell which impinge on MITF. Accumulating evidence supports the notion that MITF is involved in survival pathways during normal development as well as during neoplastic growth of melanoma.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	Fisher, DE (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, 44 Binney St, Boston, MA 02115 USA.	David_Fisher@dfci.harvard.edu		Widlund, Hans/0000-0002-7506-2447	NIAMS NIH HHS [AR43369] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043369] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Amiel J, 1998, CLIN DYSMORPHOL, V7, P17; AROCA P, 1993, J BIOL CHEM, V268, P25650; BALDWIN CT, 1992, NATURE, V355, P637, DOI 10.1038/355637a0; BENTLEY NJ, 1994, MOL CELL BIOL, V14, P7996, DOI 10.1128/MCB.14.12.7996; Bertolotto C, 1996, J CELL BIOL, V134, P747, DOI 10.1083/jcb.134.3.747; Bertolotto C, 1998, MOL CELL BIOL, V18, P694, DOI 10.1128/MCB.18.2.694; Bertolotto C, 1998, J CELL BIOL, V142, P827, DOI 10.1083/jcb.142.3.827; Blume-Jensen P, 2000, NAT GENET, V24, P157, DOI 10.1038/72814; Bondurand N, 2000, HUM MOL GENET, V9, P1907, DOI 10.1093/hmg/9.13.1907; BUNSAM KJ, 2001, AM J SURG PATHOL, V25, P197; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; CABLE J, 1995, MECH DEVELOP, V50, P139, DOI 10.1016/0925-4773(94)00331-G; Carreira S, 2000, J BIOL CHEM, V275, P21920, DOI 10.1074/jbc.M000035200; Dorsky RI, 1998, NATURE, V396, P370, DOI 10.1038/24620; Dorsky RI, 2000, GENE DEV, V14, P158; Dunn KJ, 2000, P NATL ACAD SCI USA, V97, P10050, DOI 10.1073/pnas.97.18.10050; Fuchs S, 2001, MOL MED, V7, P115, DOI 10.1007/BF03401945; FULLER BB, 1987, J BIOL CHEM, V262, P4024; GANSS R, 1994, J BIOL CHEM, V269, P29808; GIEBEL LB, 1991, P NATL ACAD SCI USA, V88, P8696, DOI 10.1073/pnas.88.19.8696; Goding CR, 2000, GENE DEV, V14, P1712; Hecht A, 2000, EMBO REP, V1, P24, DOI 10.1093/embo-reports/kvd012; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; Hemesath TJ, 1998, NATURE, V391, P298, DOI 10.1038/34681; Hertwig P., 1942, ZEITSCHR INDUKT ABSTAMM U VERERBUNGSL, V80, P220, DOI 10.1007/BF01741984; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Hornyak TJ, 2001, MECH DEVELOP, V101, P47, DOI 10.1016/S0925-4773(00)00569-4; Hou L, 2000, DEVELOPMENT, V127, P5379; HUGHES AE, 1994, NAT GENET, V7, P509, DOI 10.1038/ng0894-509; Ikeya M, 1997, NATURE, V389, P966, DOI 10.1038/40146; Imokawa G, 1996, BIOCHEM J, V314, P305, DOI 10.1042/bj3140305; Ingram DA, 2000, J EXP MED, V191, P181, DOI 10.1084/jem.191.1.181; Jacobs JJL, 2000, NAT GENET, V26, P291, DOI 10.1038/81583; Jin EJ, 2001, DEV BIOL, V233, P22, DOI 10.1006/dbio.2001.0222; KAMADA S, 1995, CANCER RES, V55, P354; King R, 1999, AM J PATHOL, V155, P731, DOI 10.1016/S0002-9440(10)65172-3; Lee M, 2000, J BIOL CHEM, V275, P37978, DOI 10.1074/jbc.M003816200; LERNER AB, 1986, J INVEST DERMATOL, V87, P299, DOI 10.1111/1523-1747.ep12524353; Lister JA, 1999, DEVELOPMENT, V126, P3757; LOWINGS P, 1992, MOL CELL BIOL, V12, P3653, DOI 10.1128/MCB.12.8.3653; MALEK ZAA, 1985, CANCER RES, V45, P4735; MAYER TC, 1979, J EXP ZOOL, V210, P81, DOI 10.1002/jez.1402100109; McCallion AS, 2001, PIGM CELL RES, V14, P161, DOI 10.1034/j.1600-0749.2001.140305.x; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; Nakamura M, 2002, J DERMATOL SCI, V28, P1, DOI 10.1016/S0923-1811(01)00158-X; Nakayama A, 1998, MECH DEVELOP, V70, P155, DOI 10.1016/S0925-4773(97)00188-3; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; Nobukuni Y, 1996, AM J HUM GENET, V59, P76; Pingault V, 1998, NAT GENET, V18, P171, DOI 10.1038/ng0298-171; Polakis P, 2000, GENE DEV, V14, P1837; Potterf SB, 2000, HUM GENET, V107, P1, DOI 10.1007/s004390050001; Price ER, 1998, J BIOL CHEM, V273, P33042, DOI 10.1074/jbc.273.49.33042; Price ER, 2001, NEURON, V30, P15, DOI 10.1016/S0896-6273(01)00259-8; Price ER, 1998, J BIOL CHEM, V273, P17983, DOI 10.1074/jbc.273.29.17983; Rimm DL, 1999, AM J PATHOL, V154, P325, DOI 10.1016/S0002-9440(10)65278-9; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUSSELL LB, 1979, GENETICS, V92, pS153; Saito H, 2002, J BIOL CHEM, V277, P28787, DOI 10.1074/jbc.M203719200; Salti GI, 2000, CANCER RES, V60, P5012; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Shibahara S, 2001, J INVEST DERM SYMP P, V6, P99, DOI 10.1046/j.0022-202x.2001.00010.x; Shin MK, 1999, NATURE, V402, P496, DOI 10.1038/990040; Smith SD, 2000, J MED GENET, V37, P446, DOI 10.1136/jmg.37.6.446; Steingrimsson E, 2002, P NATL ACAD SCI USA, V99, P4477, DOI 10.1073/pnas.072071099; Steingrimsson E, 1996, EMBO J, V15, P6280, DOI 10.1002/j.1460-2075.1996.tb01018.x; STEINGRIMSSON E, 1994, NAT GENET, V8, P256, DOI 10.1038/ng1194-256; Tachibana M, 1996, NAT GENET, V14, P50, DOI 10.1038/ng0996-50; Tachibana M, 2000, PIGM CELL RES, V13, P230, DOI 10.1034/j.1600-0749.2000.130404.x; Takeda K, 2000, J BIOL CHEM, V275, P14013, DOI 10.1074/jbc.C000113200; Takeda K, 2000, HUM MOL GENET, V9, P125, DOI 10.1093/hmg/9.1.125; TASSABEHJI M, 1994, NAT GENET, V8, P251, DOI 10.1038/ng1194-251; TASSABEHJI M, 1993, NAT GENET, V3, P26, DOI 10.1038/ng0193-26; TASSABEHJI M, 1995, HUM MOL GENET, V4, P2131, DOI 10.1093/hmg/4.11.2131; van Noort M, 2002, DEV BIOL, V244, P1, DOI 10.1006/dbio.2001.0566; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Verastegui C, 2000, J BIOL CHEM, V275, P30757, DOI 10.1074/jbc.C000445200; Watanabe A, 1998, NAT GENET, V18, P283, DOI 10.1038/ng0398-283; Weilbaecher KN, 2001, MOL CELL, V8, P749, DOI 10.1016/S1097-2765(01)00360-4; Weilbaecher KN, 1998, J EXP MED, V187, P775, DOI 10.1084/jem.187.5.775; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; WONG G, 1975, NATURE, V255, P644, DOI 10.1038/255644a0; Wu M, 2000, GENE DEV, V14, P301; Xu WD, 2000, EXP CELL RES, V255, P135, DOI 10.1006/excr.2000.4803; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1; Yasumoto K, 2002, EMBO J, V21, P2703, DOI 10.1093/emboj/21.11.2703; Yasumoto K, 1997, J BIOL CHEM, V272, P503; YASUMOTO KI, 1994, MOL CELL BIOL, V14, P8058, DOI 10.1128/MCB.14.12.8058; YOKOYAMA K, 1994, J BIOL CHEM, V269, P27080	88	285	297	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2003	22	20					3035	3041		10.1038/sj.onc.1206443	http://dx.doi.org/10.1038/sj.onc.1206443			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	682MV	12789278				2022-12-17	WOS:000183096600003
J	Stead, E; White, J; Faast, R; Conn, S; Goldstone, S; Rathjen, J; Dhingra, U; Rathjen, P; Walker, D; Dalton, S				Stead, E; White, J; Faast, R; Conn, S; Goldstone, S; Rathjen, J; Dhingra, U; Rathjen, P; Walker, D; Dalton, S			Pluripotent cell division cycles are driven by ectopic Cdk2, cyclin A/E and E2F activities	ONCOGENE			English	Article						cell cycle; pluripotent; stem cell	EMBRYONIC STEM-CELLS; DIFFERENTIATION INHIBITING ACTIVITY; RETINOIC ACID; MOUSE EMBRYOS; BREAST-CANCER; ES CELLS; RETINOBLASTOMA PROTEIN; REGULATED EXPRESSION; GERM-CELLS; IN-VITRO	Pluripotent cells of embryonic origin proliferate at unusually rapid rates and have a characteristic cell cycle structure with truncated gap phases. To define the molecular basis for this we have characterized the cell cycle control of murine embryonic stem cells and early primitive ectoderm-like cells. These cells display precocious Cdk2, cyclin A and cyclin E kinase activities that are conspicuously cell cycle independent. Suppression of Cdk2 activity significantly decreased cycling times of pluripotent cells, indicating it to be rate-limiting for rapid cell division, although this had no impact on cell cycle structure and the establishment of extended gap phases. Cdc2-cyclin B was the only Cdk activity that was identified to be cell cycle regulated in pluripotent cells. Cell cycle regulation of cyclin B levels and Y-15 regulation of Cdc2 contribute to the temporal changes in Cdc2-cyclin B activity. E2F target genes are constitutively active throughout the cell cycle, reflecting the low activity of pocket proteins such as p107 and pRb and constitutive activity of pRb-kinases. These results show that rapid cell division cycles in primitive cells of embryonic origin are driven by extreme levels of Cdk activity that lack normal cell cycle periodicity.	Univ Adelaide, Dept Mol Biosci, Adelaide, SA 5005, Australia; Univ Adelaide, Ctr Mol Genet Dev, Adelaide, SA 5005, Australia; Univ Adelaide, BresaGen Luminis Cell Therapy Program, Adelaide, SA 5005, Australia; Hoffmann La Roche, Nutley, NJ 07110 USA	University of Adelaide; University of Adelaide; University of Adelaide; Roche Holding	Dalton, S (corresponding author), Univ Adelaide, Dept Mol Biosci, Adelaide, SA 5005, Australia.	Stephen.Dalton@adelaide.edu.au	Conn, Simon/G-1191-2012	Wright, Josephine/0000-0003-4588-8827; Conn, Simon/0000-0002-1376-4515				BEDDINGTON RSP, 1989, DEVELOPMENT, V105, P733; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; Brook FA, 1997, P NATL ACAD SCI USA, V94, P5709, DOI 10.1073/pnas.94.11.5709; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; CHISHOLM JC, 1985, J EMBRYOL EXP MORPH, V86, P311; DHINGRA UH, 1998, Patent No. 5811420; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Edgar BA, 1996, SCIENCE, V274, P1646, DOI 10.1126/science.274.5293.1646; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Gabrielli BG, 1997, J BIOL CHEM, V272, P28607, DOI 10.1074/jbc.272.45.28607; GARDNER RL, 1988, J CELL SCI, P11; GARDNER RL, 1979, J EMBRYOL EXP MORPH, V52, P141; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; GrayBablin J, 1996, P NATL ACAD SCI USA, V93, P15215, DOI 10.1073/pnas.93.26.15215; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; Haas K, 1997, ONCOGENE, V15, P2615, DOI 10.1038/sj.onc.1201434; Harwell RM, 2000, CANCER RES, V60, P481; HAUB O, 1991, DEVELOPMENT, V112, P397; HEBERT JM, 1990, DEV BIOL, V138, P454, DOI 10.1016/0012-1606(90)90211-Z; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HOGAN B, 1989, MANIPULATING MOUSE E; HOSLER BA, 1989, MOL CELL BIOL, V9, P5623, DOI 10.1128/MCB.9.12.5623; Hu B, 2001, MOL CELL BIOL, V21, P2755, DOI 10.1128/MCB.21.8.2755-2766.2001; Humbert PO, 2000, MOL CELL, V6, P281, DOI 10.1016/S1097-2765(00)00029-0; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; KEYOMARSI K, 1995, ONCOGENE, V11, P941; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; KRANENBURG O, 1995, ONCOGENE, V10, P87; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Lake JA, 2000, J CELL SCI, V113, P555; MACAULEY A, 1993, DEVELOPMENT, V117, P873; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; Meijer L, 1997, METHOD ENZYMOL, V283, P113; Mumberg D, 1996, ONCOGENE, V13, P2493; MUMMERY CL, 1987, DEV BIOL, V121, P10, DOI 10.1016/0012-1606(87)90133-3; MUMMERY CL, 1987, CELL DIFFER DEV, V20, P153, DOI 10.1016/0045-6039(87)90429-5; MURRAY A, 1993, CELL CYCLE; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; NICHOLS J, 1990, DEVELOPMENT, V110, P1341; Nielsen NH, 1997, ONCOGENE, V14, P295, DOI 10.1038/sj.onc.1200833; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Nurse P, 2000, CELL, V100, P71, DOI 10.1016/S0092-8674(00)81684-0; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PEASE S, 1990, DEV BIOL, V141, P344, DOI 10.1016/0012-1606(90)90390-5; PEDERSEN RA, 1994, REPROD FERT DEVELOP, V6, P543, DOI 10.1071/RD9940543; Pelton TA, 1998, REPROD FERT DEVELOP, V10, P535, DOI 10.1071/RD98084; POWER MA, 1993, ANAT EMBRYOL, V187, P493; Rathjen J, 1999, J CELL SCI, V112, P601; RATHJEN PD, 1990, GENE DEV, V4, P2308, DOI 10.1101/gad.4.12b.2308; REMPEL RE, 1995, J BIOL CHEM, V270, P6843, DOI 10.1074/jbc.270.12.6843; RESNICK JL, 1992, NATURE, V359, P550, DOI 10.1038/359550a0; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROGERS MB, 1991, DEVELOPMENT, V113, P815; Savatier P, 1996, ONCOGENE, V12, P309; SAVATIER P, 1994, ONCOGENE, V9, P809; SCHOLER HR, 1990, EMBO J, V9, P2185, DOI 10.1002/j.1460-2075.1990.tb07388.x; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; Smith C.S., 1999, Biological Invasions, V1, P89, DOI 10.1023/A:1010091918466; SNOW MHL, 1977, J EMBRYOL EXP MORPH, V42, P293; SOLTER D, 1971, EXP CELL RES, V64, P331, DOI 10.1016/0014-4827(71)90084-X; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Sweeney C, 1996, DEVELOPMENT, V122, P53; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Wianny F, 1998, DEV DYNAM, V212, P49, DOI 10.1002/(SICI)1097-0177(199805)212:1<49::AID-AJA5>3.0.CO;2-2; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; WIMMEL A, 1994, ONCOGENE, V9, P995; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Yarden A, 1996, DEV DYNAM, V206, P1	75	285	294	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 28	2002	21	54					8320	8333		10.1038/sj.onc.1206015	http://dx.doi.org/10.1038/sj.onc.1206015			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447695				2022-12-17	WOS:000179323900010
J	Wiest, T; Schwarz, E; Enders, C; Flechtenmacher, C; Bosch, FX				Wiest, T; Schwarz, E; Enders, C; Flechtenmacher, C; Bosch, FX			Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control	ONCOGENE			English	Article						human papillomavirus; head and neck cancer; p53; pRb; E6; E7 oncogenes	HUMAN-PAPILLOMAVIRUS TYPE-16; CERVICAL-CANCER; MEDIATED PCR; DNA; CARCINOMA; INFECTION; SEQUENCES; AMPLIFICATION; MUTATIONS; OVEREXPRESSION	We have identified parameters which define a causal role of HPV16 in head and neck cancer. Twenty-eight tumours which were typed positive for HPV16 DNA, were comprehensively analysed for expression of the viral oncogenes E6 and E7, the status of the p53 gene, and the protein status of pRb and p16(INK4a). In a subset of cases, we have searched for integrated viral DNA, and have determined the genomic status of the E6 gene. Expression of E6/E7 was found in 12 tumours most of which were derived from the oropharynx, whereas p53 mutations were present in 13 tumours from various sites. The tumours either carried p53 mutations but did not express E6/E7, or they did express E6/E7 but were p53-wild-type. Coexistence of E6/E7 expression with a mutated p53 was found in only one case. Strikingly, in most p53-mutated tumours without E6/E7 expression, we found the E6 gene to be disrupted. E6/E7 expression was associated with reduced pRb and overexpressed p16(INK4a). Viral-cellular fusion transcripts were found in two cases. Our data demonstrate that HPV16 DNA-positivity in head and neck cancers is not indicative of a causal role. A causal role of HPV16 in head and neck cancer is defined by: E6/E7 expression, viral integration with an intact E6 gene, and perturbation of pRb cell cycle control. Mostly, the p53 gene is wild-type.	Univ Hals Nasen Ohrenklin, Mol Biol Lab, D-69120 Heidelberg, Germany; Deutsch Krebsforschungszentrum, Angew Tumorvirol, D-69120 Heidelberg, Germany; Heidelberg Univ, Inst Pathol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg	Bosch, FX (corresponding author), Univ Hals Nasen Ohrenklin, Mol Biol Lab, Im Neuenheimer Feld 400, D-69120 Heidelberg, Germany.	Franz_Bosch@med.uni-heidelberg.de						Andl T, 1998, CANCER RES, V58, P5; BARTEN M, 1995, VIRCHOWS ARCH, V427, P153; BERUMEN J, 1994, INT J CANCER, V56, P640, DOI 10.1002/ijc.2910560506; Chiba I, 1996, ONCOGENE, V12, P1663; CROOK T, 1992, LANCET, V339, P1070, DOI 10.1016/0140-6736(92)90662-M; CULLEN AP, 1991, J VIROL, V65, P606, DOI 10.1128/JVI.65.2.606-612.1991; DEVILLIERS EM, 1985, INT J CANCER, V36, P575, DOI 10.1002/ijc.2910360510; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELAWADY MK, 1987, VIROLOGY, V159, P389, DOI 10.1016/0042-6822(87)90478-8; Erber R, 1998, ONCOGENE, V16, P1671, DOI 10.1038/sj.onc.1201690; FUJITA M, 1992, CANCER RES, V52, P5323; Gardiol D, 1998, J GEN VIROL, V79, P1963, DOI 10.1099/0022-1317-79-8-1963; Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709; Gruttgen A, 2001, J PATHOL, V194, P311, DOI 10.1002/path.906; Harrington JJ, 2001, NAT BIOTECHNOL, V19, P440, DOI 10.1038/88107; He D, 1997, INT J CANCER, V72, P959; HOPPESEYLER F, 1994, MOL CARCINOGEN, V10, P134, DOI 10.1002/mc.2940100304; JACOBS MV, 1995, J CLIN MICROBIOL, V33, P901, DOI 10.1128/JCM.33.4.901-905.1995; KAHN T, 1994, CANCER RES, V54, P1305; Klaes R, 2001, INT J CANCER, V92, P276, DOI 10.1002/ijc.1174; Klaes R, 1999, CANCER RES, V59, P6132; Luft F, 2001, INT J CANCER, V92, P9, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1144>3.0.CO;2-L; MAITLAND NJ, 1987, BRIT J CANCER, V56, P245, DOI 10.1038/bjc.1987.185; MATSUKURA T, 1989, VIROLOGY, V172, P63, DOI 10.1016/0042-6822(89)90107-4; MILDELANGOSCH K, 1995, INT J CANCER, V63, P639, DOI 10.1002/ijc.2910630507; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; Rassekh CH, 1998, LARYNGOSCOPE, V108, P362, DOI 10.1097/00005537-199803000-00010; RESNICK RM, 1990, JNCI-J NATL CANCER I, V82, P1477, DOI 10.1093/jnci/82.18.1477; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Scholes AGM, 1997, INT J CANCER, V71, P796, DOI 10.1002/(SICI)1097-0215(19970529)71:5<796::AID-IJC17>3.0.CO;2-6; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SEEDORF K, 1985, VIROLOGY, V145, P181, DOI 10.1016/0042-6822(85)90214-4; SNIJDERS PJF, 1992, INT J CANCER, V51, P845, DOI 10.1002/ijc.2910510602; STEENBERGEN RDM, 1995, CANCER RES, V55, P5465; van Houten VMM, 2001, INT J CANCER, V93, P232, DOI 10.1002/ijc.1313; VANDENBRULE AJC, 1989, J MED VIROL, V29, P20, DOI 10.1002/jmv.1890290105; Wilczynski SP, 1998, AM J PATHOL, V152, P145; YEUDALL WA, 1991, J GEN VIROL, V72, P173, DOI 10.1099/0022-1317-72-1-173; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	40	285	297	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1510	1517		10.1038/sj.onc.1205214	http://dx.doi.org/10.1038/sj.onc.1205214			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896579				2022-12-17	WOS:000173956800006
J	Lomonosova, E; Chinnadurai, G				Lomonosova, E.; Chinnadurai, G.			BH3-only proteins in apoptosis and beyond: an overview	ONCOGENE			English	Review						BH3-only; apoptosis; autophagy; non-apoptotic functions; cancer	BCL-2 FAMILY-MEMBER; PROGRAMMED CELL-DEATH; BREAST-CANCER CELLS; MITOCHONDRIAL-MEMBRANE PERMEABILIZATION; BECLIN 1-DEPENDENT AUTOPHAGY; CHRONIC LYMPHOCYTIC-LEUKEMIA; SURVIVAL-PROMOTING PROTEINS; SMALL-MOLECULE INHIBITORS; CYTOCHROME-C RELEASE; DNA-DAMAGE RESPONSE	BH3-only BCL-2 family proteins are effectors of canonical mitochondrial apoptosis. They discharge their pro-apoptotic functions through BH1-3 pro-apoptotic proteins such as BAX and BAK, while their activity is suppressed by BH1-4 anti-apoptotic BCL-2 family members. The precise mechanism by which BH3-only proteins mediate apoptosis remains unresolved. The existing data are consistent with three mutually nonexclusive models (1) displacement of BH1-3 proteins from complexes with BH1-4 proteins; (2) direct interaction with and conformational activation of BH1-3 proteins; and (3) membrane insertion and membrane remodeling. The BH3-only proteins appear to play critical roles in restraining cancer and inflammatory diseases such as rheumatoid arthritis. Molecules that mimic the effect of BH3-only proteins are being used in treatments against these diseases. The cell death activity of a subclass of BH3-only members (BNIP3 and BNIP3L) is linked to cardiomyocyte loss during heart failure. In addition to their established role in apoptosis, several BH3-only members also regulate diverse cellular functions in cell-cycle regulation, DNA repair and metabolism. Several members are implicated in the induction of autophagy and autophagic cell death, possibly through unleashing of the BH3-only autophagic effector Beclin 1 from complexes with BCL-2/BCL-xL. The Chapters included in the current Oncogene Review issues provide in-depth discussions on various aspects of major BH3-only proteins. Oncogene (2009) 27, S2-S19; doi:10.1038/onc.2009.39	[Lomonosova, E.; Chinnadurai, G.] St Louis Univ, Inst Mol Virol, Sch Med, Doisy Res Ctr, St Louis, MO 63104 USA	Saint Louis University	Chinnadurai, G (corresponding author), St Louis Univ, Inst Mol Virol, Sch Med, Doisy Res Ctr, 1100 S Grand Blvd, St Louis, MO 63104 USA.	chinnag@slu.edu			National Cancer Institute [CA-33616, CA-116262, CA-73803]; NATIONAL CANCER INSTITUTE [R21CA116262, R01CA033616, R01CA073803] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	GC received grant support from the National Cancer Institute Grants CA-33616, CA-116262 and CA-73803. We thank John Tavis, Ling-jun Zhao and Carolyn Mulhall for reading the paper.	Akiyama T, 2003, EMBO J, V22, P6653, DOI 10.1093/emboj/cdg635; Arena V, 2003, GENE CHROMOSOME CANC, V38, P91, DOI 10.1002/gcc.10245; Bachmann PS, 2005, BLOOD, V105, P2519, DOI 10.1182/blood-2004-05-2023; Bae J, 2000, J BIOL CHEM, V275, P25255, DOI 10.1074/jbc.M909826199; Bai L, 2005, AM J PATHOL, V166, P1523, DOI 10.1016/S0002-9440(10)62368-1; Baksh S, 2005, MOL CELL, V18, P637, DOI 10.1016/j.molcel.2005.05.010; Bessho T, 2000, J BIOL CHEM, V275, P7451, DOI 10.1074/jbc.275.11.7451; Bingle CD, 2000, J BIOL CHEM, V275, P22136, DOI 10.1074/jbc.M909572199; Bivona TG, 2006, MOL CELL, V21, P481, DOI 10.1016/j.molcel.2006.01.012; Bouillet P, 2002, J CELL SCI, V115, P1567; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BOYD JM, 1995, ONCOGENE, V11, P1921; Bredel M, 2005, CANCER RES, V65, P4088, DOI 10.1158/0008-5472.CAN-04-4229; Broustas CG, 2004, J BIOL CHEM, V279, P26780, DOI 10.1074/jbc.M400159200; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Burton TR, 2006, INT J CANCER, V118, P1660, DOI 10.1002/ijc.21547; Cao XH, 2004, MOL CELL BIOL, V24, P9705, DOI 10.1128/MCB.24.22.9705-9725.2004; Cartron PF, 2004, MOL CELL, V16, P807, DOI 10.1016/j.molcel.2004.10.028; Castells A, 1999, GASTROENTEROLOGY, V117, P831, DOI 10.1016/S0016-5085(99)70341-0; Chattopadhyay A, 2001, ONCOGENE, V20, P4507, DOI 10.1038/sj.onc.1204584; Chen GG, 2001, CANCER LETT, V172, P75, DOI 10.1016/S0304-3835(01)00630-9; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Chipuk JE, 2008, TRENDS CELL BIOL, V18, P157, DOI 10.1016/j.tcb.2008.01.007; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Claveria C, 2003, BIOCHEM BIOPH RES CO, V304, P531, DOI 10.1016/S0006-291X(03)00626-0; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Cristea IM, 2004, CHEM PHYS LIPIDS, V129, P133, DOI 10.1016/j.chemphyslip.2004.02.002; Czabotar PE, 2007, P NATL ACAD SCI USA, V104, P6217, DOI 10.1073/pnas.0701297104; Dai ZY, 2006, BIOCHEM BIOPH RES CO, V351, P455, DOI 10.1016/j.bbrc.2006.10.055; Daido S, 2004, CANCER RES, V64, P4286, DOI 10.1158/0008-5472.CAN-03-3084; Danial NN, 2008, NAT MED, V14, P144, DOI 10.1038/nm1717; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; Day CL, 2008, J MOL BIOL, V380, P958, DOI 10.1016/j.jmb.2008.05.071; Denisov AY, 2006, BIOCHEMISTRY-US, V45, P2250, DOI 10.1021/bi052332s; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Diwan A, 2007, J CLIN INVEST, V117, P2825, DOI 10.1172/JCI32490; Diwan A, 2007, P NATL ACAD SCI USA, V104, P6794, DOI 10.1073/pnas.0610666104; Dorn GW, 2008, J MOL MED, V86, P1085, DOI 10.1007/s00109-008-0362-y; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Elangovan B, 1997, J BIOL CHEM, V272, P24494, DOI 10.1074/jbc.272.39.24494; Enyedy IJ, 2001, J MED CHEM, V44, P4313, DOI 10.1021/jm010016f; Esposti MD, 2001, MOL CELL BIOL, V21, P7268, DOI 10.1128/MCB.21.21.7268-7276.2001; Feng W, 2007, J MOL BIOL, V372, P223, DOI 10.1016/j.jmb.2007.06.069; Fennell DA, 2008, FRONT BIOSCI-LANDMRK, V13, P6682, DOI 10.2741/3181; Fernandez Y, 2005, CANCER RES, V65, P6294, DOI 10.1158/0008-5472.CAN-05-0686; Fernandez-Luna JL, 2008, CELL SIGNAL, V20, P1921, DOI 10.1016/j.cellsig.2008.04.015; Fleischer A, 2002, ONCOGENE, V21, P3181, DOI 10.1038/sj.onc.1205464; Garcia N, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-93; Garcia-Saez AJ, 2004, BIOCHEMISTRY-US, V43, P10930, DOI 10.1021/bi036044c; Gartner A, 2000, MOL CELL, V5, P435, DOI 10.1016/S1097-2765(00)80438-4; Gavathiotis E, 2008, NATURE, V455, P1076, DOI 10.1038/nature07396; Giatromanolaki A, 2004, CLIN CANCER RES, V10, P5566, DOI 10.1158/1078-0432.CCR-04-0076; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Gillissen B, 2007, J CELL BIOL, V179, P701, DOI 10.1083/jcb.200703040; Grinberg M, 2002, J BIOL CHEM, V277, P12237, DOI 10.1074/jbc.M104893200; Gumienny TL, 1999, DEVELOPMENT, V126, P1011; Guo B, 2001, J BIOL CHEM, V276, P2780, DOI 10.1074/jbc.M005889200; Haker G, 2007, ARCH BIOCHEM BIOPHYS, V462, P150, DOI 10.1016/j.abb.2006.12.022; Hamacher-Brady A, 2007, CELL DEATH DIFFER, V14, P146, DOI 10.1038/sj.cdd.4401936; Han J, 1996, MOL CELL BIOL, V16, P5857; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Harada H, 2004, P NATL ACAD SCI USA, V101, P15313, DOI 10.1073/pnas.0406837101; Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200; Hetz C, 2008, TRENDS CELL BIOL, V18, P38, DOI 10.1016/j.tcb.2007.10.003; Hinds MG, 2005, CURR OPIN STRUC BIOL, V15, P690, DOI 10.1016/j.sbi.2005.10.003; Hsu SY, 1998, MOL ENDOCRINOL, V12, P1432, DOI 10.1210/me.12.9.1432; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Hubner A, 2008, MOL CELL, V30, P415, DOI 10.1016/j.molcel.2008.03.025; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; Hur J, 2006, CANCER RES, V66, P10153, DOI 10.1158/0008-5472.CAN-05-3696; Hur JY, 2004, P NATL ACAD SCI USA, V101, P2351, DOI 10.1073/pnas.0307337101; Imaizumi K, 1997, J BIOL CHEM, V272, P18842, DOI 10.1074/jbc.272.30.18842; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Kamer I, 2005, CELL, V122, P593, DOI 10.1016/j.cell.2005.06.014; Kammouni W, 2007, ARTHRITIS RHEUM, V56, P2854, DOI 10.1002/art.22853; Karbowski M, 2003, CELL DEATH DIFFER, V10, P870, DOI 10.1038/sj.cdd.4401260; Karst AM, 2007, CELL MOL LIFE SCI, V64, P318, DOI 10.1007/s00018-006-6364-4; Kaufmann T, 2007, CELL, V129, P423, DOI 10.1016/j.cell.2007.03.017; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061; Kim JY, 2004, J EXP MED, V199, P113, DOI 10.1084/jem.20030613; Kitada S, 2003, J MED CHEM, V46, P4259, DOI 10.1021/jm030190z; Kluck RM, 1999, J CELL BIOL, V147, P809, DOI 10.1083/jcb.147.4.809; Komatsu K, 2000, NAT CELL BIOL, V2, P1, DOI 10.1038/71316; Krajewska M, 2002, NEOPLASIA, V4, P129, DOI 10.1038/sj.neo.7900222; Ku B, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040025; Kudla G, 2000, J BIOL CHEM, V275, P22713, DOI 10.1074/jbc.M003807200; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Lama D, 2008, PROTEINS, V73, P492, DOI 10.1002/prot.22075; Lanave C, 2004, GENE, V333, P71, DOI 10.1016/j.gene.2004.02.017; Lee JH, 2004, J PATHOL, V202, P439, DOI 10.1002/path.1532; Lee SH, 2003, APMIS, V111, P599, DOI 10.1034/j.1600-0463.2003.1110602.x; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Ley R, 2005, CELL DEATH DIFFER, V12, P1008, DOI 10.1038/sj.cdd.4401688; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Lieberman HB, 1996, P NATL ACAD SCI USA, V93, P13890, DOI 10.1073/pnas.93.24.13890; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; Liu H, 2003, J BIOL CHEM, V278, P40330, DOI 10.1074/jbc.M304455200; Liu HT, 2006, ARTHRITIS RHEUM-US, V54, P3174, DOI 10.1002/art.22132; Liu XQ, 2003, IMMUNITY, V19, P341, DOI 10.1016/S1074-7613(03)00234-6; Liu ZH, 2005, MOL CANCER RES, V3, P21; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; Losonczi JA, 2000, BIOCHEMISTRY-US, V39, P11024, DOI 10.1021/bi000919v; Lu Y, 2006, PLOS MED, V3, P2229, DOI 10.1371/journal.pmed.0030467; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Ma C, 2007, J BIOL CHEM, V282, P30901, DOI 10.1074/jbc.M608694200; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Maiuri MC, 2007, AUTOPHAGY, V3, P374, DOI 10.4161/auto.4237; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; Marshansky V, 2001, J IMMUNOL, V166, P3130, DOI 10.4049/jimmunol.166.5.3130; Matsui H, 2007, MOL CELL, V25, P99, DOI 10.1016/j.molcel.2006.12.007; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Mestre-Escorihuela C, 2007, BLOOD, V109, P271, DOI 10.1182/blood-2006-06-026500; Michalak EM, 2008, CELL DEATH DIFFER, V15, P1019, DOI 10.1038/cdd.2008.16; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Miyashita MUT, 2001, FEBS LETT, V509, P135, DOI 10.1016/S0014-5793(01)03145-3; Mok CL, 1999, J EXP MED, V189, P575, DOI 10.1084/jem.189.3.575; Morales AA, 2004, LEUKEMIA, V18, P41, DOI 10.1038/sj.leu.2403183; Mund T, 2003, FASEB J, V17, P696, DOI 10.1096/fj.02-0657fje; Nakajima K, 2004, EMBO J, V23, P3216, DOI 10.1038/sj.emboj.7600333; Nakamura M, 2005, ACTA NEUROPATHOL, V110, P402, DOI 10.1007/s00401-005-1065-x; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Naresh A, 2006, CANCER RES, V66, P6412, DOI 10.1158/0008-5472.CAN-05-2368; Nguyen M, 2007, P NATL ACAD SCI USA, V104, P19512, DOI 10.1073/pnas.0709443104; Nikrad M, 2005, MOL CANCER THER, V4, P443; O'Brien SM, 2009, BLOOD, V113, P299, DOI 10.1182/blood-2008-02-137943; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Obata T, 2003, CLIN CANCER RES, V9, P6410; Oberstein A, 2007, J BIOL CHEM, V282, P13123, DOI 10.1074/jbc.M700492200; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Okami J, 2004, CANCER RES, V64, P5338, DOI 10.1158/0008-5472.CAN-04-0089; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Petros AM, 2000, PROTEIN SCI, V9, P2528, DOI 10.1017/S096183680000331X; Pompeia C, 2004, CANCER RES, V64, P3465, DOI 10.1158/0008-5472.CAN-03-3970; Ponassi R, 2008, CELL CYCLE, V7, P3211, DOI 10.4161/cc.7.20.6830; Porzio O, 2007, Hum Mutat, V28, P1150, DOI 10.1002/humu.9511; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj/cdd/4400998; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Qin JZ, 2005, CANCER RES, V65, P6282, DOI 10.1158/0008-5472.CAN-05-0676; Ranger AM, 2003, P NATL ACAD SCI USA, V100, P9324, DOI 10.1073/pnas.1533446100; Rashmi R, 2008, ONCOGENE, V27, P1366, DOI 10.1038/sj.onc.1210783; Real PJ, 2006, FEBS LETT, V580, P5905, DOI 10.1016/j.febslet.2006.08.088; Regula KM, 2002, CIRC RES, V91, P226, DOI 10.1161/01.RES.0000029232.42227.16; Reis PP, 2002, ONCOGENE, V21, P6480, DOI 10.1038/sj.onc.1205864; Renshaw SA, 2004, J BIOL CHEM, V279, P2846, DOI 10.1074/jbc.M309769200; Rodolfo C, 2004, J BIOL CHEM, V279, P54783, DOI 10.1074/jbc.M410938200; Sandoval H, 2008, NATURE, V454, P232, DOI 10.1038/nature07006; Sanz C, 2001, EMBO J, V20, P2286, DOI 10.1093/emboj/20.9.2286; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Scatizzi JC, 2006, ARTHRITIS RHEUM, V54, P3182, DOI 10.1002/art.22133; Scatizzi JC, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2204; Schendel SL, 1999, J BIOL CHEM, V274, P21932, DOI 10.1074/jbc.274.31.21932; Schmitz R, 2006, INT J CANCER, V119, P1738, DOI 10.1002/ijc.22010; Schmutte C, 1999, CANCER RES, V59, P4564; Schumacher B, 2005, CELL DEATH DIFFER, V12, P153, DOI 10.1038/sj.cdd.4401539; Schweers RL, 2007, P NATL ACAD SCI USA, V104, P19500, DOI 10.1073/pnas.0708818104; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Seo YW, 2003, J BIOL CHEM, V278, P48292, DOI 10.1074/jbc.M308785200; Shaw J, 2008, AUTOPHAGY, V4, P427, DOI 10.4161/auto.5901; Shaw J, 2008, P NATL ACAD SCI USA, V105, P20734, DOI 10.1073/pnas.0807735105; Shibue T, 2003, GENE DEV, V17, P2233, DOI 10.1101/gad.1103603; Shibue T, 2006, EMBO J, V25, P4952, DOI 10.1038/sj.emboj.7601359; Shibue T, 2006, INT J CANCER, V119, P2036, DOI 10.1002/ijc.21751; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Shore Gordon C, 2005, Hematology Am Soc Hematol Educ Program, P226; Sinha S, 2008, AUTOPHAGY, V4, P989, DOI 10.4161/auto.6803; Sowter HM, 2001, CANCER RES, V61, P6669; St Onge RP, 1999, MOL BIOL CELL, V10, P1985; Strohecker AM, 2008, J BIOL CHEM, V283, P18269, DOI 10.1074/jbc.M802156200; Sturm I, 2006, CELL DEATH DIFFER, V13, P619, DOI 10.1038/sj.cdd.4401782; Subramanian T, 2007, J VIROL, V81, P10486, DOI 10.1128/JVI.00808-07; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Tagawa H, 2005, ONCOGENE, V24, P1348, DOI 10.1038/sj.onc.1208300; Tan KO, 2001, J BIOL CHEM, V276, P2802, DOI 10.1074/jbc.M008955200; Tan TT, 2005, CANCER CELL, V7, P227, DOI 10.1016/j.ccr.2005.02.008; Tang GZ, 2007, J MED CHEM, V50, P3163, DOI 10.1021/jm070383c; Tracy K, 2007, MOL CELL BIOL, V27, P6229, DOI 10.1128/MCB.02246-06; Tsai SC, 2000, J BIOL CHEM, V275, P3239, DOI 10.1074/jbc.275.5.3239; Tzung SP, 2001, NAT CELL BIOL, V3, P183, DOI 10.1038/35055095; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Verma S, 2001, J BIOL CHEM, V276, P4671, DOI 10.1074/jbc.M008983200; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Vogler M, 2009, CELL DEATH DIFFER, V16, P360, DOI 10.1038/cdd.2008.137; Wan GH, 2008, J BIOL CHEM, V283, P21540, DOI 10.1074/jbc.M800214200; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wang Z, 2008, ANTICANCER RES, V28, P1667; Wang ZQ, 2003, J BIOL CHEM, V278, P23861, DOI 10.1074/jbc.M301843200; Weber A, 2007, J CELL BIOL, V177, P625, DOI 10.1083/jcb.200610148; Wick W, 1996, ONCOGENE, V12, P973; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Wolff S, 2008, CELL RES, V18, P733, DOI 10.1038/cr.2008.62; Xiao CC, 2008, NAT IMMUNOL, V9, P405, DOI 10.1038/ni1575; Xie XM, 2007, CANCER CELL, V12, P52, DOI 10.1016/j.ccr.2007.05.009; Yamashita M, 2008, J EXP MED, V205, P1109, DOI 10.1084/jem.20072000; Yan NG, 2004, MOL CELL, V15, P999, DOI 10.1016/j.molcel.2004.08.022; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Yoshida K, 2002, MOL CELL BIOL, V22, P3292, DOI 10.1128/MCB.22.10.3292-3300.2002; You H, 2006, J EXP MED, V203, P1657, DOI 10.1084/jem.20060353; Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Yussman MG, 2002, NAT MED, V8, P725, DOI 10.1038/nm719; Zeng XH, 2006, J CELL SCI, V119, P259, DOI 10.1242/jcs.02735; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761; Zhang H, 1999, FEBS LETT, V448, P23, DOI 10.1016/S0014-5793(99)00335-X; Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200; Zhu HB, 2005, ONCOGENE, V24, P4993, DOI 10.1038/sj.onc.1208683; Zinkel SS, 2005, CELL, V122, P579, DOI 10.1016/j.cell.2005.06.022; Zinkel SS, 2003, GENE DEV, V17, P229, DOI 10.1101/gad.1045603	226	284	299	1	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27			1			S2	S19		10.1038/onc.2009.39	http://dx.doi.org/10.1038/onc.2009.39			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	478DA	19641503	Green Accepted			2022-12-17	WOS:000268566800001
J	Shen, SX; Weaver, Z; Xu, XL; Li, CL; Weinstein, M; Chen, L; Guan, XY; Ried, T; Deng, CX				Shen, SX; Weaver, Z; Xu, XL; Li, CL; Weinstein, M; Chen, L; Guan, XY; Ried, T; Deng, CX			A targeted disruption of the murine Brca1 gene causes gamma-irradiation hypersensitivity and genetic instability	ONCOGENE			English	Article						BRCA1; p53; radiation sensitivity and chromosome abnormality	EARLY EMBRYONIC LETHALITY; CYCLIN-DEPENDENT KINASES; STRANDED-DNA ENDS; BREAST-CANCER; P53; MOUSE; RAD51; MICE; MUTATIONS; RECOMBINATION	Germline mutations of the Brca1 gene are responsible for most cases of familial breast and ovarian cancers, but somatic mutations are rarely detected in sporadic events. Moreover, mouse embryos deficient for Brca1 have been shown to die during early embryogenesis due to a proliferation defect, These findings seem incompatible with the tumor suppress function assigned to this gene and raise questions about the mechanism by which Brca1 mutations cause tumorigenesis. We now directly demonstrate that BRCA1 is responsible for the integrity of the genome, Murine embryos carrying a Brca1 null mutation are developmentally retarded and hypersensitive to gamma-irradiation, suggesting a failure in DNA damage repair. This notion is supported by spectral karyotyping (SKY) of metaphase chromosomes, which display numerical and structural aberrations. However, massive chromosomal abnormalities are only observed when a p53(-/-) background is introduced, Thus, a p53 dependent cell cycle checkpoint arrests the mutant embryos and prevents the accumulation of damaged DNA, Brca1(-/-) fibroblasts are not viable, nor are Brca1(-/-):p53(-/-) fibroblasts, However, proliferative foci arise from Brca1(-/-):p53(-/-) cells, probably due to additional mutations that are a consequence of the accumulating DNA damage, We believe that the increased incidence of such additional mutations accounts for the mechanism of tumorigenesis associated with Brca1 mutations in humans.	NIDDKD, Biochem & Metab Lab, NIH, Bethesda, MD 20892 USA; Natl Human Genome Res Inst, Genome Technol Branch, NIH, Bethesda, MD 20892 USA; Natl Human Genome Res Inst, Canc Genet Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Deng, CX (corresponding author), NIDDKD, Biochem & Metab Lab, NIH, Bldg 10,9N105, Bethesda, MD 20892 USA.		deng, chuxia/N-6713-2016; Guan, Xin-Yuan/A-3639-2009	Weaver Ohler, Zoe/0000-0002-6287-2504; Guan, Xin-Yuan/0000-0002-4485-6017				Alberg Anthony J., 1997, Current Opinion in Oncology, V9, P505, DOI 10.1097/00001622-199711000-00003; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BENNETT LM, 1995, GENOMICS, V29, P576, DOI 10.1006/geno.1995.9963; Bienstock RJ, 1996, CANCER RES, V56, P2539; Bignell G, 1997, HUM MOL GENET, V6, P53, DOI 10.1093/hmg/6.1.53; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Casey Graham, 1997, Current Opinion in Oncology, V9, P88; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DENG CX, 1994, GENE DEV, V8, P3045, DOI 10.1101/gad.8.24.3045; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Easton D, 1997, NAT GENET, V16, P210, DOI 10.1038/ng0797-210; El-Deiry WS, 1998, CURR TOP MICROBIOL, V227, P121; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVANS E P, 1987, P93; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HARPER JW, 1993, CELL, V75, P805; Hill ADK, 1997, BRIT J SURG, V84, P1334; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Liyanage M, 1996, NAT GENET, V14, P312, DOI 10.1038/ng1196-312; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MIYASHITA T, 1995, CELL, V80, P293; MURIS DFR, 1993, NUCLEIC ACIDS RES, V21, P4586, DOI 10.1093/nar/21.19.4586; OGAWA T, 1993, COLD SPRING HARB SYM, V58, P567, DOI 10.1101/SQB.1993.058.01.063; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; RITTER MA, 1977, NATURE, V266, P653, DOI 10.1038/266653a0; Schrock E, 1996, SCIENCE, V273, P494, DOI 10.1126/science.273.5274.494; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SNOW MHL, 1977, J EMBRYOL EXP MORPH, V42, P293; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; TELENIUS H, 1992, GENE CHROMOSOME CANC, V4, P257, DOI 10.1002/gcc.2870040311; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Xu CF, 1996, SEMIN CANCER BIOL, V7, P33, DOI 10.1006/scbi.1996.0005	50	284	288	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 17	1998	17	24					3115	3124		10.1038/sj.onc.1202243	http://dx.doi.org/10.1038/sj.onc.1202243			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	147VF	9872327				2022-12-17	WOS:000077517400005
J	BATES, S; BONETTA, L; MACALLAN, D; PARRY, D; HOLDER, A; DICKSON, C; PETERS, G				BATES, S; BONETTA, L; MACALLAN, D; PARRY, D; HOLDER, A; DICKSON, C; PETERS, G			CDK6 (PLSTIRE) AND CDK4 (PSK-J3) ARE A DISTINCT SUBSET OF THE CYCLIN-DEPENDENT KINASES THAT ASSOCIATE WITH CYCLIN D1	ONCOGENE			English	Article							PROTEIN-KINASE; CELL-CYCLE; CANDIDATE ONCOGENE; CHROMOSOME 11Q13; BCL-1 GENE; G1 PHASE; EXPRESSION; FAMILY; IDENTIFICATION; ACTIVATION	Deregulated expression of cyclin D1 is a feature of several neoplastic and proliferative disorders, but its normal role in the cell cycle remains unclear. Here we show that in a squamous carcinoma cell line with ii-fold amplification of the CCND1 gene, cyclin D1 associates specifically with p33(cdk4) (PSK-J3) and p38(cdk6) (PLSTIRE), two closely related members of the cyclin-dependent kinase (CDK) family. In these tumour cells, there is little evidence for an association between cyclin D1 and other CDKs, but in diploid human fibroblasts both CDK2 and CDK5 can be co-precipitated with cyclin D1, as well as CDK4. The data suggest that D-type cyclins participate in multiple interactions with CDKs but that the nature or stoichiometry of these associations may differ in different types of cell.	IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	Cancer Research UK								AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; BUNNELL BA, 1990, P NATL ACAD SCI USA, V87, P7467, DOI 10.1073/pnas.87.19.7467; DOU QP, 1993, CANCER RES, V53, P1493; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FAUST JB, 1992, CANCER RES, V52, P2460; GOLDFARB M, 1991, ONCOGENE, V6, P65; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HALL FL, 1993, ONCOGENE, V8, P1377; Hancock D C, 1992, Methods Mol Biol, V80, P33, DOI 10.1385/0-89603-204-3:33; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARLOW E, 1988, ANTIBODIES LABORATOR; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; JIANG W, 1992, CANCER RES, V52, P2980; KATO J, 1993, GENE DEV, V7, P331; KOBAYASHI H, 1992, MOL BIOL CELL, V3, P1279, DOI 10.1091/mbc.3.11.1279; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LAMMIE GA, 1992, ONCOGENE, V7, P2381; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LAMMIE GA, 1991, ONCOGENE, V6, P439; LAPIDOTLIESON Y, 1992, P NATL ACAD SCI USA, V89, P579, DOI 10.1073/pnas.89.2.579; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Nei M., 1987, MOL EVOLUTIONARY GEN, P287; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OKUDA T, 1992, ONCOGENE, V7, P2249; PINES J, 1991, CELL GROWTH DIFFER, V2, P305; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SCHUURING E, 1992, ONCOGENE, V7, P355; SETO M, 1992, ONCOGENE, V7, P1401; SEWING A, 1993, J CELL SCI, V104, P545; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	45	284	296	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1994	9	1					71	79						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302605				2022-12-17	WOS:A1994MW24700009
J	Garzon, R; Pichiorri, F; Palumbo, T; Visentini, M; Aqeilan, R; Cimmino, A; Wang, H; Sun, H; Volinia, S; Alder, H; Calin, GA; Liu, CG; Andreeff, M; Croce, CM				Garzon, R.; Pichiorri, F.; Palumbo, T.; Visentini, M.; Aqeilan, R.; Cimmino, A.; Wang, H.; Sun, H.; Volinia, S.; Alder, H.; Calin, G. A.; Liu, C-G; Andreeff, M.; Croce, C. M.			MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia	ONCOGENE			English	Article						microRNAs; promyelocytic leukemia; NF-kappa B	NF-KAPPA-B; RAR-ALPHA; ACTIVATION; APOPTOSIS; BINDING; CELLS	MicroRNAs (miRNAs) are small non-coding RNAs of 19-25 nucleotides that are involved in the regulation of critical cell processes such as apoptosis, cell proliferation and differentiation. However, little is known about the role of miRNAs in granulopoiesis. Here, we report the expression of miRNAs in acute promyelocytic leukemia patients and cell lines during all-trans-retinoic acid (ATRA) treatment by using a miRNA microarrays platform and quantitative real time-polymerase chain reaction (qRT-PCR). We found upregulation of miR-15a, miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223, miR-342 and miR-107, whereas miR-181b was downregulated. Among the upregulated miRNAs, miR-107 is predicted to target NFI-A, a gene that has been involved in a regulatory loop involving miR-223 and C/EBPa during granulocytic differentiation. Indeed, we have confirmed that miR-107 targets NF1-A. To get insights about ATRA regulation of miRNAs, we searched for ATRA-modulated transcription factors binding sites in the upstream genomic region of the let-7a-3/let-7b cluster and identified several putative nuclear factor-kappa B (NF-kappa B) consensus elements. The use of reporter gene assays, chromatin immunoprecipitation and site-directed mutagenesis revealed that one proximal NF-kappa B binding site is essential for the transactivation of the let-7a-3/let-7b cluster. Finally, we show that ATRA downregulation of RAS and Bcl2 correlate with the activation of known miRNA regulators of those proteins, let-7a and miR-15a/miR-16-1, respectively.	Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; Univ Catania, Dept Expt & Clin Pharmacol, I-95124 Catania, Italy; Univ Roma La Sapienza, Div Clin Immunol, I-00161 Rome, Italy; Univ Texas, MD Anderson Canc Ctr, Dept Blood & Bone Marrow Transplantat, Sect Mol Hematol & Therapy, Houston, TX 77030 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University of Catania; Sapienza University Rome; University of Texas System; UTMD Anderson Cancer Center	Croce, CM (corresponding author), Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Wiseman Hall,Room 445C,400 12th Ave, Columbus, OH 43210 USA.	Carlo.Croce@osumc.edu	Wang, Huating/C-6719-2014; Young, Richard A/F-6495-2012; Aqeilan, Rami/R-4443-2016; Sun, Hao/J-9964-2013; Calin, George/E-9390-2011; sun, hao/GRS-7732-2022; Volinia, Stefano/AAA-9264-2019; Aqeilan, Rami/AAT-7785-2020; Volinia, Stefano/A-3029-2010; Garzon, Ramiro/E-3104-2011; Sun, Hao/T-5576-2019; VISENTINI, MARCELLA/K-4161-2016	Wang, Huating/0000-0001-5474-2905; Young, Richard A/0000-0001-8855-8647; Aqeilan, Rami/0000-0002-6034-023X; Sun, Hao/0000-0002-5547-9501; Volinia, Stefano/0000-0003-0910-3893; Volinia, Stefano/0000-0003-0910-3893; Sun, Hao/0000-0002-5547-9501; Cimmino, Amelia/0000-0002-0004-9299; VISENTINI, MARCELLA/0000-0002-4053-6091; Calin, George/0000-0001-6704-5615	NCI NIH HHS [P01CA76259, P01CA81534, P01 CA055164, P01CA16058] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA076259, P01CA081534, P01CA055164] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bowen DT, 2005, BLOOD, V106, P2113, DOI 10.1182/blood-2005-03-0867; BRUEL A, 1995, LEUKEMIA, V9, P1173; Chan IT, 2006, BLOOD, V108, P1708, DOI 10.1182/blood-2006-04-015040; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Cheng AM, 2005, NUCLEIC ACIDS RES, V33, P1290, DOI 10.1093/nar/gki200; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Dechend R, 1999, ONCOGENE, V18, P3316, DOI 10.1038/sj.onc.1202717; Dresios J, 2005, P NATL ACAD SCI USA, V102, P1865, DOI 10.1073/pnas.0409764102; Fazi F, 2005, CELL, V123, P819, DOI 10.1016/j.cell.2005.09.023; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kel AE, 2003, NUCLEIC ACIDS RES, V31, P3576, DOI 10.1093/nar/gkg585; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; KURLAND JF, 2001, J BIOCH CHEM, V30, P45380; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Liu CG, 2004, P NATL ACAD SCI USA, V101, P9740, DOI 10.1073/pnas.0403293101; Mathieu J, 2005, ONCOGENE, V24, P7145, DOI 10.1038/sj.onc.1208889; Meani N, 2005, ONCOGENE, V24, P3358, DOI 10.1038/sj.onc.1208498; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Mori N, 1999, BLOOD, V93, P2360; Poy MN, 2004, NATURE, V432, P226, DOI 10.1038/nature03076; PRIEL IP, 2005, MOL CANC RESER, V3, P585; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Udalova IA, 2000, MOL CELL BIOL, V20, P9113, DOI 10.1128/MCB.20.24.9113-9119.2000	26	283	319	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2007	26	28					4148	4157		10.1038/sj.onc.1210186	http://dx.doi.org/10.1038/sj.onc.1210186			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	178XD	17260024				2022-12-17	WOS:000247252700010
J	Munz, M; Kieu, C; Mack, B; Schmitt, B; Zeidler, R; Gires, O				Munz, M; Kieu, C; Mack, B; Schmitt, B; Zeidler, R; Gires, O			The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation	ONCOGENE			English	Article						EpCAM; carcinoma; c-myc; cyclines	EPSTEIN-BARR-VIRUS; MOLECULE EP-CAM; BREAST-CANCER; TARGET; CYCLE; OVEREXPRESSION; EXPRESSION; RECEPTOR; GROWTH; 17-1A	Epithelial cell adhesion molecule (EpCAM) is a membrane glycoprotein expressed on adenomatous and simple epithelia, where it is involved in homophilic adhesion at the basolateral membrane. Carcinomas strongly overexpress EpCAM through an, as yet, unknown mechanism. Interestingly, otherwise EpCAM-negative squamous epithelia are seen to express EpCAM concomitant with their transformation and de-differentiation. The amount of EpCAM and the number of expressing cells both increase with the grade of dysplasia. Despite an important amount of data correlating the expression of EpCAM with cellular proliferation and de-differentiation, such as the coexpression with Ki-67, a marker for proliferation, it is unknown whether EpCAM may directly contribute to carcinogenesis. Here, we show that EpCAM has a direct impact on cell cycle and proliferation, and the ability to rapidly upregulate the proto-oncogene c-myc and cyclin A/E. Human epithelial 293 cells as well as murine NIH3T3 fibroblasts expressing EpCAM had a decreased requirement for growth factors, enhanced metabolic activity and colony formation capacity. Importantly, the inhibition of EpCAM expression with antisense mRNA led to a strong decrease in proliferation and metabolism in human carcinoma cells. Moreover, domain swapping experiments demonstrated that the intracellular part of EpCAM is necessary and sufficient to transduce the effects described. Thus, the data presented here highlight the role of EpCAM, demonstrating for the first time a direct link to cell cycle and proliferation.	Univ Munich, Clin Cooperat Grp Mol Oncol, GSF Natl Res Ctr Environm & Hlth, D-81377 Munich, Germany; Univ Munich, Dept Otorhinolaryngol, D-81377 Munich, Germany; Univ Munich, Head & Neck Res Dept, D-81377 Munich, Germany; Vaecgene Biotech Inc, D-81377 Munich, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; University of Munich; University of Munich	Gires, O (corresponding author), Univ Munich, Clin Cooperat Grp Mol Oncol, GSF Natl Res Ctr Environm & Hlth, Marchioninistr 15, D-81377 Munich, Germany.	ogires@med.uni-muenchen.de	Gires, Olivier/V-2689-2017	Gires, Olivier/0000-0002-2292-7064				Amati B, 1998, FRONT BIOSCI, V3, pd250, DOI [10.2741/a239, DOI 10.2741/A239]; Balzar M, 1999, J MOL MED, V77, P699, DOI 10.1007/s001099900038; Blazar M, 2001, MOL CELL BIOL, V21, P2570, DOI 10.1128/MCB.21.7.2570-2580.2001; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Chaubal S, 1999, ANTICANCER RES, V19, P2237; DAKSIS JI, 1994, ONCOGENE, V9, P3635; Dang CV, 1999, EXP CELL RES, V253, P63, DOI 10.1006/excr.1999.4686; Dang CV, 1999, MOL CELL BIOL, V19, P1; Davies DE, 1996, BIOCHEM PHARMACOL, V51, P1101, DOI 10.1016/0006-2952(95)02232-5; Field J K, 1992, Eur J Cancer B Oral Oncol, V28B, P67, DOI 10.1016/0964-1955(92)90016-T; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Gastl G, 2000, LANCET, V356, P1981, DOI 10.1016/S0140-6736(00)03312-2; Gires O, 1997, EMBO J, V16, P6131, DOI 10.1093/emboj/16.20.6131; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Litvinov SV, 1997, J CELL BIOL, V139, P1337, DOI 10.1083/jcb.139.5.1337; Litvinov SV, 1996, AM J PATHOL, V148, P865; Meden H, 1997, EUR J OBSTET GYN R B, V71, P173, DOI 10.1016/S0301-2115(96)02630-9; Meyaard L, 2001, J EXP MED, V194, P107, DOI 10.1084/jem.194.1.107; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Packeisen J, 1999, HYBRIDOMA, V18, P37, DOI 10.1089/hyb.1999.18.37; Pauli C, 2003, CANCER LETT, V193, P25, DOI 10.1016/S0304-3835(03)00003-X; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; Piyathilake CJ, 2000, HUM PATHOL, V31, P482, DOI 10.1053/hp.2000.6711; RIETHMULLER G, 1994, LANCET, V343, P1177, DOI 10.1016/S0140-6736(94)92398-1; Rodrigo JP, 1996, ARCH OTOLARYNGOL, V122, P504; Roh H, 2000, ONCOGENE, V19, P6138, DOI 10.1038/sj.onc.1204001; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; Spizzo G, 2002, INT J CANCER, V98, P883, DOI 10.1002/ijc.10270; SUGDEN B, 1977, J VIROL, V23, P503, DOI 10.1128/JVI.23.3.503-508.1977; TANDON AK, 1990, CANCER RES, V50, P3317; Zornig M, 1996, CURR BIOL, V6, P1553, DOI 10.1016/S0960-9822(02)70769-0	32	283	306	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5748	5758		10.1038/sj.onc.1207610	http://dx.doi.org/10.1038/sj.onc.1207610			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15195135				2022-12-17	WOS:000222629800004
J	Akira, S				Akira, S			Roles of STAT3 defined by tissue-specific gene targeting	ONCOGENE			English	Article						STAT3; knockout; conditional gene targeting	EMBRYONIC STEM-CELLS; CHRONIC ENTEROCOLITIS; GROWTH-FACTOR; ACTIVATION; TRANSCRIPTION; TYROSINE; MICE; PROLIFERATION; INTERLEUKIN-6; APOPTOSIS	The physiological role of each individual STAT protein is now being examined through the study of 'knockout' (KO) mice, harboring a null allele for the particular gene. In contrast to other STATs deficient mice that are born alive, STAT3-deficient mice die during early embryogenesis, However, the role of STAT3 in adult tissues can be assessed by utilizing the Cre-loxP recombination system to ablate the gene in later life. Analyses of tissue-specific STAT3-deficient mice indicate that STAT3 plays a crucial role in a variety of biological functions including cell growth, suppression and induction of apoptosis, and cell motility.	Osaka Univ, Res Inst Microbial Dis, Dept Host Def, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, CREST, Suita, Osaka 5650871, Japan	Osaka University; Japan Science & Technology Agency (JST)	Akira, S (corresponding author), Osaka Univ, Res Inst Microbial Dis, Dept Host Def, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan.							Akaishi H, 1998, INT IMMUNOL, V10, P1747, DOI 10.1093/intimm/10.11.1747; Akira S, 1997, INT J BIOCHEM CELL B, V29, P1401, DOI 10.1016/S1357-2725(97)00063-0; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Boeuf H, 1997, J CELL BIOL, V138, P1207, DOI 10.1083/jcb.138.6.1207; Bonni A, 1997, SCIENCE, V278, P477, DOI 10.1126/science.278.5337.477; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Duncan SA, 1997, DEV DYNAM, V208, P190, DOI 10.1002/(SICI)1097-0177(199702)208:2<190::AID-AJA6>3.0.CO;2-D; FUHRER DK, 1995, J BIOL CHEM, V270, P24826, DOI 10.1074/jbc.270.42.24826; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Nakajima H, 1997, IMMUNITY, V7, P691, DOI 10.1016/S1074-7613(00)80389-1; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Riley JK, 1999, J BIOL CHEM, V274, P16513, DOI 10.1074/jbc.274.23.16513; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Takeda K, 1998, J IMMUNOL, V161, P4652; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; WeberNordt RM, 1996, J BIOL CHEM, V271, P27954, DOI 10.1074/jbc.271.44.27954; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	32	283	307	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2000	19	21					2607	2611		10.1038/sj.onc.1203478	http://dx.doi.org/10.1038/sj.onc.1203478			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321MN	10851059				2022-12-17	WOS:000087459400016
J	Di Renzo, MF; Olivero, M; Martone, T; Maffe, A; Maggiora, P; De Stefani, A; Valente, G; Giordano, S; Cortesina, G; Comoglio, PM				Di Renzo, MF; Olivero, M; Martone, T; Maffe, A; Maggiora, P; De Stefani, A; Valente, G; Giordano, S; Cortesina, G; Comoglio, PM			Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas	ONCOGENE			English	Article						metastasis; carcinoma; missense mutations; somatic mutations; MET oncogene	HEPATOCYTE GROWTH-FACTOR; TYROSINE KINASE RECEPTOR; C-MET; HGF RECEPTOR; MET/HGF RECEPTOR; INVASIVE-GROWTH; RENAL-CARCINOMA; MUTANT-ALLELE; PROTOONCOGENE; EXPRESSION	A metastatic cancer develops by accumulation of mutations in genes that control growth, survival and spreading. The latter genes have not yet been identified. In lymph node metastases of head and neck squamous cell carcinomas (HNSCC), we found mutations in the MET oncogene, which encodes the tyrosine kinase receptor for Scatter Factor, a cytokine that stimulates epithelial cell motility and invasiveness during embryogenesis and tissue remodeling. We identified two somatic mutations: the Y1230C, known as a MET germline mutation which predisposes to hereditary renal cell carcinoma, and the Y1235D that is novel and changes a critical tyrosine, known to regulate MET kinase activity. The mutated MET receptors are constitutively active and confer an invasive phenotype to transfected cells. Interestingly, cells carrying the MET mutations are selected during metastatic spread: transcripts of the mutant alleles are highly represented in metastases, but barely detectable in primary tumors. These data indicate that cells expressing mutant MET undergo clonal expansion during HNSCC progression and suggest that MET might be one of the long sought oncogenes controlling progression of primary cancers to metastasis.	Inst Canc Res & Treatment, IRCC, Canc Genet Lab, I-10060 Candiolo, Italy; Inst Canc Res & Treatment, IRCC, Div Mol Genet, I-10060 Candiolo, Italy; Univ Turin, Sch Med, Dept Biomed Sci, Otolaryngol Unit, I-10126 Turin, Italy; Amedeo Avogadro Univ, Dept Med Sci, I-28100 Novara, Italy; Univ Turin, Sch Med, Otolaryngol Unit, Dept Clin Physiopathol, I-10126 Turin, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; University of Eastern Piedmont Amedeo Avogadro; University of Turin	Di Renzo, MF (corresponding author), Inst Canc Res & Treatment, IRCC, Canc Genet Lab, SP 142,Km 3-95, I-10060 Candiolo, Italy.		Valente, Guido/B-9714-2013; Giordano, Silvia/J-9858-2018; olivero, martina/J-4811-2018; MARTONE, Tiziana/AAD-2706-2022; Comoglio, Paolo/G-6323-2011; DI RENZO, Maria Flavia/B-6091-2012	Giordano, Silvia/0000-0003-1854-1086; olivero, martina/0000-0002-6815-3498; MARTONE, Tiziana/0000-0002-4019-6082; DI RENZO, Maria Flavia/0000-0002-5093-3373; Comoglio, Paolo/0000-0002-7056-5328				Bardelli A, 1998, P NATL ACAD SCI USA, V95, P14379, DOI 10.1073/pnas.95.24.14379; Bardelli A, 1997, BBA-REV CANCER, V1333, pM41, DOI 10.1016/S0304-419X(97)00026-7; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Califano J, 1996, CANCER RES, V56, P2488; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DIRENZO MF, 1995, CANCER RES, V55, P1129; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; DIRENZO MF, 1992, ONCOGENE, V7, P2549; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; Fischer J, 1998, ONCOGENE, V17, P733, DOI 10.1038/sj.onc.1201983; GALEAZZI E, 1997, EUR ARCH OTO-RHINO-L, V1, pS138; Ghoussoub RAD, 1998, CANCER, V82, P1513, DOI 10.1002/(SICI)1097-0142(19980415)82:8<1513::AID-CNCR13>3.0.CO;2-7; Giordano S, 1997, P NATL ACAD SCI USA, V94, P13868, DOI 10.1073/pnas.94.25.13868; Giordano S, 2000, FASEB J, V14, P399, DOI 10.1096/fasebj.14.2.399; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; HASEGAWA Y, 1995, ONCOGENE, V10, P1441; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Liang TJ, 1996, J CLIN INVEST, V97, P2872, DOI 10.1172/JCI118744; LONGATI P, 1994, ONCOGENE, V9, P49; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; Marshall DD, 1998, LARYNGOSCOPE, V108, P1413, DOI 10.1097/00005537-199809000-00031; MASUMOTO A, 1991, BIOCHEM BIOPH RES CO, V174, P90, DOI 10.1016/0006-291X(91)90489-T; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; Meiners S, 1998, ONCOGENE, V16, P9, DOI 10.1038/sj.onc.1201486; Michieli P, 1999, ONCOGENE, V18, P5221, DOI 10.1038/sj.onc.1202899; NALDINI L, 1991, ONCOGENE, V6, P501; Olivero M, 1999, INT J CANCER, V82, P640, DOI 10.1002/(SICI)1097-0215(19990827)82:5<640::AID-IJC4>3.0.CO;2-6; Otsuka T, 1998, CANCER RES, V58, P5157; Park WS, 1999, CANCER RES, V59, P307; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; Sawatsubashi M, 1998, VIRCHOWS ARCH, V432, P331, DOI 10.1007/s004280050174; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schmidt L, 1998, CANCER RES, V58, P1719; Schmidt L, 1999, ONCOGENE, V18, P2343, DOI 10.1038/sj.onc.1202547; Sonnenberg E, 1993, EXS, V65, P381; TSUBOUCHI H, 1991, HEPATOLOGY, V13, P1; YAMASHITA J, 1994, CANCER RES, V54, P1630	44	283	290	0	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 16	2000	19	12					1547	1555		10.1038/sj.onc.1203455	http://dx.doi.org/10.1038/sj.onc.1203455			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297XN	10734314				2022-12-17	WOS:000086108100007
J	Chiappetta, G; Avantaggiato, V; Visconti, R; Fedele, M; Battista, S; Trapasso, F; Merciai, BM; Fidanza, V; Giancotti, V; Santoro, M; Simeone, A; Fusco, A				Chiappetta, G; Avantaggiato, V; Visconti, R; Fedele, M; Battista, S; Trapasso, F; Merciai, BM; Fidanza, V; Giancotti, V; Santoro, M; Simeone, A; Fusco, A			High level expression of the HMGI (Y) gene during embryonic development	ONCOGENE			English	Article						HMGI proteins; in situ hybridization; development; embryo	GROUP PROTEIN HMG-I(Y); NUCLEAR PROTEINS; THYROID-CELLS; TRANSFORMATION; CDNA; ELEMENTS; SEQUENCE; DNA; RNA	The HMGI protein family includes three proteins, named HMG-I, HMG-Y and HMGI-C, The first two proteins are coded for by the same gene, HMGI (Y), through an alternative splicing mechanism, Their expression is elevated in neoplastic tissues and cells and this overexpression has a causal role in the process of cellular neoplastic transformation, We demonstrate that the HMGI (Y) gene is expressed at very tow levels in normal adult tissues, whereas in embryonic tissues it is expressed at high levels comparable to those detected in neoplastic tissues, Specifically, a very high expression of the HMGI (Y) gene was detected in all embryonic tissues at 8.5 dpc, Then in the following days, even though the gene is expressed essentially in all tissues, an abundant gene expression was restricted to some tissues, These results indicate an important role of the HMGI (Y) gene in development.	UNIV REGGIO CALABRIA,FAC MED & CHIRURG CATANZARO,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CATANZARO,ITALY; IST NAZL TUMORI,FDN SENATORE PASCALE,I-80131 NAPLES,ITALY; CNR,IST INT GENET & BIOFIS,I-80125 NAPLES,ITALY; UNIV NAPLES,FAC MED & CHIRURG NAPOLI,CNR,DIPARTIMENTO BIOL & PATOL CELLULARE & MOL,I-80131 NAPLES,ITALY; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,THOMAS JEFFERSON CANC INST,PHILADELPHIA,PA 19107; UNIV TRIESTE,DIPARTIMENTO BIOCHIM BIOFIS & CHIM MACROMOL,I-34127 TRIESTE,ITALY	Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria; IRCCS Fondazione Pascale; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Jefferson University; University of Trieste			Fedele, Monica/C-1417-2015; Visconti, Roberta/C-5299-2009; Simeone, Antonio/ABG-5269-2020	Fedele, Monica/0000-0002-9171-1312; Simeone, Antonio/0000-0003-2693-9836; Visconti, Roberta/0000-0001-7613-3801; Fusco, Alfredo/0000-0003-3332-5197				ASHAR HR, 1995, CELL, V82, P57; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; BUSSEMAKERS MJG, 1991, CANCER RES, V51, P606; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; CHIAPPETTA G, 1995, ONCOGENE, V10, P1307; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; Fedele M, 1996, CANCER RES, V56, P1896; FRIEDMANN M, 1993, NUCLEIC ACIDS RES, V21, P4259, DOI 10.1093/nar/21.18.4259; GIANCOTTI V, 1985, CANCER RES, V45, P6051; GIANCOTTI V, 1989, EXP CELL RES, V184, P538, DOI 10.1016/0014-4827(89)90352-2; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; JOHNSON KR, 1988, J BIOL CHEM, V263, P18338; LOVELLBADGE R, 1995, NATURE, V376, P725, DOI 10.1038/376725a0; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; RAM TG, 1993, CANCER RES, V53, P2655; REEVES R, 1990, J BIOL CHEM, V265, P8576; REEVES R, 1991, P NATL ACAD SCI USA, V88, P4005; Sambrook J, 1989, MOL CLONING LAB MANU; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; THEILER K, 1989, HOUSE MOUSE; TMIMI Y, 1993, CANCER RES, V53, P5512; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; ZHAO K, 1993, EMBO J, V12, P3237, DOI 10.1002/j.1460-2075.1993.tb05993.x; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	30	283	289	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2439	2446						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957086				2022-12-17	WOS:A1996VX10800017
J	Chen, Z; Li, Y; Zhang, H; Huang, P; Luthra, R				Chen, Z.; Li, Y.; Zhang, H.; Huang, P.; Luthra, R.			Hypoxia-regulated microRNA-210 modulates mitochondrial function and decreases ISCU and COX10 expression	ONCOGENE			English	Article						miR-210; mitochondria; hypoxia; COX10; ISCU; ROS	CANCER-CELLS; DNA-REPAIR; INHIBITION; STRATEGY	The mechanisms of compromised mitochondrial function under various pathological conditions, including hypoxia, remain largely unknown. Recent studies have shown that microRNA-210 (miR-210) is induced by hypoxia under the regulation of hypoxia-inducible factor-1 alpha and has an important role in cell survival under hypoxic microenvironment. Hence, we hypothesized that miR-210 has a role in regulating mitochondrial metabolism and investigated miR-210 effects on mitochondrial function in cancer cell lines under normal and hypoxic conditions. Our results demonstrate that miR-210 decreases mitochondrial function and upregulates the glycolysis, thus make cancer cells more sensitive to glycolysis inhibitor. miR-210 can also activate the generation of reactive oxygen species (ROS). ISCU (iron-sulfur cluster scaffold homolog) and COX10 (cytochrome c oxidase assembly protein), two important factors of the mitochondria electron transport chain and the tricarboxylic acid cycle have been identified as potential targets of miR-210. The unique means by which miR-210 regulates mitochondrial function reveals an miRNA-mediated link between microenvironmental stress, oxidative phosphorylation, ROS and iron homeostasis. Oncogene (2010) 29, 4362-4368; doi:10.1038/onc.2010.193; published online 24 May 2010	[Chen, Z.; Li, Y.; Luthra, R.] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77054 USA; [Zhang, H.; Huang, P.] Univ Texas MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77054 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Luthra, R (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, 8515 Fannin St,NAO1-061A, Houston, TX 77054 USA.	rluthra@mdanderson.org						Bristow RG, 2008, NAT REV CANCER, V8, P180, DOI 10.1038/nrc2344; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Camps C, 2008, CLIN CANCER RES, V14, P1340, DOI 10.1158/1078-0432.CCR-07-1755; Chen Z, 2007, J BIOENERG BIOMEMBR, V39, P267, DOI 10.1007/s10863-007-9086-x; Crosby ME, 2009, CANCER RES, V69, P1221, DOI 10.1158/0008-5472.CAN-08-2516; Diaz F, 2006, MOL CELL BIOL, V26, P4872, DOI 10.1128/MCB.01767-05; Giannakakis A, 2008, CANCER BIOL THER, V7, P255, DOI 10.4161/cbt.7.2.5297; Greither T, 2010, INT J CANCER, V126, P73, DOI 10.1002/ijc.24687; Guzy RD, 2005, CELL METAB, V1, P401, DOI 10.1016/j.cmet.2005.05.001; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Johnson DC, 2005, ANNU REV BIOCHEM, V74, P247, DOI 10.1146/annurev.biochem.74.082803.133518; Kulshreshtha R, 2007, MOL CELL BIOL, V27, P1859, DOI 10.1128/MCB.01395-06; Lawrie CH, 2008, BRIT J HAEMATOL, V141, P672, DOI 10.1111/j.1365-2141.2008.07077.x; Lee YS, 2009, ANNU REV PATHOL-MECH, V4, P199, DOI 10.1146/annurev.pathol.4.110807.092222; Luthra R, 2008, ONCOGENE, V27, P6667, DOI 10.1038/onc.2008.256; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Pelicano H, 2003, J BIOL CHEM, V278, P37832, DOI 10.1074/jbc.M301546200; Tong WH, 2006, CELL METAB, V3, P199, DOI 10.1016/j.cmet.2006.02.003; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Xu RH, 2005, CANCER RES, V65, P613	20	282	304	2	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2010	29	30					4362	4368		10.1038/onc.2010.193	http://dx.doi.org/10.1038/onc.2010.193			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	633ZV	20498629				2022-12-17	WOS:000280547900012
J	Tsukita, S; Yamazaki, Y; Katsuno, T; Tamura, A; Tsukita, S				Tsukita, S.; Yamazaki, Y.; Katsuno, T.; Tamura, A.; Tsukita, S.			Tight junction-based epithelial microenvironment and cell proliferation	ONCOGENE			English	Review						tight junction; cell adhesion; paracellular barrier; paracellular permeability; permselectivity; epithelial cell	GALL-BLADDER EPITHELIUM; EPIDERMAL-GROWTH-FACTOR; MICE LACKING; MOLECULAR ARCHITECTURE; INTRACELLULAR CA2+; BARRIER FUNCTION; CLAUDIN; STRANDS; EXPRESSION; RECEPTOR	Belt-like tight junctions (TJs), referred to as zonula occludens, have long been regarded as a specialized differentiation of epithelial cell membranes. They are required for cell adhesion and paracellular barrier functions, and are now thought to be partly involved in fence functions and in cell polarization. Recently, the molecular bases of TJs have gradually been unveiled. TJs are constructed by TJ strands, whose basic frameworks are composed of integral membrane proteins with four transmembrane domains, designated claudins. The claudin family is supposedly composed of at least 24 members in mice and humans. Other types of integral membrane proteins with four transmembrane domains, namely occludin and tricellulin, as well as the single transmembrane proteins, JAMs (junctional adhesion molecules) and CAR (coxsackie and adenovirus receptor), are associated with TJ strands, and the high-level organization of TJ strands is likely to be established by membrane-anchored scaffolding proteins, such as ZO-1/2. Recent functional analyses of claudins in cell cultures and in mice have suggested that claudin-based TJs may have pivotal functions in the regulation of the epithelial microenvironment, which is critical for various biological functions such as control of cell proliferation. These represent the dawn of 'Barriology' (defined by Shoichiro Tsukita as the science of barriers in multicellular organisms). Taken together with recent reports regarding changes in claudin expression levels, understanding the regulation of the TJ-based microenvironment system will provide new insights into the regulation of polarization in the respect of epithelial microenvironment system and new viewpoints for developing anticancer strategies.	[Tsukita, S.; Yamazaki, Y.; Katsuno, T.; Tamura, A.; Tsukita, S.] Osaka Univ, Grad Sch Med, Grad Sch Frontier Biosci, Biol Sci Lab, Suita, Osaka 5650871, Japan	Osaka University	Tsukita, S (corresponding author), Osaka Univ, Grad Sch Med, Grad Sch Frontier Biosci, Biol Sci Lab, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	atsukita@biosci.med.osaka-u.ac.jp						Amieva MR, 2003, SCIENCE, V300, P1430, DOI 10.1126/science.1081919; ANGELOW S, 2008, AM J PHYSL IN PRESS; Behr M, 2003, DEV CELL, V5, P611, DOI 10.1016/S1534-5807(03)00275-2; Ben-Yosef T, 2003, HUM MOL GENET, V12, P2049, DOI 10.1093/hmg/ddg210; Chao JCJ, 2003, WORLD J GASTROENTERO, V9, P2261; CLAUDE P, 1978, J MEMBRANE BIOL, V39, P219, DOI 10.1007/BF01870332; Cohen CJ, 2001, P NATL ACAD SCI USA, V98, P15191, DOI 10.1073/pnas.261452898; Colegio OR, 2003, AM J PHYSIOL-CELL PH, V284, pC1346, DOI 10.1152/ajpcell.00547.2002; D'Souza T, 2007, EXP CELL RES, V313, P3364, DOI 10.1016/j.yexcr.2007.06.026; Diamond J M, 1977, Physiologist, V20, P10; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; FRIZZELL RA, 1972, J GEN PHYSIOL, V59, P318, DOI 10.1085/jgp.59.3.318; Fujita K, 2000, FEBS LETT, V476, P258, DOI 10.1016/S0014-5793(00)01744-0; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 1999, J CELL BIOL, V147, P891, DOI 10.1083/jcb.147.4.891; Furuse M, 2001, J CELL BIOL, V153, P263, DOI 10.1083/jcb.153.2.263; Furuse M, 2002, J CELL BIOL, V156, P1099, DOI 10.1083/jcb.200110122; Gonzalez-Mariscal L, 2007, PROG HISTOCHEM CYTO, V42, P1, DOI 10.1016/j.proghi.2007.01.001; Gow A, 1999, CELL, V99, P649, DOI 10.1016/S0092-8674(00)81553-6; GUMBINER BM, 1993, J CELL BIOL, V123, P1631, DOI 10.1083/jcb.123.6.1631; Hamazaki Y, 2002, J BIOL CHEM, V277, P455, DOI 10.1074/jbc.M109005200; Hartsock A, 2008, BBA-BIOMEMBRANES, V1778, P660, DOI 10.1016/j.bbamem.2007.07.012; HOPFER U, 1977, AM J PHYSIOL, V233, pE445, DOI 10.1152/ajpendo.1977.233.6.E445; Hou JH, 2006, J BIOL CHEM, V281, P36117, DOI 10.1074/jbc.M608853200; Ikenouchi J, 2005, J CELL BIOL, V171, P939, DOI 10.1083/jcb.200510043; Ikenouchi J, 2003, J CELL SCI, V116, P1959, DOI 10.1242/jcs.00389; Itoh M, 2001, J CELL BIOL, V154, P491, DOI 10.1083/jcb.200103047; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; KACHAR B, 1982, NATURE, V296, P464, DOI 10.1038/296464a0; Katahira J, 1997, J CELL BIOL, V136, P1239, DOI 10.1083/jcb.136.6.1239; Katsuno T, 2008, MOL BIOL CELL, V19, P2465, DOI 10.1091/mbc.E07-12-1215; Kitajiri SI, 2004, J CELL SCI, V117, P5087, DOI 10.1242/jcs.01393; Kominsky Scott L., 2006, Expert Reviews in Molecular Medicine, V8, P1, DOI 10.1017/S1462399406000056; Konrad M, 2006, AM J HUM GENET, V79, P949, DOI 10.1086/508617; KOTTRA G, 1993, PFLUG ARCH EUR J PHY, V425, P528, DOI 10.1007/BF00374881; KOTTRA G, 1993, PFLUG ARCH EUR J PHY, V425, P535, DOI 10.1007/BF00374882; Krause G, 2008, BBA-BIOMEMBRANES, V1778, P631, DOI 10.1016/j.bbamem.2007.10.018; Lioni M, 2007, AM J PATHOL, V170, P709, DOI 10.2353/ajpath.2007.060343; Liu Y, 2000, J CELL SCI, V113, P2363; Loh YH, 2004, GENOME RES, V14, P1248, DOI 10.1101/gr.2400004; Macarthur M, 2004, AM J PHYSIOL-GASTR L, V286, pG515, DOI 10.1152/ajpgi.00475.2003; Matsuda M, 2004, J CELL SCI, V117, P1247, DOI 10.1242/jcs.00972; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; Miyamoto T, 2005, J CELL BIOL, V169, P527, DOI 10.1083/jcb.200501154; Morita K, 2002, J INVEST DERMATOL, V118, P1073, DOI 10.1046/j.1523-1747.2002.01774.x; Morita K, 1999, J CELL BIOL, V147, P185, DOI 10.1083/jcb.147.1.185; Morita K, 1999, J CELL BIOL, V145, P579, DOI 10.1083/jcb.145.3.579; Moriwaki K, 2007, DEV BIOL, V312, P509, DOI 10.1016/j.ydbio.2007.09.049; Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070; OKADA Y, 1977, J MEMBRANE BIOL, V31, P221, DOI 10.1007/BF01869406; Pan XY, 2007, INT J GYNECOL CANCER, V17, P233, DOI 10.1111/j.1525-1438.2006.00748.x; PINTO DS, 1982, CELL, V28, P441; POWELL DW, 1981, AM J PHYSIOL, V241, pG275, DOI 10.1152/ajpgi.1981.241.4.G275; REUSS L, 1992, TIGHT JUNCTIONS, P49; Saitou M, 2000, MOL BIOL CELL, V11, P4131, DOI 10.1091/mbc.11.12.4131; Sanchez-Pulido L, 2002, TRENDS BIOCHEM SCI, V27, P599, DOI 10.1016/S0968-0004(02)02229-6; Sasaki H, 2003, P NATL ACAD SCI USA, V100, P3971, DOI 10.1073/pnas.0630649100; Schmidt A, 2004, CELL MOL LIFE SCI, V61, P1354, DOI 10.1007/s00018-004-4010-6; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; Simon DB, 1999, SCIENCE, V285, P103, DOI 10.1126/science.285.5424.103; Singh AB, 2004, J BIOL CHEM, V279, P3543, DOI 10.1074/jbc.M308682200; Song B, 2002, P NATL ACAD SCI USA, V99, P13577, DOI 10.1073/pnas.202235299; Sonoda N, 1999, J CELL BIOL, V147, P195, DOI 10.1083/jcb.147.1.195; STAEHELIN LA, 1973, J CELL SCI, V13, P763; Tamura A, 2008, GASTROENTEROLOGY, V134, P523, DOI 10.1053/j.gastro.2007.11.040; Tatum R, 2007, FEBS LETT, V581, P3887, DOI 10.1016/j.febslet.2007.07.014; Toivola DM, 2004, J CELL BIOL, V164, P911, DOI 10.1083/jcb.200308103; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Tsukita S, 2000, J CELL BIOL, V149, P13, DOI 10.1083/jcb.149.1.13; Tsukita S, 1999, TRENDS CELL BIOL, V9, P268, DOI 10.1016/S0962-8924(99)01578-0; TSUKITA S, 1989, J CELL BIOL, V108, P31, DOI 10.1083/jcb.108.1.31; TURK E, 1991, NATURE, V350, P354, DOI 10.1038/350354a0; Umeda K, 2006, CELL, V126, P741, DOI 10.1016/j.cell.2006.06.043; Van Itallie CM, 2008, J CELL SCI, V121, P298, DOI 10.1242/jcs.021485; Van Itallie CM, 2006, AM J PHYSIOL-RENAL, V291, pF1288, DOI 10.1152/ajprenal.00138.2006; Van Itallie CM, 2003, AM J PHYSIOL-RENAL, V285, pF1078, DOI 10.1152/ajprenal.00116.2003; Van Itallie CM, 2006, ANNU REV PHYSIOL, V68, P403, DOI 10.1146/annurev.physiol.68.040104.131404; VERKLEIJ AJ, 1984, BIOCHIM BIOPHYS ACTA, V779, P43, DOI 10.1016/0304-4157(84)90003-0; Vermeer PD, 2003, NATURE, V422, P322, DOI 10.1038/nature01440; Watson CJ, 2001, AM J PHYSIOL-CELL PH, V281, pC388, DOI 10.1152/ajpcell.2001.281.2.C388; Wattenhofer M, 2005, HUM MUTAT, V25, P543, DOI 10.1002/humu.20172; Wu VM, 2004, J CELL BIOL, V164, P313, DOI 10.1083/jcb.200309134; Xu JL, 2008, MOL CELL BIOL, V28, P1669, DOI 10.1128/MCB.00891-07; Yap AS, 1998, J MEMBRANE BIOL, V163, P159, DOI 10.1007/s002329900380	84	282	293	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2008	27	55					6930	6938		10.1038/onc.2008.344	http://dx.doi.org/10.1038/onc.2008.344			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375IU	19029935				2022-12-17	WOS:000261108200006
J	KHANNA, KK; LAVIN, MF				KHANNA, KK; LAVIN, MF			IONIZING-RADIATION AND UV INDUCTION OF P53 PROTEIN BY DIFFERENT PATHWAYS IN ATAXIA-TELANGIECTASIA CELLS	ONCOGENE			English	Article							RADIORESISTANT DNA-SYNTHESIS; FLOW CYTOMETRIC ANALYSIS; WILD-TYPE P53; LATE G1 PHASE; CYCLE CHECKPOINT; TOPOISOMERASE-II; KINASE-C; CANCER; PERTURBATIONS; IRRADIATION	Cell cycle anomalies have been described in ataxia-telangiectasia cells after exposure to ionizing radiation. A recent report demonstrates that cells from these patients lack the ionizing radiation-induced increase in p53 protein seen in controls. We report here that an ionizing radiation-induced p53 response is reduced and/or delayed in cells from four ataxia-telangiectasia complementation groups. On the other hand, p53 induction is normal in all A-T complementation groups after exposure to UV-B light, an agent to which these cells are not hypersensitive. Specific inhibitors of protein kinase C and serine/threonine phosphatases prevented the radiation induction of p53 protein. Agents that produced double-strand breaks in DNA and/or inhibition of transcription caused an induction of p53 in the absence of radiation in control cells but not in ataxia-telangiectasia, but inhibitors of cell cycle progression such as mimosine and aphidicolin led to an increase in p53 in both cell types in the absence of radiation. These results suggest that there is more than one signal transduction pathway responsible for activation of p53, one of which is less efficient in ataxia-telangiectasia cells.	QUEENSLAND INST MED RES, BANCROFT CTR, QUEENSLAND CANC FUND RES UNIT, BRISBANE, QLD 4029, AUSTRALIA	QIMR Berghofer Medical Research Institute			Lavin, Martin F/F-5961-2014	Lavin, Martin F/0000-0002-5940-4769; Khanna, Kum Kum/0000-0001-8650-5381				ABDELLA BR, 1984, ENV HLTH PERSPECT, V64, P3; AURIAS A, 1980, MUTAT RES, V69, P369, DOI 10.1016/0027-5107(80)90101-3; BATES P, 1985, MUTAT RES, V218, P165; BAXTER G, 1988, IMMUNOL CELL BIOL, V67, P57; BEAMISH H, IN PRESS RAD RES; BODER E, 1985, ATAXIA TELANGIECTASI, V19, P1; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; CHEN P, 1984, MUTAT RES, V129, P165, DOI 10.1016/0027-5107(84)90149-0; CHEN PC, 1978, NATURE, V274, P484, DOI 10.1038/274484a0; CORNFORTH MN, 1985, SCIENCE, V227, P1589, DOI 10.1126/science.3975628; DAVIES SM, 1989, NUCLEIC ACIDS RES, V17, P1337, DOI 10.1093/nar/17.4.1337; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EDWARDS MJ, 1980, NATURE, V287, P745, DOI 10.1038/287745a0; FORD MD, 1981, NUCLEIC ACIDS RES, V9, P1395, DOI 10.1093/nar/9.6.1395; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUJIKI H, 1990, ADV SEC MESS PHOSPH, V24, P340; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; HANAWALT PC, 1986, TRENDS GENET, V2, P124, DOI 10.1016/0168-9525(86)90201-5; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HOULDSWORTH J, 1980, NUCLEIC ACIDS RES, V8, P3709, DOI 10.1093/nar/8.16.3709; IMRAY FP, 1983, MUTAT RES, V112, P369; JASPERS NGJ, 1982, MUTAT RES, V92, P439, DOI 10.1016/0027-5107(82)90242-1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALANDE M, 1990, EXP CELL RES, V186, P332, DOI 10.1016/0014-4827(90)90313-Y; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LAVIN MF, 1987, MOL CELL BIOCHEM, V73, P45; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEHMANN AR, 1982, CELLULAR MOL LINK CA, P347; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; MCFARLIN DE, 1972, MEDICINE, V51, P281, DOI 10.1097/00005792-197207000-00002; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; MIRZAYANS R, 1989, CANCER RES, V49, P5523; MOHAMED R, 1989, BIOCHEM BIOPH RES CO, V158, P749, DOI 10.1016/0006-291X(89)92785-X; MORGAN JL, 1968, AM J DIS CHILD, V116, P557, DOI 10.1001/archpedi.1968.02100020561022; NAGASAWA H, 1983, MUTAT RES, V109, P297, DOI 10.1016/0027-5107(83)90054-4; OCONNOR PM, 1992, CELL GROWTH DIFFER, V3, P43; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAINTER RB, 1981, MUTAT RES, V84, P183, DOI 10.1016/0027-5107(81)90061-0; PATERSON MC, 1979, CANCER RES, V39, P3225; PEDRALINOY G, 1980, NUCLEIC ACIDS RES, V8, P377, DOI 10.1093/nar/8.2.377; PETERSON RD, 1964, LANCET, V1, P1193; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; ROWLEY R, 1992, NATURE, V356, P353, DOI 10.1038/356353a0; RUDOLPH NS, 1989, MUTAT RES, V211, P31, DOI 10.1016/0027-5107(89)90104-8; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; SINGH SP, 1988, NUCLEIC ACIDS RES, V16, P3919, DOI 10.1093/nar/16.9.3919; SONG Q, 1993, BIOCHEM BIOPH RES CO, V190, P45; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; TEALE B, IN PRESS J BIOL CHEM; UCKUN FM, 1992, P NATL ACAD SCI USA, V89, P9005, DOI 10.1073/pnas.89.19.9005; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAMPETTIBOSSELER F, 1981, INT J RADIAT BIOL, V39, P547, DOI 10.1080/09553008114550651	58	282	288	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1993	8	12					3307	3312						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247533				2022-12-17	WOS:A1993MG78200014
J	DUBIK, D; SHIU, RPC				DUBIK, D; SHIU, RPC			MECHANISM OF ESTROGEN ACTIVATION OF C-MYC ONCOGENE EXPRESSION	ONCOGENE			English	Article							HUMAN-BREAST-CANCER; DEOXYRIBONUCLEIC-ACID BINDING; RAT PROLACTIN GENE; RESPONSIVE ELEMENT; TRANSCRIPTIONAL ACTIVATION; PROTO-ONCOGENE; SINGLE DOMAIN; DNA-BINDING; PS2 GENE; RECEPTOR	The estrogen receptor complex is a known trans-acting factor that regulates transcription of specific genes through an interaction with a specific estrogen-responsive cis-acting element (ERE). In previous studies we have shown that in estrogen-responsive human breast cancer cells estrogen rapidly activates c-myc expression. This activated expression occurs through enhanced transcription and does not require the synthesis of new protein intermediates; therefore, an ERE is present in the human c-myc gene regulatory region. To localize the ERE, constructs containing varying lengths of the c-myc 5'-flanking region ranging from - 2327 to + 25 (relative to the PI promoter) placed adjacent to the chloramphenicol acetyl transferase reporter gene (CAT) were prepared. They were used in transient transfection studies in MCF-7 and HeLa cells co-transfected with an estrogen receptor expression vector. These studies reveal that at] constructs containing the P2 promoter region exhibited estrogen-regulated CAT expression and that a 116-bp region upstream and encompassing the P2 TATA box is necessary for this activity. Analysis of this 116-bp region failed to identify a cis-acting element with sequences resembling the consensus ERE; however, co-transfection studies with mutant estrogen receptor expression vectors showed that the DNA-binding domain of the receptor is essential for estrogen-regulated CAT gene expression. We have also observed that anti-estrogen receptor complexes can weakly trans-activate from this 116-bp region but fail to do so from the ERE-containing ApoVLDLII-CAT construct. To explain these results we propose a new mechanism of estrogen trans-activation in the c-myc gene promoter.	UNIV MANITOBA, DEPT PHYSIOL, WINNIPEG R3E 0W3, MANITOBA, CANADA	University of Manitoba								BASERGA R, 1984, EXP CELL RES, V151, P1, DOI 10.1016/0014-4827(84)90349-5; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERRY M, 1989, P NATL ACAD SCI USA, V86, P1218, DOI 10.1073/pnas.86.4.1218; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; CALLAHAN R, 1989, JNCI-J NATL CANCER I, V81, P1780, DOI 10.1093/jnci/81.23.1780; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; CATO ACB, 1988, MOL CELL BIOL, V8, P5323, DOI 10.1128/MCB.8.12.5323; CATTINI PA, 1987, NUCLEIC ACIDS RES, V15, P1297, DOI 10.1093/nar/15.3.1297; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DELLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P6497, DOI 10.1073/pnas.79.21.6497; DUBIK D, 1987, CANCER RES, V47, P6517; DUBIK D, 1988, J BIOL CHEM, V263, P12705; GARCIA I, 1989, CANCER RES, V49, P6675; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOWLEY PM, 1983, METHOD ENZYMOL, V101, P387; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; LANG JC, 1988, BRIT J CANCER, V58, P62; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1988, CURR TOP MICROBIOL, V141, P253; MARCU KB, 1987, BIOESSAYS, V6, P28, DOI 10.1002/bies.950060108; MARIANICOSTANTINI R, 1988, CANCER RES, V48, P199; MARTINEZ E, 1987, EMBO J, V6, P3719, DOI 10.1002/j.1460-2075.1987.tb02706.x; NUNEZ AM, 1989, EMBO J, V8, P823, DOI 10.1002/j.1460-2075.1989.tb03443.x; PENTECOST BT, 1990, MOL ENDOCRINOL, V4, P1000, DOI 10.1210/mend-4-7-1000; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; REMMERS EF, 1986, EMBO J, V5, P899, DOI 10.1002/j.1460-2075.1986.tb04301.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTOS GF, 1988, J BIOL CHEM, V263, P9565; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SLATER EP, 1990, MOL ENDOCRINOL, V4, P604, DOI 10.1210/mend-4-4-604; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; WALKER P, 1984, NUCLEIC ACIDS RES, V12, P8611, DOI 10.1093/nar/12.22.8611; WATERMAN ML, 1988, MOL ENDOCRINOL, V2, P14, DOI 10.1210/mend-2-1-14; WATSON PH, 1991, CANCER RES, V51, P3996; WU X, 1991, 73RD END SOC PROGR A	43	282	288	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1992	7	8					1587	1594						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630819				2022-12-17	WOS:A1992JE81300015
J	YOKOTA, J; YAMAMOTO, T; MIYAJIMA, N; TOYOSHIMA, K; NOMURA, N; SAKAMOTO, H; YOSHIDA, T; TERADA, M; SUGIMURA, T				YOKOTA, J; YAMAMOTO, T; MIYAJIMA, N; TOYOSHIMA, K; NOMURA, N; SAKAMOTO, H; YOSHIDA, T; TERADA, M; SUGIMURA, T			GENETIC ALTERATIONS OF THE C-ERBB-2 ONCOGENE OCCUR FREQUENTLY IN TUBULAR ADENOCARCINOMA OF THE STOMACH AND ARE OFTEN ACCOMPANIED BY AMPLIFICATION OF THE V-ERBA HOMOLOG	ONCOGENE			English	Article									UNIV TOKYO,INST MED SCI,MINATO KU,TOKYO 108,JAPAN; NIPPON VET & ZOOTECH COLL,MOLEC ONCOL LAB,TAITO KU,TOKYO 110,JAPAN	University of Tokyo; Nippon Veterinary & Life Science University	YOKOTA, J (corresponding author), NATL CANC CTR,RES INST,1-1 TSUKIJI S CHOME,CHUO KU,TOKYO 104,JAPAN.							AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DAYTON AI, 1984, P NATL ACAD SCI-BIOL, V81, P4495, DOI 10.1073/pnas.81.14.4495; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; FUKUSHIGE S, 1986, MOL CELL BIOL, V6, P955, DOI 10.1128/MCB.6.3.955; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; HUERRE C, 1982, P NATL ACAD SCI-BIOL, V79, P6627, DOI 10.1073/pnas.79.21.6627; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KINZLER KW, 1986, P NATL ACAD SCI USA, V83, P1031, DOI 10.1073/pnas.83.4.1031; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; MORI S, IN PRESS VIRCHOWS AR; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SPURR NK, 1984, EMBO J, V3, P159, DOI 10.1002/j.1460-2075.1984.tb01777.x; STARK GR, 1986, CANCER SURV, V5, P1; VIJVER M, 1987, MOL CELL BIOL, V7, P2019; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YOKOTA J, 1986, LANCET, V1, P765; ZABEL BU, 1984, P NATL ACAD SCI-BIOL, V81, P4874, DOI 10.1073/pnas.81.15.4874; ZHOU D, 1987, IN PRESS CANCER RES; 1981, JAPAN J SURG, V11, P140	24	282	285	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1988	2	3					283	287						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M5931	3281095				2022-12-17	WOS:A1988M593100012
J	Rao, X; Di Leva, G; Li, M; Fang, F; Devlin, C; Hartman-Frey, C; Burow, ME; Ivan, M; Croce, CM; Nephew, KP				Rao, X.; Di Leva, G.; Li, M.; Fang, F.; Devlin, C.; Hartman-Frey, C.; Burow, M. E.; Ivan, M.; Croce, C. M.; Nephew, K. P.			MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways	ONCOGENE			English	Article						microRNAs; breast cancer; antiestrogen; drug resistance; fulvestrant	ESTROGEN-RECEPTOR-ALPHA; ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR-BETA; MESSENGER-RNA; ENDOCRINE RESISTANCE; TAMOXIFEN RESISTANCE; TUMOR-SUPPRESSOR; GENE-EXPRESSION; CELLS; MICRORNAS	Fulvestrant is a selective estrogen receptor downregulator (SERD) and highly effective antagonist to hormone-sensitive breast cancers following failure of previous tamoxifen or aromatase inhibitor therapies. However, after prolonged fulvestrant therapy, acquired resistance eventually occurs in the majority of breast cancer patients, due to poorly understood mechanisms. To examine a possible role(s) of aberrantly expressed microRNAs (miRNAs) in acquired fulvestrant resistance, we compared antiestrogen-resistant and -sensitive breast cancer cells, revealing the overexpression of miR-221/222 in the SERD-resistant cell lines. Fulvestrant treatment of estradiol (E2)- and fulvestrant-sensitive MCF7 cells resulted in increased expression of endogenous miR-221/222. Ectopic upregulation of miR-221/222 in estrogen receptor-alpha (ER alpha)-positive cell lines counteracted the effects of E2 depletion or fulvestrant-induced cell death, thus also conferring hormone-independent growth and fulvestrant resistance. In cells with acquired resistance to fulvestrant, miR-221/222 expression was essential for cell growth and cell cycle progression. To identify possible miR-221/222 targets, miR-221- or miR-222-induced alterations in global gene expression profiles and target gene expression at distinct time points were determined, revealing that miR-221/222 overexpression resulted in deregulation of multiple oncogenic signaling pathways previously associated with drug resistance. Activation of beta-catenin by miR-221/222 contributed to estrogen-independent growth and fulvestrant resistance, whereas TGF-beta-mediated growth inhibition was repressed by the two miRNAs. This first in-depth investigation into the role of miR-221/222 in acquired fulvestrant resistance, a clinically important problem, demonstrates that these two 'oncomirs' may represent promising therapeutic targets for treating hormone-independent, SERD-resistant breast cancer. Oncogene (2011) 30, 1082-1097; doi:10.1038/onc.2010.487; published online 8 November 2010	[Rao, X.; Nephew, K. P.] Indiana Univ, Dept Mol & Cellular Biochem, Interdisciplinary Biochem Grad Program, Bloomington, IN USA; [Di Leva, G.; Croce, C. M.] Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; [Nephew, K. P.] Indiana Univ Sch Med, Med Sci Program, Dept Med Sci, Bloomington, IN 47405 USA; [Devlin, C.; Ivan, M.] Indiana Univ Sch Med, Dept Immunol & Microbiol, Dept Med, Indianapolis, IN USA; [Burow, M. E.] Tulane Univ, Sch Med, Dept Med, New Orleans, LA 70112 USA; [Devlin, C.; Ivan, M.; Nephew, K. P.] Indiana Univ Sch Med, IU Simon Canc Ctr, Indianapolis, IN USA; [Devlin, C.; Ivan, M.; Nephew, K. P.] Indiana Univ Sch Med, Dept Cellular & Integrat Physiol, Indianapolis, IN USA	Indiana University System; Indiana University Bloomington; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Tulane University; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington	Nephew, KP (corresponding author), Indiana Univ Sch Med, Med Sci Program, Dept Med Sci, Jordan Hall 302,1001 E 3rd St, Bloomington, IN 47405 USA.	knephew@indiana.edu	Young, Richard A/F-6495-2012; Ivan, Mircea/A-8109-2012; Burow, Matthew/D-6351-2013	Young, Richard A/0000-0001-8855-8647; Burow, Matthew/0000-0002-0642-6630; Di Leva, Gianpiero/0000-0001-6759-8682; Ivan, Mircea/0000-0003-3424-6642	Indiana Genomics Initiative of Indiana University; Lilly Endowment, Inc.; NIH [CA085289, CA113001, CA125806]; American Cancer Society [09-244-01]; Walther Cancer Foundation (Indianapolis); NATIONAL CANCER INSTITUTE [U54CA113001, R01CA085289, R01CA125806] Funding Source: NIH RePORTER	Indiana Genomics Initiative of Indiana University; Lilly Endowment, Inc.; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); Walther Cancer Foundation (Indianapolis); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Man-Wook Hur for providing the TOPflash and FOPflash plasmids, Jim Powers for assistance with fluorescence microscopy, Dr Meiyun Fan for advice on experiments and Dr Curt Balch for critical comments and paper preparation. The IUB Light Microscopy Imaging Center provided microscopy resources. The microarray studies were carried out using the facilities of the Center for Medical Genomics (Dr H Edenberg, Director and Dr J McClintick) at Indiana University School of Medicine. The Center for Medical Genomics is supported in part by the Indiana Genomics Initiative of Indiana University, which is supported in part by the Lilly Endowment, Inc. This work was supported in part by NIH grants CA085289, CA113001 and CA125806, American Cancer Society Research Scholar Grant 09-244-01, and the Walther Cancer Foundation (Indianapolis).	Adams BD, 2007, MOL ENDOCRINOL, V21, P1132, DOI 10.1210/me.2007-0022; Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Ariazi EA, 2006, CURR TOP MED CHEM, V6, P181, DOI 10.2174/156802606776173483; BASOLO F, 1994, INT J CANCER, V56, P736, DOI 10.1002/ijc.2910560521; Bhat-Nakshatri P, 2009, NUCLEIC ACIDS RES, V37, P4850, DOI 10.1093/nar/gkp500; Buck MB, 2004, MOL ENDOCRINOL, V18, P1643, DOI 10.1210/me.2003-0278; Buck MB, 2006, ANN NY ACAD SCI, V1089, P119, DOI 10.1196/annals.1386.024; Bushati N, 2007, ANNU REV CELL DEV BI, V23, P175, DOI 10.1146/annurev.cellbio.23.090506.123406; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Castellano L, 2009, P NATL ACAD SCI USA, V106, P15732, DOI 10.1073/pnas.0906947106; Chen Y, 2010, MOL CELL BIOL, V30, P3902, DOI 10.1128/MCB.01237-09; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Di Leva G, 2010, JNCI-J NATL CANCER I, V102, P706, DOI 10.1093/jnci/djq102; Draghici S, 2007, GENOME RES, V17, P1537, DOI 10.1101/gr.6202607; Fan MY, 2006, CANCER RES, V66, P11954, DOI 10.1158/0008-5472.CAN-06-1666; Felicetti F, 2008, EXPERT REV ANTICANC, V8, P1759, DOI 10.1586/14737140.8.11.1759; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Foekens JA, 2008, P NATL ACAD SCI USA, V105, P13021, DOI 10.1073/pnas.0803304105; Fornari F, 2008, ONCOGENE, V27, P5651, DOI 10.1038/onc.2008.178; Galardi S, 2007, J BIOL CHEM, V282, P23716, DOI 10.1074/jbc.M701805200; Garofalo M, 2009, CANCER CELL, V16, P498, DOI 10.1016/j.ccr.2009.10.014; Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707; Gillies JK, 2007, CELL CYCLE, V6, P2005, DOI 10.4161/cc.6.16.4526; GORSCH SM, 1992, CANCER RES, V52, P6949; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Heneghan HM, 2010, J ONCOL, V2010, DOI 10.1155/2010/950201; Howell A, 2006, CRIT REV ONCOL HEMAT, V57, P265, DOI 10.1016/j.critrevonc.2005.08.001; Howell A, 2006, ENDOCR-RELAT CANCER, V13, P689, DOI 10.1677/erc.1.00846; Huang JC, 2007, NAT METHODS, V4, P1045, DOI 10.1038/nmeth1130; Iorio MV, 2008, EUR J CANCER, V44, P2753, DOI 10.1016/j.ejca.2008.09.037; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Janicke RU, 2008, CELL DEATH DIFFER, V15, P959, DOI 10.1038/cdd.2008.33; John B, 2005, PLOS BIOL, V3, P1328, DOI 10.1371/journal.pbio.0030264; Jordan VC, 2003, NAT REV DRUG DISCOV, V2, P205, DOI 10.1038/nrd1031; KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kertesz M, 2007, NAT GENET, V39, P1278, DOI 10.1038/ng2135; Kim JY, 2006, J BIOL CHEM, V281, P10865, DOI 10.1074/jbc.M513378200; Klinge CM, 2009, CURR GENOMICS, V10, P169, DOI 10.2174/138920209788185289; Kondo N, 2008, CANCER RES, V68, P5004, DOI 10.1158/0008-5472.CAN-08-0180; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Li M, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-34; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Maragkakis M, 2009, NUCLEIC ACIDS RES, V37, pW273, DOI 10.1093/nar/gkp292; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; McDonnell DP, 2006, FASEB J, V20, P2432, DOI 10.1096/fj.06-1202ufm; McEarchern JA, 2001, INT J CANCER, V91, P76, DOI 10.1002/1097-0215(20010101)91:1<76::AID-IJC1012>3.0.CO;2-8; Miller TE, 2008, J BIOL CHEM, V283, P29897, DOI 10.1074/jbc.M804612200; Nam S, 2009, NUCLEIC ACIDS RES, V37, pW356, DOI 10.1093/nar/gkp294; Nicholson RI, 2005, ENDOCR-RELAT CANCER, V12, pS29, DOI 10.1677/erc.1.00991; Nicholson RI, 2005, BREAST CANCER RES TR, V93, pS3, DOI 10.1007/s10549-005-9036-4; Normanno N, 2005, ENDOCR-RELAT CANCER, V12, P721, DOI 10.1677/erc.1.00857; O'Brien CS, 2009, J MAMMARY GLAND BIOL, V14, P45, DOI 10.1007/s10911-009-9115-y; Pineau P, 2010, P NATL ACAD SCI USA, V107, P264, DOI 10.1073/pnas.0907904107; Sagara Y, 2004, BRIT J CANCER, V91, P959, DOI 10.1038/sj.bjc.6602029; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Shitashige M, 2008, CANCER SCI, V99, P631, DOI 10.1111/j.1349-7006.2007.00716.x; Smith IE, 2003, NEW ENGL J MED, V348, P2431, DOI 10.1056/NEJMra023246; Sovak MA, 1999, CELL GROWTH DIFFER, V10, P537; Takahashi-Yanaga F, 2010, CLIN CANCER RES, V16, P3153, DOI 10.1158/1078-0432.CCR-09-2943; Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460; Visone R, 2007, ENDOCR-RELAT CANCER, V14, P791, DOI 10.1677/ERC-07-0129; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Weldon CB, 2004, INT J ONCOL, V24, P1473; Wijayaratne AL, 1999, ENDOCRINOLOGY, V140, P5828, DOI 10.1210/en.140.12.5828; Xin FX, 2009, BIOINFORMATICS, V25, P430, DOI 10.1093/bioinformatics/btn646; Zhao JJ, 2008, J BIOL CHEM, V283, P31079, DOI 10.1074/jbc.M806041200; Zhou CH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2210; ZUGMAIER G, 1989, J CELL PHYSIOL, V141, P353, DOI 10.1002/jcp.1041410217	70	281	295	0	26	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	9					1082	1097		10.1038/onc.2010.487	http://dx.doi.org/10.1038/onc.2010.487			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729PX	21057537	Green Accepted			2022-12-17	WOS:000287964100007
J	Matsubara, H; Takeuchi, T; Nishikawa, E; Yanagisawa, K; Hayashita, Y; Ebi, H; Yamada, H; Suzuki, M; Nagino, M; Nimura, Y; Osada, H; Takahashi, T				Matsubara, H.; Takeuchi, T.; Nishikawa, E.; Yanagisawa, K.; Hayashita, Y.; Ebi, H.; Yamada, H.; Suzuki, M.; Nagino, M.; Nimura, Y.; Osada, H.; Takahashi, T.			Apoptosis induction by antisense oligonucleotides against miR-17-5p and miR-20a in lung cancers overexpressing miR-17-92	ONCOGENE			English	Article						miRNA; lung cancer; antisense; apoptosis	MESSENGER-RNA; MICRORNAS; MECHANISM	Amplification and overexpression of the miR- 17- 92 microRNAs ( miRNA) cluster at 13q31.3 has recently reported, with pointers to functional involvement in the development of B- cell lymphomas and lung cancers. In the present study, we show that inhibition of miR- 17- 5p and miR- 20a with antisense oligonucleotides ( ONs) can induce apoptosis selectively in lung cancer cells overexpressing miR- 17- 92, suggesting the possibility of 'Oncomi R addiction to expression of these miRNAs in a subset of lung cancers. In marked contrast, antisense ONs against miR-18a and miR- 19a did not exhibit such inhibitory effects, whereas inhibition of miR-92-1 resulted in only modest reduction of cell growth, showing significant distinctions among miRNAs of the miR- 17- 92 cluster in terms of their roles in cancer cell growth. During the course of this study, we also found that enforced expression of a genomic region, termed C2, residing 30 to miR- 17- 92 in the intron 3 of C13orf25 led to marked growth inhibition in association with double stranded RNA- dependent protein kinase activation. Finally, this study also revealed that the vast majority of C13orf25 transcripts are detected as Drosha- processed cleavage products on Northern blot analysis and that a novel polyadenylation site is present 30 to the miR- 17- 92 cluster and 50 to the C2 region. Taken together, the present findings contribute towards better understanding of the oncogenic roles of miR- 17- 92, which might ultimately lead to the future translation into clinical applications.	Nagoya Univ, Grad Sch Med, Ctr Neurol Dis & Canc, Div Mol Carcinogenesis,Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Grad Sch Med, Ctr Neurol Dis & Canc, Dept Surg Oncol,Showa Ku, Nagoya, Aichi, Japan; Aichi Canc Ctr, Res Inst, Div Mol Oncol, Nagoya, Aichi, Japan	Nagoya University; Nagoya University; Aichi Cancer Center	Takahashi, T (corresponding author), Nagoya Univ, Grad Sch Med, Ctr Neurol Dis & Canc, Div Mol Carcinogenesis,Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	tak@med.nagoya-u.ac.jp	Suzuki, Motoshi/I-7246-2014; Takahashi, Takashi/I-7262-2014; Yanagisawa, Kiyoshi/I-7263-2014; Nagino, Masato/I-7342-2014; Osada, Hiroyuki/AAY-6254-2020; Ebi, Hiromichi/AAA-7358-2019	Suzuki, Motoshi/0000-0003-0682-5006; Takahashi, Takashi/0000-0003-0615-7001; Ebi, Hiromichi/0000-0003-3155-7576				Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bommer UA, 2002, RNA, V8, P478, DOI 10.1017/S1355838202022586; Cullen BR, 2004, MOL CELL, V16, P861, DOI 10.1016/j.molcel.2004.12.002; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Gil J, 2000, APOPTOSIS, V5, P107, DOI 10.1023/A:1009664109241; Gleave ME, 2005, NAT REV CANCER, V5, P468, DOI 10.1038/nrc1631; Hayashita Y, 2005, CANCER RES, V65, P9628, DOI 10.1158/0008-5472.CAN-05-2352; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Macleod K, 1999, CURR OPIN GENET DEV, V9, P31, DOI 10.1016/S0959-437X(99)80005-7; Maeno K, 2006, ONCOGENE, V25, P271, DOI 10.1038/sj.onc.1209018; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Ota A, 2004, CANCER RES, V64, P3087, DOI 10.1158/0008-5472.CAN-03-3773; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; Zamore PD, 2005, SCIENCE, V309, P1519, DOI 10.1126/science.1111444; Zarudnaya MI, 2003, NUCLEIC ACIDS RES, V31, P1375, DOI 10.1093/nar/gkg241	19	281	321	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2007	26	41					6099	6105		10.1038/sj.onc.1210425	http://dx.doi.org/10.1038/sj.onc.1210425			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	207US	17384677				2022-12-17	WOS:000249277200013
J	Galluzzi, L; Larochette, N; Zamzami, N; Kroemer, G				Galluzzi, L.; Larochette, N.; Zamzami, N.; Kroemer, G.			Mitochondria as therapeutic targets for cancer chemotherapy	ONCOGENE			English	Review						apoptosis; Bcl-2; caspases; cell death; p53; permeability transition	PERMEABILITY TRANSITION-PORE; CYTOCHROME-C RELEASE; APOPTOSIS-INDUCING FACTOR; ADENINE-NUCLEOTIDE TRANSLOCATOR; DEPENDENT ANION CHANNEL; PERIPHERAL BENZODIAZEPINE-RECEPTOR; RAT-LIVER MITOCHONDRIA; MANGANESE SUPEROXIDE-DISMUTASE; DRUG-INDUCED APOPTOSIS; NECROSIS-FACTOR-ALPHA	Mitochondria are vital for cellular bioenergetics and play a central role in determining the point-of-no-return of the apoptotic process. As a consequence, mitochondria exert a dual function in carcinogenesis. Cancer-associated changes in cellular metabolism (the Warburg effect) influence mitochondrial function, and the invalidation of apoptosis is linked to an inhibition of mitochondrial outer membrane permeabilization (MOMP). On theoretical grounds, it is tempting to develop specific therapeutic interventions that target the mitochondrial Achilles' heel, rendering cancer cells metabolically unviable or subverting endogenous MOMP inhibitors. A variety of experimental therapeutic agents can directly target mitochondria, causing apoptosis induction. This applies to a heterogeneous collection of chemically unrelated compounds including positively charged alpha-helical peptides, agents designed to mimic the Bcl-2 homology domain 3 of Bcl-2-like proteins, ampholytic cations, metals and steroid-like compounds. Such MOMP inducers or facilitators can induce apoptosis by themselves (monotherapy) or facilitate apoptosis induction in combination therapies, bypassing chemoresistance against DNA-damaging agents. In addition, it is possible to design molecules that neutralize inhibitor of apoptosis proteins (IAPs) or heat shock protein 70 (HSP70). Such IAP or HSP70 inhibitors can mimic the action of mitochondrion-derived mediators (Smac/DIABLO, that is, second mitochondria-derived activator of caspases/direct inhibitor of apoptosis-binding protein with a low isoelectric point, in the case of IAPs; AIF, that is apoptosis-inducing factor, in the case of HSP70) and exert potent chemosensitizing effects.	Inst Gustave Roussy, CNRS, FRE 2939, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, FRE 2939, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	Galluzzi, Lorenzo/AAG-6432-2019; KROEMER, Guido/B-4263-2013; Galluzzi, Lorenzo/AAG-6294-2019; LAROCHETTE, Nathanael/R-4298-2017; Kroemer, Guido/AAY-9859-2020; Galluzzi, Lorenzo/AAH-3286-2021; Galluzzi, Lorenzo/K-2709-2012	KROEMER, Guido/0000-0002-9334-4405; LAROCHETTE, Nathanael/0000-0002-7936-678X; Galluzzi, Lorenzo/0000-0003-2257-8500				Abu-Amero KK, 2005, ONCOGENE, V24, P1455, DOI 10.1038/sj.onc.1208292; Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; An J, 2004, J BIOL CHEM, V279, P19133, DOI 10.1074/jbc.M400295200; AOKI H, 2002, IN PRESS J BIOL CHEM; Aqeilan R, 1999, FEBS LETT, V457, P271, DOI 10.1016/S0014-5793(99)01050-9; Arap W, 2002, P NATL ACAD SCI USA, V99, P1527, DOI 10.1073/pnas.241655998; Azoulay-Zohar H, 2004, BIOCHEM J, V377, P347, DOI 10.1042/BJ20031465; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Baines CP, 2002, CIRC RES, V90, P390, DOI 10.1161/01.RES.0000012702.90501.8D; Baines CP, 2003, CIRC RES, V92, P873, DOI 10.1161/01.RES.0000069215.36389.8D; Baksh S, 2005, MOL CELL, V18, P637, DOI 10.1016/j.molcel.2005.05.010; Banker DE, 2002, LEUKEMIA RES, V26, P91, DOI 10.1016/S0145-2126(01)00112-6; Becker JW, 2004, J MED CHEM, V47, P2466, DOI 10.1021/jm0305523; Belostotsky R, 2001, J IMMUNOL, V167, P4719, DOI 10.4049/jimmunol.167.8.4719; Belzacq AS, 2003, CANCER RES, V63, P541; Belzacq AS, 2001, ONCOGENE, V20, P7579, DOI 10.1038/sj.onc.1204953; Belzacq AS, 2001, CANCER RES, V61, P1260; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; Beutner G, 1998, BBA-BIOMEMBRANES, V1368, P7, DOI 10.1016/S0005-2736(97)00175-2; Bockbrader KM, 2005, ONCOGENE, V24, P7381, DOI 10.1038/sj.onc.1208888; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Boya P, 2003, ONCOGENE, V22, P6220, DOI 10.1038/sj.onc.1206827; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; Brustovetsky N, 2002, BIOCHEMISTRY-US, V41, P11804, DOI 10.1021/bi0200110; Cahuana GM, 2004, EXP CELL RES, V293, P22, DOI 10.1016/j.yexcr.2003.10.004; Cande C, 2004, J CELL SCI, V117, P4461, DOI 10.1242/jcs.01356; Cande C, 2004, ONCOGENE, V23, P1514, DOI 10.1038/sj.onc.1207279; Cande C, 2002, J CELL SCI, V115, P4727, DOI 10.1242/jcs.00210; Canter JA, 2005, CANCER RES, V65, P8028, DOI 10.1158/0008-5472.CAN-05-1428; Cartron PF, 2004, MOL CELL, V16, P807, DOI 10.1016/j.molcel.2004.10.028; Casares N, 2005, J EXP MED, V202, P1691, DOI 10.1084/jem.20050915; Casellas P, 2002, NEUROCHEM INT, V40, P475, DOI 10.1016/S0197-0186(01)00118-8; Castedo M, 2002, J EXP MED, V196, P1121, DOI 10.1084/jem.20021758; Castilho RF, 1997, INT J BIOCHEM CELL B, V29, P1005, DOI 10.1016/S1357-2725(97)00041-1; Castilho RF, 1998, ARCH BIOCHEM BIOPHYS, V354, P151, DOI 10.1006/abbi.1998.0657; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chandra J, 2002, BLOOD, V99, P655, DOI 10.1182/blood.V99.2.655; Chen J, 2003, NUCLEIC ACIDS RES, V31, P474, DOI 10.1093/nar/gkg086; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Chilin A, 2005, J MED CHEM, V48, P192, DOI 10.1021/jm0493919; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Chiu SM, 2005, APOPTOSIS, V10, P1357, DOI 10.1007/s10495-005-2217-0; Chua BT, 2003, NAT CELL BIOL, V5, P1083, DOI 10.1038/ncb1070; Chun KH, 2003, CANCER RES, V63, P3826; Costantini P, 2000, ONCOGENE, V19, P307, DOI 10.1038/sj.onc.1203299; Da Lozzo EJ, 1998, J BIOCHEM MOL TOXIC, V12, P291, DOI 10.1002/(SICI)1099-0461(1998)12:5<291::AID-JBT5>3.0.CO;2-G; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; de Pablo MA, 1999, APOPTOSIS, V4, P81, DOI 10.1023/A:1009694124241; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Decaudin D, 2002, CANCER RES, V62, P1388; Degterev A, 2001, NAT CELL BIOL, V3, P173, DOI 10.1038/35055085; Dilda PJ, 2005, JNCI-J NATL CANCER I, V97, P1539, DOI 10.1093/jnci/dji316; Dolce V, 2005, FEBS LETT, V579, P633, DOI 10.1016/j.febslet.2004.12.034; Dolder M, 2003, J BIOL CHEM, V278, P17760, DOI 10.1074/jbc.M208705200; Don AS, 2003, CANCER CELL, V3, P497, DOI 10.1016/S1535-6108(03)00109-0; Donald SP, 2001, CANCER RES, V61, P1810; Ellerby HM, 1999, NAT MED, V5, P1032, DOI 10.1038/12469; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; Fantin VR, 2005, CANCER RES, V65, P6891, DOI 10.1158/0008-5472.CAN-05-0395; Fantin VR, 2002, CANCER CELL, V2, P29, DOI 10.1016/S1535-6108(02)00082-X; Fernandez-Salas E, 2002, MOL CELL BIOL, V22, P3610, DOI 10.1128/MCB.22.11.3610-3620.2002; Ferri KF, 2001, BIOESSAYS, V23, P111, DOI 10.1002/1521-1878(200102)23:2<111::AID-BIES1016>3.0.CO;2-Y; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Ferri KF, 2000, J EXP MED, V192, P1081, DOI 10.1084/jem.192.8.1081; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Fulda S, 2005, NEOPLASIA, V7, P162, DOI 10.1593/neo.04442; Fulda S, 1998, CANCER RES, V58, P4453; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Fulda S, 1998, J BIOL CHEM, V273, P33942, DOI 10.1074/jbc.273.51.33942; Garofalo T, 2005, CELL DEATH DIFFER, V12, P1378, DOI 10.1038/sj.cdd.4401672; Genini D, 2000, BLOOD, V96, P3537; Gincel D, 2004, J BIOENERG BIOMEMBR, V36, P179, DOI 10.1023/B:JOBB.0000023621.72873.9e; Gincel D, 2001, BIOCHEM J, V358, P147, DOI 10.1042/0264-6021:3580147; Giordano A, 2005, CELL DEATH DIFFER, V12, P603, DOI 10.1038/sj.cdd.4401636; Giraud S, 1998, J MOL BIOL, V281, P409, DOI 10.1006/jmbi.1998.1955; Gogvadze V, 2001, J BIOL CHEM, V276, P19066, DOI 10.1074/jbc.M100614200; Gonzalez-Polo RA, 2005, ONCOGENE, V24, P7503, DOI 10.1038/sj.onc.1208907; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Green DR, 2005, J CLIN INVEST, V115, P2610, DOI 10.1172/JCI26321; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Grinberg M, 2005, MOL CELL BIOL, V25, P4579, DOI 10.1128/MCB.25.11.4579-4590.2005; Grinberg M, 2002, J BIOL CHEM, V277, P12237, DOI 10.1074/jbc.M104893200; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Gurbuxani S, 2003, ONCOGENE, V22, P6669, DOI 10.1038/sj.onc.1206794; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Han J, 2004, J BIOL CHEM, V279, P22020, DOI 10.1074/jbc.M313234200; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Haridas V, 2001, P NATL ACAD SCI USA, V98, P11557, DOI 10.1073/pnas.191363498; Haworth RA, 2000, J BIOENERG BIOMEMBR, V32, P91, DOI 10.1023/A:1005568630151; He YW, 2005, CANCER RES, V65, P10016, DOI 10.1158/0008-5472.CAN-05-1688; Heerdt BG, 2003, CANCER RES, V63, P6311; Heerdt BG, 2005, CANCER RES, V65, P9861, DOI 10.1158/0008-5472.CAN-05-2444; Heiden MGV, 2001, J BIOL CHEM, V276, P19414, DOI 10.1074/jbc.M101590200; HERMESLIMA M, 1995, FREE RADICAL BIO MED, V19, P381, DOI 10.1016/0891-5849(95)00015-P; Hirsch T, 1998, EXP CELL RES, V241, P426, DOI 10.1006/excr.1998.4084; Hwang PM, 2001, NAT MED, V7, P1111, DOI 10.1038/nm1001-1111; Isaacs JS, 2005, CANCER CELL, V8, P143, DOI 10.1016/j.ccr.2005.06.017; Jacotot E, 2001, J EXP MED, V193, P509, DOI 10.1084/jem.193.4.509; Jan G, 2002, CELL DEATH DIFFER, V9, P179, DOI 10.1038/sj.cdd.4400935; Johnson H, 2003, BLOOD, V101, P3093, DOI 10.1182/blood-2002-08-2485; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; Kidd JF, 2002, J BIOL CHEM, V277, P6504, DOI 10.1074/jbc.M106802200; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Klamt F, 2005, J BIOL CHEM, V280, P21346, DOI 10.1074/jbc.M501170200; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; Konishi A, 2003, CELL, V114, P673, DOI 10.1016/S0092-8674(03)00719-0; Konopleva M, 2004, CANCER RES, V64, P7927, DOI 10.1158/0008-5472.CAN-03-2402; Kowaltowski AJ, 1996, FEBS LETT, V378, P150, DOI 10.1016/0014-5793(95)01449-7; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kroemer G, 1999, JNCI-J NATL CANCER I, V91, P743, DOI 10.1093/jnci/91.9.743; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kudla G, 2000, J BIOL CHEM, V275, P22713, DOI 10.1074/jbc.M003807200; Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125; Kumar S, 2003, MOL PHARMACOL, V63, P276, DOI 10.1124/mol.63.2.276; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519; Latha K, 2005, MOL CELL BIOL, V25, P1737, DOI 10.1128/MCB.25.5.1737-1748.2005; Lehenkari PP, 2002, MOL PHARMACOL, V61, P1255, DOI 10.1124/mol.61.5.1255; Lemeshko VV, 2005, J BIOL CHEM, V280, P15579, DOI 10.1074/jbc.M414064200; LENARTOWICZ E, 1991, J BIOENERG BIOMEMBR, V23, P679, DOI 10.1007/BF00785817; Lenders JWM, 2005, LANCET, V366, P665, DOI 10.1016/S0140-6736(05)67139-5; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Li L, 2004, SCIENCE, V305, P1471, DOI 10.1126/science.1098231; Li XX, 2005, BIOPHYS J, V88, P2577, DOI 10.1529/biophysj.104.049403; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; Loeffler M, 2001, FASEB J, V15, P758, DOI 10.1096/fj.00-0388com; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Machida K, 2002, J BIOL CHEM, V277, P31243, DOI 10.1074/jbc.M204564200; Madesh M, 2001, J CELL BIOL, V155, P1003, DOI 10.1083/jcb.200105057; Majewski N, 2004, MOL CELL BIOL, V24, P730, DOI 10.1128/MCB.24.2.730-740.2004; Manion MK, 2004, J BIOL CHEM, V279, P2159, DOI 10.1074/jbc.M306021200; Marchetti P, 1999, CANCER RES, V59, P6257; Martinvalet D, 2005, IMMUNITY, V22, P355, DOI 10.1016/j.immuni.2005.02.004; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Mate MJ, 2002, NAT STRUCT BIOL, V9, P442, DOI 10.1038/nsb793; Mathupala SP, 1997, J BIOENERG BIOMEMBR, V29, P339, DOI 10.1023/A:1022494613613; Matsuda K, 2002, CANCER RES, V62, P2883; McJilton MA, 2003, ONCOGENE, V22, P7958, DOI 10.1038/sj.onc.1206795; Metivier D, 1998, IMMUNOL LETT, V61, P157, DOI 10.1016/S0165-2478(98)00013-3; Miccoli L, 1998, CANCER RES, V58, P5777; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Miramar MD, 2001, J BIOL CHEM, V276, P16391, DOI 10.1074/jbc.M010498200; Morshauser RC, 1999, J MOL BIOL, V289, P1387, DOI 10.1006/jmbi.1999.2776; Motoori S, 2001, CANCER RES, V61, P5382; Muscarella DE, 2003, TOXICOL SCI, V74, P66, DOI 10.1093/toxsci/kfg052; Nagahara Y, 2000, J IMMUNOL, V165, P3250, DOI 10.4049/jimmunol.165.6.3250; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Nakamura Y, 2002, J BIOL CHEM, V277, P8492, DOI 10.1074/jbc.M109760200; Nomura K, 1999, J BIOL CHEM, V274, P29294, DOI 10.1074/jbc.274.41.29294; Nonn L, 2003, MOL CELL BIOL, V23, P916, DOI 10.1128/MCB.23.3.916-922.2003; Notario B, 2003, MOL PHARMACOL, V63, P224, DOI 10.1124/mol.63.1.224; Novgorodov SA, 2005, J BIOL CHEM, V280, P16096, DOI 10.1074/jbc.M411707200; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Orsini F, 2004, J BIOL CHEM, V279, P25689, DOI 10.1074/jbc.M401844200; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; Oudard S, 2003, J NEURO-ONCOL, V63, P81, DOI 10.1023/A:1023756707900; Palmeira CM, 1997, TOXICOL APPL PHARM, V143, P338, DOI 10.1006/taap.1996.8099; Pardo J, 2001, J IMMUNOL, V167, P1222, DOI 10.4049/jimmunol.167.3.1222; Pastorino JG, 2002, J BIOL CHEM, V277, P7610, DOI 10.1074/jbc.M109950200; Patterson SD, 2000, CELL DEATH DIFFER, V7, P137, DOI 10.1038/sj.cdd.4400640; Peixoto F, 2004, PLANTA MED, V70, P1064, DOI 10.1055/s-2004-832648; Perfettini JL, 2005, TRENDS CELL BIOL, V15, P179, DOI 10.1016/j.tcb.2005.02.005; Perfettini JL, 2004, NAT CELL BIOL, V6, P386, DOI 10.1038/ncb0504-386; Perfettini JL, 2004, J EXP MED, V199, P629, DOI 10.1084/jem.20031216; Pervaiz S, 1999, BLOOD, V93, P4096, DOI 10.1182/blood.V93.12.4096.412k44_4096_4108; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; Petros JA, 2005, P NATL ACAD SCI USA, V102, P719, DOI 10.1073/pnas.0408894102; PFEIFFER DR, 1995, J BIOL CHEM, V270, P4923, DOI 10.1074/jbc.270.9.4923; Poncet D, 2003, APOPTOSIS, V8, P521, DOI 10.1023/A:1025546525894; Poncet D, 2004, J BIOL CHEM, V279, P22605, DOI 10.1074/jbc.M308408200; Rapizzi E, 2002, J CELL BIOL, V159, P613, DOI 10.1083/jcb.200205091; Rarnanathan A, 2005, P NATL ACAD SCI USA, V102, P5992, DOI 10.1073/pnas.0502267102; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Ravagnan L, 1999, ONCOGENE, V18, P2537, DOI 10.1038/sj.onc.1202625; Ren J, 2006, ONCOGENE, V25, P20, DOI 10.1038/sj.onc.1209012; Ricci JE, 2003, J CELL BIOL, V160, P65, DOI 10.1083/jcb.200208089; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(01)00274-4; Rippo MR, 2000, FASEB J, V14, P2047, DOI 10.1096/fj.99-1028com; Risso A, 2002, MOL CELL BIOL, V22, P1926, DOI 10.1128/MCB.22.6.1926-1935.2002; Robertson JD, 2000, J BIOL CHEM, V275, P32438, DOI 10.1074/jbc.C000518200; Robey RB, 2005, CELL CYCLE, V4, P654, DOI 10.4161/cc.4.5.1678; Rodic N, 2005, STEM CELLS, V23, P1314, DOI 10.1634/stemcells.2005-0119; Rodrigues CMP, 2000, MOL MED, V6, P936, DOI 10.1007/BF03401828; Rostovtseva TK, 2004, J BIOL CHEM, V279, P13575, DOI 10.1074/jbc.M310593200; Rotem R, 2005, CANCER RES, V65, P1984, DOI 10.1158/0008-5472.CAN-04-3091; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Sakurai K, 2001, J BIOL CHEM, V276, P26942, DOI 10.1074/jbc.M102029200; Salvi M, 2003, BIOCHEM PHARMACOL, V66, P2375, DOI 10.1016/j.bcp.2003.08.023; Salvi M, 2005, ENDOCRINOLOGY, V146, P2306, DOI 10.1210/en.2004-1128; Sandra F, 2005, CANCER RES, V65, P8286, DOI 10.1158/0008-5472.CAN-04-1913; Schempp CM, 2002, ONCOGENE, V21, P1242, DOI 10.1038/sj.onc.1205190; Schendel SL, 1999, J BIOL CHEM, V274, P21932, DOI 10.1074/jbc.274.31.21932; Schlattner U, 2006, BBA-MOL BASIS DIS, V1762, P164, DOI 10.1016/j.bbadis.2005.09.004; Schlattner U, 2001, J BIOL CHEM, V276, P48027, DOI 10.1074/jbc.M106524200; Schmitt E, 2003, CANCER RES, V63, P8233; Schubert A, 2004, CANCER RES, V64, P85, DOI 10.1158/0008-5472.CAN-03-0476; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Scorrano L, 2001, J BIOL CHEM, V276, P12035, DOI 10.1074/jbc.M010603200; Shidara Y, 2005, CANCER RES, V65, P1655, DOI 10.1158/0008-5472.CAN-04-2012; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Stoebner PE, 2001, CELL DEATH DIFFER, V8, P747, DOI 10.1038/sj.cdd.4400861; Sugiyama T, 2002, ONCOGENE, V21, P4944, DOI 10.1038/sj.onc.1205621; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Takahashi Y, 2005, MOL CELL BIOL, V25, P9369, DOI 10.1128/MCB.25.21.9369-9382.2005; Takuma K, 2001, J BIOL CHEM, V276, P48093, DOI 10.1074/jbc.M108622200; Tan KO, 2005, P NATL ACAD SCI USA, V102, P14623, DOI 10.1073/pnas.0503524102; Tanaka T, 2002, EMBO J, V21, P1695, DOI 10.1093/emboj/21.7.1695; Thierbach R, 2005, HUM MOL GENET, V14, P3857, DOI 10.1093/hmg/ddi410; Tolcher Anthony W, 2005, Clin Adv Hematol Oncol, V3, P635; TOLCHER AW, 2005, CLIN ADV HEMATOL ONC, V3, P662; Tzung SP, 2001, NAT CELL BIOL, V3, P183, DOI 10.1038/35055095; Vahsen N, 2004, EMBO J, V23, P4679, DOI 10.1038/sj.emboj.7600461; Vahsen N, 2006, ONCOGENE, V25, P1763, DOI 10.1038/sj.onc.1209206; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Vieira Helena L. A., 2002, Oncogene, V21, P1963, DOI 10.1038/sj.onc.1205270; Vieira HLA, 2001, ONCOGENE, V20, P4305, DOI 10.1038/sj.onc.1204575; Vieira HLA, 2000, CELL DEATH DIFFER, V7, P1146, DOI 10.1038/sj.cdd.4400778; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Walensky LD, 2004, SCIENCE, V305, P1466, DOI 10.1126/science.1099191; Walter RB, 2005, BLOOD, V106, P3584, DOI 10.1182/blood-2005-02-0711; Walter RB, 2004, BLOOD, V103, P4276, DOI 10.1182/blood-2003-11-3825; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124; Wang JL, 2000, CANCER RES, V60, P1498; Wang Y, 2006, INT J ONCOL, V28, P161; Wang Y, 2005, ANTI-CANCER DRUG, V16, P953, DOI 10.1097/01.cad.0000180123.24031.5a; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Warburg O. H., 1930, METABOLISM TUMOURS I; Watabe M, 2000, CANCER RES, V60, P5214; Watcharasit P, 2003, J BIOL CHEM, V278, P48872, DOI 10.1074/jbc.M305870200; Waterhouse NJ, 2005, J BIOL CHEM, V280, P4476, DOI 10.1074/jbc.M410985200; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Wilson-Annan J, 2003, J CELL BIOL, V162, P877, DOI 10.1083/jcb.200302144; Wu CC, 2005, MOL CANCER THER, V4, P1277, DOI 10.1158/1535-7163.MCT-05-0027; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Wudarczyk J, 1996, ARCH BIOCHEM BIOPHYS, V327, P215, DOI 10.1006/abbi.1996.0112; Xue L, 2002, P NATL ACAD SCI USA, V99, P6925, DOI 10.1073/pnas.102182299; Xue LY, 2001, ONCOGENE, V20, P3420, DOI 10.1038/sj.onc.1204441; Ye H, 2002, NAT STRUCT BIOL, V9, P680, DOI 10.1038/nsb836; Yu CJ, 2006, GENE THER, V13, P313, DOI 10.1038/sj.gt.3302672; Yu R, 2000, MOL PHARMACOL, V58, P431, DOI 10.1124/mol.58.2.431; Zaid H, 2005, CELL DEATH DIFFER, V12, P751, DOI 10.1038/sj.cdd.4401599; Zamora M, 2004, FEBS LETT, V563, P155, DOI 10.1016/S0014-5793(04)00293-5; Zamzami N, 2005, CELL DEATH DIFFER, V12, P1478, DOI 10.1038/sj.cdd.4401682; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zamzami N, 2000, ONCOGENE, V19, P6342, DOI 10.1038/sj.onc.1204030; Zhao YF, 2005, CANCER RES, V65, P3745, DOI 10.1158/0008-5472.CAN-04-3835; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	260	281	296	1	56	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2006	25	34					4812	4830		10.1038/sj.onc.1209598	http://dx.doi.org/10.1038/sj.onc.1209598			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QD	16892093				2022-12-17	WOS:000239687000017
J	Serakinci, N; Guldberg, P; Burns, JS; Abdallah, B; Schrodder, H; Jensen, T; Kassem, M				Serakinci, N; Guldberg, P; Burns, JS; Abdallah, B; Schrodder, H; Jensen, T; Kassem, M			Adult human mesenchymal stem cell as a target for neoplastic transformation	ONCOGENE			English	Article						mesenchymal stem cells; transformation; telomerase	TELOMERASE EXPRESSION; EPITHELIAL-CELLS; BRAIN-TUMORS; CANCER; IMMORTALIZATION; MARROW; MECHANISMS; BMI-1	The neoplastic process may involve a cancer stem cell. This concept has emerged largely from the careful analysis of tumour biopsy systems from haematological, breast and brain tumours. However, the experimental systems necessary to provide the cellular and molecular evidence to support this important concept have been lacking. We have used adult mesenchymal stem cells (hMSC) transduced with the telomerase hTERT gene to investigate the neoplastic potential of adult stem cells. The hTERT-transduced line, hMSC-TERT20 at population doubling level (PDL) 256 showed loss of contact inhibition, anchorage independence and formed tumours in 10/10 mice. hMSC-TERT4 showed loss of contact inhibition at PDL 95, but did not exhibit anchorage independence and did not form tumours in mice. Both lines had a normal karyotype but showed deletion of the Ink4a/ARF locus. At later passage, hMSC-TERT4 also acquired an activating mutation in KRAS. In hMSC-TERT20, expression of the cell cycle-associated gene, DBCCR1 was lost due to promoter hypermethylation. This epigenetic event correlated with acquisition of tumorigenicity. These data suggest that the adult hMSCs can be targets for neoplastic transformation and have implications for the development of novel anticancer therapeutics and for the use of hMSC in tissue engineering and transplantation protocols.	Aarhus Univ, Dept Human Genet, DK-8000 Aarhus C, Denmark; Odense Univ Hosp, Dept Endocrinol, Odense, Denmark; Danish Canc Soc, Inst Canc Biol, Copenhagen, Denmark; Odense Univ Hosp, Inst Pathol, Odense, Denmark	Aarhus University; University of Southern Denmark; Odense University Hospital; Danish Cancer Society; University of Southern Denmark; Odense University Hospital	Serakinci, N (corresponding author), Aarhus Univ, Dept Human Genet, Bartholin Bldg,Univ Pk, DK-8000 Aarhus C, Denmark.	nedi@humgen.au.dk	Kassem, Moustapha/J-7688-2013; Abdallah, Basem/G-5667-2017; Burns, Jorge/AAF-5291-2019; Kassem, Moustapha/O-3819-2019; Schrøder, Henrik Daa/E-2077-2013; Burns, Jorge S./J-3395-2012	Kassem, Moustapha/0000-0003-1557-0869; Abdallah, Basem/0000-0003-0324-8055; Kassem, Moustapha/0000-0003-1557-0869; Schrøder, Henrik Daa/0000-0001-7588-235X; Burns, Jorge S./0000-0002-8602-1536; SERAKINCI, Nedime/0000-0002-1884-0839				AHAJJ M, 2003, P NATL ACAD SCI USA, V100, P3983; Collas P, 2003, TRENDS BIOTECHNOL, V21, P354, DOI 10.1016/S0167-7799(03)00147-1; Dick JE, 2003, P NATL ACAD SCI USA, V100, P3547, DOI 10.1073/pnas.0830967100; Gronbaek K, 2000, LEUKEMIA, V14, P1727, DOI 10.1038/sj.leu.2401901; Hahn WC, 2002, NEW ENGL J MED, V347, P1593, DOI 10.1056/NEJMra021902; Hahn WC, 2001, ANN MED, V33, P123, DOI 10.3109/07853890109002067; Hamad NM, 2002, ONCOGENE, V21, P7121, DOI 10.1038/sj.onc.1205860; Helman LJ, 2003, NAT REV CANCER, V3, P685, DOI 10.1038/nrc1168; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Korbling M, 2003, NEW ENGL J MED, V349, P570, DOI 10.1056/NEJMra022361; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Lundberg AS, 2002, ONCOGENE, V21, P4577, DOI 10.1038/sj.onc.1205550; Mackall CL, 2002, CANCER CELL, V2, P175, DOI 10.1016/S1535-6108(02)00132-0; Milyavsky M, 2003, CANCER RES, V63, P7147; Nishiyama H, 2001, ONCOGENE, V20, P2956, DOI 10.1038/sj.onc.1204432; Owens DM, 2003, NAT REV CANCER, V3, P444, DOI 10.1038/nrc1096; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Passegue E, 2003, P NATL ACAD SCI USA, V100, P11842, DOI 10.1073/pnas.2034201100; Perez-Losada J, 2003, NAT REV CANCER, V3, P434, DOI 10.1038/nrc1095; Preston SL, 2003, J CLIN PATHOL-MOL PA, V56, P86, DOI 10.1136/mp.56.2.86; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Shi ST, 2002, NAT BIOTECHNOL, V20, P587, DOI 10.1038/nbt0602-587; Simonsen JL, 2002, NAT BIOTECHNOL, V20, P592, DOI 10.1038/nbt0602-592; Singh SK, 2003, CANCER RES, V63, P5821; Wang J, 2000, NATURE, V405, P755, DOI 10.1038/35015674	27	281	310	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					5095	5098		10.1038/sj.onc.1207651	http://dx.doi.org/10.1038/sj.onc.1207651			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15107831				2022-12-17	WOS:000222237300017
J	Stoneley, M; Willis, AE				Stoneley, M; Willis, AE			Cellular internal ribosome entry segments: structures, trans-acting factors and regulation of gene expression	ONCOGENE			English	Article						internal ribosome entry; IRES; translation; protein synthesis	SITE-MEDIATED TRANSLATION; TRACT-BINDING-PROTEIN; 5' UNTRANSLATED REGION; X-LINKED INHIBITOR; C-MYC-IRES; MESSENGER-RNA; INITIATION-FACTOR; IN-VITRO; NONTRANSLATED REGION; VIRUS	Initiation of translation in eukaryotic cells can occur by two distinct mechanisms, cap-dependent scanning and internal ribosome entry. The latter mechanism requires the formation of a complex RNA structural element termed an internal ribosome entry segment (IRES). IRESs are located in the 50 untranslated region of the message, and in the presence of trans-acting factors allow the ribosome to be recruited to a site that is a considerable distance from the cap structure. Many cellular mRNAs have now been shown to contain IRESs and it is likely that up to 10% of all mRNAs have the capability to initiate translation by this mechanism. The majority of IRESs that have been identified thus far are found in mRNAs whose protein products are associated with the control of cell growth and cell death, including many growth factors, proto-oncogenes and proteins required for apoptosis. In this review, we discuss the cellular situations when IRESs are required, the trans-acting factors that are necessary for IRES function and deregulation of IRES-mediated translation in tumorigenesis.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	University of Leicester	Willis, AE (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.	ms63@le.ac.uk; aew5@le.ac.uk		Willis, Anne/0000-0002-1470-8531				Belsham GJ, 2000, COLD SPRING HARBOR M, V39, P869; Bonnal S, 2003, J BIOL CHEM, V278, P39330, DOI 10.1074/jbc.M305580200; BONNEAU AM, 1987, J BIOL CHEM, V262, P11134; Chappell SA, 2000, P NATL ACAD SCI USA, V97, P1536, DOI 10.1073/pnas.97.4.1536; Chappell SA, 2000, ONCOGENE, V19, P4437, DOI 10.1038/sj.onc.1203791; Chappell SA, 2003, J BIOL CHEM, V278, P33793, DOI 10.1074/jbc.M303495200; Clemens MJ, 2000, CELL DEATH DIFFER, V7, P603, DOI 10.1038/sj.cdd.4400695; Coldwell MJ, 2000, ONCOGENE, V19, P899, DOI 10.1038/sj.onc.1203407; Coldwell MJ, 2001, ONCOGENE, V20, P4095, DOI 10.1038/sj.onc.1204547; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; Creancier L, 2000, J CELL BIOL, V150, P275, DOI 10.1083/jcb.150.1.275; Creancier L, 2001, MOL CELL BIOL, V21, P1833, DOI 10.1128/MCB.21.5.1833-1840.2001; De Quinto SL, 2000, RNA, V6, P1380, DOI 10.1017/S1355838200000753; Evans JR, 2003, ONCOGENE, V22, P8012, DOI 10.1038/sj.onc.1206645; Fernandez J, 2002, J BIOL CHEM, V277, P2050, DOI 10.1074/jbc.M109199200; Fernandez J, 2001, J BIOL CHEM, V276, P12285, DOI 10.1074/jbc.M009714200; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Henis-Korenblit S, 2000, MOL CELL BIOL, V20, P496, DOI 10.1128/MCB.20.2.496-506.2000; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Holcik M, 2003, MOL CELL BIOL, V23, P280, DOI 10.1128/MCB.23.1.280-288.2003; Holcik M, 2000, ONCOGENE, V19, P4174, DOI 10.1038/sj.onc.1203765; Holcik M, 2000, MOL CELL BIOL, V20, P4648, DOI 10.1128/MCB.20.13.4648-4657.2000; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; Hu MCY, 1999, P NATL ACAD SCI USA, V96, P1339, DOI 10.1073/pnas.96.4.1339; Huez I, 1998, MOL CELL BIOL, V18, P6178, DOI 10.1128/MCB.18.11.6178; Jackson RJ, 2000, COLD SPRING HARBOR M, V39, P127; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; JANG SK, 1989, J VIROL, V63, P1651, DOI 10.1128/JVI.63.4.1651-1660.1989; Johannes G, 1999, P NATL ACAD SCI USA, V96, P13118, DOI 10.1073/pnas.96.23.13118; Jopling CL, 2004, RNA, V10, P287, DOI 10.1261/rna.5138804; Jopling CL, 2001, ONCOGENE, V20, P2664, DOI 10.1038/sj.onc.1204404; Kieft JS, 2002, NAT STRUCT BIOL, V9, P370, DOI 10.1038/nsb781; Kim YK, 2000, J MOL BIOL, V304, P119, DOI 10.1006/jmbi.2000.4179; Kolupaeva VG, 1998, J BIOL CHEM, V273, P18599, DOI 10.1074/jbc.273.29.18599; Kullmann M, 2002, GENE DEV, V16, P3087, DOI 10.1101/gad.248902; Le Quesne JPC, 2001, J MOL BIOL, V310, P111, DOI 10.1006/jmbi.2001.4745; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; Martinez-Salas E, 2001, J GEN VIROL, V82, P973, DOI 10.1099/0022-1317-82-5-973; Miskimins WK, 2001, MOL CELL BIOL, V21, P4960, DOI 10.1128/MCB.21.15.4960-4967.2001; Mitchell SA, 2003, MOL CELL, V11, P757, DOI 10.1016/S1097-2765(03)00093-5; Mitchell SA, 2001, MOL CELL BIOL, V21, P3364, DOI 10.1128/MCB.21.10.3364-3374.2001; Morrish BC, 2002, MOL CELL BIOL, V22, P6089, DOI 10.1128/MCB.22.17.6089-6099.2002; Nevins TA, 2003, J BIOL CHEM, V278, P3572, DOI 10.1074/jbc.M206781200; Paulin FEM, 1996, ONCOGENE, V13, P505; Paulin FEM, 1998, NUCLEIC ACIDS RES, V26, P3097, DOI 10.1093/nar/26.13.3097; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; Pickering BM, 2003, NUCLEIC ACIDS RES, V31, P639, DOI 10.1093/nar/gkg146; PICKERING BM, 2004, IN PRESS MOL CELL BI; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; SHIKOKI K, 2003, NUCLEIC ACIDS RES, V30, P2851; Sizova DV, 1998, J VIROL, V72, P4775, DOI 10.1128/JVI.72.6.4775-4782.1998; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; Stoneley M, 2000, MOL CELL BIOL, V20, P1162, DOI 10.1128/MCB.20.4.1162-1169.2000; Stoneley M, 2000, NUCLEIC ACIDS RES, V28, P687, DOI 10.1093/nar/28.3.687; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; Subkhankulova T, 2001, BIOCHEM J, V359, P183, DOI 10.1042/0264-6021:3590183; West MJ, 1998, ONCOGENE, V17, P769, DOI 10.1038/sj.onc.1201990; Wilson JE, 2000, CELL, V102, P511, DOI 10.1016/S0092-8674(00)00055-6; Yaman I, 2003, CELL, V113, P519, DOI 10.1016/S0092-8674(03)00345-3; Yang Q, 1997, NUCLEIC ACIDS RES, V25, P2800, DOI 10.1093/nar/25.14.2800	61	281	297	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2004	23	18					3200	3207		10.1038/sj.onc.1207551	http://dx.doi.org/10.1038/sj.onc.1207551			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	813AJ	15094769				2022-12-17	WOS:000220879700008
J	BUSCHER, M; RAHMSDORF, HJ; LITFIN, M; KARIN, M; HERRLICH, P				BUSCHER, M; RAHMSDORF, HJ; LITFIN, M; KARIN, M; HERRLICH, P			ACTIVATION OF THE C-FOS GENE BY UV AND PHORBOL ESTER - DIFFERENT SIGNAL TRANSDUCTION PATHWAYS CONVERGE TO THE SAME ENHANCER ELEMENT	ONCOGENE			English	Article									KERNFORSCHUNGSZENTRUM KARLSRUHE GMBH,INST GENET & TOXIKOL,POSTFACH 3640,D-7500 KARLSRUHE 1,FED REP GER; UNIV CALIF SAN DIEGO,SCH MED,CTR MOLEC GENET,DEPT PHARMACOL,LA JOLLA,CA 92093	Helmholtz Association; Karlsruhe Institute of Technology; University of California System; University of California San Diego								ANDREWS GK, 1987, MOL CELL BIOL, V7, P3452, DOI 10.1128/MCB.7.10.3452; ANGEL P, 1986, MOL CELL BIOL, V6, P1760, DOI 10.1128/MCB.6.5.1760; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ANGEL P, 1985, CANCER CELL, V3, P315; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; AVISSAR S, 1986, EXP CELL RES, V165, P353, DOI 10.1016/0014-4827(86)90589-6; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BLACK HS, 1985, CANCER RES, V45, P6254; BRAVO R, 1987, CELL, V48, P251, DOI 10.1016/0092-8674(87)90428-4; BUSCHER M, 1987, BIOENGINEERING S27, V2; CASEY J, 1977, NUCLEIC ACIDS RES, V4, P1539, DOI 10.1093/nar/4.5.1539; CHANDLER VL, 1983, CELL, V33, P489, DOI 10.1016/0092-8674(83)90430-0; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHIDA K, 1986, J BIOL CHEM, V261, P3013; CLARK RB, 1987, BIOCHEM BIOPH RES CO, V145, P666, DOI 10.1016/0006-291X(87)91016-3; COLLETTA G, 1986, SCIENCE, V233, P458, DOI 10.1126/science.3726540; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; DELEO VA, 1985, PHOTOCHEM PHOTOBIOL, V41, P51; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; FRIEDMAN RL, 1985, NATURE, V314, P637, DOI 10.1038/314637a0; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; GREENGARD P, 1978, SCIENCE, V199, P146, DOI 10.1126/science.22932; GUY GR, 1986, BIOCHEM BIOPH RES CO, V135, P146, DOI 10.1016/0006-291X(86)90954-X; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HERRLICH P, 1986, ADV ENZYME REGUL, V25, P485, DOI 10.1016/0065-2571(86)90030-0; HERRLICH P, 1987, ONCOGENES GROWTH CON, P16; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; HYNES N, 1983, P NATL ACAD SCI-BIOL, V80, P3637, DOI 10.1073/pnas.80.12.3637; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; IMBRA RJ, 1987, MOL CELL BIOL, V7, P1358, DOI 10.1128/MCB.7.4.1358; KAIBUCHI K, 1985, J BIOL CHEM, V260, P1366; KARIN M, 1987, MOL CELL BIOL, V7, P606, DOI 10.1128/MCB.7.2.606; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; KARIN M, 1985, MOL CELL BIOL, V5, P2866, DOI 10.1128/MCB.5.10.2866; KARIN M, 1984, DNA-J MOLEC CELL BIO, V3, P319, DOI 10.1089/dna.1.1984.3.319; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KRAFT AS, 1982, J BIOL CHEM, V257, P13193; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; Krebs E G, 1972, Curr Top Cell Regul, V5, P99; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; KUO JF, 1969, P NATL ACAD SCI USA, V64, P1349, DOI 10.1073/pnas.64.4.1349; LASKIN JD, 1985, P NATL ACAD SCI USA, V82, P6158, DOI 10.1073/pnas.82.18.6158; LASKIN JD, 1986, P NATL ACAD SCI USA, V83, P8211, DOI 10.1073/pnas.83.21.8211; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAJORS J, 1983, P NATL ACAD SCI-BIOL, V80, P5866, DOI 10.1073/pnas.80.19.5866; MANIATIS T, 1982, MOL CLONING LABORATO; Maxam A M, 1980, Methods Enzymol, V65, P499; MONTAGUE W, 1971, BIOCHEM J, V122, P115, DOI 10.1042/bj1220115; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; MULLER R, 1984, NATURE, V311, P438, DOI 10.1038/311438a0; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PASTI G, 1986, NATURE, V324, P375, DOI 10.1038/324375a0; PONTA H, 1985, P NATL ACAD SCI USA, V82, P1020, DOI 10.1073/pnas.82.4.1020; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; RAHMSDORF HJ, 1987, NUCLEIC ACIDS RES, V15, P1643, DOI 10.1093/nar/15.4.1643; RAN W, 1986, P NATL ACAD SCI USA, V83, P8216, DOI 10.1073/pnas.83.21.8216; RODRIGUEZPENA MA, 1984, BIOCHEM BIOPH RES CO, V120, P1053; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; SCHONTHAL A, 1988, IN PRESS CELL, V54; SCHORPP M, 1984, CELL, V37, P861, DOI 10.1016/0092-8674(84)90421-5; SHIBANUMA M, 1987, EUR J BIOCHEM, V164, P15, DOI 10.1111/j.1432-1033.1987.tb10985.x; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; STUMPO DJ, 1986, P NATL ACAD SCI USA, V83, P9453, DOI 10.1073/pnas.83.24.9453; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; VALENZENO DP, 1987, PHOTOCHEM PHOTOBIOL, V46, P147, DOI 10.1111/j.1751-1097.1987.tb04749.x; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; VERMA IM, 1986, COLD SPRING HARB SYM, V51, P949, DOI 10.1101/SQB.1986.051.01.108; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WOLF M, 1985, NATURE, V317, P546, DOI 10.1038/317546a0	87	281	282	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1988	3	3					301	311						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q4367	2849742				2022-12-17	WOS:A1988Q436700009
J	Comito, G; Giannoni, E; Segura, CP; Barcellos-de-Souza, P; Raspollini, MR; Baroni, G; Lanciotti, M; Serni, S; Chiarugi, P				Comito, G.; Giannoni, E.; Segura, C. P.; Barcellos-de-Souza, P.; Raspollini, M. R.; Baroni, G.; Lanciotti, M.; Serni, S.; Chiarugi, P.			Cancer-associated fibroblasts and M2-polarized macrophages synergize during prostate carcinoma progression	ONCOGENE			English	Article						prostate carcinoma progression; cancer-associated fibroblasts; cancer-associated macrophages; M1/M2 macrophage polarization; IL-6; SDF-1	ENDOTHELIAL PROGENITOR CELLS; TUMOR PROGRESSION; OXIDATIVE STRESS; GROWTH; MICROENVIRONMENT; DIFFERENTIATION; ANGIOGENESIS; ACTIVATION; TRANSITION; MONOCYTES	Inflammation is now acknowledged as an hallmark of cancer. Cancer-associated fibroblasts (CAFs) force a malignant cross talk with cancer cells, culminating in their epithelial-mesenchymal transition and achievement of stemness traits. Herein, we demonstrate that stromal tumor-associated cells cooperate to favor malignancy of prostate carcinoma (PCa). Indeed, prostate CAFs are active factors of monocyte recruitment toward tumor cells, mainly acting through stromal-derived growth factor-1 delivery and promote their trans-differentiation toward the M2 macrophage phenotype. The relationship between M2 macrophages and CAFs is reciprocal, as M2 macrophages are able to affect mesenchymal-mesenchymal transition of fibroblasts, leading to their enhanced reactivity. On the other side, PCa cells themselves participate in this cross talk through secretion of monocyte chemotactic protein-1, facilitating monocyte recruitment and again macrophage differentiation and M2 polarization. Finally, this complex interplay among cancer cells, CAFs and M2 macrophages, cooperates in increasing tumor cell motility, ultimately fostering cancer cells escaping from primary tumor and metastatic spread, as well as in activation of endothelial cells and their bone marrow-derived precursors to drive de novo angiogenesis. In keeping with our data obtained in vitro, the analysis of patients affected by prostate cancers at different clinical stages revealed a clear increase in the M2/M1 ratio in correlation with clinical values. These data, coupled with the role of CAFs in carcinoma malignancy to elicit expression of stem-like traits, should focus great interest for innovative strategies aimed at the co-targeting of inflammatory cells and fibroblasts to improve therapeutic efficacy.	[Comito, G.; Giannoni, E.; Segura, C. P.; Barcellos-de-Souza, P.; Chiarugi, P.] Univ Florence, Dept Expt & Clin Biomed Sci, Viale Morgagni 50, I-50134 Florence, Italy; [Raspollini, M. R.; Baroni, G.] Univ Florence, Histol & Mol Diagnost Univ, Careggi Hosp, I-50134 Florence, Italy; [Lanciotti, M.; Serni, S.] Univ Florence, Careggi Hosp, Dept Urol, I-50134 Florence, Italy; [Chiarugi, P.] Ctr Res Transfer & High Educ DenoTHE, Florence, Italy	University of Florence; University of Florence; Azienda Ospedaliero Universitaria Careggi; University of Florence; Azienda Ospedaliero Universitaria Careggi	Chiarugi, P (corresponding author), Univ Florence, Dept Expt & Clin Biomed Sci, Viale Morgagni 50, I-50134 Florence, Italy.	paola.chiarugi@unifi.it	Giannoni, Elisa/AAE-2092-2020; Chiarugi, Paola/CDD-7988-2022; de Souza, Pedro Barcellos/E-4957-2017	de Souza, Pedro Barcellos/0000-0003-1903-5089; Lanciotti, Michele/0000-0002-3368-8652; Comito, Giuseppina/0000-0002-4614-067X; Chiarugi, Paola/0000-0001-7655-2969; Giannoni, Elisa/0000-0001-7136-1098	Associazione Italiana Ricerca sul Cancro (AIRC); Istituto Toscano Tumori; MIUR (PRIN); Capes (Ministerio da Educacao, Brazil)	Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Istituto Toscano Tumori; MIUR (PRIN)(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); Capes (Ministerio da Educacao, Brazil)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	This work was supported by the Associazione Italiana Ricerca sul Cancro (AIRC), by Istituto Toscano Tumori, and by MIUR (PRIN 2008). Pedro Barcellos-de-Souza was supported by postdoctoral fellowship from Capes (Ministerio da Educacao, Brazil).	Allavena P, 2008, CRIT REV ONCOL HEMAT, V66, P1, DOI 10.1016/j.critrevonc.2007.07.004; Balkwill FR, 2012, SEMIN CANCER BIOL, V22, P33, DOI 10.1016/j.semcancer.2011.12.005; Cat B, 2006, J CELL SCI, V119, P2727, DOI 10.1242/jcs.03011; Cirri P, 2012, CANCER METAST REV, V31, P195, DOI 10.1007/s10555-011-9340-x; Comito G, 2012, CANCER LETT, V324, P31, DOI 10.1016/j.canlet.2012.04.025; De Wever O, 2003, J PATHOL, V200, P429, DOI 10.1002/path.1398; Duda DG, 2010, P NATL ACAD SCI USA, V107, P21677, DOI 10.1073/pnas.1016234107; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Fiaschi T, 2012, CANCER RES, V72, P5130, DOI 10.1158/0008-5472.CAN-12-1949; Friedl P, 2004, INT J DEV BIOL, V48, P441, DOI 10.1387/ijdb.041821pf; Geldhof Anja B, 2003, Clin Dev Immunol, V10, P71, DOI 10.1080/10446670310001626580; Giannoni E, 2013, J MOL MED, V91, P103, DOI 10.1007/s00109-012-0941-9; Giannoni E, 2012, ANTIOXID REDOX SIGN, V16, P1248, DOI 10.1089/ars.2011.4280; Giannoni E, 2011, ANTIOXID REDOX SIGN, V14, P2361, DOI 10.1089/ars.2010.3727; Giannoni E, 2010, CANCER RES, V70, P6945, DOI 10.1158/0008-5472.CAN-10-0785; Guido C, 2012, CELL CYCLE, V11, P3019, DOI 10.4161/cc.21384; Hao NB, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/948098; Hembruff SL, 2010, NEOPLASIA, V12, P425, DOI 10.1593/neo.10200; Inoue H, 2005, CANCER LETT, V223, P121, DOI 10.1016/j.canlet.2004.09.053; Jinushi M, 2012, AM J CANCER RES, V2, P529; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kalluri R, 2009, J CLIN INVEST, V119, P1417, DOI 10.1172/JCI39675; Ksiazkiewicz M, 2010, IMMUNOBIOLOGY, V215, P737, DOI 10.1016/j.imbio.2010.05.019; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Mantovani A, 2007, EUR J IMMUNOL, V37, P14, DOI 10.1002/eji.200636910; Mantovani A, 2010, CURR OPIN IMMUNOL, V22, P231, DOI 10.1016/j.coi.2010.01.009; Margheri F, 2011, BLOOD, V118, P3743, DOI 10.1182/blood-2011-02-338681; Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532; Muerkoster SS, 2008, INT J CANCER, V123, P1751, DOI 10.1002/ijc.23703; Nolan DJ, 2007, GENE DEV, V21, P1546, DOI 10.1101/gad.436307; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138; Roodhart JML, 2011, CANCER CELL, V20, P370, DOI 10.1016/j.ccr.2011.08.010; Servais C, 2013, J PATHOL, V229, P198, DOI 10.1002/path.4103; Sica A, 2006, EUR J CANCER, V42, P717, DOI 10.1016/j.ejca.2006.01.003; Sica A, 2012, CANCER MICROENVIRON, V5, P133, DOI 10.1007/s12307-011-0091-6; Silzle T, 2003, EUR J IMMUNOL, V33, P1311, DOI 10.1002/eji.200323057; Solinas G, 2009, J LEUKOCYTE BIOL, V86, P1065, DOI 10.1189/jlb.0609385; Talmadge JE, 2007, CANCER METAST REV, V26, P373, DOI 10.1007/s10555-007-9072-0; Teicher BA, 2010, CLIN CANCER RES, V16, P2927, DOI 10.1158/1078-0432.CCR-09-2329; Toullec A, 2010, EMBO MOL MED, V2, P211, DOI 10.1002/emmm.201000073; Whiteside TL, 2008, ONCOGENE, V27, P5904, DOI 10.1038/onc.2008.271; Wu Y, 2009, CANCER CELL, V15, P416, DOI 10.1016/j.ccr.2009.03.016; Yoder MC, 2007, CELL STEM CELL, V1, P603, DOI 10.1016/j.stem.2007.11.005; Zumsteg A, 2009, CURR OPIN ONCOL, V21, P60, DOI 10.1097/CCO.0b013e32831bed7e	45	280	292	3	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2014	33	19					2423	2431		10.1038/onc.2013.191	http://dx.doi.org/10.1038/onc.2013.191			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH3OK	23728338				2022-12-17	WOS:000336033600002
J	Campoli, M; Ferrone, S				Campoli, M.; Ferrone, S.			HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance	ONCOGENE			English	Review						antigen processing machinery; cancer; HLA antigen; epigenetic; immune escape; NK cell-activating ligand	MHC-CLASS-II; HISTONE DEACETYLASE INHIBITORS; NATURAL-KILLER-CELLS; LOW-DOSE 5-AZA-2'-DEOXYCYTIDINE; INVARIANT CHAIN EXPRESSION; REGULATORY T-CELLS; DNA METHYLATION; GENE-EXPRESSION; B-CELL; TUMOR-CELLS	Changes in classical and nonclassical HLA class I as well as HLA class II antigens have been identified in malignant lesions. These changes, which are described in this review are believed to play a major role in the clinical course of the disease since both HLA class I and class II antigens are critical to the interaction between tumor cells and components of both innate and adaptive immune system. Abnormalities in HLA antigen expression in malignant cells, which range in frequency from 0-90%, are caused by distinct mechanisms. They include defects in beta(2)-microglobulin (beta(2)m) synthesis, loss of the gene(s) encoding HLA antigen heavy chain(s), mutations, which inhibit HLA antigen heavy chain transcription or translation, defects in the regulatory mechanisms, which control HLA antigen expression and/or abnormalities in one or more of the antigen processing, machinery (APM) components. More recently, epigenetic events associated with tumor development and progression have been found to underlie changes in HLA antigen, APM component, costimulatory molecule and tumor antigen (TA) expression in malignant cells. The types of epigenetic modi. cations that may occur in normal and malignant cells as well as their role in changes in HLA antigen expression by malignant cells have been reviewed. The epigenetic events associated with alterations in HLA antigen expression may be clinically relevant as, in some cases, they have been shown to impair the recognition of tumor cells by components of the adaptive immune system. The functional relevance and potential clinical significance of these epigenetic alterations have been addressed. Finally, unlike genetic alterations, epigenetic modi. cations can, in some cases, be reversed with pharmacologic agents that induce DNA hypomethylation or inhibit histone deacetylation. Therefore, strategies to overcome epigenetic modi. cations underlying changes in HLA antigen expression in malignant cells have been discussed.	[Ferrone, S.] Univ Pittsburgh, Inst Canc, Dept Surg, Pittsburgh, PA 15213 USA; [Ferrone, S.] Univ Pittsburgh, Inst Canc, Dept Pathol & Immunol, Pittsburgh, PA 15213 USA; [Campoli, M.] Univ Colorado, Hlth Sci Ctr, Dept Dermatol, Denver, CO 80202 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Ferrone, S (corresponding author), Univ Pittsburgh, Inst Canc, Dept Surg, Pittsburgh, PA 15213 USA.	soldano.ferrone@roswellpark.org			NATIONAL CANCER INSTITUTE [R01CA110249] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA110249-03, R01 CA110249] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acharya MR, 2005, MOL PHARMACOL, V68, P917, DOI 10.1124/mol.105.014167; Altomonte M, 2003, ONCOGENE, V22, P6564, DOI 10.1038/sj.onc.1206960; Backstrom E, 2004, SCAND J IMMUNOL, V60, P14, DOI 10.1111/j.0300-9475.2004.01475.x; Bedford MT, 2005, MOL CELL, V18, P263, DOI 10.1016/j.molcel.2005.04.003; Berezikov E, 2005, CELL, V120, P21, DOI 10.1016/j.cell.2004.12.031; Bernsen MR, 2003, BRIT J CANCER, V88, P424, DOI 10.1038/sj.bjc.6600703; Bhalla KN, 2005, J CLIN ONCOL, V23, P3971, DOI 10.1200/JCO.2005.16.600; Bluestone JA, 2005, CURR OPIN IMMUNOL, V17, P638, DOI 10.1016/j.coi.2005.09.002; Bovenzi V, 1999, ANTI-CANCER DRUG, V10, P471, DOI 10.1097/00001813-199906000-00007; CABRERA T, 1995, SCAND J IMMUNOL, V41, P398, DOI 10.1111/j.1365-3083.1995.tb03584.x; Calin GA, 2004, P NATL ACAD SCI USA, V101, P11755, DOI 10.1073/pnas.0404432101; Campoli M, 2005, CANC TREAT, V123, P61; CAMPOLI M, 2006, EXPERT REV DERMATOL, V1, P737; Campoli Michael, 2004, Breast Dis, V20, P105; Chamuleau MED, 2006, IMMUNOBIOLOGY, V211, P619, DOI 10.1016/j.imbio.2006.05.005; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Chang CC, 2005, ADV CANCER RES, V93, P189, DOI 10.1016/S0065-230X(05)93006-6; Chang CC, 2003, HUM IMMUNOL, V64, P1057, DOI 10.1016/j.humimm.2003.08.357; Chang CC, 2003, SEMIN CANCER BIOL, V13, P361, DOI 10.1016/S1044-579X(03)00027-0; Chang CC, 2007, CANCER IMMUNOL IMMUN, V56, P227, DOI 10.1007/s00262-006-0183-1; Chang CC, 2006, SEMIN CANCER BIOL, V16, P383, DOI 10.1016/j.semcancer.2006.07.001; Chattopadhyay S, 2005, CANCER IMMUNOL IMMUN, V54, P1153, DOI 10.1007/s00262-005-0699-9; Chil A, 2003, ACTA OBSTET GYN SCAN, V82, P1146, DOI 10.1046/j.1600-0412.2003.00252.x; Chiorean EG, 2003, BLOOD, V101, P3527, DOI 10.1182/blood-2002-04-1172; Chou SD, 2005, INT IMMUNOL, V17, P1483, DOI 10.1093/intimm/dxh326; Chuang JC, 2005, MOL CANCER THER, V4, P1515, DOI 10.1158/1535-7163.MCT-05-0172; CHUANG WL, 1990, CANCER, V65, P926, DOI 10.1002/1097-0142(19900215)65:4<926::AID-CNCR2820650418>3.0.CO;2-U; Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117; Coral S, 2006, J CELL PHYSIOL, V207, P58, DOI 10.1002/jcp.20540; CORAL S, 2007, CANCER RES, V66, P1105; Cresswell P, 2005, IMMUNOL REV, V207, P5, DOI 10.1111/j.0105-2896.2005.00320.x; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Demanet C, 2004, BLOOD, V103, P3122, DOI 10.1182/blood-2003-07-2500; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; DREXLER HG, 1988, CLIN EXP IMMUNOL, V71, P217; Dunker K, 2008, TISSUE ANTIGENS, V72, P137, DOI 10.1111/j.1399-0039.2008.01090.x; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Eramo A, 2005, CANCER RES, V65, P11469, DOI 10.1158/0008-5472.CAN-05-1724; Esteller M, 2006, BRIT J CANCER, V94, P179, DOI 10.1038/sj.bjc.6602918; Esteller M, 2003, LANCET ONCOL, V4, P351, DOI 10.1016/S1470-2045(03)01115-X; Fang JY, 2003, WORLD J GASTROENTERO, V9, P1976, DOI 10.3748/wjg.v9.i9.1976; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Florenes VA, 2004, MELANOMA RES, V14, P173, DOI 10.1097/01.cmr.0000129579.49313.26; Fonsatti E, 2003, INT J CANCER, V105, P430, DOI 10.1002/ijc.11077; Fonsatti E, 2007, CLIN CANCER RES, V13, P3333, DOI 10.1158/1078-0432.CCR-06-3091; Fraga MF, 2005, CELL CYCLE, V4, P1377, DOI 10.4161/cc.4.10.2113; French LE, 2002, SEMIN CANCER BIOL, V12, P51, DOI 10.1006/scbi.2001.0405; Friese MA, 2004, CANCER RES, V64, P7596, DOI 10.1158/0008-5472.CAN-04-1627; Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536; Germenis AE, 2007, IMMUNOL CELL BIOL, V85, P55, DOI 10.1038/sj.icb.7100006; Ghosh N, 2001, J BIOL CHEM, V276, P15264, DOI 10.1074/jbc.M100862200; Gollob JA, 2006, CLIN CANCER RES, V12, P4619, DOI 10.1158/1078-0432.CCR-06-0883; Grewal SIS, 2003, SCIENCE, V301, P798, DOI 10.1126/science.1086887; Guo ZS, 2006, CANCER RES, V66, P1105, DOI 10.1158/0008-5472.CAN-05-3020; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Hunt JS, 2006, REPROD BIOL ENDOCRIN, V4, DOI 10.1186/1477-7827-4-S1-S10; Insinga A, 2005, NAT MED, V11, P71, DOI 10.1038/nm1160; Issa JPJ, 2004, BLOOD, V103, P1635, DOI 10.1182/blood-2003-03-0687; Jiang Z, 1999, VIRCHOWS ARCH, V435, P32, DOI 10.1007/s004280050391; Jinushi M, 2003, INT J CANCER, V104, P354, DOI 10.1002/ijc.10966; Johnsen AK, 1999, J IMMUNOL, V163, P4224; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kanaseki T, 2003, J IMMUNOL, V170, P4980, DOI 10.4049/jimmunol.170.10.4980; Kawasaki H, 2004, NATURE, V431, P211, DOI 10.1038/nature02889; Khan ANH, 2008, CANCER IMMUNOL IMMUN, V57, P647, DOI 10.1007/s00262-007-0402-4; Khan ANH, 2004, CANCER IMMUNOL IMMUN, V53, P748, DOI 10.1007/s00262-004-0513-0; Kim R, 2007, IMMUNOLOGY, V121, P1, DOI 10.1111/j.1365-2567.2007.02587.x; Knutson KL, 2005, CANCER IMMUNOL IMMUN, V54, P721, DOI 10.1007/s00262-004-0653-2; Lachner M, 2003, J CELL SCI, V116, P2117, DOI 10.1242/jcs.00493; LECCHI M, 1989, LEUKEMIA RES, V13, P221, DOI 10.1016/0145-2126(89)90015-5; Lee N, 2003, J IMMUNOL, V171, P5264, DOI 10.4049/jimmunol.171.10.5264; Lettini AA, 2007, HISTOL HISTOPATHOL, V22, P1413, DOI 10.14670/HH-22.1413; Li H, 2004, BIOCHEM BIOPH RES CO, V324, P860, DOI 10.1016/j.bbrc.2004.09.130; Lin A, 2007, ANN ONCOL, V18, P1804, DOI 10.1093/annonc/mdm356; Lozupone F, 2003, EUR J IMMUNOL, V33, P556, DOI 10.1002/immu.200310032; Lucas DM, 2004, LEUKEMIA, V18, P1207, DOI 10.1038/sj.leu.2403388; Magner WJ, 2000, J IMMUNOL, V165, P7017, DOI 10.4049/jimmunol.165.12.7017; Maio M, 2003, ONCOGENE, V22, P6484, DOI 10.1038/sj.onc.1206956; Malmberg KJ, 2002, J CLIN INVEST, V110, P1515, DOI 10.1172/JC1200215564; Mann BS, 2007, ONCOLOGIST, V12, P1247, DOI 10.1634/theoncologist.12-10-1247; Marsman M, 2005, ADV CANCER RES, V93, P129, DOI 10.1016/S0065-230X(05)93004-2; Moore PS, 2004, BBA-MOL CELL RES, V1693, P167, DOI 10.1016/j.bbamcr.2004.07.001; Morandi F, 2007, CANCER RES, V67, P6433, DOI 10.1158/0008-5472.CAN-06-4588; Moretta L, 2005, IMMUNOL LETT, V100, P7, DOI 10.1016/j.imlet.2005.07.004; Morimoto Y, 2004, BRIT J CANCER, V90, P844, DOI 10.1038/sj.bjc.6601602; Natoni F, 2005, BBA-MOL CELL RES, V1745, P318, DOI 10.1016/j.bbamcr.2005.07.003; Neumeister P, 2002, INT J BIOCHEM CELL B, V34, P1475, DOI 10.1016/S1357-2725(02)00079-1; Nie Y, 2001, CARCINOGENESIS, V22, P1615, DOI 10.1093/carcin/22.10.1615; Ogretmen B, 1998, BIOCHEMISTRY-US, V37, P11679, DOI 10.1021/bi980573c; Ono K, 1996, J CLIN IMMUNOL, V16, P41, DOI 10.1007/BF01540971; Ostrand-Rosenberg S, 2004, CURR OPIN IMMUNOL, V16, P143, DOI 10.1016/j.coi.2004.01.003; Pierson BA, 1996, BLOOD, V88, P2279, DOI 10.1182/blood.V88.6.2279.bloodjournal8862279; Pistoia V, 2007, SEMIN CANCER BIOL, V17, P469, DOI 10.1016/j.semcancer.2007.07.004; Reith W, 2005, NAT REV IMMUNOL, V5, P793, DOI 10.1038/nri1708; Rodriguez T, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-34; Rouas-Freiss N, 2007, SEMIN CANCER BIOL, V17, P413, DOI 10.1016/j.semcancer.2007.07.003; Ruiter D J, 1991, Semin Cancer Biol, V2, P35; Satoh A, 2004, ONCOGENE, V23, P8876, DOI 10.1038/sj.onc.1208144; Scanlan MJ, 2002, IMMUNOL REV, V188, P22, DOI 10.1034/j.1600-065X.2002.18803.x; Schrump DS, 2006, CLIN CANCER RES, V12, P5777, DOI 10.1158/1078-0432.CCR-06-0669; Sebti Y, 2007, BRIT J HAEMATOL, V138, P202, DOI 10.1111/j.1365-2141.2007.06647.x; Seliger B, 2000, IMMUNOL TODAY, V21, P455, DOI 10.1016/S0167-5699(00)01692-3; SELIGER B, 2008, CANC IMMUNOL IMMUNOT; Serrano A, 2001, INT J CANCER, V94, P243, DOI 10.1002/ijc.1452; Setiadi AF, 2007, MOL CELL BIOL, V27, P7886, DOI 10.1128/MCB.01547-07; Sheu JJC, 2007, SEMIN CANCER BIOL, V17, P436, DOI 10.1016/j.semcancer.2007.06.012; Shogren-Knaak M, 2006, SCIENCE, V311, P844, DOI 10.1126/science.1124000; Sigalotti L, 2004, CANCER RES, V64, P9167, DOI 10.1158/0008-5472.CAN-04-1442; Sigalotti L, 2003, BLOOD, V101, P4644, DOI 10.1182/blood-2002-11-3458; SIGALOTTI L, 2002, BLOOD, V100, P2957; Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007; Singh NP, 2003, CANCER RES, V63, P4067; Sontheimer EJ, 2005, CELL, V122, P9, DOI 10.1016/j.cell.2005.06.030; Szyf M, 2005, BIOCHEMISTRY-MOSCOW+, V70, P533, DOI 10.1007/s10541-005-0147-7; Takamura Y, 2004, GLIA, V45, P392, DOI 10.1002/glia.10343; Tamori Y, 2005, ONCOL REP, V14, P873; Tomasi TB, 2006, CANCER IMMUNOL IMMUN, V55, P1159, DOI 10.1007/s00262-006-0164-4; van den Elsen PJ, 2000, HUM IMMUNOL, V61, P850, DOI 10.1016/S0198-8859(00)00159-2; van der Stoep N, 2002, INT J CANCER, V97, P501, DOI 10.1002/ijc.1623; VERFAILLIE C, 1990, BLOOD, V76, P401; Villar-Garea A, 2004, INT J CANCER, V112, P171, DOI 10.1002/ijc.20372; Wang E, 2005, SPRINGER SEMIN IMMUN, V27, P105, DOI 10.1007/s00281-004-0198-7; Wassenegger M, 2005, CELL, V122, P13, DOI 10.1016/j.cell.2005.06.034; Whiteside TL, 2005, ANALYZING T CELL RESPONSES: HOW TO ANALYZE CELLULAR IMMUNE RESPONSES AGAINST TUMOR ASSOCIATED ANTIGENS, P43, DOI 10.1007/1-4020-3623-X_3; Wijermans P, 2000, J CLIN ONCOL, V18, P956, DOI 10.1200/JCO.2000.18.5.956; Wischhusell J, 2007, SEMIN CANCER BIOL, V17, P459, DOI 10.1016/j.semcancer.2007.07.005; Wright KL, 2006, TRENDS IMMUNOL, V27, P405, DOI 10.1016/j.it.2006.07.007; Ye SR, 2007, MODERN PATHOL, V20, P375, DOI 10.1038/modpathol.3800751; Yie SM, 2007, LUNG CANCER, V58, P267, DOI 10.1016/j.lungcan.2007.06.011; Yie SM, 2007, ANN SURG ONCOL, V14, P2721, DOI 10.1245/s10434-007-9464-y; Yu J, 2000, MOL CELL BIOL, V20, P2592, DOI 10.1128/MCB.20.7.2592-2603.2000	132	280	289	3	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2008	27	45					5869	5885		10.1038/onc.2008.273	http://dx.doi.org/10.1038/onc.2008.273			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	355QE	18836468	Green Accepted			2022-12-17	WOS:000259722600002
J	Stoneley, M; Paulin, FEM; Le Quesne, JPC; Chappell, SA; Willis, AE				Stoneley, M; Paulin, FEM; Le Quesne, JPC; Chappell, SA; Willis, AE			C-Myc 5 ' untranslated region contains an internal ribosome entry segment	ONCOGENE			English	Article						internal ribosome entry segment (IRES); c-myc 5 ' UTR; internal initiation; translation	MESSENGER-RNA; TRANSLATIONAL CONTROL; BURKITT-LYMPHOMA; PROMOTER USAGE; INITIATION; GENE; CELLS; ONCOGENE; TRANSLOCATION; EFFICIENCY	Translation in eukaryotic cells is generally initiated by ribosome scanning from the 5' end of the capped mRNA. However, initiation of translation may also occur by a mechanism which is independent of the cap structure and in this case ribosomes are directed to the start codon by an internal ribosome entry segment (IRES). Picornaviruses represent the paradigm for this mechanism, but only a few examples exist which show that this mechanism is used by eukaryotic cells. In this report we show data which demonstrate that the 5' UTR of the proto-oncogene c-myc contains an IRES. When a dicistronic reporter vector, with c-myc 5' UTR inserted between the two cistrons, was transfected into both HepG2 and HeLa cells, the translation of the downstream cistron was increased by 50-fold, demonstrating that translational regulation of c-myc is mediated through cap-independent mechanisms. This is the first example of a proto-oncogene regulated in this manner and suggests that aberrant translational regulation of c-myc is likely to play a role in tumorigenesis.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	University of Leicester	Willis, AE (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.			Willis, Anne/0000-0002-1470-8531; Le Quesne, John/0000-0003-3552-7446				AUSUBEL RM, 1987, CURRENT PROTOCOLS MO; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BORMAN A, 1992, VIROLOGY, V188, P685, DOI 10.1016/0042-6822(92)90523-R; BORMAN AM, 1995, NUCLEIC ACIDS RES, V23, P3656, DOI 10.1093/nar/23.18.3656; BUTNICK NZ, 1985, MOL CELL BIOL, V5, P3009, DOI 10.1128/MCB.5.11.3009; DARVEAU A, 1985, P NATL ACAD SCI USA, V82, P2315, DOI 10.1073/pnas.82.8.2315; Gan WN, 1996, J BIOL CHEM, V271, P623, DOI 10.1074/jbc.271.2.623; GRAY NK, 1994, MOL BIOL REP, V19, P195, DOI 10.1007/BF00986961; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; Jackson RJ, 1995, CURR TOP MICROBIOL, V203, P1; JACKSON RJ, 1994, MOL BIOL REP, V19, P147, DOI 10.1007/BF00986957; Jackson RJ, 1995, RNA, V1, P985; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; NILSEN TW, 1984, MOL CELL BIOL, V4, P2235, DOI 10.1128/MCB.4.10.2235; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; Paulin FEM, 1996, ONCOGENE, V13, P505; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; REYNOLDS JE, 1995, EMBO J, V14, P6010, DOI 10.1002/j.1460-2075.1995.tb00289.x; SAITO H, 1983, P NATL ACAD SCI-BIOL, V80, P7476, DOI 10.1073/pnas.80.24.7476; SARNOW P, 1989, P NATL ACAD SCI USA, V86, P5795, DOI 10.1073/pnas.86.15.5795; SPOTTS GD, 1990, MOL CELL BIOL, V10, P3952, DOI 10.1128/MCB.10.8.3952; STEWART TA, 1984, SCIENCE, V226, P707, DOI 10.1126/science.6494906; SULLIVAN NF, 1989, ONCOGENE, V4, P1497; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; WATT R, 1983, P NATL ACAD SCI-BIOL, V80, P6307, DOI 10.1073/pnas.80.20.6307; West MJ, 1995, ONCOGENE, V11, P2515; WINNEPENNINCKX B, 1995, BIOTECHNIQUES, V18, P1060; YANG JQ, 1985, EMBO J, V4, P1441, DOI 10.1002/j.1460-2075.1985.tb03800.x; ZUKER M, 1989, METHOD ENZYMOL, P262	30	280	299	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	1998	16	3					423	428		10.1038/sj.onc.1201763	http://dx.doi.org/10.1038/sj.onc.1201763			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT262	9467968				2022-12-17	WOS:000071582100015
J	FILMUS, J; ROBLES, AI; SHI, W; WONG, MJ; COLOMBO, LL; CONTI, CJ				FILMUS, J; ROBLES, AI; SHI, W; WONG, MJ; COLOMBO, LL; CONTI, CJ			INDUCTION OF CYCLIN D1 OVEREXPRESSION BY ACTIVATED RAS	ONCOGENE			English	Article							INTESTINAL EPITHELIAL-CELLS; SIGNAL-TRANSDUCTION; DEPENDENT KINASES; NUCLEAR-PROTEIN; EXPRESSION; FIBROBLASTS; ONCOGENE; G(1); G1; PROGRESSION	Activated ras genes are known to alter control of cell proliferation. This is consistent with the fact that ras proteins are a key component of the biochemical pathway triggered by ligand-bound cell surface receptors that are tyrosine kinases. Although an important part of the ras signaling pathway has been recently uncovered, the molecular target(s) that mediates the effects of ras on cell cycle control remains unknown. Cyclins and cyclin-dependent kinases are key molecules in the control of cell cycle. Cyclin D1, in particular, is a critical target for proliferative signals in G(1) and it has been shown that ectopic overexpression of this cyclin can significantly alter cell cycle regulation. Here we report that activated ras induces significant overexpression of cyclin D1 in epithelial cells derived from normal rat intestine and mouse mammary gland. A definitive causal role for activated ras in this overexpression is demonstrated by using intestinal cells transfected with an inducible ras expression vector. Treatment of the ras-transformed intestinal clones with anti-sense cyclin D1 oligonucleotides reduces their rate of cell proliferation indicating that the increment in cyclin D1 expression induced by activated ras is instrumental in the higher rate of cell proliferation conferred by the ras oncogene to the IEC cells. Based on these results we propose that, at least in certain cell types, cyclin D1 can be one of the mediators of the transforming action of activated ras.	UNIV TORONTO, DEPT MED BIOPHYS, TORONTO, ON, CANADA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT CARCINOGENESIS, DIV RES, HOUSTON, TX USA	University of Toronto; University of Texas System; UTMD Anderson Cancer Center	FILMUS, J (corresponding author), SUNNYBROOK HLTH SCI CTR, DIV CANC RES, S-218, 2075 BAYVIEW AVE, TORONTO M4N 3M5, ON, CANADA.			Robles, Ana/0000-0001-5019-4374				ANDERSEN RD, 1987, MOL CELL BIOL, V7, P3574, DOI 10.1128/MCB.7.10.3574; ARNOLD A, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63; ATCHISON ML, 1989, MOL CELL BIOL, V9, P2067, DOI 10.1128/MCB.9.5.2067; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BIANCHI AB, 1993, ONCOGENE, V8, P1127; BIANCHI AB, 1990, P NATL ACAD SCI USA, V87, P6902, DOI 10.1073/pnas.87.17.6902; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BUICK RN, 1987, EXP CELL RES, V170, P300, DOI 10.1016/0014-4827(87)90308-9; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FILMUS J, 1992, ONCOGENE, V7, P521; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1993, ONCOGENE, V8, P3447; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; QUARONI A, 1981, J NATL CANCER I, V67, P1353; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WINSTON JT, 1993, MOL BIOL CELL, V4, P1133, DOI 10.1091/mbc.4.11.1133; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZHAO JM, 1993, EXP CELL RES, V204, P82, DOI 10.1006/excr.1993.1011	42	280	282	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1994	9	12					3627	3633						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970723				2022-12-17	WOS:A1994PT39200026
J	YUNIS, JJ; SORENG, AL; BOWE, AE				YUNIS, JJ; SORENG, AL; BOWE, AE			FRAGILE SITES ARE TARGETS OF DIVERSE MUTAGENS AND CARCINOGENS	ONCOGENE			English	Article											YUNIS, JJ (corresponding author), UNIV MINNESOTA,SCH MED,DEPT LAB MED & PATHOL,BOX 198,MAYO MEM BLDG,420 DELAWARE ST SE,MINNEAPOLIS,MN 55455, USA.				NATIONAL CANCER INSTITUTE [R01CA033314] Funding Source: NIH RePORTER; NCI NIH HHS [CA 33314] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; [Anonymous], 1985, DNA REPAIR; AURIAS A, 1986, HUM GENET, V72, P210, DOI 10.1007/BF00291879; BARBI G, 1984, HUM GENET, V68, P290, DOI 10.1007/BF00292586; BUCKTON KE, 1982, CYTOGENETIC ASSAYS E; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CROCE CM, 1984, LAB INVEST, V51, P258; DERVAN PB, 1986, SCIENCE, V232, P464, DOI 10.1126/science.2421408; DIAZ MO, 1986, SCIENCE, V231, P265, DOI 10.1126/science.3455787; EISSENBERG JC, 1985, ANNU REV GENET, V19, P485, DOI 10.1146/annurev.genet.19.1.485; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; ERIKSON J, 1986, SCIENCE, V232, P884, DOI 10.1126/science.3486470; GERMAN J, 1974, CHROMOSOMES CANCER; GLOVER TW, 1984, HUM GENET, V67, P136, DOI 10.1007/BF00272988; GOULIAN M, 1980, P NATL ACAD SCI-BIOL, V77, P1956, DOI 10.1073/pnas.77.4.1956; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; Jones PA, 1984, DNA METHYLATION BIOC, P165; KIHLMAN BA, 1974, MUTAT RES, V26, P105, DOI 10.1016/S0027-5107(74)80041-2; KIRSCHVOLDERS M, 1984, MUTAGENESIS CARCINOG, P6; KOHWISHIGEMATSU T, 1983, P NATL ACAD SCI-BIOL, V80, P4389, DOI 10.1073/pnas.80.14.4389; MATTES WB, 1986, NUCLEIC ACIDS RES, V14, P2971, DOI 10.1093/nar/14.7.2971; MITELMAN F, 1985, CATALOGUE CHROMOSOME; NATARAJAN AT, 1986, MUTAT RES, V167, P189, DOI 10.1016/0165-1110(86)90029-1; NAYLOR S L, 1984, American Journal of Human Genetics, V36, p35S; RAIZIS AM, 1985, HUM GENET, V70, P344, DOI 10.1007/BF00295375; ROVIGATTI U, 1986, SCIENCE, V232, P398, DOI 10.1126/science.3457468; RUSHMORE T, 1984, CHEM-BIOL INTERACT, V49, P133; SACHS L, 1982, APPLIED STATISTICS; SHEFFREY M, 1986, CHROMOSOME STRUCTURE, P39; UESUGI S, 1984, NUCLEIC ACIDS RES, V12, P1581, DOI 10.1093/nar/12.3.1581; WEINTRAUB H, 1985, HARVEY LECT, V79, P217; Yunis J J, 1986, Important Adv Oncol, P93; YUNIS JJ, 1983, SCIENCE, V221, P227, DOI 10.1126/science.6336310; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375; 1985, CYTOGENET CELL GENET, V40, P490; 1981, CYTOGENET CELL GENET, V31, P1; 1982, MONOGRAPHS EVOLUTI S, V4	38	280	281	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1987	1	1					59	69						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	J6351	3438083				2022-12-17	WOS:A1987J635100007
J	Gao, MQ; Choi, YP; Kang, S; Youn, JH; Cho, NH				Gao, M-Q; Choi, Y-P; Kang, S.; Youn, J. H.; Cho, N-H			CD24(+) cells from hierarchically organized ovarian cancer are enriched in cancer stem cells	ONCOGENE			English	Article						CD24; ovarian cancer; cancer stem cell; tumorigenicity	PROSPECTIVE IDENTIFICATION; SIDE POPULATION; CD133; RESISTANCE; INSIGHTS; MARKERS; GROWTH	Cancer stem cells (CSCs) have been identified in solid tumors and cancer cell lines. In this study, we isolated a series of cancer cell clones, which were heterogeneous in growth rate, cell cycle distribution and expression profile of genes and proteins, from ovarian tumor specimens of a patient and identified a sub-population enriched for ovarian CSCs defined by CD24 phenotype. Experiments in vitro demonstrated CD24(+) sub-population possessed stem cell-like characteristics of remaining quiescence and more chemoresistant compared with CD24(-) fraction, as well as a specific capacity for self-renewal and differentiation. In addition, injection of 5 x 10(3) CD24(+) cells was able to form tumor xenografts in nude mice, whereas equal number of CD24(-) cells remained nontumorigenic. We also found that CD24(+) cells expressed higher mRNA levels of some 'stemness' genes, including Nestin, beta-catenin, Bmi-1, Oct4, Oct3/4, Notch1 and Notch4 which were involved in modulating many functions of stem cells, and lower E-cadherin mRNA level than CD24(-) cells. Altogether, these observations suggest human ovarian tumor cells are organized as a hierarchy and CD24 demarcates an ovarian cancer-initiating cell population. These findings will have important clinical applications for developing effective therapeutic strategies to treat ovarian cancer. Oncogene (2010) 29, 2672-2680; doi:10.1038/onc.2010.35; published online 1 March 2010	[Choi, Y-P; Kang, S.; Cho, N-H] Yonsei Univ, Coll Med, Dept Pathol, Seoul 120749, South Korea; [Gao, M-Q] Yonsei Univ, Coll Med, Brain Korea Project Med Sci 21, Seoul 120749, South Korea; [Youn, J. H.] Yonsei Univ, Coll Med, Res Ctr Human Nat Def Syst, Seoul 120749, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System	Cho, NH (corresponding author), Yonsei Univ, Coll Med, Dept Pathol, 134 Shinchon Dong, Seoul 120749, South Korea.	cho1988@yuhs.ac		jo, namhun/0000-0002-0045-6441; KANG, SUKI/0000-0002-9957-3479	Ministry for Health, Welfare and Family Affairs, Republic of Korea [A062598]; National Research Foundation of Korea (NRF); Korea Government (MEST) [20090079165]	Ministry for Health, Welfare and Family Affairs, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea); National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Korea Government (MEST)(Ministry of Education, Science & Technology (MEST), Republic of KoreaKorean Government)	This work was supported by Korea Healthcare Technology R&D Project, Ministry for Health, Welfare and Family Affairs, Republic of Korea (A062598; NHC) and by the National Research Foundation of Korea (NRF) grant funded by the Korea Government (MEST) (No. 20090079165; CNH).	Ahn SM, 2008, PROTEOMICS, V8, P4946, DOI 10.1002/pmic.200800312; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Baba T, 2009, ONCOGENE, V28, P209, DOI 10.1038/onc.2008.374; Bapat SA, 2005, CANCER RES, V65, P3025, DOI 10.1158/0008-5472.CAN-04-3931; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Cannistra SA, 2004, NEW ENGL J MED, V351, P2519, DOI 10.1056/NEJMra041842; Chambers I, 2004, ONCOGENE, V23, P7150, DOI 10.1038/sj.onc.1207930; Cheng T, 2004, ONCOGENE, V23, P7256, DOI 10.1038/sj.onc.1207945; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; DEININGER M, 2004, CELL CYCLE GROWTH 5, P667; Doyle LA, 2003, ONCOGENE, V22, P7340, DOI 10.1038/sj.onc.1206938; Ferrandina G, 2008, INT J GYNECOL CANCER, V18, P506, DOI 10.1111/j.1525-1438.2007.01056.x; Friel AM, 2008, CELL CYCLE, V7, P242, DOI 10.4161/cc.7.2.5207; Fuchs E, 2004, CELL, V116, P769, DOI 10.1016/S0092-8674(04)00255-7; Goranov AI, 2009, GENE DEV, V23, P1408, DOI 10.1101/gad.1777309; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Jaksch M, 2008, CANCER RES, V68, P7882, DOI 10.1158/0008-5472.CAN-08-0723; Kristiansen G, 2002, AM J PATHOL, V161, P1215, DOI 10.1016/S0002-9440(10)64398-2; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Monzani E, 2007, EUR J CANCER, V43, P935, DOI 10.1016/j.ejca.2007.01.017; Naora H, 2005, NAT REV CANCER, V5, P355, DOI 10.1038/nrc1611; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; Patrawala L, 2005, CANCER RES, V65, P6207, DOI 10.1158/0008-5472.CAN-05-0592; Schmalhofer O, 2009, CANCER METAST REV, V28, P151, DOI 10.1007/s10555-008-9179-y; Seigel GM, 2007, MOL VIS, V13, P823; Song J, 2007, CLIN CANCER RES, V13, P6842, DOI 10.1158/1078-0432.CCR-07-0569; Stupp R, 2007, NAT BIOTECHNOL, V25, P193, DOI 10.1038/nbt0207-193; Szotek PP, 2006, P NATL ACAD SCI USA, V103, P11154, DOI 10.1073/pnas.0603672103; Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153; Zhang S, 2008, CANCER RES, V68, P4311, DOI 10.1158/0008-5472.CAN-08-0364	30	279	293	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2010	29	18					2672	2680		10.1038/onc.2010.35	http://dx.doi.org/10.1038/onc.2010.35			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592DC	20190812				2022-12-17	WOS:000277354600007
J	Keniry, M; Parsons, R				Keniry, M.; Parsons, R.			The role of PTEN signaling perturbations in cancer and in targeted therapy	ONCOGENE			English	Review						PTEN; PI3K; AKT; targeted chemotherapy	TUMOR-SUPPRESSOR GENE; PROTEIN-KINASE B; PLECKSTRIN HOMOLOGY DOMAIN; TUBEROUS SCLEROSIS; PHOSPHATIDYLINOSITOL 3-KINASE; ALVEOLAR RHABDOMYOSARCOMA; PHOSPHOINOSITIDE 3-KINASE; TRASTUZUMAB RESISTANCE; NUCLEAR-LOCALIZATION; PHOSPHATASE-ACTIVITY	The PTEN tumor suppressor was discovered by its homozygous deletion and other mutations in cancer. Since then, PTEN has been shown to be a non-redundant, evolutionarily conserved phosphatase whose function affects diverse cellular progresses such as cell cycle progression, cell proliferation, chemotaxis, apoptosis, aging, muscle contractility, DNA damage response, angiogenesis and cell polarity. In accordance with its ability to influence multiple crucial cellular processes, PTEN has a major role in the pathogenesis of numerous diseases such as diabetes, autism and almost every cancer examined. This review will discuss the diverse ways in which PTEN signaling is modified in cancer, and how these changes correlate with and might possibly affect the action of targeted chemotherapy.	[Keniry, M.; Parsons, R.] Columbia Univ, Dept Pathol, Inst Canc Genet, New York, NY 10032 USA; [Keniry, M.; Parsons, R.] Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; [Parsons, R.] Columbia Univ, Med Ctr, Dept Med, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Parsons, R (corresponding author), Columbia Univ, Med Ctr, Dept Pathol & Med, 630 W 168th St, New York, NY 10032 USA.	rep15@columbia.edu		Parsons, Ramon/0000-0002-6656-3514	DOD [PC050068]; Avon Foundation; Octoberwoman Foundation; NCI [CA097403, CA082783]; NATIONAL CANCER INSTITUTE [R01CA082783, P01CA097403] Funding Source: NIH RePORTER	DOD(United States Department of Defense); Avon Foundation; Octoberwoman Foundation; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the members of the Parsons Laboratory for the critical reading of this paper. MK received support from the DOD (PC050068). RP received support from the Avon Foundation, the Octoberwoman Foundation, and the NCI (Grants CA097403 and CA082783).	Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; Baker SJ, 2007, CELL, V128, P25, DOI 10.1016/j.cell.2006.12.023; Barr FG, 2001, ONCOGENE, V20, P5736, DOI 10.1038/sj.onc.1204599; Bayascas JR, 2005, CURR BIOL, V15, P1839, DOI 10.1016/j.cub.2005.08.066; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Bose S, 1998, ONCOGENE, V17, P123, DOI 10.1038/sj.onc.1201940; Cairns P, 1998, ONCOGENE, V16, P3215, DOI 10.1038/sj.onc.1201855; Cairns P, 1997, CANCER RES, V57, P4997; Campbell IG, 2004, CANCER RES, V64, P7678, DOI 10.1158/0008-5472.CAN-04-2933; Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933; Chang CJ, 2008, MOL CELL BIOL, V28, P3281, DOI 10.1128/MCB.00310-08; Chen ML, 2006, GENE DEV, V20, P1569, DOI 10.1101/gad.1395006; Chiariello E, 1998, ONCOGENE, V16, P541, DOI 10.1038/sj.onc.1201689; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Currie RA, 1999, BIOCHEM J, V337, P575, DOI 10.1042/0264-6021:3370575; Dahia PLM, 1997, CANCER RES, V57, P4710; Das S, 2003, P NATL ACAD SCI USA, V100, P7491, DOI 10.1073/pnas.0932835100; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deleris P, 2006, J CELL BIOCHEM, V98, P469, DOI 10.1002/jcb.20695; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Dourdin N, 2008, CANCER RES, V68, P2122, DOI 10.1158/0008-5472.CAN-07-5727; Duerr EM, 1998, ONCOGENE, V16, P2259, DOI 10.1038/sj.onc.1201756; Fang XJ, 1999, ONCOGENE, V18, P6635, DOI 10.1038/sj.onc.1203076; Feilotter HE, 1998, ONCOGENE, V16, P1743, DOI 10.1038/sj.onc.1200205; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Frattini M, 2007, BRIT J CANCER, V97, P1139, DOI 10.1038/sj.bjc.6604009; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; Fukuyama M, 2006, CURR BIOL, V16, P773, DOI 10.1016/j.cub.2006.02.073; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Furnari FB, 1998, CANCER RES, V58, P5002; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Georgescu MM, 2000, CANCER RES, V60, P7033; Gil A, 2006, MOL BIOL CELL, V17, P4002, DOI 10.1091/mbc.E06-05-0380; Goberdhan DCI, 1999, GENE DEV, V13, P3244, DOI 10.1101/gad.13.24.3244; Goswami A, 2005, MOL CELL, V20, P33, DOI 10.1016/j.molcel.2005.08.016; Gupta S, 2007, CELL, V129, P957, DOI 10.1016/j.cell.2007.03.051; Hwangbo DS, 2004, NATURE, V429, P562, DOI 10.1038/nature02549; Iijima M, 2002, CELL, V109, P599, DOI 10.1016/S0092-8674(02)00745-6; Iijima M, 2002, DEV CELL, V3, P469, DOI 10.1016/S1534-5807(02)00292-7; Janetopoulos C, 2005, DEV CELL, V8, P467, DOI 10.1016/j.devcel.2005.02.010; Jhawer M, 2008, CANCER RES, V68, P1953, DOI 10.1158/0008-5472.CAN-07-5659; Keller C, 2004, GENE DEV, V18, P2608, DOI 10.1101/gad.1243904; Kim MJ, 2002, P NATL ACAD SCI USA, V99, P2884, DOI 10.1073/pnas.042688999; Kim RH, 2005, CANCER CELL, V7, P263, DOI 10.1016/j.ccr.2005.02.010; Kitamura YI, 2005, CELL METAB, V2, P153, DOI 10.1016/j.cmet.2005.08.004; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Klinghoffer RA, 1996, MOL CELL BIOL, V16, P5905; Kokubo Y, 2005, BRIT J CANCER, V92, P1711, DOI 10.1038/sj.bjc.6602559; Laffargue M, 1999, J BIOL CHEM, V274, P32835, DOI 10.1074/jbc.274.46.32835; Lagutina I, 2002, MOL CELL BIOL, V22, P7204, DOI 10.1128/MCB.22.20.7204-7216.2002; Lee SR, 2002, J BIOL CHEM, V277, P20336, DOI 10.1074/jbc.M111899200; Leslie NR, 2003, EMBO J, V22, P5501, DOI 10.1093/emboj/cdg513; Li AG, 2006, MOL CELL, V23, P575, DOI 10.1016/j.molcel.2006.06.028; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li J, 1998, CANCER RES, V58, P5667; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Lievre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191; Lin WM, 1998, CLIN CANCER RES, V4, P2577; Lindsay Y, 2006, J CELL SCI, V119, P5160, DOI 10.1242/jcs.000133; Liu FH, 2005, J CELL BIOCHEM, V96, P221, DOI 10.1002/jcb.20525; Liu JL, 2005, MOL CELL BIOL, V25, P6211, DOI 10.1128/MCB.25.14.6211-6224.2005; Long X, 2005, CURR BIOL, V15, P702, DOI 10.1016/j.cub.2005.02.053; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Ma L, 2005, GENE DEV, V19, P1779, DOI 10.1101/gad.1314405; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Moasser MM, 2007, ONCOGENE, V26, P6469, DOI 10.1038/sj.onc.1210477; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Ogg S, 1998, MOL CELL, V2, P887, DOI 10.1016/S1097-2765(00)80303-2; Okumura K, 2006, J BIOL CHEM, V281, P26562, DOI 10.1074/jbc.M605391200; Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636; Pao W, 2005, PLOS MED, V2, P57, DOI 10.1371/journal.pmed.0020017; Parsons DW, 2005, NATURE, V436, P792, DOI 10.1038/436792a; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Puc J, 2005, CANCER CELL, V7, P193, DOI 10.1016/j.ccr.2005.01.009; Puc J, 2005, CELL CYCLE, V4, P927, DOI 10.4161/cc.4.7.1795; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Rasheed BKA, 1997, CANCER RES, V57, P4187; Rubin MA, 2000, HUM PATHOL, V31, P504, DOI 10.1053/hp.2000.6713; Saal LH, 2008, NAT GENET, V40, P102, DOI 10.1038/ng.2007.39; Saal LH, 2007, P NATL ACAD SCI USA, V104, P7564, DOI 10.1073/pnas.0702507104; Saal LH, 2005, CANCER RES, V65, P2554, DOI 10.1158/0008-5472-CAN-04-3913; Samuels Y, 2005, CANCER CELL, V7, P561, DOI 10.1016/j.ccr.2005.05.014; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sasaki AT, 2007, J CELL BIOL, V178, P185, DOI 10.1083/jcb.200611138; SERUNIAN LA, 1990, J VIROL, V64, P4718, DOI 10.1128/JVI.64.10.4718-4725.1990; Shao XY, 1998, INT J CANCER, V77, P684, DOI 10.1002/(SICI)1097-0215(19980831)77:5<684::AID-IJC4>3.3.CO;2-8; She QB, 2005, CANCER CELL, V8, P287, DOI 10.1016/j.ccr.2005.09.006; Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; Sorensen PHB, 2002, J CLIN ONCOL, V20, P2672, DOI 10.1200/JCO.2002.03.137; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Tanaka K, 1999, J BIOL CHEM, V274, P3919, DOI 10.1074/jbc.274.7.3919; Tashiro H, 1997, CANCER RES, V57, P3935; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Teng DHF, 1997, CANCER RES, V57, P5221; Tolkacheva T, 2001, CANCER RES, V61, P4985; Torres J, 2003, J BIOL CHEM, V278, P30652, DOI 10.1074/jbc.M212610200; Trotman LC, 2006, NATURE, V441, P523, DOI 10.1038/nature04809; Trotman LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040; Vasudevan KM, 2007, CANCER RES, V67, P10343, DOI 10.1158/0008-5472.CAN-07-1827; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Vazquez F, 2001, J BIOL CHEM, V276, P48627, DOI 10.1074/jbc.C100556200; Vermeij J, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-3; Vivanco I, 2007, CANCER CELL, V11, P555, DOI 10.1016/j.ccr.2007.04.021; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; Wang SI, 1998, CLIN CANCER RES, V4, P811; Wang SI, 1997, CANCER RES, V57, P4183; Wang XJ, 2007, CELL, V128, P129, DOI 10.1016/j.cell.2006.11.039; Wiencke JK, 2007, NEURO-ONCOLOGY, V9, P271, DOI 10.1215/15228517-2007-003; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008-5472.CAN-07-2488; Yao DG, 2008, J CELL SCI, V121, P1758, DOI 10.1242/jcs.021147; You MJ, 2002, P NATL ACAD SCI USA, V99, P1455, DOI 10.1073/pnas.022632099; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999; Zhao L, 2008, P NATL ACAD SCI USA, V105, P2652, DOI 10.1073/pnas.0712169105; Zhou XP, 2000, HUM MOL GENET, V9, P765, DOI 10.1093/hmg/9.5.765; Zhou XP, 2002, AM J PATHOL, V161, P439, DOI 10.1016/S0002-9440(10)64200-9; Zhou XP, 2001, LANCET, V358, P210, DOI 10.1016/S0140-6736(01)05412-5	140	279	296	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 15	2008	27	41					5477	5485		10.1038/onc.2008.248	http://dx.doi.org/10.1038/onc.2008.248			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349KW	18794882				2022-12-17	WOS:000259280700009
J	Su, ZZ; Kang, DC; Chen, YM; Pekarskaya, O; Chao, W; Volsky, DJ; Fisher, PB				Su, ZZ; Kang, DC; Chen, YM; Pekarskaya, O; Chao, W; Volsky, DJ; Fisher, PB			Identification and cloning of human astrocyte genes displaying elevated expression after infection with HIV-1 or exposure to HIV-1 envelope glycoprotein by rapid subtraction hybridization, RaSH	ONCOGENE			English	Article						AIDS; gp120; Northern hybridization; reverse Northern hybridization; neuropathogenesis	HUMAN-IMMUNODEFICIENCY-VIRUS; AIDS DEMENTIA COMPLEX; NECROSIS-FACTOR-ALPHA; HUMAN GLIAL-CELLS; GROWTH ARREST; DIFFERENTIAL EXPRESSION; GLUTAMATE TRANSPORTERS; PRODUCTIVE INFECTION; TYPE-1 INFECTION; BRAIN-INJURY	Neurodegeneration and dementia are common complications of AIDS caused by human immunodeficiency virus type 1 (HIV-1) infection of the central nervous system. HIV-1 target cells in the brain include microglia, infiltrating macrophages and astrocytes, but rarely neurons. Astrocytes play an important role in the maintenance of the synaptic micro-environment and in neuronal signal transmission. To investigate potential changes in cellular gene expression associated with HIV-1 infection of astrocytes, we employed an efficient and sensitive rapid subtraction hybridization approach, RaSH. Primary human astrocytes were isolated from abortus brain tissue and low-passage cells were infected with HIV-1. To identify genes that display both early and late expression modifications after HIV-1 infection and to avoid cloning genes displaying normal cell cycle fluctuations in astrocytes, RNAs were isolated and pooled from 6, 12, 24 h and 3 and 7 day uninfected and infected cells and used for RaSH. Temporal cDNA libraries were prepared from double-stranded cDNAs that were enzymatically digested into small fragments, ligated to adapters, PCR amplified, and hybridized by incubation of tester and driver PCR fragments. By subtracting temporal cDNAs derived from uninfected astrocytes from temporal cDNAs made from HIV-1 infected cells, genes displaying elevated expression in virus infected cells, termed astrocyte elevated genes (AEGs), were identified. Both known and novel AEGs, not reported in current DNA databases, are described that display early or late expression kinetics following HIV-1 infection or treatment with recombinant HIV-1 envelope glycoprotein (gp120). For selected AEGs, expression of their protein products was also tested by Western blotting and found to display elevated expression following HIV-1 infection. The comparable pattern of regulation of the AEGs following HIV-1 infection or gp120 treatment suggest that HIV-1 exposure of astrocytes, even in the absence of productive infection, can induce changes in cellular gene expression.	Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Urol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Neurosurg, New York, NY 10032 USA; Columbia Univ, St Lukes Roosevelt Hosp Ctr, Div Mol Virol, New York, NY 10019 USA	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Mount Sinai St. Luke's; Mount Sinai West	Fisher, PB (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Pathol, BB-1501,630 W 168th St, New York, NY 10032 USA.	pbfl@columbia.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS031492] Funding Source: NIH RePORTER; NINDS NIH HHS [P01 NS31492, P01 NS031492] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACHIM CL, 1994, J NEUROPATH EXP NEUR, V53, P284, DOI 10.1097/00005072-199405000-00010; ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Anderson CM, 2000, GLIA, V32, P1; BEALS CR, 1987, P NATL ACAD SCI USA, V84, P7886, DOI 10.1073/pnas.84.22.7886; Bencheikh M, 1999, J NEUROVIROL, V5, P115, DOI 10.3109/13550289909021993; BENOS DJ, 1994, P NATL ACAD SCI USA, V91, P494, DOI 10.1073/pnas.91.2.494; BENOS DJ, 1994, ADV NEUROIMMUNOL, V4, P175, DOI 10.1016/S0960-5428(06)80254-8; BENVENISTE EN, 1992, AM J PHYSIOL, V263, pC1, DOI 10.1152/ajpcell.1992.263.1.C1; Bezzi P, 2001, NAT NEUROSCI, V4, P702, DOI 10.1038/89490; BOUSSADIA O, 1993, BIOCHIM BIOPHYS ACTA, V1172, P64, DOI 10.1016/0167-4781(93)90270-N; Brack-Werner R, 1999, AIDS, V13, P1, DOI 10.1097/00002030-199901140-00003; BREW BJ, 1995, ANN NEUROL, V38, P563, DOI 10.1002/ana.410380404; Bristol LA, 1996, ANN NEUROL, V39, P676, DOI 10.1002/ana.410390519; Canki M, 2001, J VIROL, V75, P7925, DOI 10.1128/JVI.75.17.7925-7933.2001; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; DEWHURST S, 1987, J VIROL, V61, P3774, DOI 10.1128/JVI.61.12.3774-3782.1987; Fine SM, 1996, J BIOL CHEM, V271, P15303, DOI 10.1074/jbc.271.26.15303; Furukawa T, 1999, J HUM GENET, V44, P397, DOI 10.1007/s100380050186; Gabuzda D, 1999, J NEUROVIROL, V5, P643, DOI 10.3109/13550289909021293; Gegelashvili G, 1997, MOL PHARMACOL, V52, P6, DOI 10.1124/mol.52.1.6; Geiss GK, 2000, VIROLOGY, V266, P8, DOI 10.1006/viro.1999.0044; GONDO H, 1987, J IMMUNOL, V139, P3840; Gonos ES, 1998, ANN NY ACAD SCI, V851, P466, DOI 10.1111/j.1749-6632.1998.tb09024.x; Gorry PR, 1999, J VIROL, V73, P352, DOI 10.1128/JVI.73.1.352-361.1999; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; He JL, 1997, P NATL ACAD SCI USA, V94, P3954, DOI 10.1073/pnas.94.8.3954; HONORE B, 1994, ELECTROPHORESIS, V15, P482, DOI 10.1002/elps.1150150166; Huang F, 1999, GENE, V236, P125, DOI 10.1016/S0378-1119(99)00244-9; JEFFERS M, 1990, NUCLEIC ACIDS RES, V18, P4891; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; Jiang HP, 2000, P NATL ACAD SCI USA, V97, P12684, DOI 10.1073/pnas.220431297; Kang DC, 2001, GENE, V267, P233, DOI 10.1016/S0378-1119(01)00384-5; Kang DC, 1998, P NATL ACAD SCI USA, V95, P13788, DOI 10.1073/pnas.95.23.13788; Kaul M, 2001, NATURE, V410, P988, DOI 10.1038/35073667; Kawagoe H, 1997, CANCER RES, V57, P2516; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; Kort JJ, 1998, AIDS RES HUM RETROV, V14, P1329, DOI 10.1089/aid.1998.14.1329; Lee DK, 2001, MOL BRAIN RES, V86, P13, DOI 10.1016/S0169-328X(00)00242-4; Lino M, 2001, SCIENCE, V292, P926, DOI 10.1126/science.1058827; LIPTON SA, 1995, NEW ENGL J MED, V332, P934, DOI 10.1056/NEJM199504063321407; Ludwig E, 1999, J VIROL, V73, P8279, DOI 10.1128/JVI.73.10.8279-8289.1999; MA MH, 1994, J VIROL, V68, P6824, DOI 10.1128/JVI.68.10.6824-6828.1994; Manji HK, 2000, BIOL PSYCHIAT, V48, P518, DOI 10.1016/S0006-3223(00)00929-X; Maragakis NJ, 2001, ARCH NEUROL-CHICAGO, V58, P365, DOI 10.1001/archneur.58.3.365; Mark MD, 2000, EUR J BIOCHEM, V267, P5830, DOI 10.1046/j.1432-1327.2000.01670.x; MICHELSON AM, 1983, P NATL ACAD SCI-BIOL, V80, P472, DOI 10.1073/pnas.80.2.472; NAVIA BA, 1986, ANN NEUROL, V19, P525, DOI 10.1002/ana.410190603; NAVIA BA, 1986, ANN NEUROL, V19, P517, DOI 10.1002/ana.410190602; NIQUET J, 1994, NEUROSCI LETT, V180, P13, DOI 10.1016/0304-3940(94)90902-4; O'Regan S, 2000, P NATL ACAD SCI USA, V97, P1835, DOI 10.1073/pnas.030339697; Oliet SHR, 2001, SCIENCE, V292, P923, DOI 10.1126/science.1059162; Pope A., 1978, DYNAMIC PROPERTIES G, P13; Porter JT, 1997, PROG NEUROBIOL, V51, P439, DOI 10.1016/S0301-0082(96)00068-8; Prieto AL, 1999, BRAIN RES, V816, P646, DOI 10.1016/S0006-8993(98)01159-7; RICH BE, 1987, MOL CELL BIOL, V7, P4065, DOI 10.1128/MCB.7.11.4065; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; ROTHSTEIN JD, 1992, NEW ENGL J MED, V326, P1464, DOI 10.1056/NEJM199205283262204; Rubio ME, 1999, J NEUROCHEM, V73, P942, DOI 10.1046/j.1471-4159.1999.0730942.x; Rutka JT, 1997, J NEUROSURG, V87, P420, DOI 10.3171/jns.1997.87.3.0420; Ryo A, 2000, AIDS RES HUM RETROV, V16, P995, DOI 10.1089/08892220050058416; SAITO Y, 1994, NEUROLOGY, V44, P474, DOI 10.1212/WNL.44.3_Part_1.474; Sakai T, 2001, NAT MED, V7, P324, DOI 10.1038/85471; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SCHNEIDERSCHAULIES J, 1992, VIROLOGY, V191, P765, DOI 10.1016/0042-6822(92)90252-K; Schwarzbauer JE, 1991, CURR OPIN CELL BIOL, V3, P786, DOI 10.1016/0955-0674(91)90051-Y; SHAHABUDDIN M, 1992, PATHOBIOLOGY, V60, P195, DOI 10.1159/000163723; SHAHABUDDIN N, 1994, AIDS RES HUM RETROV, V10, P1525; Sharma G, 2001, P NATL ACAD SCI USA, V98, P4148, DOI 10.1073/pnas.071540198; Shi B, 1996, J CLIN INVEST, V98, P1979, DOI 10.1172/JCI119002; Shi SH, 2001, CELL, V105, P331, DOI 10.1016/S0092-8674(01)00321-X; Shimizu N, 1999, J VIROL, V73, P5231, DOI 10.1128/JVI.73.6.5231-5239.1999; Sidhu A, 2000, INT J DEV NEUROSCI, V18, P669, DOI 10.1016/S0736-5748(00)00033-2; Simm M, 2001, GENE, V269, P93, DOI 10.1016/S0378-1119(01)00456-5; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; Szymocha R, 2000, J VIROL, V74, P6433, DOI 10.1128/JVI.74.14.6433-6441.2000; Takahashi K, 1996, ANN NEUROL, V39, P705, DOI 10.1002/ana.410390606; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; TORNATORE C, 1994, NEUROLOGY, V44, P481, DOI 10.1212/WNL.44.3_Part_1.481; TORNATORE C, 1994, J VIROL, V68, P93, DOI 10.1128/JVI.68.1.93-102.1994; TORNATORE C, 1991, J VIROL, V65, P6094, DOI 10.1128/JVI.65.11.6094-6100.1991; TSUKADA M, 1991, J GERONTOL, V46, pB213, DOI 10.1093/geronj/46.6.B213; Ullian EM, 2001, SCIENCE, V291, P657, DOI 10.1126/science.291.5504.657; Verkhratsky A, 1998, PHYSIOL REV, V78, P99, DOI 10.1152/physrev.1998.78.1.99; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089; YOUSSOUFIAN H, 1990, AM J HUM GENET, V47, P62; Yu N, 1998, P NATL ACAD SCI USA, V95, P2624, DOI 10.1073/pnas.95.5.2624	88	279	310	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3592	3602		10.1038/sj.onc.1205445	http://dx.doi.org/10.1038/sj.onc.1205445			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032861				2022-12-17	WOS:000175793700010
J	Shuai, K				Shuai, K			Modulation of STAT signaling by STAT-interacting proteins	ONCOGENE			English	Article						STAT-interacting proteins; signal transduction; transcription	INTERFERON-ALPHA; TRANSCRIPTION FACTOR; IFN-GAMMA; TYROSINE PHOSPHORYLATION; DNA-BINDING; RESPONSIVE ELEMENT; NUCLEAR-RECEPTOR; ACTIVATION; GENE; COMPLEX	STATs (signal transducer and activator of transcription) play important roles in numerous cellular processes including immune responses, cell growth and differentiation, cell survival and apoptosis, and oncogenesis. In contrast to many other cellular signaling cascades, the STAT pathway is direct: STATs bind to receptors at the cell surface and translocate into the nucleus where they function as transcription factors to trigger gene activation, However, STATs do not act alone. A number of proteins are found to be associated with STATs, These STAT-interacting proteins function to modulate STAT signaling at various steps and mediate the crosstalk of STATs with other cellular signaling pathways. This article reviews the roles of STAT-interacting proteins in the regulation of STAT signaling.	Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Shuai, K (corresponding author), Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, 11-934 Factor Bldg,10833 LeConte Ave, Los Angeles, CA 90095 USA.							Bannasch D, 1999, ONCOGENE, V18, P6810, DOI 10.1038/sj.onc.1203090; Bao JX, 1996, ONCOGENE, V12, P2171; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Cantwell CA, 1998, MOL CELL BIOL, V18, P2108, DOI 10.1128/MCB.18.4.2108; Cella N, 1998, MOL CELL BIOL, V18, P1783, DOI 10.1128/MCB.18.4.1783; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; DUTTA A, 1997, KAM REV CELL DEV BIO, V13, P293; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; Haspel RL, 1999, P NATL ACAD SCI USA, V96, P10188, DOI 10.1073/pnas.96.18.10188; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Horvath CM, 1996, MOL CELL BIOL, V16, P6957; IMAMOTO N, 1995, FEBS LETT, V368, P415; ITO T, 1989, NUCLEIC ACIDS RES, V17, P9425, DOI 10.1093/nar/17.22.9425; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Ke SA, 1999, PROG BIOPHYS MOL BIO, V71, P405, DOI 10.1016/S0079-6107(98)00051-0; Korzus E, 1997, J BIOL CHEM, V272, P1188, DOI 10.1074/jbc.272.2.1188; Koster M, 1999, EUR J BIOCHEM, V260, P137, DOI 10.1046/j.1432-1327.1999.00149.x; Lebrun SJ, 1998, J INTERF CYTOK RES, V18, P767, DOI 10.1089/jir.1998.18.767; Lee ND, 1999, J INTERF CYTOK RES, V19, P1245, DOI 10.1089/107999099312902; Levy David E., 1997, Cytokine and Growth Factor Reviews, V8, P81, DOI 10.1016/S1359-6101(96)00054-8; LEWIS SE, 1994, J NEUROCHEM, V63, P429; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; MartinezMoczygemba M, 1997, J BIOL CHEM, V272, P20070, DOI 10.1074/jbc.272.32.20070; Mohr SE, 1999, GENE, V229, P109, DOI 10.1016/S0378-1119(99)00033-5; Moilanen AM, 1999, J BIOL CHEM, V274, P3700, DOI 10.1074/jbc.274.6.3700; Ndubuisi MI, 1999, J BIOL CHEM, V274, P25499, DOI 10.1074/jbc.274.36.25499; Pircher TJ, 1997, MOL CELL ENDOCRINOL, V133, P169, DOI 10.1016/S0303-7207(97)00164-0; Pircher TJ, 1999, MOL ENDOCRINOL, V13, P555, DOI 10.1210/mend.13.4.0263; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; Schaefer TS, 1997, MOL CELL BIOL, V17, P5307, DOI 10.1128/MCB.17.9.5307; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHMITT-NEY M, 1991, MOL CELL BIOL, V11, P3745, DOI 10.1128/MCB.11.7.3745; Sekimoto T, 1998, CYTOKINE GROWTH F R, V9, P205, DOI 10.1016/S1359-6101(98)00012-4; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Tan JA, 2000, MOL ENDOCRINOL, V14, P14, DOI 10.1210/me.14.1.14; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Valdez BC, 1997, BIOCHEM BIOPH RES CO, V234, P335, DOI 10.1006/bbrc.1997.6642; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; WINSTON LA, 1992, J BIOL CHEM, V267, P4747; Wu L, 1997, MECH DEVELOP, V65, P3, DOI 10.1016/S0925-4773(97)00032-4; Wyszomierski SL, 1999, MOL ENDOCRINOL, V13, P330, DOI 10.1210/me.13.2.330; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963; Zhang XK, 1999, MOL CELL BIOL, V19, P7138; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4	63	279	302	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2000	19	21					2638	2644		10.1038/sj.onc.1203522	http://dx.doi.org/10.1038/sj.onc.1203522			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321MN	10851063				2022-12-17	WOS:000087459400020
J	Greenberg, RA; Allsopp, RC; Chin, L; Morin, GB; DePinho, RA				Greenberg, RA; Allsopp, RC; Chin, L; Morin, GB; DePinho, RA			Expression of mouse telomerase reverse transcriptase during development, differentiation and proliferation	ONCOGENE			English	Article						telomerase; reverse transcriptase; mouse; telomere; cancer	IMMORTAL CELL-LINES; RNA COMPONENT; CANCER	We have identified the mouse telomerase reverse transcriptase component (mTERT) and demonstrate both substantial sequence homology to the human ortholog (hTERT), and the presence of reverse transcriptase and telomerase specific motifs, Furthermore, we show functional interchangeability with hTERT in in vitro telomerase reconstitution experiments, as mTERT produces strong telomerase activity in combination with the human telomerase RNA component hTR, The mouse TERT is widely expressed at low levels in adult tissues, with greatest abundance during embryogenesis and in adult thymus and intestine, The mTERT component mRNA levels were regulated during both differentiation and proliferation, while mTR levels remained constant throughout both processes, Comparison of mTERT and mTR levels to telomerase activity indicates that mTERT expression is more tightly linked to the regulation of telomerase activity during these processes than is mTR, In contrast to the situation in human cell cultures, mTERT transcript levels are present at readily detectable levels in primary cultured cells and are not upregulated following crisis, The widespread expression of mTERT in primary cells and mouse tissues could explain the increased frequency of spontaneous immortalization of mouse cells in culture and tumorigenesis in vivo.	Geron Corp, Menlo Park, CA 94025 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Div Dermatol, Bronx, NY 10461 USA	Geron Corporation; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Morin, GB (corresponding author), Geron Corp, 230 Constitut Dr, Menlo Park, CA 94025 USA.		Morin, Gregg B/E-9123-2012	Morin, Gregg B/0000-0001-8949-4374; DePinho, Ronald/0000-0002-5625-577X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028317] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY009300] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007491] Funding Source: NIH RePORTER; NEI NIH HHS [R01EY09300] Funding Source: Medline; NICHD NIH HHS [R01HD28317] Funding Source: Medline; NIGMS NIH HHS [5T32GMO7491] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Autexier C, 1996, TRENDS BIOCHEM SCI, V21, P387, DOI 10.1016/S0968-0004(96)90128-0; Avilion AA, 1996, CANCER RES, V56, P645; BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bodnar AG, 1996, EXP CELL RES, V228, P58, DOI 10.1006/excr.1996.0299; Bryan TM, 1997, HUM MOL GENET, V6, P921, DOI 10.1093/hmg/6.6.921; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Buchkovich KJ, 1996, MOL BIOL CELL, V7, P1443, DOI 10.1091/mbc.7.9.1443; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; Holt SE, 1996, MOL CELL BIOL, V16, P2932; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; Li H, 1997, J BIOL CHEM, V272, P16729, DOI 10.1074/jbc.272.27.16729; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; MILLER RA, 1991, CANCER, V68, P2496, DOI 10.1002/1097-0142(19911201)68:11+<2496::AID-CNCR2820681503>3.0.CO;2-B; Morrison SJ, 1996, IMMUNITY, V5, P207, DOI 10.1016/S1074-7613(00)80316-7; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; Rao G, 1996, ONCOGENE, V12, P1165; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; SCHREIBERAGUS N, 1993, MOL CELL BIOL, V13, P2765, DOI 10.1128/MCB.13.5.2765; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Xu HP, 1996, MAMM GENOME, V7, P16, DOI 10.1007/s003359900005; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0	35	279	300	2	14	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 2	1998	16	13					1723	1730		10.1038/sj.onc.1201933	http://dx.doi.org/10.1038/sj.onc.1201933			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZE573	9582020				2022-12-17	WOS:000072807600010
J	El-Deiry, WS				El-Deiry, WS			The role of p53 in chemosensitivity and radiosensitivity	ONCOGENE			English	Review						p53; apoptosis; cancer; chemotherapy; tissue specificity; CP-31398; prima1; MDM2; p73; Parc; Pirh2; HAUSP; ASPP1; BRCA1; PAC1; p300; ONYX-015; toxicity; stability; transcription	WILD-TYPE P53; IN-VIVO; TUMOR-SUPPRESSOR; DNA-DAMAGE; P53-DEPENDENT APOPTOSIS; TRANSCRIPTIONAL REPRESSION; ANTICANCER DRUG; CANCER-THERAPY; MUTANT P53; P53-INDUCED APOPTOSIS	The role of p53 as a central mediator of the DNA damage and other cellular stress responses is well established. The ultimate growth-suppressive function of p53 in part explains its ability to confer chemosensitivity and radiosensitivity upon tumor cells. Recent work in the field has added complexity to our understanding, in terms of identifying novel regulators of p53 stability and function, elucidation of the importance of the p53 family towards p53 function, a growing list of transcriptional targets as well as transcription-independent apoptotic effects and mechanisms, tissue specificity of the p53 response, a molecular understanding of p53-dependent therapeutic sensitization, and efforts towards molecular targeting of the p53 pathway. p53 remains an attractive target for drug development in cancer because its alteration provides a fundamental difference between normal and cancer cells. Strategies are emerging for the identification of mutant p53-specific therapies, therapies targeted at mutant p53-expressing tumors, as well as therapies that target various aspects of the p53 life cycle to enhance chemosensitization. The tools of molecular imaging are beginning to accelerate the pace of discovery and preclinical testing of p53 in animal models. The future holds promise for specific, individualized targeting of mutant or wild-type p53, or its transcriptional targets, in combination therapies with other cancer-specific drugs, to maximize tumor cell killing while protecting normal cells from toxic side effects.	Univ Penn, Sch Med, Dept Med Hematol Oncol Genet Pharmacol, Abramson Comprehens Canc Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	El-Deiry, WS (corresponding author), Univ Penn, Sch Med, Dept Med Hematol Oncol Genet Pharmacol, Abramson Comprehens Canc Ctr, 415 Curie Blvd,CRB 437A, Philadelphia, PA 19104 USA.		El-Deiry, Wafik/AAJ-6080-2020	El-Deiry, Wafik/0000-0002-9577-8266				Amundson SA, 2002, CANCER BIOL THER, V1, P145, DOI 10.4161/cbt.59; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Badciong JC, 2002, J BIOL CHEM, V277, P49668, DOI 10.1074/jbc.M208593200; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; Bergamaschi D, 2003, NAT GENET, V33, P162, DOI 10.1038/ng1070; Blagosklonny MV, 1996, INT J CANCER, V67, P386, DOI 10.1002/(SICI)1097-0215(19960729)67:3<386::AID-IJC13>3.0.CO;2-6; Blagosklonny MV, 1998, INT J CANCER, V75, P933, DOI 10.1002/(SICI)1097-0215(19980316)75:6<933::AID-IJC17>3.0.CO;2-3; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Bottger V, 1996, ONCOGENE, V13, P2141; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Burns TF, 2003, MOL CELL BIOL, V23, P5556, DOI 10.1128/MCB.23.16.5556-5571.2003; Burns TF, 2001, ONCOGENE, V20, P4601, DOI 10.1038/sj.onc.1204484; Burns Timothy F, 2003, Cancer Treat Res, V115, P319; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Choi J, 2002, MOL CELL BIOL, V22, P1094, DOI 10.1128/MCB.22.4.1094-1105.2002; Deb SP, 2002, FRONT BIOSCI, V7, pD235, DOI 10.2741/deb; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Doubrovin M, 2001, P NATL ACAD SCI USA, V98, P9300, DOI 10.1073/pnas.161091198; Dumaz N, 1999, FEBS LETT, V463, P312, DOI 10.1016/S0014-5793(99)01647-6; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; El-Deiry WS, 2002, CANCER BIOL THER, V1, P490, DOI 10.4161/cbt.1.5.162; El-Deiry WS, 2001, CELL DEATH DIFFER, V8, P1066, DOI 10.1038/sj.cdd.4400943; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Fei PW, 2002, CANCER RES, V62, P7316; Finch RA, 2002, CANCER RES, V62, P3221; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; Garcia-Cao I, 2002, EMBO J, V21, P6225, DOI 10.1093/emboj/cdf595; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Hamid O, 2003, J CLIN ONCOL, V21, P1498, DOI 10.1200/JCO.2003.09.114; Hecht JR, 2003, CLIN CANCER RES, V9, P555; Hemann MT, 2003, NAT GENET, V33, P396, DOI 10.1038/ng1091; Herbert BS, 2003, CANCER RES, V63, P1914; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; Kastan MB, 2003, CELL, V112, P1, DOI 10.1016/S0092-8674(02)01281-3; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Komarova EA, 2003, J BIOL CHEM, V278, P15465, DOI 10.1074/jbc.C300011200; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Laxman B, 2002, P NATL ACAD SCI USA, V99, P16551, DOI 10.1073/pnas.252644499; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; MacLachan TK, 2002, P NATL ACAD SCI USA, V99, P9492, DOI 10.1073/pnas.132241599; MacLachlan TK, 2002, MOL CELL BIOL, V22, P4280, DOI 10.1128/MCB.22.12.4280-4292.2002; Manfredi JJ, 2003, MOL CELL, V11, P552, DOI 10.1016/S1097-2765(03)00106-0; Massoud TF, 2003, GENE DEV, V17, P545, DOI 10.1101/gad.1047403; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Nishizaki M, 2001, CLIN CANCER RES, V7, P2887; OConnor PM, 1997, CANCER RES, V57, P4285; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Ollmann M, 2000, CELL, V101, P91, DOI 10.1016/S0092-8674(00)80626-1; Peng YH, 2003, ONCOGENE, V22, P4478, DOI 10.1038/sj.onc.1206777; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rippin TM, 2002, ONCOGENE, V21, P2119, DOI 10.1038/sj.onc.1205362; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Sax JK, 2002, NAT CELL BIOL, V4, P842, DOI 10.1038/ncb866; Sax JK, 2003, CELL DEATH DIFFER, V10, P413, DOI 10.1038/sj.cdd.4401227; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Slee EA, 2003, TOXICOL LETT, V139, P81, DOI 10.1016/S0378-4274(02)00421-6; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Song EW, 2003, NAT MED, V9, P347, DOI 10.1038/nm828; Soussi T, 2003, CANCER CELL, V3, P303, DOI 10.1016/S1535-6108(03)00081-3; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Takimoto R, 2002, CANCER BIOL THER, V1, P47, DOI 10.4161/cbt.1.1.41; Takimoto R, 2002, CANCER BIOL THER, V1, P177, DOI 10.4161/cbt.65; Tan T, 2002, MOL CELL BIOL, V22, P3247, DOI 10.1128/MCB.22.10.3247-3254.2002; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Tanikawa C, 2003, NAT CELL BIOL, V5, P216, DOI 10.1038/ncb943; Velculescu VE, 1996, CLIN CHEM, V42, P858; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wang WG, 2003, MOL CELL BIOL, V23, P2171, DOI 10.1128/MCB.23.6.2171-2181.2003; Wang WG, 2003, CANCER BIOL THER, V2, P196, DOI 10.4161/cbt.2.2.347; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; Wu GS, 1996, CLIN CANCER RES, V2, P623; Yin YX, 2003, NATURE, V422, P527, DOI 10.1038/nature01519; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Zhou BHP, 2002, SEMIN ONCOL, V29, P62, DOI 10.1053/sonc.2002.34057; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	104	278	288	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 20	2003	22	47					7486	7495		10.1038/sj.onc.1206949	http://dx.doi.org/10.1038/sj.onc.1206949			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KL	14576853				2022-12-17	WOS:000186112500018
J	Koera, K; Nakamura, K; Nakao, K; Miyoshi, J; Toyoshima, K; Hatta, T; Otani, H; Aiba, A; Katsuki, M				Koera, K; Nakamura, K; Nakao, K; Miyoshi, J; Toyoshima, K; Hatta, T; Otani, H; Aiba, A; Katsuki, M			K-ras is essential for the development of the mouse embryo	ONCOGENE			English	Article						K-ras; ras genes; gene targeting	N-MYC GENE; TARGETED DISRUPTION; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; MICE LACKING; RXR-ALPHA; PROTEIN; DEFECTS; CELLS; HEART	ras genes encode members of the small GTP-binding proteins, Ras protein is highly conserved in various species from yeast to humans and plays a key role in signal transduction, Ras is related to cell proliferation and differentiation, While, in addition, mutations in the ras genes are implicated in a variety of tumors, However, the physiological functions and specific roles of each ras gene, H-ras, K-ras and N-ras, are still not fully understood, To clarify the role of the K-Ras in vivo, we generated K-ras mutant mice by gene targeting, In contrast to the findings that H-Ras-deficient mice and N-Ras-deficient mice are born and grow normally, the K-Ras-deficient embryos die progressively between embryonic day 12.5 and term, At embryonic day 15.5, their ventricular walls are extremely thin, Besides, at embryonic day 11.5, they demonstrate increased cell death of motoneurons in the medulla and the cervical spinal cord, Our results thus indicate K-Ras to be essential for normal development in mice and residual Ras composed of H-Ras and N-Ras cannot compensate for the loss of K-Ras function in the mutant mice.	UNIV TOKYO,INST MED SCI,DEPT DNA BIOL & EMBRYO ENGN,TOKYO 108,JAPAN; OSAKA MED CTR CANC & CARDIOVASC DIS,OSAKA 537,JAPAN; SHIMANE MED UNIV,DEPT ANAT,IZUMO,SHIMANE 693,JAPAN	University of Tokyo; Osaka Medical Center for Cancer & Cardiovascular Diseases; Shimane University				zhong wei, he gui/0000-0002-3066-3564; Aiba, Atsu/0000-0002-8192-0778				BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; Chen CY, 1996, J BIOL CHEM, V271, P2376, DOI 10.1074/jbc.271.5.2376; CHEN Z, 1994, GENE DEV, V8, P2293, DOI 10.1101/gad.8.19.2293; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DECHIARA TM, 1995, CELL, V83, P313, DOI 10.1016/0092-8674(95)90172-8; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; ESCARY JL, 1993, NATURE, V363, P361, DOI 10.1038/363361a0; FEIG LA, 1994, NATURE, V370, P508, DOI 10.1038/370508a0; FUKUI Y, 1986, CELL, V44, P329, DOI 10.1016/0092-8674(86)90767-1; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GEORGE DL, 1985, EMBO J, V4, P1199, DOI 10.1002/j.1460-2075.1985.tb03760.x; HALL A, 1994, SCIENCE, V264, P1413, DOI 10.1126/science.8197454; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HARVEY JJ, 1964, NATURE, V204, P1104, DOI 10.1038/2041104b0; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; HIROTA H, 1995, P NATL ACAD SCI USA, V92, P4862, DOI 10.1073/pnas.92.11.4862; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; KASTNER P, 1994, CELL, V78, P987, DOI 10.1016/0092-8674(94)90274-7; KATAOKA T, 1984, CELL, V37, P437, DOI 10.1016/0092-8674(84)90374-X; KIRSTEN WH, 1967, J NATL CANCER I, V39, P311; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; LI M, 1995, NATURE, V378, P724, DOI 10.1038/378724a0; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARTINOU JC, 1992, NEURON, V8, P737, DOI 10.1016/0896-6273(92)90094-T; MASU Y, 1993, NATURE, V365, P27, DOI 10.1038/365027a0; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MOENS CB, 1993, DEVELOPMENT, V119, P485; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OPPENHEIM RW, 1991, SCIENCE, V251, P1616, DOI 10.1126/science.2011743; Pennica D, 1996, NEURON, V17, P63, DOI 10.1016/S0896-6273(00)80281-0; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; SAKAI N, 1994, EXP CELL RES, V215, P131, DOI 10.1006/excr.1994.1324; SATOH T, 1992, J BIOL CHEM, V267, P24149; SAWAI S, 1993, DEVELOPMENT, V117, P1445; SHIMIZU K, 1983, P NATL ACAD SCI-BIOL, V80, P2112, DOI 10.1073/pnas.80.8.2112; Shorey ML, 1909, J EXP ZOOL, V7, P25, DOI 10.1002/jez.1400070103; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SUCOV HM, 1994, GENE DEV, V8, P1007, DOI 10.1101/gad.8.9.1007; TATCHELL K, 1984, NATURE, V309, P523, DOI 10.1038/309523a0; Trent JC, 1996, EMBO J, V15, P4497, DOI 10.1002/j.1460-2075.1996.tb00827.x; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; Yoda Y., 1971, JAPANESE J ANIM REPR, V16, P147, DOI [DOI 10.1262/JRD1955.16.147, 10.1262/jrd1955.16.147]; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407	56	278	282	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 4	1997	15	10					1151	1159		10.1038/sj.onc.1201284	http://dx.doi.org/10.1038/sj.onc.1201284			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XU991	9294608				2022-12-17	WOS:A1997XU99100004
J	HIBI, K; TAKAHASHI, T; YAMAKAWA, K; UEDA, R; SEKIDO, Y; ARIYOSHI, Y; SUYAMA, M; TAKAGI, H; NAKAMURA, Y; TAKAHASHI, T				HIBI, K; TAKAHASHI, T; YAMAKAWA, K; UEDA, R; SEKIDO, Y; ARIYOSHI, Y; SUYAMA, M; TAKAGI, H; NAKAMURA, Y; TAKAHASHI, T			3 DISTINCT REGIONS INVOLVED IN 3P DELETION IN HUMAN LUNG-CANCER	ONCOGENE			English	Article							RENAL-CELL CARCINOMA; SHORT ARM; DNA-SEQUENCE; CHROMOSOME-3; HETEROZYGOSITY; GENE; ADENOCARCINOMA; EXPRESSION; MYC; ABNORMALITIES	The 3p deletion was first noted by cytogenetic analysis and was later confirmed by several independent studies using restriction fragment length polymorphism (RFLP) probes. As an initial step towards positional cloning (reverse genetics) of the tumor-suppressor gene(s) on 3p, a detailed analysis of the minimum deleted region(s) on 3p was performed with 13 RFLP probes and 48 paired human lung cancer samples. All nine small-cell lung cancer cases (100%) and 31 of 39 non-small-cell lung cancer cases (79%) showed allelic loss at one or more loci mapped on 3p. We show here that three distinct regions on 3p appear to be frequently deleted in lung cancer. These regions include 3p25, 3p21.3 and 3p14-cen. The present study should warrant future work focusing on these chromosomal regions on 3p, and may ultimately lead to the isolation of tumor-suppressor genes involved in the pathogenesis of lung cancer.	AICHI CANC CTR,RES INST,CHEMOTHERAPY LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; NAGOYA UNIV,SCH MED,DEPT SURG 2,SHOWA KU,NAGOYA,AICHI 466,JAPAN; NAGOYA UNIV,SCH MED,DEPT INTERNAL MED 1,SHOWA KU,NAGOYA,AICHI 466,JAPAN; JAPANESE FDN CANC RES,INST CANC,BIOCHEM LAB,TOSHIMA KU,TOKYO 170,JAPAN; AICHI CANC CTR,DEPT SURG,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR,IMMUNOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN	Aichi Cancer Center; Nagoya University; Nagoya University; Japanese Foundation for Cancer Research; Aichi Cancer Center; Aichi Cancer Center			Takahashi, Takashi/I-7262-2014; Yamakawa, Kazuhiro/N-5050-2015	Takahashi, Takashi/0000-0003-0615-7001; Yamakawa, Kazuhiro/0000-0002-1478-4390; Sekido, Yoshitaka/0000-0002-2428-3848				BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; BRAUCH H, 1990, GENE CHROMOSOME CANC, V1, P240, DOI 10.1002/gcc.2870010309; DALY MC, 1991, GENOMICS, V9, P113, DOI 10.1016/0888-7543(91)90227-6; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; EHLEN T, 1990, ONCOGENE, V5, P219; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HIBI K, 1991, ONCOGENE, V6, P2291; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOSOE S, 1990, GENOMICS, V8, P634, DOI 10.1016/0888-7543(90)90249-T; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOVACS G, 1988, P NATL ACAD SCI USA, V85, P1571, DOI 10.1073/pnas.85.5.1571; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; LOTHE RA, 1989, GENOMICS, V5, P134, DOI 10.1016/0888-7543(89)90097-9; NAU M, 1985, P NATL ACAD SCI USA, V83, P1092; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; PONDER B, 1988, NATURE, V335, P400, DOI 10.1038/335400a0; RABBITTS P, 1989, GENE CHROMOSOME CANC, V1, P95, DOI 10.1002/gcc.2870010115; RABBITTS P, 1990, GENE CHROMOSOME CANC, V2, P231, DOI 10.1002/gcc.2870020312; RODENHUIS S, 1987, NEW ENGL J MED, V317, P929, DOI 10.1056/NEJM198710083171504; SEIZINGER BR, 1988, NATURE, V332, P268, DOI 10.1038/332268a0; SEKIDO Y, 1991, CANCER RES, V51, P2416; TAKAHASHI T, 1989, CANCER RES, V49, P2683; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; WHANGPENG J, 1991, GENE CHROMOSOME CANC, V3, P168, DOI 10.1002/gcc.2870030303; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; YAMAKAWA K, 1991, GENOMICS, V9, P536, DOI 10.1016/0888-7543(91)90421-A; YAMAKAWA K, 1991, CANCER RES, V51, P4707; YAMAKAWA K, 1991, GENOMICS, V11, P565, DOI 10.1016/0888-7543(91)90063-K; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOTA J, 1989, CANCER RES, V49, P3598; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0	34	278	283	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1992	7	3					445	449						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1347916				2022-12-17	WOS:A1992HK00500007
J	Caldwell, SA; Jackson, SR; Shahriari, KS; Lynch, TP; Sethi, G; Walker, S; Vosseller, K; Reginato, MJ				Caldwell, S. A.; Jackson, S. R.; Shahriari, K. S.; Lynch, T. P.; Sethi, G.; Walker, S.; Vosseller, K.; Reginato, M. J.			Nutrient sensor O-GlcNAc transferase regulates breast cancer tumorigenesis through targeting of the oncogenic transcription factor FoxM1	ONCOGENE			English	Article						O-GlcNAc; OGT; FoxM1; breast cancer; glucose metabolism; p27(Kip1)	LINKED N-ACETYLGLUCOSAMINE; INSULIN-RESISTANCE; NUCLEOCYTOPLASMIC PROTEINS; GLYCOSYLATION; CELLS; BETA; PHOSPHORYLATION; INHIBITORS; EXPRESSION; GLUCOSE	Cancer cells upregulate glycolysis, increasing glucose uptake to meet energy needs. A small fraction of a cell's glucose enters the hexosamine biosynthetic pathway (HBP), which regulates levels of O-linked beta-N-acetylglucosamine (O-GlcNAc), a carbohydrate posttranslational modification of diverse nuclear and cytosolic proteins. We discovered that breast cancer cells upregulate the HBP, including increased O-GlcNAcation and elevated expression of O-GlcNAc transferase (OGT), which is the enzyme catalyzing the addition of O-GlcNAc to proteins. Reduction of O-GlcNAcation through RNA interference of OGT in breast cancer cells leads to inhibition of tumor growth both in vitro and in vivo and is associated with decreased cell-cycle progression and increased expression of the cell-cycle inhibitor p27(Kip1). Elevation of p27(Kip1) was associated with decreased expression and activity of the oncogenic transcription factor FoxM1, a known regulator of p27(Kip1) stability through transcriptional control of Skp2. Reducing O-GlcNAc levels in breast cancer cells decreased levels of FoxM1 protein and caused a decrease in multiple FoxM1-specific targets, including Skp2. Moreover, reducing O-GlcNAcation decreased cancer cell invasion and was associated with the downregulation of matrix metallo-proteinase- 2, a known FoxM1 target. Finally, pharmacological inhibition of OGT in breast cancer cells had similar anti-growth and anti-invasion effects. These findings identify O-GlcNAc as a novel mechanism through which alterations in glucose metabolism regulate cancer growth and invasion and suggest that OGT may represent novel therapeutic targets for breast cancer. Oncogene (2010) 29, 2831-2842; doi: 10.1038/onc.2010.41; published online 1 March 2010	[Caldwell, S. A.; Jackson, S. R.; Shahriari, K. S.; Lynch, T. P.; Sethi, G.; Vosseller, K.; Reginato, M. J.] Drexel Univ, Coll Med, Dept Biochem & Mol Biol, Philadelphia, PA 19104 USA; [Walker, S.] Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Drexel University; Harvard University; Harvard Medical School	Reginato, MJ (corresponding author), Drexel Univ, Coll Med, Dept Biochem & Mol Biol, 245 N 15th St, Philadelphia, PA 19104 USA.	Mauricio.Reginato@drexelmed.edu	Reginato, Mauricio/I-6155-2013; Sethi, Gautam/F-2372-2011	Reginato, Mauricio/0000-0002-7541-4094; Sethi, Gautam/0000-0002-8677-8475	Department of Defense [BC086596, BC074374]	Department of Defense(United States Department of Defense)	This study was supported by the Department of Defense, Breast Cancer Research Program Concept Award: BC086596 to MJR and Synergistic Idea Award: BC074374 to MJR and KV.	Bektas N, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-42; Boehmelt G, 2000, EMBO J, V19, P5092, DOI 10.1093/emboj/19.19.5092; Buse MG, 2002, AM J PHYSIOL-ENDOC M, V283, pE241, DOI 10.1152/ajpendo.00060.2002; Cheng XG, 2001, J BIOL CHEM, V276, P10570, DOI 10.1074/jbc.M010411200; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Comer FI, 1999, BBA-GEN SUBJECTS, V1473, P161, DOI 10.1016/S0304-4165(99)00176-2; Comer FI, 2001, ANAL BIOCHEM, V293, P169, DOI 10.1006/abio.2001.5132; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Duffy MJ, 2000, BREAST CANCER RES, V2, P252, DOI 10.1186/bcr65; Gallagher SM, 2007, CANCER RES, V67, P4182, DOI 10.1158/0008-5472.CAN-06-3184; Gartel AL, 2008, EXPERT OPIN THER TAR, V12, P663, DOI [10.1517/14728222.12.6.663, 10.1517/14728222.12.6.663 ]; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Gross BJ, 2005, J AM CHEM SOC, V127, P14588, DOI 10.1021/ja0555217; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; Hart GW, 2007, NATURE, V446, P1017, DOI 10.1038/nature05815; Housley MP, 2008, J BIOL CHEM, V283, P16283, DOI 10.1074/jbc.M802240200; Kawauchi K, 2009, P NATL ACAD SCI USA, V106, P3431, DOI 10.1073/pnas.0813210106; Laoukili J, 2008, CELL CYCLE, V7, P2720, DOI 10.4161/cc.7.17.6580; Liu F, 2004, P NATL ACAD SCI USA, V101, P10804, DOI 10.1073/pnas.0400348101; Liu MG, 2006, CANCER RES, V66, P3593, DOI 10.1158/0008-5472.CAN-05-2912; Lubas WA, 2000, J BIOL CHEM, V275, P10983, DOI 10.1074/jbc.275.15.10983; Ma RYM, 2005, J CELL SCI, V118, P795, DOI 10.1242/jcs.01657; Macauley MS, 2005, J BIOL CHEM, V280, P25313, DOI 10.1074/jbc.M413819200; Major ML, 2004, MOL CELL BIOL, V24, P2649, DOI 10.1128/MCB.24.7.2649-2661.2004; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; Marshall Stephen, 2006, Sci STKE, V2006, pre7; Myatt SS, 2008, NAT REV CANCER, V8, P244, DOI 10.1038/nrc2223-c2; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; O'Donnell N, 2004, MOL CELL BIOL, V24, P1680, DOI 10.1128/MCB.24.4.1680-1690.2004; Park HJ, 2008, MOL CELL BIOL, V28, P5162, DOI 10.1128/MCB.00387-08; Reginato MJ, 2005, MOL CELL BIOL, V25, P4591, DOI 10.1128/MCB.25.11.4591-4601.2005; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Roos MD, 1997, MOL CELL BIOL, V17, P6472, DOI 10.1128/MCB.17.11.6472; Rubio CA, 2003, EUR J CLIN INVEST, V33, P406, DOI 10.1046/j.1365-2362.2003.01151.x; Shaw RJ, 2006, CURR OPIN CELL BIOL, V18, P598, DOI 10.1016/j.ceb.2006.10.005; Slawson C, 2005, J BIOL CHEM, V280, P32944, DOI 10.1074/jbc.M503396200; Vosseller K, 2002, P NATL ACAD SCI USA, V99, P5313, DOI 10.1073/pnas.072072399; WANG XD, 2005, J ORGAN DYSFUNCT, V1, P2; Wang ZW, 2007, CANCER RES, V67, P8293, DOI 10.1158/0008-5472.CAN-07-1265; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; Wonsey DR, 2005, CANCER RES, V65, P5181, DOI 10.1158/0008-5472.CAN-04-4059; Yakes FM, 2002, CANCER RES, V62, P4132; Yang WH, 2006, NAT CELL BIOL, V8, P1074, DOI 10.1038/ncb1470; Yang XY, 2008, NATURE, V451, P964, DOI 10.1038/nature06668; Zhu WJ, 2001, EMBO J, V20, P5999, DOI 10.1093/emboj/20.21.5999	47	277	300	0	65	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2010	29	19					2831	2842		10.1038/onc.2010.41	http://dx.doi.org/10.1038/onc.2010.41			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	595DW	20190804				2022-12-17	WOS:000277591900008
J	Mukhopadhyay, A; Banerjee, S; Stafford, LJ; Xia, CZ; Liu, MY; Aggarwal, BB				Mukhopadhyay, A; Banerjee, S; Stafford, LJ; Xia, CZ; Liu, MY; Aggarwal, BB			Curcumin-induced suppression of cell proliferation correlates with down-regulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation	ONCOGENE			English	Article						curcumin; cyclin D1; CDK4; Rb; retinoic acid; NF-kappa B	NF-KAPPA-B; HUMAN BREAST-CANCER; MAMMARY-GLAND DEVELOPMENT; HUMAN LEUKEMIA-CELLS; HEPATOCELLULAR-CARCINOMA; TRANSGENIC MICE; KINASE-ACTIVITY; APOPTOSIS; ACTIVATION; OVEREXPRESSION	Cyclin D1 is a proto-oncogene that is overexpressed in many cancers including breast and prostate. It plays a role in cell proliferation through activation of cyclin-dependent kinases. Curcumin, a diferuloylmethane, is a chemopreventive agent known to inhibit the proliferation of several breast and prostate cancer cell lines. It is possible that the effect of curcumin is mediated through the regulation of cyclin D1. In the present report we show that inhibition of the proliferation of various prostate, breast and squamous cell carcinoma cell lines by curcumin correlated with the down-regulation of the expression of cyclin D1 protein. In comparison, the down-regulation by curcumin of cyclin D2 and cyclin D3 was found only in selective cell lines. The suppression of cyclin D1 by curcumin led to inhibition of CDK4-mediated phosphorylation of retinoblastoma protein. We found that curcumin-induced down-regulation of cyclin D1 was inhibited by lactacystin, an inhibitor of 26S proteosome, suggesting that curcumin represses cyclin D1 expression by promoting proteolysis. We found that curcumin also down-regulated mRNA expression, thus suggesting transcriptional regulation. Curcumin also inhibited the activity of the cyclin D1 promoter-dependent reporter gene expression. Overall our results suggest that curcumin down-regulates cyclin D1 expression through activation of both transcriptional and post-transcriptional mechanisms, and this may contribute to the antiproliferative effects of curcumin against various cell types.	Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Cytokine Res Lab, Houston, TX 77030 USA; Texas A&M Univ, Hlth Sci Ctr, Dept Med Biochem & Genet, Houston, TX 77030 USA; Texas A&M Univ, Hlth Sci Ctr, Inst Biosci & Technol, Houston, TX 77030 USA; Texas A&M Univ, Hlth Sci Ctr, Ctr Canc Biol & Nutr, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Cytokine Res Lab, 1515 Holcombe Blvd,Box 143, Houston, TX 77030 USA.		Aggarwal, Bharat B/G-3388-2013	Liu, Mingyao/0000-0001-7339-5048				ADELAIDE J, 1995, BRIT J CANCER, V71, P64, DOI 10.1038/bjc.1995.13; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Anto RJ, 2002, CARCINOGENESIS, V23, P143, DOI 10.1093/carcin/23.1.143; Arber N, 1996, GASTROENTEROLOGY, V110, P669, DOI 10.1053/gast.1996.v110.pm8608874; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARTKOVA J, 1995, CANCER RES, V55, P949; BARTKOVA J, 1994, INT J CANCER, V58, P568, DOI 10.1002/ijc.2910580420; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; Bhaumik S, 1999, FEBS LETT, V456, P311, DOI 10.1016/S0014-5793(99)00969-2; Caputi M, 1999, AM J RESP CELL MOL, V20, P746, DOI 10.1165/ajrcmb.20.4.3366; Chen H, 1999, ANTICANCER RES, V19, P3675; Chen HW, 1998, BRIT J PHARMACOL, V124, P1029, DOI 10.1038/sj.bjp.0701914; Deane NG, 2001, CANCER RES, V61, P5389; DICKSON C, 1995, CANCER LETT, V90, P43, DOI 10.1016/0304-3835(94)03676-A; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Drobnjak M, 2000, CLIN CANCER RES, V6, P1891; DUCKETT CS, 1995, J BIOL CHEM, V270, P18836, DOI 10.1074/jbc.270.32.18836; Evron E, 2001, CANCER RES, V61, P2782; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Fantl V, 2000, ADV EXP MED BIOL, V480, P1; GILLETT C, 1994, CANCER RES, V54, P1812; Gumbiner LM, 1999, PROSTATE, V38, P40, DOI 10.1002/(SICI)1097-0045(19990101)38:1<40::AID-PROS5>3.0.CO;2-I; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Han SS, 1999, CLIN IMMUNOL, V93, P152, DOI 10.1006/clim.1999.4769; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Haridas V, 1998, J IMMUNOL, V160, P3152; Henry DO, 2000, MOL CELL BIOL, V20, P8084, DOI 10.1128/MCB.20.21.8084-8092.2000; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Jiang MC, 1996, NUTR CANCER, V26, P111, DOI 10.1080/01635589609514468; Jobin C, 1999, J IMMUNOL, V163, P3474; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Kumar A, 1998, BIOCHEM PHARMACOL, V55, P775, DOI 10.1016/S0006-2952(97)00557-1; Kuo ML, 1996, BBA-MOL BASIS DIS, V1317, P95, DOI 10.1016/S0925-4439(96)00032-4; Langenfeld J, 1997, P NATL ACAD SCI USA, V94, P12070, DOI 10.1073/pnas.94.22.12070; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Liu MY, 1996, NATURE, V382, P83, DOI 10.1038/382083a0; LUKAS J, 1995, ONCOGENE, V10, P2125; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Mehta K, 1997, ANTI-CANCER DRUG, V8, P470, DOI 10.1097/00001813-199706000-00010; NISHIDA N, 1994, CANCER RES, V54, P3107; Pervin S, 2001, P NATL ACAD SCI USA, V98, P3583, DOI 10.1073/pnas.041603998; Piwocka K, 1999, EXP CELL RES, V249, P299, DOI 10.1006/excr.1999.4480; Plummer SM, 1999, ONCOGENE, V18, P6013, DOI 10.1038/sj.onc.1202980; Ramachandran C, 1999, BREAST CANCER RES TR, V54, P269, DOI 10.1023/A:1006170224414; Ranjan D, 1999, J SURG RES, V87, P1, DOI 10.1006/jsre.1999.5719; Sauter ER, 1999, CANCER RES, V59, P4876; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Sicinski P, 1997, J MAMMARY GLAND BIOL, V2, P335, DOI 10.1023/A:1026391128117; Simon A, 1998, CANCER LETT, V129, P111, DOI 10.1016/S0304-3835(98)00092-5; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Vrana JA, 2001, BLOOD, V97, P2105, DOI 10.1182/blood.V97.7.2105; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500	53	277	298	2	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 12	2002	21	57					8852	8861		10.1038/sj.onc.1206048	http://dx.doi.org/10.1038/sj.onc.1206048			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483537				2022-12-17	WOS:000179734400018
J	Thomas, A; ElRouby, S; Reed, JC; Krajewski, S; Silber, R; Potmesil, M; Newcomb, EW				Thomas, A; ElRouby, S; Reed, JC; Krajewski, S; Silber, R; Potmesil, M; Newcomb, EW			Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: Relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance	ONCOGENE			English	Article						bcl-2; bax; chronic lymphocytic leukemia; drug resistance; apoptosis	DEATH; EXPRESSION; DIFFERENTIATION	We investigated the relationship among chemosensitivity to drug-induced apoptosis in vitro, the presence of p53 gene mutations, and the expression of bcl-2 and bax proteins in B-cells from B-cell chronic lymphocytic leukemia (B-CLL) patients. Apoptosis was induced with a camptothecin analogue, 9-amino-20(s)-camptothecin, or a purine analogue, fludarabine. Cell death was monitored by propidium iodide staining and FACS analysis. Drug-induced apoptosis in B-CLL cells was p53-independent. Immunoblot analysis of bcl-2 and bax expression revealed a correlation between drug-induced apoptosis and the ratio of endogenous levels of bcl-2 to bax proteins. B-CLL cells with none to low bcl-2/bax ratios were drug-sensitive as compared to cells with high ratios that were drug-resistant Prior to drug treatment, bax protein migrated as a single species of 21 kDa. Following drug-induced apoptosis, anti-bax specific protein complexes of 36-42 kDa were up-regulated. Using two-dimensional gel electrophoresis, bax complexes were disrupted under reducing conditions to reveal homo- and heterodimers of 18 and 21 kDa suggesting that disulfide interactions were required for complex formation. The de novo appearance of the 18 kDa anti-bax specific protein together with its increased expression in drug-sensitive B-CLL B-cells undergoing cell death suggests a role for this protein in the regulation of apoptosis.	NYU, SCH MED, DEPT PATHOL, NEW YORK, NY 10016 USA; NYU, SCH MED, DEPT MED, NEW YORK, NY 10016 USA; NYU, SCH MED, DEPT RADIOL, NEW YORK, NY 10016 USA; KAPLAN COMPREHENS CANC CTR, NEW YORK, NY 10016 USA; LA JOLLA CANC RES FDN, CANC RES CTR, LA JOLLA, CA 92037 USA	New York University; New York University; New York University; Sanford Burnham Prebys Medical Discovery Institute					NATIONAL CANCER INSTITUTE [U10CA060138] Funding Source: NIH RePORTER; NCI NIH HHS [CA-60138] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APTE SS, 1995, GENOMICS, V26, P592, DOI 10.1016/0888-7543(95)80180-T; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; DOHNER H, 1995, BLOOD, V85, P1580, DOI 10.1182/blood.V85.6.1580.bloodjournal8561580; ELROUBY S, 1993, BLOOD, V82, P3452; FOON KA, 1990, ANN INTERN MED, V113, P525, DOI 10.7326/0003-4819-113-7-525; FRANKEL RH, 1992, CANCER RES, V52, P1427; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HANADA M, 1993, BLOOD, V82, P1820; HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059; KORSMEYER SJ, 1992, BLOOD, V80, P879; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MAPARA MY, 1993, EUR J IMMUNOL, V23, P702, DOI 10.1002/eji.1830230320; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; ROBERTSON LE, 1993, BLOOD, V81, P143; SCHENA M, 1992, BLOOD, V79, P2981; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SILBER R, 1994, BLOOD, V84, P3440; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; WATTEL E, 1994, BLOOD, V84, P3148, DOI 10.1182/blood.V84.9.3148.3148; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; ZHAN QM, 1994, ONCOGENE, V9, P3743	31	277	287	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					1055	1062						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649796				2022-12-17	WOS:A1996UA88400013
J	Martinez, I; Gardiner, AS; Board, KF; Monzon, FA; Edwards, RP; Khan, SA				Martinez, I.; Gardiner, A. S.; Board, K. F.; Monzon, F. A.; Edwards, R. P.; Khan, S. A.			Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells	ONCOGENE			English	Article						HPVs; microRNA; cervical cancer; oncogene	TUMOR-SUPPRESSOR; GENE-EXPRESSION; GENOMIC INSTABILITY; CANCER; LAMININ-5; P53; E6; PROTEIN; HPV; E7	Human papillomaviruses (HPVs) are involved in the pathogenesis of cancer of the cervix (CaCx). MicroRNA (miRNA) expression analysis using Ambion (Austin, TX, USA) arrays showed that three miRNAs were over-expressed and 24 underexpressed in cervical cell lines containing integrated HPV-16 DNA compared to the normal cervix. Furthermore, nine miRNAs were overexpressed and one underexpressed in integrated HPV-16 cell lines compared to the HPV-negative CaCx cell line C-33A. Based on microarray and/or quantitative realtime PCR and northern blot analyses, microRNA-218 (miR-218) was specifically underexpressed in HPV-positive cell lines, cervical lesions and cancer tissues containing HPV-16 DNA compared to both C-33A and the normal cervix. Expression of the E6 oncogene of high-risk HPV-16, but not that of low-risk HPV-6, reduced miR-218 expression, and conversely, RNA interference of E6/E7 oncogenes in an HPV-16-positive cell line increased miR-218 expression. We also demonstrate that the epithelial cell-specific marker LAMB3 is a target of miR-218. We also show that LAMB3 expression is increased in the presence of the HPV-16 E6 oncogene and this effect is mediated through miR-218. These findings may contribute to a better understanding of the molecular mechanisms involved in cervical carcinogenesis.	[Martinez, I.; Gardiner, A. S.; Board, K. F.; Khan, S. A.] Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA; [Monzon, F. A.] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA; [Monzon, F. A.] Univ Pittsburgh, Sch Med, Ctr Pathol Informat, Pittsburgh, PA 15261 USA; [Edwards, R. P.] Univ Pittsburgh, Sch Med, Magee Womens Res Inst, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute	Khan, SA (corresponding author), Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Room E 1240 Biomed Sci Tower,200 Lothrop St, Pittsburgh, PA 15261 USA.	khan@pitt.edu		Gardiner, Amy S./0000-0002-8179-4919	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [F31DE019028] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM065100] Funding Source: NIH RePORTER; NIDCD NIH HHS [DC016406] Funding Source: Medline; NIDCR NIH HHS [F31 DE019028, F31 DE019028-01A1, DE019028] Funding Source: Medline; NIGMS NIH HHS [5T32GM065100, T32 GM065100] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alazawi W, 2002, CANCER RES, V62, P6959; BAND V, 1993, EMBO J, V12, P1847, DOI 10.1002/j.1460-2075.1993.tb05833.x; Bandres E, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-29; Calaluce R, 2004, NEOPLASIA, V6, P468, DOI 10.1593/neo.03499; Calin GA, 2006, CANCER RES, V66, P7390, DOI 10.1158/0008-5472.CAN-06-0800; Culp TD, 2006, J VIROL, V80, P8940, DOI 10.1128/JVI.00724-06; Cummins JM, 2006, P NATL ACAD SCI USA, V103, P3687, DOI 10.1073/pnas.0511155103; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Dallol A, 2002, CANCER RES, V62, P5874; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Hebner CM, 2006, REV MED VIROL, V16, P83, DOI 10.1002/rmv.488; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Jiang M, 2002, ONCOGENE, V21, P6041, DOI 10.1038/sj.onc.1205878; Kim VN, 2005, NAT REV MOL CELL BIO, V6, P376, DOI 10.1038/nrm1644; Kohlberger P, 2003, GYNECOL ONCOL, V89, P391, DOI 10.1016/S0090-8258(03)00086-6; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MANOS MM, 1994, J INFECT DIS, V170, P1096, DOI 10.1093/infdis/170.5.1096; Martinez I, 2007, EUR J CANCER, V43, P415, DOI 10.1016/j.ejca.2006.09.001; Massimi P, 1996, ONCOGENE, V12, P2325; Meissner JD, 1999, J GEN VIROL, V80, P1725, DOI 10.1099/0022-1317-80-7-1725; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; Piboonniyom SO, 2003, CANCER RES, V63, P476; Skyldberg B, 1999, J NATL CANCER I, V91, P1882, DOI 10.1093/jnci/91.21.1882; STANLEY MA, 1989, INT J CANCER, V43, P672, DOI 10.1002/ijc.2910430422; Tang S, 2006, J VIROL, V80, P4249, DOI 10.1128/JVI.80.9.4249-4263.2006; Thomas M, 1999, ONCOGENE, V18, P7690, DOI 10.1038/sj.onc.1202953; Xi YG, 2006, CLIN CANCER RES, V12, P2014, DOI 10.1158/1078-0432.CCR-05-1853; Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	33	276	306	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2008	27	18					2575	2582		10.1038/sj.onc.1210919	http://dx.doi.org/10.1038/sj.onc.1210919			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	289LW	17998940	Green Accepted, Bronze			2022-12-17	WOS:000255057000007
J	Fan, F; Wey, JS; McCarty, MF; Belcheva, A; Liu, WB; Bauer, TW; Somcio, RJ; Wu, Y; Hooper, A; Hicklin, DJ; Ellis, LM				Fan, F; Wey, JS; McCarty, MF; Belcheva, A; Liu, WB; Bauer, TW; Somcio, RJ; Wu, Y; Hooper, A; Hicklin, DJ; Ellis, LM			Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells	ONCOGENE			English	Article						tyrosine kinase; angiogenesis; growth factor; colorectal cancer; signaling	BREAST-CANCER; TYROSINE KINASE; COLON-CANCER; TUMOR-CELLS; FACTOR VEGF; FLT-1; ANGIOGENESIS; PERMEABILITY; CARCINOMA; MIGRATION	Vascular endothelial growth factor ( VEGF) is associated with tumor angiogenesis and poor prognosis in human colorectal cancer (CRC). VEGF receptor-1 (VEGFR-1 or Flt-1) is a high-affinity receptor for VEGF and is typically considered specific to endothelial cells. Here we report the expression and function of VEGFR-1 in CRC cell lines. VEGFR-1 was expressed in all CRC cell lines studied as determined by RT-PCR, Western blot analysis, FACS, and ELISA. Treatment of the human CRC cell lines HT-29 and SW480 with VEGF-A ( a ligand for both VEGFR-1 and -2) or VEGF-B ( a ligand specific for VEGFR-1) led to activation of Erk-1/2, SAPK/JNK, and translocation of the p65 subunit of nuclear factor-kappa B into the nucleus. Both VEGF-A and -B led to significant induction of cell motility and invasiveness of CRC cells. Stimulation of cells with VEGF-A or -B also led to larger and more numerous colonies in soft agar. However, activation of VEGFR-1 did not increase CRC cell proliferation. In contrast to the previous paradigm that VEGFRs are not present on tumor cells of epithelial origin, we found that VEGFR-1 is present and functional on CRC cells, and activation by VEGF family ligands can activate processes involved in tumor progression and metastasis.	Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX USA; ImClone Syst Inc, New York, NY USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Eli Lilly	Ellis, LM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Box 444,1515 Holcombe Blvd, Houston, TX 77030 USA.	lellis@mdanderson.org			NCI NIH HHS [CA112390, CA16672] Funding Source: Medline; PHS HHS [T32] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA112390, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; Arora N, 1999, CANCER RES, V59, P183; Bachelder RE, 2003, CANCER RES, V63, P5230; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Bellamy WT, 1999, CANCER RES, V59, P728; BROWN LF, 1993, CANCER RES, V53, P4727; Chen WS, 2002, IN VIVO, V16, P439; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; DETMAR M, 1994, J EXP MED, V180, P1141, DOI 10.1084/jem.180.3.1141; Dias S, 2000, J CLIN INVEST, V106, P511, DOI 10.1172/JCI8978; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1; Folkman J, 2001, SEMIN ONCOL, V28, P536, DOI 10.1053/sonc.2001.29543; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Hahn D, 2000, J UROLOGY, V164, P506, DOI 10.1016/S0022-5347(05)67414-9; Hasan J, 2001, EXPERT OPIN BIOL TH, V1, P703; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Irrthum A, 2000, AM J HUM GENET, V67, P295, DOI 10.1086/303019; Jung Young D., 2001, Angiogenesis, V4, P155, DOI 10.1023/A:1012291524723; La Rosa S, 2003, HUM PATHOL, V34, P18, DOI 10.1053/hupa.2003.56; Lalla RV, 2003, ARCH OTOLARYNGOL, V129, P882, DOI 10.1001/archotol.129.8.882; LeCouter J, 2003, SCIENCE, V299, P890, DOI 10.1126/science.1079562; Liu WB, 2002, CANCER, V94, P934, DOI 10.1002/cncr.10122; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Masood R, 2001, BLOOD, V98, P1904, DOI 10.1182/blood.V98.6.1904; Mayr-Wohlfart U, 2002, BONE, V30, P472, DOI 10.1016/S8756-3282(01)00690-1; Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709; Parikh AA, 2004, AM J PATHOL, V164, P2139, DOI 10.1016/S0002-9440(10)63772-8; Patel N, 2003, J PHARMACOL EXP THER, V306, P838, DOI 10.1124/jpet.103.052167; Price DJ, 2001, CELL GROWTH DIFFER, V12, P129; Ryden L, 2003, BREAST CANCER RES TR, V82, P147, DOI 10.1023/B:BREA.0000004357.92232.cb; Shaheen RM, 2001, INT J ONCOL, V18, P221; Stoeltzing O, 2003, ANN SURG ONCOL, V10, P722, DOI 10.1245/ASO.2003.07.019; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; Von Marschall Z, 2000, GASTROENTEROLOGY, V119, P1358, DOI 10.1053/gast.2000.19578; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Zhukova LG, 2003, B EXP BIOL MED+, V135, P478, DOI 10.1023/A:1024975627843	38	276	300	4	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2005	24	16					2647	2653		10.1038/sj.onc.1208246	http://dx.doi.org/10.1038/sj.onc.1208246			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916BC	15735759				2022-12-17	WOS:000228356700006
J	Lee, JH; Han, SU; Cho, H; Jennings, B; Gerrard, B; Dean, M; Schmidt, L; Zbar, B; Vande Woude, GF				Lee, JH; Han, SU; Cho, H; Jennings, B; Gerrard, B; Dean, M; Schmidt, L; Zbar, B; Vande Woude, GF			A novel germ line juxtamembrane Met mutation in human gastric cancer	ONCOGENE			English	Article						gastric cancer; germ line; juxtamembrane Met mutation	HEPATOCYTE GROWTH-FACTOR; PAPILLARY RENAL CARCINOMAS; SCATTER FACTOR; TYROSINE KINASE; FACTOR RECEPTOR; C-MET; EPITHELIAL-CELLS; PROTOONCOGENE PRODUCT; SOMATIC MUTATIONS; TUMORIGENICITY	Activating mutations in the Met receptor tyrosine kinase, both germline and somatic, have been identified in human papillary renal cancer. Here we report a novel germline missense Met mutation, P1009S, in a patient with primary gastric cancer. The dosage of the mutant Met DNA was elevated in the tumor when compared to its matched normal DNA. Therefore, as with hereditary renal papillary cancer, the mutant Met allele may also be selectively duplicated in the tumor. Different from previously reported Met mutations, which occur in the tyrosine kinase domain, this missense mutation is located at the juxtamembrane domain, and is not constitutively activated. However, following treatment with HGF/SF, the P1009S mutant Met protein, expressed in NIH3T3 cells, displays increased and persistent tyrosine phosphorylation compared to the wild-type Met. Importantly, these cells also form colonies in soft agar, and are highly tumorigenic in athymic nude mice. A second nucleotide change in this region of Met, T1010I, was found in a breast cancer biopsy and a large cell lung cancer cell line. Although this previously reported 'polymorphism' did not stimulate NIH3T3 cell growth in soft agar, it was more active than the wild-type Met in the athymic nude mice tumorigenesis assay, suggesting that it may have effects on tumorigenesis. Met has been shown to be highly expressed in human gastric carcinoma cell lines, and our results raise the possibility that activating missense Met mutations could contribute to tumorigenesis of gastric cancer.	Van Andel Res Inst, Grand Rapids, MI 49503 USA; NCI, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; Ajou Univ, Sch Med, Dept Surg, Paldal Gu, Suwon 442749, South Korea; Ajou Univ, Sch Med, Dept Biochem, Paldal Gu, Suwon 442749, South Korea; Norfolk & Norwich Healthcare NHS Trust, Norwich, Norfolk, England; NCI, Frederick Canc Res & Dev Ctr, SAIC Frederick, Div Intramural Res Program, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, Lab Genom Divers, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, Immunobiol Lab, Frederick, MD 21702 USA	Van Andel Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Ajou University; Ajou University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Vande Woude, GF (corresponding author), Van Andel Res Inst, 333 Bostwick,NE, Grand Rapids, MI 49503 USA.		Dean, Michael/R-7501-2019; Dean, Michael C/G-8172-2012	Dean, Michael C/0000-0003-2234-0631; Cho, Hyeseong/0000-0002-4672-8887	OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-56000] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLUSCI S, 1994, ONCOGENE, V9, P1091; Blair D G, 1983, Prog Clin Biol Res, V119, P79; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Caldas C, 1999, J MED GENET, V36, P873; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; CREPALDI T, 1994, J CELL BIOL, V125, P313, DOI 10.1083/jcb.125.2.313; FALETTO DL, 1992, ONCOGENE, V7, P1149; GANDINO L, 1994, J BIOL CHEM, V269, P1815; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Guilford PJ, 1999, HUM MUTAT, V14, P249, DOI 10.1002/(SICI)1098-1004(1999)14:3<249::AID-HUMU8>3.0.CO;2-9; Higashio K, 1993, EXS, V65, P351; HONGYO T, 1993, NUCLEIC ACIDS RES, V21, P3637, DOI 10.1093/nar/21.16.3637; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1996, CELL GROWTH DIFFER, V7, P1805; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Jeffers M, 1996, ONCOGENE, V13, P853; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; Kanda H, 1993, Nihon Rinsho, V51, P380; Matturri L, 1998, ANTICANCER RES, V18, P2819; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; Olivero M, 1999, INT J CANCER, V82, P640, DOI 10.1002/(SICI)1097-0215(19990827)82:5<640::AID-IJC4>3.0.CO;2-6; Papkoff J, 1998, BIOCHEM BIOPH RES CO, V247, P851, DOI 10.1006/bbrc.1998.8888; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Park WS, 1999, CANCER RES, V59, P307; Pisani P, 1999, INT J CANCER, V83, P18, DOI 10.1002/(SICI)1097-0215(19990924)83:1&lt;18::AID-IJC5&gt;3.0.CO;2-M; PONZETTO C, 1991, ONCOGENE, V6, P553; RAO PH, 1993, DIAGN MOL PATHOL, V2, P264, DOI 10.1097/00019606-199303000-00035; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schmidt L, 1998, CANCER RES, V58, P1719; Schmidt L, 1999, ONCOGENE, V18, P2343, DOI 10.1038/sj.onc.1202547; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Tanyi J, 1999, Pathol Oncol Res, V5, P187, DOI 10.1053/paor.1999.0219; TSARFATY I, 1992, SCIENCE, V257, P1258, DOI 10.1126/science.1387731; Underhill PA, 1997, GENOME RES, V7, P996, DOI 10.1101/gr.7.10.996; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; Vigna E, 1999, ONCOGENE, V18, P4275, DOI 10.1038/sj.onc.1202791; Villa-Moruzzi E, 1998, BIOCHEM J, V336, P235, DOI 10.1042/bj3360235; Zhuang ZP, 1998, NAT GENET, V20, P66, DOI 10.1038/1727	47	276	292	0	10	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 12	2000	19	43					4947	4953		10.1038/sj.onc.1203874	http://dx.doi.org/10.1038/sj.onc.1203874			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363KF	11042681				2022-12-17	WOS:000089834300001
J	Palayoor, ST; Youmell, MY; Calderwood, SK; Coleman, CN; Price, BD				Palayoor, ST; Youmell, MY; Calderwood, SK; Coleman, CN; Price, BD			Constitutive activation of I kappa B kinase alpha and NF-kappa B in prostate cancer cells is inhibited by ibuprofen	ONCOGENE			English	Article						NF-kappa B; ibuprofen; prostate; tumor; IKK alpha; androgen	ANDROGEN RECEPTOR GENE; IKK-ALPHA; PHOSPHORYLATION; PROTEIN; BETA; SALICYLATE; EXPRESSION; APOPTOSIS; ASPIRIN; STIMULI	Apoptotic pathways controlled by the Rel/NF-kappa B family of transcription factors may regulate the response of cells to DNA damage. Here, we have examined the NF-kappa B status Of several prostate tumor cell lines. In the androgen-independent prostate tumor cells PC-3 and DU-145, the DNA-binding activity of NF-kappa B was constitutively activated and I kappa B-alpha levels were decreased, In contrast, the androgen-sensitive prostate tumor cell line LNCaP had low levels of NF-kappa B which were upregulated following exposure to cytokines or DNA damage, The activity of the I kappa B-alpha kinase, IKK alpha, which mediates NF-kappa B activation, was also measured. In PC-3 cells, IKK alpha activity was constitutively active, whereas LNCaP cells had minimal IKK alpha activity that was activated by cytokines. The anti-inflammatory agent ibuprofen inhibited the constitutive activation of NF-kappa B and IKK alpha in PC-3 and DU-145 cells, and blocked stimulated activation of NF-kappa B in LNCaP cells. However, ibuprofen did not directly inhibit I kappa B-alpha kinase, The results demonstrate that NF-kappa B is constitutively activated in the hormone-insensitive prostate tumor cell lines PC-3 and DU-145, but not in the hormone responsive LNCaP cell line. The constitutive activation of NF-kappa B in prostate tumor cells may increase expression of anti-apoptotic proteins, thereby decreasing the effectiveness of anti-tumor therapy and contributing to the development of the malignant phenotype.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Joint Ctr Radiat Therapy,Dept Adult Oncol, Boston, MA 02115 USA; NCI, Radiat Oncol Branch, Bethesda, MD 20892 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Price, BD (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Joint Ctr Radiat Therapy,Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA064585] Funding Source: NIH RePORTER; NCI NIH HHS [CA64585] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Apakama I, 1996, BRIT J CANCER, V74, P1258, DOI 10.1038/bjc.1996.526; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Basu S, 1998, BIOCHEM BIOPH RES CO, V247, P79, DOI 10.1006/bbrc.1998.8741; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; de Moissac D, 1998, J BIOL CHEM, V273, P23946, DOI 10.1074/jbc.273.37.23946; DEWITT D, 1995, CELL, V83, P345, DOI 10.1016/0092-8674(95)90109-4; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351; LASKA EM, 1986, CLIN PHARMACOL THER, V40, P1, DOI 10.1038/clpt.1986.129; Latchman DS, 1999, J CELL PHYSIOL, V179, P126; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; Nakajima Y, 1996, PROSTATE, V29, P296; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Palayoor ST, 1998, CLIN CANCER RES, V4, P763; Palvimo JJ, 1996, J BIOL CHEM, V271, P24151, DOI 10.1074/jbc.271.39.24151; PEREZ P, 1995, MOL CELL BIOL, V15, P3523; Soncin F, 1996, BIOCHEM BIOPH RES CO, V229, P479, DOI 10.1006/bbrc.1996.1829; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUPAKAR PC, 1995, J BIOL CHEM, V270, P837, DOI 10.1074/jbc.270.2.837; TEICHER BA, 1996, RADIAT ONCOL INVEST, V4, P221; TILLEY WD, 1990, CANCER RES, V50, P5382; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	31	276	292	0	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7389	7394		10.1038/sj.onc.1203160	http://dx.doi.org/10.1038/sj.onc.1203160			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602496				2022-12-17	WOS:000084119400026
J	ZerfassThome, K; Zwerschke, W; Mannhardt, B; Tindle, R; Botz, JW; JansenDurr, P				ZerfassThome, K; Zwerschke, W; Mannhardt, B; Tindle, R; Botz, JW; JansenDurr, P			Inactivation of the cdk inhibitor p27(KIP1) by the human papillomavirus type 16 E7 oncoprotein	ONCOGENE			English	Article						cdk2; cyclin A; cyclin E; HPV-16 E7; p27(KIP1)	HIGH-EFFICIENCY TRANSFORMATION; DEPENDENT KINASE INHIBITOR; GROWTH-FACTOR-BETA; HUMAN CYCLIN-E; CELL-CYCLE; HUMAN KERATINOCYTES; PHASE-TRANSITION; PROTEIN; GENE; ADENOVIRUS-E1A	Expression of the E7 oncogene of HPV-16 induces S phase entry of mammalian cells in the presence of antiproliferative signals. In particular, E7 can bypass G(0)/G(1) arrest in response to both serum withdrawal and loss of cell adhesion, two experimental conditions in which cell cycle progression is accompanied by elevated levels of the cdk inhibitor p27(KIP1). We show here that E7 can antagonize the ability of p27(KIP1) block cyclin E-associated kinase in vitro and to inhibit transcription from the cyclin A gene in transfection experiments. E7 associates with p27(KIP1) both in a reconstituted in vitro system and in extracts of mammalian cells, and association requires the C-terminal part of E7. The interaction between p27(KIP1) and E7 can also be demonstrated in a yeast two hybrid system. The data suggest that the ability of E7 to override certain forms of G(0)/G(1) arrest is mediated in part by binding to and subsequent inactivation of the cdk inhibitor p27(KIP1).	DEUTSCH KREBSFORSCHUNGSZENTRUM, FORSCH SCHWERPUNKT ANGEW TUMORVIROL, ABT 620, D-69120 HEIDELBERG, GERMANY; PRINCESS ALEXANDRA HOSP, LIONS HUMAN IMMUNOL LABS, BRISBANE, QLD 4102, AUSTRALIA	Helmholtz Association; German Cancer Research Center (DKFZ)			Jansen-Dürr, Pidder/ABG-2466-2020	Jansen-Dürr, Pidder/0000-0001-7771-3429; Zwerschke, Werner/0000-0003-1137-2953				BANKS L, 1990, ONCOGENE, V5, P833; BANKS L, 1990, ONCOGENE, V5, P1383; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CICCOLINI F, 1994, ONCOGENE, V9, P2633; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; JEWERS RJ, 1992, J VIROL, V66, P1329, DOI 10.1128/JVI.66.3.1329-1335.1992; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; MATSUMOTO K, 1990, J CELL PHYSIOL, V145, P95, DOI 10.1002/jcp.1041450114; MCINTYRE MC, 1993, J VIROL, V67, P3142, DOI 10.1128/JVI.67.6.3142-3150.1993; MIN SY, 1992, ONCOGENE, V7, P1531; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MUNGER K, 1989, J VIROL, V63, P4417; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PHELPS WC, 1992, J VIROL, V66, P2418, DOI 10.1128/JVI.66.4.2418-2427.1992; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Schulze A, 1996, MOL CELL BIOL, V16, P4632; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; ZERFASS K, 1995, J VIROL, V69, P6389, DOI 10.1128/JVI.69.10.6389-6399.1995; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; zur Hausen H, 1987, PAPILLOMAVIRUSES, P245; Zwerschke W, 1996, ONCOGENE, V12, P213	41	276	297	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	1996	13	11					2323	2330						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957073				2022-12-17	WOS:A1996VX10800004
J	MAGLIONE, D; GUERRIERO, V; VIGLIETTO, G; FERRARO, MG; APRELIKOVA, O; ALITALO, K; DELVECCHIO, S; LEI, KJ; CHOU, JY; PERSICO, MG				MAGLIONE, D; GUERRIERO, V; VIGLIETTO, G; FERRARO, MG; APRELIKOVA, O; ALITALO, K; DELVECCHIO, S; LEI, KJ; CHOU, JY; PERSICO, MG			2 ALTERNATIVE MESSENGER-RNAS CODING FOR THE ANGIOGENIC FACTOR, PLACENTA GROWTH-FACTOR (PIGF), ARE TRANSCRIBED FROM A SINGLE GENE OF CHROMOSOME-14	ONCOGENE			English	Article							ENDOTHELIAL-CELL MITOGEN; VASCULAR-PERMEABILITY FACTOR; FACTOR-A-CHAIN; ACID; CDNA; HYBRIDIZATION; SEQUENCES; INDUCTION	We have previously reported on the identification of a cDNA (placenta growth factor, PIGF) coding for a novel angiogenic factor expressed in placental tissue that is similar to vascular permeability factor/vascular endothelial growth factor (VPF/VEGF). Biochemical and functional characterization of PIGF derived from transfected COS-1 celts revealed that it is a glycosylated dimeric secreted protein able to stimulate endothelial cell growth in vitro. Here, we report the isolation and characterization of the PIGF gene located on chromosome 14. At least two different mRNAs are produced from this single-copy gene in different cell lines and tissues. Sequence comparison of the polypeptides encoded by the two different isolated cDNAs indicates that they are identical except for the insertion of a highly basic 21 amino acid stretch at the carboxyl end of the protein. RNA expression analysis of several tissues, tumors and cell tines indicates differential distribution of the two PlGF mRNAs. Finally, preliminary results indicate that the PlGF gene has been conserved in evolution, since the human PlGF cDNA hybridizes to sequences present in the genomic DNA of Drosophila, Xenopus, chicken and mouse.	CNR,INT INST GENET & BIOPHYS,VIA G MARCONI 12,I-80125 NAPLES,ITALY; SIFI SPA,I-95020 LAVINAIO,ITALY; UNIV HELSINKI,DEPT PATHOL,SF-00290 HELSINKI 29,FINLAND; FDN G PASCALE,IST NAZL STUDIO CURA TUMORI,I-80131 NAPLES,ITALY; NICHHD,HUMAN GENET LAB,BETHESDA,MD 20892	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); University of Helsinki; IRCCS Fondazione Pascale; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)			Alitalo, Kari K/J-5013-2014; Viglietto, Giuseppe/AAC-2852-2019; Del Vecchio, Silvana/F-4972-2012	Alitalo, Kari K/0000-0002-7331-0902; Viglietto, Giuseppe/0000-0003-2327-7515; DEL VECCHIO, Silvana/0000-0002-5466-1213				AUSPRUNK D, 1977, MICROVASC RES, V14, P52; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BONTHRON DT, 1988, P NATL ACAD SCI USA, V85, P1492, DOI 10.1073/pnas.85.5.1492; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; CONNOLLY DT, 1989, J BIOL CHEM, V264, P20017; DAVIDSON RL, 1976, SOMAT CELL GENET, V2, P165, DOI 10.1007/BF01542629; DONO R, 1991, AM J HUM GENET, V49, P555; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; HART IR, 1992, LANCET, V339, P1453, DOI 10.1016/0140-6736(92)92039-I; HATTORI M, 1985, NUCLEIC ACIDS RES, V13, P7913; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KOHLER PO, 1971, J CLIN ENDOCR METAB, V32, P683, DOI 10.1210/jcem-32-5-683; LEI KJ, 1992, MOL ENDOCRINOL, V6, P703, DOI 10.1210/me.6.5.703; LERACH H, 1977, BIOCHEMISTRY-US, V16, P4743; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MAGLIONE D, 1992, IN PRESS GROWTH FACT; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; PLOUZEK CA, 1991, ENDOCRINOLOGY, V129, P950, DOI 10.1210/endo-129-2-950; RAINES EW, 1992, J CELL BIOL, V116, P533, DOI 10.1083/jcb.116.2.533; RISAU W, 1990, Progress in Growth Factor Research, V2, P71, DOI 10.1016/0955-2235(90)90010-H; ROCCHI M, 1986, HUMAN GEET, V74; RORSMAN F, 1988, MOL CELL BIOL, V8, P571, DOI 10.1128/MCB.8.2.571; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; TISHER E, 1991, J BIOL CHEM, V266, P11974; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WESTERMARK B, 1991, CANCER RES, V51, P5087	35	276	314	0	18	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					925	931						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	7681160				2022-12-17	WOS:A1993KT22000014
J	Huang, B; Zhao, J; Unkeless, JC; Feng, ZH; Xiong, H				Huang, B.; Zhao, J.; Unkeless, J. C.; Feng, Z. H.; Xiong, H.			TLR signaling by tumor and immune cells: a double-edged sword	ONCOGENE			English	Review						TLR signaling; tumor; endogenous ligand	TOLL-LIKE RECEPTORS; MOBILITY GROUP BOX-1; HEAT-SHOCK PROTEINS; DOUBLE-STRANDED-RNA; LUNG-CANCER CELLS; NF-KAPPA-B; ENDOGENOUS LIGANDS; SEQUENCE VARIANTS; DENDRITIC CELLS; CUTTING EDGE	The tumor cell signaling pathways that trigger the uncontrolled proliferation, resistance to apoptosis, metastasis and escape from immune surveillance are partially understood. Toll-like receptors (TLRs), which recognize a variety of pathogen-associated molecular patterns, are centrally involved in the initiation of the innate and adaptive immune responses. However, recent evidence shows that functional TLRs are also expressed on a wide variety of tumors suggesting that TLRs may play important roles in tumor biology. Activation of tumor cell TLRs not only promotes tumor cell proliferation and resistance to apoptosis, but also enhances tumor cell invasion and metastasis by regulating metalloproteinases and integrins. Moreover, the activation of TLR signaling in tumor cells induces the synthesis of proinflammatory factors and immunosuppressive molecules, which enhance the resistance of tumor cells to cytotoxic lymphocyte attack and lead to immune evasion. Thus, the neoplastic process may usurp TLR signaling pathways to advance cancer progression, which suggests that targeting tumor TLR signaling pathways may open novel therapeutic avenues.	[Unkeless, J. C.; Xiong, H.] Mt Sinai Sch Med, Inst Immunol, New York, NY 10029 USA; [Huang, B.; Feng, Z. H.] Tongji Med Coll, Dept Biochem & Mol Biol, Wuhan, Peoples R China; [Zhao, J.] Tongji Med Coll, Dept Gynecol & Obstet, Wuhan, Peoples R China	Icahn School of Medicine at Mount Sinai; Huazhong University of Science & Technology; Huazhong University of Science & Technology	Xiong, H (corresponding author), Mt Sinai Sch Med, Inst Immunol, New York, NY 10029 USA.	tjhuangbo@yahoo.com; huabao.xiong@mssm.eduor			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK072201] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01 DK72201] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abiko Y, 1999, CANCER LETT, V143, P37, DOI 10.1016/S0304-3835(99)00171-8; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; Andersen MH, 2006, J INVEST DERMATOL, V126, P32, DOI 10.1038/sj.jid.5700001; Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; Barrat FJ, 2005, J EXP MED, V202, P1131, DOI 10.1084/jem.20050914; Beg AA, 2002, TRENDS IMMUNOL, V23, P509, DOI 10.1016/S1471-4906(02)02317-7; Biragyn A, 2002, SCIENCE, V298, P1025, DOI 10.1126/science.1075565; Bohnhorst J, 2006, LEUKEMIA, V20, P1138, DOI 10.1038/sj.leu.2404225; Boule MW, 2004, J EXP MED, V199, P1631, DOI 10.1084/jem.20031942; Camilo R, 2006, HUM PATHOL, V37, P542, DOI 10.1016/j.humpath.2005.12.019; Chen YC, 2005, CANCER RES, V65, P11771, DOI 10.1158/0008-5472.CAN-05-2078; Cheng I, 2007, CANCER EPIDEM BIOMAR, V16, P352, DOI 10.1158/1055-9965.EPI-06-0429; Ciocca DR, 2005, CELL STRESS CHAPERON, V10, P86, DOI 10.1379/CSC-99r.1; Craft N, 2005, J IMMUNOL, V175, P1983, DOI 10.4049/jimmunol.175.3.1983; Dan HC, 2004, ONCOGENE, V23, P706, DOI 10.1038/sj.onc.1207171; Dan HC, 2004, J BIOL CHEM, V279, P5405, DOI 10.1074/jbc.M312044200; Deane JA, 2006, J IMMUNOL, V177, P6573, DOI 10.4049/jimmunol.177.10.6573; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Droemann D, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-1; Ehlers M, 2007, TRENDS IMMUNOL, V28, P74, DOI 10.1016/j.it.2006.12.006; Ellerman JE, 2007, CLIN CANCER RES, V13, P2836, DOI 10.1158/1078-0432.CCR-06-1953; Ganz T, 1997, SEMIN HEMATOL, V34, P343; Gotte M, 2006, CANCER RES, V66, P10233, DOI 10.1158/0008-5472.CAN-06-1464; Gratas C, 1998, CANCER RES, V58, P2057; Guillot L, 2002, J IMMUNOL, V168, P5989, DOI 10.4049/jimmunol.168.12.5989; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harmey JH, 2002, INT J CANCER, V101, P415, DOI 10.1002/ijc.10632; Hassan F, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-281; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; He WG, 2007, MOL IMMUNOL, V44, P2850, DOI 10.1016/j.molimm.2007.01.022; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hold GL, 2007, GASTROENTEROLOGY, V132, P905, DOI 10.1053/j.gastro.2006.12.026; Huang B, 2005, CANCER RES, V65, P5009, DOI 10.1158/0008-5472.CAN-05-0784; Huang B, 2007, CANCER RES, V67, P4346, DOI 10.1158/0008-5472.CAN-06-4067; Iino N, 2007, CELL TISSUE RES, V328, P355, DOI 10.1007/s00441-006-0343-9; Ilvesaro JM, 2007, PROSTATE, V67, P774, DOI 10.1002/pros.20562; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Jego G, 2006, LEUKEMIA, V20, P1130, DOI 10.1038/sj.leu.2404226; Johnson GB, 2002, J IMMUNOL, V168, P5233, DOI 10.4049/jimmunol.168.10.5233; Kabelitz D, 2007, CURR OPIN IMMUNOL, V19, P39, DOI 10.1016/j.coi.2006.11.007; Kariko K, 2004, J BIOL CHEM, V279, P12542, DOI 10.1074/jbc.M310175200; Kawai T, 2005, CURR OPIN IMMUNOL, V17, P338, DOI 10.1016/j.coi.2005.02.007; Kelly MG, 2006, CANCER RES, V66, P3859, DOI 10.1158/0008-5472.CAN-05-3948; Khazaie K, 2006, SEMIN CANCER BIOL, V16, P124, DOI 10.1016/j.semcancer.2005.11.006; Kol A, 2000, J IMMUNOL, V164, P13, DOI 10.4049/jimmunol.164.1.13; Krieg AM, 2007, J CLIN INVEST, V117, P1184, DOI 10.1172/JCI31414; Lee J, 2003, P NATL ACAD SCI USA, V100, P6646, DOI 10.1073/pnas.0631696100; Lee JW, 2007, MOL CARCINOGEN, V46, P941, DOI 10.1002/mc.20325; Li MO, 2006, ANNU REV IMMUNOL, V24, P99, DOI 10.1146/annurev.immunol.24.021605.090737; Liu HY, 2006, P NATL ACAD SCI USA, V103, P7048, DOI 10.1073/pnas.0601554103; Liu Y, 2007, INT J CANCER, V121, P184, DOI 10.1002/ijc.22644; Lizee G, 2006, CLIN CANCER RES, V12, P4794, DOI 10.1158/1078-0432.CCR-06-0944; Marshak-Rothstein A, 2006, NAT REV IMMUNOL, V6, P823, DOI 10.1038/nri1957; Mellor AL, 2005, J IMMUNOL, V175, P5601, DOI 10.4049/jimmunol.175.9.5601; Merrell MA, 2006, MOL CANCER RES, V4, P437, DOI 10.1158/1541-7786.MCR-06-0007; Miyake K, 2007, SEMIN IMMUNOL, V19, P3, DOI 10.1016/j.smim.2006.12.002; Molteni M, 2006, CANCER LETT, V235, P75, DOI 10.1016/j.canlet.2005.04.006; Munn DH, 2007, J CLIN INVEST, V117, P1147, DOI 10.1172/JCI31178; Nieters A, 2006, GENES IMMUN, V7, P615, DOI 10.1038/sj.gene.6364337; O'Neill LAJ, 2006, CURR OPIN IMMUNOL, V18, P3, DOI 10.1016/j.coi.2005.11.012; Ohara T, 2006, INT J MOL MED, V18, P59; Okamoto M, 2006, J IMMUNOTHER, V29, P78, DOI 10.1097/01.cji.0000192106.32206.30; Okamura Y, 2001, J BIOL CHEM, V276, P10229, DOI 10.1074/jbc.M100099200; Park JS, 2004, J BIOL CHEM, V279, P7370, DOI 10.1074/jbc.M306793200; Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231; Pashenkov M, 2006, J CLIN ONCOL, V24, P5716, DOI 10.1200/JCO.2006.07.9129; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Rifkin IR, 2005, IMMUNOL REV, V204, P27, DOI 10.1111/j.0105-2896.2005.00239.x; Roelofs MF, 2006, J IMMUNOL, V176, P7021, DOI 10.4049/jimmunol.176.11.7021; Rouas-Freiss N, 2003, SEMIN CANCER BIOL, V13, P325, DOI 10.1016/S1044-579X(03)00023-3; Ru LB, 2005, ARTHRITIS RHEUM-US, V52, P2936, DOI 10.1002/art.21238; Rybarczyk BJ, 2000, CANCER RES, V60, P2033; Sanderson RD, 2004, MATRIX BIOL, V23, P341, DOI 10.1016/j.matbio.2004.08.004; Schmausser B, 2005, INT J MED MICROBIOL, V295, P179, DOI 10.1016/j.ijmm.2005.02.009; Serafini P, 2006, SEMIN CANCER BIOL, V16, P53, DOI 10.1016/j.semcancer.2005.07.005; Singh-Jasuja H, 2000, EUR J IMMUNOL, V30, P2211, DOI 10.1002/1521-4141(2000)30:8<2211::AID-IMMU2211>3.0.CO;2-0; Sioud M, 2006, TRENDS MOL MED, V12, P167, DOI 10.1016/j.molmed.2006.02.004; Smiley ST, 2001, J IMMUNOL, V167, P2887, DOI 10.4049/jimmunol.167.5.2887; Song C, 2006, CANCER BIOL THER, V5, P1285, DOI 10.4161/cbt.5.10.3304; Sun JL, 2005, JNCI-J NATL CANCER I, V97, P525, DOI 10.1093/jnci/dji070; Sutmuller RPM, 2006, J CLIN INVEST, V116, P485, DOI 10.1172/JCI25439; Szczepanski M, 2007, EUR ARCH OTO-RHINO-L, V264, P525, DOI 10.1007/s00405-006-0215-7; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Termeer C, 2002, J EXP MED, V195, P99, DOI 10.1084/jem.20001858; Tsan MF, 2004, J LEUKOCYTE BIOL, V76, P514, DOI 10.1189/jlb.0304127; Tsan MF, 2007, J ENDOTOXIN RES, V13, P6, DOI 10.1177/0968051907078604; Vicari AP, 2002, SEMIN CANCER BIOL, V12, P33, DOI 10.1006/scbi.2001.0400; Wang HY, 2007, CURR OPIN IMMUNOL, V19, P217, DOI 10.1016/j.coi.2007.02.004; Wang JH, 2003, J IMMUNOL, V170, P795, DOI 10.4049/jimmunol.170.2.795; Whitmore MM, 2004, CANCER RES, V64, P5850, DOI 10.1158/0008-5472.CAN-04-0063; Whitmore MM, 2001, CANCER IMMUNOL IMMUN, V50, P503, DOI 10.1007/s002620100227; Wingender G, 2006, EUR J IMMUNOL, V36, P12, DOI 10.1002/eji.200535602; Wu JD, 2004, J CLIN INVEST, V114, P560, DOI 10.1172/JCI200422206; Xu QB, 2002, ARTERIOSCL THROM VAS, V22, P1547, DOI 10.1161/01.ATV.0000029720.59649.50; Yang YP, 2004, NAT IMMUNOL, V5, P508, DOI 10.1038/ni1059; Yu H, 2007, NAT REV IMMUNOL, V7, P41, DOI 10.1038/nri1995; Yuan ZQ, 2003, J BIOL CHEM, V278, P23432, DOI 10.1074/jbc.M302674200; Zheng SL, 2004, CANCER RES, V64, P2918, DOI 10.1158/0008-5472.CAN-03-3280; Zhou XX, 2006, CANCER EPIDEM BIOMAR, V15, P862, DOI 10.1158/1055-9965.EPI-05-0874	102	275	311	0	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2008	27	2					218	224		10.1038/sj.onc.1210904	http://dx.doi.org/10.1038/sj.onc.1210904			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248OO	18176603				2022-12-17	WOS:000252163600008
J	Monk, M; Holding, C				Monk, M; Holding, C			Human embryonic genes re-expressed in cancer cells	ONCOGENE			English	Article						human developmental genes; human preimplantation embryo; OCT4; embryo/cancer genes; cancer gene expression	PRIMORDIAL GERM-CELLS; DNA METHYLATION; 5-METHYLCYTOSINE CONTENT; PREIMPLANTATION EMBRYOS; ENDOGENOUS RETROVIRUSES; MOUSE EMBRYOS; SEQUENCES; CULTURE; LINE; HYPOMETHYLATION	Human preimplantation embryonic cells are similar in phenotype to cancer cells. Both types of cell undergo deprogramming to a proliferative stem cell state and become potentially immortal and invasive. To investigate the hypothesis that embryonic genes are re-expressed in cancer cells, we prepare amplified cDNA from human individual preimplantation embryos and isolate embryo-specific sequences. We show that three novel embryonic genes, and also the known gene, OCT4, are expressed in human tumours but not expressed in normal somatic tissues. Genes specific to this unique phase of the human life cycle and not expressed in somatic cells may have greater potential for targeting in cancer treatment.	Inst Child Hlth, Mol Embryol Unit, London WC1N 1EH, England	University of London; University College London	Monk, M (corresponding author), Inst Child Hlth, Mol Embryol Unit, 30 Guilford St, London WC1N 1EH, England.		Pillay, Nischalan/F-9536-2012		MRC [G9900837, G9826762] Funding Source: UKRI; Medical Research Council [G9900837, G9826762] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ABDELRAHMAN B, 1995, HUM REPROD, V10, P2787, DOI 10.1093/oxfordjournals.humrep.a135792; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Blau HM, 2001, CELL, V105, P829, DOI 10.1016/S0092-8674(01)00409-3; BRANCIFORTE D, 1994, MOL CELL BIOL, V14, P2584, DOI 10.1128/MCB.14.4.2584; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; FEINBERG AP, 1988, CANCER RES, V48, P1159; FUJIMOTO T, 1977, ANAT REC, V188, P315, DOI 10.1002/ar.1091880305; GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883; Gilboa E, 1999, IMMUNITY, V11, P263, DOI 10.1016/S1074-7613(00)80101-6; GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435; Goto T, 1999, MOL HUM REPROD, V5, P851, DOI 10.1093/molehr/5.9.851; Holding C, 2000, MOL HUM REPROD, V6, P801, DOI 10.1093/molehr/6.9.801; HSIEH LL, 1987, CANCER RES, V47, P3421; Jin TR, 1999, INT J CANCER, V81, P104, DOI 10.1002/(SICI)1097-0215(19990331)81:1<104::AID-IJC18>3.0.CO;2-Q; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jurgens B, 1996, CANCER RES, V56, P5698; KARLIN S, 1990, P NATL ACAD SCI USA, V87, P2264, DOI 10.1073/pnas.87.6.2264; KARLIN S, 1993, P NATL ACAD SCI USA, V90, P5873, DOI 10.1073/pnas.90.12.5873; KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594; KUFF EL, 1988, ADV CANCER RES, V51, P183, DOI 10.1016/S0065-230X(08)60223-7; KUFF EL, 1990, CANCER CELL-MON REV, V2, P398; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; Mager DL, 1999, GENOMICS, V59, P255, DOI 10.1006/geno.1999.5877; MATSUI Y, 1992, CELL, V70, P841, DOI 10.1016/0092-8674(92)90317-6; MCMAHON A, 1983, J EMBRYOL EXP MORPH, V74, P207; MONK M, 1990, PHILOS T R SOC B, V326, P299, DOI 10.1098/rstb.1990.0013; MONK M, 1991, DEVELOPMENT, V112, P189; Monk M, 2001, INT J DEV BIOL, V45, P497; MONK M, 1987, DEVELOPMENT, V99, P371; P Liang, 1997, DIFFERENTIAL DISPLAY; PACKER AI, 1993, DEV BIOL, V157, P281, DOI 10.1006/dbio.1993.1133; PIKO L, 1984, P NATL ACAD SCI-BIOL, V81, P488, DOI 10.1073/pnas.81.2.488; SALPEKAR A, 2001, MOL HUM REPROD, V7, P101; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; Solter D, 2000, NAT REV GENET, V1, P199, DOI 10.1038/35042066; Urnovitz HB, 1996, CLIN MICROBIOL REV, V9, P72, DOI 10.1128/CMR.9.1.72	37	275	295	0	9	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 6	2001	20	56					8085	8091		10.1038/sj.onc.1205088	http://dx.doi.org/10.1038/sj.onc.1205088			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	496LJ	11781821				2022-12-17	WOS:000172396800005
J	Akagi, T; Motegi, M; Tamura, A; Suzuki, R; Hosokawa, Y; Suzuki, H; Ota, H; Nakamura, S; Morishima, Y; Taniwaki, M; Seto, M				Akagi, T; Motegi, M; Tamura, A; Suzuki, R; Hosokawa, Y; Suzuki, H; Ota, H; Nakamura, S; Morishima, Y; Taniwaki, M; Seto, M			A novel gene, MALT1 at 18q21, is involved in t(11;18) (q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue	ONCOGENE			English	Article						translocation; 18q21; MALT lymphoma; MALT1; extranodal lymphoma	T(11-18)(Q21-Q21); TRANSLOCATION; CLONING; CD22; AMPLIFICATION; EXPRESSION; MOLECULE; VECTOR; YEAST	The t(11;18) (q21;q21) translocation is a characteristic chromosomal aberration in low-grade B-cell lymphoma of mucose-associated lymphoid tissue (MALT) type. We previously identified a YAC clone y789F3, which includes the breakpoint at 18q21 in a MALT lymphoma patient. BAC and PAC contigs were constructed on the YAC, and BAC 193f9 was found to encompass the breakpoint region. In the present study, we further narrowed down the breakpoint region at 18q21 in five MALT lymphoma patients by means of FISH and Southern blot analyses using the plasmid contig constructed from BAC 193f9, The breakpoints at 18q21 in three of the five MALT lymphoma patients were found to be clustered approximately within the 20 kb region. By using exon amplification and cDNA library screening, we identified a novel cDNA spanning the breakpoint region that exhibited aberrant mRNA signals in four of the five MALT lymphoma patients. The nucleotide sequence predicted an 813 amino acid protein that shows significant sequence similarity to the CD22 beta and laminin 5 alpha 3b subunit, We refer to the gene encoding this transcript as MALT1 (Mucosa-Associated Lymphoid Tissue lymphoma translocation gene 1). The alteration of MALT1 by translocation strongly suggests that this gene plays an important role in the pathogenesis of MALT lymphoma.	Aichi Canc Ctr, Res Inst, Lab Chemotherapy, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Kyoto Prefectural Univ Med, Dept Internal Med 3, Kyoto 6020841, Japan; Shinshu Univ Hosp, Cent Clin Labs, Matsumoto, Nagano 3908621, Japan; Aichi Canc Ctr Hosp, Dept Pathol & Clin Labs, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr Hosp, Dept Hematol & Chemotherapy, Nagoya, Aichi 4648681, Japan	Aichi Cancer Center; Kyoto Prefectural University of Medicine; Shinshu University; Aichi Cancer Center; Aichi Cancer Center	Seto, M (corresponding author), Aichi Canc Ctr, Res Inst, Lab Chemotherapy, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.		Nakamura, Shigeo/I-1571-2012	Suzuki, Ritsuro/0000-0002-5974-7614				Akagi T, 1999, GENE CHROMOSOME CANC, V24, P315; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; GRIFFIN CA, 1992, GENE CHROMOSOME CANC, V4, P153, DOI 10.1002/gcc.2870040209; HARRIS NL, 1994, BLOOD, V84, P1361; HORSMAN D, 1992, GENE CHROMOSOME CANC, V4, P183, DOI 10.1002/gcc.2870040213; ISAACSON P, 1983, CANCER, V52, P1410, DOI 10.1002/1097-0142(19831015)52:8<1410::AID-CNCR2820520813>3.0.CO;2-3; LAW CL, 1994, IMMUNOL TODAY, V15, P442, DOI 10.1016/0167-5699(94)90275-5; LEROUX D, 1993, GENE CHROMOSOME CANC, V7, P54, DOI 10.1002/gcc.2870070109; LEVINE EG, 1989, BLOOD, V74, P1796; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; NEHLS M, 1994, ONCOGENE, V9, P2169; Ott G, 1997, CANCER RES, V57, P3944; POWELL LD, 1995, J BIOL CHEM, V270, P14243, DOI 10.1074/jbc.270.24.14243; RYAN MC, 1994, J BIOL CHEM, V269, P22779; Sambrook J., 1989, MOL CLONING; SARKAR FH, 1993, DNA CELL BIOL, V12, P611, DOI 10.1089/dna.1993.12.611; SETO M, 1992, ONCOGENE, V7, P1401; Silverman Gary A., 1995, V54, P65; Stoffel A, 1999, GENE CHROMOSOME CANC, V24, P156; TANIWAKI M, 1995, BLOOD, V86, P1481, DOI 10.1182/blood.V86.4.1481.bloodjournal8641481; Tedder TF, 1997, ANNU REV IMMUNOL, V15, P481, DOI 10.1146/annurev.immunol.15.1.481; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; WILSON GL, 1991, J EXP MED, V173, P137, DOI 10.1084/jem.173.1.137; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YAMAMOTO K, 1993, ONCOGENE, V8, P2617	26	275	281	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 14	1999	18	42					5785	5794		10.1038/sj.onc.1203018	http://dx.doi.org/10.1038/sj.onc.1203018			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245FG	10523859				2022-12-17	WOS:000083095100007
J	Shimizu, S; Eguchi, Y; Kamiike, W; Matsuda, H; Tsujimoto, Y				Shimizu, S; Eguchi, Y; Kamiike, W; Matsuda, H; Tsujimoto, Y			Bcl-2 expression prevents activation of the ICE protease cascade	ONCOGENE			English	Article						bcl-2; bcl-x; ICE; CPP32; Yama; apoptosis	PROGRAMMED CELL-DEATH; HUMAN FOLLICULAR LYMPHOMA; CHROMOSOMAL BREAKPOINT; GROWTH-FACTOR; C-ELEGANS; GENE; SURVIVAL; ENZYME; CED-3	The Bcl-2 family and the ICE family of cysteine proteases play important roles in regulating cell death. We show here that induction of cell death by a Ca2+ ionophore or hypoxia results in increased levels and activity of active ICE(-like) proteases and the subsequent activation of CPP32/Yama(-like) proteases, and that inhibition of these protease activities reduces the extent of cell death, Overexpression of the anti-apoptotic proteins Bcl-2 or Bcl-x(L) inhibits the cell death and the activation of ICE(-like) and CPP32/Yama(-like) proteases, indicating that Bcl-2 and Bcl-x(L) act upstream of these proteases. We also show that specific inhibition of ICE(-like) proteases in vivo prevents activation of CPP32/Yama(-like) proteases, whereas inhibition of CPP32/Yama(-like) proteases does not prevent activation of TCE(-like) proteases, suggesting the existence of a protease cascade in vivo that requires ICE(-like)proteases for activation of CPP32/Yama(-like) proteases. Induction of necrotic cell death by KCN also induces activation of ICE(-like) proteases but not of CPP32/Yama(-like) proteases, and Bcl-2 and Bcl-x(L) inhibit the activation and the cell death, suggesting that the functional site of Bcl-2 and Bcl-x(L) is also upstream of ICE(-like) proteases in at least some forms of necrosis.	OSAKA UNIV, SCH MED, DEPT SURG 1, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, SCH MED, DEPT PHYSIOL 1, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, SCH MED, DEPT MED GENET, SUITA, OSAKA 565, JAPAN	Osaka University; Osaka University; Osaka University								BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PEZZELLA F, 1990, AM J PATHOL, V137, P225; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SHIMIZU S, 1996, IN PRESS CAN RES; SHIMIZU S, 1996, IN PRESS ONCOGENE; SINGER II, 1995, J EXP MED, V182, P1447, DOI 10.1084/jem.182.5.1447; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TSUJIMOTO Y, 1989, ONCOGENE, V4, P1331; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; YAUN J, 1993, CELL, V75, P641; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H	39	275	281	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2251	2257						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649764				2022-12-17	WOS:A1996UQ22000001
J	Dalmay, T; Edwards, DR				Dalmay, T.; Edwards, D. R.			MicroRNAs and the hallmarks of cancer	ONCOGENE			English	Review						miRNAs; cancer; metastasis; invasion; angiogenesis; cell adhesion	TISSUE INHIBITOR; CELL-ADHESION; TRANSITION; PROFILES; HYPOXIA; GENES; SEED	It has become clear that particular microRNAs (miRNAs) function either as tumour suppressors or oncogenes, whose loss or overexpression, respectively, has diagnostic and prognostic significance. In several cases, miRNAs have been shown to affect target genes that are involved in the control of cell proliferation and apoptosis. However, malignant tumours display additional traits beyond the acquisition of enhanced growth potential and decreased cell death. Malignant disease is associated with altered tumour-host interactions leading to sustained angiogenesis and the ability to invade and metastasize. It is possible that miRNAs may act as master regulators of these aspects of tumour biology. Bioinformatic analysis of putative miRNA binding sites has indicated several novel potential gene targets of cancer-associated miRNAs that function in aspects of cell adhesion, neovascularization and tissue invasion. Among others, we speculate that miRNAs may find new roles in the regulation of E-cadherin, integrin alpha v beta 3, hypoxia-inducible factor-1 alpha, syndecan-1, lysyl oxidase, adamalysin metalloproteinase-17, tissue inhibitors of metalloproteinase-3, c-Met and CXCR-4 that underpin the tissue architectural changes associated with malignancy.	Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England	University of East Anglia	Dalmay, T (corresponding author), Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England.	t.dalmay@uea.ac.uk; dylan.edwards@uea.ac.uk	Dalmay, Tamas/E-1377-2011; Edwards, Dylan R/B-4734-2009	Dalmay, Tamas/0000-0003-1492-5429; Edwards, Dylan R/0000-0002-3292-2064	Medical Research Council [G0100250] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ahonen M, 2003, ONCOGENE, V22, P2121, DOI 10.1038/sj.onc.1206292; Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; CRUZMUNOZ W, 2006, ONCOGENE        0515, DOI DOI 10.1038/SJ.ONC.1209663; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Endo K, 2003, J BIOL CHEM, V278, P40764, DOI 10.1074/jbc.M306736200; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Esteller M, 2001, CANCER RES, V61, P3225; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Hwang HW, 2006, BRIT J CANCER, V94, P776, DOI 10.1038/sj.bjc.6603023; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Liu MCP, 2007, CANCER LETT, V247, P91, DOI 10.1016/j.canlet.2006.03.024; LU C, 1993, J CELL BIOL, V120, P1281, DOI 10.1083/jcb.120.5.1281; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Mohammed FF, 2004, NAT GENET, V36, P969, DOI 10.1038/ng1413; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9; Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Yang AD, 2006, CANCER RES, V66, P46, DOI 10.1158/0008-5472.CAN-05-3086; Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103	40	274	311	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2006	25	46					6170	6175		10.1038/sj.onc.1209911	http://dx.doi.org/10.1038/sj.onc.1209911			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	093HL	17028596				2022-12-17	WOS:000241158900005
J	Kannan, K; Amariglio, N; Rechavi, G; Jakob-Hirsch, J; Kela, I; Kaminski, N; Getz, G; Domany, E; Givol, D				Kannan, K; Amariglio, N; Rechavi, G; Jakob-Hirsch, J; Kela, I; Kaminski, N; Getz, G; Domany, E; Givol, D			DNA microarrays identification of primary and secondary target genes regulated by p53	ONCOGENE			English	Article						DNA microarray; cycloheximide; ts-p53; target genes; expression profile, clustering	CELL-CYCLE; EXPRESSION; GROWTH; INDUCTION; STABILITY; PROMOTER; REVEALS; BINDING; ARREST; MUTANT	The transcriptional program regulated by the tumor suppressor p53 was analysed using oligonucleotide microarrays. A human lung cancer cell line that expresses the temperature sensitive murine p53 was utilized to quantitate mRNA levels of various genes at different time points after shifting the temperature to 32 degreesC. Inhibition of protein synthesis by cycloheximide (CHX) was used to distinguish between primary and secondary target genes regulated by p53. In the absence of CHX, 259 and 125 genes were up or down-regulated respectively; only 38 and 24 of these genes were up and down-regulated by p53 also in the presence of CHX and are considered primary targets in this cell line. Cluster analysis of these data using the super paramagnetic clustering (SPC) algorithm demonstrate that the primary genes can be distinguished as a single cluster among a large pool of p53 regulated genes. This procedure identified additional genes that co-cluster with the primary targets and can also be classified as such genes, In addition to cell cycle (e.g. p21, TGF-beta, Cyclin E) and apoptosis (e.g, Fas, Bak, IAP) related genes, the primary targets of p53 include genes involved in many aspects of cell function, including cell adhesion (e.g, Thymosin, Smoothelin), signaling (e.g. H-Ras, Diacylglycerol kinase), transcription (e.g. ATF3, LISCH7), neuronal growth (e.g. Ninjurin, NSCL2) and DNA repair (e.g. BTG2, DDB2), The results suggest that p53 activates concerted opposing signals and exerts its effect through a diverse network of transcriptional changes that collectively alter the cell phenotype in response to stress.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Chaim Sheba Med Ctr, Dept Pediat Hematol Oncol, Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; Chaim Sheba Med Ctr, Funct Genom Unit, Tel Aviv, Israel	Weizmann Institute of Science; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Chaim Sheba Medical Center	Givol, D (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.		DOMANY, EYTAN/K-1560-2012	Kaminski, Naftali/0000-0001-5917-4601				Ausubel FA, 1990, CURRENT PROTOCOLS MO; Blatt M, 1996, PHYS REV LETT, V76, P3251, DOI 10.1103/PhysRevLett.76.3251; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Getz G, 2000, PHYSICA A, V279, P457, DOI 10.1016/S0378-4371(99)00524-5; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; Kaminski N, 2000, P NATL ACAD SCI USA, V97, P1778, DOI 10.1073/pnas.97.4.1778; Kannan K, 2000, FEBS LETT, V470, P77, DOI 10.1016/S0014-5793(00)01291-6; Komarova EA, 1998, ONCOGENE, V17, P1089, DOI 10.1038/sj.onc.1202303; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MICHIELI P, 1994, CANCER RES, V54, P3391; O'Hagan RC, 2000, NAT GENET, V24, P113, DOI 10.1038/72761; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Scherer SJ, 2000, J BIOL CHEM, V275, P37469, DOI 10.1074/jbc.M006990200; Sherlock G, 2000, CURR OPIN IMMUNOL, V12, P201, DOI 10.1016/S0952-7915(99)00074-6; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; Tan MJ, 2000, P NATL ACAD SCI USA, V97, P109, DOI 10.1073/pnas.97.1.109; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Young RA, 2000, CELL, V102, P9, DOI 10.1016/S0092-8674(00)00005-2; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768; Zhao RB, 2000, GENE DEV, V14, P981	30	274	291	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2001	20	18					2225	2234		10.1038/sj.onc.1204319	http://dx.doi.org/10.1038/sj.onc.1204319			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427KZ	11402317				2022-12-17	WOS:000168404500004
J	Aguilera, O; Fraga, MF; Ballestar, E; Paz, MF; Herranz, M; Espada, J; Garcia, JM; Munoz, A; Esteller, M; Gonzalez-Sancho, JM				Aguilera, O.; Fraga, M. F.; Ballestar, E.; Paz, M. F.; Herranz, M.; Espada, J.; Garcia, J. M.; Munoz, A.; Esteller, M.; Gonzalez-Sancho, J. M.			Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer	ONCOGENE			English	Article						DICKKOPF-1; Wnt; promoter methylation; colorectal cancer	BETA-CATENIN/TCF; TUMOR-SUPPRESSOR; DNA METHYLATION; MECHANISM; PROTEINS; HYPERMETHYLATION; INHIBITION; TARGET; MODEL	Colorectal cancer is a major cause of cancer death worldwide. A number of key oncogenes and tumor suppressor genes have been proposed to drive progression from healthy colonic epithelia to malignant tumors, including members of the Wnt/beta-catenin pathway. Recently, CpG island promoter hypermethylation was shown to cause inactivation of two extracellular Wnt inhibitors in colon cancer: secreted frizzled-related proteins (sFRPs) and Wnt inhibitory factor-1 (WIF-1). Here, we show for the first time that another extracellular Wnt inhibitor, the DICKKOPF-1 (DKK-1) gene, is transcriptionally silenced by CpG island promoter hypermethylation in colon cancercell lines (n = 9), whereas treatment with the DNA-demethylating agent 5-aza-2-deoxycytidine restored DKK-1 expression. Restoration of DKK-1 function in non-expressing cells bearing a truncated APC (Adenomatous Polyposis Coli) gene had no effect on beta-catenin/T-cell factor-dependent transcription, but induced tumor suppressor-like features such as reduced colony formation density and tumor growth inhibition in nude mice. These results suggest additional functions for DKK-1 other than inhibiting canonical Wnt signaling. In primary colorectal tumors, DKK-1 was found hypermethylated in 17% (nine of 54) of cases. Furthermore, while for both SFRP-1 and WIF-1 methylation- associated silencing occurred across the whole spectrum of colorectal tumorigenesis, DKK-1 promoter was selectively hypermethylated in advanced colorectal neoplasms (Duke's C and D tumors).	Spanish Natl Canc Ctr, CNIO, Canc Epigenet Lab, Mol Pathol Programme, Madrid 28029, Spain; Univ Autonoma Madrid, CSIC, Fac Med, Inst Invest Biomed Alberto Sols, Madrid, Spain; Univ Autonoma Madrid, CSIC, Fac Med, Dept Bioquim, Madrid, Spain; Hosp Univ Puerta Hierro, Madrid, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Hospital Puerta de Hierro-Majadahonda	Esteller, M (corresponding author), Spanish Natl Canc Ctr, CNIO, Canc Epigenet Lab, Mol Pathol Programme, Melchor Fernandez Almagro 3, Madrid 28029, Spain.	mesteller@cnio.es	Gonzalez-Sancho, Jose/AAA-6010-2019; Fraga, Mario F/H-7824-2017; Munoz, Alberto/O-6393-2014; Ballestar, Esteban/ABG-8561-2020; Herranz, Michel/L-2561-2016; Espada, Jesús/AAA-3198-2019; Esteller, Manel/L-5956-2014	Gonzalez-Sancho, Jose/0000-0001-5875-1964; Fraga, Mario F/0000-0001-8450-2603; Munoz, Alberto/0000-0003-3890-4251; Espada, Jesús/0000-0002-4202-4938; Esteller, Manel/0000-0003-4490-6093; Ballestar, Esteban/0000-0002-1400-2440				Alaminos M, 2005, CANCER RES, V65, P2565, DOI 10.1158/0008-5472.CAN-04-4283; Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032; Ballestar E, 2003, EMBO J, V22, P6335, DOI 10.1093/emboj/cdg604; Ballestar E, 2002, CARCINOGENESIS, V23, P1103, DOI 10.1093/carcin/23.7.1103; Chamorro MN, 2005, EMBO J, V24, P73, DOI 10.1038/sj.emboj.7600460; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Fraga MF, 2004, CANCER RES, V64, P5527, DOI 10.1158/0008-5472.CAN-03-4061; Gonzalex-Sancho JM, 2005, ONCOGENE, V24, P1098, DOI 10.1038/sj.onc.1208303; Gonzalez-Sancho JM, 2004, MOL CELL BIOL, V24, P4757, DOI 10.1128/MCB.24.11.4757-4768.2004; He BA, 2005, ONCOGENE, V24, P3054, DOI 10.1038/sj.onc.1208511; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kuhnert F, 2004, P NATL ACAD SCI USA, V101, P266, DOI 10.1073/pnas.2536800100; Lee AY, 2004, BIOCHEM BIOPH RES CO, V323, P1246, DOI 10.1016/j.bbrc.2004.09.001; Maeda K, 2003, ONCOL REP, V10, P935; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; Mazieres J, 2004, CANCER RES, V64, P4717, DOI 10.1158/0008-5472.CAN-04-1389; Mikheev AM, 2004, CARCINOGENESIS, V25, P47, DOI 10.1093/carcin/bgg190; Miller JR, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2001-3-1-reviews3001; Niida A, 2004, ONCOGENE, V23, P8520, DOI 10.1038/sj.onc.1207892; Pinto D, 2003, GENE DEV, V17, P1709, DOI 10.1101/gad.267103; Ries LAG, 2003, ONCOLOGIST, V8, P541; Sancho E, 2004, ANNU REV CELL DEV BI, V20, P695, DOI 10.1146/annurev.cellbio.20.010403.092805; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Zou HZ, 2002, CLIN CANCER RES, V8, P188	30	273	294	0	22	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2006	25	29					4116	4121		10.1038/sj.onc.1209439	http://dx.doi.org/10.1038/sj.onc.1209439			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	060KZ	16491118				2022-12-17	WOS:000238802400012
J	Niwa, Y; Kanda, H; Shikauchi, Y; Saiura, A; Matsubara, K; Kitagawa, T; Yamamoto, J; Kubo, T; Yoshikawa, H				Niwa, Y; Kanda, H; Shikauchi, Y; Saiura, A; Matsubara, K; Kitagawa, T; Yamamoto, J; Kubo, T; Yoshikawa, H			Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma	ONCOGENE			English	Article						SOCS-3; FAK; JAK/ STAT; HCC	PROTEIN-TYROSINE KINASE; FOCAL ADHESION KINASE; CONSTITUTIVE ACTIVATION; LIVER; OVEREXPRESSION; INACTIVATION; ASSOCIATION; PP125(FAK); ASSIGNMENT; FRAGMENTS	We identified that suppressor of cytokine signaling-3 (SOCS-3) gene was aberrantly methylated in its CpG island in three of 10 human hepatocellular carcinoma ( HCC) cell lines. SOCS-3 RNA was undetectable in five of the 10 HCC cell lines including the three methylated cell lines, and a demethylating agent, 5-aza-2'-deoxycytidine, reactivated SOCS-3 expression in three cell lines tested. The DNA region where we found aberrant DNA methylation includes a signal transducers and activators of transcription ( STAT) binding consensus sequence. When the DNA region was used as a promoter, DNA methylation markedly reduced promoter activity. SOCS-3 was also aberrantly methylated in six of 18 primary HCC samples. SOCS-3 expression was reduced in three of the three methylated and one of the three unmethylated primary samples examined. Restoration of SOCS-3 in cells lacking SOCS-3 expression suppressed STAT3 phosphorylation and cell growth. We found that IL-6 acted as a growth factor in HCC cells. Inhibition of SOCS-3 expression in cells whose growth was induced by IL-6 enhanced STAT3 phosphorylation and cell growth. In addition, AG490, a chemical JAK2 inhibitor, suppressed cell growth and downregulated STAT3 phosphorylation, but not FAK phosphorylation. We also found that SOCS-3 physically interacted with phosphorylated FAK and Elongin B in HCC cells. Restoration of SOCS-3 decreased FAK phosphorylation as well as FAK protein level. Inhibition of SOCS-3 expression increased FAK phosphorylation, resulting in enhancement of cell migration. These data indicate that SOCS-3 negatively regulates cell growth and cell motility by inhibiting Janus kinase (JAK)/STAT and FAK signalings in HCC cells. Thus, loss of SOCS-3 by the associated DNA methylation confers cells advantage in growth and migration.	Japanese Fdn Canc Res, Inst Canc, Dept Epigenet Carcinogenesis, Koto Ku, Tokyo 1358550, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Pathol, Koto Ku, Tokyo 1358550, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Surg, Koto Ku, Tokyo 1358550, Japan; DNA Chip Res Inc, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan	Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research; DNA Chip Research Inc.	Yoshikawa, H (corresponding author), Japanese Fdn Canc Res, Inst Canc, Dept Epigenet Carcinogenesis, Koto Ku, 3-10-6 Ariake, Tokyo 1358550, Japan.	hirohide.yoshikawa@jfcr.or.jp						Auernhammer CJ, 1999, P NATL ACAD SCI USA, V96, P6964, DOI 10.1073/pnas.96.12.6964; BEDOSSA P, 1994, HEPATOLOGY, V20, P15; Cary LA, 1996, J CELL SCI, V109, P1787; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; He B, 2003, P NATL ACAD SCI USA, V100, P14133, DOI 10.1073/pnas.2232790100; Herman JG, 1997, CANCER RES, V57, P837; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; ILLC D, 1995, NATURE, V377, P539; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Kubo T, 2004, CANCER RES, V64, P5172, DOI 10.1158/0008-5472.CAN-03-3314; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; Liu E, 2003, EMBO J, V22, P5036, DOI 10.1093/emboj/cdg503; LUO H, 1995, EMBO J, V14, P1412, DOI 10.1002/j.1460-2075.1995.tb07127.x; MIKI S, 1989, FEBS LETT, V250, P607, DOI 10.1016/0014-5793(89)80805-1; Nagamori S, 2000, J GASTROENTEROL, V35, P493, DOI 10.1007/s005350070071; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; OWENS LV, 1995, CANCER RES, V55, P2752; Sasaki A, 2003, J BIOL CHEM, V278, P2432, DOI 10.1074/jbc.C200608200; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; WeberNordt RM, 1996, BLOOD, V88, P809; Yoshida T, 2004, J EXP MED, V199, P1701, DOI 10.1084/jem.20031675; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Yoshikawa H, 1996, GENOMICS, V31, P28, DOI 10.1006/geno.1996.0005; Yoshikawa H, 1997, GENE, V197, P129, DOI 10.1016/S0378-1119(97)00251-5; Yoshikawa H, 1998, GENOMICS, V49, P237, DOI 10.1006/geno.1998.5246; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071; Zimmers TA, 2003, HEPATOLOGY, V38, P326, DOI 10.1053/jhep.2003.50318	39	273	310	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2005	24	42					6406	6417		10.1038/sj.onc.1208788	http://dx.doi.org/10.1038/sj.onc.1208788			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	966RI	16007195				2022-12-17	WOS:000232038200008
J	Ma, H; Nguyen, C; Lee, KS; Kahn, M				Ma, H; Nguyen, C; Lee, KS; Kahn, M			Differential roles for the coactivators CBP and p300 on TCF/beta-catenin-mediated survivin gene expression	ONCOGENE			English	Article						survivin; CBP; p300; TCF/catenin	BETA-CATENIN; C-MYC; CYCLIN D1; TRANSCRIPTIONAL REPRESSION; CARCINOMA-CELLS; BINDING PROTEIN; DISTINCT ROLES; APOPTOSIS; CANCER; SUPPRESSION	The inhibitor of apoptosis (IAP) protein survivin is highly expressed in cancers, but not in normal differentiated tissues. TCF/beta-catenin signaling has been reported to participate in the regulation of survivin transcription in colon cancer. We have recently characterized ICG-001, a small molecule specific inhibitor of the beta-catenin/Creb-binding protein (CBP) interaction. Inhibition of the beta-catenin/CBP interaction represses a subset of TCF/beta-catenin-mediated transcription. ICG-001 potently inhibits survivin gene transcription and expression. ICG-001-mediated downregulation of survivin expression enhanced caspase-3 activity and apoptosis, which was rescued by overexpression of wild type but not mutant (C84A) survivin. Small interfering RNA and genetic reduction of CBP also decreased survivin expression. Chromatin immunoprecipitation assay confirmed that CBP is the crucial coactivator for TCF/beta-catenin-mediated survivin transcription. Furthermore, ICG-001-induced recruitment of p300 to the survivin promoter led to concomitant recruitment of SUMO-1, HDAC6 and PML proteins, which have been associated with transcriptional repression. These findings demonstrate that CBP and p300 play very distinct roles in survivin gene transcription.	Inst Chem Genom, Dept Mol Cell Biol, Seattle, WA 98122 USA; Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Kahn, M (corresponding author), Inst Chem Genom, Dept Mol Cell Biol, 600 Broadway,Suite 580, Seattle, WA 98122 USA.	mkahn@ichemgen.org						ABARZUA P, 1995, CANCER RES, V55, P3490; Adida C, 2000, BLOOD, V96, P1921; Altieri Dario C, 2003, Methods Mol Biol, V223, P533; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032; Baluchamy S, 2003, P NATL ACAD SCI USA, V100, P9524, DOI 10.1073/pnas.1633700100; Chesire DR, 2003, ENDOCR-RELAT CANCER, V10, P537, DOI 10.1677/erc.0.0100537; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Goodman RH, 2000, GENE DEV, V14, P1553; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Jiang MC, 1996, ONCOGENE, V13, P609; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Kim JS, 2002, CANCER RES, V62, P2744; Kim PJ, 2003, LANCET, V362, P205, DOI 10.1016/S0140-6736(03)13910-4; Kumar S, 2002, SCIENCE, V297, P1290, DOI 10.1126/science.1076118; Kung AL, 2000, GENE DEV, V14, P272; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Lee YJ, 2004, MOL CELLS, V17, P217; Li FZ, 2003, J CELL PHYSIOL, V197, P8, DOI 10.1002/jcp.10327; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1999, BIOCHEM J, V344, P305, DOI 10.1042/0264-6021:3440305; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Maeda O, 2004, ONCOGENE, V23, P964, DOI 10.1038/sj.onc.1207254; Miyagishi M, 2000, J BIOL CHEM, V275, P35170, DOI 10.1074/jbc.C000258200; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; OMURA S, 1977, J ANTIBIOT, V30, P275, DOI 10.7164/antibiotics.30.275; Owens DM, 2003, NAT REV CANCER, V3, P444, DOI 10.1038/nrc1096; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Rebel VI, 2002, P NATL ACAD SCI USA, V99, P14789, DOI 10.1073/pnas.232568499; Roth JF, 2003, EMBO J, V22, P5186, DOI 10.1093/emboj/cdg473; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Speliotes EK, 2000, MOL CELL, V6, P211, DOI 10.1016/S1097-2765(00)00023-X; Spencer VA, 2003, METHODS, V31, P67, DOI 10.1016/S1046-2023(03)00089-6; Suganuma T, 2002, P NATL ACAD SCI USA, V99, P13073, DOI 10.1073/pnas.192586699; Tamm I, 1998, CANCER RES, V58, P5315; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tu SP, 2003, CANCER RES, V63, P7724; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7; Velculescu VE, 1999, NAT GENET, V23, P387, DOI 10.1038/70487; Xu ZX, 2004, J BIOL CHEM, V279, P1838, DOI 10.1074/jbc.M310987200; Yamauchi T, 2002, NAT GENET, V30, P221, DOI 10.1038/ng829; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Zhang T, 2001, CANCER RES, V61, P8664	52	273	291	2	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2005	24	22					3619	3631		10.1038/sj.onc.1208433	http://dx.doi.org/10.1038/sj.onc.1208433			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15782138				2022-12-17	WOS:000229221800009
J	Kikuchi, T; Daigo, Y; Katagiri, T; Tsunoda, T; Okada, K; Kakiuchi, S; Zembutsu, H; Furukawa, Y; Kawamura, M; Kobayashi, K; Imai, K; Nakamura, Y				Kikuchi, T; Daigo, Y; Katagiri, T; Tsunoda, T; Okada, K; Kakiuchi, S; Zembutsu, H; Furukawa, Y; Kawamura, M; Kobayashi, K; Imai, K; Nakamura, Y			Expression profiles of non-small cell lung cancers on cDNA microarrays: Identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs	ONCOGENE			English	Article						non-small cell lung cancer; gene-expression profile; chemosensitivity; lymph-node metastasis	LASER-CAPTURE MICRODISSECTION; COLORECTAL TUMORS; CARCINOMAS; CLASSIFICATION; ADENOCARCINOMA; CARCINOGENESIS; RESISTANCE; ADHESION; P53	To investigate genes involved in pulmonary carcinogenesis and those related to sensitivity of nonsmall cell lung cancers (NSCLCs) to therapeutic drugs, we performed cDNA microarray analysis of 37 NSCLCs after laser-capture microdissection of cancer cells from primary tumors. A clustering algorithm applied to the expression data easily distinguished two major histological types of non-small cell lung cancer, adenocarcinoma and squamous cell carcinoma. Subsequent analysis of the 18 adenocarcinomas identified 40 genes whose expression levels could separate cases with lymph-node metastasis from those without metastasis. In addition, we compared the expression data with measurements of the sensitivity of surgically dissected NSCLC specimens to six anti-cancer drugs (docetaxel, paclitaxel, irinotecan, cisplatin, gemcitabine, and vinorelbine), as measured by the CD-DST (collagen gel droplet embedded culture-drug sensitivity test) method. We found significant associations between expression levels of dozens of genes and chemosensitivity of NSCLCs. Our results provide valuable information for eventually identifying predictive markers and novel therapeutic target molecules for this type of cancer.	Univ Tokyo, Inst Med Sci, Ctr Human Genome, Lab Mol Med,Minato Ku, Tokyo 1088639, Japan; Sapporo Med Univ, Dept Internal Med 1, Sapporo, Hokkaido 0608543, Japan; RIKEN, Inst Phys & Chem Res, SNP Res Ctr, Lab Med Informat, Kanagawa 2300045, Japan; Keio Univ, Sch Med, Dept Surg, Div Gen Thorac Surg, Tokyo 1608582, Japan	University of Tokyo; Sapporo Medical University; RIKEN; Keio University	Nakamura, Y (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Lab Mol Med,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	yusuke@ims.u-tokyo.ac.jp	Tsunoda, Tatsuhiko/K-2061-2014	Tsunoda, Tatsuhiko/0000-0002-5439-7918; Daigo, Yataro/0000-0002-0915-3025				Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; FRANKLIN WA, 1994, INT J CANCER, P89; Fukata M, 2001, NAT REV MOL CELL BIO, V2, P887, DOI 10.1038/35103068; Furuhata T, 1996, ONCOGENE, V13, P1965; FURUKAWA T, 1995, CLIN CANCER RES, V1, P305; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Ichigotani Y, 2002, CANCER RES, V62, P2215; Kawano N, 1997, HUM PATHOL, V28, P613, DOI 10.1016/S0046-8177(97)90085-X; Kitahara O, 2001, CANCER RES, V61, P3544; Kondoh N, 2001, ANTICANCER RES, V21, P2429; Lin YM, 2002, ONCOGENE, V21, P4120, DOI 10.1038/sj.onc.1205518; Luo XL, 2002, MOL CELL, V9, P59, DOI 10.1016/S1097-2765(01)00435-X; Makino K, 2001, ONCOGENE, V20, P2537, DOI 10.1038/sj.onc.1204366; McDoniels-Silvers AL, 2002, CLIN CANCER RES, V8, P1127; Meyaard L, 2001, J EXP MED, V194, P107, DOI 10.1084/jem.194.1.107; Mitsudomi T, 2000, CLIN CANCER RES, V6, P4055; Niklinski J, 2001, LUNG CANCER, V34, pS53, DOI 10.1016/S0169-5002(01)00345-2; Okabe H, 2001, CANCER RES, V61, P2129; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Salonga D, 2000, CLIN CANCER RES, V6, P1322; Sozzi G, 2001, EUR J CANCER, V37, pS63; Turton NJ, 2001, ONCOGENE, V20, P1300, DOI 10.1038/sj.onc.1204235; UEDA K, 1987, J BIOL CHEM, V262, P505; VAMVAKOPOULOS NC, 1995, CYTOGENET CELL GENET, V68, P8, DOI 10.1159/000133878; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Watine J, 2000, BRIT MED J, V320, P379; Wieland I, 1999, ONCOGENE, V18, P4530, DOI 10.1038/sj.onc.1202806; Yanagawa R, 2001, NEOPLASIA, V3, P395, DOI 10.1038/sj.neo.7900185; Zembutsu H, 2002, CANCER RES, V62, P518	33	273	314	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2003	22	14					2192	2205		10.1038/sj.onc.1206288	http://dx.doi.org/10.1038/sj.onc.1206288			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664NJ	12687021				2022-12-17	WOS:000182066900013
J	Mechta-Grigoriou, F; Gerald, D; Yaniv, M				Mechta-Grigoriou, F; Gerald, D; Yaniv, M			The mammalian Jun proteins: redundancy and specificity	ONCOGENE			English	Review						cell cycle; transcription; ras signaling; apoptosis	CELL-CYCLE PROGRESSION; SIGNAL-TRANSDUCTION PATHWAY; STRESS-INDUCED APOPTOSIS; RAT EMBRYO CELLS; C-JUN; TRANSCRIPTION FACTOR; DNA-BINDING; FOS-JUN; MOUSE FIBROBLASTS; PROTO-ONCOGENE	The AP-1 transcription factor is composed of a mixture of homo- and hetero-dimers formed between Jun and Fos proteins, The different Jun and Fos family members vary significantly in their relative abundance and their interactions with additional proteins generating a complex network of transcriptional regulators. Thus, the functional activity of AP-1 in any given cell depends on the relative amount of specific Jun/Fos proteins which are expressed, as well as other potential interacting proteins, This diversity of AP-1 components has complicated our understanding of AP-1 function and resulted in a paucity of information about the precise role of individual AP-1 members in distinct cellular processes. We shall discuss recent studies which suggest that different Jun and Fos family members may have both opposite and overlapping functions in cellular proliferation and cell fate.	Inst Pasteur, Unite Virus Oncogenes, CNRS, URA 1644, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Yaniv, M (corresponding author), Inst Pasteur, Unite Virus Oncogenes, CNRS, URA 1644, 25 Rue Dr Roux, F-75724 Paris 15, France.		MECHTA-GRIGORIOU, Fatima/C-5253-2017	MECHTA-GRIGORIOU, Fatima/0000-0002-3751-6989				Agarwal SK, 1999, CELL, V96, P143, DOI 10.1016/S0092-8674(00)80967-8; ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOSSYWETZEL E, 1992, GENE DEV, V6, P2340, DOI 10.1101/gad.6.12a.2340; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Bouallaga I, 2000, EMBO REP, V1, P422, DOI 10.1093/embo-reports/kvd091; BRACH MA, 1992, EMBO J, V11, P1479, DOI 10.1002/j.1460-2075.1992.tb05192.x; BRENNER DA, 1989, DNA-J MOLEC CELL BIO, V8, P279, DOI 10.1089/dna.1.1989.8.279; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; Chalaux E, 1998, J BIOL CHEM, V273, P537, DOI 10.1074/jbc.273.1.537; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COFFER P, 1995, ONCOGENE, V10, P985; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; Cook SJ, 1999, MOL CELL BIOL, V19, P330; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DEGROOT RP, 1991, EMBO J, V10, P2523, DOI 10.1002/j.1460-2075.1991.tb07792.x; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P775, DOI 10.1093/nar/19.4.775; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DRAGUNOW M, 1993, MOL BRAIN RES, V18, P347, DOI 10.1016/0169-328X(93)90101-T; Eferl R, 1999, J CELL BIOL, V145, P1049, DOI 10.1083/jcb.145.5.1049; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Gajate C, 1996, BIOCHEM BIOPH RES CO, V218, P267, DOI 10.1006/bbrc.1996.0047; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Herzog KH, 1999, J NEUROSCI, V19, P4349; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HIRAI S-I, 1989, New Biologist, V1, P181; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HIRAI SI, 1990, ONCOGENE, V5, P39; Johnson R, 1996, MOL CELL BIOL, V16, P4504; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; KAWAKAMI Z, 1992, NUCLEIC ACIDS RES, V20, P914, DOI 10.1093/nar/20.4.914; Kawasaki M, 1999, EMBO J, V18, P3604, DOI 10.1093/emboj/18.13.3604; KERPPOLA TK, 1994, ONCOGENE, V9, P675; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KITABAYASHI I, 1993, J BIOL CHEM, V268, P14482; Knochel S, 2000, MECH DEVELOP, V98, P29, DOI 10.1016/S0925-4773(00)00448-2; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Leppa S, 1998, EMBO J, V17, P4404, DOI 10.1093/emboj/17.15.4404; Li BY, 1999, EMBO J, V18, P420, DOI 10.1093/emboj/18.2.420; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; Lopez-Rovira T, 2000, J BIOL CHEM, V275, P28937, DOI 10.1074/jbc.M909923199; MANOME Y, 1993, BIOCHEMISTRY-US, V32, P10607, DOI 10.1021/bi00091a010; MECHTA F, 1989, New Biologist, V1, P297; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; MECHTA F, 1994, FOS JUN FAMILIES TRA, P115; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; Neyns B, 1996, ONCOGENE, V12, P1247; Noselli S, 1998, TRENDS GENET, V14, P33, DOI 10.1016/S0168-9525(97)01320-6; Passegue E, 2001, CELL, V104, P21, DOI 10.1016/S0092-8674(01)00188-X; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; PHINNEY DG, 1994, ONCOGENE, V9, P2353; PIETTE J, 1988, P NATL ACAD SCI USA, V85, P3401, DOI 10.1073/pnas.85.10.3401; PIETTE J, 1987, MOL ASPECTS PAPOVAVI, P87; Preston GA, 1996, MOL CELL BIOL, V16, P211; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; Rebollo A, 2000, MOL CELL BIOL, V20, P3407, DOI 10.1128/MCB.20.10.3407-3416.2000; RIABOWOL K, 1992, P NATL ACAD SCI USA, V89, P157, DOI 10.1073/pnas.89.1.157; RiesgoEscovar JR, 1997, SCIENCE, V278, P669, DOI 10.1126/science.278.5338.669; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; ROZEK D, 1993, MOL CELL BIOL, V13, P5490, DOI 10.1128/MCB.13.9.5490; RYSECK RP, 1991, ONCOGENE, V6, P533; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; Schorpp-Kistner M, 1999, EMBO J, V18, P934, DOI 10.1093/emboj/18.4.934; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Schreiber M, 2000, DEVELOPMENT, V127, P4937; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sharma SC, 2000, J BIOL CHEM, V275, P33718, DOI 10.1074/jbc.M003555200; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Sjin RMTT, 1999, J BIOL CHEM, V274, P28697, DOI 10.1074/jbc.274.40.28697; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMITH MJ, 1992, BLOOD, V79, P2107; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STEIN B, 1992, PHOTOCHEM PHOTOBIOL, V55, P409, DOI 10.1111/j.1751-1097.1992.tb04255.x; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; Szabowski A, 2000, CELL, V103, P745, DOI 10.1016/S0092-8674(00)00178-1; Thepot D, 2000, DEVELOPMENT, V127, P143; THIERRY F, 1992, J VIROL, V66, P3740, DOI 10.1128/JVI.66.6.3740-3748.1992; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; VOGT PK, 1989, INT S PRINCESS TAKAM, V20, P127; Wang HL, 2000, CARCINOGENESIS, V21, P1313, DOI 10.1093/carcin/21.7.1313; WANG ZQ, 1995, CANCER RES, V55, P6244; Watson A, 1998, J NEUROSCI, V18, P751; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; ZHANG K, 1990, P NATL ACAD SCI USA, V87, P6281, DOI 10.1073/pnas.87.16.6281	134	273	284	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2001	20	19					2378	2389		10.1038/sj.onc.1204381	http://dx.doi.org/10.1038/sj.onc.1204381			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	430HP	11402334				2022-12-17	WOS:000168568700005
J	Lutz, W; Stohr, M; Schurmann, J; Wenzel, A; Lohr, A; Schwab, M				Lutz, W; Stohr, M; Schurmann, J; Wenzel, A; Lohr, A; Schwab, M			Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells	ONCOGENE			English	Article						tetracycline; cell cycle; Myc; immediate early gene; neuroblastoma	HUMAN NEURO-BLASTOMA; C-MYC; GENE-EXPRESSION; MAMMALIAN-CELLS; TRANSGENIC MICE; GROWTH-FACTOR; CYCLE ARREST; PROTEIN; AMPLIFICATION; APOPTOSIS	To elucidate the contribution of the N-Myc protein to neuroblastomas we have used a synthetic inducible expression system on the basis of the tetracycline repressor of E coli to reversibly express N-myc in a human neuroblastoma cell line in which expression of endogenous N-myc is barely detectable. Like the c-Myc protein, N-Myc up-regulates the expression of both alpha-prothymosin and ornithine decarboxylase. Induction of N-myc increases both the rate of DNA-synthesis and the proliferation rate, and shortens the G(1) phase of the cell cycle. A comparison of cell populations in which the presence of N-Myc protein was restricted to different parts of G(0)/G(1) revealed that N-Myc is rate-limiting for cell cycle progression during the first 5 h after serum stimulation of quiescent cells providing direct evidence that Myc-proteins act early after mitogenic stimulation of quiescent cells.	GERMAN CANC RES CTR, DIV CELL CYCLE & PHENOTYPE, DEPT CYTOGENET 0825, D-69120 HEIDELBERG, GERMANY; GERMAN CANC RES CTR, DIV CELL CYCLE & PHENOTYPE, DEPT APPL IMMUNOL, D-69120 HEIDELBERG, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)								AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; ASKEW DS, 1991, ONCOGENE, V6, P1915; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERNARD HU, 1985, EXP CELL RES, V158, P237, DOI 10.1016/0014-4827(85)90446-X; BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; BREIT S, 1989, J NEUROSCI RES, V24, P21, DOI 10.1002/jnr.490240105; BRONDYK WH, 1991, ONCOGENE, V6, P1269; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CORVI R, 1994, P NATL ACAD SCI USA, V91, P5523, DOI 10.1073/pnas.91.12.5523; CORVI R, 1995, CANCER RES, V55, P3471; CROUCH DH, 1993, ONCOGENE, V8, P1849; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; DILDROP R, 1989, EMBO J, V8, P1121, DOI 10.1002/j.1460-2075.1989.tb03482.x; DOBROWOLSKI S, 1994, MOL CELL BIOL, V14, P5441, DOI 10.1128/MCB.14.8.5441; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HENRIKSSON M, 1996, IN PRESS; HERMEKING H, 1995, ONCOGENE, V11, P1409; HOANG AT, 1995, MOL CELL BIOL, V15, P4031; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KARN J, 1989, ONCOGENE, V4, P773; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; MORROW MA, 1992, GENE DEV, V6, P61, DOI 10.1101/gad.6.1.61; MURGRAUER G, 1988, J CELL BIOL, V107, P1325; NEGRONI A, 1991, CELL GROWTH DIFFER, V2, P511; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PENA A, 1993, J BIOL CHEM, V268, P27277; Peverali FA, 1996, ONCOGENE, V12, P457; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIETERNELLA CM, 1995, MOL CELL BIOL, V15, P6999; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; ROSS RA, 1983, J NATL CANCER I, V71, P741; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1990, GENE CHROMOSOME CANC, V1, P181, DOI 10.1002/gcc.2870010302; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; SCHWAB M, 1985, TRENDS GENET, V1, P271, DOI 10.1016/0168-9525(85)90103-9; Schwab M, 1995, NEUROSCIENTIST, V1, P277; SCHWEIGERER L, 1990, CANCER RES, V50, P4411; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; STOHR M, 1978, STAIN TECHNOL, V53, P205; SZABO P, 1992, BIOCHEM BIOPH RES CO, V185, P953, DOI 10.1016/0006-291X(92)91719-7; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; TORRES R, 1992, Current Opinion in Cell Biology, V4, P468, DOI 10.1016/0955-0674(92)90013-3; VANTVEER LJ, 1993, EMBO J, V12, P195, DOI 10.1002/j.1460-2075.1993.tb05645.x; WADA RK, 1993, CANCER, V72, P3346, DOI 10.1002/1097-0142(19931201)72:11<3346::AID-CNCR2820721134>3.0.CO;2-E; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455; ZERLIN M, 1987, ONCOGENE, V1, P19; ZORNIG M, 1995, ONCOGENE, V11, P2165	61	273	277	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	1996	13	4					803	812						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761302				2022-12-17	WOS:A1996VD43300016
J	Zeng, YX; ElDeiry, WS				Zeng, YX; ElDeiry, WS			Regulation of p21(WAF1/CIP1) expression by p53-independent pathways	ONCOGENE			English	Article						p21(WAF1/CIP1); transcription; p53; differentiation; TPA; cell cycle	CELL-CYCLE; P53; SUPPRESSION; GROWTH; GADD45	The CDK-inhibitor p21(WAF1/CIP1) has been implicated as a growth arrest mediator in p53-tumour suppression, cellular senescence and terminal differentiation. Cell type specific differences in p53-independent p21 expression and cell cycle arrest were found following treatment of human tumour cell lines with serum, 12-O-tetra-decanoyl-phorbol-13-acetate (TPA) or okadaic (OA). TPA induced p21 in ML1, K562 and HL60 leukemia cells, whereas OA induced p21 in SW480 and GM4723 carcinoma cells as well as in leukemic cells. In addition, TPA- and serum- but not OA-induced cell cycle arrest was reversed upon return of p21 to basal levels. To further investigate the mechanisms underlying p53-independent regulation of p21, the transcription inhibitor, Actinomycin D (AMD), was used to block p21 expression. The results showed a complete inhibition of p21 mRNA and protein induction by TPA or adriamycin but little effect on p21 mRNA induced by OA in the presence of AMD. These results suggested that TPA-induced p21 expression requires transcription initiation, while a post-transcriptional mechanism may be involved in OA-induction as well. Transient transfection assays with p21 promoter-luciferase reporters and TPA or OA treatment further confirmed that TPA, and to a lesser extent, OA, initiated transcription of p21. Finally, the protein kinase C inhibitor, staurosporine, was found to interfere with p21 induction and prevent cell cycle arrest following treatment with TPA but not OA, suggesting a requirement for PKC in TPA activation of p21 expression.	UNIV PENN,SCH MED,HOWARD HUGHES MED INST,DEPT MED,LAB MOLEC ONCOL & CELL CYCLE REGULAT,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,CTR CANC,PHILADELPHIA,PA 19104	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania			El-Deiry, Wafik/AAJ-6080-2020	El-Deiry, Wafik/0000-0002-9577-8266				ATKINS KB, 1995, CELL GROWTH DIFFER, V6, P713; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BI SC, 1992, LEUKEMIA, V6, P839; CLARKE PR, 1993, MOL BIOL CELL, V4, P397, DOI 10.1091/mbc.4.4.397; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FAN SJ, 1994, CANCER RES, V54, P5824; GRANA X, 1995, ONCOGENE, V11, P211; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; HIRAMA T, 1995, BLOOD, V86, P841; JIANG HP, 1994, ONCOGENE, V9, P3397; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KATIRA A, 1993, CLIN EXP IMMUNOL, V92, P347; LI Y, 1994, ONCOGENE, V9, P2261; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHIELI P, 1994, CANCER RES, V54, P3391; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; SCHWALLER J, 1995, J CLIN INVEST, V95, P973, DOI 10.1172/JCI117806; SHAO ZM, 1995, ONCOGENE, V11, P493; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TERADA T, 1995, NATURE, V376, P358; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIONG Y, 1993, NATURE, V366, P704; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHANG W, 1995, CANCER RES, V55, P668	36	273	284	1	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1557	1564						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622872				2022-12-17	WOS:A1996UF07600020
J	PRENDERGAST, GC; KHOSRAVIFAR, R; SOLSKI, PA; KURZAWA, H; LEBOWITZ, PF; DER, CJ				PRENDERGAST, GC; KHOSRAVIFAR, R; SOLSKI, PA; KURZAWA, H; LEBOWITZ, PF; DER, CJ			CRITICAL ROLE OF RHO IN CELL-TRANSFORMATION BY ONCOGENIC RAS	ONCOGENE			English	Article						RHO; RAS; CELL TRANSFORMATION; SIGNAL TRANSDUCTION	MAMMALIAN-CELLS; GROWTH-FACTOR; GENE-PRODUCT; PROTEIN; EXPRESSION; GAP; IDENTIFICATION; FARNESYLATION; LOCALIZATION; FIBROBLASTS	We demonstrate that Rho, a regulator of cytoskeletal actin, is necessary for Ras transformation. A dominant inhibitory Rho gene (RhoB(N19)) specifically suppressed Rat1 cell focus formation induced by oncogenic Ras but not by Raf. An activated Rho gene (Rho(V14)) lacked focus formation activity but augmented the focus formation activity of both oncogenes. NIH3T3 cell lines expressing Rho(V14) grew to higher saturation density and displayed reduced serum and anchorage requirements for growth. We concluded that Rho played a role in cell growth regulation and was required for transformation by oncogenic Ras but not Raf. A model for Ras signal transduction proposing separate Rho-dependent and Raf-dependent pathways is discussed.	UNIV PENN,DEPT GENET,PHILADELPHIA,PA 19104; UNIV PENN,MOLEC BIOL GRAD GRP,PHILADELPHIA,PA 19104; UNIV N CAROLINA,CURRICULUM GENET & MOLEC BIOL,CHAPEL HILL,NC; LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC	University of Pennsylvania; University of Pennsylvania; University of North Carolina; University of North Carolina Chapel Hill	PRENDERGAST, GC (corresponding author), WISTAR INST ANAT & BIOL,3601 SPRUCE ST,PHILADELPHIA,PA 19104, USA.		Khosravi-Far, Roya/C-3789-2008	Der, Channing/0000-0002-7751-2747				ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; ADAMSON P, 1992, J BIOL CHEM, V267, P20033; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOS JL, 1990, MOL GENETICS CANCER, P273; BURRIDGE K, 1988, ANN REV CELL BIOL, V7, P337; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8232; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK GJ, 1993, P NATL ACAD SCI USA, V90, P4887, DOI 10.1073/pnas.90.11.4887; COX AD, 1994, METHOD ENZYMOL, V238, P277; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; DARTSCH PC, 1994, EUR J CELL BIOL, V63, P316; DOWNWARD J, 1992, NATURE, V359, P273, DOI 10.1038/359273a0; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FUJITA H, 1990, EXP CELL RES, V186, P115, DOI 10.1016/0014-4827(90)90217-X; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; GIBBS JB, 1993, LIPID MODIFICATIONS, P335; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HARLOW E, 1988, ANTIBODIES LABORATOR; INGBER DE, 1994, INT REV CYTOL, V150, P173; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KHOSRAVIFAR R, 1995, UNPUB; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; LO SH, 1994, CANCER METAST REV, V13, P9, DOI 10.1007/BF00690415; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; MEDEMA RH, 1992, MOL CELL BIOL, V12, P3425, DOI 10.1128/MCB.12.8.3425; MULLAUER L, 1993, ONCOGENE, V8, P2531; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; PERONA R, 1993, ONCOGENE, V8, P1285; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; PRENDERGAST GC, 1991, EMBO J, V10, P757, DOI 10.1002/j.1460-2075.1991.tb08007.x; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; PRENDERGAST GC, 1993, ADV CANCER RES, V62, P19, DOI 10.1016/S0065-230X(08)60314-0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RIDLEY AJ, 1994, BIOESSAYS, V16, P321, DOI 10.1002/bies.950160506; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SELF AJ, 1993, ONCOGENE, V8, P665; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; YAMAMOTO M, 1993, ONCOGENE, V8, P1449	58	273	277	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 15	1995	10	12					2289	2296						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784077				2022-12-17	WOS:A1995RE54300003
J	ELIYAHU, D; GOLDFINGER, N; PINHASIKIMHI, O; SHAULSKY, G; SKURNIK, Y; ARAI, N; ROTTER, V; OREN, M				ELIYAHU, D; GOLDFINGER, N; PINHASIKIMHI, O; SHAULSKY, G; SKURNIK, Y; ARAI, N; ROTTER, V; OREN, M			METH-A FIBRO-SARCOMA CELLS EXPRESS 2 TRANSFORMING MUTANT P53 SPECIES	ONCOGENE			English	Article									WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT CELL BIOL,IL-76100 REHOVOT,ISRAEL; DNAX RES INST MOLEC & CELLULAR BIOL,PALO ALTO,CA	Weizmann Institute of Science; Weizmann Institute of Science; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.				Shaulsky, Gad/0000-0002-0532-0551	NCI NIH HHS [R01 CA 40099, R01 CA 40002] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040002, R01CA040099] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; CRAWFORD L, 1983, INT REV EXP PATHOL, V25, P1; DELEO AB, 1977, J EXP MED, V146, P720, DOI 10.1084/jem.146.3.720; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINLAY C, 1988, IN PRESS MOL CELL BI; GRONOSTAJSKI RM, 1984, MOL CELL BIOL, V4, P442, DOI 10.1128/MCB.4.3.442; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KACZMAREK L, 1986, EXP CELL RES, V162, P268, DOI 10.1016/0014-4827(86)90445-3; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; KLEIN G, 1982, ADV VIRAL ONCOLOGY, V2; LAIMINS LA, 1984, J VIROL, V49, P183, DOI 10.1128/JVI.49.1.183-189.1984; MALTZMAN W, 1981, VIROLOGY, V112, P145, DOI 10.1016/0042-6822(81)90620-6; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MATLASHEWSKI G, 1984, EMBO J, V3, P3257, DOI 10.1002/j.1460-2075.1984.tb02287.x; MICHALOVITZ D, 1986, MOL CELL BIOL, V6, P3531, DOI 10.1128/MCB.6.10.3531; MICHALOVITZ D, 1988, CELLULAR MOL BIOL TU, P247; MILNER J, 1986, VIROLOGY, V154, P21, DOI 10.1016/0042-6822(86)90426-5; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; OREN M, 1985, BIOCHIM BIOPHYS ACTA, V823, P67, DOI 10.1016/0304-419X(85)90015-0; PARADA LF, 1983, MOL CELL BIOL, V3, P2298, DOI 10.1128/MCB.3.12.2298; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PENNICA D, 1984, VIROLOGY, V134, P477, DOI 10.1016/0042-6822(84)90316-7; PINHASI O, 1984, MOL CELL BIOL, V4, P2180, DOI 10.1128/MCB.4.10.2180; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; PROKOCIMER M, 1986, BLOOD, V68, P113; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; ROTTER V, 1983, J IMMUNOL, V131, P329; ROTTER V, 1985, ADV CANCER RES, V43, P113, DOI 10.1016/S0065-230X(08)60944-6; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; RUSCETTI SK, 1983, J VIROL, V46, P1022, DOI 10.1128/JVI.46.3.1022-1026.1983; SANTOS E, 1984, SCIENCE, V223, P661, DOI 10.1126/science.6695174; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SOUSSI T, 1987, ONCOGENE, V1, P71; STURZBECHER HW, 1987, ONCOGENE, V1, P201; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WOLF D, 1984, MOL CELL BIOL, V4, P552, DOI 10.1128/MCB.4.3.552; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; WOLF D, 1985, MOL CELL BIOL, V5, P127, DOI 10.1128/MCB.5.1.127; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0; ZAKUTHOURI R, 1984, CANCER CELL, V2, P393	59	273	281	2	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1988	3	3					313	321						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q4367	3060794				2022-12-17	WOS:A1988Q436700010
J	Reiling, JH; Sabatini, DM				Reiling, J. H.; Sabatini, D. M.			Stress and mTORture signaling	ONCOGENE			English	Review						mTOR; raptor; rictor; growth; cancer; hypoxia	ACTIVATED PROTEIN-KINASE; INITIATION-FACTOR 4E; MESSENGER-RNA TRANSLATION; TUMOR-SUPPRESSOR COMPLEX; CELL-CYCLE PROGRESSION; S6 KINASE; MAMMALIAN TARGET; HEAT-SHOCK; SKELETAL-MUSCLE; LIFE-SPAN	The TOR ( target of rapamycin) pathway is an evolutionarily conserved signaling module regulating cell growth ( accumulation of mass) in response to a variety of environmental cues such as nutrient availability, hypoxia, DNA damage and osmotic stress. Its pivotal role in cellular and organismal homeostasis is reflected in the fact that unrestrained signaling activity in mammals is associated with the occurrence of disease states including inflammation, cancer and diabetes. The existence of TOR homologs in unicellular organisms whose growth is affected by environmental factors, such as temperature, nutrients and osmolarity, suggests an ancient role for the TOR signaling network in the surveillance of stress conditions. Here, we will summarize recent advances in the TOR signaling field with special emphasis on how stress conditions impinge on insulin/insulin-like growth factor signaling/TOR signaling.	MIT, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute	Sabatini, DM (corresponding author), MIT, Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	sabatini@wi.mit.edu		/0000-0002-1446-7256				Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Arsham AM, 2003, J BIOL CHEM, V278, P29655, DOI 10.1074/jbc.M212770200; Bae GU, 1999, J BIOL CHEM, V274, P32596, DOI 10.1074/jbc.274.46.32596; Benhar M, 2002, EMBO REP, V3, P420, DOI 10.1093/embo-reports/kvf094; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Bolster DR, 2002, J BIOL CHEM, V277, P23977, DOI 10.1074/jbc.C200171200; Bradley JMB, 2003, INVEST OPHTH VIS SCI, V44, P5174, DOI 10.1167/iovs.03-0213; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Brenneisen P, 2000, J BIOL CHEM, V275, P4336, DOI 10.1074/jbc.275.6.4336; Broughton SJ, 2005, P NATL ACAD SCI USA, V102, P3105, DOI 10.1073/pnas.0405775102; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Brugarolas JB, 2003, CANCER CELL, V4, P147, DOI 10.1016/S1535-6108(03)00187-9; Byfield MP, 2005, J BIOL CHEM, V280, P33076, DOI 10.1074/jbc.M507201200; Cai SL, 2006, J CELL BIOL, V173, P279, DOI 10.1083/jcb.200507119; Castro AF, 2003, J BIOL CHEM, V278, P32493, DOI 10.1074/jbc.C300226200; Clancy DJ, 2002, SCIENCE, V296, P319, DOI 10.1126/science.1069366; Colombani J, 2003, CELL, V114, P739, DOI 10.1016/S0092-8674(03)00713-X; Connolly E, 2006, MOL CELL BIOL, V26, P3955, DOI 10.1128/MCB.26.10.3955-3965.2006; Constantinou C, 2005, ONCOGENE, V24, P4839, DOI 10.1038/sj.onc.1208648; Copp J, 2005, AM J PHYSIOL-CELL PH, V288, pC403, DOI 10.1152/ajpcell.00095.2004; Cota D, 2006, SCIENCE, V312, P927, DOI 10.1126/science.1124147; Crespo JL, 2001, J BIOL CHEM, V276, P34441, DOI 10.1074/jbc.M103601200; Dames SA, 2005, J BIOL CHEM, V280, P20558, DOI 10.1074/jbc.M501116200; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Desai BN, 2002, P NATL ACAD SCI USA, V99, P4319, DOI 10.1073/pnas.261702698; Dimmeler S, 1998, CIRC RES, V83, P334, DOI 10.1161/01.RES.83.3.334; Ding M, 2002, MOL CELL BIOCHEM, V234, P81, DOI 10.1023/A:1015901232124; Dong JX, 2004, GENE DEV, V18, P2479, DOI 10.1101/gad.1240504; Drummond-Barbosa D, 2001, DEV BIOL, V231, P265, DOI 10.1006/dbio.2000.0135; Dudley R, 1998, J EXP BIOL, V201, P1043; Fang YM, 2003, CURR BIOL, V13, P2037, DOI 10.1016/j.cub.2003.11.021; Feigenblum D, 1996, MOL CELL BIOL, V16, P5450; Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; FONTOURA BMA, 1992, MOL CELL BIOL, V12, P5145, DOI 10.1128/MCB.12.11.5145; Fontoura BMA, 1997, MOL CELL BIOL, V17, P3146, DOI 10.1128/MCB.17.6.3146; Frazier MR, 2001, PHYSIOL BIOCHEM ZOOL, V74, P641, DOI 10.1086/322172; Frese KK, 2003, ONCOGENE, V22, P710, DOI 10.1038/sj.onc.1206151; Frias MA, 2006, CURR BIOL, V16, P1865, DOI 10.1016/j.cub.2006.08.001; Fumarola C, 2005, J CELL PHYSIOL, V204, P155, DOI 10.1002/jcp.20272; Gan BY, 2005, J CELL BIOL, V170, P379, DOI 10.1083/jcb.200411106; Gangloff YG, 2004, MOL CELL BIOL, V24, P9508, DOI 10.1128/MCB.24.21.9508-9516.2004; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Gual P, 2003, J BIOL CHEM, V278, P26550, DOI 10.1074/jbc.M212273200; Guarente L, 2000, NATURE, V408, P255, DOI 10.1038/35041700; Guertin DA, 2005, TRENDS MOL MED, V11, P353, DOI 10.1016/j.molmed.2005.06.007; Guertin DA, 2006, CURR BIOL, V16, P958, DOI 10.1016/j.cub.2006.03.084; Hafen E, 2003, PLOS BIOL, V1, P319, DOI 10.1371/journal.pbio.0000086; Hahn-Windgassen A, 2005, J BIOL CHEM, V280, P32081, DOI 10.1074/jbc.M502876200; Hansen IA, 2005, J BIOL CHEM, V280, P20565, DOI 10.1074/jbc.M500712200; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hardie DG, 2006, J PHYSIOL-LONDON, V574, P7, DOI 10.1113/jphysiol.2006.108944; Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; Horman S, 2002, CURR BIOL, V12, P1419, DOI 10.1016/S0960-9822(02)01077-1; Hornberger TA, 2006, P NATL ACAD SCI USA, V103, P4741, DOI 10.1073/pnas.0600678103; Hornberger TA, 2006, J CELL BIOCHEM, V97, P1207, DOI 10.1002/jcb.20671; Hornberger TA, 2001, AM J PHYSIOL-CELL PH, V281, pC179, DOI 10.1152/ajpcell.2001.281.1.C179; Horton LE, 2002, ONCOGENE, V21, P5325, DOI 10.1038/sj.onc.1205662; Hresko RC, 2005, J BIOL CHEM, V280, P40406, DOI 10.1074/jbc.M508361200; Huang CS, 2002, CANCER RES, V62, P5689; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Hwangbo DS, 2004, NATURE, V429, P562, DOI 10.1038/nature02549; Ikeya T, 2002, CURR BIOL, V12, P1293, DOI 10.1016/S0960-9822(02)01043-6; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Jorgensen P, 2004, GENE DEV, V18, P2491, DOI 10.1101/gad.1228804; Jung DK, 2003, EXP CELL RES, V290, P144, DOI 10.1016/S0014-4827(03)00320-3; JURIVICH DA, 1991, J CELL PHYSIOL, V148, P252, DOI 10.1002/jcp.1041480210; Kaeberlein M, 2005, SCIENCE, V310, P1193, DOI 10.1126/science.1115535; Kandarian SC, 2006, MUSCLE NERVE, V33, P155, DOI 10.1002/mus.20442; Kapahi P, 2004, CURR BIOL, V14, P885, DOI 10.1016/j.cub.2004.03.059; Kaper F, 2006, CANCER RES, V66, P1561, DOI 10.1158/0008-5472.CAN-05-3375; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; Koritzinsky M, 2006, EMBO J, V25, P1114, DOI 10.1038/sj.emboj.7600998; Koumenis C, 2002, MOL CELL BIOL, V22, P7405, DOI 10.1128/MCB.22.21.7405-7416.2002; Kraiss LW, 2001, J SURG RES, V97, P20, DOI 10.1006/jsre.2001.6091; Kwiatkowski DJ, 2005, HUM MOL GENET, V14, pR251, DOI 10.1093/hmg/ddi260; LAMPHEAR BJ, 1991, J BIOL CHEM, V266, P2789; Leslie NR, 2003, EMBO J, V22, P5501, DOI 10.1093/emboj/cdg513; Li W, 2003, J CELL PHYSIOL, V195, P202, DOI 10.1002/jcp.10230; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Lin RZ, 1997, J BIOL CHEM, V272, P31196, DOI 10.1074/jbc.272.49.31196; Liu LP, 2006, MOL CELL, V21, P521, DOI 10.1016/j.molcel.2006.01.010; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Long X, 2005, CURR BIOL, V15, P702, DOI 10.1016/j.cub.2005.02.053; Lum JJ, 2005, NAT REV MOL CELL BIO, V6, P439, DOI 10.1038/nrm1660; Ma L, 2005, GENE DEV, V19, P1779, DOI 10.1101/gad.1314405; Mahfouz MM, 2006, PLANT CELL, V18, P477, DOI 10.1105/tpc.105.035931; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Manning BD, 2005, GENE DEV, V19, P1773, DOI 10.1101/gad.1314605; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Mannova P, 2005, J VIROL, V79, P8742, DOI 10.1128/JVI.79.14.8742-8749.2005; Marion RM, 2004, P NATL ACAD SCI USA, V101, P14315, DOI 10.1073/pnas.0405353101; Martin DE, 2004, CELL, V119, P969, DOI 10.1016/j.cell.2004.11.047; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; Moody CA, 2005, J VIROL, V79, P5499, DOI 10.1128/JVI.79.9.5499-5506.2005; Murakami M, 2004, MOL CELL BIOL, V24, P6710, DOI 10.1128/mcb.24.15.6710-6718.2004; Nobukuni T, 2005, P NATL ACAD SCI USA, V102, P14238, DOI 10.1073/pnas.0506925102; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; O'Shea C, 2005, EMBO J, V24, P1211, DOI 10.1038/sj.emboj.7600597; Ohji G, 2006, J BIOCHEM, V139, P129, DOI 10.1093/jb/mvj008; Oldham S, 2003, TRENDS CELL BIOL, V13, P79, DOI 10.1016/S0962-8924(02)00042-9; Parrott LA, 1999, J BIOL CHEM, V274, P24731, DOI 10.1074/jbc.274.35.24731; Patel PH, 2003, J CELL SCI, V116, P3601, DOI 10.1242/jcs.00661; Patel S, 2002, BIOCHEM J, V365, P537, DOI 10.1042/BJ20020266; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Peck LS, 2003, P ROY SOC B-BIOL SCI, V270, pS166, DOI 10.1098/rsbl.2003.0054; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; Peng T, 2002, MOL CELL BIOL, V22, P5575, DOI 10.1128/MCB.22.15.5575-5584.2002; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Powers RW, 2006, GENE DEV, V20, P174, DOI 10.1101/gad.1381406; Proud CG, 2002, EUR J BIOCHEM, V269, P5338, DOI 10.1046/j.1432-1033.2002.03292.x; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Reiling JH, 2004, GENE DEV, V18, P2879, DOI 10.1101/gad.322704; Reynolds TH, 2002, J BIOL CHEM, V277, P17657, DOI 10.1074/jbc.M201142200; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; Rulifson EJ, 2002, SCIENCE, V296, P1118, DOI 10.1126/science.1070058; Ruvinsky I, 2005, GENE DEV, V19, P2199, DOI 10.1101/gad.351605; Ruvinsky I, 2006, TRENDS BIOCHEM SCI, V31, P342, DOI 10.1016/j.tibs.2006.04.003; Santoro MG, 2000, BIOCHEM PHARMACOL, V59, P55, DOI 10.1016/S0006-2952(99)00299-3; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sarbassov DD, 2005, J BIOL CHEM, V280, P39505, DOI 10.1074/jbc.M506096200; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; SCHARF KD, 1982, CELL, V30, P427, DOI 10.1016/0092-8674(82)90240-9; Scott BA, 2002, SCIENCE, V296, P2388, DOI 10.1126/science.1072302; Shah OJ, 2004, CURR BIOL, V14, P1650, DOI 10.1016/j.cub.2004.08.026; Smith EM, 2005, J BIOL CHEM, V280, P18717, DOI 10.1074/jbc.M414499200; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Teleman AA, 2005, GENE DEV, V19, P1844, DOI 10.1101/gad.341505; Tettweiler G, 2005, GENE DEV, V19, P1840, DOI 10.1101/gad.1311805; Thomas G, 2002, BIOL RES, V35, P305, DOI 10.4067/S0716-97602002000200022; Thomas GV, 2006, NAT MED, V12, P122, DOI 10.1038/nm1337; Tinton SA, 1999, FEBS LETT, V446, P55, DOI 10.1016/S0014-5793(99)00185-4; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Turck F, 1998, MOL CELL BIOL, V18, P2038, DOI 10.1128/MCB.18.4.2038; Valko M, 2006, CHEM-BIOL INTERACT, V160, P1, DOI 10.1016/j.cbi.2005.12.009; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Vellai T, 2003, NATURE, V426, P620, DOI 10.1038/426620a; Vries RGJ, 1997, J BIOL CHEM, V272, P32779, DOI 10.1074/jbc.272.52.32779; Weisman R, 2001, J BIOL CHEM, V276, P7027, DOI 10.1074/jbc.M010446200; Wu Q, 2005, P NATL ACAD SCI USA, V102, P13289, DOI 10.1073/pnas.0501914102; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Wullschleger S, 2005, J BIOL CHEM, V280, P30697, DOI 10.1074/jbc.M505553200; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100; ZAPATA JM, 1991, J BIOL CHEM, V266, P16007; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222; Zhang Y, 2006, GENETICS, V172, P355, DOI 10.1534/genetics.105.051979; Zhang YG, 2001, J BIOL CHEM, V276, P20913, DOI 10.1074/jbc.M009047200	178	272	291	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2006	25	48					6373	6383		10.1038/sj.onc.1209889	http://dx.doi.org/10.1038/sj.onc.1209889			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	096MH	17041623				2022-12-17	WOS:000241380700004
J	Brantley, DM; Cheng, N; Thompson, EJ; Lin, Q; Brekken, RA; Thorpe, PE; Muraoka, RS; Cerretti, DP; Pozzi, A; Jackson, D; Lin, C; Chen, J				Brantley, DM; Cheng, N; Thompson, EJ; Lin, Q; Brekken, RA; Thorpe, PE; Muraoka, RS; Cerretti, DP; Pozzi, A; Jackson, D; Lin, C; Chen, J			Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo	ONCOGENE			English	Article						tumor angiogenesis; Eph receptor tyrosine kinase; ephrin; soluble Eph receptor; vascular window model	ENDOTHELIAL GROWTH-FACTOR; SKIN WINDOW CHAMBERS; TYROSINE KINASE; CELL-ADHESION; MOUSE; EXPRESSION; EPHRINS; GENE; MORPHOGENESIS; LIGAND	The Eph family of receptor tyrosine kinases and their ligands, known as ephrins, play a crucial role in vascular development during embryogenesis. The function of these molecules in adult angiogenesis has not been well characterized. Here, we report that blocking Eph A class receptor activation inhibits angiogenesis in two independent tumor types, the RIP-Tag transgenic model of angiogenesis-dependent pancreatic islet cell carcinoma and the 4T1 model of metastatic mammary adenocarcinoma. Ephrin-A1 ligand was expressed in both tumor and endothelial cells, and EphA2 receptor was localized primarily in tumor-associated vascular endothelial cells. Soluble EphA2-Fc or EphA3-Fc receptors inhibited tumor angiogenesis in cutaneous window assays, and tumor growth in vivo. EphA2-Fc or EphA3-Fc treatment resulted in decreased tumor vascular density, tumor volume, and cell proliferation, but increased cell apoptosis. However, EphA2-Fc had no direct effect on tumor cell growth or apoptosis in culture, yet inhibited migration of endothelial cells in response to tumor cells, suggesting that the soluble receptor inhibited blood vessel recruitment by the tumor. These data provide the first functional evidence for Eph A class receptor regulation of pathogenic angiogenesis induced by tumors and support the function of A class Eph receptors in tumor progression.	Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Radiat Oncol, Nashville, TN 37232 USA; Hope Heart Inst, Dept Vasc Biol, Seattle, WA 98122 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX USA; Immunex Res & Dev Corp, Seattle, WA 98101 USA; Amersham Pharmacia Corp, St Louis, MO 63198 USA	Vanderbilt University; Vanderbilt University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Chen, J (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, A-4323 MCN,1161 21st Ave S, Nashville, TN 37232 USA.	jin.chen@mcmail.vanderbilt.edu		Chen, Jin/0000-0002-5557-2079	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD036400] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA068485, T32CA009592] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007751] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047078] Funding Source: NIH RePORTER; NCI NIH HHS [T-32 CA09592, 2P30CA68485] Funding Source: Medline; NHLBI NIH HHS [T32-HL-07751-06] Funding Source: Medline; NICHD NIH HHS [HD36400] Funding Source: Medline; NIDDK NIH HHS [DK47078] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AALTOMAA S, 1993, J CANCER RES CLIN, V119, P288, DOI 10.1007/BF01212727; Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295; Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Brantley DM, 2000, MECH DEVELOP, V97, P149, DOI 10.1016/S0925-4773(00)00405-6; Brantley DM, 2001, MOL BIOL CELL, V12, P1445, DOI 10.1091/mbc.12.5.1445; Brekken RA, 1998, CANCER RES, V58, P1952; Chen J, 1998, J BIOL CHEM, V273, P24670, DOI 10.1074/jbc.273.38.24670; Cheng N, 2002, CYTOKINE GROWTH F R, V13, P75, DOI 10.1016/S1359-6101(01)00031-4; Daniel TO, 1996, KIDNEY INT, V50, pS73; DANKORT DL, 1996, TRANSGENIC MODELS BR; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; Davy A, 2000, EMBO J, V19, P5396, DOI 10.1093/emboj/19.20.5396; Davy A, 1999, GENE DEV, V13, P3125, DOI 10.1101/gad.13.23.3125; EASTY DJ, 1995, INT J CANCER, V60, P129, DOI 10.1002/ijc.2910600119; Easty DJ, 1999, INT J CANCER, V84, P494, DOI 10.1002/(SICI)1097-0215(19991022)84:5<494::AID-IJC8>3.3.CO;2-F; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1994, J CLIN ONCOL, V12, P441, DOI 10.1200/JCO.1994.12.3.441; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Gale NW, 1997, CELL TISSUE RES, V290, P227, DOI 10.1007/s004410050927; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; Gerety SS, 1999, MOL CELL, V4, P403, DOI 10.1016/S1097-2765(00)80342-1; Goede V, 1998, ANTICANCER RES, V18, P2199; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Hattori M, 2000, SCIENCE, V289, P1360, DOI 10.1126/science.289.5483.1360; Holder N, 1999, DEVELOPMENT, V126, P2033; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; Huai JS, 2001, J BIOL CHEM, V276, P6689, DOI 10.1074/jbc.M008127200; Huang Q, 1999, NAT BIOTECHNOL, V17, P1033, DOI 10.1038/13736; Kuehn R, 1999, PANCREAS, V18, P96, DOI 10.1097/00006676-199901000-00012; Laferriere J, 2001, J BIOL CHEM, V276, P33762, DOI 10.1074/jbc.M008564200; Li CY, 2000, JNCI-J NATL CANCER I, V92, P143, DOI 10.1093/jnci/92.2.143; Lin PN, 1998, P NATL ACAD SCI USA, V95, P8829, DOI 10.1073/pnas.95.15.8829; McBride JL, 1998, MECH DEVELOP, V77, P201, DOI 10.1016/S0925-4773(98)00142-7; Muraoka RS, 2001, J CELL BIOL, V153, P917, DOI 10.1083/jcb.153.5.917; Myers C, 2000, J CELL BIOL, V148, P343, DOI 10.1083/jcb.148.2.343; Ogawa K, 2000, ONCOGENE, V19, P6043, DOI 10.1038/sj.onc.1204004; OWENS RB, 1974, J NATL CANCER I, V53, P261, DOI 10.1093/jnci/53.1.261; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; PAPENFUSS HD, 1979, MICROVASC RES, V18, P311, DOI 10.1016/0026-2862(79)90039-6; PASSANITI A, 1992, LAB INVEST, V67, P519; Prewett M, 1999, CANCER RES, V59, P5209; PREZIOSI R, 1995, J COMP PATHOL, V113, P301, DOI 10.1016/S0021-9975(05)80117-3; RADVANYI F, 1993, MOL CELL BIOL, V13, P4223, DOI 10.1128/MCB.13.7.4223; ROCKWELL S, 1977, INT J RADIAT BIOL, V31, P153, DOI 10.1080/09553007714550171; ROCKWELL S, 1978, BRIT J CANCER, V37, P212; ROCKWELL S, 1981, CANCER RES, V41, P527; VandenBroecke C, 1996, CLIN EXP METASTAS, V14, P282, DOI 10.1007/BF00053902; Walker-Daniels J, 1999, PROSTATE, V41, P275, DOI 10.1002/(SICI)1097-0045(19991201)41:4<275::AID-PROS8>3.0.CO;2-T; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; WEIDNER N, 1992, JNCI-J NATL CANCER I, V84, P1875, DOI 10.1093/jnci/84.24.1875; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WEIDNER N, 1996, ANGIOGENESIS BREAST; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Zantek ND, 1999, CELL GROWTH DIFFER, V10, P629; Zelinski DP, 2001, CANCER RES, V61, P2301	58	272	302	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2002	21	46					7011	7026		10.1038/sj.onc.1205679	http://dx.doi.org/10.1038/sj.onc.1205679			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370823				2022-12-17	WOS:000178424900004
J	Pene, F; Claessens, YE; Muller, O; Viguie, F; Mayeux, P; Dreyfus, F; Lacombe, C; Bouscary, D				Pene, F; Claessens, YE; Muller, O; Viguie, F; Mayeux, P; Dreyfus, F; Lacombe, C; Bouscary, D			Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma	ONCOGENE			English	Article						multiple myeloma; phosphatidylinositol 3-kinase; P70-S6-kinase; p27(Kip1); Skp2	FORKHEAD TRANSCRIPTION FACTOR; DEPENDENT KINASE INHIBITOR; CELL-CYCLE PROGRESSION; GROWTH-FACTOR-I; CONSTITUTIVE ACTIVATION; FACTOR FKHR-L1; TUMOR-GROWTH; S6 KINASE; SURVIVAL; EXPRESSION	Multiple myeloma (MM) is a plasma cell malignancy preliminary localized in the bone marrow and characterized by its capacity to disseminate. IL-6 and IGF-1 have been shown to mediate proliferative and anti-apoptotic signals in plasmocytes. However, in primary plasma-cell leukemia (PCL) and in end-stage aggressive extramedullar disease, the cytokine requirement for both effects may be not mandatory. This suggests that constitutive activation of signaling pathways occurs. One of the signaling pathways whose deregulation may play an oncogenic role in MM is the phosphatidylinositol 3-kinase (PI 3-K) pathway. In human growth factor-independent MM cell lines OPM2 and RPMI8226, we show that the PI 3-K inhibitors LY294002 and Wortmannin strongly inhibited cell proliferation, whereas inhibition of the mammalian Target Of Rapamycin (mTOR)/P70-S6-kinase (P70(S6K)) pathway with rapamycin or of the Mitogen-Activated Protein Kinase (MAPK) pathway with PD98059 had minimal effect on proliferation. In both cell lines, constitutive activation of the PI 3-K/Akt/FKHRL-1, mTOR/P70(S6K) and MAPK pathways was detected. LY294002 inhibited phosphorylation of Akt, FKHRL-1 and P70(S6K) but had no effect on ERK1/2 phosphorylation, indicating that the PI 3-K and MAPK pathways are independent. IGF-1 but not IL-6 increased phosphorylation of Akt, FKHRL-1 and P70(S6K). Purified plasmocytes from four patients with MM and two patients with primary PCL were studied. In three of them including the two patients with PCL, constitutive phosphorylation of Akt, FKHRL-1 and P70(S6K) was present, inhibited by LY294002 and enhanced by IGF-1. In these patients with constitutive Akt activation, normal PTEN expression was detected. PI 3-K inhibition induced caspase-dependent apoptosis as confirmed by inhibition with the large spectrum caspase inhibitor Z-VAD-FMK and cleavage of pro-caspase-3. Both cell lines spontaneously expressed Skp2 and cyclin D1 proteins at high levels but no p27(Kip1) protein. In the presence of LY294002, cell-cycle arrest in G0/G1 was observed, p27(Kip1) protein expression was up-regulated whereas the expression of both Skp2 and cyclin D1 dramatically diminished. PI 3-K-dependent GSK-3alpha/beta constitutive phosphorylation was also detected in OPM2 cells that may contribute to high cyclin D1 expression. Overall, our results suggest that PI 3-K has a major role in the control of proliferation and apoptosis of growth factor-independent MM cell lines. Most of the biological effects of PI 3-K activation in these cell lines may be mediated by the opposite modulation of p27(Kip1) and Skp2 protein expression. Moreover, constitutive activation of this pathway is a frequent event in the biology of MM in vivo and may be more frequently observed in PCL.	Univ Paris 05, CNRS, UMR 8104, IFR 116,INSERM,U567,Inst Cochin,Dept Hematol, F-75014 Paris, France; Hop Cochin, APHP, Serv Hematol Clin & Biol, Paris, France; Hop Hotel Dieu, APHP, Lab Cytogenet, F-75181 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite	Bouscary, D (corresponding author), Univ Paris 05, CNRS, UMR 8104, IFR 116,INSERM,U567,Inst Cochin,Dept Hematol, 27 Rue Faubourg St Jacques, F-75014 Paris, France.			Pene, Frederic/0000-0003-3639-3849; Bouscary, Didier/0000-0003-3654-5064				Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Barata JT, 2001, BLOOD, V98, P1524, DOI 10.1182/blood.V98.5.1524; Brennan P, 1999, MOL CELL BIOL, V19, P4729; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; De Vos J, 2000, BRIT J HAEMATOL, V109, P823, DOI 10.1046/j.1365-2141.2000.02127.x; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Feng LX, 2000, J BIOL CHEM, V275, P25572, DOI 10.1074/jbc.M002218200; Ferlin M, 2000, BRIT J HAEMATOL, V111, P626, DOI 10.1046/j.1365-2141.2000.02364.x; FREUND GG, 1993, J IMMUNOL, V151, P1811; Ge NL, 2000, BLOOD, V96, P2856; Ge NL, 2000, ONCOGENE, V19, P4091, DOI 10.1038/sj.onc.1203801; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Hosoi H, 1999, CANCER RES, V59, P886; Hsu JH, 2001, BLOOD, V98, P2853, DOI 10.1182/blood.V98.9.2853; Hyun T, 2000, BLOOD, V96, P3560, DOI 10.1182/blood.V96.10.3560.h8003560_3560_3568; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; Latres E, 2001, P NATL ACAD SCI USA, V98, P2515, DOI 10.1073/pnas.041475098; Li WQ, 2000, CANCER RES, V60, P3909; Mahalingam M, 1996, MOL CELL BIOL, V16, P405; Mamillapalli R, 2001, CURR BIOL, V11, P263, DOI 10.1016/S0960-9822(01)00065-3; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; Ogata A, 1997, J IMMUNOL, V159, P2212; Parada Y, 2001, J BIOL CHEM, V276, P23572, DOI 10.1074/jbc.M101885200; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Puthier D, 1999, EUR J IMMUNOL, V29, P3945, DOI 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; SHI YF, 1995, CANCER RES, V55, P1982; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Takuwa N, 1999, MOL CELL BIOL, V19, P1346; Tinhofer I, 2000, BLOOD, V95, P610, DOI 10.1182/blood.V95.2.610; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Tu YP, 2000, CANCER RES, V60, P6763	48	272	309	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 26	2002	21	43					6587	6597		10.1038/sj.onc.1205923	http://dx.doi.org/10.1038/sj.onc.1205923			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242656				2022-12-17	WOS:000178202300004
J	Grana, X; Garriga, J; Mayol, X				Grana, X; Garriga, J; Mayol, X			Role of the retinoblastoma protein family, pRB, p107 and p130 in the negative control of cell growth	ONCOGENE			English	Review						CDK; CKI; transcriptional regulation; cyclins; cell cycle	CYCLIN-DEPENDENT KINASE; LARGE-T-ANTIGEN; E2F TRANSCRIPTION FACTOR; RNA-POLYMERASE-III; S-PHASE ENTRY; SKELETAL-MUSCLE CELLS; LOOP-HELIX REGULATORS; A GENE-EXPRESSION; DNA-SYNTHESIS; BINDING-SITE	The retinoblastoma family of proteins, also known as pocket proteins, includes the product of the retinoblastoma susceptibility gene and the functionally and structurally related proteins p107 and p130, Pocket proteins control growth processes in many cell types, and this has been linked to the ability of pocket proteins to interact with a multitude of cellular proteins that regulate gene expression at various levels. By regulating gene expression, pocket proteins control cell cycle progression, cell cycle entry and exit, cell differentiation and apoptosis, This review will focus on the mechanisms of regulation of pocket proteins and how modulation of pocket protein levels and phosphorylation status regulate association with their cellular targets. The coordinated regulation of pocket proteins provides the cells with a competence mechanism for passage through certain cell growth and differentiation transitions.	Temple Univ, Fels Inst Canc Res & Mol Biol, Sch Med, Philadelphia, PA 19140 USA; Temple Univ, Dept Biochem, Sch Med, Philadelphia, PA 19140 USA; Inst Municipal Invest Med, Unitat Biol Cellular & Mol, E-08003 Barcelona, Spain	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Grana, X (corresponding author), Temple Univ, Fels Inst Canc Res & Mol Biol, Sch Med, AHP Bldg,Room 553,3307 N Broad St, Philadelphia, PA 19140 USA.		Mayol, Xavier/C-1391-2012	Grana, Xavier/0000-0001-7134-0473; Mayol, Xavier/0000-0001-7288-195X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054894] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54894] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JA, 1995, BIOCHEMISTRY-US, V34, P2447, DOI 10.1021/bi00008a007; Adams PD, 1996, MOL CELL BIOL, V16, P6623; Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Batsche E, 1998, MOL CELL BIOL, V18, P3647, DOI 10.1128/MCB.18.7.3647; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; Belbrahem A, 1996, EXP CELL RES, V225, P286, DOI 10.1006/excr.1996.0178; Botz J, 1996, MOL CELL BIOL, V16, P3401; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; Castano E, 1998, MOL CELL BIOL, V18, P5380, DOI 10.1128/MCB.18.9.5380; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; Chang KH, 1997, P NATL ACAD SCI USA, V94, P9040, DOI 10.1073/pnas.94.17.9040; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; Choubey D, 1997, ONCOGENE, V15, P291, DOI 10.1038/sj.onc.1201184; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; CHRISTENSEN JB, 1995, J VIROL, V69, P3945, DOI 10.1128/JVI.69.6.3945-3948.1995; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; CORBEIL HB, 1995, ONCOGENE, V11, P909; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; Datta B, 1998, MOL CELL BIOL, V18, P1074, DOI 10.1128/MCB.18.2.1074; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DeLuca A, 1997, J BIOL CHEM, V272, P20971, DOI 10.1074/jbc.272.34.20971; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; DOU QP, 1992, P NATL ACAD SCI USA, V89, P3256, DOI 10.1073/pnas.89.8.3256; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; DYNLACHT BD, 1995, NATURE, V374, P114, DOI 10.1038/374114a0; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Garriga J, 1998, BIOCHEM J, V333, P645, DOI 10.1042/bj3330645; Gaubatz S, 1998, P NATL ACAD SCI USA, V95, P9190, DOI 10.1073/pnas.95.16.9190; Geng Y, 1996, ONCOGENE, V12, P1173; GRANA X, 1995, ONCOGENE, V11, P211; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Guo K, 1997, J BIOL CHEM, V272, P791, DOI 10.1074/jbc.272.2.791; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Hauser PJ, 1997, J BIOL CHEM, V272, P22954, DOI 10.1074/jbc.272.36.22954; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hiyama H, 1998, ONCOGENE, V16, P1513, DOI 10.1038/sj.onc.1201667; HORTON LE, 1995, CELL GROWTH DIFFER, V6, P395; Hoshikawa Y, 1998, P NATL ACAD SCI USA, V95, P8574, DOI 10.1073/pnas.95.15.8574; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; HU NP, 1994, ONCOGENE, V9, P1021; Huet X, 1996, MOL CELL BIOL, V16, P3789; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JIANG HP, 1995, ONCOGENE, V11, P1179; Johnson David G., 1998, Frontiers in Bioscience, V3, pD447; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1995, ONCOGENE, V11, P1685; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JOHNSON L F, 1992, Current Opinion in Cell Biology, V4, P149, DOI 10.1016/0955-0674(92)90025-8; Kastner A, 1998, CELL GROWTH DIFFER, V9, P857; KATO J, 1993, GENE DEV, V7, P331; KIESS M, 1995, CELL GROWTH DIFFER, V6, P1287; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Knudsen ES, 1998, ONCOGENE, V16, P1655, DOI 10.1038/sj.onc.1201682; Kobayashi M, 1998, EXP CELL RES, V239, P40, DOI 10.1006/excr.1997.3880; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; KRANENBURG O, 1995, ONCOGENE, V10, P87; Lacy S, 1997, ONCOGENE, V14, P2395, DOI 10.1038/sj.onc.1201085; Larminie CGC, 1997, EMBO J, V16, P2061, DOI 10.1093/emboj/16.8.2061; Lavender P, 1997, ONCOGENE, V14, P2721, DOI 10.1038/sj.onc.1201243; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1995, SEMIN CANCER BIOL, V6, P195, DOI 10.1006/scbi.1995.0026; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; MAANDAG ECR, 1994, EMBO J, V13, P4260, DOI 10.1002/j.1460-2075.1994.tb06746.x; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MAYOL X, 1993, ONCOGENE, V8, P2561; Mayol X, 1996, ONCOGENE, V13, P237; Mayol X, 1997, Prog Cell Cycle Res, V3, P157; MAYOL X, 1995, ONCOGENE, V11, P801; MAYOL X, 1998, FRONT BIOSCI, V3, P11; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Morkel M, 1997, NATURE, V390, P567, DOI 10.1038/37507; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Mulligan GJ, 1998, MOL CELL BIOL, V18, P206, DOI 10.1128/MCB.18.1.206; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; OGRIS E, 1993, J VIROL, V67, P1765, DOI 10.1128/JVI.67.4.1765-1771.1993; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Ohtani K, 1998, ONCOGENE, V17, P1777, DOI 10.1038/sj.onc.1202105; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; Oswald F, 1996, MOL CELL BIOL, V16, P1889; Pan HC, 1998, MOL CELL, V2, P283, DOI 10.1016/S1097-2765(00)80273-7; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; Paramio JM, 1998, ONCOGENE, V17, P949, DOI 10.1038/sj.onc.1202031; Philips A, 1998, ONCOGENE, V16, P1373, DOI 10.1038/sj.onc.1201655; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Puri PL, 1998, CANCER RES, V58, P1325; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Rampalli AM, 1998, ONCOGENE, V16, P399, DOI 10.1038/sj.onc.1201546; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; Rawls A, 1997, CELL, V89, P5, DOI 10.1016/S0092-8674(00)80175-0; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Richon VM, 1997, J BIOL CHEM, V272, P10117, DOI 10.1074/jbc.272.15.10117; Riley DJ, 1997, MOL CELL BIOL, V17, P7342, DOI 10.1128/MCB.17.12.7342; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Schulze A, 1998, J VIROL, V72, P2323, DOI 10.1128/JVI.72.3.2323-2334.1998; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Shih HH, 1998, MOL CELL BIOL, V18, P4732, DOI 10.1128/MCB.18.8.4732; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; Shiyanov P, 1996, MOL CELL BIOL, V16, P737; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; Smith EJ, 1998, CELL GROWTH DIFFER, V9, P297; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Sterner JM, 1998, MOL CELL BIOL, V18, P2748, DOI 10.1128/MCB.18.5.2748; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Stubdal H, 1997, MOL CELL BIOL, V17, P4979, DOI 10.1128/MCB.17.9.4979; SUZUKITAKAHASHI I, 1995, ONCOGENE, V10, P1691; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TAM SW, 1994, ONCOGENE, V9, P2663; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; Voit R, 1997, MOL CELL BIOL, V17, P4230, DOI 10.1128/MCB.17.8.4230; Wang J, 1996, J CELL BIOCHEM, V62, P405; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; White RJ, 1997, TRENDS BIOCHEM SCI, V22, P77, DOI 10.1016/S0968-0004(96)10067-0; Wiggan O, 1998, ONCOGENE, V16, P227, DOI 10.1038/sj.onc.1201534; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603; Yee Amy S., 1998, Frontiers in Bioscience, V3, pD532; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; ZALVIDE J, 1995, MOL CELL BIOL, V15, P5800; Zarkowska T, 1997, ONCOGENE, V14, P249, DOI 10.1038/sj.onc.1200824; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; ZERFASS K, 1995, J VIROL, V69, P6389, DOI 10.1128/JVI.69.10.6389-6399.1995; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; ZHU LG, 1995, MOL CELL BIOL, V15, P3552; ZWICKER J, 1995, NUCLEIC ACIDS RES, V23, P3822, DOI 10.1093/nar/23.19.3822; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	193	272	274	0	12	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 24	1998	17	25					3365	3383		10.1038/sj.onc.1202575	http://dx.doi.org/10.1038/sj.onc.1202575			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157EW	9916999				2022-12-17	WOS:000078048200018
J	CLARKE, AR; GLEDHILL, S; HOOPER, ML; BIRD, CC; WYLLIE, AH				CLARKE, AR; GLEDHILL, S; HOOPER, ML; BIRD, CC; WYLLIE, AH			P53 DEPENDENCE OR EARLY APOPTOTIC AND PROLIFERATIVE RESPONSES WITHIN THE MOUSE INTESTINAL EPITHELIUM FOLLOWING GAMMA-IRRADIATION	ONCOGENE			English	Article							CELL-CYCLE CHECKPOINT; WILD-TYPE P53; P53-DEFICIENT MICE; IONIZING-RADIATION; COLORECTAL-CANCER; DNA-SYNTHESIS; MUTATIONS; TUMORS; GENE; IDENTIFICATION	p53 is now well characterised as a tumour suppressor gene, with loss of normal p53 function being recorded as the commonest genetic event associated with human malignancy. In particular, its involvement with tumorigenesis within the intestine is well established. Normal p53 function has been shown to be crucial for the induction of apoptosis in tumour cell lines, murine thymocytes and murine haematopoietic cells following DNA damage. To elucidate further the role of p53 in the cellular response to DNA damage we have investigated the response to gamma-irradiation of crypt cells in vivo from the small and large intestine of mice bearing a constitutive p53 deletion. Four hours after gamma-irradiation, a time point at which wild type crypt cells show abundant apoptosis, crypt cells from p53-deficient mice differed in that they were completely resistant to the induction of apoptosis. The p53 dose dependence of this phenomenon was clearly shown by the intermediate level of apoptosis observed in p53 heterozygotes. Analysis of the mitotic index and the bromodeoxyuridine labelling index showed that two other responses of wild type crypts to gamma-irradiation, namely the G2 block and the reduction in bromodeoxyuridine incorporation, were both largely intact in p53 deficient animals. These observations demonstrate that p53 function is essential for a major component of the normal response to gamma-irradiation induced DNA damage in intestinal mucosal cells, and suggest that p53 deficiency permits a population of cells bearing DNA damage to escape the normal process of deletion.			CLARKE, AR (corresponding author), UNIV EDINBURGH,SCH MED,DEPT PATHOL,CRC LABS,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.		Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014	Clarke, Alan/0000-0002-4281-426X				ARMITAGE P, 1987, STATISTICAL METHODS, P372; BRUGAL G, 1992, CYTOMETRY, V13, P109, DOI 10.1002/cyto.990130202; CHAWLINSKI S, 1988, CELL TISSUE KINET, V21, P317; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HARVEY M, 1993, ONCOGENE, V8, P2457; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LALLEV A, 1993, EUR J BIOCHEM, V216, P177, DOI 10.1111/j.1432-1033.1993.tb18130.x; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MERRITT AJ, 1994, IN PRESS CANCER RES; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; MOSER AR, 1992, J CELL BIOL, V116, P1517, DOI 10.1083/jcb.116.6.1517; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; PAINTER RB, 1986, INT J RADIAT BIOL, V49, P771; PERRY ME, 1993, CURR OPIN GENET DEV, V3, P50, DOI 10.1016/S0959-437X(05)80340-5; POTTEN CS, 1990, INT J RADIAT BIOL, V58, P925, DOI 10.1080/09553009014552281; PURDIE CA, 1994, ONCOGENE, V9, P603; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; SU LK, 1992, SCIENCE, V256, P688; TSUKADA T, 1993, ONCOGENE, V8, P3313; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570	41	272	272	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1767	1773						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183575				2022-12-17	WOS:A1994NL81500032
J	DIMARCO, E; PIERCE, JH; FLEMING, TP; KRAUS, MH; MOLLOY, CJ; AARONSON, SA; DIFIORE, PP				DIMARCO, E; PIERCE, JH; FLEMING, TP; KRAUS, MH; MOLLOY, CJ; AARONSON, SA; DIFIORE, PP			AUTOCRINE INTERACTION BETWEEN TGF-ALPHA AND THE EGF-RECEPTOR - QUANTITATIVE REQUIREMENTS FOR INDUCTION OF THE MALIGNANT PHENOTYPE	ONCOGENE			English	Article									NCI,MOLEC & CELLULAR BIOL LAB,BLDG 37,ROOM 1E24,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Molloy, Christopher/A-6821-2013; Di Fiore, Pier Paolo/K-2130-2012; Di Marco, Eddi/AAB-5162-2021	Molloy, Christopher/0000-0003-2964-6166; Di Fiore, Pier Paolo/0000-0002-2252-0950; 				BECKMANN MP, 1988, SCIENCE, V241, P1346, DOI 10.1126/science.2842868; BETSHOLTZ C, 1986, P NATL ACAD SCI USA, V83, P6440, DOI 10.1073/pnas.83.17.6440; BOWENPOPE DF, 1984, P NATL ACAD SCI-BIOL, V81, P2396, DOI 10.1073/pnas.81.8.2396; BRINGMAN TS, 1987, CELL, V48, P429, DOI 10.1016/0092-8674(87)90194-2; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CARPENTER G, 1983, P NATL ACAD SCI-BIOL, V80, P5627, DOI 10.1073/pnas.80.18.5627; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARK AJL, 1985, P NATL ACAD SCI USA, V82, P8374, DOI 10.1073/pnas.82.24.8374; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; DECKER SJ, 1984, MOL CELL BIOL, V4, P571, DOI 10.1128/MCB.4.4.571; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DERYNCK R, 1987, CANCER RES, V47, P707; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; EVA A, 1982, NATURE, V295, P116, DOI 10.1038/295116a0; FINZI E, 1987, P NATL ACAD SCI USA, V84, P3733, DOI 10.1073/pnas.84.11.3733; FUKUSHIGE S, 1986, MOL CELL BIOL, V6, P955, DOI 10.1128/MCB.6.3.955; GAZIT A, 1984, CELL, V39, P89, DOI 10.1016/0092-8674(84)90194-6; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; HANNINK M, 1988, J CELL BIOL, V107, P287, DOI 10.1083/jcb.107.1.287; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HUANG SS, 1988, J BIOL CHEM, V263, P12608; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KING CR, 1985, NUCLEIC ACIDS RES, V13, P8477, DOI 10.1093/nar/13.23.8477; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LANG RA, 1985, CELL, V43, P531, DOI 10.1016/0092-8674(85)90182-5; LEAL F, 1985, SCIENCE, V230, P327, DOI 10.1126/science.2996133; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARQUARDT H, 1983, P NATL ACAD SCI-BIOL, V80, P4684; MARQUARDT H, 1984, SCIENCE, V223, P1079, DOI 10.1126/science.6320373; MASSAGUE J, 1983, J BIOL CHEM, V258, P3614; MAYES ELV, 1984, EMBO J, V3, P531, DOI 10.1002/j.1460-2075.1984.tb01842.x; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; RALL LB, 1985, NATURE, V313, P228, DOI 10.1038/313228a0; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; STERN DF, 1987, SCIENCE, V235, P321, DOI 10.1126/science.3492043; STOSCHECK CM, 1985, ENDOCRINOLOGY, V116, P528, DOI 10.1210/endo-116-2-528; TODARO GJ, 1976, NATURE, V264, P26, DOI 10.1038/264026a0; TODARO GJ, 1980, P NATL ACAD SCI-BIOL, V77, P5258, DOI 10.1073/pnas.77.9.5258; USHIRO H, 1980, J BIOL CHEM, V255, P8363; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; WANG JYJ, 1985, MOL CELL BIOL, V5, P3640, DOI 10.1128/MCB.5.12.3640; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; XU YH, 1984, P NATL ACAD SCI-BIOL, V81, P7308, DOI 10.1073/pnas.81.23.7308; YOKOTA J, 1986, LANCET, V1, P765	62	272	276	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1989	4	7					831	838						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE584	2755700				2022-12-17	WOS:A1989AE58400003
J	Sun, X; Ou, Z; Xie, M; Kang, R; Fan, Y; Niu, X; Wang, H; Cao, L; Tang, D				Sun, X.; Ou, Z.; Xie, M.; Kang, R.; Fan, Y.; Niu, X.; Wang, H.; Cao, L.; Tang, D.			HSPB1 as a novel regulator of ferroptotic cancer cell death	ONCOGENE			English	Article							HEAT-SHOCK PROTEINS; MOLECULAR CHAPERONES; HSP27 PHOSPHORYLATION; DRUG-RESISTANCE; IRON; KINASE; HEAT-SHOCK-PROTEIN-27; ACTIVATION; MIGRATION; APOPTOSIS	Ferroptosis is an iron-dependent form of non-apoptotic cell death, but its molecular mechanism remains largely unknown. Here, we demonstrate that heat shock protein beta-1 (HSPB1) is a negative regulator of ferroptotic cancer cell death. Erastin, a specific ferroptosis-inducing compound, stimulates heat shock factor 1 (HSF1)-dependent HSPB1 expression in cancer cells. Knockdown of HSF1 and HSPB1 enhances erastin-induced ferroptosis, whereas heat shock pretreatment and overexpression of HSPB1 inhibits erastin-induced ferroptosis. Protein kinase C-mediated HSPB1 phosphorylation confers protection against ferroptosis by reducing iron-mediated production of lipid reactive oxygen species. Moreover, inhibition of the HSF1-HSPB1 pathway and HSPB1 phosphorylation increases the anticancer activity of erastin in human xenograft mouse tumor models. Our findings reveal an essential role for HSPB1 in iron metabolism with important effects on ferroptosis-mediated cancer therapy.	[Sun, X.; Ou, Z.; Fan, Y.; Niu, X.; Tang, D.] Guangzhou Med Univ, Key Lab Major Obstetr Dis Guangdong Prov, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China; [Sun, X.; Ou, Z.; Fan, Y.; Niu, X.; Tang, D.] Guangzhou Med Univ, Key Lab Reprod, Guangzhou, Guangdong, Peoples R China; [Sun, X.; Ou, Z.; Fan, Y.; Niu, X.; Tang, D.] Guangzhou Med Univ, Genet Guangdong Higher Educ Inst, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China; [Xie, M.; Cao, L.] Cent S Univ, Dept Pediat, Xiangya Hosp, Changsha, Hunan, Peoples R China; [Kang, R.; Tang, D.] Univ Pittsburgh, Dept Surg, Inst Canc, Pittsburgh, PA USA; [Wang, H.] N Shore Univ Hosp, Dept Emergency Med, Feinstein Inst Med Res, Manhasset, NY USA	Guangzhou Medical University; Guangzhou Medical University; Guangzhou Medical University; Central South University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Northwell Health; North Shore University Hospital	Sun, X (corresponding author), Univ Pittsburgh, Dept Surg, Hillman Canc Ctr G27A, 5117 Ctr Ave, Pittsburgh, PA 15260 USA.	xiaofangsun@hotmail.com; tangd2@upmc.edu	Wang, Haichao/AAU-2237-2021; Tang, Daolin/B-2905-2010; Tang, Daolin/ABD-5062-2021; Kang, Rui/ABD-5291-2021	Wang, Haichao/0000-0002-0211-9000; Tang, Daolin/0000-0002-1903-6180; Kang, Rui/0000-0003-2725-1574	National Institutes of Health [R01CA160417]; Pancreatic Cancer Action Network-AACR Career Development Award [13-20-25-TANG]; National Natural Science Foundation-Guangdong Joint Fund [U1132005]; Science and Information Technology of Guangzhou Key Project [2011Y1-00038]; National Center of Complementary and Alternative Medicine [R01AT005076]; National Institute of General Medical Sciences [R01GM063075]; NATIONAL CANCER INSTITUTE [R01CA160417] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [R01AT005076] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063075] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pancreatic Cancer Action Network-AACR Career Development Award; National Natural Science Foundation-Guangdong Joint Fund; Science and Information Technology of Guangzhou Key Project; National Center of Complementary and Alternative Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Christine Heiner (Department of Surgery, University of Pittsburgh) for her critical reading of the manuscript. This work was supported by the National Institutes of Health (R01CA160417 to DT), a 2013 Pancreatic Cancer Action Network-AACR Career Development Award (Grant Number 13-20-25-TANG), The National Natural Science Foundation-Guangdong Joint Fund (U1132005 to XS) and Science and Information Technology of Guangzhou Key Project (2011Y1-00038 to XS). HW is supported by grants from the National Center of Complementary and Alternative Medicine (R01AT005076) and the National Institute of General Medical Sciences (R01GM063075).	Angeli JPF, 2014, NAT CELL BIOL, V16, P1180, DOI 10.1038/ncb3064; Arrigo AP, 2005, ANTIOXID REDOX SIGN, V7, P414, DOI 10.1089/ars.2005.7.414; Butt E, 2001, J BIOL CHEM, V276, P7108, DOI 10.1074/jbc.M009234200; Carver JA, 2003, IUBMB LIFE, V55, P661, DOI 10.1080/15216540310001640498; Chen HY, 2006, INT J BIOCHEM CELL B, V38, P1402, DOI 10.1016/j.biocel.2006.02.006; Dixon SJ, 2014, ELIFE, V3, DOI 10.7554/eLife.02523; Dixon SJ, 2014, NAT CHEM BIOL, V10, P9, DOI 10.1038/nchembio.1416; Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042; Dolma S, 2003, CANCER CELL, V3, P285, DOI 10.1016/S1535-6108(03)00050-3; Fuchs Y, 2011, CELL, V147, P742, DOI 10.1016/j.cell.2011.10.033; Fulda Simone, 2010, Int J Cell Biol, V2010, P370835, DOI 10.1155/2010/370835; Galluzzi L, 2015, CELL DEATH DIFFER, V22, P58, DOI 10.1038/cdd.2014.137; Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; Guay J, 1997, J CELL SCI, V110, P357; Guettouche Toumy, 2005, BMC Biochemistry, V6, DOI 10.1186/1471-2091-6-4; Hentze MW, 2010, CELL, V142, P24, DOI 10.1016/j.cell.2010.06.028; Huang J, 2012, CANCER RES, V72, P230, DOI 10.1158/0008-5472.CAN-11-2001; Huot J, 1996, CANCER RES, V56, P273; JAKOB U, 1993, J BIOL CHEM, V268, P1517; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; Lee YJ, 2005, J BIOL CHEM, V280, P18108, DOI 10.1074/jbc.M501131200; Linkermann A, 2014, P NATL ACAD SCI USA, V111, P16836, DOI 10.1073/pnas.1415518111; Livesey KM, 2012, CANCER RES, V72, P1996, DOI 10.1158/0008-5472.CAN-11-2291; OESTERREICH S, 1993, CANCER RES, V53, P4443; Ramanathan R, 2014, J AGR FOOD CHEM, V62, P2112, DOI 10.1021/jf404900y; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Shin KD, 2005, J BIOL CHEM, V280, P41439, DOI 10.1074/jbc.M507209200; Skouta R, 2014, J AM CHEM SOC, V136, P4551, DOI 10.1021/ja411006a; Tait SWG, 2014, J CELL SCI, V127, P2135, DOI 10.1242/jcs.093575; Takayama S, 2003, ONCOGENE, V22, P9041, DOI 10.1038/sj.onc.1207114; Takenawa T, 2007, NAT REV MOL CELL BIO, V8, P37, DOI 10.1038/nrm2069; Tang DL, 2011, CELL METAB, V13, P701, DOI 10.1016/j.cmet.2011.04.008; Tang DL, 2005, SHOCK, V23, P434, DOI 10.1097/01.shk.0000159556.95285.df; Torti SV, 2013, NAT REV CANCER, V13, P342, DOI 10.1038/nrc3495; Vanden Berghe T, 2014, NAT REV MOL CELL BIO, V15, P134, DOI 10.1038/nrm3737; Vidyasagar A, 2012, FIBROGENESIS TISSUE, V5, DOI 10.1186/1755-1536-5-7; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cb.11.110195.002301; Xu L, 2006, ONCOGENE, V25, P2987, DOI 10.1038/sj.onc.1209337; Yagoda N, 2007, NATURE, V447, P864, DOI 10.1038/nature05859; Yang LC, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5436; Yang WS, 2008, CHEM BIOL, V15, P234, DOI 10.1016/j.chembiol.2008.02.010; Yang WS, 2014, CELL, V156, P317, DOI 10.1016/j.cell.2013.12.010; Zhang QH, 2013, AUTOPHAGY, V9, P451, DOI 10.4161/auto.23691; Zhang X, 2010, HYPERTENSION, V55, P1412, DOI 10.1161/HYPERTENSIONAHA.109.147066	45	271	297	17	149	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 5	2015	34	45					5617	5625		10.1038/onc.2015.32	http://dx.doi.org/10.1038/onc.2015.32			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9GA	25728673	Green Accepted			2022-12-17	WOS:000364594300003
J	Jeter, CR; Liu, B; Liu, X; Chen, X; Liu, C; Calhoun-Davis, T; Repass, J; Zaehres, H; Shen, JJ; Tang, DG				Jeter, C. R.; Liu, B.; Liu, X.; Chen, X.; Liu, C.; Calhoun-Davis, T.; Repass, J.; Zaehres, H.; Shen, J. J.; Tang, D. G.			NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation	ONCOGENE			English	Article						Nanog; prostate cancer; cancer stem cells; castration resistance; self-renewal	TUMOR-INITIATING CELLS; GENE-EXPRESSION; PROSPECTIVE IDENTIFICATION; SIDE POPULATION; MARKER NANOG; BREAST; PROLIFERATION; PLURIPOTENCY; PROGRESSION; BINDING	Cancer cell molecular mimicry of stem cells (SC) imbues neoplastic cells with enhanced proliferative and renewal capacities. In support, numerous mediators of SC self-renewal have been evinced to show oncogenic potential. We have recently reported that short-hairpin RNA-mediated knockdown of the embryonic stem cell (ESC) self-renewal gene NANOG significantly reduced the clonogenic and tumorigenic capabilities of various cancer cells. In this study, we sought to test the potential pro-tumorigenic functions of NANOG, particularly, in prostate cancer (PCa). Using qRT-PCR, we first confirmed that PCa cells expressed NANOG mRNA primarily from the NANOGP8 locus on chromosome 15q14. We then constructed a lentiviral promoter reporter in which the -3.8-kb NANOGP8 genomic fragment was used to drive the expression of green fluorescence protein (GFP). We observed that NANOGP8-GFP PCa cells showed cancer stem cell (CSC) characteristics such as enhanced clonal growth and tumor regenerative capacity. To further investigate the functions and mechanisms of NANOG in tumorigenesis, we established tetracycline-inducible NANOG-overexpressing cancer cell lines, including both PCa (Du145 and LNCaP) and breast (MCF-7) cancer cells. NANOG induction promoted drug resistance in MCF-7 cells, tumor regeneration in Du145 cells and, most importantly, castration-resistant tumor development in LNCaP cells. These pro-tumorigenic effects of NANOG were associated with key molecular changes, including an upregulation of molecules such as CXCR4, IGFBP5, CD133 and ALDH1. The present gain-of-function studies, coupled with our recent loss-of-function work, establish the integral role for NANOG in neoplastic processes and shed light on its mechanisms of action. Oncogene (2011) 30, 3833-3845; doi:10.1038/onc.2011.114; published online 18 April 2011	[Jeter, C. R.; Liu, B.; Liu, X.; Chen, X.; Liu, C.; Calhoun-Davis, T.; Repass, J.; Shen, J. J.; Tang, D. G.] Univ Texas MD Anderson Canc Ctr, Dept Mol Carcinogenesis, Div Sci Pk Res, Smithville, TX 78957 USA; [Liu, B.] Univ Texas Austin, Dept Nutr Sci, Austin, TX 78712 USA; [Chen, X.; Liu, C.; Tang, D. G.] Grad Sch Biol Sci, Program Mol Carcinogenesis, Houston, TX USA; [Zaehres, H.] Max Planck Inst Mol Biomed, Munster, Germany	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Austin; Max Planck Society	Jeter, CR (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol Carcinogenesis, Div Sci Pk Res, Smithville, TX 78957 USA.	cjeter@mdanderson.org; dtang@mdanderson.org	Tang, Dean/AAI-3457-2020	Tang, Dean/0000-0001-5029-1174; Jeter, Collene/0000-0002-9627-4529; Liu, Xin/0000-0003-0847-182X; Chen, Xin/0000-0002-0566-7678	NIH [R01-ES015888, R21-ES015893, R21-CA150009]; Department of Defense [W81XWH-07-1-0616, W81XWH-08-1-0472]; Elsa Pardee Foundation; Center Grants [CCSG-5 P30 CA016672-34, ES007784]; AUA Foundation; NATIONAL CANCER INSTITUTE [R21CA150009, P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784, R01ES015888, R21ES015893] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); Elsa Pardee Foundation; Center Grants; AUA Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank P Whitney for FACS, N Otto and the Histology Core for help in IHC analysis, J Moore for assistance in animal breeding and experiments, and other members of the Tang laboratory for support and discussions. This work was supported, in part, by grants from NIH (R01-ES015888, R21-ES015893, R21-CA150009), Department of Defense (W81XWH-07-1-0616, W81XWH-08-1-0472) and the Elsa Pardee Foundation (DGT), and by two Center Grants (CCSG-5 P30 CA016672-34 and ES007784). CR Jeter and C Liu were supported in part by fellowships from the AUA Foundation and DOD, respectively.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Boiko AD, 2010, NATURE, V466, P133, DOI 10.1038/nature09161; Booth HAF, 2004, GENOMICS, V84, P229, DOI 10.1016/j.ygeno.2004.02.014; Bourguignon LYW, 2008, J BIOL CHEM, V283, P17635, DOI 10.1074/jbc.M800109200; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Chambers I, 2009, DEVELOPMENT, V136, P2311, DOI 10.1242/dev.024398; Chiou SH, 2008, CLIN CANCER RES, V14, P4085, DOI 10.1158/1078-0432.CCR-07-4404; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Engelmann K, 2008, CANCER RES, V68, P2419, DOI 10.1158/0008-5472.CAN-07-2249; Frigo DE, 2009, MOL ENDOCRINOL, V23, P1385, DOI 10.1210/me.2009-0010; Gangemi RMR, 2009, STEM CELLS, V27, P40, DOI 10.1634/stemcells.2008-0493; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Heddleston JM, 2009, CELL CYCLE, V8, P3274, DOI 10.4161/cc.8.20.9701; Hochedlinger K, 2005, CELL, V121, P465, DOI 10.1016/j.cell.2005.02.018; Huss WJ, 2005, CANCER RES, V65, P6640, DOI 10.1158/0008-5472.CAN-04-2548; Jeter CR, 2009, STEM CELLS, V27, P993, DOI 10.1002/stem.29; Klarmann GJ, 2009, CLIN EXP METASTAS, V26, P433, DOI 10.1007/s10585-009-9242-2; Li H, 2008, CANCER RES, V68, P1820, DOI 10.1158/0008-5472.CAN-07-5878; Li H, 2009, METHODS MOL BIOL, V568, P85, DOI 10.1007/978-1-59745-280-9_7; Li T, 2010, LAB INVEST, V90, P234, DOI 10.1038/labinvest.2009.127; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Liu YQ, 2009, CELL STEM CELL, V4, P336, DOI 10.1016/j.stem.2009.02.015; Ma TH, 2009, J BIOL CHEM, V284, P16071, DOI 10.1074/jbc.M109.005041; Machida K, 2009, P NATL ACAD SCI USA, V106, P1548, DOI 10.1073/pnas.0807390106; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; Medeiros RB, 2009, BMC BIOTECHNOL, V9, DOI 10.1186/1472-6750-9-59; Meng HM, 2010, CANCER BIOL THER, V9, P295, DOI 10.4161/cbt.9.4.10666; Miyake H, 2000, ENDOCRINOLOGY, V141, P2257, DOI 10.1210/en.141.6.2257; Nickerson T, 2001, CANCER RES, V61, P6276; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Patrawala L, 2006, ONCOGENE, V25, P1696, DOI 10.1038/sj.onc.1209327; Patrawala L, 2005, CANCER RES, V65, P6207, DOI 10.1158/0008-5472.CAN-05-0592; Patrawala L, 2007, CANCER RES, V67, P6796, DOI 10.1158/0008-5472.CAN-07-0490; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Piestun D, 2006, BIOCHEM BIOPH RES CO, V343, P279, DOI 10.1016/j.bbrc.2006.02.152; Po A, 2010, EMBO J, V29, P2646, DOI 10.1038/emboj.2010.131; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Singh S, 2004, LAB INVEST, V84, P1666, DOI 10.1038/labinvest.3700181; Singh SK, 2003, CANCER RES, V63, P5821; van den Hoogen C, 2010, CANCER RES, V70, P5163, DOI 10.1158/0008-5472.CAN-09-3806; Wong DJ, 2008, CELL STEM CELL, V2, P333, DOI 10.1016/j.stem.2008.02.009; Xu C, 2007, PROSTATE, V67, P1621, DOI 10.1002/pros.20655; Zbinden M, 2010, EMBO J, V29, P2659, DOI 10.1038/emboj.2010.137; Zhang JY, 2005, BIOCHEM BIOPH RES CO, V338, P1098, DOI 10.1016/j.bbrc.2005.10.071; Zhang S, 2008, CANCER RES, V68, P4311, DOI 10.1158/0008-5472.CAN-08-0364; Zhang X, 2009, J CELL BIOL, V184, P67, DOI 10.1083/jcb.200801009; Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998	48	271	285	1	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2011	30	36					3833	3845		10.1038/onc.2011.114	http://dx.doi.org/10.1038/onc.2011.114			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	817PV	21499299	Green Accepted			2022-12-17	WOS:000294687200002
J	Bafna, S; Kaur, S; Batra, SK				Bafna, S.; Kaur, S.; Batra, S. K.			Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells	ONCOGENE			English	Review						MUC4; MUC1; MUC16 (CA125); cancer; cell survival; apoptosis	INTRAMEMBRANE ERBB2 LIGAND; MUC4 MUCIN; MUC4/SIALOMUCIN COMPLEX; GENE-EXPRESSION; FACTOR RECEPTOR; MAMMARY-GLAND; TRANSMEMBRANE MUCIN; PROGNOSTIC-FACTOR; EPITHELIAL-CELLS; C-ABL	Mucins (MUC) are high molecular weight O-linked glycoproteins whose primary functions are to hydrate, protect, and lubricate the epithelial luminal surfaces of the ducts within the human body. The MUC family is comprised of large secreted gel forming and transmembrane (TM) mucins. MUC1, MUC4, and MUC16 are the well-characterized TM mucins and have been shown to be aberrantly overexpressed in various malignancies including cystic fibrosis, asthma, and cancer. Recent studies have uncovered the unique roles of these mucins in the pathogenesis of cancer. These mucins possess specific domains that can make complex associations with various signaling pathways, impacting cell survival through alterations of cell growth, proliferation, death, and autophagy. The cytoplasmic domain of MUC1 serves as a scaffold for interaction with various signaling proteins. On the other hand, MUC4 mediates its effect by stabilizing and enhancing the activity of growth factor receptor ErbB2. MUC16, previously known as CA125, is a well-known serum marker for the diagnosis of ovarian cancer and has a key role in stimulation and dissemination of ovarian cancer cells by interacting with mesothelin and galectin. Therefore, herein we discuss the function and divergent mechanisms of MUC1, MUC4, and MUC16 in carcinogenesis in the context of alteration in cell growth and survival. Oncogene (2010) 29, 2893-2904; doi:10.1038/onc.2010.87; published online 29 March 2010	[Batra, S. K.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center	Batra, SK (corresponding author), Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Eppley Inst Res Canc & Allied Dis, 985870 Nebraska Med Ctr, Omaha, NE 68198 USA.	sbatra@unmc.edu			National Institutes of Health [CA78590, CA111294, CA133774, CA131944]; Department of Defense [BC074639]; NATIONAL CANCER INSTITUTE [R01CA131944, U01CA111294, R01CA078590, R01CA133774] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors on this work are supported by grants from the National Institutes of Health (CA78590, CA111294, CA133774, and CA131944) and Department of Defense grant (BC074639). We thank Kristi L Berger for the paper editing and Dr Shantibhusan Senapati for editing figures.	Agata N, 2008, CANCER RES, V68, P6136, DOI 10.1158/0008-5472.CAN-08-0464; Ahmad R, 2007, NAT CELL BIOL, V9, P1419, DOI 10.1038/ncb1661; Andrianifahanana M, 2001, CLIN CANCER RES, V7, P4033; Arango ME, 2001, INVEST OPHTH VIS SCI, V42, P2749; Argueso P, 2003, INVEST OPHTH VIS SCI, V44, P2487, DOI 10.1167/iovs.02-0862; Aubert S, 2009, CANCER RES, V69, P5707, DOI 10.1158/0008-5472.CAN-08-4905; Bafna S, 2009, BRIT J CANCER, V101, P1155, DOI 10.1038/sj.bjc.6605285; Bafna S, 2008, CANCER RES, V68, P9231, DOI 10.1158/0008-5472.CAN-08-3135; Bast RC, 1998, INT J BIOL MARKER, V13, P179, DOI 10.1177/172460089801300402; Bitler BG, 2009, CLIN CANCER RES, V15, P100, DOI 10.1158/1078-0432.CCR-08-1745; Blalock TD, 2007, INVEST OPHTH VIS SCI, V48, P4509, DOI 10.1167/iovs.07-0430; Boivin M, 2009, GYNECOL ONCOL, V115, P407, DOI 10.1016/j.ygyno.2009.08.007; Buisine MP, 2001, GUT, V49, P544, DOI 10.1136/gut.49.4.544; CAPSTICK V, 1991, International Journal of Biological Markers, V6, P129; Carraway KL, 2007, CURR TOP DEV BIOL, V78, P1, DOI 10.1016/S0070-2153(06)78001-2; Carraway KL, 2002, PROG NUCLEIC ACID RE, V71, P149, DOI 10.1016/S0079-6603(02)71043-X; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; Chaturvedi P, 2008, FASEB J, V22, P966, DOI 10.1096/fj.07-9673rev; Chaturvedi P, 2008, CANCER RES, V68, P2065, DOI 10.1158/0008-5472.CAN-07-6041; Chaturvedi P, 2007, MOL CANCER RES, V5, P309, DOI 10.1158/1541-7786.MCR-06-0353; Chauhan SC, 2009, CANCER RES, V69, P765, DOI 10.1158/0008-5472.CAN-08-0587; Copin MC, 2001, HUM PATHOL, V32, P274, DOI 10.1053/hupa.2001.22752; Corfield AP, 2001, FRONT BIOSCI-LANDMRK, V6, pD1321, DOI 10.2741/Corfield; Croce CM, 2008, NEW ENGL J MED, V358, P502, DOI 10.1056/NEJMra072367; Davidson B, 2007, DIAGN CYTOPATHOL, V35, P756, DOI 10.1002/dc.20771; Gendler SJ, 2001, J MAMMARY GLAND BIOL, V6, P339, DOI 10.1023/A:1011379725811; Gipson IK, 2005, E SCHERING RES FDN W, V52, P219; Gubbels JAA, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-50; Gubbels JAA, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-11; Hait WN, 2006, CLIN CANCER RES, V12, P1961, DOI 10.1158/1078-0432.CCR-06-0011; Hanaoka J, 2001, CANCER-AM CANCER SOC, V92, P2148, DOI 10.1002/1097-0142(20011015)92:8<2148::AID-CNCR1557>3.0.CO;2-6; Hattrup CL, 2008, ANNU REV PHYSIOL, V70, P431, DOI 10.1146/annurev.physiol.70.113006.100659; Hattrup CL, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1515; Higuchi T, 2004, MOL CELL BIOL, V24, P7456, DOI 10.1128/MCB.24.17.7456-7468.2004; Higuchi T, 2004, J BIOL CHEM, V279, P1968, DOI 10.1074/jbc.M304558200; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Holbro T, 2004, ANNU REV PHARMACOL, V44, P195, DOI 10.1146/annurev.pharmtox.44.101802.121440; Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251; Horowitz JC, 2004, J BIOL CHEM, V279, P1359, DOI 10.1074/jbc.M306248200; Hu YP, 2003, BIOCHEM PHARMACOL, V65, P1419, DOI 10.1016/S0006-2952(03)00086-8; Huang L, 2005, CANCER RES, V65, P10413, DOI 10.1158/0008-5472.CAN-05-2474; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Itoh Y, 2008, GLYCOBIOLOGY, V18, P74, DOI 10.1093/glycob/cwm118; Jepson S, 2002, ONCOGENE, V21, P7524, DOI 10.1038/sj.onc.1205970; Kawano T, 2008, INT J ONCOL, V33, P153; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; Komatsu M, 2001, ONCOGENE, V20, P461, DOI 10.1038/sj.onc.1204106; KUI WN, 2003, J BIOL CHEM, V278, P28619, DOI DOI 10.1074/JBC.M302741200; LAN MS, 1990, J BIOL CHEM, V265, P15294; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li Gui-sen, 2005, Zhonghua Yi Xue Za Zhi, V85, P1333; Li YQ, 2003, ONCOGENE, V22, P6107, DOI 10.1038/sj.onc.1206732; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Mall AS, 2008, J CLIN PATHOL, V61, P1018, DOI 10.1136/jcp.2008.058057; Malmberg EK, 2008, BIOCHEM J, V410, P283, DOI 10.1042/BJ20071068; MATSUOKA Y, 1990, CANCER, V65, P506, DOI 10.1002/1097-0142(19900201)65:3<506::AID-CNCR2820650322>3.0.CO;2-0; Meerzaman D, 2001, AM J PHYSIOL-LUNG C, V281, pL86, DOI 10.1152/ajplung.2001.281.1.L86; Moniaux N, 2007, BRIT J CANCER, V97, P345, DOI 10.1038/sj.bjc.6603868; Moniaux N, 1999, BIOCHEM J, V338, P325, DOI 10.1042/0264-6021:3380325; Moniaux N, 2001, FRONT BIOSCI-LANDMRK, V6, pD1192, DOI 10.2741/Moniaux; Moniaux N, 2006, J BIOL CHEM, V281, P23676, DOI 10.1074/jbc.M600302200; Nakamura T, 2007, CANCER RES, V67, P7597, DOI 10.1158/0008-5472.CAN-07-0874; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; O'Brien TJ, 2002, TUMOR BIOL, V23, P154, DOI 10.1159/000064032; O'Brien TJ, 2001, TUMOR BIOL, V22, P348, DOI 10.1159/000050638; Pallesen LT, 2002, EUR J BIOCHEM, V269, P2755, DOI 10.1046/j.1432-1033.2002.02949.x; Park HU, 2003, PANCREAS, V26, pe48; Patton S, 1995, BBA-REV BIOMEMBRANES, V1241, P407, DOI 10.1016/0304-4157(95)00014-3; Pochampalli MR, 2007, ONCOGENE, V26, P1693, DOI 10.1038/sj.onc.1209976; Price-Schiavi SA, 2005, J CELL PHYSIOL, V203, P44, DOI 10.1002/jcp.20200; Raina D, 2004, J BIOL CHEM, V279, P20607, DOI 10.1074/jbc.M310538200; Raina D, 2006, EMBO J, V25, P3774, DOI 10.1038/sj.emboj.7601263; Ramsauer VP, 2006, MOL BIOL CELL, V17, P2931, DOI 10.1091/mbc.E05-09-0895; Ren J, 2006, MOL CANCER RES, V4, P873, DOI 10.1158/1541-7786.MCR-06-0204; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Roepstorff K, 2008, HISTOCHEM CELL BIOL, V129, P563, DOI 10.1007/s00418-008-0401-3; Rump A, 2004, J BIOL CHEM, V279, P9190, DOI 10.1074/jbc.M312372200; Saitou M, 2005, J CLIN PATHOL, V58, P845, DOI 10.1136/jcp.2004.023572; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Scholler N, 2007, CANCER LETT, V247, P130, DOI 10.1016/j.canlet.2006.03.029; Schroeder JA, 2004, ONCOGENE, V23, P5739, DOI 10.1038/sj.onc.1207713; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; Seelenmeyer C, 2003, J CELL SCI, V116, P1305, DOI 10.1242/jcs.00312; Shibahara H, 2004, HEPATOLOGY, V39, P220, DOI 10.1002/hep.20031; Shyu MK, 2007, HUM REPROD, V22, P2723, DOI 10.1093/humrep/dem249; Singh AP, 2006, PROSTATE, V66, P421, DOI 10.1002/pros.20372; Singh AP, 2004, CANCER RES, V64, P622, DOI 10.1158/0008-5472.CAN-03-2636; Singh PK, 2007, CANCER RES, V67, P5201, DOI 10.1158/0008-5472.CAN-06-4647; Singh PK, 2006, TRENDS CELL BIOL, V16, P467, DOI 10.1016/j.tcb.2006.07.006; Swartz MJ, 2002, AM J CLIN PATHOL, V117, P791; Tamada S, 2006, CLIN CANCER RES, V12, P4257, DOI 10.1158/1078-0432.CCR-05-2814; Taylor-Papadimitriou J, 1999, BBA-MOL BASIS DIS, V1455, P301, DOI 10.1016/S0925-4439(99)00055-1; Tsutsumida H, 2007, LUNG CANCER, V55, P195, DOI 10.1016/j.lungcan.2006.10.013; Walsh MD, 2007, HUM PATHOL, V38, P883, DOI 10.1016/j.humpath.2006.11.020; Wei XL, 2005, CANCER CELL, V7, P167, DOI 10.1016/j.ccr.2005.01.008; Wei XL, 2006, MOL CELL, V21, P295, DOI 10.1016/j.molcel.2005.11.030; Williams SJ, 2001, J BIOL CHEM, V276, P18327, DOI 10.1074/jbc.M008850200; Workman HC, 2009, CANCER RES, V69, P2845, DOI 10.1158/0008-5472.CAN-08-2089; Yin L, 2004, J BIOL CHEM, V279, P45721, DOI 10.1074/jbc.M408027200; Yin L, 2003, J BIOL CHEM, V278, P35458, DOI 10.1074/jbc.M301987200; Yin L, 2009, INT J ONCOL, V34, P1691, DOI 10.3892/ijo_00000300; Yu DH, 2000, BIOESSAYS, V22, P673, DOI 10.1002/1521-1878(200007)22:7<673::AID-BIES10>3.0.CO;2-A; Zeimet AG, 1998, TUMOR BIOL, V19, P275, DOI 10.1159/000030018; Zhao QC, 2009, CANCER RES, V69, P6799, DOI 10.1158/0008-5472.CAN-09-1096	105	271	286	0	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2010	29	20					2893	2904		10.1038/onc.2010.87	http://dx.doi.org/10.1038/onc.2010.87			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599DM	20348949	Green Accepted			2022-12-17	WOS:000277890400001
J	Budanov, AV; Shoshani, T; Faerman, A; Zelin, E; Kamer, I; Kalinski, H; Gorodin, S; Fishman, A; Chajut, A; Einat, P; Skaliter, R; Gudkov, AV; Chumakov, PM; Feinstein, E				Budanov, AV; Shoshani, T; Faerman, A; Zelin, E; Kamer, I; Kalinski, H; Gorodin, S; Fishman, A; Chajut, A; Einat, P; Skaliter, R; Gudkov, AV; Chumakov, PM; Feinstein, E			Identification of a novel stress-responsive gene Hi95 involved in regulation of cell viability	ONCOGENE			English	Article						hypoxia; p53-responsive gene; cell viability; stress response	GROWTH ARREST; TUMOR-SUPPRESSOR; MAMMALIAN-CELLS; DNA-DAMAGE; HYPOXIA; P53; EXPRESSION; PROTEIN; ACTIVATION; APOPTOSIS	cDNA microarray hybridization was used in an attempt to identify novel genes participating in cellular responses to prolonged hypoxia. One of the identified novel genes, designated Hi95 shared significant homology to a p53-regulated GADD family member PA26. In addition to its induction in response to prolonged hypoxia, the increased Hi95 transcription was observed following DNA damage or oxidative stress, but not following hyperthermia or serum starvation. Whereas induction of Hi95 by prolonged hypoxia or by oxidative stress is most likely p53-independent, its induction in response to DNA damaging treatments (gamma- or UV-irradiation, or doxorubicin) occurs in a p53-dependent manner. Overexpression of Hi95 full-length cDNA was found toxic for many types of cultured cells directly leading either to their apoptotic death or to sensitization to serum starvation and DNA damaging treatments. Unexpectedly, conditional overexpression of the Hi95 cDNA in MCF7-tet-off cells resulted in their protection against cell death induced by hypoxia/glucose deprivation or H2O2. Thus, Hi95 gene seems to be involved in complex regulation of cell viability in response to different stress conditions.	Quark Biotech Inc, QBI Enterprises Ltd, IL-70400 Ness Ziona, Israel; Cleveland Clin Fdn, Dept Biol Mol, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Chumakov, PM (corresponding author), Quark Biotech Inc, QBI Enterprises Ltd, Weizmann Sci Pk,POB 4071, IL-70400 Ness Ziona, Israel.	chumakp@ccf.org; elenaf@qbi.co.il	Budanov, Andrei V/HGD-5487-2022; Chumakov, Peter M/E-7731-2014	Budanov, Andrei V/0000-0002-7943-1000; Gudkov, Andrei/0000-0003-2548-0154; Chumakov, Peter/0000-0002-8078-2908				Alexandrova A, 2000, ONCOGENE, V19, P5826, DOI 10.1038/sj.onc.1203944; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; BATCHVAROVA N, 1995, EMBO J, V14, P4654, DOI 10.1002/j.1460-2075.1995.tb00147.x; BISCHOFF FZ, 1991, ONCOGENE, V6, P183; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DINI MM, 1980, OBSTET GYNECOL, V55, P728; Dong Z, 2001, J BIOL CHEM, V276, P18702, DOI 10.1074/jbc.M011774200; Faerman A, 1997, METHOD CELL BIOL, V52, P373, DOI 10.1016/S0091-679X(08)60388-X; Feldser D, 1999, CANCER RES, V59, P3915; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FORNACE AJ, 1992, ANN NY ACAD SCI, V663, P139, DOI 10.1111/j.1749-6632.1992.tb38657.x; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; JONES PA, 1975, CELL, V6, P245, DOI 10.1016/0092-8674(75)90015-X; Kataoka Y, 2000, INT J RADIAT BIOL, V76, P633; Komarova EA, 2000, ONCOGENE, V19, P3791, DOI 10.1038/sj.onc.1203717; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; Long XL, 1997, J CLIN INVEST, V99, P2635, DOI 10.1172/JCI119452; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; PINKERTON H, 1976, P SOC EXP BIOL MED, V151, P532; PRICE BD, 1992, CANCER RES, V52, P3814; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Semenza GL, 2000, GENE DEV, V14, P1983; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Sheikh MS, 2000, BIOCHEM PHARMACOL, V59, P43, DOI 10.1016/S0006-2952(99)00291-9; Shoshani T, 2002, MOL CELL BIOL, V22, P2283, DOI 10.1128/MCB.22.7.2283-2293.2002; Smith ML, 1996, MUTAT RES-REV GENET, V340, P109, DOI 10.1016/S0165-1110(96)90043-3; Sowter HM, 2001, CANCER RES, V61, P6669; Stratmann R, 1997, J NEUROPATH EXP NEUR, V56, P1242, DOI 10.1097/00005072-199711000-00009; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Velasco-Miguel S, 1999, ONCOGENE, V18, P127, DOI 10.1038/sj.onc.1202274; WALLACH D, 1984, J IMMUNOL, V132, P2464; WESTLEY B, 1979, BIOCHEM BIOPH RES CO, V90, P410, DOI 10.1016/0006-291X(79)91250-6; WHITEHEAD RH, 1985, JNCI-J NATL CANCER I, V74, P759; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805; Zhang W, 2001, INT J ONCOL, V18, P749	44	271	291	4	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2002	21	39					6017	6031		10.1038/sj.onc.1205877	http://dx.doi.org/10.1038/sj.onc.1205877			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203114				2022-12-17	WOS:000177671300005
J	List, K; Haudenschild, CC; Szabo, R; Chen, WJ; Wahl, SM; Swaim, W; Engelholm, LH; Behrendt, N; Bugge, TH				List, K; Haudenschild, CC; Szabo, R; Chen, WJ; Wahl, SM; Swaim, W; Engelholm, LH; Behrendt, N; Bugge, TH			Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis	ONCOGENE			English	Article						apoptosis; cell-surface proteolysis; skin; thymus; barrier function	HEPATOCYTE GROWTH-FACTOR; PROTEASE-ACTIVATED RECEPTOR-2; TRANSMEMBRANE SERINE-PROTEASE; FACTOR HGF ACTIVATOR; PLASMINOGEN-ACTIVATOR; STRATUM-CORNEUM; IN-VITRO; GENE; MUTATIONS; MICE	Matriptase/MT-SP1 is a novel tumor-associated type II transmembrane serine protease that is highly expressed in the epidermis, thymic stroma, and other epithelia. A null mutation was introduced into the Matriptase/MT-SP1 gene of mice to determine the role of Matriptase/MT-SP1 in epidermal development and neoplasia. Matriptase/MT-SP1-deficient mice developed to term but uniformly died within 48 h of birth. All epidermal surfaces of newborn mice were grossly abnormal with a dry, red, shiny, and wrinkled appearance. Matriptase/MT-SP1-deficiency caused striking malformations of the stratum corneum, characterized by dysmorphic and pleomorphic corneocytes and the absence of vesicular bodies in transitional layer cells. This aberrant skin development seriously compromised both inward and outward epidermal barrier function, leading to the rapid and fatal dehydration of Matriptase/MT-SP1-deficient pups. Loss of Matriptase/MT-SP1 also seriously affected hair follicle development resulting in generalized follicular hypoplasia, absence of erupted vibrissae, lack of vibrissal hair canal formation, ingrown vibrissae, and wholesale abortion of vibrissal follicles. Furthermore, Matriptase/MT-SP1-deficiency resulted in dramatically increased thymocyte apoptosis, and depletion of thymocytes. This study demonstrates that Matriptase/MT-SP1 has pleiotropic functions in the development of the epidermis, hair follicles, and cellular immune system.	Natl Inst Dent & Craniofacial Res, Proteases & Tissue Remodeling Unit, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; Natl Inst Dent & Craniofacial Res, Oral Infect & Immun Branch, NIH, Bethesda, MD 20892 USA; Natl Inst Dent & Craniofacial Res, Cellular Imaging Core, NIH, Bethesda, MD 20892 USA; Finsen Lab, DK-2100 Copenhagen, Denmark; Amer Red Cross, Dept Expt Pathol, Rockville, MD 20855 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); American Red Cross	Bugge, TH (corresponding author), Natl Inst Dent & Craniofacial Res, Proteases & Tissue Remodeling Unit, Oral & Pharyngeal Canc Branch, NIH, 30 Convent Dr,Room 211, Bethesda, MD 20892 USA.	thomas.bugge@nih.gov	Christian, Haudenschild C/D-1602-2009	Engelholm, Lars/0000-0002-6616-1232; Behrendt, Niels/0000-0003-1833-3922	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000046, ZIADE000699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000699, Z01DE000046] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ANDREASEN PA, 1986, MOL CELL ENDOCRINOL, V45, P137, DOI 10.1016/0303-7207(86)90141-3; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; APPEL LF, 1993, P NATL ACAD SCI USA, V90, P4937, DOI 10.1073/pnas.90.11.4937; Benaud C, 2001, EUR J BIOCHEM, V268, P1439, DOI 10.1046/j.1432-1327.2001.02016.x; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; Chen WJ, 2001, J EXP MED, V194, P439, DOI 10.1084/jem.194.4.439; Damiano BP, 1999, J PHARMACOL EXP THER, V288, P671; DAVIDSON P, 1952, J ANAT, V86, P342; DAVISSON MT, 1994, J HERED, V85, P134, DOI 10.1093/oxfordjournals.jhered.a111411; DeLaurenzi V, 1996, NAT GENET, V12, P52; Elias PM, 2001, J CELL BIOL, V153, P243, DOI 10.1083/jcb.153.2.243; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; FLANAGAN SP, 1966, GENET RES, V8, P295, DOI 10.1017/S0016672300010168; Hooper JD, 2001, J BIOL CHEM, V276, P857, DOI 10.1074/jbc.R000020200; HUBER M, 1995, SCIENCE, V267, P525, DOI 10.1126/science.7824952; Jensen PJ, 1999, J INVEST DERMATOL, V112, P240, DOI 10.1046/j.1523-1747.1999.00494.x; Jindo T, 1998, J INVEST DERMATOL, V110, P338, DOI 10.1046/j.1523-1747.1998.00144.x; KAUFMANN MH, 1999, ANAT BASIS MOUSE DEV; Kim MG, 1999, IMMUNOGENETICS, V49, P420, DOI 10.1007/s002510050515; Koch PJ, 2000, J CELL BIOL, V151, P389, DOI 10.1083/jcb.151.2.389; KUBILUS J, 1979, AM J HUM GENET, V31, P50; Lee SL, 2000, J BIOL CHEM, V275, P36720, DOI 10.1074/jbc.M007802200; Lee YR, 2001, J DERMATOL SCI, V25, P156, DOI 10.1016/S0923-1811(00)00124-9; Lin CY, 1999, J BIOL CHEM, V274, P18237, DOI 10.1074/jbc.274.26.18237; Lindner G, 2000, FASEB J, V14, P319, DOI 10.1096/fasebj.14.2.319; Lindner JR, 2000, J IMMUNOL, V165, P6504, DOI 10.4049/jimmunol.165.11.6504; Luttun A, 2000, Curr Atheroscler Rep, V2, P407, DOI 10.1007/s11883-000-0079-z; Magerl M, 2001, J INVEST DERMATOL, V116, P947, DOI 10.1046/j.0022-202x.2001.01368.x; MAGIN TM, 1992, NUCLEIC ACIDS RES, V20, P3795, DOI 10.1093/nar/20.14.3795; Manley NR, 2000, SEMIN IMMUNOL, V12, P421, DOI 10.1006/smim.2000.0263; MANN NS, 1994, P SOC EXP BIOL MED, V206, P114; Matrisian LM, 1999, CURR BIOL, V9, pR776, DOI 10.1016/S0960-9822(00)80011-1; Matsuki M, 1998, P NATL ACAD SCI USA, V95, P1044, DOI 10.1073/pnas.95.3.1044; McCawley LJ, 1998, J CELL PHYSIOL, V176, P255, DOI 10.1002/(SICI)1097-4652(199808)176:2<255::AID-JCP4>3.0.CO;2-N; Nakagawa T, 1998, SCIENCE, V280, P450, DOI 10.1126/science.280.5362.450; Nemes Z, 1999, EXP MOL MED, V31, P5, DOI 10.1038/emm.1999.2; Oberst M, 2001, AM J PATHOL, V158, P1301, DOI 10.1016/S0002-9440(10)64081-3; Presland RB, 2000, CRIT REV ORAL BIOL M, V11, P383, DOI 10.1177/10454411000110040101; RESKEKUNZ AB, 1979, J EXP MED, V149, P228, DOI 10.1084/jem.149.1.228; ROOP D, 1995, SCIENCE, V267, P474, DOI 10.1126/science.7529942; RUSSELL LJ, 1995, NAT GENET, V9, P279, DOI 10.1038/ng0395-279; Scott HS, 2001, NAT GENET, V27, P59, DOI 10.1038/83768; Sebzda E, 1999, ANNU REV IMMUNOL, V17, P829, DOI 10.1146/annurev.immunol.17.1.829; SHAPIRO LJ, 1978, LANCET, V2, P756; SHULTZ LD, 1988, CURR TOP MICROBIOL, V137, P216; Stella MC, 1999, INT J BIOCHEM CELL B, V31, P1357, DOI 10.1016/S1357-2725(99)00089-8; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Takeuchi T, 1999, P NATL ACAD SCI USA, V96, P11054, DOI 10.1073/pnas.96.20.11054; Tang BL, 2001, INT J BIOCHEM CELL B, V33, P33, DOI 10.1016/S1357-2725(00)00061-3; Tanimoto H, 2001, TUMOR BIOL, V22, P104, DOI 10.1159/000050604; Turk B, 2000, BBA-PROTEIN STRUCT M, V1477, P98, DOI 10.1016/S0167-4838(99)00263-0; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Werb Z, 1999, APMIS, V107, P11, DOI 10.1111/j.1699-0463.1999.tb01521.x; Williams O, 2001, TRENDS IMMUNOL, V22, P107, DOI 10.1016/S1471-4906(00)01797-X; Yamada K, 2000, GENE, V252, P209, DOI 10.1016/S0378-1119(00)00225-0; Yamazaki M, 1999, J INVEST DERM SYMP P, V4, P312, DOI 10.1038/sj.jidsp.5640236; Yan W, 2000, P NATL ACAD SCI USA, V97, P8525, DOI 10.1073/pnas.150149097; Zhang Y, 1998, CYTOGENET CELL GENET, V83, P56, DOI 10.1159/000015125	60	271	280	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3765	3779		10.1038/sj.onc.1205502	http://dx.doi.org/10.1038/sj.onc.1205502			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032844				2022-12-17	WOS:000175676000011
J	Lin, JX; Leonard, WJ				Lin, JX; Leonard, WJ			The role of Stat5a and Stat5b in signaling by IL-2 family cytokines	ONCOGENE			English	Review						IL-2 family cytokines; Jak kinases; Stat5; signal transduction; phosphorylation; gene regulation	RECEPTOR-BETA-CHAIN; HUMAN INTERLEUKIN-2 RECEPTOR; SEVERE COMBINED IMMUNODEFICIENCY; T-CELL PROLIFERATION; PROTEIN-TYROSINE-PHOSPHATASE; DNA-BINDING ACTIVITY; JAK-3 JANUS KINASE; MICE LACKING JAK3; P70 S6 KINASE; GAMMA-CHAIN	The activation of Stat5 proteins (Stat5a and Stat5b) is one of the earliest signaling events mediated by IL-2 family cytokines, allowing the rapid delivery of signals from the membrane to the nucleus. Among STAT family proteins, Stat5a and Stat5b are the two most closely related STAT proteins. Together with other transcription factors and co-factors, they regulate the expression of the target genes in a cytokine-specific fashion. In addition to their activation by cytokines, activities of Stat5a and Stat5b, as well as other STAT proteins, are negatively controlled by CIS/SOCS/SSI family proteins. The outcome of Stat5 activation in regulating expression of target genes varies, depending upon the complexity of the promoter region of target genes and the other signaling pathways that are activated by each cytokine as well. Here, we mainly focus on the IL2-/IL-2 receptor system, as it is one of the best-studied systems that depend on Stat5-mediated signals, We will summarize what we have learned about the molecular mechanisms of how Stat5 is activated by IL-2 family cytokines from in vitro biochemical studies as well as the role that is played by Stat5 in each of the cytokine signaling pathways from in vivo gene-targeting analyses.	NHLBI, Lab Mol Immunol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Leonard, WJ (corresponding author), NHLBI, Lab Mol Immunol, NIH, Bldg 10,Rm 7N252,9000 Rockville Pike, Bethesda, MD 20892 USA.		Leonard, Warren/AAA-1397-2022					Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Aman MJ, 1999, J BIOL CHEM, V274, P30266, DOI 10.1074/jbc.274.42.30266; Ascherman DP, 1997, J BIOL CHEM, V272, P8704, DOI 10.1074/jbc.272.13.8704; AUGUSTINE JA, 1991, MOL CELL BIOL, V11, P4431, DOI 10.1128/MCB.11.9.4431; Baird AM, 1999, CURR OPIN IMMUNOL, V11, P157, DOI 10.1016/S0952-7915(99)80027-2; BALLARD D W, 1989, New Biologist, V1, P83; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BEADLING C, 1994, EMBO J, V13, P5605, DOI 10.1002/j.1460-2075.1994.tb06898.x; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; Bovolenta C, 1999, BLOOD, V94, P4202, DOI 10.1182/blood.V94.12.4202.424k22_4202_4209; Cella N, 1998, MOL CELL BIOL, V18, P1783, DOI 10.1128/MCB.18.4.1783; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; COPELAND NG, 1995, GENOMICS, V29, P225, DOI 10.1006/geno.1995.1235; Corry DB, 1999, NATURE, V402, pB18; CROSS SL, 1989, SCIENCE, V244, P466, DOI 10.1126/science.2497520; Damjanovich S, 1997, P NATL ACAD SCI USA, V94, P13134, DOI 10.1073/pnas.94.24.13134; Demoulin JB, 1996, MOL CELL BIOL, V16, P4710; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; DESAINTBASILE G, 1987, P NATL ACAD SCI USA, V84, P7576; Eicher DM, 1998, J IMMUNOL, V161, P5430; FARRAR WL, 1989, J BIOL CHEM, V264, P12562; Fischer A, 1997, ANNU REV IMMUNOL, V15, P93, DOI 10.1146/annurev.immunol.15.1.93; Friedman MC, 1996, P NATL ACAD SCI USA, V93, P2077, DOI 10.1073/pnas.93.5.2077; Friedrich K, 1999, INT IMMUNOL, V11, P1283, DOI 10.1093/intimm/11.8.1283; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; Gadina M, 1999, J IMMUNOL, V162, P2081; Gadina M, 1998, J IMMUNOL, V160, P4657; GAFFEN SL, 1995, P NATL ACAD SCI USA, V92, P7192, DOI 10.1073/pnas.92.16.7192; Gesbert F, 1998, J BIOL CHEM, V273, P18273, DOI 10.1074/jbc.273.29.18273; Gingras S, 1999, NUCLEIC ACIDS RES, V27, P2722, DOI 10.1093/nar/27.13.2722; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GOLDSMITH MA, 1995, J BIOL CHEM, V270, P21729, DOI 10.1074/jbc.270.37.21729; GRAVES JD, 1992, J IMMUNOL, V148, P2417; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Haspel RL, 1999, P NATL ACAD SCI USA, V96, P10188, DOI 10.1073/pnas.96.18.10188; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Hofmeister R, 1999, CYTOKINE GROWTH F R, V10, P41, DOI 10.1016/S1359-6101(98)00025-2; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Horvath CM, 1997, CURR OPIN CELL BIOL, V9, P233, DOI 10.1016/S0955-0674(97)80067-1; HOU JZ, 1995, IMMUNITY, V2, P321, DOI 10.1016/1074-7613(95)90140-X; Imada K, 1998, J EXP MED, V188, P2067, DOI 10.1084/jem.188.11.2067; John S, 1999, MOL CELL BIOL, V19, P1910; JOHN S, 1995, MOL CELL BIOL, V15, P1786; John S, 1996, EMBO J, V15, P5627, DOI 10.1002/j.1460-2075.1996.tb00947.x; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; Kagami S, 2000, BLOOD, V95, P1370, DOI 10.1182/blood.V95.4.1370.004k29_1370_1377; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; KOBAYASHI N, 1993, P NATL ACAD SCI USA, V90, P4201, DOI 10.1073/pnas.90.9.4201; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; Kovanen PE, 1999, CURR BIOL, V9, pR899, DOI 10.1016/S0960-9822(00)80079-2; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; Lecine P, 1996, MOL CELL BIOL, V16, P6829; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; Leonard W.J., 1999, FUNDAMENTAL IMMUNOLO, Vfourth, P741; Leonard WJ, 1996, ANNU REV MED, V47, P229; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; Lin Jian-Xin, 1997, Cytokine and Growth Factor Reviews, V8, P313; Lin JX, 1996, J BIOL CHEM, V271, P10738, DOI 10.1074/jbc.271.18.10738; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; Lischke A, 1998, J BIOL CHEM, V273, P31222, DOI 10.1074/jbc.273.47.31222; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Lodolce JP, 1998, IMMUNITY, V9, P669, DOI 10.1016/S1074-7613(00)80664-0; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Matsumoto A, 1999, MOL CELL BIOL, V19, P6396; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; MERIDA I, 1991, J IMMUNOL, V147, P2202; Meyer WKH, 1997, J BIOL CHEM, V272, P31821, DOI 10.1074/jbc.272.50.31821; Migone TS, 1998, MOL CELL BIOL, V18, P6416, DOI 10.1128/MCB.18.11.6416; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; MINAMI Y, 1995, IMMUNITY, V2, P89, DOI 10.1016/1074-7613(95)90081-0; MINAMI Y, 1993, EMBO J, V12, P759, DOI 10.1002/j.1460-2075.1993.tb05710.x; Miyazaki T, 1998, GENE DEV, V12, P770, DOI 10.1101/gad.12.6.770; Moriggl R, 1999, IMMUNITY, V11, P225, DOI 10.1016/S1074-7613(00)80097-7; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Nakajima H, 1997, IMMUNITY, V7, P691, DOI 10.1016/S1074-7613(00)80389-1; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; Park SY, 1995, IMMUNITY, V3, P771, DOI 10.1016/1074-7613(95)90066-7; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; Pericle F, 1997, J IMMUNOL, V159, P2580; Pericle F, 1998, J IMMUNOL, V160, P28; Pfitzner E, 1998, MOL ENDOCRINOL, V12, P1582, DOI 10.1210/mend.12.10.0180; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; Ravichandran KS, 1996, P NATL ACAD SCI USA, V93, P5275, DOI 10.1073/pnas.93.11.5275; Refaeli Y, 1998, IMMUNITY, V8, P615, DOI 10.1016/S1074-7613(00)80566-X; Reif K, 1997, J BIOL CHEM, V272, P14426, DOI 10.1074/jbc.272.22.14426; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; RENAULD JC, 1995, J LEUKOCYTE BIOL, V57, P353, DOI 10.1002/jlb.57.3.353; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; ROMAN D, 1990, New Biologist, V2, P642; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; Serdobova I, 1997, J EXP MED, V185, P1211, DOI 10.1084/jem.185.7.1211; Sharfe N, 1997, P NATL ACAD SCI USA, V94, P3168, DOI 10.1073/pnas.94.7.3168; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Shuai K, 1996, ONCOGENE, V13, P247; Soldaini E, 2000, MOL CELL BIOL, V20, P389, DOI 10.1128/MCB.20.1.389-401.2000; SPERISEN P, 1995, J BIOL CHEM, V270, P10743, DOI 10.1074/jbc.270.18.10743; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Sugamura K, 1996, ANNU REV IMMUNOL, V14, P179, DOI 10.1146/annurev.immunol.14.1.179; Takemoto S, 1997, P NATL ACAD SCI USA, V94, P13897, DOI 10.1073/pnas.94.25.13897; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; TOLEDANO MB, 1990, P NATL ACAD SCI USA, V87, P1830, DOI 10.1073/pnas.87.5.1830; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; TURNER BC, 1993, P NATL ACAD SCI USA, V90, P5544, DOI 10.1073/pnas.90.12.5544; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Van Parijs L, 1999, IMMUNITY, V11, P281, DOI 10.1016/S1074-7613(00)80103-X; VanParijs L, 1997, J IMMUNOL, V158, P3738; Verdier F, 1998, MOL CELL BIOL, V18, P5852, DOI 10.1128/MCB.18.10.5852; Vinkemeier U, 1998, SCIENCE, V279, P1048, DOI 10.1126/science.279.5353.1048; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Waldmann T, 1998, Int Rev Immunol, V16, P205, DOI 10.3109/08830189809042995; Wang DM, 1996, MOL CELL BIOL, V16, P6141; Welte T, 1999, SCIENCE, V283, P222, DOI 10.1126/science.283.5399.222; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WILLERFORD DM, 1995, IMMUNITY, V3, P521, DOI 10.1016/1074-7613(95)90180-9; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Yamashita H, 1998, J BIOL CHEM, V273, P30218, DOI 10.1074/jbc.273.46.30218; YODOI J, 1992, IMMUNOL TODAY, V13, P405, DOI 10.1016/0167-5699(92)90091-K; YOSHIDA M, 1987, ANNU REV IMMUNOL, V5, P541, DOI 10.1146/annurev.iy.05.040187.002545; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Yu CL, 1997, J BIOL CHEM, V272, P14017, DOI 10.1074/jbc.272.22.14017; Yu CL, 2000, J BIOL CHEM, V275, P599, DOI 10.1074/jbc.275.1.599; Yu CR, 1996, J IMMUNOL, V157, P126; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963; Zhang XH, 1998, IMMUNITY, V8, P591, DOI 10.1016/S1074-7613(00)80564-6; Zhang ZX, 1997, J BIOL CHEM, V272, P30607, DOI 10.1074/jbc.272.49.30607; Zhu MH, 1998, J BIOL CHEM, V273, P10719, DOI 10.1074/jbc.273.17.10719; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4; ZHU XY, 1994, J BIOL CHEM, V269, P5518; ZMUIDZINAS A, 1991, MOL CELL BIOL, V11, P2794, DOI 10.1128/MCB.11.5.2794	158	271	291	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2000	19	21					2566	2576		10.1038/sj.onc.1203523	http://dx.doi.org/10.1038/sj.onc.1203523			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321MN	10851055				2022-12-17	WOS:000087459400012
J	Chelbi-Alix, MK; de The, H				Chelbi-Alix, MK; de The, H			Herpes virus induced proteasome-dependent degradation of the nuclear bodies-associated PML and Sp100 proteins	ONCOGENE			English	Article						nuclear bodies; PML; Sp100; ubiquitin; SUMO-1; HSV-1	ACUTE PROMYELOCYTIC LEUKEMIA; PRIMARY BILIARY-CIRRHOSIS; RETINOIC ACID; GROWTH-SUPPRESSOR; DOMAIN-10 ND10; PORE COMPLEX; RAR-ALPHA; CELLS; GENE; INTERFERON	The PML protein is associated to nuclear bodies (NBs) whose functions are as yet unknown. PML and two other NBs-associated proteins, Sp100 And ISG20 are directly induced by interferons (IFN). PML and Sp100 proteins are covalently linked to SUMO-1, and ubiquitin-like peptide. PML NBs are disorganized in acute promyelocytic leukemia and during several DNA virus infections. In particular, the HSV-1 ICP0 protein is known to delocalize PML from NBs. Thus, NBs could play an important role in oncogenesis, IFN response and viral infections. Here, we show that HSV-1 induced PML protein degradation without altering its mRNA level. This degradation was time- and multiplicity of infection-dependent. Sp100 protein was also degraded, while another SUMO-1 conjugated protein, RanGAP1 and the IFN-induced protein kinase PKR were not. The proteasome inhibitor MG132 abrogated the HSV-1-induced PML and Sp100 degradation and partially restored their NB-localization. HSV-1 induced PML and Sp100 degradation constitutes a new example of viral inactivation of IFN target gene products.	Univ Paris 07, Inst Univ Hematol, Com Paris Ligue Contre Canc, Lab Associe,CNRS,Unite Propre Rech 9051, Paris, France; Hop St Louis, Serv Biochim B, Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Chelbi-Alix, MK (corresponding author), Hop St Louis, CNRS, UPR 9051, 1 Ave Vellefaux, F-75475 Paris 10, France.							Boddy MN, 1996, ONCOGENE, V13, P971; Borden KLB, 1998, J VIROL, V72, P758, DOI 10.1128/JVI.72.1.758-766.1998; CAMPBELL IG, 1994, HUM MOL GENET, V3, P589, DOI 10.1093/hmg/3.4.589; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; CAYLEY PJ, 1984, EUR J BIOCHEM, V143, P165, DOI 10.1111/j.1432-1033.1984.tb08355.x; CHEBIALIX MK, 1996, PML PRIMARY TARGET G; Chelbi-Alix MK, 1998, J VIROL, V72, P1043, DOI 10.1128/JVI.72.2.1043-1051.1998; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; CHOU J, 1995, P NATL ACAD SCI USA, V92, P10516, DOI 10.1073/pnas.92.23.10516; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DANIEL MT, 1993, BLOOD, V82, P1858; DEBOIS C, 1996, SCIENCE, V273, P951; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EVERETT RD, 1994, EMBO J, V13, P5062, DOI 10.1002/j.1460-2075.1994.tb06835.x; Everett RD, 1997, EMBO J, V16, P566, DOI 10.1093/emboj/16.3.566; Everett RD, 1998, J VIROL, V72, P6581, DOI 10.1128/JVI.72.8.6581-6591.1998; FAGIOLI M, 1992, ONCOGENE, V7, P1083; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; Gale M, 1998, PHARMACOL THERAPEUT, V78, P29, DOI 10.1016/S0163-7258(97)00165-4; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Gongora C, 1997, J BIOL CHEM, V272, P19457, DOI 10.1074/jbc.272.31.19457; Grotzinger T, 1996, J BIOL CHEM, V271, P25253, DOI 10.1074/jbc.271.41.25253; Grotzinger T, 1996, EUR J BIOCHEM, V238, P554, DOI 10.1111/j.1432-1033.1996.0554z.x; GULDNER HH, 1992, J IMMUNOL, V149, P4067; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Korioth F, 1996, EXP CELL RES, V229, P155, DOI 10.1006/excr.1996.0353; LAVAU C, 1995, ONCOGENE, V11, P871; Le XF, 1998, ONCOGENE, V16, P1839, DOI 10.1038/sj.onc.1201705; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MAUL GG, 1994, J GEN VIROL, V75, P1223, DOI 10.1099/0022-1317-75-6-1223; Maul GG, 1996, VIROLOGY, V217, P67, DOI 10.1006/viro.1996.0094; Maul GG, 1995, J CELL BIOCHEM, V59, P498, DOI 10.1002/jcb.240590410; MEREDITH M, 1995, VIROLOGY, V209, P174, DOI 10.1006/viro.1995.1241; Mu ZM, 1996, LEUKEMIA LYMPHOMA, V23, P277, DOI 10.3109/10428199609054830; Mu ZM, 1997, CARCINOGENESIS, V18, P2063, DOI 10.1093/carcin/18.11.2063; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; PANDOLFI PP, 1992, EMBO J, V11, P1397, DOI 10.1002/j.1460-2075.1992.tb05185.x; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; PUVIONDUTILLEUL F, 1995, EXP CELL RES, V221, P448, DOI 10.1006/excr.1995.1396; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; Rees S, 1996, BIOTECHNIQUES, V20, P102; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; Stadler M, 1995, ONCOGENE, V11, P2565; Sternsdorf T, 1997, IMMUNOBIOLOGY, V198, P307, DOI 10.1016/S0171-2985(97)80051-4; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Szekely L, 1996, J VIROL, V70, P2562, DOI 10.1128/JVI.70.4.2562-2568.1996; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Yoshida H, 1996, CANCER RES, V56, P2945; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978	57	271	276	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	1999	18	4					935	941		10.1038/sj.onc.1202366	http://dx.doi.org/10.1038/sj.onc.1202366			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023669				2022-12-17	WOS:000078510600010
J	Stadler, M; ChelbiAlix, MK; Koken, MHM; Venturini, L; Lee, C; Saib, A; Quignon, F; Pelicano, L; Guillemin, MC; Schindler, C; deThe, H				Stadler, M; ChelbiAlix, MK; Koken, MHM; Venturini, L; Lee, C; Saib, A; Quignon, F; Pelicano, L; Guillemin, MC; Schindler, C; deThe, H			Transcriptional induction of the PML growth suppressor gene by interferons is mediated through an ISRE and a GAS element	ONCOGENE			English	Article						leukaemia; growth suppressor; promoter; STAT; cytokines	ACUTE PROMYELOCYTIC LEUKEMIA; PRIMARY BILIARY-CIRRHOSIS; DEPENDENT PROTEIN-KINASE; ZINC-FINGER; RAR-ALPHA; T(15-17) TRANSLOCATION; STIMULATED GENES; NUCLEAR-BODIES; EXPRESSION; CELLS	PML is a nuclear matrix protein with growth suppressing properties, whose expression is deregulated during oncogenesis. Moreover, in the t(15;17) translocation of acute promyelocytic leukaemia (APL), PML fusion to the retinoic acid receptor alpha (RAR alpha) is the likely molecular basis of leukaemogenesis. Here we show that interferons (IFNs) alpha, beta, and gamma upregulate PML mRNA expression. Analysis of 5' genomic sequences of the PML gene revealed an IFN-alpha/-beta stimulated response element (ISRE) and an IFN-gamma activation site (GAS) in the untranslated first exon. Binding of TFN signal transducers and activators of transcription (STATs) was demonstrated to be weak for the PML GAS, but strong for the PML ISRE which also seemed to contribute substantially to the IFN-gamma response. Thus, PML is a primary target gene of IFNs and would appear as a suitable candidate for mediating some of their antiproliferative effects. Abnormalities of PML structure, localisation or expression in human malignancy, constitute examples of how an IFN target gene may be altered in oncogenesis.	HOP ST LOUIS, CNRS, UPR A0043, F-75010 PARIS, FRANCE; COLUMBIA UNIV COLL PHYS & SURG, DIV MOLEC MED, NEW YORK, NY 10032 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Columbia University			Quignon, Frédérique/P-4249-2017; koken, marcel/N-1349-2019; koken, marcel/J-8154-2012	koken, marcel/0000-0002-0839-0125	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL021006] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL21006-19] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; BLUYSSEN HAR, 1995, P NATL ACAD SCI USA, V92, P5645, DOI 10.1073/pnas.92.12.5645; BRASCH K, 1992, EXP CELL RES, V202, P211, DOI 10.1016/0014-4827(92)90068-J; BRIKEN V, 1995, MOL CELL BIOL, V15, P975; CHELBIALIX MK, 1995, IN PRESS LEUKEMIA; DANIEL MT, 1993, BLOOD, V82, P1858; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; EVERETT RD, 1994, EMBO J, V13, P5062, DOI 10.1002/j.1460-2075.1994.tb06835.x; FAGIOLI M, 1992, ONCOGENE, V7, P1083; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FLENGHI L, 1995, BLOOD, V85, P1871, DOI 10.1182/blood.V85.7.1871.bloodjournal8571871; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; GULDNER HH, 1992, J IMMUNOL, V149, P4067; HANASH SM, 1993, GENE CHROMOSOME CANC, V8, P34, DOI 10.1002/gcc.2870080107; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KIMURA T, 1994, SCIENCE, V264, P1921, DOI 10.1126/science.8009222; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; KORIOTH F, 1995, J CELL BIOL, V130, P1, DOI 10.1083/jcb.130.1.1; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; MAUL GG, 1993, J GEN VIROL, V74, P2679, DOI 10.1099/0022-1317-74-12-2679; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; NIKOVITS W, 1990, MOL CELL BIOL, V10, P3468, DOI 10.1128/MCB.10.7.3468; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PEREZ C, 1994, MOL CELL BIOL, V14, P5023, DOI 10.1128/MCB.14.8.5023; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.bi.56.070187.003455; PINE R, 1988, NUCLEIC ACIDS RES, V16, P1371, DOI 10.1093/nar/16.4.1371; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; PUVIONDUTILLEUL F, 1995, EXP CELL RES, V218, P9, DOI 10.1006/excr.1995.1125; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; ROTHMAN P, 1994, IMMUNITY, V1, P457, DOI 10.1016/1074-7613(94)90088-4; ROUSSELOT P, 1994, ONCOGENE, V9, P545; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; STREHLOW I, 1993, J BIOL CHEM, V268, P16590; STUURMAN N, 1992, J CELL SCI, V101, P773; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; TERRIS B, 1995, CANCER RES, V55, P1590; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; WERNERT N, 1992, AM J PATHOL, V140, P119; WILLIAMS BRG, 1991, EUR J BIOCHEM, V200, P1, DOI 10.1111/j.1432-1033.1991.tb21041.x; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; WONDISFORD FE, 1989, J BIOL CHEM, V264, P14601	63	271	277	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 21	1995	11	12					2565	2573						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545113				2022-12-17	WOS:A1995TP18800012
J	Berk, AJ				Berk, AJ			Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus	ONCOGENE			English	Review						mediator; CtBP; chromatin; aggresome; ubiqutin ligase; apoptosis	VIRAL-DNA REPLICATION; E4 ORF3 PROTEIN; MESSENGER-RNA; HOST-CELL; IN-VIVO; TRANSCRIPTIONAL ACTIVATION; CO-REPRESSOR; ZINC-FINGER; ONCOGENIC TRANSFORMATION; MOLECULAR-MECHANISMS	Adenovirus continues to be an important model system for investigating basic aspects of cell biology. Interactions of several cellular proteins with E1A conserved regions ( CR) 1 and 2, and inhibition of apoptosis by E1B proteins are required for oncogenic transformation. CR2 binds RB family members, de-repressing E2F transcription factors, thus activating genes required for cell cycling. E1B-19K is a BCL2 homolog that binds and inactivates proapoptotic BAK and BAX. E1B-55K binds p53, inhibiting its transcriptional activation function. In productively infected cells, E1B-55K and E4orf6 assemble a ubiquitin ligase with cellular proteins Elongins B and C, Cullin 5 and RBX1 that polyubiquitinates p53 and one or more subunits of the MRN complex involved in DNA double-strand break repair, directing them to proteosomal degradation. E1A CR3 activates viral transcription by interacting with the MED23 Mediator subunit, stimulating preinitiation complex assembly on early viral promoters and probably also the rate at which they initiate transcription. The viral E1B-55K/E4orf6 ubiquitin ligase is also required for efficient viral late protein synthesis in many cell types, but the mechanism is not understood. E1A CR1 binds several chromatin-modifying complexes, but how this contributes to stimulation of cellular DNA synthesis and transformation is not clear. E1A CR4 binds the CtBP corepressor, but the mechanism by which this modulates the frequency of transformation remains to be determined. Clearly, adenovirus has much left to teach us about fundamental cellular processes.	Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Berk, AJ (corresponding author), Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Inst Mol Biol, 611 Charles Young Dr E, Los Angeles, CA 90095 USA.	berk@mbi.ucla.edu	BERK, ARNOLD/AAF-7052-2020					Alevizopoulos K, 1998, EMBO J, V17, P5987, DOI 10.1093/emboj/17.20.5987; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Attwooll C, 2005, J BIOL CHEM, V280, P1199, DOI 10.1074/jbc.M412509200; Avvakumov N, 2004, VIROLOGY, V329, P477, DOI 10.1016/j.virol.2004.08.007; BABISS LE, 1985, MOL CELL BIOL, V5, P2552, DOI 10.1128/MCB.5.10.2552; Baek HJ, 2002, MOL CELL BIOL, V22, P2842, DOI 10.1128/MCB.22.8.2842-2852.2002; BARBEAU D, 1992, BIOCHEM CELL BIOL, V70, P1123, DOI 10.1139/o92-158; BELTZ GA, 1979, J MOL BIOL, V131, P353, DOI 10.1016/0022-2836(79)90081-0; Ben-Israel H, 2002, FRONT BIOSCI-LANDMRK, V7, pD1369, DOI 10.2741/ben; Ben-Porath I, 2004, J CLIN INVEST, V113, P8, DOI 10.1172/JCI200420663; BERK AJ, 1979, CELL, V17, P935, DOI 10.1016/0092-8674(79)90333-7; Bhaumik SR, 2004, GENE DEV, V18, P333, DOI 10.1101/gad.1148404; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Blanchette P, 2004, MOL CELL BIOL, V24, P9619, DOI 10.1128/MCB.24.21.9619-9629.2004; Borggrefe T, 2002, J BIOL CHEM, V277, P44202, DOI 10.1074/jbc.M207195200; Bourbon HM, 2004, MOL CELL, V14, P553, DOI 10.1016/j.molcel.2004.05.011; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Boyer J, 1999, VIROLOGY, V263, P307, DOI 10.1006/viro.1999.9866; Boyer TG, 1999, NATURE, V399, P276, DOI 10.1038/20466; BRAITHWAITE AW, 1983, J VIROL, V45, P192, DOI 10.1128/JVI.45.1.192-199.1983; Brannon M, 1999, DEVELOPMENT, V126, P3159; Brockmann D, 2003, CURR TOP MICROBIOL, V272, P97; Buchwalter G, 2004, GENE, V324, P1, DOI 10.1016/j.gene.2003.09.028; Cantin GT, 2003, P NATL ACAD SCI USA, V100, P12003, DOI 10.1073/pnas.2035253100; Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; Chan HM, 2001, J CELL SCI, V114, P2363; Chattopadhyay D, 2001, J VIROL, V75, P9844, DOI 10.1128/JVI.75.20.9844-9856.2001; Chinnadurai G, 2004, CURR TOP MICROBIOL, V273, P139; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; Cuconati A, 2003, GENE DEV, V17, P2922, DOI 10.1101/gad.1156903; Cuconati A, 2002, GENE DEV, V16, P2465, DOI 10.1101/gad.1012702; CULP JS, 1988, P NATL ACAD SCI USA, V85, P6450, DOI 10.1073/pnas.85.17.6450; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; Dahiya A, 2001, MOL CELL, V8, P557, DOI 10.1016/S1097-2765(01)00346-X; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Deleu L, 2001, ONCOGENE, V20, P8270, DOI 10.1038/sj.onc.1205159; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; Doucas V, 1996, GENE DEV, V10, P196, DOI 10.1101/gad.10.2.196; Duval A, 2000, CANCER RES, V60, P3872; DYSON N, 1992, CANCER SURV, V12, P161; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Endter C, 2004, CURR TOP MICROBIOL, V273, P163; Evans JD, 2005, J VIROL, V79, P6207, DOI 10.1128/JVI.79.10.6207-6215.2005; Evans JD, 2003, J VIROL, V77, P5295, DOI 10.1128/JVI.77.9.5295-5304.2003; Fang L, 2004, J VIROL, V78, P12888, DOI 10.1128/JVI.78.23.12888-12900.2004; Flint SJ, 2003, CURR TOP MICROBIOL, V272, P287; Forman MS, 2004, NAT MED, V10, P1055, DOI 10.1038/nm1113; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; Furusawa T, 1999, MOL CELL BIOL, V19, P8581; Gallimore PH, 2001, ONCOGENE, V20, P7824, DOI 10.1038/sj.onc.1204913; Garcia-Mata R, 2002, TRAFFIC, V3, P388, DOI 10.1034/j.1600-0854.2002.30602.x; Ghosh MK, 2003, MOL CELL, V12, P255, DOI 10.1016/S1097-2765(03)00225-9; Goodman RH, 2000, GENE DEV, V14, P1553; Harada JN, 2002, J VIROL, V76, P9194, DOI 10.1128/JVI.76.18.9194-9206.2002; Harada JN, 1999, J VIROL, V73, P5333, DOI 10.1128/JVI.73.7.5333-5344.1999; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; HARRISON T, 1977, VIROLOGY, V77, P319, DOI 10.1016/0042-6822(77)90428-7; Hassler M, 2001, EMBO J, V20, P3018, DOI 10.1093/emboj/20.12.3018; Helt AM, 2003, CARCINOGENESIS, V24, P159, DOI 10.1093/carcin/24.2.159; Hobom U, 2004, J VIROL, V78, P7685, DOI 10.1128/JVI.78.14.7685-7697.2004; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; Ito M, 2000, MOL CELL, V5, P683, DOI 10.1016/S1097-2765(00)80247-6; Iyer NG, 2004, ONCOGENE, V23, P4225, DOI 10.1038/sj.onc.1207118; JONES N, 1979, P NATL ACAD SCI USA, V76, P3665, DOI 10.1073/pnas.76.8.3665; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; Kim TW, 2004, P NATL ACAD SCI USA, V101, P12153, DOI 10.1073/pnas.0401985101; KIMELMAN D, 1985, J VIROL, V53, P399, DOI 10.1128/JVI.53.2.399-409.1985; Kolli S, 2001, P NATL ACAD SCI USA, V98, P4646, DOI 10.1073/pnas.081141998; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Lang SE, 2003, ONCOGENE, V22, P2836, DOI 10.1038/sj.onc.1206376; Larschan E, 2001, GENE DEV, V15, P1946, DOI 10.1101/gad.911501; Lee TI, 2000, ANNU REV GENET, V34, P77, DOI 10.1146/annurev.genet.34.1.77; LEPPARD KN, 1989, EMBO J, V8, P2329, DOI 10.1002/j.1460-2075.1989.tb08360.x; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; Levine SS, 2004, TRENDS BIOCHEM SCI, V29, P478, DOI 10.1016/j.tibs.2004.07.007; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; Li XY, 1999, NATURE, V399, P605, DOI 10.1038/21232; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; Lis J, 1998, COLD SPRING HARB SYM, V63, P347, DOI 10.1101/sqb.1998.63.347; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; Liu Y, 2000, MOL CELL BIOL, V20, P5540, DOI 10.1128/MCB.20.15.5540-5553.2000; LIU Y, 2005, IN PRESS J VIROL; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Lund AH, 2004, CURR OPIN CELL BIOL, V16, P239, DOI 10.1016/j.ceb.2004.03.010; LYONS RH, 1987, MOL CELL BIOL, V7, P2451, DOI 10.1128/MCB.7.7.2451; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; Maquat LE, 2004, NAT REV MOL CELL BIO, V5, P89, DOI 10.1038/nrm1310; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; Martin MED, 1999, MOL CELL BIOL, V19, P3403; Martin MED, 1998, J VIROL, V72, P3146, DOI 10.1128/JVI.72.4.3146-3154.1998; Massague J, 2004, NATURE, V432, P298, DOI 10.1038/nature03094; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; Mitani K, 2004, ONCOGENE, V23, P4263, DOI 10.1038/sj.onc.1207777; Mittler G, 2001, EMBO REP, V2, P808, DOI 10.1093/embo-reports/kve186; Myers LC, 2000, ANNU REV BIOCHEM, V69, P729, DOI 10.1146/annurev.biochem.69.1.729; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Nibu Y, 1998, SCIENCE, V280, P101, DOI 10.1126/science.280.5360.101; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5054, DOI 10.1128/MCB.22.14.5054-5063.2002; Nomura H, 1998, BIOCHEM BIOPH RES CO, V248, P228, DOI 10.1006/bbrc.1998.8950; O'Shea CC, 2004, CANCER CELL, V6, P611, DOI 10.1016/j.ccr.2004.11.012; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; Packham G, 2005, IMMUNOLOGY, V114, P441, DOI 10.1111/j.1365-2567.2005.02117.x; Palmer S, 2001, J BIOL CHEM, V276, P25834, DOI 10.1074/jbc.M102343200; Park JM, 2000, MOL CELL BIOL, V20, P8709, DOI 10.1128/MCB.20.23.8709-8719.2000; Petrini JHJ, 2003, TRENDS CELL BIOL, V13, P458, DOI 10.1016/S0962-8924(03)00170-3; PILDER S, 1986, MOL CELL BIOL, V6, P470, DOI 10.1128/MCB.6.2.470; Polakis P, 2000, GENE DEV, V14, P1837; Poortinga G, 1998, EMBO J, V17, P2067, DOI 10.1093/emboj/17.7.2067; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; Punga T, 2000, FEBS LETT, V476, P248, DOI 10.1016/S0014-5793(00)01739-7; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; Roeder RG, 1998, COLD SPRING HARB SYM, V63, P201, DOI 10.1101/sqb.1998.63.201; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Saeki H, 2001, ONCOLOGY-BASEL, V61, P156, DOI 10.1159/000055367; Sang NL, 2002, FRONT BIOSCI, V7, pD407, DOI 10.2741/sang; SARNOW P, 1984, J VIROL, V49, P692, DOI 10.1128/JVI.49.3.692-700.1984; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; Satyanarayana A, 2004, J CLIN INVEST, V114, P1237, DOI 10.1172/JCI200423437; Schaeper U, 1998, J BIOL CHEM, V273, P8549, DOI 10.1074/jbc.273.15.8549; Sewalt RGAB, 1999, MOL CELL BIOL, V19, P777; Shaw G, 2002, FASEB J, V16, P869, DOI 10.1096/fj.01-0995fje; Shaw PE, 2003, INT J BIOCHEM CELL B, V35, P1210, DOI 10.1016/S1357-2725(03)00031-1; SHENK T, 1979, COLD SPRING HARB SYM, V44, P367, DOI 10.1101/SQB.1980.044.01.041; SHENK T, 2001, ADENOVIRUSES; Shepard RN, 2004, J VIROL, V78, P9924, DOI 10.1128/JVI.78.18.9924-9935.2004; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; SINGH N, 1995, GENE DEV, V9, P2251, DOI 10.1101/gad.9.18.2251; SPINDLER KR, 1985, J VIROL, V53, P742, DOI 10.1128/JVI.53.3.742-750.1985; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; Steinberg D, 2003, J CLIN ETHIC, V14, P18; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Stevens JL, 2002, SCIENCE, V296, P755, DOI 10.1126/science.1068943; Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863; SUZUKI Y, 1988, MOL CELL BIOL, V8, P4991, DOI 10.1128/MCB.8.11.4991; Tange TO, 2004, CURR OPIN CELL BIOL, V16, P279, DOI 10.1016/j.ceb.2004.03.012; Taylor JP, 2002, SCIENCE, V296, P1991, DOI 10.1126/science.1067122; Teodoro JG, 1997, J VIROL, V71, P3620, DOI 10.1128/JVI.71.5.3620-3627.1997; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; Timmers HTM, 2005, TRENDS BIOCHEM SCI, V30, P7, DOI 10.1016/j.tibs.2004.11.007; Touitou R, 2001, J VIROL, V75, P7749, DOI 10.1128/JVI.75.16.7749-7755.2001; Tran PB, 1999, TRENDS NEUROSCI, V22, P194, DOI 10.1016/S0166-2236(99)01409-5; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Trimarchi JM, 2001, P NATL ACAD SCI USA, V98, P1519, DOI 10.1073/pnas.041597698; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Vandel L, 2001, MOL CELL BIOL, V21, P6484, DOI 10.1128/MCB.21.19.6484-6494.2001; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; WAGN G, 2005, MOL CELL, V17, P683; Wang G, 2001, MOL CELL BIOL, V21, P4604, DOI 10.1128/MCB.21.14.4604-4613.2001; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WEBSTER LC, 1991, MOL CELL BIOL, V11, P4287, DOI 10.1128/MCB.11.9.4287; WEIDEN MD, 1994, P NATL ACAD SCI USA, V91, P153, DOI 10.1073/pnas.91.1.153; WHITE E, 1990, MOL CELL BIOL, V10, P120, DOI 10.1128/MCB.10.1.120; White E, 2001, ONCOGENE, V20, P7836, DOI 10.1038/sj.onc.1204861; Williams JF, 2004, CURR TOP MICROBIOL, V273, P245; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; Yudkovsky N, 2000, NATURE, V408, P225, DOI 10.1038/35041603; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821; Zhang HS, 2001, ONCOGENE, V20, P3134, DOI 10.1038/sj.onc.1204338; Zhang X, 2004, J BIOL CHEM, V279, P25122, DOI 10.1074/jbc.M403287200; Zhao HX, 2003, J VIROL, V77, P11006, DOI 10.1128/JVI.77.20.11006-11015.2003; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	185	270	278	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2005	24	52					7673	7685		10.1038/sj.onc.1209040	http://dx.doi.org/10.1038/sj.onc.1209040			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985JD	16299528				2022-12-17	WOS:000233372600004
J	Petrovics, G; Liu, AJ; Shaheduzzaman, S; Furasato, B; Sun, C; Chen, YM; Nau, M; Ravindranath, L; Chen, YD; Dobi, A; Srikantan, V; Sesterhenn, IA; McLeod, DG; Vahey, M; Moul, JW; Srivastava, S				Petrovics, G; Liu, AJ; Shaheduzzaman, S; Furasato, B; Sun, C; Chen, YM; Nau, M; Ravindranath, L; Chen, YD; Dobi, A; Srikantan, V; Sesterhenn, IA; McLeod, DG; Vahey, M; Moul, JW; Srivastava, S			Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome	ONCOGENE			English	Article						ERG1; ETS transcription factor family; prostate cancer; proto-oncogene; overexpression	EXPRESSION; ONCOGENE; FAMILY	Transcription factors encoded by the ETS family of genes are central in integrating signals that regulate cell growth and differentiation, stress responses, and tumorigenesis. This study, analysing laser microdissected paired benign and malignant prostate epithelial cells from prostate cancer (CaP) patients ( n = 114; 228 specimen) by GeneChip and quantitative real-time RT-PCR, identifies ETS-related gene ( ERG), a member of the ETS transcription factor family, as the most frequently overexpressed proto-oncogene in the transcriptome of malignant prostate epithelial cells. Combined quantitative expression analysis of ERG with two other genes commonly overexpressed in CaP, AMACR and DD3, revealed overexpression of at least one of these three genes in virtually all CaP specimen ( 54 of 55). Comprehensive evaluation of quantitative ERG1 expression with clinicopathological features also suggested that ERG1 expression level in prostate tumor cells relative to benign epithelial cells is indicator of disease-free survival after radical prostatectomy.	Ctr Prostate Dis Res, Dept Surg, Rockville, MD 20852 USA; Uniformed Serv Univ Hlth Sci, US Mil Canc Inst, Rockville, MD 20852 USA; Armed Forces Inst Pathol, Dept Genitourinary Pathol, Washington, DC 20306 USA; Walter Reed Army Inst Res, Lab Funct Genom, Rockville, MD 20850 USA; NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA; Walter Reed Army Med Ctr, Urol Serv, Washington, DC 20307 USA	Uniformed Services University of the Health Sciences - USA; United States Department of Defense; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); United States Department of Defense; United States Army; Walter Reed National Military Medical Center	Srivastava, S (corresponding author), Ctr Prostate Dis Res, Dept Surg, Rockville, MD 20852 USA.	gpetrovics@cpdr.org		Petrovics, Gyorgy/0000-0003-3732-284X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065977] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK065977] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baldus CD, 2004, P NATL ACAD SCI USA, V101, P3915, DOI 10.1073/pnas.0400272101; Bussemakers MJG, 1999, CANCER RES, V59, P5975; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Gavrilov D, 2001, EUR J CANCER, V37, P1033, DOI 10.1016/S0959-8049(01)00077-6; Gelmann EP, 2003, CRIT REV ONCOL HEMAT, V46, pS11; HART AH, 1995, ONCOGENE, V10, P1423; Hsu T, 2004, J CELL BIOCHEM, V91, P896, DOI 10.1002/jcb.20012; Hurt EM, 2004, CANCER CELL, V5, P191, DOI 10.1016/S1535-6108(04)00019-4; Isaacs W, 2001, EPIDEMIOL REV, V23, P36, DOI 10.1093/oxfordjournals.epirev.a000794; Liu AY, 1997, PROSTATE, V30, P145, DOI 10.1002/(SICI)1097-0045(19970215)30:3<145::AID-PROS1>3.0.CO;2-L; Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; Owczarek CM, 2004, GENE, V324, P65, DOI 10.1016/j.gene.2003.09.047; Petrovics G, 2004, ONCOGENE, V23, P605, DOI 10.1038/sj.onc.1207069; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; Rubin MA, 2002, JAMA-J AM MED ASSOC, V287, P1662, DOI 10.1001/jama.287.13.1662; Sementchenko VI, 1998, ONCOGENE, V17, P2883, DOI 10.1038/sj.onc.1202220; Srikantan V, 2003, PROSTATE CANCER: DIAGNOSIS AND SURGICAL TREATMENT, P25	18	270	305	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3847	3852		10.1038/sj.onc.1208518	http://dx.doi.org/10.1038/sj.onc.1208518			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15750627				2022-12-17	WOS:000229346300016
J	Sebolt-Leopold, JS				Sebolt-Leopold, JS			Development of anticancer drugs targeting the MAP kinase pathway	ONCOGENE			English	Article						mitogen-activated protein kinase (MAPK); extracellular signal-regulated kinase (ERK); MAP kinase kinase (MEK); raf	ACTIVATED PROTEIN-KINASES; EPIDERMAL-GROWTH-FACTOR; TRANSCRIPTIONAL REGULATION; BAD PHOSPHORYLATION; SIGNAL-TRANSDUCTION; CARCINOMA CELLS; IN-VITRO; RAF; INHIBITION; MEK	Since the discovery of the role of ras oncogenes in tumorigenesis, me have witnessed an explosion of research in the signal transduction area. In the quest to understand how Pas transmits extracellular growth signals, the MAP kinase (MAPK) pathway has emerged as the crucial route between membrane-bound Ras and the nucleus, The MAPK pathway encompasses a cascade of phosphorylation events involving three key kinases, namely Raf, MEK (MAP kinase kinase) and ERK (MAP kinase). This kinase cascade presents novel opportunities for the development of new cancer therapies designed to be less toxic than conventional chemotherapeutic drugs, Furthermore, as a signal transduction-based approach to cancer treatment, inhibition of any one of these targets has the potential for translational pharmacodynamic evaluation of target suppression. The rationale for targeting the MAP kinase pathway will be reviewed here along with a discussion of various pharmacological approaches and the promise they hold for a new generation of anticancer drugs.	Pfizer Global Res & Dev, Ann Arbor Labs, Ann Arbor, MI 48105 USA	Pfizer	Sebolt-Leopold, JS (corresponding author), Pfizer Global Res & Dev, Ann Arbor Labs, Ann Arbor, MI 48105 USA.							ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Allen M, 2000, J EXP MED, V191, P859, DOI 10.1084/jem.191.5.859; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BAYER CORPORATION, 2000, Patent No. 200042012; Boucher MJ, 2000, J CELL BIOCHEM, V79, P355, DOI 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.3.CO;2-S; BRUNET A, 1994, FEBS LETT, V346, P299, DOI 10.1016/0014-5793(94)00475-7; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DUMAS J, 1999, Patent No. 9932455; Dumas J., 1999, Patent, P163, Patent No. [9932106, WO 9,932,106 A1]; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; Fang XJ, 1999, ONCOGENE, V18, P6635, DOI 10.1038/sj.onc.1203076; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Finlay D, 2000, CELL DEATH DIFFER, V7, P302, DOI 10.1038/sj.cdd.4400652; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Gioeli D, 1999, CANCER RES, V59, P279; Giroux S, 1999, CURR BIOL, V9, P369, DOI 10.1016/S0960-9822(99)80164-X; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Hall-Jackson CA, 1999, CHEM BIOL, V6, P559, DOI 10.1016/S1074-5521(99)80088-X; Henry SP, 1997, ANTI-CANCER DRUG DES, V12, P409; HER JH, 1993, BIOCHEM J, V296, P25, DOI 10.1042/bj2960025; Herrera R, 1998, J CELL SCI, V111, P1039; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Holmstrom TH, 1999, MOL CELL BIOL, V19, P5991; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Kolch W, 2000, BIOCHEM J, V351, P289, DOI 10.1042/0264-6021:3510289; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Lange CA, 1998, J BIOL CHEM, V273, P31308, DOI 10.1074/jbc.273.47.31308; Lee SW, 2000, P NATL ACAD SCI USA, V97, P8302, DOI 10.1073/pnas.150024397; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Li WQ, 2000, GENE DEV, V14, P895; Lu HT, 1999, EMBO J, V18, P1845, DOI 10.1093/emboj/18.7.1845; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; McDonald OB, 1999, ANAL BIOCHEM, V268, P318, DOI 10.1006/abio.1998.3030; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; Miller S., 1999, [No title captured], Patent No. [9932436, WO9932436]; Monia BP, 1996, NAT MED, V2, P668, DOI 10.1038/nm0696-668; O'Dwyer PJ, 1999, CLIN CANCER RES, V5, P3977; Pages G, 1999, SCIENCE, V286, P1374, DOI 10.1126/science.286.5443.1374; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Persons DL, 1999, CLIN CANCER RES, V5, P1007; PERSONS DL, 2000, IN PRESS J BIOL CHEM; Petit AMV, 1997, AM J PATHOL, V151, P1523; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; SEGER R, 1992, J BIOL CHEM, V267, P14373; STANTON VP, 1987, MOL CELL BIOL, V7, P1171, DOI 10.1128/MCB.7.3.1171; Stevenson JP, 1999, J CLIN ONCOL, V17, P2227, DOI 10.1200/JCO.1999.17.7.2227; Stewart S, 1999, MOL CELL BIOL, V19, P5523; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; STORM SM, 1993, TOXICOL LETT, V67, P201, DOI 10.1016/0378-4274(93)90056-4; Tanimura S, 1998, ONCOGENE, V17, P57, DOI 10.1038/sj.onc.1201905; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WANG X, 2000, IN PRESS J BIOL CHEM; Weber CK, 2000, ONCOGENE, V19, P169, DOI 10.1038/sj.onc.1203261; Welch DR, 2000, CANCER RES, V60, P1552; Yeung K, 2000, MOL CELL BIOL, V20, P3079, DOI 10.1128/MCB.20.9.3079-3085.2000; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686; YUEN AR, 2000, FRONT BIOSCI, pD588; Yung YV, 2000, J BIOL CHEM, V275, P15799, DOI 10.1074/jbc.M910060199; Zecevic M, 1998, J CELL BIOL, V142, P1547, DOI 10.1083/jcb.142.6.1547; ZENECA LTD, 1998, Patent No. 9822103; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	75	270	294	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 27	2000	19	56					6594	6599		10.1038/sj.onc.1204083	http://dx.doi.org/10.1038/sj.onc.1204083			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415CY	11426644	Bronze			2022-12-17	WOS:000167704000005
J	Hacki, J; Egger, L; Monney, L; Conus, S; Rosse, T; Fellay, I; Borner, C				Hacki, J; Egger, L; Monney, L; Conus, S; Rosse, T; Fellay, I; Borner, C			Apoptotic crosstalk between the endoplasmic reticulum and mitochondria controlled by Bcl-2	ONCOGENE			English	Article						apoptosis; cytochrome c; caspases; Bcl-2; ER stress; BFA	PROGRAMMED CELL-DEATH; CYTOCHROME-C RELEASE; NF-KAPPA-B; BREFELDIN-A; FAMILY PROTEINS; TRANSCRIPTION FACTOR; OXIDATIVE STRESS; X-L; ACTIVATION; CERAMIDE	Apoptosis involves mitochondrial steps such as the release of the apoptogenic factor cytochrome c which are effectively blocked by Bcl-2, Although Bcl-2 may have a direct action on the mitochondrial membrane, it also resides and functions on the endoplasmic reticulum (ER), and there is increasing evidence for a role of the ER in apoptosis regulation as well. Here we uncover a hitherto unrecognized, apoptotic crosstalk between the ER and mitochondria that is controlled by Bcl-2, After triggering massive ER dilation due to an inhibition of secretion, the drug brefeldin A (BFA) induces the release of cytochrome c from mitochondria in a caspase-8- and Bid-independent manner. This is followed by caspase-3 activation and DNA/nuclear fragmentation. Surprisingly, cytochrome c release by BFA is not only blocked by wild-type Bcl-2 but also by a Bcl-2 variant that is exclusively targeted to the ER (Bcl-2/cb5), Similar findings were obtained with tunicamycin, an agent interfering with IV-linked glycosylations in the secretory system, Thus, apoptotic agents perturbing ER functions induce a novel crosstalk between the ER and mitochondria that can be interrupted by ER-based Bcl-2.	Univ Fribourg, Inst Biochem, CH-1700 Fribourg, Switzerland	University of Fribourg	Borner, C (corresponding author), Univ Fribourg, Inst Biochem, Rue Musee 5, CH-1700 Fribourg, Switzerland.		Egger, Charlotte/T-6517-2019	Egger, Charlotte/0000-0001-6501-5703				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Aridor M, 1999, NAT MED, V5, P745, DOI 10.1038/10466; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Borner C, 1996, J BIOL CHEM, V271, P12695, DOI 10.1074/jbc.271.22.12695; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Chandra NC, 1998, J BIOL CHEM, V273, P19715, DOI 10.1074/jbc.273.31.19715; Chapman R, 1998, ANNU REV CELL DEV BI, V14, P459, DOI 10.1146/annurev.cellbio.14.1.459; Chardin P, 1999, CELL, V97, P153, DOI 10.1016/S0092-8674(00)80724-2; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; GIVOL I, 1994, CELL GROWTH DIFFER, V5, P419; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Guo H, 1998, EXP CELL RES, V245, P57, DOI 10.1006/excr.1998.4235; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P374, DOI 10.1016/S0968-0004(98)01289-4; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Kowaltowski AJ, 1999, FREE RADICAL BIO MED, V26, P463, DOI 10.1016/S0891-5849(98)00216-0; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kumar S, 1999, TRENDS BIOCHEM SCI, V24, P1, DOI 10.1016/S0968-0004(98)01332-2; Kuo TH, 1998, ONCOGENE, V17, P1903, DOI 10.1038/sj.onc.1202110; Lee ST, 1999, ONCOGENE, V18, P3520, DOI 10.1038/sj.onc.1202716; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Linardic CM, 1996, CELL GROWTH DIFFER, V7, P765; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; OLDEN K, 1982, BIOCHIM BIOPHYS ACTA, V650, P209, DOI 10.1016/0304-4157(82)90017-X; Oliviero R, 1997, BIOCHEM J, V324, P75, DOI 10.1042/bj3240075; PAHL HL, 1995, EMBO J, V14, P2580, DOI 10.1002/j.1460-2075.1995.tb07256.x; Pahl HL, 1997, TRENDS BIOCHEM SCI, V22, P63, DOI 10.1016/S0968-0004(96)10073-6; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schendel SL, 1998, CELL DEATH DIFFER, V5, P372, DOI 10.1038/sj.cdd.4400365; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Stroh C, 1998, CELL DEATH DIFFER, V5, P997, DOI 10.1038/sj.cdd.4400451; TKACZ JS, 1975, BIOCHEM BIOPH RES CO, V65, P248, DOI 10.1016/S0006-291X(75)80086-6; Torgler CN, 1997, CELL DEATH DIFFER, V4, P263, DOI 10.1038/sj.cdd.4400239; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	60	270	277	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2000	19	19					2286	2295		10.1038/sj.onc.1203592	http://dx.doi.org/10.1038/sj.onc.1203592			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZR	10822379				2022-12-17	WOS:000086974300003
J	Nagai, H; Pineau, P; Tiollais, P; Buendia, MA; Dejean, A				Nagai, H; Pineau, P; Tiollais, P; Buendia, MA; Dejean, A			Comprehensive allelotyping of human hepatocellular carcinoma	ONCOGENE			English	Article						hepatocellular carcinoma; hepatitis; loss of heterozygosity; microsatellite markers; tumor suppressor genes	TUMOR-SUPPRESSOR GENE; B VIRUS INTEGRATION; FREQUENT LOSS; P53 GENE; HETEROZYGOSITY; CANCER; RETINOBLASTOMA; PROGRESSION; DNA; IDENTIFICATION	Hepatocellular carcinoma (HCC) is one of the most common cancers in many parts of the world, however the molecular mechanisms underlying liver cell transformation remain obscure. A genome-wide scan of loss of heterozygosity (LOH) in tumors provides a powerful tool to search for genes involved in neoplastic processes, To identify recurrent genetic alterations in liver tumors, we examined DNAs isolated from 120 HCCs and their adjacent non tumorous parts for LOH using a collection of 195 microsatellite markers located roughly every 20cM throughout 39 autosomal arms, The mean heterozygosity was 73%, Our findings provide additional support that LOH for loci on chromosomal arms 1p, 4q, 6q, 8p, 13q and 16p is significantly elevated in HCC. The highest percentage of LOH is found for a locus in 8p23 (42% of informative csaes), This corresponds to one of the most common genetic abnormalities reported to date in these tumors. In addition, high ratio of LOH (greater than or equal to 35%) is observed on chromosome arms which had not been implicated in previous studies, notably on 1q, 2q and 9q, No correlation was found between LOH of specific chromosomal regions and etiologic factors such as chronic infections with hepatitis B or C viruses. This first report of an extensive allelotypic analysis of HCC should help in identifying new genes whose loss of function contributes to the development of liver cancer.	INST PASTEUR,UNITE RECOMBINAISON & EXPRESS GENET,INSERM U163,F-75724 PARIS 15,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Pineau, Pascal/AAP-5614-2020; Dejean, Anne/L-5145-2018	Pineau, Pascal/0000-0002-9407-1592; 				BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; Buendia MA, 1995, DNA TUMOR VIRUSES ON, P171; BUETOW KH, 1992, P NATL ACAD SCI USA, V89, P9622, DOI 10.1073/pnas.89.20.9622; BUETOW KH, 1989, P NATL ACAD SCI USA, V86, P8852, DOI 10.1073/pnas.86.22.8852; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; COX DW, 1995, CYTOGENET CELL GENET, V69, P160; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; EMI M, 1992, CANCER RES, V52, P5368; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUJIMORI M, 1991, CANCER RES, V51, P89; FUJIWARA Y, 1993, CANCER RES, V53, P857; FUJIWARA Y, 1995, ONCOGENE, V10, P891; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HEARLY E, 1995, GENE CHROMOSOME CANC, V12, P152; Hermanek P, 1987, TNM CLASSIFICATION M; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; KUROKI T, 1995, GENE CHROMOSOME CANC, V13, P163, DOI 10.1002/gcc.2870130305; Marchio A, 1997, GENE CHROMOSOME CANC, V18, P59, DOI 10.1002/(SICI)1098-2264(199701)18:1<59::AID-GCC7>3.3.CO;2-N; MATSUBARA K, 1991, MOL BIOL HEPATITIS B, P245; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MURAKAMI Y, 1991, CANCER RES, V51, P5520; NAGAI H, 1994, CANCER RES, V54, P1545; RANFORD DM, 1995, CANCER RES, V55, P3399; SLAGLE BL, 1991, CANCER RES, V51, P49; SLAGLE BL, 1993, HEPATOLOGY, V18, P757, DOI 10.1002/hep.1840180402; TAKAHASHI K, 1993, HEPATOLOGY, V17, P794, DOI 10.1002/hep.1840170508; TAKAHASHI S, 1995, CANCER RES, V55, P4114; TAKITA J, 1995, ONCOGENE, V11, P1829; TSUDA H, 1990, P NATL ACAD SCI USA, V87, P6791, DOI 10.1073/pnas.87.17.6791; VIGNAL A, 1993, METHODS MOL GENETICS, V1; WANG HP, 1988, CYTOGENET CELL GENET, V48, P72, DOI 10.1159/000132593; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; YEH SH, 1994, CANCER RES, V54, P4188; ZHANG X, 1994, CANCER RES, V54, P4177	39	270	284	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 19	1997	14	24					2927	2933		10.1038/sj.onc.1201136	http://dx.doi.org/10.1038/sj.onc.1201136			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XF555	9205099				2022-12-17	WOS:A1997XF55500006
J	PAWSON, T				PAWSON, T			NON-CATALYTIC DOMAINS OF CYTOPLASMIC PROTEIN-TYROSINE KINASES - REGULATORY ELEMENTS IN SIGNAL TRANSDUCTION	ONCOGENE			English	Review											PAWSON, T (corresponding author), MT SINAI HOSP, RES INST, DIV MOLEC & DEV BIOL, 600 UNIV AVE, TORONTO M5G 1X5, ONTARIO, CANADA.		Pawson, Tony J/E-4578-2013					ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; ANDERSON DD, 1981, J VIROL, V37, P445, DOI 10.1128/JVI.37.1.445-458.1981; ANDERSON SK, 1987, J VIROL, V61, P1893, DOI 10.1128/JVI.61.6.1893-1900.1987; BARKER WC, 1982, P NATL ACAD SCI USA, V79, P836; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.biochem.56.1.159; BRANTON D, 1981, CELL, V24, P24, DOI 10.1016/0092-8674(81)90497-9; BRENNER S, 1987, NATURE, V329, P21, DOI 10.1038/329021a0; BRISTOL A, 1988, IN PRESS COLD SPRING, V53; BRUGGE JS, 1984, J BIOL CHEM, V259, P4550; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; BRYANT D, 1982, J VIROL, V44, P683, DOI 10.1128/JVI.44.2.683-691.1982; BUSS JE, 1984, J VIROL, V53, P7; CALLES CJ, 1988, NATURE, V332, P548; CASEY PJ, 1988, J BIOL CHEM, V263, P2577; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COURTNEIDGE SA, 1980, P NATL ACAD SCI-BIOL, V77, P3783, DOI 10.1073/pnas.77.7.3783; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; CROSS FR, 1985, MOL CELL BIOL, V5, P2789, DOI 10.1128/MCB.5.10.2789; DECLUE JE, 1987, P NATL ACAD SCI USA, V84, P9064, DOI 10.1073/pnas.84.24.9064; EDWARDS AM, 1988, MOL CELL BIOL, V8, P2655, DOI 10.1128/MCB.8.6.2655; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; FELDMAN RA, 1983, J VIROL, V45, P782, DOI 10.1128/JVI.45.2.782-791.1983; GARBER EA, 1985, MOL CELL BIOL, V5, P2781, DOI 10.1128/MCB.5.10.2781; GONZALES RA, 1985, BIOCHEM J, V232, P799, DOI 10.1042/bj2320799; GREGORY RJ, 1987, MOL CELL BIOL, V7, P2119, DOI 10.1128/MCB.7.6.2119; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HENKEMEYER MJ, 1988, MOL CELL BIOL, V8, P843, DOI 10.1128/MCB.8.2.843; HENKEMEYER MJ, 1987, CELL, V51, P821, DOI 10.1016/0092-8674(87)90105-X; HIRST R, 1986, P NATL ACAD SCI USA, V83, P6470, DOI 10.1073/pnas.83.17.6470; HOFFMANN FM, 1983, CELL, V35, P393, DOI 10.1016/0092-8674(83)90172-1; HUANG CC, 1985, J MOL BIOL, V181, P175, DOI 10.1016/0022-2836(85)90083-X; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; KAPLAN JM, 1988, MOL CELL BIOL, V8, P2435, DOI 10.1128/MCB.8.6.2435; KATAN M, 1988, CELL, V54, P171, DOI 10.1016/0092-8674(88)90549-1; KITAMURA N, 1983, J VIROL, V46, P985, DOI 10.1128/JVI.46.3.985-992.1983; LAZARIDES E, 1982, CELL, V31, P504; LEHTO VP, 1988, NATURE, V334, P388, DOI 10.1038/334388a0; LEVINSON AD, 1981, P NATL ACAD SCI-BIOL, V78, P1624, DOI 10.1073/pnas.78.3.1624; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; LOEB DM, 1987, J VIROL, V61, P2420, DOI 10.1128/JVI.61.8.2420-2427.1987; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; MAJERUS PW, 1986, SCIENCE, V234, P1519, DOI 10.1126/science.3024320; MANESS PF, 1988, P NATL ACAD SCI USA, V85, P5001, DOI 10.1073/pnas.85.14.5001; MANGER R, 1986, J VIROL, V59, P66, DOI 10.1128/JVI.59.1.66-72.1986; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; NAHARRO G, 1984, SCIENCE, V223, P63, DOI 10.1126/science.6318314; OPPERMANN H, 1981, VIROLOGY, V108, P47, DOI 10.1016/0042-6822(81)90526-2; POTTS WM, 1988, IN PRESS ONCOGENE RE; RAYMOND VW, 1987, VIROLOGY, V160, P400, DOI 10.1016/0042-6822(87)90011-0; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P3623, DOI 10.1073/pnas.80.12.3623; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; ROHRSCHNEIDER LR, 1980, P NATL ACAD SCI-BIOL, V77, P3514, DOI 10.1073/pnas.77.6.3514; ROHRSCHNEIDER LR, 1984, J VIROL, V51, P547, DOI 10.1128/JVI.51.2.547-552.1984; ROHRSCHNEIDER LR, 1984, ADV VIRAL ONCOL, V4, P269; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; SADOWSKI I, 1987, ONCOGENE, V1, P181; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WANG HCR, 1989, IN PRESS J VIROL; WEINMASTER G, 1986, EMBO J, V5, P69, DOI 10.1002/j.1460-2075.1986.tb04179.x; WEINMASTER G, 1983, J VIROL, V45, P29; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	76	270	281	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1988	3	5					491	495						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R5163	3078956				2022-12-17	WOS:A1988R516300001
J	Gonzalvez, F; Ashkenazi, A				Gonzalvez, F.; Ashkenazi, A.			New insights into apoptosis signaling by Apo2L/TRAIL	ONCOGENE			English	Review						DR4; DR5; glycosylation; caspase-8; cullin 3; p62	TRAIL-INDUCED APOPTOSIS; NF-KAPPA-B; DEATH RECEPTOR 5; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; LIGAND (TRAIL)-INDUCED APOPTOSIS; FLICE-INHIBITORY PROTEINS; FADD-DEPENDENT APOPTOSIS; CYTOCHROME-C RELEASE; INDUCED CELL-DEATH; CANCER-CELLS	Apoptosis ligand 2 tumor necrosis factor (TNF)-related apoptosis-inducing ligand (Apo2L/TRAIL) belongs to a small subset of proapoptotic protein ligands in the TNF superfamily. This subset, which also includes Fas ligand and TNF-alpha, can activate the extrinsic apoptotic cell death pathway on binding to cognate death receptors at the cell surface. Over the past 10 years, Apo2L/TRAIL has emerged as a promising candidate for cancer therapy, on the basis of its unique ability to trigger apoptosis in various types of cancer cells without significant toxicity toward normal cells. Herein, we review key advances in understanding the molecular events that control apoptosis signaling by Apo2L/TRAIL, which may aid in the development of cancer therapies based on the extrinsic apoptotic pathway. Oncogene (2010) 29, 4752-4765; doi:10.1038/onc.2010.221; published online 7 June 2010	[Gonzalvez, F.; Ashkenazi, A.] Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA	Roche Holding; Genentech	Ashkenazi, A (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way, San Francisco, CA 94080 USA.	aa@gene.com	Ashkenazi, Avi/ABG-2712-2020	Ashkenazi, Avi/0000-0002-6890-4589				Akazawa Y, 2009, GASTROENTEROLOGY, V136, P2365, DOI 10.1053/j.gastro.2009.02.071; Algeciras-Schimnich A, 2003, P NATL ACAD SCI USA, V100, P11445, DOI 10.1073/pnas.2034995100; Almasan A, 2003, CYTOKINE GROWTH F R, V14, P337, DOI 10.1016/S1359-6101(03)00029-7; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Ashkenazi A, 2008, J CLIN ONCOL, V26, P3621, DOI 10.1200/JCO.2007.15.7198; Austin CD, 2006, P NATL ACAD SCI USA, V103, P10283, DOI 10.1073/pnas.0604044103; Barnhart BC, 2003, SEMIN IMMUNOL, V15, P185, DOI 10.1016/S1044-5323(03)00031-9; Beraza N, 2009, J EXP MED, V206, P1727, DOI 10.1084/jem.20082152; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Bodmer JL, 2000, J BIOL CHEM, V275, P20632, DOI 10.1074/jbc.M909721199; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Bouchier-Hayes L, 2009, MOL CELL, V35, P830, DOI 10.1016/j.molcel.2009.07.023; Casella C R, 1997, Curr Opin Hematol, V4, P24; Cha SS, 1999, IMMUNITY, V11, P253, DOI 10.1016/S1074-7613(00)80100-4; Chaigne-Delalande B, 2009, CELL DEATH DIFFER, V16, P1654, DOI 10.1038/cdd.2009.111; Chakrabandhu K, 2007, EMBO J, V26, P209, DOI 10.1038/sj.emboj.7601456; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; Chan FKM, 2007, CYTOKINE, V37, P101, DOI 10.1016/j.cyto.2007.03.005; Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Chen M, 2002, J BIOL CHEM, V277, P50761, DOI 10.1074/jbc.M210356200; Chen XF, 2003, CANCER RES, V63, P1059; Chowdhury I, 2006, CELL MOL BIOL LETT, V11, P506, DOI 10.2478/s11658-006-0041-3; Clancy L, 2005, P NATL ACAD SCI USA, V102, P18099, DOI 10.1073/pnas.0507329102; Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356; Cretney E, 2005, IMMUNOL CELL BIOL, V83, P511, DOI 10.1111/j.1440-1711.2005.01358.x; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Diehl GE, 2004, IMMUNITY, V21, P877, DOI 10.1016/j.immuni.2004.11.008; Dumitru CA, 2007, APOPTOSIS, V12, P1533, DOI 10.1007/s10495-007-0081-9; Eckelman BP, 2006, EMBO REP, V7, P988, DOI 10.1038/sj.embor.7400795; Ehrhardt H, 2003, ONCOGENE, V22, P3842, DOI 10.1038/sj.onc.1206520; Eimon PM, 2006, CELL DEATH DIFFER, V13, P1619, DOI 10.1038/sj.cdd.4402015; Elnemr A, 2001, INT J ONCOL, V18, P311; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; Esposti MD, 2001, MOL CELL BIOL, V21, P7268, DOI 10.1128/MCB.21.21.7268-7276.2001; Fadeel B, 1999, BIOCHEM BIOPH RES CO, V266, P699, DOI 10.1006/bbrc.1999.1888; Feig C, 2007, EMBO J, V26, P221, DOI 10.1038/sj.emboj.7601460; Finnberg N, 2008, J CLIN INVEST, V118, P111, DOI 10.1172/JCI29900; Fisher MJ, 2001, CLIN CANCER RES, V7, P1688; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Gonzalvez F, 2005, CELL DEATH DIFFER, V12, P659, DOI 10.1038/sj.cdd.4401585; Gonzalvez F, 2005, CELL DEATH DIFFER, V12, P614, DOI 10.1038/sj.cdd.4401571; Gonzalvez F, 2008, J CELL BIOL, V183, P681, DOI 10.1083/jcb.200803129; Grassme H, 2003, ONCOGENE, V22, P5457, DOI 10.1038/sj.onc.1206540; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; Green D R, 1998, Results Probl Cell Differ, V24, P45; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grinberg M, 2002, J BIOL CHEM, V277, P12237, DOI 10.1074/jbc.M104893200; Grosse-Wilde A, 2008, J CLIN INVEST, V118, P100, DOI 10.1172/JCI33061; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hayakawa K, 2002, CIRCULATION, V105, P3039, DOI 10.1161/01.CIR.0000018651.89208.69; Hilliard B, 2001, J IMMUNOL, V166, P1314, DOI 10.4049/jimmunol.166.2.1314; Hinz S, 2000, ONCOGENE, V19, P5477, DOI 10.1038/sj.onc.1203936; Hughes MA, 2009, MOL CELL, V35, P265, DOI 10.1016/j.molcel.2009.06.012; Hymowitz SG, 2000, BIOCHEMISTRY-US, V39, P633, DOI 10.1021/bi992242l; Hymowitz SG, 1999, MOL CELL, V4, P563, DOI 10.1016/S1097-2765(00)80207-5; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Ishimura N, 2006, AM J PHYSIOL-GASTR L, V290, pG129, DOI 10.1152/ajpgi.00242.2005; Jin ZY, 2006, MOL CELL BIOL, V26, P8136, DOI 10.1128/MCB.00257-06; Jin ZY, 2009, CELL, V137, P721, DOI 10.1016/j.cell.2009.03.015; Jost PJ, 2009, NATURE, V460, P1035, DOI 10.1038/nature08229; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Kohlhaas SL, 2007, J BIOL CHEM, V282, P12831, DOI 10.1074/jbc.M700438200; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Labrinidis A, 2008, BLOOD, V111, P5411, DOI 10.1182/blood-2008-03-144261; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; Laguinge LM, 2008, CANCER RES, V68, P909, DOI 10.1158/0008-5472.CAN-06-1806; Lamhamedi-Cherradi SE, 2003, NAT IMMUNOL, V4, P255, DOI 10.1038/ni894; Lavrik I, 2005, J CELL SCI, V118, P265, DOI 10.1242/jcs.01610; Lavrik IN, 2005, J CLIN INVEST, V115, P2665, DOI 10.1172/JCI26252; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; Le Roy C, 2005, NAT REV MOL CELL BIO, V6, P112, DOI 10.1038/nrm1571; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Lee KH, 2006, EMBO J, V25, P1009, DOI 10.1038/sj.emboj.7601016; Lee SH, 1999, CANCER RES, V59, P5683; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li J, 2008, ONCOGENE, V27, P6194, DOI 10.1038/onc.2008.297; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lin Y, 2000, MOL CELL BIOL, V20, P6638, DOI 10.1128/MCB.20.18.6638-6645.2000; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Lluis JM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008620; Lub-de Hooge MN, 2005, ANN RHEUM DIS, V64, P854, DOI 10.1136/ard.2004.029058; Luo JL, 2004, CANCER CELL, V6, P297, DOI 10.1016/j.ccr.2004.08.012; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; Martin S, 2005, CANCER RES, V65, P11447, DOI 10.1158/0008-5472.CAN-05-1494; McKenzie M, 2004, NEUROCHEM RES, V29, P589, DOI 10.1023/B:NERE.0000014829.42364.dd; Meier P, 2000, NATURE, V407, P796, DOI 10.1038/35037734; Mejia ROS, 2001, NEUROSCIENTIST, V7, P480, DOI 10.1177/107385840100700604; Micheau O, 2002, J BIOL CHEM, V277, P45162, DOI 10.1074/jbc.M206882200; Mongkolsapaya J, 1999, NAT STRUCT BIOL, V6, P1048; Moscat J, 2007, TRENDS BIOCHEM SCI, V32, P95, DOI 10.1016/j.tibs.2006.12.002; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Newsom-Davis T, 2009, APOPTOSIS, V14, P607, DOI 10.1007/s10495-009-0321-2; Nikolaev A, 2009, NATURE, V457, P981, DOI 10.1038/nature07767; Nuutinen U, 2009, LEUKEMIA RES, V33, P829, DOI 10.1016/j.leukres.2008.09.025; Opferman JT, 2003, NAT IMMUNOL, V4, P410, DOI 10.1038/ni0503-410; Ou D, 2005, HUM IMMUNOL, V66, P799, DOI 10.1016/j.humimm.2005.03.009; Ozoren N, 2000, CANCER RES, V60, P6259; Ozoren N, 2002, NEOPLASIA, V4, P551, DOI 10.1038/sj.neo.7900270; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Papoff G, 1999, J BIOL CHEM, V274, P38241, DOI 10.1074/jbc.274.53.38241; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Petros AM, 2004, BBA-MOL CELL RES, V1644, P83, DOI 10.1016/j.bbamcr.2003.08.012; Pickart CM, 2004, CELL, V116, P181, DOI 10.1016/S0092-8674(03)01074-2; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Prasad KV, 2003, AUTOIMMUNITY, V36, P323, DOI 10.1080/08916930310001604207; Prunell GF, 2005, CNS NEUROL DISORD-DR, V4, P51, DOI 10.2174/1568007053005082; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Rohn TT, 2001, NEUROBIOL DIS, V8, P1006, DOI 10.1006/nbdi.2001.0449; Rossin A, 2009, BIOCHEM J, V419, P185, DOI 10.1042/BJ20081212; Ryu BK, 2001, J PATHOL, V194, P15, DOI 10.1002/path.835; Said TM, 2004, HUM REPROD UPDATE, V10, P39, DOI 10.1093/humupd/dmh003; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Schneider TJ, 1997, J IMMUNOL, V159, P4834; Schneider-Brachert W, 2004, IMMUNITY, V21, P415, DOI 10.1016/j.immuni.2004.08.017; Schneider-Brachert W, 2006, J CLIN INVEST, V116, P2901, DOI 10.1172/JCI23771; Schutze S, 2008, NAT REV MOL CELL BIO, V9, P655, DOI 10.1038/nrm2430; Scorrano L, 2008, J CELL BIOL, V183, P579, DOI 10.1083/jcb.200810125; Secchiero P, 2003, CIRCULATION, V107, P2250, DOI 10.1161/01.CIR.0000062702.60708.C4; Sharp DA, 2005, J BIOL CHEM, V280, P19401, DOI 10.1074/jbc.M413962200; Shell S, 2007, P NATL ACAD SCI USA, V104, P11400, DOI 10.1073/pnas.0704372104; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Spencer SL, 2009, NATURE, V459, P428, DOI 10.1038/nature08012; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Sprick MR, 2002, EMBO J, V21, P4520, DOI 10.1093/emboj/cdf441; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Sun SY, 2001, BIOCHEM BIOPH RES CO, V280, P788, DOI 10.1006/bbrc.2000.4218; Tafani M, 2002, J BIOL CHEM, V277, P10073, DOI 10.1074/jbc.M111350200; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; Tepper CG, 1999, BLOOD, V94, P1727, DOI 10.1182/blood.V94.5.1727.417k03_1727_1737; Thome M, 2001, NAT REV IMMUNOL, V1, P50, DOI 10.1038/35095508; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; Varfolomeev E, 2005, J BIOL CHEM, V280, P40599, DOI 10.1074/jbc.M509560200; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Varfolomeev E, 2008, CELL CYCLE, V7, P1511, DOI 10.4161/cc.7.11.5959; Varfolomeev E, 2009, J BIOL CHEM, V284, P34553, DOI 10.1074/jbc.M109.040139; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vitovski S, 2007, J BIOL CHEM, V282, P31601, DOI 10.1074/jbc.M706078200; Vogler M, 2008, CANCER RES, V68, P7956, DOI 10.1158/0008-5472.CAN-08-1296; Wagner KW, 2007, NAT MED, V13, P1070, DOI 10.1038/nm1627; Wandinger KP, 2003, LANCET, V361, P2036, DOI 10.1016/S0140-6736(03)13641-0; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wang L, 2001, P NATL ACAD SCI USA, V98, P13884, DOI 10.1073/pnas.241358198; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wilson NS, 2009, NAT IMMUNOL, V10, P348, DOI 10.1038/ni.1714; Wu GS, 1999, CANCER RES, V59, P2770; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Yoshida T, 2007, ONCOL REP, V18, P1239; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Yue HH, 2005, CELL DEATH DIFFER, V12, P94, DOI 10.1038/sj.cdd.4401523; Zauli G, 2004, BLOOD, V104, P2044, DOI 10.1182/blood-2004-03-1196; Zauli G, 2008, J CELL PHYSIOL, V214, P117, DOI 10.1002/jcp.21165; Zhang L, 2010, NATURE, V464, P1058, DOI 10.1038/nature08871; Zhang XD, 2003, ONCOGENE, V22, P2869, DOI 10.1038/sj.onc.1206427; Zhao XX, 2009, BIOCHEM BIOPH RES CO, V378, P21, DOI 10.1016/j.bbrc.2008.10.123; Zheng SJ, 2004, J IMMUNOL, V173, P5652, DOI 10.4049/jimmunol.173.9.5652	176	269	281	0	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2010	29	34					4752	4765		10.1038/onc.2010.221	http://dx.doi.org/10.1038/onc.2010.221			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643VB	20531300				2022-12-17	WOS:000281326400002
J	Dean, JL; Thangavel, C; McClendon, AK; Reed, CA; Knudsen, ES				Dean, J. L.; Thangavel, C.; McClendon, A. K.; Reed, C. A.; Knudsen, E. S.			Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure	ONCOGENE			English	Article						breast cancer; CDK4/6; RB; PD-0332991; cyclin D; E2F	CELL-CYCLE; RETINOBLASTOMA GENE; ESTROGEN-RECEPTOR; DEPENDENT KINASES; LUNG-CANCER; EXPRESSION; PROTEIN; RB; PHOSPHORYLATION; OVEREXPRESSION	A hallmark of cancer is the deregulation of cell-cycle machinery, ultimately facilitating aberrant proliferation that fuels tumorigenesis and disease progression. Particularly, in breast cancers, cyclin D1 has a crucial role in the development of disease. Recently, a highly specific inhibitor of CDK4/6 activity (PD-0332991) has been developed that may have efficacy in the treatment of breast cancer. To interrogate the utility of PD-0332991 in treating breast cancers, therapeutic response was evaluated on a panel of breast cancer cell lines. These analyses showed that the chronic loss of Rb is specifically associated with evolution to a CDK4/6-independent state and, ultimately, resistance to PD-0332991. However, to interrogate the functional consequence of Rb directly, knockdown experiments were performed in models that represent immortalized mammary epithelia and multiple subtypes of breast cancer. These studies showed a highly specific role for Rb in mediating the response to CDK4/6 inhibition that was dependent on transcriptional repression manifest through E2F, and the ability to attenuate CDK2 activity. Acquired resistance to PD-03322991 was specifically associated with attenuation of CDK2 inhibitors, indicating that redundancy in CDK functions represents a determinant of therapeutic failure. Despite these caveats, in specific models, PD-0332991 was a particularly effective therapy, which induced Rb-dependent cytostasis. Combined, these findings indicate the critical importance of fully understanding cell-cycle regulatory pathways in directing the utilization of CDK inhibitors in the clinic. Oncogene (2010) 29, 4018-4032; doi:10.1038/onc.2010.154; published online 17 May 2010	[Dean, J. L.; Thangavel, C.; McClendon, A. K.; Reed, C. A.; Knudsen, E. S.] Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Canc Biol, Philadelphia, PA 19107 USA	Jefferson University	Knudsen, ES (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Canc Biol, BLSB Room 1002,233 S 10th St, Philadelphia, PA 19107 USA.	eknudsen@kimmelcancercenter.org						Abukhdeir Abde M., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000744; Alle KM, 1998, CLIN CANCER RES, V4, P847; Ariazi EA, 2006, CURR TOP MED CHEM, V6, P181, DOI 10.2174/156802606776173483; Barker Stewart, 2003, Curr Opin Investig Drugs, V4, P652; BORG A, 1992, CANCER RES, V52, P2991; Brenner AJ, 1996, CLIN CANCER RES, V2, P1993; Buzdar AU, 2009, ANN ONCOL, V20, P993, DOI 10.1093/annonc/mdn739; Dannenberg Jan-Hermen, 2006, V42, P183, DOI 10.1007/002; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Donovan JCH, 2001, J BIOL CHEM, V276, P40888, DOI 10.1074/jbc.M106448200; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ENCARNACION CA, 1993, BREAST CANCER RES TR, V26, P237, DOI 10.1007/BF00665801; Fry DW, 2004, MOL CANCER THER, V3, P1427; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; GILLETT C, 1994, CANCER RES, V54, P1812; Halaban R, 1998, INT J MOL MED, V1, P419; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Jensen EV, 2003, CLIN CANCER RES, V9, P1980; KEYOMARSI K, 1994, CANCER RES, V54, P380; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; Knudsen ES, 2008, NAT REV CANCER, V8, P714, DOI 10.1038/nrc2401; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Loden M, 2002, ONCOGENE, V21, P4680, DOI 10.1038/sj.onc.1205578; Malumbres M, 2005, TRENDS BIOCHEM SCI, V30, P630, DOI 10.1016/j.tibs.2005.09.005; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Nielsen NH, 1997, ONCOGENE, V14, P295, DOI 10.1038/sj.onc.1200833; OKAMOTO A, 1994, COLD SPRING HARB SYM, V59, P49, DOI 10.1101/SQB.1994.059.01.008; Ormandy CJ, 2003, BREAST CANCER RES TR, V78, P323, DOI 10.1023/A:1023033708204; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; OTTERSON GA, 1994, ONCOGENE, V9, P3375; PIETILAINEN T, 1995, EUR J CANCER, V31A, P329, DOI 10.1016/0959-8049(94)00463-F; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Rizzi F, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003617; Robertson JFR, 1996, BRIT J CANCER, V73, P5, DOI 10.1038/bjc.1996.2; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Santamaria D, 2006, FRONT BIOSCI-LANDMRK, V11, P1164, DOI 10.2741/1871; Shapiro GI, 2006, J CLIN ONCOL, V24, P1770, DOI 10.1200/JCO.2005.03.7689; SHAPIRO GI, 1995, CANCER RES, V55, P505; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Stengel KR, 2009, J BIOL CHEM, V284, P19265, DOI 10.1074/jbc.M808740200; SUTHERLAND RL, 1983, CANCER RES, V43, P3998; Swarbrick A, 2000, MOL CELL BIOL, V20, P2581, DOI 10.1128/MCB.20.7.2581-2591.2000; Takano Y, 1999, J CANCER RES CLIN, V125, P505, DOI 10.1007/s004320050309; Toogood PL, 2005, J MED CHEM, V48, P2388, DOI 10.1021/jm049354h; Vaughn DJ, 2009, NEW ENGL J MED, V360, P423, DOI 10.1056/NEJMc0808558; Vivar OI, 2009, BIOCHEM PHARMACOL, V78, P469, DOI 10.1016/j.bcp.2009.05.008; Wakimoto N, 2008, CANCER RES, V68, P6978, DOI 10.1158/0008-5472.CAN-07-5675; Wang L, 2007, BLOOD, V110, P2075, DOI 10.1182/blood-2007-02-071266; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WATTS CKW, 1995, MOL ENDOCRINOL, V9, P1804, DOI 10.1210/me.9.12.1804; YEAGER T, 1995, CANCER RES, V55, P493; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Yu QY, 2006, CANCER CELL, V9, P23, DOI 10.1016/j.ccr.2005.12.012; Zagorski WA, 2007, CANCER RES, V67, P8264, DOI 10.1158/0008-5472.CAN-06-4753	60	269	275	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	2010	29	28					4018	4032		10.1038/onc.2010.154	http://dx.doi.org/10.1038/onc.2010.154			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	625JW	20473330	Bronze			2022-12-17	WOS:000279892400003
J	Lue, H; Thiele, M; Franz, J; Dahl, E; Speckgens, S; Leng, L; Fingerle-Rowson, G; Bucala, R; Luscher, B; Bernhagen, J				Lue, H.; Thiele, M.; Franz, J.; Dahl, E.; Speckgens, S.; Leng, L.; Fingerle-Rowson, G.; Bucala, R.; Luscher, B.; Bernhagen, J.			Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity	ONCOGENE			English	Article						MIF; JAB1; apoptosis; survival; Akt pathway; cytokine	HUMAN BREAST-CANCER; COP9 SIGNALOSOME; PROTEIN-KINASE; SIGNALING PATHWAY; PI3K/AKT PATHWAY; PTEN EXPRESSION; REGULATORY ROLE; TUMOR-GROWTH; CYTOKINE; BINDING	The phosphoinositide-3-kinase (PI3K)/Akt signaling pathway plays an important role in cell survival and the development of cancer. Macrophage migration inhibitory factor (MIF) is a critical in. ammatory cytokine that was recently associated with tumorigenesis and that potently inhibits apoptosis. This may involve inhibition of p53-dependent genes, but the initiating molecular mechanism of how MIF controls survival/apoptosis is unknown. Here, we show that MIF prevents apoptosis and promotes tumor cell survival by directly activating the Akt pathway. MIF enhanced Akt activity in primary and immortalized. broblasts (MEF and NIH/3T3), HeLa cervix carcinoma cells and various breast cancer cell lines. Activation was abolished by kinase inhibitors Ly294002 and PP2 and in Src/Yes/Fyn(SYF)(-/-) and CD74(-/-)(MEFs), while being enhanced in CD74-overexpressing MEFs, demonstrating that the MIF-induced Akt pathway encompasses signaling through the MIF receptor CD74 and the upstream kinases Src and PI3K. Akt was activated by exogenous rMIF and autocrine MIF action, as revealed by experiments in MIF-/- MEFs and antibody blockade. siRNA knockdown of CSN5/JAB1, a tumor marker and MIF-binding protein, showed that JAB1 controls autocrine MIF-mediated Akt signaling by inhibition of MIF secretion. Akt activation by MIF led to phosphorylation of the proapoptotic proteins BAD and Foxo3a. Apoptosis inhibition by MIF was functionally associated with Akt activation as it was abolished by overexpression of the Akt pathway inhibitor PTEN and occurred independently of p53. This was shown by studying DNA damage-induced apoptosis in. broblasts, the Fas death pathway in HeLa cells that do not express functional p53, and etoposide-induced apoptosis in breast carcinoma cells expressing mutant p53. Importantly, dependence of breast cancer cell survival on MIF correlated with Akt activation and the PTEN status of these cells. Thus, MIF can directly promote cell survival through activation of the PI3K/Akt pathway and this effect is critical for tumor cell survival.	Univ Hosp, Rhein Westfal TH Aachen, Dept Biochem & Mol Cell Biol, Inst Biochem, D-52074 Aachen, Germany; Univ Hosp, Rhein Westfal TH Aachen, Inst Pathol, D-52074 Aachen, Germany; Univ Hosp, Rhein Westfal TH Aachen, Dept Biochem & Mol Biol, D-52074 Aachen, Germany; Yale Univ, Sch Med, Dept Pathol & Med, New Haven, CT USA; Univ Hosp Cologne, Med Clin 1, Cologne, Germany	RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; RWTH Aachen University Hospital; Yale University; University of Cologne	Bernhagen, J (corresponding author), Univ Hosp, Rhein Westfal TH Aachen, Dept Biochem & Mol Cell Biol, Inst Biochem, Pauwelsstr 30, D-52074 Aachen, Germany.	jbernhagen@ukaachen.de	Luscher, Bernhard/A-7330-2011	Luscher, Bernhard/0000-0002-9622-8709	NIAID NIH HHS [AI43210] Funding Source: Medline; NIAMS NIH HHS [AR49610] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049610] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adler AS, 2006, NAT GENET, V38, P421, DOI 10.1038/ng1752; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Amin MA, 2006, BLOOD, V107, P2252, DOI 10.1182/blood-2005-05-2011; Amin MA, 2003, CIRC RES, V93, P321, DOI 10.1161/01.RES.0000087641.56024.DA; Bando H, 2002, JPN J CANCER RES, V93, P389, DOI 10.1111/j.1349-7006.2002.tb01269.x; Bech-Otschir D, 2002, J CELL SCI, V115, P467; BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Burger-Kentischer A, 2005, FEBS LETT, V579, P1693, DOI 10.1016/j.febslet.2005.01.080; Byrne AM, 2005, J CELL MOL MED, V9, P777, DOI 10.1111/j.1582-4934.2005.tb00379.x; Calandra T, 2003, NAT REV IMMUNOL, V3, P791, DOI 10.1038/nri1200; Chamovitz DA, 2001, EMBO REP, V2, P96, DOI 10.1093/embo-reports/kve028; Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824; Cheng JQ, 2005, ONCOGENE, V24, P7482, DOI 10.1038/sj.onc.1209088; Chesney J, 1999, MOL MED, V5, P181, DOI 10.1007/BF03402061; Datta SR, 2002, DEV CELL, V3, P631, DOI 10.1016/S1534-5807(02)00326-X; deGraffenried LA, 2004, ANN ONCOL, V15, P1510, DOI 10.1093/annonc/mdh388; Fingerle-Rowson G, 2003, P NATL ACAD SCI USA, V100, P9354, DOI 10.1073/pnas.1533295100; Flieger O, 2003, FEBS LETT, V551, P78, DOI 10.1016/S0014-5793(03)00900-1; Hagemann T, 2005, J IMMUNOL, V175, P1197, DOI 10.4049/jimmunol.175.2.1197; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Hudson JD, 1999, J EXP MED, V190, P1375, DOI 10.1084/jem.190.10.1375; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; Koyasu S, 2003, NAT IMMUNOL, V4, P313, DOI 10.1038/ni0403-313; Leng L, 2003, J EXP MED, V197, P1467, DOI 10.1084/jem.20030286; Lue HQ, 2006, CELL SIGNAL, V18, P688, DOI 10.1016/j.cellsig.2005.06.013; Mitchell RA, 2000, SEMIN CANCER BIOL, V10, P359, DOI 10.1006/scbi.2000.0328; Mitchell RA, 1999, J BIOL CHEM, V274, P18100, DOI 10.1074/jbc.274.25.18100; Mitchell RA, 2004, CELL SIGNAL, V16, P13, DOI 10.1016/j.cellsig.2003.07.002; Mitchell RA, 2002, P NATL ACAD SCI USA, V99, P345, DOI 10.1073/pnas.012511599; Morand EF, 2006, NAT REV DRUG DISCOV, V5, P399, DOI 10.1038/nrd2029; Nguyen MT, 2003, J IMMUNOL, V170, P3337, DOI 10.4049/jimmunol.170.6.3337; Nickel W, 2003, EUR J BIOCHEM, V270, P2109, DOI 10.1046/j.1432-1033.2003.03577.x; Nishihira J, 2003, ANN NY ACAD SCI, V995, P171, DOI 10.1111/j.1749-6632.2003.tb03220.x; Osaki M, 2004, APOPTOSIS, V9, P667, DOI 10.1023/B:APPT.0000045801.15585.dd; Osoegawa A, 2006, CANCER, V107, P154, DOI 10.1002/cncr.21961; Perren A, 1999, AM J PATHOL, V155, P1253, DOI 10.1016/S0002-9440(10)65227-3; Schober A, 2004, CIRCULATION, V109, P380, DOI 10.1161/01.CIR.0000109201.72441.09; Shi XR, 2006, IMMUNITY, V25, P595, DOI 10.1016/j.immuni.2006.08.020; Shimizu T, 1999, BIOCHEM BIOPH RES CO, V264, P751, DOI 10.1006/bbrc.1999.1584; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Song G, 2005, J CELL MOL MED, V9, P59, DOI 10.1111/j.1582-4934.2005.tb00337.x; Sun HW, 1996, P NATL ACAD SCI USA, V93, P5191, DOI 10.1073/pnas.93.11.5191; Takahashi N, 1998, MOL MED, V4, P707, DOI 10.1007/BF03401765; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386; Wetzker R, 2003, NAT REV MOL CELL BIO, V4, P651, DOI 10.1038/nrm1173; Wolf DA, 2003, NAT CELL BIOL, V5, P1029, DOI 10.1038/ncb1203-1029; Zapata JM, 1998, BREAST CANCER RES TR, V47, P129, DOI 10.1023/A:1005940832123	49	269	284	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2007	26	35					5046	5059		10.1038/sj.onc.1210318	http://dx.doi.org/10.1038/sj.onc.1210318			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	196MT	17310986				2022-12-17	WOS:000248487400003
J	Barbera, MJ; Puig, I; Dominguez, D; Julien-Grille, S; Guaita-Esteruelas, S; Peiro, S; Baulida, J; Franci, C; Dedhar, S; Larue, L; de Herreros, AG				Barbera, MJ; Puig, I; Dominguez, D; Julien-Grille, S; Guaita-Esteruelas, S; Peiro, S; Baulida, J; Franci, C; Dedhar, S; Larue, L; de Herreros, AG			Regulation of Snail transcription during epithelial to mesenchymal transition of tumor cells	ONCOGENE			English	Article						snail; promoter; transcription; EMT; MEK; NF-kappa B	E-CADHERIN EXPRESSION; TGF-BETA; GROWTH; REPRESSOR; MESODERM; DIFFERENTIATION; INHIBITION; LOCATION; ADHESION; SLUG	Expression of Snail transcriptional factor is a determinant in the acquisition of a mesenchymal phenotype by epithelial tumor cells. However, the regulation of the transcription of this gene is still unknown. We describe here the characterization of a human SNAIL promoter that contains the initiation of transcription and regulates the expression of this gene in tumor cells. This promoter was activated in cell lines in response to agents that induce Snail transcription and the mesenchymal phenotype, as addition of the phorbol ester PMA or overexpression of integrin-linked kinase (ILK) or oncogenes such as Ha-ras or v-Akt. Although other regions of the promoter were required for a complete stimulation by Akt or ILK, a minimal fragment ( - 78/ +59) was sufficient to maintain the mesenchymal specificity. Activity of this minimal promoter and SNAIL RNA levels were dependent on ERK signaling pathway. NFkappaB/p65 also stimulated SNAIL transcription through a region located immediately upstream the minimal promoter, between - 194 and - 78. These results indicate that Snail transcription is driven by signaling pathways known to induce epithelial to mesenchymal transition, reinforcing the role of Snail in this process.	Univ Pompeu Fabra, Unitat Bio Celluar & Mol, Inst Municipal Invest Med, Barcelona 08003, Spain; Inst Curie, CNRS, UMR 146, F-91405 Orsay, France; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6H 3Z6, Canada	Pompeu Fabra University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of British Columbia	de Herreros, AG (corresponding author), Univ Pompeu Fabra, Unitat Bio Celluar & Mol, Inst Municipal Invest Med, C Doctor Aiguader 80, Barcelona 08003, Spain.	agarcia@imim.es	Larue, Lionel/I-6532-2016; Larue, Lionel/F-7355-2013; de Herreros, A Garcia/H-3104-2014	de Herreros, A Garcia/0000-0001-5270-0808; Dedhar, Shoukat/0000-0003-4355-1657; Puig Borreil, Isabel/0000-0001-5614-4298; Dominguez-Sola, David/0000-0001-9569-8402				Ajenjo N, 2000, J BIOL CHEM, V275, P7189, DOI 10.1074/jbc.275.10.7189; Bates RC, 2003, MOL BIOL CELL, V14, P1790, DOI 10.1091/mbc.E02-09-0583; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Batlle E, 1998, J BIOL CHEM, V273, P15091, DOI 10.1074/jbc.273.24.15091; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carver EA, 2001, MOL CELL BIOL, V21, P8184, DOI 10.1128/MCB.21.23.8184-8188.2001; Christen B, 1999, DEVELOPMENT, V126, P119; Ciruna B, 2001, DEV CELL, V1, P37, DOI 10.1016/S1534-5807(01)00017-X; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Dominguez D, 2003, MOL CELL BIOL, V23, P5078, DOI 10.1128/MCB.23.14.5078-5089.2003; Ellenrieder V, 2001, CANCER RES, V61, P4222; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; Gotzmann J, 2002, J CELL SCI, V115, P1189; Grande M, 2002, J CELL SCI, V115, P4227, DOI 10.1242/jcs.00091; Grille SJ, 2003, CANCER RES, V63, P2172; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Hajra KM, 2002, CANCER RES, V62, P1613; IP YT, 1992, GENE DEV, V6, P1518, DOI 10.1101/gad.6.8.1518; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Locascio A, 2002, J BIOL CHEM, V277, P38803, DOI 10.1074/jbc.M205358200; MAYOR R, 1993, DEVELOPMENT, V119, P661; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Paznekas WA, 1999, GENOMICS, V62, P42, DOI 10.1006/geno.1999.6010; Peinado H, 2003, J BIOL CHEM, V278, P21113, DOI 10.1074/jbc.M211304200; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Poser I, 2001, J BIOL CHEM, V276, P24661, DOI 10.1074/jbc.M011224200; Spagnoli FM, 2000, J CELL SCI, V113, P3639; Tan C, 2001, ONCOGENE, V20, P133, DOI 10.1038/sj.onc.1204052; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Vleminckx K, 1999, BIOESSAYS, V21, P211, DOI 10.1002/(SICI)1521-1878(199903)21:3<211::AID-BIES5>3.3.CO;2-G; Yanez-Mo M, 2003, NEW ENGL J MED, V348, P403, DOI 10.1056/NEJMoa020809; Yao Y, 2003, P NATL ACAD SCI USA, V100, P12759, DOI 10.1073/pnas.2134254100	37	269	279	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2004	23	44					7345	7354		10.1038/sj.onc.1207990	http://dx.doi.org/10.1038/sj.onc.1207990			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	856CO	15286702				2022-12-17	WOS:000224021400005
J	Jasin, M				Jasin, M			Homologous repair of DNA damage and tumorigenesis: the BRCA connection	ONCOGENE			English	Review						BRCA1; BRCA2; DNA repair; homologous recombination; RAD51	DOUBLE-STRAND BREAKS; EMBRYONIC CELLULAR PROLIFERATION; CANCER-PREDISPOSING MUTATIONS; RETRACTED ARTICLE. SEE; NUCLEAR-LOCALIZATION; RING DOMAIN; IN-VIVO; RADIATION HYPERSENSITIVITY; GENOMIC INSTABILITY; FUNCTIONAL DOMAINS	Homologous recombination has been recognized in recent years to be an important DNA repair pathway in mammalian cells, for such damage as chromosomal double-strand breaks. Cells mutated for the genes involved in the hereditary breast and ovarian cancer susceptibility syndromes, i.e. BRCAJ and BRCA2, show defects in DNA repair by homologous recombination, implicating this repair pathway in protecting individuals against tumorigenesis. This review summarizes recent advances in our understanding of BRCA1 and BRCA2 in DNA repair, as well as insight into these proteins gleaned from structure determination of domains of these proteins and the broader evolutionary conservation than previously appreciated.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Jasin, M (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave, New York, NY 10021 USA.	m-jasin@ski.mskcc.org			NATIONAL CANCER INSTITUTE [P01CA094060] Funding Source: NIH RePORTER; NCI NIH HHS [P01CA94060] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldeyron C, 2002, ONCOGENE, V21, P1401, DOI 10.1038/sj.onc.1205200; Bassing CH, 2002, P NATL ACAD SCI USA, V99, P8173, DOI 10.1073/pnas.122228699; Baumann P, 1997, EMBO J, V16, P5198, DOI 10.1093/emboj/16.17.5198; Baumann P, 1998, P NATL ACAD SCI USA, V95, P14066, DOI 10.1073/pnas.95.24.14066; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Begg CB, 2002, J NATL CANCER I, V94, P1221; Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200; Bignell G, 1997, HUM MOL GENET, V6, P53, DOI 10.1093/hmg/6.1.53; Bork P, 1996, NAT GENET, V13, P22, DOI 10.1038/ng0596-22; Brzovic PS, 2001, J BIOL CHEM, V276, P41399, DOI 10.1074/jbc.M106551200; Brzovic PS, 2001, NAT STRUCT BIOL, V8, P833, DOI 10.1038/nsb1001-833; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Caspari T, 2002, GENE DEV, V16, P1195, DOI 10.1101/gad.221402; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Chandler J, 2001, GENESIS, V29, P72, DOI 10.1002/1526-968X(200102)29:2<72::AID-GENE1007>3.0.CO;2-B; Chen A, 2002, J BIOL CHEM, V277, P22085, DOI 10.1074/jbc.M201252200; Chen CF, 1999, J BIOL CHEM, V274, P32931, DOI 10.1074/jbc.274.46.32931; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Cressman VL, 1999, MOL CELL BIOL, V19, P7061; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Fabbro M, 2002, J BIOL CHEM, V277, P21315, DOI 10.1074/jbc.M200769200; Feldmann E, 2000, NUCLEIC ACIDS RES, V28, P2585, DOI 10.1093/nar/28.13.2585; Ganesan S, 2002, CELL, V111, P393, DOI 10.1016/S0092-8674(02)01052-8; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Gasior SL, 2001, P NATL ACAD SCI USA, V98, P8411, DOI 10.1073/pnas.121046198; Gatei M, 2000, CANCER RES, V60, P3299; Gatei M, 2001, J BIOL CHEM, V276, P17276, DOI 10.1074/jbc.M011681200; Goggins M, 1996, CANCER RES, V56, P5360; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Huber LJ, 2001, MOL CELL BIOL, V21, P4005, DOI 10.1128/MCB.21.12.4005-4015.2001; Jasin M., 2001, CONT CANC RES, VIII, P207; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Johnson RD, 2000, EMBO J, V19, P3398, DOI 10.1093/emboj/19.13.3398; Johnson RD, 2001, BIOCHEM SOC T, V29, P196, DOI 10.1042/BST0290196; Joo WS, 2002, GENE DEV, V16, P583, DOI 10.1101/gad.959202; Joukov V, 2001, P NATL ACAD SCI USA, V98, P12078, DOI 10.1073/pnas.211427098; Kojic M, 2002, MOL CELL, V10, P683, DOI 10.1016/S1097-2765(02)00632-9; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Kraakman-van der Zwet M, 2002, MOL CELL BIOL, V22, P669, DOI 10.1128/MCB.22.2.669-679.2002; Lane TF, 2000, ONCOGENE, V19, P4085, DOI 10.1038/sj.onc.1203760; Larminat F, 2002, ONCOGENE, V21, P5188, DOI 10.1038/sj.onc.1205659; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; Ludwig T, 2001, GENE DEV, V15, P1188, DOI 10.1101/gad.879201; Mak TW, 2000, NAT IMMUNOL, V1, P77, DOI 10.1038/76950; Marston NJ, 1999, MOL CELL BIOL, V19, P4633; McAllister KA, 1997, CANCER RES, V57, P3121; McAllister KA, 2002, CANCER RES, V62, P990; Merel P, 2002, ONCOGENE, V21, P5654, DOI 10.1038/sj.onc.1205742; Meza JE, 1999, J BIOL CHEM, V274, P5659, DOI 10.1074/jbc.274.9.5659; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Monteiro ANA, 2000, TRENDS BIOCHEM SCI, V25, P469, DOI 10.1016/S0968-0004(00)01632-7; Morimatsu M, 1998, CANCER RES, V58, P3441; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Moynahan ME, 2001, CANCER RES, V61, P4842; MOYNAHAN ME, 2002, IN PRESS ONCOGENE RE; Orelli BJ, 2001, ONCOGENE, V20, P4433, DOI 10.1038/sj.onc.1204485; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Paull TT, 2001, CELL, V107, P563, DOI 10.1016/S0092-8674(01)00591-8; Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998; Pellegrini L, 2002, NATURE, V420, P287, DOI 10.1038/nature01230; Pierce AJ, 2001, TRENDS CELL BIOL, V11, pS52, DOI 10.1016/S0962-8924(01)02149-3; Rodriguez JA, 2000, J BIOL CHEM, V275, P38589, DOI 10.1074/jbc.M003851200; ROUET P, 1994, MOL CELL BIOL, V14, P8096, DOI 10.1128/MCB.14.12.8096; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Sarkisian CJ, 2001, J BIOL CHEM, V276, P37640, DOI 10.1074/jbc.M106281200; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Sharan SK, 1997, GENOMICS, V40, P234, DOI 10.1006/geno.1996.4573; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Snouwaert JN, 1999, ONCOGENE, V18, P7900, DOI 10.1038/sj.onc.1203334; Spain BH, 1999, P NATL ACAD SCI USA, V96, P13920, DOI 10.1073/pnas.96.24.13920; Stark JM, 2002, J BIOL CHEM, V277, P20185, DOI 10.1074/jbc.M112132200; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; Takata M, 2002, ONCOGENE, V21, P1130, DOI 10.1038/sj.onc.1205168; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Thai TH, 1998, HUM MOL GENET, V7, P195, DOI 10.1093/hmg/7.2.195; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Tirkkonen M, 1997, CANCER RES, V57, P1222; Turner BC, 2002, CANCER RES, V62, P4054; Tutt A, 2001, EMBO J, V20, P4704, DOI 10.1093/emboj/20.17.4704; Tutt ANJ, 2002, EMBO REP, V3, P255, DOI 10.1093/embo-reports/kvf037; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Vogelstein B., 1998, GENETIC BASIS HUMAN; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Wang HC, 2001, CANCER RES, V61, P270; Wang Y, 2000, GENE DEV, V14, P927; Warren M, 2002, HUM MOL GENET, V11, P841, DOI 10.1093/hmg/11.7.841; Welcsh PL, 2000, TRENDS GENET, V16, P69, DOI 10.1016/S0168-9525(99)01930-7; Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705; Williams RS, 2001, NAT STRUCT BIOL, V8, P838, DOI 10.1038/nsb1001-838; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xia F, 2001, P NATL ACAD SCI USA, V98, P8644, DOI 10.1073/pnas.151253498; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Yamane K, 2000, BIOCHEM BIOPH RES CO, V279, P678, DOI 10.1006/bbrc.2000.3983; Yang HJ, 2002, SCIENCE, V297, P1837, DOI 10.1126/science.297.5588.1837; Yano K, 2000, BIOCHEM BIOPH RES CO, V270, P171, DOI 10.1006/bbrc.2000.2392; Ye QN, 2001, J CELL BIOL, V155, P911, DOI 10.1083/jcb.200108049; Yu VPCC, 2000, GENE DEV, V14, P1400; Yu X, 2000, J BIOL CHEM, V275, P18541, DOI 10.1074/jbc.M909494199; Yuan SSF, 1999, CANCER RES, V59, P3547; Zhong Q, 2002, J BIOL CHEM, V277, P28641, DOI 10.1074/jbc.M200748200; Zhong Q, 2002, CANCER RES, V62, P3966; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	124	269	289	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2002	21	58					8981	8993		10.1038/sj.onc.1206176	http://dx.doi.org/10.1038/sj.onc.1206176			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	626TP	12483514				2022-12-17	WOS:000179889500009
J	Schechtman, D; Mochly-Rosen, D				Schechtman, D; Mochly-Rosen, D			Adaptor proteins in protein kinase C-mediated signal transduction	ONCOGENE			English	Article						scaffold; PKC; RACK; isozymes; location	PLECKSTRIN HOMOLOGY DOMAINS; REGION-DERIVED PEPTIDES; CARDIAC CA2+ CHANNELS; BETA-SUBUNIT; PHORBOL ESTER; IN-VIVO; TYROSINE PHOSPHORYLATION; CYTOPLASMIC DOMAIN; CELL-PROLIFERATION; EPSILON-ISOZYME	Spatial and temporal organization of signal transduction is essential in determining the speed and precision by which signaling events occur. Adaptor proteins are key to organizing signaling enzymes near their select substrates and away from others in order to optimize precision and speed of response. Here, we describe the role of adaptor proteins in determining the specific function of individual protein kinase C (PKC) isozymes. These isozyme-selective proteins were called collectively RACKs (receptors for activated C-kinase). The role of RACKs in PKC-mediated signaling was determined using isozyme-specific inhibitors and activators of the binding of each isozyme to its respective RACK. In addition to anchoring activated PKC isozymes, RACKs anchor other signaling enzymes. RACK1, the anchoring protein for activated beta IIPKC, binds for example, Src tyrosine kinase, integrin, and phosphodiesterase. RACK2, the epsilon PKC-specific RACK, is a coated-vesicle protein and thus is involved in vesicular release and cell-cell communication. Therefore, RACKs are not only adaptors for PKC, but also serve as adaptor proteins for several other signaling enzymes. Because at least some of the proteins that bind to RACKs, including PKC itself, regulate cell growth, modulating their interactions with RACKs may help elucidate signaling pathways leading to carcinogenesis and could result in the identification of novel therapeutic targets.	Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA	Stanford University	Mochly-Rosen, D (corresponding author), Stanford Univ, Sch Med, Dept Mol Pharmacol, CCSR 3145,269 Campus Dr, Stanford, CA 94305 USA.		schechtman, deborah/B-7572-2012	Schechtman, Deborah/0000-0002-8874-7023; Mochly-Rosen, Daria/0000-0002-6691-8733				Aley KO, 2000, J NEUROSCI, V20, P4680, DOI 10.1523/JNEUROSCI.20-12-04680.2000; Berns H, 2000, FASEB J, V14, P2549, DOI 10.1096/fj.99-1038com; BORNER C, 1987, INT J CANCER, V40, P344, DOI 10.1002/ijc.2910400310; Burack WR, 2000, CURR OPIN CELL BIOL, V12, P211, DOI 10.1016/S0955-0674(99)00078-2; CARPENTER D, 1987, NATURE, V325, P107, DOI 10.1038/325107a0; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Chang BY, 2001, J BIOL CHEM, V276, P20346, DOI 10.1074/jbc.M101375200; Chen CH, 2001, J MOL CELL CARDIOL, V33, P581, DOI 10.1006/jmcc.2000.1330; CHOI KY, 1994, CELL, V78, P499; Csukai M, 1999, PHARMACOL RES, V39, P253, DOI 10.1006/phrs.1998.0418; Csukai M, 1997, J BIOL CHEM, V272, P29200, DOI 10.1074/jbc.272.46.29200; DECAMILLI P, 1995, CURR OPIN NEUROBIOL, V5, P559, DOI 10.1016/0959-4388(95)80059-X; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; DISATNIK MH, 1994, P NATL ACAD SCI USA, V91, P559, DOI 10.1073/pnas.91.2.559; DISATNIK MH, 1994, CELL GROWTH DIFFER, V5, P873; Dorn GW, 1999, P NATL ACAD SCI USA, V96, P12798, DOI 10.1073/pnas.96.22.12798; FONG HKW, 1987, P NATL ACAD SCI USA, V84, P3792, DOI 10.1073/pnas.84.11.3792; GarciaHiguera I, 1996, BIOCHEMISTRY-US, V35, P13985, DOI 10.1021/bi9612879; GAWLER DJ, 1995, ONCOGENE, V10, P817; Gokmen-Polar Y, 2001, CANCER RES, V61, P1375; Gray MO, 1997, J BIOL CHEM, V272, P30945, DOI 10.1074/jbc.272.49.30945; HARRISONLAVOIE KJ, 1993, EMBO J, V12, P2847, DOI 10.1002/j.1460-2075.1993.tb05946.x; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; Hu KL, 2000, AM J PHYSIOL-HEART C, V279, pH2658, DOI 10.1152/ajpheart.2000.279.6.H2658; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; Hundle B, 1997, J BIOL CHEM, V272, P15028, DOI 10.1074/jbc.272.23.15028; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; Johnson JA, 1996, CIRC RES, V79, P1086, DOI 10.1161/01.RES.79.6.1086; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; JOHNSON JA, 1995, CIRC RES, V76, P654, DOI 10.1161/01.RES.76.4.654; Kholodenko BN, 2000, TRENDS CELL BIOL, V10, P173, DOI 10.1016/S0962-8924(00)01741-4; Kieff E., 1996, EPSTEINBARR VIRUS IT, P2343; KILEY S, 1990, J BIOL CHEM, V265, P15704; Kiley SC, 1999, ONCOGENE, V18, P6748, DOI 10.1038/sj.onc.1203101; Kiley SC, 1999, CANCER RES, V59, P3230; Knauf JA, 1999, J BIOL CHEM, V274, P23414, DOI 10.1074/jbc.274.33.23414; Koehler JA, 2001, BIOCHEM BIOPH RES CO, V283, P888, DOI 10.1006/bbrc.2001.4889; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; Liu GS, 1999, J MOL CELL CARDIOL, V31, P1937, DOI 10.1006/jmcc.1999.1026; Livneh E, 1996, ONCOGENE, V12, P1545; MAEDA T, 1993, LAB INVEST, V68, P472; Mayne GC, 1998, J BIOL CHEM, V273, P24115, DOI 10.1074/jbc.273.37.24115; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Moasser MM, 1999, CANCER RES, V59, P6145; Mochly-Rosen D, 2000, CIRC RES, V86, P1173; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Mourton T, 2001, J BIOL CHEM, V276, P14896, DOI 10.1074/jbc.M010823200; Myklebust JH, 1999, J CELL PHYSIOL, V180, P71; Nakaigawa N, 1996, BIOCHEM BIOPH RES CO, V222, P95, DOI 10.1006/bbrc.1996.0703; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; Pass JM, 2001, AM J PHYSIOL-HEART C, V280, pH946, DOI 10.1152/ajpheart.2001.280.3.H946; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Reinhardt J, 2000, VET MICROBIOL, V74, P87, DOI 10.1016/S0378-1135(00)00169-3; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; Rodriguez MM, 1999, BIOCHEMISTRY-US, V38, P13787, DOI 10.1021/bi991055k; RodriguezFernandez JL, 1996, J BIOL CHEM, V271, P27895, DOI 10.1074/jbc.271.44.27895; Ron D, 1999, J BIOL CHEM, V274, P27039, DOI 10.1074/jbc.274.38.27039; RON D, 1995, P NATL ACAD SCI USA, V92, P492, DOI 10.1073/pnas.92.2.492; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; SASAGURI T, 1993, EXP CELL RES, V208, P311, DOI 10.1006/excr.1993.1251; SCHWARTZ GK, 1993, J NATL CANCER I, V85, P402, DOI 10.1093/jnci/85.5.402; Smith PR, 2000, J VIROL, V74, P3082, DOI 10.1128/JVI.74.7.3082-3092.2000; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Souroujon MC, 1998, NAT BIOTECHNOL, V16, P919, DOI 10.1038/nbt1098-919; Srivastava RK, 1999, ONCOGENE, V18, P1755, DOI 10.1038/sj.onc.1202464; STENBECK G, 1993, EMBO J, V12, P2841, DOI 10.1002/j.1460-2075.1993.tb05945.x; Thompson EB, 1999, J STEROID BIOCHEM, V69, P453, DOI 10.1016/S0960-0760(99)00063-1; Thompson LJ, 1996, J BIOL CHEM, V271, P15045, DOI 10.1074/jbc.271.25.15045; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; Tsai JH, 2000, CANCER LETT, V161, P171, DOI 10.1016/S0304-3835(00)00597-8; VALLETE A, 1987, CANCER RES, V47, P1615; vanderGeer P, 1997, MOL CELL BIOL, V17, P1840, DOI 10.1128/MCB.17.4.1840; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; Wu HL, 1999, PEPTIDES, V20, P675, DOI 10.1016/S0196-9781(99)00049-2; WYSS R, 1987, ANTICANCER RES, V7, P721; Yarwood SJ, 1999, J BIOL CHEM, V274, P14909, DOI 10.1074/jbc.274.21.14909; Yedovitzky M, 1997, J BIOL CHEM, V272, P1417, DOI 10.1074/jbc.272.3.1417; Zhang ZH, 1997, CIRC RES, V80, P720, DOI 10.1161/01.RES.80.5.720	91	269	286	0	9	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	2001	20	44					6339	6347		10.1038/sj.onc.1204778	http://dx.doi.org/10.1038/sj.onc.1204778			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NF	11607837				2022-12-17	WOS:000171640600010
J	Porter, AC; Vaillancourt, RR				Porter, AC; Vaillancourt, RR			Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis	ONCOGENE			English	Review						phosphoinositide 3-kinase; cytoskeleton; apoptosis	HEPATOCYTE GROWTH-FACTOR; FACTOR SCATTER FACTOR; MEDULLARY-THYROID CARCINOMA; SERINE-THREONINE KINASE; KAPOSIS-SARCOMA CELLS; TPR-MET ONCOPROTEIN; C-RET PROTOONCOGENE; ONCOSTATIN-M; PROTEIN-KINASE; BETA-CATENIN	Oncogenesis is a complicated process involving signal transduction pathways that mediate many different physiological events. Typically, oncogenes cause unregulated cell growth and this phenotype has been attributed to the growth-stimulating activity of oncogenes such as I as and src. In recent years, much research effort has focused an proteins that function downstream of Ras, leading to the identification of the Ras/Raf/MAPK pathway, because activation of this pathway leads to cellular proliferation. Activated receptor tyrosine kinases (RTKs) also utilize this pathway to mediate their growth-stimulating effects. However, RTKs activate many other signaling proteins that are not involved in the cellular proliferation process, pel se and me are learning that these pathways also contribute to the oncogenic process. In fact, RTKs and many of the proteins involved in RTK-dependent signal transduction can also function as oncogenes, For example, the catalytic subunit of phosphoinositide 3-kinase (PI3-K) was recently identified as an oncogenic protein. The scope of pathways that are activated by oncogenic RTKs is expanding. Thus, not only do RTKs activate Ras-dependent pathways that drive proliferation, RTKs activate PI3-K-dependent pathways which also contribute to the oncogenic mechanism. PI3-K can initiate changes in gene transcription, cytoskeletal changes through beta-catenin, changes in cell motility through the tumor suppressor, adenomatous polyposis coli (APC), and phosphorylation of BAD, a protein involved in apoptotic and anti-apoptotic signaling. There is also cross-talk between RTKs and the oncostatin cytokine receptor which may positively and negatively influence oncogenesis, For this review, we will focus on oncogenic RTKs and the network of cellular proteins that are activated by RTKs because multiple, divergent pathways are responsible for oncogenesis.	Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA	University of Arizona	Vaillancourt, RR (corresponding author), Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA.							Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Auguste P, 1997, J BIOL CHEM, V272, P15760, DOI 10.1074/jbc.272.25.15760; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BOLINO A, 1995, ONCOGENE, V10, P2415; Bongarzone I, 1996, J CLIN ENDOCR METAB, V81, P2006, DOI 10.1210/jc.81.5.2006; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Burke CL, 1997, ONCOGENE, V14, P687, DOI 10.1038/sj.onc.1200873; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; COOPER GM, 1982, SCIENCE, V217, P801, DOI 10.1126/science.6285471; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; DATTA K, 1995, MOL CELL BIOL, V15, P2304; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DAWSON TP, 1995, CANCER RES, V55, P915; delPeso L, 1997, SCIENCE, V278, P687; DIRENZO MF, 1992, ONCOGENE, V7, P2549; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; Edery P, 1997, BIOESSAYS, V19, P389, DOI 10.1002/bies.950190506; ENG C, 1995, ONCOGENE, V10, P509; FIXMAN ED, 1995, ONCOGENE, V10, P237; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; Flick MB, 1997, ONCOGENE, V14, P2553, DOI 10.1038/sj.onc.1201092; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; Hamilton JA, 1997, J LEUKOCYTE BIOL, V62, P145, DOI 10.1002/jlb.62.2.145; HEASLEY LE, 1992, MOL BIOL CELL, V3, P545, DOI 10.1091/mbc.3.5.545; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Horn D, 1990, GROWTH FACTORS, V2, P157, DOI 10.3109/08977199009071502; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; ISHIZAKA Y, 1992, ONCOGENE, V7, P1441; Ivan M, 1997, ONCOGENE, V14, P2417, DOI 10.1038/sj.onc.1201083; Jiang WG, 1997, HISTOL HISTOPATHOL, V12, P537; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Liu JW, 1997, CELL GROWTH DIFFER, V8, P667; Liu ZY, 1997, J CLIN INVEST, V99, P1798, DOI 10.1172/JCI119344; LONGATI P, 1994, ONCOGENE, V9, P49; Mak YF, 1996, CURR OPIN GENET DEV, V6, P82, DOI 10.1016/S0959-437X(96)90015-5; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; MILES SA, 1992, SCIENCE, V255, P1432, DOI 10.1126/science.1542793; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; NAIR BC, 1992, SCIENCE, V255, P1430, DOI 10.1126/science.1542792; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; Nowak F, 1997, EXP CELL RES, V231, P251, DOI 10.1006/excr.1996.3468; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Pasdar M, 1997, CELL GROWTH DIFFER, V8, P451; PEIFER M, 1994, DEV BIOL, V166, P543, DOI 10.1006/dbio.1994.1336; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; PELICCI G, 1995, ONCOGENE, V10, P1631; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; ROMANO A, 1994, ONCOGENE, V9, P2923; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1994, ONCOGENE, V9, P509; SCHIEVEN GL, 1992, J IMMUNOL, V149, P1676; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; Spence MJ, 1997, CANCER RES, V57, P2223; Stancato LF, 1997, MOL CELL BIOL, V17, P3833, DOI 10.1128/MCB.17.7.3833; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; Takahashi A, 1997, EXP CELL RES, V231, P123, DOI 10.1006/excr.1996.3459; TAKAHASHI M, 1991, ONCOGENE, V6, P297; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; THOMA B, 1994, J BIOL CHEM, V269, P6215; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; TSUZUKI T, 1995, ONCOGENE, V10, P191; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; vanPuijenbroek AAFL, 1997, ONCOGENE, V14, P1147, DOI 10.1038/sj.onc.1200911; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEINBERG RA, 1981, BIOCHIM BIOPHYS ACTA, V651, P25, DOI 10.1016/0304-419X(81)90003-2; Weiss FU, 1997, CURR OPIN GENET DEV, V7, P80, DOI 10.1016/S0959-437X(97)80113-X; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; YUASA Y, 1983, NATURE, V303, P775, DOI 10.1038/303775a0; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; ZHU H, 1994, J BIOL CHEM, V269, P29943	106	269	287	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 17	1998	17	11			SI		1343	1352		10.1038/sj.onc.1202171	http://dx.doi.org/10.1038/sj.onc.1202171			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124BW	9779982				2022-12-17	WOS:000076161900003
J	Pegram, MD; Finn, RS; Arzoo, K; Beryt, M; Pietras, RJ; Slamon, DJ				Pegram, MD; Finn, RS; Arzoo, K; Beryt, M; Pietras, RJ; Slamon, DJ			The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells	ONCOGENE			English	Article						HER-2/neu (c-erbB-2); breast cancer; ovarian cancer; drug resistance; chemotherapy	GROWTH-FACTOR-RECEPTOR; RESISTANT CHINESE-HAMSTER; C-HA-RAS; C-ERBB-2 EXPRESSION; CARCINOMA-CELLS; ENDOMETRIAL CANCER; ONCOGENE AMPLIFICATION; MONOCLONAL-ANTIBODY; PROTEIN EXPRESSION; PROGNOSTIC VALUE	Recent studies indicate that oncogenes may be involved in determining the sensitivity of human cancers to chemotherapeutic agents. To define the effect of HER-2/neu oncogene overexpression on sensitivity to chemotherapeutic drugs, a full-length, human HER-2/neu cDNA was introduced into human breast and ovarian cancer cells. In vitro dose-response curves following exposure to 7 different classes of chemotherapeutic agents were compared for HER-2- and control-transfected cells. Chemosensitivity was also tested in vivo for HER-2- and control-transfected human breast and ovarian cancer xenografts in athymic mice. These studies indicate that HER-2/neu overexpression was not sufficient to induce intrinsic, pleomorphic drug resistance. Furthermore, changes in chemosensitivity profiles resulting from HER-2/neu transfection observed in vitro were cell line specific. In vivo, HER-2/neu-overexpressing breast and ovarian cancer xenografts were responsive to different classes of chemotherapeutic drugs compared to control-treated xenografts with no statistically significant differences between HER-2/neu-overexpressing and non-overexpressing xenografts. We found no instance in which HER-2/neu-overexpressing xenografts were rendered more sensitive to chemotherapeutic drugs in vivo. HER-2/neu-overexpressing xenografts consistently exhibited more rapid regrowth than control xenografts following initial response to chemotherapy suggesting that a high rate of tumor cell proliferation rather than drug resistance may be responsible for the prognosis associated with HER-2/neu overexpression in human cancers.	UNIV CALIF LOS ANGELES,SCH MED,DIV HEMATOL ONCOL,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA				Pietras, Richard/0000-0002-2846-3192	NCI NIH HHS [1K12 CA01714, R01 CA36827] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K12CA001714, R01CA036827] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABOUDPIRAK E, 1988, J NATL CANCER I, V80, P1605, DOI 10.1093/jnci/80.20.1605; ALLRED DC, 1992, J CLIN ONCOL, V10, P599, DOI 10.1200/JCO.1992.10.4.599; ANBAZHAGAN R, 1991, ANN ONCOL, V2, P47, DOI 10.1093/oxfordjournals.annonc.a057824; ARTEAGA CL, 1994, CANCER RES, V54, P3758; BARBARESCHI M, 1992, AM J CLIN PATHOL, V98, P408, DOI 10.1093/ajcp/98.4.408; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; BERCHUCK A, 1991, AM J OBSTET GYNECOL, V164, P15, DOI 10.1016/0002-9378(91)90615-X; BERGER MS, 1988, CANCER RES, V48, P1238; BERNS EMJJ, 1995, GENE, V159, P11, DOI 10.1016/0378-1119(94)00534-Y; BORG A, 1991, ONCOGENE, V6, P137; BURT RK, 1988, CARCINOGENESIS, V9, P2329, DOI 10.1093/carcin/9.12.2329; CASCIARI JJ, 1994, J NATL CANCER I, V86, P1846, DOI 10.1093/jnci/86.24.1846; CHAZIN VR, 1992, ONCOGENE, V7, P1859; CHRISTEN RD, 1990, J CLIN INVEST, V86, P1632, DOI 10.1172/JCI114885; COHEN BE, 1986, CANCER TREAT REP, V70, P859; DICKSTEIN B, 1993, J CELL PHYSIOL, V157, P110, DOI 10.1002/jcp.1041570115; DICKSTEIN BM, 1995, MOL CELL ENDOCRINOL, V110, P205, DOI 10.1016/0303-7207(95)03535-F; DINCALCI M, 1982, CANCER CHEMOTH PHARM, V7, P141; DISAIA PJ, 1972, AM J OBSTET GYNECOL, V114, P979, DOI 10.1016/0002-9378(72)90109-3; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FELIP E, 1995, CANCER, V75, P2147, DOI 10.1002/1097-0142(19950415)75:8<2147::AID-CNCR2820750818>3.0.CO;2-8; FLICK DA, 1984, J IMMUNOL METHODS, V68, P167, DOI 10.1016/0022-1759(84)90147-9; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; GORMLEY PE, 1979, CLIN PHARMACOL THER, V25, P351; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; HANCOCK MC, 1991, CANCER RES, V51, P4575; HARLAND SJ, 1984, CANCER RES, V44, P1693; HETZEL DJ, 1992, GYNECOL ONCOL, V47, P179, DOI 10.1016/0090-8258(92)90103-P; ISONISHI S, 1991, CANCER RES, V51, P5903; KALLIONIEMI OP, 1991, INT J CANCER, V49, P650, DOI 10.1002/ijc.2910490504; KERBEL RS, 1994, COLD SPRING HARB SYM, V59, P661, DOI 10.1101/SQB.1994.059.01.076; KERBEL RS, 1995, INVAS METAST, V14, P50; KLIJN JGM, 1993, CANCER SURV, V18, P165; KOBAYASHI H, 1993, P NATL ACAD SCI USA, V90, P3294, DOI 10.1073/pnas.90.8.3294; LEE AKC, 1992, MODERN PATHOL, V5, P61; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LUKES AS, 1994, CANCER, V73, P2380, DOI 10.1002/1097-0142(19940501)73:9<2380::AID-CNCR2820730922>3.0.CO;2-G; MACMILLAN WE, 1978, CANCER RES, V38, P3479; MEYERS MB, 1986, P NATL ACAD SCI USA, V83, P5521, DOI 10.1073/pnas.83.15.5521; MEYERS MB, 1993, BIOCHEM PHARMACOL, V46, P1841, DOI 10.1016/0006-2952(93)90591-J; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; NELSON RL, 1980, CANCER TREAT REV, V7, P17, DOI 10.1016/S0305-7372(80)80003-X; NIIMI S, 1991, BRIT J CANCER, V63, P237, DOI 10.1038/bjc.1991.56; NUTI M, 1991, ANTICANCER RES, V11, P1225; PANTEL K, 1993, JNCI-J NATL CANCER I, V85, P1419, DOI 10.1093/jnci/85.17.1419; Pauletti G, 1996, ONCOGENE, V13, P63; PETERS GJ, 1993, INT J CANCER, V54, P450, DOI 10.1002/ijc.2910540316; PIETRAS RJ, 1994, ONCOGENE, V9, P1829; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; POLLER DN, 1991, BREAST CANCER RES TR, V20, P3, DOI 10.1007/BF01833351; PRESS MF, 1994, CANCER RES, V54, P5675; QUENEL N, 1995, BREAST CANCER RES TR, V35, P283, DOI 10.1007/BF00665980; QUERZOLI P, 1990, TUMORI, V76, P461, DOI 10.1177/030089169007600508; RAJKUMAR T, 1994, BREAST CANCER RES TR, V29, P3, DOI 10.1007/BF00666177; REILE H, 1990, ANAL BIOCHEM, V187, P262, DOI 10.1016/0003-2697(90)90454-H; ROBERT J, 1982, EUR J CANCER CLIN ON, V18, P739, DOI 10.1016/0277-5379(82)90072-4; SABBATINI ARM, 1994, INT J CANCER, V59, P208, DOI 10.1002/ijc.2910590212; SAFFARI B, 1995, CANCER RES, V55, P5693; SCANLON KJ, 1989, ANTICANCER RES, V9, P1301; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SESHADRI R, 1993, J CLIN ONCOL, V11, P1936, DOI 10.1200/JCO.1993.11.10.1936; SKLAR MD, 1991, CANCER RES, V51, P2118; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SMITH K, 1993, ONCOGENE, V8, P933; STAL O, 1994, CYTOMETRY, V16, P160, DOI 10.1002/cyto.990160210; TSAI CM, 1995, J NATL CANCER I, V87, P682, DOI 10.1093/jnci/87.9.682; TSAI CM, 1993, J NATL CANCER I, V85, P897, DOI 10.1093/jnci/85.11.897; WIERNIK PH, 1987, CANCER RES, V47, P2486; WRIGHT C, 1992, BRIT J CANCER, V65, P271, DOI 10.1038/bjc.1992.54; YONEMURA Y, 1991, CANCER RES, V51, P1034; Yu DH, 1996, ONCOGENE, V13, P1359	73	269	285	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 31	1997	15	5					537	547		10.1038/sj.onc.1201222	http://dx.doi.org/10.1038/sj.onc.1201222			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XN255	9247307				2022-12-17	WOS:A1997XN25500005
J	GUSTERSON, BA; ANBAZHAGAN, R; WARREN, W; MIDGELY, C; LANE, DP; OHARE, M; STAMPS, A; CARTER, R; JAYATILAKE, H				GUSTERSON, BA; ANBAZHAGAN, R; WARREN, W; MIDGELY, C; LANE, DP; OHARE, M; STAMPS, A; CARTER, R; JAYATILAKE, H			EXPRESSION OF P53 IN PREMALIGNANT AND MALIGNANT SQUAMOUS EPITHELIUM	ONCOGENE			English	Article							CARCINOMA CELL-LINES; MONOCLONAL-ANTIBODIES; LUNG-CANCER; PROTO-ONCOGENE; BREAST-CANCER; TUMOR-ANTIGEN; GENE; MUTATIONS; TRANSFORMATION; CHROMOSOME-17	Using three antibodies (JG8, CM-1 and 1081) directed to the p53 protein, strong positivity was found in 16/47 (34.0%) of mucosal squamous cell carcinomas of the head and neck and in two squamous carcinoma cell lines (LICR-LON- HN5 and HN6Rr). The presence of the mutant p53 was confirmed in the cell lines as substitutions in exon 7 (codon 238, TGT > AGT) and exon 5 (codon 152, CCG > CTG) respectively. Positive staining was seen only in the undifferentiated cells and progressively lost as the cells keratinized, both in the tumour specimens and in the cell lines. Similar results were seen in areas of dysplasia, well removed from the site of the primary tumour. Staining of epidermal lesions showed positivity in 2/12 (16.6%) cases of Bowen's disease, 0/12 (0.0%) cases of solar keratosis, 0/10 (0.0%) basal cell carcinomas and in 3/20 (15.0%) squamous cell carcinomas. These results are discussed in relation to the multifocal origin of squamous cell carcinomas, the role of p53 mutations in squamous cell carcinomas from different sites and the significance of the 'basal' distribution of p53 as a normal growth regulator. The possible significance of the distribution of p53 in squamous epithelium as it relates to papilloma virus infection is also considered.	INST CANC RES,HADDOW LABS,MOLEC CARCINOGENESIS SECT,SUTTON SM2 5NG,SURREY,ENGLAND; UNIV DUNDEE,DEPT BIOCHEM,CANC RES CAMPAIGN LABS,DUNDEE DD1 4HN,SCOTLAND	University of London; Institute of Cancer Research - UK; University of Dundee	GUSTERSON, BA (corresponding author), INST CANC RES,HADDOW LABS,PATHOL SECT,COTSWOLD RD,SUTTON SM2 5NG,SURREY,ENGLAND.		gusterson, barry a/D-3752-2009; Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; BARBOSA MS, 1989, J VIROL, V63, P1404, DOI 10.1128/JVI.63.3.1404-1407.1989; BARTEK J, 1990, ONCOGENE, V5, P893; BERG L, 1986, CELL, V46, P753, DOI 10.1016/0092-8674(86)90351-X; BURMAN JF, 1988, HEAD NECK ONCOLOGY R, P11; CARTER RL, 1985, CRC CR REV CL LAB SC, V22, P275, DOI 10.3109/10408368509165845; CATTORETTI G, 1988, INT J CANCER, V41, P178, DOI 10.1002/ijc.2910410204; CHIBA I, 1990, ONCOGENE, V5, P1603; CHOW LT, 1987, CANCER CELLS, V5, P57; Cowley GO, 1984, CANCER CELL, V1, P5; COWLEY GP, 1986, BRIT J CANCER, V53, P223, DOI 10.1038/bjc.1986.39; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EASTY DM, 1981, BRIT J CANCER, V43, P772, DOI 10.1038/bjc.1981.115; EASTY DM, 1981, BRIT J CANCER, V43, P363; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GREAVES R, 1988, THESIS U LONDON; GUSTERSON BA, 1986, DIFFERENTIATION, V30, P102; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JAMES CD, 1989, P NATL ACAD SCI USA, V86, P2858, DOI 10.1073/pnas.86.8.2858; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KNIGHT J, 1985, ULTRASTRUCT PATHOL, V7, P133; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; MACKAY J, 1988, LANCET, V2, P1384; MATLASHEWSKI G, 1986, EUR J BIOCHEM, V154, P665, DOI 10.1111/j.1432-1033.1986.tb09449.x; MCKEE PH, 1990, PATHOLOGY SKIN; MITCHELL D, 1985, J HISTOCHEM CYTOCHEM, V33, P491, DOI 10.1177/33.5.3921605; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OZANNE B, 1986, J PATHOL, V149, P9, DOI 10.1002/path.1711490104; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PFISTER H, 1984, REV PHYSIOL BIOCH P, V99, P111, DOI 10.1007/BFb0027716; RAYTER Z, 1989, EXP CELL RES, V183, P443, DOI 10.1016/0014-4827(89)90403-5; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; RUMSBY G, 1990, BRIT J CANCER, V61, P365, DOI 10.1038/bjc.1990.80; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; STYLES JM, 1990, INT J CANCER, V45, P320, DOI 10.1002/ijc.2910450219; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; VANDENBERG FM, 1989, J PATHOL, V157, P193, DOI 10.1002/path.1711570304; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252	49	269	272	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1785	1789						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1717923				2022-12-17	WOS:A1991GX11800010
J	Tarze, A; Deniaud, A; Le Bras, M; Maillier, E; Molle, D; Larochette, N; Zamzami, N; Jan, G; Kroemer, G; Brenner, C				Tarze, A.; Deniaud, A.; Le Bras, M.; Maillier, E.; Molle, D.; Larochette, N.; Zamzami, N.; Jan, G.; Kroemer, G.; Brenner, C.			GAPDH, a novel regulator of the pro-apoptotic mitochondrial membrane permeabilization	ONCOGENE			English	Article						apoptosis; mitochondria; VDAC; ANT; permeability transition; GAPDH	ADENINE-NUCLEOTIDE TRANSLOCASE; DEPENDENT ANION CHANNEL; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; TRANSITION PORE; CELL-DEATH; ADENYLATE TRANSLOCATOR; OUTER-MEMBRANE; VIRAL PROTEIN; CYCLOPHILIN-D; CYTOCHROME-C	Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a pleiotropic enzyme that is overexpressed in apoptosis and in several human chronic pathologies. Here, we report that the protein accumulates in mitochondria during apoptosis, and induces the pro-apoptotic mitochondrial membrane permeabilization, a decisive event of the intrinsic pathway of apoptosis. GAPDH was localized by immunogold labeling and identified by matrix- assisted laser desorption/ionization-time of flight and nano liquid chromatography mass spectroscopy/mass spectroscopy in the mitochondrion of various tissues and origins. In isolated mitochondria, GAPDH can be imported and interact with the voltage-dependent anion channel (VDAC1), but not the adenine nucleotide translocase (ANT). The protein mediates a cyclosporin A-inhibitable permeability transition, characterized by a loss of the inner transmembrane potential, matrix swelling, permeabilization of the inner mitochondrial membrane and the release of two pro-apoptotic proteins, cytochrome and apoptosis-inducing factor (AIF). This novel function of GAPDH might have implications for the understanding of mitochondrial biology, oncogenesis and apoptosis.	Univ Versailles, SQY, CNRS VMR 8159, F-78035 Versailles, France; INRA, UMR, STLO, Rennes, France; IGR, CNRS UMR 8125, Villejuif, France	UDICE-French Research Universities; Universite Paris Saclay; INRAE; UNICANCER; Gustave Roussy	Brenner, C (corresponding author), Univ Versailles, SQY, CNRS VMR 8159, 45 Ave Etat Unis, F-78035 Versailles, France.	cbrenner@genetique.uvsq.fr	Kroemer, Guido/AAY-9859-2020; Deniaud, Aurelien/L-5093-2019; KROEMER, Guido/B-4263-2013; LAROCHETTE, Nathanael/R-4298-2017; Jan, Gwenael/K-6767-2014; Tarze, Agathe/R-4379-2018	KROEMER, Guido/0000-0002-9334-4405; LAROCHETTE, Nathanael/0000-0002-7936-678X; Tarze, Agathe/0000-0001-6101-069X; LE BRAS, PhD, HDR, Morgane/0000-0003-4317-5591				Abdel-Rahman WM, 1999, ONCOGENE, V18, P2139, DOI 10.1038/sj.onc.1202589; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Azoulay-Zohar H, 2004, BIOCHEM J, V377, P347, DOI 10.1042/BJ20031465; Baker MA, 2004, J BIOL CHEM, V279, P4811, DOI 10.1074/jbc.M311020200; Basso E, 2005, J BIOL CHEM, V280, P18558, DOI 10.1074/jbc.C500089200; Belzacq AS, 2003, CANCER RES, V63, P541; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; Beutner G, 1998, BBA-BIOMEMBRANES, V1368, P7, DOI 10.1016/S0005-2736(97)00175-2; Beutner G, 1996, FEBS LETT, V396, P189, DOI 10.1016/0014-5793(96)01092-7; Brassard J, 2004, VET MICROBIOL, V102, P87, DOI 10.1016/j.vetmic.2004.05.008; Brenner C, 2000, METHOD ENZYMOL, V322, P243; Brenner C, 2000, SCIENCE, V289, P1150, DOI 10.1126/science.289.5482.1150; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Chuang DM, 2005, ANNU REV PHARMACOL, V45, P269, DOI 10.1146/annurev.pharmtox.45.120403.095902; Chuang DM, 1996, NAT MED, V2, P609, DOI 10.1038/nm0696-609; COLOMBINI M, 1983, J MEMBRANE BIOL, V74, P115, DOI 10.1007/BF01870500; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; Cuezva JM, 2004, CARCINOGENESIS, V25, P1157, DOI 10.1093/carcin/bgh113; Fukuhara Y, 2001, NEUROREPORT, V12, P2049, DOI 10.1097/00001756-200107030-00051; Gincel D, 2001, BIOCHEM J, V358, P147, DOI 10.1042/0264-6021:3580147; Gong YW, 1996, HEPATOLOGY, V23, P734, DOI 10.1053/jhep.1996.v23.pm0008666326; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Halestrap AP, 2003, CURR MED CHEM, V10, P1507, DOI 10.2174/0929867033457278; Han D, 2003, J BIOL CHEM, V278, P5557, DOI 10.1074/jbc.M210269200; Hara MR, 2005, NAT CELL BIOL, V7, P665, DOI 10.1038/ncb1268; Ishida A, 2005, ARCH BIOCHEM BIOPHYS, V435, P134, DOI 10.1016/j.abb.2004.11.022; Ishitani R, 1996, J PHARMACOL EXP THER, V278, P447; Ishitani R, 1998, MOL PHARMACOL, V53, P701, DOI 10.1124/mol.53.4.701; Jacotot E, 2000, J EXP MED, V191, P33, DOI 10.1084/jem.191.1.33; Korge P, 1999, EUR J BIOCHEM, V265, P273, DOI 10.1046/j.1432-1327.1999.00724.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laschet JJ, 2004, J NEUROSCI, V24, P7614, DOI 10.1523/JNEUROSCI.0868-04.2004; Le Bras M, 2005, HISTOL HISTOPATHOL, V20, P205, DOI 10.14670/HH-20.205; LEE AC, 1994, J BIOL CHEM, V269, P30974; Mazzola JL, 2003, BBA-GEN SUBJECTS, V1622, P50, DOI 10.1016/S0304-4165(03)00117-X; Mazzola JL, 2002, NEUROTOXICOLOGY, V23, P603, DOI 10.1016/S0161-813X(02)00062-1; Muller A, 2000, EMBO J, V19, P5332, DOI 10.1093/emboj/19.20.5332; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Patterson RL, 2005, P NATL ACAD SCI USA, V102, P1357, DOI 10.1073/pnas.0409657102; PFAFF E, 1968, EUR J BIOCHEM, V6, P66, DOI 10.1111/j.1432-1033.1968.tb00420.x; Poncet D, 2004, J BIOL CHEM, V279, P22605, DOI 10.1074/jbc.M308408200; Rostovtseva TK, 2004, J BIOL CHEM, V279, P13575, DOI 10.1074/jbc.M310593200; RYZLAK MT, 1988, BIOCHIM BIOPHYS ACTA, V954, P309, DOI 10.1016/0167-4838(88)90086-6; Sawa A, 1997, P NATL ACAD SCI USA, V94, P11669, DOI 10.1073/pnas.94.21.11669; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; Shi Y, 2003, BIOCHEM BIOPH RES CO, V303, P475, DOI 10.1016/S0006-291X(03)00359-0; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shirakata Y, 2003, J BIOL CHEM, V278, P22071, DOI 10.1074/jbc.M301606200; Sirover MA, 1997, J CELL BIOCHEM, V66, P133, DOI 10.1002/(SICI)1097-4644(19970801)66:2<133::AID-JCB1>3.3.CO;2-V; SUNAGA K, 1995, NEUROSCI LETT, V200, P133, DOI 10.1016/0304-3940(95)12098-O; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Tajima H, 1999, NEUROREPORT, V10, P2029, DOI 10.1097/00001756-199907130-00007; THINNES FP, 1994, BIOL CHEM H-S, V375, P315, DOI 10.1515/bchm3.1994.375.5.315; Tisdale EJ, 2004, J BIOL CHEM, V279, P54046, DOI 10.1074/jbc.M409472200; Vander Heiden MG, 2000, P NATL ACAD SCI USA, V97, P4666, DOI 10.1073/pnas.090082297; Verrier F, 2004, ONCOGENE, V23, P8049, DOI 10.1038/sj.onc.1208001; Weaver JGR, 2005, J CLIN INVEST, V115, P1828, DOI 10.1172/JCI22954; Wu SL, 1999, BBA-MOL CELL RES, V1452, P68, DOI 10.1016/S0167-4889(99)00120-2; Zaid H, 2005, CELL DEATH DIFFER, V12, P751, DOI 10.1038/sj.cdd.4401599; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zizi M, 1998, BIOPHYS J, V75, P704, DOI 10.1016/S0006-3495(98)77560-5	62	268	282	2	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2007	26	18					2606	2620		10.1038/sj.onc.1210074	http://dx.doi.org/10.1038/sj.onc.1210074			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YI	17072346				2022-12-17	WOS:000245831200008
J	Laurent-Puig, P; Zucman-Rossi, J				Laurent-Puig, P.; Zucman-Rossi, J.			Genetics of hepatocellular tumors	ONCOGENE			English	Review						hepatocellular carcinoma; hepatocellular adenoma; chromosome instability; gene mutation; tumor suppressor gene	HEPATITIS-B-VIRUS; BETA-CATENIN GENE; COMPARATIVE GENOMIC HYBRIDIZATION; P53 GENE; SHORT ARM; RETINOBLASTOMA PROTEIN; SEGREGATION ANALYSIS; GROWTH-SUPPRESSION; LIVER-CIRRHOSIS; ALLELIC LOSSES	Numerous genetic alterations are accumulated during the process of hepatocarcinogenesis. These genetic alterations can be divided into two groups. The first set of genetic alterations is specific of hepatocellular tumor risk factors. It includes integration of hepatitis B virus (HBV) DNA, R249S TP53 (tumor protein p53) mutation in aflatoxin B1-exposed patients, KRAS mutations related to vinyl chloride exposure, hepatocyte nuclear factor 1 alpha (HNF1 alpha) mutations associated to hepatocellular adenomas and adenomatosis polyposis coli (APC) germline mutations predisposing to hepatoblastomas. The second set of genetic alterations are etiological nonspecific, it includes recurrent gains and losses of chromosomes, alteration of TP53 gene, activation of WNT/beta-catenin pathway through CTNNB1/beta-catenin and AXIN (axis inhibition protein) mutations, inactivation of retinoblastoma and IGF2R (insulin-like growth factor 2 receptor) pathways through inactivation of RB1 (retinoblastoma 1), P16 and IGF2R. Comprehensive analyses of these genetic alterations have defined two pathways of hepatocarcinogenesis according to the presence or the absence of chromosomal instability. Hepatitis B virus and poorly differentiated tumors are related to chromosome instable tumors associated with frequent TP53 mutations, whereas non-HBV and well-differentiated tumors are related to chromosomal stable samples that are frequently beta-catenin activated. These classifications have clinical relevance as genetic alterations may also be related to prognosis.	INSERM, U674, F-75010 Paris, France; Univ Paris 05, Paris, France; INSERM, U775, Paris, France; Univ Paris 07, Inst Hematol, CEPH, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Zucman-Rossi, J (corresponding author), INSERM, U674, 27 Rue Juliette Dodu, F-75010 Paris, France.	zucman@cephb.fr	Laurent-Puig, Pierre/K-3641-2019; zucman-rossi, Jessica/B-5098-2009; j, zucman-rossi/AAV-3594-2021; laurent-puig, pierre/B-2226-2013	Laurent-Puig, Pierre/0000-0001-8475-5459; zucman-rossi, Jessica/0000-0002-5687-0334; j, zucman-rossi/0000-0002-5687-0334; laurent-puig, pierre/0000-0001-8475-5459				Andrisani OM, 1999, INT J ONCOL, V15, P373; Aoki H, 1996, P NATL ACAD SCI USA, V93, P7300, DOI 10.1073/pnas.93.14.7300; Bacq Y, 2003, GASTROENTEROLOGY, V125, P1470, DOI 10.1016/j.gastro.2003.07.012; Baek MJ, 2000, CANCER, V89, P60, DOI 10.1002/1097-0142(20000701)89:1<60::AID-CNCR9>3.0.CO;2-3; Balsara BR, 2001, GENE CHROMOSOME CANC, V30, P245, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1083>3.0.CO;2-M; BAUMHUETER S, 1990, GENE DEV, V4, P372, DOI 10.1101/gad.4.3.372; Biden K, 1997, HEPATOLOGY, V25, P593, DOI 10.1002/hep.510250317; Bluteau O, 2002, ONCOGENE, V21, P1225, DOI 10.1038/sj.onc.1205197; Bluteau O, 2002, NAT GENET, V32, P312, DOI 10.1038/ng1001; Boige V, 1997, CANCER RES, V57, P1986; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; Buendia MA, 2002, MED PEDIATR ONCOL, V39, P530, DOI 10.1002/mpo.10180; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Cai RL, 2003, WORLD J GASTROENTERO, V9, P2428; CEREGHINI S, 1990, EMBO J, V9, P2257, DOI 10.1002/j.1460-2075.1990.tb07396.x; Cetta F, 2003, MED PEDIATR ONCOL, V41, P496, DOI 10.1002/mpo.10362; Chen YW, 2002, HEPATOLOGY, V36, P927, DOI 10.1053/jhep.2002.36126; CHIU JH, 1992, J CLIN INVEST, V89, P539, DOI 10.1172/JCI115618; CHOUARD T, 1990, NUCLEIC ACIDS RES, V18, P5853, DOI 10.1093/nar/18.19.5853; Collonge-Rame MA, 2001, CANCER GENET CYTOGEN, V127, P49, DOI 10.1016/S0165-4608(00)00421-0; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; Diao JY, 2001, J BIOL CHEM, V276, P8328, DOI 10.1074/jbc.M006026200; EDMONDSON HA, 1976, NEW ENGL J MED, V294, P470, DOI 10.1056/NEJM197602262940904; EDMONDSON HA, 1983, SEMIN ROENTGENOL, V18, P75, DOI 10.1016/0037-198X(83)90005-6; ESSIGMANN JM, 1977, P NATL ACAD SCI USA, V74, P1870, DOI 10.1073/pnas.74.5.1870; EZAKI T, 1988, CANCER, V61, P106, DOI 10.1002/1097-0142(19880101)61:1<106::AID-CNCR2820610118>3.0.CO;2-R; FEITELSON MA, 1993, ONCOGENE, V8, P1109; Ferber MJ, 2003, ONCOGENE, V22, P3813, DOI 10.1038/sj.onc.1206528; FILSON AJ, 1993, DEVELOPMENT, V118, P731; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; FUJIMOTO J, 1991, CANCER, V67, P939, DOI 10.1002/1097-0142(19910215)67:4<939::AID-CNCR2820670414>3.0.CO;2-J; FUJIMOTO Y, 1994, CANCER RES, V54, P281; FURUYA K, 1988, CANCER, V61, P99, DOI 10.1002/1097-0142(19880101)61:1<99::AID-CNCR2820610117>3.0.CO;2-U; GRAEF E, 1994, ONCOGENE, V9, P81; GROOPMAN JD, 1981, P NATL ACAD SCI-BIOL, V78, P5445, DOI 10.1073/pnas.78.9.5445; Guan XY, 2000, GENE CHROMOSOME CANC, V29, P110; Hickman ES, 2002, CURR OPIN GENET DEV, V12, P60, DOI 10.1016/S0959-437X(01)00265-9; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Horikawa I, 2003, CARCINOGENESIS, V24, P1167, DOI 10.1093/carcin/bgg085; Hsu HC, 2000, AM J PATHOL, V157, P763, DOI 10.1016/S0002-9440(10)64590-7; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; Huang H, 1999, AM J PATHOL, V155, P1795, DOI 10.1016/S0002-9440(10)65496-X; Ishizaki Y, 2004, INT J ONCOL, V24, P1077; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; Koch A, 2004, J PATHOL, V204, P546, DOI 10.1002/path.1662; Koch A, 1999, CANCER RES, V59, P269; Kondo Y, 1999, JPN J CANCER RES, V90, P1301, DOI 10.1111/j.1349-7006.1999.tb00712.x; Koyama M, 1999, JPN J CANCER RES, V90, P951, DOI 10.1111/j.1349-7006.1999.tb00840.x; KUROKI T, 1995, GENE CHROMOSOME CANC, V13, P163, DOI 10.1002/gcc.2870130305; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Lee JW, 2005, ONCOGENE, V24, P1477, DOI 10.1038/sj.onc.1208304; Legoix P, 1999, ONCOGENE, V18, P4044, DOI 10.1038/sj.onc.1202800; Liew CT, 1999, ONCOGENE, V18, P789, DOI 10.1038/sj.onc.1202359; Lin Y., 1996, Annals Academy of Medicine Singapore, V25, P22; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Mao TL, 2001, J PATHOL, V193, P95, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH720>3.0.CO;2-3; Marchio A, 1997, GENE CHROMOSOME CANC, V18, P59, DOI 10.1002/(SICI)1098-2264(199701)18:1<59::AID-GCC7>3.3.CO;2-N; Marchio AS, 2000, ONCOGENE, V19, P3733, DOI 10.1038/sj.onc.1203713; MARTIN CN, 1977, NATURE, V267, P863, DOI 10.1038/267863a0; Matsuda Y, 1999, GASTROENTEROLOGY, V116, P394, DOI 10.1016/S0016-5085(99)70137-X; MCGLYNN KA, 1995, P NATL ACAD SCI USA, V92, P2384, DOI 10.1073/pnas.92.6.2384; MILLER C, 1986, NATURE, V319, P783, DOI 10.1038/319783a0; MILLER EC, 1978, CANCER RES, V38, P1479; Miyoshi Y, 1998, CANCER RES, V58, P2524; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Motyka B, 2000, CELL, V103, P491, DOI 10.1016/S0092-8674(00)00140-9; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; NISHIDA N, 1992, INT J CANCER, V51, P862, DOI 10.1002/ijc.2910510605; Nishimura T, 2002, GENE CHROMOSOME CANC, V35, P329, DOI 10.1002/gcc.10126; Oka Y, 2002, HEPATOLOGY, V35, P1153, DOI 10.1053/jhep.2002.32669; Okabe H, 2000, HEPATOLOGY, V31, P1073, DOI 10.1053/he.2000.6409; Okabe H, 2001, CANCER RES, V61, P2129; Paradis V, 1998, HEPATOLOGY, V28, P953, DOI 10.1002/hep.510280409; Paterlini-Brechot P, 2003, ONCOGENE, V22, P3911, DOI 10.1038/sj.onc.1206492; Piao Z, 1999, CANCER LETT, V138, P227, DOI 10.1016/S0304-3835(99)00019-1; Piao Z, 1998, INT J CANCER, V75, P29, DOI 10.1002/(SICI)1097-0215(19980105)75:1<29::AID-IJC5>3.3.CO;2-#; Piao Z, 1997, LIVER, V17, P251; Pineau P, 1999, ONCOGENE, V18, P3127, DOI 10.1038/sj.onc.1202648; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; SHEN FM, 1991, AM J HUM GENET, V49, P88; Shirota Y, 2001, HEPATOLOGY, V33, P832, DOI 10.1053/jhep.2001.23003; Smela ME, 2001, CARCINOGENESIS, V22, P535, DOI 10.1093/carcin/22.4.535; Sun CA, 2001, CARCINOGENESIS, V22, P1289, DOI 10.1093/carcin/22.8.1289; TANAKA S, 1993, CANCER RES, V53, P2884; Taniguchi K, 2002, ONCOGENE, V21, P4863, DOI 10.1038/sj.onc.1205591; TERADA T, 1993, VIRCHOWS ARCH A, V422, P381, DOI 10.1007/BF01605457; TERAMOTO T, 1994, CANCER RES, V54, P231; Terris B, 1999, ONCOGENE, V18, P6583, DOI 10.1038/sj.onc.1203051; THOMAS RM, 1992, HUM PATHOL, V23, P496, DOI 10.1016/0046-8177(92)90126-N; TSUDA H, 1990, P NATL ACAD SCI USA, V87, P6791, DOI 10.1073/pnas.87.17.6791; Van Nhieu JT, 1999, AM J PATHOL, V155, P703, DOI 10.1016/S0002-9440(10)65168-1; Vautier G, 1999, GASTROENTEROLOGY, V117, P154, DOI 10.1016/S0016-5085(99)70562-7; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; Wei Y, 2000, ONCOGENE, V19, P498, DOI 10.1038/sj.onc.1203356; Weihrauch M, 2001, BRIT J CANCER, V84, P982, DOI 10.1054/bjoc.2000.1675; WEINBERG AG, 1983, HUM PATHOL, V14, P512, DOI 10.1016/S0046-8177(83)80005-7; Wong CM, 2001, CANCER-AM CANCER SOC, V92, P136, DOI 10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0.CO;2-R; Wong N, 2000, HEPATOLOGY, V32, P1060, DOI 10.1053/jhep.2000.19349; Xu XR, 2001, P NATL ACAD SCI USA, V98, P15089, DOI 10.1073/pnas.241522398; Yakicier MC, 1999, ONCOGENE, V18, P4879, DOI 10.1038/sj.onc.1202866; Yakicier MC, 2001, ONCOGENE, V20, P5232, DOI 10.1038/sj.onc.1204674; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0; Yeh SH, 2001, GASTROENTEROLOGY, V121, P699, DOI 10.1053/gast.2001.27211; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Yu MW, 2000, J NATL CANCER I, V92, P1159, DOI 10.1093/jnci/92.14.1159; ZHANG X, 1994, CANCER RES, V54, P4177; Zucman-Rossi J, 2006, HEPATOLOGY, V43, P515, DOI 10.1002/hep.21068	112	268	280	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	27					3778	3786		10.1038/sj.onc.1209547	http://dx.doi.org/10.1038/sj.onc.1209547			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	056XY	16799619				2022-12-17	WOS:000238559600005
J	BAE, SC; YAMAGUCHIIWAI, Y; OGAWA, E; MARUYAMA, M; INUZUKA, M; KAGOSHIMA, H; SHIGESADA, K; SATAKE, M; ITO, Y				BAE, SC; YAMAGUCHIIWAI, Y; OGAWA, E; MARUYAMA, M; INUZUKA, M; KAGOSHIMA, H; SHIGESADA, K; SATAKE, M; ITO, Y			ISOLATION OF PEBP2-ALPHA-B CDNA REPRESENTING THE MOUSE HOMOLOG OF HUMAN ACUTE MYELOID-LEUKEMIA GENE, AML1	ONCOGENE			English	Article							RECEPTOR ALPHA-GENE; HA-RAS ONCOGENE; POLYOMAVIRUS ENHANCER; TRANSCRIPTION FACTOR; PROTEIN; TRANSLOCATIONS; EXPRESSION; BINDING; DOMAIN; CELLS	Breakpoints of the t(8;21) chromosome translocation in acute myeloid leukemia are clustered within the human gene, AML1, located on chromosome 21 [Miyoshi, H., Shimizu, K., Maseki, N., Kaneko, Y. & Ohki, M. (1991). Proc. Natl. Acad. Sci. USA, 88, 10431-104341. The product of AML1 has a region about 130 amino acids long that is highly homologous to the Drosophila segmentation gene runt (runt homology region). The cDNA isolated from mouse fibroblasts encoding the alpha-subunit of polyomavirus enhancer binding protein 2 (PEBP2/PEA2) revealed that it also has a runt homology region (E. Ogawa et al., submitted). In this study, a different cDNA clone presumed to represent the mouse homolog of human AML1 (PEBP2alpha(B) was isolated from a cDNA library derived from B cells. The deduced amino acid sequence of PEBP2alphaB is 99% identical to that of AML1 for the first 241 residues, including the runt homology region, though their sequences diverge thereafter. On the other hand, PEBP2alphaB and PEBP2alpha share only 92% and 82% homologies at the amino acid and nucleotide levels respectively, even for the runt homology region, indicating that these proteins are encoded by distinct genes. While PEBP2alpha is highly expressed in T-cell lines but not in most of the B-cell lines and functions as an activator of T-cell-specific genes, PEBP2alphaB is expressed in both types of cells. A possible functional relationship between PEBP2alpha and PEBP2alphaB is discussed in relation to leukemogenic potential of AML1.	KYOTO UNIV,INST VIRUS RES,DEPT VIRAL ONCOL,SHOGOIN,SAKYO KU,KYOTO 606,JAPAN; KYOTO UNIV,INST VIRUS RES,DEPT GENET & MOLEC BIOL,KYOTO 606,JAPAN	Kyoto University; Kyoto University								CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; FURUKAWA K, 1990, CELL GROWTH DIFFER, V1, P135; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; KIM KJ, 1979, J IMMUNOL, V122, P549; KRYSZKE MH, 1987, NATURE, V328, P254, DOI 10.1038/328254a0; LEIDEN JM, 1992, IMMUNOL TODAY, V13, P22, DOI 10.1016/0167-5699(92)90200-Q; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MOORE GE, 1966, JNCI-J NATL CANCER I, V36, P405; OLD LJ, 1965, CANCER RES, V25, P813; PAIGE CJ, 1978, J IMMUNOL, V121, P641; PIETTE J, 1987, EMBO J, V6, P1331, DOI 10.1002/j.1460-2075.1987.tb02372.x; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RALPH P, 1973, J NATL CANCER I, V51, P883, DOI 10.1093/jnci/51.3.883; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V14, P4767; SATAKE M, 1992, JPN J CANCER RES, V83, P714, DOI 10.1111/j.1349-7006.1992.tb01971.x; SATAKE M, 1988, ONCOGENE, V3, P69; SATAKE M, 1989, J VIROL, V63, P3669, DOI 10.1128/JVI.63.9.3669-3677.1989; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656	26	268	274	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					809	814						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437866				2022-12-17	WOS:A1993KN00800036
J	BAICHWAL, VR; SUGDEN, B				BAICHWAL, VR; SUGDEN, B			TRANSFORMATION OF BALB 3T3 CELLS BY THE BNLF-1 GENE OF EPSTEIN-BARR VIRUS	ONCOGENE			English	Article									UNIV WISCONSIN,MCARDLE LAB CANC RES,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NCI NIH HHS [CA-22443, CA07175] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA022443, P30CA007175] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1968, J CELL PHYSIOL, V72, P141, DOI 10.1002/jcp.1040720208; AUERBACH R, 1978, CANCER RES, V38, P1739; BAICHWAL VR, 1987, J VIROL, V61, P866, DOI 10.1128/JVI.61.3.866-875.1987; Bankier A T, 1983, Mol Biol Med, V1, P425; BISHOP JM, 1985, CELL, V42, P23, DOI 10.1016/S0092-8674(85)80098-2; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; DAMBAUGH T, 1986, J VIROL, V59, P453, DOI 10.1128/JVI.59.2.453-462.1986; DAMBAUGH T, 1986, EPSTEINBARR VIRUS RE, P13; HENNESSY K, 1984, P NATL ACAD SCI-BIOL, V81, P7207, DOI 10.1073/pnas.81.22.7207; HEPPEL LA, 1955, METHOD ENZYMOL, V2, P546, DOI 10.1016/S0076-6879(55)02249-0; KAVATHAS P, 1980, P NATL ACAD SCI-BIOL, V77, P4251, DOI 10.1073/pnas.77.7.4251; KNUTSON JC, 1987, ANAL BIOCHEM, V164, P44, DOI 10.1016/0003-2697(87)90365-4; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LANE MA, 1982, CELL, V28, P873, DOI 10.1016/0092-8674(82)90066-6; LIEBOWITZ D, 1986, J VIROL, V58, P223; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; MANN KP, 1987, J VIROL, V61, P2100, DOI 10.1128/JVI.61.7.2100-2108.1987; MANN KP, 1985, J VIROL, V55, P710, DOI 10.1128/JVI.55.3.710-720.1985; MILLER G, 1985, VIROLOGY, P563; NILSSON K, 1977, INT J CANCER, V19, P337, DOI 10.1002/ijc.2910190309; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SUGDEN B, 1977, J VIROL, V23, P503, DOI 10.1128/JVI.23.3.503-508.1977; Sugden B, 1979, Adv Cancer Res, V30, P239, DOI 10.1016/S0065-230X(08)60898-2; TOPP WC, 1980, DNA TUMOR VIRUSES, P205; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; ZERLIN M, 1987, ONCOGENE, V1, P19	26	268	274	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1988	2	5					461	467						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N4348	2836780				2022-12-17	WOS:A1988N434800007
J	Courtois-Cox, S; Jones, SL; Cichowski, K				Courtois-Cox, S.; Jones, S. L.; Cichowski, K.			Many roads lead to oncogene-induced senescence	ONCOGENE			English	Review						senescence; DNA damage; heterochromatic foci; negative feedback; Ras; NF1; Raf; PTEN	DAMAGE SIGNALING PATHWAY; K-RAS ONCOGENE; CELLULAR SENESCENCE; IN-VIVO; HETEROCHROMATIN FORMATION; TYPE-1 NEUROFIBROMATOSIS; PREMATURE SENESCENCE; TUMOR SUPPRESSION; HUMAN-FIBROBLASTS; MOUSE MODELS	Oncogene-induced senescence is a mechanism of tumor suppression that restricts the progression of benign tumors. Important advances have been made toward elucidating the mechanisms that regulate this response; however, there is presently no unified model that integrates all current findings. DNA damage, replicative stress, reactive oxygen species, heterochromatin formation and negative feedback signaling networks have all been proposed to play an integral role in promoting senescence in response to various oncogenic insults. In all cases, these signals have been shown to function through Rb and p53, but utilize different intermediaries. Thus, it appears that senescence is not triggered by a single, linear series of events, but instead is regulated by a complex signaling network. Accordingly, multiple proteins may cooperate to establish a senescence response, but the limiting signal(s) may be dictated by the initiating genetic alteration and/or tissue type. This review will focus on integrating current models and will highlight data that provide new insight into the signals that function to suppress human tumor development.	[Courtois-Cox, S.] Harvard Univ, Dept Med, Sch Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Cichowski, K (corresponding author), Harvard Univ, Dept Med, Sch Med, 458c NRB,77 Louis Pasteur Ave, Boston, MA 02115 USA.	kcichowski@rics.bwh.harvard.edu						Adams PD, 2007, GENE, V397, P84, DOI 10.1016/j.gene.2007.04.020; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; Brachmann SA, 2005, MOL CELL BIOL, V25, P2593, DOI 10.1128/MCB.25.7.2593-2606.2005; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Brems H, 2007, NAT GENET, V39, P1120, DOI 10.1038/ng2113; Brown JM, 2005, NAT REV CANCER, V5, P231, DOI 10.1038/nrc1560; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Courtois-Cox S, 2006, CANCER CELL, V10, P459, DOI 10.1016/j.ccr.2006.10.003; Dankort D, 2007, GENE DEV, V21, P379, DOI 10.1101/gad.1516407; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; Denchi EL, 2005, MOL CELL BIOL, V25, P2660, DOI 10.1128/MCB.25.7.2660-2672.2005; DER CJ, 1982, P NATL ACAD SCI-BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Dinulescu DM, 2005, NAT MED, V11, P63, DOI 10.1038/nm1173; Dolado I, 2007, CANCER CELL, V11, P191, DOI 10.1016/j.ccr.2006.12.013; Frippiat C, 2000, EXP GERONTOL, V35, P733, DOI 10.1016/S0531-5565(00)00167-4; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; Hemann MT, 2007, GENE DEV, V21, P1, DOI 10.1101/gad.1514207; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Holtkamp N, 2004, ACTA NEUROPATHOL, V107, P159, DOI 10.1007/s00401-003-0797-8; Kim CFB, 2005, COLD SH Q B, V70, P241, DOI 10.1101/sqb.2005.70.037; Kim HJ, 2004, NAT REV MOL CELL BIO, V5, P441, DOI 10.1038/nrm1400; Kim R, 2006, CANCER BIOL THER, V5, P1429, DOI 10.4161/cbt.5.11.3456; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Lo TL, 2006, CANCER LETT, V242, P141, DOI 10.1016/j.canlet.2005.12.032; MacLaren A, 2004, MOL CELL BIOL, V24, P9006, DOI 10.1128/MCB.24.20.9006-9018.2004; Mallette FA, 2007, CELL CYCLE, V6, P1831, DOI 10.4161/cc.6.15.4516; Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307; Meier F, 2005, FRONT BIOSCI-LANDMRK, V10, P2986, DOI 10.2741/1755; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Minamino T, 2003, CIRCULATION, V108, P2264, DOI 10.1161/01.CIR.0000093274.82929.22; Miyauchi H, 2004, EMBO J, V23, P212, DOI 10.1038/sj.emboj.7600045; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Narita M, 2006, CELL, V126, P503, DOI 10.1016/j.cell.2006.05.052; Ogawa K, 2005, ONCOL REP, V14, P1481; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; PARADA LF, 1982, NATURE, V297, P474, DOI 10.1038/297474a0; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Ray S, 2006, CANCER RES, V66, P6598, DOI 10.1158/0008-5472.CAN-05-3115; Sansom OJ, 2006, P NATL ACAD SCI USA, V103, P14122, DOI 10.1073/pnas.0604130103; Sarkisian CJ, 2007, NAT CELL BIOL, V9, P493, DOI 10.1038/ncb1567; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; Shaw AT, 2007, GENE DEV, V21, P694, DOI 10.1101/gad.1526207; Sun PQ, 2007, CELL, V128, P295, DOI 10.1016/j.cell.2006.11.050; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; Trotman LC, 2006, NATURE, V441, P523, DOI 10.1038/nature04809; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Wu CW, 2004, NATURE, V432, P640, DOI 10.1038/nature03173; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Ye XF, 2007, MOL CELL, V27, P183, DOI 10.1016/j.molcel.2007.05.034	57	267	271	2	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2008	27	20					2801	2809		10.1038/sj.onc.1210950	http://dx.doi.org/10.1038/sj.onc.1210950			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295VR	18193093				2022-12-17	WOS:000255502500001
J	Uematsu, K; He, BA; You, L; Xu, ZD; McCormick, F; Jablons, DM				Uematsu, K; He, BA; You, L; Xu, ZD; McCormick, F; Jablons, DM			Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression	ONCOGENE			English	Article						Dishevelled (Dvl); Wnt signaling; non small cell lung cancer; siRNA	BETA-CATENIN; SIGNALING PATHWAY; P53; CARCINOMAS; EXPRESSION; MUTATIONS; PROTEINS; SIAH-1; SUBSET	Non small cell lung cancer (NSCLC) is the leading cause of cancer deaths in the United States and worldwide. Unfortunately, standard therapies remain inadequate. An increased understanding of the molecular biology of lung cancer biology is required to develop more effective new therapies. In this report, we show that the Wnt pathway is activated through Dishevelled (Dvl) overexpression in NSCLC. Analysis of freshly resected tumors and lung cancer cell lines demonstrate that Dvl-3, a critical mediator of Wnt signaling, is overexpressed. Specifically, Dvl-3 was overexpressed significantly in 75% of fresh NSCLC microdissected samples compared to control paired matched normal lung samples. To evaluate the biological significance of Wnt signaling and, in particular, Dvl function in lung cancer, we transfected siRNA ( designed to inhibit selectively human Dvl-1, - 2, and - 3), to the NSCLC cell line H1703, which is known to have beta-catenin-mediated Tcf-dependent transcriptional activity. Here, we demonstrate that Dvl-specific siRNA treatment in H1703 decreases significantly Dvl and beta-catenin expression, resulting in reduction of Tcf-dependent transcriptional activity, and, importantly, growth inhibition. Taken together, these data support the novel hypothesis that Dvl overexpression is critical to Wnt signaling activation and cell growth in NSCLC.	Univ Calif San Francisco, UCSF Canc Ctr, Thorac Oncol Lab, San Francisco, CA 94115 USA; Nippon Med Coll, Dept Internal Med 4, Tokyo 1138602, Japan	University of California System; University of California San Francisco; UCSF Medical Center; Nippon Medical School	Jablons, DM (corresponding author), Univ Calif San Francisco, UCSF Canc Ctr, Thorac Oncol Lab, Campus Box 1674,1600 Divisadero St,Suite 322C, San Francisco, CA 94115 USA.							Brantjes H, 2002, BIOL CHEM, V383, P255, DOI 10.1515/BC.2002.027; Brognard J, 2002, CELL DEATH DIFFER, V9, P893, DOI 10.1038/sj.cdd.4401054; Cagatay T, 2002, ONCOGENE, V21, P7971, DOI 10.1038/sj.onc.1205919; Hommura F, 2002, CANCER-AM CANCER SOC, V94, P752, DOI 10.1002/cncr.10213; Li L, 2002, J BIOL CHEM, V277, P5977, DOI 10.1074/jbc.M111131200; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; MINNA JD, 1998, HARRISONS PRINCIPLES, V14, P522; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Polakis P, 2000, GENE DEV, V14, P1837; SEKIDO Y, 1998, BIOCHIM BIOPHYS ACTA, V1378, P21; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Sunaga N, 2001, GENE CHROMOSOME CANC, V30, P316, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1097>3.0.CO;2-9; Ueda M, 2001, BRIT J CANCER, V85, P64, DOI 10.1054/bjoc.2001.1863; Wang J, 2000, ONCOGENE, V19, P1843, DOI 10.1038/sj.onc.1203503; Wharton KA, 2003, DEV BIOL, V253, P1, DOI 10.1006/dbio.2002.0869; Winn RA, 2002, ONCOGENE, V21, P7497, DOI 10.1038/sj.onc.1205963; You Liang, 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P609	18	267	279	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 16	2003	22	46					7218	7221		10.1038/sj.onc.1206817	http://dx.doi.org/10.1038/sj.onc.1206817			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732PP	14562050				2022-12-17	WOS:000185955000013
J	Butz, K; Ristriani, T; Hengstermann, A; Denk, C; Scheffner, M; Hoppe-Seyler, F				Butz, K; Ristriani, T; Hengstermann, A; Denk, C; Scheffner, M; Hoppe-Seyler, F			siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells	ONCOGENE			English	Article						RNA interference; human papillomavirus; apoptosis; tumour virus; tumour therapy	INDUCED APOPTOSIS; RNA INTERFERENCE; MAMMALIAN-CELLS; GENE-EXPRESSION; MESSENGER-RNA; P53 PROTEIN; E7; INHIBITION; PEPTIDES; TYPE-16	The targeted inhibition of antiapoptotic factors in tumour cells may provide a rational approach towards the development of novel anticancer therapies. Using human papillomavirus (HPV)-transformed cells as a model system, we investigated if RNA interference (RNAi)-mediated gene silencing can be employed in order to overcome the apoptosis resistance of cancer cells. We found that both vector-borne and synthetic small interfering (si)RNAs, specifically directed against the antiapoptotic HPV E6 oncogene, restored dormant tumour suppressor pathways in HPV-positive cancer cells that are otherwise inactive in the presence of E6. This ultimately resulted in massive apoptotic cell death, selectively in HPV-positive tumour cells. These findings show that RNAi provides a powerful molecular strategy to inactivate intracellular E6 function efficiently. Moreover, they define E6 as a most promising therapeutic target to eliminate HPV-positive tumour cells specifically by RNAi. Thus, by sequence-specific targeting of antiapoptotic genes, siRNAs may be developed into novel therapeutics that can efficiently correct the apoptosis deficiency of cancer cells.	Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany; Univ Cologne, Fak Med, Zentrum Biochem, D-50931 Cologne, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); University of Cologne	Hoppe-Seyler, F (corresponding author), Deutsch Krebsforschungszentrum, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.	hoppe-seyler@dkfz.de	Scheffner, Martin/K-2940-2012	Scheffner, Martin/0000-0003-2229-0128; Hoppe-Seyler, Felix/0000-0002-1864-300X				Agami R, 2002, CURR OPIN CHEM BIOL, V6, P829, DOI 10.1016/S1367-5931(02)00378-2; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Butz K, 2000, P NATL ACAD SCI USA, V97, P6693, DOI 10.1073/pnas.110538897; Butz K, 1998, ONCOGENE, V17, P781, DOI 10.1038/sj.onc.1201995; BUTZ K, 1995, ONCOGENE, V10, P927; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COLE ST, 1987, J MOL BIOL, V193, P599, DOI 10.1016/0022-2836(87)90343-3; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P12513, DOI 10.1073/pnas.97.23.12513; Hoppe-Seyler F, 1999, ANTICANCER RES, V19, P4747; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Jacque JM, 2002, NATURE, V418, P435, DOI 10.1038/nature00896; Jiang M, 2002, ONCOGENE, V21, P6041, DOI 10.1038/sj.onc.1205878; Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Morris MC, 2000, CURR OPIN BIOTECH, V11, P461, DOI 10.1016/S0958-1669(00)00128-2; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Novina CD, 2002, NAT MED, V8, P681, DOI 10.1038/nm725; Paddison PJ, 2002, CANCER CELL, V2, P17, DOI 10.1016/S1535-6108(02)00092-2; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2; Reed JC, 2001, TRENDS MOL MED, V7, P314, DOI 10.1016/S1471-4914(01)02026-3; Rittner K, 2002, MOL THER, V5, P104, DOI 10.1006/mthe.2002.0523; Rothbard JB, 2000, NAT MED, V6, P1253, DOI 10.1038/81359; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; SMOTKIN D, 1989, J VIROL, V63, P1441, DOI 10.1128/JVI.63.3.1441-1447.1989; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; Thomas M, 1998, ONCOGENE, V17, P2943, DOI 10.1038/sj.onc.1202223; Thomas M, 1999, ONCOGENE, V18, P7690, DOI 10.1038/sj.onc.1202953; Venturini F, 1999, NUCLEIC ACIDS RES, V27, P1585, DOI 10.1093/nar/27.7.1585; Wells SI, 2000, EMBO J, V19, P5762, DOI 10.1093/emboj/19.21.5762; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	46	267	303	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					5938	5945		10.1038/sj.onc.1206894	http://dx.doi.org/10.1038/sj.onc.1206894			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955072				2022-12-17	WOS:000185137800002
J	Midgley, CA; Lane, DP				Midgley, CA; Lane, DP			p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding	ONCOGENE			English	Article						p53 tumour suppressor protein; Mdm2 tumour suppressor protein; protein stability; DNA damage	WILD-TYPE P53; LI-FRAUMENI SYNDROME; C-TERMINAL DOMAIN; TRANSFORMED-CELLS; SUPPRESSOR PROTEIN; BREAST-CANCER; DNA-BINDING; SV40-TRANSFORMED CELLS; IONIZING-RADIATION; IN-VITRO	The tumour suppressor protein p53 is expressed at very low levels in normal cells but accumulates in response to DNA damaging agents such as u.v. irradiation. This increase is accompanied by transcriptional upregulation of the expression of a number of proteins including Mdm2 which can in turn inhibit p53 dependent transcriptional activation, creating a feedback loop resulting in down-regulation of p53 activity. Mutant p53 proteins are however frequently detected at constitutively high levels in many tumours and tumour cell lines, indeed this phenomenon has been used in several studies to diagnose p53 mutation in patient tumours. We show here that expression of mouse mutant p53 in tumour cell lines of this type results in high levels of both the endogenous p53 protein and the exogenously expressed mutant mouse protein, whereas the human tumour line MCF7 does not exhibit high levels of either endogenous human or exogenously expressed mouse mutant p53 unless stabilisation is induced by DNA damage, This suggests that the stability of mutant p53 is not intrinsic to mutant p53 protein structure but may vary in different cell backgrounds. We present evidence that p53 protein stability in tumour cell lines is determined by association with the Mdm2 tumour suppressor protein, and that p53 mutants which are unable to bind Mdm2 are stable in MCF7 cells, We propose that tumour lines which express high levels of transcriptionally inactive mutant p53 are unable to induce the expression of the Mdm2 protein which would normally provide a feedback mechanism down-regulating p53 protein levels in the absence of DNA damage signals, MCF7 cells however express a transcriptionally active p53 and retain the feedback regulation of p53 protein levels by Mdm2.	UNIV DUNDEE,INST MED SCI,DEPT BIOCHEM,CANC RES CAMPAIGN,CELL TRANSFORMAT RES GRP,DUNDEE DD1 4HN,SCOTLAND	University of Dundee			Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; BARTEK J, 1991, ONCOGENE, V6, P1699; BENNETT WP, 1993, CANCER RES, V53, P4817; Blaydes JP, 1997, ONCOGENE, V14, P1859, DOI 10.1038/sj.onc.1201018; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; DEPPERT W, 1994, SEMIN CANCER BIOL, V5, P187; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FISCELLA M, 1993, ONCOGENE, V8, P1519; FRITSCHE M, 1993, ONCOGENE, V8, P307; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Hall AR, 1997, ONCOGENE, V14, P1371, DOI 10.1038/sj.onc.1200962; HARPER JW, 1993, CELL, V75, P805; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Lane DP, 1996, ONCOGENE, V12, P2461; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LOMAX ME, 1997, ONCOGENE, V14, P1868; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1994, BBA-REV CANCER, V1198, P197, DOI 10.1016/0304-419X(94)90014-0; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARSTON NJ, 1995, ONCOGENE, V10, P1709; MARTIN HM, 1992, INT J CANCER, V50, P859, DOI 10.1002/ijc.2910500604; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MOLINARI M, 1995, ONCOGENE, V10, P1849; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; OREN M, 1982, MOL CELL BIOL, V2, P443, DOI 10.1128/MCB.2.4.443; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; REIHSAUS E, 1990, ONCOGENE, V5, P137; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; Sambrook J., MOL CLONING LAB MANU; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SHAULIAN E, 1995, ONCOGENE, V10, P671; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SLINGERLAND JM, 1991, J CELL PHYSIOL, V148, P391, DOI 10.1002/jcp.1041480309; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; TOMINAGA O, 1993, ONCOGENE, V8, P2653; Varley JM, 1996, ONCOGENE, V12, P2437; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; VOJTESEK B, 1993, J CELL SCI, V105, P607; WILLIAMS AC, 1993, ONCOGENE, V8, P3063; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	66	267	271	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 4	1997	15	10					1179	1189		10.1038/sj.onc.1201459	http://dx.doi.org/10.1038/sj.onc.1201459			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XU991	9294611				2022-12-17	WOS:A1997XU99100007
J	Takahashi, T; Shibuya, M				Takahashi, T; Shibuya, M			The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-gamma pathway and partially induces mitotic signals in NIH3T3 fibroblasts	ONCOGENE			English	Article						vascular endothelial growth factor; tyrosine kinase receptor; signal transduction; MAP kinase	ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; TYROSINE KINASE; HEMATOPOIETIC-CELLS; BIOLOGICAL-ACTIVITY; EXPRESSION; ANGIOGENESIS; GENE; VASCULOGENESIS; BINDING	KDR/Flk-1 tyrosine kinase, one of the two receptors for Vascular Endothelial Growth Factor (VEGF) has been shown to generate the major part of mitotic signals in endothelial cells, although the mechanisms are poorly understood, Here we examined the processing and signal transduction of KDR/Flk-1. Both in endothelial cells and in NIH3T3 cells expressing KDR/Flk-1, an immature form of KDR/Flk-1 with a molecular mass of about 150 kDa was glycosylated to create a 200 kDa intermediate, and after further glycosylation a mature 230 kDa was expressed on the cell surface, Only this 230 kDa form was rapidly and transiently phosphorylated on tyrosine residues in the presence of VEGF, As a major substrate of KDR/FLk-1, PLC-gamma was found to be rapidly tyrosine-phosphorylated and associated with KDR/Flk-1 both in endothelial cells and NIH3T3 cells, Interestingly, however, a prompt activation of MAP kinase and subsequent strong mitotic signaling were generated only in the endothelial cell background, Activation of MAP kinase in NIH3T3 cells overexpressing KDR/Flk-1 showed a slower response as maximum levels were only attained after 20 min compared to 5 min in sinusoidal endothelial cells. These results suggest that the KDR/Flk-1 utilizes cell type-specific signal transduction pathway(s) for MAP kinase activation and the mitotic response in endothelial cells.	UNIV TOKYO,INST MED SCI,DEPT GENET,MINATO KU,TOKYO 108,JAPAN	University of Tokyo								APRELIKOVA O, 1992, CANCER RES, V52, P746; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; CLAUSS HSM, 1993, BLOOD, V81, P2767; COHEN T, 1995, J BIOL CHEM, V270, P11322, DOI 10.1074/jbc.270.19.11322; Cohen T, 1992, GROWTH FACTORS, V7, P131, DOI 10.3109/08977199209046402; CONNINGHAM SA, 1995, J BIOL CHEM, V270, P20254; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DOUGHERVERMAZEN M, 1994, BIOCHEM BIOPH RES CO, V205, P728, DOI 10.1006/bbrc.1994.2726; DUKSIN D, 1982, J BIOL CHEM, V257, P3105; EICHMANN A, 1993, MECH DEVELOP, V42, P33, DOI 10.1016/0925-4773(93)90096-G; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GALLAND F, 1993, ONCOGENE, V8, P1233; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; KAIPAINEN A, 1993, J EXP MED, V178, P2077, DOI 10.1084/jem.178.6.2077; KATOH O, 1995, CANCER RES, V55, P5687; KECK PJ, 1989, SCIENCE, V246, P309; KIMURA G, 1975, INT J CANCER, V15, P694, DOI 10.1002/ijc.2910150419; LAROCHELLE WJ, 1986, J IMMUNOL METHODS, V92, P65, DOI 10.1016/0022-1759(86)90504-1; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MICAELSON IC, 1948, T OPHTHAL SOC UK, V68, P137; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PEPPER MS, 1991, BIOCHEM BIOPH RES CO, V181, P902, DOI 10.1016/0006-291X(91)91276-I; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; RETTENMIER CW, 1987, MOL CELL BIOL, V7, P2378, DOI 10.1128/MCB.7.7.2378; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RISAU W, 1988, DEVELOPMENT, V102, P471; ROHRSCHNEIDER LR, 1989, MOL CELL BIOL, V9, P5081, DOI 10.1128/MCB.9.11.5081; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEETHARAM L, 1995, ONCOGENE, V10, P135; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIBUYA M, 1990, ONCOGENE, V5, P519; Shibuya M, 1995, ADV CANCER RES, V67, P281, DOI 10.1016/S0065-230X(08)60716-2; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; UNEMORI EN, 1992, J CELL PHYSIOL, V153, P557, DOI 10.1002/jcp.1041530317; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; YAMANE A, 1994, ONCOGENE, V9, P2682	50	267	288	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 1	1997	14	17					2079	2089		10.1038/sj.onc.1201047	http://dx.doi.org/10.1038/sj.onc.1201047			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW809	9160888				2022-12-17	WOS:A1997WW80900010
J	Klugbauer, S; Lengfelder, E; Demidchik, EP; Rabes, HM				Klugbauer, S; Lengfelder, E; Demidchik, EP; Rabes, HM			High prevalence of RET rearrangement in thyroid tumors of children from Belarus after the Chernobyl reactor accident	ONCOGENE			English	Article						RET oncogene; RT-PTC1; ret/PTC1; ret/PTC3; papillary thyroid carcinoma; RET/ELE transcript	TYROSINE KINASE ONCOGENES; PROTO-ONCOGENE; CARCINOMAS; ACTIVATION; CANCER; PTC; PROTOONCOGENE; EXPRESSION; GLAND; RAS	RET rearrangement was studied in papillary thyroid carcinomas (PTC) of children exposed to radioactive fallout in Belarus after the Chernobyl accident, To detect RET rearrangement in small tissue samples from thyroidectomy specimen (12 PTC of children; 2 PTC and 1 follicular carcinoma of adults; non-tumorous thyroid tissue of 4 children and 4 adults as controls), a RT-multiplex PCR was developed using primers suited to amplify fragments in different quantities depending on the presence or absence of RET rearrangements in the tissues, The type of rearrangement was determined by RT-PCR and direct sequencing using primers for ret/PTC1, 2 and 3, Two-thirds of the papillary thyroid carcinomas of the children revealed a RET rearrangement, with ret/PTC3 being more frequent by a factor of 3 than ret/PTC1. ret/PTC2 was not detected, All RET rearrangement-positive tumors had lymph node metastasis while half of the tumors with wild-type cRET had not, More than half of the cases with ret/PTC3 expressed not only the ELE/RET transcript as expected, but also the RET/ELE transcript, Intrachromosomal rearrangement involving RET and the adjacent H4 or ELE gene on chromosome no, 10 is a very frequent event in thyroid cancer of children of the Chernobyl-contaminated zone of Belarus.	UNIV MUNICH, INST PATHOL, D-80337 MUNICH, GERMANY; UNIV MUNICH, INST RADIAT BIOL, MUNICH, GERMANY; MED HIGH SCH MINSK, CHAIR ONCOL, MINSK, BELARUS	University of Munich; University of Munich								AVANTAGGIATO V, 1994, CELL GROWTH DIFFER, V5, P305; BAVERSTOCK K, 1992, NATURE, V359, P21, DOI 10.1038/359021b0; BONGARZONE I, 1989, ONCOGENE, V4, P1457; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BONGARZONE I, 1994, CANCER RES, V54, P2979; BOS JL, 1989, CANCER RES, V49, P4682; CHOU Q, 1992, NUCLEIC ACIDS RES, V20, P1717, DOI 10.1093/nar/20.7.1717; DIRENZO MF, 1992, ONCOGENE, V7, P2549; EZAKI H, 1991, J RADIAT RES, V32, P193, DOI 10.1269/jrr.32.SUPPLEMENT_193; FABIEN N, 1992, BRIT J CANCER, V66, P1094, DOI 10.1038/bjc.1992.416; FURMANCHUK AW, 1992, HISTOPATHOLOGY, V21, P401, DOI 10.1111/j.1365-2559.1992.tb00423.x; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; ISHIZAKA Y, 1991, ONCOGENE, V6, P1667; ITO T, 1993, CANCER RES, V53, P2940; ITO T, 1992, CANCER RES, V52, P1369; ITO T, 1994, LANCET, V344, P259; JHIANG SM, 1992, ONCOGENE, V7, P1331; JHIANG SM, 1994, CANCER LETT, V78, P69, DOI 10.1016/0304-3835(94)90033-7; JHIANG SM, 1994, J LAB CLIN MED, V123, P331; KAZAKOV VS, 1992, NATURE, V359, P21, DOI 10.1038/359021a0; KUMA K, 1993, MOL BIOL EVOL, V10, P539; KWOK JBJ, 1993, ONCOGENE, V8, P2575; MINOLETTI F, 1994, GENE CHROMOSOME CANC, V11, P51, DOI 10.1002/gcc.2870110108; NAGAO M, 1990, JPN J CANCER RES, V81, P309, DOI 10.1111/j.1349-7006.1990.tb02566.x; NAKAMURA T, 1994, J PATHOL, V172, P255, DOI 10.1002/path.1711720305; PIEROTTI MA, 1992, P NATL ACAD SCI USA, V89, P1616, DOI 10.1073/pnas.89.5.1616; ROTH DB, 1995, CURR BIOL, V5, P496, DOI 10.1016/S0960-9822(95)00101-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO M, 1993, BRIT J CANCER, V68, P460, DOI 10.1038/bjc.1993.370; SANTORO M, 1990, ONCOGENE, V5, P1595; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SANTORO M, 1994, ONCOGENE, V9, P509; SHORE RE, 1993, AM J EPIDEMIOL, V137, P1068, DOI 10.1093/oxfordjournals.aje.a116610; SOZZI G, 1992, GENE CHROMOSOME CANC, V5, P212, DOI 10.1002/gcc.2870050307; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TSUZUKI T, 1995, ONCOGENE, V10, P191; VANHEYNINGEN V, 1994, NATURE, V367, P319, DOI 10.1038/367319a0; WYNFORDTHOMAS D, 1993, CRIT REV ONCOGENESIS, V4, P1; ZOU MJ, 1994, CANCER, V73, P176, DOI 10.1002/1097-0142(19940101)73:1<176::AID-CNCR2820730130>3.0.CO;2-T	40	267	271	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 21	1995	11	12					2459	2467						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545102				2022-12-17	WOS:A1995TP18800001
J	Yin, Y; Shen, WH				Yin, Y.; Shen, W. H.			PTEN: a new guardian of the genome	ONCOGENE			English	Review						PTEN; p53; tumor suppressor; genome guardian; genomic instability; chromosome instability	TUMOR-SUPPRESSOR PTEN; CELL-CYCLE CONTROL; WILD-TYPE P53; HETEROZYGOUS GERMLINE MUTATION; LIPID PHOSPHATASE-ACTIVITY; MAJOR VAULT PROTEIN; COWDEN-DISEASE; BREAST-CANCER; NUCLEAR PTEN; GROWTH SUPPRESSION	The phosphatase and tensin homolog deleted on chromosome 10 (PTEN) tumor suppressor is a phosphatase that antagonizes the phosphoinositol-3-kinase/AKT signaling pathway and suppresses cell survival as well as cell proliferation. PTEN is the second most frequently mutated gene in human cancer after p53. Germline mutations of PTEN have been found in cancer susceptibility syndromes, such as Cowden syndrome, in which over 80% of patients have mutations of PTEN. Homozygous deletion of Pten causes embryonic lethality, suggesting that PTEN is essential for embryonic development. Mice heterozygous for Pten develop spontaneous tumors in a variety of organs comparable with the spectrum of its mutations in human cancer. The mechanisms of PTEN functions in tumor suppression are currently under intense investigation. Recent studies demonstrate that PTEN plays an essential role in the maintenance of chromosomal stability and that loss of PTEN leads to massive alterations of chromosomes. The tumor suppressor p53 is known as a guardian of the genome that mediates the cellular response to environmental stress, leading to cell cycle arrest or cell death. Through completely different mechanisms, PTEN also protects the genome from instability. Thus, we propose that PTEN is a new guardian of the genome. In this review, we will discuss new discoveries on the role of PTEN in tumor suppression and explore mechanisms by which PTEN maintains genomic stability.	[Yin, Y.; Shen, W. H.] Columbia Univ, Dept Radiat Oncol, Coll Phys & Surg, New York, NY 10032 USA	Columbia University	Yin, Y (corresponding author), Columbia Univ, Dept Radiat Oncol, Coll Phys & Surg, VC11-213,630 W 168th St, New York, NY 10032 USA.	yy151@columbia.edu		SHEN, WEN/0000-0002-5830-6518	National Institutes of Health [R01 CA102447]; NATIONAL CANCER INSTITUTE [R01CA102447] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Drs C Walsh and HB Lieberman for their critical comments on the manuscript. This work was supported by a grant from the National Institutes of Health (R01 CA102447 to YY).	Abounader R, 2004, ONCOGENE, V23, P9173, DOI 10.1038/sj.onc.1208146; Agrawal S, 2005, HUM MOL GENET, V14, P2459, DOI 10.1093/hmg/ddi246; Backman SA, 2001, NAT GENET, V29, P396, DOI 10.1038/ng782; Backman SA, 2004, P NATL ACAD SCI USA, V101, P1725, DOI 10.1073/pnas.0308217100; Bai F, 2006, MOL CELL BIOL, V26, P4564, DOI 10.1128/MCB.00266-06; Baker SJ, 2007, CELL, V128, P25, DOI 10.1016/j.cell.2006.12.023; Bilbao C, 2006, INT J CANCER, V119, P563, DOI 10.1002/ijc.21862; BISCHOFF FZ, 1991, ONCOGENE, V6, P183; Borresen-Dale AL, 2003, HUM MUTAT, V21, P292, DOI 10.1002/humu.10174; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chang CJ, 2008, MOL CELL BIOL, V28, P3281, DOI 10.1128/MCB.00310-08; Chang CJ, 2004, J BIOL CHEM, V279, P29841, DOI 10.1074/jbc.M401488200; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Chung JH, 2005, CANCER RES, V65, P4108, DOI 10.1158/0008-5472.CAN-05-0124; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Das S, 2003, P NATL ACAD SCI USA, V100, P7491, DOI 10.1073/pnas.0932835100; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Emerling BM, 2008, P NATL ACAD SCI USA, V105, P2622, DOI 10.1073/pnas.0706790105; Eng C, 2003, HUM MUTAT, V22, P183, DOI 10.1002/humu.10257; Eng C, 1998, NAT GENET, V19, P223, DOI 10.1038/897; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Flores-Delgado G, 2007, J PROTEOME RES, V6, P1165, DOI 10.1021/pr060504h; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Fujisawa H, 2000, LAB INVEST, V80, P65, DOI 10.1038/labinvest.3780009; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Georgescu MM, 2000, CANCER RES, V60, P7033; Gildea JJ, 2004, ONCOGENE, V23, P6788, DOI 10.1038/sj.onc.1207599; Gimm O, 2000, AM J PATHOL, V156, P1693, DOI 10.1016/S0002-9440(10)65040-7; Ginn-Pease ME, 2003, CANCER RES, V63, P282; Gu JG, 1998, J CELL BIOL, V143, P1375, DOI 10.1083/jcb.143.5.1375; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Hong TM, 2000, AM J RESP CELL MOL, V23, P355, DOI 10.1165/ajrcmb.23.3.4002; Iida S, 2000, ANTICANCER RES, V20, P1901; Iida S, 1998, INT J MOL MED, V1, P565; Kanaseki T, 2002, PATHOBIOLOGY, V70, P34, DOI 10.1159/000066001; Kang-Park S, 2003, FEBS LETT, V545, P203, DOI 10.1016/S0014-5793(03)00535-0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kato H, 2000, CLIN CANCER RES, V6, P3937; Kimura T, 2003, DEVELOPMENT, V130, P1691, DOI 10.1242/dev.00392; Koul A, 2002, CANCER, V94, P2369, DOI 10.1002/cncr.10498; Koul D, 2007, MOL CELL BIOCHEM, V300, P77, DOI 10.1007/s11010-006-9371-8; Kurose K, 2002, NAT GENET, V32, P355, DOI 10.1038/ng1013; Lachyankar MB, 2000, J NEUROSCI, V20, P1404; LANE DP, 1992, NATURE, V358, P16; Langerod A, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1675; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Leslie NR, 2007, CURR BIOL, V17, P115, DOI 10.1016/j.cub.2006.12.026; Leslie NR, 2004, BIOCHEM J, V382, P1, DOI 10.1042/BJ20040825; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levine Arnold J., 2004, Cell, VS116, pS67, DOI 10.1016/S0092-8674(04)00036-4; Li DM, 1997, CANCER RES, V57, P2124; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li J, 1998, CANCER RES, V58, P5667; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Liu FH, 2005, J CELL BIOCHEM, V96, P221, DOI 10.1002/jcb.20525; Liu JL, 2005, MOL CELL BIOL, V25, P6211, DOI 10.1128/MCB.25.14.6211-6224.2005; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Mahimainathan L, 2004, J BIOL CHEM, V279, P15258, DOI 10.1074/jbc.M314328200; Maier D, 1999, CANCER RES, V59, P5479; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Matsushima-Nishiu M, 2001, CANCER RES, V61, P3741; Mayo LD, 2002, TRENDS BIOCHEM SCI, V27, P462, DOI 10.1016/S0968-0004(02)02166-7; Mayo MW, 2002, J BIOL CHEM, V277, P11116, DOI 10.1074/jbc.M108670200; McGarrity TJ, 2003, AM J GASTROENTEROL, V98, P1429, DOI 10.1016/S0002-9270(03)00276-4; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Minaguchi T, 2006, CANCER RES, V66, P11677, DOI 10.1158/0008-5472.CAN-06-2240; Moon SK, 2004, ARCH BIOCHEM BIOPHYS, V421, P267, DOI 10.1016/j.abb.2003.11.007; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nan B, 2003, J MOL ENDOCRINOL, V31, P169, DOI 10.1677/jme.0.0310169; Okumura K, 2005, CELL CYCLE, V4, P540, DOI 10.4161/cc.4.4.1614; Paramio JM, 1999, ONCOGENE, V18, P7462, DOI 10.1038/sj.onc.1203151; Park MJ, 2002, CANCER RES, V62, P6318; Parsons R, 2004, SEMIN CELL DEV BIOL, V15, P171, DOI 10.1016/j.semcdb.2003.12.021; Perren A, 2000, AM J PATHOL, V157, P1097, DOI 10.1016/S0002-9440(10)64624-X; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Puc J, 2005, CANCER CELL, V7, P193, DOI 10.1016/j.ccr.2005.01.009; Puc J, 2005, CELL CYCLE, V4, P927, DOI 10.4161/cc.4.7.1795; QUELLE DE, 1995, ONCOGENE, V11, P635; Raftopoulou M, 2004, SCIENCE, V303, P1179, DOI 10.1126/science.1092089; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Saal LH, 2008, NAT GENET, V40, P102, DOI 10.1038/ng.2007.39; Sano T, 1999, CANCER RES, V59, P1820; Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141; Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042; Shin KH, 2002, INT J ONCOL, V21, P997; Shmueli A, 2005, CELL, V121, P963, DOI 10.1016/j.cell.2005.06.018; Shmueli A, 2004, MOL CELL, V13, P4, DOI 10.1016/S1097-2765(03)00529-X; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stambolic V, 2000, CANCER RES, V60, P3605; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STRONG LC, 1992, AM J EPIDEMIOL, V135, P190, DOI 10.1093/oxfordjournals.aje.a116271; Sulis ML, 2003, TRENDS CELL BIOL, V13, P478, DOI 10.1016/S0962-8924(03)00175-2; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tang YF, 2006, CANCER RES, V66, P736, DOI 10.1158/0008-5472.CAN-05-1557; TLSTY TD, 1994, COLD SPRING HARB SYM, V59, P265, DOI 10.1101/SQB.1994.059.01.031; Trotman LC, 2006, NATURE, V441, P523, DOI 10.1038/nature04809; Trotman LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040; Vivanco I, 2007, CANCER CELL, V11, P555, DOI 10.1016/j.ccr.2007.04.021; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Waite KA, 2002, AM J HUM GENET, V70, P829, DOI 10.1086/340026; Wang SI, 1997, CANCER RES, V57, P4183; Wang XJ, 2007, CELL, V128, P129, DOI 10.1016/j.cell.2006.11.039; WEINBERG RA, 1992, CANCER SURV, V12, P43; Weng LP, 2002, HUM MOL GENET, V11, P1687, DOI 10.1093/hmg/11.15.1687; Weng LP, 2001, HUM MOL GENET, V10, P237, DOI 10.1093/hmg/10.3.237; Weng LP, 2001, HUM MOL GENET, V10, P605, DOI 10.1093/hmg/10.6.605; Whiteman DC, 2002, INT J CANCER, V99, P63, DOI 10.1002/ijc.10294; Woiwode A, 2008, MOL CELL BIOL, V28, P4204, DOI 10.1128/MCB.01912-07; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	122	266	273	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 15	2008	27	41					5443	5453		10.1038/onc.2008.241	http://dx.doi.org/10.1038/onc.2008.241			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349KW	18794879				2022-12-17	WOS:000259280700006
J	Ferguson, DO; Alt, FW				Ferguson, DO; Alt, FW			DNA double strand break repair and chromosomal translocation: Lessons from animal models	ONCOGENE			English	Article						translocation; non-homologous end joining; homologous recombination; double strand break repair; loss of heterozygosity; oncogenesis	END-JOINING PATHWAY; V(D)J RECOMBINATION; NONRECIPROCAL TRANSLOCATIONS; GENOMIC STABILITY; VERTEBRATE CELLS; MAMMALIAN-CELLS; TUMOR-FORMATION; TUMORIGENESIS; PROTEINS; MICE	The maintenance of genomic stability is one of the most important defenses against neoplastic transformation. This objective must be accomplished despite a constant barrage of spontaneous DNA double strand breaks. These dangerous lesions are corrected by two primary pathways of double strand break repair; non homologous end joining and homologous recombination. Recent studies employing mouse models have shown that absence of either pathway leads to genomic instability, including potentially oncogenic translocations. Because translocations involve the union of different chromosomes, cellular machinery must exist that creates these structures in the context of unrepaired double strand breaks. Evidence is mounting that the pathways of double strand break repair that are so important for survival may themselves be the culprits that generate potentially fatal translocations. Evidence and models for the dual roles of double strand break repair in both preventing, and generating, oncogenic karyotypic changes are discussed.	Harvard Univ, Sch Med, Childrens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Alt, FW (corresponding author), Harvard Univ, Sch Med, Childrens Hosp, Enders Bldg,Room 861,Mail Stop EN-334,320 Longwoo, Boston, MA 02115 USA.							Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Bailey SM, 1999, P NATL ACAD SCI USA, V96, P14899, DOI 10.1073/pnas.96.26.14899; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bosco G, 1998, GENETICS, V150, P1037; Coleman AE, 1999, BLOOD, V93, P4442, DOI 10.1182/blood.V93.12.4442; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; Ferguson DO, 2000, P NATL ACAD SCI USA, V97, P6630, DOI 10.1073/pnas.110152897; Ferguson DO, 1996, P NATL ACAD SCI USA, V93, P5419, DOI 10.1073/pnas.93.11.5419; Frank KM, 2000, MOL CELL, V5, P993, DOI 10.1016/S1097-2765(00)80264-6; Fugmann SD, 2000, ANNU REV IMMUNOL, V18, P495, DOI 10.1146/annurev.immunol.18.1.495; Gao YJ, 2000, NATURE, V404, P897, DOI 10.1038/35009138; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; Haber JE, 1999, TRENDS BIOCHEM SCI, V24, P271, DOI 10.1016/S0968-0004(99)01413-9; Haber JE, 2000, CURR OPIN CELL BIOL, V12, P286, DOI 10.1016/S0955-0674(00)00090-9; Hilgenfeld E, 1999, CURR TOP MICROBIOL, V246, P169; HOLLIDAY R, 1967, MUTAT RES, V4, P275, DOI 10.1016/0027-5107(67)90022-X; Holmes AM, 1999, CELL, V96, P415, DOI 10.1016/S0092-8674(00)80554-1; HOWARD-FLANDERS P., 1966, Radiation Research, V6, P156, DOI 10.2307/3583555; Jeggo PA, 1998, RADIAT RES, V150, pS80, DOI 10.2307/3579810; Johnson RD, 2000, EMBO J, V19, P3398, DOI 10.1093/emboj/19.13.3398; Karanjawala ZE, 1999, CURR BIOL, V9, P1501, DOI 10.1016/S0960-9822(00)80123-2; KOMORI T, 1993, SCIENCE, V261, P1171, DOI 10.1126/science.8356451; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; Lieber MR, 1999, GENES CELLS, V4, P77, DOI 10.1046/j.1365-2443.1999.00245.x; Liyanage M, 1996, NAT GENET, V14, P312, DOI 10.1038/ng1196-312; Loeb KR, 2000, CARCINOGENESIS, V21, P379, DOI 10.1093/carcin/21.3.379; Malkova A, 1996, P NATL ACAD SCI USA, V93, P7131, DOI 10.1073/pnas.93.14.7131; McClintock B, 1941, GENETICS, V26, P234; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Nacht M, 1996, GENE DEV, V10, P2055, DOI 10.1101/gad.10.16.2055; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Petrini JHJ, 2000, CURR OPIN CELL BIOL, V12, P293, DOI 10.1016/S0955-0674(00)00091-0; Pfeiffer P, 2000, MUTAGENESIS, V15, P289, DOI 10.1093/mutage/15.4.289; Richardson C, 2000, NATURE, V405, P697, DOI 10.1038/35015097; Richardson C, 2000, MOL CELL BIOL, V20, P9068, DOI 10.1128/MCB.20.23.9068-9075.2000; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Sekiguchi JM, 1999, COLD SPRING HARB SYM, V64, P169, DOI 10.1101/sqb.1999.64.169; Shinohara A, 1999, MUTAT RES-DNA REPAIR, V435, P13, DOI 10.1016/S0921-8777(99)00033-6; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Vanasse GJ, 1999, J CLIN INVEST, V103, P1669, DOI 10.1172/JCI6658; Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705; Wood RD, 2001, SCIENCE, V291, P1284, DOI 10.1126/science.1056154; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743	52	266	279	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 10	2001	20	40					5572	5579		10.1038/sj.onc.1204767	http://dx.doi.org/10.1038/sj.onc.1204767			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	470TP	11607810				2022-12-17	WOS:000170887500001
J	Cabannes, E; Khan, G; Aillet, F; Jarrett, RF; Hay, RT				Cabannes, E; Khan, G; Aillet, F; Jarrett, RF; Hay, RT			Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for I kappa B alpha	ONCOGENE			English	Article						Hodgkin's lymphoma; tumour suppressor; I kappa B alpha; NF-kappa B	REED-STERNBERG CELLS; TRANSCRIPTION FACTORS; EXPRESSION; ACTIVATION; PROTEINS; KINASE; MICE; ONCOGENESIS; LINES; BETA	The NF-kappa B/Rel family of transcription factors regulates wide variety of genes whose products play a fundamental role in inflammatory and immune responses. The implication of NF-kappa B/Rel proteins and their I kappa B regulatory subunits in the control of cellular growth and oncogenesis, was suggested by the induction of fatal lymphomas in birds by the v-rel oncoprotein, and the rearrangement and amplification of several genes encoding the NF-kappa B/Rel/I kappa B signal transduction factors in human malignancies, primarily of lymphoid origin. Hodgkin's disease (HD) is a lymphoma characterized by a low frequency of malignant Hodgkin and Reed-Sternberg (H/RS) cells in a reactive background of nonneoplastic cells. The peculiar activated phenotype of Hodgkin and Reed-Sternberg cells and their pattern of cytokine secretion are believed to be a consequence of constitutive activation of the NF-kappa B transcription factor. Here, we report the detection of mutations of the 1k Ba gene, in two HD-derived cell lines and in two out of eight biopsy samples from patients with relapsed Hodgkin's disease. The presence of defective I kappa B alpha is thus likely to explain the constitutive activation of NF-kappa B in these cells and suggests that I kappa B alpha is a tumour suppressor controlling the oncogenic activation of NF-kappa B in Hodgkin and Reed-Sternberg cells.	Univ St Andrews, Sch Biomed Sci, St Andrews KY16 9ST, Fife, Scotland; Univ Glasgow, Sch Vet, Dept Vet Pathol, LRF Virus Ctr, Glasgow G61 1QH, Lanark, Scotland	University of St Andrews; University of Glasgow	Hay, RT (corresponding author), Univ St Andrews, Sch Biomed Sci, Biomol Sci Bldg, St Andrews KY16 9ST, Fife, Scotland.		Hay, Ronald T/F-9338-2011; Khan, Gulfaraz/AAC-2859-2022; Hay, Ronald/S-3233-2019; Jarrett, Ruth F/A-5570-2012	Hay, Ronald T/0000-0001-7113-9024; Khan, Gulfaraz/0000-0001-6836-1783; Hay, Ronald/0000-0001-7113-9024; 				ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Bargou RC, 1996, BLOOD, V87, P4340, DOI 10.1182/blood.V87.10.4340.bloodjournal87104340; BEAUPARLANT P, 1994, ONCOGENE, V9, P3189; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DIEHL V, 1996, BAILLIERES CLIN HAEM, V9; DREXLER HG, 1993, LEUKEMIA LYMPHOMA, V9, P1, DOI 10.3109/10428199309148499; Gilmore TD, 1996, ONCOGENE, V13, P1367; GILMORE TD, 1995, DNA PROVIRUS, P109; Gruss HJ, 1996, BAILLIERE CLIN HAEM, V9, P417, DOI 10.1016/S0950-3536(96)80019-9; Gruss HJ, 1997, IMMUNOL TODAY, V18, P156, DOI 10.1016/S0167-5699(97)84661-0; GRUSS HJ, 1992, CANCER RES, V52, P3353; Gruss HJ, 1996, LEUKEMIA LYMPHOMA, V20, P397, DOI 10.3109/10428199609052421; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; Hirano F, 1998, MOL CELL BIOL, V18, P2596, DOI 10.1128/MCB.18.5.2596; ITO CY, 1995, GENOMICS, V29, P490, DOI 10.1006/geno.1995.9977; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; JUNG M, 1995, SCIENCE, V268, P1619, DOI 10.1126/science.7777860; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; Klement JF, 1996, MOL CELL BIOL, V16, P2341; Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; Luque I, 1997, SEMIN CANCER BIOL, V8, P103, DOI 10.1006/scbi.1997.0061; Mosialos G, 1997, SEMIN CANCER BIOL, V8, P121, DOI 10.1006/scbi.1997.0063; Sonenshein GE, 1997, SEMIN CANCER BIOL, V8, P113, DOI 10.1006/scbi.1997.0062; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; Sylla BS, 1998, P NATL ACAD SCI USA, V95, P10106, DOI 10.1073/pnas.95.17.10106; TROELSTRA C, 1993, NUCLEIC ACIDS RES, V21, P419, DOI 10.1093/nar/21.3.419; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058; Wood KM, 1998, ONCOGENE, V16, P2131, DOI 10.1038/sj.onc.1201735	37	266	272	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	1999	18	20					3063	3070		10.1038/sj.onc.1202893	http://dx.doi.org/10.1038/sj.onc.1202893			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197WB	10340377				2022-12-17	WOS:000080388000001
J	RAPP, UR				RAPP, UR			ROLE OF RAF-1 SERINE THREONINE PROTEIN-KINASE IN GROWTH-FACTOR SIGNAL TRANSDUCTION	ONCOGENE			English	Article							A-RAF; V-RAF; CARRYING RETROVIRUS; SRC FAMILY; C-FOS; ONCOGENE; PHOSPHORYLATION; ACTIVATION; CELLS; TRANSFORMATION				RAPP, UR (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21702, USA.							AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BECK TW, 1991, IN PRESS BIOCH BIOPH; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HEIDECKER G, 1989, GENES SIGNAL TRANSDU, P339; HULEIHEL M, 1986, MOL CELL BIOL, V6, P2655, DOI 10.1128/MCB.6.7.2655; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; KISS Z, 1988, FEBS LETT, V240, P221, DOI 10.1016/0014-5793(88)80372-7; KOLCH W, 1990, GROWTH REGULATION CA, V1, P279; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; MARK GE, 1984, SCIENCE, V224, P285, DOI 10.1126/science.6324342; MARK GE, 1987, MOL CELL BIOL, V7, P2134, DOI 10.1128/MCB.7.6.2134; MARK GE, 1984, J BIOL S8A, V63; MIHALY A, 1990, NEUROSCI LETT, V116, P45, DOI 10.1016/0304-3940(90)90384-L; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MORRISON DK, 1989, CELL, V58, P648; NISHIDA Y, 1988, EMBO J, V7, P775, DOI 10.1002/j.1460-2075.1988.tb02875.x; OLAH Z, 1990, IN PRESS EXP BRAIN R; PRINCIPATO M, 1990, MOL CELL BIOL, V10, P3562, DOI 10.1128/MCB.10.7.3562; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAPP UR, 1987, CANCER REV, V9, P34; RAPP UR, 1988, HDB ONCOGENES, P213; RAPP UR, 1987, ONCOGENES CANCER, P55; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SIEGEL JN, 1990, IN PRESS J BIOL CHEM; SITHANANDAM G, 1990, ONCOGENE, V5, P1775; SMITH MR, 1990, MOL CELL BIOL, V10, P3828, DOI 10.1128/MCB.10.7.3828; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STORM S M, 1990, Critical Reviews in Oncogenesis, V2, P1; STORM SM, 1990, ONCOGENE, V5, P345; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TURNER B, 1990, IN PRESS P NATL ACAD; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247	43	266	272	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					495	500						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	2030909				2022-12-17	WOS:A1991FR93900001
J	Arvand, A; Denny, CT				Arvand, A; Denny, CT			Biology of EWS/ETS fusions in Ewing's family tumors	ONCOGENE			English	Review						EWS/ETS; Ewing's family tumors; aberrant transcription factors	RNA-BINDING PROTEIN; PRIMITIVE NEUROECTODERMAL TUMOR; EWS CHIMERIC TRANSCRIPTS; HUMAN MYELOID-LEUKEMIA; ROUND-CELL TUMORS; ETS-FAMILY; DNA-BINDING; CHROMOSOME-TRANSLOCATION; SARCOMA TRANSLOCATION; MALIGNANT-MELANOMA	Tumor-associated chromosomal translocations lead to the formation of chimeric fusions between the EWS gene and one of five different ETS transcription factors in Ewing's family tumors (EFTs). The resultant EWS/ETS proteins promote oncogenesis in a dominant fashion in model systems and are necessary for continued growth of EFT cell lines. EWS belongs to a family of genes that encode proteins that may serve as adapters between the RNA polymerase II complex and RNA splicing factors. EWS/ETS fusions have biochemical characteristics of aberrant transcription factors and appear to promote abnormal cellular growth by transcriptionally modulating a network of target genes. Early evidence suggests that EWS/ETS proteins may also impact gene expression through alteration in RNA processing. Elucidation of EWS/ETS target gene networks in the context of other signaling pathways will hopefully lead to biology based therapeutic strategies for EFT.	Univ Calif Los Angeles, Inst Mol Biol, Gwynee Hazen Cherry Mem Lab, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Jonsson Comprehens Ctr, Gwynee Hazen Cherry Mem Lab, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Dept Pathol & Lab Med, Gwynee Hazen Cherry Mem Lab, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Dept Pediat, Gwynee Hazen Cherry Mem Lab, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Denny, CT (corresponding author), Univ Calif Los Angeles, Inst Mol Biol, Gwynee Hazen Cherry Mem Lab, Los Angeles, CA 90024 USA.				PHS HHS [R01-87771] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Athanasiou M, 1996, CELL GROWTH DIFFER, V7, P1525; Attwooll C, 1999, ONCOGENE, V18, P7599, DOI 10.1038/sj.onc.1203156; AURIAS A, 1984, CANCER GENET CYTOGEN, V12, P21, DOI 10.1016/0165-4608(84)90003-7; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Bastian LS, 1999, BLOOD, V93, P2637, DOI 10.1182/blood.V93.8.2637.408k20_2637_2644; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; Blair DG, 2000, ONCOGENE, V19, P6472, DOI 10.1038/sj.onc.1204046; Brown LA, 2000, MECH DEVELOP, V90, P237, DOI 10.1016/S0925-4773(99)00256-7; Burchill SA, 1997, EUR J CANCER, V33, P239, DOI 10.1016/S0959-8049(96)00463-7; CAVAZZANA AO, 1987, AM J PATHOL, V127, P507; Clark J, 1996, ONCOGENE, V12, P229; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; Dalgleish P, 2000, NUCLEIC ACIDS RES, V28, P560, DOI 10.1093/nar/28.2.560; Darby TG, 1997, ONCOGENE, V15, P3067, DOI 10.1038/sj.onc.1201503; de Alava E, 1998, J CLIN ONCOL, V16, P1248, DOI 10.1200/JCO.1998.16.4.1248; DELATTRE O, 1994, NEW ENGL J MED, V331, P294, DOI 10.1056/NEJM199408043310503; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Deloulme JC, 1997, J BIOL CHEM, V272, P27369, DOI 10.1074/jbc.272.43.27369; Deveaux S, 1996, BLOOD, V87, P4678, DOI 10.1182/blood.V87.11.4678.bloodjournal87114678; Dhulipala PDK, 1998, ONCOGENE, V17, P1149, DOI 10.1038/sj.onc.1202030; Felsch JS, 1999, CURR BIOL, V9, P485, DOI 10.1016/S0960-9822(99)80214-0; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Guinamard R, 1997, SCAND J IMMUNOL, V45, P587, DOI 10.1046/j.1365-3083.1997.d01-447.x; Hahm KB, 1999, NAT GENET, V23, P481, DOI 10.1038/70611; Hallier M, 1998, J BIOL CHEM, V273, P4838, DOI 10.1074/jbc.273.9.4838; Hart A, 2000, IMMUNITY, V13, P167, DOI 10.1016/S1074-7613(00)00017-0; Hicks GG, 2000, NAT GENET, V24, P175, DOI 10.1038/72842; ICHIKAWA H, 1994, CANCER RES, V54, P2865; Im YH, 2000, CANCER RES, V60, P1536; IMMANUEL D, 1995, MOL CELL BIOL, V15, P4562; Jaishankar S, 1999, ONCOGENE, V18, P5592, DOI 10.1038/sj.onc.1202940; Javelaud D, 2000, ONCOGENE, V19, P61, DOI 10.1038/sj.onc.1203246; JEON IS, 1995, ONCOGENE, V10, P1229; Kaneko Y, 1996, GENE CHROMOSOME CANC, V15, P115, DOI 10.1002/(SICI)1098-2264(199602)15:2<115::AID-GCC6>3.0.CO;2-6; Knoop LL, 2000, J BIOL CHEM, V275, P24865, DOI 10.1074/jbc.M001661200; Kontny HU, 1998, CANCER RES, V58, P5842; KOVAR H, 1990, ONCOGENE, V5, P1067; Kovar H, 1997, ONCOGENE, V15, P2225, DOI 10.1038/sj.onc.1201397; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; Kuroda M, 2000, EMBO J, V19, P453, DOI 10.1093/emboj/19.3.453; Kwiatkowski BA, 2000, BLOOD CELL MOL DIS, V26, P84, DOI 10.1006/bcmd.2000.0282; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; LABELLE Y, 1995, HUM MOL GENET, V4, P2219, DOI 10.1093/hmg/4.12.2219; LADANYI M, 1994, CANCER RES, V54, P2837; Lambert G, 2000, BIOCHEM BIOPH RES CO, V279, P401, DOI 10.1006/bbrc.2000.3963; LESSNICK SL, 1995, ONCOGENE, V10, P423; Li RZ, 2000, ONCOGENE, V19, P6514, DOI 10.1038/sj.onc.1204035; Mager AM, 1998, INT J DEV BIOL, V42, P561; MagnaghiJaulin L, 1996, NUCLEIC ACIDS RES, V24, P1052, DOI 10.1093/nar/24.6.1052; MAO XH, 1994, J BIOL CHEM, V269, P18216; Maroulakou IG, 2000, ONCOGENE, V19, P6432, DOI 10.1038/sj.onc.1204039; Mastrangelo T, 2000, ONCOGENE, V19, P3799, DOI 10.1038/sj.onc.1203762; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Melet F, 1996, MOL CELL BIOL, V16, P2708; MEYER D, 1993, MECH DEVELOP, V44, P109, DOI 10.1016/0925-4773(93)90061-2; Mitsiades N, 1999, J NATL CANCER I, V91, P1678, DOI 10.1093/jnci/91.19.1678; Morrison SJ, 1999, CELL, V96, P737, DOI 10.1016/S0092-8674(00)80583-8; OHNO T, 1994, ONCOGENE, V9, P3087; OHNO T, 1993, CANCER RES, V53, P5859; OUCHIDA M, 1995, ONCOGENE, V11, P1049; Panagopoulos I, 1996, ONCOGENE, V12, P489; Pereira R, 1999, ONCOGENE, V18, P1597, DOI 10.1038/sj.onc.1202534; Perrotti D, 2000, MOL CELL BIOL, V20, P6159, DOI 10.1128/MCB.20.16.6159-6169.2000; Perrotti D, 1998, EMBO J, V17, P4442, DOI 10.1093/emboj/17.15.4442; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; Powers CA, 1998, MOL ENDOCRINOL, V12, P4, DOI 10.1210/mend.12.1.0043; PRASAD DDK, 1994, ONCOGENE, V9, P3717; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RAO VN, 1993, ONCOGENE, V8, P2167; RAUSCHER FJ, 1994, COLD SPRING HARB SYM, V59, P137, DOI 10.1101/SQB.1994.059.01.017; Sanceau J, 2000, ONCOGENE, V19, P3372, DOI 10.1038/sj.onc.1203670; Sarrazin S, 2000, MOL CELL BIOL, V20, P2959, DOI 10.1128/MCB.20.9.2959-2969.2000; Scotlandi K, 2000, CANCER RES, V60, P5134; Scotlandi K, 2000, INT J CANCER, V87, P328, DOI 10.1002/1097-0215(20000801)87:3<328::AID-IJC4>3.0.CO;2-1; Sjogren H, 1999, CANCER RES, V59, P5064; Sohn HW, 1998, AM J PATHOL, V153, P1937, DOI 10.1016/S0002-9440(10)65707-0; SORENSEN PHB, 1995, CANCER RES, V55, P1385; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Spyropoulos DD, 2000, MOL CELL BIOL, V20, P5643, DOI 10.1128/MCB.20.15.5643-5652.2000; STOLOW DT, 1995, NUCLEIC ACIDS RES, V23, P835, DOI 10.1093/nar/23.5.835; Tamir A, 1999, MOL CELL BIOL, V19, P4452; Tanaka K, 1997, J CLIN INVEST, V99, P239, DOI 10.1172/JCI119152; Teitell MA, 1999, LAB INVEST, V79, P1535; Thompson AD, 1999, ONCOGENE, V18, P5506, DOI 10.1038/sj.onc.1202928; Thorner P, 1996, AM J PATHOL, V148, P1125; TRICHE TJ, 1987, MAJOR PROBLEMS PATHO, V18, P145; Truong AHL, 2000, ONCOGENE, V19, P6482, DOI 10.1038/sj.onc.1204042; TURCCAREL C, 1984, CANCER GENET CYTOGEN, V12, P1, DOI 10.1016/0165-4608(84)90002-5; Urano F, 1996, BIOCHEM BIOPH RES CO, V219, P608, DOI 10.1006/bbrc.1996.0281; Watson DK, 1997, ONCOGENE, V14, P213, DOI 10.1038/sj.onc.1200839; Watson DK, 2000, ONCOGENE, V19, P6394, DOI 10.1038/sj.onc.1204070; Wei G, 2000, CANCER-AM CANCER SOC, V89, P793, DOI 10.1002/1097-0142(20000815)89:4<793::AID-CNCR11>3.0.CO;2-M; Yang L, 2000, J BIOL CHEM, V275, P37612, DOI 10.1074/jbc.M005739200; Yang L, 2000, MOL CELL BIOL, V20, P3345, DOI 10.1128/MCB.20.10.3345-3354.2000; Yang L, 1998, J BIOL CHEM, V273, P27761, DOI 10.1074/jbc.273.43.27761; ZHANG LQ, 1995, MOL CELL BIOL, V15, P6961; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; Zinszner H, 1997, J CELL SCI, V110, P1741; Zoubek A, 1996, J CLIN ONCOL, V14, P1245, DOI 10.1200/JCO.1996.14.4.1245; ZOUBEK A, 1994, BRIT J CANCER, V70, P908, DOI 10.1038/bjc.1994.419; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x; Zwerner JP, 2001, ONCOGENE, V20, P626, DOI 10.1038/sj.onc.1204133	108	265	274	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2001	20	40					5747	5754		10.1038/sj.onc.1204598	http://dx.doi.org/10.1038/sj.onc.1204598			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	470TP	11607824				2022-12-17	WOS:000170887500015
J	HIBI, K; TAKAHASHI, T; SEKIDO, Y; UEDA, R; HIDA, T; ARIYOSHI, Y; TAKAGI, H; TAKAHASHI, T				HIBI, K; TAKAHASHI, T; SEKIDO, Y; UEDA, R; HIDA, T; ARIYOSHI, Y; TAKAGI, H; TAKAHASHI, T			COEXPRESSION OF THE STEM-CELL FACTOR AND THE C-KIT GENES IN SMALL-CELL LUNG-CANCER	ONCOGENE			English	Article							GROWTH-FACTOR; SI-LOCUS; EXPRESSION; LIGAND; MOUSE; AMPLIFICATION; PROLIFERATION; RECEPTOR; INVITRO; P53	Stem cell factor (SCF) is a pluripotent growth factor which is suggested to play an important role in proliferation and differentiation in various types of fetal and adult tissues as the ligand of the c-kit proto-oncogene product. However, very little is known about expression of the SCF gene in human malignancies. We analysed DNA and RNA extracted from 28 cell lines and 16 fresh tumor specimens of lung cancer as well as 24 cancer cell lines of various origin for SCF expression. Now we report that the SCF gene is expressed in a wide variety of human cancers including lung cancer, in marked contrast to c-kit, which is expressed in very few types of cancers. As a consequence, coexpression of both the ligand and the receptor is seen only in small-cell lung cancer, suggesting possible involvement of autocrine stimulation via this ligand-receptor system in the pathogenesis of this aggressive cancer. In addition, this study revealed that the human SCF gene is transcribed into two major forms of alternatively spliced mRNAs with different molar ratio in fetal, adult and malignant tissues.	AICHI CANC CTR,CHEMOTHERAPY LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR,IMMUNOL LAB,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR,DEPT INTERNAL MED,NAGOYA,AICHI 464,JAPAN; NAGOYA UNIV,SCH MED,DEPT SURG 2,NAGOYA,AICHI 466,JAPAN; NAGOYA UNIV,SCH MED,DEPT INTERNAL MED 1,NAGOYA,AICHI 466,JAPAN	Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; Nagoya University; Nagoya University			Takahashi, Takashi/I-7262-2014; Sekido, Yoshitaka/P-9756-2015	Takahashi, Takashi/0000-0003-0615-7001; Sekido, Yoshitaka/0000-0002-2428-3848				ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; DEXTER TM, 1977, NATURE, V269, P412, DOI 10.1038/269412a0; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MATSUI Y, 1990, NATURE, V347, P667, DOI 10.1038/347667a0; MCCULLOC.EA, 1965, BLOOD-J HEMATOL, V26, P399, DOI 10.1182/blood.V26.4.399.399; MINNA JD, 1986, COLD SPRING HARB SYM, V51, P843, DOI 10.1101/SQB.1986.051.01.098; MINNA JD, 1989, CC MOL BIOL, P57; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; NAKANISHI Y, 1988, J CLIN INVEST, V82, P354, DOI 10.1172/JCI113594; SEKIDO Y, 1991, CANCER RES, V51, P2416; TAKAHASHI T, 1989, CANCER RES, V49, P2683; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1986, CANCER RES, V46, P4770; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; VOSTREJS M, 1988, J CLIN INVEST, V82, P331, DOI 10.1172/JCI113591; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	21	265	296	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2291	2296						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1722571				2022-12-17	WOS:A1991GX73500017
J	Wang, R; Wang, ZX; Yang, JS; Pan, X; De, W; Chen, LB				Wang, R.; Wang, Z-X; Yang, J-S; Pan, X.; De, W.; Chen, L-B			MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14)	ONCOGENE			English	Article						microRNA; non-small cell lung cancer; miR-451; RAB14	EXPRESSION; GROWTH; RNA; RESISTANCE; PATTERNS; MIR-451	Accumulating evidence suggests that microRNAs (miRNAs) are important gene regulators, which can have critical roles in diverse biological processes including tumorigenesis. In this study, we analyzed the miRNA expression profiles in non-small cell lung carcinoma (NSCLC) by use of a miRNA microarray platform and identified 40 differentially expressed miRNAs. We showed that miRNA (miR)-451 was the most downregulated in NSCLC tissues. The expression level of miR-451 was found to be significantly correlated with tumor differentiation, pathological stage and lymph-node metastasis. Moreover, low miR-451 expression level was also correlated with shorter overall survival of NSCLC patients (P<0.001). Ectopic miR-451 expression significantly suppressed the in vitro proliferation and colony formation of NSCLC cells and the development of tumors in nude mice by enhancing apoptosis, which might be associated with inactivation of Akt signaling pathway. Interestingly, ectopic miR-451 expression could significantly inhibit RAB14 protein expression and decrease a luciferase-reporter activity containing the RAB14 3'-untranslated region (UTR). In addition,, RNA interference silencing of RAB14 gene could recapitulate the tumor suppressor function of miR-451, whereas restoration of RAB14 expression could partially attenuate the tumor suppressor function of miR-451 in NSCLC cells. Furthermore, we also showed that strong positive immunoreactivity of RAB14 protein was significantly associated with downregulation of miR-451 (P = 0.01). These findings suggest that miR-451 regulates survival of NSCLC cells partially through the downregulation of RAB14. Therefore, targeting with the miR-451/RAB14 interaction might serve as a novel therapeutic application to treat NSCLC patients. Oncogene (2011) 30, 2644-2658; doi:10.1038/onc.2010.642; published online 28 February 2011	[Wang, R.; Chen, L-B] Nanjing Univ, Sch Med, Jinling Hosp, Dept Med Oncol, Nanjing 210002, Jiangsu, Peoples R China; [Wang, Z-X; Pan, X.] Nanjing Med Univ, Affiliated Hosp 2, Dept Oncol, Nanjing 210002, Jiangsu, Peoples R China; [Yang, J-S] Nanjing Med Univ, Affiliated Nanjing Hosp 1, Dept Oncol, Nanjing 210002, Jiangsu, Peoples R China; [Yang, J-S; De, W.] Nanjing Med Univ, Dept Biochem & Mol Biol, Nanjing 210002, Jiangsu, Peoples R China	Nanjing University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University	Chen, LB (corresponding author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Med Oncol, 315 Zhongshan E Rd, Nanjing 210002, Jiangsu, Peoples R China.	dewei_nanjing@yahoo.com.cn; chenlongbang@yeah.net			National Science Foundation of China (NSFC) [30872979, 30901440, 30973477]; National Natural Science Foundation of China [30973477, BK2010590]; Medical Science Development Subject in Science and Technology Project of Nanjing [ZKX08017, YKK08091]	National Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Medical Science Development Subject in Science and Technology Project of Nanjing	We acknowledge the excellent technical support and sincere help of the Functional Genomics and Bioinformatics cores of Harbin Medical University, and the Animal Resources Center of School of Medicine, Nanjing University. We thank Zhang Ai-Ping and Cao Lei for assistance with obtaining tissue samples, Huang Gui-Chun for assistance with BALB/c athymic node mouse, and Xu Lin-Yong for assistance with statistical analysis. This study was supported by the National Science Foundation of China (NSFC 30872979, 30901440, and 30973477), the National Natural Science Foundation of China (No. 30973477 and BK2010590), and the Medical Science Development Subject in Science and Technology Project of Nanjing (Grant No. ZKX08017 and YKK08091).	Agarwal R, 2009, TRAFFIC, V10, P1561, DOI 10.1111/j.1600-0854.2009.00969.x; Bandres E, 2009, CLIN CANCER RES, V15, P2281, DOI 10.1158/1078-0432.CCR-08-1818; Baranwal S, 2010, INT J CANCER, V126, P1283, DOI 10.1002/ijc.25014; Behm-Ansmant I, 2006, COLD SPRING HARB SYM, V71, P523, DOI 10.1101/sqb.2006.71.013; Brognard J, 2001, CANCER RES, V61, P3986; Caruso P, 2010, ARTERIOSCL THROM VAS, V30, P716, DOI 10.1161/ATVBAHA.109.202028; Chaudhuri K, 2007, DNA CELL BIOL, V26, P321, DOI 10.1089/dna.2006.0549; Cheng KW, 2005, CANCER RES, V65, P2516, DOI 10.1158/0008-5472.CAN-05-0573; Gal H, 2008, BIOCHEM BIOPH RES CO, V376, P86, DOI 10.1016/j.bbrc.2008.08.107; Gordeladze JO, 2009, ACTA PHARMACOL SIN, V30, P1369, DOI 10.1038/aps.2009.143; Guo CG, 2008, GENE CHROMOSOME CANC, V47, P939, DOI 10.1002/gcc.20596; Hu Z, 2005, CLIN CANCER RES, V11, P4646, DOI 10.1158/1078-0432.CCR-04-2013; Hui ABY, 2010, CLIN CANCER RES, V16, P1129, DOI 10.1158/1078-0432.CCR-09-2166; Hummel R, 2010, EUR J CANCER, V46, P298, DOI 10.1016/j.ejca.2009.10.027; Iorio MV, 2009, J CLIN ONCOL, V27, P5848, DOI 10.1200/JCO.2009.24.0317; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Ju XL, 2009, PEDIATR HEMAT ONCOL, V26, P1, DOI 10.1080/08880010802378338; Kardassis D, 2009, FEBS J, V276, P2947, DOI 10.1111/j.1742-4658.2009.07031.x; Kovalchuk O, 2008, MOL CANCER THER, V7, P2152, DOI 10.1158/1535-7163.MCT-08-0021; MAKOS M, 1992, P NATL ACAD SCI USA, V89, P1929, DOI 10.1073/pnas.89.5.1929; Masaki S, 2007, BIOCHEM BIOPH RES CO, V364, P509, DOI 10.1016/j.bbrc.2007.10.077; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; Peter ME, 2010, ONCOGENE, V29, P2161, DOI 10.1038/onc.2010.59; Rosenfeld JL, 2002, RECEPTOR CHANNEL, V8, P87, DOI 10.1080/10606820212398; Shenouda SK, 2009, CANCER METAST REV, V28, P369, DOI 10.1007/s10555-009-9188-5; Skaftnesmo KO, 2007, CURR PHARM BIOTECHNO, V8, P320, DOI 10.2174/138920107783018390; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tsuchiya S, 2009, NUCLEIC ACIDS RES, V37, P3821, DOI 10.1093/nar/gkp255; Williams AE, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-172; Wu FS, 2009, BIOCHEM BIOPH RES CO, V386, P549, DOI 10.1016/j.bbrc.2009.06.075; Xu T, 2009, HEPATOLOGY, V50, P113, DOI 10.1002/hep.22919; Yang F, 2000, J INVEST DERMATOL, V114, P157, DOI 10.1046/j.1523-1747.2000.00836.x; Yokoi S, 2003, CANCER SCI, V94, P344, DOI 10.1111/j.1349-7006.2003.tb01444.x; Yousef GM, 2008, BIOL CHEM, V389, P689, DOI 10.1515/BC.2008.068; Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028; Zhang HC, 2009, LIFE SCI J, V6, P71; Zhang SZ, 2005, MOL CANCER THER, V4, P1577, DOI 10.1158/1535-7163.MCT-05-0106; Zhu H, 2008, BIOCHEM PHARMACOL, V76, P582, DOI 10.1016/j.bcp.2008.06.007	38	264	290	0	54	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	23					2644	2658		10.1038/onc.2010.642	http://dx.doi.org/10.1038/onc.2010.642			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778CV	21358675				2022-12-17	WOS:000291677800005
J	Cheng, JCH; Chou, CH; Kuo, ML; Hsieh, CY				Cheng, J. C-H; Chou, C. H.; Kuo, M. L.; Hsieh, C-Y			Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K/Akt/NF-kappa B signal transduction pathway	ONCOGENE			English	Article						radiation; hepatocellular carcinoma; invasion; signal transduction	INDUCED MATRIX-METALLOPROTEINASE-9 EXPRESSION; FACTOR-KAPPA-B; INDUCED INCREASE; GENE-EXPRESSION; DOWN-REGULATION; MELANOMA-CELLS; KINASE PATHWAY; CANCER; MIGRATION; RADIOTHERAPY	This study is to investigate the molecular mechanism of radiation-enhanced cell invasiveness of hepatocellular carcinoma (HCC) correlating with clinical patients undergoing radiotherapy and subsequently developing metastasis. Three HCC cell lines (HepG2, Hep3B and Huh7) and normal hepatocyte cell line (CL-48) were irradiated with different doses. The effect of radiation on cell invasiveness was determined using the Boyden chamber assay. Radiation-enhanced invasion capability was evident in HCC cells but not in normal hepatocytes. Invasion was observed in gelatin-coated but not fibronectin-coated or type I collagen-coated membranes. Radiation upregulated matrix metalloproteinase-9 (MMP-9) mRNA level, MMP-9 protein level and MMP-9 activity. MMP-9 antisense oligonucleotides inhibited radiation-induced MMP-9 expression and thereby significantly inhibited radiation-induced HCC invasion. Furthermore, phosphatidylinositol 3-kinase (PI3K)/Akt chemical inhibitors LY294002 and wortmannin suppressed radiation-induced MMP-9 mRNA expression. Transient transfection with dominant-negative Akt plasmid also showed that the PI3K/Akt-signaling pathway was involved in this radiation-induced MMP-9 expression. Moreover, nuclear factor-kappa B (NF-kappa B) decoy oligodeoxynucleotide suppressed radiation enhanced MMP-9 promoter activity completely. PI3K/Akt chemical inhibitors inhibited radiation-induced NF-kappa B-driven luciferase promoter activity. Taken together, our results indicated that sublethal dose of radiation could enhance HCC cell invasiveness by MMP-9 expression through the PI3K/Akt/NF-kappa B signal transduction pathway.	Natl Taiwan Univ Hosp, Dept Obstet & Gynecol, Taipei 100, Taiwan; Natl Taiwan Univ Hosp, Dept Oncol, Taipei 100, Taiwan; Natl Taiwan Univ, Coll Med, Inst Toxicol, Lab Mol & Cellular Toxicol, Taipei, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University	Hsieh, CY (corresponding author), Natl Taiwan Univ Hosp, Dept Obstet & Gynecol, 7 Chung Shan S Rd, Taipei 100, Taiwan.	cheng38@ms15.hinet.net	Kuo, Min-Liang/C-4872-2009	KUO, MIN-LIANG/0000-0002-7139-0144; CHENG, JASON CHIA-HSIEN/0000-0002-2007-0220				Agarwal A, 2005, ONCOGENE, V24, P1021, DOI 10.1038/sj.onc.1208296; Aguayo A, 2001, SEMIN ONCOL, V28, P503, DOI 10.1053/sonc.2001.26953; Akimoto T, 1998, INT J RADIAT ONCOL, V41, P1171, DOI 10.1016/S0360-3016(98)00176-X; Amin ARMR, 2003, GENES CELLS, V8, P515, DOI 10.1046/j.1365-2443.2003.00652.x; Camphausen K, 2001, CANCER RES, V61, P2207; Cheng JCH, 2001, INT J CANCER, V96, P243, DOI 10.1002/ijc.1022; Chung TW, 2004, FASEB J, V18, P1123, DOI 10.1096/fj.03-1429fje; Criswell T, 2003, ONCOGENE, V22, P5813, DOI 10.1038/sj.onc.1206680; Dent P, 2003, RADIAT RES, V159, P283, DOI 10.1667/0033-7587(2003)159[0283:SARIAO]2.0.CO;2; FU KK, 1991, HEMATOL ONCOL CLIN N, V5, P737, DOI 10.1016/S0889-8588(18)30413-1; Hegedus B, 2004, J NEURO-ONCOL, V67, P147, DOI 10.1023/B:NEON.0000021826.73020.f3; Huang SC, 2005, BIOCHEM PHARMACOL, V69, P221, DOI 10.1016/j.bcp.2004.09.019; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; Kuyvenhoven JP, 2003, THROMB HAEMOSTASIS, V89, P718, DOI 10.1055/s-0037-1613578; Liang SX, 2005, CANCER-AM CANCER SOC, V103, P2181, DOI 10.1002/cncr.21012; London CA, 2003, CANCER GENE THER, V10, P823, DOI 10.1038/sj.cgt.7700642; Moon SK, 2004, J CELL PHYSIOL, V198, P417, DOI 10.1002/jcp.10435; Murawaki Y, 2000, RES COMMUN MOL PATH, V108, P351; Nakashio A, 2002, INT J CANCER, V98, P36, DOI 10.1002/ijc.10166; Nirmala C, 2000, INT J CANCER, V88, P766, DOI 10.1002/1097-0215(20001201)88:5<766::AID-IJC13>3.0.CO;2-Y; O-Charoenrat P, 2004, INT J CANCER, V111, P174, DOI 10.1002/ijc.20228; ONODA JM, 1992, RADIAT RES, V130, P281, DOI 10.2307/3578372; Qian LW, 2002, CLIN CANCER RES, V8, P1223; SATO H, 1993, ONCOGENE, V8, P395; Steinle JJ, 2002, J BIOL CHEM, V277, P43830, DOI 10.1074/jbc.M207221200; Sugioka Y, 2004, INT J CANCER, V109, P867, DOI 10.1002/ijc.20095; Susskind H, 2003, INT J RADIAT ONCOL, V56, P1161, DOI 10.1016/S0360-3016(03)00161-5; Thant AA, 2001, CLIN EXP METASTAS, V18, P423, DOI 10.1023/A:1010921730952; Wang JL, 2000, MOL CARCINOGEN, V27, P252, DOI 10.1002/(SICI)1098-2744(200004)27:4<252::AID-MC2>3.0.CO;2-3; Wei LH, 2005, ONCOGENE, V24, P390, DOI 10.1038/sj.onc.1208192; Wild-Bode C, 2001, CANCER RES, V61, P2744; Woo JH, 2003, CANCER RES, V63, P3430; Yao JHS, 2004, CIRC RES, V95, P364, DOI 10.1161/01.RES.0000138581.04174.2f; Zijlstra A, 2002, CANCER RES, V62, P7083	34	264	280	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2006	25	53					7009	7018		10.1038/sj.onc.1209706	http://dx.doi.org/10.1038/sj.onc.1209706			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	103TV	16732316				2022-12-17	WOS:000241910500001
J	Bertucci, F; Salas, S; Eysteries, S; Nasser, V; Finetti, P; Ginestier, C; Charafe-Jauffret, E; Loriod, B; Bachelart, L; Montfort, J; Victorero, G; Viret, F; Ollendorff, V; Fert, V; Giovaninni, M; Delpero, JR; Nguyen, C; Viens, P; Monges, G; Birnbaum, D; Houlgatte, R				Bertucci, F; Salas, S; Eysteries, S; Nasser, V; Finetti, P; Ginestier, C; Charafe-Jauffret, E; Loriod, B; Bachelart, L; Montfort, J; Victorero, G; Viret, F; Ollendorff, V; Fert, V; Giovaninni, M; Delpero, JR; Nguyen, C; Viens, P; Monges, G; Birnbaum, D; Houlgatte, R			Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters	ONCOGENE			English	Review						colon cancer; DNA microarray; expression profiles; microsatellite instability; prognosis	COMPARATIVE GENOMIC HYBRIDIZATION; RECEPTOR-INTERACTING PROTEIN; HUMAN COLORECTAL-CANCER; HUMAN PROSTATE-CANCER; BREAST-CANCER; MICROSATELLITE INSTABILITY; CDNA MICROARRAYS; GASTRIC-CANCER; OLIGONUCLEOTIDE ARRAYS; OVARIAN-CARCINOMA	Different diagnostic and prognostic groups of colorectal carcinoma (CRC) have been defined. However, accurate diagnosis and prediction of survival are sometimes difficult. Gene expression pro. ling might improve these classifications and bring new insights into underlying molecular mechanisms. We pro. led 50 cancerous and noncancerous colon tissues using DNA microarrrays consisting of similar to8000 spotted human cDNA. Global hierarchical clustering was to some extent able to distinguish clinically relevant subgroups, normal versus cancer tissues and metastatic versus nonmetastatic tumours. Supervised analyses improved these segregations by identifying sets of genes that discriminated between normal and tumour tissues, tumours associated or not with lymph node invasion or genetic instability, and tumours from the right or left colon. A similar approach identified a gene set that divided patients with significantly different 5-year survival (100% in one group and 40% in the other group; P = 0.005). Discriminator genes were associated with various cellular processes. An immunohistochemical study on 382 tumour and normal samples deposited onto a tissue microarray subsequently validated the upregulation of NM23 in CRC and a downregulation in poor prognosis tumours. These results suggest that microarrays may provide means to improve the classification of CRC, provide new potential targets against carcinogenesis and new diagnostic and/or prognostic markers and therapeutic targets.	INSERM, U119, F-13009 Marseille, France; Inst J Paoli I Calmettes, Dept Mol Oncol, F-13009 Marseille, France; Inst J Paoli I Calmettes, Dept Med Oncol, F-13009 Marseille, France; Univ Mediterranee, Fac Med, Marseille, France; Inst J Paoli I Calmettes, Dept Biopathol, F-13009 Marseille, France; INSERM, Lab TAGC, F-13258 Marseille, France; Inst Mediterraneen Rech Nutr, Marseille, France; Ipsogen SA, Marseille, France; Inst J Paoli I Calmettes, Dept Chirurg, F-13009 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC)	Birnbaum, D (corresponding author), INSERM, U119, IFR57,27 Bd Lei Roure, F-13009 Marseille, France.	birnbaum@marseille.inserm.fr	Nguyen, Catherine/M-4119-2016; Ginestier, Christophe/M-8828-2017; loriod, beatrice bl/L-2948-2016; Houlgatte, Remi/P-3020-2017; Finetti, Pascal/O-8669-2017; Charafe-Jauffret, emmanuelle/P-6009-2017	Nguyen, Catherine/0000-0001-9376-6360; Ginestier, Christophe/0000-0002-7477-3837; loriod, beatrice bl/0000-0001-5801-2264; DELPERO, JEAN ROBERT/0000-0002-0000-1332; Finetti, Pascal/0000-0002-2674-3123; Bertucci, Francois/0000-0002-0157-0959; Ollendorff, Vincent/0000-0001-9751-2202; Charafe-Jauffret, emmanuelle/0000-0002-0286-1299				Agrawal D, 2002, J NATL CANCER I, V94, P513; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Alon U, 1999, P NATL ACAD SCI USA, V96, P6745, DOI 10.1073/pnas.96.12.6745; Backert S, 1999, INT J CANCER, V82, P868, DOI 10.1002/(SICI)1097-0215(19990909)82:6<868::AID-IJC16>3.0.CO;2-W; Bardelli A, 2003, SCIENCE, V300, P949, DOI 10.1126/science.1082596; Barker N, 2000, ADV CANCER RES, V77, P1; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Berney CR, 1999, ANN SURG, V230, P179, DOI 10.1097/00000658-199908000-00007; Bertucci F, 1999, ONCOGENE, V18, P3905, DOI 10.1038/sj.onc.1202731; Bertucci F, 2001, LANCET ONCOL, V2, P674, DOI 10.1016/S1470-2045(01)00557-5; Bertucci F, 2002, HUM MOL GENET, V11, P863, DOI 10.1093/hmg/11.8.863; Bertucci F, 2000, HUM MOL GENET, V9, P2981, DOI 10.1093/hmg/9.20.2981; Bertucci F, 1999, HUM MOL GENET, V8, P1715, DOI 10.1093/hmg/8.9.1715; Bettuzzi S, 2000, CANCER RES, V60, P1472; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Birkenkamp-Demtroder K, 2002, CANCER RES, V62, P4352; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chen LM, 2002, INT J CANCER, V97, P323, DOI 10.1002/ijc.1601; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; Devilard E, 2002, ONCOGENE, V21, P3095, DOI 10.1038/sj.onc.1205418; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Dunican DS, 2002, ONCOGENE, V21, P3253, DOI 10.1038/sj.onc.1205431; Dursun A, 2002, PATHOLOGY, V34, P427, DOI 10.1080/0031302021000009342; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Ernst T, 2002, AM J PATHOL, V160, P2169, DOI 10.1016/S0002-9440(10)61165-0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Filippova GN, 1998, GENE CHROMOSOME CANC, V22, P26, DOI 10.1002/(SICI)1098-2264(199805)22:1<26::AID-GCC4>3.0.CO;2-9; FREDERIKSEN CM, 2003, J CANCER RES CLIN, V15, P15; Furstenberger G, 2002, LANCET ONCOL, V3, P298, DOI 10.1016/S1470-2045(02)00731-3; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Ginestier C, 2002, AM J PATHOL, V161, P1223, DOI 10.1016/S0002-9440(10)64399-4; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Grant DS, 2002, ONCOGENE, V21, P4765, DOI 10.1038/sj.onc.1205595; Gunther K, 2002, J SURG RES, V103, P68, DOI 10.1006/jsre.2001.6312; Hegde P, 2001, CANCER RES, V61, P7792; Hermanto U, 2002, MOL CELL BIOL, V22, P2345, DOI 10.1128/MCB.22.7.2345-2365.2002; Hippo Y, 2001, CANCER RES, V61, P889; Hippo Y, 2002, CANCER RES, V62, P233; Hoos A, 2001, LAB INVEST, V81, P1331, DOI 10.1038/labinvest.3780347; Huang E, 2003, LANCET, V361, P1590, DOI 10.1016/S0140-6736(03)13308-9; Iacobuzio-Donahue CA, 2003, AM J PATHOL, V162, P1151, DOI 10.1016/S0002-9440(10)63911-9; Iacopetta B, 2002, INT J CANCER, V101, P403, DOI 10.1002/ijc.10635; Indinnimeo M, 1997, CANCER LETT, V111, P1, DOI 10.1016/S0304-3835(96)04472-2; Ishikawa S, 2001, GENE, V267, P101, DOI 10.1016/S0378-1119(01)00378-X; Kajiyama H, 2003, CANCER RES, V63, P2278; Katakura H, 2002, ANN THORAC SURG, V73, P1060, DOI 10.1016/S0003-4975(01)03597-4; Kiely PA, 2002, J BIOL CHEM, V277, P22581, DOI 10.1074/jbc.M201758200; Kitahara O, 2001, CANCER RES, V61, P3544; KODERA Y, 1994, CANCER, V73, P259, DOI 10.1002/1097-0142(19940115)73:2<259::AID-CNCR2820730205>3.0.CO;2-V; Korn WM, 1999, GENE CHROMOSOME CANC, V25, P82, DOI 10.1002/(SICI)1098-2264(199906)25:2<82::AID-GCC2>3.0.CO;2-6; Lee JC, 2001, J SURG ONCOL, V76, P58, DOI 10.1002/1096-9098(200101)76:1<58::AID-JSO1010>3.0.CO;2-D; LEVEDAKOU EN, 1992, INT J CANCER, V52, P534, DOI 10.1002/ijc.2910520406; Lin YM, 2002, ONCOGENE, V21, P4120, DOI 10.1038/sj.onc.1205518; Lindmark G, 1996, BRIT J CANCER, V74, P1413, DOI 10.1038/bjc.1996.557; Lindor NM, 2002, J CLIN ONCOL, V20, P1043, DOI 10.1200/JCO.20.4.1043; Luo J, 2001, CANCER RES, V61, P4683; Maaser K, 2002, CLIN CANCER RES, V8, P3205; Magrangeas F, 2003, BLOOD, V101, P4998, DOI 10.1182/blood-2002-11-3385; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Markowitz SD, 2002, CANCER CELL, V1, P233, DOI 10.1016/S1535-6108(02)00053-3; Matei D, 2002, ONCOGENE, V21, P6289, DOI 10.1038/sj.onc.1205785; McDermott NC, 2000, J PATHOL, V190, P157; Merritt J A, 1985, Prog Clin Biol Res, V202, P423; Mohr S, 2002, J CLIN ONCOL, V20, P3165, DOI 10.1200/JCO.2002.12.073; Nabeshima K, 2002, CANCER LETT, V176, P101, DOI 10.1016/S0304-3835(01)00742-X; Nakagawa H, 1998, CANCER RES, V58, P5176; Niu Y, 2002, INT J CANCER, V98, P754, DOI 10.1002/ijc.10136; Notterman DA, 2001, CANCER RES, V61, P3124; Paris S, 2002, INT J CANCER, V97, P615, DOI 10.1002/ijc.10120; Peltomaki P, 2003, J CLIN ONCOL, V21, P1174, DOI 10.1200/JCO.2003.04.060; Perrin J, 2001, INT J ONCOL, V19, P891; Platzer P, 2002, CANCER RES, V62, P1134; Reinmuth N, 2002, LAB INVEST, V82, P1377, DOI 10.1097/01.LAB.0000032411.41603.C2; Resta N, 1998, CANCER RES, V58, P4799; Richter J, 2000, AM J PATHOL, V157, P787, DOI 10.1016/S0002-9440(10)64592-0; Ried T, 1996, GENE CHROMOSOME CANC, V15, P234, DOI 10.1002/(SICI)1098-2264(199604)15:4<234::AID-GCC5>3.0.CO;2-2; Sagawa N, 2003, BRIT J CANCER, V88, P606, DOI 10.1038/sj.bjc.6600739; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; Shaffer AL, 2001, IMMUNITY, V15, P375, DOI 10.1016/S1074-7613(01)00194-7; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Steeg PS, 2003, NAT REV CANCER, V3, P55, DOI 10.1038/nrc967; Sterner-Kock A, 2002, GENE DEV, V16, P2264, DOI 10.1101/gad.229102; Stremmel C, 2002, INT J COLORECTAL DIS, V17, P131, DOI 10.1007/s00384-001-0370-7; Takahashi M, 2001, P NATL ACAD SCI USA, V98, P9754, DOI 10.1073/pnas.171209998; Tamura G, 1996, J PATHOL, V180, P371, DOI 10.1002/(SICI)1096-9896(199612)180:4<371::AID-PATH704>3.0.CO;2-2; Tas F, 2002, AM J CLIN ONCOL-CANC, V25, P164, DOI 10.1097/00000421-200204000-00012; THEILLET C, 1993, GENE CHROMOSOME CANC, V7, P219, DOI 10.1002/gcc.2870070407; Troup S, 2003, CLIN CANCER RES, V9, P207; Tureci O, 2003, FASEB J, V17, P376, DOI 10.1096/fj.02-0478com; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Wahlberg SS, 2002, CANCER RES, V62, P3485; Walch ET, 1999, CLIN EXP METASTAS, V17, P307, DOI 10.1023/A:1006652605568; Wang QS, 1998, CARCINOGENESIS, V19, P2001, DOI 10.1093/carcin/19.11.2001; Wang S, 2002, ONCOGENE, V21, P8388, DOI 10.1038/sj.onc.1205944; Welsh JB, 2001, CANCER RES, V61, P5974; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; WEST M, 2001, P NATL ACAD SCI USA, V18, P18; Williams NS, 2003, CLIN CANCER RES, V9, P931; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; Zhou XP, 1998, GENE CHROMOSOME CANC, V21, P101, DOI 10.1002/(SICI)1098-2264(199802)21:2<101::AID-GCC4>3.0.CO;2-4; Zou TT, 2002, ONCOGENE, V21, P4855, DOI 10.1038/sj.onc.1205613	102	264	288	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2004	23	7					1377	1391		10.1038/sj.onc.1207262	http://dx.doi.org/10.1038/sj.onc.1207262			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	775HZ	14973550				2022-12-17	WOS:000189035800005
J	Desbois-Mouthon, C; Cadoret, A; Blivet-Van Eggelpoel, MJ; Bertrand, F; Cherqui, G; Perret, C; Capeau, J				Desbois-Mouthon, C; Cadoret, A; Blivet-Van Eggelpoel, MJ; Bertrand, F; Cherqui, G; Perret, C; Capeau, J			Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3 beta inhibition and Ras activation	ONCOGENE			English	Article						insulin; IGF-1; beta-catenin; PI 3-kinase; GSK-3 beta; Ras	GLYCOGEN-SYNTHASE KINASE-3; GROWTH-FACTOR-II; RECEPTOR SUBSTRATE-1 OVEREXPRESSION; HUMAN HEPATOCELLULAR CARCINOMAS; INTEGRIN-LINKED KINASE; APC TUMOR-SUPPRESSOR; HEPATITIS-B; INCREASED EXPRESSION; SIGNALING PATHWAY; GENE-PRODUCT	We examined the interplay between the insulin/LGF-1- and beta -catenin-regulated pathways, both of which are suspected to play a role in hepatocarcinogenesis. Insulin and IGF-1 stimulated the transcription of a Lef/Tcf-dependent luciferase reporter gene by 3-4-fold in HepG2 cells, This stimulation was mediated through the activation of phosphatidylinositol 3-kinase (PI 3-K)/Akt and the inhibition of glycogen synthase kinase-3 beta (GSK-3 beta) since the effects of insulin and IGF-I were inhibited by dominant-negative mutants of PI 3-K or Akt and an uninhibitable GSK-3 beta. Together with inhibiting GSK-3 beta, insulin and IGF-I increased the cytoplasmic levels of beta -catenin, The PI 3-K/Akt/GSK-3 beta pathway was not the sole to mediate insulin and IGF-1 stimulation of Lef/Tcf-dependent transcription. The Ras signalling pathway was also required as (i) the stimulatory effects of insulin and IGF-I were inhibited by dominant-negative Ras or the MEK1 inhibitor PD98059 and (ii) activated Ha-Res or constitutively active MEK synergized with catalytically inactive GSK-3 beta to stimulate Lef/Tcf-dependent transcription. This study provides the first evidence that insulin and IGF-I stimulate the beta -catenin pathway through tw a signalling cascades bifurcating downstream of PI 3-K and involving GSK-3 beta inhibition and Ras activation. These findings demonstrate for the first time the ability of insulin and IGF-I to activate the beta -catenin pathway in hepatoma cells and thereby provide new insights into the role of these factors in hepatocarcinogenesis.	Univ Paris 06, INSERM U402, F-75571 Paris 12, France; INSERM, U129, ICGM, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Desbois-Mouthon, C (corresponding author), Univ Paris 06, INSERM U402, 27 Rue Chaligny, F-75571 Paris 12, France.		Desbois-Mouthon, Christele/M-7076-2017; Perret-Mayeux, Christine/L-3297-2017; Cadoret, Axelle/L-2529-2017	Desbois-Mouthon, Christele/0000-0002-0772-1711; Cadoret, Axelle/0000-0002-4283-6864; perret, christine/0000-0003-4710-7051				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Barker N, 2000, ADV CANCER RES, V77, P1; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; BERTRAND F, 1995, J BIOL CHEM, V270, P24435, DOI 10.1074/jbc.270.41.24435; Buchmann A, 1999, CELL DEATH DIFFER, V6, P190, DOI 10.1038/sj.cdd.4400475; CARIANI E, 1988, CANCER RES, V48, P6844; CARIANI E, 1991, HEPATOLOGY, V13, P644, DOI 10.1002/hep.1840130406; Chen RH, 1998, ONCOGENE, V17, P1959, DOI 10.1038/sj.onc.1202111; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Desbois-Mouthon C, 2000, ENDOCRINOLOGY, V141, P922, DOI 10.1210/en.141.3.922; Devereux TR, 1999, ONCOGENE, V18, P4726, DOI 10.1038/sj.onc.1202858; Egawa K, 1999, J BIOL CHEM, V274, P14306, DOI 10.1074/jbc.274.20.14306; Espada J, 1999, J CELL BIOL, V146, P967, DOI 10.1083/jcb.146.5.967; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Kim SO, 1996, CANCER RES, V56, P3831; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Miyoshi Y, 1998, CANCER RES, V58, P2524; Moradpour D, 1994, J Viral Hepat, V1, P17, DOI 10.1111/j.1365-2893.1994.tb00058.x; Nardone G, 1996, HEPATOLOGY, V23, P1304, DOI 10.1053/jhep.1996.v23.pm0008675143; NISHIYAMA M, 1992, BIOCHEM BIOPH RES CO, V183, P280, DOI 10.1016/0006-291X(92)91640-C; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Ogawa K, 1999, CANCER RES, V59, P1830; Ogawa W, 1998, MOL CELL BIOCHEM, V182, P13, DOI 10.1023/A:1006862807598; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Staal FJT, 1999, INT IMMUNOL, V11, P317, DOI 10.1093/intimm/11.3.317; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SU Q, 1994, HEPATOLOGY, V20, P788, DOI 10.1002/hep.1840200404; Summers SA, 1999, J BIOL CHEM, V274, P17934, DOI 10.1074/jbc.274.25.17934; Tanaka S, 1996, CANCER RES, V56, P3391; Tanaka S, 1997, HEPATOLOGY, V26, P598; Terris B, 1999, ONCOGENE, V18, P6583, DOI 10.1038/sj.onc.1203051; Torres MA, 1999, MOL CELL BIOL, V19, P1427; Tsujiuchi T, 1999, CANCER RES, V59, P3904; Van Nhieu JT, 1999, AM J PATHOL, V155, P703, DOI 10.1016/S0002-9440(10)65168-1; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Weihl CC, 1999, J NEUROSCI, V19, P5360; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Yao YJ, 1999, ONCOGENE, V18, P3181, DOI 10.1038/sj.onc.1202659; Yuan HD, 1999, J BIOL CHEM, V274, P30419, DOI 10.1074/jbc.274.43.30419	52	264	271	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 11	2001	20	2					252	259		10.1038/sj.onc.1204064	http://dx.doi.org/10.1038/sj.onc.1204064			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KU	11313952				2022-12-17	WOS:000166410900012
J	Muraoka, M; Konishi, M; KikuchiYanoshita, R; Tanaka, K; Shitara, N; Chong, JM; Iwama, T; Miyaki, M				Muraoka, M; Konishi, M; KikuchiYanoshita, R; Tanaka, K; Shitara, N; Chong, JM; Iwama, T; Miyaki, M			p300 gene alterations in colorectal and gastric carcinomas	ONCOGENE			English	Article						p300 gene; NF2 gene; colorectal carcinoma; gastric carcinoma; somatic mutation	FAMILIAL ADENOMATOUS POLYPOSIS; CHROMOSOME-22	Colorectal tumors frequently have loss of heterozygosity on chromosome 22q, suggesting that inactivation of tumor suppressor gene(s) on 22q participates in the tumor development. Neurofibromatosis 2 (NF2) gene and E1A binding protein p300 gene, recently identified on 22q, are thought to be candidates for tumor suppressor genes. In this study, mutation of the NF2 gene in 59 colorectal carcinomas, and mutation of the p300 gene in 27 colorectal and two gastric carcinomas, were analysed using PCR-SSCP, RT-PCR-SSCP and direct sequencing methods. Missense mutations of p300 gene were detected in a colorectal carcinoma, and in a gastric carcinoma, though no mutation of NF2 gene was detected. Both p300 mutations were somatic and coupled to deletion of the second allele of the gene, which suggests inactivation of the p300 gene in these carcinomas. The mutations are located within the Cys/His-rich regions, which are assumed to play important roles in the function of p300. These are the first cases in which p300 gene has been found to be altered in both alleles, suggesting that inactivation of the p300 gene may be involved in the development of carcinomas, and that this gene may be the target of loss of 22q in carcinomas of the digestive tract.	TOKYO METROPOLITAN INST MED SCI,DEPT BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; TOKYO METROPOLITAN KOMAGOME HOSP,DEPT PATHOL,TOKYO,JAPAN; TOKYO METROPOLITAN KOMAGOME HOSP,DEPT NEUROSURG,TOKYO,JAPAN; TOKYO MED & DENT UNIV,DEPT SURG 2,BUNKYO KU,TOKYO 113,JAPAN	Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital; Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital; Tokyo Medical & Dental University (TMDU)								ARAKAWA H, 1994, HUM MOL GENET, V3, P565, DOI 10.1093/hmg/3.4.565; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; BIANCHI AB, 1994, NAT GENET, V6, P185, DOI 10.1038/ng0294-185; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; GREENBLATT MS, 1994, CANCER RES, V54, P4855; IINO H, 1994, CANCER, V73, P1324, DOI 10.1002/1097-0142(19940301)73:5<1324::AID-CNCR2820730503>3.0.CO;2-W; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3965; KONISHI M, 1993, JPN J CANCER RES, V84, P893, DOI 10.1111/j.1349-7006.1993.tb02063.x; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MIYAKI M, 1990, CANCER RES, V50, P7166; MIYAKI M, 1995, CRIT REV ONCOL HEMAT, V19, P1, DOI 10.1016/1040-8428(94)00129-H; OKAMOTO M, 1988, NATURE, V331, P273, DOI 10.1038/331273a0; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; RUBIO MP, 1994, CANCER RES, V54, P45; RUTTLEDGE MH, 1994, NAT GENET, V6, P180, DOI 10.1038/ng0294-180; SEIZINGER BR, 1986, NATURE, V322, P644, DOI 10.1038/322644a0; SEIZINGER BR, 1987, P NATL ACAD SCI USA, V84, P5419, DOI 10.1073/pnas.84.15.5419; SEIZINGER BR, 1991, CYTOGENET CELL GENET, V58, P1080, DOI 10.1159/000133722; SEKIDO Y, 1995, CANCER RES, V55, P1227; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TWIST EC, 1994, HUM MOL GENET, V3, P147, DOI 10.1093/hmg/3.1.147; YANA I, 1995, INT J CANCER, V60, P174, DOI 10.1002/ijc.2910600207	26	264	276	1	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1565	1569						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622873				2022-12-17	WOS:A1996UF07600021
J	Lopez-Serra, P; Esteller, M				Lopez-Serra, P.; Esteller, M.			DNA methylation-associated silencing of tumor-suppressor microRNAs in cancer	ONCOGENE			English	Review						DNA methylation; microRNAs; tumor-suppressor genes	EPITHELIAL OVARIAN-CANCER; DOWN-REGULATION; MESSENGER-RNAS; LET-7 MICRORNA; EPIGENETIC INACTIVATION; CIRCULATING MICRORNAS; DICER1 MUTATIONS; LUNG-CANCER; EXPRESSION; GENE	MicroRNAs (miRNAs) are recognized as being central players in many biological processes and cellular pathways. Their roles in disease have been highlighted first by observation of their aberrant expression profiles in human tumors, and then by in vitro and in vivo functional studies in transformed cells and model organisms. One of the most commonly observed features of miRNAs in malignancies is a defect in their production. Although several causes may be associated with this phenomenon, such as upstream oncogenic/tumor-suppressor defects and alterations in the miRNA-processing machinery, epigenetic inactivation is the prime suspect. The number of miRNAs with putative growth-inhibitory functions undergoing promoter CpG island hypermethylation in human cancer is growing fast and more detailed biological studies are necessary. The recognition of miR-124a and miR-34b/c as bona fide tumor-suppressor miRNAs undergoing DNA methylation-associated silencing in a wide spectrum of human neoplasms is a good starting point to be followed by other candidate miRNAs. Most importantly, even at this early stage, the transcriptional repression of miRNAs by hypermethylation of their corresponding promoter loci seems to be a common feature of all human tumors. This will have translational consequences for the management of the disease. Oncogene (2012) 31, 1609-1622; doi:10.1038/onc.2011.354; published online 22 August 2011	[Lopez-Serra, P.; Esteller, M.] Hosp Duran i Reynals, Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program, Barcelona 08908, Spain; [Esteller, M.] Univ Barcelona, Sch Med, Dept Physiol Sci 2, Barcelona, Spain; [Esteller, M.] ICREA, Barcelona, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals; University of Barcelona; ICREA	Esteller, M (corresponding author), Hosp Duran i Reynals, Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program, 3rd Floor,Avda Gran Via S-N, Barcelona 08908, Spain.	mesteller@idibell.cat	Lopez-Serra, Paula/M-6835-2015; Esteller, Manel/L-5956-2014	Lopez-Serra, Paula/0000-0001-7231-3426; Esteller, Manel/0000-0003-4490-6093	Lilly Foundation; Dr Josef Steiner Cancer Research Foundation; European Research Council;  [SAF2007-00027-65134];  [Consolider CSD2006-49]; ICREA Funding Source: Custom	Lilly Foundation; Dr Josef Steiner Cancer Research Foundation; European Research Council(European Research Council (ERC)European Commission); ; ; ICREA(ICREA)	This work was supported by grants SAF2007-00027-65134, Consolider CSD2006-49, the Lilly Foundation, the Dr Josef Steiner Cancer Research Foundation and the European Research Council Advanced Grant EPINORC.	Agirre X, 2009, CANCER RES, V69, P4443, DOI 10.1158/0008-5472.CAN-08-4025; Akao Y, 2006, BIOL PHARM BULL, V29, P903, DOI 10.1248/bpb.29.903; Ando T, 2009, INT J CANCER, V124, P2367, DOI 10.1002/ijc.24219; Arroyo JD, 2011, P NATL ACAD SCI USA, V108, P5003, DOI 10.1073/pnas.1019055108; Azzalin CM, 2007, SCIENCE, V318, P798, DOI 10.1126/science.1147182; Bahubeshi A, 2010, J MED GENET, V47, P863, DOI 10.1136/jmg.2010.081216; Balaguer F, 2010, CANCER RES, V70, P6609, DOI 10.1158/0008-5472.CAN-10-0622; Bandres E, 2009, INT J CANCER, V125, P2737, DOI 10.1002/ijc.24638; Bass BL, 2002, ANNU REV BIOCHEM, V71, P817, DOI 10.1146/annurev.biochem.71.110601.135501; Berdasco M, 2010, DEV CELL, V19, P698, DOI 10.1016/j.devcel.2010.10.005; Bin Hafeez B, 2009, CLIN CANCER RES, V15, P452, DOI 10.1158/1078-0432.CCR-08-1631; Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Borchert GM, 2006, NAT STRUCT MOL BIOL, V13, P1097, DOI 10.1038/nsmb1167; Borchert GM, 2009, HUM MOL GENET, V18, P4801, DOI 10.1093/hmg/ddp443; Bueno MJ, 2008, CANCER CELL, V13, P496, DOI 10.1016/j.ccr.2008.04.018; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995; Calin GA, 2008, P NATL ACAD SCI USA, V105, P5166, DOI 10.1073/pnas.0800121105; Ceppi P, 2010, MOL CANCER RES, V8, P1207, DOI 10.1158/1541-7786.MCR-10-0052; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Chen J, 2011, GYNECOL ONCOL, V121, P200, DOI 10.1016/j.ygyno.2010.12.339; Chen R, 2008, ONCOGENE, V27, P4712, DOI 10.1038/onc.2008.112; Chen R, 2007, AM J REPROD IMMUNOL, V57, P93, DOI 10.1111/j.1600-0897.2006.00441.x; Cheung HH, 2011, ONCOGENE, V30, P3404, DOI 10.1038/onc.2011.60; Chim CS, 2010, CARCINOGENESIS, V31, P745, DOI 10.1093/carcin/bgq033; Corney DC, 2010, CLIN CANCER RES, V16, P1119, DOI 10.1158/1078-0432.CCR-09-2642; Dangi-Garimella S, 2011, ONCOGENE, V30, P1002, DOI 10.1038/onc.2010.485; Das H, 2000, BRIT J CANCER, V82, P1682; Datta J, 2008, CANCER RES, V68, P5049, DOI 10.1158/0008-5472.CAN-07-6655; Davalos V, 2012, ONCOGENE, V31, P2062, DOI 10.1038/onc.2011.383; Dews M, 2006, NAT GENET, V38, P1060, DOI 10.1038/ng1855; Eiring AM, 2010, CELL, V140, P652, DOI 10.1016/j.cell.2010.01.007; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Frio TR, 2011, JAMA-J AM MED ASSOC, V305, P68, DOI 10.1001/jama.2010.1910; Furuta M, 2010, CARCINOGENESIS, V31, P766, DOI 10.1093/carcin/bgp250; Gallardo E, 2009, CARCINOGENESIS, V30, P1903, DOI 10.1093/carcin/bgp219; Gao XN, 2011, ONCOGENE, V30, P3416, DOI 10.1038/onc.2011.62; Grady WM, 2008, ONCOGENE, V27, P3880, DOI 10.1038/onc.2008.10; Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Grossel MJ, 2006, J CELL BIOCHEM, V97, P485, DOI 10.1002/jcb.20712; Han JJ, 2006, CELL, V125, P887, DOI 10.1016/j.cell.2006.03.043; Hashimoto Y, 2010, CARCINOGENESIS, V31, P777, DOI 10.1093/carcin/bgq013; Heinzelmann J, 2011, WORLD J UROL, V29, P367, DOI 10.1007/s00345-010-0633-4; Hildebrandt MAT, 2010, ONCOGENE, V29, P5724, DOI 10.1038/onc.2010.305; Hong LX, 2010, CANCER RES, V70, P8547, DOI 10.1158/0008-5472.CAN-10-1938; Hu ZB, 2008, J CLIN INVEST, V118, P2600, DOI 10.1172/JCI34934; Huang JF, 2010, HEPATOLOGY, V52, P60, DOI 10.1002/hep.23660; Huang YW, 2009, CANCER RES, V69, P9038, DOI 10.1158/0008-5472.CAN-09-1499; Hurteau GJ, 2006, CELL CYCLE, V5, P1951, DOI 10.4161/cc.5.17.3133; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Hutvagner G, 2002, CURR OPIN GENET DEV, V12, P225, DOI 10.1016/S0959-437X(02)00290-3; Iizasa H, 2010, J BIOL CHEM, V285, P33358, DOI 10.1074/jbc.M110.138362; Jing Q, 2005, CELL, V120, P623, DOI 10.1016/j.cell.2004.12.038; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kalimutho M, 2011, BRIT J CANCER, V104, P1770, DOI 10.1038/bjc.2011.82; Kamimae S, 2011, CANCER PREV RES, V4, P674, DOI 10.1158/1940-6207.CAPR-10-0214; Kindler T, 2004, BLOOD, V103, P3644, DOI 10.1182/blood-2003-06-2071; Kosaka N, 2010, CANCER SCI, V101, P2087, DOI 10.1111/j.1349-7006.2010.01650.x; Kozaki KI, 2008, CANCER RES, V68, P2094, DOI 10.1158/0008-5472.CAN-07-5194; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Krueger A, 2003, IMMUNOL REV, V193, P58, DOI 10.1034/j.1600-065X.2003.00047.x; Lai EC, 2002, NAT GENET, V30, P363, DOI 10.1038/ng865; Laios A, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-35; Langevin SM, 2010, CARCINOGENESIS, V31, P864, DOI 10.1093/carcin/bgq051; Lee JW, 2008, CLIN CANCER RES, V14, P2535, DOI 10.1158/1078-0432.CCR-07-1231; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Lee Y, 2004, EMBO J, V23, P4051, DOI 10.1038/sj.emboj.7600385; Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lim PK, 2011, CANCER RES, V71, P1550, DOI 10.1158/0008-5472.CAN-10-2372; Liu JD, 2004, SCIENCE, V305, P1437, DOI 10.1126/science.1102513; Lodygin D, 2008, CELL CYCLE, V7, P2591, DOI 10.4161/cc.7.16.6533; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lu L, 2007, CANCER RES, V67, P10117, DOI 10.1158/0008-5472.CAN-07-2544; Lujambio A, 2010, ONCOGENE, V29, P6390, DOI 10.1038/onc.2010.361; Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105; Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218; Lujambio A, 2009, CELL CYCLE, V8, P377, DOI 10.4161/cc.8.3.7526; Martello G, 2010, CELL, V141, P1195, DOI 10.1016/j.cell.2010.05.017; Mears R, 2004, PROTEOMICS, V4, P4019, DOI 10.1002/pmic.200400876; Medina PP, 2010, NATURE, V467, P86, DOI 10.1038/nature09284; Melo S, 2011, P NATL ACAD SCI USA, V108, P4394, DOI 10.1073/pnas.1014720108; Melo SA, 2010, CANCER CELL, V18, P303, DOI 10.1016/j.ccr.2010.09.007; Melo SA, 2009, NAT GENET, V41, P365, DOI 10.1038/ng.317; Merritt WM, 2008, NEW ENGL J MED, V359, P2641, DOI 10.1056/NEJMoa0803785; Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105; Neves Rui, 2010, BMC Res Notes, V3, P219, DOI 10.1186/1756-0500-3-219; Obad S, 2011, NAT GENET, V43, P371, DOI 10.1038/ng.786; Olive V, 2009, GENE DEV, V23, P2839, DOI 10.1101/gad.1861409; Omura N, 2008, CANCER BIOL THER, V7, P1146, DOI 10.4161/cbt.7.7.6208; Orom UA, 2008, MOL CELL, V30, P460, DOI 10.1016/j.molcel.2008.05.001; Ottaviano AJ, 2006, CANCER RES, V66, P7032, DOI 10.1158/0008-5472.CAN-05-4421; Pagano JS, 2002, NEW ENGL J MED, V347, P78, DOI 10.1056/NEJMp020056; Pang RTK, 2010, CARCINOGENESIS, V31, P1037, DOI 10.1093/carcin/bgq066; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Paroo Z, 2009, CELL, V139, P112, DOI 10.1016/j.cell.2009.06.044; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Pfeffer S, 2004, SCIENCE, V304, P734, DOI 10.1126/science.1096781; Pillai RS, 2005, SCIENCE, V309, P1573, DOI 10.1126/science.1115079; Plasterk RHA, 2002, SCIENCE, V296, P1263, DOI 10.1126/science.1072148; Png KJ, 2011, GENE DEV, V25, P226, DOI 10.1101/gad.1974211; Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144; Ponjavic J, 2007, GENOME RES, V17, P556, DOI 10.1101/gr.6036807; Rodriguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305; Roman-Gomez J, 2009, J CLIN ONCOL, V27, P1316, DOI 10.1200/JCO.2008.19.3441; Rosenfeld N, 2008, NAT BIOTECHNOL, V26, P462, DOI 10.1038/nbt1392; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020; Sandoval J, 2011, EPIGENETICS-US, V6, P692, DOI 10.4161/epi.6.6.16196; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Shen RZ, 2010, BIOCHEM BIOPH RES CO, V394, P1047, DOI 10.1016/j.bbrc.2010.03.121; Silber J, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-14; Suh SO, 2011, CARCINOGENESIS, V32, P772, DOI 10.1093/carcin/bgr036; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; Tan HX, 2010, MED ONCOL, V27, P654, DOI 10.1007/s12032-009-9264-2; Tarasov V, 2007, CELL CYCLE, V6, P1586, DOI 10.4161/cc.6.13.4436; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Toyota M, 2008, CANCER RES, V68, P4123, DOI 10.1158/0008-5472.CAN-08-0325; Tsai KW, 2011, INT J CANC IN PRESS; Ueda T, 2010, LANCET ONCOL, V11, P136, DOI 10.1016/S1470-2045(09)70343-2; Urdinguio RG, 2010, EPIGENETICS-US, V5, P656, DOI 10.4161/epi.5.7.13055; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460; Vazquez I, 2010, P NATL ACAD SCI USA, V107, pE167, DOI 10.1073/pnas.1011540107; Verdel A, 2004, SCIENCE, V303, P672, DOI 10.1126/science.1093686; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Vrba L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008697; Wang S, 2011, GENES IMMUN, V12, P149, DOI 10.1038/gene.2010.53; Wendler A, 2011, ONCOL REP, V25, P273, DOI 10.3892/or_00001071; Wiklund ED, 2011, INT J CANCER, V128, P1327, DOI 10.1002/ijc.25461; Willis L, 2010, CANCER RES, V70, P4310, DOI 10.1158/0008-5472.CAN-09-3144; Wilting SM, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-167; Xu N, 2007, NAT GENET, V39, P1390, DOI 10.1038/ng.2007.5; Xu N, 2009, CELL, V137, P647, DOI 10.1016/j.cell.2009.02.038; Yamakuchi M, 2008, P NATL ACAD SCI USA, V105, P13421, DOI 10.1073/pnas.0801613105; Yi R, 2003, GENE DEV, V17, P3011, DOI 10.1101/gad.1158803; Yin G, 2010, ONCOGENE, V29, P3545, DOI 10.1038/onc.2010.111; Yu CC, 2011, ORAL ONCOL, V47, P202, DOI 10.1016/j.oraloncology.2010.12.001; Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103	151	263	274	0	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	13					1609	1622		10.1038/onc.2011.354	http://dx.doi.org/10.1038/onc.2011.354			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	918EF	21860412	Green Published, hybrid			2022-12-17	WOS:000302231400001
J	Lee, KS; Hong, SH; Bae, SC				Lee, KS; Hong, SH; Bae, SC			Both the Smad and p38 MAPK pathways play a crucial role in Runx2 expression following induction by transforming growth factor-beta and bone morphogenetic protein	ONCOGENE			English	Article						Runx2; junB; p38; TGF-beta 1; BMP-2; osteoblast	OSTEOBLAST DIFFERENTIATION; CLEIDOCRANIAL DYSPLASIA; GENE-EXPRESSION; MYOGENIC DIFFERENTIATION; C2C12 MYOBLASTS; DNA-BINDING; CBFA1; CELLS; OSF2/CBFA1; ACTIVATION	The Runx family of transcription factors plays pivotal roles during normal development and in neoptasias. In mammals, Runx family genes are composed of Runx1 (Pehp2alphaB/Chfa2/Aml1), Runx2 (Pebp2alphaA/Cbfa1/Aml3) and Runx3 (Pehp2alphaC/Cbfa3/Aml2). Runx1 and Runx3 are known to be involved in leukemogenesis and gastric carcinogenesis, respectively. Runx2, on the other hand, is a common target of transforming growth factor-beta1 (TGF-beta1) and bone morphogenetic protein-2 (BMP-2) and plays an essential role in osteoblast differentiation. Runx2 is induced by the receptor-activated Smad; Runx2 mediates the blockage of myogenic differentiation and induces osteoblast differentiation in C2C12 pluripotent mesenchymal precursor cells. However, Smad does not directly induce Runx2 expression; an additional step of de novo protein synthesis is required. Here we report that Smad-induced junB functions as an upstream activator of Runx2 expression. Furthermore, not only the Smad pathway but also the mitogen-activated protein kinase (MAPK) cascades are involved in the induction of Runx2 by TGF-beta1 and BMP-2. Our results demonstrate that following TGF-beta and RMP induction, both the Smad and p38 MAPK pathways converge at the Runx2 gene to control mesenchymal precursor cell differentiation.	Chungbuk Natl Univ, Sch Med, Dept Biochem, Cheongju 361763, South Korea; Chungbuk Natl Univ, Inst Tumor Engn, Cheongju 361763, South Korea	Chungbuk National University; Chungbuk National University	Bae, SC (corresponding author), Chungbuk Natl Univ, Sch Med, Dept Biochem, Cheongju 361763, South Korea.	scbae@med.chungbuk.ac.kr						Chalaux E, 1998, J BIOL CHEM, V273, P537, DOI 10.1074/jbc.273.1.537; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Ducy P, 2000, DEV DYNAM, V219, P461, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1074>3.0.CO;2-C; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Gallea S, 2001, BONE, V28, P491, DOI 10.1016/S8756-3282(01)00415-X; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797-307; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Lian J B, 1995, Iowa Orthop J, V15, P118; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Nishimura R, 1998, J BIOL CHEM, V273, P1872, DOI 10.1074/jbc.273.4.1872; Noguchi K, 2000, BIOCHEM BIOPH RES CO, V267, P221, DOI 10.1006/bbrc.1999.1952; North T, 1999, DEVELOPMENT, V126, P2563; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Reimold AM, 1996, NATURE, V379, P262, DOI 10.1038/379262a0; ROBERTS AB, 1988, RECENT PROG HORM RES, V44, P157; Sambrook J, 1988, MOL CLONING LAB MANU; Vaillant F, 1999, ONCOGENE, V18, P7124, DOI 10.1038/sj.onc.1203202; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453; Xiao ZS, 1999, J CELL BIOCHEM, V74, P596, DOI 10.1002/(SICI)1097-4644(19990915)74:4<596::AID-JCB9>3.0.CO;2-F; Yamamoto N, 1997, BIOCHEM BIOPH RES CO, V238, P574, DOI 10.1006/bbrc.1997.7325; Yokomizo T, 2001, GENES CELLS, V6, P13, DOI 10.1046/j.1365-2443.2001.00393.x; Zhang YW, 2000, P NATL ACAD SCI USA, V97, P10549, DOI 10.1073/pnas.180309597	36	263	293	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2002	21	47					7156	7163		10.1038/sj.onc.1205937	http://dx.doi.org/10.1038/sj.onc.1205937			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370805				2022-12-17	WOS:000178504600003
J	Yordy, JS; Muise-Helmericks, RC				Yordy, JS; Muise-Helmericks, RC			Signal transduction and the Ets family of transcription factors	ONCOGENE			English	Review						Ets; transcription; MAP kinase; Ras; signal transduction	ACTIVATED PROTEIN-KINASE; TERNARY COMPLEX FACTORS; SERUM RESPONSE ELEMENT; THYROTROPIN-RELEASING-HORMONE; LOOP-HELIX PROTEINS; DNA-BINDING DOMAIN; C-FOS PROMOTER; MAP-KINASE; GENE-EXPRESSION; MESODERM INDUCTION	Cellular responses to environmental stimuli are controlled by a series of signaling cascades that transduce extracellular signals from ligand-activated cell surface receptors to the nucleus, Although most pathways were initially thought to be linear, it has become apparent that there is a dynamic interplay between signaling pathways that result in the complex pattern of cell-type specific responses required for proliferation, differentiation and survival. One group of nuclear effecters of these signaling pathways are the Ets family of transcription factors, directing cytoplasmic signals to the control of gene expression. This family is defined by a highly conserved DNA binding domain that binds the core consensus sequence GGAA/T, Signaling pathways such as the MAP kinases, Erk1 and 2, p38 and JNK, the PI3 kinases and Ca2+-specific signals activated by growth factors or cellular stresses, converge on the Ets family of factors, controlling their activity, protein partnerships and specification of downstream target genes, Interestingly, Ets family members can act as both upstream and downstream effecters of signaling pathways. As downstream effecters their activities are directly controlled by specific phosphorylations, resulting in their ability to activate or repress specific target genes. As upstream effecters they are responsible for the spacial and temporal expression or numerous growth factor receptors, This review provides a brief survey of what is known to date about how this family of transcription factors is regulated by cellular signaling with a special focus on Pas responsive elements (RREs), the MAP kinases (Erks, p38 and JNK) and Ca2+-specific pathways and includes a description of the multiple roles of Ets family members in the lymphoid system. Finally, we will discuss other potential mechanisms and pathways involved in the regulation of this important family of transcription factors.	Med Univ S Carolina, Hollings Canc Ctr, Ctr Mol & Struct Biol, Charleston, SC 29403 USA; Med Univ S Carolina, Dept Cell Biol & Anat, Charleston, SC 29403 USA	Medical University of South Carolina; Medical University of South Carolina	Muise-Helmericks, RC (corresponding author), Med Univ S Carolina, Hollings Canc Ctr, Ctr Mol & Struct Biol, Charleston, SC 29403 USA.							Aittomaki S, 2000, J IMMUNOL, V164, P5689, DOI 10.4049/jimmunol.164.11.5689; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Anderson KL, 1998, BLOOD, V91, P3702, DOI 10.1182/blood.V91.10.3702; Anderson KL, 1999, BLOOD, V94, P2310, DOI 10.1182/blood.V94.7.2310.419k34_2310_2318; AOYAMA A, 1993, CRIT REV ONCOGENESIS, V4, P53; BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; Blumenthal SG, 1999, J BIOL CHEM, V274, P12910, DOI 10.1074/jbc.274.18.12910; Boehlk S, 2000, EUR J IMMUNOL, V30, P1102, DOI 10.1002/(SICI)1521-4141(200004)30:4<1102::AID-IMMU1102>3.0.CO;2-X; BORTNER DM, 1993, CRIT REV ONCOGENESIS, V4, P137; BOULUKOS KE, 1990, GENE DEV, V4, P401, DOI 10.1101/gad.4.3.401; Bradford AP, 1996, J BIOL CHEM, V271, P24639, DOI 10.1074/jbc.271.40.24639; Bradford AP, 2000, J BIOL CHEM, V275, P3100, DOI 10.1074/jbc.275.5.3100; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; CHAMBERS AF, 1993, CRIT REV ONCOGENESIS, V4, P95; Chang J, 2000, ONCOGENE, V19, P151, DOI 10.1038/sj.onc.1203252; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; CHEN HM, 1995, ONCOGENE, V11, P1549; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; Chung KC, 1998, MOL CELL BIOL, V18, P2272, DOI 10.1128/MCB.18.4.2272; CORNELL RA, 1994, DEVELOPMENT, V120, P453; Cowley DO, 2000, GENE DEV, V14, P366; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; Dalgleish P, 2000, NUCLEIC ACIDS RES, V28, P560, DOI 10.1093/nar/28.2.560; DEED RW, 1993, ONCOGENE, V8, P599; DeKoter RP, 1998, EMBO J, V17, P4456, DOI 10.1093/emboj/17.15.4456; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Dube A, 1999, CIRC RES, V84, P1177, DOI 10.1161/01.RES.84.10.1177; Ducret C, 1999, MOL CELL BIOL, V19, P7076; Dwivedi PP, 2000, J BIOL CHEM, V275, P47, DOI 10.1074/jbc.275.1.47; Fisher RC, 1998, STEM CELLS, V16, P25, DOI 10.1002/stem.160025; FISHER RJ, 1994, PROTEIN SCI, V3, P257; FLEISCHMAN LF, 1993, ONCOGENE, V8, P771; FLEISCHMAN LF, 1995, MOL CELL BIOL, V15, P925; Funaoka K, 1997, BIOCHEM BIOPH RES CO, V236, P79, DOI 10.1006/bbrc.1997.6909; Gabay L, 1996, DEVELOPMENT, V122, P3355; GALANG CK, 1994, ONCOGENE, V9, P2913; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; Giovane A, 1997, MOL CELL BIOL, V17, P5667, DOI 10.1128/MCB.17.10.5667; Goetz TL, 2000, MOL CELL BIOL, V20, P81, DOI 10.1128/MCB.20.1.81-90.2000; GRANT PA, 1995, EMBO J, V14, P4501, DOI 10.1002/j.1460-2075.1995.tb00129.x; Gri G, 1998, J BIOL CHEM, V273, P6431, DOI 10.1074/jbc.273.11.6431; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Guerini D, 1997, BIOCHEM BIOPH RES CO, V235, P271, DOI 10.1006/bbrc.1997.6802; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HARA E, 1994, J BIOL CHEM, V269, P2139; Himmelmann A, 1996, BLOOD, V87, P1036, DOI 10.1182/blood.V87.3.1036.bloodjournal8731036; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; ISAACS HV, 1994, EMBO J, V13, P4469, DOI 10.1002/j.1460-2075.1994.tb06769.x; JANKNECHT R, 1995, CARCINOGENESIS, V16, P443, DOI 10.1093/carcin/16.3.443; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; Jayaraman G, 1999, J BIOL CHEM, V274, P17342, DOI 10.1074/jbc.274.24.17342; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; Kimura A, 2000, J BIOL CHEM, V275, P3667, DOI 10.1074/jbc.275.5.3667; KISTLER B, 1995, ONCOGENE, V11, P1095; KLAMBT C, 1993, DEVELOPMENT, V117, P163; KLEE CB, 1991, NEUROCHEM RES, V16, P1059, DOI 10.1007/BF00965851; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kotenko SV, 2000, ONCOGENE, V19, P2557, DOI 10.1038/sj.onc.1203524; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; KRAMER B, 1995, J BIOL CHEM, V270, P6577; KRISHNARAJU K, 1995, MOL CELL BIOL, V15, P5499; LABONNE C, 1995, DEVELOPMENT, V121, P1475; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; Lecine P, 1997, MOL CELL BIOL, V17, P2351, DOI 10.1128/MCB.17.4.2351; LEUNG S, 1993, ONCOGENE, V8, P989; Li RH, 1999, P NATL ACAD SCI USA, V96, P3876, DOI 10.1073/pnas.96.7.3876; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Lloberas J, 1999, IMMUNOL TODAY, V20, P184, DOI 10.1016/S0167-5699(99)01442-5; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LOHSE DL, 1995, STRUCTURE, V3, P987, DOI 10.1016/S0969-2126(01)00234-9; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; Luo C, 1996, P NATL ACAD SCI USA, V93, P8907, DOI 10.1073/pnas.93.17.8907; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Masutani H, 1997, ONCOGENE, V15, P1661, DOI 10.1038/sj.onc.1201328; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; Means AR, 2000, MOL ENDOCRINOL, V14, P4, DOI 10.1210/me.14.1.4; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; Mora-Garcia P, 2000, J BIOL CHEM, V275, P22418, DOI 10.1074/jbc.M001731200; Nguyen VT, 2000, J BIOL CHEM, V275, P23674, DOI 10.1074/jbc.M002482200; OHMICHI M, 1994, BIOCHEM BIOPH RES CO, V201, P642, DOI 10.1006/bbrc.1994.1749; OHMICHI M, 1994, J BIOL CHEM, V269, P3783; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; Panitz F, 1998, EMBO J, V17, P4414, DOI 10.1093/emboj/17.15.4414; PAPAS TS, 1989, CURR TOP MICROBIOL, V149, P143; Perkel JM, 1998, J IMMUNOL, V160, P241; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; RABAULT B, 1994, J BIOL CHEM, V269, P28143; Rameil P, 2000, ONCOGENE, V19, P2086, DOI 10.1038/sj.onc.1203542; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; REBAY I, 1995, CELL, V81, P857, DOI 10.1016/0092-8674(95)90006-3; Rehli M, 2000, J BIOL CHEM, V275, P9773, DOI 10.1074/jbc.275.13.9773; Rellahan BL, 1998, J IMMUNOL, V160, P2794; Rogge R, 1995, DEVELOPMENT, V121, P3947; ROMANOSPICA V, 1995, J IMMUNOL, V154, P2724; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; Sarafova S, 1999, J BIOL CHEM, V274, P16126, DOI 10.1074/jbc.274.23.16126; Scholz H, 1997, MECH DEVELOP, V62, P79, DOI 10.1016/S0925-4773(96)00652-1; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Serdobova I, 1997, J EXP MED, V185, P1211, DOI 10.1084/jem.185.7.1211; Sevilla L, 1999, MOL CELL BIOL, V19, P2624; SHAW PE, 1992, EMBO J, V11, P3011, DOI 10.1002/j.1460-2075.1992.tb05371.x; SHORE P, 1994, MOL CELL BIOL, V14, P3283, DOI 10.1128/MCB.14.5.3283; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; Soderling TR, 1999, TRENDS BIOCHEM SCI, V24, P232, DOI 10.1016/S0968-0004(99)01383-3; STEFFAN NM, 1995, J IMMUNOL, V155, P4685; STERNER R, 1979, J BIOL CHEM, V254, P1577; Sun PQ, 1996, J BIOL CHEM, V271, P3066, DOI 10.1074/jbc.271.6.3066; Tamir A, 1999, MOL CELL BIOL, V19, P4452; Tian JM, 1999, J BIOL CHEM, V274, P15173, DOI 10.1074/jbc.274.21.15173; Tokumitsu H, 1996, J BIOL CHEM, V271, P5617, DOI 10.1074/jbc.271.10.5617; Tokumitsu H, 1997, BIOCHEMISTRY-US, V36, P12823, DOI 10.1021/bi971348i; TREIER M, 1995, CELL, V83, P753, DOI 10.1016/0092-8674(95)90188-4; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VALENTINE MA, 1995, J EXP MED, V182, P1943, DOI 10.1084/jem.182.6.1943; Villafranca JE, 1996, CURR OPIN BIOTECH, V7, P397; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Wang YH, 1999, MOL ENDOCRINOL, V13, P1094, DOI 10.1210/me.13.7.1094; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; Wasylyk C, 1997, ONCOGENE, V14, P899, DOI 10.1038/sj.onc.1200914; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WASYLYK C, 1994, ONCOGENE, V9, P3665; Wayman GA, 1997, J BIOL CHEM, V272, P16073, DOI 10.1074/jbc.272.26.16073; WEN SC, 1995, EXP CELL RES, V217, P8, DOI 10.1006/excr.1995.1057; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; Yamada T, 1997, BLOOD, V89, P1383, DOI 10.1182/blood.V89.4.1383; Yamada Toshiyuki, 1997, Leukemia (Basingstoke), V11, P480; Yang BS, 1996, MOL CELL BIOL, V16, P538; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; Yang ZY, 2000, J BIOL CHEM, V275, P21272, DOI 10.1074/jbc.M000145200; Yates PR, 1999, EMBO J, V18, P968, DOI 10.1093/emboj/18.4.968; Yi HK, 1997, ONCOGENE, V14, P1259, DOI 10.1038/sj.onc.1201099; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	160	263	267	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	2000	19	55					6503	6513		10.1038/sj.onc.1204036	http://dx.doi.org/10.1038/sj.onc.1204036			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395RL	11175366				2022-12-17	WOS:000166595000012
J	Costello, PS; Turner, M; Walters, AE; Cunningham, CN; Bauer, PH; Downward, J; Tybulewicz, VLJ				Costello, PS; Turner, M; Walters, AE; Cunningham, CN; Bauer, PH; Downward, J; Tybulewicz, VLJ			Critical role for the tyrosine kinase Syk in signalling through the high affinity IgE receptor of mast cells	ONCOGENE			English	Article						Syk; Fc epsilon RI; mast cell; signal transduction; allergy	BASOPHILIC LEUKEMIA-CELLS; FC-EPSILON-RI; SEVERE COMBINED IMMUNODEFICIENCY; IMMUNOGLOBULIN-E RECEPTOR; ANTIGEN RECEPTOR; MICE LACKING; TRANSCRIPTION FACTOR; GAMMA-CHAIN; T-CELLS; PHOSPHOLIPASE C-GAMMA-1	Activation of the high affinity IgE receptor (Fc epsilon RI) of mast cells, a member of the antigen receptor family, leads to the release of allergic mediators, a critical event in the onset of immediate hypersensitivity. Stimulation of Fc epsilon RI results in the rapid association and activation of the Syk tyrosine kinase. Using Syk-deficient mast cells we show that they fail to degranulate, synthesize leukotrienes and secrete cytokines when stimulated through Fc epsilon RI, conclusively demonstrating an essential role for Syk in Fc epsilon Phi RI signalling, Furthermore, our data strongly supports a model of Fc epsilon RI engagement leading to the sequential activation of the tyrosine kinases Lyn and then Syk, A similar mechanism is likely to apply to signal transduction through all members of the antigen receptor family.	NATL INST MED RES,LONDON NW7 1AA,ENGLAND; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	MRC National Institute for Medical Research; Cancer Research UK			Turner, Martin/N-9976-2014	Turner, Martin/0000-0002-3801-9896; Downward, Julian/0000-0002-2331-4729				Adachi M, 1996, CELL, V85, P15; ALBER G, 1991, J BIOL CHEM, V266, P22613; ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BAUMANN G, 1994, EUR J IMMUNOL, V24, P1799, DOI 10.1002/eji.1830240812; BENHAMOU M, 1992, J BIOL CHEM, V267, P7310; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; BOLEN JB, 1995, CURR OPIN IMMUNOL, V7, P306, DOI 10.1016/0952-7915(95)80103-0; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; CHENG GH, 1994, P NATL ACAD SCI USA, V91, P8152, DOI 10.1073/pnas.91.17.8152; CHOI MSK, 1994, IMMUNITY, V1, P179, DOI 10.1016/1074-7613(94)90096-5; Choi OH, 1996, NATURE, V380, P634; CONNELLY PA, 1991, BIOCHEM BIOPH RES CO, V177, P192, DOI 10.1016/0006-291X(91)91967-H; DAI TN, 1995, ONCOGENE, V10, P849; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; EISEMAN E, 1992, NATURE, V355, P78; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; FUKAMACHI H, 1992, P NATL ACAD SCI USA, V89, P9524, DOI 10.1073/pnas.89.20.9524; GRAND DG, 1994, J EXP MED, V180, P673; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HIRASAWA N, 1995, J IMMUNOL, V154, P5391; HIRASAWA N, 1995, J BIOL CHEM, V270, P10960, DOI 10.1074/jbc.270.18.10960; HO AM, 1994, J BIOL CHEM, V269, P28181; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; HUTCHINSON LE, 1995, J BIOL CHEM, V270, P16333, DOI 10.1074/jbc.270.27.16333; INDIK ZK, 1995, BLOOD, V86, P4389, DOI 10.1182/blood.V86.12.4389.bloodjournal86124389; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; Kimura T, 1996, MOL CELL BIOL, V16, P1471; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; LIU CP, 1993, EMBO J, V12, P4863, DOI 10.1002/j.1460-2075.1993.tb06176.x; MALISSEN M, 1993, EMBO J, V12, P4347, DOI 10.1002/j.1460-2075.1993.tb06119.x; Mano H, 1996, FASEB J, V10, P637, DOI 10.1096/fasebj.10.5.8621063; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MINOGUCHI K, 1994, J BIOL CHEM, V269, P16902; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; NEGISHI I, 1995, NATURE, V376, P435, DOI 10.1038/376435a0; OHNO H, 1994, J EXP MED, V179, P365, DOI 10.1084/jem.179.1.365; OHNO H, 1993, EMBO J, V12, P4357, DOI 10.1002/j.1460-2075.1993.tb06120.x; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; ORTEGA E, 1989, EUR J IMMUNOL, V19, P2251, DOI 10.1002/eji.1830191211; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PARK SY, 1995, EUR J IMMUNOL, V25, P2107, DOI 10.1002/eji.1830250746; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PRIESCHL EE, 1995, J IMMUNOL, V154, P6112; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RIVERA VM, 1995, MOL CELL BIOL, V15, P1582; SCHARENBERG AM, 1995, EMBO J, V14, P3385, DOI 10.1002/j.1460-2075.1995.tb07344.x; Schultz Leonard D., 1993, Cell, V73, P1445; SHIUE L, 1995, MOL CELL BIOL, V15, P272, DOI 10.1128/MCB.15.1.272; SHIUE L, 1995, J BIOL CHEM, V270, P10498, DOI 10.1074/jbc.270.18.10498; STEVENS RL, 1989, IMMUNOL TODAY, V10, P381, DOI 10.1016/0167-5699(89)90272-7; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TAYLOR JA, 1995, MOL CELL BIOL, V15, P4149; THOMAS ML, 1995, J EXP MED, V181, P1953, DOI 10.1084/jem.181.6.1953; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; VENKATARAMAN L, 1994, IMMUNITY, V1, P189, DOI 10.1016/1074-7613(94)90097-3; WADHWA M, 1991, QUANTITATIVE BIOL AS, P309; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; YAMANASHI Y, 1993, P NATL ACAD SCI USA, V90, P3631, DOI 10.1073/pnas.90.8.3631; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P11251, DOI 10.1073/pnas.91.23.11251	73	263	269	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2595	2605						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000133				2022-12-17	WOS:A1996VZ65400009
J	MAYOL, X; GRANA, X; BALDI, A; SANG, NL; HU, QJ; GIORDANO, A				MAYOL, X; GRANA, X; BALDI, A; SANG, NL; HU, QJ; GIORDANO, A			CLONING OF A NEW MEMBER OF THE RETINOBLASTOMA GENE FAMILY (PRB2) WHICH BINDS TO THE E1A TRANSFORMING DOMAIN	ONCOGENE			English	Article							HUMAN ADENOVIRUS TYPE-5; TRANSCRIPTION FACTOR; RB GENE; HUMAN CANCER; HUMAN CDC2; PROTEIN; PRODUCT; CELLS; E2F; EXPRESSION	The product of the retinoblastoma tumor suppressor gene (pRb) and p107 share a high degree of structural homology in the pocket region, which is thought to play a primary role in the function of these proteins. It is conceivable that there exists a larger family of cellular proteins containing this pocket region. In this communication, we report cloning of a new human cDNA encoding a polypeptide that shows a high level of identity with pRb and p107 and possesses a pocket region. We have named it pRb2. From the deduced amino acid sequence, pRb2 has a predicted molecular weight of approximately 120 kD and its in vitro translated product binds to the adenovirus E1A protein. Due to its size, pRb2 may correspond to p130, which has previously been shown by us to interact with the transforming region of E1A in in vivo studies. Interestingly, pRb2 fails to bind an EIA mutant in the transforming domain 2 suggesting that pRb2 is involved in the transforming capacity of E1A.	TEMPLE UNIV,HLTH SCI CTR,SCH MED,FELS INST CANC RES & MOLEC BIOL,3307 N BROAD ST,PHILADELPHIA,PA 19140; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT PATHOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Giordano, Antonio/F-1927-2010; Mayol, Xavier/C-1391-2012; Baldi, Alfonso/ABG-2397-2021	Giordano, Antonio/0000-0002-5959-016X; Grana, Xavier/0000-0001-7134-0473; Baldi, Alfonso/0000-0002-8693-3842; Mayol, Xavier/0000-0001-7288-195X				BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; GIORDANO A, 1991, ONCOGENE, V6, P481; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HERMANN CH, 1991, J VIROL, V65, P5848; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1990, MOL CELL BIOL, V10, P3761; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LASKO D, 1991, ANNU REV GENET, V25, P281, DOI 10.1146/annurev.ge.25.120191.001433; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; NEVINS JR, 1992, SCIENCE, V258, P424; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; WAGNER S, 1991, NATURE, V352, P189, DOI 10.1038/352189a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X	31	263	269	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2561	2566						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361765				2022-12-17	WOS:A1993LT36800029
J	Wang, P; Dong, Q; Zhang, C; Kuan, PF; Liu, Y; Jeck, WR; Andersen, JB; Jiang, W; Savich, GL; Tan, TX; Auman, JT; Hoskins, JM; Misher, AD; Moser, CD; Yourstone, SM; Kim, JW; Cibulskis, K; Getz, G; Hunt, HV; Thorgeirsson, SS; Roberts, LR; Ye, D; Guan, KL; Xiong, Y; Qin, LX; Chiang, DY				Wang, P.; Dong, Q.; Zhang, C.; Kuan, P-F; Liu, Y.; Jeck, W. R.; Andersen, J. B.; Jiang, W.; Savich, G. L.; Tan, T-X; Auman, J. T.; Hoskins, J. M.; Misher, A. D.; Moser, C. D.; Yourstone, S. M.; Kim, J. W.; Cibulskis, K.; Getz, G.; Hunt, H. V.; Thorgeirsson, S. S.; Roberts, L. R.; Ye, D.; Guan, K-L; Xiong, Y.; Qin, L-X; Chiang, D. Y.			Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas	ONCOGENE			English	Article						DNA methylation; epigenetics; tumor metabolism	CELL SELF-RENEWAL; IDH2 MUTATIONS; OLLIER DISEASE; TET PROTEINS; PHENOTYPE; DNA; 5-METHYLCYTOSINE; EXPRESSION; CONVERSION; EVENTS	Mutations in the genes encoding isocitrate dehydrogenase, IDH1 and IDH2, have been reported in gliomas, myeloid leukemias, chondrosarcomas and thyroid cancer. We discovered IDH1 and IDH2 mutations in 34 of 326 (10%) intrahepatic cholangiocarcinomas. Tumor with mutations in IDH1 or IDH2 had lower 5-hydroxymethylcytosine and higher 5-methylcytosine levels, as well as increased dimethylation of histone H3 lysine 79 (H3K79). Mutations in IDH1 or IDH2 were associated with longer overall survival (P = 0.028) and were independently associated with a longer time to tumor recurrence after intrahepatic cholangiocarcinoma resection in multivariate analysis (P = 0.021). IDH1 and IDH2 mutations were significantly associated with increased levels of p53 in intrahepatic cholangiocarcinomas, but no mutations in the p53 gene were found, suggesting that mutations in IDH1 and IDH2 may cause a stress that leads to p53 activation. We identified 2309 genes that were significantly hypermethylated in 19 cholangiocarcinomas with mutations in IDH1 or IDH2, compared with cholangiocarcinomas without these mutations. Hypermethylated CpG sites were significantly enriched in CpG shores and upstream of transcription start sites, suggesting a global regulation of transcriptional potential. Half of the hypermethylated genes overlapped with DNA hypermethylation in IDH1-mutant gliobastomas, suggesting the existence of a common set of genes whose expression may be affected by mutations in IDH1 or IDH2 in different types of tumors.	[Wang, P.; Jiang, W.; Guan, K-L; Xiong, Y.] Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Shanghai 200032, Peoples R China; [Wang, P.; Jiang, W.; Ye, D.; Guan, K-L; Xiong, Y.] Fudan Univ, Inst Biomed Sci, Mol & Cell Biol Lab, Shanghai 200032, Peoples R China; [Dong, Q.; Qin, L-X] Fudan Univ, Liver Canc Inst, Shanghai 200032, Peoples R China; [Dong, Q.; Qin, L-X] Fudan Univ, Zhongshan Hosp, Inst Biomed Sci, Shanghai 200032, Peoples R China; [Zhang, C.; Liu, Y.] Univ N Carolina, Carolina Ctr Genome Sci, Dept Stat & Operat Res, Chapel Hill, NC 27599 USA; [Kuan, P-F] Univ N Carolina, Dept Biostat, Chapel Hill, NC 27599 USA; [Kuan, P-F; Jeck, W. R.; Savich, G. L.; Tan, T-X; Auman, J. T.; Hoskins, J. M.; Misher, A. D.; Yourstone, S. M.; Xiong, Y.; Chiang, D. Y.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Jeck, W. R.; Savich, G. L.; Tan, T-X; Yourstone, S. M.; Chiang, D. Y.] Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA; [Andersen, J. B.; Thorgeirsson, S. S.] NCI, Expt Carcinogenesis Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Auman, J. T.; Hoskins, J. M.; Misher, A. D.] Univ N Carolina, Inst Pharmacogen & Individualized Med, Chapel Hill, NC 27599 USA; [Moser, C. D.; Roberts, L. R.] Mayo Clin, Ctr Canc, Ctr Cell Signaling Gastroenterol, Div Gastroenterol & Hepatol, Rochester, MN USA; [Kim, J. W.] Wake Forest Univ, Baptist Med Ctr, Ctr Canc Genom, Winston Salem, NC 27109 USA; [Cibulskis, K.; Getz, G.] 7 Cambridge Ctr, Broad Inst, Genome Sequencing Anal Program & Platform, Cambridge, MA USA; [Hunt, H. V.] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; [Guan, K-L] Fudan Univ, Shanghai Med Coll, Dept Biochem, Shanghai 200032, Peoples R China; [Guan, K-L] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; [Guan, K-L] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA; [Xiong, Y.] Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	Fudan University; Fudan University; Fudan University; Fudan University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of North Carolina; University of North Carolina Chapel Hill; Mayo Clinic; Wake Forest University; Wake Forest Baptist Medical Center; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; University of North Carolina; University of North Carolina Chapel Hill; Fudan University; University of California System; University of California San Diego; University of California System; University of California San Diego; University of North Carolina; University of North Carolina Chapel Hill	Xiong, Y (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, CB 7295,450 West Dr, Chapel Hill, NC 27599 USA.	yxiong@email.unc.edu; qin.lunxiu@zs-hospital.sh.cn; chiang@med.unc.edu	Core, Mammalian Genotyping/AFU-1631-2022; Cibulskis, Kristian/AAC-7380-2019; , Pathology Services Core/CEZ-2246-2022; Chiang, Derek/L-6452-2019; Kuan, Pei Fen/GRX-4622-2022; Facility, Biospecimen Processing/AAC-7837-2022; Guan, Kun-Liang/ADK-7088-2022	Chiang, Derek/0000-0002-1131-6065; Tan, Ting Xu/0000-0002-7067-898X; Andersen, Jesper B/0000-0003-1760-5244; Roberts, Lewis/0000-0001-7885-8574; Kim, Johnny/0000-0002-5226-5460; Cibulskis, Kristian/0000-0003-1343-1582; Auman, James/0000-0002-9328-8829	985 Program from the Chinese Ministry of Education; MOST 973 [2009CB918401, 2011CB910600, 2012CB910300, 2012CB910101]; NSFC Program of International Cooperation and Exchanges [81120108016]; China National Key Projects for Infectious Disease [2008ZX10002-021, 2012ZX10002-012]; National Institutes of Health; James S McDonnell Foundation; Samuel Waxman Cancer Research Foundation; American Gastroenterological Association Foundation for Digestive Health and Nutrition; Alfred P Sloan Foundation; Nancy Stegman Cancer Research Fund; University Cancer Research Fund	985 Program from the Chinese Ministry of Education(Ministry of Education, China); MOST 973(National Basic Research Program of China); NSFC Program of International Cooperation and Exchanges; China National Key Projects for Infectious Disease; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); James S McDonnell Foundation; Samuel Waxman Cancer Research Foundation; American Gastroenterological Association Foundation for Digestive Health and Nutrition; Alfred P Sloan Foundation(Alfred P. Sloan Foundation); Nancy Stegman Cancer Research Fund; University Cancer Research Fund	The UNC Biospecimen Core Facility, Mammalian Genotyping Core Facility and Translational Pathology Laboratory provided technical assistance for this study. Funding for this research was provided by: the 985 Program from the Chinese Ministry of Education (KLG, YX), MOST 973 (No. 2009CB918401, No. 2011CB910600, No. 2012CB910300, No. 2012CB910101; DY, YX and KLG); the NSFC Program of International Cooperation and Exchanges (No. 81120108016; LXQ, YX) and the China National Key Projects for Infectious Disease (2008ZX10002-021, 2012ZX10002-012; LZQ), the National Institutes of Health (KLG, YX, SST, LRR), the James S McDonnell Foundation (YX), the Samuel Waxman Cancer Research Foundation (YX), the American Gastroenterological Association Foundation for Digestive Health and Nutrition (LRR), the Alfred P Sloan Foundation fellowship (DYC), the Nancy Stegman Cancer Research Fund (DYC) and the University Cancer Research Fund (DYC, YX).	Abdel-Wahab O, 2010, CANCER RES, V70, P447, DOI 10.1158/0008-5472.CAN-09-3783; Aishima S, 2006, HISTOPATHOLOGY, V49, P35, DOI 10.1111/j.1365-2559.2006.02414.x; Amary MF, 2011, NAT GENET, V43, P1262, DOI 10.1038/ng.994; Amary MF, 2011, J PATHOL, V224, P334, DOI 10.1002/path.2913; Andersen JB, 2012, GASTROENTEROLOGY, V142, P1021, DOI 10.1053/j.gastro.2011.12.005; Andersen JB, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001338; Blechacz B, 2008, HEPATOLOGY, V48, P308, DOI 10.1002/hep.22310; Borger DR, 2012, ONCOLOGIST, V17, P72, DOI 10.1634/theoncologist.2011-0386; Brenet F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014524; Cardinale V, 2012, NAT REV GASTRO HEPAT, V9, P231, DOI 10.1038/nrgastro.2012.23; Chapman MA, 2011, NATURE, V471, P467, DOI 10.1038/nature09837; Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617; Dunn GP, 2012, GENE DEV, V26, P756, DOI 10.1101/gad.187922.112; Fang F, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001875; Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015; He YF, 2011, SCIENCE, V333, P1303, DOI 10.1126/science.1210944; Hezel AF, 2010, J CLIN ONCOL, V28, P3531, DOI 10.1200/JCO.2009.27.4787; Hinoue T, 2012, GENOME RES, V22, P271, DOI 10.1101/gr.117523.110; Ito S, 2011, SCIENCE, V333, P1300, DOI 10.1126/science.1210597; Ito S, 2010, NATURE, V466, P1129, DOI 10.1038/nature09303; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kipp BR, 2012, HUM PATHOL; Llovet JM, 2008, JNCI-J NATL CANCER I, V100, P698, DOI 10.1093/jnci/djn134; Marcucci G, 2010, J CLIN ONCOL, V28, P2348, DOI 10.1200/JCO.2009.27.3730; Merico D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013984; Moran-Crusio K, 2011, CANCER CELL, V20, P11, DOI 10.1016/j.ccr.2011.06.001; Nagasaka T, 2004, J CLIN ONCOL, V22, P4584, DOI 10.1200/JCO.2004.02.154; Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972; Pansuriya TC, 2011, NAT GENET, V43, P1256, DOI 10.1038/ng.1004; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950; Shibata T, 2011, AM J PATHOL, V178, P1395, DOI 10.1016/j.ajpath.2010.12.011; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Turner R, 2011, HEPATOLOGY, V53, P1035, DOI 10.1002/hep.24157; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020; Watanabe T, 2009, AM J PATHOL, V174, P1149, DOI 10.2353/ajpath.2009.080958; Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Xu YF, 2011, MOL CELL, V42, P451, DOI 10.1016/j.molcel.2011.04.005; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Yang B, 2010, CELL RES, V20, P1188, DOI 10.1038/cr.2010.145; Zhao SM, 2009, SCIENCE, V324, P261, DOI 10.1126/science.1170944	46	262	291	2	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2013	32	25					3091	3100		10.1038/onc.2012.315	http://dx.doi.org/10.1038/onc.2012.315			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	168KX	22824796	Green Accepted, Green Submitted			2022-12-17	WOS:000320705700009
J	Iyengar, P; Combs, TP; Shah, SJ; Gouon-Evans, V; Pollard, JW; Albanese, C; Flanagan, L; Tenniswood, MP; Guha, C; Lisanti, MP; Pestell, RG; Scherer, PE				Iyengar, P; Combs, TP; Shah, SJ; Gouon-Evans, V; Pollard, JW; Albanese, C; Flanagan, L; Tenniswood, MP; Guha, C; Lisanti, MP; Pestell, RG; Scherer, PE			Adipocyte-secreted factors synergistically promote mammary tumorigenesis through induction of anti-apoptotic transcriptional programs and proto-oncogene stabilization	ONCOGENE			English	Review						stromal cells; heterotypic signaling; breast cancer; adipocytes; Type VI collagen	HUMAN-BREAST-CANCER; BETA-CATENIN; EPITHELIAL-CELL; GENE-EXPRESSION; ADIPOSE-TISSUE; GROWTH-FACTOR; MALIGNANT-TRANSFORMATION; EXTRACELLULAR-MATRIX; BASEMENT-MEMBRANE; MESSENGER-RNA	Mammary epithelial cells are embedded in a unique extracellular environment to which adipocytes and other stromal cells contribute. Mammary epithelial cells are critically dependent on this milieu for survival. However, it remains unknown which adipocyte-secreted factors are required for the survival of the mammary epithelia and what role these adipokines play in the process of ductal carcinoma tumorigenesis. Here, we take a systematic molecular approach to investigate the multiple ways adipocytes and adipokines can uniquely influence the characteristics and phenotypic behavior of malignant breast ductal epithelial cells. Microarray analysis and luciferase reporter assays indicate that adipokines specifically induce several transcriptional programs involved in promoting tumorigenesis, including increased cell proliferation (IGF2, FOS, JUN, cyclin D1), invasive potential (MMP1, ATF3), survival (A20, NFkappaB), and angiogenesis. One of the key changes in the transformed ductal epithelial cells associated with the cell cycle involves the induction of NFkappaB (five-fold) and cyclin D1 (three-fold). We show that by regulating the transcription of these molecules, the synergistic activity of adipocyte-derived factors can potentiate MCF-7 cell proliferation. Furthermore, compared to other stromal cell-secreted factors, the full complement of adipokines shows an unparalleled ability to promote increased cell motility, migration, and the capacity for angiogenesis. Adipocyte-secreted factors can affect tumorigenesis by increasing the stabilization of pro-oncogenic factors such as beta-catenin and CDK6 as a result of a reduction in the gene expression of their inhibitors (i.e. p18). An in vivo coinjection system using 3T3-L1 adipocytes and SUM159PT cells effectively recapitulates the host-tumor interactions in primary tumors. Type VI collagen, a soluble extracellular matrix protein abundantly expressed in adipocytes, is further upregulated in adipocytes during tumorigenesis. It promotes GSK3beta phosphorylation, beta-catenin stabilization, and increased beta-catenin activity in breast cancer cells and may critically contribute towards tumorigenesis when not counterbalanced by other factors.	Albert Einstein Coll Med, Albert Einstein Canc Ctr, Dept Cell Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Albert Einstein Canc Ctr, Dept Radiat Oncol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Albert Einstein Canc Ctr, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Georgetown Univ, Dept Oncol, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA; Univ Notre Dame, Galvin Life Sci Ctr, Notre Dame, IN 46556 USA; Albert Einstein Coll Med, Albert Einstein Canc Ctr, Dept Mol Pharmacol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Albert Einstein Canc Ctr, Div Hormone Dependent Tumor Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Georgetown University; University of Notre Dame; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Scherer, PE (corresponding author), Albert Einstein Coll Med, Albert Einstein Canc Ctr, Dept Cell Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	scherer@aecom.yu.edu	Scherer, Philipp E/K-7819-2012; Lisanti, Michael/B-6131-2018; Lisanti, Michael P/C-6866-2013	Scherer, Philipp E/0000-0003-0680-3392; Lisanti, Michael/0000-0003-2034-1382; Shah, Shalin/0000-0002-1622-8443; Gouon-Evans, Valerie/0000-0001-5424-6573	NATIONAL CANCER INSTITUTE [R01CA094173] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055758] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER; NCI NIH HHS [CA94173] Funding Source: Medline; NIDDK NIH HHS [1R01-DK55758] Funding Source: Medline; NIGMS NIH HHS [T32-GM07288] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Achison M, 2001, J BIOL CHEM, V276, P3167, DOI 10.1074/jbc.M007186200; Ahima RS, 2000, TRENDS ENDOCRIN MET, V11, P327, DOI 10.1016/S1043-2760(00)00301-5; Atkinson JC, 1996, EXP CELL RES, V228, P283, DOI 10.1006/excr.1996.0328; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BATSAKIS JG, 1983, HEAD NECK SURG, V5, P222, DOI 10.1002/hed.2890050307; Behrens J, 2000, ANN NY ACAD SCI, V910, P21; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Berking C, 2001, CANCER RES, V61, P8306; Beyaert R, 2000, BIOCHEM PHARMACOL, V60, P1143, DOI 10.1016/S0006-2952(00)00404-4; Bickel PE, 2000, BIOTECHNOL GENET ENG, V17, P417, DOI 10.1080/02648725.2000.10648000; Blajeski AL, 2001, EXP CELL RES, V270, P277, DOI 10.1006/excr.2001.5349; Brantjes H, 2002, BIOL CHEM, V383, P255, DOI 10.1515/BC.2002.027; CASTELLOT JJ, 1982, P NATL ACAD SCI-BIOL, V79, P5597, DOI 10.1073/pnas.79.18.5597; Chamras H, 1998, NUTR CANCER, V32, P59, DOI 10.1080/01635589809514719; Charpentier AH, 2000, CANCER RES, V60, P5977; Cheng YC, 2001, MOL BRAIN RES, V92, P193, DOI 10.1016/S0169-328X(01)00147-4; CHRISTIANSEN NO, 1992, ACTA BIOCHIM BIOPHYS, V26, P1; Codd JD, 1999, J PATHOL, V187, P549; Coussens LM, 2001, J EXP MED, V193, pF23, DOI 10.1084/jem.193.6.F23; Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Cunha GR, 2000, ADV EXP MED BIOL, V480, P93; de la Guardia C, 2001, HEAD NECK-J SCI SPEC, V23, P104; Dieudonne MN, 2002, BIOCHEM BIOPH RES CO, V293, P622, DOI 10.1016/S0006-291X(02)00205-X; DOBSON DE, 1990, CELL, V61, P223, DOI 10.1016/0092-8674(90)90803-M; ELLIOTT BE, 1992, INT J CANCER, V51, P416, DOI 10.1002/ijc.2910510314; Ellis MJ, 1998, BREAST CANCER RES TR, V52, P175, DOI 10.1023/A:1006127621512; Engelman JA, 2000, MOL ENDOCRINOL, V14, P1557, DOI 10.1210/me.14.10.1557; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; FIDLER I, 2001, J NATL CANC I MONOGR, V28, P10; Fidler I J, 2001, Surg Oncol Clin N Am, V10, P257; Fidler IJ, 2001, JNCI-J NATL CANCER I, V93, P1040, DOI 10.1093/jnci/93.14.1040; Flanagan L, 1999, BREAST CANCER RES TR, V58, P193, DOI 10.1023/A:1006331716981; FRIDMAN R, 1991, JNCI-J NATL CANCER I, V83, P769, DOI 10.1093/jnci/83.11.769; FRIDMAN R, 1992, INT J CANCER, V51, P740, DOI 10.1002/ijc.2910510513; Fujiwara Y, 2000, INT J ONCOL, V16, P799; Ghimenti C, 2002, GENE CHROMOSOME CANC, V33, P235, DOI 10.1002/gcc.1223; Gui GPH, 1997, BRIT J CANCER, V75, P623, DOI 10.1038/bjc.1997.113; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hansen RK, 2000, ENDOCR-RELAT CANCER, V7, P95, DOI 10.1677/erc.0.0070095; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Havel PJ, 2000, P NUTR SOC, V59, P359, DOI 10.1017/S0029665100000410; Hayward SW, 2001, CANCER RES, V61, P8135; Heber D, 1996, ADV EXP MED BIOL, V399, P41; Hernando E, 2001, INT J CANCER, V95, P223, DOI 10.1002/1097-0215(20010720)95:4<223::AID-IJC1038>3.0.CO;2-L; HOWLETT AR, 1993, EPITHELIAL CELL BIOL, V2, P79; Huang WD, 2000, MOL CELL BIOL, V20, P4149, DOI 10.1128/MCB.20.11.4149-4158.2000; Huss FRM, 2001, CELLS TISSUES ORGANS, V169, P361, DOI 10.1159/000047903; Hutchinson JN, 2000, ONCOGENE, V19, P6130, DOI 10.1038/sj.onc.1203970; Irminger-Finger I, 1998, J CELL BIOL, V143, P1329, DOI 10.1083/jcb.143.5.1329; Jellinek DA, 2000, BIOCHEM J, V350, P453, DOI 10.1042/0264-6021:3500453; JOHNSTON PG, 1992, CANCER RES, V52, P6860; Lal A, 2001, JNCI-J NATL CANCER I, V93, P1337, DOI 10.1093/jnci/93.17.1337; Lapointe J, 1996, CANCER RES, V56, P4586; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Lee H, 1999, MOL CELL, V4, P1, DOI 10.1016/S1097-2765(00)80182-3; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Lin Y, 2000, J BIOL CHEM, V275, P24255, DOI 10.1074/jbc.M002137200; Lin Y, 2001, J BIOL CHEM, V276, P42077, DOI 10.1074/jbc.M107101200; LIOTTA LA, 1988, BREAST CANCER RES TR, V11, P113, DOI 10.1007/BF01805835; LIOTTA LA, 1983, LAB INVEST, V49, P636; Liu SC, 2000, ORAL ONCOL, V36, P145, DOI 10.1016/S1368-8375(99)00076-7; Matrisian LM, 2001, CANCER RES, V61, P3844; McCann AH, 1996, HUM MOL GENET, V5, P1123, DOI 10.1093/hmg/5.8.1123; McKeon F, 1999, Breast Cancer Res, V1, P8, DOI 10.1186/bcr4; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; Mohamed-Ali V, 1998, INT J OBESITY, V22, P1145, DOI 10.1038/sj.ijo.0800770; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Myrie KA, 2000, CANCER LETT, V152, P193, DOI 10.1016/S0304-3835(00)00340-2; Novak A, 1999, CELL MOL LIFE SCI, V56, P523, DOI 10.1007/s000180050449; O'Brien SN, 1999, BIOCHEM BIOPH RES CO, V259, P695, DOI 10.1006/bbrc.1999.0843; Oh Y, 1997, ENDOCRINE, V7, P111, DOI 10.1007/BF02778076; Park CC, 2000, MOL MED TODAY, V6, P324, DOI 10.1016/S1357-4310(00)01756-1; Pentecost BT, 1998, J STEROID BIOCHEM, V64, P25, DOI 10.1016/S0960-0760(97)00140-4; Perks CM, 2000, J MAMMARY GLAND BIOL, V5, P75, DOI 10.1023/A:1009519400591; PEYRAT JP, 1988, CANCER RES, V48, P6429; RAHIMI N, 1994, DNA CELL BIOL, V13, P1189, DOI 10.1089/dna.1994.13.1189; Rahimi N, 1998, IN VITRO CELL DEV-AN, V34, P412; Rasmussen AA, 1998, BREAST CANCER RES TR, V47, P219, DOI 10.1023/A:1005903000777; Ross JS, 2001, ANN NY ACAD SCI, V947, P271; Ruhl M, 1999, J BIOL CHEM, V274, P34361, DOI 10.1074/jbc.274.48.34361; Ruiter D, 2002, LANCET ONCOL, V3, P35, DOI 10.1016/S1470-2045(01)00620-9; Sachdev D, 2001, ENDOCR-RELAT CANCER, V8, P197, DOI 10.1677/erc.0.0080197; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Scherer PE, 1998, NAT BIOTECHNOL, V16, P581, DOI 10.1038/nbt0698-581; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Schmeichel KL, 1998, J MAMMARY GLAND BIOL, V3, P201, DOI 10.1023/A:1018751124382; Shaw LM, 1999, J MAMMARY GLAND BIOL, V4, P367, DOI 10.1023/A:1018766317055; SHERR CJ, 1994, STEM CELLS, V12, P47; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shigeishi H, 2001, PATHOBIOLOGY, V69, P24, DOI 10.1159/000048754; SILVERMAN KJ, 1988, BIOCHEM BIOPH RES CO, V153, P347, DOI 10.1016/S0006-291X(88)81229-4; St Croix B, 2000, SCIENCE, V289, P1197; Sternlicht MD, 2000, ONCOGENE, V19, P1102, DOI 10.1038/sj.onc.1203347; SWEENEY TM, 1991, CANCER METAST REV, V10, P245, DOI 10.1007/BF00050795; Tani M, 1997, GENOMICS, V39, P30, DOI 10.1006/geno.1996.4483; Turton NJ, 2001, ONCOGENE, V20, P1300, DOI 10.1038/sj.onc.1204235; Wagenaar RA, 2001, CANCER RES, V61, P2097; Waltzer L, 1999, CANCER METAST REV, V18, P231, DOI 10.1023/A:1006321324190; Wiseman BS, 2002, SCIENCE, V296, P1046, DOI 10.1126/science.1067431; Ye S, 2001, CANCER RES, V61, P1296; Zangani D, 1999, EXP CELL RES, V247, P399, DOI 10.1006/excr.1998.4373; Zhang JY, 2001, CLIN EXP IMMUNOL, V125, P3, DOI 10.1046/j.1365-2249.2001.01585.x	105	262	281	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2003	22	41					6408	6423		10.1038/sj.onc.1206737	http://dx.doi.org/10.1038/sj.onc.1206737			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508521				2022-12-17	WOS:000185535300011
J	LIMPENS, J; DEJONG, D; VANKRIEKEN, JHJM; PRICE, CGA; YOUNG, BD; VANOMMEN, GJB; KLUIN, PM				LIMPENS, J; DEJONG, D; VANKRIEKEN, JHJM; PRICE, CGA; YOUNG, BD; VANOMMEN, GJB; KLUIN, PM			BCL-2/JH REARRANGEMENTS IN BENIGN LYMPHOID-TISSUES WITH FOLLICULAR HYPERPLASIA	ONCOGENE			English	Article							T(14-18) CHROMOSOMAL TRANSLOCATION; BREAKPOINT-CLUSTER REGION; NON-HODGKINS-LYMPHOMA; B-CELL NEOPLASMS; RECIPROCAL PARTNERS; HISTOLOGIC SUBTYPES; STRUCTURAL-ANALYSIS; C-MYC; GENE; ABNORMALITIES	The t(14; 18)(q32; q21) chromosomal translocation, characteristic of follicular lymphoma, couples the bcl-2 proto-oncogene on chromosome 18 to the immunoglobulin heavy-chain joining region (J(H)). This results in a deregulated transcription rate of bcl-2, suggesting a major role of the t(14; 18) translocation in lymphomagenesis. By using a sensitive polymerase chain reaction technique specific for the major breakpoint region t(14; 18), we now demonstrate the presence of bcl-2/J(H), rearrangements in lymph nodes and tonsils with follicular hyperplasia in 13 of 24 cases (54%). The approximate frequency was one translocation-positive cell in 10(5) cells. No bcl-2/J(H) rearrangements were detected in reactive lymph nodes without follicular hyperplasia or in bone marrow cells. Sequence analysis showed the amplified bcl-2/J(H) fragments to be unique to each individual sample and distinct from 24 sequenced follicular lymphoma-derived t(14; 18) junctions, thus excluding contamination artifacts. The presence of random nucleotide insertions at the breakpoint junctions suggests a pre-B-cell origin of the t(14; 18) translocation, in analogy with follicular lymphomas. We conclude that the t(14; 18) translocation can occur in non-malignant tissue and will not, on its own lead to malignancy.	LEIDEN UNIV,DEPT PATHOL,2300 RC LEIDEN,NETHERLANDS; ST BARTHOLOMEWS HOSP,IMPERIAL CANC RES FUND,DEPT MED ONCOL,LONDON EC1A BE,ENGLAND	Leiden University; Leiden University - Excl LUMC	LIMPENS, J (corresponding author), LEIDEN UNIV,SYLVIUS LAB,DEPT HUMAN GENET,WASSENAARSE WEG 72,2333 AL LEIDEN,NETHERLANDS.		van Krieken, Joannes H J M/D-4138-2009	van Krieken, Joannes H J M/0000-0001-6544-1040; Limpens, Jacqueline/0000-0002-7362-8574				ADACHI M, 1990, ONCOGENE, V5, P1653; ALTIOK E, 1989, P NATL ACAD SCI USA, V86, P6333, DOI 10.1073/pnas.86.16.6333; AURIAS A, 1980, MUTAT RES, V69, P369, DOI 10.1016/0027-5107(80)90101-3; BAKHSHI A, 1987, P NATL ACAD SCI USA, V84, P2396, DOI 10.1073/pnas.84.8.2396; BOEHM T, 1989, FASEB J, V3, P2344, DOI 10.1096/fasebj.3.12.2676678; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEARY ML, 1986, J EXP MED, V164, P315, DOI 10.1084/jem.164.1.315; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COTTER F, 1990, BLOOD, V76, P131; CRESCENZI M, 1988, P NATL ACAD SCI USA, V85, P4869, DOI 10.1073/pnas.85.13.4869; DEJONG D, 1988, NEW ENGL J MED, V318, P1373, DOI 10.1056/NEJM198805263182106; DEJONG D, 1989, J EXP MED, V169, P613, DOI 10.1084/jem.169.3.613; DEWALD GW, 1986, AM J HUM GENET, V38, P520; GAUWERKY CE, 1988, P NATL ACAD SCI USA, V85, P8548, DOI 10.1073/pnas.85.22.8548; GRANINGER WB, 1987, J CLIN INVEST, V80, P1512, DOI 10.1172/JCI113235; HECHT F, 1987, CANCER GENET CYTOGEN, V26, P95, DOI 10.1016/0165-4608(87)90137-3; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; JUNEJA S, 1990, BRIT J HAEMATOL, V76, P231, DOI 10.1111/j.1365-2141.1990.tb07877.x; KLUINNELEMANS JC, 1991, LEUKEMIA, V55, P221; KROWCZYNSKA AM, 1990, NUCLEIC ACIDS RES, V18, P1121, DOI 10.1093/nar/18.5.1121; LEVINE EG, 1985, BLOOD, V66, P1414; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; NGAN BY, 1989, BLOOD, V73, P1759; NOWELL PC, 1990, AM J CLIN PATHOL, V94, P229, DOI 10.1093/ajcp/94.2.229; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PRICE CGA, 1991, LEUKEMIA, V5, P548; PRICE CGA, 1991, J CLIN ONCOL, V9, P1527, DOI 10.1200/JCO.1991.9.9.1527; RAVETCH JV, 1981, CELL, V27, P583, DOI 10.1016/0092-8674(81)90400-1; REED JC, 1988, NATURE, V336, P259, DOI 10.1038/336259a0; ROWLEY JD, 1984, CANCER RES, V44, P3159; RUANO G, 1989, NUCLEIC ACIDS RES, V17, P5407, DOI 10.1093/nar/17.13.5407; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; STETLERSTEVENSON M, 1990, J NATL CANCER I, V82, P855, DOI 10.1093/jnci/82.10.855; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TSUJIMOTO Y, 1988, ONCOGENE, V2, P347; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TYCKO B, 1989, SCIENCE, V245, P1242, DOI 10.1126/science.2551037; TYCKO B, 1990, CANCER CELL-MON REV, V2, P1; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WEISS LM, 1987, NEW ENGL J MED, V317, P1185, DOI 10.1056/NEJM198711053171904; YUNIS JJ, 1982, NEW ENGL J MED, V307, P1231, DOI 10.1056/NEJM198211113072002; YUNIS JJ, 1987, NEW ENGL J MED, V316, P79, DOI 10.1056/NEJM198701083160204	42	262	264	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2271	2276						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1766674				2022-12-17	WOS:A1991GX73500014
J	VARLEY, JM; BRAMMAR, WJ; LANE, DP; SWALLOW, JE; DOLAN, C; WALKER, RA				VARLEY, JM; BRAMMAR, WJ; LANE, DP; SWALLOW, JE; DOLAN, C; WALKER, RA			LOSS OF CHROMOSOME-17P13 SEQUENCES AND MUTATION OF P53 IN HUMAN BREAST CARCINOMAS	ONCOGENE			English	Article							CELLULAR TUMOR-ANTIGEN; RETINOBLASTOMA GENE-PRODUCT; MONOCLONAL-ANTIBODY; PROTO-ONCOGENE; ALLELE LOSS; SHORT ARM; SV40-TRANSFORMED CELLS; COLORECTAL CARCINOMAS; INCREASED EXPRESSION; TRANSFORMED-CELLS	DNAs from ninety seven primary breast carcinoma biopsies have been examined for loss of sequences on 17p13. In addition, immunohistochemical analysis has been carried out on the majority of these cases to determine whether p53 gene expression can be detected. Detection of p53 expression is taken to indicate mutation of p53 leading to stabilisation of the protein and thus detectable levels of p53 in the cell. In 86% of breast carcinoma samples where both allele loss and expression data were available, loss of sequences on 17p13 and/or expression of p53 was detected. Alterations to p53, whether loss of one allele or mutation, are therefore by far the most common changes so far detected in primary human breast tumours. In three cases where expression of p53 could be detected by immunohistochemistry, the precise mutation to p53 was identified. All three mutations fall within the regions which are highly conserved in p53, encoded by exons 5 to 8. Two are single base changes leading to missense mutations, and the third is a single base-pair deletion. The expression of the latter gene would result in production of a truncated protein which should lack normal biological activities.	UNIV LEICESTER,DEPT PATHOL,LEICESTER LE1 7RH,ENGLAND; IMPERIAL CANC RES FUND,CLARE HALL LABS,POTTERS BAR EN6 3LD,HERTS,ENGLAND	University of Leicester	VARLEY, JM (corresponding author), UNIV LEICESTER,ICI PLC UNIV JOINT LAB,LEICESTER LE1 7RH,ENGLAND.		Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				ADDISON C, 1990, ONCOGENE, V5, P423; AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; ALI IU, 1989, J NATL CANCER I, V81, P1815, DOI 10.1093/jnci/81.23.1815; ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARTEK J, 1990, ONCOGENE, V5, P893; BENCHIMOL S, 1985, SOMAT CELL MOLEC GEN, V11, P505, DOI 10.1007/BF01534845; BENCHIMOL S, 1982, EMBO J, V1, P1055, DOI 10.1002/j.1460-2075.1982.tb01296.x; BENDAVID Y, 1988, ONCOGENE, V3, P179; CALLAHAN R, 1989, JNCI-J NATL CANCER I, V81, P1780, DOI 10.1093/jnci/81.23.1780; CATTORETTI G, 1988, INT J CANCER, V41, P178, DOI 10.1002/ijc.2910410204; CHEN LC, 1989, P NATL ACAD SCI USA, V86, P7204, DOI 10.1073/pnas.86.18.7204; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; Crawford L V, 1984, Mol Biol Med, V2, P261; CRAWFORD LV, 1981, P NATL ACAD SCI-BIOL, V78, P41, DOI 10.1073/pnas.78.1.41; DANG CV, 1989, J BIOL CHEM, V264, P18019; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FULTS D, 1989, CANCER RES, V49, P6572; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GUSTERSON BA, 1988, INT J CANCER, V42, P842, DOI 10.1002/ijc.2910420608; HICKS GG, 1988, J VIROL, V62, P4752, DOI 10.1128/JVI.62.12.4752-4755.1988; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; JAMES CD, 1989, P NATL ACAD SCI USA, V86, P2858, DOI 10.1073/pnas.86.8.2858; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JENKINS JR, 1988, ONCOGENE HDB, P403; KOEFFLER HP, 1986, P NATL ACAD SCI USA, V83, P4035, DOI 10.1073/pnas.83.11.4035; LANE DP, 1985, PROC R SOC SER B-BIO, V226, P25, DOI 10.1098/rspb.1985.0077; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LUNDBERG C, 1987, P NATL ACAD SCI USA, V84, P2372, DOI 10.1073/pnas.84.8.2372; MACKAY J, 1988, LANCET, V2, P1384; MARSHAL R, 1990, BLOOD, V75, P180; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MCBRIDE OW, 1986, P NATL ACAD SCI USA, V83, P130, DOI 10.1073/pnas.83.1.130; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MILLER C, 1986, NATURE, V319, P783, DOI 10.1038/319783a0; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MUNROE DG, 1988, ONCOGENE, V2, P621; Nakamura Y, 1988, GENOMICS, V2, P302, DOI 10.1016/0888-7543(88)90018-3; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; ROGERS J, 1983, NATURE, V305, P101, DOI 10.1038/305101a0; ROSEN PP, 1987, BREAST DISEASES; ROTTER V, 1983, P NATL ACAD SCI-BIOL, V80, P2613, DOI 10.1073/pnas.80.9.2613; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOUSSI T, 1987, ONCOGENE, V1, P71; SOUSSI T, 1990, ONCOGENE, V5, P945; STURZBECHER HW, 1990, ONCOGENE, V5, P795; STURZBECHER HW, 1987, ONCOGENE, V1, P201; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; THOMAS R, 1983, VIROLOGY, V131, P502, DOI 10.1016/0042-6822(83)90516-0; THOMPSON AM, 1990, BRIT J CANCER, V61, P74, DOI 10.1038/bjc.1990.17; TOGUCHIDA J, 1989, CANCER RES, V49, P6247; VANDENBERG FM, 1989, J PATHOL, V157, P193, DOI 10.1002/path.1711570304; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902; VARLEY JM, 1987, ONCOGENE, V1, P423; VARLEY JM, 1989, HORM RES, V32, P250, DOI 10.1159/000181357; VARLEY JM, 1988, ONCOGENE, V3, P87; VARLEY JM, 1989, ONCOGENE, V4, P725; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHITTAKER JL, 1986, INT J CANCER, V38, P651, DOI 10.1002/ijc.2910380506; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252	83	262	262	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1991	6	3					413	421						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	2011397				2022-12-17	WOS:A1991FT34400010
J	SUAREZ, HG; DUVILLARD, JA; SEVERINO, M; CAILLOU, B; SCHLUMBERGER, M; TUBIANA, M; PARMENTIER, C; MONIER, R				SUAREZ, HG; DUVILLARD, JA; SEVERINO, M; CAILLOU, B; SCHLUMBERGER, M; TUBIANA, M; PARMENTIER, C; MONIER, R			PRESENCE OF MUTATIONS IN ALL 3 RAS GENES IN HUMAN THYROID-TUMORS	ONCOGENE			English	Article									INST GUSTAVE ROUSSY,CNRS,UA 1158,F-94805 VILLEJUIF,FRANCE; INST RECH SCI CANC,CNRS,F-94802 VILLEJUIF,FRANCE	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS)								ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOS JL, 1986, NUCLEIC ACIDS RES, V14, P1209, DOI 10.1093/nar/14.3.1209; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BROWETT PJ, 1989, ONCOGENE, V4, P1029; DEVRIES MV, 1986, GENE, V50, P313; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; FUJITA J, 1988, CANCER RES, V48, P5251; FUJITA J, 1985, P NATL ACAD SCI USA, V82, P3849, DOI 10.1073/pnas.82.11.3849; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; JANSSEN JWG, 1987, P NATL ACAD SCI USA, V84, P9228, DOI 10.1073/pnas.84.24.9228; LEMOINE NR, 1989, ONCOGENE, V4, P159; LEMOINE NR, 1988, CANCER RES, V48, P4459; LEMOINE NR, 1988, ONCOGENE, V3, P541; NERI A, 1988, P NATL ACAD SCI USA, V85, P9268, DOI 10.1073/pnas.85.23.9268; RIOU G, 1988, ONCOGENE, V3, P329; RODENHUIS S, 1988, CANCER RES, V48, P5738; ROSAI J, 1981, ACKERMANS SURGICAL P, P30; SMIT VTHBM, 1988, NUCLEIC ACIDS RES, V16, P7773, DOI 10.1093/nar/16.16.7773; SPANDIDOS DA, 1987, ANTICANCER RES, V7, P991; SUAREZ HG, 1988, ONCOGENE, V2, P403; SUAREZ HG, 1985, RETROVIRUSES HUMAN P, P509; TUBIANA M, 1985, CANCER-AM CANCER SOC, V55, P794, DOI 10.1002/1097-0142(19850215)55:4<794::AID-CNCR2820550418>3.0.CO;2-Z; VANTVEER LJ, 1989, MOL CELL BIOL, V9, P3114, DOI 10.1128/MCB.9.7.3114; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WILLIAMS ED, 1979, CLIN ENDOCRINOL META, V8, P193, DOI 10.1016/S0300-595X(79)80017-1; WILLIAMS ED, 1980, RECENT RES CANCER, P47; WRIGHT PA, 1989, BRIT J CANCER, V60, P576, DOI 10.1038/bjc.1989.316; YUNIS JJ, 1989, ONCOGENE, V4, P609	30	262	262	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1990	5	4					565	570						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB853	2183158				2022-12-17	WOS:A1990DB85300016
J	Wistuba, II; Behrens, C; Milchgrub, S; Bryant, D; Hung, J; Minna, JD; Gazdar, AF				Wistuba, II; Behrens, C; Milchgrub, S; Bryant, D; Hung, J; Minna, JD; Gazdar, AF			Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma	ONCOGENE			English	Article						lung carcinoma; preneoplastic lesions; loss of heterozygosity; chromosome 3p; chromosome 9p; TP53 gene	MICROSATELLITE INSTABILITY; MUTATOR PHENOTYPE; CLONAL EVOLUTION; FORMER SMOKERS; CHROMOSOME 3P; ALLELE LOSS; FHIT GENE; CANCER; LESIONS; P53	To understand the molecular pathways involved in the pathogenesis of squamous cell lung carcinoma, we obtained DNA from 94 microdissected foci from 12 archival surgically resected tumors including histologically normal epithelium (n = 13), preneoplastic lesions (n = 54), carcinoma is situ (CIS) (n = 15) and invasive tumors (n = 12). We determined loss of heterozygosity (LOH) at 10 chromosomal regions (3p12, 3p14.2, 3p14.1-21.3, 3p21, 3p22-24, 3p25, 5q22, 9p21, 13q14 RE, and 17p13 TP53) frequently deleted in lung cancer, using 31 polymorphic microsatellite markers, including 24 that spanned the entire 3p arm. Our major findings are as follows: (1) Thirty one percent of histologically normal epithelium and 42% of mildly abnormal (hyperplasia/metaplasia) specimens had clones of cells with allelic loss at one or more regions; (2) There was a progressive increase of the overall LOH frequency within clones with increasing severity of histopathological changes; (3) The earliest and most frequent regions of allelic loss occurred at 3p21, 3p22-24, 3p25 and 9p21; (4) The size of the 3p deletions increased with progressive histologic changes; (5) TP53 allelic loss was present in many histologically advanced lesions (dysplasia and CIS); (6) Analyses of 58 normal and non-invasive foci having any molecular abnormality, indicated that 30 probably arose as independent clonal events, while 28 were potentially of the same clonal origin as the corresponding tumor; (7) Nevertheless, when the allelic losses in the 30 clonally independent lesions and their clonally unrelated tumors were compared the same parental allele was lost in 113 of 125 (90%) of comparisons. The mechanism by which this phenomenon (known as allele specific mutations) occurs is unknown; (8) Four patterns of allelic loss in clones were found. Histologically normal or mildly abnormal foci had a negative pattern (no allelic loss) or early pattern of loss while all foci of CIS and invasive tumor had an advanced pattern. However dysplasias demonstrated the entire spectrum of allelic loss patterns, and were the only histologic category having the intermediate pattern. Our findings indicate that multiple, sequentially occurring allele specific molecular changes commence in widely dispersed, apparently clonally independent foci, early in the multistage pathogenesis of squamous cell carcinomas of the lung.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Pontificia Univ Catolica Chile, Dept Pathol, Santiago, Chile	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Pontificia Universidad Catolica de Chile	Gazdar, AF (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 5323 Harry Hines Blvd,NB8-106, Dallas, TX 75235 USA.				NCI NIH HHS [P50-CA70907, N01CN45580-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI J, 1995, GENE CHROMOSOME CANC, V14, P301, DOI 10.1002/gcc.2870140409; BAND PR, 1986, CANCER DETECT PREV, V9, P157; Birch DE, 1996, NATURE, V381, P445, DOI 10.1038/381445a0; CAWKWELL L, 1994, BRIT J CANCER, V70, P813, DOI 10.1038/bjc.1994.404; Chung GTY, 1995, ONCOGENE, V11, P2591; Chung GTY, 1996, CANCER RES, V56, P1609; COLBY TV, 1995, TUMORS LOWER RESP TR; Deng GR, 1996, SCIENCE, V274, P2057, DOI 10.1126/science.274.5295.2057; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; Fishel R, 1996, J NATL CANCER I, V88, P1608, DOI 10.1093/jnci/88.22.1608; FISHER JC, 1958, NATURE, V181, P651, DOI 10.1038/181651b0; FONG KM, 1995, CANCER RES, V55, P28; Fong KM, 1997, CANCER RES, V57, P2256; Franklin WA, 1997, J CLIN INVEST, V100, P2133, DOI 10.1172/JCI119748; FROST JK, 1986, J OCCUP ENVIRON MED, V28, P692, DOI 10.1097/00043764-198608000-00031; HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P558, DOI 10.1001/jama.273.7.558; JONES MH, 1992, GENE CHROMOSOME CANC, V5, P89, DOI 10.1002/gcc.2870050113; KISHIMOTO Y, 1995, JNCI-J NATL CANCER I, V87, P1224, DOI 10.1093/jnci/87.16.1224; LOEB LA, 1991, CANCER RES, V51, P3075; LOEB LA, 1994, CANCER RES, V54, P5059; MAO L, 1994, P NATL ACAD SCI USA, V91, P9871, DOI 10.1073/pnas.91.21.9871; Mao L, 1997, J NATL CANCER I, V89, P857, DOI 10.1093/jnci/89.12.857; MERLO A, 1994, CANCER RES, V54, P2098; Minna John D., 1997, P849; Miozzo M, 1996, CANCER RES, V56, P2285; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; PARKIN DM, 1994, INT J CANCER, V59, P494, DOI 10.1002/ijc.2910590411; RISSE EKJ, 1988, ACTA CYTOL, V32, P629; SACCOMANNO G, 1974, CANCER-AM CANCER SOC, V33, P256, DOI 10.1002/1097-0142(197401)33:1<256::AID-CNCR2820330139>3.0.CO;2-G; Siegel S, 1956, NONPARAMETRIC STAT B; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; STRONG MS, 1984, J OTOLARYNGOL, V13, P1; SUNDARESAN V, 1992, ONCOGENE, V7, P1989; THIBERVILLE L, 1995, CANCER RES, V55, P5133; TOGUCHIDA J, 1993, GENOMICS, V17, P535, DOI 10.1006/geno.1993.1368; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WISTUBA II, 1995, CANCER RES, V55, P2511; Wistuba II, 1998, JAMA-J AM MED ASSOC, V279, P1554, DOI 10.1001/jama.279.19.1554; Wistuba II, 1997, CANCER RES, V57, P3154; Wistuba II, 1997, JNCI-J NATL CANCER I, V89, P1366, DOI 10.1093/jnci/89.18.1366	42	261	273	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					643	650		10.1038/sj.onc.1202349	http://dx.doi.org/10.1038/sj.onc.1202349			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989814				2022-12-17	WOS:000078394400009
J	CACACE, AM; GUADAGNO, SN; KRAUSS, RS; FABBRO, D; WEINSTEIN, IB				CACACE, AM; GUADAGNO, SN; KRAUSS, RS; FABBRO, D; WEINSTEIN, IB			THE EPSILON ISOFORM OF PROTEIN-KINASE-C IS AN ONCOGENE WHEN OVEREXPRESSED IN RAT FIBROBLASTS	ONCOGENE			English	Article							CELL-LINE; GROWTH-CONTROL; PHORBOL ESTER; PKC-EPSILON; EXPRESSION; FAMILY; TRANSFORMATION; GENE; CONSTRUCTION; PURIFICATION	We have overproduced the Ca2+-independent protein kinase C isoform, nPKCepsilon, in Rat 6 embryo fibroblasts, and examined the effects of this novel isoform on cell growth and transformation. As compared to vector control cell lines expressing only the hygromycin resistance gene, the nPKCepsilon overproducing cell lines exhibited a 7-13-fold increase in Ca2+-independent enzyme activity. Detailed analysis of seven individual nPKCepsilon over-producing clones indicated that those clones that expressed very high activity displayed a number of disorders in growth control, including: formation of dense foci in monolayer culture, decreased doubling time, increased saturation density, decreased serum requirement, growth in soft agar, and tumor formation in nude mice. These findings are in contrast to previous studies from our laboratory indicating that stable expression of high levels of cPKCbeta1 produced only a partially transformed phenotype (Housey et al., 1988). Taken together, these results provide the first direct evidence that distinct isoforms of PKC can exert different effects on growth control and malignant transformation in the same cell type.	COLUMBIA UNIV, DEPT PHARMACOL, 701 W 168 ST, NEW YORK, NY 10032 USA; COLUMBIA UNIV, DEPT GENET & DEV, NEW YORK, NY 10027 USA; COLUMBIA UNIV, CTR CANC, NEW YORK, NY 10027 USA; CIBA GEIGY AG, CH-4002 BASEL, SWITZERLAND; CUNY MT SINAI SCH MED, DEPT BIOCHEM, NEW YORK, NY 10029 USA; COLUMBIA UNIV, DEPT MED, NEW YORK, NY 10027 USA	Columbia University; Columbia University; Columbia University; Novartis; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Columbia University								BAXTER G, 1992, J BIOL CHEM, V267, P1910; BORNER C, 1992, J BIOL CHEM, V267, P12900; BORNER C, 1990, CELL GROWTH DIFFER, V1, P653; BORNER C, 1992, J BIOL CHEM, V267, P12892; BORNER C, 1991, NATURE, V353, P78, DOI 10.1038/353078a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COPPOCK DL, 1992, CELL GROWTH DIFFER, V3, P485; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; HOUSEY GM, 1987, P NATL ACAD SCI USA, V84, P1065, DOI 10.1073/pnas.84.4.1065; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; HSIAO WLW, 1986, MOL CELL BIOL, V6, P1943, DOI 10.1128/MCB.6.6.1943; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; KRAUSS RS, 1989, ONCOGENE, V4, P991; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; LIYANAGE M, 1992, BIOCHEM J, V283, P781, DOI 10.1042/bj2830781; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHNO S, 1991, ADV ENZYME REGUL, V31, P287, DOI 10.1016/0065-2571(91)90018-H; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ONO Y, 1988, J BIOL CHEM, V263, P6927; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SAIDO TC, 1992, BIOCHEMISTRY-US, V31, P482, DOI 10.1021/bi00117a026; SCHAAP D, 1989, FEBS LETT, V243, P351, DOI 10.1016/0014-5793(89)80160-7; SCHAAP D, 1990, J BIOL CHEM, V265, P7301; SCHAAP D, 1990, EUR J BIOCHEM, V191, P431, DOI 10.1111/j.1432-1033.1990.tb19139.x; SOSSIN W, 1992, NEUROSCIENCE, V12, P1160; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WEINSTEIN, 1991, COLD SPRING HARBOR S	33	261	262	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1993	8	8					2095	2104						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336936				2022-12-17	WOS:A1993LP17100009
J	Xiong, H; Ni, Z; He, J; Jiang, S; Li, X; He, J; Gong, W; Zheng, L; Chen, S; Li, B; Zhang, N; Lyu, X; Huang, G; Chen, B; Zhang, Y; He, F				Xiong, H.; Ni, Z.; He, J.; Jiang, S.; Li, X.; He, J.; Gong, W.; Zheng, L.; Chen, S.; Li, B.; Zhang, N.; Lyu, X.; Huang, G.; Chen, B.; Zhang, Y.; He, F.			LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells	ONCOGENE			English	Article							LONG NONCODING RNA; DOWN-REGULATION; USP22; CANCER; ACTIVATION; CHEMORESISTANCE; PROLIFERATION; CONTRIBUTES; MAINTENANCE; SUPPRESSES	Considerable evidences have shown that autophagy has an important role in tumor chemoresistance. However, it is still unknown whether the lncRNA HULC (highly upregulated in liver cancer) is involved in autophagy and chemoresistance of hepatocellular carcinoma (HCC). In this study, we for the first time demonstrated that treatment with antitumor reagents such as oxaliplatin, 5-fluorouracil and pirarubicin (THP) dramatically induced HULC expression and protective autophagy. Silencing of HULC sensitized HCC cells to the three antitumor reagents via inhibiting protective autophagy. Ectopic expression of HULC elicited the autophagy of HCC cells through stabilizing silent information regulator 1 (Sirt1) protein. The investigation for the corresponding mechanism by which HULC stabilized Sirt1 revealed that HULC upregulated ubiquitin-specific peptidase 22 (USP22), leading to the decrease of ubiquitin-mediated degradation of Sirt1 protein by removing the conjugated polyubiquitin chains from Sirt1. Moreover, we found that miR-6825-5p, miR-6845-5p and miR-6886-3p could decrease the level of USP22 protein by binding to the 3'-untranlated region of USP22 mRNA. All the three microRNAs (miRNAs) were downregulated by HULC, which resulted in the elevation of USP22. In addition, we showed that the level of HULC was positively correlated with that of Sirt1 protein in human HCC tissues. Collectively, our data reveals that the pathway 'HULC/USP22/Sirt1/protective autophagy' attenuates the sensitivity of HCC cells to chemotherapeutic agents, suggesting that this pathway may be a novel target for developing sensitizing strategy to HCC chemotherapy.	[Xiong, H.; Ni, Z.; Jiang, S.; Li, X.; He, J.; Gong, W.; Chen, S.; Li, B.; Zhang, N.; Lyu, X.; Huang, G.; Zhang, Y.; He, F.] Third Mil Med Univ, Coll Basic Med Sci, Dept Biochem & Mol Biol, 30 Gaotanyan, Chongqing 400038, Peoples R China; [He, J.] Third Mil Med Univ, Coll Prevent Med, Battal Students 17, Chongqing, Peoples R China; [Zheng, L.] Third Mil Med Univ, Xinqiao Hosp, Dept Hepatobiliary Surg, Chongqing, Peoples R China; [Chen, B.] Third Mil Med Univ, Lab Anim Ctr, Chongqing, Peoples R China	Army Medical University; Army Medical University; Army Medical University; Army Medical University	Chen, B; Zhang, Y; He, F (corresponding author), Third Mil Med Univ, Coll Basic Med Sci, Dept Biochem & Mol Biol, 30 Gaotanyan, Chongqing 400038, Peoples R China.	chenbb81@126.com; tmmubiozy@163.com; hefengtian06@aliyun.com	HUANG, GANG/AAO-5503-2020	zhenhong, ni/0000-0002-7464-4074	National Natural Science Foundation of China [81672377, 31470066, 81472291, 81272690]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China (81672377, 31470066, 81472291 and 81272690).	Armour SM, 2013, MOL CELL BIOL, V33, P1487, DOI 10.1128/MCB.00971-12; Bae HJ, 2014, ONCOGENE, V33, P2557, DOI 10.1038/onc.2013.216; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012; Carew JS, 2007, AUTOPHAGY, V3, P464, DOI 10.4161/auto.4311; Chen HC, 2012, ANN SURG ONCOL, V19, P2011, DOI 10.1245/s10434-011-2159-4; Chen J, 2011, CANCER RES, V71, P4138, DOI 10.1158/0008-5472.CAN-10-4274; Cui M, 2015, CANCER RES, V75, P846, DOI 10.1158/0008-5472.CAN-14-1192; Du YM, 2012, J BIOL CHEM, V287, P26302, DOI 10.1074/jbc.M112.342113; El-Serag HB, 2012, GASTROENTEROLOGY, V142, P1264, DOI 10.1053/j.gastro.2011.12.061; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Gao ZG, 2011, J BIOL CHEM, V286, P22227, DOI 10.1074/jbc.M111.228874; Guo XL, 2014, CANCER LETT, V346, P278, DOI 10.1016/j.canlet.2014.01.011; Hammerle M, 2013, HEPATOLOGY, V58, P1703, DOI 10.1002/hep.26537; Hariharan N, 2010, CIRC RES, V107, P1470, DOI 10.1161/CIRCRESAHA.110.227371; He JB, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/605946; Helwak A, 2013, CELL, V153, P654, DOI 10.1016/j.cell.2013.03.043; Hu C, 2014, ONCOGENE, V33, P2888, DOI 10.1038/onc.2013.250; Hu C, 2015, GUT, V66, P31, DOI [10.1136/gutjn1-2015-309322, DOI 10.1136/GUTJN1-2015-309322]; Khorshid M, 2013, NAT METHODS, V10, P253, DOI [10.1038/NMETH.2341, 10.1038/nmeth.2341]; Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245; Lee IH, 2008, P NATL ACAD SCI USA, V105, P3374, DOI 10.1073/pnas.0712145105; Li L, 2014, CELL STEM CELL, V15, P431, DOI 10.1016/j.stem.2014.08.001; Li Q, 2015, AUTOPHAGY, V11, P1293, DOI 10.1080/15548627.2015.1058474; Li SP, 2016, ONCOTARGET, V7, P42431, DOI 10.18632/oncotarget.9883; Lin ZH, 2012, MOL CELL, V46, P484, DOI 10.1016/j.molcel.2012.03.024; Lu ZP, 2016, ONCOTARGET, V7, P241, DOI 10.18632/oncotarget.6280; Luo T, 2016, AUTOPHAGY, V12, P1355, DOI 10.1080/15548627.2015.1034405; Peng LR, 2015, J BIOL CHEM, V290, P8904, DOI 10.1074/jbc.M114.612796; Qiu GL, 2015, FEBS LETT, V589, P2034, DOI 10.1016/j.febslet.2015.05.042; Schrecengost RS, 2014, CANCER RES, V74, P272, DOI 10.1158/0008-5472.CAN-13-1954; Shteingauz A, 2015, CANCER RES, V75, P3946, DOI 10.1158/0008-5472.CAN-15-0037; Song JR, 2009, AUTOPHAGY, V5, P1131, DOI 10.4161/auto.5.8.9996; Song YM, 2015, AUTOPHAGY, V11, P46, DOI 10.4161/15548627.2014.984271; Tang B, 2015, ONCOTARGET, V6, P12654, DOI 10.18632/oncotarget.3705; Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020; Wang JY, 2010, NUCLEIC ACIDS RES, V38, P5366, DOI 10.1093/nar/gkq285; Wang K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4596; Zhang XY, 2008, MOL CELL, V29, P102, DOI 10.1016/j.molcel.2007.12.015; Zhou P, 2014, CELL SIGNAL, V26, P1347, DOI 10.1016/j.cellsig.2014.02.020	40	260	282	5	70	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2017	36	25					3528	3540		10.1038/onc.2016.521	http://dx.doi.org/10.1038/onc.2016.521			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY3NL	28166203				2022-12-17	WOS:000403878600003
J	Lu, YL; Lin, YZ; LaPushin, R; Cuevas, B; Fang, XJ; Yu, SX; Davies, MA; Khan, H; Furui, T; Mao, ML; Zinner, R; Hung, MC; Steck, P; Siminovitch, K; Mills, GB				Lu, YL; Lin, YZ; LaPushin, R; Cuevas, B; Fang, XJ; Yu, SX; Davies, MA; Khan, H; Furui, T; Mao, ML; Zinner, R; Hung, MC; Steck, P; Siminovitch, K; Mills, GB			The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells	ONCOGENE			English	Article						PTEN/MMAC1; PI3-K (phosphatidylinositol 3-kinase); breast cancer; apoptosis; anoikis; cell cycle arrest	GLYCOGEN-SYNTHASE KINASE-3; IN-VITRO; PHOSPHATASE-ACTIVITY; GLIOBLASTOMA CELLS; GLIOMA-CELLS; PTEN; PHOSPHORYLATION; ACTIVATION; SURVIVAL; DEATH	The PTEN/MMAC1/TEP (PTEN) tumor suppressor gene at 10q23.3 is mutated in multiple types of sporadic tumors including breast cancers and also in the germline of patients with the Cowden's breast cancer predisposition syndrome. The PTEN gene encodes a multifunctional phosphatase capable of dephosphorylating the same sites in membrane phosphatidylinositols phosphorylated by phosphatidylinositol 3'-kinase (PI3K). We demonstrate herein that loss of PTEN function in breast cancer cells results in an increase in basal levels of phosphorylation of multiple components of the PI3K signaling cascade as web as an increase in duration of ligand-induced signaling through the PI3K cascade. These alterations are reversed by wild-type but not phosphatase inactive PTEN. In the presence of high concentrations of serum, enforced expression of PTEN induces a predominant G1 arrest consistent with the capacity of PTEN to evoke increases in the expression of the p27Kip1 cyclin dependent kinase inhibitor. In the presence of low concentrations of serum, enforced PTEN expression results in a marked increase in cellular apoptosis, a finding which is consistent with the capacity of PTEN to alter the phosphorylation, and presumably function, of the AKT, BAD, p70S6 kinase and GSK3 alpha apoptosis regulators. Under anchorage-independent conditions, PTEN also induces anoikis, a form of apoptosis that occurs when cells are dissociated from the extracellular matrix, which is enhanced in conjunction with low serum culture conditions. Together, these data suggest that PTEN effects on the PI3K signaling cascade are influenced by the cell stimulatory context, and that depending on the exposure to growth factors and other exogenous stimuli such as integrin ligation, PTEN can induce cell cycle arrest, apoptosis or anoikis in breast cancer cells.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Oncol, Div Med, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; Univ Toronto, Dept Med Immunol & Mol & Med Genet, Toronto, ON M5G 1X5, Canada	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Toronto	Mills, GB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Oncol, Div Med, 1515 Holcombe Blvd,Box 092, Houston, TX 77030 USA.		Siminovitch, Katherine/K-1475-2013; Hung, Mien-Chie/ABD-5911-2021; Davies, Michael/GWV-2527-2022	Hung, Mien-Chie/0000-0003-4317-4740; 	NATIONAL CANCER INSTITUTE [R01CA071418] Funding Source: NIH RePORTER; NCI NIH HHS [CA71418] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATES SE, 1990, ENDOCRINOLOGY, V126, P596, DOI 10.1210/endo-126-1-596; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cheney IW, 1998, CANCER RES, V58, P2331; Cheyney IW, 1999, CANCER RES, V59, P2318; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; Coffer PJ, 1998, BIOCHEM J, V335, P1; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davies MA, 1999, CANCER RES, V59, P2551; Davies MA, 1998, CANCER RES, V58, P5285; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; DICRISTOFANO A, 1998, LEUKEMIA, V12, P1277; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Dumont FJ, 1995, LIFE SCI, V58, P373, DOI 10.1016/0024-3205(95)02233-3; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Furnari FB, 1998, CANCER RES, V58, P5002; FURNARI FB, 1997, CANCER RES, V57, P4997; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Koester SK, 1997, CYTOMETRY, V29, P306; Li DM, 1997, CANCER RES, V57, P2124; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1998, CANCER RES, V58, P5667; LI J, 1997, NAT GENET, V15, P356; LIAW D, 1997, CANCER RES, V57, P2124; Liu TJ, 1999, CANCER GENE THER, V6, P163, DOI 10.1038/sj.cgt.7700007; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; MARSH DJ, 1997, HUM MOL GENET, V6, P1383; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; PARSONS R, 1998, ONCOGENE, V16, P89; Pepper C, 1998, LEUKEMIA RES, V22, P439, DOI 10.1016/S0145-2126(98)00013-7; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; SCHULTZ RM, 1995, ANTICANCER RES, V15, P1135; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; SHI YF, 1995, CANCER RES, V55, P1982; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; STECK PA, 1997, NAT GENET, V16, P64; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tamura M, 1999, CANCER RES, V59, P442; TAMURA M, 1998, CANCER RES, V58, P2331; Teng DHF, 1997, CANCER RES, V57, P5221; Tian XX, 1999, J NEUROPATH EXP NEUR, V58, P472, DOI 10.1097/00005072-199905000-00006; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Werner H, 1997, CRIT REV ONCOGENESIS, V8, P71, DOI 10.1615/CritRevOncog.v8.i1.40; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	51	260	289	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	1999	18	50					7034	7045		10.1038/sj.onc.1203183	http://dx.doi.org/10.1038/sj.onc.1203183			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597304				2022-12-17	WOS:000083901900010
J	Cole, MD; McMahon, SB				Cole, MD; McMahon, SB			The Myc oncoprotein: a critical evaluation of transactivation and target gene regulation	ONCOGENE			English	Article						Myc; oncoprotein; target gene; transactivation; chromatin remodelling	HUMAN C-MYC; YEAST TRANSCRIPTIONAL ACTIVATORS; HISTONE DEACETYLASE ACTIVITY; TRANSFORM NORMAL-CELLS; TATA-BINDING PROTEIN; DNA-BINDING; E-BOX; NEOPLASTIC TRANSFORMATION; ORNITHINE DECARBOXYLASE; IN-VIVO	Mutations which disrupt the regulation or expression level of the c-myc gene are among the most common found in human and animal cancers (reviewed in ref. Cole, 1986; Henriksson and Luscher, 1996; Marcu et al., 1992). Ectopic expression studies define numerous biological activities of the c-myc gene, including transformation, immortalization? blockage of cell differentiation and induction of apoptosis (Askew et al., 1991; Cole, 1986; Evan and Littlewood, 1993; Freytag et al., 1990; Henriksson and Luscher, 1996; Marcu et al., 1992). Furthermore, c-myc is required for efficient progression through the cell cycle (Goruppi et al., 1994; Prochownik et al., 1988; Yokoyama and Imamoto, 1987), although recent studies indicate that it is not absolutely essential (Mateyak et al., 1997). This fascinating array of biological activities makes the c-myc gene one of the most intriguing oncogenes and presents the challenging question of how a single gene can manifest so many different effects. The c-Myc protein exhibits sequence-specific DNA binding when dimerized with its partner Max, and DNA binding is mediated through the basic region, which recognizes the core sequence CACGTG (Berberich et al., 1992; Blackwell et al., 1993; Blackwood and Eisenman, 1991; Prendergast and Ziff, 1991; Prendergast et al., 1991), but exhibits somewhat higher affinity for the more extended sequence ACCACGTGGT (Berberich et al., 1992; Blackwell et al., 1993; Halazonetis and Kandil, 1991). There are three closely related Myc family proteins (c-Myc, N-Myc and L-Myc), each with documented oncogenic potential (Birrer et al., 1988; Schwab et al., 1985; Yancopoulos et al., 1985) and similar DNA binding properties (Mukherjee et al., 1992). For simplicity, we will use the term Myc to refer to all three proteins, but delineate any distinct activities where they apply. The goal of this review is to discuss Myc as a transcriptional activator and critically evaluate the evidence for the transactivation of specific target genes as direct downstream effecters. Since excellent comprehensive reviews on Myc have been published recently (Facchini and Penn, 1998; Henriksson and Luscher, 1996), we will focus on the latest observations that offer mechanistic insight into transactivation and oncogenic transformation.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Cole, MD (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.			McMahon, Steven/0000-0002-3405-1768				AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; ASKEW DS, 1991, ONCOGENE, V6, P1915; BARRETT J, 1992, MOL CELL BIOL, V12, P3130, DOI 10.1128/MCB.12.7.3130; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BERBERICH S, 1992, ONCOGENE, V7, P775; BIRRER MJ, 1988, MOL CELL BIOL, V8, P2668, DOI 10.1128/MCB.8.6.2668; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Boyd KE, 1997, MOL CELL BIOL, V17, P2529, DOI 10.1128/MCB.17.5.2529; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; BROUGH DE, 1995, MOL CELL BIOL, V15, P1536; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; Colman MS, 1996, NUCLEIC ACIDS RES, V24, P1971, DOI 10.1093/nar/24.10.1971; Dang CV, 1999, MOL CELL BIOL, V19, P1; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; FREYTAG SO, 1990, CELL GROWTH DIFFER, V1, P339; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; GORUPPI S, 1994, ONCOGENE, V9, P1537; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1998, TRENDS CELL BIOL, V8, P193, DOI 10.1016/S0962-8924(98)01263-X; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; HATEBOER G, 1993, P NATL ACAD SCI USA, V90, P8489, DOI 10.1073/pnas.90.18.8489; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Jones RM, 1996, MOL CELL BIOL, V16, P4754; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KOLLMAR R, 1994, J BIOL CHEM, V269, P2252; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; Lutz W, 1996, ONCOGENE, V13, P803; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MacGregor D, 1996, J CELL PHYSIOL, V167, P95, DOI 10.1002/(SICI)1097-4652(199604)167:1<95::AID-JCP11>3.3.CO;2-Q; MAHESWARAN S, 1994, MOL CELL BIOL, V14, P1147, DOI 10.1128/MCB.14.2.1147; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; Martinez E, 1998, J BIOL CHEM, V273, P23781, DOI 10.1074/jbc.273.37.23781; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; RESAR LMS, 1993, MOL CELL BIOL, V13, P1130, DOI 10.1128/MCB.13.2.1130; Saleh A, 1998, J BIOL CHEM, V273, P26559, DOI 10.1074/jbc.273.41.26559; SARID J, 1987, P NATL ACAD SCI USA, V84, P170, DOI 10.1073/pnas.84.1.170; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Smith ER, 1998, NUCLEIC ACIDS RES, V26, P2948, DOI 10.1093/nar/26.12.2948; Smith ER, 1998, P NATL ACAD SCI USA, V95, P3561, DOI 10.1073/pnas.95.7.3561; Sommer A, 1997, CURR BIOL, V7, P357, DOI 10.1016/S0960-9822(06)00183-7; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; TAVTIGIAN SV, 1994, MOL BIOL CELL, V5, P375, DOI 10.1091/mbc.5.3.375; Tsuneoka M, 1997, ONCOGENE, V14, P2301, DOI 10.1038/sj.onc.1201067; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; Wang LA, 1997, MOL CELL BIOL, V17, P519, DOI 10.1128/MCB.17.1.519; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; Xiao WH, 1997, P NATL ACAD SCI USA, V94, P7227, DOI 10.1073/pnas.94.14.7227; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455; YOKOYAMA K, 1987, P NATL ACAD SCI USA, V84, P7363, DOI 10.1073/pnas.84.21.7363; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	85	260	272	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	1999	18	19					2916	2924		10.1038/sj.onc.1202748	http://dx.doi.org/10.1038/sj.onc.1202748			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197VZ	10378688				2022-12-17	WOS:000080387800002
J	Guha, A; Feldkamp, MM; Lau, N; Boss, G; Pawson, A				Guha, A; Feldkamp, MM; Lau, N; Boss, G; Pawson, A			Proliferation of human malignant astrocytomas is dependent on Ras activation	ONCOGENE			English	Article						astrocytomas; ras; receptor tyrosine kinases; farnesyl transferase inhibitors	EPIDERMAL GROWTH-FACTOR; PROTEIN-KINASE-C; NUCLEOTIDE EXCHANGE FACTOR; RECEPTOR TYROSINE KINASES; HUMAN GLIOBLASTOMA CELLS; FARNESYLTRANSFERASE INHIBITORS BLOCK; MITOGENIC SIGNAL TRANSDUCTION; GRB2 ADAPTER PROTEIN; FACTOR BETA-RECEPTOR; HUMAN-BRAIN TUMORS	Overexpression and activation of receptor tyrosine kinases, such as platelet derived growth factor receptors (PDGFRs) and epidermal growth factor receptor (EGFR), leads to proliferation of human malignant astrocytoma cells. Although oncogenic mutations affecting Pas are not prevalent in human malignant astrocytomas, we have investigated whether levels of activated Ras.GTP might be elevated in these tumors secondary to the mitogenic signals originating from activated receptor tyrosine kinases. In support of this hypothesis high levels of Ras.GTP, similar to those found in oncogenic Pas transformed fibroblasts, were present in four established human malignant astrocytoma cell lines which express PDGFRs and EGFR, and 20 operative malignant astrocytoma specimens. Stimulation of PDGFR's and EGFR's induced tyrosine phosphorylation of the Shc adaptor protein and its association with Grb2, suggesting a mechanism by which Pas may be activated in human malignant astrocytoma cells. Furthermore, blocking Pas activation by expression of the Ha-Ras-Asn17 dominant-negative mutant, or by farnesyl transferase inhibitors, decreased in vitro proliferation of the human astrocytoma cell lines. These results support the hypothesis that proliferative signals from receptor tyrosine kinases expressed by human malignant astrocytoma cells utilize the Pas mitogenic pathway. Pharmacological inhibitors of the Ras pathway may therefore be of therapeutic value in these presently terminal tumors.	UNIV TORONTO,TORONTO HOSP,DIV NEUROSURG & SURG ONCOL,TORONTO,ON,CANADA; UNIV TORONTO,ONTARIO CANC INST,TORONTO,ON,CANADA; UNIV TORONTO,DEPT MOL & MED GENET,TORONTO,ON,CANADA; UNIV CALIF SAN DIEGO,DEPT MED,SAN DIEGO,CA 92103	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of California System; University of California San Diego	Guha, A (corresponding author), MT SINAI HOSP,SAMUEL LUNENFELD RES INST,PROGRAMME MOL BIOL & CANC,600 UNIV AVE,TORONTO,ON M5G 1X5,CANADA.		Pawson, Tony J/E-4578-2013	Boss, Gerry/0000-0002-9758-8714				AHMAD S, 1994, NEUROSURGERY, V35, P904, DOI 10.1227/00006123-199411000-00015; ANTONIADES HN, 1992, INT J CANCER, V50, P215, DOI 10.1002/ijc.2910500210; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; BASU T, 1994, ONCOGENE, V9, P3483; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BENZIL DL, 1992, CANCER RES, V52, P2951; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOS JL, 1989, CANCER RES, V49, P4682; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EKSTRAND AJ, 1995, ONCOGENE, V10, P1455; EKSTRAND AJ, 1994, ONCOGENE, V9, P2313; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; GIBBS JB, 1993, J BIOL CHEM, V268, P7617; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; GLICK RP, 1992, J NEUROSURG, V77, P445, DOI 10.3171/jns.1992.77.3.0445; GUHA A, 1995, INT J CANCER, V60, P168, DOI 10.1002/ijc.2910600206; Guha A, 1996, ONCOGENE, V12, P507; GUHA A, 1995, J NEUROL NEUROSUR PS, V58, P711, DOI 10.1136/jnnp.58.6.711; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HERMANSON M, 1992, CANCER RES, V52, P3213; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JOHN J, 1993, J BIOL CHEM, V268, P923; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KLEIHUES P, 1991, HISTOLOGICAL TYPING; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KOVALENKO M, 1994, CANCER RES, V54, P6106; Li BQ, 1996, P NATL ACAD SCI USA, V93, P1001, DOI 10.1073/pnas.93.3.1001; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIBERMANN TA, 1987, EMBO J, V6, P1627, DOI 10.1002/j.1460-2075.1987.tb02410.x; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAHALEY MS, 1989, J NEUROSURG, V71, P826, DOI 10.3171/jns.1989.71.6.0826; MANNE V, 1995, ONCOGENE, V10, P1763; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MISRAPRESS A, 1992, GLIA, V6, P188, DOI 10.1002/glia.440060306; MORRISON RS, 1991, J BIOL CHEM, V266, P728; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MUROYA K, 1992, ONCOGENE, V7, P277; NAGASU T, 1995, CANCER RES, V55, P5310; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; NISTER M, 1991, J BIOL CHEM, V266, P16755; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; OLSON JJ, 1995, NEUROSURGERY, V36, P740, DOI 10.1227/00006123-199504000-00015; PAULUS W, 1990, ACTA NEUROPATHOL, V79, P418, DOI 10.1007/BF00308718; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1995, ONCOGENE, V10, P1631; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLATE KH, 1993, CANCER RES, V53, P5822; POLLACK IF, 1990, J NEUROSURG, V73, P98, DOI 10.3171/jns.1990.73.1.0098; PRISELL P, 1987, ACTA NEUROCHIR, V89, P48, DOI 10.1007/BF01406667; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; Qui MS, 1991, NEURON, V7, P937, DOI [DOI 10.1016/0896-6273(91)90339-2, 10.1016/0896-6273(91)90339-2]; RAK J, 1995, CANCER RES, V55, P4575; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; ROSAKISADCOCK M, 1992, NATURE, V360, P689; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SANDBERGNORDQVIST AC, 1993, CANCER RES, V53, P2475; Satoh T, 1992, Semin Cancer Biol, V3, P169; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHEELE JS, 1995, P NATL ACAD SCI USA, V92, P1097, DOI 10.1073/pnas.92.4.1097; SEGATTO O, 1993, ONCOGENE, V8, P2105; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; SERVE H, 1995, EMBO J, V14, P473, DOI 10.1002/j.1460-2075.1995.tb07023.x; SHAMAH SM, 1993, MOL CELL BIOL, V13, P7203, DOI 10.1128/MCB.13.12.7203; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; STECK PA, 1988, CANCER RES, V48, P5433; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TAKAHASHI JA, 1990, P NATL ACAD SCI USA, V87, P5710, DOI 10.1073/pnas.87.15.5710; TROJAN J, 1993, SCIENCE, V259, P94, DOI 10.1126/science.8418502; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WINDEL K, 1994, NEUROSURGERY, V35, P439; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; YAN N, 1995, CANCER RES, V55, P3569; YOKOTE K, 1994, J BIOL CHEM, V269, P15337	98	260	267	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 4	1997	15	23					2755	2765		10.1038/sj.onc.1201455	http://dx.doi.org/10.1038/sj.onc.1201455			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YJ803	9419966				2022-12-17	WOS:A1997YJ80300001
J	Rzymski, T; Milani, M; Pike, L; Buffa, F; Mellor, HR; Winchester, L; Pires, I; Hammond, E; Ragoussis, I; Harris, AL				Rzymski, T.; Milani, M.; Pike, L.; Buffa, F.; Mellor, H. R.; Winchester, L.; Pires, I.; Hammond, E.; Ragoussis, I.; Harris, A. L.			Regulation of autophagy by ATF4 in response to severe hypoxia	ONCOGENE			English	Article						autophagy; UPR; cancer; hypoxia; anoxia; tumour	CELL-SURVIVAL; TRANSLATIONAL REGULATION; MOLECULAR-CLONING; PHOSPHORYLATION; RESISTANCE; DEATH; PERK; STABILIZATION; LYSOSOMES; INDUCTION	Activating transcription factor 4 (ATF4) is a transcription factor induced under severe hypoxia and a component of the PERK pathway involved in the unfolded protein response (UPR), a process that protects cells from the negative consequences of endoplasmic reticulum (ER) stress. In this study, we have used small interfering RNA (siRNA) and microarray analysis to provide the first whole-genome analysis of genes regulated by ATF4 in cancer cells in response to severe and prolonged hypoxic stress. We show that ATF4 is required for ER stress and hypoxia-induced expansion of autophagy. MAP1LC3B (LC3B) is a key component of the autophagosomal membrane, and in this study we demonstrate that ATF4 facilitates autophagy through direct binding to a cyclic AMP response element binding site in the LC3B promoter, resulting in LC3B upregulation. Previously, we have shown that Bortezomib-induced ATF4 stabilization, which then upregulated LC3B expression and had a critical role in activating autophagy, protecting cells from Bortezomib-induced cell death. We also showed that severe hypoxia stabilizes ATF4. In this study, we demonstrate that severe hypoxia leads to ER stress and induces ATF4-dependent autophagy through LC3 as a survival mechanism. In summary, we show that ATF4 has a key role in the regulation of autophagy in response to ER stress and provide a direct mechanistic link between the UPR and the autophagic machinery. Oncogene (2010) 29, 4424-4435; doi: 10.1038/onc.2010.191; published online 31 May 2010	[Rzymski, T.; Milani, M.; Pike, L.; Buffa, F.; Mellor, H. R.; Harris, A. L.] Univ Oxford, John Radcliffe Hosp, Growth Factor Grp,Mol Oncol Labs, Canc Res UK,Weatherall Inst Mol Med, Oxford OX3 9DU, England; [Winchester, L.; Ragoussis, I.] Wellcome Trust Ctr Human Genet, Genom Lab, Oxford, England; [Pires, I.; Hammond, E.] Univ Oxford, Canc Res UK, MRC Gray Inst Radiat Oncol & Biol, Churchill Hosp, Oxford OX3 9DU, England	Cancer Research UK; University of Oxford; University of Oxford; Wellcome Centre for Human Genetics; Cancer Research UK; University of Oxford	Harris, AL (corresponding author), Univ Oxford, John Radcliffe Hosp, Growth Factor Grp,Mol Oncol Labs, Canc Res UK,Weatherall Inst Mol Med, Oxford OX3 9DU, England.	aharris.lab@imm.ox.ac.uk	Harris, Adrian L/ABA-3343-2020; Buffa, Francesca/D-2574-2013; Ragoussis, Ioannis/AAD-9790-2022	Harris, Adrian L/0000-0003-1376-8409; Buffa, Francesca/0000-0003-0409-406X; Ragoussis, Ioannis/0000-0002-8515-0934; Hammond, Ester/0000-0002-2335-3146; Pires, Isabel/0000-0002-0417-2710				Ameri K, 2004, BLOOD, V103, P1876, DOI 10.1182/blood-2003-06-1859; Averous J, 2004, J BIOL CHEM, V279, P5288, DOI 10.1074/jbc.M311862200; Azad MB, 2008, AUTOPHAGY, V4, P195, DOI 10.4161/auto.5278; Bernales S, 2006, PLOS BIOL, V4, P2311, DOI 10.1371/journal.pbio.0040423; Bi MX, 2005, EMBO J, V24, P3470, DOI 10.1038/sj.emboj.7600777; Blais JD, 2006, MOL CELL BIOL, V26, P9517, DOI 10.1128/MCB.01145-06; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; He H, 2003, J BIOL CHEM, V278, P29278, DOI 10.1074/jbc.M303800200; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; Koumenis C, 2002, MOL CELL BIOL, V22, P7405, DOI 10.1128/MCB.22.21.7405-7416.2002; Kouroku Y, 2007, CELL DEATH DIFFER, V14, P230, DOI 10.1038/sj.cdd.4401984; Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Lu PD, 2004, EMBO J, V23, P169, DOI 10.1038/sj.emboj.7600030; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Milani M, 2009, CANCER RES, V69, P4415, DOI 10.1158/0008-5472.CAN-08-2839; Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704; Mujcic H, 2009, RADIOTHER ONCOL, V92, P450, DOI 10.1016/j.radonc.2009.08.017; Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06; Ohoka N, 2005, EMBO J, V24, P1243, DOI 10.1038/sj.emboj.7600596; Olive PL, 2002, RADIAT RES, V158, P159, DOI 10.1667/0033-7587(2002)158[0159:TROOIS]2.0.CO;2; Papandreou I, 2005, CANCER RES, V65, P3171, DOI 10.1158/0008-5472.CAN-04-3395; Rouschop KMA, 2010, J CLIN INVEST, V120, P127, DOI 10.1172/JCI40027; Rzymski T, 2008, ONCOGENE, V27, P4532, DOI 10.1038/onc.2008.100; Rzymski T, 2009, CELL CYCLE, V8, P3838, DOI 10.4161/cc.8.23.10086; Sarkar S, 2007, NAT CHEM BIOL, V3, P331, DOI 10.1038/nchembio883; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Semenza GL, 2008, AUTOPHAGY, V4, P534, DOI 10.4161/auto.5956; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Tu BP, 2004, J CELL BIOL, V164, P341, DOI 10.1083/jcb.200311055; Wenger RH, 1996, NATURE, V380, P100, DOI 10.1038/380100d0; Wouters BG, 1997, RADIAT RES, V147, P541, DOI 10.2307/3579620; Wu JX, 2006, BIOCHEM BIOPH RES CO, V339, P437, DOI 10.1016/j.bbrc.2005.10.211; Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33; Yorimitsu T, 2006, J BIOL CHEM, V281, P30299, DOI 10.1074/jbc.M607007200	41	259	263	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2010	29	31					4424	4435		10.1038/onc.2010.191	http://dx.doi.org/10.1038/onc.2010.191			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634DG	20514020				2022-12-17	WOS:000280559100006
J	Kishimoto, K; Liu, SM; Tsuji, T; Olson, KA; Hu, GF				Kishimoto, K; Liu, SM; Tsuji, T; Olson, KA; Hu, GF			Endogenous angiogenin in endothelial cells is a general requirement for cell proliferation and angiogenesis	ONCOGENE			English	Article						angiogenin; angiogenesis; rRNA transcription; ribosome biogenesis; nuclear translocation; angiogenic factors	NUCLEOLAR ORGANIZER REGIONS; GROWTH-FACTOR; BINDING-PROTEIN; TUMOR-GROWTH; EXPRESSION; CANCER; SERUM; MECHANISMS; ACTIN; MICE	Angiogenin is an angiogenic protein that undergoes nuclear translocation in endothelial cells where it accumulates in the nucleolus and stimulates rRNA transcription, a rate-limiting step in ribosome biogenesis, protein translation, and cell growth. Here, we report that angiogenin is required for cell proliferation induced by various other angiogenic proteins including acidic and basic fibroblast growth factors ( aFGF and bFGF), epidermal growth factor (EGF), and vascular endothelial growth factor ( VEGF). Downregulation of angiogenin in endothelial cells by small interfering RNA ( siRNA) and antisense results in a decrease in rRNA transcription, ribosome biogenesis, and cell proliferation induced by these angiogenic factors. Inhibitors of the nuclear translocation of angiogenin abolish the angiogenic activities of these factors. Stable angiogenin antisense transfection in HeLa cells reduces tumor angiogenesis in athymic mice despite the elevated expression level of bFGF and VEGF. Thus, nuclear angiogenin assumes an essential role in endothelial cell proliferation and is necessary for angiogenesis induced by other angiogenic factors. Angiogenin-stimulated rRNA transcription in endothelial cells may thus serve as a crossroad in the process of angiogenesis induced by various angiogenic factors.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Hu, GF (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 77 Ave Louis Pasteur,NRB 930, Boston, MA 02115 USA.	guofu_hu@hms.harvard.edu			NATIONAL CANCER INSTITUTE [R21CA091086] Funding Source: NIH RePORTER; NCI NIH HHS [CA91086] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams S A, 1999, Angiogenesis, V3, P189, DOI 10.1023/A:1009015512200; AU S, 1986, ANTIMICROB AGENTS CH, V30, P395, DOI 10.1128/AAC.30.3.395; Barton DPJ, 1997, CLIN CANCER RES, V3, P1579; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; BICKNELL R, 1988, P NATL ACAD SCI USA, V85, P5961, DOI 10.1073/pnas.85.16.5961; Bodner-Adler B, 2001, ANTICANCER RES, V21, P809; Eberle K, 2000, ANTICANCER RES, V20, P1679; FETT JW, 1985, BIOCHEMISTRY-US, V24, P5480, DOI 10.1021/bi00341a030; Folkman J, 2003, CURR MOL MED, V3, P643, DOI 10.2174/1566524033479465; Folkman J, 2002, CANCER CELL, V1, P113, DOI 10.1016/S1535-6108(02)00038-7; Fu XY, 1999, GROWTH FACTORS, V17, P125, DOI 10.3109/08977199909103521; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Homer JJ, 2002, CLIN OTOLARYNGOL, V27, P32, DOI 10.1046/j.0307-7772.2001.00519.x; HU GF, 1993, BIOCHEM BIOPH RES CO, V197, P682, DOI 10.1006/bbrc.1993.2533; Hu GF, 2000, J CELL BIOCHEM, V76, P452, DOI 10.1002/(SICI)1097-4644(20000301)76:3<452::AID-JCB12>3.0.CO;2-Z; Hu GF, 1998, P NATL ACAD SCI USA, V95, P9791, DOI 10.1073/pnas.95.17.9791; HU GF, 1994, P NATL ACAD SCI USA, V91, P12096, DOI 10.1073/pnas.91.25.12096; HU GF, 1993, P NATL ACAD SCI USA, V90, P1217, DOI 10.1073/pnas.90.4.1217; HU GF, 1991, P NATL ACAD SCI USA, V88, P2227, DOI 10.1073/pnas.88.6.2227; Hu GF, 1997, P NATL ACAD SCI USA, V94, P2204, DOI 10.1073/pnas.94.6.2204; Imaizumi T, 2000, THROMB HAEMOSTASIS, V83, P949; Kinoshita M, 1999, ARTERIOSCL THROM VAS, V19, P2323, DOI 10.1161/01.ATV.19.10.2323; Kushlinskii NE, 2000, B EXP BIOL MED+, V130, P691, DOI 10.1007/BF02682107; LI DC, 1994, J PATHOL, V172, P171, DOI 10.1002/path.1711720203; Liu SM, 2001, BIOCHEM BIOPH RES CO, V287, P305, DOI 10.1006/bbrc.2001.5568; MOENNER M, 1994, EUR J BIOCHEM, V226, P483, DOI 10.1111/j.1432-1033.1994.tb20073.x; Montero S, 1998, CLIN CANCER RES, V4, P2161; MOROIANU J, 1994, P NATL ACAD SCI USA, V91, P1677, DOI 10.1073/pnas.91.5.1677; OLSON KA, 1995, P NATL ACAD SCI USA, V92, P442, DOI 10.1073/pnas.92.2.442; Olson KA, 2002, INT J CANCER, V98, P923, DOI 10.1002/ijc.10282; Olson KA, 2001, CLIN CANCER RES, V7, P3598; Papetti M, 2002, AM J PHYSIOL-CELL PH, V282, pC947, DOI 10.1152/ajpcell.00389.2001; POLAKOWSKI IJ, 1993, AM J PATHOL, V143, P507; Ribatti D, 2000, GEN PHARMACOL-VASC S, V35, P227, DOI 10.1016/S0306-3623(01)00112-4; Risau W, 1996, CANCER METAST REV, V15, P149, DOI 10.1007/BF00437466; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; RUSCHOFF J, 1989, PATHOL RES PRACT, V185, P878; Shimoyama S, 1999, PANCREAS, V18, P225, DOI 10.1097/00006676-199904000-00002; Shimoyama S, 2002, ANTICANCER RES, V22, P1045; TRERE D, 1989, EXP CELL RES, V184, P131, DOI 10.1016/0014-4827(89)90371-6; Ugurel S, 2001, J CLIN ONCOL, V19, P577, DOI 10.1200/JCO.2001.19.2.577; WILLIAMS PD, 1987, ANTIMICROB AGENTS CH, V31, P570, DOI 10.1128/AAC.31.4.570; WILTING J, 1991, ANAT EMBRYOL, V183, P259; Xu ZP, 2003, BIOCHEMISTRY-US, V42, P121, DOI 10.1021/bi020465x; Xu ZP, 2002, BIOCHEM BIOPH RES CO, V294, P287, DOI 10.1016/S0006-291X(02)00479-5	45	259	279	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					445	456		10.1038/sj.onc.1208223	http://dx.doi.org/10.1038/sj.onc.1208223			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15558023				2022-12-17	WOS:000226279700015
J	Kanda, N; Seno, H; Konda, Y; Marusawa, H; Kanai, M; Nakajima, T; Kawashima, T; Nanakin, A; Sawabu, T; Uenoyama, Y; Sekikawa, A; Kawada, M; Suzuki, K; Kayahara, T; Fukui, H; Sawada, M; Chiba, T				Kanda, N; Seno, H; Konda, Y; Marusawa, H; Kanai, M; Nakajima, T; Kawashima, T; Nanakin, A; Sawabu, T; Uenoyama, Y; Sekikawa, A; Kawada, M; Suzuki, K; Kayahara, T; Fukui, H; Sawada, M; Chiba, T			STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells	ONCOGENE			English	Article						STAT3; survivin; cancer; stomach	SIGNALING INDUCES APOPTOSIS; EPIDERMAL-GROWTH-FACTOR; TRANSCRIPTION FACTOR; MESSENGER-RNA; HUMAN OVARIAN; DNA-BINDING; INHIBITION; GENE; INTERLEUKIN-6; RESISTANCE	Signal transduction and activator of transcription 3(STAT3) signaling is constitutively activated in various tumors, and is involved in cell survival and proliferation during oncogenesis. There are few reports, however, on the role of STAT3 signaling in gastric cancer. The aim of the present study was to clarify the role of STAT3 signaling in apoptosis and cellular proliferation in gastric cancer. Here we reported that STAT3 was constitutively activated in various human gastric cancer cells and its inhibition by ectopic dominant-negative STAT3 or Janus kinase inhibitor, tyrphostin AG490, induced apoptosis. Furthermore, STAT3 inhibition markedly decreased survivin expression, and forced expression of survivin rescued AGS cells from apoptosis induced by STAT3 inhibition. Although some reports demonstrated that the PI3K/Akt pathway regulates survivin expression, inhibition of the PI3K/Akt pathway did not affect survivin expression in AGS and MKN1 cells. Finally, activated form of STAT3, Tyr-705 phospho-stat3, was found in the nucleus of cancer cells in 11 of 40 (27.5%) human gastric cancer specimens. These findings suggest that constitutively activated STAT3 signaling supports gastric cancer cell survival in association with survivin expression.	Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Seno, H (corresponding author), Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sakyo Ku, Shogoin Kawara Cho 54, Kyoto 6068507, Japan.	seno@kuhp.kyoto-u.ac.jp	Kanai, Motomu/J-6807-2016	Kanai, Motomu/0000-0003-1977-7648; Seno, Hiroshi/0000-0002-8509-8128; Marusawa, Hiroyuki/0000-0002-4286-2712				AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Aoki Y, 2003, BLOOD, V101, P1535, DOI 10.1182/blood-2002-07-2130; Bisping G, 2003, BLOOD, V101, P2775, DOI 10.1182/blood-2002-09-2907; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Bromberg JF, 2001, BIOESSAYS, V23, P161, DOI 10.1002/1521-1878(200102)23:2<161::AID-BIES1023>3.0.CO;2-0; Buettner R, 2002, CLIN CANCER RES, V8, P945; Burke WM, 2001, ONCOGENE, V20, P7925, DOI 10.1038/sj.onc.1204990; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Fukuda S, 2001, BLOOD, V98, P2091, DOI 10.1182/blood.V98.7.2091; Gianani R, 2001, HUM PATHOL, V32, P119, DOI 10.1053/hupa.2001.21897; Giri D, 2001, AM J PATHOL, V159, P2159, DOI 10.1016/S0002-9440(10)63067-2; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Ikeguchi M, 2002, BRIT J CANCER, V87, P883, DOI 10.1038/sj.bjc.6600546; Izuishi K, 2000, CANCER RES, V60, P6201; Kanai M, 2003, ONCOGENE, V22, P548, DOI 10.1038/sj.onc.1206109; Kawasaki H, 1998, CANCER RES, V58, P5071; Konno R, 2000, MOL HUM REPROD, V6, P529, DOI 10.1093/molehr/6.6.529; Kube D, 2001, BLOOD, V98, P762, DOI 10.1182/blood.V98.3.762; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Marusawa H, 2003, EMBO J, V22, P2729, DOI 10.1093/emboj/cdg263; Monzo M, 1999, J CLIN ONCOL, V17, P2100, DOI 10.1200/JCO.1999.17.7.2100; Mora LB, 2002, CANCER RES, V62, P6659; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; Rahaman SO, 2002, ONCOGENE, V21, P8404, DOI 10.1038/sj.onc.1206047; Real PJ, 2002, ONCOGENE, V21, P7611, DOI 10.1038/sj.onc.1206004; RUFFJAMISON S, 1994, J BIOL CHEM, V269, P21933; Sasse J, 1997, MOL CELL BIOL, V17, P4677, DOI 10.1128/MCB.17.8.4677; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; Swana HS, 1999, NEW ENGL J MED, V341, P452, DOI 10.1056/NEJM199908053410614; Tran J, 2002, P NATL ACAD SCI USA, V99, P4349, DOI 10.1073/pnas.072586399; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; Werner M, 2001, J CANCER RES CLIN, V127, P207, DOI 10.1007/s004320000195; Zaffaroni N, 2002, CELL MOL LIFE SCI, V59, P1406, DOI 10.1007/s00018-002-8518-3; Zhang T, 2001, CANCER RES, V61, P8664; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	42	259	307	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2004	23	28					4921	4929		10.1038/sj.onc.1207606	http://dx.doi.org/10.1038/sj.onc.1207606			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15077160	Green Submitted			2022-12-17	WOS:000222104200013
J	Sattler, M; Salgia, R; Okuda, K; Uemura, N; Durstin, MA; Pisick, E; Xu, G; Li, JL; Prasad, KV; Griffin, JD				Sattler, M; Salgia, R; Okuda, K; Uemura, N; Durstin, MA; Pisick, E; Xu, G; Li, JL; Prasad, KV; Griffin, JD			The proto-oncogene product p120(CBL) and the adaptor proteins CRKL and c-CRK link c-ABL, p190(BCR/ABL) and p210(BCR/ABL) to the phosphatidylinositol-3' kinase pathway	ONCOGENE			English	Article						BCR/ABL; c-CBL; c-CRK; CRKL; phosphatidylinositol-3' kinase	ACUTE LYMPHOBLASTIC-LEUKEMIA; V-CBL; FUSED TRANSCRIPT; 3-KINASE; BINDING; DOMAIN; TRANSFORMATION; FIBROBLASTS; TRUNCATION; CELLS	Chronic myelogenous leukemia (CML) and some acute lymphoblastic leukemias (ALL) are caused by the t(9;22) chromosome translocation, which produces the constitutively activated BCR/ABL tyrosine kinase. When introduced into factor dependent hematopoietic cell lines, BCR/ABL induces the tyrosine phosphorylation of many cellular proteins. One prominent BCR/ABL substrate is p120(CBL), the cellular homolog of the v-Cbl oncoprotein. In an effort to understand the possible contribution of p120(CBL) to transformation by BCR/ABL, we looked for cellular proteins which associate with p120(CBL) in hematopoietic cell lines transformed by BCR/ABL. In addition to p210(BCR/ABL) and c-ABL, p120(CBL) coprecipitated with an 85 kDa phosphoprotein, which was identified as the p85 subunit of PI3K. Anti-p120(CBL) immunoprecipitates from BCR/ABL-transformed, but not from untransformed, cell lines contained PI3K lipid kinase activity. Interestingly, the adaptor proteins CRKL and c-CRK were also found in these complexes. In vitro binding studies indicated that the SH2 domains of CRKL and c-CRK bound directly to p120(CBL), while the SH3 domains of c-CRK and CRKL bound to BCR/ABL and c-ABL. The N-terminal and the C-terminal SH2 and the SH3 domain of p85(PI3K) bound directly in vitro to p120(CBL). The ABL-SH2, but not ABL-SH3, could also bind to p120(CBL). These data suggest that BCR/ABL may induce the formation of multimeric complexes of signaling proteins which include p120(CBL), PI3K, c-CRK or CRKL, c-ABL and BCR/ABL itself.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV TUMOR IMMUNOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School			Li, Jian-Liang/AAE-9315-2019	Li, Jian-Liang/0000-0002-6487-081X	NCI NIH HHS [CA36167, CA60821] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA036167, R01CA036167, K08CA060821] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BEDI A, 1994, BLOOD, V83, P2038; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; CLARK SS, 1987, SCIENCE, V235, P85, DOI 10.1126/science.3541203; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; ERNST TJ, 1994, J BIOL CHEM, V269, P5764; FAINSTEIN E, 1987, NATURE, V330, P386, DOI 10.1038/330386a0; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FREDERICKSON TN, 1994, J NATL CANCER I, V72, P447; Langdon W Y, 1992, Curr Top Microbiol Immunol, V182, P467; LANGDON WY, 1989, J VIROL, V63, P5420, DOI 10.1128/JVI.63.12.5420-5424.1989; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MUSHINSKI JF, 1994, ONCOGENE, V9, P2489; NICHOLS GL, 1994, BLOOD, V84, P2912; ODA T, 1994, J BIOL CHEM, V269, P22925; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; PRASAD KVS, 1993, MOL CELL BIOL, V13, P7708, DOI 10.1128/MCB.13.12.7708; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SATTLER M, 1995, EXP HEMATOL, V23, P1040; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; TENHOEVE J, 1994, BLOOD, V84, P1731; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; WALKER LC, 1987, NATURE, V329, P851, DOI 10.1038/329851a0; XIAO HY, 1995, INT J ONCOL, V6, P405; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	48	259	264	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	1996	12	4					839	846						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632906				2022-12-17	WOS:A1996TW68600015
J	BLAKE, TJ; SHAPIRO, M; MORSE, HC; LANGDON, WY				BLAKE, TJ; SHAPIRO, M; MORSE, HC; LANGDON, WY			THE SEQUENCES OF THE HUMAN AND MOUSE C-CBL PROTOONCOGENES SHOW V-CBL WAS GENERATED BY A LARGE TRUNCATION ENCOMPASSING A PROLINE-RICH DOMAIN AND A LEUCINE ZIPPER-LIKE MOTIF	ONCOGENE			English	Article							TRANSCRIPTION FACTORS; LYMPHOMAS	The murine Cas NS-1 retrovirus carries the v-cbl oncogene and induces pre-B cell lymphomas and myeloid leukemias. The cellular homolog of v-cbl has been identified in mouse and human DNA, and was recently mapped to mouse chromosome 9 and human chromosome 11q23. To determine the coding sequences of the human and mouse c-cbl proto-oncogenes cDNA clones were isolated from libraries prepared from the human T cell leukemia lines CCRF-CEM and HUT 78, and the mouse pre-B cell line 70Z/3. DNA sequencing revealed an open reading frame encoding 906 amino acids in the human cDNAs and 896 amino acids in 70Z/3. The sequence showed that v-cbl is a markedly truncated form of murine c-cbl containing 355 N-terminal amino acids. The nucleotide sequence of v-cbl is identical to murine c-cbl in this region, and the human sequence has only five amino acid changes in the v-cbl portion. The most notable features of the sequence which was lost in the generation of v-cbl is a C-terminal leucine zipper and a stretch of 208 amino acids containing 23% proline and 19% serine/threonine residues. This proline-rich sequence has similarities to the transcriptional activation domains of some transcription factors, and v-cbl's transforming potential may be due to the loss of this region and the leucine zipper.	INST MED & VET SCI,DIV HUMAN IMMUNOL,ADELAIDE,SA 5000,AUSTRALIA; NIAID,IMMUNOPATHOL LAB,BETHESDA,MD 20892	Institute Medical & Veterinary Science Australia; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)				Morse, Herbert/0000-0002-9331-3705				BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BRENDEL V, 1989, P NATL ACAD SCI USA, V86, P5698, DOI 10.1073/pnas.86.15.5698; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J; GAZDAR AF, 1980, BLOOD, V55, P409; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANGDON WY, 1989, J VIROL, V63, P5420, DOI 10.1128/JVI.63.12.5420-5424.1989; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; PAIGE CJ, 1978, J IMMUNOL, V121, P641; REGNIER DC, 1989, J VIROL, V63, P3678, DOI 10.1128/JVI.63.9.3678-3682.1989; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVAGE PD, 1990, IN PRESS CANCEER GEN; YUNIS JJ, 1986, CLIN HAEMATOL, V15, P597	17	259	266	1	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					653	657						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	2030914				2022-12-17	WOS:A1991FR93900022
J	Davalos, V; Moutinho, C; Villanueva, A; Boque, R; Silva, P; Carneiro, F; Esteller, M				Davalos, V.; Moutinho, C.; Villanueva, A.; Boque, R.; Silva, P.; Carneiro, F.; Esteller, M.			Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis	ONCOGENE			English	Article						miR-200; cancer; EMT; epigenetic; CpG methylation	MIR-200 FAMILY; DNA METHYLATION; TGF-BETA; TUMOR PROGRESSION; REPRESSORS ZEB1; CELL POLARITY; CANCER; EXPRESSION; METASTASIS; EMT	Epithelial-mesenchymal (EMT) and mesenchymal-epithelial (MET) transitions occur in the development of human tumorigenesis and are part of the natural history of the process to adapt to the changing microenvironment. In this setting, the miR-200 family is recognized as a master regulator of the epithelial phenotype by targeting ZEB1 and ZEB2, two important transcriptional repressors of the cell adherence (E-cadherin) and polarity (CRB3 and LGL2) genes. Recently, the putative DNA methylation associated inactivation of various miR-200 members has been described in cancer. Herein, we show that the miR-200ba429 and miR-200c141 transcripts undergo a dynamic epigenetic regulation linked to EMT or MET phenotypes in tumor progression. The 5'-CpG islands of both miR-200 loci were found unmethylated and coupled to the expression of the corresponding miRNAs in human cancer cell lines with epithelial features, such as low levels of ZEB1/ZEB2 and high expression of E-cadherin, CRB3 and LGL2, while CpG island hypermethylation-associated silencing was observed in transformed cells with mesenchymal characteristics. The recovery of miR-200ba429 and miR-200c141 expression by stable transfection in the hypermethylated cells restored the epithelial markers and inhibited migration in cell culture and tumoral growth and metastasis formation in nude mice. We also discovered, using both cell culture and animal models, that the miR-200 epigenetic silencing is not an static and fixed process but it can be shifted to hypermethylated or unmethylated 5'-CpG island status corresponding to the EMT and MET phenotypes, respectively. In fact, careful laser microdissection in human primary colorectal tumorigenesis unveiled that in normal colon mucosa crypts (epithelia) and stroma (mesenchyma) already are unmethylated and methylated at these loci, respectively; and that the colorectal tumors undergo selective miR-200 hypermethylation of their epithelial component. These findings indicate that the epigenetic silencing plasticity of the miR-200 family contributes to the evolving and adapting phenotypes of human tumors. Oncogene (2012) 31, 2062-2074; doi:10.1038/onc.2011.383; published online 29 August 2011	[Davalos, V.; Moutinho, C.; Boque, R.; Esteller, M.] Hosp Duran i Reynals, Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Barcelona 08908, Catalonia, Spain; [Villanueva, A.] IDIBELL Inst Catala Oncol, Translat Res Lab, Barcelona, Spain; [Silva, P.; Carneiro, F.] Univ Porto IPATIMUP, Inst Pathol & Mol Immunol, Oporto, Portugal; [Silva, P.; Carneiro, F.] Fac Med, Oporto, Portugal; [Esteller, M.] Univ Barcelona, Sch Med, Dept Ciencies Fisiol 2, Barcelona, Spain; [Esteller, M.] ICREA, Barcelona, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals; Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Universidade do Porto; Universidade do Porto; University of Barcelona; ICREA	Esteller, M (corresponding author), Hosp Duran i Reynals, Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, 3rd Floor,Av Gran Via 199-203, Barcelona 08908, Catalonia, Spain.	mesteller@idibell.cat	Davalos, Veronica/AAR-8547-2020; Esteller, Manel/L-5956-2014; Carneiro, Fatima/J-6432-2013; Boque-Sastre, Raquel/AAA-6548-2020; Carneiro, Fatima/AAV-8677-2021; Xie, Huangming/B-2260-2012; Davalos, Veronica/S-1668-2016	Esteller, Manel/0000-0003-4490-6093; Carneiro, Fatima/0000-0002-1964-1006; Carneiro, Fatima/0000-0002-1964-1006; Davalos, Veronica/0000-0003-4077-5137; , Raquel Boque-Sastre/0000-0002-0214-8848	Fondo de Investigaciones Sanitarias [PI08-1345]; Olga Torres Foundation; Consolider Grant [MEC09-05]; Dr Josef Steiner Cancer Research Foundation; Lilly Foundation; European Research Council; Health Department of the Catalan Government (Generalitat de Catalunya); Instituto de Salud Carlos III; ICREA Funding Source: Custom	Fondo de Investigaciones Sanitarias(Instituto de Salud Carlos III); Olga Torres Foundation; Consolider Grant(Spanish Government); Dr Josef Steiner Cancer Research Foundation; Lilly Foundation; European Research Council(European Research Council (ERC)European Commission); Health Department of the Catalan Government (Generalitat de Catalunya)(Generalitat de Catalunya); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); ICREA(ICREA)	We thank Dr Balazs Balint for bioinformatic support. This study was supported by Fondo de Investigaciones Sanitarias Grant PI08-1345, Olga Torres Foundation Grant, Consolider Grant MEC09-05, Dr Josef Steiner Cancer Research Foundation Award, Lilly Foundation Biomedical Research Award, European Research Council Advanced Grant EPINORC and the Health Department of the Catalan Government (Generalitat de Catalunya). VD is supported by Instituto de Salud Carlos III, Sara Borrell postdoctoral contract. ME is an Institucio Catalana de Recerca i Estudis Avancats (ICREA) Research Professor.	Abell AN, 2011, CELL STEM CELL, V8, P525, DOI 10.1016/j.stem.2011.03.008; Acloque H, 2009, J CLIN INVEST, V119, P1438, DOI 10.1172/JCI38019; Agami R, 2010, EUR J CLIN INVEST, V40, P370, DOI 10.1111/j.1365-2362.2010.02279.x; Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508; Castilla MA, 2011, J PATHOL, V223, P72, DOI 10.1002/path.2802; Aokage K, 2011, INT J CANCER, V128, P1585, DOI 10.1002/ijc.25500; Baffa R, 2009, J PATHOL, V219, P214, DOI 10.1002/path.2586; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Bryant DM, 2008, NAT REV MOL CELL BIO, V9, P887, DOI 10.1038/nrm2523; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Ceppi P, 2010, MOL CANCER RES, V8, P1207, DOI 10.1158/1541-7786.MCR-10-0052; Chaffer CL, 2007, CELLS TISSUES ORGANS, V185, P7, DOI 10.1159/000101298; Chaffer CL, 2006, CANCER RES, V66, P11271, DOI 10.1158/0008-5472.CAN-06-2044; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; Chou JL, 2010, EXPERT OPIN THER TAR, V14, P1213, DOI 10.1517/14728222.2010.525353; Christoffersen NR, 2007, RNA, V13, P1172, DOI 10.1261/rna.586807; Dumont N, 2008, P NATL ACAD SCI USA, V105, P14867, DOI 10.1073/pnas.0807146105; Dykxhoorn DM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007181; Eades G, 2011, J BIOL CHEM, V286, P25992, DOI 10.1074/jbc.M111.229401; Edwards BK, 2010, CANCER-AM CANCER SOC, V116, P544, DOI 10.1002/cncr.24760; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Etienne-Manneville S, 2008, ONCOGENE, V27, P6970, DOI 10.1038/onc.2008.347; Fujimoto K, 2002, GASTROENTEROLOGY, V123, P1941, DOI 10.1053/gast.2002.37065; Gibbons DL, 2009, GENE DEV, V23, P2140, DOI 10.1101/gad.1820209; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Huang L, 2010, CURR OPIN GENET DEV, V20, P41, DOI 10.1016/j.gde.2009.12.001; Huang YW, 2009, CANCER RES, V69, P9038, DOI 10.1158/0008-5472.CAN-09-1499; Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223; Hurteau GJ, 2007, CANCER RES, V67, P7972, DOI 10.1158/0008-5472.CAN-07-1058; Hurteau GJ, 2006, CELL CYCLE, V5, P1951, DOI 10.4161/cc.5.17.3133; Issa JPJ, 2007, CLIN CANCER RES, V13, P1634, DOI 10.1158/1078-0432.CCR-06-2076; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kaiser J, 2010, SCIENCE, V330, P576, DOI 10.1126/science.330.6004.577; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Lin T, 2010, ONCOGENE, V29, P4896, DOI 10.1038/onc.2010.234; Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105; Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218; Mack GS, 2006, J NATL CANCER I, V98, P1443, DOI 10.1093/jnci/djj447; Medina PP, 2008, CELL CYCLE, V7, P2485, DOI 10.4161/cc.7.16.6453; Moreno-Bueno G, 2008, ONCOGENE, V27, P6958, DOI 10.1038/onc.2008.346; Moreno-Bueno G, 2009, NAT PROTOC, V4, P1591, DOI 10.1038/nprot.2009.152; Neves Rui, 2010, BMC Res Notes, V3, P219, DOI 10.1186/1756-0500-3-219; Pakala SB, 2011, ONCOGENE, V30, P2230, DOI 10.1038/onc.2010.608; Pardali K, 2007, BBA-REV CANCER, V1775, P21, DOI 10.1016/j.bbcan.2006.06.004; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020; Shan B, 2008, J BIOL CHEM, V283, P21065, DOI 10.1074/jbc.M802786200; Spaderna S, 2008, CANCER RES, V68, P537, DOI 10.1158/0008-5472.CAN-07-5682; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Toyota M, 2008, CANCER RES, V68, P4123, DOI 10.1158/0008-5472.CAN-08-0325; Vantyghem SA, 2005, CLIN EXP METASTAS, V22, P351, DOI 10.1007/s10585-005-0745-1; Vrba L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008697; Wiklund ED, 2011, INT J CANCER, V128, P1327, DOI 10.1002/ijc.25461; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yang XF, 2009, J CELL SCI, V122, P2473, DOI 10.1242/jcs.049148; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183	63	258	270	0	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	16					2062	2074		10.1038/onc.2011.383	http://dx.doi.org/10.1038/onc.2011.383			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	928TP	21874049	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000303008600007
J	Ito, Y				Ito, Y			Oncogenic potential of the RUNX gene family: 'Overview'	ONCOGENE			English	Review						runt-related (RUNX); RUNX1/AML1; RUNX2; RUNX3; PEBP2/CBF; developmental regulator; heterodimeric transcription factor; leukemia, gastric cancer	ACUTE MYELOID-LEUKEMIA; CORE-BINDING-FACTOR; MULTIPLE CHROMOSOMAL TRANSLOCATIONS; DOMAIN TRANSCRIPTION FACTOR; DNA-BINDING; AML1 GENE; FUNCTIONAL COOPERATION; INTESTINAL METAPLASIA; EMBRYONAL CARCINOMA; POINT MUTATIONS	Runt-related (RUNX) gene family is composed of three members, RUNX1/AML1, RUNX2 and RUNX3, and encodes the DNA-binding ( a) subunits of the Runt domain transcription factor polyomavirus enhancer-binding protein 2 ( PEBP2)/core-binding factor (CBF), which is a heterodimeric transcription factor. RUNX1 is most frequently involved in human acute leukemia. RUNX2 shows oncogenic potential in mouse experimental system. RUNX3 is a strong candidate as a gastric cancer tumor suppressor. The beta subunit gene of PEBP2/CBF is also frequently involved in chromosome rearrangements associated with human leukemia. In this Overview, I will summarize how this growing field has been formed and what are the challenging new frontiers for better understanding of the oncogenic potential of this gene family.	Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117609, Singapore; Natl Univ Singapore, Oncol Res Inst, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; National University of Singapore	Ito, Y (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.	itoy@imcb.a-star.edu.sg						ADRIAANSEN HJ, 1993, BLOOD, V81, P3043; Ahn MY, 1998, P NATL ACAD SCI USA, V95, P1812, DOI 10.1073/pnas.95.4.1812; Akagi K, 2004, NUCLEIC ACIDS RES, V32, pD523, DOI 10.1093/nar/gkh013; Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254; AMATI P, 1985, CELL, V43, P561, DOI 10.1016/0092-8674(85)90225-9; BAE SC, 1995, GENE, V159, P245, DOI 10.1016/0378-1119(95)00060-J; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; Bangsow C, 2001, GENE, V279, P221, DOI 10.1016/S0378-1119(01)00760-0; Barnes GL, 2003, CANCER RES, V63, P2631; Berardi MJ, 1999, STRUCT FOLD DES, V7, P1247, DOI 10.1016/S0969-2126(00)80058-1; BISHOP JM, 1983, CELL, V32, P1018; Bruhn L, 1997, GENE DEV, V11, P640, DOI 10.1101/gad.11.5.640; Burns CE, 2002, EXP HEMATOL, V30, P1381, DOI 10.1016/S0301-472X(02)00955-4; Cameron ER, 2003, BLOOD CELL MOL DIS, V30, P194, DOI 10.1016/S1079-9796(03)00031-7; Chakraborty S, 2003, ONCOGENE, V22, P5229, DOI 10.1038/sj.onc.1206600; Coffman JA, 1996, DEV BIOL, V174, P43, DOI 10.1006/dbio.1996.0050; Crosier PS, 2002, INT J DEV BIOL, V46, P493; Daga A, 1996, GENE DEV, V10, P1194, DOI 10.1101/gad.10.10.1194; DePinho RA, 1999, NAT GENET, V23, P253, DOI 10.1038/15423; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Fainaru O, 2004, EMBO J, V23, P969, DOI 10.1038/sj.emboj.7600085; Goger M, 1999, NAT STRUCT BIOL, V6, P620; Golling G, 1996, MOL CELL BIOL, V16, P932; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Helms C, 2003, NAT GENET, V35, P349, DOI 10.1038/ng1268; Hess J, 2001, J BIOL CHEM, V276, P20029, DOI 10.1074/jbc.M010601200; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; Huang G, 2001, EMBO J, V20, P723, DOI 10.1093/emboj/20.4.723; Huang XM, 1999, NAT STRUCT BIOL, V6, P624; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; Imai Y, 1998, BIOCHEM BIOPH RES CO, V252, P582, DOI 10.1006/bbrc.1998.9705; Inoue K, 2002, NAT NEUROSCI, V5, P946, DOI 10.1038/nn925; Ito Y, 1999, GENES CELLS, V4, P685, DOI 10.1046/j.1365-2443.1999.00298.x; Ito Y, 2003, CURR OPIN GENET DEV, V13, P43, DOI 10.1016/S0959-437X(03)00007-8; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; Kagoshima H, 1996, J BIOL CHEM, V271, P33074, DOI 10.1074/jbc.271.51.33074; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; Kanno T, 1998, MOL CELL BIOL, V18, P2444, DOI 10.1128/MCB.18.5.2444; Kataoka H, 2000, MECH DEVELOP, V98, P139, DOI 10.1016/S0925-4773(00)00445-7; KATINKA M, 1980, CELL, V20, P393, DOI 10.1016/0092-8674(80)90625-X; Kim S, 2003, GENE DEV, V17, P1979, DOI 10.1101/gad.1119303; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; KITA K, 1992, BLOOD, V80, P470; Kitabayashi I, 2001, EMBO J, V20, P7184, DOI 10.1093/emboj/20.24.7184; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lebestky T, 2000, SCIENCE, V288, P146, DOI 10.1126/science.288.5463.146; Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797-307; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; Li FQ, 2004, J BIOL CHEM, V279, P2873, DOI 10.1074/jbc.M310759200; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Li QL, 2004, BIOCHEM BIOPH RES CO, V314, P223, DOI 10.1016/j.bbrc.2003.12.079; Libermann TA, 1999, J BIOL CHEM, V274, P24671, DOI 10.1074/jbc.274.35.24671; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; LU J, 1995, MOL CELL BIOL, V15, P1651; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; Mao SF, 1999, MOL CELL BIOL, V19, P3635; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Mulloy JC, 2002, BLOOD, V99, P15, DOI 10.1182/blood.V99.1.15; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Mutoh H, 2002, BIOCHEM BIOPH RES CO, V294, P470, DOI 10.1016/S0006-291X(02)00480-1; Nagata T, 1999, NAT STRUCT BIOL, V6, P615; Nam S, 2002, MOL CELL BIOL, V22, P547, DOI 10.1128/MCB.22.2.547-554.2002; Niini T, 2000, HAEMATOLOGICA, V85, P362; Niki M, 1997, P NATL ACAD SCI USA, V94, P5697, DOI 10.1073/pnas.94.11.5697; North T, 1999, DEVELOPMENT, V126, P2563; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okada H, 1998, ONCOGENE, V17, P2287, DOI 10.1038/sj.onc.1202151; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; Prokunina L, 2002, NAT GENET, V32, P666, DOI 10.1038/ng1020; Rennert J, 2003, BMC EVOL BIOL, V3, DOI 10.1186/1471-2148-3-4; Robertson AJ, 2002, MECH DEVELOP, V117, P327, DOI 10.1016/S0925-4773(02)00201-0; SATAKE M, 1992, JPN J CANCER RES, V83, P714, DOI 10.1111/j.1349-7006.1992.tb01971.x; Silberg DG, 2002, GASTROENTEROLOGY, V122, P689, DOI 10.1053/gast.2002.31902; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; SPECK NA, 1990, J VIROL, V64, P543, DOI 10.1128/JVI.64.2.543-550.1990; Speck NA, 2002, NAT REV CANCER, V2, P502, DOI 10.1038/nrc840; Stewart M, 1997, P NATL ACAD SCI USA, V94, P8646, DOI 10.1073/pnas.94.16.8646; Sudol M, 2000, CELL, V103, P1001, DOI 10.1016/S0092-8674(00)00203-8; Tahirov TH, 2001, CELL, V104, P755, DOI 10.1016/S0092-8674(02)02053-6; TANAKA K, 1982, EMBO J, V1, P1521, DOI 10.1002/j.1460-2075.1982.tb01349.x; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; Tanaka T, 1996, MOL CELL BIOL, V16, P3967; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Tokuhiro S, 2003, NAT GENET, V35, P341, DOI 10.1038/ng1267; Tracey WD, 1998, DEVELOPMENT, V125, P1371; VEGAFLORES M, UNPUB; Wada M, 2004, ONCOGENE, V23, P2401, DOI 10.1038/sj.onc.1207395; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; Warren AJ, 2000, EMBO J, V19, P3004, DOI 10.1093/emboj/19.12.3004; Wee HJ, 2002, EMBO REP, V3, P967, DOI 10.1093/embo-reports/kvf193; Weith A, 1996, CYTOGENET CELL GENET, V72, P114; Woolf E, 2003, P NATL ACAD SCI USA, V100, P7731, DOI 10.1073/pnas.1232420100; Wotton S, 2002, CANCER RES, V62, P7181; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; Yamaguchi Y, 2004, J BIOL CHEM, V279, P15630, DOI 10.1074/jbc.M400355200; Yokomizo T, 2001, GENES CELLS, V6, P13, DOI 10.1046/j.1365-2443.2001.00393.x; Yuasa Y, 2003, NAT REV CANCER, V3, P592, DOI 10.1038/nrc1141; Zaidi SK, 2004, EMBO J, V23, P790, DOI 10.1038/sj.emboj.7600073; Zeng CM, 1997, P NATL ACAD SCI USA, V94, P6746, DOI 10.1073/pnas.94.13.6746; Zhang YW, 2000, P NATL ACAD SCI USA, V97, P10549, DOI 10.1073/pnas.180309597	122	258	267	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2004	23	24					4198	4208		10.1038/sj.onc.1207755	http://dx.doi.org/10.1038/sj.onc.1207755			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823BZ	15156173				2022-12-17	WOS:000221586000002
J	Aoudjit, F; Vuori, K				Aoudjit, F; Vuori, K			Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells	ONCOGENE			English	Article						apoptosis; breast cancer; chemotherapeutic agent; extracellular matrix; integrin; paclitaxel	FOCAL ADHESION KINASE; INTESTINAL EPITHELIAL-CELLS; REGULATES BCL-2 EXPRESSION; RESISTANCE CAM-DR; EXTRACELLULAR-MATRIX; CYTOCHROME-C; CARCINOMA CELLS; PROTEIN-KINASE; MICROTUBULE DAMAGE; CELLULAR-SURVIVAL	Inherent or acquired drug resistance is one of the major problems in chemotherapy. The mechanisms by which cancer cells survive and escape the cytotoxic effects of chemotherapeutic agents are essentially unknown. In the present study, we demonstrate that in the MDA-MB-231 and MDA-MB-435 breast cancer cells, ligation of beta1 integrins by their extracellular matrix ligands inhibits significantly apoptosis induced by paclitaxel and vincristine, two microtubule-directed chemotherapeutic agents that are widely used in the therapy of breast cancer. We show that beta1 integrin signaling inhibits drug-induced apoptosis by inhibiting the release of cytochrome c from the mitochondria in response to drug treatment. Further, integrin-mediated protection from drug-induced apoptosis and inhibition of cytochrome c release are dependent on the activation of the PI 3-kinase/Akt pathway. Our results identify beta1 integrin signaling as an important survival pathway in drug-induced apoptosis in breast cancer cells and suggest that activation of this pathway may contribute to the generation of drug resistance.	Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Vuori, K (corresponding author), Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA.							Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Aoudjit F, 2000, BLOOD, V95, P2044, DOI 10.1182/blood.V95.6.2044; Aoudjit F, 2001, J CELL BIOL, V152, P633, DOI 10.1083/jcb.152.3.633; Blagosklonny MV, 1997, CANCER RES, V57, P130; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chadebech P, 1999, BIOCHEM BIOPH RES CO, V262, P823, DOI 10.1006/bbrc.1999.1291; COLEMAN RE, 1987, BRIT J CANCER, V55, P61, DOI 10.1038/bjc.1987.13; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; FISHER B, 1997, CANC MED; Fornier M, 1999, ONCOLOGY-NY, V13, P647; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Gooch JL, 1999, BREAST CANCER RES TR, V56, P1, DOI 10.1023/A:1006208721167; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Haldar S, 1997, CANCER RES, V57, P229; Hazlehurst LA, 2000, ONCOGENE, V19, P4319, DOI 10.1038/sj.onc.1203782; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Ilic D, 1998, J CELL BIOL, V143, P547; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kottke TJ, 1999, J BIOL CHEM, V274, P15927, DOI 10.1074/jbc.274.22.15927; KUMAR N, 1981, J BIOL CHEM, V256, P435; Le Gall M, 2000, MOL BIOL CELL, V11, P1103, DOI 10.1091/mbc.11.3.1103; Lebwohl DE, 1999, ANN ONCOL, V10, P139, DOI 10.1023/A:1008318725670; Lee JW, 2000, MOL BIOL CELL, V11, P1973, DOI 10.1091/mbc.11.6.1973; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lichtner RB, 1998, EXP CELL RES, V240, P368, DOI 10.1006/excr.1998.4012; Lundstrom A, 1998, BIOCHEM BIOPH RES CO, V250, P735, DOI 10.1006/bbrc.1998.9389; MacKeigan JP, 2000, J BIOL CHEM, V275, P38953, DOI 10.1074/jbc.C000684200; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; Nista A, 1997, INT J CANCER, V72, P133, DOI 10.1002/(SICI)1097-0215(19970703)72:1<133::AID-IJC19>3.0.CO;2-K; OBrien V, 1996, EXP CELL RES, V224, P208, DOI 10.1006/excr.1996.0130; Page C, 2000, ANTICANCER RES, V20, P407; Petitclerc E, 1999, CANCER RES, V59, P2724; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Pusztai L, 1998, ACTA ONCOL, V37, P629, DOI 10.1080/028418698429964; Rosen K, 2000, J CELL BIOL, V149, P447, DOI 10.1083/jcb.149.2.447; Rytomaa M, 2000, ONCOGENE, V19, P4461, DOI 10.1038/sj.onc.1203805; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Seftor REB, 1998, CANCER RES, V58, P5681; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; Shaw LM, 1996, CANCER RES, V56, P959; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; Srivastava RK, 1999, J EXP MED, V190, P253, DOI 10.1084/jem.190.2.253; Uhm JH, 1999, CLIN CANCER RES, V5, P1587; van der Pluijm G, 1997, LAB INVEST, V77, P665; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Wang WG, 1999, J CELL BIOCHEM, V73, P321; Wewer UM, 1997, AM J PATHOL, V151, P1191; Wong NC, 1998, CLIN EXP METASTAS, V16, P50; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yeung TK, 1999, BIOCHEM BIOPH RES CO, V263, P398, DOI 10.1006/bbrc.1999.1375; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161	63	258	276	0	9	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 16	2001	20	36					4995	5004		10.1038/sj.onc.1204554	http://dx.doi.org/10.1038/sj.onc.1204554			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526484				2022-12-17	WOS:000170439800009
J	SATO, H; KIDA, Y; MAI, M; ENDO, Y; SASAKI, T; TANAKA, J; SEIKI, M				SATO, H; KIDA, Y; MAI, M; ENDO, Y; SASAKI, T; TANAKA, J; SEIKI, M			EXPRESSION OF GENES ENCODING TYPE-IV COLLAGEN-DEGRADING METALLOPROTEINASES AND TISSUE INHIBITORS OF METALLOPROTEINASES IN VARIOUS HUMAN TUMOR-CELLS	ONCOGENE			English	Article							HUMAN FIBROBLAST COLLAGENASE; EXTRACELLULAR-MATRIX; BASEMENT-MEMBRANE; SYNOVIAL FIBROBLASTS; TRANSIN GENE; INVASION; STROMELYSIN; ONCOGENE; COMPLEX; TIMP-2	Uncontrolled expression of matrix metalloproteinases 2, 3 and 9 (MMP-2, -3 and -9) is believed to be a critical part of the invasive potential of tumor cells because of their ability to degrade type IV collagen, a major structural component of basement membranes. Availability of proteolytic activity in the vicinity of the cell surface is further affected by a local balance between the enzymes and their inhibitors produced by the cell. To determine how frequently deregulated expression of the MMPs and tissue inhibitors of metalloproteinases (TIMPs) is associated with tumor cells, 26 human tumor cell lines were examined by Northern blotting. Transcripts for MMP-2 and MMP-9 were more frequently expressed in mesenchymal tumor cells (9/9 for MMP-2 and 6/9 for MMP-9) than in epithelial tumor cells (4/17 for MMP-2 and 2/17 for MMP-9). Although expression of MMP-2 mRNA was clearly cell type-specific, MMP-9 mRNA expression in mesenchymal cells correlated well with the reported tumorigenicity of the cells. Enhanced expression of MMP-9 mRNA was also associated with the tumorigenic transformation of cells by an activated c-H-ras gene in human embryonic fibroblasts. Only 3 of the 26 tumor cells expressed MMP-3 mRNA, and 2 of the 3 were epithelial tumor cells which coordinately expressed MMP-9 and TIMP-1 mRNAs. TIMP-1 mRNA was almost undetectable in 50% of the tumor cells, but TIMP-2 mRNA was expressed in the majority of the cells. These findings provide comprehensive information about mRNA expression of the NIMPs and TIMPs in tumor cells, the deregulation of which is thought to be an integral part of the invasive potential of tumor cells.	KANAZAWA UNIV,CANC RES INST,DEPT VIROL,KANAZAWA,ISHIKAWA 920,JAPAN; KANAZAWA UNIV,CANC RES INST,DEPT SURG,KANAZAWA,ISHIKAWA 921,JAPAN; KANAZAWA UNIV,CANC RES INST,DEPT EXPTL THERAPEUT,KANAZAWA,ISHIKAWA 920,JAPAN	Kanazawa University; Kanazawa University; Kanazawa University			SATO, Hiroshi/D-8454-2015; ENDO, Yoshio/D-8428-2015; Seiki, Motoharu/K-9443-2015	ENDO, Yoshio/0000-0003-0785-2006; 				Alexander CM, 1989, CURR OPIN CELL BIOL, V1, P974, DOI 10.1016/0955-0674(89)90068-9; ALITALO R, 1990, BLOOD, V75, P1974; ASAI T, 1991, J JUZEN MED SOC, V100, P1; BRENNER CA, 1989, GENE DEV, V3, P848, DOI 10.1101/gad.3.6.848; CARMICHAEL DF, 1986, P NATL ACAD SCI USA, V83, P2407, DOI 10.1073/pnas.83.8.2407; CHIN JR, 1985, J BIOL CHEM, V260, P2367; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DECLERCK YA, 1991, J BIOL CHEM, V266, P3893; DEDHAR S, 1990, J CELL BIOL, V110, P481, DOI 10.1083/jcb.110.2.481; ENDO Y, 1990, JPN J CANCER RES, V81, P723, DOI 10.1111/j.1349-7006.1990.tb02635.x; FRISCH SM, 1990, MOL CELL BIOL, V10, P6524, DOI 10.1128/MCB.10.12.6524; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; GRANT GA, 1987, J BIOL CHEM, V262, P5886; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; JONES PA, 1980, CANCER RES, V40, P3222; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KO T, 1976, TOKYO IKA DAIGAKU ZA, V34, P577; KRAMER RH, 1986, CANCER RES, V46, P1980; KRIEG P, 1988, CARCINOGENESIS, V9, P95, DOI 10.1093/carcin/9.1.95; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1986, ANNU REV BIOCHEM, V55, P1037, DOI 10.1146/annurev.biochem.55.1.1037; LIOTTA LA, 1986, CANCER RES, V46, P1; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MOSCATELLI D, 1988, BIOCHIM BIOPHYS ACTA, V948, P67, DOI 10.1016/0304-419X(88)90005-4; NAKAJIMA M, 1987, CANCER RES, V47, P4869; NAKAJIMA M, 1990, J NATL CANCER I, V82, P1890, DOI 10.1093/jnci/82.24.1890; NAMBA M, 1985, INT J CANCER, V35, P275, DOI 10.1002/ijc.2910350221; OKADA Y, 1990, BIOCHEM BIOPH RES CO, V171, P610, DOI 10.1016/0006-291X(90)91190-4; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; OKADA Y, 1986, J BIOL CHEM, V261, P14245; PAULI BU, 1983, CANCER METAST REV, V2, P129, DOI 10.1007/BF00048966; RASHEED S, 1974, CANCER, V33, P127; SCHONTHAL A, 1988, CELL, V54, P324; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; STETLERSTEVENSON WG, 1990, J BIOL CHEM, V265, P13933; STRICKLIN GP, 1983, BIOCHEMISTRY-US, V22, P1173; TRYGGVASON K, 1987, BIOCHIM BIOPHYS ACTA, V907, P191, DOI 10.1016/0304-419X(87)90006-0; Werb Z., 1989, TXB RHEUMATOLOGY, P300; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725; WILHELM SM, 1989, J BIOL CHEM, V264, P17213	44	258	265	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1992	7	1					77	83						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1311064				2022-12-17	WOS:A1992HC22700011
J	CASEY, G; LOHSUEH, M; LOPEZ, ME; VOGELSTEIN, B; STANBRIDGE, EJ				CASEY, G; LOHSUEH, M; LOPEZ, ME; VOGELSTEIN, B; STANBRIDGE, EJ			GROWTH SUPPRESSION OF HUMAN BREAST-CANCER CELLS BY THE INTRODUCTION OF A WILD-TYPE P53 GENE	ONCOGENE			English	Article							PHENOL-CHLOROFORM EXTRACTION; CELLULAR TUMOR-ANTIGEN; SINGLE-STEP METHOD; SHORT ARM; RNA ISOLATION; LUNG-CANCER; ALLELE LOSS; MUTANT P53; TRANSFORMATION; MUTATIONS	Mutations in the p53 gene are associated with a wide variety of human tumors, including those of the breast. To assess functionally the role of the p53 gene in the development of human breast cancer, we introduced either wild-type or mutant p53 cDNA into three human breast cancer cell lines by DNA transfection. The cell lines MDA-MB 468 and T47 D contain only single mutated copies of the p53 gene, whereas the status of p53 in the breast cancer cell line MCF 7 remains equivocal. Following transfection, MCF 7 cells continued to grow unaffected both in vitro and in vivo in the presence of high levels of expression of the exogenous wild-type p53 gene. In contrast, however, the continued expression of an exogenous wild-type p53 gene was incompatible with cellular growth in both the MDA-MB 468 and T47 D cell lines. Elevated levels of expression of the exogenous mutant p53 gene did not alter the growth of the cell lines in vitro. These data strongly suggest that the wild-type p53 gene can function as a suppressor of cellular growth in breast cancer cells. That the wild-type p53 gene does not suppress the growth of MCF 7 cells indicates that at least some human breast tumors can arise without functional inactivation of the p53 gene by mutation. These tumors may represent a separate prognostic group.	JOHNS HOPKINS ONCOL CTR,BALTIMORE,MD 21231; UNIV CALIF IRVINE,DEPT MICROBIOL,IRVINE,CA 92717	Johns Hopkins University; Johns Hopkins Medicine; University of California System; University of California Irvine	CASEY, G (corresponding author), UNIV CALIF IRVINE,DEPT PHARM,IRVINE,CA 92717, USA.				NATIONAL CANCER INSTITUTE [R01CA043460, R37CA043460] Funding Source: NIH RePORTER; NCI NIH HHS [CA 43460] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLARD MW, 1991, BIOTECHNIQUES, V10, P24; ALTHERR MR, 1989, GENOMICS, V5, P581, DOI 10.1016/0888-7543(89)90026-8; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BAKER SJ, 1990, SCIENCE, V249, P217; BARTEK J, 1990, ONCOGENE, V5, P893; BARTEK J, 1990, INT J CANCER, V46, P839, DOI 10.1002/ijc.2910460515; CATTORETTI G, 1988, INT J CANCER, V41, P178, DOI 10.1002/ijc.2910410204; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; Crawford L V, 1984, Mol Biol Med, V2, P261; DEVILEE P, 1990, CYTOGENET CELL GENET, V53, P52, DOI 10.1159/000132893; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1988, ONCOGENE, V3, P313; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HIGUCHI R, 1989, AMPLIFICATIONS, V2, P1; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; MACKAY J, 1988, LANCET, V2, P1384; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MCBRIDE OW, 1986, P NATL ACAD SCI USA, V83, P130, DOI 10.1073/pnas.83.1.130; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PROSSER J, 1990, ONCOGENE, V5, P1573; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; Sambrook J., 1989, MOL CLONING LAB MANU; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; THOMPSON AM, 1990, BRIT J CANCER, V61, P74, DOI 10.1038/bjc.1990.17; VARLEY JM, 1991, ONCOGENE, V6, P413; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0	47	258	273	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1791	1797						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923504				2022-12-17	WOS:A1991GX11800011
J	FRYE, RA; BENZ, CC; LIU, E				FRYE, RA; BENZ, CC; LIU, E			DETECTION OF AMPLIFIED ONCOGENES BY DIFFERENTIAL POLYMERASE CHAIN-REACTION	ONCOGENE			English	Article									UNIV N CAROLINA,LINEBERGER CANC RES CTR,CHAPEL HILL,NC 27599; UNIV CALIF SAN FRANCISCO,CANC RES INST,SAN FRANCISCO,CA 94143; UNIV N CAROLINA,DEPT PATHOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,CURRICULUM GENET,SAN FRANCISCO,CA 94143	University of North Carolina; University of North Carolina Chapel Hill; University of California System; University of California San Francisco; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina			Liu, Edison/C-4141-2008					ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; GRAY PW, 1982, NATURE, V298, P859, DOI 10.1038/298859a0; KASHANISABET M, 1988, CANCER RES, V48, P5775; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LEE MS, 1987, SCIENCE, V237, P175, DOI 10.1126/science.3110950; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LIU E, 1987, NATURE, V330, P186, DOI 10.1038/330186a0; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	19	258	266	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1989	4	9					1153	1157						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AM531	2780051				2022-12-17	WOS:A1989AM53100017
J	Martins, I; Kepp, O; Schlemmer, F; Adjemian, S; Tailler, M; Shen, S; Michaud, M; Menger, L; Gdoura, A; Tajeddine, N; Tesniere, A; Zitvogel, L; Kroemer, G				Martins, I.; Kepp, O.; Schlemmer, F.; Adjemian, S.; Tailler, M.; Shen, S.; Michaud, M.; Menger, L.; Gdoura, A.; Tajeddine, N.; Tesniere, A.; Zitvogel, L.; Kroemer, G.			Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress	ONCOGENE			English	Article						apoptosis; autophagy; ER stress; necrosis; stress granules	CALRETICULIN EXPOSURE; TUMOR-CELLS; APOPTOSIS; CARCINOMA; PROTEINS; IMMUNITY; SURFACE; DNA; TRANSLOCATION; CHEMOTHERAPY	In contrast to other cytotoxic agents including anthracyclins and oxaliplatin (OXP), cisplatin (CDDP) fails to induce immunogenic tumor cell death that would allow to stimulate an anticancer immune response and hence to amplify its therapeutic efficacy. This failure to induce immunogenic cell death can be attributed to CDDP's incapacity to elicit the translocation of calreticulin (CRT) from the lumen of the endoplasmic reticulum (ER) to the cell surface. Here, we show that, in contrast to OXP, CDDP is unable to activate the protein kinase-like ER kinase (PERK)-dependent phosphorylation of the eukaryotic translation initiation factor 2 alpha (eIF2 alpha). Accordingly, CDDP also failed to stimulate the formation of stress granules and macroautophagy, two processes that only occur after eIF2 alpha phosphorylation. Using a screening method that monitors the voyage of CRT from the ER lumen to the cell surface, we identified thapsigargin (THAPS), an inhibitor of the sarco/ER Ca2+-ATPase as a molecule that on its own does not stimulate CRT exposure, yet endows CDDP with the capacity to do so. The combination of ER stress inducers (such as THAPS or tunicamycin) and CDDP effectively induced the translocation of CRT to the plasma membrane, as well as immunogenic cell death, although ER stress or CDDP alone was insufficient to induce CRT exposure and immunogenic cell death. Altogether, our results underscore the contribution of the ER stress response to the immunogenicity of cell death. Oncogene (2011) 30, 1147-1158; doi:10.1038/onc.2010.500; published online 13 December 2010	[Kroemer, G.] Inst Gustave Roussy, INSERM, U848, F-94805 Villejuif, Val De Marne, France; [Martins, I.; Kepp, O.; Schlemmer, F.; Adjemian, S.; Tailler, M.; Shen, S.; Michaud, M.; Menger, L.; Gdoura, A.; Tajeddine, N.; Tesniere, A.; Zitvogel, L.] Univ Paris 11, Villejuif, France; [Zitvogel, L.] INSERM, U1015, Villejuif, France; [Zitvogel, L.] CICBT507, Villejuif, France; [Kroemer, G.] Ctr Rech Cordeliers, Paris, France; [Kroemer, G.] Hop Europeen Georges Pompidou, AP HP, Paris, France; [Kroemer, G.] Univ Paris 05, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Kroemer, G (corresponding author), Inst Gustave Roussy, INSERM, U848, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, Val De Marne, France.	kroemer@orange.fr	Kepp, Oliver/N-2763-2017; Kroemer, Guido/AAY-9859-2020; SHEN, Shensi/AAW-2735-2020; ADJEMIAN, Sandy/K-7632-2012; Kepp, Oliver/GPX-8627-2022; KROEMER, Guido/B-4263-2013	Kepp, Oliver/0000-0002-6081-9558; SHEN, Shensi/0000-0002-5087-8220; ADJEMIAN, Sandy/0000-0001-5594-5499; KROEMER, Guido/0000-0002-9334-4405; Menger, Laurie/0000-0003-0949-6607; Schlemmer, Frederic/0000-0003-2113-7113; ZITVOGEL, laurence/0000-0003-1596-0998	Ligue Nationale contre le Cancer (Equipes labellisee); Agence Nationale pour la Recherche (ANR); European Commission (Apo-Sys, ChemoRes, Apop-Train); Fondation pour la Recherche Medicale (FRM); Institut National du Cancer (INCa); Canceropole Ile-de-France; AICR; FRM	Ligue Nationale contre le Cancer (Equipes labellisee); Agence Nationale pour la Recherche (ANR)(French National Research Agency (ANR)); European Commission (Apo-Sys, ChemoRes, Apop-Train)(European CommissionEuropean Commission Joint Research Centre); Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); Canceropole Ile-de-France(Region Ile-de-France); AICR; FRM(Fondation pour la Recherche Medicale)	GK is supported by the Ligue Nationale contre le Cancer (Equipes labellisee), Agence Nationale pour la Recherche (ANR), European Commission (Apo-Sys, ChemoRes, Apop-Train), Fondation pour la Recherche Medicale (FRM), Institut National du Cancer (INCa) and Canceropole Ile-de-France. IM is supported by the Ligue Nationale contre le Cancer, OK is supported by AICR and FS by FRM.	Apetoh L, 2007, IMMUNOL REV, V220, P47, DOI 10.1111/j.1600-065X.2007.00573.x; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; Casares N, 2005, J EXP MED, V202, P1691, DOI 10.1084/jem.20050915; Delmastro DA, 1997, CANCER CHEMOTH PHARM, V39, P245; Garg AD, 2010, BBA-REV CANCER, V1805, P53, DOI 10.1016/j.bbcan.2009.08.003; Ghiringhelli F, 2009, NAT MED, V15, P1170, DOI 10.1038/nm.2028; Gourdier I, 2004, ONCOGENE, V23, P7449, DOI 10.1038/sj.onc.1208047; Green DR, 2009, NAT REV IMMUNOL, V9, P353, DOI 10.1038/nri2545; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kedersha NL, 1999, J CELL BIOL, V147, P1431, DOI 10.1083/jcb.147.7.1431; Kepp O, 2010, CELL CYCLE, V9, P3072, DOI 10.4161/cc.9.15.12459; Krause KH, 1997, CELL, V88, P439, DOI 10.1016/S0092-8674(00)81884-X; Kroemer G, 2005, NAT MED, V11, P725, DOI 10.1038/nm1263; Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150; LYTTON J, 1991, J BIOL CHEM, V266, P17067; Martins I, 2009, CELL CYCLE, V8, P3723, DOI 10.4161/cc.8.22.10026; Metivier D, 1998, IMMUNOL LETT, V61, P157, DOI 10.1016/S0165-2478(98)00013-3; Obeid M, 2007, CELL DEATH DIFFER, V14, P1848, DOI 10.1038/sj.cdd.4402201; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; Orvedahl A, 2009, CURR TOP MICROBIOL, V335, P267, DOI 10.1007/978-3-642-00302-8_13; Panaretakis T, 2008, CELL DEATH DIFFER, V15, P1499, DOI 10.1038/cdd.2008.67; Panaretakis T, 2009, EMBO J, V28, P578, DOI 10.1038/emboj.2009.1; Patterson SD, 2000, CELL DEATH DIFFER, V7, P137, DOI 10.1038/sj.cdd.4400640; Rello-Varona S, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.6; Snapp EL, 2006, P NATL ACAD SCI USA, V103, P6536, DOI 10.1073/pnas.0510657103; Spisek R, 2007, BLOOD, V109, P4839, DOI 10.1182/blood-2006-10-054221; Tajeddine N, 2008, ONCOGENE, V27, P4221, DOI 10.1038/onc.2008.63; Tesniere A, 2010, ONCOGENE, V29, P482, DOI 10.1038/onc.2009.356; Tourriere H, 2003, J CELL BIOL, V160, P823, DOI 10.1083/jcb.200212128; Tufi R, 2008, CELL DEATH DIFFER, V15, P274, DOI 10.1038/sj.cdd.4402275; Vandenabeele P, 2008, TRENDS BIOCHEM SCI, V33, P352, DOI 10.1016/j.tibs.2008.05.007; von Haefen C, 2004, ONCOGENE, V23, P8320, DOI 10.1038/sj.onc.1207971; Yang ZJ, 2006, CLIN CANCER RES, V12, P5817, DOI 10.1158/1078-0432.CCR-06-1037; Zitvogel L, 2010, CELL, V140, P798, DOI 10.1016/j.cell.2010.02.015	36	257	265	2	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	10					1147	1158		10.1038/onc.2010.500	http://dx.doi.org/10.1038/onc.2010.500			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732QD	21151176				2022-12-17	WOS:000288202400002
J	Tait, SWG; Green, DR				Tait, S. W. G.; Green, D. R.			Caspase-independent cell death: leaving the set without the final cut	ONCOGENE			English	Review						caspases; mitochondria; caspase-independent cell death; mitochondrial outer membrane permeabilization; cancer	APOPTOSIS-INDUCING FACTOR; STRESS-INDUCED APOPTOSIS; TUMOR-NECROSIS-FACTOR; CYTOCHROME-C RELEASE; DIFFERENTIAL REQUIREMENT; SYMPATHETIC NEURONS; CONFERS RESISTANCE; APAF-1 EXPRESSION; DROSOPHILA CELLS; SERINE-PROTEASE	Apoptosis is dependent upon caspase activation leading to substrate cleavage and, ultimately, cell death. Although required for the apoptotic phenotype, it has become apparent that cells frequently die even when caspase function is blocked. This process, termed caspase-independent cell death (CICD), occurs in response to most intrinsic apoptotic cues, provided that mitochondrial outer membrane permeabilization has occurred. Death receptor ligation can also trigger a form of CICD termed necroptosis. In this review, we will examine the molecular mechanisms governing CICD, highlight recent findings demonstrating recovery from conditions of CICD and discuss potential pathophysiological functions of these processes.	[Tait, S. W. G.; Green, D. R.] St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Green, DR (corresponding author), St Jude Childrens Res Hosp, Dept Immunol, 332 N Lauderdale, Memphis, TN 38105 USA.	Douglas.Green@stjude.org	Green, Douglas R/N-8083-2018	Green, Douglas R/0000-0002-7332-1417; Tait, Stephen/0000-0001-7697-132X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047891] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI047891-10, R01 AI047891] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abraham MC, 2007, DEV CELL, V12, P73, DOI 10.1016/j.devcel.2006.11.012; Arnoult D, 2003, EMBO J, V22, P4385, DOI 10.1093/emboj/cdg423; Arnoult D, 2007, TRENDS CELL BIOL, V17, P6, DOI 10.1016/j.tcb.2006.11.001; Bahi N, 2006, J BIOL CHEM, V281, P22943, DOI 10.1074/jbc.M601025200; Balsam LB, 2005, J SURG RES, V124, P194, DOI 10.1016/j.jss.2004.09.017; Berry DL, 2007, CELL, V131, P1137, DOI 10.1016/j.cell.2007.10.048; Braun JS, 2007, EXP NEUROL, V206, P183, DOI 10.1016/j.expneurol.2007.03.032; Brown D, 2006, P NATL ACAD SCI USA, V103, P9918, DOI 10.1073/pnas.0603950103; Cauwels A, 2003, NAT IMMUNOL, V4, P387, DOI 10.1038/ni914; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chan PH, 2004, NEUROCHEM RES, V29, P1943, DOI 10.1007/s11064-004-6869-x; Chautan M, 1999, CURR BIOL, V9, P967, DOI 10.1016/S0960-9822(99)80425-4; Chauvier D, 2007, CELL DEATH DIFFER, V14, P387, DOI 10.1038/sj.cdd.4402044; Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046; Cheung ECC, 2006, EMBO J, V25, P4061, DOI 10.1038/sj.emboj.7601276; Chipuk JE, 2005, NAT REV MOL CELL BIO, V6, P268, DOI [10.1038/nrm1573, 10.1038/nrm2239]; Chipuk JE, 2008, TRENDS CELL BIOL, V18, P157, DOI 10.1016/j.tcb.2008.01.007; Colell A, 2007, CELL, V129, P983, DOI 10.1016/j.cell.2007.03.045; DeBerardinis RJ, 2008, CURR OPIN GENET DEV, V18, P54, DOI 10.1016/j.gde.2008.02.003; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83; Deming PB, 2004, MOL CELL BIOL, V24, P10289, DOI 10.1128/MCB.24.23.10289-10299.2004; Denmeade SR, 1999, PROSTATE, V39, P269; Deshmukh M, 2002, J NEUROSCI, V22, P8018; Deshmukh M, 1998, NEURON, V21, P695, DOI 10.1016/S0896-6273(00)80587-5; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Ekert PG, 2004, J CELL BIOL, V165, P835, DOI 10.1083/jcb.200312031; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; Fraser AG, 1997, EMBO J, V16, P6192, DOI 10.1093/emboj/16.20.6192; Fujimoto A, 2004, CANCER RES, V64, P2245, DOI 10.1158/0008-5472.CAN-03-2932; GASSER SM, 1982, J BIOL CHEM, V257, P3034; Goldstein JC, 2000, ANN NY ACAD SCI, V926, P132; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Gustafsson AB, 2008, CARDIOVASC RES, V77, P334, DOI 10.1093/cvr/cvm005; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hao ZY, 2005, CELL, V121, P579, DOI 10.1016/j.cell.2005.03.016; Haraguchi M, 2000, J EXP MED, V191, P1709, DOI 10.1084/jem.191.10.1709; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; Hoffarth S, 2008, CELL DEATH DIFFER, V15, P161, DOI 10.1038/sj.cdd.4402256; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Horvitz HR, 2003, BIOSCIENCE REP, V23, P239, DOI 10.1023/B:BIRE.0000019187.19019.e6; Jaattela M, 2003, NAT IMMUNOL, V4, P416, DOI 10.1038/ni0503-416; Jia L, 2001, BLOOD, V98, P414, DOI 10.1182/blood.V98.2.414; Johnson CE, 2007, P NATL ACAD SCI USA, V104, P20820, DOI 10.1073/pnas.0709101105; Jones JM, 2003, NATURE, V425, P721, DOI 10.1038/nature02052; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kawahara A, 1998, J CELL BIOL, V143, P1353, DOI 10.1083/jcb.143.5.1353; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Klein JA, 2002, NATURE, V419, P367, DOI 10.1038/nature01034; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Lavrik I, 2005, J CELL SCI, V118, P265, DOI 10.1242/jcs.01610; Leo C, 2007, CLIN CANCER RES, V13, P1149, DOI 10.1158/1078-0432.CCR-06-2371; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Lorenzo HK, 1999, CELL DEATH DIFFER, V6, P516, DOI 10.1038/sj.cdd.4400527; Lu M, 2007, MOL CELL, V26, P689, DOI 10.1016/j.molcel.2007.05.006; Martinou I, 1999, J CELL BIOL, V144, P883, DOI 10.1083/jcb.144.5.883; Misaghi S, 2006, CELL DEATH DIFFER, V13, P163, DOI 10.1038/sj.cdd.4401716; Munoz-Pinedo C, 2006, P NATL ACAD SCI USA, V103, P11573, DOI 10.1073/pnas.0603007103; Muro I, 2006, DEVELOPMENT, V133, P3305, DOI 10.1242/dev.02495; Ohta T, 1997, J BIOL CHEM, V272, P23111, DOI 10.1074/jbc.272.37.23111; Okuno S, 1998, J BIOL CHEM, V273, P34272, DOI 10.1074/jbc.273.51.34272; Potts PR, 2003, J CELL BIOL, V163, P789, DOI 10.1083/jcb.200307130; Pyo JO, 2005, J BIOL CHEM, V280, P20722, DOI 10.1074/jbc.M413934200; Revillion F, 2000, EUR J CANCER, V36, P1038, DOI 10.1016/S0959-8049(00)00051-4; Ricci JE, 2004, CELL, V117, P773, DOI 10.1016/j.cell.2004.05.008; Rozman-Pungercar J, 2003, CELL DEATH DIFFER, V10, P881, DOI 10.1038/sj.cdd.4401247; Sanchis D, 2003, CELL DEATH DIFFER, V10, P977, DOI 10.1038/sj.cdd.4401267; Sarin A, 1997, IMMUNITY, V6, P209, DOI 10.1016/S1074-7613(00)80427-6; Sasaki H, 2000, CANCER RES, V60, P5659; Schafer ZT, 2006, DEV CELL, V10, P549, DOI 10.1016/j.devcel.2006.04.008; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Scott CL, 2004, J CELL BIOL, V164, P89, DOI 10.1083/jcb.200310041; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Stefanis L, 2005, NEUROSCIENTIST, V11, P50, DOI 10.1177/1073858404271087; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Tamm I, 2004, HEMATOL J, V5, P489, DOI 10.1038/sj.thj.6200549; Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312; Temkin V, 2006, MOL CELL BIOL, V26, P2215, DOI 10.1128/MCB.26.6.2215-2225.2006; Vahsen N, 2004, EMBO J, V23, P4679, DOI 10.1038/sj.emboj.7600461; Vande Walle L, 2008, CELL DEATH DIFFER, V15, P453, DOI 10.1038/sj.cdd.4402291; Varkey J, 1999, J CELL BIOL, V144, P701, DOI 10.1083/jcb.144.4.701; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Waterhouse NJ, 1998, CELL DEATH DIFFER, V5, P1051, DOI 10.1038/sj.cdd.4400425; Wilkinson JC, 2004, MOL CELL BIOL, V24, P7003, DOI 10.1128/MCB.24.16.7003-7014.2004; Wolf BB, 2001, J BIOL CHEM, V276, P34244, DOI 10.1074/jbc.M011778200; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yamaguchi K, 1999, EMBO J, V18, P179, DOI 10.1093/emboj/18.1.179; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Yu L, 2008, AUTOPHAGY, V4, P567, DOI 10.4161/auto.5902; Zermati Y, 2007, MOL CELL, V28, P624, DOI 10.1016/j.molcel.2007.09.030; Zimmermann KC, 2002, J CELL BIOL, V156, P1077, DOI 10.1083/jcb.20112068; Zlobec I, 2007, EUR J CANCER, V43, P1101, DOI 10.1016/j.ejca.2007.01.029	101	257	266	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 27	2008	27	50					6452	6461		10.1038/onc.2008.311	http://dx.doi.org/10.1038/onc.2008.311			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	366RR	18955972	Green Accepted			2022-12-17	WOS:000260501600005
J	Barr, FG				Barr, FG			Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma	ONCOGENE			English	Review						rhabdomyosarcoma; transcription factor; translocation; paired box; fork head	TRANSCRIPTION FACTOR FKHR; MYOGENIC PRECURSOR CELLS; PAIRED BOX GENE; C-MET RECEPTOR; DNA-BINDING; CHROMOSOMAL TRANSLOCATION; IN-VIVO; GENOMIC ORGANIZATION; STRUCTURAL-ANALYSIS; DOMAIN GENE	The chromosomal translocations t(2;13)(q35;q14) and t(1;13)(p36;q14) are characteristic of alveolar rhabdomyosarcoma, a pediatric soft tissue cancer related to the striated muscle lineage. These translocations rearrange PAX3 and PAX7, members of the paired box transcription factor family, and juxtapose these genes with FKHR, a member of the fork head transcription factor family. This juxtaposition generates PAX3-FKHR and PAX7-FKHR chimeric genes that are expressed as chimeric transcripts that encode chimeric proteins. The fusion proteins, which contain the PAX3/PAX7 DNA binding domain and the FKHR transcriptional activation domain, activate transcription from PAX-binding sites with higher potency than the corresponding wild-type PAX proteins. This increased function results from the insensitivity of the FKHR activation domain to inhibitory effects of N-terminal PAX3/PAX7 domains. In addition to altered function, the fusion products are expressed in ARMS tumors at higher levels than the corresponding wild-type PAX products due to two distinct mechanisms. The PAX7-FKHR fusion is overexpressed as a result of in vivo amplification while the PAX3-FKHR fusion is overexpressed due to a copy number-independent increase in transcriptional rate. Finally, though FKHR subcellular localization is regulated by an AKT-dependent pathway, the fusion proteins are resistant to these signals and show exclusively nuclear localization. Therefore, these translocations alter biological activity at the levels of protein function, gene expression, and subcellular localization with the cumulative outcome postulated to be aberrant regulation of PAX3/PAX7 target genes. This aberrant gene expression program is then hypothesized to contribute to tumorigenic behavior by impacting on the control of growth, apoptosis, differentiation and motility.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Barr, FG (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, 36th St & Hamilton Walk, Philadelphia, PA 19104 USA.	barrfg@mail.med.upenn.edu			NATIONAL CANCER INSTITUTE [R01CA071838, R01CA064202, R01CA089461] Funding Source: NIH RePORTER; NCI NIH HHS [CA89461, CA71838, CA64202] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson MJ, 2001, P NATL ACAD SCI USA, V98, P1589, DOI 10.1073/pnas.98.4.1589; Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; Arden KC, 1996, GENE CHROMOSOME CANC, V16, P254, DOI 10.1002/(SICI)1098-2264(199608)16:4<254::AID-GCC5>3.0.CO;2-X; Ayyanathan K, 2000, CANCER RES, V60, P5803; BALDWIN CT, 1992, NATURE, V355, P637, DOI 10.1038/355637a0; Barr FG, 1999, CANCER RES, V59, P5443; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BARR FG, 1995, JAMA-J AM MED ASSOC, V273, P553, DOI 10.1001/jama.273.7.553; Barr FG, 1996, HUM MOL GENET, V5, P15, DOI 10.1093/hmg/5.1.15; Barr FG, 1998, CANCER GENET CYTOGEN, V102, P32, DOI 10.1016/S0165-4608(97)00287-2; Bendall AJ, 1999, DEVELOPMENT, V126, P4965; Bennicelli JL, 1999, ONCOGENE, V18, P4348, DOI 10.1038/sj.onc.1202812; Bennicelli JL, 1996, P NATL ACAD SCI USA, V93, P5455, DOI 10.1073/pnas.93.11.5455; BENNICELLI JL, 1995, ONCOGENE, V11, P119; Bernasconi M, 1996, P NATL ACAD SCI USA, V93, P13164, DOI 10.1073/pnas.93.23.13164; BIEGEL JA, 1991, GENE CHROMOSOME CANC, V3, P483, DOI 10.1002/gcc.2870030612; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BOBER E, 1994, DEVELOPMENT, V120, P603; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Borycki AG, 1999, DEVELOPMENT, V126, P1665; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURRI M, 1989, EMBO J, V8, P1183, DOI 10.1002/j.1460-2075.1989.tb03490.x; Cao Y, 2000, J BIOL CHEM, V275, P9854, DOI 10.1074/jbc.275.13.9854; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P12745, DOI 10.1073/pnas.91.26.12745; CHALEPAKIS G, 1995, GENE, V162, P267, DOI 10.1016/0378-1119(95)00345-7; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; Dahl E, 1997, BIOESSAYS, V19, P755, DOI 10.1002/bies.950190905; Daston G, 1996, DEVELOPMENT, V122, P1017; DAVIS RJ, 1995, HUM MOL GENET, V4, P2355, DOI 10.1093/hmg/4.12.2355; DAVIS RJ, 1994, CANCER RES, V54, P2869; Davis RJ, 1997, P NATL ACAD SCI USA, V94, P8047, DOI 10.1073/pnas.94.15.8047; DEALAVA E, 1995, AM J PATHOL, V147, P1584; del Peso L, 1999, ONCOGENE, V18, P7328, DOI 10.1038/sj.onc.1203159; DOUGLASS EC, 1987, CYTOGENET CELL GENET, V45, P148, DOI 10.1159/000132446; DOUGLASS EC, 1991, GENE CHROMOSOME CANC, V3, P480, DOI 10.1002/gcc.2870030611; DOWNING JR, 1995, AM J PATHOL, V146, P626; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; Epstein JA, 1998, MOL CELL BIOL, V18, P4118, DOI 10.1128/MCB.18.7.4118; EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/jbc.270.20.11719; Epstein JA, 1996, P NATL ACAD SCI USA, V93, P4213, DOI 10.1073/pnas.93.9.4213; Fitzgerald JC, 2000, CANCER GENET CYTOGEN, V117, P37, DOI 10.1016/S0165-4608(99)00130-2; Fortin AS, 1997, HUM MOL GENET, V6, P1781, DOI 10.1093/hmg/6.11.1781; FRANZ T, 1993, ANAT EMBRYOL, V187, P153; Frascella E, 1998, CANCER GENET CYTOGEN, V102, P104, DOI 10.1016/S0165-4608(97)00352-X; Fredericks WJ, 2000, MOL CELL BIOL, V20, P5019, DOI 10.1128/MCB.20.14.5019-5031.2000; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; Galibert MD, 1999, J BIOL CHEM, V274, P26894, DOI 10.1074/jbc.274.38.26894; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GOULDING M, 1994, DEVELOPMENT, V120, P957; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Henderson DJ, 1997, MECH DEVELOP, V69, P39, DOI 10.1016/S0925-4773(97)00151-2; Hillion J, 1997, BLOOD, V90, P3714, DOI 10.1182/blood.V90.9.3714; Hollenbach AD, 1999, EMBO J, V18, P3702, DOI 10.1093/emboj/18.13.3702; JOSTES B, 1990, MECH DEVELOP, V33, P27, DOI 10.1016/0925-4773(90)90132-6; Kaestner KH, 2000, GENE DEV, V14, P142; KALLUNKI P, 1995, J BIOL CHEM, V270, P21291, DOI 10.1074/jbc.270.36.21291; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; Khan J, 1998, CANCER RES, V58, P5009; Lagutina I, 2000, DEV BIOL, V222, P236; Lam PYP, 1999, MOL CELL BIOL, V19, P594; Lang D, 2000, J CLIN INVEST, V106, P963, DOI 10.1172/JCI10828; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; MACINA RA, 1995, GENOMICS, V26, P1, DOI 10.1016/0888-7543(95)80076-X; Mackall C, 2000, CLIN ORTHOP RELAT R, P25; Magnaghi P, 1998, NAT GENET, V20, P74, DOI 10.1038/1739; Mansouri A, 1996, DEVELOPMENT, V122, P831; Margue CM, 2000, ONCOGENE, V19, P2921, DOI 10.1038/sj.onc.1203607; Maroto M, 1997, CELL, V89, P139, DOI 10.1016/S0092-8674(00)80190-7; Massuda ES, 1997, P NATL ACAD SCI USA, V94, P14701, DOI 10.1073/pnas.94.26.14701; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Mennerich D, 1998, MECH DEVELOP, V73, P147, DOI 10.1016/S0925-4773(98)00046-X; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Phelan SA, 1998, J BIOL CHEM, V273, P19153, DOI 10.1074/jbc.273.30.19153; Reichmuth C, 1996, J PATHOL, V180, P50, DOI 10.1002/(SICI)1096-9896(199609)180:1<50::AID-PATH629>3.0.CO;2-C; SCHAFER BW, 1994, NUCLEIC ACIDS RES, V22, P4574, DOI 10.1093/nar/22.22.4574; Scheidler S, 1996, P NATL ACAD SCI USA, V93, P9805, DOI 10.1073/pnas.93.18.9805; Seale P, 2000, CELL, V102, P777, DOI 10.1016/S0092-8674(00)00066-0; SHAPIRO DN, 1993, CANCER RES, V53, P5108; SUBLETT JE, 1995, ONCOGENE, V11, P545; Tajbakhsh S, 1997, CELL, V89, P127, DOI 10.1016/S0092-8674(00)80189-0; Takaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; Toretsky JA, 1996, J ENDOCRINOL, V149, P367, DOI 10.1677/joe.0.1490367; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594; TREMBLAY P, 1994, PHARMACOL THERAPEUT, V61, P205, DOI 10.1016/0163-7258(94)90063-9; TSOKOS M, 1992, ARCH PATHOL LAB MED, V116, P847; TSOKOS M, 1994, SEMIN DIAGN PATHOL, V11, P26; TURCCAREL C, 1986, CANCER GENET CYTOGEN, V19, P361, DOI 10.1016/0165-4608(86)90069-5; UNDERHILL DA, 1995, P NATL ACAD SCI USA, V92, P3692, DOI 10.1073/pnas.92.9.3692; Underhill DA, 1997, J BIOL CHEM, V272, P14175, DOI 10.1074/jbc.272.22.14175; Vogan KJ, 1996, MOL CELL BIOL, V16, P6677; Vorobyov E, 1997, GENOMICS, V45, P168, DOI 10.1006/geno.1997.4915; Wang-Wuu S, 1988, Cancer Res, V48, P983; Watanabe A, 1998, NAT GENET, V18, P283, DOI 10.1038/ng0398-283; Wexler Leonard H., 1997, P799; Wiggan O, 1998, ONCOGENE, V16, P227, DOI 10.1038/sj.onc.1201534; WILLIAMS BA, 1994, DEVELOPMENT, V120, P785; Xie E, 2001, MODERN PATHOL, V14, p4P; Yang XM, 1996, DEVELOPMENT, V122, P2163	102	257	268	1	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2001	20	40					5736	5746		10.1038/sj.onc.1204599	http://dx.doi.org/10.1038/sj.onc.1204599			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	470TP	11607823				2022-12-17	WOS:000170887500014
J	Saikumar, P; Dong, Z; Patel, Y; Hall, K; Hopfer, U; Weinberg, JM; Venkatachalam, MA				Saikumar, P; Dong, Z; Patel, Y; Hall, K; Hopfer, U; Weinberg, JM; Venkatachalam, MA			Role of hypoxia-induced Bax translocation and cytochrome c release in reoxygenation injury	ONCOGENE			English	Article						hypoxia; reoxygenation; cell death; Bax; Bcl-2; cytochrome c	INDUCED CELL-DEATH; PROXIMAL TUBULES; PROTEASE CASCADE; BCL-2; APOPTOSIS; ISCHEMIA; ACTIVATION; DAMAGE; OVEREXPRESSION; CYCLOSPORINE	We investigated mechanisms of cell death during hypoxia/reoxygenation of cultured kidney cells. During glucose-fret hypoxia, cell ATP levels declined steeply resulting in the translocation of Bas from cytosol to mitochondria. Concurrently, there was cytochrome c release and caspase activation. Cells that leaked cytochrome c underwent apoptosis after reoxygenation, ATP depletion induced by a mitochondrial uncoupler resulted in similar alterations even in the presence of oxygen. Moreover, inclusion of glucose during hypoxia prevented protein translocations and reoxygenation injury by maintaining intracellular ATP, Thus, ATP depletion, rather than hypoxia per se, was the cause of protein translocations. Overexpression of Bcl-2 prevented cytochrome c release and reoxygenation injury without ameliorating ATP depletion or Bas translocation, On the other hand, caspase inhibitors did not prevent protein translocations, but inhibited apoptosis during reoxygenation, Nevertheless, they could not confer long-term viability, since mitochondria had been damaged. Omission of glucose during reoxygenation resulted in continued failure of ATP production, and cell death,vith necrotic morphology. In contrast, cells expressing Bcl-2 had functional mitochondria and remained viable during reoxygenation even,without glucose. Therefore, Bas translocation during hypoxia is a molecular trigger for cell death during reoxygenation. If ATP is available during reoxygenation, apoptosis develops; otherwise, death occurs by necrosis. By preserving mitochondrial integrity, BCL-2 prevents both forms of cell death and ensures cell viability.	Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78284 USA; Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA	University of Texas System; University of Texas Health San Antonio; Case Western Reserve University; University of Michigan System; University of Michigan	Saikumar, P (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pathol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.		Hopfer, Ulrich/B-5463-2009	Hopfer, Ulrich/0000-0003-1357-0101	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK037139, R01DK054472, R01DK048417, R01DK037139] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54472, DK48417, DK37139] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bargou RC, 1996, J CLIN INVEST, V97, P2651, DOI 10.1172/JCI118715; Borutaite V, 1996, J MOL CELL CARDIOL, V28, P2195, DOI 10.1006/jmcc.1996.0211; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Cheng Y, 1998, J CLIN INVEST, V101, P1992, DOI 10.1172/JCI2169; Cotran R.S., 1998, ROBBINS PATHOLOGIC B; Dong Z, 1998, AM J PATHOL, V152, P231; DUKE RC, 1983, P NATL ACAD SCI-BIOL, V80, P6361, DOI 10.1073/pnas.80.20.6361; DURAN MA, 1990, TOXICOL APPL PHARM, V105, P183, DOI 10.1016/0041-008X(90)90180-3; FISKUM G, 1980, P NATL ACAD SCI-BIOL, V77, P3430, DOI 10.1073/pnas.77.6.3430; Folbergrova J, 1997, EXP BRAIN RES, V114, P44, DOI 10.1007/PL00005622; GARZAQUINTERO R, 1990, AM J PHYSIOL, V258, pF1075, DOI 10.1152/ajprenal.1990.258.4.F1075; GRIFFITHS EJ, 1995, BIOCHEM J, V307, P93, DOI 10.1042/bj3070093; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; Kajstura J, 1998, AM J CARDIOL, V82, p30K, DOI 10.1016/S0002-9149(98)00535-9; Kato H, 1997, EXP NEUROL, V148, P464, DOI 10.1006/exnr.1997.6707; Kaushal GP, 1998, AM J PHYSIOL-RENAL, V274, pF587, DOI 10.1152/ajprenal.1998.274.3.F587; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li Y, 1998, J NEUROL SCI, V156, P119, DOI 10.1016/S0022-510X(98)00036-7; Lieberthal W, 1996, AM J PHYSIOL-RENAL, V271, pF477, DOI 10.1152/ajprenal.1996.271.3.F477; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LOU X, 1998, CELL, V94, P481; Mancini M, 1998, J CELL BIOL, V140, P1485, DOI 10.1083/jcb.140.6.1485; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; MIN AJ, 1997, NATURE, V385, P353; NARO F, 1993, CARDIOSCIENCE, V4, P177; Nissim I, 1996, KIDNEY INT, V49, P684, DOI 10.1038/ki.1996.97; Noda T, 1998, AM J PHYSIOL-GASTR L, V274, pG270, DOI 10.1152/ajpgi.1998.274.2.G270; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; PASTORINO JG, 1993, J BIOL CHEM, V268, P13791; PIPER HM, 1985, J MOL CELL CARDIOL, V17, P885, DOI 10.1016/S0022-2828(85)80102-4; Qian T, 1997, AM J PHYSIOL-CELL PH, V273, pC1783, DOI 10.1152/ajpcell.1997.273.6.C1783; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Shimizu S, 1996, ONCOGENE, V12, P2251; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; Simm A, 1997, J CELL SCI, V110, P819; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; VENKATACHALAM MA, 1993, SURVIVING HYPOXIA, P473; Weinberg JM, 1997, J CLIN INVEST, V100, P713, DOI 10.1172/JCI119584; Wiegele G, 1998, NEPHROL DIAL TRANSPL, V13, P1158, DOI 10.1093/ndt/13.5.1158; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Woost PG, 1996, KIDNEY INT, V50, P125, DOI 10.1038/ki.1996.295; WYLLIE AH, 1994, PHILOS T R SOC B, V345, P237, DOI 10.1098/rstb.1994.0099; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yaoita H, 1998, CIRCULATION, V97, P276, DOI 10.1161/01.CIR.97.3.276; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	63	257	269	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 31	1998	17	26					3401	3415		10.1038/sj.onc.1202590	http://dx.doi.org/10.1038/sj.onc.1202590			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157XD	10030664				2022-12-17	WOS:000078086200001
J	Sugihara, K; Nakatsuji, N; Nakamura, K; Nakao, K; Hashimoto, R; Otani, H; Sakagami, H; Kondo, H; Nozawa, S; Aiba, A; Katsuki, M				Sugihara, K; Nakatsuji, N; Nakamura, K; Nakao, K; Hashimoto, R; Otani, H; Sakagami, H; Kondo, H; Nozawa, S; Aiba, A; Katsuki, M			Rac1 is required for the formation of three germ layers during gastrulation	ONCOGENE			English	Article						Rac1; gene targeting; cell adhesion; motility; early development	GTP-BINDING PROTEIN; ACTIN STRESS FIBERS; NADPH OXIDASE; RAS TRANSFORMATION; EXCHANGE PROTEINS; PRIMITIVE-STREAK; CDC42 GTPASES; CELL-DEATH; RHO-FAMILY; ACTIVATION	The Rad, a member of the Rho family proteins, regulates actin organization of cytoskeleton and cell adhesion. We used genetic analysis to elucidate the role of Rad in mouse embryonic development. The rac1 deficient embryos showed numerous cell deaths in the space between the embryonic ectoderm and endoderm at the primitive streak stage. Investigation of the primary epiblast culture isolated from rac1 deficient embryos indicated that Rad is involved in lamellipodia formation, cell adhesion and cell migration in vivo. These results suggest that Rad-mediated cell adhesion is essential for the formation of three germ layers during gastrulation.	Univ Tokyo, Inst Med Sci, Ctr Med Expt, Div DNA Biol & Embryo Engn,Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, CREST, Minato Ku, Tokyo 1088639, Japan; Keio Univ, Sch Med, Dept Obstet & Gynecol, Shinjuku Ku, Tokyo 1608582, Japan; Natl Inst Genet, Mammalian Dev Lab, Mishima, Shizuoka 4118540, Japan; Shimane Med Univ, Dept Anat, Izumo, Shimane 6938501, Japan; Tohoku Univ, Grad Sch Med Sci, Dept Cell Biol, Div Histol,Aoba Ku, Sendai, Miyagi 9808575, Japan	University of Tokyo; Japan Science & Technology Agency (JST); University of Tokyo; Keio University; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Shimane University; Tohoku University	Katsuki, M (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Med Expt, Div DNA Biol & Embryo Engn,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.			zhong wei, he gui/0000-0002-3066-3564; Aiba, Atsu/0000-0002-8192-0778				ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ANDO S, 1992, J BIOL CHEM, V267, P25709; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; EATON S, 1995, J CELL BIOL, V131, P151, DOI 10.1083/jcb.131.1.151; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Haataja L, 1997, J BIOL CHEM, V272, P20384, DOI 10.1074/jbc.272.33.20384; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HASHIMOTO K, 1987, DEVELOPMENT, V100, P587; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V208, P985, DOI 10.1006/bbrc.1995.1431; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; MACKAY DJG, 1995, TRENDS NEUROSCI, V18, P496, DOI 10.1016/0166-2236(95)92773-J; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MIZUNO T, 1992, J BIOL CHEM, V267, P10215; MOLL J, 1991, ONCOGENE, V6, P863; NAKATSUJI N, 1986, J EMBRYOL EXP MORPH, V96, P99; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Nomura M, 1998, NATURE, V393, P786, DOI 10.1038/31693; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Sanders EJ, 1997, ANAT EMBRYOL, V195, P147, DOI 10.1007/s004290050033; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Tam PPL, 1997, MECH DEVELOP, V68, P3, DOI 10.1016/S0925-4773(97)00123-8; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295	37	257	259	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 31	1998	17	26					3427	3433		10.1038/sj.onc.1202595	http://dx.doi.org/10.1038/sj.onc.1202595			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157XD	10030666				2022-12-17	WOS:000078086200003
J	Gibson, L; Holmgreen, SP; Huang, DCS; Bernand, O; Copeland, NG; Jenkins, NA; Sutherland, GR; Baker, E; Adams, JM; Cory, S				Gibson, L; Holmgreen, SP; Huang, DCS; Bernand, O; Copeland, NG; Jenkins, NA; Sutherland, GR; Baker, E; Adams, JM; Cory, S			bcl-w, a novel member of the bcl-2 family, promotes cell survival	ONCOGENE			English	Article						bcl-2; bcl-w; apoptosis; survival; oncogene; chromosome 14	CHROMOSOMAL BREAKPOINT; CAENORHABDITIS-ELEGANS; PROTEIN IDENTIFICATION; ENDOPLASMIC-RETICULUM; PROTOONCOGENE BCL-2; SEQUENCE SIMILARITY; CONSERVED DOMAINS; MOLECULAR-CLONING; NUCLEAR-ENVELOPE; HOMOLOG BAK	The prototypic mammalian regulator of cell death is bcl-2, the oncogene implicated in the development of human follicular lymphoma. Several homologues of bcl-2 are now known. Using a PCR-based strategy we cloned a novel member of this gene family, denoted bcl-w. The gene, which is highly conserved between mouse and human, resides near the T-cell antigen receptor a gene within the central portion of mouse chromosome 14 and on human chromosome 14 at band q11. Enforced expression of bcl-w rendered lymphoid and myeloid cells refractory to several (but not all) cytotoxic conditions. Thus, like Bcl-2 and Bcl-x, the Bcl-w protein promotes cell survival, in contrast to other close homologues, Bar and Bak, which facilitate cell death. Comparison of the expected amino acid sequence of Bcl-w with that of these relatives helps to delineate residues likely to convey survival or anti-survival function. While expression of bcl-w was uncommon in B or T lymphoid cell lines, the mRNA was observed in almost all murine myeloid cell lines analysed and in a wide range of tissues. These findings suggest that bcl-w participates in the control of apoptosis in multiple cell types. Its functional similarity to bcl-2 also makes it an attractive candidate proto-oncogene.	ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, MELBOURNE, VIC 3050, AUSTRALIA; NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, FREDERICK, MD 21702 USA; ADELAIDE CHILDRENS HOSP INC, DEPT CYTOGENET & MOL GENET, ADELAIDE, SA 5006, AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Gibson, Leonie/AAM-5917-2021; Cory, Suzanne/E-1642-2013; Huang, David C. S./C-7586-2013; Sutherland, Grant Robert/D-2606-2012; Adams, Jerry M/E-1199-2013	Cory, Suzanne/0000-0002-6818-3451; Huang, David C. S./0000-0002-3101-4873; Gibson, Leonie/0000-0002-0904-8145; Adams, Jerry/0000-0002-4360-8628				BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BOYD JM, 1995, ONCOGENE, V11, P1921; BRAND SF, 1995, GENE, V154, P187, DOI 10.1016/0378-1119(94)00840-O; CALLEN DF, 1990, ANN GENET-PARIS, V33, P219; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; CHOI SS, 1995, ONCOGENE, V11, P1693; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; Green EL, 1981, GENETICS PROBABILITY, P77; HAEFLIGER JA, 1992, J BIOL CHEM, V267, P2057; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HARRIS AW, 1973, J IMMUNOL, V110, P431; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; LIN EY, 1993, J IMMUNOL, V151, P1979; LITHGOW T, 1994, CELL GROWTH DIFFER, V5, P411; LYNES MA, 1978, J IMMUNOL, V121, P2352; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; MOORE KJ, 1992, GENOMICS, V12, P388, DOI 10.1016/0888-7543(92)90389-A; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NEILAN JG, 1993, J VIROL, V67, P4391, DOI 10.1128/JVI.67.7.4391-4394.1993; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PEARSON GR, 1987, VIROLOGY, V160, P151, DOI 10.1016/0042-6822(87)90055-9; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RALPH P, 1975, J IMMUNOL, V114, P898; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; STOKKE T, 1995, GENOMICS, V26, P134, DOI 10.1016/0888-7543(95)80092-Z; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Subramanian T, 1995, ONCOGENE, V11, P2403; TANAKA S, 1993, J BIOL CHEM, V268, P10920; TEH HS, 1989, J EXP MED, V169, P795, DOI 10.1084/jem.169.3.795; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; VISVADER JE, 1992, EMBO J, V11, P4557, DOI 10.1002/j.1460-2075.1992.tb05557.x; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WHITE E, 1994, APOPTOSIS, V2, P111; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	73	257	276	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	1996	13	4					665	675						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761287				2022-12-17	WOS:A1996VD43300001
J	Kufe, DW				Kufe, D. W.			MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches	ONCOGENE			English	Review						MUC1; breast cancer; oncoprotein; signaling pathways; targeted agents	GROWTH-FACTOR RECEPTOR; CARCINOMA-ASSOCIATED ANTIGEN; MUCIN 1 ONCOPROTEIN; BETA-CATENIN; CYCLIN D1; C-SRC; PHOSPHOINOSITIDE 3-KINASE; PROGNOSTIC-SIGNIFICANCE; MONOCLONAL-ANTIBODY; METASTATIC BREAST	Mucin 1 (MUC1) is a heterodimeric protein formed by two subunits that is aberrantly overexpressed in human breast cancer and other cancers. Historically, much of the early work on MUC1 focused on the shed mucin subunit. However, more recent studies have been directed at the transmembrane MUC1-C-terminal subunit (MUC1-C) that functions as an oncoprotein. MUC1-C interacts with EGFR (epidermal growth factor receptor), ErbB2 and other receptor tyrosine kinases at the cell membrane and contributes to activation of the PI3K -> AKT and mitogen-activated protein kinase kinase (MEK)-> extracellular signal-regulated kinase (ERK) pathways. MUC1-C also localizes to the nucleus where it activates the Wnt/beta-catenin, signal transducer and activator of transcription (STAT) and NF (nuclear factor)-kappa B RelA pathways. These findings and the demonstration that MUC1-C is a druggable target have provided the experimental basis for designing agents that block MUC1-C function. Notably, inhibitors of the MUC1-C subunit have been developed that directly block its oncogenic function and induce death of breast cancer cells in vitro and in xenograft models. On the basis of these findings, a first-in-class MUC1-C inhibitor has entered phase I evaluation as a potential agent for the treatment of patients with breast cancers who express this oncoprotein. Oncogene (2013) 32, 1073-1081; doi:10.1038/onc.2012.158; published online 14 May 2012	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02215 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Kufe, DW (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 450 Brookline Ave,Dana 830, Boston, MA 02215 USA.	donald_kufe@dfci.harvard.edu			National Cancer Institute [CA97098]; NATIONAL CANCER INSTITUTE [R01CA166480, R01CA097098] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work has been supported by Grant CA97098 awarded by the National Cancer Institute.	ABE M, 1993, P NATL ACAD SCI USA, V90, P282, DOI 10.1073/pnas.90.1.282; ABE M, 1990, J CELL PHYSIOL, V143, P226, DOI 10.1002/jcp.1041430205; ABE M, 1989, CANCER RES, V49, P2834; Ahmad R, 2007, NAT CELL BIOL, V9, P1419, DOI 10.1038/ncb1661; Ahmad R, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001426; Ahmad R, 2009, CANCER RES, V69, P7013, DOI 10.1158/0008-5472.CAN-09-0523; Arlen PM, 2006, CLIN BREAST CANCER, V7, P176, DOI 10.3816/CBC.2006.n.032; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; Bieche I, 1997, CANCER GENET CYTOGEN, V98, P75, DOI 10.1016/S0165-4608(96)00410-4; Bitler BG, 2010, J CELL SCI, V123, P1716, DOI 10.1242/jcs.062661; DICKSON C, 1995, CANCER LETT, V90, P43, DOI 10.1016/0304-3835(94)03676-A; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Gaemers IC, 2001, J BIOL CHEM, V276, P6191, DOI 10.1074/jbc.M009449200; GENDLER S, 1988, J BIOL CHEM, V263, P12820; GILLETT C, 1994, CANCER RES, V54, P1812; Gulley J, 2011, SOC IMMUNOTHER CANC, P56; Gulley JL, 2008, CLIN CANCER RES, V14, P3060, DOI 10.1158/1078-0432.CCR-08-0126; Hatsell S, 2003, J MAMMARY GLAND BIOL, V8, P145, DOI 10.1023/A:1025944723047; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; HAYES DF, 1985, J CLIN INVEST, V75, P1671, DOI 10.1172/JCI111875; He C, 2002, J BIOL CHEM, V277, P38284, DOI 10.1074/jbc.M104646200; Higgins MJ, 2011, J CLIN INVEST, V121, P3797, DOI 10.1172/JCI57152; Hoppler S, 2007, J CELL SCI, V120, P385, DOI 10.1242/jcs.03363; Horn G, 2009, EXP CELL RES, V315, P1490, DOI 10.1016/j.yexcr.2009.02.011; Huang L, 2005, CANCER RES, V65, P10413, DOI 10.1158/0008-5472.CAN-05-2474; Huang L, 2003, CANCER BIOL THER, V2, P702; Ibrahim NK, 2011, CLIN CANCER RES, V17, P6822, DOI 10.1158/1078-0432.CCR-11-1151; Jin CN, 2010, INT J ONCOL, V37, P61, DOI 10.3892/ijo_00000653; Joshi MD, 2009, MOL CANCER THER, V8, P3056, DOI 10.1158/1535-7163.MCT-09-0646; Kato K, 2007, AM J PHYSIOL-LUNG C, V293, pL686, DOI 10.1152/ajplung.00423.2006; Khodarev N, 2010, ONCOGENE, V29, P920, DOI 10.1038/onc.2009.391; Khodarev NN, 2009, CANCER RES, V69, P2833, DOI 10.1158/0008-5472.CAN-08-4513; Kinlough CL, 2006, J BIOL CHEM, V281, P12112, DOI 10.1074/jbc.M512996200; Kinlough CL, 2004, J BIOL CHEM, V279, P53071, DOI 10.1074/jbc.M409360200; Kondo S, 2007, J VIROL, V81, P1554, DOI 10.1128/JVI.02222-06; Kosugi M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028234; KOVARIK A, 1993, J BIOL CHEM, V268, P9917; KUFE D, 1984, HYBRIDOMA, V3, P223, DOI 10.1089/hyb.1984.3.223; KUFE D, 2009, CANCER BIOL THER, V8, P1201; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; Lacunza E, 2010, CANCER GENET CYTOGEN, V201, P102, DOI 10.1016/j.cancergencyto.2010.05.015; Lagow EL, 2002, J CELL BIOCHEM, V86, P759, DOI 10.1002/jcb.10261; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; Landis MW, 2006, CANCER CELL, V9, P13, DOI 10.1016/j.ccr.2005.12.019; Leng YM, 2007, J BIOL CHEM, V282, P19321, DOI 10.1074/jbc.M703222200; Levitin F, 2005, J BIOL CHEM, V280, P33374, DOI 10.1074/jbc.M506047200; Li YQ, 2003, ONCOGENE, V22, P6107, DOI 10.1038/sj.onc.1206732; Li YQ, 2003, MOL CANCER RES, V1, P765; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; Li Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019102; Liao HJ, 2007, MOL BIOL CELL, V18, P1064, DOI 10.1091/mbc.E06-09-0802; LIGTENBERG MJL, 1992, J BIOL CHEM, V267, P6171; Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926; Macao B, 2006, NAT STRUCT MOL BIOL, V13, P71, DOI 10.1038/nsmb1035; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; MCGUCKIN MA, 1995, HUM PATHOL, V26, P432, DOI 10.1016/0046-8177(95)90146-9; MCINTOSH GG, 1995, ONCOGENE, V11, P885; Meerzaman D, 2001, AM J PHYSIOL-LUNG C, V281, pL86, DOI 10.1152/ajplung.2001.281.1.L86; Merlin J, 2011, ONCOGENE, V30, P2514, DOI 10.1038/onc.2010.631; MERLO GR, 1989, CANCER RES, V49, P6966; Mohebtash M, 2008, AM SOC CLIN ONC BREA; Mohebtash M, 2011, CLIN CANCER RES, V17, P7164, DOI 10.1158/1078-0432.CCR-11-0649; PANDEY P, 1995, CANCER RES, V55, P4000; Pegram MD, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2409; Pitroda SP, 2009, P NATL ACAD SCI USA, V106, P5837, DOI 10.1073/pnas.0812029106; Pochampalli MR, 2007, CANCER RES, V67, P6591, DOI 10.1158/0008-5472.CAN-06-4518; Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007; Rahn JJ, 2001, CANCER, V91, P1973, DOI 10.1002/1097-0142(20010601)91:11<1973::AID-CNCR1222>3.0.CO;2-A; Raina D, 2004, J BIOL CHEM, V279, P20607, DOI 10.1074/jbc.M310538200; Raina D, 2012, INT J ONCOL, V40, P1644, DOI 10.3892/ijo.2011.1308; Raina D, 2011, MOL CANCER THER, V10, P806, DOI 10.1158/1535-7163.MCT-10-1050; Raina D, 2009, CANCER RES, V69, P5133, DOI 10.1158/0008-5472.CAN-09-0854; Rajabi H, 2012, PROSTATE, V72, P1659, DOI 10.1002/pros.22519; Rajabi H, 2012, J BIOL CHEM, V287, P10703, DOI 10.1074/jbc.M111.323311; Rajabi Hasan, 2010, Genes Cancer, V1, P62; Rakha EA, 2005, MODERN PATHOL, V18, P1295, DOI 10.1038/modpathol.3800445; Ramasamy S, 2007, MOL CELL, V27, P992, DOI 10.1016/j.molcel.2007.07.031; Ren J, 2004, CANCER CELL, V5, P163, DOI 10.1016/S1535-6108(04)00020-0; Ren J, 2006, ONCOGENE, V25, P20, DOI 10.1038/sj.onc.1209012; Ren J, 2002, J BIOL CHEM, V277, P17616, DOI 10.1074/jbc.M200436200; Ren J, 2006, MOL CANCER RES, V4, P873, DOI 10.1158/1541-7786.MCR-06-0204; Sachdeva M, 2010, CANCER RES, V70, P378, DOI 10.1158/0008-5472.CAN-09-2021; Schroeder JA, 2004, ONCOGENE, V23, P5739, DOI 10.1038/sj.onc.1207713; Schroeder JA, 2003, ONCOGENE, V22, P1324, DOI 10.1038/sj.onc.1206291; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; SIDDIQUI J, 1988, P NATL ACAD SCI USA, V85, P2320, DOI 10.1073/pnas.85.7.2320; Singh PK, 2008, J BIOL CHEM, V283, P26985, DOI 10.1074/jbc.M805036200; Singh PK, 2007, CANCER RES, V67, P5201, DOI 10.1158/0008-5472.CAN-06-4647; Thompson EJ, 2006, MOL CANCER RES, V4, P489, DOI 10.1158/1541-7786.MCR-06-0038; Udhayakumar G, 2007, MOL CARCINOGEN, V46, P807, DOI 10.1002/mc.20311; Vermeer PD, 2003, NATURE, V422, P322, DOI 10.1038/nature01440; Wei XL, 2006, MOL CELL, V21, P295, DOI 10.1016/j.molcel.2005.11.030; Wen YF, 2003, J BIOL CHEM, V278, P38029, DOI 10.1074/jbc.M304333200; Woo JK, 2012, ONCOGENE, V31, P2187, DOI 10.1038/onc.2011.410; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; Yao MY, 2011, LUNG, V189, P453, DOI 10.1007/s00408-011-9327-y; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zaretsky JZ, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-57; Zhou YC, 2011, MOL PHARMACOL, V79, P886, DOI 10.1124/mol.110.070797	103	256	267	0	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2013	32	9					1073	1081		10.1038/onc.2012.158	http://dx.doi.org/10.1038/onc.2012.158			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110FU	22580612	Green Accepted, Bronze			2022-12-17	WOS:000316428800001
J	Eom, YW; Kim, MA; Park, SS; Goo, MJ; Kwon, HJ; Sohn, S; Kim, WH; Yoon, G; Choi, KS				Eom, YW; Kim, MA; Park, SS; Goo, MJ; Kwon, HJ; Sohn, S; Kim, WH; Yoon, G; Choi, KS			Two distinct modes of cell death induced by doxorubicin: apoptosis and cell death through mitotic catastrophe accompanied by senescence-like phenotype	ONCOGENE			English	Article						doxorubicin; mitotic catastrophe; apoptosis; senescence-like phenotype; hepatocellular carcinoma cells	TERMINAL PROLIFERATION ARREST; SIGNAL-TRANSDUCTION PATHWAY; ACTIVATED PROTEIN-KINASE; EPITHELIAL TUMOR-CELLS; NF-KAPPA-B; HEPATOCELLULAR-CARCINOMA; CLONOGENIC SURVIVAL; CHECKPOINT KINASE; GROWTH ARREST; DNA-DAMAGE	Chronic exposure of many human hepatoma cell lines to a low dose (LD) of doxorubicin induced a senescence-like phenotype (SLP) accompanied by enlargement of cells and increased senescence- associated beta-galactosidase activity. LD doxorubicin- induced SLP was preceded by multinucleation and downregulation of multiple proteins with mitotic checkpoint function, including CENP-A, Mad2, BubR1, and Chk1. LD doxorubicin-treated cells eventually underwent cell death through mitotic catastrophe. When we investigated whether LD doxorubicin-induced cell death shares biochemical characteristics with high dose (HD) doxorubicin- induced apoptosis in Huh-7 cells, we observed that externalization of phosphatidyl serine and release of mitochondrial cytochrome c into the cytosol was associated with both types of cell death. However, propidium iodide exclusion assays showed that membrane integrity was lost in the initial phase of LD doxorubicin- induced cell death through mitotic catastrophe, whereas it was lost during the late phase of HD doxorubicin- induced apoptosis. Furthermore, HD doxorubicin-induced apoptosis but not LD doxorubicin-induced mitotic catastrophe led to transient activation of NF-kappa B and strong, sustained activations of p38, c-Jun N-terminal kinase, and caspases. Collectively, these results indicate that different doses of doxorubicin activate different regulatory mechanisms to induce either apoptosis or cell death through mitotic catastrophe.	Ajou Univ, Sch Med, Lab Endocrinol, Suwon 442749, South Korea; Ajou Univ, Sch Med, Inst Med Sci, Cell Biol Lab, Suwon 442749, South Korea; Ajou Univ, Sch Med, Dept Surg, Suwon 442749, South Korea; Ajou Univ, Sch Med, Dept Biochem & Mol Biol, Suwon 442749, South Korea	Ajou University; Ajou University; Ajou University; Ajou University	Choi, KS (corresponding author), Ajou Univ, Sch Med, Lab Endocrinol, San 5,Wonchondong, Suwon 442749, South Korea.	kschoi@ajou.ac.kr	Eom, Young/AAW-4659-2021; 권, 호정/AAS-3642-2021	Choi, Kyeong Sook/0000-0003-2331-0856; Kim, Wook Hwan/0000-0003-2820-0154; Eom, Young Woo/0000-0002-5985-6490				Acunas B, 1999, EUR J RADIOL, V32, P86, DOI 10.1016/S0720-048X(99)00117-5; AEBI U, 1986, NATURE, V323, P560, DOI 10.1038/323560a0; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Chang BD, 2002, P NATL ACAD SCI USA, V99, P389, DOI 10.1073/pnas.012602599; Chang BD, 1999, CANCER RES, V59, P3761; Chang BD, 2000, ONCOGENE, V19, P2165, DOI 10.1038/sj.onc.1203573; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; Chu K, 2004, RADIAT RES, V162, P270, DOI 10.1667/RR3221; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Decaudin D, 1998, INT J ONCOL, V12, P141; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dumont P, 2000, FREE RADICAL BIO MED, V28, P361, DOI 10.1016/S0891-5849(99)00249-X; Elmore LW, 2002, J BIOL CHEM, V277, P35509, DOI 10.1074/jbc.M205477200; Gamen S, 2000, EXP CELL RES, V258, P223, DOI 10.1006/excr.2000.4924; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; Gupta S, 2001, LIFE SCI, V69, P2957, DOI 10.1016/S0024-3205(01)01404-7; He QY, 2002, INT J ONCOL, V20, P261; Hendry JH, 1997, INT J RADIAT BIOL, V71, P709, DOI 10.1080/095530097143716; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hortobagyi GN, 1997, DRUGS, V54, P1, DOI 10.2165/00003495-199700544-00003; HSU IC, 1993, CARCINOGENESIS, V14, P987, DOI 10.1093/carcin/14.5.987; Kalitsis P, 1998, GENOMICS, V47, P108, DOI 10.1006/geno.1997.5109; Kang MS, 1996, INT J CANCER, V67, P898, DOI 10.1002/(SICI)1097-0215(19960917)67:6<898::AID-IJC22>3.0.CO;2-X; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Liu L, 1998, MOL CELL BIOL, V18, P4221, DOI 10.1128/MCB.18.7.4221; Lock RB, 1996, CANCER RES, V56, P4006; Lu Wei, 2002, Di Yi Jun Yi Da Xue Xue Bao, V22, P524; Mantel C, 1999, BLOOD, V93, P1390, DOI 10.1182/blood.V93.4.1390.404k25_1390_1398; Miranda EI, 1996, MUTAT RES-FUND MOL M, V349, P173, DOI 10.1016/0027-5107(95)00164-6; Nitta M, 2004, ONCOGENE, V23, P6548, DOI 10.1038/sj.onc.1207873; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; PARK JG, 1995, INT J CANCER, V62, P276, DOI 10.1002/ijc.2910620308; PATT YZ, 1988, CANCER, V61, P1884, DOI 10.1002/1097-0142(19880501)61:9<1884::AID-CNCR2820610927>3.0.CO;2-D; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Ruth AC, 2000, CANCER RES, V60, P2576; SCIARRINO E, 1985, CANCER, V56, P2751, DOI 10.1002/1097-0142(19851215)56:12<2751::AID-CNCR2820561205>3.0.CO;2-O; Seong YS, 2002, J BIOL CHEM, V277, P32282, DOI 10.1074/jbc.M202602200; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SPETH PAJ, 1987, CANCER CHEMOTH PHARM, V20, P305; te Poele RH, 2002, CANCER RES, V62, P1876; Wang YC, 1999, ONCOGENE, V18, P2643, DOI 10.1038/sj.onc.1202632; Wang YL, 2004, ONCOGENE, V23, P1283, DOI 10.1038/sj.onc.1207244; YAN MH, 1994, NATURE, V372, P798	46	256	266	3	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2005	24	30					4765	4777		10.1038/sj.onc.1208627	http://dx.doi.org/10.1038/sj.onc.1208627			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	945CC	15870702				2022-12-17	WOS:000230477900003
J	Fuchs, SY; Spiegelman, VS; Kumar, KGS				Fuchs, SY; Spiegelman, VS; Kumar, KGS			The many faces of beta-TrCP E3 ubiquitin ligases: reflections in the magic mirror of cancer	ONCOGENE			English	Review						beta-TrCP; F-box; ubiquitin ligase; NF-kappa B; beta-catenin	NF-KAPPA-B; F-BOX PROTEIN; PHOSPHORYLATION-DEPENDENT INTERACTION; P105 REQUIRES PHOSPHORYLATION; SIGNAL-INDUCED UBIQUITINATION; PROTEASOME PATHWAY; CONSTITUTIVE ACTIVATION; ALPHA UBIQUITINATION; MEDIATED PROTEOLYSIS; DEGRADATION PATHWAY	Beta-transducin repeats-containing proteins (beta-TrCP) serve as the substrate recognition subunits for the SCFbeta-TrCP E3 ubiquitin ligases. These ligases ubiquitinate specifically phosphorylated substrates and play a pivotal role in the regulation of cell division and various signal transduction pathways, which, in turn, are essential for many aspects of tumorigenesis. We review the functions of the SCFbeta-TrCP ligases in the light of their relevance to cell growth, survival and transformation. Mechanisms underlying beta-TrCP regulation and their aberration in human and animal cancer as well as prospective of targeting beta-TrCP as a means of anticancer therapy are also discussed.	Univ Penn, Dept Anim Biol, Philadelphia, PA 19104 USA; AMC, Canc Res Ctr, Lakewood, CO 80214 USA	University of Pennsylvania; AMC Cancer Research Center	Fuchs, SY (corresponding author), Univ Penn, Dept Anim Biol, 3800 Spruce St,Rm 161E, Philadelphia, PA 19104 USA.	sfuks@vet.upenn.edu	高, 雨莉/HGU-8187-2022	Spiegelman, Vladimir S/0000-0003-4847-155X	NCI NIH HHS [CA 92900] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092900] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Akari H, 2001, J EXP MED, V194, P1299, DOI 10.1084/jem.194.9.1299; Albanese C, 2003, MOL BIOL CELL, V14, P585, DOI 10.1091/mbc.02-06-0101; ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; Bach SP, 2000, GASTROENTEROLOGY, V118, P81, DOI 10.1016/S0016-5085(00)70416-1; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Ballarino M, 2002, BBA-GENE STRUCT EXPR, V1577, P81, DOI 10.1016/S0167-4781(02)00416-5; BESNARDGUERIN C, 2003, IN PRESS J BIOL CHEM; Bharti AC, 2002, BIOCHEM PHARMACOL, V64, P883, DOI 10.1016/S0006-2952(02)01154-1; Bhatia N, 2002, ONCOGENE, V21, P1501, DOI 10.1038/sj.onc.1205311; Bian X, 2002, J BIOL CHEM, V277, P42144, DOI 10.1074/jbc.M203891200; Bour S, 2001, J BIOL CHEM, V276, P15920, DOI 10.1074/jbc.M010533200; Budunova IV, 1999, ONCOGENE, V18, P7423, DOI 10.1038/sj.onc.1203104; Cenciarelli C, 1999, CURR BIOL, V9, P1177, DOI 10.1016/S0960-9822(00)80020-2; Chiaur DS, 2000, CYTOGENET CELL GENET, V88, P255, DOI 10.1159/000015532; Chinery R, 1997, J BIOL CHEM, V272, P30356, DOI 10.1074/jbc.272.48.30356; Cong F, 2003, BMC MOL BIOL, V4, DOI 10.1186/1471-2199-4-10; Davis M, 2002, GENE DEV, V16, P439, DOI 10.1101/gad.218702; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; ELDARFINKELMAN H, 1995, J BIOL CHEM, V270, P987, DOI 10.1074/jbc.270.3.987; Fong A, 2002, J BIOL CHEM, V277, P22111, DOI 10.1074/jbc.C200151200; Fuchs SY, 2002, CANCER BIOL THER, V1, P337; Fuchs SY, 1999, ONCOGENE, V18, P2039, DOI 10.1038/sj.onc.1202760; Gao ZH, 2002, P NATL ACAD SCI USA, V99, P1182, DOI 10.1073/pnas.032468199; Gerstein AV, 2002, GENE CHROMOSOME CANC, V34, P9, DOI 10.1002/gcc.10037; Guardavaccaro D, 2003, DEV CELL, V4, P799, DOI 10.1016/S1534-5807(03)00154-0; Gunawardena K, 2002, CANCER DETECT PREV, V26, P229, DOI 10.1016/S0361-090X(02)00061-2; HADJIOLOV D, 1992, J CANCER RES CLIN, V118, P401, DOI 10.1007/BF01629420; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hatakeyama S, 1999, P NATL ACAD SCI USA, V96, P3859, DOI 10.1073/pnas.96.7.3859; Hattori K, 1999, J BIOL CHEM, V274, P29641, DOI 10.1074/jbc.274.42.29641; Hayakawa M, 2003, EMBO J, V22, P3356, DOI 10.1093/emboj/cdg332; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; Heissmeyer V, 2001, MOL CELL BIOL, V21, P1024, DOI 10.1128/MCB.21.4.1024-1035.2001; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Joyce D, 2001, CYTOKINE GROWTH F R, V12, P73, DOI 10.1016/S1359-6101(00)00018-6; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Katoh M, 2003, INT J ONCOL, V22, P209; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Koike J, 2000, BIOCHEM BIOPH RES CO, V269, P103, DOI 10.1006/bbrc.2000.2241; Kroll M, 1999, J BIOL CHEM, V274, P7941, DOI 10.1074/jbc.274.12.7941; Kumar KGS, 2003, EMBO J, V22, P5480; Lamberti C, 2001, J BIOL CHEM, V276, P42276, DOI 10.1074/jbc.M104227200; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Lang V, 2003, MOL CELL BIOL, V23, P402, DOI 10.1128/MCB.23.1.402-413.2003; Lassot I, 2001, MOL CELL BIOL, V21, P2192, DOI 10.1128/MCB.21.6.2192-2202.2001; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Mantovani F, 2003, J BIOL CHEM, V278, P42477, DOI 10.1074/jbc.M302799200; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Margottin-Goguet F, 2003, DEV CELL, V4, P813, DOI 10.1016/S1534-5807(03)00153-9; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; MAYO MW, 2000, BIOCHIM BIOPHYS ACTA, V1470, P55; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; Nakayama K, 2003, P NATL ACAD SCI USA, V100, P8752, DOI 10.1073/pnas.1133216100; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Orian A, 2000, EMBO J, V19, P2580, DOI 10.1093/emboj/19.11.2580; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; OSSWALD H, 1990, J CANCER RES CLIN, V116, P448, DOI 10.1007/BF01612992; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Polakis P, 2000, GENE DEV, V14, P1837; Reifenberger J, 2002, INT J CANCER, V100, P549, DOI 10.1002/ijc.10512; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Richmond A, 2002, NAT REV IMMUNOL, V2, P664, DOI 10.1038/nri887; Saitoh T, 2001, INT J ONCOL, V18, P959; Sakamoto KM, 2001, P NATL ACAD SCI USA, V98, P8554, DOI 10.1073/pnas.141230798; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; Shirane M, 1999, J BIOL CHEM, V274, P28169, DOI 10.1074/jbc.274.40.28169; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Smirnov AS, 2001, CELL DEATH DIFFER, V8, P621, DOI 10.1038/sj.cdd.4400853; Soldatenkov VA, 1999, CANCER RES, V59, P5085; Speigelman VS, 2001, J BIOL CHEM, V276, P27152, DOI 10.1074/jbc.M100031200; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; SPEVAK W, 1993, MOL CELL BIOL, V13, P4953, DOI 10.1128/MCB.13.8.4953; Spiegelman V, 2002, ONCOGENE, V21, P856, DOI 10.1038/sj.onc.1205132; Spiegelman VS, 2000, MOL CELL, V5, P877, DOI 10.1016/S1097-2765(00)80327-5; Spiegelman VS, 2002, J BIOL CHEM, V277, P36624, DOI 10.1074/jbc.M204524200; Suh JH, 2002, PROSTATE, V52, P183, DOI 10.1002/pros.10082; Suzuki H, 1999, BIOCHEM BIOPH RES CO, V256, P121, DOI 10.1006/bbrc.1999.0296; Suzuki H, 2000, J BIOL CHEM, V275, P2877, DOI 10.1074/jbc.275.4.2877; Suzuki H, 1999, BIOCHEM BIOPH RES CO, V256, P127, DOI 10.1006/bbrc.1999.0289; Tang WG, 2003, J BIOL CHEM, V278, P48942, DOI 10.1074/jbc.M307962200; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Winston JT, 1999, CURR BIOL, V9, P1180, DOI 10.1016/S0960-9822(00)80021-4; Wojcik EJ, 2000, CURR BIOL, V10, P1131, DOI 10.1016/S0960-9822(00)00703-X; Wu C, 1999, J BIOL CHEM, V274, P29591, DOI 10.1074/jbc.274.42.29591; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Yaron A, 1997, EMBO J, V16, P6486, DOI 10.1093/emboj/16.21.6486; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zhou PB, 2000, MOL CELL, V6, P751, DOI 10.1016/S1097-2765(00)00074-5	97	256	266	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2004	23	11					2028	2036		10.1038/sj.onc.1207389	http://dx.doi.org/10.1038/sj.onc.1207389			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	803EC	15021890				2022-12-17	WOS:000220213400007
J	Freemantle, SJ; Spinella, MJ; Dmitrovsky, E				Freemantle, SJ; Spinella, MJ; Dmitrovsky, E			Retinoids in cancer therapy and chemoprevention: promise meets resistance	ONCOGENE			English	Review						retinoids; retinoid resistance; acute promyelocytic leukemia; chemoprevention	ACUTE-PROMYELOCYTIC-LEUKEMIA; ACID-RECEPTOR-BETA; HUMAN EMBRYONAL CARCINOMA; CELL LUNG-CANCER; PML-RAR-ALPHA; HISTONE-DEACETYLASE INHIBITORS; ACUTE MYELOID-LEUKEMIA; BINDING PROTEIN-II; INDUCED GROWTH ARREST; BREAST-CANCER	Retinoids ( natural and synthetic derivatives of vitamin A) signal potent differentiation and growth-suppressive effects in diverse normal, premalignant, and malignant cells. A strong rationale exists for the use of retinoids in cancer treatment and chemoprevention based on preclinical, epidemiological, and early clinical findings. Despite the success of all-trans-retinoic acid (RA)-based differentiation therapy in acute promyelocytic leukemia (APL), the broad promise of retinoids in the clinic has not yet been realized. In addition to the expected limited activity of any single therapeutic agent, translation of retinoid activities from the laboratory to the clinic has met with intrinsic or acquired retinoid resistance. Evidence suggests that solid tumors develop intrinsic resistance to retinoids during carcinogenesis. In contrast, relapse of APL is often associated with acquired resistance to retinoid maturation induction. This review discusses what is known about retinoid resistance mechanisms in cancer therapy and chemoprevention. Strategies to overcome this resistance will be discussed, including combination therapy with other differentiation-inducing, cytotoxic or chromatin-remodeling agents, as well as the use of receptor-selective and nonclassical retinoids. Opportunities exist in the post-genomic era to bypass resistance to classical retinoids by identifying target genes and associated pathways that directly mediate the antineoplastic effects of retinoids. In this regard, the retinoids are useful pharmacological tools to reveal important pathways targeted in cancer therapy and chemoprevention.	Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Pharmacol & Toxicol, Hanover, NH 03756 USA; Dartmouth Coll Sch Med, Norris Cotton Canc Ctr, Hanover, NH 03755 USA; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Med, Hanover, NH 03756 USA; Dartmouth Hitchcock Med Ctr, Lebanon, NH 03756 USA	Dartmouth College; Dartmouth College; Norris Cotton Cancer Center; Dartmouth College; Dartmouth College	Freemantle, SJ (corresponding author), Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Pharmacol & Toxicol, Hanover, NH 03756 USA.	sarah.freemantle@dartmouth.edu	Spinella, Michael/B-7210-2014		NATIONAL CANCER INSTITUTE [R01CA062275, K01CA075154, R01CA087546] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 62275, R01 CA 87546, R01 CA062275, K01 CA 75154-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albanell J, 1996, CANCER RES, V56, P1503; Bender CM, 1998, CANCER RES, V58, P95; Benedetti L, 1997, BLOOD, V90, P1175, DOI 10.1182/blood.V90.3.1175.1175_1175_1185; Berard J, 1996, FASEB J, V10, P1091, DOI 10.1096/fasebj.10.9.8801172; Berg WJ, 1999, CLIN CANCER RES, V5, P1671; Berg WJ, 2000, SEMIN ONCOL, V27, P234; Blaner W.S., 1999, HANDB EXP PHARM, P117; Brabender J, 2002, CLIN CANCER RES, V8, P438; Brigati C, 1999, LEUKEMIA RES, V23, P105, DOI 10.1016/S0145-2126(98)00145-3; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; Budhu AS, 2002, MOL CELL BIOL, V22, P2632, DOI 10.1128/MCB.22.8.2632-2641.2002; Calleja E M, 2000, Curr Oncol Rep, V2, P519, DOI 10.1007/s11912-000-0105-x; Carapeti M, 1998, BLOOD, V91, P3127, DOI 10.1182/blood.V91.9.3127.3127_3127_3133; Castillo L, 1997, CLIN CANCER RES, V3, P2137; Cheer S M, 2000, Am J Clin Dermatol, V1, P307, DOI 10.2165/00128071-200001050-00005; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; COMIC M, 1994, LEUKEMIA, V8, P914; Conley B, 2000, J CLIN ONCOL, V18, P275, DOI 10.1200/JCO.2000.18.2.275; Cote S, 1998, ANTI-CANCER DRUG, V9, P743; Cote S, 1997, ANTI-CANCER DRUG, V8, P56; Curtin JC, 2001, ONCOGENE, V20, P2559, DOI 10.1038/sj.onc.1204370; DELVA L, 1993, BLOOD, V82, P2175; Demary K, 2001, ENDOCRINOLOGY, V142, P2600, DOI 10.1210/en.142.6.2600; DERMIME S, 1993, BLOOD, V82, P1573; Dimberg A, 2002, BLOOD, V99, P2199, DOI 10.1182/blood.V99.6.2199; Dokmanovic M, 2002, CANCER BIOL THER, V1, P24, DOI 10.4161/cbt.1.1.35; Dragnev KH, 2001, ANN NY ACAD SCI, V952, P13, DOI 10.1111/j.1749-6632.2001.tb02724.x; Early E, 1996, P NATL ACAD SCI USA, V93, P7900, DOI 10.1073/pnas.93.15.7900; Esteller M, 2002, CANCER RES, V62, P5902; Fanelli M, 1999, BLOOD, V93, P1477, DOI 10.1182/blood.V93.5.1477.405a33_1477_1481; Ferrara FF, 2001, CANCER RES, V61, P2; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Freemantle SJ, 2002, ONCOGENE, V21, P2880, DOI 10.1038/sj.onc.1205408; Gallagher RE, 2002, LEUKEMIA, V16, P1940, DOI 10.1038/sj.leu.2402719; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; GUERNSEY DL, 1988, INT J CANCER, V42, P576, DOI 10.1002/ijc.2910420419; Hayashi K, 2001, DIFFERENTIATION, V68, P13, DOI 10.1046/j.1432-0436.2001.068001013.x; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; He LZ, 2001, J CLIN INVEST, V108, P1321, DOI 10.1172/JCI200111537; Heald P, 2000, Clin Lymphoma, V1 Suppl 1, pS45, DOI 10.3816/CLM.2000.s.009; Hong Waun Ki, 1994, P597; Hong WK, 1997, SCIENCE, V278, P1073, DOI 10.1126/science.278.5340.1073; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Houldsworth J, 2002, CELL GROWTH DIFFER, V13, P257; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; Ivanova T, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-4; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Karpf AR, 2002, ONCOGENE, V21, P5496, DOI 10.1038/sj.onc.1205602; Khuri FR, 2000, SEMIN SURG ONCOL, V18, P100, DOI 10.1002/(SICI)1098-2388(200003)18:2<100::AID-SSU3>3.3.CO;2-0; Kitareewan S, 2002, P NATL ACAD SCI USA, V99, P3806, DOI 10.1073/pnas.052011299; Kitareewan S, 1999, ONCOGENE, V18, P5747, DOI 10.1038/sj.onc.1202981; KITAREEWAN S, 2003, RETINOIDS CANC PREVE, V1; Kizaki M, 1996, BLOOD, V87, P725, DOI 10.1182/blood.V87.2.725.bloodjournal872725; Kwong J, 2002, CLIN CANCER RES, V8, P131; LAMPRON C, 1995, DEVELOPMENT, V121, P539; Lemon B, 2001, NATURE, V414, P924, DOI 10.1038/414924a; LI YP, 1994, BLOOD, V83, P3298; Lian Z, 2001, BLOOD, V98, P513, DOI 10.1182/blood.V98.3.513; Licht JD, 2001, ONCOGENE, V20, P5660, DOI 10.1038/sj.onc.1204593; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; LIPPMAN SM, 1995, CANCER RES, V55, P16; Lippman SM, 2001, JNCI-J NATL CANCER I, V93, P605, DOI 10.1093/jnci/93.8.605; LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103; Lubbert M, 2000, CURR TOP MICROBIOL, V249, P135; Matsushita H, 1998, BLOOD, V91, P2452, DOI 10.1182/blood.V91.7.2452.2452_2452_2458; Maurer BJ, 2000, JNCI-J NATL CANCER I, V92, P1897, DOI 10.1093/jnci/92.23.1897; McCaffery P, 2000, CYTOKINE GROWTH F R, V11, P233, DOI 10.1016/S1359-6101(00)00002-2; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; MILLER WH, 1990, ONCOGENE, V5, P511; Milutinovic S, 2000, J BIOL CHEM, V275, P6353, DOI 10.1074/jbc.275.9.6353; MOASSER MM, 1994, ONCOGENE, V9, P833; MOGHAL N, 1995, MOL CELL BIOL, V15, P3945; Moon Richard C., 1994, P573; MOORE DM, 1994, SEMIN HEMATOL, V31, P31; Mori J, 1999, JPN J CANCER RES, V90, P660, DOI 10.1111/j.1349-7006.1999.tb00798.x; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; Nakayama T, 2001, LAB INVEST, V81, P1049, DOI 10.1038/labinvest.3780316; Nason-Burchenal K, 1998, ONCOGENE, V17, P1759, DOI 10.1038/sj.onc.1202075; NasonBurchenal K, 1997, DIFFERENTIATION, V61, P321, DOI 10.1046/j.1432-0436.1997.6150321.x; NASONBURCHENAL K, 1999, HANDB EXP PHARM, V139, P301; NASONBURCHENAL K, 1996, MOL BIOL CANC, P1547; Nau H, 1999, HANDB EXP PHARM, V139, P153; Nehme A, 2001, BRIT J CANCER, V84, P1571, DOI 10.1054/bjoc.2001.1818; Nervi C, 1998, BLOOD, V92, P2244; Njar VCO, 2002, MINI-REV MED CHEM, V2, P261, DOI 10.2174/1389557023406223; Nowfar S, 2002, BREAST CANCER RES TR, V72, P33, DOI 10.1023/A:1014912919470; Ozpolat B, 2002, LEUKEMIA LYMPHOMA, V43, P933, DOI 10.1080/10428190290021678; Ozpolat B, 2001, J BIOL REG HOMEOS AG, V15, P107; PAIETTA E, 1994, LEUKEMIA, V8, P968; Palmisano WA, 2000, CANCER RES, V60, P5954; Pandolfi PP, 2001, ONCOGENE, V20, P3116, DOI 10.1038/sj.onc.1204299; Pendino F, 2002, LEUKEMIA, V16, P826, DOI 10.1038/sj.leu.2402470; Petti MC, 2002, BLOOD, V100, P1065, DOI 10.1182/blood-2001-12-0368; Piazza F, 2001, ONCOGENE, V20, P7216, DOI 10.1038/sj.onc.1204855; Picard E, 1999, J NATL CANCER I, V91, P1059, DOI 10.1093/jnci/91.12.1059; Privalsky ML, 2001, CURR TOP MICROBIOL, V254, P117; Qiu HM, 1999, AM J PATHOL, V155, P1519, DOI 10.1016/S0002-9440(10)65467-3; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rachez C, 2001, CURR OPIN CELL BIOL, V13, P274, DOI 10.1016/S0955-0674(00)00209-X; Rastinejad F, 2001, CURR OPIN STRUC BIOL, V11, P33, DOI 10.1016/S0959-440X(00)00165-2; Reid GK, 2002, CURR OPIN MOL THER, V4, P130; Reynolds CP, 2001, HEMATOL ONCOL CLIN N, V15, P867, DOI 10.1016/S0889-8588(05)70256-2; Reynolds CP, 2000, MED PEDIATR ONCOL, V35, P597, DOI 10.1002/1096-911X(20001201)35:6<597::AID-MPO23>3.0.CO;2-B; Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068; ROBERTSON KA, 1992, BLOOD, V80, P1885; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Shao WL, 1997, BLOOD, V89, P4282, DOI 10.1182/blood.V89.12.4282; Si SP, 1996, EXP CELL RES, V223, P102, DOI 10.1006/excr.1996.0062; Silverman LR, 2002, J CLIN ONCOL, V20, P2429, DOI 10.1200/JCO.2002.04.117; Sirchia SM, 2002, CANCER RES, V62, P2455; Slack James L., 1999, Current Opinion in Oncology, V11, P9, DOI 10.1097/00001622-199901000-00003; Spinella MJ, 1998, ONCOGENE, V16, P3471, DOI 10.1038/sj.onc.1201876; Suh N, 2002, CLIN CANCER RES, V8, P3270; Suh YA, 2002, CANCER RES, V62, P3945; Sun SY, 2002, CRIT REV ONCOL HEMAT, V41, P41, DOI 10.1016/S1040-8428(01)00144-5; Takeshita A, 2000, BRIT J HAEMATOL, V108, P90, DOI 10.1046/j.1365-2141.2000.01823.x; Tallman Martin S, 2002, Curr Oncol Rep, V4, P381, DOI 10.1007/s11912-002-0031-1; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; TESTA U, 1994, CANCER RES, V54, P4508; Torrisi R, 2000, Curr Oncol Rep, V2, P263, DOI 10.1007/s11912-000-0077-x; Toulouse A, 2000, LUNG CANCER-J IASLC, V28, P127, DOI 10.1016/S0169-5002(99)00122-1; Urnov FD, 2001, CURR TOP MICROBIOL, V254, P1; Van Heusden J, 2002, BRIT J CANCER, V86, P605, DOI 10.1038/sj.bjc.6600056; VANDERBURG B, 1993, MOL CELL ENDOCRINOL, V91, P149, DOI 10.1016/0303-7207(93)90267-N; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; Wallberg AE, 2000, MOL CELL BIOL, V20, P2004, DOI 10.1128/MCB.20.6.2004-2013.2000; Wang DL, 2000, CLIN CANCER RES, V6, P3636; WARRELL RP, 1993, BLOOD, V82, P1949, DOI 10.1182/blood.V82.7.1949.bloodjournal8271949; White JA, 1997, J BIOL CHEM, V272, P18538, DOI 10.1074/jbc.272.30.18538; Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826; Widschwendter M, 1997, CANCER RES, V57, P4158; Wolbach SB, 1925, J EXP MED, V42, P753, DOI 10.1084/jem.42.6.753; Wu Q, 1997, EMBO J, V16, P1656, DOI 10.1093/emboj/16.7.1656; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Xu W, 2001, SCIENCE, V294, P2507, DOI 10.1126/science.1065961; Xu XC, 1997, JNCI-J NATL CANCER I, V89, P624, DOI 10.1093/jnci/89.9.624; Xu XC, 1997, CANCER RES, V57, P4992; XU XC, 1994, CANCER RES, V54, P3580; Yoshida H, 1996, CANCER RES, V56, P2945; Zelent A, 2001, ONCOGENE, V20, P7186, DOI 10.1038/sj.onc.1204766; Zhou DC, 2002, BLOOD, V99, P1356, DOI 10.1182/blood.V99.4.1356; Zhou DC, 1998, CANCER RES, V58, P5770; Zujewski J, 2002, ENVIRON MOL MUTAGEN, V39, P264, DOI 10.1002/em.10054	148	256	271	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2003	22	47					7305	7315		10.1038/sj.onc.1206936	http://dx.doi.org/10.1038/sj.onc.1206936			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KL	14576840				2022-12-17	WOS:000186112500005
J	Feitelson, MA; Sun, B; Tufan, NLS; Liu, J; Pan, JB; Lian, ZR				Feitelson, MA; Sun, B; Tufan, NLS; Liu, J; Pan, JB; Lian, ZR			Genetic mechanisms of hepatocarcinogenesis	ONCOGENE			English	Review						hepatocellular carcinoma; hepatitis viruses; loss of heterozygosity; mutations	HEPATITIS-B-VIRUS; HUMAN HEPATOCELLULAR-CARCINOMA; COMPARATIVE GENOMIC HYBRIDIZATION; IN-SITU HYBRIDIZATION; P53 TUMOR-SUPPRESSOR; GROWTH-FACTOR-BETA; ABERRANT DNA METHYLATION; E-CADHERIN GENE; NF-KAPPA-B; C VIRUS	The development of hepatocellular carcinoma (HCC is a multistep process associated with changes in host gene expression, some of which correlate with the appearance and progression of tumor. Preneoplastic changes in gene expression result from altered DNA methylation, the actions of hepatitis B and C viruses, and point mutations or loss of heterozygosity (LOH) in selected cellular genes. Tumor progression is characterized by LOH involving tumor suppressor genes on many chromosomes and by gene amplification of selected oncogenes. The changes observed in different HCC nodules are often distinct, suggesting heterogeneity on the molecular level. These observations suggest that there are multiple, perhaps redundant negative growth regulatory pathways that protect cells against transformation. An understanding of the molecular pathogenesis of HCC may provide new markers for tumor staging, for assessment of the relative risk of tumor formation, and open new opportunities for therapeutic intervention.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Feitelson, MA (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Room 222 Alumni Hall,1020 Locust St, Philadelphia, PA 19107 USA.	Mark.Feitelson@mail.tju.edu	Lian, Zhaorui/AAW-2379-2020	Satiroglu Tufan, N Lale/0000-0001-9399-0960	NCI NIH HHS [CA 79512, CA 66971, CA 48656] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA048656, R01CA066971, R01CA079512, R01CA048656] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBOTT PJ, 1977, BRIT J CANCER, V34, P310; Aihara T, 1998, HEPATOLOGY, V28, P86, DOI 10.1002/hep.510280113; Andersson, 1991, FLORA ECUADOR, P1; Attallah AM, 1999, CANCER LETT, V142, P65, DOI 10.1016/S0304-3835(99)00165-2; Bando K, 1999, GENE CHROMOSOME CANC, V25, P284, DOI 10.1002/(SICI)1098-2264(199907)25:3<284::AID-GCC11>3.0.CO;2-I; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; Beasley R.P., 1984, VIRAL HEPATITIS LIVE, P209; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; Boige V, 1997, CANCER RES, V57, P1986; Boix-Ferrero J, 1999, VIRCHOWS ARCH, V434, P497, DOI 10.1007/s004280050374; BOURDON JC, 1995, GASTROENTEROLOGY, V108, P1176, DOI 10.1016/0016-5085(95)90217-1; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BUETOW KH, 1992, P NATL ACAD SCI USA, V89, P9622, DOI 10.1073/pnas.89.20.9622; Cadoret A, 2001, CANCER RES, V61, P3245; Calvisi DF, 2001, CANCER RES, V61, P2085; Cao GW, 1997, GASTROENTEROLOGY, V112, P501, DOI 10.1053/gast.1997.v112.pm9024304; CHANG MH, 1989, CANCER-AM CANCER SOC, V64, P2377, DOI 10.1002/1097-0142(19891201)64:11<2377::AID-CNCR2820641130>3.0.CO;2-8; Chaubert P, 1997, HEPATOLOGY, V25, P1376, DOI 10.1002/hep.510250613; Chen QY, 1997, HEPATOLOGY, V26, P59; Collier J, 1998, HEPATOLOGY, V27, P273, DOI 10.1002/hep.510270140; DARVILLE CN, 1991, HEPATOLOGY, V13, P310, DOI 10.1002/hep.1840130217; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; DEJEAN A, 1990, MOL BIOL MED, V7, P213; DESOUZA AT, 1995, ONCOGENE, V10, P1725; DIAMANTIS ID, 1992, J HEPATOL, V15, P400, DOI 10.1016/0168-8278(92)90077-3; DING SF, 1995, J HEPATOL, V22, P230, DOI 10.1016/0168-8278(95)80434-X; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; DUNSFORD HA, 1990, CANCER RES, V50, P3400; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; Factor VM, 1997, CANCER RES, V57, P2089; Falls JG, 1999, AM J PATHOL, V154, P635, DOI 10.1016/S0002-9440(10)65309-6; Fang W, 2000, GENE CHROMOSOME CANC, V28, P269, DOI 10.1002/1098-2264(200007)28:3<269::AID-GCC4>3.0.CO;2-K; Feitelson MA, 1999, FALK SYMP, V103C, P156; FEITELSON MA, 1986, CONCEPTS VIRAL PATHO, V2, P269; Gale M, 1999, J VIROL, V73, P6506, DOI 10.1128/JVI.73.8.6506-6516.1999; Ghosh AK, 1999, J GEN VIROL, V80, P1179, DOI 10.1099/0022-1317-80-5-1179; Gozuacik D, 2001, ONCOGENE, V20, P6233, DOI 10.1038/sj.onc.1204835; Greenblatt MS, 1997, CANCER RES, V57, P426; Guo XZ, 1998, HEPATOLOGY, V28, P1481, DOI 10.1002/hep.510280606; Gupta S, 2000, SEMIN CANCER BIOL, V10, P161; GUYTON KZ, 1993, BRIT MED BULL, V49, P523, DOI 10.1093/oxfordjournals.bmb.a072628; Hayashi J, 2000, HEPATOLOGY, V32, P958, DOI 10.1053/jhep.2000.19343; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; HINO O, 1991, P NATL ACAD SCI USA, V88, P9248, DOI 10.1073/pnas.88.20.9248; Hsu HC, 2000, AM J PATHOL, V157, P763, DOI 10.1016/S0002-9440(10)64590-7; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; Huang JK, 1996, J VIROL, V70, P5582, DOI 10.1128/JVI.70.8.5582-5591.1996; Huang SF, 1999, CANCER GENET CYTOGEN, V111, P21, DOI 10.1016/S0165-4608(98)00215-5; Huo TI, 2001, ONCOGENE, V20, P3620, DOI 10.1038/sj.onc.1204495; Ido A, 2001, CANCER RES, V61, P3016; Ishido S, 1998, FEBS LETT, V438, P258, DOI 10.1016/S0014-5793(98)01312-X; Kanai Y, 1999, HEPATOLOGY, V29, P703, DOI 10.1002/hep.510290338; Kanai Y, 1996, JPN J CANCER RES, V87, P1210, DOI 10.1111/j.1349-7006.1996.tb03135.x; Kanai Y, 1997, INT J CANCER, V71, P355; Katagiri T, 1996, CANCER RES, V56, P4575; Kato N, 1997, J VIROL, V71, P8856, DOI 10.1128/JVI.71.11.8856-8859.1997; Kawamura N, 1999, JPN J CANCER RES, V90, P413, DOI 10.1111/j.1349-7006.1999.tb00763.x; Kawate S, 1999, INT J ONCOL, V14, P127; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; Kim SO, 1996, CANCER RES, V56, P3831; Kimura H, 1996, CANCER, V77, P271, DOI 10.1002/(SICI)1097-0142(19960115)77:2<271::AID-CNCR8>3.0.CO;2-P; Kishimoto Y, 1996, J CANCER RES CLIN, V122, P585, DOI 10.1007/BF01221189; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; Knuutila S, 1999, AM J PATHOL, V155, P683, DOI 10.1016/S0002-9440(10)65166-8; Kondo Y, 2000, HEPATOLOGY, V32, P970, DOI 10.1053/jhep.2000.19797; KONISHI M, 1993, JPN J CANCER RES, V84, P893, DOI 10.1111/j.1349-7006.1993.tb02063.x; Koyama M, 1999, JPN J CANCER RES, V90, P951, DOI 10.1111/j.1349-7006.1999.tb00840.x; KUROKI T, 1995, GENE CHROMOSOME CANC, V13, P163, DOI 10.1002/gcc.2870130305; Kusano N, 1999, HEPATOLOGY, V29, P1858, DOI 10.1002/hep.510290636; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Lee SM, 1996, HEPATOLOGY, V24, P987; Lee YH, 1998, J BIOL CHEM, V273, P25510, DOI 10.1074/jbc.273.39.25510; LENCIONI R, 1994, ITAL J GASTROENTEROL, V26, P163; LIANG TJ, 1995, HEPATOLOGY, V22, P1330, DOI 10.1016/0270-9139(95)90647-9; Liew CT, 1999, INT J CANCER, V81, P319, DOI 10.1002/(SICI)1097-0215(19990505)81:3<319::AID-IJC1>3.0.CO;2-K; Livezey KW, 1997, MUTAT RES-FUND MOL M, V377, P187, DOI 10.1016/S0027-5107(97)00068-7; LUCITO R, 1992, J VIROL, V66, P983, DOI 10.1128/JVI.66.2.983-991.1992; Maki CG, 1996, CANCER RES, V56, P2649; Mao TL, 2001, J PATHOL, V193, P95, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH720>3.0.CO;2-3; Marchio A, 1997, GENE CHROMOSOME CANC, V18, P59, DOI 10.1002/(SICI)1098-2264(199701)18:1<59::AID-GCC7>3.3.CO;2-N; Marusawa H, 1999, J VIROL, V73, P4713, DOI 10.1128/JVI.73.6.4713-4720.1999; Masaki T, 1998, HEPATOLOGY, V27, P1257, DOI 10.1002/hep.510270511; Masuda T, 2000, IN VITRO CELL DEV-AN, V36, P387; MCGLYNN KA, 1995, P NATL ACAD SCI USA, V92, P2384, DOI 10.1073/pnas.92.6.2384; Miyoshi Y, 1998, CANCER RES, V58, P2524; Moriya K, 1998, NAT MED, V4, P1065, DOI 10.1038/2053; MURAKAMI H, 1993, CANCER RES, V53, P1719; MURAKAMI Y, 1991, CANCER RES, V51, P5520; Nagai H, 2001, J HEPATOL, V34, P416, DOI 10.1016/S0168-8278(00)00038-6; NG IOL, 1994, CANCER-AM CANCER SOC, V74, P30, DOI 10.1002/1097-0142(19940701)74:1<30::AID-CNCR2820740107>3.0.CO;2-4; Niketeghad F, 2001, BRIT J CANCER, V85, P697, DOI 10.1054/bjoc.2001.1963; NISHIDA N, 1994, CANCER RES, V54, P3107; Noguchi O, 1996, J HEPATOL, V24, P286, DOI 10.1016/S0168-8278(96)80006-7; Ogden SK, 2000, J BIOL CHEM, V275, P27806; Ohsawa N, 1996, J HEPATOL, V25, P655, DOI 10.1016/S0168-8278(96)80235-2; Okabe H, 2001, CANCER RES, V61, P2129; Okazaki I, 1997, HEPATOLOGY, V25, P580, DOI 10.1002/hep.510250315; Okuda K, 1997, J GASTROEN HEPATOL, V12, pS314, DOI 10.1111/j.1440-1746.1997.tb00515.x; Ozaki I, 2000, CANCER RES, V60, P6519; Park US, 2000, ONCOGENE, V19, P3384, DOI 10.1038/sj.onc.1203674; PASCALE RM, 1993, ANTICANCER RES, V13, P1341; PATERLINI P, 1995, HEPATOLOGY, V21, P313, DOI 10.1002/hep.1840210208; Peng CY, 2000, ANTICANCER RES, V20, P1487; Peng Shian-Yang, 1993, Journal of the Formosan Medical Association, V92, P866; Piao Z, 1999, CANCER LETT, V138, P227, DOI 10.1016/S0304-3835(99)00019-1; Pineau P, 1999, ONCOGENE, V18, P3127, DOI 10.1038/sj.onc.1202648; Pontisso P, 1998, CANCER, V83, P1489; Poussin K, 1999, INT J CANCER, V80, P497, DOI 10.1002/(SICI)1097-0215(19990209)80:4<497::AID-IJC3>3.0.CO;2-8; Rashid A, 1999, BRIT J CANCER, V80, P59, DOI 10.1038/sj.bjc.6690321; RAY RB, 1995, VIRUS RES, V37, P209, DOI 10.1016/0168-1702(95)00034-N; Ray RB, 1998, J BIOL CHEM, V273, P2256, DOI 10.1074/jbc.273.4.2256; Ray RB, 1997, J BIOL CHEM, V272, P10983; Rossmanith W, 2001, MICROSC RES TECHNIQ, V52, P430, DOI 10.1002/1097-0029(20010215)52:4<430::AID-JEMT1028>3.0.CO;2-3; ROSSNER MT, 1992, J MED VIROL, V36, P101, DOI 10.1002/jmv.1890360207; SAKAMURO D, 1995, J VIROL, V69, P3893, DOI 10.1128/JVI.69.6.3893-3896.1995; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Shen LL, 1998, HEPATO-GASTROENTEROL, V45, P1753; Sheu JC, 1999, BRIT J CANCER, V80, P468, DOI 10.1038/sj.bjc.6690380; Shirota Y, 2001, HEPATOLOGY, V33, P832, DOI 10.1053/jhep.2001.23003; Sirivatanauksorn Y, 1999, GUT, V45, P761, DOI 10.1136/gut.45.5.761; Sirma H, 1999, FALK SYMP, V103C, P171; Sirma H, 1998, ONCOGENE, V16, P2051, DOI 10.1038/sj.onc.1201737; SLAGLE BL, 1993, HEPATOLOGY, V18, P757, DOI 10.1002/hep.1840180402; Sugimoto K, 1999, HEPATOLOGY, V30, P920, DOI 10.1002/hep.510300424; Sun M, 2001, HEPATOLOGY, V33, P1415, DOI 10.1053/jhep.2001.24751; Tannapfel A, 1999, J NATL CANCER I, V91, P1154, DOI 10.1093/jnci/91.13.1154; Tu H, 2001, CANCER RES, V61, P7803; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; Ueki T, 1997, HEPATOLOGY, V25, P862, DOI 10.1002/hep.510250413; Wada I, 1999, HEPATOLOGY, V29, P1718, DOI 10.1002/hep.510290635; Wang G, 2001, GENE CHROMOSOME CANC, V31, P221, DOI 10.1002/gcc.1138; Wang J, 2000, ONCOGENE, V19, P1843, DOI 10.1038/sj.onc.1203503; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WANG WL, 1991, CANCER RES, V51, P4971; WANG WL, 1991, HEPATOLOGY, V14, P29, DOI 10.1002/hep.1840140106; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Wong IHN, 1999, CANCER RES, V59, P71; Wong N, 1999, AM J PATHOL, V154, P37, DOI 10.1016/S0002-9440(10)65248-0; Wong N, 2001, AM J PATHOL, V159, P465, DOI 10.1016/S0002-9440(10)61718-X; Wong N, 2000, CLIN CANCER RES, V6, P4000; WU TC, 1987, HEPATOLOGY, V7, P46, DOI 10.1002/hep.1840070111; Xu L, 2001, CANCER RES, V61, P3176; Yakicier MC, 2001, ONCOGENE, V20, P5232, DOI 10.1038/sj.onc.1204674; Yano M, 1999, INT J ONCOL, V14, P447; Yeh SH, 2001, GASTROENTEROLOGY, V121, P699, DOI 10.1053/gast.2001.27211; Yoo YD, 1996, J CLIN INVEST, V97, P388, DOI 10.1172/JCI118427; Yuan BZ, 1998, CANCER RES, V58, P2196; Zhang ZS, 2000, J BIOL CHEM, V275, P15157, DOI 10.1074/jbc.M910378199; Zhao XT, 2001, CANCER RES, V61, P7383	153	256	282	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2593	2604		10.1038/sj.onc.1205434	http://dx.doi.org/10.1038/sj.onc.1205434			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971194				2022-12-17	WOS:000174918400016
J	Dechend, R; Hirano, F; Lehmann, K; Heissmeyer, V; Ansieau, S; Wulczyn, FG; Scheidereit, C; Leutz, A				Dechend, R; Hirano, F; Lehmann, K; Heissmeyer, V; Ansieau, S; Wulczyn, FG; Scheidereit, C; Leutz, A			The Bcl-3 oncoprotein acts as a bridging factor between NF-kappa B/Rel and nuclear co-regulators	ONCOGENE			English	Article						oncogene; coactivator; chromatin; gene regulation; signal transduction	CANDIDATE PROTOONCOGENE BCL-3; DNA-BINDING; B PROTEINS; TRANSCRIPTIONAL ACTIVATION; P50 HOMODIMERS; HUMAN GENES; IN-VIVO; BRCA1; ENCODES; PHOSPHORYLATION	The proto-oncoprotein Bcl-3 is a member of the I kappa B family and is present predominantly in the nucleus. To gain insight into specific nuclear functions of Bcl-3 we have isolated proteins that interact with its ankyrin repeat domain. Using the yeast two-hybrid-system we identified four novel binding partners of Bcl-3 in addition to NF-kappa B p50 and p52, previously known to associate with Bcl-3. The novel Bcl-3 interactors Jab1, Pirin, Tip60 and Bard1 are nuclear proteins which also bind to other transcription factors including c-Jun, nuclear factor I (NFI), HIV-1 Tat or the tumor suppressor and Polll holoenzyme component Brca1, respectively. Bcl-3, p50, and either Bard1, Tip60 or Pirin are sequestered into quarternary complexes on NF-kappa B DSA binding sites, whereas Jab1 enhances p50-Bcl-3-DNA complex formation. Furthermore, the histone acetylase Tip60 enhances Bcl-3-p50 activated transcription through an NF-kappa B binding site, indicating that quarternary complexes containing Bcl-3 interactors modulate NF-kappa B driven gene expression, These data implicate Bcl-3 as an adaptor between NF-kappa B p50/p52 and other transcription regulators and suggest that its gene activation function may at least in part be due to recruitment of the Tip60 histone actetylase.	Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany; Asahikawa Med Coll, Dept Internal Med 2, Asahikawa, Hokkaido 078, Japan	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Asahikawa Medical College	Scheidereit, C (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13122 Berlin, Germany.		Ansieau, Stephane/I-6195-2016; Leutz, Achim/K-9643-2013	Leutz, Achim/0000-0001-8259-927X; ANSIEAU, Stephane/0000-0003-0989-2108; Heissmeyer, Vigo/0000-0002-2263-8545				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Asano K, 1997, J BIOL CHEM, V272, P27042, DOI 10.1074/jbc.272.43.27042; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; Bundy DL, 1997, J BIOL CHEM, V272, P33132, DOI 10.1074/jbc.272.52.33132; Caamano JH, 1996, MOL CELL BIOL, V16, P1342; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Franzoso G, 1997, IMMUNITY, V6, P479, DOI 10.1016/S1074-7613(00)80291-5; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; Hilfiker A, 1997, EMBO J, V16, P2054, DOI 10.1093/emboj/16.8.2054; Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; KERR LD, 1992, GENE DEV, V6, P2352, DOI 10.1101/gad.6.12a.2352; KRETZSCHMAR M, 1992, GENE DEV, V6, P761, DOI 10.1101/gad.6.5.761; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PAN JL, 1995, J BIOL CHEM, V270, P23077, DOI 10.1074/jbc.270.39.23077; Reifsnyder C, 1996, NAT GENET, V14, P42, DOI 10.1038/ng0996-42; Schwarz EM, 1997, GENE DEV, V11, P187, DOI 10.1101/gad.11.2.187; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Siebenlist U, 1997, BBA-REV CANCER, V1332, pR7, DOI 10.1016/S0304-419X(96)00038-8; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; TAYLOR JP, 1994, J VIROL, V68, P3971, DOI 10.1128/JVI.68.6.3971-3981.1994; Watanabe N, 1997, EMBO J, V16, P3609, DOI 10.1093/emboj/16.12.3609; Wendler WMF, 1997, J BIOL CHEM, V272, P8482, DOI 10.1074/jbc.272.13.8482; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; Wulczyn FG, 1996, J MOL MED, V74, P749, DOI 10.1007/s001090050078; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595	42	256	267	0	11	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 3	1999	18	22					3316	3323		10.1038/sj.onc.1202717	http://dx.doi.org/10.1038/sj.onc.1202717			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	201HL	10362352				2022-12-17	WOS:000080589300002
J	Li, YW; Upadhyay, S; Bhuiyan, M; Sarkar, FH				Li, YW; Upadhyay, S; Bhuiyan, M; Sarkar, FH			Induction of apoptosis in breast cancer cells MDA-MB-231 by genistein	ONCOGENE			English	Article						genistein; apoptosis; breast cancer cells	POLY(ADP-RIBOSE) POLYMERASE; PROTEIN-KINASES; LEUKEMIA-CELLS; IN-VITRO; CYCLE; SUPPRESSION; INHIBITOR; GROWTH; ARREST; DIET	Breast cancer is the most common cancer among American women, whereas Asian women, who consume a traditional diet high in soy products, have a relatively low incidence, Genistein is a prominent isoflavonoid in soy products and has been proposed as the agent responsible for lowering the rate of breast cancer in Asian women. We investigated the effects of genistein on cell growth and apoptosis-related gene expression in breast cancer cells MDA-MB-231. We found upregulation of Bar and p21(WAF1) expressions and downregulation of Bcl-2 and p53 expression in genistein-treated cells. Furthermore, DNA ladder formation, CPP32 activation, and PARP cleavage were observed after treatment with genistein, indicating apoptotic cell deaths. Flow cytometry with 7-amino actinomycin D staining showed that the number of apoptotic cells increased with longer treatment of genistein. From these results, we conclude that genistein inhibits the growth of MDA-MB-231 breast cancer cells, regulates the expression of apoptosis-related genes, and induces apoptosis through a p53-independent pathway. The up-regulation of Bar and p21(WAF1) may be the molecular mechanisms by which genistein induces apoptosis, however, further definitive studies are needed. These results suggest that genistein may be a potentially effective chemopreventive or therapeutic agent against breast cancer.	Wayne State Univ, Dept Pathol, Sch Med, Karmanos Canc Inst, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University	Sarkar, FH (corresponding author), Wayne State Univ, Dept Pathol, Sch Med, Karmanos Canc Inst, 9374 Scott Hall,540 E Canfield, Detroit, MI 48201 USA.							ADLERCREUTZ H, 1991, AM J CLIN NUTR, V54, P1093, DOI 10.1093/ajcn/54.6.1093; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BARNES S, 1995, J NUTR, V125, pS777, DOI 10.1093/jn/125.3_Suppl.777S; BUCKLEY AR, 1993, MOL CELL ENDOCRINOL, V98, P17, DOI 10.1016/0303-7207(93)90231-8; CHIARUGI V, 1994, CELL MOL BIOL RES, V40, P603; CONSTANTINOU A, 1990, CANCER RES, V50, P2618; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Findley HW, 1997, BLOOD, V89, P2986, DOI 10.1182/blood.V89.8.2986; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FOTSIS T, 1995, J NUTR, V125, pS790, DOI 10.1093/jn/125.suppl_3.790S; Gescher A, 1998, BRIT J CLIN PHARMACO, V45, P1, DOI 10.1046/j.1365-2125.1998.00640.x; HARPER JW, 1993, CELL, V75, P241; Huang P, 1997, CANCER RES, V57, P3407; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kyle E, 1997, MOL PHARMACOL, V51, P193, DOI 10.1124/mol.51.2.193; LAMARTINIERE CA, 1995, P SOC EXP BIOL MED, V208, P120; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEE HP, 1991, LANCET, V337, P1197, DOI 10.1016/0140-6736(91)92867-2; LIAN F, 1998, IN PRESS NUTR CANC; MATSUKAWA Y, 1993, CANCER RES, V53, P1328; MESSINA M, 1991, JNCI-J NATL CANCER I, V83, P541, DOI 10.1093/jnci/83.8.541; MESSINA MJ, 1994, NUTR CANCER, V21, P113, DOI 10.1080/01635589409514310; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; Parker S. L., 1996, CA CANC J CLIN, V65, P5; PETERSON G, 1993, PROSTATE, V22, P335, DOI 10.1002/pros.2990220408; PETERSON G, 1991, BIOCHEM BIOPH RES CO, V179, P661, DOI 10.1016/0006-291X(91)91423-A; Philpott NJ, 1996, BLOOD, V87, P2244, DOI 10.1182/blood.V87.6.2244.bloodjournal8762244; Salomons GS, 1997, INT J CANCER, V71, P959, DOI 10.1002/(SICI)1097-0215(19970611)71:6<959::AID-IJC9>3.0.CO;2-X; SANO H, 1995, CANCER RES, V55, P3785; SEDLAK ML, 1995, P NATL ACAD SCI USA, V92, P7934; Shao ZM, 1998, J CELL BIOCHEM, V69, P44, DOI 10.1002/(SICI)1097-4644(19980401)69:1<44::AID-JCB5>3.3.CO;2-B; SPINOZZI F, 1994, LEUKEMIA RES, V18, P431, DOI 10.1016/0145-2126(94)90079-5; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; UCKUN FM, 1995, SCIENCE, V267, P886, DOI 10.1126/science.7531365; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Wang CF, 1997, NUTR CANCER, V28, P236, DOI 10.1080/01635589709514582; WANG TT, 1996, CARCINOGEN, V17, P272; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YUAN JM, 1995, BRIT J CANCER, V71, P1353, DOI 10.1038/bjc.1995.263; Zhou YH, 1998, J NATL CANCER I, V90, P381, DOI 10.1093/jnci/90.5.381	45	256	265	0	23	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	1999	18	20					3166	3172		10.1038/sj.onc.1202650	http://dx.doi.org/10.1038/sj.onc.1202650			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197WB	10340389				2022-12-17	WOS:000080388000013
J	MACGREGOR, PF; ABATE, C; CURRAN, T				MACGREGOR, PF; ABATE, C; CURRAN, T			DIRECT CLONING OF LEUCINE ZIPPER PROTEINS - JUN BINDS COOPERATIVELY TO THE CRE WITH CRE-BP1	ONCOGENE			English	Article									ROCHE INST MOLEC BIOL,ROCHE RES CTR,DEPT MOLEC ONCOL & VIROL,NUTLEY,NJ 07110	Roche Holding			Curran, Thomas/AAE-7631-2019; Curran, Tom/C-1164-2008; Curran, Tom/F-5234-2018; Curran, Tom/D-7515-2011; Abate-Shen, Cory/O-2520-2014	Curran, Thomas/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551; Abate-Shen, Cory/0000-0002-5021-0570				ABATE C, 1990, IN PRESS SEMINARS CA; ABATE C, 1990, IN PRESS P NATL ACAD; AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOS TJ, 1989, ONCOGENE, V4, P123; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; COHEN D R, 1989, Critical Reviews in Oncogenesis, V1, P65; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; COHEN DR, 1990, UNPUB; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; CURRAN T, 1987, BIOESSAYS, V7, P255, DOI 10.1002/bies.950070606; CURRAN T, 1987, ONCOGENE, V2, P79; CURRAN T, 1984, CELL, V36, P259; Curran T, 1988, ONCOGENE HDB, P307; CURRAN T, 1985, MOL CELL BIOL, V5, P157; FRANZA BR, 1987, ONCOGENE, V1, P213; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GENTZ R, 1989, P NATL ACAD SCI USA, V86, P821, DOI 10.1073/pnas.86.3.821; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; HELMS C, 1985, DNA-J MOLEC CELL BIO, V4, P39, DOI 10.1089/dna.1985.4.39; HUYNH TV, 1985, DNA CLONING PRACTICA, V1; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE WMF, 1988, MOL CELL BIOL, V8, P5521, DOI 10.1128/MCB.8.12.5521; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; Maniatis T., 1982, MOL CLONING; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; REDDY EPA, 1988, ONCOGENE HDB; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SONNENBERG JL, 1989, NEURON, V3, P359, DOI 10.1016/0896-6273(89)90260-2; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; SONNENBERG JL, 1989, J NEUROSCI RES, V24, P72, DOI 10.1002/jnr.490240111; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	46	256	263	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1990	5	4					451	458						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB853	2139203				2022-12-17	WOS:A1990DB85300001
J	Formosa, A; Markert, EK; Lena, AM; Italiano, D; Finazzi-Agro, E; Levine, AJ; Bernardini, S; Garabadgiu, AV; Melino, G; Candi, E				Formosa, A.; Markert, E. K.; Lena, A. M.; Italiano, D.; Finazzi-Agro, E.; Levine, A. J.; Bernardini, S.; Garabadgiu, A. V.; Melino, G.; Candi, E.			MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells	ONCOGENE			English	Article						microRNAs; prostate cancer; metastasis	MESENCHYMAL TRANSITION; EXPRESSION; CLUSTER; TUMOR; STEMNESS; TARGETS; MIRNAS; P53	miRNAs act as oncogenes or tumor suppressors in a wide variety of human cancers, including prostate cancer (PCa). We found a severe and consistent downregulation of miRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 region in metastatic cell lines as compared with normal prostatic epithelial cells (PrEC). In specimens of human prostate (28 normals, 99 primary tumors and 13 metastases), lower miRNA levels correlated significantly with a higher incidence of metastatic events and higher prostate specific antigen (PSA) levels, with similar trends observed for lymph node invasion and the Gleason score. We transiently transfected 10 members of the 14q32.31 cluster in normal prostatic epithelial cell lines and characterized their affect on malignant cell behaviors, including proliferation, apoptosis, migration and invasion. Finally, we identified FZD4, a gene important for epithelial-to-mesenchymal transition in (PCa), as a target of miR-377.	[Formosa, A.; Lena, A. M.; Italiano, D.; Finazzi-Agro, E.; Bernardini, S.; Melino, G.; Candi, E.] Univ Roma Tor Vergata, Dept Expt Med & Surg, I-00133 Rome, Italy; [Formosa, A.; Melino, G.] IDI IRCCS, Rome, Italy; [Markert, E. K.; Levine, A. J.] Simons Ctr Syst Biol, Inst Adv Study, Princeton, NJ USA; [Garabadgiu, A. V.] St Petersburg Technol Inst, Mol Pharmacol Lab, St Petersburg, Russia	University of Rome Tor Vergata; IRCCS Istituto Dermopatico dell'Immacolata (IDI); Institute for Advanced Study - USA; Saint Petersburg State Institute of Technology	Candi, E (corresponding author), Univ Roma Tor Vergata, Dept Expt Med & Surg, Via Montpellier 1, I-00133 Rome, Italy.	candi@uniroma2.it	Lena, Anna Maria/AAI-5042-2020; Agrò, Enrico Finazzi/N-7969-2018	Agrò, Enrico Finazzi/0000-0002-0308-8824; Garabadjiu, Alexander/0000-0001-9972-8517	AIRC grant [2013IG 13387]; AIRC [2011-IG11955]; Ministry of Education and Science of the Russian Federation [11.G34.31.0069]; Min. Salute [ric. Oncologica26/07]; IstitutoDermopatico-dell'Immacolata [RF06 c.73, RF07 c.57, RF08 c.15]; MRC [MC_U132670600] Funding Source: UKRI; Medical Research Council [MC_U132670600] Funding Source: researchfish	AIRC grant(Fondazione AIRC per la ricerca sul cancro); AIRC(Fondazione AIRC per la ricerca sul cancro); Ministry of Education and Science of the Russian Federation(Ministry of Education and Science, Russian Federation); Min. Salute(Ministry of Health, Italy); IstitutoDermopatico-dell'Immacolata; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work has been mainly supported by AIRC grant (2013IG 13387) to EC and partially supported by AIRC (2011-IG11955) and Ministry of Education and Science of the Russian Federation (11.G34.31.0069) to GM. Research described in this article was also supported in part by Min. Salute (ric. Oncologica26/07), 'IstitutoDermopatico-dell'Immacolata' (RF06 c.73, RF07 c.57, RF08 c.15, RF07 c.57) to GM.	Aberdam D, 2008, TRENDS BIOCHEM SCI, V33, P583, DOI 10.1016/j.tibs.2008.09.002; Afanasyeva EA, 2011, CELL DEATH DIFFER, V18, P974, DOI 10.1038/cdd.2010.164; Agueli C, 2010, AM J HEMATOL, V85, P575, DOI 10.1002/ajh.21758; Amelio I, 2012, J CELL BIOL, V199, P347, DOI 10.1083/jcb.201203134; Antonov AV, 2013, CELL DEATH DIFFER, V20, P367, DOI 10.1038/cdd.2012.137; Aqeilan RI, 2010, CELL DEATH DIFFER, V17, P215, DOI 10.1038/cdd.2009.69; Barlev NA, 2010, CELL DEATH DIFFER, V17, P373, DOI 10.1038/cdd.2009.73; Bartkowiak D, 1999, CYTOMETRY, V37, P191, DOI 10.1002/(SICI)1097-0320(19991101)37:3<191::AID-CYTO5>3.0.CO;2-U; Boll K, 2013, ONCOGENE, V32, P277, DOI 10.1038/onc.2012.55; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cervo PRD, 2012, P NATL ACAD SCI USA, V109, P1133, DOI 10.1073/pnas.1112257109; Costa FF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025114; Couts KL, 2013, ONCOGENE, V32, P1959, DOI 10.1038/onc.2012.209; Da Rocha ST, 2008, TRENDS GENET, V24, P306, DOI 10.1016/j.tig.2008.03.011; Devor EJ, 2012, EXP THER MED, V3, P677, DOI 10.3892/etm.2012.458; Ferlay J, 2010, IARC CANCERBASE; Formosa A, 2013, ONCOGENE, V32, P127, DOI 10.1038/onc.2012.14; Gandellini P, 2012, CELL DEATH DIFFER, V19, P1750, DOI 10.1038/cdd.2012.56; Gattolliat CH, 2011, BRIT J CANCER, V105, P1352, DOI 10.1038/bjc.2011.388; Gupta S, 2010, CANCER RES, V70, P6735, DOI 10.1158/0008-5472.CAN-10-0244; Haller F, 2010, J PATHOL, V220, P71, DOI 10.1002/path.2610; Hassan O, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-9; Hudson RS, 2013, ONCOGENE, V32, P4139, DOI 10.1038/onc.2012.424; Jurmeister S, 2012, MOL CELL BIOL, V32, P633, DOI 10.1128/MCB.06212-11; Kappelmann M, 2013, ONCOGENE, V32, P2984, DOI 10.1038/onc.2012.307; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Kuriyama M, 1996, Int J Urol, V3, P462, DOI 10.1111/j.1442-2042.1996.tb00577.x; Lavon I, 2010, NEURO-ONCOLOGY, V12, P422, DOI 10.1093/neuonc/nop061; Lena AM, 2008, CELL DEATH DIFFER, V15, P1187, DOI 10.1038/cdd.2008.69; Lin J, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.134; MacFarlane LA, 2010, CURR GENOMICS, V11, P537, DOI 10.2174/138920210793175895; Martens-Uzunova ES, 2012, ONCOGENE, V31, P978, DOI 10.1038/onc.2011.304; Musumeci M, 2011, ONCOGENE, V30, P4231, DOI 10.1038/onc.2011.140; Nair VS, 2012, JNCI-J NATL CANCER I, V104, P528, DOI 10.1093/jnci/djs027; Olive V, 2010, INT J BIOCHEM CELL B, V42, P1348, DOI 10.1016/j.biocel.2010.03.004; Peltier HJ, 2008, RNA, V14, P844, DOI 10.1261/rna.939908; Puissegur MP, 2011, CELL DEATH DIFFER, V18, P465, DOI 10.1038/cdd.2010.119; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Seitz H, 2004, GENOME RES, V14, P1741, DOI 10.1101/gr.2743304; Streicher KL, 2012, ONCOGENE, V31, P1558, DOI 10.1038/onc.2011.345; Takayama K, 2011, ONCOGENE, V30, P619, DOI 10.1038/onc.2010.436; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Thayanithy V, 2012, BONE, V50, P171, DOI 10.1016/j.bone.2011.10.012; Tucci P, 2012, P NATL ACAD SCI USA, V109, P15312, DOI 10.1073/pnas.1110977109; Ueno K, 2012, MOL CANCER THER, V11, P244, DOI 10.1158/1535-7163.MCT-11-0592; Viticchie G, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.174; Yu J, 2010, FASEB J, V24, P3950, DOI 10.1096/fj.10-157404; Zehavi L, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-44; Zhang H, 2011, CELL DEATH DIFFER, V18, P1702, DOI 10.1038/cdd.2011.28; Zhang L, 2008, P NATL ACAD SCI USA, V105, P7004, DOI 10.1073/pnas.0801615105	50	255	267	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2014	33	44					5173	5182		10.1038/onc.2013.451	http://dx.doi.org/10.1038/onc.2013.451			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR9RZ	24166498				2022-12-17	WOS:000343914900004
J	Sinibaldi, D; Wharton, W; Turkson, J; Bowman, T; Pledger, WJ; Jove, R				Sinibaldi, D; Wharton, W; Turkson, J; Bowman, T; Pledger, WJ; Jove, R			Induction of p21(WAF1/CIP1) and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: Role of activated STAT3 signaling	ONCOGENE			English	Article						cell cycle control; Src oncoprotein; STAT3; cyclin D1; p21; WAF1/CIP1	DEPENDENT KINASE INHIBITOR; EPIDERMAL GROWTH-FACTOR; PERIPHERAL-BLOOD CELLS; DNA-BINDING ACTIVITY; TRANSCRIPTIONAL ACTIVATION; CONSTITUTIVE ACTIVATION; V-SRC; CDK INHIBITORS; CELLULAR-TRANSFORMATION; POTENTIAL MEDIATOR	While the activated viral Src oncoprotein, v-Src, induces uncontrolled cell growth, the mechanisms underlying cell cycle deregulation by v-Src have not been fully defined. Previous studies demonstrated that v-Src induces constitutively active STAT3 signaling that is required for cell transformation and recent data have implicated STAT3 in the transcriptional control of critical cell cycle regulators. Here we show in mouse fibroblasts stably transformed by v-Src that mRNA and protein levels of p21 (WAF1/CIP1), cyclin D1, and cyclin E are elevated. Using reporter constructs in transient-transfection assays, the cyclin D1 and p21 promoters were both found to be transcriptionaly induced by v-Src in a STAT3-dependent manner. The kinase activities of cyclin D/CDK4, 6 and cyclin E/CDK2 complexes were only slightly elevated, consistent with the findings that coordinate increases in p21, cyclin D1 and cyclin E resulted in an increase in cyclin/CDK/p21 complexes. Similar results were obtained in NTH3T3 and BALB/c 3T3 cells stably transformed by v-Src, indicating that these regulatory events associated with STAT3 signaling represent common mechanisms independent of cell line or clonal variation. These findings suggest that STAT3 has an essential role in the regulation of critical cell cycle components in v-Src transformed mouse fibroblasts.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Oncol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Pathol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Jove, R (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.				NATIONAL CANCER INSTITUTE [R01CA067360, R01CA055652] Funding Source: NIH RePORTER; NCI NIH HHS [CA55652, CA67360] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akira S, 1999, STEM CELLS, V17, P138, DOI 10.1002/stem.170138; Barboule N, 1998, INT J CANCER, V76, P891, DOI 10.1002/(SICI)1097-0215(19980610)76:6<891::AID-IJC20>3.0.CO;2-4; Bellido T, 1998, J BIOL CHEM, V273, P21137, DOI 10.1074/jbc.273.33.21137; Besser D, 1999, MOL CELL BIOL, V19, P1401; Botz J, 1996, MOL CELL BIOL, V16, P3401; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, CELL GROWTH DIFFER, V9, P505; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Carnero A, 1998, CURR TOP MICROBIOL, V227, P43; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Catlett-Falcone Robyn, 1999, Current Opinion in Oncology, V11, P490, DOI 10.1097/00001622-199911000-00010; Chai SK, 1997, J IMMUNOL, V159, P4720; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Erber R, 1997, INT J CANCER, V74, P383, DOI 10.1002/(SICI)1097-0215(19970822)74:4<383::AID-IJC4>3.0.CO;2-R; Florenes VA, 1999, ONCOGENE, V18, P1023, DOI 10.1038/sj.onc.1202382; Frank DA, 1999, MOL MED, V5, P432; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Garcia R, 1998, J BIOMED SCI, V5, P79, DOI 10.1159/000025316; Geng Y, 1996, ONCOGENE, V12, P1173; GouilleuxGruart V, 1996, BLOOD, V87, P1692; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Hauser PJ, 1998, CELL GROWTH DIFFER, V9, P847; Hibberts NA, 1999, CLIN CANCER RES, V5, P2133; Hiyama H, 1997, ONCOGENE, V14, P2533, DOI 10.1038/sj.onc.1201080; Johnson D, 1998, ONCOGENE, V16, P2017, DOI 10.1038/sj.onc.1201727; Johnson MR, 1998, ONCOGENE, V16, P2647, DOI 10.1038/sj.onc.1201789; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; Karni R, 1999, ONCOGENE, V18, P4654, DOI 10.1038/sj.onc.1202835; Kenny FS, 1999, CLIN CANCER RES, V5, P2069; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; Lee SJ, 1998, J BIOL CHEM, V273, P10618, DOI 10.1074/jbc.273.17.10618; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Lonardo F, 1999, CANCER RES, V59, P2470; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Qin LF, 1998, INT J CANCER, V79, P424, DOI 10.1002/(SICI)1097-0215(19980821)79:4<424::AID-IJC19>3.0.CO;2-4; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shimizu M, 1999, CANCER, V85, P669, DOI 10.1002/(SICI)1097-0142(19990201)85:3<669::AID-CNCR17>3.0.CO;2-F; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; WeberNordt RM, 1996, BLOOD, V88, P809; Wen X, 1999, J BIOL CHEM, V274, P38204, DOI 10.1074/jbc.274.53.38204; Winston J, 1996, J BIOL CHEM, V271, P11253, DOI 10.1074/jbc.271.19.11253; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zong CS, 1998, J BIOL CHEM, V273, P28065, DOI 10.1074/jbc.273.43.28065	72	255	276	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 16	2000	19	48					5419	5427		10.1038/sj.onc.1203947	http://dx.doi.org/10.1038/sj.onc.1203947			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375JQ	11114718				2022-12-17	WOS:000165396100001
J	Kim, I; Kim, JH; Moon, SO; Kwak, HJ; Kim, NG; Koh, GY				Kim, I; Kim, JH; Moon, SO; Kwak, HJ; Kim, NG; Koh, GY			Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3 '-kinase/Akt signal transduction pathway	ONCOGENE			English	Article						angiopoietin-2; endothelial cells; apoptosis; PI 3 '-kinase; Akt	TIE2 RECEPTOR; ANGIOGENESIS; EXPRESSION; GROWTH; PHOSPHORYLATION; MECHANISMS; LIGANDS; CLONING; HYPOXIA; VEGF	The angiopoietin-Tie2 system in endothelial cells is an important regulator of vasculogenesis and vascular integrity, High levels of angiopoietin-2 (Ang2) mRNA are observed in vascular activation during tumorigenesis. Although Ang2 is known to be a naturally occurring antagonist of angiopoietin-1 (Ang1) in vivo, the exact function of Ang2 itself is not known. Here, we found that a high concentration of Ang2 (800 ng/ml) acts as an apoptosis survival factor for endothelial cells during serum deprivation apoptosis, The survival effect of high concentration Ang2 was blocked by pre-treatment with soluble Tie2 receptor and the PI 3'-kinase-specific inhibitors, wortmannin and LY294002. Accordingly, 800 ng/ml of Ang2 induced phosphorylation of Tie2, the p85 subunit of phosphatidylinositol 3'-kinase (PI 3'-kinase), and serine-threonine kinase Akt at Ser473 in the human umbilical vein endothelial cells; lower concentrations of Ang2 (50-400 ng/ml) did not produce notable effects. These findings indicate that at high concentrations, Ang2, like Ang1, can be an apoptosis survival factor for endothelial cells through the activation of the Tie2 receptor, PI 3'-kinase and Akt, and thus may be a positive regulator of tumor angiogenesis.	Chonbuk Univ, Sch Med, Natl Creat Res Initiat Ctr Cardiac Regenerat, Chonju 560180, South Korea; Chonbuk Univ, Sch Med, Cardiovasc Res Inst, Chonju 560180, South Korea; Chonbuk Univ, Sch Med, Dept Biomed Engn, Chonju 560180, South Korea	Jeonbuk National University; Jeonbuk National University; Jeonbuk National University	Koh, GY (corresponding author), Chonbuk Univ, Sch Med, Natl Creat Res Initiat Ctr Cardiac Regenerat, San 2-20, Chonju 560180, South Korea.		Koh, Gou Young/C-1615-2011; Kim, Injune/C-1710-2011	Kim, Injune/0000-0001-9244-815X				Asahara T, 1998, CIRC RES, V83, P233, DOI 10.1161/01.RES.83.3.233; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Dunk C, 2000, AM J PATHOL, V156, P2185, DOI 10.1016/S0002-9440(10)65089-4; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Kim I, 2000, J BIOL CHEM, V275, P18550, DOI 10.1074/jbc.M910084199; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; Kim I, 1999, J BIOL CHEM, V274, P26523, DOI 10.1074/jbc.274.37.26523; Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2; Kwak HJ, 1999, FEBS LETT, V448, P249, DOI 10.1016/S0014-5793(99)00378-6; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Mandriota SJ, 1998, CIRC RES, V83, P852, DOI 10.1161/01.RES.83.8.852; Oh H, 1999, J BIOL CHEM, V274, P15732, DOI 10.1074/jbc.274.22.15732; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; Papapetropoulos A, 1999, LAB INVEST, V79, P213; RISAU W, 1995, FASEB J, V9, P926, DOI 10.1096/fasebj.9.10.7615161; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Shyu KG, 1998, CIRCULATION, V98, P2081, DOI 10.1161/01.CIR.98.19.2081; Stratmann A, 1998, AM J PATHOL, V153, P1459, DOI 10.1016/S0002-9440(10)65733-1; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; Tanaka S, 1999, J CLIN INVEST, V103, P341, DOI 10.1172/JCI4891; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Witzenbichler B, 1998, J BIOL CHEM, V273, P18514, DOI 10.1074/jbc.273.29.18514	28	255	270	0	12	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 14	2000	19	39					4549	4552		10.1038/sj.onc.1203800	http://dx.doi.org/10.1038/sj.onc.1203800			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352UT	11002428				2022-12-17	WOS:000089236800012
J	Vrana, JA; Decker, RH; Johnson, CR; Wang, Z; Jarvis, WD; Richon, VM; Ehinger, M; Fisher, PB; Grant, S				Vrana, JA; Decker, RH; Johnson, CR; Wang, Z; Jarvis, WD; Richon, VM; Ehinger, M; Fisher, PB; Grant, S			Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-X-L, c-Jun, and p21(CIP1), but independent of p53	ONCOGENE			English	Article						SAHA; HMBA; apoptosis; differentiation; leukemia; p53	HISTONE DEACETYLASE INHIBITORS; DOMINANT-NEGATIVE MUTANT; RETINOBLASTOMA PROTEIN; TRICHOSTATIN-A; CYCLE ARREST; HL-60 CELLS; DNA-DAMAGE; DIFFERENTIATION; KINASE; EXPRESSION	Determinants of differentiation and apoptosis in myelomonocytic leukemia cells (U937) exposed to the novel hybrid polar compound SAHA. (suberoylanilide hydroxamic acid) have been examined, In contrast to hexamethylenbisacetamide (HMBA), SAHA-related maturation was limited and accompanied by marked cytoxicity. SAHA-mediated apoptosis occurred within the G(0)G(1) and S phase populations, and,vas associated with decreased mitochondrial membrane potential, caspase-3 activation, PARP degradation, hypophosphorylation/cleavage of pRB, and down-regulation of c-Myc, c-Myb, and B-Myb. Enforced expression of Bcl-2 or Bcl-x(L), inhibited SAHA-induced apoptosis, but only modestly potentiated differentiation. While SAHA induced the cyclin-dependent kinase inhibitor p21(CIP1), antisense ablation of this CDKI increased, rather than decreased, SAHA-related lethality, In contrast, conditional expression of mild-type p53 failed to modify SAHA actions, but markedly potentiated HMBA-induced apoptosis. Finally, SAHA modestly increased expression/activation of the stress-activated protein kinase (SAPK/JNK); moreover, SAHA-related lethality was partially attenuated by a dominant-negative c-jun mutant protein (TAM67). SAHA did not stimulate mitogen-activated protein kinase (MAPK), nor was Lethality diminished by the specific MEK/MAPK inhibitor PD98059. These findings indicate that SAHA potently induces apoptosis in human leukemia cells via a pathway that is p53-independent but at least partially regulated by Bcl-2/Bcl-x(L), p21(CIP1), and the c-Jun/AP-1 signaling cascade.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Med, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Biochem, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Microbiol, Richmond, VA 23298 USA; Mem Sloan Kettering Canc Ctr, Dept Dev Cell Biol & Genet, New York, NY 10021 USA; Univ Lund Hosp, Res Dept 2, S-22185 Lund, Sweden; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Urol, New York, NY 10032 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Memorial Sloan Kettering Cancer Center; Lund University; Skane University Hospital; Columbia University; Columbia University	Grant, S (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Med, MCV Stn Box 230, Richmond, VA 23298 USA.		Ehinger, Mats/H-8457-2016	Ehinger, Mats/0000-0003-2342-1679	NATIONAL CANCER INSTITUTE [R03CA077141, R01CA063753, P01CA072955] Funding Source: NIH RePORTER; NCI NIH HHS [CA77141, CA72955, CA63753] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREEFF M, 1992, BLOOD, V80, P2604; Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; BROWN PH, 1994, ONCOGENE, V9, P791; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; Dangond F, 1998, BIOCHEM BIOPH RES CO, V247, P833, DOI 10.1006/bbrc.1998.8891; DEVENTE J, 1995, CELL GROWTH DIFFER, V6, P371; Dong ZG, 1997, MOL CARCINOGEN, V19, P204, DOI 10.1002/(SICI)1098-2744(199707)19:3<204::AID-MC8>3.0.CO;2-D; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Ehinger M, 1996, BLOOD, V87, P1064, DOI 10.1182/blood.V87.3.1064.bloodjournal8731064; Franklin CC, 1995, ONCOGENE, V11, P2365; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; Grant S, 1996, EXP CELL RES, V228, P65, DOI 10.1006/excr.1996.0300; Grant S, 1996, CELL GROWTH DIFFER, V7, P603; HASS R, 1991, CELL GROWTH DIFFER, V2, P541; JIANG HP, 1994, ONCOGENE, V9, P3397; KHARBANDA S, 1994, J BIOL CHEM, V269, P872; MARTIN SJ, 1990, CLIN EXP IMMUNOL, V79, P448; McBain JA, 1997, BIOCHEM PHARMACOL, V53, P1357, DOI 10.1016/S0006-2952(96)00904-5; Medina V, 1997, CANCER RES, V57, P3697; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; NAUMOVSKI L, 1994, BLOOD, V83, P2261; Ogryzko VV, 1996, MOL CELL BIOL, V16, P5210; OHTA H, 1995, CANCER RES, V55, P691; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Richon VM, 1996, P NATL ACAD SCI USA, V93, P5705, DOI 10.1073/pnas.93.12.5705; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; Salminen A, 1998, MOL BRAIN RES, V61, P203, DOI 10.1016/S0169-328X(98)00210-1; SELVAKUMARAN M, 1994, BLOOD, V84, P1036; STEINMAN RA, 1994, ONCOGENE, V9, P3389; SUGIMOTO K, 1992, BLOOD, V79, P2378, DOI 10.1182/blood.V79.9.2378.2378; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; Tang H, 1998, J BIOL CHEM, V273, P29156, DOI 10.1074/jbc.273.44.29156; Thompson MA, 1998, CANCER RES, V58, P5168; Vaziri C, 1998, CELL GROWTH DIFFER, V9, P465; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Vrana JA, 1998, DIFFERENTIATION, V63, P33, DOI 10.1046/j.1432-0436.1998.6310033.x; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wang SJ, 1997, MOL PHARMACOL, V52, P1000, DOI 10.1124/mol.52.6.1000; Wang ZL, 1998, EXP CELL RES, V244, P105, DOI 10.1006/excr.1998.4191; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yen A, 1998, CANCER RES, V58, P3163	42	255	284	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					7016	7025		10.1038/sj.onc.1203176	http://dx.doi.org/10.1038/sj.onc.1203176			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597302				2022-12-17	WOS:000083901900008
J	FERRACINI, R; DIRENZO, MF; SCOTLANDI, K; BALDINI, N; OLIVERO, M; LOLLINI, P; CREMONA, O; CAMPANACCI, M; COMOGLIO, PM				FERRACINI, R; DIRENZO, MF; SCOTLANDI, K; BALDINI, N; OLIVERO, M; LOLLINI, P; CREMONA, O; CAMPANACCI, M; COMOGLIO, PM			THE MET/HGF RECEPTOR IS OVER-EXPRESSED IN HUMAN OSTEOSARCOMAS AND IS ACTIVATED BY EITHER A PARACRINE OR AN AUTOCRINE CIRCUIT	ONCOGENE			English	Article						OSTEOSARCOMA; GROWTH FACTORS; TYROSINE KINASE RECEPTOR	HEPATOCYTE GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; HUMAN MET PROTOONCOGENE; FACTOR SCATTER FACTOR; SINGLE CHAIN FORM; C-MET; EPITHELIAL-CELLS; PHOSPHATASE-ACTIVITY; MOLECULAR-CLONING; HEPATOPOIETIN-A	The c-MET oncogene encodes the receptor for the Hepatocyte Growth Factor/Scatter Factor (HGF), a cytokine that stimulates the invasive growth of normal and neoplastic cells. The Met/HGF receptor is expressed by epithelial cells and its ligand by cells of mesenchymal origin. Receptor-ligand interaction occurs via a paracrine circuit. We studied the expression of the Met/HGF receptor and of its ligand in mesenchymal human tumours by examining 39 clinical samples of bone tumours. The Met/HGF receptor was not detectable in the majority of bone tumours, as expected from their mesenchymal origin. Notably, the receptor was overexpressed in 60% of the osteosarcomas examined. In 12 osteosarcoma cell lines the Met/HGF receptor was overexpressed, phosphorylated by HGF stimulation and fully functional, HGF was detected in two out of seven clinical specimens of osteosarcoma. The ligand and the receptor are co-expressed in two clonal osteosarcoma cell lines. In these lines the Met/HGF receptor was constitutively phosphorylated; phosphorylation was suppressed by suramin treatment, a known blocker of autocrine loops. These data suggest that activation of the Met/HGF receptor by a paracrine or an autocrine mechanism might play a role in the particularly aggressive behaviour of osteosarcomas.	UNIV SASSARI, SCH MED, IST ISTOL & EMBRIOL, I-07100 SASSARI, ITALY; UNIV TURIN, SCH MED, IRCC, TURIN, ITALY; UNIV TURIN, SCH MED, DEPT MED SCI, TURIN, ITALY; IST ORTOPED RIZZOLI, BOLOGNA, ITALY; UNIV BOLOGNA, SCH MED, INST CANC, BOLOGNA, ITALY	University of Sassari; University of Turin; University of Turin; IRCCS Istituto Ortopedico Rizzoli; University of Bologna	FERRACINI, R (corresponding author), SALUZZO GEN HOSP, SALUZZO, ITALY.		olivero, martina/J-4811-2018; Cremona, Ottavio/AAB-8793-2019; Baldini, Nicola/J-4806-2016; Ferracini, Riccardo/AAL-4622-2020; DI RENZO, Maria Flavia/B-6091-2012; Lollini, Pier Luigi/A-7644-2008; Scotlandi, Katia/J-9009-2016	olivero, martina/0000-0002-6815-3498; Cremona, Ottavio/0000-0001-9462-1040; Baldini, Nicola/0000-0003-2228-3833; DI RENZO, Maria Flavia/0000-0002-5093-3373; Lollini, Pier Luigi/0000-0003-1702-4108; Scotlandi, Katia/0000-0001-6114-9499; Comoglio, Paolo/0000-0002-7056-5328				ARAKI N, 1991, CLIN ORTHOP RELAT R, V270, P271; ASHIHARA T, 1986, ACTA HISTOCHEM CYTOC, V19, P51, DOI 10.1267/ahc.19.51; BELLUSCI S, 1994, ONCOGENE, V9, P1091; BERNIER M, 1987, P NATL ACAD SCI USA, V84, P1844, DOI 10.1073/pnas.84.7.1844; BOCCACCIO C, 1994, J BIOL CHEM, V269, P12846; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BROWDER TM, 1989, CANCER CELL-MON REV, V1, P9; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Campanacci M., 1990, BONE SOFT TISSUE TUM, V2nd, P455; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COGLIANO A, 1991, BONE, V12, P365, DOI 10.1016/8756-3282(91)90024-D; COMOGLIO PM, 1993, HEPATOCYTE GROWTH FA, P131; COOPER CS, 1986, EMBO J, V5, P2623, DOI 10.1002/j.1460-2075.1986.tb04543.x; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DIRENZO MF, 1992, ONCOGENE, V7, P2549; DIRENZO MF, 1994, INT J CANCER, V58, P658, DOI 10.1002/ijc.2910580507; ENNEKING WF, 1991, CLIN MUSCULOSKELETAL, P411; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; FERRACINI R, 1993, IT J MINERAL ELECTRO, V3, P199; GALIMI F, 1994, UNPUB J CELL BIOL; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; GOHJI K, 1994, JPN J CANCER RES, V85, P152, DOI 10.1111/j.1349-7006.1994.tb02076.x; GOORIN AM, 1981, SURG CLIN N AM, V61, P1379; GRANO M, 1994, J BONE MINER RES, V9, P1013; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KANDA H, 1993, ONCOGENE, V8, P3047; KUNIYASU H, 1993, INT J CANCER, V55, P72, DOI 10.1002/ijc.2910550114; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU C, 1992, ONCOGENE, V7, P181; MARS WM, 1993, AM J PATHOL, V143, P949; MASUMOTO A, 1991, BIOCHEM BIOPH RES CO, V174, P90, DOI 10.1016/0006-291X(91)90489-T; MILLER CW, 1990, CANCER RES, V50, P7950; MIURA Y, 1993, CLIN ORTHOP RELAT R, V300, P225; MIYAZAWA K, 1993, J BIOL CHEM, V268, P10024; MIZUNO K, 1992, BIOCHEM BIOPH RES CO, V189, P1631, DOI 10.1016/0006-291X(92)90264-L; NAKA D, 1992, J BIOL CHEM, V267, P20114; NAKAMURA S, 1994, CYTOKINE, V6, P285, DOI 10.1016/1043-4666(94)90025-6; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; PONZETTO C, 1991, ONCOGENE, V6, P553; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; RONG S, 1993, CANCER RES, V53, P5355; RONG S, 1993, CELL GROWTH DIFFER, V4, P563; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; ROSEN EM, 1994, INT J CANCER, V57, P706, DOI 10.1002/ijc.2910570517; SCOTLANDI K, 1992, ANN ONCOL, V3, pS29, DOI 10.1093/annonc/3.suppl_2.S29; SCOTLANDI K, 1993, INT J ONCOL, V3, P963; SHIMOMURA T, 1992, CYTOTECHNOLOGY, V8, P219, DOI 10.1007/BF02522039; SHIMOMURA T, 1993, J BIOL CHEM, V268, P22927; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN GS, 1990, FASEB J, V4, P3111, DOI 10.1096/fasebj.4.13.2210157; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TEBBI CK, 1988, PEDIATR ANN, V17, P285, DOI 10.3928/0090-4481-19880401-08; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAO MS, 1993, CELL GROWTH DIFFER, V4, P571; TSUBOUCHI H, 1991, HEPATOLOGY, V13, P1; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; WU JX, 1990, ONCOGENE, V5, P989; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; ZARNEGAR R, 1989, CANCER RES, V49, P3314; ZHEN Z, 1994, ONCOGENE, V9, P1691	77	255	265	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	1995	10	4					739	749						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862451				2022-12-17	WOS:A1995QH61200014
J	Proikas-Cezanne, T; Waddell, S; Gaugel, A; Frickey, T; Lupas, A; Nordheim, A				Proikas-Cezanne, T; Waddell, S; Gaugel, A; Frickey, T; Lupas, A; Nordheim, A			WIPI-1 alpha (WIPI49), a member of the novel 7-bladed WIPI protein family, is aberrantly expressed in human cancer and is linked to starvation-induced autophagy	ONCOGENE			English	Article						WD-repeat; ATG18; WIPI49; tumor; homology modeling; autophagy	WD-REPEAT PROTEIN; VACUOLE TARGETING PATHWAY; CELL-DEATH; SACCHAROMYCES-CEREVISIAE; BETA-SUBUNIT; CYTOPLASM; IDENTIFICATION; ARCHITECTURE; SUPERFAMILY; PEXOPHAGY	WD-repeat proteins are regulatory beta-propeller platforms that enable the assembly of multiprotein complexes. Here, we report the functional and bioinformatic analysis of human WD-repeat protein Interacting with Phospho-Inosides (WIPI)-1alpha (WIPI49/Atg18), a member of a novel WD-repeat protein family with autophagic capacity in Saccharomyces cerevisiae and Caenorhabditis elegans, recently identified as phospholipid-binding effectors. Our phylogenetic analysis divides the WIPI protein family into two paralogous groups that fold into 7-bladed beta-propellers. Structural modeling identified two evolutionary conserved interaction sites in WIPI propellers, one of which may bind phospholipids. Human WIPI-1alpha has LXXLL signature motifs for nuclear receptor interactions and binds androgen and estrogen receptors in vitro. Strikingly, human WIPI genes were found aberrantly expressed in a variety of matched tumor tissues including kidney, pancreatic and skin cancer. We found that endogenous hWIPI-1 protein colocalizes in part with the autophagosomal marker LC3 at punctate cytoplasmic structures in human melanoma cells. In addition, hWIPI-1 accumulated in large vesicular and cup-shaped structures in the cytoplasm when autophagy was induced by amino-acid deprivation. These cytoplasmic formations were blocked by wortmannin, a classic inhibitor of PI-3 kinase-mediated autophagy. Our data suggest that WIPI proteins share an evolutionary conserved function in autophagy and that autophagic capacity may be compromised in human cancers.	Univ Tubingen, Inst Cell Biol, Dept Mol Biol, Tubingen, Germany; Univ Massachusetts, Sch Med, Dept Neurobiol, Worcester, MA USA; Max Planck Inst Dev Biol, Tubingen, Germany; Univ Tubingen, Inst Cell Biol, Proteome Ctr Tuebingen, Tubingen, Germany	Eberhard Karls University of Tubingen; University of Massachusetts System; University of Massachusetts Worcester; Max Planck Society; Eberhard Karls University of Tubingen	Proikas-Cezanne, T (corresponding author), Univ Tubingen, Inst Cell Biol, Dept Mol Biol, Morgenstelle 15, Tubingen, Germany.	tassula.proikas-cezanne@uni-tuebingen.de		Waddell, Scott/0000-0003-4503-6229; Proikas-Cezanne, Prof. Dr. Tassula/0000-0001-6934-132X				Barth H, 2001, FEBS LETT, V508, P23, DOI 10.1016/S0014-5793(01)03016-2; Blommaart EFC, 1997, EUR J BIOCHEM, V243, P240, DOI 10.1111/j.1432-1033.1997.0240a.x; Chernova OB, 2001, ONCOGENE, V20, P5378, DOI 10.1038/sj.onc.1204694; Cuff JA, 2000, PROTEINS, V40, P502, DOI 10.1002/1097-0134(20000815)40:3<502::AID-PROT170>3.0.CO;2-Q; Dove SK, 2004, EMBO J, V23, P1922, DOI 10.1038/sj.emboj.7600203; Edinger AL, 2003, CANCER CELL, V4, P422, DOI 10.1016/S1535-6108(03)00306-4; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; Frickey T, 2004, BIOINFORMATICS; FRUCHTERMAN TMJ, 1991, SOFTWARE PRACT EXPER, V21, P1129, DOI 10.1002/spe.4380211102; Garcia-Higuera I, 1998, J BIOL CHEM, V273, P9041, DOI 10.1074/jbc.273.15.9041; GarciaHiguera I, 1996, BIOCHEMISTRY-US, V35, P13985, DOI 10.1021/bi9612879; Georgakopoulos T, 2001, YEAST, V18, P1155, DOI 10.1002/yea.764; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Guan J, 2001, MOL BIOL CELL, V12, P3821, DOI 10.1091/mbc.12.12.3821; Honore B, 2002, ONCOGENE, V21, P1123, DOI 10.1038/sj.onc.1205186; Jeffries TR, 2004, MOL BIOL CELL, V15, P2652, DOI 10.1091/mbc.E03-10-0732; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Klionsky DJ, 2004, NATURE, V431, P31, DOI 10.1038/431031a; Lee CY, 2001, DEVELOPMENT, V128, P1443; Li D, 2001, CELL MOL LIFE SCI, V58, P2085, DOI 10.1007/PL00000838; Melendez A, 2003, SCIENCE, V301, P1387, DOI 10.1126/science.1087782; MITCHENER JS, 1976, AM J PATHOL, V83, P485; Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704; Mizushima N, 2003, J CELL SCI, V116, P1679, DOI 10.1242/jcs.00381; Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421; Munafo DB, 2001, J CELL SCI, V114, P3619; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; Paoli M, 2001, PROG BIOPHYS MOL BIO, V76, P103, DOI 10.1016/S0079-6107(01)00007-4; Paoli M, 2001, NAT STRUCT BIOL, V8, P744, DOI 10.1038/nsb0901-744; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; Puntervoll P, 2003, NUCLEIC ACIDS RES, V31, P3625, DOI 10.1093/nar/gkg545; SALI A, 1995, PROTEINS, V23, P318, DOI 10.1002/prot.340230306; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Simonsen A, 2004, J CELL SCI, V117, P4239, DOI 10.1242/jcs.01287; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Stromhaug PE, 2004, MOL BIOL CELL, V15, P3553, DOI 10.1091/mbc.E04-02-0147; Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009; Van de Peer Y, 2002, GENE, V295, P205, DOI 10.1016/S0378-1119(02)00689-3; van Nocker S, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-50; Waddell S, 2001, ONCOGENE, V20, P6001, DOI 10.1038/sj.onc.1204702; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Yu LH, 2000, PROTEIN SCI, V9, P2470, DOI 10.1110/ps.9.12.2470	47	254	273	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2004	23	58					9314	9325		10.1038/sj.onc.1208331	http://dx.doi.org/10.1038/sj.onc.1208331			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT	15602573				2022-12-17	WOS:000225764100003
J	Hastak, K; Gupta, S; Ahmad, N; Agarwal, MK; Agarwal, ML; Mukhtar, H				Hastak, K; Gupta, S; Ahmad, N; Agarwal, MK; Agarwal, ML; Mukhtar, H			Role of p53 and NF-kappa B in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells	ONCOGENE			English	Article						epigallocatechin-3-gallate; prostate cancer; p53; NF-kappa B; Bax; Bcl-2; caspases; apoptosis	TEA CONSTITUENT (-)-EPIGALLOCATECHIN-3-GALLATE; CYCLE ARREST; GROWTH-INHIBITION; GREEN; ACTIVATION; EXPRESSION; PHOSPHORYLATION; GALLATE; FAMILY; GENES	We have recently shown that oral consumption of green tea polyphenols inhibits prostate carcinogenesis in transgenic mouse model of prostate cancer and suggested that induction of apoptosis in prostate cancer cells is responsible for these effects. Much of the chemopreventive effects of green tea are attributed to its major polyphenolic constituent (-) epigallocatechin-3-gallate (EGCG). In the present study, we report that EGCG-induced apoptosis in human prostate carcinoma LNCaP cells is mediated via modulation of two related pathways: (a) stabilization of p53 by phosphorylation on critical serine residues and p14(ARF)-mediated downregulation of murine double minute 2(MDM2) protein, and (b) negative regulation of NF-kappaB activity, thereby decreasing the expression of the proapoptotic protein Bcl-2. EGCG-induced stabilization of p53 caused an upregulation in its transcriptional activity, thereby resulting in activation of its downstream targets p21/WAF1 and Bax. Thus, EGCG had a concurrent effect on two important transcription factors p53 and NF-kappaB, causing a change in the ratio of Bax/Bcl-2 in a manner that favors apoptosis. This altered expression of Bcl-2 family members triggered the activation of initiator capsases 9 and 8 followed by activation of effector caspase 3. Activation of the caspases was followed by poly (ADP-ribose) polymerase cleavage and induction of apoptosis. Taken together, the data indicate that EGCG induces apoptosis in human prostate carcinoma cells by shifting the balance between pro- and antiapoptotic proteins in favor of apoptosis.	Univ Wisconsin, Dept Dermatol, Madison, WI 53706 USA; Case Western Reserve Univ, Dept Environm Hlth Sci, Cleveland, OH 44106 USA; Cleveland Clin, Dept Mol Biol, Learner Res Inst, Cleveland, OH 44106 USA; Case Western Reserve Univ, Jim & Eillen Dicke Res Lab, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Inst Res, Cleveland, OH 44106 USA	University of Wisconsin System; University of Wisconsin Madison; Case Western Reserve University; Cleveland Clinic Foundation; Case Western Reserve University; University Hospitals of Cleveland	Mukhtar, H (corresponding author), Univ Wisconsin, Dept Dermatol, Madison, WI 53706 USA.	hmukhtar@wisc.edu		Gupta, Sanjay/0000-0002-9492-3249	NATIONAL CANCER INSTITUTE [R01CA078809] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 78809] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Ahmad N, 2000, ARCH BIOCHEM BIOPHYS, V376, P338, DOI 10.1006/abbi.2000.1742; Ahmad N, 1997, JNCI-J NATL CANCER I, V89, P1881, DOI 10.1093/jnci/89.24.1881; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; Budram-Mahadeo V, 2002, ONCOGENE, V21, P6123, DOI 10.1038/sj.onc.1205842; Burns TF, 2001, ONCOGENE, V20, P4601, DOI 10.1038/sj.onc.1204484; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chen ZP, 1998, CANCER LETT, V129, P173, DOI 10.1016/S0304-3835(98)00108-6; Conney AH, 1999, P SOC EXP BIOL MED, V220, P229, DOI 10.1046/j.1525-1373.1999.d01-39.x; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Fotedar R, 1999, ONCOGENE, V18, P3652, DOI 10.1038/sj.onc.1202693; Gartel AL, 2002, MOL CANCER THER, V1, P639; Gupta S, 2000, TOXICOL APPL PHARM, V164, P82, DOI 10.1006/taap.1999.8885; Gupta S, 2003, ARCH BIOCHEM BIOPHYS, V410, P177, DOI 10.1016/S0003-9861(02)00668-9; Gupta S, 2001, P NATL ACAD SCI USA, V98, P10350, DOI 10.1073/pnas.171326098; Jackson MW, 2001, J BIOL CHEM, V276, P25336, DOI 10.1074/jbc.M010685200; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kuo PL, 2003, J BIOMED SCI, V10, P219, DOI 10.1159/000068711; Levites Y, 2002, J BIOL CHEM, V277, P30574, DOI 10.1074/jbc.M202832200; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; Otsuka T, 1998, LIFE SCI, V63, P1397, DOI 10.1016/S0024-3205(98)00406-8; Pianetti S, 2002, CANCER RES, V62, P652; Sheikh MS, 2000, J CELL PHYSIOL, V182, P171, DOI 10.1002/(SICI)1097-4652(200002)182:2<171::AID-JCP5>3.0.CO;2-3; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Shibata MA, 2001, CANCER GENE THER, V8, P23, DOI 10.1038/sj.cgt.7700275; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; TOHYAMA M, 1999, BIOL CHEM, V274, P8531; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vogelstein B, 2001, NATURE, V412, P865, DOI 10.1038/35091170; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Weisburger JH, 1999, P SOC EXP BIOL MED, V220, P271, DOI 10.1046/j.1525-1373.1999.d01-46.x; Wu XW, 2002, FRONT BIOSCI, V7, pD151, DOI 10.2741/wu1; Yang CS, 2000, J NUTR, V130, p472S, DOI 10.1093/jn/130.2.472S; Yang GY, 1998, CARCINOGENESIS, V19, P611, DOI 10.1093/carcin/19.4.611; Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0	44	254	279	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2003	22	31					4851	4859		10.1038/sj.onc.1206708	http://dx.doi.org/10.1038/sj.onc.1206708			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894226				2022-12-17	WOS:000184344600008
J	Umbricht, CB; Evron, E; Gabrielson, E; Ferguson, A; Marks, J; Sukumar, S				Umbricht, CB; Evron, E; Gabrielson, E; Ferguson, A; Marks, J; Sukumar, S			Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer	ONCOGENE			English	Article						breast cancer; 14-3-3 sigma; methylation; MSP; DCIS; preneoplasia	DNA METHYLATION; ADJACENT; TISSUE; LEADS; CELLS	We have identified 14-3-3 sigma (sigma) as a gene whose expression is lost in breast carcinomas, primarily by methylation-mediated silencing. In this report, we investigated the timing of loss of sigma gene expression during breast tumorigenesis in vivo. We analysed the methylation status of sigma in breast cancer precursor lesions using microdissection for selective tissue sampling. We found hypermethylation of sigma in 24 of 25 carcinomas (96%), 15 of 18 (83%) of ductal carcinoma in situ, and three of eight (38%) of atypical hyperplasias. None of the five hyperplasias without atypia showed sigma -hypermethylation. Unexpectedly, patients with breast cancer showed sigma hypermethylation in adjacent histologically normal breast epithelium, while this was never observed in individuals without evidence of breast cancer. Also, samples of periductal stromal breast tissue were consistently hypermethylated, underscoring the importance of selective tissue sampling for accurate assessment of 14-3-3-sigma methylation in breast epithelium, These results suggest that hypermethylation of 14-3-3-sigma occurs at an early stage in the progression to invasive breast cancer, and may occur in apparently normal epithelium adjacent to breast cancer. These results provide evidence that loss of expression of sigma is an early event in neoplastic transformation.	Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21231 USA; Mol Devices Corp, Sunnyvale, CA 94085 USA; Duke Univ, Med Ctr, Durham, NC 27710 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Duke University	Sukumar, S (corresponding author), Johns Hopkins Oncol Ctr, Breast Canc Program, CCRB Room 410,1650 Orleans St, Baltimore, MD 21231 USA.			Evron, Ella/0000-0002-1003-5042	NCI NIH HHS [P21 CA/ES 66204, P50 CA88843-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA088843] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baylin SB, 1998, ADV CANCER RES, V72, P141; Botti C, 2000, J AM COLL SURGEONS, V190, P530, DOI 10.1016/S1072-7515(00)00252-0; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Dellambra E, 2000, J CELL BIOL, V149, P1117, DOI 10.1083/jcb.149.5.1117; Deng GR, 1996, SCIENCE, V274, P2057, DOI 10.1126/science.274.5295.2057; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Nacht M, 1999, CANCER RES, V59, P5464; PRASAD GL, 1992, CELL GROWTH DIFFER, V3, P507; Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461; Sidransky D, 1997, SCIENCE, V278, P1054, DOI 10.1126/science.278.5340.1054; Soria JC, 1999, CLIN CANCER RES, V5, P971; Umbricht CB, 1999, ONCOGENE, V18, P3407, DOI 10.1038/sj.onc.1202714	15	254	271	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2001	20	26					3348	3353		10.1038/sj.onc.1204438	http://dx.doi.org/10.1038/sj.onc.1204438			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	441UW	11423985				2022-12-17	WOS:000169248800005
J	Landesman-Bollag, E; Romieu-Mourez, R; Song, DH; Sonenshein, GE; Cardiff, RD; Seldin, DC				Landesman-Bollag, E; Romieu-Mourez, R; Song, DH; Sonenshein, GE; Cardiff, RD; Seldin, DC			Protein kinase CK2 in mammary gland tumorigenesis	ONCOGENE			English	Article						casein kinase II; CK2; transgenic mice; breast cancer; NF-kappa B; beta-catenin	NF-KAPPA-B; CASEIN KINASE-2; TRANSGENIC MICE; C-MYC; BREAST-CANCER; BETA-CATENIN; PEST DOMAIN; HA-RAS; EXPRESSION; ACTIVATION	Protein kinase CK2 is a ubiquitous and evolutionarily conserved serine/threonine kinase that is upregulated in many human cancers and can serve as an oncogene in lymphocytes. Recently, we have demonstrated that CK2 potentiates Wnt/beta -catenin signaling in mammary epithelial cells. To determine whether CK2 overexpression contributes to mammary tumorigenesis, we have performed comparative studies of human and rat breast cancer specimens and we have engineered transgenic mice with dysregulated expression of CK2 alpha in the mammary gland. We find that CK2 is highly expressed in human breast tumor specimens and in carcinogen-induced rat mammary tumors. Overexpression of CK2 alpha in the mammary gland of transgenic mice, under control of the MMTV-LTR, causes hyperplasia and dysplasia of the female mammary gland. Thirty per cent of the female MMTV-CK2 alpha transgenic mice develop mammary adenocarcinomas at a median of 23 months of age, often associated with Wnt pathway activation, as evidenced by upregulation of beta -catenin protein, NF-kappaB activation and upregulation of c-Myc also occur frequently. Thus, in mice, rats, and humans, dysregulated expression of CK2 is associated with and is capable of contributing to mammary tumorigenesis, Targeted inhibition of CK2 could be useful in the treatment of breast cancer.	Boston Med Ctr, Dept Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA; Boston Univ, Dept Chem, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Univ Calif Davis, Ctr Comparat Med, Davis, CA 95616 USA	Boston Medical Center; Boston University; Boston University; Boston University; Boston University; University of California System; University of California Davis	Seldin, DC (corresponding author), Boston Med Ctr, Dept Med, 650 Albany St,426A, Boston, MA 02118 USA.			Seldin, David C/0000-0003-0168-2333	NATIONAL CANCER INSTITUTE [R01CA082742] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 82742] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; AHMED K, 1994, CELL MOL BIOL RES, V40, P1; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Arsura M, 1997, CELL GROWTH DIFFER, V8, P1049; Barker N, 1999, AM J PATHOL, V154, P29, DOI 10.1016/S0002-9440(10)65247-9; Birchmeier C, 1996, ACTA ANAT, V156, P217; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; Bren GD, 2000, J MOL BIOL, V297, P1245, DOI 10.1006/jmbi.2000.3630; Bui TD, 1997, ONCOGENE, V14, P1249, DOI 10.1038/sj.onc.1200936; Cardiff RD, 1999, J MAMMARY GLAND BIOL, V4, P105, DOI 10.1023/A:1018712905244; Cardiff RD, 1996, J MAMMARY GLAND BIOL, V1, P61, DOI 10.1007/BF02096303; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Dale TC, 1996, CANCER RES, V56, P4320; DAYAMAKIN M, 1994, CANCER RES, V54, P2262; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; Faust RA, 1996, CANCER LETT, V101, P31, DOI 10.1016/0304-3835(96)04110-9; Foo SY, 1999, TRENDS GENET, V15, P229; Ford HL, 2000, J BIOL CHEM, V275, P22245, DOI 10.1074/jbc.M002446200; GAPANY M, 1995, MOL MED, V1, P659, DOI 10.1007/BF03401606; Glover CVC, 1998, PROG NUCLEIC ACID RE, V59, P95; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Heilker R, 1999, EUR J BIOCHEM, V259, P253, DOI 10.1046/j.1432-1327.1999.00028.x; HELLERHARRISON RA, 1989, BIOCHEMISTRY-US, V28, P9053, DOI 10.1021/bi00449a014; HOWARD DK, 1983, IN VITRO CELL DEV B, V19, P58, DOI 10.1007/BF02617995; HUGGINS C, 1961, NATURE, V189, P204, DOI 10.1038/189204a0; HUGUET EL, 1994, CANCER RES, V54, P2615; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; Janosch P, 1996, J BIOL CHEM, V271, P13868, DOI 10.1074/jbc.271.23.13868; JOHNSON GG, 1988, J BIOL CHEM, V263, P9079; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; KESSLER DJ, 1992, J EXP MED, V176, P787, DOI 10.1084/jem.176.3.787; Kim DW, 2000, CARCINOGENESIS, V21, P871, DOI 10.1093/carcin/21.5.871; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; Kuhl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landesman-Bollag E, 1998, ONCOGENE, V16, P2965, DOI 10.1038/sj.onc.1201854; Lin RT, 1996, MOL CELL BIOL, V16, P1401; Liu ZP, 1997, GENE DEV, V11, P3413, DOI 10.1101/gad.11.24.3413; Mahler JF, 1996, TOXICOL PATHOL, V24, P710, DOI 10.1177/019262339602400606; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; MESTRES P, 1994, ACTA ANAT, V149, P13; Mitev Vanio, 1994, Journal of Dermatological Science, V8, P45, DOI 10.1016/0923-1811(94)90320-4; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MORRIS JJ, 1992, MED HYPOTHESES, V38, P177, DOI 10.1016/0306-9877(92)90090-Y; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; NEBERT DW, 1987, BIOCHEM SOC T, V15, P586, DOI 10.1042/bst0150586; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; OHI Y, 1992, VIRCHOWS ARCH B, V62, P365, DOI 10.1007/BF02899705; OLEMOIYOI OK, 1993, EMBO J, V12, P1621, DOI 10.1002/j.1460-2075.1993.tb05807.x; Orlandini M, 1998, J BIOL CHEM, V273, P21291, DOI 10.1074/jbc.273.33.21291; Pancetti F, 1996, BIOCHEM BIOPH RES CO, V218, P35, DOI 10.1006/bbrc.1996.0007; Pando MP, 2000, J BIOL CHEM, V275, P21278, DOI 10.1074/jbc.M002532200; PENA JM, 1983, CANCER RES, V43, P1172; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; PEREZ M, 1988, FEBS LETT, V238, P273, DOI 10.1016/0014-5793(88)80495-2; PERFETTI V, 1991, LEUKEMIA, V5, P1110; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; RANDERATH E, 1985, CARCINOGENESIS, V6, P1117, DOI 10.1093/carcin/6.8.1117; ROGERS AE, 1981, CANCER RES, V41, P3735; Roig J, 1999, MOL CELL BIOCHEM, V191, P229, DOI 10.1023/A:1006808816770; ROMIEUMOUREZ R, 2001, IN PRESS CANC RES; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; SAFE S, 1984, CRC CR REV TOXICOL, V13, P319, DOI 10.3109/10408448409023762; Schlosshauer PW, 2000, CARCINOGENESIS, V21, P1453, DOI 10.1093/carcin/21.7.1453; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; Song DH, 2000, J BIOL CHEM, V275, P23790, DOI 10.1074/jbc.M909107199; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; Willert K, 1997, EMBO J, V16, P3089, DOI 10.1093/emboj/16.11.3089; Xu X, 1999, NAT GENET, V23, P118, DOI 10.1038/12729	80	254	270	1	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2001	20	25					3247	3257		10.1038/sj.onc.1204411	http://dx.doi.org/10.1038/sj.onc.1204411			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	440ET	11423974				2022-12-17	WOS:000169163500008
J	Patel, NM; Nozaki, S; Shortle, NH; Bhat-Nakshatri, P; Newton, TR; Rice, S; Gelfanov, V; Boswell, SH; Goulet, RJ; Sledge, GW; Nakshatri, H				Patel, NM; Nozaki, S; Shortle, NH; Bhat-Nakshatri, P; Newton, TR; Rice, S; Gelfanov, V; Boswell, SH; Goulet, RJ; Sledge, GW; Nakshatri, H			Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappa B is enhanced by I kappa B alpha super-repressor and parthenolide	ONCOGENE			English	Article						breast cancer; parthenolide; paclitaxel; NF-kB	TUMOR-NECROSIS-FACTOR; INDUCED APOPTOSIS; SESQUITERPENE LACTONE; NEGATIVE REGULATION; DRUG-RESISTANCE; KINASE COMPLEX; CYCLIN D1; ACTIVATION; EXPRESSION; INHIBITION	The transcription factor nuclear factor-kappa B (NF-KB) regulates genes important for tumor invasion, metastasis and chemoresistance. Normally, NF-kappa B remains sequestered in an inactive state by cytoplasmic inhibitor-of-kappa B (I kappa B) proteins, NF-kappa B translocates to nucleus and activates gene expression upon exposure of cells to growth factors and cytokines, We and others have shown previously that NF-kappa B is constitutively active in a subset of breast cancers. In this study, we show that constitutive activation of NF-kappa B leads to overexpression of the antiapoptotic genes c-inhibitor of apoptosis 2 (c-IAP2) and manganese superoxide dismutase (Mn-SOD) in breast cancer cells, Furthermore, expression of the antiapoptotic tumor necrosis factor receptor associated factor 1 (TRAF1) and defender-against cell death (DAD-1) is regulated by NF-kappa B in certain breast cancer cells. We also demonstrate that NF-kappa B-inducible genes protect cancer cells against paclitaxel as MDA-MB-231 breast cancer cells modified to overexpress I kappa B alpha required lower concentrations of paclitaxel to arrest at the G2/M phase of the cell cycle and undergo apoptosis when compared to parental cells. The effect of NF-kappa B on paclitaxel-sensitivity appears to be specific to cancer cells because normal fibroblasts derived from embryos lacking p65 subunit of NF-kappa B and wild type littermate embryos were insensitive to paclitaxel-induced G2/M cell cycle arrest. Parthenolide, an active ingredient of herbal remedies such as feverfew (tanacetum parthenium), mimicked the effects of I kappa B alpha by inhibiting NF-kappa B DNA binding activity and Mn-SOD expression, and increasing paclitaxel-induced apoptosis of breast cancer cells. These results suggest that active ingredients of herbs with anti-inflammatory properties may be useful in increasing the sensitivity of cancers with constitutively active NF-kappa B to chemotherapeutic drugs.	Indiana Univ, Sch Med, Dept Surg, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Pathol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Nakshatri, H (corresponding author), Indiana Canc Res Inst, 1044 W Walnut St,R4-202, Indianapolis, IN 46202 USA.			Nakshatri, Harikrishna/0000-0001-8876-0052; Gelfanov, Vasily/0000-0001-5216-5227				Amato SF, 1998, CANCER RES, V58, P241; Ambrosone CB, 1999, CANCER RES, V59, P602; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldini N, 1997, NAT MED, V3, P378, DOI 10.1038/nm0497-378; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Bargou RC, 1996, J CLIN INVEST, V97, P2651, DOI 10.1172/JCI118715; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bentires-Alj M, 1999, CANCER RES, V59, P811; BERENBAUM MC, 1981, ADV CANCER RES, V35, P269, DOI 10.1016/S0065-230X(08)60912-4; Bhat-Nakshatri P, 1998, P NATL ACAD SCI USA, V95, P6971, DOI 10.1073/pnas.95.12.6971; BISWAS DK, 1993, J ACQ IMMUN DEF SYND, V6, P778; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; Blagosklonny MV, 1996, CANCER RES, V56, P1851; Bork PM, 1997, FEBS LETT, V402, P85, DOI 10.1016/S0014-5793(96)01502-5; Cassimeris L, 1999, CURR OPIN CELL BIOL, V11, P134, DOI 10.1016/S0955-0674(99)80017-9; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dong G, 1999, CANCER RES, V59, P3495; Ferlini C, 1997, BRIT J CANCER, V75, P884, DOI 10.1038/bjc.1997.156; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Fukuda K, 1999, PLANTA MED, V65, P381, DOI 10.1055/s-2006-960795; Galien R, 1997, NUCLEIC ACIDS RES, V25, P2424, DOI 10.1093/nar/25.12.2424; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Habtemariam S, 1998, PLANTA MED, V64, P683, DOI 10.1055/s-2006-957558; Hehner SP, 1999, J IMMUNOL, V163, P5617; Hehner SP, 1998, J BIOL CHEM, V273, P1288, DOI 10.1074/jbc.273.3.1288; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Jiang F, 1998, J PATHOL, V185, P382; Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970; Kelleher DJ, 1997, P NATL ACAD SCI USA, V94, P4994, DOI 10.1073/pnas.94.10.4994; Kumar A, 1998, BIOCHEM PHARMACOL, V55, P775, DOI 10.1016/S0006-2952(97)00557-1; Kumar R, 1996, CLIN CANCER RES, V2, P1215; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Legrand O, 1998, BLOOD, V91, P4480, DOI 10.1182/blood.V91.12.4480.412k28_4480_4488; Levkau B, 1998, J EXP MED, V187, P579, DOI 10.1084/jem.187.4.579; Levkau B, 1999, NAT CELL BIOL, V1, P227, DOI 10.1038/12050; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Lin ZP, 1998, CANCER RES, V58, P3059; Ling YH, 1998, J BIOL CHEM, V273, P18984, DOI 10.1074/jbc.273.30.18984; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Lyss G, 1998, J BIOL CHEM, V273, P33508, DOI 10.1074/jbc.273.50.33508; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MILLER AD, 1989, BIOTECHNIQUES, V7, P984; MILLER AD, 1989, BIOTECHNIQUES, V7, P989; Miyake H, 2000, CANCER RES, V60, P170; MURPHY JJ, 1988, LANCET, V2, P189; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Newton TR, 1999, J BIOL CHEM, V274, P18827, DOI 10.1074/jbc.274.26.18827; Oberley TD, 1997, HISTOL HISTOPATHOL, V12, P525; Panvichian R, 1998, CANCER RES, V58, P4667; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; PRICE JE, 1990, CANCER RES, V50, P717; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; ShattuckBrandt RL, 1997, CANCER RES, V57, P3032; Shen SC, 1998, CELL GROWTH DIFFER, V9, P23; SOMMERS CL, 1994, BREAST CANCER RES TR, V31, P325, DOI 10.1007/BF00666165; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Torres K, 1998, CANCER RES, V58, P3620; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang FJ, 1998, J NUTR, V128, P2334, DOI 10.1093/jn/128.12.2334; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Zandi E, 1999, MOL CELL BIOL, V19, P4547; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	76	254	273	1	18	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2000	19	36					4159	4169		10.1038/sj.onc.1203768	http://dx.doi.org/10.1038/sj.onc.1203768			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	347XU	10962577				2022-12-17	WOS:000088955100010
J	Gerondakis, S; Grossmann, M; Nakamura, Y; Pohl, T; Grumont, R				Gerondakis, S; Grossmann, M; Nakamura, Y; Pohl, T; Grumont, R			Genetic approaches in mice to understand Rel/NF-kappa B and I kappa B function: transgenics and knockouts	ONCOGENE			English	Review						NF-kappa B; Rel; I kappa B; IKK; knockout mice; transgenic mice; mouse genetics	TRANSCRIPTION FACTORS; IMMUNE-RESPONSES; T-CELLS; SPLENIC MICROARCHITECTURE; PROLIFERATIVE RESPONSES; TARGETED DISRUPTION; MULTIFOCAL DEFECTS; ONCOPROTEIN BCL-3; INHIBITOR PROTEIN; EXHIBIT DEFECTS	Rel/NF-kappa B transcription factors have been implicated in regulating a wide variety of genes important in cellular processes that include cell division, cell survival, differentiation and immunity. Here genetic models in which various Rel/NF-kappa B and I kappa B proteins have either been over-expressed or deleted in mice will be reviewed. Although expressed fairly ubiquitously, homozygous disruption of individual Rel/NF-kappa B genes generally affects the development of proper immune cell function. One exception is rela, which is essential for embryonic liver development. The disruption of genes encoding the individual subunits of the I kappa B kinase, namely IKK alpha and IKK beta, has demonstrated that IKK beta transmits the response to most common NF-kappa B inducing agents, whereas IKK alpha has an unexpected role in keratinocyte differentiation. Future studies will no doubt focus on the effect of multiple gene disruptions of members of this signaling pathway, on tissue-specific disruptions of these genes, and on the use of these mice as models for human diseases.	Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia	Royal Melbourne Hospital; Walter & Eliza Hall Institute	Gerondakis, S (corresponding author), Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, PO, Parkville, Vic 3050, Australia.		Nakamura, Yukio/A-5263-2016	Nakamura, Yukio/0000-0001-8056-4946				Attar RM, 1998, MOL CELL BIOL, V18, P477, DOI 10.1128/MCB.18.1.477; Attar RM, 1997, SEMIN CANCER BIOL, V8, P93, DOI 10.1006/scbi.1997.0060; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; Boothby MR, 1997, J EXP MED, V185, P1897, DOI 10.1084/jem.185.11.1897; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BURKLY L, 1995, NATURE, V373, P531, DOI 10.1038/373531a0; Bushdid PB, 1998, NATURE, V392, P615, DOI 10.1038/33435; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; Caamano JH, 1996, MOL CELL BIOL, V16, P1342; CAAMANO JH, 1999, IN PRESS J IMMUNOL; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; Carrasco D, 1997, J EXP MED, V186, P279, DOI 10.1084/jem.186.2.279; Carrasco D, 1998, J EXP MED, V187, P973, DOI 10.1084/jem.187.7.973; Cheng JD, 1998, J EXP MED, V188, P1055, DOI 10.1084/jem.188.6.1055; Doi TS, 1997, J EXP MED, V185, P953, DOI 10.1084/jem.185.5.953; Doi TS, 1999, P NATL ACAD SCI USA, V96, P2994, DOI 10.1073/pnas.96.6.2994; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; Gerondakis S, 1996, P NATL ACAD SCI USA, V93, P3405, DOI 10.1073/pnas.93.8.3405; Gerondakis S, 1998, CURR OPIN IMMUNOL, V10, P353, DOI 10.1016/S0952-7915(98)80175-1; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; Govind S, 1999, ONCOGENE, V18, P6875, DOI 10.1038/sj.onc.1203223; Grigoriadis G, 1996, EMBO J, V15, P7099, DOI 10.1002/j.1460-2075.1996.tb01101.x; GROSSMANN M, 1999, IN PRESS P NATL ACAD; Grumont RJ, 1998, J EXP MED, V187, P663, DOI 10.1084/jem.187.5.663; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Harling-McNabb L, 1999, INT IMMUNOL, V11, P1431, DOI 10.1093/intimm/11.9.1431; Hettmann T, 1999, J EXP MED, V189, P145, DOI 10.1084/jem.189.1.145; Horwitz BH, 1999, J IMMUNOL, V162, P1941; Horwitz BH, 1997, IMMUNITY, V6, P765, DOI 10.1016/S1074-7613(00)80451-3; Howard TD, 1997, NAT GENET, V15, P36, DOI 10.1038/ng0197-36; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Ishikawa H, 1998, J EXP MED, V187, P985, DOI 10.1084/jem.187.7.985; Ishikawa H, 1997, J EXP MED, V186, P999, DOI 10.1084/jem.186.7.999; Kanegae Y, 1998, NATURE, V392, P611, DOI 10.1038/33429; Klement JF, 1996, MOL CELL BIOL, V16, P2341; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li Z, 1997, MOL CELL BIOL, V17, P6184, DOI 10.1128/MCB.17.10.6184; MEMET S, 1999, IN PRESS J IMMUNOL; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; PEREZ P, 1995, MOL CELL BIOL, V15, P3523; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Schwarz EM, 1997, GENE DEV, V11, P187, DOI 10.1101/gad.11.2.187; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Snapper CM, 1996, J IMMUNOL, V156, P183; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Weih F, 1997, J IMMUNOL, V158, P5211; Weih F, 1997, J EXP MED, V185, P1359, DOI 10.1084/jem.185.7.1359; Weih F, 1996, ONCOGENE, V12, P445; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; Wu L, 1998, IMMUNITY, V9, P839, DOI 10.1016/S1074-7613(00)80649-4; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	62	254	258	0	12	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 22	1999	18	49					6888	6895		10.1038/sj.onc.1203236	http://dx.doi.org/10.1038/sj.onc.1203236			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259LZ	10602464				2022-12-17	WOS:000083896500006
J	Alitalo, A; Detmar, M				Alitalo, A.; Detmar, M.			Interaction of tumor cells and lymphatic vessels in cancer progression	ONCOGENE			English	Review						lymphangiogenesis; metastasis; lymph node; VEGF-C; VEGF; therapy	ENDOTHELIAL-GROWTH-FACTOR; FACTOR-C; BREAST-CANCER; VEGF-C; IN-VIVO; MACROPHAGE RECRUITMENT; FACTOR RECEPTOR-3; NODE METASTASIS; INDUCED LYMPHANGIOGENESIS; THERAPEUTIC IMPLICATIONS	Metastatic spread of cancer through the lymphatic system affects hundreds of thousands of patients yearly. Growth of new lymphatic vessels, lymphangiogenesis, is activated in cancer and inflammation, but is largely inactive in normal physiology, and therefore offers therapeutic potential. Key mediators of lymphangiogenesis have been identified in developmental studies. During embryonic development, lymphatic endothelial cells derive from the blood vascular endothelium and differentiate under the guidance of lymphatic-specific regulators, such as the prospero homeobox 1 transcription factor. Vascular endothelial growth factor-C (VEGF-C) and VEGF receptor 3 signaling are essential for the further development of lymphatic vessels and therefore they provide a promising target for inhibition of tumor lymphangiogenesis. Lymphangiogenesis is important for the progression of solid tumors as shown for melanoma and breast cancer. Tumor cells may use chemokine gradients as guidance cues and enter lymphatic vessels through intercellular openings between endothelial cell junctions or, possibly, by inducing larger discontinuities in the endothelial cell layer. Tumor-draining sentinel lymph nodes show enhanced lymphangiogenesis even before cancer metastasis and they may function as a permissive 'lymphovascular niche' for the survival of metastatic cells. Although our current knowledge indicates that the development of anti-lymphangiogenic therapies may be beneficial for the treatment of cancer patients, several open questions remain with regard to the frequency, mechanisms and biological importance of lymphatic metastases.	[Alitalo, A.; Detmar, M.] Swiss Fed Inst Technol, Swiss Fed Inst Technol, Inst Pharmaceut Sci, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Detmar, M (corresponding author), Swiss Fed Inst Technol, Swiss Fed Inst Technol, Inst Pharmaceut Sci, Wolfgang Pauli Str 10,HCI H303, CH-8093 Zurich, Switzerland.	michael.detmar@pharma.ethz.ch			Swiss National Science Foundation [3100A0108207, 31003A-130627]; Commission of the European Communities [LSHCCT2005518178]; Advanced European Research Council; Oncosuisse; Krebsliga Zurich	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Commission of the European Communities(European Commission); Advanced European Research Council(European Research Council (ERC)); Oncosuisse; Krebsliga Zurich	Work in the authors' lab is supported by the Swiss National Science Foundation (grant numbers 3100A0108207and 31003A-130627); Commission of the European Communities (grant number LSHCCT2005518178); Advanced European Research Council (grant LYVICAM); and Oncosuisse and Krebsliga Zurich (to MD).	Anisimov A, 2009, CIRC RES, V104, P1302, DOI 10.1161/CIRCRESAHA.109.197830; Azzali G, 2007, AM J PATHOL, V170, P334, DOI 10.2353/ajpath.2007.060447; Baluk P, 2005, J CLIN INVEST, V115, P247, DOI 10.1172/JCI200522037; Bertozzi CC, 2010, ARTERIOSCL THROM VAS, V30, P2368, DOI 10.1161/ATVBAHA.110.217281; Bertozzi CC, 2010, BLOOD, V116, P661, DOI 10.1182/blood-2010-02-270876; Bos FL, 2011, CIRC RES, V109, P486, DOI 10.1161/CIRCRESAHA.111.250738; Burton JB, 2008, CANCER RES, V68, P7828, DOI 10.1158/0008-5472.CAN-08-1488; Cady B, 2007, ANN SURG ONCOL, V14, P1790, DOI 10.1245/s10434-006-9234-2; Cao RH, 2004, CANCER CELL, V6, P333, DOI 10.1016/j.ccr.2004.08.034; Carreira CM, 2001, CANCER RES, V61, P8079; Catalano O, 2010, AM J ROENTGENOL, V194, P735, DOI 10.2214/AJR.09.2422; Caunt M, 2008, CANCER CELL, V13, P331, DOI 10.1016/j.ccr.2008.01.029; Chang LK, 2004, P NATL ACAD SCI USA, V101, P11658, DOI 10.1073/pnas.0404272101; Chen L, 2010, J CELL BIOL, V189, P417, DOI 10.1083/jcb.200912037; Cho CH, 2007, CIRC RES, V100, pE47, DOI 10.1161/01.RES.0000259564.92792.93; Christiansen A, 2011, GENES CANC; Cueni LN, 2010, BLOOD, V116, P4376, DOI 10.1182/blood-2010-04-278564; Cursiefen C, 2004, J CLIN INVEST, V113, P1040, DOI 10.1172/JCI200420465; Dadiani M, 2006, CANCER RES, V66, P8037, DOI 10.1158/0008-5472.CAN-06-0728; Dadras SS, 2005, MODERN PATHOL, V18, P1232, DOI 10.1038/modpathol.3800410; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; Fantin A, 2010, BLOOD, V116, P829, DOI 10.1182/blood-2009-12-257832; Ferlay J, 2010, EUR J CANCER, V46, P765, DOI 10.1016/j.ejca.2009.12.014; Fukumura D, 2010, MICROCIRCULATION, V17, P206, DOI 10.1111/j.1549-8719.2010.00029.x; Galvagni F, 2010, CIRC RES, V106, P1839, DOI 10.1161/CIRCRESAHA.109.206326; Garcia M, 2007, GLOBAL CANC FACTS FI; Giampieri S, 2009, NAT CELL BIOL, V11, P1287, DOI 10.1038/ncb1973; Gluzman-Poltorak Z, 2000, J BIOL CHEM, V275, P18040, DOI 10.1074/jbc.M909259199; Gordon EJ, 2010, DEVELOPMENT, V137, P3899, DOI 10.1242/dev.050021; Haiko P, 2008, MOL CELL BIOL, V28, P4843, DOI 10.1128/MCB.02214-07; Halin C, 2007, BLOOD, V110, P3158, DOI 10.1182/blood-2007-01-066811; Harris NC, 2011, FASEB J, V25, P2615, DOI 10.1096/fj.10-179788; He YL, 2005, CANCER RES, V65, P4739, DOI 10.1158/0008-5472.CAN-04-4576; Hirakawa S, 2005, J EXP MED, V201, P1089, DOI 10.1084/jem.20041896; Hirakawa S, 2007, BLOOD, V109, P1010, DOI 10.1182/blood-2006-05-021758; Hirakawa S, 2009, CANCER SCI, V100, P983, DOI 10.1111/j.1349-7006.2009.01142.x; Hong YK, 2004, FASEB J, V18, P1111, DOI 10.1096/fj.03-1179fje; Hoshida T, 2006, CANCER RES, V66, P8065, DOI 10.1158/0008-5472.CAN-06-1392; Isaka N, 2004, CANCER RES, V64, P4400, DOI 10.1158/0008-5472.CAN-04-0752; Jackson DG, 2009, IMMUNOL REV, V230, P216, DOI 10.1111/j.1600-065X.2009.00803.x; Kabashima K, 2007, AM J PATHOL, V171, P1249, DOI 10.2353/ajpath.2007.070225; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Kajiya K, 2005, EMBO J, V24, P2885, DOI 10.1038/sj.emboj.7600763; Kang J, 2010, BLOOD, V116, P140, DOI 10.1182/blood-2009-11-252270; Karkkainen MJ, 2001, P NATL ACAD SCI USA, V98, P12677, DOI 10.1073/pnas.221449198; Karkkainen MJ, 2004, NAT IMMUNOL, V5, P74, DOI 10.1038/ni1013; Karpanen T, 2001, CANCER RES, V61, P1786; Kerjaschki D, 2011, J CLIN INVEST, V121, P2000, DOI 10.1172/JCI44751; Kim KE, 2009, AM J PATHOL, V175, P1733, DOI 10.2353/ajpath.2009.090133; Kim M, 2010, CANCER RES, V70, P10411, DOI 10.1158/0008-5472.CAN-10-2591; Krag DN, 2010, LANCET ONCOL, V11, P927, DOI 10.1016/S1470-2045(10)70207-2; Kunstfeld R, 2004, BLOOD, V104, P1048, DOI 10.1182/blood-2003-08-2964; Kyzas PA, 2005, J PATHOL, V206, P170, DOI 10.1002/path.1776; Laakkonen P, 2007, CANCER RES, V67, P593, DOI 10.1158/0008-5472.CAN-06-3567; Leong SPL, 2011, J SURG ONCOL, V103, P607, DOI 10.1002/jso.21841; Leong SPL, 2011, J SURG ONCOL, V103, P518, DOI 10.1002/jso.21815; Leppanen VM, 2011, BLOOD, V117, P1507, DOI 10.1182/blood-2010-08-301549; Lin JM, 2005, CANCER RES, V65, P6901, DOI 10.1158/0008-5472.CAN-05-0408; Louis-Sylvestre C, 2004, J CLIN ONCOL, V22, P97, DOI 10.1200/JCO.2004.12.108; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; Marino D, 2011, J VASC RES, V48, P236, DOI 10.1159/000320620; Maruyama K, 2007, AM J PATHOL, V170, P1178, DOI 10.2353/ajpath.2007.060018; Moehrle M, 2004, DERMATOL SURG, V30, P1319, DOI 10.1111/j.1524-4725.2004.30376.x; Moussai D, 2011, J INVEST DERMATOL, V131, P229, DOI 10.1038/jid.2010.266; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Mumprecht V, 2010, CANCER RES, V70, P8842, DOI 10.1158/0008-5472.CAN-10-0896; Murakami M, 2008, ARTERIOSCL THROM VAS, V28, P658, DOI 10.1161/ATVBAHA.107.150433; Nagy JA, 2002, J EXP MED, V196, P1497, DOI 10.1084/jem.20021244; Neufeld G, 2008, NAT REV CANCER, V8, P632, DOI 10.1038/nrc2404; Nilsson I, 2010, EMBO J, V29, P1377, DOI 10.1038/emboj.2010.30; Norrmen C, 2009, J CELL BIOL, V185, P439, DOI 10.1083/jcb.200901104; Oliver G, 2008, ANN NY ACAD SCI, V1131, P75, DOI 10.1196/annals.1413.006; Padera TP, 2002, SCIENCE, V296, P1883, DOI 10.1126/science.1071420; Pflicke H, 2009, J EXP MED, V206, P2925, DOI 10.1084/jem.20091739; Proulx ST, 2010, CANCER RES, V70, P7053, DOI 10.1158/0008-5472.CAN-10-0271; Qian CN, 2006, CANCER RES, V66, P10365, DOI 10.1158/0008-5472.CAN-06-2977; Ran S, 2010, PATHOPHYSIOLOGY, V17, P229, DOI DOI 10.1016/J.PATH0PHYS.2009.11.003; Rinderknecht M, 2009, LYMPHANGIOGENESIS CA; Rinderknecht M, 2008, J CELL PHYSIOL, V216, P347, DOI 10.1002/jcp.21494; Rissanen TT, 2003, CIRC RES, V92, P1098, DOI 10.1161/01.RES.0000073584.46059.E3; Roberts N, 2006, CANCER RES, V66, P2650, DOI 10.1158/0008-5472.CAN-05-1843; Ruddell A, 2008, NEOPLASIA, V10, P706, DOI 10.1593/neo.08342; Saaristo A, 2006, AM J PATHOL, V169, P1080, DOI 10.2353/ajpath.2006.051251; Sahai E, 2007, NAT REV CANCER, V7, P737, DOI 10.1038/nrc2229; Schacht V, 2003, EMBO J, V22, P3546, DOI 10.1093/emboj/cdg342; Schledzewski K, 2006, J PATHOL, V209, P67, DOI 10.1002/path.1942; Schoppmann SF, 2002, AM J PATHOL, V161, P947, DOI 10.1016/S0002-9440(10)64255-1; Shaul ME, 2010, DIABETES, V59, P1171, DOI 10.2337/db09-1402; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; Skobe M, 2001, AM J PATHOL, V159, P893, DOI 10.1016/S0002-9440(10)61765-8; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; Sung HK, 2006, BIOCHEM BIOPH RES CO, V345, P545, DOI 10.1016/j.bbrc.2006.04.121; Tammela T, 2008, NATURE, V454, P656, DOI 10.1038/nature07083; Tammela T, 2011, NAT CELL BIOL, V13, P1202, DOI 10.1038/ncb2331; Tammela T, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001699; Thiele W, 2006, J BIOTECHNOL, V124, P224, DOI 10.1016/j.jbiotec.2006.01.007; van Akkooi ACJ, 2006, ANN ONCOL, V17, P1578, DOI 10.1093/annonc/mdl176; Van den Eynden GG, 2007, CANCER LETT, V256, P279, DOI 10.1016/j.canlet.2007.07.005; Van der Auwera I, 2005, CLIN CANCER RES, V11, P7637, DOI 10.1158/1078-0432.CCR-05-1142; van der Schaft DWJ, 2007, CANCER LETT, V254, P128, DOI 10.1016/j.canlet.2007.03.001; Veikkola T, 2001, EMBO J, V20, P1223, DOI 10.1093/emboj/20.6.1223; Viehl CT, 2011, J SURG ONCOL, V103, P531, DOI 10.1002/jso.21693; Wick N, 2008, AM J PATHOL, V173, P1202, DOI 10.2353/ajpath.2008.080101; Wigle JT, 1999, CELL, V98, P769, DOI 10.1016/S0092-8674(00)81511-1; Wiley HE, 2001, J NATL CANCER I, V93, P1638, DOI 10.1093/jnci/93.21.1638; Wirzenius M, 2007, J EXP MED, V204, P1431, DOI 10.1084/jem.20062642; Wong SY, 2005, CANCER RES, V65, P9789, DOI 10.1158/0008-5472.CAN-05-0901; Xu YL, 2010, J CELL BIOL, V188, P115, DOI 10.1083/jcb.200903137; Yang H, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-36; Yoshimatsu Y, 2011, J CELL SCI, V124, P2753, DOI 10.1242/jcs.083998; Yuan L, 2002, DEVELOPMENT, V129, P4797; Zhang LQ, 2010, CELL RES, V20, P1319, DOI 10.1038/cr.2010.116; Zheng W, 2011, BLOOD, V118, P1154, DOI 10.1182/blood-2010-11-317800	114	253	268	1	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	42					4499	4508		10.1038/onc.2011.602	http://dx.doi.org/10.1038/onc.2011.602			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	022SH	22179834				2022-12-17	WOS:000309982100001
J	Yu, F; Deng, H; Yao, H; Liu, Q; Su, F; Song, E				Yu, F.; Deng, H.; Yao, H.; Liu, Q.; Su, F.; Song, E.			Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells	ONCOGENE			English	Article						microRNA; cancer stem cell; breast cancer; Ubc9; ITGB3	CANCER STEM-CELLS; IN-VITRO PROPAGATION; EXPRESSION; UBC9; MECHANISMS; INTEGRINS; ANOIKIS	Accumulating evidence indicates that a sub-population of cancer cells with stem-like properties, termed tumor-initiating cells (T-ICs), exist in many different kinds of malignancies, which have a pivotal role in tumorigenesis, tumor progression, metastasis and post-treatment relapse. However, how the stem-like properties of T-ICs are regulated remains obscure. Our previous study showed that reduction of let-7 microRNA ( miRNA) in breast tumor-initiating cells (BT-ICs) contributes to the maintenance of their self-renewal capacity and undifferentiated status. In this study we show the effect of mir-30 reduction on the stem-like features of BT-ICs. Similar to let-7, mir-30 is reduced in BT-ICs, and the protein level of Ubc9 (ubiquitin-conjugating enzyme 9) and ITGB3 ( integrin b3), the target genes of mir-30, is markedly upregulated. Enforced constitutive expression of mir-30 in BT-ICs inhibits their self-renewal capacity by reducing Ubc9, and induces apoptosis through silencing ITGB3. On the contrary, blocking the miRNA with a specific antisense oligonucleotide (ASO) in differentiated breast cancer cells revived their self-renewal capacity. Furthermore, ectopic expression of mir-30 in BT-IC xenografts reduces tumorigenesis and lung metastasis in nonobese diabetic/severe combined immunodeficient mice, whereas blocking mir-30 expression enhances tumorigenesis and metastasis. Together, our data suggest mir-30 as one of the important miRNAs in regulating the stem-like features of T-ICs. Oncogene ( 2010) 29, 4194-4204; doi: 10.1038/onc.2010.167; published online 24 May 2010	[Yu, F.; Deng, H.; Liu, Q.; Su, F.; Song, E.] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Breast Surg, Guangzhou 510120, Guangdong, Peoples R China; [Yao, H.] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Med Oncol, Guangzhou 510120, Guangdong, Peoples R China; [Liu, Q.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Song, E.] Sun Yat Sen Univ, Sch Life Sci, Guangzhou 510120, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Harvard University; Dana-Farber Cancer Institute; Sun Yat Sen University	Song, E (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 2, Dept Breast Surg, 107 Yanjiang W Rd, Guangzhou 510120, Guangdong, Peoples R China.	songerwei02@yahoo.com.cn		Liu, Qiang/0000-0002-5451-4862	Natural Science Foundation of China [30921140312, 30830110, 30772550, 30973396, 30525022, 30671930, 30973505]; Ministry of Science and Technology of China [2010CB912800, 2009CB521706, 2005CB724605]; Natural Science Foundation of Guangdong Province [8251008901000011]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology of China(Ministry of Science and Technology, China); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province)	This work was supported by the Natural Science Foundation of China Grant (30921140312, 30830110, 30772550, 30973396, 30525022, 30671930, 30973505), 973 (2010CB912800, 2009CB521706, 2005CB724605) Projects from the Ministry of Science and Technology of China, and Natural Science Foundation of Guangdong Province (8251008901000011).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Al-Hajj M, 2007, CURR OPIN ONCOL, V19, P61; Chen CZ, 2005, NEW ENGL J MED, V353, P1768, DOI 10.1056/NEJMp058190; Cho RW, 2008, CURR OPIN GENET DEV, V18, P48, DOI 10.1016/j.gde.2008.01.017; Croce CM, 2005, CELL, V122, P6, DOI 10.1016/j.cell.2005.06.036; Dalerba P, 2007, CELL STEM CELL, V1, P241, DOI 10.1016/j.stem.2007.08.012; Dalerba P, 2007, ANNU REV MED, V58, P267, DOI 10.1146/annurev.med.58.062105.204854; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Gilmore AP, 2005, CELL DEATH DIFFER, V12, P1473, DOI 10.1038/sj.cdd.4401723; Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412; Gupta PB, 2009, NAT MED, V15, P1010, DOI 10.1038/nm0909-1010; Ji Q, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006816; Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808; Mizejewski GJ, 1999, P SOC EXP BIOL MED, V222, P124, DOI 10.1046/j.1525-1373.1999.d01-122.x; Mo YY, 2005, ONCOGENE, V24, P2677, DOI 10.1038/sj.onc.1208210; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Park SW, 2007, NAT STRUCT MOL BIOL, V14, P68, DOI 10.1038/nsmb1185; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Pontier SM, 2009, J CELL SCI, V122, P207, DOI 10.1242/jcs.040394; Watanabe M, 2008, ACTA BIOCHIM POL, V55, P681; Wu FT, 2009, CLIN CANCER RES, V15, P1550, DOI 10.1158/1078-0432.CCR-08-0820; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054; Zhan M, 2004, HISTOL HISTOPATHOL, V19, P973, DOI 10.14670/HH-19.973; Zhang ZH, 2007, FASEB J, V21, P3042, DOI 10.1096/fj.06-6914com	24	253	277	1	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 22	2010	29	29					4194	4204		10.1038/onc.2010.167	http://dx.doi.org/10.1038/onc.2010.167			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	628VL	20498642				2022-12-17	WOS:000280151500007
J	Nahta, R; Esteva, FJ				Nahta, R.; Esteva, F. J.			Trastuzumab: triumphs and tribulations	ONCOGENE			English	Review						breast neoplasms; erbB-2 receptor; monoclonal antibodies; antineoplastic agents	METASTATIC BREAST-CANCER; DEPENDENT CELLULAR CYTOTOXICITY; PROGRESSION-FREE SURVIVAL; EXTRACELLULAR DOMAIN; MONOCLONAL-ANTIBODY; PHASE-II; ADJUVANT CHEMOTHERAPY; GENE AMPLIFICATION; LAPATINIB GW572016; 1ST-LINE TREATMENT	The human epidermal growth factor receptor 2 (HER2) tyrosine kinase receptor is overexpressed in approximately 20-30% of human breast cancers, and is associated with reduced survival. Hence, numerous therapeutic strategies have been tested for their ability to target the HER2 protein. The humanized monoclonal antibody trastuzumab (Herceptin) was the first HER2-targeted agent approved for clinical use in breast cancer patients. Response rates to single-agent trastuzumab range from 12 to 34% for metastatic breast cancer (MBC), and significant improvements in survival rates are achieved in patients with early-stage HER2-overexpressing breast cancer in the adjuvant setting. Despite its initial efficacy, acquired resistance to trastuzumab develops in a majority of patients with MBC, and a large subset never responds, demonstrating primary resistance. Molecular mechanisms of trastuzumab antineoplastic activity and potential mechanisms contributing to its resistance will be discussed in this review. Novel agents that may enhance trastuzumab efficacy will also be discussed.	Univ Texas, MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Breast Med Oncol, Breast Canc Translat Res Lab, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Dept Mol & Cellular Oncol, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System	Nahta, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Breast Med Oncol, 1515 Holocombe Blvd,Unit 1354, Houston, TX 77030 USA.	rnahta@mdanderson.org; festeva@mdanderson.org			NCI NIH HHS [K01 CA118174, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, K01CA118174] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams CW, 2006, CANCER IMMUNOL IMMUN, V55, P717, DOI 10.1007/s00262-005-0058-x; Agus DB, 2002, CANCER CELL, V2, P127, DOI 10.1016/S1535-6108(02)00097-1; Ali SM, 2006, J CLIN ONCOL, V24, P500, DOI [10.1200/jco.2006.24.18_suppl.500, DOI 10.1200/JCO.2006.24.18_SUPPL.500]; Anido J, 2006, EMBO J, V25, P3234, DOI 10.1038/sj.emboj.7601191; Arnould L, 2006, BRIT J CANCER, V94, P259, DOI 10.1038/sj.bjc.6602930; Baselga J, 2001, SEMIN ONCOL, V28, P4, DOI 10.1053/sonc.2001.28544; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Burstein HJ, 2005, ANN ONCOL, V16, P1772, DOI 10.1093/annonc/mdi371; Buzdar AU, 2005, J CLIN ONCOL, V23, P3676, DOI 10.1200/JCO.2005.07.032; Camirand A, 2002, MED SCI MONITOR, V8, pBR521; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; Christianson TA, 1998, CANCER RES, V58, P5123; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Colomer R, 2000, CLIN CANCER RES, V6, P2356; Cooley S, 1999, EXP HEMATOL, V27, P1533, DOI 10.1016/S0301-472X(99)00089-2; DIGIOVANNA MP, 2006, P AM ASSOC CANC RES, V47, P1226; Esteva FJ, 2002, J CLIN ONCOL, V20, P1800, DOI 10.1200/JCO.2002.07.058; Esteva FJ, 2005, BREAST CANCER RES, V7, pR436, DOI 10.1186/bcr1020; Franklin MC, 2004, CANCER CELL, V5, P317, DOI 10.1016/S1535-6108(04)00083-2; Gennari R, 2004, CLIN CANCER RES, V10, P5650, DOI 10.1158/1078-0432.CCR-04-0225; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Hayes DF, 2001, CLIN CANCER RES, V7, P2703; Izumi Y, 2002, NATURE, V416, P279, DOI 10.1038/416279b; Jerome L, 2006, CANCER RES, V66, P7245, DOI 10.1158/0008-5472.CAN-05-3555; Konecny GE, 2006, CANCER RES, V66, P1630, DOI 10.1158/0008-5472.CAN-05-1182; Kos KS, 2003, CANCER-AM CANCER SOC, V98, P1377, DOI 10.1002/cncr.11656; Kostler WJ, 2004, CLIN CANCER RES, V10, P1618, DOI 10.1158/1078-0432.CCR-0385-3; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; Le XF, 2003, J BIOL CHEM, V278, P23441, DOI 10.1074/jbc.M300848200; LEITZEL K, 1995, J CLIN ONCOL, V13, P1129, DOI 10.1200/JCO.1995.13.5.1129; LIN YZJ, 1991, ONCOGENE, V6, P639; Lu YH, 2004, INT J CANCER, V108, P334, DOI 10.1002/ijc.11445; Lu YH, 2001, JNCI-J NATL CANCER I, V93, P1852, DOI 10.1093/jnci/93.24.1852; Marty M, 2005, J CLIN ONCOL, V23, P4265, DOI 10.1200/JCO.2005.04.173; Molina MA, 2002, CLIN CANCER RES, V8, P347; Molina MA, 2001, CANCER RES, V61, P4744; Nahta R, 2004, CANCER RES, V64, P3981, DOI 10.1158/0008-5472.CAN-03-3900; Nahta R, 2006, CANCER LETT, V232, P123, DOI 10.1016/j.canlet.2005.01.041; Nahta R, 2005, CANCER RES, V65, P11118, DOI 10.1158/0008-5472.CAN-04-3841; Nahta R, 2004, CANCER RES, V64, P2343, DOI 10.1158/0008-5472.CAN-03-3856; Nahta R, 2006, NAT CLIN PRACT ONCOL, V3, P269, DOI 10.1038/ncponc0509; Neve RM, 2000, ONCOGENE, V19, P1647, DOI 10.1038/sj.onc.1203470; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Press MF, 1997, J CLIN ONCOL, V15, P2894, DOI 10.1200/JCO.1997.15.8.2894; PUPA SM, 1993, ONCOGENE, V8, P2917; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Seidman AD, 2001, J CLIN ONCOL, V19, P2587, DOI 10.1200/JCO.2001.19.10.2587; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sliwkowski MX, 1999, SEMIN ONCOL, V26, P60; Tanner M, 2004, MOL CANCER THER, V3, P1585; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; Wen XF, 2006, ONCOGENE, V25, P6986, DOI 10.1038/sj.onc.1209685; Xia WL, 2005, ONCOGENE, V24, P6213, DOI 10.1038/sj.onc.1208774; Xia WL, 2002, ONCOGENE, V21, P6255, DOI 10.1038/sj.onc.1205794; Yakes FM, 2002, CANCER RES, V62, P4132; Yamauchi H, 1997, J CLIN ONCOL, V15, P2518, DOI 10.1200/JCO.1997.15.7.2518; ZABRECKY JR, 1991, J BIOL CHEM, V266, P1716	61	253	269	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	25					3637	3643		10.1038/sj.onc.1210379	http://dx.doi.org/10.1038/sj.onc.1210379			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172PK	17530017				2022-12-17	WOS:000246816100006
J	Denko, NC; Fontana, LA; Hudson, KM; Sutphin, PD; Raychaudhuri, S; Altman, R; Giaccia, AJ				Denko, NC; Fontana, LA; Hudson, KM; Sutphin, PD; Raychaudhuri, S; Altman, R; Giaccia, AJ			Investigating hypoxic tumor physiology through gene expression patterns	ONCOGENE			English	Article						hypoxic gene induction; HIF-1; VHL	ENDOTHELIAL GROWTH-FACTOR; INDUCIBLE FACTOR-I; MESSENGER-RNA; TRANSCRIPTION FACTOR; OXYGENATION PREDICTS; PROLYL HYDROXYLATION; ERYTHROPOIETIN GENE; GLYCOLYTIC-ENZYMES; FIBRIN DEPOSITION; CARCINOMA CELLS	Clinical evidence shows that tumor hypoxia is an independent prognostic indicator of poor patient outcome. Hypoxic tumors have altered physiologic processes, including increased regions of angiogenesis, increased local invasion, increased distant metastasis and altered apoptotic programs. Since hypoxia is a potent controller of gene expression, identifying hypoxia-regulated genes is a means to investigate the molecular response to hypoxic stress. Traditional experimental approaches have identified physiologic changes in hypoxic cells. Recent studies have identified hypoxia-responsive genes that may define the mechanism(s) underlying these physiologic changes. For example, the regulation of glycolytic genes by hypoxia can explain some characteristics of the Warburg effect. The converse of this logic is also true. By identifying new classes of hypoxia-regulated gene(s), we can infer the physiologic pressures that require the induction of these genes and their protein products. Furthermore, these physiologically driven hypoxic gene expression changes give us insight as to the poor outcome of patients with hypoxic tumors. Approximately 1-1.5% of the genome is transcriptionally responsive to hypoxia. However, there is significant heterogeneity in the transcriptional response to hypoxia between different cell types. Moreover, the coordinated change in the expression of families of genes supports the model of physiologic pressure leading to expression changes. Understanding the evolutionary pressure to develop a 'hypoxic response' provides a framework to investigate the biology of the hypoxic tumor microenvironment.	Stanford Univ, Dept Radiat Oncol, Div Radiat & Canc Biol, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA	Stanford University; Stanford University	Denko, NC (corresponding author), Stanford Univ, Dept Radiat Oncol, Div Radiat & Canc Biol, Sch Med, Stanford, CA 94305 USA.	ndenko@stanford.edu	denko, nicholas/F-8444-2010	Raychaudhuri, Soumya/0000-0002-1901-8265	NCI NIH HHS [CA67166] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA067166] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Becerra M, 2002, MOL MICROBIOL, V43, P545, DOI 10.1046/j.1365-2958.2002.02724.x; Bhattacharya S, 1999, GENE DEV, V13, P64, DOI 10.1101/gad.13.1.64; Brizel DM, 1996, CANCER RES, V56, P941; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; BRUICK RK, 2001, SCIENCE, V11, P11; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Caro J, 2001, HIGH ALT MED BIOL, V2, P145, DOI 10.1089/152702901750265251; Chan DA, 2002, J BIOL CHEM, V277, P40112, DOI 10.1074/jbc.M206922200; Chen EY, 1999, TERATOLOGY, V60, P215; Chen G, 1999, J BIOL CHEM, V274, P7, DOI 10.1074/jbc.274.1.7; De Jaeger K, 2001, BRIT J CANCER, V84, P1280; Denko N, 2003, J BIOL CHEM, V278, P5744, DOI 10.1074/jbc.M212534200; Denko N, 2000, CLIN CANCER RES, V6, P480; Denko NC, 2001, CANCER RES, V61, P795; Denko NC, 2000, EXP CELL RES, V258, P82, DOI 10.1006/excr.2000.4928; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; Ebert BL, 1996, BIOCHEM J, V313, P809, DOI 10.1042/bj3130809; Elson DA, 2000, CANCER RES, V60, P6189; Enholm B, 1997, ONCOGENE, V14, P2475, DOI 10.1038/sj.onc.1201090; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Faller DV, 1999, CLIN EXP PHARMACOL P, V26, P74, DOI 10.1046/j.1440-1681.1999.02992.x; FANDREY J, 1993, BLOOD, V81, P617; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Friedrich CA, 1999, CANCER-AM CANCER SOC, V86, P2478, DOI 10.1002/(SICI)1097-0142(19991201)86:11+<2478::AID-CNCR4>3.0.CO;2-5; GLEADLE JM, 1995, AM J PHYSIOL-CELL PH, V268, pC1362, DOI 10.1152/ajpcell.1995.268.6.C1362; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Graham CH, 1998, BLOOD, V91, P3300, DOI 10.1182/blood.V91.9.3300.3300_3300_3307; Green J, 2001, ADV MICROB PHYSIOL, V44, P1, DOI 10.1016/S0065-2911(01)44010-0; Grunstein J, 1999, CANCER RES, V59, P1592; Hockel M, 1996, CANCER RES, V56, P4509; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767; IMAGAWA S, 1991, BLOOD, V77, P278; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Ivanov S, 2001, AM J PATHOL, V158, P905, DOI 10.1016/S0002-9440(10)64038-2; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Kamada K, 2001, CELL, V106, P71, DOI 10.1016/S0092-8674(01)00417-2; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Koong AC, 2000, CANCER RES, V60, P883; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; KOUREMBANAS S, 1993, J CLIN INVEST, V92, P99, DOI 10.1172/JCI116604; Laderoute KR, 2000, CLIN CANCER RES, V6, P2941; Mandriota SJ, 1998, CIRC RES, V83, P852, DOI 10.1161/01.RES.83.8.852; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; Millhorn DE, 1996, ADV EXP MED BIOL, V410, P135; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; Nakayama M, 1998, BIOCHEM BIOPH RES CO, V243, P514, DOI 10.1006/bbrc.1998.8131; Niitsu Y, 1999, MOL BRAIN RES, V74, P26, DOI 10.1016/S0169-328X(99)00245-4; Nordsmark M, 1996, RADIOTHER ONCOL, V41, P31, DOI 10.1016/S0167-8140(96)91811-3; Oikawa M, 2001, BIOCHEM BIOPH RES CO, V289, P39, DOI 10.1006/bbrc.2001.5927; Oosthuyse B, 2001, NAT GENET, V28, P131, DOI 10.1038/88842; ORourke JF, 1996, EUR J BIOCHEM, V241, P403, DOI 10.1111/j.1432-1033.1996.00403.x; Ozawa K, 2001, CANCER RES, V61, P4206; Pinsky DJ, 1998, J CLIN INVEST, V102, P919, DOI 10.1172/JCI307; PLATE KH, 1993, CANCER RES, V53, P5822; Postovit LM, 2002, J BIOL CHEM, V277, P35730, DOI 10.1074/jbc.M204529200; Raychaudhuri S, 2000, Pac Symp Biocomput, P455; ROLL DE, 1991, MOL CELL BIOCHEM, V103, P141; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Saarikoski ST, 2002, FEBS LETT, V530, P186, DOI 10.1016/S0014-5793(02)03475-0; Salceda S, 1996, ARCH BIOCHEM BIOPHYS, V334, P389, DOI 10.1006/abbi.1996.0469; Scandurro AB, 2001, INT J ONCOL, V19, P129; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; Seagroves TN, 2001, MOL CELL BIOL, V21, P3436, DOI 10.1128/MCB.21.10.3436-3444.2001; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Sowter HM, 2001, CANCER RES, V61, P6669; Suzuma K, 1998, INVEST OPHTH VIS SCI, V39, P1028; Tazuke SI, 1998, P NATL ACAD SCI USA, V95, P10188, DOI 10.1073/pnas.95.17.10188; TEICHER BA, 1994, CANCER METAST REV, V13, P139, DOI 10.1007/BF00689633; Ten Vadim S, 2002, Curr Opin Crit Care, V8, P242, DOI 10.1097/00075198-200206000-00008; Tenan M, 2000, J EXP MED, V191, P1789, DOI 10.1084/jem.191.10.1789; Wang CG, 2000, DNA CELL BIOL, V19, P71, DOI 10.1089/104454900314582; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; Warren SM, 2001, J SURG RES, V99, P147, DOI 10.1006/jsre.2001.6128; Wykoff CC, 2000, ONCOGENE, V19, P6297, DOI 10.1038/sj.onc.1204012; Yan SF, 1998, P NATL ACAD SCI USA, V95, P8298, DOI 10.1073/pnas.95.14.8298; Yan SF, 1999, J BIOL CHEM, V274, P15030, DOI 10.1074/jbc.274.21.15030; Yun Z, 2002, DEV CELL, V2, P331, DOI 10.1016/S1534-5807(02)00131-4; Zitomer RS, 1997, KIDNEY INT, V51, P507, DOI 10.1038/ki.1997.71	86	253	267	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2003	22	37					5907	5914		10.1038/sj.onc.1206703	http://dx.doi.org/10.1038/sj.onc.1206703			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	717JV	12947397				2022-12-17	WOS:000185086100017
J	Chinni, SR; Li, YW; Upadhyay, S; Koppolu, PK; Sarkar, FH				Chinni, SR; Li, YW; Upadhyay, S; Koppolu, PK; Sarkar, FH			Indole3-carbinol (I3C) induced cell growth inhibition, G1 cell cycle arrest and apoptosis in prostate cancer cells	ONCOGENE			English	Article						G1 cell cycle arrest; apoptosis; indole-3-carbinol (I3C); prostate cancer (PCa)	DEPENDENT KINASE INHIBITOR; FACTOR-BETA; TRANSCRIPTIONAL ACTIVATION; ESTRADIOL METABOLISM; POTENTIAL MEDIATOR; EPITHELIAL-CELLS; LEUKEMIC-CELLS; CDK INHIBITOR; DNA-ADDUCTS; INDOLE-3-CARBINOL	Prostate cancer is one of the most common cancers in men and it is the second leading cause of cancer related death in men in the United States. Recent dietary and epidemiological studies have suggested the benefit of dietary intake of fruits and vegetables in lowering the incidence of prostate cancer. A diet rich in fruits and vegetables provides phytochemicals, particularly indole-3-carbinol (I3C), which may be responsible for the prevention of many types of cancer, including hormone-related cancers such as prostate. Studies to elucidate the role and the molecular mechanism(s) of action of I3C in prostate cancer, however, have not been conducted. In the current study, we investigated whether I3C had any effect against prostate cancer cells and, if so, attempts were made to identify the potential molecular mechanism(s) by which I3C elicits its biological effects on prostate cancer cells. Here we report for the first time that I3C inhibits the growth of PC-3 prostate cancer cells. Induction of G1 cell cycle arrest was also observed in PC-3 cells treated with I3C, which may be due to the observed effects of I3C in the up-regulation of p21(WAF1) and p27(Klp1) CDK inhibitors, followed by their association with cyclin D1 and E and down-regulation of CDK6 protein kinase levels and activity. The induction of p21(WAF1) appears to be transcriptionally upregulated and independent of the p53 responsive element. In addition, I3C inhibited the hyperpohosphorylation of the Retinoblastoma (Rb) protein in PC-3 cells. Induction of apoptosis was also observed in this cell line when treated with I3C, as measured by DNA laddering and poly (ADP-ribose) polymersae (PARP) cleavage. We also found an up-regulation of Bax, and down-regulation of Bcl-2 in I3C-treated cells. These effects may also be mediated by the down-regulation of NF-kappaB observed in I3C treated PC-3 cells. From these results, we conclude that I3C inhibits the growth of PC-3 prostate cancer cells by inducing G1 cell cycle arrest leading to apoptosis, and regulates the expression of apoptosis-related genes. These findings suggest that I3C may be an effective chemopreventive or therapeutic agent against prostate! cancer. Oncogene (2001) 20, 2927-2936.	Wayne State Univ, Sch Med, Dept Pathol, Karmanos Canc Inst, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University	Sarkar, FH (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, Karmanos Canc Inst, 9374 Scott Hall,540 E Canfield Ave, Detroit, MI 48201 USA.							*ACS, 2000, CANC FACTS FIG; BAILEY G, 1987, ENVIRON HEALTH PERSP, V71, P147, DOI 10.2307/3430422; BEIER RC, 1990, REV ENVIRON CONTAM T, V113, P47; Biggs JR, 1999, J BIOL CHEM, V274, P36987, DOI 10.1074/jbc.274.52.36987; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; BRADFIELD CA, 1991, ADV EXP MED BIOL, V289, P153; Broadbent TA, 1998, CURR MED CHEM, V5, P469; Cohen JH, 2000, JNCI-J NATL CANCER I, V92, P61, DOI 10.1093/jnci/92.1.61; Costello JF, 1997, CANCER RES, V57, P1250; Cover CM, 1998, J BIOL CHEM, V273, P3838, DOI 10.1074/jbc.273.7.3838; CRAM EJ, 2000, AM ASS CANC RES, V91, P10; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Dashwood RH, 1998, CHEM-BIOL INTERACT, V110, P1, DOI 10.1016/S0009-2797(97)00115-4; DASHWOOD RH, 1989, CARCINOGENESIS, V10, P175, DOI 10.1093/carcin/10.1.175; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Feldman D., 1996, SYNTHETIC POLYM, DOI [DOI 10.1002/(SICI)1097-4644(1996)25+<1::AID-JCB1>3.0.CO;2-4, 10.1002/(SICI)1097-0126(199701)42:13.0.CO;2-G, DOI 10.1002/(SICI)1097-0126(199701)42:13.0.CO;2-G]; Gartel AL, 1996, EXP CELL RES, V227, P171, DOI 10.1006/excr.1996.0264; Ge XK, 1996, BIOCHEM BIOPH RES CO, V228, P153, DOI 10.1006/bbrc.1996.1631; GRUBBS CJ, 1995, ANTICANCER RES, V15, P709; Herman DG, 1995, CARCINOGENESIS, V16, P2931, DOI 10.1093/carcin/16.12.2931; Huang P, 1997, CANCER RES, V57, P3407; Huber WW, 1997, MUTAT RES-FUND MOL M, V376, P115, DOI 10.1016/S0027-5107(97)00033-X; Katdare M, 1998, ONCOL REP, V5, P311; Kim DJ, 1997, CARCINOGENESIS, V18, P377, DOI 10.1093/carcin/18.2.377; KOJIMA T, 1994, CANCER RES, V54, P1446; Kolonel LN, 2000, CANCER EPIDEM BIOMAR, V9, P795; Krongrad A, 1998, Semin Urol Oncol, V16, P30; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Michnovicz JJ, 1997, JNCI-J NATL CANCER I, V89, P718, DOI 10.1093/jnci/89.10.718; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; NIWA T, 1994, STEROIDS, V59, P523, DOI 10.1016/0039-128X(94)90070-1; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; SAFE SH, 1995, ENVIRON HEALTH PERSP, V103, P346, DOI 10.2307/3432287; SAKR WA, 1995, PATHOL RES PRACT, V191, P838, DOI 10.1016/S0344-0338(11)80965-9; Salomons GS, 1997, INT J CANCER, V71, P959, DOI 10.1002/(SICI)1097-0215(19970611)71:6<959::AID-IJC9>3.0.CO;2-X; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; Steinmetz KA, 1996, J AM DIET ASSOC, V96, P1027, DOI 10.1016/S0002-8223(96)00273-8; Teixeira C, 1997, MOL ENDOCRINOL, V11, P1191, DOI 10.1210/me.11.9.1191; Telang NT, 1997, P SOC EXP BIOL MED, V216, P246, DOI 10.3181/00379727-216-44174; Timmermann S, 1997, CELL GROWTH DIFFER, V8, P361; TIWARI RK, 1994, J NATL CANCER I, V86, P126, DOI 10.1093/jnci/86.2.126; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wong GYC, 1997, J CELL BIOCHEM, P111; Xu M, 1996, CARCINOGENESIS, V17, P1429, DOI 10.1093/carcin/17.7.1429	57	253	269	4	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2001	20	23					2927	2936		10.1038/sj.onc.1204365	http://dx.doi.org/10.1038/sj.onc.1204365			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	435VA	11420705				2022-12-17	WOS:000168901800008
J	YonedaKato, N; Look, AT; Kirstein, MN; Valentine, MB; Raimondi, SC; Cohen, KJ; Carroll, AJ; Morris, SW				YonedaKato, N; Look, AT; Kirstein, MN; Valentine, MB; Raimondi, SC; Cohen, KJ; Carroll, AJ; Morris, SW			The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1	ONCOGENE			English	Article						acute myeloid leukemia; fusion gene; myelodysplasia-myeloid leukemia factor 1 (MLF 1); nucleophosmin (NPM); t(3;5) chromosomal translocation	ACUTE NONLYMPHOCYTIC LEUKEMIA; MAJOR NUCLEOLAR PROTEINS; TRANSLOCATION T(3-5); NUCLEAR PROTEINS; NUMATRIN; DNA; B23; PHOSPHORYLATION; LEUKEMOGENESIS; IDENTIFICATION	A t(3;5)(q25.1;q34) chromosomal translocation associated with myelodysplastic syndrome and acute myeloid leukemia (AML) was found to rearrange part of the nucleophosmin (NPM) gene on chromosome 5 with sequences from a novel gene on chromosome 3. Chimeric transcripts expressed by these cells contain 5' NPM coding sequences fused in-frame to those of the new gene, which we named myelodysplasia/myeloid leukemia factor 1 (MLF1). RNA-based polymerase chain reaction analysis revealed identical NPM-MLF1 mRNA fusions in each of the three t(3;5)-positive cases of AML examined, The predicted MLF1 amino acid sequence lacked homology to previously characterized proteins and did not contain known functional motifs. Normal MLF1 transcripts were expressed in a variety of tissues, most abundantly in testis, ovary, skeletal muscle, heart, kidney and colon. Anti-MLF1 antibodies detected the wild-type 31 kDa protein in K562 and HEL erythroleukemia cell Lines, but not in HL-60, U937 or KG-1 myeloid leukemia lines. By contrast, t(3;5)-positive leukemia cells expressed a 54 kDa NPM-MLF1 protein, but not normal MLF1. Immunostaining experiments indicated that MLF1 is normally located in the cytoplasm, whereas NPM-MLF1 is targeted to the nucleus, with highest levels in the nucleolus. The nuclear/nucleolar localization of NPM-MLF1 mirrors that of NPM, indicating that NPM trafficking signals direct MLF1 to an inappropriate cellular compartment in myeloid leukemia cells.	ST JUDE CHILDRENS RES HOSP, DEPT EXPTL ONCOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL & ONCOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT PATHOL, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, COLL MED, DEPT PEDIAT, MEMPHIS, TN USA; JOHNS HOPKINS UNIV HOSP, DEPT PEDIAT ONCOL, BALTIMORE, MD 21287 USA; UNIV ALABAMA, MED GENET LAB, BIRMINGHAM, AL USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; Johns Hopkins University; Johns Hopkins Medicine; University of Alabama System; University of Alabama Birmingham			Raimondi, Susana C/N-8166-2018		NATIONAL CANCER INSTITUTE [P01CA020180, K08CA001702, P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA 20180, K08 CA 01702, CA 21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMREIN H, 1994, CELL, V76, P735, DOI 10.1016/0092-8674(94)90512-6; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BERGER R, 1987, CANCER GENET CYTOGEN, V28, P261, DOI 10.1016/0165-4608(87)90212-3; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; CHAN PK, 1986, J BIOL CHEM, V261, P14335; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; CHATTERJEE A, 1991, BIOCHEM BIOPH RES CO, V180, P805, DOI 10.1016/S0006-291X(05)81136-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DUMBAR TS, 1989, BIOCHEMISTRY-US, V28, P9495, DOI 10.1021/bi00450a037; FEUERSTEIN N, 1991, EXP CELL RES, V194, P289, DOI 10.1016/0014-4827(91)90367-4; FEUERSTEIN N, 1990, BIOCHIM BIOPHYS ACTA, V1087, P127, DOI 10.1016/0167-4781(90)90196-9; FEUERSTEIN N, 1991, J BIOL CHEM, V266, P16200; FONAGY A, 1994, CANCER RES, V54, P1859; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; HERNANDEZVERDUN D, 1991, J CELL SCI, V99, P465; INOUYE CJ, 1994, J BIOL CHEM, V269, P6506; KEYES LN, 1992, CELL, V68, P933, DOI 10.1016/0092-8674(92)90036-C; KOEFFLER HP, 1986, SEMIN HEMATOL, V23, P223; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; KRAEMER D, 1994, P NATL ACAD SCI USA, V91, P1519, DOI 10.1073/pnas.91.4.1519; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LIU QR, 1991, EUR J BIOCHEM, V200, P715, DOI 10.1111/j.1432-1033.1991.tb16236.x; LOOK AT, 1995, ADV CANCER RES; MORISHITA K, 1990, ONCOGENE RES, V5, P221; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; MORRIS SW, 1992, GENE CHROMOSOME CANC, V5, P385, DOI 10.1002/gcc.2870050414; OSHIMURA M, 1976, CANCER, V38, P748, DOI 10.1002/1097-0142(197608)38:2<748::AID-CNCR2820380218>3.0.CO;2-U; PERLAKY L, 1992, CANCER RES, V52, P428; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; PI D, 1986, CANCER GENET CYTOGEN, V20, P171, DOI 10.1016/0165-4608(86)90122-6; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAIMONDI SC, 1989, LEUKEMIA, V3, P42; REDNER RL, 1994, BLOOD, V84, pA375; ROWLEY JD, 1976, BLOOD, V47, P705; SCHMIDTZACHMANN MS, 1988, CHROMOSOMA, V96, P417, DOI 10.1007/BF00303035; SCHMIDTZACHMANN MS, 1987, EMBO J, V6, P1881, DOI 10.1002/j.1460-2075.1987.tb02447.x; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SHARP RA, 1987, LEUKEMIA RES, V11, P629, DOI 10.1016/0145-2126(87)90035-X; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SMADJA N, 1986, CANCER GENET CYTOGEN, V20, P173, DOI 10.1016/0165-4608(86)90123-8; Steinmann-Zwicky M, 1990, Adv Genet, V27, P189; TAKEMURA M, 1994, BIOCHEM BIOPH RES CO, V199, P46, DOI 10.1006/bbrc.1994.1191; VALDEZ BC, 1994, J BIOL CHEM, V269, P23776; VONLINDERN M, 1992, MOL CELL BIOL, V12, P3346, DOI 10.1128/MCB.12.8.3346; WERNERFAVRE C, 1985, CANCER GENET CYTOGEN, V16, P279, DOI 10.1016/0165-4608(85)90056-1; YUNG BYM, 1987, BIOCHIM BIOPHYS ACTA, V925, P74, DOI 10.1016/0304-4165(87)90149-8	47	253	263	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	1996	12	2					265	275						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570204				2022-12-17	WOS:A1996TR53800006
J	ENG, C; SMITH, DP; MULLIGAN, LM; HEALEY, CS; ZVELEBIL, MJ; STONEHOUSE, TJ; PONDER, MA; JACKSON, CE; WATERFIELD, MD; PONDER, BAJ				ENG, C; SMITH, DP; MULLIGAN, LM; HEALEY, CS; ZVELEBIL, MJ; STONEHOUSE, TJ; PONDER, MA; JACKSON, CE; WATERFIELD, MD; PONDER, BAJ			A NOVEL POINT MUTATION IN THE TYROSINE KINASE DOMAIN OF THE RET PROTOONCOGENE IN SPORADIC MEDULLARY-THYROID CARCINOMA AND IN A FAMILY WITH FMTC	ONCOGENE			English	Article						MULTIPLE ENDOCRINE NEOPLASIA TYPE 2; RECEPTOR TYROSINE KINASE GENE	MULTIPLE ENDOCRINE NEOPLASIA; PROTOONCOGENE; FEATURES	Germline mutations within one of six codons of the RET proto-oncogene account for the majority of cases of multiple endocrine neoplasia (MEN) type 2A and type 2B and familial medullary thyroid carcinoma (FMTC). MEN 2A and FMTC mutations characterised thus far occur exclusively in the cysteine-rich domain of the extracellular region of RET. We now report a missense mutation in the intracellular tyrosine kinase domain of RET in the germline of a family with FMTC that does not have a cysteine codon mutation. In this family, the mutation, which alters GAG (GIu) to GAC (Asp) at codon 768, segregates with the FMTC phenotype. The same mutation was also detected in sporadic MTC but not in corresponding constitutional DNA, confirming that it is likely to be of pathological significance rather than a rare polymorphism.	UNIV CAMBRIDGE, DEPT PATHOL, CRC, HUMAN CANC GENET RES GRP, CAMBRIDGE CB2 1QP, ENGLAND; HARVARD UNIV, SCH MED,DANA FARBER CANC INST,DEPT MED, DIV MED ONCOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED,DANA FARBER CANC INST,DEPT MED, DIV CANC EPIDEMIOL & CONTROL, BOSTON, MA 02115 USA; QUEENS UNIV, DEPT PEDIAT, KINGSTON, ON K7L 3N6, CANADA; QUEENS UNIV, DEPT PATHOL, KINGSTON, ON K7L 3N6, CANADA; LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND; HENRY FORD HOSP, DEPT MED, DETROIT, MI 48202 USA; UCL, DEPT BIOCHEM & MOLEC BIOL, LONDON, ENGLAND	University of Cambridge; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Queens University - Canada; Queens University - Canada; Ludwig Institute for Cancer Research; Henry Ford Health System; Henry Ford Hospital; University of London; University College London				Zvelebil, Marketa/0000-0001-8018-5591; Eng, Charis/0000-0002-3693-5145				CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; ENG C, IN PRESS GENES CHROM; FARNDON JR, 1986, BRIT J SURG, V73, P278, DOI 10.1002/bjs.1800730411; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; IWAMOTO T, 1993, ONCOGENE, V8, P1087; JACKSON C E, 1986, Materia Medica Polona, V18, P59; JACKSON CE, 1973, ANN INTERN MED, V78, P845, DOI 10.7326/0003-4819-78-6-845; KNIGHTON DR, 1993, P NATL ACAD SCI USA, V90, P5001, DOI 10.1073/pnas.90.11.5001; MATHEW CGP, 1987, NATURE, V328, P524, DOI 10.1038/328524a0; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; NAKAMURA T, 1994, J PATHOL, V172, P255, DOI 10.1002/path.1711720305; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAZIN MJ, 1992, TRENDS BIOCHEM SCI, V17, P374, DOI 10.1016/0968-0004(92)90003-R; RESH MD, 1993, BIOCHIM BIOPHYS ACTA, V1155, P307, DOI 10.1016/0304-419X(93)90012-2; SANTORO M, 1990, ONCOGENE, V5, P1595; SCHIMKE RN, 1984, ANNU REV MED, V35, P25, DOI 10.1146/annurev.me.35.020184.000325; SUGAYA R, 1994, MECH DEVELOP, V45, P139, DOI 10.1016/0925-4773(94)90027-2; WOLFE HJ, 1973, NEW ENGL J MED, V289, P437, DOI 10.1056/NEJM197308302890901	22	253	257	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					509	513						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845675				2022-12-17	WOS:A1995QF64800011
J	LOVEC, H; SEWING, A; LUCIBELLO, FC; MULLER, R; MOROY, T				LOVEC, H; SEWING, A; LUCIBELLO, FC; MULLER, R; MOROY, T			ONCOGENIC ACTIVITY OF CYCLIN D1 REVEALED THROUGH COOPERATION WITH HA-RAS - LINK BETWEEN CELL-CYCLE CONTROL AND MALIGNANT TRANSFORMATION	ONCOGENE			English	Note							RETINOBLASTOMA GENE-PRODUCT; EXPRESSION; CARCINOMAS; BCL-1	Circumstantial evidence implicates the putative cell cycle regulator cyclin D1 in the process of malignant transformation. Overexpression of cyclin D1 is observed in mammary carcinomas as a result of gene amplification and in parathyroid adenomas and centrocytic B-cell lymphomas as a consequence of chromosomal rearrangements and juxtaposition of the cyclin D1 gene to strong transcriptional control elements. These findings suggest that deregulation of cyclin D1 expression may contribute to malignant transformation in these tumours. To date, however, an oncogenic potential of cyclin D1 has not been demonstrated and the mechanism of its oncogenic activation remains obscure although overexpression of the wild-type protein is likely. We report here that the overexpression of cyclin D1 induces transformation in primary rat embryo fibroblasts in cooperation with activated Ha-uas. Cyclin D1/Ha-ras transformed cells are immortalized, show anchorage independence and give rise to fibrosarcomas in nude mice. Our data directly demonstrate that cyclin D1 is a proto-oncogene that can be activated by transcriptional deregulation. Its previously demonstrated ability to interact with putative cell cycle regulators suggests that cyclin D1 defines a new class of proto-oncogenes.	PHILIPPS UNIV MARBURG, INST MOLEK BIOL & TUMORFORSCH, D-35037 MARBURG, GERMANY	Philipps University Marburg			Moroy, Tarik/D-9923-2011; Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; JIANG W, 1992, CANCER RES, V52, P2980; LAMMIE GA, 1991, ONCOGENE, V6, P439; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; ROSENBERG CL, 1993, ONCOGENE, V8, P519; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SCHUERMANN M, 1990, NUCLEIC ACIDS RES, V18, P4945, DOI 10.1093/nar/18.16.4945; SCHUURING E, 1992, ONCOGENE, V7, P355; SEWING A, 1993, J CELL SCI, V104, P545; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	20	253	262	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1994	9	1					323	326						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302597				2022-12-17	WOS:A1994MW24700040
J	SAKAI, E; TSUCHIDA, N				SAKAI, E; TSUCHIDA, N			MOST HUMAN SQUAMOUS-CELL CARCINOMAS IN THE ORAL CAVITY CONTAIN MUTATED P53 TUMOR-SUPPRESSOR GENES	ONCOGENE			English	Article							POLYMERASE CHAIN-REACTION; EPIDERMAL GROWTH-FACTOR; LUNG-CANCER; HUMAN HEAD; C-MYC; EXPRESSION; AMPLIFICATION; FREQUENT; DNA; MUTATIONS	Oral squamous cell carcinoma cell lines and tumor tissues used for cell line establishment were examined for p53 tumor-suppressor gene mutation using cellular DNAs and RNAs. For sensitive and rapid detection, a newly designed two-stage filtration strategy was used. Full advantage was taken of the single-strand conformation polymorphism (SSCP) of cDNA and cellular DNA fragments amplified by the polymerase chain reaction (PCR), followed by DNA sequencing of mutated fragments. Fourteen out of 15 cell lines and the corresponding five tumor tissues had p53 mutations within the region of exons 5-8. Loss of normal alleles was noted in 14 lines, but not in one in which only mutated transcripts were detected. DNA sequencing indicated six out of 14 mutations to be in positions that have so far not been reported. In two special cases, novel mutations were found in the splicing donor sequence of exon 6, and consequently the cryptic splice site had to be used. Extremely frequent p53 gene mutations indicated that the mutations are likely be intimately involved in the carcinogenesis of oral squamous cell carcinoma.	TOKYO MED & DENT UNIV,FAC DENT,DEPT MOLEC CELLULAR ONCOL & MICROBIOL,1-5-45 YUSHIMA,BUNKYO KU,TOKYO 113,JAPAN; TOKYO MED & DENT UNIV,FAC DENT,DEPT ORAL & MAXILLOFACIAL SURG 2,BUNKYO KU,TOKYO 113,JAPAN	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)								BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARTEK J, 1990, ONCOGENE, V5, P893; BERENSON JR, 1989, ONCOGENE, V4, P1111; BOS JL, 1989, CANCER RES, V49, P4682; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHIBA I, 1990, ONCOGENE, V5, P1603; CROOK T, 1991, ONCOGENE, V6, P873; CROOK T, 1991, ONCOGENE, V6, P1251; FABRICANT RN, 1977, P NATL ACAD SCI USA, V74, P565, DOI 10.1073/pnas.74.2.565; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; Favaloro J, 1980, Methods Enzymol, V65, P718; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIELD JK, 1989, ONCOGENE, V4, P1463; FIELD JK, 1987, J ORAL PATHOL MED, V16, P97, DOI 10.1111/j.1600-0714.1987.tb01474.x; FRIEDL F, 1970, P SOC EXP BIOL MED, V135, P543; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; GEY G, 1952, CANCER RES, V12, P246; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KAMATA N, 1986, CANCER RES, V46, P1648; KOIKE K, 1983, NUCLEIC ACIDS RES, V11, P5391, DOI 10.1093/nar/11.16.5391; Maniatis T., 1982, MOL CLONING; MCALLISTER RM, 1971, CANCER-AM CANCER SOC, V27, P397, DOI 10.1002/1097-0142(197102)27:2<397::AID-CNCR2820270224>3.0.CO;2-X; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MOMOSE F, 1989, J ORAL PATHOL MED, V18, P391, DOI 10.1111/j.1600-0714.1989.tb01570.x; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; MURAKAMI Y, 1991, CANCER RES, V51, P3356; NIGRO JM, 1989, NATURE, V342, P725; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; RIKIMARU K, 1992, IN PRESS HEAD NECK; ROMANO JW, 1989, ONCOGENE, V4, P1483; RUMSBY G, 1990, BRIT J CANCER, V61, P365, DOI 10.1038/bjc.1990.80; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHENG ZM, 1990, BRIT J CANCER, V62, P398, DOI 10.1038/bjc.1990.306; SILVERBERG E, 1989, CA-CANCER J CLIN, V39, P3; SOMERS KD, 1990, ONCOGENE, V5, P915; TADOKORO K, 1989, ONCOGENE, V4, P499; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; UEDA M, 1990, JPN J ORAL MAXILLOFA, V36, P2211; VARLEY JM, 1991, ONCOGENE, V6, P413; WEISS R, 1982, RNA TUMOUR VIRUSES M; YAMAMOTO K, 1991, IN PRESS EXP GERONTO; YAMAMOTO T, 1986, CANCER RES, V46, P414; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x	55	253	255	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1992	7	5					927	933						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1570156				2022-12-17	WOS:A1992HP64200012
J	VARLEY, JM; ARMOUR, J; SWALLOW, JE; JEFFREYS, AJ; PONDER, BAJ; TANG, A; FUNG, YKT; BRAMMAR, WJ; WALKER, RA				VARLEY, JM; ARMOUR, J; SWALLOW, JE; JEFFREYS, AJ; PONDER, BAJ; TANG, A; FUNG, YKT; BRAMMAR, WJ; WALKER, RA			THE RETINOBLASTOMA GENE IS FREQUENTLY ALTERED LEADING TO LOSS OF EXPRESSION IN PRIMARY BREAST-TUMORS	ONCOGENE			English	Article									UNIV LEICESTER,DEPT GENET,LEICESTER LE1 7RH,ENGLAND; UNIV LEICESTER,DEPT PATHOL,LEICESTER LE1 7RH,ENGLAND; INST CANC RES,SUTTON SM2 5NG,SURREY,ENGLAND; UNIV SO CALIF,CHILDRENS HOSP LOS ANGELES,DIV HEMATOL ONCOL,LOS ANGELES,CA 90027; UNIV SO CALIF,DEPT OPHTHAMOL & PEDIAT,LOS ANGELES,CA 90027	University of Leicester; University of Leicester; University of London; Institute of Cancer Research - UK; Children's Hospital Los Angeles; University of Southern California; University of Southern California	VARLEY, JM (corresponding author), UNIV LEICESTER,ICI UNIV JOINT LAB,LEICESTER LE1 7RH,ENGLAND.			Armour, John/0000-0002-8558-8506				ABRAMSON DH, 1984, OPHTHALMOLOGY, V91, P1351; CAVENEE W, 1984, AM J HUM GENET, V36, P10; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEVESA SS, 1975, AM J OPHTHALMOL, V80, P263, DOI 10.1016/0002-9394(75)90143-9; DRAPER GJ, 1986, BRIT J CANCER, V53, P661, DOI 10.1038/bjc.1986.110; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; ELSTON CW, 1982, BRIT J CANCER, V45, P4834; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GORDON H, 1974, MED GENETICS TODAY; HANSEN MF, 1985, P NATL ACAD SCI USA, V82, P6216, DOI 10.1073/pnas.82.18.6216; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARTLEY AL, 1986, BRIT J CANCER, V54, P819, DOI 10.1038/bjc.1986.245; HIGGINS MJ, 1989, MOL CELL BIOL, V9, P1; KNUDSON AG, 1986, ANNU REV GENET, V20, P231; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LEE EYHP, 1988, P NATL ACAD SCI USA, V85, P6017, DOI 10.1073/pnas.85.16.6017; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; NEWMAN B, 1988, P NATL ACAD SCI USA, V85, P3044, DOI 10.1073/pnas.85.9.3044; OTTMAN R, 1986, AM J EPIDEMIOL, V123, P15, DOI 10.1093/oxfordjournals.aje.a114209; SANDERS BM, 1988, BRIT J OPHTHALMOL, V72, P576, DOI 10.1136/bjo.72.8.576; SATTIN RW, 1985, JAMA-J AM MED ASSOC, V253, P1908, DOI 10.1001/jama.253.13.1908; SPARKES RS, 1980, SCIENCE, V208, P1042, DOI 10.1126/science.7375916; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; VARLEY JM, 1987, ONCOGENE, V1, P423; VARLEY JM, 1988, ONCOGENE, V3, P87; VARLEY JM, 1989, IN PRESS REV END REL; WHITTAKER JL, 1986, INT J CANCER, V38, P651, DOI 10.1002/ijc.2910380506; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WIGGS J, 1988, NEW ENGL J MED, V318, P151, DOI 10.1056/NEJM198801213180305; WONG Z, 1987, ANN HUM GENET, V51, P259; YUNIS JJ, 1978, AM J DIS CHILD, V132, P161, DOI 10.1001/archpedi.1978.02120270059012	36	253	254	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1989	4	6					725	729						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA660	2543943				2022-12-17	WOS:A1989AA66000008
J	FURTH, ME; ALDRICH, TH; CORDONCARDO, C				FURTH, ME; ALDRICH, TH; CORDONCARDO, C			EXPRESSION OF RAS PROTOONCOGENE PROTEINS IN NORMAL HUMAN-TISSUES	ONCOGENE			English	Article									MEM SLOAN KETTERING CANC CTR, DEPT PATHOL, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, DEWITT WALLACE RES LAB, GRAD PROGRAM MOLEC BIOL, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center				Garcia Vidal, Jessica Jazmin/0000-0002-3505-9606	NATIONAL CANCER INSTITUTE [P01CA016599, R01CA040620, P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [CA08748, CA16599, CA40620] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARNEKOW A, 1984, BIOCHIM BIOPHYS ACTA, V782, P94, DOI 10.1016/0167-4781(84)90110-6; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; CHANG EH, 1982, NATURE, V297, P479, DOI 10.1038/297479a0; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; DEFEO D, 1981, P NATL ACAD SCI-BIOL, V78, P3328, DOI 10.1073/pnas.78.6.3328; ELLIS RW, 1982, MOL CELL BIOL, V2, P1339, DOI 10.1128/MCB.2.11.1339; ERLANDSON RA, 1984, AM J SURG PATHOL, V8, P803, DOI 10.1097/00000478-198411000-00001; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GALLICK GE, 1985, P NATL ACAD SCI USA, V82, P1795, DOI 10.1073/pnas.82.6.1795; GEORGE DL, 1986, P NATL ACAD SCI USA, V83, P1651, DOI 10.1073/pnas.83.6.1651; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; GOYETTE M, 1984, MOL CELL BIOL, V4, P1493, DOI 10.1128/MCB.4.8.1493; GOYETTE M, 1983, SCIENCE, V219, P510, DOI 10.1126/science.6297003; HALLIDAY KR, 1984, J CYCLIC NUCL PROT, V9, P435; HAND PH, 1984, P NATL ACAD SCI-BIOL, V81, P5227, DOI 10.1073/pnas.81.16.5227; HAYASHI K, 1983, GANN, V74, P798; HSU SM, 1981, AM J CLIN PATHOL, V75, P816, DOI 10.1093/ajcp/75.6.816; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; KATAOKA T, 1984, CELL, V37, P437, DOI 10.1016/0092-8674(84)90374-X; Le Blond CP, 1976, STEM CELLS RENEWING, P7; MANNE V, 1985, P NATL ACAD SCI USA, V82, P376, DOI 10.1073/pnas.82.2.376; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MULLER R, 1983, MOL CELL BIOL, V3, P1062; PAWSON T, 1985, MOL CELL BIOL, V5, P33, DOI 10.1128/MCB.5.1.33; POTTEN CS, 1975, B CANCER, V62, P419; REYMOND CD, 1985, P NATL ACAD SCI USA, V82, P7005, DOI 10.1073/pnas.82.20.7005; REYMOND CD, 1984, CELL, V39, P141, DOI 10.1016/0092-8674(84)90199-5; RIOU G, 1984, CR ACAD SCI III-VIE, V299, P575; SCHEINBERG DA, 1981, P NATL ACAD SCI-BIOL, V78, P55, DOI 10.1073/pnas.78.1.55; SCHWAB M, 1983, NATURE, V303, P497, DOI 10.1038/303497a0; SEGAL D, 1986, MOL CELL BIOL, V6, P2241, DOI 10.1128/MCB.6.6.2241; SHIH TY, 1980, NATURE, V287, P686, DOI 10.1038/287686a0; SHILO BZ, 1981, P NATL ACAD SCI-BIOL, V78, P6789, DOI 10.1073/pnas.78.11.6789; SHIMIZU K, 1983, P NATL ACAD SCI-BIOL, V80, P2112, DOI 10.1073/pnas.80.8.2112; SHIMIZU K, 1983, NATURE, V304, P497, DOI 10.1038/304497a0; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; SLAMON DJ, 1984, P NATL ACAD SCI-BIOL, V81, P7141, DOI 10.1073/pnas.81.22.7141; SORGE JP, 1985, AM J PATHOL, V119, P151; SPANDIDOS DA, 1984, BRIT J CANCER, V49, P681, DOI 10.1038/bjc.1984.108; SWANSON ME, 1986, J CELL BIOL, V103, P485, DOI 10.1083/jcb.103.2.485; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; TATCHELL K, 1984, NATURE, V309, P523, DOI 10.1038/309523a0; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIOLA MV, 1985, J EXP MED, V161, P1213, DOI 10.1084/jem.161.5.1213; VIOLA MV, 1986, NEW ENGL J MED, V314, P133, DOI 10.1056/NEJM198601163140301; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0; WILLINGHAM MC, 1983, EXP CELL RES, V149, P141, DOI 10.1016/0014-4827(83)90387-7; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4	53	253	254	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1987	1	1					47	58						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	J6351	3125507				2022-12-17	WOS:A1987J635100006
J	Fang, L; Deng, Z; Shatseva, T; Yang, J; Peng, C; Du, WW; Yee, AJ; Ang, LC; He, C; Shan, SW; Yang, BB				Fang, L.; Deng, Z.; Shatseva, T.; Yang, J.; Peng, C.; Du, W. W.; Yee, A. J.; Ang, L. C.; He, C.; Shan, S. W.; Yang, B. B.			MicroRNA miR-93 promotes tumor growth and angiogenesis by targeting integrin-beta 8	ONCOGENE			English	Article						microRNA; siRNA; integrin; angiogenesis; tumorigenesis	MIR-17-92 CLUSTER; FACTOR-BETA; ALPHA-V-BETA-8-MEDIATED ACTIVATION; CELL-SURVIVAL; LUNG CANCERS; EXPRESSION; SUPPRESSOR; ROLES; APOPTOSIS; BLOOD	It has been reported that the miR-106b similar to 25 cluster, a paralog of the miR-17 similar to 92 cluster, possesses oncogenic activities. However, the precise role of each microRNA (miRNA) in the miR-106b similar to 25 cluster is not yet known. In this study, we examined the function of miR-93, one of the microRNAs within the miR-106b similar to 25 cluster, in angiogenesis and tumor formation. We found that miR-93 enhanced cell survival, promoted sphere formation and augmented tumor growth. Most strikingly, when miR-93-overexpressing U87 cells were co-cultured with endothelial cells, they supported endothelial cell spreading, growth, migration and tube formation. In vivo studies revealed that miR-93-expressing cells induced blood vessel formation, allowing blood vessels to extend to tumor tissues in high densities. Angiogenesis promoted by miR-93 in return facilitated cell survival, resulting in enhanced tumor growth. We further showed that integrin-beta 8 is a target of miR-93. Higher levels of integrin-beta 8 are associated with cell death in tumor mass and in human glioblastoma. Silencing of integrin-beta 8 expression using small interfering RNA promoted cell proliferation, whereas ectopic expression of integrin-beta 8 decreased cell growth. These findings showed that miR-93 promotes tumor growth and angiogenesis by suppressing, at least in part, integrin-beta 8 expression. Our results suggest that inhibition of miR-93 function may be a feasible approach to suppress angiogenesis and tumor growth. Oncogene (2011) 30, 806-821; doi:10.1038/onc.2010.465; published online 18 October 2010	[Fang, L.; Deng, Z.; Shatseva, T.; Du, W. W.; Yee, A. J.; Shan, S. W.; Yang, B. B.] Sunnybrook Hlth Sci Ctr, Sunnybrook Res Inst, Toronto, ON M4N 3M5, Canada; [Fang, L.; He, C.] Jilin Univ, China Japan Union Hosp, Jilin, Peoples R China; [Yang, J.; Peng, C.] York Univ, Dept Biol, Toronto, ON M3J 2R7, Canada; [Ang, L. C.] Univ Western Ontario, Dept Pathol, London, ON, Canada; [Fang, L.; Deng, Z.; Shatseva, T.; Shan, S. W.; Yang, B. B.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Jilin University; York University - Canada; Western University (University of Western Ontario); University of Toronto	Yang, BB (corresponding author), Sunnybrook Hlth Sci Ctr, Sunnybrook Res Inst, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	byang@sri.utoronto.ca	Yang, Bai/F-6483-2012	SHAN, SW/0000-0001-6876-9914	Heart and Stroke Foundation of Ontario [NA6282, CI5958]; Canadian Institutes of Health Research [MOP-102635]; China Scholarship Council; Ontario Women's Health Council/CIHR	Heart and Stroke Foundation of Ontario(Heart & Stroke Foundation of Ontario); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); China Scholarship Council(China Scholarship Council); Ontario Women's Health Council/CIHR(Canadian Institutes of Health Research (CIHR))	We thank the Brain Tumour Tissue Bank (London, Ontario) for glioblastoma slides. This work was supported by a grant from the Heart and Stroke Foundation of Ontario (NA6282) and a grant from Canadian Institutes of Health Research (MOP-102635) to BBY, who is the recipient of a Career Investigator Award (CI5958) from the Heart and Stroke Foundation of Ontario. LF is supported by a Scholarship from China Scholarship Council. CP is supported by a Mid-Career Award from Ontario Women's Health Council/CIHR.	Aguda BD, 2008, P NATL ACAD SCI USA, V105, P19678, DOI 10.1073/pnas.0811166106; Bonci D, 2008, NAT MED, V14, P1271, DOI 10.1038/nm.1880; Bullitt E, 2007, RADIOLOGY, V245, P824, DOI 10.1148/radiol.2453061889; Cambier S, 2005, AM J PATHOL, V166, P1883, DOI 10.1016/S0002-9440(10)62497-2; Cambier S, 2000, CANCER RES, V60, P7084; Dews M, 2006, NAT GENET, V38, P1060, DOI 10.1038/ng1855; Du LQ, 2009, MOL CANCER RES, V7, P1234, DOI 10.1158/1541-7786.MCR-08-0507; Fjellbirkeland L, 2003, AM J PATHOL, V163, P533, DOI 10.1016/S0002-9440(10)63681-4; Fontana L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002236; Hagendoorn J, 2006, CANCER RES, V66, P3360, DOI 10.1158/0008-5472.CAN-05-2655; Hayashita Y, 2005, CANCER RES, V65, P9628, DOI 10.1158/0008-5472.CAN-05-2352; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Hirschhaeuser F, 2010, J BIOTECHNOL, V148, P3, DOI 10.1016/j.jbiotec.2010.01.012; Koralov SB, 2008, CELL, V132, P860, DOI 10.1016/j.cell.2008.02.020; Landais S, 2007, CANCER RES, V67, P5699, DOI 10.1158/0008-5472.CAN-06-4478; Lee DY, 2007, P NATL ACAD SCI USA, V104, P20350, DOI 10.1073/pnas.0706901104; Lee DY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004527; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Lee YS, 2004, CELL, V117, P69, DOI 10.1016/S0092-8674(04)00261-2; Li Y, 2009, CANCER SCI, V100, P1234, DOI 10.1111/j.1349-7006.2009.01164.x; Mansfield JH, 2004, NAT GENET, V36, P1079, DOI 10.1038/ng1421; Matsubara H, 2007, ONCOGENE, V26, P6099, DOI 10.1038/sj.onc.1210425; Mendell JT, 2008, CELL, V133, P217, DOI 10.1016/j.cell.2008.04.001; Novotny GW, 2007, CELL DEATH DIFFER, V14, P879, DOI 10.1038/sj.cdd.4402090; Ota A, 2004, CANCER RES, V64, P3087, DOI 10.1158/0008-5472.CAN-03-3773; Petrocca F, 2008, CANCER RES, V68, P8191, DOI 10.1158/0008-5472.CAN-08-1768; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Shan SW, 2009, NAT CELL BIOL, V11, P1031, DOI 10.1038/ncb1917; Sharma A, 2009, P NATL ACAD SCI USA, V106, P5761, DOI 10.1073/pnas.0808743106; Sylvestre Y, 2007, J BIOL CHEM, V282, P2135, DOI 10.1074/jbc.M608939200; Takakura S, 2008, CANCER SCI, V99, P1147, DOI 10.1111/j.1349-7006.2008.00800.x; Tomari Y, 2005, CURR BIOL, V15, pR61, DOI 10.1016/j.cub.2004.12.057; Uziel T, 2009, P NATL ACAD SCI USA, V106, P2812, DOI 10.1073/pnas.0809579106; Ventura A, 2008, CELL, V132, P875, DOI 10.1016/j.cell.2008.02.019; Wang CH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002420; Wang Q, 2008, P NATL ACAD SCI USA, V105, P2889, DOI 10.1073/pnas.0800178105; Xiao CC, 2008, NAT IMMUNOL, V9, P405, DOI 10.1038/ni1575; Yeung ML, 2008, CANCER RES, V68, P8976, DOI 10.1158/0008-5472.CAN-08-0769; Zheng PS, 2004, FASEB J, V18, P754, DOI 10.1096/fj.03-0545fje	39	252	263	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	7					806	821		10.1038/onc.2010.465	http://dx.doi.org/10.1038/onc.2010.465			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722OT	20956944				2022-12-17	WOS:000287444600005
J	Prendergast, GC				Prendergast, G. C.			Immune escape as a fundamental trait of cancer: focus on IDO	ONCOGENE			English	Review						immunosuppression; immunotherapy; indoleamine 2,3-dioxygenase; Bin1; IDO2	PLASMACYTOID DENDRITIC CELLS; SMALL-MOLECULE INHIBITORS; TUMOR-SUPPRESSOR BIN1; DRAINING LYMPH-NODES; REGULATORY T-CELLS; INDOLEAMINE 2,3-DIOXYGENASE; TRYPTOPHAN CATABOLISM; LUNG-CANCER; MAST-CELLS; C-MYC	Immune escape is a critical gateway to malignancy. The emergence of this fundamental trait of cancer represents the defeat of immune surveillance, a potent, multi-armed and essential mode of cancer suppression that may influence the ultimate clinical impact of an early stage tumor. Indeed, immune escape may be a central modi. er of clinical outcomes, by affecting tumor dormancy versus progression, licensing invasion and metastasis and impacting therapeutic response. Although relatively little studied until recently, immune suppression and escape in tumors are now hot areas with clinical translation of several new therapeutic agents already under way. The interconnections between signaling pathways that control immune escape and those that control proliferation, senescence, apoptosis, metabolic alterations, angiogenesis, invasion and metastasis remain virtually unexplored, offering rich new areas for investigation. Here, an overview of this area is provided with a focus on the tryptophan catabolic enzyme indoleamine 2,3-dioxygenase (IDO) and its recently discovered relative IDO2 that are implicated in suppressing T-cell immunity in normal and pathological settings including cancer. Emerging evidence suggests that during cancer progression activation of the IDO pathway might act as a preferred nodal modi. er pathway for immune escape, for example analogous to the PI3K pathway for survival or the VEGF pathway for angiogenesis. Small molecule inhibitors of IDO and IDO2 heighten chemotherapeutic efficacy in mouse models of cancer in a nontoxic fashion and an initial lead compound entered phase I clinical trials in late 2007. New modalities in this area offer promising ways to broaden the combinatorial attack on advanced cancers, where immune escape mechanisms likely provide pivotal support.	[Prendergast, G. C.] Lankenau Inst Med Res, Wynnewood, PA 19096 USA; [Prendergast, G. C.] Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; [Prendergast, G. C.] Thomas Jefferson Univ, Jefferson Med Sch, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Lankenau Medical Center; Lankenau Institute for Medical Research; Jefferson University; Jefferson University	Prendergast, GC (corresponding author), Lankenau Inst Med Res, 100 Lancaster Ave, Wynnewood, PA 19096 USA.	prendergast@limr.org			NCI NIH HHS [R01 CA82222, R01 CA100123, R01 CA109542] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA109542, R01CA082222, R01CA100123] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622; Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; Ball HJ, 2007, GENE, V396, P203, DOI 10.1016/j.gene.2007.04.010; BANERJEE T, 2008, ONCOGENE IN PRESS; Bild AH, 2002, EMBO J, V21, P3255, DOI 10.1093/emboj/cdf351; Blank C, 2006, INT J CANCER, V119, P317, DOI 10.1002/ijc.21775; Bronte V, 2005, NAT REV IMMUNOL, V5, P641, DOI 10.1038/nri1668; Chang MY, 2007, CANCER RES, V67, P7605, DOI 10.1158/0008-5472.CAN-07-1100; Chang MY, 2007, CANCER RES, V67, P100, DOI 10.1158/0008-5472.CAN-06-2742; Colombo MP, 2007, NAT REV CANCER, V7, P880, DOI 10.1038/nrc2250; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Curti A, 2007, BLOOD, V109, P2871, DOI 10.1182/blood-2006-07-036863; Curtis RE, 1997, NEW ENGL J MED, V336, P897, DOI 10.1056/NEJM199703273361301; DuHadaway JB, 2003, ONCOGENE, V22, P3578, DOI 10.1038/sj.onc.1206481; DuHadaway JB, 2001, CANCER RES, V61, P3151; Dunn GP, 2004, IMMUNITY, V21, P137, DOI 10.1016/j.immuni.2004.07.017; Elliott K, 1999, ONCOGENE, V18, P3564, DOI 10.1038/sj.onc.1202670; Elliott K, 2000, ONCOGENE, V19, P4669, DOI 10.1038/sj.onc.1203681; Engels EA, 2007, CANCER RES, V67, P6520, DOI 10.1158/0008-5472.CAN-07-0370; Fallarino F, 2003, NAT IMMUNOL, V4, P1206, DOI 10.1038/ni1003; Fallarino F, 2006, J IMMUNOL, V176, P6752, DOI 10.4049/jimmunol.176.11.6752; Fallarino I, 2002, CELL DEATH DIFFER, V9, P1069, DOI 10.1038/sj.cdd.4401073; Friberg M, 2002, INT J CANCER, V101, P151, DOI 10.1002/ijc.10645; Gabrilovich DI, 2007, CURR CANCER DRUG TAR, V7, P1, DOI 10.2174/156800907780006850; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Gaspari P, 2006, J MED CHEM, V49, P684, DOI 10.1021/jm0508888; Ge K, 2000, INT J CANCER, V86, P155, DOI 10.1002/(SICI)1097-0215(20000415)86:2<155::AID-IJC2>3.0.CO;2-M; Ge K, 1999, P NATL ACAD SCI USA, V96, P9689, DOI 10.1073/pnas.96.17.9689; Ge K, 2000, INT J CANCER, V85, P376; Grohmann U, 2007, NAT MED, V13, P579, DOI 10.1038/nm1563; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hou DY, 2007, CANCER RES, V67, P792, DOI 10.1158/0008-5472.CAN-06-2925; Huber S, 2006, FRONT BIOSCI-LANDMRK, V11, P1014, DOI 10.2741/1859; Hunter KW, 2006, CANCER RES, V66, P1251, DOI 10.1158/0008-5472.CAN-05-3705; Iwai Y, 2002, P NATL ACAD SCI USA, V99, P12293, DOI 10.1073/pnas.192461099; Karni R, 2007, NAT STRUCT MOL BIOL, V14, P185, DOI 10.1038/nsmb1209; Knoepfler PS, 2006, EMBO J, V25, P2723, DOI 10.1038/sj.emboj.7601152; Koebel CM, 2007, NATURE, V450, P903, DOI 10.1038/nature06309; Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005; Lu LF, 2006, NATURE, V442, P997, DOI 10.1038/nature05010; Machiels JPH, 2001, CANCER RES, V61, P3689; MEHTA RG, 1995, CARCINOGENESIS, V16, P399, DOI 10.1093/carcin/16.2.399; Mellor AL, 2001, NAT IMMUNOL, V2, P64, DOI 10.1038/83183; Mellor AL, 2004, INT IMMUNOL, V16, P1391, DOI 10.1093/intimm/dxh140; Mellor AL, 2004, NAT REV IMMUNOL, V4, P762, DOI 10.1038/nri1457; Mellor AL, 2008, NAT REV IMMUNOL, V8, P74, DOI 10.1038/nri2233; Metz R, 2007, CANCER RES, V67, P7082, DOI 10.1158/0008-5472.CAN-07-1872; Miaczynska M, 2004, CELL, V116, P445, DOI 10.1016/S0092-8674(04)00117-5; Muller AJ, 2005, EXPERT OPIN THER TAR, V9, P831, DOI 10.1517/14728222.9.4.831; Muller AJ, 2004, CANCER BIOL THER, V3, P1236, DOI 10.4161/cbt.3.12.1232; Muller AJ, 2005, NAT MED, V11, P312, DOI 10.1038/nm1196; Muller AJ, 2007, CURR CANCER DRUG TAR, V7, P31, DOI 10.2174/156800907780006896; Muller AJ, 2006, NAT REV CANCER, V6, P613, DOI 10.1038/nrc1929; Munn DH, 2007, J CLIN INVEST, V117, P1147, DOI 10.1172/JCI31178; Munn DH, 2005, IMMUNITY, V22, P633, DOI 10.1016/j.immuni.2005.03.013; Munn DH, 1998, SCIENCE, V281, P1191, DOI 10.1126/science.281.5380.1191; Munn DH, 2004, J CLIN INVEST, V114, P280, DOI 10.1172/JCI200421583; Muto S, 2007, CANCER SCI, V98, P1549, DOI 10.1111/j.1349-7006.2007.00577.x; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; Popovic PJ, 2007, J NUTR, V137, p1681S, DOI 10.1093/jn/137.6.1681S; Prendergast GC, 2007, CANCER RES, V67, P3500, DOI 10.1158/0008-5472.CAN-06-4626; Ramalingam A, 2007, CELL CYCLE, V6, P1655, DOI 10.4161/cc.6.13.4413; Ramalingam A, 2007, CELL CYCLE, V6, P1914, DOI 10.4161/cc.6.15.4514; Ren G, 2006, MICROBIOL MOL BIOL R, V70, P37, DOI 10.1128/MMBR.70.1.37-120.2006; ROSE DP, 1967, LANCET, V1, P239; Routhier EL, 2003, ONCOGENE, V22, P637, DOI 10.1038/sj.onc.1206162; Roy M, 2005, NUCLEIC ACIDS RES, V33, P5026, DOI 10.1093/nar/gki792; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Schlee M, 2007, ADV CANCER RES, V97, P167, DOI 10.1016/S0065-230X(06)97007-9; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Sharma MD, 2007, J CLIN INVEST, V117, P2570, DOI 10.1172/JCI31911; Soucek L, 2007, NAT MED, V13, P1211, DOI 10.1038/nm1649; Swensen SJ, 2005, RADIOLOGY, V235, P259, DOI 10.1148/radiol.2351041662; Tajiri T, 2003, CLIN CANCER RES, V9, P3345; Uyttenhove C, 2003, NAT MED, V9, P1269, DOI 10.1038/nm934; Wingender G, 2006, EUR J IMMUNOL, V36, P12, DOI 10.1002/eji.200535602; Xu Q, 2003, NUCLEIC ACIDS RES, V31, P5635, DOI 10.1093/nar/gkg786; Zou WP, 2005, NAT REV CANCER, V5, P263, DOI 10.1038/nrc1586	78	252	274	1	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2008	27	28					3889	3900		10.1038/onc.2008.35	http://dx.doi.org/10.1038/onc.2008.35			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	318JZ	18317452				2022-12-17	WOS:000257089000001
J	Watanabe, S; Umehara, H; Murayama, K; Okabe, M; Kimura, T; Nakano, T				Watanabe, S; Umehara, H; Murayama, K; Okabe, M; Kimura, T; Nakano, T			Activation of Akt signaling is sufficient to maintain pluripotency in mouse and primate embryonic stem cells	ONCOGENE			English	Article						Akt; ES cells; pluripotency; stem cell system	SELF-RENEWAL; ES CELLS; PROTEIN; MAINTENANCE; STAT3; DIFFERENTIATION; EXPRESSION; PATHWAY; PROLIFERATION; SUPPRESSION	Embryonic stem (ES) cells can self-renew indefinitely without losing their differentiation ability to any cell types. Phosphoinositide-3 kinase (PI3K)/Akt signaling plays a pivotal role in various stem cell systems, including the formation of embryonic germ (EG) cells from primordial germ cells and self-renewal of neural stem cells. Here, we show that myristoylated, active form of Akt (myr-Akt) maintained the undifferentiated phenotypes in mouse ES cells without the addition of leukemia inhibitory factor (LIF). The effects of myr-Akt were reversible, because LIF dependence and pluripotent differentiation activity were restored by the deletion of myr-Akt. In addition, myr-Akt-Mer fusion protein, whose enzymatic activity is controlled by 4-hydroxy-tamoxifen, also maintained the pluripotency of not only mouse but also cynomolgus monkey ES cells. These results clearly demonstrate that Akt signaling sufficiently maintains pluripotency in mouse and primate ES cells, and support the notion that PI3K/Akt signaling axis regulates 'stemness' in a broad spectrum of stem cell systems.	Osaka Univ, Grad Sch Med, Dept Pathol, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Frontier Biosci, Suita, Osaka, Japan; Osaka Univ, Genome Informat Res Ctr, Suita, Osaka, Japan	Osaka University; Osaka University; Osaka University	Kimura, T (corresponding author), Osaka Univ, Grad Sch Med, Dept Pathol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	tkimura@patho.med.osaka-u.ac.jp; tnakano@patho.med.osaka-u.ac.jp	Okabe, Masaru/B-6917-2015	Okabe, Masaru/0000-0002-0803-9044; Kimura, Tohru/0000-0001-9227-0996				Ben-Shushan E, 1998, MOL CELL BIOL, V18, P1866, DOI 10.1128/MCB.18.4.1866; Boeuf H, 1997, J CELL BIOL, V138, P1207, DOI 10.1083/jcb.138.6.1207; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Burdon T, 2002, TRENDS CELL BIOL, V12, P432, DOI 10.1016/S0962-8924(02)02352-8; Burdon T, 1999, DEV BIOL, V210, P30, DOI 10.1006/dbio.1999.9265; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chambers I, 2004, ONCOGENE, V23, P7150, DOI 10.1038/sj.onc.1207930; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Daheron L, 2004, STEM CELLS, V22, P770, DOI 10.1634/stemcells.22-5-770; Furuya M, 2003, GENESIS, V37, P180, DOI 10.1002/gene.10246; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Humphrey RK, 2004, STEM CELLS, V22, P522, DOI 10.1634/stemcells.22-4-522; Jirmanova L, 2002, ONCOGENE, V21, P5515, DOI 10.1038/sj.onc.1205728; Kielman MF, 2002, NAT GENET, V32, P594, DOI 10.1038/ng1045; Kim SJ, 2005, FEBS LETT, V579, P534, DOI 10.1016/j.febslet.2004.12.024; Kimura T, 2003, DEVELOPMENT, V130, P1691, DOI 10.1242/dev.00392; Kimura T, 2003, MOL CELL BIOL, V23, P1304, DOI 10.1128/MCB.23.4.1304-1315.2003; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; Masuyama N, 2001, J BIOL CHEM, V276, P32799, DOI 10.1074/jbc.M105431200; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Nagata M, 2003, J GENE MED, V5, P921, DOI 10.1002/jgm.431; Nakano T, 1996, SCIENCE, V272, P722, DOI 10.1126/science.272.5262.722; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Paling NRD, 2004, J BIOL CHEM, V279, P48063, DOI 10.1074/jbc.M406467200; Pesce M, 2001, STEM CELLS, V19, P271, DOI 10.1634/stemcells.19-4-271; Qi XX, 2004, P NATL ACAD SCI USA, V101, P6027, DOI 10.1073/pnas.0401367101; Saitou M, 2002, NATURE, V418, P293, DOI 10.1038/nature00927; Sato M, 2002, MECH DEVELOP, V113, P91, DOI 10.1016/S0925-4773(02)00002-3; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Stiles B, 2004, DEV BIOL, V273, P175, DOI 10.1016/j.ydbio.2004.06.008; Stiles B, 2002, MOL CELL BIOL, V22, P3842, DOI 10.1128/MCB.22.11.3842-3851.2002; Suemori H, 2003, METHOD ENZYMOL, V365, P419; Sumi T, 2004, STEM CELLS, V22, P861, DOI 10.1634/stemcells.22-5-861; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Takahashi K, 2003, NATURE, V423, P541, DOI 10.1038/nature01646; Xu RH, 2005, NAT METHODS, V2, P185, DOI 10.1038/NMETH744; Ying QL, 2003, NAT BIOTECHNOL, V21, P183, DOI 10.1038/nbt780; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X	42	252	268	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2006	25	19					2697	2707		10.1038/sj.onc.1209307	http://dx.doi.org/10.1038/sj.onc.1209307			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	039AW	16407845	Bronze			2022-12-17	WOS:000237272900001
J	Xu, CJ; Shen, GX; Chen, C; Gelinas, C; Kong, ANT				Xu, CJ; Shen, GX; Chen, C; Gelinas, C; Kong, ANT			Suppression of NF-kappa B and NF-kappa B-regulated gene expression by sulforaphane and PEITC through I kappa B alpha, IKK pathway in human prostate cancer PC-3 cells	ONCOGENE			English	Article						sulforaphane; phenethyl isothiocyanate; NF-kappa B; I kappa B alpha; IKK	PHENETHYL ISOTHIOCYANATE; TYROSINE PHOSPHORYLATION; INFLAMMATORY STIMULI; SIGNALING PATHWAY; INDUCED APOPTOSIS; POTENT INDUCTION; TERMINAL KINASE; DOWN-REGULATION; UP-REGULATION; ACTIVATION	Recent studies indicate that natural isothiocyanates, such as sulforaphane (SFN) and phenethyl isothiocyanate ( PEITC) possess strong antitumor activities in vitro and in vivo. The nuclear factor kappa B (NF-kappa B) is believed to play an important role in cancer chemoprevention due to its involvement in tumor cell growth, proliferation, angiogenesis, invasion, apoptosis, and survival. In this study, we investigated the effects and the molecular mechanisms of SFN and PEITC on NF-kappa B transcriptional activation and NF-kappa B-regulated gene expression in human prostate cancer PC-3 C4 cells. Treatment with SFN ( 20 and 30 mu M) and PEITC ( 5 and 7.5 mu M) significantly inhibited NF-kappa B transcriptional activity, nuclear transloction of p65, and gene expression of NF-kappa B-regulated VEGF, cylcin D1, and Bcl-X-L in PC- 3 C4 cells. To further elucidate the mechanism, we utilized the dominant-negative mutant of inhibitor of NF-kappa B alpha (I kappa B alpha) (SR-I kappa B alpha). Analogous to treatments with SFN and PEITC, SR-I kappa B alpha also strongly inhibited NF-kappa B transcriptional activity as well as VEGF, cylcin D1, and Bcl-X-L expression. Furthermore, SFN and PEITC also inhibited the basal and UVC-induced phosphorylation of I kappa B alpha and blocked UVC-induced I kappa B alpha degradation in PC-3 C4 cells. In examining the upstream signaling, we found that the dominant-negative mutant of IKK beta (dnIKK beta) possessed inhibitory effects similar to SFN and PEITC on NF-kappa B, VEGF, cylcin D1, Bcl-X-L as well as I kappa B alpha phosphorylation. In addition, treatment with SFN and PEITC potently inhibited phosphorylation of both IKKb and IKK alpha and significantly inhibited the in vitro phosphorylation of I kappa B alpha mediated by IKKb. Taken together, these results suggest that the inhibition of SFN and PEITC on NF-kappa B transcriptional activation as well as NF-kappa B-regulated VEGF, cyclin D1, and Bcl-X-L gene expression is mainly mediated through the inhibition of IKK phosphorylation, particularly IKK beta, and the inhibition of I kappa B alpha phosphorylation and degradation, as well as the decrease of nuclear translocation of p65 in PC-3 cells.	Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmaceut, Piscataway, NJ 08854 USA; Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center	Kong, ANT (corresponding author), Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmaceut, 160 Frelinghuysen Rd,Room 226, Piscataway, NJ 08854 USA.	kongt@cop.rutgers.edu	Kong, Ah-Ng Tony/AAX-2828-2020; Chen, Chi/B-4618-2008; Chen, Chi/AAF-5343-2020	Chen, Chi/0000-0001-9703-604X	NCI NIH HHS [R01-CA54999, R01-CA073674] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054999, R01CA073674] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggarwal Bharat B., 2004, Indian Journal of Experimental Biology, V42, P341; Amit S, 2003, SEMIN CANCER BIOL, V13, P15, DOI 10.1016/S1044-579X(02)00096-2; Bremner P, 2002, J PHARM PHARMACOL, V54, P453, DOI 10.1211/0022357021778637; Brooks JD, 2001, CANCER EPIDEM BIOMAR, V10, P949; Brooks JD, 1999, PROSTATE CANCER P D, V2, pS8, DOI 10.1038/sj.pcan.4500334; Catley MC, 2004, J BIOL CHEM, V279, P18457, DOI 10.1074/jbc.M400765200; Chen YR, 2002, J BIOL CHEM, V277, P39334, DOI 10.1074/jbc.M202070200; Chiao JW, 2002, INT J ONCOL, V20, P631; Chung FL, 2000, CARCINOGENESIS, V21, P2287, DOI 10.1093/carcin/21.12.2287; Cohen JH, 2000, JNCI-J NATL CANCER I, V92, P61, DOI 10.1093/jnci/92.1.61; Fan CG, 2003, J BIOL CHEM, V278, P2072, DOI 10.1074/jbc.M206718200; Gasparian AV, 2002, J CELL SCI, V115, P141; Gasparian AV, 2002, MOL CANCER THER, V1, P1079; Greten FR, 2004, CANCER LETT, V206, P193, DOI 10.1016/j.canlet.2003.08.029; Hecht SS, 2000, DRUG METAB REV, V32, P395, DOI 10.1081/DMR-100102342; Heiss E, 2001, J BIOL CHEM, V276, P32008, DOI 10.1074/jbc.M104794200; Henttu P, 1998, BIOCHEM BIOPH RES CO, V244, P167, DOI 10.1006/bbrc.1998.8238; Holmes-McNary M, 2000, CANCER RES, V60, P3477; Hu R, 2004, J PHARMACOL EXP THER, V310, P263, DOI 10.1124/jpet.103.064261; Huang SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/sj.onc.1204535; Jeong WS, 2004, PHARM RES-DORDR, V21, P661, DOI 10.1023/B:PHAM.0000022413.43212.cf; Kolonel LN, 2000, CANCER EPIDEM BIOMAR, V9, P795; Kong ANT, 2001, MUTAT RES-FUND MOL M, V480, P231, DOI 10.1016/S0027-5107(01)00182-8; Manna SK, 1999, J IMMUNOL, V163, P6800; Mathas S, 2003, BLOOD, V102, P1028, DOI 10.1182/blood-2002-04-1154; Nomura M, 2000, CARCINOGENESIS, V21, P1885, DOI 10.1093/carcin/21.10.1885; O'Mahony A, 2000, MOL CELL BIOL, V20, P1170, DOI 10.1128/MCB.20.4.1170-1178.2000; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Shukla S, 2004, CLIN CANCER RES, V10, P3169, DOI 10.1158/1078-0432.CCR-03-0586; Singh AV, 2004, CARCINOGENESIS, V25, P83, DOI 10.1093/carcin/bgg178; Srivastava SK, 2004, CARCINOGENESIS, V25, P1701, DOI 10.1093/carcin/bgh179; Steinmetz KA, 1996, J AM DIET ASSOC, V96, P1027, DOI 10.1016/S0002-8223(96)00273-8; Suh J, 2004, J CELL BIOCHEM, V91, P100, DOI 10.1002/jcb.10729; Suh JH, 2002, PROSTATE, V52, P183, DOI 10.1002/pros.10082; Takada Y, 2004, J BIOL CHEM, V279, P26287, DOI 10.1074/jbc.M400963200; Takada Y, 2004, J BIOL CHEM, V279, P15096, DOI 10.1074/jbc.M311192200; Takada Y, 2004, J BIOL CHEM, V279, P4750, DOI 10.1074/jbc.M304546200; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Talalay P, 2001, J NUTR, V131, p3027S, DOI 10.1093/jn/131.11.3027S; Willis MS, 2003, CLIN CHIM ACTA, V330, P57, DOI 10.1016/S0009-8981(03)00048-2; Xiao D, 2002, CANCER RES, V62, P3615	42	252	266	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2005	24	28					4486	4495		10.1038/sj.onc.1208656	http://dx.doi.org/10.1038/sj.onc.1208656			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	940PT	15856023				2022-12-17	WOS:000230157100002
J	Asano, T; Yao, YX; Zhu, JJ; Li, DH; Abbruzzese, JL; Reddy, SAG				Asano, T; Yao, YX; Zhu, JJ; Li, DH; Abbruzzese, JL; Reddy, SAG			The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappa B and c-Myc in pancreatic cancer cells	ONCOGENE			English	Article						pancreatic cancer; PI 3-kinase; Akt; NF-kappa B; c-Myc; PTEN	TUMOR-SUPPRESSOR; PHOSPHATIDYLINOSITOL 3-KINASE; IN-VIVO; DEPENDENT PHOSPHORYLATION; DUCTAL ADENOCARCINOMA; CARCINOMA CELLS; PROSTATE-CANCER; AKT ACTIVATION; GROWTH-FACTOR; INHIBITION	The persistent activation of signaling cascades results in dramatic consequences that include loss of cellular growth control and neoplastic transformation. We show here that phosphoinositide 3-kinase (PI 3-kinase) and its mediator Akt were constitutively activated in pancreatic cancer and that this might be due to the aberrant expression of their natural antagonist MMAC/PTEN. Indeed, our results show that MMAC/PTEN expression was either lost or significantly reduced in five of eight cell lines and in twelve of seventeen tumor specimens examined. That the poor expression of MMAC/PTEN in pancreatic cancer cells could be due to promoter methylation was indicated by methylation-specific PCR analysis. Our studies also indicated that PI 3-kinase targeted two important transcription factors in pancreatic cancer cells. The ability of constitutively activated NF-kappaB to induce gene expression and the stabilization of c-MYC protein by decreased phosphorylation of Thr58 were both dependent on PI 3-kinase activity. When pancreatic cancer cells were treated with a peptide antagonist of NF-kappaB nuclear translocation, or stably transfected with a dominant-negative mutant of MYC, their proliferation was markedly inhibited. Taken together, these data indicate that the aberrant expression of MMAC/PTEN contributes to the activation of the PI 3-kinase/Akt pathway and its transcription factor mediators in pancreatic cancer.	Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Reddy, SAG (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Unit 426,1515 Holcombe Blvd, Houston, TX 77030 USA.	sa08366@odin.mdacc.tmc.edu			NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA016672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adsay NV, 1999, PANCREAS, V18, P111, DOI 10.1097/00006676-199903000-00001; Arlt A, 2003, ONCOGENE, V22, P3243, DOI 10.1038/sj.onc.1206390; Bondar VM, 2002, MOL CANCER THER, V1, P989; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Dang CV, 1999, EXP CELL RES, V253, P63, DOI 10.1006/excr.1999.4686; Davies MA, 1998, CANCER RES, V58, P5285; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Ebert MPA, 2002, BRIT J CANCER, V86, P257, DOI 10.1038/sj/bjc/6600031; Evans D B, 1997, Cancer Treat Res, V90, P109; Fahy BN, 2003, BRIT J CANCER, V89, P391, DOI 10.1038/sj.bjc.6601037; Friess H, 1999, DIGEST SURG, V16, P281, DOI 10.1159/000018737; Ghosh AK, 1999, GENE, V235, P85, DOI 10.1016/S0378-1119(99)00206-1; Grewe M, 1999, CANCER RES, V59, P3581; Grumont RJ, 2002, MOL CELL, V10, P1283, DOI 10.1016/S1097-2765(02)00779-7; Hilgers W, 1999, GENE CHROMOSOME CANC, V26, P1; James L, 2002, P NATL ACAD SCI USA, V99, P10429, DOI 10.1073/pnas.162369299; Kolenko V, 1999, J IMMUNOL, V163, P590; Koul D, 2001, J BIOL CHEM, V276, P11402, DOI 10.1074/jbc.M007806200; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; LILLEMOE KD, 1995, ANN SURG, V221, P133, DOI 10.1097/00000658-199502000-00003; Longnecker DS, 1999, ANN NY ACAD SCI, V880, P74, DOI 10.1111/j.1749-6632.1999.tb09511.x; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030; Mills GB, 2001, P NATL ACAD SCI USA, V98, P10031, DOI 10.1073/pnas.191379498; Mutter GL, 2000, JNCI-J NATL CANCER I, V92, P924, DOI 10.1093/jnci/92.11.924; Nagy A, 2001, ANTICANCER RES, V21, P1321; Ng SSW, 2000, CANCER RES, V60, P5451; Ng SSW, 2001, CLIN CANCER RES, V7, P3269; Okami K, 1998, CANCER RES, V58, P509; Perugini RA, 2000, J SURG RES, V90, P39, DOI 10.1006/jsre.2000.5833; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Reddy SAG, 1997, J BIOL CHEM, V272, P29167, DOI 10.1074/jbc.272.46.29167; Reddy SAG, 2001, CANCER J, V7, P274; Reddy SAG, 2000, J IMMUNOL, V164, P1355, DOI 10.4049/jimmunol.164.3.1355; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sakurada A, 1997, JPN J CANCER RES, V88, P1025, DOI 10.1111/j.1349-7006.1997.tb00324.x; Salvesen HB, 2001, INT J CANCER, V91, P22, DOI 10.1002/1097-0215(20010101)91:1<22::AID-IJC1002>3.0.CO;2-S; Schleger C, 2002, MODERN PATHOL, V15, P462, DOI 10.1038/modpathol.3880547; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Shah SA, 2001, J GASTROINTEST SURG, V5, P603, DOI 10.1016/S1091-255X(01)80102-5; Shi Q, 2001, CANCER RES, V61, P4143; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; STAAL SP, 1977, P NATL ACAD SCI USA, V74, P3065, DOI 10.1073/pnas.74.7.3065; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tanno S, 2001, CANCER RES, V61, P589; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Wang WX, 1999, CLIN CANCER RES, V5, P119; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199; Yao Z, 2002, PANCREAS, V24, P42, DOI 10.1097/00006676-200201000-00006	56	252	268	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8571	8580		10.1038/sj.onc.1207902	http://dx.doi.org/10.1038/sj.onc.1207902			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15467756				2022-12-17	WOS:000224988800002
J	Castedo, M; Perfettini, JL; Roumier, T; Valent, A; Raslova, H; Yakushijin, K; Horne, D; Feunteun, J; Lenoir, G; Medema, R; Vainchenker, W; Kroemer, G				Castedo, M; Perfettini, JL; Roumier, T; Valent, A; Raslova, H; Yakushijin, K; Horne, D; Feunteun, J; Lenoir, G; Medema, R; Vainchenker, W; Kroemer, G			Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy	ONCOGENE			English	Article						aneuploidy; cancer; caspases; Chk-2; programmed cell death	CYTOCHROME-C RELEASE; GLYCOPROTEIN COMPLEX; CHECKPOINT KINASE-2; TUMOR-CELLS; MITOCHONDRIA; CASPASE-2; P53; INSTABILITY; CANCER; ACTIVATION	A conflict in cell cycle progression or DNA damage can lead to mitotic catastrophe when the DNA structure checkpoints are inactivated, for instance when the checkpoint kinase Chk2 is inhibited. Here we show that in such conditions, cells die during the metaphase of the cell cycle, as a result of caspase activation and subsequent mitochondrial damage. Molecular ordering of these phenomena reveals that mitotic catastrophe occurs in a p53-independent manner and involves a primary activation of caspase-2, upstream of cytochrome c release, followed by caspase-3 activation and chromatin condensation. Suppression of caspase-2 by RNA interference or pseudosubstrate inhibitors as well as blockade of the mitochondrial membrane permeabilization prevent the mitotic catastrophe and allow cells to further proceed the cell cycle beyond the metaphase, leading to asymmetric cell division. Heterokarya generated by the fusion of nonsynchronized cells can be driven to divide into three or more daughter cells when Chk2 and caspases are simultaneously inhibited. Such multipolar divisions, resulting from suppressed mitotic catastrophe, lead to the asymmetric distribution of cytoplasm (anisocytosis), DNA (anisokaryosis) and chromosomes (aneuploidy). Similarly, in a model of DNA damage-induced mitotic catastrophe, suppression of apoptosis leads to the generation of aneuploid cells. Our findings delineate a molecular pathway through which DNA damage, failure to arrest the cell cycle and inhibition of apoptosis can favor the occurrence of cytogenetic abnormalities that are likely to participate in oncogenesis.	Inst Gustave Roussy, CNRS, UMR 8125, F-94805 Villejuif, France; Inst Gustave Roussy, Lab Gen Cellulaire Canc, F-94805 Villejuif, France; Inst Gustave Roussy, INSERM, U362, F-94805 Villejuif, France; Oregon State Univ, Dept Chem, Corvallis, OR 97331 USA; Netherlands Canc Inst, Div Mol Biol H8, NL-1066 CX Amsterdam, Netherlands	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Oregon State University; Netherlands Cancer Institute	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, UMR 8125, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	Feunteun, Jean/AAZ-1267-2020; PERFETTINI, Jean-Luc/N-4699-2017; Raslova, Hana/N-3562-2018; Medema, Rene H/E-2981-2013; KROEMER, Guido/B-4263-2013; Medema, Rene H/G-5415-2011; Kroemer, Guido/AAY-9859-2020	PERFETTINI, Jean-Luc/0000-0002-2427-2604; Raslova, Hana/0000-0001-8846-5299; KROEMER, Guido/0000-0002-9334-4405; Feunteun, Jean/0000-0003-1212-9189; Medema, Rene/0000-0002-6754-0381; Vainchenker, William/0000-0003-4705-202X				Ahn JW, 2003, J BIOL CHEM, V278, P20480, DOI 10.1074/jbc.M213185200; Brenner C, 2000, SCIENCE, V289, P1150, DOI 10.1126/science.289.5482.1150; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Burns TF, 2003, MOL CELL BIOL, V23, P5556, DOI 10.1128/MCB.23.16.5556-5571.2003; Castedo M, 2004, ONCOGENE, V23, P4353, DOI 10.1038/sj.onc.1207573; Castedo M, 2001, J EXP MED, V194, P1097, DOI 10.1084/jem.194.8.1097; Castedo M, 2002, EMBO J, V21, P4070, DOI 10.1093/emboj/cdf391; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Choma D, 2001, BRIT J CANCER, V85, P14, DOI 10.1054/bjoc.2001.1892; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; DeWitt N, 2002, NATURE, V416, P354, DOI 10.1038/416354a; Ferri KF, 2000, CELL DEATH DIFFER, V7, P1137, DOI 10.1038/sj.cdd.4400748; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Ferri KF, 2000, J EXP MED, V192, P1081, DOI 10.1084/jem.192.8.1081; Ferri KF, 2000, EXP CELL RES, V261, P119, DOI 10.1006/excr.2000.5062; Goldmacher VS, 1999, P NATL ACAD SCI USA, V96, P12536, DOI 10.1073/pnas.96.22.12536; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Jallepalli PV, 2001, NAT REV CANCER, V1, P109, DOI 10.1038/35101065; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Lock RB, 1996, CANCER RES, V56, P4006; Lockshin RA, 2002, CURR OPIN CELL BIOL, V14, P727, DOI 10.1016/S0955-0674(02)00383-6; Masuda A, 2002, ONCOGENE, V21, P6884, DOI 10.1038/sj.onc.1205566; Mendelsohn AR, 2002, P NATL ACAD SCI USA, V99, P6871, DOI 10.1073/pnas.072290599; Nabha SM, 2002, CLIN CANCER RES, V8, P2735; Paroni G, 2002, J BIOL CHEM, V277, P15147, DOI 10.1074/jbc.M112338200; Penninger JM, 2003, NAT CELL BIOL, V5, P97, DOI 10.1038/ncb0203-97; Penninger JM, 1998, ADV IMMUNOL, V68, P51, DOI 10.1016/S0065-2776(08)60558-1; Raslova H, 2003, BLOOD, V101, P541, DOI 10.1182/blood-2002-05-1553; Ravagnan L, 2002, J CELL PHYSIOL, V192, P131, DOI 10.1002/jcp.10111; Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Roschke AV, 2002, NEOPLASIA, V4, P19, DOI 10.1038/sj.neo.7900197; Ruth AC, 2000, CANCER RES, V60, P2576; Shih IM, 2001, CANCER RES, V61, P818; Slovak ML, 2000, BLOOD, V96, P4075, DOI 10.1182/blood.V96.13.4075; Sosa ACB, 2000, J ORG CHEM, V65, P610, DOI 10.1021/jo991277o; Takada S, 2003, CELL, V113, P87, DOI 10.1016/S0092-8674(03)00202-2; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Tort F, 2002, BLOOD, V100, P4602, DOI 10.1182/blood-2002-04-1078; Valent A, 2001, AM J PATHOL, V158, P1579, DOI 10.1016/S0002-9440(10)64112-0; Vieira HLA, 2001, ONCOGENE, V20, P4305, DOI 10.1038/sj.onc.1204575; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang XD, 2001, GENE DEV, V15, P2922; Wurmser AE, 2002, NATURE, V416, P485, DOI 10.1038/416485a; Zamzami N, 2003, CURR BIOL, V13, pR71, DOI 10.1016/S0960-9822(02)01433-1	54	252	263	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2004	23	25					4362	4370		10.1038/sj.onc.1207572	http://dx.doi.org/10.1038/sj.onc.1207572			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	824CJ	15048075				2022-12-17	WOS:000221661300002
J	Friedman, AD				Friedman, AD			Transcriptional regulation of granulocyte and monocyte development	ONCOGENE			English	Review						granulocyte; monocyte; differentiation; C/EBP; PU.1	COLONY-STIMULATING FACTOR; WILMS-TUMOR SUPPRESSOR; BINDING PROTEIN ALPHA; ZINC-FINGER GENE; EOSINOPHIL LINEAGE COMMITMENT; CHICKEN LYSOZYME ENHANCER; FACTOR-RECEPTOR PROMOTER; MAF NUCLEAR ONCOPROTEIN; CENTRAL-NERVOUS-SYSTEM; EARLY MYELOID GENE	Granulocytes and monocytes develop from a common myeloid progenitor. Early granulopoiesis requires the C/ EBPalpha, PU.1, RAR, CBF, and c-Myb transcription factors, and terminal neutrophil differentiation is dependent upon C/EBPepsilon, PU.1, Sp1, CDP, and HoxA10. Monopoiesis can be induced by Maf-B, c-Jun, or Egr-1 and is dependent upon PU.1, Sp1, and ICSBP. Signals eminating from cytokine receptors modulate factor activities but do not determine cell fates. Orchestration of the myeloid developmental program is achieved via cooperative gene regulation, via synergistic and inhibitory protein-protein interactions, via promoter auto-regulation and cross-regulation, via regulation of factor levels, and via induction of cell cycle arrest: For example, c-Myb and C/EBPalpha cooperate to activate the mim-1 and NE promoters, PU.1, C/EBPalpha,, and CBF, regulate the NE, MPO, and M-CSF Receptor genes. PU.1:GATA-1 interaction and C/EBP suppression of FOG transcription inhibits erythroid and megakaryocyte gene expression. c-Jun:PU.1, ICSBP:PU.1, and perhaps Maf:Jun complexes induce monocytic genes. PU.1 and C/EBPa activate their own promoters, C/EBPalpha rapidly induces PU.1 and C/EBPepsilon RNA expression, and RARalpha activates the C/ EBPepsilon promoter. Higher levels of PU.1 are required for monopoiesis than for B-lymphopoiesis, and higher C/ EBP levels may favor granulopoiesis over monopoiesis. CBF and c-Myb stimulate proliferation whereas C/EBPa induces a G1/S arrest; cell cycle arrest is required for terminal myelopoiesis, perhaps due to expression of p53 or hypo-phosphorylated Rb.	Johns Hopkins Univ, Div Pediat Oncol, Baltimore, MD 21231 USA	Johns Hopkins University	Friedman, AD (corresponding author), Johns Hopkins Univ, Div Pediat Oncol, Canc Res Bldg,Room 253,1650 Orleans St, Baltimore, MD 21231 USA.	adfrdman@jhmi.edu						AHNE B, 1994, J BIOL CHEM, V269, P17794; Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Anderson KL, 1999, BLOOD, V94, P2310, DOI 10.1182/blood.V94.7.2310.419k34_2310_2318; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; Antonson P, 1996, GENOMICS, V35, P30, DOI 10.1006/geno.1996.0319; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BAE SC, 1993, ONCOGENE, V8, P809; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; BAVISOTTO L, 1991, J EXP MED, V174, P1097, DOI 10.1084/jem.174.5.1097; Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; Behre G, 1999, BLOOD, V94, p684A; Bellon T, 1997, BLOOD, V90, P1828, DOI 10.1182/blood.V90.5.1828; Bergh G, 1999, BLOOD, V94, P1971; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BIES J, 1995, CELL GROWTH DIFFER, V6, P59; Bourette RP, 2000, GROWTH FACTORS, V17, P155, DOI 10.3109/08977190009001065; BritosBray M, 1997, MOL CELL BIOL, V17, P5127, DOI 10.1128/MCB.17.9.5127; Bromleigh VC, 2000, GENE DEV, V14, P2581, DOI 10.1101/gad.817100; Calkhoven CF, 2000, GENE DEV, V14, P1920; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; Cao WS, 1997, ONCOGENE, V15, P1315, DOI 10.1038/sj.onc.1201305; Cao WS, 1998, J BIOL CHEM, V273, P31534, DOI 10.1074/jbc.273.47.31534; CARLSSON L, 1995, EUR J IMMUNOL, V25, P2308, DOI 10.1002/eji.1830250829; Castilla LH, 1999, NAT GENET, V23, P144, DOI 10.1038/13776; Catt D, 1999, BLOOD, V94, P3151, DOI 10.1182/blood.V94.9.3151.421k38_3151_3160; Chang CP, 1996, MOL CELL BIOL, V16, P1734; Chang DH, 2000, NAT IMMUNOL, V1, P169, DOI 10.1038/77861; CHEN HM, 1995, BLOOD, V85, P2918, DOI 10.1182/blood.V85.10.2918.bloodjournal85102918; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CHEN HM, 1995, ONCOGENE, V11, P1549; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; Chen SS, 2000, MOL CELL BIOL, V20, P7292, DOI 10.1128/MCB.20.19.7292-7299.2000; Cheng T, 1996, P NATL ACAD SCI USA, V93, P13158, DOI 10.1073/pnas.93.23.13158; Chiang MY, 2001, J IMMUNOL, V166, P6091, DOI 10.4049/jimmunol.166.10.6091; Chih DY, 1997, BLOOD, V90, P2987, DOI 10.1182/blood.V90.8.2987; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; Christensen JE, 2001, INT IMMUNOL, V13, P593, DOI 10.1093/intimm/13.4.593; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; Chumakov AM, 1997, MOL CELL BIOL, V17, P1375, DOI 10.1128/MCB.17.3.1375; Chylicki K, 2000, CELL GROWTH DIFFER, V11, P561; Collins SJ, 2001, BLOOD, V98, P2382, DOI 10.1182/blood.V98.8.2382; COOPER C, 1995, NUCLEIC ACIDS RES, V23, P4371, DOI 10.1093/nar/23.21.4371; Corsetti MT, 1997, BLOOD, V89, P2359, DOI 10.1182/blood.V89.7.2359; CROSBY SD, 1991, MOL CELL BIOL, V11, P3835, DOI 10.1128/MCB.11.8.3835; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; de Koning JP, 2000, ONCOGENE, V19, P3290, DOI 10.1038/sj.onc.1203627; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P775, DOI 10.1093/nar/19.4.775; DeKoter RP, 1998, EMBO J, V17, P4456, DOI 10.1093/emboj/17.15.4456; DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; Du J, 1998, BLOOD, V92, p191A; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Eferl R, 1999, J CELL BIOL, V145, P1049, DOI 10.1083/jcb.145.5.1049; Ehinger M, 1998, EXP HEMATOL, V26, P1043; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; Eklund EA, 1999, J IMMUNOL, V163, P6095; Eklund EA, 2000, J BIOL CHEM, V275, P20117, DOI 10.1074/jbc.M907915199; Erickson PF, 1996, BLOOD, V88, P1813; Faust N, 1999, DNA CELL BIOL, V18, P631, DOI 10.1089/104454999315042; Fisher RC, 1998, MOL CELL BIOL, V18, P4347, DOI 10.1128/MCB.18.7.4347; Ford AM, 1996, P NATL ACAD SCI USA, V93, P10838, DOI 10.1073/pnas.93.20.10838; Friedman AD, 1999, LEUKEMIA, V13, P1932, DOI 10.1038/sj.leu.2401590; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; Friedman AD, 1996, CANCER RES, V56, P3250; Friedman AD, 1996, CURR TOP MICROBIOL, V211, P149; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; Gaboli M, 2001, GENE DEV, V15, P1625, DOI 10.1101/gad.902301; GOETHE R, 1994, J BIOL CHEM, V269, P31302; GOLAY J, 1991, BLOOD, V77, P149; Gombart AF, 2001, BLOOD, V97, P2561, DOI 10.1182/blood.V97.9.2561; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; Hegde SP, 1999, BLOOD, V94, P1578, DOI 10.1182/blood.V94.5.1578.417k18_1578_1589; Hegde SP, 1998, MOL CELL BIOL, V18, P2729, DOI 10.1128/MCB.18.5.2729; Henkel GW, 1999, BLOOD, V93, P2849; Herzer U, 1999, CURR BIOL, V9, P837, DOI 10.1016/S0960-9822(99)80369-8; Hetherington CJ, 1999, J IMMUNOL, V162, P503; Heydemann A, 1996, MOL CELL BIOL, V16, P1676; HOHAUS S, 1995, MOL CELL BIOL, V15, P5830; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; HROMAS R, 1991, J BIOL CHEM, V266, P14183; Hu HM, 1998, J IMMUNOL, V160, P2334; Inoue K, 1998, BLOOD, V91, P2969, DOI 10.1182/blood.V91.8.2969.2969_2969_2976; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Johansen LM, 2001, MOL CELL BIOL, V21, P3789, DOI 10.1128/MCB.21.11.3789-3806.2001; Jones LC, 2002, BLOOD, V99, P2032, DOI 10.1182/blood.V99.6.2032; KASTAN MB, 1991, CANCER RES, V51, P4279; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; Kataoka K, 1996, ONCOGENE, V12, P53; Kelly LM, 2000, EMBO J, V19, P1987, DOI 10.1093/emboj/19.9.1987; KERPPOLA TK, 1994, ONCOGENE, V9, P675; Khanna-Gupta A, 2000, BLOOD, V95, P3734; Khanna-Gupta A, 2001, P NATL ACAD SCI USA, V98, P8000, DOI 10.1073/pnas.141229598; KhannaGupta A, 1997, BLOOD, V90, P2784, DOI 10.1182/blood.V90.7.2784.2784_2784_2795; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kondo M, 2000, NATURE, V407, P383, DOI 10.1038/35030112; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Krishnaraju K, 1998, BLOOD, V92, P1957, DOI 10.1182/blood.V92.6.1957.418k24_1957_1966; KRISHNARAJU K, 1995, MOL CELL BIOL, V15, P5499; Krishnaraju K, 2001, BLOOD, V97, P1298, DOI 10.1182/blood.V97.5.1298; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; Labrecque J, 1998, BLOOD, V92, P607, DOI 10.1182/blood.V92.2.607.414k06_607_615; Lacaud G, 1998, IMMUNITY, V9, P827, DOI 10.1016/S1074-7613(00)80648-2; Lagasse E, 1997, CELL, V89, P1021, DOI 10.1016/S0092-8674(00)80290-1; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LAWRENCE HJ, 1995, EXP HEMATOL, V23, P1160; Lawson ND, 1998, BLOOD, V91, P2517, DOI 10.1182/blood.V91.7.2517.2517_2517_2524; LeCouter JE, 1998, MOL CELL BIOL, V18, P7455, DOI 10.1128/MCB.18.12.7455; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee SL, 1996, MOL CELL BIOL, V16, P4566; Lekstrom-Himes JA, 1999, J EXP MED, V189, P1847, DOI 10.1084/jem.189.11.1847; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; Li AC, 1998, J BIOL CHEM, V273, P5389, DOI 10.1074/jbc.273.9.5389; LI JM, 1994, CELL GROWTH DIFFER, V5, P743; LIESCHKE GJ, 1994, BLOOD, V84, P1737; Liu FL, 1996, IMMUNITY, V5, P491, DOI 10.1016/S1074-7613(00)80504-X; Liu FL, 1997, BLOOD, V90, P2583, DOI 10.1182/blood.V90.7.2583.2583_2583_2590; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Loeb DM, 2000, BLOOD, V96, p284A; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; Lou JR, 2000, ONCOGENE, V19, P2695, DOI 10.1038/sj.onc.1203588; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Luo W, 1996, J BIOL CHEM, V271, P18203, DOI 10.1074/jbc.271.30.18203; Lutz PG, 2001, BLOOD, V97, P2449, DOI 10.1182/blood.V97.8.2449; Manz MG, 2001, BLOOD, V97, P3333, DOI 10.1182/blood.V97.11.3333; Mao SF, 1999, MOL CELL BIOL, V19, P3635; Marecki S, 2001, J IMMUNOL, V166, P6829, DOI 10.4049/jimmunol.166.11.6829; Martinelli R, 1997, ONCOGENE, V15, P607, DOI 10.1038/sj.onc.1201218; Maurer U, 1997, EXP HEMATOL, V25, P945; McDevitt MA, 1997, P NATL ACAD SCI USA, V94, P6781, DOI 10.1073/pnas.94.13.6781; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Meraro D, 1999, J IMMUNOL, V163, P6468; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; Montecino-Rodriguez E, 2001, NAT IMMUNOL, V2, P83, DOI 10.1038/83210; MORRIS JF, 1995, BLOOD, V86, P3640; MORRIS JF, 1994, MOL CELL BIOL, V14, P1786, DOI 10.1128/MCB.14.3.1786; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Muller C, 1995, EMBO J, V14, P6127, DOI 10.1002/j.1460-2075.1995.tb00303.x; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; Nakajima H, 2001, BLOOD, V98, P897, DOI 10.1182/blood.V98.4.897; Nerlov C, 1998, GENE DEV, V12, P2413, DOI 10.1101/gad.12.15.2413; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; Niki M, 1997, P NATL ACAD SCI USA, V94, P5697, DOI 10.1073/pnas.94.11.5697; Nuchprayoon I, 1999, J BIOL CHEM, V274, P1085, DOI 10.1074/jbc.274.2.1085; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; Nuchprayoon I, 1997, BLOOD, V89, P4546, DOI 10.1182/blood.V89.12.4546; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; OGATA K, 1992, P NATL ACAD SCI USA, V89, P6428, DOI 10.1073/pnas.89.14.6428; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Olson MC, 1995, IMMUNITY, V3, P703, DOI 10.1016/1074-7613(95)90060-8; PAHL HL, 1993, J BIOL CHEM, V268, P5014; Pan Z, 1999, J BIOL CHEM, V274, P23242, DOI 10.1074/jbc.274.33.23242; Park DJ, 1999, J CLIN INVEST, V103, P1399, DOI 10.1172/JCI2887; Passegue E, 2001, CELL, V104, P21, DOI 10.1016/S0092-8674(01)00188-X; Peters UR, 1999, CANCER RES, V59, P4233; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; Querfurth E, 2000, GENE DEV, V14, P2515, DOI 10.1101/gad.177200; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; REISS K, 1991, J CELL PHYSIOL, V148, P338, DOI 10.1002/jcp.1041480303; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; Rodel JE, 1996, BLOOD, V87, P858, DOI 10.1182/blood.V87.3.858.bloodjournal873858; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Roodman GD, 1996, ENDOCR REV, V17, P308, DOI 10.1210/er.17.4.308; ROSMARIN AG, 1995, P NATL ACAD SCI USA, V92, P801, DOI 10.1073/pnas.92.3.801; ROSMARIN AG, 1995, J BIOL CHEM, V270, P23627, DOI 10.1074/jbc.270.40.23627; Rosmarin AG, 1998, J BIOL CHEM, V273, P13097, DOI 10.1074/jbc.273.21.13097; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; SATAKE M, 1992, JPN J CANCER RES, V83, P714, DOI 10.1111/j.1349-7006.1992.tb01971.x; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SCOTT LM, 1992, BLOOD, V80, P1725; SCREPANTI I, 1995, EMBO J, V14, P1932, DOI 10.1002/j.1460-2075.1995.tb07185.x; Seymour JF, 1997, BLOOD, V90, P3037, DOI 10.1182/blood.V90.8.3037; SHAPIRO LH, 1995, J BIOL CHEM, V270, P8763, DOI 10.1074/jbc.270.15.8763; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; Shimozaki K, 1997, J BIOL CHEM, V272, P25184, DOI 10.1074/jbc.272.40.25184; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; Slomiany BA, 2000, MOL CELL BIOL, V20, P5986, DOI 10.1128/MCB.20.16.5986-5997.2000; Smith LT, 1996, BLOOD, V88, P1234, DOI 10.1182/blood.V88.4.1234.bloodjournal8841234; Smith SI, 1998, BLOOD, V91, P764, DOI 10.1182/blood.V91.3.764.764_764_773; Soddu S, 1996, MOL CELL BIOL, V16, P487; Strom DK, 2000, J BIOL CHEM, V275, P3438, DOI 10.1074/jbc.275.5.3438; SUZOW J, 1993, MOL CELL BIOL, V13, P2141, DOI 10.1128/MCB.13.4.2141; SZABO E, 1994, CELL GROWTH DIFFER, V5, P439; Tamura T, 2000, IMMUNITY, V13, P155, DOI 10.1016/S1074-7613(00)00016-9; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; Tavner FJ, 1998, MOL CELL BIOL, V18, P989, DOI 10.1128/MCB.18.2.989; Thorsteinsdottir U, 1997, MOL CELL BIOL, V17, P495, DOI 10.1128/MCB.17.1.495; Timchenko NA, 1999, MOL CELL BIOL, V19, P2936; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x; Traver D, 2001, BLOOD, V98, P627, DOI 10.1182/blood.V98.3.627; Tsai FY, 1998, DEV BIOL, V196, P218, DOI 10.1006/dbio.1997.8842; TSAI S, 1993, P NATL ACAD SCI USA, V90, P7153, DOI 10.1073/pnas.90.15.7153; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; van Dijk TB, 1998, BLOOD, V91, P2126, DOI 10.1182/blood.V91.6.2126.2126_2126_2132; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG Q, 2002, IN PRESS BLOOD, V99; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; Wang W, 2001, LEUKEMIA, V15, P779, DOI 10.1038/sj.leu.2402094; Wang XP, 1999, BLOOD, V94, P560, DOI 10.1182/blood.V94.2.560.414k41_560_571; Ward AC, 2000, LEUKEMIA, V14, P973, DOI 10.1038/sj.leu.2401808; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; Williamson EA, 1998, J BIOL CHEM, V273, P14796, DOI 10.1074/jbc.273.24.14796; Yamaguchi Y, 1999, BLOOD, V94, P1429, DOI 10.1182/blood.V94.4.1429.416k13_1429_1439; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P13187, DOI 10.1073/pnas.94.24.13187; ZHANG DE, 1994, J BIOL CHEM, V269, P11425; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085; Zhang P, 2000, BLOOD, V96, P2641; Zhang P, 1998, J EXP MED, V188, P1173, DOI 10.1084/jem.188.6.1173; Zhang P., 1996, Blood, V88, p631A	234	252	259	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2002	21	21					3377	3390		10.1038/sj.onc.1205324	http://dx.doi.org/10.1038/sj.onc.1205324			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	552RL	12032776				2022-12-17	WOS:000175633300011
J	Tzivion, G; Shen, YH; Zhu, J				Tzivion, G; Shen, YH; Zhu, J			14-3-3 proteins; bringing new definitions to scaffolding	ONCOGENE			English	Review						14-3-3; phosphorylation; signal transduction; cell cycle	CREUTZFELDT-JAKOB-DISEASE; INSULIN-RECEPTOR SUBSTRATE-1; CELL-CYCLE PROGRESSION; IN-VIVO; SIGNALING PROTEINS; NUCLEAR-LOCALIZATION; KINASE-ACTIVITY; DNA-DAMAGE; T-CELLS; 14-3-3-PROTEINS ASSOCIATE	The 14-3-3 proteins are a part of an emerging family of proteins and protein domains that bind to serine/threonine-phosphorylated residues in a context specific manner, analogous to the Src homology 2 (SH2) and phospho-tyrosine binding (PTB) domains. 14-3-3 proteins bind and regulate key proteins involved in various physiological processes such as intracellular signaling (e.g. Raf, MLK, MEKK, PI-3 kinase, IRS-1), cell cycling (e.g. Cdc25, Wee1, CDK2, centrosome), apoptosis (e.g. BAD, ASK-1) and transcription regulation (e.g. FKHRL1, DAF-16, p53, TAZ, TLX-2, histone deacetylase). In contrast to SH2 and PTB domains, which serve mainly to mediate protein-protein interactions, 14-3-3 proteins in many cases alter the function of the target protein, thus allowing them to serve as direct regulators of their targets. This review focuses on the various mechanisms employed by the 14-3-3 proteins in the regulation of their diverse targets, the structural basis for 14-3-3-target protein interaction with emphasis on the role of 14-3-3 dimerization in target protein binding and regulation and provides an insight on 14-3-3 regulation itself.	Texas A&M Univ, Syst Hlth Sci Ctr, Coll Med, Div Mol Cardiol,Cardiovasc Res Inst, Temple, TX 76504 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Tzivion, G (corresponding author), Texas A&M Univ, Syst Hlth Sci Ctr, Coll Med, Div Mol Cardiol,Cardiovasc Res Inst, Temple, TX 76504 USA.	tzivion@medicine.tamu.edu	Tzivion, Guri/D-8954-2011					AITKEN A, 1995, MOL CELL BIOCHEM, V149, P41, DOI 10.1007/BF01076562; AITKEN A, 1995, J BIOL CHEM, V270, P5706, DOI 10.1074/jbc.270.11.5706; AITKEN A, 1995, BIOCHEM SOC T, V23, P605, DOI 10.1042/bst0230605; Barinaga M, 1999, SCIENCE, V283, P1247, DOI 10.1126/science.283.5406.1247; Benzing T, 2000, J BIOL CHEM, V275, P28167; Bihn EA, 1997, PLANT J, V12, P1439, DOI 10.1046/j.1365-313x.1997.12061439.x; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; Broadie K, 1997, NEURON, V19, P391, DOI 10.1016/S0896-6273(00)80948-4; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cahill CM, 2001, J BIOL CHEM, V276, P13402, DOI 10.1074/jbc.M010042200; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chang HC, 1997, GENE DEV, V11, P1132, DOI 10.1101/gad.11.9.1132; Chapman T, 2000, NEUROLOGY, V55, P1396, DOI 10.1212/WNL.55.9.1396; CHEN FS, 1994, FEBS LETT, V347, P128, DOI 10.1016/0014-5793(94)00520-6; Chiang CW, 2001, BLOOD, V97, P1289, DOI 10.1182/blood.V97.5.1289; Chung HJ, 1999, TRENDS PLANT SCI, V4, P367, DOI 10.1016/S1360-1385(99)01462-4; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; Cotelle V, 2000, EMBO J, V19, P2869, DOI 10.1093/emboj/19.12.2869; Craparo A, 1997, J BIOL CHEM, V272, P11663; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; Dubois T, 1997, J BIOL CHEM, V272, P28882, DOI 10.1074/jbc.272.46.28882; Dubois T, 1997, J PROTEIN CHEM, V16, P513, DOI 10.1023/A:1026321813463; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Finnie C, 1999, PLANT MOL BIOL, V40, P545, DOI 10.1023/A:1006211014713; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Furlanetto RW, 1997, BIOCHEM J, V327, P765; FURUKAWA Y, 1993, BIOCHEM BIOPH RES CO, V194, P144, DOI 10.1006/bbrc.1993.1796; Garcia-Guzman M, 1999, J BIOL CHEM, V274, P5762, DOI 10.1074/jbc.274.9.5762; Green AJE, 2001, NEUROLOGY, V56, P986, DOI 10.1212/WNL.56.7.986; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Gu MY, 1998, J BIOL CHEM, V273, P33465, DOI 10.1074/jbc.273.50.33465; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Honda R, 1997, BIOCHEM BIOPH RES CO, V230, P262, DOI 10.1006/bbrc.1996.5933; Hsu SY, 1997, MOL ENDOCRINOL, V11, P1858, DOI 10.1210/me.11.12.1858; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; ICHIMURA T, 1988, P NATL ACAD SCI USA, V85, P7084, DOI 10.1073/pnas.85.19.7084; Ichimura T, 1997, FEBS LETT, V413, P273, DOI 10.1016/S0014-5793(97)00910-1; ICHIMURA T, 1995, J BIOL CHEM, V270, P28515, DOI 10.1074/jbc.270.48.28515; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; JONES DH, 1995, FEBS LETT, V368, P55, DOI 10.1016/0014-5793(95)00598-4; Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kockel L, 1997, GENE DEV, V11, P1140, DOI 10.1101/gad.11.9.1140; Kosaki A, 1998, J BIOL CHEM, V273, P940, DOI 10.1074/jbc.273.2.940; Ku NO, 1998, EMBO J, V17, P1892, DOI 10.1093/emboj/17.7.1892; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; Laronga C, 2000, J BIOL CHEM, V275, P23106, DOI 10.1074/jbc.M905616199; Layfield R, 1996, NEUROSCI LETT, V209, P57, DOI 10.1016/0304-3940(96)12598-2; Lee KH, 1997, ELECTROPHORESIS, V18, P502, DOI 10.1002/elps.1150180327; Li W, 1997, DEVELOPMENT, V124, P4163; Liao J, 1996, J CELL BIOL, V133, P345, DOI 10.1083/jcb.133.2.345; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Liu YC, 1996, J BIOL CHEM, V271, P14591, DOI 10.1074/jbc.271.24.14591; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; Liu YH, 1999, J IMMUNOL, V162, P7095; Liu YM, 2001, J CLIN INVEST, V107, P917, DOI 10.1172/JCI11947; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; LUO ZJ, 1995, J BIOL CHEM, V270, P23681, DOI 10.1074/jbc.270.40.23681; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; Marshall CJ, 1996, NATURE, V383, P127, DOI 10.1038/383127a0; Masters SC, 1999, BIOCHEMISTRY-US, V38, P5216, DOI 10.1021/bi982492m; MEGIDISH T, 1995, BIOCHEM BIOPH RES CO, V216, P739, DOI 10.1006/bbrc.1995.2684; Megidish T, 1998, J BIOL CHEM, V273, P21834, DOI 10.1074/jbc.273.34.21834; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; Mils V, 2000, ONCOGENE, V19, P1257, DOI 10.1038/sj.onc.1203419; Muller WEG, 2000, MECH AGEING DEV, V116, P193, DOI 10.1016/S0047-6374(00)00112-3; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; Nakanishi Kozo, 1997, Human Antibodies, V8, P189; Obsil T, 2001, CELL, V105, P257, DOI 10.1016/S0092-8674(01)00316-6; Ogihara T, 1997, J BIOL CHEM, V272, P25267, DOI 10.1074/jbc.272.40.25267; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; Pan SQ, 1999, PLANT CELL, V11, P1591, DOI 10.1105/tpc.11.8.1591; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pawson T, 2000, GENE DEV, V14, P1027; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Perego L, 1997, MOL REPROD DEV, V47, P370, DOI 10.1002/(SICI)1098-2795(199708)47:4&lt;370::AID-MRD3&gt;3.0.CO;2-H; Pietromonaco SF, 1996, BLOOD CELL MOL DIS, V22, P225, DOI 10.1006/bcmd.1996.0103; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Roberts MR, 2000, CURR OPIN PLANT BIOL, V3, P400, DOI 10.1016/S1369-5266(00)00103-5; Roberts RL, 1997, CELL, V89, P1055, DOI 10.1016/S0092-8674(00)80293-7; ROBINSON K, 1994, BIOCHEM J, V299, P853, DOI 10.1042/bj2990853; Rosenquist M, 2000, J MOL EVOL, V51, P446, DOI 10.1007/s002390010107; Seimiya H, 2000, EMBO J, V19, P2652, DOI 10.1093/emboj/19.11.2652; Shaw A, 2000, CURR BIOL, V10, pR400, DOI 10.1016/S0960-9822(00)00519-4; Shoji Masahiro, 1994, Human Antibodies and Hybridomas, V5, P123; Skoulakis EMC, 1996, NEURON, V17, P931, DOI 10.1016/S0896-6273(00)80224-X; Skoulakis EMC, 1998, MOL NEUROBIOL, V16, P269, DOI 10.1007/BF02741386; Suzuki H, 2000, CANCER RES, V60, P4353; Tang SJ, 1998, J BIOL CHEM, V273, P25356, DOI 10.1074/jbc.273.39.25356; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; Tien AC, 1999, MECH DEVELOP, V81, P209, DOI 10.1016/S0925-4773(98)00238-X; Todd A, 1998, BIOCHEMISTRY-US, V37, P14317, DOI 10.1021/bi980768k; Tzivion G, 2000, J BIOL CHEM, V275, P29772, DOI 10.1074/jbc.M001207200; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Van der Hoeven PCJ, 2000, BIOCHEM J, V345, P297, DOI 10.1042/0264-6021:3450297; van Zeijl MJ, 2000, FEBS LETT, V473, P292, DOI 10.1016/S0014-5793(00)01545-3; Vercoutter-Edouart AS, 2001, CANCER RES, V61, P76; Villaret DB, 2000, LARYNGOSCOPE, V110, P374, DOI 10.1097/00005537-200003000-00008; Vincenz C, 1996, J BIOL CHEM, V271, P20029, DOI 10.1074/jbc.271.33.20029; Wang AH, 2000, MOL CELL BIOL, V20, P6904, DOI 10.1128/MCB.20.18.6904-6912.2000; Wang BC, 1999, BIOCHEMISTRY-US, V38, P12499, DOI 10.1021/bi991353h; Wang HN, 1998, J BIOL CHEM, V273, P16297, DOI 10.1074/jbc.273.26.16297; Wang WF, 1996, J MOL EVOL, V43, P384; Wang YL, 2000, CELL GROWTH DIFFER, V11, P211; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Weiner H, 1999, FEBS LETT, V455, P75, DOI 10.1016/S0014-5793(99)00868-6; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Xing HM, 2000, EMBO J, V19, P349, DOI 10.1093/emboj/19.3.349; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yaffe MB, 1999, NATURE, V402, P30; Yaffe MB, 2001, CURR OPIN CELL BIOL, V13, P131, DOI 10.1016/S0955-0674(00)00189-7; Yang J, 1999, EMBO J, V18, P2174, DOI 10.1093/emboj/18.8.2174; Zeidler M, 2000, ANN NEUROL, V47, P683, DOI 10.1002/1531-8249(200005)47:5<683::AID-ANA25>3.0.CO;2-V; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang LX, 1997, J BIOL CHEM, V272, P13717, DOI 10.1074/jbc.272.21.13717; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511; Zhang SS, 1999, J BIOL CHEM, V274, P24865, DOI 10.1074/jbc.274.35.24865	130	252	259	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2001	20	44					6331	6338		10.1038/sj.onc.1204777	http://dx.doi.org/10.1038/sj.onc.1204777			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NF	11607836				2022-12-17	WOS:000171640600009
J	Chen, XF; Thakkar, H; Tyan, F; Gim, S; Robinson, H; Lee, C; Pandey, SK; Nwokorie, C; Onwudiwe, N; Srivastava, RK				Chen, XF; Thakkar, H; Tyan, F; Gim, S; Robinson, H; Lee, C; Pandey, SK; Nwokorie, C; Onwudiwe, N; Srivastava, RK			Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer	ONCOGENE			English	Article						TRAIL; apoptosis; prostate cancer; mitochondria; Akt; PTEN	PROTEIN-KINASE-B; FORKHEAD TRANSCRIPTION FACTORS; INDUCED APOPTOSIS; TUMOR-SUPPRESSOR; CYTOCHROME-C; CELL-DEATH; FREQUENT INACTIVATION; TUMORICIDAL ACTIVITY; NEGATIVE REGULATION; SURVIVAL SIGNALS	TRAIL/Apo-2L is a member of the tumor necrosis factor superfamily and has recently been shown to induce apoptosis in cancer cells, but not in normal cells. In nude mice injected with human tumors, TRAIL reduces the size of these tumors without side effects. Akt promotes cell survival and block apoptosis. Some prostate cancer cells express high levels of Akt due to lack of active lipid phosphatase PTEN, a negative regulator of PI-3 kinase pathway, which may be responsible for drug resistance. The objective of this paper is to investigate the intracellular molecules that regulate TRAIL resistance. We have examined caspase-8 activity, BID cleavage, Akt activity, mitochondrial membrane potential (AT.) and apoptosis in prostate cancer (LNCap, PC-3, PC-3M and DU145) cells treated with or without TRAIL. PC-3, PC-3M and DU145 cells are sensitive to TRAIL, whereas LNCap cells are resistant. LNCap cells express the highest level of constitutively active Akt, which is directly correlated with TRAIL resistance. TRAIL activates caspase-8 in all the cell lines. Downregulation of constitutively active Akt by PI-3 kinase inhibitors (wortmannin and LY-294002), dominant negative Akt or PTEN, renders LNCap cells sensitive to TRAIL. Inhibition of TRAIL sensitivity occurs at the level of BID cleavage. Inhibition of protein synthesis by cycloheximide also causes LNCap cells sensitive to TRAIL. Overexpression of Bcl-2 or Bcl-X-L inhibits TRAIL-induced Delta Psi (m) and apoptosis. Overexpression of constitutively active Akt in PC-3M cells (express very low levels of constitutively active Akt) restores TRAIL resistance. These data suggest that elevated Akt activity protects LNCap cells from TRAIL-induced apoptosis, and the PI-3 kinase/Akt pathway may inhibit apoptotic signals by inhibiting processing of BID. Thus, constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer.	Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; NIA, Clin Invest Lab, NIH, Baltimore, MD 21224 USA	University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Srivastava, RK (corresponding author), Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Greenebaum Canc Ctr, 20 N Pine St, Baltimore, MD 21201 USA.							Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cairns P, 1997, CANCER RES, V57, P4997; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cheney IW, 1998, CANCER RES, V58, P2331; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; French LE, 1999, NAT MED, V5, P146, DOI 10.1038/5505; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Green D R, 1998, Results Probl Cell Differ, V24, P45; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Griffith TS, 1998, J IMMUNOL, V161, P2833; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Griffith TS, 1999, J EXP MED, V189, P1343, DOI 10.1084/jem.189.8.1343; Guldberg P, 1997, CANCER RES, V57, P3660; Gura T, 1997, SCIENCE, V277, P768, DOI 10.1126/science.277.5327.768; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Ittmann MM, 1998, ONCOL REP, V5, P1329; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Keane MM, 1999, CANCER RES, V59, P734; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Keogh SA, 2000, FEBS LETT, V471, P93, DOI 10.1016/S0014-5793(00)01375-2; Kim EJ, 2001, INT J ONCOL, V18, P187; Kim JH, 2000, INTELL AUTOM SOFT CO, V6, P3, DOI 10.1080/10798587.2000.10768155; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; Kohno T, 1998, GENE CHROMOSOME CANC, V22, P152, DOI 10.1002/(SICI)1098-2264(199806)22:2<152::AID-GCC10>3.0.CO;2-S; Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Korsmeyer SJ, 1999, COLD SPRING HARB SYM, V64, P343, DOI 10.1101/sqb.1999.64.343; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Liu WG, 1997, CANCER RES, V57, P5254; Long RJ, 1997, J ANDROL, V18, P15; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lynch DK, 1999, ONCOGENE, V18, P8024, DOI 10.1038/sj.onc.1203258; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Mori S, 1999, J IMMUNOL, V162, P5616; Muzio M, 1998, INT J CLIN LAB RES, V28, P141, DOI 10.1007/s005990050035; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Okami K, 1998, CANCER RES, V58, P509; Orlinick J R, 1999, Int Rev Immunol, V18, P293, DOI 10.3109/08830189909088485; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Petrylak DP, 1999, UROLOGY, V54, P30, DOI 10.1016/S0090-4295(99)00452-5; Pisters LL, 1999, SEMIN ONCOL, V26, P202; Rasheed BKA, 1997, CANCER RES, V57, P4187; Richie JP, 1999, UROLOGY, V54, P15, DOI 10.1016/S0090-4295(99)00449-5; Rieger J, 1999, ACTA NEUROPATHOL, V97, P1, DOI 10.1007/s004010050948; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schneider P, 1997, FEBS LETT, V416, P329, DOI 10.1016/S0014-5793(97)01231-3; Screaton GR, 1997, CURR BIOL, V7, P693, DOI 10.1016/S0960-9822(06)00297-1; Sekulic A, 2000, CANCER RES, V60, P3504; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Snell V, 1997, BRIT J HAEMATOL, V99, P618, DOI 10.1046/j.1365-2141.1997.4393250.x; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Srivastava Rakesh K., 2000, Molecular Cell Biology Research Communications, V4, P67, DOI 10.1006/mcbr.2001.0265; Srivastava RK, 1999, J EXP MED, V190, P253, DOI 10.1084/jem.190.2.253; Srivastava RK, 1999, MOL CELL BIOL, V19, P5659; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suliman A, 2001, ONCOGENE, V20, P2122, DOI 10.1038/sj.onc.1204282; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tashiro H, 1997, CANCER RES, V57, P3935; Teng DHF, 1997, CANCER RES, V57, P5221; Tonks NK, 1999, SCIENCE, V286, P2096, DOI 10.1126/science.286.5447.2096; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vlietstra RJ, 1998, CANCER RES, V58, P2720; Wajant H, 2000, J BIOL CHEM, V275, P24357, DOI 10.1074/jbc.M000811200; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Weng LP, 2001, HUM MOL GENET, V10, P605, DOI 10.1093/hmg/10.6.605; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587	87	252	262	1	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2001	20	42					6073	6083		10.1038/sj.onc.1204736	http://dx.doi.org/10.1038/sj.onc.1204736			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593415				2022-12-17	WOS:000171056300015
J	Grooteclaes, ML; Frisch, SM				Grooteclaes, ML; Frisch, SM			Evidence for a function of CtBP in epithelial gene regulation and anoikis	ONCOGENE			English	Article						E1a; CtBP; epithelial phenotype; anoikis; E-cadherin	E-CADHERIN EXPRESSION; ZINC-FINGER; CELLULAR PHOSPHOPROTEIN; TRANSCRIPTION FACTOR; NEGATIVE MODULATION; TUMOR PROGRESSION; SUPPRESSOR GENE; BREAST-CANCER; E1A PROTEIN; REPRESSION	Previously, we reported that adenovirus E1a protein behaves as a tumor suppressor in human cells. It apparently functions by transcriptionally inducing an array of epithelial cell adhesion genes, while repressing other cell-type specific genes, thus producing an epithelial phenotype. Concomitantly, the cells become sensitive to anoikis (apoptosis of epithelial cells detached from extracellular matrix), potentially causing tumor suppression. E1a protein interacts with the nuclear acetylases p300, CBP and P/CAF, and also with the co-repressor protein CtBP. In this study, we have determined the role of these interactions in E1a's phenotypic effects on human tumor cells. The results indicate that E1a's interaction with CtBP activates at least three epithelial cell adhesion gene promoters. The E-cadherin repressor appeared to be the CtBP-interacting protein delta EF1/ZEB, which bound the ras-repressible E-boxes of the E-cadherin promoter. The E1a-CtBP interaction also contributed to anoikis-sensitization. E1a's interactions with the nuclear acetylases conferred epithelial morphologies but did not activate epithelial genes. These latter interactions did not sensitize tumor cells to anoikis but nevertheless conferred tumor suppression. These results implicate CtBP as an antagonist of the epithelial phenotype and anoikis, They also indicate a new but undefined role for nuclear acetylases in maintaining the transformed phenotype.	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Frisch, SM (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.							Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Behrens J, 1999, CANCER METAST REV, V18, P15, DOI 10.1023/A:1006200102166; BIRCHMEIER W, 1995, CANCER SURV, V24, P129; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; COOK JL, 1989, J VIROL, V63, P3408, DOI 10.1128/JVI.63.8.3408-3415.1989; CORBEIL HB, 1994, J VIROL, V68, P6697, DOI 10.1128/JVI.68.10.6697-6709.1994; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; DSOUZA B, 1994, P NATL ACAD SCI USA, V91, P7202, DOI 10.1073/pnas.91.15.7202; FLEMING TP, 1988, ANNU REV CELL BIOL, V4, P459, DOI 10.1146/annurev.cellbio.4.1.459; FRISCH SM, 1990, MOL CELL BIOL, V10, P6524, DOI 10.1128/MCB.10.12.6524; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1991, P NATL ACAD SCI USA, V88, P9077, DOI 10.1073/pnas.88.20.9077; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 1999, CURR BIOL, V9, P1047, DOI 10.1016/S0960-9822(99)80455-2; Frisch SM, 1997, BIOESSAYS, V19, P705, DOI 10.1002/bies.950190811; FRISCH SM, 1995, CANCER RES, V55, P5551; FRISCH SM, 1994, J CELL BIOL, V127, P1085, DOI 10.1083/jcb.127.4.1085; Giroldi LA, 1997, BIOCHEM BIOPH RES CO, V241, P453, DOI 10.1006/bbrc.1997.7831; GOPALAKRISHNAN S, 1995, CELL GROWTH DIFFER, V6, P985; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Guilford P, 1999, MOL MED TODAY, V5, P172, DOI 10.1016/S1357-4310(99)01461-6; Hajra KM, 1999, ONCOGENE, V18, P7274, DOI 10.1038/sj.onc.1203336; Higashi Y, 1997, J EXP MED, V185, P1467, DOI 10.1084/jem.185.8.1467; Inukai T, 1999, MOL CELL, V4, P343, DOI 10.1016/S1097-2765(00)80336-6; Ji XD, 1997, CELL GROWTH DIFFER, V8, P773; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; KOSMAN D, 1991, SCIENCE, V254, P118, DOI 10.1126/science.1925551; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; Mannervik M, 1999, SCIENCE, V284, P606, DOI 10.1126/science.284.5414.606; Mymryk JS, 1996, ONCOGENE, V13, P1581; Postigo AA, 1997, EMBO J, V16, P3924, DOI 10.1093/emboj/16.13.3924; Postigo AA, 1997, EMBO J, V16, P3935, DOI 10.1093/emboj/16.13.3935; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Reid JL, 1998, EMBO J, V17, P4469, DOI 10.1093/emboj/17.15.4469; Remacle JE, 1999, EMBO J, V18, P5073, DOI 10.1093/emboj/18.18.5073; ROCHETTEEGLY C, 1990, GENE DEV, V4, P137, DOI 10.1101/gad.4.1.137; Savagner P, 1997, J CELL BIOL, V137, P1403, DOI 10.1083/jcb.137.6.1403; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; SEKIDO R, 1994, MOL CELL BIOL, V14, P5692, DOI 10.1128/MCB.14.9.5692; SUBRAMANIAN T, 1989, ONCOGENE, V4, P415; Takagi T, 1998, DEVELOPMENT, V125, P21; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Verschueren K, 1999, J BIOL CHEM, V274, P20489, DOI 10.1074/jbc.274.29.20489; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745	51	252	260	0	11	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2000	19	33					3823	3828		10.1038/sj.onc.1203721	http://dx.doi.org/10.1038/sj.onc.1203721			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949939				2022-12-17	WOS:000088568400017
J	Yasumoto, S; Kunimura, C; Kikuchi, K; Tahara, H; Ohji, H; Yamamoto, H; Ide, T; Utakoji, T				Yasumoto, S; Kunimura, C; Kikuchi, K; Tahara, H; Ohji, H; Yamamoto, H; Ide, T; Utakoji, T			Telomerase activity in normal human epithelial cells	ONCOGENE			English	Article						telomerase activity; normal human cells; epithelial cells	HUMAN-FIBROBLASTS; EPIDERMAL-CELLS; IMMORTAL CELLS; BURN WOUNDS; IN-VIVO; KERATINOCYTES; LYMPHOCYTES; TISSUES; RNA	Telomerase activity is found in most cancer tissues and many immortalized cell lines as well as in germ line cells but it is generally undetected in normal human somatic tissues. There is weak telomerase activity in some cell types of hematopoietic lineage in which a stem cell-like subpopulation may exist. Likewise, physiologically regenerating somatic tissues and organs such as skin, small intestine, and most other epithelia of the human body are supposed to contain similar cell lineages to maintain their renewal throughout the life span of individuals. It is therefore of interest whether telomerase activity is present in physiologically regenerating epithelial cells. Telomerase activity was detected, though very weakly, in cultured normal epidermal keratinocytes and at higher levels in a subpopulation that adhere rapidly on collagen IV-coated culture dishes. No telomerase activity was detected in a subpopulation that was less adherent on the coated dishes. The rapidly adherent subpopulation of keratinocytes was enriched in small proliferating cells with macrocolony forming potential. It was also passaged through more generations in culture, and expressed integrin beta 1 at higher levels than the less adherent subpopulation. Telomerase activity was similarly found in ectocervical keratinocytes as well as in simple endocervical epithelial cells. These findings provide the evidence of a telomerase-positive population among physiologically regenerating normal human epithelial cells. The identity of the telomerase-positive cells remains to be defined.	NISSHO COOPERAT,RES & DEV,KUSATU SHI,JAPAN; HIROSHIMA UNIV,SCH MED,DEPT CELLULAR & MOL BIOL,MINAMI KU,HIROSHIMA 734,JAPAN	Hiroshima University	Yasumoto, S (corresponding author), KANAGAWA CANC CTR,RES INST,MOL CELL BIOL LAB,ASAHI KU,54-2 NAKAO CHO,YOKOHAMA,KANAGAWA 241,JAPAN.							ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; BARRANDON Y, 1987, P NATL ACAD SCI USA, V84, P2302, DOI 10.1073/pnas.84.8.2302; BARRANDON Y, 1985, P NATL ACAD SCI USA, V82, P5390, DOI 10.1073/pnas.82.16.5390; CARTER WG, 1990, J CELL BIOL, V110, P1387, DOI 10.1083/jcb.110.4.1387; CHADENEAU C, 1995, ONCOGENE, V11, P893; COMPTON CC, 1989, LAB INVEST, V60, P600; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; GALLICO GG, 1984, NEW ENGL J MED, V311, P448, DOI 10.1056/NEJM198408163110706; GREEN H, 1988, NEWS PHYSIOL SCI, V3, P53; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HASHIDA T, 1991, J GEN VIROL, V72, P1569, DOI 10.1099/0022-1317-72-7-1569; HIYAMA E, 1995, NAT MED, V1, P294; HIYAMA K, 1995, J NATL CANCER I, V87, P895, DOI 10.1093/jnci/87.12.895; HIYAMA K, 1995, J IMMUNOL, V155, P3711; JONES PH, 1995, CELL, V80, P83, DOI 10.1016/0092-8674(95)90453-0; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; LEVY MZ, 1992, J MOL BIOL, V225, P114; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; NILSSON P, 1994, ONCOGENE, V9, P3043; Piatyszek Mieczyslaw A., 1995, Methods in Cell Science, V17, P1, DOI 10.1007/BF00981880; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; TAHARA H, 1995, CANCER RES, V55, P2734; Tahara H, 1995, CLIN CANCER RES, V1, P1245; TSUTSUMI K, 1993, AM J PATHOL, V143, P1150; YASUMOTO S, 1991, J VIROL, V65, P2000, DOI 10.1128/JVI.65.4.2000-2009.1991; YASUMOTO S, 1992, TISSUE CULT RES COMM, V11, P13; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0	35	252	262	1	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 18	1996	13	2					433	439						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710384				2022-12-17	WOS:A1996VA25200024
J	Zhou, L; Liu, XD; Sun, M; Zhang, X; German, P; Bai, S; Ding, Z; Tannir, N; Wood, CG; Matin, SF; Karam, JA; Tamboli, P; Sircar, K; Rao, P; Rankin, EB; Laird, DA; Hoang, AG; Walker, CL; Giaccia, AJ; Jonasch, E				Zhou, L.; Liu, X-D; Sun, M.; Zhang, X.; German, P.; Bai, S.; Ding, Z.; Tannir, N.; Wood, C. G.; Matin, S. F.; Karam, J. A.; Tamboli, P.; Sircar, K.; Rao, P.; Rankin, E. B.; Laird, D. A.; Hoang, A. G.; Walker, C. L.; Giaccia, A. J.; Jonasch, E.			Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma	ONCOGENE			English	Article							RECEPTOR TYROSINE KINASES; CABOZANTINIB XL184; C-MET; GROWTH; EXPRESSION; CANCER; ANGIOGENESIS; PROGRESSION; METASTASIS; ACTIVATION	Antiangiogenic therapy resistance occurs frequently in patients with metastatic renal cell carcinoma (RCC). The purpose of this study was to understand the mechanism of resistance to sunitinib, an antiangiogenic small molecule, and to exploit this mechanism therapeutically. We hypothesized that sunitinib-induced upregulation of the prometastatic MET and AXL receptors is associated with resistance to sunitinib and with more aggressive tumor behavior. In the present study, tissue microarrays containing sunitinib-treated and untreated RCC tissues were stained with MET and AXL antibodies. The low malignant RCC cell line 786-O was chronically treated with sunitinib and assayed for AXL, MET, epithelial-mesenchymal transition (EMT) protein expression and activation. Co-culture experiments were used to examine the effect of sunitinib pretreatment on endothelial cell growth. The effects of AXL and MET were evaluated in various cell-based models by short hairpin RNA or inhibition by cabozantinib, the multi-tyrosine kinases inhibitor that targets vascular endothelial growth factor receptor, MET and AXL. Xenograft mouse models tested the ability of cabozantinib to rescue sunitinib resistance. We demonstrated that increased AXL and MET expression was associated with inferior clinical outcome in patients. Chronic sunitinib treatment of RCC cell lines activated both AXL and MET, induced EMT-associated gene expression changes, including upregulation of Snail and beta-catenin, and increased cell migration and invasion. Pretreatment with sunitinib enhanced angiogenesis in 786-0/human umbilical vein endothelial cell co-culture models. The suppression of AXL or MET expression and the inhibition of AXL and MET activation using cabozantinib both impaired chronic sunitinib treatment-induced prometastatic behavior in cell culture and rescued acquired resistance to sunitinib in xenograft models. In summary, chronic sunitinib treatment induces the activation of AXL and MET signaling and promotes prometastatic behavior and angiogenesis. The inhibition of AXL and MET activity may overcome resistance induced by prolonged sunitinib therapy in metastatic RCC.	[Zhou, L.; Liu, X-D; Sun, M.; Zhang, X.; German, P.; Bai, S.; Ding, Z.; Tannir, N.; Jonasch, E.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, 1155 Hermann Pressler Dr, Houston, TX 77030 USA; [Wood, C. G.; Matin, S. F.; Karam, J. A.] Univ Texas MD Anderson Canc Ctr, Div Surg, Dept Urol, Houston, TX 77030 USA; [Tamboli, P.; Sircar, K.; Rao, P.; Hoang, A. G.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Rankin, E. B.; Giaccia, A. J.] Stanford Univ, Sch Med, Dept Radiat Oncol, Stanford, CA 94305 USA; [Laird, D. A.] Exelixis Inc, San Francisco, CA USA; [Walker, C. L.] Texas A&M Hlth Sci Ctr, Inst Biosci & Technol, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Stanford University; Exelixis, Inc.; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Jonasch, E (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, 1155 Hermann Pressler Dr, Houston, TX 77030 USA.	ejonasch@mdanderson.org		Liu, xiande/0000-0002-9639-0458	Exelixis; Renee Kaye Cure Fur Cancer Foundation; Monteleone Family Foundation; UT MD Anderson Cancer Center P30 Cancer Center Support Grant; NATIONAL CANCER INSTITUTE [R01CA143811, P30CA016672, P01CA067166, R01CA198291] Funding Source: NIH RePORTER	Exelixis; Renee Kaye Cure Fur Cancer Foundation; Monteleone Family Foundation; UT MD Anderson Cancer Center P30 Cancer Center Support Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by Exelixis, Renee Kaye Cure Fur Cancer Foundation, the Monteleone Family Foundation and the UT MD Anderson Cancer Center P30 Cancer Center Support Grant.	Bentzien F, 2013, THYROID, V23, P1569, DOI 10.1089/thy.2013.0137; Betsunoh H, 2007, CANCER SCI, V98, P491, DOI 10.1111/j.1349-7006.2007.00412.x; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Chinchar E, 2014, VASC CELL, V6, DOI 10.1186/2045-824X-6-12; Choueiri TK, 2014, ANN ONCOL, V25, P1603, DOI 10.1093/annonc/mdu184; Chung BI, 2003, DNA CELL BIOL, V22, P533, DOI 10.1089/10445490360708946; Domblides C, 2013, EXPERT OPIN EMERG DR, V18, P495, DOI 10.1517/14728214.2013.858697; Ellison AR, 2003, J STEROID BIOCHEM, V86, P15, DOI 10.1016/S0960-0760(03)00257-7; Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016; Garofalo M, 2012, NAT MED, V18, P74, DOI 10.1038/nm.2577; Gherardi E, 2012, NAT REV CANCER, V12, P89, DOI 10.1038/nrc3205; Gibney GT, 2013, ANN ONCOL, V24, P343, DOI 10.1093/annonc/mds463; Griffioen AW, 2012, CLIN CANCER RES, V18, P3961, DOI 10.1158/1078-0432.CCR-12-0002; Gujral TS, 2013, ONCOGENE, V32, P3470, DOI 10.1038/onc.2012.378; Gustafsson A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007575; Gustafsson A, 2009, CLIN CANCER RES, V15, P4742, DOI 10.1158/1078-0432.CCR-08-2514; Harshman LC, 2013, CANCER J, V19, P316, DOI 10.1097/PPO.0b013e31829e3c9a; Ho MY, 2012, MOL CANCER RES, V10, P1109, DOI 10.1158/1541-7786.MCR-12-0160; Holland SJ, 2005, CANCER RES, V65, P9294, DOI 10.1158/0008-5472.CAN-05-0993; Horie S, 1999, J UROLOGY, V161, P990, DOI 10.1016/S0022-5347(01)61834-2; Huang D, 2010, CANCER RES, V70, P1063, DOI 10.1158/0008-5472.CAN-09-3965; Jonasch E, 2010, CANCER-AM CANCER SOC, V116, P57, DOI 10.1002/cncr.24685; Jonasch E, 2009, J CLIN ONCOL, V27, P4076, DOI 10.1200/JCO.2008.21.3660; Kanesvaran Ravindran, 2014, J Carcinog, V13, P3, DOI 10.4103/1477-3163.127638; Kim J, 2009, CLIN CANCER RES, V15, P81, DOI 10.1158/1078-0432.CCR-08-0170; Kumar R, 2009, BRIT J CANCER, V101, P1717, DOI 10.1038/sj.bjc.6605366; Leconet W, 2014, ONCOGENE, V33, P5405, DOI 10.1038/onc.2013.487; Linger RMA, 2008, ADV CANCER RES, V100, P35, DOI 10.1016/S0065-230X(08)00002-X; Linger RM, 2010, EXPERT OPIN THER TAR, V14, P1073, DOI 10.1517/14728222.2010.515980; Miyata Y, 2006, CLIN CANCER RES, V12, P4876, DOI 10.1158/1078-0432.CCR-06-0362; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Pao-Chun L, 2009, J BIOL CHEM, V284, P34954, DOI 10.1074/jbc.M109.072660; Peters S, 2012, NAT REV CLIN ONCOL, V9, P314, DOI 10.1038/nrclinonc.2012.71; Plimack ER, 2009, CANCER-AM CANCER SOC, V115, P1859, DOI 10.1002/cncr.24211; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; Rankin EB, 2014, P NATL ACAD SCI USA, V111, P13373, DOI 10.1073/pnas.1404848111; Rankin EB, 2010, CANCER RES, V70, P7570, DOI 10.1158/0008-5472.CAN-10-1267; Ruan GX, 2012, EMBO J, V31, P1692, DOI 10.1038/emboj.2012.21; Sennino B, 2012, CANCER DISCOV, V2, P270, DOI 10.1158/2159-8290.CD-11-0240; Singhal E, 2011, INT J BIOCHEM CELL B, V43, P1134, DOI 10.1016/j.biocel.2011.04.006; Smith DC, 2013, J CLIN ONCOL, V31, P412, DOI 10.1200/JCO.2012.45.0494; THOENES W, 1986, PATHOL RES PRACT, V181, P125, DOI 10.1016/S0344-0338(86)80001-2; Tsavachidou-Fenner D, 2010, ANN ONCOL, V21, P1599, DOI 10.1093/annonc/mdp600; WEIDNER N, 1995, AM J PATHOL, V147, P9; Ye X, 2010, ONCOGENE, V29, P5254, DOI 10.1038/onc.2010.268; Zhang Y, 2010, IDRUGS, V13, P112; Zhang ZF, 2012, NAT GENET, V44, P852, DOI 10.1038/ng.2330	47	251	258	1	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2016	35	21					2687	2697		10.1038/onc.2015.343	http://dx.doi.org/10.1038/onc.2015.343			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MJ	26364599	Green Accepted			2022-12-17	WOS:000377472700003
J	Nickoloff, BJ; Osborne, BA; Miele, L				Nickoloff, BJ; Osborne, BA; Miele, L			Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents	ONCOGENE			English	Review						Notch; cancer; leukemia; therapeutic targets; signalling	NF-KAPPA-B; INTRACELLULAR DOMAIN; ACTIVATED NOTCH1; HUMAN HOMOLOG; STEM-CELLS; NEOPLASTIC TRANSFORMATION; INHIBITS DIFFERENTIATION; INDUCED APOPTOSIS; DENDRITIC CELLS; LEUKEMIA CELLS	Notch signaling controls cell fate decisions including during development and stem cell renewal and differentiation in many postnatal tissues. Increasing evidence suggests that the Notch signaling network is frequently deregulated in human malignancies and that genetic or pharmacological manipulation of Notch signaling is a novel potential strategy for the treatment of human neoplasms. This review article summarizes the most recent preclinical and clinical evidence linking Notch signaling to cancer, delineates questions that remain unanswered and explores potential biopharmacological strategies to manipulate Notch signaling in vivo.	Univ Illinois, Dept Biopharmaceut Sci, Chicago, IL 60612 USA; Loyola Univ, Dept Pathol, Chicago, IL 60611 USA; Loyola Univ, Cardinal Bernardin Canc Ctr, Chicago, IL 60611 USA; Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA; Univ Illinois, Ctr Canc, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Loyola University Chicago; Loyola University Chicago; University of Massachusetts System; University of Massachusetts Amherst; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Miele, L (corresponding author), Univ Illinois, Dept Biopharmaceut Sci, 833 S Wood St,M-C 865,Room 335, Chicago, IL 60612 USA.	lmiele@uic.edu		Miele, Lucio/0000-0002-5853-7287	NATIONAL CANCER INSTITUTE [P01CA059327, R01CA084065] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016690] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA84065-01, P01 CA59327] Funding Source: Medline; NIA NIH HHS [R01 AG 16690] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Allman D, 2002, CELL, V109, pS1, DOI 10.1016/S0092-8674(02)00689-X; Anderson AC, 2001, CURR OPIN GENET DEV, V11, P554, DOI 10.1016/S0959-437X(00)00232-X; Apelqvist A, 1999, NATURE, V400, P877, DOI 10.1038/23716; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Axelrod JD, 1996, SCIENCE, V271, P1826, DOI 10.1126/science.271.5257.1826; Beatus P, 2001, MECH DEVELOP, V104, P3, DOI 10.1016/S0925-4773(01)00373-2; Beatus P, 1999, DEVELOPMENT, V126, P3925; Bellavia D, 2000, EMBO J, V19, P3337, DOI 10.1093/emboj/19.13.3337; Berezovska O, 1999, NEUROSCIENCE, V93, P433, DOI 10.1016/S0306-4522(99)00157-8; Berezovska O, 1998, J NEUROPATH EXP NEUR, V57, P738, DOI 10.1097/00005072-199808000-00003; Berset T, 2001, SCIENCE, V291, P1055, DOI 10.1126/science.1055642; Blair SS, 1996, SCIENCE, V271, P1822, DOI 10.1126/science.271.5257.1822; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Bocchetta M, 2003, ONCOGENE, V22, P81, DOI 10.1038/sj.onc.1206097; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Callahan R, 2001, J MAMMARY GLAND BIOL, V6, P23, DOI 10.1023/A:1009512414430; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; Carmena A, 2002, DEV BIOL, V244, P226, DOI 10.1006/dbio.2002.0606; CHATURVEDI V, 2003, IN PRESS J INVEST DE; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng PY, 2001, J IMMUNOL, V167, P4458, DOI 10.4049/jimmunol.167.8.4458; Dang TP, 2000, J NATL CANCER I, V92, P1355, DOI 10.1093/jnci/92.16.1355; Daniel B, 1997, J GEN VIROL, V78, P1095, DOI 10.1099/0022-1317-78-5-1095; Deftos ML, 2000, IMMUNITY, V13, P73, DOI 10.1016/S1074-7613(00)00009-1; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Engel I, 2002, P NATL ACAD SCI USA, V99, P11322, DOI 10.1073/pnas.162373999; Felli MP, 1999, INT IMMUNOL, V11, P1017, DOI 10.1093/intimm/11.7.1017; Fitzgerald K, 2000, ONCOGENE, V19, P4191, DOI 10.1038/sj.onc.1203766; Foltz DR, 2002, CURR BIOL, V12, P1006, DOI 10.1016/S0960-9822(02)00888-6; Fortini ME, 2000, NATURE, V406, P357, DOI 10.1038/35019233; Fowlkes BJ, 2002, J IMMUNOL, V169, P1817, DOI 10.4049/jimmunol.169.4.1817; Gailani M R, 1999, Adv Dermatol, V14, P261; Garces C, 1997, J BIOL CHEM, V272, P29729, DOI 10.1074/jbc.272.47.29729; Gartel AL, 2002, MOL CANCER THER, V1, P639; Grandbarbe L, 2003, DEVELOPMENT, V130, P1391, DOI 10.1242/dev.00374; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; Hendrix MJC, 2002, CANCER RES, V62, P665; Hsieh JJD, 1999, P NATL ACAD SCI USA, V96, P23, DOI 10.1073/pnas.96.1.23; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Hubmann R, 2002, BLOOD, V99, P3742, DOI 10.1182/blood.V99.10.3742; Ikeya T, 1999, DEVELOPMENT, V126, P4455; Ingles-Esteve J, 2001, J BIOL CHEM, V276, P44873, DOI 10.1074/jbc.M104703200; Ishii H, 2001, RHEUMATOL INT, V21, P10, DOI 10.1007/s002960100119; Izon DJ, 2002, CURR OPIN IMMUNOL, V14, P192, DOI 10.1016/S0952-7915(02)00321-7; Jang MS, 2000, CURR OPIN MOL THER, V2, P55; Jeffries S, 2000, MOL CELL BIOL, V20, P3928, DOI 10.1128/MCB.20.11.3928-3941.2000; Jehn BM, 2002, J BIOL CHEM, V277, P8033, DOI 10.1074/jbc.M108552200; Jehn BM, 1999, J IMMUNOL, V162, P635; Johnson J, 2001, MECH DEVELOP, V109, P355, DOI 10.1016/S0925-4773(01)00523-8; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; Jundt F, 2002, BLOOD, V99, P3398, DOI 10.1182/blood.V99.9.3398; Kao HY, 1998, GENE DEV, V12, P2269, DOI 10.1101/gad.12.15.2269; Kortschak RD, 2001, DEV GENES EVOL, V211, P350; Krebs LT, 2000, GENE DEV, V14, P1343; Kumano K, 2001, BLOOD, V98, P3283, DOI 10.1182/blood.V98.12.3283; Kurooka K, 2000, J BIOL CHEM, V275, P17211, DOI 10.1074/jbc.M000909200; Leethanakul C, 2000, ONCOGENE, V19, P3220, DOI 10.1038/sj.onc.1203703; Leong KG, 2002, MOL CELL BIOL, V22, P2830, DOI 10.1128/MCB.22.8.2830-2841.2002; Lewis J, 1998, NATURE, V393, P304, DOI 10.1038/30597; Li LH, 1998, IMMUNITY, V8, P43, DOI 10.1016/S1074-7613(00)80457-4; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Liu ZJ, 2003, MOL CELL BIOL, V23, P14, DOI 10.1128/MCB.23.1.14-25.2003; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Lowell S, 2000, CURR BIOL, V10, P491, DOI 10.1016/S0960-9822(00)00451-6; Mailhos C, 2001, DIFFERENTIATION, V69, P135, DOI 10.1046/j.1432-0436.2001.690207.x; MAINE EM, 1995, MOL PHYLOGENET EVOL, V4, P139, DOI 10.1006/mpev.1995.1014; Matsuno K, 2002, DEVELOPMENT, V129, P1049; Matsuno K, 1998, NAT GENET, V19, P74, DOI 10.1038/ng0598-74; Miele L., 2000, Journal of Investigative Dermatology, V114, P758; Miele L, 1999, J CELL PHYSIOL, V181, P393, DOI 10.1002/(SICI)1097-4652(199912)181:3<393::AID-JCP3>3.0.CO;2-6; Mizuguchi T, 2001, J CELL PHYSIOL, V189, P106, DOI 10.1002/jcp.1136; Mizutani T, 2001, P NATL ACAD SCI USA, V98, P9026, DOI 10.1073/pnas.161269998; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Mori S, 2003, DEV GROWTH DIFFER, V45, P7, DOI 10.1046/j.1440-169X.2003.00670.x; Morrison SJ, 2000, CELL, V101, P499, DOI 10.1016/S0092-8674(00)80860-0; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Nair P, 2003, J VIROL, V77, P7106, DOI 10.1128/JVI.77.12.7106-7112.2003; Nakazawa M, 2001, ARTHRITIS RHEUM-US, V44, P1545, DOI 10.1002/1529-0131(200107)44:7<1545::AID-ART278>3.0.CO;2-Q; Nickoloff BJ, 2002, CELL DEATH DIFFER, V9, P842, DOI 10.1038/sj.cdd.4401036; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; Ohishi K, 2002, J CLIN INVEST, V110, P1165, DOI 10.1172/JCI200216167; Ohishi K, 2002, INT J HEMATOL, V75, P449, DOI 10.1007/BF02982106; Ohishi K, 2001, BLOOD, V98, P1402, DOI 10.1182/blood.V98.5.1402; Okajima T, 2002, CELL, V111, P893, DOI 10.1016/S0092-8674(02)01114-5; Ordentlich P, 1998, MOL CELL BIOL, V18, P2230, DOI 10.1128/MCB.18.4.2230; Osborne B, 1999, IMMUNITY, V11, P653, DOI 10.1016/S1074-7613(00)80140-5; Osborne BA, 2000, CURR OPIN IMMUNOL, V12, P301, DOI 10.1016/S0952-7915(00)00091-1; Parks AL, 2000, DEVELOPMENT, V127, P1373; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Petcherski AG, 2000, CURR BIOL, V10, pR471, DOI 10.1016/S0960-9822(00)00577-7; Pui JC, 1999, IMMUNITY, V11, P299, DOI 10.1016/S1074-7613(00)80105-3; QIN JZ, 2003, IN PRESS J INVEST DE; Qiu L, 2000, J BIOL CHEM, V275, P35734, DOI 10.1074/jbc.M007300200; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; Rae FK, 2000, INT J CANCER, V88, P726, DOI 10.1002/1097-0215(20001201)88:5<726::AID-IJC7>3.0.CO;2-H; Rand MD, 2000, MOL CELL BIOL, V20, P1825, DOI 10.1128/MCB.20.5.1825-1835.2000; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; Rangarajan A, 2001, VIROLOGY, V286, P23, DOI 10.1006/viro.2001.0867; Ronchini C, 2001, MOL CELL BIOL, V21, P5925, DOI 10.1128/MCB.21.17.5925-5934.2001; Ronchini C, 2000, ONCOGENE, V19, P3914, DOI 10.1038/sj.onc.1203719; Rosenfield RL, 2000, HORM RES, V54, P269, DOI 10.1159/000053270; Royet J, 1998, EMBO J, V17, P7351, DOI 10.1093/emboj/17.24.7351; Ruiz-Hidalgo MJ, 1999, INT J ONCOL, V14, P777; Santolini E, 2000, J CELL BIOL, V151, P1345, DOI 10.1083/jcb.151.6.1345; Saxena MT, 2001, J BIOL CHEM, V276, P40268, DOI 10.1074/jbc.M107234200; Shaye DD, 2002, NATURE, V420, P686, DOI 10.1038/nature01234; Shelly LL, 1999, J CELL BIOCHEM, V73, P164, DOI 10.1002/(SICI)1097-4644(19990501)73:2<164::AID-JCB3>3.0.CO;2-0; Shimizu K, 2000, MOL CELL BIOL, V20, P6913, DOI 10.1128/MCB.20.18.6913-6922.2000; Shimizu K, 2002, BIOCHEM BIOPH RES CO, V291, P775, DOI 10.1006/bbrc.2002.6528; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Suzuki T, 2000, INT J ONCOL, V17, P1131; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; Talora C, 2002, GENE DEV, V16, P2252, DOI 10.1101/gad.988902; Tohda S, 2001, LEUKEMIA LYMPHOMA, V42, P467, DOI 10.3109/10428190109064603; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; Varnum-Finney B, 1998, BLOOD, V91, P4084, DOI 10.1182/blood.V91.11.4084.411k05_4084_4091; Varnum-Finney B, 2003, BLOOD, V101, P1784, DOI 10.1182/blood-2002-06-1862; Wang WL, 2002, J BIOL CHEM, V277, P21723, DOI 10.1074/jbc.M202224200; Weijzen S, 2003, J CELL PHYSIOL, V194, P356, DOI 10.1002/jcp.10217; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754; Weijzen S, 2002, J IMMUNOL, V169, P4273, DOI 10.4049/jimmunol.169.8.4273; Weng AP, 2003, MOL CELL BIOL, V23, P655, DOI 10.1128/MCB.23.2.655-664.2003; Wilson A, 2000, J IMMUNOL, V165, P5397, DOI 10.4049/jimmunol.165.10.5397; Wolfer A, 2001, NAT IMMUNOL, V2, P235, DOI 10.1038/85294; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644; Xia XF, 2001, P NATL ACAD SCI USA, V98, P10863, DOI 10.1073/pnas.191284198; Xue YZ, 1999, HUM MOL GENET, V8, P723, DOI 10.1093/hmg/8.5.723; Yamamoto N, 2001, J BIOL CHEM, V276, P45031, DOI 10.1074/jbc.M105245200; Yang Q, 2001, SCIENCE, V294, P2155, DOI 10.1126/science.1065718; Yasutomo K, 2000, NATURE, V404, P506, DOI 10.1038/35006664; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414; Zecchini V, 1999, CURR BIOL, V9, P460, DOI 10.1016/S0960-9822(99)80211-5; Zhou SF, 2000, MOL CELL BIOL, V20, P2400, DOI 10.1128/MCB.20.7.2400-2410.2000; Zlobin A., 2000, Current Pharmaceutical Biotechnology, V1, P83, DOI 10.2174/1389201003379013	136	251	292	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2003	22	42					6598	6608		10.1038/sj.onc.1206758	http://dx.doi.org/10.1038/sj.onc.1206758			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	728DV	14528285				2022-12-17	WOS:000185700700017
J	Real, PJ; Sierra, A; de Juan, A; Segovia, JC; Lopez-Vega, JM; Fernandez-Luna, JL				Real, PJ; Sierra, A; de Juan, A; Segovia, JC; Lopez-Vega, JM; Fernandez-Luna, JL			Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells	ONCOGENE			English	Article						Stat3; Bcl-2; chemoresistance	GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITOR; FACTOR-I RECEPTOR; CONSTITUTIVE ACTIVATION; SIGNAL TRANSDUCER; EPITHELIAL-CELLS; CARCINOMA CELLS; APOPTOSIS; EXPRESSION; STAT3	Disruption of apoptosis may allow metastatic cell survival and confer resistance to chemotherapeutic drugs. We have analysed the molecular pathways that activate these survival genes in specific sites of metastasis. Estrogen receptor-negative breast cancer cell line MDA-MB435 and two metastatic sublines derived from lung (435L) and brain (435B) were analysed for the expression of members of the Bcl-2 family of apoptosis regulators. The levels of Bcl-2 were higher in the metastatic sublines than in parental cells, which correlated with the activation of Stat3, but not with the expression and/or activation of known bcl-2 transcription factors (CREB and WT1). In the brain subline, both expression of Bcl-2 and Stat3 activation were induced by epidermal growth factor and abrogated after treatment with kinase inhibitors specific for epidermal growth factor receptor or Jak2. Furthermore, transfection of 435B with a dominant-negative Stat3 markedly reduced the expression of Bcl-2 protein, whereas transient expression of a constitutively active Stat3 increased Bcl-2 in parental 435 cells. In addition, blockade of Stat3 activation by treatment with epidermal growth factor receptor and Jak2 kinase inhibitors or transfection with a dominant negative Stat3, sensitizes 435B cells to chemotherapy-induced apoptosis. Our data suggest that an increased activation of the Stat3-Bcl-2 pathway in estrogen receptor-negative metastatic breast cancer cell lines confer a survival advantage to these cells and contribute to their chemoresistance.	Hosp Univ Marques de Valdecilla, Unidad Genet Mol, Edificio Escuela Univ Enfermeria, Santander 39008, Spain; Hosp Univ Marques de Valdecilla, Med Oncol Serv, Santander 39008, Spain; Ctr Mol Oncol, Inst Recerca Oncol, Barcelona 08907, Spain; Ctr Invest Energet Medioambientales & Tecnol, Madrid 28040, Spain	Hospital Universitario Marques de Valdecilla (HUMV); Hospital Universitario Marques de Valdecilla (HUMV); Centro de Investigaciones Energeticas, Medioambientales Tecnologicas	Fernandez-Luna, JL (corresponding author), Hosp Univ Marques de Valdecilla, Unidad Genet Mol, Edificio Escuela Univ Enfermeria, Av Valdecilla S-N, Santander 39008, Spain.	inmflj@humv.es	Segovia, Jose Carlos/L-2922-2014; Real, Pedro J./K-2994-2014; Real, Pedro J./ABH-3493-2021	Segovia, Jose Carlos/0000-0003-4101-6124; Real, Pedro J./0000-0001-7968-5353; Sierra, Angels/0000-0003-1023-3492				Alas S, 2001, CANCER RES, V61, P5137; BARGOU RC, 1995, INT J CANCER, V60, P854, DOI 10.1002/ijc.2910600622; Bartucci M, 2001, CANCER RES, V61, P6747; BENITO A, 1995, AM J PATHOL, V146, P481; Benito A, 1996, BLOOD, V87, P3837, DOI 10.1182/blood.V87.9.3837.bloodjournal8793837; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bruns CJ, 2000, CANCER RES, V60, P2926; Bundred NJ, 2001, ENDOCR-RELAT CANCER, V8, P183, DOI 10.1677/erc.0.0080183; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; DelBufalo D, 1997, FASEB J, V11, P947, DOI 10.1096/fasebj.11.12.9337147; Dong LA, 1999, J BIOL CHEM, V274, P32099, DOI 10.1074/jbc.274.45.32099; Ellis PA, 1998, BREAST CANCER RES TR, V48, P107, DOI 10.1023/A:1005933815809; Fernandes A, 1999, INT J CANCER, V83, P564, DOI 10.1002/(SICI)1097-0215(19991112)83:4<564::AID-IJC20>3.0.CO;2-Q; Fernandez Y, 2000, CELL DEATH DIFFER, V7, P350, DOI 10.1038/sj.cdd.4400662; Fry DW, 1998, P NATL ACAD SCI USA, V95, P12022, DOI 10.1073/pnas.95.20.12022; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Glinsky GV, 1997, CANCER LETT, V115, P185, DOI 10.1016/S0304-3835(97)04738-1; Harris A L, 1992, J Natl Cancer Inst Monogr, P181; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Krajewski S, 1999, ENDOCR-RELAT CANCER, V6, P29, DOI 10.1677/erc.0.0060029; Kumar R, 1996, CLIN CANCER RES, V2, P1215; Ma L, 1998, INT J CANCER, V78, P112, DOI 10.1002/(SICI)1097-0215(19980925)78:1<112::AID-IJC18>3.0.CO;2-D; Mayo MW, 1999, EMBO J, V18, P3990, DOI 10.1093/emboj/18.14.3990; Nakamura N, 1996, J BIOL CHEM, V271, P19483, DOI 10.1074/jbc.271.32.19483; NICOLSON GL, 1993, CANCER METAST REV, V12, P325, DOI 10.1007/BF00665961; Perillo B, 2000, MOL CELL BIOL, V20, P2890, DOI 10.1128/MCB.20.8.2890-2901.2000; PRICE JE, 1990, CANCER RES, V50, P717; Sanz C, 2001, EXP HEMATOL, V29, P728, DOI 10.1016/S0301-472X(01)00635-X; Schorr K, 1999, CANCER RES, V59, P2541; Sierra A, 2000, INT J CANCER, V89, P142, DOI 10.1002/(SICI)1097-0215(20000320)89:2<142::AID-IJC7>3.3.CO;2-2; Sierra A, 1996, CLIN CANCER RES, V2, P1887; Sierra A, 1997, LAB INVEST, V77, P357; Silberstein GB, 1997, P NATL ACAD SCI USA, V94, P8132, DOI 10.1073/pnas.94.15.8132; Silva M, 1999, J BIOL CHEM, V274, P22165, DOI 10.1074/jbc.274.32.22165; Stephanou A, 2000, CELL DEATH DIFFER, V7, P329, DOI 10.1038/sj.cdd.4400656; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Wu JX, 1996, ANTICANCER RES, V16, P2233; Yarden RI, 2001, J CELL BIOCHEM, P232; Yu DH, 1996, ONCOGENE, V13, P1359; Zhong HY, 1999, BIOCHEM J, V344, P889, DOI 10.1042/0264-6021:3440889; Zong CS, 2000, J BIOL CHEM, V275, P15099, DOI 10.1074/jbc.M000089200	44	251	271	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 31	2002	21	50					7611	7618		10.1038/sj.onc.1206004	http://dx.doi.org/10.1038/sj.onc.1206004			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	606VW	12400004				2022-12-17	WOS:000178756200001
J	Sebti, SM; Hamilton, AD				Sebti, SM; Hamilton, AD			Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: Lessons from mechanism and bench-to-bedside translational studies	ONCOGENE			English	Article						farnesyltransferase; geranylgeranyltransferase I; FTI; GGTI; Ras; cancer therapy; hypothesis-driven clinical trials	PROTEIN TRANSFERASE INHIBITOR; TUMOR-CELL LINES; MALIGNANT GLIOMA GROWTH; RAS-TRANSFORMED CELLS; K-RAS; PEPTIDOMIMETIC INHIBITORS; ACTIVATE RAF-1; PHASE-I; CENP-E; H-RAS	In 1990, more than 10 years after the discovery that the low molecular weight GTPase Pas is a major contributor to human cancer, farnesylation, a lipid posttranslational modification required for the cancer-causing activity of Ras, emerged as a major target for the development of novel anticancer agents. However, it took only 5 years from 1993, when the first farnesyltransferase inhibitors (FTIs) were reported, to 1998 when results from the first phase I clinical trials were described. This rapid progress was due to the demonstration of outstanding antitumor activity and lack of toxicity of FTls in preclinical models. Although, many FTIs are currently in phase II and at least one is in phase III clinical trial, the mechanism of FTI antitumor activity is not known, In this review a brief summary of the development of FTIs as antitumor agents mill be given. The focus of the review will be on important mechanistic and bench-to-bedside translational issues. Among the issues that will be addressed are: evidence for and against inhibition of the prenylation of Pas and RhoB proteins in the mechanism of action of FTIs; implications of the alternative prenylation of K-Ras by geranylgeranyl-transferase I (when FTase is inhibited) in cancer therapy; GGTase I inhibitors (GGTIs) as antitumor agents; effects of FTIs and GGTIs on cell cycle machinery and progression and potential mechanisms by which FTIs and GGTIs induce apoptosis in human cancer cells. A thorough discussion about bench-to-bedside issues relating to hypothesis-driven clinical trials with proof-of-principle in man will also be included. This section will cover issues relating to whether the biochemical target (FTase) is inhibited and the level of inhibition of FTase required for clinical response; are signaling pathways such as H-Ras/PI3K/ Akt and/or K-Ras/Raf/MEK/Erk relevant biological readouts?; is Ras (particularly N-Ras and H-Ras) mutation status a good predictor of clinical response?; in phase I trials should effective biological dose, not maximally tolerated dose, be used to determine phase II dose?; and finally, in phase II/III trials what are the most appropriate clinical end points for anti-signaling molecules such as FTIs? Parts of this topic have been recently reviewed (Sebti and Hamilton, 2000c).	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Oncol,Drug Discovery Program, Tampa, FL 33612 USA; Yale Univ, Dept Chem, New Haven, CT USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Yale University	Sebti, SM (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Oncol,Drug Discovery Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.							ADAMSON P, 1992, J BIOL CHEM, V267, P20033; Adjei AA, 2000, CANCER RES, V60, P1871; Adnane J, 1998, MOL CELL BIOL, V18, P6962, DOI 10.1128/MCB.18.12.6962; Ashar HR, 2000, J BIOL CHEM, V275, P30451, DOI 10.1074/jbc.M003469200; Barbacid M, 1986, Important Adv Oncol, P3; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Bernhard EJ, 1996, CANCER RES, V56, P1727; Bernhard EJ, 1998, CANCER RES, V58, P1754; Bredel M, 1998, NEUROSURGERY, V43, P124, DOI 10.1097/00006123-199807000-00081; BRITTEN CD, 1999, P AN M AM SOC CLIN, V18, pA155; CASEY PJ, 1992, J LIPID RES, V33, P1731; Chen Z, 2000, J BIOL CHEM, V275, P17974, DOI 10.1074/jbc.C000145200; Cox AD, 1997, BIOCHIM BIOPHYS ACTA, V1333, P51; CRESPO NC, 2001, IN PRESS J BIOL CHEM; Du W, 1999, CANCER RES, V59, P5492; Du W, 1999, CANCER RES, V59, P4208; ESKENS F, 1999, P AN M AM SOC CLIN, V18, pA156; Gibbs JB, 1997, ANNU REV PHARMACOL, V37, P143, DOI 10.1146/annurev.pharmtox.37.1.143; GIBBS JB, 2000, FARNESYLTRANSFERASE, P65; HAHN SM, 2000, P AN M AM SOC CLIN, V19, pA231; HUDES G, 1999, P AN M AM SOC CLIN, V18, pA156; HURWITZ HI, 2000, P AN M AM SOC CLIN, V19, pA185; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; Jiang K, 2000, MOL CELL BIOL, V20, P139, DOI 10.1128/MCB.20.1.139-148.2000; Kapus A, 1999, J BIOL CHEM, V274, P8093, DOI 10.1074/jbc.274.12.8093; KAUFFMANN RC, 1995, P NATL ACAD SCI USA, V92, P10919, DOI 10.1073/pnas.92.24.10919; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KHURI FR, 2000, P AN M AM SOC CLIN, V19, pA205; LANCET J, 2000, P AN M AM SOC CLIN, V19, pA3; Lantry LE, 2000, CARCINOGENESIS, V21, P113, DOI 10.1093/carcin/21.1.113; LEBOWITZ PF, 1995, MOL CELL BIOL, V15, P6613; Lebowitz PF, 1997, CANCER RES, V57, P708; Lebowitz PF, 1997, J BIOL CHEM, V272, P15591, DOI 10.1074/jbc.272.25.15591; Lee J, 2000, MOL REPROD DEV, V56, P51, DOI 10.1002/(SICI)1098-2795(200005)56:1&lt;51::AID-MRD7&gt;3.0.CO;2-N; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; LERNER EC, 1995, J BIOL CHEM, V270, P26770, DOI 10.1074/jbc.270.45.26770; Lerner EC, 1997, ONCOGENE, V15, P1283, DOI 10.1038/sj.onc.1201296; Liu AX, 2000, MOL CELL BIOL, V20, P6105, DOI 10.1128/MCB.20.16.6105-6113.2000; McGuire TF, 1996, J BIOL CHEM, V271, P27402, DOI 10.1074/jbc.271.44.27402; NAGASU T, 1995, CANCER RES, V55, P5310; NIGAM M, 1993, J BIOL CHEM, V268, P20695; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Omer CA, 2000, CANCER RES, V60, P2680; PATNAIK A, 2000, FARNESYLTRANSFERASE, P233; Pollack IF, 1999, NEUROSURGERY, V45, P1208, DOI 10.1097/00006123-199911000-00039; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; QIAN YM, 1994, BIOORG MED CHEM LETT, V4, P2579, DOI 10.1016/S0960-894X(01)80287-0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; Robinet G, 2000, B CANCER, V87, P253; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; RYAN DP, 2000, ASCO ANN M NEW ORL L; Sebti S M, 1997, Expert Opin Investig Drugs, V6, P1711, DOI 10.1517/13543784.6.11.1711; Sebti S. M., 2000, FARNESYLTRANSFERASE, P197; Sebti SM, 2000, EXPERT OPIN INV DRUG, V9, P2767, DOI 10.1517/13543784.9.12.2767; Sebti SM, 1997, PHARMACOL THERAPEUT, V74, P103, DOI 10.1016/S0163-7258(97)00014-4; Sepp-Lorenzino L, 1998, J BIOL CHEM, V273, P20243, DOI 10.1074/jbc.273.32.20243; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; SHIH TY, 1982, J BIOL CHEM, V257, P1767; Soignet S., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P517; SUN JZ, 1995, CANCER RES, V55, P4243; Sun JZ, 1999, CANCER RES, V59, P4919; Sun JZ, 1998, ONCOGENE, V16, P1467, DOI 10.1038/sj.onc.1201656; Suzuki N, 1998, P NATL ACAD SCI USA, V95, P15356, DOI 10.1073/pnas.95.26.15356; Vogt A, 1997, J BIOL CHEM, V272, P27224, DOI 10.1074/jbc.272.43.27224; Vogt A, 1996, ONCOGENE, V13, P1991; Voice JK, 1999, J BIOL CHEM, V274, P17164, DOI 10.1074/jbc.274.24.17164; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052; ZALCMAN G, 1995, ONCOGENE, V10, P1935; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181; Zujewski J, 2000, J CLIN ONCOL, V18, P927, DOI 10.1200/JCO.2000.18.4.927	73	251	262	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 27	2000	19	56					6584	6593		10.1038/sj.onc.1204146	http://dx.doi.org/10.1038/sj.onc.1204146			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415CY	11426643				2022-12-17	WOS:000167704000004
J	Chen, FE; Ghosh, G				Chen, FE; Ghosh, G			Regulation of DNA binding by Rel/NF-kappa B transcription factors: structural views	ONCOGENE			English	Review						Rel; NF-kappa B; I kappa B; DNA; structure; transcription	FACTOR NF-KAPPA; V-REL; DIMERIZATION DOMAINS; CRYSTAL-STRUCTURE; C-REL; P65; ACTIVATION; HOMODIMER; COMPLEX; P50	Rel/NF-kappa B transcription factors form homo- and heterodimers with different DNA binding site specificities and DNA binding affinities. Several intracellular pathways evoked by a wide range of biological factors and environmental conditions can lead to the activation of Rel/NF-kappa B dimers by signaling degradation of the inhibitory I kappa B protein. In the nucleus Rel/NF-kappa B dimers modulate the expression of a variety of genes including those encoding cytokines, growth factors, acute phase response proteins, immunoreceptors, other transcription factors, cell adhesion molecules, viral proteins and regulators of apoptosis, The primary focus of this review is on structural and functional aspects of Rel/NF kappa B:DNA complexes and their formation. The salient features of the Rel/NF-kappa B dimer:DNA structure are described, as are modes of transcriptional regulation by phosphorylation, altered DNA binding properties, varying protein conformations, and interactions with I kappa B proteins.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Ghosh, G (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, 9500 Gilman Dr,MC 0359, La Jolla, CA 92093 USA.				NCI NIH HHS [CA71871] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071871] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen YQ, 1998, NAT STRUCT BIOL, V5, P67, DOI 10.1038/nsb0198-67; COLEMAN TA, 1993, MOL CELL BIOL, V13, P3850, DOI 10.1128/MCB.13.7.3850; Cramer P, 1997, EMBO J, V16, P7078, DOI 10.1093/emboj/16.23.7078; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GANCHI PA, 1993, MOL CELL BIOL, V13, P7826, DOI 10.1128/MCB.13.12.7826; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; HAYASHI T, 1993, J BIOL CHEM, V268, P26790; HRDLICKOVA R, 1995, J VIROL, V69, P3369; Huang DB, 1997, STRUCTURE, V5, P1427, DOI 10.1016/S0969-2126(97)00293-1; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; Kushner DB, 1999, MOL CELL BIOL, V19, P2169; LI CCH, 1994, BIOCHEM J, V303, P499, DOI 10.1042/bj3030499; LI CCH, 1994, J BIOL CHEM, V269, P30089; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; Nehyba J, 1997, ONCOGENE, V14, P2881, DOI 10.1038/sj.onc.1201150; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Rottjakob EM, 1996, J VIROL, V70, P3176, DOI 10.1128/JVI.70.5.3176-3188.1996; SCHRECK R, 1990, NUCLEIC ACIDS RES, V18, P6497, DOI 10.1093/nar/18.22.6497; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; Sengchanthalangsy LL, 1999, J MOL BIOL, V289, P1029, DOI 10.1006/jmbi.1999.2823; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Tisne C, 1998, J MOL BIOL, V279, P127, DOI 10.1006/jmbi.1998.1757; Tisne C, 1999, BIOCHEMISTRY-US, V38, P3883, DOI 10.1021/bi982402d; TOLEDANO MB, 1993, MOL CELL BIOL, V13, P852, DOI 10.1128/MCB.13.2.852; ZABEL U, 1991, J BIOL CHEM, V266, P252; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	38	251	258	0	14	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 22	1999	18	49					6845	6852		10.1038/sj.onc.1203224	http://dx.doi.org/10.1038/sj.onc.1203224			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259LZ	10602460				2022-12-17	WOS:000083896500002
J	HERBER, B; TRUSS, M; BEATO, M; MULLER, R				HERBER, B; TRUSS, M; BEATO, M; MULLER, R			INDUCIBLE REGULATORY ELEMENTS IN THE HUMAN CYCLIN-D1 PROMOTER	ONCOGENE			English	Article							CELL-CYCLE; CANDIDATE ONCOGENE; FOS JUN; DNA; GENE; FIBROBLASTS; IDENTIFICATION; EXPRESSION; COMPLEXES; FAMILY	To be able to elucidate the function of cyclin D1 in the control of cell cycle progression and its role as an oncogene in tumourigenesis, it is of paramount importance to understand the mechanisms involved in the regulation of its expression. In the present study, we have cloned the human cyclin D1 gene and analysed the structure and function of 3kb of its 5'-flanking region. Several regulatory regions involved in both basal level and serum-induced expression were identified, two of which turned out to be of particular interest. One of these regions is involved in serum induction and is located 848-944 bp upstream of the initiation site. In agreement with this result, in vivo footprinting revealed a novel, strongly inducible protein binding site around positions -928 to -921. A second constitutively occupied binding site was mapped to a potential CRE at position -52. Cotransfection experiments showed that the cyclin D1 promoter is inducible by c-Jun, and that this induction is mediated predominantly through the protected putative CRE at -52.	UNIV MARBURG, INST MOLEK BIOL & TUMORFORSCH, EMIL MANNKOPFF STR 2, D-35037 MARBURG, GERMANY	Philipps University Marburg			Beato, Miguel/B-5564-2015; Müller, Rolf/L-4997-2016	Beato, Miguel/0000-0002-2878-2222; Müller, Rolf/0000-0003-3339-4248				ABKEN H, 1992, NUCLEIC ACIDS RES, V20, P3527, DOI 10.1093/nar/20.13.3527; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BOLSHOY A, 1991, P NATL ACAD SCI USA, V88, P2312, DOI 10.1073/pnas.88.6.2312; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GOOD L, 1992, NUCLEIC ACIDS RES, V20, P4934, DOI 10.1093/nar/20.18.4934; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HERSKOWITZ I, 1988, MICROBIOL REV, V52, P536, DOI 10.1128/MMBR.52.4.536-553.1988; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KATO J, 1993, GENE DEV, V7, P331; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LAMMIE GA, 1992, ONCOGENE, V7, P2381; LAMMIE GA, 1991, ONCOGENE, V6, P439; Lew D J, 1992, Trends Cell Biol, V2, P77, DOI 10.1016/0962-8924(92)90076-Y; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LUCIBELLO F C, 1991, Critical Reviews in Oncogenesis, V2, P259; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MULLER R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P151, DOI 10.1016/0304-419X(93)90003-U; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; PRUNELL A, 1982, EMBO J, V1, P173, DOI 10.1002/j.1460-2075.1982.tb01143.x; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEIDEREIT C, 1984, P NATL ACAD SCI-BIOL, V81, P3029, DOI 10.1073/pnas.81.10.3029; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	46	251	257	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1994	9	4					1295	1304						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134134				2022-12-17	WOS:A1994NC04800037
J	Zhao, WD; Hisamuddin, IM; Nandan, MO; Babbin, BA; Lamb, NE; Yang, VW				Zhao, WD; Hisamuddin, IM; Nandan, MO; Babbin, BA; Lamb, NE; Yang, VW			Identification of Kruppel-like factor 4 as a potential tumor suppressor gene in colorectal cancer	ONCOGENE			English	Article						gut-enriched Kruppel-like factor; GKLF; KLF4; loss of heterozygosity; methylation; point mutation; colon cancer; tumor suppressor	KRUPPEL-LIKE FACTOR; COLONIC CELL-GROWTH; ZINC-FINGER PROTEIN; EPITHELIAL-CELLS; MUTATIONS OCCUR; LINE RKO; EXPRESSION; TUMORIGENESIS; FACTOR-4; METHYLATION	Kruppel-like factor 4 (KLF4 or GKLF) is an inhibitor of the cell cycle. The gene encoding KLF4 is localized on chromosome 9q, previously shown to exhibit allelic loss in colorectal cancer (CRC). In this study, we show that the mean level of KLF4 mRNA in a panel of 30 CRC was 52% that of paired normal colonic tissues. Similarly, the levels of KLF4 mRNA and protein in a panel of six established CRC cell lines were significantly lower than those of an untransformed colonic epithelial cell line. Using highly polymorphic DNA markers that flank the KLF4 locus, we found evidence for loss of heterozygosity (LOH) in two of eight surgically resected CRC specimens. In addition, LOH was observed in five of six CRC cell lines with one additional cell line exhibiting hemizygous deletion in the KLF4 gene. We also found that the 5'-untranslated region of KLF4 was hypermethylated in a subset of resected CRC specimens and cell lines. Lastly, the open-reading frame of KLF4 in two of three CRC cell lines examined contained several point mutations that resulted in a diminished ability to activate the p21(WAF1#47;Cip1) promoter. These findings indicate that KLF4 is a potential tumor suppressor gene in CRC.	Emory Univ, Sch Med, Dept Med, Div Digest Dis, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Human Genet, Div Digest Dis, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University; Emory University	Yang, VW (corresponding author), Emory Univ, Sch Med, Dept Med, Div Digest Dis, 201 Whitehead Res Bldg,615 Michael St, Atlanta, GA 30322 USA.	vyang@emory.edu		Mandayam, Nandan/0000-0002-4061-9348	NATIONAL CANCER INSTITUTE [R01CA084197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R24DK064399, R01DK052230] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA084197, CA84197] Funding Source: Medline; NIDDK NIH HHS [DK64399, R24 DK064399, DK52230, R01 DK052230] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		*AM CANC SOC, 2003, CANC FACTS FIG; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1990, CANCER RES, V50, P7717; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Bird AP, 1996, CANCER SURV, V28, P87; Chen XM, 2001, J BIOL CHEM, V276, P30423, DOI 10.1074/jbc.M101194200; Chen ZY, 2002, J BIOL CHEM, V277, P46831, DOI 10.1074/jbc.M204816200; Conkright MD, 1999, NUCLEIC ACIDS RES, V27, P1263, DOI 10.1093/nar/27.5.1263; Dang DT, 2000, INT J BIOCHEM CELL B, V32, P1103, DOI 10.1016/S1357-2725(00)00059-5; Dang DT, 2003, ONCOGENE, V22, P3424, DOI 10.1038/sj.onc.1206413; Dang DT, 2001, ONCOGENE, V20, P4884, DOI 10.1038/sj.onc.1204645; Dang DT, 2000, FEBS LETT, V476, P203, DOI 10.1016/S0014-5793(00)01727-0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; Geiman DE, 2000, NUCLEIC ACIDS RES, V28, P1106, DOI 10.1093/nar/28.5.1106; Goel A, 2003, CANCER RES, V63, P1608; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Gryfe R, 1997, CURR PROB CANCER, V21, P238, DOI 10.1016/S0147-0272(97)80003-7; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Ilyas M, 1999, EUR J CANCER, V35, P1986, DOI 10.1016/S0959-8049(99)00298-1; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jubb AM, 2001, J PATHOL, V195, P111, DOI 10.1002/path.923; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Ohnishi S, 2000, DEV DYNAM, V217, P421, DOI 10.1002/(SICI)1097-0177(200004)217:4<421::AID-DVDY9>3.0.CO;2-1; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Shie JL, 2000, AM J PHYSIOL-GASTR L, V279, pG806, DOI 10.1152/ajpgi.2000.279.4.G806; Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Stone CD, 2002, FEBS LETT, V530, P147, DOI 10.1016/S0014-5793(02)03449-X; Sun RG, 2001, J BIOL CHEM, V276, P6897, DOI 10.1074/jbc.C000870200; Thiagalingam S, 2001, P NATL ACAD SCI USA, V98, P2698, DOI 10.1073/pnas.051625398; Ton-That H, 1997, FEBS LETT, V419, P239, DOI 10.1016/S0014-5793(97)01465-8; Yang V W, 1999, Curr Gastroenterol Rep, V1, P449, DOI 10.1007/s11894-999-0028-0; Yet SF, 1998, J BIOL CHEM, V273, P1026, DOI 10.1074/jbc.273.2.1026; Yoon HS, 2003, J BIOL CHEM, V278, P2101, DOI 10.1074/jbc.M211027200; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200	42	250	277	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					395	402		10.1038/sj.onc.1207067	http://dx.doi.org/10.1038/sj.onc.1207067			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724568	Green Accepted			2022-12-17	WOS:000188098300009
J	Vogt, PK				Vogt, PK			Jun, the oncoprotein	ONCOGENE			English	Review						oncogenic transformation; downstream target; dimerization; leucine zipper; transactivation	CHICKEN-EMBRYO FIBROBLASTS; DNA-BINDING ACTIVITY; GROWTH-FACTOR-BETA; AP-1 TRANSCRIPTION FACTORS; ACTIVATED PROTEIN-KINASES; N-TERMINAL KINASE; TRANSFORMED AVIAN FIBROBLASTS; VASCULAR ENDOTHELIAL-CELLS; PUTATIVE TUMOR-SUPPRESSOR; LEUCINE ZIPPER DOMAIN	Cellular Jun (c-Jun) and viral Jun (v-Jun) can induce oncogenic transformation, For this activity, c-Jun requires an upstream signal, delivered by the,Jun N-terminal kinase (JNK), v-Jun does not interact with JNK; it is autonomous and constitutively active. v-Jun and c-Jun address overlapping but not identical sets of genes. Whether all genes essential for transformation reside within the overlap of the v-Jun and c-Jun target spectra remains to be determined. The search for transformation-relevant targets of Jun is moving into a new stage with the application of DNA microarrays technology. Genetic screens and functional tests remain a necessity for the identification of genes that control the oncogenic phenotype.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Vogt, PK (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Dr, La Jolla, CA 92037 USA.		Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ADLER V, 1994, J BIOL CHEM, V269, P11186; ADLER V, 1992, J BIOL CHEM, V267, P17001; ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ADLER V, 1995, CELL GROWTH DIFFER, V6, P1437; Ainbinder E, 1997, EUR J BIOCHEM, V243, P49, DOI 10.1111/j.1432-1033.1997.0049a.x; ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8; ALLEGRETTO EA, 1990, J CELL BIOCHEM, V42, P193, DOI 10.1002/jcb.240420403; ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Antinore MJ, 1996, EMBO J, V15, P1950, DOI 10.1002/j.1460-2075.1996.tb00546.x; Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; Bader AG, 2000, VIROLOGY, V270, P98, DOI 10.1006/viro.2000.0222; Bahr MJ, 1999, HEPATOLOGY, V29, P839, DOI 10.1002/hep.510290333; BAICHWAL VR, 1991, NATURE, V352, P165, DOI 10.1038/352165a0; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Barila D, 2000, EMBO J, V19, P273, DOI 10.1093/emboj/19.2.273; Basso J, 2000, ONCOGENE, V19, P4876, DOI 10.1038/sj.onc.1203863; Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BLACK EJ, 1994, ONCOGENE, V9, P2363; BLACK EJ, 1991, ONCOGENE, V6, P1949; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; Bornberg-Bauer E, 1998, NUCLEIC ACIDS RES, V26, P2740, DOI 10.1093/nar/26.11.2740; Bos T J, 1986, Princess Takamatsu Symp, V17, P23; BOS TJ, 1989, ONCOGENE, V4, P123; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; Bos TJ, 1999, INT J CANCER, V81, P404, DOI 10.1002/(SICI)1097-0215(19990505)81:3<404::AID-IJC14>3.0.CO;2-I; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; BROWN PH, 1993, ONCOGENE, V8, P877; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; CAVALIERI F, 1985, VIROLOGY, V143, P680, DOI 10.1016/0042-6822(85)90412-X; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; Cheng JK, 2000, MOL CELL BIOL, V20, P2334, DOI 10.1128/MCB.20.7.2334-2342.2000; Chida K, 1999, CELL MOL LIFE SCI, V55, P297, DOI 10.1007/s000180050291; CHIDA K, 1992, P NATL ACAD SCI USA, V89, P4290, DOI 10.1073/pnas.89.10.4290; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Clark W, 1997, CELL GROWTH DIFFER, V8, P371; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; COHEN SB, IN PRESS ONCOGENE; DAI TN, 1995, ONCOGENE, V10, P849; De Graeve F, 1999, ONCOGENE, V18, P3491, DOI 10.1038/sj.onc.1202723; De Ruiter ND, 2000, MOL CELL BIOL, V20, P8480, DOI 10.1128/MCB.20.22.8480-8488.2000; Dennler S, 2000, J BIOL CHEM, V275, P28858, DOI 10.1074/jbc.M910358199; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DeRisi J, 1996, NAT GENET, V14, P457; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; Erlichman J, 1999, EUR J BIOCHEM, V263, P797, DOI 10.1046/j.1432-1327.1999.00561.x; Fialka I, 1996, J CELL BIOL, V132, P1115, DOI 10.1083/jcb.132.6.1115; FRAME MC, 1991, ONCOGENE, V6, P205; FRANKLIN CC, 1993, CELL GROWTH DIFFER, V4, P377; Fritz G, 1999, ONCOGENE, V18, P1033, DOI 10.1038/sj.onc.1202394; Fritz G, 1999, MOL CELL BIOL, V19, P1768; Fu SL, 2000, ONCOGENE, V19, P3537, DOI 10.1038/sj.onc.1203691; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Gao MH, 1996, CANCER RES, V56, P4229; GARCIA M, 1993, P NATL ACAD SCI USA, V90, P8837, DOI 10.1073/pnas.90.19.8837; GARCIA M, 1990, J VIROL, V64, P4684, DOI 10.1128/JVI.64.10.4684-4690.1990; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; Goller ME, 1998, ONCOGENE, V16, P2945, DOI 10.1038/sj.onc.1201819; Gonzalez MV, 2000, J CELL BIOL, V150, P1199, DOI 10.1083/jcb.150.5.1199; Gottlicher M, 1998, J MOL MED-JMM, V76, P480, DOI 10.1007/s001090050242; GROSSI M, 1991, ONCOGENE, V6, P1767; HADMAN M, 1993, ONCOGENE, V8, P1895; Hadman M, 1998, ONCOGENE, V16, P655, DOI 10.1038/sj.onc.1201574; Hadman M, 1996, ONCOGENE, V12, P135; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HALUSKA FG, 1988, P NATL ACAD SCI USA, V85, P2215, DOI 10.1073/pnas.85.7.2215; Hartkamp J, 1999, CANCER RES, V59, P2195; HARTL M, 1995, P NATL ACAD SCI USA, V92, P11731, DOI 10.1073/pnas.92.25.11731; Hartl M, 1998, ONCOGENE, V17, P2901, DOI 10.1038/sj.onc.1202219; HARTL M, 1992, CELL GROWTH DIFFER, V3, P899; HARTL M, 1995, VIROLOGY, V207, P321, DOI 10.1006/viro.1995.1086; HARTL M, 1991, ONCOGENE, V6, P1623; HARTL M, 1992, CELL GROWTH DIFFER, V3, P909; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HAWKER KL, 1993, J VIROL, V67, P5487, DOI 10.1128/JVI.67.9.5487-5495.1993; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Himly M, 1998, VIROLOGY, V248, P295, DOI 10.1006/viro.1998.9290; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; Hirst JD, 1996, PROTEIN ENG, V9, P657, DOI 10.1093/protein/9.8.657; Hubank M, 1999, METHOD ENZYMOL, V303, P325; HUGHES M, 1992, CELL GROWTH DIFFER, V3, P889; Huguier S, 1998, MOL CELL BIOL, V18, P7020, DOI 10.1128/MCB.18.12.7020; Hussain S, 1998, CELL GROWTH DIFFER, V9, P677; Imafuku I, 1999, J CELL BIOL, V147, P121, DOI 10.1083/jcb.147.1.121; IMLER JL, 1988, NUCLEIC ACIDS RES, V16, P3005, DOI 10.1093/nar/16.7.3005; ITO T, 2000, IN PRESS J BIOL CHEM; JURDIC P, 1995, ONCOGENE, V11, P1699; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KAMEDA T, 1993, P NATL ACAD SCI USA, V90, P9369, DOI 10.1073/pnas.90.20.9369; Kameda T, 1997, CELL GROWTH DIFFER, V8, P495; Kameda T, 1998, CANCER RES, V58, P867; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; Kilbey A, 1996, ONCOGENE, V12, P2409; Kim S, 1996, ONCOGENE, V12, P1043; Kirch HC, 1999, ONCOGENE, V18, P2728, DOI 10.1038/sj.onc.1202626; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; Kralova J, 1998, MOL CELL BIOL, V18, P2997, DOI 10.1128/MCB.18.5.2997; Kruse U, 1997, P NATL ACAD SCI USA, V94, P12396, DOI 10.1073/pnas.94.23.12396; Kumazaki T, 1996, MECH AGEING DEV, V88, P111, DOI 10.1016/0047-6374(96)01712-5; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Lavery DJ, 1997, P NATL ACAD SCI USA, V94, P6831, DOI 10.1073/pnas.94.13.6831; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIANG P, 1995, CURR OPIN IMMUNOL, V7, P274, DOI 10.1016/0952-7915(95)80015-8; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Lin XY, 2000, MOL CELL BIOL, V20, P7259, DOI 10.1128/MCB.20.19.7259-7272.2000; Lin XY, 1997, CANCER RES, V57, P2304; Lin XY, 1996, J BIOL CHEM, V271, P28430, DOI 10.1074/jbc.271.45.28430; Ljungdahl S, 1997, EUR J BIOCHEM, V249, P648, DOI 10.1111/j.1432-1033.1997.t01-1-00648.x; Loftus TM, 1997, BIOCHEMISTRY-US, V36, P8224, DOI 10.1021/bi970288d; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MARSHALL GM, 1992, VIROLOGY, V188, P373, DOI 10.1016/0042-6822(92)90768-K; MATTEI MG, 1990, ONCOGENE, V5, P151; May GHW, 1998, CURR BIOL, V8, P117, DOI 10.1016/S0960-9822(98)70043-0; May GHW, 1998, J BIOL CHEM, V273, P33429, DOI 10.1074/jbc.273.50.33429; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; METIVIER C, 1993, ONCOGENE, V8, P2311; METTOUCHI A, 1994, EMBO J, V13, P5668, DOI 10.1002/j.1460-2075.1994.tb06905.x; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MONTECLARO FS, 1993, P NATL ACAD SCI USA, V90, P6726, DOI 10.1073/pnas.90.14.6726; MORGAN IM, 1993, ONCOGENE, V8, P1135; MORGAN IM, 1994, ONCOGENE, V9, P2793; MORGAN JI, 1991, DISCUSS NEUROSCI, V7, P11; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; Neyns B, 1999, INT J CANCER, V82, P687; NG L, 1993, NUCLEIC ACIDS RES, V21, P5831, DOI 10.1093/nar/21.25.5831; Nika J, 1997, YEAST, V13, P1155, DOI 10.1002/(SICI)1097-0061(19970930)13:12<1155::AID-YEA166>3.3.CO;2-F; NISHIMURA T, 1988, ONCOGENE, V3, P659; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; Oberst C, 1997, ONCOGENE, V14, P1109, DOI 10.1038/sj.onc.1200930; OEHLER T, 1993, ONCOGENE, V8, P1141; OLIVIERO S, 1992, GENE DEV, V6, P1799, DOI 10.1101/gad.6.9.1799; Olman MA, 1999, BLOOD, V94, P2029, DOI 10.1182/blood.V94.6.2029.418k25_2029_2038; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; PETRAK D, 1994, J IMMUNOL, V153, P2046; PULVERER BJ, 1993, ONCOGENE, V8, P407; Qing J, 2000, J BIOL CHEM, V275, P38802, DOI 10.1074/jbc.M004731200; RANSONE LJ, 1990, MOL CELL BIOL, V10, P4565, DOI 10.1128/MCB.10.9.4565; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; RANSONE LJ, 1990, P NATL ACAD SCI USA, V87, P3806, DOI 10.1073/pnas.87.10.3806; RANSONE LJ, 1989, INT J CANCER, P10; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; RAPP UR, 1994, ONCOGENE, V9, P3493; RASMUSSEN R, 1991, P NATL ACAD SCI USA, V88, P561, DOI 10.1073/pnas.88.2.561; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RINAUDO JA, 1995, J CELL BIOCHEM, V58, P237, DOI 10.1002/jcb.240580212; Rinehart-Kim J, 2000, INT J CANCER, V88, P180, DOI 10.1002/1097-0215(20001015)88:2<180::AID-IJC6>3.0.CO;2-H; RITTLING SR, 1989, NUCLEIC ACIDS RES, V17, P1619, DOI 10.1093/nar/17.4.1619; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHERER SJ, 2000, J BIOL CHEM, V12, P12; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; SCHUH AC, 1990, NATURE, V346, P756, DOI 10.1038/346756a0; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUUR ER, 1993, CELL GROWTH DIFFER, V4, P761; SCHUUR ER, 1995, CELL GROWTH DIFFER, V6, P219; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; Smith LM, 1999, ONCOGENE, V18, P6063, DOI 10.1038/sj.onc.1202989; STRUHL K, 1987, CELL, V50, P841, DOI 10.1016/0092-8674(87)90511-3; SU HY, 1991, ONCOGENE, V6, P1759; Sutcliffe JG, 2000, P NATL ACAD SCI USA, V97, P1976, DOI 10.1073/pnas.040537997; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; SUZUKI T, 1991, JPN J CANCER RES, V82, P58, DOI 10.1111/j.1349-7006.1991.tb01746.x; TAGAWA T, 1995, J CELL BIOL, V130, P255, DOI 10.1083/jcb.130.2.255; TEURICH S, 1995, CHEM SENSES, V20, P251, DOI 10.1093/chemse/20.2.251; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; Ubeda M, 1999, MOL CELL BIOL, V19, P7589; Ui M, 1998, FEBS LETT, V429, P289, DOI 10.1016/S0014-5793(98)00618-8; Ui M, 2000, BIOCHEM BIOPH RES CO, V278, P97, DOI 10.1006/bbrc.2000.3777; USUI H, 1994, J NEUROSCI, V14, P4915; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; Vandel L, 1996, MOL CELL BIOL, V16, P1881; VANDEL L, 1995, ONCOGENE, V10, P495; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Vial E, 2000, ONCOGENE, V19, P1772, DOI 10.1038/sj.onc.1203493; Vial E, 2000, ONCOGENE, V19, P5020, DOI 10.1038/sj.onc.1203867; VOGT PK, 1987, P NATL ACAD SCI USA, V84, P3316, DOI 10.1073/pnas.84.10.3316; Wang NP, 1999, CIRC RES, V85, P387, DOI 10.1161/01.RES.85.5.387; Watson A, 1998, J NEUROSCI, V18, P751; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; Wong C, 1999, MOL CELL BIOL, V19, P1821; WONG WY, 1992, ONCOGENE, V7, P2077; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; Xiao L, 2000, CANCER RES, V60, P400; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; Zhang WP, 2000, BIOCHEM BIOPH RES CO, V274, P872, DOI 10.1006/bbrc.2000.3244; Zhang XK, 1999, MOL CELL BIOL, V19, P7138; Zoumpourlis V, 2000, ONCOGENE, V19, P4011, DOI 10.1038/sj.onc.1203732	222	250	262	2	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2001	20	19					2365	2377		10.1038/sj.onc.1204443	http://dx.doi.org/10.1038/sj.onc.1204443			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	430HP	11402333				2022-12-17	WOS:000168568700004
J	BROWN, PH; ALANI, R; PREIS, LH; SZABO, E; BIRRER, MJ				BROWN, PH; ALANI, R; PREIS, LH; SZABO, E; BIRRER, MJ			SUPPRESSION OF ONCOGENE-INDUCED TRANSFORMATION BY A DELETION MUTANT OF C-JUN	ONCOGENE			English	Article							TRANSCRIPTION FACTOR AP-1; DNA-BINDING ACTIVITY; RAT EMBRYO CELLS; LEUCINE ZIPPER; HETERODIMER FORMATION; ENHANCER ELEMENTS; PROTO-ONCOGENE; V-JUN; FOS; ACTIVATION	Jun and Fos proteins are DNA-binding proteins that are involved in the control of gene expression through transcriptional regulation. We have made a deletion mutant of the c-jun gene that lacks amino acids 3-122 of c-jun, and thus is missing the major transactivation domain of c-jun, but retains the DNA-binding and leucine zipper domains. Unlike c-Jun, the mutant protein is unable to stimulate the transcription of an AP-1 responsive gene, and unlike c-jun this mutant gene is unable to transform rat embryo celts in cooperation with an activated ras gene. However, this mutant protein blocks in vitro DNA binding of Jun-Jun homodimers and Jun-Fos heterodimers, transcriptional activation induced by c-jun or c-fos and transformation of rat embryo cells induced by an activated ras gene and a deregulated c-jun or c-fos gene. In addition, transformation of rat embryo cells induced by an activated ras gene in the presence of the tumor promoter 12-0-tetradecanoyl phorbol 13-acetate (TPA) or by ras plus SV40 large T antigen is also inhibited by this dominant-negative mutant, suggesting that a member of the jun or fos family is involved in the pathways leading to transformation in these systems as well. The possible molecular mechanisms by which this dominant-negative mutant of c-jun blocks the functions of wild-type jun and fos family members are discussed.	NCI, DIV CANC PREVENT & CONTROL, BIOMARKERS & PREVENT RES BRANCH, 5516 NICHOLSON LANE,ROOM 100, KENSINGTON, MD 20895 USA; UNIV HLTH SCI, UNIFORMED SERV, BETHESDA, MD 20814 USA; HOWARD HUGHES MED INST, BETHESDA, MD 20814 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Howard Hughes Medical Institute				Szabo, Eva/0000-0003-3891-0942; Alani, Rhoda/0000-0003-2741-2665; Brown, Powel/0000-0002-3398-163X				ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BENBROOK DM, 1990, ONCOGENE, V5, P295; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BIRRER MJ, 1988, MOL CELL BIOL, V8, P2668, DOI 10.1128/MCB.8.6.2668; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; DAVENPORT EA, 1988, ANTICANCER RES, V8, P959; DOSAKA AH, 1991, ONCOGENE, V6, P371; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRANGERSCHNARR M, 1992, P NATL ACAD SCI USA, V89, P4236, DOI 10.1073/pnas.89.10.4236; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HIRAI SI, 1990, ONCOGENE, V5, P39; HSIAO WLW, 1986, MOL CELL BIOL, V6, P1943, DOI 10.1128/MCB.6.6.1943; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MULLER R, 1987, ONCOGENE RES, V2, P19; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; OKUNO H, 1991, ONCOGENE, V6, P1491; OLIVIERO S, 1992, GENE DEV, V6, P1799, DOI 10.1101/gad.6.9.1799; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; RANSONE LJ, 1990, P NATL ACAD SCI USA, V87, P3806, DOI 10.1073/pnas.87.10.3806; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SAMBROOK J, 1987, MOL CLONING LABORATO, P1666; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; STRUHL K, 1988, NATURE, V332, P649, DOI 10.1038/332649a0; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	54	250	254	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1993	8	4					877	886						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455942				2022-12-17	WOS:A1993KT22000008
J	REYNOLDS, AB; HERBERT, L; CLEVELAND, JL; BERG, ST; GAUT, JR				REYNOLDS, AB; HERBERT, L; CLEVELAND, JL; BERG, ST; GAUT, JR			P120, A NOVEL SUBSTRATE OF PROTEIN TYROSINE KINASE RECEPTORS AND OF P60V-SRC IS RELATED TO CADHERIN-BINDING FACTORS BETA-CATENIN, PLAKOGLOBIN AND ARMADILLO	ONCOGENE			English	Article							SEGMENT POLARITY GENE; PHOSPHORYLATION; REGION; PDGF; SEQUENCE; CLONING; COMPLEX; HOMOLOG; CELLS; GAP	A novel protein tyrosine kinase (PTK) substrate, p120, has been previously implicated in ligand-induced signaling through the epidermal growth factor, platelet-derived growth factor and colony-stimulating factor 1 receptors, and in cell transformation by p60v-src. We have isolated a near full-length cDNA encoding murine p120. The encoded protein lacks significant homology with any reported protein, but it contains four copies of an imperfect 42 amino acid repeat that occurs 12.5 times in the protein encoded by Drosophila armadillo (arm), and its direct homologs, human plakoglobin (plak) and Xenopus laevis beta-catenin (beta-cat). The presence of this motif implies that p120 may share at least one aspect of its function with the arm protein and its homologs.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA	St Jude Children's Research Hospital	REYNOLDS, AB (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, 332 N LAUDERDALE, MEMPHIS, TN 38105 USA.				NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765] Funding Source: Medline; NCRR NIH HHS [RR05584] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		CHIRGWIN JM, 1977, BIOCHEMISTRY-US, V1, P5294; Cleveland J L, 1988, Oncogene Res, V3, P357; DOWNING JR, 1991, ONCOGENE, V6, P607; FRANKE WW, 1989, P NATL ACAD SCI USA, V86, P4027, DOI 10.1073/pnas.86.11.4027; HIRANO S, 1987, J CELL BIOL, V105, P2501, DOI 10.1083/jcb.105.6.2501; HONG W, 1991, MOL CELL BIOL, V11, P5113; KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LINDER ME, 1988, P NATL ACAD SCI USA, V85, P2608, DOI 10.1073/pnas.85.8.2608; Maniatis T., 1982, MOL CLONING; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; RIGGLEMAN B, 1989, GENE DEV, V3, P96, DOI 10.1101/gad.3.1.96; SCHALLER MD, 1992, IN PRESS P NATL ACAD; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WALLACE RB, 1987, METHOD ENZYMOL, V152, P432	25	250	257	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	1992	7	12					2439	2445						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1334250				2022-12-17	WOS:A1992KA85600008
J	ROYERPOKORA, B; LOOS, U; LUDWIG, WD				ROYERPOKORA, B; LOOS, U; LUDWIG, WD			TTG-2, A NEW GENE ENCODING A CYSTEINE-RICH PROTEIN WITH THE LIM MOTIF, IS OVEREXPRESSED IN ACUTE T-CELL LEUKEMIA WITH THE T(11-14)(P13-Q11)	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; BREAKPOINT CLUSTER REGION; CHROMOSOMAL TRANSLOCATIONS; DEVELOPMENTAL REGULATION; CHAIN LOCUS; ALPHA-CHAIN; RECEPTOR; 11P13; REARRANGEMENTS; HOMEODOMAIN	We have cloned 70 kb of DNA from chromosome 11p13 at the site of a recurrent translocation in T-cell leukaemia (T-ALL): t(11;14)(p13;q11). The translocation involves the TCR-delta-gene on 14q11 and a new site on 11p13. Two new and 10 previously identified translocations all mapped within 25 kb on 11p13, the 11p13 T-cell translocation cluster (11p13 ttc). A search for expressed sequences surrounding the breakpoint cluster region on 11p13 identified a gene telomeric of all breakpoints which is overexpressed in three T-ALL samples with a t(11;14). The gene T-cell translocation gene (TTG-2) encodes a small cysteine-rich protein. Forty-eight per cent of the amino acids are identical with another translocation-deregulated gene, TTG-1 (T-cell translocation gene 1 or rhombotin) in 11p15. There are two copies of a cysteine-rich motif in both proteins. Two tandem copies of the same cysteine-rich motif are also present in the recently described lin-11, isl-1 and mec-3 gene products, and one motif is found in the CRIP protein. Therefore the proteins encoded by these two translocation-deregulated genes belong to this new class of cysteine-rich proteins with the 'LIM' motif, which are important in normal development.	KLINIKUM STEGLITZ,DEPT HEMATOL & ONCOL,W-1000 BERLIN,GERMANY		ROYERPOKORA, B (corresponding author), INST HUMANGENET & ANTHROPOL,NEUENHEIMER FELD 328,W-6900 HEIDELBERG,GERMANY.							BIRKENMEIER EH, 1986, P NATL ACAD SCI USA, V83, P2516, DOI 10.1073/pnas.83.8.2516; BOEHM T, 1990, EMBO J, V9, P857, DOI 10.1002/j.1460-2075.1990.tb08183.x; BOEHM T, 1989, EMBO J, V8, P2621, DOI 10.1002/j.1460-2075.1989.tb08402.x; BOEHM T, 1990, ONCOGENE, V5, P1103; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BOEHM T, 1988, EMBO J, V7, P2011, DOI 10.1002/j.1460-2075.1988.tb03040.x; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHENG JT, 1990, J EXP MED, V171, P489, DOI 10.1084/jem.171.2.489; ERIKSON J, 1985, SCIENCE, V229, P784, DOI 10.1126/science.3875152; FORONI L, 1990, GENE CHROMOSOME CANC, V1, P301, DOI 10.1002/gcc.2870010407; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GREENBERG JM, 1990, NATURE, V344, P158, DOI 10.1038/344158a0; GUEBLER U, 1983, GENE, V25, P263; HARVEY RC, 1989, ONCOGENE, V4, P341; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; LAMPERT F, 1988, BLUT, V56, P117, DOI 10.1007/BF00320016; LEWIS WH, 1985, NATURE, V317, P544, DOI 10.1038/317544a0; MCGUIRE EA, 1991, BLOOD, V77, P599; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; RAIMONDI SC, 1988, BLOOD, V72, P1560; ROYERPOKORA B, 1989, HUM GENET, V82, P264, DOI 10.1007/BF00291167; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SEALEY L, 1987, MOL CELL BIOL, V7, P787, DOI 10.1128/MCB.7.2.787; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; WILLIAMS DL, 1984, CELL, V36, P101, DOI 10.1016/0092-8674(84)90078-3; YOFFE G, 1989, BLOOD, V74, P374; ZUTTER M, 1990, P NATL ACAD SCI USA, V87, P3161, DOI 10.1073/pnas.87.8.3161	29	250	263	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1887	1893						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923511				2022-12-17	WOS:A1991GX11800023
J	SANTORO, M; ROSATI, R; GRIECO, M; BERLINGIERI, MT; DAMATO, GL; DEFRANCISCIS, V; FUSCO, A				SANTORO, M; ROSATI, R; GRIECO, M; BERLINGIERI, MT; DAMATO, GL; DEFRANCISCIS, V; FUSCO, A			THE RET PROTOONCOGENE IS CONSISTENTLY EXPRESSED IN HUMAN PHEOCHROMOCYTOMAS AND THYROID MEDULLARY CARCINOMAS	ONCOGENE			English	Note									NAPLES UNIV, FAC MED & CHIRURG 2, DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC, I-80131 NAPLES, ITALY; UNIV REGGIO CALABRIA, FAC MED & CHIRURG CATANZARO, IST ONCOL CLIN & SPERIMENTALE, I-88100 CATANZARO, ITALY	University of Naples Federico II; Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria	SANTORO, M (corresponding author), NAPLES UNIV, CNR, CTR ENDOCRINOL & ONCOL SPERIMENTALE, VIA PANSINI 5, I-80131 NAPLES, ITALY.			Fusco, Alfredo/0000-0003-3332-5197; Grieco, Michele/0000-0002-4212-7814				BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BONGARZONE I, 1989, ONCOGENE, V4, P1457; DEBUSTROS A, 1985, J BIOL CHEM, V260, P98; DEBUSTROS A, 1986, J BIOL CHEM, V261, P8036; DONGHI R, 1989, ONCOGENE, V4, P521; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; ISHIZAKA Y, 1989, ONCOGENE, V4, P789; ISHIZAKA Y, 1989, ONCOGENE, V4, P1519; KODA T, 1988, Hokkaido Journal of Medical Science, V63, P913; LEDOUARIN NM, 1986, SCIENCE, V231, P1515, DOI 10.1126/science.3952494; Leong S, 1981, ADV THYROID NEOPLASI, P95; MATHEW CGP, 1987, NATURE, V328, P527, DOI 10.1038/328527a0; NAGAO M, 1990, JPN J CANCER RES, V81, P309, DOI 10.1111/j.1349-7006.1990.tb02566.x; NAKAMURA Y, 1989, GENOMICS, V5, P199, DOI 10.1016/0888-7543(89)90046-3; NELKIN BD, 1984, BIOCHEM BIOPH RES CO, V123, P648, DOI 10.1016/0006-291X(84)90278-X; Sambrook J., 1989, MOL CLONING LAB MANU; SIMPSON NE, 1987, NATURE, V328, P528, DOI 10.1038/328528a0; TAHIRA T, 1988, BIOCHEM BIOPH RES CO, V153, P1290, DOI 10.1016/S0006-291X(88)81368-8; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1988, ONCOGENE, V3, P571; VECCHIO G, 1989, ONCOGENE, V4, P897	25	250	268	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1990	5	10					1595	1598						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK502	1701232				2022-12-17	WOS:A1990EK50200022
J	Zhang, S; Mercado-Uribe, I; Xing, Z; Sun, B; Kuang, J; Liu, J				Zhang, S.; Mercado-Uribe, I.; Xing, Z.; Sun, B.; Kuang, J.; Liu, J.			Generation of cancer stem-like cells through the formation of polyploid giant cancer cells	ONCOGENE			English	Article						polyploid giant cancer cells; cancer stem cells; endocycle; cell fusion; asymmetric cell division	TUMOR-CELLS; NEOSIS; OXYGEN; DEATH; GENE	Polyploid giant cancer cells (PGCCs) have been observed by pathologists for over a century. PGCCs contribute to solid tumor heterogeneity, but their functions are largely undefined. Little attention has been given to these cells, largely because PGCCs have been generally thought to originate from repeated failure of mitosis/cytokinesis and have no capacity for long-term survival or proliferation. Here we report our successful purification and culture of PGCCs from human ovarian cancer cell lines and primary ovarian cancer. These cells are highly resistant to oxygen deprivation and could form through endoreduplication or cell fusion, generating regular-sized cancer cells quickly through budding or bursting similar to simple organisms like fungi. They express normal and cancer stem cell markers, they divide asymmetrically and they cycle slowly. They can differentiate into adipose, cartilage and bone. A single PGCC formed cancer spheroids in vitro and generated tumors in immunodeficient mice. These PGCC-derived tumors gained a mesenchymal phenotype with increased expression of cancer stem cell markers CD44 and CD133 and become more resistant to treatment with cisplatin. Taken together, our results reveal that PGCCs represent a resistant form of human cancer using an ancient, evolutionarily conserved mechanism in response to hypoxia stress; they can contribute to the generation of cancer stem-like cells, and also play a fundamental role in regulating tumor heterogeneity, tumor growth and chemoresistance in human cancer.	[Zhang, S.; Mercado-Uribe, I.; Xing, Z.; Liu, J.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Zhang, S.] Nankai Univ, Affiliated Hosp, Dept Pathol, Tianjin 300071, Peoples R China; [Sun, B.] Tianjin Med Univ, Dept Pathol, Tianjin, Peoples R China; [Sun, B.] Tianjin Canc Inst, Tianjin, Peoples R China; [Kuang, J.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Nankai University; Tianjin Medical University; Tianjin Medical University; University of Texas System; UTMD Anderson Cancer Center	Liu, J (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Pathol, Unit 85, 1515 Holcombe Blvd,Box 0085, Houston, TX 77030 USA.	jliu@mdanderson.org			National Institutes of Health [R01CA131183-01A2, P50CA83638]; Cancer Prevention and Research Institute of Texas (CPRIT) [RP1105995]; Cancer Center Support Grant [CA016672]; NATIONAL CANCER INSTITUTE [P50CA083638, R01CA131183, P30CA016672, P50CA083639] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention and Research Institute of Texas (CPRIT); Cancer Center Support Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the Department of Scientific Publications and Ms Christine Wogan for their excellent editorial assistance on the manuscript and Ms Kim Vu for help in figure preparation. Jinsong Liu was supported by an R01 Grant (R01CA131183-01A2) and an ovarian cancer Specialized Programs of Research Excellence (SPORE) grant (P50CA83638) from the National Institutes of Health and a multi-investigator grant from Cancer Prevention and Research Institute of Texas (CPRIT) (RP1105995). Short tandem repeat DNA fingerprinting was carried out by the Cancer Center Support Grant-funded Characterized Cell Line core, NCI No. CA016672.	Alberts B, 2002, MOL BIOL CELL, V4th; Brodbeck WG, 2009, CURR OPIN HEMATOL, V16, P53, DOI 10.1097/MOH.0b013e32831ac52e; Comai L, 2005, NAT REV GENET, V6, P836, DOI 10.1038/nrg1711; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Erenpreisa J, 2005, CELL BIOL INT, V29, P1012, DOI 10.1016/j.cellbi.2005.10.005; Erenpreisa J, 2005, CELL BIOL INT, V29, P1005, DOI 10.1016/j.cellbi.2005.10.008; Erenpreisa J, 2007, CELL BIOL INT, V31, P1507, DOI 10.1016/j.cellbi.2007.08.013; Erenpreisa J, 2011, CELL BIOL INT, V35, P687, DOI 10.1042/CBI20100762; Erenpreisa Jekaterina, 2001, Cancer Cell Int, V1, P1, DOI 10.1186/1475-2867-1-1; Geigl JB, 2008, TRENDS GENET, V24, P64, DOI 10.1016/j.tig.2007.11.006; Glotzer M, 2005, SCIENCE, V307, P1735, DOI 10.1126/science.1096896; Gurdon JB, 2008, SCIENCE, V322, P1811, DOI 10.1126/science.1160810; Heddleston JM, 2009, CELL CYCLE, V8, P3274, DOI 10.4161/cc.8.20.9701; HEPPNER GH, 1984, CANCER RES, V44, P2259; Ho VT, 1996, BIOCHEM BIOPH RES CO, V223, P175, DOI 10.1006/bbrc.1996.0865; Holland AJ, 2009, NAT REV MOL CELL BIO, V10, P478, DOI 10.1038/nrm2718; Keith B, 2007, CELL, V129, P465, DOI 10.1016/j.cell.2007.04.019; Knop M, 2011, CR BIOL, V334, P599, DOI 10.1016/j.crvi.2011.05.007; Konopleva MY, 2011, J CLIN ONCOL, V29, P591, DOI 10.1200/JCO.2010.31.0904; Kumar V.A., 2010, ROBBINS CONTRAN PATH, P262; Kusumbe AP, 2009, CANCER RES, V69, P9245, DOI 10.1158/0008-5472.CAN-09-2802; Lee HO, 2009, GENE DEV, V23, P2461, DOI 10.1101/gad.1829209; Liu GZ, 2010, JNCI-J NATL CANCER I, V102, P812, DOI 10.1093/jnci/djq127; Liu JS, 2004, CANCER RES, V64, P1655, DOI 10.1158/0008-5472.CAN-03-3380; Lu X, 2009, CANCER RES, V69, P8536, DOI 10.1158/0008-5472.CAN-09-2159; Malpica A, 2004, AM J SURG PATHOL, V28, P496, DOI 10.1097/00000478-200404000-00009; Mohyeldin A, 2010, CELL STEM CELL, V7, P150, DOI 10.1016/j.stem.2010.07.007; Piret JP, 2002, ANN NY ACAD SCI, V973, P443, DOI 10.1111/j.1749-6632.2002.tb04680.x; Rajaraman R, 2005, CELL BIOL INT, V29, P1084, DOI 10.1016/j.cellbi.2005.10.003; Siller KH, 2009, NAT CELL BIOL, V11, P365, DOI 10.1038/ncb0409-365; Sundaram M, 2004, CANCER BIOL THER, V3, P207, DOI 10.4161/cbt.3.2.663; Trail F, 2007, FEMS MICROBIOL LETT, V276, P12, DOI 10.1111/j.1574-6968.2007.00900.x; Vakifahmetoglu H, 2008, CELL DEATH DIFFER, V15, P1153, DOI 10.1038/cdd.2008.47; Walen KH, 2006, IN VITRO CELL DEV-AN, V42, P216; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; Yang G, 2004, J BIOL CHEM, V279, P4339, DOI 10.1074/jbc.M311153200; Zhang WH, 2011, CANCER-AM CANCER SOC, V117, P4092, DOI 10.1002/cncr.26021	37	249	263	0	41	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2014	33	1					116	128		10.1038/onc.2013.96	http://dx.doi.org/10.1038/onc.2013.96			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	282YU	23524583	Green Accepted			2022-12-17	WOS:000329212000013
J	Lowery, DM; Lim, D; Yaffe, MB				Lowery, DM; Lim, D; Yaffe, MB			Structure and function of Polo-like kinases	ONCOGENE			English	Review						Polo-like kinase; polo-box domain; mitosis; phosphorylation-dependent binding; modular signalling domain	REPLICATION CHECKPOINT RESPONSE; SACCHAROMYCES-CEREVISIAE CDC5; ANAPHASE-PROMOTING COMPLEX; INTEGRIN-BINDING PROTEIN; CELL-CYCLE REGULATION; KINESIN-LIKE PROTEIN; P38 MAP KINASE; CRYSTAL-STRUCTURE; SUBCELLULAR-LOCALIZATION; PROGNOSTIC-SIGNIFICANCE	Polo-like kinases play critical roles during multiple stages of cell cycle progression. All Polo-like kinases contain an N-terminal Ser/Thr kinase catalytic domain and a C-terminal region that contains one or two Polo-boxes. For Polo-like kinase 1, 2, and 3, and their homologs, the entire C-terminal region, including both Polo-boxes, functions as a single modular phosphoserine/threonine-binding domain known as the Polo-box domain (PBD). In the absence of a bound substrate, the PBD inhibits the basal activity of the kinase domain. Phosphorylation-dependent binding of the PBD to its ligands releases the kinase domain, while simultaneously localizing Polo-like kinases to specific subcellular structures. These observations suggest two different models for how the PBD integrates signals arising from other mitotic kinases to target the activated kinase towards distinct substrates. The recent X-ray crystal structures of the PBD provide insights into the structural basis for PBD function and kinase regulation. Molecular modelling of the structure of the isolated kinase domain reveals a potential basis for motif-dependent substrate specificity.	MIT, Ctr Canc Res, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Yaffe, MB (corresponding author), MIT, Ctr Canc Res, E18-580,77 Massachusetts Ave, Cambridge, MA 02139 USA.	myaffe@mit.edu			NIGMS NIH HHS [GM60594] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060594] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Avides MD, 2001, NAT CELL BIOL, V3, P421, DOI 10.1038/35070110; Bahassi EM, 2002, ONCOGENE, V21, P6633, DOI 10.1038/sj.onc.1205850; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Bayliss R, 2003, MOL CELL, V12, P851, DOI 10.1016/S1097-2765(03)00392-7; BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; Burns TF, 2003, MOL CELL BIOL, V23, P5556, DOI 10.1128/MCB.23.16.5556-5571.2003; Casenghi M, 2003, DEV CELL, V5, P113, DOI 10.1016/S1534-5807(03)00193-X; Charles JF, 1998, CURR BIOL, V8, P497, DOI 10.1016/S0960-9822(98)70201-5; Cheetham GMT, 2002, J BIOL CHEM, V277, P42419, DOI 10.1074/jbc.C200426200; Cheng KY, 2003, EMBO J, V22, P5757, DOI 10.1093/emboj/cdg558; Cheng L, 1998, MOL CELL BIOL, V18, P7360, DOI 10.1128/MCB.18.12.7360; Conn CW, 2000, CANCER RES, V60, P6826; deAzevedo WF, 1996, P NATL ACAD SCI USA, V93, P2735, DOI 10.1073/pnas.93.7.2735; Dewitte W, 2003, ANNU REV PLANT BIOL, V54, P235, DOI 10.1146/annurev.arplant.54.031902.134836; Dietzmann K, 2001, J NEURO-ONCOL, V53, P1, DOI 10.1023/A:1011808200978; DONOHUE PJ, 1995, J BIOL CHEM, V270, P10351, DOI 10.1074/jbc.270.17.10351; Elez R, 2003, ONCOGENE, V22, P69, DOI 10.1038/sj.onc.1206038; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Ellinger-Ziegelbauer H, 2000, GENES CELLS, V5, P491, DOI 10.1046/j.1365-2443.2000.00337.x; Erikson E, 2004, J BIOL CHEM, V279, P32219, DOI 10.1074/jbc.M403840200; Fabbro D, 2002, PHARMACOL THERAPEUT, V93, P79, DOI 10.1016/S0163-7258(02)00179-1; Felsenstein J, 1997, SYST BIOL, V46, P101, DOI 10.2307/2413638; Fitzgerald CE, 2003, NAT STRUCT BIOL, V10, P764, DOI 10.1038/nsb949; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Golan A, 2002, J BIOL CHEM, V277, P15552, DOI 10.1074/jbc.M111476200; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; Hardy CFJ, 1996, MOL CELL BIOL, V16, P6775; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; Hudson JW, 2000, GENE, V241, P65, DOI 10.1016/S0378-1119(99)00467-9; Hudson JW, 2001, CURR BIOL, V11, P441, DOI 10.1016/S0960-9822(01)00117-8; Jackman M, 2003, NAT CELL BIOL, V5, P143, DOI 10.1038/ncb918; Jang YJ, 2002, J BIOL CHEM, V277, P44115, DOI 10.1074/jbc.M202172200; Jang YJ, 2002, P NATL ACAD SCI USA, V99, P1984, DOI 10.1073/pnas.042689299; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kauselmann G, 1999, EMBO J, V18, P5528, DOI 10.1093/emboj/18.20.5528; Kelm O, 2002, J BIOL CHEM, V277, P25247, DOI 10.1074/jbc.M202855200; Knecht R, 1999, CANCER RES, V59, P2794; Kneisel L, 2002, J CUTAN PATHOL, V29, P354, DOI 10.1034/j.1600-0560.2002.290605.x; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(05)00092-4; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; LEE KS, 1995, MOL CELL BIOL, V15, P7143; Lee KS, 1998, P NATL ACAD SCI USA, V95, P9301, DOI 10.1073/pnas.95.16.9301; Lee KS, 1997, MOL CELL BIOL, V17, P3408, DOI 10.1128/MCB.17.6.3408; Leung GC, 2002, NAT STRUCT BIOL, V9, P719, DOI 10.1038/nsb848; Liby K, 2001, DNA SEQUENCE, V11, P527, DOI 10.3109/10425170109041337; Lin CY, 2000, P NATL ACAD SCI USA, V97, P12589, DOI 10.1073/pnas.220423497; Lin HR, 2003, J BIOL CHEM, V278, P35979, DOI 10.1074/jbc.M210659200; Lindon C, 2004, J CELL BIOL, V164, P233, DOI 10.1083/jcb.200309035; Liu XQ, 2004, J CELL SCI, V117, P3233, DOI 10.1242/jcs.01173; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; Logarinho E, 1998, J CELL SCI, V111, P2897; Ma S, 2003, MOL CANCER RES, V1, P376; May KM, 2002, J CELL BIOL, V156, P23, DOI 10.1083/jcb.200106150; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Moshe Y, 2004, P NATL ACAD SCI USA, V101, P7937, DOI 10.1073/pnas.0402442101; Moutinho-Santos T, 1999, BIOL CELL, V91, P585, DOI 10.1016/S0248-4900(00)88523-8; Mundt KE, 1997, BIOCHEM BIOPH RES CO, V239, P377, DOI 10.1006/bbrc.1997.7378; Nakajima H, 2003, J BIOL CHEM, V278, P25277, DOI 10.1074/jbc.C300126200; Neef R, 2003, J CELL BIOL, V162, P863, DOI 10.1083/jcb.200306009; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Noble MEM, 2004, SCIENCE, V303, P1800, DOI 10.1126/science.1095920; Nowakowski J, 2002, STRUCTURE, V10, P1659, DOI 10.1016/S0969-2126(02)00907-3; Pak DTS, 2003, SCIENCE, V302, P1368, DOI 10.1126/science.1082475; Pargellis C, 2002, NAT STRUCT BIOL, V9, P268, DOI 10.1038/nsb770; Pellicena P, 1998, J BIOL CHEM, V273, P15325, DOI 10.1074/jbc.273.25.15325; Qian YW, 1999, MOL CELL BIOL, V19, P8625; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Qian YW, 1998, SCIENCE, V282, P1701, DOI 10.1126/science.282.5394.1701; Ruan Q, 2004, EXP CELL RES, V294, P51, DOI 10.1016/j.yexcr.2003.10.022; Sakchaisri K, 2004, P NATL ACAD SCI USA, V101, P4124, DOI 10.1073/pnas.0400641101; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Scott MP, 2000, BIOCHEMISTRY-US, V39, P14531, DOI 10.1021/bi001850u; Seong YS, 2002, J BIOL CHEM, V277, P32282, DOI 10.1074/jbc.M202602200; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; Song S, 2000, MOL CELL BIOL, V20, P286, DOI 10.1128/MCB.20.1.286-298.2000; Song SG, 2001, J CELL BIOL, V152, P451, DOI 10.1083/jcb.152.3.451; Spankuch-Schmitt B, 2002, ONCOGENE, V21, P3162, DOI 10.1038/sj.onc.1205412; Stout TJ, 2004, CURR PHARM DESIGN, V10, P1069, DOI 10.2174/1381612043452695; SUNKEL CE, 1988, J CELL SCI, V89, P25; Sutterlin C, 2001, P NATL ACAD SCI USA, V98, P9128, DOI 10.1073/pnas.161283998; Takahashi T, 2003, CANCER SCI, V94, P148, DOI 10.1111/j.1349-7006.2003.tb01411.x; Takai N, 2001, CANCER LETT, V164, P41, DOI 10.1016/S0304-3835(00)00703-5; Tavares AAM, 1996, EMBO J, V15, P4873, DOI 10.1002/j.1460-2075.1996.tb00868.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tokumitsu Y, 1999, INT J ONCOL, V15, P687; Tong L, 1997, NAT STRUCT BIOL, V4, P311, DOI 10.1038/nsb0497-311; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; Walter SA, 2003, J BIOL CHEM, V278, P18221, DOI 10.1074/jbc.M212556200; Wang Q, 2002, MOL CELL BIOL, V22, P3450, DOI 10.1128/MCB.22.10.3450-3459.2002; Watanabe N, 2004, P NATL ACAD SCI USA, V101, P4419, DOI 10.1073/pnas.0307700101; Wind M, 2002, PROTEOMICS, V2, P1516, DOI 10.1002/1615-9861(200211)2:11<1516::AID-PROT1516>3.0.CO;2-Y; Wolf G, 2000, PATHOL RES PRACT, V196, P753, DOI 10.1016/S0344-0338(00)80107-7; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862; Xie SQ, 2004, ONCOGENE, V23, P3822, DOI 10.1038/sj.onc.1207479; Xie SQ, 2001, J BIOL CHEM, V276, P43305, DOI 10.1074/jbc.M106050200; Xie SQ, 2002, CELL CYCLE, V1, P424, DOI 10.4161/cc.1.6.271; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870; Yarm FR, 2002, MOL CELL BIOL, V22, P6209, DOI 10.1128/MCB.22.17.6209-6221.2002; Yoo HY, 2004, CELL, V117, P575, DOI 10.1016/S0092-8674(04)00417-9; Yuan JP, 2002, ONCOGENE, V21, P8282, DOI 10.1038/sj.onc.1206011; Zhou T, 2003, DEV CELL, V5, P127, DOI 10.1016/S1534-5807(03)00186-2	117	249	280	4	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2005	24	2					248	259		10.1038/sj.onc.1208280	http://dx.doi.org/10.1038/sj.onc.1208280			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	885UR	15640840				2022-12-17	WOS:000226183100005
J	Duensing, A; Medeiros, F; McConarty, B; Joseph, NE; Panigrahy, D; Singer, S; Fletcher, CDM; Demetri, GD; Fletcher, JA				Duensing, A; Medeiros, F; McConarty, B; Joseph, NE; Panigrahy, D; Singer, S; Fletcher, CDM; Demetri, GD; Fletcher, JA			Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs)	ONCOGENE			English	Article						KIT; imatinib; GIST; kinase; signal transduction	STEM-CELL FACTOR; RECEPTOR TYROSINE KINASE; HUMAN LEUKEMIA-CELLS; SRC FAMILY KINASES; C-KIT; INTERSTITIAL-CELLS; GERMLINE MUTATION; ACTIVATING MUTATIONS; JUXTAMEMBRANE DOMAIN; HEMATOPOIETIC-CELLS	Most gastrointestinal stromal tumors (GISTs) express constitutively activated forms of the KIT receptor tyrosine kinase protein, resulting from oncogenic mutations in the extracellular, juxtamembrane, or kinase domains. KIT oncoproteins are detected early in GIST tumorigenesis, and most GIST patients respond well to treatment with the KIT kinase inhibitor imatinib mesylate (STI571, Gleevec(R)). However, GISTs can develop resistance to imatinib, and additional therapeutic strategies are needed. Little is known about oncogenic KIT signal transduction in GISTs, and whether the type of KIT mutation accounts for selective activation of downstream signaling intermediates. We therefore evaluated KIT downstream signaling profiles in 15 primary GISTs with mutations in KIT exons 9, 11, 13, and 17, and in two human GIST cell lines. All GISTs showed constitutive phosphorylation at KIT tyrosine residues Y703 and Y721. Additionally, most GISTs showed activation of MAPK p42/44, AKT, S6K, STAT1, and STAT3. STAT5 and JNK were not demonstrably activated in any GIST. Using GIST in vitro models, we showed that activation of MAPK p42/44, AKT, and S6K was KIT dependent, whereas STAT1 and STAT3 phosphorylation was only partially dependent on KIT activation. Correlation of activated signaling pathways with the type of KIT mutation revealed low levels of AKT phosphorylation in exon 9 mutant GISTs in contrast to a subset of GISTs with exon 11 mutations. However, additional factors are likely to modify the engagement of signaling pathways in GISTs as suggested by the fact that four GISTs with identical KIT exon 9 mutations had differential activation of MAPK p42/44 and STAT proteins. In summary, in this first report on KIT signal transduction in primary GISTs and GIST cell lines, we identified pathways that are constitutively activated in a KIT-dependent manner and therefore warrant further study as molecular targets in GISTs.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Dept Surg, Boston, MA 02115 USA; Mem Sloan Kettering Canc Ctr, Dept Surg Oncol, New York, NY 10021 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Memorial Sloan Kettering Cancer Center; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Duensing, A (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.	aduensing@rics.bwh.harvard.edu; jfletcher@partners.org		Duensing, Anette/0000-0002-0168-4067; Singer, Samuel/0000-0001-9713-8230				Beghini A, 2001, CANCER, V92, P657, DOI 10.1002/1097-0142(20010801)92:3<657::AID-CNCR1367>3.0.CO;2-D; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Brizzi MF, 1999, J BIOL CHEM, V274, P16965, DOI 10.1074/jbc.274.24.16965; Caruana G, 1999, ONCOGENE, V18, P5573, DOI 10.1038/sj.onc.1202939; Casteran N, 2003, ONCOGENE, V22, P4710, DOI 10.1038/sj.onc.1206587; Chen H, 2003, INT J CANCER, V105, P130, DOI 10.1002/ijc.11025; Chian RJ, 2001, BLOOD, V98, P1365, DOI 10.1182/blood.V98.5.1365; Corless CL, 2002, AM J PATHOL, V160, P1567, DOI 10.1016/S0002-9440(10)61103-0; De Miguel MP, 2002, P NATL ACAD SCI USA, V99, P10458, DOI 10.1073/pnas.122249399; DeBerry C, 1997, BIOCHEM J, V327, P73, DOI 10.1042/bj3270073; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Dolci S, 2001, J BIOL CHEM, V276, P40225, DOI 10.1074/jbc.M105143200; Ernst SI, 1998, LAB INVEST, V78, P1633; Feng LX, 2000, J BIOL CHEM, V275, P25572, DOI 10.1074/jbc.M002218200; Fletcher CDM, 2002, HUM PATHOL, V33, P459, DOI 10.1053/hupa.2002.123545; Frost MJ, 2002, MOL CANCER THER, V1, P1115; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Heinrich MC, 2003, J CLIN ONCOL, V21, P4342, DOI 10.1200/JCO.2003.04.190; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Hirota S, 2000, AM J SURG PATHOL, V24, P326, DOI 10.1097/00000478-200002000-00045; Hornick JL, 2002, AM J CLIN PATHOL, V117, P188; HUIZINGA JD, 1995, NATURE, V373, P347, DOI 10.1038/373347a0; Isozaki K, 2000, AM J PATHOL, V157, P1581, DOI 10.1016/S0002-9440(10)64795-5; Joensuu H, 2001, NEW ENGL J MED, V344, P1052, DOI 10.1056/NEJM200104053441404; Kindblom LG, 1998, AM J PATHOL, V152, P1259; Klejman A, 2002, EMBO J, V21, P5766, DOI 10.1093/emboj/cdf562; LAI CF, 1995, J BIOL CHEM, V270, P23254, DOI 10.1074/jbc.270.40.23254; Lasota J, 1999, AM J PATHOL, V154, P53, DOI 10.1016/S0002-9440(10)65250-9; Lennartsson J, 1999, ONCOGENE, V18, P5546, DOI 10.1038/sj.onc.1202929; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; Linnekin D, 1999, INT J BIOCHEM CELL B, V31, P1053, DOI 10.1016/S1357-2725(99)00078-3; Linnekin D, 1996, ACTA HAEMATOL-BASEL, V95, P224; Lux ML, 2000, AM J PATHOL, V156, P791, DOI 10.1016/S0002-9440(10)64946-2; Maeyama H, 2001, GASTROENTEROLOGY, V120, P210; Nieborowska-Skorska M, 2002, BLOOD, V99, P4531, DOI 10.1182/blood.V99.12.4531; Ning ZQ, 2001, LEUKEMIA LYMPHOMA, V41, P513, DOI 10.3109/10428190109060342; Ning ZQ, 2001, BLOOD, V97, P3559, DOI 10.1182/blood.V97.11.3559; Nishida T, 1998, NAT GENET, V19, P323, DOI 10.1038/1209; Rubin BP, 2001, CANCER RES, V61, P8118; Sircar K, 1999, AM J SURG PATHOL, V23, P377, DOI 10.1097/00000478-199904000-00002; Sommer G, 2003, P NATL ACAD SCI USA, V100, P6706, DOI 10.1073/pnas.1037763100; Taniguchi M, 1999, CANCER RES, V59, P4297; Taylor ML, 2000, HEMATOL ONCOL CLIN N, V14, P517, DOI 10.1016/S0889-8588(05)70294-X; Thommes K, 1999, BIOCHEM J, V341, P211, DOI 10.1042/0264-6021:3410211; TSAI M, 1993, EUR J IMMUNOL, V23, P3286, DOI 10.1002/eji.1830231234; Tuveson DA, 2001, ONCOGENE, V20, P5054, DOI 10.1038/sj.onc.1204704; van Oosterom AT, 2001, LANCET, V358, P1421, DOI 10.1016/S0140-6736(01)06535-7; Voytyuk O, 2003, J BIOL CHEM, V278, P9159, DOI 10.1074/jbc.M211726200; Weiler SR, 1996, BLOOD, V87, P3688, DOI 10.1182/blood.V87.9.3688.bloodjournal8793688; Wu M, 2000, GENE DEV, V14, P301; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x	51	249	264	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					3999	4006		10.1038/sj.onc.1207525	http://dx.doi.org/10.1038/sj.onc.1207525			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15007386				2022-12-17	WOS:000221382000012
J	Powell, SN; Kachnic, LA				Powell, SN; Kachnic, LA			Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation	ONCOGENE			English	Article						breast cancer; BRCA genes; tumor suppressor genes; DNA repair; ionizing radiation; homologous recombination; DNA replication	FAMILIAL BREAST-CANCER; TRANSCRIPTION-COUPLED REPAIR; SUSCEPTIBILITY GENE BRCA1; POLYMERASE-II HOLOENZYME; OVARIAN-CANCER; DAMAGE RESPONSE; CHROMOSOMAL BREAKS; DIRECTED REPAIR; PROTEIN-KINASE; S-PHASE	Inheritance of one defective copy of either of the two breast cancer susceptibility genes, BRCA1 and BRCA2, predisposes individuals to breast and ovarian cancers. Current progress in determining the function of these genes suggests that they participate in a common pathway to facilitate orderly homologous recombination and thereby maintain genomic integrity. As a consequence of this defect in homologous recombination, tumors that arise in BRCA carriers are likely to be more sensitive to ionizing radiation. This review summarizes recent investigations about the nature of the defect in DNA repair, and highlights the unanswered questions about the tumor suppressor paradox of BRCA genes. The unsolved mystery is the other genetic changes that must occur to turn a BRCA-deficient cell from a nonviable cell into a tumor cell capable of endless growth.	Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA; Boston Med Ctr, Dept Radiat Oncol, Boston, MA USA	Harvard University; Massachusetts General Hospital; Boston Medical Center	Powell, SN (corresponding author), Massachusetts Gen Hosp, Dept Radiat Oncol, Cox 302,100 Blossom St, Boston, MA 02114 USA.							Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200; Chen CF, 1999, J BIOL CHEM, V274, P32931, DOI 10.1074/jbc.274.46.32931; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Chen JJ, 1999, CANCER RES, V59, p1752S; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Crook T, 1998, ONCOGENE, V17, P1681, DOI 10.1038/sj.onc.1202106; Crook T, 1997, LANCET, V350, P638, DOI 10.1016/S0140-6736(05)63327-2; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Deng CX, 2000, BIOESSAYS, V22, P728; Dibiase SJ, 2000, CANCER RES, V60, P1245; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; Futamura M, 2000, CANCER RES, V60, P1531; Gatei M, 2001, J BIOL CHEM, V276, P17276, DOI 10.1074/jbc.M011681200; Goodman MF, 2000, TRENDS BIOCHEM SCI, V25, P189, DOI 10.1016/S0968-0004(00)01564-4; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Haber JE, 2001, CELL, V107, P551, DOI 10.1016/S0092-8674(01)00593-1; Haile DT, 1999, J BIOL CHEM, V274, P2113, DOI 10.1074/jbc.274.4.2113; Hakem R, 1998, J MAMMARY GLAND BIOL, V3, P431, DOI 10.1023/A:1018792200700; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hofmann W, 2000, J CANCER RES CLIN, V126, P487, DOI 10.1007/s004320000140; Jacks T, 1998, SCIENCE, V280, P1035, DOI 10.1126/science.280.5366.1035; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Kraakman-van der Zwet M, 2002, MOL CELL BIOL, V22, P669, DOI 10.1128/MCB.22.2.669-679.2002; Lakhani SR, 2000, CLIN CANCER RES, V6, P782; Lakhani SR, 2002, J CLIN ONCOL, V20, P2310, DOI 10.1200/JCO.2002.09.023; Lakhani SR, 1998, JNCI-J NATL CANCER I, V90, P1138, DOI 10.1093/jnci/90.15.1138; Le Page F, 2000, CANCER RES, V60, P5548; LEHMANN AR, 1986, INT J RADIAT BIOL, V49, P639; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; Marmorstein LY, 2001, CELL, V104, P247, DOI 10.1016/S0092-8674(01)00209-4; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Milner J, 2000, ONCOGENE, V19, P4441, DOI 10.1038/sj.onc.1203793; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Moynahan ME, 2001, CANCER RES, V61, P4842; Paakkonen K, 2001, GENET EPIDEMIOL, V20, P239, DOI 10.1002/1098-2272(200102)20:2<239::AID-GEPI6>3.0.CO;2-Y; Parvin JD, 2001, P NATL ACAD SCI USA, V98, P5952, DOI 10.1073/pnas.121184998; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998; Pellegrini L, 2002, NATURE, V420, P287, DOI 10.1038/nature01230; Peto J, 1999, J NATL CANCER I, V91, P943, DOI 10.1093/jnci/91.11.943; Powell SN, 2002, MOL CELL, V10, P1262, DOI 10.1016/S1097-2765(02)00789-X; Satagopan JM, 2001, CANCER EPIDEM BIOMAR, V10, P467; Schlegel BP, 2000, P NATL ACAD SCI USA, V97, P3148, DOI 10.1073/pnas.070452397; Schubert EK, 1997, AM J HUM GENET, V60, P1031; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Smith PD, 1999, ONCOGENE, V18, P2451, DOI 10.1038/sj.onc.1202565; Snouwaert JN, 1999, ONCOGENE, V18, P7900, DOI 10.1038/sj.onc.1203334; Somasundaram K, 1999, ONCOGENE, V18, P6605, DOI 10.1038/sj.onc.1203284; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; Taghian DG, 1997, MOL CELL BIOL, V17, P6386, DOI 10.1128/MCB.17.11.6386; Thangaraju M, 2000, J BIOL CHEM, V275, P33487, DOI 10.1074/jbc.M005824200; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Tutt A, 2001, EMBO J, V20, P4704, DOI 10.1093/emboj/20.17.4704; Wang HC, 2001, CANCER RES, V61, P270; Wang Y, 2000, GENE DEV, V14, P927; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Wu X, 2000, Science, V289, P11; Xia F, 2001, P NATL ACAD SCI USA, V98, P8644, DOI 10.1073/pnas.151253498; Xu B, 2002, CANCER RES, V62, P4588; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Yang HJ, 2002, SCIENCE, V297, P1837, DOI 10.1126/science.297.5588.1837; Yu VPCC, 2000, GENE DEV, V14, P1400; Yuan SSF, 1999, CANCER RES, V59, P3547; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	76	249	258	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 1	2003	22	37					5784	5791		10.1038/sj.onc.1206678	http://dx.doi.org/10.1038/sj.onc.1206678			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	717JV	12947386				2022-12-17	WOS:000185086100006
J	Arai, K; Morishita, K; Shinmura, K; Kohno, T; Kim, SR; Nohmi, T; Taniwaki, M; Ohwada, S; Yokota, J				Arai, K; Morishita, K; Shinmura, K; Kohno, T; Kim, SR; Nohmi, T; Taniwaki, M; Ohwada, S; Yokota, J			Cloning of a human homolog of the yeast OGG1 gene that is involved in the repair of oxidative DNA damage	ONCOGENE			English	Article						oxidative DNA damage; 8-hydroxyguanine; DNA repair; mutagenesis; DNA glycosylase; endonuclease	ESCHERICHIA-COLI; SUBSTRATE-SPECIFICITY; IONIZING-RADIATION; 8-HYDROXYGUANINE; MUTAGENESIS; 8-HYDROXYDEOXYGUANOSINE; 8-OXOGUANINE; GLYCOSYLASE; EXCISION; CANCER	We report the cloning of a human homolog of the yeast OGG1 gene, which encodes a DNA glycosylase that excises an oxidatively damaged form of guanine, 8-hydroxyguanine (also known as 7,8-dihydro-8-oxoguanine), Since the deduced amino acid sequence (68 amino acids) of a human expressed sequence tag, N55394, matched a short stretch of yeast OGG1 protein with greater than 40% amino acid identity, a full Length cDNA clone was isolated from a HeLa cell cDNA Library with the N55394 clone as a probe, The cDNA clone encodes a predicted protein of 345 amino acids which is homologous to yeast OGG1 protein throughout the entire polypeptide sequence and shares 38% amino acid identity with yeast OGG1 protein, Moreover, we found that both a human homolog and yeast OGG1 protein possess two distinct DNA binding motifs, a helix-hairpin-helix (HhH) motif and a C2H2 zinc finger like motif, and a domain homologous to human and E. coli MutY proteins. Expression of a human homolog suppressed spontaneous mutagenesis of an E. coli (mutM mutY) mutant as in the case of yeast OGG1 protein. The gene mas ubiquitously expressed in a variety of human organs and mapped to chromosome 3p26.2. These results strongly suggest that the gene isolated here is a human counterpart of the yeast OGG1 gene and is involved in the repair of oxidative DNA damage in human cells.	NATL CANC CTR,RES INST,DIV BIOL,CHUO KU,TOKYO 104,JAPAN; GUNMA UNIV,SCH MED,DEPT SURG 2,MAEBASHI,GUMMA 371,JAPAN; NATL INST HLTH SCI,DIV GENET & MUTAGENESIS,SETAGAYA KU,TOKYO 158,JAPAN; KYOTO PREFECTURAL UNIV MED,DEPT INTERNAL MED 3,KAMIGYO KU,KYOTO 602,JAPAN	National Cancer Center - Japan; Gunma University; National Institute of Health Sciences - Japan; Kyoto Prefectural University of Medicine			Shinmura, Kazuya/K-8940-2012	Shinmura, Kazuya/0000-0003-4963-746X				AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; AU KG, 1989, P NATL ACAD SCI USA, V86, P8771; BOITEUX S, 1992, BIOCHEMISTRY-US, V31, P106, DOI 10.1021/bi00116a016; CHENG KC, 1992, J BIOL CHEM, V267, P166; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; Doherty AJ, 1996, NUCLEIC ACIDS RES, V24, P2488, DOI 10.1093/nar/24.13.2488; GAJEWSKI E, 1990, BIOCHEMISTRY-US, V29, P7876, DOI 10.1021/bi00486a014; GAZDAR AF, 1994, ANTICANCER RES, V13, P261; GROLLMAN AP, 1993, TRENDS GENET, V9, P246, DOI 10.1016/0168-9525(93)90089-Z; HIBI K, 1992, ONCOGENE, V7, P445; ISHINO Y, 1986, MOL GEN GENET, V204, P1, DOI 10.1007/BF00330179; KASAI H, 1991, OXIDATIVE STRESS OXI, P99; KASAI H, 1984, JPN J CANCER RES, V75, P565; KASAI H, 1984, JPN J CANCER RES, V75, P841; KOHNO T, 1995, HUM MOL GENET, V4, P667, DOI 10.1093/hmg/4.4.667; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MICHAELS ML, 1992, BIOCHEMISTRY-US, V31, P10964, DOI 10.1021/bi00160a004; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; NAGASHIMA M, 1995, CARCINOGENESIS, V16, P1441, DOI 10.1093/carcin/16.6.1441; Nagashima M, 1997, MUTAT RES-DNA REPAIR, V383, P49, DOI 10.1016/S0921-8777(96)00045-6; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Schwarz R, 1979, ATLAS PROTEIN SEQUEN, P353, DOI DOI 10.2307/2408678; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SHIMODA R, 1994, CANCER RES, V54, P3171; Smith T.F., 1981, ADV APPL MATH, V2, P482, DOI DOI 10.1016/0196-8858(81)90046-4; TANIWAKI M, 1994, BLOOD, V83, P2962, DOI 10.1182/blood.V83.10.2962.2962; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; TOTTER JR, 1980, P NATL ACAD SCI-BIOL, V77, P1763, DOI 10.1073/pnas.77.4.1763; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; YOKOTA J, 1993, FASEB J, V7, P920, DOI 10.1096/fasebj.7.10.8344488	35	249	259	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 12	1997	14	23					2857	2861		10.1038/sj.onc.1201139	http://dx.doi.org/10.1038/sj.onc.1201139			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD643	9190902				2022-12-17	WOS:A1997XD64300014
J	Chen, R; Alvero, AB; Silasi, DA; Kelly, MG; Fest, S; Visintin, I; Leiser, A; Schwartz, PE; Rutherford, T; Mor, G				Chen, R.; Alvero, A. B.; Silasi, D. A.; Kelly, M. G.; Fest, S.; Visintin, I.; Leiser, A.; Schwartz, P. E.; Rutherford, T.; Mor, G.			Regulation of IKK beta by miR-199a affects NF-kappa B activity in ovarian cancer cells	ONCOGENE			English	Article						inflammation; ovarian cancer; IKK beta; MyD88; chemoresistance	TOLL-LIKE RECEPTORS; KINASE-ACTIVITY; INFLAMMATION; ACTIVATION; APOPTOSIS; TUMORIGENESIS; INJURY; CHEMORESISTANCE; PROLIFERATION; STATISTICS	Cancer progression is an abnormal form of tissue repair characterized by chronic inflammation. I kappa B kinase-beta (IKK beta) required for nuclear factor-kappa B (NF-kappa B) activation plays a critical role in this process. Using EOC cells isolated from malignant ovarian cancer ascites and solid tumors, we identified IKKb as a major factor promoting a functional TLR-MyD88-NF-kappa B pathway that confers to EOC cell the capacity to constitutively secrete proinflammatory/protumor cytokines and therefore promoting tumor progression and chemoresistance. Furthermore, we describe for the first time the identification of the microRNA hsa-miR-199a as a regulator of IKK beta expression. Our study describes the property of ovarian cancer cells to enhance the inflammatory microenvironment as a result of the expression of an active IKKb pathway. Identification of these markers in patients' tumor samples may facilitate the adequate selection of treatment and open new venues for the development of effective therapy for chemoresistant ovarian cancers.	[Mor, G.] Yale Univ, Sch Med, Reprod Immunol Unit, Dept Obstet Gynecol & Reprod Sci, New Haven, CT 06520 USA; [Chen, R.] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA	Yale University; Yale University	Mor, G (corresponding author), Yale Univ, Sch Med, Reprod Immunol Unit, Dept Obstet Gynecol & Reprod Sci, 333 Cedar St,FMB 301, New Haven, CT 06520 USA.	Gil.Mor@yale.edu		Alvero, Ayesha/0000-0002-6593-3595	NATIONAL CANCER INSTITUTE [R01CA127913, R01CA118678] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA127913, R01 CA127913-02, R01 CA118678, R01 CA118678-02, R01 CA127913-01A2] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Balkwill F, 2004, NATURE, V431, P405, DOI 10.1038/431405a; Barnhart BC, 2003, CELL, V114, P148, DOI 10.1016/S0092-8674(03)00561-0; Baumgartner B, 2002, LEUKEMIA, V16, P2062, DOI 10.1038/sj.leu.2402641; Chen R, 2007, AM J REPROD IMMUNOL, V57, P93, DOI 10.1111/j.1600-0897.2006.00441.x; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Duan Z, 2002, CYTOKINE, V17, P234, DOI 10.1006/cyto.2001.1008; Flick MB, 2004, J SOC GYNECOL INVEST, V11, P252, DOI 10.1016/j.jsgi.2003.11.003; Fukata M, 2005, AM J PHYSIOL-GASTR L, V288, pG1055, DOI 10.1152/ajpgi.00328.2004; Greten FR, 2004, CANCER LETT, V206, P193, DOI 10.1016/j.canlet.2003.08.029; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; HACKER H, 2006, SCI STKE, DOI DOI 10.1126/STKE.3572006RE13; HARROCH S, 1995, NUCLEIC ACIDS RES, V23, P3539, DOI 10.1093/nar/23.17.3539; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Jiang DH, 2005, NAT MED, V11, P1173, DOI 10.1038/nm1315; Kamsteeg M, 2003, ONCOGENE, V22, P2611, DOI 10.1038/sj.onc.1206422; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kelly MG, 2006, CANCER RES, V66, P3859, DOI 10.1158/0008-5472.CAN-05-3948; Leung CH, 2006, MOL PHARMACOL, V70, P1946, DOI 10.1124/mol.106.028480; Li L, 2004, CANCER-AM CANCER SOC, V101, P2351, DOI 10.1002/cncr.20605; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Liu BG, 2006, P NATL ACAD SCI USA, V103, P17202, DOI 10.1073/pnas.0604481103; Ludwig L, 2001, CANCER RES, V61, P4526; Luo JL, 2005, J CLIN INVEST, V115, P2625, DOI 10.1172/JCI26322; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Maeda S, 2003, IMMUNITY, V19, P725, DOI 10.1016/S1074-7613(03)00301-7; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Nakanishi C, 2005, NAT REV CANCER, V5, P297, DOI 10.1038/nrc1588; ODWYER PJ, 1994, CANCER RES, V54, P724; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Pull SL, 2005, P NATL ACAD SCI USA, V102, P99, DOI 10.1073/pnas.0405979102; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Rakoff-Nahoum S, 2007, SCIENCE, V317, P124, DOI 10.1126/science.1140488; Romieu-Mourez R, 2001, CANCER RES, V61, P3810; Rothwarf D M, 1999, Sci STKE, V1999, pRE1, DOI 10.1126/stke.1999.5.re1; Schwartz Peter E, 2002, Cancer Treat Res, V107, P99; Shishodia S, 2004, BIOCHEM PHARMACOL, V68, P1071, DOI 10.1016/j.bcp.2004.04.026; Tamatani T, 2001, CANCER LETT, V171, P165, DOI 10.1016/S0304-3835(01)00611-5; Yang JM, 2001, CANCER RES, V61, P4901	43	248	269	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2008	27	34					4712	4723		10.1038/onc.2008.112	http://dx.doi.org/10.1038/onc.2008.112			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QM	18408758	Green Accepted			2022-12-17	WOS:000258236300009
J	Jebar, AH; Hurst, CD; Tomlinson, DC; Johnston, C; Taylor, CF; Knowles, MA				Jebar, AH; Hurst, CD; Tomlinson, DC; Johnston, C; Taylor, CF; Knowles, MA			FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma	ONCOGENE			English	Article						bladder cancer; FGFR3; HRAS; NRAS; KRAS2; mutation	GROWTH-FACTOR RECEPTOR-3; HUMAN BLADDER CANCERS; HUMAN URINARY-BLADDER; CODON 12 MUTATION; H-RAS; TISSUE-CULTURE; K-RAS; N-RAS; LINES; ACTIVATION	Fibroblast growth factor receptor 3 (FGFR3) mutations are frequent in superficial urothelial cell carcinoma (UCC). Ras gene mutations are also found in UCC. As oncogenic activation of both FGFR3 and Ras is predicted to result in stimulation of the mitogen-activated protein kinase ( MAPK) pathway, we hypothesized that these might be mutually exclusive events. HRAS mutation has been widely studied in UCC, but all three Ras gene family members have not been screened for mutation in the same sample series. We screened 98 bladder tumours and 31 bladder cell lines for mutations in FGFR3, HRAS, NRAS and KRAS2. FGFR3 mutations were present in 54 tumours (55%) and three cell lines (10%), and Ras gene mutations in 13 tumours (13%) and four cell lines (13%). These included mutations in all three Ras genes; ten in HRAS, four in KRAS2 and four in NRAS and these were not associated with either tumour grade or stage. In no cases were Ras and FGFR3 mutation found together. This mutual exclusion suggests that FGFR3 and Ras gene mutation may represent alternative means to confer the same phenotype on UCC cells. If these events have biological equivalence, Ras mutant invasive UCC may represent a novel subgroup.	St Jamess Univ Hosp, Canc Res UK Clin Ctr, Leeds LS9 7TF, W Yorkshire, England; St Jamess Univ Hosp, Canc Res UK Mutat Detect Facil, Leeds LS9 7TF, W Yorkshire, England	Cancer Research UK; Saint James's University Hospital; University of Leeds; Saint James's University Hospital; University of Leeds	Knowles, MA (corresponding author), St Jamess Univ Hosp, Canc Res UK Clin Ctr, Beckett St, Leeds LS9 7TF, W Yorkshire, England.	margaret.knowles@cancer.org.uk		/0000-0002-3081-7850; Tomlinson, Darren/0000-0003-4134-7484; Knowles, Margaret/0000-0002-9363-8657				Ayan S., 2001, International Urology and Nephrology, V33, P363, DOI 10.1023/A:1015213713048; Bakkar AA, 2003, CANCER RES, V63, P8108; Bellus GA, 2000, AM J HUM GENET, V67, P1411, DOI 10.1086/316892; Billerey C, 2001, AM J PATHOL, V158, P1955, DOI 10.1016/S0002-9440(10)64665-2; BURCHILL SA, 1994, BRIT J UROL, V73, P516, DOI 10.1111/j.1464-410X.1994.tb07636.x; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; Chesi M, 2001, BLOOD, V97, P729, DOI 10.1182/blood.V97.3.729; CZERNIAK B, 1990, BRIT J CANCER, V62, P762, DOI 10.1038/bjc.1990.374; DER CJ, 1982, P NATL ACAD SCI-BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637; ELLIOTT AY, 1974, JNCI-J NATL CANCER I, V53, P1341, DOI 10.1093/jnci/53.5.1341; Ellis CA, 2000, CELL SIGNAL, V12, P425, DOI 10.1016/S0898-6568(00)00084-X; FITZGERALD JM, 1995, J NATL CANCER I, V87, P129, DOI 10.1093/jnci/87.2.129; Fogh J, 1978, Natl Cancer Inst Monogr, P5; FUJITA J, 1984, NATURE, V309, P464, DOI 10.1038/309464a0; GRIMMOND SM, 1992, UROL RES, V20, P121, DOI 10.1007/BF00296523; GROSSMAN HB, 1986, J UROLOGY, V136, P953, DOI 10.1016/S0022-5347(17)45139-1; Hart KC, 2000, ONCOGENE, V19, P3309, DOI 10.1038/sj.onc.1203650; Huang MY, 1997, ONCOL RES, V9, P611; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Knowles MA, 1999, BJU INT, V84, P412; KNOWLES MA, 1993, CANCER RES, V53, P133; KYRIAZIS AA, 1984, CANCER RES, V44, P3997; LEVESQUE P, 1993, INT J CANCER, V55, P785, DOI 10.1002/ijc.2910550516; MASTERS JRW, 1986, CANCER RES, V46, P3630; NAYAK SK, 1977, BRIT J CANCER, V35, P142, DOI 10.1038/bjc.1977.21; Olderoy G, 1998, ANTICANCER RES, V18, P2675; OOI A, 1994, INT J ONCOL, V4, P85; OTOOLE C, 1978, BRIT J CANCER, V38, P64, DOI 10.1038/bjc.1978.164; OTOOLE C, 1976, INT J CANCER, V17, P707, DOI 10.1002/ijc.2910170604; Oxford G, 2003, J UROLOGY, V170, P1987, DOI 10.1097/01.ju.0000088670.02905.78; PAULIE S, 1983, INT J CANCER, V31, P297, DOI 10.1002/ijc.2910310308; Pratsinis H, 1998, IN VITRO CELL DEV-AN, V34, P722; PROCTOR AJ, 1991, ONCOGENE, V6, P789; Przybojewska B, 2000, CANCER GENET CYTOGEN, V121, P73, DOI 10.1016/S0165-4608(00)00223-5; RASHEED S, 1977, J NATL CANCER I, V58, P881, DOI 10.1093/jnci/58.4.881; REZNIKOFF CA, 1993, SEMIN CANCER BIOL, V4, P143; REZNIKOFF CA, 1988, CARCINOGENESIS, V9, P1427, DOI 10.1093/carcin/9.8.1427; RIGBY CC, 1970, BRIT J CANCER, V24, P746, DOI 10.1038/bjc.1970.89; Sarkar S, 2000, CANCER RES, V60, P3862; Sibley K, 2001, ONCOGENE, V20, P686, DOI 10.1038/sj.onc.1204110; TACHIBANA M, 1995, CANCER RES, V55, P3438; Taylor Claire F, 2004, Methods Mol Med, V92, P9; THEODORESCU D, 1990, P NATL ACAD SCI USA, V87, P9047, DOI 10.1073/pnas.87.22.9047; Tzeng CC, 1996, ANTICANCER RES, V16, P1797; UCHIDA T, 1995, UROL INT, V55, P63, DOI 10.1159/000282753; van Rhijn BSW, 2004, CANCER RES, V64, P1911, DOI 10.1158/0008-5472.CAN-03-2421; van Rhijn BWG, 2001, CANCER RES, V61, P1265; VISVANATHAN KV, 1988, ONCOGENE RES, V3, P77; WAGNER HE, 1990, ONCOGENE, V5, P557; Webster MK, 1997, TRENDS GENET, V13, P178, DOI 10.1016/S0168-9525(97)01131-1; WILLIAMS RD, 1980, INVEST UROL, V17, P359; Williams SV, 2002, GENE CHROMOSOME CANC, V34, P86, DOI 10.1002/gcc.10050; Yeager TR, 1998, GENE DEV, V12, P163, DOI 10.1101/gad.12.2.163; Zhang ZT, 1999, CANCER RES, V59, P3512; Zhang ZT, 2001, ONCOGENE, V20, P1973, DOI 10.1038/sj.onc.1204315	55	248	274	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2005	24	33					5218	5225		10.1038/sj.onc.1208705	http://dx.doi.org/10.1038/sj.onc.1208705			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	951XB	15897885				2022-12-17	WOS:000230964600008
J	Huynh, KD; Bardwell, VJ				Huynh, KD; Bardwell, VJ			The BCL-6 POZ domain and other POZ domains interact with the co-repressors N-CoR and SMRT	ONCOGENE			English	Article						POZ domain; BCL-6; transcriptional repression; N-CoR; SMRT	NUCLEAR HORMONE RECEPTORS; GERMINAL-CENTER FORMATION; ZINC-FINGER PROTEINS; CENTER B-CELLS; ACUTE PROMYELOCYTIC LEUKEMIA; POSITION-EFFECT VARIEGATION; GAGA TRANSCRIPTION FACTOR; NON-HODGKINS-LYMPHOMAS; BTB/POZ DOMAIN; DNA-BINDING	Virtually all diffuse large cell lymphomas and a significant fraction of follicular lymphomas contain translocations and/or point mutations in the 5' noncoding region of the putative oncogene BCL-6, that are presumed to deregulate its expression. BCL-6 encodes a Cys(2)-His(2) zinc finger transcriptional repressor with a POZ domain at its amino-terminus, The POZ (or BTB) domain, a 120-amino-acid motif, mediates homomeric and, in some proteins, heteromeric POZ-POZ interactions. In addition, the POZ domain is required for transcriptional repression of several proteins, including BCL-6, Using a yeast two-hybrid screen, we identified N-CoR and SMRT as BCL-6 interacting proteins. Both N-CoR and SMRT, which were originally identified as co-repressors for the unliganded nuclear thyroid hormone and retinoic acid receptors, are components of large complexes containing histone deacetylases, We show that the interaction between BCL-6 and these co-repressors is also detected in the more physiologically relevant mammalian two-hybrid assay. The POZ domain is necessary and sufficient for interaction with these corepressors. BCL-6 and N-CoR co-localize to punctate regions of the nucleus. Furthermore, when BCL-6 is bound to its consensus recognition sequence in vivo, it can interact with N-CoR and SMRT, We find, in vitro, that POZ domains from a variety of other POZ domain-containing proteins, including the transcriptional repressor PLZF, as well as ZID, GAGA and a vaccinia virus protein, SalF17R, also interact with varying affinities with N-CoR and SMRT, We find that BCL-6 POZ domain mutations that disrupt the interaction with N-CoR and SMRT no longer repress transcription. In addition, these mutations no longer self associate suggesting that self interaction is required for interaction with the co-repressors and for repression. More recently N-CoR has also been implicated in transcriptional repression by the Mad/Mxi proteins. Our demonstration that N-CoR and SMRT interact with the POZ domain containing proteins indicates that these co-repressors are likely involved in the mediation of repression by multiple classes of repressors and may explain, in part, how POZ domain containing repressors mediate transcriptional repression.	Univ Minnesota, Dept Biochem, Minneapolis, MN 55455 USA; Univ Minnesota, Biochem Mol Biol & Biophys Program, Minneapolis, MN 55455 USA; Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA; Univ Minnesota, Inst Human Genet, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Bardwell, VJ (corresponding author), Univ Minnesota, Dept Biochem, 4-225 Millard Hall,435 Delaware St SE, Minneapolis, MN 55455 USA.				NCI NIH HHS [5R29CA71540, R29 CA071540] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA071540] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albagli O, 1996, BIOCHEM BIOPH RES CO, V220, P911, DOI 10.1006/bbrc.1996.0505; ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; BARON BW, 1995, GENE CHROMOSOME CANC, V13, P221, DOI 10.1002/gcc.2870130314; Baron BW, 1997, GENE CHROMOSOME CANC, V19, P14, DOI 10.1002/(SICI)1098-2264(199705)19:1<14::AID-GCC3>3.0.CO;2-3; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Chen WY, 1998, BLOOD, V91, P603, DOI 10.1182/blood.V91.2.603.603_603_607; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; DEWEINDT C, 1993, GENE CHROMOSOME CANC, V8, P149, DOI 10.1002/gcc.2870080303; DEWEINDT C, 1995, CELL GROWTH DIFFER, V6, P1495; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Dhordain P, 1995, ONCOGENE, V11, P2689; DORN R, 1993, P NATL ACAD SCI USA, V90, P11376, DOI 10.1073/pnas.90.23.11376; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FLENGHI L, 1995, AM J PATHOL, V147, P405; Fukuda T, 1997, J EXP MED, V186, P439, DOI 10.1084/jem.186.3.439; GERASIMOVA TI, 1995, CELL, V82, P587, DOI 10.1016/0092-8674(95)90031-4; Goldman PS, 1997, RECENT PROG HORM RES, V52, P103; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; HOWARD ST, 1991, VIROLOGY, V180, P633, DOI 10.1016/0042-6822(91)90077-O; HSU HL, 1994, P NATL ACAD SCI USA, V91, P3181, DOI 10.1073/pnas.91.8.3181; Kaplan J, 1997, NUCLEIC ACIDS RES, V25, P1108, DOI 10.1093/nar/25.6.1108; KAWAMATA N, 1994, BIOCHEM BIOPH RES CO, V204, P366, DOI 10.1006/bbrc.1994.2468; KOONIN EV, 1992, TRENDS BIOCHEM SCI, V17, P213, DOI 10.1016/0968-0004(92)90379-N; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Li XM, 1997, J BIOL CHEM, V272, P27324, DOI 10.1074/jbc.272.43.27324; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; LO CF, 1994, BLOOD, V83, P1757; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; MIKI T, 1994, BLOOD, V83, P217; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NUMOTO M, 1993, NUCLEIC ACIDS RES, V21, P3767, DOI 10.1093/nar/21.16.3767; OFFIT K, 1994, NEW ENGL J MED, V331, P74, DOI 10.1056/NEJM199407143310202; OHNO H, 1994, JPN J CANCER RES, V85, P592, DOI 10.1111/j.1349-7006.1994.tb02401.x; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; OTSUKI T, 1995, BLOOD, V85, P2877, DOI 10.1182/blood.V85.10.2877.bloodjournal85102877; Pittaluga S, 1996, J PATHOL, V179, P145; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; Seol W, 1996, MOL ENDOCRINOL, V10, P1646, DOI 10.1210/me.10.12.1646; Seyfert VL, 1996, ONCOGENE, V12, P2331; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; Soderstrom M, 1997, MOL ENDOCRINOL, V11, P682, DOI 10.1210/me.11.6.682; SOELLER WC, 1993, MOL CELL BIOL, V13, P7961, DOI 10.1128/MCB.13.12.7961; STEIN H, 1992, NEOPLASTIC HEMATOPAT, P675; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; WALL G, 1995, EMBO J, V14, P1727, DOI 10.1002/j.1460-2075.1995.tb07162.x; Wilkinson JR, 1997, J BIOL CHEM, V272, P23824, DOI 10.1074/jbc.272.38.23824; XIONG WC, 1993, GENE DEV, V7, P1085, DOI 10.1101/gad.7.6.1085; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YE BH, 1993, BIOCHEM BIOPH RES CO, V53, P2732; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835; Zamir I, 1996, MOL CELL BIOL, V16, P5458; ZARKOWER D, 1992, CELL, V70, P237, DOI 10.1016/0092-8674(92)90099-X; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717	73	248	254	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 12	1998	17	19					2473	2484		10.1038/sj.onc.1202197	http://dx.doi.org/10.1038/sj.onc.1202197			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	137QQ	9824158	Bronze			2022-12-17	WOS:000076927300007
J	David, G; Alland, L; Hong, SH; Wong, CW; DePinho, RA; Dejean, A				David, G; Alland, L; Hong, SH; Wong, CW; DePinho, RA; Dejean, A			Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein	ONCOGENE			English	Article						mSin3; histone deacetylases; APL; PLZF; Kruppel-like proteins	ZINC-FINGER GENE; RETINOIC ACID; TRANSCRIPTIONAL REPRESSION; ENCODING GENE; RAR-ALPHA; TRANSLOCATION; DOMAIN; RECEPTORS; REGULATOR; SIN3	The PLZF gene was identified first by its fusion with the retinoic acid receptor alpha gene in the t(11;17) translocation associated with a retinoic acid resistant form of acute promyelocytic leukemia (APL). It encodes a kruppel-like zinc finger protein with a POZ domain shared with a subset of regulatory proteins including the BCL6 leukemogenic protein. PLZF, like BCL6, strongly represses transcription initiated from different promoters. Here we show that PLZF associates in vitro and in vivo with the Mad co-repressor mSin3A and the histone deacetylase HDAC1. Two domains in PLZF and the PAH1 structure of mSin3A mediate these interactions. Trichostatin A, a specific inhibitor of histone deacetylases, significantly reduces PLZF repression. These data strongly suggest that, like nuclear receptors and Mad, PLZF represses transcription by recruiting a histone deacetylase through the SMRT-mSin3-HDAC co-repressor complex. We also show that BCL6 associates with HDAC1 indicating that this type of regulation might be common to POZ/Zinc finger proteins involved in human leukemias. This work supports a role far deregulated histone deacetylation in the development of both lymphoid and myeloid neoplasia in human and suggests that targeted histone deacetylase inhibitors may be useful for treatment of certain types of malignancies.	Inst Pasteur, INSERM, U163, Unite Recombinaison & Express Genet, F-75724 Paris 15, France; Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Pediat, Bronx, NY 10461 USA; Univ Calif Davis, Div Biol Sci, Microbiol Sect, Davis, CA 95616 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of California System; University of California Davis	Dejean, A (corresponding author), Inst Pasteur, INSERM, U163, Unite Recombinaison & Express Genet, 28 Rue Dr Roux, F-75724 Paris 15, France.		Dejean, Anne/L-5145-2018	, gregory/0000-0002-3371-4558; Hong, Suk-Hyun/0000-0001-7541-4847; DePinho, Ronald/0000-0002-5625-577X				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BREITMAN TR, 1990, CANCER RES, V50, P6268; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN JD, 1995, ANTURE, V377, P454; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; COOK M, 1995, P NATL ACAD SCI USA, V92, P2249, DOI 10.1073/pnas.92.6.2249; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DEWEINDT C, 1995, CELL GROWTH DIFFER, V6, P1495; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GUIDEZ F, 1994, LEUKEMIA, V8, P312; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Rao G, 1996, ONCOGENE, V12, P1165; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SEYFERT VL, 1996, ONCOGENE, V12, P2113; Sitterlin D, 1997, ONCOGENE, V14, P1067, DOI 10.1038/sj.onc.1200916; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; WANG HM, 1990, MOL CELL BIOL, V10, P5927, DOI 10.1128/MCB.10.11.5927; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; YEYATI PL, 1997, UNPUB; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	43	248	276	0	11	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 14	1998	16	19					2549	2556		10.1038/sj.onc.1202043	http://dx.doi.org/10.1038/sj.onc.1202043			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN694	9627120				2022-12-17	WOS:000073672300012
J	TSUJIMOTO, Y				TSUJIMOTO, Y			STRESS-RESISTANCE CONFERRED BY HIGH-LEVEL OF BCL-2-ALPHA-PROTEIN IN HUMAN B-LYMPHOBLASTOID CELL	ONCOGENE			English	Article											TSUJIMOTO, Y (corresponding author), WISTAR INST,3601 SPRUCE ST,PHILADELPHIA,PA 19104, USA.							ADACHI M, 1989, P NATL ACAD SCI USA, V86, P2771, DOI 10.1073/pnas.86.8.2771; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; FUKUHARA S, 1979, CANCER RES, V39, P3119; IIDA H, 1984, J CELL BIOL, V99, P1441, DOI 10.1083/jcb.99.4.1441; KINGSTON RE, 1984, NATURE, V312, P280, DOI 10.1038/312280a0; NEVINS JR, 1982, CELL, V29, P913, DOI 10.1016/0092-8674(82)90453-6; OFARRELL PH, 1976, J BIOL CHEM, V250, P4007; REED JC, 1988, NATURE, V336, P259, DOI 10.1038/336259a0; SAITO H, 1983, P NATL ACAD SCI-BIOL, V80, P7476, DOI 10.1073/pnas.80.24.7476; SETO M, 1988, EMBO J, V7, P125; SHIN DY, 1987, MOL CELL BIOL, V7, P244, DOI 10.1128/MCB.7.1.244; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WEISS LM, 1985, NEW ENGL J MED, V5, P1185; WESTRA A, 1971, INT J RADIAT BIOL RE, V19, P467, DOI 10.1080/09553007114550601; YAHARA I, 1986, CELL STRUCT FUNCT, V11, P65, DOI 10.1247/csf.11.65; YATES J, 1984, P NATL ACAD SCI-BIOL, V81, P3806, DOI 10.1073/pnas.81.12.3806; YUNIS JJ, 1983, SCIENCE, V221, P227, DOI 10.1126/science.6336310	20	248	256	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1989	4	11					1331	1336						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AX659	2554236				2022-12-17	WOS:A1989AX65900009
J	TAPLEY, P; HORWITZ, A; BUCK, C; DUGGAN, K; ROHRSCHNEIDER, L				TAPLEY, P; HORWITZ, A; BUCK, C; DUGGAN, K; ROHRSCHNEIDER, L			INTEGRINS ISOLATED FROM ROUS-SARCOMA VIRUS-TRANSFORMED CHICKEN-EMBRYO FIBROBLASTS	ONCOGENE			English	Article									UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104; WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104	University of Pennsylvania; The Wistar Institute	TAPLEY, P (corresponding author), FRED HUTCHINSON CANC RES CTR,DEPT CELL BIOL,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.				NCI NIH HHS [CA20551, CA19144, CA40987] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA019144, R01CA040987, R01CA019144, R01CA020551] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA SK, 1986, J CELL BIOL, V102, P442, DOI 10.1083/jcb.102.2.442; AKIYAMA SK, 1987, J BIOL CHEM, V262, P17536; ALI IU, 1977, CELL, V11, P115, DOI 10.1016/0092-8674(77)90322-1; AMINI S, 1986, MOL CELL BIOL, V6, P2305, DOI 10.1128/MCB.6.7.2305; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; ARQUINT M, 1987, P NATL ACAD SCI USA, V84, P600, DOI 10.1073/pnas.84.2.600; BARANY G, 1979, PEPTIDES, P3; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; BUCK CA, 1987, ANNU REV CELL BIOL, V3, P179, DOI 10.1146/annurev.cb.03.110187.001143; BUCK CA, 1986, J CELL BIOL, V103, P2421, DOI 10.1083/jcb.103.6.2421; BURNS GF, 1988, J CELL BIOL, V107, P1225, DOI 10.1083/jcb.107.3.1225; BURR JG, 1980, P NATL ACAD SCI-BIOL, V77, P3484, DOI 10.1073/pnas.77.6.3484; BURRIDGE K, 1983, J CELL BIOL, V97, P359, DOI 10.1083/jcb.97.2.359; BURRIDGE K, 1980, CELL, V19, P587, DOI 10.1016/S0092-8674(80)80035-3; BURRIDGE K, 1986, Cancer Reviews, V4, P18; BURRIDGE K, 1984, NATURE, V308, P744, DOI 10.1038/308744a0; CHEN JM, 1987, CELL, V48, P193, DOI 10.1016/0092-8674(87)90423-5; CHEN WT, 1985, J CELL BIOL, V100, P1103, DOI 10.1083/jcb.100.4.1103; CHEN WT, 1986, J CELL BIOL, V103, P1649, DOI 10.1083/jcb.103.5.1649; CHEN YC, 1979, J BIOL CHEM, V254, P1678; COMOGLIO PM, 1984, EMBO J, V3, P483, DOI 10.1002/j.1460-2075.1984.tb01834.x; DAMSKY CH, 1985, J CELL BIOL, V100, P1528, DOI 10.1083/jcb.100.5.1528; DECLUE JE, 1987, MOL CELL BIOL, V7, P371, DOI 10.1128/MCB.7.1.371; DUFOUR S, 1988, EMBO J, V7, P2661, DOI 10.1002/j.1460-2075.1988.tb03119.x; EDWARDS AM, 1988, MOL CELL BIOL, V8, P2655, DOI 10.1128/MCB.8.6.2655; EVANS RR, 1984, J BIOL CHEM, V259, P3916; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; GEIGER B, 1979, CELL, V18, P193, DOI 10.1016/0092-8674(79)90368-4; GIBSON W, 1974, VIROLOGY, V62, P319, DOI 10.1016/0042-6822(74)90395-X; HANAFUSA H, 1977, COMPREHENSIVE VIROLO, V10, P401; HEMLER ME, 1987, J BIOL CHEM, V262, P3300; HIRST R, 1986, P NATL ACAD SCI USA, V83, P6470, DOI 10.1073/pnas.83.17.6470; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HORWITZ A, 1985, J CELL BIOL, V101, P2134, DOI 10.1083/jcb.101.6.2134; HUNTER T, 1982, J BIOL CHEM, V257, P4843; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; ITO S, 1983, J BIOL CHEM, V258, P4626; KISHIMOTO TK, 1987, CELL, V48, P681, DOI 10.1016/0092-8674(87)90246-7; KNUDSEN KA, 1985, EXP CELL RES, V157, P218, DOI 10.1016/0014-4827(85)90164-8; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; PASQUALE EB, 1986, P NATL ACAD SCI USA, V83, P5507, DOI 10.1073/pnas.83.15.5507; PIERCE M, 1986, J BIOL CHEM, V261, P772; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; ROEBROEK AJM, 1986, EMBO J, V5, P2197, DOI 10.1002/j.1460-2075.1986.tb04484.x; ROHRSCHNEIDER L, 1983, MOL CELL BIOL, V3, P731, DOI 10.1128/MCB.3.4.731; ROHRSCHNEIDER LR, 1980, P NATL ACAD SCI-BIOL, V77, P3514, DOI 10.1073/pnas.77.6.3514; ROSOK MJ, 1983, MOL CELL BIOL, V3, P475, DOI 10.1128/MCB.3.3.475; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SCHROER E, 1985, EUR J BIOCHEM, V153, P515, DOI 10.1111/j.1432-1033.1985.tb09332.x; SEFTON BM, 1980, CELL, V20, P807, DOI 10.1016/0092-8674(80)90327-X; SEFTON BM, 1981, CELL, V24, P165, DOI 10.1016/0092-8674(81)90512-2; SPIEGEL S, 1986, J CELL BIOL, V102, P1898, DOI 10.1083/jcb.102.5.1898; SUZUKI S, 1986, P NATL ACAD SCI USA, V83, P8614, DOI 10.1073/pnas.83.22.8614; TAMKUN JW, 1986, CELL, V46, P271, DOI 10.1016/0092-8674(86)90744-0; WILKINS JA, 1986, J CELL BIOL, V102, P1085, DOI 10.1083/jcb.102.3.1085; YONEMOTO W, 1987, MOL CELL BIOL, V7, P905, DOI 10.1128/MCB.7.2.905	59	248	250	1	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1989	4	3					325	333						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5676	2468126				2022-12-17	WOS:A1989U567600008
J	Dodelet, VC; Pasquale, EB				Dodelet, VC; Pasquale, EB			Eph receptors and ephrin ligands: embryogenesis to tumorigenesis	ONCOGENE			English	Review						receptor tyrosine kinase; tissue patterning; axon guidance; cell segregation; angiogenesis	PROTEIN-TYROSINE KINASE; RETINAL AXON GUIDANCE; CARDIOVASCULAR DEVELOPMENT; TRANSMEMBRANE LIGANDS; MELANOMA PROGRESSION; COMMISSURAL AXONS; MOLECULAR-CLONING; CELL-ADHESION; UP-REGULATION; IN-VITRO	Protein tyrosine kinase genes are the largest family of oncogenes, This is not surprising since tyrosine kinases are important components of signal transduction pathways that control cell shape, proliferation, differentiation, and migration, At 14 distinct members, the Eph kinases constitute the largest family of receptor tyrosine kinases, Although they have been most intensively studied for their roles in embryonic development, increasing evidence also implicates Eph family proteins in cancer. This review will address the recent progress in understanding the function of Eph receptors in normal development and how disregulation of these functions could promote tumorigenesis.	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Pasquale, EB (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.							Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295; ANDRES AC, 1994, ONCOGENE, V9, P1461; Banyard J, 2000, ONCOGENE, V19, P580, DOI 10.1038/sj.onc.1203338; BENNETT BD, 1994, J BIOL CHEM, V269, P14211; Berclaz G, 1996, BIOCHEM BIOPH RES CO, V226, P869, DOI 10.1006/bbrc.1996.1442; Birgbauer E, 2000, DEVELOPMENT, V127, P1231; BOHME B, 1993, ONCOGENE, V8, P2857; Bruckner K, 1998, CURR OPIN NEUROBIOL, V8, P375, DOI 10.1016/S0959-4388(98)80064-0; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; Buchert M, 1999, J CELL BIOL, V144, P361, DOI 10.1083/jcb.144.2.361; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; Cowan CA, 2000, NEURON, V26, P417, DOI 10.1016/S0896-6273(00)81174-5; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; DANIEL TO, 1996, KIDNEY INT S, V57, P73; Davy A, 1999, GENE DEV, V13, P3125, DOI 10.1101/gad.13.23.3125; Dodelet VC, 1999, J BIOL CHEM, V274, P31941, DOI 10.1074/jbc.274.45.31941; Donoghue MJ, 1999, J NEUROSCI, V19, P5967, DOI 10.1523/JNEUROSCI.19-14-05967.1999; Dottori M, 1998, P NATL ACAD SCI USA, V95, P13248, DOI 10.1073/pnas.95.22.13248; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; DRESCHER U, 1997, CURR BIOL, V7, pR779; EASTY DJ, 1995, CANCER RES, V55, P2528; Easty DJ, 1999, INT J CANCER, V84, P494, DOI 10.1002/(SICI)1097-0215(19991022)84:5<494::AID-IJC8>3.3.CO;2-F; Feldheim DA, 1998, NEURON, V21, P1303, DOI 10.1016/S0896-6273(00)80650-9; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Flanagan JG, 1997, CELL, V90, P403; Flenniken AM, 1996, DEV BIOL, V179, P382, DOI 10.1006/dbio.1996.0269; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Frisen J, 1998, NEURON, V20, P235, DOI 10.1016/S0896-6273(00)80452-3; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Gerety SS, 1999, MOL CELL, V4, P403, DOI 10.1016/S1097-2765(00)80342-1; Hanahan D, 1996, EUR J CANCER, V32A, P2386, DOI 10.1016/S0959-8049(96)00401-7; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; Huynh-Do U, 1999, EMBO J, V18, P2165, DOI 10.1093/emboj/18.8.2165; Imondi R, 2000, DEVELOPMENT, V127, P1397; Jones TL, 1998, P NATL ACAD SCI USA, V95, P576, DOI 10.1073/pnas.95.2.576; Kalo MS, 1999, CELL TISSUE RES, V298, P1, DOI 10.1007/PL00008807; KIYOKAWA E, 1994, CANCER RES, V54, P3645; Labrador JP, 1997, EMBO J, V16, P3889, DOI 10.1093/emboj/16.13.3889; Lin D, 1999, J BIOL CHEM, V274, P3726, DOI 10.1074/jbc.274.6.3726; Linnemann T, 1999, J BIOL CHEM, V274, P13556, DOI 10.1074/jbc.274.19.13556; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; MARU Y, 1988, MOL CELL BIOL, V8, P3770, DOI 10.1128/MCB.8.9.3770; MARU Y, 1990, ONCOGENE, V5, P445; McBride JL, 1998, MECH DEVELOP, V77, P201, DOI 10.1016/S0925-4773(98)00142-7; Mellitzer G, 1999, NATURE, V400, P77, DOI 10.1038/21907; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; Monschau B, 1997, EMBO J, V16, P1258, DOI 10.1093/emboj/16.6.1258; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; Nikolova Z, 1998, J CELL SCI, V111, P2741; Orioli D, 1996, EMBO J, V15, P6035, DOI 10.1002/j.1460-2075.1996.tb00992.x; Orsulic S, 2000, J CELL SCI, V113, P1793; PANDEY A, 1995, CURR BIOL, V5, P986, DOI 10.1016/S0960-9822(95)00195-3; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; Pasquale EB, 1997, CURR OPIN CELL BIOL, V9, P608, DOI 10.1016/S0955-0674(97)80113-5; Smith A, 1997, CURR BIOL, V7, P561, DOI 10.1016/S0960-9822(06)00255-7; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; TAKAHASHI H, 1995, ONCOGENE, V11, P879; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; Vanderhaeghen P, 2000, NAT NEUROSCI, V3, P358, DOI 10.1038/73929; Vogt T, 1998, CLIN CANCER RES, V4, P791; Wahl S, 2000, J CELL BIOL, V149, P263, DOI 10.1083/jcb.149.2.263; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; Winning RS, 1996, DEV BIOL, V179, P309, DOI 10.1006/dbio.1996.0262; Xu QL, 1999, NATURE, V399, P267, DOI 10.1038/20452; Xu QL, 1995, DEVELOPMENT, V121, P4005; Yancopoulos GD, 1998, CELL, V93, P661, DOI 10.1016/S0092-8674(00)81426-9; Zantek ND, 1999, CELL GROWTH DIFFER, V10, P629; Zhang JH, 1996, J NEUROSCI, V16, P7182; Zisch AH, 1997, J NEUROSCI RES, V47, P655, DOI 10.1002/(SICI)1097-4547(19970315)47:6<655::AID-JNR12>3.0.CO;2-U; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181; Zou JX, 1999, P NATL ACAD SCI USA, V96, P13813, DOI 10.1073/pnas.96.24.13813	76	247	281	0	11	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 20	2000	19	49					5614	5619		10.1038/sj.onc.1203856	http://dx.doi.org/10.1038/sj.onc.1203856			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	379TV	11114742				2022-12-17	WOS:000165659300009
J	STURZBECHER, HW; BRAIN, R; ADDISON, C; RUDGE, K; REMM, M; GRIMALDI, M; KEENAN, E; JENKINS, JR				STURZBECHER, HW; BRAIN, R; ADDISON, C; RUDGE, K; REMM, M; GRIMALDI, M; KEENAN, E; JENKINS, JR			A C-TERMINAL ALPHA-HELIX PLUS BASIC REGION MOTIF IS THE MAJOR STRUCTURAL DETERMINANT OF P53 TETRAMERIZATION	ONCOGENE			English	Article							LARGE T-ANTIGEN; TUMOR SUPPRESSOR PROTEIN; DNA-BINDING PROTEINS; MONOCLONAL-ANTIBODIES; WILD-TYPE; TRANSFORMED-CELLS; TRANS-ACTIVATION; CELLULAR PROTEIN; LEUCINE ZIPPER; SV40 ORIGIN	The p53 gene product has been implicated in both human and animal tumorigenesis. p53 forms heterologous complexes with the transforming proteins encoded by several different DNA tumor viruses. p53 also assembles into stable homo-oligomers. We demonstrate that the major structural determinant for the tetramerization of p53 is an alpha-helical plus basic region motif near the C-terminus of the protein. A monomeric p53 mutant adopts a conformation distinct from both `wild-type' and `mutant' form as defined by PAb1620 and PAb240 monoclonal antibody recognition. Nevertheless, monomeric and dimeric mutant p53 proteins retain the ability to suppress SV40 origin-directed DNA replication in vivo. Thus, p53-p53 interaction and expression of the PAb1620 epitope is not a prerequisite for such activity. We present data suggesting that suppression of replication by p53 may occur by a mechanism that is independent of detectable p53-T antigen association.	MARIE SKLODOWSKA CURIE MEM INST,CELL PROLIFERAT LAB,OXTED RH8 0TL,SURREY,ENGLAND; ESTONIAN BIOCTR,TARTU,ESTONIA,USSR	Estonian Biocentre			Remm, Maido/L-9072-2019	Remm, Maido/0000-0003-3966-8422				ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ADDISON C, 1990, ONCOGENE, V5, P423; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUNG MC, 1988, J VIROL METHODS, V19, P33, DOI 10.1016/0166-0934(88)90005-5; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GENTZ R, 1989, P NATL ACAD SCI USA, V86, P821, DOI 10.1073/pnas.86.3.821; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; JENKINS JR, 1988, ONCOGENE HDB, P403; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; MCCORMICK F, 1981, NATURE, V292, P63, DOI 10.1038/292063a0; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHMIEG FI, 1988, VIROLOGY, V164, P132, DOI 10.1016/0042-6822(88)90628-9; STURZBECHER HW, 1990, ONCOGENE, V5, P795; STURZBECHER HW, 1988, ONCOGENE, V3, P405; STURZBECHER HW, 1987, ONCOGENE, V1, P201; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WILLIAMS T, 1991, SCIENCE, V251, P1067, DOI 10.1126/science.1998122	53	247	254	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1513	1523						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1321401				2022-12-17	WOS:A1992JE81300007
J	Wu, WKK; Lee, CW; Cho, CH; Fan, D; Wu, K; Yu, J; Sung, JJY				Wu, W. K. K.; Lee, C. W.; Cho, C. H.; Fan, D.; Wu, K.; Yu, J.; Sung, J. J. Y.			MicroRNA dysregulation in gastric cancer: a new player enters the game	ONCOGENE			English	Review						microRNA; gastric cancer; signaling pathway; proliferation; apoptosis; metastasis	MIGRATION INHIBITORY FACTOR; EPSTEIN-BARR-VIRUS; CELL-CYCLE ARREST; TUMOR-SUPPRESSOR; HELICOBACTER-PYLORI; INCREASED RISK; DECREASED EXPRESSION; TRANSCRIPTION FACTOR; INDUCE APOPTOSIS; EPITHELIAL-CELLS	Gastric carcinogenesis is a multistep process involving genetic and epigenetic alteration of protein-coding proto-oncogenes and tumor-suppressor genes. Recent discoveries have shed new light on the involvement of a class of noncoding RNA known as microRNA (miRNA) in gastric cancer. A substantial number of miRNAs show differential expression in gastric cancer tissues. Genes coding for these miRNAs have been characterized as novel proto-oncogenes and tumor-suppressor genes based on findings that these miRNAs control malignant phenotypes of gastric cancer cells. In this connection, miRNA dysregulation promotes cell-cycle progression, confers resistance to apoptosis, and enhances invasiveness and metastasis. Moreover, certain polymorphisms in miRNA genes are associated with increased risks for atrophic gastritis and gastric cancer, whereas circulating levels of miRNAs may serve as biomarkers for early diagnosis. Several miRNAs have also been shown to correlate with gastric cancer progression, and thus may be used as prognostic markers. Elucidating the biological aspects of miRNA dysregulation may help us better understand the pathogenesis of gastric cancer and promote the development of miRNA-directed therapeutics against this deadly disease. Oncogene (2010) 29, 5761-5771; doi: 10.1038/onc.2010.352; published online 30 August 2010	[Wu, W. K. K.; Lee, C. W.; Cho, C. H.; Yu, J.; Sung, J. J. Y.] Chinese Univ Hong Kong, Inst Digest Dis, LKS Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China; [Wu, W. K. K.; Lee, C. W.; Cho, C. H.; Yu, J.; Sung, J. J. Y.] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China; [Cho, C. H.] Chinese Univ Hong Kong, Fac Med, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China; [Fan, D.; Wu, K.] Fourth Mil Med Univ, Xijing Hosp, State Key Lab Canc Biol, Xian 710032, Peoples R China; [Fan, D.; Wu, K.] Fourth Mil Med Univ, Xijing Hosp, Inst Digest Dis, Xian 710032, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Air Force Military Medical University; Air Force Military Medical University	Yu, J (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Inst Digest Dis, LKS Inst Hlth Sci, 7-F LKS Med Sci Bldg, Shatin, Hong Kong, Peoples R China.	junyu@cuhk.edu.hk; joesung@cuhk.edu.hk	Wu, William K.K./A-3277-2009; Xiao, Yang/B-5668-2012; Yu, Jun/D-8569-2015; Sung, Joseph J. Y./R-3203-2018; Cho, Chi Hin/C-6543-2014	Wu, William K.K./0000-0002-5662-5240; Yu, Jun/0000-0001-5008-2153; Sung, Joseph J. Y./0000-0003-3125-5199; Cho, Chi Hin/0000-0002-7658-3260	National Basic Research Program of China (973 Program) [2010CB529305]; CUHK [3110043]	National Basic Research Program of China (973 Program)(National Basic Research Program of China); CUHK(Chinese University of Hong Kong)	This work was supported by research grant from the National Basic Research Program of China (973 Program, 2010CB529305). CUHK Group Research Scheme (3110043) and CUHK Focused Investments Scheme-Scheme C.	Agrawal S, 2007, BLOOD, V109, P3895, DOI 10.1182/blood-2006-08-040147; Ando T, 2009, INT J CANCER, V124, P2367, DOI 10.1002/ijc.24219; Araya M, 1997, J SURG ONCOL, V65, P232, DOI 10.1002/(SICI)1096-9098(199708)65:4<232::AID-JSO2>3.0.CO;2-6; Arisawa T, 2007, DIGEST DIS SCI, V52, P1691, DOI 10.1007/s10620-006-9648-5; Balch C, 2009, ENDOCRINOLOGY, V150, P4003, DOI 10.1210/en.2009-0404; Bandres E, 2009, CLIN CANCER RES, V15, P2281, DOI 10.1158/1078-0432.CCR-08-1818; Benvenuti S, 2007, J CELL PHYSIOL, V213, P316, DOI 10.1002/jcp.21183; Bernard D, 2006, ONCOGENE, V25, P1358, DOI 10.1038/sj.onc.1209179; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Beswick EJ, 2008, INFECT IMMUN, V76, P3233, DOI 10.1128/IAI.01534-07; Beswick EJ, 2006, J IMMUNOL, V176, P6794, DOI 10.4049/jimmunol.176.11.6794; BLASER MJ, 1995, CANCER RES, V55, P2111; Canepa ET, 2007, IUBMB LIFE, V59, P419, DOI 10.1080/15216540701488358; Carthew RW, 2009, CELL, V136, P642, DOI 10.1016/j.cell.2009.01.035; Catalano V, 2009, CRIT REV ONCOL HEMAT, V71, P127, DOI 10.1016/j.critrevonc.2009.01.004; Chan SH, 2008, ANTICANCER RES, V28, P907; Che XM, 2000, CANCER LETT, V148, P181, DOI 10.1016/S0304-3835(99)00335-3; Chen Y, 2010, J GASTROINTEST SURG, V14, P1170, DOI 10.1007/s11605-010-1202-2; Chendrimada TP, 2005, NATURE, V436, P740, DOI 10.1038/nature03868; Chiosea S, 2007, CANCER RES, V67, P2345, DOI 10.1158/0008-5472.CAN-06-3533; Chiosea S, 2006, AM J PATHOL, V169, P1812, DOI 10.2353/ajpath.2006.060480; Choy EYW, 2008, J EXP MED, V205, P2551, DOI 10.1084/jem.20072581; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Cotter TG, 2009, NAT REV CANCER, V9, P501, DOI 10.1038/nrc2663; Danaei G, 2005, LANCET, V366, P1784, DOI 10.1016/S0140-6736(05)67725-2; Davis BN, 2008, NATURE, V454, P56, DOI 10.1038/nature07086; di Mario F, 2008, DIGEST LIVER DIS, V40, P523, DOI 10.1016/j.dld.2008.02.028; Diaz-Meco MT, 2009, CELL CYCLE, V8, P2518, DOI 10.4161/cc.8.16.9384; Du Y, 2009, J GASTROENTEROL, V44, P556, DOI 10.1007/s00535-009-0037-7; Faber C, 2009, VIRCHOWS ARCH, V454, P359, DOI 10.1007/s00428-009-0751-9; Fehri LF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009500; Fusaro G, 2003, J BIOL CHEM, V278, P47853, DOI 10.1074/jbc.M305171200; Gao CP, 2010, CANCER-AM CANCER SOC, V116, P41, DOI 10.1002/cncr.24743; Geiger TR, 2009, BBA-REV CANCER, V1796, P293, DOI 10.1016/j.bbcan.2009.07.006; Gorouhi F, 2008, BRIT J CANCER, V98, P1443, DOI 10.1038/sj.bjc.6604277; Guo JM, 2009, J GASTROEN HEPATOL, V24, P652, DOI 10.1111/j.1440-1746.2008.05666.x; Hashimoto Y, 2010, CARCINOGENESIS, V31, P777, DOI 10.1093/carcin/bgq013; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; He XX, 2006, GUT, V55, P797, DOI 10.1136/gut.2005.078113; Houghton J, 2005, GASTROENTEROLOGY, V128, P1567, DOI 10.1053/j.gastro.2005.03.037; Humar B, 2002, ONCOGENE, V21, P8192, DOI 10.1038/sj.onc.1205921; Hwang HW, 2009, P NATL ACAD SCI USA, V106, P7016, DOI 10.1073/pnas.0811523106; Inui M, 2010, NAT REV MOL CELL BIO, V11, P252, DOI 10.1038/nrm2868; Ji Q, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-266; Jiang Z, 2010, J GASTROENTEROL, V45, P17, DOI 10.1007/s00535-009-0135-6; Jonjic N, 1997, ANTICANCER RES, V17, P3883; Katada T, 2009, INT J ONCOL, V34, P537, DOI 10.3892/ijo_00000179; Kikuyama S, 1998, ONCOL REP, V5, P867; Kim DN, 2007, J VIROL, V81, P1033, DOI 10.1128/JVI.02271-06; Kim MS, 2010, J PATHOL, V221, P139, DOI 10.1002/path.2683; Kim YK, 2009, NUCLEIC ACIDS RES, V37, P1672, DOI 10.1093/nar/gkp002; Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003; Lai KW, 2010, EUR J CANCER, V46, P1456, DOI 10.1016/j.ejca.2010.01.036; Lazzaretti D, 2009, RNA, V15, P1059, DOI 10.1261/rna.1606309; Lee EJ, 2008, RNA, V14, P35, DOI 10.1261/rna.804508; Lee WP, 2005, CLIN CANCER RES, V11, P6431, DOI 10.1158/1078-0432.CCR-05-0942; Lee Y, 2006, EMBO J, V25, P522, DOI 10.1038/sj.emboj.7600942; Lee Y, 2006, COLD SPRING HARB SYM, V71, P51, DOI 10.1101/sqb.2006.71.041; Legesse-Miller A, 2009, J BIOL CHEM, V284, P6605, DOI 10.1074/jbc.C900002200; Li GQ, 2009, WORLD J GASTROENTERO, V15, P5541, DOI 10.3748/wjg.15.5541; Li XH, 2010, GUT, V59, P579, DOI 10.1136/gut.2008.175497; Liu T, 2009, CANCER LETT, V273, P233, DOI 10.1016/j.canlet.2008.08.003; Lund E, 2004, SCIENCE, V303, P95, DOI 10.1126/science.1090599; Maeda K, 1998, ONCOLOGY-BASEL, V55, P594, DOI 10.1159/000011918; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Marlow R, 2008, CANCER RES, V68, P7819, DOI 10.1158/0008-5472.CAN-08-1357; Matsushima K, 2011, INT J CANCER, V128, P361, DOI 10.1002/ijc.25348; Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022; Meng FY, 2006, GASTROENTEROLOGY, V130, P2113, DOI 10.1053/j.gastro.2006.02.057; Motoyama K, 2008, CLIN CANCER RES, V14, P2334, DOI 10.1158/1078-0432.CCR-07-4667; Motoyama K, 2010, INT J ONCOL, V36, P1089, DOI 10.3892/ijo_00000590; Mott JL, 2009, HEPATOLOGY, V50, P630, DOI 10.1002/hep.23010; NEKARDA H, 1994, CANCER RES, V54, P2900; Niida H, 2006, MUTAGENESIS, V21, P3, DOI 10.1093/mutage/gei063; Pateras IS, 2009, MOL CANCER RES, V7, P1902, DOI 10.1158/1541-7786.MCR-09-0317; Peng S, 2010, DIGEST DIS SCI, V55, P2288, DOI 10.1007/s10620-009-1007-x; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Pfannkuche K, 2009, STEM CELL REV REP, V5, P224, DOI 10.1007/s12015-009-9078-9; Pfeffer S, 2004, SCIENCE, V304, P734, DOI 10.1126/science.1096781; Poon TCW, 2006, GASTROENTEROLOGY, V130, P1858, DOI 10.1053/j.gastro.2006.02.011; Pulukuri SM, 2007, ONCOGENE, V26, P5229, DOI 10.1038/sj.onc.1210329; Qiao L, 2009, DRUG RESIST UPDATE, V12, P55, DOI 10.1016/j.drup.2009.02.002; Rachagani S, 2010, CANCER LETT, V292, P8, DOI 10.1016/j.canlet.2009.11.010; Rastogi S, 2006, MOL CELL BIOL, V26, P4161, DOI 10.1128/MCB.02142-05; Rocha GA, 2005, INT J CANCER, V115, P678, DOI 10.1002/ijc.20935; Romano MF, 2009, IDRUGS, V12, P253; Saadat M, 2006, CANCER SCI, V97, P505, DOI 10.1111/j.1349-7006.2006.00207.x; Saito H, 1999, ONCOLOGY-BASEL, V56, P253, DOI 10.1159/000011973; Saito Y, 2009, ONCOGENE, V28, P2738, DOI 10.1038/onc.2009.140; Sakuma K, 2005, INT J CANCER, V115, P93, DOI 10.1002/ijc.20903; Sasaki N, 2001, CLIN CANCER RES, V7, P4136; Schmid BC, 2007, BREAST CANCER RES TR, V106, P333, DOI 10.1007/s10549-007-9504-0; Shah KM, 2009, CLIN MICROBIOL INFEC, V15, P982, DOI 10.1111/j.1469-0691.2009.03033.x; Shen HM, 2009, APOPTOSIS, V14, P348, DOI 10.1007/s10495-009-0315-0; Shen RZ, 2010, BIOCHEM BIOPH RES CO, V394, P1047, DOI 10.1016/j.bbrc.2010.03.121; Shen WW, 2007, NEOPLASIA, V9, P812, DOI 10.1593/neo.07403; Shinozaki A, 2010, CANCER RES, V70, P4719, DOI 10.1158/0008-5472.CAN-09-4620; Shou WY, 1996, MOL BIOL CELL, V7, P457, DOI 10.1091/mbc.7.3.457; Squillaro T, 2010, FASEB J, V24, P1593, DOI 10.1096/fj.09-143057; Stella MC, 2009, MOL BIOL CELL, V20, P642, DOI 10.1091/mbc.E08-03-0321; Sun L, 2008, EUR J CANCER PREV, V17, P446, DOI 10.1097/CEJ.0b013e328305a140; Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199; Tada T, 2006, JNCI-J NATL CANCER I, V98, P396, DOI 10.1093/jnci/djj093; Takagi T, 2009, ONCOLOGY-BASEL, V77, P12, DOI 10.1159/000218166; Takano Y, 2000, AM J PATHOL, V156, P585, DOI 10.1016/S0002-9440(10)64763-3; Theiss AL, 2009, MOL BIOL CELL, V20, P4412, DOI 10.1091/mbc.E09-05-0361; Thomson JM, 2006, GENE DEV, V20, P2202, DOI 10.1101/gad.1444406; Tie J, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000879; Tijsterman M, 2004, CELL, V117, P1, DOI 10.1016/S0092-8674(04)00293-4; Tsujiura M, 2010, BRIT J CANCER, V102, P1174, DOI 10.1038/sj.bjc.6605608; Tsukamoto Y, 2010, CANCER RES, V70, P2339, DOI 10.1158/0008-5472.CAN-09-2777; Ueda T, 2010, LANCET ONCOL, V11, P136, DOI 10.1016/S1470-2045(09)70343-2; Unoki M, 2003, ONCOGENE, V22, P2172, DOI 10.1038/sj.onc.1206222; Vogiatzi P, 2006, CANCER BIOL THER, V5, P371, DOI 10.4161/cbt.5.4.2748; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wada R, 2010, INT J CANCER, V127, P1106, DOI 10.1002/ijc.25126; Wan HY, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-16; Wang B, 2003, CANCER CELL, V4, P19, DOI 10.1016/S1535-6108(03)00164-8; Wang QZ, 2009, CURR CANCER DRUG TAR, V9, P572, DOI 10.2174/156800909788486731; Watanabe N, 2004, P NATL ACAD SCI USA, V101, P4419, DOI 10.1073/pnas.0307700101; Wu J, 2010, ONCOGENE, V29, P1987, DOI 10.1038/onc.2009.481; Wu Q, 2010, BIOCHEM BIOPH RES CO, V392, P340, DOI 10.1016/j.bbrc.2009.12.182; Xia L, 2008, INT J CANCER, V123, P372, DOI 10.1002/ijc.23501; Xiang SL, 2006, NAT BIOTECHNOL, V24, P697, DOI 10.1038/nbt1211; Xiao BX, 2009, CLIN CHIM ACTA, V400, P97, DOI 10.1016/j.cca.2008.10.021; Yamaguchi N, 2001, LANCET ONCOL, V2, P88, DOI 10.1016/S1470-2045(00)00225-4; Yamamura Y, 2006, J BIOL CHEM, V281, P5267, DOI 10.1074/jbc.M512151200; Yamanaka Y, 2009, BLOOD, V114, P3265, DOI 10.1182/blood-2009-06-222794; YONEMURA Y, 1994, ONCOLOGY, V51, P251; Yoo YD, 1999, INT J CANCER, V83, P512, DOI 10.1002/(SICI)1097-0215(19991112)83:4<512::AID-IJC13>3.0.CO;2-Z; Yuasa-Kawada J, 2009, P NATL ACAD SCI USA, V106, P14530, DOI 10.1073/pnas.0801262106; Zambon CF, 2004, GASTROENTEROLOGY, V126, P382, DOI 10.1053/j.gastro.2003.08.042; Zhang HH, 2007, WORLD J GASTROENTERO, V13, P2883, DOI 10.3748/wjg.v13.i20.2883; Zhang Q, 2007, NAT MED, V13, P1341, DOI 10.1038/nm1659; Zhang XL, 2010, BIOCHEM BIOPH RES CO, V395, P275, DOI 10.1016/j.bbrc.2010.04.005; ZHANG Y, 2009, MED ONCOL; Zhang ZY, 2008, LAB INVEST, V88, P1358, DOI 10.1038/labinvest.2008.94; Zheng ZH, 2007, CHINESE MED J-PEKING, V120, P2099, DOI 10.1097/00029330-200712010-00007; Zhou H, 2010, J MOL MED, V88, P709, DOI 10.1007/s00109-010-0617-2; Zhou Y, 2007, INT J CANCER, V121, P1481, DOI 10.1002/ijc.22833; ZHU W, 2010, INT J CANC	143	246	266	0	51	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	43					5761	5771		10.1038/onc.2010.352	http://dx.doi.org/10.1038/onc.2010.352			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	672LY	20802530				2022-12-17	WOS:000283586200001
J	Dohn, M; Zhang, SZ; Chen, XB				Dohn, M; Zhang, SZ; Chen, XB			p63 alpha and Delta Np63 alpha can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes	ONCOGENE			English	Article						apoptosis; cell cycle arrest; p63; p53; p73	P53-REGULATED PROTEIN GADD45; TUMOR-SUPPRESSOR P53; KINASE C-ABL; DNA-DAMAGE; TRANSCRIPTIONAL ACTIVITIES; P53-RELATED PROTEIN; HUMAN CANCERS; P73; P63; EXPRESSION	The p53 tumor suppressor protein plays a critical role in the regulation of the cell cycle and apoptosis, The importance of p53's functions is underscored by the high incidence of p53 mutations in human cancers, Recently, two p53-related proteins, p73 and p63, were identified as members of the p53 gene family, Multiple isoforms of p73 have been found, including DeltaN variants in which the N-termini are truncated, p63 is expressed as three major forms, p63 alpha, p63 beta and p63 gamma, each of which differ in their C-termini, All three forms can be alternatively transcribed from a cryptic promoter located within intron 3, producing Delta Np63 alpha, Delta Np63 beta and Delta Np63 gamma, The high degree of similarity of p73 and p63 to evolutionarily conserved regions of p53 suggests that these proteins play an important and potentially redundant role in regulating cell cycle arrest and apoptosis, Here we describe the characterization of cell lines generated to inducibly express p63 alpha and Delta Np63 alpha. We have found that p63 alpha and Delta Np63 alpha can differentially regulate endogenous p53 target genes and induce cell cycle arrest and apoptosis, Deletion of the N-terminal 26 amino acids of Delta Np63 alpha abolished its ability to transactivate p53 target genes and induce cell cycle arrest and apoptosis, This indicates that a putative transactivation domain exists within the N-terminus of the DeltaN variants of p63, Furthermore, the differential regulation of p53 target genes by p63a and Delta Np63 alpha suggests that p63 and p53 utilize both similar and different signaling pathways to execute their cellular functions.	Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Chen, XB (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA.				NATIONAL CANCER INSTITUTE [R01CA081237, R29CA076069] Funding Source: NIH RePORTER; NCI NIH HHS [R29 CA76069, R01 CA81237] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 1999, NATURE, V399, P809; Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Barbosa MS, 1996, CRIT REV ONCOGENESIS, V7, P1; Boyer SN, 1996, CANCER RES, V56, P4620; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chen XB, 1999, MOL MED TODAY, V5, P387, DOI 10.1016/S1357-4310(99)01545-2; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; Crook T, 2000, ONCOGENE, V19, P3439, DOI 10.1038/sj.onc.1203656; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; De Laurenzi V, 2000, BIOCHEM BIOPH RES CO, V273, P342, DOI 10.1006/bbrc.2000.2932; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Evans SC, 1997, MOL MED TODAY, V3, P390, DOI 10.1016/S1357-4310(97)01105-2; Gong JG, 1999, NATURE, V399, P806; Gu ZM, 2000, MOL CELL BIOL, V20, P233, DOI 10.1128/MCB.20.1.233-241.2000; Hall PA, 2000, CARCINOGENESIS, V21, P153, DOI 10.1093/carcin/21.2.153; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levrero M, 1999, CELL DEATH DIFFER, V6, P1146, DOI 10.1038/sj.cdd.4400624; Levrero M, 2000, J CELL SCI, V113, P1661; Liefer KM, 2000, CANCER RES, V60, P4016; Lohrum MAE, 2000, TRENDS CELL BIOL, V10, P197, DOI 10.1016/S0962-8924(00)01736-0; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; MIYASHITA T, 1995, CELL, V80, P293; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prives C, 1999, J PATHOL, V187, P112; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Scharnhorst V, 2000, J BIOL CHEM, V275, P10202, DOI 10.1074/jbc.275.14.10202; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Senoo M, 1998, BIOCHEM BIOPH RES CO, V248, P603, DOI 10.1006/bbrc.1998.9013; Shaul Y, 2000, CELL DEATH DIFFER, V7, P10, DOI 10.1038/sj.cdd.4400626; Shimada A, 1999, CANCER RES, V59, P2781; Smith CL, 1997, J BIOL CHEM, V272, P27493, DOI 10.1074/jbc.272.44.27493; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; Ueda Y, 1999, ONCOGENE, V18, P4993, DOI 10.1038/sj.onc.1202817; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yin YX, 1998, NATURE, V391, P707, DOI 10.1038/35648; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika AI, 1999, CANCER RES, V59, P3257; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhu JH, 2000, MOL CELL BIOL, V20, P5602, DOI 10.1128/MCB.20.15.5602-5618.2000; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030; Zhu JH, 1998, CANCER RES, V58, P5061; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690	73	246	260	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 31	2001	20	25					3193	3205		10.1038/sj.onc.1204427	http://dx.doi.org/10.1038/sj.onc.1204427			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	440ET	11423969				2022-12-17	WOS:000169163500003
J	Schmale, H; Bamberger, C				Schmale, H; Bamberger, C			A novel protein with strong homology to the tumor suppressor p53	ONCOGENE			English	Article						keratinocyte; taste bud; differentiation; gene evolution	CRYSTAL-STRUCTURE; CELLS; EXPRESSION; SEQUENCE; ONCOPROTEIN; ANTIGEN; DOMAIN	The p53 tumor important genes apoptosis. Mice deficient for p53 show a high incidence of cancer but are developmentally normal suggesting that compensatory mechanisms exist in embryogenesis and differentiation. The new KET protein is the first mammalian protein with strong homology to p53 in all evolutionary conserved regions. This conservation makes a functional redundancy of the two proteins in cell-cycle control possible. KET is expressed during embryonic development and in certain adult tissues. Among all of the known p53 proteins of different species KET is most closely related to that found in squid. The relationship between KET and the invertebrate p53 protein sheds light on the evolutionary origin of p53. KET appears to be an ancestral p53-related protein in vertebrates,vith a possible role in development and differentiation while the ubiquitously expressed p53 protein attained its general role as 'guardian of the genome' during evolution.			Schmale, H (corresponding author), UNIV HAMBURG,HOSP EPPENDORF,INST ZELLBIOCHEM & KLIN NEUROBIOL,MARTINISTR 52,D-20246 HAMBURG,GERMANY.		Bamberger, Casimir/E-7356-2011; Bamberger, Tom Casimir/D-1292-2014	Bamberger, Tom Casimir/0000-0002-3830-4486				BEIDLER LM, 1965, J CELL BIOL, V27, P263, DOI 10.1083/jcb.27.2.263; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ISHIOKA C, 1995, ONCOGENE, V10, P1485; Jacks T, 1996, NATURE, V381, P643, DOI 10.1038/381643a0; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LASSAR A, 1994, CURR OPIN CELL BIOL, V6, P432, DOI 10.1016/0955-0674(94)90037-X; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MCLAUGHLIN SK, 1992, NATURE, V357, P563, DOI 10.1038/357563a0; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SCHMALE H, 1995, EXPT CELL BIOL TASTE, P147; SCHMID P, 1991, DEVELOPMENT, V113, P857; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; SOUSSI T, 1988, NUCLEIC ACIDS RES, V16, P11384, DOI 10.1093/nar/16.23.11384; STONE LM, 1995, P NATL ACAD SCI USA, V92, P1916, DOI 10.1073/pnas.92.6.1916; STRIEM B J, 1991, Cellular Physiology and Biochemistry, V1, P46, DOI 10.1159/000154592; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; VONGAUDECKER B, 1991, ANAT EMBRYOL, V183, P1; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x	24	246	266	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 11	1997	15	11					1363	1367		10.1038/sj.onc.1201500	http://dx.doi.org/10.1038/sj.onc.1201500			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315105				2022-12-17	WOS:A1997XV84500015
J	Sakamuro, D; Sabbatini, P; White, E; Prendergast, GC				Sakamuro, D; Sabbatini, P; White, E; Prendergast, GC			The polyproline region of p53 is required to activate apoptosis but not growth arrest	ONCOGENE			English	Article						p53; apoptosis; transformation; cell cycle	WILD-TYPE P53; P53-MEDIATED G(1) ARREST; NUCLEAR TYROSINE KINASE; TUMOR-SUPPRESSOR P53; CELL-CYCLE ARREST; P53-DEPENDENT APOPTOSIS; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; E1A-INDUCED APOPTOSIS; EMBRYO FIBROBLASTS	p53 is a pivotal regulator of apoptosis but its mechanism of action is obscure. We report that the polyproline (PP) region located between p53's transactivation and DNA binding domains is necessary to induce apoptosis but not cell growth arrest. The PP region was dispensable for DNA binding, inhibition of SAOS-2 tumor cell growth, suppression of E1A+RAS cell transformation, and cell cycle inhibition. A temperature-sensitive dominant inhibitory p53 mutant lacking PP (p53ts Delta PP) retained its ability to cooperate with adenovirus E1A in transformation of primary BRK cells. However, while activation of wt p53 induced apoptosis in E1A+p53ts-transformed cells, activation of p53 Delta PP induced cell cycle arrest but not apoptosis in E1A+p53ts Delta PP-transformed cells. Similarly, PP deletion abolished apoptosis in LoVo colon carcinoma cells, which are killed by wt p53 overexpression. Transactivation was largely unaffected by PP deletion, Significantly, BAX induction was intact, indicating that additional events are required for p53 to induce apoptosis. As a recently described site for familial mutation in at least one breast cancer family, the PP region represents a domain that may be altered in human tumors. We concluded that p53's ability to induce apoptosis is dispensable for inhibiting cell growth and transformation and that the PP region plays a crucial role in apoptotic signaling.	WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104; RUTGERS STATE UNIV,CTR ADV BIOTECHNOL & MED,DEPT MOL BIOL & BIOCHEM,PISCATAWAY,NJ 08854; CANC INST NEW JERSEY,PISCATAWAY,NJ 08854	The Wistar Institute; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey			White, Eileen/ABD-6745-2021	White, Eileen/0000-0003-2961-3065	NCI NIH HHS [CA60088] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060088] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CANCE WG, 1994, CELL GROWTH DIFFER, V5, P1347; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CRAVEN RJ, 1995, CANCER RES, V55, P3969; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; GOGA A, 1995, ONCOGENE, V11, P791; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; GOTTLIEB MT, 1996, BIOCHIM BIOPHYS ACTA, V1287, P77; GUILLOUF C, 1995, ONCOGENE, V10, P2263; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; Hansen R, 1995, ONCOGENE, V11, P2535; Harlow E LD, 1988, ANTIBODIES LAB MANUA; HARPER JW, 1993, CELL, V75, P805; HARVEY M, 1993, ONCOGENE, V8, P2457; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HULBOY DL, 1994, CELL GROWTH DIFFER, V5, P1023; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kobayashi T, 1995, ONCOGENE, V11, P2311; KOYAMA S, 1993, CELL, V72, P945, DOI 10.1016/0092-8674(93)90582-B; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; LIN YP, 1995, MOL CELL BIOL, V15, P6045; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MICHALOVITZ D, 1987, J VIROL, V61, P2648, DOI 10.1128/JVI.61.8.2648-2654.1987; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; Pendergast AM, 1996, CURR OPIN CELL BIOL, V8, P174, DOI 10.1016/S0955-0674(96)80063-9; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; PRENDERGAST GC, 1992, GENE DEV, V6, P2429, DOI 10.1101/gad.6.12a.2429; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sakamuro D, 1995, ONCOGENE, V11, P2411; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; STEWART N, 1995, ONCOGENE, V10, P109; Sun XF, 1996, ONCOGENE, V13, P407; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WALDMAN T, 1995, CANCER RES, V55, P5187; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YONISHROUACH E, 1996, ONCOGENE, V12, P2197	74	246	253	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 21	1997	15	8					887	898		10.1038/sj.onc.1201263	http://dx.doi.org/10.1038/sj.onc.1201263			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XR767	9285684				2022-12-17	WOS:A1997XR76700002
J	SHEIKH, MS; LI, XS; CHEN, JC; SHAO, ZM; ORDONEZ, JV; FONTANA, JA				SHEIKH, MS; LI, XS; CHEN, JC; SHAO, ZM; ORDONEZ, JV; FONTANA, JA			MECHANISMS OF REGULATION OF WAF1 CIP1 GENE-EXPRESSION IN HUMAN BREAST-CARCINOMA - ROLE OF P53-DEPENDENT AND INDEPENDENT SIGNAL-TRANSDUCTION PATHWAYS	ONCOGENE			English	Article							DNA-DAMAGING AGENTS; P53 PROTEIN EXPRESSION; WILD-TYPE P53; TRANSCRIPTIONAL ACTIVITY; CANCER CELLS; GROWTH; BINDING; SUPPRESSION; MUTATIONS; CYCLE	WAF1/Cip1 was recently identified as the wild-type p53 target that appears to mediate the tumor suppressing effects of p53. We investigated the mechanisms of regulation of WAF1/Cip1 gene expression in human breast carcinoma (HBC) cells. Our results demonstrate that the HBC cells harboring wild-type p53 express 26-33-fold higher WAF1/Cip1 mRNA levels than the cells harboring mutant p53. The DNA damaging agent etoposide induced p53 accumulation only in cells harboring wild-type p53 yet it induced WAF1/Cip1 gene expression in cells carrying wild-type or mutant p53, suggesting the involvement of p53-dependent and independent signaling pathways in the regulation of WAF1/Cip1 gene expression. Serum starvation-induced growth arrest although not altering the endogenous p53 levels or its ability to transactivate the reporter gene, induced WAF1/Cip1 gene expression in cells carrying wild-type as well as mutant p53. These results further implicated the involvement of p53-independent signal transduction pathways in WAF1/Cip1 gene regulation. Our data also suggest that WAF1/Cip1 gene expression is tightly associated with cell cycle progression in cells containing either wild-type or mutant p53. WAF1/Cip1 expression was transiently induced in response to serum treatment and declined as the cells passed through the S-phase of the cell cycle. We thus provide evidence that the mechanisms of WAF1/Cip1 gene regulation involve p53-dependent and independent signaling pathways in HBC.	UNIV MARYLAND,SCH MED,DEPT MED,DIV ONCOL,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,CTR CANC,BALTIMORE,MD 21201; VET ADM MED CTR,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA)				Fontana, Joseph/0000-0003-3829-3358	NATIONAL CANCER INSTITUTE [R01CA063335] Funding Source: NIH RePORTER; NCI NIH HHS [CA 63335] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLRED DC, 1993, J NATL CANCER I, V85, P200, DOI 10.1093/jnci/85.3.200; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN JY, 1993, ONCOGENE, V8, P2159; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MCGREGOR GR, 1987, SOMAT CELL MOLEC GEN, V13, P253; MICHIELI P, 1994, CANCER RES, V54, P3391; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; SHEIKH MS, 1993, ANTICANCER RES, V13, P1387; SHEIKH MS, 1993, J CELL BIOCHEM, V53, P394, DOI 10.1002/jcb.240530417; SHEIKH MS, 1993, J CELL PHYSIOL, V155, P556, DOI 10.1002/jcp.1041550314; TISHLER RB, 1993, CANCER RES, V53, P2212; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOJTESEK B, 1993, J CELL SCI, V105, P607; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAMBETTI GP, 1992, GENE DEV, V7, P1126; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHANG W, 1993, CANCER RES, V53, P4772; ZHANG W, 1993, ONCOGENE, V8, P2555	38	246	248	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3407	3415						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970699				2022-12-17	WOS:A1994PT39200001
J	KITAGAWA, M; OKABE, T; OGINO, H; MATSUMOTO, H; SUZUKITAKAHASHI, I; KOKUBO, T; HIGASHI, H; SAITOH, S; TAYA, Y; YASUDA, H; OHBA, Y; NISHIMURA, S; TANAKA, N; OKUYAMA, A				KITAGAWA, M; OKABE, T; OGINO, H; MATSUMOTO, H; SUZUKITAKAHASHI, I; KOKUBO, T; HIGASHI, H; SAITOH, S; TAYA, Y; YASUDA, H; OHBA, Y; NISHIMURA, S; TANAKA, N; OKUYAMA, A			BUTYROLACTONE-I, A SELECTIVE INHIBITOR OF CDK2 AND CDC2 KINASE	ONCOGENE			English	Article							TRANSCRIPTION FACTOR E2F; RETINOBLASTOMA-SUSCEPTIBILITY GENE; MATURATION-PROMOTING FACTOR; CELL-CYCLE CONTROL; PROTEIN-KINASE; POTENT INHIBITOR; RB PROTEIN; SACCHAROMYCES-CEREVISIAE; S-PHASE; PHOSPHORYLATION	We screened cdc2 kinase inhibitors from cultured mediums of micro organisms using purified mouse cyclin B-cdc2 kinase and a specific substrate peptide for cdc2 kinase. A selective inhibitor of cdc2 kinase was isolated from the cultured medium of Aspergillus species F-25799, and identified as butyrolactone I. Butyrolactone I inhibited cdc2 and cdk2 kinases but it had little effect on mitogen-activated protein kinase, protein kinase C, cyclic-AMP dependent kinase, casein kinase II, casein kinase I or epidermal growth factor-receptor tyrosine kinase. Its inhibitory effect was found to be due to competition with ATP. Butyrolactone I selectively inhibited the H1 histone phosphorylation in nuclear extracts. It also inhibited the phosphorylation of the product of retinoblastoma susceptibility gene in nuclear extracts and intact cells. Thus butyrolactone I should be very useful for elucidating the function of cdc2 and cdk2 kinases in cell cycle regulation.	MERCK RES LABS, BANYU TSUKUBA RES INST COLLABORAT, OKUBO 3, TSUKUBA 30033, JAPAN; NATL CANC CTR, RES INST, DIV BIOL, CHUO KU, TOKYO 104, JAPAN; KANAZAWA UNIV, FAC PHARMACEUT SCI, DIV BIOL, KANAZAWA, ISHIKAWA 920, JAPAN	National Cancer Center - Japan; Kanazawa University			Higashi, Hideaki/F-6872-2012					ABE K, 1991, EXP CELL RES, V192, P122, DOI 10.1016/0014-4827(91)90166-R; AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; AKIYAMA T, 1990, ONCOGENE, V5, P179; Beavo J A, 1974, Methods Enzymol, V38, P299; BRAUN S, 1984, J BIOL CHEM, V259, P2051; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KIRIYAMA N, 1977, CHEM PHARM BULL, V25, P2593; KITAGAWA M, 1992, ONCOGENE, V7, P1067; KITAGAWA M, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P431; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MINEO C, 1986, EXP CELL RES, V167, P53, DOI 10.1016/0014-4827(86)90203-X; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NAKAJO S, 1986, BIOCHEM INT, V13, P701; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PARKER PJ, 1985, EUR J BIOCHEM, V148, P579, DOI 10.1111/j.1432-1033.1985.tb08879.x; PINES J, 1990, New Biologist, V2, P389; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RAY LB, 1988, J BIOL CHEM, V263, P12721; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SETO M, 1992, ONCOGENE, V7, P1401; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SZEPETOWSKI P, 1992, ONCOGENE, V7, P751; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; TAYA Y, 1990, GENETIC BASIS FOR CARCINOGENESIS, P171; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; USUI T, 1991, J CELL BIOL, V115, P1275, DOI 10.1083/jcb.115.5.1275; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x; YASUDA H, 1981, BIOCHEMISTRY-US, V20, P4414, DOI 10.1021/bi00518a028; YASUDA H, 1991, CELL STRUCT FUNCT, V16, P105, DOI 10.1247/csf.16.105; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	73	246	255	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1993	8	9					2425	2432						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8395680				2022-12-17	WOS:A1993LT36800013
J	DEVILEE, P; VANVLIET, M; VANSLOUN, P; DIJKSHOORN, NK; HERMANS, J; PEARSON, PL; CORNELISSE, CJ				DEVILEE, P; VANVLIET, M; VANSLOUN, P; DIJKSHOORN, NK; HERMANS, J; PEARSON, PL; CORNELISSE, CJ			ALLELOTYPE OF HUMAN BREAST-CARCINOMA - A 2ND MAJOR SITE FOR LOSS OF HETEROZYGOSITY IS ON CHROMOSOME-6Q	ONCOGENE			English	Article							RECESSIVE MUTATION; CANCER; GENE; TUMORS; RETINOBLASTOMA; EXPRESSION; HOMOZYGOSITY; DELETION; REGIONS	Loss of heterozygosity (LOH), which is detected with polymorphic DNA markers by comparing constitutional and tumor genotypes, has been observed at a number of different chromosome arms in primary breast tumors. These include 1p, 1q, 3p, 11p, 13q, 17p and 18q. We present here the results of a screening of all nonacrocentric chromosome arms, including those of the X chromosome, with at least one polymorphic marker per arm, in a total of 86 breast carcinomas. This dataset, termed an allelotype, indicates that in addition to the chromosome regions listed above, allelic loss may be observed in more than 30% of informative cases on 6q, 8q, 9q, 15q, and 16q. Multiple LOH involving at least two different chromosomes in a single tumor was observed in approximately 75% of the investigated tumors, and revealed complex chromosome involvement. Six different combinations of concurrent LOH at two different chromosome arms were found to be significantly correlated (r > 0.45; P < 0.01). Tumors showing LOH at 3p or 17p were preferentially aneuploid, while LOH at 6q and 17q was inversely correlated with the number of positive lymph nodes and age respectively.	LEIDEN UNIV,FAC MED,DEPT PATHOL,2333 AL LEIDEN,NETHERLANDS; LEIDEN UNIV,FAC MED,DEPT MED STAT,2333 AL LEIDEN,NETHERLANDS	Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC	DEVILEE, P (corresponding author), LEIDEN UNIV,FAC MED,DEPT HUMAN GENET,WASSENAARSEWEG 72,2333 AL LEIDEN,NETHERLANDS.		DEVILEE, PETER/ABR-2140-2022					ALI IU, 1989, J NATL CANCER I, V81, P1815, DOI 10.1093/jnci/81.23.1815; ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; BEERMAN H, 1990, INT J CANCER, V45, P34, DOI 10.1002/ijc.2910450108; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHEN LC, 1989, P NATL ACAD SCI USA, V86, P7204, DOI 10.1073/pnas.86.18.7204; CROPP CS, 1990, P NATL ACAD SCI USA, V87, P7737, DOI 10.1073/pnas.87.19.7737; DEVILEE P, 1990, CYTOGENET CELL GENET, V53, P52, DOI 10.1159/000132893; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; DEVILEE P, 1991, CANCER RES, V51, P1020; DEVILEE P, 1991, ONCOGENE, V6, P311; DEVILEE P, 1991, CANCER SURV, V9, P605; DUTRILLAUX B, 1990, CANCER GENET CYTOGEN, V49, P203, DOI 10.1016/0165-4608(90)90143-X; EHLEN T, 1990, ONCOGENE, V5, P219; FULTS D, 1990, CANCER RES, V50, P5784; GENDLER SJ, 1990, INT J CANCER, V45, P431, DOI 10.1002/ijc.2910450309; GENUARDI M, 1989, AM J HUM GENET, V45, P73; GERBAULTSEUREAU M, 1987, ANN GENET-PARIS, V30, P138; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; KIDD KJ, 1989, CYTOGENET CELL GENET, V51; LARSSON C, 1990, GENE CHROMOSOME CANC, V2, P191, DOI 10.1002/gcc.2870020305; LUNDBERG C, 1987, P NATL ACAD SCI USA, V84, P2372, DOI 10.1073/pnas.84.8.2372; MACKAY J, 1988, LANCET, V2, P1384; MARS WM, 1990, CANCER METAST REV, V9, P35, DOI 10.1007/BF00047587; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MITCHELL ELD, 1990, GENE CHROMOSOME CANC, V2, P278, DOI 10.1002/gcc.2870020405; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PROSSER J, 1990, ONCOGENE, V5, P1573; RODGERS CS, 1984, CANCER GENET CYTOGEN, V13, P95, DOI 10.1016/0165-4608(84)90052-9; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SATO T, 1990, CANCER RES, V50, P7184; SEIZINGER BR, 1986, NATURE, V322, P644, DOI 10.1038/322644a0; SUZUKI T, 1989, CANCER RES, V49, P1095; THOMAS GA, 1991, CANCER RES, V51, P639; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; TRENT JM, 1987, ONCOGENES HORMONES B, P142; VANDERVIJER MJ, 1991, BIOCHIM BIOPHYS ACTA, V1072, P35; VARLEY JM, 1989, ONCOGENE, V4, P725; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; YAMADA H, 1990, ONCOGENE, V5, P1141; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252	42	246	246	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1705	1711						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1681492				2022-12-17	WOS:A1991GX27400030
J	ADNANE, J; GAUDRAY, P; DIONNE, CA; CRUMLEY, G; JAYE, M; SCHLESSINGER, J; JEANTEUR, P; BIRNBAUM, D; THEILLET, C				ADNANE, J; GAUDRAY, P; DIONNE, CA; CRUMLEY, G; JAYE, M; SCHLESSINGER, J; JEANTEUR, P; BIRNBAUM, D; THEILLET, C			BEK AND FLG, 2 RECEPTORS TO MEMBERS OF THE FGF FAMILY, ARE AMPLIFIED IN SUBSETS OF HUMAN BREAST CANCERS	ONCOGENE			English	Article							FIBROBLAST GROWTH-FACTOR; HER-2 NEU ONCOGENE; PROTO-ONCOGENE; AMPLIFICATION; GENE; CARCINOMAS; TUMORS; DNA; EXPRESSION; PHENOTYPE	Tumor DNA samples from 387 breast carcinomas have been investigated for amplification of BEK and FLG genes, both of which have been shown to code for cell surface receptors to FGFs. BEK and FLG were found amplified in 11.5 and 12.7% of breast tumors respectively. Statistical analysis, performed on the subset of 297 primary cancers without presurgical therapy, showed for BEK a trend of preferential amplification in patients above 50 years (P = 0.055), whereas amplification of FLG could significantly be correlated with nodal involvement (P = 0.032) and seemed prevalent in steroid hormones receptor positive tumors. Since the same tumors were previously analysed for the amplification of MYC, ERBB2 and HST/INT2/BCL1 possible associations with BEK and FLG amplifications were looked for. BEK was found significantly correlated with MYC and FLG with HST/INT2/BCL1. The amplification of these two FGF receptor genes may therefore represent additional steps in the molecular phenotyping of breast cancer.	FAC MED NICE,LGMCH,AV VALOMBROSE,F-06034 NICE,FRANCE; INSERM,U119,F-13009 MARSEILLE,FRANCE; RHONE POULENC RORER CENT RES,KING OF PRUSSIA,PA 19406; UNIV MONTPELLIER 2,GENET MOLEC LAB,CNRS,UA 1191,F-34095 MONTPELLIER 2,FRANCE; CTR PAUL LAMARQUE,BIOCHIM LAB,F-34094 MONTPELLIER 2,FRANCE; NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Universite de Montpellier; New York University			Theillet, Charles/O-7634-2018	Theillet, Charles/0000-0001-5555-2759; Birnbaum, Daniel/0000-0001-7920-9883				ADNANE J, 1989, ONCOGENE, V4, P1389; ALI IU, 1988, BREAST CANCER CELLUL, P25; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; GIULOTTO E, 1987, CELL, V48, P837, DOI 10.1016/0092-8674(87)90080-8; GOMPEL C, 1983, PRINCIPLES PRACTICES, V1, P245; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; RUTA M, 1988, ONCOGENE, V3, P9; SAFRAN A, 1990, ONCOGENE, V5, P635; SAINSBURY JRC, 1987, LANCET, V1, P1398; SAINTRUF C, 1990, GENE CHROMOSOME CANC, V2, P18, DOI 10.1002/gcc.2870020105; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TANDON AK, 1989, J CLIN ONCOL, V7, P1120, DOI 10.1200/JCO.1989.7.8.1120; THEILLET C, 1989, ONCOGENE, V4, P915; VARLEY JM, 1988, ONCOGENE, V3, P87; WILLIAMS BP, 1988, ONCOGENE, V3, P345; ZEILLINGER R, 1989, ONCOGENE, V4, P109; 1982, TUMORI, V68, P181	24	246	267	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					659	663						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1851551				2022-12-17	WOS:A1991FR93900023
J	Gong, C; Bauvy, C; Tonelli, G; Yue, W; Delomenie, C; Nicolas, V; Zhu, Y; Domergue, V; Marin-Esteban, V; Tharinger, H; Delbos, L; Gary-Gouy, H; Morel, AP; Ghavami, S; Song, E; Codogno, P; Mehrpour, M				Gong, C.; Bauvy, C.; Tonelli, G.; Yue, W.; Delomenie, C.; Nicolas, V.; Zhu, Y.; Domergue, V.; Marin-Esteban, V.; Tharinger, H.; Delbos, L.; Gary-Gouy, H.; Morel, A-P; Ghavami, S.; Song, E.; Codogno, P.; Mehrpour, M.			Beclin 1 and autophagy are required for the tumorigenicity of breast cancer stem-like/progenitor cells	ONCOGENE			English	Article						breast cancer; autophagy; cancer stem-like/progenitor cell; Beclin 1	EPITHELIAL-MESENCHYMAL TRANSITION; IN-VITRO PROPAGATION; SELF-RENEWAL; IDENTIFICATION; INHIBITION; MODULATION; ACTIVATION; INDUCTION; SURVIVAL; GROWTH	Malignant breast tissue contains a rare population of multi-potent cells with the capacity to self-renew; these cells are known as cancer stem-like cells (CSCs) or tumor-initiating cells. Primitive mammary CSCs/progenitor cells can be propagated in culture as floating spherical colonies termed 'mammospheres'. We show here that the expression of the autophagy protein Beclin 1 is higher in mammospheres established from human breast cancers or breast cancer cell lines (MCF-7 and BT474) than in the parental adherent cells. As a result, autophagic flux is more robust in mammospheres. We observed that basal and starvation-induced autophagy flux is also higher in aldehyde dehydrogenase 1-positive (ALDH1(+)) population derived from mammospheres than in the bulk population. Beclin 1 is critical for CSC maintenance and tumor development in nude mice, whereas its expression limits the development of tumors not enriched with breast CSCs/progenitor cells. We found that decreased survival in autophagy-deficient cells (MCF-7 Atg7 knockdown cells) during detachment does not contribute to an ultimate deficiency in mammosphere formation. This study demonstrates that a prosurvival autophagic pathway is critical for CSC maintenance, and that Beclin 1 plays a dual role in tumor development.	[Gong, C.; Bauvy, C.; Tonelli, G.; Yue, W.; Codogno, P.; Mehrpour, M.] INSERM, Fac Pharm, U984, Chatenay Malabry, France; [Gong, C.; Zhu, Y.; Song, E.] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Breast Tumor Ctr, Guangzhou 510120, Guangdong, Peoples R China; [Bauvy, C.; Tonelli, G.; Yue, W.; Delomenie, C.; Nicolas, V.; Domergue, V.; Marin-Esteban, V.; Tharinger, H.; Delbos, L.; Gary-Gouy, H.; Codogno, P.; Mehrpour, M.] Univ Paris 11, Fac Pharm, UMRS 996, F-92296 Chatenay Malabry, France; [Delomenie, C.; Nicolas, V.; Domergue, V.; Tharinger, H.; Delbos, L.; Gary-Gouy, H.] IFR 141 IPSIT, Fac Pharm, UMRS 996, Chatenay Malabry, France; [Marin-Esteban, V.] INSERM, Fac Pharm, UMRS 996, Chatenay Malabry, France; [Morel, A-P] INSERM, U520, F-69008 Lyon, France; [Ghavami, S.] Univ Manitoba, Dept Physiol, Winnipeg, MB, Canada	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Sun Yat Sen University; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Manitoba	Song, E (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Breast Tumor Ctr, 107 Yanjiang West Rd, Guangzhou 510120, Guangdong, Peoples R China.	songerwei02@yahoo.com.cn; patrice.codogno@u-psud.fr; mehrpourmaryam@yahoo.fr	Codogno, Patrice/G-1384-2013; Mehrpour, Maryam/D-8640-2017; MOREL, Anne-Pierre/AAN-7072-2021; Ghavami, Saeid/GLT-0606-2022; Marin-Esteban, Viviana/A-8856-2014; Ghavami, Saeid/Q-8918-2016	Codogno, Patrice/0000-0002-5492-3180; Ghavami, Saeid/0000-0001-5948-508X; Delomenie, Claudine/0000-0002-6326-966X	INSERM; Universite Paris-Sud 11; PHC-PFCC programme francais de cooperation avec la Chine; INCa; ANR; National Natural Science Foundation of China [30830110, 30921140312, 30801376, 30972785, 81172524]; 973 Projects from Ministry of Science and Technology of China [2010CB912800, 2011CB504203, 2009CB521706]; Development of Important New Drugs from Ministry of Health of China [2011ZX09102-010-02]; Clinical Key Project of Public Health Administration of China; Sun Yat-sen University Training Project [11ykpy28, 11ykzd12]; Key Laboratory of malignant tumor gene regulation and target therapy of Guangdong Higher Education Institutes, Sun Yat-sen University [KLB09001]; Parker B Francis Fellowship in Respiratory Disease	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Universite Paris-Sud 11; PHC-PFCC programme francais de cooperation avec la Chine; INCa(Institut National du Cancer (INCA) France); ANR(French National Research Agency (ANR)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); 973 Projects from Ministry of Science and Technology of China; Development of Important New Drugs from Ministry of Health of China; Clinical Key Project of Public Health Administration of China; Sun Yat-sen University Training Project; Key Laboratory of malignant tumor gene regulation and target therapy of Guangdong Higher Education Institutes, Sun Yat-sen University; Parker B Francis Fellowship in Respiratory Disease	We thank B Levine for providing us with the MCF-7.beclin 1 cell line, M Jaattela and N Brady for providing the MCF-7 GFP-LC3 and the mCherry-GFP-LC3 cell lines, respectively. We thank A Hamai for his careful reading of our manuscript. We thank N Modjtahedi for helpful discussions. This work was supported by grants from INSERM, Universite Paris-Sud 11, PHC-PFCC programme francais de cooperation avec la Chine, INCa, ANR, the National Natural Science Foundation of China (30830110, 30921140312, 30801376, 30972785, 81172524), 973 Projects from Ministry of Science and Technology of China (2010CB912800, 2011CB504203, 2009CB521706), Development of Important New Drugs from Ministry of Health of China (2011ZX09102-010-02), Clinical Key Project of Public Health Administration of China, Sun Yat-sen University Training Project (11ykpy28,11ykzd12) and Key Laboratory of malignant tumor gene regulation and target therapy of Guangdong Higher Education Institutes, Sun Yat-sen University (KLB09001). SG was supported with Parker B Francis Fellowship in Respiratory Disease.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Charafe-Jauffret E, 2010, CLIN CANCER RES, V16, P45, DOI 10.1158/1078-0432.CCR-09-1630; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Clement V, 2007, CURR BIOL, V17, P165, DOI 10.1016/j.cub.2006.11.033; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751; Dikic I, 2010, CANCER RES, V70, P3431, DOI 10.1158/0008-5472.CAN-09-4027; Djavaheri-Mergny M, 2006, J BIOL CHEM, V281, P30373, DOI 10.1074/jbc.M602097200; Dontu G, 2003, CELL PROLIFERAT, V36, P59, DOI 10.1046/j.1365-2184.36.s.1.6.x; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Fung C, 2008, MOL BIOL CELL, V19, P797, DOI 10.1091/mbc.E07-10-1092; Gangemi R, 2009, CURR MED CHEM, V16, P1688, DOI 10.2174/092986709788186147; Gao P, 2010, J BIOL CHEM, V285, P25570, DOI 10.1074/jbc.M110.118125; Ghavami S, 2012, AM J PHYSIOL-LUNG C, V302, pL420, DOI 10.1152/ajplung.00312.2011; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Gupta PB, 2011, CELL, V146, P633, DOI 10.1016/j.cell.2011.07.026; Hippert MM, 2006, CANCER RES, V66, P9349, DOI 10.1158/0008-5472.CAN-06-1597; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Kimura S, 2007, AUTOPHAGY, V3, P452, DOI 10.4161/auto.4451; Korkaya H, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000121; Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254; Mathew R, 2011, CURR OPIN GENET DEV, V21, P113, DOI 10.1016/j.gde.2010.12.008; Mehrpour M, 2010, CELL RES, V20, P748, DOI 10.1038/cr.2010.82; Mizushima N, 2011, COLD SPRING HARB SYM, VLXXVI, P3; Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207; Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028; Moreau K, 2010, CURR OPIN CELL BIOL, V22, P206, DOI 10.1016/j.ceb.2009.12.002; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Mortensen M, 2011, J EXP MED, V208, P455, DOI 10.1084/jem.20101145; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Reynolds BA, 1996, DEV BIOL, V175, P1, DOI 10.1006/dbio.1996.0090; Rubinsztein DC, 2009, AUTOPHAGY, V5, P585, DOI 10.4161/auto.5.5.8823; Singh SK, 2003, CANCER RES, V63, P5821; Wei HJ, 2011, GENE DEV, V25, P1510, DOI 10.1101/gad.2051011; Weidberg H, 2011, ANNU REV BIOCHEM, V80, P125, DOI 10.1146/annurev-biochem-052709-094552; White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023; Wu YT, 2010, J BIOL CHEM, V285, P10850, DOI 10.1074/jbc.M109.080796; Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100; Zhou JB, 2007, P NATL ACAD SCI USA, V104, P16158, DOI 10.1073/pnas.0702596104; Zhu H, 2009, AUTOPHAGY, V5, P816, DOI 10.4161/auto.9064	50	245	254	1	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2013	32	18					2261	2272		10.1038/onc.2012.252	http://dx.doi.org/10.1038/onc.2012.252			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140VF	22733132	Green Published			2022-12-17	WOS:000318683600003
J	Avruch, J; Hara, K; Lin, Y; Liu, M; Long, X; Ortiz-Vega, S; Yonezawa, K				Avruch, J.; Hara, K.; Lin, Y.; Liu, M.; Long, X.; Ortiz-Vega, S.; Yonezawa, K.			Insulin and amino-acid regulation of mTOR signaling and kinase activity through the Rheb GTPase	ONCOGENE			English	Review						TOR; Rheb; TSC; S6K; raptor; leucine	P70 S6 KINASE; RAPAMYCIN-INDUCED INHIBITION; TUMOR-SUPPRESSOR COMPLEX; REPRESSOR PHAS-I; B-RAF KINASE; MAMMALIAN TARGET; TUBEROUS-SCLEROSIS; PROTEIN-KINASE; CELL-GROWTH; PHOSPHATIDYLINOSITOL 3-KINASE	Target of Rapamycin ( TOR), a giant protein kinase expressed by all eucaryotic cells, controls cell size in response to nutrient signals. In metazoans, cell and organismal growth is controlled by nutrients and the insulin/insulin-like growth factor (IGF) system, and the understanding of how these inputs coordinately regulate TOR signaling has advanced greatly in the past 5 years. In single-cell eucaryotes and Caenorhabditis elegans, TOR is a dominant regulator of overall mRNA translation, whereas in higher metazoans, TOR controls the expression of a smaller fraction of mRNAs that is especially important to cell growth. TOR signals through two physically distinct multiprotein complexes, and the control of cell growth is mediated primarily by TOR complex 1 (TORC1), which contains the polypeptides raptor and LST8. Raptor is the substrate binding element of TORC1, and the ability of raptor to properly present substrates, such as the translational regulators 4E-BP and p70 S6 kinase, to the TOR catalytic domain is essential for their TOR-catalysed phosphorylation, and is inhibited by the Rapamycin/FKBP-12 complex. The dominant proximal regulator of TORC1 signaling and kinase activity is the ras-like small GTPase Rheb. Rheb binds directly to the mTOR catalytic domain, and Rheb-GTP enables TORC1 to attain an active configuration. Insulin/IGF enhances Rheb GTP charging through the ability of activated Akt to inhibit the Rheb-GTPase-activating function of the tuberous sclerosis heterodimer (TSC1/TSC2). Conversely, energy depletion reduces Rheb-GTP charging through the ability of the adenosine monophosphate-activated protein kinase to phosphorylate TSC2 and stimulate its Rheb-GTPase activating function, as well as by HIF alpha-mediated transcriptional responses that act upstream of the TSC1/2 complex. Amino-acid depletion inhibits TORC1 acting predominantly downstream of the TSC complex, by interfering with the ability of Rheb to bind to mTOR. The components of the insulin/IGF pathway to TORC1 are now well established, whereas the elements mediating the more ancient and functionally dominant input of amino acids remain largely unknown.	Massachusetts Gen Hosp, Dept Mol Biol, Diabet Res Lab, Boston, MA 02114 USA; Kobe Univ, Grad Sch Med, Div Internal & Geriatr Med, Cyuo Ku, Kobe, Hyogo 657, Japan; Kobe Univ, Biosignal Res Ctr, Kobe, Hyogo, Japan	Harvard University; Massachusetts General Hospital; Kobe University; Kobe University	Avruch, J (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, Diabet Res Lab, Simches Res Bldg 6408,185 Cambridge St, Boston, MA 02114 USA.	avruch@molbio.mgh.harvard.edu	Long, Samuel/AAR-8118-2021	Long, Samuel/0000-0001-7559-3232	NCI NIH HHS [CA73818] Funding Source: Medline; NIDDK NIH HHS [DK17776] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017776, R37DK017776] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham RT, 2004, DNA REPAIR, V3, P883, DOI 10.1016/j.dnarep.2004.04.002; Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Ali SM, 2005, J BIOL CHEM, V280, P19445, DOI 10.1074/jbc.C500125200; Arsham AM, 2003, J BIOL CHEM, V278, P29655, DOI 10.1074/jbc.M212770200; Aspuria PJ, 2004, CELL SIGNAL, V16, P1105, DOI 10.1016/j.cellsig.2004.03.019; Avruch J, 2005, CURR OPIN CLIN NUTR, V8, P67, DOI 10.1097/00075197-200501000-00010; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; Beugnet A, 2003, J BIOL CHEM, V278, P40717, DOI 10.1074/jbc.M308573200; BIERER BE, 1991, TRANSPLANT P, V23, P2850; Biondi RM, 2001, EMBO J, V20, P4380, DOI 10.1093/emboj/20.16.4380; Bolster DR, 2002, J BIOL CHEM, V277, P23977, DOI 10.1074/jbc.C200171200; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Brugarolas JB, 2003, CANCER CELL, V4, P147, DOI 10.1016/S1535-6108(03)00187-9; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0; Byfield MP, 2005, J BIOL CHEM, V280, P33076, DOI 10.1074/jbc.M507201200; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; Castro AF, 2003, J BIOL CHEM, V278, P32493, DOI 10.1074/jbc.C300226200; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEATHAM L, 1995, P NATL ACAD SCI USA, V92, P11696, DOI 10.1073/pnas.92.25.11696; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; Choi JW, 1996, SCIENCE, V273, P239, DOI 10.1126/science.273.5272.239; Choi KM, 2003, J BIOL CHEM, V278, P19667, DOI 10.1074/jbc.M301142200; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Colicelli John, 2004, Sci STKE, V2004, pRE13, DOI 10.1126/stke.2502004re13; Corradetti MN, 2005, J BIOL CHEM, V280, P9769, DOI 10.1074/jbc.C400557200; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Dong JX, 2004, GENE DEV, V18, P2479, DOI 10.1101/gad.1240504; Drenan RM, 2004, J BIOL CHEM, V279, P772, DOI 10.1074/jbc.M305912200; Dumont FJ, 1995, LIFE SCI, V58, P373, DOI 10.1016/0024-3205(95)02233-3; ERIKSON E, 1985, P NATL ACAD SCI USA, V82, P742, DOI 10.1073/pnas.82.3.742; ERIKSON E, 1986, J BIOL CHEM, V261, P350; Fang YM, 2003, CURR BIOL, V13, P2037, DOI 10.1016/j.cub.2003.11.021; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Gautam N, 1998, CELL SIGNAL, V10, P447, DOI 10.1016/S0898-6568(98)00006-0; Giannattasio S, 2005, J BIOL CHEM, V280, P42528, DOI 10.1074/jbc.M509187200; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; Hahn-Windgassen A, 2005, J BIOL CHEM, V280, P32081, DOI 10.1074/jbc.M502876200; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Hu CD, 1995, J BIOL CHEM, V270, P30274, DOI 10.1074/jbc.270.51.30274; Im E, 2002, ONCOGENE, V21, P6356, DOI 10.1038/sj.onc.1205792; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Isotani S, 1999, J BIOL CHEM, V274, P34493, DOI 10.1074/jbc.274.48.34493; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; Kam Y, 2004, FASEB J, V18, P311, DOI 10.1096/fj.03-0731com; Karbowniczek M, 2004, J BIOL CHEM, V279, P29930, DOI 10.1074/jbc.M402591200; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kimura N, 2003, GENES CELLS, V8, P65, DOI 10.1046/j.1365-2443.2003.00615.x; KOLTIN Y, 1991, MOL CELL BIOL, V11, P1718, DOI 10.1128/MCB.11.3.1718; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; Kwiatkowski DJ, 2003, ANN HUM GENET, V67, P87, DOI 10.1046/j.1469-1809.2003.00012.x; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Li Y, 2004, MOL CELL BIOL, V24, P7965, DOI 10.1128/MCB.24.18.7965-7975.2004; Liu ZC, 2001, EMBO J, V20, P7209, DOI 10.1093/emboj/20.24.7209; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Long X, 2005, CURR BIOL, V15, P702, DOI 10.1016/j.cub.2005.02.053; Long XM, 2005, J BIOL CHEM, V280, P23433, DOI 10.1074/jbc.C500169200; Long XM, 2002, CURR BIOL, V12, P1448, DOI 10.1016/S0960-9822(02)01091-6; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Mirshahi T, 2002, J BIOL CHEM, V277, P36345, DOI 10.1074/jbc.M205359200; NEMENOFF RA, 1988, J BIOL CHEM, V263, P19455; Nobukuni T, 2005, P NATL ACAD SCI USA, V102, P14238, DOI 10.1073/pnas.0506925102; Nojima H, 2003, J BIOL CHEM, V278, P15461, DOI 10.1074/jbc.C200665200; Oldham S, 2003, TRENDS CELL BIOL, V13, P79, DOI 10.1016/S0962-8924(02)00042-9; Oshiro N, 2004, GENES CELLS, V9, P359, DOI 10.1111/j.1356-9597.2004.00727.x; Patel PH, 2003, J CELL SCI, V116, P3601, DOI 10.1242/jcs.00661; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; PRICE DJ, 1989, J BIOL CHEM, V264, P13825; PRICE DJ, 1991, J BIOL CHEM, V266, P16281; PRICE DJ, 1990, P NATL ACAD SCI USA, V87, P7944, DOI 10.1073/pnas.87.20.7944; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Radimerski T, 2002, GENE DEV, V16, P2627, DOI 10.1101/gad.239102; Reiling JH, 2004, GENE DEV, V18, P2879, DOI 10.1101/gad.322704; Roccio M, 2006, ONCOGENE, V25, P657, DOI 10.1038/sj.onc.1209106; RodriguezViciana P, 1996, PHILOS T ROY SOC B, V351, P225, DOI 10.1098/rstb.1996.0020; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; SEHGAL SN, 2003, TRANSPLANT P       S, V3, P75; Sekulic A, 2000, CANCER RES, V60, P3504; Smith EM, 2005, J BIOL CHEM, V280, P18717, DOI 10.1074/jbc.M414499200; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Sofer A, 2005, MOL CELL BIOL, V25, P5834, DOI 10.1128/MCB.25.14.5834-5845.2005; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; Takahashi K, 2005, J BIOL CHEM, V280, P32768, DOI 10.1074/jbc.M506280200; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Urano J, 2005, MOL MICROBIOL, V58, P1074, DOI 10.1111/j.1365-2958.2005.04877.x; van Slegtenhorst M, 2004, J BIOL CHEM, V279, P12706, DOI 10.1074/jbc.M313874200; VEZINA C, 1975, J ANTIBIOT, V28, P721, DOI 10.7164/antibiotics.28.721; Wedaman KP, 2003, MOL BIOL CELL, V14, P1204, DOI 10.1091/mbc.E02-09-0609; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WENG QP, 1995, MOL CELL BIOL, V15, P2333; Wu SL, 2002, BBA-MOL CELL RES, V1542, P41, DOI 10.1016/S0167-4889(01)00164-1; YAMAGATA K, 1994, J BIOL CHEM, V269, P16333; Yang WL, 2001, MOL MICROBIOL, V41, P1339, DOI 10.1046/j.1365-2958.2001.02599.x; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999	128	245	259	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2006	25	48					6361	6372		10.1038/sj.onc.1209882	http://dx.doi.org/10.1038/sj.onc.1209882			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	096MH	17041622				2022-12-17	WOS:000241380700003
J	Takada, Y; Bhardwaj, A; Potdar, P; Aggarwal, BB				Takada, Y; Bhardwaj, A; Potdar, P; Aggarwal, BB			Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappa B activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation	ONCOGENE			English	Article						NSAID; NF-kappa B; I kappa B alpha; COX-2; cyclin D1; proliferation	NECROSIS-FACTOR-ALPHA; NUCLEAR-FACTOR; GENE-EXPRESSION; TRANSCRIPTIONAL REGULATION; SIGNALING PATHWAY; RANDOMIZED-TRIAL; PHORBOL ESTER; IN-VITRO; ASPIRIN; KINASE	Nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin have been shown to suppress transcription factor NF-kappaB, which controls the expression of genes such as cyclooxygenase (COX)-2 and cyclin D1, leading to inhibition of proliferation of tumor cells. There is no systematic study as to how these drugs differ in their ability to suppress NF-kappaB activation and NF-kappaB-regulated gene expression or cell proliferation. In the present study, we investigated the effect of almost a dozen different commonly used NSAIDs on tumor necrosis factor (TNF)-induced NF-kappaB activation and NF-kappaB-regulated gene products, and on cell proliferation. Dexamethasone, an anti-inflammatory steroid, was included for comparison with NSAIDs. As indicated by DNA binding, none of the drugs alone activated NF-kappaB. All compounds inhibited TNF-induced NF-kappaB activation, but with highly variable efficacy. The 50% inhibitory concentration required was 5.67, 3.49, 3.03, 1.25, 0.94, 0.60, 0.38, 0.084, 0.043, 0.027, 0.024, and 0.010 mM for aspirin, ibuprofen, sulindac, phenylbutazone, naproxen, indomethacin, diclofenac, resveratrol, curcumin, dexamethasone, celecoxib, and tamoxifen, respectively. All drugs inhibited IkappaBalpha kinase and suppressed IkappaBalpha degradation and NF-kappaB-regulated reporter gene expression. They also suppressed NF-kappaB-regulated COX-2 and cyclin D1 protein expression in a dose-dependent manner. All compounds inhibited the proliferation of tumor cells, with 50% inhibitory concentrations of 6.09, 1.12, 0.65, 0.49, 1.01, 0.19, 0.36, 0.012, 0.016, 0.047, 0.013, and 0.008 mM for aspirin, ibuprofen, sulindac, phenylbutazone, naproxen, indomethacin, diclofenac, resveratrol, curcumin, dexamethasone, celecoxib, and tamoxifen, respectively. Overall these results indicate that aspirin and ibuprofen are least potent, while resveratrol, curcumin, celecoxib, and tamoxifen are the most potent anti-inflammatory and antiproliferative agents of those we studied.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, Box 143,1515 Holcombe Blvd, Houston, TX 77030 USA.	aggarwal@mdanderson.org	Aggarwal, Bharat B/G-3388-2013		NATIONAL CANCER INSTITUTE [P01CA091844] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA91844] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Ashikawa K, 2002, J IMMUNOL, V169, P6490, DOI 10.4049/jimmunol.169.11.6490; Baron JA, 2003, NEW ENGL J MED, V348, P891, DOI 10.1056/NEJMoa021735; Bharti AC, 2002, BIOCHEM PHARMACOL, V64, P883, DOI 10.1016/S0006-2952(02)01154-1; Bharti AC, 2004, J BIOL CHEM, V279, P6065, DOI 10.1074/jbc.M308062200; Botting JH, 1999, DRUG TODAY, V35, P225, DOI 10.1358/dot.1999.35.4-5.552199; Bryant CE, 2003, AM J VET RES, V64, P211, DOI 10.2460/ajvr.2003.64.211; Callejas NA, 2002, HEPATOLOGY, V35, P341, DOI 10.1053/jhep.2002.31163; Chuang SE, 2002, BIOCHEM PHARMACOL, V63, P1709, DOI 10.1016/S0006-2952(02)00931-0; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; de Arriba AF, 1999, MOL PHARMACOL, V55, P753; EBLE JN, 1971, NATURE, V231, P181, DOI 10.1038/231181a0; Ferlini C, 1999, BRIT J CANCER, V79, P257, DOI 10.1038/sj.bjc.6690042; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Giercksky KE, 2001, BEST PRACT RES CL GA, V15, P821, DOI 10.1053/bega.2001.0237; Goel A, 2003, CLIN CANCER RES, V9, P383; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; HASS R, 1992, BIOCHEM PHARMACOL, V44, P1569, DOI 10.1016/0006-2952(92)90474-W; Hinz M, 1999, MOL CELL BIOL, V19, P2690; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; Jack DB, 1997, LANCET, V350, P437, DOI 10.1016/S0140-6736(97)07087-6; Jung M, 2001, SEMIN RADIAT ONCOL, V11, P346, DOI 10.1053/srao.2001.26034; KAZMI SMI, 1995, J CELL BIOCHEM, V57, P299, DOI 10.1002/jcb.240570214; Kisley LR, 2002, CARCINOGENESIS, V23, P1653, DOI 10.1093/carcin/23.10.1653; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Lawrence T, 2002, NAT REV IMMUNOL, V2, P787, DOI 10.1038/nri915; Manna SK, 2000, J IMMUNOL, V164, P6509, DOI 10.4049/jimmunol.164.12.6509; Miller C, 1998, J CELL BIOCHEM, V69, P392, DOI 10.1002/(SICI)1097-4644(19980615)69:4<392::AID-JCB2>3.3.CO;2-Z; Moysich KB, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-31; Nasuhara Y, 1999, J BIOL CHEM, V274, P19965, DOI 10.1074/jbc.274.28.19965; Niederberger E, 2001, FASEB J, V15, P1622, DOI 10.1096/fj.00-0716fje; O'Neill EA, 1998, NATURE, V396, P15, DOI 10.1038/23810; ROTH GJ, 1994, BLOOD, V83, P885; Sandler RS, 2003, NEW ENGL J MED, V348, P883, DOI 10.1056/NEJMoa021633; Scheuren N, 1998, BRIT J PHARMACOL, V123, P645, DOI 10.1038/sj.bjp.0701652; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Stark LA, 2001, FASEB J, V15, P1273, DOI 10.1096/fj.00-0529fje; Takada Y, 2004, J BIOL CHEM, V279, P26287, DOI 10.1074/jbc.M400963200; Takada Y, 2003, J IMMUNOL, V171, P3278, DOI 10.4049/jimmunol.171.6.3278; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Takada Y, 2003, J BIOL CHEM, V278, P23390, DOI 10.1074/jbc.M213237200; Tegeder I, 2001, FASEB J, V15, P2057, DOI 10.1096/fj.01-0390rev; Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563; Williams CS, 2000, CANCER RES, V60, P6045; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Yamamoto Y, 1999, J BIOL CHEM, V274, P27307, DOI 10.1074/jbc.274.38.27307; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948	47	245	257	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2004	23	57					9247	9258		10.1038/sj.onc.1208169	http://dx.doi.org/10.1038/sj.onc.1208169			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	878HR	15489888				2022-12-17	WOS:000225638000010
J	Lakka, SS; Gondi, CS; Yanamandra, N; Olivero, WC; Dinh, DH; Gujrati, M; Rao, JS				Lakka, SS; Gondi, CS; Yanamandra, N; Olivero, WC; Dinh, DH; Gujrati, M; Rao, JS			Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis	ONCOGENE			English	Article						siRNA; proteases; glioma; invasion; angiogenesis	HUMAN BRAIN-TUMORS; IN-VITRO; MATRIX METALLOPROTEINASES; IV COLLAGENASE; ANTISENSE OLIGONUCLEOTIDES; BASEMENT-MEMBRANE; MAMMALIAN-CELLS; PLASMA-MEMBRANE; MESSENGER-RNA; MATRIX-METALLOPROTEINASE-9	Extracellular proteases have been shown to cooperatively influence matrix degradation and tumor cell invasion through proteolytic cascades, with individual proteases having distinct roles in tumor growth, invasion, migration and angiogenesis. Matrix metalloproteases (MMP)-9 and cathepsin B have been shown to participate in the processes of tumor growth, vascularization and invasion of gliomas. In the present study, we used a cytomegalovirus promoter-driven DNA template approach to induce hairpin RNA (hpRNA)-triggered RNA interference (RNAi) to block MMP-9 and cathepsin B gene expression with a single construct. Transfection of a plasmid vector-expressing double-stranded RNA (dsRNA) for MMP-9 and cathepsin B significantly inhibited MMP-9 and cathepsin B expression and reduced the invasive behavior of SNB19, glioblastoma cell line in Matrigel and spheroid invasion models. Downregulation of MMP-9 and cathepsin B using RNAi in SNB19 cells reduced cell-cell interaction of human microvascular endothelial cells, resulting in the disruption of capillary network formation in both in vitro and in vivo models. Direct intratumoral injections of plasmid DNA expressing hpRNA for MMP-9 and cathepsin B significantly inhibited established glioma tumor growth and invasion in intracranial tumors in vivo. Further intraperitoneal (ip) injections of plasmid DNA expressing hpRNA for MMP-9 and cathepsin B completely regressed pre-established tumors for a long time (4 months) without any indication of these tumor cells. For the first time, these observations demonstrate that the simultaneous RNAi-mediated targeting of MMP-9 and cathepsin B has potential application for the treatment of human gliomas.	Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Program Canc Biol, Peoria, IL 61656 USA; Univ Illinois, Dept Neurosurg, Peoria, IL USA; Univ Illinois, Dept Pathol, Peoria, IL USA	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria	Rao, JS (corresponding author), Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Program Canc Biol, Box 1649, Peoria, IL 61656 USA.	jsrao@uic.edu		Gondi, Christopher/0000-0002-3036-9920	NATIONAL CANCER INSTITUTE [R01CA085216, R01CA075557] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047699] Funding Source: NIH RePORTER; NCI NIH HHS [CA 75557, CA 85216] Funding Source: Medline; NINDS NIH HHS [NS47699] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arkona C, 1996, BIOL CHEM, V377, P695, DOI 10.1515/bchm3.1996.377.11.695; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Bertrand JR, 2002, BIOCHEM BIOPH RES CO, V296, P1000, DOI 10.1016/S0006-291X(02)02013-2; Bervar A, 2003, BIOL CHEM, V384, P447, DOI 10.1515/BC.2003.050; Boike G, 1992, Melanoma Res, V1, P333, DOI 10.1097/00008390-199201000-00004; Chandrasekar N, 2000, CLIN EXP METASTAS, V18, P337, DOI 10.1023/A:1010833730407; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; EMMERTBUCK MR, 1994, AM J PATHOL, V145, P1285; Go Y, 1997, CLIN EXP METASTAS, V15, P440, DOI 10.1023/A:1018410523635; GUINEC N, 1993, BIOL CHEM H-S, V374, P1135, DOI 10.1515/bchm3.1993.374.7-12.1135; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; HIMELSTEIN BP, 1994, INVAS METAST, V14, P246; Hua J, 1996, CANCER RES, V56, P5279; Itoh T, 1999, CLIN EXP METASTAS, V17, P177, DOI 10.1023/A:1006603723759; Jen KY, 2000, STEM CELLS, V18, P307, DOI 10.1634/stemcells.18-5-307; Kachra Z, 1999, CLIN EXP METASTAS, V17, P555, DOI 10.1023/A:1006760632766; KOBAYASHI H, 1992, CANCER RES, V52, P3610; KOBAYASHI H, 1993, BIOCHIM BIOPHYS ACTA, V1178, P55, DOI 10.1016/0167-4889(93)90109-3; Kondraganti S, 2000, CANCER RES, V60, P6851; Konduri SD, 2001, ONCOGENE, V20, P6938, DOI 10.1038/sj.onc.1204847; Lakka SS, 2002, ONCOGENE, V21, P8011, DOI 10.1038/sj.onc.1205894; Lakka SS, 2000, CLIN EXP METASTAS, V18, P245, DOI 10.1023/A:1006724826083; LEUNIG M, 1992, CANCER RES, V52, P6553; Lewis DL, 2002, NAT GENET, V32, P107, DOI 10.1038/ng944; LIOTTA LA, 1986, ANNU REV BIOCHEM, V55, P1037, DOI 10.1146/annurev.biochem.55.1.1037; Mai JX, 2002, BIOL CHEM, V383, P1407, DOI 10.1515/BC.2002.159; McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a; Miyagishi M, 2003, ANTISENSE NUCLEIC A, V13, P1, DOI 10.1089/108729003764097296; Mohanam S, 2001, ONCOGENE, V20, P3665, DOI 10.1038/sj.onc.1204480; Pozzi A, 2002, ONCOGENE, V21, P272, DOI 10.1038/sj.onc.1205045; Premzl A, 2003, EXP CELL RES, V283, P206, DOI 10.1016/S0014-4827(02)00055-1; Raithatha SA, 2000, NEURO-ONCOLOGY, V2, P145, DOI 10.1093/neuonc/2.3.145; RAO JS, 1993, CANCER RES, V53, P2208; REDWOOD SM, 1992, CANCER, V69, P1212; Rooprai HK, 1998, INT J ONCOL, V13, P1153; Simon C, 1998, CANCER RES, V58, P1135; SLOANE BF, 1986, P NATL ACAD SCI USA, V83, P2483, DOI 10.1073/pnas.83.8.2483; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Zamore PD, 2001, NAT STRUCT BIOL, V8, P746, DOI 10.1038/nsb0901-746	43	245	276	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2004	23	27					4681	4689		10.1038/sj.onc.1207616	http://dx.doi.org/10.1038/sj.onc.1207616			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZX	15122332				2022-12-17	WOS:000221799200004
J	LI, JJ; OBERLEY, LW; STCLAIR, DK; RIDNOUR, LA; OBERLEY, TD				LI, JJ; OBERLEY, LW; STCLAIR, DK; RIDNOUR, LA; OBERLEY, TD			PHENOTYPIC CHANGES INDUCED IN HUMAN BREAST-CANCER CELLS BY OVEREXPRESSION OF MANGANESE-CONTAINING SUPEROXIDE-DISMUTASE	ONCOGENE			English	Article						BREAST; CANCER; MNSOD; TRANSFECTION; SOFT AGAR; NUDE MICE	SYRIAN-HAMSTER TISSUES; GLUTATHIONE-PEROXIDASE; ANTIOXIDANT ENZYMES; IMMUNOHISTOCHEMICAL LOCALIZATION; KIDNEY DEVELOPMENT; TRANSFECTED CELLS; EXPRESSION VECTOR; TRANSGENIC MICE; MAMMALIAN-CELLS; DOWNS-SYNDROME	Human manganese containing superoxide dismutase (MnSOD) cDNA was transfected into a human breast cancer cell line (MCF-7) in order to examine the effect of increased functional MnSOD on the cellular phenotype. A MnSOD-overexpressing clone was compared to control vector-transfected cells and to wild type MCF-7 cells. Southern blotting indicated incorporation of MnSOD cDNA into genomic DNA in the MnSOD overexpressing cell line. The MnSOD overexpressing cell line showed a 5.7-fold increase in MnSOD activity compared to wild type MCF-7 cells. Similar increases in MnSOD immunoreactive protein and mRNA levels were observed by Western and Northern blotting as well as using RT-PCR, The plating efficiency of cells grown in different concentrations of serum (1 to 20%) was decreased in the MnSOD overexpressing cell line. The fraction in soft agar culture was also after MnSOD cDNA transfection. When inoculated in nude mice, tumor growth was markedly inhibited in MnSOD overexpressing cells compared to wild type MCF-7 cells or plasmid control cells, These results support the hypothesis that increased MnSOD expression suppresses the malignant phenotype of human breast cancer cells and suggests that the MnSOD gene is a tumor suppressor gene in human breast cancer.	UNIV IOWA, RADIAT RES LAB, MED LABS 14, IOWA CITY, IA 52242 USA; UNIV KENTUCKY, GRAD CTR TOXICOL, LEXINGTON, KY 40506 USA; WILLIAM S MIDDLETON MEM VET ADM MED CTR, PATHOL SERV, MADISON, WI 53705 USA	University of Iowa; University of Kentucky; US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital				Li, Jian Jian/0000-0003-3694-9675; Ridnour, Lisa A./0000-0001-9446-8349	NATIONAL CANCER INSTITUTE [R29CA049797, R01CA049797, R01CA041267] Funding Source: NIH RePORTER; NCI NIH HHS [CA 41267, CA 49797] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AITKEN SC, 1985, CANCER RES, V45, P1611; AMSTAD P, 1991, BIOCHEMISTRY-US, V30, P9305, DOI 10.1021/bi00102a024; AMSTAD P, 1994, J BIOL CHEM, V269, P1606; AVRAHAM KB, 1988, CELL, V54, P823, DOI 10.1016/S0092-8674(88)91153-1; Beauchamp Charles, ANAL BIOCHEM, V44, P276, DOI [DOI 10.1016/0003-2697(71)90370-8, 10.1016/0003-2697(71)90370-8]; BECKMAN JS, 1988, J BIOL CHEM, V263, P6884; CEBALLOS I, 1988, BIOCHIM BIOPHYS ACTA, V949, P58, DOI 10.1016/0167-4781(88)90054-1; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; CHURCH SL, 1992, GENOMICS, V14, P823, DOI 10.1016/S0888-7543(05)80202-2; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DUTRILLAUX B, 1990, CANCER GENET CYTOGEN, V49, P203, DOI 10.1016/0165-4608(90)90143-X; ELROYSTEIN O, 1986, EMBO J, V5, P615, DOI 10.1002/j.1460-2075.1986.tb04255.x; ELROYSTEIN O, 1988, CELL, V52, P259, DOI 10.1016/0092-8674(88)90515-6; EMANUEL JR, 1991, NUCLEIC ACIDS RES, V19, P2790, DOI 10.1093/nar/19.10.2790; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FERNANDEZPOL JA, 1982, CANCER RES, V42, P609; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HAINSWORTH PJ, 1991, CANCER GENET CYTOGEN, V53, P205, DOI 10.1016/0165-4608(91)90097-E; HO YS, 1988, FEBS LETT, V229, P256, DOI 10.1016/0014-5793(88)81136-0; KATZENELLENBOGEN BS, 1987, CANCER RES, V47, P4355; KELNER MJ, 1990, J BIOL CHEM, V265, P10872; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPPMAN M, 1976, CANCER RES, V36, P4595; LOVEN DP, 1984, INT J CANCER, V33, P783, DOI 10.1002/ijc.2910330612; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T, 1989, MOL CLONING; MINCGOLOMB D, 1991, EMBO J, V10, P2119, DOI 10.1002/j.1460-2075.1991.tb07745.x; NEGRINI M, 1994, CANCER RES, V54, P1331; NORRIS KH, 1990, MUTAT RES, V237, P95, DOI 10.1016/0921-8734(90)90015-J; Oberley L.W., 1985, HDB METHODS OXYGEN R, P217; OBERLEY LW, 1988, MOL CELL BIOCHEM, V84, P147, DOI 10.1007/BF00421049; OBERLEY LW, 1979, CANCER RES, V39, P1141; OBERLEY LW, 1989, FREE RADICAL BIO MED, V6, P379, DOI 10.1016/0891-5849(89)90083-X; OBERLEY LW, 1994, DRUGS DIET DIS, P47; OBERLEY TD, 1991, AM J PATHOL, V139, P355; OBERLEY TD, 1990, AM J PATHOL, V137, P199; OBERLEY TD, 1991, FREE RADICAL BIO MED, V10, P79, DOI 10.1016/0891-5849(91)90024-W; ODONNELLTORMEY J, 1987, J EXP MED, V165, P500, DOI DOI 10.1074/jbc.RA117.001068; OMAR BA, 1990, FREE RADICAL BIO MED, V9, P473, DOI 10.1016/0891-5849(90)90124-2; ROSENBERG CD, 1990, CANCER RES, V50, P1559; SAFFORD SE, 1994, CANCER RES, V54, P4261; SIMONSEN CC, 1983, P NATL ACAD SCI-BIOL, V80, P2495, DOI 10.1073/pnas.80.9.2495; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPITZ DR, 1989, ANAL BIOCHEM, V179, P8, DOI 10.1016/0003-2697(89)90192-9; SPITZ DR, 1990, ARCH BIOCHEM BIOPHYS, V279, P249, DOI 10.1016/0003-9861(90)90489-L; STCLAIR DK, 1991, FEBS LETT, V293, P199, DOI 10.1016/0014-5793(91)81186-C; WILLETT W, 1989, NATURE, V338, P389, DOI 10.1038/338389a0	49	245	250	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	1995	10	10					1989	2000						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761099				2022-12-17	WOS:A1995QZ92600013
J	Domina, AM; Vrana, JA; Gregory, MA; Hann, SR; Craig, RW				Domina, AM; Vrana, JA; Gregory, MA; Hann, SR; Craig, RW			MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol	ONCOGENE			English	Article						MCL1; BCL2; 12-O-tetradecanoylphorbol 13-acetate; extracellular signal regulated kinase; mitogen activated protein kinase; taxol; protein phosphorylation; protein phosphatase 1/2A	UBIQUITIN-DEPENDENT DEGRADATION; C-MYC PROTEOLYSIS; BCL-2 FAMILY; PROTEASOME PATHWAY; CYCLE PROGRESSION; GENE-PRODUCT; PROTEIN; KINASE; APOPTOSIS; SURVIVAL	BCL2 family members are subject to regulation at multiple levels, providing checks on their ability to contribute to tumorigenesis. However, findings on post-translational BCL2 phosphorylation in different systems have been difficult to integrate. Another antiapoptotic family member, MCL1, exhibits a difference in electrophoretic mobility upon phosphorylation induced by an activator of PKC (12-O-tetradecanoylphorbol 13-acetate; TPA) versus agents that act on microtubules or protein phosphatases 1/2A. A multiple pathway model is now presented, which demonstrates that MCL1 can undergo distinct phosphorylation events-mediated through separate signaling processes and involving different target sites-in cells that remain viable in the presence of TPA versus cells destined to die upon exposure to taxol or okadaic acid. Specifically, TPA induces phosphorylation at a conserved extracellular signal-regulated kinase (ERK) site in the PEST region (Thr 163) and slows turnover of the normally rapidly degraded MCL1 protein; however, okadaic acid and taxol induce ERK-independent MCL1 phosphorylation at additional discrete sites. These findings add a new dimension to our understanding of the complex regulation of antiapoptotic BCL2 family members by demonstrating that, in addition to transcriptional and post-transcriptional regulation, MCL1 is subject to multiple, separate, post-translational phosphorylation events, produced in living versus dying cells at ERK-inducible versus ERK-independent sites.	Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37232 USA	Dartmouth College; Vanderbilt University	Craig, RW (corresponding author), Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA.	ruth.w.craig@dartmouth.edu			NCI NIH HHS [R01-CA57359, R01 CA057359] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057359] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akgul C, 2000, FEBS LETT, V478, P72, DOI 10.1016/S0014-5793(00)01809-3; Basu A, 1998, INT J ONCOL, V13, P659; Basu A, 2000, INT J ONCOL, V16, P497; Bingle CD, 2000, J BIOL CHEM, V275, P22136, DOI 10.1074/jbc.M909572199; Blagosklonny MV, 2001, LEUKEMIA, V15, P869, DOI 10.1038/sj.leu.2402134; Blagosklonny MV, 1997, CANCER RES, V57, P130; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; Chen MC, 2000, BIOCHEM BIOPH RES CO, V279, P725, DOI 10.1006/bbrc.2000.3977; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Craig RW, 2002, LEUKEMIA, V16, P444, DOI 10.1038/sj.leu.2402416; Cuconati A, 2003, GENE DEV, V17, P2922, DOI 10.1101/gad.1156903; Deng XM, 2000, P NATL ACAD SCI USA, V97, P1578, DOI 10.1073/pnas.97.4.1578; Deng XM, 2004, P NATL ACAD SCI USA, V101, P153, DOI 10.1073/pnas.2533920100; Deng XM, 2001, J BIOL CHEM, V276, P23681, DOI 10.1074/jbc.M100279200; Dimmeler S, 1999, J EXP MED, V189, P1815, DOI 10.1084/jem.189.11.1815; Domina AM, 2000, J BIOL CHEM, V275, P21688, DOI 10.1074/jbc.M000915200; Du LH, 2004, J BIOL CHEM, V279, P11957, DOI 10.1074/jbc.M304935200; Fan MY, 2000, J BIOL CHEM, V275, P29980, DOI 10.1074/jbc.M003776200; Furukawa Y, 2000, J BIOL CHEM, V275, P21661, DOI 10.1074/jbc.M906893199; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Gregory MA, 2003, J BIOL CHEM, V278, P51606, DOI 10.1074/jbc.M310722200; Haldar S, 1998, CANCER RES, V58, P1609; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Inoshita S, 2002, J BIOL CHEM, V277, P43730, DOI 10.1074/jbc.M207951200; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Li XQ, 1998, J BIOL CHEM, V273, P34970, DOI 10.1074/jbc.273.52.34970; Luciano F, 2003, ONCOGENE, V22, P6785, DOI 10.1038/sj.onc.1206792; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; Matsuoka K, 2002, EUR J BIOCHEM, V269, P3511, DOI 10.1046/j.1432-1033.2002.03033.x; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; MAY WS, 1994, J BIOL CHEM, V269, P26865; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Rechsteiner M, 1990, Semin Cell Biol, V1, P433; Reynolds JE, 1996, EXP CELL RES, V225, P430, DOI 10.1006/excr.1996.0194; REYNOLDS JE, 1994, CANCER RES, V54, P6348; RIVIERE LR, 1996, CURRENT PROTOCOLS PR, V2; Ruvolo PP, 2001, LEUKEMIA, V15, P515, DOI 10.1038/sj.leu.2402090; Scatena CD, 1998, J BIOL CHEM, V273, P30777, DOI 10.1074/jbc.273.46.30777; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; STEINMANN KE, 1991, P NATL ACAD SCI USA, V88, P6843, DOI 10.1073/pnas.88.15.6843; Thomas A, 2000, ONCOGENE, V19, P5259, DOI 10.1038/sj.onc.1203895; Townsend KJ, 1998, ONCOGENE, V17, P1223, DOI 10.1038/sj.onc.1202035; Townsend KJ, 1999, J BIOL CHEM, V274, P1801, DOI 10.1074/jbc.274.3.1801; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Vantieghem A, 2002, J BIOL CHEM, V277, P37718, DOI 10.1074/jbc.M204348200; Vrana JA, 2002, CANCER RES, V62, P892; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yang T, 1996, J CELL PHYSIOL, V166, P523, DOI 10.1002/(SICI)1097-4652(199603)166:3<523::AID-JCP7>3.0.CO;2-R; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; Zhou P, 2001, BLOOD, V97, P3902, DOI 10.1182/blood.V97.12.3902; Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630; Zhou P, 1998, BLOOD, V92, P3226, DOI 10.1182/blood.V92.9.3226.421k49_3226_3239	62	244	250	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2004	23	31					5301	5315		10.1038/sj.onc.1207692	http://dx.doi.org/10.1038/sj.onc.1207692			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15241487				2022-12-17	WOS:000222491600006
J	Goruppi, S; Ruaro, E; Schneider, C				Goruppi, S; Ruaro, E; Schneider, C			Gas6, the ligand of Axl tyrosine kinase receptor, has mitogenic and survival activities for serum starved NIH3T3 fibroblasts	ONCOGENE			English	Article						gas6; axl; growth arrest; growth factors	ARREST-SPECIFIC GENE; GROWTH ARREST; PROTEIN-S; SIGNAL-TRANSDUCTION; CELL-DEATH; MURINE FIBROBLASTS; BLOOD-COAGULATION; SYSTEM; PURIFICATION; EXPRESSION	Reversible growth arrest has been characterised for enhanced expression of a set of genes called gas (growth arrest specific). gas6 product (Gas6) is a secreted protein that was identified as the ligand for the tyrosine kinase receptor Axl. Here we report that Gas6 is able to induce cell cycle division entry in serum starved NIH3T3 cells. This mitogenic activity of Gas6 strictly correlates with its ability to interact with NIH3T3 endogenous Axl receptor since it can be abolished by soluble Axl extracellular domain and activates both Axl intrinsic kinase activity and the downstream MAPK pathway. Moreover when ectopic Axl overexpression is performed by microinjection in serum starved NIH3T3 cells, addition of a non mitogenic level of Gas6 induces selective entry into S phase in Axl overexpressing cells. Interestingly, Axl overexpression per se is not able to induce S phase entry. Finally we present evidences indicating that Gas6 is able to protect serum starved NIH3T3 cells from cell death by apoptosis as induced by complete growth factor depletion. The reported survival activity seems to be independent of Gas6 mitogenic activity, thus implicating a double and separable activity for Gas6 during growth arrest.	LAB NAZL CONSORZIO INTERUNIV BIOTECNOL, I-34012 TRIESTE, ITALY; INT CTR GENET ENGN & BIOTECHNOL, I-34012 TRIESTE, ITALY	International Center for Genetic Engineering & Biotechnology (ICGEB)								AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BARLAT I, 1993, CELL GROWTH DIFFER, V4, P105; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; BELLOSTA P, 1995, MOL CELL BIOL, V15, P614; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRANCOLINI C, 1992, J CELL BIOL, V117, P1251, DOI 10.1083/jcb.117.6.1251; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRAVEN RJ, 1995, INT J CANCER, V60, P791, DOI 10.1002/ijc.2910600611; DAHLBACK B, 1983, BIOCHEM J, V209, P837, DOI 10.1042/bj2090837; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; DELSAL G, 1994, BIOTECHNIQUES, V16, P134; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FAUST M, 1992, ONCOGENE, V7, P1287; FUJIMOTO J, 1994, ONCOGENE, V9, P693; GASIC GP, 1992, P NATL ACAD SCI USA, V89, P2317, DOI 10.1073/pnas.89.6.2317; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; GODOWSKI PJ, 1995, CELL, V82, P355, DOI 10.1016/0092-8674(95)90424-7; GORUPPI S, 1994, ONCOGENE, V9, P1537; GRAHAM DK, 1994, CELL GROWTH DIFFER, V5, P647; GRAHAM DK, 1995, ONCOGENE, V10, P2349; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; JIA R, 1994, J BIOL CHEM, V269, P1839; KERR JFR, 1971, J PATHOL, V105, P13, DOI 10.1002/path.1711050103; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LIN YZJ, 1991, ONCOGENE, V6, P639; LUNDWALL A, 1986, P NATL ACAD SCI USA, V83, P6716, DOI 10.1073/pnas.83.18.6716; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; MARK MR, 1994, J BIOL CHEM, V269, P10720; MOUREY RJ, 1994, CURR OPIN GENET DEV, V4, P31, DOI 10.1016/0959-437X(94)90088-4; NEUBAUER A, 1994, BLOOD, V84, P1931; OBRYAN JP, 1995, J BIOL CHEM, V270, P551, DOI 10.1074/jbc.270.2.551; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OHASHI K, 1994, ONCOGENE, V9, P699; PELICCI G, 1995, ONCOGENE, V10, P1631; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RESCIGNO J, 1991, ONCOGENE, V6, P1909; Sambrook J., 1989, MOL CLONING LAB MANU; SCHER CD, 1982, J CELL PHYSIOL, V113, P211, DOI 10.1002/jcp.1041130205; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; TAMM I, 1991, P NATL ACAD SCI USA, V88, P3372, DOI 10.1073/pnas.88.8.3372; TAMM I, 1990, J CELL PHYSIOL, V143, P494, DOI 10.1002/jcp.1041430314; TAMM I, 1991, J CELL PHYSIOL, V148, P85, DOI 10.1002/jcp.1041480111; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251	59	244	253	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	1996	12	3					471	480						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637702				2022-12-17	WOS:A1996TV59700002
J	YAMANE, A; SEETHARAM, L; YAMAGUCHI, S; GOTOH, N; TAKAHASHI, T; NEUFELD, G; SHIBUYA, M				YAMANE, A; SEETHARAM, L; YAMAGUCHI, S; GOTOH, N; TAKAHASHI, T; NEUFELD, G; SHIBUYA, M			A NEW COMMUNICATION-SYSTEM BETWEEN HEPATOCYTES AND SINUSOIDAL ENDOTHELIAL-CELLS IN LIVER THROUGH VASCULAR ENDOTHELIAL GROWTH-FACTOR AND FLT TYROSINE KINASE RECEPTOR FAMILY (FLT-1 AND KDR/FLK-1)	ONCOGENE			English	Article							C-MET PROTOONCOGENE; MOLECULAR-CLONING; RAT-TISSUES; EXPRESSION; BINDING; GENE; IDENTIFICATION; PURIFICATION; SEQUENCE; MITOGEN	Hepatocyte Growth Factor (HGF)/Scatter Factor secreted from sinusoidal endothelial cells and Kupffer cells in liver activates the c-Met tyrosine kinase receptor expressed on hepatocytes. Here we report yet another possible communication system through a different ligand and tyrosine kinase receptor in an opposite direction. We isolated and determined the primary structure of the entire coding region of rat flt-1 (fms-like tyrosine kinase), a receptor for Vascular Endothelial Growth Factor (VEGF). Using rat flt-1 cDNA as a probe we found that the flt-1 mRNA was expressed at very high levels in sinusoidal endothelial cells in normal rat liver, but was hardly detectable in hepatocytes. The transcripts of another VEGF receptor KDR/Flk-1 structurally related to Flt-1 was also expressed specifically in sinusoidal endothelial cells. On the other hand, VEGF mRNA was expressed weakly in hepatocytes, but not in the nonparenchymal cell fraction. Furthermore, in an in vitro culture system, VEGF demonstrated a remarkably specific growth-stimulatory activity as well as maintenance activity on the sinusoidal endothelial cells. These results suggest that hepatocytes regulate the proliferation and survival of the sinusoidal endothelial cells in liver in a paracrine manner. Therefore two reciprocal communication systems, VEGF-Flt receptor family and HGF-Met receptor, may exist in hepatic tissue.	UNIV TOKYO, INST MED SCI, DEPT GENET, MINATO KU, TOKYO 108, JAPAN; TECHNION ISRAEL INST TECHNOL, DEPT BIOL, IL-32000 HAIFA, ISRAEL	University of Tokyo; Technion Israel Institute of Technology			GOTOH, Noriko/D-8430-2015; Neufeld, Gera/F-1524-2019					APRELIKOVA O, 1992, CANCER RES, V52, P746; ASAMI O, 1991, J BIOCHEM-TOKYO, V109, P8; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Cohen T, 1992, GROWTH FACTORS, V7, P131, DOI 10.3109/08977199209046402; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; ECIHMANN A, 1993, MECH DEVELOP, V42, P33; ESCH F, 1985, P NATL ACAD SCI USA, V82, P6507, DOI 10.1073/pnas.82.19.6507; ESCOBEDO JA, 1988, NATURE, V335, P85, DOI 10.1038/335085a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FINNERTY H, 1993, ONCOGENE, V8, P2293; GALLAND F, 1993, ONCOGENE, V8, P1233; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; HIGUCHI O, 1992, FEBS LETT, V301, P282, DOI 10.1016/0014-5793(92)80257-H; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; KAIPAINEN A, 1993, J EXP MED, V178, P2077, DOI 10.1084/jem.178.6.2077; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NOJI S, 1990, BIOCHEM BIOPH RES CO, V173, P42, DOI 10.1016/S0006-291X(05)81018-6; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; RAMADORI G, 1992, BIOCHEM BIOPH RES CO, V183, P739, DOI 10.1016/0006-291X(92)90545-V; SARZANI R, 1992, BIOCHEM BIOPH RES CO, V186, P706, DOI 10.1016/0006-291X(92)90804-T; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHIMAOKA S, 1987, EXP CELL RES, V172, P228, DOI 10.1016/0014-4827(87)90109-1; TANAKA K, 1978, J BIOCHEM-TOKYO, V84, P937, DOI 10.1093/oxfordjournals.jbchem.a132207; TASHIRO K, 1990, P NATL ACAD SCI USA, V87, P3200, DOI 10.1073/pnas.87.8.3200; TERMAN BI, 1991, ONCOGENE, V6, P1677; THOMAS KA, 1985, P NATL ACAD SCI USA, V82, P6409, DOI 10.1073/pnas.82.19.6409; YASMAGUCHI TP, 1993, DEVELOPMENT, V118, P489	41	244	256	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1994	9	9					2683	2690						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058332				2022-12-17	WOS:A1994PC05400029
J	Yang, L; Xie, G; Fan, Q; Xie, J				Yang, L.; Xie, G.; Fan, Q.; Xie, J.			Activation of the hedgehog-signaling pathway in human cancer and the clinical implications	ONCOGENE			English	Review						hedgehog; smoothened; cancer; signal transduction; clinical trials and animal model	BASAL-CELL CARCINOMAS; SMALL-MOLECULE INHIBITOR; GLI-MEDIATED TRANSCRIPTION; SONIC-HEDGEHOG; STEM-CELLS; INTRAFLAGELLAR TRANSPORT; COMBINATION THERAPY; POLARIZING ACTIVITY; KRUPPEL FAMILY; PRIMARY CILIA	The hedgehog pathway, initially discovered by two Nobel laureates Drs E Wieschaus and C Nusslein-Volhard in Drosophila, is a major regulator for cell differentiation, tissue polarity and cell proliferation. Studies from many laboratories reveal activation of this pathway in a variety of human cancer, including basal cell carcinomas (BCCs), medulloblastomas, leukemia, gastrointestinal, lung, ovarian, breast and prostate cancers. It is thus believed that targeted inhibition of hedgehog signaling may be effective in treatment and prevention of human cancer. Even more exciting is the discovery and synthesis of specific signaling antagonists for the hedgehog pathway, which have significant clinical implications in novel cancer therapeutics. In this review, we will summarize major advances in the last 2 years in our understanding of hedgehog signaling activation in human cancer, interactions between hedgehog signaling and other pathways in carcinogenesis, potential antagonists for hedgehog signaling inhibition and their clinical implications for human cancer treatment. Oncogene (2010) 29, 469-481; doi:10.1038/onc.2009.392; published online 23 November 2009	[Xie, J.] Indiana Univ, Dept Pediat, Div Hematol & Oncol, Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; Indiana Univ, IU Simon Canc Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Xie, J (corresponding author), Indiana Univ, Dept Pediat, Div Hematol & Oncol, Wells Ctr Pediat Res, 980 W Walnut St,R3-520, Indianapolis, IN 46202 USA.	jinxie@iupui.edu	Liu, Bingya/GMW-5655-2022; Xie, J/AAR-7259-2020	Xie, Guorui/0000-0002-2414-1241	National Cancer Institute [CA94160]; Wells Center for Pediatric Research; NATIONAL CANCER INSTITUTE [R01CA094160] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Wells Center for Pediatric Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Current research in my laboratory is supported by grants from the National Cancer Institute CA94160 and Wells Center for Pediatric Research.	Abe Y, 2008, P NATL ACAD SCI USA, V105, P4838, DOI 10.1073/pnas.0712216105; Baena-Lopez LA, 2008, P NATL ACAD SCI USA, V105, P9645, DOI 10.1073/pnas.0803747105; Allen BL, 2007, GENE DEV, V21, P1244, DOI 10.1101/gad.1543607; Amano K, 2008, J BIOL CHEM, V283, P29513, DOI 10.1074/jbc.M803681200; Arai MA, 2008, BIOORGAN MED CHEM, V16, P9420, DOI 10.1016/j.bmc.2008.09.053; Aszterbaum M, 1999, J INVEST DERM SYMP P, V4, P41, DOI 10.1038/sj.jidsp.5640179; Aszterbaum M, 1999, NAT MED, V5, P1285, DOI 10.1038/15242; Athar M, 2004, CANCER RES, V64, P7545, DOI 10.1158/0008-5472.CAN-04-1393; Bailey JM, 2009, ONCOGENE, V28, P3513, DOI 10.1038/onc.2009.220; Bale AE, 2002, ANNU REV GENOM HUM G, V3, P47, DOI 10.1146/annurev.genom.3.022502.103031; Barnfield PC, 2005, DIFFERENTIATION, V73, P397, DOI 10.1111/j.1432-0436.2005.00042.x; Beauchamp E, 2009, J BIOL CHEM, V284, P9074, DOI 10.1074/jbc.M806233200; Beckett K, 2008, TRENDS CELL BIOL, V18, P360, DOI 10.1016/j.tcb.2008.06.001; Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Bhattacharya R, 2008, CLIN CANCER RES, V14, P7659, DOI 10.1158/1078-0432.CCR-08-1414; Bijlsma MF, 2006, PLOS BIOL, V4, P1397, DOI 10.1371/journal.pbio.0040232; Bitgood MJ, 1996, CURR BIOL, V6, P298, DOI 10.1016/S0960-9822(02)00480-3; Borzillo GV, 2005, CURR TOP MED CHEM, V5, P147, DOI 10.2174/1568026053507732; Brellier F, 2008, ONCOGENE, V27, P6601, DOI 10.1038/onc.2008.260; Buglino JA, 2008, J BIOL CHEM, V283, P22076, DOI 10.1074/jbc.M803901200; Cai QS, 2009, J BIOL CHEM, V284, P2150, DOI 10.1074/jbc.M803235200; Capurro MI, 2008, DEV CELL, V14, P700, DOI 10.1016/j.devcel.2008.03.006; CHANG DT, 1994, DEVELOPMENT, V120, P3339; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Chen JK, 2002, P NATL ACAD SCI USA, V99, P14071, DOI 10.1073/pnas.182542899; Chen MH, 2005, MOL CELL BIOL, V25, P7042, DOI 10.1128/MCB.25.16.7042-7053.2005; Chen MH, 2009, GENE DEV, V23, P1910, DOI 10.1101/gad.1794109; Cheng SY, 2002, P NATL ACAD SCI USA, V99, P5442, DOI 10.1073/pnas.082096999; Cheung HOL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000405; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Chuang PT, 1999, NATURE, V397, P617, DOI 10.1038/17611; Cooper MK, 1998, SCIENCE, V280, P1603, DOI 10.1126/science.280.5369.1603; Corbit KC, 2005, NATURE, V437, P1018, DOI 10.1038/nature04117; Corcoran RB, 2008, CANCER RES, V68, P8788, DOI 10.1158/0008-5472.CAN-08-2135; Cortellino S, 2009, DEV BIOL, V325, P225, DOI 10.1016/j.ydbio.2008.10.020; Couve-Privat S, 2002, CANCER RES, V62, P7186; Cummings DE, 1996, NATURE, V382, P622, DOI 10.1038/382622a0; di Magliano MP, 2006, GENE DEV, V20, P3161, DOI 10.1101/gad.1470806; di Magliano MP, 2003, NAT REV CANCER, V3, P903, DOI 10.1038/nrc1229; Di Marcotullio L, 2006, NAT CELL BIOL, V8, P1415, DOI 10.1038/ncb1510; Dierker T, 2009, J BIOL CHEM, V284, P8013, DOI 10.1074/jbc.M806838200; Dierks C, 2008, CANCER CELL, V14, P238, DOI 10.1016/j.ccr.2008.08.003; Dierks C, 2007, NAT MED, V13, P944, DOI 10.1038/nm1614; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; Eggenschwiler JT, 2001, NATURE, V412, P194, DOI 10.1038/35084089; Ehtesham M, 2007, ONCOGENE, V26, P5752, DOI 10.1038/sj.onc.1210359; Endoh-Yamagami S, 2009, CURR BIOL, V19, P1320, DOI 10.1016/j.cub.2009.06.046; Epstein E, 2001, MED PEDIATR ONCOL, V36, P555, DOI 10.1002/mpo.1129; Epstein EH, 2008, NAT REV CANCER, V8, P743, DOI 10.1038/nrc2503; Evangelista M, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1162925; Fan L, 2004, ENDOCRINOLOGY, V145, P3961, DOI 10.1210/en.2004-0079; Feldmann G, 2008, MOL CANCER THER, V7, P2725, DOI 10.1158/1535-7163.MCT-08-0573; Feldmann G, 2007, CANCER RES, V67, P2187, DOI 10.1158/0008-5472.CAN-06-3281; Fiaschi M, 2009, CANCER RES, V69, P4810, DOI 10.1158/0008-5472.CAN-08-3938; Frank-Kamenetsky Maria, 2002, J Biol, V1, P10, DOI 10.1186/1475-4924-1-10; Gao J, 2009, CELL STEM CELL, V4, P548, DOI 10.1016/j.stem.2009.03.015; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Guardavaccaro D, 2003, DEV CELL, V4, P799, DOI 10.1016/S1534-5807(03)00154-0; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; Han YG, 2009, NAT MED, V15, P1062, DOI 10.1038/nm.2020; Hatton BA, 2008, CANCER RES, V68, P1768, DOI 10.1158/0008-5472.CAN-07-5092; Haycraft CJ, 2005, PLOS GENET, V1, P480, DOI 10.1371/journal.pgen.0010053; He J, 2006, J BIOL CHEM, V281, P35598, DOI 10.1074/jbc.C600200200; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Hofmann I, 2009, CELL STEM CELL, V4, P559, DOI 10.1016/j.stem.2009.03.016; Hoover AN, 2008, DEVELOPMENT, V135, P4049, DOI 10.1242/dev.029835; Hosoya T, 2008, CHEMBIOCHEM, V9, P1082, DOI 10.1002/cbic.200700511; Hu D, 1999, DEVELOPMENT, V126, P4873; Huang SH, 2006, CARCINOGENESIS, V27, P1334, DOI 10.1093/carcin/bgi378; Huangfu D, 2005, P NATL ACAD SCI USA, V102, P11325, DOI 10.1073/pnas.0505328102; Huangfu D, 2006, DEVELOPMENT, V133, P3, DOI 10.1242/dev.02169; Huangfu DW, 2003, NATURE, V426, P83, DOI 10.1038/nature02061; Huntzicker EG, 2006, GENE DEV, V20, P276, DOI 10.1101/gad.1380906; Hyman JM, 2009, P NATL ACAD SCI USA, V106, P14132, DOI 10.1073/pnas.0907134106; Ingham PW, 2006, NAT REV GENET, V7, P841, DOI 10.1038/nrg1969; Ji ZY, 2007, J BIOL CHEM, V282, P14048, DOI 10.1074/jbc.M611089200; Jia JH, 2004, NATURE, V432, P1045, DOI 10.1038/nature03179; Jia JP, 2009, DEV BIOL, V330, P452, DOI 10.1016/j.ydbio.2009.04.009; Jiang J, 2006, CELL CYCLE, V5, P2457, DOI 10.4161/cc.5.21.3406; Jiang J, 2008, DEV CELL, V15, P801, DOI 10.1016/j.devcel.2008.11.010; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962; Kasai K, 2008, CANCER RES, V68, P7723, DOI 10.1158/0008-5472.CAN-07-6661; Kasper M, 2006, MOL CELL BIOL, V26, P6283, DOI 10.1128/MCB.02317-05; Kasper M, 2009, CARCINOGENESIS, V30, P903, DOI 10.1093/carcin/bgp048; Kasperczyk H, 2009, FASEB J, V23, P21, DOI 10.1096/fj.08-111096; Kawakami T, 2002, DEVELOPMENT, V129, P5753, DOI 10.1242/dev.00178; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; Kise Y, 2009, BIOCHEM BIOPH RES CO, V387, P569, DOI 10.1016/j.bbrc.2009.07.087; Koga K, 2008, ANTICANCER RES, V28, P731; Kogerman P, 1999, NAT CELL BIOL, V1, P312, DOI 10.1038/13031; Kovacs JJ, 2008, SCIENCE, V320, P1777, DOI 10.1126/science.1157983; Koziel L, 2004, DEV CELL, V6, P801, DOI 10.1016/j.devcel.2004.05.009; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; Kubo M, 2004, CANCER RES, V64, P6071, DOI 10.1158/0008-5472.CAN-04-0416; Lam CW, 1999, ONCOGENE, V18, P833, DOI 10.1038/sj.onc.1202360; Laner-Plamberger S, 2009, ONCOGENE, V28, P1639, DOI 10.1038/onc.2009.10; Lauth M, 2007, P NATL ACAD SCI USA, V104, P8455, DOI 10.1073/pnas.0609699104; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; Lee Y, 2007, ONCOGENE, V26, P6442, DOI 10.1038/sj.onc.1210467; Liao XY, 2009, CARCINOGENESIS, V30, P131, DOI 10.1093/carcin/bgn230; Lindemann RK, 2008, CANCER RES, V68, P961, DOI 10.1158/0008-5472.CAN-07-5500; Lum L, 2003, SCIENCE, V299, P2039, DOI 10.1126/science.1081403; Ma XL, 2006, INT J CANCER, V118, P139, DOI 10.1002/ijc.21295; Ma XL, 2005, CARCINOGENESIS, V26, P1698, DOI 10.1093/carcin/bgi130; Martinelli DC, 2007, GENE DEV, V21, P1231, DOI 10.1101/gad.1546307; May SR, 2005, DEV BIOL, V287, P378, DOI 10.1016/j.ydbio.2005.08.050; McLellan JS, 2008, NATURE, V455, P979, DOI 10.1038/nature07358; Merchant M, 2005, MOL CELL BIOL, V25, P7054, DOI 10.1128/MCB.25.16.7054-7068.2005; Mistretta CM, 2003, DEV BIOL, V254, P1, DOI 10.1016/S0012-1606(02)00014-3; Molckovsky A, 2008, J HEMATOL ONCOL, V1, DOI 10.1186/1756-8722-1-20; Molnar C, 2007, P NATL ACAD SCI USA, V104, P7963, DOI 10.1073/pnas.0702374104; Morton JP, 2007, P NATL ACAD SCI USA, V104, P5103, DOI 10.1073/pnas.0701158104; Motoyama J, 1998, NAT GENET, V20, P54, DOI 10.1038/1711; Nieuwenhuis E, 2006, MOL CELL BIOL, V26, P6609, DOI 10.1128/MCB.00295-06; Nolan-Stevaux O, 2009, GENE DEV, V23, P24, DOI 10.1101/gad.1753809; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Ogden SK, 2008, NATURE, V456, P967, DOI 10.1038/nature07459; Okada A, 2006, NATURE, V444, P369, DOI 10.1038/nature05246; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Pan Y, 2006, MOL CELL BIOL, V26, P3365, DOI 10.1128/MCB.26.9.3365-3377.2006; Parathath SR, 2008, DEVELOPMENT, V135, P3291, DOI 10.1242/dev.022871; Park HL, 2000, DEVELOPMENT, V127, P1593; Petersen PH, 2002, NATURE, V419, P929, DOI 10.1038/nature01124; Philipp M, 2008, MOL BIOL CELL, V19, P5478, DOI 10.1091/mbc.E08-05-0448; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Qi M, 1996, P NATL ACAD SCI USA, V93, P1571, DOI 10.1073/pnas.93.4.1571; Read TA, 2009, CANCER CELL, V15, P135, DOI 10.1016/j.ccr.2008.12.016; Reifenberger J, 2005, BRIT J DERMATOL, V152, P43, DOI 10.1111/J.1365-2133.2005.06353.X; Reifenberger J, 1998, CANCER RES, V58, P1798; Reiter JF, 2006, GENE DEV, V20, P22, DOI 10.1101/gad.1363606; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; Riobo NA, 2006, P NATL ACAD SCI USA, V103, P12607, DOI 10.1073/pnas.0600880103; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; Rohatgi R, 2009, P NATL ACAD SCI USA, V106, P3196, DOI 10.1073/pnas.0813373106; Romer JT, 2004, CANCER CELL, V6, P229, DOI 10.1016/j.ccr.2004.08.019; Rubin LL, 2006, NAT REV DRUG DISCOV, V5, P1026, DOI 10.1038/nrd2086; Rudin CM, 2009, NEW ENGL J MED, V361, P1173, DOI 10.1056/NEJMoa0902903; RUPPERT JM, 1988, MOL CELL BIOL, V8, P3104, DOI 10.1128/MCB.8.8.3104; Sanchez P, 2004, P NATL ACAD SCI USA, V101, P12561, DOI 10.1073/pnas.0404956101; Sanchez P, 2005, MECH DEVELOP, V122, P223, DOI 10.1016/j.mod.2004.10.002; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Scales SJ, 2009, TRENDS PHARMACOL SCI, V30, P303, DOI 10.1016/j.tips.2009.03.007; Schnidar H, 2009, CANCER RES, V69, P1284, DOI 10.1158/0008-5472.CAN-08-2331; Scholey JM, 2006, CELL, V125, P439, DOI 10.1016/j.cell.2006.04.013; Seppala M, 2007, J CLIN INVEST, V117, P1575, DOI 10.1172/JCI32032; Shaw G, 2008, CANCER CELL INT, V8, DOI 10.1186/1475-2867-8-3; Sheng T, 2006, J BIOL CHEM, V281, P9, DOI 10.1074/jbc.C500300200; Sheng T, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-29; Sims-Mourtada J, 2006, CLIN CANCER RES, V12, P6565, DOI 10.1158/1078-0432.CCR-06-0176; Singer JD, 1999, GENE DEV, V13, P2375, DOI 10.1101/gad.13.18.2375; So PL, 2008, MOL CANCER THER, V7, P1275, DOI 10.1158/1535-7163.MCT-07-2043; St-Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072; Stanton BZ, 2009, NAT CHEM BIOL, V5, P154, DOI 10.1038/nchembio.142; Stecca B, 2007, P NATL ACAD SCI USA, V104, P5895, DOI 10.1073/pnas.0700776104; Stecca B, 2009, EMBO J, V28, P663, DOI 10.1038/emboj.2009.16; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Svard J, 2006, DEV CELL, V10, P187, DOI 10.1016/j.devcel.2005.12.013; Tenzen T, 2006, DEV CELL, V10, P647, DOI 10.1016/j.devcel.2006.04.004; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Tian H, 2009, P NATL ACAD SCI USA, V106, P4254, DOI 10.1073/pnas.0813203106; Toyoda H, 2000, J BIOL CHEM, V275, P21856, DOI 10.1074/jbc.M003540200; Tremblay MR, 2009, J MED CHEM, V52, P4400, DOI 10.1021/jm900305z; Varjosalo M, 2006, DEV CELL, V10, P177, DOI 10.1016/j.devcel.2005.12.014; Varjosalo M, 2008, CELL, V133, P537, DOI 10.1016/j.cell.2008.02.047; Von Hoff DD, 2009, NEW ENGL J MED, V361, P1164, DOI 10.1056/NEJMoa0905360; Wang BW, 2006, P NATL ACAD SCI USA, V103, P33, DOI 10.1073/pnas.0509927103; Wang Y, 2009, P NATL ACAD SCI USA, V106, P2623, DOI 10.1073/pnas.0812110106; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Williams JA, 2003, P NATL ACAD SCI USA, V100, P4616, DOI 10.1073/pnas.0732813100; Wilson CW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005182; Wilson CW, 2009, NATURE, V459, P98, DOI 10.1038/nature07883; Wong SY, 2009, NAT MED, V15, P1055, DOI 10.1038/nm.2011; XIE J, 2009, SYSTEM TBOROTUOT, P1; Xie JW, 2008, ACTA BIOCH BIOPH SIN, V40, P670, DOI 10.1111/j.1745-7270.2008.00431.x; Xie JW, 2008, CURR ONCOL REP, V10, P107, DOI 10.1007/s11912-008-0018-7; Xie J, 2008, ADV EXP MED BIOL, V624, P241, DOI 10.1007/978-0-387-77574-6_19; Xie Jingwu, 2005, Future Oncol, V1, P331, DOI 10.1517/14796694.1.3.331; Xie JW, 2001, P NATL ACAD SCI USA, V98, P9255, DOI 10.1073/pnas.151173398; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Yanai K, 2008, CANCER LETT, V263, P145, DOI 10.1016/j.canlet.2007.12.030; Yang SH, 2008, NAT GENET, V40, P1130, DOI 10.1038/ng.192; Yao SQ, 2006, CELL, V125, P343, DOI 10.1016/j.cell.2006.02.040; YAUCH RL, 2009, SCIENCE; Yauch RL, 2008, NATURE, V455, P406, DOI 10.1038/nature07275; Yoshikawa R, 2008, BRIT J CANCER, V98, P1670, DOI 10.1038/sj.bjc.6604361; Yue S, 2009, ONCOGENE, V28, P492, DOI 10.1038/onc.2008.403; Zhang C, 2004, P NATL ACAD SCI USA, V101, P17900, DOI 10.1073/pnas.0408093101; Zhang QH, 2005, LAB INVEST, V85, P45, DOI 10.1038/labinvest.3700207; Zhang W, 2006, DEV CELL, V10, P657, DOI 10.1016/j.devcel.2006.04.005; Zhang XM, 2001, CELL, V105, P781, DOI 10.1016/S0092-8674(01)00385-3; Zhang YM, 2009, NEOPLASIA, V11, P96, DOI 10.1593/neo.81264; Zhao C, 2009, NATURE, V458, P776, DOI 10.1038/nature07737; Zhao Y, 2007, NATURE, V450, P252, DOI 10.1038/nature06225; Zwerner JP, 2008, ONCOGENE, V27, P3282, DOI 10.1038/sj.onc.1210991	201	243	264	0	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2010	29	4					469	481		10.1038/onc.2009.392	http://dx.doi.org/10.1038/onc.2009.392			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	549WH	19935712				2022-12-17	WOS:000274084600001
J	Tagawa, H; Karnan, S; Suzuki, R; Matsuo, K; Zhang, XH; Ota, A; Morishima, Y; Nakamura, S; Seto, M				Tagawa, H; Karnan, S; Suzuki, R; Matsuo, K; Zhang, XH; Ota, A; Morishima, Y; Nakamura, S; Seto, M			Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM	ONCOGENE			English	Article						mantle cell lymphoma; array CGH; BIM; 2q 13; chromosome alteration	IN-SITU HYBRIDIZATION; TUMOR-SUPPRESSOR GENE; FAMILY-MEMBER BIM; BCL-2 FAMILY; AGGRESSIVE VARIANTS; CHROMOSOME 17P13.3; TISSUE-TYPE; ATM GENE; APOPTOSIS; OVEREXPRESSION	Mantle cell lymphoma (MCL) is characterized by 11q13 chromosomal translocation and CCND1 overexpression, but additional genomic changes are also important for lymphomagenesis. To identify the genomic aberrations of MCL at higher resolutions, we analysed 29 patient samples and seven cell lines using array-based comparative genomic hybridization (array CGH) consisting of 2348 artificial chromosome clones, which cover the whole genome at a 1.3 mega base resolution. The incidence of identified genomic aberrations was generally higher than that determined with chromosomal CGH. The most frequent imbalances detected by array CGH were gains of chromosomes 3q26 (48%), 7p21 (34%), 6p25 (24%), 8q24 (24 %), 10p12 (21 %) and 17q23 (17 %), and losses of chromosomes 2p11 (83%), 11q22 (59%), 13q21 (55%), 1p21-p22 (52%), 13q34 (52%), 9q22 (45%), 17p13 (45%), 9p21 (41%), 9p24 (41%), 6q23-q24 (38%), 1p36 (31%), 8p23 (34%), 10p14 (31%), 19p13 (28%), 5q21 (21%), 22q12 (21%), 1q42 (17%) and 2q13 (17%). Our analyses also detected several novel recurrent regions of loss located at 1p36, 1q42.2-q43, 2p11.2, 2q13, 17p13.3 and 19p13.2-p13.3, as well as recurrent regions of homozygous loss such as 2p11 (IgK), 2q13 and 9p21.3-p24.1 (INK4a/ARF). Of the latter, we investigated the 2q13 loss, which led to identification of homozygous deletions of the proapoptotic gene BIM. The high-resolution array CGH technology allowed for the precise identification of genomic aberrations and identification of BIM as a novel candidate tumor suppressor gene in MCL.	Aichi Canc Ctr, Res Inst, Div Mol Med, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr, Res Inst, Div Epidemiol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr Hosp, Dept Hematol & Chemotherapy, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr Hosp, Dept Pathol & Mol Diagnost, Nagoya, Aichi 4648681, Japan; Yan An Univ, Sch Med, Dept Pathol, Yan An 716000, Peoples R China; Immunol Biol Labs Co Ltd, Gunma 3750005, Japan	Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; Yanan University	Seto, M (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Med, Chikusa Ku, 1-1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	mseto@aichi-cc.jp	Matsuo, Keitaro/H-6758-2019; Ota, Akinobu/AAI-9396-2020; Nakamura, Shigeo/I-1571-2012; Ota, Akinobu/CAC-5999-2022; Ota, Akinobu/H-4510-2019	Matsuo, Keitaro/0000-0003-1761-6314; Ota, Akinobu/0000-0002-6296-2921; Suzuki, Ritsuro/0000-0002-5974-7614				Allen JE, 2002, BRIT J HAEMATOL, V116, P291, DOI 10.1046/j.1365-2141.2002.03260.x; Amin HM, 2003, ARCH PATHOL LAB MED, V127, P424; Bea S, 1999, BLOOD, V93, P4365; Bea S, 2001, CANCER RES, V61, P2409; Bentz M, 2000, GENE CHROMOSOME CANC, V27, P285, DOI 10.1002/(SICI)1098-2264(200003)27:3<285::AID-GCC9>3.0.CO;2-M; Bigoni R, 2001, LEUKEMIA LYMPHOMA, V40, P581, DOI 10.3109/10428190109097656; Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; COGEN PH, 1992, AM J HUM GENET, V50, P584; Cuneo A, 1999, BLOOD, V93, P1372, DOI 10.1182/blood.V93.4.1372.404k21_1372_1380; Dreyling MH, 1997, CANCER RES, V57, P4608; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Enders A, 2003, J EXP MED, V198, P1119, DOI 10.1084/jem.20030411; FUJIMORI M, 1991, CANCER RES, V51, P89; Greiner TC, 1996, BLOOD, V87, P4302, DOI 10.1182/blood.V87.10.4302.bloodjournal87104302; Hernandez L, 1996, BLOOD, V87, P3351, DOI 10.1182/blood.V87.8.3351.bloodjournal8783351; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; Hofmann WK, 2001, BLOOD, V98, P787, DOI 10.1182/blood.V98.3.787; JAFFE E, 2001, WORLD HLTH CLASSIFIC; Jeon HJ, 1998, BRIT J HAEMATOL, V102, P1323, DOI 10.1046/j.1365-2141.1998.00911.x; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kohlhammer H, 2004, BLOOD, V104, P795, DOI 10.1182/blood-2003-12-4175; Konishi H, 2002, CANCER RES, V62, P271; Liu JW, 2002, CANCER RES, V62, P2976; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; Martinez N, 2003, CANCER RES, V63, P8226; Martinez-Climent JA, 2001, BLOOD, V98, P3479, DOI 10.1182/blood.V98.12.3479; Miyashita MUT, 2001, FEBS LETT, V509, P135, DOI 10.1016/S0014-5793(01)03145-3; Monni O, 1998, GENE CHROMOSOME CANC, V21, P298, DOI 10.1002/(SICI)1098-2264(199804)21:4<298::AID-GCC3>3.0.CO;2-U; Motegi M, 2000, AM J PATHOL, V156, P807, DOI 10.1016/S0002-9440(10)64948-6; NACHEVA E, 1993, BLOOD, V82, P231, DOI 10.1182/blood.V82.1.231.bloodjournal821231; Nomura K, 2003, CANCER GENET CYTOGEN, V140, P49, DOI 10.1016/S0165-4608(02)00632-5; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Ota A, 2004, CANCER RES, V64, P3087, DOI 10.1158/0008-5472.CAN-03-3773; Phillips NJ, 1996, CANCER RES, V56, P606; PINKEL D, 1998, NAT GENET, V23, P41; Pinyol M, 1997, BLOOD, V89, P272, DOI 10.1182/blood.V89.1.272.272_272_280; Rosenwald A, 2003, CANCER CELL, V3, P185, DOI 10.1016/S1535-6108(03)00028-X; SALTMAN DL, 1988, BLOOD, V72, P2026, DOI 10.1182/blood.V72.6.2026.2026; SAXENA A, 1992, CANCER RES, V52, P6716; Schaffner C, 2000, P NATL ACAD SCI USA, V97, P2773, DOI 10.1073/pnas.050400997; Schultz DC, 1996, CANCER RES, V56, P1997; SETO M, 1992, ONCOGENE, V7, P1401; Stilgenbauer S, 1999, BLOOD, V94, P3262, DOI 10.1182/blood.V94.9.3262.421a33_3262_3264; Suzuki R, 1999, LEUKEMIA, V13, P1335, DOI 10.1038/sj.leu.2401485; Zhang XH, 2004, CANCER SCI, V95, P809, DOI 10.1111/j.1349-7006.2004.tb02186.x	45	243	252	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2005	24	8					1348	1358		10.1038/sj.onc.1208300	http://dx.doi.org/10.1038/sj.onc.1208300			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898QZ	15608680				2022-12-17	WOS:000227092600005
J	Ljungman, M; Zhang, FF; Chen, F; Rainbow, AJ; McKay, BC				Ljungman, M; Zhang, FF; Chen, F; Rainbow, AJ; McKay, BC			Inhibition of RNA polymerase II as a trigger for the p53 response	ONCOGENE			English	Article						transcription; p53; p21(WAF1); apoptosis	WILD-TYPE P53; DNA-DAMAGING AGENTS; TRANSCRIPTIONALLY ACTIVE P53; CYCLE CHECKPOINT PATHWAY; SUPPRESSOR PROTEIN P53; CELL-CYCLE; IN-VIVO; TUMOR-SUPPRESSOR; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION	The mechanisms by which the p53 response is triggered following exposure to DNA-damaging agents have not yet been clearly elucidated. We and others have previously suggested that blockage of RNA polymerase II may be the trigger for induction of the p53 response following exposure to ultraviolet light. Here we report on the correlation between inhibition of mRNA synthesis and the induction of p53, p21(WAF1) and apoptosis in diploid human fibroblasts treated with either UV light, cisplatin or the RNA synthesis inhibitors actinomycin D, DRB, H7 and alpha-amanitin. Exposure to ionizing radiation or the proteasome inhibitor LLnL, however, induced p53 and p21(WAF1) without affecting mRNA synthesis. Importantly, induction of p53 by the RNA synthesis or proteasome inhibitors did not correlate with the induction of DNA strand breaks. Furthermore, cisplatin-induced accumulation of active p53 in repair-deficient XP-A cells occurred despite the lack of DNA strand break induction. Our results suggest that the induction of the p53 response by certain toxic agents is not triggered by DNA strand breaks but rather, may be linked to inhibition of mRNA synthesis either directly by the poisoning of RNA polymerase II or indirectly by the induction of elongation-blocking DNA lesions.	Univ Michigan, Ctr Comprehens Canc, Dept Radiat Oncol, Div Canc Biol, Ann Arbor, MI 48109 USA; McMaster Univ, Dept Biol, Hamilton, ON L8S 4K1, Canada	University of Michigan System; University of Michigan; McMaster University	Ljungman, M (corresponding author), Univ Michigan, Ctr Comprehens Canc, Dept Radiat Oncol, Div Canc Biol, Ann Arbor, MI 48109 USA.		McKay, Bruce C/I-4081-2013	McKay, Bruce C/0000-0002-7921-1331				Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; AHNSTROM G, 1981, MEASUREMENT STRAND B, P403; Andera L, 1997, MOL MED, V3, P852, DOI 10.1007/BF03401721; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; CANMAN CE, 1994, CANCER RES, V54, P5054; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; CHODOSH LA, 1989, J BIOL CHEM, V264, P2250; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Chung DH, 1998, RADIAT RES, V149, P187, DOI 10.2307/3579929; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CORDA Y, 1993, BIOCHEMISTRY-US, V32, P8582, DOI 10.1021/bi00084a027; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; Drexler HCA, 1997, P NATL ACAD SCI USA, V94, P855, DOI 10.1073/pnas.94.3.855; DUBOIS MF, 1994, J BIOL CHEM, V269, P13331; Dumaz N, 1997, MOL CARCINOGEN, V20, P340, DOI 10.1002/(SICI)1098-2744(199712)20:4<340::AID-MC3>3.0.CO;2-N; EASTMAN A, 1986, BIOCHEMISTRY-US, V25, P3912, DOI 10.1021/bi00361a026; EGYHAZI E, 1976, NATURE, V262, P319, DOI 10.1038/262319a0; Eller MS, 1997, P NATL ACAD SCI USA, V94, P12627, DOI 10.1073/pnas.94.23.12627; ERIXON K, 1979, MUTAT RES, V59, P257, DOI 10.1016/0027-5107(79)90164-7; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FERGUSON LR, 1994, ENVIRON MOL MUTAGEN, V24, P245, DOI 10.1002/em.2850240402; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; FRITSCHE M, 1993, ONCOGENE, V8, P307; Fu LN, 1996, EMBO J, V15, P4392, DOI 10.1002/j.1460-2075.1996.tb00812.x; GIARDINA C, 1993, J BIOL CHEM, V268, P23806; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Gonen H, 1997, FEBS LETT, V406, P17, DOI 10.1016/S0014-5793(97)00225-1; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Harris CC, 1996, CARCINOGENESIS, V17, P1187, DOI 10.1093/carcin/17.6.1187; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JARVIS WD, 1994, CANCER RES, V54, P1707; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Kastan MB, 1996, BIOESSAYS, V18, P617, DOI 10.1002/bies.950180804; KHANNA KK, 1993, ONCOGENE, V8, P3307; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Koumenis C, 1997, MOL CELL BIOL, V17, P7306, DOI 10.1128/MCB.17.12.7306; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; KUWANO M, 1973, EXP CELL RES, V82, P454, DOI 10.1016/0014-4827(73)90365-0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Liu M, 1998, CANCER RES, V58, P1723; Ljungman M, 1996, BBA-GENE STRUCT EXPR, V1307, P171, DOI 10.1016/0167-4781(96)00037-1; Ljungman M, 1996, ONCOGENE, V13, P823; LJUNGMAN M, 1995, NUCLEIC ACIDS RES, V23, P1782, DOI 10.1093/nar/23.10.1782; Loignon M, 1997, CANCER RES, V57, P3390; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUCHNIK AN, 1988, NUCLEIC ACIDS RES, V16, P5175, DOI 10.1093/nar/16.11.5175; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Maki CG, 1996, CANCER RES, V56, P2649; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MATSUMOTO H, 1994, CANCER LETT, V87, P39, DOI 10.1016/0304-3835(94)90407-3; McKay BC, 1998, ONCOGENE, V17, P545, DOI 10.1038/sj.onc.1201963; McKay BC, 1997, CARCINOGENESIS, V18, P245, DOI 10.1093/carcin/18.2.245; MELLO JA, 1995, BIOCHEMISTRY-US, V34, P14783, DOI 10.1021/bi00045a020; Mukhopadhyay T, 1997, ONCOGENE, V14, P379, DOI 10.1038/sj.onc.1200835; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Nguyen VT, 1996, NUCLEIC ACIDS RES, V24, P2924, DOI 10.1093/nar/24.15.2924; Ohnishi T, 1998, ONCOGENE, V16, P1507, DOI 10.1038/sj.onc.1201663; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; PERRY RP, 1970, J CELL PHYSIOL, V76, P127, DOI 10.1002/jcp.1040760202; Plaumann B, 1996, ONCOGENE, V13, P1605; Poon RYC, 1998, ONCOGENE, V16, P1333, DOI 10.1038/sj.onc.1201897; RODI CP, 1989, J CELL PHYSIOL, V141, P346, DOI 10.1002/jcp.1041410216; SAUERBIER W, 1978, ANNU REV GENET, V12, P329, DOI 10.1146/annurev.ge.12.120178.001553; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SEHGAL PB, 1976, CELL, V9, P473, DOI 10.1016/0092-8674(76)90092-1; SELBY CP, 1990, J BIOL CHEM, V265, P21330; Shinohara K, 1996, BIOCHEM J, V317, P385, DOI 10.1042/bj3170385; SMITH ML, 1995, ONCOGENE, V10, P1053; SOBELL HM, 1985, P NATL ACAD SCI USA, V82, P5328, DOI 10.1073/pnas.82.16.5328; Steegenga WT, 1996, J MOL BIOL, V263, P103, DOI 10.1006/jmbi.1996.0560; TISHLER RB, 1993, CANCER RES, V53, P2212; TISHLER RB, 1995, CANCER RES, V55, P6021; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/s0079-6603(08)60611-x; Wim JM, 1997, MOL CELL BIOL, V17, P5016, DOI 10.1128/MCB.17.9.5016; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; YANKULOV K, 1995, J BIOL CHEM, V270, P23922, DOI 10.1074/jbc.270.41.23922; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZANDOMENI R, 1986, J BIOL CHEM, V261, P3414; Zeng YX, 1996, ONCOGENE, V12, P1557; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805	91	243	243	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	1999	18	3					583	592		10.1038/sj.onc.1202356	http://dx.doi.org/10.1038/sj.onc.1202356			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989808				2022-12-17	WOS:000078394400003
J	Lock, FE; McDonald, PC; Lou, Y; Serrano, I; Chafe, SC; Ostlund, C; Aparicio, S; Winum, JY; Supuran, CT; Dedhar, S				Lock, F. E.; McDonald, P. C.; Lou, Y.; Serrano, I.; Chafe, S. C.; Ostlund, C.; Aparicio, S.; Winum, J-Y; Supuran, C. T.; Dedhar, S.			Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche	ONCOGENE			English	Article						CAIX; cancer stem cell; breast cancer; hypoxia; EMT; mTOR	EPITHELIAL-MESENCHYMAL-TRANSITION; TUMOR-INITIATING CELLS; MAMMALIAN TARGET; METASTASIS; EXPRESSION; IDENTIFICATION; PROLIFERATION; INHIBITORS; RAPAMYCIN; OXYGEN	The sub-population of tumor cells termed 'cancer stem cells' (CSCs) possess the capability to generate tumors, undergo epithelial-mesenchymal transition (EMT) and are implicated in metastasis, making treatments to specifically target CSCs an attractive therapeutic strategy. Tumor hypoxia plays a key role in regulating EMT and cancer stem cell function. Carbonic anhydrase IX (CAIX) is a hypoxia-inducible protein that regulates cellular pH to promote cancer cell survival and invasion in hypoxic microenvironments and is a biomarker of poor prognosis for breast cancer metastasis and survival. Here, we demonstrate that inhibition of CAIX expression or activity with novel small-molecule inhibitors in breast cancer cell lines, or in primary metastatic breast cancer cells, results in the inhibition of breast CSC expansion in hypoxia. We identify the mTORC1 axis as a critical pathway downstream of CAIX in the regulation of cancer stem cell function. CAIX is also required for expression of EMT markers and regulators, as well as drivers of 'stemness', such as Notch1 and Jagged1 in isolated CSCs. In addition, treatment of mice bearing orthotopic breast tumors with CAIX-specific small-molecule inhibitors results in significant depletion of CSCs within these tumors. Furthermore, combination treatment with paclitaxel results in enhanced tumor growth delay and eradication of lung metastases. These data demonstrate that CAIX is a critical mediator of the expansion of breast CSCs in hypoxic niches by sustaining the mesenchymal and 'stemness' phenotypes of these cells, making CAIX an important therapeutic target for selectively depleting breast CSCs.	[Lock, F. E.; McDonald, P. C.; Lou, Y.; Serrano, I.; Chafe, S. C.; Ostlund, C.; Dedhar, S.] BC Canc Res Ctr, Dept Integrat Oncol, Vancouver, BC V5Z 1L3, Canada; [Aparicio, S.] BC Canc Res Ctr, Dept Mol Oncol, Vancouver, BC V5Z 1L3, Canada; [Winum, J-Y] Univ Montpellier 1 & 2, Ecole Natl Super Chim Montpellier, Inst Biomol Max Mousseron, UMR CNRS 5247, Montpellier, France; [Supuran, C. T.] Univ Florence, Dept Lab Chim Bioinorgan, Florence, Italy; [Dedhar, S.] Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V5Z 1M9, Canada	British Columbia Cancer Agency; British Columbia Cancer Agency; Centre National de la Recherche Scientifique (CNRS); Ecole nationale superieure de chimie de Montpellier; Universite de Montpellier; University of Florence; University of British Columbia	Dedhar, S (corresponding author), BC Canc Res Ctr, Dept Integrat Oncol, 675 West 10th Ave, Vancouver, BC V5Z 1L3, Canada.	sdedhar@bccrc.ca	WINUM, Jean-Yves/P-3387-2016; WINUM, Jean-Yves/AAC-9578-2019	WINUM, Jean-Yves/0000-0003-3197-3414; WINUM, Jean-Yves/0000-0003-3197-3414; Aparicio, Samuel/0000-0002-0487-9599; Supuran, Claudiu/0000-0003-4262-0323; Dedhar, Shoukat/0000-0003-4355-1657	Canadian Institutes of Health Research (CIHR)	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR))	This work was supported by a grant from the Canadian Institutes of Health Research (CIHR) to SD.	Abraham BK, 2005, CLIN CANCER RES, V11, P1154; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Balgi AD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021549; Barnes EA, 2010, AM J PATHOL, V177, P1765, DOI 10.2353/ajpath.2010.090233; Bhat-Nakshatri P, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-411; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; Calcagno AM, 2010, JNCI-J NATL CANCER I, V102, P1637, DOI 10.1093/jnci/djq361; Charafe-Jauffret E, 2010, CLIN CANCER RES, V16, P45, DOI 10.1158/1078-0432.CCR-09-1630; Chaudary N, 2007, CLIN CANCER RES, V13, P1947, DOI 10.1158/1078-0432.CCR-06-2971; Creighton CJ, 2010, J MAMMARY GLAND BIOL, V15, P253, DOI 10.1007/s10911-010-9173-1; Croker AK, 2012, BREAST CANCER RES TR, V133, P75, DOI 10.1007/s10549-011-1692-y; Das B, 2008, STEM CELLS, V26, P1818, DOI 10.1634/stemcells.2007-0724; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Grimshaw MJ, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2106; Gulhati P, 2011, CANCER RES, V71, P3246, DOI 10.1158/0008-5472.CAN-10-4058; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Haase VH, 2009, KIDNEY INT, V76, P492, DOI 10.1038/ki.2009.222; Harma V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010431; Hartwell KA, 2006, P NATL ACAD SCI USA, V103, P18969, DOI 10.1073/pnas.0608636103; Horree N, 2007, HUM PATHOL, V38, P1232, DOI 10.1016/j.humpath.2007.01.008; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Hwang-Verslues WW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008377; Joo KM, 2012, CANCER RES, V72, P3828, DOI 10.1158/0008-5472.CAN-11-3760; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Knaup KX, 2009, MOL CANCER RES, V7, P88, DOI 10.1158/1541-7786.MCR-08-0288; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Lefkovits I, 1999, LIMITING DILUTION AN, pxvi; Liao ND, 2011, CANCER CYTOPATHOL, V119, P346, DOI 10.1002/cncy.20153; Liu JC, 2007, CANCER RES, V67, P8671, DOI 10.1158/0008-5472.CAN-07-1486; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lou YM, 2011, CANCER RES, V71, P3364, DOI 10.1158/0008-5472.CAN-10-4261; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marcato P, 2011, STEM CELLS, V29, P32, DOI 10.1002/stem.563; Martinez-Moragon E, 1998, RESPIRATION, V65, P108, DOI 10.1159/000029240; Mohyeldin A, 2010, CELL STEM CELL, V7, P150, DOI 10.1016/j.stem.2010.07.007; O'Brien CA, 2009, SEMIN RADIAT ONCOL, V19, P71, DOI 10.1016/j.semradonc.2008.11.001; Oloumi A, 2000, CANCER RES, V60, P5747; Pacchiano F, 2011, J MED CHEM, V54, P1896, DOI 10.1021/jm101541x; Pannuti A, 2010, CLIN CANCER RES, V16, P3141, DOI 10.1158/1078-0432.CCR-09-2823; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Reuben JM, 2011, EUR J CANCER, V47, P1527, DOI 10.1016/j.ejca.2011.01.011; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rota LM, 2012, J MAMMARY GLAND BIOL, V17, P119, DOI 10.1007/s10911-012-9258-0; Russell RC, 2011, DEVELOPMENT, V138, P3343, DOI 10.1242/dev.058230; Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533; Shorning BY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016209; Singh SK, 2003, CANCER RES, V63, P5821; Smith KM, 2010, EMBO MOL MED, V2, P371, DOI 10.1002/emmm.201000093; Supuran CT, 2008, NAT REV DRUG DISCOV, V7, P168, DOI 10.1038/nrd2467; Svastova E, 2003, EXP CELL RES, V290, P332, DOI 10.1016/S0014-4827(03)00351-3; Swietach P, 2010, ONCOGENE, V29, P6509, DOI 10.1038/onc.2010.455; Touisni N, 2011, J MED CHEM, V54, P8271, DOI 10.1021/jm200983e; Trimboli AJ, 2008, CANCER RES, V68, P937, DOI 10.1158/0008-5472.CAN-07-2148; Turner FE, 2006, J BIOL CHEM, V281, P21321, DOI 10.1074/jbc.M509731200; Vignot S, 2005, ANN ONCOL, V16, P525, DOI 10.1093/annonc/mdi113; Wang XY, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-221; Wright MH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1855; Xing F, 2011, ONCOGENE, V30, P4075, DOI 10.1038/onc.2011.122	60	242	247	4	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 31	2013	32	44					5210	5219		10.1038/onc.2012.550	http://dx.doi.org/10.1038/onc.2012.550			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245XH	23208505				2022-12-17	WOS:000326497100004
J	Zhang, H; Wong, CCL; Wei, H; Gilkes, DM; Korangath, P; Chaturvedi, P; Schito, L; Chen, J; Krishnamachary, B; Winnard, PT; Raman, V; Zhen, L; Mitzner, WA; Sukumar, S; Semenza, GL				Zhang, H.; Wong, C. C. L.; Wei, H.; Gilkes, D. M.; Korangath, P.; Chaturvedi, P.; Schito, L.; Chen, J.; Krishnamachary, B.; Winnard, P. T., Jr.; Raman, V.; Zhen, L.; Mitzner, W. A.; Sukumar, S.; Semenza, G. L.			HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs	ONCOGENE			English	Article						breast cancer; metastasis; hypoxia	INDUCIBLE FACTOR-I; LYSYL OXIDASE; FACTOR-1-ALPHA; OVEREXPRESSION; PROGNOSIS; PREDICTS; BIOLOGY; SERIES; GENES	Most cases of breast cancer (BrCa) mortality are due to vascular metastasis. BrCa cells must intravasate through endothelial cells (ECs) to enter a blood vessel in the primary tumor and then adhere to ECs and extravasate at the metastatic site. In this study we demonstrate that inhibition of hypoxia-inducible factor (HIF) activity in BrCa cells by RNA interference or digoxin treatment inhibits primary tumor growth and also inhibits the metastasis of BrCa cells to the lungs by blocking the expression of angiopoietin-like 4 (ANGPTL4) and L1 cell adhesion molecule (L1CAM). ANGPTL4 is a secreted factor that inhibits EC-EC interaction, whereas L1CAM increases the adherence of BrCa cells to ECs. Interference with HIF, ANGPTL4 or L1CAM expression inhibits vascular metastasis of BrCa cells to the lungs. Oncogene (2012) 31, 1757-1770; doi: 10.1038/onc.2011.365; published online 22 August 2011	[Zhang, H.; Wong, C. C. L.; Wei, H.; Gilkes, D. M.; Chaturvedi, P.; Schito, L.; Chen, J.; Semenza, G. L.] Johns Hopkins Univ, Vasc Program, Inst Cell Engn, Sch Med, Baltimore, MD 21205 USA; [Zhang, H.; Korangath, P.; Sukumar, S.; Semenza, G. L.] Johns Hopkins Univ, Dept Oncol, Sch Med, Baltimore, MD 21205 USA; [Wong, C. C. L.; Wei, H.; Gilkes, D. M.; Chaturvedi, P.; Chen, J.; Semenza, G. L.] Johns Hopkins Univ, McKusick Nathans Inst Genet Med, Sch Med, Baltimore, MD 21205 USA; [Krishnamachary, B.; Winnard, P. T., Jr.; Raman, V.] Johns Hopkins Univ, Dept Radiol, Sch Med, Baltimore, MD 21205 USA; [Zhang, H.] Univ Sci & Technol China, Sch Life Sci, Hefei 230026, Anhui, Peoples R China; [Schito, L.] Univ Roma La Sapienza, Rome, Italy; [Zhen, L.; Mitzner, W. A.] Johns Hopkins Univ, Div Physiol, Sch Publ Hlth, Baltimore, MD 21205 USA; [Semenza, G. L.] Johns Hopkins Univ, Dept Pediat, Sch Med, Baltimore, MD 21205 USA; [Semenza, G. L.] Johns Hopkins Univ, Dept Med, Sch Med, Baltimore, MD 21205 USA; [Semenza, G. L.] Johns Hopkins Univ, Dept Radiat Oncol, Sch Med, Baltimore, MD 21205 USA; [Semenza, G. L.] Johns Hopkins Univ, Dept Biol Chem, Sch Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Sapienza University Rome; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Semenza, GL (corresponding author), Johns Hopkins Univ, Vasc Program, Inst Cell Engn, Sch Med, 733 N Broadway,Suite 671, Baltimore, MD 21205 USA.	gsemenza@jhmi.edu	Zhang, Huafeng/A-7188-2012; Gilkes, Daniele M/AAI-8133-2020; Wong, Carmen Chak Lui/C-4660-2009	Gilkes, Daniele M/0000-0003-3984-9338; Korangath, Preethi/0000-0002-6623-493X; Wong, Carmen Chak Lui/0000-0001-5866-4705; Chen, Jasper/0000-0001-6070-5940	Emerald Foundation; National Institutes of Health [U54-CA143868]; Johns Hopkins Institute for Cell Engineering; Postdoctoral Training Program in Nanotechnology for Cancer Medicine [T32-CA130840]; NATIONAL CANCER INSTITUTE [U54CA143868, T32CA130840] Funding Source: NIH RePORTER	Emerald Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Johns Hopkins Institute for Cell Engineering; Postdoctoral Training Program in Nanotechnology for Cancer Medicine; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Karen Padgett of Novus Biologicals for generous gifts of antibodies against HIF-1 alpha, HIF-2 alpha and L1CAM. This work was supported by the Emerald Foundation, the National Institutes of Health (U54-CA143868) and the Johns Hopkins Institute for Cell Engineering. DMG was supported by the Postdoctoral Training Program in Nanotechnology for Cancer Medicine (T32-CA130840). GLS is the C Michael Armstrong Professor at Johns Hopkins University School of Medicine.	Belanger AJ, 2002, J MOL CELL CARDIOL, V34, P765, DOI 10.1006/jmcc.2002.2021; Bos R, 2003, CANCER, V97, P1573, DOI 10.1002/cncr.11246; Bos R, 2001, JNCI-J NATL CANCER I, V93, P309, DOI 10.1093/jnci/93.4.309; Buffa FM, 2010, BRIT J CANCER, V102, P428, DOI 10.1038/sj.bjc.6605450; CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661; Caniggia I, 2000, J CLIN INVEST, V105, P577, DOI 10.1172/JCI8316; Chambers AF, 2009, CANCER RES, V69, P5292, DOI 10.1158/0008-5472.CAN-09-1528; Chintala S, 2010, CANCER CHEMOTH PHARM, V66, P899, DOI 10.1007/s00280-009-1238-8; Dales JP, 2005, INT J CANCER, V116, P734, DOI 10.1002/ijc.20984; Dewhirst MW, 2008, NAT REV CANCER, V8, P425, DOI 10.1038/nrc2397; Erler JT, 2009, CANCER CELL, V15, P35, DOI 10.1016/j.ccr.2008.11.012; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Fukuda R, 2007, CELL, V129, P111, DOI 10.1016/j.cell.2007.01.047; Galaup A, 2006, P NATL ACAD SCI USA, V103, P18721, DOI 10.1073/pnas.0609025103; Generali D, 2006, CLIN CANCER RES, V12, P4562, DOI 10.1158/1078-0432.CCR-05-2690; Giatromanolaki A, 2004, CLIN CANCER RES, V10, P7972, DOI 10.1158/1078-0432.CCR-04-1068; Gupta GP, 2007, NATURE, V446, P765, DOI 10.1038/nature05760; Helczynska K, 2008, CANCER RES, V68, P9212, DOI 10.1158/0008-5472.CAN-08-1135; Issa Y, 2009, J MOL MED, V87, P99, DOI 10.1007/s00109-008-0410-7; Krishnamachary B, 2006, CANCER RES, V66, P2725, DOI 10.1158/0008-5472.CAN-05-3719; Kronblad A, 2006, INT J CANCER, V118, P2609, DOI 10.1002/ijc.21676; Liao D, 2007, CANCER RES, V67, P563, DOI 10.1158/0008-5472.CAN-06-2701; Liotta LA, 2000, CANC MED, P121; Manalo DJ, 2005, BLOOD, V105, P659, DOI 10.1182/blood-2004-07-2958; Melillo G, 2007, CANCER METAST REV, V26, P341, DOI 10.1007/s10555-007-9059-x; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Nishi H, 2004, ENDOCRINOLOGY, V145, P4113, DOI 10.1210/en.2003-1639; Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046; Pal SK, 2011, BREAST CANCER RES TR, V125, P627, DOI 10.1007/s10549-010-1293-1; Palmieri C, 2010, NAT REV CLIN ONCOL, V7, P561, DOI 10.1038/nrclinonc.2010.122; Schindl M, 2002, CLIN CANCER RES, V8, P1831; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; Subarsky P, 2003, CLIN EXP METASTAS, V20, P237, DOI 10.1023/A:1022939318102; Tafani M, 2010, CANCER SCI, V101, P1014, DOI 10.1111/j.1349-7006.2010.01493.x; Talmadge JE, 2010, CANCER RES, V70, P5649, DOI 10.1158/0008-5472.CAN-10-1040; Trastour C, 2007, INT J CANCER, V120, P1451, DOI 10.1002/ijc.22436; Ueno M, 2011, AM J PHYSIOL-LUNG C, V300, pL740, DOI 10.1152/ajplung.00146.2010; Vaupel P, 2004, METHOD ENZYMOL, V381, P335; Verheul HMW, 2008, CLIN CANCER RES, V14, P3589, DOI 10.1158/1078-0432.CCR-07-4306; Vleugel MM, 2005, J CLIN PATHOL, V58, P172, DOI 10.1136/jcp.2004.019885; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Yamamoto Y, 2008, BREAST CANCER RES TR, V110, P465, DOI 10.1007/s10549-007-9742-1; Zhang HF, 2008, P NATL ACAD SCI USA, V105, P19579, DOI 10.1073/pnas.0809763105	43	242	253	1	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	14					1757	1770		10.1038/onc.2011.365	http://dx.doi.org/10.1038/onc.2011.365			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925TT	21860410	Green Accepted			2022-12-17	WOS:000302785200002
J	Braun, J; Hoang-Vu, C; Dralle, H; Huettelmaier, S				Braun, J.; Hoang-Vu, C.; Dralle, H.; Huettelmaier, S.			Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas	ONCOGENE			English	Article						ATC; microRNA; TGF beta; EMT; TGFBR1; SMAD2	MESENCHYMAL TRANSITION; MIR-200 FAMILY; E-CADHERIN; CANCER-CELLS; EXPRESSION; ZEB1; METASTASIS; GROWTH; TUMORS; GENES	Anaplastic thyroid carcinomas (ATCs) arise from epithelial thyroid cells by mesenchymal de-/transdifferentiation and rapidly invade the adjacent tissue. Specific microRNA signatures were suggested to distinguish ATCs from normal thyroid tissue and other thyroid carcinomas of follicular origin. Whether distinct microRNA patterns correlate with de-/transdifferentiation and invasion of ATCs remained elusive. We identified two significantly decreased microRNA families that unambiguously distinguish ATCs from papillary and follicular thyroid carcinomas: miR-200 and miR-30. Expression of these microRNAs in mesenchymal ATC-derived cells reduced their invasive potential and induced mesenchymal-epithelial transition (MET) by regulating the expression of MET marker proteins. Supporting the role of transforming growth factor (TGF)beta signaling in modulating MET/epithelial- mesenchymal transition (EMT), expression of SMAD2 and TGFBR1, upregulated in most primary ATCs, was controlled by members of the miR-30 and/or miR-200 families in ATC-derived cells. Inhibition of TGF beta receptor 1 (TGFBR1) in these cells induced MET and reduction of prometastatic miR-21, but caused an increase of the miR-200 family. These findings identify altered microRNA signatures as potent markers for ATCs that promote de-/transdifferentiation (EMT) and invasion of these neoplasias. Hence, TGFBR1 inhibition could have a significant potential for the treatment of ATCs and possibly other invasive tumors. Oncogene (2010) 29, 4237-4244; doi: 10.1038/onc.2010.169; published online 24 May 2010	[Huettelmaier, S.] Univ Halle Wittenberg, Dept Mol Cell Biol, ZAMED, D-06120 Halle, Sachsen Anhalt, Germany; [Hoang-Vu, C.; Dralle, H.] Univ Halle Wittenberg, Dept Gen Visceral & Vasc Surg, D-06120 Halle, Sachsen Anhalt, Germany	Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg	Huettelmaier, S (corresponding author), Univ Halle Wittenberg, Dept Mol Cell Biol, ZAMED, Heinrich Damerow Str 1, D-06120 Halle, Sachsen Anhalt, Germany.	stefan.huettelmaier@medizin.uni-halle.de	Hüttelmaier, Stefan/AAQ-1203-2021; Dralle, Henning/ABD-4454-2020	Braun, Juliane/0000-0002-2491-5788	DFG; BMBF [FKZ 01ZZ0404]	DFG(German Research Foundation (DFG)); BMBF(Federal Ministry of Education & Research (BMBF))	This work was supported by DFG and BMBF (FKZ 01ZZ0404) funding to Stefan Huttelmaier.	BRABANT G, 1993, CANCER RES, V53, P4987; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Budhu A, 2008, HEPATOLOGY, V47, P897, DOI 10.1002/hep.22160; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Davis BN, 2008, NATURE, V454, P56, DOI 10.1038/nature07086; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Guzinska-Ustymowicz K, 2005, WORLD J GASTROENTERO, V11, P1193, DOI 10.3748/wjg.v11.i8.1193; He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102; Kim YK, 2009, NUCLEIC ACIDS RES, V37, P1672, DOI 10.1093/nar/gkp002; Kondo T, 2006, NAT REV CANCER, V6, P292, DOI 10.1038/nrc1836; Mercatelli N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004029; Nikiforova MN, 2008, J CLIN ENDOCR METAB, V93, P1600, DOI 10.1210/jc.2007-2696; Pallante P, 2006, ENDOCR-RELAT CANCER, V13, P497, DOI 10.1677/erc.1.01209; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Piek E, 1999, J CELL SCI, V112, P4557; Resnick MB, 1998, MODERN PATHOL, V11, P735; Rocha AS, 2003, HISTOPATHOLOGY, V42, P580, DOI 10.1046/j.1365-2559.2003.01642.x; Safina A, 2007, ONCOGENE, V26, P2407, DOI 10.1038/sj.onc.1210046; Schwertheim S, 2009, HORM METAB RES, V41, P475, DOI 10.1055/s-0029-1215593; Shao ES, 2009, BLOOD, V114, P2197, DOI 10.1182/blood-2009-01-199166; Vasko V, 2007, P NATL ACAD SCI USA, V104, P2803, DOI 10.1073/pnas.0610733104; Visone R, 2007, ONCOGENE, V26, P7590, DOI 10.1038/sj.onc.1210564; Weber F, 2006, J CLIN ENDOCR METAB, V91, P3584, DOI 10.1210/jc.2006-0693; Zhu SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24	26	242	257	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 22	2010	29	29					4237	4244		10.1038/onc.2010.169	http://dx.doi.org/10.1038/onc.2010.169			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	628VL	20498632				2022-12-17	WOS:000280151500011
J	Jaattela, M				Jaattela, M			Multiple cell death pathways as regulators of tumour initiation and progression	ONCOGENE			English	Review						cancer; caspase independent; cell death; lysosome; transformation	MITOCHONDRIAL PERMEABILITY TRANSITION; NECROSIS-FACTOR-ALPHA; BREAST-CANCER CELLS; VITAMIN-D COMPOUNDS; WILD-TYPE P53; CATHEPSIN-B; C-MYC; DEPENDENT APOPTOSIS; CYTOCHROME-C; DAP KINASE	Acquired defects in signalling pathways leading to programmed cell death (PCD) are among the major hallmarks of cancer. Although focus has been on caspase-dependent apoptotic death pathways, evidence is now accumulating that nonapoptotic PCD also can form an important barrier against tumour initiation and progression. Akin to the earlier landmark discoveries that lead to the identification of the major cancer-related proteins like p53, c-Myc and Bcl-2 as controllers of spontaneous and therapy-induced apoptosis, numerous proteins with properties of tumour suppressors and oncoproteins have recently been identified as key regulators of alternative death programmes. The emerging data on the molecular mechanisms regulating nonapoptotic PCD may have potent therapeutic consequences.	Danish Canc Soc, Inst Canc Biol, Apoptosis Lab, DK-2100 Copenhagen, Denmark	Danish Cancer Society	Jaattela, M (corresponding author), Danish Canc Soc, Inst Canc Biol, Apoptosis Lab, Strandblvd 49, DK-2100 Copenhagen, Denmark.	mhj@biobase.dk	Jäättelä, Marja/AAT-7932-2021	Jäättelä, Marja/0000-0001-5950-7111				Alexander CM, 1996, J CELL BIOL, V135, P1669, DOI 10.1083/jcb.135.6.1669; Alonso M, 2003, MOL CANCER THER, V2, P139; Altairac S, 2003, CELL DEATH DIFFER, V10, P548, DOI 10.1038/sj.cdd.4401195; Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Bao JJ, 2002, CANCER RES, V62, P7264; Bidere N, 2003, J BIOL CHEM, V278, P31401, DOI 10.1074/jbc.M301911200; Boya P, 2003, J EXP MED, V197, P1323, DOI 10.1084/jem.20021952; Brunk UT, 1999, REDOX REP, V4, P3, DOI 10.1179/135100099101534675; Brunk UT, 2001, REDOX REP, V6, P91, DOI 10.1179/135100001101536094; Bursch W, 1996, CARCINOGENESIS, V17, P1595, DOI 10.1093/carcin/17.8.1595; Chan HTC, 2003, CANCER RES, V63, P5480; Charette SJ, 2001, J BIOL CHEM, V276, P36071, DOI 10.1074/jbc.C100340200; Chen G, 1997, ONCOGENE, V15, P1643, DOI 10.1038/sj.onc.1201347; Chi SJ, 1999, ONCOGENE, V18, P2281, DOI 10.1038/sj.onc.1202538; Choi WS, 2001, J NEUROCHEM, V77, P1531, DOI 10.1046/j.1471-4159.2001.00368.x; CIRMAN T, 2003, J BIOL CHEM     1027; Coultas L, 2003, SEMIN CANCER BIOL, V13, P115, DOI 10.1016/S1044-579X(02)00129-3; Creagh EM, 2000, EXP CELL RES, V257, P58, DOI 10.1006/excr.2000.4856; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Duffy MJ, 1996, CLIN CANCER RES, V2, P613; Elliott K, 2000, ONCOGENE, V19, P4669, DOI 10.1038/sj.onc.1203681; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; Foghsgaard L, 2002, J BIOL CHEM, V277, P39499, DOI 10.1074/jbc.M206669200; Forcet C, 2001, P NATL ACAD SCI USA, V98, P3416, DOI 10.1073/pnas.051378298; Frese S, 2003, J THORAC CARDIOV SUR, V126, P748, DOI 10.1016/S0022-5223(03)00703-7; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gong JG, 1999, NATURE, V399, P806; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Inbal B, 2002, J CELL BIOL, V157, P455, DOI 10.1083/jcb.200109094; Jaattela M, 2003, NAT IMMUNOL, V4, P416, DOI 10.1038/ni0503-416; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; JIN Y, 2003, J BIOL CHEM     1006; Joseph B, 2002, ONCOGENE, V21, P65, DOI 10.1038/sj/onc/1205018; Kaufmann SH, 2001, TRENDS CELL BIOL, V11, P526, DOI 10.1016/S0962-8924(01)02173-0; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kennedy NJ, 2003, GENE DEV, V17, P629, DOI 10.1101/gad.1062903; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Khwaja A, 1999, J BIOL CHEM, V274, P36817, DOI 10.1074/jbc.274.51.36817; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; Komata T, 2003, BRIT J CANCER, V88, P1277, DOI 10.1038/sj.bjc.6600862; Kothari S, 2003, ONCOGENE, V22, P4734, DOI 10.1038/sj.onc.1206666; Kubasiak LA, 2002, P NATL ACAD SCI USA, V99, P12825, DOI 10.1073/pnas.202474099; Kuopio T, 1998, CANCER RES, V58, P432; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Lamy L, 2003, J BIOL CHEM, V278, P23915, DOI 10.1074/jbc.M301869200; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Liao DJ, 2003, LAB INVEST, V83, P1437, DOI 10.1097/01.LAB.0000090153.13977.AE; Liossis SNC, 1997, J IMMUNOL, V158, P5668; Liu N, 2003, EMBO J, V22, P5313, DOI 10.1093/emboj/cdg510; Lockshin RA, 2002, CURR OPIN CELL BIOL, V14, P727, DOI 10.1016/S0955-0674(02)00383-6; Lotem J, 1996, P NATL ACAD SCI USA, V93, P12507, DOI 10.1073/pnas.93.22.12507; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Luschen S, 2000, J BIOL CHEM, V275, P24670, DOI 10.1074/jbc.M003280200; Madge LA, 2003, J BIOL CHEM, V278, P21295, DOI 10.1074/jbc.M212837200; Mateo V, 1999, NAT MED, V5, P1277, DOI 10.1038/15233; Mateo W, 2002, BLOOD, V100, P2882, DOI 10.1182/blood-2001-12-0217; Mathiasen IS, 2002, TRENDS MOL MED, V8, P212, DOI 10.1016/S1471-4914(02)02328-6; Mathiasen IS, 1999, CANCER RES, V59, P4848; Mathiasen IS, 2002, J BIOL CHEM, V277, P30738, DOI 10.1074/jbc.M201558200; Mattson MP, 2000, TRENDS NEUROSCI, V23, P222, DOI 10.1016/S0166-2236(00)01548-4; Multhoff G, 1997, J IMMUNOL, V158, P4341; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Nylandsted J, 2002, CANCER RES, V62, P7139; Nylandsted J, 2000, P NATL ACAD SCI USA, V97, P7871, DOI 10.1073/pnas.97.14.7871; Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0; Pattingre S, 2003, J BIOL CHEM, V278, P16667, DOI 10.1074/jbc.M210998200; Pettersen RD, 2001, J IMMUNOL, V166, P4931, DOI 10.4049/jimmunol.166.8.4931; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Raveh T, 2001, EXP CELL RES, V264, P185, DOI 10.1006/excr.2000.5134; Raveh T, 2001, NAT CELL BIOL, V3, P1, DOI 10.1038/35050500; Reed JC, 2001, TRENDS MOL MED, V7, P314, DOI 10.1016/S1471-4914(01)02026-3; Reggiori F, 2002, EUKARYOT CELL, V1, P11, DOI 10.1128/EC.01.1.11-21.2002; Roberg K, 2002, AM J PATHOL, V161, P89, DOI 10.1016/S0002-9440(10)64160-0; Roshy S, 2003, CANCER METAST REV, V22, P271, DOI 10.1023/A:1023007717757; Saeki K, 2000, CELL DEATH DIFFER, V7, P1263, DOI 10.1038/sj.cdd.4400759; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Scorrano L, 2001, J BIOL CHEM, V276, P12035, DOI 10.1074/jbc.M010603200; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Sperandio S, 2000, P NATL ACAD SCI USA, V97, P14376, DOI 10.1073/pnas.97.26.14376; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Tal-Or P, 2003, PROSTATE, V55, P147, DOI 10.1002/pros.10200; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Thome M, 2001, NAT REV IMMUNOL, V1, P50, DOI 10.1038/35095508; Tolkovsky AM, 2002, BIOCHIMIE, V84, P233, DOI 10.1016/S0300-9084(02)01371-8; Torriglia A, 1998, MOL CELL BIOL, V18, P3612, DOI 10.1128/MCB.18.6.3612; Turk B, 2002, BIOL CHEM, V383, P1035, DOI 10.1515/BC.2002.112; van Eijk M, 1999, J IMMUNOL, V163, P2478; Vancompernolle K, 1998, FEBS LETT, V438, P150, DOI 10.1016/S0014-5793(98)01275-7; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Von Ahsen O, 2000, CELL DEATH DIFFER, V7, P1192, DOI 10.1038/sj.cdd.4400782; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wang XC, 2002, SCIENCE, V298, P1587, DOI 10.1126/science.1076194; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wilson CA, 2002, CELL DEATH DIFFER, V9, P1321, DOI 10.1038/sj.cdd.4401107; Wu GS, 1998, ONCOGENE, V16, P2177, DOI 10.1038/sj.onc.1201755; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yanagisawa H, 2003, CELL DEATH DIFFER, V10, P798, DOI 10.1038/sj.cdd.4401246; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869; YAO XR, 1993, P NATL ACAD SCI USA, V90, P7946, DOI 10.1073/pnas.90.17.7946; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Yuan XM, 2002, P NATL ACAD SCI USA, V99, P6286, DOI 10.1073/pnas.092135599; Zang Y, 2001, CELL DEATH DIFFER, V8, P477, DOI 10.1038/sj.cdd.4400843; Zanke BW, 1998, CANCER RES, V58, P2801; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681	131	242	264	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2004	23	16					2746	2756		10.1038/sj.onc.1207513	http://dx.doi.org/10.1038/sj.onc.1207513			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO	15077138				2022-12-17	WOS:000220799600002
J	Burke, WM; Jin, XH; Lin, HJ; Huang, M; Liu, R; Reynolds, RK; Lin, JY				Burke, WM; Jin, XH; Lin, HJ; Huang, M; Liu, R; Reynolds, RK; Lin, JY			Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells	ONCOGENE			English	Article						Stat3; AG490; Bcl-X-L; JAK2; apoptosis; ovarian cancer; breast cancer	CHEMOTHERAPY-INDUCED APOPTOSIS; BCL-X-L; CARCINOMA CELLS; KINASE-ACTIVITY; ACTIVATION; BCL-X(L); FAMILY; PHOSPHORYLATION; TRANSCRIPTION; RESISTANCE	Signal transducers and activators of transcription (STATs) are transcription factors activated in response to cytokines and growth factors. Constitutively active Stat3 has been shown to mediate oncogenic transformation in cultured cells and induce tumor formation in mice. An increasing number of tumor-derived cell lines as well as samples from human cancer have been reported to express constitutively active Stat3 protein. We previously demonstrated that ovarian cancer cell lines express high levels of constitutively active Stat3. In this study, we show that inhibition of the Stat3 signaling pathway using the Janus Kinase-selective inhibitor, AG490, and a dominant negative Stat3 (Stat3 beta) significantly suppresses the growth of ovarian and breast cancer cell lines harboring constitutively active Stat3. In the ovarian cancer cell lines, AG490 also diminished the phosphorylation of Stat3, Stat3 DNA binding activity, and the expression of Bcl-X-L. Further, AG490 induced significant apoptosis in ovarian and breast cancer cell lines expressing high levels of constitutively active Stat3 but had a less profound effect on normal cells lacking constitutively active Stat3. AG490 also enhanced apoptosis induced by cisplatin in ovarian cancer cells. These results suggest that inhibition of Stat3 signaling may provide a potential therapeutic approach for treating ovarian and breast cancers.	Univ Michigan, Ctr Comprehens Canc, Div Gynecol Oncol, Dept Obstet & Gynecol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Lin, JY (corresponding author), Univ Michigan, Ctr Comprehens Canc, Div Gynecol Oncol, Dept Obstet & Gynecol, 1500 E Med Ctr Dr,CCGC 4215, Ann Arbor, MI 48109 USA.		Lin, Huey-Jen/E-3514-2011; Lin, Jiayuh/E-3515-2011					Akira S, 2000, ONCOGENE, V19, P2607, DOI 10.1038/sj.onc.1203478; Akira S, 1999, STEM CELLS, V17, P138, DOI 10.1002/stem.170138; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Briscoe J, 1996, TRENDS CELL BIOL, V6, P336, DOI 10.1016/0962-8924(96)10028-3; Bromberg J, 2000, BREAST CANCER RES, V2, P86, DOI 10.1186/bcr38; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; BUDDE RJA, 1994, CANCER BIOCHEM BIOPH, V14, P171; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Campbell GS, 1997, J BIOL CHEM, V272, P2591, DOI 10.1074/jbc.272.5.2591; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DOLE MG, 1995, CANCER RES, V55, P2576; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Huang M, 2000, GYNECOL ONCOL, V79, P67, DOI 10.1006/gyno.2000.5931; Liu JR, 1998, GYNECOL ONCOL, V70, P398, DOI 10.1006/gyno.1998.5125; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; Ni Z, 2000, CANCER RES, V60, P1225; Nielsen M, 1999, LEUKEMIA, V13, P735, DOI 10.1038/sj.leu.2401415; Niu GL, 1999, CANCER RES, V59, P5059; Niu GL, 2001, CANCER RES, V61, P3276; Page C, 2000, INT J ONCOL, V17, P23; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Sartor CI, 1997, CANCER RES, V57, P978; Shen YH, 2001, P NATL ACAD SCI USA, V98, P1543, DOI 10.1073/pnas.041588198; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; WATSON CJ, 1995, BRIT J CANCER, V71, P840, DOI 10.1038/bjc.1995.162; Wiener JR, 1999, CLIN CANCER RES, V5, P2164; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Zhang Y, 2000, J BIOL CHEM, V275, P24935, DOI 10.1074/jbc.M002383200; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zong CS, 2000, J BIOL CHEM, V275, P15099, DOI 10.1074/jbc.M000089200	36	242	279	1	16	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 29	2001	20	55					7925	7934		10.1038/sj.onc.1204990	http://dx.doi.org/10.1038/sj.onc.1204990			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	494NL	11753675				2022-12-17	WOS:000172288700001
J	Wurster, AL; Tanaka, T; Grusby, MJ				Wurster, AL; Tanaka, T; Grusby, MJ			The biology of Stat4 and Stat6	ONCOGENE			English	Review						Stat4; Stat6; T helper cells	NF-KAPPA-B; INTERLEUKIN-4-INDUCED TRANSCRIPTION FACTOR; GERMLINE EPSILON-PROMOTER; CYTOKINE GENE-EXPRESSION; T-CELL DIFFERENTIATION; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; IL-4 RECEPTOR; DNA-BINDING; TH2 CELLS	regulators of the proliferation, differentiation and functional capacity of lymphocytes, STATs (signal transducers and activators of transcription) are transcription factors that provide a direct link between the cytokine receptors and cytokine induced gene transcription. Stat6 and Stat4 are two STAT family members that specifically mediate signals that emanate from the IL-4 and IL-12 receptors, respectively, Recently a great deal of progress has been made in understanding the specific roles that Stat6 and Stat4 play in lymphocyte function through in vitro as well as in vivo studies using Stat6 and Stat4-deficient mice. This report will summarize and describe the recent advances made in understanding the activation and regulation of Stat6 and Stat4 as well as their roles in the development of an immune response.	Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School	Grusby, MJ (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, 665 Huntington Ave, Boston, MA 02115 USA.		Tanaka, Takashi/O-8254-2015					Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Agarwal S, 1998, IMMUNITY, V9, P765, DOI 10.1016/S1074-7613(00)80642-1; Akimoto T, 1998, J EXP MED, V187, P1537, DOI 10.1084/jem.187.9.1537; Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; Andre I, 1996, P NATL ACAD SCI USA, V93, P2260, DOI 10.1073/pnas.93.6.2260; BACON CM, 1995, P NATL ACAD SCI USA, V92, P7307, DOI 10.1073/pnas.92.16.7307; BERBERICH I, 1994, J IMMUNOL, V153, P4357; Carter LL, 1999, J EXP MED, V189, P1355, DOI 10.1084/jem.189.8.1355; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Cho SS, 1996, J IMMUNOL, V157, P4781; DELPHIN S, 1995, J EXP MED, V181, P181, DOI 10.1084/jem.181.1.181; Dent AL, 1998, P NATL ACAD SCI USA, V95, P13823, DOI 10.1073/pnas.95.23.13823; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; dePaterHuijsen FL, 1997, IMMUNOL LETT, V57, P47, DOI 10.1016/S0165-2478(97)00044-8; Dumler I, 1999, J BIOL CHEM, V274, P24059, DOI 10.1074/jbc.274.34.24059; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Galon J, 1999, J IMMUNOL, V162, P7256; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; Hoey T, 1999, Adv Immunol, V71, P145; Holz A, 1999, J IMMUNOL, V163, P5374; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; Iciek LA, 1997, J IMMUNOL, V158, P4769; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; JACOBSON NG, 1995, J EXP MED, V181, P1755, DOI 10.1084/jem.181.5.1755; Kamogawa Y, 1998, J IMMUNOL, V161, P1074; Kaplan MH, 1998, J EXP MED, V188, P1191, DOI 10.1084/jem.188.6.1191; Kaplan MH, 1998, J IMMUNOL, V160, P1850; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; Kaplan MH, 1998, MOL CELL BIOL, V18, P1996, DOI 10.1128/MCB.18.4.1996; KAPSENBERG ML, 1991, IMMUNOL TODAY, V12, P392, DOI 10.1016/0167-5699(91)90137-I; Karras JG, 1997, J IMMUNOL, V159, P4350; Karras JG, 1996, J IMMUNOL, V157, P39; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; Kim JI, 1999, IMMUNITY, V10, P745, DOI 10.1016/S1074-7613(00)80073-4; KOHLER I, 1993, EUR J IMMUNOL, V23, P3066, DOI 10.1002/eji.1830231204; KOHLER I, 1994, FEBS LETT, V345, P187, DOI 10.1016/0014-5793(94)00438-2; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; Kotanides H, 1996, J BIOL CHEM, V271, P25555, DOI 10.1074/jbc.271.41.25555; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; Kuperman D, 1998, J EXP MED, V187, P939, DOI 10.1084/jem.187.6.939; Kurata H, 1999, IMMUNITY, V11, P677, DOI 10.1016/S1074-7613(00)80142-9; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; Linehan LA, 1998, J IMMUNOL, V161, P302; Lohoff M, 1997, IMMUNITY, V6, P681, DOI 10.1016/S1074-7613(00)80444-6; Losman JA, 1999, J IMMUNOL, V162, P3770; Lu BF, 1997, J IMMUNOL, V159, P1255; Magram J, 1996, IMMUNITY, V4, P471, DOI 10.1016/S1074-7613(00)80413-6; Mascareno E, 1998, P NATL ACAD SCI USA, V95, P5590, DOI 10.1073/pnas.95.10.5590; Messner B, 1997, J IMMUNOL, V159, P3330; Mikita T, 1998, J BIOL CHEM, V273, P17634, DOI 10.1074/jbc.273.28.17634; Mikita T, 1998, J IMMUNOL, V161, P1822; Mikita T, 1996, MOL CELL BIOL, V16, P5811; Moriggl R, 1997, MOL CELL BIOL, V17, P3663, DOI 10.1128/MCB.17.7.3663; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Naka T, 1998, P NATL ACAD SCI USA, V95, P15577, DOI 10.1073/pnas.95.26.15577; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; NobenTrauth N, 1997, P NATL ACAD SCI USA, V94, P10838, DOI 10.1073/pnas.94.20.10838; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; Ouyang W, 1998, IMMUNITY, V9, P745, DOI 10.1016/S1074-7613(00)80671-8; Ouyang W, 1999, P NATL ACAD SCI USA, V96, P3888, DOI 10.1073/pnas.96.7.3888; Patel BKR, 1996, J BIOL CHEM, V271, P22175, DOI 10.1074/jbc.271.36.22175; Patel BKR, 1998, P NATL ACAD SCI USA, V95, P172, DOI 10.1073/pnas.95.1.172; Paul WE, 1997, CIBA F SYMP, V204, P208; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; RACKE MK, 1994, J EXP MED, V180, P1961, DOI 10.1084/jem.180.5.1961; RICHARDS ML, 1994, J IMMUNOL, V152, P3453; Ryan JJ, 1996, IMMUNITY, V4, P123, DOI 10.1016/S1074-7613(00)80677-9; Schaffer A, 1999, J IMMUNOL, V162, P5327; SCHINDLER C, 1994, EMBO J, V13, P1350, DOI 10.1002/j.1460-2075.1994.tb06388.x; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; Seyfert VL, 1996, ONCOGENE, V12, P2331; Shen CH, 1998, MOL CELL BIOL, V18, P3395, DOI 10.1128/MCB.18.6.3395; Sherman MA, 1999, J IMMUNOL, V162, P2703; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Sinigaglia F, 1999, IMMUNOL REV, V170, P65, DOI 10.1111/j.1600-065X.1999.tb01329.x; SMERZBERTLING C, 1995, J BIOL CHEM, V270, P966, DOI 10.1074/jbc.270.2.966; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Subramaniam SV, 1999, BIOCHEM BIOPH RES CO, V262, P14, DOI 10.1006/bbrc.1999.1156; Szabo SJ, 1997, J EXP MED, V185, P817, DOI 10.1084/jem.185.5.817; Takeda K, 1996, J IMMUNOL, V157, P3220; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Takemoto S, 1997, P NATL ACAD SCI USA, V94, P13897, DOI 10.1073/pnas.94.25.13897; Taki S, 1997, IMMUNITY, V6, P673, DOI 10.1016/S1074-7613(00)80443-4; Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0; Venkataraman C, 1999, J IMMUNOL, V162, P4053; Vinkemeier U, 1998, SCIENCE, V279, P1048, DOI 10.1126/science.279.5353.1048; Wang KS, 1999, J IMMUNOL, V162, P299; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wu CY, 1997, J IMMUNOL, V159, P1658; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3; ZURAWSKI SM, 1995, J BIOL CHEM, V270, P13869, DOI 10.1074/jbc.270.23.13869	103	242	267	1	20	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 15	2000	19	21					2577	2584		10.1038/sj.onc.1203485	http://dx.doi.org/10.1038/sj.onc.1203485			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321MN	10851056				2022-12-17	WOS:000087459400013
J	Hori, T; Osaka, F; Chiba, T; Miyamoto, C; Okabayashi, K; Shimbara, N; Kato, S; Tanaka, K				Hori, T; Osaka, F; Chiba, T; Miyamoto, C; Okabayashi, K; Shimbara, N; Kato, S; Tanaka, K			Covalent modification of all members of human cullin family proteins by NEDD8	ONCOGENE			English	Article						cullin; NEDD8; SCF; ubiquitin; ubiquitin-like protein	UBIQUITIN-LIKE PROTEIN; F-BOX PROTEIN; CELL-CYCLE; LIGASE COMPLEX; HUMAN CUL-1; PATHWAY; GENE; PROTEOLYSIS; SUMO-1; SYSTEM	Recently we found that NEDD8, a ubiquitin-like protein, was linked covalently to human cullin-4A (abbreviated Cul-4A) by a new ubiquitin-related pathway that is analogous to but distinct from the ligating system for SUMO1, another ubiquitin-like protein. However, it remained unknown whether the other five members of the family of human cullin/Cdc53 proteins are modified by NEDD8, Here we report that all Hs-Cul family proteins, such as Cul-1, Cul-2, Cul-3, Cul-4B, and Cul-5, in addition to Cul-4A, were modified by covalent attachment of NEDD8 in rabbit reticulocyte lysates, Moreover, by comprehensive Northern-blot analyses, we examined multiple tissue distributions of the messages for all Cul-family proteins, NEDD8, and the NEDD8-ligating system consisting of APP-BP1/hUba3, and hUbc12, which function as E1- and E2-like enzymes, respectively, The expressions of Cul-1, Cul-2, and Cul-3 resembled each other and were apparently correlated to those of NEDD8 and the NEDD8-ligating system in various human cells and tissues. However, the mRNA levels of Cul-4A, Cul-4B, and Cul-5 differed considerably from each other as well as from other Cul-family proteins. The enhanced expression of all Cul-family proteins except Cul-5 was observed in a variety of tumor cell lines.	Tokyo Metropolitan Inst Med Sci, Bunkyo Ku, Tokyo 1130021, Japan; Hoffmann La Roche Inc, Nutley, NJ 07110 USA; Japan Sci & Technol Corp, Sagami Chem Res Ctr, ERATO, Kato Cytoprot Network Project, Kanagawa 2290012, Japan; Sumitomo Elect Ind Ltd, Biomed R&D Dept, Sakae Ku, Yokohama, Kanagawa 2448588, Japan	Tokyo Metropolitan Institute of Medical Science; Roche Holding; Japan Science & Technology Agency (JST); Sumitomo Electric Industries	Tanaka, K (corresponding author), Tokyo Metropolitan Inst Med Sci, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1130021, Japan.							Chen LC, 1998, CANCER RES, V58, P3677; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Drury LS, 1997, EMBO J, V16, P5966, DOI 10.1093/emboj/16.19.5966; Du M, 1998, J BIOL CHEM, V273, P24289, DOI 10.1074/jbc.273.38.24289; Elledge SJ, 1998, BBA-REV CANCER, V1377, pM61, DOI 10.1016/S0304-419X(98)00005-5; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; HANDELI S, 1992, CELL, V71, P599, DOI 10.1016/0092-8674(92)90594-3; Harper JW, 1999, NAT CELL BIOL, V1, pE5, DOI 10.1038/8952; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hatakeyama S, 1999, P NATL ACAD SCI USA, V96, P3859, DOI 10.1073/pnas.96.7.3859; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hochstrasser M, 1998, GENE DEV, V12, P901, DOI 10.1101/gad.12.7.901; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kamitani T, 1997, J BIOL CHEM, V272, P28557, DOI 10.1074/jbc.272.45.28557; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; KUMAR S, 1993, BIOCHEM BIOPH RES CO, V195, P393, DOI 10.1006/bbrc.1993.2056; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Li FN, 1997, EMBO J, V16, P5629, DOI 10.1093/emboj/16.18.5629; Liakopoulos D, 1999, P NATL ACAD SCI USA, V96, P5510, DOI 10.1073/pnas.96.10.5510; Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Lyapina SA, 1998, P NATL ACAD SCI USA, V95, P7451, DOI 10.1073/pnas.95.13.7451; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Michel JJ, 1998, CELL GROWTH DIFFER, V9, P435; Osaka F, 1998, GENE DEV, V12, P2263, DOI 10.1101/gad.12.15.2263; Patton EE, 1998, GENE DEV, V12, P692, DOI 10.1101/gad.12.5.692; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Russell A, 1999, ONCOGENE, V18, P1983, DOI 10.1038/sj.onc.1202511; Saitoh H, 1997, TRENDS BIOCHEM SCI, V22, P374, DOI 10.1016/S0968-0004(97)01102-X; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Suzuki H, 1999, BIOCHEM BIOPH RES CO, V256, P127, DOI 10.1006/bbrc.1999.0289; Tanaka K, 1998, MOL CELLS, V8, P503; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159	40	242	257	2	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6829	6834		10.1038/sj.onc.1203093	http://dx.doi.org/10.1038/sj.onc.1203093			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597293				2022-12-17	WOS:000083792000027
J	Clark, J; Lu, YJ; Sidhar, SK; Parker, C; Gill, S; Smedley, D; Hamoudi, R; Linehan, WM; Shipley, J; Cooper, CS				Clark, J; Lu, YJ; Sidhar, SK; Parker, C; Gill, S; Smedley, D; Hamoudi, R; Linehan, WM; Shipley, J; Cooper, CS			Fusion of splicing factor genes PSF and NonO (p54(nrb)) to the TFE3 gene in papillary renal cell carcinoma	ONCOGENE			English	Article						renal cell carcinoma; PSF splicing factor; NonO (p54(nrb)) splicing factor; chromosome translocations; TFE3 transcription factor	TUMOR-SUPPRESSOR GENE; ALVEOLAR RHABDOMYOSARCOMA; TRANSLOCATION X-1; BINDING PROTEIN; TRANSCRIPTION; CYTOGENETICS; RNA; BREAKPOINT; SARCOMA; ADENOCARCINOMA	We demonstrate that the cytogenetically defined translocation t(X;1)(p11.2;p34) observed in papillary renal cell carcinomas results in the fusion of the splicing factor gene PSF located at 1p34 to the TFE3 helix-loop-helix transcription factor gene at Xp11.2. In addition we define an X chromosome inversion inv(X)(p11.2;q12) that results in the fusion of the NonO (p54(nrb)) gene to TFE3. NonO (p54(nrb)), the human homologue of the Drosophila gene NonA(diss) which controls the male courtship song, is closely related to PSF and also believed to be involved in RNA splicing. In each case the rearrangement results in the fusion of almost the entire splicing factor protein to the TFE3 DIVA-binding domain. These observations suggest the possibility of intriguing links between the processes of RNA splicing, DNA transcription and oncogenesis.	INST CANC RES, HADDOW LABS, SECT CELL BIOL & EXPT PATHOL, SUTTON SM2 5NG, SURREY, ENGLAND; INST CANC RES, HADDOW LABS, CANC GENE CLONING LAB, SUTTON SM2 5NG, SURREY, ENGLAND; NCI, UROL ONCOL SECT, BETHESDA, MD 20892 USA	University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Clark, J (corresponding author), INST CANC RES, HADDOW LABS, SECT MOL CARCINOGENESIS, SUTTON SM2 5NG, SURREY, ENGLAND.			Shipley, Janet/0000-0001-6748-8678; Hamoudi, Rifat/0000-0002-1402-0868; Lu, Yong-Jie/0000-0001-6174-6621				ANGLARD P, 1992, CANCER RES, V52, P348; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; DAVIS RJ, 1994, CANCER RES, V54, P2869; DEJONG B, 1986, CANCER GENET CYTOGEN, V21, P165, DOI 10.1016/0165-4608(86)90042-7; DIJKHUIZEN T, 1995, GENE CHROMOSOME CANC, V14, P43, DOI 10.1002/gcc.2870140108; DONG BH, 1993, NUCLEIC ACIDS RES, V21, P4085, DOI 10.1093/nar/21.17.4085; ELFVING P, 1995, CYTOGENET CELL GENET, V69, P90, DOI 10.1159/000133945; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; GOZANI O, 1994, EMBO J, V13, P3356, DOI 10.1002/j.1460-2075.1994.tb06638.x; Hallier M, 1996, J BIOL CHEM, V271, P11177, DOI 10.1074/jbc.271.19.11177; HASTIE ND, 1994, ANNU REV GENET, V28, P523; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; JEON IS, 1995, ONCOGENE, V10, P1229; KOVACS G, 1991, GENE CHROMOSOME CANC, V3, P249, DOI 10.1002/gcc.2870030403; KOVACS G, 1993, ADV CANCER RES, V62, P89, DOI 10.1016/S0065-230X(08)60316-4; KOVACS G, 1987, INT J CANCER, V40, P171, DOI 10.1002/ijc.2910400208; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; MELONI AM, 1993, CANCER GENET CYTOGEN, V65, P1, DOI 10.1016/0165-4608(93)90050-V; Mitelman F., 1994, CATALOG CHROMOSOME A; Murphy W, 1994, ATLAS TUMOUR PATHOLO; OHJIMI Y, 1993, CANCER GENET CYTOGEN, V70, P77, DOI 10.1016/0165-4608(93)90136-A; PATTON JG, 1993, GENE DEV, V7, P393, DOI 10.1101/gad.7.3.393; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Savage Paul D., 1994, Current Opinion in Oncology, V6, P301, DOI 10.1097/00001622-199405000-00013; SHIPLEY JM, 1995, CYTOGENET CELL GENET, V71, P280, DOI 10.1159/000134127; SHIPLEY JM, 1993, CYTOGENET CELL GENET, V64, P233, DOI 10.1159/000133585; Sidhar SK, 1996, HUM MOL GENET, V5, P1333, DOI 10.1093/hmg/5.9.1333; TOMLINSON GE, 1991, CANCER GENET CYTOGEN, V57, P11, DOI 10.1016/0165-4608(91)90184-V; TONK V, 1995, CANCER GENET CYTOGEN, V81, P72, DOI 10.1016/S0165-4608(94)00195-2; VANDENBERG E, 1993, INT J CANCER, V55, P223, DOI 10.1002/ijc.2910550210; Weterman MAJ, 1996, P NATL ACAD SCI USA, V93, P15294, DOI 10.1073/pnas.93.26.15294; Weterman MAJ, 1996, CYTOGENET CELL GENET, V75, P2, DOI 10.1159/000134444; YANG YS, 1993, MOL CELL BIOL, V13, P5593, DOI 10.1128/MCB.13.9.5593; YOSHIDA AA, 1995, P ANN ASS CANC RES, V26, P31; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	37	242	259	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	1997	15	18					2233	2239		10.1038/sj.onc.1201394	http://dx.doi.org/10.1038/sj.onc.1201394			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YD019	9393982	Green Published			2022-12-17	WOS:A1997YD01900012
J	BUIJS, A; SHERR, S; VANBAAL, S; VANBEZOUW, S; VANDERPLAS, D; VANKESSEL, AG; RIEGMAN, P; DEPREZ, RL; ZWARTHOFF, E; HAGEMEIJER, A; GROSVELD, G				BUIJS, A; SHERR, S; VANBAAL, S; VANBEZOUW, S; VANDERPLAS, D; VANKESSEL, AG; RIEGMAN, P; DEPREZ, RL; ZWARTHOFF, E; HAGEMEIJER, A; GROSVELD, G			TRANSLOCATION (12-22) (P13-Q11) IN MYELOPROLIFERATIVE DISORDERS RESULTS IN FUSION OF THE ETS-LIKE TEL GENE ON 12P13 TO THE MN1 GENE ON 22Q11	ONCOGENE			English	Article						TRANSLOCATION; TEL; MN1; MYELOID LEUKEMIA; CHROMOSOME 12P	ACUTE NONLYMPHOCYTIC LEUKEMIA; MYELOID-LEUKEMIA; CHROMOSOMAL REARRANGEMENT; SUBSTRATE RECOGNITION; PROTEIN; IDENTIFICATION; ACTIVATION; BREAKPOINT; KINASES; DOMAIN	In myeloid and lymphoid leukemias recurrent chromosomal aberrations can be detected in chromosome region 12p13, We characterized the genes involved in t(12;22) (p13;q11) in two patients with myeloid leukemia and one with myelodysplastic syndrome (MDS). MN1, a gene on chromosome 22q11 was shown to be fused to TEL, a member of the family of ETS transcription factors on chromosome 12p13. The translocation results in transcription of the reciprocal fusion mRNAs, MN1-TEL and TEL-MN1, of which MN1-TEL is likely to encode an aberrant transcription factor containing the ETS DNA-binding domain of TEL. In addition to fusion of TEL to the PDGF beta receptor in t(5;12) in chronic myelomonocytic leukemia (CMML), our data suggest that the involvement of this protein in myeloid leukemogenesis could be dual; its isolated protein-protein dimerization and DNA-binding domains may be crucial for the oncogenic activation of functionally different fusion proteins.	ST JUDE CHILDRENS RES HOSP, DEPT GENET, MEMPHIS, TN 38101 USA; ERASMUS UNIV ROTTERDAM, DEPT PATHOL, 3000 DR ROTTERDAM, NETHERLANDS; ERASMUS UNIV ROTTERDAM, DEPT CELL BIOL & GENET, 3000 DR ROTTERDAM, NETHERLANDS; UNIV NIJMEGEN HOSP, DEPT HUMAN GENET, 6500 HB NIJMEGEN, NETHERLANDS	St Jude Children's Research Hospital; Erasmus University Rotterdam; Erasmus University Rotterdam; Radboud University Nijmegen			van Kessel, Ad Geurts/A-2810-2010; Riegman, Peter/GLS-0041-2022		NCI NIH HHS [P30 CA21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADRIAANSEN HJ, 1992, THESIS ERASMUS U ROT, P123; ALCALAY M, 1992, P NATL ACAD SCI USA, V89, P4840, DOI 10.1073/pnas.89.11.4840; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BELYAVSKY A, 1989, NUCLEIC ACIDS RES, V17, P2919, DOI 10.1093/nar/17.8.2919; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; BUIJS A, 1995, ONCOGENE, V10, P1511; CALLEN DF, 1991, CANCER GENET CYTOGEN, V51, P255, DOI 10.1016/0165-4608(91)90138-K; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; DELATTRE O, 1992, NATURE, V359, P1962; DEPREZ RHL, 1991, AM J HUM GENET, V48, P783; ENGEL E, 1977, NEW ENGL J MED, V296, P1295; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; HAGEMEIJER A, 1981, CANCER GENET CYTOGEN, V3, P109, DOI 10.1016/0165-4608(81)90065-0; HAGEMEIJER A, 1979, CYTOGENET CELL GENET, V23, P208, DOI 10.1159/000131327; HAGEMEIJER A, 1993, GENE CHROMOSOME CANC, V8, P237, DOI 10.1002/gcc.2870080406; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JOHANSSON B, 1990, CANCER GENET CYTOGEN, V48, P119, DOI 10.1016/0165-4608(90)90224-X; KASHIMURA M, 1993, CANCER GENET CYTOGEN, V65, P81, DOI 10.1016/0165-4608(93)90066-U; KRANCE RA, 1992, LEUKEMIA, V6, P251; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; Mertens F., 1991, CATALOG CHROMOSOME A; MORRIS SW, 1992, GENE CHROMOSOME CANC, V5, P385, DOI 10.1002/gcc.2870050414; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; RAIMONDI SC, 1986, BLOOD, V68, P69; Sambrook J., 1989, MOL CLONING LAB MANU; SAWYERS CL, 1994, CELL, V77, P171, DOI 10.1016/0092-8674(94)90307-7; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; VANDERBLIJPHILIPSEN M, 1977, HUM GENET, V39, P229, DOI 10.1007/BF00287017; VANDERPLAS DC, 1995, LEUKEMIA, V8, P2041; VANKESSEL AG, 1994, CANCER GENET CYTOGEN, V72, P105, DOI 10.1016/0165-4608(94)90124-4; VANKESSEL AHMG, 1981, CYTOGENET CELL GENET, V30, P83; VERMA RS, 1979, CYTOGENET CELL GENET, V23, P274, DOI 10.1159/000131338; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x	43	242	249	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1511	1519						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731705				2022-12-17	WOS:A1995QU68100006
J	Yang, W; Du, WW; Li, X; Yee, AJ; Yang, BB				Yang, W.; Du, W. W.; Li, X.; Yee, A. J.; Yang, B. B.			Foxo3 activity promoted by non-coding effects of circular RNA and Foxo3 pseudogene in the inhibition of tumor growth and angiogenesis	ONCOGENE			English	Article							GENE-EXPRESSION; TRANSCRIPTION FACTORS; MICRORNA SPONGES; CANCER; METASTASIS; SURVIVAL; TUMORIGENESIS; INVASION; DIFFERENTIATION; PROTEINS	It has recently been shown that the upregulation of a pseudogene specific to a protein-coding gene could function as a sponge to bind multiple potential targeting microRNAs (miRNAs), resulting in increased gene expression. Similarly, it was recently demonstrated that circular RNAs can function as sponges for miRNAs, and could upregulate expression of mRNAs containing an identical sequence. Furthermore, some mRNAs are now known to not only translate protein, but also function to sponge miRNA binding, facilitating gene expression. Collectively, these appear to be effective mechanisms to ensure gene expression and protein activity. Here we show that expression of a member of the forkhead family of transcription factors, Foxo3, is regulated by the Foxo3 pseudogene (Foxo3P), and Foxo3 circular RNA, both of which bind to eight miRNAs. We found that the ectopic expression of the Foxo3P, Foxo3 circular RNA and Foxo3 mRNA could all suppress tumor growth and cancer cell proliferation and survival. Our results showed that at least three mechanisms are used to ensure protein translation of Foxo3, which reflects an essential role of Foxo3 and its corresponding non-coding RNAs.	[Yang, W.; Du, W. W.; Li, X.; Yee, A. J.; Yang, B. B.] Sunnybrook Hlth Sci Ctr, Sunnybrook Res Inst, Toronto, ON, Canada; [Yang, W.; Du, W. W.; Li, X.; Yang, B. B.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Li, X.] Guangdong Inst Microbiol, State Key Lab Appl Microbiol Southern China, Guangzhou, Guangdong, Peoples R China; [Yang, B. B.] Univ Toronto, Inst Med Sci, Toronto, ON, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Guangdong Academy of Sciences; Institute of Microbiology, Guangdong Academy of Sciences; University of Toronto	Yee, AJ; Yang, BB (corresponding author), Univ Toronto, Sunnybrook Res Inst, S Wing Res Bldg,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	albert.yee@sunnybrook.ca; byang@sri.utoronto.ca		Yang, Burton B/0000-0002-2892-7209	Natural Sciences and Engineering Research Council of Canada (NSERC) [227937-2012]; Heart and Stroke Foundation of Ontario [CI 7418]; Canadian Institutes of Health Research; Breast Cancer Foundation of Ontario	Natural Sciences and Engineering Research Council of Canada (NSERC)(Natural Sciences and Engineering Research Council of Canada (NSERC)); Heart and Stroke Foundation of Ontario(Heart & Stroke Foundation of Ontario); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Breast Cancer Foundation of Ontario	This work was supported by a Discovery Grant from the Natural Sciences and Engineering Research Council of Canada (NSERC; 227937-2012) to BBY, who is the recipient of a Career Investigator Award (CI 7418) from the Heart and Stroke Foundation of Ontario. WY is supported by a Graduate Scholarship from Canadian Institutes of Health Research. WWD is supported by a Postdoctoral Fellowship from the Breast Cancer Foundation of Ontario.	AbouHaidar MG, 2014, P NATL ACAD SCI USA, V111, P14542, DOI 10.1073/pnas.1402814111; Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; Bartell SM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4773; Bella L, 2014, CURR DRUG TARGETS, V15, P1; Boulias K, 2012, CELL METAB, V15, P439, DOI 10.1016/j.cmet.2012.02.014; Bowman A, 2011, CANCER CELL, V20, P415, DOI 10.1016/j.ccr.2011.10.003; Cao L, 2000, J CELL BIOCHEM, V77, P569, DOI 10.1002/(SICI)1097-4644(20000615)77:4<569::AID-JCB5>3.0.CO;2-K; CAPEL B, 1993, CELL, V73, P1019, DOI 10.1016/0092-8674(93)90279-Y; Cesana M, 2011, CELL, V147, P358, DOI 10.1016/j.cell.2011.09.028; Chen QH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015288; Cho EC, 2014, ONCOTARGET, V5, P4834, DOI 10.18632/oncotarget.2044; COCQUERELLE C, 1993, FASEB J, V7, P155, DOI 10.1096/fasebj.7.1.7678559; Du WW, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.305; Ebert MS, 2010, RNA, V16, P2043, DOI 10.1261/rna.2414110; Fang L, 2012, CELL CYCLE, V11, P4352, DOI 10.4161/cc.22670; Haeusler RA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6190; Haimovich G, 2013, CELL, V153, P1000, DOI 10.1016/j.cell.2013.05.012; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Hentze MW, 2013, EMBO J, V32, P923, DOI 10.1038/emboj.2013.53; Jeck WR, 2014, NAT BIOTECHNOL, V32, P453, DOI 10.1038/nbt.2890; Jeck WR, 2013, RNA, V19, P141, DOI 10.1261/rna.035667.112; Jeyapalan Z, 2011, NUCLEIC ACIDS RES, V39, P3026, DOI 10.1093/nar/gkq1003; Keniry M, 2013, GENE DEV, V27, P916, DOI 10.1101/gad.214049.113; Kloet DEA, 2011, BBA-MOL CELL RES, V1813, P1926, DOI 10.1016/j.bbamcr.2011.04.003; Kumar MS, 2014, NATURE, V505, P212, DOI 10.1038/nature12785; LaPierre DP, 2007, CANCER RES, V67, P4742, DOI 10.1158/0008-5472.CAN-06-3610; Lee DY, 2007, P NATL ACAD SCI USA, V104, P20350, DOI 10.1073/pnas.0706901104; Lee DY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004527; Li J, 2015, TUMOR BIOL, V36, P685, DOI 10.1007/s13277-014-2698-y; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928; Moriishi T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086629; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Nam Y, 2011, CELL, V147, P1080, DOI 10.1016/j.cell.2011.10.020; Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144; Rutnam ZJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms3914; Rutnam ZJ, 2012, J CELL SCI, V125, P2075, DOI 10.1242/jcs100818; Salazar M, 2015, CELL DEATH DIFFER, V22, P131, DOI 10.1038/cdd.2014.133; Bilbao PS, 2013, BBA-GEN SUBJECTS, V1830, P4456, DOI 10.1016/j.bbagen.2013.05.034; Segura MF, 2009, P NATL ACAD SCI USA, V106, P1814, DOI 10.1073/pnas.0808263106; Seitz H, 2003, NAT GENET, V34, P261, DOI 10.1038/ng1171; Shan SW, 2009, NAT CELL BIOL, V11, P1031, DOI 10.1038/ncb1917; Shatseva T, 2011, J CELL SCI, V124, P2826, DOI 10.1242/jcs.077529; Siragam V, 2012, ONCOTARGET, V3, P1370, DOI 10.18632/oncotarget.717; Sykes SM, 2011, CELL, V146, P697, DOI 10.1016/j.cell.2011.07.032; Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang CH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002420; Wilusz JE, 2013, SCIENCE, V340, P440, DOI 10.1126/science.1238522; Yang BL, 2000, J BIOL CHEM, V275, P21255, DOI 10.1074/jbc.M001443200; Yang XL, 2013, NUCLEIC ACIDS RES, V41, P9688, DOI 10.1093/nar/gkt680	51	241	255	3	58	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2016	35	30					3919	3931		10.1038/onc.2015.460	http://dx.doi.org/10.1038/onc.2015.460			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8DJ	26657152				2022-12-17	WOS:000381013100004
J	Ling, H; Vincent, K; Pichler, M; Fodde, R; Berindan-Neagoe, I; Slack, FJ; Calin, GA				Ling, H.; Vincent, K.; Pichler, M.; Fodde, R.; Berindan-Neagoe, I.; Slack, F. J.; Calin, G. A.			Junk DNA and the long non-coding RNA twist in cancer genetics	ONCOGENE			English	Review							GENOME-WIDE ASSOCIATION; NATURAL ANTISENSE TRANSCRIPTS; CHRONIC LYMPHOCYTIC-LEUKEMIA; X-CHROMOSOME INACTIVATION; PROSTATE-CANCER; COLORECTAL-CANCER; HEPATOCELLULAR-CARCINOMA; CHROMATIN INTERACTIONS; ULTRACONSERVED REGION; RANGE INTERACTION	The central dogma of molecular biology states that the flow of genetic information moves from DNA to RNA to protein. However, in the last decade this dogma has been challenged by new findings on non-coding RNAs (ncRNAs) such as microRNAs (miRNAs). More recently, long non-coding RNAs (lncRNAs) have attracted much attention due to their large number and biological significance. Many lncRNAs have been identified as mapping to regulatory elements including gene promoters and enhancers, ultraconserved regions and intergenic regions of protein-coding genes. Yet, the biological function and molecular mechanisms of lncRNA in human diseases in general and cancer in particular remain largely unknown. Data from the literature suggest that lncRNA, often via interaction with proteins, functions in specific genomic loci or use their own transcription loci for regulatory activity. In this review, we summarize recent findings supporting the importance of DNA loci in lncRNA function and the underlying molecular mechanisms via cis or trans regulation, and discuss their implications in cancer. In addition, we use the 8q24 genomic locus, a region containing interactive SNPs, DNA regulatory elements and lncRNAs, as an example to illustrate how single-nucleotide polymorphism (SNP) located within lncRNAs may be functionally associated with the individual's susceptibility to cancer.	[Ling, H.; Vincent, K.; Pichler, M.; Berindan-Neagoe, I.; Calin, G. A.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Fodde, R.] Univ Med Ctr Rotterdam, Erasmus MC Canc Inst, Dept Pathol, Rotterdam, Netherlands; [Berindan-Neagoe, I.] Univ Med & Pharm I Hatieganu, Dept Immunol, Cluj Napoca, Romania; [Berindan-Neagoe, I.] Univ Med & Pharm I Hatieganu, Res Ctr Funct Genom Biomed & Translat Med, Cluj Napoca, Romania; [Berindan-Neagoe, I.] Oncol Inst Ion Chiricuta, Dept Funct Genom, Cluj Napoca, Romania; [Slack, F. J.] Harvard Univ, Sch Med, Dept Pathol, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA	University of Texas System; UTMD Anderson Cancer Center; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Iuliu Hatieganu University of Medicine & Pharmacy; Iuliu Hatieganu University of Medicine & Pharmacy; Oncology Institute Prof. Dr. Ion Chiricuta; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Calin, GA (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, 1881 East Rd,Unit 1950,APT 1125, Houston, TX 77030 USA.	gcalin@mdanderson.org	Calin, George/E-9390-2011; Berindan-Neagoe, Ioana/AAH-9854-2019; Fodde, Riccardo/AAW-9394-2021	Fodde, Riccardo/0000-0001-9839-4324; Slack, Frank/0000-0001-8263-0409; Calin, George/0000-0002-7427-0578; Calin, George/0000-0001-6704-5615	Odyssey Program at The University of Texas MD Anderson Cancer Center; NIH/NCI [1UH2TR00943-01, 1 R01 CA182905-01]; UT MD Anderson Cancer Center SPORE in Melanoma grant from NCI [P50 CA093459]; Aim at Melanoma Foundation; Miriam and Jim Mulva research funds; Brain SPORE [2P50CA127001]; Center for radiation Oncology Research Project; Center for Cancer Epigenetics Pilot project; Knowledge GAP MDACC grant; CLL Moonshot pilot project; UT MD Anderson Cancer Center Duncan Family Institute for Cancer Prevention and Risk Assessment; SINF grant in colon cancer; Laura and John Arnold Foundation; RGK Foundation; Estate of C. G. Johnson; Erwin-Schroedinger Scholarship of the Austrian Science Funds [J3389-B23]; NIH [CA131301, CA157749]; Austrian Science Fund (FWF) [J 3389] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [P50CA127001, R01CA182905, R01CA157749, R01CA131301, P50CA093459, P50CA100632, P50CA097007] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UH2TR000943] Funding Source: NIH RePORTER	Odyssey Program at The University of Texas MD Anderson Cancer Center; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); UT MD Anderson Cancer Center SPORE in Melanoma grant from NCI; Aim at Melanoma Foundation; Miriam and Jim Mulva research funds; Brain SPORE; Center for radiation Oncology Research Project; Center for Cancer Epigenetics Pilot project; Knowledge GAP MDACC grant; CLL Moonshot pilot project; UT MD Anderson Cancer Center Duncan Family Institute for Cancer Prevention and Risk Assessment; SINF grant in colon cancer; Laura and John Arnold Foundation; RGK Foundation; Estate of C. G. Johnson; Erwin-Schroedinger Scholarship of the Austrian Science Funds; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	HL is an Odyssey Fellow, and his work is supported in part by the Odyssey Program at The University of Texas MD Anderson Cancer Center. GAC is The Alan M. Gewirtz Leukemia & Lymphoma Society Scholar. Work in Dr Calin's laboratory is supported in part by the NIH/NCI grants 1UH2TR00943-01 and 1 R01 CA182905-01, the UT MD Anderson Cancer Center SPORE in Melanoma grant from NCI (P50 CA093459), Aim at Melanoma Foundation and the Miriam and Jim Mulva research funds, the Brain SPORE (2P50CA127001), the Center for radiation Oncology Research Project, the Center for Cancer Epigenetics Pilot project, a 2014 Knowledge GAP MDACC grant, a CLL Moonshot pilot project, the UT MD Anderson Cancer Center Duncan Family Institute for Cancer Prevention and Risk Assessment, a SINF grant in colon cancer, the Laura and John Arnold Foundation, the RGK Foundation and the Estate of C. G. Johnson, Jr. MP is supported by an Erwin-Schroedinger Scholarship of the Austrian Science Funds (project no. J3389-B23). IBN is a Fulbright Scholar at MD Anderson Cancer Center. FS was supported by NIH grants CA131301 and CA157749. We apologize to all colleagues whose work was not cited because of space restrictions.	Allen TA, 2004, NAT STRUCT MOL BIOL, V11, P816, DOI 10.1038/nsmb813; Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012; Bejerano G, 2004, SCIENCE, V304, P1321, DOI 10.1126/science.1098119; Beltran M, 2008, GENE DEV, V22, P756, DOI 10.1101/gad.455708; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bertani S, 2011, MOL CELL, V43, P1040, DOI 10.1016/j.molcel.2011.08.019; Bertucci F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037943; Blackwood EM, 1998, SCIENCE, V281, P60, DOI 10.1126/science.281.5373.60; Braconi C, 2011, P NATL ACAD SCI USA, V108, P786, DOI 10.1073/pnas.1011098108; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2007, CANCER CELL, V12, P215, DOI 10.1016/j.ccr.2007.07.027; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Cech TR, 2014, CELL, V157, P77, DOI 10.1016/j.cell.2014.03.008; Chen DY, 2014, CELL IMMUNOL, V289, P91, DOI 10.1016/j.cellimm.2014.03.015; Chu C, 2011, MOL CELL, V44, P667, DOI 10.1016/j.molcel.2011.08.027; Chung SY, 2011, CANCER SCI, V102, P245, DOI 10.1111/j.1349-7006.2010.01737.x; COMINGS DE, 1972, ADV HUM GENET, P237; Core LJ, 2008, SCIENCE, V322, P1845, DOI 10.1126/science.1162228; Di Ruscio A, 2013, NATURE, V503, P371, DOI 10.1038/nature12598; Djebali S, 2012, NATURE, V489, P101, DOI 10.1038/nature11233; Du YM, 2012, J BIOL CHEM, V287, P26302, DOI 10.1074/jbc.M112.342113; Du Z, 2013, NAT STRUCT MOL BIOL, V20, P908, DOI 10.1038/nsmb.2591; Easton DF, 2007, NATURE, V447, P1087, DOI 10.1038/nature05887; Eeles RA, 2008, NAT GENET, V40, P316, DOI 10.1038/ng.90; Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074; Faghihi MA, 2009, NAT REV MOL CELL BIO, V10, P637, DOI 10.1038/nrm2738; Fatica A, 2014, NAT REV GENET, V15, P7, DOI 10.1038/nrg3606; Feng JC, 2006, GENE DEV, V20, P1470, DOI 10.1101/gad.1416106; Ferdin J, 2013, CELL DEATH DIFFER, V20, P1675, DOI 10.1038/cdd.2013.119; Fu XQ, 2006, DNA CELL BIOL, V25, P135, DOI 10.1089/dna.2006.25.135; Gaudet MM, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001183; Geisler S, 2013, NAT REV MOL CELL BIO, V14, P699, DOI 10.1038/nrm3679; Ghoussaini M, 2008, JNCI-J NATL CANCER I, V100, P962, DOI 10.1093/jnci/djn190; Gong CG, 2011, NATURE, V470, P284, DOI 10.1038/nature09701; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Gutschner T, 2013, CANCER RES, V73, P1180, DOI 10.1158/0008-5472.CAN-12-2850; Gutschner T, 2012, RNA BIOL, V9, P703, DOI 10.4161/rna.20481; Hafner M, 2010, CELL, V141, P129, DOI 10.1016/j.cell.2010.03.009; Hindorff LA, 2009, P NATL ACAD SCI USA, V106, P9362, DOI 10.1073/pnas.0903103106; Hnisz D, 2013, CELL, V155, P934, DOI 10.1016/j.cell.2013.09.053; Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040; Hung T, 2011, NAT GENET, V43, P621, DOI 10.1038/ng.848; Huppi Konrad, 2012, Frontiers in Genetics, V3, P69, DOI 10.3389/fgene.2012.00069; Jeon Y, 2011, CELL, V146, P119, DOI 10.1016/j.cell.2011.06.026; Ji P, 2003, ONCOGENE, V22, P8031, DOI 10.1038/sj.onc.1206928; Jia L, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000597; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Katayama S, 2005, SCIENCE, V309, P1564, DOI 10.1126/science.1112009; Khalil AM, 2009, P NATL ACAD SCI USA, V106, P11667, DOI 10.1073/pnas.0904715106; Kim HS, 2013, CELL, V152, P387, DOI 10.1016/j.cell.2013.01.027; Kim K, 2013, ONCOGENE, V32, P1616, DOI 10.1038/onc.2012.193; Kim TK, 2010, NATURE, V465, P182, DOI 10.1038/nature09033; Kim T, 2014, P NATL ACAD SCI USA, V111, P4173, DOI 10.1073/pnas.1400350111; Koch F, 2011, NAT STRUCT MOL BIOL, V18, P956, DOI 10.1038/nsmb.2085; Kogo R, 2011, CANCER RES, V71, P6320, DOI 10.1158/0008-5472.CAN-11-1021; Kumar V, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003201; Lai F, 2013, NATURE, V494, P497, DOI 10.1038/nature11884; Lee JT, 2013, CELL, V152, P1308, DOI 10.1016/j.cell.2013.02.016; Lee JT, 2009, GENE DEV, V23, P1831, DOI 10.1101/gad.1811209; Lee JT, 1999, NAT GENET, V21, P400, DOI 10.1038/7734; Levine M, 2003, NATURE, V424, P147, DOI 10.1038/nature01763; Li LJ, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-104; Ling H, 2013, NAT REV DRUG DISCOV, V12, P847, DOI 10.1038/nrd4140; Ling H, 2013, GENOME RES, V23, P1446, DOI 10.1101/gr.152942.112; Liu Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035145; Liz J, 2014, MOL CELL, V55, P138, DOI 10.1016/j.molcel.2014.05.005; Maenner S, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000276; Mariner PD, 2008, MOL CELL, V29, P499, DOI 10.1016/j.molcel.2007.12.013; Martin L, 2012, NAT METHODS, V9, P1192, DOI [10.1038/nmeth.2225, 10.1038/NMETH.2225]; Matouk IJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000845; Melo CA, 2013, MOL CELL, V49, P524, DOI 10.1016/j.molcel.2012.11.021; Mercer TR, 2013, NAT STRUCT MOL BIOL, V20, P300, DOI 10.1038/nsmb.2480; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nagano T, 2008, SCIENCE, V322, P1717, DOI 10.1126/science.1163802; Niinuma T, 2012, CANCER RES, V72, P1126, DOI 10.1158/0008-5472.CAN-11-1803; Ning SW, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-152; Novikova IV, 2012, NUCLEIC ACIDS RES, V40, P5034, DOI 10.1093/nar/gks071; Ogawa Y, 2008, SCIENCE, V320, P1336, DOI 10.1126/science.1157676; Orom UA, 2013, CELL, V154, P1190, DOI 10.1016/j.cell.2013.08.028; Orom UA, 2010, CELL, V143, P46, DOI 10.1016/j.cell.2010.09.001; Paige JS, 2011, SCIENCE, V333, P642, DOI 10.1126/science.1207339; Pasmant E, 2007, CANCER RES, V67, P3963, DOI 10.1158/0008-5472.CAN-06-2004; Pasmant E, 2011, J NATL CANCER I, V103, P1713, DOI 10.1093/jnci/djr416; Pasmant E, 2011, FASEB J, V25, P444, DOI 10.1096/fj.10-172452; Plath K, 2003, SCIENCE, V300, P131, DOI 10.1126/science.1084274; Pomerantz MM, 2009, NAT GENET, V41, P882, DOI 10.1038/ng.403; Prensner JR, 2014, CANCER RES, V74, P1651, DOI 10.1158/0008-5472.CAN-13-3159; Prensner JR, 2011, NAT BIOTECHNOL, V29, P742, DOI 10.1038/nbt.1914; Redis RS, 2013, ONCOTARGET, V4, P1748, DOI 10.18632/oncotarget.1292; Ren SC, 2013, EUR J CANCER, V49, P2949, DOI 10.1016/j.ejca.2013.04.026; Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022; Rittenhouse H, 2013, CLIN CHEM, V59, P32, DOI 10.1373/clinchem.2012.198739; Sanford JR, 2009, GENOME RES, V19, P381, DOI 10.1101/gr.082503.108; Schmitz KM, 2010, GENE DEV, V24, P2264, DOI 10.1101/gad.590910; Seila AC, 2008, SCIENCE, V322, P1849, DOI 10.1126/science.1162253; Simon MD, 2013, NATURE, V504, P465, DOI 10.1038/nature12719; Srikantan V, 2000, P NATL ACAD SCI USA, V97, P12216, DOI 10.1073/pnas.97.22.12216; Sun BK, 2006, MOL CELL, V21, P617, DOI 10.1016/j.molcel.2006.01.028; Sur I, 2013, CANCER RES, V73, P4180, DOI 10.1158/0008-5472.CAN-13-0789; Sur IK, 2012, SCIENCE, V338, P1360, DOI 10.1126/science.1228606; Tomlinson I, 2007, NAT GENET, V39, P984, DOI 10.1038/ng2085; Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002; Tseng YY, 2014, NATURE, V512, P82, DOI 10.1038/nature13311; Tuupanen S, 2009, NAT GENET, V41, P885, DOI 10.1038/ng.406; Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020; Ulitsky I, 2011, CELL, V147, P1537, DOI 10.1016/j.cell.2011.11.055; Verhaegh GW, 2008, EUR UROL, V54, P1118, DOI 10.1016/j.eururo.2008.01.060; Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018; Wang KC, 2011, NATURE, V472, P120, DOI 10.1038/nature09819; Wang XJ, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-4-r30; Wapinski O, 2011, TRENDS CELL BIOL, V21, P354, DOI 10.1016/j.tcb.2011.04.001; Wojcik SE, 2010, CARCINOGENESIS, V31, P208, DOI 10.1093/carcin/bgp209; Xiang JF, 2014, CELL RES, V24, P513, DOI 10.1038/cr.2014.35; Xue Y, 2013, PROSTATE CANCER P D, V16, P139, DOI 10.1038/pcan.2013.6; Yakovchuk P, 2009, P NATL ACAD SCI USA, V106, P5569, DOI 10.1073/pnas.0810738106; Yang L, 2014, TRENDS BIOCHEM SCI, V39, P35, DOI 10.1016/j.tibs.2013.10.002; Yang LQ, 2013, NATURE, V500, P598, DOI 10.1038/nature12451; Yang Z, 2011, ANN SURG ONCOL, V18, P1243, DOI 10.1245/s10434-011-1581-y; Yap KL, 2010, MOL CELL, V38, P662, DOI 10.1016/j.molcel.2010.03.021; Yeager M, 2007, NAT GENET, V39, P645, DOI 10.1038/ng2022; Yildirim E, 2013, CELL, V152, P727, DOI 10.1016/j.cell.2013.01.034; Yu WQ, 2008, NATURE, V451, P202, DOI 10.1038/nature06468; Zhang L, 2013, CARCINOGENESIS, V34, P577, DOI 10.1093/carcin/bgs381; Zhang X, 2010, ENDOCRINOLOGY, V151, P939, DOI 10.1210/en.2009-0657	124	241	249	0	85	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2015	34	39					5003	5011		10.1038/onc.2014.456	http://dx.doi.org/10.1038/onc.2014.456			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR9RC	25619839	Green Accepted, Green Submitted			2022-12-17	WOS:000361693300001
J	Sparks, CA; Guertin, DA				Sparks, C. A.; Guertin, D. A.			Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy	ONCOGENE			English	Review						mTOR; mTORC2; AKT; SGK; rapamycin; Rictor	AKT/PROTEIN-KINASE-B; MAMMALIAN TARGET; TOR COMPLEX-2; CELL-GROWTH; MOTIF PHOSPHORYLATION; ACTIN CYTOSKELETON; TSC1-TSC2 COMPLEX; BINDING PARTNER; PROTEINS SLM1; SIGNAL RELAY	Small molecule inhibitors that selectively target cancer cells and not normal cells would be valuable anti-cancer therapeutics. The mammalian target of rapamycin complex 2 (mTORC2) is emerging as a promising candidate target for such an inhibitor. Recent studies in cancer biology indicate that mTORC2 activity is essential for the transformation and vitality of a number of cancer cell types, but in many normal cells, mTORC2 activity is less essential. These studies are intensifying interest in developing inhibitors that specifically target mTORC2. However, there are many open questions regarding the function and regulation of mTORC2 and its function in both normal and cancer cells. Here, we summarize exciting new research into the biology of mTORC2 signaling and highlight the current state and future prospects for mTOR-targeted therapy. Oncogene (2010) 29, 3733-3744; doi: 10.1038/onc.2010.139; published online 26 April 2010	[Sparks, C. A.; Guertin, D. A.] Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Guertin, DA (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, 373 Plantat St, Worcester, MA 01605 USA.	david.guertin@umassmed.edu			National Institutes of Health [R00 CA129613]; Charles Hood Foundation; UMass Center for Clinical and Translational Sciences; NATIONAL CANCER INSTITUTE [R00CA129613] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Charles Hood Foundation; UMass Center for Clinical and Translational Sciences; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	DAG is supported by grants from the National Institutes of Health (R00 CA129613), the Charles Hood Foundation, and the UMass Center for Clinical and Translational Sciences.	Acosta-Jaquez HA, 2009, MOL CELL BIOL, V29, P4308, DOI 10.1128/MCB.01665-08; Akcakanat A, 2007, BIOCHEM BIOPH RES CO, V362, P330, DOI 10.1016/j.bbrc.2007.07.151; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Aronova S, 2008, CELL METAB, V7, P148, DOI 10.1016/j.cmet.2007.11.015; Audhya A, 2004, EMBO J, V23, P3747, DOI 10.1038/sj.emboj.7600384; Barquilla A, 2008, P NATL ACAD SCI USA, V105, P14579, DOI 10.1073/pnas.0802668105; Bentzinger CF, 2008, CELL METAB, V8, P411, DOI 10.1016/j.cmet.2008.10.002; Berchtold D, 2009, MOL BIOL CELL, V20, P1565, DOI 10.1091/mbc.E08-10-1001; Bozulic L, 2009, CURR OPIN CELL BIOL, V21, P256, DOI 10.1016/j.ceb.2009.02.002; Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/jCI34739, 10.1172/JCI34739]; Chresta CM, 2010, CANCER RES, V70, P288, DOI 10.1158/0008-5472.CAN-09-1751; Copp J, 2009, CANCER RES, V69, P1821, DOI 10.1158/0008-5472.CAN-08-3014; Cybulski N, 2009, P NATL ACAD SCI USA, V106, P9902, DOI 10.1073/pnas.0811321106; Dibble CC, 2009, MOL CELL BIOL, V29, P5657, DOI 10.1128/MCB.00735-09; EFEYAN A, 2009, CURR OPIN CELL BIOL, V22, P1; Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890; Facchinetti V, 2008, EMBO J, V27, P1932, DOI 10.1038/emboj.2008.120; Fadri M, 2005, MOL BIOL CELL, V16, P1883, DOI 10.1091/mbc.e04-07-0564; Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038; Frias MA, 2006, CURR BIOL, V16, P1865, DOI 10.1016/j.cub.2006.08.001; Gangloff YG, 2004, MOL CELL BIOL, V24, P9508, DOI 10.1128/MCB.24.21.9508-9516.2004; Garcia-Martinez JM, 2009, BIOCHEM J, V421, P29, DOI 10.1042/BJ20090489; Garcia-Martinez JM, 2008, BIOCHEM J, V416, P375, DOI 10.1042/BJ20081668; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Guertin DA, 2006, DEV CELL, V11, P859, DOI 10.1016/j.devcel.2006.10.007; Guertin DA, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.267pe24; Guertin DA, 2009, CANCER CELL, V15, P148, DOI 10.1016/j.ccr.2008.12.017; Gulhati P, 2009, CLIN CANCER RES, V15, P7207, DOI 10.1158/1078-0432.CCR-09-1249; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hayashi T, 2007, GENES CELLS, V12, P1357, DOI 10.1111/j.1365-2443.2007.01141.x; Hietakangas V, 2007, GENE DEV, V21, P632, DOI 10.1101/gad.416307; Hietakangas V, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-282; Hresko RC, 2005, J BIOL CHEM, V280, P40406, DOI 10.1074/jbc.M508361200; Huang JX, 2008, MOL CELL BIOL, V28, P4104, DOI 10.1128/MCB.00289-08; Huang J, 2008, BIOCHEM J, V412, P179, DOI 10.1042/BJ20080281; Huang JX, 2009, CANCER RES, V69, P6107, DOI 10.1158/0008-5472.CAN-09-0975; Ikenoue T, 2008, EMBO J, V27, P1919, DOI 10.1038/emboj.2008.119; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Jacinto E, 2008, BIOCHEM J, V410, P19, DOI 10.1042/BJ20071518; Jacinto E, 2006, CELL, V127, P125, DOI 10.1016/j.cell.2006.08.033; Janes MR, 2010, NAT MED, V16, P205, DOI 10.1038/nm.2091; Jones KT, 2009, PLOS BIOL, V7, P604, DOI 10.1371/journal.pbio.1000060; Julien LA, 2010, MOL CELL BIOL, V30, P908, DOI 10.1128/MCB.00601-09; Kamada Y, 2005, MOL CELL BIOL, V25, P7239, DOI 10.1128/MCB.25.16.7239-7248.2005; Kamimura Y, 2008, CURR BIOL, V18, P1034, DOI 10.1016/j.cub.2008.06.068; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kim E, 2009, CELL CYCLE, V8, P1014, DOI 10.4161/cc.8.7.8124; Koike-Kumagai M, 2009, EMBO J, V28, P3879, DOI 10.1038/emboj.2009.312; Kumar A, 2008, MOL CELL BIOL, V28, P61, DOI 10.1128/MCB.01405-07; Laplante M, 2009, CURR BIOL, V19, pR1046, DOI 10.1016/j.cub.2009.09.058; Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011; Lee S, 2005, MOL BIOL CELL, V16, P4572, DOI 10.1091/mbc.E05-04-0342; Lee S, 1999, MOL BIOL CELL, V10, P2829, DOI 10.1091/mbc.10.9.2829; Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Martiny-Baron G, 2007, PHARMACOL RES, V55, P477, DOI 10.1016/j.phrs.2007.04.001; Masri J, 2007, CANCER RES, V67, P11712, DOI 10.1158/0008-5472.CAN-07-2223; McManus EJ, 2004, EMBO J, V23, P2071, DOI 10.1038/sj.emboj.7600218; Murakami M, 2004, MOL CELL BIOL, V24, P6710, DOI 10.1128/mcb.24.15.6710-6718.2004; Nardella C, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000189; Nojima H, 2003, J BIOL CHEM, V278, P15461, DOI 10.1074/jbc.C200665200; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Pearce LR, 2007, BIOCHEM J, V405, P513, DOI 10.1042/BJ20070540; Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046; Phung TL, 2006, CANCER CELL, V10, P159, DOI 10.1016/j.ccr.2006.07.003; Recher C, 2005, CELL CYCLE, V4, P1540; Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Schroder W, 2005, CELL SIGNAL, V17, P761, DOI 10.1016/j.cellsig.2004.10.015; Schroder WA, 2007, CELL SIGNAL, V19, P1279, DOI 10.1016/j.cellsig.2007.01.013; Shiota C, 2006, DEV CELL, V11, P583, DOI 10.1016/j.devcel.2006.08.013; Shor B, 2008, CANCER RES, V68, P2934, DOI 10.1158/0008-5472.CAN-07-6487; Shor B, 2009, CELL CYCLE, V8, P3831, DOI 10.4161/cc.8.23.10070; Soukas AA, 2009, GENE DEV, V23, P496, DOI 10.1101/gad.1775409; Sturgill TW, 2008, EUKARYOT CELL, V7, P1819, DOI 10.1128/EC.00088-08; Tabuchi M, 2006, MOL CELL BIOL, V26, P5861, DOI 10.1128/MCB.02403-05; Tessier M, 2006, J CELL BIOCHEM, V98, P1391, DOI 10.1002/jcb.20894; Thedieck K, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001217; Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200; Treins C, 2010, ONCOGENE, V29, P1003, DOI 10.1038/onc.2009.401; Vasudevan KM, 2009, CANCER CELL, V16, P21, DOI 10.1016/j.ccr.2009.04.012; Wang X, 2009, TRENDS CELL BIOL, V19, P260, DOI 10.1016/j.tcb.2009.03.005; White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023; Witzig TE, 2005, J CLIN ONCOL, V23, P5347, DOI 10.1200/JCO.2005.13.466; Witzig Thomas E, 2006, Curr Treat Options Oncol, V7, P285, DOI 10.1007/s11864-006-0038-1; Woo SY, 2007, J BIOL CHEM, V282, P25604, DOI 10.1074/jbc.M704343200; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Wullschleger S, 2005, J BIOL CHEM, V280, P30697, DOI 10.1074/jbc.M505553200; Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6; Yang Q, 2006, P NATL ACAD SCI USA, V103, P6811, DOI 10.1073/pnas.0602282103; Yang Q, 2006, GENE DEV, V20, P2820, DOI 10.1101/gad.1461206; Yu K, 2009, CANCER RES, V69, P6232, DOI 10.1158/0008-5472.CAN-09-0299; Yuan RR, 2009, J HEMATOL ONCOL, V2, DOI 10.1186/1756-8722-2-45; Zeng ZH, 2007, BLOOD, V109, P3509, DOI 10.1182/blood-2006-06-030833; Zhang HB, 2007, J CLIN INVEST, V117, P730, DOI 10.1172/JCI28984; Zhang Y, 2006, GENETICS, V172, P355, DOI 10.1534/genetics.105.051979	103	241	256	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2010	29	26					3733	3744		10.1038/onc.2010.139	http://dx.doi.org/10.1038/onc.2010.139			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	618VW	20418915	Green Accepted			2022-12-17	WOS:000279385200001
J	Mikels, AJ; Nusse, R				Mikels, A. J.; Nusse, R.			Wnts as ligands: processing, secretion and reception	ONCOGENE			English	Review						Wnt; receptors; secretion; signaling	HEPARAN-SULFATE PROTEOGLYCANS; SEGMENT POLARITY GENES; CYSTEINE-RICH DOMAIN; LONG-RANGE ACTION; SIGNALING PATHWAY; REQUIRES RETROMER; FRIZZLED FAMILY; PORCUPINE GENE; LIPID RAFTS; WINGLESS	Cell to cell communication is vital throughout the development of multicellular organisms and during adult homeostasis. One way in which communication is achieved is through the secretion of signaling molecules that are received by neighboring responding cells. Wnt ligands comprise a large family of secreted, hydrophobic, glycoproteins that control a variety of developmental and adult processes in all metazoan organisms. By binding to various receptors present on receiving cells, Wnts initiate intracellular signaling cascades resulting in changes in gene transcription. Misregulation of Wnt signaling contributes to cancer and other degenerative disorders; thus, much effort has been made to understand the ways in which the pathway is controlled. Although ample research into the regulatory mechanisms that influence intracellular signaling events has proved fruitful, a great deal still remains to be elucidated regarding the mechanisms that control Wnt protein processing and secretion from cells, transport through the extracellular space, and protein reception on neighboring cells. This review attempts to consolidate the current data regarding these essential processes.	Stanford Univ, Sch Med, Beckman Ctr, Howard Hughes Med Inst,Dept Dev Biol, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University	Nusse, R (corresponding author), Stanford Univ, Sch Med, Beckman Ctr, Howard Hughes Med Inst,Dept Dev Biol, Stanford, CA 94305 USA.	rnusse@stanford.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067834] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baeg GH, 2001, DEVELOPMENT, V128, P87; Banziger C, 2006, CELL, V125, P509, DOI 10.1016/j.cell.2006.02.049; Bartscherer K, 2006, CELL, V125, P523, DOI 10.1016/j.cell.2006.04.009; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Binari RC, 1997, DEVELOPMENT, V124, P2623; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BURRUS LW, 1995, EXP CELL RES, V220, P363, DOI 10.1006/excr.1995.1327; Cadigan KM, 1998, CELL, V93, P767, DOI 10.1016/S0092-8674(00)81438-5; Carron C, 2003, J CELL SCI, V116, P2541, DOI 10.1242/jcs.00451; Chen CM, 2004, P NATL ACAD SCI USA, V101, P15961, DOI 10.1073/pnas.0407103101; Chen W, 2003, SCIENCE, V301, P1391, DOI 10.1126/science.1082808; Ching W, 2006, CELL, V125, P432, DOI 10.1016/j.cell.2006.04.018; Clevers H, 2006, CANCER RES, V66, P2, DOI 10.1158/0008-5472.CAN-05-3849; Cong F, 2004, DEVELOPMENT, V131, P5103, DOI 10.1242/dev.01318; Coudreuse DYM, 2006, SCIENCE, V312, P921, DOI 10.1126/science.1124856; Davidson G, 2005, NATURE, V438, P867, DOI 10.1038/nature04170; de Iongh RU, 2006, FRONT BIOSCI-LANDMRK, V11, P2442, DOI 10.2741/1982; Djiane A, 2000, DEVELOPMENT, V127, P3091; DU SJ, 1995, MOL CELL BIOL, V15, P2625; Forrester WC, 2004, GENETICS, V168, P1951, DOI 10.1534/genetics.104.031781; Forrester WC, 2002, CELL MOL LIFE SCI, V59, P83, DOI 10.1007/s00018-002-8407-9; Fox S, 2006, FRONT BIOSCI-LANDMRK, V11, P2106, DOI 10.2741/1953; Greco V, 2001, CELL, V106, P633, DOI 10.1016/S0092-8674(01)00484-6; Hacker U, 1997, DEVELOPMENT, V124, P3565; He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117; Hofmann K, 2000, TRENDS BIOCHEM SCI, V25, P111, DOI 10.1016/S0968-0004(99)01539-X; Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899; Hsieh JC, 1999, P NATL ACAD SCI USA, V96, P3546, DOI 10.1073/pnas.96.7.3546; Kadowaki T, 1996, GENE DEV, V10, P3116, DOI 10.1101/gad.10.24.3116; Katanaev VL, 2005, CELL, V120, P111, DOI 10.1016/j.cell.2004.11.014; KITAMI Y, 1992, BLOOD PRESSURE S3, V1, P12; Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551; Kroiher M, 2001, BIOESSAYS, V23, P69, DOI 10.1002/1521-1878(200101)23:1<69::AID-BIES1009>3.3.CO;2-B; Kuhl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x; Li Yonghe, 2005, Future Oncol, V1, P673, DOI 10.2217/14796694.1.5.673; Liepinsh E, 2006, J MOL BIOL, V357, P942, DOI 10.1016/j.jmb.2006.01.047; Lin XH, 2002, GLYCOCONJUGATE J, V19, P363, DOI 10.1023/A:1025329323438; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Liu GZ, 2003, MOL CELL BIOL, V23, P5825, DOI 10.1128/MCB.23.16.5825-5835.2003; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Lu WG, 2004, CELL, V119, P97, DOI 10.1016/j.cell.2004.09.019; Manoukian AS, 1995, DEVELOPMENT, V121, P4037; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; MASON JO, 1992, MOL BIOL CELL, V3, P521, DOI 10.1091/mbc.3.5.521; Matsuda T, 2001, MECH DEVELOP, V105, P153, DOI 10.1016/S0925-4773(01)00383-5; Mikels AJ, 2006, PLOS BIOL, V4, P570, DOI 10.1371/journal.pbio.0040115; Neumann CJ, 1997, DEVELOPMENT, V124, P871; NOORDERMEER J, 1995, MECH DEVELOP, V51, P145, DOI 10.1016/0925-4773(95)00348-7; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; Nusse R, 2003, DEVELOPMENT, V130, P5297, DOI 10.1242/dev.00821; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; Oishi I, 2003, GENES CELLS, V8, P645, DOI 10.1046/j.1365-2443.2003.00662.x; Panakova D, 2005, NATURE, V435, P58, DOI 10.1038/nature03504; Polakis P, 2000, GENE DEV, V14, P1837; Povelones M, 2005, EMBO J, V24, P3493, DOI 10.1038/sj.emboj.7600817; Prasad BC, 2006, DEVELOPMENT, V133, P1757, DOI 10.1242/dev.02357; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Schulte G, 2005, J NEUROCHEM, V92, P1550, DOI 10.1111/j.1471-4159.2004.03022.x; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Spellman PT, 2002, GENOME BIOL, V3; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Tanaka K, 2002, J BIOL CHEM, V277, P12816, DOI 10.1074/jbc.M200187200; Tanaka K, 2000, EUR J BIOCHEM, V267, P4300, DOI 10.1046/j.1432-1033.2000.01478.x; Tao QH, 2005, CELL, V120, P857, DOI 10.1016/j.cell.2005.01.013; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; Verges M, 2004, NAT CELL BIOL, V6, P763, DOI 10.1038/ncb1153; Wang HY, 2004, CELL MOL LIFE SCI, V61, P69, DOI 10.1007/s00018-003-3165-x; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Wu CH, 2002, J BIOL CHEM, V277, P41762, DOI 10.1074/jbc.M207850200; Xu YK, 1998, CURR BIOL, V8, pR405, DOI 10.1016/S0960-9822(98)70262-3; Yamaguchi TP, 1999, DEVELOPMENT, V126, P1211; Yoda A, 2003, J RECEPT SIG TRANSD, V23, P1, DOI 10.1081/RRS-120018757; Yoshikawa S, 2003, NATURE, V422, P583, DOI 10.1038/nature01522; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1; Zeng X, 2005, NATURE, V438, P873, DOI 10.1038/nature04185; Zhai L, 2004, J BIOL CHEM, V279, P33220, DOI 10.1074/jbc.M403407200	81	241	263	0	20	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2006	25	57					7461	7468		10.1038/sj.onc.1210053	http://dx.doi.org/10.1038/sj.onc.1210053			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	112GX	17143290				2022-12-17	WOS:000242514900004
J	Pandey, P; Farber, R; Nakazawa, A; Kumar, S; Bharti, A; Nalin, C; Weichselbaum, R; Kufe, D; Kharbanda, S				Pandey, P; Farber, R; Nakazawa, A; Kumar, S; Bharti, A; Nalin, C; Weichselbaum, R; Kufe, D; Kharbanda, S			Hsp27 functions as a negative regulator of cytochrome c-dependent activation of procaspase-3	ONCOGENE			English	Article						Hsp27; cytochrome c; caspase-3; apoptosis	HEAT-SHOCK PROTEIN; PROGRAMMED CELL-DEATH; EMBRYONIC STEM-CELLS; ALPHA-B-CRYSTALLIN; CAENORHABDITIS-ELEGANS; PROTEOLYTIC ACTIVATION; ICE/CED-3 PROTEASE; INDUCED APOPTOSIS; CARCINOMA-CELLS; DNA-DAMAGE	The release of mitochondrial cytochrome c by genotoxic stress induces the formation of a cytosolic complex with Apaf-1 (mammalian CED4 homolog) and thereby the activation of procaspase-3 (cas-3) and procaspase-9 (cas-9). Here we demonstrate that heat-shock protein 27 (Hsp27) inhibits cytochrome c (cyt c)-dependent activation of cas-3. Hsp27 had no effect on cyt c release, Apaf-1 and cas-9 activation. By contrast, our results show that Hsp27 associates with cas-3, but not Apaf-1 or cas-9, and inhibits activation of cas-3 by cas-9-mediated proteolysis, Furthermore, the present results demonstrate that immunodepletion of Hsp27 depletes cas-3, Importantly, treatment of cells with DNA damaging agents dissociates the Hsp27/cas-3 complex and relieves inhibition of cas-3 activation. These findings define a novel function for Hsp27 and provide the first evidence that a heat shock protein represses cas-3 activation.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Novartis Pharmaceut, E Hanover, NJ 07936 USA; Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Novartis; University of Chicago	Kharbanda, S (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA075216, R01CA029431] Funding Source: NIH RePORTER; NCI NIH HHS [CA29431, CA75216] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; ARRIGO AP, 1994, HEAT SHOCK PROTEINS, P335; Chaufour S, 1996, CELL STRESS CHAPERON, V1, P225, DOI 10.1379/1466-1268(1996)001<0225:TAPACI>2.3.CO;2; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; ESPOSITO F, 1994, BIOCHEM J, V301, P649, DOI 10.1042/bj3010649; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; Ito H, 1997, J BIOL CHEM, V272, P29934, DOI 10.1074/jbc.272.47.29934; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; KIRKEN RA, 1995, PROTEIN EXPRES PURIF, V6, P707, DOI 10.1006/prep.1995.1093; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mancini M, 1998, J CELL BIOL, V140, P1485, DOI 10.1083/jcb.140.6.1485; MANSER PW, 1999, J BIOL CHEM, V274, P22635; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; Mehlen P, 1997, J BIOL CHEM, V272, P31657, DOI 10.1074/jbc.272.50.31657; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; MEHLEN P, 1994, EUR J BIOCHEM, V221, P327, DOI 10.1111/j.1432-1033.1994.tb18744.x; MEHLEN P, 1995, BIOCHEM J, V312, P367, DOI 10.1042/bj3120367; MING Z, 1993, J BIOL CHEM, V268, P35; Narula J, 1999, P NATL ACAD SCI USA, V96, P8144, DOI 10.1073/pnas.96.14.8144; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; PAULI D, 1990, J CELL BIOL, V111, P817, DOI 10.1083/jcb.111.3.817; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; SHAKOORI AR, 1992, J CELL BIOCHEM, V48, P277, DOI 10.1002/jcb.240480308; SPECTOR NL, 1992, J IMMUNOL, V148, P1668; STAHL J, 1992, DIFFERENTIATION, V51, P33, DOI 10.1111/j.1432-0436.1992.tb00677.x; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; Vaux DL, 1997, CELL, V90, P389, DOI 10.1016/S0092-8674(00)80497-3; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	46	241	253	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2000	19	16					1975	1981		10.1038/sj.onc.1203531	http://dx.doi.org/10.1038/sj.onc.1203531			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	306TT	10803458				2022-12-17	WOS:000086613200001
J	Chaudhary, PM; Jasmin, A; Eby, MT; Hood, L				Chaudhary, PM; Jasmin, A; Eby, MT; Hood, L			Modulation of the NF-kappa B pathway by virally encoded death effector domains-containing proteins	ONCOGENE			English	Article						vFLIP; NF-kappa B; TNFR; apoptosis; HHV8	NECROSIS-FACTOR RECEPTOR; INDUCED CELL-DEATH; KAPOSIS-SARCOMA; HERPESVIRUS HUMAN-HERPESVIRUS-8; INDUCED APOPTOSIS; SIGNAL-TRANSDUCTION; CD95 FAS/APO-1; KINASE-ALPHA; TNF; ACTIVATION	Death Effector Domains (DEDs) have been known to mediate the recruitment of Caspase 8 and its homologs to the aggregated death-inducing signaling complex (DISC), consisting of the death domain (DD)-containing receptors and various signaling proteins. In addition, several viruses were recently shown to encode proteins with DEDs (also called FLICE inhibitory proteins or vFLIPs) which have the ability of blocking cell death induced by DD-containing receptors. We provide evidence that vFLIPs can also modulate the NF-kappa B pathway and physically interact with several signaling proteins, such as the TRAFs, RIP, NIK and the IKKs, Modulation of the NF-kappa B pathway may play a role in the natural history of infection by these viruses.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75235 USA; Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Washington; University of Washington Seattle	Chaudhary, PM (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.		Chaudhary, Preet/E-1970-2018					Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; Beauparlant Pierre, 1996, Cytokine and Growth Factor Reviews, V7, P175, DOI 10.1016/1359-6101(96)00020-2; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BERBERICH I, 1994, J IMMUNOL, V153, P4357; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Birthistle K, 1997, J INFECTION, V34, P21, DOI 10.1016/S0163-4453(97)80005-9; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Brooks LA, 1997, J PATHOL, V182, P262, DOI 10.1002/(SICI)1096-9896(199707)182:3<262::AID-PATH836>3.0.CO;2-Q; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Gallo R C, 1998, J Natl Cancer Inst Monogr, P55; Gilmore TD, 1996, ONCOGENE, V13, P1367; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; Hettmann T, 1999, J EXP MED, V189, P145, DOI 10.1084/jem.189.1.145; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu SM, 1997, J BIOL CHEM, V272, P9621; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; JUNG M, 1995, SCIENCE, V268, P1619, DOI 10.1126/science.7777860; Karp JE, 1996, HEMATOL ONCOL CLIN N, V10, P1031, DOI 10.1016/S0889-8588(05)70383-X; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Miles SA, 1996, HEMATOL ONCOL CLIN N, V10, P1011, DOI 10.1016/S0889-8588(05)70381-6; Moore PS, 1996, SCIENCE, V274, P1739, DOI 10.1126/science.274.5293.1739; Mosialos G, 1997, SEMIN CANCER BIOL, V8, P121, DOI 10.1006/scbi.1997.0063; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Natoli G, 1997, J BIOL CHEM, V272, P26079, DOI 10.1074/jbc.272.42.26079; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Rainbow L, 1997, J VIROL, V71, P5915, DOI 10.1128/JVI.71.8.5915-5921.1997; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothe M, 1996, P NATL ACAD SCI USA, V93, P8241, DOI 10.1073/pnas.93.16.8241; Sarid R, 1998, J VIROL, V72, P1005, DOI 10.1128/JVI.72.2.1005-1012.1998; Schulz TF, 1998, J GEN VIROL, V79, P1573, DOI 10.1099/0022-1317-79-7-1573; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Varfolomeev EE, 1996, J EXP MED, V183, P1271, DOI 10.1084/jem.183.3.1271; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	59	241	246	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 14	1999	18	42					5738	5746		10.1038/sj.onc.1202976	http://dx.doi.org/10.1038/sj.onc.1202976			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245FG	10523854				2022-12-17	WOS:000083095100002
J	Nishimori, H; Shiratsuchi, T; Urano, T; Kimura, Y; Kiyono, K; Tatsumi, K; Yoshida, S; Ono, M; Kuwano, M; Nakamura, Y; Tokino, T				Nishimori, H; Shiratsuchi, T; Urano, T; Kimura, Y; Kiyono, K; Tatsumi, K; Yoshida, S; Ono, M; Kuwano, M; Nakamura, Y; Tokino, T			A novel brain-specific p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis	ONCOGENE			English	Article						BAI1; thrombospondin type 1 repeat; p53; angiogenesis	GLIOBLASTOMA CELLS; P53; EXPRESSION; PROTEIN; METASTASIS; CANCERS; SITES; DNA	The genetic alteration of p53 is associated with neovascularization during progression of glioma to its more malignant form, glioblastoma, Hence, one or more of the genes transactivated by p53 is likely to function as an angiogenesis inhibitors, We isolated a novel p53-inducible gene that encodes a 1584-amino-acid product containing five thrombospondin type 1 (TSP-type 1) repeats and is specifically expressed in the brain, A recombinant protein corresponding to the TSP-type 1 repeats of this gene product inhibited in vivo neovascularization induced by bFGF in the rat cornea, The expression of this gene, designated BAI1 (brain-specific angiogenesis inhibitor 1) was absent or significantly reduced in eight of nine glioblastoma cell lines, suggesting BAI1 plays a significant role in angiogenesis inhibition, as a mediator of p53.	UNIV TOKYO, INST MED SCI, MOL MED LAB, TOKYO, JAPAN; KYUSHU UNIV, SCH MED, DEPT BIOCHEM, FUKUOKA 812, JAPAN; OTSUKA PHARMACEUT CO LTD, FUJII MEM RES INST, TOKUSHIMA, JAPAN	University of Tokyo; Kyushu University; Otsuka Pharmaceutical			Tokino, Takashi/AAI-9887-2021; Urano, Tomohiko/AFS-9574-2022	Yoshida, Shigeo/0000-0003-1049-8909				BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DSOUZA SE, 1991, TRENDS BIOCHEM SCI, V16, P246, DOI 10.1016/0968-0004(91)90096-E; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Furuhata T, 1996, ONCOGENE, V13, P1965; HAAS TA, 1994, CURR OPIN CELL BIOL, V6, P656, DOI 10.1016/0955-0674(94)90091-4; HAMANN J, 1995, J IMMUNOL, V155, P1942; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Ishikawa S, 1997, DNA Res, V4, P35, DOI 10.1093/dnares/4.1.35; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KIMURA Y, IN PRESS ONCOGENE; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; NAN HJ, 1995, HUM MOL GENET, V4, P237, DOI 10.1093/hmg/4.2.237; Roberts DD, 1996, FASEB J, V10, P1183, DOI 10.1096/fasebj.10.10.8751720; SOLOVYEV VV, 1994, NUCLEIC ACIDS RES, V22, P5156, DOI 10.1093/nar/22.24.5156; TOKINO T, 1991, AM J HUM GENET, V48, P258; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; VAN MEIR EG, 1994, CANCER RES, V54, P649; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; XU Y, 1995, COMPUT APPL BIOSCI, V11, P117	28	241	260	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	1997	15	18					2145	2150		10.1038/sj.onc.1201542	http://dx.doi.org/10.1038/sj.onc.1201542			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YD019	9393972				2022-12-17	WOS:A1997YD01900002
J	PICKSLEY, SM; VOJTESEK, B; SPARKS, A; LANE, DP				PICKSLEY, SM; VOJTESEK, B; SPARKS, A; LANE, DP			IMMUNOCHEMICAL ANALYSIS OF THE INTERACTION OF P53 WITH MDM2 - FINE MAPPING OF THE MDM2 BINDING-SITE ON P53 USING SYNTHETIC PEPTIDES	ONCOGENE			English	Article							TUMOR-SUPPRESSOR P53; VIRUS-40 T-ANTIGEN; MONOCLONAL-ANTIBODIES; PROTEIN COMPLEXES; GENE-EXPRESSION; DNA-BINDING; 3T3 CELLS; TRANSCRIPTION; ONCOPROTEIN; MUTANT	The function of p53 is modulated by binding to a number of cellular and viral proteins, such as MDM2 and SV40 large T antigen. An initial immunochemical characterization of the p53-MDM2 complex in a rat fibroblast cell line (Clone 6) suggested that the anti-p53 monoclonal antibody Bp53-19 failed to immunoprecipitate the complex, and only recognized a fraction of the available p53 protein. Following the recent identification of the Bp53-19 epitope at the N-terminal end of p53, in the vicinity of where MDM2 protein was known to bind, we investigated the possibility that Bp53-19 might identify a region of p53 that interacts with MDM2 protein. MDM2 was found to bind with great specificity to short synthetic peptides derived from the N-terminus of p53. Several p53 synthetic peptides libraries, and an alanine substitution series at the optimal binding site, were used to establish the MDM2 binding site, in fine detail, to the sequence TFSGLW (aa 18-23) in mouse and TFSDLW in man (aa 18-23). The key residues required for MDM2 binding are almost identical to those required for the monoclonal antibody Bp53-19 to bind and this region of p53 is recognised by many other anti-p53 antibodies.	UNIV DUNDEE,INST MED SCI,DEPT BIOCHEM,CRC,CELL TRANSFORMAT GRP,DUNDEE DD1 4HN,SCOTLAND; MASARY MEM CANC INST,ZLUTY KOPEC,CR-65653 BRNO,CZECH REPUBLIC	University of Dundee; Masaryk Memorial Cancer Institute			Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BARTEK J, 1993, J PATHOL, V169, P27, DOI 10.1002/path.1711690106; BROWN DR, 1993, MOL CELL BIOL, V13, P6849, DOI 10.1128/MCB.13.11.6849; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; DYSON N, 1992, J VIROL, V66, P4606, DOI 10.1128/JVI.66.7.4606-4611.1992; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1991, NATURE, V349, P802; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1988, ANTIBODIES LABORATOR; HARPER JW, 1993, CELL, V75, P805; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SCHLICHTHOLTZ B, 1993, CANCER RES, V52, P6380; SOUSSI T, 1990, ONCOGENE, V5, P945; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x	38	241	273	1	15	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2523	2529						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058315				2022-12-17	WOS:A1994PC05400011
J	Essafi, A; de Mattos, SF; Hassen, YAM; Soeiro, I; Mufti, GJ; Thomas, NSB; Medema, RH; Lam, EWF				Essafi, A; de Mattos, SF; Hassen, YAM; Soeiro, I; Mufti, GJ; Thomas, NSB; Medema, RH; Lam, EWF			Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells	ONCOGENE			English	Article						Bim; FoxO; Bcr-Abl; apoptosis; transcription	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; TYROSINE KINASE-ACTIVITY; FAMILY-MEMBER BIM; BCL-2 FAMILY; CYCLIN D2; IMATINIB MESYLATE; SIGNALING PATHWAY; BH3-ONLY PROTEIN; MAMMALIAN-CELLS	In this study, we have used the human BV173 and the mouse BaF3/Bcr-Abl-expressing cell lines as model systems to investigate the molecular mechanisms whereby STI571 and FoxO3a regulate Bim expression and apoptosis. FoxO3a lies downstream of Ber-Abl signalling and is constitutively phosphorylated in the Bcr-Abl-positive BV173 and BaF3/Bcr-Abl cells. Inhibition of Bcr-Abl kinase by STI571 results in FoxO3a activation, induction of Bim expression and apoptosis. Using reporter gene assays, we demonstrate that STI571 and FoxO3a activate Bim transcription through a FoxO-binding site (FHRE) located within the promoter. This was verified by DNA pull-down and chromatin immunoprecipitation analyses. We find that conditional activation of FoxO3a leads to induction of Bim expression and apoptosis. Conversely, silencing of FoxO3a in Bcr-Abl-expressing cells abolishes STI571-mediated Bim induction and apoptosis. Together, the results presented clearly confirm FoxO3a as a key regulator of apoptosis induced by ST1571, and show that Bim is a direct transcriptional target of FoxO3a that mediates the STI571-induced apoptosis. Thus, STI571 induces an accumulation of FoxO3a activity which in turn binds directly to an FHRE in the promoter to activate Bim expression and apoptosis.	Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Canc Med, Canc Res UK Labs, London W12 0NN, England; Univ London Kings Coll, Guys Kings & St Thomas Sch Med, Dept Haematol Med, Leukaemia Sci Labs,Rayne Inst, London SE5 9NU, England; Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands	Cancer Research UK; Imperial College London; University of London; King's College London; Netherlands Cancer Institute	Lam, EWF (corresponding author), Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Canc Med, Canc Res UK Labs, MRC Cyclotron Bldg,Du Cane Rd, London W12 0NN, England.	eric.lam@imperial.ac.uk	Essafi, Abdelkader/A-6602-2009; de Mattos, Silvia Fernández/K-5153-2014; Medema, Rene H/E-2981-2013; Medema, Rene H/G-5415-2011; Lam, Eric W-F/AAW-8566-2020	de Mattos, Silvia Fernández/0000-0003-4144-3687; Lam, Eric W-F/0000-0003-1274-3576; Medema, Rene/0000-0002-6754-0381				Akiyama T, 2003, EMBO J, V22, P6653, DOI 10.1093/emboj/cdg635; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Banerji L, 2001, ONCOGENE, V20, P7352, DOI 10.1038/sj.onc.1204951; Birkenkamp KU, 2003, BIOCHEM SOC T, V31, P292, DOI 10.1042/bst0310292; Birkenkamp KU, 2003, J IMMUNOL, V171, P1623, DOI 10.4049/jimmunol.171.4.1623; Biswas SC, 2002, J BIOL CHEM, V277, P49511, DOI 10.1074/jbc.M208086200; Borthakur G, 2004, INT J HEMATOL, V79, P411, DOI 10.1532/IJH97.04054; Bouillet P, 2001, MAMM GENOME, V12, P163, DOI 10.1007/s003350010242; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Burgering BMT, 2003, J LEUKOCYTE BIOL, V73, P689, DOI 10.1189/jlb.1202629; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; de Mattos SF, 2004, MOL CELL BIOL, V24, P10058, DOI 10.1128/MCB.24.22.10058-10071.2004; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Deininger MWN, 2001, CANCER RES, V61, P8005; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; EPNER DE, 1990, ANN INTERN MED, V113, P3, DOI 10.7326/0003-4819-113-1-3; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; Ghaffari S, 2003, P NATL ACAD SCI USA, V100, P6523, DOI 10.1073/pnas.0731871100; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Harada Hisashi, 2003, Rev Clin Exp Hematol, V7, P117; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; Haskovec C, 1998, BRIT J HAEMATOL, V103, P1104, DOI 10.1046/j.1365-2141.1998.01098.x; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; Komatsu N, 2003, J BIOL CHEM, V278, P6411, DOI 10.1074/jbc.M211562200; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; Kuribara R, 2004, MOL CELL BIOL, V24, P6172, DOI 10.1128/MCB.24.14.6172-6183.2004; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Ley R, 2004, J BIOL CHEM, V279, P8837, DOI 10.1074/jbc.M311578200; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Luciano F, 2003, ONCOGENE, V22, P6785, DOI 10.1038/sj.onc.1206792; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Mitsiades CS, 2004, CURR CANCER DRUG TAR, V4, P235, DOI 10.2174/1568009043333032; NUSSINOV R, 1983, J THEOR BIOL, V100, P319, DOI 10.1016/0022-5193(83)90355-7; Parada Y, 2001, J BIOL CHEM, V276, P23572, DOI 10.1074/jbc.M101885200; RAMAKRISHNAN L, 1989, BIOCHIM BIOPHYS ACTA, V989, P209, DOI 10.1016/0304-419X(89)90043-7; Scheijen B, 2004, ONCOGENE, V23, P3338, DOI 10.1038/sj.onc.1207456; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Seward RJ, 2003, MOL IMMUNOL, V39, P983, DOI 10.1016/S0161-5890(03)00047-6; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Strasser A, 2000, ANN NY ACAD SCI, V917, P541; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Tang TTL, 2002, J BIOL CHEM, V277, P14255, DOI 10.1074/jbc.M110901200; Tauchi T, 2004, INT J HEMATOL, V79, P434, DOI 10.1532/IJH97.04013; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0	51	240	251	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2005	24	14					2317	2329		10.1038/sj.onc.1208421	http://dx.doi.org/10.1038/sj.onc.1208421			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909RC	15688014				2022-12-17	WOS:000227877400005
J	Nakata, S; Yoshida, T; Horinaka, M; Shiraishi, T; Wakada, M; Sakai, T				Nakata, S; Yoshida, T; Horinaka, M; Shiraishi, T; Wakada, M; Sakai, T			Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells	ONCOGENE			English	Article						death receptor 5; histone deacetylase inhibitors; TRAIL; apoptosis; Bid; caspases	TRAIL-INDUCED APOPTOSIS; WAF1/CIP1 GENE PROMOTER; DECOY RECEPTORS; LEUKEMIA-CELLS; LIGAND TRAIL; HUMAN COLON; SP1 SITES; TUMORICIDAL ACTIVITY; KILLER/DR5 GENE; GROWTH ARREST	Death receptor 5 (DR5) is a receptor for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). TRAIL is a promising candidate for cancer therapeutics due to its ability to induce apoptosis selectively in cancer cells. Here, we report that histone deacetylase inhibitors (HDACIs) such as trichostatin A (TSA), sodium butyrate, and suberoylanilide hydroxamic acid (SAHA) upregulated DR5 expression in various human malignant tumor cells. An RNase protection assay demonstrated that HDACIs induced DR5 mRNA markedly but not that of other death receptor family members in Jurkat cells. HDACIs increased DR5 mRNA and protein in a dose- and time-dependent manner. We also show TSA increased DR5 promoter activity using a luciferase promoter assay. Furthermore, we demonstrated that HDACIs strongly sensitized exogenous soluble recombinant human TRAIL-induced apoptosis synergistically in Jurkat and HL-60 cells that were tolerant to TRAIL alone. The combined use of HDACIs and TRAIL in suboptimal concentrations induced Bid cleavage and activation of caspase-8, -10, -3, and -9. Human recombinant DR5/Fc chimera protein, zVAD-fmk pancaspase inhibitor, and caspase-8 and -10 inhibitors efficiently reduced apoptosis induced by cotreatment with HDACIs and TRAIL. Furthermore, TSA did not significantly induce DR5 protein and HDACIs did not enhance TRAIL-induced apoptosis in normal human peripheral blood mononuclear cells. These results suggest that this combined treatment with HDACIs and TRAIL is a promising strategy for new cancer therapeutics.	Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Targeting Canc Prevent, Kamigyo Ku, Kyoto 6028566, Japan; Kyoto Prefectural Univ, Dept Appl Biochem, Kyoto 6068522, Japan; Kyoto Prefectural Univ Med, Dept Urol, Kyoto 6028566, Japan	Kyoto Prefectural University of Medicine; Kyoto Prefectural University; Kyoto Prefectural University of Medicine	Sakai, T (corresponding author), Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Targeting Canc Prevent, Kamigyo Ku, Kyoto 6028566, Japan.	tsakai@koto.kpu-m.ac.jp						Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Davie JR, 1998, CURR OPIN GENET DEV, V8, P173, DOI 10.1016/S0959-437X(98)80138-X; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Gong BD, 2000, CANCER RES, V60, P5754; Griffith TS, 1999, J IMMUNOL, V162, P2597; He Q, 2002, ONCOGENE, V21, P6032, DOI 10.1038/sj.onc.1205897; He Q, 2002, ONCOGENE, V21, P2623, DOI 10.1038/sj.onc.1205345; Hirose T, 2003, ONCOGENE, V22, P7762, DOI 10.1038/sj.onc.1207091; Hitomi T, 2003, FEBS LETT, V554, P347, DOI 10.1016/S0014-5793(03)01186-4; Huang LL, 2000, ONCOGENE, V19, P5712, DOI 10.1038/sj.onc.1203963; Huang Y, 2001, CANCER RES, V61, P6918; Ichikawa K, 2001, NAT MED, V7, P954, DOI 10.1038/91000; Inoue H, 2002, INT J MOL MED, V9, P521; Jang YJ, 2003, CANCER LETT, V194, P107, DOI 10.1016/S0304-3835(02)00680-8; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Keane MM, 1999, CANCER RES, V59, P734; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Koornstra JJ, 2003, J PATHOL, V200, P327, DOI 10.1002/path.1364; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; Kramer OH, 2001, TRENDS ENDOCRIN MET, V12, P294, DOI 10.1016/S1043-2760(01)00438-6; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; LaVallee TM, 2003, CANCER RES, V63, P468; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Mariani SM, 1997, J CELL BIOL, V137, P221, DOI 10.1083/jcb.137.1.221; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Meng RD, 2001, EXP CELL RES, V262, P154, DOI 10.1006/excr.2000.5073; Mitsiades N, 2001, CANCER RES, V61, P2704; Muhlenbeck F, 1998, J BIOL CHEM, V273, P33091, DOI 10.1074/jbc.273.49.33091; Nagane M, 2000, CANCER RES, V60, P847; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Neuzil H, 2004, BIOCHEM BIOPH RES CO, V314, P186, DOI 10.1016/j.bbrc.2003.12.074; Oh SC, 2001, MOL CELLS, V11, P192; Ohtsuka T, 2003, ONCOGENE, V22, P2034, DOI 10.1038/sj.onc.1206290; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Rosato RR, 2003, MOL CANCER THER, V2, P1273; Screaton GR, 1997, CURR BIOL, V7, P693, DOI 10.1016/S0960-9822(06)00297-1; Sheikh MS, 1998, CANCER RES, V58, P1593; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shigeno M, 2003, ONCOGENE, V22, P1653, DOI 10.1038/sj.onc.1206139; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Sun SY, 1999, ONCOGENE, V18, P2357, DOI 10.1038/sj.onc.1202543; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Tang XM, 2002, CANCER RES, V62, P4903; Walczak H, 2000, CANCER RES, V60, P3051; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wen JH, 2000, BLOOD, V96, P3900, DOI 10.1182/blood.V96.12.3900.h8003900_3900_3906; Wu GS, 1999, ONCOGENE, V18, P6411, DOI 10.1038/sj.onc.1203025; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; YOSHIDA M, 1988, EXP CELL RES, V177, P122, DOI 10.1016/0014-4827(88)90030-4; Yoshida T, 2001, FEBS LETT, V507, P381, DOI 10.1016/S0014-5793(01)02947-7; Zhang XD, 2003, BIOCHEM PHARMACOL, V66, P1537, DOI 10.1016/S0006-2952(03)00509-4	59	240	251	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2004	23	37					6261	6271		10.1038/sj.onc.1207830	http://dx.doi.org/10.1038/sj.onc.1207830			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC	15208660				2022-12-17	WOS:000223399000010
J	Azzam, EI; de Toledo, SM; Little, JB				Azzam, EI; de Toledo, SM; Little, JB			Oxidative metabolism, gap junctions and the ionizing radiation-induced bystander effect	ONCOGENE			English	Article						bystander response; ionizing radiation; alpha-particles; gap-junction intercellular communication; oxidative stress	SISTER-CHROMATID EXCHANGES; FIBROBLAST-GROWTH-FACTOR; NITRIC-OXIDE SYNTHASE; TUMOR-NECROSIS-FACTOR; TISSUE-CULTURE MODEL; VERY-LOW FLUENCES; ALPHA-PARTICLES; INTERCELLULAR COMMUNICATION; SIGNAL-TRANSDUCTION; MAMMALIAN-CELLS	Evidence accumulated over the past two decades has indicated that exposure of cell populations to ionizing radiation results in significant biological effects occurring in both the irradiated and nonirradiated cells in the population. This phenomenon, termed the 'bystander response', has been shown to occur both in vitro and in vivo and has been postulated to impact both the estimation of risks of exposure to low doses/low fluences of ionizing radiation and radiotherapy. Several mechanisms involving secreted soluble factors, oxidative metabolism and gap-junction intercellular communication have been proposed to regulate the radiation-induced bystander effect. Our current knowledge of the biochemical and molecular events involved in the latter two processes is reviewed in this article.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Radiol, Newark, NJ 07103 USA; Harvard Univ, Sch Med, Radiobiol Lab, Boston, MA USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Harvard University; Harvard Medical School	Azzam, EI (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Radiol, 185 S Orange Ave, Newark, NJ 07103 USA.				NATIONAL CANCER INSTITUTE [R01CA092262] Funding Source: NIH RePORTER; NCI NIH HHS [1R01-CA92262-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7; Azzam EI, 2002, CANCER RES, V62, P5436; Azzam EI, 1998, RADIAT RES, V150, P497, DOI 10.2307/3579865; Azzam EI, 2001, P NATL ACAD SCI USA, V98, P473, DOI 10.1073/pnas.011417098; AZZAM EI, 2003, IN PRESS CANC RES; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Barcellos-Hoff MH, 2001, RADIAT RES, V156, P618, DOI 10.1667/0033-7587(2001)156[0618:ESTTMA]2.0.CO;2; BEDFORD JS, 1974, BRIT J RADIOL, V47, P687, DOI 10.1259/0007-1285-47-562-687; Bevans CG, 1998, J BIOL CHEM, V273, P2808, DOI 10.1074/jbc.273.5.2808; Bishayee A, 1999, RADIAT RES, V152, P88, DOI 10.2307/3580054; Bishayee A, 2001, RADIAT RES, V155, P335, DOI 10.1667/0033-7587(2001)155[0335:FRIAGJ]2.0.CO;2; Blackburn RV, 1999, FREE RADICAL BIO MED, V26, P419, DOI 10.1016/S0891-5849(98)00217-2; Bruzzone R, 1996, BIOESSAYS, V18, P709, DOI 10.1002/bies.950180906; Burdon RH, 1996, BIOCHEM SOC T, V24, P1028, DOI 10.1042/bst0241028; Burkitt MJ, 2001, BIOCHEM BIOPH RES CO, V282, P329, DOI 10.1006/bbrc.2001.4578; Chipman JK, 2003, TOXICOL SCI, V71, P146, DOI 10.1093/toxsci/71.2.146; CHUAQUI CA, 1987, RADIAT PHYS CHEM, V30, P365; Clutton SM, 1996, CARCINOGENESIS, V17, P1633, DOI 10.1093/carcin/17.8.1633; D'Angio CT, 2000, MOL GENET METAB, V71, P371, DOI 10.1006/mgme.2000.3074; De Maio A, 2002, J CELL PHYSIOL, V191, P269, DOI 10.1002/jcp.10108; DOBLE BW, 1995, MOL CELL BIOCHEM, V143, P81, DOI 10.1007/BF00925930; Dowling-Warriner CV, 2000, NEUROSCIENCE, V95, P859; Echetebu CO, 1999, MOL HUM REPROD, V5, P757, DOI 10.1093/molehr/5.8.757; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; EMERIT I, 1995, FREE RADICAL BIO MED, V18, P985, DOI 10.1016/0891-5849(94)00220-E; Feinendegen LE, 2002, HUM EXP TOXICOL, V21, P85, DOI 10.1191/0960327102ht216oa; Fernandez-Cobo M, 1999, CYTOKINE, V11, P216, DOI 10.1006/cyto.1998.0422; Finkel T, 2000, FEBS LETT, V476, P52, DOI 10.1016/S0014-5793(00)01669-0; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Gabbita SP, 2000, ARCH BIOCHEM BIOPHYS, V376, P1, DOI 10.1006/abbi.1999.1685; Goldberg GS, 1999, NAT CELL BIOL, V1, P457, DOI 10.1038/15693; HAIMOVITZFRIEDMAN A, 1991, CANCER RES, V51, P2552; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; Herrlich P, 2000, BIOCHEM PHARMACOL, V59, P35, DOI 10.1016/S0006-2952(99)00298-1; HOLLOWELL JG, 1968, P SOC EXP BIOL MED, V129, P240; Hosoi Y, 2001, INT J CANCER, V96, P270, DOI 10.1002/ijc.1030; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; Huo LH, 2001, RADIAT RES, V156, P521, DOI 10.1667/0033-7587(2001)156[0521:HMIIBC]2.0.CO;2; IGNARRO LJ, 1993, P NATL ACAD SCI USA, V90, P8103, DOI 10.1073/pnas.90.17.8103; Iyer R, 2000, CANCER RES, V60, P1290; John SA, 1999, J BIOL CHEM, V274, P236, DOI 10.1074/jbc.274.1.236; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; Kasper M, 1996, HISTOCHEM CELL BIOL, V106, P419; Khan MA, 1998, INT J RADIAT ONCOL, V40, P467, DOI 10.1016/S0360-3016(97)00736-0; Kojima T, 1997, CELL STRUCT FUNCT, V22, P347, DOI 10.1247/csf.22.347; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; Lampe PD, 2000, ARCH BIOCHEM BIOPHYS, V384, P205, DOI 10.1006/abbi.2000.2131; Lehnert BE, 1997, CANCER RES, V57, P2164; Liu K, 1997, RADIAT RES, V147, P437, DOI 10.2307/3579500; Lo CW, 1996, J BIOENERG BIOMEMBR, V28, P379, DOI 10.1007/BF02110114; LOPEZBARNEO J, 1988, SCIENCE, V241, P580, DOI 10.1126/science.2456613; Lorimore SA, 2001, ONCOGENE, V20, P7085, DOI 10.1038/sj.onc.1204903; Lyng FM, 2000, BRIT J CANCER, V83, P1223, DOI 10.1054/bjoc.2000.1433; Lyng FM, 2001, BIOCHEM SOC T, V29, P350; Matsumoto H, 2001, RADIAT RES, V155, P387, DOI 10.1667/0033-7587(2001)155[0387:IORBAN]2.0.CO;2; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Meplan C, 2000, BIOCHEM PHARMACOL, V59, P25, DOI 10.1016/S0006-2952(99)00297-X; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; Mothersill C, 2000, BRIT J CANCER, V82, P1740; MUSIL LS, 1991, J CELL BIOL, V115, P1357, DOI 10.1083/jcb.115.5.1357; Nagasawa H, 2002, CANCER RES, V62, P2531; NAGASAWA H, 1992, CANCER RES, V52, P6394; Narayanan PK, 1997, CANCER RES, V57, P3963; Narayanan PK, 1999, RADIAT RES, V152, P57, DOI 10.2307/3580049; Ohba K, 1998, GUT, V43, P575, DOI 10.1136/gut.43.4.575; Paulson AF, 2000, J CELL SCI, V113, P3037; PETKAU A, 1978, PHOTOCHEM PHOTOBIOL, V28, P765, DOI 10.1111/j.1751-1097.1978.tb07015.x; Pike LJ, 2003, J LIPID RES, V44, P655, DOI 10.1194/jlr.R200021-JLR200; PRICE BD, 1992, CANCER RES, V52, P3814; Prise KM, 1998, INT J RADIAT BIOL, V74, P793, DOI 10.1080/095530098141087; RUBANYI GM, 1991, BIOCHEM BIOPH RES CO, V181, P1392, DOI 10.1016/0006-291X(91)92093-Y; Schubert AL, 2002, BIOCHEMISTRY-US, V41, P5754, DOI 10.1021/bi0121656; Schulze-Osthoff Klaus, 1997, P239; Shao C, 2002, INT J RADIAT BIOL, V78, P837, DOI 10.1080/09553000210149786; SHERMAN MP, 1993, BIOCHEM BIOPH RES CO, V191, P1301, DOI 10.1006/bbrc.1993.1359; Simon AM, 1998, TRENDS CELL BIOL, V8, P477, DOI 10.1016/S0962-8924(98)01372-5; Spitz DR, 2000, ANN NY ACAD SCI, V899, P349, DOI 10.1111/j.1749-6632.2000.tb06199.x; Suchyna TM, 1999, BIOPHYS J, V77, P2968, DOI 10.1016/S0006-3495(99)77129-8; Tonon R, 2002, BIORHEOLOGY, V39, P153; Trosko JE, 1997, STEM CELLS, V15, P59; UCHIDA A, 1989, IMMUNOPHARM IMMUNOT, V11, P507, DOI 10.3109/08923978909005381; Vance MM, 1999, RADIAT RES, V152, P544, DOI 10.2307/3580152; Veenstra RD, 1996, J BIOENERG BIOMEMBR, V28, P327, DOI 10.1007/BF02110109; Weill D, 1996, J INTERF CYTOK RES, V16, P395, DOI 10.1089/jir.1996.16.395; Willecke K, 2002, BIOL CHEM, V383, P725, DOI 10.1515/BC.2002.076; Wink DA, 1996, CURR TOP CELL REGUL, V34, P159, DOI 10.1016/S0070-2137(96)80006-9; Wu LJ, 1999, P NATL ACAD SCI USA, V96, P4959, DOI 10.1073/pnas.96.9.4959; XIE QW, 1994, J BIOL CHEM, V269, P4705; Zhou HN, 2000, P NATL ACAD SCI USA, V97, P2099, DOI 10.1073/pnas.030420797	90	240	255	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 13	2003	22	45					7050	7057		10.1038/sj.onc.1206961	http://dx.doi.org/10.1038/sj.onc.1206961			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	731UB	14557810				2022-12-17	WOS:000185903900010
J	Qiao, D; Zeeman, AM; Deng, W; Looijenga, LH; Lin, HF				Qiao, D; Zeeman, AM; Deng, W; Looijenga, LH; Lin, HF			Molecular characterization of hiwi, a human member of the piwi gene family whose overexpression is correlated to seminomas	ONCOGENE			English	Article						hiwi; piwi; spermatogenesis; germline; stem cells; seminoma	GERM-CELL TUMORS; COMPARATIVE GENOMIC HYBRIDIZATION; CARCINOMA-IN-SITU; ALKALINE-PHOSPHATASE; STEM-CELLS; CHROMOSOMAL CONSTITUTION; SPERMATOCYTIC SEMINOMA; TESTICULAR CANCER; RNA INTERFERENCE; MESSENGER-RNA	The piwi family genes are highly conserved during evolution and play essential roles in stem cell self-renewal, gametogenesis, and RNA interference in diverse organisms ranging from Drosophila rnelanogaster and C. elegans to Arabidopsis. Here we report the molecular characterization of hiwi, a human member of the piwi gene family. hiwi maps to the long arm of chromosome 12, band 12q24.33, a genomic region that displays genetic linkage to the development of testicular germ cell tumors of adolescents and adults (TGCTs), i.e., seminomas and nonseminomas. In addition, gain of this chromosomal region has been found in some TGCTs. hiwi encodes a 3.6 kb mRNA that is expressed abundantly in the adult testis. It encodes a highly basic 861-amino-acid protein that shares significant homology throughout its entire length with other members of the PIWI family proteins in Drosophila, C. elegans and mammals. In normal human testes, him is specifically expressed in germline cells, with its expression detectable in spermatocytes and round spermatids during spermatogenesis. No expresssion was observed in testicular tumors of somatic origin, such as Sertoli cell and Leydig cell tumors. Enhanced expression was found in 12 out of 19 sampled testicular seminomas-tumors originating from embryonic germ cells with retention of germ cell phenotype. In contrast, no enhanced expression was detected in 10 nonseminomas-testicular tumors that originate from the same precursor cells as seminomas yet have lost their germ cell characteristics. Finally, no enhanced expression was detected in four spermatocytic seminomas-testicular tumors that most likely originate from germ cells capable of partial meiosis. Thus, hind is specifically expressed in both normal and malignant spermatogenic cells in a maturation stage-dependent pattern, in which it might function in germ cell proliferation.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Erasmus Univ, Josephine Nefkens Inst, Univ Hosp Rotterdam Daniel, Pathol Lab Expt Pathooncol, NL-3000 DR Rotterdam, Netherlands	Duke University; Erasmus University Rotterdam; Erasmus MC	Lin, HF (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, POB 3709, Durham, NC 27710 USA.	h.lin@cellbio.duke.edu	Looijenga, Leendert/B-8145-2019	Looijenga, Leendert/0000-0002-8146-1911; Zeeman, Anne-Marie/0000-0002-0157-4669	NICHD NIH HHS [HD42012, HD33760] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD033760, R01HD042012] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Benfey PN, 1999, CURR BIOL, V9, pR171, DOI 10.1016/S0960-9822(99)80105-5; Bohmert K, 1998, EMBO J, V17, P170, DOI 10.1093/emboj/17.1.170; Bosl GJ, 1997, NEW ENGL J MED, V337, P242, DOI 10.1056/NEJM199707243370406; Brabender J, 2001, J GASTROINTEST SURG, V5, P174, DOI 10.1016/S1091-255X(01)80031-7; Burke A, 1993, J UROL PATHOL, V1, P21; Cerutti L, 2000, TRENDS BIOCHEM SCI, V25, P481, DOI 10.1016/S0968-0004(00)01641-8; Cox DN, 1998, GENE DEV, V12, P3715, DOI 10.1101/gad.12.23.3715; Cox DN, 2000, DEVELOPMENT, V127, P503; COX DN, 1999, FUNCTION DROSOPHILA; deJong B, 1997, CANCER GENET CYTOGEN, V95, P88, DOI 10.1016/S0165-4608(96)00273-7; DEKKER I, 1992, CANCER, V69, P993, DOI 10.1002/1097-0142(19920215)69:4<993::AID-CNCR2820690427>3.0.CO;2-8; DeMeyts ER, 1996, J PATHOL, V178, P166; DENG W, 2002, IN PRESS DEV CELL; GONDOS B, 1993, EUR UROL, V23, P68; ISAACS WB, 1989, J BIOL CHEM, V264, P17953; JORGENSEN N, 1995, LAB INVEST, V72, P223; Korn WM, 1996, GENE CHROMOSOME CANC, V17, P78, DOI 10.1002/(SICI)1098-2264(199610)17:2<78::AID-GCC2>3.0.CO;2-Y; Lau YFC, 2000, CYTOGENET CELL GENET, V91, P160, DOI 10.1159/000056838; Lin HF, 1997, DEVELOPMENT, V124, P2463; Looijenga L, 1998, APMIS, V106, P71; Looijenga LHJ, 1999, REV REPROD, V4, P90, DOI 10.1530/ror.0.0040090; Looijenga LHJ, 1999, INT J CANCER, V83, P809, DOI 10.1002/(SICI)1097-0215(19991210)83:6<809::AID-IJC20>3.0.CO;2-0; Looijenga LHJ, 2000, J PATHOL, V191, P187, DOI 10.1002/(SICI)1096-9896(200006)191:2<187::AID-PATH584>3.0.CO;2-T; Meng XJ, 2001, CANCER RES, V61, P3267; MOLLER H, 1989, J NATL CANCER I, V81, P1668, DOI 10.1093/jnci/81.21.1668-a; Mostert MMC, 1996, CANCER GENET CYTOGEN, V89, P146, DOI 10.1016/0165-4608(96)00043-X; Moussian B, 1998, EMBO J, V17, P1799, DOI 10.1093/emboj/17.6.1799; NICHOLSON PW, 1995, BRIT J CANCER, V71, P421, DOI 10.1038/bjc.1995.86; Ogawa T, 1998, CANCER GENET CYTOGEN, V100, P36, DOI 10.1016/S0165-4608(97)00004-6; Oosterhuis JW, 1997, CANCER GENET CYTOGEN, V95, P96, DOI 10.1016/S0165-4608(96)00275-0; OOSTERHUIS JW, 1993, EUR UROL, V23, P245; OOSTERHUIS JW, 1993, EUR UROL, V23, P16; Ottesen AM, 1997, GENE CHROMOSOME CANC, V20, P412; RADFORD DM, 1990, CANCER RES, V50, P6146; Roelofs H, 1999, J PATHOL, V189, P236; Rosenberg C, 1999, LAB INVEST, V79, P1447; Rosenberg C, 1998, GENE CHROMOSOME CANC, V23, P286, DOI 10.1002/(SICI)1098-2264(199812)23:4<286::AID-GCC2>3.0.CO;2-6; Ross MH., 1995, HISTOLOGY TEXT ATLAS, V3; Rothe M, 2000, AM J PATHOL, V157, P1597, DOI 10.1016/S0002-9440(10)64797-9; Schmidt A, 1999, GENETICS, V151, P749; Sharma AK, 2001, BLOOD, V97, P426, DOI 10.1182/blood.V97.2.426; Sharp PA, 2000, SCIENCE, V287, P2431, DOI 10.1126/science.287.5462.2431; Shigenari A, 1998, CANCER RES, V58, P5079; SKAKKEBAEK NE, 1972, LANCET, V2, P516; Stewart EA, 1997, GENOME RES, V7, P422, DOI 10.1101/gr.7.5.422; Stoop H, 2001, LAB INVEST, V81, P919, DOI 10.1038/labinvest.3780302; Summersgill B, 1998, BRIT J CANCER, V77, P305, DOI 10.1038/bjc.1998.47; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; VANECHTEN J, 1995, GENE CHROMOSOME CANC, V14, P133, DOI 10.1002/gcc.2870140208; [No title captured]	50	240	264	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2002	21	25					3988	3999		10.1038/sj.onc.1205505	http://dx.doi.org/10.1038/sj.onc.1205505			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556VP	12037681				2022-12-17	WOS:000175869900005
J	Dhanasekaran, N; Reddy, EP				Dhanasekaran, N; Reddy, EP			Signaling by dual specificity kinases	ONCOGENE			English	Review						oncogene; apoptosis; cell transformation; MAP kinase; MEKK; MEK; MKK; ERK; JNK; signal transduction	ACTIVATED PROTEIN-KINASE; JUN NH2-TERMINAL KINASE; MAMMALIAN SOMATIC-CELLS; N-TERMINAL KINASE; P38 MAP KINASE; NIH 3T3 CELLS; C-JUN; TRANSDUCTION PATHWAY; TYROSINE PHOSPHORYLATION; TRANSCRIPTIONAL ACTIVITY	Dual specificity kinases that phosphorylate the Thr- and Tyr-residues within the TXY motif of MAP-kinases of play a central role in the regulation of various processes of cell growth. These dual specificity kinases also known as MAP kinase kinases are constituents of the sequential kinase signaling modules. Seven distinct mammalian MAP kinases kinases have been identified. Same of the unique signaling properties of these kinases are discussed here.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19104 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19104 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Dhanasekaran, N (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19104 USA.		Reddy, E. Premkumar/F-6233-2011					Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; AFTI A, 1997, J BIOL CHEM, V272, P1429; AHN NG, 1991, J BIOL CHEM, V266, P4220; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BROTT BK, 1993, CELL GROWTH DIFFER, V4, P921; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; ERREDE B, 1993, NATURE, V362, P261, DOI 10.1038/362261a0; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; Finch A, 1997, FEBS LETT, V418, P144, DOI 10.1016/S0014-5793(97)01364-1; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; FUKUNAGA R, 1997, EMBO J, V16, P1909; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Han JH, 1997, FEBS LETT, V403, P19, DOI 10.1016/S0014-5793(97)00021-5; HAN JH, 1993, J BIOL CHEM, V268, P25009; Hirai S, 1997, J BIOL CHEM, V272, P15167, DOI 10.1074/jbc.272.24.15167; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Huang S, 1997, IMMUNITY, V6, P739, DOI 10.1016/S1074-7613(00)80449-5; HUANG WD, 1995, MOL BIOL CELL, V6, P237, DOI 10.1091/mbc.6.3.237; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P318; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lawler S, 1997, FEBS LETT, V414, P153, DOI 10.1016/S0014-5793(97)00990-3; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MATSUDA S, 1994, J LEUKOCYTE BIOL, V56, P548, DOI 10.1002/jlb.56.5.548; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; NEBREDA AR, 1993, FEBS LETT, V333, P183, DOI 10.1016/0014-5793(93)80401-F; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SANGHERA JS, 1992, MOL BIOL CELL, V3, P775, DOI 10.1091/mbc.3.7.775; SETH A, 1992, J BIOL CHEM, V267, P24796; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; Takekawa M, 1997, EMBO J, V16, P4973, DOI 10.1093/emboj/16.16.4973; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Toyoshima F, 1997, J CELL BIOL, V139, P1005, DOI 10.1083/jcb.139.4.1005; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; WANG XS, 1997, J BIOL CHEM, V271, P31607; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; Wu ZG, 1997, MOL CELL BIOL, V17, P7407, DOI 10.1128/MCB.17.12.7407; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378; Yu W, 1998, CURR BIOL, V8, P56, DOI 10.1016/S0960-9822(98)70020-X; Zechner D, 1997, J CELL BIOL, V139, P115, DOI 10.1083/jcb.139.1.115; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	117	240	256	1	12	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 17	1998	17	11			SI		1447	1455		10.1038/sj.onc.1202251	http://dx.doi.org/10.1038/sj.onc.1202251			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124BW	9779990				2022-12-17	WOS:000076161900011
J	ROSENBERG, CL; KIM, HG; SHOWS, TB; KRONENBERG, HM; ARNOLD, A				ROSENBERG, CL; KIM, HG; SHOWS, TB; KRONENBERG, HM; ARNOLD, A			REARRANGEMENT AND OVEREXPRESSION OF D11S287E, A CANDIDATE ONCOGENE ON CHROMOSOME 11Q13 IN BENIGN PARATHYROID TUMORS	ONCOGENE			English	Article							ENDOCRINE NEOPLASIA TYPE-1; B-CELL LYMPHOMAS; HORMONE GENE; MOLECULAR-CLONING; DNA POLYMORPHISMS; PROTO-ONCOGENE; BREAST-CANCER; AMPLIFICATION; INT-2; ABNORMALITIES	We report the detailed molecular characterization of a human parathyroid adenoma with a clonal parathyroid hormone gene rearrangement. This rearrangement is similar to one we characterized recently in an independent adenoma. In these two, plus a third partially characterized adenoma, one allele of the PTH gene, on 11p15, is rearranged with DNA from the D11S287 region on 11q13. This region contains a transcribed sequence, D11S287E, distinct from known 11q13 oncogenes, that is expressed in all parathyroid tissues examined, but is overexpressed dramatically in all three tumors with PTH gene-D11S287 rearrangements. These findings suggest that overexpression of D11S287E, perhaps driven by the misplaced PTH gene's regulatory elements, contributed to the development of these benign tumors. D11S287E is a new candidate oncogene with potential importance in parathyroid adenomas and perhaps other tumors with 11q13 abnormalities.	MASSACHUSETTS GEN HOSP,ENDOCRINE UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,HEMATOL ONCOL UNIT,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02115; NEW YORK STATE DEPT HLTH,ROSWELL PK MEM INST,DEPT HUMAN GENET,BUFFALO,NY 14263	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Roswell Park Cancer Institute					NIDDK NIH HHS [DK11794, DK07028] Funding Source: Medline; NIGMS NIH HHS [GM20454] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007028, P01DK011794] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020454] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADELAIDE J, 1988, ONCOGENE, V2, P413; ARNOLD A, 1989, J CLIN ENDOCR METAB, V69, P496, DOI 10.1210/jcem-69-3-496; ARNOLD A, 1988, NEW ENGL J MED, V318, P658, DOI 10.1056/NEJM198803173181102; ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; ARNOLD A, 1983, NEW ENGL J MED, V309, P1593, DOI 10.1056/NEJM198312293092601; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BERENSON JR, 1989, ONCOGENE, V4, P1111; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; CROCE CM, 1985, BLOOD, V65, P1; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIEDMAN E, 1990, J CLIN ENDOCR METAB, V71, P293, DOI 10.1210/jcem-71-2-293; FRIEDMAN E, 1989, NEW ENGL J MED, V321, P213, DOI 10.1056/NEJM198907273210402; FRIEND SH, 1988, NEW ENGL J MED, V318, P618; GONZALEZ IL, 1985, P NATL ACAD SCI USA, V82, P7666, DOI 10.1073/pnas.82.22.7666; IGARASHI T, 1986, MOL CELL BIOL, V6, P1830, DOI 10.1128/MCB.6.5.1830; KIDD KK, 1989, CYTOGENET CELL GENET, V51, P622, DOI 10.1159/000132810; KODURU PRK, 1989, ONCOGENE, V4, P929; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LARSSON C, 1988, NATURE, V332, P85, DOI 10.1038/332085a0; LAZO PA, 1990, P NATL ACAD SCI USA, V87, P170, DOI 10.1073/pnas.87.1.170; LEON J, 1988, MOL CELL BIOL, V8, P786, DOI 10.1128/MCB.8.2.786; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; NAKAI H, 1986, CYTOGENET CELL GENET, V43, P215, DOI 10.1159/000132324; NAYLOR SL, 1983, J EXP MED, V57, P1020; RABBITTS PH, 1988, ONCOGENE, V3, P99; Sambrook J., 1989, MOL CLONING LAB MANU; SEALEY PG, 1985, NUCLEIC ACIDS RES, V13, P1905, DOI 10.1093/nar/13.6.1905; SEIZINGER BR, 1986, NATURE, V322, P644, DOI 10.1038/322644a0; SEIZINGER BR, 1987, P NATL ACAD SCI USA, V84, P5419, DOI 10.1073/pnas.84.15.5419; SHOWS T, 1984, SOMAT CELL MOLEC GEN, V10, P315, DOI 10.1007/BF01535253; SHOWS TB, 1982, ADV HUM GENET, V12, P341; THAKKER RV, 1989, NEW ENGL J MED, V321, P218, DOI 10.1056/NEJM198907273210403; THEILLET C, 1990, ONCOGENE, V5, P147; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; VASICEK TJ, 1983, P NATL ACAD SCI-BIOL, V80, P2127, DOI 10.1073/pnas.80.8.2127; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; ZABEL BU, 1985, CYTOGENET CELL GENET, V39, P200, DOI 10.1159/000132135	41	240	241	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1991	6	3					449	453						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	2011400				2022-12-17	WOS:A1991FT34400015
J	SPENCER, CA; GROUDINE, M				SPENCER, CA; GROUDINE, M			TRANSCRIPTION ELONGATION AND EUKARYOTIC GENE-REGULATION	ONCOGENE			English	Review									UNIV WASHINGTON, SCH MED, DEPT RADIAT ONCOL, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle	SPENCER, CA (corresponding author), FRED HUTCHINSON CANC RES CTR, 1124 COLUMBIA ST, SEATTLE, WA 98104 USA.				NATIONAL CANCER INSTITUTE [P01CA028151] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI027291] Funding Source: NIH RePORTER; NCI NIH HHS [CA 28151] Funding Source: Medline; NIAID NIH HHS [AI 27291] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHEARN JM, 1987, J BIOL CHEM, V262, P10695; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; BACHMANN M, 1990, CELL, V60, P85, DOI 10.1016/0092-8674(90)90718-T; BARIK S, 1987, CELL, V50, P885, DOI 10.1016/0092-8674(87)90515-0; BARTHOLOMEW B, 1986, J BIOL CHEM, V261, P14226; BEAR DG, 1988, TRENDS BIOCHEM SCI, V13, P343, DOI 10.1016/0968-0004(88)90104-1; BENDER TP, 1988, CURR TOP MICROBIOL, V141, P324; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; BENGAL E, 1989, J BIOL CHEM, V264, P18926; BENGAL E, 1989, J BIOL CHEM, V264, P9791; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; BURTON ZF, 1988, MOL CELL BIOL, V8, P1602, DOI 10.1128/MCB.8.4.1602; CHAMBERLIN M, 1989, ADV ONCOLOGY, V4, P2; CHEN CYA, 1986, CELL, V46, P1023, DOI 10.1016/0092-8674(86)90701-4; CHINSKY JM, 1989, J BIOL CHEM, V264, P14561; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CONNELLY S, 1989, MOL CELL BIOL, V9, P5254, DOI 10.1128/MCB.9.11.5254; CORDEN JL, 1985, P NATL ACAD SCI USA, V82, P7934, DOI 10.1073/pnas.82.23.7934; DEVEGVAR HEN, 1986, CELL, V47, P259; EICK D, 1987, ONCOGENE, V2, P61; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; FLORES O, 1989, J BIOL CHEM, V264, P8913; FORT P, 1987, NUCLEIC ACIDS RES, V15, P5657, DOI 10.1093/nar/15.14.5657; FRIEDMAN DI, 1987, ANNU REV GENET, V21, P453; GILMOUR DS, 1986, MOL CELL BIOL, V6, P3984, DOI 10.1128/MCB.6.11.3984; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; GOURSE RL, 1986, CELL, V44, P197, DOI 10.1016/0092-8674(86)90498-8; GRAYHACK EJ, 1985, CELL, V42, P259, DOI 10.1016/S0092-8674(85)80121-5; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; HAY N, 1982, CELL, V29, P183, DOI 10.1016/0092-8674(82)90102-7; HAY N, 1985, MOL CELL BIOL, V5, P1327, DOI 10.1128/MCB.5.6.1327; HERNANDEZ N, 1986, CELL, V47, P249, DOI 10.1016/0092-8674(86)90447-2; HERNANDEZ N, 1988, EMBO J, V7, P3125, DOI 10.1002/j.1460-2075.1988.tb03179.x; HORWITZ RJ, 1987, CELL, V51, P631, DOI 10.1016/0092-8674(87)90132-2; JAKOBOVITS A, 1988, MOL CELL BIOL, V8, P2555, DOI 10.1128/MCB.8.6.2555; JOHNSTON JM, 1985, J VIROL, V56, P378, DOI 10.1128/JVI.56.2.378-385.1985; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KERPPOLA TK, 1988, MOL CELL BIOL, V8, P4389, DOI 10.1128/MCB.8.10.4389; KESSLER M, 1989, GENE, V84, P65, DOI 10.1016/0378-1119(89)90140-6; KIM WY, 1988, J BIOL CHEM, V263, P18880; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; KURODA MI, 1986, J BACTERIOL, V167, P792, DOI 10.1128/jb.167.3.792-798.1986; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; LATTIER DL, 1989, NUCLEIC ACIDS RES, V17, P1061, DOI 10.1093/nar/17.3.1061; LAYBOURN PJ, 1989, J BIOL CHEM, V264, P6693; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; LEE JM, 1989, P NATL ACAD SCI USA, V86, P3624, DOI 10.1073/pnas.86.10.3624; LINDSTEN T, 1988, EMBO J, V7, P2787, DOI 10.1002/j.1460-2075.1988.tb03133.x; MADERIOUS A, 1984, P NATL ACAD SCI-BIOL, V81, P5931, DOI 10.1073/pnas.81.19.5931; MAHADEVAN S, 1987, CELL, V50, P485, DOI 10.1016/0092-8674(87)90502-2; MARTIN FH, 1980, NUCLEIC ACIDS RES, V8, P2295, DOI 10.1093/nar/8.10.2295; MCGEADY ML, 1986, DNA-J MOLEC CELL BIO, V5, P289, DOI 10.1089/dna.1986.5.289; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; MIDDLETON KM, 1990, MOL CELL BIOL, V10, P727, DOI 10.1128/MCB.10.2.727; MILLER H, 1989, MOL CELL BIOL, V9, P5340, DOI 10.1128/MCB.9.12.5340; MORGAN EA, 1986, J BACTERIOL, V168, P1; MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9; NEPVEU A, 1987, GENE DEV, V1, P938, DOI 10.1101/gad.1.9.938; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; PARRY HD, 1989, NUCLEIC ACIDS RES, V17, P3633, DOI 10.1093/nar/17.10.3633; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; PETERLIN BM, 1986, P NATL ACAD SCI USA, V83, P9734, DOI 10.1073/pnas.83.24.9734; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; RAMAMURTHY V, 1990, MOL CELL BIOL, V10, P1484, DOI 10.1128/MCB.10.4.1484; RAPPAPORT J, 1987, J BIOL CHEM, V262, P5227; RAPPAPORT J, 1988, MOL CELL BIOL, V8, P3136, DOI 10.1128/MCB.8.8.3136; REDDY CD, 1989, P NATL ACAD SCI USA, V86, P7326, DOI 10.1073/pnas.86.19.7326; REINBERG D, 1987, J BIOL CHEM, V262, P3331; REINES D, 1989, J BIOL CHEM, V264, P10799; REZNIKOV O, 1989, J BIOL CHEM, V264, P9953; ROBERT J, 1987, CELL, V51, P483, DOI 10.1016/0092-8674(87)90644-1; ROBERTS JW, 1969, NATURE, V224, P1168, DOI 10.1038/2241168a0; ROBERTS JW, 1988, CELL, V52, P5, DOI 10.1016/0092-8674(88)90523-5; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; SANCAR GB, 1982, CELL, V28, P523, DOI 10.1016/0092-8674(82)90207-0; SCHNEIDERSCHAULIES J, 1987, EUR J IMMUNOL, V17, P713, DOI 10.1002/eji.1830170521; SELBY MJ, 1989, GENE DEV, V3, P547, DOI 10.1101/gad.3.4.547; SELLITTI MA, 1987, P NATL ACAD SCI USA, V84, P3199, DOI 10.1073/pnas.84.10.3199; SHARP PA, 1989, CELL, V59, P229, DOI 10.1016/0092-8674(89)90279-1; SHIMOTSU H, 1986, J BACTERIOL, V166, P461, DOI 10.1128/jb.166.2.461-471.1986; SHUMAN S, 1987, J BIOL CHEM, V262, P12372; SHUMAN S, 1988, J BIOL CHEM, V263, P6220; SIEBERG M, 1987, VIRUS GENES, V1, P97; SKARNES WC, 1988, J MOL BIOL, V203, P153, DOI 10.1016/0022-2836(88)90099-X; SLUDER AE, 1989, J BIOL CHEM, V264, P8963; SOPTA M, 1985, J BIOL CHEM, V260, P353; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; TOMIZAWA J, 1987, CELL, V51, P623, DOI 10.1016/0092-8674(87)90131-0; TOOHEY MG, 1989, GENE DEV, V3, P265, DOI 10.1101/gad.3.3.265; VANDERHOORN F, 1986, NUCLEIC ACIDS RES, V14, P8771, DOI 10.1093/nar/14.22.8771; WARREN F, 1984, P NATL ACAD SCI-BIOL, V81, P3612, DOI 10.1073/pnas.81.12.3612; WATSON RJ, 1988, ONCOGENE, V2, P267; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938; WRIGHT S, 1989, P NATL ACAD SCI USA, V86, P505, DOI 10.1073/pnas.86.2.505; YANG XJ, 1989, P NATL ACAD SCI USA, V86, P5301, DOI 10.1073/pnas.86.14.5301; YANOFSKY C, 1987, TRENDS GENET, V3, P356, DOI 10.1016/0168-9525(87)90297-6; ZEHRING WA, 1988, P NATL ACAD SCI USA, V85, P3698, DOI 10.1073/pnas.85.11.3698	104	240	241	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1990	5	6					777	785						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP553	2193290				2022-12-17	WOS:A1990DP55300001
J	Kim, LC; Cook, RS; Chen, J				Kim, L. C.; Cook, R. S.; Chen, J.			mTORC1 and mTORC2 in cancer and the tumor microenvironment	ONCOGENE			English	Review							ADVANCED SOLID TUMORS; I DOSE-ESCALATION; TRANSFER-RNA SYNTHETASE; P70 S6 KINASE; PHASE-I; MAMMALIAN TARGET; PI3K/MTOR INHIBITOR; TUBEROUS SCLEROSIS; COMPLEX 2; PHOSPHOPROTEOME REVEALS	The mammalian target of rapamycin (mTOR) is a crucial signaling node that integrates environmental cues to regulate cell survival, proliferation and metabolism, and is often deregulated in human cancer. mTOR kinase acts in two functionally distinct complexes, mTOR complex 1 (mTORC1) and 2 (mTORC2), whose activities and substrate specificities are regulated by complex co-factors. Deregulation of this centralized signaling pathway has been associated with a variety of human diseases including diabetes, neurodegeneration and cancer. Although mTORC1 signaling has been extensively studied in cancer, recent discoveries indicate a subset of human cancers harboring amplifications in mTORC2-specific genes as the only actionable genomic alterations, suggesting a distinct role for mTORC2 in cancer as well. This review will summarize recent advances in dissecting the relative contributions of mTORC1 versus mTORC2 in cancer, their role in tumor-associated blood vessels and tumor immunity, and provide an update on mTOR inhibitors.	[Kim, L. C.; Cook, R. S.; Chen, J.] Vanderbilt Univ, Dept Canc Biol, Nashville, TN 37232 USA; [Cook, R. S.; Chen, J.] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; [Chen, J.] Vanderbilt Univ, Dept Med, Div Rheumatol & Immunol, Nashville, TN 37232 USA; [Chen, J.] Vanderbilt Univ, Dept Cell & Dev Biol, Nashville, TN 37232 USA; [Chen, J.] Tennessee Valley Healthcare Syst, Vet Affairs Med Ctr, Nashville, TN USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Chen, J (corresponding author), Vanderbilt Univ, Sch Med, Dept Canc Biol, Med Ctr North T3207E, 1161 21st Ave South, Nashville, TN 37232 USA.; Chen, J (corresponding author), Vanderbilt Univ, Sch Med, Cell & Dev Biol, Med Ctr North T3207E, 1161 21st Ave South, Nashville, TN 37232 USA.	jin.chen@vanderbilt.edu		Chen, Jin/0000-0002-5557-2079	Department of Veterans Affairs; NIH [R01 CA95004, R01 CA177681, T-32 CA009592]; NATIONAL CANCER INSTITUTE [R01CA095004, T32CA009592, R01CA114301, R01CA177681] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000134] Funding Source: NIH RePORTER	Department of Veterans Affairs(US Department of Veterans Affairs); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Veterans Affairs(US Department of Veterans Affairs)	We thank Deanna Edwards for careful review of the manuscript. This work was supported by the Department of Veterans Affairs through a VA Merit Award and a Research Career Scientist Award (J Chen), NIH grants R01 CA95004 and R01 CA177681 (J Chen) and T-32 CA009592 (L Kim).	Araki K, 2009, NATURE, V460, P108, DOI 10.1038/nature08155; Aylett CHS, 2016, SCIENCE, V351, P48, DOI 10.1126/science.aaa3870; Bakker WJ, 2007, MOL CELL, V28, P941, DOI 10.1016/j.molcel.2007.10.035; Balko JM, 2014, CANCER DISCOV, V4, P232, DOI 10.1158/2159-8290.CD-13-0286; Basu B, 2015, CLIN CANCER RES, V21, P3412, DOI 10.1158/1078-0432.CCR-14-2422; Ben-Sahra I, 2016, SCIENCE, V351, P728, DOI 10.1126/science.aad0489; Ben-Sahra I, 2013, SCIENCE, V339, P1323, DOI 10.1126/science.1228792; Bendell JC, 2015, CANCER-AM CANCER SOC, V121, P3481, DOI 10.1002/cncr.29422; Bendell JC, 2015, INVEST NEW DRUG, V33, P187, DOI 10.1007/s10637-014-0177-3; Benjamin D, 2011, NAT REV DRUG DISCOV, V10, P868, DOI 10.1038/nrd3531; Bernardi R, 2006, NATURE, V442, P779, DOI 10.1038/nature05029; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; Bonfils G, 2012, MOL CELL, V46, P105, DOI 10.1016/j.molcel.2012.02.009; Britten CD, 2014, INVEST NEW DRUG, V32, P510, DOI 10.1007/s10637-013-0062-5; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Browne GJ, 2004, MOL CELL BIOL, V24, P2986, DOI 10.1128/MCB.24.7.2986-2997.2004; Brugarolas JB, 2003, CANCER CELL, V4, P147, DOI 10.1016/S1535-6108(03)00187-9; Byles V, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3834; Carriere A, 2008, CURR BIOL, V18, P1269, DOI 10.1016/j.cub.2008.07.078; Chatterjee S, 2013, J CLIN INVEST, V123, P1732, DOI 10.1172/JCI65385; Cheng HY, 2015, CANCER DISCOV, V5, P1262, DOI 10.1158/2159-8290.CD-14-0971; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Delgoffe GM, 2009, IMMUNITY, V30, P832, DOI 10.1016/j.immuni.2009.04.014; Dolly SO, 2016, CLIN CANCER RES, V22, P2874, DOI 10.1158/1078-0432.CCR-15-2225; Dowling RJO, 2010, SCIENCE, V328, P1172, DOI 10.1126/science.1187532; Duvel K, 2010, MOL CELL, V39, P171, DOI 10.1016/j.molcel.2010.06.022; Farhan MA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135245; Fazio N, 2016, ANTICANCER RES, V36, P713; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Fokas E, 2012, CANCER RES, V72, P239, DOI 10.1158/0008-5472.CAN-11-2263; Gasser JA, 2014, MOL CELL, V56, P595, DOI 10.1016/j.molcel.2014.09.023; Gaubitz C, 2015, MOL CELL, V58, P977, DOI 10.1016/j.molcel.2015.04.031; Granot Z, 2015, CANCER RES, V75, P4441, DOI 10.1158/0008-5472.CAN-15-1502; Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128; Guertin DA, 2006, DEV CELL, V11, P859, DOI 10.1016/j.devcel.2006.10.007; Guertin DA, 2009, CANCER CELL, V15, P148, DOI 10.1016/j.ccr.2008.12.017; Guo F, 2016, ONCOGENE, V35, P816, DOI 10.1038/onc.2015.139; Han JM, 2012, CELL, V149, P410, DOI 10.1016/j.cell.2012.02.044; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Heikamp EB, 2014, NAT IMMUNOL, V15, P457, DOI 10.1038/ni.2867; Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024; Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912; Hsu PP, 2011, SCIENCE, V332, P1317, DOI 10.1126/science.1199498; Hudes G, 2007, NEW ENGL J MED, V356, P2271, DOI 10.1056/NEJMoa066838; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Humphrey SJ, 2013, CELL METAB, V17, P1009, DOI 10.1016/j.cmet.2013.04.010; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Janne PA, 2014, J THORAC ONCOL, V9, P316, DOI 10.1097/JTO.0000000000000088; Jewell JL, 2015, SCIENCE, V347, P194, DOI 10.1126/science.1259472; Joly MM, 2016, CANCER RES, V76, P4752, DOI 10.1158/0008-5472.CAN-15-3393; Kantidakis T, 2010, P NATL ACAD SCI USA, V107, P11823, DOI 10.1073/pnas.1005188107; Kim YC, 2015, J CLIN INVEST, V125, P25, DOI 10.1172/JCI73939; Kleffel S, 2015, CELL, V162, P1242, DOI 10.1016/j.cell.2015.08.052; LaGory EL, 2016, NAT CELL BIOL, V18, P356, DOI 10.1038/ncb3330; Lane HA, 2009, CLIN CANCER RES, V15, P1612, DOI 10.1158/1078-0432.CCR-08-2057; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Lastwika KJ, 2016, CANCER RES, V76, P227, DOI 10.1158/0008-5472.CAN-14-3362; Lee K, 2013, BLOOD, V122, P2369, DOI 10.1182/blood-2013-01-477505; Lee K, 2012, J EXP MED, V209, P713, DOI 10.1084/jem.20111470; Lee K, 2010, IMMUNITY, V32, P743, DOI 10.1016/j.immuni.2010.06.002; Liu PD, 2015, CANCER DISCOV, V5, P1194, DOI 10.1158/2159-8290.CD-15-0460; Liu PD, 2013, NAT CELL BIOL, V15, P1340, DOI 10.1038/ncb2860; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; Mahadevan D, 2012, EUR J CANCER, V48, P3319, DOI 10.1016/j.ejca.2012.06.027; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; del Campo JM, 2016, GYNECOL ONCOL, V142, P62, DOI 10.1016/j.ygyno.2016.04.019; Markman B, 2012, ANN ONCOL, V23, P2399, DOI 10.1093/annonc/mds011; Masri J, 2007, CANCER RES, V67, P11712, DOI 10.1158/0008-5472.CAN-07-2223; Masui K, 2013, CELL METAB, V18, P726, DOI 10.1016/j.cmet.2013.09.013; Mateo J, 2016, BRIT J CANCER, V114, P889, DOI 10.1038/bjc.2016.59; Mayer C, 2004, GENE DEV, V18, P423, DOI 10.1101/gad.285504; Mayerhofer M, 2002, BLOOD, V100, P3767, DOI 10.1182/blood-2002-01-0109; Morrison MM, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005291; Munster P, 2016, CLIN CANCER RES, V22, P1932, DOI 10.1158/1078-0432.CCR-15-1665; Naing A, 2012, BRIT J CANCER, V107, P1093, DOI 10.1038/bjc.2012.368; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Palm W, 2015, CELL, V162, P259, DOI 10.1016/j.cell.2015.06.017; Papadopoulos KP, 2015, LEUKEMIA LYMPHOMA, V56, P1763, DOI 10.3109/10428194.2014.974040; Papadopoulos KP, 2014, CLIN CANCER RES, V20, P2445, DOI 10.1158/1078-0432.CCR-13-2403; Peterson TR, 2011, CELL, V146, P408, DOI 10.1016/j.cell.2011.06.034; Phung TL, 2006, CANCER CELL, V10, P159, DOI 10.1016/j.ccr.2006.07.003; Pollizzi KN, 2015, J CLIN INVEST, V125, P2090, DOI 10.1172/JCI77746; Porstmann T, 2008, CELL METAB, V8, P224, DOI 10.1016/j.cmet.2008.07.007; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Powles T, 2016, J CLIN ONCOL, V34, P1660, DOI 10.1200/JCO.2015.64.8808; Powles T, 2016, EUR UROL, V69, P450, DOI 10.1016/j.eururo.2015.08.035; Pusapati RV, 2016, CANCER CELL, V29, P548, DOI 10.1016/j.ccell.2016.02.018; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Raez LE, 2013, CANCER CHEMOTH PHARM, V71, P523, DOI 10.1007/s00280-012-2045-1; Ricoult SJH, 2016, ONCOGENE, V35, P1250, DOI 10.1038/onc.2015.179; Robitaille AM, 2013, SCIENCE, V339, P1320, DOI 10.1126/science.1228771; Rodrik-Outmezguine VS, 2016, NATURE, V534, P272, DOI 10.1038/nature17963; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; Roy D, 2013, CANCER RES, V73, P2235, DOI 10.1158/0008-5472.CAN-12-1851; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535; Sancak Y, 2007, MOL CELL, V25, P903, DOI 10.1016/j.molcel.2007.03.003; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Seront E, 2016, BJU INT, V118, P408, DOI 10.1111/bju.13415; Shah OJ, 2004, CURR BIOL, V14, P1650, DOI 10.1016/j.cub.2004.08.026; Shapiro GI, 2015, CLIN CANCER RES, V21, P1888, DOI 10.1158/1078-0432.CCR-14-1306; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Shimobayashi M, 2016, CELL RES, V26, P7, DOI 10.1038/cr.2015.146; Shinohara ET, 2005, ONCOGENE, V24, P5414, DOI 10.1038/sj.onc.1208715; Shor B, 2010, J BIOL CHEM, V285, P15380, DOI 10.1074/jbc.M109.071639; Sommer EM, 2013, BIOCHEM J, V452, P499, DOI 10.1042/BJ20130342; Stracka D, 2014, J BIOL CHEM, V289, P25010, DOI 10.1074/jbc.M114.574335; Sun SG, 2015, CANCER CELL, V28, P758, DOI 10.1016/j.ccell.2015.10.004; Sun SY, 2005, CANCER RES, V65, P7052, DOI 10.1158/0008-5472.CAN-05-0917; Tanaka K, 2011, CANCER DISCOV, V1, P524, DOI 10.1158/2159-8290.CD-11-0124; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Thedieck K, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001217; Thorpe LM, 2015, NAT REV CANCER, V15, P7, DOI 10.1038/nrc3860; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Vander Haar E, 2007, NAT CELL BIOL, V9, P316, DOI 10.1038/ncb1547; Vinals F, 1999, J BIOL CHEM, V274, P26776, DOI 10.1074/jbc.274.38.26776; Wang LF, 2007, J BIOL CHEM, V282, P20036, DOI 10.1074/jbc.M702376200; Wang S, 2015, MOL CELL BIOL, V35, P1299, DOI 10.1128/MCB.00306-14; Wang SY, 2015, SCIENCE, V347, P188, DOI 10.1126/science.1257132; Weiler M, 2014, P NATL ACAD SCI USA, V111, P409, DOI 10.1073/pnas.1314469111; Wen PY, 2015, NEURO-ONCOLOGY, V17, P1275, DOI 10.1093/neuonc/nov083; White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941; Wilhelm K, NATURE; Wolfson RL, 2016, SCIENCE, V351, P43, DOI 10.1126/science.aab2674; Yang G, 2015, CELL REP, V12, P937, DOI 10.1016/j.celrep.2015.07.016; Yang HJ, 2013, NATURE, V497, P217, DOI 10.1038/nature12122; Yu K, 2009, CANCER RES, V69, P6232, DOI 10.1158/0008-5472.CAN-09-0299; Yu YH, 2011, SCIENCE, V332, P1322, DOI 10.1126/science.1199484; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100; Zhang JF, 2016, MOL CELL, V62, P929, DOI 10.1016/j.molcel.2016.04.023; Zhang LJ, 2016, CELL REP, V14, P1206, DOI 10.1016/j.celrep.2015.12.095; Zhuang GL, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003572; Zinzalla V, 2011, CELL, V144, P757, DOI 10.1016/j.cell.2011.02.014	143	239	249	6	122	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	2017	36	16					2191	2201		10.1038/onc.2016.363	http://dx.doi.org/10.1038/onc.2016.363			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DM	27748764	Green Accepted			2022-12-17	WOS:000399782700001
J	Cook, DR; Rossman, KL; Der, CJ				Cook, D. R.; Rossman, K. L.; Der, C. J.			Rho guanine nucleotide exchange factors: regulators of Rho GTPase activity in development and disease	ONCOGENE			English	Review						Rac1; RhoA; Cdc42; guanine nucleotide exchange factors; cancer; mouse models	EXPRESSION CDNA CLONING; LINKED MENTAL-RETARDATION; SIGNAL TRANSDUCER VAV1; CELL LYMPHOMA INVASION; RAC ACTIVATOR TIAM1; METASTASIS 2 TIAM2; PROTEIN-KINASE-C; B-CELL; PROSTATE-CANCER; T-CELL	The aberrant activity of Ras homologous (Rho) family small GTPases (20 human members) has been implicated in cancer and other human diseases. However, in contrast to the direct mutational activation of Ras found in cancer and developmental disorders, Rho GTPases are activated most commonly in disease by indirect mechanisms. One prevalent mechanism involves aberrant Rho activation via the deregulated expression and/or activity of Rho family guanine nucleotide exchange factors (RhoGEFs). RhoGEFs promote formation of the active GTP-bound state of Rho GTPases. The largest family of RhoGEFs is comprised of the Dbl family RhoGEFs with 70 human members. The multitude of RhoGEFs that activate a single Rho GTPase reflects the very specific role of each RhoGEF in controlling distinct signaling mechanisms involved in Rho activation. In this review, we summarize the role of Dbl RhoGEFs in development and disease, with a focus on Ect2 (epithelial cell transforming squence 2), Tiam1 (T-cell lymphoma invasion and metastasis 1), Vav and P-Rex1/2 (PtdIns(3,4,5) P3 (phosphatidylinositol (3,4,5)-triphosphate)-dependent Rac exchanger).	[Cook, D. R.] Univ N Carolina, Div Chem Biol & Med Chem, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Rossman, K. L.; Der, C. J.] Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; [Rossman, K. L.; Der, C. J.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Der, CJ (corresponding author), Univ N Carolina, Dept Pharmacol, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.	cjder@med.unc.edu		Der, Channing/0000-0002-7751-2747	NIH; AACR/Pancreatic Cancer Action Network; Lustgarten Pancreatic Cancer Foundation;  [CA71341];  [CA159821]; NATIONAL CANCER INSTITUTE [F31CA159821, R01CA042978, T32CA071341] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); AACR/Pancreatic Cancer Action Network; Lustgarten Pancreatic Cancer Foundation; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Adrienne D Cox for careful and critical reading of our manuscript. We apologize to colleagues whose studies we did not cite due to space limitations. CJD is supported by grants from the NIH, AACR/Pancreatic Cancer Action Network and the Lustgarten Pancreatic Cancer Foundation. DRC was supported by a T32 training grant (CA71341) and an F31 predoctoral fellowship (CA159821).	Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Adam L, 2001, J BIOL CHEM, V276, P28443, DOI 10.1074/jbc.M009769200; Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Alto NM, 2006, CELL, V124, P133, DOI 10.1016/j.cell.2005.10.031; Aoki Y, 2013, INT J HEMATOL, V97, P30, DOI 10.1007/s12185-012-1239-y; Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; Balakrishnan A, 2007, CANCER RES, V67, P3545, DOI 10.1158/0008-5472.CAN-07-0065; Barrio-Real L, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003543; Bartolome RA, 2006, CANCER RES, V66, P248, DOI 10.1158/0008-5472.CAN-05-2489; Berger MF, 2012, NATURE, V485, P502, DOI 10.1038/nature11071; Berken A, 2005, NATURE, V436, P1176, DOI 10.1038/nature03883; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bourguignon LYW, 2000, J BIOL CHEM, V275, P1829, DOI 10.1074/jbc.275.3.1829; Brambilla R, 1997, NATURE, V390, P281, DOI 10.1038/36849; Buchsbaum RJ, 2003, J BIOL CHEM, V278, P18833, DOI 10.1074/jbc.M207876200; Buchsbaum RJ, 2002, MOL CELL BIOL, V22, P4073, DOI 10.1128/MCB.22.12.4073-4085.2002; Buchwald G, 2002, EMBO J, V21, P3286, DOI 10.1093/emboj/cdf329; Bulgin R, 2010, INFECT IMMUN, V78, P1417, DOI 10.1128/IAI.01250-09; Burkard ME, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000111; Bustelo XR, 2007, BIOESSAYS, V29, P356, DOI 10.1002/bies.20558; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; Bustelo XR, 2002, FRONT BIOSCI, V7, pD24, DOI 10.2741/bustelo; Bustelo XR, 2001, ONCOGENE, V20, P6372, DOI 10.1038/sj.onc.1204780; Cahill ME, 2009, P NATL ACAD SCI USA, V106, P13058, DOI 10.1073/pnas.0904636106; Cai HB, 2005, J NEUROSCI, V25, P7567, DOI 10.1523/JNEUROSCI.1645-05.2005; Chan AML, 1996, ONCOGENE, V12, P1259; CHAN AML, 1994, ONCOGENE, V9, P1057; Chen JS, 2012, INT J CANCER, V130, P1302, DOI 10.1002/ijc.26117; Chiu CY, 1999, GENOMICS, V61, P66, DOI 10.1006/geno.1999.5936; Citterio C, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002962; Clapcott SJ, 2003, MAMM GENOME, V14, P495, DOI 10.1007/s00335-002-2258-4; Coleman Natalia, 2012, Cell Logist, V2, P132; Cook Danielle R, 2011, Genes Cancer, V2, P932, DOI 10.1177/1947601912437035; Cote JF, 2002, J CELL SCI, V115, P4901, DOI 10.1242/jcs.00219; Cox Adrienne D, 2010, Small GTPases, V1, P2; Creedon Helen, 2012, Critical Reviews in Oncogenesis, V17, P145; de Mora JF, 2003, EMBO J, V22, P3039, DOI 10.1093/emboj/cdg280; Delague V, 2007, AM J HUM GENET, V81, P1, DOI 10.1086/518428; Deng HX, 2007, HUM MOL GENET, V16, P2911, DOI 10.1093/hmg/ddm251; Devon RS, 2006, P NATL ACAD SCI USA, V103, P9595, DOI 10.1073/pnas.0510197103; Devon RS, 2003, CLIN GENET, V64, P210, DOI 10.1034/j.1399-0004.2003.00138.x; Donald S, 2004, FEBS LETT, V572, P172, DOI 10.1016/j.febslet.2004.06.096; Donald S, 2008, P NATL ACAD SCI USA, V105, P4483, DOI 10.1073/pnas.0712324105; Dong N, 2010, EMBO J, V29, P1363, DOI 10.1038/emboj.2010.33; Dong ZY, 2006, MOL ENDOCRINOL, V20, P2315, DOI 10.1210/me.2006-0048; Doody GM, 2001, NAT IMMUNOL, V2, P542, DOI 10.1038/88748; Engers R, 2006, BRIT J CANCER, V95, P1081, DOI 10.1038/sj.bjc.6603385; Engers R, 2001, J BIOL CHEM, V276, P41889, DOI 10.1074/jbc.M105049200; Esteban LM, 2000, MOL CELL BIOL, V20, P6410, DOI 10.1128/MCB.20.17.6410-6413.2000; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; EVA A, 1987, ONCOGENE, V1, P355; Eymard-Pierre E, 2002, AM J HUM GENET, V71, P518, DOI 10.1086/342359; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; Fernandez-Medarde A, 2002, MOL CELL BIOL, V22, P2498, DOI 10.1128/MCB.22.8.2498-2504.2002; Fernandez-Zapico ME, 2005, CANCER CELL, V7, P39, DOI 10.1016/j.ccr.2004.11.024; Fields AP, 2010, ADV ENZYME REGUL, V50, P190, DOI 10.1016/j.advenzreg.2009.10.010; Fine B, 2009, SCIENCE, V325, P1261, DOI 10.1126/science.1173569; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; Francis SA, 2006, BLOOD, V107, P1627, DOI 10.1182/blood-2005-03-1164; Fujikawa K, 2003, J EXP MED, V198, P1595, DOI 10.1084/jem.20030874; Galan JE, 2009, CELL HOST MICROBE, V5, P571, DOI 10.1016/j.chom.2009.04.008; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Garcia-Mata R, 2011, NAT REV MOL CELL BIO, V12, P493, DOI 10.1038/nrm3153; Genot E, 2012, J CELL SCI, V125, P3265, DOI 10.1242/jcs.093419; Gerloff DL, 2012, FEBS LETT, V586, P2711, DOI 10.1016/j.febslet.2012.05.005; Giese KP, 2001, NEUROPHARMACOLOGY, V41, P791, DOI 10.1016/S0028-3908(01)00096-X; Girkontaite I, 2001, NAT IMMUNOL, V2, P855, DOI 10.1038/ni0901-855; GRAY BN, 1992, AUST NZ J SURG, V62, P105; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hadano S, 2006, HUM MOL GENET, V15, P233, DOI 10.1093/hmg/ddi440; Hadano S, 2001, NAT GENET, V29, P166, DOI 10.1038/ng1001-166; Hall A, 2012, BIOCHEM SOC T, V40, P1378, DOI 10.1042/BST20120103; Hardt WD, 1998, CELL, V93, P815, DOI 10.1016/S0092-8674(00)81442-7; Harenberg A, 2005, EUR J IMMUNOL, V35, P1977, DOI 10.1002/eji.200425769; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; Harvey K, 2004, J NEUROSCI, V24, P5816, DOI 10.1523/JNEUROSCI.1184-04.2004; Heid I, 2011, GASTROENTEROLOGY, V141, P719, DOI 10.1053/j.gastro.2011.04.043; HENSKE EP, 1995, ANN HUM GENET, V59, P25, DOI 10.1111/j.1469-1809.1995.tb01603.x; Himmel KL, 2002, J BIOL CHEM, V277, P13463, DOI 10.1074/jbc.M110981200; Hirata D, 2009, CLIN CANCER RES, V15, P256, DOI 10.1158/1078-0432.CCR-08-1672; Hirsch E, 2002, MOL CELL BIOL, V22, P3140, DOI 10.1128/MCB.22.9.3140-3148.2002; Hocker HJ, 2013, P NATL ACAD SCI USA, V110, P10201, DOI 10.1073/pnas.1300016110; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; Hornstein I, 2003, J PATHOL, V199, P526, DOI 10.1002/path.1314; Hoshinoso M, 1999, J BIOL CHEM, V274, P17837, DOI 10.1074/jbc.274.25.17837; Itier JM, 1998, NATURE, V393, P125, DOI 10.1038/30120; Iyoda M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014082; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Jin H, 2011, HUM PATHOL, V42, P541, DOI 10.1016/j.humpath.2010.08.013; Jordan P, 1999, ONCOGENE, V18, P6835, DOI 10.1038/sj.onc.1203233; Jung Y, 2011, CLIN CANCER RES, V17, P700, DOI 10.1158/1078-0432.CCR-10-1300; Justilien V, 2009, ONCOGENE, V28, P3597, DOI 10.1038/onc.2009.217; Kaartinen V, 2002, DEV DYNAM, V223, P517, DOI 10.1002/dvdy.10071; Kaartinen V, 2001, DEVELOPMENT, V128, P4217; Kalscheuer VM, 2009, HUM MUTAT, V30, P61, DOI 10.1002/humu.20814; Kanekura K, 2005, J BIOL CHEM, V280, P4532, DOI 10.1074/jbc.M410508200; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; Kawasaki Y, 2010, J BIOL CHEM, V285, P1199, DOI 10.1074/jbc.M109.040691; Kawasaki Y, 2009, EMBO REP, V10, P1355, DOI 10.1038/embor.2009.233; Kim JE, 2005, J BIOL CHEM, V280, P5733, DOI 10.1074/jbc.M409298200; Kimura K, 2000, J BIOL CHEM, V275, P17233, DOI 10.1074/jbc.C000212200; Kino T, 2006, J BIOL CHEM, V281, P9118, DOI 10.1074/jbc.M509339200; Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359; Lambert JM, 2002, NAT CELL BIOL, V4, P621, DOI 10.1038/ncb833; Lane Jane, 2008, Int Semin Surg Oncol, V5, P23, DOI 10.1186/1477-7800-5-23; Lange S, 2009, J CELL SCI, V122, P2640, DOI 10.1242/jcs.046193; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Lazer G, 2011, CELL SIGNAL, V23, P969, DOI 10.1016/j.cellsig.2010.10.022; Lazer G, 2009, J PATHOL, V219, P25, DOI 10.1002/path.2579; Lesca G, 2011, AM J MED GENET A, V155A, P1706, DOI 10.1002/ajmg.a.34004; Leung CCY, 2011, CELL CYCLE, V10, P2461, DOI 10.4161/cc.10.15.16312; Lin KY, 2012, MOL CANCER RES, V10, P750, DOI 10.1158/1541-7786.MCR-11-0598-T; Lindsay CR, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1560; Liot C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023676; Liu L, 2006, NEOPLASIA, V8, P917, DOI 10.1593/neo.06364; Liu Y, 2008, CANCER RES, V68, P6396, DOI 10.1158/0008-5472.CAN-08-0645; Lyons LS, 2008, MOL ENDOCRINOL, V22, P597, DOI 10.1210/me.2007-0158; Lyons LS, 2006, MOL ENDOCRINOL, V20, P1061, DOI 10.1210/me.2005-0346; Ma XM, 2008, J NEUROSCI, V28, P12368, DOI 10.1523/JNEUROSCI.4269-08.2008; Malliri A, 2006, J BIOL CHEM, V281, P543, DOI 10.1074/jbc.M507582200; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; Mandela P, 2012, NEURAL PLAST, V2012, DOI 10.1155/2012/728161; Marco EJ, 2008, J MED GENET, V45, P100, DOI 10.1136/jmg.2007.052324; Maurer T, 2012, P NATL ACAD SCI USA, V109, P5299, DOI 10.1073/pnas.1116510109; Mayers CM, 2010, J BIOL CHEM, V285, P12344, DOI 10.1074/jbc.M110.106856; Meller N, 2005, J CELL SCI, V118, P4937, DOI 10.1242/jcs.02671; Mikelis CM, 2013, J BIOL CHEM, V288, P12232, DOI 10.1074/jbc.M112.428599; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; Miller MB, 2013, NEUROSCIENTIST, V19, P255, DOI 10.1177/1073858413475486; Minard ME, 2006, CLIN EXP METASTAS, V23, P301, DOI 10.1007/s10585-006-9040-z; Missy K, 2008, MOL CELL BIOL, V28, P3776, DOI 10.1128/MCB.00507-07; Mochly-Rosen D, 2012, NAT REV DRUG DISCOV, V11, P937, DOI 10.1038/nrd3871; Montero JC, 2011, ONCOGENE, V30, P1059, DOI 10.1038/onc.2010.489; Mossessova E, 2003, MOL CELL, V12, P1403, DOI 10.1016/S1097-2765(03)00475-1; Movilla N, 1999, MOL CELL BIOL, V19, P7870; Nagawa Shingo, 2010, Small GTPases, V1, P78, DOI 10.4161/sgtp.1.2.14544; NOGUCHI T, 1988, ONCOGENE, V3, P709; Nomura T, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-27; O'Brien SP, 2000, P NATL ACAD SCI USA, V97, P12074, DOI 10.1073/pnas.97.22.12074; Orchard RC, 2012, CELL MICROBIOL, V14, P10, DOI 10.1111/j.1462-5822.2011.01703.x; Otomo A, 2003, HUM MOL GENET, V12, P1671, DOI 10.1093/hmg/ddg184; Pakes Nicholl K, 2013, Small GTPases, V4, P22, DOI 10.4161/sgtp.22087; Papadopoulos T, 2007, EMBO J, V26, P3888, DOI 10.1038/sj.emboj.7601819; PASTERIS NG, 1994, CELL, V79, P669; Peng YJ, 2010, J BIOL CHEM, V285, P24834, DOI 10.1074/jbc.M109.096537; Perry NA, 2013, IUBMB LIFE, V65, P479, DOI 10.1002/iub.1157; Peyroche A, 1999, MOL CELL, V3, P275, DOI 10.1016/S1097-2765(00)80455-4; Prieto-Sanchez RM, 2006, BRIT J HAEMATOL, V133, P642, DOI 10.1111/j.1365-2141.2006.06094.x; Qian XL, 2000, EMBO J, V19, P642, DOI 10.1093/emboj/19.4.642; Qin J, 2009, ONCOGENE, V28, P1853, DOI 10.1038/onc.2009.30; Ramakers GJA, 2012, HUM MOL GENET, V21, P268, DOI 10.1093/hmg/ddr457; Rao S, 2012, ONCOGENE, V31, P716, DOI 10.1038/onc.2011.273; Rath N, 2012, EMBO REP, V13, P900, DOI 10.1038/embor.2012.127; Roberts AE, 2007, NAT GENET, V39, P70, DOI 10.1038/ng1926; Robineau S, 2000, P NATL ACAD SCI USA, V97, P9913, DOI 10.1073/pnas.170290597; Rodon J, 2013, NAT REV CLIN ONCOL, V10, P143, DOI 10.1038/nrclinonc.2013.10; Rosenfeldt H, 2004, FEBS LETT, V572, P167, DOI 10.1016/j.febslet.2004.06.097; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Roversi G, 2006, ONCOGENE, V25, P1571, DOI 10.1038/sj.onc.1209177; Rubtsov A, 2005, IMMUNITY, V23, P527, DOI 10.1016/j.immuni.2005.09.018; Ruiz S, 2007, MOL CELL BIOL, V27, P8127, DOI 10.1128/MCB.00912-07; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Saito S, 2004, J BIOL CHEM, V279, P7169, DOI 10.1074/jbc.M306725200; Saito S, 2003, J CELL BIOCHEM, V90, P819, DOI 10.1002/jcb.10688; Salhia B, 2008, AM J PATHOL, V173, P1828, DOI 10.2353/ajpath.2008.080043; Sano M, 2006, ONCOL REP, V16, P1093; Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Schuebel KE, 1996, ONCOGENE, V13, P363; Shang X, 2013, P NATL ACAD SCI USA, V110, P3155, DOI 10.1073/pnas.1212324110; Shang X, 2012, CHEM BIOL, V19, P699, DOI 10.1016/j.chembiol.2012.05.009; Shimojima K, 2011, J HUM GENET, V56, P561, DOI 10.1038/jhg.2011.58; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Solski PA, 2004, J BIOL CHEM, V279, P25226, DOI 10.1074/jbc.M313792200; Sosa MS, 2010, MOL CELL, V40, P877, DOI 10.1016/j.molcel.2010.11.029; Spindler MJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062705; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; Stebel A, 2009, ONCOL REP, V21, P217, DOI 10.3892/or_00000211; Stendel C, 2007, AM J HUM GENET, V81, P158, DOI 10.1086/518770; Strumane K, 2009, J CANCER RES CLIN, V135, P69, DOI 10.1007/s00432-008-0437-8; Sugihara K, 1998, ONCOGENE, V17, P3427, DOI 10.1038/sj.onc.1202595; Sun Q, 2012, ANGEW CHEM INT EDIT, V51, P6140, DOI 10.1002/anie.201201358; Tanaka M, 2004, EMBO J, V23, P1075, DOI 10.1038/sj.emboj.7600128; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; Tartaglia M, 2007, NAT GENET, V39, P75, DOI 10.1038/ng1939; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; Tedford K, 2001, NAT IMMUNOL, V2, P548, DOI 10.1038/88756; Terawaki S, 2010, EMBO J, V29, P236, DOI 10.1038/emboj.2009.323; TOKSOZ D, 1994, ONCOGENE, V9, P621; Tolias KF, 2007, P NATL ACAD SCI USA, V104, P7265, DOI 10.1073/pnas.0702044104; Topp JD, 2004, J BIOL CHEM, V279, P24612, DOI 10.1074/jbc.M313504200; Trenkle T, 2000, GENE, V245, P139, DOI 10.1016/S0378-1119(00)00026-3; Turner M, 2002, NAT REV IMMUNOL, V2, P476, DOI 10.1038/nri840; Uhlenbrock K, 2004, J CELL SCI, V117, P4863, DOI 10.1242/jcs.01367; Van de Putte T, 2001, MECH DEVELOP, V102, P33, DOI 10.1016/S0925-4773(01)00279-9; Vega FM, 2007, CELL, V129, P1430, DOI 10.1016/j.cell.2007.06.021; Vigil D, 2010, NAT REV CANCER, V10, P842, DOI 10.1038/nrc2960; VONCKEN JW, 1995, CELL, V80, P719, DOI 10.1016/0092-8674(95)90350-X; Wang DZM, 1997, GENE DEV, V11, P309, DOI 10.1101/gad.11.3.309; Wang ZL, 2009, J BIOL CHEM, V284, P28599, DOI 10.1074/jbc.M109.047282; Weeks A, 2012, AM J PATHOL, V181, P662, DOI 10.1016/j.ajpath.2012.04.011; Welch HCE, 2005, CURR BIOL, V15, P1867, DOI 10.1016/j.cub.2005.09.050; Welch HCE, 2002, CELL, V108, P809, DOI 10.1016/S0092-8674(02)00663-3; Wennerberg K, 2005, J CELL SCI, V118, P843, DOI 10.1242/jcs.01660; WHITEHEAD I, 1995, ONCOGENE, V10, P713; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; Wirth A, 2008, NAT MED, V14, P64, DOI 10.1038/nm1666; Wolfe BA, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000110; Wu G, 2000, PLANT PHYSIOL, V124, P1625, DOI 10.1104/pp.124.4.1625; Yamanaka K, 2006, ANN NEUROL, V60, P95, DOI 10.1002/ana.20888; Yang J, 2009, SCIENCE, V325, P1398, DOI 10.1126/science.1174468; Yang Y, 2001, NAT GENET, V29, P160, DOI 10.1038/ng1001-160; YANG ZB, 1993, P NATL ACAD SCI USA, V90, P8732, DOI 10.1073/pnas.90.18.8732; Yoo S, 2012, MOL CELLS, V34, P103, DOI 10.1007/s10059-012-0119-x; Yoon B, 2005, MOL CELL BIOL, V25, P11184, DOI 10.1128/MCB.25.24.11184-11190.2005; Yu BK, 2010, CELL, V140, P246, DOI 10.1016/j.cell.2009.12.033; Zhang ML, 2008, HEPATOB PANCREAT DIS, V7, P533; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0; Zizer E, 2010, GASTROENTEROLOGY, V139, P1344, DOI 10.1053/j.gastro.2010.06.041	225	239	245	0	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2014	33	31					4021	4035		10.1038/onc.2013.362	http://dx.doi.org/10.1038/onc.2013.362			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AN4YG	24037532	Green Accepted, Green Submitted			2022-12-17	WOS:000340595300001
J	Wilda, M; Fuchs, U; Wossmann, W; Borkhardt, A				Wilda, M; Fuchs, U; Wossmann, W; Borkhardt, A			Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi)	ONCOGENE			English	Article						RNA interference; BCR/ABL rearrangement; apoptosis; STI 571; gene therapy	ABL TYROSINE KINASE; CHRONIC MYELOGENOUS LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; POLYMERASE-CHAIN-REACTION; BCR-ABL; CLINICAL-SIGNIFICANCE; INHIBITOR; RESISTANCE; GROWTH	Short 21-mer double-stranded RNA (dsRNA) molecules have recently been employed for the sequence-specific silencing of endogenous human genes. This mechanism, called RNA interference (RNAi), is extremely potent and requires only a few dsRNA molecules per cell to silence homologous gene mRNA expression. We used dsRNA targeting the M-BCR/ABL fusion site to kill leukemic cells with such a rearrangement. Transfection of dsRNA specific for the M-BCR/ABL fusion mRNA into K562 cells depleted the corresponding mRNA and the M-BCR/ABL oncoprotein. This was demonstrated by real-time quantitative PCR and Western blots. The BCR/ABL knockdown was accompanied by strong induction of apoptotic cell death. Leukemic cells without BCR/ABL rearrangement were not killed by M-BCR/ABL-dsRNA. In addition, to corroborate the extraordinary sequence specificity of RNAi, we designed another RNA oligo matching the M-BCR/ABL fusion site but having two point mutations within its central region. We show that these two point mutations abolished both p210 reduction and induction of apoptosis in K562 cells. Finally, we compared leukemic cell killing by RNAi to that caused by the ABL kinase tyrosine inhibitor, STI 571, Imatinib. For full induction of apoptosis, dsRNA targeting M-BCR/ABL required 24 h more than Imatinib. This may be caused by the relatively long half-life of the BCR/ABL oncoprotein, which is not targeted by the RNAi mechanism, but is affected by STI 571. When we applied ds M-BCR/ABL RNA and STI 571 in combination, we did not observe a further increase in the induction of apoptosis. Nevertheless, these data may open a field for further studies towards gene-therapeutic approaches using RNA interference to kill tumor cells with specific genetic abnormalities.	Univ Giessen, Dept Pediat Hematol & Oncol, D-35392 Giessen, Germany	Justus Liebig University Giessen	Borkhardt, A (corresponding author), Pediat Hematol & Oncol, Feulgenstr 12, D-35392 Giessen, Germany.	Arndt.Borkhardt@paediat.med.uni-giessen.de						Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DHUT S, 1990, LEUKEMIA, V4, P745; DOBROVIC A, 1991, LEUKEMIA, V5, P187; Druker B J, 2001, Hematology Am Soc Hematol Educ Program, P87; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Goldman JM, 2001, NEW ENGL J MED, V344, P1084, DOI 10.1056/NEJM200104053441409; Goldman JM, 2001, BLOOD, V98, P2039, DOI 10.1182/blood.V98.7.2039; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Hochhaus A, 2001, SCIENCE, V293, P2163; HOOBERMAN AL, 1989, P NATL ACAD SCI USA, V86, P4259, DOI 10.1073/pnas.86.11.4259; LESTINGI TM, 1993, HEMATOL ONCOL CLIN N, V7, P161, DOI 10.1016/S0889-8588(18)30262-4; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Mahon FX, 2000, BLOOD, V96, P1070, DOI 10.1182/blood.V96.3.1070.015k17_1070_1079; MAURER J, 1991, LANCET, V337, P1055, DOI 10.1016/0140-6736(91)91706-Z; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; Rabbitts TH, 1998, NEW ENGL J MED, V338, P192, DOI 10.1056/NEJM199801153380311; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAY S, 1994, CANCER CHEMOTH PHARM, V34, P365, DOI 10.1007/s002800050156; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Rowley JD, 1999, SEMIN HEMATOL, V36, P59; RUBIN CM, 1988, P NATL ACAD SCI USA, V85, P2795, DOI 10.1073/pnas.85.8.2795; Scadden ADJ, 2001, EMBO REP, V2, P1107, DOI 10.1093/embo-reports/kve244; SKORSKI T, 1994, P NATL ACAD SCI USA, V91, P4504, DOI 10.1073/pnas.91.10.4504; SMETSERS TFCM, 1994, LEUKEMIA, V8, P129; Spiller DG, 1998, BLOOD, V91, P4738, DOI 10.1182/blood.V91.12.4738.412k31_4738_4746; Stein Cy A., 1994, Current Opinion in Oncology, V6, P587, DOI 10.1097/00001622-199411000-00010; Tuschl T, 2002, NAT BIOTECHNOL, V20, P446, DOI 10.1038/nbt0502-446; WESTBROOK CA, 1992, BLOOD, V80, P2983	36	239	365	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2002	21	37					5716	5724		10.1038/sj.onc.1205653	http://dx.doi.org/10.1038/sj.onc.1205653			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173041				2022-12-17	WOS:000177463400006
J	Gardiol, D; Kuhne, C; Glaunsinger, B; Lee, SS; Javier, R; Banks, L				Gardiol, D; Kuhne, C; Glaunsinger, B; Lee, SS; Javier, R; Banks, L			Oncogenic human papillomavirus E6 proteins target the discs large tumour suppressor for proteasome-mediated degradation	ONCOGENE			English	Article						HPV E6; DLG; proteasome; transformation	CERVICAL-CANCER; PDZ DOMAINS; HPV-18 E6; GUANYLATE KINASES; HUMAN HOMOLOG; GENE-PRODUCT; IN-VIVO; BINDING; P53; INHIBITION	Previous studies have shown that the oncogenic HPV E6 proteins form a complex with the human homologue of the Drosophila tumour suppressor protein, discs large (Dlg), This is mediated by the carboxy terminus of the E6 proteins and involves recognition of at least one PDZ domain of Dig, This region of E6 is not conserved amongst E6 proteins from the low risk papillomavirus types and, hence, binding of HPV E6 proteins to Dig correlates with the oncogenic potential of these viruses. We have performed studies to investigate the consequences of the interaction between E6 and Dig, Mutational analysis of both the HPV18 E6 and Dig proteins has further defined the regions of E6 and Dig necessary for complex formation. Strikingly, co-expression of wild type HPV18 E6 with Dig in vitro or in vivo results in a dramatic decrease in the amount of Dig protein, whereas mutants of E6 which fail to complex with Dig have minimal effect on Dig protein levels. The oncogenic HPV16 E6 also decreased the Dig levels, but this was not observed with the low risk HPV11 E6 protein. Moreover, a region within the first 544 amino acids of Dig containing the three PDZ domains confers susceptibility to E6 mediated degradation. Finally, treatment of cells with a proteasome inhibitor overrides the capacity of E6 to degrade Dig, These results demonstrate that Dig is targeted by high risk HPV E6 proteins for proteasome mediated degradation.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; Baylor Coll Med, Div Mol Virol, Houston, TX 77030 USA	International Center for Genetic Engineering & Biotechnology (ICGEB); Baylor College of Medicine	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.				NATIONAL CANCER INSTITUTE [R01CA058541] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA58541, R01 CA058541] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson JM, 1996, CURR BIOL, V6, P382, DOI 10.1016/S0960-9822(02)00501-8; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BURNETT AF, 1992, GYNECOL ONCOL, V47, P343, DOI 10.1016/0090-8258(92)90137-8; CHEN JJ, 1995, SCIENCE, V269, P529, DOI 10.1126/science.7624774; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FRANCO EL, 1992, CANCER EPIDEM BIOMAR, V1, P499; Goode S, 1997, GENE DEV, V11, P2532, DOI 10.1101/gad.11.19.2532; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; Kim E, 1996, NEUROPHARMACOLOGY, V35, P993, DOI 10.1016/0028-3908(96)00093-7; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Kuhne C, 1998, J BIOL CHEM, V273, P34302, DOI 10.1074/jbc.273.51.34302; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Marfatia SM, 1996, J CELL BIOL, V135, P753, DOI 10.1083/jcb.135.3.753; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; PIM D, 1994, ONCOGENE, V9, P1869; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; Thomas M, 1998, ONCOGENE, V17, P2943, DOI 10.1038/sj.onc.1202223; THOMAS M, 1995, ONCOGENE, V10, P261; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; VOUSDEN KH, 1994, ADV CANCER RES, V64, P1, DOI 10.1016/S0065-230X(08)60833-7; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; WOODS DF, 1993, MECH DEVELOP, V44, P85, DOI 10.1016/0925-4773(93)90059-7; ZHANG JW, 1995, GYNECOL ONCOL, V57, P170, DOI 10.1006/gyno.1995.1120; zur Hausen H, 1987, PAPILLOMAVIRUSES, P245	40	239	250	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	1999	18	40					5487	5496		10.1038/sj.onc.1202920	http://dx.doi.org/10.1038/sj.onc.1202920			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	241QU	10523825				2022-12-17	WOS:000082894700001
J	Bounacer, A; Wicker, R; Caillou, B; Cailleux, AF; Sarasin, A; Schlumberger, M; Suarez, HG				Bounacer, A; Wicker, R; Caillou, B; Cailleux, AF; Sarasin, A; Schlumberger, M; Suarez, HG			High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation	ONCOGENE			English	Article						radiation-associated tumors; ret protooncogene; activating rearrangements; RET/PTC oncogene	CHERNOBYL NUCLEAR ACCIDENT; TYROSINE KINASE; PAPILLARY CARCINOMAS; MOLECULAR CHARACTERIZATION; PROTOONCOGENE ACTIVATION; TRANSFORMING GENE; RET/PTC ONCOGENE; MUTATIONS; CANCER; RAS	A high frequency (about 60%) of ret rearrangements in papillary thyroid carcinomas of children exposed to radioactive fallout in Belarus the Chernobyl after accident, has been reported by three recent studies (Fugazzola et al., 1995; Ito et al., 1994; Klugbauer et al., 1995). These studies suggested that the radiation exposure may be a direct inducer of activating rearrangements in the vet gene. In order to confirm the postulated link between irradiation and the role of the ret protooncogene in thyroid tumorigenesis, we analysed for the presence of ret activating rearrangements using RT-PCR, XL-PCR, Southern blot and direct sequencing techniques, 39 human thyroid tumors (19 papillary carcinomas and 20 follicular adenomas), from patients who had received external radiation for benign or malignant conditions. As controls, eve studied 39 'spontaneous' tumors (20 papillary carcinomas and 19 follicular adenomas). Our data concerning the radiation-associated tumors, showed that: (1) the overall frequency of ret rearrangements was 84% in papillary carcinomas (16/19) and 45% (9/20) in follicular adenomas; (2) in contrast with the results obtained in the Chernobyl tumors, the most frequently observed chimeric gene was RET/PTC1 instead of the RET/PTC3 and (3) all the tumors were negative for RET/PTC2. In the 'spontaneous' tumors, only the papillary carcinomas presented a I et rearrangement (15%:3/20): 1 RET/PTC1, 1 RET/ PTC3 and 1 uncharacterized. In conclusion, our results confirm the crucial role played by the ret proto-oncogene activating rearrangements in the development of radiation-associated thyroid tumors appearing after therapeutic or accidental ionizing irradiation, and show, for the first time, the presence of RET/PTC genes in follicular adenomas appeared after external irradiation.	INST RECH SCI CANC, GENET MOL LAB, UPR 42, CNRS IFC 1, F-94801 VILLEJUIF, FRANCE; INST GUSTAVE ROUSSY, F-94805 VILLEJUIF, FRANCE	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy								BONGARZONE I, 1989, ONCOGENE, V4, P1457; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BONGARZONE I, 1994, CANCER RES, V54, P2979; CHALLETON C, 1995, ONCOGENE, V11, P601; CONARD RA, 1970, J AMER MED ASSOC, V214, P316, DOI 10.1001/jama.214.2.316; Delvincourt C, 1996, CLIN BIOCHEM, V29, P267, DOI 10.1016/0009-9120(96)00006-9; Diallo I, 1996, RADIOTHER ONCOL, V38, P269, DOI 10.1016/0167-8140(96)01713-6; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; DUFFY BJ, 1950, J CLIN ENDOCRINOL, V10, P1296, DOI 10.1210/jcem-10-10-1296; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; Fogelfeld L, 1996, J CLIN ENDOCR METAB, V81, P3039, DOI 10.1210/jc.81.8.3039; FRAKER DL, 1995, SURG CLIN N AM, V75, P365, DOI 10.1016/S0039-6109(16)46627-2; Fugazzola L, 1996, ONCOGENE, V13, P1093; FUGAZZOLA L, 1995, CANCER RES, V55, P5617; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HEDINGER C, 1989, CANCER-AM CANCER SOC, V63, P908, DOI 10.1002/1097-0142(19890301)63:5<908::AID-CNCR2820630520>3.0.CO;2-I; ISHIZAKA Y, 1991, ONCOGENE, V6, P1667; ITO T, 1993, CANCER RES, V53, P2940; ITO T, 1994, LANCET, V344, P259; JACKSON DP, 1989, LANCET, V1, P1391; JHIANG SM, 1992, ONCOGENE, V7, P1331; KAZAKOV VS, 1992, NATURE, V359, P21, DOI 10.1038/359021a0; Klugbauer S, 1995, ONCOGENE, V11, P2459; LEMOINE NR, 1988, CANCER RES, V48, P4459; MICHELIN S, 1993, ONCOGENE, V8, P1983; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; Nikiforov YE, 1996, ONCOGENE, V13, P687; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; RON E, 1995, RADIAT RES, V141, P259, DOI 10.2307/3579003; RUSSO D, 1995, J CLIN ENDOCR METAB, V80, P1347, DOI 10.1210/jc.80.4.1347; SAID S, 1994, J ENDOCRINOL INVEST, V17, P371, DOI 10.1007/BF03349004; SANGER F, 1977, P NATL ACAD SCI USA, V82, P488; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; SANTORO M, 1994, ONCOGENE, V9, P509; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SHORE RE, 1993, AM J EPIDEMIOL, V137, P1068, DOI 10.1093/oxfordjournals.aje.a116610; SHORE RE, 1992, RADIAT RES, V131, P98, DOI 10.2307/3578322; SHORE RE, 1985, J NATL CANCER I, V74, P1177; SMANIK PA, 1995, HUM MOL GENET, V4, P2313, DOI 10.1093/hmg/4.12.2313; STARY A, 1992, NUCLEIC ACIDS RES, V20, P4269, DOI 10.1093/nar/20.16.4269; STOPPALYONNET D, 1990, P NATL ACAD SCI USA, V87, P1551, DOI 10.1073/pnas.87.4.1551; SUAREZ HG, 1991, ONCOGENE, V6, P677; SUAREZ HG, 1990, ONCOGENE, V5, P565; Sugg SL, 1996, J CLIN ENDOCR METAB, V81, P3360, DOI 10.1210/jc.81.9.3360; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; WAJJWALKU W, 1992, JPN J CANCER RES, V83, P671, DOI 10.1111/j.1349-7006.1992.tb01963.x; WOOD JW, 1969, AM J EPIDEMIOL, V89, P4, DOI 10.1093/oxfordjournals.aje.a120914; WRIGHT PA, 1991, ONCOGENE, V6, P471; WYNFORDTHOMAS D, 1993, CRIT REV ONCOGENESIS, V4, P1; ZOU MJ, 1994, CANCER, V73, P176, DOI 10.1002/1097-0142(19940101)73:1<176::AID-CNCR2820730130>3.0.CO;2-T	56	239	252	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	1997	15	11					1263	1273		10.1038/sj.onc.1200206	http://dx.doi.org/10.1038/sj.onc.1200206			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315093				2022-12-17	WOS:A1997XV84500003
J	Terradillos, O; Billet, O; Renard, CA; Levy, R; Molina, T; Briand, P; Buendia, MA				Terradillos, O; Billet, O; Renard, CA; Levy, R; Molina, T; Briand, P; Buendia, MA			The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice	ONCOGENE			English	Article						hepatitis B virus; hepatocellular carcinoma; transactivation; oncogene; apoptosis	GROWTH-FACTOR-ALPHA; HEPATOCELLULAR-CARCINOMA; NUCLEOTIDE-SEQUENCE; TRANSCRIPTIONAL ACTIVITY; DNA-BINDING; HBX GENE; IN-VIVO; PROTEIN; ACTIVATION; EXPRESSION	The hepatitis B virus X protein (HBx) is thought to be implicated in the development of hepatocellular carcinoma, but its exact function remains controversial, Transgenic mice from PEX7 and AX16 lineages that express HBx in the liver under control of different viral regulatory elements develop no liver pathology (Billet ed al., 1995), We have crossed these two mouse lineages with WHV/c-myc oncomice in which liver-specific expression of c-myc driven by woodchuck hepatitis virus (WHV) regulatory sequences causes liver cancer in all animals, The average tumor latency was shortened by 2 to 3 months in bitransgenic animals from all populations compared with simple c-myc transgenic littermates, At preneoplastic stages, adult bitransgenic mice showed four to fivefold enhanced expression of the c-myc transgene, increased hepatocyte proliferation and more extensive liver lesions compared with simple WHV/c-myc transgenics, Thus in this model, HBx alone has no direct pathological effect but it is shown to accelerate tumor development induced by c-myc. The data presented here firmly establish the oncogenic potential of HBx, apparently acting as a tumor promoter, This model offers unique opportunities to investigate the mechanisms by which HBx trans-activates the expression of target genes and deregulates the hepatocyte growth control in vivo.	INST PASTEUR,DEPT RETROVIRUS,INSERM U163,UNITE RECOMBINAISON & EXPRESS GENET,F-75724 PARIS 15,FRANCE; INST COCHIN GENET MOL,INSERM U380,UNITE GENET & PATHOL EXPT,F-75014 PARIS,FRANCE; UNIV PARIS,HOTEL DIEU,FAC BROUSSAIS,LAB RECH HISTOPATHOL,PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite			Molina, Thierry/ABA-5214-2020	Molina, Thierry/0000-0002-3929-9754				ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; AUFIERO B, 1990, EMBO J, V9, P497, DOI 10.1002/j.1460-2075.1990.tb08136.x; AVANTAGGIATI ML, 1993, ONCOGENE, V8, P1567; BALSANO C, 1991, BIOCHEM BIOPH RES CO, V176, P985, DOI 10.1016/0006-291X(91)90379-L; BALSANO C, 1993, ARCH VIROL         S, V8, P63; BEASLEY RP, 1981, LANCET, V2, P1129; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; BENVENISTY N, 1992, ONCOGENE, V7, P2399; BILLET O, 1995, J VIROL, V69, P5912, DOI 10.1128/JVI.69.9.5912-5916.1995; BUENDIA MA, 1992, ADV CANCER RES, V59, P167, DOI 10.1016/S0065-230X(08)60306-1; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLGROVE R, 1989, J VIROL, V63, P4019, DOI 10.1128/JVI.63.9.4019-4026.1989; Dandri M, 1996, J VIROL, V70, P5246, DOI 10.1128/JVI.70.8.5246-5254.1996; DUFLOT A, 1995, HEPATOLOGY, V21, P1483, DOI 10.1016/0270-9139(95)90448-4; ETIEMBLE J, 1994, ONCOGENE, V9, P727; FAKTOR O, 1990, J VIROL, V64, P1861, DOI 10.1128/JVI.64.4.1861-1863.1990; FAKTOR O, 1990, ONCOGENE, V5, P867; FEITELSON MA, 1993, ONCOGENE, V8, P1109; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; GALIBERT F, 1982, J VIROL, V41, P51, DOI 10.1128/JVI.41.1.51-65.1982; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GU JR, 1986, J CELL PHYSL S, V4, P13; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HAVIV I, 1995, MOL CELL BIOL, V15, P1079; HIMENO Y, 1988, LIVER, V8, P208; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; Huang JK, 1996, J VIROL, V70, P5582, DOI 10.1128/JVI.70.8.5582-5591.1996; KAY A, 1991, J MED VIROL, V33, P228, DOI 10.1002/jmv.1890330404; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KOIKE K, 1994, HEPATOLOGY, V19, P810, DOI 10.1002/hep.1840190403; KOSHY R, 1991, ADV AP BIOT, V13, P159; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; LEE TH, 1990, J VIROL, V64, P5939, DOI 10.1128/JVI.64.12.5939-5947.1990; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MARION PL, 1986, P NATL ACAD SCI USA, V83, P4543, DOI 10.1073/pnas.83.12.4543; MOROY T, 1985, EMBO J, V4, P1507, DOI 10.1002/j.1460-2075.1985.tb03810.x; MURAKAMI H, 1993, CANCER RES, V53, P1719; NAGAYA T, 1987, GENE DEV, V1, P773, DOI 10.1101/gad.1.8.773; NATOLI G, 1994, ONCOGENE, V9, P2837; OGSTON CW, 1982, CELL, V29, P385, DOI 10.1016/0092-8674(82)90155-6; PATERLINI P, 1995, HEPATOLOGY, V21, P313, DOI 10.1002/hep.1840210208; PERFUMO S, 1992, J VIROL, V66, P6819, DOI 10.1128/JVI.66.11.6819-6823.1992; QADRI I, 1995, P NATL ACAD SCI USA, V92, P1003, DOI 10.1073/pnas.92.4.1003; SANDGREN EP, 1993, MOL CELL BIOL, V13, P320, DOI 10.1128/MCB.13.1.320; Slagle BL, 1996, MOL CARCINOGEN, V15, P261, DOI 10.1002/(SICI)1098-2744(199604)15:4<261::AID-MC3>3.0.CO;2-J; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; SUMMERS J, 1978, P NATL ACAD SCI USA, V75, P4533, DOI 10.1073/pnas.75.9.4533; TAKADA S, 1990, P NATL ACAD SCI USA, V87, P5628, DOI 10.1073/pnas.87.15.5628; TRUANT R, 1995, J VIROL, V69, P1951; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; TWU JS, 1993, VIROLOGY, V192, P346, DOI 10.1006/viro.1993.1041; UNGER T, 1990, EMBO J, V9, P1889, DOI 10.1002/j.1460-2075.1990.tb08315.x; WANG XW, 1995, CANCER RES, V55, P6012; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; Wei Y, 1996, J GEN VIROL, V77, P177, DOI 10.1099/0022-1317-77-2-177; WEI Y, 1995, J MED VIROL, V45, P82, DOI 10.1002/jmv.1890450116; WEI Y, 1992, J VIROL, V66, P5265, DOI 10.1128/JVI.66.9.5265-5276.1992; WILLIAMS JS, 1995, P NATL ACAD SCI USA, V92, P3819, DOI 10.1073/pnas.92.9.3819; WOLLERSHEIM M, 1988, ONCOGENE, V3, P545; Yen BTS, 1996, J BIOMED SCI, V3, P20; ZHANG XK, 1990, ONCOGENE, V5, P909; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	71	239	259	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 30	1997	14	4					395	404		10.1038/sj.onc.1200850	http://dx.doi.org/10.1038/sj.onc.1200850			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WE364	9053836				2022-12-17	WOS:A1997WE36400002
J	KEARSEY, JM; COATES, PJ; PRESCOTT, AR; WARBRICK, E; HALL, PA				KEARSEY, JM; COATES, PJ; PRESCOTT, AR; WARBRICK, E; HALL, PA			GADD45 IS A NUCLEAR-CELL CYCLE-REGULATED PROTEIN WHICH INTERACTS WITH P21(CIP1)	ONCOGENE			English	Article						GADD45; P21(CIP1); PCNA; P53; CELL CYCLE	IONIZING-RADIATION; P53 PROTEIN; DNA-BINDING; ANTIGEN; EXPRESSION; INDUCTION; SEQUENCE; REPAIR; GENE; IDENTIFICATION	GADD45 was originally identified as a cDNA clone induced by growth arrest and DNA damage. We show that Gadd45 is a nuclear protein, widely expressed in normal tissues, particularly in quiescent cellular populations. Using cell synchronisation methods we show that Gadd45 levels are highest in the G1 phase of the cell cycle, and are greatly reduced during S phase. Immunoprecipitation of Gadd45 from mammalian cells reveals that it is tightly associated with a protein which reacts with antibodies to the cyclin dependent kinase inhibitor p21(Cip1). Binding of recombinant Gadd45 protein to overlapping p21(Cip1) peptides in ELISA assays and use of the yeast two hybrid assay show that Gadd45 directly interacts with this cell cycle inhibitor. These data suggest that Gadd45 may act in the regulation of the cell cycle. It is postulated that the interactions of Gadd45 with both p21(Cip1) and PCNA are important for the modulation of cell cycles, and for the inhibition of DNA replication.	UNIV DUNDEE,DEPT PATHOL,DUNDEE DD1 9SY,SCOTLAND; UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 9SY,SCOTLAND; UNIV DUNDEE,DEPT ANAT & PHYSIOL,DUNDEE DD1 9SY,SCOTLAND	University of Dundee; University of Dundee; University of Dundee			Prescott, Alan/Y-5956-2018; Coates, Philip J/H-6854-2019; Warbrick, Emma/C-6424-2008	Prescott, Alan/0000-0002-0747-7317; Coates, Philip J/0000-0003-1518-6306; 				ABDOLLAHI A, 1991, ONCOGENE, V6, P165; BAE IS, 1995, CANCER RES, V55, P2387; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CARRIER F, 1994, J BIOL CHEM, V269, P32672; CHALUT C, 1994, BIOESSAYS, V16, P651, DOI 10.1002/bies.950160910; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FREDERSDORF S, 1995, IN PRESS AM J PATHOL; FRIEDBERG EC, 1995, DNA REPAIR; GERDES J, 1984, J IMMUNOL, V133, P1710; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GOUBIN F, 1995, ONCOGENE, V10, P2281; GUJULUVA CN, 1994, ONCOGENE, V9, P1819; HALL PA, 1995, ONCOGENE, V10, P2427; HALL PA, 1990, J PATHOL, V162, P285, DOI 10.1002/path.1711620403; HALL PA, 1993, ONCOGENE, V8, P203; HARLOW E, 1988, ANTIBODIES LABORATOR; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; JONES CJ, 1992, NUCLEIC ACIDS RES, V20, P991, DOI 10.1093/nar/20.5.991; JONES PH, 1995, CELL, V80, P83, DOI 10.1016/0092-8674(95)90453-0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEARSEY JM, 1995, IN PRESS SCI; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LI Y, 1994, ONCOGENE, V9, P2261; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MATSUOKA S, 1994, J BIOL CHEM, V269, P11030; MERRITT AJ, 1994, CANCER RES, V54, P614; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MIURA M, 1992, J CELL PHYSIOL, V150, P370, DOI 10.1002/jcp.1041500221; MIYASHITA T, 1995, CELL, V80, P293; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PRICE BD, 1992, CANCER RES, V52, P3814; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROSE MD, 1990, METHODS YEAST GENETI; Sambrook J., 1989, MOL CLONING LAB MANU; SANCHEZ Y, 1995, BIOESSAYS, V17, P545, DOI 10.1002/bies.950170611; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STEIN GS, 1972, J CELL BIOL, V52, P292, DOI 10.1083/jcb.52.2.292; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALKER LJ, 1993, MOL CELL BIOL, V13, P5370, DOI 10.1128/MCB.13.9.5370; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAHN Q, 1995, INT J ONCOL, V6, P937; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	67	239	249	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1675	1683						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478594				2022-12-17	WOS:A1995TD09400001
J	CHARLES, CH; ABLER, AS; LAU, LF				CHARLES, CH; ABLER, AS; LAU, LF			CDNA SEQUENCE OF A GROWTH FACTOR-INDUCIBLE IMMEDIATE EARLY GENE AND CHARACTERIZATION OF ITS ENCODED PROTEIN	ONCOGENE			English	Note							EXPRESSION; CELLS; SET	We report the cDNA sequence of 3CH134, an immediate early gene whose transcription is rapidly and transiently stimulated by serum growth factors. 3CH134 encodes a 367 amino acid protein that does not share significant sequence similarity with any known protein. 3CH134 is inducible through multiple signal transduction pathways, and in the adult mouse is expressed predominantly in the lung. Using affinity-purified antibodies, we have identified the 3CH134 protein in serum-stimulated Balb/c 3T3 cells and determined that it has a short half-life.	UNIV ILLINOIS,COLL MED,DEPT GENET,808 S WOOD ST,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital				Lau, Lester/0000-0002-4364-2914	NCI NIH HHS [R01 CA46565] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046565] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRAVO R, 1990, CELL GROWTH DIFFER, V1, P305; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; HARLOW E, 1988, ANTIBODIES LABORATOR; HAZEL TG, 1991, MOL CELL BIOL, V11, P3239, DOI 10.1128/MCB.11.6.3239; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LAU LF, 1991, MOL ASPECTS CELLULAR, V6, P257; NATHANS D, 1988, COLD SPRING HARB SYM, V53, P893, DOI 10.1101/SQB.1988.053.01.102; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WILLIAMS GT, 1992, MOL CELLULAR APPROAC, P115	15	239	247	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1992	7	1					187	190						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1741163				2022-12-17	WOS:A1992HC22700025
J	Chan, SWL; Blackburn, EH				Chan, SWL; Blackburn, EH			New ways not to make ends meet: telomerase, DNA damage proteins and heterochromatin	ONCOGENE			English	Review						telomere; telomerase; heterochromatin; telomere capping; DNA damage	SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; BINDING-PROTEIN; IN-VIVO; TERMINAL TRANSFERASE; FISSION YEAST; LIFE-SPAN; RNA; LENGTH; RAP1	Telomeres are stabilized, and telomeric DNA is replenished, by the action of the ribonucleoprotein reverse transcriptase telomerase. Telomere capping functions include the ability of telomeres to protect chromosome ends from cellular DNA-damage responses such as cell cycle arrest or apoptosis. This property of telomeres is especially important for cancer cells, which continue proliferating despite chromosome aberrations. Telomere capping is influenced by multiple, mutually reinforcing factors including telomere length, although telomere length is only one of several determinants of telomere functionality. For example, many cancer cells express high levels of telomerase yet maintain relatively short telomeres. We consider three aspects of telomere capping that have emerged relatively recently: (1) a new role for telomerase in telomere capping independent of its function in telomere elongation. Support for this novel function comes from experiments showing an increase in replicative potential with the reactivation of telomerase, without net telomere lengthening; (2) the role at telomeres of DNA damage proteins. We propose a model in which two factors specifically target telomeres for the action of telomerase, as opposed to recombination or non-homologous end-joining: binding by telomeric proteins that limits DNA damage responses at telomeres, and the affinity of the telomerase RNP for telomeric proteins and DNA; and (3) we discuss a potential protective role of amplified subtelomeric DNAs, which may aid capping of telomeres maintained by non-telomerase based mechanisms through the formation of heterochromatin.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Blackburn, EH (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.	telomer@itsa.ucsf.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026259, R01GM026259] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26259] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; BAIRD SE, 1989, GENE DEV, V3, P585, DOI 10.1101/gad.3.5.585; Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Beattie TL, 2001, MOL CELL BIOL, V21, P6151, DOI 10.1128/MCB.21.18.6151-6160.2001; Blackburn EH, 2000, COLD SPRING HARB SYM, V65, P253, DOI 10.1101/sqb.2000.65.253; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Blackburn EH, 1995, TELOMERES; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Broccoli D, 1996, MOL CELL BIOL, V16, P3765; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Chan SWL, 2001, CURR BIOL, V11, P1240, DOI 10.1016/S0960-9822(01)00391-8; Chang THT, 1997, ONCOGENE, V14, P2383, DOI 10.1038/sj.onc.1201196; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; Craven RJ, 1999, GENETICS, V152, P1531; de Bruin D, 2000, MOL CELL BIOL, V20, P7991, DOI 10.1128/MCB.20.21.7991-8000.2000; de Bruin D, 2001, NATURE, V409, P109, DOI 10.1038/35051119; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; DERNBURG AF, 1995, TELOMERES; Diede SJ, 1999, CELL, V99, P723, DOI 10.1016/S0092-8674(00)81670-0; Dorer DR, 1997, GENETICS, V147, P1181; Downs JA, 2000, NATURE, V408, P1001, DOI 10.1038/35050000; DuBois ML, 2000, COLD SPRING HARB SYM, V65, P281, DOI 10.1101/sqb.2000.65.281; Ducray C, 1999, ONCOGENE, V18, P4211, DOI 10.1038/sj.onc.1202797; Evans SK, 2000, J CELL SCI, V113, P3357; Evans SK, 1999, SCIENCE, V286, P117, DOI 10.1126/science.286.5437.117; Ford LP, 2001, J BIOL CHEM, V276, P32198, DOI 10.1074/jbc.M104469200; Fu WM, 2000, J MOL NEUROSCI, V14, P3, DOI 10.1385/JMN:14:1-2:003; Fulton TB, 1998, MOL CELL BIOL, V18, P4961, DOI 10.1128/MCB.18.9.4961; Gasser SM, 2000, SCIENCE, V288, P1377, DOI 10.1126/science.288.5470.1377; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Gonzalez-Suarez E, 2001, EMBO J, V20, P2619, DOI 10.1093/emboj/20.11.2619; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Gravel S, 1998, SCIENCE, V280, P741, DOI 10.1126/science.280.5364.741; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Grunstein M, 1998, CELL, V93, P325, DOI 10.1016/S0092-8674(00)81160-5; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; Hammond PW, 1997, MOL CELL BIOL, V17, P296, DOI 10.1128/MCB.17.1.296; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARRINGTON LA, 1991, NATURE, V353, P451, DOI 10.1038/353451a0; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Huffman KE, 2000, J BIOL CHEM, V275, P19719, DOI 10.1074/jbc.M002843200; JARACZEWSKI JW, 1993, GENE DEV, V7, P95, DOI 10.1101/gad.7.1.95; KARATZA C, 1984, J CELL SCI, V65, P163; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim SH, 1999, NAT GENET, V23, P405, DOI 10.1038/70508; Klapper W, 2001, J NEUROSCI RES, V64, P252, DOI 10.1002/jnr.1073; Krauskopf A, 1996, NATURE, V383, P354, DOI 10.1038/383354a0; Krauskopf A, 1998, P NATL ACAD SCI USA, V95, P12486, DOI 10.1073/pnas.95.21.12486; KYRION G, 1992, MOL CELL BIOL, V12, P5159, DOI 10.1128/MCB.12.11.5159; LEE MS, 1993, MOL CELL BIOL, V13, P6586, DOI 10.1128/MCB.13.10.6586; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Li BB, 2000, CELL, V101, P471, DOI 10.1016/S0092-8674(00)80858-2; Lieb JD, 2001, NAT GENET, V28, P327, DOI 10.1038/ng569; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Liu Y, 2000, CURR BIOL, V10, P1459, DOI 10.1016/S0960-9822(00)00805-8; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; LUSTIG AJ, 1990, SCIENCE, V250, P549, DOI 10.1126/science.2237406; Marcand S, 1997, SCIENCE, V275, P986, DOI 10.1126/science.275.5302.986; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; McEachern MJ, 1996, GENE DEV, V10, P1822, DOI 10.1101/gad.10.14.1822; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; Metcalfe JA, 1996, NAT GENET, V13, P350, DOI 10.1038/ng0796-350; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Mishra K, 1999, CURR BIOL, V9, P1123, DOI 10.1016/S0960-9822(99)80483-7; Moreau S, 1999, MOL CELL BIOL, V19, P556; Naito T, 1998, NAT GENET, V20, P203, DOI 10.1038/2517; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; OLOVNIKO.AM, 1971, DOKL AKAD NAUK SSSR+, V201, P1496; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; PARDUE M, 1995, TELOMERES; Pardue ML, 1999, GENETICA, V107, P189, DOI 10.1023/A:1003905210770; Peterson SE, 2001, NAT GENET, V27, P64, DOI 10.1038/83778; Prescott J, 1997, GENE DEV, V11, P528, DOI 10.1101/gad.11.4.528; Prescott J, 1997, GENE DEV, V11, P2790, DOI 10.1101/gad.11.21.2790; Prescott JC, 2000, MOL CELL BIOL, V20, P2941, DOI 10.1128/MCB.20.8.2941-2948.2000; Ranganathan V, 2001, CURR BIOL, V11, P962, DOI 10.1016/S0960-9822(01)00267-6; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; Ritchie KB, 2000, GENETICS, V155, P475; Ritchie KB, 1999, MOL CELL BIOL, V19, P6065; Roy J, 1998, GENE DEV, V12, P3286, DOI 10.1101/gad.12.20.3286; Schulz VP, 1996, HUM GENET, V97, P750; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Smith CD, 1999, J CELL BIOL, V145, P203, DOI 10.1083/jcb.145.2.203; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; Stampfer MR, 2001, P NATL ACAD SCI USA, V98, P4498, DOI 10.1073/pnas.071483998; SUGAWARA N, 1992, MOL CELL BIOL, V12, P563, DOI 10.1128/MCB.12.2.563; Suja JA, 1994, CHROMOSOME RES, V2, P361, DOI 10.1007/BF01552795; VAZIRI H, 1993, AM J HUM GENET, V52, P661; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; Wellinger RJ, 1996, CELL, V85, P423, DOI 10.1016/S0092-8674(00)81120-4; WELLINGER RJ, 1993, CELL, V72, P51, DOI 10.1016/0092-8674(93)90049-V; Weng NP, 1997, P NATL ACAD SCI USA, V94, P10827, DOI 10.1073/pnas.94.20.10827; Wenz C, 2001, EMBO J, V20, P3526, DOI 10.1093/emboj/20.13.3526; Wood LD, 2001, ONCOGENE, V20, P278, DOI 10.1038/sj.onc.1204072; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; YU GL, 1991, CELL, V67, P823, DOI 10.1016/0092-8674(91)90077-C; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhu HY, 2000, J NEUROCHEM, V75, P117, DOI 10.1046/j.1471-4159.2000.0750117.x; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	110	238	253	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2002	21	4					553	563		10.1038/sj.onc.1205082	http://dx.doi.org/10.1038/sj.onc.1205082			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	513QU	11850780				2022-12-17	WOS:000173390500007
J	Dhakshinamoorthy, S; Jaiswal, AK				Dhakshinamoorthy, S; Jaiswal, AK			Functional characterization and role of INrf2 in antioxidant response element-mediated expression and antioxidant induction of NAD(P)H : quinone oxidoreductase 1 gene	ONCOGENE			English	Article						NQO1; hARE; Nrf2; INrf2; antioxidant	TRANSCRIPTION FACTOR; NF-E2-RELATED FACTOR-2; COORDINATED INDUCTION; HEME OXYGENASE-1; ACTIN-BINDING; SUBUNIT GENE; C-FOS; NRF2; PROTEIN; ACTIVATION	Antioxidant response element (ARE) and nuclear transcription factor Nrf2 are known to regulate expression and coordinated induction of NQO1 and other detoxifying enzyme genes in response to antioxidants and xenobiotics, A cytosolic inhibitor of Nrf2, INrf2, that retains Nrf2 in the cytoplasm, was cloned and sequenced, Treatment of cells with antioxidants and xenobiotics results in the release of Nrf2 from INrf2, Nrf2 then moves in the nucleus, This leads to the induction of ARE-mediated NQO1 and other detoxifying enzyme genes expression, INrf2 after dissociation from Nrf2 remains in the cytosol, Overexpression of INrf2 repressed ARE-mediated NQO1 gene expression, Deletion mapping of INrf2 revealed the requirement of KELCH domain (amino acid residues 361-597) and C-terminal region (amino acid residues 598-624) in retention of Nrf2 in the cytosol, Both these regions of INrf2 independently retained Nrf2 in the cytosol leading to the repression of ARE-mediated NQO1 gene expression, These results may indicate that two different regions of INrf2 interact with a single molecule of Nrf2 or two or more molecules of Nrf2 interact with a single molecule of INrf2, The transcription of Nrf2 and INrf2 did not change in response to antioxidants and xenobiotics, This indicated that INrf2 and/or Nrf2 might be post-transcriptionally modified in response to antioxidants and xenobiotics leading to the release of Nrf2 from INrf2 and induction of ARE-mediated NQO1 and other detoxifying enzyme genes expression.	Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA	Baylor College of Medicine	Jaiswal, AK (corresponding author), Baylor Coll Med, Dept Pharmacol, 1 Baylor Plaza, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047466, R01GM047466] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47466] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; Bauer CE, 1999, ANNU REV MICROBIOL, V53, P495, DOI 10.1146/annurev.micro.53.1.495; BERGELSON S, 1994, ONCOGENE, V9, P565; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; Chan PK, 1999, BIOCHEM BIOPH RES CO, V264, P305, DOI 10.1006/bbrc.1999.1255; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; DELONG MJ, 1987, CARCINOGENESIS, V8, P1549, DOI 10.1093/carcin/8.10.1549; Dhakshinamoorthy S, 2000, CURR TOP CELL REGUL, V36, P201; Dhakshinamoorthy S, 2000, J BIOL CHEM, V275, P40134, DOI 10.1074/jbc.M003531200; Huang HC, 2000, P NATL ACAD SCI USA, V97, P12475, DOI 10.1073/pnas.220418997; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; JAISWAL AK, 1994, J BIOL CHEM, V269, P14502; Jaiswal AK, 1999, INT CONGR SER, V1172, P103; JAISWAL AK, 1990, BIOCHEMISTRY-US, V29, P1899, DOI 10.1021/bi00459a034; Kim IF, 1999, GENE, V228, P73, DOI 10.1016/S0378-1119(99)00006-2; Kobayashi A, 1999, J BIOL CHEM, V274, P6443, DOI 10.1074/jbc.274.10.6443; LI Y, 1992, J BIOL CHEM, V267, P15097; LI Y, 1994, EUR J BIOCHEM, V226, P31, DOI 10.1111/j.1432-1033.1994.tb20023.x; Long DJ, 2000, CANCER RES, V60, P5913; Marini MG, 1997, J BIOL CHEM, V272, P16490, DOI 10.1074/jbc.272.26.16490; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; MULKAHY RT, 1997, J BIOL CHEM, V272, P7445; Nguyen T, 2000, J BIOL CHEM, V275, P15466, DOI 10.1074/jbc.M000361200; PUGA A, 1992, DNA CELL BIOL, V11, P269, DOI 10.1089/dna.1992.11.269; QIAGEN, 2000, QI AEXPRESSIONIST HD; Radjendirane V, 1999, BIOCHEM PHARMACOL, V58, P597, DOI 10.1016/S0006-2952(99)00143-4; Radjendirane Venugopal, 1997, P441; RUSHMORE TH, 1993, J BIOL CHEM, V268, P11475; Sambrook J, 1989, MOL CLONING LAB MANU; SCHMITT J, 1993, MOL BIOL REP, V18, P223, DOI 10.1007/BF01674434; Schulze-Osthoff Klaus, 1997, P239; Talalay P, 1995, TOXICOL LETT, V82-3, P173, DOI 10.1016/0378-4274(95)03553-2; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; Wild AC, 1998, BIOCHEM J, V332, P373, DOI 10.1042/bj3320373; Yu R, 2000, J BIOL CHEM, V275, P2322, DOI 10.1074/jbc.275.4.2322; Yu R, 2000, J BIOL CHEM, V275, P39907, DOI 10.1074/jbc.M004037200	42	238	245	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 28	2001	20	29					3906	3917		10.1038/sj.onc.1204506	http://dx.doi.org/10.1038/sj.onc.1204506			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439354				2022-12-17	WOS:000169494700016
J	Leethanakul, C; Patel, V; Gillespie, J; Pallente, M; Ensley, JF; Koontongkaew, S; Liotta, LA; Emmert-Buck, M; Gutkind, JS				Leethanakul, C; Patel, V; Gillespie, J; Pallente, M; Ensley, JF; Koontongkaew, S; Liotta, LA; Emmert-Buck, M; Gutkind, JS			Distinct pattern of expression of differentiation and growth-related genes in squamous cell carcinomas of the head and neck revealed by the use of laser capture microdissection and cDNA arrays	ONCOGENE			English	Article						oral cancel; tumor progression; oncogenes; tumor suppressor genes; biomarkers	APOPTOSIS; DISEASE; CANCER	Although risk factors for squamous cell carcinomas of the head and neck (HNSCC) are well recognized, very little is known about the molecular mechanisms responsible for this malignancy. Furthermore, the ability to investigate gene expression profiles at different stages of tumor progression is usually limited by the remarkable heterogeneity of these neoplastic lesions. Here, we show the successful use of laser capture microdissection (LCM) to procure specific cell populations. The 5000 cells from representative sets of HNSCC and their matching normal tissues are sufficient to extract RNA of high integrity for the synthesis of labeled amplified cDNA probes which can then be hybridized to these membranes arrayed with known human cancer-related cDNAs. Furthermore, when compared to normal tissues, we demonstrate a consistent decrease in expression of differentiation markers such as cytokeratins, and an increase in the expression of a number of signal transducing and cell cycle regulatory molecules, as well as growth and angiogenic factors and tissue degrading proteases. Unexpectedly, we also found that most HNSCC overexpress members of the wnt and notch growth and differentiation regulatory system, thus suggesting that the,wnt and notch pathways mag contribute in squamous cell carcinogenesis. This experimental approach may facilitate the identification candidate markers for the early detection of preneoplastic lesions, as well as novel targets for pharmacological intervention in this disease.	Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA; Wayne State Univ, Div Hematol Oncol, Detroit, MI USA; Prince Songkla Univ, Fac Dent, Dept Oral Biol & Occlus, Hat Yai, Thailand	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Wayne State University; Prince of Songkla University	Gutkind, JS (corresponding author), Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, 30 Convent Dr,Bldg 30,Room 212, Bethesda, MD 20892 USA.		Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016	Gutkind, J. Silvio/0000-0002-5150-4482	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000558] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; BARTKOVA J, 1995, CANCER RES, V55, P949; Desai SB, 1999, J IMMUNOTHER, V22, P186, DOI 10.1097/00002371-199905000-00002; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; Granville DJ, 1998, LAB INVEST, V78, P893; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Liu YL, 1996, GENOMICS, V31, P58, DOI 10.1006/geno.1996.0009; Mao EJ, 1998, J ORAL PATHOL MED, V27, P297; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; Parkin DM, 1999, CA-CANCER J CLIN, V49, P33, DOI 10.3322/canjclin.49.1.33; Peterson LA, 1998, CANCER RES, V58, P5326; Shelly LL, 1999, J CELL BIOCHEM, V73, P164, DOI 10.1002/(SICI)1097-4644(19990501)73:2<164::AID-JCB3>3.0.CO;2-0; Simone NL, 1998, TRENDS GENET, V14, P272, DOI 10.1016/S0168-9525(98)01489-9; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59	15	238	271	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2000	19	28					3220	3224		10.1038/sj.onc.1203703	http://dx.doi.org/10.1038/sj.onc.1203703			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KX	10918578				2022-12-17	WOS:000088019200012
J	Damaraju, VL; Damaraju, S; Young, JD; Baldwin, SA; Mackey, J; Sawyer, MB; Cass, CE				Damaraju, VL; Damaraju, S; Young, JD; Baldwin, SA; Mackey, J; Sawyer, MB; Cass, CE			Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy	ONCOGENE			English	Review						nucleoside transporters; anticancer nucleosides; polymorphisms; SNPs; drug resistance	SINGLE-NUCLEOTIDE POLYMORPHISMS; BORDER MEMBRANE-VESICLES; NECROSIS-FACTOR-ALPHA; MOLECULAR-CLONING; FUNCTIONAL-CHARACTERIZATION; RECOMBINANT HUMAN; PHASE-II; LEUKEMIA-CELLS; NITROBENZYLTHIOINOSINE-BINDING; RIBONUCLEOTIDE REDUCTASE	The clinical efficacy of anticancer nucleoside drugs depends on a complex interplay of transporters mediating entry of nucleoside drugs into cells, efflux mechanisms that remove drugs from intracellular compartments and cellular metabolism to active metabolites. Nucleoside transporters (NTs) are important determinants for salvage of preformed nucleosides and mediated uptake of antimetabolite nucleoside drugs into target cells. The focus of this review is the two families of human nucleoside transporters (hENTs, hCNTs) and their role in transport of cytotoxic chemotherapeutic nucleoside drugs. Resistance to anticancer nucleoside drugs is a major clinical problem in which NTs have been implicated. Single nucleotide polymorphisms ( SNPs) in drug transporters may contribute to interindividual variation in response to nucleoside drugs. In this review, we give an overview of the functional and molecular characteristics of human NTs and their potential role in resistance to nucleoside drugs and discuss the potential use of genetic polymorphism analyses for NTs to address drug resistance.	Cross Canc Inst, Dept Oncol, Edmonton, AB T6G 1Z2, Canada; Univ Alberta, Membrane Prot Res Grp, Edmonton, AB T6G 2M7, Canada; Univ Alberta, Dept Oncol, Edmonton, AB T6G 2M7, Canada; Univ Alberta, Dept Physiol, Edmonton, AB T6G 2M7, Canada; Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of Alberta; University of Alberta; University of Alberta; University of Alberta; University of Leeds	Cass, CE (corresponding author), Cross Canc Inst, Dept Oncol, 11560 Univ Ave, Edmonton, AB T6G 1Z2, Canada.	carol.cass@cancerboard.ab.ca						ABBRUZZESE JL, 1991, J CLIN ONCOL, V9, P491, DOI 10.1200/JCO.1991.9.3.491; Acimovic Y, 2002, MOL BIOL EVOL, V19, P2199, DOI 10.1093/oxfordjournals.molbev.a004044; BAKER CH, 1991, J MED CHEM, V34, P1879, DOI 10.1021/jm00110a019; BALDWIN S, 2003, PFLUGERS ARCH   0628; Baldwin SA, 1999, MOL MED TODAY, V5, P216, DOI 10.1016/S1357-4310(99)01459-8; Belanger K, 2002, J CLIN ONCOL, V20, P2567, DOI 10.1200/JCO.2002.12.047; BELT J, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P20; BELT JA, 1993, ADV ENZYME REGUL, V33, P235; Blum JL, 1999, J CLIN ONCOL, V17, P485, DOI 10.1200/JCO.1999.17.2.485; BROCKMAN RW, 1977, BIOCHEM PHARMACOL, V26, P2193, DOI 10.1016/0006-2952(77)90275-1; Brookes AJ, 1999, GENE, V234, P177, DOI 10.1016/S0378-1119(99)00219-X; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Cabrita MA, 2002, BIOCHEM CELL BIOL, V80, P623, DOI 10.1139/O02-153; Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290; CARSON DA, 1992, P NATL ACAD SCI USA, V89, P2970, DOI 10.1073/pnas.89.7.2970; Cass, 1994, P AM ASSOC CANC RES, V35; Cass C E, 1999, Pharm Biotechnol, V12, P313; Cass CE, 1998, BIOCHEM CELL BIOL, V76, P761, DOI 10.1139/bcb-76-5-761; CASS CE, 1995, DRUG TRANSPORT ANTIM, P403; CATAPANO CV, 1991, CANCER RES, V51, P1829; Chandrasena G, 1997, BIOCHEM PHARMACOL, V53, P1909, DOI 10.1016/S0006-2952(97)00170-6; Chen R, 2000, BIOCHEM PHARMACOL, V60, P215, DOI 10.1016/S0006-2952(00)00334-8; CHEN SF, 1986, CANCER RES, V46, P3449; CHUN HG, 1991, J CLIN ONCOL, V9, P175, DOI 10.1200/JCO.1991.9.1.175; Clarke Marilyn L, 2002, Cancer Treat Res, V112, P27; Coe I, 2002, FEBS LETT, V517, P201, DOI 10.1016/S0014-5793(02)02622-4; Coe IR, 1997, GENOMICS, V45, P459, DOI 10.1006/geno.1997.4928; Crawford CR, 1998, J BIOL CHEM, V273, P5288, DOI 10.1074/jbc.273.9.5288; DAMARAJU S, 2002, GENOMIC APPROACHES C; DANHAUSER L, 1986, CANCER CHEMOTH PHARM, V18, P145; DELICADO EG, 1991, BIOCHEM J, V279, P651, DOI 10.1042/bj2790651; DIMOPOULOS MA, 1994, J CLIN ONCOL, V12, P2694, DOI 10.1200/JCO.1994.12.12.2694; Ecker Gerhard, 2002, Curr Opin Investig Drugs, V3, P1533; ELLISON RR, 1968, BLOOD, V32, P507, DOI 10.1182/blood.V32.4.507.507; ELLISON RR, 1967, CLIN PHARMACOL THER, V8, P800; FIDEU MD, 1992, NEUROCHEM RES, V17, P1099, DOI 10.1007/BF00967287; FIDEU MD, 1993, CELL MOL NEUROBIOL, V13, P493, DOI 10.1007/BF00711458; Flanagan SA, 1997, J BIOL CHEM, V272, P18026, DOI 10.1074/jbc.272.29.18026; FRAM RJ, 1983, LEUKEMIA RES, V7, P243, DOI 10.1016/0145-2126(83)90014-0; FURTH JJ, 1968, CANCER RES, V28, P2061; Galmarini CM, 2002, BRIT J HAEMATOL, V117, P860, DOI 10.1046/j.1365-2141.2002.03538.x; Gati WP, 1998, LEUKEMIA LYMPHOMA, V32, P45, DOI 10.3109/10428199809059245; Genini D, 2000, BLOOD, V96, P3537; Giles FJ, 2003, J CLIN ONCOL, V21, P1050, DOI 10.1200/JCO.2003.04.023; Giles FJ, 2001, J CLIN ONCOL, V19, P762, DOI 10.1200/JCO.2001.19.3.762; Goh LB, 1995, ANTICANCER RES, V15, P2575; Goldman ID, 2002, CLIN CANCER RES, V8, P4; Gourdeau H, 2001, CANCER RES, V61, P7217; Graham KA, 2000, NUCLEOS NUCLEOT NUCL, V19, P415, DOI 10.1080/15257770008033018; Gray JH, 2003, CLIN PHARMACOL THER, V73, pP59, DOI 10.1016/S0009-9236(03)90574-1; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; Griffiths M, 1997, BIOCHEM J, V328, P739, DOI 10.1042/bj3280739; Grove KL, 1996, CANCER RES, V56, P4187; GROVE KL, 1995, CANCER RES, V55, P3008; Guida L, 2002, J BIOL CHEM, V277, P47097, DOI 10.1074/jbc.M207793200; GUTIERREZ MM, 1993, BIOCHIM BIOPHYS ACTA, V1149, P202, DOI 10.1016/0005-2736(93)90202-B; GUTIERREZ MM, 1992, BIOCHIM BIOPHYS ACTA, V1105, P1, DOI 10.1016/0005-2736(92)90156-G; GUTIERREZ MM, 1994, BIOCHEM PHARMACOL, V48, P2251, DOI 10.1016/0006-2952(94)00411-0; Hamajima Nobuyuki, 2002, J Epidemiol, V12, P229; Handa M, 2001, GENE, V262, P301, DOI 10.1016/S0378-1119(00)00555-2; HANDE KR, 1978, CANCER RES, V38, P579; HEINEMANN V, 1992, CANCER RES, V52, P533; HEINEMANN V, 1988, CANCER RES, V48, P4024; Hoff PM, 2001, J CLIN ONCOL, V19, P2282, DOI 10.1200/JCO.2001.19.8.2282; Huang M, 2003, J PHARMACOL EXP THER, V304, P753, DOI 10.1124/jpet.102.044214; HUANG P, 1995, SEMIN ONCOL, V22, P19; HUANG P, 1990, J BIOL CHEM, V265, P16617; HUANG P, 1991, MOL PHARMACOL, V39, P449; Hyde RJ, 2001, MOL MEMBR BIOL, V18, P53, DOI 10.1080/09687680110033765; Iida A, 2001, J HUM GENET, V46, P590, DOI 10.1007/s100380170026; Illmer T, 2002, CANCER RES, V62, P4955; Ishikawa T, 1998, CANCER RES, V58, P685; Jennings LL, 2001, NEUROPHARMACOLOGY, V40, P722, DOI 10.1016/S0028-3908(00)00207-0; JONES KW, 1994, BRAIN RES, V660, P104, DOI 10.1016/0006-8993(94)90844-3; Kaye SB, 1998, BRIT J CANCER, V78, P1, DOI 10.1038/bjc.1998.747; Kichenin K, 2000, EUR J IMMUNOL, V30, P366, DOI 10.1002/1521-4141(200002)30:2<366::AID-IMMU366>3.0.CO;2-D; KING KM, 2003, P AM ASSOC CANC RES, V44, P1500; Kiss A, 2000, BIOCHEM J, V352, P363, DOI 10.1042/0264-6021:3520363; KUFE DW, 1980, J BIOL CHEM, V255, P8997; KWONG FYP, 1993, J BIOL CHEM, V268, P22127; Lamont EB, 1999, CLIN CANCER RES, V5, P2289; Lang TT, 2001, MOL PHARMACOL, V60, P1143, DOI 10.1124/mol.60.5.1143; Lassota Piotr, 1994, Archivum Immunologiae et Therapiae Experimentalis, V42, P17; LEE CW, 1991, BIOCHEM J, V274, P85, DOI 10.1042/bj2740085; LEE CW, 1994, BIOCHEM J, V300, P407, DOI 10.1042/bj3000407; Lindemalm S, 2003, HAEMATOLOGICA, V88, P324; Loewen SK, 1999, J BIOL CHEM, V274, P24475, DOI 10.1074/jbc.274.35.24475; Lu Xin, 2002, J Exp Ther Oncol, V2, P200, DOI 10.1046/j.1359-4117.2002.01035.x; Lum PY, 2000, CANCER CHEMOTH PHARM, V45, P273, DOI 10.1007/s002800050040; Mackey JR, 1998, CANCER RES, V58, P4349; Mackey JR, 1998, DRUG RESIST UPDATE, V1, P310, DOI 10.1016/S1368-7646(98)80047-2; Mackey JR, 2002, CLIN CANCER RES, V8, P110; Mackey JR, 1999, JNCI-J NATL CANCER I, V91, P1876, DOI 10.1093/jnci/91.21.1876; Mata JF, 2001, MOL PHARMACOL, V59, P1542, DOI 10.1124/mol.59.6.1542; MURRAY AW, 1971, ANNU REV BIOCHEM, V40, P811, DOI 10.1146/annurev.bi.40.070171.004115; Neff T, 1996, EXP HEMATOL, V24, P1340; Ngo LY, 2001, AM J PHYSIOL-GASTR L, V280, pG475, DOI 10.1152/ajpgi.2001.280.3.G475; Osato DH, 2003, PHARMACOGENETICS, V13, P297, DOI 10.1097/00008571-200305000-00010; Osses N, 1996, BIOCHEM J, V317, P843, DOI 10.1042/bj3170843; OWENS JK, 1992, CANCER RES, V52, P2389; PARKER WB, 1991, CANCER RES, V51, P2386; PARKER WB, 1988, MOL PHARMACOL, V34, P485; Parker WB, 1999, MOL PHARMACOL, V55, P515; Parodi J, 2002, CIRC RES, V90, P570, DOI 10.1161/01.RES.0000012582.11979.8B; Paterson AR, 1993, P AM ASSOC CANC RES, V34, pA84; Patil SD, 1997, AM J PHYSIOL-GASTR L, V272, pG1314, DOI 10.1152/ajpgi.1997.272.6.G1314; Pennycooke M, 2001, BIOCHEM BIOPH RES CO, V280, P951, DOI 10.1006/bbrc.2000.4205; Pettitt AR, 1999, BRIT J HAEMATOL, V105, P986, DOI 10.1046/j.1365-2141.1999.01448.x; Pettitt AR, 1999, BRIT J HAEMATOL, V106, P1049; PLUNKETT W, 1995, SEMIN ONCOL, V22, P3; Possinger K, 1995, ANTI-CANCER DRUG, V6, P55, DOI 10.1097/00001813-199512006-00009; Ritzel MWL, 1998, MOL MEMBR BIOL, V15, P203; Ritzel MWL, 1997, AM J PHYSIOL-CELL PH, V272, pC707, DOI 10.1152/ajpcell.1997.272.2.C707; Ritzel MWL, 2001, MOL MEMBR BIOL, V18, P65, DOI 10.1080/09687680010026313; Ritzel MWL, 2001, J BIOL CHEM, V276, P2914, DOI 10.1074/jbc.M007746200; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; Sandoval A, 1996, CLIN CANCER RES, V2, P1731; Sankar N, 2002, NUCLEIC ACIDS RES, V30, P4339, DOI 10.1093/nar/gkf564; SCHACHTER JB, 1995, CELL SIGNAL, V7, P659, DOI 10.1016/0898-6568(95)00037-P; Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954; Schmoll HJ, 1999, SEMIN ONCOL, V26, P589; SenGupta DJ, 2002, BIOCHEMISTRY-US, V41, P1512, DOI 10.1021/bi015833w; SEYMOUR JF, 1994, BLOOD, V83, P2906, DOI 10.1182/blood.V83.10.2906.2906; Shryock JC, 1997, AM J CARDIOL, V79, P2, DOI 10.1016/S0002-9149(97)00256-7; SIROTNAK FM, 1983, CANCER RES, V43, P104; SOKOLOSKI JA, 1991, LEUKEMIA RES, V15, P1051, DOI 10.1016/0145-2126(91)90111-6; Soler C, 1998, J BIOL CHEM, V273, P26939, DOI 10.1074/jbc.273.41.26939; Soler C, 2000, J LEUKOCYTE BIOL, V67, P345, DOI 10.1002/jlb.67.3.345; Soler C, 2001, FASEB J, V15, P1979, DOI 10.1096/fj.01-0022com; Soler C, 2001, J BIOL CHEM, V276, P30043, DOI 10.1074/jbc.M101807200; Stadler WM, 1997, J CLIN ONCOL, V15, P3394, DOI 10.1200/JCO.1997.15.11.3394; Stam RW, 2003, BLOOD, V101, P1270, DOI 10.1182/blood-2002-05-1600; Strohman R, 2002, SCIENCE, V296, P701, DOI 10.1126/science.1070534; Sundaram M, 1998, J BIOL CHEM, V273, P21519, DOI 10.1074/jbc.273.34.21519; Sundaram M, 2001, J BIOL CHEM, V276, P45270, DOI 10.1074/jbc.M107169200; Sundaram M, 2001, BIOCHEMISTRY-US, V40, P8146, DOI 10.1021/bi0101805; Talbot DC, 2002, BRIT J CANCER, V86, P1367, DOI 10.1038/sj.bjc.6600261; Townsley CA, 2003, J CLIN ONCOL, V21, P1524, DOI 10.1200/JCO.2003.03.057; Vickers MF, 2002, BIOCHEM CELL BIOL, V80, P639, DOI 10.1139/O02-148; VICKERS MF, 2000, EMERGING THERAPEUTIC, V4, P515; VIJAYALAKSHMI D, 1988, J BIOL CHEM, V263, P19419; Visser F, 2002, J BIOL CHEM, V277, P395, DOI 10.1074/jbc.M105324200; von der Maase H, 2000, J CLIN ONCOL, V18, P3068, DOI 10.1200/JCO.2000.18.17.3068; Wang J, 1997, AM J PHYSIOL-RENAL, V273, pF1058, DOI 10.1152/ajprenal.1997.273.6.F1058; Ward JL, 2000, J BIOL CHEM, V275, P8375, DOI 10.1074/jbc.275.12.8375; Wijnholds J, 2000, P NATL ACAD SCI USA, V97, P7476, DOI 10.1073/pnas.120159197; WILEY JS, 1983, EUR J CANCER CLIN ON, V19, P1067, DOI 10.1016/0277-5379(83)90029-9; Xie KC, 1996, CANCER RES, V56, P3030; YANG SW, 1992, J BIOL CHEM, V267, P2345; Yao SYM, 2002, J BIOL CHEM, V277, P24938, DOI 10.1074/jbc.M200966200; Yao SYM, 2001, MOL MEMBR BIOL, V18, P161, DOI 10.1080/09687680110048318; Yao SYM, 1997, J BIOL CHEM, V272, P28423, DOI 10.1074/jbc.272.45.28423; Young JD, 2001, CURR TOP MEMBR, V50, P329; ZIMMERMAN TP, 1987, J BIOL CHEM, V262, P5748	155	237	246	1	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2003	22	47					7524	7536		10.1038/sj.onc.1206952	http://dx.doi.org/10.1038/sj.onc.1206952			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KL	14576856				2022-12-17	WOS:000186112500021
J	Fukushima, T; Suzuki, S; Mashiko, M; Ohtake, T; Endo, Y; Takebayashi, Y; Sekikawa, K; Hagiwara, K; Takenoshita, S				Fukushima, T; Suzuki, S; Mashiko, M; Ohtake, T; Endo, Y; Takebayashi, Y; Sekikawa, K; Hagiwara, K; Takenoshita, S			BRAF mutations in papillary carcinomas of the thyroid	ONCOGENE			English	Article						BRAF; RAS; papillary carcinoma of the thyroid; follicular carcinoma of the thyroid; MAP kinase pathway	MOLECULAR-GENETICS; ACTIVATION; ONCOGENES	BRAF is a serine/threonine kinase that receives a mitogenic signal from RAS and transmits it to the MAP kinase pathway. Recent studies have reported that mutations of the BRAF gene were detected with varying frequencies in several cancers, notably more than 60% in melanoma. We analysed mutations of BRAF and RAS genes in 100 cases of thyroid carcinoma to investigate genetic aberrations in the RAS/RAF/MEK/MAP kinase pathway. BRAF mutations were detected exclusively in papillary carcinomas ( 40 in 76 cases: 53%), and were exclusively V599E, a mutation frequently observed in other carcinomas. NRAS mutation was observed in six cases (6%), all in histological types other than papillary carcinoma, and was exclusively Q61R. No mutations were found in KRAS or HRAS. Our results suggest that BRAF mutations may play a critical role in the carcinogenesis of papillary carcinoma of the thyroid.	Fukushima Med Univ, Dept Surg, Fukushima 9601295, Japan; Saitama Med Sch, Dept Resp Med, Moroyama, Saitama 3500495, Japan	Fukushima Medical University; Saitama Medical University	Fukushima, T (corresponding author), Fukushima Med Univ, Dept Surg, 1 Hikarigaoka, Fukushima 9601295, Japan.							Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Halaban R, 2000, PIGM CELL RES, V13, P4, DOI 10.1034/j.1600-0749.2000.130103.x; Lazzereschi D, 1997, J EXP CLIN CANC RES, V16, P325; Learoyd DL, 2000, WORLD J SURG, V24, P923, DOI 10.1007/s002680010164; Ledent C, 1991, Thyroidology, V3, P97; MANENTI G, 1994, EUR J CANCER, V30A, P987, DOI 10.1016/0959-8049(94)90130-9; Naoki K, 2002, CANCER RES, V62, P7001; Pierotti MA, 1996, GENE CHROMOSOME CANC, V16, P1; Sebolt-Leopold JS, 2000, ONCOGENE, V19, P6594, DOI 10.1038/sj.onc.1204083; Sugg SL, 1999, SURGERY, V125, P46, DOI 10.1016/S0039-6060(99)70287-4; Yuen ST, 2002, CANCER RES, V62, P6451	12	237	249	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 25	2003	22	41					6455	6457		10.1038/sj.onc.1206739	http://dx.doi.org/10.1038/sj.onc.1206739			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508525				2022-12-17	WOS:000185535300015
J	Tejpar, S; Nollet, F; Li, C; Wunder, JS; Michils, G; dal Cin, P; Van Cutsem, E; Bapat, B; van Roy, F; Cassiman, JJ; Alman, BA				Tejpar, S; Nollet, F; Li, C; Wunder, JS; Michils, G; dal Cin, P; Van Cutsem, E; Bapat, B; van Roy, F; Cassiman, JJ; Alman, BA			Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor)	ONCOGENE			English	Article						beta-catenin; aggressive fibromatosis; mutational analysis; immunohistochemistry; tyrosine phosphorylation	ADENOMATOUS POLYPOSIS; COLORECTAL-CANCER; HEPATOCELLULAR CARCINOMAS; FUNCTIONAL INTERACTION; APC GENE; PHOSPHORYLATION; ACTIVATION; RECEPTOR; UNCOMMON; PROTEIN	Aggressive fibromatosis (also called desmoid tumor) occurs as a sporadic lesion or as part of Familial Adenomatous Polyposis, which is caused by germ line mutations in the Adenomatous polyposis Coli (APC) gene. APC is involved in the regulation of the cellular level of beta-catenin, which is a mediator in Wnt signaling, Mutational analysis of the beta-catenin and APC genes was performed in 42 sporadic aggressive fibromatoses. Nine tumors had mutations in APC, and 22 had a point mutation in beta-catenin at either codon 45 or codon 41 (producing a stabilized beta-catenin protein product). Immunohistochemistry showed an elevated beta-catenin protein level in all tumors, regardless of mutational status. Beta-catenin localized to the nucleus, and was not tyrosine phosphorylated in the six tumors in which this was tested. The demonstration of mutations in two mediators in the Wnt-APC-beta-catenin pathway implicates beta-catenin stabilization as the key factor in the pathogenesis of aggressive fibromatosis. This is the first demonstration of somatic beta-catenin mutations in a locally invasive, but non metastatic lesion composed of spindle cells, illustrating the importance of beta-catenin stabilization in a variety of cell types and neoplastic processes. Moreover, this tumor has one of the highest reported frequencies of beta-catenin mutations of any tumor type.	Hosp Sick Children, Div Orthopaed Surg, Programme Dev Biol, Toronto, ON M5G 1X8, Canada; Katholieke Univ Leuven, Ctr Human Genet, B-3000 Louvain, Belgium; VIB Univ Ghent, Dept Mol Biol, Mol Cell Biol Unit, B-9000 Ghent, Belgium; Mt Sinai Hosp, Dept Surg, Div Orthopaed Surg, Toronto, ON M5G 1X5, Canada; Univ Toronto, Toronto, ON M5G 1X5, Canada; Katholieke Univ Leuven, Dept Gastroenterol, B-3000 Louvain, Belgium; Mt Sinai Hosp, Dept Lab Med & Pathobiol, Toronto, ON M5G 1X5, Canada; Hosp Sick Children, Dept Surg, Div Orthopaed Surg, Toronto, ON M5G 1X8, Canada; Univ Toronto, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); KU Leuven; Flanders Institute for Biotechnology (VIB); Ghent University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; KU Leuven; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Alman, BA (corresponding author), Hosp Sick Children, Div Orthopaed Surg, Programme Dev Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.		Bapat, Bharati/B-5839-2014; van Roy, Frans M/C-6123-2009; Van+Cutsem, Eric/ABE-1762-2021	van Roy, Frans M/0000-0003-4358-1039; 				Alman BA, 1997, AM J PATHOL, V151, P329; Alman BA, 1997, DIAGN MOL PATHOL, V6, P98, DOI 10.1097/00019606-199704000-00005; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BOSMAN FT, 1992, J CLIN PATHOL, V45, P120, DOI 10.1136/jcp.45.2.120; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Eccles DM, 1996, AM J HUM GENET, V59, P1193; Fukuchi T, 1998, CANCER RES, V58, P3526; Garcia-Rostan G, 1999, CANCER RES, V59, P1811; Giarola M, 1998, BRIT J CANCER, V78, P582, DOI 10.1038/bjc.1998.544; Iwao K, 1998, CANCER RES, V58, P1021; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kitaeva MN, 1997, CANCER RES, V57, P4478; Koch A, 1999, CANCER RES, V59, P269; Li C, 1998, AM J PATHOL, V153, P709, DOI 10.1016/S0002-9440(10)65614-3; Li MM, 1996, HUM PATHOL, V27, P939, DOI 10.1016/S0046-8177(96)90221-X; Liu D, 1997, LAB INVEST, V77, P557; Miyoshi Y, 1998, CANCER RES, V58, P2524; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; PLUKKER JT, 1995, BRIT J SURG, V82, P510, DOI 10.1002/bjs.1800820424; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; Rimm DL, 1999, AM J PATHOL, V154, P325, DOI 10.1016/S0002-9440(10)65278-9; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sparks AB, 1998, CANCER RES, V58, P1130; Takayama T, 1998, BRIT J CANCER, V77, P605, DOI 10.1038/bjc.1998.97; vanDiest PJ, 1997, J CLIN PATHOL, V50, P801, DOI 10.1136/jcp.50.10.801; vanDiest PJ, 1996, ANAL QUANT CYTOL, V18, P351; Voeller HJ, 1998, CANCER RES, V58, P2520; Zurawel RH, 1998, CANCER RES, V58, P896	33	237	248	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6615	6620		10.1038/sj.onc.1203041	http://dx.doi.org/10.1038/sj.onc.1203041			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597266				2022-12-17	WOS:000083709200026
J	Liu, YN; Yin, JJ; Abou-Kheir, W; Hynes, PG; Casey, OM; Fang, L; Yi, M; Stephens, RM; Seng, V; Sheppard-Tillman, H; Martin, P; Kelly, K				Liu, Y-N; Yin, J. J.; Abou-Kheir, W.; Hynes, P. G.; Casey, O. M.; Fang, L.; Yi, M.; Stephens, R. M.; Seng, V.; Sheppard-Tillman, H.; Martin, P.; Kelly, K.			MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms	ONCOGENE			English	Article						prostate cancer; EMT; SLUG; miR-1; miR-200	EPITHELIAL-MESENCHYMAL TRANSITION; DOWN-REGULATION; TGF-BETA; PROSTATE; INVASION; ZEB1; METASTASIS; REPRESSION; CADHERIN; FAMILY	Epithelial-mesenchymal transition (EMT) is a developmental program of signaling pathways that determine commitment to epithelial and mesenchymal phenotypes. In the prostate, EMT processes have been implicated in benign prostatic hyperplasia and prostate cancer progression. In a model of Pten- and TP53-null prostate adenocarcinoma that progresses via transforming growth factor beta-induced EMT, mesenchymal transformation is characterized by plasticity, leading to various mesenchymal lineages and the production of bone. Here we show that SLUG is a major regulator of mesenchymal differentiation. As microRNAs (miRs) are pleiotropic regulators of differentiation and tumorigenesis, we evaluated miR expression associated with tumorigenesis and EMT. Mir-1 and miR-200 were reduced with progression of prostate adenocarcinoma, and we identify Slug as one of the phylogenetically conserved targets of these miRs. We demonstrate that SLUG is a direct repressor of miR-1 and miR-200 transcription. Thus, SLUG and miR-1/miR-200 act in a self-reinforcing regulatory loop, leading to amplification of EMT. Depletion of Slug inhibited EMT during tumorigenesis, whereas forced expression of miR-1 or miR-200 inhibited both EMT and tumorigenesis in human and mouse model systems. Various miR targets were analyzed, and our findings suggest that miR-1 has roles in regulating EMT and mesenchymal differentiation through Slug and functions in tumor-suppressive programs by regulating additional targets. Oncogene (2013) 32, 296-306; doi:10.1038/onc.2012.58; published online 27 February 2012	[Liu, Y-N; Yin, J. J.; Abou-Kheir, W.; Hynes, P. G.; Casey, O. M.; Fang, L.; Seng, V.; Sheppard-Tillman, H.; Martin, P.; Kelly, K.] NCI, Cell & Canc Biol Branch, NIH, Bethesda, MD 20892 USA; [Yi, M.; Stephens, R. M.] NCI, Adv Biomed Comp Ctr, FCRDC, Frederick, MD 21701 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kelly, K (corresponding author), NCI, Cell & Canc Biol Branch, NIH, 37 Convent Dr,Room 1068, Bethesda, MD 20892 USA.	kellyka@mail.nih.gov	Abou-Kheir, Wassim/AAP-2587-2020; Liu, Yen-Nien/AAW-4698-2021; Tillman, Heather/N-2526-2018	Abou-Kheir, Wassim/0000-0001-9719-9324; Tillman, Heather/0000-0002-9623-2812; Yi, Ming/0000-0001-9098-1364	Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research, USA; NATIONAL CANCER INSTITUTE [ZIABC010802] Funding Source: NIH RePORTER	Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research, USA; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge the support of the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research, USA. We thank Dr Chi-Ping Day, Dr Yvona Ward and Ross Lake for assistance.	Abou-Kheir WG, 2010, STEM CELLS, V28, P2129, DOI 10.1002/stem.538; Adler HL, 1999, J UROLOGY, V161, P182, DOI 10.1016/S0022-5347(01)62092-5; Alonso-Magdalena P, 2009, P NATL ACAD SCI USA, V106, P2859, DOI 10.1073/pnas.0812666106; Ambs S, 2008, CANCER RES, V68, P6162, DOI 10.1158/0008-5472.CAN-08-0144; Ao MF, 2006, CANCER RES, V66, P8007, DOI 10.1158/0008-5472.CAN-05-4451; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Casas E, 2011, CANCER RES, V71, P245, DOI 10.1158/0008-5472.CAN-10-2330; Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173; Datta J, 2008, CANCER RES, V68, P5049, DOI 10.1158/0008-5472.CAN-07-6655; Day CP, 2009, PIGM CELL MELANOMA R, V22, P283, DOI 10.1111/j.1755-148X.2009.00545.x; Ganem NJ, 2004, J CELL BIOL, V166, P473, DOI 10.1083/jcb.200404012; Gravdal K, 2007, CLIN CANCER RES, V13, P7003, DOI 10.1158/1078-0432.CCR-07-1263; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Hansel DE, 2006, AM J SURG PATHOL, V30, P1316, DOI 10.1097/01.pas.0000209838.92842.bf; Iliopoulos D, 2010, MOL CELL, V39, P761, DOI 10.1016/j.molcel.2010.08.013; Jaggi M, 2006, PROSTATE, V66, P193, DOI 10.1002/pros.20334; Jones E, 2009, EXPERT OPIN THER TAR, V13, P227, DOI [10.1517/14728220802705696, 10.1517/14728220802705696 ]; Lambertini E, 2009, CELL MOL LIFE SCI, V66, P3641, DOI 10.1007/s00018-009-0149-5; Liu YN, 2011, MOL CELL BIOL, V32, P941; Martin P, 2011, AM J PATHOL, V179, P422, DOI 10.1016/j.ajpath.2011.03.035; Molchadsky A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003707; Nasser MW, 2008, J BIOL CHEM, V283, P33394, DOI 10.1074/jbc.M804788200; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Suzuki H, 2011, CANCER RES, V71, P5646, DOI 10.1158/0008-5472.CAN-11-1076; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Torreggiani E, 2012, J CELL MOL MED, V16, P740, DOI 10.1111/j.1582-4934.2011.01352.x; Wang SP, 2009, NAT CELL BIOL, V11, P694, DOI 10.1038/ncb1875; Ward Y, 2011, CANCER RES, V71, P7301, DOI 10.1158/0008-5472.CAN-11-2381; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Wikstrom P, 1998, PROSTATE, V37, P19, DOI 10.1002/(SICI)1097-0045(19980915)37:1<19::AID-PROS4>3.0.CO;2-3; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Yin JJ, 2007, MOL CELL BIOL, V27, P7538, DOI 10.1128/MCB.00955-07; Zhu M, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-8-r77	34	236	242	0	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2013	32	3					296	306		10.1038/onc.2012.58	http://dx.doi.org/10.1038/onc.2012.58			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087BP	22370643	Green Accepted			2022-12-17	WOS:000314736600004
J	van Vugt, MATM; Medema, RH				van Vugt, MATM; Medema, RH			Getting in and out of mitosis with Polo-like kinase-1	ONCOGENE			English	Review						spindle; checkpoint; DNA damage; cyclin; cytokinesis; APC/cyclosome	ANAPHASE-PROMOTING COMPLEX; DNA-DAMAGE CHECKPOINT; CELL-CYCLE REGULATION; XENOPUS EGG EXTRACTS; KINESIN-LIKE PROTEIN; SISTER-CHROMATID SEPARATION; COHESIN SUBUNIT SCC1; DOUBLE-STRAND BREAK; CENTRAL SPINDLE; MAMMALIAN-CELLS	Research in different species has shown that Polo- like kinases are essential for successful cell division. In human cells, Polo- like kinase- 1 ( Plk1) has been implicated in the regulation of different processes, including mitotic entry, spindle formation and cytokinesis. Recently, a range of new downstream targets of Plk1 has been identified, as well as a molecular mechanism that explains recruitment of Plk1 to potential substrate proteins through its polobox domain. On the basis of these reports, we discuss possible mechanisms by which Polo- like kinases can exert their multiple functions during mitosis. Polo- like kinases also function in DNA damage checkpoints. Plk1 has been shown to be a target of the G2 DNA damage checkpoint, while Cdc5, the Polo- like kinase in Saccharomyces cerevisiae, has long been known to be required for adaptation to persistent DNA damage. Just recently, a similar requirement for Polo- like kinases during checkpoint adaptation was demonstrated in multicellular organisms. Moreover, Plk1 was also shown to be required for checkpoint recovery following checkpoint inactivation, that is, in cells where the damage is completely repaired. Thus, Plk1 appears to play a role at multiple points during a restart of the cell cycle following DNA damage. Based on these novel observations, we discuss possible consequences of using Plk1 as a target in anticancer strategies.	Netherlands Canc Inst, Div Mol Biol H8, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Medema, RH (corresponding author), Univ Utrecht, Med Ctr, Stratenum 2-103,Univ Weg 100, NL-3584 CG Utrecht, Netherlands.	r.h.medema@med.uu.nl	Medema, Rene H/E-2981-2013; Medema, Rene H/G-5415-2011	Medema, Rene/0000-0002-6754-0381				Abrieu A, 1998, J CELL SCI, V111, P1751; Adams RR, 1998, GENE DEV, V12, P1483, DOI 10.1101/gad.12.10.1483; Alexandru G, 2001, CELL, V105, P459, DOI 10.1016/S0092-8674(01)00362-2; Arnaud L, 1998, CHROMOSOMA, V107, P424, DOI 10.1007/s004120050326; ATHERTONFESSLER S, 1993, MOL CELL BIOL, V13, P1675, DOI 10.1128/MCB.13.3.1675; Avides MD, 2001, NAT CELL BIOL, V3, P421, DOI 10.1038/35070110; Bahassi ELM, 2004, ONCOGENE, V23, P2658, DOI 10.1038/sj.onc.1207425; BAILLY E, 1992, J CELL SCI, V101, P529; BAILLY E, 1989, EMBO J, V8, P3985, DOI 10.1002/j.1460-2075.1989.tb08581.x; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Bin OY, 1999, ONCOGENE, V18, P6029, DOI 10.1038/sj.onc.1202983; Booher RN, 1997, J BIOL CHEM, V272, P22300, DOI 10.1074/jbc.272.35.22300; Budde PP, 2001, J CELL BIOL, V153, P149, DOI 10.1083/jcb.153.1.149; Canman JC, 2003, NATURE, V424, P1074, DOI 10.1038/nature01860; Casenghi M, 2003, DEV CELL, V5, P113, DOI 10.1016/S1534-5807(03)00193-X; Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Conn CW, 2000, CANCER RES, V60, P6826; Dechant R, 2003, DEV CELL, V4, P333, DOI 10.1016/S1534-5807(03)00057-1; den Elzen N, 2001, J CELL BIOL, V153, P121, DOI 10.1083/jcb.153.1.121; den Elzen NR, 2004, EMBO J, V23, P908, DOI 10.1038/sj.emboj.7600105; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Ellinger-Ziegelbauer H, 2000, GENES CELLS, V5, P491, DOI 10.1046/j.1365-2443.2000.00337.x; Esashi F, 1999, MOL CELL, V4, P167, DOI 10.1016/S1097-2765(00)80364-0; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Feng Y, 1999, BIOCHEM J, V339, P435, DOI 10.1042/0264-6021:3390435; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Gabrielli BG, 1997, J BIOL CHEM, V272, P28607, DOI 10.1074/jbc.272.45.28607; Gachet Y, 1999, J CELL SCI, V112, P1257; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; Geley S, 2001, J CELL BIOL, V153, P137, DOI 10.1083/jcb.153.1.137; Gimenez-Abian JF, 2004, CURR BIOL, V14, P1187, DOI 10.1016/j.cub.2004.06.052; Glotzer M, 2001, ANNU REV CELL DEV BI, V17, P351, DOI 10.1146/annurev.cellbio.17.1.351; Golan A, 2002, J BIOL CHEM, V277, P15552, DOI 10.1074/jbc.M111476200; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; Guardavaccaro D, 2003, DEV CELL, V4, P799, DOI 10.1016/S1534-5807(03)00154-0; Haber JE, 2000, TRENDS GENET, V16, P259, DOI 10.1016/S0168-9525(00)02022-9; Hagting A, 1998, EMBO J, V17, P4127, DOI 10.1093/emboj/17.14.4127; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; Hames RS, 2001, EMBO J, V20, P7117, DOI 10.1093/emboj/20.24.7117; Hauf S, 2001, SCIENCE, V293, P1320, DOI 10.1126/science.1061376; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Hirano T, 2000, ANNU REV BIOCHEM, V69, P115, DOI 10.1146/annurev.biochem.69.1.115; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; Hornig NCD, 2004, EMBO J, V23, P3144, DOI 10.1038/sj.emboj.7600303; Hudson JW, 2001, CURR BIOL, V11, P441, DOI 10.1016/S0960-9822(01)00117-8; Jackman M, 2003, NAT CELL BIOL, V5, P143, DOI 10.1038/ncb918; Jallepalli PV, 2001, CELL, V105, P445, DOI 10.1016/S0092-8674(01)00340-3; Jantsch-Plunger V, 2000, J CELL BIOL, V149, P1391, DOI 10.1083/jcb.149.7.1391; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; Kang DM, 2002, J CELL BIOL, V156, P249, DOI 10.1083/jcb.200108016; Kelm O, 2002, J BIOL CHEM, V277, P25247, DOI 10.1074/jbc.M202855200; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; Kneisel L, 2002, J CUTAN PATHOL, V29, P354, DOI 10.1034/j.1600-0560.2002.290605.x; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Kraft C, 2003, EMBO J, V22, P6598, DOI 10.1093/emboj/cdg627; Kramer A, 2004, NAT CELL BIOL, V6, P884, DOI 10.1038/ncb1165; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Kurasawa Y, 1999, ONCOGENE, V18, P5131, DOI 10.1038/sj.onc.1203133; Lammer C, 1998, J CELL SCI, V111, P2445; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; LEE KS, 1995, MOL CELL BIOL, V15, P7143; Leroy C, 2003, MOL CELL, V11, P827, DOI 10.1016/S1097-2765(03)00058-3; Leung GC, 2002, NAT STRUCT BIOL, V9, P719, DOI 10.1038/nsb848; Li J, 1997, P NATL ACAD SCI USA, V94, P502, DOI 10.1073/pnas.94.2.502; Lin CY, 2000, P NATL ACAD SCI USA, V97, P12589, DOI 10.1073/pnas.220423497; Lincoln AJ, 2002, NAT GENET, V30, P446, DOI 10.1038/ng856; Lindon C, 2004, J CELL BIOL, V164, P233, DOI 10.1083/jcb.200309035; Litvak V, 2004, MOL CELL, V14, P319, DOI 10.1016/S1097-2765(04)00214-X; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; Liu XQ, 2004, J CELL SCI, V117, P3233, DOI 10.1242/jcs.01173; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; Losada A, 2002, GENE DEV, V16, P3004, DOI 10.1101/gad.249202; MAITY A, 1995, EMBO J, V14, P603, DOI 10.1002/j.1460-2075.1995.tb07036.x; Margottin-Goguet F, 2003, DEV CELL, V4, P813, DOI 10.1016/S1534-5807(03)00153-9; Matsusaka T, 2004, J CELL BIOL, V166, P507, DOI 10.1083/jcb.200401139; Matuliene J, 2004, MOL BIOL CELL, V15, P3083, DOI 10.1091/mbc.E03-12-0888; Mishima M, 2004, NATURE, V430, P908, DOI 10.1038/nature02767; Mishima M, 2002, DEV CELL, V2, P41, DOI 10.1016/S1534-5807(01)00110-1; Moore JD, 1999, J CELL BIOL, V144, P213, DOI 10.1083/jcb.144.2.213; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Moshe Y, 2004, P NATL ACAD SCI USA, V101, P7937, DOI 10.1073/pnas.0402442101; Mundt KE, 1997, BIOCHEM BIOPH RES CO, V239, P377, DOI 10.1006/bbrc.1997.7378; NAGATA A, 1991, NEW BIOL, V3, P959; Nakajima H, 2003, J BIOL CHEM, V278, P25277, DOI 10.1074/jbc.C300126200; Nasmyth K, 2000, SCIENCE, V288, P1379, DOI 10.1126/science.288.5470.1379; Neef R, 2003, J CELL BIOL, V162, P863, DOI 10.1083/jcb.200306009; Nitta M, 2004, ONCOGENE, V23, P6548, DOI 10.1038/sj.onc.1207873; Pellicioli A, 2001, MOL CELL, V7, P293, DOI 10.1016/S1097-2765(01)00177-0; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; PIAGGIO G, 1995, EXP CELL RES, V216, P396, DOI 10.1006/excr.1995.1050; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; Qian YW, 1999, MOL CELL BIOL, V19, P8625; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Qian YW, 1998, SCIENCE, V282, P1701, DOI 10.1126/science.282.5394.1701; Qian YW, 2001, MOL BIOL CELL, V12, P1791, DOI 10.1091/mbc.12.6.1791; Reimann JDR, 2001, CELL, V105, P645, DOI 10.1016/S0092-8674(01)00361-0; Reimann JDR, 2001, GENE DEV, V15, P3278, DOI 10.1101/gad.945701; Ruan Q, 2004, EXP CELL RES, V294, P51, DOI 10.1016/j.yexcr.2003.10.022; Rudner AD, 2000, J CELL BIOL, V149, P1377, DOI 10.1083/jcb.149.7.1377; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; Seong YS, 2002, J BIOL CHEM, V277, P32282, DOI 10.1074/jbc.M202602200; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Simizu S, 2000, NAT CELL BIOL, V2, P852, DOI 10.1038/35041102; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; Spankuch B, 2004, JNCI-J NATL CANCER I, V96, P862, DOI 10.1093/jnci/djh146; Spankuch-Schmitt B, 2002, JNCI-J NATL CANCER I, V94, P1863, DOI 10.1093/jnci/94.24.1863; Sumara I, 2002, MOL CELL, V9, P515, DOI 10.1016/S1097-2765(02)00473-2; SUNKEL CE, 1988, J CELL SCI, V89, P25; Sutterlin C, 2001, P NATL ACAD SCI USA, V98, P9128, DOI 10.1073/pnas.161283998; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Takizawa CG, 1999, P NATL ACAD SCI USA, V96, P7938, DOI 10.1073/pnas.96.14.7938; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; Tsvetkov L, 2003, J BIOL CHEM, V278, P8468, DOI 10.1074/jbc.M211202200; Uchiumi T, 1997, J BIOL CHEM, V272, P9166; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6; van Vugt MATM, 2001, J BIOL CHEM, V276, P41656, DOI 10.1074/jbc.M101831200; van Vugt MATM, 2004, MOL CELL, V15, P799, DOI 10.1016/j.molcel.2004.07.015; van Vugt MATM, 2004, J BIOL CHEM, V279, P36841, DOI 10.1074/jbc.M313681200; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Waizenegger IC, 2000, CELL, V103, P399, DOI 10.1016/S0092-8674(00)00132-X; Walter SA, 2003, J BIOL CHEM, V278, P18221, DOI 10.1074/jbc.M212556200; Warnke S, 2004, CURR BIOL, V14, P1200, DOI 10.1016/j.cub.2004.06.059; Watanabe N, 2004, P NATL ACAD SCI USA, V101, P4419, DOI 10.1073/pnas.0307700101; Weichert W, 2004, BRIT J CANCER, V90, P815, DOI 10.1038/sj.bjc.6601610; Weichert W, 2004, PROSTATE, V60, P240, DOI 10.1002/pros.20050; Xie SQ, 2001, J BIOL CHEM, V276, P43305, DOI 10.1074/jbc.M106050200; Yamada S, 2004, ONCOGENE, V23, P5901, DOI 10.1038/sj.onc.1207782; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; Yarm FR, 2002, MOL CELL BIOL, V22, P6209, DOI 10.1128/MCB.22.17.6209-6221.2002; Yoo HY, 2004, CELL, V117, P575, DOI 10.1016/S0092-8674(04)00417-9; Yu HT, 2002, CURR OPIN CELL BIOL, V14, P706, DOI 10.1016/S0955-0674(02)00382-4; Yuan JP, 2002, CANCER RES, V62, P4186; Yuan JP, 2002, ONCOGENE, V21, P8282, DOI 10.1038/sj.onc.1206011; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039; Zhou T, 2003, DEV CELL, V5, P127, DOI 10.1016/S1534-5807(03)00186-2	152	236	243	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2005	24	17					2844	2859		10.1038/sj.onc.1208617	http://dx.doi.org/10.1038/sj.onc.1208617			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	917MI	15838519				2022-12-17	WOS:000228465800009
J	Wu, SQ; Cetinkaya, C; Munoz-Alonso, MJ; von der Lehr, N; Bahram, F; Beuger, V; Eilers, M; Leon, J; Larsson, LG				Wu, SQ; Cetinkaya, C; Munoz-Alonso, MJ; von der Lehr, N; Bahram, F; Beuger, V; Eilers, M; Leon, J; Larsson, LG			Myc represses differentiation-induced p21CIP1 expression via Miz-1-dependent interaction with the p21 core promoter	ONCOGENE			English	Article						Myc; Miz-1; p21Cip1; differentiation; cell cycle; transcription	C-MYC; CELL-CYCLE; MYC/MAX/MAD NETWORK; HISTONE ACETYLATION; ESSENTIAL COFACTOR; LEUKEMIA-CELLS; GENE; GROWTH; ACTIVATION; P15(INK4B)	Inhibition of cellular differentiation is one of the well-known biological activities of c-Myc-family proteins. We show here that Myc represses differentiation-induced expression of the cyclin-dependent kinase (CDK) inhibitor p21CIP1 (CDKN1A, p21), known to play an important role in cell fate decisions during growth and differentiation, in hematopoietic cells. Our results demonstrate that the c-Myc-responsive region is situated in the p21 core promoter. c-Myc binds to this region in vitro and in vivo through interaction with the initiator-binding Zn-finger transcription factor Miz-1, which associates directly with the promoter. Association of Myc with the promoter in vivo correlates inversely with p21 expression. Using mutants of c-Myc with impaired binding to Miz-1, our results further show that repression of p21 promoter/reporters as well as the endogenous p21 gene by Myc depends on interaction with Miz-1. Expression of Miz-1 increases during hematopoietic differentiation and Miz-1 activates the p21 promoter under conditions of low Myc levels, indicating a positive role for free Miz-1 in this process. In conclusion, repression of differentiation-induced p21 expression through Miz-1 may be an important mechanism by which Myc blocks differentiation.	Swedish Univ Agr Sci, Dept Plant Biol, Uppsala Genet Ctr, S-75007 Uppsala, Sweden; Univ Cantabria, Dept Biol Mol, E-39005 Santander, Spain; Univ Cantabria, CSIC, Unidad Asociada, E-39005 Santander, Spain; Inst Mol Biol & Tumor Res, Marburg, Germany	Swedish University of Agricultural Sciences; Universidad de Cantabria; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Cantabria	Larsson, LG (corresponding author), Swedish Univ Agr Sci, Dept Plant Biol, Uppsala Genet Ctr, Box 7080, S-75007 Uppsala, Sweden.		Larsson, Lars-Gunnar/D-9747-2012; Leon, Javier/K-4615-2014	Leon, Javier/0000-0001-5803-0112; Eilers, Martin/0000-0002-0376-6533				Amati B, 2001, BBA-REV CANCER, V1471, pM135, DOI 10.1016/S0304-419X(01)00020-8; Bahram F, 1999, BLOOD, V93, P3900, DOI 10.1182/blood.V93.11.3900.411a42_3900_3912; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Ceballos E, 2000, ONCOGENE, V19, P2194, DOI 10.1038/sj.onc.1203541; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Delgado MD, 2000, ONCOGENE, V19, P783, DOI 10.1038/sj.onc.1203384; DELGADO MD, 1995, ONCOGENE, V10, P1659; Eberhardy SR, 2000, J BIOL CHEM, V275, P33798, DOI 10.1074/jbc.M005154200; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; James L, 2002, P NATL ACAD SCI USA, V99, P10429, DOI 10.1073/pnas.162369299; JIANG HP, 1994, ONCOGENE, V9, P3397; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; Levens D, 2002, P NATL ACAD SCI USA, V99, P5757, DOI 10.1073/pnas.102173199; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Mitchell KO, 1999, CELL GROWTH DIFFER, V10, P223; O'Hagan RC, 2000, NAT GENET, V24, P113, DOI 10.1038/72761; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; Ricci AR, 2002, MOL CELL BIOL, V22, P4033, DOI 10.1128/MCB.22.12.4033-4042.2002; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Steinman RA, 2002, ONCOGENE, V21, P3403, DOI 10.1038/sj.onc.1205325; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Warner BJ, 1999, MOL CELL BIOL, V19, P5913; Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676; Yang W, 2001, ONCOGENE, V20, P1688, DOI 10.1038/sj.onc.1204245; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zezula J, 2001, EMBO REP, V2, P27, DOI 10.1093/embo-reports/kve008; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213	41	236	244	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 23	2003	22	3					351	360		10.1038/sj.onc.1206145	http://dx.doi.org/10.1038/sj.onc.1206145			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545156				2022-12-17	WOS:000180379100004
J	Fiucci, G; Ravid, D; Reich, R; Liscovitch, M				Fiucci, G; Ravid, D; Reich, R; Liscovitch, M			Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells	ONCOGENE			English	Article						anchorage-independent growth; anoikis; breast cancer; caveolin; invasiveness; MCF-7 cells; multidrug resistance	PHOSPHOINOSITIDE 3-OH KINASE; MULTIDRUG-RESISTANCE; IN-VIVO; METASTATIC ACTIVITIES; UROKINASE RECEPTOR; UP-REGULATION; EXPRESSION; PROTEIN; MEMBRANE; INTEGRIN	Caveolin-1 is an essential structural constituent of caveolae that has been implicated in mitogenic signaling and oncogenesis. Caveolin-1 is down-regulated in oncogene-transformed and tumor-derived cells. Antisense suppression of caveolin-1 or expression of a dominant negative form are sufficient for inducing cellular transformation. Expression of recombinant caveolin-1 inhibits anchorage-independent growth in cancer cells. The present study was designed to determine whether this is caused by inhibition of cancer cell survival or cell proliferation, and to test if another important property of cancer cells, i.e. matrix invasion, is modulated by expression of caveolin. Utilizing MCF-7 human breast adenocarcinoma cells stably transfected with caveolin-1 (MCF-7/Cav1), we demonstrate that caveolin-1 expression decreases MCF-7 cell proliferation rate and markedly reduces their capacity to form colonies in soft agar. The loss of anchorage-independent growth is not associated with stimulation of anoikis; in fact, MCF-7/Cav1 cells exhibit increased survival after detachment as compared with MCF-7 cells, indicating that in these cells caveolin-1 inhibits anoikis. Analysis of matrix metalloprotease release and matrix invasion revealed that expression of caveolin-1 inhibits also these important metastasis-related phenomena. Plating MCF-7 cells on a laminin matrix resulted in activation of ERK1/2, which was dramatically inhibited in MCF-7/Cav1 cells. We conclude that high expression level of caveolin-1 in human breast cancer cells exerts a negative modulatory effect on anchorage-independent growth by inhibiting cell proliferation even though matrix-independent cell survival is enhanced. Caveolin-1 expression inhibits also matrix invasion and blocks laminin-dependent activation of ERK1/2. The inhibitory effect of caveolin-1 on these transformation-dependent processes supports the hypothesis that caveolin-1 acts as a tumor suppressor protein which may impose major phenotypic changes when expressed in human cancer cells.	Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; Hebrew Univ Jerusalem, Fac Med, Dept Pharmacol, Jerusalem, Israel	Weizmann Institute of Science; Hebrew University of Jerusalem	Liscovitch, M (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, POB 26, IL-76100 Rehovot, Israel.	moti.liscovitch@weizmann.ac.il						Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; BALLIN M, 1988, BIOCHEM BIOPH RES CO, V154, P832, DOI 10.1016/0006-291X(88)90215-X; BENARD J, 1989, INT J CANCER, V43, P471, DOI 10.1002/ijc.2910430322; Bender FC, 2000, CANCER RES, V60, P5870; BIEDLER JL, 1994, CANCER METAST REV, V13, P191, DOI 10.1007/BF00689636; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Campbell L, 1999, BIOCHEM BIOPH RES CO, V262, P744, DOI 10.1006/bbrc.1999.1280; Carriero MV, 1999, CANCER RES, V59, P5307; Chao C, 1996, CANCER RES, V56, P4811; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; Engelman JA, 1999, FEBS LETT, V448, P221, DOI 10.1016/S0014-5793(99)00365-8; Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; FAIRCHILD CR, 1987, CANCER RES, V47, P5141; Fielding CJ, 1999, BIOCHEMISTRY-US, V38, P2506, DOI 10.1021/bi981012o; Fielding CJ, 2000, BBA-MOL CELL BIOL L, V1529, P210, DOI 10.1016/S1388-1981(00)00150-5; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Galbiati F, 2001, MOL BIOL CELL, V12, P2229, DOI 10.1091/mbc.12.8.2229; Galbiati F, 1998, P NATL ACAD SCI USA, V95, P10257, DOI 10.1073/pnas.95.17.10257; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Gambaletta D, 2000, J BIOL CHEM, V275, P10604, DOI 10.1074/jbc.275.14.10604; Gargalovic P, 2001, J BIOL CHEM, V276, P26164, DOI 10.1074/jbc.M011291200; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Hayashi K, 2001, CANCER RES, V61, P2361; Hurlstone AFL, 1999, ONCOGENE, V18, P1881, DOI 10.1038/sj.onc.1202491; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Kurata H, 2000, EXP CELL RES, V254, P180, DOI 10.1006/excr.1999.4738; Lavie Y, 1998, J BIOL CHEM, V273, P32380, DOI 10.1074/jbc.273.49.32380; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; Li LK, 2001, CANCER RES, V61, P4386; Li WP, 2001, J CELL SCI, V114, P1397; LISANTI MP, 1995, METHOD ENZYMOL, V250, P655; Lisanti MP, 1999, METH MOL B, V116, P51; Liscovitch M, 2000, TRENDS BIOCHEM SCI, V25, P530, DOI 10.1016/S0968-0004(00)01668-6; Liu J, 2001, AM J PHYSIOL-CELL PH, V280, pC823, DOI 10.1152/ajpcell.2001.280.4.C823; Ludes-Meyers JH, 2001, ONCOGENE, V20, P2771, DOI 10.1038/sj.onc.1204377; MATTERN J, 1990, ANTICANCER RES, V10, P177; Matveev S, 1999, J LIPID RES, V40, P1647; Mikol DD, 1999, GLIA, V27, P39; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; Montesano R, 1999, CELL GROWTH DIFFER, V10, P317; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Ogretmen B, 1997, ONCOGENE, V14, P499, DOI 10.1038/sj.onc.1200855; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Parolini I, 1999, J BIOL CHEM, V274, P25718, DOI 10.1074/jbc.274.36.25718; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; Racine C, 1999, BIOCHEM BIOPH RES CO, V255, P580, DOI 10.1006/bbrc.1999.0236; Razani B, 2001, J BIOL CHEM, V276, P38121; REICH R, 1995, CLIN EXP METASTAS, V13, P134, DOI 10.1007/BF00133618; REICH R, 1989, BIOCHEM BIOPH RES CO, V160, P559, DOI 10.1016/0006-291X(89)92469-8; SAGER R, 1994, COLD SPRING HARB SYM, V59, P537, DOI 10.1101/SQB.1994.059.01.060; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; Schwartz BM, 2001, GYNECOL ONCOL, V81, P291, DOI 10.1006/gyno.2001.6124; Scotlandi K, 1996, CANCER RES, V56, P2434; Scotlandi K, 1999, ONCOGENE, V18, P739, DOI 10.1038/sj.onc.1202330; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; SHTIL A, 1994, EXP TOXICOL PATHOL, V46, P257, DOI 10.1016/S0940-2993(11)80096-5; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; TERRANOVA VP, 1986, JNCI-J NATL CANCER I, V77, P311; Timme TL, 2000, ONCOGENE, V19, P3256, DOI 10.1038/sj.onc.1203654; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; Welch DR, 2000, CANCER RES, V60, P1552; WOSIKOWSKI K, 1995, CELL GROWTH DIFFER, V6, P1395; Xu LH, 2000, J BIOL CHEM, V275, P30597, DOI 10.1074/jbc.M910027199; Xu LH, 1996, CELL GROWTH DIFFER, V7, P413; Yang CPH, 1998, FEBS LETT, V439, P368, DOI 10.1016/S0014-5793(98)01354-4; Yung Y, 1997, FEBS LETT, V408, P292, DOI 10.1016/S0014-5793(97)00442-0; Zundel W, 2000, MOL CELL BIOL, V20, P1507, DOI 10.1128/MCB.20.5.1507-1514.2000	81	236	253	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2365	2375		10.1038/sj.onc.1205300	http://dx.doi.org/10.1038/sj.onc.1205300			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948420				2022-12-17	WOS:000174635600009
J	Basso, AD; Solit, DB; Munster, PN; Rosen, N				Basso, AD; Solit, DB; Munster, PN; Rosen, N			Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2	ONCOGENE			English	Article						Akt; HER2; cyclin D; ansamycins	HER2/NEU-OVEREXPRESSING METASTATIC BREAST; EPIDERMAL GROWTH-FACTOR; PROTEIN-KINASE; PHOSPHOINOSITIDE 3-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; GLUCOCORTICOID RECEPTOR; MONOCLONAL-ANTIBODY; PHASE-II; GELDANAMYCIN; HSP90	Ansamycin antibiotics, such as 17-allylaminogeldanamycin (17-AAG), bind to Hsp90 and regulate its function, resulting in the proteasomal degradation of a subset of signaling proteins that require Hsp90 for conformational maturation. HER2 is a very sensitive target of these drugs. Ansamycins cause RB-dependent G1 arrest that is associated with loss of D-cyclins via a PI3 kinase, Akt dependent pathway. Downregulation of D-cyclin was due, in part, to loss of Akt expression in response to drug. Moreover, in HER2 overexpressing breast cancer cells, 17-AAG caused rapid inhibition of Akt activity prior to any change in Akt protein. Ansamycins; caused rapid degradation of HER2 and a concomitant loss in HER3 associated PI3 kinase activity. This led to a loss of Akt activity, dephosphorylation of Akt substrates, and loss of D-cyclin expression. Introduction into cells of a constitutively membrane bound form of PI3 kinase prevented the effects of the drug on Akt activity and D-cyclins. Thus, in breast cancer cells with high HER2, Akt activation by HER2/HER3 heterodimers; is required for D-cyclin expression. In murine xenograft models, non-toxic doses of 17-AAG markedly reduced the expression of HER2 and phosphorylation of Akt and inhibited tumor growth. Thus, pharmacological inhibition of Akt activation is achievable with ansamycins and may be useful for the treatment of HER2 driven tumors.	Mem Sloan Kettering Canc Ctr, Program Cell Biol, New York, NY 10021 USA; Cornell Univ, Weill Grad Sch Med Sci, Program Pharmacol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University	Rosen, N (corresponding author), Mem Sloan Kettering Canc Ctr, Program Cell Biol, 1275 York Ave, New York, NY 10021 USA.		Rosen, Neal/ABF-2677-2020; Solit, David B./AAC-5309-2019		NCI NIH HHS [P50 CA068425-05, CA0951, P50 CA 68425] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA068425] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Bardelli A, 1999, ONCOGENE, V18, P1139, DOI 10.1038/sj.onc.1202607; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Czar MJ, 1997, BIOCHEMISTRY-US, V36, P7776, DOI 10.1021/bi970648x; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Gilewski T, 2000, CANCER CHEMOTH PHARM, V46, pS23, DOI 10.1007/PL00014044; Hellyer NJ, 1998, BIOCHEM J, V333, P757, DOI 10.1042/bj3330757; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Munster PN, 2001, CLIN CANCER RES, V7, P2228; Page C, 2000, ANTICANCER RES, V20, P407; Pegram M, 1999, ONCOGENE, V18, P2241, DOI 10.1038/sj.onc.1202526; Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659; Penuel E, 1999, MOL BIOL CELL, V10, P1693, DOI 10.1091/mbc.10.6.1693; Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; Schulte TW, 1996, MOL CELL BIOL, V16, P5839; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Srethapakdi M, 2000, CANCER RES, V60, P3940; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stancato LF, 1997, J BIOL CHEM, V272, P4013, DOI 10.1074/jbc.272.7.4013; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; TAL M, 1988, CANCER RES, V48, P1517; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; Webb CP, 2000, CANCER RES, V60, P342; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; Xu WP, 2001, J BIOL CHEM, V276, P3702, DOI 10.1074/jbc.M006864200	39	236	243	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 14	2002	21	8					1159	1166		10.1038/sj.onc.1205184	http://dx.doi.org/10.1038/sj.onc.1205184			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850835	Green Accepted			2022-12-17	WOS:000173729400003
J	Saaristo, A; Karpanen, T; Alitalo, K				Saaristo, A; Karpanen, T; Alitalo, K			Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis	ONCOGENE			English	Review						breast cancer; metastasis; lymphatic vessels; VEGF; VEGF-C	RECEPTOR TYROSINE KINASE; FACTOR-C EXPRESSION; IN-VIVO; VEGF-C; INTEGRIN ALPHA(V)BETA(3); MONOCLONAL-ANTIBODY; BLOOD-VESSELS; MESSENGER-RNA; UP-REGULATION; CELL GROWTH	There is a constant requirement for vascular supply in solid tumors. Tumor-associated neovascularization allows the tumor cells to express their critical growth advantage. Axillary lymph node status is the most important prognostic factor in operable breast cancer, and experimental and clinical evidence suggests that the process of metastasis is also angiogenesis-dependent. Various angiogenic growth factors and cytokines induce neovascularization in tumors, namely members of the vascular endothelial growth factor (VEGF) and angiopoietin (Ang) gene families. A strong correlation has been found between VEGF expression and increased tumor microvasculature, malignancy, and metastasis in breast cancer, Anti-angiogenic therapy approaches offer a new promising anti-cancer strategy and a remarkably diverse group of over 20 such drugs is currently undergoing evaluation in clinical trials.	Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland; Univ Helsinki, Haartman Inst, Ludwig Inst Canc Res, FIN-00014 Helsinki, Finland	University of Helsinki; Ludwig Institute for Cancer Research; University of Helsinki	Alitalo, K (corresponding author), Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, POB 21,Haartmaninkatu 3, FIN-00014 Helsinki, Finland.		Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902; Karpanen, Terhi/0000-0002-2803-083X				Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295; APRELIKOVA O, 1992, CANCER RES, V52, P746; Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; Arap Wadih, 1998, Current Opinion in Oncology, V10, P560, DOI 10.1097/00001622-199811000-00014; Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964; Benjamin LE, 1997, P NATL ACAD SCI USA, V94, P8761, DOI 10.1073/pnas.94.16.8761; Brekken RA, 1998, CANCER RES, V58, P1952; BREM SS, 1978, CANCER, V41, P239, DOI 10.1002/1097-0142(197801)41:1<239::AID-CNCR2820410133>3.0.CO;2-X; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Browder T, 2000, CANCER RES, V60, P1878; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DENEKAMP J, 1993, BRIT J RADIOL, V66, P181, DOI 10.1259/0007-1285-66-783-181; Detmar M, 1998, J INVEST DERMATOL, V111, P1, DOI 10.1046/j.1523-1747.1998.00262.x; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; DVORAK HF, 1989, J NATL CANCER I, V81, P497, DOI 10.1093/jnci/81.7.497; Enholm B, 1997, ONCOGENE, V14, P2475, DOI 10.1038/sj.onc.1201090; Eriksson U, 1999, CURR TOP MICROBIOL, V237, P41; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FOLKMAN J, 1971, J EXP MED, V133, P275, DOI 10.1084/jem.133.2.275; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; Fukumura D, 1997, AM J PATHOL, V151, P679; Gasparini G, 1997, J NATL CANCER I, V89, P139, DOI 10.1093/jnci/89.2.139; Gately S, 1997, P NATL ACAD SCI USA, V94, P10868, DOI 10.1073/pnas.94.20.10868; Gleadle JM, 1998, MOL MED TODAY, V4, P122, DOI 10.1016/S1357-4310(97)01198-2; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; Goldman CK, 1998, P NATL ACAD SCI USA, V95, P8795, DOI 10.1073/pnas.95.15.8795; Grunstein J, 1999, CANCER RES, V59, P1592; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Hashizume H, 2000, AM J PATHOL, V156, P1363, DOI 10.1016/S0002-9440(10)65006-7; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Holder N, 1999, DEVELOPMENT, V126, P2033; Holmgren L, 1996, CANCER METAST REV, V15, P241, DOI 10.1007/BF00437478; Hyder SM, 2000, CANCER RES, V60, P3183; Isner JM, 1996, LANCET, V348, P370, DOI 10.1016/S0140-6736(96)03361-2; Jain RK, 1998, P NATL ACAD SCI USA, V95, P10820, DOI 10.1073/pnas.95.18.10820; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Joukov V, 1998, J BIOL CHEM, V273, P6599, DOI 10.1074/jbc.273.12.6599; Kaban LB, 1999, PEDIATRICS, V103, P1145, DOI 10.1542/peds.103.6.1145; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; KALEBIC T, 1983, SCIENCE, V221, P281, DOI 10.1126/science.6190230; Karkkainen MJ, 2000, NAT GENET, V25, P153, DOI 10.1038/75997; Kerbel RS, 1997, NATURE, V390, P335, DOI 10.1038/36978; Kerbel RS, 1998, MOL MED, V4, P286, DOI 10.1007/BF03401737; KERBEL RS, 1991, BIOESSAYS, V13, P31, DOI 10.1002/bies.950130106; Kim I, 1999, FEBS LETT, V443, P353, DOI 10.1016/S0014-5793(99)00008-3; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kim S, 2000, AM J PATHOL, V156, P1345, DOI 10.1016/S0002-9440(10)65005-5; Klement G, 2000, J CLIN INVEST, V105, pR15, DOI 10.1172/JCI8829; Koivunen E, 1999, NAT BIOTECHNOL, V17, P768, DOI 10.1038/11703; Kong HL, 1998, HUM GENE THER, V9, P823, DOI 10.1089/hum.1998.9.6-823; Kremer C, 1997, CANCER RES, V57, P3852; Kukk E, 1996, DEVELOPMENT, V122, P3829; LEU AJ, 2000, IN PRESS CANC RES; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Makinen T, 1999, J BIOL CHEM, V274, P21217, DOI 10.1074/jbc.274.30.21217; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Melder RJ, 1996, NAT MED, V2, P992, DOI 10.1038/nm0996-992; Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363; Migdal M, 1998, J BIOL CHEM, V273, P22272, DOI 10.1074/jbc.273.35.22272; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; NAGY JA, 1989, BIOCHIM BIOPHYS ACTA, V948, P305, DOI 10.1016/0304-419X(89)90004-8; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; NICOLSON GL, 1988, CANCER METAST REV, V7, P143, DOI 10.1007/BF00046483; O'Reilly MS, 1999, SCIENCE, V285, P1926, DOI 10.1126/science.285.5435.1926; Ogawa S, 1998, J BIOL CHEM, V273, P31273, DOI 10.1074/jbc.273.47.31273; Ohta Y, 1999, BRIT J CANCER, V81, P54, DOI 10.1038/sj.bjc.6690650; Okada F, 1998, P NATL ACAD SCI USA, V95, P3609, DOI 10.1073/pnas.95.7.3609; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Paavonen K, 2000, AM J PATHOL, V156, P1499, DOI 10.1016/S0002-9440(10)65021-3; Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659; Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958; Persico MG, 1999, CURR TOP MICROBIOL, V237, P31; Petit AMV, 1997, AM J PATHOL, V151, P1523; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Presta LG, 1997, CANCER RES, V57, P4593; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; ROBERTS AB, 1989, AM REV RESPIR DIS, V140, P1126, DOI 10.1164/ajrccm/140.4.1126; Ruoslahti E, 1999, ADV CANCER RES, V76, P1, DOI 10.1016/S0065-230X(08)60772-1; Saaristo A, 2000, AM J PATHOL, V157, P7, DOI 10.1016/S0002-9440(10)64510-5; Senger DR, 1996, AM J PATHOL, V149, P1; Shutter JR, 2000, GENE DEV, V14, P1313; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Siemeister G, 1996, CANCER RES, V56, P2299; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; SURI C, 1997, CELL, V87, P1161; Taipale J, 1998, ADV CANCER RES, V75, P87, DOI 10.1016/S0065-230X(08)60740-X; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; Tsurusaki T, 1999, BRIT J CANCER, V80, P309, DOI 10.1038/sj.bjc.6690356; Valenzuela DM, 1999, P NATL ACAD SCI USA, V96, P1904, DOI 10.1073/pnas.96.5.1904; Valtola R, 1999, AM J PATHOL, V154, P1381, DOI 10.1016/S0002-9440(10)65392-8; Veikkola T, 2000, CANCER RES, V60, P203; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; Whitelock JM, 1996, J BIOL CHEM, V271, P10079, DOI 10.1074/jbc.271.17.10079; Wise LM, 1999, P NATL ACAD SCI USA, V96, P3071, DOI 10.1073/pnas.96.6.3071; Witte M H, 1997, EXS, V79, P65; YlaHerttuala S, 1997, CURR OPIN LIPIDOL, V8, P72; Yonemura Y, 1999, CLIN CANCER RES, V5, P1823	113	236	268	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 11	2000	19	53					6122	6129		10.1038/sj.onc.1203969	http://dx.doi.org/10.1038/sj.onc.1203969			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	387KH	11156525				2022-12-17	WOS:000166121400005
J	Costantini, P; Belzacq, AS; La Vieira, H; Larochette, N; de Pablo, MA; Zamzami, N; Susin, SA; Brenner, C; Kroemer, G				Costantini, P; Belzacq, AS; La Vieira, H; Larochette, N; de Pablo, MA; Zamzami, N; Susin, SA; Brenner, C; Kroemer, G			Oxidation of a critical thiol residue of the adenine nucleotide translocator enforces Bcl-2-independent permeability transition pore opening and apoptosis	ONCOGENE			English	Article						ADP/ATP carrier; Bcl-2; cell death; mitochondria; permeability transition	MITOCHONDRIAL BENZODIAZEPINE RECEPTOR; DEPENDENT ANION CHANNEL; CYTOCHROME-C; ADP/ATP CARRIER; BCL-2; MEMBRANE; RELEASE; INDUCTION; PROTEIN; PHENANTHROLINE	Mitochondrial membrane permeabilization is a critical event in the process leading to physiological or chemotherapy-induced apoptosis. This permeabilization event is at least in part under the control of the permeability transition pore complex (PTPC), which interacts with oncoproteins from the Bcl-2 family as well as with tumor suppressor proteins from the Bar family, which inhibit or facilitate membrane permeabilization, respectively. Here we show that thiol crosslinking agents including diazenedicarboxylic acid bis SN,N-dimethylamide (diamide), dithiodipyridine (DTDP), or bis-maleimido-hexane (BMH) can act on the adenine nucleotide translocator (ANT), one of the proteins within the PTPC. ANT alone reconstituted into artificial lipid bilayers suffices to confer a membrane permeabilization response to thiol crosslinking agents. Diamide, DTDP, and BMH but not tert-butylhydroperoxide or arsenite cause the oxidation of a critical cysteine residue (Cys 56) of ANT. Thiol modification within ANT is observed in intact cells, isolated mitochondria, and purified ANT. Recombinant Bcl-2 fails to prevent thiol modification of ANT. Concomitantly, a series of different thiol crosslinking agents (diamide, DTDP, and BMH, phenylarsine oxide) but not tert-butylhydroperoxide or arsenite induce mitochondrial membrane permeabilization and cell death irrespective of the expression level of Bcl-2. These data indicate that thiol crosslinkers cause a covalent modification of ANT which, beyond any control by Bcl-2, leads to mitochondrial membrane permeabilization and cell death.	CNRS, ERS 1984, F-94801 Villejuif, France; Univ Technol Compiegne, CNRS, UPRES A6022, F-60205 Compiegne, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Picardie Universites; Universite de Technologie de Compiegne	Kroemer, G (corresponding author), CNRS, ERS 1984, 19 Rue Guy Moquet, F-94801 Villejuif, France.		Susin, Santos A/Q-6754-2017; Kroemer, Guido/AAY-9859-2020; LAROCHETTE, Nathanael/R-4298-2017; KROEMER, Guido/B-4263-2013	Susin, Santos A/0000-0002-3366-1628; LAROCHETTE, Nathanael/0000-0002-7936-678X; KROEMER, Guido/0000-0002-9334-4405; Vieira, Helena/0000-0001-9415-3742				Beutner G, 1998, BBA-BIOMEMBRANES, V1368, P7, DOI 10.1016/S0005-2736(97)00175-2; Beyer K, 1996, BIOCHEMISTRY-US, V35, P15784, DOI 10.1021/bi9610055; BRENNER C, 1999, IN PRESS ONCOGENE; Brustovetsky N, 1996, BIOCHEMISTRY-US, V35, P8483, DOI 10.1021/bi960833v; COSTANTINI P, 1995, TOXICOLOGY, V99, P77, DOI 10.1016/0300-483X(94)02997-9; Costantini P, 1998, BBA-BIOENERGETICS, V1365, P385, DOI 10.1016/S0005-2728(98)00090-5; COSTANTINI P, 1995, FEBS LETT, V362, P239, DOI 10.1016/0014-5793(95)00256-9; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; GironCalle J, 1996, BIOCHEMISTRY-US, V35, P15440, DOI 10.1021/bi960840j; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Halestrap AP, 1997, J BIOL CHEM, V272, P3346, DOI 10.1074/jbc.272.6.3346; Heiskanen KM, 1999, J BIOL CHEM, V274, P5654, DOI 10.1074/jbc.274.9.5654; Hirsch T, 1998, EXP CELL RES, V241, P426, DOI 10.1006/excr.1998.4084; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KLINGENBERG M, 1993, J BIOENERG BIOMEMBR, V25, P447, DOI 10.1007/BF01108402; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MAJIMA E, 1995, J BIOL CHEM, V270, P29548, DOI 10.1074/jbc.270.49.29548; Mancini M, 1998, J CELL BIOL, V140, P1485, DOI 10.1083/jcb.140.6.1485; Marchetti P, 1996, J IMMUNOL, V157, P4830; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; PALMIERI F, 1994, FEBS LETT, V346, P48, DOI 10.1016/0014-5793(94)00329-7; Pedersen P L, 1978, Methods Cell Biol, V20, P411, DOI 10.1016/S0091-679X(08)62030-0; Ravagnan L, 1999, ONCOGENE, V18, P2537, DOI 10.1038/sj.onc.1202625; Ruck A, 1998, FEBS LETT, V426, P97, DOI 10.1016/S0014-5793(98)00317-2; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; SUSIN SA, 1999, IN PRESS METH ENZYMO; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Woodfield K, 1998, BIOCHEM J, V336, P287, DOI 10.1042/bj3360287; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zamzami N, 1998, ONCOGENE, V16, P1055, DOI 10.1038/sj.onc.1201864	45	236	246	0	13	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 13	2000	19	2					307	314		10.1038/sj.onc.1203299	http://dx.doi.org/10.1038/sj.onc.1203299			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10645010				2022-12-17	WOS:000084844400017
J	Roussel, MF				Roussel, MF			The INK4 family of cell cycle inhibitors in cancer	ONCOGENE			English	Article							D-DEPENDENT KINASES; P16(INK4A) TUMOR-SUPPRESSOR; RETINOBLASTOMA-PROTEIN; CDK INHIBITORS; GROWTH SUPPRESSION; CRYSTAL-STRUCTURE; MICE LACKING; P16 MTS1; MELANOMA; GENE		St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Roussel, MF (corresponding author), St Jude Childrens Res Hosp, Dept Tumor Cell Biol, 332 N Lauderdale St, Memphis, TN 38105 USA.		Roussel, Martine F/F-1469-2016	Roussel, Martine F/0000-0002-1740-8139	NATIONAL CANCER INSTITUTE [P01CA071907, P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA-71907, CA-21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi M, 1997, BLOOD, V90, P126; Arap W, 1997, ONCOGENE, V14, P603, DOI 10.1038/sj.onc.1200870; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Brotherton DH, 1998, NATURE, V395, P244, DOI 10.1038/26164; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Drexler HG, 1998, LEUKEMIA, V12, P845, DOI 10.1038/sj.leu.2401043; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541; Franklin DS, 1996, MOL BIOL CELL, V7, P1587, DOI 10.1091/mbc.7.10.1587; Franklin DS, 1998, GENE DEV, V12, P2899, DOI 10.1101/gad.12.18.2899; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Hannah M. J., 1994, TERRA ANTARCTICA, V1, P371; Hara E, 1996, MOL CELL BIOL, V16, P859; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HARPER JW, 1993, CELL, V75, P805; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HIRAMA T, 1995, BLOOD, V86, P841; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Lamphere L, 1997, ONCOGENE, V14, P1999, DOI 10.1038/sj.onc.1201036; Li JN, 1999, BIOCHEMISTRY-US, V38, P2930, DOI 10.1021/bi982286e; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Mahony D, 1998, ONCOGENE, V16, P603, DOI 10.1038/sj.onc.1201570; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Miller CW, 1997, ONCOGENE, V15, P231, DOI 10.1038/sj.onc.1201185; Morse L, 1997, IMMUNITY, V6, P47, DOI 10.1016/S1074-7613(00)80241-1; Nakayama K, 1998, BIOESSAYS, V20, P1020, DOI 10.1002/(SICI)1521-1878(199812)20:12<1020::AID-BIES8>3.0.CO;2-D; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Noh SJ, 1999, CANCER RES, V59, P558; OKUDA T, 1995, BLOOD, V85, P2321, DOI 10.1182/blood.V85.9.2321.bloodjournal8592321; Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; SCHMIDT EE, 1994, CANCER RES, V54, P6321; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr Charles J., 1994, Trends in Cell Biology, V4, P15, DOI 10.1016/0962-8924(94)90033-7; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; SHERR CJ, 1999, IN PRESS GENES DEV; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; STONE S, 1995, CANCER RES, V55, P2988; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Venkataramani R, 1998, NAT STRUCT BIOL, V5, P74, DOI 10.1038/nsb0198-74; WASHIMI O, 1995, CANCER RES, V55, P514; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANG R, 1995, CANCER RES, V55, P2503; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zindy F, 1997, CELL GROWTH DIFFER, V8, P1139; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	72	236	247	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	1999	18	38					5311	5317		10.1038/sj.onc.1202998	http://dx.doi.org/10.1038/sj.onc.1202998			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	240CP	10498883				2022-12-17	WOS:000082808400009
J	Harari, D; Tzahar, E; Romano, J; Shelly, M; Pierce, JH; Andrews, GC; Yarden, Y				Harari, D; Tzahar, E; Romano, J; Shelly, M; Pierce, JH; Andrews, GC; Yarden, Y			Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase	ONCOGENE			English	Article						growth factor; oncogene; pancreas; signal transduction; tyrosine kinase	NEU DIFFERENTIATION FACTOR; SIGNAL-TRANSDUCTION; CARDIAC DEVELOPMENT; CELLULAR-RESPONSE; FACTOR FAMILY; EGF DOMAIN; HEREGULIN; LIGAND; BINDING; ACTIVATION	The ErbB/HER family of receptor tyrosine kinases consists of four receptors that bind a large number of growth factor ligands sharing an epidermal growth factor- (EGF)-like motif, Whereas ErbB-1 binds seven different ligands whose prototype is EGF, the three families of neuregulins (NRGs) activate ErbB-3 and/or ErbB-4. Here we characterize a fourth neuregulin, NRG-4, that acts through ErbB-4. The predicted pro-NRG-4 is a transmembrane protein carrying a unique EGF-like motif and a short cytoplasmic domain. A synthetic peptide encompassing the full-length EGF-like domain can induce growth of interleukin-dependent cells ectopically expressing ErbB-4, but not cells expressing the other three ErbB proteins or their combinations. Consistent with specificity to ErbB-4, NRG-4 can displace an ErbB-4-bound NRG-1 and can activate signaling downstream of this receptor, Expression of NRG-4 mRNA was detected in the adult pancreas and weakly in muscle; other tissues displayed no detectable NRG-4 mRNA. The primary structure and the pattern of expression of NRG-4, together with the strict specificity of this growth factor to ErbB-4, suggest a physiological role distinct from that of the known ErbB ligands.	Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; NCI, Bethesda, MD 20892 USA; Pfizer Inc, Cent Res, Groton, CT 06340 USA	Weizmann Institute of Science; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Pfizer	Yarden, Y (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.		YARDEN, YOSEF/K-1467-2012	shelly, maya/0000-0002-2211-1751				Alimandi M, 1997, EMBO J, V16, P5608, DOI 10.1093/emboj/16.18.5608; BARBACCI EG, 1995, J BIOL CHEM, V270, P9585, DOI 10.1074/jbc.270.16.9585; Ben-Baruch Noa, 1998, P145; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; Busfield SJ, 1997, MOL CELL BIOL, V17, P4007, DOI 10.1128/MCB.17.7.4007; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; CHAN SDH, 1995, J BIOL CHEM, V270, P22608, DOI 10.1074/jbc.270.38.22608; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; Cohen BD, 1996, J BIOL CHEM, V271, P30897, DOI 10.1074/jbc.271.48.30897; Elenius K, 1997, EMBO J, V16, P1268, DOI 10.1093/emboj/16.6.1268; Erickson SL, 1997, DEVELOPMENT, V124, P4999; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GREGORY H, 1979, GASTROENTEROLOGY, V77, P313; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Higashiyama S, 1997, J BIOCHEM-TOKYO, V122, P675; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Jones JT, 1998, J BIOL CHEM, V273, P11667, DOI 10.1074/jbc.273.19.11667; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KARUNAGARAN D, 1995, J BIOL CHEM, V270, P9982, DOI 10.1074/jbc.270.17.9982; Klapper LN, 1997, ONCOGENE, V14, P2099, DOI 10.1038/sj.onc.1201029; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; LIN YZ, 1988, BIOCHEMISTRY-US, V27, P5640, DOI 10.1021/bi00415a037; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARQUARDT H, 1984, SCIENCE, V223, P1079, DOI 10.1126/science.6320373; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; Pinkas-Kramarski R, 1998, MOL CELL BIOL, V18, P6090, DOI 10.1128/MCB.18.10.6090; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PinkasKramarski R, 1997, ONCOGENE, V15, P2803, DOI 10.1038/sj.onc.1201466; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; Reddy CC, 1996, NAT BIOTECHNOL, V14, P1696, DOI 10.1038/nbt1296-1696; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1996, ONCOGENE, V12, P345; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; Riethmacher D, 1997, NATURE, V389, P725, DOI 10.1038/39593; SAMUEL K, 1990, P NATL ACAD SCI USA, V87, P2264; Shelly M, 1998, J BIOL CHEM, V273, P10496, DOI 10.1074/jbc.273.17.10496; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Smith T.F., 1981, ADV APPL MATH, V2, P482, DOI DOI 10.1016/0196-8858(81)90046-4; TAM JP, 1983, J AM CHEM SOC, V105, P6442, DOI 10.1021/ja00359a014; TOYODA H, 1995, J BIOL CHEM, V270, P7495, DOI 10.1074/jbc.270.13.7495; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Tzahar E, 1998, BBA-REV CANCER, V1377, pM25, DOI 10.1016/S0304-419X(97)00032-2; Tzahar E, 1997, EMBO J, V16, P4938, DOI 10.1093/emboj/16.16.4938; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; Wang LM, 1998, P NATL ACAD SCI USA, V95, P6809, DOI 10.1073/pnas.95.12.6809; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; Yung Y, 1997, FEBS LETT, V408, P292, DOI 10.1016/S0014-5793(97)00442-0; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562	60	236	275	0	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 29	1999	18	17					2681	2689		10.1038/sj.onc.1202631	http://dx.doi.org/10.1038/sj.onc.1202631			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FH	10348342				2022-12-17	WOS:000080124900003
J	Eliopoulos, AG; Young, LS				Eliopoulos, AG; Young, LS			Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1)	ONCOGENE			English	Article						LMP1; JNK/SAPK; AP1; NF-kappa B; signalling	KAPPA-B ACTIVATION; C-JUN; LYMPHOCYTE TRANSFORMATION; EPITHELIAL-CELLS; TRANSCRIPTION; DOMAIN; GENE; INDUCTION; CD40; MEMBRANE-PROTEIN-1	Expression of the oncogenic Epstein-Barr virus (EBV)-encoded Latent Membrane Protein 1 (LMP1) activates signalling on the NF-kappa B axis through two distinct domains in the cytoplasmic C-terminus of the protein, namely CTAR1 (aa 187-231) and CTAR2 (aa 351-386), Whilst this effect is responsible for some of the functional consequences of LMP1 expression, additional LMP1-mediated signalling pathways may exist which contribute to the pleiotropic activities of this protein, In this study me provide evidence of a kinase cascade being activated by LMP1. Thus, we demonstrate that stable or transient expression of the LMP1 prototype from B95.8 in cells of epithelial or B cell origin activates the c-Jun N-terminal kinase (JNK, also known as the stress-activated protein kinase, SAPK) pathway, an effect which was found to be mediated through CTAR2 but not CTAR1, LMP1 from the Cao viral strain or LMP1 homologoues from the simian EBV naturally infecting baboons and rhesus monkeys were also able to activate JNK, This phenomenon translates to induction of AP-1, a transcription factor which is readily activated by growth factors and mitogens, Interestingly, an LMP1/CD40 chimaera comprising of the N-terminus and transmembrane domain of LMP1 and the cytoplasmic tail of CD40 which shares a common TRAF binding motif with CTAR1, effectively induced JNK, As NF-kappa B and JNK are co-activated in LMP1-expressing cells, we investigated whether the two pathways are overlapping or independent, We have found that inhibition of NF-kappa B by metabolic inhibitors or a constitutively active mutated I kappa-B alpha does not impair the ability of LMP1 to signal on the JNK axis, Conversely, whilst a dominant negative mutated SEK (JNKK) inhibited LMP1-induced JNK activation, it did not affect NF-kappa B suggesting that these two LMP1-mediated pathways are divergent.	Univ Birmingham, Sch Med, CRC, Inst Canc Studies, Birmingham B15 2TA, W Midlands, England	University of Birmingham	Young, LS (corresponding author), Univ Birmingham, Sch Med, CRC, Inst Canc Studies, Vincent Dr, Birmingham B15 2TA, W Midlands, England.		ELIOPOULOS, ARISTIDES/ABI-6632-2020; Young, Lawrence S/B-7213-2009; ELIOPOULOS, ARISTIDES/R-9449-2018	ELIOPOULOS, ARISTIDES/0000-0002-6403-6761; Young, Lawrence S/0000-0003-3919-4298; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761				ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; Antinore MJ, 1996, EMBO J, V15, P1950, DOI 10.1002/j.1460-2075.1996.tb00546.x; BAICHWAL VR, 1988, ONCOGENE, V2, P461; Berberich I, 1996, EMBO J, V15, P92, DOI 10.1002/j.1460-2075.1996.tb00337.x; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Eliopoulos AG, 1996, ONCOGENE, V13, P2243; Eliopoulos AG, 1997, ONCOGENE, V14, P2899, DOI 10.1038/sj.onc.1201258; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; Floettmann JE, 1996, VIROLOGY, V223, P29, DOI 10.1006/viro.1996.0452; Franken M, 1996, J VIROL, V70, P7819, DOI 10.1128/JVI.70.11.7819-7826.1996; GONZALEZ AL, 1995, TRENDS GENET, V11, P216, DOI 10.1016/S0168-9525(00)89051-4; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAMMERSCHMIDT W, 1989, J VIROL, V63, P2469, DOI 10.1128/JVI.63.6.2469-2475.1989; HUEN DS, 1995, ONCOGENE, V10, P549; KAYE KM, 1995, J VIROL, V69, P675, DOI 10.1128/JVI.69.2.675-683.1995; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Liebowitz David, 1993, P107; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lu JJY, 1996, J GEN VIROL, V77, P1883, DOI 10.1099/0022-1317-77-8-1883; Miller WE, 1997, J VIROL, V71, P586, DOI 10.1128/JVI.71.1.586-594.1997; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; NAKAGOMI H, 1994, INT J CANCER, V57, P240, DOI 10.1002/ijc.2910570218; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROWE M, 1994, J VIROL, V68, P5602, DOI 10.1128/JVI.68.9.5602-5612.1994; Sakata N, 1995, J BIOL CHEM, V270, P30823, DOI 10.1074/jbc.270.51.30823; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; YAN MH, 1994, NATURE, V372, P798; Young L S, 1992, Semin Cancer Biol, V3, P273; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	45	236	246	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 2	1998	16	13					1731	1742		10.1038/sj.onc.1201694	http://dx.doi.org/10.1038/sj.onc.1201694			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZE573	9582021				2022-12-17	WOS:000072807600011
J	WANG, HG; MIYASHITA, T; TAKAYAMA, S; SATO, T; TORIGOE, T; KRAJEWSKI, S; TANAKA, S; HOVEY, L; TROPPMAIR, J; RAPP, UR; REED, JC				WANG, HG; MIYASHITA, T; TAKAYAMA, S; SATO, T; TORIGOE, T; KRAJEWSKI, S; TANAKA, S; HOVEY, L; TROPPMAIR, J; RAPP, UR; REED, JC			APOPTOSIS REGULATION BY INTERACTION OF BCL-2 PROTEIN AND RAF-1 KINASE	ONCOGENE			English	Note							EPSTEIN-BARR-VIRUS; CELL-DEATH; PROTOONCOGENE EXPRESSION; RAS; ONCOPROTEIN; ACTIVATION; LINE; PHOSPHORYLATION; ONCOGENES; PROSTATE	The Bcl-2 protein is over-produced in many types of human tumors and suppresses apoptosis induced by a wide-variety of stimuli, including chemotherapeutic drugs and gamma-irradiation. The biochemical mechanism of action of the Bcl-2 protein however remains enigmatic. Here we show that Bcl-2 can be co-immunoprecipitated with the serine/ threonine-specific Raf-1 kinase both in a mammalian hemopoietic cell 32D.3 and when the two proteins are produced in Sf9 insect cells using recombinant baculoviruses. Though analysis of-Raf-1 deletion mutants suggested that the C-terminal half of the protein which contains the catalytic domain is sufficient for co-immunoprecipitation with Bcl-2, Raf-1 does not appear to induce phosphorylation of Bcl-2 protein in 32D.3 and Sf9 cells. Furthermore, a mutant form of Raf-1 that lacks kinase activity could still be co-immunoprecipitated with Bcl-2 in Sf9 cells, suggesting that the interaction of these proteins does not reflect a kinase-substrate relation, Gene transfer experiments using 32D.3 hemopoietic cells demonstrated functional synergy between Bcl-2 and Raf-1 with regards to suppression of apoptosis induced by growth factor withdrawal. Taken together, these observations for the first time functionally link Bcl-2 to a signal transducing protein and suggest that the interaction of the Bcl-2 and Raf-1 proteins may be responsible for their ability to cooperate in the suppression of apoptosis.	LA JOLLA CANC RES FDN,CANC RES CTR,LA JOLLA,CA 92037; NCI,FREDERICK CANC RES FACIL,TUMOR VIROL LAB,FREDERICK,MD 21702	Sanford Burnham Prebys Medical Discovery Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Wang, Hong-Gang/A-3018-2015	Wang, Hong-Gang/0000-0003-0551-0571; Troppmair, Jakob/0000-0002-0611-3837	NCI NIH HHS [CA-54957] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054957] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAFFY G, 1993, J BIOL CHEM, V268, P6511; CAMPOS I, 1993, BLOOD, V18, P3091; CLEVELAND J, IN PRESS ONCOGENE; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; COLOMBEL M, 1993, AM J PATHOL, V143, P390; DEJONG D, 1994, CANCER RES, V54, P256; DELIA D, 1992, BLOOD, V79, P1291, DOI 10.1182/blood.V79.5.1291.bloodjournal7951291; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; HANADA M, 1993, BLOOD, V82, P1820; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; IKEGAKI B, 1994, CANCER RES, V54, P6; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KOCACHE MM, 1990, INTERVIROLOGY, V31, P1; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; LU QL, 1993, INT J CANCER, V53, P29, DOI 10.1002/ijc.2910530107; MARILIO F, 1989, ONCOGENE, V4, P301; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; MIYASHITA T, 1993, BLOOD, V81, P151; MIYASHITA T, 1992, CANCER RES, V52, P5407; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; NGAN BY, 1988, NEW ENGL J MED, V318, P1638, DOI 10.1056/NEJM198806233182502; PEZELLA F, 1993, NEW ENGL J MED, V329, P690; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; REED JC, 1991, CELL GROWTH DIFFER, V2, P235; REED JC, 1994, ANN ONCOL, V5, pS61, DOI 10.1093/annonc/5.suppl_1.S61; REED JC, 1992, ANAL BIOCHEM, V205, P70, DOI 10.1016/0003-2697(92)90580-Z; REED JC, 1991, CANCER RES, V51, P6529; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; REY I, 1994, ONCOGENE, V9, P686; SATO T, IN PRESS P NATL ACAD; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; Troppmair J, 1992, Curr Top Microbiol Immunol, V182, P453; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YUNIS JJ, 1989, NEW ENGL J MED, V320, P1047, DOI 10.1056/NEJM198904203201605; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	47	236	245	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2751	2756						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058342				2022-12-17	WOS:A1994PC05400040
J	SANDGREN, EP; QUAIFE, CJ; PINKERT, CA; PALMITER, RD; BRINSTER, RL				SANDGREN, EP; QUAIFE, CJ; PINKERT, CA; PALMITER, RD; BRINSTER, RL			ONCOGENE-INDUCED LIVER NEOPLASIA IN TRANSGENIC MICE	ONCOGENE			English	Article									UNIV WASHINGTON, HOWARD HUGHES MED INST, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	SANDGREN, EP (corresponding author), UNIV PENN, SCH VET MED, REPROD PHYSIOL LAB, ROOM 100E, PHILADELPHIA, PA 19104 USA.			Pinkert, Carl/0000-0001-7460-3881; Brinster, Ralph/0000-0003-1408-7656	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD009172, R37HD009172] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA038635] Funding Source: NIH RePORTER; NCI NIH HHS [CA 38635] Funding Source: Medline; NICHD NIH HHS [HD 09172] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ANDRES AC, 1987, P NATL ACAD SCI USA, V84, P1299, DOI 10.1073/pnas.84.5.1299; ANDRES AC, 1988, GENE DEV, V2, P1486, DOI 10.1101/gad.2.11.1486; BAETGE EE, 1988, P NATL ACAD SCI USA, V85, P3648, DOI 10.1073/pnas.85.10.3648; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BEHRINGER RR, 1988, P NATL ACAD SCI USA, V85, P2648, DOI 10.1073/pnas.85.8.2648; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; BRINSTER RL, 1986, HARVEY LECT, V80, P1; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CHAMBERS PL, 1987, MOUSE LIVER TUMORS S, V10; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; CORY S, 1988, ANNU REV IMMUNOL, V6, P25; DURNAM DM, 1983, ANAL BIOCHEM, V131, P385, DOI 10.1016/0003-2697(83)90188-4; EFRAT S, 1988, NEURON, V1, P605, DOI 10.1016/0896-6273(88)90110-9; FARBER E, 1987, LAB INVEST, V56, P4; FARBER E, 1986, CANCER SURV, V5, P695; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; FRITH CH, 1979, J ENVIRON PATHOL TOX, V3, P329; GUTIERREZ C, 1988, SCIENCE, V240, P1202, DOI 10.1126/science.3287614; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HELD WA, 1989, EMBO J, V8, P183, DOI 10.1002/j.1460-2075.1989.tb03363.x; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365, DOI 10.1002/j.1460-2075.1987.tb02513.x; JAENISCH R, 1988, SCIENCE, V240, P1468, DOI 10.1126/science.3287623; KEW MC, 1986, CANCER SURV, V5, P719; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; KNUDSON AG, 1986, ANNU REV GENET, V20, P231; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; MARONPOT RR, 1987, ARCH TOXICOL, P10; MESSING A, 1985, NATURE, V316, P461, DOI 10.1038/316461a0; OBRIEN W, 1986, P NATL ACAD SCI USA, V83, P8659; ORNITZ DM, 1987, SCIENCE, V238, P188, DOI 10.1126/science.2821617; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; QUAIFE CJ, 1987, CELL, V48, P1023, DOI 10.1016/0092-8674(87)90710-0; REYNOLDS SH, 1986, P NATL ACAD SCI USA, V83, P33, DOI 10.1073/pnas.83.1.33; REYNOLDS SH, 1987, SCIENCE, V237, P1309, DOI 10.1126/science.3629242; RHIM JS, 1985, SCIENCE, V227, P1250, DOI 10.1126/science.2579430; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; SCHOENENBERGER CA, 1988, EMBO J, V7, P169, DOI 10.1002/j.1460-2075.1988.tb02797.x; SEEBURG PH, 1982, DNA-J MOLEC CELL BIO, V1, P239, DOI 10.1089/dna.1.1982.1.239; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SONTAG JM, 1976, NCI CARCINOGENESIS T, V1; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; STUDZINSKI GP, 1988, SCIENCE, V240, P1202, DOI 10.1126/science.240.4856.1202-a; STUDZINSKI GP, 1986, SCIENCE, V234, P467, DOI 10.1126/science.3532322; SUDA Y, 1987, EMBO J, V6, P4055, DOI 10.1002/j.1460-2075.1987.tb02751.x; TOOZE J, 1980, MOL BIOL TUMOR VIRUS; TOWNES TM, 1985, EMBO J, V4, P1715, DOI 10.1002/j.1460-2075.1985.tb03841.x; WEINSTEIN IB, 1987, J CELL BIOCHEM, V33, P213, DOI 10.1002/jcb.240330308; WISEMAN RW, 1986, P NATL ACAD SCI USA, V83, P5825, DOI 10.1073/pnas.83.16.5825; YUSPA SH, 1988, ADV CANCER RES, V50, P25, DOI 10.1016/S0065-230X(08)60434-0; [No title captured]	60	236	239	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1989	4	6					715	724						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA660	2543942				2022-12-17	WOS:A1989AA66000007
J	Humbert, PO; Grzeschik, NA; Brumby, AM; Galea, R; Elsum, I; Richardson, HE				Humbert, P. O.; Grzeschik, N. A.; Brumby, A. M.; Galea, R.; Elsum, I.; Richardson, H. E.			Control of tumourigenesis by the Scribble/Dlg/Lgl polarity module	ONCOGENE			English	Review						Scribble; Dlg; Lgl; cell polarity; tumour suppressors	LETHAL-GIANT-LARVAE; TUMOR-SUPPRESSOR PROTEIN; EPITHELIAL-CELL POLARITY; COMPARATIVE GENOMIC HYBRIDIZATION; UBIQUITIN-MEDIATED DEGRADATION; PDZ-CONTAINING PROTEINS; REGULATES SELF-RENEWAL; DOMAIN-BINDING MOTIF; NEURAL-TUBE DEFECTS; HUMAN HOMOLOG	The neoplastic tumour suppressors, Scribble, Dlg and Lgl, originally discovered in the vinegar fly Drosophila melanogaster, are currently being actively studied for their potential role in mammalian tumourigenesis. In Drosophila, these tumour suppressors function in a common genetic pathway to regulate apicobasal cell polarity and also play important roles in the control of cell proliferation, survival, differentiation and in cell migration/invasion. The precise mechanism by which Scribble, Dlg and Lgl function is not clear; however, they have been implicated in the regulation of signalling pathways, vesicle trafficking and in the Myosin II-actin cytoskeleton. We review the evidence for the involvement of Scribble, Dlg, and Lgl in cancer, and how the various functions ascribed to these tumour suppressors in Drosophila and mammalian systems may impact on the process of tumourigenesis.	[Humbert, P. O.; Galea, R.; Elsum, I.] Peter MacCallum Canc Inst, Div Res, Cell Cycle & Canc Genet Lab, Melbourne, Vic 8006, Australia; [Grzeschik, N. A.; Brumby, A. M.; Richardson, H. E.] Peter MacCallum Canc Inst, Div Res, Cell Cycle & Dev Lab, Melbourne, Vic 8006, Australia	Peter Maccallum Cancer Center; Peter Maccallum Cancer Center	Humbert, PO (corresponding author), Peter MacCallum Canc Inst, Div Res, Cell Cycle & Canc Genet Lab, Locked Bag 1,Abeckett St, Melbourne, Vic 8006, Australia.	patrick.humbert@petermac.org	Richardson, Helena E/A-8080-2013; Humbert, Patrick O/L-4264-2016	Richardson, Helena E/0000-0003-3852-4953; Humbert, Patrick O/0000-0002-1366-6691; Elsum, Imogen/0000-0003-4525-0727	Career Development Award; Australian NHMRC; Cancer Council Victoria; Association for International Cancer Research UK; Australian Cancer Council Victoria	Career Development Award; Australian NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); Association for International Cancer Research UK; Australian Cancer Council Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria)	We thank Linda Parsons and Sarah Russell for critical reading of the manuscript and numerous discussions. We also thank Shernaz Bamji, Lawrence Banks, Chris Doe, Scott Goode, Daniela Grifoni, Juergen Knoblich and Senthil Muthuswamy for communicating results before publication. We apologize to those authors whose work was not cited directly owing to space limitations. POH was supported by a Career Development Award, HER by a Senior Research Fellowship from the Australian NHMRC and IE by a Postgraduate Cancer Research Scholarship from the Cancer Council Victoria. This work was supported by grants from the Australian NHMRC (POH, AMB, NAG and HER), Association for International Cancer Research UK (POH) and Australian Cancer Council Victoria (POH and HER).	Adachi-Yamada T, 2004, J BIOCHEM, V136, P13, DOI 10.1093/jb/mvh099; Adey NB, 2000, CANCER RES, V60, P35; Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508; Albertson R, 2004, J CELL SCI, V117, P6061, DOI 10.1242/jcs.01525; Albertson R, 2003, NAT CELL BIOL, V5, P166, DOI 10.1038/ncb922; Anderson JM, 1996, CURR BIOL, V6, P382, DOI 10.1016/S0960-9822(02)00501-8; Aranda V, 2008, ONCOGENE, V27, P6878, DOI 10.1038/onc.2008.340; Arpin-Andre C, 2007, J BIOL CHEM, V282, P33132, DOI 10.1074/jbc.M702279200; Arquier N, 2001, DEVELOPMENT, V128, P2209; Assemat E, 2008, BBA-BIOMEMBRANES, V1778, P614, DOI 10.1016/j.bbamem.2007.08.029; Audebert S, 2004, CURR BIOL, V14, P987, DOI 10.1016/j.cub.2004.05.051; Barros CS, 2003, DEV CELL, V5, P829, DOI 10.1016/S1534-5807(03)00359-9; Beaucher M, 2007, DEV BIOL, V303, P625, DOI 10.1016/j.ydbio.2006.12.001; Beaucher M, 2007, DEV BIOL, V301, P287, DOI 10.1016/j.ydbio.2006.09.019; Betschinger J, 2005, CURR BIOL, V15, P276, DOI 10.1016/j.cub.2005.01.012; Betschinger J, 2006, CELL, V124, P1241, DOI 10.1016/j.cell.2006.01.038; Betschinger J, 2003, NATURE, V422, P326, DOI 10.1038/nature01486; Bialucha CU, 2007, J CELL BIOL, V178, P575, DOI 10.1083/jcb.200612022; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Bilder D, 2003, NAT CELL BIOL, V5, P53, DOI 10.1038/ncb897; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Blankenship JT, 2007, J CELL SCI, V120, P3099, DOI 10.1242/jcs.004770; Boone JQ, 2008, DEV NEUROBIOL, V68, P1185, DOI 10.1002/dneu.20648; Bossinger O, 2001, DEV BIOL, V230, P29, DOI 10.1006/dbio.2000.0113; Boussioutas A, 2003, CANCER RES, V63, P2569; Bowman SK, 2008, DEV CELL, V14, P535, DOI 10.1016/j.devcel.2008.03.004; Brumby A, 2004, GENETICS, V168, P227, DOI 10.1534/genetics.104.026617; Brumby AM, 2005, NAT REV CANCER, V5, P626, DOI 10.1038/nrc1671; Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; Bryant PJ, 2000, NAT CELL BIOL, V2, pE141, DOI 10.1038/35019616; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Caruana G, 2001, MOL CELL BIOL, V21, P1475, DOI 10.1128/MCB.21.5.1475-1483.2001; Caussinus E, 2005, NAT GENET, V37, P1125, DOI 10.1038/ng1632; Cavatorta AL, 2004, INT J CANCER, V111, P373, DOI 10.1002/ijc.20275; Chabu C, 2008, DEVELOPMENT, V135, P2739, DOI 10.1242/dev.024059; Clark PA, 2007, DEV DYNAM, V236, P3297, DOI 10.1002/dvdy.21381; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; de la Cova C, 2004, CELL, V117, P107, DOI 10.1016/S0092-8674(04)00214-4; Dollar GL, 2005, NATURE, V437, P1376, DOI 10.1038/nature04116; Dow LE, 2007, ONCOGENE, V26, P2272, DOI 10.1038/sj.onc.1210016; Dow LE, 2003, ONCOGENE, V22, P9225, DOI 10.1038/sj.onc.1207154; DOW LE, 2008, ONCOGENE        0721, DOI DOI 10.1038/ONC.2008.219; Dow LE, 2007, INT REV CYTOL, V262, P253, DOI 10.1016/S0074-7696(07)62006-3; Eder AM, 2005, P NATL ACAD SCI USA, V102, P12519, DOI 10.1073/pnas.0505641102; Etienne-Manneville S, 2005, J CELL BIOL, V170, P895, DOI 10.1083/jcb.200412172; Etienne-Manneville S, 2008, ONCOGENE, V27, P6970, DOI 10.1038/onc.2008.347; Even-Faitelson L, 2006, MOL BIOL CELL, V17, P2869, DOI 10.1091/mbc.e05-11-1001; Fan Y, 2008, DEV CELL, V14, P399, DOI 10.1016/j.devcel.2008.01.003; Farkas R, 2000, CELL DEATH DIFFER, V7, P89, DOI 10.1038/sj.cdd.4400621; Farnie G, 2007, STEM CELL REV, V3, P169, DOI 10.1007/s12015-007-0023-5; Franklin JL, 2005, EXP CELL RES, V303, P457, DOI 10.1016/j.yexcr.2004.10.007; Frese KK, 2006, EMBO J, V25, P1406, DOI 10.1038/sj.emboj.7601030; Frese KK, 2003, ONCOGENE, V22, P710, DOI 10.1038/sj.onc.1206151; Fuja TJ, 2004, CANCER RES, V64, P942, DOI 10.1158/0008-5472.CAN-03-2100; Funke L, 2005, ANNU REV BIOCHEM, V74, P219, DOI 10.1146/annurev.biochem.74.082803.133339; Gallant P, 2005, CANCER RES, V65, P6485, DOI 10.1158/0008-5472.CAN-05-1101; Gangar A, 2005, CURR BIOL, V15, P1136, DOI 10.1016/j.cub.2005.05.046; Garcia-Mata R, 2007, MOL CELL BIOL, V27, P8683, DOI 10.1128/MCB.00157-07; Gardiol D, 2006, INT J CANCER, V119, P1285, DOI 10.1002/ijc.21982; GATEFF E, 1974, ROUX ARCH DEV BIOL, V176, P23, DOI 10.1007/BF00577830; GATEFF E, 1978, SCIENCE, V200, P1448, DOI 10.1126/science.96525; Giebel B, 2006, CURR BIOL, V16, pR91, DOI 10.1016/j.cub.2006.01.022; Gonzalez C, 2007, NAT REV GENET, V8, P462, DOI 10.1038/nrg2103; Goode S, 2005, DEV DYNAM, V232, P855, DOI 10.1002/dvdy.20336; Goulev Y, 2008, CURR BIOL, V18, P435, DOI 10.1016/j.cub.2008.02.034; Grifoni D, 2007, ONCOGENE, V26, P5960, DOI 10.1038/sj.onc.1210389; Grifoni D, 2004, ONCOGENE, V23, P8688, DOI 10.1038/sj.onc.1208023; Grzeschik NA, 2007, DEV BIOL, V311, P106, DOI 10.1016/j.ydbio.2007.08.025; Hanada N, 2000, INT J CANCER, V86, P480, DOI 10.1002/(SICI)1097-0215(20000515)86:4<480::AID-IJC6>3.0.CO;2-6; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harris TJC, 2004, J CELL BIOL, V167, P135, DOI 10.1083/jcb.200406024; Harvey K, 2007, NAT REV CANCER, V7, P182, DOI 10.1038/nrc2070; Hawkins ED, 2008, ONCOGENE, V27, P7003, DOI 10.1038/onc.2008.350; Hering H, 2002, FEBS LETT, V521, P185, DOI 10.1016/S0014-5793(02)02831-4; Hirata A, 2004, VIROLOGY, V318, P327, DOI 10.1016/j.virol.2003.10.006; Hough CD, 1997, GENE DEV, V11, P3242, DOI 10.1101/gad.11.23.3242; Huh JR, 2004, CURR BIOL, V14, P1262, DOI 10.1016/j.cub.2004.06.015; Humbert PO, 2006, TRENDS CELL BIOL, V16, P622, DOI 10.1016/j.tcb.2006.10.005; Hutterer A, 2004, DEV CELL, V6, P845, DOI 10.1016/j.devcel.2004.05.003; Igaki T, 2006, CURR BIOL, V16, P1139, DOI 10.1016/j.cub.2006.04.042; Iizuka-Kogo A, 2007, DEVELOPMENT, V134, P1799, DOI 10.1242/dev.02830; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; Jang ACC, 2007, J MAMMARY GLAND BIOL, V12, P103, DOI 10.1007/s10911-007-9042-8; Januschke J, 2008, ONCOGENE, V27, P6994, DOI 10.1038/onc.2008.349; Javier RT, 2008, ONCOGENE, V27, P7031, DOI 10.1038/onc.2008.352; Kallay LM, 2006, J CELL BIOCHEM, V99, P647, DOI 10.1002/jcb.20992; Kamei Y, 2007, HUM PATHOL, V38, P1273, DOI 10.1016/j.humpath.2007.01.026; Karp CM, 2008, CANCER RES, V68, P4105, DOI 10.1158/0008-5472.CAN-07-6814; Kim SW, 2007, GENE CHROMOSOME CANC, V46, P1, DOI 10.1002/gcc.20384; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Klein TJ, 2005, ANNU REV CELL DEV BI, V21, P155, DOI 10.1146/annurev.cellbio.21.012704.132806; Klezovitch O, 2004, GENE DEV, V18, P559, DOI 10.1101/gad.1178004; Kojima Y, 2008, HUM PATHOL, V39, P824, DOI 10.1016/j.humpath.2007.11.001; Koppen M, 2001, NAT CELL BIOL, V3, P983, DOI 10.1038/ncb1101-983; Korshunov A, 2006, ACTA NEUROPATHOL, V111, P465, DOI 10.1007/s00401-006-0057-9; Kuphal S, 2006, ONCOGENE, V25, P103, DOI 10.1038/sj.onc.1209008; Lahuna O, 2005, EMBO J, V24, P1364, DOI 10.1038/sj.emboj.7600616; Langevin J, 2005, CURR BIOL, V15, P955, DOI 10.1016/j.cub.2005.04.054; Laprise P, 2004, J BIOL CHEM, V279, P10157, DOI 10.1074/jbc.M309843200; Lassmann S, 2007, J MOL MED-JMM, V85, P289, DOI 10.1007/s00109-006-0126-5; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee CY, 2006, NATURE, V439, P594, DOI 10.1038/nature04299; Legouis R, 2000, NAT CELL BIOL, V2, P415, DOI 10.1038/35017046; Legouis R, 2003, EMBO REP, V4, P1096, DOI 10.1038/sj.embor.7400006; Lin HT, 2004, GYNECOL ONCOL, V93, P422, DOI 10.1016/j.ygyno.2004.01.025; Lu H, 2005, NAT CELL BIOL, V7, P1232, DOI 10.1038/ncb1324; Ludford-Menting MJ, 2005, IMMUNITY, V22, P737, DOI 10.1016/j.immuni.2005.04.009; Mahoney ZX, 2006, P NATL ACAD SCI USA, V103, P19872, DOI 10.1073/pnas.0609326103; Mantovani F, 2001, J CELL SCI, V114, P4285; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Massimi P, 2006, ONCOGENE, V25, P4276, DOI 10.1038/sj.onc.1209457; Mathew D, 2002, CURR BIOL, V12, P531, DOI 10.1016/S0960-9822(02)00758-3; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; McMahon L, 2001, J CELL SCI, V114, P2265; MECHLER BM, 1985, EMBO J, V4, P1551, DOI 10.1002/j.1460-2075.1985.tb03816.x; Menut L, 2007, GENETICS, V177, P1667, DOI 10.1534/genetics.107.078360; Montcouquiol M, 2003, NATURE, V423, P173, DOI 10.1038/nature01618; Montcouquiol M, 2006, J NEUROSCI, V26, P5265, DOI 10.1523/JNEUROSCI.4680-05.2006; Moreno E, 2004, CELL, V117, P117, DOI 10.1016/S0092-8674(04)00262-4; Moreno-Bueno G, 2008, ONCOGENE, V27, P6958, DOI 10.1038/onc.2008.346; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Murdoch JN, 2003, HUM MOL GENET, V12, P87, DOI 10.1093/hmg/ddg014; Murdoch JN, 2001, GENOMICS, V78, P55, DOI 10.1006/geno.2001.6638; Musch A, 2002, MOL BIOL CELL, V13, P158, DOI 10.1091/mbc.01-10-0496; Nagasaka K, 2006, CANCER SCI, V97, P1217, DOI 10.1111/j.1349-7006.2006.00315.x; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Navarro C, 2005, ONCOGENE, V24, P4330, DOI 10.1038/sj.onc.1208632; Naylor TL, 2005, BREAST CANCER RES, V7, pR1186, DOI 10.1186/bcr1356; Nechiporuk T, 2007, DEV CELL, V13, P338, DOI 10.1016/j.devcel.2007.07.017; Nguyen ML, 2003, J VIROL, V77, P6957, DOI 10.1128/JVI.77.12.6957-6964.2003; Nguyen MM, 2003, MOL CELL BIOL, V23, P8970, DOI 10.1128/MCB.23.24.8970-8981.2003; Ninomiya H, 2008, NAT CELL BIOL, V10, P61, DOI 10.1038/ncb1669; Ohshiro T, 2000, NATURE, V408, P593, DOI 10.1038/35046087; Osmani N, 2006, CURR BIOL, V16, P2395, DOI 10.1016/j.cub.2006.10.026; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Peng CY, 2000, NATURE, V408, P596, DOI 10.1038/35046094; Perez-Garijo A, 2004, DEVELOPMENT, V131, P5591, DOI 10.1242/dev.01432; Plant PJ, 2003, NAT CELL BIOL, V5, P301, DOI 10.1038/ncb948; Qin Y, 2005, J CELL BIOL, V171, P1061, DOI 10.1083/jcb.200506094; Radisky D, 2001, SEMIN CANCER BIOL, V11, P87, DOI 10.1006/scbi.2000.0360; Regala RP, 2005, CANCER RES, V65, P8905, DOI 10.1158/0008-5472.CAN-05-2372; Roegiers F, 2005, MOL BIOL CELL, V16, P3480, DOI 10.1091/mbc.E05-03-0177; Roh MH, 2003, J CELL SCI, V116, P2895, DOI 10.1242/jcs.00500; Rolls MM, 2003, J CELL BIOL, V163, P1089, DOI 10.1083/jcb.200306079; Rosenberg M, 2006, MOL BIOL CELL, V17, P1364, DOI 10.1091/mbc.e05-07-0597; Roy M, 2007, CURR OPIN GENET DEV, V17, P52, DOI 10.1016/j.gde.2006.12.001; Ryoo HD, 2004, DEV CELL, V7, P491, DOI 10.1016/j.devcel.2004.08.019; Sans N, 2005, NAT CELL BIOL, V7, P1179, DOI 10.1038/ncb1325; Santoni MJ, 2002, TRENDS GENET, V18, P494, DOI 10.1016/S0168-9525(02)02738-5; Schimanski CC, 2005, ONCOGENE, V24, P3100, DOI 10.1038/sj.onc.1208520; Sonawane M, 2005, DEVELOPMENT, V132, P3255, DOI 10.1242/dev.01904; Sotillos S, 2004, J CELL BIOL, V166, P549, DOI 10.1083/jcb.200311031; Spaderna S, 2008, CANCER RES, V68, P537, DOI 10.1158/0008-5472.CAN-07-5682; Stephenson LM, 2007, MOL CELL BIOL, V27, P7574, DOI 10.1128/MCB.00439-07; STRAND D, 1994, J CELL BIOL, V127, P1361, DOI 10.1083/jcb.127.5.1361; STRAND D, 1995, ONCOGENE, V11, P291; Su ZW, 2001, BIOCHEMISTRY-US, V40, P3606, DOI 10.1021/bi010082j; SUN Y, SCRIBBLE INTER UNPUB; Suzuki T, 1999, ONCOGENE, V18, P5967, DOI 10.1038/sj.onc.1203008; Szafranski P, 2007, DEV DYNAM, V236, P364, DOI 10.1002/dvdy.21020; Takizawa S, 2006, GENES CELLS, V11, P453, DOI 10.1111/j.1365-2443.2006.00954.x; Tanentzapf G, 2003, NAT CELL BIOL, V5, P46, DOI 10.1038/ncb896; Tapper J, 2001, CANCER GENET CYTOGEN, V128, P1, DOI 10.1016/S0165-4608(01)00386-7; Tepass U, 2001, ANNU REV GENET, V35, P747, DOI 10.1146/annurev.genet.35.102401.091415; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thomas M, 2005, ONCOGENE, V24, P6222, DOI 10.1038/sj.onc.1208757; Thomas M, 2008, ONCOGENE, V27, P7018, DOI 10.1038/onc.2008.351; Uhlirova M, 2005, P NATL ACAD SCI USA, V102, P13123, DOI 10.1073/pnas.0504170102; Uhlirova M, 2006, EMBO J, V25, P5294, DOI 10.1038/sj.emboj.7601401; Vaccari T, 2008, J CELL BIOL, V180, P755, DOI 10.1083/jcb.200708127; Valiente M, 2005, J BIOL CHEM, V280, P28936, DOI 10.1074/jbc.M504761200; Velthuis AJWT, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-129; Vermeer PD, 2003, NATURE, V422, P322, DOI 10.1038/nature01440; Vervenne HBVK, 2008, DEV BIOL, V320, P267, DOI 10.1016/j.ydbio.2008.05.529; Vidal M, 2006, CURR OPIN GENET DEV, V16, P10, DOI 10.1016/j.gde.2005.12.004; Wada H, 2005, DEVELOPMENT, V132, P2273, DOI 10.1242/dev.01810; Wang H, 2006, GENE DEV, V20, P3453, DOI 10.1101/gad.1487506; Wasenius VM, 2003, CLIN CANCER RES, V9, P68; Watson RA, 2002, CARCINOGENESIS, V23, P1791, DOI 10.1093/carcin/23.11.1791; Wenthold RJ, 2003, ANNU REV PHARMACOL, V43, P335, DOI 10.1146/annurev.pharmtox.43.100901.135803; Whiteman EL, 2008, ONCOGENE, V27, P3875, DOI 10.1038/onc.2008.9; Wirtz-Peitz F, 2006, TRENDS CELL BIOL, V16, P234, DOI 10.1016/j.tcb.2006.03.006; WIRTZPEITZ F, 2008, CELL IN PRESS; Wodarz A, 2000, CURR BIOL, V10, pR624, DOI 10.1016/S0960-9822(00)00658-8; Wodarz A, 2007, NAT CELL BIOL, V9, P1016, DOI 10.1038/ncb433; WOLF AM, 2008, J NEUROSCI, V3456, P3; WOODHOUSE E, 1994, CELL GROWTH DIFFER, V5, P151; Woodhouse E, 1998, DEV GENES EVOL, V207, P542, DOI 10.1007/s004270050145; WOODS DF, 1989, DEV BIOL, V134, P222, DOI 10.1016/0012-1606(89)90092-4; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; Xia J, 2000, NEURON, V28, P499, DOI 10.1016/S0896-6273(00)00128-8; Yamamoto Y, 2004, ONCOGENE, V23, P3889, DOI 10.1038/sj.onc.1207495; Yamanaka T, 2003, CURR BIOL, V13, P734, DOI 10.1016/S0960-9822(03)00244-6; Yamanaka T, 2008, FRONT BIOSCI-LANDMRK, V13, P6693, DOI 10.2741/3182; Yamanaka T, 2006, J CELL SCI, V119, P2107, DOI 10.1242/jcs.02938; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yasumi M, 2005, J BIOL CHEM, V280, P6761, DOI 10.1074/jbc.C400440200; Yeaman C, 1999, CURR BIOL, V9, pR515, DOI 10.1016/S0960-9822(99)80324-8; Zarbalis K, 2004, PLOS BIOL, V2, P1177, DOI 10.1371/journal.pbio.0020219; Zeitler J, 2004, J CELL BIOL, V167, P1137, DOI 10.1083/jcb.200407158; Zeng Q, 2008, CANCER CELL, V13, P188, DOI 10.1016/j.ccr.2008.02.011; Zhang X, 2007, NAT CELL BIOL, V9, P743, DOI 10.1038/ncb1603; Zhang XY, 2005, J CELL BIOL, V170, P273, DOI 10.1083/jcb.200502055; Zhao M, 2008, GENETICS, V178, P1947, DOI 10.1534/genetics.108.086983	206	235	243	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2008	27	55					6888	6907		10.1038/onc.2008.341	http://dx.doi.org/10.1038/onc.2008.341			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375IU	19029932				2022-12-17	WOS:000261108200003
J	Sato, N; Fukushima, N; Maehara, N; Matsubayashi, H; Koopmann, J; Su, GH; Hruban, RH; Goggins, M				Sato, N; Fukushima, N; Maehara, N; Matsubayashi, H; Koopmann, J; Su, GH; Hruban, RH; Goggins, M			SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions	ONCOGENE			English	Article						SPARC; methylation; pancreatic cancer; tumor-stromal interaction	CELL-CYCLE PROGRESSION; SPARC-NULL MICE; GENE-EXPRESSION; NEOPLASTIC PROGRESSION; DUCTAL ADENOCARCINOMA; DESMOPLASTIC RESPONSE; CPG ISLANDS; CANCER; INVASION; PROTEIN	Deregulated expression of SPARC/osteonectin, a secreted glycoprotein with multiple biological functions, has been associated with the progression of various cancers. Using microarrays, we previously identified SPARC as one of the genes induced by treatment with a DNA methylation inhibitor in pancreatic cancer cells. We therefore analysed the expression pattern and methylation status of the SPARC gene in pancreatic cancer. Gene expression profiting by oligonucleotide microarray and reverse transcription-PCR analyses demonstrated that SPARC mRNA was expressed in non-neoplastic pancreatic ductal epithelial cells, but was not expressed in a majority of pancreatic cancer cell lines. The loss of SPARC expression was associated with aberrant hypermethylation of its CpG island. Immunohistochemical labeling revealed that the SPARC protein was overexpressed in the stromal fibroblasts immediately adjacent to the neoplastic epithelium in primary pancreatic cancers, but rarely expressed in the cancers themselves. Primary fibroblasts derived from pancreatic cancer strongly expressed SPARC mRNA and secreted SPARC protein into the conditioned media, and treatment of pancreatic cancer cells with exogenous SPARC resulted in growth suppression. SPARC expression in fibroblasts from noncancerous pancreatic tissue was augmented by coculture with pancreatic cancer cells. These findings suggest that SPARC is a frequent target for aberrant methylation in pancreatic cancer and that SPARC expression in fibroblasts adjacent to pancreatic cancer cells is regulated through tumor-stromal interactions.	Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Goggins, M (corresponding author), Johns Hopkins Med Inst, Dept Pathol, 632 Ross Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.	mgoggins@jhmi.edu		Su, Gloria/0000-0002-5158-6019	NCI NIH HHS [CA62924] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA062924] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLAHCENE A, 1995, AM J PATHOL, V146, P95; Bradshaw AD, 1999, MOL BIOL CELL, V10, P1569, DOI 10.1091/mbc.10.5.1569; Bradshaw AD, 2001, J CLIN INVEST, V107, P1049, DOI 10.1172/JCI12939; Brekken RA, 2003, J CLIN INVEST, V111, P487, DOI 10.1172/JCI200316804; Brekken Rolf A., 2001, Matrix Biology, V19, P816; Briggs J, 2002, ONCOGENE, V21, P7077, DOI 10.1038/sj.onc.1205857; Dhanesuan N, 2002, BREAST CANCER RES TR, V75, P73, DOI 10.1023/A:1016536725958; Francki A, 1999, J BIOL CHEM, V274, P32145, DOI 10.1074/jbc.274.45.32145; Francki A, 2003, J CELL BIOCHEM, V88, P802, DOI 10.1002/jcb.10424; Fukushima N, 2003, CANCER BIOL THER, V2, P78; Fukushima N, 2002, AM J PATHOL, V160, P1573, DOI 10.1016/S0002-9440(10)61104-2; FUNK SE, 1991, P NATL ACAD SCI USA, V88, P2648, DOI 10.1073/pnas.88.7.2648; FUNK SE, 1993, J CELL PHYSIOL, V154, P53, DOI 10.1002/jcp.1041540108; Goggins M, 2000, J SURG ONCOL, V74, P243, DOI 10.1002/1096-9098(200008)74:4<243::AID-JSO1>3.0.CO;2-C; HAHN SA, 1995, CANCER RES, V55, P4670; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Iacobuzio-Donahue CA, 2003, AM J PATHOL, V162, P1151, DOI 10.1016/S0002-9440(10)63911-9; Iacobuzio-Donahue CA, 2002, CANCER RES, V62, P5351; Iacobuzio-Donahue CA, 2002, AM J PATHOL, V160, P91, DOI 10.1016/S0002-9440(10)64353-2; Jacob K, 1999, CANCER RES, V59, P4453; Jansen M, 2002, CANCER BIOL THER, V1, P293, DOI 10.4161/cbt.84; Jendraschak E, 1996, SEMIN CANCER BIOL, V7, P139, DOI 10.1006/scbi.1996.0019; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kern SE, 2000, MED CLIN N AM, V84, P691, DOI 10.1016/S0025-7125(05)70251-0; Le Bail B, 1999, J PATHOL, V189, P46; Ledda F, 1997, J INVEST DERMATOL, V108, P210, DOI 10.1111/1523-1747.ep12334263; Maehara N, 2001, BRIT J CANCER, V84, P864, DOI 10.1054/bjoc.2000.1682; Massi D, 1999, HUM PATHOL, V30, P339, DOI 10.1016/S0046-8177(99)90014-X; Matsubayashi H, 2003, CLIN CANCER RES, V9, P1446; Mok SC, 1996, ONCOGENE, V12, P1895; Paley PJ, 2000, GYNECOL ONCOL, V78, P336, DOI 10.1006/gyno.2000.5894; Porte H, 1998, CLIN CANCER RES, V4, P1375; PORTE H, 1995, INT J CANCER, V64, P70, DOI 10.1002/ijc.2910640114; PORTER PL, 1995, J HISTOCHEM CYTOCHEM, V43, P791, DOI 10.1177/43.8.7622842; Rempel SA, 1999, CLIN CANCER RES, V5, P237; Rosty C, 2002, CANCER RES, V62, P1868; Rosty C, 2002, HEMATOL ONCOL CLIN N, V16, P37, DOI 10.1016/S0889-8588(01)00007-7; Rosty C, 2002, AM J PATHOL, V160, P45, DOI 10.1016/S0002-9440(10)64347-7; Ryu B, 2001, CANCER RES, V61, P1833; Sato N, 2003, JNCI-J NATL CANCER I, V95, P327, DOI 10.1093/jnci/95.4.327; Sato N, 2002, GASTROENTEROLOGY, V123, P365, DOI 10.1053/gast.2002.34160; SATO N, 2003, IN PRESS CANC RES; Schultz C, 2002, CANCER RES, V62, P6270; Thomas R, 2000, CLIN CANCER RES, V6, P1140; Ueki T, 2000, CANCER RES, V60, P1835; Ueki T, 2002, ONCOGENE, V21, P2114, DOI 10.1038/sj.onc.1205275; Ueki T, 2001, CANCER RES, V61, P8540; WEWER UM, 1988, AM J PATHOL, V132, P345; Yamanaka M, 2001, J UROLOGY, V166, P2495, DOI 10.1016/S0022-5347(05)65623-6; Yan Q, 1999, J HISTOCHEM CYTOCHEM, V47, P1495, DOI 10.1177/002215549904701201; Yiu GK, 2001, AM J PATHOL, V159, P609, DOI 10.1016/S0002-9440(10)61732-4	51	235	248	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	2003	22	32					5021	5030		10.1038/sj.onc.1206807	http://dx.doi.org/10.1038/sj.onc.1206807			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902985				2022-12-17	WOS:000184578900010
J	Ramana, CV; Chatterjee-Kishore, M; Nguyen, H; Stark, GR				Ramana, CV; Chatterjee-Kishore, M; Nguyen, H; Stark, GR			Complex roles of Stat1 in regulating gene expression	ONCOGENE			English	Review						constitutive transcription; negative regulation; interferons; growth factors; crosstalk	INTERFERON-GAMMA RECEPTOR; PROTEIN-TYROSINE-PHOSPHATASE; KINASE INHIBITOR P21(WAF1/CIP1); NECROSIS-FACTOR-ALPHA; SMOOTH-MUSCLE CELLS; IFN-GAMMA; GROWTH-FACTOR; DNA-BINDING; TRANSCRIPTION FACTOR; SIGNAL TRANSDUCER	Stat1 is a fascinating and complex protein with multiple, yet contrasting transcriptional functions. Upon activation, it drives the expression of many genes but also suppresses the transcription of others, These opposing characteristics also apply to its role in facilitating crosstalk between signal transduction pathways, as it participates in both synergistic activation and inhibition of gene expression, Stat1 is a functional transcription factor even in the absence of inducer-mediated activation, participating in the constitutive expression of some genes. This review summarizes the well studied involvement of Stat1 in IFN-dependent and growth factor-dependent signaling and then describes the roles of Stat1 in positive, negative and constitutive regulation of gene expression as well as its participation in crosstalk between signal transduction pathways.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Stark, GR (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.			chilakamarti, ramana/0000-0002-5153-8252				Abril E, 1998, CANCER IMMUNOL IMMUN, V47, P113, DOI 10.1007/s002620050511; Ala-aho R, 2000, ONCOGENE, V19, P248, DOI 10.1038/sj.onc.1203306; ASHIZAWA K, 1989, J CLIN ENDOCR METAB, V69, P475, DOI 10.1210/jcem-69-2-475; Bach EA, 1996, MOL CELL BIOL, V16, P3214; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; BENNETT MR, 1994, CIRC RES, V74, P525, DOI 10.1161/01.RES.74.3.525; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; BLUYSSEN HAR, 1995, P NATL ACAD SCI USA, V92, P5645, DOI 10.1073/pnas.92.12.5645; Bluyssen HAR, 1997, J BIOL CHEM, V272, P4600, DOI 10.1074/jbc.272.7.4600; Boehm U, 1998, J IMMUNOL, V161, P6715; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Chatterjee-Kishore M, 1998, J BIOL CHEM, V273, P16177, DOI 10.1074/jbc.273.26.16177; Chelbi-Alix MK, 1999, LEUKEMIA, V13, P1167, DOI 10.1038/sj.leu.2401469; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; DALE TC, 1989, EMBO J, V8, P831, DOI 10.1002/j.1460-2075.1989.tb03444.x; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1993, J BIOL CHEM, V268, P6593; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Gao JJ, 1997, J BIOL CHEM, V272, P1226, DOI 10.1074/jbc.272.2.1226; Gauzzi MC, 1996, J BIOL CHEM, V271, P20494, DOI 10.1074/jbc.271.34.20494; Gollob JA, 1999, J IMMUNOL, V162, P4472; GouilleuxGruart V, 1996, BLOOD, V87, P1692; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; Han MC, 1997, KSME INT J, V11, P1; Han YL, 1996, J BIOL CHEM, V271, P5947, DOI 10.1074/jbc.271.10.5947; Haque SJ, 1997, P NATL ACAD SCI USA, V94, P8563, DOI 10.1073/pnas.94.16.8563; Haspel RL, 1999, P NATL ACAD SCI USA, V96, P10188, DOI 10.1073/pnas.96.18.10188; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Horvath CM, 1996, MOL CELL BIOL, V16, P6957; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; Ikeda Y, 1999, BIOCHEM BIOPH RES CO, V262, P494, DOI 10.1006/bbrc.1999.1226; Illa I, 1997, AM J PATHOL, V151, P81; IMAM AMA, 1990, NUCLEIC ACIDS RES, V18, P6573, DOI 10.1093/nar/18.22.6573; IOZZO RV, 1994, BIOCHEM J, V302, P625, DOI 10.1042/bj3020625; JOHN J, 1991, MOL CELL BIOL, V11, P4189, DOI 10.1128/MCB.11.8.4189; Johnson LR, 1999, AM J PHYSIOL-CELL PH, V276, pC419, DOI 10.1152/ajpcell.1999.276.2.C419; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Kaplan DH, 1996, J BIOL CHEM, V271, P9, DOI 10.1074/jbc.271.1.9; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Kominsky S, 1998, ONCOGENE, V17, P2973, DOI 10.1038/sj.onc.1202217; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Korzus E, 1997, J BIOL CHEM, V272, P1188, DOI 10.1074/jbc.272.2.1188; KOTENKO SV, 1995, J BIOL CHEM, V270, P20915, DOI 10.1074/jbc.270.36.20915; Kovarik P, 1999, P NATL ACAD SCI USA, V96, P13956, DOI 10.1073/pnas.96.24.13956; Kovarik P, 1998, EMBO J, V17, P3660, DOI 10.1093/emboj/17.13.3660; Krishnan K, 1996, ONCOGENE, V13, P125; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Kung AWC, 1998, J MOL ENDOCRINOL, V20, P293, DOI 10.1677/jme.0.0200293; Lackmann M, 1998, GROWTH FACTORS, V16, P39, DOI 10.3109/08977199809017490; Leaman DW, 1996, MOL CELL BIOL, V16, P369; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; Lee CK, 1999, J EXP MED, V190, P1451, DOI 10.1084/jem.190.10.1451; Lee CK, 2000, J IMMUNOL, V164, P1286, DOI 10.4049/jimmunol.164.3.1286; Lewis M, 1999, J CELL BIOCHEM, V72, P373, DOI 10.1002/(SICI)1097-4644(19990301)72:3<373::AID-JCB7>3.0.CO;2-N; Li XX, 1996, J BIOL CHEM, V271, P5790, DOI 10.1074/jbc.271.10.5790; Li XX, 1998, BIOCHIMIE, V80, P703, DOI 10.1016/S0300-9084(99)80023-6; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; MELAMED D, 1993, MOL CELL BIOL, V13, P5255, DOI 10.1128/MCB.13.9.5255; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Min W, 1996, J IMMUNOL, V156, P3174; Min W, 1998, CIRC RES, V83, P815, DOI 10.1161/01.RES.83.8.815; Miyazaki A, 1999, ENDOCRINOLOGY, V140, P4214, DOI 10.1210/en.140.9.4214; Ogbourne S, 1998, BIOCHEM J, V331, P1; Ohe K, 1996, MOL ENDOCRINOL, V10, P826, DOI 10.1210/me.10.7.826; OHMORI Y, 1994, J IMMUNOL, V153, P2204; Ohmori Y, 1997, J BIOL CHEM, V272, P14899, DOI 10.1074/jbc.272.23.14899; OUCHI T, 2000, IN PRESS P NATL ACAD; Pine R, 1997, NUCLEIC ACIDS RES, V25, P4346, DOI 10.1093/nar/25.21.4346; Qin HW, 1998, J IMMUNOL, V161, P6664; QURESHI SA, 1995, P NATL ACAD SCI USA, V92, P3829, DOI 10.1073/pnas.92.9.3829; Ramana CV, 2000, EMBO J, V19, P263, DOI 10.1093/emboj/19.2.263; Richer JK, 1998, J BIOL CHEM, V273, P31317, DOI 10.1074/jbc.273.47.31317; Sachsenmaier C, 1999, ONCOGENE, V18, P3583, DOI 10.1038/sj.onc.1202694; SAKATSUME M, 1995, J BIOL CHEM, V270, P17528, DOI 10.1074/jbc.270.29.17528; Sampath D, 1999, J CLIN INVEST, V103, P1353, DOI 10.1172/JCI6130; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; Sekimoto T, 1996, J BIOL CHEM, V271, P31017, DOI 10.1074/jbc.271.49.31017; Sharma B, 1998, J BIOL CHEM, V273, P4642, DOI 10.1074/jbc.273.8.4642; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Shimoda K, 1997, BLOOD, V90, P597, DOI 10.1182/blood.V90.2.597.597_597_604; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; Sibinga NES, 1999, J BIOL CHEM, V274, P12139, DOI 10.1074/jbc.274.17.12139; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; Stancato LF, 1996, J BIOL CHEM, V271, P4134; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Sun WH, 1998, BLOOD, V91, P570, DOI 10.1182/blood.V91.2.570.570_570_576; Takaoka A, 1999, EMBO J, V18, P2480, DOI 10.1093/emboj/18.9.2480; TAMAI K, 1995, J BIOL CHEM, V270, P392, DOI 10.1074/jbc.270.1.392; TANNENBAUM CS, 1993, J IMMUNOL, V151, P6833; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; VAIRO G, 1995, ONCOGENE, V10, P1969; Venkataraman C, 1999, J IMMUNOL, V162, P4053; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; Vignais ML, 1999, MOL CELL BIOL, V19, P3727; Vinkemeier U, 1998, SCIENCE, V279, P1048, DOI 10.1126/science.279.5353.1048; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; WeberNordt RM, 1996, BLOOD, V88, P809; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; White LC, 1996, IMMUNITY, V5, P365, DOI 10.1016/S1074-7613(00)80262-9; Wong LH, 1997, J BIOL CHEM, V272, P28779, DOI 10.1074/jbc.272.45.28779; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Yie JM, 1999, P NATL ACAD SCI USA, V96, P13108, DOI 10.1073/pnas.96.23.13108; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416; Yuan WH, 1999, J CELL PHYSIOL, V179, P97, DOI 10.1002/(SICI)1097-4652(199904)179:1<97::AID-JCP12>3.3.CO;2-5; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4; Zhu XJ, 1997, MOL CELL BIOL, V17, P6618, DOI 10.1128/MCB.17.11.6618	124	235	243	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2000	19	21					2619	2627		10.1038/sj.onc.1203525	http://dx.doi.org/10.1038/sj.onc.1203525			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321MN	10851061				2022-12-17	WOS:000087459400018
J	Sharma, SV; Agatsuma, T; Nakano, H				Sharma, SV; Agatsuma, T; Nakano, H			Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol	ONCOGENE			English	Article						radicicol; molecular chaperones; transformation suppression; HSP90; Raf	HEAT-SHOCK PROTEIN; KINASE KINASE KINASE; ROUS-SARCOMA VIRUS; MAP KINASE; FARNESYLTRANSFERASE INHIBITORS; HETEROPROTEIN COMPLEX; TYROSINE KINASE; RAS; RAF-1; ACTIVATION	Radicicol, a macrocyclic anti-fungal antibiotic, has the ability to suppress transformation by diverse oncogenes such as Src, Ras and Mos. Despite this useful property, the mechanism by which radicicol exerts its anti-transformation effects is currently unknown, To understand the transformation-suppressing effects of radicicol, a biotinylated derivative of radicicol was chemically synthesized and used as a probe in a Western-blot format to visualize cellular proteins that interact with radicicol, In transformed and untransformed mouse fibroblasts, the most prominent cellular protein that bound to radicicol had a molecular weight of approximately 90 kDa, Further analysis revealed that this protein was the mouse homologue of the 90 kDa heat shock protein (HSP90). This was confirmed by demonstrating the ability of radicicol to specifically bind purified human HSP90, Specificity of binding was demonstrated by the inhibition of binding of biotinylated radicicol by the native drug, Taken together with other studies the present observations suggest that the anti-transformation effects of radicicol may be mediated, at least in part, by the association of radicicol with HSP90 and the consequent dissociation of the Raf/HSP90 complex leading to the attenuation of the Ras/MAP kinase signal transduction pathway.	Univ Tennessee, Dept Microbiol & Immunol, Memphis, TN 38163 USA; Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, Tokyo 194, Japan	University of Tennessee System; University of Tennessee Health Science Center; Kyowa Kirin Ltd	Sharma, SV (corresponding author), Univ Tennessee, Dept Microbiol & Immunol, 858 Madison Ave, Memphis, TN 38163 USA.				NCI NIH HHS [R01 CA55983] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055983] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An WG, 1997, CANCER CHEMOTH PHARM, V40, P60, DOI 10.1007/s002800050626; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; AYER WA, 1980, CAN J MICROBIOL, V26, P766, DOI 10.1139/m80-133; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; Gibbs JB, 1996, BREAST CANCER RES TR, V38, P75, DOI 10.1007/BF01803786; GRENERT JP, 1997, IN PRESS J BIOL CHEM; Hartson SD, 1996, BIOCHEMISTRY-US, V35, P13451, DOI 10.1021/bi961332c; Hunter T, 1997, TRENDS CELL BIOL, V7, P157, DOI 10.1016/S0962-8924(97)01027-1; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Johnson JL, 1997, CELL, V90, P201, DOI 10.1016/S0092-8674(00)80327-X; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Koblan KS, 1996, BIOCHEM SOC T, V24, P688, DOI 10.1042/bst0240688; KWON HJ, 1995, J BIOCHEM-TOKYO, V118, P221, DOI 10.1093/oxfordjournals.jbchem.a124882; KWON HJ, 1992, CANCER RES, V52, P6926; KWON HJ, 1992, BIOSCI BIOTECH BIOCH, V56, P538; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Marais R, 1996, CANCER SURV, V27, P101; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MARSHALL CJ, 1995, ANN ONCOL, V6, P63; MARSHALL M, 1995, MOL REPROD DEV, V42, P493, DOI 10.1002/mrd.1080420418; MIMNAUGH EG, 1995, J BIOL CHEM, V270, P28654, DOI 10.1074/jbc.270.48.28654; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MOORE SK, 1990, DNA CELL BIOL, V9, P387, DOI 10.1089/dna.1990.9.387; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Oliff A, 1996, SCI AM, V275, P144, DOI 10.1038/scientificamerican0996-144; OPPERMANN H, 1981, P NATL ACAD SCI-BIOL, V78, P1067, DOI 10.1073/pnas.78.2.1067; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Prodromou C, 1997, NAT STRUCT BIOL, V4, P477, DOI 10.1038/nsb0697-477; REBBE NF, 1989, J BIOL CHEM, V264, P15006; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; Schulte TW, 1996, MOL CELL BIOL, V16, P5839; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; Sharma SV, 1997, ONCOGENE, V14, P2641, DOI 10.1038/sj.onc.1201115; Soga S, 1998, J BIOL CHEM, V273, P822, DOI 10.1074/jbc.273.2.822; Stancato LF, 1997, J BIOL CHEM, V272, P4013, DOI 10.1074/jbc.272.7.4013; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; ZHAO JF, 1995, ONCOGENE, V11, P161	45	235	239	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 21	1998	16	20					2639	2645		10.1038/sj.onc.1201790	http://dx.doi.org/10.1038/sj.onc.1201790			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN934	9632140				2022-12-17	WOS:000073698200008
J	Li, T; Xie, J; Shen, C; Cheng, D; Shi, Y; Wu, Z; Deng, X; Chen, H; Shen, B; Peng, C; Li, H; Zhan, Q; Zhu, Z				Li, T.; Xie, J.; Shen, C.; Cheng, D.; Shi, Y.; Wu, Z.; Deng, X.; Chen, H.; Shen, B.; Peng, C.; Li, H.; Zhan, Q.; Zhu, Z.			RETRACTED: Upregulation of long noncoding RNA ZEB1-AS1 promotes tumor metastasis and predicts poor prognosis in hepatocellular carcinoma (Retracted article. See vol. 41, pg. 4839, 2022)	ONCOGENE			English	Article; Retracted Publication							GENE; EXPRESSION; SEQUENCE; TRANSCRIPTION; PROGRESSION; CHROMATIN; MALAT1; ROLES; HULC; EMT	Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. Despite progress in diagnostics and treatment of HCC, its prognosis remains poor. Emerging studies showed that long noncoding RNAs (lncRNAs) have crucial regulatory roles in cancer biology. In the current study, differentially expressed lncRNAs between HCC and paired non-tumor tissues were identified using microarrays. The effects of a specific differentially expressed lncRNA (termed ZEB1-AS1) on tumor progression were investigated in vitro and in vivo. We found that ZEB1-AS1 is frequently upregulated in HCC samples, especially in metastatic tumor tissues. DNA methylation analysis shows a tumor-specific ZEB1-AS1 promoter hypomethylation. Aberrant methylation is tightly correlated with overexpression of ZEB1-AS1 in HCC. Patients with ZEB1-AS1 hypomethylation or with high ZEB1-AS1 expression have poor recurrence-free survival. Functionally, ZEB1-AS1 promotes tumor growth and metastasis, acts as an oncogene in HCC. The ZEB1-AS1 gene is located in physical contiguity with ZEB1 and positively regulates the ZEB1 expression. ZEB1 inhibition partially abrogates ZEB1-AS1-induced epithelial to mesenchymal transition (EMT) and cancer metastasis. Our results provide novel insights into the function of lncRNA-driven hepatocarcinogenesis, highlight the important role of ZEB1-AS1 and ZEB1 in HCC progression, and indicate that ZEB1-AS1 may be served as a valuable prognostic biomarker for HCC.	[Li, T.; Xie, J.; Shen, C.; Cheng, D.; Shi, Y.; Wu, Z.; Deng, X.; Chen, H.; Shen, B.; Peng, C.; Li, H.; Zhan, Q.; Zhu, Z.] Shanghai Jiao Tong Univ, Dept Hepatobiliopancreat Surg, Shanghai Inst Digest Surg, Rui Jin Hosp, Ruijin Er Rd 197, Shanghai 200025, Peoples R China	Shanghai Jiao Tong University	Zhu, Z (corresponding author), Shanghai Jiao Tong Univ, Dept Hepatobiliopancreat Surg, Shanghai Inst Digest Surg, Rui Jin Hosp, Ruijin Er Rd 197, Shanghai 200025, Peoples R China.	zhuzhecheng@126.com		WU, Zhichong/0000-0002-6166-755X; Peng, Chenghong/0000-0002-5573-7873				Abdulghani J, 2008, AM J PATHOL, V172, P1717, DOI 10.2353/ajpath.2008.071054; Babajko S, 2009, CELLS TISSUES ORGANS, V189, P115, DOI 10.1159/000151748; Befeler AS, 2002, GASTROENTEROLOGY, V122, P1609, DOI 10.1053/gast.2002.33411; Braconi C, 2011, ONCOGENE, V30, P4750, DOI 10.1038/onc.2011.193; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Du Z, 2013, NAT STRUCT MOL BIOL, V20, P908, DOI 10.1038/nsmb.2591; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Fan Y, 2014, CLIN CANCER RES, V20, P1531, DOI 10.1158/1078-0432.CCR-13-1455; Fatica A, 2014, NAT REV GENET, V15, P7, DOI 10.1038/nrg3606; Gong CG, 2011, NATURE, V470, P284, DOI 10.1038/nature09701; Guo F, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/1756-8722-7-19; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Gutschner T, 2013, CANCER RES, V73, P1180, DOI 10.1158/0008-5472.CAN-12-2850; Hammerle M, 2013, HEPATOLOGY, V58, P1703, DOI 10.1002/hep.26537; Hasuwa H, 2013, SCIENCE, V341, P71, DOI 10.1126/science.1237999; He Y, 2014, CANCER LETT, V344, P20, DOI 10.1016/j.canlet.2013.10.021; Ho MY, 2013, CANCER RES, V73, P439, DOI 10.1158/0008-5472.CAN-12-2220; Huang JL, 2014, CARCINOGENESIS, V35, P507, DOI 10.1093/carcin/bgt405; Khaitan D, 2011, CANCER RES, V71, P3852, DOI 10.1158/0008-5472.CAN-10-4460; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Kurihara M, 2014, J MOL BIOL, V426, P3069, DOI 10.1016/j.jmb.2014.06.018; Lepoivre C, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-914; Majid S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067686; Malkowski Piotr, 2006, Przegl Epidemiol, V60, P731; Panzitt K, 2007, GASTROENTEROLOGY, V132, P330, DOI 10.1053/j.gastro.2006.08.026; Prensner JR, 2011, NAT BIOTECHNOL, V29, P742, DOI 10.1038/nbt.1914; Quagliata L, 2014, HEPATOLOGY, V59, P911, DOI 10.1002/hep.26740; Sanchez-Tillo E, 2011, P NATL ACAD SCI USA, V108, P19204, DOI 10.1073/pnas.1108977108; Sanchez-Tillo E, 2011, AM J CANCER RES, V1, P897; Shah PP, 2015, ONCOGENE, V34, P1709, DOI 10.1038/onc.2014.97; Soini Y, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-73; Sun L, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt646; Tsai MC, 2011, CANCER RES, V71, P3, DOI 10.1158/0008-5472.CAN-10-2483; Valastyan S, 2010, CANCER RES, V70, P5147, DOI 10.1158/0008-5472.CAN-10-0410; Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150; Wang KC, 2011, NATURE, V472, P120, DOI 10.1038/nature09819; Wang WJ, 2014, BMC MED GENOMICS, V7, DOI 10.1186/1755-8794-7-49; Wei W, 2011, TRENDS GENET, V27, P267, DOI 10.1016/j.tig.2011.04.002; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Wu WJ, 2013, GASTROENTEROLOGY, V144, P956, DOI 10.1053/j.gastro.2013.01.019; Xia LM, 2013, HEPATOLOGY, V57, P610, DOI 10.1002/hep.26029; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Yang JD, 2010, NAT REV GASTRO HEPAT, V7, P448, DOI 10.1038/nrgastro.2010.100; Yang WT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088827; Yang Z, 2011, ANN SURG ONCOL, V18, P1243, DOI 10.1245/s10434-011-1581-y	45	234	249	3	74	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2016	35	12					1575	1584		10.1038/onc.2015.223	http://dx.doi.org/10.1038/onc.2015.223			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RJ	26073087				2022-12-17	WOS:000373063600010
J	Gerondakis, S; Grumont, R; Gugasyan, R; Wong, L; Isomura, I; Ho, W; Banerjee, A				Gerondakis, S.; Grumont, R.; Gugasyan, R.; Wong, L.; Isomura, I.; Ho, W.; Banerjee, A.			Unravelling the complexities of the NF-kappa B signalling pathway using mouse knockout and transgenic models	ONCOGENE			English	Review						NF-kappa B; IKK; I kappa B; knockout mice; transgenics	REL TRANSCRIPTION FACTORS; CELL-INTRINSIC EXPRESSION; SEVERE LIVER DEGENERATION; C-H TRANSCRIPTION; MATURE T-CELLS; MICE LACKING; IKK-BETA; TARGETED DISRUPTION; DENDRITIC CELLS; GERMINAL CENTER	The nuclear factor-kappa B (NF-kappa B) signalling pathway serves a crucial role in regulating the transcriptional responses of physiological processes that include cell division, cell survival, differentiation, immunity and inflammation. Here we outline studies using mouse models in which the core components of the NF-kappa B pathway, namely the I kappa B kinase subunits (IKK alpha, IKK beta and NEMO), the I kappa B ;proteins (I kappa B alpha, I kappa B beta, I kappa B epsilon and Bcl-3) and the five NF-kappa B transcription factors (NF-kappa B1, NF-kappa B2, c-Rel, RelA and RelB), have been genetically manipulated using transgenic and knock out technology.	Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia	Walter & Eliza Hall Institute	Gerondakis, S (corresponding author), Walter & Eliza Hall Inst Med Res, 1G Royal Parade, Melbourne, Vic 3050, Australia.	gerondakis@wehi.edu.au	Wong, W. Wei-Lynn/A-6851-2015	Wong, W. Wei-Lynn/0000-0003-3155-1211				Alcamo E, 2002, J EXP MED, V195, P233, DOI 10.1084/jem.20011885; Alcamo E, 2001, J IMMUNOL, V167, P1592, DOI 10.4049/jimmunol.167.3.1592; Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Arkan MC, 2005, NAT MED, V11, P191, DOI 10.1038/nm1185; Aronica MA, 1999, J IMMUNOL, V163, P5116; Artis D, 2005, J IMMUNOL, V174, P7154, DOI 10.4049/jimmunol.174.11.7154; Artis D, 2003, J IMMUNOL, V170, P1995, DOI 10.4049/jimmunol.170.4.1995; Attar RM, 1998, MOL CELL BIOL, V18, P477, DOI 10.1128/MCB.18.1.477; Aune TM, 1999, J IMMUNOL, V162, P5805; Banerjee A, 2006, P NATL ACAD SCI USA, V103, P3274, DOI 10.1073/pnas.0511113103; Banerjee D, 2005, IMMUNITY, V23, P445, DOI 10.1016/j.immuni.2005.09.012; Basseres DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; Beinke S, 2004, BIOCHEM J, V382, P393, DOI 10.1042/BJ20040544; Bendall HH, 1999, MOL IMMUNOL, V36, P187, DOI 10.1016/S0161-5890(99)00031-0; Bonizzi G, 2004, EMBO J, V23, P4202, DOI 10.1038/sj.emboj.7600391; Boothby MR, 1997, J EXP MED, V185, P1897, DOI 10.1084/jem.185.11.1897; BURKLY L, 1995, NATURE, V373, P531, DOI 10.1038/373531a0; Caamano J, 1999, J IMMUNOL, V163, P4453; Caamano J, 2000, J IMMUNOL, V165, P5720, DOI 10.4049/jimmunol.165.10.5720; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; Cai DS, 2004, CELL, V119, P285, DOI 10.1016/j.cell.2004.09.027; Cai DS, 2005, NAT MED, V11, P183, DOI 10.1038/nm1166; Campbell IK, 2000, J CLIN INVEST, V105, P1799, DOI 10.1172/JCI8298; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; Cariappa A, 2000, J EXP MED, V192, P1175, DOI 10.1084/jem.192.8.1175; Carlsen H, 2002, J IMMUNOL, V168, P1441, DOI 10.4049/jimmunol.168.3.1441; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; Carrasco D, 1997, J EXP MED, V186, P279, DOI 10.1084/jem.186.2.279; Carrasco D, 1998, J EXP MED, V187, P973, DOI 10.1084/jem.187.7.973; Castglioni P, 2002, SCAND J IMMUNOL, V56, P219, DOI 10.1046/j.1365-3083.2002.01144.x; Chaisson ML, 2002, J CLIN INVEST, V110, P193, DOI 10.1172/JCI200215295; Chen CL, 2000, J IMMUNOL, V165, P5418, DOI 10.4049/jimmunol.165.10.5418; Chen LW, 2003, NAT MED, V9, P575, DOI 10.1038/nm849; Chen XX, 2005, MOL CELL BIOL, V25, P3209, DOI 10.1128/MCB.25.8.3209-3219.2005; Cheng JD, 1998, J EXP MED, V188, P1055, DOI 10.1084/jem.188.6.1055; Cheng SH, 2003, ONCOGENE, V22, P8472, DOI 10.1038/sj.onc.1206917; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Corn RA, 2005, J IMMUNOL, V175, P2102, DOI 10.4049/jimmunol.175.4.2102; Corn RA, 2003, J IMMUNOL, V171, P1816, DOI 10.4049/jimmunol.171.4.1816; Courtois G, 2006, ONCOGENE, V25, P6831, DOI 10.1038/sj.onc.1209939; Das J, 2001, NAT IMMUNOL, V2, P45, DOI 10.1038/83158; Dawn B, 2001, J MOL CELL CARDIOL, V33, P161, DOI 10.1006/jmcc.2000.1291; Doi TS, 1999, P NATL ACAD SCI USA, V96, P2994, DOI 10.1073/pnas.96.6.2994; Elewaut D, 2003, J EXP MED, V197, P1623, DOI 10.1084/jem.20030141; Esslinger CW, 1997, J IMMUNOL, V158, P5075; Ferreira V, 1999, J IMMUNOL, V162, P6442; Finn PW, 2001, J IMMUNOL, V167, P5994, DOI 10.4049/jimmunol.167.10.5994; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; Franzoso G, 1997, IMMUNITY, V6, P479, DOI 10.1016/S1074-7613(00)80291-5; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; Fridmacher V, 2003, J NEUROSCI, V23, P9403; Gadjeva M, 2004, J IMMUNOL, V173, P5786, DOI 10.4049/jimmunol.173.9.5786; GELINAS C, 2006, ONCOGENE, V25, P6800; Gerondakis S, 1999, ONCOGENE, V18, P6888, DOI 10.1038/sj.onc.1203236; Gerondakis S, 2003, SEMIN IMMUNOL, V15, P159, DOI 10.1016/S1044-5323(03)00036-8; Gerondakis S, 1996, P NATL ACAD SCI USA, V93, P3405, DOI 10.1073/pnas.93.8.3405; Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954; Gilmore TD, 2004, ONCOGENE, V23, P2275, DOI 10.1038/sj.onc.1207410; Goudeau B, 2003, P NATL ACAD SCI USA, V100, P15800, DOI 10.1073/pnas.2535880100; Graham B, 2005, CELL CYCLE, V4, P1342, DOI 10.4161/cc.4.10.2047; Grigoriadis G, 1996, EMBO J, V15, P7099, DOI 10.1002/j.1460-2075.1996.tb01101.x; Grossmann M, 2000, EMBO J, V19, P6351, DOI 10.1093/emboj/19.23.6351; Grossmann M, 1999, P NATL ACAD SCI USA, V96, P11848, DOI 10.1073/pnas.96.21.11848; Grumont R, 2004, IMMUNITY, V21, P19, DOI 10.1016/j.immuni.2004.06.004; Grumont R, 2001, J EXP MED, V194, P1021, DOI 10.1084/jem.194.8.1021; Grumont RJ, 1998, J EXP MED, V187, P663, DOI 10.1084/jem.187.5.663; Grumont RJ, 2002, MOL CELL, V10, P1283, DOI 10.1016/S1097-2765(02)00779-7; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Guerin S, 2002, EUR J IMMUNOL, V32, P1; Gugasyan R, 2004, MOL CELL BIOL, V24, P5733, DOI 10.1128/MCB.24.13.5733-5745.2004; Hatada EN, 2003, J IMMUNOL, V171, P761, DOI 10.4049/jimmunol.171.2.761; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Herrmann O, 2005, NAT MED, V11, P1322, DOI 10.1038/nm1323; Hettmann T, 2000, J IMMUNOL, V165, P5004, DOI 10.4049/jimmunol.165.9.5004; Hettmann T, 1999, J EXP MED, V189, P145, DOI 10.1084/jem.189.1.145; Hilliard BA, 2002, J CLIN INVEST, V110, P843, DOI 10.1172/JCI200215254; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; Horwitz BH, 1999, J IMMUNOL, V162, P1941; Horwitz BH, 1997, IMMUNITY, V6, P765, DOI 10.1016/S1074-7613(00)80451-3; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Hunter RB, 2004, J CLIN INVEST, V114, P1504, DOI 10.1172/JCI200421696; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Ishikawa H, 1998, J EXP MED, V187, P985, DOI 10.1084/jem.187.7.985; Ishikawa H, 1997, J EXP MED, V186, P999, DOI 10.1084/jem.186.7.999; Kaisho T, 2001, J EXP MED, V193, P417, DOI 10.1084/jem.193.4.417; Kaltschmidt B, 2006, MOL CELL BIOL, V26, P2936, DOI 10.1128/MCB.26.8.2936-2946.2006; Kanters E, 2004, BLOOD, V103, P934, DOI 10.1182/blood-2003-05-1450; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kim S, 2003, P NATL ACAD SCI USA, V100, P1203, DOI 10.1073/pnas.0337707100; Klement JF, 1996, MOL CELL BIOL, V16, P2341; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; Lamhamedi-Cherradi SE, 2003, J IMMUNOL, V171, P4886, DOI 10.4049/jimmunol.171.9.4886; Lavon I, 2000, NAT MED, V6, P573, DOI 10.1038/75057; Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; Levenson JM, 2004, J NEUROSCI, V24, P3933, DOI 10.1523/JNEUROSCI.5646-03.2004; Li M, 2001, J BIOL CHEM, V276, P1185, DOI 10.1074/jbc.M006647200; Li QT, 2005, P NATL ACAD SCI USA, V102, P12425, DOI 10.1073/pnas.0505997102; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li ZW, 2003, J IMMUNOL, V170, P4630, DOI 10.4049/jimmunol.170.9.4630; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Lind MH, 2004, P NATL ACAD SCI USA, V101, P4972, DOI 10.1073/pnas.0307106101; Liou HC, 2003, BIOESSAYS, V25, P767, DOI 10.1002/bies.10306; Lo JC, 2006, BLOOD, V107, P1048, DOI 10.1182/blood-2005-06-2452; Luedde T, 2005, J CLIN INVEST, V115, P849, DOI 10.1172/JCI200523493; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Maeda S, 2003, IMMUNITY, V19, P725, DOI 10.1016/S1074-7613(03)00301-7; Magness ST, 2004, J IMMUNOL, V173, P1561, DOI 10.4049/jimmunol.173.3.1561; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; Mason NJ, 2004, J IMMUNOL, V172, P3704, DOI 10.4049/jimmunol.172.6.3704; Meffert MK, 2005, TRENDS NEUROSCI, V28, P37, DOI 10.1016/j.tins.2004.11.002; Meffert MK, 2003, NAT NEUROSCI, V6, P1072, DOI 10.1038/nn1110; Memet S, 1999, J IMMUNOL, V163, P5994; Mintern JD, 2002, J IMMUNOL, V168, P3283, DOI 10.4049/jimmunol.168.7.3283; Mora AL, 2003, CELL DEATH DIFFER, V10, P1032, DOI 10.1038/sj.cdd.4401257; Norlin S, 2005, DIABETES, V54, P125, DOI 10.2337/diabetes.54.1.125; O'Donnell SM, 2005, J CLIN INVEST, V115, P2341, DOI 10.1172/JCI22428; O'Keeffe M, 2005, BLOOD, V106, P3457, DOI 10.1182/blood-2004-12-4965; Ong ST, 1998, ONCOGENE, V16, P2333, DOI 10.1038/sj.onc.1201771; Ouaaz F, 2002, IMMUNITY, V16, P257, DOI 10.1016/S1074-7613(02)00272-8; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Park JM, 2005, IMMUNITY, V23, P319, DOI 10.1016/j.immuni.2005.08.010; Pasparakis M, 2002, J EXP MED, V196, P743, DOI 10.1084/jem.20020907; Pasparakis M, 2002, NATURE, V417, P861, DOI 10.1038/nature00820; Perkins ND, 2006, ONCOGENE, V25, P6717, DOI 10.1038/sj.onc.1209937; Pizzi M, 2002, J BIOL CHEM, V277, P20717, DOI 10.1074/jbc.M201014200; Pizzi M, 2005, CELL DEATH DIFFER, V12, P761, DOI 10.1038/sj.cdd.4401598; Pohl T, 2002, P NATL ACAD SCI USA, V99, P4514, DOI 10.1073/pnas.072071599; Prendes M, 2003, J IMMUNOL, V171, P3963, DOI 10.4049/jimmunol.171.8.3963; Rao S, 2003, J IMMUNOL, V170, P3724, DOI 10.4049/jimmunol.170.7.3724; Romieu-Mourez R, 2003, MOL CELL BIOL, V23, P5738, DOI 10.1128/MCB.23.16.5738-5754.2003; Rudolph D, 2000, GENE DEV, V14, P854; Ruocco MG, 2005, J EXP MED, V201, P1677, DOI 10.1084/jem.20042081; Rupec RA, 2005, IMMUNITY, V22, P479, DOI 10.1016/j.immuni.2005.02.009; Samson SI, 2004, BLOOD, V103, P4573, DOI 10.1182/blood-2003-08-2975; Sanjabi S, 2000, P NATL ACAD SCI USA, V97, P12705, DOI 10.1073/pnas.230436397; Scheidereit C, 2006, ONCOGENE, V25, P6685, DOI 10.1038/sj.onc.1209934; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; Schmidt-Supprian M, 2004, P NATL ACAD SCI USA, V101, P4566, DOI 10.1073/pnas.0400885101; Schmidt-Supprian M, 2003, IMMUNITY, V19, P377, DOI 10.1016/S1074-7613(03)00237-1; Schmidt-Ullrich R, 2001, DEVELOPMENT, V128, P3843; SchmidtUllrich R, 1996, DEVELOPMENT, V122, P2117; Schwabe RF, 2006, AM J PHYSIOL-GASTR L, V290, pG583, DOI 10.1152/ajpgi.00422.2005; Schwarz EM, 1997, GENE DEV, V11, P187, DOI 10.1101/gad.11.2.187; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Senftleben U, 2001, IMMUNITY, V14, P217, DOI 10.1016/S1074-7613(01)00104-2; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Sil AK, 2004, NATURE, V428, P660, DOI 10.1038/nature02421; Sivakumar V, 2003, J EXP MED, V197, P1613, DOI 10.1084/jem.20022234; Snapper CM, 1996, J IMMUNOL, V156, P183; Speirs K, 2004, J IMMUNOL, V172, P752, DOI 10.4049/jimmunol.172.2.752; Speirs K, 2002, J IMMUNOL, V168, P4406, DOI 10.4049/jimmunol.168.9.4406; Strasser A, 1999, EUR J IMMUNOL, V29, P928, DOI 10.1002/(SICI)1521-4141(199903)29:03<928::AID-IMMU928>3.3.CO;2-G; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Tato CM, 2006, INT IMMUNOL, V18, P505, DOI 10.1093/intimm/dxh391; Tato CM, 2003, J IMMUNOL, V170, P3139, DOI 10.4049/jimmunol.170.6.3139; Thomas R, 2005, ARTHRITIS RES THER, V7, P170, DOI 10.1186/ar1784; van Hogerlinden M, 1999, CANCER RES, V59, P3299; Voll RE, 2000, IMMUNITY, V13, P677, DOI 10.1016/S1074-7613(00)00067-4; Wang Y, 2004, CANCER RES, V64, P6240, DOI 10.1158/0008-5472.CAN-04-0591; Waterfield MR, 2003, MOL CELL, V11, P685, DOI 10.1016/S1097-2765(03)00070-4; Weih DS, 2001, J IMMUNOL, V167, P1909, DOI 10.4049/jimmunol.167.4.1909; Weih F, 2003, IMMUNOL REV, V195, P91, DOI 10.1034/j.1600-065X.2003.00064.x; Weih F, 1997, J EXP MED, V185, P1359, DOI 10.1084/jem.185.7.1359; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; Wu L, 1998, IMMUNITY, V9, P839, DOI 10.1016/S1074-7613(00)80649-4; Xing LP, 2002, J BONE MINER RES, V17, P1200, DOI 10.1359/jbmr.2002.17.7.1200; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Yan MH, 2001, CURR BIOL, V11, P1547, DOI 10.1016/S0960-9822(01)00481-X; Yang H, 2002, TRANSPLANTATION, V74, P291, DOI 10.1097/00007890-200208150-00002; Yilmaz ZB, 2003, EMBO J, V22, P121, DOI 10.1093/emboj/cdg004; Zanetti M, 2003, ANN NY ACAD SCI, V987, P249, DOI 10.1111/j.1749-6632.2003.tb06056.x; Zhang JY, 2004, GENE DEV, V18, P17, DOI 10.1101/gad.1160904; Zheng Y, 2003, J EXP MED, V197, P861, DOI 10.1084/jem.20021610	184	234	245	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2006	25	51					6781	6799		10.1038/sj.onc.1209944	http://dx.doi.org/10.1038/sj.onc.1209944			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	100KD	17072328				2022-12-17	WOS:000241666700008
J	Yu, CR; Bruzek, LM; Meng, XW; Gores, GJ; Carter, CA; Kaufmann, SH; Adjei, AA				Yu, CR; Bruzek, LM; Meng, XW; Gores, GJ; Carter, CA; Kaufmann, SH; Adjei, AA			The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006	ONCOGENE			English	Article						Mcl-1; apoptosis; BAY 43-9006 (sorafenib); MEK; Raf; adaphostin	CHRONIC LYMPHOCYTIC-LEUKEMIA; CELLS IN-VITRO; B-RAF; KINASE ACTIVATION; SIGNALING PATHWAY; HUMAN CANCER; BRAF GENE; APOPTOSIS; MUTATIONS; EXPRESSION	BAY 43-9006, a multikinase inhibitor that targets Raf, prevents tumor cell proliferation in vitro and inhibits diverse human tumor xenografts in vivo. The mechanism of action of BAY 43-9006 remains incompletely defined. In the present study, the effects of BAY 43-9006 on the antiapoptotic Bcl-2 family member Mcl-1 were examined. Treatment of A549 lung cancer cells with BAY 43-9006 diminished Mcl-1 levels in a time- and dose-dependent manner without affecting other Bcl-2 family members. Similar BAY 43-9006-induced Mcl-1 downregulation was observed in ACHN (renal cell), HT-29 (colon), MDA-MB-231 (breast), KMCH (cholangiocarcinoma), Jurkat (acute T-cell leukemia), K562 (chronic myelogenous leukemia) and MEC-2 ( chronic lymphocytic leukemia) cells. Mcl-1 mRNA levels did not change in BAY 43-9006-treated cells. Instead, BAY 43-9006 enhanced proteasome-mediated Mcl-1 degradation. This Mcl-1 downregulation was followed by mitochondrail cytochrome c release and caspase activation as well as enhanced sensitivity to other proapoptotic agents. The caspase inhibitor Boc-D-fmk inhibited BAY 43-9006-induced caspase activation but not cytochrome c release. In contrast, Mcl-1 overexpression inhibited cytochrome c release and other features of BAY 43-9006-induced apoptosis. Conversely, Mcl-1 downregulation by short hairpin RNA enhanced BAY 43-9006-induced apoptosis. Collectively, these findings demonstrate that drug-induced Mcl-1 downregulation contributes to the proapoptotic effects of BAY 43-9006.	Mayo Clin & Mayo Fdn, Div Med Oncol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Med, Rochester, MN 55905 USA; Bayer Healthcare, West Haven, CT 06516 USA	Mayo Clinic; Mayo Clinic; Bayer AG; Bayer Healthcare Pharmaceuticals	Adjei, AA (corresponding author), Mayo Clin & Mayo Fdn, Div Med Oncol, 200 1st St SW, Rochester, MN 55905 USA.	adjei.alex@mayo.edu		Kaufmann, Scott/0000-0002-4900-7145	NCI NIH HHS [R01 CA69008] Funding Source: Medline; NIDDK NIH HHS [R01 DK59427] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adjei AA, 2001, CLIN CANCER RES, V7, P1438; Ahmad T, 2004, CLIN CANCER RES, V10, p6388S, DOI 10.1158/1078-0432.CCR-040028; Aichberger KJ, 2005, BLOOD, V105, P3303, DOI 10.1182/blood-2004-02-0749; Boucher MJ, 2000, J CELL BIOCHEM, V79, P355, DOI 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.3.CO;2-S; Chandra J, 2003, BLOOD, V102, P4512, DOI 10.1182/blood-2003-02-0562; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Cohen J, 2003, J NATL CANCER I, V95, P625, DOI 10.1093/jnci/95.8.625; Craig RW, 2002, LEUKEMIA, V16, P444, DOI 10.1038/sj.leu.2402416; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dhillon AS, 2003, MOL CELL BIOL, V23, P1983, DOI 10.1128/MCB.23.6.1983-1993.2003; Domina AM, 2000, J BIOL CHEM, V275, P21688, DOI 10.1074/jbc.M000915200; Domina AM, 2004, ONCOGENE, V23, P5301, DOI 10.1038/sj.onc.1207692; FLAHERTY KT, 2004, P AM SOC CLIN ONCOL, V23; Gojo I, 2002, CLIN CANCER RES, V8, P3527; Inoshita S, 2002, J BIOL CHEM, V277, P43730, DOI 10.1074/jbc.M207951200; Karasarides M, 2004, ONCOGENE, V23, P6292, DOI 10.1038/sj.onc.1207785; Kaufmann SH, 1998, BLOOD, V91, P991, DOI 10.1182/blood.V91.3.991.991_991_1000; Kitada S, 1998, BLOOD, V91, P3379, DOI 10.1182/blood.V91.9.3379; KOBAYASHI S, 2005, IN PRESS GASTROENTER; Meng XW, 2003, J BIOL CHEM, V278, P47326, DOI 10.1074/jbc.M304793200; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Milella M, 2001, J CLIN INVEST, V108, P851, DOI 10.1172/JCI200112807; Moshynska O, 2004, JNCI-J NATL CANCER I, V96, P673, DOI 10.1093/jnci/djh122; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Opferman JT, 2005, SCIENCE, V307, P1101, DOI 10.1126/science.1106114; Pollock PM, 2002, CANCER CELL, V2, P5, DOI 10.1016/S1535-6108(02)00089-2; Ratain MJ, 2004, J CLIN ONCOL, V22, p382S; Singer G, 2003, J NATL CANCER I, V95, P484, DOI 10.1093/jnci/95.6.484; Strumberg D, 2005, J CLIN ONCOL, V23, P965, DOI 10.1200/JCO.2005.06.124; STRUMBERG D, 2004, J CLIN ONCOL, V21, P21; Svingen PA, 2000, CLIN CANCER RES, V6, P237; Taniai M, 2004, CANCER RES, V64, P3517, DOI 10.1158/0008-5472.CAN-03-2770; Tannapfel A, 2003, GUT, V52, P706, DOI 10.1136/gut.52.5.706; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Yu CR, 2004, ONCOGENE, V23, P1364, DOI 10.1038/sj.onc.1207248; Yu CR, 2003, BLOOD, V102, P3765, DOI 10.1182/blood-2003-03-0737	37	234	241	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2005	24	46					6861	6869		10.1038/sj.onc.1208841	http://dx.doi.org/10.1038/sj.onc.1208841			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	975ZD	16007148				2022-12-17	WOS:000232701700001
J	Muller, S; Ledl, A; Schmidt, D				Muller, S; Ledl, A; Schmidt, D			SUMO: a regulator of gene expression and genome integrity	ONCOGENE			English	Review						SUMO; ubiquitin; transcription; DNA repair	UBIQUITIN-LIKE PROTEINS; NUCLEAR-PORE COMPLEX; COVALENT MODIFICATION; TOPOISOMERASE-I; ANDROGEN RECEPTOR; ACTIVATED STAT; E3 LIGASE; TRANSCRIPTIONAL ACTIVATION; FUNCTIONAL INTERACTIONS; PROGESTERONE-RECEPTOR	Post-translational modi. cation with the ubiquitin-like SUMO protein is involved in the regulation of many cellular key processes. The SUMO system modulates signal transduction pathways, including cytokine, Wnt, growth factor and steroid hormone signalling. SUMO frequently restrains the activity of downstream transcription factors in these pathways presumably by facilitating the recruitment of corepressors or mediating the assembly of repressor complexes. Additionally, evidence is accumulating that SUMO controls pathways important for the surveillance of genome integrity. SUMO regulates the PML/p53 tumour suppressor network, a key determinant in the cellular response to DNA damage. Moreover, proteins that maintain genomic stability by functioning at the interface between DNA replication, recombination and repair processes undergo SUMOylation. We will discuss some key findings that exemplify the role of SUMO in transcriptional regulation and genome surveillance.	Max Planck Inst Biochem, Dept Mol Cell Biol, D-82152 Martinsried, Germany	Max Planck Society	Muller, S (corresponding author), Max Planck Inst Biochem, Dept Mol Cell Biol, Klopferspitz 18, D-82152 Martinsried, Germany.	stmuelle@biochem.mpg.de		Muller, Stefan/0000-0002-8792-7700				Abdel-Hafiz H, 2002, J BIOL CHEM, V277, P33950, DOI 10.1074/jbc.M204573200; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Bachant J, 2002, MOL CELL, V9, P1169, DOI 10.1016/S1097-2765(02)00543-9; Baumann CT, 2001, MOL ENDOCRINOL, V15, P485, DOI 10.1210/me.15.4.485; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Bernier-Villamor V, 2002, CELL, V108, P345, DOI 10.1016/S0092-8674(02)00630-X; Bies J, 2002, J BIOL CHEM, V277, P8999, DOI 10.1074/jbc.M110453200; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; BOSSIS G, 2003, UNPUB; Chauchereau A, 2003, J BIOL CHEM, V278, P12335, DOI 10.1074/jbc.M207148200; Chen LH, 2003, ONCOGENE, V22, P5348, DOI 10.1038/sj.onc.1206851; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Dahle O, 2003, EUR J BIOCHEM, V270, P1338, DOI 10.1046/j.1432-1033.2003.03504.x; David G, 2002, J BIOL CHEM, V277, P23658, DOI 10.1074/jbc.M203690200; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Dotzlaw H, 2002, MOL ENDOCRINOL, V16, P661, DOI 10.1210/me.16.4.661; Eaton EM, 2003, J BIOL CHEM, V278, P33416, DOI 10.1074/jbc.M305680200; Epps JL, 1998, CURR BIOL, V8, P1277, DOI 10.1016/S0960-9822(07)00538-6; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Galy A, 2002, DEV BIOL, V248, P251, DOI 10.1006/dbio.2002.0736; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Gottifredi V, 2001, TRENDS CELL BIOL, V11, P184, DOI 10.1016/S0962-8924(01)01983-3; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Hang J, 2002, J BIOL CHEM, V277, P19961, DOI 10.1074/jbc.M201799200; Hardeland U, 2002, EMBO J, V21, P1456, DOI 10.1093/emboj/21.6.1456; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Hirano Y, 2003, J BIOL CHEM, V278, P16809, DOI 10.1074/jbc.M212448200; Ho JCY, 2001, NUCLEIC ACIDS RES, V29, P4179, DOI 10.1093/nar/29.20.4179; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Horie K, 2002, ONCOGENE, V21, P7913, DOI 10.1038/sj.onc.1205917; Imoto S, 2003, J BIOL CHEM, V278, P34253, DOI 10.1074/jbc.M304961200; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; Jimenez-Lara AM, 2002, FEBS LETT, V526, P142, DOI 10.1016/S0014-5793(02)03154-X; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kawabe Y, 2000, J BIOL CHEM, V275, P20963, DOI 10.1074/jbc.C000273200; Khan MM, 2001, MOL CELL, V7, P1233, DOI 10.1016/S1097-2765(01)00257-X; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Kotaja N, 2002, J BIOL CHEM, V277, P30283, DOI 10.1074/jbc.M204768200; Kurki S, 2003, J CELL SCI, V116, P3917, DOI 10.1242/jcs.00714; Kwek SSS, 2001, ONCOGENE, V20, P2587, DOI 10.1038/sj.onc.1204362; Le Drean Y, 2002, ENDOCRINOLOGY, V143, P3482, DOI 10.1210/en.2002-220135; Lee PSW, 2003, J BIOL CHEM, V278, P27853, DOI 10.1074/jbc.M301755200; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Li WH, 2000, NUCLEIC ACIDS RES, V28, P1145, DOI 10.1093/nar/28.5.1145; Lin X, 2003, J BIOL CHEM, V278, P31043, DOI 10.1074/jbc.C300112200; Lin X, 2003, J BIOL CHEM, V278, P18714, DOI 10.1074/jbc.M302243200; Long JY, 2003, P NATL ACAD SCI USA, V100, P9791, DOI 10.1073/pnas.1733973100; Louria-Hayon I, 2003, J BIOL CHEM, V278, P33134, DOI 10.1074/jbc.M301264200; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mao Y, 2000, J BIOL CHEM, V275, P26066, DOI 10.1074/jbc.M001831200; Mao Y, 2000, P NATL ACAD SCI USA, V97, P4046, DOI 10.1073/pnas.080536597; Matsuzaki K, 2003, BIOCHEM BIOPH RES CO, V306, P32, DOI 10.1016/S0006-291X(03)00910-0; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Megidish T, 2002, J BIOL CHEM, V277, P8255, DOI 10.1074/jbc.C200001200; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Miyauchi Y, 2002, J BIOL CHEM, V277, P50131, DOI 10.1074/jbc.M208319200; Mo YY, 2002, J BIOL CHEM, V277, P2958, DOI 10.1074/jbc.M108263200; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Nakagawa K, 2002, FEBS LETT, V530, P204, DOI 10.1016/S0014-5793(02)03486-5; Nelson V, 2001, APOPTOSIS, V6, P221, DOI 10.1023/A:1011392811628; Nishida T, 2000, EUR J BIOCHEM, V267, P6423, DOI 10.1046/j.1432-1327.2000.01729.x; Nishida T, 2002, J BIOL CHEM, V277, P41311, DOI 10.1074/jbc.M206741200; Orlando V, 2003, CELL, V112, P599, DOI 10.1016/S0092-8674(03)00157-0; Panse VG, 2003, NAT CELL BIOL, V5, P21, DOI 10.1038/ncb893; Pearson M, 2001, ONCOGENE, V20, P7250, DOI 10.1038/sj.onc.1204856; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Pichler A, 2002, TRAFFIC, V3, P381, DOI 10.1034/j.1600-0854.2002.30601.x; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Rallabhandi P, 2002, J BIOL CHEM, V277, P40020, DOI 10.1074/jbc.M200388200; Rivera OJ, 2003, MOL ENDOCRINOL, V17, P128, DOI 10.1210/me.2002-0165; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rogers RS, 2003, J BIOL CHEM, V278, P30091, DOI 10.1074/jbc.M301344200; Ross S, 2002, MOL CELL, V10, P831, DOI 10.1016/S1097-2765(02)00682-2; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Saitoh H, 2002, J BIOL CHEM, V277, P4755, DOI 10.1074/jbc.M104453200; Sapetschnig A, 2002, EMBO J, V21, P5206, DOI 10.1093/emboj/cdf510; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Schmidt D, 2003, CELL MOL LIFE SCI, V60, P2561, DOI 10.1007/s00018-003-3129-1; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Seeler JS, 1999, CURR OPIN GENET DEV, V9, P362, DOI 10.1016/S0959-437X(99)80054-9; Seeler JS, 2001, ONCOGENE, V20, P7243, DOI 10.1038/sj.onc.1204758; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shen ZY, 1996, GENOMICS, V37, P183, DOI 10.1006/geno.1996.0540; Shuai K, 2000, ONCOGENE, V19, P2638, DOI 10.1038/sj.onc.1203522; Stelter P, 2003, NATURE, V425, P188, DOI 10.1038/nature01965; Subramanian L, 2003, J BIOL CHEM, V278, P9134, DOI 10.1074/jbc.M210440200; Takahashi Y, 2001, J BIOL CHEM, V276, P48973, DOI 10.1074/jbc.M109295200; Takahashi Y, 2001, GENE, V275, P223, DOI 10.1016/S0378-1119(01)00662-X; Takahashi Y, 2000, J BIOCHEM-TOKYO, V128, P723, DOI 10.1093/oxfordjournals.jbchem.a022807; Tian S, 2002, BIOCHEM J, V367, P907, DOI 10.1042/BJ20021085; Tojo M, 2002, J BIOL CHEM, V277, P46576, DOI 10.1074/jbc.M205987200; Tussie-Luna MI, 2002, P NATL ACAD SCI USA, V99, P12807, DOI 10.1073/pnas.192464499; Ungureanu D, 2003, BLOOD, V102, P3311, DOI 10.1182/blood-2002-12-3816; Verdin E, 2003, TRENDS GENET, V19, P286, DOI 10.1016/S0168-9525(03)00073-8; Verger A, 2003, EMBO REP, V4, P137, DOI 10.1038/sj.embor.embor738; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Wei XL, 2003, J BIOL CHEM, V278, P29288, DOI 10.1074/jbc.M212215200; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; West SC, 2003, NAT REV MOL CELL BIO, V4, P435, DOI 10.1038/nrm1127; Wible BA, 2002, J BIOL CHEM, V277, P17852, DOI 10.1074/jbc.M201689200; Wood LD, 2003, P NATL ACAD SCI USA, V100, P3257, DOI 10.1073/pnas.0637114100; Xirodimas DP, 2002, FEBS LETT, V528, P207, DOI 10.1016/S0014-5793(02)03310-0; Yamamoto H, 2003, EMBO J, V22, P2047, DOI 10.1093/emboj/cdg204; Yang SH, 2003, MOL CELL, V12, P63, DOI 10.1016/S1097-2765(03)00265-X; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Zhang H, 2002, MOL CELL BIOL, V22, P6498, DOI 10.1128/MCB.22.18.6498-6508.2002; Zhang Q, 2002, J IMMUNOL, V168, P466, DOI 10.4049/jimmunol.168.1.466; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583	125	234	248	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2004	23	11					1998	2008		10.1038/sj.onc.1207415	http://dx.doi.org/10.1038/sj.onc.1207415			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	803EC	15021887				2022-12-17	WOS:000220213400004
J	Kaufmann, SH; Vaux, DL				Kaufmann, SH; Vaux, DL			Alterations in the apoptotic machinery and their potential role in anticancer drug resistance	ONCOGENE			English	Review						apoptosis; caspases; carcinogenesis; Bcl-2; IAP; drug resistance; stress response	CHRONIC MYELOGENOUS LEUKEMIA; PROGRAMMED CELL-DEATH; BCL-2 ANTISENSE OLIGONUCLEOTIDE; CHRONIC LYMPHOCYTIC-LEUKEMIA; UBIQUITIN-PROTEIN LIGASE; ABL TYROSINE KINASE; CHEMOTHERAPY-INDUCED APOPTOSIS; TRAIL-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; X-LINKED INHIBITOR	Anticancer drugs can potentially kill cells in two fundamentally different ways, by interfering with cellular processes that are essential for maintenance of viability or by triggering an endogenous physiological cell death mechanism. Apoptosis is a form of physiological cell death mediated by caspases, a unique family of intracellular cysteine proteases. Zymogen forms of these proteases are found in virtually all somatic cells, but remain latent until their activation is induced by ligation of specific cell surface receptors (the so- called 'death receptors'), by mitochondrial alterations that allow release of cytochrome c and other intermembrane components, or possibly by other mechanisms. Most anticancer drugs activate the mitochondrial pathway. This apoptotic pathway is regulated by pro- and antiapoptotic members of the Bcl-2 family of proteins. Once activated, certain caspases might also be controlled by the inhibitor of apoptosis (IAP) proteins. Alterations in apoptotic pathway components or their regulators have been detected in a variety of cancers, suggesting that loss of the ability of cells to undergo apoptosis might contribute to carcinogenesis. Because cancer therapies such as radiation, glucocorticoids, and chemotherapeutic drugs exert their beneficial effects, at least in part, by inducing apoptosis of cancer cells, the same alterations in apoptotic pathways would be predicted to contribute to resistance. A key issue is whether the direct toxic activity of these treatments is of benefit when neoplastic cells contain changes that diminish their ability to undergo apoptosis.	Mayo Clin & Mayo Fdn, Div Oncol Res, Rochester, MN 55905 USA; Mayo Clin & Mayo Grad Sch Med, Dept Mol Pharmacol, Rochester, MN 55905 USA; Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia	Mayo Clinic; Mayo Clinic; Walter & Eliza Hall Institute	Kaufmann, SH (corresponding author), Mayo Clin & Mayo Fdn, Div Oncol Res, Guggenheim 1342C,200 1st St SW, Rochester, MN 55905 USA.	Kaufmann.Scott@Mayo.edu	Vaux, David L/C-7249-2013	Vaux, David L/0000-0003-2703-1651; Kaufmann, Scott/0000-0002-4900-7145	NATIONAL CANCER INSTITUTE [R01CA069008] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Adrain C, 2001, EMBO J, V20, P6627, DOI 10.1093/emboj/20.23.6627; Aebersold DM, 2001, INT J CANCER, V96, P41, DOI 10.1002/1097-0215(20010220)96:1<41::AID-IJC5>3.0.CO;2-F; Amarante-Mendes GP, 1998, ONCOGENE, V16, P1383, DOI 10.1038/sj.onc.1201664; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; Arnt CR, 2002, J BIOL CHEM, V277, P44236, DOI 10.1074/jbc.M207578200; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Bai C, 2000, P NATL ACAD SCI USA, V97, P1230, DOI 10.1073/pnas.97.3.1230; Bairey O, 1999, CLIN CANCER RES, V5, P2860; Banerjee D, 2001, Curr Opin Investig Drugs, V2, P574; Banks DP, 2000, BLOOD, V96, P4002, DOI 10.1182/blood.V96.12.4002.h8004000c_4002_4003; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Blajeski AL, 2001, EXP CELL RES, V270, P277, DOI 10.1006/excr.2001.5349; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Boudard D, 2002, AM J HEMATOL, V70, P115, DOI 10.1002/ajh.10108; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Brady HJM, 1996, EMBO J, V15, P1221, DOI 10.1002/j.1460-2075.1996.tb00463.x; Brown JM, 1999, CANCER RES, V59, P1391; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Bullrich F, 1999, CANCER RES, V59, P24; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Byrd JC, 2002, BLOOD, V99, P1038, DOI 10.1182/blood.V99.3.1038; CAMPOS L, 1994, BLOOD, V84, P595; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chakravarti A, 2002, J CLIN ONCOL, V20, P1063, DOI 10.1200/JCO.20.4.1063; Chandra J, 1998, BLOOD, V92, P4220, DOI 10.1182/blood.V92.11.4220.423k49_4220_4229; Chen FL, 2000, SCIENCE, V287, P1485, DOI 10.1126/science.287.5457.1485; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Chi KN, 2001, CLIN CANCER RES, V7, P3920; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Conte D, 2001, P NATL ACAD SCI USA, V98, P5049, DOI 10.1073/pnas.081547998; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Cotter Finbarr E., 1999, Seminars in Hematology, V36, P9; Coultas L, 2003, SEMIN CANCER BIOL, V13, P115, DOI 10.1016/S1044-579X(02)00129-3; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Dan S, 1998, CELL DEATH DIFFER, V5, P710, DOI 10.1038/sj.cdd.4400400; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Degterev A, 2001, NAT CELL BIOL, V3, P173, DOI 10.1038/35055085; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Eggert A, 2001, CANCER RES, V61, P1314; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; Elnemr A, 2001, INT J ONCOL, V18, P311; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Estrov Z, 1998, BLOOD, V92, P3090, DOI 10.1182/blood.V92.9.3090; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Fang GF, 2000, BLOOD, V96, P2246, DOI 10.1182/blood.V96.6.2246.h8002246_2246_2253; Finkel E, 1999, SCIENCE, V286, P2256, DOI 10.1126/science.286.5448.2256; Fortin A, 2001, J CELL BIOL, V155, P207, DOI 10.1083/jcb.200105137; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Green D R, 1994, Important Adv Oncol, P37; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Griffith TS, 1998, J IMMUNOL, V161, P2833; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Grotzer MA, 2000, ONCOGENE, V19, P4604, DOI 10.1038/sj.onc.1203816; Guo F, 2002, BLOOD, V99, P3419, DOI 10.1182/blood.V99.9.3419; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; HANADA M, 1993, BLOOD, V82, P1820; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hannun YA, 1997, BLOOD, V89, P1845, DOI 10.1182/blood.V89.6.1845; Harlin H, 2001, MOL CELL BIOL, V21, P3604, DOI 10.1128/MCB.21.10.3604-3608.2001; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HASHIMOTO H, 1995, CLIN CANCER RES, V1, P369; Hausmann G, 2000, J CELL BIOL, V149, P623, DOI 10.1083/jcb.149.3.623; Hay BA, 2000, CELL DEATH DIFFER, V7, P1045, DOI 10.1038/sj.cdd.4400765; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Holcik M, 2000, ONCOGENE, V19, P4174, DOI 10.1038/sj.onc.1203765; Holtz MS, 2002, BLOOD, V99, P3792, DOI 10.1182/blood.V99.10.3792; Honarpour N, 2000, DEV BIOL, V218, P248, DOI 10.1006/dbio.1999.9585; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; Houghton Janet A., 1999, Current Opinion in Oncology, V11, P475, DOI 10.1097/00001622-199911000-00008; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Huang HK, 2000, J BIOL CHEM, V275, P26661; Ichikawa K, 2001, NAT MED, V7, P954, DOI 10.1038/91000; Igata E, 1999, GENE, V238, P407, DOI 10.1016/S0378-1119(99)00348-0; Ionov Y, 2000, P NATL ACAD SCI USA, V97, P10872, DOI 10.1073/pnas.190210897; Irmler M, 1997, FEBS LETT, V406, P189, DOI 10.1016/S0014-5793(97)00271-8; Izquierdo M, 1999, EMBO J, V18, P156, DOI 10.1093/emboj/18.1.156; Jansen B, 2000, LANCET, V356, P1728, DOI 10.1016/S0140-6736(00)03207-4; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kamihira S, 2001, BRIT J HAEMATOL, V114, P63, DOI 10.1046/j.1365-2141.2001.02902.x; Kannan K, 2001, ONCOGENE, V20, P3449, DOI 10.1038/sj.onc.1204446; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; Kasof GM, 2001, J BIOL CHEM, V276, P3238, DOI 10.1074/jbc.M003670200; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; Kaufmann SH, 1998, BLOOD, V91, P991, DOI 10.1182/blood.V91.3.991.991_991_1000; Kaufmann SH, 2000, BIOESSAYS, V22, P1007, DOI 10.1002/1521-1878(200011)22:11<1007::AID-BIES7>3.3.CO;2-W; Keating MJ, 2002, SEMIN ONCOL, V29, P70, DOI 10.1053/sonc.2002.30142; Kipps TJ, 2002, SEMIN ONCOL, V29, P98, DOI 10.1053/sonc.2002.30146; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kohler T, 2002, ANTICANCER RES, V22, P1553; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Kottke TJ, 2002, J BIOL CHEM, V277, P804, DOI 10.1074/jbc.M108419200; Kruh GD, 2003, ONCOGENE, V22, P7537, DOI 10.1038/sj.onc.1206953; KYPRIANOU N, 1990, CANCER RES, V50, P3748; Kyprianou N, 1997, INT J CANCER, V70, P341, DOI 10.1002/(SICI)1097-0215(19970127)70:3<341::AID-IJC16>3.0.CO;2-I; La Rosee P, 2002, LEUKEMIA, V16, P1213, DOI 10.1038/sj.leu.2402555; LANEUVILLE P, 1994, CANCER RES, V54, P1360; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lejeune FJ, 1998, CURR OPIN IMMUNOL, V10, P573, DOI 10.1016/S0952-7915(98)80226-4; Li FZ, 1999, CANCER RES, V59, P3143; Li JL, 2001, ENDOCRINOLOGY, V142, P370, DOI 10.1210/en.142.1.370; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LI X, 1994, LEUKEMIA LYMPHOMA, V13, P65, DOI 10.3109/10428199409052678; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Liu R, 1999, AM J PATHOL, V155, P1861, DOI 10.1016/S0002-9440(10)65505-8; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Lock RB, 1996, CANCER RES, V56, P4006; Lowe Scott W., 1995, Current Opinion in Oncology, V7, P547, DOI 10.1097/00001622-199511000-00013; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; MARTIN DS, 1994, CANCER INVEST, V12, P296, DOI 10.3109/07357909409023028; Martin SJ, 2002, CELL, V109, P793, DOI 10.1016/S0092-8674(02)00802-4; Martins LM, 1997, BLOOD, V90, P4283, DOI 10.1182/blood.V90.11.4283.4283_4283_4296; MATTHEWS DE, 1988, USING UNDERSTANDING; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; Meng XW, 2002, J BIOL CHEM, V277, P3776, DOI 10.1074/jbc.M107218200; Merritt AJ, 1997, ONCOGENE, V14, P2759, DOI 10.1038/sj.onc.1201126; Metzstein MM, 1998, TRENDS GENET, V14, P410, DOI 10.1016/S0168-9525(98)01573-X; Miramar MD, 2001, J BIOL CHEM, V276, P16391, DOI 10.1074/jbc.M010498200; MIYASHITA T, 1993, BLOOD, V81, P151; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1995, J BIOL CHEM, V270, P26049, DOI 10.1074/jbc.270.44.26049; MIYASHITA T, 1992, CANCER RES, V52, P5407; Moriishi K, 1999, P NATL ACAD SCI USA, V96, P9683, DOI 10.1073/pnas.96.17.9683; Mow BMF, 2002, BLOOD, V99, P664, DOI 10.1182/blood.V99.2.664; Mow BMF, 2001, CURR OPIN ONCOL, V13, P453, DOI 10.1097/00001622-200111000-00007; Neshat MS, 2000, MOL CELL BIOL, V20, P1179, DOI 10.1128/MCB.20.4.1179-1186.2000; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Newton K, 2001, ADV IMMUNOL, V76, P179, DOI 10.1016/S0065-2776(01)76020-8; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Nicholson DW, 2003, SCIENCE, V299, P214, DOI 10.1126/science.1081274; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Okada H, 2002, MOL CELL BIOL, V22, P3509, DOI 10.1128/MCB.22.10.3509-3517.2002; Park WS, 2002, ONCOGENE, V21, P2919, DOI 10.1038/sj.onc.1205394; Paroni G, 2002, J BIOL CHEM, V277, P15147, DOI 10.1074/jbc.M112338200; Pettitt AR, 2001, BLOOD, V98, P814, DOI 10.1182/blood.V98.3.814; Pitti RM, 1998, NATURE, V396, P699, DOI 10.1038/25387; Pritchard DM, 1998, CANCER RES, V58, P5453; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj/cdd/4400998; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Rai KR, 2000, NEW ENGL J MED, V343, P1750, DOI 10.1056/NEJM200012143432402; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Reed J C, 1997, Adv Pharmacol, V41, P501, DOI 10.1016/S1054-3589(08)61070-4; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; REED JC, 1990, CANCER RES, V50, P6565; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; Renatus M, 2001, P NATL ACAD SCI USA, V98, P14250, DOI 10.1073/pnas.231465798; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Robles AI, 2001, CANCER RES, V61, P6660; Rudin CM, 2002, ANN ONCOL, V13, P539, DOI 10.1093/annonc/mdf124; RYAN AJ, 1991, NUCLEIC ACIDS RES, V19, P3295, DOI 10.1093/nar/19.12.3295; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Schmitt CA, 2001, BLOOD CELL MOL DIS, V27, P206, DOI 10.1006/bcmd.2000.0372; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Seiter K, 1997, J CLIN ONCOL, V15, P44, DOI 10.1200/JCO.1997.15.1.44; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; Sherr CJ, 2000, CANCER RES, V60, P3689; Shin MS, 2001, CANCER RES, V61, P4942; Shin MS, 2002, BLOOD, V99, P4094, DOI 10.1182/blood.V99.11.4094; Shin MS, 2002, ONCOGENE, V21, P4129, DOI 10.1038/sj.onc.1205527; Shivapurkar N, 2002, CANCER BIOL THER, V1, P65, DOI 10.4161/cbt.1.1.45; Shuai K, 1996, ONCOGENE, V13, P247; Silke J, 2001, J CELL SCI, V114, P1821; Simonian PL, 1997, BLOOD, V90, P1208, DOI 10.1182/blood.V90.3.1208.1208_1208_1216; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Slee EA, 2001, J BIOL CHEM, V276, P7320, DOI 10.1074/jbc.M008363200; Smith KGC, 1996, EMBO J, V15, P5167, DOI 10.1002/j.1460-2075.1996.tb00901.x; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; Stahnke K, 2001, BLOOD, V98, P3066, DOI 10.1182/blood.V98.10.3066; Stoelcker B, 2000, AM J PATHOL, V156, P1171, DOI 10.1016/S0002-9440(10)64986-3; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; STRASSER A, 1993, ONCOGENE, V8, P1; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Tamm I, 2000, CLIN CANCER RES, V6, P1796; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Theodorakis P, 2002, CANCER RES, V62, P3373; Theodoropoulos PA, 1999, CANCER RES, V59, P4625; Thomas A, 1996, ONCOGENE, V12, P1055; Tillman DM, 1999, CLIN CANCER RES, V5, P425; Tolcher AW, 2001, SEMIN ONCOL, V28, P67, DOI 10.1016/S0093-7754(01)90158-7; Tzung SP, 2001, NAT CELL BIOL, V3, P183, DOI 10.1038/35055095; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2002, APOPTOSIS, V7, P163, DOI 10.1023/A:1014318615955; Villunger A, 1997, CANCER RES, V57, P3331; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Vucic D, 2000, CURR BIOL, V10, P1359, DOI 10.1016/S0960-9822(00)00781-8; Wachenfeld C, 2001, EUR J ENDOCRINOL, V145, P335, DOI 10.1530/eje.0.1450335; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; Wang JL, 2000, CANCER RES, V60, P1498; Waters JS, 2000, J CLIN ONCOL, V18, P1812, DOI 10.1200/JCO.2000.18.9.1812; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wu JW, 2001, MOL CELL, V8, P95, DOI 10.1016/S1097-2765(01)00282-9; WYLLIE AH, 1985, ANTICANCER RES, V5, P131; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang LL, 2003, CANCER RES, V63, P831; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; YIN DX, 1995, CANCER RES, V55, P4922; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zheng TS, 1999, CELL DEATH DIFFER, V6, P1043, DOI 10.1038/sj.cdd.4400593; Zheng TS, 2000, EXP CELL RES, V256, P67, DOI 10.1006/excr.2000.4841; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou P, 2001, BLOOD, V97, P3902, DOI 10.1182/blood.V97.12.3902; Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	243	234	245	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2003	22	47					7414	7430		10.1038/sj.onc.1206945	http://dx.doi.org/10.1038/sj.onc.1206945			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KL	14576849				2022-12-17	WOS:000186112500014
J	Clark, SJ; Melki, J				Clark, SJ; Melki, J			DNA methylation and gene silencing in cancer: which is the guilty party?	ONCOGENE			English	Article						DNA methylation; gene expression; silencing; trigger; cancer	CPG-ISLAND METHYLATION; ACUTE MYELOID-LEUKEMIA; DE-NOVO METHYLATION; METHYLTRANSFERASE GENE; MAMMALIAN DEVELOPMENT; P16(INK4) EXPRESSION; MOUSE; PROMOTER; CELLS; HYPOMETHYLATION	The DNA methylation pattern of a cell is exquisitely controlled during early development resulting in distinct methylation patterns. The tight control of DNA methylation is released in the cancer cell characterized by a reversal of methylation states. CpG island associated genes, in particular tumour suppressor or related genes, are often hypermethylated and this is associated with silencing of these genes. Therefore methylation is commonly convicted as a critical causal event in silencing this important class of genes in cancer. In this review, we argue that methylation is not the initial guilty party in triggering gene silencing in cancer, but that methylation of CpG islands is a consequence of prior gene silencing, similar to the role of methylation in maintaining the silencing of CpG island genes on the inactive X chromosome. We propose that gene silencing is the critical precursor in cancer, as it changes the dynamic interplay between de novo methylation and demethylation of the CpG island and tilts the balance to favour hypermethylation and chromatin inactivation.	CSIRO Mol Sci, Sydney Lab, N Ryde, NSW 1670, Australia; Royal Prince Alfred Hosp, Kanematsu Labs, Sydney Canc Ctr, Camperdown, NSW 2050, Australia; Univ Sydney, Fac Med, Sydney, NSW 2050, Australia	Commonwealth Scientific & Industrial Research Organisation (CSIRO); University of Sydney; University of Sydney	Clark, SJ (corresponding author), CSIRO Mol Sci, Sydney Lab, POB 184, N Ryde, NSW 1670, Australia.		Clark, Susan J/U-7365-2019; Clark, Susan J/B-2272-2008	Clark, Susan J/0000-0001-5925-5030; Clark, Susan J/0000-0001-5925-5030				Aggerholm A, 1999, CANCER RES, V59, P436; Alves G, 1996, GENE, V176, P39, DOI 10.1016/0378-1119(96)00205-3; ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Baylin SB, 1998, ADV CANCER RES, V72, P141; BELINSKY SA, 1996, P NATL ACAD SCI USA, V93, P4054; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; Bestor TH, 1996, NAT GENET, V12, P363, DOI 10.1038/ng0496-363; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Cameron EE, 1999, BLOOD, V94, P2445, DOI 10.1182/blood.V94.7.2445.419k19_2445_2451; Cervoni N, 2001, J BIOL CHEM, V276, P40778, DOI 10.1074/jbc.M103921200; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Costello JF, 2001, J MED GENET, V38, P285, DOI 10.1136/jmg.38.5.285; Csankovszki G, 2001, J CELL BIOL, V153, P773, DOI 10.1083/jcb.153.4.773; De Smet C, 1999, MOL CELL BIOL, V19, P7327; Ehrlich M, 2000, J CLIN LIGAND ASSAY, V23, P144; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gitan RS, 2002, GENOME RES, V12, P158, DOI 10.1101/gr.202801; HOLLIDAY R, 1975, SCIENCE, V187, P226, DOI 10.1126/science.1111098; HOWLETT SK, 1991, DEVELOPMENT, V113, P119; Huschtscha LI, 1998, CANCER RES, V58, P3508; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Jost JP, 1997, NUCLEIC ACIDS RES, V25, P4545, DOI 10.1093/nar/25.22.4545; Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10366, DOI 10.1073/pnas.93.19.10366; LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; Mayer W, 2000, NATURE, V403, P501, DOI 10.1038/35000656; Melki JR, 2000, BLOOD, V95, P3208; Melki JR, 1999, CANCER RES, V59, P3730; Melki JR, 1998, LEUKEMIA, V12, P311, DOI 10.1038/sj.leu.2400932; Mermoud JE, 2002, CURR BIOL, V12, P247, DOI 10.1016/S0960-9822(02)00660-7; Millar DS, 2000, J BIOL CHEM, V275, P24893, DOI 10.1074/jbc.M906538199; Millar DS, 1999, ONCOGENE, V18, P1313, DOI 10.1038/sj.onc.1202415; Mizuno S, 2001, BLOOD, V97, P1172, DOI 10.1182/blood.V97.5.1172; MOLLOY PL, 1990, PHILOS T ROY SOC B, V326, P267, DOI 10.1098/rstb.1990.0010; MONK M, 1990, PHILOS T R SOC B, V326, P299, DOI 10.1098/rstb.1990.0013; MONK M, 1987, DEVELOPMENT, V99, P371; Morgan HD, 1999, NAT GENET, V23, P314, DOI 10.1038/15490; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Noble JR, 1996, ONCOGENE, V13, P1259; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; Pogribny IP, 1997, CANCER LETT, V115, P31, DOI 10.1016/S0304-3835(97)04708-3; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; RIGGS AD, 1975, CYTOGENET CELL GENET, V14, P9, DOI 10.1159/000130315; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Schmutte C, 1996, CANCER RES, V56, P2375; Schwarz S, 2000, EUR J CELL BIOL, V79, P488, DOI 10.1078/0171-9335-00070; Song JZ, 2002, ONCOGENE, V21, P1048, DOI 10.1038/sj.onc.1205153; Stern LL, 2000, CANCER EPIDEM BIOMAR, V9, P849; Stirzaker C, 1997, CANCER RES, V57, P2229; THAYER RE, 1993, GENE, V133, P273, DOI 10.1016/0378-1119(93)90651-I; VACHTENHEIM J, 1994, CANCER RES, V54, P1145; Warnecke PM, 1998, GENOMICS, V51, P182, DOI 10.1006/geno.1998.5371; Warnecke PM, 1999, MOL CELL BIOL, V19, P164; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5	71	234	244	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	2002	21	35					5380	5387		10.1038/sj.onc.1205598	http://dx.doi.org/10.1038/sj.onc.1205598			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579VC	12154400	Bronze			2022-12-17	WOS:000177197700004
J	Glaunsinger, BA; Lee, SS; Thomas, M; Banks, L; Javier, R				Glaunsinger, BA; Lee, SS; Thomas, M; Banks, L; Javier, R			Interactions of the PDZ-protein MAGI-1 with adenovirus E4-ORF1 and high-risk papillomavirus E6 oncoproteins	ONCOGENE			English	Article						adenovirus E4-ORF1; MAGI-1; papillomavirus; E6; PDZ	LARGE TUMOR-SUPPRESSOR; READING FRAME-1 ENCODES; MOLECULAR CHARACTERIZATION; TIGHT JUNCTION; SEPTATE JUNCTIONS; GUANYLATE KINASE; MAMMARY-TUMORS; HUMAN HOMOLOG; CREF CELLS; TYPE-9	The oncoproteins of small DNA tumor viruses promote tumorigenesis by complexing with cellular factors intimately involved in the control of cell proliferation. The major oncogenic determinants for human adenovirus type 9 (Ad9) and high-risk human papillomaviruses (HPV) are the E4-ORF1 and E6 proteins, respectively. These seemingly unrelated viral oncoproteins are similar in that their transforming activities in cells depend, in part, on a carboxyl-terminal PDZ domain-binding motif which mediates interactions with the cellular PDZ-protein DLG. Here we demonstrated that both Ad9 E4-ORF1 and high-risk HPV E6 proteins also bind to the DLG-related PDZ-protein MAGI-1. These interactions resulted in MAGI-1 being aberrantly sequestered in the cytoplasm by the Ad9 E4-ORF1 protein or being targeted for degradation by high-risk HPV E6 proteins. Transformation-defective mutant viral proteins, however, were deficient for these activities. Our findings indicate that MAGI-1 is a member of a select group of cellular PDZ proteins targeted by both adenovirus E4-ORF1 and high-risk HPV E6 proteins and, in addition, suggest that the tumorigenic potentials of these viral oncoproteins depend, in part, on an ability to inhibit the function of MAGI-1 in cells.	Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	Baylor College of Medicine; International Center for Genetic Engineering & Biotechnology (ICGEB)	Javier, R (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R01CA058541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007471] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA058541, R01CA58541, R01 CA058541-06] Funding Source: Medline; NIAID NIH HHS [T32 AI007471, T32AI07471] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Dobrosotskaya I, 1997, J BIOL CHEM, V272, P31589, DOI 10.1074/jbc.272.50.31589; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; FISHER PB, 1982, P NATL ACAD SCI-BIOL, V79, P3527, DOI 10.1073/pnas.79.11.3527; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Gottardi CJ, 1996, P NATL ACAD SCI USA, V93, P10779, DOI 10.1073/pnas.93.20.10779; Harlow E, 1988, ANTIBODIES LABORATOR, P359; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; Howley M. P., 1996, FIELDS VIROLOGY, P2045; JAVIER R, 1991, J VIROL, V65, P3192, DOI 10.1128/JVI.65.6.3192-3202.1991; JAVIER RT, 1994, J VIROL, V68, P3917, DOI 10.1128/JVI.68.6.3917-3924.1994; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; MCALLISTER RM, 1971, NATURE-NEW BIOL, V230, P279, DOI 10.1038/newbio230279a0; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; NEVINS JR, 1996, FIELDS VIROLOGY, V1, P301; Philipp S, 1997, FEBS LETT, V413, P243, DOI 10.1016/S0014-5793(97)00877-6; PRASAD R, 1993, CANCER RES, V53, P5624; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHENK T, 1996, FIELDS VIROLOGY, V2, P2111; SMITH DB, 1994, CURRENT PROTOCOLS MO, V2; Thomas DL, 1999, J VIROL, V73, P3071, DOI 10.1128/JVI.73.4.3071-3079.1999; Thomas U, 1997, MECH DEVELOP, V62, P161, DOI 10.1016/S0925-4773(97)00658-8; Weiss RS, 1997, J VIROL, V71, P4385, DOI 10.1128/JVI.71.6.4385-4394.1997; Weiss RS, 1996, J VIROL, V70, P862, DOI 10.1128/JVI.70.2.862-872.1996; Weiss RS, 1997, J VIROL, V71, P7873, DOI 10.1128/JVI.71.10.7873-7880.1997; Weiss RS, 1997, J VIROL, V71, P1857, DOI 10.1128/JVI.71.3.1857-1870.1997; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Wu HJ, 1998, J CELL SCI, V111, P2365; Yang N, 1998, EXP CELL RES, V241, P242, DOI 10.1006/excr.1998.4053	37	234	247	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	2000	19	46					5270	5280		10.1038/sj.onc.1203906	http://dx.doi.org/10.1038/sj.onc.1203906			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	369HK	11077444	Green Accepted			2022-12-17	WOS:000165059700008
J	Shimizu, S; Eguchi, Y; Kamiike, W; Waguri, S; Uchiyama, Y; Matsuda, H; Tsujimoto, Y				Shimizu, S; Eguchi, Y; Kamiike, W; Waguri, S; Uchiyama, Y; Matsuda, H; Tsujimoto, Y			Retardation of chemical hypoxia-induced necrotic cell death by Bcl-2 and ICE inhibitors: Possible involvement of common mediators in apoptotic and necrotic signal transductions	ONCOGENE			English	Article						bcl-2; bcl-x; apoptosis; necrosis; hypoxia; cell death; mitochondria	GROWTH-FACTOR; GENE CED-3; EXPRESSION; PROTEIN; ENZYME; SURVIVAL; ENCODES; INJURY; LINES	Inhibition of the respiratory chain reaction by cyanide, rotenone or antimycin A (chemical hypoxia) induces necrotic cell death characterized by apparently intact chromatin, remarkable mitochondrial swelling with loss of crista structure, and loss of plasma membrane integrity, The treatments induce no apoptotic cell death, as defined by fragmented nuclei with condensed chromatin, fragmented or condensed cytoplasm, The anti-apoptotic proteins Bcl-2 and Bcl-x(L) effectively retard the chemical hypoxia-induced necrotic cell death, The necrotic cell death is also retarded by inhibitors of ICE(-like) proteases, including interleukin-1 beta converting enzyme (ICE), which are common mediators of apoptosis, These results indicate that Bcl-2/Bcl-x(L) and ICE(-like) proteases modulate apoptotic and at least some forms of necrotic cell death, Both cell death pathways appear to involve some common mediators; however necrotic or apoptotic cell death signals might be transduced through multiple pathways, because Bcl-2/Bcl-x(L) or inhibitors of ICE(-like) proteases are relatively less potent in blocking necrotic cell death than in preventing apoptosis.	OSAKA UNIV, SCH MED, BIOMED RES CTR, DEPT MED GENET, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, DEPT SURG 1, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, DEPT PHYSIOL 1, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, DEPT ANAT 1, SUITA, OSAKA 565, JAPAN	Osaka University; Osaka University; Osaka University; Osaka University								ALISON MR, 1994, GUT, V35, P577, DOI 10.1136/gut.35.5.577; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; DAVIES KJA, 1986, J BIOL CHEM, V261, P3060; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GORES GJ, 1990, HEPATOLOGY, V11, P690, DOI 10.1002/hep.1840110425; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAWKINS HK, 1972, AM J PATHOL, V68, P255; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; KANE DJ, 1995, J NEUROSCI RES, V40, P269, DOI 10.1002/jnr.490400216; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PEZZELLA F, 1990, AM J PATHOL, V137, P225; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SHIMIZU S, 1996, IN PRESS CANC RES; SHIMIZU S, 1996, IN PRESS ONCOGENE; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TSUJIMOTO Y, 1989, ONCOGENE, V4, P1331; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TSUJIMOTO Y, 1995, APOPTOSIS BCL 2 ANTI; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H	34	234	237	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	1996	12	10					2045	2050						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668329				2022-12-17	WOS:A1996UP28300002
J	YAMAIZUMI, M; SUGANO, T				YAMAIZUMI, M; SUGANO, T			UV-INDUCED NUCLEAR ACCUMULATION OF P53 IS EVOKED THROUGH DNA-DAMAGE OF ACTIVELY TRANSCRIBED GENES INDEPENDENT OF THE CELL-CYCLE	ONCOGENE			English	Article							TUMOR-ANTIGEN; COCKAYNE SYNDROME; SV40-TRANSFORMED CELLS; ATAXIA-TELANGIECTASIA; ULTRAVIOLET-RADIATION; TRANSFORMED-CELLS; ALPHA-AMANITIN; T-ANTIGEN; PROTEIN; REPAIR	Induction of p53 in u.v.-irradiated primary human fibroblasts was monitored by immunostaining and Western blotting. Minimum u.v. doses required for induction of nuclear accumulation of p53 (minimum response dose: MRD) were estimated in various cells with different DNA repair capacities. The MRD in repair deficient xeroderma pigmentosum (XP) group A cells is eightfold lower than in normal cells, indicating that nuclear accumulation of p53 is related to DNA repair capacity. Cells from patients with another u.v. sensitive disorder, Cockayne syndrome (CS), which have normal repair capacity for the overall genome but have a specific defect in preferential repair of lesions in active genes, have the same low MRD as of XP-A cells. Furthermore, the MRD in XP-C cells, which have normal preferential repair but have defects in overall genome repair, is as high as that of normal cells. DNA damage induced by X-ray is repaired at similar rates in normal, XP and CS cells. In contrast to u.v.-irradiation, the minimum dose of X-rays that induces nuclear accumulation of p53 is the same in these cells. Inhibition of transcription with alpha-amanitin evokes nuclear accumulation of p53 both in normal cells and in XP cells. These results strongly suggest that u.v.-induced nuclear accumulation of p53 is evoked through DNA damage of actively transcribed genes. Nuclear accumulation of p53 is observed in any phase of the cell cycle at both low and high u.v. doses.			YAMAIZUMI, M (corresponding author), KUMAMOTO UNIV,SCH MED,INST MOLEC EMBRYOL & GENET,KUMAMOTO 862,JAPAN.							AHMED FE, 1978, BIOCHIM BIOPHYS ACTA, V521, P805, DOI 10.1016/0005-2787(78)90319-2; ANDREWS AD, 1978, P NATL ACAD SCI USA, V75, P1984, DOI 10.1073/pnas.75.4.1984; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CLEAVER J, 1989, METABOLIC BASIS INHE, P2948; COULIER F, 1985, EMBO J, V4, P3413, DOI 10.1002/j.1460-2075.1985.tb04098.x; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRIEDBERG EC, 1985, DNA REPAIR, P503; Harlow E, 1988, ANTIBODIES LABORATOR, P359; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JACOB ST, 1970, NATURE, V225, P60, DOI 10.1038/225060b0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KEDINGER C, 1970, BIOCHEM BIOPH RES CO, V38, P165, DOI 10.1016/0006-291X(70)91099-5; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LANE DP, 1992, NATURE, V358, P17; LEHMANN AR, 1977, CANCER RES, V37, P904; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; OREN M, 1983, EMBO J, V2, P1633, DOI 10.1002/j.1460-2075.1983.tb01637.x; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; TOSCHI L, 1988, J CELL BIOL, V107, P1623, DOI 10.1083/jcb.107.5.1623; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; WADE MH, 1979, MUTAT RES, V59, P49, DOI 10.1016/0027-5107(79)90194-5; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0	40	234	235	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2775	2784						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084582				2022-12-17	WOS:A1994PG82200002
J	HU, NP; GUTSMANN, A; HERBERT, DC; BRADLEY, A; LEE, WH; LEE, EYHP				HU, NP; GUTSMANN, A; HERBERT, DC; BRADLEY, A; LEE, WH; LEE, EYHP			HETEROZYGOUS RB-1(DELTA-20)/+ MICE ARE PREDISPOSED TO TUMORS OF THE PITUITARY-GLAND WITH A NEARLY COMPLETE PENETRANCE	ONCOGENE			English	Article							RETINOBLASTOMA GENE-PRODUCT; BLADDER-CARCINOMA CELLS; SV40 LARGE-T; SUSCEPTIBILITY GENE; INTERMEDIATE LOBE; CELLULAR PROTEINS; MOLECULAR-CLONING; ENCODED PROTEIN; BINDING PROTEIN; CDC2 KINASE	Humans with a germline mutation of the RB gene are predisposed to retinoblastoma with a 90% penetrance and are at higher risk for other rare tumors. We have established a mouse strain carrying a germ-line mutation of the Rh-1 gene. Here we describe a nearly 100% incidence of spontaneous pituitary tumors which arise in Rb-1 heterozygous mice from ages 2 to 11 months. Histological and immunological analysis indicate that these tumors originate from the intermediate lobe of the pituitary gland, which is a vestigial structure in adult humans. Progression of the tumors can be followed by the elevated level of a specific proteotytic product of pro-opiomelanocortin prohormone, alpha-melanocyte stimulating hormone, in the circulating blood of the tumor-bearing animals. Multiple foci are frequently seen in the tiny intermediate lobe of the pituitary gland which contains approximately 1.5 x 10(5) cells. The tumor tissues invariably lose expression of full-length Rb protein due to loss of the single wild-type Rb-1 allele. The Rb knock out mouse strain provides a unique model for addressing tissue-specific tumor predisposition by inactivation of a ubiquitously expressed tumor suppressor gene.	UNIV TEXAS,HLTH SCI CTR,CTR MOLEC MED,INST BIOTECHNOL,SAN ANTONIO,TX 78284; UNIV TEXAS,HLTH SCI CTR,DEPT CELLULAR & STRUCT BIOL,SAN ANTONIO,TX 78284; BAYLOR COLL MED,INST MOLEC GENET,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute				Bradley, Allan/0000-0002-2349-8839				BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CASTRO MG, 1989, J NEUROCHEM, V52, P1619, DOI 10.1111/j.1471-4159.1989.tb09217.x; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHANG CY, 1993, CELL GROWTH DIFFER, V4, P1057; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DONOSO LA, 1985, ARCH OPHTHALMOL-CHIC, V103, P855, DOI 10.1001/archopht.1985.01050060115039; DRYJA TP, 1986, P NATL ACAD SCI USA, V83, P7391, DOI 10.1073/pnas.83.19.7391; Eipper B A, 1980, Endocr Rev, V1, P1; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GLASER T, 1990, SCIENCE, V250, P823, DOI 10.1126/science.2173141; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; GOODRICH DW, 1992, CANCER RES, V52, P1968; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOLMES RL, 1974, PITUITARY GLAND COMP, P5; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATO J, 1993, GENE DEV, V7, P331; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; KYRITSIS AP, 1984, NATURE, V307, P471, DOI 10.1038/307471a0; LAMBERTS SWJ, 1982, J CLIN ENDOCR METAB, V54, P286, DOI 10.1210/jcem-54-2-286; LEE EYH, 1991, DIVERSE MUTATIONS LE; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEE WH, 1991, COLD SH Q B, V56, P211; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MATSUNAGA E, 1980, HUM GENET, V56, P127; MAYOL X, 1993, ONCOGENE, V8, P2561; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MIRSHAHI M, 1986, CANCER-AM CANCER SOC, V57, P1497, DOI 10.1002/1097-0142(19860415)57:8<1497::AID-CNCR2820570810>3.0.CO;2-H; NEVINS JR, 1992, SCIENCE, V258, P424; PENNY RJ, 1978, NEUROENDOCRINOLOGY, V25, P193, DOI 10.1159/000122741; PEREZ FM, 1990, ENDOCRINOLOGY, V127, P1877, DOI 10.1210/endo-127-4-1877; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; ROBERTS JL, 1980, BIOCHEM, V17, P3609; RODRIGUES MM, 1987, OPHTHALMOLOGY, V94, P378; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SZEKELY L, 1992, CELL GROWTH DIFFER, V3, P139; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; VOGEL F, 1979, HUM GENET, V52, P1; VOSS JW, 1992, CELL, V70, P527, DOI 10.1016/0092-8674(92)90422-9; WANG NP, 1993, ONCOGENE, V8, P279; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WINGSTRAND KG, 1966, PITUITARY GLAND, P1; XU HJ, 1989, ONCOGENE, V4, P807	67	234	236	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1021	1027						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134105				2022-12-17	WOS:A1994NC04800003
J	GIORDANO, S; DIRENZO, MF; NARSIMHAN, RP; COOPER, CS; ROSA, C; COMOGLIO, PM				GIORDANO, S; DIRENZO, MF; NARSIMHAN, RP; COOPER, CS; ROSA, C; COMOGLIO, PM			BIOSYNTHESIS OF THE PROTEIN ENCODED BY THE C-MET PROTO-ONCOGENE	ONCOGENE			English	Article									UNIV TURIN,DEPT BIOMED SCI & ONCOL,C SO MASSIMO DAZEGLIO 52,I-10126 TURIN,ITALY; INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND	University of Turin; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK			Giordano, Silvia/J-9858-2018; DI RENZO, Maria Flavia/B-6091-2012	Giordano, Silvia/0000-0003-1854-1086; DI RENZO, Maria Flavia/0000-0002-5093-3373; Comoglio, Paolo/0000-0002-7056-5328				BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHAN AML, 1987, ONCOGENE, V1, P229; COMOGLIO PM, 1984, EMBO J, V3, P483, DOI 10.1002/j.1460-2075.1984.tb01834.x; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DEAN M, 1987, MOL CELL BIOL, V7, P921, DOI 10.1128/MCB.7.2.921; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; DEUTSCH PJ, 1983, P NATL ACAD SCI-BIOL, V80, P133, DOI 10.1073/pnas.80.1.133; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; GIORDANO S, 1988, MOL CELL BIOL, V8, P3510, DOI 10.1128/MCB.8.8.3510; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GOLDSTEIN BJ, 1988, J BIOL CHEM, V263, P12809; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; HEDO JA, 1983, J BIOL CHEM, V258, P20; KUDLOW JE, 1986, J BIOL CHEM, V261, P4134; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OLSON TS, 1987, J BIOL CHEM, V262, P6816; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; RONNETT GV, 1984, J BIOL CHEM, V259, P4566; TEMPEST PR, 1988, BRIT J CANCER, V58, P3, DOI 10.1038/bjc.1988.150; TEMPEST PR, 1986, FEBS LETT, V209, P357, DOI 10.1016/0014-5793(86)81142-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	23	234	244	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1989	4	11					1383	1388						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AX659	2554238				2022-12-17	WOS:A1989AX65900016
J	Peterson, LF; Zhang, DE				Peterson, LF; Zhang, DE			The 8; 21 translocation in leukemogenesis	ONCOGENE			English	Review						translocation; myeloid leukemia; RUNX; AML; ETO; MTG8	ACUTE MYELOID-LEUKEMIA; CORE-BINDING-FACTOR; ACUTE MYELOGENOUS LEUKEMIA; T(8/21) FUSION PROTEIN; ZINC-FINGER PROTEIN; DROSOPHILA SEGMENTATION GENE; STIMULATING FACTOR-RECEPTOR; T-CELL-RECEPTOR; DNA-BINDING; GRANULOCYTIC DIFFERENTIATION	A common chromosomal translocation in acute myeloid leukemia (AML) involves the AML1 ( acute myeloid leukemia 1, also called RUNX1, core binding factor protein (CBFalpha), and PEBP2alphaB) gene on chromosome 21 and the ETO (eight-twenty one, also called MTG8) gene on chromosome 8. This translocation generates an AML1-ETO fusion protein. t(8; 21) is associated with 12% of de novo AML cases and up to 40% in the AML subtype M2 of the French-American-British classification. Furthermore, it is also reported in a small portion of M0, M1, and M4 AML samples. Despite numerous studies on the function of AML1-ETO, the precise mechanism by which the fusion protein is involved in leukemia development is still not fully understood. In this review, we will discuss structural aspects of the fusion protein and the accumulated knowledge from in vitro analyses on AML1-ETO functions, and outline putative mechanisms of its leukemogenic potential.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Zhang, DE (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, Mail Drop MEM-L51, La Jolla, CA 92037 USA.	dzhang@scripps.edu	Molina, Maria del Carmen MC/H-9399-2015	Molina, Maria del Carmen MC/0000-0002-8397-5887	NCI NIH HHS [CA072009, CA096735] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA096735, P01CA072009] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn MY, 1998, P NATL ACAD SCI USA, V95, P1812, DOI 10.1073/pnas.95.4.1812; Alcalay M, 2003, J CLIN INVEST, V112, P1751, DOI 10.1172/JCI17595; Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Aplan PD, 1997, EMBO J, V16, P2408, DOI 10.1093/emboj/16.9.2408; Barseguian K, 2002, P NATL ACAD SCI USA, V99, P15434, DOI 10.1073/pnas.242588499; Burel SA, 2001, MOL CELL BIOL, V21, P5577, DOI 10.1128/MCB.21.16.5577-5590.2001; Calabi F, 1998, GENOMICS, V52, P332, DOI 10.1006/geno.1998.5429; Chen JD, 1998, CRIT REV EUKAR GENE, V8, P169, DOI 10.1615/CritRevEukarGeneExpr.v8.i2.40; Chen XN, 1997, BLOOD, V90, P156; Chevallier N, 2004, BLOOD, V103, P1454, DOI 10.1182/blood-2003-06-2081; Davie JR, 1999, BIOCHEM CELL BIOL, V77, P265, DOI 10.1139/bcb-77-4-265; Davie JR, 1997, MOL BIOL REP, V24, P197, DOI 10.1023/A:1006811817247; Davis JN, 1999, ONCOGENE, V18, P1375, DOI 10.1038/sj.onc.1202412; de Guzman CG, 2002, MOL CELL BIOL, V22, P5506, DOI 10.1128/MCB.22.15.5506-5517.2002; DEGREEF GE, 1995, LEUKEMIA, V9, P282; DUFFY JB, 1991, GENE DEV, V5, P2176, DOI 10.1101/gad.5.12a.2176; Elagib KE, 2003, BLOOD, V101, P4333, DOI 10.1182/blood-2002-09-2708; Elsasser A, 2003, ONCOGENE, V22, P5646, DOI 10.1038/sj.onc.1206673; ERICKSON P, 1992, BLOOD, V80, P1825; ERICKSON PF, 1994, CANCER RES, V54, P1782; FEINSTEIN PG, 1995, GENETICS, V140, P573; Felix CA, 1998, BBA-GENE STRUCT EXPR, V1400, P233, DOI 10.1016/S0167-4781(98)00139-0; Frank R, 1995, ONCOGENE, V11, P2667; Fukuyama T, 2001, ONCOGENE, V20, P6225, DOI 10.1038/sj.onc.1204794; GAO JZ, 1991, P NATL ACAD SCI USA, V88, P4882, DOI 10.1073/pnas.88.11.4882; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Ghozi MC, 1996, P NATL ACAD SCI USA, V93, P1935, DOI 10.1073/pnas.93.5.1935; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759; Goetz TL, 2000, MOL CELL BIOL, V20, P81, DOI 10.1128/MCB.20.1.81-90.2000; Grisolano JL, 2003, P NATL ACAD SCI USA, V100, P9506, DOI 10.1073/pnas.1531730100; Gross CT, 1996, EMBO J, V15, P1961, DOI 10.1002/j.1460-2075.1996.tb00547.x; Gu TL, 2000, MOL CELL BIOL, V20, P91, DOI 10.1128/MCB.20.1.91-103.2000; Harada Y, 2001, BIOCHEM BIOPH RES CO, V284, P714, DOI 10.1006/bbrc.2001.5005; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; Hildebrand D, 2001, J BIOL CHEM, V276, P9889, DOI 10.1074/jbc.M010582200; Hock H, 2003, IMMUNITY, V18, P109, DOI 10.1016/S1074-7613(02)00501-0; HSIANG YHH, 1993, J IMMUNOL, V150, P3905; Hug BA, 2002, CANCER RES, V62, P2906; Hwang ES, 1999, FEBS LETT, V446, P86, DOI 10.1016/S0014-5793(99)00190-8; Imai Y, 1998, BIOCHEM BIOPH RES CO, V252, P582, DOI 10.1006/bbrc.1998.9705; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; Kanno T, 1998, MOL CELL BIOL, V18, P2444, DOI 10.1128/MCB.18.5.2444; Karsunky H, 2002, ONCOGENE, V21, P1571, DOI 10.1038/sj/onc/1205216; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; Kitabayashi I, 1998, MOL CELL BIOL, V18, P846, DOI 10.1128/MCB.18.2.846; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; Kohzaki H, 1999, ONCOGENE, V18, P4055, DOI 10.1038/sj.onc.1202735; Komori A, 1999, JPN J CANCER RES, V90, P60, DOI 10.1111/j.1349-7006.1999.tb00666.x; KOZU T, 1993, BLOOD, V82, P1270; Kurokawa M, 1996, ONCOGENE, V12, P883; Le XF, 1998, EUR J HAEMATOL, V60, P217; Levanon D, 1996, DNA CELL BIOL, V15, P175, DOI 10.1089/dna.1996.15.175; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Levanon D, 2001, GENE, V262, P23, DOI 10.1016/S0378-1119(00)00532-1; Li FQ, 2004, J BIOL CHEM, V279, P2873, DOI 10.1074/jbc.M310759200; Libermann TA, 1999, J BIOL CHEM, V274, P24671, DOI 10.1074/jbc.274.35.24671; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; Liu PT, 2003, NAT IMMUNOL, V4, P525, DOI 10.1038/ni925; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Lutterbach B, 1998, MOL CELL BIOL, V18, P3604, DOI 10.1128/MCB.18.6.3604; Mao SF, 1999, MOL CELL BIOL, V19, P3635; Mayall TP, 1997, GENE DEV, V11, P887, DOI 10.1101/gad.11.7.887; McGhee L, 2003, J CELL BIOCHEM, V89, P1005, DOI 10.1002/jcb.10548; McNeil S, 1999, P NATL ACAD SCI USA, V96, P14882, DOI 10.1073/pnas.96.26.14882; Melnick A, 2000, BLOOD, V96, P3939, DOI 10.1182/blood.V96.12.3939.h8003939_3939_3947; Melnick AM, 2000, MOL CELL BIOL, V20, P2075, DOI 10.1128/MCB.20.6.2075-2086.2000; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Mulloy JC, 2003, BLOOD, V102, P4369, DOI 10.1182/blood-2003-05-1762; Mulloy JC, 2002, BLOOD, V99, P15, DOI 10.1182/blood.V99.1.15; NISSON PE, 1992, CANCER GENET CYTOGEN, V63, P81, DOI 10.1016/0165-4608(92)90384-K; Odaka R, 2000, ONCOGENE, V19, P3584, DOI 10.1038/sj.onc.1203689; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; Rhoades KL, 1996, P NATL ACAD SCI USA, V93, P11895, DOI 10.1073/pnas.93.21.11895; ROWLEY JD, 1973, ANN GENET-PARIS, V16, P109; Saleque S, 2002, GENE DEV, V16, P301, DOI 10.1101/gad.959102; Schwieger M, 2002, J EXP MED, V196, P1227, DOI 10.1084/jem.20020824; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; Shimada H, 2002, LEUKEMIA, V16, P874, DOI 10.1038/sj.leu.2402465; Shimada H, 2000, BLOOD, V96, P655; SHIMIZU K, 1992, CANCER RES, V52, P6945; Shimizu K, 2000, BLOOD, V96, P288, DOI 10.1182/blood.V96.1.288.013k05_288_296; SUN WW, 1995, J VIROL, V69, P4941, DOI 10.1128/JVI.69.8.4941-4949.1995; TIGHE JE, 1993, BLOOD, V81, P592; TIGHE JE, 1995, CLIN SCI, V89, P215, DOI 10.1042/cs0890215; Tong B, 1998, MOL CELL BIOL, V18, P2462, DOI 10.1128/MCB.18.5.2462; TONKS A, 2002, BLOOD, V101, P2002; VANGALA RK, 2002, BLOOD, V101, P2002; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Wolford JK, 1998, GENE, V212, P103, DOI 10.1016/S0378-1119(98)00141-3; Wood JD, 2000, J CELL BIOL, V150, P939, DOI 10.1083/jcb.150.5.939; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; Xiao Z, 2001, LEUKEMIA, V15, P1906, DOI 10.1038/sj.leu.2402318; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Yuan YZ, 2001, P NATL ACAD SCI USA, V98, P10398, DOI 10.1073/pnas.171321298; Zeng CM, 1998, P NATL ACAD SCI USA, V95, P1585, DOI 10.1073/pnas.95.4.1585; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085; Zhang JS, 2001, MOL CELL BIOL, V21, P156, DOI 10.1128/MCB.21.1.156-163.2001; Zhang YM, 2002, P NATL ACAD SCI USA, V99, P3070, DOI 10.1073/pnas.042702899	113	233	258	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2004	23	24					4255	4262		10.1038/sj.onc.1207727	http://dx.doi.org/10.1038/sj.onc.1207727			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823BZ	15156181				2022-12-17	WOS:000221586000010
J	Krappmann, D; Emmerich, F; Kordes, U; Scharschmidt, E; Dorken, B; Scheidereit, C				Krappmann, D; Emmerich, F; Kordes, U; Scharschmidt, E; Dorken, B; Scheidereit, C			Molecular mechanisms of constitutive NF-kappa B/Rel activation in Hodgkin/Reed-Sternberg cells	ONCOGENE			English	Article						Hodgkin's disease; lymphoma; NF-kappa B; I kappa-B	UBIQUITIN-PROTEASOME PATHWAY; SIGNAL-INDUCED DEGRADATION; TUMOR-NECROSIS-FACTOR; B-ALPHA PROTEOLYSIS; RIBOSOMAL S6 KINASE; IN-VIVO; CYTOPLASMIC RETENTION; NUCLEAR TRANSLOCATION; INDUCED APOPTOSIS; DNA-BINDING	A common characteristic of malignant cells derived from patients wifh Hodgkin's disease (HD) is a high level of constitutive nuclear NF-kappa B/Rel activity, which stimulates proliferation and confers resistance to apoptosis, We have analysed the mechanisms that account for NF-kappa B activation in a panel of Hodgkin/Reed-Sternberg (H-RS) cell lines. Whereas two cell lines (L428 and KMH-2) expressed inactive I kappa B alpha, no significant changes in NF-kappa B or I kappa B expression were seen in other H-RS cells (L591, L1236 and HDLM-2), Constitutive NF-kappa-B was susceptible to inhibition by recombinant I kappa B alpha, suggesting that neither mutations in the NF-KB genes nor posttranslational modifications of NF-kappa B were involved. Endogenous I kappa B alpha was bound to p65 and displayed a very short half-life. I kappa B alpha. degradation could be blocked by inhibitors of the NF-kappa B activating pathway. Proteasomal inhibition caused an accumulation of phosphorylated I kappa B alpha and a reduction of NF-kappa B activity in HDLM-2 and L1236 cells. By in vitro kinase assays we demonstrate constitutive I kappa B kinase (IKK) activity in H-RS cells, indicating ongoing signal transduction, Furthermore, HRS cells secrete one or more factor(s) that were able to trigger NF-kappa B activation. We conclude that aberrant activation of IKK's, and in some cases defective I kappa Bs, lead to constitutive nuclear NF-kappa B activity, which in turn results in a growth advantage of Hodgkin's disease tumor cells.	Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany; Humboldt Univ, Univ Klinikum Charite, D-13122 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Scheidereit, C (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13122 Berlin, Germany.		Krappmann, Daniel/AAT-4354-2021; Krappmann, Daniel/ABF-4038-2021	Krappmann, Daniel/0000-0001-7640-3234; Krappmann, Daniel/0000-0001-7640-3234; Kordes, Uwe R./0000-0001-6375-2320				Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Bargou RC, 1996, BLOOD, V87, P4340, DOI 10.1182/blood.V87.10.4340.bloodjournal87104340; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; ERNST MK, 1995, MOL CELL BIOL, V15, P872; FOSS HD, 1993, BRIT J HAEMATOL, V84, P627, DOI 10.1111/j.1365-2141.1993.tb03138.x; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; Gilmore TD, 1997, J CLIN INVEST, V100, P2935, DOI 10.1172/JCI119843; HATADA EN, 1993, EMBO J, V12, P2781, DOI 10.1002/j.1460-2075.1993.tb05939.x; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Hirano F, 1998, MOL CELL BIOL, V18, P2596, DOI 10.1128/MCB.18.5.2596; HSU PL, 1989, AM J PATHOL, V135, P735; HSU SM, 1994, CRIT REV ONCOGENESIS, V5, P213, DOI 10.1615/CritRevOncog.v5.i2-3.60; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; Kanzler H, 1996, BLOOD, V87, P3429, DOI 10.1182/blood.V87.8.3429.bloodjournal8783429; KAUFMAN D, 1992, CRIT REV ONCOL HEMAT, V13, P135, DOI 10.1016/1040-8428(92)90021-H; Krappmann D, 1997, IMMUNOBIOLOGY, V198, P3, DOI 10.1016/S0171-2985(97)80022-8; Krappmann D, 1996, EMBO J, V15, P6716, DOI 10.1002/j.1460-2075.1996.tb01061.x; Kuppers R, 1996, ANN ONCOL, V7, P27; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Luque I, 1997, SEMIN CANCER BIOL, V8, P103, DOI 10.1006/scbi.1997.0061; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; MAY MJ, 1997, SEMIN CANCER BIOL, V8, P61; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Miyamoto S, 1998, MOL CELL BIOL, V18, P19, DOI 10.1128/MCB.18.1.19; MIYAMOTO S, 1994, MOL CELL BIOL, V14, P3276, DOI 10.1128/MCB.14.5.3276; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; RODRIGUEZ C, 1995, YEAST, V11, P15, DOI 10.1002/yea.320110103; Rodriguez MS, 1996, ONCOGENE, V12, P2425; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SchmidtUllrich R, 1996, DEVELOPMENT, V122, P2117; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; Serrano D, 1997, HAEMATOLOGICA, V82, P542; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Sonenshein GE, 1997, SEMIN CANCER BIOL, V8, P113, DOI 10.1006/scbi.1997.0062; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Visconti R, 1997, ONCOGENE, V15, P1987, DOI 10.1038/sj.onc.1201373; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Watanabe N, 1997, EMBO J, V16, P3609, DOI 10.1093/emboj/16.12.3609; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Wolf J, 1996, BLOOD, V87, P3418, DOI 10.1182/blood.V87.8.3418.bloodjournal8783418; Wood KM, 1998, ONCOGENE, V16, P2131, DOI 10.1038/sj.onc.1201735; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Wulczyn FG, 1998, NUCLEIC ACIDS RES, V26, P1724, DOI 10.1093/nar/26.7.1724; Wulczyn FG, 1996, J MOL MED, V74, P749, DOI 10.1007/s001090050078; XERRI L, 1992, INT J CANCER, V50, P689, DOI 10.1002/ijc.2910500504; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	70	233	239	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					943	953		10.1038/sj.onc.1202351	http://dx.doi.org/10.1038/sj.onc.1202351			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023670				2022-12-17	WOS:000078510600011
J	Ichimura, K; Schmidt, EE; Goike, HM; Collins, VP				Ichimura, K; Schmidt, EE; Goike, HM; Collins, VP			Human glioblastomas with no alterations of the CDKN2A (p16(INK4A), MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene	ONCOGENE			English	Article						astrocytomas; RB1; cell cycle; cyclin-dependent kinase inhibitor	DEPENDENT KINASE INHIBITORS; TUMOR-SUPPRESSOR GENE; HOMOZYGOUS DELETION; SUSCEPTIBILITY GENE; MALIGNANT GLIOMAS; HUMAN CANCER; CELL-LINES; C-MYC; AMPLIFICATION; EXPRESSION	A series of 195 human gliomas were studied as to the status of their CDKN2A, CDK4 and RB1 genes, Among 120 glioblastomas, 40% had no wild-type CDKN2A gene, 12% amplified the CDK4 gene, and 14% had no wild-type RB1 gene, With two exceptions, each tumour had only one of these abnormalities, Thus the majority of the glioblastomas (64%) had distinct genetic aberrations which would obviously disrupt the control of transition from G(1) to the S-phase of the cell cycle, A further 30% had loss of one allele of the CDKN2A and/or RB1 genes, Only seven (6%) glioblastomas had no abnormalities of these genes, Anaplastic astrocytomas showed similar changes to the glioblastomas but at lower frequencies - 34% showing no aberrations of the genes analysed, The astrocytomas showed solely loss of one allele of the RB1 gene in 28% of tumours, with retention of one wild-type copy, In the glioblastomas with no alterations of CDKN2A, CDK4 or RB1, several other genes (CCND1, CCND2, CCND3, CDK6, E2F, CDK7, MYC and MYCN) whose products take part in cell cycle regulation were examined, No abnormalities were detected, Thus some aberration of the CDKN2A, CDK4 and RB1 genes appears to be almost obligatory in glioblastomas.	KAROLINSKA HOSP,STOCKHOLM BRANCH,INST ONCOL & PATHOL,DIV TUMOR PATHOL,S-17176 STOCKHOLM,SWEDEN; KAROLINSKA HOSP,STOCKHOLM BRANCH,LUDWIG INST CANC RES,S-17176 STOCKHOLM,SWEDEN	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Ludwig Institute for Cancer Research								AAGAARD L, 1995, INT J CANCER, V61, P115, DOI 10.1002/ijc.2910610120; BLANQUET V, 1995, HUM MOL GENET, V4, P383, DOI 10.1093/hmg/4.3.383; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; COLLINS VP, 1993, FASEB J, V7, P926, DOI 10.1096/fasebj.7.10.8344489; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GAO X, 1995, ONCOGENE, V11, P1395; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; GRANA X, 1995, ONCOGENE, V11, P211; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HAMEL PA, 1993, FASEB J, V7, P846, DOI 10.1096/fasebj.7.10.8344484; HE J, 1994, CANCER RES, V54, P5804; HENSON JW, 1994, ANN NEUROL, V36, P714, DOI 10.1002/ana.410360505; HIRAMA T, 1995, BLOOD, V86, P841; HOGG A, 1993, P NATL ACAD SCI USA, V90, P7351, DOI 10.1073/pnas.90.15.7351; ICHIMURA K, 1994, CANCER RES, V54, P3127; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; LIU Y, 1995, HUM MOL GENET, V4, P727, DOI 10.1093/hmg/4.4.727; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; POLEDNAK AP, 1995, CANCER, V75, P330, DOI 10.1002/1097-0142(19950101)75:1+<330::AID-CNCR2820751315>3.0.CO;2-5; REIFENBERGER G, 1994, CANCER RES, V54, P4299; RUSSELL DS, 1989, PATHOLOGY TUMOURS NE, P83; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SACHSE R, 1994, ONCOGENE, V9, P39; SAKAI T, 1991, AM J HUM GENET, V48, P880; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SCRRANO M, 1993, NATURE, V366, P704; SHEFFIELD VC, 1993, GENOMICS, V16, P325, DOI 10.1006/geno.1993.1193; SHIMIZU T, 1994, AM J HUM GENET, V54, P793; SIMPSON JR, 1993, INT J RADIAT ONCOL, V26, P239, DOI 10.1016/0360-3016(93)90203-8; TOGUCHIDA J, 1993, GENOMICS, V17, P535, DOI 10.1006/geno.1993.1368; TRENT J, 1986, P NATL ACAD SCI USA, V83, P470, DOI 10.1073/pnas.83.2.470; Ueki K, 1996, CANCER RES, V56, P150; VENTER DJ, 1991, ONCOGENE, V6, P445; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	39	233	235	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					1065	1072						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806696				2022-12-17	WOS:A1996VG76600020
J	SETO, M; YAMAMOTO, K; IIDA, S; AKAO, Y; UTSUMI, KR; KUBONISHI, I; MIYOSHI, I; OHTSUKI, T; YAWATA, Y; NAMBA, M; MOTOKURA, T; ARNOLD, A; TAKAHASHI, T; UEDA, R				SETO, M; YAMAMOTO, K; IIDA, S; AKAO, Y; UTSUMI, KR; KUBONISHI, I; MIYOSHI, I; OHTSUKI, T; YAWATA, Y; NAMBA, M; MOTOKURA, T; ARNOLD, A; TAKAHASHI, T; UEDA, R			GENE REARRANGEMENT AND OVEREXPRESSION OF PRAD1 IN LYMPHOID MALIGNANCY WITH T(11/14)(Q13/Q32) TRANSLOCATION	ONCOGENE			English	Article							BCL-1 LOCUS; MOLECULAR-CLONING; CHROMOSOME 11Q13; SQUAMOUS-CELL; AMPLIFICATION; ESTABLISHMENT; BREAKPOINT; ONCOGENE; TUMORS; EXPRESSION	The proto-oncogene PRAD1 (parathyroid adenoma 1) on chromosome 11q13 was found to be overexpressed in all five B-cell lines with t(11;14)(q13;q32) translocation tested. One B-cell lymphoma and four myeloma cell lines with this translocation demonstrated more than 10-fold overexpression as determined by Northern blot analysis, when compared with normal lymphoid tissues such as thymus, spleen and lymph node. Hematopoietic cell lines without the translocation were also examined, but none of these demonstrated the overexpression, confirming that overexpression of the PRAD1 gene is associated with t(11;14) translocation. A truncated form of mRNA was seen in one of five cell lines with the translocation, SP-49. Hybridization with different regions of the PRAD1 cDNA revealed that the truncated form of mRNA retained the coding region but had lost the 3' untranslated region. Southern blot analysis demonstrated a gene rearrangement in this SP-49 cell line. To study the genetic alteration responsible for the truncated form of mRNA in this cell line, the rearranged allele as well as the germline allele were cloned. The restriction map revealed that the rearranged portion was at the 3' end of the PRAD1 gene, eliminating the mRNA-destabilizing signal AUUUA. Human-rodent hybrid cell analysis demonstrated that the region introduced 3' of PRAD1 was derived from chromosome 11. suggesting that the PRAD1 gene region is deleted at the 3' end. Overexpression of the PRAD1 gene in association with t(11;14)(q13;q32) translocation suggested that in these cases the regulation of PRAD1 was altered by the juxtaposed gene, most likely the immunoglobulin heavy-chain gene from chromosome 14.	AICHI CANC CTR, DEPT HEMATOL & CHEMOTHERAPY, NAGOYA, AICHI 464, JAPAN; AICHI CANC CTR, ULTRASTRUCT RES LAB, NAGOYA, AICHI 464, JAPAN; KOCHI MED SCH, DEPT INTERNAL MED, NANKOKU, KOCHI 78151, JAPAN; KAWASAKI MED SCH, DEPT INTERNAL MED, KURASHIKI, OKAYAMA 70101, JAPAN; OKAYAMA UNIV, SCH MED,INST CANC RES,DEPT PATHOL, OKAYAMA 700, JAPAN; MASSACHUSETTS GEN HOSP, ENDOCRINE UNIT, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; AICHI CANC CTR, IMMUNOL LAB,CHIKUSA KU, NAGOYA, AICHI 464, JAPAN	Aichi Cancer Center; Aichi Cancer Center; Kochi University; Kawasaki Medical School; Okayama University; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Aichi Cancer Center	SETO, M (corresponding author), AICHI CANC CTR, CHEMOTHERAPY LAB, CHIKUSA KU, NAGOYA, AICHI 464, JAPAN.		Motokura, Toru/X-3682-2019		NCI NIH HHS [CA55909] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055909] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI IU, 1989, ONCOGENE, V4, P89; ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; BERENSON JR, 1989, ONCOGENE, V4, P1111; CROCE CM, 1985, BLOOD, V65, P1; DAIBATA M, 1987, JPN J CANCER RES, V78, P1182; DAIBATA M, 1989, CANCER, V64, P1248, DOI 10.1002/1097-0142(19890915)64:6<1248::AID-CNCR2820640614>3.0.CO;2-5; LAMMIE GA, 1991, ONCOGENE, V6, P439; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEDEIROS LJ, 1990, BLOOD, V76, P2086; MEEKER TC, 1989, BLOOD, V74, P1801; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NAGAI T, 1991, INT J HEMATOL, V54, P141; NISHIKURA K, 1983, P NATL ACAD SCI-BIOL, V80, P4822, DOI 10.1073/pnas.80.15.4822; OHTSUKI T, 1989, BRIT J HAEMATOL, V73, P199, DOI 10.1111/j.1365-2141.1989.tb00252.x; PROCTOR AJ, 1991, ONCOGENE, V6, P789; RABBITTS PH, 1988, ONCOGENE, V3, P99; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SETO M, 1991, JPN J CANCER RES, V82, P65, DOI 10.1111/j.1349-7006.1991.tb01747.x; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SILVERMAN GA, 1990, P NATL ACAD SCI USA, V87, P9913, DOI 10.1073/pnas.87.24.9913; THEILLET C, 1989, ONCOGENE, V4, P915; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; WILLIAMS ME, 1991, BLOOD, V78, P493; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	27	233	235	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1992	7	7					1401	1406						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1535701				2022-12-17	WOS:A1992HZ97100019
J	Fulda, S; Kogel, D				Fulda, S.; Koegel, D.			Cell death by autophagy: emerging molecular mechanisms and implications for cancer therapy	ONCOGENE			English	Review							SUBEROYLANILIDE HYDROXAMIC ACID; HISTONE DEACETYLASE INHIBITOR; PROSTATE-CANCER; REGULATES AUTOPHAGY; BETULINIC ACID; UP-REGULATION; APOPTOSIS; OBATOCLAX; GX15-070; LEUKEMIA	Autophagy is a tightly-regulated catabolic process of cellular self-digestion by which cellular components are targeted to lysosomes for their degradation. Key functions of autophagy are to provide energy and metabolic precursors under conditions of starvation and to alleviate stress by removal of damaged proteins and organelles, which are deleterious for cell survival. Therefore, autophagy appears to serve as a pro-survival stress response in most settings. However, the role of autophagy in modulating cell death is highly dependent on the cellular context and its extent. There is an increasing evidence for cell death by autophagy, in particular in developmental cell death in lower organisms and in autophagic cancer cell death induced by novel cancer drugs. The death-promoting and - executing mechanisms involved in the different paradigms of autophagic cell death (ACD) are very diverse and complex, but a draft scenario of the key molecular targets involved in ACD is beginning to emerge. This review provides an up-to-date and comprehensive report on the molecular mechanisms of drug-induced autophagy-dependent cell death and highlights recent key findings in this exciting field of research.	[Fulda, S.] Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, D-60528 Frankfurt, Germany; [Fulda, S.] German Canc Consortium DKTK, Heidelberg, Germany; [Fulda, S.] German Canc Res Ctr, Heidelberg, Germany; [Koegel, D.] Goethe Univ Hosp, Ctr Neurol & Neurosurg, Expt Neurosurg, Frankfurt, Germany	Goethe University Frankfurt; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Goethe University Frankfurt; Goethe University Frankfurt Hospital	Fulda, S (corresponding author), Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, Komturstr 3a, D-60528 Frankfurt, Germany.	simone.fulda@kgu.de; koegel@em.uni-frankfurt.de		Kogel, Donat/0000-0003-1209-0210; Fulda, Simone/0000-0002-0459-6417	BMBF	BMBF(Federal Ministry of Education & Research (BMBF))	The expert secretarial assistance of C Hugenberg is greatly appreciated. This work has been partly supported by a grant from the BMBF (to SF).	Azad MB, 2008, AUTOPHAGY, V4, P195, DOI 10.4161/auto.5278; Balakrishnan K, 2008, BLOOD, V112, P1971, DOI 10.1182/blood-2007-12-126946; Basit F, 2013, CELL DEATH DIFFER, V20, P1161, DOI 10.1038/cdd.2013.45; Berry DL, 2007, CELL, V131, P1137, DOI 10.1016/j.cell.2007.10.048; Bonapace L, 2010, J CLIN INVEST, V120, P1310, DOI 10.1172/JCI39987; Brem EA, 2011, BRIT J HAEMATOL, V153, P599, DOI 10.1111/j.1365-2141.2011.08669.x; Calvo-Garrido J, 2010, AUTOPHAGY, V6, P686, DOI 10.4161/auto.6.6.12513; Cao Q, 2008, INT J BIOCHEM CELL B, V40, P272, DOI 10.1016/j.biocel.2007.07.020; Cea M, 2012, BLOOD, V120, P3519, DOI 10.1182/blood-2012-03-416776; Chen Y, 2008, CELL DEATH DIFFER, V15, P171, DOI 10.1038/sj.cdd.4402233; Chen YJ, 2014, ONCOTARGET, V5, P4845, DOI 10.18632/oncotarget.2045; Cheng P, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.17; Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751; Elgendy M, 2011, MOL CELL, V42, P23, DOI 10.1016/j.molcel.2011.02.009; Fimia GM, 2007, NATURE, V447, P1121, DOI 10.1038/nature05925; Frankel LB, 2011, EMBO J, V30, P4628, DOI 10.1038/emboj.2011.331; Friesen C, 2007, CANCER RES, V67, P1950, DOI 10.1158/0008-5472.CAN-06-3569; Fulda S, 2009, DRUG DISCOV TODAY, V14, P885, DOI 10.1016/j.drudis.2009.05.015; Galluzzi L, 2015, CELL DEATH DIFFER, V22, P58, DOI 10.1038/cdd.2014.137; Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96; Gao P, 2010, J BIOL CHEM, V285, P25570, DOI 10.1074/jbc.M110.118125; Ginet V, 2014, AUTOPHAGY, V10, P603, DOI 10.4161/auto.27722; Gonzalez P, 2012, CELL DEATH DIFFER, V19, P1337, DOI 10.1038/cdd.2012.10; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910; Heidari N, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.53; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hetschko H, 2008, NEOPLASIA, V10, P873, DOI 10.1593/neo.07842; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kanzawa T, 2005, ONCOGENE, V24, P980, DOI 10.1038/sj.onc.1208095; Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359; Katayama M, 2007, CELL DEATH DIFFER, V14, P548, DOI 10.1038/sj.cdd.4402030; Kaza N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096733; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Knizhnik AV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055665; Kroemer G, 2005, NAT MED, V11, P725, DOI 10.1038/nm1263; Lamy L, 2013, CANCER CELL, V23, P435, DOI 10.1016/j.ccr.2013.02.017; Lian J, 2011, CELL DEATH DIFFER, V18, P60, DOI 10.1038/cdd.2010.74; Lian JQ, 2010, AUTOPHAGY, V6, P1201, DOI [10.4161/auto.6.8.13549, 10.1038/cdd.2010.74]; Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426; Liu Y, 2013, P NATL ACAD SCI USA, V110, P20364, DOI 10.1073/pnas.1319661110; Liu YL, 2010, AUTOPHAGY, V6, P1057, DOI 10.4161/auto.6.8.13365; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735; Martin AP, 2009, CANCER BIOL THER, V8, P2084; Martin AP, 2009, MOL PHARMACOL, V76, P327, DOI 10.1124/mol.109.056309; McCoy F, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.86; Meng Y, 2008, MOL CANCER THER, V7, P2192, DOI 10.1158/1535-7163.MCT-08-0333; Munoz-Pinedo C, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.246; Nihira K, 2014, CANCER SCI, V105, P568, DOI 10.1111/cas.12396; Nikoletopoulou V, 2013, BBA-MOL CELL RES, V1833, P3448, DOI 10.1016/j.bbamcr.2013.06.001; Pan JX, 2010, CANCER LETT, V293, P167, DOI 10.1016/j.canlet.2010.01.006; Paoluzzi L, 2008, BLOOD, V111, P5350, DOI 10.1182/blood-2007-12-129833; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Pattingre S, 2006, CANCER RES, V66, P2885, DOI 10.1158/0008-5472.CAN-05-4412; Potze L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.139; Puissant A, 2010, CANCER RES, V70, P1042, DOI 10.1158/0008-5472.CAN-09-3537; Rami A, 2008, AUTOPHAGY, V4, P422, DOI 10.4161/auto.5778; Salazar M, 2009, J CLIN INVEST, V119, P1359, DOI 10.1172/JCI37948; Samara C, 2008, CELL DEATH DIFFER, V15, P105, DOI 10.1038/sj.cdd.4402231; Scarlatti F, 2008, CELL DEATH DIFFER, V15, P1318, DOI 10.1038/cdd.2008.51; Schwartz-Roberts JL, 2013, MOL CANCER THER, V12, P448, DOI 10.1158/1535-7163.MCT-12-0617; Shen HM, 2011, AUTOPHAGY, V7, P457, DOI 10.4161/auto.7.5.14226; Shen S, 2011, ONCOGENE, V30, P4544, DOI 10.1038/onc.2011.168; Sinha S, 2008, ONCOGENE, V27, pS137, DOI 10.1038/onc.2009.51; Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634; Tang Y, 2012, MOL PHARMACOL, V82, P322, DOI 10.1124/mol.112.078907; Vara D, 2011, CELL DEATH DIFFER, V18, P1099, DOI 10.1038/cdd.2011.32; Voss V, 2010, MOL CANCER RES, V8, P1002, DOI 10.1158/1541-7786.MCR-09-0562; Wang WJ, 2014, NAT CHEM BIOL, V10, P133, DOI [10.1038/NCHEMBIO.1406, 10.1038/nchembio.1406]; Wei Y, 2010, CLIN CANCER RES, V16, P3923, DOI 10.1158/1078-0432.CCR-10-0032; Wolter KG, 2006, NEOPLASIA, V8, P163, DOI 10.1593/neo.05691; Yamamoto S, 2008, ANTICANCER RES, V28, P1585; Yu L, 2006, P NATL ACAD SCI USA, V103, P4952, DOI 10.1073/pnas.0511288103; Yuan Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.191; Zhaorigetu S, 2008, AUTOPHAGY, V4, P1079, DOI 10.4161/auto.7066	76	232	236	1	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2015	34	40					5105	5113		10.1038/onc.2014.458	http://dx.doi.org/10.1038/onc.2014.458			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CS6ZP	25619832				2022-12-17	WOS:000362233400001
J	Yuan, X; Cai, C; Chen, S; Chen, S; Yu, Z; Balk, SP				Yuan, X.; Cai, C.; Chen, S.; Chen, S.; Yu, Z.; Balk, S. P. p			Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis	ONCOGENE			English	Review						androgen; androgen receptor; prostate cancer; castration-resistant prostate cancer	SERINE 81 PHOSPHORYLATION; LIGAND-BINDING DOMAIN; NUCLEAR RECEPTOR; SPLICE VARIANTS; GENE-EXPRESSION; BETA-CATENIN; STRUCTURAL BASIS; CELL-GROWTH; TYROSINE PHOSPHORYLATION; TRANSCRIPTIONAL ACTIVITY	The metabolic functions of androgen receptor (AR) in normal prostate are circumvented in prostate cancer (PCa) to drive tumor growth, and the AR also can acquire new growth-promoting functions during PCa development and progression through genetic and epigenetic mechanisms. Androgen deprivation therapy (ADT, surgical or medical castration) is the standard treatment for metastatic PCa, but patients invariably relapse despite castrate androgen levels (castration-resistant PCa, CRPC). Early studies from many groups had shown that AR was highly expressed and transcriptionally active in CRPC, and indicated that steroids from the adrenal glands were contributing to this AR activity. More recent studies showed that CRPC cells had increased expression of enzymes mediating androgen synthesis from adrenal steroids, and could synthesize androgens de novo from cholesterol. Phase III clinical trials showing a survival advantage in CRPC for treatment with abiraterone (inhibitor of the enzyme CYP17A1 required for androgen synthesis that markedly reduces androgens and precursor steroids) and for enzalutamide (new AR antagonist) have now confirmed that AR activity driven by residual androgens makes a major contribution to CRPC, and led to the recent Food and Drug Administration approval of both agents. Unfortunately, patients treated with these agents for advanced CRPC generally relapse within a year and AR appears to be active in the relapsed tumors, but the molecular mechanisms mediating intrinsic or acquired resistance to these AR-targeted therapies remain to be defined. This review outlines AR functions that contribute to PCa development and progression, the roles of intratumoral androgen synthesis and AR structural alterations in driving AR activity in CRPC, mechanisms of action for abiraterone and enzalutamide, and possible mechanisms of resistance to these agents.	[Yuan, X.; Cai, C.; Chen, S.; Chen, S.; Yu, Z.; Balk, S. P. p] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Hematol Oncol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Balk, SP (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Hematol Oncol, 330 Brookline Ave, Boston, MA 02215 USA.	sbalk@bidmc.harvard.edu	Cai, Changmeng/AAE-6835-2020; CHEN, Shaoyong/ABF-3357-2021	Cai, Changmeng/0000-0002-8701-2586	National Institutes of Health; Department of Defense Prostate Cancer Research Program; Prostate Cancer Foundation; NATIONAL CANCER INSTITUTE [K99CA166507] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense Prostate Cancer Research Program(United States Department of Defense); Prostate Cancer Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Work from the authors cited in this review has been supported by awards from the National Institutes of Health, Department of Defense Prostate Cancer Research Program and the Prostate Cancer Foundation. We apologize to the many colleagues whose work we were unable to discuss or cite.	Acevedo VD, 2007, CANCER CELL, V12, P559, DOI 10.1016/j.ccr.2007.11.004; Agoulnik IU, 2006, CANCER RES, V66, P10594, DOI 10.1158/0008-5472.CAN-06-1023; Agoulnik IU, 2005, CANCER RES, V65, P7959, DOI 10.1158/0008-5472.CAN-04-3541; Andersen RJ, 2010, CANCER CELL, V17, P535, DOI 10.1016/j.ccr.2010.04.027; Balk Steven P, 2008, Nucl Recept Signal, V6, pe001, DOI 10.1621/nrs.06001; Belandia B, 2005, MOL CELL BIOL, V25, P1425, DOI 10.1128/MCB.25.4.1425-1436.2005; BELANGER B, 1989, J STEROID BIOCHEM, V32, P695, DOI 10.1016/0022-4731(89)90514-1; Bhatt RS, 2011, OPEN PROSTATE CANC J, V4, P1; Bohl CE, 2007, J BIOL CHEM, V282, P13648, DOI 10.1074/jbc.M611711200; Bohl CE, 2005, P NATL ACAD SCI USA, V102, P6201, DOI 10.1073/pnas.0500381102; Cai CM, 2013, J CLIN INVEST, V123, P1109, DOI 10.1172/JCI66666; Cai CM, 2011, CANCER CELL, V20, P457, DOI 10.1016/j.ccr.2011.09.001; Cai CM, 2011, CANCER RES, V71, P6503, DOI 10.1158/0008-5472.CAN-11-0532; Cai CM, 2011, ENDOCR-RELAT CANCER, V18, pR175, DOI 10.1530/ERC-10-0339; Cai CM, 2009, CANCER RES, V69, P6027, DOI 10.1158/0008-5472.CAN-09-0395; Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008; Chan SC, 2012, J BIOL CHEM, V287, P19736, DOI 10.1074/jbc.M112.352930; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chen SY, 2006, P NATL ACAD SCI USA, V103, P15969, DOI 10.1073/pnas.0604193103; Chen SY, 2012, J BIOL CHEM, V287, P8571, DOI 10.1074/jbc.M111.325290; Chen SY, 2009, J BIOL CHEM, V284, P25576, DOI 10.1074/jbc.M109.043133; Chen SY, 2006, MOL CELL BIOL, V26, P929, DOI 10.1128/MCB.26.3.929-939.2006; Cheng ST, 2002, MOL ENDOCRINOL, V16, P1492, DOI 10.1210/me.16.7.1492; Chesire DR, 2002, ONCOGENE, V21, P8453, DOI 10.1038/sj.onc.1206049; Chinnaiyan AM, 2008, NEOPLASIA, V10, P177, DOI 10.1593/neo.07822; Chng KR, 2012, EMBO J, V31, P2810, DOI 10.1038/emboj.2012.112; Clegg NJ, 2012, CANCER RES, V72, P1494, DOI 10.1158/0008-5472.CAN-11-3948; CULIG Z, 1993, MOL ENDOCRINOL, V7, P1541, DOI 10.1210/me.7.12.1541; Curtin D, 2001, MOL ENDOCRINOL, V15, P1906, DOI 10.1210/me.15.11.1906; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; Dehm SM, 2008, CANCER RES, V68, P5469, DOI 10.1158/0008-5472.CAN-08-0594; Dehm SM, 2011, ENDOCR-RELAT CANCER, V18, pR183, DOI 10.1530/ERC-11-0141; DEWINTER JAR, 1994, AM J PATHOL, V144, P735; Dillard PR, 2008, MOL CELL ENDOCRINOL, V295, P115, DOI 10.1016/j.mce.2008.08.013; Eisenberger MA, 1998, NEW ENGL J MED, V339, P1036, DOI 10.1056/NEJM199810083391504; Ettinger SL, 2004, CANCER RES, V64, P2212, DOI 10.1158/0008-5472.CAN-2148-2; Fang Z, 2012, J BIOL CHEM, V287, P2090, DOI 10.1074/jbc.M111.323303; Farla P, 2005, J CELL SCI, V118, P4187, DOI 10.1242/jcs.02546; Gamble SC, 2007, ONCOGENE, V26, P1757, DOI 10.1038/sj.onc.1209967; Garcia-Bassets I, 2007, CELL, V128, P505, DOI 10.1016/j.cell.2006.12.038; Gaughan L, 2005, NUCLEIC ACIDS RES, V33, P13, DOI 10.1093/nar/gki141; Gaughan L, 2011, NUCLEIC ACIDS RES, V39, P1266, DOI 10.1093/nar/gkq861; GELLER J, 1985, SEMIN ONCOL, V12, P28; GELLER J, 1987, UROL RES, V15, P151; GELLER J, 1984, J UROLOGY, V132, P693, DOI 10.1016/S0022-5347(17)49829-6; Gioeli D, 2006, MOL ENDOCRINOL, V20, P503, DOI 10.1210/me.2005-0351; Gioeli D, 2012, MOL CELL ENDOCRINOL, V352, P70, DOI 10.1016/j.mce.2011.07.004; Gordon V, 2010, MOL ENDOCRINOL, V24, P2267, DOI 10.1210/me.2010-0238; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Gregory CW, 2004, J BIOL CHEM, V279, P7119, DOI 10.1074/jbc.M307649200; Gregory CW, 1998, CANCER RES, V58, P5718; Gregory CW, 2001, CANCER RES, V61, P4315; Grosse A, 2012, MOL CELL ENDOCRINOL, V352, P46, DOI 10.1016/j.mce.2011.06.032; Guo ZY, 2006, CANCER CELL, V10, P309, DOI 10.1016/j.ccr.2006.08.021; Guo ZY, 2009, CANCER RES, V69, P2305, DOI 10.1158/0008-5472.CAN-08-3795; Ha S, 2013, ONCOGENE, V32, P3992, DOI 10.1038/onc.2012.412; Ha S, 2011, ENDOCR-RELAT CANCER, V18, P245, DOI 10.1530/ERC-10-0204; He B, 2004, MOL CELL, V16, P425, DOI 10.1016/j.molcel.2004.09.036; He HSHS, 2010, NAT GENET, V42, P343, DOI 10.1038/ng.545; Hodgson MC, 2005, J BIOL CHEM, V280, P6511, DOI 10.1074/jbc.M408972200; Hodgson MC, 2008, MOL CANCER THER, V7, P3187, DOI 10.1158/1535-7163.MCT-08-0461; Hodgson MC, 2007, CANCER RES, V67, P8388, DOI 10.1158/0008-5472.CAN-07-0617; Hofland J, 2010, CANCER RES, V70, P1256, DOI 10.1158/0008-5472.CAN-09-2092; Holzbeierlein J, 2004, AM J PATHOL, V164, P217, DOI 10.1016/S0002-9440(10)63112-4; Hu Q, 2008, P NATL ACAD SCI USA, V105, P19199, DOI 10.1073/pnas.0810634105; Hu R, 2012, CANCER RES, V72, P3457, DOI 10.1158/0008-5472.CAN-11-3892; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; Huang ZH, 2012, ONCOTARGET, V3, P651, DOI 10.18632/oncotarget.531; Hur E, 2004, PLOS BIOL, V2, P1303, DOI 10.1371/journal.pbio.0020274; Jouravel N, 2007, ACTA CRYSTALLOGR D, V63, P1198, DOI 10.1107/S0907444907045702; Kang ZG, 2004, MOL ENDOCRINOL, V18, P2633, DOI 10.1210/me.2004-0245; Klokk TI, 2007, MOL CELL BIOL, V27, P1823, DOI 10.1128/MCB.01297-06; Knudsen KE, 1998, J BIOL CHEM, V273, P20213, DOI 10.1074/jbc.273.32.20213; Ko S, 2011, MOL ENDOCRINOL, V25, P433, DOI 10.1210/me.2010-0482; Kraus S, 2006, CANCER RES, V66, P11047, DOI 10.1158/0008-5472.CAN-06-0596; Kumar A, 2011, P NATL ACAD SCI USA, V108, P17087, DOI 10.1073/pnas.1108745108; Li Y, 2012, ONCOGENE, V31, P4759, DOI 10.1038/onc.2011.637; Li YM, 2013, CANCER RES, V73, P483, DOI 10.1158/0008-5472.CAN-12-3630; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Lin HK, 2003, J BIOL CHEM, V278, P50902, DOI 10.1074/jbc.M300676200; Lin HK, 2001, P NATL ACAD SCI USA, V98, P7200, DOI 10.1073/pnas.121173298; Locke JA, 2008, CANCER RES, V68, P6407, DOI 10.1158/0008-5472.CAN-07-5997; Locke JA, 2009, J STEROID BIOCHEM, V115, P126, DOI 10.1016/j.jsbmb.2009.03.011; Lu LF, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-22; Lu S, 1999, MOL ENDOCRINOL, V13, P376, DOI 10.1210/me.13.3.376; Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018; Mahajan NP, 2007, P NATL ACAD SCI USA, V104, P8438, DOI 10.1073/pnas.0700420104; MAHONEY EM, 1972, J UROLOGY, V108, P936, DOI 10.1016/S0022-5347(17)60911-X; Masiello D, 2002, J BIOL CHEM, V277, P26321, DOI 10.1074/jbc.M203310200; Massie CE, 2011, EMBO J, V30, P2719, DOI 10.1038/emboj.2011.158; Matias PM, 2000, J BIOL CHEM, V275, P26164, DOI 10.1074/jbc.M004571200; Mendiratta P, 2009, J CLIN ONCOL, V27, P2022, DOI 10.1200/JCO.2008.17.2882; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Metzger E, 2008, NAT CELL BIOL, V10, P53, DOI 10.1038/ncb1668; Metzger E, 2010, NATURE, V464, P792, DOI 10.1038/nature08839; Mizokami A, 2004, CANCER RES, V64, P765, DOI 10.1158/0008-5472.CAN-03-0130; Moehren U, 2007, MOL ENDOCRINOL, V21, P1039, DOI 10.1210/me.2006-0468; Mohler JL, 2004, CLIN CANCER RES, V10, P440, DOI 10.1158/1078-0432.CCR-1146-03; Montgomery RB, 2008, CANCER RES, V68, P4447, DOI 10.1158/0008-5472.CAN-08-0249; Mostaghel EA, 2007, CANCER RES, V67, P5033, DOI 10.1158/0008-5472.CAN-06-3332; Mostaghel EA, 2011, CLIN CANCER RES, V17, P5913, DOI 10.1158/1078-0432.CCR-11-0728; Mulholland DJ, 2011, CANCER CELL, V19, P792, DOI 10.1016/j.ccr.2011.05.006; Mulholland DJ, 2003, ONCOGENE, V22, P5602, DOI 10.1038/sj.onc.1206802; Nishiyama T, 2004, CLIN CANCER RES, V10, P7121, DOI 10.1158/1078-0432.CCR-04-0913; Page ST, 2006, J CLIN ENDOCR METAB, V91, P3850, DOI 10.1210/jc.2006-0968; Perillo B, 2008, SCIENCE, V319, P202, DOI 10.1126/science.1147674; Ryan CJ, 2013, NEW ENGL J MED, V368, P138, DOI 10.1056/NEJMoa1209096; Sack JS, 2001, P NATL ACAD SCI USA, V98, P4904, DOI 10.1073/pnas.081565498; Samson DJ, 2002, CANCER, V95, P361, DOI 10.1002/cncr.10647; Schaeffer EM, 2008, ONCOGENE, V27, P7180, DOI 10.1038/onc.2008.327; Schaufele F, 2005, P NATL ACAD SCI USA, V102, P9802, DOI 10.1073/pnas.0408819102; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Shah S, 2003, J BIOL CHEM, V278, P48137, DOI 10.1074/jbc.M307154200; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Sharma A, 2010, J CLIN INVEST, V120, P4478, DOI 10.1172/JCI44239; Shen HC, 2012, MOL ENDOCRINOL, V26, P1836, DOI 10.1210/me.2012-1222; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Small EJ, 2004, J CLIN ONCOL, V22, P1025, DOI 10.1200/JCO.2004.06.037; Song LN, 2004, MOL ENDOCRINOL, V18, P70, DOI 10.1210/me.2003-0189; Stanbrough M, 2006, CANCER RES, V66, P2815, DOI 10.1158/0008-5472.CAN-05-4000; Sun SH, 2010, J CLIN INVEST, V120, P2715, DOI 10.1172/JCI41824; Taneja SS, 2005, J BIOL CHEM, V280, P40916, DOI 10.1074/jbc.M508442200; Taplin ME, 2009, CLIN CANCER RES, V15, P7099, DOI 10.1158/1078-0432.CCR-09-1722; Taplin ME, 1999, CANCER RES, V59, P2511; Taplin ME, 2003, J CLIN ONCOL, V21, P2673, DOI 10.1200/JCO.2003.11.102; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; THALMANN GN, 1994, CANCER RES, V54, P2577; Thomsen MK, 2008, DEV BIOL, V316, P302, DOI 10.1016/j.ydbio.2008.01.030; Thomsen MK, 2010, CANCER RES, V70, P979, DOI 10.1158/0008-5472.CAN-09-2370; Titus MA, 2005, CLIN CANCER RES, V11, P4653, DOI 10.1158/1078-0432.CCR-05-0525; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tomlins SA, 2007, NAT GENET, V39, P41, DOI 10.1038/ng1935; Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175; Truica CI, 2000, CANCER RES, V60, P4709; van Royen ME, 2007, J CELL BIOL, V177, P63, DOI 10.1083/jcb.200609178; van Royen ME, 2012, J CELL SCI, V125, P1970, DOI 10.1242/jcs.096792; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; Verras M, 2007, CANCER RES, V67, P967, DOI 10.1158/0008-5472.CAN-06-3552; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Wang H, 2008, CANCER RES, V68, P1625, DOI 10.1158/0008-5472.CAN-07-5915; Wang HY, 2007, CANCER RES, V67, P528, DOI 10.1158/0008-5472.CAN-06-1672; Wang HY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041330; Wang JX, 2007, NATURE, V446, P882, DOI 10.1038/nature05671; Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056; Watson PA, 2010, P NATL ACAD SCI USA, V107, P16759, DOI 10.1073/pnas.1012443107; Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546; Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604; Xu KX, 2009, CANCER CELL, V15, P270, DOI 10.1016/j.ccr.2009.02.021; Xu YY, 2006, CANCER RES, V66, P7783, DOI 10.1158/0008-5472.CAN-05-4472; Yamane K, 2006, CELL, V125, P483, DOI 10.1016/j.cell.2006.03.027; YAN GC, 1992, MOL ENDOCRINOL, V6, P2123, DOI 10.1210/me.6.12.2123; Yang FJ, 2002, J BIOL CHEM, V277, P11336, DOI 10.1074/jbc.M111962200; Yap TA, 2008, CURR OPIN PHARMACOL, V8, P449, DOI 10.1016/j.coph.2008.06.004; Yoon HG, 2006, MOL ENDOCRINOL, V20, P1048, DOI 10.1210/me.2005-0324; Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018; Yu X, 2001, MOL CELL BIOL, V21, P4614, DOI 10.1128/MCB.21.14.4614-4625.2001; Yuan X, 2001, J BIOL CHEM, V276, P46647, DOI 10.1074/jbc.M108404200; Yuan X, 2006, AM J PATHOL, V169, P682, DOI 10.2353/ajpath.2006.051047; Zegarra-Moro OL, 2002, CANCER RES, V62, P1008; Zhang XT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027970; Zhao JC, 2012, GENOME RES, V22, P322, DOI 10.1101/gr.131508.111; Zhao XY, 2000, NAT MED, V6, P703, DOI 10.1038/76287; Zhu P, 2006, CELL, V124, P615, DOI 10.1016/j.cell.2005.12.032	164	232	240	1	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2014	33	22					2815	2825		10.1038/onc.2013.235	http://dx.doi.org/10.1038/onc.2013.235			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EI	23752196	Green Accepted			2022-12-17	WOS:000337231800001
J	Zhang, X; George, J; Deb, S; Degoutin, JL; Takano, EA; Fox, SB; Bowtell, DDL; Harvey, KF				Zhang, X.; George, J.; Deb, S.; Degoutin, J. L.; Takano, E. A.; Fox, S. B.; Bowtell, D. D. L.; Harvey, K. F.		AOCS Study Grp	The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene	ONCOGENE			English	Article						ovarian cancer; Hippo pathway; YAP; oncogenic transformation; clear cell cancer	YES-ASSOCIATED PROTEIN; TUMOR-SUPPRESSOR GENE; CELL CONTACT INHIBITION; SIZE-CONTROL; PROMOTES APOPTOSIS; CYCLE EXIT; ORGAN SIZE; PROLIFERATION; DROSOPHILA; SALVADOR	The Salvador-Warts-Hippo (SWH) pathway was first discovered in Drosophila melanogaster as a potent inhibitor of tissue growth. The SWH pathway is highly conserved between D. melanogaster and mammals, both in function and in the mechanism of signal transduction. The mammalian SWH pathway limits tissue growth by inhibiting the nuclear access and expression of the transcriptional co-activator, Yes-associated protein (YAP). Mutation and altered expression of SWH pathway proteins has been observed in several types of human cancer, but the contribution of these events to tumorigenesis has been unclear. Here we show that YAP can enhance the transformed phenotype of ovarian cancer cell lines and that YAP confers resistance to chemotherapeutic agents that are commonly used to treat ovarian cancer. We find that high nuclear YAP expression correlates with poor patient prognosis in a cohort of 268 invasive epithelial ovarian cancer samples. Segregation by histo-type shows that the correlation between nuclear YAP and poor survival is predominantly associated with clear cell tumors, independent of stage. Collectively our findings suggest that YAP derepression contributes to the genesis of ovarian clear cell carcinoma and that the SWH pathway is an attractive therapeutic target. Oncogene (2011) 30, 2810-2822; doi: 10.1038/onc.2011.8; published online 14 February 2011	[Zhang, X.; George, J.; Deb, S.; Degoutin, J. L.; Takano, E. A.; Fox, S. B.; Bowtell, D. D. L.; Harvey, K. F.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia; [Zhang, X.; George, J.; Degoutin, J. L.; Bowtell, D. D. L.; Harvey, K. F.] Univ Melbourne, Melbourne, Vic, Australia; Queensland Inst Med Res, Brisbane, Qld 4006, Australia; [AOCS Study Grp] Univ Sydney, Westmead Hosp, Westmead Millennium Inst, Westmead Inst Canc Res, Sydney, NSW 2006, Australia	Peter Maccallum Cancer Center; University of Melbourne; QIMR Berghofer Medical Research Institute; University of Sydney; Westmead Institute for Medical Research	Harvey, KF (corresponding author), Peter MacCallum Canc Ctr, 7 St Andrews Pl, Melbourne, Vic 3072, Australia.	kieran.harvey@petermac.org	George, Joshy/K-4841-2019; Bowtell, David/H-1007-2016; Harvey, Kieran/AAD-5268-2022; Fox, Stephen/G-9719-2016	Bowtell, David/0000-0001-9089-7525; Fox, Stephen/0000-0002-7648-8896; Harvey, Kieran/0000-0001-7845-369X	US Army Medical Research and Materiel Command [DAMD17-01-1-0729]; Cancer Council Victoria; Queensland Cancer Fund; Cancer Council New South Wales; Cancer Council South Australia; Cancer Foundation of Western Australia; Cancer Council Tasmania; National Health and Medical Research Council of Australia (NHMRC); International Human Frontier Science Program Organization; NHMRC of Australia; Victorian Breast Cancer Research Consortium	US Army Medical Research and Materiel Command(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC)); Cancer Council Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); Queensland Cancer Fund; Cancer Council New South Wales(Cancer Council New South Wales); Cancer Council South Australia(Cancer Council South Australia); Cancer Foundation of Western Australia(Cancer Council Western Australia); Cancer Council Tasmania(Cancer Council Tasmania); National Health and Medical Research Council of Australia (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); International Human Frontier Science Program Organization(Human Frontier Science Program); NHMRC of Australia(National Health and Medical Research Council (NHMRC) of Australia); Victorian Breast Cancer Research Consortium	We thank the study nurses and research assistants for their contribution to AOCS (http://www.aocstudy.org/) and thank all the women who participated in the study. AOCS was approved by the Human Research Ethics Committees at the Peter Mac, QIMR and participating hospitals. The study was supported by the US Army Medical Research and Materiel Command under DAMD17-01-1-0729, The Cancer Council Victoria, Queensland Cancer Fund, The Cancer Council New South Wales, The Cancer Council South Australia, The Cancer Foundation of Western Australia, The Cancer Council Tasmania and the National Health and Medical Research Council of Australia (NHMRC). We thank D Thomas for comments, D Haber for pBABE-YAP2L and the Peter Mac, Pfizer Incorporated TORCH program for ovarian cancer cell lines. KFH is a Sylvia and Charles Viertel Senior Medical Research Fellow. This work was supported by a Career Development Award from the International Human Frontier Science Program Organization and a Project Grant from the NHMRC of Australia to KFH and the Victorian Breast Cancer Research Consortium to SBF.	Camargo FD, 2007, CURR BIOL, V17, P2054, DOI 10.1016/j.cub.2007.10.039; Chan SW, 2008, CANCER RES, V68, P2592, DOI 10.1158/0008-5472.CAN-07-2696; Chen LM, 2010, GENE DEV, V24, P290, DOI 10.1101/gad.1865310; Chosdol K, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-5; Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Fernandez A, 2009, GENE DEV, V23, P2729, DOI 10.1101/gad.1824509; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Grusche FA, 2010, CURR BIOL, V20, pR574, DOI 10.1016/j.cub.2010.05.023; Hao YW, 2008, J BIOL CHEM, V283, P5496, DOI 10.1074/jbc.M709037200; Harvey KF, 2003, CELL, V114, P457, DOI 10.1016/S0092-8674(03)00557-9; Harvey K, 2007, NAT REV CANCER, V7, P182, DOI 10.1038/nrc2070; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Jia JH, 2003, GENE DEV, V17, P2514, DOI 10.1101/gad.1134003; Lai ZC, 2005, CELL, V120, P675, DOI 10.1016/j.cell.2004.12.036; Lee KP, 2010, P NATL ACAD SCI USA, V107, P8248, DOI 10.1073/pnas.0912203107; Lei QY, 2008, MOL CELL BIOL, V28, P2426, DOI 10.1128/MCB.01874-07; Li Z, 2010, GENE DEV, V24, P235, DOI 10.1101/gad.1865810; Nakaya K, 2007, ONCOGENE, V26, P5300, DOI 10.1038/sj.onc.1210330; Oka T, 2008, J BIOL CHEM, V283, P27534, DOI 10.1074/jbc.M804380200; Ota M, 2008, DEVELOPMENT, V135, P4059, DOI 10.1242/dev.027151; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Pantalacci S, 2003, NAT CELL BIOL, V5, P921, DOI 10.1038/ncb1051; Qi C, 2009, INT J CANCER, V124, P793, DOI 10.1002/ijc.23775; Reiner A, 2003, BIOINFORMATICS, V19, P368, DOI 10.1093/bioinformatics/btf877; Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; SMYTH GK, 2005, LIMMA LINEAR MODELS, P397; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Steinhardt AA, 2008, HUM PATHOL, V39, P1582, DOI 10.1016/j.humpath.2008.04.012; Stewart B.W., 2003, WORLD CANC REPORT; Takahashi Y, 2005, CLIN CANCER RES, V11, P1380, DOI 10.1158/1078-0432.CCR-04-1773; Tan DSP, 2007, J CLIN PATHOL, V60, P355, DOI 10.1136/jcp.2006.040030; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Tian W, 2010, P NATL ACAD SCI USA, V107, P7293, DOI 10.1073/pnas.1000293107; Tothill RW, 2008, CLIN CANCER RES, V14, P5198, DOI 10.1158/1078-0432.CCR-08-0196; Udan RS, 2003, NAT CELL BIOL, V5, P914, DOI 10.1038/ncb1050; Wang Y, 2010, CANCER SCI, V101, P1279, DOI 10.1111/j.1349-7006.2010.01511.x; Wu S, 2003, CELL, V114, P445, DOI 10.1016/S0092-8674(03)00549-X; Xu MZ, 2009, CANCER-AM CANCER SOC, V115, P4576, DOI 10.1002/cncr.24495; Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030; Zeng Q, 2008, CANCER CELL, V13, P188, DOI 10.1016/j.ccr.2008.02.011; Zhang JM, 2008, CANCER RES, V68, P2789, DOI 10.1158/0008-5472.CAN-07-6205; Zhang XM, 2009, CANCER RES, V69, P6033, DOI 10.1158/0008-5472.CAN-08-4592; Zhang XM, 2006, INT J CANCER, V118, P2072, DOI 10.1002/ijc.21592; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810; Zhou DW, 2009, CANCER CELL, V16, P425, DOI 10.1016/j.ccr.2009.09.026; Zorn KK, 2005, CLIN CANCER RES, V11, P6422, DOI 10.1158/1078-0432.CCR-05-0508	48	232	249	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	25					2810	2822		10.1038/onc.2011.8	http://dx.doi.org/10.1038/onc.2011.8			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	781ZV	21317925				2022-12-17	WOS:000291977800002
J	Gualberto, A; Pollak, M				Gualberto, A.; Pollak, M.			Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions	ONCOGENE			English	Review						insulin-like growth factor-I receptor inhibitors; clinical trials; targeted therapies	FACTOR-I RECEPTOR; BREAST-CANCER-CELLS; MONOCLONAL-ANTIBODY CP-751,871; SMALL-MOLECULE INHIBITORS; CIRCULATING TUMOR-CELLS; PROSTATE-CANCER; IGF-1 RECEPTOR; PHASE-I; THERAPEUTIC TARGET; HORMONE RECEPTOR	Preclinical evidence that targeting the insulin-like growth factor receptor (IGF-IR) is effective in cancer treatment has been accumulating for almost two decades. Efforts to develop drugs began in the late 1990s, and initial data from clinical trials were reported in 2006. The biological rationale for IGF-IR targeting has potential relevance to many tumor types, and early results have justified expanded programs to evaluate IGF-IR-targeting agents in many areas of clinical need. More than two dozen drug candidates have been developed and clinical trials are underway for at least 12 of these. Early clinical trials reveal an acceptable safety pro. le together with pharmacodynamic evidence that the receptor can be successfully targeted. It is premature to draw conclusions regarding efficacy, but well-documented instances of single-agent activity were noted during phase I evaluations, and recent evidence from a phase II study suggests that co-administration of an anti-IGF-IR antibody with chemotherapy for non-small-cell lung cancer improves objective response rate and progression-free survival. With more than 70 trials involving a variety of drug candidates underway, the IGF-IR is becoming one of the most intensively investigated molecular targets in oncology. Early results justify the continuation of ongoing research across a broad range of cancer indications. Oncogene (2009) 28, 3009-3021; doi:10.1038/onc.2009.172; published online 6 July 2009	[Pollak, M.] McGill Univ, Segal Canc Ctr, Dept Oncol, Montreal, PQ H3T 1E2, Canada; [Gualberto, A.] Pfizer Oncol, Clin Dept, New London, CT USA; [Gualberto, A.] Brown Univ, Dept Pathol, Alpert Sch Med, Providence, RI 02912 USA	McGill University; Pfizer; Brown University	Pollak, M (corresponding author), McGill Univ, Segal Canc Ctr, Dept Oncol, 3755 Chemin Cote St Catherine,Room E-763, Montreal, PQ H3T 1E2, Canada.	michael.pollak@mcgill.ca	Pollak, Michael/G-9094-2011	Pollak, Michael/0000-0003-3047-0604	Pfizer Inc.	Pfizer Inc.(Pfizer)	We thank D Yee and numerous colleagues for constructive criticism and encouragement. Editorial assistance was provided by ACUMED, Tytherington, UK and was funded by Pfizer Inc. This study was supported by funding from Pfizer Inc.	Adelaide J, 2007, CANCER RES, V67, P11565, DOI 10.1158/0008-5472.CAN-07-2536; Ahlgren M, 2004, NEW ENGL J MED, V351, P1619, DOI 10.1056/NEJMoa040576; Allen GW, 2007, CANCER RES, V67, P1155, DOI 10.1158/0008-5472.CAN-06-2000; ARTEAGA CL, 1989, J CLIN INVEST, V84, P1418, DOI 10.1172/JCI114315; Attard G, 2006, J CLIN ONCOL, V24, p126S; Atzori F, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.3519; Barr Sharon M., 2007, Proceedings of the American Association for Cancer Research Annual Meeting, V48, P608; Baserga R, 2003, INT J CANCER, V107, P873, DOI 10.1002/ijc.11487; Belfiore A, 2007, CURR PHARM DESIGN, V13, P671, DOI 10.2174/138161207780249173; Benini S, 2001, CLIN CANCER RES, V7, P1790; Benyoucef S, 2007, BIOCHEM J, V403, P603, DOI 10.1042/BJ20061709; Best Carolyn J. M., 2006, Proceedings of the American Association for Cancer Research Annual Meeting, V47, P290; BRITTEN C, 2008, 20 EORTC NCI AACR S; Buck E, 2008, CANCER RES, V68, P8322, DOI 10.1158/0008-5472.CAN-07-6720; Cao L, 2008, CANCER RES, V68, P8039, DOI 10.1158/0008-5472.CAN-08-1712; Ceda G P, 2005, J Endocrinol Invest, V28, P96; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; Chitnis MM, 2008, CLIN CANCER RES, V14, P6364, DOI 10.1158/1078-0432.CCR-07-4879; Cohen BD, 2005, CLIN CANCER RES, V11, P2063, DOI 10.1158/1078-0432.CCR-04-1070; CORTES J, 2008, 50 ASH ANN M EXP SAN; Cox ME, 2009, PROSTATE, V69, P33, DOI 10.1002/pros.20852; de Bono JS, 2007, CLIN CANCER RES, V13, P3611, DOI 10.1158/1078-0432.CCR-07-0268; DEBONO JS, 2008, MOL TARG CANC THER C; del Rincon JP, 2007, DIABETES, V56, P1638, DOI 10.2337/db06-0299; Diorio C, 2005, CANCER EPIDEM BIOMAR, V14, P1065, DOI 10.1158/1055-9965.EPI-04-0706; Dong MQ, 2007, SCIENCE, V317, P660, DOI 10.1126/science.1139952; Feng Y, 2008, CURR OPIN DRUG DISC, V11, P178; Gebre-Medhin M, 2001, AM J PATHOL, V158, P1217, DOI 10.1016/S0002-9440(10)64071-0; Girnita A, 2004, CANCER RES, V64, P236, DOI 10.1158/0008-5472.CAN-03-2522; Glait C, 2006, EXP CELL RES, V312, P3899, DOI 10.1016/j.yexcr.2006.08.016; Goodin S, 2008, AM J HEALTH-SYST PH, V65, pS3, DOI 10.2146/ajhp080100; Goodwin PJ, 2002, J CLIN ONCOL, V20, P42, DOI 10.1200/JCO.20.1.42; Gualberto A, 2008, J CLIN ONCOL, V26; Gualberto A, 2008, ANN ONCOL, V19, P62; GUALBERTO A, 2009, CLIN LU IN PRESS JUN; Guix M, 2008, J CLIN INVEST, V118, P2609, DOI 10.1172/JCI34588; Haluska P, 2007, CLIN CANCER RES, V13, P5834, DOI 10.1158/1078-0432.CCR-07-1118; Hartog H, 2007, EUR J CANCER, V43, P1895, DOI 10.1016/j.ejca.2007.05.021; Hidalgo M, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.3520; HIGANO CS, 2007, 2007 PROST CANC S OR; Hochberg Z, 2002, HORM RES, V58, P33, DOI 10.1159/000064764; Huang F, 2009, CANCER RES, V69, P161, DOI 10.1158/0008-5472.CAN-08-0835; Hyun T, 2000, BLOOD, V96, P3560, DOI 10.1182/blood.V96.10.3560.h8003560_3560_3568; Ji QS, 2007, MOL CANCER THER, V6, P2158, DOI 10.1158/1535-7163.MCT-07-0070; Karp DD, 2009, J CLIN ONCOL, V27, P2516, DOI 10.1200/JCO.2008.19.9331; Klinakis A, 2009, P NATL ACAD SCI USA, V106, P2359, DOI 10.1073/pnas.0810221106; Kopchick JJ, 2002, ENDOCR REV, V23, P623, DOI 10.1210/er.2001-0022; Lacy MQ, 2008, J CLIN ONCOL, V26, P3196, DOI 10.1200/JCO.2007.15.9319; LAMMERS R, 1989, EMBO J, V8, P1369, DOI 10.1002/j.1460-2075.1989.tb03517.x; Law JH, 2008, CANCER RES, V68, P10238, DOI 10.1158/0008-5472.CAN-08-2755; LEONG S, 2007, AACR NCI EORTC MOL T; LINDSAY CR, 2009, J CLIN ONCOL S, V27, pS15; Lu YH, 2001, JNCI-J NATL CANCER I, V93, P1852, DOI 10.1093/jnci/93.24.1852; Ma J, 2008, LANCET ONCOL, V9, P1039, DOI 10.1016/S1470-2045(08)70235-3; Majeed N, 2005, ONCOGENE, V24, P4736, DOI 10.1038/sj.onc.1208572; Martin MJ, 2006, MOL CELL BIOL, V26, P1754, DOI 10.1128/MCB.26.5.1754-1769.2006; Mendelsohn J, 2006, SEMIN ONCOL, V33, P369, DOI 10.1053/j.seminoncol.2006.04.003; MORROW LA, 1994, J CLIN ENDOCR METAB, V79, P205, DOI 10.1210/jc.79.1.205; MYAL Y, 1984, CANCER RES, V44, P5486; Natrajan R, 2006, CANCER RES, V66, P11148, DOI 10.1158/0008-5472.CAN-06-1931; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; OLMOS D, 2007, AACR NCI EORTC MOL T; OLMOS D, 2008, J CLIN ONCOL, V26, pS553; Plymate SR, 2007, CLIN CANCER RES, V13, P6429, DOI 10.1158/1078-0432.CCR-07-0648; Pollak M, 2001, BRIT J CANCER, V85, P428, DOI 10.1054/bjoc.2001.1895; POLLAK M, 2007, AACR M; Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536; Pollak M, 2008, CURR OPIN PHARMACOL, V8, P384, DOI 10.1016/j.coph.2008.07.004; POLLAK MN, 1987, CANCER LETT, V38, P223, DOI 10.1016/0304-3835(87)90218-7; Pollak MN, 2004, NAT REV CANCER, V4, P505, DOI 10.1038/nrc1387; POSTELVINAY S, 2008, 20 EORTC NCI AACR S; RODON J, 2007, J CLIN ONCOL, V25, pS160; Rodon J, 2008, MOL CANCER THER, V7, P2575, DOI 10.1158/1535-7163.MCT-08-0265; ROTHENBERG ML, 2007, AACR NCI EORTC MOL T; Russo VC, 2005, ENDOCR REV, V26, P916, DOI 10.1210/er.2004-0024; RYAN PD, 2008, 31 ANN SAN ANT BREAS; Sachdev D, 2006, CANCER RES, V66, P2391, DOI 10.1158/0008-5472.CAN-05-3126; Sachdev D, 2007, MOL CANCER THER, V6, P1, DOI 10.1158/1535-7163.MCT-06-0080; Samani AA, 2007, ENDOCR REV, V28, P20, DOI 10.1210/er.2006-0001; SARANTOPOULOS J, 2008, J CLIN ONCOL, V26, pS173; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SERAJ J, 2007, AACR NCI EORTC MOL T; Shaw RJ, 2005, SCIENCE, V310, P1642, DOI 10.1126/science.1120781; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Smith C.W., 2007, REV FINANC, V11, P1, DOI DOI 10.1093/ROF/RFM001; TABERNERO J, 2008, 33 ESMO C STOCKH SWE; Tao Y, 2007, NAT CLIN PRACT ONCOL, V4, P591, DOI 10.1038/ncponc0934; Tarn C, 2008, P NATL ACAD SCI USA, V105, P8387, DOI 10.1073/pnas.0803383105; TOLCHER AW, 2007, J CLIN ONCOL S, V25, pS118; TOLCHER AW, 2008, J CLIN ONCOL, V26, pS173; Wan X, 2007, ONCOGENE, V26, P1932, DOI 10.1038/sj.onc.1209990; Weroha S, 2008, J MAMMARY GLAND BIOL, V13, P471, DOI 10.1007/s10911-008-9104-6; WISEMAN LR, 1993, EUR J CANCER, V29A, P2256, DOI 10.1016/0959-8049(93)90218-5; WITT K, 2008, OSI PHARM ONCOLOGY P; Wolpin BM, 2009, J CLIN ONCOL, V27, P176, DOI 10.1200/JCO.2008.17.9945; Wu JD, 2005, CLIN CANCER RES, V11, P3065, DOI 10.1158/1078-0432.CCR-04-1586; Wu JD, 2006, CLIN CANCER RES, V12, P6153, DOI 10.1158/1078-0432.CCR-06-0443; Wu YP, 2003, CANCER RES, V63, P4384; Yee D, 2006, BRIT J CANCER, V94, P465, DOI 10.1038/sj.bjc.6602963; YIN D, 2008, J CLIN ONCOL, V26, pS118; Yuen JSP, 2008, EXPERT OPIN THER TAR, V12, P589, DOI 10.1517/14728222.12.5.589 ; Zhang H, 2007, CANCER RES, V67, P391, DOI 10.1158/0008-5472.CAN-06-1712; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	103	232	243	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2009	28	34					3009	3021		10.1038/onc.2009.172	http://dx.doi.org/10.1038/onc.2009.172			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487ZU	19581933				2022-12-17	WOS:000269319000001
J	Aghi, M; Martuza, RL				Aghi, M; Martuza, RL			Oncolytic viral therapies - the clinical experience	ONCOGENE			English	Review						oncolytic virus; clinical trials; adenovirus; herpesvirus; vaccinia virus; Newcastle disease virus	HERPES-SIMPLEX-VIRUS; REPLICATION-SELECTIVE ADENOVIRUS; PHASE-I TRIAL; RECURRENT PROSTATE-CANCER; NEWCASTLE-DISEASE VIRUS; SUICIDE GENE-THERAPY; LONG-TERM SURVIVAL; NECK-CANCER; ATTENUATED ADENOVIRUS; MALIGNANT GLIOMA	It has been 9 years since the beginning of the first clinical trial in which an oncolytic virus was administered to cancer patients. Since then, oncolytic viruses from five different species have been taken to phase I and II clinical trials in over 300 cancer patients. While additional studies will be required to ascertain if the efficacy of any of these agents is high enough to warrant adding them to the existing therapeutic regimen, it has been reassuring that DNA viruses engineered to achieve tumor selectivity and RNA viruses with relative inherent natural tumor selectivity have proven reasonably safe at the wide range of doses that were tested. Here, we review the biology and clinical results of these five species of viruses and discuss lessons learned and challenges for the future.	Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Aghi, M (corresponding author), Massachusetts Gen Hosp, Dept Neurosurg, White Bldg Room 502,55 Fruit St, Boston, MA 02114 USA.	maghi@partners.org						Aghi M, 2000, J GENE MED, V2, P148, DOI 10.1002/(SICI)1521-2254(200005/06)2:3<148::AID-JGM105>3.0.CO;2-Q; Batliwalla FM, 1998, MOL MED, V4, P783, DOI 10.1007/BF03401771; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; BOVIATSIS EJ, 1994, CANCER RES, V54, P5745; BOVIATSIS EJ, 1994, GENE THER, V1, P323; Brown SM, 1997, J VIROL, V71, P9442, DOI 10.1128/JVI.71.12.9442-9449.1997; Chiocca EA, 2004, MOL THER, V10, P958, DOI 10.1016/j.ymthe.2004.07.021; Coffey MC, 1998, SCIENCE, V282, P1332, DOI 10.1126/science.282.5392.1332; Cohen J, 2002, SCIENCE, V298, P2312, DOI 10.1126/science.298.5602.2312; DeWeese TL, 2001, CANCER RES, V61, P7464; EDELSTEIN M, 2005, J GENE MED; FONG YKN, 2002, 38 ANN M AM SOC CLIN; FREEMAN AI, 2004, 40 ANN M AM SOC CLIN; Freytag SO, 2002, CANCER RES, V62, P4968; Freytag SO, 2003, CANCER RES, V63, P7497; Galanis E, 2005, GENE THER, V12, P437, DOI 10.1038/sj.gt.3302436; Ganly I, 2000, CLIN CANCER RES, V6, P798; Gomella LG, 2001, J UROLOGY, V166, P1291, DOI 10.1016/S0022-5347(05)65755-2; Goodrum FD, 1998, J VIROL, V72, P9479, DOI 10.1128/JVI.72.12.9479-9490.1998; Groot-Wassink T, 2002, HUM GENE THER, V13, P1723, DOI 10.1089/104303402760293565; Habib N, 2002, CANCER GENE THER, V9, P254, DOI 10.1038/sj.cgt.7700431; Habib NA, 2001, HUM GENE THER, V12, P219, DOI 10.1089/10430340150218369; Hamid O, 2003, J CLIN ONCOL, V21, P1498, DOI 10.1200/JCO.2003.09.114; Harrow S, 2004, GENE THER, V11, P1648, DOI 10.1038/sj.gt.3302289; Hecht JR, 2003, CLIN CANCER RES, V9, P555; Heise C, 1997, NAT MED, V3, P639, DOI 10.1038/nm0697-639; Heise CC, 1999, CANCER RES, V59, P2623; Hermann LL, 2004, J VIROL, V78, P6171, DOI 10.1128/JVI.78.12.6171-6179.2004; HOTTE SJ, 2003, 39 ANN M AM SOC CLIN; HU JCM, 2003, 39 ANN M AM SOC CLIN; Khuri FR, 2000, NAT MED, V6, P879, DOI 10.1038/78638; Kramm CM, 1997, HUM GENE THER, V8, P2057, DOI 10.1089/hum.1997.8.17-2057; LEE SS, 1994, CANCER RES, V54, P3325; LORENCE RM, 1988, J NATL CANCER I, V80, P1305, DOI 10.1093/jnci/80.16.1305; MacKay JA, 2005, BRAIN RES, V1035, P139, DOI 10.1016/j.brainres.2004.12.007; MacKie RM, 2001, LANCET, V357, P525, DOI 10.1016/S0140-6736(00)04048-4; Makower D, 2003, CLIN CANCER RES, V9, P693; Markert JM, 2000, GENE THER, V7, P867, DOI 10.1038/sj.gt.3301205; MARTUZA RL, 1991, SCIENCE, V252, P854, DOI 10.1126/science.1851332; Mastrangelo MJ, 1999, CANCER GENE THER, V6, P409, DOI 10.1038/sj.cgt.7700066; Mohr I, 1996, EMBO J, V15, P4759, DOI 10.1002/j.1460-2075.1996.tb00853.x; Morley S, 2004, CLIN CANCER RES, V10, P4357, DOI 10.1158/1078-0432.CCR-03-0443; MORRIS DG, 2002, 38 ANN M AM SOC CLIN; Mukherjee S, 2000, CANCER GENE THER, V7, P663, DOI 10.1038/sj.cgt.7700133; Mulvihlll S, 2001, GENE THER, V8, P308, DOI 10.1038/sj.gt.3301398; *NAT I HLTH REC DN, 2002, ASS AD VECT SAF TOX, V13, P3; Nemunaitis J, 2000, CANCER RES, V60, P6359; Nemunaitis J, 2003, CANCER GENE THER, V10, P341, DOI 10.1038/sj.cgt.7700585; Nemunaitis J, 2001, GENE THER, V8, P746, DOI 10.1038/sj.gt.3301424; Nemunaitis J, 2001, J CLIN ONCOL, V19, P289, DOI 10.1200/JCO.2001.19.2.289; O'Shea CC, 2004, CANCER CELL, V6, P611, DOI 10.1016/j.ccr.2004.11.012; Papanastassiou V, 2002, GENE THER, V9, P398, DOI 10.1038/sj.gt.3301664; Pecora AL, 2002, J CLIN ONCOL, V20, P2251, DOI 10.1200/JCO.2002.08.042; Peng KW, 2002, NAT MED, V8, P527, DOI 10.1038/nm0502-527; Rampling R, 2000, GENE THER, V7, P859, DOI 10.1038/sj.gt.3301184; Rauen KA, 2002, CANCER RES, V62, P3812; Reid T, 2001, GENE THER, V8, P1618, DOI 10.1038/sj.gt.3301512; Reid T, 2002, CANCER RES, V62, P6070; Rogulski KR, 2000, CANCER RES, V60, P1193; Rudin CM, 2003, J CLIN ONCOL, V21, P4546, DOI 10.1200/JCO.2003.03.544; SOUTHAM CHESTER M., 1960, TRANS NEW YORK ACAD SCI, V22, P657; Todo T, 1999, HUM GENE THER, V10, P2741, DOI 10.1089/10430349950016483; Vasey PA, 2002, J CLIN ONCOL, V20, P1562, DOI 10.1200/JCO.20.6.1562; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wang Q, 1997, GENE THER, V4, P1300, DOI 10.1038/sj.gt.3300535; Wein LM, 2003, CANCER RES, V63, P1317; Wu JT, 2004, B MATH BIOL, V66, P605, DOI 10.1016/j.bulm.2003.08.016; Xu Rui-Hua, 2003, Ai Zheng, V22, P1307; Yuan Zhong-Yu, 2003, Ai Zheng, V22, P310	69	232	247	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2005	24	52					7802	7816		10.1038/sj.onc.1209037	http://dx.doi.org/10.1038/sj.onc.1209037			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985JD	16299539	Bronze			2022-12-17	WOS:000233372600015
J	Henry-Mowatt, J; Dive, C; Martinou, JC; James, D				Henry-Mowatt, J; Dive, C; Martinou, JC; James, D			Role of mitochondrial membrane permeabilization in apoptosis and cancer	ONCOGENE			English	Review						mitochondria; cancer therapy; apoptosis; Bcl-2 family; permeability transition pore	CYTOCHROME-C RELEASE; PROGRAMMED CELL-DEATH; ADENINE-NUCLEOTIDE TRANSLOCATOR; HISTONE DEACETYLASE INHIBITOR; WD-40 REPEAT REGION; BCL-2 FAMILY; IN-VIVO; MICROSATELLITE INSTABILITY; CHEMOTHERAPEUTIC DRUGS; ENDOPLASMIC-RETICULUM	The release of proteins from the intermembrane space of mitochondria is one of the pivotal events in the apoptotic process, which can lead to the activation of caspases and the ultimate demise of the cell. How these proteins exit the mitochondria is still a matter of intense debate. Here, we discuss the possible mechanisms behind the release of apoptogenic proteins, the ways in which cancer cells subvert these mechanisms, and the therapeutic regimens that aim to promote the timely loss of integrity of the outer mitochondrial membrane.	Univ Geneva, Dept Cell Biol, CH-1211 Geneva 4, Switzerland; Paterson Inst Canc Res, Cellular & Mol Pharmacol Grp, Manchester M20 4BX, Lancs, England	University of Geneva; Paterson Institute for Cancer Research	James, D (corresponding author), Univ Geneva, Dept Cell Biol, Quai Ernest Ansermet 30, CH-1211 Geneva 4, Switzerland.	dominic.james@cellbio.unige.ch	James, Dominic/G-6435-2016	James, Dominic/0000-0002-0452-2178; martinou, Jean-claude/0000-0002-9847-2051; Dive, Caroline/0000-0002-1726-8850				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Adrain C, 1999, J BIOL CHEM, V274, P20855, DOI 10.1074/jbc.274.30.20855; AmaranteMendes GP, 1997, CELL DEATH DIFFER, V4, P548, DOI 10.1038/sj.cdd.4400276; Amundson SA, 2000, CANCER RES, V60, P6101; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Arnoult D, 2003, EMBO J, V22, P4385, DOI 10.1093/emboj/cdg423; Arnt CR, 2002, J BIOL CHEM, V277, P44236, DOI 10.1074/jbc.M207578200; Azoulay-Zohar H, 2004, BIOCHEM J, V377, P347, DOI 10.1042/BJ20031465; Banerjee D, 2001, Curr Opin Investig Drugs, V2, P574; Barbu A, 2002, MOL CELL ENDOCRINOL, V190, P75, DOI 10.1016/S0303-7207(02)00009-6; Bottero V, 2001, CANCER RES, V61, P7785; Boya P, 2003, ONCOGENE, V22, P6220, DOI 10.1038/sj.onc.1206827; Breckenridge DG, 2003, J CELL BIOL, V160, P1115, DOI 10.1083/jcb.200212059; Bryson JM, 2002, J BIOL CHEM, V277, P11392, DOI 10.1074/jbc.M110927200; Cain K, 2002, BIOCHIMIE, V84, P203, DOI 10.1016/S0300-9084(02)01376-7; Cassina AM, 2000, J BIOL CHEM, V275, P21409, DOI 10.1074/jbc.M909978199; Catasus L, 2000, CANCER, V88, P2290, DOI 10.1002/(SICI)1097-0142(20000515)88:10<2290::AID-CNCR13>3.0.CO;2-I; Cheong JW, 2003, CLIN CANCER RES, V9, P5018; Chun KH, 2003, CANCER RES, V63, P3826; Collins TJ, 2002, EMBO J, V21, P1616, DOI 10.1093/emboj/21.7.1616; Colombini M, 1980, Ann N Y Acad Sci, V341, P552, DOI 10.1111/j.1749-6632.1980.tb47198.x; Colquhoun A, 1998, BIOCHEM MOL BIOL INT, V45, P331; Csordas G, 2002, EMBO J, V21, P2198, DOI 10.1093/emboj/21.9.2198; Cusack JC, 2003, ANN SURG ONCOL, V10, P852, DOI 10.1245/ASO.2003.07.518; De Giorgi F, 2002, FASEB J, V16, P607, DOI 10.1096/fj.01-0269fje; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Deshmukh M, 2000, J CELL BIOL, V150, P131, DOI 10.1083/jcb.150.1.131; Deveraux Quinn L., 2001, Cardiology Clinics, V19, P57; Dewson G, 2003, ONCOGENE, V22, P2643, DOI 10.1038/sj.onc.1206326; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Duvoix A, 2003, BIOCHEM PHARMACOL, V66, P1475, DOI 10.1016/S0006-2952(03)00501-X; Dvorakova K, 2002, MOL CANCER THER, V1, P185; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; El-Deiry WS, 2003, ONCOGENE, V22, P7486, DOI 10.1038/sj.onc.1206949; Epand RF, 2002, BIOCHEM J, V367, P849, DOI 10.1042/BJ20020986; Epand RF, 2004, BIOCHEM J, V377, P509, DOI 10.1042/BJ20030938; Epand RF, 2002, BIOCHEM BIOPH RES CO, V298, P744, DOI 10.1016/S0006-291X(02)02544-5; Epand RF, 2002, J BIOL CHEM, V277, P32632, DOI 10.1074/jbc.M202396200; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Esposti MD, 2001, MOL CELL BIOL, V21, P7268, DOI 10.1128/MCB.21.21.7268-7276.2001; Esposti MD, 2003, BIOCHEM BIOPH RES CO, V304, P455, DOI 10.1016/S0006-291X(03)00617-X; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Fisk HA, 1997, J CELL BIOL, V138, P485, DOI 10.1083/jcb.138.3.485; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Fukazawa T, 2003, J BIOL CHEM, V278, P25428, DOI 10.1074/jbc.M302058200; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Gottlieb RA, 2000, DRUG NEWS PERSPECT, V13, P471; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Guo F, 2002, BLOOD, V99, P3419, DOI 10.1182/blood.V99.9.3419; Gurbuxani S, 2003, ONCOGENE, V22, P6669, DOI 10.1038/sj.onc.1206794; Haga N, 2003, ONCOGENE, V22, P5579, DOI 10.1038/sj.onc.1206576; Hajnoczky G, 2001, IUBMB LIFE, V52, P237, DOI 10.1080/15216540152846055; Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5; Hardwick JM, 2002, MOL CELL, V10, P963, DOI 10.1016/S1097-2765(02)00751-7; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; Hu YP, 2003, CLIN CANCER RES, V9, P2826; HUNTER DR, 1976, J BIOL CHEM, V251, P5069; Iaccarino I, 2003, CELL DEATH DIFFER, V10, P599, DOI 10.1038/sj.cdd.4401211; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Inoue K, 2000, LEUKEMIA RES, V24, P255, DOI 10.1016/S0145-2126(99)00182-4; James DI, 2003, J BIOL CHEM, V278, P36373, DOI 10.1074/jbc.M303758200; Juin P, 2002, MOL CELL BIOL, V22, P6158, DOI 10.1128/MCB.22.17.6158-6169.2002; Ka H, 2003, CANCER LETT, V196, P143, DOI 10.1016/S0304-3835(03)00238-6; Kannan, 2000, Pathophysiology, V7, P153, DOI 10.1016/S0928-4680(00)00053-5; Karbowski M, 2002, J CELL BIOL, V159, P931, DOI 10.1083/jcb.200209124; Karbowski M, 2003, CELL DEATH DIFFER, V10, P870, DOI 10.1038/sj.cdd.4401260; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karran P, 2000, CURR OPIN GENET DEV, V10, P144, DOI 10.1016/S0959-437X(00)00069-1; Kaufmann SH, 2003, ONCOGENE, V22, P7414, DOI 10.1038/sj.onc.1206945; Kim JS, 2003, BIOCHEM BIOPH RES CO, V304, P463, DOI 10.1016/S0006-291X(03)00618-1; Kim SH, 1999, CANCER RES, V59, P4012; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Li JL, 2001, ENDOCRINOLOGY, V142, P370, DOI 10.1210/en.142.1.370; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Lim MLR, 2001, FEBS LETT, V503, P69, DOI 10.1016/S0014-5793(01)02693-X; Lohret TA, 1996, J BIOL CHEM, V271, P4846; Ly JD, 2003, APOPTOSIS, V8, P115, DOI 10.1023/A:1022945107762; Makin G, 2000, CELL TISSUE RES, V301, P143, DOI 10.1007/s004419900160; Martelli AM, 2003, LEUKEMIA, V17, P1794, DOI 10.1038/sj.leu.2403044; Martinou I, 1999, J CELL BIOL, V144, P883, DOI 10.1083/jcb.144.5.883; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Moncada S, 2002, NAT REV MOL CELL BIO, V3, P214, DOI 10.1038/nrm762; Mortenson M.M., 2003, J SURG RES, V114, P302, DOI DOI 10.1016/J.JSS.2003.08.103; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; Nutt LK, 2002, J BIOL CHEM, V277, P20301, DOI 10.1074/jbc.M201604200; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; Pacher P, 2001, EMBO J, V20, P4107, DOI 10.1093/emboj/20.15.4107; Pastorino JG, 2002, J BIOL CHEM, V277, P7610, DOI 10.1074/jbc.M109950200; Patterson SD, 2000, CELL DEATH DIFFER, V7, P137, DOI 10.1038/sj.cdd.4400640; Pavlov EV, 2001, J CELL BIOL, V155, P725, DOI 10.1083/jcb.200107057; Rapizzi E, 2002, J CELL BIOL, V159, P613, DOI 10.1083/jcb.200205091; Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Reed JC, 2002, MOL CELL, V9, P1, DOI 10.1016/S1097-2765(02)00437-9; Rosato RR, 2003, CANCER RES, V63, P3637; Roucou X, 2002, BIOCHEM J, V368, P915, DOI 10.1042/BJ20020972; Roucou X, 2002, BIOCHEM J, V363, P547, DOI 10.1042/0264-6021:3630547; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Santel A, 2001, J CELL SCI, V114, P867; Sax JK, 2002, NAT CELL BIOL, V4, P842, DOI 10.1038/ncb866; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; SCORRANO L, 2003, CELL DEATH DIFFER, V8, P8; Shi YG, 2001, NAT STRUCT BIOL, V8, P394, DOI 10.1038/87548; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Singh TR, 2003, CANCER RES, V63, P5390; Smaili SS, 2001, CELL DEATH DIFFER, V8, P909, DOI 10.1038/sj.cdd.4400889; Smirnova E, 1998, J CELL BIOL, V143, P351, DOI 10.1083/jcb.143.2.351; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Swamy SMK, 2003, MOL CELL BIOCHEM, V245, P127, DOI 10.1023/A:1022807207948; Tamm I, 2000, CLIN CANCER RES, V6, P1796; THOMAS SM, 1989, BIOCHIM BIOPHYS ACTA, V1002, P189, DOI 10.1016/0005-2760(89)90286-5; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Vaux DL, 1998, SPRINGER SEMIN IMMUN, V19, P271, DOI 10.1007/BF00787224; von Ahsen O, 2000, J CELL BIOL, V150, P1027, DOI 10.1083/jcb.150.5.1027; Von Ahsen O, 2000, CELL DEATH DIFFER, V7, P1192, DOI 10.1038/sj.cdd.4400782; Wacheck V, 2003, BRIT J CANCER, V89, P1352, DOI 10.1038/sj.bjc.6601254; Wagenknecht B, 2000, J NEUROCHEM, V75, P2288, DOI 10.1046/j.1471-4159.2000.0752288.x; Waterhouse NJ, 2002, BIOCHIMIE, V84, P113, DOI 10.1016/S0300-9084(02)01379-2; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; WEI YQ, 1995, CANCER IMMUNOL IMMUN, V40, P73, DOI 10.1007/s002620050146; Wigdal SS, 2002, J NEUROCHEM, V82, P1029, DOI 10.1046/j.1471-4159.2002.01049.x; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang L, 2003, CANCER RES, V63, P6815; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zamzami N, 2003, CURR BIOL, V13, pR71, DOI 10.1016/S0960-9822(02)01433-1; Zhang JH, 2003, P NATL ACAD SCI USA, V100, P15782, DOI 10.1073/pnas.2636393100; Zhang XD, 2003, BIOCHEM PHARMACOL, V66, P1537, DOI 10.1016/S0006-2952(03)00509-4	139	232	242	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2004	23	16					2850	2860		10.1038/sj.onc.1207534	http://dx.doi.org/10.1038/sj.onc.1207534			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO	15077148				2022-12-17	WOS:000220799600012
J	Ehrhardt, H; Fulda, S; Schmid, I; Hiscott, J; Debatin, KM; Jeremias, I				Ehrhardt, H; Fulda, S; Schmid, I; Hiscott, J; Debatin, KM; Jeremias, I			TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappa B	ONCOGENE			English	Article						TRAIL; proliferation; survival; apoptosis resistance; NF-kappa B	HUMAN T-CELLS; ACTIVATION; DEATH; FAS; CONTRIBUTES; EXPRESSION; CASPASE-8; PATHWAYS; PROTEIN; KINASE	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potent inducer of apoptosis in cancer cells. Examining primary cells of children with untreated acute leukemia, TRAIL induced apoptosis in 50% of cells, but to our surprise attenuated spontaneous apoptosis in the remaining samples or, most importantly, even mediated proliferation. W e therefore examined tumor cell lines of leukemic and nonleukemic origin with apoptosis resistance towards TRAIL because of absent Caspase-8 or dysfunctional FADD. In all cell lines tested, TRAIL treatment increased cell numbers in average to 163% within 4 days and accelerated doubling time from 24 to 19 h. TRAIL-mediated proliferation was completely abrogated by blockade of NF-kappaB activation using proteasome inhibitors or in RIP-negative, IKKgamma-negative cells or in cells overexpressing dominant-negative IkappaBalpha. Our data describe the biological significance of TRAIL-mediated activation of NF-kappaB in cancer cells resistant to TRAIL-mediated apoptosis: TRAIL leads to an increase in tumor cell count by a prosurvival and possibly mitogenic function. Given the promising therapeutic potential of TRAIL as a novel anticancer drug, TRAIL-mediated survival or proliferation of target cells may restrict its use to apoptosis-sensitive tumors.	Univ Kinderklin, Dept Hematol Oncol, D-89075 Ulm, Germany; Dr Von Haunerschen Kinderspital, Dept Hematol Oncol, D-80337 Munich, Germany; McGill Univ, Lady Davis Inst Med Res, Montreal, PQ, Canada	Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; Lady Davis Institute; McGill University	Debatin, KM (corresponding author), Univ Kinderklin, Dept Hematol Oncol, Prittwitzstr 43, D-89075 Ulm, Germany.		Ehrhardt, Harald/L-9007-2018; Jeremias, Irmela/C-6090-2015; Jeremias, Irmela/Q-5934-2019; Fulda, Simone/D-5864-2011; Debatin, Klaus-Michael/J-9704-2014	Ehrhardt, Harald/0000-0003-4587-1734; Jeremias, Irmela/0000-0003-1773-7677; Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417				Baetu TM, 2001, J IMMUNOL, V167, P3164, DOI 10.4049/jimmunol.167.6.3164; Budd RC, 2002, J CLIN INVEST, V109, P437, DOI 10.1172/JC1200215077; Fulda S, 2002, ONCOGENE, V21, P2295, DOI 10.1038/sj.onc.1205255; Harhaj EW, 2000, ONCOGENE, V19, P1448, DOI 10.1038/sj.onc.1203445; Herr I, 1999, CELL DEATH DIFFER, V6, P130, DOI 10.1038/sj.cdd.4400467; Hueber AO, 2000, J BIOL CHEM, V275, P10453, DOI 10.1074/jbc.275.14.10453; Jeremias I, 1998, BLOOD, V91, P4624, DOI 10.1182/blood.V91.12.4624.412k19_4624_4631; Jeremias I, 1998, EUR J IMMUNOL, V28, P143, DOI 10.1002/(SICI)1521-4141(199801)28:01<143::AID-IMMU143>3.0.CO;2-3; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kupatt C, 1999, CIRC RES, V84, P392, DOI 10.1161/01.RES.84.4.392; Lin Y, 2000, MOL CELL BIOL, V20, P6638, DOI 10.1128/MCB.20.18.6638-6645.2000; MAPARA MY, 1993, EUR J IMMUNOL, V23, P702, DOI 10.1002/eji.1830230320; Muhlenbeck F, 1998, J BIOL CHEM, V273, P33091, DOI 10.1074/jbc.273.49.33091; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Thilenius ARB, 1997, EUR J IMMUNOL, V27, P1108, DOI 10.1002/eji.1830270510; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x	20	232	253	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2003	22	25					3842	3852		10.1038/sj.onc.1206520	http://dx.doi.org/10.1038/sj.onc.1206520			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	691NH	12813457				2022-12-17	WOS:000183612000003
J	SHAO, ZM; DAWSON, MI; LI, XS; RISHI, AK; SHEIKH, MS; HAN, QX; ORDONEZ, JV; SHROOT, B; FONTANA, JA				SHAO, ZM; DAWSON, MI; LI, XS; RISHI, AK; SHEIKH, MS; HAN, QX; ORDONEZ, JV; SHROOT, B; FONTANA, JA			P53 INDEPENDENT G(0)/G(1) ARREST AND APOPTOSIS INDUCED BY A NOVEL RETINOID IN HUMAN BREAST-CANCER CELLS	ONCOGENE			English	Article						RETINOIDS; BREAST CANCER; APOPTOSIS	ACID RECEPTOR-GAMMA; D-TYPE CYCLINS; X-RECEPTOR; THYROID-HORMONE; RESPONSE ELEMENTS; NUCLEAR RECEPTORS; GROWTH; DEATH; GENE; IDENTIFICATION	The biological activity of a novel synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (AHPN) was investigated in human breast carcinoma (HBC) cells. Although capable of selective binding to the RAR gamma nuclear receptor, AHPN inhibited the growth of a number of HBC cell lines via RAR- or RXR-independent pathways. AHPN also inhibited the growth of the human leukemia cell line HL-60R which does not possess functional RARs. RA significantly inhibited AP-1 mediated gene activation in MCF-7 cells while AHPN displayed no such anti-AP-1 activity. Retinoids normally are cytostatic in their inhibition of breast carcinoma growth and permit cell proliferation upon their removal, whereas AHPN induced G(0)/G(1) arrest within 6 h followed by apoptosis. In MCF-7 cells that harbor wild type p53, AHPN-induced G(0)/G(1) arrest and apoptosis was accompanied by p53-independent regulation of WAF1/CIP1 as well as bar mRNA levels while bcl-2 mRNA levels were decreased. In MDA-MB-231 cells which possess a mutant p53, AHPN-mediated G(0)/G(1) arrest and apoptosis was also associated with a concomitant up regulation of WAF1/CIP1 mRNA while these cells did not express bar or bcl-2 messages. Thus, AHPN represents a novel retinoid that induces G(0)/G(1) arrest and apoptosis via a unique pathway which appears to involve activation of known downstream effecters of p53 in a p53-independent manner.	UNIV MARYLAND, CTR CANC, DEPT MED, DIV HEMATOL & MED ONCOL, BALTIMORE, MD 21201 USA; DEPT VET AFFAIRS MED CTR, BALTIMORE, MD 21201 USA; SRI INT, DIV LIFE SCI, MENLO PK, CA 94025 USA; CTR INT RECH DERMATOL GALDERMA, VALBONNE, FRANCE	University System of Maryland; University of Maryland Baltimore; SRI International; Galderma R&D SNC				Fontana, Joseph/0000-0003-3829-3358	NCI NIH HHS [CA 63335, CA 51993] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA051993, R01CA063335] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLENBY G, 1994, J BIOL CHEM, V269, P16689; APFEL R, 1994, MOL CELL BIOL, V14, P7025, DOI 10.1128/MCB.14.10.7025; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BEARD RL, 1994, BIOORG MED CHEM LETT, V4, P1447, DOI 10.1016/S0960-894X(01)80511-4; BERNARD BA, 1992, BIOCHEM BIOPH RES CO, V186, P977, DOI 10.1016/0006-291X(92)90842-9; BOEHM MF, 1994, J MED CHEM, V37, P2930, DOI 10.1021/jm00044a014; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; BUSAM KJ, 1992, J BIOL CHEM, V267, P19971; CASANOVA J, 1994, MOL CELL BIOL, V14, P5756, DOI 10.1128/MCB.14.9.5756; DAVIES PJA, 1993, MAR AM ASS CANC RES; DAWSON MI, 1983, J MED CHEM, V26, P1653, DOI 10.1021/jm00365a021; DAWSON MI, 1992, RETINOIDS NEW TRENDS, P205; DAWSON MI, UNPUB; DHRIKH MD, 1993, ANTICANCER RES, V13, P1387; DOMINIANNI SJ, 1977, J ORG CHEM, V42, P344, DOI 10.1021/jo00422a037; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FONTANA JA, 1987, EXP CELL BIOL, V55, P136; GRAUPNER G, 1991, BIOCHEM BIOPH RES CO, V179, P1554, DOI 10.1016/0006-291X(91)91750-7; GUDAS LJ, 1992, CELL GROWTH DIFFER, V3, P655; GUDAS LJ, 1994, J BIOL CHEM, V269, P15399; HALDAR S, 1994, CANCER RES, V54, P2095; HERMANN T, 1993, ONCOGENE, V8, P55; HERMANN T, 1992, MOL ENDOCRINOL, V6, P1153, DOI 10.1210/me.6.7.1153; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Isaacs John T., 1994, Current Opinion in Oncology, V6, P82, DOI 10.1097/00001622-199401000-00012; JAFFEY P, 1992, CANCER RES, V52, P2384; JIANG HP, 1994, ONCOGENE, V9, P3397; JIANG W, 1993, ONCOGENE, V8, P3447; JONG L, 1993, J MED CHEM, V36, P2605, DOI 10.1021/jm00070a003; KIM HS, 1992, MOL ENDOCRINOL, V6, P1489, DOI 10.1210/me.6.9.1489; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LEHMANN JM, 1991, CANCER RES, V51, P4804; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LI E, 1993, P NATL ACAD SCI USA, V90, P1590, DOI 10.1073/pnas.90.4.1590; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; LOHNES D, 1992, CELL SCI S, V16, P69; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; MACGREGOR GR, 1987, SOMAT CELL MOLEC GEN, V13, P253, DOI 10.1007/BF01535207; MADER S, 1993, J BIOL CHEM, V268, P591; MICHIELI P, 1994, CANCER RES, V54, P3391; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOASSER MM, 1994, ONCOGENE, V9, P833; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; NERVI C, 1989, P NATL ACAD SCI USA, V86, P5854, DOI 10.1073/pnas.86.15.5854; NIEWOLIK D, 1995, ONCOGENE, V10, P881; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; REICHERT U, 1993, MOL BIOL THERAPEUTIC, V5, P117; ROBERTSON KA, 1992, BLOOD, V80, P1885; ROMAN SD, 1993, CANCER RES, V53, P5940; RUDD CJ, 1993, CANCER LETT, V73, P41, DOI 10.1016/0304-3835(93)90186-D; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SHEIKH MS, 1993, J CELL BIOCHEM, V53, P394, DOI 10.1002/jcb.240530417; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHEIKH MS, 1994, J BIOL CHEM, V269, P21440; SHEIKH MS, 1992, BIOCHEM BIOPH RES CO, V183, P1003, DOI 10.1016/S0006-291X(05)80290-6; SHROOT B, 1990, Patent No. 4940696; SONG C, 1994, P NATL ACAD SCI USA, V91, P10809, DOI 10.1073/pnas.91.23.10809; SPORN MB, 1991, MOL ENDOCRINOL, V5, P3, DOI 10.1210/mend-5-1-3; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TRAN P, 1992, MOL CELL BIOL, V12, P4666, DOI 10.1128/MCB.12.10.4666; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VANDERBURG B, 1993, MOL CELL ENDOCRINOL, V91, P149, DOI 10.1016/0303-7207(93)90267-N; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZHAN QM, 1994, ONCOGENE, V9, P3743; ZHANG XK, 1994, MOL CELL BIOL, V14, P4311, DOI 10.1128/MCB.14.6.4311; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	86	232	250	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	1995	11	3					493	504						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630633				2022-12-17	WOS:A1995RN53000009
J	Byles, V; Zhu, L; Lovaas, JD; Chmilewski, LK; Wang, J; Faller, DV; Dai, Y				Byles, V.; Zhu, L.; Lovaas, J. D.; Chmilewski, L. K.; Wang, J.; Faller, D. V.; Dai, Y.			SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis	ONCOGENE			English	Article						SIRT1; EMT; prostate cancer; migration; metastasis; E-cadherin	E-CADHERIN EXPRESSION; REPRESSES E-CADHERIN; MESENCHYMAL TRANSITION; BREAST-CANCER; CALORIE RESTRICTION; POOR-PROGNOSIS; CARCINOMA; PROGRESSION; SIRTUINS; FAMILY	The epithelial-to-mesenchymal transition (EMT) is a crucial program for the invasion and metastasis of epithelial tumors that involves loss of cell-cell adhesion and increased cell mobility; however, mechanisms underlying this transition are not fully elucidated. Here, we propose a novel mechanism through which the nicotinamide adenine dinucleotide-dependent histone deacetylase SIRT1 regulates EMT in prostate cancer cells through cooperation with the EMT inducing transcription factor ZEB1. We found that forced expression of SIRT1 in non-transformed PZ-HPV-7 prostate epithelial cells disrupts the epithelial morphology concomitant with decreased expression of the epithelial marker, E-cadherin, and increased expression of mesenchymal markers. In contrast, silencing SIRT1 in metastatic prostate tumor cells restores cell-cell adhesion and induces a shift toward an epithelial morphology concomitant with increased expression of E-cadherin and decreased expression of mesenchymal markers. We also found that SIRT1 has a physiologically relevant role in endogenous EMT induced by EGF signaling in prostate cancer cells. We propose that the regulation of EMT by SIRT1 involves modulation of, and cooperation with, the EMT inducing transcription factor ZEB1. Specifically, we show that SIRT1 silencing reduces expression of ZEB1 and that SIRT1 is recruited to the E-cadherin proximal promoter by ZEB1 to deacetylate histone H3 and to reduce binding of RNA polymerase II, ultimately suppressing E-cadherin transcription. We thus identify a necessary role for ZEB1 in SIRT1-mediated EMT. Finally, we show that reduction of SIRT1 decreases prostate cancer cell migration in vitro and metastasis in vivo in immunodeficient mice, which is largely independent of any general effects of SIRT1 on prostate cancer growth and survival. We therefore identify SIRT1 as a positive regulator of EMT and metastatic growth of prostate cancer cells and our findings implicate overexpressed SIRT1 as a potential therapeutic target to reverse EMT and to prevent prostate cancer progression.	[Dai, Y.] Boston Univ, Sch Med, Ctr Canc, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA	Boston University; Boston University	Dai, Y (corresponding author), Boston Univ, Sch Med, Ctr Canc, 72 E Concord St,L913, Boston, MA 02118 USA.	yandai@bu.edu		Dai, Yan/0000-0002-6894-6930	National Cancer Institute [1R21CA141036, CA101992]; Clinical and Translational Science Institute award of NIH [UL1RR025771]; Karin Grunebaum Cancer Research Foundation; American Cancer Society [IRG-72-001-27-IRG]; Department of Medicine Pilot Project Grant Award; NATIONAL CANCER INSTITUTE [R01CA101992, R21CA129046, R21CA141036] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025771] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Clinical and Translational Science Institute award of NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Karin Grunebaum Cancer Research Foundation; American Cancer Society(American Cancer Society); Department of Medicine Pilot Project Grant Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	We thank Dr F Picard (Laval University, Canada), Dr Michael Korn (USCF, CA), Dr M Ott (UCSF, CA) for providing plasmid constructs. We greatly thank the technical support in tumor cell s.c. injection from Dr Zhijun Luo (Boston University School of Medicine). We thank Lora Forman for the technical assistant (Boston University) and Christine Chiao (Boston University) for the proofreading of this manuscript. This work was supported by grants from the National Cancer Institute (1R21CA141036) (YD), the Clinical and Translational Science Institute award of NIH (UL1RR025771) (YD), the National Cancer Institute (CA101992) (DVF), the Karin Grunebaum Cancer Research Foundation (YD and DVF), the American Cancer Society (IRG-72-001-27-IRG) (YD), and the Department of Medicine Pilot Project Grant Award (YD).	Baum B, 2008, SEMIN CELL DEV BIOL, V19, P294, DOI 10.1016/j.semcdb.2008.02.001; Bordone L, 2005, NAT REV MOL CELL BIO, V6, P298, DOI 10.1038/nrm1616; Cha EJ, 2009, CLIN CANCER RES, V15, P4453, DOI 10.1158/1078-0432.CCR-08-3329; Dai Y, 2008, TRANSLATIONAL ONCOGE, V3, P137; Dai Y, 2008, CARCINOGENESIS, V29, P1725, DOI 10.1093/carcin/bgn117; Dai Y, 2007, MOL ENDOCRINOL, V21, P1807, DOI 10.1210/me.2006-0467; Eades G, 2011, J BIOL CHEM, V286, P25992, DOI 10.1074/jbc.M111.229401; Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429; Ellis AL, 2010, J VIROL, V84, P6139, DOI 10.1128/JVI.02706-09; Giannakou ME, 2004, TRENDS CELL BIOL, V14, P408, DOI 10.1016/j.tcb.2004.07.006; Graham TR, 2008, CANCER RES, V68, P2479, DOI 10.1158/0008-5472.CAN-07-2559; Guarente L, 2007, COLD SPRING HARB SYM, V72, P483, DOI 10.1101/sqb.2007.72.024; Guarente L, 2005, CELL, V120, P473, DOI 10.1016/j.cell.2005.01.029; Hajra KM, 2002, CANCER RES, V62, P1613; Hajra KM, 1999, ONCOGENE, V18, P7274, DOI 10.1038/sj.onc.1203336; Huffman DM, 2007, CANCER RES, V67, P6612, DOI 10.1158/0008-5472.CAN-07-0085; Jang KY, 2008, AM J SURG PATHOL, V32, P1523, DOI 10.1097/PAS.0b013e31816b6478; Kim EJ, 2008, BMB REP, V41, P751, DOI 10.5483/BMBRep.2008.41.11.751; Kwon HS, 2008, TRENDS BIOCHEM SCI, V33, P517, DOI 10.1016/j.tibs.2008.08.001; Lacher MD, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-91; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Lee H, 2011, HUM PATHOL, V42, P204, DOI 10.1016/j.humpath.2010.05.023; Liu T, 2009, CANCER RES, V69, P1702, DOI 10.1158/0008-5472.CAN-08-3365; Michael E, 2001, CURR PROTOC CELL BIO, P1921; Mimeault M, 2006, CARCINOGENESIS, V27, P1, DOI 10.1093/carcin/bgi229; Moreno-Bueno G, 2008, ONCOGENE, V27, P6958, DOI 10.1038/onc.2008.346; Peinado HC, 2004, INT J DEV BIOL, V48, P365, DOI 10.1387/ijdb.041794hp; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Potente M, 2007, GENE DEV, V21, P2644, DOI 10.1101/gad.435107; Richmond PJM, 1997, CANCER RES, V57, P3189; ROSS JS, 1994, MODERN PATHOL, V7, P835; Sanchez-Tillo E, 2010, ONCOGENE, V29, P3490, DOI 10.1038/onc.2010.102; Saunders LR, 2007, ONCOGENE, V26, P5489, DOI 10.1038/sj.onc.1210616; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Shtutman M, 2006, CANCER RES, V66, P11370, DOI 10.1158/0008-5472.CAN-06-2106; Smith JS, 2002, TRENDS CELL BIOL, V12, P404, DOI 10.1016/S0962-8924(02)02342-5; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Tryndyak VP, 2010, INT J CANCER, V126, P2575, DOI 10.1002/ijc.24972; Tseng RC, 2009, NEOPLASIA, V11, P763, DOI 10.1593/neo.09470; UMBAS R, 1992, CANCER RES, V52, P5104; Vandewalle C, 2005, NUCLEIC ACIDS RES, V33, P6566, DOI 10.1093/nar/gki965; Vandewalle C, 2009, CELL MOL LIFE SCI, V66, P773, DOI 10.1007/s00018-008-8465-8; Voulgari A, 2009, BBA-REV CANCER, V1796, P75, DOI 10.1016/j.bbcan.2009.03.002; Wallerand H, 2010, UROL ONCOL-SEMIN ORI, V28, P473, DOI 10.1016/j.urolonc.2008.12.018; Yamamoto H, 2007, MOL ENDOCRINOL, V21, P1745, DOI 10.1210/me.2007-0079; Zhang Y, 2009, ONCOGENE, V28, P445, DOI 10.1038/onc.2008.388	47	231	247	4	42	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	43					4619	4629		10.1038/onc.2011.612	http://dx.doi.org/10.1038/onc.2011.612			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029WP	22249256	Green Accepted			2022-12-17	WOS:000310528200005
J	Howard, G; Eiges, R; Gaudet, F; Jaenisch, R; Eden, A				Howard, G.; Eiges, R.; Gaudet, F.; Jaenisch, R.; Eden, A.			Activation and transposition of endogenous retroviral elements in hypomethylation induced tumors in mice	ONCOGENE			English	Article						DNA hypomethylation; transposable elements; Notch1; T-cell lymphoma	DNA HYPOMETHYLATION; C-MYC; METHYLATION; GENE; TRANSCRIPTION; CHROMOSOME-1; EXPRESSION; INDUCTION; LEUKEMIA; CANCER	Genomewide DNA hypomethylation is a consistent finding in human tumors, but the importance of this change for human tumorigenesis remains an open question. We have previously reported that mice carrying a hypomorphic allele for the maintenance DNA methyltransferase (Dnmt1(chip/-)) are hypomethylated and develop thymic lymphomas, demonstrating that genomewide DNA hypomethylation can induce tumors. Hypomethylated cells exhibit inherent chromosomal instability, which is revealed in the lymphomas as a consistent trisomy of chromosome 15. We now report another aspect of the molecular basis for tumor development upon DNA hypomethylation. Seven out of 16 hypomethylation-induced lymphomas were found to contain an intracisternal A particle (IAP) somatic insertion in the middle of the Notch1 genomic locus, leading to generation of an oncogenic form of Notch1 in the tumors. This finding suggests that the molecular basis for hypomethylation-induced tumors in this model involves chromosomal instability events accompanied by activation of endogenous retroviral elements. Our findings validate the proposed role of DNA methylation in suppression of transposable elements in mammalian cells and demonstrate the importance of DNA methylation for normal cell function as well as the potential consequences of spontaneously occurring or chemically induced DNA hypomethylation.	[Howard, G.; Eiges, R.; Eden, A.] Hebrew Univ Jerusalem, Inst Life Sci, Dept Anim & Cell Biol, IL-91904 Jerusalem, Israel; [Gaudet, F.; Jaenisch, R.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; [Gaudet, F.; Jaenisch, R.] MIT, Dept Biol, Cambridge, MA USA	Hebrew University of Jerusalem; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Eden, A (corresponding author), Hebrew Univ Jerusalem, Inst Life Sci, Dept Anim & Cell Biol, IL-91904 Jerusalem, Israel.	eden@vms.huji.ac.il		eiges, rachel/0000-0001-8139-0933				AnsariLari MA, 1996, BIOTECHNIQUES, V21, P34; BOEKE JD, 1997, COLD SPRING LAB, P343; CHRISTY RJ, 1988, MOL CELL BIOL, V8, P1093, DOI 10.1128/MCB.8.3.1093; Druker R, 2004, NUCLEIC ACIDS RES, V32, P5800, DOI 10.1093/nar/gkh914; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Ehrlich M, 2003, CANCER GENET CYTOGEN, V141, P97, DOI 10.1016/S0165-4608(02)00668-4; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; Hoemann CD, 2000, MOL CELL BIOL, V20, P3831, DOI 10.1128/MCB.20.11.3831-3842.2000; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jaenisch R, 1997, TRENDS GENET, V13, P323, DOI 10.1016/S0168-9525(97)01180-3; JAHNER D, 1980, NATURE, V287, P456, DOI 10.1038/287456a0; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; KUFF EL, 1990, CANCER CELL-MON REV, V2, P398; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MICHAUD EJ, 1994, GENE DEV, V8, P1463, DOI 10.1101/gad.8.12.1463; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Rakyan VK, 2003, P NATL ACAD SCI USA, V100, P2538, DOI 10.1073/pnas.0436776100; Schulz WA, 2002, GENE CHROMOSOME CANC, V35, P58, DOI 10.1002/gcc.10092; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Tsuda H, 2002, AM J PATHOL, V161, P859, DOI 10.1016/S0002-9440(10)64246-0; Walsh CP, 1998, NAT GENET, V20, P116, DOI 10.1038/2413; Wong N, 2001, AM J PATHOL, V159, P465, DOI 10.1016/S0002-9440(10)61718-X; Yamada Y, 2005, P NATL ACAD SCI USA, V102, P13580, DOI 10.1073/pnas.0506612102; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5; Zweidler-McKay PA, 2004, SEMIN CANCER BIOL, V14, P329, DOI 10.1016/j.semcancer.2004.04.012	29	231	238	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2008	27	3					404	408		10.1038/sj.onc.1210631	http://dx.doi.org/10.1038/sj.onc.1210631			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17621273				2022-12-17	WOS:000252256000017
J	Esteller, M; Herman, JG				Esteller, M; Herman, JG			Generating mutations but providing chemosensitivity: the role of O-6-methylguanine DNA methyltransferase in human cancer	ONCOGENE			English	Review						O-6-methylguanine DNA methyltransferase; MGMT; CpG island hypermethylation; transition mutations; alkylating agents	TUMOR-SUPPRESSOR GENES; HMLH1 PROMOTER HYPERMETHYLATION; N-NITROSO COMPOUNDS; CELL LUNG-CANCER; REPAIR GENE; O6-METHYLGUANINE-DNA METHYLTRANSFERASE; CPG ISLAND; K-RAS; O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; MESSENGER-RNA	O-6-methylguanine DNA methyltransferase (MGMT) is a key enzyme in the DNA repair network. MGMT removes mutagenic and cytotoxic adducts from O-6-guanine in DNA, the preferred point of attack of many carcinogens (i.e. methylnitrosourea) and alkylating chemotherapeutic agents (i.e. BCNU, temozolamide, etc.). Hypermethylation of the CpG island located in the promoter region of MGMT is primarily responsible for the loss of MGMT function in many tumor types. The methylation-mediated silencing of MGMT has two consequences for cancer. First, tumors with MGMT methylation have a new mutator phenotype characterized by the generation of transition point mutations in genes involved in cancer etiology, such as the tumor suppressor p53 and the oncogene K-ras. Second, MGMT hypermethylation demonstrates the possibility of pharmacoepigenomics: methylated tumors are more sensitive to the killing effects of alkylating drugs used in chemotherapy. These recent results underscore the importance of MGMT in basic and translational cancer research.	Spanish Natl Canc Ctr CNIO, Mol Pathol Program, Canc Epigenet Lab, Madrid 28029, Spain; Johns Hopkins Sch Med, Sidney Kimmel Comprehens Canc Ctr Johsn Hopkins, Baltimore, MD 21231 USA	Centro Nacional de Investigaciones Oncologicas (CNIO); Johns Hopkins University; Johns Hopkins Medicine	Esteller, M (corresponding author), Spanish Natl Canc Ctr CNIO, Mol Pathol Program, Canc Epigenet Lab, Melchor Fernandez Almagro 3, Madrid 28029, Spain.	mesteller@cnio.es; hermanji@jhmi.edu	Esteller, Manel/L-5956-2014	Esteller, Manel/0000-0003-4490-6093	NATIONAL CANCER INSTITUTE [P50CA058184, U01CA084986] Funding Source: NIH RePORTER; NCI NIH HHS [CA84986, P50CA58184] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AQUILINA G, 1992, CANCER RES, V52, P6471; Ballestar E, 2002, CARCINOGENESIS, V23, P1103, DOI 10.1093/carcin/23.7.1103; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARTSCH H, 1990, MUTAT RES, V238, P255, DOI 10.1016/0165-1110(90)90017-6; Belanich M, 1996, CANCER RES, V56, P783; Biswas T, 1999, ONCOGENE, V18, P525, DOI 10.1038/sj.onc.1202320; BOCKER T, 1999, BIOCHIM BIOPHYS ACTA, V1423, P1; BONFANTI M, 1991, NUCLEIC ACIDS RES, V19, P5739, DOI 10.1093/nar/19.20.5739; BOS JL, 1989, CANCER RES, V49, P4682; Brabender J, 2003, CLIN CANCER RES, V9, P223; CAI Y, 2001, CANCER RES, V60, P5464; Cai YN, 1999, CANCER RES, V59, P3059; CECCOTTI S, 1993, BIOCHEMISTRY-US, V32, P13664, DOI 10.1021/bi00212a035; Choy KW, 2002, INVEST OPHTH VIS SCI, V43, P1344; CITRON M, 1992, J NATL CANCER I, V84, P337, DOI 10.1093/jnci/84.5.337; COLVIN M, 1981, CANCER TREAT REP, V65, P89; COSTELLO JF, 1996, CANCER RES, V271, P13916; COULONDRE C, 1977, J MOL BIOL, V117, P577, DOI 10.1016/0022-2836(77)90059-6; Danam RP, 1999, MOL CARCINOGEN, V24, P85, DOI 10.1002/(SICI)1098-2744(199902)24:2<85::AID-MC2>3.0.CO;2-C; DAY RS, 1980, NATURE, V288, P724, DOI 10.1038/288724a0; DOLAN ME, 1990, P NATL ACAD SCI USA, V87, P5368, DOI 10.1073/pnas.87.14.5368; Dolan ME, 1997, CLIN CANCER RES, V3, P837; DUMENCO LL, 1993, SCIENCE, V259, P219, DOI 10.1126/science.8421782; Edara S, 1996, CANCER RES, V56, P5571; Egyhazi S, 2002, Hum Mutat, V20, P408, DOI 10.1002/humu.9078; Engelbergs J, 1998, P NATL ACAD SCI USA, V95, P1635, DOI 10.1073/pnas.95.4.1635; ERICKSON LC, 1980, NATURE, V288, P727, DOI 10.1038/288727a0; Esteller M, 1999, CANCER RES, V59, P67; Esteller M, 2001, CANCER RES, V61, P4689; Esteller M, 1998, ONCOGENE, V17, P2413, DOI 10.1038/sj.onc.1202178; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; Esteller M, 1999, CANCER RES, V59, P793; Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901; Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024; Esteller M, 2001, CANCER RES, V61, P3225; Esteller M, 1999, AM J PATHOL, V155, P1767, DOI 10.1016/S0002-9440(10)65492-2; Esteller M, 2000, CANCER RES, V60, P2368; Esteller M, 2002, J NATL CANCER I, V94, P26; Esteller M, 2000, EUR J CANCER, V36, P2294, DOI 10.1016/S0959-8049(00)00303-8; Fleisher AS, 1999, CANCER RES, V59, P1090; FORNACE AJ, 1990, CANCER RES, V50, P7908; Fraga ME, 2002, BIOTECHNIQUES, V33, P632, DOI 10.2144/02333rv01; Fraga MF, 2003, NUCLEIC ACIDS RES, V31, P1765, DOI 10.1093/nar/gkg249; Friedman HS, 1999, CANCER CHEMOTH PHARM, V43, P80; Gamcsik MP, 1999, CURR PHARM DESIGN, V5, P587; Gerson SL, 2002, J CLIN ONCOL, V20, P2388, DOI 10.1200/JCO.2002.06.110; GERSON SL, 1986, CARCINOGENESIS, V7, P745, DOI 10.1093/carcin/7.5.745; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HARRIS LC, 1991, NUCLEIC ACIDS RES, V19, P6163, DOI 10.1093/nar/19.22.6163; Harris LC, 1996, CANCER RES, V56, P2029; Hayashi H, 2002, JPN J CANCER RES, V93, P184, DOI 10.1111/j.1349-7006.2002.tb01257.x; HEPBURN PA, 1991, J BIOL CHEM, V266, P7985; Herfarth KKF, 1999, MOL CARCINOGEN, V24, P90, DOI 10.1002/(SICI)1098-2744(199902)24:2<90::AID-MC3>3.0.CO;2-B; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Hongeng S, 1997, CLIN CANCER RES, V3, P2459; HORSFALL MJ, 1990, ENVIRON MOL MUTAGEN, V15, P107, DOI 10.1002/em.2850150208; Hussain SP, 1998, RECENT RES CANCER, V154, P22; Hussain SP, 2000, MUTAT RES-REV MUTAT, V462, P311, DOI 10.1016/S1383-5742(00)00015-6; IMAI Y, 1995, CARCINOGENESIS, V16, P2441; Inoue R, 2000, PHARMACOGENETICS, V10, P59, DOI 10.1097/00008571-200002000-00008; Jaeckle KA, 1998, J CLIN ONCOL, V16, P3310, DOI 10.1200/JCO.1998.16.10.3310; Kane MF, 1997, CANCER RES, V57, P808; Kawate H, 2000, CARCINOGENESIS, V21, P301, DOI 10.1093/carcin/21.2.301; Kawate H, 1998, P NATL ACAD SCI USA, V95, P5116, DOI 10.1073/pnas.95.9.5116; Kohya N, 2003, INT J MOL MED, V11, P65; Kohya N, 2002, ANN SURG ONCOL, V9, P371, DOI 10.1245/aso.2002.9.4.371; Kondo Y, 2003, MOL CELL BIOL, V23, P206, DOI 10.1128/MCB.23.1.206-215.2003; KROES RA, 1995, CARCINOGENESIS, V16, P2255, DOI 10.1093/carcin/16.9.2255; KUNKEL TA, 1993, NATURE, V362, P709; Lee S, 2002, AM J PATHOL, V161, P1015, DOI 10.1016/S0002-9440(10)64262-9; Liu LL, 1999, CARCINOGENESIS, V20, P279, DOI 10.1093/carcin/20.2.279; LIU PK, 1983, P NATL ACAD SCI-BIOL, V80, P797, DOI 10.1073/pnas.80.3.797; LUDLUM DB, 1990, MUTAT RES, V233, P117, DOI 10.1016/0027-5107(90)90156-X; Markowitz S, 2000, J CLIN ONCOL, V18, p75S; Maruyama R, 2002, CLIN CANCER RES, V8, P514; Mattern J, 1998, INT J CANCER, V77, P919, DOI 10.1002/(SICI)1097-0215(19980911)77:6<919::AID-IJC20>3.0.CO;2-V; Middleton MR, 2003, LANCET ONCOL, V4, P37, DOI 10.1016/S1470-2045(03)00959-8; MITRA G, 1989, P NATL ACAD SCI USA, V86, P8650, DOI 10.1073/pnas.86.22.8650; Nakamura M, 2001, CARCINOGENESIS, V22, P1715, DOI 10.1093/carcin/22.10.1715; Palmisano WA, 2000, CANCER RES, V60, P5954; Park TJ, 2001, CANCER, V92, P2760, DOI 10.1002/1097-0142(20011201)92:11<2760::AID-CNCR10123>3.0.CO;2-8; Patel SA, 1997, MOL CELL BIOL, V17, P5813, DOI 10.1128/MCB.17.10.5813; Paz MF, 2003, CANCER RES, V63, P1114; PEGG AE, 1995, PROG NUCLEIC ACID RE, V51, P167, DOI 10.1016/S0079-6603(08)60879-X; PEGG AE, 1990, CANCER RES, V50, P6119; Pfeifer GP, 2000, MUTAT RES-FUND MOL M, V450, P155, DOI 10.1016/S0027-5107(00)00022-1; PHEAR G, 1987, P NATL ACAD SCI USA, V84, P4450, DOI 10.1073/pnas.84.13.4450; PIEPER RO, 1990, CANCER COMMUN, V2, P13, DOI 10.3727/095535490820874812; Pourquier P, 2001, CANCER RES, V61, P53; Qian XLC, 1997, CANCER RES, V57, P3672; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; Rosas SLB, 2001, CANCER RES, V61, P939; ROWLAND IR, 1991, CARCINOGENESIS, V12, P1395, DOI 10.1093/carcin/12.8.1395; Rusin M, 1999, Hum Mutat, V14, P269, DOI 10.1002/(SICI)1098-1004(1999)14:3<269::AID-HUMU13>3.0.CO;2-6; Sanchez-Cespedes M, 2000, CANCER RES, V60, P892; Silber JR, 1998, CANCER RES, V58, P1068; SILBER JR, 1993, CANCER RES, V53, P3416; Smith-Sorensen B, 2002, ONCOGENE, V21, P8878, DOI 10.1038/sj.onc.1205978; Srivenugopal KS, 2002, ONCOGENE, V21, P5940, DOI 10.1038/sj.onc.1205762; Srivenugopal KS, 2000, CANCER RES, V60, P282; Srivenugopal KS, 1996, BIOCHEMISTRY-US, V35, P1328, DOI 10.1021/bi9518205; STRAUSS BS, 1992, CANCER RES, V52, P249; SUKUMAR S, 1983, NATURE, V306, P658, DOI 10.1038/306658a0; Teicher Beverly A., 1997, P405; TORNALETTI S, 1995, ONCOGENE, V10, P1493; Toyooka S, 2001, MOL CANCER THER, V1, P61; Virmani AK, 2001, CLIN CANCER RES, V7, P584; Wang L, 1997, INT J CANCER, V71, P719, DOI 10.1002/(SICI)1097-0215(19970529)71:5<719::AID-IJC5>3.0.CO;2-U; WARD FW, 1989, FOOD CHEM TOXICOL, V27, P445, DOI 10.1016/0278-6915(89)90030-6; Watts GS, 1997, MOL CELL BIOL, V17, P5612, DOI 10.1128/MCB.17.9.5612; Weinstein JN, 2000, NEW ENGL J MED, V343, P1408, DOI 10.1056/NEJM200011093431910; WHITE GRM, 1986, CARCINOGENESIS, V7, P2077, DOI 10.1093/carcin/7.12.2077; Whitehall VLJ, 2001, CANCER RES, V61, P827; Wolf P, 2001, CANCER RES, V61, P8113; Yin D, 2003, MOL CARCINOGEN, V36, P23, DOI 10.1002/mc.10094; ZAIDI NH, 1995, CARCINOGENESIS, V16, P451, DOI 10.1093/carcin/16.3.451; Zhang YJ, 2003, INT J CANCER, V103, P440, DOI 10.1002/ijc.10852	117	231	246	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					1	8		10.1038/sj.onc.1207316	http://dx.doi.org/10.1038/sj.onc.1207316			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712205				2022-12-17	WOS:000187895300001
J	Pianetti, S; Arsura, M; Romieu-Mourez, R; Coffey, RJ; Sonenshein, GE				Pianetti, S; Arsura, M; Romieu-Mourez, R; Coffey, RJ; Sonenshein, GE			Her-2/neu overexpression induces NF-kappa B via a PI3-kinase/Akt pathway involving calpain-mediated degradation of I kappa-B-alpha that can be inhibited by the tumor suppressor PTEN	ONCOGENE			English	Article						breast cancer; EGF receptor; transgenic mice; NF-kappa B; I kappa B-alpha; calpain	GROWTH-FACTOR-ALPHA; BREAST-CANCER; TRANSCRIPTION FACTOR; C-MYC; CONSTITUTIVE ACTIVATION; NECROSIS-FACTOR; PHOSPHOINOSITIDE 3-KINASE; MAMMARY EPITHELIUM; NEU PROTOONCOGENE; INDUCED APOPTOSIS	The Nuclear Factor (NF)-kappaB family of transcription factors controls expression of genes which promote cell growth, survival, and neoplastic transformation, Recently we demonstrated aberrant constitutive activation of NF-kappaB in primary human and rat breast cancer specimens and in cell lines. Overexpression of the epidermal growth factor receptor (EGFR) family member Her-2/neu, seen in approximately 30% of breast cancers, is associated with poor prognosis. Previously, Her-2/neu has been shown to signal via a phosphatidylinositol 3 (PI3)-kinase to Akt/protein kinase B (PKB) pathway. Since this signaling pathway was recently shown to activate NF-kappaB, here we have tested the hypothesis that Her-2/neu can activate TF-kappaB in breast cancer, Overexpression of Her-2/neu and EGFR-4 in Ba/F3 cells led to constitutive PI3- and Akt kinase activities, and induction of classical NF-kappaB (p50/p65). Similarly, a tumor cell line and tumors derived from MMTV-Her-2/neu transgenic mice displayed elevated levels of classical NF-kappaB, Engagement of Her-2/neu receptor downregulated the level of NF-kappaB. NF-kappaB binding and activity in the cultured cells was reduced upon inhibition of the PI3- to Akt kinase signaling pathway via ectopic expression of kinase inactive mutants, incubation with wortmannin, or expression of the tumor suppressor phosphatase PTEN, Inhibitors of calpain, but not the proteasome, blocked I kappaB-alpha degradation. Inhibition of Akt did not affect IKK activity, These results indicate that Her-2/neu activates NF-kappaB via a P13- to Akt kinase signaling pathway that can be inhibited via the tumor suppressor PTEN, and is mediated by calpain rather than the I kappaB kinase complex.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Boston Univ, Sch Med, Program Res Womens Hlth, Boston, MA 02118 USA; Vanderbilt Univ, Sch Med, Nashville, TN 37232 USA	Boston University; Boston University; Vanderbilt University	Sonenshein, GE (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA.				NCI NIH HHS [CA 82742, CA78616] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082742, R01CA078616] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Arsura M, 1997, CELL GROWTH DIFFER, V8, P1049; Arsura M, 2000, MOL CELL BIOL, V20, P5381, DOI 10.1128/MCB.20.15.5381-5391.2000; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Besancon F, 1998, P NATL ACAD SCI USA, V95, P8081, DOI 10.1073/pnas.95.14.8081; BROWN K, 1995, CELL, V84, P853; CALAF G, 1993, CARCINOGENESIS, V14, P483, DOI 10.1093/carcin/14.3.483; CHEN ZJ, 1996, MOL CELL BIOL, V16, P1295; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; Duffey DC, 1999, CANCER RES, V59, P3468; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; DUYAO MP, 1992, J BIOL CHEM, V267, P16288; ELSON A, 1995, J BIOL CHEM, V270, P26116, DOI 10.1074/jbc.270.44.26116; Fields ER, 2000, J IMMUNOL, V164, P4762, DOI 10.4049/jimmunol.164.9.4762; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hortobagyi GN, 1999, SEMIN ONCOL, V26, P11; Ignatoski KMW, 2000, BRIT J CANCER, V82, P666, DOI 10.1054/bjoc.1999.0979; Jeay S, 2000, MOL ENDOCRINOL, V14, P650, DOI 10.1210/me.14.5.650; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; KESSLER DJ, 1992, J EXP MED, V176, P787, DOI 10.1084/jem.176.3.787; Kim DW, 2000, CARCINOGENESIS, V21, P871, DOI 10.1093/carcin/21.5.871; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; Miyajima A, 1999, INT J HEMATOL, V69, P137; Miyamoto S, 1998, MOL CELL BIOL, V18, P19, DOI 10.1128/MCB.18.1.19; Mori N, 1999, BLOOD, V93, P2360; Muller WJ, 1996, MOL CELL BIOL, V16, P5726; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Ozes ON, 1999, NATURE, V401, P82; Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659; Rawadi G, 1999, J BIOL CHEM, V274, P30794, DOI 10.1074/jbc.274.43.30794; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; REGNIER CH, 1997, SCIENCE, V278, P866; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Ross, 1998, Oncologist, V3, P237; Schoonbroodt S, 2000, J IMMUNOL, V164, P4292, DOI 10.4049/jimmunol.164.8.4292; SHATTUCK RL, 1994, MOL CELL BIOL, V14, P791, DOI 10.1128/MCB.14.1.791; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sovak MA, 1999, CELL GROWTH DIFFER, V10, P537; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Sumitomo M, 1999, J UROLOGY, V161, P674, DOI 10.1016/S0022-5347(01)61993-1; Sumitomo M, 1999, HUM GENE THER, V10, P37, DOI 10.1089/10430349950019174; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; Tam S. W., 1997, Leukemia (Basingstoke), V11, P363; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; Wang WX, 1999, CLIN CANCER RES, V5, P119; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	70	231	242	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2001	20	11					1287	1299		10.1038/sj.onc.1204257	http://dx.doi.org/10.1038/sj.onc.1204257			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	411JM	11313873				2022-12-17	WOS:000167495000003
J	Kanno, S; Oda, N; Abe, M; Terai, Y; Ito, M; Shitara, K; Tabayashi, K; Shibuya, M; Sato, Y				Kanno, S; Oda, N; Abe, M; Terai, Y; Ito, M; Shitara, K; Tabayashi, K; Shibuya, M; Sato, Y			Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial calls	ONCOGENE			English	Article						VEGF; Flt-1; KDR; migration; proliferation	PLACENTA GROWTH-FACTOR; FOCAL ADHESION KINASE; DOMAIN-CONTAINING RECEPTOR; TYROSINE KINASE; MONOCLONAL-ANTIBODIES; PLASMINOGEN-ACTIVATOR; EXTRACELLULAR DOMAIN; CELL-MIGRATION; PHOSPHORYLATION; EXPRESSION	Vascular endothelial growth factor (VEGF) is a principal regulator of vasculogenesis and angiogenesis, VEGF expresses its effects by binding to two VEGF receptors, Flt-1 and KDR, However, properties of FI-l and KDR in the signal transduction of VEGF-mediated effects in endothelial cells (ECs) were not entirely clarified, We investigated this issue by using two newly developed blocking monoclonal antibodies (mAbs) against Flt-1 and KDR, VEGF elicits DKA. synthesis and cell migration of human umbilical, vein endothelial cells (HUVECs). The pattern of inhibition of these effects by two mAbs indicates that DNA. synthesis is preferentially mediated by KDR, In contrast, the regulation of cell migration by VEGF appears to be more complicated. Flt-1 regulates cell, migration through modulating actin reorganization, which is essential for cell motility. a distinct signal is generated by KDR, which influences cell migration by regulating cell adhesion via the assembly of vinculin in focal adhesion plaque and tyrosine-phosphorylation of focal adhesion kinase (FAK) and paxillin.	Tohoku Univ, Inst Dev Aging & Canc, Dept Vasc Biol, Sendai, Miyagi 9808575, Japan; Tohoku Univ, Sch Med, Dept Thorac & Cardiovasc Surg, Sendai, Miyagi 980, Japan; Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, Machida 194, Japan; Univ Tokyo, Dept Genet, Inst Med Sci, Tokyo, Japan	Tohoku University; Tohoku University; Kyowa Kirin Ltd; University of Tokyo	Sato, Y (corresponding author), Tohoku Univ, Inst Dev Aging & Canc, Dept Vasc Biol, Sendai, Miyagi 9808575, Japan.		Kanno, Shin-ichiro/AAE-4549-2019					Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Bernatchez PN, 1999, J BIOL CHEM, V274, P31047, DOI 10.1074/jbc.274.43.31047; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; Craig SW, 1996, CURR OPIN CELL BIOL, V8, P74, DOI 10.1016/S0955-0674(96)80051-2; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HANAI N, 1986, CANCER RES, V46, P4438; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lewis JM, 1996, J CELL BIOL, V134, P1323, DOI 10.1083/jcb.134.5.1323; PARK JE, 1994, J BIOL CHEM, V269, P25646; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; SEETHARAM L, 1995, ONCOGENE, V10, P135; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHEN H, 1993, BLOOD, V81, P2767; SHIBUYA M, 1990, ONCOGENE, V5, P519; Shinkai A, 1998, J BIOL CHEM, V273, P31283, DOI 10.1074/jbc.273.47.31283; SHITARA K, 1987, CANCER RES, V47, P1267; Slack BE, 1998, P NATL ACAD SCI USA, V95, P7281, DOI 10.1073/pnas.95.13.7281; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; Tanaka K, 1997, JPN J CANCER RES, V88, P867, DOI 10.1111/j.1349-7006.1997.tb00463.x; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Zhu ZP, 1998, CANCER RES, V58, P3209; Ziegler BL, 1999, SCIENCE, V285, P1553, DOI 10.1126/science.285.5433.1553	39	231	254	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 20	2000	19	17					2138	2146		10.1038/sj.onc.1203533	http://dx.doi.org/10.1038/sj.onc.1203533			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	308TB	10815805				2022-12-17	WOS:000086728000007
J	Bubb, VJ; Curtis, LJ; Cunningham, C; Dunlop, MG; Carothers, AD; Morris, RG; White, S; Bird, CC; Wyllie, AH				Bubb, VJ; Curtis, LJ; Cunningham, C; Dunlop, MG; Carothers, AD; Morris, RG; White, S; Bird, CC; Wyllie, AH			Microsatellite instability and the role of hMSH2 in sporadic colorectal cancer	ONCOGENE			English	Article						replication errors; sporadic colorectal cancer; hMSH2; prognosis	GENETIC INSTABILITY; GENOMIC INSTABILITY; MUTATIONS; CARCINOMA; HOMOLOG; TUMORS; COLON	Microsatellite instability (MSI) occurs in most tumours from patients with hereditary non-polyposis colorectal cancer (HNPCC) and in around 17% of sporadic colorectal cancers. Germline defects in mismatch repair (MMR) genes are responsible for the majority of large HNPCC families, with hMSH2 accounting for at least 50%. MMR gene defects also occur in a small proportion of sporadic colorectal tumours with MSI. Here we report a systematic analysis of mismatch repair deficiency in 215 Scottish patients with sporadic colorectal tumours. We found that 16.4% of tumours exhibited MSI; survival analysis by Cox proportional hazards method showed a substantial survival advantage for patients with tumours showing MSI, independent of other prognostic factors. Tumours with MSI were screened for hMSH2 mutations and although 61% were found to have alterations, of these only 1/24 was exonic. The majority of these changes were reductions in length at intronic mononucleotide tracts and we postulate that these alterations are the result of a genetic defect elsewhere, although they may compromise hMSH2 function as a second step in tumourigenesis. Our findings indicate that instability confers an improved prognosis in colorectal cancer and, despite the fact that these two groups of tumours share similar biological characteristics, the genetic basis of HNPCC and sporadic colorectal cancer with MSI is different.	UNIV EDINBURGH, ROYAL INFIRM, DEPT SURG, EDINBURGH EH3 9YW, MIDLOTHIAN, SCOTLAND; WESTERN GEN HOSP, MRC, HUMAN GENET UNIT, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND	Royal Infirmary of Edinburgh; University of Edinburgh; University of Edinburgh	Bubb, VJ (corresponding author), UNIV EDINBURGH, SCH MED, DEPT PATHOL, CRC LABS, TEVIOT PL, EDINBURGH EH8 9AG, MIDLOTHIAN, SCOTLAND.		Dunlop, Malcolm G/F-1973-2011	Dunlop, Malcolm G/0000-0002-3033-5851				AALTONEN LA, 1994, CANCER RES, V54, P1645; AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BASSAM BJ, 1991, ANAL BIOCHEM, V196, P80, DOI 10.1016/0003-2697(91)90120-I; BORRESEN AL, 1995, HUM MOL GENET, V4, P2065, DOI 10.1093/hmg/4.11.2065; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; *CANC RES CAMP, 1993, 181 CANC RES CAMP; CHEN JS, 1995, CANCER RES, V55, P174; CHONG JM, 1994, CANCER RES, V54, P4595; CHU CS, 1993, NAT GENET, V3, P151, DOI 10.1038/ng0293-151; CURTIS L, 1994, EUR J CANCER, V30A, P984, DOI 10.1016/0959-8049(94)90129-5; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FONG KM, 1995, CANCER RES, V55, P28; GAO XA, 1994, ONCOGENE, V9, P2999; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HALL NR, 1994, EUR J CANCER, V30A, P1550, DOI 10.1016/0959-8049(94)00326-Z; HAN HJ, 1993, CANCER RES, V53, P5087; HONCHEL R, 1994, CANCER RES, V54, P1159; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KIM HG, 1994, AM J PATHOL, V145, P148; KOBAYASHI Y, 1988, FOCUS, V10, P73; KOLODNER RD, 1994, GENOMICS, V24, P516, DOI 10.1006/geno.1994.1661; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LIU B, 1994, CANCER RES, V54, P4590; LOTHE RA, 1993, CANCER RES, V53, P5849; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MARY JL, 1994, HUM MOL GENET, V3, P2067; MELTZER SJ, 1994, CANCER RES, V54, P3379; MERLO A, 1994, CANCER RES, V54, P2098; MIRONOV NM, 1994, CANCER RES, V54, P41; NAN HJ, 1995, HUM MOL GENET, V4, P237, DOI 10.1093/hmg/4.2.237; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PATEL U, 1994, ONCOGENE, V9, P3695; PELTOMAKI P, 1993, CANCER RES, V53, P5853; PERCESEPPE A, 1994, INT J CANCER, V58, P799, DOI 10.1002/ijc.2910580608; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; PURDIE CA, 1991, AM J PATHOL, V138, P807; RHYU MG, 1994, ONCOGENE, V9, P29; RISINGER JI, 1993, CANCER RES, V53, P5100; SHRIDHAR V, 1994, CANCER RES, V54, P2084; STORTS DR, 1993, PROMEGA NOTES, V42, P10; SUZUKI H, 1994, CANCER RES, V54, P4841; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; WIERINGA B, 1984, CELL, V37, P915, DOI 10.1016/0092-8674(84)90426-4; WIJNEN J, 1994, HUM MOL GENET, V3, P2268, DOI 10.1093/hmg/3.12.2268-a; WIJNEN J, 1995, AM J HUM GENET, V56, P1060; WU C, 1994, ONCOGENE, V9, P991; YOUNG J, 1993, HUM MUTAT, V2, P351, DOI 10.1002/humu.1380020505	55	231	235	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	1996	12	12					2641	2649						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700523				2022-12-17	WOS:A1996UW48700018
J	KOKEN, MHM; LINARESCRUZ, G; QUIGNON, F; VIRON, A; CHELBIALIX, MK; SOBCZAKTHEPOT, J; JUHLIN, L; DEGOS, L; CALVO, F; DETHE, H				KOKEN, MHM; LINARESCRUZ, G; QUIGNON, F; VIRON, A; CHELBIALIX, MK; SOBCZAKTHEPOT, J; JUHLIN, L; DEGOS, L; CALVO, F; DETHE, H			THE PML GROWTH-SUPPRESSOR HAS AN ALTERED EXPRESSION IN HUMAN ONCOGENESIS	ONCOGENE			English	Article						ANTIONCOGENE; NUCLEAR BODIES; INTERFERON; STROMA; NEOANGIOGENESIS	ACUTE PROMYELOCYTIC LEUKEMIA; PRIMARY BILIARY-CIRRHOSIS; DNA-BINDING PROTEIN; ZINC FINGER; NUCLEAR-BODIES; TRANSCRIPTION FACTOR; TUMOR-CELLS; RAR-ALPHA; GENE; DIFFERENTIATION	Altered sub-nuclear localisation of the nuclear body-associated PML protein in acute promyelocytic leukaemia, has been proposed to contribute to leukaemogenesis. We have recently shown that PML is a primary target gene of interferons. Here, it is shown that PML has growth suppressive properties and displays an altered expression pattern during human oncogenesis. PML is widely expressed in cell-lines and is cell-cycle regulated. Overexpression of the protein induces a sharp reduction in growth rates in vitro and in vivo. In contrast with cell-lines, in normal tissues (including those that rapidly proliferate) only a few cells have detectable PML levels. However, these can be upregulated by soluble factors (e.g. IFN, estrogens.). Human epithelial tumors show a gradual increase of PML levels as the lesion progresses from benign dysplasia to carcinoma. A similar induction is found in the surrounding stroma and vessels, which likely results from paracrine interactions, Strikingly, when malignant cells turn invasive, they loose PML expression, while expression is conserved in the stromal compartment. These observations point to the existence of a consistent deregulation in the expression of the PML growth-suppressor during human oncogenesis.	HOP ST LOUIS, CTR HAYEM, CNRS, UPR 43, F-75475 PARIS 10, FRANCE; HOP ST LOUIS, IGM, PHARMACOL EXPTL LAB, PARIS, FRANCE; INST RECH SCI CANC, CNRS, UPR 272, VILLEJUIF, FRANCE; HOP NECKER ENFANTS MALAD, INSERM, U370, PARIS, FRANCE; UNIV UPPSALA HOSP, DEPT DERMATOL, S-75014 UPPSALA 14, SWEDEN; HOP ST LOUIS, SERV CLIN MALAD SANG, PARIS, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Uppsala University; Uppsala University Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite			Quignon, Frédérique/P-4249-2017; koken, marcel/N-1349-2019; koken, marcel/J-8154-2012	koken, marcel/0000-0002-0839-0125; Sobczak, Joelle/0000-0001-7180-2789; calvo, fabien/0000-0002-0298-7633				ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; Ashihara T, 1979, Methods Enzymol, V58, P248; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BENCHETRIT E, 1988, J EXP MED, V167, P1560, DOI 10.1084/jem.167.5.1560; BRASCH K, 1992, EXP CELL RES, V202, P211, DOI 10.1016/0014-4827(92)90068-J; DANIEL MT, 1993, BLOOD, V82, P1858; de The G., 1960, B ASSOC FR ETUD CANC, V47, P570; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FAGIOLI M, 1992, ONCOGENE, V7, P1083; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; FUSCONI M, 1991, CLIN EXP IMMUNOL, V83, P291; GAKEN J, 1992, BIOTECHNIQUES, V13, P32; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; GULDNER HH, 1992, J IMMUNOL, V149, P4067; HUMBERT C, 1992, J CELL SCI, V103, P97; ISOMURA T, 1992, NUCLEIC ACIDS RES, V20, P5305, DOI 10.1093/nar/20.20.5305; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LINARESCRUZ G, 1994, J MICROSC-OXFORD, V173, P27, DOI 10.1111/j.1365-2818.1994.tb03425.x; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; MAUL GG, 1994, J GEN VIROL, V75, P1223, DOI 10.1099/0022-1317-75-6-1223; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; PERRY LJ, 1986, J GEN VIROL, V67, P2365, DOI 10.1099/0022-1317-67-11-2365; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; REVEL M, 1986, TRENDS BIOCHEM SCI, V11, P166, DOI 10.1016/0968-0004(86)90134-9; SATO H, 1993, ONCOGENE, V8, P395; STUURMAN N, 1992, J CELL SCI, V101, P773; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; TAGAWA M, 1990, J BIOL CHEM, V265, P20021; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; TERASAKI M, 1984, CELL, V38, P101, DOI 10.1016/0092-8674(84)90530-0; TSAI S, 1992, GENE DEV, V6, P2258, DOI 10.1101/gad.6.12a.2258; TSAI S, 1993, P NATL ACAD SCI USA, V90, P7153, DOI 10.1073/pnas.90.15.7153; UYEMURA K, 1993, J INVEST DERMATOL, V101, P701, DOI 10.1111/1523-1747.ep12371679; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0; VISA N, 1993, EXP CELL RES, V208, P19, DOI 10.1006/excr.1993.1218; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; WERNERT N, 1992, AM J PATHOL, V140, P119	46	231	240	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1315	1324						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731682				2022-12-17	WOS:A1995QR65100008
J	WANG, YS; SZEKELY, L; OKAN, I; KLEIN, G; WIMAN, KG				WANG, YS; SZEKELY, L; OKAN, I; KLEIN, G; WIMAN, KG			WILD-TYPE P53-TRIGGERED APOPTOSIS IS INHIBITED BY BCL-2 IN A V-MYC-INDUCED T-CELL LYMPHOMA LINE	ONCOGENE			English	Note							TUMOR SUPPRESSOR GENE; C-MYC; B-CELLS; CHROMOSOME-TRANSLOCATION; FOLLICULAR LYMPHOMA; MEMBRANE PROTEIN; P53; DEATH; EXPRESSION; BREAKPOINT	Using a temperature sensitive p53 construct (ts p53), we have earlier shown that expression of wild-type (wt) p53 triggers apoptosis in a v-myc-induced T-cell lymphoma line that lacks endogenous p53, and in a Burkitt lymphoma line that carries mutant p53. We have suggested that apoptosis is elicited by the contradictory signals emanating from the constitutively activated myc gene and the growth arresting signal of wt p53 (Ramqvist et al., 1993; Wang et al., 1993). Work in other laboratories has shown that constitutive c-myc expression can induce apoptosis when cell proliferation is inhibited due to the lack of growth stimulating factors. Expression of bcl-2 could inhibit apoptosis. In order to test whether p53-induced apoptosis can be prevented by bcl-2, we have introduced a retrovirally driven bcl-2 construct into our v-myc-induced murine T-cell lymphoma line, previously transfected with ts p53. About 90% of the parental ts p53 transfected cells died of apoptosis within 3 days after induction of wt p53 expression at 32 degrees C. Two clones of ts p53/bcl-2 double transfectants that expressed high levels of bcl-2 from the introduced construct were completely protected from apoptosis, following transfer of the cells to 32 degrees C. One clone that expressed the exogenous bcl-2 only at a low level was partially protected from wt p53-induced apoptosis. Clones of the parental ts p53 carrying cells transfected with the puromycin resistance gene vector, without the bcl-2 gene underwent 90% apoptosis. These results suggest that bcl-2 may prevent apoptosis in cells simultaneously exposed to the proliferation-stimulating effect of activated myc and the growth arresting signal of wt p53.			WANG, YS (corresponding author), KAROLINSKA INST,DEPT TUMOR BIOL,BOX 60400,S-10401 STOCKHOLM,SWEDEN.		Wiman, Klas/AAB-8399-2021; Szekely, Laszlo/B-1268-2009	Wiman, Klas/0000-0002-7113-524X; 	NATIONAL CANCER INSTITUTE [R01CA014054] Funding Source: NIH RePORTER; NCI NIH HHS [CA14054] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALNEMRI ES, 1992, CANCER RES, V52, P491; ASKEW DS, 1991, ONCOGENE, V6, P1915; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; DEJONG D, 1988, NEW ENGL J MED, V318, P1373, DOI 10.1056/NEJM198805263182106; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FRITSCHE M, 1993, ONCOGENE, V8, P307; GAUWERKY CE, 1988, P NATL ACAD SCI USA, V85, P8548, DOI 10.1073/pnas.85.22.8548; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; PEGORARO L, 1984, P NATL ACAD SCI-BIOL, V81, P7166, DOI 10.1073/pnas.81.22.7166; RAMQVIST T, 1993, ONCOGENE, V8, P1495; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; Sambrook J., 1989, MOL CLONING LAB MANU; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; STRASSER A, 1993, ONCOGENE, V8, P1; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WANG YS, 1992, ONCOGENE, V7, P1241; WANG YS, 1993, CELL GROWTH DIFFER, V4, P467; WIMAN KG, 1991, ONCOGENE, V6, P1633; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	38	231	243	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3427	3431						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247547				2022-12-17	WOS:A1993MG78200029
J	OLSON, DC; MARECHAL, V; MOMAND, J; CHEN, JD; ROMOCKI, C; LEVINE, AJ				OLSON, DC; MARECHAL, V; MOMAND, J; CHEN, JD; ROMOCKI, C; LEVINE, AJ			IDENTIFICATION AND CHARACTERIZATION OF MULTIPLE MDM-2 PROTEINS AND MDM-2-P53 PROTEIN COMPLEXES	ONCOGENE			English	Article							CELLULAR TUMOR-ANTIGEN; P53 PROTEIN; WILD-TYPE; SV40-TRANSFORMED CELLS; ACTIVATING MUTATIONS; TRANSFORMED-CELLS; GENE-EXPRESSION; T-ANTIGEN; SV40; PRODUCT	A protein product of the mdm-2 oncogene (p90) has been recently shown to associate with the protein encoded by the tumor-suppressor gene p53. The mdm-2 gene was originally identified as a gene amplified in a spontaneously transformed Balb/c 3T3 cell line (3T3DM). This report describes the characterization of mdm-2 gene products and their interactions with the p53 protein. Polyclonal and monoclonal antibodies were generated against murine and human mdm-2 protein. These antibodies detected the mdm-2 p90 protein and at least four additional polypeptides (p85, p76, p74, p58-p57) in cultured cells. These additional proteins may arise from different spliced mRNA forms of the mdm-2 gene or post-translational modifications of the mdm-2 protein. The monoclonal antibodies distinguished at least three sets of mdm-2 proteins with distinct combinations of epitopes (p90 and p85; p76 and p74; p58-57). One or two of these proteins forms a complex with the p53 protein (p90, p58). These mdm-2 proteins were found to be overexpressed in 3T3DM cells and a subset of these proteins were complexed with p53. In 3T3DM cells, p90, like p53, had a short half-life of approximately 20 min and was localized to the cell nucleus. In resting cells stimulated with serum p90 levels and p90/p53 complex levels increased in the late G1 phase of the cell cycle. The p90 mdm-2 protein could regulate p53 activity in the late G1 phase of the cell cycle.	PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Princeton University			Momand, Jamil/F-8154-2012; marechal, vincent/P-7719-2017		NCI NIH HHS [CA09258-07, P01 CA41086, 5 F32 CA08771] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA008771, P01CA041086] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN JH, 1993, UNPUB; CORDONCARDO C, 1993, UNPUB; ELDEIRY WS, 1992, NAT GENET, V1, P44; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINZER DIH, 1979, VIROLOGY, V98, P308, DOI 10.1016/0042-6822(79)90554-3; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OREN M, 1982, MOL CELL BIOL, V2, P443, DOI 10.1128/MCB.2.4.443; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; WU X, 1993, UNPUB; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	33	231	235	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2353	2360						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	7689721				2022-12-17	WOS:A1993LT36800005
J	Bartucci, M; Dattilo, R; Moriconi, C; Pagliuca, A; Mottolese, M; Federici, G; Di Benedetto, A; Todaro, M; Stassi, G; Sperati, F; Amabile, MI; Pilozzi, E; Patrizii, M; Biffoni, M; Maugeri-Sacca, M; Piccolo, S; De Maria, R				Bartucci, M.; Dattilo, R.; Moriconi, C.; Pagliuca, A.; Mottolese, M.; Federici, G.; Di Benedetto, A.; Todaro, M.; Stassi, G.; Sperati, F.; Amabile, M. I.; Pilozzi, E.; Patrizii, M.; Biffoni, M.; Maugeri-Sacca, M.; Piccolo, S.; De Maria, R.			TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells	ONCOGENE			English	Article						breast cancer; cancer stem cells; chemotherapy; TAZ; metastasis	EPITHELIAL-MESENCHYMAL TRANSITION; CIRCULATING TUMOR-CELLS; IN-VITRO PROPAGATION; IDENTIFICATION; RESISTANCE; PHENOTYPE; PATHWAY; BLOOD; BONE	Metastatic growth in breast cancer (BC) has been proposed as an exclusive property of cancer stem cells (CSCs). However, formal proof of their identity as cells of origin of recurrences at distant sites and the molecular events that may contribute to tumor cell dissemination and metastasis development are yet to be elucidated. In this study, we analyzed a set of patient-derived breast cancer stem cell (BCSC) lines. We found that in vitro BCSCs exhibit a higher chemoresistance and migratory potential when compared with differentiated, nontumorigenic, breast cancer cells (dBCCs). By developing an in vivo metastatic model simulating the disease of patients with early BC, we observed that BCSCs is the only cell population endowed with metastatic potential. Gene-expression profile studies comparing metastagenic and non-metastagenic cells identified TAZ, a transducer of the Hippo pathway and biomechanical cues, as a central mediator of BCSCs metastatic ability involved in their chemoresistance and tumorigenic potential. Overexpression of TAZ in low-expressing dBCCs induced cell transformation and conferred tumorigenicity and migratory activity. Conversely, loss of TAZ in BCSCs severely impaired metastatic colonization and chemoresistance. In clinical data from 99 BC patients, high expression levels of TAZ were associated with shorter disease-free survival in multivariate analysis, thus indicating that TAZ may represent a novel independent negative prognostic factor. Overall, this study designates TAZ as a novel biomarker and a possible therapeutic target for BC.	[Bartucci, M.; Dattilo, R.; Moriconi, C.; Pagliuca, A.; Patrizii, M.; Biffoni, M.] Ist Super Sanita, Dept Hematol Oncol & Mol Med, I-00161 Rome, Italy; [Mottolese, M.; Federici, G.; Di Benedetto, A.; Sperati, F.; Maugeri-Sacca, M.; De Maria, R.] Regina Elena Inst Canc Res, Rome, Italy; [Todaro, M.; Stassi, G.] Univ Palermo, Dept Surg & Oncol Sci, Palermo, Italy; [Amabile, M. I.] Univ Roma La Sapienza, Dept Surg Sci, Rome, Italy; [Pilozzi, E.] Univ Roma La Sapienza, St Andrea Hosp, Dept Clin & Mol Med, Rome, Italy; [Piccolo, S.] Univ Padua, Sch Med, Dept Histol Microbiol & Med Biotechnol, Padua, Italy	Istituto Superiore di Sanita (ISS); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Palermo; Sapienza University Rome; Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; University of Padua	Bartucci, M (corresponding author), Ist Super Sanita, Dept Hematol Oncol & Mol Med, I-00161 Rome, Italy.	monicabartucci@yahoo.com	Dattilo, Rosanna/B-3014-2018; De Maria, Ruggero/S-6385-2019; Dattilo, Rosanna/AAD-1910-2021; Stassi, Giorgio/AAC-1175-2022; todaro, matilde/AAC-1003-2022; PILOZZI, Emanuela/AAC-1854-2022; Biffoni, Mauro/J-8318-2016; Pagliuca, Alfredo/AAI-3689-2020; Federici, Giulia/K-7587-2016; Sperati, Francesca/K-5843-2016; Federici, Giulia/AAC-8820-2019; Maugeri-Saccà, Marcello/K-2350-2014; Moriconi, Chiara/B-7638-2015	Dattilo, Rosanna/0000-0002-1462-5891; De Maria, Ruggero/0000-0003-2255-0583; todaro, matilde/0000-0001-8686-8043; PILOZZI, Emanuela/0000-0002-7110-9172; Biffoni, Mauro/0000-0002-1304-9060; Federici, Giulia/0000-0002-4684-0270; Sperati, Francesca/0000-0002-6038-2798; Federici, Giulia/0000-0002-4684-0270; Maugeri-Saccà, Marcello/0000-0003-2287-9581; Moriconi, Chiara/0000-0001-7942-2166; pagliuca, alfredo/0000-0002-8703-2077; Di Benedetto, Anna/0000-0002-9853-8671; PICCOLO, STEFANO/0000-0002-2037-0004	Associazione Italiana Ricerca sul Cancro (AIRC) [IG-10254, IG 13431]	Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro)	We thank Associazione Italiana Ricerca sul Cancro (AIRC) grants IG-10254 (MT) and IG 13431 (RDM) for financial support. We are grateful to Giuseppe Loreto for figure editing, Michele Signore and Mario Falchi for confocal acquisitions.	Abraham BK, 2005, CLIN CANCER RES, V11, P1154; Aktas B, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2333; Baccelli I, 2013, NAT BIOTECHNOL, V31, P539, DOI 10.1038/nbt.2576; Balic M, 2006, CLIN CANCER RES, V12, P5615, DOI 10.1158/1078-0432.CCR-06-0169; Bartucci M, 2012, CELL DEATH DIFFER, V19, P768, DOI 10.1038/cdd.2011.170; Bonci D, 2003, GENE THER, V10, P630, DOI 10.1038/sj.gt.3301936; Cardoso F, 2008, J CLIN ONCOL, V26, P729, DOI 10.1200/JCO.2007.14.3222; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chan SW, 2008, CANCER RES, V68, P2592, DOI 10.1158/0008-5472.CAN-07-2696; Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048; D'Amico L, 2013, BRIT J CANCER, V108, P2525, DOI 10.1038/bjc.2013.271; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Eramo A, 2008, CELL DEATH DIFFER, V15, P504, DOI 10.1038/sj.cdd.4402283; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Gonzalez-Angulo AM, 2007, ADV EXP MED BIOL, V608, P1; Grefte S, 2012, BIOMED MATER, V7, DOI 10.1088/1748-6041/7/5/055004; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Kakarala M, 2008, J CLIN ONCOL, V26, P2813, DOI 10.1200/JCO.2008.16.3931; Lai D, 2011, CANCER RES, V71, P2728, DOI 10.1158/0008-5472.CAN-10-2711; Lei QY, 2008, MOL CELL BIOL, V28, P2426, DOI 10.1128/MCB.01874-07; Liu R, 2007, NEW ENGL J MED, V356, P217, DOI 10.1056/NEJMoa063994; Lladser A, 2011, ADV CANCER RES, V111, P1, DOI 10.1016/B978-0-12-385524-4.00001-5; Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Maugeri-Sacca M, 2011, CLIN CANCER RES, V17, P4942, DOI 10.1158/1078-0432.CCR-10-2538; Morris PG, 2009, EXPERT OPIN PHARMACO, V10, P967, DOI [10.1517/14656560902834961, 10.1517/14656560902834961 ]; Pagliuca A, 2013, ONCOGENE, V32, P4806, DOI 10.1038/onc.2012.495; Perrone G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043110; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Saini V, 2010, CANCER SCI, V101, P16, DOI 10.1111/j.1349-7006.2009.01371.x; Schatton T, 2008, NATURE, V451, P345, DOI 10.1038/nature06489; Theodoropoulos PA, 2010, CANCER LETT, V288, P99, DOI 10.1016/j.canlet.2009.06.027; Yin D, 2010, INT J CANCER, V127, P2257, DOI 10.1002/ijc.25257; Zhao B, 2008, CURR OPIN CELL BIOL, V20, P638, DOI 10.1016/j.ceb.2008.10.001; Zhou BBS, 2009, NAT REV DRUG DISCOV, V8, P806, DOI 10.1038/nrd2137	36	230	233	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2015	34	6					681	690		10.1038/onc.2014.5	http://dx.doi.org/10.1038/onc.2014.5			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DG	24531710				2022-12-17	WOS:000348853800002
J	Sun, B; Karin, M				Sun, B.; Karin, M.			NF-kappa B signaling, liver disease and hepatoprotective agents	ONCOGENE			English	Review						NF-kappa B; liver disease; hepatitis; hepatocellular carcinoma; apoptosis	HEPATITIS-C VIRUS; HELICOBACTER-PYLORI INFECTION; CYTOLETHAL DISTENDING TOXIN; CHRONIC ACTIVE HEPATITIS; STELLATE CELL APOPTOSIS; NITRIC-OXIDE; MICE LACKING; GROWTH-FACTOR; TNF-ALPHA; CYCLOOXYGENASE-2 EXPRESSION	The NF-kappa B signaling pathway has particular relevance to several liver diseases including hepatitis (liver infection by Helicobacter, viral hepatitis induced by HBV and HCV), liver fibrosis and cirrhosis and hepatocellular carcinoma. Furthermore, the NF-kappa B signaling pathway is a potential target for development of hepatoprotective agents. Several types of drugs including: selective estrogen receptor modulators (SERMs), antioxidants, proteasome inhibitors, IKK inhibitors and nucleic acid-based decoys have been shown to interfere with NF-kappa B activity at different levels and may be useful for the treatment of liver diseases. However, NF-kappa B also plays an important hepatoprotective function that needs to be taken into consideration during development of new therapeutic regimens.	[Karin, M.] Univ Calif San Diego, Sch Med, Lab Gene Regulat & Signal Transduct, Dept Pharmacol & Pathol,Canc Ctr, La Jolla, CA 92093 USA; [Sun, B.] Nanjing Med Univ, Ctr Canc, Nanjing, Jiangsu Prov, Peoples R China; [Sun, B.] Nanjing Med Univ, Affiliated Hosp 1, Liver Transplantat Ctr, Nanjing, Jiangsu Prov, Peoples R China	University of California System; University of California San Diego; Nanjing Medical University; Nanjing Medical University	Karin, M (corresponding author), Univ Calif San Diego, Sch Med, Lab Gene Regulat & Signal Transduct, Dept Pharmacol & Pathol,Canc Ctr, 9500 Gilman Dr, La Jolla, CA 92093 USA.	karinoffice@ucsd.edu		Sun, Beicheng/0000-0002-8657-7024	Jiangsu Province's Outstanding Medical Academic Leader program [RC2007057]; Natural Science Foundation of China [30672367]; Ministry of Health, China [Wkj2006-2-021]; Jiangsu Province 'six adults just' high peak [06-B-032]; National Institutes of Health (NIH); American Association for Cancer Research (AACR)	Jiangsu Province's Outstanding Medical Academic Leader program; Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Health, China; Jiangsu Province 'six adults just' high peak; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Association for Cancer Research (AACR)	Work in BS laboratory is supported by Jiangsu Province's Outstanding Medical Academic Leader program (RC2007057, BS), grants from Natural Science Foundation of China (30672367, BS) and Ministry of Health, China (Wkj2006-2-021, BS), and Jiangsu Province 'six adults just' high peak: (06-B-032). Work in MK laboratory is supported by grants from the National Institutes of Health (NIH) and American Association for Cancer Research (AACR). MK is an American Cancer Society Research Professor.	Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; Anan A, 2006, HEPATOLOGY, V43, P335, DOI 10.1002/hep.21036; Andersen LP, 2001, DIGEST DIS, V19, P112, DOI 10.1159/000050664; Atabay HI, 1998, J APPL MICROBIOL, V84, P1017, DOI 10.1046/j.1365-2672.1998.00438.x; Bae MK, 2006, ONCOL REP, V15, P1557; Bataller R, 2005, J CLIN INVEST, V115, P209, DOI 10.1172/JCI200524282; Bautista AP, 2002, FRONT BIOSCI-LANDMRK, V7, pA117; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Benelli R, 2001, FASEB J, V15, P267, DOI 10.1096/fj.01-0651fje; Bernier M, 2006, J BIOL CHEM, V281, P2551, DOI 10.1074/jbc.M511878200; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; Bose S, 2003, J INTERF CYTOK RES, V23, P401, DOI 10.1089/107999003322277810; Bose S, 2003, P NATL ACAD SCI USA, V100, P10890, DOI 10.1073/pnas.1832775100; Cervello M, 2004, INT J MOL MED, V13, P741; Chaisson ML, 2002, J CLIN INVEST, V110, P193, DOI 10.1172/JCI200215295; Chang CS, 2007, HEPATO-GASTROENTEROL, V54, P2061; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Chen CJ, 2007, NAT MED, V13, P851, DOI 10.1038/nm1603; Chen D, 2008, HISTOL HISTOPATHOL, V23, P487, DOI 10.14670/HH-23.487; Chen LW, 2003, NAT MED, V9, P575, DOI 10.1038/nm849; Chen Y, 2008, PHARM RES-DORDR, V25, P72, DOI 10.1007/s11095-007-9504-0; Cheng Y, 2007, CHINESE MED J-PEKING, V120, P794, DOI 10.1097/00029330-200705010-00011; Chong LW, 2006, J BIOMED SCI, V13, P403, DOI 10.1007/s11373-006-9079-5; Chuang SE, 2000, FOOD CHEM TOXICOL, V38, P991, DOI 10.1016/S0278-6915(00)00101-0; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Cooper A, 2005, J IMMUNOL, V175, P3165, DOI 10.4049/jimmunol.175.5.3165; Coornaert B, 2008, NAT IMMUNOL, V9, P263, DOI 10.1038/ni1561; Crispe IN, 2003, NAT REV IMMUNOL, V3, P51, DOI 10.1038/nri981; Diao JY, 2001, CYTOKINE GROWTH F R, V12, P189, DOI 10.1016/S1359-6101(00)00034-4; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; Elsharkawy AM, 2007, HEPATOLOGY, V46, P590, DOI 10.1002/hep.21802; Elsharkawy AM, 2005, APOPTOSIS, V10, P927, DOI 10.1007/s10495-005-1055-4; Elsharkawy AM, 1999, HEPATOLOGY, V30, P761, DOI 10.1002/hep.510300327; Fan CG, 2004, J CLIN INVEST, V113, P746, DOI 10.1172/JCI17337; Farinati F, 2007, J VIRAL HEPATITIS, V14, P821, DOI 10.1111/1365-2893.2007.00878.x; FOX JG, 1995, J CLIN MICROBIOL, V33, P445, DOI 10.1128/JCM.33.2.445-454.1995; FOX JG, 1994, J CLIN MICROBIOL, V32, P1238, DOI 10.1128/JCM.32.5.1238-1245.1994; Gao B, 2008, HEPATOLOGY, V47, P729, DOI 10.1002/hep.22034; Gasperini S, 1999, J IMMUNOL, V162, P4928; Gerondakis S, 2006, ONCOGENE, V25, P6781, DOI 10.1038/sj.onc.1209944; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Greten FR, 2007, CELL, V130, P918, DOI 10.1016/j.cell.2007.07.009; HACKER H, 2006, SCI STKE, DOI DOI 10.1126/STKE.3572006RE13; Hayden Matthew S, 2006, Cell, V127, P1286; Hegewisch-Becker S, 2004, J CLIN ONCOL, V22, P4089; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; Hemming AW, 2001, ANN SURG, V233, P652, DOI 10.1097/00000658-200105000-00009; Hildt E, 1998, RECENT RES CANCER, V154, P315; Hiscott J, 2003, ANN NY ACAD SCI, V1010, P237, DOI 10.1196/annals.1299.042; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Hopkins RJ, 1996, GASTROENTEROLOGY, V110, P1244, DOI 10.1053/gast.1996.v110.pm8613015; Hoshino K, 1999, J IMMUNOL, V162, P3749; Hu KQ, 2008, AM J GASTROENTEROL, V103, P1824, DOI 10.1111/j.1572-0241.2008.01878.x; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Huang IC, 2006, J GEN VIROL, V87, P1715, DOI 10.1099/vir.0.81718-0; Hurgin V, 2007, P NATL ACAD SCI USA, V104, P5044, DOI 10.1073/pnas.0611608104; Hwang ES, 2006, EXP BIOL MED, V231, P322; Iredale JP, 1998, J CLIN INVEST, V102, P538, DOI 10.1172/JCI1018; Ishikawa T, 2008, DIGEST DIS SCI, V53, P1785, DOI 10.1007/s10620-007-0070-4; Ito K, 2008, DIGEST DIS SCI, V53, P2541, DOI 10.1007/s10620-007-0164-z; Jaiswal M, 2001, AM J PHYSIOL-GASTR L, V281, pG626, DOI 10.1152/ajpgi.2001.281.3.G626; Johnson CL, 2007, J BIOL CHEM, V282, P10792, DOI 10.1074/jbc.M610361200; Joo MS, 2005, J VIROL, V79, P7648, DOI 10.1128/JVI.79.12.7648-7657.2005; Joshi-Barve S, 2003, HEPATOLOGY, V38, P1178, DOI 10.1053/jhep.2003.50470; Kalaitzidis D, 2005, TRENDS ENDOCRIN MET, V16, P46, DOI 10.1016/j.tem.2005.01.004; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kawai T, 2001, J IMMUNOL, V167, P5887, DOI 10.4049/jimmunol.167.10.5887; Kayano K, 2000, J GASTROENTEROL, V35, P250, DOI 10.1007/s005350050339; Khan N, 2008, ANTIOXID REDOX SIGN, V10, P475, DOI 10.1089/ars.2007.1740; Kiechl S, 2002, NEW ENGL J MED, V347, P185, DOI 10.1056/NEJMoa012673; Lang A, 2000, J HEPATOL, V33, P49, DOI 10.1016/S0168-8278(00)80159-2; Lawrence T, 2007, SCIENCE, V317, P51, DOI 10.1126/science.1146052; Lazarus DD, 1997, INT J IMMUNOPHARMACO, V19, P49, DOI 10.1016/S0192-0561(96)00052-5; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Liang MC, 2003, MOL PHARMACOL, V64, P123, DOI 10.1124/mol.64.1.123; Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044-579X(02)00128-1; Luedde T, 2005, J CLIN INVEST, V115, P849, DOI 10.1172/JCI200523493; Luedde T, 2007, CANCER CELL, V11, P119, DOI 10.1016/j.ccr.2006.12.016; Maaroos HI, 1999, SCAND J GASTROENTERO, V34, P864, DOI 10.1080/003655299750025318; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Maeda S, 2003, IMMUNITY, V19, P725, DOI 10.1016/S1074-7613(03)00301-7; Maher SG, 2007, CURR MED CHEM, V14, P1279, DOI 10.2174/092986707780597907; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; Malmgaard L, 2004, J INTERF CYTOK RES, V24, P439, DOI 10.1089/1079990041689665; Mann EA, 2006, VIRUS RES, V121, P51, DOI 10.1016/j.virusres.2006.04.001; Mannick EE, 1996, CANCER RES, V56, P3238; Marino M, 2005, J ENDOCRINOL INVEST, V28, P280, DOI 10.1007/BF03345386; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Mukherjee S, 2008, GASTROENTEROLOGY, V134, P1777, DOI 10.1053/j.gastro.2008.02.035; Naugler WE, 2007, SCIENCE, V317, P121, DOI 10.1126/science.1140485; Oakley F, 2003, AM J PATHOL, V163, P1849, DOI 10.1016/S0002-9440(10)63544-4; Olivier S, 2006, MOL PHARMACOL, V69, P1615, DOI 10.1124/mol.105.020479; Osada S, 2004, J SURG ONCOL, V85, P48, DOI 10.1002/jso.20006; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; Peng ZH, 2005, INT J ONCOL, V26, P467; Pham CG, 2004, CELL, V119, P529, DOI 10.1016/j.cell.2004.10.017; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Prusty BK, 2007, MOL MED, V13, P518, DOI 10.2119/2007-00055.Prusty; Renshaw M, 2002, J IMMUNOL, V169, P4697, DOI 10.4049/jimmunol.169.9.4697; Ribeiro PS, 2004, AM J GASTROENTEROL, V99, P1708, DOI 10.1111/j.1572-0241.2004.40009.x; Ristimaki A, 1997, CANCER RES, V57, P1276; Rius J, 2008, NATURE, V453, P807, DOI 10.1038/nature06905; Rogers AB, 2007, CANCER RES, V67, P11536, DOI 10.1158/0008-5472.CAN-07-1479; Rothwarf D M, 1999, Sci STKE, V1999, pRE1, DOI 10.1126/stke.1999.5.re1; Rudolph D, 2000, GENE DEV, V14, P854; Saile B, 2001, EUR J CELL BIOL, V80, P554, DOI 10.1078/0171-9335-00182; Saile B, 2004, LAB INVEST, V84, P1037, DOI 10.1038/labinvest.3700116; Sakurai T, 2008, CANCER CELL, V14, P156, DOI 10.1016/j.ccr.2008.06.016; Sakurai T, 2006, P NATL ACAD SCI USA, V103, P10544, DOI 10.1073/pnas.0603499103; SALVEMINI D, 1993, P NATL ACAD SCI USA, V90, P7240, DOI 10.1073/pnas.90.15.7240; Sato Y, 2006, GUT, V55, P1801, DOI 10.1136/gut.2005.070417; Scheidereit C, 2006, ONCOGENE, V25, P6685, DOI 10.1038/sj.onc.1209934; Schwabe RF, 2003, HEPATOLOGY, V37, P824, DOI 10.1053/jhep.2003.50135; Schwabe RF, 2006, GASTROENTEROLOGY, V130, P1886, DOI 10.1053/j.gastro.2006.01.038; Seki E, 2007, NAT MED, V13, P1324, DOI 10.1038/nm1663; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Solnick JV, 2001, CLIN MICROBIOL REV, V14, P59, DOI 10.1128/CMR.14.1.59-97.2001; STANLEY J, 1994, MICROBIOL-UK, V140, P3441, DOI 10.1099/13500872-140-12-3441; Stein M, 2000, P NATL ACAD SCI USA, V97, P1263, DOI 10.1073/pnas.97.3.1263; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; Suerbaum Sebastian, 2002, Trends in Microbiology, V10, P351, DOI 10.1016/S0966-842X(02)02398-3; Suetsugu H, 2005, GUT, V54, P835, DOI 10.1136/gut.2004.043034; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Sung JJY, 2000, AM J PATHOL, V157, P729, DOI 10.1016/S0002-9440(10)64586-5; Sunitha S, 2001, FITOTERAPIA, V72, P516, DOI 10.1016/S0367-326X(01)00259-3; Szabo G, 2002, FRONT BIOSCI-LANDMRK, V7, pA80, DOI 10.2741/szabo; Tai DI, 2000, HEPATOLOGY, V31, P656, DOI 10.1002/hep.510310316; Takada Y, 2004, ONCOGENE, V23, P9247, DOI 10.1038/sj.onc.1208169; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka K, 2006, INT J MOL MED, V17, P827; Tang WL, 2007, AM J PATHOL, V171, P1831, DOI 10.2353/ajpath.2007.070413; Thumann C, 2008, GASTROEN CLIN BIOL, V32, P59, DOI 10.1016/j.gcb.2007.12.006; TIEGS G, 1992, J CLIN INVEST, V90, P196, DOI 10.1172/JCI115836; Tissing WJE, 2003, LEUKEMIA, V17, P17, DOI 10.1038/sj.leu.2402733; Toledo LP, 2003, NUTR CANCER, V47, P62, DOI 10.1207/s15327914nc4701_8; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Trejo-Avila L, 2007, ANN HEPATOL, V6, P174; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Turini ME, 2002, ANNU REV MED, V53, P35, DOI 10.1146/annurev.med.53.082901.103952; Uchinami H, 2002, AM J PHYSIOL-GASTR L, V282, pG962, DOI 10.1152/ajpgi.00466.2001; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; Um HR, 2007, VIRUS RES, V125, P1, DOI 10.1016/j.virusres.2006.11.007; Umemura T, 2003, CARCINOGENESIS, V24, P1105, DOI 10.1093/carcin/bgg053; Vergani D, 2004, Minerva Gastroenterol Dietol, V50, P113; Wahl C, 1998, J CLIN INVEST, V101, P1163, DOI 10.1172/JCI992; WARD JM, 1994, AM J PATHOL, V145, P959; WARD JM, 1994, JNCI-J NATL CANCER I, V86, P1222, DOI 10.1093/jnci/86.16.1222; Waris G, 2003, J BIOL CHEM, V278, P40778, DOI 10.1074/jbc.M303248200; Waris G, 2003, J BIOSCIENCES, V28, P311, DOI 10.1007/BF02970150; Waris G, 2002, BIOCHEM PHARMACOL, V64, P1425, DOI 10.1016/S0006-2952(02)01300-X; Weil R, 1999, MOL CELL BIOL, V19, P6345; Wiegand J, 2008, INTERNIST, V49, P817, DOI 10.1007/s00108-008-2146-4; Williams CS, 1997, J CLIN INVEST, V100, P1325, DOI 10.1172/JCI119651; Wong CM, 2008, LIVER INT, V28, P160, DOI 10.1111/j.1478-3231.2007.01637.x; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Yan MS, 2007, STEROIDS, V72, P415, DOI 10.1016/j.steroids.2007.02.004; Yin M, 2001, J IMMUNOL, V166, P4737, DOI 10.4049/jimmunol.166.7.4737; Young VB, 2000, J INFECT DIS, V182, P620, DOI 10.1086/315705; Young VB, 2000, INFECT IMMUN, V68, P184, DOI 10.1128/IAI.68.1.184-191.2000; Yun C, 2002, CANCER LETT, V184, P97, DOI 10.1016/S0304-3835(02)00187-8; Zarrilli R, 1999, CELL MICROBIOL, V1, P93, DOI 10.1046/j.1462-5822.1999.00018.x; Zhao YH, 2005, CHINESE J CHEM ENG, V13, P96; Zimmermann M, 2008, J HEPATOL, V48, P51, DOI 10.1016/j.jhep.2007.08.008	175	230	245	2	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2008	27	48					6228	6244		10.1038/onc.2008.300	http://dx.doi.org/10.1038/onc.2008.300			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	361YB	18931690				2022-12-17	WOS:000260162800005
J	Schon, MP; Schon, M				Schoen, M. P.; Schoen, M.			TLR7 and TLR8 as targets in cancer therapy	ONCOGENE			English	Review						TLR7; TLR8; skin cancer; imiquimod; imidazoquinolines; cancer immunity	IMIQUIMOD 5-PERCENT CREAM; BASAL-CELL-CARCINOMA; IMMUNE-RESPONSE MODIFIER; TOLL-LIKE RECEPTOR-7; MELANOMA IN-SITU; PLASMACYTOID DENDRITIC CELLS; VEHICLE-CONTROLLED TRIALS; ACTINIC KERATOSIS; DOUBLE-BLIND; TOPICAL APPLICATION	Small-molecule agonists at Toll-like receptor 7 (TLR7) and TLR8 have sparked a vivid interest in cancer research owing to their profound antitumoral activity. The lead compound of the imidazoquinoline family, imiquimod, is marketed as a topical formulation. It is efficacious against many primary skin tumors and cutaneous metastases. Using different imidazoquinoline species, distinct functions of TLR7 and TLR8 have been discovered. The predominant antitumoral mode of action of these agents is TLR7/8-mediated activation of the central transcription factor nuclear factor-kappa B, which leads to induction of proinflammatory cytokines and other mediators. Cutaneous dendritic cells are the primary responsive cell type and initiate a strong Th1-weighted antitumoral cellular immune response. Recent research has shown that dendritic cells themselves acquire direct antitumoral activity upon stimulation by imiquimod. In addition, there are a number of secondary effects on the molecular and cellular level that can be explained through the activation of TLR7/8. The proinflammatory activity of imiquimod, but not resiquimod, appears to be augmented by suppression of a regulatory mechanism, which normally limits inflammatory responses. This is achieved independently of TLR7/8 through interference with adenosine receptor signaling pathways. Finally, at higher concentrations imiquimod exerts Bcl-2- and caspase-dependent proapoptotic activity against tumor cells.	[Schoen, M. P.; Schoen, M.] Univ Wurzburg, Rudolf Virchow Ctr, DFG Res Ctr Expt Biomed, D-97078 Wurzburg, Germany; [Schoen, M. P.; Schoen, M.] Univ Wurzburg, Dept Dermatol, D-97078 Wurzburg, Germany	German Research Foundation (DFG); University of Wurzburg; University of Wurzburg	Schon, MP (corresponding author), Univ Wurzburg, Rudolf Virchow Ctr, DFG Res Ctr Expt Biomed, Versbacher Str 9, D-97078 Wurzburg, Germany.	michael.schoen@virchow.uni-wuerzburg.de						Ambach A, 2004, MOL IMMUNOL, V40, P1307, DOI 10.1016/j.molimm.2004.01.002; Barland CO, 2004, J INVEST DERMATOL, V122, P330, DOI 10.1046/j.0022-202X.2004.22203.x; Bath-Hextall F, 2004, BMJ-BRIT MED J, V329, P705, DOI 10.1136/bmj.38219.515266.AE; Berman B, 2003, BRIT J DERMATOL, V149, P59, DOI 10.1046/j.0366-077X.2003.05634.x; BERNSTEIN DI, 1995, VACCINE, V13, P72, DOI 10.1016/0264-410X(95)80014-5; BERSTEIN DI, 2000, J INFECT DIS, V183, P844; Bishop GA, 2001, CELL IMMUNOL, V208, P9, DOI 10.1006/cimm.2001.1769; Bong AB, 2002, DERMATOLOGY, V205, P135, DOI 10.1159/000063904; Bottrel RLA, 1999, ANTIMICROB AGENTS CH, V43, P856, DOI 10.1128/AAC.43.4.856; Brown VL, 2005, ARCH DERMATOL, V141, P985, DOI 10.1001/archderm.141.8.985; Buates S, 2001, ANTIMICROB AGENTS CH, V45, P1137, DOI 10.1128/AAC.45.4.1137-1142.2001; Burns RP, 2000, CLIN IMMUNOL, V94, P13, DOI 10.1006/clim.1999.4804; CHEN M, 1988, ANTIMICROB AGENTS CH, V32, P678, DOI 10.1128/AAC.32.5.678; Chong A, 2004, J Dermatolog Treat, V15, P118; Craft N, 2005, J IMMUNOL, V175, P1983, DOI 10.4049/jimmunol.175.3.1983; Deeths MJ, 2005, J AM ACAD DERMATOL, V52, P275, DOI 10.1016/j.jaad.2004.04.049; Dendorfer M, 2003, EUR J DERMATOL, V13, P80; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Dockrell DH, 2001, J ANTIMICROB CHEMOTH, V48, P751, DOI 10.1093/jac/48.6.751; Dummer R, 2003, BRIT J DERMATOL, V149, P57, DOI 10.1046/j.0366-077X.2003.05630.x; Dummer R, 2003, DERMATOLOGY, V207, P116, DOI 10.1159/000070962; Fleming CJ, 2004, BRIT J DERMATOL, V151, P485, DOI 10.1111/j.1365-2133.2004.05983.x; Frotscher B, 2002, J INVEST DERMATOL, V119, P1059, DOI 10.1046/j.1523-1747.2002.19531.x; Geisse J, 2004, J AM ACAD DERMATOL, V50, P722, DOI 10.1016/j.jaad.2003.11.066; Gerster JF, 2005, J MED CHEM, V48, P3481, DOI 10.1021/jm049211v; Giannotti B, 2003, CLIN EXP DERMATOL, V28, P33, DOI 10.1046/j.1365-2230.28.s1.11.x; GIBSON SJ, 1995, J INTERF CYTOK RES, V15, P537, DOI 10.1089/jir.1995.15.537; Gibson SJ, 2002, CELL IMMUNOL, V218, P74, DOI 10.1016/S0008-8749(02)00517-8; Gollnick H, 2005, EUR J DERMATOL, V15, P374; Gollnick H, 2001, INT J STD AIDS, V12, P22, DOI 10.1258/0956462011916695; Gorden KB, 2005, J IMMUNOL, V174, P1259, DOI 10.4049/jimmunol.174.3.1259; Gorden KKB, 2006, J IMMUNOL, V177, P8164, DOI 10.4049/jimmunol.177.11.8164; Gorden KKB, 2006, J IMMUNOL, V177, P6584, DOI 10.4049/jimmunol.177.10.6584; Gorski KS, 2006, INT IMMUNOL, V18, P1115, DOI 10.1093/intimm/dxl046; Hadley G, 2006, J INVEST DERMATOL, V126, P1251, DOI 10.1038/sj.jid.5700264; HARRISON CJ, 1994, ANTIMICROB AGENTS CH, V38, P2059, DOI 10.1128/AAC.38.9.2059; HARRISON CJ, 1988, ANTIVIR RES, V10, P209, DOI 10.1016/0166-3542(88)90032-0; HEIL F, 2004, SCIENCE, V33, P2987; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Hengge UR, 2004, DERMATOL SURG, V30, P1101, DOI 10.1111/j.1524-4725.2004.30335.x; Hornung V, 2005, NAT MED, V11, P263, DOI 10.1038/nm1191; Hurwitz DJ, 2003, ARCH DERMATOL, V139, P1347, DOI 10.1001/archderm.139.10.1347; Imbertson LM, 1998, J INVEST DERMATOL, V110, P734, DOI 10.1046/j.1523-1747.1998.00174.x; Judge AD, 2005, NAT BIOTECHNOL, V23, P457, DOI 10.1038/nbt1081; Jurk M, 2002, NAT IMMUNOL, V3, P499, DOI 10.1038/ni0602-499; Jurk M, 2006, EUR J IMMUNOL, V36, P1815, DOI 10.1002/eji.200535806; Kamin A, 2005, J AM ACAD DERMATOL, V52, pS51, DOI 10.1016/j.jaad.2004.07.047; Kariko K, 2005, IMMUNITY, V23, P165, DOI 10.1016/j.immuni.2005.06.008; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Korman N, 2005, ARCH DERMATOL, V141, P467, DOI 10.1001/archderm.141.4.467; Lebwohl M, 2004, J AM ACAD DERMATOL, V50, P714, DOI 10.1016/j.jaad.2003.12.010; Lee J, 2003, P NATL ACAD SCI USA, V100, P6646, DOI 10.1073/pnas.0631696100; Levy O, 2006, BLOOD, V108, P1284, DOI 10.1182/blood-2005-12-4821; Lonsdale-Eccles AA, 2006, BRIT J DERMATOL, V155, P215, DOI 10.1111/j.1365-2133.2006.07297.x; Lore K, 2003, J IMMUNOL, V171, P4320, DOI 10.4049/jimmunol.171.8.4320; Lund JM, 2004, P NATL ACAD SCI USA, V101, P5598, DOI 10.1073/pnas.0400937101; MA Y, 2007, J IMMUNOL, V178, P36; MEGYERI K, 1995, MOL CELL BIOL, V15, P2207; Meyer T, 2003, BRIT J DERMATOL, V149, P9, DOI 10.1046/j.0366-077X.2003.05632.x; Miggin SM, 2006, J LEUKOCYTE BIOL, V80, P220, DOI 10.1189/jlb.1105672; Miller RL, 2002, INT IMMUNOPHARMACOL, V2, P443, DOI 10.1016/S1567-5769(01)00184-9; NAVI D, 2004, DERMATOL ONLINE, V10; Nishiya T, 2004, J BIOL CHEM, V279, P19008, DOI 10.1074/jbc.M311618200; Nishiya T, 2005, J BIOL CHEM, V280, P37107, DOI 10.1074/jbc.M504951200; Odashima M, 2005, GASTROENTEROLOGY, V129, P26, DOI 10.1053/j.gastro.2005.05.032; Palamara F, 2004, J IMMUNOL, V173, P3051, DOI 10.4049/jimmunol.173.5.3051; Patel GK, 2006, J AM ACAD DERMATOL, V54, P1025, DOI 10.1016/j.jaad.2006.01.055; Peres K, 2003, EUR J DERMATOL, V13, P413; Peris K, 2006, J AM ACAD DERMATOL, V55, P324, DOI 10.1016/j.jaad.2006.04.004; POPE BL, 1995, CELL IMMUNOL, V162, P333, DOI 10.1006/cimm.1995.1087; Prins RM, 2006, J IMMUNOL, V176, P157, DOI 10.4049/jimmunol.176.1.157; Prinz BM, 2004, TRANSPLANTATION, V77, P790, DOI 10.1097/01.TP.0000113445.02908.06; Qin JZ, 2006, J BIOL CHEM, V281, P21013, DOI 10.1074/jbc.M512908200; Ray CM, 2005, INT J DERMATOL, V44, P428, DOI 10.1111/j.1365-4632.2005.02582.x; Rechtsteiner G, 2005, J IMMUNOL, V174, P2476, DOI 10.4049/jimmunol.174.5.2476; REITER MJ, 1994, J LEUKOCYTE BIOL, V55, P234, DOI 10.1002/jlb.55.2.234; Roach JC, 2005, P NATL ACAD SCI USA, V102, P9577, DOI 10.1073/pnas.0502272102; Roseeuw D, 2003, CLIN EXP DERMATOL, V28, P30, DOI 10.1046/j.1365-2230.28.s1.10.x; Sauder DN, 2003, ANTIMICROB AGENTS CH, V47, P3846, DOI 10.1128/AAC.47.12.3846-3852.2003; Schon M, 2007, CURR MED CHEM, V14, P681, DOI 10.2174/092986707780059625; Schon MP, 2006, J INVEST DERMATOL, V126, P1338, DOI 10.1038/sj.jid.5700286; Schon M, 2003, J NATL CANCER I, V95, P1138, DOI 10.1093/jnci/djg016; Schulze HJ, 2005, BRIT J DERMATOL, V152, P939, DOI 10.1111/j.1365-2133.2005.06486.x; Schwarz K, 2003, EUR J IMMUNOL, V33, P1465, DOI 10.1002/eji.200323919; SHACKLETON M, 2004, CANC IMMUN, V23, P9; Sidbury R, 2003, J INVEST DERMATOL, V121, P1205, DOI 10.1046/j.1523-1747.2003.12521.x; SIDKY YA, 1992, CANCER RES, V52, P3528; Smith KJ, 2001, DERMATOL SURG, V27, P561, DOI 10.1046/j.1524-4725.2001.00149.x; Stanley MA, 2002, CLIN EXP DERMATOL, V27, P571, DOI 10.1046/j.1365-2230.2002.01151.x; Stary G, 2007, J EXP MED, V204, P1441, DOI 10.1084/jem.20070021; Steinmann A, 2000, J AM ACAD DERMATOL, V43, P555, DOI 10.1067/mjd.2000.107954; Stephanou A, 2005, GROWTH FACTORS, V23, P177, DOI 10.1080/08977190500178745; Sterry W, 2002, BRIT J DERMATOL, V147, P1227, DOI 10.1046/j.1365-2133.2002.05069.x; Stockfleth E, 2002, ARCH DERMATOL, V138, P1498, DOI 10.1001/archderm.138.11.1498; Stockfleth E, 2001, BRIT J DERMATOL, V144, P1050, DOI 10.1046/j.1365-2133.2001.04197.x; Suchin KR, 2002, ARCH DERMATOL, V138, P1137, DOI 10.1001/archderm.138.9.1137; Sullivan TP, 2003, DERMATOL SURG, V29, P1181, DOI 10.1111/j.1524-4725.2003.29399.x; Suzuki H, 2000, J INVEST DERMATOL, V114, P135, DOI 10.1046/j.1523-1747.2000.00833.x; Szeimies RM, 2004, J AM ACAD DERMATOL, V51, P547, DOI 10.1016/j.jaad.2004.02.022; Thomsen LL, 2004, VACCINE, V22, P1799, DOI 10.1016/j.vaccine.2003.09.052; Tomai MA, 2000, CELL IMMUNOL, V203, P55, DOI 10.1006/cimm.2000.1673; Ugurel S, 2002, BRIT J DERMATOL, V147, P621, DOI 10.1046/j.1365-2133.2002.488811.x; Urosevic M, 2005, J NATL CANCER I, V97, P1143, DOI 10.1093/jnci/dji207; Urosevic M, 2004, CLIN CANCER RES, V10, P4959, DOI 10.1158/1078-0432.CCR-04-0193; Urosevic M, 2003, ARCH DERMATOL, V139, P1325, DOI 10.1001/archderm.139.10.1325; Vidal D, 2004, BRIT J DERMATOL, V151, P656, DOI 10.1111/j.1365-2133.2004.06094.x; Wagner TL, 1997, CYTOKINE, V9, P837, DOI 10.1006/cyto.1997.0239; Wagner TL, 1999, CELL IMMUNOL, V191, P10, DOI 10.1006/cimm.1998.1406; WEEKS CE, 1994, J INTERFERON RES, V14, P81, DOI 10.1089/jir.1994.14.81; Wille-Reece U, 2006, J EXP MED, V203, P1249, DOI 10.1084/jem.20052433; Wolf IH, 2003, ARCH DERMATOL, V139, P273, DOI 10.1001/archderm.139.3.273; Wolf IH, 2005, ARCH DERMATOL, V141, P510, DOI 10.1001/archderm.141.4.510; Zeitouni NC, 2005, BRIT J DERMATOL, V152, P376, DOI 10.1111/j.1365-2133.2005.06307.x; Zuber AK, 2004, VACCINE, V22, P1791, DOI 10.1016/j.vaccine.2003.10.051	114	230	252	4	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2008	27	2					190	199		10.1038/sj.onc.1210913	http://dx.doi.org/10.1038/sj.onc.1210913			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248OO	18176600				2022-12-17	WOS:000252163600005
J	Dillon, RL; White, DE; Muller, WJ				Dillon, R. L.; White, D. E.; Muller, W. J.			The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer	ONCOGENE			English	Review						PI3K; Akt; PTEN; ILK; breast cancer	INTEGRIN-LINKED KINASE; NF-KAPPA-B; GLYCOGEN-SYNTHASE KINASE; EPITHELIAL-MESENCHYMAL TRANSITION; MAMMARY-GLAND INVOLUTION; TUMOR-SUPPRESSOR GENE; PROTEIN-KINASE; COWDEN-DISEASE; EXPRESSION INCREASES; TRANSCRIPTION FACTOR	The phosphatidyl inositol 3-kinase (PI3K)/Akt pathway is activated downstream of a variety of extracellular signals and activation of this signaling pathway impacts a number of cellular processes including cell growth, proliferation and survival. The alteration of components of this pathway, through either activation of oncogenes or inactivation of tumor suppressors, disrupts a signaling equilibrium and can thus lead to cellular transformation. The frequent dysregulation of the PI3K/Akt pathway in human cancer has made components of this pathway attractive for therapeutic targeting; however, a more comprehensive understanding of the signaling intricacies is necessary to develop pharmacological agents to target not only specific molecules, but also specific functions. Here, we review a series of experiments examining the contribution of molecules of this signaling network including PI3K, phosphatase and tensin homolog deleted on chromosome 10, integrin-linked kinase and Akt and address the significance to human breast cancer.	McGill Univ, Mol Oncol Grp, Montreal, PQ, Canada; McGill Univ, Dept Biochem, Montreal, PQ, Canada; McGill Univ, Dept Med, Montreal, PQ, Canada	McGill University; McGill University; McGill University	Muller, WJ (corresponding author), Royal Victoria Hosp, Mol Oncol Grp, Room H5-63,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	william.muller@mcgill.ca			PHS HHS [NCI 102036] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Ackler S, 2002, ONCOGENE, V21, P198, DOI 10.1038/sj.onc.1205052; Ahmed N, 2003, J PATHOL, V201, P229, DOI 10.1002/path.1441; Arboleda MJ, 2003, CANCER RES, V63, P196; Attwell S, 2000, ONCOGENE, V19, P3811, DOI 10.1038/sj.onc.1203711; Bachman KE, 2004, CANCER BIOL THER, V3, P772, DOI 10.4161/cbt.3.8.994; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; Brakebusch C, 2003, EMBO J, V22, P2324, DOI 10.1093/emboj/cdg245; Bravou V, 2006, J PATHOL, V208, P91, DOI 10.1002/path.1860; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Chung DH, 1998, VIRCHOWS ARCH, V433, P113, DOI 10.1007/s004280050225; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Dahia PLM, 1997, CANCER RES, V57, P4710; Dai DL, 2003, CLIN CANCER RES, V9, P4409; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Deprez J, 1997, J BIOL CHEM, V272, P17269, DOI 10.1074/jbc.272.28.17269; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Easton RM, 2005, MOL CELL BIOL, V25, P1869, DOI 10.1128/MCB.25.5.1869-1878.2005; Edwards LA, 2005, ONCOGENE, V24, P3596, DOI 10.1038/sj.onc.1208427; Garcia JM, 1999, BREAST CANCER RES TR, V57, P237, DOI 10.1023/A:1006273516976; Graff JR, 2001, CLIN CANCER RES, V7, P1987; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Hutchinson J, 2001, MOL CELL BIOL, V21, P2203, DOI 10.1128/MCB.21.6.2203-2212.2001; Hutchinson JN, 2004, CANCER RES, V64, P3171, DOI 10.1158/0008-5472.CAN-03-3465; Irie HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kang SY, 2005, P NATL ACAD SCI USA, V102, P802, DOI 10.1073/pnas.0408864102; Kawakami Y, 2004, J BIOL CHEM, V279, P47720, DOI 10.1074/jbc.M408797200; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Koul D, 2005, MOL CANCER THER, V4, P1681, DOI 10.1158/1535-7163.MCT-05-0258; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Li G, 2002, DEVELOPMENT, V129, P4159; Li Y, 2004, TRENDS BIOCHEM SCI, V29, P32, DOI 10.1016/j.tibs.2003.11.007; Li Y, 2001, BMC Mol Biol, V2, P2, DOI 10.1186/1471-2199-2-2; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Lynch DK, 1999, ONCOGENE, V18, P8024, DOI 10.1038/sj.onc.1203258; Mackinnon AC, 2002, CURR BIOL, V12, P787, DOI 10.1016/S0960-9822(02)00810-2; Marotta A, 2001, ONCOGENE, V20, P6250, DOI 10.1038/sj.onc.1204791; Minobea K, 1999, CANCER LETT, V144, P9, DOI 10.1016/S0304-3835(99)00181-0; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; Nelen MR, 1997, HUM MOL GENET, V6, P1383, DOI 10.1093/hmg/6.8.1383; Ozes ON, 1999, NATURE, V401, P82; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Rhei E, 1997, CANCER RES, V57, P3657; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Saal LH, 2005, CANCER RES, V65, P2554, DOI 10.1158/0008-5472-CAN-04-3913; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Schwertfeger KL, 2001, MOL ENDOCRINOL, V15, P867, DOI 10.1210/me.15.6.867; Schwertfeger KL, 2003, J LIPID RES, V44, P1100, DOI 10.1194/jlr.M300045-JLR200; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Stal O, 2003, BREAST CANCER RES, V5, pR37, DOI 10.1186/bcr569; Stambolic V, 2000, CANCER RES, V60, P3605; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; Tan C, 2004, CANCER CELL, V5, P79, DOI 10.1016/S1535-6108(03)00281-2; Teng DHF, 1997, CANCER RES, V57, P5221; Thant AA, 2001, CLIN EXP METASTAS, V18, P423, DOI 10.1023/A:1010921730952; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Tschopp O, 2005, DEVELOPMENT, V132, P2943, DOI 10.1242/dev.01864; Tu YZ, 2001, J CELL BIOL, V153, P585, DOI 10.1083/jcb.153.3.585; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Wang SY, 2006, P NATL ACAD SCI USA, V103, P1480, DOI 10.1073/pnas.0510652103; West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6; White DE, 2001, ONCOGENE, V20, P7064, DOI 10.1038/sj.onc.1204910; Wu CY, 2001, J CELL SCI, V114, P2549; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; Yamaji S, 2001, J CELL BIOL, V153, P1251, DOI 10.1083/jcb.153.6.1251; Yoeli-Lerner M, 2005, MOL CELL, V20, P539, DOI 10.1016/j.molcel.2005.10.033; Younes MN, 2005, MOL CANCER THER, V4, P1146, DOI 10.1158/1535-7163.MCT-05-0078; Zervas CG, 2002, CURR BIOL, V12, pR350, DOI 10.1016/S0960-9822(02)00856-4; Zervas CG, 2001, J CELL BIOL, V152, P1007, DOI 10.1083/jcb.152.5.1007; Zhou BP, 2001, NAT CELL BIOL, V3, P438	81	230	244	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2007	26	9					1338	1345		10.1038/sj.onc.1210202	http://dx.doi.org/10.1038/sj.onc.1210202			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DU	17322919				2022-12-17	WOS:000244558700011
J	Fernandis, AZ; Prasad, A; Band, H; Klosel, R; Ganju, RK				Fernandis, AZ; Prasad, A; Band, H; Klosel, R; Ganju, RK			Regulation of CXCR4-mediated chemotaxis and chemoinvasion of breast cancer cells	ONCOGENE			English	Article						CXCR4; chemotaxis; chemoinvasion; focal adhesion; metastasis; signaling	FOCAL ADHESION PROTEINS; RECEPTOR CCR5 SIGNALS; TYROSINE PHOSPHORYLATION; CHEMOKINE RECEPTORS; FACTOR-I; MATRIX METALLOPROTEINASES; ALPHA-CHEMOKINE; TUMOR-GROWTH; KINASE; CBL	The chemokine-CXCL12 and its receptor, CXCR4, have recently been shown to play an important role in regulating the directional migration of breast cancer cells to sites of metastasis. In the present study, we showed that CXCL12 enhanced the chemotaxis, chemoinvasion and adhesive properties of breast cancer cells; parameters that are critical for development of metastasis. We have also evaluated the signaling mechanisms that regulate CXCL12-induced and CXCR4-mediated breast cancer cell motility and invasion. These studies revealed that CXCL12 induces the tyrosine phosphorylation of focal adhesion kinase (FAK) at residues 397 and 577, and of RAFTK/Pyk2 at residues 402 and 579/580. The cytoskeletal proteins paxillin and Crk, as well as tyrosine phosphatase SHP2 and adaptor protein Cbl, were also phosphorylated. CXCL12 induced the activation of PI 3-kinase, and increased its association with Cbl and SHP2. PI 3-kinase, RAFTK/Pyk2 and tyrosine phosphatase inhibitors significantly blocked CXCL12-induced chemotaxis and chemoinvasion. The role of SHP2 and Cbl in CXCL12-induced chemotaxis and chemoinvasion in breast cancer cells was further defined by transiently overexpressing wild-type SHP2, wild-type Cbl, dominant-negative SHP2, Cbl mutants 70Z/3 and G306E or double transfectants of the Cbl and SHP2 constructs. We found a novel role of Cbl in CXCL12-induced chemotaxis, which may be mediated through the activation and formation of a multimeric complex comprised of Cbl, SHP2 and PI 3-kinase. We also observed the activation of matrix metalloproteinases 2 and 9 upon CXCL12 stimulation. These studies provide new information regarding signaling pathways that may regulate CXCL12-induced metastasis in breast cancer cells.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Inst Med,Div Expt Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA; Biontex Labs GmbH, D-80807 Munich, Germany	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Ganju, RK (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Inst Med,Div Expt Med, 4 Blackfan Circle,Room 343, Boston, MA 02115 USA.	rganju@bidmc.harvard.edu	Fernandis, Aaron/C-3718-2012					ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; Arboleda MJ, 2003, CANCER RES, V63, P196; Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Camacho SA, 2001, NAT IMMUNOL, V2, P523, DOI 10.1038/88720; Cass I, 2001, GYNECOL ONCOL, V80, P56, DOI 10.1006/gyno.2000.6027; Cherla RP, 2001, J IMMUNOL, V166, P3067, DOI 10.4049/jimmunol.166.5.3067; Chernock RD, 2001, BLOOD, V97, P608, DOI 10.1182/blood.V97.3.608; Duong LT, 2000, CELL MOTIL CYTOSKEL, V47, P174, DOI 10.1002/1097-0169(200011)47:3<174::AID-CM2>3.0.CO;2-N; Fernandis AZ, 2003, J BIOL CHEM, V278, P9536, DOI 10.1074/jbc.M211803200; Feshchenko EA, 1999, ONCOGENE, V18, P3703, DOI 10.1038/sj.onc.1202672; Fournier TM, 2000, MOL BIOL CELL, V11, P3397, DOI 10.1091/mbc.11.10.3397; Fuortes M, 1999, J CLIN INVEST, V104, P327, DOI 10.1172/JCI6018; Ganju RK, 2000, J BIOL CHEM, V275, P17263, DOI 10.1074/jbc.M000689200; Ganju RK, 1998, BLOOD, V91, P791, DOI 10.1182/blood.V91.3.791.791_791_797; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Geminder H, 2001, J IMMUNOL, V167, P4747, DOI 10.4049/jimmunol.167.8.4747; Gonzalo JA, 2000, J IMMUNOL, V165, P499, DOI 10.4049/jimmunol.165.1.499; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Hatch WC, 1998, BLOOD, V91, P3967, DOI 10.1182/blood.V91.10.3967.3967_3967_3973; Hilakivi-Clarke L, 2000, CANCER RES, V60, P4993; Huminiecki L, 2002, GENOMICS, V79, P547, DOI 10.1006/geno.2002.6745; Hyder SM, 2001, INT J CANCER, V92, P469, DOI 10.1002/ijc.1236; Inoue K, 2000, CANCER RES, V60, P2290; Inoue K, 2000, CLIN CANCER RES, V6, P2104; Itoh Y, 2002, ESSAYS BIOCHEM, V38, P21, DOI 10.1042/bse0380021; Janowska-Wieczorek A, 2000, EXP HEMATOL, V28, P1274, DOI 10.1016/S0301-472X(00)00532-4; Kim H, 1999, EXP CELL RES, V253, P78, DOI 10.1006/excr.1999.4706; Libura J, 2002, BLOOD, V100, P2597, DOI 10.1182/blood-2002-01-0031; Lill NL, 2000, J BIOL CHEM, V275, P367, DOI 10.1074/jbc.275.1.367; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; Luca M, 1997, AM J PATHOL, V151, P1105; Lupher ML, 1999, IMMUNOL TODAY, V20, P375, DOI 10.1016/S0167-5699(99)01484-X; Manes S, 1999, MOL CELL BIOL, V19, P3125; Mashino K, 2002, CANCER RES, V62, P2937; McEarchern JA, 2001, INT J CANCER, V91, P76, DOI 10.1002/1097-0215(20010101)91:1<76::AID-IJC1012>3.0.CO;2-8; McPherson K, 2000, BMJ-BRIT MED J, V321, P624, DOI 10.1136/bmj.321.7261.624; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Mohle R, 2000, BRIT J HAEMATOL, V110, P563, DOI 10.1046/j.1365-2141.2000.02157.x; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murakami T, 2002, CANCER RES, V62, P7328; Nabeshima K, 2002, PATHOL INT, V52, P255, DOI 10.1046/j.1440-1827.2002.01343.x; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Payne AS, 2002, J INVEST DERMATOL, V118, P915, DOI 10.1046/j.1523-1747.2002.01725.x; Premack BA, 1996, NAT MED, V2, P1174, DOI 10.1038/nm1196-1174; Price John T, 2002, Expert Opin Ther Targets, V6, P217; Robledo MM, 2001, J BIOL CHEM, V276, P45098, DOI 10.1074/jbc.M106912200; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; Saphner T, 1996, J CLIN ONCOL, V14, P2738, DOI 10.1200/JCO.1996.14.10.2738; Saxton TM, 1999, P NATL ACAD SCI USA, V96, P3790, DOI 10.1073/pnas.96.7.3790; Scaife RM, 2000, J CELL SCI, V113, P215; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Scotton CJ, 2001, CANCER RES, V61, P4961; Scotton CJ, 2002, CANCER RES, V62, P5930; Taichman RS, 2002, CANCER RES, V62, P1832; Uemura N, 1999, J BIOL CHEM, V274, P37525, DOI 10.1074/jbc.274.53.37525; Verbeek BS, 1998, FEBS LETT, V425, P145, DOI 10.1016/S0014-5793(98)00224-5; Wade R, 2002, ONCOGENE, V21, P96, DOI 10.1038/sj.onc.1205013; Wang JF, 2000, BLOOD, V95, P2505, DOI 10.1182/blood.V95.8.2505.008k24_2505_2513; Yoshie O, 2000, INT J HEMATOL, V72, P399; Youngs SJ, 1997, INT J CANCER, V71, P257, DOI 10.1002/(SICI)1097-0215(19970410)71:2<257::AID-IJC22>3.0.CO;2-D; Zhang XF, 2001, BLOOD, V97, P3342, DOI 10.1182/blood.V97.11.3342	64	230	242	0	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					157	167		10.1038/sj.onc.1206910	http://dx.doi.org/10.1038/sj.onc.1206910			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712221	Bronze			2022-12-17	WOS:000187895300017
J	Gurbuxani, S; Schmitt, E; Cande, C; Parcellier, A; Hammann, A; Daugas, E; Kouranti, I; Spahr, C; Pance, A; Kroemer, G; Garrido, C				Gurbuxani, S; Schmitt, E; Cande, C; Parcellier, A; Hammann, A; Daugas, E; Kouranti, I; Spahr, C; Pance, A; Kroemer, G; Garrido, C			Heat shock protein 70 binding inhibits the nuclear import of apoptosis-inducing factor	ONCOGENE			English	Article						HSP70; AIF; apoptosis; nuclear import	CYTOCHROME-C; GLYCOPROTEIN COMPLEX; SELECTIVE DEPLETION; CELL-DEATH; PROTEIN; ACTIVATION; CASPASES; AIF	Heat shock protein 70 ( HSP70) can inhibit apoptosis by neutralizing and interacting with apoptosis-inducing factor (AIF), a mitochondrial. avoprotein that translocates upon apoptosis induction to the nucleus, via the cytosol. Here, we show that only members of the HSP70 family interact with AIF. Systematic deletion mapping revealed the existence of three distinct functional regions in the AIF protein: ( 1) a region between amino acids 150 and 228 that binds HSP70, ( 2) a domain between residues 367 and 459 that includes a nuclear localization sequence (NLS) and ( 3) a C-terminal domain beyond residue 567 required for its chromatin-condensing activity. Deletion of the 150 - 268 domain completely abolished HSP70 binding and facilitated the nuclear import of AIF, resulting in a gain-of-function phenotype with enhanced AIF-mediated chromatin condensation as compared to wild-type AIF. This gain-of-function phenotype was observed in wild-type control cells ( which express low but significant levels of HSP70), yet was lost when AIFD150-268 was introduced into HSP70 knockout cells, underscoring the functional importance of the AIF - HSP70 interaction. Altogether, our data demonstrate that AIF inhibition by HSP70 involves cytosolic retention of AIF. Moreover, it appears that endogenous HSP70 protein levels are sufficiently elevated to modulate the lethal action of AIF.	Fac Med & Pharm Dijon, INSERM, U517, F-21033 Dijon, France; Inst Gustave Roussy, CNRS, UMR 1599, F-94805 Villejuif, France; Amgen Inc, Amgen Ctr, Mammalian Genom, Thousand Oaks, CA 91320 USA; Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Amgen; University of Cambridge	Garrido, C (corresponding author), Fac Med & Pharm Dijon, INSERM, U517, 7 Blvd Jeanne Darc, F-21033 Dijon, France.	cgarrido@u-bourgogne.fr	Kroemer, Guido/AAY-9859-2020; Garrido, carmen/G-1633-2018; Garrido, Carolina/GWM-5557-2022; KROEMER, Guido/B-4263-2013; Pance, Alena/AAH-2878-2021	Garrido, carmen/0000-0003-1368-1493; KROEMER, Guido/0000-0002-9334-4405; Pance, Alena/0000-0002-9017-2644; DAUGAS, Eric/0000-0001-7256-7979				BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Castedo M, 2001, J EXP MED, V194, P1097, DOI 10.1084/jem.194.8.1097; Courchesne PL, 1998, ELECTROPHORESIS, V19, P956, DOI 10.1002/elps.1150190611; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Ferri KF, 2000, J EXP MED, V192, P1081, DOI 10.1084/jem.192.8.1081; Garrido C, 1999, FASEB J, V13, P2061, DOI 10.1096/fasebj.13.14.2061; Garrido C, 2001, BIOCHEM BIOPH RES CO, V286, P433, DOI 10.1006/bbrc.2001.5427; Gurbuxani S, 2001, ONCOGENE, V20, P7478, DOI 10.1038/sj.onc.1204948; Hu YM, 1999, EMBO J, V18, P3586, DOI 10.1093/emboj/18.13.3586; JAATTELA M, 1995, INT J CANCER, V60, P689, DOI 10.1002/ijc.2910600520; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Loeffler M, 2001, FASEB J, V15, P758, DOI 10.1096/fj.00-0388com; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Miramar MD, 2001, J BIOL CHEM, V276, P16391, DOI 10.1074/jbc.M010498200; Munster PN, 2001, CLIN CANCER RES, V7, P2228; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; Nylandsted J, 2000, P NATL ACAD SCI USA, V97, P7871, DOI 10.1073/pnas.97.14.7871; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Seo JS, 1996, BIOCHEM BIOPH RES CO, V218, P582, DOI 10.1006/bbrc.1996.0103; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; Solary E, 2000, LEUKEMIA, V14, P1833, DOI 10.1038/sj.leu.2401902; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Volloch VZ, 1999, ONCOGENE, V18, P3648, DOI 10.1038/sj.onc.1202525; Wang XC, 2002, SCIENCE, V298, P1587, DOI 10.1126/science.1076194; Ye H, 2002, NAT STRUCT BIOL, V9, P680, DOI 10.1038/nsb836	30	230	243	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	2003	22	43					6669	6678		10.1038/sj.onc.1206794	http://dx.doi.org/10.1038/sj.onc.1206794			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729XA	14555980				2022-12-17	WOS:000185799300002
J	Tonini, T; Rossi, F; Claudio, PP				Tonini, T; Rossi, F; Claudio, PP			Molecular basis of angiogenesis and cancer	ONCOGENE			English	Review						angiogenesis; proangiogenic factors; antiangiogenic factors	ENDOTHELIAL GROWTH-FACTOR; BINDING COMPETITIVE INHIBITOR; HYPOXIA-INDUCIBLE FACTOR-1; HUMAN NEUROBLASTOMA-CELLS; FACTOR GENE-TRANSCRIPTION; TUMOR ANGIOGENESIS; IN-VIVO; SIGNAL-TRANSDUCTION; SOLID TUMORS; CARDIOVASCULAR DEVELOPMENT	Angiogenesis is a term that describes the formation of new capillaries from a pre-existing vasculature. This process is very important in physiologic conditions because it helps healing injured tissues, and in female populations it helps forming the placenta after fertilization and reconstructs the inside layer of the uterus after menstruation. Angiogenesis is the result of an intricate balance between proangiogenic and antiangiogenic factors and is now very well recognized as a powerful control point in tumor development. In this particular environment, the. ne modulation among proangiogenic and antiangiogenic factors is disrupted, leading to inappropriate vessels growth. In this review, we discuss the molecular basis of angiogenesis during tumor growth and we also illustrate some of the molecules that are involved in this angiogenic switch.	Temple Univ, Dept Biotechnol, Philadelphia, PA 19122 USA; Univ Naples 2, Dipartimento Pediat, Naples, Italy; Univ Naples Federico II, Dipartimento Sci Odontostomatol & Maxillofacciali, Naples, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Universita della Campania Vanvitelli; University of Naples Federico II	Claudio, PP (corresponding author), Temple Univ, Dept Biotechnol, 1900 N 12th St,Room 333, Philadelphia, PA 19122 USA.	claudio@temple.edu	Claudio, Pier Paolo/AAW-7282-2021	Claudio, Pier Paolo/0000-0001-7790-1622; Rossi, Francesca/0000-0003-2879-6277				Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295; Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; Baish JW, 2000, CANCER RES, V60, P3683; Bhushan M, 2002, BRIT J DERMATOL, V147, P418, DOI 10.1046/j.1365-2133.2002.05003.x; Breit S, 2000, CANCER RES, V60, P4596; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Buschmann I, 2000, J PATHOL, V190, P338, DOI 10.1002/(SICI)1096-9896(200002)190:3<338::AID-PATH594>3.0.CO;2-7; Carmeliet P, 1999, NATURE, V401, P657, DOI 10.1038/44304; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Casanova ML, 2002, CANCER RES, V62, P3402; Charvat S, 1999, ANTICANCER RES, V19, P557; Chavakis E, 2002, ARTERIOSCL THROM VAS, V22, P887, DOI 10.1161/01.ATV.0000017728.55907.A9; Cheng SY, 1997, P NATL ACAD SCI USA, V94, P12081, DOI 10.1073/pnas.94.22.12081; DANGELO G, 1995, P NATL ACAD SCI USA, V92, P6374, DOI 10.1073/pnas.92.14.6374; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DENEKAMP J, 1993, BRIT J RADIOL, V66, P181, DOI 10.1259/0007-1285-66-783-181; Dulak J, 2003, ANTIOXID REDOX SIGN, V5, P123, DOI 10.1089/152308603321223612; Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97; DVORAK HF, 1988, AM J PATHOL, V133, P95; Eberhard A, 2000, CANCER RES, V60, P1388; EHRMANN RL, 1968, J NATL CANCER I, V41, P1329; Eriksson U, 1999, CURR TOP MICROBIOL, V237, P41; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1; FOLKMAN J, 1971, J EXP MED, V133, P275, DOI 10.1084/jem.133.2.275; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Folkman J, 1992, Semin Cancer Biol, V3, P65; FOLKMAN J, 1985, ADV CANCER RES, V43, P175, DOI 10.1016/S0065-230X(08)60946-X; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Fotsis T, 1999, EUR J BIOCHEM, V263, P757, DOI 10.1046/j.1432-1327.1999.00575.x; Gamble J, 1999, ENDOTHELIUM-NEW YORK, V7, P23, DOI 10.3109/10623329909165309; Gastl G, 1997, ONCOLOGY-BASEL, V54, P177; Gerety SS, 1999, MOL CELL, V4, P403, DOI 10.1016/S1097-2765(00)80342-1; GREENBLATT M, 1968, JNCI-J NATL CANCER I, V41, P111; Hanai J, 2002, J BIOL CHEM, V277, P16464, DOI 10.1074/jbc.M112274200; Hashizume H, 2000, AM J PATHOL, V156, P1363, DOI 10.1016/S0002-9440(10)65006-7; Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177; Hobbs SK, 1998, P NATL ACAD SCI USA, V95, P4607, DOI 10.1073/pnas.95.8.4607; HOGG PJ, 1993, J BIOL CHEM, V268, P7139; HOGG PJ, 1993, J BIOL CHEM, V268, P21811; Hong YK, 2000, CLIN CANCER RES, V6, P3354; HORI A, 1991, CANCER RES, V51, P6180; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Jain RK, 1996, CANCER METAST REV, V15, P195, DOI 10.1007/BF00437472; Jiang BH, 1997, CANCER RES, V57, P5328; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Juczewska M, 1997, Rocz Akad Med Bialymst, V42 Suppl 1, P86; Kageyama K, 2002, J BIOL CHEM, V277, P19255, DOI 10.1074/jbc.M112377200; Kerbel RS, 2000, CARCINOGENESIS, V21, P505, DOI 10.1093/carcin/21.3.505; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; Kim YM, 2000, CANCER RES, V60, P5410; Klagsbrun M, 1999, CHEM BIOL, V6, pR217, DOI 10.1016/S1074-5521(99)80081-7; Lahm H, 1996, BIOCHEM BIOPH RES CO, V220, P334, DOI 10.1006/bbrc.1996.0406; Landgren E, 1998, ONCOGENE, V16, P359, DOI 10.1038/sj.onc.1201545; Liekens S, 2001, BIOCHEM PHARMACOL, V61, P253, DOI 10.1016/S0006-2952(00)00529-3; Lingen MW, 1998, CANCER RES, V58, P5551; LIOTTA LA, 1991, CANCER RES, V51, pS5054; MacDonald NJ, 2001, J BIOL CHEM, V276, P25190, DOI 10.1074/jbc.M100743200; Majewski S, 1996, J INVEST DERMATOL, V106, P1114, DOI 10.1111/1523-1747.ep12340161; Malonne H, 1999, CLIN EXP METASTAS, V17, P1, DOI 10.1023/A:1026443925807; McDonald DM, 2000, CANCER METAST REV, V19, P109, DOI 10.1023/A:1026529222845; Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363; MINCHENKO A, 1994, LAB INVEST, V71, P374; Nangia-Makker P, 2000, AM J PATHOL, V156, P899, DOI 10.1016/S0002-9440(10)64959-0; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Nor JE, 2000, J VASC RES, V37, P209, DOI 10.1159/000025733; Ogawa S, 1998, J BIOL CHEM, V273, P31273, DOI 10.1074/jbc.273.47.31273; Pluda JM, 1997, SEMIN ONCOL, V24, P203; POTGENS AJG, 1994, J BIOL CHEM, V269, P32879; RAK J, 1995, CANCER RES, V55, P4575; Rak J, 1995, CANCER METAST REV, V14, P263, DOI 10.1007/BF00690598; Ruiter D J, 1993, Behring Inst Mitt, P258; Ryan CJ, 2000, DRUG AGING, V17, P249, DOI 10.2165/00002512-200017040-00001; Sargiannidou I, 2001, EXP BIOL MED, V226, P726, DOI 10.1177/153537020222600803; Scappaticci FA, 2001, MOL THER, V3, P186, DOI 10.1006/mthe.2000.0243; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; SILVERMAN KJ, 1988, BIOCHEM BIOPH RES CO, V153, P347, DOI 10.1016/S0006-291X(88)81229-4; Soff GA, 2000, CANCER METAST REV, V19, P97, DOI 10.1023/A:1026525121027; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; SONOBE MH, 1991, ONCOGENE, V6, P1531; Stack MS, 1999, BIOCHEM J, V340, P77, DOI 10.1042/0264-6021:3400077; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Taraboletti G, 2000, FASEB J, V14, P1674; Taraboletti G, 1997, CELL GROWTH DIFFER, V8, P471; TISCHER E, 1989, BIOCHEM BIOPH RES CO, V165, P1198, DOI 10.1016/0006-291X(89)92729-0; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; Valentinis B, 1997, MOL CELL BIOL, V17, P3744, DOI 10.1128/MCB.17.7.3744; Volpert OV, 2002, NAT MED, V8, P349, DOI 10.1038/nm0402-349; von Marschall Z, 2003, J NATL CANCER I, V95, P437, DOI 10.1093/jnci/95.6.437; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Werner H, 2000, MOL GENET METAB, V71, P315, DOI 10.1006/mgme.2000.3044; WHEELER DG, 1995, NUCLEIC ACIDS RES, V23, P3268, DOI 10.1093/nar/23.16.3268; White FC, 1997, GROWTH FACTORS, V14, P199, DOI 10.3109/08977199709021520; Wouters BG, 2003, SEMIN RADIAT ONCOL, V13, P31, DOI 10.1053/srao.2003.50004; Yang S, 1999, AM J PATHOL, V155, P887, DOI 10.1016/S0002-9440(10)65188-7; Yao L, 2002, J LEUKOCYTE BIOL, V71, P47	100	230	276	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2003	22	42					6549	6556		10.1038/sj.onc.1206816	http://dx.doi.org/10.1038/sj.onc.1206816			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	728DV	14528279				2022-12-17	WOS:000185700700011
J	Jones, PA				Jones, PA			DNA methylation and cancer	ONCOGENE			English	Article						epigenetics; DNA methylation; chromatic; structure; silencing; tumor suppressor gene		There is tremendous ferment in the field of epigenetics as the relationships between chromatin structure and DNA methylation patterns become clearer. Central to this activity is the realization that the 'histone code', which involves the post-translational modification of histones and which has important ramifications for chromatin structure, may be linked to the DNA cytosine methylation pattern. New discoveries have suggested that histone lysine 9 methylation is implicated in the spread of heterochromatin in Drosophila and other organisms. Very recently it has been found that histone lysine 9 methylation is also necessary for some DNA methylation in Neurospora and plants. There is therefore the possibility that these two processes are closely linked, suggesting ways in which DNA methylation patterns may be established during normal development. Understanding these processes is fundamental to understanding what goes awry during the process of aging and carcinogenesis where DNA methylation patterns become substantially altered and contribute to the malignant phenotype.	Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Keck Sch Med, Dept Urol, Los Angeles, CA 90089 USA; Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Jones, PA (corresponding author), Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Keck Sch Med, Dept Urol, 1441 Eastlake Ave,MS 8302L, Los Angeles, CA 90089 USA.								0	230	254	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	2002	21	35					5358	5360		10.1038/sj.onc.1205597	http://dx.doi.org/10.1038/sj.onc.1205597			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579VC	12154398				2022-12-17	WOS:000177197700002
J	Regad, T; Chelbi-Alix, MK				Regad, T; Chelbi-Alix, MK			Role and fate of PML nuclear bodies in response to interferon and viral infections	ONCOGENE			English	Review						signalling; transcriptional repression; HFV; APL; SUMO; RBCC; TRIM	ACUTE PROMYELOCYTIC LEUKEMIA; MAMMARY-TUMOR VIRUS; PROTEIN-KINASE PKR; VESICULAR STOMATITIS-VIRUS; HEPATITIS-C VIRUS; JAK-STAT PATHWAY; RETINOIC ACID; HUMAN CYTOMEGALOVIRUS; INFLUENZA-VIRUS; GENE-PRODUCT	Interferons (IFNs) are a family of secreted proteins with antiviral, antiproliferative and immunomodulatory activities. The different biological actions of IFN are believed to be mediated by the products of specifically induced cellular genes in the target cells. The promyelocytic leukaemia (PML) protein localizes both in the nucleoplasm and in matrix-associated multi-protein complexes known as nuclear bodies (NBs). PML is essential for the proper formation and the integrity of the NBs. Modification of PML by the Small Ubiquitin MOdifier (SUMO) was shown to be required for its localization in NBs. The number and the intensity of PML NBs increase in response to interferon (IFN). Inactivation of the IFN-induced PML gene by its fusion to retinoic acid receptor alpha alters the normal localization of PML from the punctuate nuclear patterns of NBs to microdispersed tiny dots and results in uncontrolled growth in Acute Promyelocytic Leukaemia. The NBs-associated proteins, PML, Sp100, Sp140, Sp110, ISG20 and PA28 are induced by IFN suggesting that nuclear bodies could play a role in IFN response. Although the function of PML NBs is still unclear, some results indicate that they may represent preferential targets for viral infections and that PML could play a role in the mechanism of the antiviral action of IFNs. Viruses, which require the cellular machinery for their replication, have evolved different ways to counteract the action of IFN by inhibiting IFN signalling, by blocking the activities of specific antiviral mediators or by altering PML expression and/or localization on nuclear bodies.	Inst Andre Lwoff, UPR 9045 CNRS, F-94801 Villejuif, France		Chelbi-Alix, MK (corresponding author), Inst Andre Lwoff, UPR 9045 CNRS, 7 Rue Guy Moquet, F-94801 Villejuif, France.	mchelbi@infobiogen.fr	Regad, Tarik/A-6095-2012	Regad, Tarik/0000-0003-4028-6368				Adelson ME, 1999, EUR J BIOCHEM, V264, P806, DOI 10.1046/j.1432-1327.1999.00661.x; Ahn JH, 2000, VIROLOGY, V274, P39, DOI 10.1006/viro.2000.0448; Ahn JH, 1999, J VIROL, V73, P10458, DOI 10.1128/JVI.73.12.10458-10471.1999; Ahn JH, 1998, MOL CELL BIOL, V18, P4899, DOI 10.1128/MCB.18.8.4899; ALCALAY M, 1992, P NATL ACAD SCI USA, V89, P4840, DOI 10.1073/pnas.89.11.4840; ARNHEITER H, 1990, New Biologist, V2, P851; Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; Barnard P, 1999, VIROLOGY, V259, P305, DOI 10.1006/viro.1999.9771; Bell P, 2000, J VIROL, V74, P5329, DOI 10.1128/JVI.74.11.5329-5336.2000; Bell P, 2000, J VIROL, V74, P11800, DOI 10.1128/JVI.74.24.11800-11810.2000; Bergmann M, 2000, J VIROL, V74, P6203, DOI 10.1128/JVI.74.13.6203-6206.2000; BLACK TL, 1989, J VIROL, V63, P2244, DOI 10.1128/JVI.63.5.2244-2251.1989; Bloch DB, 1996, J BIOL CHEM, V271, P29198, DOI 10.1074/jbc.271.46.29198; Bloch DB, 1999, MOL CELL BIOL, V19, P4423; Bloch DB, 2000, MOL CELL BIOL, V20, P6138, DOI 10.1128/MCB.20.16.6138-6146.2000; Borden KLB, 1998, J VIROL, V72, P758, DOI 10.1128/JVI.72.1.758-766.1998; Borden KLB, 1997, FEBS LETT, V418, P30, DOI 10.1016/S0014-5793(97)01344-6; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Borden KLB, 1998, J VIROL, V72, P3819, DOI 10.1128/JVI.72.5.3819-3826.1998; Burysek L, 1999, J VIROL, V73, P7334; Burysek L, 2001, J VIROL, V75, P2345, DOI 10.1128/JVI.75.5.2345-2352.2001; Cai RR, 2000, ARCH BIOCHEM BIOPHYS, V373, P361, DOI 10.1006/abbi.1999.1583; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; CAYLEY PJ, 1984, EUR J BIOCHEM, V143, P165, DOI 10.1111/j.1432-1033.1984.tb08355.x; CHEBATH J, 1987, NATURE, V330, P587, DOI 10.1038/330587a0; Chelbi-Alix MK, 1999, LEUKEMIA, V13, P1167, DOI 10.1038/sj.leu.2401469; Chelbi-Alix MK, 1998, J VIROL, V72, P1043, DOI 10.1128/JVI.72.2.1043-1051.1998; Chelbi-Alix MK, 1999, ONCOGENE, V18, P935, DOI 10.1038/sj.onc.1202366; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; CHELBIALIX MK, TUMOR BIOL, V99, P17; Cheng GF, 2001, J VIROL, V75, P3666, DOI 10.1128/JVI.75.8.3666-3674.2001; CHENIK M, 1995, J VIROL, V69, P707, DOI 10.1128/JVI.69.2.707-712.1995; COCCIA EM, 1990, VIROLOGY, V179, P228, DOI 10.1016/0042-6822(90)90292-Y; DANIEL MT, 1993, BLOOD, V82, P1858; Day PM, 1998, J VIROL, V72, P142, DOI 10.1128/JVI.72.1.142-150.1998; Dent AL, 1996, BLOOD, V88, P1423, DOI 10.1182/blood.V88.4.1423.bloodjournal8841423; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; DER SD, 1995, P NATL ACAD SCI USA, V92, P8841, DOI 10.1073/pnas.92.19.8841; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; DiazGuerra M, 1997, VIROLOGY, V227, P220, DOI 10.1006/viro.1996.8294; Djavani M, 2001, J VIROL, V75, P6204, DOI 10.1128/JVI.75.13.6204-6208.2001; Dwyer EJC, 2000, J VIROL, V74, P3293, DOI 10.1128/JVI.74.7.3293-3300.2000; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Everett RD, 1999, TRENDS BIOCHEM SCI, V24, P293, DOI 10.1016/S0968-0004(99)01433-4; Everett RD, 1998, J VIROL, V72, P6581, DOI 10.1128/JVI.72.8.6581-6591.1998; Fabunmi RP, 2001, J CELL SCI, V114, P29; Foss GS, 1999, J BIOL CHEM, V274, P35196, DOI 10.1074/jbc.274.49.35196; Gale M, 1999, J VIROL, V73, P6506, DOI 10.1128/JVI.73.8.6506-6516.1999; Gale M, 1998, PHARMACOL THERAPEUT, V78, P29, DOI 10.1016/S0163-7258(97)00165-4; Gongora C, 2000, NUCLEIC ACIDS RES, V28, P2333, DOI 10.1093/nar/28.12.2333; Gongora C, 1997, J BIOL CHEM, V272, P19457, DOI 10.1074/jbc.272.31.19457; Goodbourn S, 2000, J GEN VIROL, V81, P2341, DOI 10.1099/0022-1317-81-10-2341; Grotzinger T, 1996, J BIOL CHEM, V271, P25253, DOI 10.1074/jbc.271.41.25253; GULDNER HH, 1992, J IMMUNOL, V149, P4067; GUNNERY S, 1990, P NATL ACAD SCI USA, V87, P8687, DOI 10.1073/pnas.87.22.8687; Guo JJ, 2000, J VIROL, V74, P1892, DOI 10.1128/JVI.74.4.1892-1899.2000; Haller O, 1998, REV SCI TECH OIE, V17, P220, DOI 10.20506/rst.17.1.1084; HASSEL BA, 1993, EMBO J, V12, P3297, DOI 10.1002/j.1460-2075.1993.tb05999.x; Hatada E, 1999, J VIROL, V73, P2425, DOI 10.1128/JVI.73.3.2425-2433.1999; He FL, 1996, J VIROL, V70, P3902, DOI 10.1128/JVI.70.6.3902-3908.1996; Heim MH, 1999, J VIROL, V73, P8469, DOI 10.1128/JVI.73.10.8469-8475.1999; IMANI F, 1988, P NATL ACAD SCI USA, V85, P7887, DOI 10.1073/pnas.85.21.7887; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; KUMAR R, 1988, J VIROL, V62, P3175, DOI 10.1128/JVI.62.9.3175-3181.1988; LANOTTE M, 1991, BLOOD, V77, P1080; LAVAU C, 1995, ONCOGENE, V11, P871; Lecellier CH, 2000, VIROLOGY, V271, P1, DOI 10.1006/viro.2000.0216; Leonard GT, 1997, J VIROL, V71, P5095, DOI 10.1128/JVI.71.7.5095-5101.1997; Li SY, 1999, ONCOGENE, V18, P5727, DOI 10.1038/sj.onc.1202960; Linial ML, 1999, J VIROL, V73, P1747, DOI 10.1128/JVI.73.3.1747-1755.1999; Look DC, 1998, IMMUNITY, V9, P871, DOI 10.1016/S1074-7613(00)80652-4; MARCHETTI A, 1995, J VIROL, V69, P1932, DOI 10.1128/JVI.69.3.1932-1938.1995; Martinand C, 1999, J VIROL, V73, P290, DOI 10.1128/JVI.73.1.290-296.1999; MAUL GG, 1994, J GEN VIROL, V75, P1223, DOI 10.1099/0022-1317-75-6-1223; MEIER E, 1988, J VIROL, V62, P2386, DOI 10.1128/JVI.62.7.2386-2393.1988; Melville MW, 1999, J BIOL CHEM, V274, P3797, DOI 10.1074/jbc.274.6.3797; Meurs EF, 1995, VIROLOGY, V214, P653, DOI 10.1006/viro.1995.0080; MEURS EF, 1992, J VIROL, V66, P5805, DOI 10.1128/JVI.66.10.5805-5814.1992; Miller DM, 1999, J IMMUNOL, V162, P6107; Miller DM, 1998, J EXP MED, V187, P675, DOI 10.1084/jem.187.5.675; Morris-Desbois C, 1999, J CELL SCI, V112, P3331; Muller S, 1999, J VIROL, V73, P5137; NasonBurchenal K, 1996, BLOOD, V88, P3926, DOI 10.1182/blood.V88.10.3926.bloodjournal88103926; Nguyen LH, 2001, BIOCHEMISTRY-US, V40, P7174, DOI 10.1021/bi010141t; PAVLOVIC J, 1990, J VIROL, V64, P3370, DOI 10.1128/JVI.64.7.3370-3375.1990; Pelicano L, 1999, ONCOGENE, V18, P3944, DOI 10.1038/sj.onc.1202802; Pellegrini S, 1997, EUR J BIOCHEM, V248, P615, DOI 10.1111/j.1432-1033.1997.00615.x; Pfeffer LM, 1998, CANCER RES, V58, P2489; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; Player MR, 1998, PHARMACOL THERAPEUT, V78, P55, DOI 10.1016/S0163-7258(97)00167-8; Poppers J, 2000, J VIROL, V74, P11215, DOI 10.1128/JVI.74.23.11215-11221.2000; Puvion-Dutilleul F, 1999, BIOL CELL, V91, P617, DOI 10.1016/S0248-4900(00)88526-3; PUVIONDUTILLEUL F, 1995, EXP CELL RES, V218, P9, DOI 10.1006/excr.1995.1125; Rechsteiner M, 2000, BIOCHEM J, V345, P1, DOI 10.1042/0264-6021:3450001; Regad T, 2001, EMBO J, V20, P3495, DOI 10.1093/emboj/20.13.3495; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHRODER HC, 1990, FASEB J, V4, P3124, DOI 10.1096/fasebj.4.13.1698680; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; Sharp TV, 1997, EUR J BIOCHEM, V250, P85, DOI 10.1111/j.1432-1033.1997.00085.x; SHARP TV, 1993, NUCLEIC ACIDS RES, V21, P4483, DOI 10.1093/nar/21.19.4483; Sharp TV, 1998, VIROLOGY, V250, P302, DOI 10.1006/viro.1998.9365; Stadler M, 1995, ONCOGENE, V11, P2565; Staeheli Peter, 1993, Trends in Cell Biology, V3, P268, DOI 10.1016/0962-8924(93)90055-6; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Sternsdorf T, 1997, IMMUNOBIOLOGY, V198, P307, DOI 10.1016/S0171-2985(97)80051-4; Szekely L, 1996, J VIROL, V70, P2562, DOI 10.1128/JVI.70.4.2562-2568.1996; Tanahashi N, 1997, GENES CELLS, V2, P195, DOI 10.1046/j.1365-2443.1997.d01-308.x; Taylor DR, 1999, SCIENCE, V285, P107, DOI 10.1126/science.285.5424.107; TESTA U, 1994, CANCER RES, V54, P4508; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Zhou AM, 1997, EMBO J, V16, P6355, DOI 10.1093/emboj/16.21.6355; Zhou AM, 1999, VIROLOGY, V258, P435, DOI 10.1006/viro.1999.9738; Zimring JC, 1998, J VIROL, V72, P701, DOI 10.1128/JVI.72.1.701-707.1998; ZURCHER T, 1992, VIROLOGY, V187, P796, DOI 10.1016/0042-6822(92)90481-4; ZURCHER T, 1992, J VIROL, V66, P5059	119	230	242	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2001	20	49					7274	7286		10.1038/sj.onc.1204854	http://dx.doi.org/10.1038/sj.onc.1204854			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487TM	11704856	Bronze			2022-12-17	WOS:000171891900016
J	SHAY, JW; WRIGHT, WE; BRASISKYTE, D; VANDERHAEGEN, BA				SHAY, JW; WRIGHT, WE; BRASISKYTE, D; VANDERHAEGEN, BA			E6 OF HUMAN PAPILLOMAVIRUS TYPE-16 CAN OVERCOME THE M1 STAGE OF IMMORTALIZATION IN HUMAN MAMMARY EPITHELIAL-CELLS BUT NOT IN HUMAN FIBROBLASTS	ONCOGENE			English	Article							HUMAN BREAST-CANCER; RETINOBLASTOMA SUSCEPTIBILITY GENE; HUMAN-DIPLOID FIBROBLASTS; LARGE TUMOR-ANTIGEN; LARGE T-ANTIGEN; P53 MUTATIONS; SV40-TRANSFORMED CELLS; CELLULAR SENESCENCE; TRANSFORMED-CELLS; GROWTH	Immortalization is the consequence of the inactivation or bypass of two mortality stage mechanisms, M1 and M2, which are controlled by several genes including Rb and p53 in human fibroblasts. Abrogation of the M1 controls can be obtained through the activity of DNA tumor virus genes such as E6 and E7 of human papillomavirus 16 (HPV16). Fibroblasts expressing both E6 (which binds p53) and E7 (which binds Rb) bypass MI and continue replicating (exhibit an extended lifespan) until an independent mechanism, M2, is activated. The inactivation of the M2 mechanism finally results in celt immortalization. The present study establishes a difference in the tissue-specific mechanisms for the control of the M1 stage of cellular senescence. The expression of HPV16 E6 was sufficient to bypass the MI stage of cellular senescence and confer an extended lifespan in human mammary epithelial cells but not in fibroblasts. This implies that the M1 mechanism in human mammary epithelial cells does not involve the constitutive activation of Rb function as it does in fibroblasts. In addition, the results confirmed that the expression of HPV16 E6 (or both E6 and E7) did not directly immortalize the human mammary epithelial cells, since the inactivation of a second event, M2, was required to achieve immortalization. These observations are considered in the context of the telomere shortening model of cellular senescence.			SHAY, JW (corresponding author), UNIV TEXAS,SW MED CTR,DEPT CELL BIOL & NEUROSCI,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.		Shay, Jerry W/F-7878-2011		NCI NIH HHS [CA50195] Funding Source: Medline; NIA NIH HHS [AG07992] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG007992] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLSOP RC, 1992, IN PRESS P NATL ACAD; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BARTEK J, 1990, ONCOGENE, V5, P893; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BRONSTEIN I, 1990, BIOTECHNIQUES, V8, P310; COLES C, 1992, CANCER RES, V52, P5291; COOKE HJ, 1986, COLD SPRING HARB SYM, V51, P213, DOI 10.1101/SQB.1986.051.01.026; DAVIDOFF AM, 1991, P NATL ACAD SCI USA, V88, P5006, DOI 10.1073/pnas.88.11.5006; DAVIDOFF AM, 1991, CANCER RES, V51, P2605; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DUNBAR BS, 1987, 2 DIMENSIONAL ELECTR, P335; GILLESPIE PG, 1991, P NATL ACAD SCI USA, V88, P2563, DOI 10.1073/pnas.88.6.2563; GIRARDI AJ, 1965, J CELL COMPAR PHYSL, V65, P69, DOI 10.1002/jcp.1030650110; GRIEDER CW, 1990, BIOESSAYS, V12, P363; HALBERT CL, 1992, J VIROL, V66, P2125, DOI 10.1128/JVI.66.4.2125-2134.1992; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P538; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HAYFLICK L, 1980, AGING ITS CHEM, P227; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUSCHTSCHA LI, 1983, J CELL SCI, V63, P77; KIPLING D, 1992, HUM MOL GENET, V1, P3, DOI 10.1093/hmg/1.1.3-a; KOVACH JS, 1991, JNCI-J NATL CANCER I, V83, P1004, DOI 10.1093/jnci/83.14.1004; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; LINDER S, 1990, EXP CELL RES, V191, P1, DOI 10.1016/0014-4827(90)90027-8; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARTIN GM, 1977, AM J PATHOL, V89, P484; MAZARS R, 1992, CANCER RES, V52, P3918; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; MUNGER K, 1989, J VIROL, V63, P4417; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; OSBORNE RJ, 1991, CANCER RES, V51, P6194; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; PIRISI L, 1992, J VIROL, V44, P268; Pollock Raphael E., 1992, Cancer Bulletin (Houston), V44, P268; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; SCHEFFNER M, 1990, CELL, V63, P11291; SEEDORF K, 1985, VIROLOGY, V145, P181, DOI 10.1016/0042-6822(85)90214-4; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAY JW, 1992, EXP GERONTOL, V27, P477, DOI 10.1016/0531-5565(92)90003-I; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SHAY JW, 1992, MUTAT RES, V277, P163, DOI 10.1016/0165-1110(92)90003-R; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; SIDRANSKY D, 1992, CANCER RES, V52, P2984; STAMPFER M, 1980, IN VITRO CELL DEV B, V16, P415; STAMPS AC, 1992, EUR J CANCER, V28A, P1495, DOI 10.1016/0959-8049(92)90552-D; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; STEIN GH, 1985, J CELL PHYSIOL, V125, P36, DOI 10.1002/jcp.1041250106; VANDERHAEGEN BA, 1993, IN PRESS IN VIGRO CE; VARLEY JM, 1991, ONCOGENE, V6, P413; WATANABE S, 1989, J VIROL, V63, P965, DOI 10.1128/JVI.63.2.965-969.1989; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WOODWORTH CD, 1989, J VIROL, V63, P159, DOI 10.1128/JVI.63.1.159-164.1989; WRIGHT WE, 1992, EXP GERONTOL, V27, P383, DOI 10.1016/0531-5565(92)90069-C; WRIGHT WE, 1992, TRENDS GENET, V8, P193, DOI 10.1016/0168-9525(92)90232-S; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088	79	230	239	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1407	1413						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8389027				2022-12-17	WOS:A1993LE06400002
J	Jin, L; Alesi, GN; Kang, S				Jin, L.; Alesi, G. N.; Kang, S.			Glutaminolysis as a target for cancer therapy	ONCOGENE			English	Review							KIDNEY-TYPE GLUTAMINASE; GLUTAMATE-DEHYDROGENASE; OXIDATIVE STRESS; REDUCTIVE CARBOXYLATION; CELL-PROLIFERATION; BREAST-CANCER; METABOLISM; GROWTH; GLUCOSE; GLYCOLYSIS	Cancer cells display an altered metabolic circuitry that is directly regulated by oncogenic mutations and loss of tumor suppressors. Mounting evidence indicates that altered glutamine metabolism in cancer cells has critical roles in supporting macromolecule biosynthesis, regulating signaling pathways, and maintaining redox homeostasis, all of which contribute to cancer cell proliferation and survival. Thus, intervention in these metabolic processes could provide novel approaches to improve cancer treatment. This review summarizes current findings on the role of glutaminolytic enzymes in human cancers and provides an update on the development of small molecule inhibitors to target glutaminolysis for cancer therapy.	[Jin, L.; Alesi, G. N.; Kang, S.] Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA USA	Emory University	Jin, L; Kang, S (corresponding author), Emory Univ, Sch Med, Winship Canc Inst Emory, Dept Hematol & Med Oncol, 1365-C Clifton Rd NE,Room C3006, Atlanta, GA 30322 USA.	LJIN4@emory.edu; smkang@emory.edu			ACS grant [RSG-11-081-01]; NIH [R01 CA175316, F31 CA183365]; NATIONAL CANCER INSTITUTE [R01CA175316] Funding Source: NIH RePORTER	ACS grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge Dr Anthea Hammond for editorial assistance. We apologize to authors whose contributions were not directly cited in this review due to space limitations. This study is supported in part by ACS grant RSG-11-081-01 and NIH grants R01 CA175316 (S.K.) and F31 CA183365 (G.A.). S.K. is a Georgia Cancer Coalition Scholar, Robbins Scholar, and an American Cancer Society Basic Research Scholar.	Adam J, 2011, CANCER CELL, V20, P524, DOI 10.1016/j.ccr.2011.09.006; AHLUWALIA GS, 1990, PHARMACOL THERAPEUT, V46, P243, DOI 10.1016/0163-7258(90)90094-I; Bhutia YD, 2015, CANCER RES, V75, P1782, DOI 10.1158/0008-5472.CAN-14-3745; Chen RH, 2014, P NATL ACAD SCI USA, V111, P14217, DOI 10.1073/pnas.1409653111; Cheng TL, 2011, P NATL ACAD SCI USA, V108, P8674, DOI 10.1073/pnas.1016627108; Choo AY, 2010, MOL CELL, V38, P487, DOI 10.1016/j.molcel.2010.05.007; Colombo SL, 2011, P NATL ACAD SCI USA, V108, P21069, DOI 10.1073/pnas.1117500108; Csibi A, 2013, CELL, V153, P840, DOI 10.1016/j.cell.2013.04.023; Csibi A, 2014, CURR BIOL, V24, P2274, DOI 10.1016/j.cub.2014.08.007; Dang CV, 2010, CELL CYCLE, V9, P3884, DOI 10.4161/cc.9.19.13302; DeBerardinis RJ, 2010, ONCOGENE, V29, P313, DOI 10.1038/onc.2009.358; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; DeLaBarre B, 2014, CHEM BIOL, V21, P1143, DOI 10.1016/j.chembiol.2014.08.007; Duran RV, 2012, MOL CELL, V47, P349, DOI 10.1016/j.molcel.2012.05.043; Elhammali A, 2014, CANCER DISCOV, V4, P828, DOI 10.1158/2159-8290.CD-13-0572; Elorza A, 2012, MOL CELL, V48, P681, DOI 10.1016/j.molcel.2012.09.017; Eng CH, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000911; Frezza C, 2009, SEMIN CANCER BIOL, V19, P4, DOI 10.1016/j.semcancer.2008.11.008; Friday E, 2011, J CELL PHYSIOL, V226, P511, DOI 10.1002/jcp.22360; Gao MH, 2015, MOL CELL, V59, P298, DOI 10.1016/j.molcel.2015.06.011; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Ghesquiere B, 2014, NATURE, V511, P167, DOI 10.1038/nature13312; Giacobbe A, 2013, CELL CYCLE, V12, P1395, DOI 10.4161/cc.24478; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Gross MI, 2014, MOL CANCER THER, V13, P890, DOI 10.1158/1535-7163.MCT-13-0870; Haigis MC, 2006, CELL, V126, P941, DOI 10.1016/j.cell.2006.06.057; Harris IS, 2015, CANCER CELL, V27, P211, DOI 10.1016/j.ccell.2014.11.019; Hassanein M, 2015, INT J CANCER, V137, P1587, DOI 10.1002/ijc.29535; Hassanein M, 2013, CLIN CANCER RES, V19, P560, DOI 10.1158/1078-0432.CCR-12-2334; Hensley CT, 2013, J CLIN INVEST, V123, P3678, DOI 10.1172/JCI69600; Herranz D, 2015, NAT MED, V21, P1182, DOI 10.1038/nm.3955; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Hu WW, 2010, P NATL ACAD SCI USA, V107, P7455, DOI 10.1073/pnas.1001006107; Jin LT, 2015, CANCER CELL, V27, P257, DOI 10.1016/j.ccell.2014.12.006; Katt WP, 2014, DRUG DISCOV TODAY, V19, P450, DOI 10.1016/j.drudis.2013.10.008; Katt WP, 2012, MOL CANCER THER, V11, P1269, DOI 10.1158/1535-7163.MCT-11-0942; Kim JW, 2006, CANCER RES, V66, P8927, DOI 10.1158/0008-5472.CAN-06-1501; Korangath P, 2015, CLIN CANCER RES, V21, P3263, DOI 10.1158/1078-0432.CCR-14-1200; KOVACEVIC Z, 1983, PHYSIOL REV, V63, P547, DOI 10.1152/physrev.1983.63.2.547; LACEY JM, 1990, NUTR REV, V48, P297, DOI 10.1111/j.1753-4887.1990.tb02967.x; Le A, 2012, CELL METAB, V15, P110, DOI 10.1016/j.cmet.2011.12.009; Li CH, 2006, J BIOL CHEM, V281, P10214, DOI 10.1074/jbc.M512792200; Li J, 2015, P NATL ACAD SCI USA, V112, pE21, DOI 10.1073/pnas.1417015112; Lorin S, 2013, AUTOPHAGY, V9, P850, DOI 10.4161/auto.24083; Lu WQ, 2010, CANCER CELL, V18, P199, DOI 10.1016/j.ccr.2010.08.017; Martin-Rufian M, 2014, J MOL MED, V92, P277, DOI 10.1007/s00109-013-1105-2; Mates JM, 2013, CURR MOL MED, V13, P514; MCKEEHAN WL, 1982, CELL BIOL INT REP, V6, P635, DOI 10.1016/0309-1651(82)90125-4; MEDINA MA, 1990, INT J BIOCHEM, V22, P681, DOI 10.1016/0020-711X(90)90001-J; MEDINA MA, 1992, MOL CELL BIOCHEM, V113, P1; Medina MA, 2001, J NUTR, V131, p2539S, DOI 10.1093/jn/131.9.2539S; Metallo CM, 2012, NATURE, V481, P380, DOI 10.1038/nature10602; Moncada S, 2012, BIOCHEM J, V446, P1, DOI 10.1042/BJ20120427; MOREADITH RW, 1984, J BIOL CHEM, V259, P6215; Mullen AR, 2014, CELL REP, V7, P1679, DOI 10.1016/j.celrep.2014.04.037; Mullen AR, 2012, NATURE, V481, P385, DOI 10.1038/nature10642; Murphy TA, 2013, METAB ENG, V15, P206, DOI 10.1016/j.ymben.2012.07.008; NEWSHOLME EA, 1985, Q J EXP PHYSIOL CMS, V70, P473, DOI 10.1113/expphysiol.1985.sp002935; Nicklin P, 2009, CELL, V136, P521, DOI 10.1016/j.cell.2008.11.044; Ooi A, 2011, CANCER CELL, V20, P511, DOI 10.1016/j.ccr.2011.08.024; Plaitakis A, 2011, NEUROCHEM INT, V59, P495, DOI 10.1016/j.neuint.2011.03.015; Qing GL, 2012, CANCER CELL, V22, P631, DOI 10.1016/j.ccr.2012.09.021; Reynolds MR, 2014, ONCOGENE, V33, P556, DOI 10.1038/onc.2012.635; Robinson MM, 2007, BIOCHEM J, V406, P407, DOI 10.1042/BJ20070039; Schulze A, 2012, NATURE, V491, P364, DOI 10.1038/nature11706; Shroff EH, 2015, P NATL ACAD SCI USA, V112, P6539, DOI 10.1073/pnas.1507228112; Shukla K, 2012, J MED CHEM, V55, P10551, DOI 10.1021/jm301191p; Smith TJ, 2008, TRENDS BIOCHEM SCI, V33, P557, DOI 10.1016/j.tibs.2008.07.007; Son J, 2013, NATURE, V496, P101, DOI 10.1038/nature12040; SOUBA WW, 1993, ANN SURG, V218, P715, DOI 10.1097/00000658-199312000-00004; Stalnecker CA, 2015, P NATL ACAD SCI USA, V112, P394, DOI 10.1073/pnas.1414056112; Stanley CA, 1998, NEW ENGL J MED, V338, P1352, DOI 10.1056/NEJM199805073381904; Suzuki S, 2010, P NATL ACAD SCI USA, V107, P7461, DOI 10.1073/pnas.1002459107; Tanaka K, 2015, J CLIN INVEST, V125, P1591, DOI 10.1172/JCI78239; Thangavelu K, 2012, P NATL ACAD SCI USA, V109, P7705, DOI 10.1073/pnas.1116573109; Thornburg JM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2154; Ulanet DB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115144; Wang JB, 2010, CANCER CELL, V18, P207, DOI 10.1016/j.ccr.2010.08.009; Wang Q, 2014, INT J CANCER, V135, P1060, DOI 10.1002/ijc.28749; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Wellen KE, 2010, GENE DEV, V24, P2784, DOI 10.1101/gad.1985910; Willems L, 2013, BLOOD, V122, P3521, DOI 10.1182/blood-2013-03-493163; Wise DR, 2010, TRENDS BIOCHEM SCI, V35, P427, DOI 10.1016/j.tibs.2010.05.003; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Xiang LS, 2013, BBA-MOL CELL RES, V1833, P2996, DOI 10.1016/j.bbamcr.2013.08.003; Xiang Y, 2015, J CLIN INVEST, V125, P2293, DOI 10.1172/JCI75836; Yang CD, 2009, CANCER RES, V69, P7986, DOI 10.1158/0008-5472.CAN-09-2266; Yang H, 2015, EMBO J, V34, P1110, DOI 10.15252/embj.201591041; Yuneva M, 2007, J CELL BIOL, V178, P93, DOI 10.1083/jcb.200703099; Zhang J, 2014, MOL CELL, V56, P205, DOI 10.1016/j.molcel.2014.08.018	90	229	232	5	67	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2016	35	28					3619	3625		10.1038/onc.2015.447	http://dx.doi.org/10.1038/onc.2015.447			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UQ	26592449	Green Accepted			2022-12-17	WOS:000379622800001
J	Davis, FM; Azimi, I; Faville, RA; Peters, AA; Jalink, K; Putney, JW; Goodhill, GJ; Thompson, EW; Roberts-Thomson, SJ; Monteith, GR				Davis, F. M.; Azimi, I.; Faville, R. A.; Peters, A. A.; Jalink, K.; Putney, J. W., Jr.; Goodhill, G. J.; Thompson, E. W.; Roberts-Thomson, S. J.; Monteith, G. R.			Induction of epithelial-mesenchymal transition (EMT) in breast cancer cells is calcium signal dependent	ONCOGENE			English	Article						epithelial-mesenchymal transition; calcium; vimentin; STAT3; signal transduction; breast cancer	UP-REGULATION; MIGRATION; ACTIVATION; CHANNELS; TRPM7; CONTRIBUTES; PROGRESSION; METASTASIS; EXPRESSION; ROLES	Signals from the tumor microenvironment trigger cancer cells to adopt an invasive phenotype through epithelial-mesenchymal transition (EMT). Relatively little is known regarding key signal transduction pathways that serve as cytosolic bridges between cell surface receptors and nuclear transcription factors to induce EMT. A better understanding of these early EMT events may identify potential targets for the control of metastasis. One rapid intracellular signaling pathway that has not yet been explored during EMT induction is calcium. Here we show that stimuli used to induce EMT produce a transient increase in cytosolic calcium levels in human breast cancer cells. Attenuation of the calcium signal by intracellular calcium chelation significantly reduced epidermal growth factor (EGF)-and hypoxia-induced EMT. Intracellular calcium chelation also inhibited EGF-induced activation of signal transducer and activator of transcription 3 (STAT3), while preserving other signal transduction pathways such as Akt and extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation. To identify calcium-permeable channels that may regulate EMT induction in breast cancer cells, we performed a targeted siRNA-based screen. We found that transient receptor potential-melastatin- like 7 (TRPM7) channel expression regulated EGF-induced STAT3 phosphorylation and expression of the EMT marker vimentin. Although intracellular calcium chelation almost completely blocked the induction of many EMT markers, including vimentin, Twist and N-cadherin, the effect of TRPM7 silencing was specific for vimentin protein expression and STAT3 phosphorylation. These results indicate that TRPM7 is a partial regulator of EMT in breast cancer cells, and that other calcium-permeable ion channels are also involved in calcium-dependent EMT induction. In summary, this work establishes an important role for the intracellular calcium signal in the induction of EMT in human breast cancer cells. Manipulation of calcium-signaling pathways controlling EMT induction in cancer cells may therefore be an important therapeutic strategy for preventing metastases.	[Davis, F. M.; Azimi, I.; Peters, A. A.; Roberts-Thomson, S. J.; Monteith, G. R.] Univ Queensland, Sch Pharm, Brisbane, Qld 4072, Australia; [Faville, R. A.; Goodhill, G. J.] Univ Queensland, Queensland Brain Inst, Brisbane, Qld 4072, Australia; [Jalink, K.] Netherlands Canc Inst, Div Cell Biol, Amsterdam, Netherlands; [Putney, J. W., Jr.] NIEHS, Lab Signal Transduct, Res Triangle Pk, NC 27709 USA; [Goodhill, G. J.] Univ Queensland, Sch Math & Phys, Brisbane, Qld 4072, Australia; [Thompson, E. W.] St Vincents Inst, Fitzroy, Vic, Australia; [Thompson, E. W.] Univ Melbourne, St Vincents Hosp, Dept Surg, Fitzroy, Vic 3065, Australia	University of Queensland; University of Queensland; Netherlands Cancer Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Queensland; St. Vincent's Institute of Medical Research; St Vincent's Hospital Melbourne; University of Melbourne	Monteith, GR (corresponding author), Univ Queensland, Sch Pharm, Brisbane, Qld 4072, Australia.	gregm@uq.edu.au	Putney, James W/F-7247-2019; Peters, Amelia/AAP-3886-2021; Davis, Felicity M/P-1387-2016; Monteith, Gregory/B-1626-2008; Azimi, Iman/E-2043-2011; Peters, Amelia A/E-4254-2010; Roberts-Thomson, Sarah J/B-4282-2011; Thompson, Erik W/A-1425-2009; Roberts-Thomson, Sarah/W-5676-2019; Thompson, Erik/GPK-2067-2022	Putney, James W/0000-0002-3379-4789; Peters, Amelia/0000-0002-0700-7817; Davis, Felicity M/0000-0001-9112-118X; Monteith, Gregory/0000-0002-4345-530X; Azimi, Iman/0000-0001-9477-9999; Roberts-Thomson, Sarah J/0000-0001-8202-5786; Thompson, Erik W/0000-0002-9723-4924; Roberts-Thomson, Sarah/0000-0001-8202-5786; Thompson, Erik/0000-0002-9723-4924; Jalink, Kees/0000-0001-7019-3440; Goodhill, Geoffrey/0000-0001-9789-9355	National Health and Medical Research Council (NHMRC) [569645, 1022263]; Intramural Research Program of the US National Institutes of Health, National Institute of Environmental Health Sciences (NIEHS); NHMRC Biomedical Postgraduate Scholarship [511262]; UQ Postdoctoral Fellowship; National Breast Cancer Foundation; National Breast Cancer Foundation [CG-10-04] Funding Source: researchfish; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES090087] Funding Source: NIH RePORTER	National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Intramural Research Program of the US National Institutes of Health, National Institute of Environmental Health Sciences (NIEHS); NHMRC Biomedical Postgraduate Scholarship(National Health and Medical Research Council (NHMRC) of Australia); UQ Postdoctoral Fellowship; National Breast Cancer Foundation; National Breast Cancer Foundation; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	The research was partially supported by the National Health and Medical Research Council (NHMRC; project grants 569645 and 1022263) and the Intramural Research Program of the US National Institutes of Health, National Institute of Environmental Health Sciences (NIEHS). FD was funded by an NHMRC Biomedical Postgraduate Scholarship (511262), RF was funded by a UQ Postdoctoral Fellowship and EWT was funded in part by the National Breast Cancer Foundation.	Nieto MA, 2011, ANNU REV CELL DEV BI, V27, P347, DOI 10.1146/annurev-cellbio-092910-154036; Berg T, 2008, CURR OPIN CHEM BIOL, V12, P464, DOI 10.1016/j.cbpa.2008.07.023; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bonnomet A, 2012, ONCOGENE, V31, P3741, DOI 10.1038/onc.2011.540; Chang HY, 2005, P NATL ACAD SCI USA, V102, P3738, DOI 10.1073/pnas.0409462102; Cheng XP, 2010, CELL, V141, P331, DOI 10.1016/j.cell.2010.03.013; Chubanov V, 2012, BRIT J PHARMACOL, V166, P1357, DOI 10.1111/j.1476-5381.2012.01855.x; Clark K, 2006, EMBO J, V25, P290, DOI 10.1038/sj.emboj.7600931; Colomiere M, 2009, BRIT J CANCER, V100, P134, DOI 10.1038/sj.bjc.6604794; Cook SJ, 1997, J BIOL CHEM, V272, P13309, DOI 10.1074/jbc.272.20.13309; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Davis FM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036923; Davis FM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023464; Dimeo TA, 2009, CANCER RES, V69, P5364, DOI 10.1158/0008-5472.CAN-08-4135; Elgoyhen AB, 2001, P NATL ACAD SCI USA, V98, P3501, DOI 10.1073/pnas.051622798; Gao HX, 2011, CELL CALCIUM, V50, P559, DOI 10.1016/j.ceca.2011.09.003; Gilles C, 1999, J CELL SCI, V112, P4615; Grande M, 2002, J CELL SCI, V115, P4227, DOI 10.1242/jcs.00091; Grice DM, 2010, J BIOL CHEM, V285, P37458, DOI 10.1074/jbc.M110.163329; Hu JJ, 2011, BIOCHEM BIOPH RES CO, V411, P786, DOI 10.1016/j.bbrc.2011.07.025; Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223; Ji QS, 2000, ONCOGENE, V19, P1853, DOI 10.1038/sj.onc.1203517; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Langeslag M, 2007, J BIOL CHEM, V282, P232, DOI 10.1074/jbc.M605300200; Lester RD, 2007, J CELL BIOL, V178, P425, DOI 10.1083/jcb.200701092; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Lo HW, 2007, CANCER RES, V67, P9066, DOI 10.1158/0008-5472.CAN-07-0575; Lundgren K, 2009, BRIT J CANCER, V101, P1769, DOI 10.1038/sj.bjc.6605369; Mancini M, 2009, NAT REV CANCER, V9, P810, DOI 10.1038/nrc2735; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mellstrom B, 2008, PHYSIOL REV, V88, P421, DOI 10.1152/physrev.00041.2005; Middelbeek J, 2012, CANCER RES, V72, P4250, DOI 10.1158/0008-5472.CAN-11-3863; Monet M, 2010, CANCER RES, V70, P1225, DOI 10.1158/0008-5472.CAN-09-2205; Monteith GR, 2012, J BIOL CHEM, V287, P31666, DOI 10.1074/jbc.R112.343061; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Prevarskaya N, 2011, NAT REV CANCER, V11, P609, DOI 10.1038/nrc3105; Proia TA, 2011, CELL STEM CELL, V8, P149, DOI 10.1016/j.stem.2010.12.007; Ramsey IS, 2006, ANNU REV PHYSIOL, V68, P619, DOI 10.1146/annurev.physiol.68.040204.100431; Ronnov-Jessen L, 2009, TRENDS MOL MED, V15, P5, DOI 10.1016/j.molmed.2008.11.001; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Shabir S, 2008, CELL CALCIUM, V44, P453, DOI 10.1016/j.ceca.2008.02.008; Su LT, 2011, BIOCHEM J, V434, P513, DOI 10.1042/BJ20101678; Suchanek KM, 2002, MOL CARCINOGEN, V34, P165, DOI 10.1002/mc.10061; Takahashi T, 1999, CIRC RES, V85, P884; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Vultur A, 2004, ONCOGENE, V23, P2600, DOI 10.1038/sj.onc.1207378; Wei CL, 2009, NATURE, V457, P901, DOI 10.1038/nature07577; Wyckoff J, 2004, CANCER RES, V64, P7022, DOI 10.1158/0008-5472.CAN-04-1449; Yang SL, 2009, ONCOGENE, V28, P1320, DOI 10.1038/onc.2008.475; Yang SY, 2009, CANCER CELL, V15, P124, DOI 10.1016/j.ccr.2008.12.019; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183	53	229	237	3	68	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2014	33	18					2307	2316		10.1038/onc.2013.187	http://dx.doi.org/10.1038/onc.2013.187			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AG5ID	23686305	Green Accepted, Green Submitted			2022-12-17	WOS:000335451800004
J	Kumar, SM; Liu, S; Lu, H; Zhang, H; Zhang, PJ; Gimotty, PA; Guerra, M; Guo, W; Xu, X				Kumar, S. M.; Liu, S.; Lu, H.; Zhang, H.; Zhang, P. J.; Gimotty, P. A.; Guerra, M.; Guo, W.; Xu, X.			Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation	ONCOGENE			English	Article						Oct4; cancer stem cell; melanoma; dedifferentiation; hypoxia	MELANOMA-CELLS; INITIATING CELLS; GENE-EXPRESSION; HYPOXIA; DIFFERENTIATION; PROMOTES; OCT4; SUBPOPULATION; PLURIPOTENCY; GENERATION	There is enormous interest to target cancer stem cells (CSCs) for clinical treatment because these cells are highly tumorigenic and resistant to chemotherapy. Oct4 is expressed by CSC-like cells in different types of cancer. However, function of Oct4 in tumor cells is unclear. In this study, we showed that expression of Oct4 gene or transmembrane delivery of Oct4 protein promoted dedifferentiation of melanoma cells to CSC-like cells. The dedifferentiated melanoma cells showed significantly decreased expression of melanocytic markers and acquired the ability to form tumor spheroids. They showed markedly increased resistance to chemotherapeutic agents and hypoxic injury. In the subcutaneous xenograft and tail vein injection assays, these cells had significantly increased tumorigenic capacity. The dedifferentiated melanoma cells acquired features associated with CSCs such as multipotent differentiation capacity and expression of melanoma CSC markers such as ABCB5 and CD271. Mechanistically, Oct4-induced dedifferentiation was associated with increased expression of endogenous Oct4, Nanog and Klf4, and global gene expression changes that enriched for transcription factors. RNAi-mediated knockdown of Oct4 in dedifferentiated cells led to diminished CSC phenotypes. Oct4 expression in melanoma was regulated by hypoxia and its expression was detected in a sub-population of melanoma cells in clinical samples. Our data indicate that Oct4 is a positive regulator of tumor dedifferentiation. The results suggest that CSC phenotype is dynamic and may be acquired through dedifferentiation. Oct4-mediated tumor cell dedifferentiation may have an important role during tumor progression. Oncogene (2012) 31, 4898-4911; doi:10.1038/onc.2011.656; published online 30 January 2012	[Xu, X.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Lu, H.; Guo, W.] Univ Penn, Dept Biol, Philadelphia, PA 19104 USA; [Gimotty, P. A.; Guerra, M.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Xu, X (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, 3400 Spruce St, Philadelphia, PA 19104 USA.	xug@mail.med.upenn.edu	Gimotty, Phyllis/GWZ-4136-2022	Gimotty, Phyllis/0000-0002-3850-9799; Liu, Shujing/0000-0002-2958-093X; Zhang, Hongtao/0000-0001-9173-0049	National Institute of Health [AR-054593, CA-116103, CA-093372]; NATIONAL CANCER INSTITUTE [R21CA116103, P50CA093372] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR054593] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM085146] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr M Herlyn (The Wistar Institute) for providing the melanoma cell lines; Dr GQ Daley (Harvard) for providing shRNA to Oct4; Dr W Lee (University of Pennsylvania) for suggestions to manuscript editing. This work was supported by the grants AR-054593, CA-116103 and CA-093372 from National Institute of Health to XX.	Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; BENNETT DC, 1983, CELL, V34, P445, DOI 10.1016/0092-8674(83)90378-1; Boiko AD, 2010, NATURE, V466, P133, DOI 10.1038/nature09161; Chan EM, 2009, NAT BIOTECHNOL, V27, P1033, DOI 10.1038/nbt.1580; Chen YP, 2008, J BIOL CHEM, V283, P17969, DOI 10.1074/jbc.M802917200; Chen Z, 2009, J SURG ONCOL, V99, P414, DOI 10.1002/jso.21270; Covello KL, 2006, GENE DEV, V20, P557, DOI 10.1101/gad.1399906; Daley GQ, 2008, COLD SH Q B, V73, P171, DOI 10.1101/sqb.2008.73.041; GABBERT H, 1985, CLIN EXP METASTAS, V3, P257, DOI 10.1007/BF01585081; Hanna J, 2009, NATURE, V462, P595, DOI 10.1038/nature08592; Helczynska K, 2003, CANCER RES, V63, P1441; Hochedlinger K, 2005, CELL, V121, P465, DOI 10.1016/j.cell.2005.02.018; Hu L, 2010, BRIT J CANCER, V102, P1276, DOI 10.1038/sj.bjc.6605626; Hu TS, 2008, CANCER RES, V68, P6533, DOI 10.1158/0008-5472.CAN-07-6642; Jogi A, 2002, P NATL ACAD SCI USA, V99, P7021, DOI 10.1073/pnas.102660199; Kang SK, 2006, STEM CELLS DEV, V15, P423, DOI 10.1089/scd.2006.15.423; Kawamura T, 2009, NATURE, V460, P1140, DOI 10.1038/nature08311; Kim JB, 2009, NATURE, V461, P649, DOI 10.1038/nature08436; Kim JB, 2009, CELL, V136, P411, DOI 10.1016/j.cell.2009.01.023; Kumar SM, 2007, CANCER RES, V67, P3177, DOI 10.1158/0008-5472.CAN-06-3312; Li WL, 2009, STEM CELLS, V27, P2992, DOI 10.1002/stem.240; Li ZZ, 2010, CURR TOP MICROBIOL, V345, P21, DOI 10.1007/82_2010_75; Liu T, 2010, MOL CELL BIOCHEM, V340, P265, DOI 10.1007/s11010-010-0426-5; Lobo NA, 2007, ANNU REV CELL DEV BI, V23, P675, DOI 10.1146/annurev.cellbio.22.010305.104154; Magnifico A, 2009, CLIN CANCER RES, V15, P2010, DOI 10.1158/1078-0432.CCR-08-1327; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Masuda K, 2006, ONCOGENE, V25, P7740, DOI 10.1038/sj.onc.1209745; Monzani E, 2007, EUR J CANCER, V43, P935, DOI 10.1016/j.ejca.2007.01.017; Morrison SJ, 2000, J NEUROSCI, V20, P7370; Peng S, 2010, ONCOGENE, V29, P2153, DOI 10.1038/onc.2009.500; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Quintana E, 2010, CANCER CELL, V18, P510, DOI 10.1016/j.ccr.2010.10.012; Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020; Saigusa S, 2009, ANN SURG ONCOL, V16, P3488, DOI 10.1245/s10434-009-0617-z; Schatton T, 2008, NATURE, V451, P345, DOI 10.1038/nature06489; Schoenhals M, 2009, BIOCHEM BIOPH RES CO, V383, P157, DOI 10.1016/j.bbrc.2009.02.156; Strizzi L, 2008, CELL CYCLE, V7, P1931, DOI 10.4161/cc.7.13.6236; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Viswanathan SR, 2009, NAT GENET, V41, P843, DOI 10.1038/ng.392; Yu H, 2010, J INVEST DERMATOL, V130, P1227, DOI 10.1038/jid.2009.322; Yu JY, 2009, SCIENCE, V324, P797, DOI 10.1126/science.1172482; Zaehres H, 2005, STEM CELLS, V23, P299, DOI 10.1634/stemcells.2004-0252; Zhang XY, 2010, JPN J CLIN ONCOL, V40, P961, DOI 10.1093/jjco/hyq066; Zhou HY, 2009, CELL STEM CELL, V4, P381, DOI 10.1016/j.stem.2009.04.005	46	229	242	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	47					4898	4911		10.1038/onc.2011.656	http://dx.doi.org/10.1038/onc.2011.656			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041VU	22286766	Green Accepted			2022-12-17	WOS:000311430200002
J	Li, C; Iida, M; Dunn, EF; Ghia, AJ; Wheeler, DL				Li, C.; Iida, M.; Dunn, E. F.; Ghia, A. J.; Wheeler, D. L.			Nuclear EGFR contributes to acquired resistance to cetuximab	ONCOGENE			English	Article						EGFR; nuclear; cetuximab; resistance; src-family kinases; dasatinib	GROWTH-FACTOR RECEPTOR; DEPENDENT PROTEIN-KINASE; PROGNOSTIC VALUE; TYROSINE KINASE; IN-VIVO; CANCER; LOCALIZATION; ACTIVATION; MECHANISMS; EXPRESSION	Epidermal growth factor receptor (EGFR) is a ubiquitously expressed receptor tyrosine kinase involved in the etiology of several human cancers. Cetuximab is an EGFR-blocking antibody that has been approved for the treatment of patients with head and neck squamous cell carcinoma and metastatic colorectal cancer. Previous reports have shown that EGFR translocation to the nucleus is associated with cell proliferation. Here we investigated mechanisms of acquired resistance to cetuximab using a model derived from the non-small cell lung cancer line H226. We demonstrated that cetuximab-resistant cells overexpress HER family ligands including epidermal growth factor (EGF), amphiregulin, heparin-binding EGF and beta-cellulin. Overexpression of these ligands is associated with the nuclear translocation of the EGFR and this process was mediated by the Src family kinases (SFK). Treatment of cetuximab-resistant cells with the SFK inhibitor, dasatinib, resulted in loss of nuclear EGFR, increased membrane expression of the EGFR and resensitization to cetuximab. In addition, expression of a nuclear localization sequence-tagged EGFR in cetuximab-sensitive cells increased resistance to cetuximab both in vitro and in mouse xenografts. Collectively, these data suggest that nuclear expression of EGFR may be an important molecular determinant of resistance to cetuximab therapy and provides a rationale for investigating nuclear EGFR as a biomarker for cetuximab response. Further, these data suggest a rationale for the design of clinical trials that examine the value of treating patients with cetuximab-resistant tumors with inhibitors of SFKs in combination with cetuximab. Oncogene (2009) 28, 3801-3813; doi:10.1038/onc.2009.234; published online 17 August 2009	[Wheeler, D. L.] Univ Wisconsin, Dept Human Oncol, Ctr Comprehens Canc, Sch Med & Publ Hlth, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison	Wheeler, DL (corresponding author), Univ Wisconsin, Dept Human Oncol, Ctr Comprehens Canc, Sch Med & Publ Hlth, 600 Highland Ave K4-364 CSC, Madison, WI 53792 USA.	dlwheeler@wisc.edu	Li, Chunrong/F-6955-2011; Wheeler, Deric/B-7175-2013	Wheeler, Deric/0000-0001-5915-3675	NATIONAL CANCER INSTITUTE [P30CA014520] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA014520, P30 CA014520-30] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arteaga CL, 2003, J CLIN ONCOL, V21, p289S, DOI 10.1200/JCO.2003.10.523; Bandyopadhyay D, 1998, J BIOL CHEM, V273, P1568, DOI 10.1074/jbc.273.3.1568; Bianco R, 2005, ENDOCR-RELAT CANCER, V12, pS159, DOI 10.1677/erc.1.00999; Borrell-Pages M, 2003, EMBO J, V22, P1114, DOI 10.1093/emboj/cdg111; Camp ER, 2005, CLIN CANCER RES, V11, P397; CAO H, 1995, ENDOCRINOLOGY, V136, P3163, DOI 10.1210/en.136.7.3163; Dittmann K, 2005, J BIOL CHEM, V280, P31182, DOI 10.1074/jbc.M506591200; Friedmann BJ, 2006, MOL CANCER THER, V5, P209, DOI 10.1158/1535-7163.MCT-05-0239; Giri DK, 2005, MOL CELL BIOL, V25, P11005, DOI 10.1128/MCB.25.24.11005-11018.2005; Gupta AK, 2002, CLIN CANCER RES, V8, P885; Hanada N, 2006, MOL CARCINOGEN, V45, P10, DOI 10.1002/mc.20147; Hsu SC, 2007, J BIOL CHEM, V282, P10432, DOI 10.1074/jbc.M610014200; Hung LY, 2008, NUCLEIC ACIDS RES, V36, P4337, DOI 10.1093/nar/gkn417; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Liao HJ, 2007, MOL BIOL CELL, V18, P1064, DOI 10.1091/mbc.E06-09-0802; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Lo HW, 2006, J CELL BIOCHEM, V98, P1570, DOI 10.1002/jcb.20876; Lo HW, 2006, BRIT J CANCER, V94, P184, DOI 10.1038/sj.bjc.6602941; Lo HW, 2006, BREAST CANCER RES TR, V95, P211, DOI 10.1007/s10549-005-9011-0; Lo HW, 2005, CANCER CELL, V7, P575, DOI 10.1016/j.ccr.2005.05.007; Lo HW, 2005, CANCER RES, V65, P338; Lu Y, 2007, CANCER RES, V67, P8240, DOI 10.1158/0008-5472.CAN-07-0589; MARTI U, 1991, HEPATOLOGY, V13, P15, DOI 10.1016/0270-9139(91)90210-M; Massie C, 2006, NAT REV CANCER, V6, P403, DOI 10.1038/nrc1882; Mukohara T, 2005, JNCI-J NATL CANCER I, V97, P1185, DOI 10.1093/jnci/dji238; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Offterdinger M, 2002, J CELL BIOL, V157, P929, DOI 10.1083/jcb.200109033; Pao W, 2005, PLOS MED, V2, P57, DOI 10.1371/journal.pmed.0020017; Psyrri A, 2005, CLIN CANCER RES, V11, P5856, DOI 10.1158/1078-0432.CCR-05-0420; Psyrri A, 2008, CANCER EPIDEM BIOMAR, V17, P1486, DOI 10.1158/1055-9965.EPI-07-2684; Rajput A, 2007, CANCER RES, V67, P665, DOI 10.1158/0008-5472.CAN-06-2773; Ritter CA, 2007, CLIN CANCER RES, V13, P4909, DOI 10.1158/1078-0432.CCR-07-0701; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Viloria-Petit A, 2001, CANCER RES, V61, P5090; Viloria-Petit AM, 2004, INT J RADIAT ONCOL, V58, P914, DOI 10.1016/j.ijrobp.2003.09.091; Wang SC, 2004, CANCER CELL, V6, P251, DOI 10.1016/j.ccr.2004.07.012; Wang SC, 2006, NAT CELL BIOL, V8, P1359, DOI 10.1038/ncb1501; Wheeler DL, 2008, ONCOGENE, V27, P3944, DOI 10.1038/onc.2008.19; Wheeler DL, 2009, CANCER BIOL THER, V8, P696, DOI 10.4161/cbt.8.8.7903; Xia WY, 2009, MOL CARCINOGEN, V48, P610, DOI 10.1002/mc.20504; XIE YM, 1994, BIOCHEM BIOPH RES CO, V203, P1589, DOI 10.1006/bbrc.1994.2368; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	42	229	237	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2009	28	43					3801	3813		10.1038/onc.2009.234	http://dx.doi.org/10.1038/onc.2009.234			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512KT	19684613	Green Accepted, Bronze			2022-12-17	WOS:000271248400004
J	Pollock, PM; Gartside, MG; Dejeza, LC; Powell, MA; Mallon, MA; Davies, H; Mohammadi, M; Futreal, PA; Stratton, MR; Trent, JM; Goodfellow, PJ				Pollock, P. M.; Gartside, M. G.; Dejeza, L. C.; Powell, M. A.; Mallon, M. A.; Davies, H.; Mohammadi, M.; Futreal, P. A.; Stratton, M. R.; Trent, J. M.; Goodfellow, P. J.			Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes	ONCOGENE			English	Article						endometrial cancer; mutation; FGFR2; apert; syndrome	FIBROBLAST-GROWTH-FACTOR; FACTOR RECEPTOR-3; STRUCTURAL BASIS; SPLICE SITES; EXPRESSION; CANCER; SPECIFICITY	Endometrial carcinoma is the most common gynecological malignancy in the United States. Although most women present with early disease confined to the uterus, the majority of persistent or recurrent tumors are refractory to current chemotherapies. We have identified a total of 11 different FGFR2 mutations in 3/10 ( 30%) of endometrial cell lines and 19/187 ( 10%) of primary uterine tumors. Mutations were seen primarily in tumors of the endometrioid histologic subtype ( 18/115 cases investigated, 16%). The majority of the somatic mutations identified were identical to germline activating mutations in FGFR2 and FGFR3 that cause Apert Syndrome, Beare-Stevenson Syndrome, hypochondroplasia, achondroplasia and SADDAN syndrome. The two most common somatic mutations identified were S252W ( in eight tumors) and N550K ( in five samples). Four novel mutations were identified, three of which are also likely to result in receptor gain-of-function. Extensive functional analyses have already been performed on many of these mutations, demonstrating they result in receptor activation through a variety of mechanisms. The discovery of activating FGFR2 mutations in endometrial carcinoma raises the possibility of employing anti-FGFR molecularly targeted therapies in patients with advanced or recurrent endometrial carcinoma.	Translat Genom Res Inst, Canc & Cell Biol Div, Phoenix, AZ 85004 USA; Translat Genom Res Inst, DNA Sequencing Ctr, Pharmaceut Genom Div, Phoenix, AZ 85004 USA; Washington Univ, Sch Med, Dept Obstet & Gynecol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; NYU, Sch Med, Dept Pharmacol, New York, NY USA; Translat Genom Res Inst, Genet Basis Human Dis Div, Phoenix, AZ 85004 USA	Translational Genomics Research Institute; Translational Genomics Research Institute; Washington University (WUSTL); Washington University (WUSTL); New York University; Translational Genomics Research Institute	Pollock, PM (corresponding author), Translat Genom Res Inst, Canc & Cell Biol Div, 445 N 5th St, Phoenix, AZ 85004 USA.	ppollock@tgen.org	kasaei, fahime/T-7197-2018; Mohammadi, Moosa/ABA-6745-2020	Mohammadi, Moosa/0000-0003-2434-9437; Pollock, Pamela/0000-0001-8420-1026	NATIONAL CANCER INSTITUTE [R01CA071754, P30CA091842, R01CA109544] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA109544, P30 CA091842, CA091842, R01 CA071754, R01 CA71754] Funding Source: Medline; Wellcome Trust [077012] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Wellcome Trust(Wellcome TrustEuropean Commission)		Burgar HR, 2002, J BIOL CHEM, V277, P4018, DOI 10.1074/jbc.M107785200; Burset M, 2000, NUCLEIC ACIDS RES, V28, P4364, DOI 10.1093/nar/28.21.4364; Cho JY, 2004, P NATL ACAD SCI USA, V101, P609, DOI 10.1073/pnas.2237184100; Chong A, 2004, GENOMICS, V84, P762, DOI 10.1016/j.ygeno.2004.05.007; GOLD LI, 1994, CANCER RES, V54, P2347; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Ibrahimi OA, 2004, HUM MOL GENET, V13, P2313, DOI 10.1093/hmg/ddh235; Ibrahimi OA, 2001, P NATL ACAD SCI USA, V98, P7182, DOI 10.1073/pnas.121183798; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Mohammadi M, 2005, CYTOKINE GROWTH F R, V16, P107, DOI 10.1016/j.cytogfr.2005.01.008; Moller B, 2001, MOL HUM REPROD, V7, P65, DOI 10.1093/molehr/7.1.65; Monsonego-Ornan E, 2000, MOL CELL BIOL, V20, P516, DOI 10.1128/MCB.20.2.516-522.2000; Obel Jennifer C, 2006, Clin Adv Hematol Oncol, V4, P459; Ornitz DM, 2001, GENOME BIOL, V2; Passos-Bueno MR, 1999, HUM MUTAT, V14, P115; Sangha RK, 1997, LAB INVEST, V77, P389; Tsai SJ, 2002, ENDOCRINOLOGY, V143, P2715, DOI 10.1210/en.143.7.2715; van Rhijn BWG, 2001, CANCER RES, V61, P1265; Wilkie AOM, 2005, CYTOKINE GROWTH F R, V16, P187, DOI 10.1016/j.cytogfr.2005.03.001; Wilkie AOM, 2002, AM J MED GENET, V112, P266, DOI 10.1002/ajmg.10775; Yu K, 2000, P NATL ACAD SCI USA, V97, P14536, DOI 10.1073/pnas.97.26.14536; Zhang XQ, 2006, J BIOL CHEM, V281, P15694, DOI 10.1074/jbc.M601252200	22	229	279	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2007	26	50					7158	7162		10.1038/sj.onc.1210529	http://dx.doi.org/10.1038/sj.onc.1210529			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228GF	17525745	Green Accepted			2022-12-17	WOS:000250715000010
J	Chendil, D; Ranga, RS; Meigooni, D; Sathishkumar, S; Ahmed, MM				Chendil, D; Ranga, RS; Meigooni, D; Sathishkumar, S; Ahmed, MM			Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3	ONCOGENE			English	Article						prostate; curcumin; radiation; TNF-alpha; NF kappa B; Bcl-2; apoptosis	NF-KAPPA-B; CHEMOPREVENTIVE AGENT; CYCLE PROGRESSION; GENE-EXPRESSION; APOPTOSIS; ACTIVATION; BCL-2; PROLIFERATION; INHIBITION; INDUCTION	Curcumin (Diferuloylmethane) is a major chemical component of turmeric (curcuma longa) and is used as a spice to give a specific flavor and yellow color in Asian food. Curcumin exhibits growth inhibitory effects in a broad range of tumors as well as in TPA-induced skin tumors in mice. This study was undertaken to investigate the radiosensitizing effects of curcumin in p53 mutant prostate cancer cell line PC-3. Compared to cells that were irradiated alone (SF2=0.635; D-0=231 cGy), curcumin at 2 and 4 muM concentrations in combination with radiation showed significant enhancement to radiation-induced clonogenic inhibition (SF2=0.224: D-0=97 cGy and SF2=0.080: D-0=38 cGy) and apoptosis. It has been reported that curcumin inhibits TNF-alpha-induced NFkappaB activity that is essential for Bcl-2 protein induction. In PC-3 cells, radiation upregulated TNF-alpha protein leading to an increase in NFkappaB activity resulting in the induction of Bcl-2 protein. However, curcumin in combination with radiation treated showed inhibition of TNF-alpha-mediated NFkappaB activity resulting in bcl-2 protein downregulation. Bax protein levels remained constant in these cells after radiation or curcumin plus radiation treatments. However, the downregulation of Bcl-2 and no changes in Bax protein levels in curcumin plus radiation-treated PC-3 cells, together, altered the Bcl2:Bax ratio and this caused the enhanced radiosensitization effect. In addition, significant activation of cytochrome c and caspase-9 and -3 were observed in curcumin plus radiation treatments. Together, these mechanisms strongly suggest that the natural compound curcumin is a potent radio-sesitizer, and it acts by overcoming the effects of radiation-induced prosurvival gene expression in prostate cancer.	Univ Kentucky, Coll Hlth Sci, Div Clin Hlth Sci, Dept Clin Sci, Lexington, KY 40536 USA; Univ Kentucky, Dept Radiat Med, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Chendil, D (corresponding author), Univ Kentucky, Coll Hlth Sci, Div Clin Hlth Sci, Dept Clin Sci, Room 209D,900 S Limestone St, Lexington, KY 40536 USA.	dchen2@uky.edu	Ahmed, Mansoor/AAK-5988-2020					Ahmed MM, 1996, J BIOL CHEM, V271, P29231, DOI 10.1074/jbc.271.46.29231; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bhaumik S, 1999, FEBS LETT, V456, P311, DOI 10.1016/S0014-5793(99)00969-2; Bierhaus A, 1997, THROMB HAEMOSTASIS, V77, P772; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; Chen H, 1999, ANTICANCER RES, V19, P3675; Chen HW, 1998, BRIT J PHARMACOL, V124, P1029, DOI 10.1038/sj.bjp.0701914; Chendil D, 2002, CANCER BIOL THER, V1, P152, DOI 10.4161/cbt.61; Cheng AL, 2001, ANTICANCER RES, V21, P2895; Dixon EP, 1997, BRAIN RES, V776, P222, DOI 10.1016/S0006-8993(97)01040-8; DONG ZG, 1995, CARCINOGENESIS, V16, P749, DOI 10.1093/carcin/16.4.749; Dorai T, 2001, PROSTATE, V47, P293, DOI 10.1002/pros.1074; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; HALLAHAN DE, 1989, P NATL ACAD SCI USA, V86, P10104, DOI 10.1073/pnas.86.24.10104; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Huang MT, 1998, CARCINOGENESIS, V19, P1697, DOI 10.1093/carcin/19.9.1697; HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292; Inayat MS, 2002, CANCER BIOL THER, V1, P539, DOI 10.4161/cbt.1.5.174; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Jee SH, 1998, J INVEST DERMATOL, V111, P656, DOI 10.1046/j.1523-1747.1998.00352.x; Jiang MC, 1996, NUTR CANCER, V26, P111, DOI 10.1080/01635589609514468; Jobin C, 1999, J IMMUNOL, V163, P3474; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Khar A, 1999, FEBS LETT, V445, P165, DOI 10.1016/S0014-5793(99)00114-3; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuo ML, 1996, BBA-MOL BASIS DIS, V1317, P95, DOI 10.1016/S0925-4439(96)00032-4; Mehta K, 1997, ANTI-CANCER DRUG, V8, P470, DOI 10.1097/00001813-199706000-00010; Mohandas K M, 1999, Indian J Gastroenterol, V18, P118; Mow BMF, 2001, CURR OPIN ONCOL, V13, P453, DOI 10.1097/00001622-200111000-00007; Mukhopadhyay A, 2001, ONCOGENE, V20, P7597, DOI 10.1038/sj.onc.1204997; Ohta T, 1997, J BIOL CHEM, V272, P23111, DOI 10.1074/jbc.272.37.23111; Piwocka K, 1999, EXP CELL RES, V249, P299, DOI 10.1006/excr.1999.4480; Plummer SM, 1999, ONCOGENE, V18, P6013, DOI 10.1038/sj.onc.1202980; RAO CV, 1995, CANCER RES, V55, P2310; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHARMA OP, 1976, BIOCHEM PHARMACOL, V25, P1811, DOI 10.1016/0006-2952(76)90421-4; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Sikora E, 1997, BIOCHEM PHARMACOL, V54, P899, DOI 10.1016/S0006-2952(97)00251-7; Singh AK, 1996, CANCER LETT, V107, P109, DOI 10.1016/0304-3835(96)04357-1; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wilkinson S, 2002, J UROLOGY, V168, P2505, DOI 10.1016/S0022-5347(05)64178-X	48	229	245	0	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2004	23	8					1599	1607		10.1038/sj.onc.1207284	http://dx.doi.org/10.1038/sj.onc.1207284			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14985701				2022-12-17	WOS:000189219500014
J	Han, SH; Jeon, JH; Ju, HR; Jung, U; Kim, KY; Sook, H; Yoo, HS; Lee, YH; Song, KS; Hwang, HM; Na, YS; Yang, Y; Lee, KN; Choi, I				Han, SH; Jeon, JH; Ju, HR; Jung, U; Kim, KY; Sook, H; Yoo, HS; Lee, YH; Song, KS; Hwang, HM; Na, YS; Yang, Y; Lee, KN; Choi, I			VDUP1 upregulated by TGF-beta 1 and 1,25-dihydorxyvitamin D-3 inhibits tumor cell growth by blocking cell-cycle progression	ONCOGENE			English	Article						VDUP1; tumor; TGF-beta 1; cell cycle; PLZF	ACUTE PROMYELOCYTIC LEUKEMIA; ZINC-FINGER PROTEIN; PML-RAR-ALPHA; HISTONE DEACETYLASE; MONOCYTIC DIFFERENTIATION; THIOREDOXIN FUNCTION; HL-60 CELLS; GENE; PLZF; EXPRESSION	Vitamin D-3 upregulated protein 1 (VDUP1) is a 1,25-dihydroxyvitamin D-3 (1,25(OH)(2)D-3) upregulated protein, and it is induced by various stresses. In human tumor tissues, VDUP1 expression was downregulated. Upon stimulation by growth-inhibitory signals such as TGF-beta1 and 1,25(OH)(2)D-3, its expression was rapidly upregulated as the cell growth was retarded. The transfection of VDUP1 in tumor cells reduced cell growth. The VDUP1 expression was also increased when the cell-cycle progression was arrested. Transfection of VDUP1 induced cell-cycle arrest at the G0/G1 phase, indicating that VDUP1 possesses a tumor-suppressive activity. In addition, it was found that VDUP1 interacted with promyelocytic leukemia zinc-finger, Fanconi anemia zinc-finger, and histone deacetylase 1, which are known to be transcriptional corepressors. VDUP1 itself suppressed IL-3 receptor and cyclin A2 promoter activity. Taken together, these results suggest that VDUP1 is a novel antitumor gene which forms a transcriptional repressor complex.	Korea Res Inst Biosci & Biotechnol, Immunol Lab, Taejon 305333, South Korea; Korea Res Inst Biosci & Biotechnol, Genome Res Ctr, Taejon 305333, South Korea; Chungnam Natl Univ, Coll Med, Dept Pathol, Dept Anat, Taejon 301131, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea Research Institute of Bioscience & Biotechnology (KRIBB); Chungnam National University	Choi, I (corresponding author), Korea Res Inst Biosci & Biotechnol, Immunol Lab, Taejon 305333, South Korea.			Yang, Young/0000-0003-4239-0804				BANERJEE D, 1995, CELL GROWTH DIFFER, V6, P1405; Bocchia M, 1997, LEUKEMIA RES, V21, P439, DOI 10.1016/S0145-2126(96)00085-9; Butler LM, 2002, P NATL ACAD SCI USA, V99, P11700, DOI 10.1073/pnas.182372299; CHEN KS, 1994, BBA-GENE STRUCT EXPR, V1219, P26, DOI 10.1016/0167-4781(94)90242-9; Corn PG, 2002, BIOESSAYS, V24, P83, DOI 10.1002/bies.10036; Costoya JA, 2001, CURR OPIN HEMATOL, V8, P212, DOI 10.1097/00062752-200107000-00006; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; Hoatlin ME, 1999, BLOOD, V94, P3737, DOI 10.1182/blood.V94.11.3737.423k39_3737_3747; Junn E, 2000, J IMMUNOL, V164, P6287, DOI 10.4049/jimmunol.164.12.6287; Kirshenbaum LA, 2001, CIRC RES, V88, P978, DOI 10.1161/hh1001.091865; Kramer OH, 2001, TRENDS ENDOCRIN MET, V12, P294, DOI 10.1016/S1043-2760(01)00438-6; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Ludwig DL, 2001, GENE, V269, P103, DOI 10.1016/S0378-1119(01)00455-3; Melnick A, 2000, BLOOD, V96, P3939, DOI 10.1182/blood.V96.12.3939.h8003939_3939_3947; Melnick A, 2002, MOL CELL BIOL, V22, P1804, DOI 10.1128/MCB.22.6.1804-1818.2002; Muller C, 2000, BLOOD, V96, P3894, DOI 10.1182/blood.V96.12.3894.h8003894_3894_3899; Nishiyama A, 1999, J BIOL CHEM, V274, P21645, DOI 10.1074/jbc.274.31.21645; Olsson I, 1996, EUR J HAEMATOL, V57, P1; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Piazza F, 2001, ONCOGENE, V20, P7216, DOI 10.1038/sj.onc.1204855; Piek JMJ, 2001, HISTOPATHOLOGY, V38, P481, DOI 10.1046/j.1365-2559.2001.1163c.x; Rego EM, 2000, P NATL ACAD SCI USA, V97, P10173, DOI 10.1073/pnas.180290497; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Sainty D, 2000, BLOOD, V96, P1287; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Sherr CJ, 2000, CANCER RES, V60, P3689; Takahashi Y, 2002, ONCOL REP, V9, P75; Taplick J, 2001, J MOL BIOL, V308, P27, DOI 10.1006/jmbi.2001.4569; Wang CG, 2001, FRONT BIOSCI-LANDMRK, V6, pD610, DOI 10.2741/1wang1; Wang XN, 2001, J CELL BIOCHEM, V80, P471, DOI 10.1002/1097-4644(20010315)80:4<471::AID-JCB1001>3.0.CO;2-J; Wang YL, 2002, J BIOL CHEM, V277, P26496, DOI 10.1074/jbc.M202133200; Ward JO, 2001, BLOOD, V98, P3290, DOI 10.1182/blood.V98.12.3290; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Yang XQ, 1998, BREAST CANCER RES TR, V48, P33, DOI 10.1023/A:1005929714900; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375; Zheng L, 2001, EXP CELL RES, V264, P2, DOI 10.1006/excr.2000.5129	37	229	241	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 26	2003	22	26					4035	4046		10.1038/sj.onc.1206610	http://dx.doi.org/10.1038/sj.onc.1206610			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821938				2022-12-17	WOS:000183707600007
J	Engels, IH; Stepczynska, A; Stroh, C; Lauber, K; Berg, C; Schwenzer, R; Wajant, H; Janicke, RUU; Porter, AG; Belka, C; Gregor, M; Schulze-Osthoff, K; Wesselborg, S				Engels, IH; Stepczynska, A; Stroh, C; Lauber, K; Berg, C; Schwenzer, R; Wajant, H; Janicke, RUU; Porter, AG; Belka, C; Gregor, M; Schulze-Osthoff, K; Wesselborg, S			Caspase-8/FLICE functions as an executioner caspase in anticancer drug-induced apoptosis	ONCOGENE			English	Article						anticancer drugs; apoptosis; caspase-8; caspase-9; CD95	APO-1/FAS RECEPTOR/LIGAND SYSTEM; CYTOCHROME-C RELEASE; DEATH RECEPTORS; NEUROBLASTOMA-CELLS; MEDIATED APOPTOSIS; LEUKEMIA-CELLS; WILD-TYPE; ACTIVATION; BCL-2; MITOCHONDRIA	Caspase-8 plays an essential role in apoptosis triggered by death receptors, Through the cleavage of Bid, a proapoptotic Bcl-2 member, it further activates the mitochondrial cytochrome c/Apaf-1 pathway. Because caspase-8 can be processed also by anticancer drugs independently of death receptors, we investigated its exact role and order in the caspase cascade. We show that in Jurkat cells either deficient for caspase-8 or overexpressing its inhibitor c-FLIP apoptosis mediated by CD95, but not by anticancer drugs was inhibited. In the absence of active caspase-8, anticancer drugs still induced the processing of caspase-9, -3 and Bid, indicating that Bid cleavage does not require caspase-8, Overexpression of Bcl-x(L) prevented the processing of caspase-8 as well as caspase-9, -6 and Bid in response to drugs, but was less effective in CD95-induced apoptosis, Similar responses were observed by overexpression of a dominant-negative caspase-9 mutant, To further determine the order of caspase-8 activation, we employed MCF7 cells lacking caspase-3, In contrast to caspase-9 that was cleaved in these cells, anticancer drugs induced caspase-8 activation only in caspase-3 transfected MCF7 cells. Thus, our data indicate that, unlike its proximal role in receptor signaling, in the mitochondrial pathway caspase-8 rather functions as an amplifying executioner caspase.	Univ Tubingen, Dept Internal Med 1, D-72076 Tubingen, Germany; Univ Munster, Dept Immunol & Cell Biol, D-4400 Munster, Germany; Univ Stuttgart, Inst Cell Biol & Immunol, D-7000 Stuttgart, Germany; Univ Tubingen, Dept Radiat & Oncol, D-72074 Tubingen, Germany	Eberhard Karls University of Tubingen; University of Munster; University of Stuttgart; Eberhard Karls University of Tubingen	Wesselborg, S (corresponding author), Univ Tubingen, Dept Internal Med 1, Otfried Muller Str 10, D-72076 Tubingen, Germany.		Wajant, Harald/A-3020-2017; Schulze-Osthoff, Klaus/N-9025-2013	Wajant, Harald/0000-0002-2005-3949; Schulze-Osthoff, Klaus/0000-0003-1443-2720; Wesselborg, Sebastian/0000-0002-5236-942X				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Bantel H, 1999, CANCER RES, V59, P2083; Belka C, 1999, ONCOGENE, V18, P4983, DOI 10.1038/sj.onc.1202878; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Day CL, 1999, CELL DEATH DIFFER, V6, P1125, DOI 10.1038/sj.cdd.4400584; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fulda S, 1997, CANCER RES, V57, P4956; Fulda S, 1998, CANCER RES, V58, P4453; Fulda S, 1997, CANCER RES, V57, P3823; Gamen S, 1997, FEBS LETT, V417, P360, DOI 10.1016/S0014-5793(97)01282-9; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Han JH, 1998, MOL CELL BIOL, V18, P6052, DOI 10.1128/MCB.18.10.6052; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kataoka T, 1998, J IMMUNOL, V161, P3936; Kawahara A, 1998, ONCOGENE, V17, P2549, DOI 10.1038/sj.onc.1202192; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; Moriishi K, 1999, P NATL ACAD SCI USA, V96, P9683, DOI 10.1073/pnas.96.17.9683; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Qin HX, 1999, NATURE, V399, P549, DOI 10.1038/21124; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Stroh C, 1998, CELL DEATH DIFFER, V5, P997, DOI 10.1038/sj.cdd.4400451; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tolomeo M, 1998, CELL DEATH DIFFER, V5, P735, DOI 10.1038/sj.cdd.4400406; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Villunger A, 1997, CANCER RES, V57, P3331; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	58	229	234	3	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2000	19	40					4563	4573		10.1038/sj.onc.1203824	http://dx.doi.org/10.1038/sj.onc.1203824			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	356HQ	11030145				2022-12-17	WOS:000089438200002
J	Fang, XJ; Yu, SX; Eder, A; Mao, ML; Bast, RC; Boyd, D; Mills, GB				Fang, XJ; Yu, SX; Eder, A; Mao, ML; Bast, RC; Boyd, D; Mills, GB			Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway	ONCOGENE			English	Article						BAD; MAPK; Ras; Akt; phosphorylation; apoptosis	GROWTH-FACTOR-I; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNALING PATHWAY; AKT; SURVIVAL; APOPTOSIS; INSULIN; DEATH; TRANSFORMATION; EXPRESSION	The function of the pro-apoptotic molecule BAD is regulated by phosphorylation of two sites, serine-112 (Ser-112) and serine-136 (Ser-136), Phosphorylation at either site results in loss of the ability of BAD to heterodimerize with the survival proteins BCL-X-L or BCL-2, Phosphorylated BAD binds to 14-3-3 and is sequestered in the cytoplasm, It has been shown that phosphorylation of BAD at Ser-136 is mediated by the serine/threonine protein kinase Akt-1/PKB which is downstream of phosphatidylinositol 3-kinase (PI3K), The signaling process leading to phosphorylation of BAD at Ser-112 has not been identified. In this study, we show that phosphorylation of the two serine residues of BAD is differentially regulated. While Ser-136 phosphorylation is concordant with activation of Akt, Ser-112. phosphorylation does not correlate with Akt activation. Instead, we demonstrate that activated Ras and Raf, which are upstream of mitogen-activated protein kinases (MAPK), stimulate selective phosphorylation of BAD at Ser-112, Furthermore, phosphorylation of Ser-112, but not Ser-136 requires activation of the MAPK pathway as the MEK inhibitor, PD 98059, blocks EGF-, as web as activated Ras- or Raf-mediated phosphorylation of BAD at Ser-112, Therefore, the PI3K-Akt and Ras-MAPK pathways converge at BAD by mediating phosphorylation of distinct serine residues.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Clin Invest, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Mills, GB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Oncol, Box 317,1515 Holcombe Blvd, Houston, TX 77030 USA.		Bast, Robert C/E-6585-2011	Bast, Robert C/0000-0003-4621-8462	NATIONAL CANCER INSTITUTE [P01CA064602] Funding Source: NIH RePORTER; NCI NIH HHS [CA 64602] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Craddock BL, 1999, J BIOL CHEM, V274, P10633, DOI 10.1074/jbc.274.15.10633; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FANG XJ, 1992, CANCER RES, V52, P173; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; Parrizas M, 1997, J BIOL CHEM, V272, P154; Patton SE, 1998, CANCER RES, V58, P2253; Salomoni P, 1998, J EXP MED, V187, P1995, DOI 10.1084/jem.187.12.1995; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; SOUTHERLAND C, 1993, BIOCHEM J, V296, P15; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	31	229	233	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6635	6640		10.1038/sj.onc.1203076	http://dx.doi.org/10.1038/sj.onc.1203076			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597268				2022-12-17	WOS:000083792000002
J	Kim, YB; Lee, KH; Sugita, K; Yoshida, M; Horinouchi, S				Kim, YB; Lee, KH; Sugita, K; Yoshida, M; Horinouchi, S			Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase	ONCOGENE			English	Article						histone acetylation; cell cycle; p21(WAF1/cip1); antitumor	CHROMOBACTERIUM-VIOLACEUM NO-968; TRICHOSTATIN-A; TRANSCRIPTIONAL REPRESSION; MORPHOLOGICAL TRANSFORMATION; GELSOLIN EXPRESSION; CHROMATIN STRUCTURE; SODIUM-BUTYRATE; CARCINOMA CELL; NIH3T3 CELLS; ACETYLTRANSFERASE	Oxamflatin [(2E)-5-[3-](phenylsufonyl)amino]phenyl]pent-2-en-4-ynohydroxamic acid] induces transcriptional activation of junD and morphological reversion in various NIH3T3-dtrived transformed cell lines. We found that oxamflatin showed in vitro antiproliferative activity against various mouse and human tumor cell lines with drastic changes in the cell morphology and in vivo antitumor activity against B16 melanoma, Oxamflatin caused an elongated cell shape with filamentous protrusions as well as arrest of the cell cycle at the G1 phase in HeLa cells, These phenotypic changes of HeLa cells were apparently similar to those by trichostatin A (TSA), a specific inhibitor of histone deacetylase (HDAC), The effect of oxamflatin on the transcriptional activity of the cytomegalovirus (CMV) promoter was examined and compared with known HDAC inhibitors, TSA, sodium n-butyrate, and FR901228, Oxamflatin as well as all these inhibitors greatly enhanced the transcriptional activity of the CMV promoter in a dose-dependent manner. Oxamflatin, like TSA, inhibited intracellular HDAC activity, as a result of which marked amounts of acetylated histone species accumulated. Finally, effects on expression of several endogenous genes in,oh td in cell morphology and cell cycle control in HeLa cells were analysed. Expression of gelsolin, cyclin E and Cdk inhibitors including p21(WAF1/Cip1) was highly augmented, while that of cyclin A and cyclin D1 was decreased by oxamflatin. These results suggest that changes in the expression pattern of the genes regulating cell morphology and the cell cycle due to histone hyperacetylation are responsible for the antitumor activity, the morphological change and the cell cycle arrest induced by oxamflatin.	Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 113, Japan; Shionogi & Co Ltd, Shionogi Res Labs, Hukushima Ku, Osaka 533, Japan	University of Tokyo; Shionogi & Company Limited	Yoshida, M (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Yayoi 1-1-1, Tokyo 113, Japan.		Yoshida, Minoru/C-8049-2014	Yoshida, Minoru/0000-0002-4376-5674				AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; CHAPONNIER C, 1989, AM J PATHOL, V134, P597; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; Chen WY, 1997, P NATL ACAD SCI USA, V94, P5798, DOI 10.1073/pnas.94.11.5798; COUSENS LS, 1979, J BIOL CHEM, V254, P1716; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; Dion LD, 1997, VIROLOGY, V231, P201, DOI 10.1006/viro.1997.8538; FALLON RJ, 1979, J CELL PHYSIOL, V100, P251, DOI 10.1002/jcp.1041000206; FUTAMURA M, 1995, ONCOGENE, V10, P1119; GOLBERG YP, 1992, J CELL BIOCHEM, V49, P74; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; HOSHIKAWA Y, 1994, EXP CELL RES, V214, P189, DOI 10.1006/excr.1994.1248; INAGAKI M, 1985, J BIOL CHEM, V260, P2922; INOUE A, 1970, BIOCHIM BIOPHYS ACTA, V220, P307, DOI 10.1016/0005-2744(70)90015-X; ITAZAKI H, 1990, J ANTIBIOT, V43, P1524, DOI 10.7164/antibiotics.43.1524; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Khochbin S, 1997, FEBS LETT, V419, P157, DOI 10.1016/S0014-5793(97)01423-3; KIJIMA M, 1993, J BIOL CHEM, V268, P22429; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kwon HJ, 1998, P NATL ACAD SCI USA, V95, P3356, DOI 10.1073/pnas.95.7.3356; Kwon HJ, 1997, ONCOGENE, V15, P2625, DOI 10.1038/sj.onc.1201443; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; MORIYA S, 1994, INT J ONCOL, V5, P1347; MORIYA S, 1996, CELL, V87, P1261; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MULLAUER L, 1993, ONCOGENE, V8, P2531; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nakajima H, 1998, EXP CELL RES, V241, P126, DOI 10.1006/excr.1998.4027; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NOGUCHI PD, 1978, J HISTOCHEM CYTOCHEM, V26, P761, DOI 10.1177/26.9.361885; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; PORTER RM, 1993, J PATHOL, V170, P435, DOI 10.1002/path.1711700406; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Siddique H, 1998, ONCOGENE, V16, P2283, DOI 10.1038/sj.onc.1202003; Sonoda H, 1996, ONCOGENE, V13, P143; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; SUGITA K, 1992, CANCER RES, V52, P168; Supuran CT, 1997, J ENZYM INHIB, V12, P175, DOI 10.3109/14756369709029313; Tamura Y, 1998, J MED CHEM, V41, P640, DOI 10.1021/jm9707582; TANAKA J, 1991, VIROLOGY, V185, P271, DOI 10.1016/0042-6822(91)90774-6; TANAKA M, 1995, CANCER RES, V55, P3228; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; UEDA H, 1994, J ANTIBIOT, V47, P301; VANDEKERCKHOVE J, 1990, J CELL BIOL, V111, P95, DOI 10.1083/jcb.111.1.95; VanLint C, 1996, GENE EXPRESSION, V5, P245; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YOSHIDA M, 1988, EXP CELL RES, V177, P122, DOI 10.1016/0014-4827(88)90030-4; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510	64	229	261	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	1999	18	15					2461	2470		10.1038/sj.onc.1202564	http://dx.doi.org/10.1038/sj.onc.1202564			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AC	10229197				2022-12-17	WOS:000079703300006
J	Kumar, CC				Kumar, CC			Signaling by integrin receptors	ONCOGENE			English	Review						integrins; cell adhesion; cell survival; focal adhesion complexes	FOCAL ADHESION KINASE; CELL-CYCLE PROGRESSION; ACTIN STRESS FIBERS; PHOSPHATIDYLINOSITOL 4-PHOSPHATE 5-KINASE; ACTIVATED PROTEIN-KINASE; SRC FAMILY KINASES; SMALL GTPASE-RHO; EXTRACELLULAR-MATRIX; MEDIATED ACTIVATION; AKT PROTOONCOGENE	Adhesive interactions are critical for the proliferation, survival and function of all cells. Integrin receptors as the major family of adhesion receptors have been the focus of study for more than a decade. These studies have tremendously enhanced our understanding of the integrin-mediated adhesive interactions and have unraveled novel integrin functions in cell survival mechanisms and in the activation of divergent signaling pathways. The signals from integrin receptors are integrated from those originating from growth factor receptors in order to organize the cytoskeleton, stimulate cell proliferation and rescue cells from matrix detachment-induced programmed cell death. These functions are critical in the regulation of multiple processes such as tissue development, inflammation, angiogenesis, tumor cell growth and metastasis and programmed cell death.	Schering Plough Res Inst, Dept Tumor Biol, Kenilworth, NJ 07033 USA	Merck & Company; Schering-Plough Research Institute	Kumar, CC (corresponding author), Schering Plough Res Inst, Dept Tumor Biol, 2015,Galloping Hill Rd, Kenilworth, NJ 07033 USA.							Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; BATES RC, 1994, J CELL BIOL, V125, P403, DOI 10.1083/jcb.125.2.403; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Brown MC, 1996, J CELL BIOL, V135, P1109, DOI 10.1083/jcb.135.4.1109; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cary LA, 1996, J CELL SCI, V109, P1787; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; CHIRZANOWSKAWON.M, 1996, J CELL BIOL, V133, P1403; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Craig SW, 1996, CURR OPIN CELL BIOL, V8, P74, DOI 10.1016/S0955-0674(96)80051-2; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; FLORES ME, 1992, EXP CELL RES, V201, P526, DOI 10.1016/0014-4827(92)90305-R; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GIANCOTTI F, 1977, CURR OPIN CELL BIOL, V9, P691; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYNES RO, 1994, BIOESSAYS, V16, P663, DOI 10.1002/bies.950160912; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KENNEDY S, 1997, GENE DEV, V11, P703; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Kolanus W, 1997, CURR OPIN CELL BIOL, V9, P725, DOI 10.1016/S0955-0674(97)80127-5; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; LO SH, 1994, CANCER METAST REV, V13, P9, DOI 10.1007/BF00690415; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; Pasqualini R, 1997, NAT BIOTECHNOL, V15, P542, DOI 10.1038/nbt0697-542; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PIERSCHBACHER MD, 1994, J CELL BIOCHEM, V56, P150, DOI 10.1002/jcb.240560205; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; Ren XD, 1996, MOL BIOL CELL, V7, P435, DOI 10.1091/mbc.7.3.435; Renshaw MW, 1996, J BIOL CHEM, V271, P21691, DOI 10.1074/jbc.271.36.21691; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Schwartz MA, 1996, EMBO J, V15, P6525, DOI 10.1002/j.1460-2075.1996.tb01043.x; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; TAMKUN JW, 1986, CELL, V46, P271, DOI 10.1016/0092-8674(86)90744-0; TOKSOZ D, 1994, ONCOGENE, V9, P621; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	92	229	244	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 17	1998	17	11			SI		1365	1373		10.1038/sj.onc.1202172	http://dx.doi.org/10.1038/sj.onc.1202172			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124BW	9779984				2022-12-17	WOS:000076161900005
J	DAVIES, BR; DAVIES, MPA; GIBBS, FEM; BARRACLOUGH, R; RUDLAND, PS				DAVIES, BR; DAVIES, MPA; GIBBS, FEM; BARRACLOUGH, R; RUDLAND, PS			INDUCTION OF THE METASTATIC PHENOTYPE BY TRANSFECTION OF A BENIGN RAT MAMMARY EPITHELIAL-CELL LINE WITH THE GENE FOR P9KA, A RAT CALCIUM-BINDING PROTEIN, BUT NOT WITH THE ONCOGENE EJ-RAS-1	ONCOGENE			English	Article							FIBROBLAST-LIKE CELLS; MESSENGER-RNA; GEL ELECTROPHORESIS; ELONGATED CELLS; CARCINOMA-CELLS; DNA; CLONING; GROWTH; S-100; TUMOR	The rat mammary epithelial cell tine, Rama 37, yields benign, non-metastasizing adenomatous tumours in syngeneic Wistar-Furth rats. Transfection of this line with a drug resistance plasmid containing both the gene for resistance to Geneticin (neo) and the gene for p9Ka (pSV2neo-p9Ka), a rat calcium-binding protein, or with a similar plasmid containing neo and the oncogene EJ-ras-1 (pSV2neo-ras) yields drug-resistant transformants that express high levels of the p9Ka or EJ-ras-I mRNAs and proteins. These transfected cells all produce tumours when injected at subcutaneous sites with a shorter median latent period than the tumours produced by the parental untransfected Rama 37 cells in syngeneic hosts. Cells transfected with pSV2neo-p9Ka yield a higher incidence of tumours than untransfected Rama 37 cells, many of which metastasize to lungs and/or lymph nodes in syngeneic rats. However, cells transfected with pSV2neo-ras or pSV2neo plasmid alone yield tumours that fail to metastasize. Immunofluorescent studies suggest an association of p9Ka with the cytoskeleton, as depicted by F-actin staining with the reagent phalloidin. It is suggested that the transfection of copies of the gene for the rat calcium-binding protein p9Ka can enhance the tumorigenic potential and induce the metastatic phenotype in this rat mammary model, whereas transfection of control plasmid DNA or the oncogene EJ-ras-I fails to induce the metastatic phenotype, although EJ-ras-I transfectants, like those containing p9Ka, possess increased growth properties in vivo.	UNIV LIVERPOOL, DEPT BIOCHEM, CANCER & POLIO RES FUND LABS, LIVERPOOL L69 3BX, ENGLAND	University of Liverpool			Barraclough, Roger/AAH-6516-2020; Davies, Michael/GWV-2527-2022	Barraclough, Roger/0000-0002-7203-1194; Davies, Michael Peter Alan/0000-0002-7609-4977	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAILEY JM, 1976, ANAL BIOCHEM, V70, P75, DOI 10.1016/S0003-2697(76)80049-8; BARRACLOUGH R, 1984, NUCLEIC ACIDS RES, V12, P8097, DOI 10.1093/nar/12.21.8097; BARRACLOUGH R, 1987, J CELL PHYSIOL, V131, P393, DOI 10.1002/jcp.1041310311; BARRACLOUGH R, 1987, J MOL BIOL, V198, P13, DOI 10.1016/0022-2836(87)90453-0; BARRACLOUGH R, 1982, EUR J BIOCHEM, V129, P335, DOI 10.1111/j.1432-1033.1982.tb07056.x; BARRACLOUGH R, 1990, BIOCHEM BIOPH RES CO, V169, P660, DOI 10.1016/0006-291X(90)90381-V; BARRACLOUGH R, 1984, BIOCHEM BIOPH RES CO, V120, P351, DOI 10.1016/0006-291X(84)91261-0; BARRACLOUGH R, 1991, NOVEL CALCIUM BINDIN, P105; BAUDIER J, 1988, J BIOL CHEM, V263, P5876; BENNETT DC, 1978, CELL, V15, P283, DOI 10.1016/0092-8674(78)90104-6; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEAR TN, 1990, MOL ASPECTS MED, V11, P243, DOI 10.1016/0098-2997(90)90005-M; DEVOUGE MW, 1992, ONCOGENE, V7, P109; DUNNINGTON DJ, 1983, J NATL CANCER I, V71, P1227; DUNNINGTON DJ, 1984, CANCER RES, V44, P5338; DUNNINGTON DJ, 1984, THESIS U LONDON; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; Fidler I J, 1978, Adv Cancer Res, V28, P149, DOI 10.1016/S0065-230X(08)60648-X; GAO J, 1987, PATHOL RES PRACT, V182, P48, DOI 10.1016/S0344-0338(87)80141-3; GERKE V, 1985, EMBO J, V4, P2917, DOI 10.1002/j.1460-2075.1985.tb04023.x; GERKE V, 1991, NOVEL CALCIUM BINDIN, P140; GOTO K, 1988, J BIOCHEM-TOKYO, V103, P48, DOI 10.1093/oxfordjournals.jbchem.a122237; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HART IR, 1991, BRIT J CANCER, V63, P9, DOI 10.1038/bjc.1991.4; HART IR, 1989, BIOCHIM BIOPHYS ACTA, V989, P65, DOI 10.1016/0304-419X(89)90035-8; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; ISHHOROWICZ D, 1981, NUCLEIC ACIDS RES, V9, P2989, DOI 10.1093/nar/9.13.2989; JACKSONGRUSBY LL, 1987, NUCLEIC ACIDS RES, V15, P6677, DOI 10.1093/nar/15.16.6677; JAMIESON S, 1990, INT J CANCER, V46, P1071, DOI 10.1002/ijc.2910460621; JAMIESON S, 1990, PATHOBIOLOGY, V58, P329, DOI 10.1159/000163605; JAMIESON S, 1987, THESIS U LONDON; KERBEL RS, 1987, P NATL ACAD SCI USA, V84, P1263, DOI 10.1073/pnas.84.5.1263; MAREEL MM, 1986, ANTICANCER RES, V6, P419; MCKAY IA, 1986, MOL CELL BIOL, V6, P3382, DOI 10.1128/MCB.6.10.3382; ORMEROD EJ, 1985, IN VITRO CELL DEV B, V21, P143, DOI 10.1007/BF02621351; RADLERPOHL A, 1988, INT J CANCER, V41, P840, DOI 10.1002/ijc.2910410611; RUDLAND PS, 1987, CANCER METAST REV, V6, P55, DOI 10.1007/BF00047609; Sambrook J., 1989, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPANDIDOS DA, 1984, TRANSCRIPTION TRANSL, P1; THORGEIRSSON UP, 1985, MOL CELL BIOL, V5, P259, DOI 10.1128/MCB.5.1.259; TULCHINSKY E, 1992, IN PRESS ONCOGENE; VANROY FM, 1986, CANCER RES, V46, P4787; VERRELLE P, 1987, ANTICANCER RES, V7, P181; VOUSDEN KH, 1986, INT J CANCER, V37, P425, DOI 10.1002/ijc.2910370315; WAGHORNE C, 1987, ONCOGENE, V1, P149; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WYLLIE AH, 1987, BRIT J CANCER, V56, P251, DOI 10.1038/bjc.1987.186	49	229	231	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1993	8	4					999	1008						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455951				2022-12-17	WOS:A1993KT22000023
J	Jones, DTW; Kocialkowski, S; Liu, L; Pearson, DM; Ichimura, K; Collins, VP				Jones, D. T. W.; Kocialkowski, S.; Liu, L.; Pearson, D. M.; Ichimura, K.; Collins, V. P.			Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma	ONCOGENE			English	Article						RAF1; BRAF; SRGAP3; fusion gene; pilocytic astrocytoma; MAPK	HUMAN CANCER; GENE; REGION; TUMORS	Pilocytic astrocytomas (PAs), WHO malignancy grade I, are the most frequently occurring central nervous system tumour in 5- to 19-year-olds. Recent reports have highlighted the importance of MAPK pathway activation in PAs, particularly through a tandem duplication leading to an oncogenic BRAF fusion gene. Here, we report two alternative mechanisms resulting in MAPK activation in PAs. Firstly, in striking similarity to the common BRAF fusion, tandem duplication at 3p25 was observed, which produces an in-frame oncogenic fusion between SRGAP3 and RAF1. This fusion includes the Raf1 kinase domain, and shows elevated kinase activity when compared with wild-type Raf1. Secondly, a novel 3 bp insertion at codon 598 in BRAF mimics the hotspot V600E mutation to produce a transforming, constitutively active BRaf kinase. Although these two alterations are not common, they bring the number of cases with an identified 'hit' on the Ras/Raf-signalling pathway to 36 from our series of 44 (82%), confirming its central importance to the development of pilocytic astrocytomas. Oncogene (2009) 28, 2119-2123; doi:10.1038/onc.2009.73; published online 13 April 2009	[Jones, D. T. W.; Kocialkowski, S.; Liu, L.; Pearson, D. M.; Ichimura, K.; Collins, V. P.] Univ Cambridge, Dept Pathol, Div Mol Histopathol, Cambridge CB2 0QQ, Cambs, England	University of Cambridge	Jones, DTW (corresponding author), Univ Cambridge, Addenbrookes Hosp, Div Mol Histopathol, Dept Pathol, Box 231,Level 3 Lab Block,Hills Rd, Cambridge CB2 0QQ, Cambs, England.	davidjones@cantab.net	Jones, David TW/G-9588-2013; Jones, David T. W./Z-1963-2019	Jones, David TW/0000-0002-2036-5141; 	Cancer Research UK; Samantha Dickson Brain Tumour Trust; CAMPOD	Cancer Research UK(Cancer Research UK); Samantha Dickson Brain Tumour Trust; CAMPOD	We thank Dr MG McCabe, Dr M Dimitriadi, Miss S Rigby, Miss F McDuff, Dr S Turner and Professor Y Yuasa for their help and for reagents. We also thank the Mapping and Microarray Facility groups of the Wellcome Trust Sanger Institute, UK and the Centre for Microarray resources in the Department of Pathology, University of Cambridge for technical assistance. This work was supported by grants from Cancer Research UK, the Samantha Dickson Brain Tumour Trust and CAMPOD.	BONNER T, 1984, SCIENCE, V223, P71, DOI 10.1126/science.6691137; *CENTR BRAIN TUM R, 2005, STAT REP PRIM BRAIN; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dirven CMF, 1997, CHILD NERV SYST, V13, P17, DOI 10.1007/s003810050033; Emuss V, 2005, CANCER RES, V65, P9719, DOI 10.1158/0008-5472.CAN-05-1683; Endris V, 2002, P NATL ACAD SCI USA, V99, P11754, DOI 10.1073/pnas.162241099; Giannini C, 1997, BRAIN PATHOL, V7, P785, DOI 10.1111/j.1750-3639.1997.tb01064.x; Icking A, 2006, FEBS LETT, V580, P223, DOI 10.1016/j.febslet.2005.11.078; Janzarik WG, 2007, NEUROPEDIATRICS, V38, P61, DOI 10.1055/s-2007-984451; Jones DTW, 2008, CANCER RES, V68, P8673, DOI 10.1158/0008-5472.CAN-08-2097; Jones DTW, 2006, J NEUROPATH EXP NEUR, V65, P1049, DOI 10.1097/01.jnen.0000240465.33628.87; Le LQ, 2007, ONCOGENE, V26, P4609, DOI 10.1038/sj.onc.1210261; Listernick R, 1999, AM J MED GENET, V89, P38, DOI 10.1002/(SICI)1096-8628(19990326)89:1<38::AID-AJMG8>3.0.CO;2-M; Louis DN, 2007, WHO CLASSIFICATION T; Maltzman TH, 1997, CANCER EPIDEM BIOMAR, V6, P239; Moretti S, 2006, ONCOGENE, V25, P4235, DOI 10.1038/sj.onc.1209448; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; Sharma MK, 2005, NEUROLOGY, V65, P1335, DOI 10.1212/01.wnl.0000180409.78098.d7; Shimizu K, 1986, Princess Takamatsu Symp, V17, P85; Soderling SH, 2007, J NEUROSCI, V27, P355, DOI 10.1523/JNEUROSCI.3209-06.2006; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; TAHIRA T, 1987, NUCLEIC ACIDS RES, V15, P4809, DOI 10.1093/nar/15.12.4809; The KIDSREEN Group, 2004, KIDSCREEN 52 HLTH QU, P1; TOMLINSON FH, 1994, J CHILD NEUROL, V9, P301, DOI 10.1177/088307389400900317; Yang Y, 2006, EXP CELL RES, V312, P2379, DOI 10.1016/j.yexcr.2006.04.001; Zebisch A, 2006, CELL MOL LIFE SCI, V63, P1314, DOI 10.1007/s00018-006-6005-y	26	228	236	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 21	2009	28	20					2119	2123		10.1038/onc.2009.73	http://dx.doi.org/10.1038/onc.2009.73			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	448BI	19363522	Green Accepted			2022-12-17	WOS:000266235800006
J	Grady, WM; Parkin, RK; Mitchell, PS; Lee, JH; Kim, YH; Tsuchiya, KD; Washington, MK; Paraskeva, C; Willson, JKV; Kaz, AM; Kroh, EM; Allen, A; Fritz, BR; Markowitz, SD; Tewari, M				Grady, W. M.; Parkin, R. K.; Mitchell, P. S.; Lee, J. H.; Kim, Y-H; Tsuchiya, K. D.; Washington, M. K.; Paraskeva, C.; Willson, J. K. V.; Kaz, A. M.; Kroh, E. M.; Allen, A.; Fritz, B. R.; Markowitz, S. D.; Tewari, M.			Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in colorectal cancer	ONCOGENE			English	Article						microRNA; epigenetic; colorectal cancer; colon cancer; methylation; apoptosis	OLIGONUCLEOTIDE ARRAYS; EXPRESSION PROFILES; COLON-CANCER; IDENTIFICATION; TARGETS; TUMOR; HYPERMETHYLATION; SIGNATURE; NEOPLASIA; MECHANISM	MicroRNAs are small, non-coding RNAs that influence gene regulatory networks by post-transcriptional regulation of specific messenger RNA targets. MicroRNA expression is dysregulated in human malignancies, frequently leading to loss of expression of certain microRNAs. We report that expression of hsa-miR-342, a microRNA encoded in an intron of the gene EVL, is commonly suppressed in human colorectal cancer. The expression of hsa-miR- 342 is coordinated with that of EVL and our results indicate that the mechanism of silencing is CpG island methylation upstream of EVL. We found methylation at the EVL/hsa-miR-342 locus in 86% of colorectal adenocarcinomas and in 67% of adenomas, indicating that it is an early event in colorectal carcinogenesis. In addition, we observed a higher frequency of methylation ( 56%) in histologically normal colorectal mucosa from individuals with concurrent cancer compared to mucosa from individuals without colorectal cancer ( 12%), suggesting the existence of a 'field defect' involving methylated EVL/hsa-miR-342. Furthermore, reconstitution of hsa-miR- 342 in the colorectal cancer cell line HT-29 induced apoptosis, suggesting that this microRNA could function as a proapoptotic tumor suppressor. In aggregate, these results support a novel mechanism for silencing intronic microRNAs in cancer by epigenetic alterations of cognate host genes.	[Grady, W. M.; Lee, J. H.; Kim, Y-H; Tsuchiya, K. D.; Kaz, A. M.; Tewari, M.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA; [Grady, W. M.; Kaz, A. M.] Univ Washington, Sch Med, Div Gastroenterol, Seattle, WA USA; [Grady, W. M.; Kaz, A. M.] VA Puget Sound Healthcare Syst, Seattle, WA USA; [Parkin, R. K.; Mitchell, P. S.; Kroh, E. M.; Fritz, B. R.; Tewari, M.] Fred Hutchinson Canc Res Ctr, Human Biol Div, Seattle, WA 98109 USA; [Lee, J. H.; Kim, Y-H] Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Seoul, South Korea; [Tsuchiya, K. D.] Seattle Childrens Hosp & Reg Med Ctr, Seattle, WA USA; [Washington, M. K.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA; [Paraskeva, C.] Univ Bristol, Bristol, Avon, England; [Willson, J. K. V.] Univ Texas SW, Sch Med, Dallas, TX USA; [Allen, A.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA; [Markowitz, S. D.] Case Western Reserve Univ, Sch Med, Cleveland, OH USA; [Markowitz, S. D.] Univ Hosp Cleveland, Cleveland, OH 44106 USA; [Markowitz, S. D.] Howard Hughes Med Inst, Cleveland, OH USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; Fred Hutchinson Cancer Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Seattle Children's Hospital; Vanderbilt University; University of Bristol; University of Texas System; University of Texas Southwestern Medical Center Dallas; Fred Hutchinson Cancer Center; Case Western Reserve University; University Hospitals of Cleveland; Howard Hughes Medical Institute	Tewari, M (corresponding author), Fred Hutchinson Canc Res Ctr, Human Biol & Clin Res Div, 1100 Fairview Ave N,Mailstop D4-100, Seattle, WA 98109 USA.	mtewari@fhcrc.org		Mitchell, Patrick/0000-0001-8375-9060	NCI NIH HHS [P30 CA015704] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alon U, 1999, P NATL ACAD SCI USA, V96, P6745, DOI 10.1073/pnas.96.12.6745; Bandres E, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-29; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Brueckner B, 2007, CANCER RES, V67, P1419, DOI 10.1158/0008-5472.CAN-06-4074; Cummins JM, 2006, P NATL ACAD SCI USA, V103, P3687, DOI 10.1073/pnas.0511155103; Grady WM, 2001, CANCER RES, V61, P900; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Kim YH, 2006, GENE CHROMOSOME CANC, V45, P781, DOI 10.1002/gcc.20341; Kim YK, 2007, EMBO J, V26, P775, DOI 10.1038/sj.emboj.7601512; Kondo Y, 2004, CANCER METAST REV, V23, P29, DOI 10.1023/A:1025806911782; Krause M, 2003, ANNU REV CELL DEV BI, V19, P541, DOI 10.1146/annurev.cellbio.19.050103.103356; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218; Michael MZ, 2003, MOL CANCER RES, V1, P882; Myohanen SK, 1998, CANCER RES, V58, P591; Notterman DA, 2001, CANCER RES, V61, P3124; Ohm JE, 2007, CELL CYCLE, V6, P1040, DOI 10.4161/cc.6.9.4210; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Rodriguez A, 2004, GENOME RES, V14, P1902, DOI 10.1101/gr.2722704; Saini HK, 2007, P NATL ACAD SCI USA, V104, P17719, DOI 10.1073/pnas.0703890104; Saito Y, 2006, CELL CYCLE, V5, P2220, DOI 10.4161/cc.5.19.3340; Toyota M, 1999, CANCER RES, V59, P2307; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941; Wijnhoven BPL, 2007, BRIT J SURG, V94, P23, DOI 10.1002/bjs.5673; Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028; Zou TT, 2002, ONCOGENE, V21, P4855, DOI 10.1038/sj.onc.1205613	29	228	246	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2008	27	27					3880	3888		10.1038/onc.2008.10	http://dx.doi.org/10.1038/onc.2008.10			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	315UC	18264139				2022-12-17	WOS:000256904700013
J	Momparler, RL				Momparler, RL			Cancer epigenetics	ONCOGENE			English	Review						DNA methylation; histone deacetylation; gene actuation; 5-aza-2 ' deoxycytidine; cancer chemotherapy	HISTONE DEACETYLASE INHIBITION; E-CADHERIN EXPRESSION; ACID RECEPTOR-BETA; DNA METHYLATION; CPG-ISLAND; ANTINEOPLASTIC ACTION; HUMAN BREAST; LUNG-CANCER; 5-AZA-2'-DEOXYCYTIDINE DECITABINE; PROMOTER HYPERMETHYLATION	Aberrant DNA methylation of the promoter region is a key mechanism for inactivation of genes that suppress tumorigenesis. Genes that are involved in every step of tumor formation can be silenced by this mechanism. Inhibitors of DNA methylation, such as 5-azadeoxycytidine (5AZA), can reverse this epigenetic event suggesting a potential use in cancer therapy. The structure of chromatin can also play an important role with respect to the regulation of gene expression. Chromatin containing hypoacetylated lysines in histones has a compact structure that is repressive for transcription. Inhibitors of histone deacetylase (HDAC) can convert chromatin to an open structure and activate certain genes that inhibit tumor growth. These HDAC inhibitors also have potential in cancer therapy. A 'cross-talk' between DNA methylation and histone deacetylation can occur and work in concert to silence gene expression. The molecular mechanism involves the attachment of a methylated CpG binding protein (MBP) to the methylated promoters and its recruitment of HDAC to form a complex that suppresses transcription. These two epigenetic modi. cations represent an interesting target for therapeutic intervention using 5AZA and HDAC inhibitors. These agents in combination have been shown to produce a synergistic reactivation of tumor suppressor genes and an enhanced antineoplastic effect against tumor cells, and should be investigated as a novel form of epigenetic therapy for cancer.	Univ Montreal, Hop St Justine, Ctr Rech, Dept Pharmacol, Montreal, PQ H3T 1C5, Canada	Universite de Montreal	Momparler, RL (corresponding author), Univ Montreal, Hop St Justine, Ctr Rech, Dept Pharmacol, 3175 Cote Ste Catherine, Montreal, PQ H3T 1C5, Canada.	richard.l.momparler@umontreal.ca	Momparler, Richard/AAU-6945-2020	Momparler, Richard/0000-0002-9186-6269				Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Bachman KE, 1999, CANCER RES, V59, P798; Baylin SB, 2002, SEMIN CANCER BIOL, V12, P331, DOI 10.1016/S1044-579X(02)00053-6; Bianco T, 2000, CARCINOGENESIS, V21, P147, DOI 10.1093/carcin/21.2.147; Boivin AJ, 2002, ANTI-CANCER DRUG, V13, P869, DOI 10.1097/00001813-200209000-00013; Bovenzi V, 2001, CANCER CHEMOTH PHARM, V48, P71, DOI 10.1007/s002800100294; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Cote S, 1998, ANTI-CANCER DRUG, V9, P743; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Esteller M, 1999, CANCER RES, V59, P67; Esteller M, 2000, EUR J CANCER, V36, P2294, DOI 10.1016/S0959-8049(00)00303-8; Fahrner JA, 2002, CANCER RES, V62, P7213; Gagnon J, 2003, ANTI-CANCER DRUG, V14, P193, DOI 10.1097/00001813-200303000-00002; Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727; GRAFF JR, 1995, CANCER RES, V55, P5195; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Issa JP, 1999, CRIT REV ONCOL HEMAT, V32, P31, DOI 10.1016/S1040-8428(99)00019-0; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kantarjian HM, 1997, LEUKEMIA, V11, P1617, DOI 10.1038/sj.leu.2400796; Kissil JL, 1997, ONCOGENE, V15, P403, DOI 10.1038/sj.onc.1201172; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Li Q, 1999, ONCOGENE, V18, P3284, DOI 10.1038/sj.onc.1202663; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; MOMPARLER RL, 1985, PHARMACOL THERAPEUT, V30, P277, DOI 10.1016/0163-7258(85)90052-X; Momparler RL, 2000, J CELL PHYSIOL, V183, P145, DOI 10.1002/(SICI)1097-4652(200005)183:2<145::AID-JCP1>3.0.CO;2-V; Momparler RL, 2001, LUNG CANCER, V34, pS111; Nephew KP, 2003, CANCER LETT, V190, P125, DOI 10.1016/S0304-3835(02)00511-6; Nguyen CT, 2002, CANCER RES, V62, P6456; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Palmisano WA, 2000, CANCER RES, V60, P5954; Paz MF, 2003, CANCER RES, V63, P1114; PINTO A, 1993, LEUKEMIA, V7, P51; Primeau M, 2003, INT J CANCER, V103, P177, DOI 10.1002/ijc.10789; Qian XLC, 1997, CANCER RES, V57, P3672; Ramchandani S, 1999, P NATL ACAD SCI USA, V96, P6107, DOI 10.1073/pnas.96.11.6107; RIVARD GE, 1981, LEUKEMIA RES, V5, P453, DOI 10.1016/0145-2126(81)90116-8; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Shaker S, 2003, LEUKEMIA RES, V27, P437, DOI 10.1016/S0145-2126(02)00222-9; Shi HD, 2002, CANCER RES, V62, P3214; Stimson KM, 2002, J BIOL CHEM, V277, P4951, DOI 10.1074/jbc.M109809200; Strathdee G, 2002, EXPERT OPIN INV DRUG, V11, P747; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Tsou JA, 2002, ONCOGENE, V21, P5450, DOI 10.1038/sj.onc.1205605; Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438; Vertino PM, 2002, CELL CYCLE, V1, P416, DOI 10.4161/cc.1.6.270; Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621	58	228	247	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2003	22	42					6479	6483		10.1038/sj.onc.1206774	http://dx.doi.org/10.1038/sj.onc.1206774			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	728DV	14528271				2022-12-17	WOS:000185700700003
J	Shai, R; Shi, T; Kremen, TJ; Horvath, S; Liau, LM; Cloughesy, TF; Mischel, PS; Nelson, SF				Shai, R; Shi, T; Kremen, TJ; Horvath, S; Liau, LM; Cloughesy, TF; Mischel, PS; Nelson, SF			Gene expression profiling identifies molecular subtypes of gliomas	ONCOGENE			English	Article						glioblastoma; gene expression profiling; microarray; glioma	DELTA-CATENIN; CLASSIFICATION; MICROARRAY; PREDICTION; PROTEIN; COMPLEX; TUMORS; RNA	Identification of distinct molecular subtypes is a critical challenge for cancer biology. In this study, we used Affymetrix high-density oligonucleotide arrays to identify the global gene expression signatures associated with gliomas of different types and grades. Here, we show that the global transcriptional profiles of gliomas of different types and grades are distinct from each other and from the normal brain. To determine whether our data could be used to uncover molecular subtypes without prior knowledge of pathologic type and grade, we performed K-means clustering analysis and found evidence for three clusters with the aid of multidimensional scaling plots. These clusters corresponded to glioblastomas, lower grade astrocytomas and oligodendrogliomas (P<0.00001). A predictor constructed from the 170 genes that are most differentially expressed between the subsets correctly identified the type and grade of all samples, indicating that a relatively small number of genes can be used to distinguish between these molecular subtypes. These results further define molecular subsets of gliomas which may potentially be used for patient stratification, and suggest potential targets for treatment.	Univ Calif Los Angeles, Dept Pathol & Lab Med, Henry E Singleton Brain Tumor Program, Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Human Genet, Henry E Singleton Brain Tumor Program, Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Biostat, Henry E Singleton Brain Tumor Program, Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Neurosurg, Henry E Singleton Brain Tumor Program, Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Neurol, Henry E Singleton Brain Tumor Program, Sch Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Mischel, PS (corresponding author), Univ Calif Los Angeles, Dept Pathol & Lab Med, Henry E Singleton Brain Tumor Program, Sch Med, Los Angeles, CA 90095 USA.	pmischel@mednet.ucla.edu	Cloughesy, Timothy Francis/AGV-1013-2022; Nelson, Stanley F/D-4771-2009	Nelson, Stanley F/0000-0002-2082-3114; Kremen, Thomas/0000-0003-1643-4869; Liau, Linda/0000-0002-4053-0052; , Tao/0000-0001-5489-2655	NATIONAL CANCER INSTITUTE [U01CA088127] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS043147] Funding Source: NIH RePORTER; NCI NIH HHS [U01 CA88127] Funding Source: Medline; NINDS NIH HHS [K08NS43147] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alizadeh AA, 2001, J PATHOL, V195, P41, DOI 10.1002/path.889; Burger MJ, 2002, INT J CANCER, V100, P228, DOI 10.1002/ijc.10468; Coyle JH, 2003, MOL CELL BIOL, V23, P92, DOI 10.1128/MCB.23.1.92-103.2003; De Luca A, 2003, CANCER RES, V63, P1430; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Hastie T., 2001, ELEMENTS STAT LEARNI, P236, DOI DOI 10.1007/978-0-387-21606-5; Hastie T, 2001, GENOME BIOL, V2; Her C, 2003, CANCER RES, V63, P865; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Kaufmann L., 1990, FINDING GROUPS DATA; Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215; Lal A, 2002, CANCER RES, V62, P3335; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Ljubimova JY, 2001, CANCER RES, V61, P5601; Lu Q, 1999, J CELL BIOL, V144, P519, DOI 10.1083/jcb.144.3.519; Lykke-Andersen J, 2001, SCIENCE, V293, P1836, DOI 10.1126/science.1062786; MacDonald TJ, 2001, NAT GENET, V29, P143, DOI 10.1038/ng731; Matter N, 2002, NATURE, V420, P691, DOI 10.1038/nature01153; McCusker D, 1997, GENOMICS, V45, P362, DOI 10.1006/geno.1997.4948; Mischel PS, 2003, BRAIN PATHOL, V13, P52; Mischel PS, 2003, ONCOGENE, V22, P2361, DOI 10.1038/sj.onc.1206344; Najib S, 2002, J CELL BIOCHEM, V86, P99, DOI 10.1002/jcb.10198; Nandi D, 1997, EMBO J, V16, P5363, DOI 10.1093/emboj/16.17.5363; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Okuda M, 2002, ONCOGENE, V21, P6170, DOI 10.1038/sj.onc.1205708; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Rickman DS, 2001, CANCER RES, V61, P6885; Robinson RC, 2001, SCIENCE, V294, P1679, DOI 10.1126/science.1066333; Sallinen SL, 2000, CANCER RES, V60, P6617; Shav-Tal Y, 2002, FEBS LETT, V531, P109, DOI 10.1016/S0014-5793(02)03447-6; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Tanahashi N, 1998, BIOCHEM BIOPH RES CO, V243, P229, DOI 10.1006/bbrc.1997.7892; Venables W., 2013, MODERN APPL STAT S, V53, P86; Yano T, 2002, MOL ASPECTS MED, V23, P345, DOI 10.1016/S0098-2997(02)00011-0; Zhang W, 2002, BRAIN PATHOL, V12, P87	37	228	236	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2003	22	31					4918	4923		10.1038/sj.onc.1206753	http://dx.doi.org/10.1038/sj.onc.1206753			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894235				2022-12-17	WOS:000184344600017
J	KEYOMARSI, K; CONTE, D; TOYOFUKU, W; FOX, MP				KEYOMARSI, K; CONTE, D; TOYOFUKU, W; FOX, MP			DEREGULATION OF CYCLIN-E IN BREAST-CANCER	ONCOGENE			English	Article						BREAST CANCER; CELL CYCLE; CYCLIN E; ALTERNATIVE SPLICING	CELL-CYCLE; CANDIDATE ONCOGENE; ESOPHAGEAL CANCER; EXPRESSION; OVEREXPRESSION; PROTEIN; GENE; AMPLIFICATION; FIBROBLASTS; PHASE	Cyclin E, a regulatory subunit of cyclin dependent kinase-2, is thought to be rate limiting for the G1/S transition during the mammalian cell cycle. Previously, we showed severe alterations in cyclin E protein expression in human mammary epithelial cell lines and in surgical material obtained from patients with various malignancies. To understand the functional basis of these alterations we analyse here the regulation of cyclin E in breast cancer cells. We find that while cyclin E protein and its associated kinase activity in normal cells are cell cycle regulated, in tumor cells it remains in an active complex throughout the cell cycle. We also analysed cyclin E for possible deletions which could result in its constitutive function and found two novel truncated variants in its coding region. These variant forms of cyclin E were detected in several normal and tumor cell lines and tissue specimens. However, Western blot analysis indicated that only the multiple isoforms of cyclin E protein were expressed in tumor but not the normal tissue specimen, suggesting post transcriptional regulation of cyclin E. Lastly, in vitro analyses indicated that these truncated variant forms of cyclin E are biochemically active in their ability to phosphorylate histone H1. Collectively these observations suggest the presence of more than one form of cyclin E mRNA in all cells, normal and tumor. Once translated in tumor cells, the protein products of these truncated forms could give rise to a constitutively active form of cyclin E containing complexes.			KEYOMARSI, K (corresponding author), WADSWORTH CTR, DIV MOLEC MED, DIAGNOST ONCOL LAB, ALBANY, NY 12201 USA.		Keyomarsi, Khandan/H-2716-2016	Keyomarsi, Khandan/0000-0002-5440-0849				BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; BIANCHI AB, 1993, ONCOGENE, V8, P1127; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CRISSMAN HA, 1974, SCIENCE, V184, P1297, DOI 10.1126/science.184.4143.1297; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1993, ONCOGENE, V8, P3447; JIANG W, 1992, CANCER RES, V52, P2980; KEYOMARSI K, 1994, CANCER RES, V54, P380; KEYOMARSI K, 1991, CANCER RES, V51, P3602; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEACH FS, 1993, CANCER RES, V53, P1986; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LOVEC H, 1994, ONCOGENE, V9, P323; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; SEWING A, 1994, J CELL SCI, V107, P581; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SOULE HD, 1990, CANCER RES, V50, P6075; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	48	228	232	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	1995	11	5					941	950						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675453				2022-12-17	WOS:A1995RU79800015
J	HOFFMAN, B; LIEBERMANN, DA				HOFFMAN, B; LIEBERMANN, DA			MOLECULAR CONTROLS OF APOPTOSIS - DIFFERENTIATION/GROWTH ARREST PRIMARY RESPONSE GENES, PROTOONCOGENES, AND TUMOR-SUPPRESSOR GENES AS POSITIVE AND NEGATIVE MODULATORS	ONCOGENE			English	Review							PROGRAMMED CELL-DEATH; WILD-TYPE P53; TRANSFORMING GROWTH FACTOR-BETA-1; LEUKEMIA INHIBITORY FACTOR; IMMEDIATE EARLY RESPONSE; CONSTITUTIVE C-MYC; TERMINAL DIFFERENTIATION; HUMAN CANCER; BCL-2; CYCLE				HOFFMAN, B (corresponding author), TEMPLE UNIV, SCH MED, FELS INST CANC RES & MOLEC BIOL, PHILADELPHIA, PA 19140 USA.							ABDOLLAHI A, 1991, ONCOGENE, V6, P165; ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; ASKEW DS, 1991, ONCOGENE, V6, P1915; BEALDING C, 1993, P NATL ACAD SCI USA, V90, P2719; BISHOP JM, 1991, COLD SH Q B, V56, P99; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHOU J, 1992, P NATL ACAD SCI USA, V89, P3266, DOI 10.1073/pnas.89.8.3266; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COFFEY RJ, 1988, CANCER RES, V48, P1596; COGSWELL JP, 1993, MOL CELL BIOL, V13, P2858, DOI 10.1128/MCB.13.5.2858; COHEN JJ, 1991, ADV IMMUNOL, V50, P55; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cellbio.7.1.663; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FORNACE AJ, 1992, ANN NY ACAD SCI, V663, P139, DOI 10.1111/j.1749-6632.1992.tb38657.x; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOOPER WC, 1991, LEUKEMIA RES, V15, P179, DOI 10.1016/0145-2126(91)90118-D; JUVEN T, 1993, ONCOGENE, V8, P3411; KARTASOVA T, 1988, MOL CELL BIOL, V8, P2195, DOI 10.1128/MCB.8.5.2195; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KORSMEYER SJ, 1992, BLOOD, V80, P879; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; LAIHO M, 1991, MOL CELL BIOL, V11, P972, DOI 10.1128/MCB.11.2.972; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LEVY N, 1993, MOL CELL BIOL, V13, P7942, DOI 10.1128/MCB.13.12.7942; Liebermann D A, 1994, Curr Opin Hematol, V1, P24; LORD KA, 1990, ONCOGENE, V5, P387; LORD KA, 1990, CELL GROWTH DIFFER, V1, P637; LORD KA, 1990, NUCLEIC ACIDS RES, V18, P2823, DOI 10.1093/nar/18.9.2823; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MARX J, 1993, SCIENCE, V259, P760, DOI 10.1126/science.8430327; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MCGEOCH DJ, 1991, NATURE, V353, P609, DOI 10.1038/353609b0; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIYASHITA T, 1993, BLOOD, V81, P151; MIYASHITA T, 1992, CANCER RES, V52, P5407; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PIENTENPOL JA, 1990, CELL, V61, P777; QUESENBERRY PJ, 1990, HEMATOLOGY, P129; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; ROTELLO RJ, 1991, P NATL ACAD SCI USA, V88, P3412, DOI 10.1073/pnas.88.8.3412; RUSCETTI FW, 1991, ANN NY ACAD SCI, V628, P31, DOI 10.1111/j.1749-6632.1991.tb17220.x; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SELVAKUMARAN M, 1993, BLOOD, V81, P2257; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; STANBRIDGE EJ, 1990, CELL, V63, P867, DOI 10.1016/0092-8674(90)90490-6; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WANG YS, 1993, ONCOGENE, V8, P3427; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533	84	228	239	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1994	9	7					1807	1812						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208526				2022-12-17	WOS:A1994NR68500001
J	BARBACID, M				BARBACID, M			NERVE GROWTH-FACTOR - A TALE OF 2 RECEPTORS	ONCOGENE			English	Review							TYROSINE PROTEIN-KINASE; HIGH-AFFINITY RECEPTORS; TUMOR-NECROSIS-FACTOR; HUMAN NEUROTROPHIC FACTOR; HUMAN NGF RECEPTOR; MOLECULAR-CLONING; TRK PROTOONCOGENE; FACTOR FAMILY; NEURONAL DIFFERENTIATION; GENE-TRANSFER				BARBACID, M (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,POB 4000,PRINCETON,NJ 08543, USA.							Barbacid Mariano, 1993, P123; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; BERG MM, 1991, P NATL ACAD SCI USA, V88, P7106, DOI 10.1073/pnas.88.16.7106; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BERND P, 1984, J BIOL CHEM, V259, P5509; BIRREN SJ, 1992, SCIENCE, V257, P395, DOI 10.1126/science.1321502; BOTHWELL M, 1991, CELL, V65, P915, DOI 10.1016/0092-8674(91)90540-F; CHAO MV, 1986, SCIENCE, V232, P518, DOI 10.1126/science.3008331; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; CHESA PG, 1988, J HISTOCHEM CYTOCHEM, V36, P383, DOI 10.1177/36.4.2831267; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; DISTEFANO PS, 1988, P NATL ACAD SCI USA, V85, P270, DOI 10.1073/pnas.85.1.270; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; ERNFORS P, 1988, NEURON, V1, P983, DOI 10.1016/0896-6273(88)90155-9; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; HEMPSTEAD BL, 1990, J BIOL CHEM, V265, P9595; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HOSANG M, 1987, EMBO J, V6, P1197, DOI 10.1002/j.1460-2075.1987.tb02354.x; HOSANG M, 1985, J BIOL CHEM, V260, P655; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; IP NY, 1993, IN PRESS NEURON; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; KAISHO Y, 1990, FEBS LETT, V266, P187, DOI 10.1016/0014-5793(90)81536-W; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KAPLAN DR, 1991, NATURE, V350, P150; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1992, NEURON, V8, P947, DOI 10.1016/0896-6273(92)90209-V; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1990, DEVELOPMENT, V109, P845; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LARGE TH, 1989, NEURON, V2, P1123, DOI 10.1016/0896-6273(89)90179-7; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MAHER PA, 1988, P NATL ACAD SCI USA, V85, P6788, DOI 10.1073/pnas.85.18.6788; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MALLETT S, 1990, EMBO J, V9, P1063, DOI 10.1002/j.1460-2075.1990.tb08211.x; MARSH HN, 1993, IN PRESS J NEUROSCI; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MASSAGUE J, 1981, J BIOL CHEM, V256, P9419; MATSUSHIMA H, 1990, MOL CELL BIOL, V10, P5015, DOI 10.1128/MCB.10.9.5015; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; MEAKIN SO, 1991, NEURON, V6, P153, DOI 10.1016/0896-6273(91)90130-R; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; PLEASURE SJ, 1990, P NATL ACAD SCI USA, V87, P8496, DOI 10.1073/pnas.87.21.8496; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RAKOWICZSZULCZYNSKA EM, 1986, P NATL ACAD SCI USA, V83, P3728, DOI 10.1073/pnas.83.11.3728; RAKOWICZSZULCZYNSKA EM, 1988, CANCER RES, V48, P7200; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; RODRIGUEZTEBAR A, 1992, EMBO J, V11, P917, DOI 10.1002/j.1460-2075.1992.tb05130.x; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHECHTER AL, 1981, CELL, V24, P867, DOI 10.1016/0092-8674(81)90112-4; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; STEININGER TL, 1993, IN PRESS BRAIN RES; SUTTER A, 1979, J BIOL CHEM, V254, P5972; TANIUCHI M, 1986, P NATL ACAD SCI USA, V83, P4094, DOI 10.1073/pnas.83.11.4094; THOMSON TM, 1988, EXP CELL RES, V174, P533, DOI 10.1016/0014-4827(88)90323-0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WELCHER AA, 1991, P NATL ACAD SCI USA, V88, P159, DOI 10.1073/pnas.88.1.159; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; YAN H, 1991, SCIENCE, V252, P561, DOI 10.1126/science.1850551; YAN Q, 1989, J COMP NEUROL, V290, P585, DOI 10.1002/cne.902900411	79	228	235	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2033	2042						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336933				2022-12-17	WOS:A1993LP17100002
J	Smith, AL; Iwanaga, R; Drasin, DJ; Micalizzi, DS; Vartuli, RL; Tan, AC; Ford, HL				Smith, A. L.; Iwanaga, R.; Drasin, D. J.; Micalizzi, D. S.; Vartuli, R. L.; Tan, A-C; Ford, H. L.			The miR-106b-25 cluster targets Smad7, activates TGF-beta signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer	ONCOGENE			English	Article						Six1; miRNA; TGF-beta; epithelial-to-mesenchymal transition; tumor-initiating cell	EPITHELIAL-MESENCHYMAL TRANSITION; STEM-CELLS; MICRORNA CLUSTER; CARCINOMA CELLS; OVEREXPRESSION; METASTASIS; MECHANISM; PROTEIN; GROWTH; LUNG	The role of TGF-beta signaling in tumorigenesis is paradoxical: it can be tumor suppressive or tumor promotional, depending on context. The metastatic regulator, Six1, was recently shown to mediate this switch, providing a novel means to explain this elusive 'TGF-beta paradox'. Herein, we identify a mechanism by which Six1 activates the tumor promotional arm of TGF-beta signaling, via its ability to upregulate the miR-106b-25 microRNA cluster, and further identify a novel function for this cluster of microRNAs. Although expression of the miR-106b-25 cluster is known to overcome TGF-beta-mediated growth suppression via targeting p21 and BIM, we demonstrate for the first time that this same cluster can additionally target the inhibitory Smad7 protein, resulting in increased levels of the TGF-beta type I receptor and downstream activation of TGF-beta signaling. We further show that the miR-106b-25 cluster is sufficient to induce an epithelial-to-mesenchymal transition and a tumor initiating cell phenotype, and that it is required downstream of Six1 to induce these phenotypes. Finally, we demonstrate a significant correlation between miR-106b, Six1, and activated TGF-beta signaling in human breast cancers, and further show that high levels of miR-106b and miR-93 in breast tumors significantly predicts shortened time to relapse. These findings expand the spectrum of oncogenic functions of miR-106b-25, and may provide a novel molecular explanation, through the Six1 regulated miR-106b-25 cluster, by which TGF-beta signaling shifts from tumor suppressive to tumor promoting. Oncogene (2012) 31, 5162-5171; doi:10.1038/onc.2012.11; published online 30 January 2012	[Ford, H. L.] Univ Colorado Anschutz Med Campus, Dept Obstet & Gynecol, Program Mol Biol, Med Scientist Training Program, Aurora, CO 80045 USA; [Tan, A-C] Univ Colorado Anschutz Med Campus, Dept Med, Aurora, CO 80045 USA; [Ford, H. L.] Univ Colorado Anschutz Med Campus, Dept Biochem & Mol Genet, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Ford, HL (corresponding author), Univ Colorado Anschutz Med Campus, Dept Obstet & Gynecol, Program Mol Biol, Med Scientist Training Program, 12700 E 19th St,RC2,Rm 3100C, Aurora, CO 80045 USA.	heide.ford@ucdenver.edu	Tan, Aik Choon/A-3135-2011; Reever, Larson/H-9685-2019	Tan, Aik Choon/0000-0003-2955-8369; Reever, Larson/0000-0002-5692-4793; Micalizzi, Douglas/0000-0002-0306-9914	National Cancer Institute [2ROI-CA095277]; American Cancer Society [RSG-07-183-01-DDC]; Department of Defense Breast Cancer Research Program [W81XWH-10-1-0296, W81XWH-06-1-0757]; NATIONAL CANCER INSTITUTE [P30CA046934, R01CA095277] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); Department of Defense Breast Cancer Research Program(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was funded by grants from the National Cancer Institute (2ROI-CA095277) and The American Cancer Society (no. RSG-07-183-01-DDC) to HLF. ALS is funded by a predoctoral fellowship from the Department of Defense Breast Cancer Research Program (W81XWH-10-1-0296). DSM was funded by a predoctoral fellowship from the Department of Defense Breast Cancer Research Program (W81XWH-06-1-0757).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Brett JO, 2011, AGING-US, V3, P108, DOI 10.18632/aging.100285; Buffa FM, 2011, CANCER RES, V71, P5635, DOI 10.1158/0008-5472.CAN-11-0489; Chopra VS, 2006, BIOESSAYS, V28, P445, DOI 10.1002/bies.20401; Coletta RD, 2008, CANCER RES, V68, P2204, DOI 10.1158/0008-5472.CAN-07-3141; Fang L, 2011, ONCOGENE, V30, P806, DOI 10.1038/onc.2010.465; Farabaugh SM, 2012, ONCOGENE, V31, P552, DOI 10.1038/onc.2011.259; Ford HL, 1998, P NATL ACAD SCI USA, V95, P12608, DOI 10.1073/pnas.95.21.12608; Ford HL, 2000, J BIOL CHEM, V275, P22245, DOI 10.1074/jbc.M002446200; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Ho J, 2011, J AM SOC NEPHROL, V22, P1053, DOI 10.1681/ASN.2010080841; Hu YL, 2010, NUCLEIC ACIDS RES, V38, P5472, DOI 10.1093/nar/gkq337; Inman GJ, 2011, CURR OPIN GENET DEV, V21, P93, DOI 10.1016/j.gde.2010.12.004; Jorgensen S, 2010, METHODS, V52, P375, DOI 10.1016/j.ymeth.2010.07.002; Kakarala M, 2008, J CLIN ONCOL, V26, P2813, DOI 10.1200/JCO.2008.16.3931; Kan T, 2009, GASTROENTEROLOGY, V136, P1689, DOI 10.1053/j.gastro.2009.02.002; Li Y, 2009, CANCER SCI, V100, P1234, DOI 10.1111/j.1349-7006.2009.01164.x; Li ZH, 2011, EMBO J, V30, P823, DOI 10.1038/emboj.2011.2; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; McCoy EL, 2009, J CLIN INVEST, V119, P2663, DOI 10.1172/JCI37691; Micalizzi DS, 2010, CANCER RES, V70, P10371, DOI 10.1158/0008-5472.CAN-10-1354; Micalizzi DS, 2009, J CLIN INVEST, V119, P2678, DOI 10.1172/JCI37815; Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Poliseno L, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000594; Qian S, 2008, BIOCHEM BIOPH RES CO, V377, P668, DOI 10.1016/j.bbrc.2008.10.052; Reichenberger KJ, 2005, CANCER RES, V65, P2668, DOI 10.1158/0008-5472.CAN-04-4286; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Shtutman M, 2006, CANCER RES, V66, P11370, DOI 10.1158/0008-5472.CAN-06-2106; Tian M, 2009, FUTURE ONCOL, V5, P259, DOI 10.2217/14796694.5.2.259; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Wong DJ, 2008, CELL STEM CELL, V2, P333, DOI 10.1016/j.stem.2008.02.009; Yan XH, 2011, BIOCHEM J, V434, P1, DOI 10.1042/BJ20101827; Yan XH, 2009, ACTA BIOCH BIOPH SIN, V41, P263, DOI 10.1093/abbs/gmp018	35	227	248	0	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2012	31	50					5162	5171		10.1038/onc.2012.11	http://dx.doi.org/10.1038/onc.2012.11			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055WY	22286770	Green Accepted			2022-12-17	WOS:000312449800005
J	Walter, M; Liang, S; Ghosh, S; Hornsby, PJ; Li, R				Walter, M.; Liang, S.; Ghosh, S.; Hornsby, P. J.; Li, R.			Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cells	ONCOGENE			English	Article						adipose stromal cells; cofilin-1; IL-6; breast tumor cells; migration; invasion	BODY-MASS INDEX; CARCINOMA-CELLS; STEM-CELLS; COFILIN PHOSPHORYLATION; MAMMARY-GLAND; TUMOR-GROWTH; OBESITY; TISSUE; INCREASE; DISEASE	Excessive adiposity has long been associated with increased incidence of breast cancer in post-menopausal women, and with increased mortality from breast cancer, regardless of the menopausal status. Although adipose tissue-derived estrogen contributes to obesity-associated risk for estrogen receptor (ER)-positive breast cancer, the estrogen-independent impact of adipose tissue on tumor invasion and progression needs to be elucidated. Here, we show that adipose stromal cells (ASCs) significantly stimulate migration and invasion of ER-negative breast cancer cells in vitro and tumor invasion in a co-transplant xenograft mouse model. Our study also identifies cofilin-1, a known regulator of actin dynamics, as a determinant of the tumor-promoting activity of ASCs. The cofilin-1-dependent pathway affects the production of interleukin 6 (IL-6) in ASCs. Depletion of IL-6 from the ASC-conditioned medium abrogated the stimulatory effect of ASCs on the migration and invasion of breast tumor cells. Thus, our study uncovers a link between a cytoskeleton-based pathway in ASCs and the stromal impact on breast cancer cells. Oncogene (2009) 28, 2745-2755; doi:10.1038/onc.2009.130; published online 1 June 2009	[Walter, M.; Ghosh, S.; Li, R.] Univ Texas Hlth Sci Ctr San Antonio, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA; [Liang, S.; Hornsby, P. J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Li, R (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Inst Biotechnol, Dept Mol Med, 15355 Lambda Dr, San Antonio, TX 78245 USA.	lir3@uthscsa.edu			NCI [CA93506]; DOD [W81XWH-06-1-034]; NIA; Owens Medical Research Foundation; Glenn Foundation for Medical Research; NATIONAL CANCER INSTITUTE [R01CA093506] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DOD(United States Department of Defense); NIA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Owens Medical Research Foundation; Glenn Foundation for Medical Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Adam Katz for ASCs. The work was supported by grants to RL from the NCI (CA93506) and DOD (W81XWH-06-1-034), and by grants to PJH from the NIA, the Owens Medical Research Foundation, and the Glenn Foundation for Medical Research.	Ailhaud G, 2006, CR BIOL, V329, P570, DOI 10.1016/j.crvi.2005.12.012; Amemori Sadahiro, 2007, Am J Physiol Gastrointest Liver Physiol, V292, pG923; Ara T, 2009, CANCER RES, V69, P329, DOI 10.1158/0008-5472.CAN-08-0613; Bissell MJ, 2002, DIFFERENTIATION, V70, P537, DOI 10.1046/j.1432-0436.2002.700907.x; Bulun SE, 2005, PHARMACOL REV, V57, P359, DOI 10.1124/pr.57.3.6; Carmichael AR, 2006, OBES REV, V7, P333, DOI 10.1111/j.1467-789X.2006.00261.x; Carmichael AR, 2006, BJOG-INT J OBSTET GY, V113, P1160, DOI 10.1111/j.1471-0528.2006.01021.x; Celis JE, 2005, MOL CELL PROTEOMICS, V4, P492, DOI 10.1074/mcp.M500030-MCP200; Cooke PS, 2004, EXP BIOL MED, V229, P1127, DOI 10.1177/153537020422901107; Dawood S, 2008, CLIN CANCER RES, V14, P1718, DOI 10.1158/1078-0432.CCR-07-1479; Ferrante AW, 2007, J INTERN MED, V262, P408, DOI 10.1111/j.1365-2796.2007.01852.x; Gaggioli C, 2007, NAT CELL BIOL, V9, P1392, DOI 10.1038/ncb1658; Gao SP, 2007, J CLIN INVEST, V117, P3846, DOI 10.1172/JCI31871; Ghosh S, 2007, AM J PHYSIOL-ENDOC M, V292, pE246, DOI 10.1152/ajpendo.00242.2006; Gimble JM, 2007, CIRC RES, V100, P1249, DOI 10.1161/01.RES.0000265074.83288.09; Hennighausen L, 2005, NAT REV MOL CELL BIO, V6, P715, DOI 10.1038/nrm1714; Hjartaker A, 2008, ADV EXP MED BIOL, V630, P72; Hoene M, 2008, OBES REV, V9, P20, DOI 10.1111/j.1467-789X.2007.00410.x; Hong DS, 2007, CANCER-AM CANCER SOC, V110, P1911, DOI 10.1002/cncr.22999; Kamat A, 2002, TRENDS ENDOCRIN MET, V13, P122, DOI 10.1016/S1043-2760(02)00567-2; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Katz AJ, 2005, STEM CELLS, V23, P412, DOI 10.1634/stemcells.2004-0021; Kilroy GE, 2007, J CELL PHYSIOL, V212, P702, DOI 10.1002/jcp.21068; Knupfer H, 2007, BREAST CANCER RES TR, V102, P129, DOI 10.1007/s10549-006-9328-3; LaVecchia C, 1997, BRIT J CANCER, V75, P441, DOI 10.1038/bjc.1997.73; Li ZP, 2005, SURG CLIN N AM, V85, P681, DOI 10.1016/j.suc.2005.04.006; Lin SY, 2008, EXP CELL RES, V314, P3107, DOI 10.1016/j.yexcr.2008.07.028; Lin YF, 2006, MOL CELL BIOCHEM, V285, P69, DOI 10.1007/s11010-005-9056-8; Liu D, 2007, NEOPLASIA, V9, P418, DOI 10.1593/neo.07205; Liu D, 2007, CANCER RES, V67, P3117, DOI 10.1158/0008-5472.CAN-06-3452; Manabe Y, 2003, J PATHOL, V201, P221, DOI 10.1002/path.1430; Marcoux N, 2005, CELL SIGNAL, V17, P1449, DOI 10.1016/j.cellsig.2005.03.001; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Paduch R, 2005, CELL BIOL TOXICOL, V21, P247, DOI 10.1007/s10565-005-0002-z; Pederson T, 2008, J CELL BIOL, V180, P1061, DOI 10.1083/jcb.200709082; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Pupa SM, 2002, J CELL PHYSIOL, V192, P259, DOI 10.1002/jcp.10142; Raman D, 2007, CANCER LETT, V256, P137, DOI 10.1016/j.canlet.2007.05.013; Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533; Sasser AK, 2007, FASEB J, V21, P3763, DOI 10.1096/fj.07-8832com; Schaffler A, 2007, NAT CLIN PRACT ENDOC, V3, P345, DOI 10.1038/ncpendmet0456; Song XY, 2006, J CELL SCI, V119, P2871, DOI 10.1242/jcs.03017; Spalding KL, 2008, NATURE, V453, P783, DOI 10.1038/nature06902; Tang W, 2008, SCIENCE, V322, P583, DOI 10.1126/science.1156232; Tessitore L, 2004, INT J ONCOL, V24, P1529; Tholpady SS, 2006, CLIN PLAST SURG, V33, P55, DOI 10.1016/j.cps.2005.08.004; Wang WG, 2007, NAT REV CANCER, V7, P429, DOI 10.1038/nrc2148; Whiteman MK, 2005, CANCER EPIDEM BIOMAR, V14, P2009, DOI 10.1158/1055-9965.EPI-05-0106; Zalesin KC, 2008, ENDOCRIN METAB CLIN, V37, P663, DOI 10.1016/j.ecl.2008.06.004	49	227	231	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	30					2745	2755		10.1038/onc.2009.130	http://dx.doi.org/10.1038/onc.2009.130			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476OW	19483720	Green Accepted			2022-12-17	WOS:000268452900005
J	Baril, P; Gangeswaran, R; Mahon, PC; Caulee, K; Kocher, HM; Harada, T; Zhu, M; Kalthoff, H; Crnogorac-Jurcevic, T; Lemoine, NR				Baril, P.; Gangeswaran, R.; Mahon, P. C.; Caulee, K.; Kocher, H. M.; Harada, T.; Zhu, M.; Kalthoff, H.; Crnogorac-Jurcevic, T.; Lemoine, N. R.			Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the beta(4) integrin and the PI3k pathway	ONCOGENE			English	Article						pancreatic cancer; periostin; invasion; survival; hypoxia; PI3kinase	GROWTH-FACTOR-BETA; IN-VITRO; EXTRACELLULAR-MATRIX; ADHESION MOLECULE; ALPHA-6-BETA-4 INTEGRIN; PROGNOSTIC MARKER; SEQUENCE-ANALYSIS; SERUM LEVEL; FASCICLIN-I; EXPRESSION	Pancreatic ductal adenocarcinoma is a devastating disease, characterized by a rapid progression and poor treatment response. Using gene expression pro. ling of pancreatic cancer tissues, we previously identified periostin as a potential diagnostic and therapeutic target. In this study, we report the overexpression of periostin in a larger set of pancreatic cancer tissues and show that although the periostin transcript is exclusively expressed in tumour cells, the protein product is only detected in the extracellular matrix adjacent to cancer cells. Using an enzyme-linked immunosorbent assay (ELISA) assay, we show significantly increased levels of periostin in the sera of pancreatic cancer patients compared to non-cancer controls. We demonstrate that periostin promotes the invasiveness of tumour cells by increasing the motility of cells without inducing expression of proteases, and enhances the survival of tumour cells exposed to hypoxic conditions. At the molecular level, we provide evidence that the alpha(6)beta(4) integrin complex acts as the cell receptor of periostin in pancreatic cancer cells and that interaction promotes phosphorylation of focal adhesion kinase (FAK) and protein kinase B (AKT) though activation of the PI3 kinase pathway, but not the RAS/MEK/ERK pathway. These findings suggest an important role of periostin in pancreatic cancer and provide a rationale to study periostin for diagnostic and therapeutic applications.	Ctr Mol Oncol, Inst Canc, Barts & The London, London, England; John Vane Sci Ctr, London Sch Med & Dent, London EC1M 6BQ, England; CR UK Clin Ctr, Barts & The London, London, England; Ctr Tumour Biol, Barts & The London, Inst Canc, London, England; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol Oncol, Los Angeles, CA 90024 USA; Univ Kiel, Clin Gen Surg & Thorac Surg, D-24098 Kiel, Germany	University of London; Queen Mary University London; University of London; Queen Mary University London; University of London; Queen Mary University London; University of London; Queen Mary University London; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Kiel	Lemoine, NR (corresponding author), Ctr Mol Oncol, Inst Canc, Barts & The London, London, England.	nick.lemoine@cancer.org.uk	Kalthoff, Holger/B-1618-2010	Kocher, Hemant M/0000-0001-6771-1905; BARIL, Patrick/0000-0001-8290-9899				Akakura N, 2001, CANCER RES, V61, P6548; Bao SD, 2004, CANCER CELL, V5, P329, DOI 10.1016/S1535-6108(04)00081-9; Billings PC, 2002, J BIOL CHEM, V277, P28003, DOI 10.1074/jbc.M106837200; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Bornstein P, 2002, CURR OPIN CELL BIOL, V14, P608, DOI 10.1016/S0955-0674(02)00361-7; Boukerche H, 2000, CANCER RES, V60, P5848; Crnogorac-Jurcevic T, 2003, J PATHOL, V201, P63, DOI 10.1002/path.1418; DiMagno EP, 1999, GASTROENTEROLOGY, V117, P1464, DOI 10.1016/S0016-5085(99)70298-2; Dowen SE, 2005, AM J PATHOL, V166, P81, DOI 10.1016/S0002-9440(10)62234-1; Framson PE, 2004, J CELL BIOCHEM, V92, P679, DOI 10.1002/jcb.20091; Gibson MA, 1997, J HISTOCHEM CYTOCHEM, V45, P1683, DOI 10.1177/002215549704501212; Gillan L, 2002, CANCER RES, V62, P5358; Gleason B, 2005, J HISTOCHEM CYTOCHEM, V53, P799, DOI 10.1369/jhc.4B6522.2005; HALL PA, 1991, J PATHOL, V165, P33, DOI 10.1002/path.1711650107; Horiuchi K, 1999, J BONE MINER RES, V14, P1239, DOI 10.1359/jbmr.1999.14.7.1239; Hosotani Ryo, 2002, Pancreas, V25, pe30, DOI 10.1097/00006676-200208000-00021; Hruban RH, 2000, CLIN CANCER RES, V6, P2969; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Kii I, 2006, BIOCHEM BIOPH RES CO, V342, P766, DOI 10.1016/j.bbrc.2006.02.016; Kim CJ, 2005, INT J CANCER, V117, P51, DOI 10.1002/ijc.21120; Kim MO, 2003, NEUROSCI LETT, V336, P93, DOI 10.1016/S0304-3940(02)01260-0; Koninger J, 2004, BIOCHEM BIOPH RES CO, V322, P943, DOI 10.1016/j.bbrc.2004.08.008; Koong AC, 2000, INT J RADIAT ONCOL, V48, P919, DOI 10.1016/S0360-3016(00)00803-8; LEBARON RG, 1995, J INVEST DERMATOL, V104, P844, DOI 10.1111/1523-1747.ep12607024; Li P, 2004, J APPL PHYSIOL, V97, P1550, DOI 10.1152/japplphysiol.01311.2003; Lindner V, 2005, ARTERIOSCL THROM VAS, V25, P77, DOI 10.1161/01.ATV.0000149141.81230.c6; Lipscomb EA, 2005, CANCER METAST REV, V24, P413, DOI 10.1007/s10555-005-5133-4; Litvin J, 2005, ANAT REC PART A, V287A, P1205, DOI 10.1002/ar.a.20237; Morgan MR, 2004, J BIOL CHEM, V279, P26533, DOI 10.1074/jbc.M401736200; Rich JN, 2003, J BIOL CHEM, V278, P15951, DOI 10.1074/jbc.M211498200; Rios H, 2005, MOL CELL BIOL, V25, P11131, DOI 10.1128/MCB.25.24.11131-11144.2005; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sasaki H, 2003, BREAST CANCER RES TR, V77, P245, DOI 10.1023/A:1021899904332; Sasaki H, 2002, J PEDIATR SURG, V37, P1293, DOI 10.1053/jpsu.2002.34985; Sasaki H, 2001, CANCER-AM CANCER SOC, V92, P843, DOI 10.1002/1097-0142(20010815)92:4<843::AID-CNCR1391>3.0.CO;2-P; Sasaki H, 2001, JPN J CANCER RES, V92, P869, DOI 10.1111/j.1349-7006.2001.tb01174.x; Sasaki H, 2001, CANCER LETT, V172, P37, DOI 10.1016/S0304-3835(01)00633-4; Shao R, 2004, MOL CELL BIOL, V24, P3992, DOI 10.1128/MCB.24.9.3992-4003.2004; Shi Q, 2004, J BIOL CHEM, V279, P52200, DOI 10.1074/jbc.M409630200; SKONIER J, 1992, DNA CELL BIOL, V11, P511, DOI 10.1089/dna.1992.11.511; Stoll V, 2005, GUT, V54, P109, DOI 10.1136/gut.2004.046706; Tai IT, 2005, CARCINOGENESIS, V26, P908, DOI 10.1093/carcin/bgi034; TAKESHITA S, 1993, BIOCHEM J, V294, P271, DOI 10.1042/bj2940271; Yoon SO, 2005, CANCER RES, V65, P2761, DOI 10.1158/0008-5472.CAN-04-4122; Zhao HR, 2004, J BIOL CHEM, V279, P8592, DOI 10.1074/jbc.M308708200; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0	46	227	243	2	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	14					2082	2094		10.1038/sj.onc.1210009	http://dx.doi.org/10.1038/sj.onc.1210009			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	151TJ	17043657				2022-12-17	WOS:000245313400010
J	de Silanes, IL; Fan, JS; Yang, XL; Zonderman, AB; Potapova, O; Pizer, ES; Gorospe, M				de Silanes, IL; Fan, JS; Yang, XL; Zonderman, AB; Potapova, O; Pizer, ES; Gorospe, M			Role of the RNA-binding protein HuR in colon carcinogenesis	ONCOGENE			English	Article						HuR; ELAV; colon cancer; mRNA turnover; carcinogenesis	MESSENGER-RNA; STABILITY FACTOR; EXPRESSION; CANCER; RICH; STABILIZATION; ELEMENT; GROWTH; ELAV; CONTAINS	Immunohistochemical analysis of paired tumor and normal tissue specimens revealed that the expression and cytoplasmic abundance of the RNA-binding protein HuR increased with malignancy, particularly in colon carcinomas. Interventions to modulate HuR expression in human RKO colon cancer cells altered gene expression profiles and identified beta-catenin mRNA as a novel HuR target. Subcutaneous injection of HuR-overexpressing RKO cells into nude mice produced signfiicantly larger tumors than those arising from control populations; conversely, RKO cells expressing reduced HuR through small interference RNA- or antisense HuR-based approaches developed significantly more slowly. We propose that HuR-regulated target mRNA expression contributes to colon cancer growth. Our results suggest a pivotal function for HuR in colon carcinogenesis.	NIA, Cellular & Mol Biol Lab, Intramural Res Program, NIH, Baltimore, MD 21224 USA; NIA, Res Resources Branch, Intramural Res Program, NIH, Baltimore, MD 21224 USA; SUGEN Inc, Preclin Res & Translat Med, San Francisco, CA 94080 USA; Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Pfizer; Johns Hopkins University; Johns Hopkins Medicine	Gorospe, M (corresponding author), NIA, Cellular & Mol Biol Lab, Intramural Res Program, NIH, Box 12,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	myriam-gorospe@nih.gov	Zonderman, Alan B/A-5807-2013; Lopez de Silanes, Isabel/K-4962-2015	Zonderman, Alan B/0000-0003-3530-2319; Lopez de Silanes, Isabel/0000-0001-6762-9792; Zonderman, Alan B/0000-0002-6523-4778	NATIONAL INSTITUTE ON AGING [Z01AG000511, ZIAAG000511] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Antic D, 1997, AM J HUM GENET, V61, P273, DOI 10.1086/514866; Atasoy U, 1998, J CELL SCI, V111, P3145; Balkwill F, 2002, CYTOKINE GROWTH F R, V13, P135, DOI 10.1016/S1359-6101(01)00020-X; Blaxall BC, 2000, MOL CARCINOGEN, V28, P76; Bosher JM, 2000, NAT CELL BIOL, V2, pE31, DOI 10.1038/35000102; Brennan CM, 2000, J CELL BIOL, V151, P1, DOI 10.1083/jcb.151.1.1; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Cheadle C, 2003, J MOL DIAGN, V5, P73, DOI 10.1016/S1525-1578(10)60455-2; Chen CYA, 2002, MOL CELL BIOL, V22, P7268, DOI 10.1128/MCB.22.20.7268-7278.2002; DALMAU J, 1990, ANN NEUROL, V27, P544, DOI 10.1002/ana.410270515; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI12973; Fan JS, 2002, P NATL ACAD SCI USA, V99, P10611, DOI 10.1073/pnas.162212399; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Gorospe M, 1998, MOL CELL BIOL, V18, P1400, DOI 10.1128/MCB.18.3.1400; JOOSS KU, 1995, ONCOGENE, V10, P603; Joseph B, 1998, J BIOL CHEM, V273, P20511, DOI 10.1074/jbc.273.32.20511; Keene JD, 2002, MOL CELL, V9, P1161, DOI 10.1016/S1097-2765(02)00559-2; Keene JD, 1999, P NATL ACAD SCI USA, V96, P5, DOI 10.1073/pnas.96.1.5; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Morrell CH, 1997, AM STAT, V51, P338, DOI 10.2307/2685902; Nabors LB, 2001, CANCER RES, V61, P2154; Sager R, 1997, P NATL ACAD SCI USA, V94, P952, DOI 10.1073/pnas.94.3.952; SAS Institute Inc, 1999, SAS STAT US GUID VER; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; Tenenbaum SA, 2000, P NATL ACAD SCI USA, V97, P14085, DOI 10.1073/pnas.97.26.14085; Vawter MP, 2001, BRAIN RES BULL, V55, P641, DOI 10.1016/S0361-9230(01)00522-6; Wang W, 2002, MOL CELL BIOL, V22, P3425, DOI 10.1128/MCB.22.10.3425-3436.2002; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Wang WG, 2001, MOL CELL BIOL, V21, P5889, DOI 10.1128/MCB.21.17.5889-5898.2001; Wong NACS, 2002, AM J PATHOL, V160, P389, DOI 10.1016/S0002-9440(10)64856-0	36	227	233	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2003	22	46					7146	7154		10.1038/sj.onc.1206862	http://dx.doi.org/10.1038/sj.onc.1206862			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732PP	14562043				2022-12-17	WOS:000185955000006
J	Zhu, J; Emerson, SG				Zhu, J; Emerson, SG			Hematopoietic cytokines, transcription factors and lineage commitment	ONCOGENE			English	Review						transcription factor; cytokines; hematopoiesis	COLONY-STIMULATING FACTOR; STEM-CELL FACTOR; BINDING PROTEIN-ALPHA; TUMOR-NECROSIS-FACTOR; MYELOID PROGENITOR CELLS; HUMAN CD34(+) CELLS; T-CELL; B-CELL; IN-VIVO; TRANSFORMING GROWTH-FACTOR-BETA-1	The past two decades have witnessed significant advances in our understanding of the cellular physiology and molecular regulation of hematopoiesis. At the heart of stem cell self-renewal and lineage commitment decisions lies the relative expression levels of lineage-specific transcription factors. The expression of these transcription factors in early stem cells may be promiscuous and fluctuate, but ultimately comes under the influence of extracellular regulatory signals in the form of hematopoietic cytokines. In this review, we first summarize our current understanding of the phenotypic characterization of hematopoietic stem cells. Next, we describe key known transcription factors which govern stem cell self-renewal and lineage commitment decisions. Finally, we review data concerning the role of specific cytokines in influencing these decisions. From this review, a picture emerges in which stem cell fate decisions are governed by the integrated effects of intrinsic transcription factors and external signaling pathways initiated by regulatory cytokines.	Univ Penn, Sch Med, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Emerson, SG (corresponding author), Univ Penn, Sch Med, Dept Med, Div Hematol Oncol, Maloney 510,3600 Spruce St, Philadelphia, PA 19104 USA.	emersons@mail.med.upenn.edu						Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Akashi K, 2000, CURR OPIN IMMUNOL, V12, P144, DOI 10.1016/S0952-7915(99)00064-3; Allman D, 1999, J EXP MED, V189, P735, DOI 10.1084/jem.189.4.735; Anderson KL, 1998, BLOOD, V91, P3702, DOI 10.1182/blood.V91.10.3702; Anderson KL, 1998, BLOOD, V92, P1576, DOI 10.1182/blood.V92.5.1576.417k29_1576_1585; Antonchuk J, 2001, EXP HEMATOL, V29, P1125, DOI 10.1016/S0301-472X(01)00681-6; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; Barnache S, 1998, ONCOGENE, V16, P2989, DOI 10.1038/sj.onc.1202095; Batard P, 2000, J CELL SCI, V113, P383; Benbernou N, 2000, J BIOL CHEM, V275, P7060, DOI 10.1074/jbc.275.10.7060; Bhardwaj G, 2001, NAT IMMUNOL, V2, P172, DOI 10.1038/84282; Bhatia M, 1999, J EXP MED, V189, P1139, DOI 10.1084/jem.189.7.1139; Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; Blazsek I, 2000, BLOOD, V96, P3763, DOI 10.1182/blood.V96.12.3763.h8003763_3763_3771; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Brandon C, 2000, BLOOD, V96, P4132, DOI 10.1182/blood.V96.13.4132.h8004132_4132_4141; Brass AL, 1999, EMBO J, V18, P977, DOI 10.1093/emboj/18.4.977; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Bromleigh VC, 2000, GENE DEV, V14, P2581, DOI 10.1101/gad.817100; Broudy VC, 1997, BLOOD, V90, P1345, DOI 10.1182/blood.V90.4.1345.1345_1345_1364; Broudy VC, 1996, BLOOD, V88, P75; Bryder D, 2000, BLOOD, V96, P1748, DOI 10.1182/blood.V96.5.1748.h8001748_1748_1755; Busslinger M, 2000, CURR OPIN IMMUNOL, V12, P151, DOI 10.1016/S0952-7915(99)00065-5; CHEN HM, 1995, ONCOGENE, V11, P1549; Chen Z, 1997, PHARMACOL THERAPEUT, V76, P141, DOI 10.1016/S0163-7258(97)00090-9; Cheng T, 2000, NAT MED, V6, P1235, DOI 10.1038/81335; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Chiang MY, 1999, BLOOD, V94, P3621, DOI 10.1182/blood.V94.11.3621.423k38_3621_3632; Choi K, 1998, DEVELOPMENT, V125, P725; Ciau-Uitz A, 2000, CELL, V102, P787, DOI 10.1016/S0092-8674(00)00067-2; Coutts M, 1999, BLOOD, V93, P3369, DOI 10.1182/blood.V93.10.3369.410k11_3369_3378; Crispino JD, 1999, MOL CELL, V3, P219, DOI 10.1016/S1097-2765(00)80312-3; Cumano A, 2001, CURR OPIN IMMUNOL, V13, P166, DOI 10.1016/S0952-7915(00)00200-4; Daga A, 2000, EXP HEMATOL, V28, P569, DOI 10.1016/S0301-472X(00)00135-1; Deftos ML, 2000, CURR OPIN IMMUNOL, V12, P166, DOI 10.1016/S0952-7915(99)00067-9; DeKoter RP, 1998, EMBO J, V17, P4456, DOI 10.1093/emboj/17.15.4456; DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439; Drexler HG, 1998, LEUKEMIA RES, V22, P927, DOI 10.1016/S0145-2126(98)00088-5; Ducos K, 2000, J CELL PHYSIOL, V184, P80, DOI 10.1002/(SICI)1097-4652(200007)184:1<80::AID-JCP8>3.0.CO;2-Q; Dybedal I, 2001, BLOOD, V98, P1782, DOI 10.1182/blood.V98.6.1782; Egawa T, 2001, IMMUNITY, V15, P323, DOI 10.1016/S1074-7613(01)00185-6; Elwood NJ, 1998, BLOOD, V91, P3756; Engel I, 2001, J EXP MED, V194, P733, DOI 10.1084/jem.194.6.733; Enver T, 1998, CELL, V94, P9, DOI 10.1016/S0092-8674(00)81215-5; Evans CA, 1999, BLOOD, V94, P1504, DOI 10.1182/blood.V94.5.1504.417a27_1504_1514; Francis JM, 2000, J BIOL CHEM, V275, P39137, DOI 10.1074/jbc.M007212200; Fujimaki S, 2001, BRIT J HAEMATOL, V113, P52, DOI 10.1046/j.1365-2141.2001.02736.x; Fuller JF, 1999, BLOOD, V93, P3391, DOI 10.1182/blood.V93.10.3391.410k26_3391_3400; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; GIAMPAOLO A, 1994, BLOOD, V84, P3637, DOI 10.1182/blood.V84.11.3637.bloodjournal84113637; Giannola DM, 2000, J EXP MED, V192, P1479, DOI 10.1084/jem.192.10.1479; GURNEY AL, 1994, SCIENCE, V265, P1445, DOI 10.1126/science.8073287; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Hao SX, 2000, MOL CELL BIOL, V20, P1149, DOI 10.1128/MCB.20.4.1149-1161.2000; Harris KW, 1998, BLOOD, V92, P1219, DOI 10.1182/blood.V92.4.1219.416k07_1219_1224; Hartman ML, 2001, BLOOD, V97, P1086, DOI 10.1182/blood.V97.4.1086; Helgason CD, 1996, BLOOD, V87, P2740, DOI 10.1182/blood.V87.7.2740.bloodjournal8772740; Heyworth C, 1999, GENE DEV, V13, P1847, DOI 10.1101/gad.13.14.1847; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Hsu HC, 2000, BLOOD, V96, P3757, DOI 10.1182/blood.V96.12.3757.h8003757_3757_3762; Hu M, 1997, GENE DEV, V11, P774, DOI 10.1101/gad.11.6.774; Huang S, 2000, MOL CELL BIOL, V20, P2248, DOI 10.1128/MCB.20.6.2248-2259.2000; Huang SM, 2000, EMBO J, V19, P6792, DOI 10.1093/emboj/19.24.6792; ICHIKAWA Y, 1970, J CELL PHYSIOL, V76, P175, DOI 10.1002/jcp.1040760207; Ikonomi P, 2000, EXP HEMATOL, V28, P1423, DOI 10.1016/S0301-472X(00)00553-1; Izon DJ, 2001, IMMUNITY, V14, P253, DOI 10.1016/S1074-7613(01)00107-8; Jackson KA, 1999, P NATL ACAD SCI USA, V96, P14482, DOI 10.1073/pnas.96.25.14482; Jakubowiak A, 2000, J BIOL CHEM, V275, P40282, DOI 10.1074/jbc.C000485200; JUST U, 1991, CELL, V64, P1163, DOI 10.1016/0092-8674(91)90271-Y; Kapur R, 2001, J BIOL CHEM, V276, P1099, DOI 10.1074/jbc.M007442200; Kapur R, 1999, BLOOD, V94, P1915; Karanu FN, 2000, J EXP MED, V192, P1365, DOI 10.1084/jem.192.9.1365; Kee BL, 1998, J EXP MED, V188, P699, DOI 10.1084/jem.188.4.699; Kelly LM, 2000, EMBO J, V19, P1987, DOI 10.1093/emboj/19.9.1987; Kiger AA, 2000, NATURE, V407, P750, DOI 10.1038/35037606; Klug CA, 1998, P NATL ACAD SCI USA, V95, P657, DOI 10.1073/pnas.95.2.657; Koipally J, 1999, EMBO J, V18, P3090, DOI 10.1093/emboj/18.11.3090; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; Kondo M, 2000, NATURE, V407, P383, DOI 10.1038/35030112; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Krishnaraju K, 2001, BLOOD, V97, P1298, DOI 10.1182/blood.V97.5.1298; Krosl J, 1998, ONCOGENE, V16, P3403, DOI 10.1038/sj.onc.1201883; KRYSTAL G, 1994, J EXP MED, V180, P851, DOI 10.1084/jem.180.3.851; Lacaud G, 1998, IMMUNITY, V9, P827, DOI 10.1016/S1074-7613(00)80648-2; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Lin RJ, 1999, TRENDS GENET, V15, P179, DOI 10.1016/S0168-9525(99)01710-2; Liu YJ, 2001, NAT IMMUNOL, V2, P585, DOI 10.1038/89726; Maeno M, 1996, BLOOD, V88, P1965, DOI 10.1182/blood.V88.6.1965.bloodjournal8861965; Maguer-Satta V, 2000, BLOOD, V96, P4118; Maitra S, 2000, MOL CELL BIOL, V20, P1911, DOI 10.1128/MCB.20.6.1911-1922.2000; Manaia A, 2000, DEVELOPMENT, V127, P643; Marshall CJ, 2000, BLOOD, V96, P1591, DOI 10.1182/blood.V96.4.1591.h8001591_1591_1593; Matsumura I, 2000, BLOOD, V96, P2440; Medvinsky A, 1996, CELL, V86, P897, DOI 10.1016/S0092-8674(00)80165-8; Meng XJ, 2000, SCIENCE, V287, P1489, DOI 10.1126/science.287.5457.1489; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Montecino-Rodriguez E, 2001, NAT IMMUNOL, V2, P83, DOI 10.1038/83210; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; Morimura T, 2001, J IMMUNOL, V166, P3277, DOI 10.4049/jimmunol.166.5.3277; Morimura T, 2000, J BIOL CHEM, V275, P36523, DOI 10.1074/jbc.M006415200; Mullen AC, 2001, SCIENCE, V292, P1907, DOI 10.1126/science.1059835; Nerlov C, 2000, BLOOD, V95, P2543, DOI 10.1182/blood.V95.8.2543.008k19_2543_2551; Nerlov C, 1998, GENE DEV, V12, P2403, DOI 10.1101/gad.12.15.2403; Nichogiannopoulou A, 1999, J EXP MED, V190, P1201, DOI 10.1084/jem.190.9.1201; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Nutt SL, 1999, BIOL CHEM, V380, P601, DOI 10.1515/BC.1999.077; Nutt SL, 1997, GENE DEV, V11, P476, DOI 10.1101/gad.11.4.476; Nutt SL, 1999, NATURE, V401, P556, DOI 10.1038/44076; O'Riordan M, 1999, IMMUNITY, V11, P21, DOI 10.1016/S1074-7613(00)80078-3; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; Oh IH, 1998, MOL CELL BIOL, V18, P499, DOI 10.1128/MCB.18.1.499; Ohneda O, 1998, BLOOD, V92, P908; Okuda T, 2000, MOL CELL BIOL, V20, P319, DOI 10.1128/MCB.20.1.319-328.2000; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Ordentlich P, 1998, MOL CELL BIOL, V18, P2230, DOI 10.1128/MCB.18.4.2230; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Pan Q, 2001, J ENDOCRINOL, V169, P153, DOI 10.1677/joe.0.1690153; Pan QT, 1999, J BIOL CHEM, V274, P8437, DOI 10.1074/jbc.274.13.8437; Papayannopoulou T, 2000, BLOOD, V95, P1274, DOI 10.1182/blood.V95.4.1274.004k45_1274_1282; Passegue E, 2001, CELL, V104, P21, DOI 10.1016/S0092-8674(01)00188-X; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Pawlak G, 2000, EXP HEMATOL, V28, P1164, DOI 10.1016/S0301-472X(00)00522-1; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; Phillips RL, 2000, SCIENCE, V288, P1635, DOI 10.1126/science.288.5471.1635; Pierelli L, 2000, BLOOD, V95, P3001; Porcher C, 1999, DEVELOPMENT, V126, P4603; Pui JC, 1999, IMMUNITY, V11, P299, DOI 10.1016/S1074-7613(00)80105-3; Querfurth E, 2000, GENE DEV, V14, P2515, DOI 10.1101/gad.177200; Racke FK, 2001, J BIOL CHEM, V276, P522, DOI 10.1074/jbc.M005236200; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; Raz R, 1999, P NATL ACAD SCI USA, V96, P2846, DOI 10.1073/pnas.96.6.2846; Rebel VI, 1999, J EXP MED, V190, P1493, DOI 10.1084/jem.190.10.1493; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; Robertson SM, 2000, DEVELOPMENT, V127, P2447; ROJNUCKARIN P, 2001, J BIOL CHEM, V4, P4; Rolink AG, 1999, NATURE, V401, P603, DOI 10.1038/44164; Rothenberg EV, 2000, CURR OPIN GENET DEV, V10, P370, DOI 10.1016/S0959-437X(00)00098-8; Sabbattini P, 2001, EMBO J, V20, P2812, DOI 10.1093/emboj/20.11.2812; Sakamaki S, 1999, BLOOD, V94, P1961, DOI 10.1182/blood.V94.6.1961.418k17_1961_1970; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; Schmidt M, 1998, BLOOD, V91, P22, DOI 10.1182/blood.V91.1.22.22_22_29; Schroeder T, 2000, EXP HEMATOL, V28, P1206, DOI 10.1016/S0301-472X(00)00534-8; Schroeder T, 2000, EMBO J, V19, P2558, DOI 10.1093/emboj/19.11.2558; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Semerad CL, 1999, IMMUNITY, V11, P153, DOI 10.1016/S1074-7613(00)80090-4; Shi Q, 1998, BLOOD, V92, P362, DOI 10.1182/blood.V92.2.362.414k38_362_367; Solanilla A, 2000, BLOOD, V95, P3758; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Tamura T, 2000, IMMUNITY, V13, P155, DOI 10.1016/S1074-7613(00)00016-9; Tamura T, 1999, ONCOGENE, V18, P6488, DOI 10.1038/sj.onc.1203062; Thorsteinsdottir U, 1999, BLOOD, V94, P2605, DOI 10.1182/blood.V94.8.2605.420k19_2605_2612; Ting CN, 1996, NATURE, V384, P474, DOI 10.1038/384474a0; Tonelli R, 2000, HUM GENET, V107, P225, DOI 10.1007/s004390000357; Trinh LA, 2001, GENE DEV, V15, P1817, DOI 10.1101/gad.905601; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Tsuzuki S, 2000, MOL CELL BIOL, V20, P6276, DOI 10.1128/MCB.20.17.6276-6286.2000; Uchida M, 2001, INT J HEMATOL, V73, P78, DOI 10.1007/BF02981906; Vannucchi AM, 2000, BLOOD, V95, P2559; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; Wang JH, 1996, IMMUNITY, V5, P537, DOI 10.1016/S1074-7613(00)80269-1; Wang XP, 1999, BLOOD, V94, P560, DOI 10.1182/blood.V94.2.560.414k41_560_571; Winandy S, 1999, J EXP MED, V190, P1039, DOI 10.1084/jem.190.8.1039; WU L, 1991, J EXP MED, V174, P1617, DOI 10.1084/jem.174.6.1617; Yamada Y, 1998, P NATL ACAD SCI USA, V95, P3890, DOI 10.1073/pnas.95.7.3890; Yamagata T, 2000, EMBO J, V19, P4676, DOI 10.1093/emboj/19.17.4676; Yang FC, 1998, BLOOD, V92, P4632, DOI 10.1182/blood.V92.12.4632.424k28_4632_4640; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang P, 2000, BLOOD, V96, P2641; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705; Zhao Y, 2000, BLOOD, V96, P3016; Zhou YH, 1998, EMBO J, V17, P6689, DOI 10.1093/emboj/17.22.6689; Zhuang YA, 1998, MOL CELL BIOL, V18, P3340, DOI 10.1128/MCB.18.6.3340; Ziegler BL, 1999, SCIENCE, V285, P1553, DOI 10.1126/science.285.5433.1553	180	227	239	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2002	21	21					3295	3313		10.1038/sj.onc.1205318	http://dx.doi.org/10.1038/sj.onc.1205318			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	552RL	12032771				2022-12-17	WOS:000175633300006
J	Negorev, D; Maul, GG				Negorev, D; Maul, GG			Cellular proteins localized at and interacting within ND10/PML nuclear bodies/PODs suggest functions of a nuclear depot	ONCOGENE			English	Article						ND10; PML; Daxx; Sp100; nuclear bodies; protein interaction	ACUTE PROMYELOCYTIC LEUKEMIA; CREB-BINDING-PROTEIN; RNA-POLYMERASE-II; IMMORTALIZED HUMAN-CELLS; NEOPLASTIC HUMAN TISSUES; PML PROTEIN; SERINE/THREONINE KINASE; COVALENT MODIFICATION; VIRUS-REPLICATION; GROWTH-SUPPRESSOR	ND10, PML bodies or PODS have become the defining nuclear structure for a highly complex protein complement involved in cell activities such as aging, apoptosis, the cell cycle, stress response, hormone signaling, transcriptional regulation and development. ND10 are present in many but not all cell types and are not essential for cell survival. Here, we review the cellular proteins found in ND10, their few known interactions and their contribution to the ND10 structure per se and to functions elsewhere in the nucleus. The discrepancy between the functions of the ND10 proteins and the nonessential nature of the structure in which they are aggregated at their highest concentrations leads to the conclusion that the proteins function elsewhere. The regulated recruitment of specific proteins into ND10 as well as their controlled release upon external induced stress points to a regulated nuclear depot function for ND10. These nuclear depot functions seem important as nuclear defense against viral attack and other external insults.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	The Wistar Institute	Maul, GG (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.							Alcalay M, 1998, MOL CELL BIOL, V18, P1084, DOI 10.1128/MCB.18.2.1084; Anton LC, 1999, J CELL BIOL, V146, P113, DOI 10.1083/jcb.146.1.113; ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; Bell P, 2000, J VIROL, V74, P5329, DOI 10.1128/JVI.74.11.5329-5336.2000; BELL P, 2001, IN PRESS J VIROL; BERNHARD W, 1969, J ULTRA MOL STRUCT R, V27, P250, DOI 10.1016/S0022-5320(69)80016-X; Bloch DB, 1999, MOL CELL BIOL, V19, P4423; Boddy MN, 1996, ONCOGENE, V13, P971; Boisvert FM, 2000, J CELL BIOL, V148, P283, DOI 10.1083/jcb.148.2.283; Boisvert FM, 2001, J CELL BIOL, V152, P1099, DOI 10.1083/jcb.152.5.1099; Bond U, 2000, INT J BIOCHEM CELL B, V32, P643, DOI 10.1016/S1357-2725(00)00008-X; BRASCH K, 1992, EXP CELL RES, V202, P211, DOI 10.1016/0014-4827(92)90068-J; BREGMAN DB, 1995, J CELL BIOL, V129, P287, DOI 10.1083/jcb.129.2.287; Bryan TM, 1997, EUR J CANCER, V33, P767, DOI 10.1016/S0959-8049(97)00065-8; Cao TY, 1998, J CELL SCI, V111, P1319; Carlile GW, 1998, BIOCHEM J, V335, P691, DOI 10.1042/bj3350691; Cho YM, 1998, INT J MOL MED, V1, P717; Colgin LM, 1999, CURR OPIN GENET DEV, V9, P97, DOI 10.1016/S0959-437X(99)80014-8; DANIEL MT, 1993, BLOOD, V82, P1858; de The G., 1960, B ASSOC FR ETUD CANC, V47, P570; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2633, DOI 10.1073/pnas.96.6.2633; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; Everett RD, 1999, J CELL SCI, V112, P3443; Everett RD, 1999, J VIROL, V73, P417, DOI 10.1128/JVI.73.1.417-426.1999; Fabunmi RP, 2001, J CELL SCI, V114, P29; FLENGHI L, 1995, BLOOD, V85, P1871, DOI 10.1182/blood.V85.7.1871.bloodjournal8571871; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Gambacorta M, 1996, AM J PATHOL, V149, P2023; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Gongora C, 1997, J BIOL CHEM, V272, P19457, DOI 10.1074/jbc.272.31.19457; GOODSON ML, 2001, J BIOL CHEM, V15, P15; Grande MA, 1996, J CELL BIOCHEM, V63, P280, DOI 10.1002/(SICI)1097-4644(19961201)63:3<280::AID-JCB3>3.0.CO;2-T; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; HINGLAISGUILLAU.N, 1961, B CANCER, V48, P282; Hsu WL, 2001, J VIROL, V75, P3819, DOI 10.1128/JVI.75.8.3819-3831.2001; Ishov AM, 1996, J CELL BIOL, V134, P815, DOI 10.1083/jcb.134.4.815; Ishov AM, 1997, J CELL BIOL, V138, P5, DOI 10.1083/jcb.138.1.5; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; JACKSON DA, 1993, EMBO J, V12, P1059, DOI 10.1002/j.1460-2075.1993.tb05747.x; Jiang WQ, 1996, EXP CELL RES, V229, P289, DOI 10.1006/excr.1996.0374; Johnson FB, 2001, EMBO J, V20, P905, DOI 10.1093/emboj/20.4.905; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kass-Eisler A, 2000, TRENDS BIOCHEM SCI, V25, P200, DOI 10.1016/S0968-0004(00)01557-7; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; KOKEN MHM, 1995, ONCOGENE, V10, P1315; Lai HK, 2000, ONCOGENE, V19, P1623, DOI 10.1038/sj.onc.1203473; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; LAM YW, 1995, EXP CELL RES, V221, P344, DOI 10.1006/excr.1995.1384; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; Lehembre F, 2001, ONCOGENE, V20, P1, DOI 10.1038/sj.onc.1204063; Lehming N, 1998, P NATL ACAD SCI USA, V95, P7322, DOI 10.1073/pnas.95.13.7322; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Lombard DB, 2000, CANCER RES, V60, P2331; MAUL GG, 1994, J GEN VIROL, V75, P1223, DOI 10.1099/0022-1317-75-6-1223; Maul GG, 1998, CELL GROWTH DIFFER, V9, P743; Maul GG, 1998, BIOESSAYS, V20, P660, DOI 10.1002/(SICI)1521-1878(199808)20:8<660::AID-BIES9>3.0.CO;2-M; Maul GG, 1995, J CELL BIOCHEM, V59, P498, DOI 10.1002/jcb.240590410; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Negorev D, 2001, J CELL SCI, V114, P59; OCHS RL, 1995, MOL BIOL CELL, V6, P345, DOI 10.1091/mbc.6.3.345; PADYKULA HA, 1981, ANAT RECORD, V201, P679, DOI 10.1002/ar.1092010412; Plehn-Dujowich D, 2000, CHROMOSOMA, V109, P266, DOI 10.1007/s004120000073; PUVIONDUTILLEUL F, 1995, EXP CELL RES, V218, P9, DOI 10.1006/excr.1995.1125; REGAD T, 2001, IN PRESS EMBO J; Rochat-Steiner V, 2000, J EXP MED, V192, P1165, DOI 10.1084/jem.192.8.1165; Ruthardt M, 1998, ONCOGENE, V16, P1945, DOI 10.1038/sj.onc.1201722; Seeler JS, 1999, CURR OPIN GENET DEV, V9, P362, DOI 10.1016/S0959-437X(99)80054-9; Seeler JS, 1998, P NATL ACAD SCI USA, V95, P7316, DOI 10.1073/pnas.95.13.7316; Seeler JS, 2001, MOL CELL BIOL, V21, P3314, DOI 10.1128/MCB.21.10.3314-3324.2001; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Tang QY, 2000, J VIROL, V74, P9694, DOI 10.1128/JVI.74.20.9694-9700.2000; Tokutake Y, 1998, BIOCHEM BIOPH RES CO, V247, P765, DOI 10.1006/bbrc.1998.8876; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Trost M, 2000, J BIOL CHEM, V275, P7373, DOI 10.1074/jbc.275.10.7373; Tsukamoto T, 2000, NAT CELL BIOL, V2, P871, DOI 10.1038/35046510; Vallian S, 1998, MOL CELL BIOL, V18, P7147, DOI 10.1128/MCB.18.12.7147; von Mikecz A, 2000, J CELL BIOL, V150, P265, DOI 10.1083/jcb.150.1.265; WANSINK DG, 1993, J CELL BIOL, V122, P283, DOI 10.1083/jcb.122.2.283; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wu GK, 2000, J BIOL CHEM, V275, P30618, DOI 10.1074/jbc.C000390200; Wu WS, 2001, MOL CELL BIOL, V21, P2259, DOI 10.1128/MCB.21.7.2259-2268.2001; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yankiwski V, 2000, P NATL ACAD SCI USA, V97, P5214, DOI 10.1073/pnas.090525897; Yeager TR, 1999, CANCER RES, V59, P4175; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752	95	227	230	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 29	2001	20	49					7234	7242		10.1038/sj.onc.1204764	http://dx.doi.org/10.1038/sj.onc.1204764			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487TM	11704851				2022-12-17	WOS:000171891900011
J	Midgley, CA; Desterro, JMP; Saville, MK; Howard, S; Sparks, A; Hay, RT; Lane, DP				Midgley, CA; Desterro, JMP; Saville, MK; Howard, S; Sparks, A; Hay, RT; Lane, DP			An N-terminal p14(ARF) peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo	ONCOGENE			English	Article						p53 tumour suppressor; Mdm2; p14(ARF); ubiquitination; protein stability; transcriptional activation	TUMOR-SUPPRESSOR P53; CELL-CYCLE ARREST; NUCLEAR EXPORT; DNA-BINDING; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; ONCOPROTEIN MDM2; MAMMALIAN-CELLS; STABILIZES P53; HUMAN SARCOMAS	The p53 tumour suppressor protein is down-regulated by the action of Mdm2, which targets p53 for rapid degradation by the ubiquitin-proteasome pathway. The p14(ARF) protein is also a potent tumour suppressor that acts by binding to Mdm2 and blocking Mdm2-dependent p53 degradation and transcriptional silencing, We have screened a series of overlapping synthetic peptides derived from the p14(ARF) protein sequence and found that a peptide corresponding to the first 20 amino acids of ARF (Peptide 3) could bind human Mdm2, The binding site for Peptide 3 on Mdm2 was determined by deletion mapping and lies adjacent to the binding site of the anti-Mdm2 antibody 2A10, which on microinjection into cells can activate p53-dependent transactivation of a reporter plasmid, To determine whether Peptide 3 could similarly activate p53, we expressed a fusion of green fluorescent protein and Peptide 3 in MCF7 and U-2 OS cells and were able to demonstrate induction of p53 protein and p53-dependent transcription. Peptide 3 was able to block in vitro ubiquitination of p53 mediated by Mdm2, Small peptides which are sufficient to block degradation of p53 could provide therapeutic agents able to restore p53-dependent cell death pathways in tumours that retain wild-type p53 expression.	Univ Dundee, Dept Biochem, Canc Res Campaign Cell Transformat Grp, Dundee DD1 5EH, Scotland; Univ St Andrews, Sch Biomed Sci, St Andrews KY16 9TS, Fife, Scotland	University of Dundee; University of St Andrews	Lane, DP (corresponding author), Univ Dundee, Dept Biochem, Canc Res Campaign Cell Transformat Grp, WTB-MSI Bldg,Dow St, Dundee DD1 5EH, Scotland.		Lane, David P/C-4920-2008; Hay, Ronald T/F-9338-2011	Hay, Ronald T/0000-0001-7113-9024; Desterro, Joana/0000-0002-6359-7233; Lane, David/0000-0003-0551-3545				BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Blaydes JP, 1997, ONCOGENE, V14, P1859, DOI 10.1038/sj.onc.1201018; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Bottger V, 1996, ONCOGENE, V13, P2141; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CIECHANOVER A, 1980, P NATL ACAD SCI-BIOL, V77, P1365, DOI 10.1073/pnas.77.3.1365; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; FLORENES VA, 1994, J NATL CANCER I, V86, P1297, DOI 10.1093/jnci/86.17.1297; Foulkes WD, 1997, MOL MED, V3, P5, DOI 10.1007/BF03401664; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HAAS AL, 1982, J BIOL CHEM, V257, P2543; Hansen S, 1996, J BIOL CHEM, V271, P3917; Hansen S, 1998, J MOL BIOL, V275, P575, DOI 10.1006/jmbi.1997.1507; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lain S, 1999, EXP CELL RES, V248, P457, DOI 10.1006/excr.1999.4433; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu HS, 1999, BIOCHEM BIOPH RES CO, V260, P712, DOI 10.1006/bbrc.1999.0954; LUNA RMD, 1995, NATURE, V378, P203; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MAKI CG, 1996, CANCER RES, V56, P2694; MIDGLEY CA, 1992, J CELL SCI, V101, P183; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Shaw P, 1996, ONCOGENE, V12, P921; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; VOJTESEK B, 1993, J CELL SCI, V105, P607; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; zur Hausen H, 1987, PAPILLOMAVIRUSES, P245	65	227	238	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2000	19	19					2312	2323		10.1038/sj.onc.1203593	http://dx.doi.org/10.1038/sj.onc.1203593			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZR	10822382				2022-12-17	WOS:000086974300006
J	Piette, J; Neel, H; Marechal, V				Piette, J; Neel, H; Marechal, V			Mdm2: Keeping p53 under control	ONCOGENE			English	Review						Mdm2; p53; cancer; oncogene	WILD-TYPE P53; AUTOREGULATORY FEEDBACK LOOP; NUCLEAR POLYHEDROSIS-VIRUS; SOFT-TISSUE SARCOMAS; 5S RIBOSOMAL-RNA; TRANSCRIPTIONAL ACTIVATION; GENE AMPLIFICATION; TUMOR-SUPPRESSOR; DNA-DAMAGE; P53-ASSOCIATED PROTEIN	The Mdm2 gene is overexpressed in several human tumors, The oncogenic potential of Mdm2 is partially explained by the inhibition of the activity of the tumor suppressor protein p53, Determination of the three-dimensional structure of complexes between Mdm2 and the N-terminal p53 peptide provided a molecular basis for the inhibition of the transcriptional function of p53 by Mdm2. More dramatically, p53 is targeted by Mdm2 for rapid degradation, The Mdm2 gene itself is activated by p53, which gives the opportunity for feed-back control of p53 activity, Keeping p53 under control is most likely the major task of Mdm2 during early development, Recently, evidence was provided for an alternative, p53-independent function of Mdm2.	HOP ROTHSCHILD, MICROBIOL SERV, F-75571 PARIS, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Rothschild - APHP; UDICE-French Research Universities; Sorbonne Universite	Piette, J (corresponding author), CNRS, INST GENET MOL MONTPELLIER, BP5051, 1919 ROUTE MENDE, F-34033 MONTPELLIER 01, FRANCE.		marechal, vincent/P-7719-2017					Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; AYRES MD, 1994, VIROLOGY, V202, P586, DOI 10.1006/viro.1994.1380; BAE IS, 1995, CANCER RES, V55, P2387; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; BERBERICH S, 1994, ONCOGENE, V9, P1469; BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; BODDY MN, 1994, TRENDS BIOCHEM SCI, V19, P198, DOI 10.1016/0968-0004(94)90020-5; Bottger V, 1996, ONCOGENE, V13, P2141; BOULIANNE GL, 1991, EMBO J, V10, P2975, DOI 10.1002/j.1460-2075.1991.tb07848.x; BUESORAMOS CE, 1993, BLOOD, V82, P2617; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; Carrier F, 1996, MUTAT RES-FUND MOL M, V352, P79, DOI 10.1016/0027-5107(95)00255-3; Chang KW, 1996, CARCINOGENESIS, V17, P595, DOI 10.1093/carcin/17.3.595; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CORDONCARDO C, 1994, CANCER RES, V54, P794; COX LS, 1994, ONCOGENE, V9, P2951; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Dazard JE, 1997, ONCOGENE, V14, P1123, DOI 10.1038/sj.onc.1200922; DubsPoterszman MC, 1995, ONCOGENE, V11, P2445; Elenbaas B, 1996, MOL MED, V2, P439, DOI 10.1007/BF03401903; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Fiddler TA, 1996, MOL CELL BIOL, V16, P5048; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FISCELLA M, 1993, ONCOGENE, V8, P1519; FLORENES VA, 1994, J NATL CANCER I, V86, P1297, DOI 10.1093/jnci/86.17.1297; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Gottlieb E, 1997, EMBO J, V16, P1381, DOI 10.1093/emboj/16.6.1381; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GUDDAT U, 1990, CELL, V60, P619, DOI 10.1016/0092-8674(90)90665-2; GUILLOUF C, 1995, BLOOD, V85, P2691, DOI 10.1182/blood.V85.10.2691.bloodjournal85102691; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; Hall PA, 1997, CURR BIOL, V7, pR144, DOI 10.1016/S0960-9822(97)70074-5; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Jones SN, 1996, GENE, V175, P209, DOI 10.1016/0378-1119(96)00151-5; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1991, CANCER RES, V51, P6304; Kastan MB, 1996, BIOESSAYS, V18, P617, DOI 10.1002/bies.950180804; KHATIB ZA, 1993, CANCER RES, V53, P5535; KNIPPSCHILD U, 1995, ONCOGENE, V11, P683; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; KONDO S, 1995, ONCOGENE, V10, P2001; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LACONI S, 1995, CANCER RES, V55, P2560; LADANYI M, 1995, J PATHOL, V175, P211, DOI 10.1002/path.1711750209; LANDERS JE, 1994, ONCOGENE, V9, P2745; LEACH FS, 1993, CANCER RES, V53, P2231; LENG P, 1995, ONCOGENE, V10, P1275; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Lohrum M, 1996, ONCOGENE, V13, P2527; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; Lu X, 1996, ONCOGENE, V13, P413; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; LUNA RMD, 1995, NATURE, V378, P203; Luna RMDO, 1996, GENOMICS, V33, P352, DOI 10.1006/geno.1996.0210; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; MacCallum DE, 1996, ONCOGENE, V13, P2575; MARCHETTI A, 1995, DIAGN MOL PATHOL, V4, P93, DOI 10.1097/00019606-199506000-00004; Marechal V, 1997, ONCOGENE, V14, P1427, DOI 10.1038/sj.onc.1200967; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; Marks DI, 1996, BRIT J HAEMATOL, V92, P890, DOI 10.1046/j.1365-2141.1996.439978.x; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MAXWELL SA, 1994, ANTICANCER RES, V14, P2541; Mayo LD, 1996, ONCOGENE, V13, P2315; MCCANN AH, 1995, BRIT J CANCER, V71, P981, DOI 10.1038/bjc.1995.189; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1996, ONCOGENE, V12, P2279; Momand J, 1997, J CELL BIOCHEM, V64, P343; Murdoch KJ, 1996, EXP CELL RES, V227, P332, DOI 10.1006/excr.1996.0282; NICOL CJ, 1995, NAT GENET, V10, P181, DOI 10.1038/ng0695-181; NILBERT M, 1995, CANCER GENET CYTOGEN, V83, P32, DOI 10.1016/S0165-4608(95)00016-X; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; PERRY ME, 1994, MT SINAI J MED, V61, P291; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PICKSLEY SM, 1993, BIOESSAYS, V15, P689, DOI 10.1002/bies.950151008; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; PRICE BD, 1994, CANCER RES, V54, P896; QUESNEL B, 1994, BRIT J HAEMATOL, V88, P415, DOI 10.1111/j.1365-2141.1994.tb05044.x; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Rudt F, 1996, EMBO J, V15, P1383, DOI 10.1002/j.1460-2075.1996.tb00480.x; SCHOTTELIUS A, 1994, LEUKEMIA, V8, P1673; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; SHVARTS A, IN PRESS GENOMICS; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Soddu S, 1996, J CELL BIOL, V134, P193, DOI 10.1083/jcb.134.1.193; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; STEITZ JA, 1988, J CELL BIOL, V106, P545, DOI 10.1083/jcb.106.3.545; TCHANG F, 1993, DEV BIOL, V159, P163, DOI 10.1006/dbio.1993.1230; WANG Y, 1995, ONCOGENE, V10, P779; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; ZHOU MX, 1995, BLOOD, V85, P1608, DOI 10.1182/blood.V85.6.1608.bloodjournal8561608	111	227	234	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	1997	15	9					1001	1010		10.1038/sj.onc.1201432	http://dx.doi.org/10.1038/sj.onc.1201432			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XT161	9285554				2022-12-17	WOS:A1997XT16100001
J	Huang, DCS; Cory, S; Strasser, A				Huang, DCS; Cory, S; Strasser, A			Bcl-2, Bcl-x(L) and adenovirus protein E1B19kD are functionally equivalent in their ability to inhibit cell death	ONCOGENE			English	Article						apoptosis; Bcl-2; Bcl-x(L); E1B19kD adenovirus protein; Fas/APO-1 (CD95); TNF	TUMOR-NECROSIS-FACTOR; ANTI-FAS ANTIBODY; TRANSGENIC MICE; CAENORHABDITIS-ELEGANS; PROTOONCOGENE BCL-2; NEGATIVE SELECTION; INDUCED APOPTOSIS; MULTIPLE FORMS; LYMPHOID-CELLS; T-CELLS	Apoptosis is the physiological process by which unwanted cells in an organism are killed. Bcl-2, a membrane-bound cytoplasmic protein, is an effective inhibitor of apoptotic cell death induced by many cytotoxic agents. Survival-promoting homologues of Bcl-2 include its close relative, Bcl-x(L) and the 19 kD protein encoded by the E1B gene of adenoviruses. Whether these proteins are functionally equivalent and whether they can antagonise all or only some pathways to apoptosis is unresolved. We have carried out a systematic comparison of Bcl-2, Bcl-x(L) and adenovirus E1B19kD activity, using several cell lines and a range of cytotoxic conditions. High levels of expression of each of these proteins inhibited apoptosis induced by growth factor deprivation or treatment with gamma-radiation, glucocorticoid and various cytotoxic drugs. In contrast, none of them could effectively counter apoptosis induced via the TNF receptor or Fas/APO-1 (CD95). Biochemical analysis revealed that all three proteins can associate with Bar and Bah, members of the Bcl-2 protein subfamily that can facilitate apoptosis. The results provide evidence that Bcl-2, Bcl-x(L), and adenovirus protein E1B19kD are indistinguishable in their ability to regulate the cell death effector machinery.	ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,MELBOURNE,VIC 3050,AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute			Cory, Suzanne/E-1642-2013; Huang, David C. S./C-7586-2013; Strasser, Andreas/C-7581-2013	Cory, Suzanne/0000-0002-6818-3451; Huang, David C. S./0000-0002-3101-4873; Strasser, Andreas/0000-0002-5020-4891				Acton D, 1992, Curr Top Microbiol Immunol, V182, P293; ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CHAO DT, 1995, J EXP MED, V182, P821, DOI 10.1084/jem.182.3.821; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cellbio.7.1.663; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; Gibson L, 1996, ONCOGENE, V13, P665; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; GRILLOT DAM, 1995, J EXP MED, V182, P1973, DOI 10.1084/jem.182.6.1973; HASHIMOTO S, 1991, INT IMMUNOL, V3, P343, DOI 10.1093/intimm/3.4.343; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1994, NATURE, V369, P318, DOI 10.1038/369318a0; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; ITOH N, 1993, J IMMUNOL, V151, P621; JAATTELA M, 1995, ONCOGENE, V10, P2297; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; LEBRUN DP, 1993, AM J PATHOL, V142, P743; Lin EY, 1996, BLOOD, V87, P983, DOI 10.1182/blood.V87.3.983.bloodjournal873983; LINETTE GP, 1995, BLOOD, V86, P1255, DOI 10.1182/blood.V86.4.1255.bloodjournal8641255; LINETTE GP, 1994, IMMUNITY, V1, P197, DOI 10.1016/1074-7613(94)90098-1; LITHGOW T, 1994, CELL GROWTH DIFFER, V5, P411; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MEMON SA, 1995, J IMMUNOL, V155, P4644; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PEZZELLA F, 1990, AM J PATHOL, V137, P225; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; REAP EA, 1995, J IMMUNOL, V154, P936; REYNOLDS JE, 1994, CANCER RES, V54, P6348; Rodriguez I, 1996, J EXP MED, V183, P1031, DOI 10.1084/jem.183.3.1031; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; Smith KGC, 1996, EMBO J, V15, P5167, DOI 10.1002/j.1460-2075.1996.tb00901.x; STRASSER A, 1993, ONCOGENE, V8, P1; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; STRASSER A, 1994, NATURE, V368, P457, DOI 10.1038/368457a0; STRASSER A, 1995, CURR OPIN IMMUNOL, V7, P228, DOI 10.1016/0952-7915(95)80007-7; STRASSER A, 1995, CELL GROWTH DIFFER, V6, P799; STRASSER A, 1994, P NATL ACAD SCI USA, V91, P1376, DOI 10.1073/pnas.91.4.1376; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VANHAESEBROECK B, 1993, ONCOGENE, V8, P1075; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; VAUX DL, 1992, INT IMMUNOL, V4, P821, DOI 10.1093/intimm/4.7.821; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	81	227	235	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 30	1997	14	4					405	414		10.1038/sj.onc.1200848	http://dx.doi.org/10.1038/sj.onc.1200848			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WE364	9053837				2022-12-17	WOS:A1997WE36400003
J	QUELLE, DE; ASHMUN, RA; HANNON, GJ; REHBERGER, PA; TRONO, D; RICHTER, KH; WALKER, C; BEACH, D; SHERR, CJ; SERRANO, M				QUELLE, DE; ASHMUN, RA; HANNON, GJ; REHBERGER, PA; TRONO, D; RICHTER, KH; WALKER, C; BEACH, D; SHERR, CJ; SERRANO, M			CLONING AND CHARACTERIZATION OF MURINE P16(INK4A) AND P15(INK4B) GENES	ONCOGENE			English	Article						P16(INK4A); P15(INK4B); CDK; MEL CELLS; D CYCLINS; PRB	CELL-CYCLE PROGRESSION; FACTOR-I RECEPTOR; MOUSE CHROMOSOME-4; RAT CHROMOSOME-5; G(1); DNA; D1; TRANSFORMATION; OVEREXPRESSION; FIBROBLASTS	Progression through the G1 phase of the cell cycle is regulated in part by the D-type cyclin-dependent kinases, cdk4 and cdk6. Genes encoding two specific inhibitors of these kinases, human p16((INK4A/MTSI)) and p15((INK4B/MTS2)), map to a region of common cytogenetic abnormalities on chromosome 9p21. The murine cognates of these genes were isolated and identified as mouse p16(INK4a) and p15(INK4b) based on their homology to their human counterparts and their selective transcriptional induction by SV40T-antigen and TGF-beta, respectively. Both genes map to position C3-C6 on mouse chromosome 4, in a region syntenic with human chromosome 9p. Amplification of polyadenylated mRNA by polymerase chain reactions revealed no expression of mouse p16(INK4a) in many normal tissues, whereas p15(INK4b) was expressed ubiquitously. Like human p16(INK4a), mouse p16(INK4a) binds specifically to cdk4 and cdk6 in vitro and inhibits the phosphorylation of the retinoblastoma protein, pRb, by each of these cyclin D-dependent kinases. In mouse MEL erythroleukemia cells, p16(INK4a) associates preferentially with cdk6 under conditions where cdk4 and cdk6 are coexpressed at equivalent levels. Expression vectors encoding human or mouse p16(INK4a) caused G1 phase arrest in NIH3T3 fibroblasts, and cyclin D1- and cdk4-dependent pRb kinase activities were inhibited in the p16(INK4a)-arrested cells.	ST JUDE CHILDRENS RES HOSP, HOWARD HUGHES MED INST, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT EXPTL ONCOL, MEMPHIS, TN 38105 USA; COLD SPRING HARBOR LAB, HOWARD HUGHES MED INST, COLD SPRING HARBOR, NY 11724 USA; GERMAN CANC RES CTR, DEPT BIOCHEM TISSUE SPECIF REGULAT, D-69120 HEIDELBERG, GERMANY; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT CARCINOGENESIS, SMITHVILLE, TX 78957 USA	Howard Hughes Medical Institute; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; Cold Spring Harbor Laboratory; Howard Hughes Medical Institute; Helmholtz Association; German Cancer Research Center (DKFZ); University of Texas System; UTMD Anderson Cancer Center			Hannon, Gregory/AAB-3568-2019; Sherr, Charles J/N-8074-2018; Serrano, Manuel/H-2634-2015	Sherr, Charles J/0000-0002-5516-6206; Serrano, Manuel/0000-0001-7177-9312; Quelle, Dawn/0000-0001-8776-0122	NATIONAL CANCER INSTITUTE [R35CA047064, R01CA063613] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA63613, CA-47064] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBOTT CM, 1993, MAMM GENOME, V4, pS58, DOI 10.1007/BF00360830; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BATES S, 1994, ONCOGENE, V9, P1633; BATES S, 1994, ONCOGENE, V9, P71; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DOWNING JR, 1991, MOL CELL BIOL, V11, P2489, DOI 10.1128/MCB.11.5.2489; DOWNING JR, 1988, MOL CELL BIOL, V8, P1795, DOI 10.1128/MCB.8.4.1795; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNA Z, 1993, ONCOGENE, V8, P1661; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HEBERT J, 1994, BLOOD, V84, P4038, DOI 10.1182/blood.V84.12.4038.bloodjournal84124038; HERZOG CR, 1994, CANCER RES, V54, P4007; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; ISLAM MQ, 1989, J CELL SCI, V92, P147; JIANG W, 1993, ONCOGENE, V8, P3447; JON J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KHATIB ZA, 1993, CANCER RES, V53, P5535; KIYOKAWA H, 1994, MOL CELL BIOL, V14, P7195, DOI 10.1128/MCB.14.11.7195; KNAPEK DF, 1995, IN PRESS CANCER RES; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LITZKAS P, 1984, MOL CELL BIOL, V4, P2549, DOI 10.1128/MCB.4.11.2549; LOOK AT, 1984, J CLIN INVEST, V73, P1617, DOI 10.1172/JCI111368; LOVEC H, 1994, ONCOGENE, V9, P323; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEDEMA RH, 1995, IN PRESS P NATL ACAD; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; NEVINS JR, 1992, SCIENCE, V258, P424; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OKUDA T, 1995, BLOOD, V85, P2321, DOI 10.1182/blood.V85.9.2321.bloodjournal8592321; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; PINCS J, 1993, TRENDS BIOCHEM SCI, V18, P195; PINKEL D, 1988, P NATL ACAD SCI USA, V85, P9138, DOI 10.1073/pnas.85.23.9138; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; REIFENBERGER G, 1994, CANCER RES, V54, P4299; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHEAFF RJ, 1995, CURR BIOL, V5, P28, DOI 10.1016/S0960-9822(95)00009-1; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; STAMATATOS L, 1988, BIOCHEMISTRY-US, V27, P3917, DOI 10.1021/bi00411a005; SZPIRER C, 1990, GENOMICS, V6, P679, DOI 10.1016/0888-7543(90)90504-N; TAM SW, 1994, ONCOGENE, V9, P2663; TAM SW, 1994, CANCER RES, V54, P5816; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WASHIMI O, 1995, CANCER RES, V55, P514; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; ZAMOYSKA R, 1985, CELL, V43, P153, DOI 10.1016/0092-8674(85)90020-0	70	227	240	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 17	1995	11	4					635	645						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651726				2022-12-17	WOS:A1995RQ46900004
J	BOLINO, A; SCHUFFENECKER, I; LUO, Y; SERI, M; SILENGO, M; TOCCO, T; CHABRIER, G; HOUDENT, C; MURAT, A; SCHLUMBERGER, M; TOURNIAIRE, J; LENOIR, GM; ROMEO, G				BOLINO, A; SCHUFFENECKER, I; LUO, Y; SERI, M; SILENGO, M; TOCCO, T; CHABRIER, G; HOUDENT, C; MURAT, A; SCHLUMBERGER, M; TOURNIAIRE, J; LENOIR, GM; ROMEO, G			RET MUTATIONS IN EXON-13 AND EXON-14 OF FMTC PATIENTS	ONCOGENE			English	Note						FAMILIAL MEDULLARY THYROID CARCINOMA; RET PROTOONCOGENE; MUTATIONS; SINGLE STRAND CONFORMATION POLYMORPHISM	ENDOCRINE NEOPLASIA TYPE-2A; CHROMOSOME 10Q11.2; PROTOONCOGENE; GENE; LINKAGE; REGION; MEN2A; LOCUS; MAP; 2A	RET is a receptor tyrosine kinase gene which is responsible for three different inherited cancer syndromes namely multiple endocrine neoplasia type 2A (MEN 2A), type 2B (MEN 2B) and familial medullary thyroid carcinoma (FMTC) as web as for Hirschsprung disease (HSCR), a congenital disorder affecting the intestinal motility. Germ-line mutations in the RET exons 10 and 11 were demonstrated in the majority of the MEN 2A and FMTC patients, On the other hand, one codon of RET exon 16 is preferentially changed in MEN 2B patients, Recently, a germ-line mutation in the exon 13 was described in one FMTC family as well as in four sporadic MTCs. In the present study, we observed the same exon 13 mutation in two FMTC families. In addition, we identified a previously unreported substitution of RET exon 14 in two unrelated FMTC families. Both mutations segregate with the disease in these four FMTC families and involve the tyrosine kinase domain of RET. Haplotype analysis using polymorphic markers tightly Linked to the RET gene indicates that in each pedigree the mutation arose as an independent event.	IST GIANNINA GASLINI,GENET MOLEC LAB,I-16148 GENOA,ITALY; HOP EDOUARD HERRIOT,GENET LAB,LYON 03,FRANCE; UNIV TURIN,IST SCI PEDIAT,I-10100 TURIN,ITALY; HOP HAUTE PIERRE,SERV MED INTERNE,STRASBOURG,FRANCE; HOP BOIS GUILLAUME,SERV ENDOCRINOL,ROUEN,FRANCE; HOP HOTEL DIEU,SERV ENDOCRINOL,NANTES,FRANCE; INST GUSTAVE ROUSSY,NUCL MED SERV,PARIS,FRANCE; HOP ANTIQUAILLE,SERV ENDOCRINOL,LYON,FRANCE	University of Genoa; IRCCS Istituto Giannina Gaslini; CHU Lyon; University of Turin; CHU Strasbourg; CHU de Rouen; Nantes Universite; CHU de Nantes; UNICANCER; Gustave Roussy; CHU Lyon			Bolino, Alessandra/O-2933-2013; Seri, Marco/A-4339-2014	Silengo, Margherita/0000-0002-6255-1532; Seri, Marco/0000-0003-2425-2176; Bolino, Alessandra/0000-0002-8980-4878				BROOKSWILSON AR, 1990, NUCLEIC ACIDS RES, V18, P16; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CECCHERINI I, 1994, J ENDOCRINOL INVEST, V17, P201; CECCHERINI I, 1994, ONCOGENE, V9, P1; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; ENG C, 1994, IN PRESS ONCOGENE; GARDNER E, 1993, HUM MOL GENET, V2, P241, DOI 10.1093/hmg/2.3.241; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; LAIRMORE TC, 1993, P NATL ACAD SCI USA, V90, P492, DOI 10.1073/pnas.90.2.492; LAIRMORE TC, 1991, GENOMICS, V9, P181, DOI 10.1016/0888-7543(91)90237-9; LOVE DR, 1993, HUM MOL GENET, V2, P491, DOI 10.1093/hmg/2.4.491-a; MCMAHON R, 1994, HUM MOL GENET, V3, P643, DOI 10.1093/hmg/3.4.643; MOLE SE, 1993, HUM MOL GENET, V2, P247, DOI 10.1093/hmg/2.3.247; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; NAKAMURA Y, 1989, GENOMICS, V5, P199, DOI 10.1016/0888-7543(89)90046-3; NORUM RA, 1990, GENOMICS, V8, P313, DOI 10.1016/0888-7543(90)90287-5; PASINI B, 1995, IN PRESS NATURE GENE; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHUFFENECKER I, 1994, HUM MOL GENET, V3, P1939, DOI 10.1093/hmg/3.11.1939; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TAHIRA T, 1990, NUCLEIC ACIDS RES, V18, P7472, DOI 10.1093/nar/18.24.7472-a	23	227	234	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 15	1995	10	12					2415	2419						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784092				2022-12-17	WOS:A1995RE54300019
J	SUAREZ, HG; DUVILLARD, JA; CAILLOU, B; SCHLUMBERGER, M; PARMENTIER, C; MONIER, R				SUAREZ, HG; DUVILLARD, JA; CAILLOU, B; SCHLUMBERGER, M; PARMENTIER, C; MONIER, R			GSP MUTATIONS IN HUMAN THYROID-TUMORS	ONCOGENE			English	Note							HUMAN PITUITARY-TUMORS; RAS GENE-MUTATIONS; ADENYLATE-CYCLASE; ONCOGENE; PROLIFERATION; STIMULATION; LEUKEMIAS; CANCER	The presence of gsp mutations at codons 201 and 227 in the gene coding for the alpha-subunit of the GTP-binding G(s) protein which stimulates adenylyl cyclase (AC) has been investigated in 31 samples of differentiated thyroid tumours, which had been previously characterized with respect to their adenylyl cyclase activity (ACA) before and after stimulation by thryoid-stimulating hormone (TSH). Polymerase chain reaction (PCR) amplification of DNA extracted from these tumours, followed by high stringency oligonucleotide probing, enabled the detection of mutations in three samples originating from tumours with high constitutive ACA, which was not significantly further stimulated by TSH. Two mutations were at codon 227 and replaced Gln227 by His or Lys, and one was at codon 201, with the substitution of Arg201 by Ser. Because thyrocytes belong to the subset of differentiated cells which are programmed to proliferate in response to elevated cAMP levels, the gsp mutations observed in some differentiated thyroid carcinomas probably contributed to their tumorigenic phenotype.	CNRS,INST RECH SCI CANC,F-94802 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,CNRS,URA 1158,F-94805 VILLEJUIF,FRANCE	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy								BILLESTRUP N, 1986, P NATL ACAD SCI USA, V83, P6854, DOI 10.1073/pnas.83.18.6854; BROWETT PJ, 1989, ONCOGENE, V4, P1029; CARAYON P, 1980, J CLIN ENDOCR METAB, V51, P915, DOI 10.1210/jcem-51-4-915; CLEMENTI E, 1990, ONCOGENE, V5, P1059; DEVRIES MV, 1986, GENE, V50, P313; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; HEDINGER C, 1989, CANCER-AM CANCER SOC, V63, P908, DOI 10.1002/1097-0142(19890301)63:5<908::AID-CNCR2820630520>3.0.CO;2-I; JANSSEN JWG, 1987, P NATL ACAD SCI USA, V84, P9228, DOI 10.1073/pnas.84.24.9228; KOSAZA T, 1988, P NATL ACAD SCI USA, V85, P2081; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEMOINE NR, 1989, ONCOGENE, V4, P159; LEMOINE NR, 1988, CANCER RES, V48, P4459; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MULDER MP, 1989, ONCOGENE, V4, P1345; SPADA A, 1984, ENDOCRINOLOGY, V115, P1203, DOI 10.1210/endo-115-3-1203; SUAREZ HG, 1990, ONCOGENE, V5, P565; THOMASMORVAN C, 1982, ACTA ENDOCRINOL-COP, V101, P25, DOI 10.1530/acta.0.1010025; VANTVEER LJ, 1989, MOL CELL BIOL, V9, P3114, DOI 10.1128/MCB.9.7.3114; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WRIGHT PA, 1989, BRIT J CANCER, V60, P576, DOI 10.1038/bjc.1989.316; YUNIS JJ, 1989, ONCOGENE, V4, P609	21	227	230	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					677	679						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1903197				2022-12-17	WOS:A1991FR93900027
J	An, ZY; Aksoy, O; Zheng, TN; Fan, QW; Weiss, WA				An, Zhenyi; Aksoy, Ozlem; Zheng, Tina; Fan, Qi-Wen; Weiss, William A.			Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies	ONCOGENE			English	Review							PHASE-II; INTRATUMORAL HETEROGENEITY; TYROSINE PHOSPHORYLATION; NUCLEAR TRANSLOCATION; TUMOR-SUPPRESSOR; GLIOMA GROWTH; CELL-SURVIVAL; IN-VITRO; ACTIVATION; AKT	Amplification of epidermal growth factor receptor (EGFR) and its active mutant EGFRvIII occurs frequently in glioblastoma (GBM). While EGFR and EGFRvIII play critical roles in pathogenesis, targeted therapy with EGFR-tyrosine kinase inhibitors (TKIs) or antibodies has only shown limited efficacy in patients. Here we discuss signaling pathways mediated by EGFR/EGFRvIII, current therapeutics, and novel strategies to target EGFR/EGFRvIII-amplified GBM.	[An, Zhenyi; Aksoy, Ozlem; Zheng, Tina; Fan, Qi-Wen; Weiss, William A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94131 USA; [Weiss, William A.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA; [Weiss, William A.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94131 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco	Weiss, WA (corresponding author), Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94131 USA.; Weiss, WA (corresponding author), Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.; Weiss, WA (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94131 USA.	waweiss@gmail.com		Weiss, William/0000-0003-2230-9132	Alex's Lemonade Stand Foundation; Program for Breakthrough Biomedical Research - Sandler Foundation; NIH [CA148699, NS091620, NS0883555, NS089868, CA183692, CA176287, CA82103]; Children's Tumor Foundation; Katie Dougherty Foundation; Pediatric Brain Tumor Foundation; Ross K. MacNeill Foundation; St. Baldrick Foundation; Samuel G. Waxman Foundation; Evelyn and Mattie Anderson Chair; NATIONAL CANCER INSTITUTE [R01CA159859, P30CA082103, P01CA217959, U01CA217864] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007618] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS088355, R01NS091620, R01NS089868] Funding Source: NIH RePORTER	Alex's Lemonade Stand Foundation; Program for Breakthrough Biomedical Research - Sandler Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Children's Tumor Foundation; Katie Dougherty Foundation; Pediatric Brain Tumor Foundation; Ross K. MacNeill Foundation; St. Baldrick Foundation; Samuel G. Waxman Foundation; Evelyn and Mattie Anderson Chair; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	ZA is supported by the Alex's Lemonade Stand Foundation and by Program for Breakthrough Biomedical Research, which is partially funded by the Sandler Foundation. The Weiss lab is supported by NIH grants CA148699, NS091620, NS0883555, NS089868, CA183692, CA176287, and CA82103; the Alex's Lemonade Stand, Children's Tumor, Katie Dougherty, Pediatric Brain Tumor, Ross K. MacNeill, St. Baldrick, and Samuel G. Waxman Foundations; and the Evelyn and Mattie Anderson Chair.	Aeder SE, 2004, ONCOGENE, V23, P9062, DOI 10.1038/sj.onc.1208093; Akhavan D, 2013, CANCER DISCOV, V3, P534, DOI 10.1158/2159-8290.CD-12-0502; Al-Nedawi K, 2008, NAT CELL BIOL, V10, P619, DOI 10.1038/ncb1725; Amos S, 2005, J BIOL CHEM, V280, P7729, DOI 10.1074/jbc.M409056200; Antal CE, 2015, CELL, V160, P489, DOI 10.1016/j.cell.2015.01.001; Appelboom G, 2016, NEURO-ONCOLOGY, V18, P1601, DOI 10.1093/neuonc/now137; Arteaga CL, 2014, CANCER CELL, V25, P282, DOI 10.1016/j.ccr.2014.02.025; Babic I, 2013, CELL METAB, V17, P1000, DOI 10.1016/j.cmet.2013.04.013; Barkovich KJ, 2012, CANCER DISCOV, V2, P450, DOI 10.1158/2159-8290.CD-11-0287; BATRA SK, 1995, CELL GROWTH DIFFER, V6, P1251; Bianco R, 2003, ONCOGENE, V22, P2812, DOI 10.1038/sj.onc.1206388; Boerner JL, 2004, MOL CELL BIOL, V24, P7059, DOI 10.1128/MCB.24.16.7059-7071.2004; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Bonavia R, 2012, ONCOGENE, V31, P4054, DOI 10.1038/onc.2011.563; Boyd PS, 2016, NANOSCALE, V8, P20037, DOI 10.1039/c6nr05880a; Brand TM, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aag1064; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712; Chakravarti A, 2002, CANCER RES, V62, P200; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Choi BD, 2013, P NATL ACAD SCI USA, V110, P270, DOI 10.1073/pnas.1219817110; Chong DQ, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1191-3; Chou RH, 2014, DEV CELL, V30, P224, DOI 10.1016/j.devcel.2014.06.008; Chow KKH, 2011, IMMUNOTHERAPY-UK, V3, P423, DOI 10.2217/IMT.10.110; Clark PA, 2012, NEOPLASIA, V14, P420, DOI 10.1596/neo.12432; Cleary JM, 2015, INVEST NEW DRUG, V33, P671, DOI 10.1007/s10637-015-0234-6; Cloughesy TF, 2014, ANNU REV PATHOL-MECH, V9, P1, DOI 10.1146/annurev-pathol-011110-130324; Congdon KL, 2014, NEURO-ONCOLOGY, V16, pviii20, DOI 10.1093/neuonc/nou236; Cross DAE, 2014, CANCER DISCOV, V4, P1046, DOI 10.1158/2159-8290.CD-14-0337; Cvrljevic AN, 2011, J CELL SCI, V124, P2938, DOI 10.1242/jcs.083295; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; de la Iglesia N, 2008, GENE DEV, V22, P449, DOI 10.1101/gad.1606508; Deschenes-Simard X, 2014, CANCER RES, V74, P412, DOI 10.1158/0008-5472.CAN-13-2381; Ding H, 2003, CANCER RES, V63, P1106; Dreier A, 2012, TUMOR BIOL, V33, P85, DOI 10.1007/s13277-011-0248-4; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; EKSTRAND AJ, 1995, ONCOGENE, V10, P1455; Er EE, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004015; Eskilsson E, 2016, NEURO-ONCOLOGY, V18, P1644, DOI 10.1093/neuonc/now113; Fan Q. W., 2009, SCI SIGNAL, V2, pra4, DOI DOI 10.1126/SCISIGNAL.2000014; Fan QW, 2013, CANCER CELL, V24, P438, DOI 10.1016/j.ccr.2013.09.004; Feng H, 2014, ONCOGENE, V33, P2504, DOI 10.1038/onc.2013.198; Feng HZ, 2012, P NATL ACAD SCI USA, V109, P3018, DOI 10.1073/pnas.1121457109; Fenton TR, 2012, P NATL ACAD SCI USA, V109, P14164, DOI 10.1073/pnas.1211962109; Fousek K, 2015, CLIN CANCER RES, V21, P3384, DOI 10.1158/1078-0432.CCR-14-2675; Francis JM, 2014, CANCER DISCOV, V4, P956, DOI 10.1158/2159-8290.CD-13-0879; Furnari FB, 2015, NAT REV CANCER, V15, P302, DOI 10.1038/nrc3918; Gan HK, 2012, CANCER RES, V72, P2924, DOI 10.1158/0008-5472.CAN-11-3898; Garg R, 2014, ONCOGENE, V33, P5225, DOI 10.1038/onc.2013.524; Garner JM, 2013, J BIOL CHEM, V288, P26167, DOI 10.1074/jbc.M113.477950; Garnett J, 2013, NEOPLASIA, V15, P73, DOI 10.1593/neo.121536; Gong AH, 2015, CANCER RES, V75, P2337, DOI 10.1158/0008-5472.CAN-14-2800; Grandal MV, 2007, CARCINOGENESIS, V28, P1408, DOI 10.1093/carcin/bgm058; Greenall SA, 2015, ONCOGENE, V34, P5277, DOI 10.1038/onc.2014.448; Guo G, 2015, CANCER RES, V75, P3436, DOI 10.1158/0008-5472.CAN-15-0989; Halatsch ME, 2000, J NEUROSURG, V92, P297, DOI 10.3171/jns.2000.92.2.0297; Halatsch ME, 2004, J NEUROSURG, V100, P523, DOI 10.3171/jns.2004.100.3.0523; Han JF, 2015, SCI REP-UK, V5, DOI 10.1038/srep11483; He KY, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003900; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Holland EC, 1998, GENE DEV, V12, P3675, DOI 10.1101/gad.12.23.3675; Holliger P, 2005, NAT BIOTECHNOL, V23, P1126, DOI 10.1038/nbt1142; Horvath S, 2006, P NATL ACAD SCI USA, V103, P17402, DOI 10.1073/pnas.0608396103; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Hwang Y, 2011, MOL CANCER RES, V9, P1199, DOI 10.1158/1541-7786.MCR-11-0229; Inda MD, 2010, GENE DEV, V24, P1731, DOI 10.1101/gad.1890510; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Iwanami A, 2013, P NATL ACAD SCI USA, V110, P4339, DOI 10.1073/pnas.1217602110; Jahani-Asl A, 2016, NAT NEUROSCI, V19, P798, DOI 10.1038/nn.4295; Jawhari S, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.318; Johnson LA, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4963; Jun HJ, 2014, STEM CELLS, V32, P338, DOI 10.1002/stem.1554; Kadamur G, 2013, ANNU REV PHYSIOL, V75, P127, DOI 10.1146/annurev-physiol-030212-183750; Kancha RK, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-39; Katanasaka Y, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-31; Kim E, 2013, CANCER CELL, V23, P839, DOI 10.1016/j.ccr.2013.04.008; Kim J, 2007, CANCER RES, V67, P9229, DOI 10.1158/0008-5472.CAN-07-1333; Klempner SJ, 2013, CANCER DISCOV, V3, P1345, DOI 10.1158/2159-8290.CD-13-0063; Kolch W, 2015, NAT REV CANCER, V15, P515, DOI 10.1038/nrc3983; Lal A, 2002, CANCER RES, V62, P3335; Latha K, 2013, INT J CANCER, V132, P509, DOI 10.1002/ijc.27690; Lee JV, 2014, CELL METAB, V20, P306, DOI 10.1016/j.cmet.2014.06.004; Li L, 2015, ONCOGENE, V34, P129, DOI 10.1038/onc.2013.534; Li L, 2014, ONCOGENE, V33, P4253, DOI 10.1038/onc.2013.400; Li LN, 2010, J NEUROSURG, V113, P192, DOI 10.3171/2010.2.JNS091211; Li W, 2012, NEURO-ONCOLOGY, V14, P958, DOI 10.1093/neuonc/nos116; Liccardi G, 2011, CANCER RES, V71, P1103, DOI 10.1158/0008-5472.CAN-10-2384; Liu F, 2015, MOL CELL, V60, P307, DOI 10.1016/j.molcel.2015.09.002; Lo HW, 2008, CLIN CANCER RES, V14, P6042, DOI 10.1158/1078-0432.CCR-07-4923; Lo HW, 2010, MOL CANCER RES, V8, P232, DOI 10.1158/1541-7786.MCR-09-0391; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Luwor RB, 2004, ONCOGENE, V23, P6095, DOI 10.1038/sj.onc.1207870; Ma L, 2013, CELL, V152, P599, DOI 10.1016/j.cell.2012.12.028; Malkki H, 2016, NAT REV NEUROL, V12, DOI [10.1038/nrneurol.2016.79, 10.1038/nrneurol.2016.22, 10.1038/nrneurol.2016.78, 10.1038/nrneurol.2016.30, 10.1038/nrneurol.2016.117, 10.1038/nrneurol.2016.52, 10.1038/nrneurol.2016.58, 10.1038/nrneurol.2016.151, 10.1038/nrneurol.2016.139, 10.1038/nrneurol.2016.175]; Mattoon DR, 2004, BMC BIOL, V2, DOI 10.1186/1741-7007-2-24; Mawrin C, 2003, INT J ONCOL, V23, P641; Mayer BJ, 2015, NAT REV MOL CELL BIO, V16, P691, DOI 10.1038/nrm4068; Mellinghoff IK, 2005, NEW ENGL J MED, V353, P2012, DOI 10.1056/NEJMoa051918; Miller TE, 2017, NATURE, V547, P355, DOI 10.1038/nature23000; Moscatello DK, 1996, ONCOGENE, V13, P85; Nagane M, 1996, CANCER RES, V56, P5079; Nathanson DA, 2014, SCIENCE, V343, P72, DOI 10.1126/science.1241328; Neyns B, 2009, ANN ONCOL, V20, P1596, DOI 10.1093/annonc/mdp032; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; Novellasdemunt L, 2013, J BIOL CHEM, V288, P10640, DOI 10.1074/jbc.M113.455998; O'Shea JJ, 2015, ANNU REV MED, V66, P311, DOI 10.1146/annurev-med-051113-024537; Ohgaki H, 2013, CLIN CANCER RES, V19, P764, DOI 10.1158/1078-0432.CCR-12-3002; Ozawa T, 2014, CANCER CELL, V26, P288, DOI 10.1016/j.ccr.2014.06.005; Ozes ON, 1999, NATURE, V401, P82; Papke B, 2017, SCIENCE, V355, P1158, DOI 10.1126/science.aam7622; Park OK, 1996, P NATL ACAD SCI USA, V93, P13704, DOI 10.1073/pnas.93.24.13704; Patel AP, 2014, SCIENCE, V344, P1396, DOI 10.1126/science.1254257; Pedersen MW, 2004, INT J CANCER, V108, P643, DOI 10.1002/ijc.11566; Ramnarain DB, 2006, CANCER RES, V66, P867, DOI 10.1158/0008-5472.CAN-05-2753; Rathmell JC, 2003, MOL CELL BIOL, V23, P7315, DOI 10.1128/MCB.23.20.7315-7328.2003; Reardon DA, 2015, NEURO-ONCOLOGY, V17, P430, DOI 10.1093/neuonc/nou160; Reardon DA, 2013, CLIN CANCER RES, V19, P900, DOI 10.1158/1078-0432.CCR-12-1707; Rosell R, 2006, CLIN CANCER RES, V12, P7222, DOI 10.1158/1078-0432.CCR-06-0627; Roth P, 2014, NEURO-ONCOLOGY, V16, pviii14, DOI 10.1093/neuonc/nou222; Sampson JH, 2009, MOL CANCER THER, V8, P2773, DOI 10.1158/1535-7163.MCT-09-0124; Schijns VEJC, 2015, VACCINE, V33, P2690, DOI 10.1016/j.vaccine.2015.03.095; Schuster J, 2015, NEURO-ONCOLOGY, V17, P854, DOI 10.1093/neuonc/nou348; See AP, 2012, J NEURO-ONCOL, V110, P359, DOI 10.1007/s11060-012-0981-6; Shinojima N, 2003, CANCER RES, V63, P6962; Shir A, 2002, NAT BIOTECHNOL, V20, P895, DOI 10.1038/nbt730; Singh B, 2014, ANNU REV PHYSIOL, V76, P275, DOI 10.1146/annurev-physiol-021113-170406; Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800; Snuderl M, 2011, CANCER CELL, V20, P810, DOI 10.1016/j.ccr.2011.11.005; Spiegel J, 2014, NAT CHEM BIOL, V10, P613, DOI 10.1038/nchembio.1560; Stommel JM, 2007, SCIENCE, V318, P287, DOI 10.1126/science.1142946; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; Swartz AM, 2014, IMMUNOTHERAPY-UK, V6, P679, DOI [10.2217/IMT.14.21, 10.2217/imt.14.21]; Szerlip NJ, 2012, P NATL ACAD SCI USA, V109, P3041, DOI 10.1073/pnas.1114033109; Tan CS, 2015, LANCET ONCOL, V16, pE447, DOI 10.1016/S1470-2045(15)00246-6; Thorpe LM, 2015, NAT REV CANCER, V15, P7, DOI 10.1038/nrc3860; Turner KM, 2017, NATURE, V543, P122, DOI 10.1038/nature21356; Uht RM, 2007, ONCOGENE, V26, P2885, DOI 10.1038/sj.onc.1210090; Unni AM, 2015, ELIFE, V4, DOI 10.7554/eLife.06907; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Vivanco I, 2012, CANCER DISCOV, V2, P458, DOI 10.1158/2159-8290.CD-11-0284; Wang RC, 2012, SCIENCE, V338, P956, DOI 10.1126/science.1225967; Wang SC, 2006, NAT CELL BIOL, V8, P1359, DOI 10.1038/ncb1501; Wang SC, 2009, CLIN CANCER RES, V15, P6484, DOI 10.1158/1078-0432.CCR-08-2813; Weiss WA, 2003, CANCER RES, V63, P1589; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Zahonero C, 2015, MOL CANCER THER, V14, P1548, DOI 10.1158/1535-7163.MCT-14-0736; ZUSSMAN BM, 2015, NEUROSURGERY, V76	149	226	235	4	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	12					1561	1575		10.1038/s41388-017-0045-7	http://dx.doi.org/10.1038/s41388-017-0045-7			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GA8YC	29321659	Green Accepted, Green Submitted			2022-12-17	WOS:000428626700002
J	Aye, Y; Li, M; Long, MJC; Weiss, RS				Aye, Y.; Li, M.; Long, M. J. C.; Weiss, R. S.			Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies	ONCOGENE			English	Review							CELL LUNG-CANCER; SMALL-SUBUNIT P53R2; DNA-DAMAGE RESPONSE; CHRONIC LYMPHOCYTIC-LEUKEMIA; ONCOGENE-INDUCED SENESCENCE; IN-VITRO; ESCHERICHIA-COLI; MAMMALIAN-CELLS; DEOXYCYTIDINE KINASE; MITOCHONDRIAL-DNA	Accurate DNA replication and repair is essential for proper development, growth and tumor-free survival in all multicellular organisms. A key requirement for the maintenance of genomic integrity is the availability of adequate and balanced pools of deoxyribonucleoside triphosphates (dNTPs), the building blocks of DNA. Notably, dNTP pool alterations lead to genomic instability and have been linked to multiple human diseases, including mitochondrial disorders, susceptibility to viral infection and cancer. In this review, we discuss how a key regulator of dNTP biosynthesis in mammals, the enzyme ribonucleotide reductase (RNR), impacts cancer susceptibility and serves as a target for anti-cancer therapies. Because RNR-regulated dNTP production can influence DNA replication fidelity while also supporting genome-protecting DNA repair, RNR has complex and stage-specific roles in carcinogenesis. Nevertheless, cancer cells are dependent on RNR for de novo dNTP biosynthesis. Therefore, elevated RNR expression is a characteristic of many cancers, and an array of mechanistically distinct RNR inhibitors serve as effective agents for cancer treatment. The dNTP metabolism machinery, including RNR, has been exploited for therapeutic benefit for decades and remains an important target for cancer drug development.	[Aye, Y.] Cornell Univ, Dept Chem & Chem Biol, Ithaca, NY USA; [Aye, Y.] Weill Cornell Med Coll, Dept Biochem, New York, NY USA; [Li, M.; Weiss, R. S.] Cornell Univ, Dept Biomed Sci, Ithaca, NY USA; [Long, M. J. C.] Brandeis Univ, Grad Program Biochem, Waltham, MA USA	Cornell University; Cornell University; Cornell University; Brandeis University	Aye, Y (corresponding author), 224 Baker Lab Chem & Chem Biol, Ithaca, NY 14853 USA.	ya222@cornell.edu; rsw26@cornell.edu		Long, marcus/0000-0002-0343-9671	ACCEL program; NSF [SBE-0547373]; President's Council of Cornell Women; Milstein sesquicentennial junior faculty fellowship; HHMI; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [DP2GM114850] Funding Source: NIH RePORTER	ACCEL program; NSF(National Science Foundation (NSF)); President's Council of Cornell Women; Milstein sesquicentennial junior faculty fellowship; HHMI(Howard Hughes Medical Institute); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Professors Rick Cerione and Jennifer Surtees for helpful discussion and comments on the manuscript. YA acknowledges a faculty development grant from the ACCEL program supported by NSF (SBE-0547373), an Affinito-Stewart grant from the President's Council of Cornell Women and a Milstein sesquicentennial junior faculty fellowship. MJCL acknowledges an HHMI international student predoctoral fellowship.	Ahluwalia D, 2013, P NATL ACAD SCI USA, V110, P18596, DOI 10.1073/pnas.1310849110; Aird KM, 2014, CELL CYCLE, V13, P199, DOI 10.4161/cc.26953; Aird KM, 2013, CELL REP, V3, P1252, DOI 10.1016/j.celrep.2013.03.004; AKERBLOM L, 1981, P NATL ACAD SCI-BIOL, V78, P2159, DOI 10.1073/pnas.78.4.2159; Akita H, 2009, ONCOGENE, V28, P2903, DOI 10.1038/onc.2009.158; Alvarez-Salas LM, 2008, CURR TOP MED CHEM, V8, P1379, DOI 10.2174/156802608786141133; Anderson DD, 2012, J BIOL CHEM, V287, P7051, DOI 10.1074/jbc.M111.333120; Anglana M, 2003, CELL, V114, P385, DOI 10.1016/S0092-8674(03)00569-5; Avolio TM, 2007, ANTI-CANCER DRUG, V18, P377, DOI 10.1097/CAD.0b013e328013c04f; AVRAMIS VI, 1983, BIOCHEM BIOPH RES CO, V113, P35, DOI 10.1016/0006-291X(83)90428-X; Aye Y, 2012, J BIOL CHEM, V287, P35768, DOI 10.1074/jbc.M112.396911; Aye Y, 2012, CHEM BIOL, V19, P799, DOI 10.1016/j.chembiol.2012.05.015; Aye Y, 2011, P NATL ACAD SCI USA, V108, P9815, DOI 10.1073/pnas.1013274108; BEBENEK K, 1992, J BIOL CHEM, V267, P3589; Bepler G, 2004, J CLIN ONCOL, V22, P1878, DOI 10.1200/JCO.2004.12.002; Bepler G, 2008, J THORAC ONCOL, V3, P1112, DOI 10.1097/JTO.0b013e3181874936; Bepler G, 2006, J CLIN ONCOL, V24, P4731, DOI 10.1200/JCO.2006.06.1101; Bergman AM, 2005, CANCER RES, V65, P9510, DOI 10.1158/0008-5472.CAN-05-0989; Bester AC, 2011, CELL, V145, P435, DOI 10.1016/j.cell.2011.03.044; Bonate PL, 2006, NAT REV DRUG DISCOV, V5, P855, DOI 10.1038/nrd2055; Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040; Burkhalter MD, 2009, DNA REPAIR, V8, P1258, DOI 10.1016/j.dnarep.2009.07.009; Burrell RA, 2013, NATURE, V494, P492, DOI 10.1038/nature11935; CARAS IW, 1988, MOL CELL BIOL, V8, P2698, DOI 10.1128/MCB.8.7.2698; Ceppi P, 2006, ANN ONCOL, V17, P1818, DOI 10.1093/annonc/mdl300; Chabes A, 2000, J BIOL CHEM, V275, P17747, DOI 10.1074/jbc.M000799200; Chabes A, 2003, CELL, V112, P391, DOI 10.1016/S0092-8674(03)00075-8; Chabes AL, 2004, J BIOL CHEM, V279, P10796, DOI 10.1074/jbc.M312482200; Chabes AL, 2003, P NATL ACAD SCI USA, V100, P3925, DOI 10.1073/pnas.0330774100; Chandra D, 2006, CELL, V125, P1333, DOI 10.1016/j.cell.2006.05.026; Chang LF, 2008, P NATL ACAD SCI USA, V105, P18519, DOI 10.1073/pnas.0803313105; Chaston TB, 2003, CLIN CANCER RES, V9, P402; Chimploy K, 2013, J BIOL CHEM, V288, P13145, DOI 10.1074/jbc.M113.461111; COHEN A, 1978, P NATL ACAD SCI USA, V75, P472, DOI 10.1073/pnas.75.1.472; CORY JG, 1994, BIOCHEM PHARMACOL, V48, P335, DOI 10.1016/0006-2952(94)90105-8; Cotruvo JA, 2011, ANNU REV BIOCHEM, V80, P733, DOI 10.1146/annurev-biochem-061408-095817; Courbet S, 2008, NATURE, V455, P557, DOI 10.1038/nature07233; D'Angiolella V, 2012, CELL, V149, P1023, DOI 10.1016/j.cell.2012.03.043; Davidson JD, 2004, CANCER RES, V64, P3761, DOI 10.1158/0008-5472.CAN-03-3363; Dong XP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092320; Duxbury MS, 2004, ONCOGENE, V23, P1539, DOI 10.1038/sj.onc.1207272; Duxbury MS, 2004, SURGERY, V136, P261, DOI 10.1016/j.surg.2004.04.029; ELFORD HL, 1970, J BIOL CHEM, V245, P5228; ELLEDGE SJ, 1993, BIOESSAYS, V15, P333, DOI 10.1002/bies.950150507; ENGSTROM Y, 1985, J BIOL CHEM, V260, P9114; ENGSTROM Y, 1988, EMBO J, V7, P1615, DOI 10.1002/j.1460-2075.1988.tb02987.x; ENGSTROM Y, 1984, EMBO J, V3, P863, DOI 10.1002/j.1460-2075.1984.tb01897.x; ERIKSSON S, 1984, J BIOL CHEM, V259, P1695; Faderl S, 2005, BLOOD, V105, P940, DOI 10.1182/blood-2004-05-1933; Fairman JW, 2011, NAT STRUCT MOL BIOL, V18, P316, DOI 10.1038/nsmb.2007; Fan HZ, 1998, CANCER RES, V58, P1650; Fan HZ, 1996, P NATL ACAD SCI USA, V93, P14036, DOI 10.1073/pnas.93.24.14036; Fan HZ, 1997, P NATL ACAD SCI USA, V94, P13181, DOI 10.1073/pnas.94.24.13181; FEIG DI, 1994, CANCER RES, V54, pS1890; Ferracin M, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-123; Ferrandina G, 2010, CANCER CHEMOTH PHARM, V65, P679, DOI 10.1007/s00280-009-1073-y; FERSHT AR, 1979, P NATL ACAD SCI USA, V76, P4946, DOI 10.1073/pnas.76.10.4946; Filatov D, 1996, J BIOL CHEM, V271, P23698, DOI 10.1074/jbc.271.39.23698; Finch RA, 2000, BIOCHEM PHARMACOL, V59, P983, DOI 10.1016/S0006-2952(99)00419-0; Fisher SB, 2013, CANCER-AM CANCER SOC, V119, P445, DOI 10.1002/cncr.27619; Fu Y, 2013, BIOCHEMISTRY-US, V52, P7050, DOI 10.1021/bi400781z; Gautam A, 2003, ONCOGENE, V22, P2135, DOI 10.1038/sj.onc.1206232; Gautam A, 2006, CANCER RES, V66, P6497, DOI 10.1158/0008-5472.CAN-05-4462; Ge XQ, 2007, GENE DEV, V21, P3331, DOI 10.1101/gad.457807; Gon S, 2011, P NATL ACAD SCI USA, V108, P19311, DOI 10.1073/pnas.1113664108; Gong WY, 2012, LUNG CANCER, V75, P374, DOI 10.1016/j.lungcan.2011.08.003; Gonzalez H, 1998, HEMATOL CELL THER, V40, P113; GRASLUND A, 1982, J BIOL CHEM, V257, P5711; Guittet O, 2001, J BIOL CHEM, V276, P40647, DOI 10.1074/jbc.M106088200; Guittet O, 2008, NITRIC OXIDE-BIOL CH, V19, P84, DOI 10.1016/j.niox.2008.04.011; Hakansson P, 2006, J BIOL CHEM, V281, P7834, DOI 10.1074/jbc.M512894200; HEHLMANN R, 1993, BLOOD, V82, P398, DOI 10.1182/blood.V82.2.398.bloodjournal822398; Hofer A, 2012, CRIT REV BIOCHEM MOL, V47, P50, DOI 10.3109/10409238.2011.630372; Hu CM, 2012, CANCER CELL, V22, P36, DOI 10.1016/j.ccr.2012.04.038; HURTA RAR, 1992, J BIOL CHEM, V267, P7066; Itoi T, 2007, J GASTROENTEROL, V42, P389, DOI 10.1007/s00535-007-2017-0; Johansson E, 1998, J BIOL CHEM, V273, P29816, DOI 10.1074/jbc.273.45.29816; Jordheim LP, 2011, LANCET ONCOL, V12, P693, DOI 10.1016/S1470-2045(10)70244-8; Jordheim LP, 2005, MOL CANCER THER, V4, P1268, DOI 10.1158/1535-7163.MCT-05-0121; Jorgensen CLT, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-541; Kashlan OB, 2003, BIOCHEMISTRY-US, V42, P1696, DOI 10.1021/bi020634d; Kimura T, 2003, NAT GENET, V34, P440, DOI 10.1038/ng1212; King KM, 2006, MOL PHARMACOL, V69, P346, DOI 10.1124/mol.105.015768; Kollberg G, 2009, NEUROMUSCULAR DISORD, V19, P147, DOI 10.1016/j.nmd.2008.11.014; KUNZ BA, 1991, ANNU REV GENET, V25, P339, DOI 10.1146/annurev.ge.25.120191.002011; Lee Y, 2003, CANCER RES, V63, P2802; LEVIN VA, 1992, SEMIN ONCOL, V19, P34; Lin ZP, 2004, J BIOL CHEM, V279, P27030, DOI 10.1074/jbc.M402056200; Lindemalm S, 2004, CANCER LETT, V210, P171, DOI 10.1016/j.canlet.2004.03.007; Lis ET, 2008, DNA REPAIR, V7, P801, DOI 10.1016/j.dnarep.2008.02.007; Liu XY, 2006, CLIN CANCER RES, V12, P6337, DOI 10.1158/1078-0432.CCR-06-0799; Liu XY, 2013, CLIN SCI, V124, P567, DOI 10.1042/CS20120240; Liu XY, 2011, CANCER RES, V71, P3202, DOI 10.1158/0008-5472.CAN-11-0054; Lu AG, 2012, WORLD J GASTROENTERO, V18, P4704, DOI 10.3748/wjg.v18.i34.4704; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746; Manegold C, 2000, INVEST NEW DRUG, V18, P29, DOI 10.1023/A:1006327729228; Mannava S, 2012, AGING-US, V4, P917, DOI 10.18632/aging.100512; Mannava S, 2013, AM J PATHOL, V182, P142, DOI 10.1016/j.ajpath.2012.09.011; Mansson E, 2003, BIOCHEM PHARMACOL, V65, P237, DOI 10.1016/S0006-2952(02)01484-3; Martin KR, 2002, HUM EXP TOXICOL, V21, P71, DOI 10.1191/0960327102ht213oa; Mathews CK, 2006, FASEB J, V20, P1300, DOI 10.1096/fj.06-5730rev; Matsushita S, 2012, J DERMATOL SCI, V68, P19, DOI 10.1016/j.jdermsci.2012.07.005; MCCLARTY GA, 1987, BIOCHEMISTRY-US, V26, P8004, DOI 10.1021/bi00398a068; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; Meyer Y, 2009, ANNU REV GENET, V43, P335, DOI 10.1146/annurev-genet-102108-134201; Minnihan EC, 2013, ACCOUNTS CHEM RES, V46, P2524, DOI 10.1021/ar4000407; Morikawa T, 2010, HISTOPATHOLOGY, V57, P885, DOI 10.1111/j.1365-2559.2010.03725.x; Morikawa T, 2010, HUM PATHOL, V41, P1742, DOI 10.1016/j.humpath.2010.06.001; Moss J, 2010, GENE DEV, V24, P2705, DOI 10.1101/gad.1970810; Nakahira S, 2007, INT J CANCER, V120, P1355, DOI 10.1002/ijc.22390; Nakano K, 2000, ONCOGENE, V19, P4283, DOI 10.1038/sj.onc.1203774; Niida H, 2010, GENE DEV, V24, P333, DOI 10.1101/gad.1863810; Nocentini G, 1996, CRIT REV ONCOL HEMAT, V22, P89, DOI 10.1016/1040-8428(95)00187-5; Nordlund N, 2006, ANNU REV BIOCHEM, V75, P681, DOI 10.1146/annurev.biochem.75.103004.142443; Nutting CM, 2009, ANN ONCOL, V20, P1275, DOI 10.1093/annonc/mdn775; NYHOLM S, 1993, BIOCHEMISTRY-US, V32, P11569, DOI 10.1021/bi00094a013; Oh YK, 2009, ADV DRUG DELIVER REV, V61, P850, DOI 10.1016/j.addr.2009.04.018; Ohtaka K, 2008, ONCOL REP, V20, P279, DOI 10.3892/or_00000004; Okumura H, 2006, CLIN CANCER RES, V12, P3740, DOI 10.1158/1078-0432.CCR-05-2416; Okumura H, 2005, BRIT J CANCER, V92, P284, DOI 10.1038/sj.bjc.6602322; PERRINO FW, 1989, J BIOL CHEM, V264, P2898; PETRUSKA J, 1988, P NATL ACAD SCI USA, V85, P6252, DOI 10.1073/pnas.85.17.6252; Pfisterer J, 2005, INT J GYNECOL CANCER, V15, P36, DOI 10.1111/j.1525-1438.2005.15355.x; PLUNKETT W, 1987, CANCER RES, V47, P3005; Pontarin G, 2007, J BIOL CHEM, V282, P16820, DOI 10.1074/jbc.M701310200; Pontarin G, 2012, P NATL ACAD SCI USA, V109, P13302, DOI 10.1073/pnas.1211289109; Pontarin G, 2008, P NATL ACAD SCI USA, V105, P17801, DOI 10.1073/pnas.0808198105; Popovic-Bijelic A, 2011, J INORG BIOCHEM, V105, P1422, DOI 10.1016/j.jinorgbio.2011.07.003; Rahman MA, 2012, J CONTROL RELEASE, V159, P384, DOI 10.1016/j.jconrel.2012.01.045; Rampazzo C, 2010, MUTAT RES-GEN TOX EN, V703, P2, DOI 10.1016/j.mrgentox.2010.06.002; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; REICHARD P, 1961, J BIOL CHEM, V236, P1150; Reischl D, 2009, NANOMED-NANOTECHNOL, V5, P8, DOI 10.1016/j.nano.2008.06.001; Reubold TF, 2012, CELL SIGNAL, V24, P1420, DOI 10.1016/j.cellsig.2012.03.007; Reynolds C, 2009, J CLIN ONCOL, V27, P5808, DOI 10.1200/JCO.2009.21.9766; Rodriguez J, 2011, EUR J CANCER, V47, P839, DOI 10.1016/j.ejca.2010.11.032; Rofougaran R, 2006, J BIOL CHEM, V281, P27705, DOI 10.1074/jbc.M605573200; Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751; Sabouri N, 2008, NUCLEIC ACIDS RES, V36, P5660, DOI 10.1093/nar/gkn555; SAHLIN M, 1989, BIOCHEMISTRY-US, V28, P2618, DOI 10.1021/bi00432a039; Sandler A, 1999, Oncologist, V4, P241; Saven A, 1998, BLOOD, V92, P1918, DOI 10.1182/blood.V92.6.1918; Shaibani A, 2009, ARCH NEUROL-CHICAGO, V66, P1028, DOI 10.1001/archneurol.2009.139; Shao J, 2006, CURR CANCER DRUG TAR, V6, P409, DOI 10.2174/156800906777723949; Sigal DS, 2010, BLOOD, V116, P2884, DOI 10.1182/blood-2010-02-246140; Sigmond J, 2010, ANTI-CANCER DRUG, V21, P591, DOI 10.1097/CAD.0b013e32833a3543; Simon G, 2007, J CLIN ONCOL, V25, P2741, DOI 10.1200/JCO.2006.08.2099; Spasokoukotskaja T, 1998, ADV EXP MED BIOL, V431, P641; Spasokoukotskaja T, 1999, EUR J CANCER, V35, P1862, DOI 10.1016/S0959-8049(99)00223-3; Sterkers Y, 1998, BLOOD, V91, P616, DOI 10.1182/blood.V91.2.616.616_616_622; Stover PJ, 2012, CANCER CELL, V22, P3, DOI 10.1016/j.ccr.2012.06.010; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; Stubbe JA, 1995, CHEM BIOL, V2, P793, DOI 10.1016/1074-5521(95)90084-5; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Tang H, 2013, CLIN CANCER RES, V19, P1577, DOI 10.1158/1078-0432.CCR-12-2321; Temperini C, 2006, BIOORG MED CHEM LETT, V16, P4316, DOI 10.1016/j.bmcl.2006.05.068; Tyynismaa H, 2009, AM J HUM GENET, V85, P290, DOI 10.1016/j.ajhg.2009.07.009; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; ULLMAN B, 1980, J BIOL CHEM, V255, P8308; Uramoto H, 2006, ANTICANCER RES, V26, P983; Walker S, 2009, HEALTH TECHNOL ASSES, V13, P35, DOI 10.3310/hta13suppl1/06; Wang J, 2007, P NATL ACAD SCI USA, V104, P14324, DOI 10.1073/pnas.0706803104; Wang LM, 2012, CHINESE MED J-PEKING, V125, P2151, DOI 10.3760/cma.j.issn.0366-6999.2012.12.013; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; WEINBERG G, 1981, P NATL ACAD SCI-BIOL, V78, P2447, DOI 10.1073/pnas.78.4.2447; Wheeler LJ, 2005, DNA REPAIR, V4, P1450, DOI 10.1016/j.dnarep.2005.09.003; Wonganan P, 2012, CANCER BIOL THER, V13, P908, DOI 10.4161/cbt.20843; WRIGHT JA, 1987, SOMAT CELL MOLEC GEN, V13, P155, DOI 10.1007/BF01534695; Xu X, 2008, CANCER RES, V68, P2652, DOI 10.1158/0008-5472.CAN-07-5873; Xue LJ, 2007, CANCER RES, V67, P16, DOI 10.1158/0008-5472.CAN-06-3200; Yamaguchi T, 2001, CANCER RES, V61, P8256; Yanamoto S, 2005, CANCER LETT, V223, P67, DOI 10.1016/j.canlet.2004.10.019; Yanamoto S, 2003, CANCER LETT, V190, P233, DOI 10.1016/S0304-3835(02)00588-8; Yanamoto S, 2009, ORAL ONCOL, V45, P521, DOI 10.1016/j.oraloncology.2008.07.005; Yokomakura N, 2007, ONCOL REP, V18, P561; Zhang KQ, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-11; Zhang YW, 2009, J BIOL CHEM, V284, P18085, DOI 10.1074/jbc.M109.003020; Zheng Z, 2007, NEW ENGL J MED, V356, P800, DOI 10.1056/NEJMoa065411; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhu LJ, 2009, BIOCHEM PHARMACOL, V78, P1178, DOI 10.1016/j.bcp.2009.06.103	181	226	232	3	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2015	34	16					2011	2021		10.1038/onc.2014.155	http://dx.doi.org/10.1038/onc.2014.155			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG3IL	24909171				2022-12-17	WOS:000353173400001
J	Zheng, H; Kang, Y				Zheng, H.; Kang, Y.			Multilayer control of the EMT master regulators	ONCOGENE			English	Review						cancer metastasis; EMT; Snail; Twist; Zeb; E3-ubiquitin ligase	EPITHELIAL-MESENCHYMAL TRANSITION; SMAD-INTERACTING PROTEIN-1; F-BOX PROTEIN; GLYCOGEN-SYNTHASE KINASE-3; TRANSCRIPTION FACTOR SNAIL; HYPOXIA-INDUCIBLE FACTOR; NEGATIVE FEEDBACK LOOP; E-CADHERIN EXPRESSION; CANCER METASTASIS; MIR-200 FAMILY	Metastasis is the leading cause of cancer-associated death in most tumor types. Metastatic dissemination of cancer cells from the primary tumor is believed to be initiated by the reactivation of an embryonic development program referred to as epithelial-mesenchymal transition (EMT), whereby epithelial cells lose apicobasal polarity and cell-cell contacts, and gain mesenchymal phenotypes with increased migratory and invasive capabilities. EMT has also been implicated in the regulation of cancer stem cell property, immune suppression and cancer regression. Several transcription factors have been identified as master regulators of EMT, including the Snail, Zeb and Twist families, and their expression is tightly regulated at different steps of transcription, translation and protein stability control by a variety of cell-intrinsic pathways as well as extracellular cues. Here, we review the recent literature on the signaling pathways and mechanisms that control the expression of these master transcription factors during EMT and cancer progression.	[Zheng, H.; Kang, Y.] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Kang, Y (corresponding author), Princeton Univ, Dept Mol Biol, LTL255,Washington Rd, Princeton, NJ 08544 USA.	ykang@princeton.edu		Zheng, Hanqiu/0000-0002-8062-1215; Kang, Yibin/0000-0002-1626-6730	National Institutes of Health [R01CA134519, R01CA141062]; Komen for the Cure; Brewster Foundation; Champalimaud Foundation; Komen for the Cure Postdoctoral Fellowship [KG111164]; NATIONAL CANCER INSTITUTE [R01CA134519, R01CA141062] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Komen for the Cure(Susan G. Komen Breast Cancer Foundation); Brewster Foundation; Champalimaud Foundation; Komen for the Cure Postdoctoral Fellowship(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We apologize to researchers whose studies we were unable to cite due to the space limitation of this review. We thank W Li and HA Smith for reading the manuscript and providing insightful advises. Research in our laboratory is supported by grants from the National Institutes of Health R01CA134519 and R01CA141062, Komen for the Cure, the Brewster Foundation and the Champalimaud Foundation. H Zheng is a recipient of a Komen for the Cure Postdoctoral Fellowship (KG111164).	Acloque H, 2011, DEV CELL, V21, P546, DOI 10.1016/j.devcel.2011.07.005; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Nieto MA, 2011, ANNU REV CELL DEV BI, V27, P347, DOI 10.1146/annurev-cellbio-092910-154036; Ansieau S, 2008, CANCER CELL, V14, P79, DOI 10.1016/j.ccr.2008.06.005; Arima Y, 2012, J BIOL CHEM, V287, P7896, DOI 10.1074/jbc.M111.313759; Bachelder RE, 2005, J CELL BIOL, V168, P29, DOI 10.1083/jcb.200409067; Barr S, 2008, CLIN EXP METASTAS, V25, P685, DOI 10.1007/s10585-007-9121-7; Bastea LI, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030459; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bialek P, 2004, DEV CELL, V6, P423, DOI 10.1016/S1534-5807(04)00058-9; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Brabletz T, 2012, CANCER CELL, V22, P699, DOI 10.1016/j.ccr.2012.11.009; Brabletz T, 2012, NAT REV CANCER, V12, P425, DOI 10.1038/nrc3265; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Casas E, 2011, CANCER RES, V71, P245, DOI 10.1158/0008-5472.CAN-10-2330; Celia-Terrassa T, 2012, J CLIN INVEST, V122, P1849, DOI 10.1172/JCI59218; Chaffer CL, 2006, CANCER RES, V66, P11271, DOI 10.1158/0008-5472.CAN-06-2044; Chakrabarti R, 2012, NAT CELL BIOL, V14, P1212, DOI 10.1038/ncb2607; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chang CJ, 2011, ONCOL REP, V26, P1003, DOI 10.3892/or.2011.1360; Chao YL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-179; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; Cieply B, 2012, CANCER RES, V72, P2440, DOI 10.1158/0008-5472.CAN-11-4038; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Copple BL, 2010, LIVER INT, V30, P669, DOI 10.1111/j.1478-3231.2010.02205.x; Dontu G, 2003, CELL PROLIFERAT, V36, P59, DOI 10.1046/j.1365-2184.36.s.1.6.x; Du C, 2010, CANCER RES, V70, P7810, DOI 10.1158/0008-5472.CAN-09-4481; Eckert MA, 2011, CANCER CELL, V19, P372, DOI 10.1016/j.ccr.2011.01.036; Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429; Eiseler T, 2012, J BIOL CHEM, V287, P32367, DOI 10.1074/jbc.M112.370999; El-Haibi CP, 2012, P NATL ACAD SCI USA, V109, P17460, DOI 10.1073/pnas.1206653109; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Franci C, 2006, ONCOGENE, V25, P5134, DOI 10.1038/sj.onc.1209519; Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016; Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Gupta-Rossi N, 2001, J BIOL CHEM, V276, P34371, DOI 10.1074/jbc.M101343200; Hajra KM, 2002, CANCER RES, V62, P1613; Hartwell KA, 2006, P NATL ACAD SCI USA, V103, P18969, DOI 10.1073/pnas.0608636103; HEBROK M, 1994, DEV BIOL, V165, P537, DOI 10.1006/dbio.1994.1273; Hong J, 2011, CANCER RES, V71, P3980, DOI 10.1158/0008-5472.CAN-10-2914; Hu JJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045965; Huang D, 2008, WORLD J GASTROENTERO, V14, P1823, DOI 10.3748/wjg.14.1823; Hubbard EJA, 1997, GENE DEV, V11, P3182, DOI 10.1101/gad.11.23.3182; Imai T, 2003, AM J PATHOL, V163, P1437, DOI 10.1016/S0002-9440(10)63501-8; Imamichi Y, 2007, ONCOGENE, V26, P2381, DOI 10.1038/sj.onc.1210012; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jenkins RH, 2012, BIOCHEM SOC T, V40, P762, DOI 10.1042/BST20120085; Jeschke U, 2007, ANTICANCER RES, V27, P1969; Jung A, 2001, AM J PATHOL, V159, P1613, DOI 10.1016/S0002-9440(10)63007-6; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Karreth FA, 2011, CELL, V147, P382, DOI 10.1016/j.cell.2011.09.032; Kim NH, 2011, J CELL BIOL, V195, P417, DOI 10.1083/jcb.201103097; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Korpal M, 2011, NAT MED, V17, P1101, DOI 10.1038/nm.2401; Krishnamachary B, 2006, CANCER RES, V66, P2725, DOI 10.1158/0008-5472.CAN-05-3719; Krupa A, 2010, J AM SOC NEPHROL, V21, P438, DOI 10.1681/ASN.2009050530; Kudo-Saito C, 2009, CANCER CELL, V15, P195, DOI 10.1016/j.ccr.2009.01.023; Kumarswamy R, 2012, INT J CANCER, V130, P2044, DOI 10.1002/ijc.26218; Laffin B, 2008, MOL CELL BIOL, V28, P1936, DOI 10.1128/MCB.01701-07; Lander R, 2011, J CELL BIOL, V194, P17, DOI 10.1083/jcb.201012085; Lee MR, 2010, STEM CELLS, V28, P1550, DOI 10.1002/stem.490; Lester RD, 2007, J CELL BIOL, V178, P425, DOI 10.1083/jcb.200701092; Li B, 2012, FEBS J, V279, P2393, DOI 10.1111/j.1742-4658.2012.08618.x; Liskova P, 2007, HUM MUTAT, V28, DOI 10.1002/humu.9495; Liu N, 2010, J BIOL CHEM, V285, P18858, DOI 10.1074/jbc.M109.099440; Liu SJ, 2012, J PATHOL, V226, P61, DOI 10.1002/path.2964; Liu XQ, 2011, BIOCHEM J, V440, P23, DOI 10.1042/BJ20111006; Liu YN, 2013, ONCOGENE, V32, P296, DOI 10.1038/onc.2012.58; Liu YN, 2012, MOL CELL BIOL, V32, P941, DOI 10.1128/MCB.06306-11; Long JY, 2005, J BIOL CHEM, V280, P35477, DOI 10.1074/jbc.M504477200; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Maeda G, 2005, INT J ONCOL, V27, P1535; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mani SA, 2007, P NATL ACAD SCI USA, V104, P10069, DOI 10.1073/pnas.0703900104; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mejlvang J, 2007, MOL BIOL CELL, V18, P4615, DOI 10.1091/mbc.E07-05-0406; Lopez-Novoa JM, 2009, EMBO MOL MED, V1, P303, DOI 10.1002/emmm.200900043; Miyoshi A, 2004, BRIT J CANCER, V90, P1265, DOI 10.1038/sj.bjc.6601685; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; Nairismagi ML, 2012, ONCOGENE, V31, P4960, DOI 10.1038/onc.2011.650; Nalls D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024099; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Ocana OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012; Park D, 2007, APMIS, V115, P52, DOI 10.1111/j.1600-0463.2007.apm_524.x; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Peinado H, 2003, J BIOL CHEM, V278, P21113, DOI 10.1074/jbc.M211304200; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Polyak Kornelia, 2012, Cancer Cell, V22, P562, DOI 10.1016/j.ccr.2012.06.021; Pon YL, 2008, CANCER RES, V68, P6524, DOI 10.1158/0008-5472.CAN-07-6302; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Remacle JE, 1999, EMBO J, V18, P5073, DOI 10.1093/emboj/18.18.5073; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Romano LA, 2000, DEV BIOL, V223, P91, DOI 10.1006/dbio.2000.9750; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Sahlgren C, 2008, P NATL ACAD SCI USA, V105, P6392, DOI 10.1073/pnas.0802047105; Saini S, 2011, CANCER RES, V71, P6208, DOI 10.1158/0008-5472.CAN-11-0073; Saini S, 2011, CLIN CANCER RES, V17, P5287, DOI 10.1158/1078-0432.CCR-10-2619; Sethi N, 2011, NAT REV CANCER, V11, P735, DOI 10.1038/nrc3125; Siemens H, 2011, CELL CYCLE, V10, P4256, DOI 10.4161/cc.10.24.18552; Spaderna S, 2008, CANCER RES, V68, P537, DOI 10.1158/0008-5472.CAN-07-5682; Spaderna S, 2006, GASTROENTEROLOGY, V131, P830, DOI 10.1053/j.gastro.2006.06.016; Spoelstra NS, 2006, CANCER RES, V66, P3893, DOI 10.1158/0008-5472.CAN-05-2881; Taki M, 2006, INT J ONCOL, V28, P487; Tarin D, 2005, CANCER RES, V65, P5996, DOI 10.1158/0008-5472.CAN-05-0699; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thompson EW, 2011, NAT MED, V17, P1048, DOI 10.1038/nm.2437; Thompson EW, 2008, CLIN EXP METASTAS, V25, P591, DOI 10.1007/s10585-008-9189-8; Thompson EW, 2005, CANCER RES, V65, P5991, DOI 10.1158/0008-5472.CAN-05-0616; Thuault S, 2008, J BIOL CHEM, V283, P33437, DOI 10.1074/jbc.M802016200; Timmerman LA, 2004, GENE DEV, V18, P99, DOI 10.1101/gad.276304; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Tsuji T, 2008, CANCER RES, V68, P10377, DOI 10.1158/0008-5472.CAN-08-1444; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Van de Putte T, 2003, AM J HUM GENET, V72, P465, DOI 10.1086/346092; Vandewalle C, 2005, NUCLEIC ACIDS RES, V33, P6566, DOI 10.1093/nar/gki965; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Vernon AE, 2006, DEVELOPMENT, V133, P3359, DOI 10.1242/dev.02504; Vinas-Castells R, 2010, J BIOL CHEM, V285, P3794, DOI 10.1074/jbc.M109.065995; Voulgari A, 2009, BBA-REV CANCER, V1796, P75, DOI 10.1016/j.bbcan.2009.03.002; Wakamatsu N, 2001, NAT GENET, V27, P369, DOI 10.1038/86860; Wang FE, 2010, FASEB J, V24, P1552, DOI 10.1096/fj.08-125856; Wang XH, 2007, CANCER RES, V67, P7184, DOI 10.1158/0008-5472.CAN-06-4729; Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005; Welcker M, 2004, CURR BIOL, V14, P1852, DOI 10.1016/j.cub.2004.09.083; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; White NMA, 2011, BRIT J CANCER, V105, P1741, DOI 10.1038/bjc.2011.401; Wu ZQ, 2012, P NATL ACAD SCI USA, V109, P16654, DOI 10.1073/pnas.1205822109; Xia HP, 2012, J BIOL CHEM, V287, P9962, DOI 10.1074/jbc.M111.332627; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099; Yang WH, 2012, NAT CELL BIOL, V14, P366, DOI 10.1038/ncb2455; Yang ZB, 2005, CANCER RES, V65, P3179, DOI 10.1158/0008-5472.CAN-04-3480; Yin G, 2013, ONCOGENE, V32, P39, DOI 10.1038/onc.2012.33; Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508; Zhang HJ, 2011, CANCER RES, V71, P1292, DOI 10.1158/0008-5472.CAN-10-2825; Zhang K, 2012, EMBO J, V31, P29, DOI 10.1038/emboj.2011.357; Zhang Zhiqian, 2011, Genes Cancer, V2, P782, DOI 10.1177/1947601911429743; Zhao D, 2010, CANCER RES, V70, P4728, DOI 10.1158/0008-5472.CAN-10-0040; Zhou BHP, 2005, CELL CYCLE, V4, P772, DOI 10.4161/cc.4.6.1744; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	152	226	236	2	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2014	33	14					1755	1763		10.1038/onc.2013.128	http://dx.doi.org/10.1038/onc.2013.128			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RE	23604123				2022-12-17	WOS:000334345500002
J	Jechlinger, M; Grunert, S; Tamir, IH; Janda, E; Ludemann, S; Waerner, T; Seither, P; Weith, A; Beug, H; Kraut, N				Jechlinger, M; Grunert, S; Tamir, IH; Janda, E; Ludemann, S; Waerner, T; Seither, P; Weith, A; Beug, H; Kraut, N			Expression profiling of epithelial plasticity in tumor progression	ONCOGENE			English	Article						epithelial-mesenchymal transition; microarray; ras; TGF beta	GROWTH-FACTOR RECEPTOR; BREAST-CANCER; MESENCHYMAL TRANSITIONS; SIGNALING PATHWAYS; CELL PLASTICITY; BETA-CATENIN; E-CADHERIN; HA-RAS; GENE; METASTASIS	Epithelial-to-mesenchymal transition (EMT), a switch of polarized epithelial cells to a migratory, fibroblastoid phenotype, is increasingly considered as an important event during malignant tumor progression and metastasis. To identify molecular players involved in EMT and metastasis, we performed expression pro. ling of a set of combined in vitro/in vivo cellular models, based on clonal, fully polarized mammary epithelial cells. Seven closely related cell pairs were used, which were modified by defined oncogenes and/or external factors and showed specific aspects of epithelial plasticity relevant to cell migration, local invasion and metastasis. Since mRNA levels do not necessarily reflect protein levels in cells, we used an improved expression pro. ling method based on polysome-bound RNA, suitable to analyse global gene expression on Affymetrix chips. A substantial fraction of all regulated genes was found to be exclusively controlled at the translational level. Further more, pro. ling of the above multiple cell pairs allowed one to identify small numbers of genes by cluster analysis, specifically correlating gene expression with EMT, metastasis, scattering and/or oncogene function. A small set of genes specifically regulated during EMT was identified, including key regulators and signaling pathways involved in cell proliferation, epithelial polarity, survival and trans-differentiation to mesenchymal-like cells with invasive behavior.	Res Inst Mol Pathol, IMP, A-1030 Vienna, Austria; Boehringer Ingelheim Pharma KG, Genom Grp, D-88397 Biberach, Germany	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Boehringer Ingelheim	Beug, H (corresponding author), Res Inst Mol Pathol, IMP, Dr Bohrgasse 7, A-1030 Vienna, Austria.		Gruenert, Stefan/B-7598-2016; Jechlinger, Martin/AAC-9442-2020; Janda, Elzbieta/AAD-5126-2022; Gruenert, Stefan/T-7755-2019; Janda, Elzbieta/AFQ-7061-2022	Gruenert, Stefan/0000-0003-0241-9297; Janda, Elzbieta/0000-0002-6787-7291; Gruenert, Stefan/0000-0003-0241-9297; Janda, Elzbieta/0000-0002-6787-7291; Jechlinger, Martin/0000-0002-3710-4466				Anderson NL, 1998, ELECTROPHORESIS, V19, P1853, DOI 10.1002/elps.1150191103; Arthur HM, 2000, DEV BIOL, V217, P42, DOI 10.1006/dbio.1999.9534; Berquin IM, 1996, ADV EXP MED BIOL, V389, P281; Boyer B, 2000, BIOCHEM PHARMACOL, V60, P1091, DOI 10.1016/S0006-2952(00)00427-5; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; Damm K, 2001, EMBO J, V20, P6958, DOI 10.1093/emboj/20.24.6958; De Jong JS, 1998, J PATHOL, V184, P44; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Eger A, 2000, J CELL BIOL, V148, P173, DOI 10.1083/jcb.148.1.173; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Gotzmann J, 2002, J CELL SCI, V115, P1189; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hay ED, 1995, ACTA ANAT, V154, P8; Hocevar BA, 2001, EMBO J, V20, P2789, DOI 10.1093/emboj/20.11.2789; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Janda E, 2002, ONCOGENE, V21, P5148, DOI 10.1038/sj.onc.1205661; Kiemer AK, 2001, ONCOGENE, V20, P6679, DOI 10.1038/sj.onc.1204872; Kumar S, 1999, CANCER RES, V59, P856; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Mikulits W, 2000, FASEB J, V14, P1641, DOI 10.1096/fj.14.11.1641; Muraoka RS, 2002, J CLIN INVEST, V109, P1551, DOI 10.1172/JCI200215234; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Petersen OW, 2003, AM J PATHOL, V162, P391, DOI 10.1016/S0002-9440(10)63834-5; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Sager R, 1997, P NATL ACAD SCI USA, V94, P952, DOI 10.1073/pnas.94.3.952; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vignais ML, 1999, MOL CELL BIOL, V19, P3727; Webb DJ, 1999, J BIOL CHEM, V274, P7412, DOI 10.1074/jbc.274.11.7412; Yang YA, 2002, J CLIN INVEST, V109, P1607, DOI 10.1172/JCI200215333; Zavadil J, 2001, P NATL ACAD SCI USA, V98, P6686, DOI 10.1073/pnas.111614398; ZHANG H, 1995, MECH DEVELOP, V50, P119, DOI 10.1016/0925-4773(94)00329-L; Zhou J, 2001, J BIOL CHEM, V276, P27793, DOI 10.1074/jbc.M102803200; Zong Q, 1999, P NATL ACAD SCI USA, V96, P10632, DOI 10.1073/pnas.96.19.10632	50	226	250	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 16	2003	22	46					7155	7169		10.1038/sj.onc.1206887	http://dx.doi.org/10.1038/sj.onc.1206887			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732PP	14562044				2022-12-17	WOS:000185955000007
J	Paterlini-Brechot, P; Saigo, K; Murakami, Y; Chami, M; Gozuacik, D; Mugnier, C; Lagorce, D; Brechot, C				Paterlini-Brechot, P; Saigo, K; Murakami, Y; Chami, M; Gozuacik, D; Mugnier, C; Lagorce, D; Brechot, C			Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene	ONCOGENE			English	Article						Hepatitis B Virus; insertional mutagenesis; hepatocellular carcinoma; hTERT	HUMAN COLORECTAL CARCINOMAS; CELLS-IN-VITRO; HEPATOCELLULAR-CARCINOMA; THERAPEUTIC TARGETS; HUMAN GENOME; INTEGRATION; ACTIVATION; RECEPTOR; DNA; PROTEIN	Integration of Hepatitis B Virus (HBV) DNA into liver cell DNA has been well established, but its implication in liver carcinogenesis is still being debated. In particular, insertion of the viral genome into cellular genes has been viewed as a rare event. By using HBV-Alu PCR, we have now isolated, from nine hepatocellular carcinomas, nine HBV-DNA integration sites showing that the viral genome mutates key regulatory cellular genes: neurotropic tyrosin receptor kinase 2 (NTRK2) gene, IL-1R-associated kinase 2 (IRAK2) gene, p42 mitogen-activated protein kinase 1 (p42MAPK1) gene, inositol 1,4,5-triphosphate receptor type 2 (IP3R2) gene, inositol 1,4,5-triphosphate receptor (IP3R) type 1 (IP3R1) gene, alpha 2,3 sialyltransferase (ST3GAL VI or SITA) gene, thyroid hormone uncoupling protein (TRUP) gene, EMX2-like gene, and human telomerase reverse transcriptase (hTERT) gene. This result brings to 15 the total number of genes targeted by HBV in a study of 22 human liver cancers. Overall, we found that both the inositol 1,4,5-triphosphate receptor gene and the telomerase gene were targeted by HBV in two different tumors. Thus, HBV frequently targets cellular genes involved in cell signalling and some of them may be preferential targets of the viral integration.	Hop Necker Enfants Malad, INSERM, Pasteur Unit 370, Fac Med Necker, F-75015 Paris, France; Chiba Univ, Dept Surg 2, Sch Med, Chiba 2608670, Japan; Hop Necker Enfants Malad, Dept Biostat & Med Informat, F-75015 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Chiba University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Paterlini-Brechot, P (corresponding author), Hop Necker Enfants Malad, INSERM, Pasteur Unit 370, Fac Med Necker, F-75015 Paris, France.	paterlini@necker.fr	Chami, Mounia/S-6471-2019; Devrim, Gozuacik/C-3330-2008	Chami, Mounia/0000-0003-1498-7187; Devrim, Gozuacik/0000-0001-7739-2346; Paterlini- Brechot, Patrizia/0000-0001-7981-6325				Berasain C, 1998, ONCOGENE, V16, P1277, DOI 10.1038/sj.onc.1201893; Brechot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321; Buendia M A, 1992, Semin Cancer Biol, V3, P309; BURRIS TP, 1995, P NATL ACAD SCI USA, V92, P9525, DOI 10.1073/pnas.92.21.9525; Chami M, 2000, ONCOGENE, V19, P2877, DOI 10.1038/sj.onc.1203605; CORCORAN LM, 1984, CELL, V37, P113, DOI 10.1016/0092-8674(84)90306-4; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; FOUREL G, 1994, EMBO J, V13, P2526, DOI 10.1002/j.1460-2075.1994.tb06542.x; Fourel G, 1994, PRIMARY LIVER CANC E, P89; GARCIA M, 1993, P NATL ACAD SCI USA, V90, P89, DOI 10.1073/pnas.90.1.89; Gozuacik D, 2001, ONCOGENE, V20, P6233, DOI 10.1038/sj.onc.1204835; GRAEF E, 1994, ONCOGENE, V9, P81; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Horikawa I, 2001, J NATL CANCER I, V93, P1171, DOI 10.1093/jnci/93.15.1171; Kroes RA, 2000, CANCER LETT, V156, P191, DOI 10.1016/S0304-3835(00)00462-6; MacDonald TJ, 2001, NAT GENET, V29, P143, DOI 10.1038/ng731; MATSUBARA K, 1990, MOL BIOL MED, V7, P243; McDermott EP, 2002, J BIOL CHEM, V277, P7808, DOI 10.1074/jbc.M108133200; Meyerson M, 2000, J CLIN ONCOL, V18, P2626, DOI 10.1200/JCO.2000.18.13.2626; MINAMI M, 1995, GENOMICS, V29, P403, DOI 10.1006/geno.1995.9004; Nakashio R, 1997, INT J CANCER, V74, P141, DOI 10.1002/(SICI)1097-0215(19970422)74:2<141::AID-IJC1>3.0.CO;2-Z; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; PAYNE GS, 1982, NATURE, V21, P209; Petretti T, 2000, GUT, V46, P359, DOI 10.1136/gut.46.3.359; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; ROBINSON WS, 1987, HEPATOLOGY, V7, pS64, DOI 10.1002/hep.1840070712; Russo G, 1997, J BIOL CHEM, V272, P5229, DOI 10.1074/jbc.272.8.5229; SCHERDIN U, 1990, J VIROL, V64, P907, DOI 10.1128/JVI.64.2.907-912.1990; Schneider F, 2001, CANCER RES, V61, P4605; Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4; Shibayama E, 1996, AM J PATHOL, V148, P1807; Sugimoto T, 2001, JPN J CANCER RES, V92, P152, DOI 10.1111/j.1349-7006.2001.tb01077.x; TAHARA H, 1995, CANCER RES, V55, P2734; Tu H, 2001, CANCER RES, V61, P7803; Urashima T, 1997, J HEPATOL, V26, P771, DOI 10.1016/S0168-8278(97)80241-3; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; Wang YX, 2000, INT J ONCOL, V16, P757; Weber G, 1996, ANTICANCER RES, V16, P3271; YU C, 2002, 93 ANN M AM ASS CANC, V43; Zhu YT, 2001, BBA-MOL BASIS DIS, V1536, P148, DOI 10.1016/S0925-4439(01)00044-8	40	226	235	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2003	22	25					3911	3916		10.1038/sj.onc.1206492	http://dx.doi.org/10.1038/sj.onc.1206492			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	691NH	12813464				2022-12-17	WOS:000183612000010
J	Gupta, S; Afaq, F; Mukhtar, H				Gupta, S; Afaq, F; Mukhtar, H			Involvement of nuclear factor-kappa B, Bax and Bcl-2 in induction of cell cycle arrest and apoptosis by apigenin in human prostate carcinoma cells	ONCOGENE			English	Article						apigenin; prostate cancer; apoptosis; cell-cycle arrest; chemoprevention; nuclear factor-kappa B (NF-kappa B)	CANCER-CELLS; FLAVONOIDS; GROWTH; INHIBITION; ANTIGEN; GENE; CYCLOOXYGENASE; PROLIFERATION; EXPRESSION; REGULATORS	Apigenin, a common dietary flavonoid abundantly present in fruits and vegetables, may have the potential for prevention and therapy for prostate cancer. Here, we report for the first time that apigenin inhibits the growth of androgen-responsive human prostate carcinoma LNCaP cells and provide molecular understanding of this effect. The cell growth inhibition achieved by apigenin treatment resulted in a significant decrease in AR protein expression along with a decrease in intracellular and secreted forms of PSA. These effects were also observed in DHT-stimulated cells. Further, apigenin treatment of LNCaP cells resulted in G1 arrest in cell cycle progression which was associated with a marked decrease in the protein expression of cyclin D1, D2 and E and their activating partner cdk2, 4 and 6 with concomitant induction of WAFT/p21 and KIP1/p27. The induction of WAFT/p21 appears to be transcriptionally upregulated and is p53 dependent. In addition, apigenin inhibited the hyperphosphorylation of the pRb protein in these cells. Apigenin treatment also resulted in induction of apoptosis as determined by DNA fragmentation, PARP cleavage, fluorescence microscopy and flow cytometry. These effects were found to correlate with a shift in Bax/Bcl-2 ratio more towards apoptosis. Apigenin treatment also resulted in down-modulation of the constitutive expression. of NF-kappaB/p65. Taken together, these findings suggest that apigenin has strong potential for development as an agent for prevention against prostate cancer.	Case Western Reserve Univ, Dept Dermatol, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Inst Res, Cleveland, OH 44106 USA	Case Western Reserve University; University Hospitals of Cleveland	Gupta, S (corresponding author), Case Western Reserve Univ, Dept Dermatol, 11100 Euclid Ave, Cleveland, OH 44106 USA.	gxs44@po.cwru.edu		Gupta, Sanjay/0000-0002-9492-3249	NATIONAL CANCER INSTITUTE [R01CA078809] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA 78809] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams PD, 2001, BBA-REV CANCER, V1471, pM123, DOI 10.1016/S0304-419X(01)00019-1; Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Ahmad N, 1999, ONCOGENE, V18, P1891, DOI 10.1038/sj.onc.1202493; Ahmad N, 2000, ARCH BIOCHEM BIOPHYS, V376, P338, DOI 10.1006/abbi.2000.1742; Birt DF, 1997, ANTICANCER RES, V17, P85; BIRT DF, 1998, CHEMOPREVENTION CANC, P1263; Bours V, 2000, BIOCHEM PHARMACOL, V60, P1085, DOI 10.1016/S0006-2952(00)00391-9; Caltagirone S, 2000, INT J CANCER, V87, P595, DOI 10.1002/1097-0215(20000815)87:4&lt;595::AID-IJC21&gt;3.0.CO;2-5; CHAUMONTET C, 1994, CARCINOGENESIS, V15, P2325, DOI 10.1093/carcin/15.10.2325; Cohen JH, 2000, JNCI-J NATL CANCER I, V92, P61, DOI 10.1093/jnci/92.1.61; Duthie G, 2000, CURR OPIN LIPIDOL, V11, P43, DOI 10.1097/00041433-200002000-00007; Fotsis T, 1998, BAILLIERE CLIN ENDOC, V12, P649, DOI 10.1016/S0950-351X(98)80009-8; Gupta S, 2001, BIOCHEM BIOPH RES CO, V287, P914, DOI 10.1006/bbrc.2001.5672; HENTTU P, 1990, INT J CANCER, V45, P654, DOI 10.1002/ijc.2910450414; Herness EA, 2001, FRONT BIOSCI-LANDMRK, V6, pD1083, DOI 10.2741/Herness; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hollman PCH, 1999, FREE RADICAL RES, V31, pS75, DOI 10.1080/10715769900301351; Hollman PCH, 1999, FOOD CHEM TOXICOL, V37, P937, DOI 10.1016/S0278-6915(99)00079-4; Kim HP, 1998, PROSTAG LEUKOTR ESS, V58, P17, DOI 10.1016/S0952-3278(98)90125-9; Kolonel LN, 2000, CANCER EPIDEM BIOMAR, V9, P795; KUO ML, 1994, CANCER LETT, V87, P91, DOI 10.1016/0304-3835(94)90414-6; KUO ML, 1992, MUTAT RES, V270, P87, DOI 10.1016/0027-5107(92)90119-M; Lamb DJ, 2001, VITAM HORM, V62, P199, DOI 10.1016/S0083-6729(01)62005-3; LEE C, 1995, ENDOCRINOLOGY, V136, P796, DOI 10.1210/en.136.2.796; Lee JI, 1998, J CLIN PHARMACOL, V38, P981, DOI 10.1177/009127009803801101; Lepley DM, 1997, MOL CARCINOGEN, V19, P74, DOI 10.1002/(SICI)1098-2744(199707)19:2<74::AID-MC2>3.0.CO;2-L; Lepley DM, 1996, CARCINOGENESIS, V17, P2367, DOI 10.1093/carcin/17.11.2367; Liang YC, 1999, CARCINOGENESIS, V20, P1945, DOI 10.1093/carcin/20.10.1945; Masciullo V, 2000, INT J ONCOL, V17, P897; McVean M, 2000, CARCINOGENESIS, V21, P633, DOI 10.1093/carcin/21.4.633; Meyers FJ, 1998, CANCER, V83, P2534, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2534::AID-CNCR19>3.3.CO;2-M; MIDDLETON E, 1984, TRENDS PHARMACOL SCI, V5, P335; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; Mueller A, 1997, CANCER RES, V57, P5542; NAVONE NM, 1993, J NATL CANCER I, V85, P1657, DOI 10.1093/jnci/85.20.1657; Panes Julian, 1996, Microcirculation (Philadelphia), V3, P279, DOI 10.3109/10739689609148302; Pestell RG, 1999, ENDOCR REV, V20, P501, DOI 10.1210/er.20.4.501; Pucci B, 2000, NEOPLASIA, V2, P291, DOI 10.1038/sj.neo.7900101; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; Sandhu C, 2000, CANCER DETECT PREV, V24, P107; STAMEY TA, 1987, NEW ENGL J MED, V317, P909, DOI 10.1056/NEJM198710083171501; Takahashi T, 1998, BIOSCI BIOTECH BIOCH, V62, P2199, DOI 10.1271/bbb.62.2199; Vidal A, 2000, GENE, V247, P1, DOI 10.1016/S0378-1119(00)00092-5; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang LG, 1997, CANCER RES, V57, P714; Wang WQ, 2000, MOL CARCINOGEN, V28, P102; WEI HC, 1990, CANCER RES, V50, P499; Yin F, 2001, ANTICANCER RES, V21, P413; Yin F, 1999, THYROID, V9, P369, DOI 10.1089/thy.1999.9.369; YIN XM, 1994, COLD SPRING HARB SYM, V59, P387, DOI 10.1101/SQB.1994.059.01.043; Zornig M, 2001, BBA-REV CANCER, V1551, pF1, DOI 10.1016/S0304-419X(01)00031-2	51	226	247	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3727	3738		10.1038/sj.onc.1205474	http://dx.doi.org/10.1038/sj.onc.1205474			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032841				2022-12-17	WOS:000175676000008
J	Hinz, S; Trauzold, A; Boenicke, L; Sandberg, C; Beckmann, S; Bayer, E; Walczak, H; Kalthoff, H; Ungefroren, H				Hinz, S; Trauzold, A; Boenicke, L; Sandberg, C; Beckmann, S; Bayer, E; Walczak, H; Kalthoff, H; Ungefroren, H			Bcl-X-L protects pancreatic adenocarcinoma cells against CD95-and TRAIL-receptor-mediated apoptosis	ONCOGENE			English	Article						TRAIL; Bcl-X-L; Bax; apoptosis; pancreatic carcinoma; human	MYELOMA CELLS; CYTOCHROME-C; DEATH DOMAIN; LIGAND TRAIL; B-CELLS; FAS; EXPRESSION; BCL-X(L); FAMILY; GENE	In this study we sought to clarify the role of the proapoptotic potential of mitochondria in the death pathway emanating from the TRAIL (APO-2L) and CD95 receptors in pancreatic carcinoma cells. We focused on the role of the Bcl-2 family member Bcl-X-L, using three pancreatic carcinoma cell lines as a model system, two of which have high (Panc-1, PancTuI) and one has low (Colo357) Bcl-X-L expression. In these cell lines, the expression of Bcl-X-L correlated with sensitivity to apoptosis induced by TRAIL or anti-CD95. Flow cytometric analysis revealed cell surface expression of TRAIL-Ri and TRAIL-R2 on PancTuI and Colo357, and TRAIL-R2 on Panc-1 cells. In Colo357 cells retrovirally transduced with Bcl-X-L, caspase-8 activation in response to treatment with TRAIL or anti-CD95 antibody was not different from parental cells and EGFP-transfected controls, however, apoptosis was completely suppressed as measured by the mitochondrial transmembrane potential Delta Psim, caspase-3 activity (PARP cleavage) and DNA-fragmentation, Inhibition of Bcl-X-L function by overexpression of Bax or administration of antisense oligonucleotides against Bcl-X-L mRNA resulted in sensitization of Panc-1 cells to TRAIL and PancTuI cells to anti-CD95 antibody-induced cell death. The results show that Bcl-X-L can protect pancreatic cancer cells from CD95- and TRAIL-mediated apoptosis, Thus, in these epithelial tumour cells the mitochondrially mediated 'type II' pathway of apoptosis induction is not only operative regarding the CD95 system but also regarding the TRAIL system.	Univ Kiel, Res Unit Mol Oncol, Clin Gen Surg & Thorac Surg, D-24105 Kiel, Germany; Deutsch Krebsforschungszentrum, Tumor Immunol Program, Apoptosis Res Grp G0310, D-69120 Heidelberg, Germany; Univ Tubingen, Inst Organ Chem, D-72076 Tubingen, Germany	University of Kiel; Helmholtz Association; German Cancer Research Center (DKFZ); Eberhard Karls University of Tubingen	Ungefroren, H (corresponding author), Univ Kiel, Res Unit Mol Oncol, Clin Gen Surg & Thorac Surg, Arnold Heller Str 7, D-24105 Kiel, Germany.		Trauzold, Anna/P-4398-2014; Kalthoff, Holger/B-1618-2010; Walczak, Henning/AAV-2214-2020	Walczak, Henning/0000-0002-6312-4591				Ackermann EJ, 1999, J BIOL CHEM, V274, P11245, DOI 10.1074/jbc.274.16.11245; Alam MK, 1997, EUR J IMMUNOL, V27, P3485, DOI 10.1002/eji.1830271249; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; BRAMHALL SR, 1997, INT J PANCREATOL, V21, P58; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Friess H, 1998, ANN SURG, V228, P780, DOI 10.1097/00000658-199812000-00009; Gauthier ER, 1996, CANCER RES, V56, P1451; Gazitt Y, 1999, LEUKEMIA, V13, P1817, DOI 10.1038/sj.leu.2401501; Griffith TS, 1998, J IMMUNOL, V161, P2833; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Howard BD, 2000, CANCER GENE THER, V7, P927, DOI 10.1038/sj.cgt.7700180; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; JAATTELA M, 1995, ONCOGENE, V10, P2297; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Kawahara A, 1998, ONCOGENE, V17, P2549, DOI 10.1038/sj.onc.1202192; Keogh SA, 2000, FEBS LETT, V471, P93, DOI 10.1016/S0014-5793(00)01375-2; Kim KH, 2000, CLIN CANCER RES, V6, P335; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kondo S, 1998, ONCOGENE, V17, P2585, DOI 10.1038/sj.onc.1202194; Kondo S, 1996, INT J CANCER, V68, P727, DOI 10.1002/(SICI)1097-0215(19961211)68:6<727::AID-IJC6>3.0.CO;2-5; Kothny-Wilkes G, 1999, J BIOL CHEM, V274, P28916, DOI 10.1074/jbc.274.41.28916; Krammer P H, 1999, Adv Immunol, V71, P163; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Lee SH, 1999, CANCER RES, V59, P5683; Leverkus M, 2000, CANCER RES, V60, P553; Liu R, 1999, AM J PATHOL, V155, P1861, DOI 10.1016/S0002-9440(10)65505-8; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; MEMON SA, 1995, J IMMUNOL, V155, P4644; Miyamoto Y, 1999, ONCOLOGY-BASEL, V56, P73, DOI 10.1159/000011933; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1998, FEBS LETT, V424, P41, DOI 10.1016/S0014-5793(98)00135-5; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Perkins CL, 2000, CANCER RES, V60, P1645; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schneider TJ, 1997, J IMMUNOL, V159, P4834; Seol DW, 1999, J BIOL CHEM, V274, P2072, DOI 10.1074/jbc.274.4.2072; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shinoura N, 1999, CANCER RES, V59, P4119; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Truneh A, 2000, J BIOL CHEM, V275, P23319, DOI 10.1074/jbc.M910438199; Ungefroren H, 1996, J BIOL CHEM, V271, P15787, DOI 10.1074/jbc.271.26.15787; Ungefroren H, 1998, CANCER RES, V58, P1741; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; WALCZAK H, 2000, CANCER RES, V60, P351; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yamada H, 1999, BIOCHEM BIOPH RES CO, V265, P130, DOI 10.1006/bbrc.1999.1641; Zhang XD, 1999, CANCER RES, V59, P2747	57	226	243	0	10	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 16	2000	19	48					5477	5486		10.1038/sj.onc.1203936	http://dx.doi.org/10.1038/sj.onc.1203936			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375JQ	11114725				2022-12-17	WOS:000165396100008
J	Walter, AO; Seghezzi, W; Korver, W; Sheung, J; Lees, E				Walter, AO; Seghezzi, W; Korver, W; Sheung, J; Lees, E			The mitotic serine/threonine kinase Aurora2/AIK is regulated by phosphorylation and degradation	ONCOGENE			English	Article						mitotic kinase; phosphorylation; degradation; cell cycle	CHROMOSOME SEGREGATION REGULATORS; CAENORHABDITIS-ELEGANS EMBRYOS; HUMAN PROTEIN-KINASE; POLO-LIKE KINASES; CELL-CYCLE; DROSOPHILA-AURORA; BUDDING YEAST; M-PHASE; CHECKPOINT; CENTROSOME	Aurora2 is a cell cycle regulated serine/threonine protein kinase which is overexpressed in many tumor cell lines. We demonstrate that Aurora2 is regulated by phosphorylation in a cell cycle dependent manner. This phosphorylation occurs on a conserved residue, Threonine 288, within the activation loop of the catalytic domain of the kinase and results in a significant increase in the enzymatic activity. Threonine 288 resides within consensus motif for the cAMP dependent kinase and can be phosphorylated by PKA in vitro. The protein phosphatase 1 is shown to dephosphorylate this site in vitro, and in vivo the phosphorylation of T288 is induced by okadaic acid treatment. Furthermore, we show that the Aurora2 kinase is regulated by proteasome dependent degradation and that Aurora2 phosphorylated on T288 may be targeted for degradation during mitosis, Our experiments suggest that phosphorylation of T288 is important for regulation of the Aurora2 kinase both for its activity and its stability.	DNAX Res Inst Mol & Cellular Biol Inc, Palo Alto, CA 94304 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Lees, E (corresponding author), DNAX Res Inst Mol & Cellular Biol Inc, 901 Calif Ave, Palo Alto, CA 94304 USA.							Andresson T, 1998, EMBO J, V17, P5627, DOI 10.1093/emboj/17.19.5627; Bernard M, 1998, GENOMICS, V53, P406, DOI 10.1006/geno.1998.5522; Biggins S, 1999, GENE DEV, V13, P532, DOI 10.1101/gad.13.5.532; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; Bloecher A, 1999, GENE DEV, V13, P517, DOI 10.1101/gad.13.5.517; CHAN CSM, 1993, GENETICS, V135, P677; Farruggio DC, 1999, P NATL ACAD SCI USA, V96, P7306, DOI 10.1073/pnas.96.13.7306; FERNANDEZ A, 1992, J CELL BIOL, V116, P1421, DOI 10.1083/jcb.116.6.1421; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; Giet R, 1999, J CELL SCI, V112, P3591; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Gopalan G, 1997, J CELL BIOL, V138, P643, DOI 10.1083/jcb.138.3.643; Grieco D, 1996, SCIENCE, V271, P1718, DOI 10.1126/science.271.5256.1718; Hardwick KG, 1998, TRENDS GENET, V14, P1, DOI 10.1016/S0168-9525(97)01340-1; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Kimura M, 1997, J BIOL CHEM, V272, P13766, DOI 10.1074/jbc.272.21.13766; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; Mayor T, 1999, FEBS LETT, V452, P92, DOI 10.1016/S0014-5793(99)00534-7; Morgan DO, 1996, NATURE, V382, P295, DOI 10.1038/382295a0; Morgan DO, 1999, NAT CELL BIOL, V1, pE47, DOI 10.1038/10039; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Orr-Weaver TL, 1998, NATURE, V392, P223, DOI 10.1038/32520; Page AM, 1997, CANCER SURV, V29, P133; Pfleger CM, 2000, GENE DEV, V14, P655; Roghi C, 1998, J CELL SCI, V111, P557; Sassoon I, 1999, GENE DEV, V13, P545, DOI 10.1101/gad.13.5.545; Schumacher JM, 1998, DEVELOPMENT, V125, P4391; Schumacher JM, 1998, J CELL BIOL, V143, P1635, DOI 10.1083/jcb.143.6.1635; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; Shindo M, 1998, BIOCHEM BIOPH RES CO, V244, P285, DOI 10.1006/bbrc.1998.8250; Straight AF, 1997, CURR BIOL, V7, pR613, DOI 10.1016/S0960-9822(06)00315-0; TAKAI A, 1992, BIOCHEM J, V284, P539, DOI 10.1042/bj2840539; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Tseng TC, 1998, DNA CELL BIOL, V17, P823, DOI 10.1089/dna.1998.17.823; Vorlaufer E, 1998, MOL BIOL CELL, V9, P1817, DOI 10.1091/mbc.9.7.1817; Walter AO, 1999, ONCOGENE, V18, P1911, DOI 10.1038/sj.onc.1202513; Yanai A, 1997, ONCOGENE, V14, P2943, DOI 10.1038/sj.onc.1201144; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	41	226	233	0	9	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 5	2000	19	42					4906	4916		10.1038/sj.onc.1203847	http://dx.doi.org/10.1038/sj.onc.1203847			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	362BB	11039908				2022-12-17	WOS:000089757800013
J	Ziv, Y; BarShira, A; Pecker, I; Russell, P; Jorgensen, TJ; Tsarfati, I; Shiloh, Y				Ziv, Y; BarShira, A; Pecker, I; Russell, P; Jorgensen, TJ; Tsarfati, I; Shiloh, Y			Recombinant ATM protein complements the cellular A-T phenotype	ONCOGENE			English	Article						ataxia-telangiectasia; ATM; FLAG epitope; radiosensitivity; cell cycle checkpoints; mutations	ATAXIA-TELANGIECTASIA GENE; EPSTEIN-BARR VIRUS; PEPTIDE ELUTION; KINASE; PURIFICATION; EXPRESSION; CELLS; FIBROBLASTS; ACTIVATION; RADIATION	Ataxia-telangiectasia (A-T) is an autosomal recessive disorder characterized by neurodegeneration, immunodeficiency, cancer predisposition, genome instability and radiation sensitivity, The cellular phenotype of A-T points to defects in signal transduction pathways involved in activation of cell cycle checkpoints by free radical damage, and other pathways that mediate the transmission of specific mitogenic stimuli, The product of the responsible gene, ATM, belongs to a family of large proteins that contribute to maintaining genome stability and cell cycle progression in various organisms, A recombinant vector that stably expresses a full-length ATM protein is a valuable tool for its functional analysis, We constructed and cloned a recombinant, full-length open reading frame of ATM using a combination of vectors and hosts that overcame an inherent instability of this sequence, Recombinant ATM was stably expressed in insect cells using a baculovirus vector, albeit at a low level, and in human A-T cells using an episomal expression vector, An amino-terminal FLAG epitope added to the protein allowed highly specific detection of the recombinant molecule by immunoblotting, immunoprecipitation and immunostaining, and its isolation using immunoaffinity, Similar to endogenous ATM, the recombinant protein is located mainly in the nucleus, with low levels in the cytoplasm, Ectopic expression of ATM in A-T cells restored normal sensitivity to ionizing radiation and the radiomimetic drug neocarzinostatin, and a normal pattern of post-irradiation DNA synthesis, which represents an S-phase checkpoint. These observations indicate that the recombinant, epitope-tagged protein is functional, Introduction into this molecule of a known A-T missense mutation, Glu2904Gly, resulted in apparent instability of the protein and inability to complement the A-T phenotype, These findings indicate that the physiological defects characteristic of A-T cells result from the absence of the ATM protein, and that this deficiency can be corrected by ectopic expression of this protein.	TEL AVIV UNIV,SACKLER SCH MED,DEPT HUMAN MICROBIOL,IL-69978 RAMAT AVIV,ISRAEL; GEORGETOWN UNIV,MED CTR,VINCENT T LOMBARDI CANC RES CTR,DEPT RADIAT MED,WASHINGTON,DC 20007	Tel Aviv University; Sackler Faculty of Medicine; Georgetown University	Ziv, Y (corresponding author), TEL AVIV UNIV,SACKLER SCH MED,DEPT HUMAN GENET,IL-69978 RAMAT AVIV,ISRAEL.			Tsarfaty, Ilan/0000-0002-5230-7093	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031763] Funding Source: NIH RePORTER; NINDS NIH HHS [NS31763] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALNABULSI I, 1994, CANCER RES, V54, P5614; ARTUSO M, 1995, ONCOGENE, V11, P1427; Baumer A, 1996, HUM GENET, V98, P246, DOI 10.1007/s004390050202; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; BRIZZARD BL, 1994, BIOTECHNIQUES, V16, P730; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brown KD, 1997, P NATL ACAD SCI USA, V94, P1840, DOI 10.1073/pnas.94.5.1840; Byrd PJ, 1996, HUM MOL GENET, V5, P145, DOI 10.1093/hmg/5.1.145; CANMAN CE, 1994, CANCER RES, V54, P5054; Chen G, 1996, J BIOL CHEM, V271, P33693, DOI 10.1074/jbc.271.52.33693; CHIANG CM, 1993, PEPTIDE RES, V6, P62; DENT P, 1995, MOL CELL BIOL, V15, P4125; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Gilad S, 1996, HUM MOL GENET, V5, P2033, DOI 10.1093/hmg/5.12.2033; Gilad S, 1996, HUM MOL GENET, V5, P433, DOI 10.1093/hmg/5.4.433; GILAD S, 1997, IN PRESS HUM MUTAT; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; JACKSON SP, 1995, CURR BIOL, V5, P1210, DOI 10.1016/S0960-9822(95)00238-7; JORGENSEN TJ, 1995, RADIAT RES, V143, P219, DOI 10.2307/3579160; Jung M, 1997, CANCER RES, V57, P24; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; KHANNA KK, 1997, IN PRESS J BIOL CHEM; Lakin ND, 1996, ONCOGENE, V13, P2707; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; LIU F, 1995, MOL CELL BIOL, V15, P3479; Luckow Verne A., 1993, Current Opinion in Biotechnology, V4, P564, DOI 10.1016/0958-1669(93)90078-B; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; Morgan SE, 1997, MOL CELL BIOL, V17, P2020, DOI 10.1128/MCB.17.4.2020; PETERSON C, 1991, GENE, V107, P279, DOI 10.1016/0378-1119(91)90328-9; ROTMAN G, 1909, IN PRSS CANC SURVEYS; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; SHILOH Y, 1982, CANCER RES, V42, P2247; Shiloh Y, 1996, J CLIN IMMUNOL, V16, P254, DOI 10.1007/BF01541389; SMITH GE, 1985, P NATL ACAD SCI USA, V82, P8404, DOI 10.1073/pnas.82.24.8404; TAYLOR AMR, 1994, INT J RADIAT BIOL, V65, P65, DOI 10.1080/09553009414550091; Telatar M, 1996, AM J HUM GENET, V59, P40; WATTERS D, 1997, IN PRESS ONCOGENE; WHITE RJ, 1995, MOL CELL BIOL, V15, P1983; Wright J, 1996, AM J HUM GENET, V59, P839; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8; ZIV Y, 1989, CANCER RES, V49, P2495; ZIV Y, 1995, SOMAT CELL MOLEC GEN, V21, P99, DOI 10.1007/BF02255785	47	226	229	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 10	1997	15	2					159	167		10.1038/sj.onc.1201319	http://dx.doi.org/10.1038/sj.onc.1201319			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK372	9244351				2022-12-17	WOS:A1997XK37200004
J	BRUNET, A; PAGES, G; POUYSSEGUR, J				BRUNET, A; PAGES, G; POUYSSEGUR, J			CONSTITUTIVELY ACTIVE MUTANTS OF MAP KINASE KINASE (MEK1) INDUCE GROWTH FACTOR-RELAXATION AND ONCOGENICITY WHEN EXPRESSED IN FIBROBLASTS	ONCOGENE			English	Article							PROTEIN-KINASE; HAMSTER FIBROBLASTS; SIGNALING PATHWAYS; NA+/H+ ANTIPORTER; ACTIVATION; CELLS; RAS; PHOSPHATASE; CASCADE; PHOSPHORYLATION	The Mitogen Activated Protein Kinase (MAPK) module operates downstream of Pas to convey cell surface signals to the nucleus via the nuclear translocation of p42/p44 MAPKs. We have previously established that MAPK activation is obligatory and must persist in the G1 phase to allow resting fibroblasts to exit from G0 (Pages et al., Proc. Natl. Acad. Sci.1993, 90, 8319-8323). It remained to be established whether MAPK activation was sufficient to trigger cell proliferation. To this aim, we generated and expressed in Chinese hamster lung fibroblasts, constitutively active mutants of hamster MAP kinase kinase (MAPKK). Three mutants: S218D, S222D and S218D/S222D in which we substituted the Raf1/MAPKKK-dependent regulatory phosphorylation sites by aspartic acid residues, displayed increased basal activity when expressed in fibroblasts. Two of them, S218D and S218D/S222D which have a basal activity higher than serum-stimulated wild type-MAPKK (respectively 2- and 5-fold), induced activation of p42 MAPK in growth factor-deprived cells. Interestingly, only these two mutants led to a growth factor-independent state as judged by early gene transcription (activation of the fos promoter), increased sensitivity to growth factors for reinitiation of DNA synthesis, autonomous cell cycling and rapid tumor formation in nude mice. Therefore we conclude that the downstream elements of the growth factor signalling cascade, MAPKK-MAPK, are both necessary and sufficient to promote growth factor signals and autonomous cell cycling in fibroblasts.	UNIV NICE,CTR BIOCHIM,CNRS,F-06108 NICE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur			Pages, Gilles/N-7135-2017					ALESSI DR, 1993, ONCOGENE, V8, P2015; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BRUNET A, 1994, FEBS LETT, V346, P299, DOI 10.1016/0014-5793(94)00475-7; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DUBOIS MF, 1994, IN PRESS EMBO J; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; ELLIS L, 1986, COLD SPRING HARB SYM, V51, P773, DOI 10.1101/SQB.1986.051.01.090; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GOTOH Y, 1994, ONCOGENE, V9, P1891; HAYSTEAD TAJ, 1992, FEBS LETT, V306, P17, DOI 10.1016/0014-5793(92)80828-5; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LANGECARTER CA, 1993, SCIENCE, V260, P318; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MORDRET G, 1993, BIOL CELL, V79, P193, DOI 10.1016/0248-4900(93)90138-5; NEIMAN AM, 1993, TRENDS GENET, V9, P390, DOI 10.1016/0168-9525(93)90139-9; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; PEREZRODRIGUEZ R, 1981, J CELL PHYSIOL, V109, P387, DOI 10.1002/jcp.1041090303; PEREZRODRIGUEZ R, 1982, INT J CANCER, V29, P309, DOI 10.1002/ijc.2910290314; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; POYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SEUWEN K, 1988, EMBO J, V7, P161, DOI 10.1002/j.1460-2075.1988.tb02796.x; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; WANG YZ, 1992, BIOCHEM J, V287, P589, DOI 10.1042/bj2870589	57	226	229	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3379	3387						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936666				2022-12-17	WOS:A1994PM65800035
J	PIM, D; COLLINS, M; BANKS, L				PIM, D; COLLINS, M; BANKS, L			HUMAN PAPILLOMAVIRUS TYPE-16 E5 GENE STIMULATES THE TRANSFORMING ACTIVITY OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR	ONCOGENE			English	Article							CARCINOMA CELL-LINES; OPEN READING FRAME; CERVICAL-CARCINOMA; ADENOVIRUS E1A; EGF RECEPTOR; E7 PROTEIN; DNA; IDENTIFICATION; ENCODES; EXPRESSION	We have until recently made several unsuccessful attempts to assign any activity to the human papillomavirus type 16 (HPV-16) E5 gene product. However, studies with the bovine papilloma virus 1 (BPV-1) E5 protein indicated an interaction with the epidermal growth factor receptor (EGFR). In light of the overall similarity between the HPV and BPV E5 proteins we attempted to determine whether the HPV-16 E5 gene had any common activity. In cells expressing high levels of EGFR plus HPV-16 E5 we found a dramatically increased proliferative activity in soft-agar assays in the presence of EGF. The specificity of this activity was monitored by the addition of other mitogenic agents. The phorbol ester phorbol 12-myristate 13-acetate (PMA) had no effect on the E5-containing cells, although insulin weakly stimulated their growth in soft agar. Further analysis revealed the same number of EGF receptors were present on the E5-containing cells as on the control cells, although the E5 cells were more sensitive to lower concentrations of EGF. These results imply that E5 is amplifying the mitogenic signals from the EGFR in an as yet unknown manner, but which may form the basis of interactions with a variety of growth factor receptors. This report brings to three the number of transforming genes encoded by HPV-16.	INT CTR GENET ENGN & BIOTECHNOL,PADRICIANO 99,I-34012 TRIESTE,ITALY; ROYAL CANC HOSP,INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND	International Center for Genetic Engineering & Biotechnology (ICGEB); Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK								ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; BANKNECHT T, 1989, J CLIN RES CLIN ONCO, V115, P193; BANKS L, 1990, ONCOGENE, V5, P1383; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BURKHARDT A, 1987, EMBO J, V6, P2381, DOI 10.1002/j.1460-2075.1987.tb02515.x; CHEN SL, 1990, J VIROL, V64, P3226, DOI 10.1128/JVI.64.7.3226-3233.1990; COLLINS MKL, 1988, J CELL PHYSIOL, V137, P293, DOI 10.1002/jcp.1041370212; COLLINS MKL, 1983, J BIOL CHEM, V258, P1689; CROOK T, 1989, EMBO J, V8, P513, DOI 10.1002/j.1460-2075.1989.tb03405.x; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; GISSMANN L, 1983, P NATL ACAD SCI-BIOL, V80, P560, DOI 10.1073/pnas.80.2.560; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; GOPPINGER A, 1989, J CANCER RES CLIN, V115, P259, DOI 10.1007/BF00391699; GREEN M, 1987, CELL, V51, P795, DOI 10.1016/0092-8674(87)90102-4; HALBERT CL, 1988, J VIROL, V62, P1071, DOI 10.1128/JVI.62.3.1071-1075.1988; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HOROWITZ BH, 1989, J VIROL, V63, P4515; KOHLER M, 1989, ANTICANCER RES, V9, P1537; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; KRIS RM, 1985, CELL, V40, P619, DOI 10.1016/0092-8674(85)90210-7; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MUNGER K, 1989, J VIROL, V63, P4417; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; SCHILLER JT, 1984, P NATL ACAD SCI-BIOL, V81, P7880, DOI 10.1073/pnas.81.24.7880; SCHILLER JT, 1986, J VIROL, V57, P1; SCHLEGEL R, 1986, SCIENCE, V233, P464, DOI 10.1126/science.3014660; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; VANDENBRULE AJC, 1989, J MED VIROL, V29, P20, DOI 10.1002/jmv.1890290105; VOUSDEN KH, 1988, ONCOGENE RES, V3, P167; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WILKINSON D, 1988, J EXP MED, V164, P14; YANG YC, 1985, P NATL ACAD SCI USA, V82, P1030, DOI 10.1073/pnas.82.4.1030	41	226	230	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1992	7	1					27	32						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1311063				2022-12-17	WOS:A1992HC22700004
J	Pietsch, EC; Sykes, SM; McMahon, SB; Murphy, ME				Pietsch, E. C.; Sykes, S. M.; McMahon, S. B.; Murphy, M. E.			The p53 family and programmed cell death	ONCOGENE			English	Review						p53; p63; p73; apoptosis; transcription; mitochondria	DNA-BINDING DOMAIN; YES-ASSOCIATED PROTEIN; TUMOR-SUPPRESSOR P53; WILD-TYPE P53; MITOCHONDRIAL-MEMBRANE PERMEABILIZATION; APOPTOTIC TARGET GENES; PROLYL ISOMERASE PIN1; KINASE C-ABL; IN-VIVO; P53-DEPENDENT APOPTOSIS	The p53 tumor suppressor continues to hold distinction as the most frequently mutated gene in human cancer. The ability of p53 to induce programmed cell death, or apoptosis, of cells exposed to environmental or oncogenic stress constitutes a major pathway whereby p53 exerts its tumor suppressor function. In the past decade, we have discovered that p53 is not alone in its mission to destroy damaged or aberrantly proliferating cells: it has two homologs, p63 and p73, that in various cellular contexts and stresses contribute to this process. In this review, the mechanisms whereby p53, and in some cases p63 and p73, induce apoptosis are discussed. Other reviews have focused more extensively on the contribution of individual p53-regulated genes to apoptosis induction by this protein, whereas in this review, we focus more on those factors that mediate the decision between growth arrest and apoptosis by p53, p63 and p73, and on the post-translational modi. cations and protein-protein interactions that influence this decision.	[Pietsch, E. C.; Murphy, M. E.] Fox Chase Canc Ctr, Div Med Sci, Philadelphia, PA 19111 USA; [Sykes, S. M.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; [McMahon, S. B.] Thomas Jefferson Med Coll, Kimmel Canc Ctr, Dept Canc Biol, Philadelphia, PA USA	Fox Chase Cancer Center; Harvard University; Brigham & Women's Hospital; Jefferson University	Murphy, ME (corresponding author), Fox Chase Canc Ctr, Div Med Sci, 333 Cottman Ave, Philadelphia, PA 19111 USA.	steven.mcmahon@mail.jci.tju.edu; Maureen.Murphy@FCCC.edu		McMahon, Steven/0000-0002-3405-1768; Murphy, Maureen/0000-0001-7644-7296	NCI NIH HHS [R01 CA080854-10, R01 CA080854, R01 CA102184-04, R01 CA102184] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080854, R01CA102184] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abida WM, 2007, J BIOL CHEM, V282, P1797, DOI 10.1074/jbc.M609001200; Agami R, 1999, NATURE, V399, P809; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Bergamaschi D, 2004, MOL CELL BIOL, V24, P1341, DOI 10.1128/MCB.24.3.1341-1350.2004; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; Bergamaschi D, 2003, NAT GENET, V33, P162, DOI 10.1038/ng1070; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Budhram-Mahadeo VS, 2006, NUCLEIC ACIDS RES, V34, P6640, DOI 10.1093/nar/gkl878; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Cam H, 2006, CANCER CELL, V10, P281, DOI 10.1016/j.ccr.2006.08.024; Chao C, 2006, MOL CELL BIOL, V26, P6859, DOI 10.1128/MCB.00062-06; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chen XB, 2001, ONCOGENE, V20, P769, DOI 10.1038/sj.onc.1204149; Chipuk JE, 2005, SCIENCE, V309, P1732, DOI 10.1126/science.1114297; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Concin N, 2004, CANCER RES, V64, P2449, DOI 10.1158/0008-5472.CAN-03-1060; Corn PG, 1999, CANCER RES, V59, P3352; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; Das S, 2007, CELL, V130, P624, DOI 10.1016/j.cell.2007.06.013; DeYoung MP, 2007, ONCOGENE, V26, P5169, DOI 10.1038/sj.onc.1210337; DeYoung MP, 2006, CANCER RES, V66, P9362, DOI 10.1158/0008-5472.CAN-06-1619; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Di Stefano V, 2005, ONCOGENE, V24, P5431, DOI 10.1038/sj.onc.1208717; Dietz S, 2002, FEBS LETT, V525, P93, DOI 10.1016/S0014-5793(02)03093-4; Ding HF, 2000, J BIOL CHEM, V275, P38905, DOI 10.1074/jbc.M004714200; Ding HF, 1998, J BIOL CHEM, V273, P28378, DOI 10.1074/jbc.273.43.28378; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; Dominguez G, 2006, J CLIN ONCOL, V24, P805, DOI 10.1200/JCO.2005.02.2350; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Erster S, 2004, MOL CELL BIOL, V24, P6728, DOI 10.1128/MCB.24.15.6728-6741.2004; Feng LJ, 2006, CELL CYCLE, V5, P2812, DOI 10.4161/cc.5.23.3526; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Gan L, 1996, P NATL ACAD SCI USA, V93, P3920, DOI 10.1073/pnas.93.9.3920; Gao CF, 1999, JPN J CANCER RES, V90, P180, DOI 10.1111/j.1349-7006.1999.tb00731.x; Gong JG, 1999, NATURE, V399, P806; Gressner O, 2005, EMBO J, V24, P2458, DOI 10.1038/sj.emboj.7600708; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Han MK, 2008, CELL STEM CELL, V2, P241, DOI 10.1016/j.stem.2008.01.002; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Haupt Ygal, 1997, Leukemia (Basingstoke), V11, P337; Helton ES, 2008, ONCOGENE, V27, P2843, DOI 10.1038/sj.onc.1210948; Hudson CD, 2005, J BIOL CHEM, V280, P11851, DOI 10.1074/jbc.M408679200; Ihrie RA, 2005, CELL, V120, P843, DOI 10.1016/j.cell.2005.01.008; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Johnson TM, 2008, P NATL ACAD SCI USA, V105, P1215, DOI 10.1073/pnas.0706764105; Johnson TM, 2005, NAT GENET, V37, P145, DOI 10.1038/ng1498; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kartasheva NN, 2002, ONCOGENE, V21, P4715, DOI 10.1038/sj.onc.1205584; Katoh I, 2000, ONCOGENE, V19, P3126, DOI 10.1038/sj.onc.1203644; Kawano S, 1999, BLOOD, V94, P1113; Keyes WM, 2006, P NATL ACAD SCI USA, V103, P8435, DOI 10.1073/pnas.0602477103; KEYES WM, 2008, GENE DEV, V19, P1986; Knights CD, 2006, J CELL BIOL, V173, P533, DOI 10.1083/jcb.200512059; Koga F, 2003, CLIN CANCER RES, V9, P5501; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Le Cam L, 2006, CELL, V127, P775, DOI 10.1016/j.cell.2006.09.031; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levy D, 2007, CELL DEATH DIFFER, V14, P743, DOI 10.1038/sj.cdd.4402063; Levy D, 2008, MOL CELL, V29, P350, DOI 10.1016/j.molcel.2007.12.022; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Liu L, 1999, MOL CELL BIOL, V19, P1202; Luo JL, 2001, ONCOGENE, V20, P320, DOI 10.1038/sj.onc.1204080; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; Mantovani F, 2004, MOL CELL, V14, P625, DOI 10.1016/j.molcel.2004.05.007; Mantovani F, 2007, NAT STRUCT MOL BIOL, V14, P912, DOI 10.1038/nsmb1306; Marchenko ND, 2007, EMBO J, V26, P923, DOI 10.1038/sj.emboj.7601560; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Martins CP, 2006, CELL, V127, P1323, DOI 10.1016/j.cell.2006.12.007; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Melino G, 2004, J BIOL CHEM, V279, P8076, DOI 10.1074/jbc.M307469200; Melino G, 2003, TRENDS BIOCHEM SCI, V28, P663, DOI 10.1016/j.tibs.2003.10.004; Michalak EM, 2008, CELL DEATH DIFFER, V15, P1019, DOI 10.1038/cdd.2008.16; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Muller M, 2006, DRUG RESIST UPDATE, V9, P288, DOI 10.1016/j.drup.2007.01.001; Muller M, 2005, CELL DEATH DIFFER, V12, P1564, DOI 10.1038/sj.cdd.4401774; Murray-Zmijewski F, 2006, CELL DEATH DIFFER, V13, P962, DOI 10.1038/sj.cdd.4401914; Nemajerova A, 2005, FEBS LETT, V579, P6079, DOI 10.1016/j.febslet.2005.09.074; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Okada Y, 2002, EXP CELL RES, V276, P194, DOI 10.1006/excr.2002.5535; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Olsson A, 2007, CELL DEATH DIFFER, V14, P1561, DOI 10.1038/sj.cdd.4402196; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Palacios G, 2006, ONCOGENE, V25, P6133, DOI 10.1038/sj.onc.1209641; Park BJ, 2000, CANCER RES, V60, P3370; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Petitjean A, 2008, CARCINOGENESIS, V29, P273, DOI 10.1093/carcin/bgm258; Petros AM, 2004, FEBS LETT, V559, P171, DOI 10.1016/s0014-5793(04)00059-6; Pietsch EC, 2008, J BIOL CHEM, V283, P21294, DOI 10.1074/jbc.M710539200; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Rinaldo C, 2007, MOL CELL, V25, P739, DOI 10.1016/j.molcel.2007.02.008; Rocco JW, 2006, CANCER CELL, V9, P45, DOI 10.1016/j.ccr.2005.12.013; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Sanchez-Prieto R, 2002, ONCOGENE, V21, P974, DOI 10.1038/sj.onc.1205134; Sansome C, 2001, FEBS LETT, V488, P110, DOI 10.1016/S0014-5793(00)02368-1; Sayan AE, 2008, ONCOGENE, V27, P4363, DOI 10.1038/onc.2008.64; Sayan BS, 2007, P NATL ACAD SCI USA, V104, P10871, DOI 10.1073/pnas.0700761104; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Senoo M, 2004, CANCER CELL, V6, P85, DOI 10.1016/j.ccr.2004.06.005; Shaw PE, 2007, EMBO REP, V8, P40, DOI 10.1038/sj.embor.7400873; Sniezek JC, 2004, LARYNGOSCOPE, V114, P2063, DOI 10.1097/01.mlg.0000149437.35855.4b; Sot B, 2007, J BIOL CHEM, V282, P29193, DOI 10.1074/jbc.M705544200; Stiewe T, 2002, J BIOL CHEM, V277, P14177, DOI 10.1074/jbc.M200480200; Strano S, 2005, MOL CELL, V18, P447, DOI 10.1016/j.molcel.2005.04.008; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; Strano S, 2002, J BIOL CHEM, V277, P18817, DOI 10.1074/jbc.M201405200; Strom E, 2006, NAT CHEM BIOL, V2, P474, DOI 10.1038/nchembio809; Sykes SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026; Taira N, 2007, MOL CELL, V25, P725, DOI 10.1016/j.molcel.2007.02.007; Talos F, 2005, CANCER RES, V65, P9971, DOI 10.1158/0008-5472.CAN-05-1084; Tang Y, 2006, MOL CELL, V24, P827, DOI 10.1016/j.molcel.2006.11.021; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Tomita Y, 2006, J BIOL CHEM, V281, P8600, DOI 10.1074/jbc.M507611200; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; Urist MJ, 2002, AM J PATHOL, V161, P1199, DOI 10.1016/S0002-9440(10)64396-9; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wager M, 2006, BRIT J CANCER, V95, P1062, DOI 10.1038/sj.bjc.6603410; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wang JL, 2007, J BIOL CHEM, V282, P29152, DOI 10.1074/jbc.M703408200; Weber A, 2002, INT J CANCER, V99, P22, DOI 10.1002/ijc.10296; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei XL, 2005, CANCER CELL, V7, P167, DOI 10.1016/j.ccr.2005.01.008; Welchman RL, 2005, NAT REV MOL CELL BIO, V6, P599, DOI 10.1038/nrm1700; Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003; Wu GJ, 2003, CANCER RES, V63, P2351; Xiang MQ, 1996, P NATL ACAD SCI USA, V93, P11950, DOI 10.1073/pnas.93.21.11950; Yan Y, 1997, J BIOL CHEM, V272, P15220, DOI 10.1074/jbc.272.24.15220; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika A, 2001, J BIOL CHEM, V276, P11310, DOI 10.1074/jbc.M005737200; Zeng XY, 2000, MOL CELL BIOL, V20, P1299, DOI 10.1128/MCB.20.4.1299-1310.2000; Zeng XY, 2001, CARCINOGENESIS, V22, P215, DOI 10.1093/carcin/22.2.215; Zheng HW, 2002, NATURE, V419, P849, DOI 10.1038/nature01116	156	225	243	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2008	27	50					6507	6521		10.1038/onc.2008.315	http://dx.doi.org/10.1038/onc.2008.315			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	366RR	18955976	Green Accepted			2022-12-17	WOS:000260501600009
J	Dong, LF; Low, P; Dyason, JC; Wang, XF; Prochazka, L; Witting, PK; Freeman, R; Swettenham, E; Valis, K; Liu, J; Zobalova, R; Turanek, J; Spitz, DR; Domann, FE; Scheffler, IE; Ralph, SJ; Neuzil, J				Dong, L-F; Low, P.; Dyason, J. C.; Wang, X-F; Prochazka, L.; Witting, P. K.; Freeman, R.; Swettenham, E.; Valis, K.; Liu, J.; Zobalova, R.; Turanek, J.; Spitz, D. R.; Domann, F. E.; Scheffler, I. E.; Ralph, S. J.; Neuzil, J.			alpha-tocopheryl succinate induces apoptosis by targeting ubiquinone-binding sites in mitochondrial respiratory complex II	ONCOGENE			English	Article						alpha-tocopheryl succinate; complex II; ubiquinonebinding sites; reactive oxygen species; apoptosis; anti-cancer drug target	VITAMIN-E SUCCINATE; BREAST-CANCER CELLS; ELECTRON-TRANSPORT; E ANALOGS; 3-NITROPROPIONIC ACID; OXIDATIVE STRESS; LIVER-CANCER; OXYGEN; DEHYDROGENASE; ANTIOXIDANT	alpha-Tocopheryl succinate (alpha-TOS)is a selective inducer of apoptosis in cancer cells, which involves the accumulation of reactive oxygen species (ROS). The molecular target of alpha-TOS has not been identified. Here, we show that alpha-TOS inhibits succinate dehydrogenase (SDH) activity of complex II (CII) by interacting with the proximal and distal ubiquinone (UbQ)-binding site (Q(P) and Q(D), respectively). This is based on biochemical analyses and molecular modelling, revealing similar or stronger interaction energy of a- TOS compared to that of UbQ for the QP and QD sites, respectively. CybL-mutant cells with dysfunctional CII failed to accumulate ROS and underwent apoptosis in the presence of alpha-TOS. Similar resistance was observed when CybL was knocked down with siRNA. Reconstitution of functional CII rendered CybL-mutant cells susceptible to alpha-TOS. We propose that alpha-TOS displaces UbQ in CII causing electrons generated by SDH to recombine with molecular oxygen to yield ROS. Our data highlight CII, a known tumour suppressor, as a novel target for cancer therapy.	[Low, P.; Ralph, S. J.] Griffith Univ, Sch Med Sci, Genom Res Ctr, Southport, Qld 4215, Australia; [Dong, L-F; Wang, X-F; Freeman, R.; Swettenham, E.; Liu, J.; Zobalova, R.; Neuzil, J.] Griffith Univ, Sch Med Sci, Apoptosis Res Grp, Southport, Qld 4215, Australia; [Dyason, J. C.] Griffith Univ, Inst Glycom, Southport, Qld 4215, Australia; [Prochazka, L.; Turanek, J.] Vet Res Inst, Dept Immunol, CS-62132 Brno, Czech Republic; [Witting, P. K.] Concord Hosp, Med Res Inst, ANZAC, Sydney, NSW, Australia; [Valis, K.; Zobalova, R.; Neuzil, J.] Acad Sci Czech Republ, Inst Biotechnol, Mol Therapy Grp, Prague, Czech Republic; [Spitz, D. R.; Domann, F. E.] Univ Iowa, Dept Radiat Oncol, Free Rad & Radiat Biol Program, Iowa City, IA USA; [Scheffler, I. E.] Univ Calif San Diego, Div Biol, San Diego, CA 92103 USA	Griffith University; Griffith University; Griffith University; Czech Veterinary Research Institute; Concord Repatriation General Hospital; Czech Academy of Sciences; Institute of Biotechnology of the Czech Academy of Sciences; University of Iowa; University of California System; University of California San Diego	Ralph, SJ (corresponding author), Griffith Univ, Sch Med Sci, Genom Res Ctr, Southport, Qld 4215, Australia.	s.ralph@grif.th.edu.au; j.neuzil@grif.th.edu.au	Vališ, Karel/D-6463-2017; Prochazka, Lubomir/J-5284-2014; Dyason, Jeffrey C/L-5534-2014; DONG, LANFENG/S-8805-2019; Zobalova, Renata/H-7242-2014; Ralph, Stephen J./AAE-4888-2019; Witting, Paul/ABD-2053-2020; Witting, Paul/L-9786-2019; Neuzil, Jiri/H-7204-2014	Vališ, Karel/0000-0002-3036-4345; Ralph, Stephen J./0000-0002-4335-092X; Witting, Paul/0000-0003-2237-7004; Neuzil, Jiri/0000-0002-2478-2460; Dong, Lanfeng/0000-0002-9857-6352; Zobalova, Renata/0000-0002-9097-4700; Spitz, Douglas/0000-0002-1254-8765; Domann, Frederick/0000-0002-0489-2179	NATIONAL CANCER INSTITUTE [R01CA100045, R01CA073612] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA100045-04, R01-CA73612, R01 CA073612-08, R01 CA073612, R01-CA100045, R01 CA100045-05, R01 CA073612-07, R01 CA100045-03, R01 CA100045] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*ACC INC, 2001, INS, V2; Adam-Vizi V, 2006, TRENDS PHARMACOL SCI, V27, P639, DOI 10.1016/j.tips.2006.10.005; Albayrak T, 2003, MOL BIOL CELL, V14, P3082, DOI 10.1091/mbc.e02-10-0631; Allen FH, 2002, ACTA CRYSTALLOGR B, V58, P380, DOI 10.1107/S0108768102003890; Allen RG, 2003, EXP CELL RES, V289, P307, DOI 10.1016/S0014-4827(03)00279-9; Alleva R, 2001, FEBS LETT, V503, P46, DOI 10.1016/S0014-5793(01)02694-1; BERRIDGE MV, 1993, ARCH BIOCHEM BIOPHYS, V303, P474, DOI 10.1006/abbi.1993.1311; Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020; BURNELL JN, 1975, BIOCHEM J, V150, P527, DOI 10.1042/bj1500527; Case D.A., 2002, AMBER, V7; Cheng VWT, 2006, J BIOL CHEM, V281, P27662, DOI 10.1074/jbc.M604900200; CHOUDHRY ZM, 1985, FEBS LETT, V182, P171, DOI 10.1016/0014-5793(85)81177-7; CHOUDHRY ZM, 1986, BIOCHIM BIOPHYS ACTA, V850, P131, DOI 10.1016/0005-2728(86)90017-4; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; Degterev A, 2001, NAT CELL BIOL, V3, P173, DOI 10.1038/35055085; Dias N, 2005, BIOCHEM PHARMACOL, V70, P1, DOI 10.1016/j.bcp.2005.03.021; Don AS, 2004, TRENDS MOL MED, V10, P372, DOI 10.1016/j.molmed.2004.06.005; Dong LF, 2007, CANCER RES, V67, P11906, DOI 10.1158/0008-5472.CAN-07-3034; Fariss MW, 2001, FREE RADICAL BIO MED, V31, P530, DOI 10.1016/S0891-5849(01)00615-3; Geschwind JFH, 2002, CANCER RES, V62, P3909; Gottlieb E, 2005, NAT REV CANCER, V5, P857, DOI 10.1038/nrc1737; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hail N, 2005, APOPTOSIS, V10, P687, DOI 10.1007/s10495-005-0792-8; Hartshorn MJ, 2002, J COMPUT AID MOL DES, V16, P871, DOI 10.1023/A:1023813504011; Huang LS, 2006, J BIOL CHEM, V281, P5965, DOI 10.1074/jbc.M511270200; Ishii N, 1998, NATURE, V394, P694, DOI 10.1038/29331; Ishii T, 2005, CANCER RES, V65, P203; James AM, 2005, J BIOL CHEM, V280, P21295, DOI 10.1074/jbc.M501527200; James AM, 2007, J BIOL CHEM, V282, P14708, DOI 10.1074/jbc.M611463200; Kang YH, 2004, INT J CANCER, V112, P385, DOI 10.1002/ijc.20424; Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200; Ko YH, 2004, BIOCHEM BIOPH RES CO, V324, P269, DOI 10.1016/j.bbrc.2004.09.047; Ko YH, 2001, CANCER LETT, V173, P83, DOI 10.1016/S0304-3835(01)00667-X; Kogure K, 2002, CANCER LETT, V186, P151, DOI 10.1016/S0304-3835(02)00344-0; Lahouel M, 2007, BIOCHEM BIOPH RES CO, V355, P252, DOI 10.1016/j.bbrc.2007.01.145; Le SB, 2007, J BIOL CHEM, V282, P8860, DOI 10.1074/jbc.M611777200; MAEHARA Y, 1988, ONCOLOGY-BASEL, V45, P434, DOI 10.1159/000226660; McLennan HR, 2000, J BIOENERG BIOMEMBR, V32, P153, DOI 10.1023/A:1005507913372; Milanesi E, 2006, J BIOL CHEM, V281, P10066, DOI 10.1074/jbc.M513708200; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Neuzil J, 2005, BIOCHEM BIOPH RES CO, V327, P1024, DOI 10.1016/j.bbrc.2004.12.115; Neuzil J, 2001, FASEB J, V15, P403, DOI 10.1096/fj.00-0251com; Neuzil J, 2001, BRIT J CANCER, V84, P87, DOI 10.1054/bjoc.2000.1559; Neuzil J, 2007, J BIOENERG BIOMEMBR, V39, P65, DOI 10.1007/s10863-006-9060-z; Neuzil J, 2007, MOL PHARMACOL, V71, P1185, DOI 10.1124/mol.106.030122; Neuzil J, 2006, FEBS LETT, V580, P5125, DOI 10.1016/j.febslet.2006.05.072; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Niemann S, 2000, NAT GENET, V26, P268, DOI 10.1038/81551; OOSTVEEN FG, 1995, J BIOL CHEM, V270, P26104, DOI 10.1074/jbc.270.44.26104; Rice J.E., 1997, SUBCELLULAR FRACTION, V1st, P107; Robinson BWS, 2005, LANCET, V366, P397, DOI 10.1016/S0140-6736(05)67025-0; SAFFORD SE, 1994, CANCER RES, V54, P4261; SANBORN BM, 1971, BIOCHIM BIOPHYS ACTA, V227, P219, DOI 10.1016/0005-2744(71)90055-6; Sanner MF, 1999, J MOL GRAPH MODEL, V17, P57; Scallet AC, 2003, ANN NY ACAD SCI, V993, P305, DOI 10.1111/j.1749-6632.2003.tb07538.x; Seo BB, 1998, P NATL ACAD SCI USA, V95, P9167, DOI 10.1073/pnas.95.16.9167; Sever N, 2004, J BIOL CHEM, V279, P43136, DOI 10.1074/jbc.M406406200; Shiau CW, 2006, J BIOL CHEM, V281, P11819, DOI 10.1074/jbc.M511015200; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slane BG, 2006, CANCER RES, V66, P7615, DOI 10.1158/0008-5472.CAN-06-0833; Soller M, 2007, MOL PHARMACOL, V71, P1535, DOI 10.1124/mol.107.034371; SPENCER TL, 1976, BIOCHEM J, V160, P121, DOI 10.1042/bj1600121; Stapelberg M, 2005, J BIOL CHEM, V280, P25369, DOI 10.1074/jbc.M414498200; Sun F, 2005, CELL, V121, P1043, DOI 10.1016/j.cell.2005.05.025; Swettenham E, 2005, J NEUROCHEM, V94, P1448, DOI 10.1111/j.1471-4159.2005.03298.x; Trachootham D, 2006, CANCER CELL, V10, P241, DOI 10.1016/j.ccr.2006.08.009; Tran QM, 2006, J BIOL CHEM, V281, P32310, DOI 10.1074/jbc.M607476200; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wang XF, 2005, BIOCHEM BIOPH RES CO, V326, P282, DOI 10.1016/j.bbrc.2004.11.028; Wang XF, 2007, CANCER RES, V67, P3337, DOI 10.1158/0008-5472.CAN-06-2480; Weber T, 2003, BIOCHEMISTRY-US, V42, P4277, DOI 10.1021/bi020527j; Weber T, 2002, CLIN CANCER RES, V8, P863; Word JM, 1999, J MOL BIOL, V285, P1735, DOI 10.1006/jmbi.1998.2401; Xu RH, 2005, CANCER RES, V65, P613; Yankovskaya V, 2003, SCIENCE, V299, P700, DOI 10.1126/science.1079605; YU L, 1983, BIOCHIM BIOPHYS ACTA, V723, P139, DOI 10.1016/0005-2728(83)90113-5; Zhang JG, 2001, ARCH BIOCHEM BIOPHYS, V393, P87, DOI 10.1006/abbi.2001.2486; Zhao ZW, 2006, BIOCHEM CELL BIOL, V84, P1013, DOI 10.1139/O06-188	79	225	235	1	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2008	27	31					4324	4335		10.1038/onc.2008.69	http://dx.doi.org/10.1038/onc.2008.69			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	326WY	18372923	Green Accepted, Green Published			2022-12-17	WOS:000257691100007
J	Ying, J; Li, H; Seng, TJ; Langford, C; Srivastava, G; Tsao, SW; Putti, T; Murray, P; Chan, ATC; Tao, Q				Ying, J; Li, H; Seng, TJ; Langford, C; Srivastava, G; Tsao, SW; Putti, T; Murray, P; Chan, ATC; Tao, Q			Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation	ONCOGENE			English	Article						Protocadherin; tumor suppressor gene; methylation; epigenetic; promoter; carcinoma	REPRESENTATIONAL DIFFERENCE ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; E-CADHERIN; ABERRANT METHYLATION; ADHESION MOLECULE; GASTRIC-CANCER; CELL-ADHESION; CO-REPRESSOR; HUMAN BREAST; H-CADHERIN	Protocadherins constitute the largest subgroup in the cadherin superfamily of cell adhesion molecules. Their major functions are poorly understood, although some are implicated in nervous system development. As tumorspecific promoter methylation is a marker for tumor suppressor genes (TSG), we searched for epigenetically inactivated TSGs using methylation-subtraction combined with pharmacologic demethylation, and identified the PCDH10 CpG island as a methylated sequence in nasopharyngeal carcinoma (NPC). PCDH10 is broadly expressed in all normal adult and fetal tissues including the epithelia, though at different levels. It resides at 4q28.3-a region with hemizygous deletion detected by array-CGH in NPC cell lines; however, PCDH10 itself is not located within the deletion. In contrast, its transcriptional silencing and promoter methylation were frequently detected in multiple carcinoma cell lines in a biallelic way, including 12/12 nasopharyngeal, 13/16 esophageal, 3/4 breast, 5/5 colorectal, 3/4 cervical, 2/5 lung and 2/8 hepatocellular carcinoma cell lines, but not in any immortalized normal epithelial cell line. Aberrant methylation was further frequently detected in multiple primary carcinomas (82% in NPC, 42-51% for other carcinomas), but not normal tissues. The transcriptional silencing of PCDH10 could be reversed by pharmacologic demethylation with 5-aza-2'-deoxycytidine or genetic demethylation with double knockout of DNMT1 and DNMT3B, indicating a direct epigenetic mechanism. Ectopic expression of PCDH10 strongly suppressed tumor cell growth, migration, invasion and colony formation. Although the epigenetic and genetic disruptions of several classical cadherins as TSGs have been well documented in tumors, this is the first report that a widely expressed protocadherin can also function as a TSG that is frequently inactivated epigenetically in multiple carcinomas.	Chinese Univ Hong Kong, Dept Clin Oncol, Canc Epigenet Lab, YK Pao Canc Ctr, Shatin, Hong Kong, Peoples R China; Wellcome Trust Sanger Inst, Microarray Facil, Cambridge, England; Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Anat, Hong Kong, Hong Kong, Peoples R China; Natl Univ Singapore Hosp, Dept Pathol, Singapore 117548, Singapore; Univ Birmingham, Canc Res UK Inst Canc Studies, Birmingham, W Midlands, England	Chinese University of Hong Kong; Wellcome Trust Sanger Institute; University of Hong Kong; University of Hong Kong; National University of Singapore; Cancer Research UK; University of Birmingham	Tao, Q (corresponding author), Chinese Univ Hong Kong, Dept Clin Oncol, Canc Epigenet Lab, YK Pao Canc Ctr, Shatin, Hong Kong, Peoples R China.	qtao@clo.cuhk.edu.hk	Chan, Anthony Tak Cheung/R-3940-2018; Tsao, George/C-4422-2009; Tao, Qian/T-4743-2018	Chan, Anthony Tak Cheung/0000-0002-6912-8091; Tao, Qian/0000-0001-5383-4808				Angst BD, 2001, J CELL SCI, V114, P629; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; Bolz H, 2001, NAT GENET, V27, P108, DOI 10.1038/83667; Chan ATC, 2004, J CLIN ONCOL, V22, P1373, DOI 10.1200/JCO.2004.04.185; DI PF, 2001, NAT GENET, V27, P103; DUNNE J, 1995, GENOMICS, V30, P207, DOI 10.1006/geno.1995.9884; Fanto M, 2003, DEVELOPMENT, V130, P763, DOI 10.1242/dev.00304; Fiegler H, 2003, GENE CHROMOSOME CANC, V36, P361, DOI 10.1002/gcc.10155; Frank M, 2002, CURR OPIN CELL BIOL, V14, P557, DOI 10.1016/S0955-0674(02)00365-4; GRAFF JR, 1995, CANCER RES, V55, P5195; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; GUMBINER BM, 1995, CURR OPIN CELL BIOL, V7, P615, DOI 10.1016/0955-0674(95)80101-4; Hirano S, 1999, J NEUROSCI, V19, P995; Hukku B, 1997, CANCER GENET CYTOGEN, V93, P125, DOI 10.1016/S0165-4608(96)00210-5; Hurst CD, 2004, ONCOGENE, V23, P2250, DOI 10.1038/sj.onc.1207260; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kaneda A, 2003, ANN NY ACAD SCI, V983, P131, DOI 10.1111/j.1749-6632.2003.tb05968.x; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; Lee SW, 1996, NAT MED, V2, P776, DOI 10.1038/nm0796-776; MAHONEY PA, 1991, CELL, V67, P853, DOI 10.1016/0092-8674(91)90359-7; Matthews JM, 2000, EUR J BIOCHEM, V267, P1030, DOI 10.1046/j.1432-1327.2000.01095.x; Miotto E, 2004, CANCER RES, V64, P8156, DOI 10.1158/0008-5472.CAN-04-3000; Nakao S, 2005, MOL BRAIN RES, V134, P294, DOI 10.1016/j.molbrainres.2004.11.017; Okazaki N, 2002, CARCINOGENESIS, V23, P1139, DOI 10.1093/carcin/23.7.1139; Paz MF, 2003, HUM MOL GENET, V12, P2209, DOI 10.1093/hmg/ddg226; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Qiu GH, 2004, ONCOGENE, V23, P4793, DOI 10.1038/sj.onc.1207632; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; Siemens J, 2004, NATURE, V428, P950, DOI 10.1038/nature02483; Siemens J, 2002, P NATL ACAD SCI USA, V99, P14946, DOI 10.1073/pnas.232579599; Sollner C, 2004, NATURE, V428, P955, DOI 10.1038/nature02484; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Suzuki ST, 2000, EXP CELL RES, V261, P13, DOI 10.1006/excr.2000.5039; Szyf M, 2004, CANCER LETT, V211, P133, DOI 10.1016/j.canlet.2004.04.009; Tao Q, 1999, AM J PATHOL, V155, P619, DOI 10.1016/S0002-9440(10)65157-7; Tao Q, 1998, J VIROL, V72, P7075, DOI 10.1128/JVI.72.9.7075-7083.1998; Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091; Toyooka KO, 2001, CANCER RES, V61, P4556; Tsao SW, 2002, BBA-MOL CELL RES, V1590, P150, DOI 10.1016/S0167-4889(02)00208-2; Ushijima T, 1997, P NATL ACAD SCI USA, V94, P2284, DOI 10.1073/pnas.94.6.2284; Waha A, 2005, NEOPLASIA, V7, P193, DOI 10.1593/neo.04490; Wolverton T, 2001, GENOMICS, V76, P66, DOI 10.1006/geno.2001.6592; Wu Q, 2000, P NATL ACAD SCI USA, V97, P3124, DOI 10.1073/pnas.060027397; Yagi T, 2000, GENE DEV, V14, P1169; YING J, 2005, IN PRESS CLIN CANC R; Ying JM, 2004, BLOOD, V103, P743, DOI 10.1182/blood-2003-09-3193; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416; Yu L, 2005, NAT GENET, V37, P265, DOI 10.1038/ng1521	52	225	245	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	7					1070	1080		10.1038/sj.onc.1209154	http://dx.doi.org/10.1038/sj.onc.1209154			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	012SX	16247458				2022-12-17	WOS:000235361000011
J	Xia, WL; Gerard, CM; Liu, LH; Baudson, NM; Ory, TL; Spector, NL				Xia, WL; Gerard, CM; Liu, LH; Baudson, NM; Ory, TL; Spector, NL			Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells	ONCOGENE			English	Article						survivin; vaccine; tyrosine kinase; ErbB2; antibodies; breast cancer	MONOCLONAL-ANTIBODY; ANTITUMOR-ACTIVITY; SINGLE-AGENT; IN-VIVO; RECEPTOR; PROTEIN; GROWTH; HER-2/NEU; SURVIVIN; CHEMOTHERAPY	Antibodies and small molecule tyrosine kinase inhibitors targeting ErbB2 exhibit distinct, noncross resistant mechanisms of action. Here, apoptosis of ErbB2-over-expressing breast cancer cells was enhanced by combining lapatinib, an inhibitor of ErbB1 and ErbB2 tyrosine kinases, with anti-ErbB2 antibodies, including (i) trastuzumab, a humanized monoclonal antibody, and(ii) pAb, rabbit polyclonal antisera generated by vaccination with a human ErbB2 fusion protein. Treating ErbB2-over-expressing breast cancer cell lines with a relatively low concentration of lapatinib alone resulted in a minimal increase in tumor cell apoptosis with an associated decrease in steady-state protein levels of p-ErbB2, p-Akt, p-Erk1/2, and notably survivin, compared to baseline. Exposure to pAb alone reduced total ErbB2 protein, disrupting ErbB3 transactivation, leading to a marked inhibition of p-Akt; however, survivin protein levels remained unchanged and apoptosis only increased slightly. Treatment with trastuzumab alone had relatively little effect on survivin and apoptosis was unaffected. Combining lapatinib with either pAb or trastuzumab markedly downregulated survivin protein and enhanced tumor cell apoptosis. The association between the inhibition of survivin and enhanced apoptosis following the combination of ErbB2-targeted therapies provides a biological effect in order to identify therapeutic strategies that promote tumor cell apoptosis and might improve clinical response.	GlaxoSmithKline Inc, Dept Discovery Med, Res Triangle Pk, NC 27709 USA; GlasoSmithKline Biol, Canc Vaccine Program, Rixensart, Belgium	GlaxoSmithKline	Spector, NL (corresponding author), GlaxoSmithKline Inc, Dept Discovery Med, 5 Moore Dr,POB 13398, Res Triangle Pk, NC 27709 USA.	Neil.L.Spector@gsk.com						Agus DB, 2002, CANCER CELL, V2, P127, DOI 10.1016/S1535-6108(02)00097-1; ALIMANDI M, 1995, ONCOGENE, V10, P1813; Arteaga CL, 2003, EXP CELL RES, V284, P122, DOI 10.1016/S0014-4827(02)00104-0; ARTEAGA CL, 2004, BREAST CANC RES TR S, V88, pA25; BACUS SS, 1994, AM J CLIN PATHOL S1, V102, P13; Baselga J, 1998, CANCER RES, V58, P2825; Brognard J, 2001, CANCER RES, V61, P3986; BURRIS HA, 2004, BREAST CANC RES T S1, V88, pA3043; Carter BZ, 2001, BLOOD, V97, P2784, DOI 10.1182/blood.V97.9.2784; Chen XF, 2001, ONCOGENE, V20, P6073, DOI 10.1038/sj.onc.1204736; Christianson TA, 1998, CANCER RES, V58, P5123; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Cockerill S, 2001, BIOORG MED CHEM LETT, V11, P1401, DOI 10.1016/S0960-894X(01)00219-0; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; Fry DW, 2003, EXP CELL RES, V284, P131, DOI 10.1016/S0014-4827(02)00095-2; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HERBST RS, 2004, J CLIN ONCOL, V22, P759; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Huang SM, 2004, CANCER RES, V64, P5355, DOI 10.1158/0008-5472.CAN-04-0562; JOHNSON DH, 2002, ANN ONCOL, V13, P127; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; MAIER LA, 1991, CANCER RES, V51, P5361; Marusawa H, 2003, EMBO J, V22, P2729, DOI 10.1093/emboj/cdg263; Matar P, 2004, CLIN CANCER RES, V10, P6487, DOI 10.1158/1078-0432.CCR-04-0870; Molina MA, 2002, CLIN CANCER RES, V8, P347; Molina MA, 2001, CANCER RES, V61, P4744; Moulder SL, 2001, CANCER RES, V61, P8887; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; Park J W, 1992, Cancer Treat Res, V61, P193; Pegram M, 1999, ONCOGENE, V18, P2241, DOI 10.1038/sj.onc.1202526; PIETRAS RJ, 1994, ONCOGENE, V9, P1829; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; RODRIGUEZ GC, 1993, AM J OBSTET GYNECOL, V168, P228, DOI 10.1016/S0002-9378(12)90918-7; Rusnak DW, 2001, CANCER RES, V61, P7196; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1999, SEMIN ONCOL S12, V26, P14661; Song ZY, 2003, J BIOL CHEM, V278, P23130, DOI 10.1074/jbc.M300957200; Tamm I, 1998, CANCER RES, V58, P5315; Tenzer A, 2001, CANCER RES, V61, P8203; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; Wood ER, 2004, CANCER RES, V64, P6652, DOI 10.1158/0008-5472.CAN-04-1168; Xia WL, 2004, ONCOGENE, V23, P646, DOI 10.1038/sj.onc.1207166; Xia WL, 2002, ONCOGENE, V21, P6255, DOI 10.1038/sj.onc.1205794; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	51	225	238	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2005	24	41					6213	6221		10.1038/sj.onc.1208774	http://dx.doi.org/10.1038/sj.onc.1208774			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964JM	16091755				2022-12-17	WOS:000231877100002
J	Lasorella, A; Uo, T; Iavarone, A				Lasorella, A; Uo, T; Iavarone, A			Id proteins at the cross-road of development and cancer	ONCOGENE			English	Article						cell differentiation; cell cycle; retinoblastoma protein; Id2; neuroblastoma; angiogenesis	LOOP-HELIX PROTEIN; RETINOBLASTOMA PROTEIN; CELL-CYCLE; TRANSCRIPTION FACTORS; NEGATIVE REGULATOR; PANCREATIC-CANCER; HUMAN FIBROBLASTS; INHIBITOR ID2; EXPRESSION; DIFFERENTIATION	A large body of evidence has been, accumulated that demonstrates dominant effects of Id proteins on different aspects of cellular growth. Generally, constitutive expression of Id not only blocks cell differentiation but also drives proliferation. In some settings, it is sufficient to render cells immortal or induce oncogenic transformation. The participation of Id proteins in advanced human malignancy, where they are frequently deregulated, has been dramatically bolstered by the recent discovery that Id exert pivotal contributions to many of the essential alterations that collectively dictate malignant growth. Relentless proliferation associated with self-sufficiency in growth signals and insensitivity to growth inhibitory signals, sustained neoangiogenesis, tissue invasiveness and migration capabilities of tumor cells all share dependency on the unlimited availability of Id proteins. It is remarkable that many of these features recapitulate those physiologically propelled by Id proteins to support normal development. We propose that the participation of Id in multiple fundamental traits of cancer may be the basis for unprecedented therapeutic opportunities.	Yeshiva Univ Albert Einstein Coll Med, Dept Neurol, Dev & Mol Biol & Comprehens Canc Ctr, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Iavarone, A (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Neurol, Dev & Mol Biol & Comprehens Canc Ctr, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NCI NIH HHS [R01-CA85628] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085628] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Bain G, 2001, NAT IMMUNOL, V2, P165, DOI 10.1038/84273; BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; Beger C, 2001, P NATL ACAD SCI USA, V98, P130, DOI 10.1073/pnas.98.1.130; Belletti B, 2001, J BIOL CHEM, V276, P13867, DOI 10.1074/jbc.M010509200; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Chen HP, 1999, BIOCHEM BIOPH RES CO, V256, P614, DOI 10.1006/bbrc.1999.0386; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; Cooper CL, 1997, BLOOD, V89, P3155, DOI 10.1182/blood.V89.9.3155; Deed RW, 1997, MOL CELL BIOL, V17, P6815, DOI 10.1128/MCB.17.12.6815; Desprez PY, 1998, MOL CELL BIOL, V18, P4577, DOI 10.1128/MCB.18.8.4577; DESPREZ PY, 1995, MOL CELL BIOL, V15, P3398; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Florio M, 1998, MOL CELL BIOL, V18, P5435, DOI 10.1128/MCB.18.9.5435; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hara E, 1996, MOL CELL BIOL, V16, P859; Hara E, 1997, EMBO J, V16, P332, DOI 10.1093/emboj/16.2.332; HARA E, 1994, J BIOL CHEM, V269, P2139; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Ishiguro A, 1996, BLOOD, V87, P5225, DOI 10.1182/blood.V87.12.5225.bloodjournal87125225; Israel MA, 1999, CANCER RES, V59, p1726S; Jen Y, 1997, DEV DYNAM, V208, P92, DOI 10.1002/(SICI)1097-0177(199701)208:1<92::AID-AJA9>3.0.CO;2-X; Katzenstein Howard M., 1998, Current Opinion in Oncology, V10, P43, DOI 10.1097/00001622-199801000-00008; Kebebew E, 2000, SURGERY, V128, P952, DOI 10.1067/msy.2000.111082; Kee BL, 2001, NAT IMMUNOL, V2, P242, DOI 10.1038/85303; Kim D, 1999, MOL CELL BIOL, V19, P8240; Kleeff J, 1998, CANCER RES, V58, P3769; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Langlands K, 2000, CANCER RES, V60, P5929; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; LASORELLA A, 2002, IN PRESS CANC RES, V62; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; Lin CQ, 2000, CANCER RES, V60, P1332; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; Martinsen BJ, 1998, SCIENCE, V281, P988, DOI 10.1126/science.281.5379.988; Maruyama H, 1999, AM J PATHOL, V155, P815, DOI 10.1016/S0002-9440(10)65180-2; Mori S, 2000, EMBO J, V19, P5772, DOI 10.1093/emboj/19.21.5772; Morrow MA, 1999, MOL IMMUNOL, V36, P491, DOI 10.1016/S0161-5890(99)00071-1; NAGATA Y, 1994, BIOCHEM BIOPH RES CO, V199, P1355, DOI 10.1006/bbrc.1994.1380; NAGATA Y, 1995, BIOCHEM BIOPH RES CO, V207, P916, DOI 10.1006/bbrc.1995.1273; NEUMAN T, 1993, DEV BIOL, V160, P186, DOI 10.1006/dbio.1993.1297; Nickoloff BJ, 2000, J BIOL CHEM, V275, P27501; Norton JD, 2000, J CELL SCI, V113, P3897; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; Norton JD, 1998, MOL CELL BIOL, V18, P2371, DOI 10.1128/MCB.18.4.2371; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Polsky D, 2001, CANCER RES, V61, P6008; Roberts EC, 2001, MOL CELL BIOL, V21, P524, DOI 10.1128/MCB.21.2.524-533.2001; Sablitzky F, 1998, CELL GROWTH DIFFER, V9, P1015; Schindl M, 2001, CANCER RES, V61, P5703; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Slack RS, 1998, J CELL BIOL, V140, P1497, DOI 10.1083/jcb.140.6.1497; Takai N, 2001, CANCER LETT, V165, P185, DOI 10.1016/S0304-3835(01)00433-5; Toma JG, 2000, J NEUROSCI, V20, P7648; Walterhouse D O, 1997, Cancer Treat Res, V92, P3; Wang SL, 2001, NEURON, V29, P603, DOI 10.1016/S0896-6273(01)00237-9; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wice BM, 1998, J BIOL CHEM, V273, P25310, DOI 10.1074/jbc.273.39.25310; Yates PR, 1999, EMBO J, V18, P968, DOI 10.1093/emboj/18.4.968; Yokota Y, 1999, NATURE, V397, P702, DOI 10.1038/17812	67	225	238	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 20	2001	20	58					8326	8333		10.1038/sj.onc.1205093	http://dx.doi.org/10.1038/sj.onc.1205093			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512HT	11840325				2022-12-17	WOS:000173319500006
J	Eliopoulos, AG; Stack, M; Dawson, CW; Kaye, KM; Hodgkin, L; Sihota, S; Rowe, M; Young, LS				Eliopoulos, AG; Stack, M; Dawson, CW; Kaye, KM; Hodgkin, L; Sihota, S; Rowe, M; Young, LS			Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-kappa B pathway involving TNF receptor-associated factors	ONCOGENE			English	Article						LMP1; CD40; TRAF; IL6; NF-kappa B; keratinocytes	LATENT MEMBRANE-PROTEIN; ZINC-FINGER PROTEIN; TRANSFORMING PROTEIN; TRANSCRIPTION FACTOR; ACTIVATION MOLECULE; CYTOPLASMIC DOMAIN; INTERLEUKIN-6 GENE; T-LYMPHOCYTES; UP-REGULATION; IN-VITRO	Expression of the Epstein-Barr virus (EBV) transforming LMP1 in B cells activates the transcription factor NF-kappa B and induces phenotypic changes through two distinct domains in the cytoplasmic C-terminus of the protein, The aa 187-231 domain of LMP1, which is important for growth transformation, binds tumour necrosis factor (TNF) receptor associated factor (TRAF) 1 and TRAF3 and this interaction mediates subsequent signalling events, The TRAFs also associate with CD40, a member of the TNFR family, which upon ligation activates NF-kappa B and induces phenotypic changes similar to those mediated by LMP1. This study demonstrates that LMP1 expression in carcinoma cell lines and SV40-transformed keratinocytes results in induction of the pleiotropic cytokine interleukin 6 (IL6), an effect which is also observed upon CD40 Ligation. The mechanism by which either LMP1 expression or CD40 ligation induces IL6 production was found to be NF-kappa B-dependent. Mutational analysis identified domains in the C-terminus of LMP1 which are important for NF-KB activation and IL6 secretion, LMP1 and CD40 share a common PxQxT core TRAF binding motif and mutations in or adjacent to this sequence impaired the ability of LMP1 or CD40 to induce NF-kappa B activation and IL6 secretion, The importance of TRAF interactions in mediating these effects was confirmed using dominant negative TRAF2 and TRAF3 mutants which also identified differences in the signalling events mediated by the two NF-kappa B activating domains of LMP1. A20, an anti-apoptotic protein which interacts with TRAF2 and blocks CD40-mediated NF-kappa B activity, also blocked NF-kappa B and IL6 secretion in LMP1-transfected epithelial cells, These results suggest that LMP1 regulates IL6 production in epithelial cells in a manner similar to CD40 ligation and implicate TRAFs as common mediators in the transduction of signals generated via the CD40 and LMP1 pathways, As a role for IL6 in regulating epithelial cell growth has previously been suggested, the control of IL6 secretion via the CD4O and LMP1 pathways may have implications for the growth of both normal and transformed epithelial cells.	UNIV BIRMINGHAM,SCH MED,CRC,INST CANC STUDIES,BIRMINGHAM B15 2TJ,W MIDLANDS,ENGLAND; UNIV WALES COLL MED,DEPT MED,CARDIFF CF4 4XN,S GLAM,WALES; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,BOSTON,MA 02115	University of Birmingham; Cardiff University; Harvard University; Brigham & Women's Hospital; Harvard Medical School			ELIOPOULOS, ARISTIDES/ABI-6632-2020; Rowe, Martin/B-2880-2009; ELIOPOULOS, ARISTIDES/R-9449-2018; Young, Lawrence S/B-7213-2009	ELIOPOULOS, ARISTIDES/0000-0002-6403-6761; Rowe, Martin/0000-0003-4139-7326; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761; Young, Lawrence S/0000-0003-3919-4298				AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; ARENZANASEISDEDOS F, 1993, J VIROL, V67, P6596, DOI 10.1128/JVI.67.11.6596-6604.1993; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; BAICHWAL VR, 1988, ONCOGENE, V2, P461; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; CHEN L, 1991, J BIOL REG HOMEOS AG, V5, P125; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; CHOI MSK, 1995, EUR J IMMUNOL, V25, P1352, DOI 10.1002/eji.1830250533; CLARK EA, 1986, P NATL ACAD SCI USA, V83, P4494, DOI 10.1073/pnas.83.12.4494; CLARK EA, 1990, J IMMUNOL, V145, P1400; CLARK EA, 1994, NATURE, V367, P425, DOI 10.1038/367425a0; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Eliopoulos AG, 1996, ONCOGENE, V13, P2243; ELIOPOULOS AG, 1995, ONCOGENE, V11, P1217; Floettmann JE, 1996, VIROLOGY, V223, P29, DOI 10.1006/viro.1996.0452; Franken M, 1996, J VIROL, V70, P7819, DOI 10.1128/JVI.70.11.7819-7826.1996; GAJEWSKI TF, 1995, J IMMUNOL, V154, P5637; GONZALEZ AL, 1995, TRENDS GENET, V11, P216, DOI 10.1016/S0168-9525(00)89051-4; GORDON J, 1995, BLOOD REV, V9, P53, DOI 10.1016/0268-960X(95)90040-3; GROSSMAN RM, 1989, P NATL ACAD SCI USA, V86, P6367, DOI 10.1073/pnas.86.16.6367; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HENDERSON SA, 1994, SEMIN VIROL, V5, P391, DOI 10.1006/smvy.1994.1043; HESS S, 1995, J IMMUNOL, V155, P4588; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HU HM, 1994, J BIOL CHEM, V269, P30069; HUEN DS, 1995, ONCOGENE, V10, P549; HUTCHINS D, 1994, INT J CANCER, V58, P80, DOI 10.1002/ijc.2910580114; INUI S, 1990, EUR J IMMUNOL, V20, P1747, DOI 10.1002/eji.1830200819; Jaattela M, 1996, J IMMUNOL, V156, P1166; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; KATIRA A, 1995, LEUKOCYTE TYPING, V5; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LEDERMAN S, 1992, J IMMUNOL, V149, P3817; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; Liebowitz David, 1993, P107; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Noelle RJ, 1996, IMMUNITY, V4, P415, DOI 10.1016/S1074-7613(00)80408-2; NOELLE RJ, 1992, IMMUNOL TODAY, V13, P431, DOI 10.1016/0167-5699(92)90068-I; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROWE M, 1994, J VIROL, V68, P5602, DOI 10.1128/JVI.68.9.5602-5612.1994; SARMA V, 1995, J BIOL CHEM, V270, P12343, DOI 10.1074/jbc.270.21.12343; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; STADNYK AW, 1994, FASEB J, V8, P1041, DOI 10.1096/fasebj.8.13.7926369; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; TAKIZAWA H, 1993, CANCER RES, V53, P4175; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; YELLIN MJ, 1995, J LEUKOCYTE BIOL, V58, P209, DOI 10.1002/jlb.58.2.209; Young L S, 1992, Semin Cancer Biol, V3, P273; YOUNG LS, 1989, INT J CANCER, V43, P786, DOI 10.1002/ijc.2910430508; YOUNG LS, 1988, J GEN VIROL, V69, P1051, DOI 10.1099/0022-1317-69-5-1051	65	225	230	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 19	1997	14	24					2899	2916		10.1038/sj.onc.1201258	http://dx.doi.org/10.1038/sj.onc.1201258			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XF555	9205097				2022-12-17	WOS:A1997XF55500004
J	Riese, DJ; Bermingham, Y; vanRaaij, TM; Buckley, S; Plowman, GD; Stern, DF				Riese, DJ; Bermingham, Y; vanRaaij, TM; Buckley, S; Plowman, GD; Stern, DF			Betacellulin activates the epidermal growth factor receptor and erbB-4, and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-beta	ONCOGENE			English	Article						betacellulin; EGF; neuregulin; EGF receptor; ErbB receptors; signaling	TYROSINE PHOSPHORYLATION; EGF RECEPTOR; PROTEIN; CELLS; EXPRESSION; BINDING; KINASE; LINE; HETERODIMERIZATION; ANTIBODIES	Betacellulin is a member of the epidermal growth factor (EGF) family. These soluble proteins are ligands for one or more of the four receptor tyrosine kinases encoded by the erbB gene family (erbB-1/epidermal growth factor receptor (EGFR), neu/erbB-2/HER2, erbB-3/HER3 and erbB-4/HER4). While evidence suggests that betacellulin is a ligand for the EGFR, the ability of betacellulin to regulate other erbB family receptors has not been analysed. Previously we engineered derivatives of the mouse Ba/F3 hematopoietic cell line to ectopically express erbB family receptors, singly and in pairwise combinations. We have stimulated this panel of cell lines with betacellulin and two other EGF family members, EGF itself and neuregulin-beta (NRG-beta). In the cell lines expressing a single erbB family receptor, betacellulin not only stimulated EGFR tyrosine phosphorylation, but it activated erbB-4 as well. Furthermore, in the double recombinant Ba/F3 derivatives, betacellulin stimulated a complex pattern of receptor phosphorylation distinct from the patterns activated by NRG-beta and EGF. Moreover, betacellulin stimulated a complex pattern of interleukin-3 independence in the Ba/F3 derivatives distinct from those activated by NRG-beta and EGF. These data identify a novel receptor for betacellulin and establish that different EGF family ligands activate distinct patterns of receptor phosphorylation and coupling to cellular signaling pathways.	YALE UNIV,SCH MED,DEPT PATHOL,NEW HAVEN,CT 06520; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121; SUGEN INC,REDWOOD CITY,CA 94063	Yale University; Bristol-Myers Squibb			Riese, David/AAF-3581-2020; PLOWMAN, Greg D/E-2012-2011	Riese, David/0000-0002-8823-5802	NATIONAL CANCER INSTITUTE [R01CA045708] Funding Source: NIH RePORTER; NCI NIH HHS [CA-45708] Funding Source: Medline; NICHD NIH HHS [HD-07149] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; AVIEZER D, 1994, P NATL ACAD SCI USA, V91, P12173, DOI 10.1073/pnas.91.25.12173; BARBACCI EG, 1995, J BIOL CHEM, V270, P9585, DOI 10.1074/jbc.270.16.9585; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BENEDETTI M, 1993, P NATL ACAD SCI USA, V90, P7859, DOI 10.1073/pnas.90.16.7859; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CHAO MV, 1994, J NEUROBIOL, V25, P1373, DOI 10.1002/neu.480251106; CONNELLY PA, 1990, P NATL ACAD SCI USA, V87, P6054, DOI 10.1073/pnas.87.16.6054; COOK PW, 1995, J CELL PHYSIOL, V163, P407, DOI 10.1002/jcp.1041630221; COOK PW, 1995, J CELL PHYSIOL, V163, P418, DOI 10.1002/jcp.1041630222; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; DIGIOVANNA MP, 1995, CANCER RES, V55, P1946; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; ECKENSTEIN FP, 1994, J NEUROBIOL, V25, P1467; FAZIOLI F, 1992, J BIOL CHEM, V267, P5155; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; GILL GN, 1984, J BIOL CHEM, V259, P7755; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HARWERTH IM, 1992, J BIOL CHEM, V267, P15160; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; IBANEZ CF, 1994, J NEUROBIOL, V25, P1349, DOI 10.1002/neu.480251104; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON GR, 1994, J BIOL CHEM, V269, P27149; JOHNSON GR, 1993, J BIOL CHEM, V268, P2924; KARUNAGARAN D, 1995, J BIOL CHEM, V270, P9982, DOI 10.1074/jbc.270.17.9982; KIM HH, 1994, J BIOL CHEM, V269, P24747; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KITA YA, 1994, FEBS LETT, V349, P139, DOI 10.1016/0014-5793(94)00644-X; LANGTON BC, 1991, CANCER RES, V51, P2593; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; QIAN XL, 1992, P NATL ACAD SCI USA, V89, P1330, DOI 10.1073/pnas.89.4.1330; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; SASADA R, 1993, BIOCHEM BIOPH RES CO, V190, P1173, DOI 10.1006/bbrc.1993.1173; SEFTON B, 1979, J VIROL, V28, P957; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; THORNE BA, 1994, MOL CELL BIOL, V14, P1635, DOI 10.1128/MCB.14.3.1635; UENO H, 1992, J BIOL CHEM, V267, P1470; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WATANABE T, 1994, J BIOL CHEM, V269, P9966; Zar, 2001, BIOSTAT ANAL	54	225	231	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					345	353						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570211				2022-12-17	WOS:A1996TR53800013
J	ESHLEMAN, JR; LANG, EZ; BOWERFIND, GK; PARSONS, R; VOGELSTEIN, B; WILLSON, JKV; VEIGL, ML; SEDWICK, WD; MARKOWITZ, SD				ESHLEMAN, JR; LANG, EZ; BOWERFIND, GK; PARSONS, R; VOGELSTEIN, B; WILLSON, JKV; VEIGL, ML; SEDWICK, WD; MARKOWITZ, SD			INCREASED MUTATION-RATE AT THE HPRT LOCUS ACCOMPANIES MICROSATELLITE INSTABILITY IN COLON-CANCER	ONCOGENE			English	Article						REPLICATION ERRORS (RER); GENOMIC INSTABILITY; COLON CANCER; HPRT; HPRT (HEREDITARY NONPOLYPOSIS COLON CANCER)	NONPOLYPOSIS COLORECTAL-CANCER; MISMATCH REPAIR; HUMAN-LYMPHOBLASTS; CELLS; CARCINOMA; MECHANISM; CULTURE; HOMOLOG	Hereditary Non-Polyposis Colon Cancer (HNPCC) tumors and some sporadic colon cancers acquire somatic changes in the length of microsatellite sequences, We hypothesized that this 'replication error' (RER) phenotype in these cancers reflects a more general defect which should result in hypermutability of expressed genes. To test this hypothesis mutations of hprt were studied in RER and non-PER tumor cell lines. Increased mutation rates of greater than 100-fold were found in RER compared to non-RER lines. Heterogeneity within the RER group suggests the likely existence of different classes of RER tumors. One non-REP demonstrated a greater than 10-fold increase mutation rate, suggesting that a novel mutator phenotype may exist in some non-PER tumors.	UNIV CLEVELAND HOSP,DEPT PATHOL,CLEVELAND,OH 44106; UNIV CLEVELAND HOSP,DEPT MED,CLEVELAND,OH 44106; UNIV CLEVELAND HOSP,IRELAND CANC CTR,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,CLEVELAND,OH 44106; JOHNS HOPKINS UNIV,SCH MED,CTR ONCOL,BALTIMORE,MD 21231	Case Western Reserve University; Johns Hopkins University; Johns Hopkins Medicine				Parsons, Ramon/0000-0002-6656-3514	NCI NIH HHS [CA 54031, R01 CA 57208, R29 CA 51504] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA054031, R29CA051504, R01CA057208] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1994, CANCER RES, V54, P1645; AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; BRATTAIN MG, 1981, ONCODEV BIOL MED, V2, P355; BRONNER CE, 1994, NATURE, V17, P258; CAPIZZI RL, 1973, MUTAT RES, V17, P147, DOI 10.1016/0027-5107(73)90265-0; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FURTH EE, 1981, ANAL BIOCHEM, V110, P1, DOI 10.1016/0003-2697(81)90103-2; GIVER CR, 1993, ENVIRON MOL MUTAGEN, V22, P138, DOI 10.1002/em.2850220305; Glantz S.A., 1981, PRIMER BIOSTATISTICS, V2nd ed.; HONCHEL R, 1994, CANCER RES, V54, P1159; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; Luria SE, 1943, GENETICS, V28, P491; LYNCH HT, 1991, CANCER GENET CYTOGEN, V53, P143, DOI 10.1016/0165-4608(91)90093-A; MARKOWITZ SD, 1994, J CLIN INVEST, V93, P1005, DOI 10.1172/JCI117048; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; NELSON SL, 1994, CARCINOGENESIS, V15, P495, DOI 10.1093/carcin/15.3.495; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; RISINGER JI, 1993, CANCER RES, V53, P5100; SCHAAPER RM, 1993, J BIOL CHEM, V268, P23762; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; UMAR A, 1994, J BIOL CHEM, V269, P14367; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; WILLSON JKV, 1987, CANCER RES, V47, P2704; WOTRING LL, 1980, CANCER RES, V40, P1458; YOTTI LP, 1979, SCIENCE, V206, P1089, DOI 10.1126/science.493994	30	225	237	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 5	1995	10	1					33	37						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824277				2022-12-17	WOS:A1995QA98000005
J	DAKSIS, JI; LU, RY; FACCHINI, LM; MARHIN, WW; PENN, LJZ				DAKSIS, JI; LU, RY; FACCHINI, LM; MARHIN, WW; PENN, LJZ			MYC INDUCES CYCLIN D1 EXPRESSION IN THE ABSENCE OF DE-NOVO PROTEIN-SYNTHESIS AND LINKS MITOGEN-STIMULATED SIGNAL-TRANSDUCTION TO THE CELL-CYCLE	ONCOGENE			English	Review							HUMAN C-MYC; DNA-BINDING; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; GROWTH-FACTOR; ORNITHINE DECARBOXYLASE; RETINOBLASTOMA PROTEIN; MESSENGER-RNA; NEGATIVE AUTOREGULATION; MAMMALIAN FIBROBLASTS	Mitogen-activated signal transduction frequently leads to the induction of the c-myc proto-oncogene, but the subsequent molecular events downstream of Myc protein expression which promote cell cycle progression remain unclear. To study Myc-specific effects, without the complexity of the broader proliferative response evoked by serum, we employed the MycER-inducible system in the non-transformed Rat-1 cell line. We demonstrate that activation of wild-type, but not mutant, MycER is sufficient to transiently induce cyclin D1 RNA as well as protein expression to physiological levels, and promote G0/G1 to S phase transition of the cell cycle. Stimulation of endogenous cyclin D1 RNA is rapid and clearly evident within 30 min of MycER-activation, reaching a peak at 3 h. Nuclear run-on analysis demonstrates that this induction occurs at the transcriptional level with a fivefold increase in the rate of transcription. Moreover, MycER induces cyclin D1 transcription with equal efficacy in the presence or absence of de novo protein synthesis. Our work shows that Myc and cyclin D1 lie consecutively in a major proliferation-control pathway, and together create a pivotal connection between signal transduction and cell cycle control.	UNIV TORONTO, TORONTO M5G 1X8, ON, CANADA; HOSP SICK CHILDREN, DEPT MICROBIOL, TORONTO M5G 1X8, ON, CANADA; HOSP SICK CHILDREN, DEPT IMMUNOL & CANC RES, TORONTO M5G 1X8, ON, CANADA	University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)								AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; ASKEW DS, 1991, ONCOGENE, V6, P1915; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BATES S, 1994, ONCOGENE, V9, P71; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BERBERICH S, 1992, ONCOGENE, V7, P775; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; COCKS BG, 1992, J BIOL CHEM, V267, P12307; CROUCH DH, 1993, ONCOGENE, V8, P1849; DAKSIS JI, 1992, VIROLOGY, V189, P196, DOI 10.1016/0042-6822(92)90695-L; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FACCHINI LM, 1994, CELL GROWTH DIFFER, V5, P637; FREYTAG SO, 1990, CELL GROWTH DIFFER, V1, P339; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HERBER B, 1994, ONCOGENE, V9, P1295; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1993, ONCOGENE, V8, P3447; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KARN J, 1989, ONCOGENE, V4, P773; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMMIE GA, 1991, ONCOGENE, V6, P439; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LAU LF, 1991, MOL ASPECTS CELLULAR, V6, P257; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LOVEC H, 1994, ONCOGENE, V9, P323; LUKAS J, 1994, ONCOGENE, V9, P707; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; NIKAIDO T, 1991, EXP CELL RES, V192, P102, DOI 10.1016/0014-4827(91)90163-O; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PALMERO I, 1993, ONCOGENE, V8, P1049; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PENA A, 1993, J BIOL CHEM, V268, P27277; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; PENN LJZ, 1990, C MYC EVIDENCE MULTI, P69; PETERS G, 1990, CELL GROWTH DIFFER, V1, P503; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; REDDY CD, 1992, ONCOGENE, V7, P2085; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSENBERG CL, 1993, ONCOGENE, V8, P519; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; ROUSSEL MF, 1989, P NATL ACAD SCI USA, V86, P7924, DOI 10.1073/pnas.86.20.7924; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; Sambrook J., 1989, MOL CLONING LAB MANU; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WATERS CM, 1991, ONCOGENE, V6, P797; WINSTON JT, 1993, MOL BIOL CELL, V4, P1133, DOI 10.1091/mbc.4.11.1133; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	105	225	229	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1994	9	12					3635	3645						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7526316				2022-12-17	WOS:A1994PT39200027
J	JANSSEN, JWG; SCHULZ, AS; STEENVOORDEN, ACM; SCHMIDBERGER, M; STREHL, S; AMBROS, PF; BARTRAM, CR				JANSSEN, JWG; SCHULZ, AS; STEENVOORDEN, ACM; SCHMIDBERGER, M; STREHL, S; AMBROS, PF; BARTRAM, CR			A NOVEL PUTATIVE TYROSINE KINASE RECEPTOR WITH ONCOGENIC POTENTIAL	ONCOGENE			English	Article							GEL-ELECTROPHORESIS; SEQUENCES; DNA; PROTEIN; CELLS; FRAGMENTS; LEUKEMIA; HYBRIDIZATION; CLEAVAGE; DOMAINS	We have detected transforming activity by a tumorigenicity assay using NIH3T3 cells transfected with DNA from a chronic myeloproliferative disorder patient. Here, we report the cDNA cloning of the corresponding oncogene, designated UFO, in allusion to the as yet unidentified function of its protein. Nucleotide sequence analysis of a 3116 bp cDNA clone revealed a 2682-bp-long open reading frame capable of directing the synthesis of a 894 amino acid polypeptide. The predicted UFO protein exhibits characteristic features of a transmembrane receptor with associated tyrosine kinase activity. The UFO proto-oncogene maps to human chromosome 19q13.1 and is transcribed into two 5.0 kb and 3.2 kb mRNAs in human bone marrow and human tumor cell lines. The UFO locus is evolutionarily conserved between vertebrate species. A 4.0 kb mRNA of the murine UFO homolog is expressed in a variety of different mouse tissues. We thus have identified a novel element of the complex signaling network involved in the control of cell proliferation and differentiation.	UNIV ULM,DEPT PEDIAT 2,INTERNAL DIS PROPEDEUT SECT,PRITTWITZSTR 43,W-7900 ULM,GERMANY; DEPT TRANSFUS MED,W-7900 ULM,GERMANY; CHILDRENS CANC RES INST,A-1090 VIENNA,AUSTRIA	Ulm University; Saint Anna Children's Hospital			Ambros, Peter/AAA-1266-2021	Ambros, Peter/0000-0002-5507-7211; Strehl, Sabine/0000-0002-0179-0628				AFFRAY C, 1980, EUR J BIOCHEM, V107, P303; AMBROS PF, 1987, HUM GENET, V77, P251, DOI 10.1007/BF00284479; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BIGNER SH, 1988, CANCER RES, V48, P405; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; GORMAN CM, 1983, NUCLEIC ACIDS RES, V11, P7631, DOI 10.1093/nar/11.21.7631; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; JANSSEN JWG, 1987, ONCOGENE, V1, P175; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZMA SC, 1988, EMBO J, V7, P147, DOI 10.1002/j.1460-2075.1988.tb02794.x; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LYON MF, 1987, MOUSE NEWS LETT, V787, P12; Maniatis T., 1982, MOL CLONING; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROPERS HH, 1990, CYTOGENET CELL GENET, V55, P218, DOI 10.1159/000133015; RUBIN CM, 1980, NATURE, V284, P372, DOI 10.1038/284372a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEALEY PG, 1985, NUCLEIC ACIDS RES, V13, P1905, DOI 10.1093/nar/13.6.1905; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; UESHIMA Y, 1985, INT J CANCER, V36, P287, DOI 10.1002/ijc.1985.36.3.287; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOGELSTEIN B, 1987, ANAL BIOCHEM, V160, P115, DOI 10.1016/0003-2697(87)90620-8; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WHITTAKER PA, 1988, NUCLEIC ACIDS RES, V16, P6725, DOI 10.1093/nar/16.14.6725; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3	42	225	254	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					2113	2120						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1834974				2022-12-17	WOS:A1991GX11900023
J	Unoki, M; Nishidate, T; Nakamura, Y				Unoki, M; Nishidate, T; Nakamura, Y			ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG through its SRA domain	ONCOGENE			English	Article						ICBP90; methyl-CpG-binding protein; HDAC1; SRA domain; E2F-1; UHRF1BP1	CELL-CYCLE; UBIQUITIN LIGASE; DOWN-REGULATION; PARTNER KAISO; PROTEIN; NP95; GENE; NIRF; TRANSCRIPTION; EXPRESSION	ICBP90, invertedCCA AT box-binding protein of 90 kDa, has been reported as a regulator of topoisomerase IIalpha expression. We present evidence here that ICBP90 binds to methyl-CpG when at least one symmetrically methylated-CpG dinucleotides is presented as its recognition sequence. A SET and RING finger-associated(SRA) domain accounts for the high binding affinity of ICBP90 for methyl-CpG dinucleotides. This protein constitutes a complex with HDAC1 also via its SRA domain, and bound to methylated promoter regions of various tumor suppressor genes, including p16(INK4A) and p14(ARF), in cancer cells. It has been reported that expression of ICBP90 was upregulated by E2F-1, and we confirmed that the upregulation was caused by binding of E2F-1 to the intron1 of ICBP90, which contains two E2F-1-binding motifs. Our data also revealed accumulation of ICBP90 in breast-cancer cells, where it might suppress expression of tumor suppressor genes through deacetylation of histones after recruitment of HDAC1. The data reported here suggest that ICBP90 is involved in cell proliferation by way of methylation-mediated regulation of certain genes.	Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Nakamura, Y (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, 4-6-1 Shiorokanedai, Tokyo 1088639, Japan.	yusuke@ims.u-tokyo.ac.jp	Unoki, Motoko/X-3285-2019	Unoki, Motoko/0000-0002-9629-3818				Arima Y, 2004, GENES CELLS, V9, P131, DOI 10.1111/j.1356-9597.2004.00710.x; Ballestar E, 2001, EUR J BIOCHEM, V268, P1, DOI 10.1046/j.1432-1327.2001.01869.x; Baumbusch LO, 2001, NUCLEIC ACIDS RES, V29, P4319, DOI 10.1093/nar/29.21.4319; Bonapace IM, 2002, J CELL BIOL, V157, P909, DOI 10.1083/jcb.200201025; Burri N, 2001, LAB INVEST, V81, P217, DOI 10.1038/labinvest.3780230; Citterio E, 2004, MOL CELL BIOL, V24, P2526, DOI 10.1128/MCB.24.6.2526-2535.2004; Daniel JM, 2002, NUCLEIC ACIDS RES, V30, P2911, DOI 10.1093/nar/gkf398; Daniel JM, 1999, MOL CELL BIOL, V19, P3614; Fujimori A, 1998, MAMM GENOME, V9, P1032, DOI 10.1007/s003359900920; Hopfner R, 2002, ANTICANCER RES, V22, P3165; Hopfner R, 2000, CANCER RES, V60, P121; Li YY, 2004, BIOCHEM BIOPH RES CO, V319, P464, DOI 10.1016/j.bbrc.2004.04.190; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Miki K, 2000, ONCOL RES, V12, P335, DOI 10.3727/096504001108747783; Miura M, 2001, EXP CELL RES, V263, P202, DOI 10.1006/excr.2000.5115; Mori T, 2004, FEBS LETT, V557, P209, DOI 10.1016/S0014-5793(03)01495-9; Mori T, 2002, BIOCHEM BIOPH RES CO, V296, P530, DOI 10.1016/S0006-291X(02)00890-2; Mousli M, 2003, BRIT J CANCER, V89, P120, DOI 10.1038/sj.bjc.6601068; Nguyen CT, 2001, NUCLEIC ACIDS RES, V29, P4598, DOI 10.1093/nar/29.22.4598; NISHIDATE T, 2004, IN PRESS INT J ONCOL; Prokhortchouk A, 2001, GENE DEV, V15, P1613, DOI 10.1101/gad.198501; Shimokawa T, 2003, CANCER RES, V63, P6116; Trotzier MA, 2004, BIOCHEM BIOPH RES CO, V319, P590, DOI 10.1016/j.bbrc.2004.05.028; Uemura T, 2000, CELL STRUCT FUNCT, V25, P149, DOI 10.1247/csf.25.149; Unoki M, 2003, FEBS LETT, V554, P67, DOI 10.1016/S0014-5793(03)01092-5; Unoki M, 2003, ONCOGENE, V22, P2172, DOI 10.1038/sj.onc.1206222; Yoon HG, 2003, MOL CELL, V12, P723, DOI 10.1016/j.molcel.2003.08.008	27	224	244	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2004	23	46					7601	7610		10.1038/sj.onc.1208053	http://dx.doi.org/10.1038/sj.onc.1208053			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	859ZK	15361834				2022-12-17	WOS:000224306700001
J	Xiao, D; Choi, S; Johnson, DE; Vogel, VG; Johnson, CS; Trump, DL; Lee, YJ; Singh, SV				Xiao, D; Choi, S; Johnson, DE; Vogel, VG; Johnson, CS; Trump, DL; Lee, YJ; Singh, SV			Diallyl trisulfide-induced apoptosis in human prostate cancer cells involves c-Jun N-terminal kinase and extracellular-signal regulated kinase-mediated phosphorylation of Bcl-2	ONCOGENE			English	Article						diallyl trisulfide; JNK; ERK; Bcl-2; apoptosis; prostate cancer	OCCURRING ORGANOSULFUR COMPOUNDS; METABOLIC OXIDATIVE STRESS; PROTEIN-KINASE; COLON-CANCER; S-ALLYLMERCAPTOCYSTEINE; MAMMARY CARCINOGENESIS; ALLIUM VEGETABLES; CYTOCHROME-C; P38 MAPK; DISULFIDE	Garlic-derived organosulfides (OSCs) including diallyl trisulfide (DATS) are highly effective in affording protection against chemically induced cancer in animals. Evidence is also mounting to indicate that some naturally occurring OSCs can suppress proliferation of cancer cells by causing apoptosis, but the sequence of events leading to proapoptotic effect of OSCs is poorly defined. Using PC-3 and DU145 human prostate cancer cells as a model, we now demonstrate that DATS is a significantly more potent apoptosis inducer than diallyl sulfide (DAS) or diallyl disulfide (DADS). DATS-induced apoptosis in PC-3 cells was associated with phosphorylation of Bcl-2, reduced Bcl-2: Bax interaction, and cleavage of procaspase-9 and -3. Bcl-2 overexpressing PC-3 cells were significantly more resistant to apoptosis induction by DATS compared with vector-transfected control cells. DATS treatment resulted in activation of extracellular-signal regulated kinase 1/2 (ERK1/2) and c-jun N-terminal kinase 1 (JNK1) and/or JNK2, but not p38 mitogen-activated protein kinase. Phosphorylation of Bcl-2 in DATS-treated PC-3 cells was fully blocked in the presence of JNK-specific inhibitor SP600125. Moreover, JNK inhibitor afforded significant protection against DATS-induced apoptosis in both cells. DATS-induced Bcl-2 phosphorylation and apoptosis were partially attenuated by pharmacological inhibition of ERK1/2 using PD98059 or U0126. Overexpression of catalase inhibited DATS-mediated activation of JNK1/2, but not ERK1\/2, and apoptosis induction in DU145 cells suggesting involvement of hydrogen peroxide as a second messenger in DATS-induced apoptosis. In conclusion, our data point towards important roles for Bcl-2, JNK and ERK in DATS-induced apoptosis in human prostate cancer cells.	Univ Pittsburgh, Pittsburgh Canc Inst, Hillman Canc Ctr, Sch Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol & Med, Pittsburgh, PA 15261 USA; Roswell Pk Canc Inst, Buffalo, NY 14263 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Roswell Park Cancer Institute	Singh, SV (corresponding author), Univ Pittsburgh, Pittsburgh Canc Inst, Hillman Canc Ctr, Sch Med, Res Pavil,Suite 2-32A,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	singhs@msx.upmc.edu			NATIONAL CANCER INSTITUTE [R01CA101753, R01CA095191, R01CA096989] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Agarwal KC, 1996, MED RES REV, V16, P111, DOI 10.1002/(SICI)1098-1128(199601)16:1&lt;111::AID-MED4&gt;3.0.CO;2-5; Blagosklonny MV, 2001, LEUKEMIA, V15, P869, DOI 10.1038/sj.leu.2402134; Blagosklonny MV, 1996, CANCER RES, V56, P1851; DAUSCH JG, 1990, PREV MED, V19, P346, DOI 10.1016/0091-7435(90)90034-H; Deng XM, 2001, J BIOL CHEM, V276, P23681, DOI 10.1074/jbc.M100279200; DORANT E, 1993, BRIT J CANCER, V67, P424, DOI 10.1038/bjc.1993.82; Fang GF, 1998, CANCER RES, V58, P3202; Ferreira CG, 2002, CLIN CANCER RES, V8, P2024; Filomeni G, 2003, CANCER RES, V63, P5940; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Haldar S, 1996, CANCER RES, V56, P1253; Halliwell B, 1996, BIOCHEM SOC T, V24, P1023, DOI 10.1042/bst0241023; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hsing AW, 2002, J NATL CANCER I, V94, P1648, DOI 10.1093/jnci/94.21.1648; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Knowles LM, 1998, NUTR CANCER, V30, P169, DOI 10.1080/01635589809514659; Knowles LM, 2001, J NUTR, V131, p1061S, DOI 10.1093/jn/131.3.1061S; Kwon KB, 2002, BIOCHEM PHARMACOL, V63, P41, DOI 10.1016/S0006-2952(01)00860-7; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; MAY WS, 1994, J BIOL CHEM, V269, P26865; NAGAE S, 1994, PLANTA MED, V60, P214, DOI 10.1055/s-2006-959461; Nakagawa H, 2001, CARCINOGENESIS, V22, P891, DOI 10.1093/carcin/22.6.891; REDDY BS, 1993, CANCER RES, V53, P3493; Robert V, 2001, CARCINOGENESIS, V22, P1155, DOI 10.1093/carcin/22.8.1155; Rosini P, 2000, BIOCHEM BIOPH RES CO, V278, P753, DOI 10.1006/bbrc.2000.3871; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Scatena CD, 1998, J BIOL CHEM, V273, P30777, DOI 10.1074/jbc.273.46.30777; Schaffer EM, 1996, CANCER LETT, V102, P199, DOI 10.1016/0304-3835(96)04160-2; Sheen LY, 1996, FOOD CHEM TOXICOL, V34, P971, DOI 10.1016/S0278-6915(96)00066-X; Shirin H, 2001, CANCER RES, V61, P725; Song JJ, 2003, BIOCHEM J, V373, P845, DOI 10.1042/BJ20030275; Song JJ, 2002, J BIOL CHEM, V277, P46566, DOI 10.1074/jbc.M206826200; SPARNINS VL, 1988, CARCINOGENESIS, V9, P131, DOI 10.1093/carcin/9.1.131; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; SUMIYOSHI H, 1990, CANCER RES, V50, P5084; Sundaram SG, 1996, CARCINOGENESIS, V17, P669, DOI 10.1093/carcin/17.4.669; Suzui N, 1997, JPN J CANCER RES, V88, P705, DOI 10.1111/j.1349-7006.1997.tb00440.x; TAKAHASHI S, 1992, CARCINOGENESIS, V13, P1513, DOI 10.1093/carcin/13.9.1513; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Torcia M, 2001, J BIOL CHEM, V276, P39027, DOI 10.1074/jbc.M102970200; Vantieghem A, 2002, J BIOL CHEM, V277, P37718, DOI 10.1074/jbc.M204348200; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; WARGOVICH MJ, 1987, CARCINOGENESIS, V8, P487, DOI 10.1093/carcin/8.3.487; WARGOVICH MJ, 1988, CANCER RES, V48, P6872; WATTENBERG LW, 1989, CANCER RES, V49, P2689; Xiao D, 2003, CARCINOGENESIS, V24, P891, DOI 10.1093/carcin/bgg023; Xiao D, 2002, CANCER RES, V62, P3615; Xiao DH, 2003, CANCER RES, V63, P6825; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; YOU WC, 1989, J NATL CANCER I, V81, P162, DOI 10.1093/jnci/81.2.162	53	224	235	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5594	5606		10.1038/sj.onc.1207747	http://dx.doi.org/10.1038/sj.onc.1207747			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15184882				2022-12-17	WOS:000222629500004
J	Wang, JYJ				Wang, JYJ			Regulation of cell death by the Abl tyrosine kinase	ONCOGENE			English	Review						Bcr-Abl; retinoblastoma tumor suppressor; ATM; p53; p73	C-ABL; RETINOBLASTOMA PROTEIN; INDUCED APOPTOSIS; IONIZING-RADIATION; BINDING DOMAIN; CYTOCHROME-C; CYCLE ARREST; DNA; ACTIVATION; BCR	The c-abl proto-oncogene encodes a protein tyrosine kinase that is distributed in the nucleus and the cytoplasm of proliferating cells. In the nucleus, c-Abl activity is negatively regulated by the retinoblastoma protein (RB) and positively regulated by DNA damage signals. Activation of the c-Abl kinase by DIVA damage requires the function of ATM, which regulates cell cycle checkpoint, DNA repair and apoptosis in response to DNA damage. Cells lacking c-Abl can activate cell cycle checkpoints and DNA repair, but show defects in apoptosis, The apoptosis defect of c-Abl deficient cells is correlated with a defect in the induction and activation of p73, which is a functional homologue! of the p53 tumor suppressor protein and has pro-apoptotic activity, The inhibition of c-Abl by RE is consistent with RB's ability to block apoptosis; while the activation of c-Abl by ATM is consistent with ATM's ability to activate cell death. The oncogenic Bcr-Abl tyrosine kinase is a potent inhibitor of apoptosis, and it is retained exclusively in the cytoplasm of transformed cells. Interestingly, when Bcr-Abl is trapped inside of the nucleus through a combined disruption of its cytoplasmic retention and its nuclear export, this oncogenic Abl kinase induces apoptosis, Taken together, the current results support a role for the nuclear c-Abl tyrosine kinase in the regulation of apoptosis, Whether the cytoplasmic c-Abl kinase can actively inhibit apoptosis remains to be determined; however, a deliberate retention of c-Abl in the cytoplasm could potentially contribute to the attenuation of apoptosis response.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Wang, JYJ (corresponding author), Univ Calif San Diego, Dept Biol, 9500 Gilman Dr,0322,Bonner Hall 3326, La Jolla, CA 92093 USA.				NATIONAL CANCER INSTITUTE [R01CA058320, R37CA043054, R01CA043054] Funding Source: NIH RePORTER; NCI NIH HHS [CA43054, CA58320, R37 CA043054, R01 CA043054] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 1999, NATURE, V399, P809; ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barila D, 2000, EMBO J, V19, P273, DOI 10.1093/emboj/19.2.273; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Brugarolas J, 1999, P NATL ACAD SCI USA, V96, P1002, DOI 10.1073/pnas.96.3.1002; Buchdunger E, 1996, CANCER RES, V56, P100; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chen G, 1999, J BIOL CHEM, V274, P12748, DOI 10.1074/jbc.274.18.12748; Chong MJ, 2000, P NATL ACAD SCI USA, V97, P889, DOI 10.1073/pnas.97.2.889; Cong F, 1999, P NATL ACAD SCI USA, V96, P13819, DOI 10.1073/pnas.96.24.13819; Dan S, 1999, ONCOGENE, V18, P1277, DOI 10.1038/sj.onc.1202423; David-Cordonnier MH, 1998, BIOCHEMISTRY-US, V37, P6065, DOI 10.1021/bi973030w; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Golub TR, 1996, MOL CELL BIOL, V16, P4107; Gong JG, 1999, NATURE, V399, P806; Hardin JD, 1996, ONCOGENE, V12, P2669; Harrington EA, 1998, P NATL ACAD SCI USA, V95, P11945, DOI 10.1073/pnas.95.20.11945; Iijima Y, 2000, BLOOD, V95, P2126; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KNUDSEN KE, 2000, IN PRESS MOL CELL BI, V20; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Lanier LM, 2000, CURR OPIN NEUROBIOL, V10, P80, DOI 10.1016/S0959-4388(99)00058-6; Levrero M, 1999, CELL DEATH DIFFER, V6, P1146, DOI 10.1038/sj.cdd.4400624; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Li BJ, 2000, NAT GENET, V24, P304, DOI 10.1038/73542; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MCGAHON AJ, 1995, J BIOL CHEM, V270, P22625, DOI 10.1074/jbc.270.38.22625; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; Miao YJ, 1996, J BIOL CHEM, V271, P22823, DOI 10.1074/jbc.271.37.22823; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Takao N, 2000, J BIOL CHEM, V275, P725, DOI 10.1074/jbc.275.2.725; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; Tan XQ, 1997, J BIOL CHEM, V272, P9613; Theis S, 1998, ONCOGENE, V17, P557, DOI 10.1038/sj.onc.1201973; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; Wang JYJ, 2000, NATURE, V405, P404, DOI 10.1038/35013171; Wang JYJ, 2000, CANC DRUG DISC DEV, V5, P303; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704	72	224	235	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2000	19	49					5643	5650		10.1038/sj.onc.1203878	http://dx.doi.org/10.1038/sj.onc.1203878			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	379TV	11114745				2022-12-17	WOS:000165659300012
J	Brown, R; Hirst, GL; Gallagher, WM; McIlwrath, AJ; Margison, GP; vanderZee, AGJ; Anthoney, DA				Brown, R; Hirst, GL; Gallagher, WM; McIlwrath, AJ; Margison, GP; vanderZee, AGJ; Anthoney, DA			hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents.	ONCOGENE			English	Article						cisplatin; drug resistance; mismatch repair; ovarian cancer	MISMATCH REPAIR; MICROSATELLITE INSTABILITY; MOLECULAR ANALYSIS; CISPLATIN; DNA; CANCER; TOLERANCE; ADDUCTS; LINES; ACCUMULATION	Loss of expression of the hMLH1 and hPMS2 subunits of the MutL alpha-mismatch repair complex is a frequent event (9/10) in independent cisplatin resistant derivatives of a human ovarian carcinoma cell line, However, only hMLH1 mRNA is decreased in these MutL alpha-deficient lines, No alterations in the levels of the hMSH2 and hMSH6 (GTBP) subunits of the MutS alpha-comples are observed, An increase in the proportion of ovarian tumours negative for the hMLH1 subunit is observed in samples taken at second look laporotomy after chemotherapy (36%: 4/11), compared to untreated tumours (10%: 4/39), No significant difference is observed for hMSH2, hMSH6 or hPMS2. Furthermore, cisplatin and doxorubicin-resistant ovarian lines deficient in hMLH1 expression are cross-resistant to 6-thioguanine and the methylating agent N-methyl-N-nitrosourea (MNU). Depletion of O-6-alkylguanine-DNA-alkyltransferase (ATase) activity confers only limited increased sensitivity to MNU. Thus the mismatch repair deficient lines retain DNA damage tolerance even after ATase depletion, The hMLH1 deficient lines also lose ability to engage G1 and G2 cell cycle arrest after cisplatin damage, Together these data suggest that loss of hMLH1 expression may be a high frequency event following exposure of ovarian tumour cells to cisplatin and may be critically involved in the development of drug resistance, Thus, the hMLH1 status of these cells appears to be highly correlated with the ability to engage cell death and cell cycle arrest after DNA damage induced by cisplatin.	CHRISTIE HOSP NHS TRUST,PATERSON INST CANC RES,CRC,DEPT CARCINOGENESIS,MANCHESTER M20 9BX,LANCS,ENGLAND; UNIV GRONINGEN HOSP,DEPT GYNAECOL ONCOL,GRONINGEN,NETHERLANDS	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; University of Groningen	Brown, R (corresponding author), UNIV GLASGOW,CRC,BEATSON LABS,DEPT MED ONCOL,SWITCHBACK RD,GLASGOW G61 1BD,LANARK,SCOTLAND.		Margison, Geoff/E-4146-2019	Gallagher, William/0000-0002-4307-5999; Hirst, Gillian/0000-0002-4502-0035				Aebi S, 1996, CANCER RES, V56, P3087; Anthoney DA, 1996, CANCER RES, V56, P1374; AQUILINA G, 1990, CANCER RES, V50, P4248; BERANEK DT, 1990, MUTAT RES, V231, P11, DOI 10.1016/0027-5107(90)90173-2; BROWN R, 1993, INT J CANCER, V55, P678, DOI 10.1002/ijc.2910550428; Bubb VJ, 1996, ONCOGENE, V12, P2641; Chambers SR, 1996, MOL CELL BIOL, V16, P6110; DOLAN ME, 1990, CANCER COMMUN, V2, P371, DOI 10.3727/095535490820873985; Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; EVANS DL, 1994, CANCER RES, V54, P1596; FICHTINGERSCHEPMAN AMJ, 1985, BIOCHEMISTRY-US, V24, P707, DOI 10.1021/bi00324a025; Fink D, 1996, CANCER RES, V56, P4881; Fujita M, 1995, INT J CANCER, V64, P361, DOI 10.1002/ijc.2910640602; Gallagher WM, 1997, ONCOGENE, V14, P185; HAWN MT, 1995, CANCER RES, V55, P3721; Hoffmann JS, 1996, P NATL ACAD SCI USA, V93, P13766, DOI 10.1073/pnas.93.24.13766; HOFFMANN JS, 1995, P NATL ACAD SCI USA, V92, P5356, DOI 10.1073/pnas.92.12.5356; KARRAN P, 1994, BIOESSAYS, V16, P833, DOI 10.1002/bies.950161110; Kaye SB, 1996, ANN ONCOL, V7, P9; KING BL, 1995, BRIT J CANCER, V72, P376, DOI 10.1038/bjc.1995.341; KOI M, 1994, CANCER RES, V54, P4308; MAMENTA EL, 1994, CANCER RES, V54, P3500; Mello JA, 1996, CHEM BIOL, V3, P579, DOI 10.1016/S1074-5521(96)90149-0; Moggs JG, 1996, J BIOL CHEM, V271, P7177, DOI 10.1074/jbc.271.12.7177; MORTEN JEN, 1988, CARCINOGENESIS, V9, P45, DOI 10.1093/carcin/9.1.45; MURPHY DS, 1995, J NATL CANCER I, V87, P1694, DOI 10.1093/jnci/87.22.1694; ORMEROD MG, 1994, EXP CELL RES, V211, P231, DOI 10.1006/excr.1994.1082; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; Paulson TG, 1996, CANCER RES, V56, P4021; REED E, 1995, SEMIN ONCOL, V22, P90; SORENSON CM, 1990, JNCI-J NATL CANCER I, V82, P749, DOI 10.1093/jnci/82.9.749; SZYMKOWSKI DE, 1992, P NATL ACAD SCI USA, V89, P10772, DOI 10.1073/pnas.89.22.10772; UMAR A, 1994, J BIOL CHEM, V269, P14367; VANDERZEE AGJ, 1995, J CLIN ONCOL, V13, P70, DOI 10.1200/JCO.1995.13.1.70; VANDERZEE AGJ, 1994, ANN ONCOL, V5, P75, DOI 10.1093/oxfordjournals.annonc.a058700; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; Yamada M, 1997, NUCLEIC ACIDS RES, V25, P491, DOI 10.1093/nar/25.3.491; ZAMPLE DB, 1995, TIBS, V20, P435	41	224	224	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 3	1997	15	1					45	52		10.1038/sj.onc.1201167	http://dx.doi.org/10.1038/sj.onc.1201167			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XH586	9233776				2022-12-17	WOS:A1997XH58600005
J	LAVAU, C; MARCHIO, A; FAGIOLI, M; JANSEN, J; FALINI, B; LEBON, P; GROSVELD, F; PANDOLFI, PP; PELICCI, PG; DEJEAN, A				LAVAU, C; MARCHIO, A; FAGIOLI, M; JANSEN, J; FALINI, B; LEBON, P; GROSVELD, F; PANDOLFI, PP; PELICCI, PG; DEJEAN, A			THE ACUTE PROMYELOCYTIC LEUKEMIA-ASSOCIATED PML GENE IS INDUCED BY INTERFERON	ONCOGENE			English	Article						ACUTE PROMYELOCYTIC LEUKEMIA; T(15-17) TRANSLOCATION; PML-RAR-ALPHA; NUCLEAR BODIES; INTERFERON	PRIMARY BILIARY-CIRRHOSIS; TRANS RETINOIC ACID; T(15-17) TRANSLOCATION; MONOCLONAL-ANTIBODY; NUCLEAR-BODIES; LEUKEMIA FUSES; RAR-ALPHA; EXPRESSION; RECEPTOR; CELLS	The PML protein concentrates within discrete nuclear structures known as nuclear bodies, also called NDs or PODs, which contain several proteins including the interferon (IFN)-inducible SP100 product, The function of these structures remains elusive, We and others have shown recently that they represent specific targets for adenovirus and herpes simplex virus. This prompted us to investigate whether PML, like SP100, might be induced by IFN and to explore the role of PML in viral infection, Here we report that PML mRNA levels increase rapidly in response to interferon treatment, This accumulation of. PML transcripts is a primary IFN response since it does not require de novo protein synthesis, The IFN-induced activation of the PML gene is accompanied by enhanced protein expression as revealed by immunolabelling, Both the intensity of the staining and the number of labelled structures increased upon interferon exposure, To probe the role of PML in IFN action, we compared the antiviral state established by alpha-interferon in embryonic fibroblasts (EFs) derived from null mutant mice for PML and from wild-type control mice, The resistance to viral infection conferred by IFN-alpha was identical in both PML(+/+) and PML(m/m) fibroblasts indicating that PML is not an essential mediator of the antiviral effect of interferon, We also noted that DNA-binding factors are normally activated by IFN in PML(m/m) cells.	UNIV PERUGIA,POLICLIN PERUGIA,IST CLIN MED 1,I-06100 PERUGIA,ITALY; HOP ST VINCENT DE PAUL,SERV BACTERIOL VIROL,F-75674 PARIS 14,FRANCE; NATL INST MED RES,GENE STRUCT & EXPRESS LAB,LONDON NW7 1AA,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT HAEMATOL,LONDON W12 0HS,ENGLAND; EUROPEAN INST ONCOL,I-20141 MILAN,ITALY	University of Perugia; Azienda Ospedaliera di Perugia; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; MRC National Institute for Medical Research; Imperial College London; IRCCS European Institute of Oncology (IEO)	LAVAU, C (corresponding author), INST PASTEUR,UNITE RECOMBINAISON & EXPRESS GENET,INSERM,U163,28 RUE DR ROUX,F-75724 PARIS 15,FRANCE.		Dejean, Anne/L-5145-2018; Pelicci, Pier Giuseppe/AAL-6572-2020; Lavau, Catherine/Q-2928-2019; Jansen, J.H./H-8054-2014	Jansen, J.H./0000-0001-9459-568X; Lavau, Catherine/0000-0003-4800-1320; FALINI, Brunangelo/0000-0002-7198-5965				ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; ALLEN G, 1982, J GEN VIROL, V63, P207, DOI 10.1099/0022-1317-63-1-207; ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BOUTEILLE M, 1974, CELL NUCLEUS, P5; BRASCH K, 1992, EXP CELL RES, V202, P211, DOI 10.1016/0014-4827(92)90068-J; BREITMAN TR, 1981, BLOOD, V57, P1000; CARVALHO T, 1995, IN PRESS J CELL BIOL; CHAN EKL, 1991, J CLIN INVEST, V87, P68, DOI 10.1172/JCI115003; CHOMIENNE C, 1990, BLOOD, V76, P1710; COLUCCIGUYON E, 1994, CELL, V79, P679, DOI 10.1016/0092-8674(94)90553-3; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EPSTEIN AL, 1984, J VIROL, V50, P372, DOI 10.1128/JVI.50.2.372-379.1984; EVERETT RD, 1994, EMBO J, V13, P5062, DOI 10.1002/j.1460-2075.1994.tb06835.x; FAGIOLI M, 1992, ONCOGENE, V7, P1083; FLENGHI L, 1995, BLOOD, V85, P1871, DOI 10.1182/blood.V85.7.1871.bloodjournal8571871; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GRIGNANI F, 1994, BLOOD, V83, P10; GULDNER HH, 1992, J IMMUNOL, V149, P4067; HORISBERGER MA, 1987, J GEN VIROL, V68, P945, DOI 10.1099/0022-1317-68-3-945; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; JANSEN JH, 1995, IN PRESS P NATL ACAD; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LAVAU C, 1994, LEUKEMIA, V8, P1615; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; MAUL GG, 1993, J GEN VIROL, V74, P2679, DOI 10.1099/0022-1317-74-12-2679; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; PADYKULA HA, 1981, CELL NUCLEUS, V9, P309; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PATARCA R, 1988, P NATL ACAD SCI USA, V85, P2733, DOI 10.1073/pnas.85.8.2733; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; Staeheli P, 1990, Adv Virus Res, V38, P147, DOI 10.1016/S0065-3527(08)60862-3; STUURMAN N, 1992, J CELL SCI, V101, P773; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; TERRIS B, 1995, CANCER RES, V55, P1590; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; XIE KW, 1993, MOL CELL BIOL, V13, P6170, DOI 10.1128/MCB.13.10.6170	51	224	226	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 7	1995	11	5					871	878						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7545807				2022-12-17	WOS:A1995RU79800007
